<SEC-DOCUMENT>0001125345-24-000060.txt : 20240307
<SEC-HEADER>0001125345-24-000060.hdr.sgml : 20240307
<ACCEPTANCE-DATETIME>20240307160340
ACCESSION NUMBER:		0001125345-24-000060
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		88
CONFORMED PERIOD OF REPORT:	20231231
FILED AS OF DATE:		20240307
DATE AS OF CHANGE:		20240307

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MACROGENICS INC
		CENTRAL INDEX KEY:			0001125345
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36112
		FILM NUMBER:		24729983

	BUSINESS ADDRESS:	
		STREET 1:		9704 MEDICAL CENTER DRIVE
		CITY:			Rockville
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		301-251-5172

	MAIL ADDRESS:	
		STREET 1:		9704 MEDICAL CENTER DRIVE
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>mgnx-20231231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mgnx="http://macrogenics.com/20231231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>mgnx-20231231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-33">false</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-34">2023</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-35">FY</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-36">0001125345</ix:nonNumeric><ix:nonNumeric contextRef="c-6" name="ecd:TrdArrDuration" format="ixt-sec:durday" id="f-50">494</ix:nonNumeric><ix:nonNumeric contextRef="c-9" name="ecd:TrdArrDuration" format="ixt-sec:durday" id="f-51">468</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="mgnx-20231231.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">mgnx:JamesKarrelsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">mgnx:JamesKarrelsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">mgnx:JamesKarrelsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">mgnx:JeffreyPetersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">mgnx:JeffreyPetersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">mgnx:JeffreyPetersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromCollaborativeAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromCollaborativeAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromCollaborativeAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:ContractManufacturingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:ContractManufacturingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:ContractManufacturingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromRoyalityAgreementsMemberMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromRoyalityAgreementsMemberMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromRoyalityAgreementsMemberMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromGovernmentAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromGovernmentAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromGovernmentAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>mgnx:Segment</xbrli:measure></xbrli:unit><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:ASDHealthcareAndOncologySupplyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:ProventionBioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:ProventionBioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:ZaiLabLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:ZaiLabLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:CardinalHealthIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:ASDHealthcareAndOncologySupplyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:ZaiLabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:ProventionBioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mgnx:LaboratoryAndOfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mgnx:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mgnx:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mgnx:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:InventoryValuationReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:InventoryValuationReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:InventoryValuationReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:InventoryValuationReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:InventoryValuationReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:InventoryValuationReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:InventoryValuationReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mgnx:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mgnx:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:SynaffixBVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:SynaffixBVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:SynaffixBVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:DRIHealthcareAcquisitionsLPDRIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:DRIHealthcareAcquisitionsLPDRIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-08</xbrli:startDate><xbrli:endDate>2023-03-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mgnx:UndesignatedPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mgnx:UndesignatedPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-01</xbrli:startDate><xbrli:endDate>2017-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-01</xbrli:startDate><xbrli:endDate>2017-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="performanceobligation"><xbrli:measure>mgnx:performanceObligation</xbrli:measure></xbrli:unit><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-01</xbrli:startDate><xbrli:endDate>2017-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteClinicalSupplyAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteClinicalSupplyAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteClinicalSupplyAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteCommercialSupplyAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteCommercialSupplyAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteCommercialSupplyAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2022GileadCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:GileadMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2022GileadCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:GileadMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-14</xbrli:startDate><xbrli:endDate>2022-10-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2022GileadCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:GileadMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2022GileadCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:GileadMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2022GileadCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:GileadMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2022GileadCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:GileadMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:GileadMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:GileadFirstResearchProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:GileadMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:GileadFirstResearchProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2021ZaiLabAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2021ZaiLabAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2021ZaiLabAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2021ZaiLabAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-179"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2021ZaiLabAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2021ZaiLabAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2021ZaiLabAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ProventionLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV3279Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-01</xbrli:startDate><xbrli:endDate>2018-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ProventionLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV3279Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-184"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:AssetPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-01</xbrli:startDate><xbrli:endDate>2018-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-185"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:AssetPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-186"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:AssetPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-01</xbrli:startDate><xbrli:endDate>2022-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-187"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-01</xbrli:startDate><xbrli:endDate>2018-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-189"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:AssetPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-190"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:AssetPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-191"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:AssetPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-192"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:AssetPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-193"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-194"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:DRIHealthcareAcquisitionsLPDRIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-195"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-196"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromCMOAgreementsMemberMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-197"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromCMOAgreementsMemberMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-198"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromCMOAmendmentAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-199"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromCMOAmendmentAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-200"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromCMOAgreementsMemberMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromCMOAgreementsMemberMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromCMOAgreementsMemberMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:ProventionBioCMOAgreeemntMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:ProventionBioCMOAgreeemntMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-205"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromGrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromGrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromGrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromGrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:TwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-05-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:TwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-01</xbrli:startDate><xbrli:endDate>2017-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-01</xbrli:startDate><xbrli:endDate>2017-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:TwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:StockIncentivePlan2013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:StockIncentivePlan2013Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:StockIncentivePlan2023MemberMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:StockIncentivePlan2023MemberMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:StockIncentivePlan2023MemberMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-232"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-233"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-234"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-235"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">mgnx:DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-236"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">mgnx:DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">mgnx:TaxYear2025To2037Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-237"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">mgnx:IndefiniteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">mgnx:DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-238"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i69aaf560e98645139c7ed7af73a9eafe_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C.&#160;&#160;20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-K</ix:nonNumeric> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Mark One)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:7.844%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:89.956%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox" id="f-2">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3"><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="f-4">December 31</ix:nonNumeric>, 2023</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:7.844%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:89.956%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="f-5">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to &#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commission File Number </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-6">001-36112</ix:nonNumeric></span></div><div><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-7">MACROGENICS, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Exact name of registrant)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:46.993%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:47.142%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-8">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-9">06-1591613</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(State of organization)&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(I.R.S. Employer Identification Number)</span></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-10">9704 Medical Center Drive</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-11">Rockville</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-12">Maryland</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-13">20850</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Address of principal executive offices and zip code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-14">301</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">)&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-15">251-5172</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Registrant's telephone number)</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.222%"><tr><td style="width:1.0%"/><td style="width:37.245%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.193%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.262%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-16">Common Stock, par value $0.01 per share</ix:nonNumeric></span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-17">MGNX</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-18">Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(g) of the Act: None</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityWellKnownSeasonedIssuer" id="f-19">Yes</ix:nonNumeric>&#160; </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9745; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> No&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Exchange Act.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Yes&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityVoluntaryFilers" id="f-20">No</ix:nonNumeric>&#160;&#160;</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9745;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-21">Yes</ix:nonNumeric>&#160;&#160;&#160;</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9745;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> No&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-22">Yes</ix:nonNumeric>&#160;&#160;&#160;</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9745;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> No&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer a smaller reporting company, or an emerging growth company.&#160;&#160;See the definitions of "large accelerated filer," "accelerated filer", "smaller reporting company", and "emerging growth company"  in Rule 12b-2 of the Exchange Act.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"><tr><td style="width:1.0%"/><td style="width:22.294%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:44.618%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.447%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.113%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-23">Accelerated filer</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="f-24">&#9744;</ix:nonNumeric></span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="f-25">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:4pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.  </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-true" id="f-26">&#9745;</ix:nonNumeric></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt:fixed-false" id="f-27">&#9744;</ix:nonNumeric></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9744;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Yes&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" id="f-28">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> No&#160;&#160;&#160;</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9745;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate market value of the registrant's common stock, par value $0.01 per share, held by non-affiliates of the registrant on June&#160;30, <ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-29">2023</ix:nonNumeric>, the last business day of the registrant's most recently completed second fiscal quarter, was approximately $<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-5" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="6" id="f-30">322.5</ix:nonFraction> million based on the closing price of the registrant's common stock on the Nasdaq Global Select Market on that date.&#160;&#160;Exclusion of shares held by any person should not be construed to indicate that such person possesses the power, direct or indirect, to direct or cause the direction of management or policies of the registrant, or that such person is controlled by or under common control with the registrant.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of shares of the registrant's common stock outstanding on March&#160;1, 2024 was <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-31">62,432,013</ix:nonFraction>.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="f-32" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Portions of MacroGenics, Inc.'s definitive proxy statement for the 2024 annual meeting of stockholders are incorporated by reference into Part III of this Annual Report.</span></div></ix:nonNumeric><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i69aaf560e98645139c7ed7af73a9eafe_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MACROGENICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANNUAL REPORT ON FORM 10-K</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-bottom:12pt;text-align:center"><span><br/></span></div><div style="margin-bottom:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:87.170%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i69aaf560e98645139c7ed7af73a9eafe_13">PART I</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i69aaf560e98645139c7ed7af73a9eafe_16">Business</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i69aaf560e98645139c7ed7af73a9eafe_19">Risk Factors</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1B</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i69aaf560e98645139c7ed7af73a9eafe_22">Unresolved Staff Comments</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1C</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i69aaf560e98645139c7ed7af73a9eafe_822">Cybersecurity</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i69aaf560e98645139c7ed7af73a9eafe_25">Properties</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i69aaf560e98645139c7ed7af73a9eafe_28">Legal Proceedings</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i69aaf560e98645139c7ed7af73a9eafe_31">Mine Safety Disclosures</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i69aaf560e98645139c7ed7af73a9eafe_34">PART II</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 5</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i69aaf560e98645139c7ed7af73a9eafe_37">Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 6</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i69aaf560e98645139c7ed7af73a9eafe_40">Reserved</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 7</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i69aaf560e98645139c7ed7af73a9eafe_43">Management's Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 7A</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i69aaf560e98645139c7ed7af73a9eafe_64">Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 8</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i69aaf560e98645139c7ed7af73a9eafe_67">Financial Statements and Supplementary Data</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i69aaf560e98645139c7ed7af73a9eafe_70">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9A</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i69aaf560e98645139c7ed7af73a9eafe_73">Controls and Procedures</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9B</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i69aaf560e98645139c7ed7af73a9eafe_76">Other Information</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9C</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="#i69aaf560e98645139c7ed7af73a9eafe_79">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i69aaf560e98645139c7ed7af73a9eafe_85">PART III</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 10</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i69aaf560e98645139c7ed7af73a9eafe_88">Directors, Executive Officers and Corporate Governance</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 11</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i69aaf560e98645139c7ed7af73a9eafe_91">Executive Compensation</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 12</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i69aaf560e98645139c7ed7af73a9eafe_94">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 13</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i69aaf560e98645139c7ed7af73a9eafe_97">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 14</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i69aaf560e98645139c7ed7af73a9eafe_100">Principal Accountant Fees and Services</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i69aaf560e98645139c7ed7af73a9eafe_103">PART IV</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 15</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i69aaf560e98645139c7ed7af73a9eafe_106">Exhibits and Financial Statement Schedules</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 16</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i69aaf560e98645139c7ed7af73a9eafe_109">Form 10-K Summary</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i69aaf560e98645139c7ed7af73a9eafe_112">Signatures</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i69aaf560e98645139c7ed7af73a9eafe_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORWARD-LOOKING STATEMENTS</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This report includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements include statements that may relate to our plans, objectives, goals, strategies, future events, future revenues or performance, capital expenditures, financing needs and other information that is not historical information. Many of these statements appear, in particular, under the headings "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in this Annual Report on Form 10-K. Forward-looking statements can often be identified by the use of terminology such as "subject to", "believe", "anticipate", "plan", "expect", "intend", "estimate", "project", "may", "will", "should", "would", "could", "can", the negatives thereof, variations thereon and similar expressions, or by discussions of strategy.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All forward-looking statements, including, without limitation, our examination of historical operating trends, are based upon our current expectations and various assumptions. We believe there is a reasonable basis for our expectations and beliefs, but they are inherently uncertain. We may not realize our expectations, and our beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements. The following uncertainties and factors, among others (including those set forth under "Risk Factors"), could affect future performance and cause actual results to differ materially from those matters expressed in or implied by forward-looking statements:</span></div><div style="margin-bottom:3pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans to develop and commercialize our product candidates;</span></div><div style="margin-bottom:3pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the outcomes of our ongoing and planned clinical trials and the timing of those outcomes, including when clinical trials will be initiated or completed, enrollment of trials, and when data will be reported or regulatory filings will be made;</span></div><div style="margin-bottom:3pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing of and our ability to obtain and maintain regulatory approvals for our product candidates and the labeling for any approved products;</span></div><div style="margin-bottom:3pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;</span></div><div style="margin-bottom:3pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to raise additional capital through the capital markets or through one or more corporate partnerships, equity offerings, debt financings, collaborations, licensing arrangements or asset sales;</span></div><div style="margin-bottom:3pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding product candidates currently being developed by our collaborators;</span></div><div style="margin-bottom:3pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">&#8226; the compromise of our or our third parties&#8217; information technology systems and resultant costs, disruptions in our operations or related impact on our reputation;</span></div><div style="margin-bottom:3pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to enter into new collaborations or to identify additional products or product candidates with significant commercial potential that are consistent with our commercial objectives;</span></div><div style="margin-bottom:3pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential benefits and future operation of our existing collaborations; </span></div><div style="margin-bottom:3pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to recover the investment in our manufacturing capabilities;</span></div><div style="margin-bottom:3pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the rate and degree of market acceptance and clinical utility of our products;</span></div><div style="margin-bottom:3pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our commercialization, marketing and manufacturing capabilities and strategy;</span></div><div style="margin-bottom:3pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">significant competition in our industry;</span></div><div style="margin-bottom:3pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs of litigation and the failure to successfully defend lawsuits and other claims against us and our expectations regarding the outcome of any regulatory or legal proceedings;</span></div><div style="margin-bottom:3pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">economic, political and other risks associated with our international operations;</span></div><div style="margin-bottom:3pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to receive research funding and achieve anticipated milestones under our collaborations;</span></div><div style="margin-bottom:3pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to protect and enforce patents and other intellectual property;</span></div><div style="margin-bottom:3pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs of compliance and our failure to comply with new and existing governmental regulations including, but not limited to, tax regulations;</span></div><div style="margin-bottom:3pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">loss or retirement of key members of management;</span></div><div style="margin-bottom:3pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to successfully execute our growth strategy, including any delays in our planned future growth;</span></div><div style="margin-bottom:3pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our failure to maintain effective internal controls; and</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the severity and duration of the impact of a global pandemic on our business, operations, clinical programs, manufacturing, financial results and other aspects of our business.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consequently, forward-looking statements speak only as of the date that they are made and should be regarded solely as our current plans, estimates and beliefs. You should not place undue reliance on forward-looking statements. We cannot guarantee future results, events, levels of activity, performance or achievements. Except as required by law, we do not undertake and specifically decline any obligation to update, republish or revise forward-looking statements to reflect future events or circumstances or to reflect the occurrences of unanticipated events.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i69aaf560e98645139c7ed7af73a9eafe_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div id="i69aaf560e98645139c7ed7af73a9eafe_16"></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1.&#160;&#160;&#160;&#160;BUSINESS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Except as otherwise indicated herein or as the context otherwise requires, references in this annual report on Form 10-K to "MacroGenics," the "company," "we," "us" and "our" refer to MacroGenics, Inc. and its consolidated subsidiaries.</span><span style="color:#1f497d;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">MacroGenics</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">, the MacroGenics logo, DART</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">, TRIDENT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">, MARGENZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> and the phrases Breakthrough Biologics, Life-Changing Medicines&#174; and Developing Breakthrough Biologics, Life-Changing Medicines</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> are our trademark</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">s. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> The other trademarks, trade names and service marks appearing in this report are the property of their respective owners.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Overview</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer. We have a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. These candidates are being evaluated in clinical trials sponsored by us or our collaborators or are in preclinical development. Our clinical product candidates include multiple oncology programs which have either been created using our proprietary, antibody-based technology platforms or enabled through our technology licensing arrangements with other companies. We believe our product candidates have the potential, if approved for marketing by regulatory authorities, to have a meaningful effect on treating patients' unmet medical needs as monotherapy or, in some cases, in combination with other therapeutic agents. To date, three products originating from our pipeline of proprietary or partnered product candidates have received U.S. Food and Drug Administration (FDA) approval.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our lead pipeline program is vobramitamab duocarmazine (vobra duo), an antibody-drug conjugate (ADC) that targets B7-H3, a molecule in the B7 family of immune regulator proteins that is widely expressed by several different tumor types. In addition, we are developing MGC026, a B7-H3-based ADC that delivers a different cytotoxic payload than that of vobra duo. Beyond these two B7-H3-targeted ADCs, we have historically pursued development of enoblituzumab, an Fc-optimized monoclonal antibody (mAb) that also targets B7-H3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Enoblituzumab is currently being studied in an investigator-sponsored trial.  </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beyond our B7-H3-targeted product candidates, our pipeline includes molecules that target programmed cell death protein 1 (PD-1), a protein that is important in the regulation of the immune system&#8217;s response to cancer. Our clinical pipeline includes two product candidates based on our proprietary, bispecific DART technology that co-engage both PD-1 and other checkpoint inhibitor molecules. These candidates include lorigerlimab, which targets PD-1 and CTLA-4, or cytotoxic T-lymphocyte-associated protein 4, and tebotelimab, which targets PD-1 and LAG-3, or lymphocyte-activation gene 3. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we are developing MGD024, a next-generation bispecific DART molecule that engages CD3 on immune effector cells to kill CD123-expressing cancer cells in certain hematological malignancies, including acute myeloid leukemia (AML), in collaboration with a partner. We are developing several preclinical molecules as well, including MGC028, an ADC that targets ADAM9, a cell surface protein over-expressed in several solid tumor types.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our partners are developing or commercializing product candidates for which we retain certain economic rights. These include two products approved by the FDA: ZYNYZ&#174; (retifanlimab-dlwr), an anti-PD-1 mAb that we out-licensed; and TZIELD&#174; (teplizumab-mzwv), an anti-CD3 mAb that we sold to a partner.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, we and our commercialization partner commenced U.S. marketing of MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist mAb we developed that is indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finally, in addition to manufacturing antibody-based products and product candidates in our commercial-scale facility for our own needs, we provide outsourced contract development and manufacturing services to a small number of companies, including collaboration partners.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have created our product candidates based on the following antibody-based technologies:</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">ADC platforms, which we have licensed from collaboration partners to leverage third-party proprietary linker payloads, and which link mAbs that specifically target cancer cells with cytotoxins that are designed to trigger cancer cell death. </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">Multi-specific platforms, which enable us to design antibodies that can bind to two (in the case of our bispecific DART product candidates) or more distinct targets, each with antibody-like specificity, with the goal of creating a </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">more significant biological effect than binding any one of the targets as with an antibody or two or more of them separately as a combination. We have specifically utilized our DART platform to generate product candidates for use in the following modalities:</span></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.46pt">Bispecific checkpoints</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We leverage our proprietary DART platform to enable simultaneous targeting of multiple co-inhibitory receptors or checkpoints, such as those involved in inhibiting T-cell responses. Targeting two immunoregulatory pathways, such as two checkpoints in a single molecule, affords the clinical benefit of the combination together with the potential for improved efficacy and/or safety, as well as advantages in manufacturing, simplified clinical development and enhanced patient convenience.</span></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.46pt">Next-Generation T-Cell Engagers.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We have extensive experience applying our proprietary multi-specific DART and TRIDENT&#174; platforms to develop molecules that redirect T-cell activation and killing which: (1) recognize and bind to structures expressed on a cancer cell, (2) recruit all types of cytotoxic, or cell killing, T cells, irrespective of their ability to recognize cancer cells, and (3) trigger T-cell activation, expansion, and cell-killing mechanisms to destroy a cancer cell.  MacroGenics&#8217; next-generation T-cell engagers incorporate a CD3 component that is designed to minimize cytokine-release syndrome (CRS), a potentially life-threatening toxicity, while increasing the magnitude of antitumor activity with a longer half-life to permit intermittent dosing.</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">Fc Optimization platform, which introduces certain mutations into the Fc domain of a mAb to modulate antibody interaction with immune effector cells to enhance the killing of cancer cells.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our continued strategy is to be a fully-integrated biotechnology company leading in the discovery, development, manufacturing and commercialization of antibody-based biologics for the treatment of patients with cancer.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Pipeline of Oncology Product Candidates for Which We Retain Commercial Rights</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below depicts the status of our diverse portfolio of oncology product candidates for which we retain commercialization or other important rights in the U.S. or more broadly:</span></div><div><img src="mgnx-20231231_g1.jpg" alt="Clinical Pipeline.jpg" style="height:245px;margin-bottom:5pt;vertical-align:text-bottom;width:681px"/></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;The &#8220;Help Elucidate &amp; Attack Longitudinally&#8221; (HEAT) study is an investigator-sponsored trial. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;MacroGenics currently has no ongoing tebotelimab studies.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">B7-H3 Programs</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have three clinical-stage programs, vobra duo, MGC026 and enoblituzumab, that target B7-H3 (CD276), an immune checkpoint molecule that is overexpressed in cancer tissues while showing limited expression in normal tissues. B7-H3 is a member of the B7 family of immune regulator proteins that is widely expressed by different tumor types and may play a key role in regulating the immune response to various cancers. There are no currently approved therapeutic agents directed against B7-H3.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vobramitamab Duocarmazine</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vobra duo (previously known as MGC018) is an investigational ADC with a cleavable peptide linker designed to deliver a DNA-alkylating duocarmycin payload to dividing and non-dividing cells on solid tumors that express B7-H3. The </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">underlying ADC technology was licensed from Byondis B.V. (Byondis). After completing a dose escalation study in 2020, we conducted a </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase 1/2 dose expansion study of v</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">obra duo</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in patients with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">metastatic castration-resistant prostate cancer (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mCRPC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">non-small cell lung cancer (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NSCLC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, melanoma, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">squamous cell carcinoma of the head and neck (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SCCHN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">triple negative breast cancer (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TNBC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The purpose of this study was to evaluate the safety and tolerability, pharmacokinetics, pharmacodynamics and preliminary antitumor activity of the molecule. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preliminary clinical data in mCRPC patients treated with vobra duo from the Phase 1/2 dose expansion study was presented at the 2021 European Society of Medical Oncology (ESMO) Annual Meeting. Based on this data, we initiated the TAMARACK Phase 2 study in late 2022. This study focuses on mCRPC patients who have had prior exposure to a taxane and at least one androgen receptor axis-targeted, or ARAT, agent (including abiraterone, enzalutamide or apalutimide), and a PARP (poly adenosine diphosphate-ribose polymerase) inhibitor, if appropriate. The TAMARACK study is designed to evaluate 100 patients across two experimental arms in which participants receive vobra duo at either 2.0 mg/kg or 2.7 mg/kg once every four weeks (Q4W), rather than the 3.0 mg/kg dose received every three weeks (Q3W) in the earlier dose expansion study. We completed enrollment of the study in the fourth quarter of 2023, having enrolled a total of 177 patients, exceeding the targeted number of patients. We expect to provide a clinical update in the second quarter of 2024 and potentially again later in 2024.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to expand the tumor types being evaluated in the TAMARACK study by recruiting patients with NSCLC, small cell lung cancer (SCLC), melanoma, SCCHN and anal cancer. We expect to initiate dosing in these additional cohorts in mid-2024.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finally, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> early 2022, w</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e initiated a Phase 1/2 dose escalation study of v</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">obra duo</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in combination with lorigerlimab</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a bispecific DART molecule designed to block PD-1 and CTLA-4, in patients with solid tumors. This study is ongoing.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">MGC026</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MGC026 is an investigational ADC incorporating a B7-H3-targeting antibody and a novel topoisomerase I inhibitor-based linker-payload, SYNtecan E&#8482;. This cleavable linker-payload is based on exatecan, a clinically validated and potent camptothecin, and is site-specifically conjugated using the GlycoConnect&#8482; technology developed by our collaboration partner, Synaffix (a Lonza company). </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recently initiated a Phase 1 dose escalation study of MGC026 in patients with advanced solid tumors.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With distinct mechanisms of action, vobra duo and MGC026 may address different cancers, tumor stages, or be used in combination with alternate agents or potentially with one another to enhance their clinical utility. We view MGC026, with its topoisomerase I inhibition strategy, as a complementary approach to targeting B7-H3 beyond vobra duo and as an additional, potentially valuable tool in our therapeutic repertoire.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In preclinical studies, MGC026 exhibited a favorable profile, with potent in vivo activity toward B7-H3-expressing tumor xenografts representing a range of cancer indications. MGC026 was tolerated in cynomolgus monkeys, a relevant toxicology model, at exposure levels exceeding those likely required for antitumor activity in patients. We plan to present MGC026 preclinical data at the American Association for Cancer Research (AACR) Annual Meeting in April 2024. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Enoblituzumab</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Enoblituzumab (previously known as MGA271) is an investigational mAb that targets B7-H3 and has been engineered using our Fc Optimization platform. A Phase 2 study evaluating enoblituzumab in combination with either retifanlimab (anti-PD-1 monoclonal antibody) or tebotelimab (PD-1 &#215; LAG-3 bispecific DART molecule) in the first-line treatment of patients with recurrent or metastatic SCCHN was discontinued in July 2022 after an internal review of safety data, as previously disclosed. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on results presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting and subsequently published in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nature Medicine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> from a Phase 2 investigator-sponsored study of enoblituzumab in men with prostate cancer, our collaborators at multiple academic institutions recently initiated the HEAT study. This is an investigator-sponsored, randomized Phase 2 clinical trial that will evaluate the activity of neoadjuvant enoblituzumab given prior to radical prostatectomy in up to 219 men with high-risk localized prostate cancer.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Immune Checkpoint Inhibitors</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Checkpoint inhibition has become an important staple of oncology. Our clinical pipeline includes three product candidates in clinical development that target checkpoint molecules for the potential treatment of a broad range of solid tumors. These candidates include two bispecific DART product candidates that co-engage PD-1 and other checkpoint molecules and an anti-PD-1 mAb that we have out-licensed to a partner.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lorigerlimab </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approved mAbs that target the immune checkpoints PD-1 and CTLA-4 have shown enhanced clinical antitumor activity when given in combination in various cancers, including renal cell carcinoma and NSCLC with high tumor mutational burden. Lorigerlimab (previously known as MGD019) is an investigational, bispecific tetravalent DART molecule designed to enable simultaneous and/or independent blockade of PD-1 and CTLA-4, with potentially enhanced CTLA-4 blockade on T cells co-expressing these immune checkpoint molecules.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Data from a Phase 1/2 dose escalation study of lorigerlimab in patients with advanced solid tumors was reported at the 2020 ESMO Annual Meeting. More recently, we evaluated lorigerlimab in a Phase 1/2 dose expansion study in patients with mCRPC, microsatellite stable colorectal cancer (MSS CRC), melanoma and checkpoint-na&#239;ve NSCLC, and reported on preliminary data at the ASCO Genitourinary Cancers Symposium in February 2023. As of the December 12, 2022 data cut-off, 118 patients were enrolled at the dose of 6.0 mg/kg, administered intravenously Q3W. Confirmed objective responses were observed across the histology-specific cohorts; preliminary efficacy results for mCRPC were presented in the poster.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Preliminary Safety Results</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The safety analysis is based on 127 patients who received lorigerlimab at a dose of 6 mg/kg Q3W, including 118 enrolled in the four dose expansion cohorts plus nine patients from dose escalation. Median exposure was 14.4 weeks (range: 1.9 - 100.1 weeks) with a median of four infusions administered per patient. Twenty-four patients remained on lorigerlimab as of the December 12, 2022 data cut-off; 103 discontinued for the following reasons: progressive disease (PD) (n=66), adverse events (AE) (n=31), patient/physician decision (n=5), or death due to PD (n=1).</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results demonstrated a manageable overall safety profile. Treatment-related adverse events (TRAEs) of any grade occurred in 86.6% of patients, with the most common among them (&#8805;15%) being fatigue, rash, pruritus, hypothyroidism, and pyrexia. Rates of grade &#8805;3 TRAEs and immune-related AEs were 35.4% and 7.9%, respectively. AEs resulted in treatment discontinuation in 25.2% of patients. There were no fatal AEs related to lorigerlimab.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Preliminary Anti-tumor Activity in mCRPC Cohort</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As of the December 12, 2022 data cut-off, 42 patients had been enrolled in the mCRPC expansion cohort. Patients had previously received a median of two prior therapies (range: 1 &#8211; 9) for advanced disease, with 35 patients (83.3%) having received docetaxel and 34 patients (81.0%) having received ARAT therapy. The median exposure to lorigerlimab was 19.2 weeks (range: 3.3 - 55.1 weeks), with a median of five infusions administered per patient.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A total of 35 patients with mCRPC had measurable soft tissue disease per RECIST v1.1 at study entry. Nine of the 35 patients (25.7%) achieved confirmed partial responses (cPR). The median duration of response for these nine patients was 4.6 months (range: 2.8 &#8211; 8.6+ months), with four patients remaining on lorigerlimab as of data cut-off. Among the other five patients who had achieved cPR, four discontinued due to unrelated AEs, and one patient discontinued due to physician decision.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reductions in prostate-specific antigen (PSA) levels of &#8805; 50% were observed in 12 of 42 patients (28.6%), and 9 of the 12 maintained PSA50 response &#8805; 3 months. Nine of 42 patients (21.4%), including the nine who achieved cPR, had reductions in their PSA levels of &#8805; 90% as of the data cut-off.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the above data, we initiated the randomized Phase 2 LORIKEET study of lorigerlimab in combination with docetaxel vs. docetaxel in second-line, chemotherapy-na&#239;ve mCRPC patients in the second half of 2023. A total of 150 patients are planned to be randomized 2:1. The current study design includes a primary study endpoint of radiographic progression-free survival (rPFS). We plan to provide a trial update in the second half of 2024.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Tebotelimab</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tebotelimab (previously known as MGD013) is an investigational, first-in-class bispecific, tetravalent DART molecule targeting PD-1 and LAG-3. At this time, we have no active/ongoing studies of tebotelimab. We have engineered tebotelimab to concomitantly or independently bind to PD-1 and LAG-3 and disrupt these non-redundant inhibitory pathways to further restore exhausted T-cell function. Data from prior dose expansion studies of tebotelimab have previously been reported; in addition, a combination trial with enoblituzumab in patients with SCCHN was initiated, but terminated in July 2022 after an internal review of safety data, as previously disclosed.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our November 2018 license and collaboration agreement with Zai Lab Limited (Zai Lab Limited and Zai Lab US LLC, either singularly or collectively are referred to herein as Zai Lab), Zai Lab led regional studies evaluating tebotelimab in various indications in their territory. In November 2023, Zai Lab provided notice of termination of this agreement, effective as of May 2024.</span></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">IMGC936 </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IMGC936</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is an ADC that targets ADAM9 (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">d</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">isintegrin </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nd </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">m</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">etalloprotease domain 9) with a maytansinoid payload. IMGC936 was advanced under a co-development agreement with ImmunoGen, Inc. (ImmunoGen, now part of AbbVie). Under the 50/50 collaboration, ImmunoGen led clinical development and completed Phase 1 dose escalation and dose expansion studies. Neither MacroGenics nor AbbVie intends to further pursue development of IMGC936, as the molecule did not achieve our pre-established clinical safety and efficacy benchmarks.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">MGC028</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MGC028 is the second of our ADC molecules incorporating Synaffix&#8217;s novel glycan-linked topoisomerase I inhibitor, and the second ADAM9-targeted ADC that we have pursued. ADAM9 is a member of the ADAM family of multifunctional type 1 transmembrane proteins that play a role in tumorigenesis and cancer progression and is overexpressed in multiple cancers, making it an attractive target for cancer treatment.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In preclinical studies, MGC028 exhibited specific, dose-dependent in vivo antitumor activity toward ADAM9-positive CDX and PDX models, including in gastric, lung, pancreatic, colorectal, and head and neck cancers. MGC028 was well tolerated in a repeat-dose non-human primate toxicology study, up to 55 mg/kg, the highest dose level tested. Observations were limited to mild, reversible increases in liver enzymes, without microscopic correlates, and decreased lymphoid cellularity in the thymus. Of note, ocular toxicities that are typically seen with maytansinoid payloads &#8211; and which were observed in our IMGC936 cynomolgus toxicology study - were not observed in the MGC028 pilot toxicology study.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">We plan to present preclinical MGC028 data at the AACR Annual Meeting in April 2024. We currently anticipate submitting an investigational new drug (IND) application for MGC028 by the end of 2024.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Partnered Programs</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the molecules identified above, we have out-licensed various product candidates for which we retain certain economic rights. These molecules provide potential sources of future cash flow and platform validation and are identified below:</span></div><div><img src="mgnx-20231231_g2.jpg" alt="Partnered Pipeline (updated_.jpg" style="height:265px;margin-bottom:5pt;vertical-align:text-bottom;width:681px"/></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;We entered a risk-sharing collaboration with Eversana in November 2020, under which we book U.S. sales and Eversana leads execution of U.S. commercialization of MARGENZA. For all other currently partnered programs for which a license option has been exercised, the partner would book any future worldwide sales, if approved, and we would be entitled to receive milestones and royalties.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketed Products</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">MARGENZA</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our commercial partner, Eversana Life Science Services, LLC (Eversana), are currently marketing MARGENZA (margetuximab-cmkb), in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">metastatic disease. Margetuximab is an Fc-engineered mAb that targets the HER2 oncoprotein. HER2 is a protein found on the surface of some cancer cells that promotes growth and is associated with aggressive disease and poor prognosis.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our November 2018 license and collaboration agreement, Zai Lab received the rights to develop margetuximab in mainland China, Hong Kong, Macau and Taiwan. In August 2023, the China National Medical Products Administration approved the New Drug Application (NDA) for margetuximab for patients with pretreated metastatic HER2-positive breast cancer. In November 2023, Zai Lab provided notice of termination of this agreement, effective as of May 2024.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adverse reactions occurring in greater than twenty percent of patients with MARGENZA in combination with chemotherapy were fatigue/asthenia (57%), nausea (33%), diarrhea (25%), and vomiting (21%). The MARGENZA U.S. Prescribing Information has a BOXED WARNING for left ventricular dysfunction and embryo-fetal toxicity. In addition, MARGENZA can cause infusion-related reactions (IRRs). IRRs occurred in 13% of patients treated with MARGENZA, with the majority reported as Grade 2 or less. Grade 3 IRRs occurred in 1.5% of patients.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ZYNYZ</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, we licensed retifanlimab (previously known as MGA012), a mAb targeting PD-1, to Incyte Corporation (Incyte) under a global collaboration and license agreement (Incyte Agreement); we retain the right to develop the molecule in combination with product candidates from our pipeline. In March 2023, the FDA approved ZYNYZ (retifanlimab-dlwr) for the treatment of adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma. ZYNYZ is marketed by Incyte. Under the terms of the Incyte Agreement, we are eligible to receive up to $650 million in remaining development, regulatory and commercial milestones from Incyte. In addition, we are eligible to receive tiered royalties of 15% to 24% on any global net sales of the product.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incyte has stated it is pursuing development of retifanlimab in other potentially registration-enabling studies, including in patients with squamous carcinoma of the anal canal, microsatellite instability-high, or MSI-high, endometrial cancer and NSCLC. Incyte is also pursuing development of retifanlimab in combination with multiple product candidates from its pipeline.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TZIELD</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, we entered into an asset purchase agreement (Provention APA) with Provention Bio, Inc., subsequently acquired by Sanofi S.A. (Sanofi), pursuant to which they acquired our interest in teplizumab, a mAb we had been developing for the treatment of type 1 diabetes. Teplizumab was granted Breakthrough Therapy Designation by the FDA and PRIority MEdicines (PRIME) designation by the European Medicines Agency (EMA).</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2022, the U.S. FDA approved TZIELD (teplizumab-mzwv) to delay the onset of Stage 3 type 1 diabetes (T1D) in adult and pediatric patients aged 8 years and older with Stage 2 T1D, which triggered a $60.0 million milestone payment to us. Under the Provention APA, Sanofi has a remaining obligation to pay us contingent milestone payments totaling $105 million upon the achievement of certain regulatory approval milestones, in addition to contingent milestone payments totaling $225 million upon the achievement of certain sales milestones. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023, we sold our royalty interest in TZIELD to a wholly-owned subsidiary of DRI Healthcare Trust for $100.0 million. Such royalty interest was subsequently acquired by Sanofi. In July 2023, Sanofi reported that the PROTECT placebo-controlled study investigating TZIELD in patients with newly-diagnosed stage 3 T1D met its primary endpoint, having demonstrated preservation of beta cell function. This positive study outcome triggered payment of a $50.0 million milestone to us by Sanofi. We retain the right to receive a 50% share of the royalty on global net sales above a certain annual threshold. In addition, we are eligible to receive $50.0 million if TZIELD achieves a certain level of net sales.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">PRV-3279</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, we entered into a license agreement with Provention (now Sanofi) pursuant to which we granted them exclusive global rights for the purpose of developing and commercializing PRV-3279 (previously known as MGD010), a CD32B &#215; CD79B DART molecule being developed for the treatment of autoimmune indications. Sanofi is initially developing PRV-3279 for the interception of systemic lupus erythematosus (SLE), a chronic autoimmune disorder characterized by an abnormal overactivation of B cells and subsequent pathologic production of auto-antibodies.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provention disclosed in the first quarter of 2022 that they had initiated a Phase 2a trial in SLE of PRV-3279. The PREVAIL-2 study is a Phase 2a proof-of-concept (POC) study in moderate-to-severe SLE patients. Patients are induced into response with a short course of corticosteroids, and then monitored for relapse, after randomization to either PRV-3279 or placebo treatment. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">T-cell Engaging Bispecific DART Molecules</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are developing clinical and preclinical bispecific DART molecule that can simultaneously target T-cells and tumor cell surface antigens to engage and promote redirected T-cell killing of cancer cells. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">MGD024</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MGD024 is an investigational, next-generation, bispecific CD123 &#215; CD3 DART molecule designed to engage CD3 expressed on immune effector cells, such as T cells, to kill CD123-expressing cancer cells for the potential treatment of certain hematologic malignancies, including AML. MGD024 was designed to minimize cytokine-release syndrome, while maintaining anti-tumor cytolytic activity, and permitting intermittent dosing through a longer half-life. CD123, the interleukin-3 receptor alpha chain, is widely overexpressed in various hematologic malignancies, including AML and myelodysplastic syndrome (MDS), making it an attractive therapeutic target. Various drugs have been developed to target CD123, but none have received FDA approval for the treatment of AML. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A Phase 1 dose escalation study of MGD024 in patients with CD123-positive hematologic malignancies was initiated in July 2022 and is ongoing.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022, we and Gilead Sciences, Inc. (Gilead) entered into an exclusive option and collaboration agreement (Gilead Agreement) to develop and commercialize MGD024 and create up to two separate bispecific cancer target research programs using our DART platform and undertake their early development. Under the Gilead Agreement, we will continue the ongoing phase 1 trial for MGD024 according to a development plan, during which Gilead will have the right to exercise an option granted to them to obtain an exclusive license to develop and commercialize MGD024 and other bispecific antibodies of ours that bind CD123 and CD3 (CD123 Option). The agreement also grants Gilead the right, within the first two years, to nominate a bispecific cancer target set for up to two research programs conducted by us and to exercise separate options to obtain an exclusive license for the development, commercialization and exploitation of molecules created under each research program (Research Program Option). </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the Gilead Agreement, Gilead paid us a non-refundable upfront payment of $60.0 million, and we will be eligible to receive up to $1.7 billion in target nomination fees and option fees, as well as development, regulatory and commercial milestones, assuming Gilead exercises the CD123 Option and Research Program Option, successfully develops and commercializes MGD024 or other CD123 products developed under the agreement, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and assuming products result from the two additional </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">research programs. Assuming exercise of the CD123 Option, we will also be eligible to receive tiered, low double-digit royalties on worldwide net sales of MGD024 (or other CD123 products developed under the agreement) and assuming exercise of the Research Program Option, a flat royalty on worldwide net sales of any products resulting from the two research programs.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Early Bispecific Research Program</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2023, Gilead nominated the first of two potential research programs under the Research Program Option as part of the Gilead Agreement, leveraging our DART and TRIDENT platforms for generating bispecific antibodies. This nomination granted Gilead an exclusive option to license worldwide rights to the research program, upon achievement of a pre-defined preclinical milestone.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">HIV DART Molecules</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are conducting clinical studies of MGD014 and MGD020 under a contract awarded to us in September 2015 by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). These bispecific DART molecules are designed to target the viral envelope (Env) protein of human immunodeficiency virus (HIV) infected cells and CD3 on T cells to redirect the immune system's T cells to kill HIV-infected cells. A Phase 1 study of MGD014 in persons with HIV maintained on antiretroviral therapy has been completed and a Phase 1 study of MGD020 alone and combined with MGD014 was initiated in 2022. The completion of this contract is anticipated by the end of 2024.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ancillary Contract Development and Manufacturing Services</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to manufacturing antibody-based products and product candidates in our commercial-scale facility for our own needs, we provide outsourced contract development and manufacturing services to a small number of clients, including </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">collaboration partners.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Incyte</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, we entered into an agreement with Incyte to provide manufacturing services to produce certain Incyte bulk drug substance over a three-year period. Under the terms of this agreement, we received an upfront payment of $10.0 million and are eligible to receive annual fixed payments paid quarterly over the term of the contract totaling $14.4 million. We will also be reimbursed for materials used to manufacture product as well as other costs incurred to provide manufacturing </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">services. In July 2022, we and Incyte executed an amendment to the agreement which extended the term for one year and provided for an additional annual fixed payment of $5.1 million.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provention Bio, Inc.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, we entered into an agreement with Provention (now part of Sanofi) to provide manufacturing services to produce certain Provention bulk drug substance. Under the terms of this agreement, we received an upfront payment and payments in accordance with the manufacturing schedule and are reimbursed for materials used to manufacture product as well as other costs incurred to provide manufacturing services.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Emergent BioSolutions</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2023 and December 2023, we entered into agreements with Emergent BioSolutions (Emergent) to provide manufacturing services to produce certain Emergent bulk drug substances. Under the terms of the agreements, we receive payments in accordance with the manufacturing schedule and are reimbursed for materials used to manufacture product, as well as other costs incurred to provide manufacturing services.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Therapeutic Area Focus: Cancer</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cancer is a broad group of diseases in which cells divide and grow in an uncontrolled manner, forming malignancies that can invade other parts of the body. In normal tissues, the rates of new cell growth and cell death are tightly regulated and kept in balance. In cancerous tissues, this balance is disrupted as a result of mutations, causing unregulated cell division or proliferation that leads to tumor formation and growth. While tumors can grow slowly or rapidly, the dividing cells will nevertheless accumulate, and the normal organization of the tissue will become disrupted. Cancers subsequently can spread throughout the body by processes known as invasion and metastasis. Once cancer spreads to sites beyond the primary tumor, it generally becomes more difficult to treat and may be incurable. Cancer cells that arise in the lymphatic system and bone marrow are referred to as hematological malignancies. Cancer cells that arise in other tissues or organs are referred to as solid tumors. Cancer can arise in virtually any part of the body, with the most common types arising in the prostate gland, breast, lung, colon and skin. Cancer is the second leading cause of death in the United States, exceeded only by heart disease. An increasing number of people are also living longer with cancer.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our platforms position us very well strategically to actively develop approaches for the treatment of both solid tumors and hematologic malignancies.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Platforms and Technology Expertise</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We apply our understanding of disease biology, immune-mediated mechanisms and next-generation antibody technologies to design specifically targeted antibody-based product candidates based on our DART, Fc Optimization and licensed ADC platforms. Through these platforms, we have designed antibody-based product candidates that have the potential to improve on standard treatments by having one or more of the following attributes: (1) multiple specificities; (2) increased abilities to interact with the body's immune system to fight tumors; (3) capacity to bind more avidly to antigen targets; (4) increased potency; (5) reduced immunogenicity or (6) the ability to target and kill cancer cells that are resistant to standard treatments. Moreover, these technology platforms are complementary in certain cases and can be combined to address the complex biology of cancer.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">DART and TRIDENT Platforms: Our Proprietary Approach to Engineer Multi-Specific Antibodies</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use our DART platform to create derivatives of antibodies with the ability to bind to two distinct targets instead of a single target as with traditional mAbs. DART product candidates are therefore bispecific. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because cancer cells have developed ways to escape the immune system, we have created DART molecules, which are alternative antibody-like structures with more potent immune properties than the parent antibody molecules from which they are derived. The two variable regions of an antibody are mono-specific and are able to target only a single type structural component of an antigen. For many years, researchers have sought to create recombinant molecules that are capable of targeting two antigens or epitopes (i.e., specific part of an antigen bound by the antibody) within the same molecule. The challenges in creating such molecules have been the instability of the resulting bispecific molecules and their inherently short half-lives, as well as the inefficiencies in manufacturing these compounds. We believe our DART platform has overcome these engineering challenges by incorporating proprietary covalent di-sulfide linkages and particular amino acid sequences that efficiently pair the chains of the DART molecule. This is designed to provide a structure with enhanced manufacturability, long-term structural stability and the ability to tailor the half-lives of the DART molecules to their clinical needs. This engineered antibody-like protein has a compact and stable structure and enables the targeting of two different antigens with a single recombinant molecule.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The DART platform has been specifically engineered to accommodate virtually any variable region sequence with predictable expression, folding and antigen recognition. We believe our multi-specific platforms may provide a significant advantage over current biological interventions in cancer, autoimmune disorders and infectious disease by enabling a range of modalities.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the ability to tailor a DART molecule's valency, we have the capacity to modify the strength by which the binding sites attach to their targets and the molecule's half-life in the blood circulation after delivery to a patient. Furthermore, when an Fc domain is coupled with a DART molecule, additional changes can be included that can modulate the DART molecule's engagement with different immune cells.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently developing product candidates using our DART technology, including lorigerlimab and MGD024, in clinical trials, as well as others in preclinical development.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also advanced beyond our DART platform to establish a TRIDENT platform, which reflects the continuing evolution of our multi-specific antibody-based targeting expertise. Built on the DART module, the trivalent TRIDENT platform incorporates in an Ig-like format an additional domain capable of engaging an independent antigen. With the inclusion of a third targeting arm, TRIDENT molecules enable a broader range of mechanisms of action than bispecific targeting, allowing, for instance, the engagement of multiple antigens on a single or on different cells or enabling enhanced target selectivity by modulating the avidity of one of two antigens. Product candidates using this technology are currently in preclinical development.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fc Optimization Platform: Our Proprietary Approach to Enhance Immune-Mediated Cancer Cell Killing</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To enhance the body's immune ability, we developed our Fc Optimization platform which introduces certain mutations into the Fc region of an antibody and is able to modulate antibody interaction with immune effector cells. Such interaction enhances the body's immune ability to mediate the killing of cancer cells through antibody-dependent cellular cytotoxicity (ADCC).</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Fc region mediates the function of IgG antibodies by binding to different activating and inhibitory receptors, referred to as Fc&#947;Rs, on immune effector cells found within the innate immune system. By engineering Fc regions to bind with an increased affinity to the activating Fc&#947;Rs and with a reduced affinity to the inhibitory Fc&#947;Rs, we have been able to impart a more effective immune response and improve effector functions, such as ADCC. This is another example in which small changes in antibody structure can confer improvements on normal immune processes.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established a proprietary platform to engineer, screen, identify and test antibodies' Fc regions with customizable activity. In particular, we have licenses to use transgenic mice that express human Fc&#947;Rs. These mice can be used for in vivo testing of antibodies that incorporate Fc domain variants, including those antibodies intended for cancer therapy.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have successfully incorporated our Fc variants in two of our antibody-based molecules, margetuximab and enoblituzumab. In vitro, the modified Fc region of margetuximab increases binding to the activating Fc receptor FCGR3A (CD16A) and decreases binding to the inhibitor Fc receptor FCGR2B (CD32B). These changes lead to greater in vitro ADCC and NK cell activation. The clinical significance of in vitro data is unknown.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Licensed ADC Platforms</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have licensed ADC platforms from collaboration partners to leverage their past investment in proprietary linker-toxin technology and know-how. While we don&#8217;t necessarily believe there is a single best linker-toxin technology capable of addressing all targets and indications, we have selected what we believe are best-in-class technologies for construction of each of our ADC product candidates. For example, to date we have utilized linker-toxin payloads developed by Byondis for vobra duo and by Synaffix B.V. (Synaffix) for multiple molecules, including MGC026 and MGC028.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Collaborations</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Throughout our company's history, we have entered into collaborations with other biopharmaceutical companies and plan to continue to do so. We enter into collaborations when there is a strategic advantage to us and when we believe the financial terms of the collaboration are favorable for meeting our short-term and long-term strategic objectives. We are not dependent upon any one of these collaborations, but in many cases, we have rights to receive sales royalties and other significant financial payments if the partnered product candidates achieve certain development and sales milestones. We endeavor to establish collaborations that preserve our right to participate in future commercialization, for example by securing co-promotion or profit-sharing rights under certain circumstances.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We pursue a balanced approach between product candidates that we develop ourselves and those that we develop with our collaborators. Under our strategic collaborations to date, we have received significant non-dilutive funding and continue to have rights to additional funding upon completion of certain research, achievement of key product development milestones and royalties and other payments upon the commercial sale of products. Each of our collaborations has a unique set of terms and conditions.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We strive to protect the proprietary technologies that we believe are important to our business, including seeking and maintaining patents intended to protect, for example, the composition of matter of our product candidates, their methods of use, their formulation, the technology platforms used to generate them, related technologies and/or other aspects of the inventions that are important to our business. We also rely on trade secrets, confidentiality and invention assignment agreements and careful monitoring of our proprietary information to protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success will depend significantly on our ability to obtain and maintain patent and other proprietary protection for commercially important technology, inventions and know-how related to our business. In addition, there is cost and risk to our business in defending and enforcing our patents, maintaining our licenses to use intellectual property owned by third parties and preserving the confidentiality of our trade secrets and operating without infringing the valid and enforceable patents and other proprietary rights of third parties. We also rely on know-how, continuing technological innovation and in-licensing opportunities to develop, strengthen and maintain our proprietary positions. We currently use multiple industry-standard patent monitoring systems to monitor new United States Patent and Trademark Office (USPTO) filings for any applications by third parties that may infringe on our patents.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent positions of biopharmaceutical companies like us are generally uncertain and involve complex legal, scientific and factual questions. In addition, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted by the courts after issuance. Consequently, we do not know whether any of our product candidates will be protectable or remain protected by enforceable patents. We cannot predict whether the patent applications we are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient proprietary protection from competitors. Any patents that we hold may be challenged, narrowed, circumvented or invalidated by third parties.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A third party may hold patents or other intellectual property rights that are important to or necessary for the development of our product candidates or use of our technology platforms. It may be necessary for us to use the patented or proprietary technology of third parties to commercialize our product candidates, in which case we would be required to obtain a license from these third parties on commercially reasonable terms, or our business could be harmed, possibly materially. For example, certain patents held by third parties cover Fc engineering methods and mutations in Fc regions to enhance the binding of Fc regions to Fc receptors on immune cells. Although we believe that these patents are not infringed, invalid, and unenforceable, should a court find that they cover margetuximab or enoblituzumab and we are unable to invalidate them, or if licenses for them are not available on commercially reasonable terms, our business could be harmed, perhaps materially.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because patent applications in the United States and certain other jurisdictions can be maintained in secrecy for 18 months or potentially even longer, and because publication of discoveries in the scientific or patent literature often lags behind actual discoveries, we cannot be certain of the priority of inventions covered by pending patent applications. Moreover, we may have to participate in interference proceedings declared by the USPTO to determine priority of invention. In the ordinary course of business we participate in post-grant challenge proceedings, such as oppositions, that challenge the patentability of third party patents. Such proceedings could result in substantial cost, even if the eventual outcome is favorable to us.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pipeline Patent Protection</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, we held 97 patents in the United States with 40 patent applications pending and 760 patents in other countries of the world with 457 patent applications pending. In addition to patents and patent applications generally providing protection for various aspects of our Fc Optimization, DART, and TRIDENT platforms, we have patent and patent applications for the composition of matter of each of our clinical pipeline product candidates and, in some cases, we also have other patents and patent application related to various aspects of the technology underlying these product candidates or their methods of use.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patent terms may be adjusted or extended, as described in greater detail below, in certain circumstances. However, assuming no adjustments or extensions, the primary composition of matter patent for each of our clinical pipeline product candidates is expected to expire in the following timeframes:</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.707%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:51.093%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#d9d9d9;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Product or Product Candidate</span></td><td colspan="3" style="background-color:#d9d9d9;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expiration Date</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">margetuximab</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">enoblituzumab</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2031</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">retifanlimab</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2036</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">tebotelimab</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2036</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">lorigerlimab</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2036</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">vobramitamab duocarmazine</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2037</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MGD024</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2039</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MGD026</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2044*</span></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">* pending</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patent Term Extension and Reference Product Exclusivity</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Hatch-Waxman Act permits a patent term extension for FDA-approved drugs, including biological products, of up to five years beyond the expiration of the patent. The length of the patent term extension is related to the length of time the drug is under regulatory review. Patent extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval and only one patent applicable to an approved drug may be extended. Similar provisions are available in Europe and other jurisdictions to extend the term of a patent that covers an approved drug. If and when our pharmaceutical product candidates receive FDA approval, we expect to apply, or have applied, for patent term extensions on patents covering those products. We intend to seek, and are seeking, patent term extensions to our issued patents in any jurisdiction where these are available. For example, we have submitted a request to obtain patent term extension of U.S. Patent No. 8,802,093, the primary composition of matter patent for margetuximab. Additionally, we have submitted a request to obtain patent term extension of U.S. Patent No. 10,577,422, the primary composition of matter of retifanlimab. However, there is no guarantee that the applicable authorities, including the FDA in the United States, will agree with our assessment of whether such extensions should be granted, and even if granted, the length of such extensions.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Patient Protection and Affordable Care Act, as amended by the Healthcare and Education Affordability Reconciliation Act (collectively the ACA) created a regulatory scheme authorizing the FDA to approve biosimilars via an abbreviated licensure pathway. In many cases, this allows biosimilars to be brought to market without conducting the full suite of clinical trials typically required of originators. Under the ACA, a manufacturer may submit an application for licensure of a biologic product that is "biosimilar to" or "interchangeable with" a previously approved biological product or "reference product." The "biosimilar" application must include specific information demonstrating biosimilarity based on data derived from: (1) analytical studies, (2) animal studies, and (3) a clinical study or studies that are sufficient to demonstrate safety, purity, and potency in one or more appropriate conditions of use for which the reference product is licensed, except that FDA may waive some of these requirements for a given application. Under this new statutory scheme, an application for a biosimilar product may not be submitted to the FDA until four years after the date of first licensure. The FDA may not approve a biosimilar product until 12 years from the date on which the reference product was first licensed. The law does not change the duration of patents granted on biological products. Even if a product is considered to be a reference product eligible for exclusivity, another company could market a competing version of that product if the FDA approves a full BLA for such product containing the sponsor's own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of their product. There have been persistent proposals to repeal or modify the ACA and it is uncertain how any of those proposals, if in the future approved, would affect these provisions.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Trade Secrets</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also rely on trade secret protection for our confidential and proprietary information. Although we take steps to protect our proprietary information and trade secrets, including through contractual means with our employees and consultants, third parties may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets or disclose our technology. Thus, we may not be able to meaningfully protect our trade secrets. It is our policy to require our employees, consultants, outside scientific collaborators, sponsored researchers and other advisors to enter into agreements with confidentiality terms prior to sharing any of our proprietary and confidential information with them. These agreements provide that all confidential information concerning our business or financial affairs developed or made known to the individual during the course of the individual's relationship with us is to be kept confidential and not disclosed to third parties except in specific circumstances.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the case of employees, the agreements provide that all inventions made, conceived, created or reduced to practice by the individual, and which are related to our current or planned business or research and development or made during normal working hours, on our premises or using our equipment or proprietary information, are our exclusive property. In many cases our agreements with consultants, outside scientific collaborators, sponsored researchers </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and other advisors require them to assign or grant us licenses to inventions they invent as a result the work or services they render under such agreements or grant us an option to negotiate a license to use such inventions.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In-Licensed Intellectual Property</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into patent and know-how license agreements that grant us the rights to use certain technologies related to biological manufacturing for our commercial and clinical product candidates such as, but not limited to, technology related to the conjugation of cytotoxic payloads to our antibody molecules. We anticipate using these technologies for future product candidates. These licensors have businesses dedicated to licensing this type of technology and we anticipate that licenses to use these technologies for our future products will be available. The licenses typically include yearly maintenance payments and sales royalties, and may also include upfront payments or milestone payments.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently manufacture drug substance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for most of our clinical trials at our manufacturing facility located in Rockville, Maryland. We also rely on our licensees and contract manufacturers, including Byondis, Synaffix and Millipore Sigma, for producing components of our ADC candidates. We have supplemented our drug substance manufacturing capacity through an arrangement with AGC Biologics, Inc. (AGC, formerly CMC Biologics, Inc.), a contract manufacturing organization, and commercially produced initial margetuximab commercial supply and inventory at AGC. We have an FDA-approved commercial manufacturing site at 9704 Medical Center Drive in Rockville, Maryland for the manufacture of MARGENZA and ZYNYZ drug substance. We commercially produce material for MARGENZA and ZYNYZ as well as intend to commercially produce our</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product candidates when and if approved by the FDA. In addition, we currently rely on and will continue to rely on contract fill-finish service providers, primarily Ajinomoto Bio-Pharma Services, BSP Pharmaceuticals, and Simtra BioPharma Solutions, to fulfill our fill-finish needs for our current and future product candidates.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most of the principal materials we use in our manufacturing operations are available from more than one source. However, we obtain certain raw materials principally from only one source. In the event one of these suppliers was unable to provide the materials or product, we generally seek to maintain sufficient inventory to supply the market until an alternative source of supply can be implemented. However, in the event of an extended failure of a supplier or general national supply chain disruption, it is possible that we could experience an interruption in supply until we established new sources or, in some cases, implemented alternative processes.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Production processes for biological therapeutic products are complex, highly regulated, and vary widely from product to product. Shifting or adding manufacturing capacity can be a very lengthy process requiring significant capital expenditures, process modifications, and regulatory approvals. Accordingly, if we were to experience extended plant shutdowns at our own facility, extended failure of a contract supplier or contract manufacturing organization, or extraordinary unplanned increases in demand, we could experience an interruption in supply of certain products or product shortages until production could be resumed or expanded.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commercialization</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of the three products that originated from our pipeline and for which U.S. approval for commercialization has been received, MARGENZA is the only product for which we retain the majority of commercial rights. In November 2020, we partnered with Eversana, a pioneer of next-generation commercial services to the global life sciences industry, to commercialize margetuximab in the U.S. by leveraging their integrated commercial services. Under the terms of the agreement, we maintain ownership of margetuximab, including all manufacturing, regulatory and development responsibilities for the product. Eversana received a co-exclusive right to conduct approved commercialization activities. Eversana utilizes its internal capabilities to support marketing, channel management services, medical affairs and other commercial and patient access related services; we book MARGENZA sales. We and Eversana equally share in funding Eversana&#8217;s commercialization expenses. In exchange for co-funding these expenses, Eversana is eligible to earn future revenue share payments which shall be capped at 125% of Eversana&#8217;s cumulative service fees. The term of the agreement is five years following the date of FDA approval, subject to predefined termination provisions.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot market or promote a new product in a country until a marketing application has been approved by the appropriate regulatory authority for that jurisdiction. Subject to receiving marketing authorization in a jurisdiction, we believe we will be able to commercialize in that market through arrangements with third-party commercial partners. Other than through our arrangement with Eversana for MARGENZA, we have not established any sales, marketing or distribution capabilities. If we are unable to enter into third-party commercial arrangements for other product candidates that may be approved in the future, with respect to the United States we believe that we could potentially build the capabilities to commercialize our </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approved product or products. Outside the United States, our strategy is to enter into arrangements with third-party commercial partners for any of our product candidates that obtain marketing approval.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are a large number of companies developing or marketing treatments for cancer, including many major pharmaceutical and biotechnology companies. These treatments consist both of small molecule drug products, as well as biologic therapeutics that work by using next-generation antibody technology platforms to address specific cancer targets. For example, MARGENZA is directed against HER2 and many companies have cancer therapeutics directed against HER2 that are either currently approved and on the market or may be in development, such as F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (Roche), particularly through its affiliate, Genentech, Inc., as well as Puma Biotechnology, Inc., Daiichi Sankyo Company, Limited and AstraZeneca plc. (AstraZeneca), Seagen Inc. (now Pfizer), Zymeworks, Inc., </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shanghai Hengrui Pharmaceutical, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and Byondis, many of which have significantly greater resources than we do. Market competition has limited the utilization of MARGENZA as a therapeutic, and these competitors as well as biosimilar trastuzumab competition may limit such utilization in the future.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the immuno-oncology field is competitive, with treatments currently approved, on the market, or in development for various tumor types and patient populations from a variety of different companies such as Merck &amp; Co., Inc. (Merck), The Bristol-Myers Squibb Company (BMS), and Roche, all of which have significantly greater resources than we do. Many of our pipeline programs, if successful, will likely face significant competition both by therapeutics that are already being marketed as well as those that will be approved for marketing before our programs. In particular, we are developing PD-1-directed product candidates, including a mAb that we have outlicensed and two DART molecules. Merck, BMS, Roche, AstraZeneca, Pfizer Inc., Merck KGaA, and Regeneron Pharmaceuticals, Inc. all have approved products that target either the PD-1 receptor or its ligand, PD-L1, and there are several other companies that have anti-PD-1 or anti-PD-L1 antibodies in clinical development, all of which would compete with our PD-1-directed programs. In addition, these and other companies are developing product candidates directed against other immuno-oncology targets that we are pursuing through our bispecific approaches.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, several companies are also developing therapeutics that work by targeting multiple specificities using a single recombinant molecule. Amgen Inc. has obtained marketing approval for one product that works by targeting antigens both on immune effector cell populations and those expressed on certain cancer cells, and has other product candidates in development that use this mechanism. In addition, other companies are developing new treatments for cancer that utilize multi-specific approaches, including Abbvie Inc., Affimed N.V., Eli Lilly and Company, Genmab A/S, Merus B.V., Regeneron, Roche, AstraZeneca, Xencor, Inc. and Zymeworks, Inc.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finally, our competition in the contract development and manufacturing organization (CDMO) service market includes a number of full-service contract manufacturers and large pharmaceutical companies offering third-party development and manufacturing services to fill their excess capacity. Large pharmaceutical companies have been seeking to divest portions of their manufacturing capacity, and any such divested businesses may compete with us in the future. In addition, most of our competitors have substantially greater financial, marketing, technical or other resources than we do.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our competitors have significantly greater financial, manufacturing, marketing, drug development, technical and human resources than we do. Mergers and acquisitions in the pharmaceutical, biotechnology and diagnostic industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining top qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The key competitive factors affecting the success of all our therapeutic product candidates, if approved, are likely to be their efficacy, safety, dosing convenience, price, the effectiveness of companion diagnostics in guiding the use of related therapeutics, the level of generic or biosimilar competition and the availability of reimbursement from government and other third-party payors. In addition, the standard of medical care provided to cancer patients continues to evolve as more scientific and medical information becomes available. These changes in medical care relate to pharmaceutical products, but are also affected by other factors, and such changes can positively or negatively affect the prospects of our product candidates as well as those of our competitors.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are more effective, have fewer or less severe effects, are more convenient or are less expensive than any products that we may develop, or the standards of care for cancer patients change while our clinical trials are ongoing. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">result in our competitors establishing a strong market position before we are able to enter the market. In addition, our ability to compete may be affected in many cases by insurers or other third-party payors seeking to encourage the use of biosimilar products. Biosimilar products are expected to become available over the coming years. For example, trastuzumab biosimilars have been approved in the U.S. by the FDA.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The most common methods of treating patients with cancer are surgery, radiation and drug therapy. There are a variety of available drug therapies marketed for cancer. Many of these approved drugs are well established therapies and are widely accepted by physicians, patients and third-party payors. In many cases, these drugs are administered in combination to enhance efficacy. The treatment landscape for cancer is complex due to the sequential order in which oncology drugs are administered. Initially, first-line treatments are prescribed, followed by second-line treatments when the first no longer yields results, and so on with third-line treatments and beyond. While our product candidates may compete with many existing drug and other therapies, to the extent an approved drug is ultimately used in combination with or as an adjunct to these therapies, our product candidates will not be competitive with the approved drug.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation and Product Approval</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government authorities in the United States, at the federal, state and local level, and in other countries extensively regulate, among other things, the research, development, testing, manufacture, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, pricing, reimbursement, marketing, import and export of pharmaceutical products such as those we are developing. The processes for obtaining regulatory approvals in the United States and in foreign countries, along with subsequent compliance with applicable statutes and regulations, require the expenditure of substantial time and financial resources.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">FDA Regulation</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our current product candidates are subject to regulation in the United States by the FDA as biological products (biologics). The FDA subjects biologics to extensive pre- and post-market regulation. The Public Health Service Act, the Federal Food, Drug, and Cosmetic Act (FDCA) and other federal and state statutes and regulations, govern, among other things, the research, development, testing, manufacture, storage, recordkeeping, approval, labeling, promotion and marketing, distribution, post-approval monitoring and reporting, sampling, and import and export of biologics. Failure to comply with applicable U.S. requirements may subject a company to a variety of administrative or judicial sanctions, such as FDA refusal to approve pending BLAs, withdrawal of approvals, clinical holds, warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties, or criminal penalties.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Preclinical Studies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Drug development in our industry is complex, challenging and risky; failure rates are high. Product development cycles are long - approximately 10 to 15 years from discovery to market. A potential new biological product must undergo many years of preclinical and clinical testing to establish it is pure, potent and safe.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preclinical studies include laboratory evaluation of product chemistry, formulation and toxicity, pharmacology, as well as animal trials to assess the characteristics and potential safety and efficacy of the product. The conduct of the preclinical tests must comply with federal regulations and requirements including the FDA's good laboratory practice (GLP) regulations and the U.S. Department of Agriculture's regulations implementing the Animal Welfare Act. After laboratory analysis and preclinical testing in animals, we file an IND application with the FDA to begin human testing. An IND sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature, and a proposed clinical trial protocol, among other things, to the FDA as part of an IND application. Certain preclinical tests, such as animal tests of reproductive toxicity and carcinogenicity, may continue even after the IND application is submitted. An IND application automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to one or more proposed clinical trials and places the clinical trial on a clinical hold or agrees on an alternate approach with us. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the IND application is cleared and the clinical trial can begin. As a result, submission of an IND application may not result in the FDA allowing clinical trials to commence.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical Development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Clinical trials involve the administration of the investigational drug to human subjects (healthy volunteers or patients) under the supervision of a qualified investigator. Clinical trials must be conducted: (i) in compliance with all applicable federal regulations and guidance, including those pertaining to good clinical practice (GCP) standards that are meant to protect the rights, safety, and welfare of human subjects and to define the roles of clinical trial sponsors, investigators, and monitors; as well as (ii) under protocols detailing, among other things, the objectives of the trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated. Each protocol involving testing of a new drug in the United States (whether in patients or healthy volunteers) must be included in the IND application submission, and the FDA must be notified of subsequent protocol amendments. In addition, the protocol must be reviewed and approved by an institutional review board (IRB) and all study subjects must provide informed consent prior to participating in the study. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Typically, each institution participating in the clinical trial will require review of the protocol before any clinical trial commences at that institution. Information about certain clinical trials must be submitted within specific timeframes to NIH for public dissemination on their ClinicalTrials.gov website. Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and there are additional, more frequent reporting requirements for suspected unexpected serious adverse events.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A study sponsor might choose to discontinue a clinical trial or a clinical development program for a variety of reasons. In addition, the FDA may impose a temporary or permanent clinical hold, or other sanctions, if it believes that the clinical trial either is not being conducted in accordance with FDA requirements or presents an unacceptable risk to the clinical trial subjects. An IRB may also require the clinical trial at the site to be halted, either temporarily or permanently, for failure to comply with the IRB's requirements, or may impose other conditions.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials to support BLAs for marketing approval are typically conducted in three pre-approval phases, but the phases may overlap or be combined, particularly in testing for oncology indications. In Phase 1, testing is conducted in a small group of subjects who may be patients with the target disease or condition or healthy volunteers, to evaluate its safety, determine a safe dosage range, and identify side effects. In Phase 2, the drug is given to a larger group of subjects with the target condition to further evaluate its safety and gather preliminary evidence of efficacy. Phase 3 studies typically last multiple years for oncology indications. In Phase 3, the drug is given to a large group of subjects with the target disease or condition (several hundred to several thousand), often at multiple geographical sites, to confirm its effectiveness, monitor side effects, and collect data to support drug approval. In some cases, the FDA may require post-market studies, known as Phase 4 studies, to be conducted as a condition of approval in order to gather additional information on the drug's effect in various populations and any side effects associated with long-term use. Depending on the risks posed by the drugs, other post-market requirements may be imposed. Only a small percentage of investigational drugs complete all three phases and obtain marketing approval.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Approval</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. After completion of the required clinical testing, a BLA can be prepared and submitted to the FDA. FDA approval of the BLA is required before marketing of the product may begin in the United States. The BLA must include the results of preclinical, clinical and other testing and a compilation of data relating to the product's chemistry, manufacture and controls. The cost of preparing and submitting a BLA is substantial. Under federal law, the submission of most BLAs is additionally subject to a substantial application user fee, and annual program user fees also apply. These fees are typically increased annually.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has 60 days from its receipt of a BLA to determine whether the application will be accepted for filing based on the FDA's threshold determination that it is sufficiently complete to permit substantive review. Once the submission is accepted for filing, the FDA begins a substantive review, and the review period under the PDUFA begins. The standard for reviewing a BLA is whether the product is safe, pure and potent, which has been interpreted to include that the product is safe and effective and has a favorable benefit-risk profile. The FDA's current performance goals call for the FDA to complete review of 90 percent of standard (non-priority) BLAs within 10 months of filing and within six months for priority BLAs, which is 12 months and eight months, respectively, if the 60-day review of the initial application is included in the timeline. In addition, the FDA has developed approaches intended to make certain qualifying products available to patients rapidly - Priority Review, Breakthrough Therapy, Accelerated Approval, and Fast Track. While the timelines for approval under these pathways may be shorter, there are requirements and conditions associated with each pathway, and there can be no assurance that any of our investigational products will be able to meet the conditions or requirements necessary to receive any such designation or be able to receive the review or approval benefits associated with such designations.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may refer applications for novel products or products that present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes outside clinicians and other experts, for review, evaluation and a recommendation as to whether sufficient data exist in the application to support product approval. The FDA is not bound by the recommendation of an advisory committee, but it generally gives significant deference to such recommendations.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before approving a BLA, the FDA will typically inspect one or more clinical sites and possibly the sponsor itself to assure compliance with GCP. Additionally, the FDA will typically inspect the facility or the facilities at which the drug is manufactured. The FDA will not approve the product unless compliance with current Good Manufacturing Practices (cGMPs) is satisfactory. The FDA also reviews the proposed labeling submitted with the BLA and typically requires changes in the labeling text.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After the FDA evaluates the BLA and the manufacturing and testing facilities, it issues either an approval letter or a complete response letter. Complete response letters generally outline the deficiencies in the submission and delineate the additional testing or information needed in order for the FDA to reconsider the application. If and when deficiencies outlined in a complete response letter have been addressed to the FDA's satisfaction in a resubmission of the BLA, the FDA will issue an </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approval letter. The FDA has committed to reviewing 90 percent of resubmissions within two or six months from receipt depending on the type of information included.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An approval letter authorizes commercial marketing of the drug for the approved indication or indications and the other conditions of use set out in the approved prescribing information. Once granted, product approvals may be withdrawn if compliance with regulatory standards is not maintained or problems are identified following initial marketing.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a condition of BLA approval, the FDA may require substantial post-approval testing and surveillance to monitor the drug's safety or efficacy and may impose other conditions, including labeling restrictions that can materially affect the potential market and profitability of the product. As a condition of approval, or after approval, the FDA also may require submission of a risk evaluation and mitigation strategy (REMS) to mitigate any identified or suspected serious risks. The REMS may include medication guides, physician communication plans, assessment plans, and elements to assure safe use, such as restricted distribution methods, patient registries, or other risk minimization tools.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other U.S. Post-Marketing Regulatory Requirements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Once a BLA is approved, a product will be subject to certain post-approval requirements, including those relating to advertising, promotion, adverse event reporting, recordkeeping, and cGMPs, as well as registration, listing, and inspection. There also are continuing, annual program user fee requirements for marketed products, as well as new application fees for supplemental applications with clinical data.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA regulates the content and format of prescription drug labeling, advertising, and promotion, including direct-to-consumer advertising and promotional Internet communications. The FDA also establishes parameters for permissible non-promotional communications between industry and the medical community, including industry-supported scientific and educational activities. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion for uses not consistent with the approved labeling, and a company that is found to have improperly promoted off-label uses or otherwise not to have met applicable promotion rules may be subject to significant liability under both the FDCA and other statutes, including the False Claims Act. See "Other Healthcare Laws and Compliance Requirements" below for more information.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All aspects of pharmaceutical manufacture must conform to cGMPs after approval. Drug manufacturers and certain of their subcontractors are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA during which the FDA inspects manufacturing facilities to assess compliance with cGMPs. Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMPs and impose reporting and documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the areas of production and quality control to maintain compliance with cGMPs.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Products may be marketed only for the approved indications and in accordance with the provisions of the approved labeling. Changes to some of the conditions established in an approved application, including changes in indications, labeling, product formulation or manufacturing processes or facilities, require submission and FDA approval of a new BLA or BLA supplement, in some cases before the change may be implemented. A BLA supplement for a new indication typically requires clinical data similar to that in the original application, and the FDA uses the same procedures and actions in reviewing BLA supplements as it does in reviewing BLAs.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturers are subject to requirements for adverse event reporting and submission of periodic reports following FDA approval of a BLA. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, or failure of Phase 4 studies to meet their specified endpoints, may result in revisions to the approved labeling to add new safety information, the need to conduct additional post-market studies or clinical trials to assess new safety risks, imposition of distribution or other restrictions under a REMS program, or recall of the product and withdrawal of the BLA.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Noncompliance with post-marketing requirements can result in one or more of the following consequences:</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Warning letters;</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Holds on post-approval clinical trials;</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Refusal of the FDA to approve pending BLAs or supplements to approved BLAs, or suspension or revocation of product license approvals;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Product seizure or detention, or refusal to permit the import or export of products; or</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Injunctions or the imposition of civil or criminal penalties.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the distribution of prescription pharmaceutical products is subject to the Prescription Drug Marketing Act (PDMA) which regulates the distribution of drugs and drug samples at the federal level and sets minimum standards for the registration and regulation of drug distributors by the states. Both the PDMA and state laws limit the distribution of prescription pharmaceutical product samples and impose requirements to ensure accountability in distribution.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Approval of Biosimilars. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ACA authorized the FDA to approve biosimilars via a separate, abbreviated pathway. In many cases, this allows biosimilars to be brought to market without conducting the full suite of clinical trials typically required of originators. The law establishes a period of 12 years of exclusivity for reference products in order to preserve incentives for future innovation, and outlines statutory criteria for science-based biosimilar approval standards that take into account patient safety considerations. Under this framework, exclusivity protects innovator products by prohibiting others, for a period of 12 years, from being granted FDA approval based in part on reliance on or reference to the innovator's data in their application to the FDA. The law does not change the duration of patents granted on biological products. There are regular legislative proposals to rescind or reduce the biologics exclusivity provisions of the ACA and it is uncertain whether or if any of those proposals may be approved, and if approved, how exclusivity for biologics would be affected.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Healthcare Laws and Compliance Requirements</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to various federal and state laws pertaining to health care &#8220;fraud and abuse,&#8221; including anti-kickback and false claims laws, as well as laws related to health care transparency and data protection. Anti-kickback laws generally prohibit a prescription drug manufacturer from soliciting, offering, receiving, or paying any remuneration to generate business, including the purchase or prescription of a particular drug. Although the specific provisions of these laws vary, their scope is generally broad and there may not be regulations, guidance or court decisions that apply the laws to particular industry practices. There is therefore a possibility that our practices might be challenged under such anti-kickback laws. False claims laws prohibit anyone from knowingly and willingly presenting, or causing to be presented, any claims for payment for reimbursed drugs or services to third party payers (including Medicare and Medicaid) that are false or fraudulent. Violations of fraud and abuse laws may be punishable by criminal or civil sanctions, including fines and civil monetary penalties, and/or exclusion from federal health care programs (including Medicare and Medicaid).</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Laws and regulations enacted by the federal government and various states to regulate the sales and marketing practices of pharmaceutical manufacturers with marketed products generally limit financial interactions between manufacturers and health care providers and/or require disclosure to the government and public of such interactions. State laws may also require disclosure of pharmaceutical pricing information and marketing expenditures. Many of these laws and regulations contain ambiguous requirements or require administrative guidance for implementation. We are subject to federal, state and foreign laws that govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways, thus complicating compliance efforts. Given the lack of clarity in laws and their implementation, our activities could be subject to the penalty provisions of the pertinent laws and regulations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">International Regulation</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to regulations in the United States, we and our collaborators, may be subject to a variety of foreign regulations governing clinical trials, drug registration, commercial sales and distribution of our product candidates outside the United States. These regulations can vary between jurisdictions and can be more onerous than regulations in the United States. Whether or not we obtain FDA approval for a product candidate, we must obtain approval from the comparable regulatory authorities of foreign countries or economic areas, such as the European Union (EU) before we may commence clinical trials or market products in those countries or areas. The approval process and requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary greatly from place to place, and the time to approval may be longer or shorter than that required for FDA approval.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain countries outside of the United States have a process that requires the submission of a clinical trial application (CTA) much like an IND prior to the commencement of human clinical trials. In Europe, for example, a CTA must be submitted to the competent national health authority and to independent ethics committees in each country in which a company intends to conduct clinical trials. Once the CTA is approved in accordance with a country&#8217;s requirements, clinical trial development may proceed in that country. In all cases, the clinical trials must be conducted in accordance with GCP, and other applicable regulatory requirements. A separate CTA must be submitted for each clinical trial to be conducted.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, for example, to obtain regulatory approval of an investigational medicinal product, we must submit a marketing authorisation application (MAA). The content of the MAA is similar to that of a New Drug Application or BLA filed </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the United States, with the exception of, among other things, EU-specific document requirements. Under the EU regulatory system, a company may submit marketing authorisation applications either under a centralised or decentralised procedure. Under the centralised procedure in the EU, a MAA is submitted to the European Medicines Agency (EMA) where it will be evaluated by the Committee for Medicinal Products for Human Use (CHMP). The maximum timeframe for a CHMP evaluation of an MAA that has been validated is 210 days, excluding time taken by an applicant to respond to questions. A favorable opinion on the application by the CHMP will typically result in the granting of the marketing authorisation by the European Commission within 67 days of receipt of the opinion. Generally, the entire review process takes approximately 13-14 months. Accelerated evaluation might be granted by the CHMP in exceptional cases, when a medicinal product is expected to be of a major public health interest, particularly from the point of view of therapeutic innovation. In this circumstance, the EMA ensures that the opinion of the CHMP is given within 150 days, excluding time taken by an applicant to respond to questions.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As in the United States, we or our collaborators may apply for designation of a product as an orphan drug for the treatment of a specific indication in the EU before the MAA is made. Orphan drugs in Europe enjoy certain benefits, including up to 10 years of exclusivity for the approved indication unless another applicant can show that its product is safer, more effective or otherwise clinically superior to the orphan designated product. The PRIME initiative was established by the EMA to help promote and foster the development of new medicines in the EU that demonstrate potential for a major therapeutic advantage in areas of unmet medical need. Benefits from the PRIME designation include early confirmation of potential for accelerated assessment, early dialogue and increased interaction with relevant regulatory committees to discuss development options, scientific advice at key development milestones, and proactive regulatory support from the EMA.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we, or our collaborators, fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BioPharmaceutical Coverage, Pricing, Reimbursement, and Health Care Reform</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States and other countries, sales of any products for which we receive regulatory approval for commercial sale will depend in part on the availability of adequate reimbursement from third-party payors, including government health administrative authorities, managed care providers, private health insurers, and other organizations. Third-party payors are increasingly examining the medical necessity and cost effectiveness of medical products and services in addition to safety and efficacy and, accordingly, significant uncertainty exists as to the reimbursement status of newly approved therapeutics. Third-party reimbursement adequate to enable us to realize an appropriate return on our investment in research and product development may not be available or optimal for our products. Further, coverage policies and third-party payor reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future. In addition, companion diagnostic tests require coverage and reimbursement separate and apart from the coverage and reimbursement for their companion pharmaceutical or biological products. Similar challenges to obtaining coverage and reimbursement, applicable to pharmaceutical or biological products, will apply to companion diagnostics.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug prices have become a subject of increased focus in recent years. Although there are currently no direct government price controls over private sector purchases in the U.S., federal law requires pharmaceutical manufacturers to pay prescribed rebates on certain government or Medicaid-reimbursed drugs to enable them to be eligible for reimbursement under certain public healthcare programs such as Medicaid and Medicare Part B. Various states have adopted further mechanisms that seek to control drug prices, including by disfavoring certain higher priced drugs or by seeking supplemental rebates from manufacturers. Managed care has also become a potent force in the marketplace that increases downward pressure on the prices of pharmaceutical products.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Public and private healthcare payers control costs and influence drug pricing through a variety of mechanisms, including through negotiating discounts with the manufacturers and through the use of tiered formularies and other mechanisms that provide preferential access to certain drugs over others within a therapeutic class. Payers also set other criteria to govern the uses of a drug that will be deemed medically appropriate and therefore reimbursed or otherwise covered.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, in the U.S., there have been several presidential executive orders, congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Human Capital Management</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, we had 339 full-time employees, 289 of whom were primarily engaged in research, development and manufacturing activities, and 67 of whom had an M.D. and/or Ph.D. Our employees are critically important to the achievement of our company&#8217;s mission and goals. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our senior leadership oversees all human capital management matters and is committed to attracting, developing, engaging and retaining the best people. We strive to offer our employees an intellectually challenging and diverse work environment, opportunities to expand their knowledge and skills, feedback on performance, and paths for career advancement. We believe management&#8217;s relationships with our employees is very positive and they are not subject to a collective bargaining agreement or represented by a trade or labor union.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compensation and Benefits</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our compensation programs are designed to align our employees' interests with our business goals and stockholder returns. We provide employee wages that are competitive within our industry, and we engage an outside compensation and benefits consulting firm to independently evaluate the effectiveness of our compensation and benefit programs and to provide benchmarking against our peers within the industry. We link annual changes in compensation to overall Company performance, as well as each individual&#8217;s contribution to the results achieved. The emphasis on overall Company performance is intended to align the employee&#8217;s financial interests with the interests of stockholders. MacroGenics is committed to providing our employees with a benefits program that is both comprehensive and competitive. Our benefits program offers health care, dental and vision coverage, along with benefits designed to provide increased financial security to our employees and their families.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain an Employee Stock Purchase Plan under which employees may purchase Company common stock through payroll deductions at a price equal to 85% of the fair market value of the stock as of the end of the offering periods.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Culture; Diversity Equity and Inclusion</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Living Values are the backbone of our culture: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patients First, Do It Right, Innovate, Pitch In, Take Action </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Be Inclusive. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022 and continuing into 2023, we kicked off a number of initiatives to reinforce the importance of a diverse workforce and culture of belonging to our Company&#8217;s success. We added the Living Value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, Be Inclusive</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and completed company-wide training on Diversity, Equity and Inclusion (DEI). To further champion our DEI efforts, we formed an employee-led DEI Team with sponsorship from our senior leadership team. The team focused on raising awareness of DEI and promoting a sense of belonging in 2023, and held a number of focus groups and company-wide events.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All employees are required to observe high standards of business and personal ethics and must adhere to our Code of Business Conduct and Ethics, for which they receive training annually. The Code requires reporting any actual or suspected misconduct, illegal activities or fraud. To that end, we maintain a Speak Up Culture where all employees are encouraged to raise issues, report concerns, and ask questions. We also maintain an anonymous hotline that is available to all of our employees, contractors and vendors to report any matter of concern. Communications to the hotline (which is facilitated by an independent third party) are routed to our General Counsel (or, if the General Counsel is the subject of the communication, to the Chair of our Audit Committee) for investigation and resolution. We also maintain a policy of no retaliation, where employees who report any misconduct are to be free of any harassment, retaliation or adverse employment consequence.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We periodically conduct employee engagement surveys to understand our employees&#8217; perspectives and endeavor to listen, change and improve on how we work together in response to these perspectives. In 2022, 84% of our workforce participated in our engagement survey, and we anticipate conducting another survey in 2024. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Learning and Development</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to invest in our employees to achieve their goals and to lead our company through learning and development. We conduct regular performance reviews. We encourage all employees to take advantage of our leadership, management and technical skill trainings and resources. In addition, we provide focused development for managers and emerging leaders who are designated as &#8220;key talent&#8221; based on performance and leadership potential.  </span></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Community</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe in giving back and supporting the local communities where we work as well as initiatives consistent with our areas of focus. Employees are encouraged to participate in charitable causes and receive eight hours of voluntary paid time off annually to participate in local opportunities to give back to the community.  </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Available Securities and Exchange Commission Filing Information</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our main company website address is www.macrogenics.com. We post links to http://ir.macrogenics.com/financial-information/sec-filings for the following filings as soon as reasonably practicable after they are electronically filed with or furnished to the Securities and Exchange Commission (SEC): annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, proxy statements, and any amendments to those reports filed or furnished pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended. All such filings are available through our website free of charge. In addition, the SEC makes available at its website (www.sec.gov), free of charge, reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><div id="i69aaf560e98645139c7ed7af73a9eafe_19"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A. &#160;&#160;&#160;&#160;RISK FACTORS</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The discussion below addresses material factors, of which we are currently aware, that could have a material and adverse effect on our business, results of operations and financial condition. These risk factors and other forward-looking statements that relate to future events, expectations, trends and operating periods involve certain factors that are subject to change, and important risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties should not be considered a complete discussion of all the risks and uncertainties we may face and although the risks are organized by headings and each risk is discussed separately, many are interrelated. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of Risk Factors Affecting Our Business </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is subject to numerous risks. The following summary highlights some of the risks you should consider with respect to our business and prospects. This summary is not complete and the risks summarized below are not the only risks we face. You should review and consider carefully the risks and uncertainties described in the &#8220;Risk Factors&#8221; section of this Annual Report on Form 10-K, which includes a more complete discussion of the risks summarized below as well as a discussion of other risks related to our business and an investment in our common stock, as well as our other SEC filings. </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We depend substantially on the success of the clinical development of our products and product candidates, through our own efforts or those of our collaborators, including vobra duo and lorigerlimab. If we are unable to successfully complete clinical development, obtain additional regulatory approvals and commercialize our products and product candidates, or experience significant delays in doing so, our business will be materially harmed and we may not be able to generate sufficient revenues and cash flows to continue our operations. </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Clinical drug development involves a lengthy and expensive process, with a highly uncertain outcome. We expect to incur significant additional costs related to the development of vobra duo, lorigerlimab, and our other product candidates and may experience delays in completing, or ultimately be unable to complete, the development and commercialization of our other products and product candidates.</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will require substantial additional funding, which may not be available to us on acceptable terms, or at all, and, if not available, may require us to delay, scale back, or cease our product development programs or operations.</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our product candidates may have undesirable side effects which may delay or prevent further clinical development or marketing approval, or, if approval is received, require them to be taken off the market, require them to include safety warnings or otherwise limit their sales. </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our existing therapeutic collaborations are important to our business, and future collaborations may also be important to us. If we are unable to maintain any of these collaborations, or if these collaborations are not successful, our business could be adversely affected.</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If clinical trials for our product candidates are prolonged, delayed or stopped for any reason, including for safety reasons or lack of efficacy, we may be unable to obtain regulatory approval and commercialize our product candidates on a timely basis, which would require us to incur additional costs and delay our receipt of any product revenue. </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The results of previous clinical trials may not be predictive of future results, and interim or top line data may be subject to change or qualification based the complete analysis of data. In addition, the results of our current or planned clinical trials may not satisfy the requirements of the FDA or non-U.S. regulatory authorities for product approval. </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have incurred significant losses since inception and anticipate that we will continue to incur losses for the foreseeable future. Our first commercial product, MARGENZA, launched in March 2021 and to date has not resulted in revenues sufficient for us to reach profitability. Accordingly, we may never achieve or sustain profitability.</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We face significant competition and if our competitors continue to develop and market products that are more effective, safer or less expensive than our product and our product candidates, our current or future commercial opportunities may be negatively impacted. </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We use or may use novel technologies in the development of our product candidates and the FDA and other regulatory authorities have not approved or may not approve products that utilize these technologies. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may not be successful in our efforts to use and expand our technology platforms to build a pipeline of product candidates. We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success. </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Vobra duo, lorigerlimab, or any other product or product candidate that we develop may fail to achieve or maintain market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success.</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The manufacture of vobra duo, lorigerlimab, and other products or product candidates, for ourselves and our collaborators, is complex, and we may encounter difficulties in production. There can be no assurance that we will be able to effectively manufacture clinical quantities of our product candidates in the future. Further, we have limited experience in large-scale commercial manufacturing, and there can be no assurance that we will be able to effectively manufacture commercial quantities of our products or product candidates for ourselves or our collaborators, if and when approved. </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our manufacturing facilities are subject to significant government regulations and approvals, which are often costly and could result in adverse consequences to our business if we fail to comply with the regulations or maintain the approvals.  </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Public health crises</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">such as pandemics or similar outbreaks may have a significant negative impact on our clinical trials, nonclinical studies, development, manufacturing and commercialization of our product candidates and other aspects of our business, staff, and operations.</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have limited experience in launching and marketing internally developed products. If our products achieve regulatory approval and we are unable to further develop marketing and sales capabilities or enter into agreements with third parties to market and sell our products, or our existing arrangements are not successful, we may not be able to generate substantial product sales revenue. </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel. </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Actual or anticipated changes to the laws and regulations governing the health care system may have a negative impact on cost and access to health insurance coverage and reimbursement of health care items and services. </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Reimbursement decisions by third-party payors, including government payors, may have an adverse effect on pricing and market acceptance. </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If any product liability lawsuits are successfully brought against us or any of our collaborators, we may incur substantial liabilities and may be required to limit commercialization of our product candidates. </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish substantial rights. </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We contract with, and may in the future contract with, third parties for components of the manufacturing of our products and product candidates, including our antibody drug conjugate candidates. Failure of third-party contractors to successfully perform their obligations could harm our ability to develop or commercialize our product or product candidates. </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If our information technology systems or those third parties upon which we rely for our data, are or were compromised, we could experience adverse consequences resulting from such compromise, including but not limited to regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; loss of customers or sales; and other adverse consequences.</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our success depends significantly on our ability to operate without infringing the valid patents and other proprietary rights of third parties. </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to obtain and enforce patent protection for our products and our product candidates and related technology, our business could be materially harmed. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have been and may in the future be subject to securities litigation, which is expensive and could divert management attention and adversely impact our business.</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Failure to successfully develop and commercialize companion diagnostics with third party contractors for use with our product candidates could harm our ability to commercialize our product candidates.</span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Business and the Development and Commercialization of Our Products and Product Candidates </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend substantially on the success of the clinical development of our products and product candidates, through our own efforts or those of our collaborators, including vobra duo and lorigerlimab. If we are unable to successfully complete clinical development, obtain additional regulatory approvals and commercialize our products and product candidates, or experience significant delays in doing so, our business will be materially harmed</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">and we may not be able to generate sufficient revenues and cash flows to continue our operations.  </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business depends on the successful development, regulatory approval and commercialization of our products and product candidates, including vobra duo and lorigerlimab. We have invested and will continue to invest a significant portion of our efforts and financial resources in the development of our product candidates, including vobra duo and lorigerlimab. The success of our products and product candidates depends on many factors, including but not limited to: </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successful enrollment in, and completion of, clinical trials, as well as completion of nonclinical studies; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the acceptability and adequacy of safety, tolerability and efficacy data from our clinical trials and other studies;</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the sufficiency of our financial resources and ability to obtain additional funding for the development of our products and product candidates;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">receipt of regulatory approvals; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the performance by clinical research organizations (CROs) or other third parties we may retain of their duties to us in a manner that complies with our protocols and applicable laws and that protects the integrity of the resulting data; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining and maintaining patent, trade secret and other intellectual property protection and regulatory exclusivity; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ensuring we do not infringe, misappropriate or otherwise violate the valid patent, trade secret or other intellectual property rights of third parties; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successfully launching our product candidates, including vobra duo or lorigerlimab, if and when approved; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintaining commercial manufacturing capabilities, either by utilizing our current manufacturing facilities or making arrangements with third-party manufacturers; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manufacturing or obtaining sufficient supplies of our products and product candidates that may be necessary for use in clinical trials for evaluation of our product candidates and commercialization of our products; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining favorable reimbursement from third-party payors for products and product candidates; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competition with other products; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">post-marketing commitments to regulatory agencies following regulatory approval; and</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continued acceptable safety profile following regulatory approval.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical drug development involves a lengthy and expensive process, with a highly uncertain outcome. We expect to incur significant additional costs related to the development of vobra duo, lorigerlimab, and our other product candidates and may experience delays in completing, or ultimately be unable to complete, the development and commercialization of our other products and product candidates.  </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The research, testing, manufacturing, labeling, approval, selling, marketing and distribution of drug products are subject to extensive regulation by the FDA and non-U.S. regulatory authorities, which regulations differ from country to country. We are not permitted to market our product candidates in the United States or in other countries until we receive approval of a Biologics License Application (BLA) from the FDA or marketing approval from applicable regulatory authorities outside the United States. Our product candidates are in various stages of development and are subject to the risks of failure inherent in drug development. For example, in July 2022 we announced the closure of our Phase 2 study evaluating the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">investigational regimen of enoblituzumab in combination with either retifanlimab or tebotelimab in the first-line treatment of patients with recurrent or metastatic SCCHN. The decision to discontinue the study was based on an internal review of safety data. The approval of a BLA can be a lengthy, expensive and uncertain process. In addition, failure to comply with FDA and non-U.S. regulatory requirements may, either before or after product approval, subject our company or our collaborators to administrative or judicially imposed sanctions, including: </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on our ability to conduct clinical trials, including full or partial clinical holds on ongoing or planned trials; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on the products, manufacturers, manufacturing facilities or manufacturing process; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fines, warning letters or untitled letters; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">civil and criminal penalties; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injunctions; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspension or withdrawal of regulatory approvals; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product seizures, detentions or import bans; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">voluntary or mandatory product recalls;</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the issuance of safety alerts, Dear Healthcare Provider letters, press releases and other communications containing warnings or other safety information about the product; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">total or partial suspension of production; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">consent decrees, corporate integrity agreements, debarment or exclusion from federal healthcare programs;</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">imposition of restrictions on marketing or operations, including costly new manufacturing requirements; and </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusal to approve pending BLAs or supplements to approved BLAs or analogous marketing approvals outside the United States. </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and foreign regulatory authorities also have substantial discretion in the drug approval process. The number of nonclinical studies and clinical trials that will be required for regulatory approval varies depending on the product candidate, the disease or condition that the product candidate is designed to address, and the regulations applicable to any particular drug candidate. Regulatory agencies can delay, limit or deny approval of a product candidate for many reasons, including: </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a product candidate may not be deemed safe or effective; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results may not confirm the positive results from earlier nonclinical studies or clinical trials; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory agencies may not find the data from nonclinical studies and clinical trials sufficient or meaningful; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory agencies might not approve or might require changes to our manufacturing processes or facilities; or </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory agencies may change their approval policies or adopt new regulations. </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any delay in obtaining or failure to obtain required approvals could materially adversely affect our ability to generate revenue from the particular product candidate, which likely would result in significant harm to our financial position and adversely impact our stock price. Furthermore, any regulatory approval to market a product may be subject to limitations on the indicated uses for which we may market the product. These limitations may limit the size of the potential market for a product candidate, if approved.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If clinical trials for our product candidates are prolonged, delayed or stopped, for any reason, we may be unable to obtain regulatory approval and commercialize our product candidates on a timely basis, which would require us to incur additional costs and delay our receipt of any product revenue. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We, or our collaborators, are either currently enrolling patients in clinical trials or anticipate initiating, continuing, or designing, or supporting clinical trials for molecules that include vobra duo, lorigerlimab, retifanlimab, enoblituzumab, MGD024, and MGC026 or other molecules, as monotherapies or in combination with other product candidates. For example, in </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024 academic collaborators have initiated or will initiate an investigator sponsored trial for enoblituzuumab. We anticipate in the future collaborators will initiate or continue clinical trials of one or more our product candidates. The continuation, modification, or commencement of existing or new clinical trials could be substantially delayed or prevented by several factors, including: </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">further discussions with the FDA or other regulatory agencies regarding the scope or design of our clinical trials; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the limited number of, and competition for, suitable sites to conduct our clinical trials, many of which may already be engaged in other clinical trial programs, including some that may be for the same indication as our product candidates; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any delay or failure in patient recruitment or enrollment in our or our collaborators&#8217; trials for any reason; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any delay or failure to obtain regulatory approval or agreement to commence a clinical trial in any of the countries where enrollment is planned; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability to obtain sufficient funds required for a clinical trial; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clinical holds on, or other regulatory objections to, a new or ongoing clinical trial; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delay or failure to manufacture sufficient supplies of the product candidate for our clinical trials; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delay or failure to reach agreement on acceptable clinical trial terms or clinical trial protocols with prospective sites or CROs the terms of which can be subject to extensive negotiation and may vary significantly among different sites or CROs; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delay or failure to obtain IRB approval to conduct a clinical trial at a prospective site; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">significant competition of product candidates that are expected to be more effective or have a more favorable safety profile;</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approval of potential therapies by competitors;</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The progress or completion of our, or our collaborators', clinical trials have been and could also be substantially delayed or prevented by many factors, including: </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unforeseen safety issues, including severe or unexpected drug-related adverse effects experienced by patients, including actual and possible deaths; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in expected site initiation, patient recruitment and enrollment, for any reason; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure of patients to complete the clinical trial; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">lack of efficacy during clinical trials; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">termination of our clinical trials by one or more clinical trial sites; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability or unwillingness of patients or clinical investigators to follow our clinical trial protocols; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">economic and political instability in countries where our trial sites are located, including terrorist attacks, civil unrest and actual or threatened armed conflict;</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability to monitor patients adequately during or after treatment by us, our collaboration partners and/or our CROs; and </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the need to repeat or terminate clinical trials as a result of inconclusive or negative results or unforeseen complications in testing. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in regulatory requirements and guidance may also occur and we may need to significantly amend clinical trial protocols to reflect these changes with appropriate regulatory authorities. Amendments may require us to renegotiate terms with CROs or resubmit clinical trial protocols to IRBs for re-examination, which may impact the costs, timing or successful completion of a clinical trial. Our clinical trials may be suspended or terminated at any time by the FDA, other regulatory authorities, the IRB overseeing the clinical trial at issue, any of our clinical trial sites with respect to that site, or us, due to a number of factors, including: </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unforeseen safety issues or any determination that a clinical trial presents unacceptable health risks; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">lack of adequate funding to continue the clinical trial due to unforeseen costs or other business decisions; and </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">upon a breach or pursuant to the terms of any agreement with, or for any other reason by, current or future collaborators that have responsibility for the clinical development of any of our product candidates. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials of our product candidates are subject to partial or full clinical holds from time to time. A clinical hold received in the midst of conducting a trial may delay the progress of a clinical trial, or may require us to modify or discontinue such trial. Any failure or significant delay in completing clinical trials for our product candidates would adversely affect our ability to obtain regulatory approval and our commercial prospects and ability to generate product revenue will be diminished.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The results of previous clinical trials may not be predictive of future results, and interim or top line data may be subject to change or qualification, based on several factors, including a complete analysis of data, or in the case of interim analysis, the continued or ongoing accrual of data. In addition, the results of our current and planned clinical trials may not satisfy the requirements of the FDA or non-U.S. regulatory authorities for product approval. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical failure can occur at any stage of clinical development. Clinical trials may produce negative or inconclusive results, and we or any of our current and future collaborators may decide, or regulators may require us, to conduct additional clinical or nonclinical testing. Success in early clinical trials does not mean that future larger registration clinical trials will be successful because product candidates in later-stage clinical trials may fail to demonstrate sufficient safety and efficacy to the satisfaction of the FDA and non-U.S. regulatory authorities despite having progressed through initial clinical trials. A number of companies in the pharmaceutical industry, including those with greater resources and experience than us, have suffered significant setbacks in advanced clinical trials, even after obtaining promising results in earlier clinical trials. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We may publicly disclose top line or interim data from time to time, which is based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial or continued progress of the study or trial. The top line or interim results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Top line and interim data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. In addition, the achievement of one primary endpoint for a trial does not guarantee that additional co-primary endpoints or secondary endpoints will be achieved, which may have an adverse effect on our ability to obtain or retain additional regulatory approval of products or product candidates in the U.S. or in other jurisdictions. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We use or may use novel technologies in the development of our product candidates and the FDA and other regulatory authorities have not approved products that utilize these technologies. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products in development are based on our technology platforms, including Fc Optimization, DART and TRIDENT technologies. Given the novelty of these technologies, we intend to work closely with the FDA and other regulatory authorities to perform the requisite scientific analyses and evaluation of our methods to obtain regulatory approval for our product candidates. Even though MARGENZA, which incorporates an Fc variation created using our Fc Optimization platform, was approved by the FDA, there is no assurance that the FDA will approve future product candidates using such technology. The validation process takes time and resources, may require independent third-party analyses, and may not be accepted by the FDA and other regulatory authorities. For some of our product candidates that are based on these technology platforms, the regulatory approval path and requirements may not be clear or evolve as more data becomes available for this product candidates, which could add significant delay and expense. Delays or failure to obtain regulatory approval of any of the product candidates that we develop would adversely affect our business. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be successful in our efforts to use and expand our technology platforms to build a pipeline of product candidates. We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.  </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A key element of our strategy is to use and expand our technology platforms to continue to build a pipeline of product candidates and progress several of these product candidates through clinical development for the treatment of a variety of different types of diseases. Although our research and development efforts to date have resulted in a pipeline of product candidates directed at various cancers, as well as autoimmune disorders and infectious diseases, we may not be able to develop product candidates that are safe and effective. Even if we are successful in continuing to build our pipeline, the potential </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product candidates that we identify may not be suitable for initial or continued clinical development, including as a result of being shown to have harmful side effects or other characteristics that indicate that they are unlikely to be products that will receive marketing approval and achieve market acceptance. If we do not continue to successfully develop and begin to commercialize product candidates, we will face difficulty in obtaining product revenues in future periods, which could result in significant harm to our financial position and adversely affect our stock price. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we have limited financial and managerial resources, we focus on research programs and product candidates that we identify for specific indications. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Vobra duo, lorigerlimab, or any other product or product candidate that we developed or may develop may fail to achieve or maintain market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vobra duo, lorigerlimab, or any other product or product candidate that we developed or may develop may fail to achieve or maintain market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success. For example, revenues from MARGENZA are not anticipated to enable us to reach profitability.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If product candidates that we develop do not achieve an adequate level of acceptance, we may not generate significant product revenues and we may not become profitable. The degree of market acceptance of any product candidates that we develop will depend on a number of factors, including but not limited to: </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the efficacy and potential advantages compared to alternative treatments; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prevalence and severity of any side effects; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any safety events that may have occurred in connection with the development of the product candidate; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to offer our products for sale at competitive prices; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the convenience and ease of administration compared to alternative treatments; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the willingness of physicians to prescribe the product or other new therapies, and of the patient population to try the product or these therapies; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the strength of marketing, sales, and distribution support; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of third-party coverage and adequate reimbursement; and </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any restrictions on the use of our products together with other medications. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The potential market opportunities for our product candidates are difficult to precisely estimate. A product&#8217;s market acceptance depends significantly on the medical community&#8217;s determination of clinical benefit and safety compared to alternative therapies available both now and in the future. Our internal estimates of the potential market opportunities for vobra duo, lorigerlimab, and our other product candidates include several key assumptions based on a variety of factors, which may include our industry knowledge, industry publications, third-party research reports, assessment of competition, and other surveys. While we believe that our internal assumptions are reasonable, no independent source has verified such assumptions. If any of these assumptions proves to be inaccurate, then the actual market for vobra duo, lorigerlimab, or our other product candidates could be smaller than our estimates of our potential market opportunity</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8239;Our product candidates may have undesirable side effects which may delay or prevent further clinical development or marketing approval, or, if approval is received, require them to be taken off the market, require them to include safety warnings or otherwise limit their sales.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although all of our product candidates have undergone or will undergo safety testing, not all adverse effects of drugs can be predicted or anticipated. Unforeseen side effects from any of our product candidates could arise either during clinical development or after the approved product has been marketed. Ongoing or future trials of our product candidates may not </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">support the conclusion that one or more of these product candidates have acceptable safety profiles. The results of future clinical or nonclinical trials may show undesirable or unacceptable side effects, which could interrupt, delay or halt clinical trials, and result in delay of, or failure to obtain, marketing approval from the FDA and other regulatory authorities, or result in marketing approval from the FDA and other regulatory authorities with restrictive label warnings, risk management measures, or potential product liability claims. For example, in July 2022 we announced the discontinuation of our Phase 2 trial of enoblituzumab in combination with either retifanlimab or tebotelimab in the treatment of patients with recurrent or metastatic SCCHN, based on an internal review of safety data.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or others later identify undesirable or unacceptable side effects potentially caused by such products: </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may require us to take our approved product off the market; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may require the addition of labeling statements, specific warnings, a contraindication or field alerts to physicians and pharmacies;</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be required to change the way the product is administered, impose other risk-management measures, conduct additional clinical trials or change the labeling of the product; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be subject to limitations on how we may promote the product; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales of the product may decrease significantly; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be subject to litigation or product liability claims; and </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our reputation may suffer. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, the prescribing information for MARGENZA include warnings and precautions for infusion-related reactions, as well as a boxed warning related to left ventricular dysfunction and embryo-fetal toxicity. Based on the possible identification of future adverse events, we may be required to further revise the prescribing information, including MARGENZA&#8217;s boxed warning, which could negatively impact sales of MARGENZA or adversely affect MARGENZA&#8217;s acceptance in the market. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these events could prevent us, our collaborators or our potential future partners from achieving or maintaining market acceptance of the affected product or could substantially increase commercialization costs and expenses, which in turn could delay or prevent us from generating significant revenue from the sale of our products </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our manufacturing facilities are subject to significant government regulations and approvals, which are often costly and could result in adverse consequences to our business if we fail to comply with the regulations or maintain the approvals. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We must comply with the FDA&#8217;s cGMP requirements, as set out in statute, regulations and interpreted through guidance. We may encounter difficulties in achieving quality control and quality assurance and may experience shortages in qualified personnel. We are subject to inspections by the FDA and comparable agencies in other jurisdictions to confirm compliance with applicable regulatory requirements. See &#8220;Other U.S. Post-Marketing Regulatory Requirements&#8221; above for additional information. Any failure to follow cGMP or other regulatory requirements or delay, interruption or other issues that arise in the manufacture, fill-finish, packaging, or storage of our product or product candidates as a result of a failure of our facilities or the facilities or operations of third parties to comply with regulatory requirements or pass any regulatory authority inspection could significantly impair our ability to develop and commercialize our product or product candidates, including leading to significant delays in the availability of drug product for sale and our clinical trials or the termination or hold on a clinical trial, or the delay or prevention of a filing or approval of marketing applications for our product candidates. Significant noncompliance could also result in the imposition of sanctions, including fines, injunctions, civil penalties, failure of regulatory authorities to grant marketing approvals for our product candidates, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of products, operating restrictions and criminal prosecutions, any of which could damage our reputation or negatively impact a product&#8217;s commercial success. If we are not able to maintain regulatory compliance, we may not be permitted to market our product candidates and/or may be subject to product recalls, seizures, injunctions, or criminal prosecution. Additionally, if the FDA or a comparable foreign regulatory authority does not approve of our facilities for the manufacture of a customer product or if it withdraws such approval in the future, our customers may choose to identify alternative manufacturing facilities and/or relationships, which could significantly impact our ability to expand our CDMO capacity and capabilities and achieve profitability.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face significant competition and if our competitors continue to develop and market products that are more effective, safer or less expensive than our product and our product candidates, our current or future commercial opportunities may be negatively impacted. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The life sciences industry is highly competitive and subject to rapid and significant technological change. We are currently developing therapeutics that will compete with other drugs and therapies that currently exist or are being developed. Products we may develop in the future are also likely to face competition from other drugs and therapies, some of which we may not currently be aware. We have competitors both in the United States and internationally, including major multinational pharmaceutical companies, established biotechnology companies, specialty pharmaceutical companies, universities and other research institutions. Many of our competitors have significantly greater financial, manufacturing, marketing, drug development, technical and human resources than we do. Large pharmaceutical companies, in particular, have extensive experience in clinical testing, obtaining regulatory approvals, recruiting patients and manufacturing pharmaceutical products. These companies also have significantly greater research and marketing capabilities than we do and may also have products that have been approved or are in late stages of development, and collaborative arrangements in our target markets with leading companies and research institutions. Established pharmaceutical companies may also invest heavily to accelerate discovery and development of novel compounds or to in-license novel compounds that could make the product candidates that we develop obsolete. As a result of all of these factors, our competitors may succeed, or may have succeeded, in obtaining patent protection and/or FDA approval or discovering, developing and commercializing products in our field before we do. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specifically, there are a large number of companies developing or marketing potential treatments for cancer, including many major pharmaceutical and biotechnology companies. These treatments consist both of small molecule drug products, as well as biologic therapeutics that work by using next-generation antibody technology platforms to address specific cancer targets. In addition, several companies are developing therapeutics that work by targeting multiple specificities using a single recombinant molecule. See &#8220;Competition&#8221; above for additional information. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our commercial opportunity for MARGENZA is very limited, and the commercial opportunity for future product candidates including vobra duo or lorigerlimab may be reduced or limited if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe effects, are more convenient or are less expensive than any products that we may develop. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours. In addition, our ability to compete may be affected in many cases by insurers or other third-party payors seeking to encourage the use of biosimilar products. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Smaller and other early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. In addition, the biopharmaceutical industry is characterized by rapid technological change. If we fail to stay at the forefront of technological change, we may be unable to compete effectively. Technological advances or products developed by our competitors may render our technologies, products or product candidates obsolete, less competitive or not economical. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The manufacture of vobra duo, lorigerlimab, and other products or product candidates, for ourselves and our collaborators, is complex, and we may encounter difficulties in production. There can be no assurance that we will be able to effectively manufacture clinical quantities of our product candidates in the future. Further, we have limited experience in large-scale commercial manufacturing, and there can be no assurance that we will be able to effectively manufacture commercial quantities of our products  or product candidates for ourselves or our collaborators, if and when approved.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently manufacture product and product candidates for ourselves and our collaborators in our in-house manufacturing facility, and we anticipate manufacturing both commercial product as well as product candidates in the future, including for example commercial manufacturing of MARGENZA. We have limited experience in manufacturing at commercial scale. The process of commercial or clinical biotechnology manufacturing for ourselves and our collaborators is highly susceptible to delays or product loss due to a variety of factors, including but not limited to contamination, equipment failure, improper installation or operation of equipment, vendor or operator error, inconsistency in yields, variability in product characteristics, difficulties in scaling the production process, and vendor supply chain disruptions or fluctuations. Even minor deviations from manufacturing processes could result in reduced production yields, product defects and other supply disruptions. If microbial, viral or other contaminations are discovered in our products or  product candidates or in the manufacturing facilities in which our products  and our product candidates are made, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination. Any adverse developments affecting manufacturing operations for our products and our product candidates, if any are approved, may result in shipment delays, inventory shortages, lot failures, product withdrawals or recalls, or other interruptions in the supply of our products. We may also have to take inventory write-offs and incur other charges and expenses for products that fail to meet specifications, undertake costly remediation efforts or seek more costly manufacturing alternatives. In addition, if we fail to supply required quantities of a product or a product candidate for one of our collaborators, our collaborator may terminate our agreement.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we currently maintain insurance coverage against damage to our property and to cover business interruption and research and development restoration expenses, our insurance coverage may not reimburse us, or may not be sufficient to reimburse us, for any expenses or losses we may suffer. If there were to be a catastrophic event or failure of our manufacturing facilities or processes, we may be unable to meet our requirements for supply of our products or product candidates.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Public health crises such as pandemics or similar outbreaks may have a significant negative impact on our clinical trials, nonclinical studies, development, manufacturing and commercialization of our product candidates and other aspects of our business, staff, and operations.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Public health crises such as pandemics or similar outbreaks may have a material impact our business. For instance, the COVID-19 pandemic impaired, and future public health crises may in the future impair, our ability to enroll patients in clinical trials, continue ongoing clinical trials and activate clinical trial sites. Further, product commercialization may be impaired due to an outbreak in a specific geography, the shifting of healthcare resources toward a future health crises or pandemic or the closing of or limiting of access to clinical facilities, and reduced or eliminated in-person access to physicians and health care centers. Furthermore, patients may be unable or unwilling to enroll in our clinical trials or be unable to comply with clinical trial protocols if public health restrictions impede patient movement or interrupt healthcare services. Public health crises may also negatively affect the operations of third-party CROs that we rely upon to carry out our clinical trials, or the operations of other service providers, which could result in delays or disruptions in the supply of our product candidates or other aspects of our business or that of our collaborators. Any negative impact public health crises could adversely affect our ability to seek and obtain regulatory approval for and to commercialize any approved product candidates, increase our operating expenses and have a material adverse effect on our business and financial results. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We have limited experience in launching and marketing internally developed products. If our products achieve regulatory approval and we are unable to further develop marketing and sales capabilities or enter into agreements with third parties to market and sell our products, or our existing arrangements are not successful, we may not be able to generate substantial product sales revenue. </span></div><div><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, the FDA approved MARGENZA, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. We launched MARGENZA in March 2021. In conjunction with Eversana, we continue to  support commercialization of MARGENZA in the United States in a manner we believe to be appropriate in light of the limited size of the market opportunity. We have limited internal commercialization capabilities, and any additional products or product candidates that we may develop or in-license, will require significant capital expenditures, management resources and time. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have limited experience in commercializing our products. For example, we have limited experience in building and managing a commercial team, conducting a comprehensive market analysis or managing distributors and a field force for our products. We compete with many companies that currently have extensive and well-funded sales and marketing operations. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For commercialization of any or all of our product candidates, we will have to compete with other pharmaceutical and biotechnology companies to recruit, hire, train and retain marketing and sales personnel. If we are unable to, or decide not to, further develop internal sales, marketing, and commercial distribution capabilities for any or all of our products, we will likely pursue additional collaborative arrangements regarding the sales and marketing of our products. However, there can be no assurance that we will be able to establish or maintain such collaborative arrangements, or if we are able to do so, that they will be effective. Any revenue we receive will depend upon the efforts of such third parties. We may have little or no control over the marketing and sales efforts of such third parties, and our revenue from product sales may be lower than if we had commercialized our products ourselves. We also face competition in our search for third parties to assist us with the commercialization of our products. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There can be no assurance that we will be able to further develop or successfully maintain internal sales and commercial capabilities or establish or maintain relationships with third-party collaborators to successfully commercialize any product, and as a result, we may not be able to generate substantial product sales revenue.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Actual or anticipated changes to the laws and regulations governing the health care system may have a negative impact on cost and access to health insurance coverage and reimbursement of healthcare items and services.  </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The United States and several foreign jurisdictions are considering, or have already enacted, a number of legislative and regulatory proposals to change the healthcare system in ways that could affect our ability to sell any of our future approved products profitably. Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs through lowering prescription drug prices, improving quality and/or expanding access to healthcare. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives, including the Patient </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively, the ACA, which became law in 2010. While it is difficult to assess the impact of the ACA in isolation, either in general or on our business specifically, it is widely thought that the ACA increases the likelihood of downward pressure on pharmaceutical reimbursement, which could negatively affect market acceptance of, and the price we may charge for, any products we develop that receive regulatory approval. Further, the United State and foreign governments regularly consider additional reform measures that affect healthcare coverage and costs. Such reforms may include changes to the coverage and reimbursement of healthcare services and products. In particular, there have been executive, judicial and Congressional challenges to the ACA, which could have an impact on coverage and reimbursement for healthcare services covered by plans authorized by the ACA. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While Congress has not passed comprehensive repeal legislation, several bills affecting the implementation of certain taxes under the ACA have been signed into law. The Tax Cuts and Jobs Act of 2017 (Tax Act) included a provision which repealed, effective January 1, 2019, the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual mandate.&#8221; On June 17, 2021, the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. Prior to the U.S. Supreme Court ruling, on January 28, 2021, President Biden issued an executive order that initiated a special enrollment period for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. In addition, on August 16, 2022, President Biden signed the Inflation Reduction Act of 2022 (IRA) into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The IRA also eliminates the &#8220;donut hole&#8221; under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and creating a new manufacturer discount program. It is possible that the ACA will be subject to judicial or Congressional challenges in the future. It is unclear how such challenges and any healthcare reform measures of the Biden administration will impact the ACA and our business. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, there has been heightened governmental scrutiny in the United States of pharmaceutical pricing practices in light of the rising cost of prescription drugs. Such scrutiny has resulted in several recent congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. For example, in July 2021, the Biden administration released an executive order, &#8220;Promoting Competition in the American Economy,&#8221; with multiple provisions aimed at prescription drugs. In response to Biden&#8217;s executive order, on September 9, 2021, the U.S. Department of Health and Human Services (HHS) released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue as well as potential administrative actions HHS can take to advance these principles. In addition, the IRA, among other things, (i) directs HHS to negotiate the price of certain high-expenditure, single-source drugs and biologics covered under Medicare, and subject drug manufacturers to civil monetary penalties and a potential excise tax by offering a price that is not equal to or less than the negotiated &#8220;maximum fair price&#8221; for such drugs and biologics under the law, and (ii) imposes rebates with respect to certain drugs and biologics covered under Medicare Part B or Medicare Part D to penalize price increases that outpace inflation. The IRA permits HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years. These provisions take effect progressively starting in fiscal year 2023. On August 29, 2023, HHS announced the list of the first ten drugs that will be subject to price negotiations, although the Medicare drug price negotiation program is currently subject to legal challenges. It is unclear how the IRA will be implemented but is likely to have a significant impact on the pharmaceutical industry. In response to the Biden administration&#8217;s October 2022 executive order, on February 14, 2023, HHS released a report outlining three new models for testing by the Centers for Medicare &amp; Medicaid Services, or CMS, Innovation Center which will be evaluated on their ability to lower the cost of drugs, promote accessibility, and improve quality of care. It is unclear whether the models will be utilized in any health reform measures in the future. Further, on December 7, 2023, the Biden administration announced an initiative to control the price of prescription drugs through the use of march-in rights under the Bayh-Dole Act. On December 8, 2023, the National Institute of Standards and Technology published for comment a Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights which for the first time includes the price of a product as one factor an agency can use when deciding to exercise march-in rights. While march-in rights have not previously been exercised, it is uncertain if that will continue under the new framework. We cannot predict what healthcare initiatives, if any, will be implemented at the federal or state level, however, government and other regulatory oversight and future regulatory and government interference with the healthcare systems could adversely impact our business and results of operations. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to experience pricing pressures in connection with the sale of any products that we develop, due to the trend toward managed healthcare, the increasing influence of various and evolving payor models and additional legislative proposals.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reimbursement decisions by third-party payors may have an adverse effect on pricing and market acceptance. If there is not sufficient reimbursement for our products, it is less likely that our products will be widely used.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Market acceptance and sales of our products and product candidates, if approved for sale by the appropriate regulatory authorities, may depend on reimbursement policies and may be affected by future healthcare reform measures. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which drugs they will reimburse and establish payment levels and, in some cases, utilization management strategies, such as tiered formularies and prior authorization. We cannot be certain that reimbursement will be available for our products or any products that we develop. Also, we cannot be certain that reimbursement policies will not reduce the demand for, or the price paid for, our products. Our ability to commercialize our products may depend, in part, on the extent to which reimbursement for the products will be available from government authorities and third-party payors. If reimbursement for our products is not available or is available on a limited basis, or if the reimbursement amount for our products is inadequate to support a product&#8217;s price, we may not be able to successfully commercialize any of our approved products. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is uncertainty related to third-party payor coverage and reimbursement of newly approved products. In the United States, for example, principal decisions about reimbursement for new products are typically made by CMS, an agency within HHS. CMS decides whether and to what extent a new product will be covered and reimbursed under Medicare, and private third-party payors often follow CMS&#8217;s decisions regarding coverage and reimbursement to a substantial degree. However, one third-party payor&#8217;s determination to provide coverage for a product candidate does not assure that other payors will also provide coverage for the product candidate. Further, no uniform policy for coverage and reimbursement exists in the United States, and coverage and reimbursement can differ significantly from payor to payor. As a result, the coverage and reimbursement determination process is often time-consuming and costly. This process may require us to provide scientific and clinical information to support the coverage or reimbursement of our products to each third-party payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As federal and state governments implement additional health care cost containment measures, including measures to lower prescription drug pricing, we cannot be sure that our products and our product candidates, if approved, will be covered, or remain covered, by private or public payors, and if covered, whether the reimbursement will be perceived by product purchasers as adequate. Health reform actions by federal and state governments and health plans may put additional downward pressure on pharmaceutical pricing and health care costs, which could negatively impact coverage and reimbursement for our product or our product candidates, if approved, our revenue, and our ability to compete with other marketed products and to recoup the costs of our research and development. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Increasingly, third-party payors are requiring that biopharmaceutical manufacturers provide them with discounts from list prices and are challenging the prices charged for medical products. Further, such payors are increasingly challenging the price, examining the medical necessity and reviewing the cost effectiveness of medical products. There may be especially significant delays in obtaining coverage and reimbursement for newly approved drugs. Third-party payors may limit coverage to specific products and product candidates on an approved list, known as a formulary, which might not include all FDA-approved drugs for a particular indication. We may need to conduct expensive pharmaco-economic studies to demonstrate the medical necessity and cost effectiveness of our products. Nonetheless, our products may not be considered medically necessary or cost effective. We cannot be sure that coverage and reimbursement will be available for any approved product that we commercialize and, if reimbursement is available, what the level of reimbursement will be. Further, coverage policies and third-party payor reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained, less favorable coverage policies and reimbursement rates may be implemented in the future. Additionally, we or our collaborators may develop companion diagnostic tests for use with our product candidates where appropriate. We or our collaborators will be required to obtain coverage and reimbursement for these tests separate and apart from the coverage and reimbursement we may seek for our product candidates. While we have not yet developed any companion diagnostic tests for our product candidates, if we do, there is significant uncertainty regarding our ability to obtain coverage and adequate reimbursement for the same reasons applicable to our product candidates.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If any product liability lawsuits are successfully brought against us or any of our collaborators, we may incur substantial liabilities and may be required to limit commercialization of our products or product candidates. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face an inherent risk of product liability lawsuits related to the sale of our products to, use of our products by, and testing of our product candidates in, seriously ill patients. Product liability claims may be brought against us or our collaborators by participants enrolled in our clinical trials, patients, health care providers or others using, administering or selling any of our approved products. If we cannot successfully defend ourselves against any such claims, we may incur substantial liabilities. Regardless of their merit or eventual outcome, liability claims may result in:</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased demand for our current or future approved products; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injury to our reputation; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">withdrawal of clinical trial participants; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">termination of clinical trial sites or entire trial programs; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased regulatory scrutiny; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">significant litigation costs; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">substantial monetary awards to or costly settlement with patients or other claimants; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product recalls or a change in the indications for which they may be used; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">loss of revenue; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">diversion of management and scientific resources from our business operations; and </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inability to commercialize our product candidates.  </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to vobra duo, lorigerlimab, and any of our other products or product candidates that are approved for commercial sale, we are, and will be, highly dependent upon physician and patient perceptions of us and the safety and quality of our products. We could be adversely affected if we are subject to negative publicity. We could also be adversely affected if any of our products or any similar products distributed by other companies prove to be, or are asserted to be, harmful to patients. Because of our dependence upon consumer perceptions, any adverse publicity associated with illness or other adverse effects resulting from patients&#8217; use or misuse of our products or any similar products distributed by other companies could have a material adverse impact on our financial condition or results of operations. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, we hold $20 million in product liability insurance coverage in the aggregate, with a per incident limit of $20 million, which may not be adequate to cover all liabilities that we may incur. We may need to increase our insurance coverage when we begin the commercialization of additional product candidates. Insurance coverage is becoming increasingly expensive. As a result, we may be unable to maintain or obtain sufficient insurance at a reasonable cost to protect us against losses that could have a material adverse effect on our business. A successful product liability claim or series of claims brought against us, particularly if judgments exceed any insurance coverage we may have, could decrease our cash resources and adversely affect our business, financial condition and results of operation. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we and our collaborators obtain regulatory approvals to market our current and any future approved products, we and our collaborators will remain subject to extensive ongoing regulatory obligations and oversight, including post-approval requirements, that could result in significant additional expense and could negatively impact our and our collaborators' ability to commercialize our current and any future approved products. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our collaborators are subject to extensive ongoing obligations and continued regulatory review from applicable regulatory agencies with respect to any product obtaining regulatory approval, including vobra duo, lorigerlimab, and our other products and product candidates, such as continued adverse event reporting requirements and post-marketing commitments, all of which may result in significant expense and limit our and our collaborators' ability to commercialize our current and any future approved products. For example, the FDA's approval of MARGENZA included a requirement that we provide to the FDA the data from the final overall survival endpoint from our SOPHIA study, which we reported in September 2021. Moreover, in connection with MARGENZA&#8217;s approval, the labeling and advertising and promotion of MARGENZA are subject to additional regulatory requirements, which could entail significant expense and could negatively impact the potential commercialization of MARGENZA. To the extent other product candidates or those of our partners are approved by the FDA, we or our collaborators may be subject to similar post-marketing obligations. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and the manufacturers of our current and any future approved products are also required, or will be required, to comply with cGMP regulations, which include requirements relating to quality control and quality assurance as well as the corresponding maintenance of records and documentation. Further, regulatory agencies must approve these manufacturing facilities before they can be used to manufacture our products and product candidates, and these facilities are subject to ongoing regulatory inspections. In addition, regulatory agencies subject an approved product, its manufacturer and the manufacturer&#8217;s facilities to continual review and inspections, including periodic unannounced inspections. The subsequent discovery of previously unknown problems with our current or any future approved products, including adverse events of unanticipated severity or frequency, or problems with the facilities where our current or any future approved products are manufactured, may result in restrictions on the marketing of our current or any such future approved products, up to and including withdrawal of the affected product from the market. If our manufacturing facilities, our collaborators' manufacturing facilities, or those of our </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">respective suppliers, fail to comply with applicable regulatory requirements, such noncompliance could result in regulatory action and additional costs to us. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to comply with applicable FDA and other regulatory requirements may subject us to administrative or judicially imposed sanctions, including: notices or Warning Letters by the FDA or other regulatory agencies; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">issuance of Form FDA 483 notices or Warning Letters by the FDA or other regulatory agencies; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">imposition of fines and other civil penalties; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">criminal prosecutions; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injunctions, suspensions or revocations of regulatory approvals; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspension of any ongoing clinical trials; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">total or partial suspension of manufacturing; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in commercialization; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusal by the FDA to approve pending applications or supplements to approved applications submitted by us; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusals to permit drugs to be imported into or exported from the United States; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on operations, including costly new manufacturing requirements; and </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product recalls or seizures. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The policies of the FDA and other regulatory agencies may change and additional government regulations may be enacted that could prevent or delay regulatory approval of vobra duo, our other product candidates or of MARGENZA in any additional indications or territories, or further restrict or regulate post-approval activities. We cannot predict the likelihood, nature or extent of adverse government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are not able to maintain regulatory compliance, we or our collaborators might not be permitted to market our current or any future approved products and our business would suffer. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We and/or our collaboration partners may never obtain approval or commercialize our products outside of the United States, which would limit our ability to realize their full market potential.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to market any products outside of the United States, we and our current and potential collaboration partners must establish and comply with numerous and varying regulatory requirements of other countries regarding safety and efficacy. Clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not mean that regulatory approval will be obtained in any other country. Approval procedures vary among countries and may require additional nonclinical studies or clinical trials or additional administrative review periods, which could result in significant delays, difficulties and costs for us. In addition, our failure to obtain regulatory approval in any country may delay or have negative effects on the process for regulatory approval in other countries. Further, even if a product candidate receives regulatory approval outside of the United States, the collaborator may not commercialize the product or may not commercialize the product effectively. For example, our partner Zai Lab obtained regulatory approval of MARGENZA in China, but did not commercialize the product and in November 2023 provided notice of termination of the agreement.  Although we obtained FDA approval of MARGENZA in December 2020, we do not have any Company products or product candidates being commercialized in any international market. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, our target market will be reduced and our ability to realize the full market potential of our products will be harmed. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inadequate funding for the FDA and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies on which our operations may rely, including those that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the past decade, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA, and other government employees and pause or stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Certain of our contracts include government contractor requirements. Laws and regulations affecting government contracts may make it more costly and difficult for us to successfully conduct our business. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We must comply with numerous laws and regulations relating to the procurement, formation, administration and performance of government contracts. Failure to comply with these laws could result in significant civil and criminal penalties. Among the most significant government contracting regulations that may affect our business are: the Federal Acquisition Regulation (FAR) and NIH-NIAID-specific regulations supplemental to the FAR, which comprehensively regulate the procurement, formation, administration and performance of government contracts; business ethics and public integrity obligations, which govern conflicts of interest and the hiring of former government employees, restrict the granting of gratuities and funding of lobbying activities and incorporate other requirements such as the Anti-Kickback Act, the Procurement Integrity Act, and the False Claims Act; export and import control laws and regulations; and laws, regulations and executive orders restricting the use and dissemination of sensitive information we may receive pursuant to our performance of the government contract. U.S. government agencies routinely audit and investigate government contractors for compliance with applicable laws and standards. If we are audited, such audit could result in disallowance of expected cost reimbursement, or if such audit were to uncover improper or illegal activities, we could be subject to civil and criminal penalties, administrative sanctions, including suspension or debarment from government contracting and significant reputational harm. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in U.S. tax law may have a material adverse effect on our business, financial condition and results of operations, and changes in international trade relations may have a material adverse effect on the commercialization of some or all of our product candidates.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in laws and policy relating to taxes may have an adverse effect on our business, financial condition and results of operations. Recent tax reforms in the United States have resulted in significant changes to preexisting U.S. tax rules and regulations. These changes may trigger an adverse effect on our business, financial conditions and results of operations. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the U.S. government may seek to implement more protective trade measures with countries in which we plan to conduct business in, with great deal of uncertainty regarding trade policies, tariffs and government regulations, which if altered could have the potential to create a significant adverse effect on trade between the United States and other countries. Overall, changes in international trade relations, such as the imposition of or increase in tariffs or other trade barriers, could materially and adversely impact our costs, the ability to make sales of our product candidates to any of our significant customers in other countries, and reduce the competitiveness of our product candidates. </span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Financial Position and Need for Additional Capital </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will require substantial additional funding, which may not be available to us on acceptable terms, or at all, and, if not available, may require us to delay, scale back, or cease our product development programs or operations. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are advancing our product candidates through clinical development and have commercialized MARGENZA in collaboration with Eversana. Developing and commercializing pharmaceutical products, including conducting nonclinical studies and clinical trials, is expensive. In order to obtain such regulatory approval of product candidates, we will be required to conduct clinical trials for each indication for each of our product candidates. We will continue to require additional funding beyond what was raised in our public offerings and through our collaborations and license agreements to complete the development and commercialization of our product candidates and to continue to advance the development of our other product candidates. Due to worsening global economic conditions, including high rates of inflation and interest rates and concerns of a recession in the United States or other major markets, the recent disruptions to and volatility in the credit and financial markets in the United States and worldwide, and geopolitical instability, including resulting from the ongoing conflicts between Russia and Ukraine and Israel and Hamas and increasing tensions between China and Taiwan, such funding may not be available on acceptable terms or at all. Although it is difficult to predict our funding requirements, we anticipate that our cash, cash equivalents and marketable securities as of December&#160;31, 2023, combined with anticipated and potential collaboration payments, product revenue, contract manufacturing revenue, and royalties, should enable us to fund our operations into 2026. Such guidance does not reflect anticipated expenditures related to the potential late-stage development of vobra duo in mCRPC or further expansion of studies currently ongoing. Because development of our product candidates is uncertain, we are unable to estimate accurately the actual funds we will require to complete research, development and clinical testing to commercialize our product candidates. Our future funding requirements will depend on many factors, including but not limited to: </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> the number and characteristics of other product candidates and indications that we pursue; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope, progress, timing, cost and results of research, nonclinical development, and clinical trials, in particular, our planned potential registrational path trial for MCG018; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs, timing and outcome of seeking and obtaining FDA and non-U.S. regulatory approvals; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs associated with manufacturing our product candidates; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of establishing sales, marketing, and distribution capabilities; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to maintain, expand, and defend the scope of our intellectual property portfolio, including the amount and timing of any payments we may be required to make in connection with the licensing, filing, defense and enforcement of any patents or other intellectual property rights; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our need and ability to hire additional management, scientific, and medical personnel; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effect of competing products that may limit market penetration of our product candidates; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our need to implement additional internal systems and infrastructure, including financial and reporting systems; and </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the economic and other terms, timing of and success of our existing collaborations, and any collaboration, licensing, or other arrangements into which we may enter in the future, including the timing of receipt of any milestone or royalty payments under these agreements.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until we can generate a sufficient amount of product revenue to finance our cash requirements, which we may never do, we expect to finance future cash needs primarily through a combination of public or private equity offerings, debt financings, strategic collaborations, and grant funding. If sufficient funds on acceptable terms are not available when needed, or at all, we could be forced to significantly reduce operating expenses and delay, scale back or eliminate one or more of our development programs or our business operations. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred significant losses since inception and anticipate that we will continue to incur losses for the foreseeable future. Our first commercial product, MARGENZA, launched in March 2021 and has not resulted in revenues sufficient for us to reach profitability, to date, and we do not expect it to in the future. Accordingly, we may never achieve or sustain profitability. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred significant losses since our inception. As of December&#160;31, 2023, our accumulated deficit was approximately $1.1&#160;billion. We expect to continue to incur losses for the foreseeable future, and we expect our accumulated deficit to increase as we continue our research and development of, and seek regulatory approvals for, our product candidates, manufacture product and product candidate inventory, prepare for and begin to commercialize any future approved products, and add infrastructure and personnel if needed to support our product development efforts and operations as a public company. The net losses and negative cash flows incurred to date, together with expected future losses, have had, and likely will continue to have, an adverse effect on our stockholders' deficit and working capital. The amount of future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the numerous risks and uncertainties associated with pharmaceutical product development and commercialization, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. For example, our expenses could increase if we are required by the FDA to perform trials in addition to those that we currently expect to perform, or if there are any delays in completing our currently planned clinical trials or in the development of any of our product candidates. Our expenses would significantly increase to the extent we build out a sales force and other commercially relevant functions to support the commercialization of any of our product candidates.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> To become and remain profitable, we must succeed in developing and commercializing products with significant market potential. For example, revenues from MARGENZA are highly unlikely to be sufficient to enable us to reach profitability. In order to commercialize any additional product candidates, we will need to be successful in a range of challenging activities for which we are only in the preliminary stages, including developing product candidates, obtaining regulatory approval for them, and manufacturing, marketing and selling approved products and product candidates for which we may obtain regulatory approval. We may never succeed in these activities and may never generate revenue from product sales that is significant enough to achieve profitability. Even if we achieve profitability in the future, we may not be able to sustain profitability in subsequent periods. Our failure to become or remain profitable would depress our market value and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">could impair our ability to raise capital, expand our business, develop other product candidates, or continue our operations. A decline in the value of our company could also cause you to lose all or part of your investment. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business could be adversely affected by economic downturns, inflation, increases in interest rates, natural disasters,  political crises, geopolitical events, such as the ongoing military conflict in Ukraine, or other macroeconomic conditions, which have in the past and may in the future negatively impact our business and financial performance.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The global economy, including credit and financial markets, has experienced extreme volatility and disruptions, including, among other things, severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, supply chain shortages, increases in inflation rates, higher interest rates and uncertainty about economic stability. The Federal Reserve recently raised interest rates multiple times in response to concerns about inflation and it may raise them again. Higher interest rates, coupled with reduced government spending and volatility in financial markets may increase economic uncertainty and affect consumer spending. Similarly, the ongoing military conflicts between Russia and Ukraine, Israel and Hamas and increasing tensions between China and Taiwan have created extreme volatility in the global capital markets and is expected to have further global economic consequences, including disruptions of the global supply chain and energy markets. Any such volatility and disruptions may adversely affect our business or the third parties on whom we rely. If the equity and credit markets deteriorate, including as a result of political unrest or war, it may make any necessary debt or equity financing more costly or more dilutive or more difficult to obtain in a timely manner or on favorable terms, if at all. Increased inflation rates can adversely affect us by increasing our costs, including labor and employee benefit costs.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish substantial rights. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these new securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing, if available at all, may involve agreements that include covenants limiting or restricting our ability to take specific actions such as incurring additional debt, making capital expenditures, or declaring dividends. If we raise additional funds through collaborations, strategic alliances, or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, MARGENZA, product candidates, or future revenue streams, or grant licenses on terms that are not favorable to us. We cannot assure you that we will be able to obtain additional funding if and when necessary. If we are unable to obtain adequate financing on a timely basis, we could be required to delay, scale back or eliminate one or more of our development programs or grant rights to develop and market MARGENZA or product candidates that we would otherwise prefer to develop and market ourselves. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to use our net operating loss carryforwards and other tax attributes may be limited. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to utilize our federal net operating losses (NOLs) and federal tax credits is currently limited, and may be limited further, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended. The limitations apply if an ownership change, as defined by Section&#8239;382, occurs. Generally, an ownership change occurs when certain shareholders increase their aggregate ownership by more than 50 percentage points over their lowest ownership percentage in a testing period, which is typically three years or since the last ownership change. We are already subject to Section&#8239;382 limitations due to acquisitions we made in 2002 and 2008.&#8239;As of December&#160;31, 2023, we had federal and state NOL carryforwards of approximately $670.0 million and federal research and development tax credits of approximately $94.4 million available. Future changes in stock ownership may also trigger an ownership change and, consequently, another Section&#8239;382 limitation. Any limitation may result in expiration of a portion of the net operating loss or tax credit carryforwards before utilization which would reduce our gross deferred income tax assets and corresponding valuation allowance. As a result, if we earn net taxable income, our ability to use our pre-change NOL carryforwards and tax credit carryforwards to reduce United States federal income tax may be subject to limitations, which could potentially result in increased future cash tax liability to us. </span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Dependence on Third Parties </span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our existing therapeutic collaborations are important to our business, and future collaborations may also be important to us. If we are unable to maintain any of these collaborations, or if these collaborations are not successful, our business could be adversely affected. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have limited capabilities for drug development and have little to no internal capability for sales, marketing or distribution. We have entered into collaborations with other companies that we believe can provide such capabilities, including our agreements with, for example, Gilead Sciences, Inc, and Incyte Corporation. These current collaborations also have provided us with important funding for our development programs and technology platforms and we expect to receive additional funding under these collaborations in the future. Our existing therapeutic collaborations, and any future collaborations we enter into, may pose a number of risks, including the following:  </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may not perform their obligations as expected; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may not pursue development and commercialization of any product candidates that achieve regulatory approval or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborators' strategic focus or available funding, or external factors, such as an acquisition, that divert resources or create competing priorities; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our products or product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product candidates discovered in collaboration with us may be viewed by our collaborators as competitive with their own product candidates or products, which may cause collaborators to cease to devote resources to the commercialization of our product candidates; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a collaborator with marketing and distribution rights to one or more of our product candidates that achieve regulatory approval may not commit sufficient resources to the marketing and distribution of such product or products; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disagreements with collaborators, including disagreements over proprietary rights, contract interpretation or the preferred course of development, might cause delays in payment, or non-payment, of royalties, milestones or other monies owed, delays or termination of the research, development or commercialization of product candidates, might lead to additional responsibilities for us with respect to product candidates, or might result in litigation or arbitration, any of which would be time-consuming and expensive; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability; and </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborations may be terminated for the convenience of the collaborator and, if terminated, we could be required to raise additional capital to pursue further development or commercialization of the applicable product candidates. For example, each of our collaboration and license agreements may be terminated for convenience upon the completion of a specified notice period.  </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our therapeutic collaborations do not result in the successful development and commercialization of products or if one of our collaborators terminates its agreement with us, we may not receive any future research funding or milestone or royalty payments under the collaboration. All of the risks relating to product development, regulatory approval and commercialization described in this Annual Report on Form 10-K also apply to the activities of our program collaborators. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, subject to its contractual obligations to us, if one of our collaborators is involved in a business combination, the collaborator might de-emphasize or terminate the development or commercialization of MARGENZA or any product candidate licensed to it by us. For example, in November 2023 Zai Lab provided notice of termination of our collaboration agreement with respect to MARGENZA. If one of our collaborators terminates its agreement with us, we may find it more difficult to attract new collaborators. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For vobra duo, lorigerlimab, and our other product candidates, we may in the future decide to collaborate with additional pharmaceutical and biotechnology companies for development and potential commercialization. We face significant competition in seeking appropriate collaborators. Our ability to reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. These factors may include the design or results of clinical trials, the likelihood of approval by the FDA or similar regulatory authorities outside the United States, the potential </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing products, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge and industry and market conditions generally. The collaborator may also consider alternative products, product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us for our product candidate. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaborations are complex and time-consuming to negotiate and document. In addition, there have been a significant number of business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators. If we are unable to reach agreements with suitable collaborators on a timely basis, on acceptable terms, or at all, we may have to curtail the development of vobra duo, lorigerlimab, or our other product candidates, reduce or delay one or more of our other development programs, delay the commercialization of a product candidate or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to fund and undertake development or commercialization activities on our own, we may need to obtain additional expertise and additional capital, which may not be available to us on acceptable terms or at all. If we fail to enter into collaborations and do not have sufficient funds or expertise to undertake the necessary development and commercialization activities, we may not be able to further develop vobra duo, lorigerlimab, or our other product candidates or bring them to market or continue to develop our technology platforms and our business may be materially and adversely affected. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also be restricted under collaboration agreements from entering into additional agreements on certain terms with potential collaborators. Most of our existing therapeutic collaborations contain a restriction on our engaging in activities that are the subject of the collaboration with third parties for specified periods of time.  </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We contract with, and may in the future contract with, third parties for components of the manufacturing of our products and our product candidates, including our antibody drug conjugate candidates.  Failure of third-party contractors to successfully perform their obligations could harm our ability to develop or commercialize our product or product candidates.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have one cGMP manufacturing facility located in Rockville, Maryland in compliance with cGMP to support future clinical and commercial production of our and our collaborators&#8217; product candidates. We manufacture drug substance lots at this facility that we use for clinical trials of our and our collaborators&#8217; product candidates. We will continue to rely on third parties for bioconjugation to produce ADCs and for fill finish activities, neither of which our cGMP manufacturing facility can currently accommodate.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have the capability to manufacture commercial supply of MARGENZA. Although we believe we currently have capacity to produce most or all of the material required for our and our collaborators&#8217; clinical trials and for the commercial supply of MARGENZA, we may not be able to do so in the future and may continue to rely on arrangements with third parties.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into agreements with contract manufacturing organizations in the past to supplement our clinical supply and internal capacity as we commercialize MARGENZA and advance vobra duo, lorigerlimab and other product candidates in our pipeline. In addition, in the future, we may use third parties for the manufacture of some or all components of our product candidates for clinical testing, including antibody drug conjugates, as well as for commercial manufacture of some of our product candidates that receive marketing approval and that are not manufactured by us or one of our third-party collaborators. We may be unable to reach agreement with any of these contract manufacturers, or to identify and reach arrangements on satisfactory terms with other contract manufacturers, to manufacture any of our product candidates. Additionally, the facilities used by any contract manufacturer to manufacture any of our product candidates must be the subject of a satisfactory inspection before the FDA and other regulatory authorities approve a BLA or marketing authorization for the product candidate manufactured at that facility. We will depend on these third-party manufacturing partners for compliance with the FDA&#8217;s requirements for the manufacture of our finished products. If our manufacturers cannot successfully manufacture material that conforms to our specifications and the FDA and other regulatory authorities&#8217; cGMP requirements, our product candidates will not be approved or, if already approved, may be subject to recalls. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reliance on third-party manufacturers entails risks to which we would not be subject if we manufactured products or product candidates ourselves, including: </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the possibility of a breach of the manufacturing agreements by the third parties because of factors beyond our control; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the possibility of termination or nonrenewal of the agreements by the third parties before we are able to arrange for a qualified replacement third-party manufacturer; and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the possibility that we may not be able to secure a manufacturer or manufacturing capacity in a timely manner and on satisfactory terms in order to meet our manufacturing needs. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these factors could adversely impact the commercialization of our products or product candidates, delay approval of our product candidates, or cause us to incur higher costs or prevent us from commercializing our products or product candidates successfully. Furthermore, if contract manufacturers fail to deliver the required commercial quantities of finished product on a timely basis and at commercially reasonable prices, and we are unable to find one or more replacement manufacturers capable of production at a substantially equivalent cost, in substantially equivalent volumes and quality and on a timely basis, we would likely be unable to meet demand for our products and could lose potential revenue. It may take several years to establish an alternative source of supply for our products or product candidates and to have any such new source approved by the FDA or any other relevant regulatory authorities. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Failure to successfully develop and commercialize companion diagnostics with third party contractors for use with our product candidates could harm our ability to commercialize our product candidates. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to develop, or engage third parties to develop, companion diagnostics for our product candidates where appropriate. At least in some cases, the FDA and similar regulatory authorities outside the United States may request or require the development and regulatory approval of a companion diagnostic as a condition to approving one or more of our product candidates. We do not have experience or capabilities in developing or commercializing diagnostics and are relying, and in the future plan to continue to rely, in large part on third parties to perform these functions. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In most cases, we will likely outsource the development, production and commercialization of companion diagnostics to third parties. By outsourcing these companion diagnostics to third parties, we become dependent on the efforts of our third party contractors to successfully develop and commercialize these companion diagnostics. Our contractors: </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> may not perform their obligations as expected; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">may encounter production difficulties that could constrain the supply of the companion diagnostic; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">may have difficulties gaining acceptance of the use of the companion diagnostic in the clinical community; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">may not commit sufficient resources to the marketing and distribution of such product; and </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">may terminate their relationship with us. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any companion diagnostic for use with one of our product candidates fails to gain market acceptance, our ability to derive revenues from sales of such product candidate could be harmed. If our third-party contractors fail to commercialize such companion diagnostic, we may not be able to enter into arrangements with another diagnostic company to obtain supplies of an alternative diagnostic test for use in connection with such product candidate or do so on commercially reasonable terms, which could adversely affect and delay the development or commercialization of such product candidate.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Independent clinical investigators and CROs that we engage to conduct our clinical trials may not devote sufficient time or attention to our clinical trials or be able to repeat their past success. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to depend on independent clinical investigators and CROs to conduct our clinical trials, including future trials for vobra duo, lorigerlimab and other product candidates. CROs may also assist us in the collection and analysis of data. There is a limited number of third-party service providers that specialize or have the expertise required to achieve our business objectives. Identifying, qualifying and managing performance of third-party service providers can be difficult, time consuming and cause delays in our development programs. These investigators and CROs will not be our employees and we will not be able to control, other than by contract, the amount of resources, including time, which they devote to our product candidates and clinical trials. If independent investigators or CROs fail to devote sufficient resources to the development of our product candidates, or if their performance is substandard, it may delay or compromise the prospects for approval and commercialization of any product candidates that we develop. In addition, the use of third-party service providers requires us to disclose our proprietary information to these parties, which could increase the risk that this information will be misappropriated. Further, the FDA requires that we comply with standards, commonly referred to as current Good Clinical Practice (GCP) for conducting, recording and reporting clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial subjects are protected. Failure of clinical investigators or CROs to meet their obligations to us or comply with GCP procedures could adversely affect the clinical development of our product candidates and harm our business. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commercialization collaborations will be important to our business. If we are unable to maintain commercialization collaborations, or if commercialization collaborations are not successful, our business could be adversely affected. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have limited capabilities for drug commercialization, with little to no internal capability for sales, marketing or distribution. For example, we are a party to a collaboration with Eversana to support the commercialization of MARGENZA in the United States, and we may enter into commercial collaborations in the future for our products or our product candidates. Our existing commercialization collaboration, and any future commercialization collaborations we enter into, may pose a number of risks, including the following: </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may have significant discretion in determining the efforts and resources that they will apply to these collaborations; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may not perform their obligations as expected; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may not pursue commercialization our products or  any product candidates that achieve regulatory approval or may elect not to continue commercialization based on clinical trial results, changes in the collaborators' strategic focus or other factors that divert resources or create competing priorities; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators could independently commercialize products that compete directly or indirectly with our products or product candidates if the collaborators believe that competitive products are more likely to be successfully commercialized under terms that are more economically attractive than ours; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators with marketing and distribution rights to our products or our product candidates that achieve regulatory approval may not commit sufficient resources to the marketing and distribution of such product or products; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disagreements with collaborators, including disagreements on contract interpretation, commercialization strategy or tactics, might cause delays or termination of the commercialization of products or product candidates, might lead to additional responsibilities for us with respect to our products or product candidates, or might result in litigation or arbitration, any of which would be time-consuming and expensive; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may not properly utilize our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may violate, or be investigated for potentially violating, health care compliance and related laws and regulations, which may expose us to litigation, enforcement actions or inquiries, or other potential liability; and </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborations may be terminated for the convenience of the collaborator and, if terminated, we could be required to raise additional capital to pursue further commercialization of our products or applicable product candidates. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the risks relating to commercialization, and health care legal compliance described in this Annual Report on Form 10-K also apply to the commercialization activities of our collaborators.  </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, subject to its contractual obligations to us, if one of our collaborators is involved in a business combination, the collaborator might de-emphasize or terminate the development or commercialization of a product or product candidate MARGENZA licensed to it by us. If one of our collaborators terminates its agreement with us, we may find it more difficult to attract new collaborators. For example, Zai Lab provided notice of termination of our collaboration agreement, in November 2023 with respect to MARGENZA and tebotelimab, and we may be unable to attract new collaborators for the products in the covered territory or elsewhere. We may also be restricted under commercialization collaboration agreements from entering into future agreements on certain terms with potential collaborators. For example, our collaboration with Eversana contains a restriction on our engaging in activities that are the subject of the collaboration with third parties for specified periods of time among other conditions. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercialization collaborations are complex and time-consuming to negotiate and document. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators. If we are unable to reach agreements with suitable collaborators on a timely basis, on acceptable terms, or at all, we may have to curtail the commercialization of a product or product candidate, reduce the scope of any sales or marketing activities, or increase our expenditures and undertake or commercialization activities at our own expense. If in the future we elect to fund and undertake commercialization activities on our own, we may need to obtain additional expertise and additional capital, which may not be available to us on acceptable terms or at all. If we fail to enter into collaborations to commercialize our product candidates and do not have sufficient funds or expertise to undertake the necessary commercialization activities, we may not be able to commercialize our product candidates or bring them to market or continue and our business may be materially and adversely affected. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our information technology systems or those third parties upon which we rely for our data, are or were compromised, we could experience adverse consequences resulting from such compromise, including but not limited to regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; loss of customers or sales; and other adverse consequences.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of our business, we and the third parties upon which we rely, process, collect, receive, store, process, generate, use, transfer, disclose, make accessible, protect, secure, dispose of, transmit, and share (collectively, process) proprietary, confidential, and sensitive data, including personal data (such as health-related data), intellectual property, trade secrets and any other sensitive data the we may process, e.g., business plans, transactions, financial information, etc. (collectively, sensitive information). </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cyber-attacks, malicious internet-based activity, online and offline fraud, and other similar activities threaten the confidentiality, integrity, and availability of our sensitive information and information technology systems, and those of the third parties upon which we rely.  Such threats are prevalent and continue to rise, are increasingly difficult to detect, and come from a variety of sources, including traditional computer &#8220;hackers,&#8221; threat actors, &#8220;hacktivists,&#8221; organized criminal threat actors, personnel (such as through theft or misuse), sophisticated nation states, and nation-state-supported actors.  </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some actors now engage and are expected to continue to engage in cyber-attacks, including without limitation nation-state actors for geopolitical reasons and in conjunction with military conflicts and defense activities.  During times of war and other major conflicts, we, the third parties upon which we rely, and our customers may be vulnerable to a heightened risk of these attacks, including retaliatory cyber-attacks, that could materially disrupt our systems and operations, supply chain, and ability to produce, sell and distribute our goods and services.  </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and the third parties upon which we rely are subject to a variety of evolving threats, including but not limited to social-engineering attacks (including through deep fakes and the use of Artificial Intelligence (AI)), which may be increasingly more difficult to identify as fake, and phishing attacks), malicious code (such as viruses and worms), malware (including as a result of advanced persistent threat intrusions), denial-of-service attacks, credential stuffing attacks, credential harvesting, personnel misconduct or error, ransomware attacks, supply-chain attacks, software bugs, server malfunctions, software or hardware failures, loss of data or other information technology assets, adware, telecommunications failures, earthquakes, fires, floods, attacks enhanced or facilitated by AI, and other similar threats. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Severe ransomware attacks are becoming increasingly prevalent and can lead to significant interruptions in our operations, ability to provide our products or services, loss of sensitive data and income, reputational harm, and diversion of funds.  Extortion payments may alleviate the negative impact of a ransomware attack, but we may be unwilling or unable to make such payments due to, for example, applicable laws or regulations prohibiting such payments. Remote work has become more common and has increased risks to our information technology systems and data, as more of our employees utilize network connections, computers and devices outside our premises or network, including working at home, while in transit and in public locations.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future or past business transactions (such as acquisitions or integrations) could expose us to additional cybersecurity risks and vulnerabilities, as our systems could be negatively affected by vulnerabilities present in acquired or integrated entities&#8217; systems and technologies.  Furthermore, we may discover security issues that were not found during due diligence of such acquired or integrated entities, and it may be difficult to integrate companies into our information technology environment and security program.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on third-party service providers and technologies to operate critical business systems to process sensitive information in a variety of contexts, including, without limitation, encryption and authentication technology, employee email, content delivery to customers, and other functions. Our ability to monitor these third parties&#8217; information security practices is limited, as is our ability to determine whether these third parties may not have adequate information security measures in place.  If our third-party service providers experience a security incident or other interruption, we could experience adverse consequences.  While we may be entitled to damages if our third-party service providers fail to satisfy their privacy or security-related obligations to us, any award may be insufficient to cover our damages, or we may be unable to recover such award. In addition, supply-chain attacks have increased in frequency and severity, and we cannot guarantee that third parties&#8217; infrastructure in our supply chain or our third-party partners&#8217; supply chains have not been compromised.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we have implemented security measures designed to protect against security incidents, there can be no assurance that these measures will be effective. Any of the previously identified or similar threats could cause a security incident or other interruption that could result in unauthorized, unlawful, or accidental acquisition, modification, destruction, loss, alteration, encryption, disclosure of, or access to our sensitive information or our information technology systems, or those of the third parties upon whom we rely. A security incident or other interruption could disrupt our ability (and that of third parties upon whom we rely) to provide our products.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may expend significant resources or modify our business activities (including our clinical trial activities) to try to protect against security incidents. Certain data privacy and security obligations may require us to implement and maintain specific security measures or industry-standard or reasonable security measures to protect our information technology systems and sensitive information. Applicable data privacy and security obligations may require us to notify relevant stakeholders, including affected individuals, customers, regulators, and investors, of security incidents. Such disclosures are costly, and the disclosure or the failure to comply with such requirements could lead to adverse consequences. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we (or a third party upon whom we rely) experience a security incident or are perceived to have experienced a security incident, we may experience adverse consequences, such as government enforcement actions (for example, investigations, fines, penalties, audits, and inspections); additional reporting requirements and/or oversight; restrictions on processing sensitive information (including personal data); litigation (including class claims); indemnification obligations; negative publicity; reputational harm; monetary fund diversions; diversion of management attention; interruptions in our operations (including availability of data); financial loss; and other similar harms. Security incidents and attendant consequences may prevent or cause customers to stop using our products, deter new customers from using our products, and negatively impact our ability to grow and operate our business. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contracts may not contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in our contracts are sufficient to protect us from liabilities, damages, or claims related to our data privacy and security obligations. We cannot be sure that our insurance coverage will be adequate or sufficient to protect us from or to mitigate liabilities arising out of our privacy and security practices, that such coverage will continue to be available on commercially reasonable terms or at all, or that such coverage will pay future claims. An information security training program is in place to educate our personnel on information security and data protection measures.  The program is managed by information security personnel.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Intellectual Property </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our success depends significantly on our ability to operate without infringing the valid patents and other proprietary rights of third parties.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success will depend in part on our ability to operate without infringing the proprietary rights of third parties. Third parties may have or obtain patents or proprietary rights that could limit our ability to make, use, sell, offer for sale or import our future approved products or impair our competitive position. For example, certain patents held by third parties cover Fc engineering methods and mutations in Fc regions to enhance the binding of Fc regions to Fc receptors on immune cells. Although we believe that these patents are not infringed, and/or are invalid and/or unenforceable, if a court should find that they cover our products, such as MARGENZA or enoblituzumab, and we are unable to invalidate such patents, or if licenses for them are not available on commercially reasonable terms, our business could be harmed, perhaps materially. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third parties could possess patents that we may ultimately be found to infringe, or such third-party patents could issue in the future. Third parties may have or may obtain valid and enforceable patents or proprietary rights that could block us from developing product candidates using our technology. Our failure to obtain a license to any technology that we require may materially harm our business, financial condition and results of operations. Moreover, our failure to maintain a license to any technology that we require may also materially harm our business, financial condition, and results of operations. Furthermore, we would be exposed to a threat of litigation. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the pharmaceutical industry, significant litigation and other proceedings regarding patents, patent applications, trademarks and other intellectual property rights have become commonplace. The types of situations in which we may become a party to such litigation or proceedings include: </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or our collaborators may initiate litigation or other proceedings against third parties seeking to invalidate the patents held by those third parties or to obtain a judgment that our products or processes do not infringe those third parties' patents; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">if our competitors file patent applications that claim technology also claimed by us or our licensors, we or our licensors may be required to participate in interference, opposition or other proceedings to determine the priority of invention, which could jeopardize our patent rights and potentially provide a third party with a dominant patent position; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">if third parties initiate litigation claiming that our processes or products infringe their patent or other intellectual property rights, we and our collaborators will need to defend against such proceedings; and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">if a license to necessary technology is terminated, the licensor may initiate litigation claiming that our processes or products infringe or misappropriate their patent or other intellectual property rights and/or that we breached our obligations under the license agreement, and we and our collaborators would need to defend against such proceedings.  </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These lawsuits would be costly and could affect our results of operations and divert the attention of our management and scientific personnel. There is a risk that a court would decide that we or our collaborators are infringing the third party&#8217;s patents and would order us or our collaborators to stop the activities covered by the patents. In that event, we or our collaborators may not have a viable alternative to the technology protected by the patent and may need to halt work on the affected product candidate or cease commercialization of an approved product. In addition, there is a risk that a court will order us or our collaborators to pay the other party damages. An adverse outcome in any litigation or other proceeding could subject us to significant liabilities to third parties and require us to cease using the technology that is at issue or to license the technology from third parties. We may not be able to obtain any required licenses on commercially acceptable terms or at all. Any of these outcomes could have a material adverse effect on our business.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pharmaceutical and biotechnology industries have produced a significant number of patents, and it may not always be clear to industry participants, including us, which patents cover various types of products, methods of use, or processes. The coverage of patents is subject to interpretation by the courts, and the interpretation is not always uniform or predictable. If we are sued for patent infringement, we would need to demonstrate that our products, methods, or processes either do not infringe the patent claims of the relevant patent or that the patent claims are invalid, and we may not be able to do so. Proving invalidity is difficult. For example, in the United States, proving invalidity requires a showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents. Even if we are successful in these proceedings, we may incur substantial costs and divert management&#8217;s time and attention in pursuing these proceedings, which could have a material adverse effect on us. If we are unable to avoid infringing the patent rights of others, we may be required to seek a license, defend an infringement action or challenge the validity of the patents in court. Patent litigation is costly and time consuming. We may not have sufficient resources to bring these actions to a successful conclusion. In addition, if we do not obtain a license, develop or obtain non-infringing technology, fail to defend an infringement action successfully or have infringed patents declared invalid, we may incur substantial monetary damages, encounter significant delays in bringing our product candidates to market and be precluded from manufacturing or selling our product candidates. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cost of any patent litigation or other proceeding, even if resolved in our favor, could be substantial. Some of our competitors may be able to sustain the cost of such litigation and proceedings more effectively than we can because of their substantially greater resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace. Patent litigation and other proceedings may also absorb significant management time. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to obtain and enforce patent protection for our products and our product candidates and related technology, our business could be materially harmed. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> &#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Issued patents may be challenged, narrowed, invalidated or circumvented. In addition, court decisions may introduce uncertainty in the enforceability or scope of patents owned by biotechnology companies. The legal systems of certain countries do not favor the aggressive enforcement of patents, and the laws of foreign countries may not allow us to protect our inventions with patents to the same extent as the laws of the United States.  Patent applications in the United States and many foreign jurisdictions are typically not published until 18 months after filing, or in some cases not at all.  Publications of discoveries in scientific literature lag behind actual discoveries, thus we cannot be certain that we were the first to make the inventions claimed in our issued patents or pending patent applications, or that we were the first to file for protection of the inventions set forth in our patents or patent applications. As a result, we may not be able to obtain or maintain protection for certain inventions. Therefore, the enforceability and scope of our patents in the United States and in foreign countries cannot be predicted with certainty and, as a result, any patents that we own or license may not provide sufficient protection against competitors. We may not be able to obtain or maintain patent protection from our pending patent applications, from those we may file in the future, or from those we may license from third parties. Moreover, even if we can obtain patent protection, it may be of insufficient scope to achieve our business objectives. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our strategy depends on our ability to identify and seek patent protection for our discoveries. This process is expensive and time consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost,in a timely manner, or in all jurisdictions where protection may be commercially advantageous. Despite our efforts to protect our proprietary rights, unauthorized parties may be able to obtain and use information that we regard as proprietary. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The issuance of a patent does not ensure that a court or agency finds or will find the patent valid or enforceable, so even if we obtain patents, they may not be valid or enforceable against third parties. In addition, the issuance of a patent does </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">not give us the right to practice the patented invention. Third parties may have blocking patents that could prevent us from marketing our own patented product and practicing our own patented technology. Third parties may also seek to market biosimilar versions of any approved products. Alternatively, third parties may seek approval to market their own products, which are similar to or otherwise competitive with our products. In these circumstances, we may need to defend and/or assert our patents, including by filing lawsuits alleging patent infringement. In any of these types of proceedings, a court or agency with jurisdiction may find our patents invalid and/or unenforceable. Even if we have valid and enforceable patents, these patents still may not provide protection against competing products or processes sufficient to achieve our business objectives. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent position of pharmaceutical or biotechnology companies, including ours, is generally uncertain and involves complex legal and factual considerations. The standards which the United States Patent and Trademark Office (USPTO) and its foreign counterparts use to grant patents are not always applied predictably or uniformly and can change. There is also no uniform, worldwide policy regarding the subject matter and scope of claims granted or allowable in pharmaceutical or biotechnology patents. The laws of some foreign countries do not protect proprietary information to the same extent as the laws of the United States, and many companies have encountered significant problems and costs in protecting their proprietary information in these foreign countries. Outside the United States, patent protection must be sought in individual jurisdictions, further adding to the cost and uncertainty of obtaining adequate patent protection outside of the United States. Accordingly, we cannot predict whether additional patents protecting our technology will issue in the United States or in foreign jurisdictions, or whether any patents that do issue will have claims of adequate scope to provide competitive advantage. Moreover, we cannot predict whether third parties will be able to successfully obtain claims or the breadth of such claims. The allowance of broader claims may increase the incidence and cost of patent interference proceedings, opposition proceedings, and/or reexamination proceedings, the risk of infringement litigation, and the vulnerability of the claims to challenge. On the other hand, the allowance of narrower claims does not eliminate the potential for adversarial proceedings and may fail to provide a competitive advantage. Our issued patents may not contain claims sufficiently broad to protect us against third parties with similar technologies or products or provide us with any competitive advantage. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may become involved in lawsuits to protect or enforce our patents, which could be expensive, time consuming and unsuccessful. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even after they have been issued, our patents and any patents which we license may be challenged, narrowed, invalidated or circumvented. If our patents are invalidated or otherwise limited or will expire prior to the commercialization of our approved products and product candidates, other companies may be better able to develop products that compete with ours, which could adversely affect our competitive business position, business prospects and financial condition. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following are examples of litigation and other adversarial proceedings or disputes that we could become a party to involving our patents or patents licensed to us: </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or our collaborators may initiate litigation or other proceedings against third parties to enforce our patent rights; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">third parties may initiate litigation or other proceedings seeking to invalidate patents owned by or licensed to us or to obtain a declaratory judgment that their product or technology does not infringe our patents or patents licensed to us; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">third parties may initiate opposition, reexamination or inter partes review proceedings challenging the validity or scope of our patent rights, requiring us or our collaborators and/or licensors to participate in such proceedings to defend the validity and scope of our patents; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">there may be a challenge or dispute regarding inventorship or ownership of patents currently identified as being owned by or licensed to us; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the USPTO may initiate an interference between patents or patent applications owned by or licensed to us and those of our competitors, requiring us or our collaborators and/or licensors to participate in an interference proceeding to determine the priority of invention, which could jeopardize our patent rights; or </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">third parties may seek approval to market biosimilar versions of our future approved products prior to expiration of relevant patents owned by or licensed to us, requiring us to defend our patents, including by filing lawsuits alleging patent infringement. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These lawsuits and proceedings would be costly and could affect our results of operations and divert the attention of our managerial and scientific personnel. There is a risk that a court or administrative body would decide that our patents are invalid or not infringed by a third party&#8217;s activities, or that the scope of certain issued claims must be further limited. An </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">adverse outcome in a litigation or proceeding involving our own patents could limit our ability to assert our patents against these or other competitors, affect our ability to receive royalties or other licensing consideration from our licensees, and may curtail or preclude our ability to exclude third parties from making, using and selling similar or competitive products. Any of these occurrences could adversely affect our competitive business position, business prospects and financial condition. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The degree of future protection for our proprietary rights is uncertain because legal means afford only limited protection and may not adequately protect our rights or permit us to gain or keep our competitive advantage. For example:</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others may be able to develop a platform that is similar to, or better than, ours in a way that is not covered by the claims of our patents; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others may be able to make compounds that are similar to our product candidates but that are not covered by the claims of our patents; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we might not have been the first to make the inventions covered by patents or pending patent applications; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we might not have been the first to file patent applications for these inventions; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any patents that we obtain may not provide us with any competitive advantages or may ultimately be found invalid or unenforceable; or </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not develop additional proprietary technologies that are patentable. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with our obligations under our intellectual property licenses with third parties, we could lose license rights that are important to our business.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently party to various intellectual property license agreements. These license agreements impose, and we expect that future license agreements may impose, various diligence, milestone payment, royalty, insurance and other obligations on us. For example, we entered into patent and know-how license agreements that grant us the right to use certain technologies related to biological manufacturing to manufacture our clinical product candidates. These licenses typically include an obligation to pay yearly maintenance payments and royalties on sales and may also include upfront and milestone payments. If we fail to comply with our obligations under the licenses, the licensors may have the right to terminate their respective license agreements, in which event we might not be able to market any product that is covered by the agreements. Termination of the license agreements or reduction or elimination of our licensed rights may result in our having to negotiate new or reinstated licenses with less favorable terms, which could adversely affect our competitive business position and harm our business. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to protect the confidentiality of our proprietary information, the value of our technology and products could be adversely affected. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to patent protection, we also rely on other proprietary rights, including protection of trade secrets, and other proprietary information. To maintain the confidentiality of trade secrets and proprietary information, we enter into confidentiality agreements with our employees, consultants, collaborators and others upon the commencement of their relationships with us. These agreements require that all confidential information developed by the individual or made known to the individual by us during the course of the individual&#8217;s relationship with us be kept confidential and not disclosed to third parties. Our agreements with employees and our personnel policies also provide that any inventions conceived by the individual while rendering services to us shall be our exclusive property. However, we may not obtain these agreements in all circumstances, and individuals with whom we have these agreements may not comply with their terms. Thus, despite such agreement, such inventions may become assigned to third parties. In the event of unauthorized use or disclosure of our trade secrets or proprietary information, these agreements, even if obtained, may not provide meaningful protection, particularly for our trade secrets or other confidential information. To the extent that our employees, consultants or contractors use technology or know-how owned by third parties in their work for us, disputes may arise between us and those third parties as to the rights in related inventions. To the extent that an individual who is not obligated to assign rights in intellectual property to us is rightfully an inventor of intellectual property, we may need to obtain an assignment or a license to that intellectual property from that individual, or a third party or from that individual&#8217;s assignee. Such assignment or license may not be available on commercially reasonable terms or at all. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adequate remedies may not exist in the event of unauthorized use or disclosure of our proprietary information. The disclosure of our trade secrets would impair our competitive position and may materially harm our business, financial condition and results of operations. Costly and time-consuming litigation could be necessary to enforce and determine the scope of our proprietary rights, and failure to maintain trade secret protection could adversely affect our competitive business position. In </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">addition, others may independently discover or develop our trade secrets and proprietary information, and the existence of our own trade secrets affords no protection against such independent discovery. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is common in the biotechnology and pharmaceutical industries, we employ individuals who were previously or concurrently employed at research institutions and/or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. We may be subject to claims that these employees, or we, have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers, or that patents and applications we have filed to protect inventions of these employees, even those related to one or more of our product candidates, are rightfully owned by their former or concurrent employer. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management.  </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obtaining and maintaining our patent protection depends on compliance with various procedural, documentary, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to the USPTO and various foreign patent offices at various points over the lifetime of our patents and/or applications. We have systems in place to remind us to pay these fees, and we rely on our outside counsel or our agents to pay these fees when due. Additionally, the USPTO and various foreign patent offices require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply, and in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with rules applicable to the particular jurisdiction. However, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. If such an event were to occur, it could have a material adverse effect on our business. In addition, we may be responsible for the payment of patent fees for patent rights that we license from other parties. If any licensor of these patents does not itself elect to make these payments, and we fail to do so, we may be liable to the licensor for any costs and consequences of any resulting loss of patent rights. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we do not obtain protection under the Hatch-Waxman Amendments and similar foreign legislation for extending the term of patents covering each of our product candidates, our business may be materially harmed. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depending upon the timing, duration and conditions of FDA marketing approval of our product candidates, one or more of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent term extension of up to five years for a patent covering an approved product as compensation for effective patent term lost during product development and the FDA regulatory review process. However, we may not receive an extension if we fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. Moreover, the length of the extension could be less than we request. If we are unable to obtain patent term extension or the term of any such extension is less than we request, the period during which we can enforce our patent rights for that product will be shortened and our competitors may obtain approval to market competing products sooner. As a result, our revenue from applicable products could be reduced, possibly materially. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Legal Compliance Matters  </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to the U.S. Foreign Corrupt Practices Act and other anti-corruption laws. If we fail to comply with these laws, we could be subject to civil or criminal penalties, other remedial measures, and legal expenses, which could adversely affect our business, results of operations and financial condition. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> &#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations are subject to anti-corruption laws, including the U.S. Foreign Corrupt Practices Act, (FCPA) and other anti-corruption laws that apply in countries where we do business. The FCPA and these other laws generally prohibit us and our employees and intermediaries from bribing, being bribed or making other prohibited payments to government officials or other persons to obtain or retain business or gain some other business advantage. We and our commercial partners operate in a number of jurisdictions that pose a risk of potential FCPA violations, and we participate in collaborations and relationships with third parties whose actions could potentially subject us to liability under the FCPA or other anti-corruption laws. There is no assurance that we will be completely effective in ensuring our compliance with all applicable anti-corruption laws. If we violate provisions of the FCPA or other anti-corruption laws or are subject to an investigation or audit pursuant to these laws, we may be subject to criminal and civil penalties, disgorgement and other sanctions and remedial measures and legal expenses, which could have an adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we do not comply with laws regulating the protection of the environment and health and human safety, our business could be adversely affected.  </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development involves, and may in the future involve, the use of potentially hazardous materials and chemicals. Our operations may produce hazardous waste products. Although we believe that our safety procedures for handling and disposing of these materials comply with the standards mandated by local, state and federal laws and regulations, the risk of accidental contamination or injury from these materials cannot be eliminated. If an accident occurs, we could be held liable for resulting damages, which could be substantial. We are also subject to numerous environmental, health and workplace safety laws and regulations and fire and building codes, including those governing laboratory procedures, exposure to blood-borne pathogens, use and storage of flammable agents and the handling of biohazardous materials. Although we maintain workers&#8217; compensation insurance as prescribed by the States of Maryland and California to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of these materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us. Additional federal, state and local laws and regulations affecting our operations may be adopted in the future. We may incur substantial costs to comply with, and substantial fines or penalties if we violate, any of these laws or regulations. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We and our collaborators are subject to various healthcare laws, and our failure, or the failure of our collaborators, to comply with those laws could result in significant penalties and adversely affect our business, operations and financial condition. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, our operations, and those of our collaborators, are subject to regulation by various local, state, federal authorities in addition to the FDA, including but not limited to, CMS, other divisions of HHS (such as the Office of Inspector General, Office for Civil Rights and the Health Resources and Service Administration), the U.S. Department of Justice (DOJ) and individual U.S. Attorney offices within the DOJ, and state and local governments. We and our collaborators are or may be subject to broadly applicable &#8220;fraud and abuse&#8221; laws, such as false claims, anti-kickback laws, transparency laws, and privacy and security laws. Federal false claims laws, including the federal civil False Claims Act, prohibit, among other things, any person or entity from knowingly presenting, or causing to be presented, a false claim for payment to the federal government or knowingly making, or causing to be made, a false statement to get a claim paid. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal healthcare program anti-kickback statute prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving remuneration to induce, or in return for, purchasing, leasing, ordering or arranging for the purchase, lease or order of any healthcare item or service reimbursable under Medicare, Medicaid or other federally financed healthcare programs. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers and formulary managers on the other. Although there are several statutory exemptions and regulatory safe harbors protecting certain common activities from prosecution, the exemptions and safe harbors are drawn narrowly, and practices that involve remuneration intended to induce prescribing, purchasing or recommending may be subject to scrutiny if they do not qualify for an exemption or safe harbor. Failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the federal anti-kickback statute. Instead, the legality of the arrangement will be evaluated on a case-by-case basis based on a cumulative review of all of its facts and circumstances. Our practices, or those of our collaborators, may not in all cases meet all of the criteria for protection under a statutory exception or regulatory safe harbor. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the intent standard under the federal anti-kickback statute and the criminal healthcare fraud statutes (discussed below) was amended by the ACA to a stricter standard such that a person or entity no longer needs to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. In addition, the ACA codified case law that a claim including items or services resulting from a violation of the federal anti-kickback statute constitutes a false or fraudulent claim for purposes of the federal civil false claims act. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal Health Insurance Portability and Accountability Act of 1996 (HIPAA) which prohibits, among other things, knowingly and willfully executing, or attempting to execute, a scheme or artifice to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private), willfully obstructing a criminal investigation of a healthcare offense, and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false, fictitious or fraudulent statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters. Similar to the federal anti-kickback statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, under the federal Physician Payment Sunshine Act provisions of the ACA, covered manufacturers of drugs, devices, biological and medical supplies for which payment is available under a federal health care program (with certain exceptions) are subject to annual federal reporting and disclosure requirements with regard to payments or other transfers of value made to physicians defined to include doctors, dentists, optometrists, podiatrists and chiropractors, other healthcare </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">professionals (such as physician assistants and nurse practitioners), and teaching hospitals as well as information regarding certain ownership and investment interests held by physicians and their immediate family members. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most states also have statutes or regulations similar to the federal anti-kickback law and federal false claims laws, which may apply to items such as pharmaceutical products and services reimbursed by private insurers. Some state laws also prohibit certain gifts to healthcare providers, require pharmaceutical companies to report payments to healthcare professionals, and/or require companies to adopt compliance programs or codes of conduct. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Over the past few years, a number of pharmaceutical and other healthcare companies have been prosecuted under these laws for a variety of promotional and marketing activities, such as: providing free trips, free goods, improper consulting fees and grants and other monetary benefits to prescribers; reporting to pricing services inflated average wholesale prices that were then used by federal programs to set reimbursement rates; engaging in off-label promotion; and submitting inflated best price information to the Medicaid Rebate Program to reduce liability for Medicaid rebates. At such time as we or our collaborators market MARGENZA or any of our future approved products and these products are paid for by governmental programs, it is possible that some of our business activities could also be subject to challenge under one or more of these &#8220;fraud and abuse&#8221; laws. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, in order to distribute products commercially in the United States, we or our collaborators must also comply with state laws that require the registration of manufacturers and wholesale distributors of pharmaceutical products in a state, including, in certain states, manufacturers, and distributors who ship products into the state even if such manufacturers or distributors have no place of business within the state. Some states also impose requirements on manufacturers and distributors to establish the pedigree of product in the chain of distribution, including some states that require manufacturers and others to adopt new technology capable of tracking and tracing product as it moves through the distribution chain. Several states have enacted legislation requiring pharmaceutical companies to establish marketing compliance programs, file periodic reports with the state, make periodic public disclosures on sales, marketing, pricing, track, and report gifts, compensation and other remuneration made to physicians and other healthcare providers, clinical trials and other activities, and/or register their sales representatives, as well as to prohibit pharmacies and other healthcare entities from providing certain physician prescribing data to pharmaceutical companies for use in sales and marketing, and to prohibit certain other sales and marketing practices. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our operations, or those of our collaborators marketing, distributing or commercializing any of our products on our behalf, are found to be in violation of any of the federal and state healthcare laws described above or any other governmental regulations that apply to us, we may be subject to penalties, including without limitation, significant civil, criminal and/or administrative penalties, damages, fines, disgorgement, exclusion from participation in government programs, such as Medicare and Medicaid, injunctions, private &#8220;qui tam&#8221; actions brought by individual whistleblowers in the name of the government, or refusal to allow us to enter into government contracts, contractual damages, reputational harm, administrative burdens, diminished profits and future earnings, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our operations and those of our collaborators may be subject to analogous foreign health care laws in the jurisdictions in which we operate. </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to stringent and evolving U.S. and foreign laws, regulations, and rules, contractual obligations, industry standards, policies and other obligations related to data privacy and security. Our actual or perceived failure to comply with such obligations could lead to regulatory investigations or actions; litigation (including class claims) and mass arbitration demands; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; loss of customers; and other adverse business consequences.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, we process personal data and other sensitive information, including proprietary and confidential business data, trade secrets, intellectual property, data we collect about trial participants in connection with clinical trials, sensitive third-party data, and other sensitive data, e.g., business plans, transactions, financial information, etc. Our data processing activities subject us to numerous data privacy and security obligations, such as various laws, regulations, guidance, industry standards, external and internal privacy and security policies, contractual requirements, and other obligations relating to data privacy and security. Data privacy and security have become significant issues in the United States, Europe, and in many other jurisdictions where we or our partners may in the future conduct our operations. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In the United States, federal, state, and local governments have enacted numerous data privacy and security laws and regulations, including data breach notification laws, personal data privacy laws, consumer protection laws (e.g., Section 5 of the Federal Trade Commission Act), and other similar laws (e.g., wiretapping laws). These laws and regulations involve the collection, storage, handling, use, disclosure, transfer, and security of personal data. Certain states, such as California, also impose stricter requirements for processing certain personal data, including sensitive information, such as conducting data privacy impact assessments, and may result in liability through private actions. For example, the California Consumer Privacy </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Act of 2018, as amended by the California Privacy Rights Act of 2020 (CPRA), (collectively, CCPA) applies to personal data of consumers, business representatives, and employees who are California residents, and requires businesses to provide specific disclosures in privacy notices and honor requests of such individuals to exercise certain privacy rights. The CCPA provides for fines of up to $7,500 per intentional violation and allows private litigants affected by certain data breaches to recover significant statutory damages. Although the CCPA exempts some data processed in the context of clinical trials, the CCPA increases compliance costs and potential liability with respect to other personal data we maintain about California residents. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the United States, an increasing number of laws, regulations, and industry standards govern data privacy and security. For example, the European Union&#8217;s General Data Protection Regulation (EU GDPR),  companies may face temporary or definitive bans on data processing and other corrective actions; fines of up to 20 million Euros under the EU GDPR, 17.5 million pounds sterling under the UK GDPR or, in each case, 4% of annual global revenue, whichever is greater; or private litigation related to processing of personal data brought by classes of data subjects or consumer protection organizations authorized at law to represent their interests. In Canada, the Personal Information Protection and Electronic Documents Act (PIPEDA) and various related provincial laws,may apply to our operations. As another example, Australia&#8217;s Privacy Act of 1998 may apply to our operations. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obligations related to data privacy and security (and consumers&#8217; data privacy expectations) are quickly changing, becoming increasingly stringent, and creating uncertainty. Additionally, these obligations may be subject to differing applications and interpretations, which may be inconsistent or conflict among jurisdictions. Failure to comply with these current and future laws, policies, industry standards or legal obligations or any security incident resulting in the unauthorized access to, or acquisition, release or transfer of personal information may result in governmental enforcement actions, litigation, fines and penalties or adverse publicity and could cause our customers to lose trust in us, which could have a material adverse effect on our business and results of operations.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may at times fail (or be perceived to have failed) in our efforts to comply with our data privacy and security obligations. Moreover, despite our efforts, our personnel or third parties on whom we rely may fail to comply with such obligations, which could negatively impact our business operations. If we or the third parties on which we rely fail, or are perceived to have failed, to address or comply with applicable data privacy and security obligations, we could face significant consequences, including but not limited to: government enforcement actions (e.g., investigations, fines, penalties, audits, inspections, and similar); litigation (including class-action claims) and mass arbitration demands; additional reporting requirements and/or oversight; bans on processing personal data; orders to destroy or not use personal data; and imprisonment of company officials.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In particular, plaintiffs have become increasingly more active in bringing privacy-related claims against companies, including class claims and mass arbitration demands. Some of these claims allow for the recovery of statutory damages on a per violation basis, and, if viable, carry the potential for monumental statutory damages, depending on the volume of data and the number of violations. Any of these events could have a material adverse effect on our reputation, business, or financial condition, including but not limited to: loss of customers; interruptions or stoppages in our business operations (including, clinical trials); inability to process personal data or to operate in certain jurisdictions; limited ability to develop or commercialize our products; expenditure of time and resources to defend any claim or inquiry; adverse publicity; or substantial changes to our business model or operations.  </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> &#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk of employee fraud or other misconduct. Misconduct by employees could include intentional failures to comply with FDA regulations, to provide accurate information to the FDA or other agencies, to comply with federal and state health care fraud and abuse laws and regulations, to report financial information or data accurately or to disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the health care industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. Employee misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. We have adopted a code of conduct, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Relating to Employee Matters and Human Capital Management  </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are highly dependent on the research and development, clinical and business development expertise of certain of our executive officers and other key employees. Although we have entered into employment agreements with our executive officers, each of them may terminate their employment with us at any time. The loss of the services of our executive officers or other key employees could impede the achievement of our research, development, manufacturing and commercialization objectives and seriously harm our ability to successfully implement our business strategy. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recruiting and retaining qualified scientific, clinical, manufacturing and other personnel will also be critical to our success. For example, we have experienced employee turnover, consistent with the broader American economy, and we may continue to experience employee turnover in the future that may have an adverse effect on our business strategy. New hires require significant training and, in most cases, take significant time before they achieve full productivity. New employees may not become as productive as we expect, and we may be unable to hire or retain sufficient numbers of qualified individuals. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to successfully develop, gain regulatory approval of and commercialize products. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. Such competition may increase due to the recent move by companies to offer a remote or hybrid work environment. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. If we are unable to continue to attract and retain high quality personnel, motivate existing employees, or maintain our corporate culture in a hybrid or remote work environment and in the midst of higher turnover, our ability to pursue our growth strategy will be limited. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, in January 2023, the U.S. Federal Trade Commission published a proposed rule that would generally prohibit post-employment non-compete clauses (or other clauses with comparable effect) in agreements between employers and their employees. If this rule goes into effect, or if we fail to adequately address any of the issues referred to above, it could adversely impact our ability to recruit and retain our skilled employees which may result in a material adverse effect on our business, operating results and financial condition.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may undertake internal restructuring activities, including associated workforce reductions, that could result in disruptions to our business or otherwise materially harm our results of operations or financial condition.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may undertake internal restricting activities, including associated workforce reductions, as we continue to evaluate and attempt to optimize our cost and operating structure in light of developments in our business strategy and long-term operating plans. For example, in August 2022, we announced a reduction in workforce by approximately 15% in connection with the restructuring of our business to prioritize and focus on our lead assets, and, as a result, we incurred certain restructuring charges, including employee termination-related charges. Any restructuring activities that we may undertake in the future may result in write-offs or other restructuring charges, including employee termination-related charges in connection with any associated workforce reductions. We may not realize, in full or in part, the anticipated benefits, savings and improvements in our operating structure from any restructuring efforts due to unforeseen difficulties, delays or unexpected costs. If we are unable to realize the expected operational efficiencies and cost savings from any restructuring, our results of operation and financial condition could be adversely affected. Furthermore, any strategic restructuring plan may be disruptive to our operations. For example, any workforce reductions could yield unanticipated consequences, such as attrition beyond planned staff reductions, increased difficulties in our day-to-day operations and reduced employee morale. Any employees not affected by any reduction in force may seek alternate employment, which could result in us seeking contract support which may result in unplanned additional expense or harm our productivity. Any workforce reductions could also harm our ability to attract and retain qualified management, scientific, clinical, and manufacturing personnel who are critical to our business. Any failure to attract or retain qualified personnel could prevent us from successfully developing our product candidates in the future.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may need to grow or contract our organization, and we may experience difficulties in managing this growth or contraction, which could disrupt our operations.  </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, we had 339 full-time employees.  In addition to the risks associated with a reduction in force, as our finances, development and commercialization plans and strategies evolve, we may choose to expand or contract our employee base for managerial, operational, manufacturing, financial and other resources. Future growth or additional contraction would impose significant costs as well as added responsibilities on members of management, including the potential need to identify, recruit, maintain, motivate and integrate additional employees. Also, our management may need to divert a disproportionate amount of their attention away from our day-to-day activities and devote a substantial amount of time to managing either growth or contraction activities. We may not be able to effectively manage our operations which may result in </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">weaknesses in our infrastructure, give rise to operational errors, loss of business opportunities, loss of employees and reduced productivity among remaining employees. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Growth could require significant capital expenditures and may divert financial resources from other projects, such as the development of existing and additional product candidates. If our management is unable to effectively manage such growth, our expenses may increase more than expected, our ability to generate and/or grow revenue could be reduced and we may not be able to implement our business strategy. Our future financial performance and our ability to commercialize MARGENZA, our product candidates and compete effectively with others in our industry will depend, in part, on our ability to effectively manage any such growth. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Relating to Our Common Stock </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have been and may in the future be subject to securities litigation, which is expensive and could divert management attention and adversely impact our business. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> &#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market price of our common stock has been and may continue to be volatile. Companies that have experienced volatility in the market price of their common stock are often subject to securities class action litigation. For example, on September 13, 2019, a securities class action complaint was filed against us, and certain of our officers and/or directors in the U.S. District Court for the District of Maryland. On September 29, 2021, the District Court issued an Order dismissing the case, with prejudice, and on March 2, 2023 the Fourth Circuit affirmed the District Court&#8217;s dismissal. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This or any future securities litigation brought by private parties or government enforcement agencies could result in substantial costs and diversion of management&#8217;s attention and resources, which could adversely impact our business. Any adverse determination in litigation could also subject us to significant liabilities. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market price of our stock may fluctuate unpredictably in response to factors unrelated to our operating performance. The stock market has recently experienced significant volatility, particularly with respect to pharmaceutical, biotechnology, and other life sciences company stocks. The volatility of pharmaceutical, biotechnology, and other life sciences company stocks often does not relate to the operating performance of the companies represented by the stock. Some of the factors that may cause the market price of our common stock to fluctuate include: </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">results and timing of our clinical trials and clinical trials of our competitors&#8217; products; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure or discontinuation of any of our development programs; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">issues in manufacturing our product candidates or future approved products; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory developments or enforcement in the United States and foreign countries with respect to our product candidates or our competitors&#8217; products; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competition from existing products or new products that may emerge; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments or disputes concerning patents or other proprietary rights; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">introduction of technological innovations or new commercial products by us or our competitors; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements by us, our collaborators or our competitors of significant acquisitions, strategic partnerships, joint ventures, collaborations or capital commitments; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in estimates or recommendations by securities analysts, if any cover our common stock; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fluctuations in the valuation of companies perceived by investors to be comparable to us; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">public concern over our product candidates or any future approved products; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">threatened or actual litigation; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">future or anticipated sales of our common stock; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">share price and volume fluctuations attributable to inconsistent trading volume levels of our shares; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additions or departures of key personnel; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the structure of health care payment systems in the United States or overseas; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure of any of MARGENZA or our product candidates, if approved, to achieve commercial success; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">economic and other external factors or other disasters or crises; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">period-to-period fluctuations in our financial condition and results of operations, including the timing of receipt of any milestone or other payments under commercialization or licensing agreements; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general market conditions and market conditions for biopharmaceutical stocks; and</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">overall fluctuations in U.S. equity markets.</span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in the past, when the market price of a stock has been volatile, holders of that stock have sometimes instituted securities class action litigation against the company that issued the stock. For example, one such securities class action lawsuit was brought against us. We could incur substantial costs defending this or similar lawsuits, as well as diversion of the time and attention of our management, any or all of which could seriously harm our business. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provisions of our charter, bylaws, third-party agreements and Delaware law may make an acquisition of us or a change in our management more difficult. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain provisions of our restated certificate of incorporation and amended and restated bylaws could discourage, delay, or prevent a merger, acquisition, or other change in control that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. These provisions also could limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. Stockholders who wish to participate in these transactions may not have the opportunity to do so. Furthermore, since our board of directors is responsible for appointing the members of our management team, these provisions could prevent or frustrate attempts by our stockholders to replace or remove our management by making it more difficult for stockholders to replace members of our board of directors. These provisions: </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">allow the authorized number of directors to be changed only by resolution of our board of directors; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish a classified board of directors, providing that not all members of the board of directors be elected at one time; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">authorize our board of directors to issue without stockholder approval blank check preferred stock that, if issued, could operate as a "poison pill" to dilute the stock ownership of a potential hostile acquirer to prevent an acquisition that is not approved by our board of directors; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require that stockholder actions must be effected at a duly called stockholder meeting and prohibit stockholder action by written consent; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish advance notice requirements for stockholder nominations to our board of directors or for stockholder proposals that can be acted on at stockholder meetings; </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limit who may call stockholder meetings; and </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require the approval of the holders of 75% of the outstanding shares of our capital stock entitled to vote in order to amend certain provisions of our restated certificate of incorporation and restated bylaws.  </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, in the ordinary course of our business, from time to time we discuss and enter into collaborations, licenses and other transactions with various third parties, including other pharmaceutical companies and biotechnology companies. When we deem it appropriate, our agreements with such third parties may include standstill provisions. These standstill provisions, several of which may be in force from time-to-time, typically prohibit such parties from acquiring our securities for a period of time, which may discourage such parties from acquiring MacroGenics even if doing so would be beneficial to our stockholders. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, because we are incorporated in Delaware, we are governed by the provisions of Section&#8239;203 of the Delaware General Corporation Law, which may, unless certain criteria are met, prohibit large stockholders, in particular those owning 15% or more of our outstanding voting stock, from merging or combining with us for a prescribed period of time. This provision could have the effect of delaying or preventing a change of control, whether or not it is desired by or beneficial to our stockholders. </span></div><div id="i69aaf560e98645139c7ed7af73a9eafe_22"></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1B.&#160;&#160;&#160;&#160;UNRESOLVED STAFF COMMENTS</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div id="i69aaf560e98645139c7ed7af73a9eafe_822"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1C. CYBERSECURITY</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risk management and strategy</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have implemented and maintain various information security processes designed to identify, assess, and manage material risks from cybersecurity threats to our critical computer networks, third party hosted services, communications systems, hardware and software, and our critical data, including intellectual property, confidential information that is proprietary, strategic or competitive in nature, and clinical trial data (Information Systems and Data).  </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our information security function, which is led by our Executive Director of Information Technology, with support from our Senior Information Security Manager, our legal team, a management-level Technology Steering Committee, and the Audit Committee of the Board, helps identify, assess, and manage the Company&#8217;s cybersecurity threats and risks. We identify and assess cybersecurity risks by monitoring and evaluating our threat environment using various methods including, for example using automated tools, subscribing to reports and services that identify cybersecurity threats, evaluating threats reported to us, evaluating our and our industry&#8217;s risk profile, analyzing reports of threats and actors, audits, conducting vulnerability assessments, and conducting tabletop incident response exercises.  </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depending on the environment and system, we implement and maintain various technical, physical, and organizational measures, processes, and policies designed to manage and mitigate material risks from cybersecurity threats to our Information Systems and Data, including: an incident response plan and procedures, incident detection and response playbook, business continuity plans, encryption of certain data, network security controls, identity management and access controls, physical security controls, 24/7 systems monitoring, vendor risk management processes, employee cybersecurity and privacy training, penetration testing, cybersecurity insurance, and dedicated cybersecurity staff. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our assessment and management of material risks from cybersecurity threats are integrated into our overall risk management processes. For example, (1) cybersecurity risk is addressed as a component of  our enterprise risk management program and identified in our risk register; (2) the information security function works with management to prioritize our risk management processes and mitigate cybersecurity threats that are more likely to lead to a material impact to our business; (3) our Technology Steering Committee evaluates material risks from cybersecurity threats against our overall business objectives and reports to the Audit Committee of the board of directors, which evaluates our overall enterprise risk.  </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use third-party service providers to assist us to identify, assess, and manage material risks from cybersecurity threats, including professional services firms, cybersecurity consultants, cybersecurity software providers, managed cybersecurity service providers, penetration testing firms, and dark web monitoring services.   </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use third-party service providers to perform a variety of functions throughout our business, such as application providers, hosting companies, contract research organizations, distributors, and supply chain management resources. We have vendor management processes to manage cybersecurity risks associated with our use of certain of these providers, such as reviewing security questionnaires, reviewing the vendor&#8217;s written security program, conducting risk assessments for certain vendors, arranging security assessment calls with the vendor&#8217;s security personnel, reviewing security assessments, or imposing contractual obligations on the vendor. Depending on the nature of the services provided, the sensitivity of the Information Systems and Data at issue, and the identity of the provider, our vendor management process may involve different levels of assessment designed to help identify and mitigate cybersecurity risks associated with a provider. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a description of the risks from cybersecurity threats that may materially affect the Company and how they may do so, see our risk factors under Part 1. Item 1A. Risk Factors in this Annual Report on Form 10-K.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Governance</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our board of directors addresses the Company&#8217;s cybersecurity risk management as part of its general oversight function. The board of directors&#8217; Audit Committee and management&#8217;s Technology Steering Committee are responsible for overseeing the Company&#8217;s cybersecurity risk management processes, including oversight and mitigation of risks from cybersecurity threats.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cybersecurity risk assessment and management processes are implemented and maintained by certain Company management, including our Executive Director, Information Technology, who has fourteen years of information security experience and holds a Certified Information Systems Security Professional (CISSP) certification. Our Senior Information Security Manager holds CISSP certification, an MSc. in Information Security, and has over 20 years government and industry cybersecurity experience.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company management is responsible for hiring appropriate personnel, helping to integrate cybersecurity risk considerations into the Company&#8217;s overall risk management strategy, and communicating key priorities to relevant personnel. Company management is also responsible for approving budgets, helping prepare for cybersecurity incidents, approving cybersecurity processes, and reviewing security assessments and other security-related reports. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cybersecurity incident response processes are designed to escalate certain cybersecurity incidents to members of management depending on the circumstances and incident severity, including our Executive Director Information Technology who works with the Company&#8217;s incident response team to help the Company mitigate and remediate cybersecurity incidents. In addition, the Company&#8217;s incident response process includes reporting to the audit and technology steering committees of the board of directors for certain cybersecurity incidents. </span></div><div style="margin-bottom:6pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The board of directors&#8217; Audit Committee receives periodic reports from our Executive Director Information Technolog concerning the Company&#8217;s significant cybersecurity threats and risk and the processes the Company has implemented to address them. The board of directors also receives regular reports, summaries or presentations related to cybersecurity threats, risk, and mitigation. </span></div><div id="i69aaf560e98645139c7ed7af73a9eafe_25"></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.&#160;&#160;&#160;&#160;PROPERTIES</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We lease a total of approximately 205,000 square feet of manufacturing, office, laboratory and warehouse space in Maryland. Our headquarters building in Rockville, Maryland currently houses laboratory, office and manufacturing operations to support clinical and commercial quantities and scale. This location is occupied under a lease that expires in 2035. Our leases each have one or more five-year options to renew. We believe that our properties are generally in good condition, well maintained, suitable and adequate to carry on our business. We believe our capital resources are sufficient to lease any additional facilities required to meet our expected growth needs.</span></div><div style="margin-bottom:3pt;text-indent:36pt"><span><br/></span></div><div id="i69aaf560e98645139c7ed7af73a9eafe_28"></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.&#160;&#160;&#160;&#160;LEGAL PROCEEDINGS</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, we are or may be involved in various legal or regulatory proceedings, claims or class actions related to alleged patent infringements and other intellectual property rights, or alleged violation of commercial, corporate, securities, labor and employment, and other matters incidental to our business. We do not, however, expect such legal proceedings to have a material adverse effect on our business, financial condition or results of operations. However, depending on the nature and timing of a given dispute, an eventual unfavorable resolution could materially affect our current or future results of operations or cash flows.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div id="i69aaf560e98645139c7ed7af73a9eafe_31"></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4.&#160;&#160;&#160;&#160; MINE SAFETY DISCLOSURES</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><div id="i69aaf560e98645139c7ed7af73a9eafe_34"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div id="i69aaf560e98645139c7ed7af73a9eafe_37"></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 5. &#160;&#160;&#160;&#160;MARKET FOR REGISTRANT'S COMMON EQUITY,&#160;RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Market Information</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock is listed on the Nasdaq Global Select Market under the symbol "MGNX".&#160;As of March&#160;1, 2024, we had 62,432,013 shares of common stock outstanding held by approximately 57 holders of record, which include shares held by a broker, bank or other nominee.&#160;We have never declared or paid any cash dividends.&#160;We do not anticipate declaring or paying cash dividends for the foreseeable future.&#160;Instead, we will retain our earnings, if any, for the future operation and expansion of our business.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Performance Graph</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following graph compares the five-year cumulative total return of our common stock with the  Nasdaq Composite Index (U.S.) and the Nasdaq Biotechnology Index.&#160;The comparison assumes a $100 investment on December 31, 2018 in our common stock, the stocks comprising the Nasdaq Composite Index, and the stocks comprising the Nasdaq Biotechnology Index, and assumes reinvestment of the full amount of all dividends, if any.&#160;Historical stockholder return is not necessarily indicative of the performance to be expected for any future periods.</span></div><div style="margin-bottom:9pt;text-align:center"><img src="mgnx-20231231_g3.jpg" alt="1186" style="height:380px;margin-bottom:5pt;vertical-align:text-bottom;width:650px"/></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information set forth under the heading "Performance Graph" shall not be deemed to be "soliciting material" or to be "filed" with the SEC or subject to liabilities of Section 18 of the Exchange Act, except to the extent that we specifically request that such information be treated as soliciting material or specifically be incorporated by reference into a filing under the Securities Act of 1933, as amended, or the Exchange Act.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span><br/></span></div><div id="i69aaf560e98645139c7ed7af73a9eafe_40"></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6.&#160;&#160;&#160;&#160;[RESERVED]</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div id="i69aaf560e98645139c7ed7af73a9eafe_43"></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:72pt;text-indent:-72pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 7.&#160;&#160;&#160;&#160;MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion of our financial condition and results of operations should be read together with our selected consolidated financial data and the consolidated financial statements and related notes included elsewhere herein. This discussion contains forward-looking statements that involve risks and uncertainties. As a result of many factors including, but not limited to, those set forth under the sections entitled "Risk Factors" and "Forward-Looking Statements", our actual results may differ materially from those anticipated in such forward-looking statements.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the discussion of our financial condition and results of operations for the year ended December&#160;31, 2022 compared to the year ended December&#160;31, 2021, please refer to Part II, Item 7, "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our Annual Report on Form 10-K for the year ended December&#160;31, 2022 filed with the SEC on March&#160;15, 2023.</span></div><div style="text-indent:36pt"><span><br/></span></div><div id="i69aaf560e98645139c7ed7af73a9eafe_46"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer.  We have a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. These candidates are being evaluated in clinical trials sponsored by us or our collaborators or are in preclinical development. Our clinical product candidates include multiple oncology programs which have either been created using our proprietary, antibody-based technology platforms or enabled through our technology licensing arrangements with other companies. We believe our product candidates have the potential, if approved for marketing by regulatory authorities, to have a meaningful effect on treating patients' unmet medical needs as monotherapy or, in some cases, in combination with other therapeutic agents. To date, three products originating from our pipeline of proprietary or partnered product candidates have received U.S. Food and Drug Administration (FDA) approval. In March 2021, we and our commercialization partner commenced U.S. marketing of MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. In November 2022, the FDA approved TZIELD&#8482; (teplizumab-mzwv) to delay the onset of Stage 3 Type 1 Diabetes (T1D) in adult and pediatric patients aged 8 years and older with Stage 2 T1D. Teplizumab was acquired from us by Provention Bio, Inc. (Provention) in 2018, pursuant to an asset purchase agreement (Provention APA).  In March 2023, the FDA approved ZYNYZ&#8482; (retifanlimab-dlwr), a humanized monoclonal antibody targeting programmed death receptor-1 (PD-1). Retifanlimab was previously developed by us and licensed to Incyte Corporation (Incyte) pursuant to an exclusive global collaboration and license agreement in October 2017.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations to date have concentrated on developing our technology platforms, identifying potential product candidates, undertaking preclinical studies, conducting clinical trials, developing collaborations, operating manufacturing facilities, business planning and raising capital. We only began generating revenues from the sale of products in 2021. We have financed our operations primarily through the public and private offerings of our securities, and collaborations with other biopharmaceutical companies.&#160;Although it is difficult to predict our funding requirements, we anticipate that our cash, cash equivalents and marketable securities as of December&#160;31, 2023, combined with anticipated and potential collaboration payments, product revenue, contract manufacturing revenue, and royalties, should enable us to fund our operations into 2026. Our expected funding requirements reflect anticipated expenditures related to the Phase 2 TAMARACK clinical trial of vobramitamab duocarmazine (vobra duo) in metastatic castration-resistant prostate cancer  (mCRPC), our Phase 2 LORIKEET study of lorigerlimab in mCRPC as well as our other clinical and preclinical studies currently ongoing. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through December&#160;31, 2023, we had an accumulated deficit of $1.1 billion.&#160;We expect that over the next several years this deficit will increase as we continue to incur research and development expense in connection with our ongoing activities and several clinical trials.&#160;</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Macroeconomic Conditions </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The global economy, credit markets and financial markets have and may continue to experience significant volatility as a result of significant worldwide events, including adverse events involving financial institutions or the financial services industry, inflation and rising interest rates and geopolitical upheaval (collectively, the Macroeconomic Conditions). These Macroeconomic Conditions have and may continue to create supply chain disruptions, inventory disruptions, and fluctuations in economic growth, including fluctuations in employment rates, inflation, energy prices and consumer sentiment. It remains difficult to assess or predict the ultimate duration and economic impact of the Macroeconomic Conditions. Prolonged uncertainty with respect to Macroeconomic Conditions could cause further economic slowdown or cause other unpredictable events, each of which could adversely affect our business, results of operations or financial condition. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span><br/></span></div><div id="i69aaf560e98645139c7ed7af73a9eafe_49"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaborations</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We pursue a balanced approach between product candidates that we develop ourselves and those that we develop with our collaborators. Under our strategic collaborations to date, we have received significant non-dilutive funding and continue to have rights to additional funding upon completion of certain research, achievement of key product development milestones and royalties and other payments upon the commercial sale of products. Our current collaborations include the following:</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#252525;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12.53pt">Incyte. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have an exclusive global collaboration and license agreement with Incyte  for retifanlimab, an investigational monoclonal antibody that inhibits PD-1(Incyte License Agreement). Under this agreement, as amended, Incyte has obtained exclusive worldwide rights for the development and commercialization of retifanlimab in all indications, while we retain the right to develop our pipeline assets in combination with retifanlimab. We received an upfront payment of $150.0 million and milestone payments totaling $115.0 million from Incyte through December&#160;31, 2023, including $15.0 million upon the FDA approval of ZYNYZ (retifanlimab-dlwr) in March 2023</span><span style="color:#008080;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We are eligible to receive an additional $320.0 million in development and regulatory milestones and $330.0 million in commercial milestones. We are also eligible to receive tiered royalties of 15% to 24% on any global net sales and we have the option to co-promote retifanlimab with Incyte. We retain the right to develop our pipeline assets in combination with retifanlimab, with Incyte commercializing retifanlimab and us commercializing our asset(s), if any such potential combinations are approved. We also have an agreement with Incyte under which we are to perform development and manufacturing services for Incyte's clinical needs of retifanlimab (Incyte Clinical Supply Agreement) and another agreement under which we are entitled to manufacture a portion of Incyte&#8217;s global commercial supply of retifanlimab (Incyte Commercial Supply Agreement).</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12.53pt">Gilead</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In October 2022, we and Gilead Sciences, Inc. (Gilead) entered into an exclusive option and collaboration agreement (Gilead Agreement) to develop and commercialize MGD024 </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and create bispecific cancer antibodies using our DART platform and undertake their early development under a maximum of two separate bispecific cancer target research programs. Under t</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he Gilead Agreement, we </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">will continue the ongoing phase 1 trial for MGD024 accordi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ng to a development plan</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, during which Gilead will have the right to exercise an option granted to Gilead to obtain an exclusive license to develop and commercialize MGD024 and other bispecific antibodies of ours that bind CD123 and CD3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (CD123 Option). The agreement also grants Gilead the right, within its first two years, to nominate a bispecific cancer target set for up to two research programs conducted by us and to exercise separate options to obtain an exclusive license for the development, commercialization and exploitation of molecules created under each research program (Research Program Option). As part of the Gilead Agreement, Gilead paid us a non-refundable upfront payment of $60.0&#160;million and we will be eligible to receive up to $1.7&#160;billion in target nomination, option fees, and development, regulatory and commercial milestones, assuming Gilead exercises the CD123 Option and Research Program Option, successfully develops and commercializes MGD024 or other CD123 products developed under the agreement, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and products result from the two additional research programs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assuming exercise of the CD123 Option, w</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e will also be eligible to receive tiered, low double-digit royalties on worldwide net sales of MGD024 </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(or other CD123 products developed under the agreement) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assuming exercise of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research Program Option, a flat royalty on worldwide net sales of any products resulting from the two research programs.</span><span style="color:#008080;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2023, Gilead nominated the first of the two research programs contemplated in the Gilead Agreement (First Research Program), we granted Gilead a research license, and the parties agreed on a research plan for the First Research Program under which we will provide research and development services. Gilead paid us a $15.7 million nomination fee in October 2023.  </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Provention</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In 2018, we entered into the Provention APA pursuant to which Provention acquired our interest in teplizumab. Under the Provention APA, if Provention successfully develops, obtains regulatory approval for, and commercializes teplizumab, we will be eligible to receive up to $170.0 million in regulatory milestones, and up to $225.0 million in commercial milestones. In November 2022, the FDA approved TZIELD (teplizumab-mzwv) to delay the onset of Stage 3 T1D in adult and pediatric patients aged 8 years and older with Stage 2 T1D, and we recognized $60.0 million in milestone revenue during the year ended December 31, 2022. In November 2022 we and Provention amended the Provention APA. Under the amended Provention APA, the $60.0&#160;million milestone for a first approval was split into four $15.0&#160;million payments, all of which were received prior to June 30, 2023.  Under the Provention APA we are also eligible to receive single-digit royalties on net sales of TZIELD. Provention has also agreed to pay third-party obligations, including low single-digit royalties, a portion of which </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is creditable against royalties payable to us, aggregate milestone payments of up to approximately $1.3 million and other consideration, for certain third-party intellectual property under agreements Provention assumed pursuant to the Provention APA. Further, Provention is required to pay us a low double-digit percentage of certain consideration to the extent it is received in connection with a grant of rights by Provention to a third party. </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="margin-bottom:9pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023, we sold our single-digit royalty interest in TZIELD (Royalty Interest) to a wholly-owned subsidiary of DRI Healthcare Trust (DRI) and received a $100.0 million payment from DRI under a Royalty Purchase Agreement. We retain our other economic interests related to TZIELD, including future potential regulatory and commercial milestones. We retain the right to receive a 50% share of the royalty on global net sales above a certain annual threshold (Retained Interest). In addition, we received $50.0 million upon the occurrence of the primary endpoint milestone event in September 2023, and we are also eligible to receive an additional $50.0 million if TZIELD achieves a certain level of net sales (the Sales Milestone Payment). In April 2023, we entered into an agreement (the Tripartite Agreement) with DRI and a subsidiary of Sanofi S.A. (Sanofi), whereby we consented to the sale of DRI&#8217;s Royalty Interest and the related milestone payment obligations to Sanofi. The Tripartite Agreement eliminated our obligation to deliver payments to DRI related to the Royalty Interest and removed all of our other obligations under the Royalty Purchase Agreement. The Royalty Interest will be paid directly to Sanofi by Provention, therefore we no longer have any obligation to pay DRI. There was no modification to our Retained Interest in the Tripartite Agreement. </span></div><div style="padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2023, we and Sanofi executed Amendment No. 2 to the Provention APA to incorporate the Sales Milestone Payment obligation from the Royalty Purchase Agreement into the Provention APA and terminated the Royalty Purchase Agreement. As a result, the remaining $50.0 million Sales Milestone Payment under the Royalty Purchase Agreement was incorporated into the Provention APA.</span></div><div style="padding-left:18pt"><span><br/></span></div><div id="i69aaf560e98645139c7ed7af73a9eafe_52"></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Operations Overview</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue consists of the following:</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">revenue from collaborative and other agreements which includes amounts recognized relating to upfront nonrefundable payments for licenses or options to obtain future licenses, amounts earned by performing development and manufacturing services, research and development funding and milestone payments earned under our collaboration and license agreements with our strategic collaborators;</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product sales, net which reflects sales of MARGENZA which was launched in 2021.  Product revenue is recorded net of applicable reserves for variable consideration, including discounts and other allowances;</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">contract manufacturing revenue which is earned from manufacturing third parties&#8217; drug substance; and </span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">government agreements revenue which reflects amounts earned through grants and/or contracts with the U.S. government and other research institutions on behalf of the U.S. government, primarily with respect to research and development activities related to infectious disease product candidates. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Product Sales</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of product sales relates to sales of MARGENZA.  These costs include materials and manufacturing costs, as well as royalties payable on net sales of MARGENZA and inventory reserves.  All product costs incurred prior to FDA approval of MARGENZA in December 2020 were expensed as research and development expense.  We expect cost of product sales to continue to be positively impacted for the next four to five years as we sell through inventory that was expensed prior to FDA approval of MARGENZA. </span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Manufacturing Services</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of manufacturing services consists of the costs to provide manufacturing services to produce certain bulk drug substance under manufacturing and clinical supply agreements with third parties, including salaries and benefits and related stock-based compensation, materials, overhead and other related costs.</span></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expense</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense consists of expenses incurred in performing research and development activities. These expenses include conducting preclinical experiments and studies, clinical trials, manufacturing efforts and regulatory filings for all product candidates, and other indirect expenses in support of our research and development activities. We capture research and development expense on a program-by-program basis for our product candidates and recognize these expenses as they are incurred. The following are items we include in research and development expense:</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">employee-related expenses, such as salaries and benefits;</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">employee-related overhead expenses, such as facilities and other allocated items;</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">stock-based compensation expense to employees engaged in research and development activities;</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">depreciation of laboratory and manufacturing equipment, computers and leasehold improvements;</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fees paid to consultants, subcontractors, clinical research organizations (CROs) and other third party vendors for work performed under our preclinical and clinical trials including, but not limited to, investigator grants, laboratory work and analysis, database management, statistical analysis, and other items;</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">amounts paid to vendors and suppliers for laboratory supplies;</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">internal and third party costs related to manufacturing clinical trial materials, including vialing, packaging and testing;</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">license fees and other third party vendor payments related to in-licensed product candidates and technology; and</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs related to compliance with regulatory requirements.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is difficult to determine with certainty the duration and completion costs of our current or future preclinical programs and clinical trials of our product candidates, or if, when or to what extent we will generate revenues from the commercialization and sale of any of our product candidates that obtain regulatory approval.  The duration, costs and timing of clinical trials and development of our product candidates will depend on a variety of factors, including the uncertainties of future clinical trials and preclinical studies, uncertainties in clinical trial enrollment rates and significant and changing government regulation. In addition, the probability of success for each product candidate will depend on numerous factors, including competition, manufacturing capability and commercial viability. We will determine which programs to pursue and how much to fund each program in response to the scientific and clinical success of each product candidate, as well as an assessment of each product candidate's commercial potential.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative Expense</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expense consists of salaries and related benefit costs for employees in our executive, finance, legal and intellectual property, business development, human resources, information technology and other support functions.  Selling, general and administrative expense also includes costs incurred under the arrangement with our commercialization partner, Eversana Life Science Services, LLC, and other legal and professional fees.  </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Gain on Royalty Monetization Arrangement</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2023, we entered into the Tripartite Agreement with DRI and Sanofi, whereby we consented to the sale of DRI&#8217;s Royalty Interest and the related milestone payment obligations to Sanofi. The execution of the Tripartite Agreement resulted in a modification to the liability related to future royalties, and we recognized a $100.9 million gain on royalty monetization arrangement.  In July 2023, Sanofi reported achievement of the primary endpoint milestone event related to a $50.0 million milestone, which resulted in an additional $50.0 million gain on royalty monetization arrangement. In September 2023, we amended the Provention APA and terminated the Royalty Purchase Agreement with DRI. See Note 7, Royalty Monetization Arrangement, of the Notes to Consolidated Financial Statements, for additional information.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span><br/></span></div><div id="i69aaf560e98645139c7ed7af73a9eafe_55"></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Estimates</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management's discussion and analysis of financial conditions and results of operations is based on our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP). The preparation of these consolidated financial statements requires us to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">liabilities as of the date of the balance sheets and the reported amount of the revenue and expenses recorded during the reporting period. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable. We review and evaluate these estimates on an on-going basis. These assumptions and estimates form the basis for making judgments about the carrying values of assets and liabilities and amounts that have been recorded as revenues and expenses. Actual results and experiences may differ from these estimates. We did not make any material changes to these assumptions during the year ended December&#160;31, 2023, and do not expect any material changes in the near term to the underlying assumptions.  If we were to adjust our assumptions, the results of any material revisions would be reflected in the consolidated financial statements prospectively from the date of the change in estimate. Management considers an accounting estimate to be critical if:</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">it requires a significant level of estimation uncertainty; and </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the estimate are reasonably likely to have a material effect on our financial condition or results of operations.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While a summary of significant accounting policies is described fully in Note 2 in our consolidated financial statements, we believe that the following accounting policies are the most critical to assist you in fully understanding and evaluating our financial results and the effect of the estimates and judgments we used in preparing our consolidated financial statements.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liability related to the sale of future royalties and related interest expense</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The liability related to future royalties is presented net of unamortized issuance costs on our consolidated balance sheets. Interest expense on the liability related to future royalties is recognized using the effective interest rate method over the life of the arrangement. We calculate an effective interest rate which will amortize our related obligation to zero over the anticipated repayment period. The liability related to future royalties and the related interest expense are based on our current estimates of future royalties expected to be received over the life of the arrangement, which we determine by using internal sales projections and external information from market data sources, which are considered Level 3 inputs. We periodically assess the expected payments and to the extent our estimates of future royalty payments are greater or less than previous estimates or the estimated timing of such payments is materially different than previous estimates, we will adjust the effective interest rate and recognize related non-cash interest expense on a prospective basis. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Upon changes in facts and circumstances, for example as a result of a modification to the existing agreements, we re-evaluate our rights and obligations and account for the change in accordance with the respective accounting guidance.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Revenue Recognition</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue under Accounting Standards Codification (ASC) Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s, (ASC 606) when our customer obtains control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. To determine revenue recognition for arrangements that we determine are within the scope of ASC 606, management performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy a performance obligation. We recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Collaborative and other agreements</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into licensing agreements that are within the scope of ASC 606, under which we may license rights to research, develop, manufacture and commercialize our product candidates to third parties. The terms of these arrangements typically include payment to us of one or more of the following: non-refundable, upfront license fees; reimbursement of certain costs; customer option exercise fees; development, regulatory and commercial milestone payments;&#160;and royalties on net sales of licensed products. We may also enter into development and manufacturing service agreements with our collaborators.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each arrangement that results in revenues, we identify all performance obligations, which may include a license to intellectual property and know-how, research and development activities, transition activities and/or manufacturing services. In order to determine the transaction price, in addition to any upfront payment, management estimates the amount of variable consideration at the outset of the contract either utilizing the expected value or most likely amount method, depending on the facts and circumstances relative to the contract. We constrain (reduce) the estimates of variable consideration such that it is probable that a significant reversal of previously recognized revenue will not occur. When determining if variable consideration should be constrained, management considers whether there are factors outside our control that could result in a significant </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reversal of revenue. In making these assessments, management considers the likelihood and magnitude of a potential reversal of revenue. These estimates are re-assessed each reporting period as required. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once the estimated transaction price is established, amounts are allocated to the performance obligations that have been identified. The transaction price is generally allocated to each separate performance obligation on a relative standalone selling price basis. We must develop assumptions that require judgment to determine the standalone selling price in order to account for these agreements. To determine the standalone selling price, management&#8217;s assumptions may include (i)  the probability of obtaining marketing approval for the product candidate, (ii) estimates regarding the timing and the expected costs to develop and commercialize the product candidate, and (iii) estimates of future cash flows from potential product sales with respect to the product candidate. Standalone selling prices used to perform the initial allocation are not updated after contract inception. We do not include a financing component to its estimated transaction price at contract inception unless we estimate that certain performance obligations will not be satisfied within one year.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts received prior to revenue recognition are recorded as deferred revenue. Amounts expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as current portion of deferred revenue in the accompanying consolidated balance sheets. Amounts not expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as deferred revenue, net of current portion. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Licenses. </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When we grant a license to our intellectual property, we </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">determine whether the </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nature of the intellectual property to which the customer will have rights is functional intellectual property (functional IP), which has significant standalone functionality, or symbolic intellectual property (symbolic IP) which does not have significant standalone functionality.  Revenue from functional IP is recognized at the point in time when control of the distinct license is transferred to the customer. Revenue from symbolic IP is recognized over the access period to our intellectual property.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the license to our intellectual property is determined to be distinct from the other promises or performance obligations identified in the arrangement, we recognize revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and when (or as) the customer is able to use and benefit from the license. In assessing whether a promise or performance obligation is distinct from the other promises, we consider factors such as the research, development, manufacturing and commercialization capabilities of the licensee and the availability of the associated expertise in the general marketplace. In addition, we consider whether the licensee can benefit from a promise for its intended purpose without the receipt of the remaining promise, whether the value of the promise is dependent on the unsatisfied promise, whether there are other vendors that could provide the remaining promise, and whether it is separately identifiable from the remaining promise. For licenses that are combined with other promises, management utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. The measure of progress, and thereby periods over which revenue should be recognized, are subject to estimates by management and may change over the course of the research and development and licensing agreement. Such a change could have a material impact on the amount of revenue we record in future periods. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research, Development and/or Manufacturing Services. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The promises under our agreements may include research and development or manufacturing services to be performed by us on behalf of the counterparty. If these services are determined to be distinct from the other promises or performance obligations identified in the arrangement, we recognize the transaction price allocated to these services as revenue over time based on an appropriate measure of progress when the performance by us does not create an asset with an alternative use and we have an enforceable right to payment for the performance completed to date. If these services are determined not to be distinct from the other promises or performance obligations identified in the arrangement, we recognize the transaction price allocated to the combined performance obligation as the related performance obligations are satisfied. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Customer Options. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an arrangement contains customer options, we evaluate whether the options are material rights because they allow the customer to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement. We allocate the transaction price to material rights based on the relative standalone selling price, which is determined using assumptions regarding estimated costs, discount rates, post-option development timeline, the probability of technical and regulatory success and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until, at the earliest, the option is exercised or expires. If the options are deemed not to be a material right, they are excluded as performance obligations at the outset of the arrangement. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes development milestone payments, management evaluates whether the milestones are considered probable of being achieved and estimates the amount to be </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within our control or the licensee's control, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. We evaluate factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, management reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For arrangements that include sales-based royalties which are the result of a customer-vendor relationship and for which the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We analyze our collaboration arrangements to assess whether such arrangements involve joint operating activities performed by parties who are both active participants in the activities and are both exposed to significant risks and rewards dependent on the commercial success of such activities. Such arrangements generally are within the scope of ASC 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 808). While ASC 808 defines collaborative arrangements and provides guidance on income statement presentation, classification, and disclosures related to such arrangements, it does not address recognition and measurement matters, such as (1)&#160;determining the appropriate unit of accounting or (2) when the recognition criteria are met. Therefore, the accounting for these arrangements is either based on an analogy to other accounting literature or an accounting policy election by management. We account for certain components of the collaboration agreement that are reflective of a vendor-customer relationship (e.g., licensing arrangement) based on ASC 606. We account for other components based on a reasonable, rational and consistently applied accounting policy election.&#160;Reimbursements from the counter-party that are the result of a collaborative relationship with the counter-party, instead of a customer relationship, such as co-development activities, are recorded as a reduction to research and development expense as the services are performed.</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Product sales, net</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We entered into a limited number of arrangements with specialty distributors in the United States to distribute MARGENZA. The delivery of our product represents a single performance obligation for these transactions and we record net product revenue when control is transferred to the customer, generally upon receipt by the customer.  The transaction price for net product revenue represents the amount we expect to receive, which is net of estimated government-mandated rebates and chargebacks, distribution fees, estimated product returns, and other deductions. Accruals are established for these deductions, and actual amounts incurred are offset against applicable accruals. Customer discounts are recorded as reductions of accounts receivable on the consolidated balance sheets. Allowance for product returns, provider chargebacks, government and other rebates and service fees are recorded as a component of accrued expenses and other current liabilities on the consolidated balance sheets. Sales deductions are based on management's estimates that consider payor mix in target markets and experience to-date. These estimates involve a substantial degree of judgment, in particular, for government-mandated rebates and chargebacks, such as for the Medicaid and 340B programs.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Contract manufacturing revenue</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into agreements with third parties to manufacture their drug substance at our GMP facility. The terms of these arrangements typically include an upfront payment to us to reserve manufacturing capacity, scheduled payments during the manufacturing process and reimbursement for materials used to manufacture product.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue over time on a straight-line basis as the manufacturing services are performed, as we believe that our efforts in providing the manufacturing services are incurred evenly throughout the performance period and therefore straight-line revenue recognition closely approximates the level of effort for the manufacturing services. Variable consideration relating to the reimbursed materials and other reimbursed costs incurred to manufacture product are allocated to the related manufacturing activities and are recognized as revenue as those activities occur.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expense, Including Clinical Trial Accruals/Expenses</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense consists of costs we incur for our own research and development activities and costs incurred by our collaborators under cost sharing arrangements. Research and development costs consist of salaries and benefits, including related stock-based compensation, laboratory supplies and facility costs, as well as fees paid to other entities that conduct certain research and development activities on our behalf, such as </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CROs, and the cost of acquiring and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">manufacturing clinical trial materials, including costs incurred under agreements with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">contract manufacturing organizations (CMOs). Research and development costs are expensed as incurred. We receive estimates from our collaborators when we are sharing development expenses, and use these estimates to record an increase or decrease in research and development expense, depending on how much we have each spent during the period. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trial expenses are a significant component of research and development expense, and we outsource a significant portion of these costs to third parties. Third party clinical trial expenses include investigator fees, site and patient costs, CRO costs, costs for central laboratory testing, data management and CMO costs. The accrual for site and patient costs includes inputs such as estimates of patient enrollment, patient cycles incurred, clinical site activations, and other pass-through costs. These inputs are required to be estimated due to a lag in receiving the actual clinical information from third parties. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected on the consolidated balance sheets as a prepaid asset or accrued expenses. These third party agreements are generally cancelable, and related costs are recorded as research and development expense as incurred. Non-refundable advance clinical payments for goods or services that will be used or rendered for future research and development activities are recorded as a prepaid asset and recognized as expense as the related goods are delivered or the related services are</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> performed.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> When evaluating the adequacy of the accrued expenses, we analyze progress of the studies, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates may be made in determining the accrued balances at the end of any reporting period. Actual results could differ from the estimates made. The historical clinical accrual estimates have not been materially different from the actual costs.</span></div><div style="margin-bottom:9pt;text-indent:-0.01pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Recent Accounting Pronouncements</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 2, Summary of Significant Accounting Policies, to the consolidated financial statements for information under the caption "Recent Accounting Pronouncements."</span></div><div style="text-indent:36pt"><span><br/></span></div><div id="i69aaf560e98645139c7ed7af73a9eafe_58"></div><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following represents a comparison of our revenue for the years ended December&#160;31, 2023 and 2022 (dollars in millions):<br/><br/></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:43.671%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.154%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.154%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.154%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.159%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase/(Decrease)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaborative and other agreements</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract manufacturing </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NM</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government agreements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(93.2)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NM:  Not Meaningful</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease of $90.3 million in revenue from collaborative and other agreements for the year ended December&#160;31, 2023 compared to the year ended December&#160;31, 2022 was primarily due to:</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a net decrease of $54.5 million in revenue recognized under the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Provention APA due to the recognition of a $60.0 million milestone</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in 2022 compared to $5.5&#160;million recognized in 2023 related to other consideration under the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provention APA</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Side Letter Agreement;</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decrease of </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$22.1 million in revenue recognized under our agreements with Zai Lab;</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decrease of $10.0 million in revenue recognized under the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incyte License Agreement; and</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decrease of $5.1 million in revenue recognized under the I-Mab License Agreement.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These decreases were partially offset by an increase of $2.2 million in revenue recognized under the Gilead Agreement.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from collaborative and other agreements may vary substantially from period to period depending on the progress made by our collaborators with their product candidates and the timing of milestones achieved under current agreements, and whether we enter into additional collaboration agreements. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in product sales, net is primarily due to an increase in volume.  Revenue from product sales is recorded net of applicable provisions for rebates, chargebacks and discounts, distribution-related fees and other sales-related deductions.  The table below includes a reconciliation of the accounts associated with these deductions (in millions):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.981%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.885%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;Rebates and chargebacks </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;Distribution fees, product returns and other </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;Total </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provisions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments/credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provisions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments related to  prior year sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments/credits </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2023</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract manufacturing revenue </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the years ended December&#160;31, 2023 and 2022 consists of revenue recognized from providing manufacturing services under the Incyte Manufacturing and Clinical Supply Agreement. </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract manufacturing revenue </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the year ended December&#160;31, 2022 also includes revenue recognized from providing manufacturing services under the Provention Manufacturing and Clinical Supply Agreement.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Product Sales</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of product sales was $0.6&#160;million and $3.4&#160;million for the years ended December&#160;31, 2023 and 2022, respectively. Cost of product sales includes product royalties and fill finish costs for both years, and cost of product sales for 2022 also includes reserves for unsaleable inventory. Product sold during both periods consisted of drug product that was previously charged to research and development expense prior to FDA approval of MARGENZA, which favorably impacted our gross margin. We expect cost of product sales to continue to be positively impacted as we sell through this drug product.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Manufacturing Services</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of manufacturing services was $7.6&#160;million and $4.0&#160;million for the years ended December&#160;31, 2023 and 2022, respectively. Cost of manufacturing services includes the costs to provide manufacturing services to produce certain Incyte bulk drug substance under the Incyte Manufacturing and Clinical Supply Agreement for both years. Cost of manufacturing services for the year ended December&#160;31, 2022 also includes costs to provide manufacturing services to produce certain bulk drug substance under the Provention Manufacturing and Clinical Supply Agreement. We expect cost of manufacturing services to vary from period to period based on the agreed-upon manufacturing schedule. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following represents a comparison of our research and development expense for the years ended December&#160;31, 2023 and 2022 (dollars in millions):</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br/><br/></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"/><td style="width:43.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.213%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.131%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.213%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.131%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.213%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.131%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.998%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase/(Decrease)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vobramitamab duocarmazine</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lorigerlimab</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Margetuximab</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MGC028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NM</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MGC026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other antibody-drug conjugates (ADCs)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Next-generation T-cell engagers (a)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MGD024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tebotelimab</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Enoblituzumab</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retifanlimab</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Flotetuzumab</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IMGC936</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DART molecules under HIV government contract</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other programs (a)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40.4)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Includes research and discovery projects, as well as early preclinical molecules and molecules not advanced to clinical development.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NM:  Not Meaningful</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense for the year ended December&#160;31, 2023 decreased by $40.4 million compared to the year ended December&#160;31, 2022. This decrease was primarily attributable to:</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased manufacturing related costs for vobra duo;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased development and clinical trial costs related to margetuximab, including expenses under the 2018 Zai Lab Agreement; </span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased development and clinical trial costs related to flotetuzumab due to discontinued development of this molecule;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased development, manufacturing and clinical trial costs related to enoblituzumab;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased development, manufacturing and clinical trial costs related to tebotelimab; and</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased development costs related to other programs.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These decreases were partially offset by:</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased development costs related to MGC026 and MGC028; and</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased clinical trial costs related to lorigerlimab.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are uncertainties associated with our research and development expenses for future periods which are impacted by multiple variables, including timing of wind down activities for recently closed studies and current and expected expenditures associated with our ongoing clinical studies.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative Expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses were $52.2 million and $58.9 million for the years ended December&#160;31, 2023 and 2022, respectively. The decrease is primarily due to decreased MARGENZA-related selling expenses.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Gain on Royalty Monetization Arrangement</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2023, we entered into the Tripartite Agreement with DRI and Sanofi, whereby we consented to the sale of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DRI&#8217;s Royalty Interest and the related milestone payment obligations to Sanofi. The execution of the Tripartite Agreement resulted in a modification to the liability related to future royalties, and we recognized a $100.9 million gain on royalty monetization arrangement.  In July 2023, Sanofi reported achievement of the primary endpoint milestone event related to a $50.0 million milestone, which resulted in an additional $50.0 million gain on royalty monetization arrangement. In September 2023, we amended the Provention APA and terminated the Royalty Purchase Agreement with DRI. See Note 7, Royalty Monetization Arrangement, of the Notes to Consolidated Financial Statements, for additional information.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest and Other Income</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The increase of $8.0 million in interest and other income for the year ended December&#160;31, 2023 compared to the year ended December&#160;31, 2022 is primarily due to increased investment balances and higher interest rates. </span></div><div><span><br/></span></div><div id="i69aaf560e98645139c7ed7af73a9eafe_61"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents a summary of our cash flows for the years ended December&#160;31, 2023 and 2022 (dollars in millions):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.431%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase/(Decrease)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash provided by (used in):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(150.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NM</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net decrease in cash and cash equivalents</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.9)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.6)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NM:  Not Meaningful</span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities consists of our net loss adjusted for non-cash items such as depreciation and amortization expense and stock-based compensation, gain on royalty monetization arrangement which is classified as a financing activity, and changes in working capital. Net cash used in operating activities for the year ended December&#160;31, 2023 benefited from $45.0 million in milestone payments received from Provention and a $15.0 million milestone payment received from Incyte under the Incyte License Agreement. Net cash used in operating activities for the year ended December&#160;31, 2022 benefited from the $60.0 million upfront payment under the Gilead Agreement, a $30.0 million milestone payment received from Incyte, and $15.0 million received from Provention. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing Activities</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities during the year ended December&#160;31, 2023 is primarily due to purchases of marketable securities, partially offset by maturities of marketable securities. Net cash provided by investing activities during the year ended December&#160;31, 2022 is primarily due to maturities of marketable securities, partially offset by purchases of marketable securities.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing Activities</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities for the year ended December&#160;31, 2023 includes net cash proceeds from our Royalty Purchase Agreement with DRI of $149.7 million.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our multiple product candidates currently under development will require significant additional research and development efforts that include extensive preclinical studies and clinical testing, and regulatory approval prior to commercial use. Our future success is dependent on our ability to identify and develop our product candidates, and ultimately upon our ability to attain profitable operations. We have devoted substantially all of our financial resources and efforts to research and development and general and administrative expense to support such research and development. Net losses and negative cash flows have had, and will continue to have, an adverse effect on our stockholders&#8217; equity and working capital, and accordingly, our ability to execute our future operating plans.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a biotechnology company, we have primarily funded our operations with proceeds from the sale of our common stock in equity offerings and revenue from our multiple collaboration agreements.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management regularly reviews our available </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">liquidity relative to our operating budget and forecast to monitor the sufficiency of our working capital, and anticipates continuing to draw upon available sources of capital, including equity and debt instruments, to support our product development activities. There can be no assurances that new sources of capital will be available to us on commercially acceptable terms, if at all. Also, any future collaborations, strategic alliances and marketing, distribution or licensing arrangements may require us to give up some or all rights to a product or technology at less than its full potential value. If we are unable to enter into new arrangements or to perform under current or future agreements or obtain additional capital, we will assess our capital resources and may be required to delay, reduce the scope of, or eliminate one or more of our product research and development programs or clinical studies, and/or downsize our organization</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although it is difficult to predict our funding requirements, we anticipate that our cash, cash equivalents and marketable securities as of December&#160;31, 2023, combined with anticipated and potential collaboration payments, product revenue, contract manufacturing revenue, and royalties, should enable us to fund our operations into 2026. Our expected funding requirements reflect anticipated expenditures related to the Phase 2 TAMARACK clinical trial of vobra duo in mCRPC, our Phase 2 study of lorigerlimab in mCRPC as well as our other clinical and preclinical studies currently ongoing. </span></div><div style="margin-bottom:9pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Material Cash Requirements</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our short-term and long-term material cash requirements consist of operational and capital expenditures, some of which contain contractual obligations. Our primary uses of cash relate to paying salaries and benefits, administering clinical trials and providing the technology and facilities necessary to support our operations. The most significant contractual obligations are the operating leases at our facilities in Maryland. Our future minimum lease payments as of December&#160;31, 2023 totaled $4.0&#160;million related to short-term lease liabilities, and $66.3&#160;million related to long-term lease liabilities.  See Note 6, Commitments and Contingencies, in the Notes to the Financial Statements in this Annual Report on Form 10-K for additional information about our contractual obligations. We expect to fund these requirements with current cash, cash equivalents and marketable securities as well as anticipated and potential collaboration payments, and product revenues. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have any off-balance sheet arrangements, as defined under the rules and regulations of the Securities and Exchange Commission.</span></div><div style="margin-bottom:9pt"><span><br/></span></div><div id="i69aaf560e98645139c7ed7af73a9eafe_64"></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 7A.&#160;&#160;&#160;&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary objective when considering our investment activities is to preserve capital in order to fund our operations.&#160;We also seek to maximize income from our investments without assuming significant risk.&#160;Our current investment policy is to invest principally in deposits and securities issued by the U.S. government and its agencies, Government Sponsored Enterprise agency debt obligations, corporate debt obligations and money market instruments.&#160;As of December&#160;31, 2023, we had cash, cash equivalents and marketable securities of $229.8 million.&#160;Our primary exposure to market risk is related to changes in interest rates.&#160;</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the short-term maturities of our cash equivalents and marketable securities and the low risk profile of our marketable securities, an immediate 100 basis point change in interest rates would not have a material effect on the fair market value of our cash equivalents and marketable securities. We have the ability to hold our marketable securities until maturity, and we therefore do not expect a change in market interest rates to affect our operating results or cash flows to any significant degree.</span></div><div style="text-indent:36pt"><span><br/></span></div><div id="i69aaf560e98645139c7ed7af73a9eafe_67"></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 8.&#160;&#160;&#160;&#160;FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is set forth beginning on page F-1 in this Annual Report on Form 10-K.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div id="i69aaf560e98645139c7ed7af73a9eafe_70"></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9.&#160;&#160;&#160;&#160;CHANGES AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL DISCLOSURE</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i69aaf560e98645139c7ed7af73a9eafe_73"></div><div style="padding-left:36pt;text-indent:-36pt"><span><br/></span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9A.&#160;&#160;&#160;&#160;CONTROLS AND PROCEDURES</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Disclosure Controls and Procedures</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, including our principal executive and principal financial officers, has evaluated the effectiveness of our disclosure controls and procedures as of December&#160;31, 2023. Our disclosure controls and procedures are designed to provide reasonable assurance that the information required to be disclosed in this Annual Report on Form 10-K has been appropriately recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission's rules and forms, and that such information is accumulated and communicated to our management, including our principal executive and principal financial officers, to allow timely decisions regarding required disclosure.&#160;Based on that </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">evaluation, our principal executive and principal financial officers have concluded that our disclosure controls and procedures are effective at the reasonable assurance level.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control</span></div><div style="margin-bottom:8pt;text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, including our principal executive and principal financial officers, has evaluated any changes in our internal control over financial reporting that occurred during the quarterly period ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2023</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and has concluded that there was no change that occurred during the quarterly period ended</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> December&#160;31, 2023 that have materially affected, or are reasonably likely to materially effect, the Company's internal control over financial reporting.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management's Report on Internal Control over Financial Reporting</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The management of the Company is responsible for establishing and maintaining adequate internal control over financial reporting.&#160;Internal control over financial reporting is defined in Rule 13a-15(f) or 15d-15(f) promulgated under the Securities Exchange Act of 1934, as amended, as a process designed by, or under the supervision of, the Company's principal executive and principal financial officers and effected by the Company's board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles and includes those policies and procedures that:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pertain to the management of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the Company;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company; and</span></div><div style="margin-bottom:6pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company's assets that could have a material effect on the financial statements.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements.&#160;Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.&#160;All internal control systems, no matter how well designed, have inherent limitations.&#160;Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's management assessed the effectiveness of the Company's internal control over financial reporting as of December&#160;31, 2023.&#160;In making this assessment, the Company's management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (COSO) in Internal Control-Integrated Framework.&#160;Based on our assessment, management believes that, as of December&#160;31, 2023, the Company's internal control over financial reporting is effective based on those criteria.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effectiveness of our internal control over financial reporting as of December&#160;31, 2023 has been audited by Ernst &amp; Young, LLP, an independent registered public accounting firm, as stated in their report which is included herein on  page 71.</span></div><div id="i69aaf560e98645139c7ed7af73a9eafe_76"></div><div style="margin-bottom:3pt;margin-top:9pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9B.&#160;&#160;&#160;&#160;OTHER INFORMATION</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10b5-1 Trading Plans</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended December&#160;31, 2023 the following Section 16 officer and directors <ix:nonNumeric contextRef="c-4" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-37">adopted</ix:nonNumeric>, modified or <ix:nonNumeric contextRef="c-4" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-38"><ix:nonNumeric contextRef="c-4" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-39">terminated</ix:nonNumeric></ix:nonNumeric> a &#8220;Rule 10b5-1 trading arrangement&#8221; (as defined in Item 408 of Regulation S-K of the Exchange Act):</span></div><div style="text-indent:13.5pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><ix:nonNumeric contextRef="c-5" name="ecd:MtrlTermsOfTrdArrTextBlock" id="f-40" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"><ix:nonNumeric contextRef="c-6" name="ecd:TrdArrIndName" id="f-41">James Karrels</ix:nonNumeric>, <ix:nonNumeric contextRef="c-6" name="ecd:TrdArrIndTitle" id="f-42">Senior Vice President and Chief Financial Officer</ix:nonNumeric>, <ix:nonNumeric contextRef="c-6" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true" id="f-43">adopted</ix:nonNumeric> a new trading plan on December 8, 2023 (with the first trade possible under the new plan no sooner than April 16, 2024).  The trading plan will be effective until April 15, 2025 and covers the potential sale of up to <ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="0" id="f-44">490,000</ix:nonFraction> shares of common stock. (1)</span></ix:nonNumeric></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"><ix:nonNumeric contextRef="c-8" name="ecd:MtrlTermsOfTrdArrTextBlock" id="f-45" escape="true"><ix:nonNumeric contextRef="c-9" name="ecd:TrdArrIndName" id="f-46">Jeffrey Peters</ix:nonNumeric>, <ix:nonNumeric contextRef="c-9" name="ecd:TrdArrIndTitle" id="f-47">Senior Vice President and General Counsel</ix:nonNumeric>, <ix:nonNumeric contextRef="c-9" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true" id="f-48">adopted</ix:nonNumeric> a new trading plan on December 8, 2023 (with the first trade possible under the new plan no sooner than April 4, 2024).  The trading plan will be effective until March 20, 2025 and covers the potential sale of up to <ix:nonFraction unitRef="shares" contextRef="c-10" decimals="INF" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="0" id="f-49">370,842</ix:nonFraction> shares of common stock.</ix:nonNumeric> (2)</span></div><div style="margin-bottom:3pt;padding-left:58.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> &#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mr. Karrels&#8217; plan as adopted December 8, 2023 covered the potential sale of additional shares that were since sold under a prior existing plan. The total provided here reflects the maximum remaining shares available to sell under the December 8, 2023 plan as of March 5, 2024. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;padding-left:58.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;Mr. Peters&#8217; plan as adopted December 8, 2023 covered the potential sale of additional shares that were since sold under a prior existing plan. The total provided here reflects the maximum remaining shares available to sell under the December 8, 2023 plan  as of March 5, 2024. </span></div><div><span><br/></span></div><div id="i69aaf560e98645139c7ed7af73a9eafe_79"></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9C.&#160;&#160;&#160;&#160;DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><div id="i69aaf560e98645139c7ed7af73a9eafe_82"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">To the Shareholders and the Board of Directors of MacroGenics, Inc. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on Internal Control over Financial Reporting</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited MacroGenics, Inc.&#8217;s internal control over financial reporting as of December&#160;31, 2023, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, MacroGenics, Inc. (the Company) maintained, in all material respects, effective internal control over financial reporting as of December&#160;31, 2023, based on the COSO criteria.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December&#160;31, 2023 and 2022, the related consolidated statements of operations and comprehensive loss, stockholders&#8217; equity and cash flows for each of the three years in the period ended December&#160;31, 2023, and the related notes and our report dated March&#160;7, 2024, expressed an unqualified opinion thereon. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management&#8217;s Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Definition and Limitations of Internal Control Over Financial Reporting</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Ernst &amp; Young LLP</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tysons, Virginia</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;7, 2024 </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><div id="i69aaf560e98645139c7ed7af73a9eafe_85"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div id="i69aaf560e98645139c7ed7af73a9eafe_88"></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 10.&#160;&#160;&#160;&#160;DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incorporate herein by reference the relevant information concerning directors, executive officers and corporate governance to be included in our definitive proxy statement for the 2024 annual meeting of stockholders (the 2024 Proxy Statement) under the captions "Directors and Nominees" "Corporate Governance," "Executive Officers," and "Delinquent Section 16(a) Reports".</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted a Code of Business Conduct and Ethics (the &#8220;Code&#8221;) that applies to all of our employees, officers and directors.  The Code is available under the Corporate Governance section of our website at http://ir.macrogenics.com/governance. We expect that any amendments to the Code, or any waivers of its requirements, will be disclosed on our website.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div id="i69aaf560e98645139c7ed7af73a9eafe_91"></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 11.&#160;&#160;&#160;&#160;EXECUTIVE COMPENSATION</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incorporate herein by reference the relevant information concerning executive compensation to be included in the 2024 Proxy Statement under the captions "Executive Compensation Information," CEO Pay Ratio Disclosure," and "Director Compensation".</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div id="i69aaf560e98645139c7ed7af73a9eafe_94"></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 12.&#160;&#160;&#160;&#160;SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incorporate herein by reference the relevant information concerning security ownership of certain beneficial owners and management to be included in the 2024 Proxy Statement under the captions "Security Ownership of Certain Beneficial Owners and Management" and "Information About Equity Compensation Plans".</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div id="i69aaf560e98645139c7ed7af73a9eafe_97"></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 13. &#160;&#160;&#160;&#160;CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incorporate herein by reference the relevant information concerning certain other relationships and related transactions to be included in the 2024 Proxy Statement under the captions "Corporate Governance" and "Certain Relationships and Related Party Transactions".</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div id="i69aaf560e98645139c7ed7af73a9eafe_100"></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 14.&#160;&#160;&#160;&#160;PRINCIPAL ACCOUNTANT FEES AND SERVICES</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incorporate herein by reference the relevant information concerning principal accountant fees and services to be included in the 2024 Proxy Statement under the caption "Principal Accountant Fees and Services".</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><div id="i69aaf560e98645139c7ed7af73a9eafe_103"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div id="i69aaf560e98645139c7ed7af73a9eafe_106"></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 15. &#160;&#160;&#160;&#160;EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) The following documents are filed as part of this Annual Report on Form 10-K:</span></div><div style="margin-bottom:9pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Consolidated Financial Statements:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.912%"><tr><td style="width:1.0%"/><td style="width:71.745%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.055%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Report of Ernst &amp; Young LLP, Independent Registered Public Accounting Firm</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i69aaf560e98645139c7ed7af73a9eafe_118">F - </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i69aaf560e98645139c7ed7af73a9eafe_118">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Balance Sheets</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i69aaf560e98645139c7ed7af73a9eafe_121">F - </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i69aaf560e98645139c7ed7af73a9eafe_121">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Statements of Operations and Comprehensive Loss</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i69aaf560e98645139c7ed7af73a9eafe_124">F - </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i69aaf560e98645139c7ed7af73a9eafe_124">4</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Statements of Stockholders' Equity</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i69aaf560e98645139c7ed7af73a9eafe_127">F - </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i69aaf560e98645139c7ed7af73a9eafe_127">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Statements of Cash Flows</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i69aaf560e98645139c7ed7af73a9eafe_130">F - </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i69aaf560e98645139c7ed7af73a9eafe_130">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i69aaf560e98645139c7ed7af73a9eafe_133">F - </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i69aaf560e98645139c7ed7af73a9eafe_133">7</a></span></div></td></tr></table></div><div style="margin-bottom:9pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Financial Statement Schedules:</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All financial statement schedules have been omitted because they are not applicable, not required or the information required is shown in the financial statements or the notes thereto.&#160;</span></div><div style="margin-bottom:9pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Exhibits:</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exhibits filed as part of this Annual Report on Form 10-K are set forth on the Exhibit Index immediately following our consolidated financial statements. The Exhibit Index is incorporated herein by reference.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div id="i69aaf560e98645139c7ed7af73a9eafe_109"></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 16.&#160;&#160;&#160;&#160;FORM 10-K SUMMARY</span></div><div style="margin-bottom:6pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><div id="i69aaf560e98645139c7ed7af73a9eafe_112"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:center;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section 13 or 15(d) of the Securities Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"/><td style="width:47.713%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.615%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:42.372%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MacroGenics, Inc.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Scott Koenig</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Scott Koenig, M.D., Ph.D.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">President and CEO and Director</span></td></tr></table></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Act of 1934, as amended, this Report has been signed by the following persons on behalf of the registrant and in the capacities and on the dates indicated:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"/><td style="width:38.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.318%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.714%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.429%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.384%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Signature</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Date</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Scott Koenig</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and CEO and Director<br/>(Principal Executive Officer)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March&#160;7, 2024</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Scott Koenig, M.D., Ph.D.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ James Karrels</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President, Chief <br/>Financial Officer and Secretary <br/>(Principal Financial Officer)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March&#160;7, 2024</span></div></td></tr><tr style="height:24pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">James Karrels</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Lynn Cilinski</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vice President, Controller and Treasurer<br/>(Principal Accounting Officer)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March&#160;7, 2024</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lynn Cilinski</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Karen Ferrante, M.D.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March&#160;7, 2024</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Karen Ferrante, M.D.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ William Heiden</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March&#160;7, 2024</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">William Heiden</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Edward Hurwitz</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March&#160;7, 2024</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Edward Hurwitz</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Scott Jackson</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March&#160;7, 2024</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Scott Jackson</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Meenu Chhabra Karson</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March&#160;7, 2024</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Meenu Chhabra Karson</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Margaret A. Liu, M.D.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March&#160;7, 2024</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Margaret A. Liu, M.D.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Federica O&#8217;Brien</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March&#160;7, 2024</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federica O&#8217;Brien</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Jay Siegel, M.D.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March&#160;7, 2024</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jay Siegel, M.D.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ David Stump, M.D.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March&#160;7, 2024</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David Stump, M.D.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><div id="i69aaf560e98645139c7ed7af73a9eafe_115"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i69aaf560e98645139c7ed7af73a9eafe_118">Report of Ernst &amp; Young LLP, Independent Registered Public Accounting Firm (PCAOB ID: </a></span><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><ix:nonNumeric contextRef="c-1" name="dei:AuditorFirmId" id="f-52">42</ix:nonNumeric></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i69aaf560e98645139c7ed7af73a9eafe_118">)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i69aaf560e98645139c7ed7af73a9eafe_118">F - </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i69aaf560e98645139c7ed7af73a9eafe_118">1</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i69aaf560e98645139c7ed7af73a9eafe_121">Consolidated Balance Sheets at December 31, 2023 and December 31, 2022</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i69aaf560e98645139c7ed7af73a9eafe_121">F - </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i69aaf560e98645139c7ed7af73a9eafe_121">3</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i69aaf560e98645139c7ed7af73a9eafe_124">Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 2023, 2022 and 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i69aaf560e98645139c7ed7af73a9eafe_124">F - </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i69aaf560e98645139c7ed7af73a9eafe_124">4</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i69aaf560e98645139c7ed7af73a9eafe_127">Consolidated Statements of Stockholders' Equity for the years ended December 31, 2023, 2022 and 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i69aaf560e98645139c7ed7af73a9eafe_127">F - </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i69aaf560e98645139c7ed7af73a9eafe_127">5</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i69aaf560e98645139c7ed7af73a9eafe_130">Consolidated Statements of Cash Flows for the years ended December 31, 2023, 2022 and 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i69aaf560e98645139c7ed7af73a9eafe_130">F - </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i69aaf560e98645139c7ed7af73a9eafe_130">6</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i69aaf560e98645139c7ed7af73a9eafe_133">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i69aaf560e98645139c7ed7af73a9eafe_133">F - </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i69aaf560e98645139c7ed7af73a9eafe_133">7</a></span></div></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i69aaf560e98645139c7ed7af73a9eafe_118"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Shareholders and the Board of Directors of MacroGenics, Inc. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Financial Statements</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of MacroGenics, Inc. (the Company) as of December&#160;31, 2023 and 2022, the related consolidated statements of operations and comprehensive loss, stockholders&#8217; equity and cash flows for each of the three years in the period ended December&#160;31, 2023, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">financial statements present fairly, in all material respects, the financial position of the Company at December&#160;31, 2023 and 2022, and the results of its operations and its cash flows for each of the three years in the period ended December&#160;31, 2023, in conformity with U.S. generally accepted accounting principles.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company&#8217;s internal control over financial reporting as of December&#160;31, 2023, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) and our report dated March&#160;7, 2024 expressed an unqualified opinion thereon. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Audit Matter </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.  </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:13.958%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:83.842%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Accounting for the Royalty Monetization Arrangement</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Description of the Matter</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 7 of the consolidated financial statements, on March 8, 2023, the Company entered into a Purchase and Sale Agreement to sell its royalty interest on future global sales of TZIELD (teplizumab-mzwv) to a wholly-owned subsidiary of DRI Healthcare Trust (&#8220;DRI&#8221;) for consideration of up to $200 million (&#8220;Royalty Monetization Arrangement&#8221;). The Company accounted for the Royalty Monetization Arrangement as a financing transaction. Subsequent transactions among various parties amended the Royalty Monetization Agreement.  </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounting for the Royalty Monetization Arrangement and related amendments required the Company to make significant judgments, including but not limited to the evaluation of the key terms of the Royalty Monetization Arrangement and other related amendments to determine the applicable accounting. As a result, auditing the Royalty Monetization Arrangement and related amendments required especially complex auditor judgment.</span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:13.958%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:83.842%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">How We Addressed the Matter in Our Audit</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We obtained an understanding, evaluated the design, and tested the operating effectiveness of controls addressing the risks of material misstatement relating to the accounting for the Royalty Monetization Arrangement. For example, we tested controls over management's process for performing technical accounting analyses and related evaluations of the applicable authoritative guidance.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">To audit the Company&#8217;s accounting for the Royalty Monetization Arrangement and related amendments, we performed audit procedures that included, among others, inspecting the executed agreements and related accounting analyses performed by management and evaluating the conclusions.  In addition, we obtained representations from management and performed inquiries of external and internal legal counsel to corroborate the Company&#8217;s interpretation of the terms of the Royalty Monetization Arrangement and related amendments. We also involved our subject matter resources to assist with auditing the significant and judgmental conclusions reached by management including the evaluation of the terms of the agreements and the application of the related accounting guidance.</span></div><div><span><br/></span></div></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ <ix:nonNumeric contextRef="c-1" name="dei:AuditorName" id="f-53">Ernst &amp; Young LLP</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We have served as the Company's auditor since 2006.</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:AuditorLocation" id="f-54">Tysons, Virginia</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 7, 2024</span></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 2</span></div></div></div><div id="i69aaf560e98645139c7ed7af73a9eafe_121"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> MACROGENICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share and per share data)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-55">100,956</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-56">108,884</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="us-gaap:Investments" format="ixt:num-dot-decimal" scale="3" id="f-57">128,849</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:Investments" format="ixt:num-dot-decimal" scale="3" id="f-58">45,462</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-59">10,367</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-60">56,222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-61">1,221</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-62">1,451</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="f-63">9,946</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="f-64">10,161</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-65">251,339</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-66">222,180</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, equipment and software, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-67">21,847</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-68">29,575</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-69">23,846</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-70">27,335</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-71">1,386</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-72">1,378</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-73">298,418</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-74">280,468</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and stockholders' equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-75">6,443</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-76">4,899</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-77">24,239</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-78">28,998</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="us-gaap:DeferredRevenueCurrent" format="ixt:num-dot-decimal" scale="3" id="f-79">21,651</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:DeferredRevenueCurrent" format="ixt:num-dot-decimal" scale="3" id="f-80">9,988</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-81">3,775</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-82">4,726</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-83">56,108</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-84">48,611</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="us-gaap:DeferredRevenueNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-85">59,243</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:DeferredRevenueNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-86">59,480</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-87">30,196</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-88">30,106</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="f-89">258</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="f-90">258</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-91">145,805</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-92">138,455</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders' equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, <ix:nonFraction unitRef="usdPerShare" contextRef="c-2" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-93"><ix:nonFraction unitRef="usdPerShare" contextRef="c-11" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-94">0.01</ix:nonFraction></ix:nonFraction> par value -- <ix:nonFraction unitRef="shares" contextRef="c-2" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-95"><ix:nonFraction unitRef="shares" contextRef="c-11" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-96">125,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="shares" contextRef="c-2" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-97">62,070,627</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-11" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-98">61,701,467</ix:nonFraction> shares outstanding at December&#160;31, 2023 and December&#160;31, 2022, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-99">621</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-100">617</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-101">1,254,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-102">1,235,095</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="f-103">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="f-104">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-105">1,102,752</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-106">1,093,694</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders' equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-107">152,613</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-108">142,013</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders' equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-109">298,418</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-110">280,468</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 3</span></div></div></div><div id="i69aaf560e98645139c7ed7af73a9eafe_124"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MACROGENICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share and per share data)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaborative and other agreements</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-111">28,990</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-112">119,303</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-113">63,294</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-114">17,939</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-115">16,727</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-116">12,349</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract manufacturing </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-117">9,833</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-118">13,988</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="3" id="f-119">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:Revenues" scale="3" id="f-120">431</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="3" id="f-121">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="3" id="f-122">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government agreements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-123">1,556</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-124">1,923</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-125">1,804</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-126">58,749</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-127">151,941</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-128">77,447</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of product sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="f-129">619</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-130">3,351</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-131">2,651</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of manufacturing services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="mgnx:CostOfManufacturingServices" format="ixt:num-dot-decimal" scale="3" id="f-132">7,603</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="mgnx:CostOfManufacturingServices" format="ixt:num-dot-decimal" scale="3" id="f-133">4,033</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="mgnx:CostOfManufacturingServices" format="ixt:fixed-zero" scale="3" id="f-134">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-135">166,583</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-136">207,026</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-137">214,577</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-138">52,188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-139">58,949</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-140">63,014</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total costs and expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-141">226,993</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-142">273,359</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-143">280,242</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-144">168,244</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-145">121,418</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-146">202,795</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on royalty monetization arrangement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="mgnx:GainOnRoyaltyMonetizationArrangement" format="ixt:num-dot-decimal" scale="3" id="f-147">150,930</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="mgnx:GainOnRoyaltyMonetizationArrangement" format="ixt:fixed-zero" scale="3" id="f-148">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="mgnx:GainOnRoyaltyMonetizationArrangement" format="ixt:fixed-zero" scale="3" id="f-149">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-150">9,686</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-151">1,660</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-152">680</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="f-153">1,430</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:InterestExpense" format="ixt:fixed-zero" scale="3" id="f-154">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:InterestExpense" format="ixt:fixed-zero" scale="3" id="f-155">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-156">9,058</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-157">119,758</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-158">202,115</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain (loss) on investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="f-159">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="f-160">56</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="f-161">54</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-162">9,059</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-163">119,702</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-164">202,169</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:13pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted net loss per common share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-165"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-166">0.15</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-27" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-167"><ix:nonFraction unitRef="usdPerShare" contextRef="c-27" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-168">1.95</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-28" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-169"><ix:nonFraction unitRef="usdPerShare" contextRef="c-28" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-170">3.37</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted weighted average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-171"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-172">61,929,198</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-27" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-173"><ix:nonFraction unitRef="shares" contextRef="c-27" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-174">61,433,124</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-28" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-175"><ix:nonFraction unitRef="shares" contextRef="c-28" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-176">59,944,717</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 4</span></div></div></div><div id="i69aaf560e98645139c7ed7af73a9eafe_127"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MACROGENICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share amounts)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:27.993%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.057%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.482%"/><td style="width:0.1%"/></tr><tr style="height:25pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Paid-In</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Capital</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deficit</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Comprehensive Income (Loss)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stockholders'</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-29" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-177">56,244,771</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-178">562</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-179">1,067,150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-180">771,821</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="f-181">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-182">295,884</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-183">23,126</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-184">23,126</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock, net of offering costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-35" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-185">4,580,653</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-186">46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-187">117,772</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-188">117,818</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock plan related activity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-35" decimals="INF" name="mgnx:StockIssuedDuringPeriodSharesStockPlanActivity" format="ixt:num-dot-decimal" scale="0" id="f-189">482,004</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="mgnx:StockIssuedDuringPeriodValueStockPlanActivity" scale="3" id="f-190">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="mgnx:StockIssuedDuringPeriodValueStockPlanActivity" format="ixt:num-dot-decimal" scale="3" id="f-191">4,954</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="mgnx:StockIssuedDuringPeriodValueStockPlanActivity" format="ixt:num-dot-decimal" scale="3" id="f-192">4,959</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized loss on investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" sign="-" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="f-193">54</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" sign="-" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="f-194">54</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-195">202,115</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-196">202,115</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-38" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-197">61,307,428</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-198">613</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-199">1,213,002</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-200">973,936</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="f-201">61</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-202">239,618</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-203">20,438</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-204">20,438</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock, net of offering costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-44" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-205">160,480</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-206">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-207">1,083</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-208">1,085</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock plan related activity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-44" decimals="INF" name="mgnx:StockIssuedDuringPeriodSharesStockPlanActivity" format="ixt:num-dot-decimal" scale="0" id="f-209">233,559</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" name="mgnx:StockIssuedDuringPeriodValueStockPlanActivity" scale="3" id="f-210">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="mgnx:StockIssuedDuringPeriodValueStockPlanActivity" scale="3" id="f-211">572</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="mgnx:StockIssuedDuringPeriodValueStockPlanActivity" scale="3" id="f-212">574</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain on investments</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="f-213">56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="f-214">56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-215">119,758</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-216">119,758</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-47" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-217">61,701,467</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-218">617</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-219">1,235,095</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-220">1,093,694</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="f-221">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-222">142,013</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-223">18,373</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-224">18,373</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock, net of offering costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-52" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-225">167,270</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-226">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-227">1,037</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-228">1,039</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock plan related activity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-52" decimals="INF" name="mgnx:StockIssuedDuringPeriodSharesStockPlanActivity" format="ixt:num-dot-decimal" scale="0" id="f-229">201,890</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="mgnx:StockIssuedDuringPeriodValueStockPlanActivity" scale="3" id="f-230">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" name="mgnx:StockIssuedDuringPeriodValueStockPlanActivity" scale="3" id="f-231">245</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="mgnx:StockIssuedDuringPeriodValueStockPlanActivity" scale="3" id="f-232">247</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized loss on investments</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" sign="-" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="f-233">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="f-234">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-235">9,058</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-236">9,058</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-55" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-237">62,070,627</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-238">621</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-239">1,254,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-240">1,102,752</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="f-241">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-242">152,613</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 5</span></div></div></div><div id="i69aaf560e98645139c7ed7af73a9eafe_130"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MACROGENICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-243">9,058</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-244">119,758</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-245">202,115</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-246">9,645</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-247">11,865</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-248">11,258</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of premiums and discounts on marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" format="ixt:num-dot-decimal" scale="3" id="f-249">5,004</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="f-250">403</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" format="ixt:num-dot-decimal" scale="3" id="f-251">1,607</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-252">18,373</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-253">20,438</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-254">23,126</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on royalty monetization arrangement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="mgnx:GainOnRoyaltyMonetizationArrangement" format="ixt:num-dot-decimal" scale="3" id="f-255">150,930</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="mgnx:GainOnRoyaltyMonetizationArrangement" format="ixt:fixed-zero" scale="3" id="f-256">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="mgnx:GainOnRoyaltyMonetizationArrangement" format="ixt:fixed-zero" scale="3" id="f-257">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="mgnx:NonCashInterestExpenseRecognized" format="ixt:num-dot-decimal" scale="3" id="f-258">1,430</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="mgnx:NonCashInterestExpenseRecognized" format="ixt:fixed-zero" scale="3" id="f-259">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="mgnx:NonCashInterestExpenseRecognized" format="ixt:fixed-zero" scale="3" id="f-260">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash lease expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="mgnx:OperatingLeaseNoncashExpense" format="ixt:num-dot-decimal" scale="3" id="f-261">3,489</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="mgnx:OperatingLeaseNoncashExpense" format="ixt:num-dot-decimal" scale="3" id="f-262">3,341</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="mgnx:OperatingLeaseNoncashExpense" format="ixt:num-dot-decimal" scale="3" id="f-263">2,690</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-cash items</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="f-264">423</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-265">2,882</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-266">2,035</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on disposal of assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:GainLossOnDispositionOfAssets" scale="3" id="f-267">111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:GainLossOnDispositionOfAssets" format="ixt:fixed-zero" scale="3" id="f-268">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:GainLossOnDispositionOfAssets" format="ixt:fixed-zero" scale="3" id="f-269">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-270">45,855</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-271">45,836</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-272">12,696</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="f-273">230</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="f-274">55</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="f-275">6,424</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidExpense" scale="3" id="f-276">215</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidExpense" format="ixt:num-dot-decimal" scale="3" id="f-277">11,009</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidExpense" format="ixt:num-dot-decimal" scale="3" id="f-278">4,188</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="f-279">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:num-dot-decimal" scale="3" id="f-280">14,045</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:num-dot-decimal" scale="3" id="f-281">3,225</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-282">1,281</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-283">10,860</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-284">7,125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-285">4,823</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-286">4,638</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="f-287">607</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="mgnx:IncreaseDecreaseInLeaseLiabilities" scale="3" id="f-288">861</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="mgnx:IncreaseDecreaseInLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-289">9,364</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" sign="-" name="mgnx:IncreaseDecreaseInLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-290">3,780</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-291">11,426</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-292">48,821</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-293">9,264</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="mgnx:IncreaseDecreaseInDeferredRent" format="ixt:fixed-zero" scale="3" id="f-294">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="mgnx:IncreaseDecreaseInDeferredRent" format="ixt:fixed-zero" scale="3" id="f-295">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="mgnx:IncreaseDecreaseInDeferredRent" scale="3" id="f-296">258</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-297">78,205</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-298">86,959</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-299">143,830</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:13pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from investing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="f-300">239,683</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="f-301">120,602</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="f-302">231,208</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sales and maturities of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-303">161,299</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-304">194,940</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-305">200,800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property, equipment and software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-306">1,764</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-307">3,623</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-308">6,201</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sales of equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromSaleOfMachineryAndEquipment" scale="3" id="f-309">64</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:ProceedsFromSaleOfMachineryAndEquipment" format="ixt:fixed-zero" scale="3" id="f-310">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:ProceedsFromSaleOfMachineryAndEquipment" format="ixt:fixed-zero" scale="3" id="f-311">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-312">80,084</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-313">70,715</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-314">36,609</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:13pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock, net of offering costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="f-315">616</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-316">1,085</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-317">117,818</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from stock option exercises and ESPP purchases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases" scale="3" id="f-318">553</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases" scale="3" id="f-319">574</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases" format="ixt:num-dot-decimal" scale="3" id="f-320">4,959</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxes paid related to net share settlement of equity awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="f-321">306</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="f-322">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="f-323">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal payments on royalty monetization arrangement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="mgnx:PrincipalPaymentsOnRoyaltyMonetizationArrangement" scale="3" id="f-324">157</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="mgnx:PrincipalPaymentsOnRoyaltyMonetizationArrangement" format="ixt:fixed-zero" scale="3" id="f-325">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="mgnx:PrincipalPaymentsOnRoyaltyMonetizationArrangement" format="ixt:fixed-zero" scale="3" id="f-326">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net proceeds from sale of future royalties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="mgnx:NetProceedsFromSaleOfFutureRoyalties" format="ixt:num-dot-decimal" scale="3" id="f-327">149,655</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="mgnx:NetProceedsFromSaleOfFutureRoyalties" format="ixt:fixed-zero" scale="3" id="f-328">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="mgnx:NetProceedsFromSaleOfFutureRoyalties" format="ixt:fixed-zero" scale="3" id="f-329">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-330">150,361</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-331">1,659</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-332">122,777</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-333">7,928</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-334">14,585</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-335">57,662</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-336">108,884</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-337">123,469</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-338">181,131</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-339">100,956</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-340">108,884</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-341">123,469</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:13pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-cash operating and investing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment included in accounts payable or accruals</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="f-342">505</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="f-343">118</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="f-344">508</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 6</span></div></div></div><div id="i69aaf560e98645139c7ed7af73a9eafe_133"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MACROGENICS, INC.</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div id="i69aaf560e98645139c7ed7af73a9eafe_136"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="c-1" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="f-345" continuedAt="f-345-1" escape="true">Organization and Nature of Operations</ix:nonNumeric></span></div><ix:continuation id="f-345-1"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MacroGenics, Inc. (the Company) is incorporated in the state of Delaware. The Company is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer. The Company has a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. These candidates are being evaluated in clinical trials sponsored by the Company or its collaborators or are in preclinical development. The Company&#8217;s clinical product candidates include multiple oncology programs which have either been created using its proprietary, antibody-based technology platforms or enabled through its technology licensing arrangements with other companies. The Company believes its product candidates have the potential, if approved for marketing by regulatory authorities, to have a meaningful effect on treating patients' unmet medical needs as monotherapy or, in some cases, in combination with other therapeutic agents. To date, three products originating from the Company&#8217;s pipeline of proprietary or partnered product candidates have received U.S. Food and Drug Administration (FDA) approval. In March 2021, the Company and its commercialization partner commenced U.S. marketing of MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. In November 2022, the FDA approved TZIELD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (teplizumab-mzwv) to delay the onset of Stage 3 Type 1 Diabetes (T1D) in adult and pediatric patients aged 8 years and older with Stage 2 T1D. Teplizumab was acquired from the Company by Provention Bio, Inc. (Provention) in May 2018, pursuant to an asset purchase agreement. In March 2023, the FDA approved ZYNYZ&#8482; (retifanlimab-dlwr), a humanized monoclonal antibody targeting programmed death receptor-1 (PD-1). Retifanlimab was previously developed by the Company and licensed to Incyte Corporation (Incyte) pursuant to an exclusive global collaboration and license agreement in October 2017.</span></div><div style="margin-bottom:6pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s multiple product candidates currently under development will require significant additional research and development efforts that include extensive preclinical studies and clinical testing, and regulatory approval prior to commercial use.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The future success of the Company is dependent on its ability to identify and develop its product candidates, and ultimately upon its ability to attain profitable operations. The Company has devoted substantially all of its financial resources and efforts to research and development and general and administrative expense to support such research and development. Net losses and negative cash flows have had, and will continue to have, an adverse effect on the Company&#8217;s stockholders&#8217; equity and working capital, and accordingly, its ability to execute its future operating plans.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a biotechnology company, the Company has primarily funded its operations with proceeds from the sale of its common stock in equity offerings and revenue from its multiple collaboration agreements.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management regularly reviews the Company&#8217;s available liquidity relative to its operating budget and forecast to monitor the sufficiency of the Company&#8217;s working capital.  The Company plans to meet its future operating requirements by generating revenue from current and future strategic collaborations or other arrangements, product sales and royalties.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company anticipates continuing to draw upon available sources of capital, including equity and debt instruments, to support its product development activities.  If the Company is unable to enter into new arrangements or to perform under current or future agreements or obtain additional capital, the Company will assess its capital resources and may be required to delay, reduce the scope of, or eliminate one or more of its product research and development programs or clinical studies, reduce other operating expenses, and/or downsize its organization. Based on the Company&#8217;s most recent cash flow forecast, the Company believes its current resources are sufficient to fund its operating plans for a minimum of twelve months from the date that this Annual Report on Form 10-K was filed.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similar to the other risk factors pertinent to the Company's business, including significant equity market volatility and availability of funding in the biotechnology sector, as well as potential issues in the global economy, credit markets and financial markets as a result of significant worldwide events, including adverse events involving financial institutions or the financial services industry, inflation and rising interest rates and geopolitical upheaval, might unfavorably impact the Company's ability to generate such additional funding. Given the uncertainty in the rapidly changing market and economic conditions related to these uncertainties, the Company will continue to evaluate the nature and extent of the impact of these uncertainties on its business and financial position.</span></div></ix:continuation><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div id="i69aaf560e98645139c7ed7af73a9eafe_139"></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="c-1" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="f-346" continuedAt="f-346-1" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="f-347" continuedAt="f-347-1" escape="true"><ix:continuation id="f-346-1" continuedAt="f-346-2"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Principles of Consolidation</span></div></ix:continuation></ix:nonNumeric><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-346-2" continuedAt="f-346-3"><ix:continuation id="f-347-1"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, MacroGenics UK Limited and MacroGenics Limited.&#160;All intercompany accounts and transactions have been eliminated in consolidation. The Company currently operates in <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="f-348">one</ix:nonFraction> operating segment. Operating segments are defined as components of an enterprise about which separate discrete information is available for the chief operating decision maker, or decision making group, in deciding how to allocate resources and assessing performance. The Company views its operations and manages its business in <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="f-349">one</ix:nonFraction> segment, which is developing and commercializing monoclonal antibody-based therapeutics.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:UseOfEstimates" id="f-350" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the financial statements in accordance with generally accepted accounting principles (GAAP) requires the Company to make estimates and judgments in certain circumstances that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. In preparing these consolidated financial statements, management has made its best estimates and judgments of certain amounts included in the financial statements, giving due consideration to materiality. On an ongoing basis, the Company evaluates its estimates, including those related to revenue recognition, fair values of assets, inventory, preclinical study and clinical trial accruals and other contingencies. Management bases its estimates on historical experience or on various other assumptions that it believes to be reasonable under the circumstances. Although actual results could differ from these estimates, management does not believe that such differences would be material.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="f-351" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents and Marketable Securities</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all investments in highly liquid financial instruments with a maturity of 90 days or less at the date of purchase to be cash equivalents. Cash and cash equivalents includes investments in money market funds with commercial banks and financial institutions, securities issued by the U.S. government and its agencies, Government Sponsored Enterprise agency debt obligations and corporate debt obligations. Cash equivalents are stated at amortized cost, plus accrued interest, which approximates fair value.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company carries marketable securities classified as available-for-sale at fair value as determined by prices for identical or similar securities at the balance sheet date. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Classification of marketable securities between current and non-current is dependent upon the maturity date at the balance sheet date taking into consideration the Company&#8217;s ability and intent to hold the investment to maturity. </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities consist of Level 2 financial instruments in the fair-value hierarchy. The Company records unrealized gains and losses as a component of other comprehensive loss within the statements of operations and comprehensive loss and as a separate component of stockholders' equity. Realized gains or losses on available-for-sale securities are determined using the specific identification method and the Company includes net realized gains and losses in other income, along with interest income and amortization of premiums and discounts.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="f-352" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable arise from product sales, amounts due from the Company&#8217;s collaborative partners and contract manufacturing work performed by the Company.  The amount from product sales represents amounts due from specialty distributors. Accounts receivable that management has the intent and ability to collect are reported in the consolidated balance sheets at outstanding amounts, less an allowance for doubtful accounts. The Company writes off uncollectible receivables when the likelihood of collection is remote.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates the collectability of accounts receivable on a regular basis. The allowance, if any, is based upon various factors including the financial condition and payment history of customers, an overall review of collections experience on other accounts and economic factors or events expected to affect future collections experience. No allowance was recorded as of December&#160;31, 2023 or 2022, as the Company has a history of collecting on all outstanding accounts.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="f-353" continuedAt="f-353-1" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's financial instruments consist of cash and cash equivalents, marketable securities, accounts receivable, accounts payable and accrued expenses.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of accounts receivable, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of their short-term nature.&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for recurring and non-recurring fair value measurements in accordance with the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements and Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 820). ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements. The ASC 820 hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-346-3" continuedAt="f-346-4"><ix:continuation id="f-353-1" continuedAt="f-353-2"><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 &#8211; Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 &#8211; Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data.</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 &#8211; Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity &#8211; e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security.</span></div></ix:continuation><div style="margin-bottom:9pt;text-indent:36pt"><ix:continuation id="f-353-2" continuedAt="f-353-3"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC 820 hierarchy.  </span></ix:continuation><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-353-3">There were no transfers between levels during the periods presented.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="f-354" escape="true"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets measured at fair value on a recurring basis were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:51.616%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.612%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.121%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.584%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.852%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement at December&#160;31, 2023</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-355">91,665</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-356">91,665</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-357">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-358">31,179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-359">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-360">31,179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-361">45,043</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-362">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-363">45,043</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-364">52,627</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-365">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-366">52,627</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-367">220,514</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-368">91,665</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-369">128,849</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.677%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.958%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.115%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.108%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement at December&#160;31, 2022</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-370">41,564</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-371">41,564</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-372">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-sponsored enterprise</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-373">32,811</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-374">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-375">32,811</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-376">17,626</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-377">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-378">17,626</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-379">92,001</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-380">41,564</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-381">50,437</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:15pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Total assets measured at fair value at December&#160;31, 2023 includes approximately $<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-382">91.7</ix:nonFraction> million reported as cash and cash equivalents and $<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-5" name="us-gaap:Investments" format="ixt:num-dot-decimal" scale="6" id="f-383">128.8</ix:nonFraction>&#160;million reported as marketable securities on the balance sheet.</span></div><div style="margin-bottom:9pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Total assets measured at fair value at December&#160;31, 2022 includes approximately $<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-384">46.5</ix:nonFraction> million reported as cash and cash equivalents and $<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-5" name="us-gaap:Investments" format="ixt:num-dot-decimal" scale="6" id="f-385">45.5</ix:nonFraction>&#160;million reported as marketable securities on the balance sheet.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ConcentrationRiskCreditRisk" id="f-386" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents, marketable securities and accounts receivable. </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains its cash and money market funds with financial institutions that are federally insured. While balances deposited in these institutions often exceed Federal Deposit Insurance Corporation limits, the Company has not experienced any losses on related accounts to date.&#160;The Company's investment policy limits investments to certain types of debt securities issued by the U.S. government, its agencies and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The counterparties are various corporations, financial institutions and government agencies of high credit standing.</span></div></ix:nonNumeric><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's revenue relates to agreements with various collaborators, MARGENZA net product sales and&#160;contracts and research grants received from U.S. government agencies.&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="f-387" continuedAt="f-387-1" escape="true">The following table includes those counterparties </ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-346-4" continuedAt="f-346-5"><ix:continuation id="f-387-1"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that represent more than 10% of total revenue earned in the periods indicated:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:68.119%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.620%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.620%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.683%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incyte</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-86" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-388">53</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-87" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-389">26</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-88" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-390">31</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">McKesson Plasma &amp; Biologics and McKesson Specialty Care Distribution LLC (McKesson)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-89" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-391">12</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ASD Healthcare and Oncology Supply (ASD)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-90" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-392">10</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provention</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-91" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-393">10</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-92" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-394">43</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zai Lab Limited (Zai Lab)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-93" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-395">15</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-94" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-396">30</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I-Mab Biopharma (I-Mab)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-95" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-397">16</ix:nonFraction>%</span></td></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Amount is less than 10% for the period indicated.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table includes those counterparties that represent more than 10% of accounts receivable at the date indicated:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:72.946%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.363%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incyte</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-96" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-398">25</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health, Inc</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-97" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-399">18</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">McKesson</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-98" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-400">16</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ASD</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-99" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-401">15</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zai Lab</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-100" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-402">12</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provention</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-101" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-403">84</ix:nonFraction>%</span></td></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Balance is less than 10% as of the date indicated.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:InventoryPolicyTextBlock" id="f-404" escape="true"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When the Company believes regulatory approval is probable and expects future economic benefit from the sales of a product candidate to be realized, the Company capitalizes manufacturing costs (whether internally produced or through third-party contract manufacturing organizations) as inventory.  Prior to receiving its first approval from the FDA in December 2020, the Company expensed all costs incurred related to the manufacture of MARGENZA as research and development expense because of the inherent risks associated with the development of a product candidate, the uncertainty about the regulatory approval process and the lack of history for the Company of regulatory approval of drug candidates.  Subsequent to FDA approval in December 2020, the Company began capitalizing its MARGENZA third-party contract manufacturing inventory costs.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory is composed of raw materials, work-in-process, and finished goods, which are goods that are available for sale. The Company values its inventories at the lower of cost or estimated net realizable value. The Company determines the cost of its inventories, which includes amounts related to materials and third-party contract manufacturing costs, on a first-in, first-out basis. The Company performs an assessment of the recoverability of capitalized inventory during each reporting period, and it writes down any excess, obsolete or unsaleable inventories to their estimated realizable value in the period in which the impairment is first identified. Such write downs, should they occur, are recorded within the cost of product sales in the statement of operations.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="f-405" continuedAt="f-405-1" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property, Equipment and Software</span></div></ix:nonNumeric><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-405-1">Property, equipment and software are stated at cost. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation or amortization are removed from the accounts and any resulting gain or loss is credited or charged to operations. Repairs and maintenance costs are expensed as incurred.</ix:continuation> <ix:nonNumeric contextRef="c-1" name="mgnx:PropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock" id="f-406" continuedAt="f-406-1" escape="true">Depreciation and amortization are computed using the straight-line method over the following estimated useful lives:</ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-346-5" continuedAt="f-346-6"><ix:continuation id="f-406-1"><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.046%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.754%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-102" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-407">3</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-103" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-408">3</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-104" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-409">10</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory and office equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-105" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-410">5</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter of lease term or useful life</span></td></tr></table></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="f-411" continuedAt="f-411-1" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div></ix:nonNumeric><div style="margin-bottom:9pt;text-indent:36pt"><ix:continuation id="f-411-1" continuedAt="f-411-2"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses the recoverability of its long-lived assets in accordance with the provisions of ASC 360, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property, Plant and Equipment </span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-411-2">(ASC 360). ASC 360 requires that long-lived assets be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of the long-lived asset is measured by a comparison of the carrying amount of the asset to future undiscounted net cash flows expected to be generated by the asset or asset group. If carrying value exceeds the sum of undiscounted cash flows, the Company then determines the fair value of the underlying asset group. Any impairment to be recognized is measured by the amount by which the carrying amount of the asset group exceeds the estimated fair value of the asset group. Assets to be disposed of are reported at the lower of the carrying amount or fair value, less costs to sell.</ix:continuation> For the years ended December&#160;31, 2023, and 2022, the Company determined that there were no impaired assets.</span></div><ix:nonNumeric contextRef="c-1" name="mgnx:LiabilityRelatedToFutureRoyaltiesAndRelatedInterestExpensePolicyTextBlock" id="f-412" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liability related to the sale of future royalties and related interest expense</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses the relevant accounting criteria under ASC 470, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 470) to determine whether the upfront payment received from the purchaser should be accounted for as debt or deferred income depending on the facts and circumstances.  If the criteria in ASC 470 is met, the Company accounts for net proceeds from sales of its rights to receive future royalty payments as a liability that is amortized using the effective interest method over the term of the arrangement. The liability related to future royalties is presented net of unamortized issuance costs on the consolidated balance sheets. Interest expense on the liability related to future royalties is recognized using the effective interest rate method over the life of the arrangement. The Company calculates an effective interest rate which will amortize its related obligation to zero over the anticipated repayment period. The liability related to future royalties and the related interest expense are based on the Company&#8217;s current estimates of future royalties expected to be received over the life of the arrangement, which the Company determines by using internal sales projections and external information from market data sources, which are considered Level 3 inputs. The Company periodically assesses the expected payments and to the extent the Company&#8217;s estimates of future royalty payments are greater or less than previous estimates or the estimated timing of such payments is materially different than previous estimates, the Company will adjust the effective interest rate and recognize related non-cash interest expense on a prospective basis. Non-cash amortization is reflected as interest expense in the consolidated statements of operations and comprehensive loss.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Upon changes in facts and circumstances, for example as a result of a modification to the existing agreements, the Company re-evaluates its rights and obligations and accounts for the change in accordance with the respective accounting guidance.</span></div></ix:nonNumeric><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="f-413" continuedAt="f-413-1" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue recognition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue under ASC Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s (ASC 606) when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Collaborative and other agreements</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into licensing agreements that are within the scope of ASC 606, under which it may license rights to research, develop, manufacture and commercialize its product candidates to third parties. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, upfront license fees; reimbursement of certain costs; customer option exercise fees; development, regulatory and commercial milestone payments;&#160;and royalties on net sales of licensed products. The Company may also enter into development and manufacturing service agreements with its collaborators.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-413-1" continuedAt="f-413-2"><ix:continuation id="f-346-6" continuedAt="f-346-7"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each arrangement that results in revenues, the Company identifies all performance obligations, which may include a license to intellectual property and know-how, research and development activities, transition activities and/or manufacturing services. In order to determine the transaction price, in addition to any upfront payment, the Company estimates the amount of variable consideration at the outset of the contract either utilizing the expected value or most likely amount method, depending on the facts and circumstances relative to the contract. The Company constrains (reduces) the estimates of variable consideration such that it is probable that a significant reversal of previously recognized revenue will not occur. When determining if variable consideration should be constrained, management considers whether there are factors outside the Company&#8217;s control that could result in a significant reversal of revenue. In making these assessments, the Company considers the likelihood and magnitude of a potential reversal of revenue. These estimates are re-assessed each reporting period as required. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once the estimated transaction price is established, amounts are allocated to the performance obligations that have been identified. The transaction price is generally allocated to each separate performance obligation on a relative standalone selling price basis. The Company must develop assumptions that require judgment to determine the standalone selling price in order to account for these agreements. To determine the standalone selling price, the Company&#8217;s assumptions may include (i)  the probability of obtaining marketing approval for the product candidate, (ii) estimates regarding the timing and the expected costs to develop and commercialize the product candidate, and (iii) estimates of future cash flows from potential product sales with respect to the product candidate. Standalone selling prices used to perform the initial allocation are not updated after contract inception. The Company does not include a financing component to its estimated transaction price at contract inception unless it estimates that certain performance obligations will not be satisfied within one year.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts received prior to revenue recognition are recorded as deferred revenue. Amounts expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as current portion of deferred revenue in the accompanying consolidated balance sheets. Amounts not expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as deferred revenue, net of current portion. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Licenses. </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When the Company grants a license to its intellectual property, it </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">determines whether the </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nature of the intellectual property to which the customer will have rights is functional intellectual property (functional IP), which has significant standalone functionality, or symbolic intellectual property (symbolic IP) which does not have significant standalone functionality.  Revenue from functional IP is recognized at the point in time when control of the distinct license is transferred to the customer. Revenue from symbolic IP is recognized over the access period to the Company&#8217;s intellectual property</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the license to the Company&#8217;s intellectual property is determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and when (or as) the customer is able to use and benefit from the license. In assessing whether a promise or performance obligation is distinct from the other promises, the Company considers factors such as the research, development, manufacturing and commercialization capabilities of the licensee and the availability of the associated expertise in the general marketplace. In addition, the Company considers whether the licensee can benefit from a promise for its intended purpose without the receipt of the remaining promise, whether the value of the promise is dependent on the unsatisfied promise, whether there are other vendors that could provide the remaining promise, and whether it is separately identifiable from the remaining promise. For licenses that are combined with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The measure of progress, and thereby periods over which revenue should be recognized, are subject to estimates by management and may change over the course of the research and development and licensing agreement. Such a change could have a material impact on the amount of revenue the Company records in future periods. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research, Development and/or Manufacturing Services. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The promises under the Company&#8217;s agreements may include research and development or manufacturing services to be performed by the Company on behalf of the counterparty. If these services are determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes the transaction price allocated to these services as revenue over time based on an appropriate measure of progress when the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. If these services are determined not to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes the transaction price allocated to the combined performance obligation as the related performance obligations are satisfied. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Customer Options. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an arrangement contains customer options, the Company evaluates whether the options are material rights because they allow the customer to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the </span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-413-2" continuedAt="f-413-3"><ix:continuation id="f-346-7" continuedAt="f-346-8"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">outset of the arrangement. The Company allocates the transaction price to material rights based on the relative standalone selling price, which is determined using assumptions regarding estimated costs, discount rates, post-option development timeline, the probability of technical and regulatory success and the probability  that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until, at the earliest, the option is exercised. If the options are deemed not to be a material right, they are excluded as performance obligations at the outset of the arrangement. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes development milestone payments, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For arrangements that include sales-based royalties which are the result of a customer-vendor relationship and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company analyzes its collaboration arrangements to assess whether such arrangements involve joint operating activities performed by parties who are both active participants in the activities and are both exposed to significant risks and rewards dependent on the commercial success of such activities. Such arrangements generally are within the scope of ASC 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 808). While ASC 808 defines collaborative arrangements and provides guidance on income statement presentation, classification, and disclosures related to such arrangements, it does not address recognition and measurement matters, such as (1)&#160;determining the appropriate unit of accounting or (2) when the recognition criteria are met. Therefore, the accounting for these arrangements is either based on an analogy to other accounting literature or an accounting policy election by the Company. The Company accounts for certain components of the collaboration agreement that are reflective of a vendor-customer relationship (e.g., licensing arrangement) based on ASC 606. The Company accounts for other components based on a reasonable, rational and consistently applied accounting policy election.&#160; Reimbursements from the counter-party that are the result of a collaborative relationship with the counter-party, instead of a customer relationship, such as co-development activities, are recorded as a reduction to research and development expense as the services are performed.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a complete discussion of accounting for revenue from collaborative and other agreements, see Note 9, Revenue.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Product sales, net</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company entered into a limited number of arrangements with specialty distributors in the United States to distribute MARGENZA. These arrangements are considered to be contracts with customers and are in the scope of ASC 606. The Company has written contracts with each of its customers that have a single performance obligation - to deliver products upon receipt of a customer order - and these obligations are satisfied when delivery occurs and the customer receives the product.  The specialty distributors subsequently resell the Company&#8217;s product to healthcare providers.  Product revenue is recorded net of applicable reserves for variable consideration, including discounts and other allowances. Shipping and handling costs for product shipments occur prior to the customer obtaining control of the goods and are recorded in cost of sales. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reserves for Variable Consideration.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from product sales is recorded at the net sales price, which includes estimates of variable consideration. Components of variable consideration typically include discounts, product returns, provider chargebacks and discounts and government rebates. Variable consideration is estimated following the expected value method in accordance with ASC 606 and includes such factors as current contractual and statutory requirements, specific known market events and trends, industry data, and forecasted customer buying and payment patterns. The amount of variable consideration that is included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized under the contract will not occur in a future period. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Customer Discounts and Service Fees.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may provide customers with discounts which are explicitly stated in the contracts. These discounts are recorded as a reduction of revenue in the period the related product revenue is </span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-346-8" continuedAt="f-346-9"><ix:continuation id="f-413-3" continuedAt="f-413-4"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recognized. In addition, these contracts may include written service arrangements whereby the Company pays fees to customers who provide services such as sales order management, data, contract administration and distribution services, at rates which the Company believes to be consistent with fair market value. The Company has determined such services received to date are not distinct from the Company&#8217;s sale of products to its customers and, therefore, these payments have been recorded as a reduction of revenue within the statement of operations. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Returns.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consistent with industry practice, the Company offers the specialty distributors product return rights pursuant to written contracts and/or Company returned goods policies. The Company estimates the amount of its product sales that may be returned by its customers and records an estimated liability and a reduction of revenue in the period the related product revenue is recognized. The Company currently estimates product returns using industry benchmarking as well as other information available, such as visibility into the inventory remaining in the distribution channel, since the Company does not have its own returns experience. The Company's estimates of product returns may be adjusted in the future based on actual returns experience, known or expected changes in the marketplace, or other factors.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provider Chargebacks and Discounts.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chargebacks for fees and discounts to healthcare providers represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices charged to customers who directly purchase the product from the Company. In such cases, customers charge the Company for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers. The reserve for chargebacks is established in the same period that the related revenue is recognized, resulting in a reduction of product revenue. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider by customers, and the Company generally issues credits for such amounts within a few weeks of the customer&#8217;s notification to the Company of the resale. Chargebacks consist of credits the Company expects to issue for units that remain in the distribution channel at each reporting period end that the Company expects will be sold to qualified healthcare providers and chargebacks that customers have claimed, but for which the Company has not yet issued a credit. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Rebates.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to discount and/or rebate obligations under state Medicaid programs, Medicare and contractual agreements with and statutory obligations to certain Federal and State entities. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue. The Company&#8217;s liability for these rebates consists of invoices received for claims from prior quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimates of future claims that will be made for product that has been recognized as revenue, but which remains in the distribution channel at the end of each reporting period. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customer discounts are recorded as a reduction of accounts receivable on the consolidated balance sheets. Allowance for product returns, provider chargebacks, government and other rebates and service fees are recorded as a component of accrued expenses and other current liabilities on the consolidated balance sheets.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Contract manufacturing revenue</span></div></ix:continuation><div style="text-indent:36pt"><ix:continuation id="f-413-4"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into agreements with third parties to manufacture their drug substance at its GMP facility. The terms of these arrangements typically include an upfront payment to the Company to reserve manufacturing capacity, scheduled payments during the manufacturing process and reimbursement for materials used to manufacture product.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue over time on a straight-line basis as the manufacturing services are performed, as the Company believes that its efforts in providing the manufacturing services are incurred evenly throughout the performance period and therefore straight-line revenue recognition closely approximates the level of effort for the manufacturing services. Variable consideration relating to the reimbursed materials and other reimbursed costs incurred to manufacture product are allocated to the related manufacturing activities and are recognized as revenue as those activities occur.</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:CostOfSalesPolicyTextBlock" id="f-414" escape="true"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Cost of Product Sales</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of product sales relates to sales of MARGENZA.  These costs include material, manufacturing and shipping costs, as well as royalties payable on net sales of MARGENZA and inventory reserves.  All product costs incurred prior to FDA approval of MARGENZA in December 2020 were expensed as research and development expense.  The Company expects cost of product sales to continue to be positively impacted for the next four to five years as the Company sells through inventory that was expensed prior to FDA approval of MARGENZA. </span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Manufacturing Services</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of manufacturing services consists of the costs to provide manufacturing services to produce certain bulk drug substance under manufacturing and clinical supply agreements with third parties, including salaries and benefits and related stock-based compensation, materials, overhead and other related costs.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-346-9" continuedAt="f-346-10"><ix:nonNumeric contextRef="c-1" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="f-415" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expense, Including Clinical Trial Accruals/Expenses</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenditures are expensed as incurred. Research and development costs primarily consist of employee related expenses, including salaries and benefits, expenses incurred under agreements with contract research organizations (CROs), investigative sites and consultants that conduct the Company's clinical trials, the cost of acquiring and manufacturing clinical trial materials, including costs incurred under agreements with contract manufacturing organizations (CMOs), and other allocated expenses, license fees for and milestone payments related to in-licensed products and technologies, stock-based compensation expense, and costs associated with non-clinical activities and regulatory approvals.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-to-develop agreements may contain cost-sharing provisions whereby the Company and the collaborator share the cost of research and development activities. Reimbursement of research and development expenses received in connection with these agreements is recorded as a reduction of such expenses.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trial expenses are a significant component of research and development expense, and the Company outsources  a significant portion of these costs to third parties. Third party clinical trial expenses include investigator fees, site and patient costs, CRO costs, costs for central laboratory testing, data management and CMO costs. The accrual for site and patient costs includes inputs such as estimates of patient enrollment, patient cycles incurred, clinical site activations, and other pass-through costs. These inputs are required to be estimated due to a lag in receiving the actual clinical information from third parties. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected on the consolidated balance sheets as a prepaid asset or accrued expenses. These third party agreements are generally cancellable, and related costs are recorded as research and development expenses as incurred</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Non-refundable advance clinical payments for goods or services that will be used or rendered for future research and development activities are recorded as a prepaid asset and recognized as expense as the related goods are delivered or the related services are performed.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> When evaluating the adequacy of the accrued expenses, management  analyzes progress of the studies, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates may be made in determining the accrued balances at the end of any reporting period. Actual results could differ from the estimates made. The historical clinical accrual estimates have not been materially different from the actual costs.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeLeasesPolicyTextBlock" id="f-416" continuedAt="f-416-1" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div></ix:nonNumeric><div style="margin-bottom:9pt;text-indent:36pt"><ix:continuation id="f-416-1" continuedAt="f-416-2"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines whether an arrangement is or contains a lease at the inception of an arrangement under ASC 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-416-2">. For leases where the Company is the lessee, right-of-use (ROU) assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term of the lease for which the rate is estimated. Certain adjustments to the ROU asset may be required for items such as initial direct costs paid or incentives received. The lease terms used to calculate the ROU asset and related lease liabilities include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for operating leases is recognized on a straight-line basis over the lease term as an operating expense while the expense for finance leases is recognized as depreciation expense and interest expense using the accelerated interest method of recognition.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="f-417" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss represents net loss adjusted for the change during the periods attributed to unrealized gains and losses on available-for-sale debt securities.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerSharePolicyTextBlock" id="f-418" continuedAt="f-418-1" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</span></div></ix:nonNumeric><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-418-1">Basic and diluted loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period. All stock options and restricted stock units (RSUs) are excluded from the per share calculations as such securities were anti-dilutive for all periods presented.</ix:continuation> <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="f-419" continuedAt="f-419-1" escape="true">The following table presents the number of stock options and RSUs that were excluded from the calculation of net loss per share:</ix:nonNumeric></span><ix:continuation id="f-419-1"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"/><td style="width:44.036%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.377%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.015%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.377%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.015%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.380%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options and RSUs</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-106" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-420">13,129,251</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-107" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-421">10,514,013</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-108" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-422">8,395,421</ix:nonFraction></span></td></tr></table></ix:continuation></div><div style="text-indent:36pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-423" continuedAt="f-423-1" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-423-1"><ix:continuation id="f-346-10"><div style="text-align:justify;text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has implemented all applicable accounting pronouncements that are in effect. These pronouncements did not have any material impact on the financial statements unless otherwise disclosed, and the Company does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.</span></div></ix:continuation></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><div id="i69aaf560e98645139c7ed7af73a9eafe_142"></div><div style="margin-bottom:9pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="c-1" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="f-424" continuedAt="f-424-1" escape="true">Marketable Securities</ix:nonNumeric></span></div><ix:continuation id="f-424-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="f-425" escape="true"><div style="margin-bottom:9pt;text-indent:31.5pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale marketable securities as of December&#160;31, 2023 and 2022 were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:49.707%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.650%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-426">31,177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-427">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-428">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-429">31,179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-430">45,041</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-431">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-432">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-433">45,043</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-434">52,637</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-435">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-436">15</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-437">52,627</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-438">128,855</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-439">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-440">22</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-441">128,849</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:49.707%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.650%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-sponsored enterprises</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-442">32,812</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-443">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-444">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-445">32,810</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-446">12,655</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-447">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-448">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-449">12,652</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-450">45,467</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-451">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-452">11</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-453">45,462</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company's available-for-sale securities held at December&#160;31, 2023 and 2022 had contractual maturities of less than one year.  All of the Company&#8217;s available-for-sale marketable debt securities in an unrealized loss position as of </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and 2022 were in a loss position for less than twelve months.&#160; Unrealized losses on available-for-sale debt securities as of </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2023 and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022 </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">were not </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">significant and were primarily due to changes in interest rates, including market credit spreads, and not due to increased credit risks associated with specific securities.  Accordingly, <ix:nonFraction unitRef="usd" contextRef="c-11" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" format="ixt-sec:numwordsen" scale="0" id="f-454"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" format="ixt-sec:numwordsen" scale="0" id="f-455">no</ix:nonFraction></ix:nonFraction> allowance for credit losses related to the Company's available-for-sale debt securities was recorded for the years ended </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2023 and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022. </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not intend to sell these investments and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost bases, which may be at maturity.</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded interest income of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:InterestIncomeOther" format="ixt:num-dot-decimal" scale="6" id="f-456">4.0</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:InterestIncomeOther" format="ixt:num-dot-decimal" scale="6" id="f-457">1.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:InterestIncomeOther" format="ixt:num-dot-decimal" scale="6" id="f-458">2.0</ix:nonFraction> million during the years ended December&#160;31, 2023, 2022 and 2021, respectively, which is included in interest and other income on the consolidated statements of operations and comprehensive loss.</span></div></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 16</span></div></div></div><div id="i69aaf560e98645139c7ed7af73a9eafe_145"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="c-1" name="us-gaap:InventoryDisclosureTextBlock" id="f-459" continuedAt="f-459-1" escape="true">Inventory, Net</ix:nonNumeric></span></div><ix:continuation id="f-459-1"><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company's inventory relates to the manufacturing of MARGENZA.  <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="f-460" continuedAt="f-460-1" escape="true">The following table sets forth the Company's inventory, net of reserves (in thousands):</ix:nonNumeric></span></div><ix:continuation id="f-460-1"><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.011%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.761%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="us-gaap:InventoryWorkInProcess" scale="3" id="f-461">261</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:InventoryWorkInProcess" scale="3" id="f-462">409</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="us-gaap:InventoryFinishedGoods" scale="3" id="f-463">960</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:InventoryFinishedGoods" format="ixt:num-dot-decimal" scale="3" id="f-464">1,042</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-465">1,221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-466">1,451</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:continuation><div style="padding-left:31.5pt"><span><br/></span></div><div style="margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to FDA approval of MARGENZA in December 2020, the cost of materials and expenses associated with the manufacturing of MARGENZA were recorded as research and development expense. Subsequent to FDA approval, the Company began capitalizing inventory costs related to the manufacture of MARGENZA. The inventory balance as of December&#160;31, 2023 and December&#160;31, 2022 is net of a reserve of $<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-5" name="us-gaap:InventoryValuationReserves" format="ixt:num-dot-decimal" scale="6" id="f-467">3.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-5" name="us-gaap:InventoryValuationReserves" format="ixt:num-dot-decimal" scale="6" id="f-468">4.9</ix:nonFraction> million, respectively, for unsaleable inventory. These reserves are reflected in cost of product sales during the period they are recorded.   </span></div><div style="margin-top:3pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="mgnx:ScheduleOfInventoryReservesTableTextBlock" id="f-469" escape="true"><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.952%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Inventory Reserves (in thousands)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at Beginning of Year</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additions Charged to Expenses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deductions</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at End of Year</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ended December&#160;31, 2023</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="f-470">4,917</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" format="ixt:fixed-zero" scale="3" id="f-471">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="3" id="f-472">1,798</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="f-473">3,119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ended December 31, 2022</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="f-474">2,035</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" format="ixt:num-dot-decimal" scale="3" id="f-475">2,882</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:fixed-zero" scale="3" id="f-476">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="f-477">4,917</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ended December 31, 2021</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:fixed-zero" scale="3" id="f-478">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" format="ixt:num-dot-decimal" scale="3" id="f-479">2,035</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:fixed-zero" scale="3" id="f-480">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="f-481">2,035</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:3pt"><span><br/></span></div><div id="i69aaf560e98645139c7ed7af73a9eafe_148"></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="f-482" continuedAt="f-482-1" escape="true">Property, Equipment and Software</ix:nonNumeric></span></div><ix:continuation id="f-482-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="f-483" escape="true"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, equipment and software consists of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-484">3,542</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-485">3,489</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-486">9,759</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-487">9,604</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and office equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-488">706</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-489">713</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Motor vehicles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-490">50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-491">50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-492">46,452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-128" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-493">46,474</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-494">48,620</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-495">52,974</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="us-gaap:ConstructionInProgressGross" format="ixt:num-dot-decimal" scale="3" id="f-496">1,112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:ConstructionInProgressGross" scale="3" id="f-497">356</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, equipment and software</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-498">110,241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-499">113,660</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-500">88,394</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-501">84,085</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, equipment and software, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-502">21,847</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-503">29,575</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense related to property, equipment and software for the years ended December&#160;31, 2023, 2022 and 2021 was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="f-504">9.6</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="f-505">11.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="f-506">11.3</ix:nonFraction> million, respectively.</span></div></ix:continuation><div id="i69aaf560e98645139c7ed7af73a9eafe_151"></div><div style="margin-bottom:9pt;margin-top:15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-507" continuedAt="f-507-1" escape="true">Commitments and Contingencies</ix:nonNumeric></span><ix:continuation id="f-507-1" continuedAt="f-507-2"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></ix:continuation></div><ix:continuation id="f-507-2" continuedAt="f-507-3"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has non-cancelable operating leases for manufacturing, laboratory, office and warehouse space in Maryland  The Company&#8217;s leases each have one or more <ix:nonNumeric contextRef="c-131" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="f-508">five-year</ix:nonNumeric> options to renew</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In December 2022, the Company amended the existing lease on its headquarters space to extend the lease term through 2035 in exchange for certain concessions from the </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-507-3"><div style="margin-bottom:9pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">lessor.  This amendment was accounted for as a lease modification, and the right-of-use asset and lease liability were remeasured at the modification date, resulting in an increase to both balances of approximately $<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-5" name="mgnx:RightOfUseAssetAndLeaseLiabilityIncrease" format="ixt:num-dot-decimal" scale="6" id="f-509">14.0</ix:nonFraction> million.  </span></div><ix:nonNumeric contextRef="c-1" name="mgnx:ScheduleOfSupplementalBalanceSheetInformationOperatingLeasesTableTextBlock" id="f-510" continuedAt="f-510-1" escape="true"><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents supplemental balance sheet information related to operating leases:</span></div></ix:nonNumeric><div><ix:continuation id="f-510-1"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.092%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.013%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Weighted-average remaining lease term (in years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-2" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-511">11.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-11" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-512">11.1</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2" decimals="3" name="us-gaap:LesseeOperatingLeaseDiscountRate" scale="-2" id="f-513">12.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-11" decimals="3" name="us-gaap:LesseeOperatingLeaseDiscountRate" scale="-2" id="f-514">12.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2023 and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 2022, t</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he Company made cash payments for operating leases of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="6" id="f-515">5.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="6" id="f-516">6.9</ix:nonFraction> million, respectively. As of December&#160;31, 2023 and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 2022,</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the Company&#8217;s ROU assets were valued at $<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="f-517">23.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="f-518">27.3</ix:nonFraction> million, respectively.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LeaseCostTableTextBlock" id="f-519" escape="true"><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease cost for the years ended </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and 2022 were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.225%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.946%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.948%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating lease cost</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-520">7,459</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-521">5,597</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-522">1,316</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-523">1,451</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Sublease income</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:SubleaseIncome" format="ixt:num-dot-decimal" scale="3" id="f-524">1,109</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:SubleaseIncome" format="ixt:num-dot-decimal" scale="3" id="f-525">1,076</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net lease cost</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-526">7,666</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-527">5,972</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="f-528" escape="true"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the maturities of the Company&#8217;s operating lease liabilities were as follows (in thousands): </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.473%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.327%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-529">4,004</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-530">5,084</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="f-531">4,209</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="f-532">4,927</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" format="ixt:num-dot-decimal" scale="3" id="f-533">6,049</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" format="ixt:num-dot-decimal" scale="3" id="f-534">46,003</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="f-535">70,276</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="f-536">36,306</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-537">33,970</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In-licensing arrangement</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, the Company entered into a non-exclusive license agreement with Synaffix B.V., a Lonza company, (Synaffix) to develop, manufacture and commercialize up to three antibody-drug conjugate targets using Synaffix&#8217;s proprietary technology. The Company made an upfront payment to Synaffix upon contract execution. In March 2023, the Company and Synaffix amended the agreement, adding four additional targets. Assuming all seven targets are successfully developed and commercialized, the Company would be obligated to pay up to $<ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-5" name="mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" format="ixt:num-dot-decimal" scale="9" id="f-538">2.8</ix:nonFraction>&#160;billion for development, regulatory and sales milestones. Finally, pursuant to the terms of this license agreement, as amended, upon commencement of commercial sales of any products developed from these targets, the Company would be required to pay Synaffix tiered royalties in the low&#8209;single digit percentages on net sales of the respective products. The Company may terminate this agreement at any time with 30 days&#8217; notice to Synaffix. Amounts paid to Synaffix under this agreement are recorded as research and development expense in the consolidated statement of operations.  The Company incurred $<ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-539">2.8</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-134" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-540">1.0</ix:nonFraction>&#160;million in expense under this agreement during the years ended December&#160;31, 2023 and 2022, respectively.</span></div></ix:continuation><div style="margin-bottom:9pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 18</span></div></div></div><div id="i69aaf560e98645139c7ed7af73a9eafe_808"></div><hr style="page-break-after:always"/><div style="min-height:42.7pt;width:100%"><div><span><br/></span></div></div><ix:nonNumeric contextRef="c-1" name="mgnx:LiabilityRelatedToSaleOfFutureRoyaltiesTextBlock" id="f-541" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.  Royalty Monetization Arrangement</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023, the Company entered into a Purchase and Sale Agreement (Royalty Purchase Agreement) with DRI Healthcare Acquisitions LP (DRI), a wholly owned subsidiary of DRI Healthcare Trust, for the sale to DRI of the Company&#8217;s single-digit royalty interest on global net sales of TZIELD (teplizumab-mzwv) under the Company&#8217;s asset purchase agreement dated May 7, 2018, as amended (the Provention APA), with Provention. The Company retained its other economic interests related to TZIELD under the Provention APA, including future potential development, regulatory, and commercial milestones.  </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Royalty Purchase Agreement, the Company received $<ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-5" name="mgnx:UpfrontPayment" format="ixt:num-dot-decimal" scale="6" id="f-542">100.0</ix:nonFraction>&#160;million from DRI for its single-digit royalty interest on global net sales of TZIELD under the Provention APA (the Royalty Interest). Additionally, the Company has the right to receive a <ix:nonFraction unitRef="number" contextRef="c-136" decimals="2" name="mgnx:ProceedsfromRoyaltiesPercent" scale="-2" id="f-543">50</ix:nonFraction>% share of the royalty on global net sales above a certain annual threshold (the Retained Interest). In addition, the Company was eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-5" name="mgnx:GainOnRoyaltyMonetizationArrangement" format="ixt:num-dot-decimal" scale="6" id="f-544">50.0</ix:nonFraction>&#160;million upon the occurrence of pre-specified events tied to the advancement of TZIELD for the treatment of newly diagnosed type 1 diabetes. This milestone was achieved in July 2023 as described below. The Company is also eligible to receive an additional $<ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-5" name="mgnx:FutureRevenue" format="ixt:num-dot-decimal" scale="6" id="f-545">50.0</ix:nonFraction>&#160;million milestone if TZIELD achieves a certain level of net sales (Sales Milestone Payment). </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $<ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-5" name="mgnx:UpfrontPayment" format="ixt:num-dot-decimal" scale="6" id="f-546">100.0</ix:nonFraction>&#160;million proceeds received from DRI for the Royalty Interest were recorded as a liability related to future royalties, net of transaction costs of $<ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-5" name="mgnx:TransactionCost" format="ixt:num-dot-decimal" scale="6" id="f-547">0.3</ix:nonFraction>&#160;million, which was to be amortized over the term of the arrangement using the effective interest rate method. At inception, the Company accounted for the Royalty Purchase Agreement as a financing arrangement because the Company had significant continuing involvement in the delivery of future royalty payments to DRI and other existing obligations under the Provention APA. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2023, the Company entered into an agreement (the Tripartite Agreement) with DRI and a subsidiary of Sanofi S.A. (Sanofi), whereby the Company consented to the sale of DRI&#8217;s Royalty Interest and related milestone payment obligations to Sanofi. The Tripartite Agreement eliminated the Company&#8217;s obligation to deliver payments to DRI related to the Royalty Interest and removed all of the Company&#8217;s other obligations under the Royalty Purchase Agreement. The Royalty Interest will be paid directly to Sanofi by Provention. As a result, the Company&#8217;s royalty rights are only for the Retained Interest. This change in rights and obligations resulted in a change in the terms of the liability related to future royalties which was evaluated by the Company in accordance with ASC 470-50, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt &#8212; Modifications and Extinguishments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company concluded that the execution of the Tripartite Agreement resulted in a modification to the liability related to future royalties.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the terms of the new liability related to the single-digit future royalties and the original liability related to future royalties were substantially different as the Company no longer receives payments for the Royalty Interest and therefore has a significantly reduced liability to make payments in accordance with the Royalty Purchase Agreement. The new liability related to future royalties was determined to be de minimis.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-5" name="mgnx:GainOnRoyaltyMonetizationArrangement" format="ixt:num-dot-decimal" scale="6" id="f-548">100.9</ix:nonFraction>&#160;million within other income on the statement of operations and comprehensive loss during the three months ended June 30, 2023. There was no modification to the Company's Retained Interest in the Tripartite Agreement.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2023, Sanofi reported achievement of the primary endpoint milestone event related to the $<ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-5" name="mgnx:GainOnRoyaltyMonetizationArrangement" format="ixt:num-dot-decimal" scale="6" id="f-549">50.0</ix:nonFraction>&#160;million milestone noted above. Given that the Company has no continuing obligation to pay the Royalty Interest to Sanofi, the Company recorded this milestone within other income on the statement of operations and comprehensive loss during the three months ended September 30, 2023.  Also in September 2023, the Company and Sanofi executed Amendment No. 2 to the Provention APA to incorporate the Sales Milestone Payment obligation from the Royalty Purchase Agreement into the Provention APA.  In addition, the Company and Sanofi terminated the Royalty Purchase Agreement, which did not result in a material impact to the financial statements given the fair value of the liability related to future royalties was de minimis.   </span></div><ix:nonNumeric contextRef="c-1" name="mgnx:LiabilityRelatedToFutureRoyaltyTableTextBlock" id="f-550" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes to the liability related to future royalties were as follows for the year ended December&#160;31, 2023 (in thousands):</span></div><div style="text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.636%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.580%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability related to future royalties - beginning balance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="mgnx:LiabilityRelatedToFutureRoyalties" format="ixt:fixed-zero" scale="3" id="f-551">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sale of future royalties</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="mgnx:ProceedsFromSaleOfFutureRoyalties" format="ixt:num-dot-decimal" scale="3" id="f-552">150,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred transaction costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="mgnx:DeferredTransactionCosts" scale="3" id="f-553">343</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty revenue payable to DRI</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="mgnx:PrincipalPaymentsOnRoyaltyMonetizationArrangement" scale="3" id="f-554">157</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense recognized</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="mgnx:NonCashInterestExpenseRecognized" format="ixt:num-dot-decimal" scale="3" id="f-555">1,430</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on royalty monetization arrangement</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="mgnx:GainOnRoyaltyMonetizationArrangement" format="ixt:num-dot-decimal" scale="3" id="f-556">150,930</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability related to future royalties - ending balance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="mgnx:LiabilityRelatedToFutureRoyalties" format="ixt:fixed-zero" scale="3" id="f-557">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:nonNumeric><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 19</span></div></div></div><div id="i69aaf560e98645139c7ed7af73a9eafe_154"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-558" continuedAt="f-558-1" escape="true">Stockholders' Equity</ix:nonNumeric></span></div><ix:continuation id="f-558-1"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's amended and restated certificate of incorporation authorizes <ix:nonFraction unitRef="shares" contextRef="c-2" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-559">125,000,000</ix:nonFraction> shares of common stock, and <ix:nonFraction unitRef="shares" contextRef="c-139" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-560">5,000,000</ix:nonFraction> shares of undesignated preferred stock, both with a par value of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-139" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-561"><ix:nonFraction unitRef="usdPerShare" contextRef="c-140" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-562">0.01</ix:nonFraction></ix:nonFraction> per share.&#160;There were <ix:nonFraction unitRef="shares" contextRef="c-139" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-563"><ix:nonFraction unitRef="shares" contextRef="c-140" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-564"><ix:nonFraction unitRef="shares" contextRef="c-139" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-565"><ix:nonFraction unitRef="shares" contextRef="c-140" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-566">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares of undesignated preferred stock issued or outstanding as of December&#160;31, 2023 or 2022. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, the Company entered into a sales agreement (Sales Agreement) with an agent to sell, from time to time, shares of its common stock having an aggregate sales price of up to $<ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-5" name="mgnx:CommonStockMaximumAmountAvailableForIssuance" format="ixt:num-dot-decimal" scale="6" id="f-567">100.0</ix:nonFraction> million through an &#8220;at the market offering&#8221; (ATM Offering) as defined in Rule 415 under the Securities Act of 1933, as amended. The Company sold <ix:nonFraction unitRef="shares" contextRef="c-142" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-568">3,622,186</ix:nonFraction> shares of common stock resulting in net proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-569">98.2</ix:nonFraction>&#160;million through December 31, 2021 under the Sales Agreement. In April 2021, the Company entered into Amendment No. 1 to the Sales Agreement which increased the amount of the Company&#8217;s common stock that can be sold by the Company through its agent under the ATM Offering, from an aggregate offering price of up to $<ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-5" name="mgnx:CommonStockMaximumAmountAvailableForIssuance" format="ixt:num-dot-decimal" scale="6" id="f-570">100.0</ix:nonFraction>&#160;million to an aggregate offering price of up to $<ix:nonFraction unitRef="usd" contextRef="c-143" decimals="-5" name="mgnx:CommonStockMaximumAmountAvailableForIssuanceIncrease" format="ixt:num-dot-decimal" scale="6" id="f-571">300.0</ix:nonFraction>&#160;million. During the year ended December 31, 2022, the Company sold <ix:nonFraction unitRef="shares" contextRef="c-144" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-572">160,480</ix:nonFraction> shares of common stock at a weighted average price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-145" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-573">6.87</ix:nonFraction>, resulting in net proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-574">1.1</ix:nonFraction> million, net of underwriting discounts and commissions and other offering expenses. In March 2023, the Company terminated the Sales Agreement and entered into a new sales agreement with an agent to sell, from time to time, shares of its common stock having an aggregate sales price of up to $<ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-5" name="mgnx:CommonStockMaximumAmountAvailableForIssuance" format="ixt:num-dot-decimal" scale="6" id="f-575">100.0</ix:nonFraction>&#160;million through an ATM Offering. During the year ended December&#160;31, 2023, the Company sold <ix:nonFraction unitRef="shares" contextRef="c-146" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-576">95,000</ix:nonFraction> shares of common stock at a weighted average price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-147" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-577">6.60</ix:nonFraction>, resulting in net proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="c-146" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-578">0.6</ix:nonFraction> million, net of offering expenses.</span></div></ix:continuation><div id="i69aaf560e98645139c7ed7af73a9eafe_157"></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="c-1" name="mgnx:CollaborationAndLicenseAgreementsDisclosureTextBlock" id="f-579" continuedAt="f-579-1" escape="true">Revenue</ix:nonNumeric></span></div><ix:continuation id="f-579-1" continuedAt="f-579-2"><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Collaborative and Other Agreements </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Incyte Corporation</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Incyte License Agreement</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, the Company entered into an exclusive global collaboration and license agreement with Incyte, which was amended in March 2018, April 2022 and July 2022, for retifanlimab, an investigational monoclonal antibody that inhibits PD-1 (Incyte License Agreement). Incyte has obtained exclusive worldwide rights for the development and commercialization of retifanlimab in all indications, while the Company retains the right to develop its pipeline assets in combination with retifanlimab. Under the terms of the Incyte License Agreement, Incyte paid the Company an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-5" name="mgnx:NonRefundableUpfrontFees" format="ixt:num-dot-decimal" scale="6" id="f-580">150.0</ix:nonFraction> million in 2017. MacroGenics will manufacture a portion of Incyte&#8217;s global commercial supply of retifanlimab. In March 2023, the FDA approved Incyte's Biologics License Application (BLA) for ZYNYZ (retifanlimab-dlwr) for the treatment of adults with metastatic or recurrent locally advanced Merkel cell carcinoma. Incyte has stated it is pursuing development of retifanlimab in potentially registration-enabling studies, including in patients with Merkel cell carcinoma, squamous cell carcinoma of the anal canal, MSI-high endometrial cancer and non-small cell lung cancer.  Incyte is also pursuing development of retifanlimab in combination with multiple product candidates from its pipeline.  </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Incyte License Agreement, as amended, Incyte will lead global development of retifanlimab. Assuming successful development and commercialization by Incyte in multiple indications, the Company could receive up to a total of  $<ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-5" name="mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" format="ixt:num-dot-decimal" scale="6" id="f-581">435.0</ix:nonFraction> million in development and regulatory milestones, and up to $<ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-5" name="mgnx:PotentialCommercialMilestonePaymentsUnderAgreement" format="ixt:num-dot-decimal" scale="6" id="f-582">330.0</ix:nonFraction> million in commercial milestones. From the inception of the Incyte License Agreement through </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company has recognized $<ix:nonFraction unitRef="usd" contextRef="c-150" decimals="-5" name="mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" format="ixt:num-dot-decimal" scale="6" id="f-583">115.0</ix:nonFraction> million in development milestones under the Incyte License Agreement, including $<ix:nonFraction unitRef="usd" contextRef="c-151" decimals="-5" name="mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" format="ixt:num-dot-decimal" scale="6" id="f-584">15.0</ix:nonFraction> million received following the FDA approval of ZYNYZ. The Company is eligible to receive tiered royalties of <ix:nonFraction unitRef="number" contextRef="c-152" decimals="2" name="mgnx:ProceedsfromRoyaltiesPercent" scale="-2" id="f-585">15</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-153" decimals="2" name="mgnx:ProceedsfromRoyaltiesPercent" scale="-2" id="f-586">24</ix:nonFraction>% on global net sales. The Company retains the right to develop its pipeline assets in combination with retifanlimab, with Incyte commercializing retifanlimab and the Company commercializing its asset(s), if any such potential combinations are approved. In addition, the Company retains the right to manufacture a portion of both companies' global commercial supply needs of retifanlimab, subject to the separate commercial supply agreement. </span></div><div style="margin-bottom:9pt;text-indent:42pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the Incyte License Agreement under the provisions of ASC 606 at inception and identified the following <ix:nonFraction unitRef="performanceobligation" contextRef="c-154" decimals="INF" name="mgnx:NumberOfPerformanceObligations" format="ixt-sec:numwordsen" scale="0" id="f-587">two</ix:nonFraction> performance obligations under the agreement: (i) the license of retifanlimab and (ii) the performance of certain clinical activities through a brief technology transfer period. The Company determined that the license and clinical activities are separate performance obligations because they are capable of being distinct, and are distinct in the context of the contract. The license has standalone functionality as it is sublicensable, Incyte has significant capabilities in performing clinical trials, and Incyte is capable of performing these activities without the Company's involvement; the Company performed the activities during the transfer period as a matter of convenience. The Company determined that the transaction price of the Incyte License Agreement at inception was $<ix:nonFraction unitRef="usd" contextRef="c-155" decimals="-5" name="mgnx:CollaborativeAgreementTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="f-588">154.0</ix:nonFraction> million, consisting of the consideration to which the Company was entitled in exchange for the license and an estimate of the consideration for clinical activities to be performed. The transaction price was allocated to each performance obligation based on their relative standalone selling price. The standalone selling price of the license was determined using the adjusted market assessment approach considering similar collaboration and license </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-579-2" continuedAt="f-579-3"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">agreements. The standalone selling price for the agreed-upon clinical activities to be performed was determined using the expected cost approach based on similar arrangements the Company has with other parties. The potential development and regulatory milestone payments are </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fully constrained until the Company concludes that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and as such have been excluded from the transaction price. Any consideration related to sales-based milestones and royalties will be recognized when the related sales occur, as they were determined to relate predominantly to the license granted to Incyte and, therefore, have also been excluded from the transaction price. The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur. </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From 2018 through December&#160;31, 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">it became probable that a significant reversal of cumulative revenue would not occur for development milestones totaling </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-150" decimals="-5" name="mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" format="ixt:num-dot-decimal" scale="6" id="f-589">115.0</ix:nonFraction> million</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> related to clinical and regulatory activities related to the further advancement of retifanlimab.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Therefore</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the associated consideration was added to the estimated transaction price and was recognized as revenue. </span></div><div style="margin-bottom:9pt;text-indent:42pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-590">150.0</ix:nonFraction> million</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> allocated to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">license when it satisfied its performance obligation and transferred the license to Incyte in 2017. The $<ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-5" name="mgnx:RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" format="ixt:num-dot-decimal" scale="6" id="f-591">4.0</ix:nonFraction> million allocated to the clinical activities was recognized ratably as services were performed during 2017 and 2018.  The Company recognized the $<ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-592">15.0</ix:nonFraction> million ZYNYZ approval milestone as revenue under the Incyte License Agreement during the year ended December&#160;31, 2023. The Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-593">15.0</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-594">30.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-595">15.0</ix:nonFraction> million under the Incyte License Agreement during the years ended December&#160;31, 2023, 2022 and 2021, respectively, all of which was related to development milestones.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:42pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Incyte Clinical Supply Agreement</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:42pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, the Company entered into an agreement with Incyte under which the Company is to perform development and manufacturing services for Incyte&#8217;s clinical needs of retifanlimab (Incyte Clinical Supply Agreement). The Company evaluated this agreement under ASC 606 and identified one performance obligation under the agreement: to perform services related to the development and manufacturing of the clinical supply of retifanlimab. The transaction price is based on the costs incurred to develop and manufacture drug product and drug substance, and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. The transaction price is being recognized using the input method reflecting the costs incurred (including resources consumed and labor hours expended) related to the manufacturing services. During the years ended </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, 2022 and 2021, the Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-596">1.9</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-597">0.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-163" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-598">1.5</ix:nonFraction> million, respectively, for services performed under this agreement. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:42pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Incyte Commercial Supply Agreement</span></div><div style="text-indent:42pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, the Company entered into an agreement with Incyte pursuant to which the Company is entitled to manufacture a portion of the global commercial supply needs for retifanlimab (Incyte Commercial Supply Agreement). Unless terminated earlier, the term of the Incyte Commercial Supply Agreement will expire upon the expiration of Incyte&#8217;s obligation to pay royalties under the Incyte License Agreement.  The Company evaluated this agreement under ASC 606 and identified one performance obligation under the agreement: to perform services related to manufacturing the commercial supply of retifanlimab. The transaction price is based on a fixed price per batch of bulk drug substance to be manufactured and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. The transaction price is being recognized using the input method reflecting the costs incurred (including resources consumed and labor costs incurred) related to the manufacturing services. During the years ended </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2023, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022, and 2021 the Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="c-164" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-599">4.2</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-600">0.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-601">7.8</ix:nonFraction>&#160;million, respectively, for services performed under this agreement. </span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%">Gilead Sciences, Inc </span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022, the Company and Gilead Sciences, Inc. (Gilead) entered into an exclusive option and collaboration agreement (Gilead Agreement) to develop and commercialize MGD024, an investigational, bispecific antibody that binds CD123 and CD3, and create bispecific cancer antibodies using the Company&#8217;s DART platform and undertake their early development under a maximum of two separate bispecific cancer target research programs. Under the agreement, the Company will continue the ongoing phase 1 trial for MGD024 accordi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ng to a development plan</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, during which Gilead will have the right to exercise an option granted to Gilead to obtain an exclusive license under the Company&#8217;s intellectual property to develop and commercialize MGD024 and other bispecific antibodies of MacroGenics that bind CD123 and CD3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (CD123 Option). The agreement also grants Gilead the right, within its first two years, to nominate a bispecific cancer target set for up to two research programs conducted by the Company and to exercise separate options to obtain an exclusive license for the development, commercialization and exploitation of molecules created under each research program (Research Program Option). Gilead nominated the first of the two research programs in September 2023.  </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-579-3" continuedAt="f-579-4"><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Gilead Agreement, in October 2022 Gilead paid the Company an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="c-167" decimals="-5" name="mgnx:NonRefundableUpfrontFees" format="ixt:num-dot-decimal" scale="6" id="f-602">60.0</ix:nonFraction>&#160;million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assuming Gilead exercises the CD123 Option and Research Program Option and successfully develops and commercializes MGD024, or other CD123 products developed under the agreement, and products result from the two additional research programs, the Company would be eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="c-168" decimals="-5" name="mgnx:PotentialTargetNominationOptionFeesAndMilestonePayments" format="ixt:num-dot-decimal" scale="9" id="f-603">1.7</ix:nonFraction> billion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in target nomination, option fees, and development, regulatory and commercial milestones. Assuming exercise of the CD123 Option, the Company will also be eligible to receive tiered, low double-digit royalties on worldwide net sales of MGD024 (or other CD123 products developed under the agreement) and assuming exercise of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research Program Option,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> a flat royalty on worldwide net sales of any products resulting from the two research programs.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the Gilead Agreement under the provisions of ASC 606 and identified the following material promises under the agreement: (i) a license to perform any activities allocated to Gilead under the MGD024 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">development plan</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">; (ii) development activities regarding MGD024, including manufacturing, research and early clinical development activities, necessary to deliver an informational package of development and clinical data, information and materials specified in the Gilead Agreement during the period </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which Gilead can exercise the CD123 Option; (iii) the CD123 Option and (iv) the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research Program Option</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company concluded that the license under the MGD024 developme</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nt plan</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and development activities are not distinct from one another, as the license has limited value without the Company&#8217;s performance of the development activities. Therefore, the Company determined that the development term license and development activities should be combined into a single performance obligation (Development Activities). The CD123 Option is considered a material right as the value of the exclusive license exceeds the payment to be made by Gilead if they exercise their option to obtain an exclusive license to develop and commercialize MGD024 or an alternative CD123 product, and is therefore a distinct performance obligation. The Company determined that the Research Program Option does not provide a material right, as there is no discount on its standalone selling price.</span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC 606, the Company determined that the initial transaction price under the Gilead Agreement was $<ix:nonFraction unitRef="usd" contextRef="c-167" decimals="-5" name="mgnx:NonRefundableUpfrontFees" format="ixt:num-dot-decimal" scale="6" id="f-604">60.0</ix:nonFraction>&#160;million, consisting of the upfront, non-refundable payment paid by Gilead. The CD123 Option and Research Program Option payments are excluded from the initial transaction price at contract inception along with any future development, regulatory, and commercial milestone payments (including royalties) following the CD123 Option and Research Program Option exercise.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company will reassess the amount of variable consideration included in the transaction price every reporting period.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:13.5pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company allocated the $<ix:nonFraction unitRef="usd" contextRef="c-167" decimals="-5" name="mgnx:NonRefundableUpfrontFees" format="ixt:num-dot-decimal" scale="6" id="f-605">60.0</ix:nonFraction>&#160;million upfront payment in the transaction price to the Development Activities and the CD123 Option based on each performance obligation&#8217;s relative standalone selling price. The standalone selling price for the Development Activities was calculated using an expected cost-plus margin approach </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the pre-option development timeline.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the standalone selling price of the CD123 Option, the Company utilized an income-based approach which included the following key assumptions:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">post-option development timeline and costs, forecasted revenues, discount rates and probabilities of technical and regulatory success. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is recognizing revenue related to the Development Activities performance obligation over the estimated period to complete the Development Activities using an input method reflecting the costs incurred (including resources consumed and labor hours expended) related to the Development Activities. The Company has deferred revenue recognition related to the CD123 Option.  If Gilead exercises the CD123 Option and obtains an exclusive license, the Company will recognize revenue as it fulfills its obligations under the Gilead Agreement. If the CD123 Option is not exercised, the Company will recognize the entirety of the revenue in the period when the CD123 Option expires.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and 2022, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company recorded revenue of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-169" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-606">1.5</ix:nonFraction>&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-170" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-607">0.2</ix:nonFraction>&#160;million respectively, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">related to the Gilead Agreement. As of </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-171" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="f-608">58.3</ix:nonFraction>&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in revenue was deferred under this agreement, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-171" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="f-609">2.2</ix:nonFraction>&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of which was current and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-171" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-610">56.1</ix:nonFraction>&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of which was non-current.As of December&#160;31, 2022, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-172" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="f-611">59.8</ix:nonFraction>&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in revenue was deferred under this agreement, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-172" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="f-612">1.8</ix:nonFraction>&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of which was current and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-172" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-613">58.0</ix:nonFraction>&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of which was non-current.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2023, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company and Gilead executed a Letter Agreement through which Gilead nominated the first of the two research programs contemplated in the Gilead Agreement (First Research Program), the Company granted Gilead a research license, and the parties agreed on a research plan for the First Research Program under which the Company will provide research and development services. Gilead paid the Company a $<ix:nonFraction unitRef="usd" contextRef="c-173" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="f-614">15.7</ix:nonFraction>&#160;million nomination fee.  The Company evaluated the Letter Agreement under the terms of ASC 606, and concluded that it is a modification to the Gilead Agreement that results in a separate contract since the modification is for additional goods and services that are distinct and at standalone selling price. The Company determined that the license and the related research and development activities were not distinct from one another, as the license has limited value without the performance of the research and development activities. As such, the Company determined that these should be combined into a single performance obligation. Gilead also has the </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-579-4" continuedAt="f-579-5"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">exclusive option to pay the Company $<ix:nonFraction unitRef="usd" contextRef="c-173" decimals="-5" name="mgnx:OptInFee" format="ixt:num-dot-decimal" scale="6" id="f-615">10.0</ix:nonFraction>&#160;million to obtain a license to exploit the research molecule and research product with respect to the First Research Program. The Company determined that this exclusive option does not provide a material right, as there is no discount on its standalone selling price.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC 606, the Company determined that the initial transaction price for the First Research Program agreement was $<ix:nonFraction unitRef="usd" contextRef="c-173" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="f-616">15.7</ix:nonFraction>&#160;million, consisting of the non-refundable payment paid by Gilead. The Company is recognizing revenue over the estimated period to complete the services using the input method reflecting the costs incurred (including resources consumed and labor hours expended) related to the research and development services.  </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company recorded revenue of $<ix:nonFraction unitRef="usd" contextRef="c-174" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-617">0.8</ix:nonFraction>&#160;million </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">related to the First Research Program.  As of December&#160;31, 2023, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-173" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="f-618">14.9</ix:nonFraction>&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in revenue was deferred under this agreement, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-173" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="f-619">11.8</ix:nonFraction>&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of which was current and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-173" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-620">3.1</ix:nonFraction>&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of which was non-current. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Zai Lab US LLC</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, the Company entered into a collaboration and license agreement with Zai Lab US LLC (Zai Lab Limited and Zai Lab US LLC, either singularly or collectively are referred to herein as Zai Lab) involving collaboration programs and license-only programs (collectively, the Programs) encompassing four separate immuno-oncology molecules (2021 Zai Lab Agreement). During 2022, the Company and Zai Lab agreed to discontinue research and development of the lead program, and in August 2023, the parties mutually agreed to terminate the 2021 Zai Lab Agreement. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the execution of the 2021 Zai Lab Agreement, Zai Lab paid the Company an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-5" name="mgnx:NonRefundableUpfrontFees" format="ixt:num-dot-decimal" scale="6" id="f-621">25.0</ix:nonFraction>&#160;million. Additionally, as part of the consideration for the rights granted to Zai Lab under the 2021 Zai Lab Agreement, the Company and Zai Lab entered into a stock purchase agreement whereby Zai Lab paid the Company approximately $<ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-622">30.0</ix:nonFraction> million to purchase shares of the Company&#8217;s common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="c-2" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-623">0.01</ix:nonFraction>, at a fixed price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-176" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-624">31.30</ix:nonFraction> which represented a $<ix:nonFraction unitRef="usd" contextRef="c-177" decimals="-5" name="mgnx:PremiumReceivedOnStockPurchase" format="ixt:num-dot-decimal" scale="6" id="f-625">10.4</ix:nonFraction> million premium over the share price on the stock purchase agreement date. The Company was also entitled to receive reimbursements from Zai Lab for certain research and development costs incurred by the Company and milestones and tiered royalties on annual net sales of products in Zai Lab&#8217;s territory assuming successful development and commercialization of the Programs.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the 2021 Zai Lab Agreement under the provisions of ASC 606 and identified the following material promises: (i) exclusive licenses to develop, manufacture and commercialize the products in Zai Lab&#8217;s territory for each Program and (ii) certain research and development activities for the lead program. The Company determined that for the lead program, the license was not distinct from the related research and development activities, considering the early stage of development of the molecule and the Company&#8217;s significant expertise in this area and as such, the research and development services were expected to significantly modify and customize the license. Therefore, for the lead program, the license and the services were combined into a single performance obligation. Since the other programs each represented distinct intellectual property and there were no other services included in the 2021 Zai Lab Agreement related to these licenses, each license was considered to be a distinct performance obligation. As such, there were four performance obligations included in the 2021 Zai Lab Agreement.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company concluded that the estimated transaction price was $<ix:nonFraction unitRef="usd" contextRef="c-176" decimals="-5" name="mgnx:CollaborativeAgreementTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="f-626">40.4</ix:nonFraction> million, consisting of the $<ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-5" name="mgnx:NonRefundableUpfrontFees" format="ixt:num-dot-decimal" scale="6" id="f-627">25.0</ix:nonFraction> million upfront payment, the $<ix:nonFraction unitRef="usd" contextRef="c-177" decimals="-5" name="mgnx:PremiumReceivedOnStockPurchase" format="ixt:num-dot-decimal" scale="6" id="f-628">10.4</ix:nonFraction> million premium related to the purchase of the Company&#8217;s common stock, and the $<ix:nonFraction unitRef="usd" contextRef="c-178" decimals="-5" name="mgnx:EstimatedReimbursementForResearchAndDevelopmentT" format="ixt:num-dot-decimal" scale="6" id="f-629">5.0</ix:nonFraction> million estimated reimbursement by Zai Lab for research and development activities for the lead program. The potential milestone payments were deemed to be fully constrained until the Company concludes that achievement of the milestone is probable, and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such were excluded from the transaction price. Any consideration related to royalties would have been recognized if and when the related sales occurred, as they were determined to relate predominantly to the license granted to Zai Lab and, therefore, were also excluded from the transaction price. The Company re-assessed the transaction price in each reporting period and when events whose outcomes were resolved or other changes in circumstances occurred.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transaction price of $<ix:nonFraction unitRef="usd" contextRef="c-176" decimals="-5" name="mgnx:CollaborativeAgreementTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="f-630">40.4</ix:nonFraction> million was then allocated to the four performance obligations based on their relative standalone selling price. The standalone selling price of the performance obligations was not directly observable; therefore, the Company estimated the standalone selling price using an adjusted market assessment approach, representing the amount that the Company believed a market participant was willing to pay for the product or service. The estimate was based on consideration of observable inputs, such as, values of other preclinical collaboration arrangements adjusted for the Company&#8217;s estimate of the probability of success for each Program. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue related to the lead program license and related research and development services performance obligation was recognized over time as the research and development activities were performed. The Company utilized a cost-based input method according to costs incurred to date compared to estimated total costs. The transfer of control occurred over this time </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-579-5" continuedAt="f-579-6"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">period and, in management&#8217;s judgment, was the best measure of progress towards satisfying the performance obligations. The Company recognized revenue allocated to the other programs at a point in time upon transfer of the licenses to Zai Lab in June 2021. During the year ended </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2023, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-179" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-631">no</ix:nonFraction></span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">revenue was recognized under the 2021 Zai Lab Agreement. During the years ended December&#160;31, 2022,</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and 2021, the Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="c-180" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-632">16.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-181" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-633">20.3</ix:nonFraction> million</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">respectively, under the 2021 Zai Lab Agreement. </span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provention Bio, Inc.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, the Company entered into a license agreement with Provention pursuant to which the Company granted Provention exclusive global rights for the purpose of developing and commercializing MGD010 (renamed PRV-3279), a CD32B x CD79B DART molecule being developed for the treatment of autoimmune indications (Provention License Agreement). As partial consideration for the Provention License Agreement, Provention granted the Company a warrant to purchase shares of Provention&#8217;s common stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-182" decimals="INF" name="mgnx:CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare" scale="0" id="f-634">2.50</ix:nonFraction> per share. If Provention successfully develops, obtains regulatory approval for, and commercializes PRV-3279, the Company will be eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="c-183" decimals="-5" name="mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" format="ixt:num-dot-decimal" scale="6" id="f-635">65.0</ix:nonFraction> million in development and regulatory milestones and up to $<ix:nonFraction unitRef="usd" contextRef="c-183" decimals="-5" name="mgnx:PotentialCommercialMilestonePaymentsUnderAgreement" format="ixt:num-dot-decimal" scale="6" id="f-636">225.0</ix:nonFraction> million in commercial milestones. As of December&#160;31, 2023, the Company has not recognized any milestone revenue under this agreement. If commercialized, the Company would be eligible to receive single-digit royalties on net sales of the product. The license agreement may be terminated by either party upon a material breach or bankruptcy of the other party, by Provention without cause upon prior notice to the Company, and by the Company in the event that Provention challenges the validity of any licensed patent under the agreement, but only with respect to the challenged patent.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, in 2018, the Company entered into the Provention APA pursuant to which Provention acquired the Company&#8217;s interest in teplizumab (renamed PRV-031), a monoclonal antibody being developed for the treatment of type 1 diabetes. As partial consideration for the Provention APA, Provention granted the Company a warrant to purchase shares of Provention&#8217;s common stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-184" decimals="INF" name="mgnx:CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare" scale="0" id="f-637">2.50</ix:nonFraction> per share. Under the Provention APA, Provention is obligated to pay the Company contingent milestone payments totaling $<ix:nonFraction unitRef="usd" contextRef="c-185" decimals="-5" name="mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" format="ixt:num-dot-decimal" scale="6" id="f-638">170.0</ix:nonFraction> million upon the achievement of certain regulatory milestones.  In addition, Provention is obligated to make contingent milestone payments to the Company totaling $<ix:nonFraction unitRef="usd" contextRef="c-185" decimals="-5" name="mgnx:PotentialCommercialMilestonePaymentsUnderAgreement" format="ixt:num-dot-decimal" scale="6" id="f-639">225.0</ix:nonFraction> million upon the achievement of certain commercial milestones as well as single-digit royalties on net sales of the product. In March 2023, the Company entered into a Royalty Purchase Agreement with DRI; see Note 7, Royalty Monetization Arrangement, for additional information. The FDA approved the BLA for TZIELD in November 2022, and the Company recognized $<ix:nonFraction unitRef="usd" contextRef="c-186" decimals="-5" name="mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" format="ixt:num-dot-decimal" scale="6" id="f-640">60.0</ix:nonFraction> million in revenue related to this regulatory milestone during the year ended December 31, 2022.  In November 2022, the Company and Provention amended the Provention APA. Under this amendment, the milestone for first approval was split into four equal payments, all of which were received prior to June 30, 2023.  Provention has also agreed to pay third-party obligations, including low single-digit royalties, of which a portion is creditable against royalties payable to the Company, aggregate milestone payments of up to approximately $<ix:nonFraction unitRef="usd" contextRef="c-185" decimals="-5" name="mgnx:PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement" format="ixt:num-dot-decimal" scale="6" id="f-641">1.3</ix:nonFraction> million and other consideration, for certain third-party intellectual property under agreements Provention assumed pursuant to the Provention APA. Further, Provention is required to pay the Company a low double-digit percentage of certain consideration to the extent it is received in connection with a future grant of rights to PRV-031 by Provention to a third party.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the Provention License Agreement and Provention APA under the provisions of ASC 606 and determined that they should be accounted for as a single contract and identified two performance obligations within that contract: (i) the license of MGD010 and (ii) the title to teplizumab. The Company determined that the transaction price of the Provention agreements was $<ix:nonFraction unitRef="usd" contextRef="c-187" decimals="-5" name="mgnx:CollaborativeAgreementTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="f-642">6.1</ix:nonFraction> million, based on the Black-Scholes valuation of the warrants to purchase a total of <ix:nonFraction unitRef="shares" contextRef="c-187" decimals="INF" name="mgnx:CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares" format="ixt:num-dot-decimal" scale="0" id="f-643">2,432,688</ix:nonFraction> shares of Provention's common stock. The transaction price was allocated to each performance obligation based on the number of shares of common stock the Company is entitled to purchase under each warrant. The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such were excluded from the initial transaction price. Any consideration related to sales-based milestones and royalties will be recognized when the related sales occur, therefore they have also been excluded from the transaction price. The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur. The Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="c-188" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-644">6.1</ix:nonFraction> million when it satisfied its performance obligations under the agreements and transferred the MGD010 license and teplizumab assets to Provention in 2018. In 2019, the Company exercised the warrants on a cashless basis, and subsequently sold all the shares of Provention common stock acquired through the exercise. No shares of Provention stock were held subsequent to the sale of stock in 2019. During the year ended December 31, 2022, </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">it became probable that a significant reversal of cumulative revenue would not occur for a regulatory milestone of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-186" decimals="-5" name="mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" format="ixt:num-dot-decimal" scale="6" id="f-645">60.0</ix:nonFraction> million</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, t</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">herefore</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the associated consideration was added to the estimated transaction price and was recognized as revenue. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2023, </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022 and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021, the Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="c-189" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-646">5.6</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-647">60.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-648">1.3</ix:nonFraction> million, respectively, under these agreements.   </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-579-6" continuedAt="f-579-7"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 27, 2023, Sanofi completed its acquisition of Provention and the Company entered into a Tripartite Agreement, as discussed in Note 7, Royalty Monetization Arrangement. Also on April 27, 2023, the Company and a subsidiary of Sanofi entered into a Side Letter Agreement which specified certain post-closing covenants and also accelerated certain payments due to the Company under the Provention APA upon the closing of the merger between Sanofi and Provention. The Company evaluated the Side Letter Agreement as a contract modification under the provisions of ASC 606. As a result, </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">during the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">year ended December 31, 2023</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-649">5.5</ix:nonFraction>&#160;million related to other consideration under the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provention APA</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Side Letter Agreement. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2023, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-650">0.3</ix:nonFraction>&#160;million in royalty revenue under the Provention APA based on sales of TZIELD. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 7, in September 2023, the Company and Sanofi executed Amendment No. 2 to the Provention APA and terminated the Royalty Purchase Agreement with DRI.  As a result, the remaining $<ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-5" name="mgnx:FutureRevenue" format="ixt:num-dot-decimal" scale="6" id="f-651">50.0</ix:nonFraction>&#160;million milestone under the Royalty Purchase Agreement was incorporated into the Provention APA.  The Company evaluated the amendment as a contract modification under the provisions of ASC 606 which did not result in any additional revenue being recognized during the year ended December&#160;31, 2023. </span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing Services Agreements</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Incyte </span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, the Company entered into a Manufacturing and Clinical Supply Agreement with Incyte (Incyte Manufacturing and Clinical Supply Agreement) to provide manufacturing services to produce certain Incyte bulk drug substance over a <ix:nonNumeric contextRef="c-195" name="mgnx:CollaborativeArrangementTerm" format="ixt-sec:durwordsen" id="f-652">three-year</ix:nonNumeric> period at one of the Company&#8217;s manufacturing facilities. Under the terms of the Incyte Manufacturing and Clinical Supply Agreement, the Company received an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="c-196" decimals="-5" name="mgnx:NonRefundableUpfrontFees" format="ixt:num-dot-decimal" scale="6" id="f-653">10.0</ix:nonFraction>&#160;million and is eligible to receive annual fixed payments paid quarterly over the term of the contract totaling $<ix:nonFraction unitRef="usd" contextRef="c-197" decimals="-5" name="mgnx:TotalAnnualFixedPayments" format="ixt:num-dot-decimal" scale="6" id="f-654">14.4</ix:nonFraction>&#160;million. The Company will also be reimbursed for materials used to manufacture product as well as other costs incurred to provide manufacturing services. In July 2022, the Company and Incyte executed an amendment to the Incyte Manufacturing and Clinical Supply Agreement which extended the term for <ix:nonNumeric contextRef="c-195" name="mgnx:CollaborativeArrangementExtensionTerm" format="ixt-sec:durwordsen" id="f-655">one year</ix:nonNumeric> and provided for an additional annual fixed payment of $<ix:nonFraction unitRef="usd" contextRef="c-198" decimals="-5" name="mgnx:AdditionalAnnualFixedPayments" format="ixt:num-dot-decimal" scale="6" id="f-656">5.1</ix:nonFraction>&#160;million (July 2022 Incyte Amendment). </span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the Incyte Manufacturing and Clinical Supply Agreement and the July 2022 Incyte Amendment under the provisions of ASC 606 and identified one performance obligation to provide manufacturing runs to Incyte, as and when requested by Incyte, over the term of the contract that is part of a series of goods and services. The Company determined that the transaction price consists of the upfront payment received of $<ix:nonFraction unitRef="usd" contextRef="c-196" decimals="-5" name="mgnx:NonRefundableUpfrontFees" format="ixt:num-dot-decimal" scale="6" id="f-657">10.0</ix:nonFraction>&#160;million and the annual fixed payments totaling $<ix:nonFraction unitRef="usd" contextRef="c-199" decimals="-5" name="mgnx:TotalAnnualFixedPayments" format="ixt:num-dot-decimal" scale="6" id="f-658">19.5</ix:nonFraction>&#160;million. The Company will recognize revenue over time on a straight-line basis as the manufacturing services are provided to Incyte, as the Company determined that its efforts in providing the manufacturing services will be incurred evenly throughout the performance period and therefore straight-line revenue recognition closely approximates the level of effort for the manufacturing services. Variable consideration relating to the reimbursed materials and other reimbursed costs incurred to manufacture product for Incyte will be allocated to the related manufacturing activities and will be recognized as revenue as those activities occur.  Materials purchased by the Company to manufacture the product for Incyte are considered costs to fulfill a contract and will be capitalized and expensed as the materials are used to provide the manufacturing services. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2023 and 2022, the Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="c-200" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-659">9.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-201" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-660">8.7</ix:nonFraction>&#160;million, respectively, under the Incyte Manufacturing and Clinical Supply Agreement. As of </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2023, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-197" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="f-661">7.0</ix:nonFraction>&#160;million</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in revenue was deferred under this agreement, all of which was current. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, $<ix:nonFraction unitRef="usd" contextRef="c-202" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="f-662">9.6</ix:nonFraction>&#160;million in revenue was deferred under this agreement, $<ix:nonFraction unitRef="usd" contextRef="c-202" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="f-663">8.1</ix:nonFraction>&#160;million of which was current and $<ix:nonFraction unitRef="usd" contextRef="c-202" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-664">1.5</ix:nonFraction>&#160;million of which was non-current.  </span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provention</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, the Company entered into a Manufacturing and Clinical Supply Agreement with Provention (Provention Manufacturing and Clinical Supply Agreement) to provide manufacturing services to produce certain Provention bulk drug substance. Under the terms of the Provention Manufacturing and Clinical Supply Agreement, the Company received an upfront payment and payments in accordance with the manufacturing schedule.  The Company was also reimbursed for materials used to manufacture product as well as other costs incurred to provide manufacturing services.</span></div><div style="margin-bottom:6pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the Provention Manufacturing and Clinical Supply Agreement under the provisions of ASC 606 and identified one performance obligation to provide manufacturing services to Provention. The Company determined that the transaction price consisted of the upfront and other fixed payments totaling $<ix:nonFraction unitRef="usd" contextRef="c-203" decimals="-5" name="mgnx:UpfrontAndFixedPayments" format="ixt:num-dot-decimal" scale="6" id="f-665">4.6</ix:nonFraction>&#160;million. The Company will recognize revenue over time on a straight-line basis as the manufacturing services are provided to Provention, as the Company determined that its efforts in providing the manufacturing services will be incurred evenly throughout the performance period and therefore straight-line revenue recognition closely approximates the level of effort for the manufacturing services. Variable consideration relating to the reimbursed materials and other reimbursed costs incurred to manufacture product for Provention will be allocated </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-579-7"><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to the related manufacturing activities and will be recognized as revenue as those activities occur.  Materials purchased by the Company to manufacture the product for Provention are considered costs to fulfill a contract and will be capitalized and expensed as the materials are used to provide the manufacturing services. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized de minimis revenue during the year ended December&#160;31, 2023 under the Provention Manufacturing and Clinical Supply Agreement. During the year ended 2022, the Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="c-204" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-666">5.3</ix:nonFraction>&#160;million under the Provention Manufacturing and Clinical Supply Agreement.</span></div><div style="margin-bottom:6pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Agreement</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NIAID Contract</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company entered into a contract with the National Institute of Allergy and Infectious Diseases (NIAID), effective as of September 15, 2015,&#160;to perform product development and to advance up to <ix:nonFraction unitRef="usd" contextRef="c-205" decimals="INF" name="mgnx:NumberOfProductCandidates" format="ixt-sec:numwordsen" scale="0" id="f-667">two</ix:nonFraction> DART molecules, MGD014 and MGD020 (NIAID Contract). Under the NIAID Contract, the Company will develop these product candidates for Phase 1/2 clinical trials as therapeutic agents, in combination with latency reversing treatments, to deplete cells infected with human immunodeficiency virus (HIV) infection. NIAID does not receive goods or services from the Company under this contract, therefore the Company does not consider NIAID to be a customer and concluded this contract is outside the scope of ASC 606.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since the inception of the NIAID Contract, NIAID has exercised the two options contemplated in the original contract and executed modifications such that the total funded contract value as of December&#160;31, 2023 is $<ix:nonFraction unitRef="usd" contextRef="c-206" decimals="-5" name="mgnx:TotalPotentialValueUnderAgreement" format="ixt:num-dot-decimal" scale="6" id="f-668">25.1</ix:nonFraction> million. In addition, the most recent modification changed the period of performance under the NIAID Contract to end in July 2023.  The Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="c-207" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-669">1.6</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-208" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-670">1.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-209" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-671">1.8</ix:nonFraction> million under the NIAID contract during the years ended December&#160;31, 2023, 2022 and 2021, respectively.</span></div></ix:continuation><div id="i69aaf560e98645139c7ed7af73a9eafe_160"></div><div><span><br/></span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-672" continuedAt="f-672-1" escape="true">Stock-based Compensation</ix:nonNumeric></span></div><ix:continuation id="f-672-1" continuedAt="f-672-2"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2017, the Company&#8217;s stockholders approved the 2016 Employee Stock Purchase Plan (the 2016 ESPP). The 2016 ESPP is structured as a qualified employee stock purchase plan under Section 423 of the Internal Revenue Code of 1986, as amended, and is not subject to the provisions of the Employee Retirement Income Security Act of 1974. The Company reserved <ix:nonFraction unitRef="shares" contextRef="c-210" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-673">800,000</ix:nonFraction> shares of common stock for issuance under the 2016 ESPP. The 2016 ESPP allows eligible employees to purchase shares of the Company&#8217;s common stock at a discount through payroll deductions of up to <ix:nonFraction unitRef="number" contextRef="c-211" decimals="INF" name="mgnx:EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" scale="-2" id="f-674">10</ix:nonFraction>% of their eligible compensation, subject to any plan limitations. The 2016 ESPP provides for <ix:nonNumeric contextRef="c-212" name="mgnx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" format="ixt-sec:durwordsen" id="f-675">six-month</ix:nonNumeric> offering periods ending on May 31 and November 30 of each year. At the end of each offering period, employees are able to purchase shares at <ix:nonFraction unitRef="number" contextRef="c-211" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="f-676">85</ix:nonFraction>% of the fair market value of the Company&#8217;s common stock on the last day of the offering period. During the year ended December&#160;31, 2023, employees purchased <ix:nonFraction unitRef="shares" contextRef="c-213" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-677">81,541</ix:nonFraction> shares of common stock under the 2016 ESPP for net proceeds to the Company of approximately $<ix:nonFraction unitRef="usd" contextRef="c-213" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="f-678">0.5</ix:nonFraction>&#160;million.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Incentive Plans</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2013, the Company implemented the 2013 Equity Incentive Plan (2013 Plan).&#160;The 2013 Plan provides for the grant of stock options and other stock-based awards, as well as cash-based performance awards. In May 2023, the 2013 Plan was terminated, and no further awards may be issued under the plan. If an option granted under the 2013 Plan expires or terminates for any reason without having been fully exercised, if any shares of restricted stock are forfeited, or if any award terminates, expires or is settled without all or a portion of the shares of common stock covered by the award being issued, such shares will become available for issuance under the 2023 Equity Incentive Plan (2023 Plan). As of December&#160;31, 2023, under the 2013 Plan, there were options to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-214" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-679">11,805,515</ix:nonFraction> shares of common stock outstanding at a weighted average exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-214" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-680">15.45</ix:nonFraction> per share. As of December&#160;31, 2023, there were <ix:nonFraction unitRef="shares" contextRef="c-215" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-681">854,114</ix:nonFraction> unvested restricted stock units (RSUs) outstanding under the 2013 Plan.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2023 Plan was effective as of stockholder approval in May 2023. The 2023 Plan provides for grants of stock options and other stock-based awards, as well as cash-based performance awards. Initially, the maximum number of shares of the Company&#8217;s common stock that may be issued under the 2023 Plan will not exceed <ix:nonFraction unitRef="shares" contextRef="c-216" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-682">4,850,000</ix:nonFraction> shares. If an option expires or terminates for any reason without having been fully exercised, if any shares of restricted stock are forfeited, or if any award terminates, expires or is settled without all or a portion of the shares of common stock covered by the award being issued, such shares are available for the grant of additional awards. However, any shares that are withheld (or delivered) to pay withholding taxes or to pay the exercise price of an option are not available for the grant of additional awards. As of December&#160;31, 2023, under the 2023 Plan, there were options to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-217" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-683">418,122</ix:nonFraction> shares of common stock outstanding at a weighted </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-672-2" continuedAt="f-672-3"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">average exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-217" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-684">5.31</ix:nonFraction> per share. As of December&#160;31, 2023, there were <ix:nonFraction unitRef="shares" contextRef="c-218" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-685">51,500</ix:nonFraction> unvested RSUs outstanding under the 2023 Plan.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="f-686" escape="true"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following stock-based compensation amounts were recognized for the periods indicated (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-219" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-687">9,190</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-220" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-688">10,094</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-221" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-689">11,337</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-222" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-690">9,183</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-223" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-691">10,344</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-224" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-692">11,789</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-693">18,373</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-694">20,438</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-695">23,126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Options</span></div><div style="text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for stock-based compensation to employees and non-employee directors in accordance with ASC Topic 718, </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation &#8211; Stock Compensation</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company estimates the fair value of stock option awards using the Black-Scholes option pricing model on the date of grant using the assumptions in the table below. Stock options granted to employees generally vest over <ix:nonNumeric contextRef="c-225" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" format="ixt-sec:durwordsen" id="f-696"><ix:nonNumeric contextRef="c-225" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-697">four years</ix:nonNumeric></ix:nonNumeric> and have a term of <ix:nonNumeric contextRef="c-225" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="f-698">ten years</ix:nonNumeric>. Stock-based compensation expense for stock options is recognized as expense over the requisite service period, which is the vesting period. As the Company has not paid dividends since inception, nor does it expect to pay any dividends for the foreseeable future, the expected dividend yield assumption is zero. The expected volatility is based on the historical stock volatility of the Company&#8217;s own common stock over a period equal to the expected term of the options. The risk-free rate of the stock options is based on the U.S. Treasury rate in effect at the time of grant for the expected term of the stock options. The Company used the simplified method to calculate expected term during 2021.  Beginning in 2022, the computation of expected term was determined based on the historical experience with similar awards, giving consideration to the contractual terms of the share-based awards, vesting schedules and expectations of future employee behavior.  In addition, the Company  estimates the expected forfeiture rate and only recognizes expense for those shares expected to vest. The Company estimates the forfeiture rate based on historical experience and its expectations regarding future pre-vesting termination behavior of employees. The Company reviews its estimate of the expected forfeiture rate annually, and stock-based compensation expense is adjusted accordingly.</span></div><div style="text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="f-699" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"/><td style="width:56.211%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="f-700">0</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-27" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="f-701">0</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-28" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="f-702">0</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-226" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-703">76</ix:nonFraction>% -<ix:nonFraction unitRef="number" contextRef="c-227" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-704">96</ix:nonFraction>%</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-228" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-705">88</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-229" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-706">92</ix:nonFraction>%</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-230" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-707">86</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-708">87</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-226" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-709">3.5</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-227" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-710">4.8</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-228" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-711">1.4</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-229" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-712">4.0</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-230" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-713">0.6</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-714">1.6</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-715">5.88</ix:nonNumeric> years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-27" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-716">5.95</ix:nonNumeric> years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-28" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-717">6.25</ix:nonNumeric> years</span></div></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-672-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="f-718" escape="true"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity for 2023:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercise Price</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contractual Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Years)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-11" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-719">10,098,929</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-11" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-720">18.58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-27" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-721">6.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-722">3,367,777</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-723">4.97</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-724">34,608</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="f-725">3.73</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-726">365,942</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="f-727">9.49</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-728">842,519</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="f-729">19.12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-2" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-730">12,223,637</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-2" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-731">15.11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-732">6.7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-733">16,974</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of December&#160;31, 2023:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-2" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="f-734">7,892,753</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-2" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="f-735">18.92</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-736">5.6</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="3" id="f-737">4,509</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-2" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-738">11,346,207</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-2" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="f-739">15.59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-740">6.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-741">14,692</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2023, 2022 and 2021 the Company issued <ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-742">34,608</ix:nonFraction>, <ix:nonFraction unitRef="shares" contextRef="c-27" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-743">120,900</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-28" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-744">332,767</ix:nonFraction> shares of common stock, respectively, in conjunction with stock option exercises.&#160;The Company received cash proceeds from the exercise of stock options of approximately $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="6" id="f-745">0.1</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="6" id="f-746">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="6" id="f-747">5.8</ix:nonFraction> million during 2023, 2022 and 2021, respectively.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant-date fair value of options granted during 2023, 2022 and 2021 was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-748">3.83</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-27" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-749">6.84</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-28" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-750">15.20</ix:nonFraction> per share, respectively. The total intrinsic value of options exercised during 2023, 2022 and 2021 was approximately $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="f-751">0.1</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="f-752">0.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="f-753">3.3</ix:nonFraction> million, respectively.&#160;The total fair value of stock options which vested during 2023, 2022 and 2021 was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" format="ixt:num-dot-decimal" scale="6" id="f-754">16.4</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" format="ixt:num-dot-decimal" scale="6" id="f-755">19.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" format="ixt:num-dot-decimal" scale="6" id="f-756">20.2</ix:nonFraction> million, respectively.&#160;As of December&#160;31, 2023, the total unrecognized compensation expense related to non-vested stock options, net of related forfeiture estimates, was $<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="f-757">19.5</ix:nonFraction> million, which the Company expects to recognize over a weighted-average period of approximately <ix:nonNumeric contextRef="c-1" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-758">1.2</ix:nonNumeric> years.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company awards RSUs to employees. RSUs are valued based on the closing price of the Company&#8217;s common stock on the date of the grant. The fair value of RSUs is recognized and amortized on a straight-line basis over the requisite service period of the award</span><span style="color:#252525;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" id="f-759" escape="true"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes RSU activity for 2023:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.163%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.268%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.115%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.954%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Grant Date Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-232" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-760">415,084</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-232" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-761">8.83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-233" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-762">707,635</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-233" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-763">4.88</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-233" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" format="ixt:num-dot-decimal" scale="0" id="f-764">135,396</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-233" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-765">8.32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-233" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-766">81,709</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-233" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-767">7.17</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-234" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-768">905,614</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-234" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-769">5.97</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2023, there was $<ix:nonFraction unitRef="usd" contextRef="c-234" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="6" id="f-770">2.3</ix:nonFraction> million of total unrecognized compensation cost related to unvested RSUs, which the Company expects to recognize over a remaining weighted-average period of <ix:nonNumeric contextRef="c-233" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-771">1.2</ix:nonNumeric> years.</span></div></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><div id="i69aaf560e98645139c7ed7af73a9eafe_163"></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxDisclosureTextBlock" id="f-772" continuedAt="f-772-1" escape="true">Income Taxes </ix:nonNumeric></span></div><ix:continuation id="f-772-1" continuedAt="f-772-2"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2023, 2022 and 2021 there was <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="f-773">no</ix:nonFraction> provision for income taxes due to taxable losses generated, fully offset by a valuation allowance.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-772-2" continuedAt="f-772-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="f-774" escape="true"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The significant components of the Company's deferred income tax assets (liabilities) were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal U.S. net operating loss carryforward</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" format="ixt:num-dot-decimal" scale="3" id="f-775">140,706</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" format="ixt:num-dot-decimal" scale="3" id="f-776">163,071</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State net operating loss carryforward</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" format="ixt:num-dot-decimal" scale="3" id="f-777">33,350</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" format="ixt:num-dot-decimal" scale="3" id="f-778">44,784</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development credit, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="3" id="f-779">68,251</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="3" id="f-780">65,084</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Orphan drug credit, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsOther" format="ixt:num-dot-decimal" scale="3" id="f-781">33,330</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsOther" format="ixt:num-dot-decimal" scale="3" id="f-782">35,703</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="mgnx:DeferredTaxAssetsOperatingLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-783">9,078</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="mgnx:DeferredTaxAssetsOperatingLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-784">9,585</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="us-gaap:DeferredTaxAssetsDeferredIncome" format="ixt:num-dot-decimal" scale="3" id="f-785">17,442</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:DeferredTaxAssetsDeferredIncome" format="ixt:fixed-zero" scale="3" id="f-786">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 174 deferred tax asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="mgnx:Section174DeferredTaxAsset" format="ixt:num-dot-decimal" scale="3" id="f-787">48,421</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="mgnx:Section174DeferredTaxAsset" format="ixt:num-dot-decimal" scale="3" id="f-788">43,192</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity based compensation</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="f-789">16,217</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="f-790">15,228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" format="ixt:num-dot-decimal" scale="3" id="f-791">6,617</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" format="ixt:num-dot-decimal" scale="3" id="f-792">4,663</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred income tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-793">373,412</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-794">381,310</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-795">365,010</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-796">372,267</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred income tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-797">8,402</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-798">9,043</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:13pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease ROU assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="mgnx:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" format="ixt:num-dot-decimal" scale="3" id="f-799">6,372</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="mgnx:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" format="ixt:num-dot-decimal" scale="3" id="f-800">7,522</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenditures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPrepaidExpenses" format="ixt:num-dot-decimal" scale="3" id="f-801">2,030</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPrepaidExpenses" format="ixt:num-dot-decimal" scale="3" id="f-802">1,521</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred income tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-803">8,402</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-804">9,043</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred income tax asset/(liability)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:fixed-zero" scale="3" id="f-805">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:fixed-zero" scale="3" id="f-806">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes valuation allowances to reduce deferred tax assets to the amount that is more likely than not to be realized. In assessing the likelihood of realization, management considers (i) future reversals of existing taxable temporary differences; (ii) future taxable income exclusive of reversing temporary difference and carryforwards; (iii) taxable income in prior carryback years if carryback is permitted under applicable tax law; and (iv) tax planning strategies. The Company's net deferred income tax asset is not more likely than not to be utilized due to the lack of sufficient sources of future taxable income and cumulative book losses which have resulted over the years.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:SummaryOfValuationAllowanceTextBlock" id="f-807" escape="true"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The activity in the valuation allowance on deferred tax assets was as follows (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.970%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.859%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.859%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.859%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.861%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at Beginning of Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deductions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at End of Year</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ended December 31, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-808">372,267</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="mgnx:ValuationAllowanceDeferredTaxAssetIncreaseAmount" format="ixt:fixed-zero" scale="3" id="f-809">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="mgnx:ValuationAllowanceDeferredTaxAssetDecreaseAmount" format="ixt:num-dot-decimal" scale="3" id="f-810">7,257</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-811">365,010</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ended December 31, 2022</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-812">327,592</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="mgnx:ValuationAllowanceDeferredTaxAssetIncreaseAmount" format="ixt:num-dot-decimal" scale="3" id="f-813">44,675</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="mgnx:ValuationAllowanceDeferredTaxAssetDecreaseAmount" format="ixt:fixed-zero" scale="3" id="f-814">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-815">372,267</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ended December 31, 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-816">263,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="mgnx:ValuationAllowanceDeferredTaxAssetIncreaseAmount" format="ixt:num-dot-decimal" scale="3" id="f-817">64,192</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="mgnx:ValuationAllowanceDeferredTaxAssetDecreaseAmount" format="ixt:fixed-zero" scale="3" id="f-818">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-819">327,592</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the Company has U.S. federal and state net operating loss (NOL) carryforwards of approximately $<ix:nonFraction unitRef="usd" contextRef="c-235" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" format="ixt:num-dot-decimal" scale="6" id="f-820">670.0</ix:nonFraction> million. Of these NOLs, $<ix:nonFraction unitRef="usd" contextRef="c-236" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" format="ixt:num-dot-decimal" scale="6" id="f-821">65.5</ix:nonFraction> million will expire in various years beginning in 2035 through 2037. $<ix:nonFraction unitRef="usd" contextRef="c-237" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" format="ixt:num-dot-decimal" scale="6" id="f-822">604.5</ix:nonFraction> million of NOLs were generated post December 31, 2017 and carryforward indefinitely. In addition, the Company has U.S. federal tax credits of $<ix:nonFraction unitRef="usd" contextRef="c-238" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="f-823">94.4</ix:nonFraction> million which will expire in various years beginning in 2024 through 2043.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-772-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="f-824" escape="true"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of the reported estimated income tax benefit to the amount that would result by applying the U.S. federal statutory tax rate to the net income is as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States federal tax at statutory rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="3" id="f-825">1,902</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="3" id="f-826">25,149</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="3" id="f-827">42,445</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes (net of federal benefit)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="3" id="f-828">163</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" format="ixt:num-dot-decimal" scale="3" id="f-829">7,385</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" format="ixt:num-dot-decimal" scale="3" id="f-830">12,806</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="mgnx:EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount" format="ixt:num-dot-decimal" scale="3" id="f-831">5,024</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="mgnx:EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount" scale="3" id="f-832">308</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="mgnx:EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount" scale="3" id="f-833">473</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred state blended rate adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="mgnx:EffectiveIncomeTaxRateReconciliationDeferredStateBlendedRateAdjustmentsAmount" format="ixt:num-dot-decimal" scale="3" id="f-834">1,841</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="mgnx:EffectiveIncomeTaxRateReconciliationDeferredStateBlendedRateAdjustmentsAmount" format="ixt:fixed-zero" scale="3" id="f-835">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="mgnx:EffectiveIncomeTaxRateReconciliationDeferredStateBlendedRateAdjustmentsAmount" format="ixt:fixed-zero" scale="3" id="f-836">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research credit, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" format="ixt:num-dot-decimal" scale="3" id="f-837">3,168</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" format="ixt:num-dot-decimal" scale="3" id="f-838">4,569</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" format="ixt:num-dot-decimal" scale="3" id="f-839">10,243</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Orphan drug credit, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="mgnx:EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount" format="ixt:num-dot-decimal" scale="3" id="f-840">2,374</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="mgnx:EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount" format="ixt:num-dot-decimal" scale="3" id="f-841">10,846</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="mgnx:EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount" format="ixt:num-dot-decimal" scale="3" id="f-842">1,449</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other permanent items</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationOtherReconcilingItems" format="ixt:num-dot-decimal" scale="3" id="f-843">1,301</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:IncomeTaxReconciliationOtherReconcilingItems" format="ixt:num-dot-decimal" scale="3" id="f-844">1,362</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:IncomeTaxReconciliationOtherReconcilingItems" format="ixt:num-dot-decimal" scale="3" id="f-845">1,199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="f-846">1,950</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="f-847">1,604</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="f-848">1,079</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-849">7,257</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-850">44,675</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-851">64,192</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense/(benefit)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-852">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-853">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-854">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="f-855" escape="true"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-856">7,376</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-857">7,197</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-858">6,126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases for current year tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="f-859">449</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="f-860">548</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="f-861">965</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases/(decreases) for prior year tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="mgnx:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" scale="3" id="f-862">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" sign="-" name="mgnx:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" scale="3" id="f-863">369</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="mgnx:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" scale="3" id="f-864">106</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-865">7,821</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-866">7,376</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-867">7,197</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023 and 2022, of the total gross unrecognized tax benefits, approximately $<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="6" id="f-868">7.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="6" id="f-869">7.4</ix:nonFraction> million would favorably impact the Company's effective income tax rate, respectively. Although, due to the Company's determination that the deferred income tax asset would not more likely than not be realized, a valuation allowance would be recorded, therefore, zero net impact would result within the Company's effective income tax rate. The Company's uncertain income tax position liability has been recorded to deferred income taxes to offset the tax attribute carryforward amounts.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2023, 2022 and 2021, the Company has <ix:nonFraction unitRef="usd" contextRef="c-28" decimals="INF" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" format="ixt:fixed-zero" scale="0" id="f-870"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="INF" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" format="ixt:fixed-zero" scale="0" id="f-871"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" format="ixt:fixed-zero" scale="0" id="f-872">not</ix:nonFraction></ix:nonFraction></ix:nonFraction> recognized any interest or penalties related to the uncertain income tax positions due to the fact such position is related to tax attribute carryforwards which have not yet been utilized. The Company does not expect its unrecognized income tax position to significantly decrease within the next twelve months.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's U.S. Federal and state income tax returns from 2004 </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">forward remain open to examination due to the carryover of unused income tax credits, and from 2004 forward due to the carryover of unused net operating losses.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Internal Revenue Code (IRC) Section 174</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For tax years beginning on or after January 1, 2022, the Tax Cuts and Jobs Act of 2017 eliminates the option to currently deduct research and development expenses and requires taxpayers to capitalize and amortize them over five years for research activities performed in the United States and 15 years for research activities performed outside the United States pursuant to IRC Section 174. Although Congress is considering legislation that would repeal or defer this capitalization and amortization requirement, it is not certain that this provision will be repealed or otherwise modified. If the requirement is not repealed or replaced, it could increase our U.S. federal and state cash taxes and reduce cash flows in future years.</span></div></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><div id="i69aaf560e98645139c7ed7af73a9eafe_166"></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="c-1" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="f-873" continuedAt="f-873-1" escape="true">Employee Benefit Plan</ix:nonNumeric></span></div><ix:continuation id="f-873-1" continuedAt="f-873-2"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2002, the Company established the MacroGenics 401(k) Plan (the Plan) for its employees under Section 401(k) of the IRC. Under this Plan, all employees at least <ix:nonNumeric contextRef="c-1" name="mgnx:EmployeesEligibleAgeToParticipateInBenefitPlan" format="ixt-sec:duryear" id="f-874">21</ix:nonNumeric> years of age are eligible to participate in the Plan, starting on the first day of employment. Employees may contribute up to <ix:nonFraction unitRef="number" contextRef="c-1" decimals="INF" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" scale="-2" id="f-875">100</ix:nonFraction>% of their salary, subject to government maximums.</span></div></ix:continuation><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-873-2">Employees are <ix:nonFraction unitRef="number" contextRef="c-1" decimals="INF" name="mgnx:DefinedContributionPlanEmployeesContributionVestedPercentage" scale="-2" id="f-876">100</ix:nonFraction>% vested in their contributions to the Plan. The Company's contribution to the Plan, as determined by the Board of Directors, is discretionary. For the years ended December&#160;31, 2023, 2022 and 2021, the Company's contributions to the Plan totaled $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" format="ixt:num-dot-decimal" scale="6" id="f-877">2.1</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" format="ixt:num-dot-decimal" scale="6" id="f-878">2.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" format="ixt:num-dot-decimal" scale="6" id="f-879">1.6</ix:nonFraction> million, respectively.</ix:continuation> </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 30</span></div></div></div><div id="i69aaf560e98645139c7ed7af73a9eafe_172"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT INDEX </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:8.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.419%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:85.704%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">No.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restated Certificate of Incorporation of the Company and Certificate of Correction to the Restated Certificate of Incorporation of the Company (incorporated by reference to Exhibits </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1125345/000119312513402831/d613759dex31.htm">3.1</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> and </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1125345/000119312513402831/d613759dex33.htm">3.3</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, respectively, to the Company's Current Report on Form 8-K filed on October 18, 2013)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001125345/000112534521000052/a8-k_bylawxamendmentxexx3x1.htm">Amended and Restated By-Laws of the Company (incorporated by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K (File No. 001-36112) filed on April 2, 2021)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1125345/000119312513394786/d575431dex42.htm">Specimen Stock Certificate (incorporated by reference to Exhibit 4.2 to the Registration Statement on Form S-1 (File No. 333-190994) filed by the Company on October 9, 2013)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1125345/000112534521000035/mgnxexhibit4-2202010xk.htm">Description of Common Stock (incorporated by reference to Exhibit 4.2 to the Company&#8217;s Annual Report on Form 10-K filed on February 25, 2021)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1125345/000119312513386872/d575431dex1014.htm">Form of Indemnification Agreement (incorporated by reference to Exhibit 10.14 to the Registration Statement on Form S-1 (File No. 333-190994) filed by the Company on October 1, 2013)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2&#8224;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1125345/000112534518000022/exhibit10-3201710xkfinal.htm">Global Collaboration and License Agreement by and between the Company and Incyte Corporation, dated October 24, 2017 (incorporated by reference to Exhibit 10.3 to the Company's Annual Report on Form 10-K filed on February 27, 2018)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1125345/000119312513386872/d575431dex105.htm">Company 2013 Equity Incentive Plan (incorporated by reference to Exhibit 10.5 to the Registration Statement on Form S-1 (File No. 333-190994) filed by the Company on October 1, 2013)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1125345/000119312513386872/d575431dex106.htm">Form of Incentive Stock Option Agreement under 2013 Equity Incentive Plan (incorporated by reference to Exhibit 10.6 to the Registration Statement on Form S-1 (File No. 333-190994) filed by the Company on October 1, 2013)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1125345/000119312513386872/d575431dex107.htm">Form of Nonstatutory Stock Option Agreement under 2013 Equity Incentive Plan (incorporated by reference to Exhibit 10.7 to the Registration Statement on Form S-1 (File No. 333-190994) filed by the Company on October 1, 2013)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1125345/000112534515000013/exhibit10-2.htm">Form of Restricted Stock Units Grant Notice under 2013 Equity Incentive Plan (incorporated by reference to Exhibit 10.2 to the Company's Quarterly Report on Form 10-Q filed on May 6, 2015)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1125345/000112534523000102/form_s-8x2023eipxex991.htm">Company 20</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1125345/000112534523000102/form_s-8x2023eipxex991.htm">2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1125345/000112534523000102/form_s-8x2023eipxex991.htm">3 Equity Incentive Plan (incorporated by reference to Exhibit </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1125345/000112534523000102/form_s-8x2023eipxex991.htm">99.1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1125345/000112534523000102/form_s-8x2023eipxex991.htm"> to the Registration Statement on Form S-</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1125345/000112534523000102/form_s-8x2023eipxex991.htm">8</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1125345/000112534523000102/form_s-8x2023eipxex991.htm"> (File No. 333-</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1125345/000112534523000102/form_s-8x2023eipxex991.htm">272451</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1125345/000112534523000102/form_s-8x2023eipxex991.htm">) filed by the Company on </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1125345/000112534523000102/form_s-8x2023eipxex991.htm">June 6, 2023</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1125345/000112534523000102/form_s-8x2023eipxex991.htm">)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8+*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit108employeestockopt.htm">Form of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit108employeestockopt.htm">Employee</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit108employeestockopt.htm"> Stock Option </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit108employeestockopt.htm">Grant </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit108employeestockopt.htm">Notice and </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit108employeestockopt.htm">Stock Option </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit108employeestockopt.htm">Agreement under 20</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit108employeestockopt.htm">2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit108employeestockopt.htm">3 Equity Incentive Plan </a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9+*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit109employeersuaward.htm">Form of Employee Restricted Stock Unit Award Grant Notice and Award Agreement under 2023 Equity Incentive Plan </a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.10+*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1010bodoptiongrantn.htm">Form of Director Stock Option Grant Notice and Stock Option Agreement under 2023 Equity Incentive Plan </a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11+*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1011bodrsuawardgran.htm">Form of Director Restricted Stock Unit Award Grant Notice and Award Agreement under 2023 Equity Incentive Plan </a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.12+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1125345/000155278116002035/e00576_ex4-1.htm">2016 Employee Stock Purchase Plan (incorporated by reference to Exhibit 4.1 to the Registration Statement on Form S-8 (File No. 333-214386) filed by the Company on November 2, 2016)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.13+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1125345/000112534516000046/exhibit1014.htm">Employment Agreement between the Company and Scott Koenig, M.D., Ph.D. (incorporated by reference to Exhibit 10.14 to the Company's Annual Report on Form 10-K filed by the Company on February 29, 2016)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.14+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1125345/000112534516000046/exhibit1015.htm">Employment Agreement between the Company and James Karrels (incorporated by reference to Exhibit 10.15 to the Company's Annual Report on Form 10-K filed by the Company on February 29, 2016)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.15+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1125345/000112534516000056/exhibit10-3.htm">Employment Agreement between the Company and Ezio Bonvini, M.D. (incorporated by reference to Exhibit 10.3 to the Company's Quarterly Report on Form 10-Q filed on May 4, 2016)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.16+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1125345/000112534517000041/exhibit1016.htm">Employment Agreement between the Company and Eric Risser (incorporated by reference to Exhibit 10.16 to the Company's Annual Report on Form 10-K filed on February 28, 2017)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.17+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001125345/000112534521000060/exhibit101stepheneckemploy.htm">Employment Agreement between the Company and Stephen Eck, M.D. (incorporated by reference to Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q filed on April 29, 2021)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.18+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1125345/000112534522000047/ex101spitznagelemploymenta.htm">Employment Agreement between the Company and Thomas Spitznagel Ph.D. (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q filed on May 3, 2022)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:8.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.419%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:85.704%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.19&#8224;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1125345/000112534518000058/exhibit101incyteamendment.htm">Amendment No, 1 to the Global Collaboration and License Agreement by and between the Company and Incyte Corporation, dated March 15, 2018 (incorporated by reference to Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q filed on May 7, 2018)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.20#</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1125345/000112534522000090/exhibit101-incyte2ndamend.htm">Amendment No. 2 to the Global Collaboration and License Agreement by and between the Company and Incyte Corporation, dated April 7, 2022 (incorporated by reference to Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q filed on August 8, 2022)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.21#</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1125345/000112534522000104/exhibit101-incyte3rdamend.htm">Amendment No. 3 to the Global Collaboration and License Agreement by and between the Company and Incyte Corporation, dated April 7, 2022 (incorporated by reference to Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q filed on November 3, 2022)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.22#</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001125345/000112534521000035/exhibit1016incytecommercia.htm">Commercial Supply Agreement by and between Incyte Corporation and the Company, dated October 13, 2020 (incorporated by reference to Exhibit 10.16 to the Company&#8217;s Annual Report on Form 10-K filed on February 25, 2021)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.23#</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1125345/000112534523000059/a1022_gileadcollab.htm">Collaboration and License Agreement by and between the Company and Gilead Sciences, Inc., dated October 14, 2022 (incorporated by reference to Exhibit 10.22 to the Company's Annual Report on Form 10-K filed by the Company on March 15, 2023)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.24#</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1125345/000112534523000059/a1023_proventionapa.htm">Asset Purchase Agreement by and between the Company and Provention Bio, Inc., dated May 7, 2018 (incorporated by reference to Exhibit 10.23 to the Company's Annual Report on Form 10-K filed by the Company on March 15, 2023)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.25#</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1125345/000112534523000059/a1024_proventionapaamendme.htm">Amendment No. 1 to the Asset Purchase Agreement by and between the Company and Provention Bio, Inc., dated November 30, 2022 (incorporated by reference to Exhibit 10.24 to the Company's Annual Report on Form 10-K filed by the Company on March 15, 2023)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.26#</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1125345/000112534523000124/exhibit101q32023.htm">Amendment No. 2 to the Asset Purchase Agreement by and between the Company and Provention Bio, Inc., dated September 19, 2023 (incorporated by reference to Exhibit 10.1 to the </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1125345/000112534523000124/exhibit101q32023.htm">Company</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1125345/000112534523000124/exhibit101q32023.htm">&#8217;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1125345/000112534523000124/exhibit101q32023.htm">s </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1125345/000112534523000124/exhibit101q32023.htm">Quarterly Report on Form 10-Q filed</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1125345/000112534523000124/exhibit101q32023.htm"> on </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1125345/000112534523000124/exhibit101q32023.htm">November 6</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1125345/000112534523000124/exhibit101q32023.htm">, 2023</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.27#</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1125345/000112534523000059/a1025_hqlease.htm">Lease by and between BMR-Medical Center Drive LLC and J. Craig Venter Institute, Inc., dated May 3, 2010 (incorporated by reference to Exhibit 10.25 to the Company's Annual Report on Form 10-K filed by the Company on March 15, 2023)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.28#</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1125345/000112534523000059/a1026_firstamendmenttohqle.htm">First Amendment to Lease by and between BMR-Medical Center Drive LLC and J. Craig Venter Institute, Inc. dated March 26, 2014 (incorporated by reference to Exhibit 10.26 to the Company's Annual Report on Form 10-K filed by the Company on March 15, 2023)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.29#</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1125345/000112534523000059/a1027_secondamendmenttohql.htm">Second Amendment to Lease by and between the Company and BMR-Medical Center Drive LLC, dated July 31, 2015 (incorporated by reference to Exhibit 10.27 to the Company's Annual Report on Form 10-K filed by the Company on March 15, 2023)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.30#</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1125345/000112534523000059/a1028_thirdamendmenttohqle.htm">Third Amendment to Lease by and between the Company and BMR-Medical Center Drive LLC, dated November 5, 2015 (incorporated by reference to Exhibit 10.28 to the Company's Annual Report on Form 10-K filed by the Company on March 15, 2023)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.31#</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1125345/000112534523000059/a1029_fourthamendmenttolea.htm">Fourth Amendment to Lease by and between the Company and BMR-Medical Center Drive LLC, dated July 21, 2017 (incorporated by reference to Exhibit 10.29 to the Company's Annual Report on Form 10-K filed by the Company on March 15, 2023)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.32#</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1125345/000112534523000059/a1030_fifthamendmenttohqle.htm">Fifth Amendment to Lease by and between the Company and ARE-Maryland No. 45, LLC, dated December 14, 2022 (incorporated by reference to Exhibit 10.30 to the Company's Annual Report on Form 10-K filed by the Company on March 15, 2023)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1* </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="mgnxexhibit23-1202310xk.htm">Consent of Ernst &amp; Young, LLP, Independent Registered Public Accounting Firm</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="mgnxexhibit31-1202310xk.htm">Rule 13a-14(a) Certification of Principal Executive Officer</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="mgnxexhibit31-2202310xk.htm">Rule 13a-14(a) Certification of Principal Financial Officer</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1**</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="mgnxexhibit32-1202310xk.htm">Section 1350 Certification of Principal Executive Officer</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2**</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="mgnxexhibit32-2202310xk.htm">Section 1350 Certification of Principal Financial Officer</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.1*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="mgnxex97-1clawbackpolicy.htm">MacroGenics.Inc. Incentive Compensation Recoupment Policy </a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Schema Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Calculation Linkbase Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:8.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.419%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:85.704%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Definition Linkbase Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Labels Linkbase Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Presentation Linkbase Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data (formatted as Inline XBRL and contained in Exhibit 101 filed herewith)</span></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8224;&#160;&#160;&#160;&#160;Portions of this exhibit (indicated by asterisks) have been omitted pursuant to a request for confidential treatment granted by the SEC.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">#&#160;&#160;&#160;&#160;Portions of this document (indicated by &#8220;[***]&#8221; have been omitted because they are not material and are the type that MacroGenics, Inc. treats as private and confidential.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">            </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+&#160;&#160;&#160;&#160;Indicates management contract or compensatory plan.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Filed herewith.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">**&#160;&#160;&#160;&#160;Furnished herewith.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.8
<SEQUENCE>2
<FILENAME>exhibit108employeestockopt.htm
<DESCRIPTION>EX-10.8
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i485c43224bf7437e9fe51beaa3c327ed_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 10.8</font></div></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">MacroGenics, Inc.<br>Stock Option Grant Notice<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(2023 Equity Incentive Plan)</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">MacroGenics, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), pursuant to its 2023 Equity Incentive Plan (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), has granted to you (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Optionholder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) an option to purchase the number of shares of Common Stock set forth below (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  Your Option is subject to all of the terms and conditions as set forth herein and in the Plan, and the Stock Option Agreement, all of which are attached hereto and incorporated herein in their entirety.  Capitalized terms not explicitly defined herein but defined in the Plan or the Stock Option Agreement shall have the meanings set forth in the Plan or the Stock Option Agreement, as applicable.</font></div><div style="margin-bottom:9pt;text-align:justify"><font><br></font></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.878%"><tr><td style="width:1.0%"></td><td style="width:30.504%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:67.296%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;padding-right:4.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Optionholder&#58;</font></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:12pt;padding-left:9.05pt;text-align:justify"><font><br></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;padding-right:4.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Grant Number&#58;</font></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:12pt;padding-left:9.05pt;text-align:justify"><font><br></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;padding-right:4.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date of Grant&#58;</font></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:12pt;padding-left:9.05pt;text-align:justify"><font><br></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;padding-right:4.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exercise Price per Share&#58;</font></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:12pt;padding-left:9.05pt;text-align:justify"><font><br></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;padding-right:4.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Total Number of Options&#58;</font></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:12pt;padding-left:9.05pt;text-align:justify"><font><br></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;padding-right:4.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Type of Option&#58;</font></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:12pt;padding-left:9.05pt;text-align:justify"><font><br></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;padding-right:4.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Expiration Date&#58;</font></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:12pt;padding-left:9.05pt;text-align:justify"><font><br></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;padding-right:4.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Vesting Schedule&#58;</font></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:12pt;padding-left:9.05pt;text-align:justify"><font><br></font></div></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify"><font><br></font></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Optionholder Acknowledgements&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  By your signature below or by electronic acceptance or authentication in a form authorized by the Company, you understand and agree that&#58;</font></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:31.8pt">The Option is governed by this Stock Option Grant Notice, and the provisions of the Plan and the Stock Option Agreement, all of which are made a part of this document.  Unless otherwise provided in the Plan, this Grant Notice and the Stock Option Agreement (together, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Option Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) may not be modified, amended or revised except in a writing signed by you and a duly authorized officer of the Company.  </font></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:31.8pt">If the Option is an Incentive Stock Option, it (plus other outstanding Incentive Stock Options granted to you) cannot be first </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">exercisable</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> for more than $100,000 in value (measured by exercise price) in any calendar year.  Any excess over $100,000 is a Nonstatutory Stock Option.</font></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:31.8pt">You consent to receive this Grant Notice, the Stock Option Agreement, the Plan, the Prospectus and any other Plan-related documents by electronic delivery and to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%"> </font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">participate in the Plan through an on-line or electronic system established and maintained by the Company or another third party designated by the Company.  </font></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:31.8pt">You have read and are familiar with the provisions of the Plan, the Stock Option Agreement, and the Prospectus.  In the event of any conflict between the provisions in this Grant Notice, the Option Agreement, or the Prospectus and the terms of the Plan, the terms of the Plan shall control.  </font></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:31.8pt">The Option Agreement sets forth the entire understanding between you and the Company regarding the acquisition of Common Stock and supersedes all prior oral and written agreements, promises and&#47;or representations on that subject with the exception of other equity awards previously granted to you and any written employment agreement, offer letter, severance agreement, written severance plan or policy, or other written agreement between the Company and you in each case that specifies the terms that should govern this Option.  You understand that your employment or service with the Company is for an unspecified duration, can be terminated at any time (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">i.e. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">is &#8220;at-will&#8221;), and that nothing in this Notice, the Option Agreement or the Plan changes the at-will nature of that relationship.</font></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:31.8pt">Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act or other applicable law) or other transmission method and any counterpart so delivered will be deemed to have been duly and validly delivered and be valid and effective for all purposes.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">MacroGenics, Inc.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Signature</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Optionholder&#58;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Signature</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div></td></tr></table></div><div style="margin-bottom:9pt;padding-left:85.5pt;text-align:justify;text-indent:-85.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Attachments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58;  Stock Option Agreement, 2023 Equity Incentive Plan </font></div><div style="margin-bottom:9pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%"> </font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Attachment I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14.5pt;font-weight:700;line-height:120%"><br><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Stock Option Agreement </font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">As reflected by your Stock Option Grant Notice (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Grant Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), MacroGenics, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) has granted you an option under its 2023</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Equity Incentive Plan (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) to purchase a number of shares of Common Stock at the exercise price indicated in your Grant Notice (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  Capitalized terms not explicitly defined in this Agreement but defined in the Grant Notice or the Plan shall have the meanings set forth in the Grant Notice or Plan, as applicable.  The terms of your Option as specified in the Grant Notice and this Stock Option Agreement constitute your Option Agreement.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The general terms and conditions applicable to your Option are as follows&#58;</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;&#160;Governing Plan Document.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Your Option is subject to all the provisions of the Plan., including but not limited to the provisions in&#58;</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 6 regarding the impact of a Capitalization Adjustment, dissolution, liquidation, or Corporate Transaction on your Option&#59;</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 9(e) regarding the Company&#8217;s retained rights to terminate your Continuous Service notwithstanding the grant of the Option&#59; and </font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 8(c) regarding the tax consequences of your Option.  </font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Your Option is further subject to all interpretations, amendments, rules and regulations, which may from time to time be promulgated and adopted pursuant to the Plan.  In the event of any conflict between the Option Agreement and the provisions of the Plan, the provisions of the Plan shall control.  </font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;Vesting.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Your Option will vest as provided in your Grant Notice, subject to the provisions contained herein and the terms of the Plan.  Vesting will cease upon the termination of your Continuous Service.  </font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;Exercise.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">You may generally exercise the vested portion of your Option for whole shares of Common Stock at any time during its term by delivery of payment of the exercise price and applicable withholding taxes and other required documentation to the Plan Administrator in accordance with the exercise procedures established by the Plan Administrator, which may include an electronic submission.  Please review Sections 4(i), 4(j) and 7(b)(v) of the Plan, which may restrict or prohibit your ability to exercise your Option during certain periods.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">To the extent permitted by Applicable Law, you may pay your Option exercise price as follows&#58;</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(i)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">cash, check, bank draft or money order&#59;  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%"> </font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(ii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">pursuant to a &#8220;cashless exercise&#8221; program as further described in Section 4(c)(ii) of the Plan if at the time of exercise the Common Stock is publicly traded&#59;</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(iii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">subject to Company and&#47;or Committee consent at the time of exercise, by delivery of previously owned shares of Common Stock as further described in Section 4(c)(iii) of the Plan&#59; or</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(iv)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">subject to Company and&#47;or Committee consent at the time of exercise, if the Option is a Nonstatutory Stock Option, by a &#8220;net exercise&#8221; arrangement as further described in Section 4(c)(iv) of the Plan.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4.&#160;&#160;&#160;&#160;Term.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  You may not exercise your Option before the commencement of its term or after its term expires.  The term of your Option commences on the Date of Grant and expires upon the earliest of the following&#58;</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">immediately upon the termination of your Continuous Service for Cause&#59;</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">three months after the termination of your Continuous Service for any reason other than Cause, Disability or death&#59;</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12 months after the termination of your Continuous Service due to your Disability&#59;</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">18 months after your death if you die during your Continuous Service&#59;</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(e)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">immediately upon a Corporate Transaction if the Board has determined that the Option will terminate in connection with a Corporate Transaction,</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(f)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">the Expiration Date indicated in your Grant Notice&#59; or</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(g)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">the day before the 10th anniversary of the Date of Grant.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notwithstanding the foregoing, if you die during the period provided in Section 4(b) or 4(c) above, the term of your Option shall not expire until the earlier of (i) 18 months after your death, (ii) upon any termination of the Option in connection with a Corporate Transaction, (iii) the Expiration Date indicated in your Grant Notice, or (iv) the day before the tenth anniversary of the Date of Grant.  Additionally, the Post-Termination Exercise Period of your Option may be extended as provided in Section 4(i) of the Plan.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">To obtain the federal income tax advantages associated with an Incentive Stock Option, the Code requires that at all times beginning on the date of grant of your Option and ending on the day three months before the date of your Option&#8217;s exercise, you must be an employee of the Company or an Affiliate, except in the event of your death or Disability.  If the Company provides for the extended exercisability of your Option under certain circumstances for your benefit, your Option will not necessarily be treated as an Incentive Stock Option if you exercise your Option more than three months after the date your employment terminates.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5.&#160;&#160;&#160;&#160;Withholding Obligations.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">As further provided in Section 8 of the Plan&#58; (a) you may not exercise your Option unless the applicable tax withholding obligations are satisfied, and (b) at the time you exercise your Option, in whole or in part, or at any time thereafter as </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%"> </font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">requested by the Company, you hereby authorize withholding from payroll and any other amounts payable to you, and otherwise agree to make adequate provision for (including by means of a &#8220;cashless exercise&#8221; pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board to the extent permitted by the Company), any sums required to satisfy the federal, state, local and foreign tax withholding obligations, if any, which arise in connection with the exercise of your Option in accordance with the withholding procedures established by the Company.  Accordingly, you may not be able to exercise your Option even though the Option is vested, and the Company shall have no obligation to issue shares of Common Stock subject to your Option, unless and until such obligations are satisfied.  In the event that the amount of the Company&#8217;s withholding obligation in connection with your Option was greater than the amount actually withheld by the Company, you agree to indemnify and hold the Company harmless from any failure by the Company to withhold the proper amount.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6.&#160;&#160;&#160;&#160;Incentive Stock Option Disposition Requirement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  If your Option is an Incentive Stock Option, you must notify the Company in writing within 15 days after the date of any disposition of any of the shares of the Common Stock issued upon exercise of your Option that occurs within two years after the date of your Option grant or within one year after such shares of Common Stock are transferred upon exercise of your Option.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.&#160;&#160;&#160;&#160;Transferability.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Except as otherwise provided in Section 4(e) of the Plan, your Option is not transferable, except by will or by the applicable laws of descent and distribution, and is exercisable during your life only by you.  </font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">8.&#160;&#160;&#160;&#160;Corporate Transaction.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Your Option is subject to the terms of any agreement governing a Corporate Transaction involving the Company, including, without limitation, a provision for the appointment of a stockholder representative that is authorized to act on your behalf with respect to any escrow, indemnities and any contingent consideration. </font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">9.&#160;&#160;&#160;&#160;No Liability for Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  As a condition to accepting the Option, you hereby (a) agree to not make any claim against the Company, or any of its Officers, Directors, Employees or Affiliates related to tax liabilities arising from the Option or other Company compensation and (b) acknowledge that you were advised to consult with your own personal tax, financial and other legal advisors regarding the tax consequences of the Option and have either done so or knowingly and voluntarily declined to do so. Additionally, you acknowledge that the Option is exempt from Section 409A only if the exercise price is at least equal to the &#8220;fair market value&#8221; of the Common Stock on the date of grant as determined by the Internal Revenue Service and there is no other impermissible deferral of compensation associated with the Option.  Additionally, as a condition to accepting the Option, you agree not make any claim against the Company, or any of its Officers, Directors, Employees or Affiliates in the event that the Internal Revenue Service asserts that such exercise is less than the &#8220;fair market value&#8221; of the Common Stock on the date of grant as subsequently determined by the Internal Revenue Service.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10.&#160;&#160;&#160;&#160;Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  If any part of this Option Agreement or the Plan is declared by any court or governmental authority to be unlawful or invalid, such unlawfulness or invalidity will not invalidate any portion of this Option Agreement or the Plan not declared to be unlawful or invalid.&#160;&#160;Any Section of this Option Agreement (or part of such a Section) so declared to be </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%"> </font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">unlawful or invalid will, if possible, be construed in a manner which will give effect to the terms of such Section or part of a Section to the fullest extent possible while remaining lawful and valid</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">11.&#160;&#160;&#160;&#160;Other Documents.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;You hereby acknowledge receipt of or the right to receive a document providing the information required by Rule 428(b)(1) promulgated under the Securities Act, which includes the Prospectus.&#160;&#160;In addition, you acknowledge receipt of the Company&#8217;s Trading Policy.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">12.&#160;&#160;&#160;&#160;Questions. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> If you have questions regarding these or any other terms and conditions applicable to your Option, including a summary of the applicable federal income tax consequences please see the Prospectus.</font></div><div style="margin-bottom:9pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">*  *  * </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%"> </font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><font><br></font></div></td></tr></table></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.9
<SEQUENCE>3
<FILENAME>exhibit109employeersuaward.htm
<DESCRIPTION>EX-10.9
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="ia057ff5c9bda4417a63974b7dec157ab_1"></div><div style="min-height:67.5pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 10.9</font></div></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">MacroGenics, Inc.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14.5pt;font-weight:700;line-height:120%"><br>RSU Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%"> Grant Notice<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(2023 Equity Incentive Plan)</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MacroGenics, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) has awarded to you (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Participant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) the number of restricted stock units specified and on the terms set forth below in consideration of your services (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">RSU Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).  Your RSU Award is subject to all of the terms and conditions as set forth herein and in the Company&#8217;s 2023</font><font style="color:#4f81bd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity Incentive Plan (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) and the Award Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), which are attached hereto and incorporated herein in their entirety.  Capitalized terms not explicitly defined herein but defined in the Plan or the Agreement shall have the meanings set forth in the Plan or the Agreement.</font></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.717%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #003366;border-right:1pt solid #000;border-top:0.75pt solid #003366;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Participant&#58;</font></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #003366;border-right:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Number of RSUs Awarded &#58;</font></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #003366;border-right:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Date of Grant &#58;</font></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #003366;border-right:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Vest Commencement Date &#58;</font></td></tr><tr><td colspan="3" style="border-bottom:0.75pt solid #003366;border-left:0.75pt solid #003366;border-right:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Vesting Schedule&#58;</font></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify"><font><br></font></div><div style="margin-bottom:9pt;padding-left:90pt;text-align:justify;text-indent:-90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Issuance Schedule&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One share of Common Stock will be issued for each restricted stock unit which vests at the time set forth in Section 6 of the Agreement.</font></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Participant Acknowledgements&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  By your signature below or by electronic acceptance or authentication in a form authorized by the Company, you understand and agree that&#58;</font></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:31.8pt">The RSU Award is governed by this RSU Award Grant Notice (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Grant Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), and the provisions of the Plan and the Agreement, all of which are made a part of this document.  Unless otherwise provided in the Plan, this Grant Notice and the Agreement (together, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">RSU Award Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) may not be modified, amended or revised except in a writing signed by you and a duly authorized officer of the Company.  </font></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:31.8pt">You have read and are familiar with the provisions of the Plan, the RSU Award Agreement and the Prospectus.  In the event of any conflict between the provisions in the RSU Award Agreement, or the Prospectus and the terms of the Plan, the terms of the Plan shall control.  </font></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:31.8pt">The RSU Award Agreement sets forth the entire understanding between you and the Company regarding the acquisition of Common Stock and supersedes all prior oral and written agreements, promises and&#47;or representations on that subject with the exception of&#58; (i) other equity awards previously granted to you, and (ii) any written employment agreement, offer letter, severance agreement, written severance plan or policy, or other written agreement between the Company and you in each case that specifies the terms that should govern this RSU Award.</font></div><div style="margin-bottom:9pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MacroGenics, Inc.&#160;&#160;&#160;&#160;Participant&#58;</font></div><div style="margin-bottom:3pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Signature&#160;&#160;&#160;&#160;Signature</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Title&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Date&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:9pt;padding-left:85.5pt;text-align:justify;text-indent:-85.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Attachments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#58; &#160;&#160;&#160;&#160;RSU Award Agreement, 2023</font><font style="color:#4f81bd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity Incentive Plan</font></div><div style="height:67.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div></div></div><div id="ia057ff5c9bda4417a63974b7dec157ab_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:100%">MacroGenics, Inc.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:100%">2023 Equity Incentive Plan</font></div><div style="margin-bottom:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:100%">Award Agreement (RSU Award)</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">As reflected by your Restricted Stock Unit Grant Notice (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Grant Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) MacroGenics, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) has granted you a RSU Award under its 2023 Equity Incentive Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) for the number of restricted stock units as indicated in your Grant Notice (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">RSU Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  The terms of your RSU Award as specified in this Award Agreement for your RSU Award (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and the Grant Notice constitute your &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">RSU Award Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;. Defined terms not explicitly defined in this Agreement but defined in the Grant Notice or the Plan shall have the same definitions as in the Grant Notice or Plan, as applicable.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The general terms applicable to your RSU Award are as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.&#160;&#160;&#160;&#160;Governing Plan Document.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Your RSU Award is subject to all the provisions of the Plan, including but not limited to the provisions in&#58; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 6 of the Plan regarding the impact of a Capitalization Adjustment, dissolution, liquidation, or Corporate Transaction on your RSU Award&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 9(e) of the Plan regarding the Company&#8217;s retained rights to terminate your Continuous Service notwithstanding the grant of the RSU Award&#59; and </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 8(c) of the Plan regarding the tax consequences of your RSU Award.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Your RSU Award is further subject to all interpretations, amendments, rules and regulations, which may from time to time be promulgated and adopted pursuant to the Plan.  In the event of any conflict between the RSU Award Agreement and the provisions of the Plan, the provisions of the Plan shall control.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.&#160;&#160;&#160;&#160;Grant of the RSU Award.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This RSU Award represents your right to be issued on a future date the number of shares of the Company&#8217;s Common Stock that is equal to the number of restricted stock units indicated in the Grant Notice as modified to reflect any Capitalization Adjustment and subject to your satisfaction of the vesting conditions set forth therein (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Restricted Stock Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  Any additional Restricted Stock Units that become subject to the RSU Award pursuant to Capitalization Adjustments as set forth in the Plan and the provisions of Section 4 below, if any, shall be subject, in a manner determined by the Board, to the same forfeiture restrictions, restrictions on transferability, and time and manner of delivery as applicable to the other Restricted Stock Units covered by your RSU Award.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.&#160;&#160;&#160;&#160;Vesting.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Your Restricted Stock Units will vest, if at all, in accordance with the vesting schedule provided in the Grant Notice, subject to the provisions contained herein and the terms of the Plan.  Vesting will cease upon the termination of your Continuous Service.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.&#160;&#160;&#160;&#160;Dividends.&#160; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You may become entitled to receive payments equal to any cash dividends and other distributions paid with respect to a corresponding number of shares of Common Stock to be issued in respect of the Restricted Stock Units covered by your RSU Award.&#160; Any such dividends or distributions shall be subject to the same forfeiture restrictions as apply to the Restricted Stock Units and shall be paid at the same time that the corresponding shares are issued in respect of your vested Restricted Stock Units, provided, however that to the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A-1</font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">extent any such dividends or distributions are paid in shares of Common Stock, then you will automatically be granted a corresponding number of additional Restricted Stock Units subject to the RSU Award (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Dividend Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), and further provided that such Dividend Units shall be subject to the same forfeiture restrictions and restrictions on transferability, and same timing requirements for issuance of shares, as apply to the Restricted Stock Units subject to the RSU Award with respect to which the Dividend Units relate.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.&#160;&#160;&#160;&#160;Withholding Obligations.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">As further provided in Section 8 of the Plan, you hereby authorize withholding from payroll and any other amounts payable to you, and otherwise agree to make adequate provision for, any sums required to satisfy the federal, state, local and foreign tax withholding obligations, if any, which arise in connection with your RSU Award (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Withholding Obligation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) in accordance with the withholding procedures established by the Company.  Unless the Withholding Obligation is satisfied, the Company shall have no obligation to deliver to you any Common Stock in respect of the RSU Award.  In the event the Withholding Obligation of the Company arises prior to the delivery to you of Common Stock or it is determined after the delivery of Common Stock to you that the amount of the Withholding Obligation was greater than the amount withheld by the Company, you agree to indemnify and hold the Company harmless from any failure by the Company to withhold the proper amount.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">6.&#160;&#160;&#160;&#160;Date of Issuance.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The issuance of shares in respect of the Restricted Stock Units is intended to comply with Treasury Regulations Section 1.409A-1(b)(4) and will be construed and administered in such a manner.  Subject to the satisfaction of the Withholding Obligation, if any, in the event one or more Restricted Stock Units vests, the Company shall issue to you one (1) share of Common Stock for each Restricted Stock Unit  (subject to any adjustment under Section 4 above, and subject to any different provisions in the Grant Notice) that vests on the applicable vesting date(s) or on a later date as determined by the Company but in no event later than the Issuance Deadline (as defined below). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In addition, the following provisions shall apply to the extent applicable at a vesting date when shares of Common Stock are registered under the Securities Act, unless otherwise determined by the Company. If&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(i)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the applicable vest date does not occur (1) during an &#8220;open window period&#8221; applicable to you, as determined by the Company in accordance with the Company&#8217;s then-effective policy on trading in Company securities, or (2) on a date when you are otherwise permitted to sell shares of Common Stock on an established stock exchange or stock market (including but not limited to under a previously established written trading plan that meets the requirements of Rule 10b5-1 under the Exchange Act and was entered into in compliance with the Company&#8217;s policies (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">10b5-1 Arrangement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) or under such other policy expressly approved by the Company), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">and</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(ii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">either (1) a Withholding Obligation does not apply, or (2) the Company decides, prior to the applicable vest date, (A) not to satisfy the Withholding Obligation by withholding shares of Common Stock from the shares otherwise due to you under this RSU Award, and (B) not to permit you to enter into a &#8220;same day sale&#8221; commitment with a broker-dealer (including but not limited to a commitment under a 10b5-1 Arrangement) and (C) not to permit you to pay your Withholding Obligation in cash, </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">then</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> the shares that would otherwise be issued to you on the applicable vest date will not be delivered on such applicable vest date and will instead be delivered on the first business day when you are not prohibited from selling shares of the Company&#8217;s Common Stock in the open </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A-2</font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">public market or on such other date determined by the Company, but in no event later than the Issuance Deadline.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Issuance Deadline</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means (a) December 31 of the calendar year in which the applicable vest date occurs (that is, the last day of your taxable year in which the applicable vest date occurs), or (b) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">if and only if</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> permitted in a manner that complies with Treasury Regulations Section 1.409A-1(b)(4), no later than the date that is the 15th day of the third calendar month of the applicable year following the year in which the shares of Common Stock issuable as a result of the applicable vest date under this RSU Award are no longer subject to a &#8220;substantial risk of forfeiture&#8221; within the meaning of Treasury Regulations Section 1.409A-1(d).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">To the extent the RSU Award is a Non-Exempt Award, the provisions of Section 11 of the Plan shall apply.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7.&#160;&#160;&#160;&#160;Transferability.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Except as otherwise provided in the Plan, your RSU Award is not transferable, except by will or by the applicable laws of descent and distribution.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8.&#160;&#160;&#160;&#160;Corporate Transaction.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Your RSU Award is subject to the terms of any agreement governing a Corporate Transaction involving the Company, including, without limitation, a provision for the appointment of a stockholder representative that is authorized to act on your behalf with respect to any escrow, indemnities and any contingent consideration.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">9.&#160;&#160;&#160;&#160;No Liability for Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  As a condition to accepting the RSU Award, you hereby (a) agree to not make any claim against the Company, or any of its Officers, Directors, Employees or Affiliates related to tax liabilities arising from the RSU Award or other Company compensation and (b) acknowledge that you were advised to consult with your own personal tax, financial and other legal advisors regarding the tax consequences of the RSU Award and have either done so or knowingly and voluntarily declined to do so.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">10.&#160;&#160;&#160;&#160;Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If any part of this Agreement or the Plan is declared by any court or governmental authority to be unlawful or invalid, such unlawfulness or invalidity will not invalidate any portion of this Agreement or the Plan not declared to be unlawful or invalid.&#160;&#160;Any Section of this Agreement (or part of such a Section) so declared to be unlawful or invalid will, if possible, be construed in a manner which will give effect to the terms of such Section or part of a Section to the fullest extent possible while remaining lawful and valid.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">11.&#160;&#160;&#160;&#160;Other Documents.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;You hereby acknowledge receipt of or the right to receive a document providing the information required by Rule 428(b)(1) promulgated under the Securities Act, which includes the Prospectus.&#160;&#160;In addition, you acknowledge receipt of the Company&#8217;s Trading Policy.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">12.&#160;&#160;&#160;&#160;Questions. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> If you have questions regarding these or any other terms and conditions applicable to your RSU Award, including a summary of the applicable federal income tax consequences please see the Prospectus.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A-3</font></div><div style="text-align:justify"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.10
<SEQUENCE>4
<FILENAME>exhibit1010bodoptiongrantn.htm
<DESCRIPTION>EX-10.10
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i4f8ab0ff09454bcb841ebad0e80ff340_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 10.10</font></div></div><div style="margin-bottom:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:100%">MacroGenics, Inc.<br>Stock Option Grant Notice<br>(2023 Equity Incentive Plan)</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">MacroGenics, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), pursuant to its 2023 Equity Incentive Plan (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), has granted to you (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Optionholder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) an option to purchase the number of shares of the Common Stock set forth below (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  Your Option is subject to all of the terms and conditions as set forth herein and in the Plan and the Stock Option Agreement, all of which are attached hereto and incorporated herein in their entirety.  Capitalized terms not explicitly defined herein but defined in the Plan or the Stock Option Agreement shall have the meanings set forth in the Plan or the Stock Option Agreement, as applicable.</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.878%"><tr><td style="width:1.0%"></td><td style="width:49.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.333%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;padding-right:4.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:109%">Optionholder&#58;</font></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:12pt;padding-left:9.05pt;text-align:justify"><font><br></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;padding-right:4.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:109%">Date of Grant&#58;</font></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:12pt;padding-left:9.05pt;text-align:justify"><font><br></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;padding-right:4.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:109%">Exercise Price per Share&#58;</font></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:12pt;padding-left:9.05pt;text-align:justify"><font><br></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;padding-right:4.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:109%">Number of Shares of Common Stock Subject to Option&#58;</font></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:12pt;padding-left:9.05pt;text-align:justify"><font><br></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;padding-right:4.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:109%">Type of Option&#58;</font></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:12pt;padding-left:9.05pt;text-align:justify"><font><br></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;padding-right:4.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:109%">Expiration Date&#58;</font></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:12pt;padding-left:9.05pt;text-align:justify"><font><br></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;padding-right:4.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:109%">Vesting Schedule*&#58;</font></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:12pt;padding-left:9.05pt;text-align:justify"><font><br></font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:10pt;padding-left:90pt;text-align:justify;text-indent:-90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">*</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> Subject to the Optionholder&#8217;s Continuous Service through each applicable vesting date.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Optionholder Acknowledgements&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  By your signature below or by electronic acceptance or authentication in a form authorized by the Company, you understand and agree that&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:31.8pt">The Option is governed by this Stock Option Grant Notice, and the provisions of the Plan and the Stock Option Agreement, all of which are made a part of this document.  Unless otherwise provided in the Plan, this Grant Notice and the Stock Option Agreement (together, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Option Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) may not be modified, amended or revised except in a writing signed by you and a duly authorized officer of the Company.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:31.8pt">You consent to receive this Grant Notice, the Stock Option Agreement, the Plan, the Prospectus and any other Plan-related documents by electronic delivery and to participate in the Plan through an on-line or electronic system established and maintained by the Company or another third party designated by the Company.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:31.8pt">You have read and are familiar with the provisions of the Plan, the Stock Option Agreement, and the Prospectus.  In the event of any conflict between the provisions in this Grant Notice, the Option Agreement, or the Prospectus and the terms of the Plan, the terms of the Plan shall control.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:31.8pt">The Option Agreement sets forth the entire understanding between you and the Company regarding the acquisition of Common Stock and supersedes all prior oral and written agreements, promises and&#47;or representations on that subject with the exception of other equity awards previously granted to you and any written employment agreement, offer letter, severance agreement, written severance plan or policy, or other written agreement </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">between the Company and you in each case that specifies the terms that should govern this Option.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:31.8pt">Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act or other applicable law) or other transmission method and any counterpart so delivered will be deemed to have been duly and validly delivered and be valid and effective for all purposes.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MacroGenics, Inc.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Signature</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Date&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Optionholder&#58;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Signature</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Date&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:85.5pt;text-align:justify;text-indent:-85.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Attachments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58;  Stock Option Agreement and 2023 Equity Incentive Plan </font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%"> </font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Attachment I</font></div><div style="margin-bottom:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14.5pt;font-weight:700;line-height:100%">2023 Equity Incentive Plan<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:100%">Stock Option Agreement </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">As reflected by your Stock Option Grant Notice (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Grant Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), MacroGenics, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) has granted you an option under its 2023</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Equity Incentive Plan (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) to purchase a number of shares of Common Stock at the exercise price indicated in your Grant Notice (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  Capitalized terms not explicitly defined in this Agreement but defined in the Grant Notice or the Plan shall have the meanings set forth in the Grant Notice or Plan, as applicable.  The terms of your Option as specified in the Grant Notice and this Stock Option Agreement constitute your Option Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The general terms and conditions applicable to your Option are as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.&#160;&#160;&#160;&#160;Governing Plan Document.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Your Option is subject to all the provisions of the Plan, including but not limited to the provisions in&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 6 regarding the impact of a Capitalization Adjustment, dissolution, liquidation, or Corporate Transaction on your Option&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 9(e) regarding the Company&#8217;s retained rights to terminate your Continuous Service notwithstanding the grant of the Option&#59; and </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 8(c) regarding the tax consequences of your Option. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Your Option is further subject to all interpretations, amendments, rules and regulations, which may from time to time be promulgated and adopted pursuant to the Plan.  In the event of any conflict between the Option Agreement and the provisions of the Plan, the provisions of the Plan shall control.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.&#160;&#160;&#160;&#160;Vesting.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Your Option will vest as provided in your Grant Notice, subject to the provisions contained herein and the terms of the Plan.  Vesting will cease upon the termination of your Continuous Service.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.&#160;&#160;&#160;&#160;Exercise.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You may generally exercise the vested portion of your Option for whole shares of Common Stock at any time during its term by delivery of payment of the exercise price and applicable withholding taxes and other required documentation to the Plan Administrator in accordance with the exercise procedures established by the Plan Administrator, which may include an electronic submission.  Please review Sections 4(i), 4(j) and 7(b)(v) of the Plan, which may restrict or prohibit your ability to exercise your Option during certain periods.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">To the extent permitted by Applicable Law, you may pay your Option exercise price as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(i)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">cash, check, bank draft or money order&#59;  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(ii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">pursuant to a &#8220;cashless exercise&#8221; program as further described in Section 4(c)(ii) of the Plan if at the time of exercise the Common Stock is publicly traded&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%"> </font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(iii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">subject to Company and&#47;or Committee consent at the time of exercise, by delivery of previously owned shares of Common Stock as further described in Section 4(c)(iii) of the Plan&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(iv)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">subject to Company and&#47;or Committee consent at the time of exercise, by a &#8220;net exercise&#8221; arrangement as further described in Section 4(c)(iv) of the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.&#160;&#160;&#160;&#160;Term.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  You may not exercise your Option before the commencement of its term or after its term expires.  The term of your Option commences on the Date of Grant and expires upon the earliest of the following&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">immediately upon the termination of your Continuous Service for Cause&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">three months after the termination of your Continuous Service for any reason other than Cause, Disability or death&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12 months after the termination of your Continuous Service due to your Disability&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">18 months after your death if you die during your Continuous Service&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(e)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">immediately upon a Corporate Transaction if the Board has determined that the Option will terminate in connection with a Corporate Transaction,</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(f)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Expiration Date indicated in your Grant Notice&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(g)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the day before the 10th anniversary of the Date of Grant.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding the foregoing, if you die during the period provided in Section 4(b) or 4(c) above, the term of your Option shall not expire until the earlier of (i) 18 months after your death, (ii) upon any termination of the Option in connection with a Corporate Transaction, (iii) the Expiration Date indicated in your Grant Notice, or (iv) the day before the tenth anniversary of the Date of Grant.  Additionally, the Post-Termination Exercise Period of your Option may be extended as provided in Section 4(i) of the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.&#160;&#160;&#160;&#160;Withholding Obligations.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">As further provided in Section 8 of the Plan&#58; (a) you may not exercise your Option unless the applicable tax withholding obligations are satisfied, and (b) at the time you exercise your Option, in whole or in part, or at any time thereafter as requested by the Company, you hereby authorize withholding from payroll and any other amounts payable to you, and otherwise agree to make adequate provision for (including by means of a &#8220;cashless exercise&#8221; pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board to the extent permitted by the Company), any sums required to satisfy the federal, state, local and foreign tax withholding obligations, if any, which arise in connection with the exercise of your Option in accordance with the withholding procedures established by the Company.  Accordingly, you may not be able to exercise your Option even though the Option is vested, and the Company shall have no obligation to issue shares of Common Stock subject to your Option, unless and until such obligations are satisfied.  In the event that the amount of the Company&#8217;s withholding obligation in connection with your Option was greater than the amount actually withheld by the Company, you agree to indemnify and hold the Company harmless from any failure by the Company to withhold the proper amount.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%"> </font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">6.&#160;&#160;&#160;&#160;Transferability.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Except as otherwise provided in Section 4(e) of the Plan, your Option is not transferable, except by will or by the applicable laws of descent and distribution, and is exercisable during your life only by you.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7.&#160;&#160;&#160;&#160;Corporate Transaction.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Your Option is subject to the terms of any agreement governing a Corporate Transaction involving the Company, including, without limitation, a provision for the appointment of a stockholder representative that is authorized to act on your behalf with respect to any escrow, indemnities and any contingent consideration. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8.&#160;&#160;&#160;&#160;No Liability for Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  As a condition to accepting the Option, you hereby (a) agree to not make any claim against the Company, or any of its Officers, Directors, Employees or Affiliates related to tax liabilities arising from the Option or other Company compensation and (b) acknowledge that you were advised to consult with your own personal tax, financial and other legal advisors regarding the tax consequences of the Option and have either done so or knowingly and voluntarily declined to do so. Additionally, you acknowledge that the Option is exempt from Section 409A only if the exercise price is at least equal to the &#8220;fair market value&#8221; of the Common Stock on the date of grant as determined by the Internal Revenue Service and there is no other impermissible deferral of compensation associated with the Option.  Additionally, as a condition to accepting the Option, you agree not make any claim against the Company, or any of its Officers, Directors, Employees or Affiliates in the event that the Internal Revenue Service asserts that such exercise is less than the &#8220;fair market value&#8221; of the Common Stock on the date of grant as subsequently determined by the Internal Revenue Service.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">9.&#160;&#160;&#160;&#160;Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If any part of this Option Agreement or the Plan is declared by any court or governmental authority to be unlawful or invalid, such unlawfulness or invalidity will not invalidate any portion of this Option Agreement or the Plan not declared to be unlawful or invalid.&#160;&#160;Any Section of this Option Agreement (or part of such a Section) so declared to be unlawful or invalid will, if possible, be construed in a manner which will give effect to the terms of such Section or part of a Section to the fullest extent possible while remaining lawful and valid</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">10.&#160;&#160;&#160;&#160;Other Documents.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;You hereby acknowledge receipt of or the right to receive a document providing the information required by Rule 428(b)(1) promulgated under the Securities Act, which includes the Prospectus.&#160;&#160;In addition, you acknowledge receipt of the Company&#8217;s Trading Policy.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">11.&#160;&#160;&#160;&#160;Questions. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> If you have questions regarding these or any other terms and conditions applicable to your Option, including a summary of the applicable federal income tax consequences please see the Prospectus.</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%"> </font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><font><br></font></div></td></tr></table></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.11
<SEQUENCE>5
<FILENAME>exhibit1011bodrsuawardgran.htm
<DESCRIPTION>EX-10.11
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i4d01a96669e64eef8ced9b9caa91634f_1"></div><div style="min-height:48.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">MacroGenics, Inc.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14.5pt;font-weight:700;line-height:120%"><br>RSU Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%"> Grant Notice<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(2023 Equity Incentive Plan)</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MacroGenics, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) has awarded to you (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Participant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) the number of restricted stock units specified and on the terms set forth below in consideration of your services (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">RSU Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).  Your RSU Award is subject to all of the terms and conditions as set forth herein and in the Company&#8217;s 2023</font><font style="color:#4f81bd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity Incentive Plan (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) and the Award Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), which are attached hereto and incorporated herein in their entirety.  Capitalized terms not explicitly defined herein but defined in the Plan or the Agreement shall have the meanings set forth in the Plan or the Agreement.</font></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.855%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Participant&#58;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Number of RSUs Awarded &#58;</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Date of Grant &#58;</font></td></tr></table></div><div style="margin-bottom:9pt;padding-left:90pt;text-indent:-89.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Vesting Schedule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#58; &#160;&#160;&#160;&#160;Subject to the Participant&#8217;s Continuous Service through each applicable vesting date, the RSU Award will vest as follows&#58;</font></div><div style="margin-bottom:9pt;padding-left:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Restricted Stock Units subject to the RSU Award will vest on the one year anniversary of the Date of Grant, or the day prior to the Company&#8217;s next Annual Meeting of Stockholders, if earlier.</font></div><div style="margin-bottom:9pt;padding-left:90pt;text-align:justify;text-indent:-90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Issuance Schedule&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One share of Common Stock will be issued for each restricted stock unit which vests at the time set forth in Section 6 of the Agreement.</font></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Participant Acknowledgements&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  By your signature below or by electronic acceptance or authentication in a form authorized by the Company, you understand and agree that&#58;</font></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.3pt">The RSU Award is governed by this RSU Award Grant Notice (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Grant Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), and the provisions of the Plan and the Agreement, all of which are made a part of this document.  Unless otherwise provided in the Plan, this Grant Notice and the Agreement (together, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">RSU Award Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) may not be modified, amended or revised except in a writing signed by you and a duly authorized officer of the Company.  </font></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.3pt">You have read and are familiar with the provisions of the Plan, the RSU Award Agreement and the Prospectus.  In the event of any conflict between the provisions in the RSU Award Agreement, or the Prospectus and the terms of the Plan, the terms of the Plan shall control.  </font></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.3pt">The RSU Award Agreement sets forth the entire understanding between you and the Company regarding the acquisition of Common Stock and supersedes all prior oral and written agreements, promises and&#47;or representations on that subject with the exception of&#58; (i) other equity awards previously granted to you, and (ii) any written employment agreement, offer letter, severance agreement, written severance plan or policy, or other written agreement between the Company and you in each case that specifies the terms that should govern this RSU Award.</font></div><div style="margin-bottom:9pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MacroGenics, Inc.&#160;&#160;&#160;&#160;Participant&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Signature&#160;&#160;&#160;&#160;Signature</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Title&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Date&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:9pt;padding-left:85.5pt;text-align:justify;text-indent:-85.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Attachments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#58; &#160;&#160;&#160;&#160;RSU Award Agreement, 2023</font><font style="color:#4f81bd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity Incentive Plan</font></div><div style="height:48.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div></div></div><div id="i4d01a96669e64eef8ced9b9caa91634f_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:100%">MacroGenics, Inc.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:100%">2023 Equity Incentive Plan</font></div><div style="margin-bottom:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:100%">Award Agreement (RSU Award)</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">As reflected by your Restricted Stock Unit Grant Notice (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Grant Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) MacroGenics, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) has granted you a RSU Award under its 2023 Equity Incentive Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) for the number of restricted stock units as indicated in your Grant Notice (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">RSU Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  The terms of your RSU Award as specified in this Award Agreement for your RSU Award (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and the Grant Notice constitute your &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">RSU Award Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;. Defined terms not explicitly defined in this Agreement but defined in the Grant Notice or the Plan shall have the same definitions as in the Grant Notice or Plan, as applicable.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The general terms applicable to your RSU Award are as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.&#160;&#160;&#160;&#160;Governing Plan Document.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Your RSU Award is subject to all the provisions of the Plan, including but not limited to the provisions in&#58; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 6 of the Plan regarding the impact of a Capitalization Adjustment, dissolution, liquidation, or Corporate Transaction on your RSU Award&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 9(e) of the Plan regarding the Company&#8217;s retained rights to terminate your Continuous Service notwithstanding the grant of the RSU Award&#59; and </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 8(c) of the Plan regarding the tax consequences of your RSU Award. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Your RSU Award is further subject to all interpretations, amendments, rules and regulations, which may from time to time be promulgated and adopted pursuant to the Plan.  In the event of any conflict between the RSU Award Agreement and the provisions of the Plan, the provisions of the Plan shall control.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.&#160;&#160;&#160;&#160;Grant of the RSU Award.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This RSU Award represents your right to be issued on a future date the number of shares of the Company&#8217;s Common Stock that is equal to the number of restricted stock units indicated in the Grant Notice as modified to reflect any Capitalization Adjustment and subject to your satisfaction of the vesting conditions set forth therein (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Restricted Stock Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  Any additional Restricted Stock Units that become subject to the RSU Award pursuant to Capitalization Adjustments as set forth in the Plan and the provisions of Section 4 below, if any, shall be subject, in a manner determined by the Board, to the same forfeiture restrictions, restrictions on transferability, and time and manner of delivery as applicable to the other Restricted Stock Units covered by your RSU Award.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.&#160;&#160;&#160;&#160;Vesting.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Your Restricted Stock Units will vest, if at all, in accordance with the vesting schedule provided in the Grant Notice, subject to the provisions contained herein and the terms of the Plan.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.&#160;&#160;&#160;&#160;Dividends.&#160; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You will receive no benefit or adjustment to this RSU Award with respect to any cash dividend, stock dividend or other distribution except as provided in the Plan with respect to a Capitalization Adjustment. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.&#160;&#160;&#160;&#160;Withholding Obligations.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">As further provided in Section 8 of the Plan, and as applicable, you hereby authorize withholding any amounts payable to you, and otherwise agree </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A-1</font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to make adequate provision for, any sums required to satisfy the federal, state, local and foreign tax withholding obligations, if any, which arise in connection with your RSU Award (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Withholding Obligation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) in accordance with the withholding procedures established by the Company.  Unless the Withholding Obligation is satisfied, the Company shall have no obligation to deliver to you any Common Stock in respect of the RSU Award.  In the event the Withholding Obligation of the Company arises prior to the delivery to you of Common Stock or it is determined after the delivery of Common Stock to you that the amount of the Withholding Obligation was greater than the amount withheld by the Company, you agree to indemnify and hold the Company harmless from any failure by the Company to withhold the proper amount.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">6.&#160;&#160;&#160;&#160;Date of Issuance.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The issuance of shares in respect of the Restricted Stock Units is intended to comply with Treasury Regulations Section 1.409A-1(b)(4) and will be construed and administered in such a manner.  Subject to the satisfaction of the Withholding Obligation, if any, in the event one or more Restricted Stock Units vests, the Company shall issue to you one (1) share of Common Stock for each Restricted Stock Unit  (subject to any adjustment under Section 4 above, and subject to any different provisions in the Grant Notice) that vests on the applicable vesting date(s) or on a later date as determined by the Company but in no event later than the Issuance Deadline (as defined below). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In addition, the following provisions shall apply to the extent applicable at a vesting date when shares of Common Stock are registered under the Securities Act, unless otherwise determined by the Company. If&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(i)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the applicable vest date does not occur (1) during an &#8220;open window period&#8221; applicable to you, as determined by the Company in accordance with the Company&#8217;s then-effective policy on trading in Company securities, or (2) on a date when you are otherwise permitted to sell shares of Common Stock on an established stock exchange or stock market (including but not limited to under a previously established written trading plan that meets the requirements of Rule 10b5-1 under the Exchange Act and was entered into in compliance with the Company&#8217;s policies (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">10b5-1 Arrangement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) or under such other policy expressly approved by the Company), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">and</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(ii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">either (1) a Withholding Obligation does not apply, or (2) the Company decides, prior to the applicable vest date, (A) not to satisfy the Withholding Obligation by withholding shares of Common Stock from the shares otherwise due to you under this RSU Award, and (B) not to permit you to enter into a &#8220;same day sale&#8221; commitment with a broker-dealer (including but not limited to a commitment under a 10b5-1 Arrangement) and (C) not to permit you to pay your Withholding Obligation in cash, </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">then</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> the shares that would otherwise be issued to you on the applicable vest date will not be delivered on such applicable vest date and will instead be delivered on the first business day when you are not prohibited from selling shares of the Company&#8217;s Common Stock in the open public market or on such other date determined by the Company, but in no event later than the Issuance Deadline.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Issuance Deadline</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means (a) December 31 of the calendar year in which the applicable vest date occurs (that is, the last day of your taxable year in which the applicable vest date occurs), or (b) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">if and only if</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> permitted in a manner that complies with Treasury Regulations Section 1.409A-1(b)(4), no later than the date that is the 15th day of the third calendar month of the applicable year following the year in which the shares of Common Stock issuable as a result of the applicable vest date under this RSU Award are no longer subject to a &#8220;substantial risk of forfeiture&#8221; within the meaning of Treasury Regulations Section 1.409A-1(d).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">To the extent the RSU Award is a Non-Exempt Award, the provisions of Section 11 of the Plan shall apply.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7.&#160;&#160;&#160;&#160;Transferability.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Except as otherwise provided in the Plan, your RSU Award is not transferable, except by will or by the applicable laws of descent and distribution.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8.&#160;&#160;&#160;&#160;Corporate Transaction.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Your RSU Award is subject to the terms of any agreement governing a Corporate Transaction involving the Company, including, without limitation, a provision for the appointment of a stockholder representative that is authorized to act on your behalf with respect to any escrow, indemnities and any contingent consideration.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">9.&#160;&#160;&#160;&#160;No Liability for Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  As a condition to accepting the RSU Award, you hereby (a) agree to not make any claim against the Company, or any of its Officers, Directors, Employees or Affiliates related to tax liabilities arising from the RSU Award or other Company compensation and (b) acknowledge that you were advised to consult with your own personal tax, financial and other legal advisors regarding the tax consequences of the RSU Award and have either done so or knowingly and voluntarily declined to do so.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">10.&#160;&#160;&#160;&#160;Personal Data.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  You acknowledge and agree that the Company will process and retain certain personal data for the purposes of (1) calculating RSU Awards, (2) monitoring RSU Award terms and conditions, and (3) otherwise administering the Plan and Awards made under it.  Such personal data may include, among other things, your address and social security number, pay data, job title, and employment dates.  You consent to such processing, and to the sharing of such personal data with the Company, its agents, its advisers, its regulators, and tax authorities, wherever appropriate.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">11.&#160;&#160;&#160;&#160;Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If any part of this Agreement or the Plan is declared by any court or governmental authority to be unlawful or invalid, such unlawfulness or invalidity will not invalidate any portion of this Agreement or the Plan not declared to be unlawful or invalid.&#160;&#160;Any Section of this Agreement (or part of such a Section) so declared to be unlawful or invalid will, if possible, be construed in a manner which will give effect to the terms of such Section or part of a Section to the fullest extent possible while remaining lawful and valid.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">12.&#160;&#160;&#160;&#160;Other Documents.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;You hereby acknowledge receipt of or the right to receive a document providing the information required by Rule 428(b)(1) promulgated under the Securities Act, which includes the Prospectus.&#160;&#160;In addition, you acknowledge receipt of the Company&#8217;s Trading Policy.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">13.&#160;&#160;&#160;&#160;Questions. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> If you have questions regarding these or any other terms and conditions applicable to your RSU Award, including a summary of the applicable federal income tax consequences please see the Prospectus.</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</font></div><div style="text-align:justify"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>6
<FILENAME>mgnxexhibit23-1202310xk.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="icfd64df5251740d3bf81ea89a7c447a5_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EXHIBIT 23.1</font></div><div style="margin-top:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consent to the incorporation by reference in the following Registration Statements&#58;</font></div><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.5pt">Registration Statement (Form S-8 No. 333-192277) pertaining to the 2000 Stock Option and Incentive Plan, the 2003 Equity Incentive Plan, and 2013 Equity Incentive Plan of MacroGenics, Inc.,</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.5pt">Registration Statements (Form S-8 No. 333-202470) pertaining to the 2013 Equity Incentive Plan of MacroGenics, Inc.,</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.5pt">Registration Statements (Form S-8 No. 333-209812) pertaining to the 2013 Equity Incentive Plan of MacroGenics, Inc.,</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.5pt">Registration Statements (Form S-8 No. 333-217620) pertaining to the 2013 Equity Incentive Plan of MacroGenics, Inc.,</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.5pt">Registration Statements (Form S-8 No. 333-223682) pertaining to the 2013 Equity Incentive Plan of MacroGenics, Inc.,</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.5pt">Registration Statements (Form S-8 No. 333-230292) pertaining to the 2013 Equity Incentive Plan of MacroGenics, Inc.,</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.5pt">Registration Statements (Form S-8 No. 333-237127) pertaining to the 2013 Equity Incentive Plan of MacroGenics, Inc.,</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.5pt">Registration Statements (Form S-8 No. 333-253502) pertaining to the 2013 Equity Incentive Plan of MacroGenics, Inc.,</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.5pt">Registration Statements (Form S-8 No. 333-262967) pertaining to the 2013 Equity Incentive Plan of MacroGenics, Inc.,</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:5.5pt">Registration Statement (Form S-8 No. 333-270562) pertaining to the 2013 Equity Incentive Plan of MacroGenics, Inc., </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:5.5pt">Registration Statement (Form S-8 No. 333-214386) pertaining to the 2016 Employee Stock Purchase Plan of MacroGenics, Inc.,</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:5.5pt">Registration Statement (Form S-8 No. 333-272451) pertaining to the 2023 Equity Incentive Plan of MacroGenics, Inc., and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Registration Statement (Form S-3 No. 333-275343) of MacroGenics, Inc.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of our reports dated March&#160;7, 2024, with respect to the consolidated financial statements of MacroGenics, Inc. and the effectiveness of internal control over financial reporting of MacroGenics, Inc. included in this Annual Report (Form 10-K) of MacroGenics, Inc. for the year ended  December&#160;31, 2023.</font></div><div style="margin-bottom:3pt;margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Ernst&#160;&#38; Young LLP</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tysons, Virginia</font></div><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;7, 2024</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>7
<FILENAME>mgnxexhibit31-1202310xk.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i652f274762604e5aa9b04493e0eee0f3_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EXHIBIT 31.1</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Scott Koenig, certify that&#58;</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">I have reviewed this Annual Report on Form 10-K for the period ended December&#160;31, 2023 of MacroGenics, Inc.&#59;</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:9pt;padding-left:126pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:9pt;padding-left:126pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:9pt;padding-left:126pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:9pt;padding-left:126pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:9pt;padding-left:126pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:9pt;padding-left:126pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="padding-left:126pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.538%"><tr><td style="width:1.0%"></td><td style="width:40.053%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.418%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.229%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Scott&#160;Koenig</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Scott Koenig, M.D., Ph.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></div></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated&#58;&#160;March&#160;7, 2024&#160;</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>8
<FILENAME>mgnxexhibit31-2202310xk.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i3aa2b88da67e45ccbd0f0c7dbed1e70e_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EXHIBIT 31.2</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, James Karrels, certify that&#58;</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">I have reviewed this Annual Report on Form 10-K for the period ended December&#160;31, 2023 of MacroGenics, Inc.&#59;</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:9pt;padding-left:144pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:9pt;padding-left:144pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:9pt;padding-left:144pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:9pt;padding-left:144pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)</font></div><div style="margin-bottom:9pt;padding-left:144pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:9pt;padding-left:144pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:9pt;padding-left:108pt;text-indent:-18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.339%"><tr><td style="width:1.0%"></td><td style="width:22.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.370%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:56.179%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; James Karrels</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">James Karrels</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President and Chief Financial Officer</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></div></td></tr></table></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated&#58;&#160;March&#160;7, 2024&#160;</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>9
<FILENAME>mgnxexhibit32-1202310xk.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="id98cb0fafd144d149dfc06ba5c03262f_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EXHIBIT 32.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of Principal Executive Officer Pursuant to 18 U.S.C. 1350 (Section 906 of the Sarbanes-Oxley Act of 2002)</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Scott Koenig, President and Chief Executive Officer (principal executive officer) of MacroGenics, Inc. (the &#8220;Registrant&#8221;), certify, to the best of my knowledge, based upon a review of the Annual Report on Form 10-K for the period ended December&#160;31, 2023 of the Registrant (the &#8220;Report&#8221;), that&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:20.23pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The Report fully complies with the requirements of Section&#160;13(a) or 15(d)&#160;of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="padding-left:20.23pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-indent:288pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Scott Koenig </font></div><div style="text-indent:288pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name&#58; Scott Koenig, M.D., Ph.D.</font></div><div style="text-indent:288pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58;  March&#160;7, 2024 </font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>10
<FILENAME>mgnxexhibit32-2202310xk.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i525de2623edd40b6880d344bad7540ca_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EXHIBIT 32.2</font></div><div style="margin-top:6pt;text-align:center"><font><br></font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of Principal Financial Officer Pursuant to 18 U.S.C. 1350 (Section 906 of the Sarbanes-Oxley Act of 2002)</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, James Karrels, Senior Vice President and Chief Financial Officer (principal financial officer) of MacroGenics, Inc. (the &#8220;Registrant&#8221;), certify, to the best of my knowledge, based upon a review of the Annual Report on Form 10-K for the period ended December&#160;31, 2023 of the Registrant (the &#8220;Report&#8221;), that&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:20.23pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The Report fully complies with the requirements of Section&#160;13(a) or 15(d)&#160;of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="padding-left:20.23pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.</font></div><div><font><br></font></div><div style="text-indent:288pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; James Karrels&#160;&#160;&#160;&#160;</font></div><div style="text-indent:288pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name&#58; James Karrels</font></div><div style="text-indent:288pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; March&#160;7, 2024</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97.1
<SEQUENCE>11
<FILENAME>mgnxex97-1clawbackpolicy.htm
<DESCRIPTION>EX-97.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="idde8e87abe4044cf986957f5cf0075cf_35"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 97.1</font></div></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">MACROGENICS, INC.</font></div><div style="margin-bottom:9pt;text-align:center;text-indent:76.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">INCENTIVE COMPENSATION RECOUPMENT POLICY</font></div><div style="margin-bottom:9pt;text-align:center;text-indent:76.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(Adopted November 30, 2023)</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:9pt">INTRODUCTION</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:41.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Board of Directors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">MacroGenics,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Inc., a Delaware corporation (the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">has</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">determined</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">that it is</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">in the best interests of the Company and its stockholders to adopt a policy (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) providing for the Company&#8217;s recoupment of certain Incentive Compensation (as defined below) paid to Covered Officers (as defined below) of the Company under certain circumstances.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Board may delegate determinations to be made under</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">the Policy to</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">the Compensation Committee of</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">the Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Compensation Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">and the Board and the Compensation Committee are collectively referred to in this Policy as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.&#8221;</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This Policy shall be administered by the Board and, except as specifically provided herein, the Board shall have full and final authority to make any and all determinations required under this Policy. Any determination by the Board with respect to this Policy shall be final, conclusive, and binding on all interested parties. Subject to applicable law, the Board may authorize and empower any officer or employee of the Company to take any and all actions that the Board, in its sole discretion, deems necessary or appropriate to carry out the purpose and intent of this Policy (other than with respect to any recovery under this Policy involving such officer or employee).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Board may amend or terminate this Policy at any time.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This Policy is designed to comply with, and shall be interpreted to be consistent with, Section 10D of the Securities Exchange Act of 1934 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Exchange Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), Rule 10D-1 promulgated thereunder (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Rule 10D-1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) and Nasdaq Listing Rule 5608 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Listing Standards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:9.75pt">EFFECTIVE DATE</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This Policy shall apply to all Incentive Compensation that is received by a Covered Officer on or after October 2, 2023 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;). Incentive Compensation is deemed &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">received</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; in the Company&#8217;s fiscal period in which the Financial Reporting Measure (as defined below) specified in the Incentive Compensation award is attained, even if the payment or grant of such Incentive Compensation occurs after the end of that period.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:9.75pt">DEFINITIONS</font></div><div style="margin-bottom:9pt;text-indent:42pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For purposes of this Policy, the following terms shall have the meanings set forth below&#58; </font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Accounting Restatement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means an accounting restatement that the Company is required to prepare due to the material noncompliance of the Company with any financial reporting requirement under the securities laws, including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements, or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Accounting Restatement Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the earlier to occur of (a) the date that the Board, a committee of the Board authorized to take such action, or the officer or officers of the Company authorized to take such action if Board action is not required, concludes, or reasonably should have concluded, that the Company is required to prepare an Accounting Restatement, or (b) the date that a court, regulator or other legally authorized body directs the Company to prepare an Accounting Restatement.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the U.S. Internal Revenue Code of 1986, as amended, and the regulations promulgated thereunder.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Covered Officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">means</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">each</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">current</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">former</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Officer.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Exchange</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the Nasdaq Stock Market.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Executive Officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the Company&#8217;s president, principal financial officer, principal accounting officer (or if there is no such accounting officer, the controller), any vice-president of the Company in charge of a principal business unit, division, or function (such as sales, administration, or finance), any other officer who performs a policy-making function, or any other person who performs similar policy-making functions for the Company. Executive officers of the Company&#8217;s parent(s) or subsidiaries are deemed executive officers of the Company if they perform such policy-making functions for the Company. Policy-making function is not intended to include policy-making functions that are not significant. Identification of an executive officer for purposes of this Policy would include at a minimum executive officers identified pursuant to Item 401(b) of Regulation S-K promulgated under the Exchange Act.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Financial Reporting Measures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means measures that are determined and presented in accordance with the accounting principles used in preparing the Company&#8217;s financial statements, and any measures derived wholly or in part from such measures, including Company stock price and total stockholder return (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">TSR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). A measure need not be presented in the Company&#8217;s financial statements or included in a filing with the Securities and Exchange Commission (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">SEC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) in order to be a Financial Reporting Measure.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:42pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Incentive Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any compensation that is granted, earned, or vested based in whole or in part on the attainment of a Financial Reporting Measure.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Lookback Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the three completed fiscal years immediately preceding the Accounting Restatement Date, as well as any transition period (resulting from a change in the Company&#8217;s fiscal year) within or immediately following those three completed fiscal years (except that a transition period of at least nine months shall count as a completed fiscal year). Notwithstanding the foregoing, the Lookback Period shall not include fiscal years completed prior to the Effective Date. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Recoverable Incentive Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means Incentive Compensation received by a Covered Officer during the Lookback Period that exceeds the amount of Incentive Compensation that would have been received had such amount been determined based on the Accounting Restatement, computed without regard to any taxes paid (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">i.e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, on a gross basis without regard to tax withholdings and other deductions). For any compensation plans or programs that take into account Incentive Compensation, the amount of Recoverable Incentive Compensation for purposes of this Policy shall include, without limitation, the amount contributed to any notional account based on Recoverable Incentive Compensation and any earnings to date on that notional amount. For any Incentive Compensation that is based on stock price or TSR, where the Recoverable Incentive Compensation is not subject to mathematical recalculation directly from the information in an Accounting Restatement, the Board will determine the amount of Recoverable Incentive Compensation based on a reasonable estimate of the effect of the Accounting Restatement on the stock price or TSR upon which the Incentive Compensation was received. The Company shall maintain documentation of the determination of that reasonable estimate and provide such documentation to the Exchange in accordance with the Listing Standards.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:9.75pt">RECOUPMENT</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:10.37pt">Applicability of Policy. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This Policy applies to Incentive Compensation received by a Covered Officer (i) after beginning services as an Executive Officer, (ii) who served as an Executive Officer at any time during the performance period for such Incentive Compensation, (iii) while the Company had a class of securities listed on a national securities exchange or a national securities association, and (iv) during the Lookback Period. </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:9.75pt">Recoupment Generally.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Pursuant to the provisions of this Policy, if there is an Accounting Restatement, the Company must reasonably promptly recoup the full amount of the Recoverable Incentive Compensation, unless the conditions of one or more subsections of Section 4(c) of this Policy are met and the Compensation Committee or a majority of the independent directors serving on the Board, has made a determination that recoupment would be impracticable. Recoupment is required regardless of whether the Covered Officer engaged in any misconduct and regardless of fault, and the Company&#8217;s obligation to recoup Recoverable Incentive Compensation is not dependent on whether or when any restated financial statements are filed.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:10.37pt">Impracticability of Recovery.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Recoupment may be determined to be impracticable if, and only if&#58;</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-align:justify;text-indent:-23.27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18pt">the direct expense paid to a third party to assist in enforcing this Policy would exceed the amount of the applicable Recoverable Incentive Compensation&#59; provided that, before concluding that it would be impracticable to recover any amount of Recoverable Incentive Compensation based on expense of enforcement, the Company shall make a reasonable attempt to recover such Recoverable Incentive Compensation, document such reasonable attempt(s) to recover, and provide that documentation to the Exchange in accordance with the Listing Standards&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-align:justify;text-indent:-26.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt">recoupment of the applicable Recoverable Incentive Compensation </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to employees of the Company, to fail to meet the requirements of Code Section 401(a)(13) or Code Section 411(a) and regulations thereunder.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:9.14pt">Sources of Recoupment. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">To the extent permitted by applicable law, the Board shall, in its sole discretion, determine the timing and method for recouping Recoverable Incentive Compensation hereunder, provided that such recoupment is undertaken reasonably promptly. The Board may, in its discretion, seek recoupment from a Covered Officer from any of the following sources or a combination thereof, whether the applicable compensation was approved, awarded, granted, payable or paid to the Covered Officer prior to, on or after the Effective Date&#58; (i) direct repayment of Recoverable Incentive Compensation previously paid to the Covered Officer&#59; (ii) cancelling prior cash or equity-based awards (whether vested or unvested and whether paid or unpaid)&#59; (iii) cancelling or offsetting against any planned future cash or equity-based awards&#59; (iv) forfeiture of deferred compensation, subject to compliance with Code Section 409A&#59; and (v) any other method authorized by applicable law or contract. Subject to compliance with any applicable law, the Board may effectuate recoupment under this Policy from any amount otherwise payable to the Covered Officer, including amounts payable to such individual under any otherwise applicable Company plan or program, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, base salary, bonuses or commissions and compensation previously deferred by the Covered Officer. The Board need not utilize the same method of recovery for all Covered Officers or with respect to all types of Recoverable Incentive Compensation.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:10.37pt">No Indemnification of Covered Officers.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Notwithstanding any indemnification agreement, applicable insurance policy or any other agreement or provision of the Company&#8217;s certificate of incorporation or bylaws to the contrary, no Covered Officer shall be entitled to indemnification or advancement of expenses in connection with any enforcement of this Policy by the Company, including paying or reimbursing such Covered Officer for insurance premiums to cover potential obligations to the Company under this Policy.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">f.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:11.59pt">Indemnification of the Board.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Any members of the Board who assist in the administration of this Policy, shall not be personally liable for any action, determination or interpretation made with respect to this Policy and shall be indemnified by the Company to the fullest extent under applicable law and Company policy with respect to any such action, determination, or interpretation. The foregoing sentence shall not limit any other rights to indemnification of the members of the Board under applicable law or Company policy.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:9.75pt">No &#8220;Good Reason&#8221; for Covered Officers.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Any action by the Company to recoup or any recoupment of Recoverable Incentive Compensation under this Policy from a Covered Officer shall not be deemed (i) &#8220;good reason&#8221; for resignation or to serve as a basis for a claim of constructive termination under any benefits or compensation arrangement applicable to such Covered Officer, or (ii) to constitute a breach of a contract or other arrangement to which such Covered Officer is party.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:9.75pt">SEVERABILITY</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:42.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">any</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">provision</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">this</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">or</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">application</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">any</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">such</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">provision</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">to</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">any</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Covered</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">shall be</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">adjudicated</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">to</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">be</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">invalid,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">illegal,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">or</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">unenforceable</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">in</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">any</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">respect,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">such</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">invalidity,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">illegality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">unenforceability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">shall</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">not</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">affect</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">any</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">other</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">provisions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">this</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Policy,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">and</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">invalid,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">illegal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">or</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">unenforceable provisions shall be deemed amended to the minimum extent necessary to render any such provision or application enforceable.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:9.75pt">NO IMPAIRMENT OF OTHER REMEDIES</font></div><div style="margin-bottom:9pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Nothing contained in this Policy, and no recoupment or recovery as contemplated herein, shall limit any claims, damages or other legal remedies the Company or any of its affiliates may have against a Covered Officer arising out of or resulting from any actions or omissions by the Covered Officer. This Policy does not preclude the Company from taking any other action to enforce a Covered Officer&#8217;s obligations to the Company, including, without limitation, termination of employment and&#47;or institution of civil proceedings.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This Policy is in addition to the requirements of Section 304 of the Sarbanes-Oxley Act of 2002 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">SOX 304</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8221;)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that are applicable to the Company&#8217;s Chief Executive Officer and Chief Financial Officer and to any other compensation recoupment policy and&#47;or similar provisions in any employment, equity plan, equity award, or other individual agreement, to which the Company is a party or which the Company has adopted or may adopt and maintain from time to time&#59; provided, however, that compensation recouped pursuant to this Policy shall not be duplicative of compensation recouped pursuant to SOX 304 or any such compensation recoupment policy and&#47;or similar provisions in any such employment, equity plan, equity award, or other individual agreement except as may be required by law.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:9.75pt">SUCCESSORS</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This Policy shall be binding and enforceable against all Covered Officers and, to the extent required by Rule 10D-1 and&#47;or the applicable Listing Standards, their beneficiaries, heirs, executors, administrators or other legal representatives.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:9.75pt"> REQUIRED FILINGS</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">            </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company shall make any disclosures and filings with respect to this Policy that are required by law, including as required by the SEC.</font></div><div style="margin-bottom:9pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:9pt"><font><br></font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">MACROGENICS, INC.</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Incentive Compensation Recoupment Policy</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Form of Executive Acknowledgment</font></div><div style="margin-bottom:9pt"><font><br></font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">I, the undersigned, agree and acknowledge that I am bound by, and subject to, the MacroGenics, Inc. Incentive Compensation Recoupment Policy, as may be amended, restated, supplemented, or otherwise modified from time to time (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;). In the event of any inconsistency between the Policy and the terms of any employment agreement, offer letter or other individual agreement with MacroGenics, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) to which I am a party, or the terms of any compensation plan, program, or agreement, whether or not written, under which any compensation has been granted, awarded, earned or paid to me, the terms of the Policy shall govern.</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In the event that the Board determines that any compensation granted, awarded, earned, or paid to me must be forfeited or reimbursed to the Company pursuant to the Policy, I will promptly take any action necessary to effectuate such forfeiture and&#47;or reimbursement. I further agree and acknowledge that I am not entitled to indemnification, and hereby waive any right to advancement of expenses, in connection with any enforcement of the Policy by the Company.</font></div><div style="margin-bottom:9pt"><font><br></font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Agreed and Acknowledged&#58;</font></div><div style="margin-bottom:9pt"><font><br></font></div><div style="margin-bottom:9pt"><font><br></font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Name&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">                                                             </font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Title&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">                                                               </font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Date&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">                                                               </font></div><div style="margin-bottom:9pt"><font><br></font></div><div style="margin-bottom:9pt"><font><br></font></div><div style="margin-bottom:9pt"><font><br></font></div><div style="margin-bottom:9pt"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>12
<FILENAME>mgnx-20231231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:8dbce59b-e7cb-41de-8446-707f712a2a92,g:3e6229e4-32a7-4caa-a132-cb74eb6cd115-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:mgnx="http://macrogenics.com/20231231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://macrogenics.com/20231231">
  <xs:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2023" schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mgnx-20231231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mgnx-20231231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mgnx-20231231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mgnx-20231231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://macrogenics.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://macrogenics.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETS" roleURI="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS">
        <link:definition>0000003 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>0000004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS">
        <link:definition>0000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
        <link:definition>0000006 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>0000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandNatureofOperations" roleURI="http://macrogenics.com/role/OrganizationandNatureofOperations">
        <link:definition>0000008 - Disclosure - Organization and Nature of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>0000009 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecurities" roleURI="http://macrogenics.com/role/MarketableSecurities">
        <link:definition>0000010 - Disclosure - Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventory" roleURI="http://macrogenics.com/role/Inventory">
        <link:definition>0000011 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyEquipmentandSoftware" roleURI="http://macrogenics.com/role/PropertyEquipmentandSoftware">
        <link:definition>0000012 - Disclosure - Property, Equipment and Software</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://macrogenics.com/role/CommitmentsandContingencies">
        <link:definition>0000013 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RoyaltyMonetizationArrangement" roleURI="http://macrogenics.com/role/RoyaltyMonetizationArrangement">
        <link:definition>0000014 - Disclosure - Royalty Monetization Arrangement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://macrogenics.com/role/StockholdersEquity">
        <link:definition>0000015 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenue" roleURI="http://macrogenics.com/role/Revenue">
        <link:definition>0000016 - Disclosure - Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensation" roleURI="http://macrogenics.com/role/StockbasedCompensation">
        <link:definition>0000017 - Disclosure - Stock-based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://macrogenics.com/role/IncomeTaxes">
        <link:definition>0000018 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlan" roleURI="http://macrogenics.com/role/EmployeeBenefitPlan">
        <link:definition>0000019 - Disclosure - Employee Benefit Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>9954472 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesTables" roleURI="http://macrogenics.com/role/MarketableSecuritiesTables">
        <link:definition>9954473 - Disclosure - Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryNetTables" roleURI="http://macrogenics.com/role/InventoryNetTables">
        <link:definition>9954474 - Disclosure - Inventory, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyEquipmentandSoftwareTables" roleURI="http://macrogenics.com/role/PropertyEquipmentandSoftwareTables">
        <link:definition>9954475 - Disclosure - Property, Equipment and Software (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesTables" roleURI="http://macrogenics.com/role/CommitmentsandContingenciesTables">
        <link:definition>9954476 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RoyaltyMonetizationArrangementTables" roleURI="http://macrogenics.com/role/RoyaltyMonetizationArrangementTables">
        <link:definition>9954477 - Disclosure - Royalty Monetization Arrangement (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationTables" roleURI="http://macrogenics.com/role/StockbasedCompensationTables">
        <link:definition>9954478 - Disclosure - Stock-based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://macrogenics.com/role/IncomeTaxesTables">
        <link:definition>9954479 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesDetails" roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesDetails">
        <link:definition>9954480 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails" roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails">
        <link:definition>9954481 - Disclosure - Summary of Significant Accounting Policies - Summary of Fair Value Measurement Financial Asset and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails" roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails">
        <link:definition>9954482 - Disclosure - Summary of Significant Accounting Policies - Summary of Collaborators that Represent More Than 10% of Total Revenue Earned and Accounts Receivable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails" roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails">
        <link:definition>9954483 - Disclosure - Summary of Significant Accounting Policies - Estimated Useful Lives (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromtheCalculationofDilutedLossPerShareDetails" roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromtheCalculationofDilutedLossPerShareDetails">
        <link:definition>9954484 - Disclosure - Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from the Calculation of Diluted Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesDetails" roleURI="http://macrogenics.com/role/MarketableSecuritiesDetails">
        <link:definition>9954485 - Disclosure - Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesAvailableForSaleSecuritiesDetails" roleURI="http://macrogenics.com/role/MarketableSecuritiesAvailableForSaleSecuritiesDetails">
        <link:definition>9954486 - Disclosure - Marketable Securities - Available-For-Sale Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryNetScheduleofInventoryDetails" roleURI="http://macrogenics.com/role/InventoryNetScheduleofInventoryDetails">
        <link:definition>9954487 - Disclosure - Inventory, Net - Schedule of Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryNetDetails" roleURI="http://macrogenics.com/role/InventoryNetDetails">
        <link:definition>9954488 - Disclosure - Inventory, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyEquipmentandSoftwareDetails" roleURI="http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails">
        <link:definition>9954489 - Disclosure - Property, Equipment and Software (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesDetails" roleURI="http://macrogenics.com/role/CommitmentsandContingenciesDetails">
        <link:definition>9954490 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RoyaltyMonetizationArrangementDetails" roleURI="http://macrogenics.com/role/RoyaltyMonetizationArrangementDetails">
        <link:definition>9954491 - Disclosure - Royalty Monetization Arrangement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RoyaltyMonetizationArrangementRollforwardDetails" roleURI="http://macrogenics.com/role/RoyaltyMonetizationArrangementRollforwardDetails">
        <link:definition>9954492 - Disclosure - Royalty Monetization Arrangement Rollforward (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDetails" roleURI="http://macrogenics.com/role/StockholdersEquityDetails">
        <link:definition>9954493 - Disclosure - Stockholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueIncyteCorporationDetails" roleURI="http://macrogenics.com/role/RevenueIncyteCorporationDetails">
        <link:definition>9954494 - Disclosure - Revenue - Incyte Corporation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueGileadSciencesIncDetails" roleURI="http://macrogenics.com/role/RevenueGileadSciencesIncDetails">
        <link:definition>9954495 - Disclosure - Revenue - Gilead Sciences Inc (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueZaiLabDetails" roleURI="http://macrogenics.com/role/RevenueZaiLabDetails">
        <link:definition>9954496 - Disclosure - Revenue - Zai Lab (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueProventionDetails" roleURI="http://macrogenics.com/role/RevenueProventionDetails">
        <link:definition>9954497 - Disclosure - Revenue - Provention (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueManufacturingServiceAgreementsDetails" roleURI="http://macrogenics.com/role/RevenueManufacturingServiceAgreementsDetails">
        <link:definition>9954498 - Disclosure - Revenue - Manufacturing Service Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueNIAIDContractDetails" roleURI="http://macrogenics.com/role/RevenueNIAIDContractDetails">
        <link:definition>9954499 - Disclosure - Revenue - NIAID Contract (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationNarrativeDetails" roleURI="http://macrogenics.com/role/StockbasedCompensationNarrativeDetails">
        <link:definition>9954500 - Disclosure - Stock-based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationStockBasedCompensationExpenseDetails" roleURI="http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails">
        <link:definition>9954501 - Disclosure - Stock-based Compensation - Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationOptionPricingAssumptionsDetails" roleURI="http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails">
        <link:definition>9954502 - Disclosure - Stock-based Compensation - Option Pricing Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails" roleURI="http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails">
        <link:definition>9954503 - Disclosure - Stock-based Compensation - Stock Option and Restricted Stock Unit Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesAdditionalInformationDetails" roleURI="http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails">
        <link:definition>9954504 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails" roleURI="http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails">
        <link:definition>9954505 - Disclosure - Income Taxes - Components of the Company's Deferred Tax Assets (Liabilities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesValuationAllowanceActivityDetails" roleURI="http://macrogenics.com/role/IncomeTaxesValuationAllowanceActivityDetails">
        <link:definition>9954506 - Disclosure - Income Taxes - Valuation Allowance Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails" roleURI="http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails">
        <link:definition>9954507 - Disclosure - Income Taxes - Reconciliation of Reported Estimated Income Tax Benefit (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesReconciliationoftheBeginningandEndingAmountofGrossUnrecognizedTaxBenefitsDetails" roleURI="http://macrogenics.com/role/IncomeTaxesReconciliationoftheBeginningandEndingAmountofGrossUnrecognizedTaxBenefitsDetails">
        <link:definition>9954508 - Disclosure - Income Taxes - Reconciliation of the Beginning and Ending Amount of Gross Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlanDetails" roleURI="http://macrogenics.com/role/EmployeeBenefitPlanDetails">
        <link:definition>9954509 - Disclosure - Employee Benefit Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="mgnx_StockIssuedDuringPeriodValueStockPlanActivity" abstract="false" name="StockIssuedDuringPeriodValueStockPlanActivity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement" abstract="false" name="PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock" abstract="false" name="CollaborationAndLicenseAgreementsDisclosureTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="mgnx_Section174DeferredTaxAsset" abstract="false" name="Section174DeferredTaxAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_IncyteMGA012AgreementMember" abstract="true" name="IncyteMGA012AgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mgnx_RevenuesFromGrantsMember" abstract="true" name="RevenuesFromGrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mgnx_PremiumReceivedOnStockPurchase" abstract="false" name="PremiumReceivedOnStockPurchase" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_ValuationAllowanceDeferredTaxAssetIncreaseAmount" abstract="false" name="ValuationAllowanceDeferredTaxAssetIncreaseAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_CommonStockMaximumAmountAvailableForIssuance" abstract="false" name="CommonStockMaximumAmountAvailableForIssuance" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_StockOptionsAndRestrictedStockUnitsMember" abstract="true" name="StockOptionsAndRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mgnx_IncyteCommercialSupplyAgreementMember" abstract="true" name="IncyteCommercialSupplyAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mgnx_LiabilityRelatedToFutureRoyaltiesAndRelatedInterestExpensePolicyTextBlock" abstract="false" name="LiabilityRelatedToFutureRoyaltiesAndRelatedInterestExpensePolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="mgnx_LiabilityRelatedToFutureRoyaltyTableTextBlock" abstract="false" name="LiabilityRelatedToFutureRoyaltyTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="mgnx_TaxYear2025To2037Member" abstract="true" name="TaxYear2025To2037Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mgnx_LiabilityRelatedToSaleOfFutureRoyaltiesTextBlock" abstract="false" name="LiabilityRelatedToSaleOfFutureRoyaltiesTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="mgnx_ScheduleOfInventoryReservesTableTextBlock" abstract="false" name="ScheduleOfInventoryReservesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="mgnx_ProventionBioMember" abstract="true" name="ProventionBioMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock" abstract="false" name="PropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="mgnx_ScheduleOfSupplementalBalanceSheetInformationOperatingLeasesTableTextBlock" abstract="false" name="ScheduleOfSupplementalBalanceSheetInformationOperatingLeasesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="mgnx_RevenuesFromLicenseAgreementsMember" abstract="true" name="RevenuesFromLicenseAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mgnx_AssetPurchaseAgreementMember" abstract="true" name="AssetPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mgnx_ProceedsfromRoyaltiesPercent" abstract="false" name="ProceedsfromRoyaltiesPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="mgnx_RightOfUseAssetAndLeaseLiabilityIncrease" abstract="false" name="RightOfUseAssetAndLeaseLiabilityIncrease" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_LiabilityRelatedToFutureRoyaltyLineItems" abstract="true" name="LiabilityRelatedToFutureRoyaltyLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mgnx_UpfrontAndFixedPayments" abstract="false" name="UpfrontAndFixedPayments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_ZaiLabLimitedMember" abstract="true" name="ZaiLabLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases" abstract="false" name="ProceedsfromStockOptionsExercisedAndESPPPurchases" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_RevenuesFromCMOAgreementsMemberMember" abstract="true" name="RevenuesFromCMOAgreementsMemberMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mgnx_IncreaseDecreaseInDeferredRent" abstract="false" name="IncreaseDecreaseInDeferredRent" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_NumberOfPerformanceObligations" abstract="false" name="NumberOfPerformanceObligations" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mgnx_IncyteCorporationMember" abstract="true" name="IncyteCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mgnx_ValuationAllowanceDeferredTaxAssetDecreaseAmount" abstract="false" name="ValuationAllowanceDeferredTaxAssetDecreaseAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_EstimatedReimbursementForResearchAndDevelopmentT" abstract="false" name="EstimatedReimbursementForResearchAndDevelopmentT" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_PotentialTargetNominationOptionFeesAndMilestonePayments" abstract="false" name="PotentialTargetNominationOptionFeesAndMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_OptInFee" abstract="false" name="OptInFee" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_LaboratoryAndOfficeEquipmentMember" abstract="true" name="LaboratoryAndOfficeEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mgnx_CostOfManufacturingServices" abstract="false" name="CostOfManufacturingServices" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_AtTheMarketOfferingMember" abstract="true" name="AtTheMarketOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mgnx_TransactionCost" abstract="false" name="TransactionCost" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_IncyteClinicalSupplyAgreementMember" abstract="true" name="IncyteClinicalSupplyAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember" abstract="true" name="TwoThousandSixteenEmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mgnx_GileadMember" abstract="true" name="GileadMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mgnx_TotalAnnualFixedPayments" abstract="false" name="TotalAnnualFixedPayments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember" abstract="true" name="McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare" abstract="false" name="CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="mgnx_NonRefundableUpfrontFees" abstract="false" name="NonRefundableUpfrontFees" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_ProceedsFromSaleOfFutureRoyalties" abstract="false" name="ProceedsFromSaleOfFutureRoyalties" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_FurnitureAndOfficeEquipmentMember" abstract="true" name="FurnitureAndOfficeEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mgnx_StockIssuedDuringPeriodSharesStockPlanActivity" abstract="false" name="StockIssuedDuringPeriodSharesStockPlanActivity" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="mgnx_GainOnRoyaltyMonetizationArrangement" abstract="false" name="GainOnRoyaltyMonetizationArrangement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" abstract="false" name="DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount" abstract="false" name="EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_RoyaltyMonetizationArrangementAbstract" abstract="true" name="RoyaltyMonetizationArrangementAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mgnx_GileadFirstResearchProgramMember" abstract="true" name="GileadFirstResearchProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" abstract="false" name="PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_NetProceedsFromSaleOfFutureRoyalties" abstract="false" name="NetProceedsFromSaleOfFutureRoyalties" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_RevenueFromCollaborativeAgreementsMember" abstract="true" name="RevenueFromCollaborativeAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" abstract="false" name="RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_ProventionPRV3279Member" abstract="true" name="ProventionPRV3279Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mgnx_IMabBiopharmaMember" abstract="true" name="IMabBiopharmaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mgnx_StockIncentivePlan2023MemberMember" abstract="true" name="StockIncentivePlan2023MemberMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_DeferredTaxAssetsOperatingLeaseLiabilities" abstract="false" name="DeferredTaxAssetsOperatingLeaseLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_ContractManufacturingMember" abstract="true" name="ContractManufacturingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mgnx_TotalPotentialValueUnderAgreement" abstract="false" name="TotalPotentialValueUnderAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_OperatingLeaseNoncashExpense" abstract="false" name="OperatingLeaseNoncashExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_AdditionalAnnualFixedPayments" abstract="false" name="AdditionalAnnualFixedPayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_UndesignatedPreferredStockMember" abstract="true" name="UndesignatedPreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mgnx_ValuationAllowanceRollForward" abstract="true" name="ValuationAllowanceRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mgnx_JeffreyPetersMember" abstract="true" name="JeffreyPetersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares" abstract="false" name="CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" abstract="false" name="EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="mgnx_StockIncentivePlan2013Member" abstract="true" name="StockIncentivePlan2013Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mgnx_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" abstract="false" name="UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_ProventionLicenseAgreementMember" abstract="true" name="ProventionLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mgnx_NumberOfProductCandidates" abstract="false" name="NumberOfProductCandidates" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mgnx_JamesKarrelsMember" abstract="true" name="JamesKarrelsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_A2022GileadCollaborationAndLicenseAgreementMember" abstract="true" name="A2022GileadCollaborationAndLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mgnx_EffectiveIncomeTaxRateReconciliationDeferredStateBlendedRateAdjustmentsAmount" abstract="false" name="EffectiveIncomeTaxRateReconciliationDeferredStateBlendedRateAdjustmentsAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan" abstract="false" name="EmployeesEligibleAgeToParticipateInBenefitPlan" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="mgnx_CardinalHealthIncMember" abstract="true" name="CardinalHealthIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_CollaborationAndLicenseAgreementsAbstract" abstract="true" name="CollaborationAndLicenseAgreementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="mgnx_PotentialCommercialMilestonePaymentsUnderAgreement" abstract="false" name="PotentialCommercialMilestonePaymentsUnderAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_CollaborativeAgreementTransactionPrice" abstract="false" name="CollaborativeAgreementTransactionPrice" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_ASDHealthcareAndOncologySupplyMember" abstract="true" name="ASDHealthcareAndOncologySupplyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mgnx_A2021ZaiLabAgreementsMember" abstract="true" name="A2021ZaiLabAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mgnx_RevenuesFromCMOAmendmentAgreementMember" abstract="true" name="RevenuesFromCMOAmendmentAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mgnx_ProventionBioCMOAgreeemntMember" abstract="true" name="ProventionBioCMOAgreeemntMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mgnx_RevenueFromGovernmentAgreementsMember" abstract="true" name="RevenueFromGovernmentAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mgnx_FutureRevenue" abstract="false" name="FutureRevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_AuditorInformationAbstract" abstract="true" name="AuditorInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" abstract="true" name="NationalInstituteOfAllergyAndInfectiousDiseasesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mgnx_DRIHealthcareAcquisitionsLPDRIMember" abstract="true" name="DRIHealthcareAcquisitionsLPDRIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage" abstract="false" name="DefinedContributionPlanEmployeesContributionVestedPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="mgnx_SynaffixBVMember" abstract="true" name="SynaffixBVMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mgnx_ZaiLabMember" abstract="true" name="ZaiLabMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mgnx_RevenueFromRoyalityAgreementsMemberMember" abstract="true" name="RevenueFromRoyalityAgreementsMemberMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" abstract="false" name="DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount" abstract="false" name="EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_DeferredTransactionCosts" abstract="false" name="DeferredTransactionCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_RoyaltyMonetizationArrangementTable" abstract="true" name="RoyaltyMonetizationArrangementTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease" abstract="false" name="CommonStockMaximumAmountAvailableForIssuanceIncrease" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_CollaborativeArrangementTerm" abstract="false" name="CollaborativeArrangementTerm" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="mgnx_LiabilityRelatedToFutureRoyalties" abstract="false" name="LiabilityRelatedToFutureRoyalties" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_IndefiniteMember" abstract="true" name="IndefiniteMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember" abstract="true" name="DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mgnx_ProventionPRV031Member" abstract="true" name="ProventionPRV031Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mgnx_NonCashInterestExpenseRecognized" abstract="false" name="NonCashInterestExpenseRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_IncreaseDecreaseInLeaseLiabilities" abstract="false" name="IncreaseDecreaseInLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_CollaborativeArrangementExtensionTerm" abstract="false" name="CollaborativeArrangementExtensionTerm" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="mgnx_UpfrontPayment" abstract="false" name="UpfrontPayment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_PrincipalPaymentsOnRoyaltyMonetizationArrangement" abstract="false" name="PrincipalPaymentsOnRoyaltyMonetizationArrangement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>13
<FILENAME>mgnx-20231231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:8dbce59b-e7cb-41de-8446-707f712a2a92,g:3e6229e4-32a7-4caa-a132-cb74eb6cd115-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="mgnx-20231231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_36698c5a-62d6-414b-bc4e-aa2ea5bf88db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_2f30e232-2a26-4b50-a513-b3f67e8fc288" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_36698c5a-62d6-414b-bc4e-aa2ea5bf88db" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_2f30e232-2a26-4b50-a513-b3f67e8fc288" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_284e30e4-0f67-465e-aea2-5ba692d7eee0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_36698c5a-62d6-414b-bc4e-aa2ea5bf88db" xlink:to="loc_us-gaap_AssetsCurrent_284e30e4-0f67-465e-aea2-5ba692d7eee0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_9d7c3531-4e7d-46ff-8930-69bd12e667f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_36698c5a-62d6-414b-bc4e-aa2ea5bf88db" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_9d7c3531-4e7d-46ff-8930-69bd12e667f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_39eaf6cf-b189-4daa-bc93-706a01033b8d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_36698c5a-62d6-414b-bc4e-aa2ea5bf88db" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_39eaf6cf-b189-4daa-bc93-706a01033b8d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_079ae1ba-d39d-49c1-89e5-87f81764338d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_ac8aed45-45a8-42a7-9060-8e9d3d24d381" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_079ae1ba-d39d-49c1-89e5-87f81764338d" xlink:to="loc_us-gaap_CommonStockValue_ac8aed45-45a8-42a7-9060-8e9d3d24d381" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_28b50509-a1e0-47cb-8751-3b929a310401" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_079ae1ba-d39d-49c1-89e5-87f81764338d" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_28b50509-a1e0-47cb-8751-3b929a310401" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_7cb361c9-d050-4444-ae32-91f9cb048ba4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_079ae1ba-d39d-49c1-89e5-87f81764338d" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_7cb361c9-d050-4444-ae32-91f9cb048ba4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4a813774-b575-4042-bbec-7f2e7aa49964" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_079ae1ba-d39d-49c1-89e5-87f81764338d" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4a813774-b575-4042-bbec-7f2e7aa49964" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_f1029540-6343-46e8-8c46-70ceb3e7ec7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_2df6d5d7-40ab-484c-a119-531666d9678a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f1029540-6343-46e8-8c46-70ceb3e7ec7b" xlink:to="loc_us-gaap_AccountsPayableCurrent_2df6d5d7-40ab-484c-a119-531666d9678a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_f91eb5ff-ce25-4a36-ae45-9f2ffc573a15" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f1029540-6343-46e8-8c46-70ceb3e7ec7b" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_f91eb5ff-ce25-4a36-ae45-9f2ffc573a15" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueCurrent_51954c58-ce3d-40af-88e5-60b4d979152b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f1029540-6343-46e8-8c46-70ceb3e7ec7b" xlink:to="loc_us-gaap_DeferredRevenueCurrent_51954c58-ce3d-40af-88e5-60b4d979152b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_87f21484-a876-40d7-871c-51066ff4e06c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f1029540-6343-46e8-8c46-70ceb3e7ec7b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_87f21484-a876-40d7-871c-51066ff4e06c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_4432e6e0-21e9-4a3a-af92-b7d30746fc3d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_2affa402-f99c-453d-8da3-667e214388f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_4432e6e0-21e9-4a3a-af92-b7d30746fc3d" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_2affa402-f99c-453d-8da3-667e214388f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_ddda8005-d0d8-4635-bdbb-343a91eeaee1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_4432e6e0-21e9-4a3a-af92-b7d30746fc3d" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_ddda8005-d0d8-4635-bdbb-343a91eeaee1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_5cda8ba2-b107-4b53-b4b6-c481f1e73dd1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_4432e6e0-21e9-4a3a-af92-b7d30746fc3d" xlink:to="loc_us-gaap_LiabilitiesCurrent_5cda8ba2-b107-4b53-b4b6-c481f1e73dd1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_ddfe77f4-606b-42d4-a77d-e1ab1f46e8d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_4432e6e0-21e9-4a3a-af92-b7d30746fc3d" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_ddfe77f4-606b-42d4-a77d-e1ab1f46e8d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_f11445b2-f6cf-421d-abf4-c4b1c5311d1f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_2d2cf66f-4166-4118-8131-e417c2842e73" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f11445b2-f6cf-421d-abf4-c4b1c5311d1f" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_2d2cf66f-4166-4118-8131-e417c2842e73" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_6286ef1c-62cc-4900-b87d-47c485bbddfc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f11445b2-f6cf-421d-abf4-c4b1c5311d1f" xlink:to="loc_us-gaap_InventoryNet_6286ef1c-62cc-4900-b87d-47c485bbddfc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments_753e3fa3-1c0d-4826-adab-b182fdb1cef5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Investments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f11445b2-f6cf-421d-abf4-c4b1c5311d1f" xlink:to="loc_us-gaap_Investments_753e3fa3-1c0d-4826-adab-b182fdb1cef5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_32428bbf-615e-477c-8b16-fa969b8e0f7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f11445b2-f6cf-421d-abf4-c4b1c5311d1f" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_32428bbf-615e-477c-8b16-fa969b8e0f7e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4b60bb38-fc9e-483c-adef-fde7fb6e9507" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f11445b2-f6cf-421d-abf4-c4b1c5311d1f" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4b60bb38-fc9e-483c-adef-fde7fb6e9507" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_00f5fa2b-faad-4351-8832-3609b682e93e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_adcc640e-18fc-4f0f-b1c1-1153d89c15f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_00f5fa2b-faad-4351-8832-3609b682e93e" xlink:to="loc_us-gaap_Liabilities_adcc640e-18fc-4f0f-b1c1-1153d89c15f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f3de6aee-b2d5-4760-be80-816506e86ef4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_00f5fa2b-faad-4351-8832-3609b682e93e" xlink:to="loc_us-gaap_StockholdersEquity_f3de6aee-b2d5-4760-be80-816506e86ef4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="mgnx-20231231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_79403010-91df-4e27-b02d-f5c9fa88cf66" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_GainOnRoyaltyMonetizationArrangement_d3feed02-5876-4d3e-94c8-513c62a18329" xlink:href="mgnx-20231231.xsd#mgnx_GainOnRoyaltyMonetizationArrangement"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_79403010-91df-4e27-b02d-f5c9fa88cf66" xlink:to="loc_mgnx_GainOnRoyaltyMonetizationArrangement_d3feed02-5876-4d3e-94c8-513c62a18329" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_2e77baf4-cfca-480c-b345-2a895a27991e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_79403010-91df-4e27-b02d-f5c9fa88cf66" xlink:to="loc_us-gaap_OperatingIncomeLoss_2e77baf4-cfca-480c-b345-2a895a27991e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_6f03649f-d20f-4625-9aa8-61209d7c2be3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_79403010-91df-4e27-b02d-f5c9fa88cf66" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_6f03649f-d20f-4625-9aa8-61209d7c2be3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_45a097a2-2832-4f8c-85c0-dcb0155f0825" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_79403010-91df-4e27-b02d-f5c9fa88cf66" xlink:to="loc_us-gaap_InterestExpense_45a097a2-2832-4f8c-85c0-dcb0155f0825" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_aa4ad569-8cb0-4758-9934-0e7cc01ed5e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_7c682583-b4c7-4242-bd49-433e01dca7fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_aa4ad569-8cb0-4758-9934-0e7cc01ed5e1" xlink:to="loc_us-gaap_Revenues_7c682583-b4c7-4242-bd49-433e01dca7fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_a62e9cbc-2ddc-40ba-8c85-38c193c4bb26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_aa4ad569-8cb0-4758-9934-0e7cc01ed5e1" xlink:to="loc_us-gaap_CostsAndExpenses_a62e9cbc-2ddc-40ba-8c85-38c193c4bb26" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_57441d48-b587-4d57-baaf-4b03a20017b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1f9bcd41-e8f0-4826-b949-457ecb2726ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_57441d48-b587-4d57-baaf-4b03a20017b8" xlink:to="loc_us-gaap_NetIncomeLoss_1f9bcd41-e8f0-4826-b949-457ecb2726ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_42c91dbd-d08d-4ec8-a710-2073420454eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_57441d48-b587-4d57-baaf-4b03a20017b8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_42c91dbd-d08d-4ec8-a710-2073420454eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_6e6b4b33-35ea-469e-9e2d-28b5cade5e2b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CostOfManufacturingServices_785ac066-9e46-43e9-8578-b3ba39a16d29" xlink:href="mgnx-20231231.xsd#mgnx_CostOfManufacturingServices"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_6e6b4b33-35ea-469e-9e2d-28b5cade5e2b" xlink:to="loc_mgnx_CostOfManufacturingServices_785ac066-9e46-43e9-8578-b3ba39a16d29" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_3b81f13f-a22b-4ebc-b539-24a68912b6c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_6e6b4b33-35ea-469e-9e2d-28b5cade5e2b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_3b81f13f-a22b-4ebc-b539-24a68912b6c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_eac804bd-c84a-4fff-810e-e71ca96663c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_6e6b4b33-35ea-469e-9e2d-28b5cade5e2b" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_eac804bd-c84a-4fff-810e-e71ca96663c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_fd062c2d-4dba-43c4-8274-501b69947ce0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_6e6b4b33-35ea-469e-9e2d-28b5cade5e2b" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_fd062c2d-4dba-43c4-8274-501b69947ce0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="mgnx-20231231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_67610145-d397-4a42-8a21-8d4f25e15ca5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_b8b8694a-2a89-4efb-bac5-36539d208b82" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_67610145-d397-4a42-8a21-8d4f25e15ca5" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_b8b8694a-2a89-4efb-bac5-36539d208b82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_OperatingLeaseNoncashExpense_f06688bd-1130-4e6b-8f94-74208fabc7b6" xlink:href="mgnx-20231231.xsd#mgnx_OperatingLeaseNoncashExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_67610145-d397-4a42-8a21-8d4f25e15ca5" xlink:to="loc_mgnx_OperatingLeaseNoncashExpense_f06688bd-1130-4e6b-8f94-74208fabc7b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_9da9b783-4b1c-4f6b-be4d-157d677ac926" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_67610145-d397-4a42-8a21-8d4f25e15ca5" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_9da9b783-4b1c-4f6b-be4d-157d677ac926" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_c7721a4e-32a2-49bf-bb31-e0a8c0c3bf0b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_67610145-d397-4a42-8a21-8d4f25e15ca5" xlink:to="loc_us-gaap_ShareBasedCompensation_c7721a4e-32a2-49bf-bb31-e0a8c0c3bf0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonCashInterestExpenseRecognized_e2c439c9-5c67-4029-b9bd-270f53182f9a" xlink:href="mgnx-20231231.xsd#mgnx_NonCashInterestExpenseRecognized"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_67610145-d397-4a42-8a21-8d4f25e15ca5" xlink:to="loc_mgnx_NonCashInterestExpenseRecognized_e2c439c9-5c67-4029-b9bd-270f53182f9a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_6ed209fd-6d93-4188-beac-fcc97af68d3b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_67610145-d397-4a42-8a21-8d4f25e15ca5" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_6ed209fd-6d93-4188-beac-fcc97af68d3b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_379da971-dd83-416c-bab8-dc2f0b8a3b23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_67610145-d397-4a42-8a21-8d4f25e15ca5" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_379da971-dd83-416c-bab8-dc2f0b8a3b23" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_a6891997-dad7-4190-8761-14ba5f07569a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_67610145-d397-4a42-8a21-8d4f25e15ca5" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_a6891997-dad7-4190-8761-14ba5f07569a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncreaseDecreaseInLeaseLiabilities_0bd557da-c0eb-46bd-902e-7970ecf04317" xlink:href="mgnx-20231231.xsd#mgnx_IncreaseDecreaseInLeaseLiabilities"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_67610145-d397-4a42-8a21-8d4f25e15ca5" xlink:to="loc_mgnx_IncreaseDecreaseInLeaseLiabilities_0bd557da-c0eb-46bd-902e-7970ecf04317" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_673ad3f9-27e5-4734-8674-27accc2f1387" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_67610145-d397-4a42-8a21-8d4f25e15ca5" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_673ad3f9-27e5-4734-8674-27accc2f1387" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_GainOnRoyaltyMonetizationArrangement_340bd845-1b97-41c2-9556-3ff8e9614751" xlink:href="mgnx-20231231.xsd#mgnx_GainOnRoyaltyMonetizationArrangement"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_67610145-d397-4a42-8a21-8d4f25e15ca5" xlink:to="loc_mgnx_GainOnRoyaltyMonetizationArrangement_340bd845-1b97-41c2-9556-3ff8e9614751" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_4bf26454-71d2-4f3c-9325-c26c9c14a1f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_67610145-d397-4a42-8a21-8d4f25e15ca5" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_4bf26454-71d2-4f3c-9325-c26c9c14a1f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_fdf74195-1ac4-464a-a4ba-90ecadb77757" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_67610145-d397-4a42-8a21-8d4f25e15ca5" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_fdf74195-1ac4-464a-a4ba-90ecadb77757" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_6bb6e48a-d7a1-4c5d-8f58-60ed4f03f444" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_67610145-d397-4a42-8a21-8d4f25e15ca5" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_6bb6e48a-d7a1-4c5d-8f58-60ed4f03f444" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6f781501-7a91-408a-a5eb-e14433ee0bcf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_67610145-d397-4a42-8a21-8d4f25e15ca5" xlink:to="loc_us-gaap_NetIncomeLoss_6f781501-7a91-408a-a5eb-e14433ee0bcf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncreaseDecreaseInDeferredRent_11d01b3f-c922-4ed1-83c3-fbe6fd194773" xlink:href="mgnx-20231231.xsd#mgnx_IncreaseDecreaseInDeferredRent"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_67610145-d397-4a42-8a21-8d4f25e15ca5" xlink:to="loc_mgnx_IncreaseDecreaseInDeferredRent_11d01b3f-c922-4ed1-83c3-fbe6fd194773" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets_404044fa-5b28-4bfe-9cf6-67bc90b7288e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <link:calculationArc order="17" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_67610145-d397-4a42-8a21-8d4f25e15ca5" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets_404044fa-5b28-4bfe-9cf6-67bc90b7288e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_60254003-752f-410a-b7d0-4ffa49dd09f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="18" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_67610145-d397-4a42-8a21-8d4f25e15ca5" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_60254003-752f-410a-b7d0-4ffa49dd09f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_df3d1d2c-72ec-4667-ad6c-dd82755e9fab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_70d94bd6-29b9-4c59-a8be-1450101d6690" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_df3d1d2c-72ec-4667-ad6c-dd82755e9fab" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_70d94bd6-29b9-4c59-a8be-1450101d6690" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f1303c28-c41e-49c1-a34d-7206561fbeeb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_df3d1d2c-72ec-4667-ad6c-dd82755e9fab" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f1303c28-c41e-49c1-a34d-7206561fbeeb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_381c6672-29cd-46ef-97e9-76472ea7c5ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_df3d1d2c-72ec-4667-ad6c-dd82755e9fab" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_381c6672-29cd-46ef-97e9-76472ea7c5ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9b5338db-afc2-4fa8-b901-00fe4d61dac8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_c00793ce-ffc6-404e-8ee7-65ba7114f620" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9b5338db-afc2-4fa8-b901-00fe4d61dac8" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_c00793ce-ffc6-404e-8ee7-65ba7114f620" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfMachineryAndEquipment_2258c9ad-c311-4ac2-9732-c1ec00c0aec0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfMachineryAndEquipment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9b5338db-afc2-4fa8-b901-00fe4d61dac8" xlink:to="loc_us-gaap_ProceedsFromSaleOfMachineryAndEquipment_2258c9ad-c311-4ac2-9732-c1ec00c0aec0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_2591b116-8a38-4b26-b57c-247b14faab23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9b5338db-afc2-4fa8-b901-00fe4d61dac8" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_2591b116-8a38-4b26-b57c-247b14faab23" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_d36b1e64-0d8a-4db4-9c6f-e12737035f03" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9b5338db-afc2-4fa8-b901-00fe4d61dac8" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_d36b1e64-0d8a-4db4-9c6f-e12737035f03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7ec90469-b8fc-4d67-8668-54a501b97418" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PrincipalPaymentsOnRoyaltyMonetizationArrangement_034aa63d-5474-4037-aecb-b50077589995" xlink:href="mgnx-20231231.xsd#mgnx_PrincipalPaymentsOnRoyaltyMonetizationArrangement"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7ec90469-b8fc-4d67-8668-54a501b97418" xlink:to="loc_mgnx_PrincipalPaymentsOnRoyaltyMonetizationArrangement_034aa63d-5474-4037-aecb-b50077589995" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_228cbc36-242b-4a13-af0a-8d7cd433732c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7ec90469-b8fc-4d67-8668-54a501b97418" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_228cbc36-242b-4a13-af0a-8d7cd433732c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NetProceedsFromSaleOfFutureRoyalties_88a769b4-76eb-4aed-802b-6d9f3359b2ca" xlink:href="mgnx-20231231.xsd#mgnx_NetProceedsFromSaleOfFutureRoyalties"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7ec90469-b8fc-4d67-8668-54a501b97418" xlink:to="loc_mgnx_NetProceedsFromSaleOfFutureRoyalties_88a769b4-76eb-4aed-802b-6d9f3359b2ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases_9dab3a4a-759f-4c89-86d3-5ef9a06474cd" xlink:href="mgnx-20231231.xsd#mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7ec90469-b8fc-4d67-8668-54a501b97418" xlink:to="loc_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases_9dab3a4a-759f-4c89-86d3-5ef9a06474cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_7b8be5be-15d0-4046-8e37-c3aca54f34e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7ec90469-b8fc-4d67-8668-54a501b97418" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_7b8be5be-15d0-4046-8e37-c3aca54f34e5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails" xlink:type="simple" xlink:href="mgnx-20231231.xsd#SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_1baa1d9c-6459-4e90-9dc4-b643e2e5de42" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_b62884f3-6df8-4a55-8795-03aa8fca4eed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_1baa1d9c-6459-4e90-9dc4-b643e2e5de42" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_b62884f3-6df8-4a55-8795-03aa8fca4eed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5c696cf6-ab45-42d6-aaed-dd8d22f164d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_1baa1d9c-6459-4e90-9dc4-b643e2e5de42" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5c696cf6-ab45-42d6-aaed-dd8d22f164d2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecuritiesDetails" xlink:type="simple" xlink:href="mgnx-20231231.xsd#MarketableSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/MarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_9087a5fb-e789-4647-9012-c2d319d26c85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_8bd89eda-ddec-495b-9a98-ddc94b9c6357" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_9087a5fb-e789-4647-9012-c2d319d26c85" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_8bd89eda-ddec-495b-9a98-ddc94b9c6357" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_8c546f90-3984-4916-9210-5745913153d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_9087a5fb-e789-4647-9012-c2d319d26c85" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_8c546f90-3984-4916-9210-5745913153d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_31fa97c2-547e-4fb7-b97c-ba146d6e685d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_9087a5fb-e789-4647-9012-c2d319d26c85" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_31fa97c2-547e-4fb7-b97c-ba146d6e685d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails" xlink:type="simple" xlink:href="mgnx-20231231.xsd#PropertyEquipmentandSoftwareDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_5877007c-ec9a-4310-a0f9-dc95d3855ee0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_2bbc83a4-edfa-4908-ae5b-9dc8e912f46f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_5877007c-ec9a-4310-a0f9-dc95d3855ee0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_2bbc83a4-edfa-4908-ae5b-9dc8e912f46f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_318eb6a8-776b-4680-8dfa-7ebf055e0e3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_5877007c-ec9a-4310-a0f9-dc95d3855ee0" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_318eb6a8-776b-4680-8dfa-7ebf055e0e3c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails" xlink:type="simple" xlink:href="mgnx-20231231.xsd#IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_0ce2487a-77c7-4546-998f-907664106b9d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_bba7b700-0112-4682-87c4-ce878ffe8173" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_0ce2487a-77c7-4546-998f-907664106b9d" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_bba7b700-0112-4682-87c4-ce878ffe8173" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_e3782390-4480-4e82-b17c-7597441811f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_0ce2487a-77c7-4546-998f-907664106b9d" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_e3782390-4480-4e82-b17c-7597441811f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_6c75e4c4-0d9b-4f87-9e6a-e3ff0c31deb5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_3b780475-df47-4cb6-9da5-2bb788b5f589" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_6c75e4c4-0d9b-4f87-9e6a-e3ff0c31deb5" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_3b780475-df47-4cb6-9da5-2bb788b5f589" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_e86a9271-e5cb-4af4-8c69-ebd1ba145597" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_6c75e4c4-0d9b-4f87-9e6a-e3ff0c31deb5" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_e86a9271-e5cb-4af4-8c69-ebd1ba145597" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_fd646ebe-5c1c-42ef-9579-00e96b70f45c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_6c75e4c4-0d9b-4f87-9e6a-e3ff0c31deb5" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_fd646ebe-5c1c-42ef-9579-00e96b70f45c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_Section174DeferredTaxAsset_15558346-a96a-4411-bcd1-5dcedf6bcad4" xlink:href="mgnx-20231231.xsd#mgnx_Section174DeferredTaxAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_6c75e4c4-0d9b-4f87-9e6a-e3ff0c31deb5" xlink:to="loc_mgnx_Section174DeferredTaxAsset_15558346-a96a-4411-bcd1-5dcedf6bcad4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_f8e77b89-4c18-4b10-8762-e75a8d877be6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_6c75e4c4-0d9b-4f87-9e6a-e3ff0c31deb5" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_f8e77b89-4c18-4b10-8762-e75a8d877be6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_9076997d-0626-4db5-90db-a7ce70315eff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_6c75e4c4-0d9b-4f87-9e6a-e3ff0c31deb5" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_9076997d-0626-4db5-90db-a7ce70315eff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther_78aa1f49-1e9b-48ae-aa8d-4410656c6d4a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_6c75e4c4-0d9b-4f87-9e6a-e3ff0c31deb5" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther_78aa1f49-1e9b-48ae-aa8d-4410656c6d4a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DeferredTaxAssetsOperatingLeaseLiabilities_4276de20-f845-4f33-91e2-4d0e38fbdfbd" xlink:href="mgnx-20231231.xsd#mgnx_DeferredTaxAssetsOperatingLeaseLiabilities"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_6c75e4c4-0d9b-4f87-9e6a-e3ff0c31deb5" xlink:to="loc_mgnx_DeferredTaxAssetsOperatingLeaseLiabilities_4276de20-f845-4f33-91e2-4d0e38fbdfbd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_f43afee6-51a7-425d-99d0-6bcd83c9b432" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_6c75e4c4-0d9b-4f87-9e6a-e3ff0c31deb5" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_f43afee6-51a7-425d-99d0-6bcd83c9b432" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_90694e05-c75c-4b0c-a190-c7e26a13243e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_b8de834b-2a91-44c7-b691-e2f6f02e0da6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_90694e05-c75c-4b0c-a190-c7e26a13243e" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_b8de834b-2a91-44c7-b691-e2f6f02e0da6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_7bcdd4a1-92d3-4609-8037-2bb0da49f11d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_90694e05-c75c-4b0c-a190-c7e26a13243e" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_7bcdd4a1-92d3-4609-8037-2bb0da49f11d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_7cee0d31-5e2b-4e25-bf22-192be8086569" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_1d339f57-7548-4a01-bf2b-6a237fe6e528" xlink:href="mgnx-20231231.xsd#mgnx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_7cee0d31-5e2b-4e25-bf22-192be8086569" xlink:to="loc_mgnx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_1d339f57-7548-4a01-bf2b-6a237fe6e528" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_ad4845b3-f708-4975-8910-f02b3b4e1da4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_7cee0d31-5e2b-4e25-bf22-192be8086569" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_ad4845b3-f708-4975-8910-f02b3b4e1da4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails" xlink:type="simple" xlink:href="mgnx-20231231.xsd#IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_43a0fb16-c041-4c37-b37a-d3b9d54a1869" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_62852c74-13ea-448f-a1fb-c625953f80a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_43a0fb16-c041-4c37-b37a-d3b9d54a1869" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_62852c74-13ea-448f-a1fb-c625953f80a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_8db4f698-6f80-4d8a-81be-e025511ed178" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_43a0fb16-c041-4c37-b37a-d3b9d54a1869" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_8db4f698-6f80-4d8a-81be-e025511ed178" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount_ce541885-e124-4f80-9b61-88c91867f0d8" xlink:href="mgnx-20231231.xsd#mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_43a0fb16-c041-4c37-b37a-d3b9d54a1869" xlink:to="loc_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount_ce541885-e124-4f80-9b61-88c91867f0d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_004b03e2-9dd7-4d53-9ee6-2776a9db9adb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_43a0fb16-c041-4c37-b37a-d3b9d54a1869" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_004b03e2-9dd7-4d53-9ee6-2776a9db9adb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount_fe6383c7-8d20-49ed-b801-a61a51fb3448" xlink:href="mgnx-20231231.xsd#mgnx_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_43a0fb16-c041-4c37-b37a-d3b9d54a1869" xlink:to="loc_mgnx_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount_fe6383c7-8d20-49ed-b801-a61a51fb3448" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_00462ea4-fe5d-4631-a7b7-82ab60026b23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_43a0fb16-c041-4c37-b37a-d3b9d54a1869" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_00462ea4-fe5d-4631-a7b7-82ab60026b23" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_f82767f8-b515-4ebd-adca-d28e32524e90" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_43a0fb16-c041-4c37-b37a-d3b9d54a1869" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_f82767f8-b515-4ebd-adca-d28e32524e90" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_6f2ee057-0035-48e3-9eb1-9ba82dd9060c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_43a0fb16-c041-4c37-b37a-d3b9d54a1869" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_6f2ee057-0035-48e3-9eb1-9ba82dd9060c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EffectiveIncomeTaxRateReconciliationDeferredStateBlendedRateAdjustmentsAmount_54cf0399-ec22-41c1-b884-fbe0b327f0c3" xlink:href="mgnx-20231231.xsd#mgnx_EffectiveIncomeTaxRateReconciliationDeferredStateBlendedRateAdjustmentsAmount"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_43a0fb16-c041-4c37-b37a-d3b9d54a1869" xlink:to="loc_mgnx_EffectiveIncomeTaxRateReconciliationDeferredStateBlendedRateAdjustmentsAmount_54cf0399-ec22-41c1-b884-fbe0b327f0c3" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>14
<FILENAME>mgnx-20231231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:8dbce59b-e7cb-41de-8446-707f712a2a92,g:3e6229e4-32a7-4caa-a132-cb74eb6cd115-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="mgnx-20231231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_fde490db-5143-47a8-b7ba-066991bc2495" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ec44c3f6-0c45-499a-9178-6adaf288df75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_fde490db-5143-47a8-b7ba-066991bc2495" xlink:to="loc_us-gaap_StatementTable_ec44c3f6-0c45-499a-9178-6adaf288df75" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_67c41ae7-48ad-4ad3-a403-c3b1079e4da8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_ec44c3f6-0c45-499a-9178-6adaf288df75" xlink:to="loc_srt_ProductOrServiceAxis_67c41ae7-48ad-4ad3-a403-c3b1079e4da8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_67c41ae7-48ad-4ad3-a403-c3b1079e4da8_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_67c41ae7-48ad-4ad3-a403-c3b1079e4da8" xlink:to="loc_srt_ProductsAndServicesDomain_67c41ae7-48ad-4ad3-a403-c3b1079e4da8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_08911c99-a8ac-4fee-aa36-01d29cd5dbf4" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_67c41ae7-48ad-4ad3-a403-c3b1079e4da8" xlink:to="loc_srt_ProductsAndServicesDomain_08911c99-a8ac-4fee-aa36-01d29cd5dbf4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromCollaborativeAgreementsMember_b60040ac-33ff-4058-b7f3-60a0c24a08ac" xlink:href="mgnx-20231231.xsd#mgnx_RevenueFromCollaborativeAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_08911c99-a8ac-4fee-aa36-01d29cd5dbf4" xlink:to="loc_mgnx_RevenueFromCollaborativeAgreementsMember_b60040ac-33ff-4058-b7f3-60a0c24a08ac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromGovernmentAgreementsMember_7cf98039-2e4a-4bd5-8e0e-6d7d652580ff" xlink:href="mgnx-20231231.xsd#mgnx_RevenueFromGovernmentAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_08911c99-a8ac-4fee-aa36-01d29cd5dbf4" xlink:to="loc_mgnx_RevenueFromGovernmentAgreementsMember_7cf98039-2e4a-4bd5-8e0e-6d7d652580ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_6396f28d-b5e7-4add-bb9c-c5aedc132b78" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_08911c99-a8ac-4fee-aa36-01d29cd5dbf4" xlink:to="loc_us-gaap_ProductMember_6396f28d-b5e7-4add-bb9c-c5aedc132b78" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ContractManufacturingMember_b8cbbbb4-8342-483d-b7d5-bde58d697200" xlink:href="mgnx-20231231.xsd#mgnx_ContractManufacturingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_08911c99-a8ac-4fee-aa36-01d29cd5dbf4" xlink:to="loc_mgnx_ContractManufacturingMember_b8cbbbb4-8342-483d-b7d5-bde58d697200" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromRoyalityAgreementsMemberMember_3b655484-c0cf-459f-853d-e67ef2716991" xlink:href="mgnx-20231231.xsd#mgnx_RevenueFromRoyalityAgreementsMemberMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_08911c99-a8ac-4fee-aa36-01d29cd5dbf4" xlink:to="loc_mgnx_RevenueFromRoyalityAgreementsMemberMember_3b655484-c0cf-459f-853d-e67ef2716991" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_46baf2c6-5845-45cd-a98c-abb33ce3396b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_fde490db-5143-47a8-b7ba-066991bc2495" xlink:to="loc_us-gaap_RevenuesAbstract_46baf2c6-5845-45cd-a98c-abb33ce3396b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_6b8a4d7f-8e74-4c49-8167-0ecbb992623e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_46baf2c6-5845-45cd-a98c-abb33ce3396b" xlink:to="loc_us-gaap_Revenues_6b8a4d7f-8e74-4c49-8167-0ecbb992623e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_4ff953c1-f463-433a-b99b-0d1fbb4bcc92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_fde490db-5143-47a8-b7ba-066991bc2495" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_4ff953c1-f463-433a-b99b-0d1fbb4bcc92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_4051f614-df86-47c3-89b5-9b4c8505407b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_4ff953c1-f463-433a-b99b-0d1fbb4bcc92" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_4051f614-df86-47c3-89b5-9b4c8505407b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CostOfManufacturingServices_8df1e4bd-ce87-408c-8b6e-05b0862f3da6" xlink:href="mgnx-20231231.xsd#mgnx_CostOfManufacturingServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_4ff953c1-f463-433a-b99b-0d1fbb4bcc92" xlink:to="loc_mgnx_CostOfManufacturingServices_8df1e4bd-ce87-408c-8b6e-05b0862f3da6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_1f58a1cb-bb3d-4c07-930e-a46429f849ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_4ff953c1-f463-433a-b99b-0d1fbb4bcc92" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_1f58a1cb-bb3d-4c07-930e-a46429f849ec" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_48445ae5-eccf-47f7-908c-cf097784c6f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_4ff953c1-f463-433a-b99b-0d1fbb4bcc92" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_48445ae5-eccf-47f7-908c-cf097784c6f0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_cb1b1512-081c-4b97-82ba-64838fdd63ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_4ff953c1-f463-433a-b99b-0d1fbb4bcc92" xlink:to="loc_us-gaap_CostsAndExpenses_cb1b1512-081c-4b97-82ba-64838fdd63ff" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_44198d1d-63e0-4ccf-81dd-601d09aebfdc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_fde490db-5143-47a8-b7ba-066991bc2495" xlink:to="loc_us-gaap_OperatingIncomeLoss_44198d1d-63e0-4ccf-81dd-601d09aebfdc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_GainOnRoyaltyMonetizationArrangement_6f85ddad-20c5-4064-b468-bfe3451c1a02" xlink:href="mgnx-20231231.xsd#mgnx_GainOnRoyaltyMonetizationArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_fde490db-5143-47a8-b7ba-066991bc2495" xlink:to="loc_mgnx_GainOnRoyaltyMonetizationArrangement_6f85ddad-20c5-4064-b468-bfe3451c1a02" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_4f72eebc-6586-444d-aaab-ff2e289c3418" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_fde490db-5143-47a8-b7ba-066991bc2495" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_4f72eebc-6586-444d-aaab-ff2e289c3418" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_889ad33f-a047-4844-a0fe-11b38971e5bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_fde490db-5143-47a8-b7ba-066991bc2495" xlink:to="loc_us-gaap_InterestExpense_889ad33f-a047-4844-a0fe-11b38971e5bf" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_4592fe69-0f94-4cd7-a439-7556705dd801" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_fde490db-5143-47a8-b7ba-066991bc2495" xlink:to="loc_us-gaap_NetIncomeLoss_4592fe69-0f94-4cd7-a439-7556705dd801" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_5b4d200a-ce8f-4359-8bf5-a46b0198cf53" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_fde490db-5143-47a8-b7ba-066991bc2495" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_5b4d200a-ce8f-4359-8bf5-a46b0198cf53" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_0a2c5704-41bd-40ec-94e8-63d46f027a7a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_5b4d200a-ce8f-4359-8bf5-a46b0198cf53" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_0a2c5704-41bd-40ec-94e8-63d46f027a7a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_508440d3-120e-4423-acde-440256600aeb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_5b4d200a-ce8f-4359-8bf5-a46b0198cf53" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_508440d3-120e-4423-acde-440256600aeb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_4f78a284-263f-4d83-82d2-f5e232a8d987" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_fde490db-5143-47a8-b7ba-066991bc2495" xlink:to="loc_us-gaap_EarningsPerShareBasic_4f78a284-263f-4d83-82d2-f5e232a8d987" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_e82cdb0d-c5b4-497c-98a5-bb79eff21b32" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_fde490db-5143-47a8-b7ba-066991bc2495" xlink:to="loc_us-gaap_EarningsPerShareDiluted_e82cdb0d-c5b4-497c-98a5-bb79eff21b32" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c9e9cf31-76dc-407c-a4e5-f17da37ba53f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_fde490db-5143-47a8-b7ba-066991bc2495" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c9e9cf31-76dc-407c-a4e5-f17da37ba53f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_685028d2-c952-4eb2-a06d-46147640a3b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_fde490db-5143-47a8-b7ba-066991bc2495" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_685028d2-c952-4eb2-a06d-46147640a3b6" xlink:type="arc" order="11"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="mgnx-20231231.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_9b6498b3-b6d0-4c97-b132-51194864d6fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_a39f87dd-5933-4ced-ac7d-b49a0fc6b23a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_9b6498b3-b6d0-4c97-b132-51194864d6fa" xlink:to="loc_us-gaap_StatementTable_a39f87dd-5933-4ced-ac7d-b49a0fc6b23a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_87d09e4b-df48-4fa2-8634-1a82f31cf085" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_a39f87dd-5933-4ced-ac7d-b49a0fc6b23a" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_87d09e4b-df48-4fa2-8634-1a82f31cf085" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_87d09e4b-df48-4fa2-8634-1a82f31cf085_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_87d09e4b-df48-4fa2-8634-1a82f31cf085" xlink:to="loc_us-gaap_EquityComponentDomain_87d09e4b-df48-4fa2-8634-1a82f31cf085_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6fa015d0-f811-4eee-82c6-0d042f9248e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_87d09e4b-df48-4fa2-8634-1a82f31cf085" xlink:to="loc_us-gaap_EquityComponentDomain_6fa015d0-f811-4eee-82c6-0d042f9248e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_a33e5f64-6bf2-4996-821e-0f736abaad45" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6fa015d0-f811-4eee-82c6-0d042f9248e7" xlink:to="loc_us-gaap_CommonStockMember_a33e5f64-6bf2-4996-821e-0f736abaad45" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_0af29f76-08a4-4b56-b7d1-34c7a89b7fca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6fa015d0-f811-4eee-82c6-0d042f9248e7" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_0af29f76-08a4-4b56-b7d1-34c7a89b7fca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_4a4ca3fb-d93d-486c-afcc-2d2ef08ccd29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6fa015d0-f811-4eee-82c6-0d042f9248e7" xlink:to="loc_us-gaap_RetainedEarningsMember_4a4ca3fb-d93d-486c-afcc-2d2ef08ccd29" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c30ee7fb-2c3f-48ed-8722-177cefbe4d24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6fa015d0-f811-4eee-82c6-0d042f9248e7" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c30ee7fb-2c3f-48ed-8722-177cefbe4d24" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_ca434e83-8af2-4aee-aa55-0e38c505e95f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9b6498b3-b6d0-4c97-b132-51194864d6fa" xlink:to="loc_us-gaap_SharesIssued_ca434e83-8af2-4aee-aa55-0e38c505e95f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e655ea37-3f8b-43b0-a0df-d79280d39371" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9b6498b3-b6d0-4c97-b132-51194864d6fa" xlink:to="loc_us-gaap_StockholdersEquity_e655ea37-3f8b-43b0-a0df-d79280d39371" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_addcc66e-7246-48b1-8d4a-d3b3ba285c76" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9b6498b3-b6d0-4c97-b132-51194864d6fa" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_addcc66e-7246-48b1-8d4a-d3b3ba285c76" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1e3da63f-7295-4b3e-ba60-69c3b6e67da0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9b6498b3-b6d0-4c97-b132-51194864d6fa" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1e3da63f-7295-4b3e-ba60-69c3b6e67da0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_fc6caf7d-a796-4e6d-9c7c-03aceba5f4ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9b6498b3-b6d0-4c97-b132-51194864d6fa" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_fc6caf7d-a796-4e6d-9c7c-03aceba5f4ae" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity_da7f5b5f-72f5-42a9-89bc-69e2b8dbc606" xlink:href="mgnx-20231231.xsd#mgnx_StockIssuedDuringPeriodSharesStockPlanActivity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9b6498b3-b6d0-4c97-b132-51194864d6fa" xlink:to="loc_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity_da7f5b5f-72f5-42a9-89bc-69e2b8dbc606" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIssuedDuringPeriodValueStockPlanActivity_9d90c424-2f73-432d-91b2-dbab7416df63" xlink:href="mgnx-20231231.xsd#mgnx_StockIssuedDuringPeriodValueStockPlanActivity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9b6498b3-b6d0-4c97-b132-51194864d6fa" xlink:to="loc_mgnx_StockIssuedDuringPeriodValueStockPlanActivity_9d90c424-2f73-432d-91b2-dbab7416df63" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_16785732-733b-483c-baac-096aa1a0e50a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9b6498b3-b6d0-4c97-b132-51194864d6fa" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_16785732-733b-483c-baac-096aa1a0e50a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_4c116bc1-a52c-4e7a-9372-aaee376de9e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9b6498b3-b6d0-4c97-b132-51194864d6fa" xlink:to="loc_us-gaap_NetIncomeLoss_4c116bc1-a52c-4e7a-9372-aaee376de9e7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_bc15f074-e8b7-4752-89b8-952aedcb540e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_93b970ea-3ab4-42a0-b94c-dc33fcddc364" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails" xlink:type="simple" xlink:href="mgnx-20231231.xsd#SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d8dac65d-34c8-49c1-98df-0a89e53c4879" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0f4d55ed-c2e2-4802-9e2d-ef0b573249a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d8dac65d-34c8-49c1-98df-0a89e53c4879" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0f4d55ed-c2e2-4802-9e2d-ef0b573249a2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4667ad3e-49f5-45cd-92d4-de63bbed65cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0f4d55ed-c2e2-4802-9e2d-ef0b573249a2" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4667ad3e-49f5-45cd-92d4-de63bbed65cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4667ad3e-49f5-45cd-92d4-de63bbed65cc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4667ad3e-49f5-45cd-92d4-de63bbed65cc" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4667ad3e-49f5-45cd-92d4-de63bbed65cc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9b05cb24-1883-4715-a969-231f8210f3cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4667ad3e-49f5-45cd-92d4-de63bbed65cc" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9b05cb24-1883-4715-a969-231f8210f3cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_48d630b1-aa00-41b9-a31f-a5d04d3df76b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9b05cb24-1883-4715-a969-231f8210f3cd" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_48d630b1-aa00-41b9-a31f-a5d04d3df76b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_218a0c26-0eb6-4536-ac20-f43b5a48ffcd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9b05cb24-1883-4715-a969-231f8210f3cd" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_218a0c26-0eb6-4536-ac20-f43b5a48ffcd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_c55be5bc-4deb-4afb-ac9e-c6ba2347bef2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0f4d55ed-c2e2-4802-9e2d-ef0b573249a2" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_c55be5bc-4deb-4afb-ac9e-c6ba2347bef2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_c55be5bc-4deb-4afb-ac9e-c6ba2347bef2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_c55be5bc-4deb-4afb-ac9e-c6ba2347bef2" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_c55be5bc-4deb-4afb-ac9e-c6ba2347bef2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_dfc272bc-9e96-43d1-a7b4-ce1daed052ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_c55be5bc-4deb-4afb-ac9e-c6ba2347bef2" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_dfc272bc-9e96-43d1-a7b4-ce1daed052ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_2ad62ccb-7e80-42b2-af25-5f30aa3aa973" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_dfc272bc-9e96-43d1-a7b4-ce1daed052ef" xlink:to="loc_us-gaap_MoneyMarketFundsMember_2ad62ccb-7e80-42b2-af25-5f30aa3aa973" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_ff963dc7-63bc-4555-b127-9e1f0e487755" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_dfc272bc-9e96-43d1-a7b4-ce1daed052ef" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_ff963dc7-63bc-4555-b127-9e1f0e487755" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_cc56595c-48c5-4ed4-90cd-6333c96e8fa3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_dfc272bc-9e96-43d1-a7b4-ce1daed052ef" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_cc56595c-48c5-4ed4-90cd-6333c96e8fa3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_d7258c22-b42f-4cda-99ac-3e4eaff2f1d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_dfc272bc-9e96-43d1-a7b4-ce1daed052ef" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_d7258c22-b42f-4cda-99ac-3e4eaff2f1d9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_744f28b8-d19b-4253-a902-f936badc937b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0f4d55ed-c2e2-4802-9e2d-ef0b573249a2" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_744f28b8-d19b-4253-a902-f936badc937b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_744f28b8-d19b-4253-a902-f936badc937b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_744f28b8-d19b-4253-a902-f936badc937b" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_744f28b8-d19b-4253-a902-f936badc937b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_fcaf6c59-3d30-47c2-8b3c-4c972f4f9211" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_744f28b8-d19b-4253-a902-f936badc937b" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_fcaf6c59-3d30-47c2-8b3c-4c972f4f9211" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_5f8deedb-8926-45ad-8c6d-862fe2cb7b2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_fcaf6c59-3d30-47c2-8b3c-4c972f4f9211" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_5f8deedb-8926-45ad-8c6d-862fe2cb7b2a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_e95f966c-3041-489a-8c7b-ca05581fad77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d8dac65d-34c8-49c1-98df-0a89e53c4879" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_e95f966c-3041-489a-8c7b-ca05581fad77" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_63c876b7-bcbe-424f-b9ec-932549fbbaa0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_e95f966c-3041-489a-8c7b-ca05581fad77" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_63c876b7-bcbe-424f-b9ec-932549fbbaa0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2f44cee3-c510-47c5-bd6b-daae14f5baa3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_e95f966c-3041-489a-8c7b-ca05581fad77" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2f44cee3-c510-47c5-bd6b-daae14f5baa3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_f237fa7f-a5dd-4158-ae63-66dda54615e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_e95f966c-3041-489a-8c7b-ca05581fad77" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_f237fa7f-a5dd-4158-ae63-66dda54615e5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments_cdc0c037-1388-4557-ac88-b6f5bff49ab3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Investments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d8dac65d-34c8-49c1-98df-0a89e53c4879" xlink:to="loc_us-gaap_Investments_cdc0c037-1388-4557-ac88-b6f5bff49ab3" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails" xlink:type="simple" xlink:href="mgnx-20231231.xsd#SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_8c74a141-711f-4c77-b4d8-1e0cc08e1bf3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_38d57a6d-23a0-4f4f-9ba7-8810a73e423c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_8c74a141-711f-4c77-b4d8-1e0cc08e1bf3" xlink:to="loc_us-gaap_ConcentrationRiskTable_38d57a6d-23a0-4f4f-9ba7-8810a73e423c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_fb8a61fd-d564-49ec-9666-740f394e7e72" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_38d57a6d-23a0-4f4f-9ba7-8810a73e423c" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_fb8a61fd-d564-49ec-9666-740f394e7e72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_fb8a61fd-d564-49ec-9666-740f394e7e72_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_fb8a61fd-d564-49ec-9666-740f394e7e72" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_fb8a61fd-d564-49ec-9666-740f394e7e72_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_782f62ba-44a7-4527-a2dd-1f80791baabe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_fb8a61fd-d564-49ec-9666-740f394e7e72" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_782f62ba-44a7-4527-a2dd-1f80791baabe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_94f80397-7596-4216-9316-c59c1104175a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_782f62ba-44a7-4527-a2dd-1f80791baabe" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_94f80397-7596-4216-9316-c59c1104175a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_cc3cbd8b-408e-4074-95f5-7680220bbb8d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_38d57a6d-23a0-4f4f-9ba7-8810a73e423c" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_cc3cbd8b-408e-4074-95f5-7680220bbb8d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_cc3cbd8b-408e-4074-95f5-7680220bbb8d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_cc3cbd8b-408e-4074-95f5-7680220bbb8d" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_cc3cbd8b-408e-4074-95f5-7680220bbb8d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_19e62664-ec44-41d7-9529-53917b660ba0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_cc3cbd8b-408e-4074-95f5-7680220bbb8d" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_19e62664-ec44-41d7-9529-53917b660ba0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_9bf6f020-9082-4f2d-a34c-c3505c061a52" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_19e62664-ec44-41d7-9529-53917b660ba0" xlink:to="loc_us-gaap_SalesRevenueNetMember_9bf6f020-9082-4f2d-a34c-c3505c061a52" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_14c8c464-9c7a-46d8-b388-2922e902a4ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_19e62664-ec44-41d7-9529-53917b660ba0" xlink:to="loc_us-gaap_AccountsReceivableMember_14c8c464-9c7a-46d8-b388-2922e902a4ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_b2fa673e-381c-4f95-b5f1-633d1c325330" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_38d57a6d-23a0-4f4f-9ba7-8810a73e423c" xlink:to="loc_srt_MajorCustomersAxis_b2fa673e-381c-4f95-b5f1-633d1c325330" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_b2fa673e-381c-4f95-b5f1-633d1c325330_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_b2fa673e-381c-4f95-b5f1-633d1c325330" xlink:to="loc_srt_NameOfMajorCustomerDomain_b2fa673e-381c-4f95-b5f1-633d1c325330_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_05369e62-9fda-475a-adf0-0210b782a3a4" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_b2fa673e-381c-4f95-b5f1-633d1c325330" xlink:to="loc_srt_NameOfMajorCustomerDomain_05369e62-9fda-475a-adf0-0210b782a3a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteCorporationMember_3b4c5eaa-f670-4263-ace7-698e98c00455" xlink:href="mgnx-20231231.xsd#mgnx_IncyteCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_05369e62-9fda-475a-adf0-0210b782a3a4" xlink:to="loc_mgnx_IncyteCorporationMember_3b4c5eaa-f670-4263-ace7-698e98c00455" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember_05d85d5d-704d-4b55-8e19-af09e6900cbe" xlink:href="mgnx-20231231.xsd#mgnx_McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_05369e62-9fda-475a-adf0-0210b782a3a4" xlink:to="loc_mgnx_McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember_05d85d5d-704d-4b55-8e19-af09e6900cbe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CardinalHealthIncMember_542e1437-55da-4943-aa29-7f3d28fb3b35" xlink:href="mgnx-20231231.xsd#mgnx_CardinalHealthIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_05369e62-9fda-475a-adf0-0210b782a3a4" xlink:to="loc_mgnx_CardinalHealthIncMember_542e1437-55da-4943-aa29-7f3d28fb3b35" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ASDHealthcareAndOncologySupplyMember_e7ab86fd-0571-49c3-a514-4861fc4f316c" xlink:href="mgnx-20231231.xsd#mgnx_ASDHealthcareAndOncologySupplyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_05369e62-9fda-475a-adf0-0210b782a3a4" xlink:to="loc_mgnx_ASDHealthcareAndOncologySupplyMember_e7ab86fd-0571-49c3-a514-4861fc4f316c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionBioMember_af7412db-9def-459e-94a2-a8eaf2a448c1" xlink:href="mgnx-20231231.xsd#mgnx_ProventionBioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_05369e62-9fda-475a-adf0-0210b782a3a4" xlink:to="loc_mgnx_ProventionBioMember_af7412db-9def-459e-94a2-a8eaf2a448c1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabLimitedMember_c63daecc-ca37-40fc-8608-00fb3f4a71e5" xlink:href="mgnx-20231231.xsd#mgnx_ZaiLabLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_05369e62-9fda-475a-adf0-0210b782a3a4" xlink:to="loc_mgnx_ZaiLabLimitedMember_c63daecc-ca37-40fc-8608-00fb3f4a71e5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IMabBiopharmaMember_ddbaac97-91dc-4ab7-9c26-6de408db3648" xlink:href="mgnx-20231231.xsd#mgnx_IMabBiopharmaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_05369e62-9fda-475a-adf0-0210b782a3a4" xlink:to="loc_mgnx_IMabBiopharmaMember_ddbaac97-91dc-4ab7-9c26-6de408db3648" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabMember_3ee8d7ee-1cbc-4eca-b949-6b17085ea18a" xlink:href="mgnx-20231231.xsd#mgnx_ZaiLabMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_05369e62-9fda-475a-adf0-0210b782a3a4" xlink:to="loc_mgnx_ZaiLabMember_3ee8d7ee-1cbc-4eca-b949-6b17085ea18a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_ec877a29-d6dd-492c-a24a-af756d3aac30" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_8c74a141-711f-4c77-b4d8-1e0cc08e1bf3" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_ec877a29-d6dd-492c-a24a-af756d3aac30" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails" xlink:type="simple" xlink:href="mgnx-20231231.xsd#SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b6086003-9513-48b8-bb8f-6ecd43bd63d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_de34bef6-568d-466d-bf21-fe9f357c5cd2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b6086003-9513-48b8-bb8f-6ecd43bd63d5" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_de34bef6-568d-466d-bf21-fe9f357c5cd2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f27c0a9f-70cb-4f99-95b4-4f5030be9f64" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_de34bef6-568d-466d-bf21-fe9f357c5cd2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f27c0a9f-70cb-4f99-95b4-4f5030be9f64" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f27c0a9f-70cb-4f99-95b4-4f5030be9f64_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f27c0a9f-70cb-4f99-95b4-4f5030be9f64" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f27c0a9f-70cb-4f99-95b4-4f5030be9f64_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bb41e8b7-7bb0-4f10-879c-98504b29cb65" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f27c0a9f-70cb-4f99-95b4-4f5030be9f64" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bb41e8b7-7bb0-4f10-879c-98504b29cb65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_e516bc65-253f-4ee6-bc2d-db59f8860ebb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bb41e8b7-7bb0-4f10-879c-98504b29cb65" xlink:to="loc_us-gaap_ComputerEquipmentMember_e516bc65-253f-4ee6-bc2d-db59f8860ebb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_f3738924-bb63-4ddb-916a-db57ad476426" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bb41e8b7-7bb0-4f10-879c-98504b29cb65" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_f3738924-bb63-4ddb-916a-db57ad476426" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_53195e0b-2e8c-4c28-848d-56f92b3d5681" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bb41e8b7-7bb0-4f10-879c-98504b29cb65" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_53195e0b-2e8c-4c28-848d-56f92b3d5681" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_LaboratoryAndOfficeEquipmentMember_3f7652b6-f45c-41d5-93e9-04895f9dccea" xlink:href="mgnx-20231231.xsd#mgnx_LaboratoryAndOfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bb41e8b7-7bb0-4f10-879c-98504b29cb65" xlink:to="loc_mgnx_LaboratoryAndOfficeEquipmentMember_3f7652b6-f45c-41d5-93e9-04895f9dccea" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_49b9be3b-2f25-4f5b-923d-5c93351de504" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b6086003-9513-48b8-bb8f-6ecd43bd63d5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_49b9be3b-2f25-4f5b-923d-5c93351de504" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromtheCalculationofDilutedLossPerShareDetails" xlink:type="simple" xlink:href="mgnx-20231231.xsd#SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromtheCalculationofDilutedLossPerShareDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromtheCalculationofDilutedLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_17cc2768-6865-43a9-acc3-2a8e928ae7ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d801cb2b-62be-4755-bd3e-8944ffbda7e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_17cc2768-6865-43a9-acc3-2a8e928ae7ef" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d801cb2b-62be-4755-bd3e-8944ffbda7e3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_74b6ef0f-7079-4945-acad-f60c64f19978" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d801cb2b-62be-4755-bd3e-8944ffbda7e3" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_74b6ef0f-7079-4945-acad-f60c64f19978" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_74b6ef0f-7079-4945-acad-f60c64f19978_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_74b6ef0f-7079-4945-acad-f60c64f19978" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_74b6ef0f-7079-4945-acad-f60c64f19978_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1a346431-97fa-45c0-affe-1e90cea07609" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_74b6ef0f-7079-4945-acad-f60c64f19978" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1a346431-97fa-45c0-affe-1e90cea07609" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockOptionsAndRestrictedStockUnitsMember_15c8a00d-09f2-4dda-8deb-cc77db8901f7" xlink:href="mgnx-20231231.xsd#mgnx_StockOptionsAndRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1a346431-97fa-45c0-affe-1e90cea07609" xlink:to="loc_mgnx_StockOptionsAndRestrictedStockUnitsMember_15c8a00d-09f2-4dda-8deb-cc77db8901f7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_db4dd1c7-ffb5-4b02-a2f5-715cc7f6b771" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_17cc2768-6865-43a9-acc3-2a8e928ae7ef" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_db4dd1c7-ffb5-4b02-a2f5-715cc7f6b771" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecuritiesDetails" xlink:type="simple" xlink:href="mgnx-20231231.xsd#MarketableSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/MarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ea161c02-f143-48c5-8c2f-b75ed1806d33" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_948c658a-1b73-47ce-bb38-b657759508fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ea161c02-f143-48c5-8c2f-b75ed1806d33" xlink:to="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_948c658a-1b73-47ce-bb38-b657759508fe" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_2cc90f6a-fba4-454c-8334-29787a6c2c8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_948c658a-1b73-47ce-bb38-b657759508fe" xlink:to="loc_us-gaap_FinancialInstrumentAxis_2cc90f6a-fba4-454c-8334-29787a6c2c8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2cc90f6a-fba4-454c-8334-29787a6c2c8b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_2cc90f6a-fba4-454c-8334-29787a6c2c8b" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2cc90f6a-fba4-454c-8334-29787a6c2c8b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b33e42c3-5958-4560-8eab-c42d00e349a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_2cc90f6a-fba4-454c-8334-29787a6c2c8b" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b33e42c3-5958-4560-8eab-c42d00e349a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_cef1eb60-0a80-4b8c-b69a-ed812c6a837b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b33e42c3-5958-4560-8eab-c42d00e349a8" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_cef1eb60-0a80-4b8c-b69a-ed812c6a837b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_e511c3b9-dce1-49c3-9ae7-403d5d05b2f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b33e42c3-5958-4560-8eab-c42d00e349a8" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_e511c3b9-dce1-49c3-9ae7-403d5d05b2f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_5124a559-cf30-411c-873d-b77fd67bc10b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b33e42c3-5958-4560-8eab-c42d00e349a8" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_5124a559-cf30-411c-873d-b77fd67bc10b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a4e16237-467c-46fa-9292-8dff035964ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ea161c02-f143-48c5-8c2f-b75ed1806d33" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a4e16237-467c-46fa-9292-8dff035964ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_224448dd-8df4-486f-a9d9-105c318e9e92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ea161c02-f143-48c5-8c2f-b75ed1806d33" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_224448dd-8df4-486f-a9d9-105c318e9e92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_15b5fce7-d882-4b56-8e76-64061514008a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ea161c02-f143-48c5-8c2f-b75ed1806d33" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_15b5fce7-d882-4b56-8e76-64061514008a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d93c252a-b5cd-4551-8d1e-ac1d8a27f35b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ea161c02-f143-48c5-8c2f-b75ed1806d33" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d93c252a-b5cd-4551-8d1e-ac1d8a27f35b" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/InventoryNetDetails" xlink:type="simple" xlink:href="mgnx-20231231.xsd#InventoryNetDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/InventoryNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_e453ea6b-44d4-4563-bebb-9066d211f112" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_dabd04cf-a138-4c4c-b6c1-14e99c56a9d0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_e453ea6b-44d4-4563-bebb-9066d211f112" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_dabd04cf-a138-4c4c-b6c1-14e99c56a9d0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_75638779-cb52-445b-bb37-f405dd1a7eb0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_dabd04cf-a138-4c4c-b6c1-14e99c56a9d0" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_75638779-cb52-445b-bb37-f405dd1a7eb0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_75638779-cb52-445b-bb37-f405dd1a7eb0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_75638779-cb52-445b-bb37-f405dd1a7eb0" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_75638779-cb52-445b-bb37-f405dd1a7eb0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_71662898-f317-4807-92e6-ca179a2463b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_75638779-cb52-445b-bb37-f405dd1a7eb0" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_71662898-f317-4807-92e6-ca179a2463b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserveMember_d009929d-fb39-4e9c-9688-6bcddf04e754" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryValuationReserveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_71662898-f317-4807-92e6-ca179a2463b4" xlink:to="loc_us-gaap_InventoryValuationReserveMember_d009929d-fb39-4e9c-9688-6bcddf04e754" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_4d2f2866-c068-4516-96d5-d938114cd1fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_e453ea6b-44d4-4563-bebb-9066d211f112" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_4d2f2866-c068-4516-96d5-d938114cd1fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_0b48983f-f11b-4a37-babd-65d65659fb81" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_e453ea6b-44d4-4563-bebb-9066d211f112" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_0b48983f-f11b-4a37-babd-65d65659fb81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_773fb2e4-f4b0-494f-8ba6-f51d8a63db69" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_e453ea6b-44d4-4563-bebb-9066d211f112" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_773fb2e4-f4b0-494f-8ba6-f51d8a63db69" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_3e410219-2dc0-4d3e-a229-45cc881a3676" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails" xlink:type="simple" xlink:href="mgnx-20231231.xsd#PropertyEquipmentandSoftwareDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d0123bbe-ad84-451b-9623-6832cb9343cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_04945da0-1188-46da-a9c6-25832e91ae8f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d0123bbe-ad84-451b-9623-6832cb9343cd" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_04945da0-1188-46da-a9c6-25832e91ae8f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6feab077-9bf5-4b8e-aec5-35a3ddfab4b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_04945da0-1188-46da-a9c6-25832e91ae8f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6feab077-9bf5-4b8e-aec5-35a3ddfab4b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6feab077-9bf5-4b8e-aec5-35a3ddfab4b1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6feab077-9bf5-4b8e-aec5-35a3ddfab4b1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6feab077-9bf5-4b8e-aec5-35a3ddfab4b1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_03b3f95a-1959-449e-9dfb-70385fbf04a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6feab077-9bf5-4b8e-aec5-35a3ddfab4b1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_03b3f95a-1959-449e-9dfb-70385fbf04a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_3f20b790-a045-40dc-b4a3-e9d1ec7075e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_03b3f95a-1959-449e-9dfb-70385fbf04a0" xlink:to="loc_us-gaap_ComputerEquipmentMember_3f20b790-a045-40dc-b4a3-e9d1ec7075e5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_8da83d1d-ee3f-4a51-b5b5-d931194dc8e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_03b3f95a-1959-449e-9dfb-70385fbf04a0" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_8da83d1d-ee3f-4a51-b5b5-d931194dc8e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_FurnitureAndOfficeEquipmentMember_ecfb224a-56d0-4f84-87ad-f885ec21aa34" xlink:href="mgnx-20231231.xsd#mgnx_FurnitureAndOfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_03b3f95a-1959-449e-9dfb-70385fbf04a0" xlink:to="loc_mgnx_FurnitureAndOfficeEquipmentMember_ecfb224a-56d0-4f84-87ad-f885ec21aa34" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VehiclesMember_d48c104d-9f9b-49f2-8741-9c9b50deb274" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VehiclesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_03b3f95a-1959-449e-9dfb-70385fbf04a0" xlink:to="loc_us-gaap_VehiclesMember_d48c104d-9f9b-49f2-8741-9c9b50deb274" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_a98fa465-f727-4d40-b02a-0025b34719b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_03b3f95a-1959-449e-9dfb-70385fbf04a0" xlink:to="loc_us-gaap_EquipmentMember_a98fa465-f727-4d40-b02a-0025b34719b4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_2220331a-8af9-4fcb-9207-dce54c845724" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_03b3f95a-1959-449e-9dfb-70385fbf04a0" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_2220331a-8af9-4fcb-9207-dce54c845724" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_446d3509-881a-4337-bca9-1759869055aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d0123bbe-ad84-451b-9623-6832cb9343cd" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_446d3509-881a-4337-bca9-1759869055aa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_2c16b15a-2127-44a3-a80a-eaf9ad91c4ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d0123bbe-ad84-451b-9623-6832cb9343cd" xlink:to="loc_us-gaap_ConstructionInProgressGross_2c16b15a-2127-44a3-a80a-eaf9ad91c4ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_fd16f8b3-e0ef-43d8-82a1-8f01ca074ed5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d0123bbe-ad84-451b-9623-6832cb9343cd" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_fd16f8b3-e0ef-43d8-82a1-8f01ca074ed5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_b6339d1c-585b-411d-b6be-11dec1f81627" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d0123bbe-ad84-451b-9623-6832cb9343cd" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_b6339d1c-585b-411d-b6be-11dec1f81627" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_5759cacf-761b-4320-bbc6-881838d4c2ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d0123bbe-ad84-451b-9623-6832cb9343cd" xlink:to="loc_us-gaap_Depreciation_5759cacf-761b-4320-bbc6-881838d4c2ef" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="mgnx-20231231.xsd#CommitmentsandContingenciesDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_0a4b84f7-05c5-4a5c-9064-e63ab5446393" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_526b7f91-1aed-4d99-a7ab-2c0492c0bc11" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0a4b84f7-05c5-4a5c-9064-e63ab5446393" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_526b7f91-1aed-4d99-a7ab-2c0492c0bc11" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_a3f6b652-e4d3-45f9-a043-436b1065338b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_526b7f91-1aed-4d99-a7ab-2c0492c0bc11" xlink:to="loc_srt_CounterpartyNameAxis_a3f6b652-e4d3-45f9-a043-436b1065338b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a3f6b652-e4d3-45f9-a043-436b1065338b_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_a3f6b652-e4d3-45f9-a043-436b1065338b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a3f6b652-e4d3-45f9-a043-436b1065338b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_904160e3-9443-4a9d-aa95-b5275086cca9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_a3f6b652-e4d3-45f9-a043-436b1065338b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_904160e3-9443-4a9d-aa95-b5275086cca9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_SynaffixBVMember_97ce37eb-c1f8-40ba-a2af-296e38139408" xlink:href="mgnx-20231231.xsd#mgnx_SynaffixBVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_904160e3-9443-4a9d-aa95-b5275086cca9" xlink:to="loc_mgnx_SynaffixBVMember_97ce37eb-c1f8-40ba-a2af-296e38139408" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3e3a5255-7f6e-405f-97be-22b13ece9371" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_526b7f91-1aed-4d99-a7ab-2c0492c0bc11" xlink:to="loc_srt_RangeAxis_3e3a5255-7f6e-405f-97be-22b13ece9371" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3e3a5255-7f6e-405f-97be-22b13ece9371_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_3e3a5255-7f6e-405f-97be-22b13ece9371" xlink:to="loc_srt_RangeMember_3e3a5255-7f6e-405f-97be-22b13ece9371_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_64e83c6a-8180-482b-80d0-961cc519d428" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_3e3a5255-7f6e-405f-97be-22b13ece9371" xlink:to="loc_srt_RangeMember_64e83c6a-8180-482b-80d0-961cc519d428" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_9d9a2b32-8908-48e2-9c2c-c790626badbf" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_64e83c6a-8180-482b-80d0-961cc519d428" xlink:to="loc_srt_MinimumMember_9d9a2b32-8908-48e2-9c2c-c790626badbf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_c3182f50-152b-4691-aed3-cc030c2f83de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0a4b84f7-05c5-4a5c-9064-e63ab5446393" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_c3182f50-152b-4691-aed3-cc030c2f83de" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RightOfUseAssetAndLeaseLiabilityIncrease_2c339b05-2132-4953-b3bb-8eccc84218f9" xlink:href="mgnx-20231231.xsd#mgnx_RightOfUseAssetAndLeaseLiabilityIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0a4b84f7-05c5-4a5c-9064-e63ab5446393" xlink:to="loc_mgnx_RightOfUseAssetAndLeaseLiabilityIncrease_2c339b05-2132-4953-b3bb-8eccc84218f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_caa4be35-0962-4ce0-8a3d-de1f7bf26e7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0a4b84f7-05c5-4a5c-9064-e63ab5446393" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_caa4be35-0962-4ce0-8a3d-de1f7bf26e7e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate_469f9327-dd24-4ffc-b535-db145aecbd07" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0a4b84f7-05c5-4a5c-9064-e63ab5446393" xlink:to="loc_us-gaap_LesseeOperatingLeaseDiscountRate_469f9327-dd24-4ffc-b535-db145aecbd07" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_4fe0a73a-1a74-4f96-8f2c-3ad8563bf76d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0a4b84f7-05c5-4a5c-9064-e63ab5446393" xlink:to="loc_us-gaap_OperatingLeasePayments_4fe0a73a-1a74-4f96-8f2c-3ad8563bf76d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_86b7417d-bf73-4bdf-ab4f-3020ea3b08aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0a4b84f7-05c5-4a5c-9064-e63ab5446393" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_86b7417d-bf73-4bdf-ab4f-3020ea3b08aa" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_772eeb46-d7f1-459f-9c1c-77aca8fec96a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0a4b84f7-05c5-4a5c-9064-e63ab5446393" xlink:to="loc_us-gaap_OperatingLeaseCost_772eeb46-d7f1-459f-9c1c-77aca8fec96a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_cd2dbcf8-6db8-4e86-9c00-61f6524b924f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0a4b84f7-05c5-4a5c-9064-e63ab5446393" xlink:to="loc_us-gaap_VariableLeaseCost_cd2dbcf8-6db8-4e86-9c00-61f6524b924f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_3ed73f87-80ee-407f-b743-459e397e80fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubleaseIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0a4b84f7-05c5-4a5c-9064-e63ab5446393" xlink:to="loc_us-gaap_SubleaseIncome_3ed73f87-80ee-407f-b743-459e397e80fb" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_fce78cc1-c337-42af-ac16-1992abdcd739" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0a4b84f7-05c5-4a5c-9064-e63ab5446393" xlink:to="loc_us-gaap_LeaseCost_fce78cc1-c337-42af-ac16-1992abdcd739" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_389c8367-3f55-4604-b177-e41d85b648be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0a4b84f7-05c5-4a5c-9064-e63ab5446393" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_389c8367-3f55-4604-b177-e41d85b648be" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_58e8c8d8-fbbd-4a4d-9754-cd7fd19e15af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0a4b84f7-05c5-4a5c-9064-e63ab5446393" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_58e8c8d8-fbbd-4a4d-9754-cd7fd19e15af" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_c84115b6-701a-441b-9018-c6f95b29fd26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0a4b84f7-05c5-4a5c-9064-e63ab5446393" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_c84115b6-701a-441b-9018-c6f95b29fd26" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_71e01921-9523-4862-92f0-cdff319eef17" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0a4b84f7-05c5-4a5c-9064-e63ab5446393" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_71e01921-9523-4862-92f0-cdff319eef17" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_c8facccf-d0b4-4e03-a491-f4625b6e6480" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0a4b84f7-05c5-4a5c-9064-e63ab5446393" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_c8facccf-d0b4-4e03-a491-f4625b6e6480" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_c23442c8-777a-401f-a0fb-31b671dc02b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0a4b84f7-05c5-4a5c-9064-e63ab5446393" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_c23442c8-777a-401f-a0fb-31b671dc02b8" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0614ebe0-ceeb-4525-bc8c-b32e980938c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0a4b84f7-05c5-4a5c-9064-e63ab5446393" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0614ebe0-ceeb-4525-bc8c-b32e980938c8" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_b8e7d7b4-b24b-4ec9-8d0f-436db3d437ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0a4b84f7-05c5-4a5c-9064-e63ab5446393" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_b8e7d7b4-b24b-4ec9-8d0f-436db3d437ac" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_261f1fa3-bbc6-42e3-b941-579ba162b319" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0a4b84f7-05c5-4a5c-9064-e63ab5446393" xlink:to="loc_us-gaap_OperatingLeaseLiability_261f1fa3-bbc6-42e3-b941-579ba162b319" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_7b292d46-9d83-48d2-867b-fdb6fbebe9e2" xlink:href="mgnx-20231231.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0a4b84f7-05c5-4a5c-9064-e63ab5446393" xlink:to="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_7b292d46-9d83-48d2-867b-fdb6fbebe9e2" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_40f797ab-400a-49e9-8d56-d2389594a687" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0a4b84f7-05c5-4a5c-9064-e63ab5446393" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_40f797ab-400a-49e9-8d56-d2389594a687" xlink:type="arc" order="20"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/RoyaltyMonetizationArrangementDetails" xlink:type="simple" xlink:href="mgnx-20231231.xsd#RoyaltyMonetizationArrangementDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/RoyaltyMonetizationArrangementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_LiabilityRelatedToFutureRoyaltyLineItems_8771e23e-2143-4862-8d0c-68ea77cede45" xlink:href="mgnx-20231231.xsd#mgnx_LiabilityRelatedToFutureRoyaltyLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RoyaltyMonetizationArrangementTable_ab9307c1-2cf7-455e-86d9-8f45c35e73b8" xlink:href="mgnx-20231231.xsd#mgnx_RoyaltyMonetizationArrangementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_mgnx_LiabilityRelatedToFutureRoyaltyLineItems_8771e23e-2143-4862-8d0c-68ea77cede45" xlink:to="loc_mgnx_RoyaltyMonetizationArrangementTable_ab9307c1-2cf7-455e-86d9-8f45c35e73b8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_b321ec33-cac4-4265-84a1-8a499765b022" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mgnx_RoyaltyMonetizationArrangementTable_ab9307c1-2cf7-455e-86d9-8f45c35e73b8" xlink:to="loc_srt_CounterpartyNameAxis_b321ec33-cac4-4265-84a1-8a499765b022" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b321ec33-cac4-4265-84a1-8a499765b022_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_b321ec33-cac4-4265-84a1-8a499765b022" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b321ec33-cac4-4265-84a1-8a499765b022_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_375f471c-c25b-4ff8-ae31-0e2ae9fe6d95" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_b321ec33-cac4-4265-84a1-8a499765b022" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_375f471c-c25b-4ff8-ae31-0e2ae9fe6d95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DRIHealthcareAcquisitionsLPDRIMember_f789e2d2-258b-4d19-82ac-7b805338e2a5" xlink:href="mgnx-20231231.xsd#mgnx_DRIHealthcareAcquisitionsLPDRIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_375f471c-c25b-4ff8-ae31-0e2ae9fe6d95" xlink:to="loc_mgnx_DRIHealthcareAcquisitionsLPDRIMember_f789e2d2-258b-4d19-82ac-7b805338e2a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_UpfrontPayment_7039b17c-4046-4b77-92eb-0faa54fefb39" xlink:href="mgnx-20231231.xsd#mgnx_UpfrontPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mgnx_LiabilityRelatedToFutureRoyaltyLineItems_8771e23e-2143-4862-8d0c-68ea77cede45" xlink:to="loc_mgnx_UpfrontPayment_7039b17c-4046-4b77-92eb-0faa54fefb39" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromRoyaltiesPercent_f782a13e-2aa9-4398-99eb-2ad46a04b333" xlink:href="mgnx-20231231.xsd#mgnx_ProceedsfromRoyaltiesPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mgnx_LiabilityRelatedToFutureRoyaltyLineItems_8771e23e-2143-4862-8d0c-68ea77cede45" xlink:to="loc_mgnx_ProceedsfromRoyaltiesPercent_f782a13e-2aa9-4398-99eb-2ad46a04b333" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_GainOnRoyaltyMonetizationArrangement_cd96a360-b3d5-415f-8f1e-cc4dd47483b8" xlink:href="mgnx-20231231.xsd#mgnx_GainOnRoyaltyMonetizationArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mgnx_LiabilityRelatedToFutureRoyaltyLineItems_8771e23e-2143-4862-8d0c-68ea77cede45" xlink:to="loc_mgnx_GainOnRoyaltyMonetizationArrangement_cd96a360-b3d5-415f-8f1e-cc4dd47483b8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_FutureRevenue_321fbb28-1d33-4727-9e64-5b56b54dfbf8" xlink:href="mgnx-20231231.xsd#mgnx_FutureRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mgnx_LiabilityRelatedToFutureRoyaltyLineItems_8771e23e-2143-4862-8d0c-68ea77cede45" xlink:to="loc_mgnx_FutureRevenue_321fbb28-1d33-4727-9e64-5b56b54dfbf8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TransactionCost_b7d4e526-96f4-48c3-b3d8-2b89721603f4" xlink:href="mgnx-20231231.xsd#mgnx_TransactionCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mgnx_LiabilityRelatedToFutureRoyaltyLineItems_8771e23e-2143-4862-8d0c-68ea77cede45" xlink:to="loc_mgnx_TransactionCost_b7d4e526-96f4-48c3-b3d8-2b89721603f4" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="mgnx-20231231.xsd#StockholdersEquityDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/StockholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_3ff81396-a04d-4d2d-8f3d-205ca22b5e50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_8cec61d6-5aa8-47ef-9ebf-04318825f3de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_3ff81396-a04d-4d2d-8f3d-205ca22b5e50" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_8cec61d6-5aa8-47ef-9ebf-04318825f3de" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_028719da-d4f8-48d1-a811-6577069cad08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_8cec61d6-5aa8-47ef-9ebf-04318825f3de" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_028719da-d4f8-48d1-a811-6577069cad08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_028719da-d4f8-48d1-a811-6577069cad08_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_028719da-d4f8-48d1-a811-6577069cad08" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_028719da-d4f8-48d1-a811-6577069cad08_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_44f750f1-bf3b-4bbf-be7c-83bf6a59114a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_028719da-d4f8-48d1-a811-6577069cad08" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_44f750f1-bf3b-4bbf-be7c-83bf6a59114a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AtTheMarketOfferingMember_9b07bee6-3628-4cca-ac88-0cfc85637cca" xlink:href="mgnx-20231231.xsd#mgnx_AtTheMarketOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_44f750f1-bf3b-4bbf-be7c-83bf6a59114a" xlink:to="loc_mgnx_AtTheMarketOfferingMember_9b07bee6-3628-4cca-ac88-0cfc85637cca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_658260b3-5a83-4c4f-a000-29f80a567e30" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_8cec61d6-5aa8-47ef-9ebf-04318825f3de" xlink:to="loc_us-gaap_StatementClassOfStockAxis_658260b3-5a83-4c4f-a000-29f80a567e30" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_658260b3-5a83-4c4f-a000-29f80a567e30_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_658260b3-5a83-4c4f-a000-29f80a567e30" xlink:to="loc_us-gaap_ClassOfStockDomain_658260b3-5a83-4c4f-a000-29f80a567e30_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_aa336f64-1f53-4e09-a757-040674703173" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_658260b3-5a83-4c4f-a000-29f80a567e30" xlink:to="loc_us-gaap_ClassOfStockDomain_aa336f64-1f53-4e09-a757-040674703173" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_UndesignatedPreferredStockMember_5ed3d48d-4ca9-448f-b562-61a8a96bd7b0" xlink:href="mgnx-20231231.xsd#mgnx_UndesignatedPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_aa336f64-1f53-4e09-a757-040674703173" xlink:to="loc_mgnx_UndesignatedPreferredStockMember_5ed3d48d-4ca9-448f-b562-61a8a96bd7b0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_0c0705af-6b67-4f73-bd70-56c409f57aea" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_8cec61d6-5aa8-47ef-9ebf-04318825f3de" xlink:to="loc_srt_CounterpartyNameAxis_0c0705af-6b67-4f73-bd70-56c409f57aea" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0c0705af-6b67-4f73-bd70-56c409f57aea_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_0c0705af-6b67-4f73-bd70-56c409f57aea" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0c0705af-6b67-4f73-bd70-56c409f57aea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_03295fed-bdf5-444f-8bfb-bcb2badbcbfb" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_0c0705af-6b67-4f73-bd70-56c409f57aea" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_03295fed-bdf5-444f-8bfb-bcb2badbcbfb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteCorporationMember_206c9bc9-1e64-472c-a55c-570a90fa8505" xlink:href="mgnx-20231231.xsd#mgnx_IncyteCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_03295fed-bdf5-444f-8bfb-bcb2badbcbfb" xlink:to="loc_mgnx_IncyteCorporationMember_206c9bc9-1e64-472c-a55c-570a90fa8505" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabMember_55356315-18bb-4615-b43f-2ef26ef792dc" xlink:href="mgnx-20231231.xsd#mgnx_ZaiLabMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_03295fed-bdf5-444f-8bfb-bcb2badbcbfb" xlink:to="loc_mgnx_ZaiLabMember_55356315-18bb-4615-b43f-2ef26ef792dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_128e4409-cd99-4406-a287-8eb46992f371" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_8cec61d6-5aa8-47ef-9ebf-04318825f3de" xlink:to="loc_srt_RangeAxis_128e4409-cd99-4406-a287-8eb46992f371" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_128e4409-cd99-4406-a287-8eb46992f371_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_128e4409-cd99-4406-a287-8eb46992f371" xlink:to="loc_srt_RangeMember_128e4409-cd99-4406-a287-8eb46992f371_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_13c41bb7-ae91-4c0f-be02-990694a1b947" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_128e4409-cd99-4406-a287-8eb46992f371" xlink:to="loc_srt_RangeMember_13c41bb7-ae91-4c0f-be02-990694a1b947" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_aee6fead-0993-47da-b1f8-ea56ed43d4b9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_13c41bb7-ae91-4c0f-be02-990694a1b947" xlink:to="loc_srt_MaximumMember_aee6fead-0993-47da-b1f8-ea56ed43d4b9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_f9f8b89f-da73-4142-a606-b12f38fd5214" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_8cec61d6-5aa8-47ef-9ebf-04318825f3de" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_f9f8b89f-da73-4142-a606-b12f38fd5214" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_f9f8b89f-da73-4142-a606-b12f38fd5214_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_f9f8b89f-da73-4142-a606-b12f38fd5214" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_f9f8b89f-da73-4142-a606-b12f38fd5214_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_14d2e780-87a4-433e-bcd0-1689c7f9391b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_f9f8b89f-da73-4142-a606-b12f38fd5214" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_14d2e780-87a4-433e-bcd0-1689c7f9391b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012AgreementMember_bc1d784f-466e-40f3-a67d-d46a635dd561" xlink:href="mgnx-20231231.xsd#mgnx_IncyteMGA012AgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_14d2e780-87a4-433e-bcd0-1689c7f9391b" xlink:to="loc_mgnx_IncyteMGA012AgreementMember_bc1d784f-466e-40f3-a67d-d46a635dd561" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_A2021ZaiLabAgreementsMember_e4a0126c-7db2-4f94-8caa-bd12c575dc18" xlink:href="mgnx-20231231.xsd#mgnx_A2021ZaiLabAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_14d2e780-87a4-433e-bcd0-1689c7f9391b" xlink:to="loc_mgnx_A2021ZaiLabAgreementsMember_e4a0126c-7db2-4f94-8caa-bd12c575dc18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_3120c420-8f33-4c0a-8f00-3ccc3c1a9123" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3ff81396-a04d-4d2d-8f3d-205ca22b5e50" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_3120c420-8f33-4c0a-8f00-3ccc3c1a9123" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_67ff3e82-1a88-4883-845c-533c9c203806" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3ff81396-a04d-4d2d-8f3d-205ca22b5e50" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_67ff3e82-1a88-4883-845c-533c9c203806" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_789ef9af-e64e-488f-8b13-9be0cc16a0ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3ff81396-a04d-4d2d-8f3d-205ca22b5e50" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_789ef9af-e64e-488f-8b13-9be0cc16a0ca" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_81a94c94-8f34-44d1-a4fd-8b6e5b9fffd6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3ff81396-a04d-4d2d-8f3d-205ca22b5e50" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_81a94c94-8f34-44d1-a4fd-8b6e5b9fffd6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_059602ec-7d97-408b-8e48-a7a8ba77aa3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3ff81396-a04d-4d2d-8f3d-205ca22b5e50" xlink:to="loc_us-gaap_PreferredStockSharesIssued_059602ec-7d97-408b-8e48-a7a8ba77aa3f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_42f73d63-8b2e-4841-996d-bceeadcee2fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3ff81396-a04d-4d2d-8f3d-205ca22b5e50" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_42f73d63-8b2e-4841-996d-bceeadcee2fc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_75913291-bfe2-4073-862c-c18368def1cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3ff81396-a04d-4d2d-8f3d-205ca22b5e50" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_75913291-bfe2-4073-862c-c18368def1cd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_03b5b40b-ee2a-4ca6-86be-4156671243e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_27293f24-b925-4202-a1db-2c97d017e57c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3ff81396-a04d-4d2d-8f3d-205ca22b5e50" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_27293f24-b925-4202-a1db-2c97d017e57c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CommonStockMaximumAmountAvailableForIssuance_9409c801-af11-46e5-9723-d728550052a3" xlink:href="mgnx-20231231.xsd#mgnx_CommonStockMaximumAmountAvailableForIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3ff81396-a04d-4d2d-8f3d-205ca22b5e50" xlink:to="loc_mgnx_CommonStockMaximumAmountAvailableForIssuance_9409c801-af11-46e5-9723-d728550052a3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_5fd74512-d40d-444e-9191-2fc1300e719f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3ff81396-a04d-4d2d-8f3d-205ca22b5e50" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_5fd74512-d40d-444e-9191-2fc1300e719f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_4196c4ad-d116-40b0-b499-2e5f8bd48b7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3ff81396-a04d-4d2d-8f3d-205ca22b5e50" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_4196c4ad-d116-40b0-b499-2e5f8bd48b7b" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_9596c5f5-0bdc-403a-8a1e-f4d7de3b29ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3ff81396-a04d-4d2d-8f3d-205ca22b5e50" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_9596c5f5-0bdc-403a-8a1e-f4d7de3b29ed" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease_7b21bceb-e429-4d6b-845e-286b3c6bbeab" xlink:href="mgnx-20231231.xsd#mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3ff81396-a04d-4d2d-8f3d-205ca22b5e50" xlink:to="loc_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease_7b21bceb-e429-4d6b-845e-286b3c6bbeab" xlink:type="arc" order="13"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/RevenueIncyteCorporationDetails" xlink:type="simple" xlink:href="mgnx-20231231.xsd#RevenueIncyteCorporationDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/RevenueIncyteCorporationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4746a641-20d2-43ea-bd82-b1f0c53da3c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4c4fcf2c-1f94-4c8d-860f-2778ceb07dae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4746a641-20d2-43ea-bd82-b1f0c53da3c3" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4c4fcf2c-1f94-4c8d-860f-2778ceb07dae" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_7ed15482-b7ff-48bf-b824-c8f14768c20d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4c4fcf2c-1f94-4c8d-860f-2778ceb07dae" xlink:to="loc_srt_ProductOrServiceAxis_7ed15482-b7ff-48bf-b824-c8f14768c20d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7ed15482-b7ff-48bf-b824-c8f14768c20d_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_7ed15482-b7ff-48bf-b824-c8f14768c20d" xlink:to="loc_srt_ProductsAndServicesDomain_7ed15482-b7ff-48bf-b824-c8f14768c20d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7f77762d-7d7c-4ab7-99e7-4d05120be16b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_7ed15482-b7ff-48bf-b824-c8f14768c20d" xlink:to="loc_srt_ProductsAndServicesDomain_7f77762d-7d7c-4ab7-99e7-4d05120be16b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember_7024034d-4f93-4705-8571-7801fc36e35a" xlink:href="mgnx-20231231.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7f77762d-7d7c-4ab7-99e7-4d05120be16b" xlink:to="loc_mgnx_RevenuesFromLicenseAgreementsMember_7024034d-4f93-4705-8571-7801fc36e35a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_46b14598-42b6-4e87-a568-2f7ba74c4b36" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4c4fcf2c-1f94-4c8d-860f-2778ceb07dae" xlink:to="loc_srt_RangeAxis_46b14598-42b6-4e87-a568-2f7ba74c4b36" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_46b14598-42b6-4e87-a568-2f7ba74c4b36_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_46b14598-42b6-4e87-a568-2f7ba74c4b36" xlink:to="loc_srt_RangeMember_46b14598-42b6-4e87-a568-2f7ba74c4b36_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_56728bf3-a7af-4b45-9672-c59278f4a5a6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_46b14598-42b6-4e87-a568-2f7ba74c4b36" xlink:to="loc_srt_RangeMember_56728bf3-a7af-4b45-9672-c59278f4a5a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_a7507d42-7921-4681-9d3a-2643b11b7470" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_56728bf3-a7af-4b45-9672-c59278f4a5a6" xlink:to="loc_srt_MinimumMember_a7507d42-7921-4681-9d3a-2643b11b7470" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1a3d946b-1b18-4cf7-9c93-eba30c0a5523" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_56728bf3-a7af-4b45-9672-c59278f4a5a6" xlink:to="loc_srt_MaximumMember_1a3d946b-1b18-4cf7-9c93-eba30c0a5523" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_c8f2e95d-fca7-4692-97f4-ad80186cb1e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4c4fcf2c-1f94-4c8d-860f-2778ceb07dae" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_c8f2e95d-fca7-4692-97f4-ad80186cb1e2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_c8f2e95d-fca7-4692-97f4-ad80186cb1e2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_c8f2e95d-fca7-4692-97f4-ad80186cb1e2" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_c8f2e95d-fca7-4692-97f4-ad80186cb1e2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_ba9dd458-51b2-4f39-b60b-6aca927c2f39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_c8f2e95d-fca7-4692-97f4-ad80186cb1e2" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_ba9dd458-51b2-4f39-b60b-6aca927c2f39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012AgreementMember_bf67396c-164b-4b45-a428-18cc2ef76297" xlink:href="mgnx-20231231.xsd#mgnx_IncyteMGA012AgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_ba9dd458-51b2-4f39-b60b-6aca927c2f39" xlink:to="loc_mgnx_IncyteMGA012AgreementMember_bf67396c-164b-4b45-a428-18cc2ef76297" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteClinicalSupplyAgreementMember_5be417dc-e3ca-41eb-965a-0494e04f3127" xlink:href="mgnx-20231231.xsd#mgnx_IncyteClinicalSupplyAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_ba9dd458-51b2-4f39-b60b-6aca927c2f39" xlink:to="loc_mgnx_IncyteClinicalSupplyAgreementMember_5be417dc-e3ca-41eb-965a-0494e04f3127" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteCommercialSupplyAgreementMember_1f2efc33-8eb0-4bdc-85fa-2212ab3c975d" xlink:href="mgnx-20231231.xsd#mgnx_IncyteCommercialSupplyAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_ba9dd458-51b2-4f39-b60b-6aca927c2f39" xlink:to="loc_mgnx_IncyteCommercialSupplyAgreementMember_1f2efc33-8eb0-4bdc-85fa-2212ab3c975d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_31300163-5479-4f2e-b344-740100218a5f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4c4fcf2c-1f94-4c8d-860f-2778ceb07dae" xlink:to="loc_srt_CounterpartyNameAxis_31300163-5479-4f2e-b344-740100218a5f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_31300163-5479-4f2e-b344-740100218a5f_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_31300163-5479-4f2e-b344-740100218a5f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_31300163-5479-4f2e-b344-740100218a5f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_495f3eed-4eb9-4bc5-89f7-45d4ee383b73" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_31300163-5479-4f2e-b344-740100218a5f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_495f3eed-4eb9-4bc5-89f7-45d4ee383b73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteCorporationMember_53a27b57-360f-4bf4-8acd-f184f7399b6e" xlink:href="mgnx-20231231.xsd#mgnx_IncyteCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_495f3eed-4eb9-4bc5-89f7-45d4ee383b73" xlink:to="loc_mgnx_IncyteCorporationMember_53a27b57-360f-4bf4-8acd-f184f7399b6e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_eb1acee6-b78a-4b7a-b110-b12ec28fac5e" xlink:href="mgnx-20231231.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4746a641-20d2-43ea-bd82-b1f0c53da3c3" xlink:to="loc_mgnx_NonRefundableUpfrontFees_eb1acee6-b78a-4b7a-b110-b12ec28fac5e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_95529ac2-8a46-4485-840b-456a92b9b3bb" xlink:href="mgnx-20231231.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4746a641-20d2-43ea-bd82-b1f0c53da3c3" xlink:to="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_95529ac2-8a46-4485-840b-456a92b9b3bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_cef68922-98b3-4f9f-b197-b609df71c47d" xlink:href="mgnx-20231231.xsd#mgnx_PotentialCommercialMilestonePaymentsUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4746a641-20d2-43ea-bd82-b1f0c53da3c3" xlink:to="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_cef68922-98b3-4f9f-b197-b609df71c47d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_7b687541-d11c-4a8b-8c54-dab071ae7d81" xlink:href="mgnx-20231231.xsd#mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4746a641-20d2-43ea-bd82-b1f0c53da3c3" xlink:to="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_7b687541-d11c-4a8b-8c54-dab071ae7d81" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromRoyaltiesPercent_6e50d524-beb9-465f-9822-a53d6886998a" xlink:href="mgnx-20231231.xsd#mgnx_ProceedsfromRoyaltiesPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4746a641-20d2-43ea-bd82-b1f0c53da3c3" xlink:to="loc_mgnx_ProceedsfromRoyaltiesPercent_6e50d524-beb9-465f-9822-a53d6886998a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfPerformanceObligations_6d2edb5a-2a18-452f-945a-203e7e46e100" xlink:href="mgnx-20231231.xsd#mgnx_NumberOfPerformanceObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4746a641-20d2-43ea-bd82-b1f0c53da3c3" xlink:to="loc_mgnx_NumberOfPerformanceObligations_6d2edb5a-2a18-452f-945a-203e7e46e100" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementTransactionPrice_a9485451-1d25-4086-aa83-98f0a1bb84c6" xlink:href="mgnx-20231231.xsd#mgnx_CollaborativeAgreementTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4746a641-20d2-43ea-bd82-b1f0c53da3c3" xlink:to="loc_mgnx_CollaborativeAgreementTransactionPrice_a9485451-1d25-4086-aa83-98f0a1bb84c6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_8c85b9fa-1af6-439c-9290-61f75cabb818" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4746a641-20d2-43ea-bd82-b1f0c53da3c3" xlink:to="loc_us-gaap_Revenues_8c85b9fa-1af6-439c-9290-61f75cabb818" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_c9775b05-74be-41f9-b9ff-2ee24dba494e" xlink:href="mgnx-20231231.xsd#mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4746a641-20d2-43ea-bd82-b1f0c53da3c3" xlink:to="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_c9775b05-74be-41f9-b9ff-2ee24dba494e" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/RevenueGileadSciencesIncDetails" xlink:type="simple" xlink:href="mgnx-20231231.xsd#RevenueGileadSciencesIncDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/RevenueGileadSciencesIncDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4f1db51-8415-4dea-a104-4a96efe33f77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_85f5d0fd-bd92-475e-a4da-c05d9f3ae9f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4f1db51-8415-4dea-a104-4a96efe33f77" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_85f5d0fd-bd92-475e-a4da-c05d9f3ae9f5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_8eeb5d34-0be4-40fc-a6e0-6a385d70453c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_85f5d0fd-bd92-475e-a4da-c05d9f3ae9f5" xlink:to="loc_srt_CounterpartyNameAxis_8eeb5d34-0be4-40fc-a6e0-6a385d70453c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8eeb5d34-0be4-40fc-a6e0-6a385d70453c_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_8eeb5d34-0be4-40fc-a6e0-6a385d70453c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8eeb5d34-0be4-40fc-a6e0-6a385d70453c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6d4b3023-0252-4773-8f9d-46f9a82f708c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_8eeb5d34-0be4-40fc-a6e0-6a385d70453c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6d4b3023-0252-4773-8f9d-46f9a82f708c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_GileadMember_2e84776b-da5d-49e2-b70f-c639a283d5c3" xlink:href="mgnx-20231231.xsd#mgnx_GileadMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6d4b3023-0252-4773-8f9d-46f9a82f708c" xlink:to="loc_mgnx_GileadMember_2e84776b-da5d-49e2-b70f-c639a283d5c3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_4a5b644c-4c4f-439a-ab04-00707b0705c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_85f5d0fd-bd92-475e-a4da-c05d9f3ae9f5" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_4a5b644c-4c4f-439a-ab04-00707b0705c3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_4a5b644c-4c4f-439a-ab04-00707b0705c3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_4a5b644c-4c4f-439a-ab04-00707b0705c3" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_4a5b644c-4c4f-439a-ab04-00707b0705c3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_4e9ce99a-26d9-40d0-8bc9-a5acc693e3df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_4a5b644c-4c4f-439a-ab04-00707b0705c3" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_4e9ce99a-26d9-40d0-8bc9-a5acc693e3df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_A2022GileadCollaborationAndLicenseAgreementMember_5602e14e-b2fe-488b-a518-61038f5be57f" xlink:href="mgnx-20231231.xsd#mgnx_A2022GileadCollaborationAndLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_4e9ce99a-26d9-40d0-8bc9-a5acc693e3df" xlink:to="loc_mgnx_A2022GileadCollaborationAndLicenseAgreementMember_5602e14e-b2fe-488b-a518-61038f5be57f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_GileadFirstResearchProgramMember_624558e7-2a7c-4ea6-a34b-aa97697a16b0" xlink:href="mgnx-20231231.xsd#mgnx_GileadFirstResearchProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_4e9ce99a-26d9-40d0-8bc9-a5acc693e3df" xlink:to="loc_mgnx_GileadFirstResearchProgramMember_624558e7-2a7c-4ea6-a34b-aa97697a16b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_f9c84c83-16a4-44fe-af52-bb6cf7b70739" xlink:href="mgnx-20231231.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4f1db51-8415-4dea-a104-4a96efe33f77" xlink:to="loc_mgnx_NonRefundableUpfrontFees_f9c84c83-16a4-44fe-af52-bb6cf7b70739" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialTargetNominationOptionFeesAndMilestonePayments_5f39744c-9f41-4d16-bf06-d0a761a42109" xlink:href="mgnx-20231231.xsd#mgnx_PotentialTargetNominationOptionFeesAndMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4f1db51-8415-4dea-a104-4a96efe33f77" xlink:to="loc_mgnx_PotentialTargetNominationOptionFeesAndMilestonePayments_5f39744c-9f41-4d16-bf06-d0a761a42109" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_f3abc706-3821-413a-8794-a0f11e233030" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4f1db51-8415-4dea-a104-4a96efe33f77" xlink:to="loc_us-gaap_Revenues_f3abc706-3821-413a-8794-a0f11e233030" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_7d62f750-b9b2-4b1d-9a0e-2a2f0fd0f41f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4f1db51-8415-4dea-a104-4a96efe33f77" xlink:to="loc_us-gaap_ContractWithCustomerLiability_7d62f750-b9b2-4b1d-9a0e-2a2f0fd0f41f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_2cf9cbff-76b0-4bc8-a600-854c4e5b53b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4f1db51-8415-4dea-a104-4a96efe33f77" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_2cf9cbff-76b0-4bc8-a600-854c4e5b53b3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_00162e52-ef5d-4cc6-9a12-b6d89d1d8cd1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4f1db51-8415-4dea-a104-4a96efe33f77" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_00162e52-ef5d-4cc6-9a12-b6d89d1d8cd1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_01ebd7a9-5bcd-4ca9-bda1-556987dc942f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4f1db51-8415-4dea-a104-4a96efe33f77" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_01ebd7a9-5bcd-4ca9-bda1-556987dc942f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_OptInFee_531cf01e-5ca1-457c-82fb-13b741a84f9e" xlink:href="mgnx-20231231.xsd#mgnx_OptInFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4f1db51-8415-4dea-a104-4a96efe33f77" xlink:to="loc_mgnx_OptInFee_531cf01e-5ca1-457c-82fb-13b741a84f9e" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/RevenueZaiLabDetails" xlink:type="simple" xlink:href="mgnx-20231231.xsd#RevenueZaiLabDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/RevenueZaiLabDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8868b628-5402-4892-8138-f7dcd1dbf06f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4ea0e5d3-ef5c-4e13-8a3d-0925f13e0f28" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8868b628-5402-4892-8138-f7dcd1dbf06f" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4ea0e5d3-ef5c-4e13-8a3d-0925f13e0f28" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_2757571e-6872-4c13-ad49-eb499290b1f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4ea0e5d3-ef5c-4e13-8a3d-0925f13e0f28" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_2757571e-6872-4c13-ad49-eb499290b1f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2757571e-6872-4c13-ad49-eb499290b1f4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_2757571e-6872-4c13-ad49-eb499290b1f4" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2757571e-6872-4c13-ad49-eb499290b1f4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_586c4970-82d9-4220-b484-51fc81361e93" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_2757571e-6872-4c13-ad49-eb499290b1f4" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_586c4970-82d9-4220-b484-51fc81361e93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_A2021ZaiLabAgreementsMember_da6a82ce-b658-4a79-8cbb-7970f2b7da32" xlink:href="mgnx-20231231.xsd#mgnx_A2021ZaiLabAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_586c4970-82d9-4220-b484-51fc81361e93" xlink:to="loc_mgnx_A2021ZaiLabAgreementsMember_da6a82ce-b658-4a79-8cbb-7970f2b7da32" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_e5630bca-8eb4-452e-87c5-e90c7bd69982" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4ea0e5d3-ef5c-4e13-8a3d-0925f13e0f28" xlink:to="loc_srt_CounterpartyNameAxis_e5630bca-8eb4-452e-87c5-e90c7bd69982" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e5630bca-8eb4-452e-87c5-e90c7bd69982_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_e5630bca-8eb4-452e-87c5-e90c7bd69982" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e5630bca-8eb4-452e-87c5-e90c7bd69982_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d5a7bc08-d3a8-43f6-85b5-fffb04d59c33" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_e5630bca-8eb4-452e-87c5-e90c7bd69982" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d5a7bc08-d3a8-43f6-85b5-fffb04d59c33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabMember_b9a68787-ca31-4dc3-a31a-1017b76f0201" xlink:href="mgnx-20231231.xsd#mgnx_ZaiLabMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d5a7bc08-d3a8-43f6-85b5-fffb04d59c33" xlink:to="loc_mgnx_ZaiLabMember_b9a68787-ca31-4dc3-a31a-1017b76f0201" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_97cdb69a-6e7a-453e-87c7-3533f6dd373d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4ea0e5d3-ef5c-4e13-8a3d-0925f13e0f28" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_97cdb69a-6e7a-453e-87c7-3533f6dd373d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_97cdb69a-6e7a-453e-87c7-3533f6dd373d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_97cdb69a-6e7a-453e-87c7-3533f6dd373d" xlink:to="loc_us-gaap_EquityComponentDomain_97cdb69a-6e7a-453e-87c7-3533f6dd373d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_0aeef096-c68f-4421-a048-e3ad6b681eee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_97cdb69a-6e7a-453e-87c7-3533f6dd373d" xlink:to="loc_us-gaap_EquityComponentDomain_0aeef096-c68f-4421-a048-e3ad6b681eee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_41d90038-1130-4e8d-9bc2-4bb845f3d29b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0aeef096-c68f-4421-a048-e3ad6b681eee" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_41d90038-1130-4e8d-9bc2-4bb845f3d29b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_5c973d65-b753-4b89-b114-61aa291a8af5" xlink:href="mgnx-20231231.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8868b628-5402-4892-8138-f7dcd1dbf06f" xlink:to="loc_mgnx_NonRefundableUpfrontFees_5c973d65-b753-4b89-b114-61aa291a8af5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_80cefb5e-297e-4cce-90d5-8747215dd3af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8868b628-5402-4892-8138-f7dcd1dbf06f" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_80cefb5e-297e-4cce-90d5-8747215dd3af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_69cbfdf1-ff52-4734-8a1b-3169a8898ff9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8868b628-5402-4892-8138-f7dcd1dbf06f" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_69cbfdf1-ff52-4734-8a1b-3169a8898ff9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_f2521bb9-e08c-4306-b52a-0e057aa8133b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8868b628-5402-4892-8138-f7dcd1dbf06f" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_f2521bb9-e08c-4306-b52a-0e057aa8133b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementTransactionPrice_f8f17c2e-1a7a-40ad-afe7-7b92d7c6556b" xlink:href="mgnx-20231231.xsd#mgnx_CollaborativeAgreementTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8868b628-5402-4892-8138-f7dcd1dbf06f" xlink:to="loc_mgnx_CollaborativeAgreementTransactionPrice_f8f17c2e-1a7a-40ad-afe7-7b92d7c6556b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PremiumReceivedOnStockPurchase_c5ccfd0b-cfa5-4d95-9433-3c4072abf0eb" xlink:href="mgnx-20231231.xsd#mgnx_PremiumReceivedOnStockPurchase"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8868b628-5402-4892-8138-f7dcd1dbf06f" xlink:to="loc_mgnx_PremiumReceivedOnStockPurchase_c5ccfd0b-cfa5-4d95-9433-3c4072abf0eb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EstimatedReimbursementForResearchAndDevelopmentT_e81fb230-ae81-4c1c-ab9a-155fd199c9bc" xlink:href="mgnx-20231231.xsd#mgnx_EstimatedReimbursementForResearchAndDevelopmentT"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8868b628-5402-4892-8138-f7dcd1dbf06f" xlink:to="loc_mgnx_EstimatedReimbursementForResearchAndDevelopmentT_e81fb230-ae81-4c1c-ab9a-155fd199c9bc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_115c1b73-2ffe-4bbe-80e2-1bc76837e39b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8868b628-5402-4892-8138-f7dcd1dbf06f" xlink:to="loc_us-gaap_Revenues_115c1b73-2ffe-4bbe-80e2-1bc76837e39b" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/RevenueProventionDetails" xlink:type="simple" xlink:href="mgnx-20231231.xsd#RevenueProventionDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/RevenueProventionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fa05a100-ebbd-4278-b230-e62ba0ef5223" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0e85fbf2-1ce9-4f44-bee5-70ddf3b2ef57" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fa05a100-ebbd-4278-b230-e62ba0ef5223" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0e85fbf2-1ce9-4f44-bee5-70ddf3b2ef57" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_010b9c09-2bf2-4a9d-b5f1-d7a488e44210" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0e85fbf2-1ce9-4f44-bee5-70ddf3b2ef57" xlink:to="loc_srt_CounterpartyNameAxis_010b9c09-2bf2-4a9d-b5f1-d7a488e44210" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_010b9c09-2bf2-4a9d-b5f1-d7a488e44210_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_010b9c09-2bf2-4a9d-b5f1-d7a488e44210" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_010b9c09-2bf2-4a9d-b5f1-d7a488e44210_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d6c669cc-3ef5-4996-aff1-a14e0a158747" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_010b9c09-2bf2-4a9d-b5f1-d7a488e44210" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d6c669cc-3ef5-4996-aff1-a14e0a158747" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionBioMember_470b60d2-2888-4684-80a6-5f7aa9a6fc0d" xlink:href="mgnx-20231231.xsd#mgnx_ProventionBioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d6c669cc-3ef5-4996-aff1-a14e0a158747" xlink:to="loc_mgnx_ProventionBioMember_470b60d2-2888-4684-80a6-5f7aa9a6fc0d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DRIHealthcareAcquisitionsLPDRIMember_afee3330-14dd-4b38-bcef-646f791cf240" xlink:href="mgnx-20231231.xsd#mgnx_DRIHealthcareAcquisitionsLPDRIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d6c669cc-3ef5-4996-aff1-a14e0a158747" xlink:to="loc_mgnx_DRIHealthcareAcquisitionsLPDRIMember_afee3330-14dd-4b38-bcef-646f791cf240" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_89ceba84-823c-4046-9e7b-fbb5b71be1f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0e85fbf2-1ce9-4f44-bee5-70ddf3b2ef57" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_89ceba84-823c-4046-9e7b-fbb5b71be1f6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_89ceba84-823c-4046-9e7b-fbb5b71be1f6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_89ceba84-823c-4046-9e7b-fbb5b71be1f6" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_89ceba84-823c-4046-9e7b-fbb5b71be1f6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_b1690717-19b4-4c0b-84de-93299b7a2f18" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_89ceba84-823c-4046-9e7b-fbb5b71be1f6" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_b1690717-19b4-4c0b-84de-93299b7a2f18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionPRV3279Member_2e64d0eb-6f60-4428-8163-14bb6b1219d9" xlink:href="mgnx-20231231.xsd#mgnx_ProventionPRV3279Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_b1690717-19b4-4c0b-84de-93299b7a2f18" xlink:to="loc_mgnx_ProventionPRV3279Member_2e64d0eb-6f60-4428-8163-14bb6b1219d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionPRV031Member_2ec1ba9d-7c5f-4255-aeee-582fe87bc7af" xlink:href="mgnx-20231231.xsd#mgnx_ProventionPRV031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_b1690717-19b4-4c0b-84de-93299b7a2f18" xlink:to="loc_mgnx_ProventionPRV031Member_2ec1ba9d-7c5f-4255-aeee-582fe87bc7af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_8fe6adaf-44e0-465a-a999-2ea1b96678e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0e85fbf2-1ce9-4f44-bee5-70ddf3b2ef57" xlink:to="loc_us-gaap_TypeOfArrangementAxis_8fe6adaf-44e0-465a-a999-2ea1b96678e0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8fe6adaf-44e0-465a-a999-2ea1b96678e0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8fe6adaf-44e0-465a-a999-2ea1b96678e0" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8fe6adaf-44e0-465a-a999-2ea1b96678e0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_41184408-e8c8-4d5f-a1e2-7161af6595f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8fe6adaf-44e0-465a-a999-2ea1b96678e0" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_41184408-e8c8-4d5f-a1e2-7161af6595f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionLicenseAgreementMember_59137357-f95f-451f-bbd7-51beee9c16f2" xlink:href="mgnx-20231231.xsd#mgnx_ProventionLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_41184408-e8c8-4d5f-a1e2-7161af6595f6" xlink:to="loc_mgnx_ProventionLicenseAgreementMember_59137357-f95f-451f-bbd7-51beee9c16f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AssetPurchaseAgreementMember_45fcac5e-9042-44f1-a519-3a620c15a28b" xlink:href="mgnx-20231231.xsd#mgnx_AssetPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_41184408-e8c8-4d5f-a1e2-7161af6595f6" xlink:to="loc_mgnx_AssetPurchaseAgreementMember_45fcac5e-9042-44f1-a519-3a620c15a28b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_2e015e95-750c-46fc-b5f7-983f0e879561" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0e85fbf2-1ce9-4f44-bee5-70ddf3b2ef57" xlink:to="loc_srt_ProductOrServiceAxis_2e015e95-750c-46fc-b5f7-983f0e879561" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2e015e95-750c-46fc-b5f7-983f0e879561_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_2e015e95-750c-46fc-b5f7-983f0e879561" xlink:to="loc_srt_ProductsAndServicesDomain_2e015e95-750c-46fc-b5f7-983f0e879561_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2d66b893-3db4-47e0-a55a-968171a711e6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_2e015e95-750c-46fc-b5f7-983f0e879561" xlink:to="loc_srt_ProductsAndServicesDomain_2d66b893-3db4-47e0-a55a-968171a711e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember_fe7de64a-f24e-4009-8f5c-2ebd73959758" xlink:href="mgnx-20231231.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2d66b893-3db4-47e0-a55a-968171a711e6" xlink:to="loc_mgnx_RevenuesFromLicenseAgreementsMember_fe7de64a-f24e-4009-8f5c-2ebd73959758" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AssetPurchaseAgreementMember_5dea7763-f6a5-43f0-b882-ea575dbe930a" xlink:href="mgnx-20231231.xsd#mgnx_AssetPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2d66b893-3db4-47e0-a55a-968171a711e6" xlink:to="loc_mgnx_AssetPurchaseAgreementMember_5dea7763-f6a5-43f0-b882-ea575dbe930a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_58349b2a-6c95-4bfc-844e-7a8889dc8d25" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2d66b893-3db4-47e0-a55a-968171a711e6" xlink:to="loc_us-gaap_RoyaltyMember_58349b2a-6c95-4bfc-844e-7a8889dc8d25" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare_9fd63d8e-ca7a-492e-a857-f5b188f47221" xlink:href="mgnx-20231231.xsd#mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fa05a100-ebbd-4278-b230-e62ba0ef5223" xlink:to="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare_9fd63d8e-ca7a-492e-a857-f5b188f47221" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_052c3dda-c65d-4c55-9a58-5324cc55cb7f" xlink:href="mgnx-20231231.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fa05a100-ebbd-4278-b230-e62ba0ef5223" xlink:to="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_052c3dda-c65d-4c55-9a58-5324cc55cb7f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_5f11760d-9459-4edd-b750-720b3686b875" xlink:href="mgnx-20231231.xsd#mgnx_PotentialCommercialMilestonePaymentsUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fa05a100-ebbd-4278-b230-e62ba0ef5223" xlink:to="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_5f11760d-9459-4edd-b750-720b3686b875" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_8adf96e8-8e0d-401a-bd0c-9ebefcb2b747" xlink:href="mgnx-20231231.xsd#mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fa05a100-ebbd-4278-b230-e62ba0ef5223" xlink:to="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_8adf96e8-8e0d-401a-bd0c-9ebefcb2b747" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement_82005fe6-61e7-474b-9b93-6c61870c69ee" xlink:href="mgnx-20231231.xsd#mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fa05a100-ebbd-4278-b230-e62ba0ef5223" xlink:to="loc_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement_82005fe6-61e7-474b-9b93-6c61870c69ee" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementTransactionPrice_868c5518-72fc-4cea-b74b-d26680f52821" xlink:href="mgnx-20231231.xsd#mgnx_CollaborativeAgreementTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fa05a100-ebbd-4278-b230-e62ba0ef5223" xlink:to="loc_mgnx_CollaborativeAgreementTransactionPrice_868c5518-72fc-4cea-b74b-d26680f52821" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares_5be29f04-398d-497e-aa9b-abdc3dc97045" xlink:href="mgnx-20231231.xsd#mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fa05a100-ebbd-4278-b230-e62ba0ef5223" xlink:to="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares_5be29f04-398d-497e-aa9b-abdc3dc97045" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_46341777-37e2-4bcd-815b-805728159ad4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fa05a100-ebbd-4278-b230-e62ba0ef5223" xlink:to="loc_us-gaap_Revenues_46341777-37e2-4bcd-815b-805728159ad4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_FutureRevenue_47504475-291d-465e-b235-d2d1d00ba767" xlink:href="mgnx-20231231.xsd#mgnx_FutureRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fa05a100-ebbd-4278-b230-e62ba0ef5223" xlink:to="loc_mgnx_FutureRevenue_47504475-291d-465e-b235-d2d1d00ba767" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/RevenueManufacturingServiceAgreementsDetails" xlink:type="simple" xlink:href="mgnx-20231231.xsd#RevenueManufacturingServiceAgreementsDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/RevenueManufacturingServiceAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_41e08c2f-a23a-4603-a60f-ddfe7fac3a1b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e49f182b-2361-41a8-b8a1-90d33f3a4fa0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_41e08c2f-a23a-4603-a60f-ddfe7fac3a1b" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e49f182b-2361-41a8-b8a1-90d33f3a4fa0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_ba6a6d49-52c6-435d-9873-920027eb20cf" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e49f182b-2361-41a8-b8a1-90d33f3a4fa0" xlink:to="loc_srt_CounterpartyNameAxis_ba6a6d49-52c6-435d-9873-920027eb20cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ba6a6d49-52c6-435d-9873-920027eb20cf_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_ba6a6d49-52c6-435d-9873-920027eb20cf" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ba6a6d49-52c6-435d-9873-920027eb20cf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a3234af6-514e-4a12-a04a-b08edc86ad81" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_ba6a6d49-52c6-435d-9873-920027eb20cf" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a3234af6-514e-4a12-a04a-b08edc86ad81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteCorporationMember_a452ebe8-fdf8-434f-93ea-ea930d8fc11a" xlink:href="mgnx-20231231.xsd#mgnx_IncyteCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a3234af6-514e-4a12-a04a-b08edc86ad81" xlink:to="loc_mgnx_IncyteCorporationMember_a452ebe8-fdf8-434f-93ea-ea930d8fc11a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionBioMember_14319136-3148-4703-a0d6-c140bb40f397" xlink:href="mgnx-20231231.xsd#mgnx_ProventionBioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a3234af6-514e-4a12-a04a-b08edc86ad81" xlink:to="loc_mgnx_ProventionBioMember_14319136-3148-4703-a0d6-c140bb40f397" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_a1248d9f-f349-4139-8732-79fca21ed41a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e49f182b-2361-41a8-b8a1-90d33f3a4fa0" xlink:to="loc_us-gaap_TypeOfArrangementAxis_a1248d9f-f349-4139-8732-79fca21ed41a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a1248d9f-f349-4139-8732-79fca21ed41a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a1248d9f-f349-4139-8732-79fca21ed41a" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a1248d9f-f349-4139-8732-79fca21ed41a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bbd42043-06bd-48c0-a23d-41fa97917dd3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a1248d9f-f349-4139-8732-79fca21ed41a" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bbd42043-06bd-48c0-a23d-41fa97917dd3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_014b2e7e-b61b-4a6a-a62a-a0ad8c17fdf6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bbd42043-06bd-48c0-a23d-41fa97917dd3" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_014b2e7e-b61b-4a6a-a62a-a0ad8c17fdf6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_8db1214d-716e-407a-a667-e328f85eb73c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e49f182b-2361-41a8-b8a1-90d33f3a4fa0" xlink:to="loc_srt_ProductOrServiceAxis_8db1214d-716e-407a-a667-e328f85eb73c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8db1214d-716e-407a-a667-e328f85eb73c_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_8db1214d-716e-407a-a667-e328f85eb73c" xlink:to="loc_srt_ProductsAndServicesDomain_8db1214d-716e-407a-a667-e328f85eb73c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ecef7283-2e09-4c39-8d39-818045a1f7b3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_8db1214d-716e-407a-a667-e328f85eb73c" xlink:to="loc_srt_ProductsAndServicesDomain_ecef7283-2e09-4c39-8d39-818045a1f7b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromCMOAgreementsMemberMember_afacab4a-267a-468f-aa3d-0fc1f166acaf" xlink:href="mgnx-20231231.xsd#mgnx_RevenuesFromCMOAgreementsMemberMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ecef7283-2e09-4c39-8d39-818045a1f7b3" xlink:to="loc_mgnx_RevenuesFromCMOAgreementsMemberMember_afacab4a-267a-468f-aa3d-0fc1f166acaf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromCMOAmendmentAgreementMember_6239595c-404d-45af-aadf-08da6174cf23" xlink:href="mgnx-20231231.xsd#mgnx_RevenuesFromCMOAmendmentAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ecef7283-2e09-4c39-8d39-818045a1f7b3" xlink:to="loc_mgnx_RevenuesFromCMOAmendmentAgreementMember_6239595c-404d-45af-aadf-08da6174cf23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionBioCMOAgreeemntMember_befb49fa-12e0-4a0e-a105-585a656de380" xlink:href="mgnx-20231231.xsd#mgnx_ProventionBioCMOAgreeemntMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ecef7283-2e09-4c39-8d39-818045a1f7b3" xlink:to="loc_mgnx_ProventionBioCMOAgreeemntMember_befb49fa-12e0-4a0e-a105-585a656de380" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeArrangementTerm_bf47d965-f8be-436f-b8df-cad74821902f" xlink:href="mgnx-20231231.xsd#mgnx_CollaborativeArrangementTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_41e08c2f-a23a-4603-a60f-ddfe7fac3a1b" xlink:to="loc_mgnx_CollaborativeArrangementTerm_bf47d965-f8be-436f-b8df-cad74821902f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_16055097-6410-4ed8-9ff5-c3a181b5ddd4" xlink:href="mgnx-20231231.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_41e08c2f-a23a-4603-a60f-ddfe7fac3a1b" xlink:to="loc_mgnx_NonRefundableUpfrontFees_16055097-6410-4ed8-9ff5-c3a181b5ddd4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TotalAnnualFixedPayments_c5dfb4e1-de58-4149-99dd-6bb9be068c2a" xlink:href="mgnx-20231231.xsd#mgnx_TotalAnnualFixedPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_41e08c2f-a23a-4603-a60f-ddfe7fac3a1b" xlink:to="loc_mgnx_TotalAnnualFixedPayments_c5dfb4e1-de58-4149-99dd-6bb9be068c2a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeArrangementExtensionTerm_9e6b4e2c-038e-450a-b0bc-d258517ecbb7" xlink:href="mgnx-20231231.xsd#mgnx_CollaborativeArrangementExtensionTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_41e08c2f-a23a-4603-a60f-ddfe7fac3a1b" xlink:to="loc_mgnx_CollaborativeArrangementExtensionTerm_9e6b4e2c-038e-450a-b0bc-d258517ecbb7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AdditionalAnnualFixedPayments_c0038ced-de05-40e7-9e2b-c5dea0fa5c29" xlink:href="mgnx-20231231.xsd#mgnx_AdditionalAnnualFixedPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_41e08c2f-a23a-4603-a60f-ddfe7fac3a1b" xlink:to="loc_mgnx_AdditionalAnnualFixedPayments_c0038ced-de05-40e7-9e2b-c5dea0fa5c29" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_c0c23799-03c4-4104-afc6-671e87e7c52d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_41e08c2f-a23a-4603-a60f-ddfe7fac3a1b" xlink:to="loc_us-gaap_Revenues_c0c23799-03c4-4104-afc6-671e87e7c52d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_df44ff43-12dd-4328-830f-c65d639fb700" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_41e08c2f-a23a-4603-a60f-ddfe7fac3a1b" xlink:to="loc_us-gaap_ContractWithCustomerLiability_df44ff43-12dd-4328-830f-c65d639fb700" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_225f2cae-1c5f-434c-9d7d-c1dd0a974519" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_41e08c2f-a23a-4603-a60f-ddfe7fac3a1b" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_225f2cae-1c5f-434c-9d7d-c1dd0a974519" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_af382196-ccae-4afc-907d-a8e05e494d68" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_41e08c2f-a23a-4603-a60f-ddfe7fac3a1b" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_af382196-ccae-4afc-907d-a8e05e494d68" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_UpfrontAndFixedPayments_7feab07e-4e40-45fd-8d68-a65756d2119a" xlink:href="mgnx-20231231.xsd#mgnx_UpfrontAndFixedPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_41e08c2f-a23a-4603-a60f-ddfe7fac3a1b" xlink:to="loc_mgnx_UpfrontAndFixedPayments_7feab07e-4e40-45fd-8d68-a65756d2119a" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/RevenueNIAIDContractDetails" xlink:type="simple" xlink:href="mgnx-20231231.xsd#RevenueNIAIDContractDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/RevenueNIAIDContractDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_47efd281-e019-415d-8709-007dbd87f101" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f02aaf57-4a33-45ce-9989-a99d71becd0b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_47efd281-e019-415d-8709-007dbd87f101" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f02aaf57-4a33-45ce-9989-a99d71becd0b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_084d8057-1daa-41c7-bef6-1c30a85f28c0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f02aaf57-4a33-45ce-9989-a99d71becd0b" xlink:to="loc_srt_ProductOrServiceAxis_084d8057-1daa-41c7-bef6-1c30a85f28c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_084d8057-1daa-41c7-bef6-1c30a85f28c0_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_084d8057-1daa-41c7-bef6-1c30a85f28c0" xlink:to="loc_srt_ProductsAndServicesDomain_084d8057-1daa-41c7-bef6-1c30a85f28c0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f35f060d-06e5-464b-b013-11f069e01551" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_084d8057-1daa-41c7-bef6-1c30a85f28c0" xlink:to="loc_srt_ProductsAndServicesDomain_f35f060d-06e5-464b-b013-11f069e01551" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromGrantsMember_0d456f57-7ca1-4577-8830-33b1f40ee787" xlink:href="mgnx-20231231.xsd#mgnx_RevenuesFromGrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f35f060d-06e5-464b-b013-11f069e01551" xlink:to="loc_mgnx_RevenuesFromGrantsMember_0d456f57-7ca1-4577-8830-33b1f40ee787" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_7b2b69e9-8fb0-4d28-a166-10ae0d7ce675" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f02aaf57-4a33-45ce-9989-a99d71becd0b" xlink:to="loc_srt_CounterpartyNameAxis_7b2b69e9-8fb0-4d28-a166-10ae0d7ce675" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7b2b69e9-8fb0-4d28-a166-10ae0d7ce675_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_7b2b69e9-8fb0-4d28-a166-10ae0d7ce675" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7b2b69e9-8fb0-4d28-a166-10ae0d7ce675_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f52d9ac6-05b3-4ae2-b942-06392ca3f9cf" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_7b2b69e9-8fb0-4d28-a166-10ae0d7ce675" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f52d9ac6-05b3-4ae2-b942-06392ca3f9cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_65d7ea02-21aa-4498-b12c-3130b1f4a06e" xlink:href="mgnx-20231231.xsd#mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f52d9ac6-05b3-4ae2-b942-06392ca3f9cf" xlink:to="loc_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_65d7ea02-21aa-4498-b12c-3130b1f4a06e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfProductCandidates_d1a0ecb6-199b-4654-a67f-f4a536da35fe" xlink:href="mgnx-20231231.xsd#mgnx_NumberOfProductCandidates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_47efd281-e019-415d-8709-007dbd87f101" xlink:to="loc_mgnx_NumberOfProductCandidates_d1a0ecb6-199b-4654-a67f-f4a536da35fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TotalPotentialValueUnderAgreement_0228667e-1805-4e87-a839-2e18ea054a69" xlink:href="mgnx-20231231.xsd#mgnx_TotalPotentialValueUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_47efd281-e019-415d-8709-007dbd87f101" xlink:to="loc_mgnx_TotalPotentialValueUnderAgreement_0228667e-1805-4e87-a839-2e18ea054a69" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_2448a006-cb70-4fb6-9287-cbbfe8a90b85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_47efd281-e019-415d-8709-007dbd87f101" xlink:to="loc_us-gaap_Revenues_2448a006-cb70-4fb6-9287-cbbfe8a90b85" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockbasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="mgnx-20231231.xsd#StockbasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/StockbasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5461c8e0-9f06-4c0c-8db9-903cc3b85be9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0a9fbbd7-bc33-436f-8b63-5f590822b30d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5461c8e0-9f06-4c0c-8db9-903cc3b85be9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0a9fbbd7-bc33-436f-8b63-5f590822b30d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_962cde7e-6a96-47d2-b383-016e16181e0b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0a9fbbd7-bc33-436f-8b63-5f590822b30d" xlink:to="loc_us-gaap_PlanNameAxis_962cde7e-6a96-47d2-b383-016e16181e0b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_962cde7e-6a96-47d2-b383-016e16181e0b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_962cde7e-6a96-47d2-b383-016e16181e0b" xlink:to="loc_us-gaap_PlanNameDomain_962cde7e-6a96-47d2-b383-016e16181e0b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_a1aa003a-34c1-411d-b9fc-f2f675ce26fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_962cde7e-6a96-47d2-b383-016e16181e0b" xlink:to="loc_us-gaap_PlanNameDomain_a1aa003a-34c1-411d-b9fc-f2f675ce26fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember_8e94177f-0281-4e95-9f25-89439d35ee10" xlink:href="mgnx-20231231.xsd#mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_a1aa003a-34c1-411d-b9fc-f2f675ce26fa" xlink:to="loc_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember_8e94177f-0281-4e95-9f25-89439d35ee10" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIncentivePlan2023MemberMember_d173eb68-3283-4719-b988-64a8dab80c8b" xlink:href="mgnx-20231231.xsd#mgnx_StockIncentivePlan2023MemberMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_a1aa003a-34c1-411d-b9fc-f2f675ce26fa" xlink:to="loc_mgnx_StockIncentivePlan2023MemberMember_d173eb68-3283-4719-b988-64a8dab80c8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIncentivePlan2013Member_1b24433c-1fee-48c2-b400-f52338722161" xlink:href="mgnx-20231231.xsd#mgnx_StockIncentivePlan2013Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_a1aa003a-34c1-411d-b9fc-f2f675ce26fa" xlink:to="loc_mgnx_StockIncentivePlan2013Member_1b24433c-1fee-48c2-b400-f52338722161" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_21d4aa62-49ae-4b15-8b30-0b32a2ce5046" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0a9fbbd7-bc33-436f-8b63-5f590822b30d" xlink:to="loc_us-gaap_AwardTypeAxis_21d4aa62-49ae-4b15-8b30-0b32a2ce5046" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_21d4aa62-49ae-4b15-8b30-0b32a2ce5046_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_21d4aa62-49ae-4b15-8b30-0b32a2ce5046" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_21d4aa62-49ae-4b15-8b30-0b32a2ce5046_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_96121e11-1681-4bfb-aac6-bc8f20325103" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_21d4aa62-49ae-4b15-8b30-0b32a2ce5046" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_96121e11-1681-4bfb-aac6-bc8f20325103" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_d7108a82-be44-4515-83a5-e9eb88f43836" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_96121e11-1681-4bfb-aac6-bc8f20325103" xlink:to="loc_us-gaap_EmployeeStockMember_d7108a82-be44-4515-83a5-e9eb88f43836" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_07c1c59c-7206-4cd4-8e76-4716de389c98" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_96121e11-1681-4bfb-aac6-bc8f20325103" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_07c1c59c-7206-4cd4-8e76-4716de389c98" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_1634b8ac-12e2-4eb3-a332-8383fb1d048c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5461c8e0-9f06-4c0c-8db9-903cc3b85be9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_1634b8ac-12e2-4eb3-a332-8383fb1d048c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_5ce0a782-3078-4530-9596-1298698b812d" xlink:href="mgnx-20231231.xsd#mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5461c8e0-9f06-4c0c-8db9-903cc3b85be9" xlink:to="loc_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_5ce0a782-3078-4530-9596-1298698b812d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_98aea995-f000-473e-bd88-e3b1ac7fe76d" xlink:href="mgnx-20231231.xsd#mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5461c8e0-9f06-4c0c-8db9-903cc3b85be9" xlink:to="loc_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_98aea995-f000-473e-bd88-e3b1ac7fe76d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_5b79547b-4550-404b-a196-717547fd2dfb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5461c8e0-9f06-4c0c-8db9-903cc3b85be9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_5b79547b-4550-404b-a196-717547fd2dfb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_b558f1a6-5c74-4897-a11b-8b63ffd0f263" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5461c8e0-9f06-4c0c-8db9-903cc3b85be9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_b558f1a6-5c74-4897-a11b-8b63ffd0f263" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_e2d70747-7006-41e0-a2d4-91fceaf979a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5461c8e0-9f06-4c0c-8db9-903cc3b85be9" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_e2d70747-7006-41e0-a2d4-91fceaf979a0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7c53353a-6d29-46cf-9c7d-4d3cdacae1c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5461c8e0-9f06-4c0c-8db9-903cc3b85be9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7c53353a-6d29-46cf-9c7d-4d3cdacae1c8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_81a803f8-4d02-4170-8806-4927606f9d2b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5461c8e0-9f06-4c0c-8db9-903cc3b85be9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_81a803f8-4d02-4170-8806-4927606f9d2b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f8aa5748-7389-496c-9786-0ec58b50f9d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5461c8e0-9f06-4c0c-8db9-903cc3b85be9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f8aa5748-7389-496c-9786-0ec58b50f9d5" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_c795878f-9d2e-413b-aa92-62fe74cfbbcf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5461c8e0-9f06-4c0c-8db9-903cc3b85be9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_c795878f-9d2e-413b-aa92-62fe74cfbbcf" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_794df8b2-29e5-454b-97a3-a2fd7fd162f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5461c8e0-9f06-4c0c-8db9-903cc3b85be9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_794df8b2-29e5-454b-97a3-a2fd7fd162f1" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_5302655e-b788-4977-a8c1-960ea98fda5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5461c8e0-9f06-4c0c-8db9-903cc3b85be9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_5302655e-b788-4977-a8c1-960ea98fda5a" xlink:type="arc" order="11"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="mgnx-20231231.xsd#StockbasedCompensationStockBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_824957e9-a39d-4ff5-b7be-a83547530a5f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c4168877-4596-47d6-8d61-7b3e3901992b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_824957e9-a39d-4ff5-b7be-a83547530a5f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c4168877-4596-47d6-8d61-7b3e3901992b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_46719c8e-38f7-455b-8921-b553c3a71609" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c4168877-4596-47d6-8d61-7b3e3901992b" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_46719c8e-38f7-455b-8921-b553c3a71609" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_46719c8e-38f7-455b-8921-b553c3a71609_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_46719c8e-38f7-455b-8921-b553c3a71609" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_46719c8e-38f7-455b-8921-b553c3a71609_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9d64085f-7c22-4105-8747-7def621fa442" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_46719c8e-38f7-455b-8921-b553c3a71609" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9d64085f-7c22-4105-8747-7def621fa442" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_dc4b412a-a223-44c7-83c4-6a042b282002" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9d64085f-7c22-4105-8747-7def621fa442" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_dc4b412a-a223-44c7-83c4-6a042b282002" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_3b420ee4-2117-49e4-974f-9c288f5e9cc1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9d64085f-7c22-4105-8747-7def621fa442" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_3b420ee4-2117-49e4-974f-9c288f5e9cc1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_dc8ce1e5-3855-4c55-831f-7fd22797baff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_824957e9-a39d-4ff5-b7be-a83547530a5f" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_dc8ce1e5-3855-4c55-831f-7fd22797baff" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails" xlink:type="simple" xlink:href="mgnx-20231231.xsd#StockbasedCompensationOptionPricingAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d749c301-040f-45ae-ae46-fd6ff2f03f77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ac6fdf9b-73d9-443c-87f1-32938cc8b558" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d749c301-040f-45ae-ae46-fd6ff2f03f77" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ac6fdf9b-73d9-443c-87f1-32938cc8b558" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f8ea0b14-f42d-43d8-bda5-ad0194fa3ae4" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ac6fdf9b-73d9-443c-87f1-32938cc8b558" xlink:to="loc_srt_RangeAxis_f8ea0b14-f42d-43d8-bda5-ad0194fa3ae4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f8ea0b14-f42d-43d8-bda5-ad0194fa3ae4_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_f8ea0b14-f42d-43d8-bda5-ad0194fa3ae4" xlink:to="loc_srt_RangeMember_f8ea0b14-f42d-43d8-bda5-ad0194fa3ae4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_58ab4f17-3381-4493-a793-ecbb8b0fd0fa" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_f8ea0b14-f42d-43d8-bda5-ad0194fa3ae4" xlink:to="loc_srt_RangeMember_58ab4f17-3381-4493-a793-ecbb8b0fd0fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b6514423-84a2-49ba-a0bb-be471d314115" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_58ab4f17-3381-4493-a793-ecbb8b0fd0fa" xlink:to="loc_srt_MinimumMember_b6514423-84a2-49ba-a0bb-be471d314115" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0697546f-6e29-4b3b-b019-a77f1edcb925" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_58ab4f17-3381-4493-a793-ecbb8b0fd0fa" xlink:to="loc_srt_MaximumMember_0697546f-6e29-4b3b-b019-a77f1edcb925" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3f602b55-f96a-410e-bb9d-67830255dd5f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d749c301-040f-45ae-ae46-fd6ff2f03f77" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3f602b55-f96a-410e-bb9d-67830255dd5f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_634c783c-0418-4ac3-abfa-9a6040a3e6e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d749c301-040f-45ae-ae46-fd6ff2f03f77" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_634c783c-0418-4ac3-abfa-9a6040a3e6e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_33d4c678-29be-4f8f-b7ac-cb95db3d9f14" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d749c301-040f-45ae-ae46-fd6ff2f03f77" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_33d4c678-29be-4f8f-b7ac-cb95db3d9f14" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_fc3f23c0-af30-4521-8991-c60c60d234a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d749c301-040f-45ae-ae46-fd6ff2f03f77" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_fc3f23c0-af30-4521-8991-c60c60d234a2" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails" xlink:type="simple" xlink:href="mgnx-20231231.xsd#StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13a6e990-23c4-412b-bbb4-ff93ca6cbab2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1d31942c-e2f7-4907-8af7-a2dd15823d13" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13a6e990-23c4-412b-bbb4-ff93ca6cbab2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1d31942c-e2f7-4907-8af7-a2dd15823d13" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e5b8a88c-2fc4-4b31-8632-bcfd50a79133" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1d31942c-e2f7-4907-8af7-a2dd15823d13" xlink:to="loc_us-gaap_AwardTypeAxis_e5b8a88c-2fc4-4b31-8632-bcfd50a79133" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e5b8a88c-2fc4-4b31-8632-bcfd50a79133_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_e5b8a88c-2fc4-4b31-8632-bcfd50a79133" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e5b8a88c-2fc4-4b31-8632-bcfd50a79133_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b155218b-4d3e-4f79-9b4a-f912b6571544" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_e5b8a88c-2fc4-4b31-8632-bcfd50a79133" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b155218b-4d3e-4f79-9b4a-f912b6571544" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_3f354231-f62f-44b9-9d8b-5ca08faa8c28" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b155218b-4d3e-4f79-9b4a-f912b6571544" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_3f354231-f62f-44b9-9d8b-5ca08faa8c28" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_e3dc649d-285d-4823-9ddd-7d9ed214e6a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1d31942c-e2f7-4907-8af7-a2dd15823d13" xlink:to="loc_us-gaap_PlanNameAxis_e3dc649d-285d-4823-9ddd-7d9ed214e6a2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_e3dc649d-285d-4823-9ddd-7d9ed214e6a2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_e3dc649d-285d-4823-9ddd-7d9ed214e6a2" xlink:to="loc_us-gaap_PlanNameDomain_e3dc649d-285d-4823-9ddd-7d9ed214e6a2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_800be13f-426a-479c-ab32-5e7cdfbb61b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_e3dc649d-285d-4823-9ddd-7d9ed214e6a2" xlink:to="loc_us-gaap_PlanNameDomain_800be13f-426a-479c-ab32-5e7cdfbb61b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIncentivePlan2013Member_6231ea56-6c5f-44d8-a001-46ab84d80ca1" xlink:href="mgnx-20231231.xsd#mgnx_StockIncentivePlan2013Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_800be13f-426a-479c-ab32-5e7cdfbb61b9" xlink:to="loc_mgnx_StockIncentivePlan2013Member_6231ea56-6c5f-44d8-a001-46ab84d80ca1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8d64c90f-0c0c-487f-9cc4-f2d1fa084517" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13a6e990-23c4-412b-bbb4-ff93ca6cbab2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8d64c90f-0c0c-487f-9cc4-f2d1fa084517" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_de7fdd4a-4c35-4a88-bbff-2a23d9cf8ff3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8d64c90f-0c0c-487f-9cc4-f2d1fa084517" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_de7fdd4a-4c35-4a88-bbff-2a23d9cf8ff3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_10452ffb-db85-49a4-988a-0e73318e1170" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8d64c90f-0c0c-487f-9cc4-f2d1fa084517" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_10452ffb-db85-49a4-988a-0e73318e1170" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b71e67e7-1f56-419b-bd89-20d3de43ac3a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8d64c90f-0c0c-487f-9cc4-f2d1fa084517" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b71e67e7-1f56-419b-bd89-20d3de43ac3a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_57dbfe4d-8738-4b37-8c90-519e52501ec8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8d64c90f-0c0c-487f-9cc4-f2d1fa084517" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_57dbfe4d-8738-4b37-8c90-519e52501ec8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_f7bf4c40-34eb-4a92-ae08-23ad9fa8fd23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8d64c90f-0c0c-487f-9cc4-f2d1fa084517" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_f7bf4c40-34eb-4a92-ae08-23ad9fa8fd23" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_06218069-0161-4b0e-8e43-08c04ea750f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_eea69c83-2914-4566-a855-ae0f3d0f60a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8d64c90f-0c0c-487f-9cc4-f2d1fa084517" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_eea69c83-2914-4566-a855-ae0f3d0f60a8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_a24e9e09-18a4-4645-bff3-6a7c7f9e3395" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8d64c90f-0c0c-487f-9cc4-f2d1fa084517" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_a24e9e09-18a4-4645-bff3-6a7c7f9e3395" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_034ef461-a5be-4bbd-9350-e985bdbfe884" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13a6e990-23c4-412b-bbb4-ff93ca6cbab2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_034ef461-a5be-4bbd-9350-e985bdbfe884" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8d877c75-588b-4fbc-8dc3-b4348a1b1c6a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_034ef461-a5be-4bbd-9350-e985bdbfe884" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8d877c75-588b-4fbc-8dc3-b4348a1b1c6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_68f5ae66-1e44-43c0-8f29-ba65e3f43489" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_034ef461-a5be-4bbd-9350-e985bdbfe884" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_68f5ae66-1e44-43c0-8f29-ba65e3f43489" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_92c072bc-e812-4a8a-a83c-3e42ceca404f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_034ef461-a5be-4bbd-9350-e985bdbfe884" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_92c072bc-e812-4a8a-a83c-3e42ceca404f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_49c33d88-3e26-4c54-aff3-a3259d0a1244" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_034ef461-a5be-4bbd-9350-e985bdbfe884" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_49c33d88-3e26-4c54-aff3-a3259d0a1244" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_896ef6fa-7b44-489e-8847-2b9c2512977d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_034ef461-a5be-4bbd-9350-e985bdbfe884" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_896ef6fa-7b44-489e-8847-2b9c2512977d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_418942d2-8c0e-4b5b-9e4e-cd7226afc532" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_158ba202-334c-400c-a669-f180140d4238" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_034ef461-a5be-4bbd-9350-e985bdbfe884" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_158ba202-334c-400c-a669-f180140d4238" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_e8a140fb-c0f9-4697-ba1a-bfc94f3e8b4f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_034ef461-a5be-4bbd-9350-e985bdbfe884" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_e8a140fb-c0f9-4697-ba1a-bfc94f3e8b4f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_27cf5c2b-f81d-43f6-a63e-b58cd787c9a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13a6e990-23c4-412b-bbb4-ff93ca6cbab2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_27cf5c2b-f81d-43f6-a63e-b58cd787c9a5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_db9a360a-30a7-4a2a-b083-4bcf00301b37" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_27cf5c2b-f81d-43f6-a63e-b58cd787c9a5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_db9a360a-30a7-4a2a-b083-4bcf00301b37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_5bd322c7-a884-404c-8b6e-e37943793583" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_27cf5c2b-f81d-43f6-a63e-b58cd787c9a5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_5bd322c7-a884-404c-8b6e-e37943793583" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_8e644a2e-1c15-4e0f-8c18-5b4dc569d334" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_27cf5c2b-f81d-43f6-a63e-b58cd787c9a5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_8e644a2e-1c15-4e0f-8c18-5b4dc569d334" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_8d42055a-db0f-4239-b36f-5090256038b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_27cf5c2b-f81d-43f6-a63e-b58cd787c9a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_8d42055a-db0f-4239-b36f-5090256038b5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_bb6b7c7b-bf52-40ad-ab8d-fe1ec9bdff40" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_27cf5c2b-f81d-43f6-a63e-b58cd787c9a5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_bb6b7c7b-bf52-40ad-ab8d-fe1ec9bdff40" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_4990cbb7-b80d-422a-9ed3-9ed9f9b3a1ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_27cf5c2b-f81d-43f6-a63e-b58cd787c9a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_4990cbb7-b80d-422a-9ed3-9ed9f9b3a1ac" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f609f40a-d698-40d1-a939-e5fdc3890fde" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13a6e990-23c4-412b-bbb4-ff93ca6cbab2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f609f40a-d698-40d1-a939-e5fdc3890fde" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8a77c2ad-a7bc-487c-9d2f-5c1dd61ed9f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f609f40a-d698-40d1-a939-e5fdc3890fde" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8a77c2ad-a7bc-487c-9d2f-5c1dd61ed9f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e770aa98-f4a3-4c3e-b2dc-c0520bdded78" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f609f40a-d698-40d1-a939-e5fdc3890fde" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e770aa98-f4a3-4c3e-b2dc-c0520bdded78" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_92f64b61-df24-4f64-b689-8f7baf335afc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f609f40a-d698-40d1-a939-e5fdc3890fde" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_92f64b61-df24-4f64-b689-8f7baf335afc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_ca295e9d-ba07-4768-a3a5-6c880764092a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f609f40a-d698-40d1-a939-e5fdc3890fde" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_ca295e9d-ba07-4768-a3a5-6c880764092a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_aa2f7c8f-da36-48bf-aa0e-78ec5f7b7508" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_148a669b-4cf6-4303-a6cf-3678bcd08882" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13a6e990-23c4-412b-bbb4-ff93ca6cbab2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_148a669b-4cf6-4303-a6cf-3678bcd08882" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_c271d65d-856c-45ef-a93a-2c509baf3376" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_148a669b-4cf6-4303-a6cf-3678bcd08882" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_c271d65d-856c-45ef-a93a-2c509baf3376" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_139fa993-6760-432a-9e4d-b002b7e99ecd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_148a669b-4cf6-4303-a6cf-3678bcd08882" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_139fa993-6760-432a-9e4d-b002b7e99ecd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_9afe4ea9-d014-4159-b1ac-60f8f25aa68a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_148a669b-4cf6-4303-a6cf-3678bcd08882" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_9afe4ea9-d014-4159-b1ac-60f8f25aa68a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_09328cd5-407f-4c81-ab3a-dfea3e9c6180" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_148a669b-4cf6-4303-a6cf-3678bcd08882" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_09328cd5-407f-4c81-ab3a-dfea3e9c6180" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_626619bf-9b8e-451f-b512-069036969961" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_8e95a3e2-0306-49e1-8ad5-20b44212b757" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13a6e990-23c4-412b-bbb4-ff93ca6cbab2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_8e95a3e2-0306-49e1-8ad5-20b44212b757" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_7719a031-922c-4c7f-af1f-d78a97df53a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13a6e990-23c4-412b-bbb4-ff93ca6cbab2" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_7719a031-922c-4c7f-af1f-d78a97df53a1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_dc20a3dd-3d90-480f-a4b2-cbdff5224397" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13a6e990-23c4-412b-bbb4-ff93ca6cbab2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_dc20a3dd-3d90-480f-a4b2-cbdff5224397" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_5a7ff6fc-624f-4488-9a13-657c40675173" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13a6e990-23c4-412b-bbb4-ff93ca6cbab2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_5a7ff6fc-624f-4488-9a13-657c40675173" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_3f263ef1-1a46-435a-93f4-e17c2504c226" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13a6e990-23c4-412b-bbb4-ff93ca6cbab2" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_3f263ef1-1a46-435a-93f4-e17c2504c226" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_019c30d7-6315-4d40-ae9c-d7b904408610" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13a6e990-23c4-412b-bbb4-ff93ca6cbab2" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_019c30d7-6315-4d40-ae9c-d7b904408610" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_fe558a6d-8b6e-49bc-b9f8-d58c45bf6222" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13a6e990-23c4-412b-bbb4-ff93ca6cbab2" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_fe558a6d-8b6e-49bc-b9f8-d58c45bf6222" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_29b83e02-8e81-4559-a6eb-96e7a4b3f9cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_b160e5cd-4407-44bb-b841-dc6141300c42" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13a6e990-23c4-412b-bbb4-ff93ca6cbab2" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_b160e5cd-4407-44bb-b841-dc6141300c42" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_6ec37dfd-bf5c-43c5-b718-2018f83ea242" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="simple" xlink:href="mgnx-20231231.xsd#IncomeTaxesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationLineItems_ba3e4b63-55d0-4356-b7e1-4c4bcb15a45d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExaminationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_3c3cf31e-73ea-4829-a42c-63aff1a41479" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_ba3e4b63-55d0-4356-b7e1-4c4bcb15a45d" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_3c3cf31e-73ea-4829-a42c-63aff1a41479" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_fdbad976-864a-484d-93f2-7b3a6b159bf5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_3c3cf31e-73ea-4829-a42c-63aff1a41479" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_fdbad976-864a-484d-93f2-7b3a6b159bf5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_fdbad976-864a-484d-93f2-7b3a6b159bf5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_fdbad976-864a-484d-93f2-7b3a6b159bf5" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_fdbad976-864a-484d-93f2-7b3a6b159bf5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_1b8876c8-bd41-49a2-b90e-cfff2d6ba696" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_fdbad976-864a-484d-93f2-7b3a6b159bf5" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_1b8876c8-bd41-49a2-b90e-cfff2d6ba696" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember_78ce14fd-3747-4b52-8f63-3c4919e85ab7" xlink:href="mgnx-20231231.xsd#mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1b8876c8-bd41-49a2-b90e-cfff2d6ba696" xlink:to="loc_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember_78ce14fd-3747-4b52-8f63-3c4919e85ab7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_a4ac5efe-dfbf-49fa-aab8-9c0a6c8ac371" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1b8876c8-bd41-49a2-b90e-cfff2d6ba696" xlink:to="loc_us-gaap_DomesticCountryMember_a4ac5efe-dfbf-49fa-aab8-9c0a6c8ac371" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis_5833a1c3-3cdb-48d9-ab46-846f8466d536" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_3c3cf31e-73ea-4829-a42c-63aff1a41479" xlink:to="loc_us-gaap_TaxPeriodAxis_5833a1c3-3cdb-48d9-ab46-846f8466d536" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_5833a1c3-3cdb-48d9-ab46-846f8466d536_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxPeriodAxis_5833a1c3-3cdb-48d9-ab46-846f8466d536" xlink:to="loc_us-gaap_TaxPeriodDomain_5833a1c3-3cdb-48d9-ab46-846f8466d536_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_6d8943d1-9537-439c-be46-6725e1384b08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxPeriodAxis_5833a1c3-3cdb-48d9-ab46-846f8466d536" xlink:to="loc_us-gaap_TaxPeriodDomain_6d8943d1-9537-439c-be46-6725e1384b08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TaxYear2025To2037Member_382a85b2-429f-4e69-bf04-f3adaa0d739b" xlink:href="mgnx-20231231.xsd#mgnx_TaxYear2025To2037Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_6d8943d1-9537-439c-be46-6725e1384b08" xlink:to="loc_mgnx_TaxYear2025To2037Member_382a85b2-429f-4e69-bf04-f3adaa0d739b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IndefiniteMember_0a9801a7-1f93-4c19-a496-74cf2c4cefe2" xlink:href="mgnx-20231231.xsd#mgnx_IndefiniteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_6d8943d1-9537-439c-be46-6725e1384b08" xlink:to="loc_mgnx_IndefiniteMember_0a9801a7-1f93-4c19-a496-74cf2c4cefe2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6e724de7-7887-4d7c-95ba-37bb9b974ab7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_3c3cf31e-73ea-4829-a42c-63aff1a41479" xlink:to="loc_srt_RangeAxis_6e724de7-7887-4d7c-95ba-37bb9b974ab7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6e724de7-7887-4d7c-95ba-37bb9b974ab7_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_6e724de7-7887-4d7c-95ba-37bb9b974ab7" xlink:to="loc_srt_RangeMember_6e724de7-7887-4d7c-95ba-37bb9b974ab7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_02de64ee-4d7a-4e3b-87f1-ae5cd610fea7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_6e724de7-7887-4d7c-95ba-37bb9b974ab7" xlink:to="loc_srt_RangeMember_02de64ee-4d7a-4e3b-87f1-ae5cd610fea7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_4214acbd-1b25-4250-bfae-917d29c14603" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_02de64ee-4d7a-4e3b-87f1-ae5cd610fea7" xlink:to="loc_srt_MinimumMember_4214acbd-1b25-4250-bfae-917d29c14603" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_4326e2a7-c389-4033-a49d-6931d9671e43" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_02de64ee-4d7a-4e3b-87f1-ae5cd610fea7" xlink:to="loc_srt_MaximumMember_4326e2a7-c389-4033-a49d-6931d9671e43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_b59bee6a-cbb0-402d-a439-b51389d346cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_ba3e4b63-55d0-4356-b7e1-4c4bcb15a45d" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_b59bee6a-cbb0-402d-a439-b51389d346cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_6f7da6a7-f891-4213-87c9-4934f2cac786" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_ba3e4b63-55d0-4356-b7e1-4c4bcb15a45d" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_6f7da6a7-f891-4213-87c9-4934f2cac786" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_6c482ad8-fd7b-43cd-a15b-4e54203679a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_ba3e4b63-55d0-4356-b7e1-4c4bcb15a45d" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_6c482ad8-fd7b-43cd-a15b-4e54203679a6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_3c6fae31-86a9-44fb-8b6e-207892151340" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_ba3e4b63-55d0-4356-b7e1-4c4bcb15a45d" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_3c6fae31-86a9-44fb-8b6e-207892151340" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_6861436f-6f33-40e2-947c-bdf2f7f39dac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_ba3e4b63-55d0-4356-b7e1-4c4bcb15a45d" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_6861436f-6f33-40e2-947c-bdf2f7f39dac" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#AwardTypeOnly"/>
  <link:definitionLink xlink:role="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockMember" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#IndividualsOnly"/>
  <link:definitionLink xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_JamesKarrelsMember_6da662c9-4333-464c-8882-dac7d34dd52c" xlink:href="mgnx-20231231.xsd#mgnx_JamesKarrelsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_mgnx_JamesKarrelsMember_6da662c9-4333-464c-8882-dac7d34dd52c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_JeffreyPetersMember_ea1920f5-7283-430a-a7c2-c1b5589560d3" xlink:href="mgnx-20231231.xsd#mgnx_JeffreyPetersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_mgnx_JeffreyPetersMember_ea1920f5-7283-430a-a7c2-c1b5589560d3" xlink:type="arc" order="3"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>15
<FILENAME>mgnx-20231231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:8dbce59b-e7cb-41de-8446-707f712a2a92,g:3e6229e4-32a7-4caa-a132-cb74eb6cd115-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_FutureRevenue_358f6b66-e3fd-4cda-af55-7a076fb5a3c2_terseLabel_en-US" xlink:label="lab_mgnx_FutureRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future revenue from DRI</link:label>
    <link:label id="lab_mgnx_FutureRevenue_label_en-US" xlink:label="lab_mgnx_FutureRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Revenue</link:label>
    <link:label id="lab_mgnx_FutureRevenue_documentation_en-US" xlink:label="lab_mgnx_FutureRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Future Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_FutureRevenue" xlink:href="mgnx-20231231.xsd#mgnx_FutureRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_FutureRevenue" xlink:to="lab_mgnx_FutureRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PayVsPerformanceDisclosureLineItems_label_en-US" xlink:label="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_d703a94f-f86b-405b-bea4-a504689b420c_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_0a045a3e-65bc-4f68-b617-92fac972f284_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage_ea50410b-667b-4665-a0ab-80d27b786fce_terseLabel_en-US" xlink:label="lab_mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of employee vested contribution</link:label>
    <link:label id="lab_mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage_label_en-US" xlink:label="lab_mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Employees Contribution, Vested Percentage</link:label>
    <link:label id="lab_mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage_documentation_en-US" xlink:label="lab_mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage vested of employee's contributions to defined contribution plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage" xlink:href="mgnx-20231231.xsd#mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage" xlink:to="lab_mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_52f17e4e-c7b4-40ae-992b-d74976b04265_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryValuationReserves_a8229bc0-7b5b-4c12-9718-96206d74e933_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory valuation reserves</link:label>
    <link:label id="lab_us-gaap_InventoryValuationReserves_label_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Valuation Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryValuationReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryValuationReserves" xlink:to="lab_us-gaap_InventoryValuationReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_bbee45e9-dc88-4217-a190-25f4af13fcf6_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_83e33f1f-f89c-4e52-a4df-91b0b5c7d230_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_terseLabel_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change</link:label>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_label_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:to="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_e7037d8c-5a9d-49e1-825c-1b650ebbe38d_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options granted, maximum term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_DRIHealthcareAcquisitionsLPDRIMember_493dd473-a0d0-4203-b5b0-6f8a1fb5843a_terseLabel_en-US" xlink:label="lab_mgnx_DRIHealthcareAcquisitionsLPDRIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">DRI Healthcare Acquisitions LP (DRI)</link:label>
    <link:label id="lab_mgnx_DRIHealthcareAcquisitionsLPDRIMember_label_en-US" xlink:label="lab_mgnx_DRIHealthcareAcquisitionsLPDRIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">DRI Healthcare Acquisitions LP (DRI) [Member]</link:label>
    <link:label id="lab_mgnx_DRIHealthcareAcquisitionsLPDRIMember_documentation_en-US" xlink:label="lab_mgnx_DRIHealthcareAcquisitionsLPDRIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">DRI Healthcare Acquisitions LP (DRI)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DRIHealthcareAcquisitionsLPDRIMember" xlink:href="mgnx-20231231.xsd#mgnx_DRIHealthcareAcquisitionsLPDRIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_DRIHealthcareAcquisitionsLPDRIMember" xlink:to="lab_mgnx_DRIHealthcareAcquisitionsLPDRIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeOther_ecc03841-aa29-472a-aced-12f177bd16f5_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest Income, Other</link:label>
    <link:label id="lab_us-gaap_InterestIncomeOther_label_en-US" xlink:label="lab_us-gaap_InterestIncomeOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Income, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeOther" xlink:to="lab_us-gaap_InterestIncomeOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_78a214be-b9c0-44d3-945d-6b4c296749da_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardGrantDateFairValue_terseLabel_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value as of Grant Date</link:label>
    <link:label id="lab_ecd_AwardGrantDateFairValue_label_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardGrantDateFairValue" xlink:to="lab_ecd_AwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a9c240d7-ccf2-41b5-8ba3-d6ae5f98bfa1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding nonvested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b941f90a-384f-49fb-9a1a-86e41e15cb63_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3c80dcdf-037b-4735-85a4-903e6abfcf4d_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_df3d67c7-acce-4c97-8148-bab4e1f9889a_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_89a55901-3396-4741-b867-6453f60fb939_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Expenses, Including Clinical Trial Accruals/Expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_e0f0accb-b0ec-4f42-92b1-f16ca95b9670_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined contribution plan, employer discretionary contribution amount</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Employer Discretionary Contribution Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_IncreaseDecreaseInLeaseLiabilities_c8f7544e-b280-4470-b7ae-ba24824a6a37_terseLabel_en-US" xlink:label="lab_mgnx_IncreaseDecreaseInLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_mgnx_IncreaseDecreaseInLeaseLiabilities_label_en-US" xlink:label="lab_mgnx_IncreaseDecreaseInLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) in lease liabilities</link:label>
    <link:label id="lab_mgnx_IncreaseDecreaseInLeaseLiabilities_documentation_en-US" xlink:label="lab_mgnx_IncreaseDecreaseInLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (decrease) in lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncreaseDecreaseInLeaseLiabilities" xlink:href="mgnx-20231231.xsd#mgnx_IncreaseDecreaseInLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IncreaseDecreaseInLeaseLiabilities" xlink:to="lab_mgnx_IncreaseDecreaseInLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_terseLabel_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_label_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:to="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_79f7847c-d142-4a83-80f3-c5c0f54726ec_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_8163f41f-73f6-43ac-a068-231a4cecc71e_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average remaining contractual term, Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_98ece0ae-296b-4688-b6c0-f3e7d3fe8f57_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computer equipment</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_NetProceedsFromSaleOfFutureRoyalties_cf4f10e3-666b-49d9-8e7a-55b151c3aed9_terseLabel_en-US" xlink:label="lab_mgnx_NetProceedsFromSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net proceeds from sale of future royalties</link:label>
    <link:label id="lab_mgnx_NetProceedsFromSaleOfFutureRoyalties_label_en-US" xlink:label="lab_mgnx_NetProceedsFromSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net proceeds from sale of future royalties</link:label>
    <link:label id="lab_mgnx_NetProceedsFromSaleOfFutureRoyalties_documentation_en-US" xlink:label="lab_mgnx_NetProceedsFromSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net proceeds from sale of future royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NetProceedsFromSaleOfFutureRoyalties" xlink:href="mgnx-20231231.xsd#mgnx_NetProceedsFromSaleOfFutureRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_NetProceedsFromSaleOfFutureRoyalties" xlink:to="lab_mgnx_NetProceedsFromSaleOfFutureRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDateAxis_terseLabel_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date:</link:label>
    <link:label id="lab_ecd_RestatementDateAxis_label_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDateAxis" xlink:to="lab_ecd_RestatementDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_DeferredTaxAssetsOperatingLeaseLiabilities_f9dbddad-8da4-46c2-8e78-73b323e879b3_terseLabel_en-US" xlink:label="lab_mgnx_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_mgnx_DeferredTaxAssetsOperatingLeaseLiabilities_label_en-US" xlink:label="lab_mgnx_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Lease Liabilities</link:label>
    <link:label id="lab_mgnx_DeferredTaxAssetsOperatingLeaseLiabilities_documentation_en-US" xlink:label="lab_mgnx_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:href="mgnx-20231231.xsd#mgnx_DeferredTaxAssetsOperatingLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:to="lab_mgnx_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_5b5d700d-bbd2-4ee9-911b-a17fe62e97b9_terseLabel_en-US" xlink:label="lab_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">NIAID</link:label>
    <link:label id="lab_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_label_en-US" xlink:label="lab_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">National Institute of Allergy and Infectious Diseases [Member]</link:label>
    <link:label id="lab_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_documentation_en-US" xlink:label="lab_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents a collaborators with which entity has an agreement related to contracts and research grants received from U.S. government agencies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:href="mgnx-20231231.xsd#mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:to="lab_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_678a6ffb-1378-4aff-befd-b2074a98c4db_verboseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_558111d8-c51c-44de-950d-8a946875b193_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingPoliciesProcLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_b852ba06-4913-48b7-bac0-ffe3dd4f2032_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_545ab918-e69e-478a-86cf-b554b8a9372f_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction in Progress, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressGross" xlink:to="lab_us-gaap_ConstructionInProgressGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:to="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_29f6501f-6c85-43dc-8f30-f2fe17cce860_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRevenueCurrent_933048f6-e3d9-4ece-986f-1dedcb0493b2_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueCurrent_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueCurrent" xlink:to="lab_us-gaap_DeferredRevenueCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_terseLabel_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement does not require Recovery</link:label>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_label_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_58e1307b-ac2a-43fa-8e3e-391a0cf4c381_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_2f1fc23c-b544-448c-bebb-0c96292597a7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate intrinsic value, Vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_cdf9ab33-f804-4b51-8d64-2c75db2e81b3_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock, net of offering costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_6d8575af-0673-4a5e-8355-68ac76a14d88_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee service period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_c67f7264-34a9-4f5e-a456-8aa00047312d_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock_0a1e0587-600e-4aa5-8495-9ee2d7432886_terseLabel_en-US" xlink:label="lab_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated Useful Lives</link:label>
    <link:label id="lab_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock_label_en-US" xlink:label="lab_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property Plant And Equipment Estimated Useful Life Table [Table Text Block]</link:label>
    <link:label id="lab_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock_documentation_en-US" xlink:label="lab_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Property plant and equipment estimated useful life.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock" xlink:href="mgnx-20231231.xsd#mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock" xlink:to="lab_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_fe64da27-9337-4a5d-a0f4-877dfed5d31e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_aa2678e2-2181-4a25-b5a7-f045d53c4dc5_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_494532c7-8d68-433b-9c00-a0475dd829a3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_d249d0dc-11cf-405b-a72e-afb878e6f073_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_fde5e8ff-12a6-4a72-85e7-3d45d69796dd_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_498f01d4-cda9-495a-8239-c3695f28e9b3_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_c2655001-afe9-4900-8db4-69a1dfbb34cf_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_7c46f41c-cc3d-48a0-9d39-c70b90b71c26_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember_a5c6fade-a60f-4f43-94a9-ba47a55add68_terseLabel_en-US" xlink:label="lab_mgnx_McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">McKesson Plasma &amp; Biologics and McKesson Specialty Care Distribution LLC</link:label>
    <link:label id="lab_mgnx_McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember_label_en-US" xlink:label="lab_mgnx_McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">McKesson Plasma &amp; Biologics and McKesson Specialty Care Distribution LLC [Member]</link:label>
    <link:label id="lab_mgnx_McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember_documentation_en-US" xlink:label="lab_mgnx_McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">McKesson Plasma &amp; Biologics and McKesson Specialty Care Distribution LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember" xlink:href="mgnx-20231231.xsd#mgnx_McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember" xlink:to="lab_mgnx_McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_970ad4a6-0514-4a16-9035-11cdcd84855c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_9c8853be-b6e0-4975-a1c1-fac9851d4161_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Undesignated preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_73f3fa47-7706-4a98-85aa-19617b9cf5b0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0cf07f89-2736-49d0-9096-dcab5180e444_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_c07578f1-d723-4037-8d48-639af0974fae_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted net loss per common share, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_4ebaead3-fb7c-4754-82cf-5fd5c4096110_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized Gain (Loss) on Investments</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoTotalCompAmt_label_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoTotalCompAmt" xlink:to="lab_ecd_PeoTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_LiabilityRelatedToFutureRoyalties_a6700109-824f-45c5-b798-aad4b459cf6d_terseLabel_en-US" xlink:label="lab_mgnx_LiabilityRelatedToFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liability related to future royalties</link:label>
    <link:label id="lab_mgnx_LiabilityRelatedToFutureRoyalties_label_en-US" xlink:label="lab_mgnx_LiabilityRelatedToFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability related to future royalties</link:label>
    <link:label id="lab_mgnx_LiabilityRelatedToFutureRoyalties_documentation_en-US" xlink:label="lab_mgnx_LiabilityRelatedToFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Liability related to future royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_LiabilityRelatedToFutureRoyalties" xlink:href="mgnx-20231231.xsd#mgnx_LiabilityRelatedToFutureRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_LiabilityRelatedToFutureRoyalties" xlink:to="lab_mgnx_LiabilityRelatedToFutureRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ee3f7db6-e698-45eb-bdb6-71734e35251e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_159a3dcb-2874-47e9-bfa3-13dbf035f6be_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CollaborativeArrangementTerm_6382f89d-4e0a-4618-b21d-b9e886253e06_terseLabel_en-US" xlink:label="lab_mgnx_CollaborativeArrangementTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative arrangement, term</link:label>
    <link:label id="lab_mgnx_CollaborativeArrangementTerm_label_en-US" xlink:label="lab_mgnx_CollaborativeArrangementTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Term</link:label>
    <link:label id="lab_mgnx_CollaborativeArrangementTerm_documentation_en-US" xlink:label="lab_mgnx_CollaborativeArrangementTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeArrangementTerm" xlink:href="mgnx-20231231.xsd#mgnx_CollaborativeArrangementTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CollaborativeArrangementTerm" xlink:to="lab_mgnx_CollaborativeArrangementTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_0a86f152-1276-45db-8548-a956eaba8189_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and expected to vest (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrByIndTable_terseLabel_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual</link:label>
    <link:label id="lab_ecd_TradingArrByIndTable_label_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrByIndTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="lab_ecd_TradingArrByIndTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock_919002de-09dd-47cb-b2ad-683da98c6130_terseLabel_en-US" xlink:label="lab_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock_label_en-US" xlink:label="lab_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration And License Agreements Disclosure [Text Block]</link:label>
    <link:label id="lab_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock_documentation_en-US" xlink:label="lab_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The entire disclosure for collaboration and license agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock" xlink:href="mgnx-20231231.xsd#mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock" xlink:to="lab_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2167315c-cba2-4f35-9f7f-54f96276a915_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation arrangement by share-based payment award, options, outstanding, number (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_439ed581-5169-48eb-a9f6-aeab4cfe224c_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7bd68bb4-71cd-4ce8-a308-5a341342d038_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RevenueFromRoyalityAgreementsMemberMember_4b430ea8-0387-4da9-b2b3-4c66cf2dccd3_terseLabel_en-US" xlink:label="lab_mgnx_RevenueFromRoyalityAgreementsMemberMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RevenueFromRoyalityAgreementsMember</link:label>
    <link:label id="lab_mgnx_RevenueFromRoyalityAgreementsMemberMember_label_en-US" xlink:label="lab_mgnx_RevenueFromRoyalityAgreementsMemberMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">RevenueFromRoyalityAgreementsMember [Member]</link:label>
    <link:label id="lab_mgnx_RevenueFromRoyalityAgreementsMemberMember_documentation_en-US" xlink:label="lab_mgnx_RevenueFromRoyalityAgreementsMemberMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">RevenueFromRoyalityAgreementsMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromRoyalityAgreementsMemberMember" xlink:href="mgnx-20231231.xsd#mgnx_RevenueFromRoyalityAgreementsMemberMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RevenueFromRoyalityAgreementsMemberMember" xlink:to="lab_mgnx_RevenueFromRoyalityAgreementsMemberMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_be690332-c2c1-4575-b847-43610fa8ed59_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RevenuesFromCMOAgreementsMemberMember_fc29e42c-2815-451f-93f9-a7a4d6f0f5e8_terseLabel_en-US" xlink:label="lab_mgnx_RevenuesFromCMOAgreementsMemberMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RevenuesFromCMOAgreementsMember</link:label>
    <link:label id="lab_mgnx_RevenuesFromCMOAgreementsMemberMember_label_en-US" xlink:label="lab_mgnx_RevenuesFromCMOAgreementsMemberMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">RevenuesFromCMOAgreementsMember [Member]</link:label>
    <link:label id="lab_mgnx_RevenuesFromCMOAgreementsMemberMember_documentation_en-US" xlink:label="lab_mgnx_RevenuesFromCMOAgreementsMemberMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">RevenuesFromCMOAgreementsMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromCMOAgreementsMemberMember" xlink:href="mgnx-20231231.xsd#mgnx_RevenuesFromCMOAgreementsMemberMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RevenuesFromCMOAgreementsMemberMember" xlink:to="lab_mgnx_RevenuesFromCMOAgreementsMemberMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d55f0124-9393-4f8b-a87d-1aa4e8439523_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fb147636-3f67-49d5-b350-28fe7a98f797_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average grant-date fair value of options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7c7b4a16-e5e5-45ee-af5b-ce5880f27e0a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_811e8bef-6b04-4c2a-9bce-c04894973aee_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_a757c186-920f-4ce9-8d36-906e4c7ba3db_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Income (Loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_e2bd5df9-17b7-4d40-baa3-f73577c0b565_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RightOfUseAssetAndLeaseLiabilityIncrease_2a61d186-19ab-4bfc-b2b7-a933380d22cd_terseLabel_en-US" xlink:label="lab_mgnx_RightOfUseAssetAndLeaseLiabilityIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right of use asset and lease liability increase</link:label>
    <link:label id="lab_mgnx_RightOfUseAssetAndLeaseLiabilityIncrease_label_en-US" xlink:label="lab_mgnx_RightOfUseAssetAndLeaseLiabilityIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right of Use asset and Lease Liability Increase</link:label>
    <link:label id="lab_mgnx_RightOfUseAssetAndLeaseLiabilityIncrease_documentation_en-US" xlink:label="lab_mgnx_RightOfUseAssetAndLeaseLiabilityIncrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Right of Use asset and Lease Liability Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RightOfUseAssetAndLeaseLiabilityIncrease" xlink:href="mgnx-20231231.xsd#mgnx_RightOfUseAssetAndLeaseLiabilityIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RightOfUseAssetAndLeaseLiabilityIncrease" xlink:to="lab_mgnx_RightOfUseAssetAndLeaseLiabilityIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_label_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:to="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CollaborativeArrangementExtensionTerm_20f95c7d-6d43-48b8-8dad-7983100f4d95_terseLabel_en-US" xlink:label="lab_mgnx_CollaborativeArrangementExtensionTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative arrangement, extension term</link:label>
    <link:label id="lab_mgnx_CollaborativeArrangementExtensionTerm_label_en-US" xlink:label="lab_mgnx_CollaborativeArrangementExtensionTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Extension Term</link:label>
    <link:label id="lab_mgnx_CollaborativeArrangementExtensionTerm_documentation_en-US" xlink:label="lab_mgnx_CollaborativeArrangementExtensionTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Extension Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeArrangementExtensionTerm" xlink:href="mgnx-20231231.xsd#mgnx_CollaborativeArrangementExtensionTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CollaborativeArrangementExtensionTerm" xlink:to="lab_mgnx_CollaborativeArrangementExtensionTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureName_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureName_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureName" xlink:to="lab_ecd_CoSelectedMeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_NonRefundableUpfrontFees_67573bc8-3f30-4a89-b48f-5e1804ee908a_terseLabel_en-US" xlink:label="lab_mgnx_NonRefundableUpfrontFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-refundable upfront payment</link:label>
    <link:label id="lab_mgnx_NonRefundableUpfrontFees_label_en-US" xlink:label="lab_mgnx_NonRefundableUpfrontFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-refundable upfront payment</link:label>
    <link:label id="lab_mgnx_NonRefundableUpfrontFees_documentation_en-US" xlink:label="lab_mgnx_NonRefundableUpfrontFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Initial fee received from collaboration or license agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees" xlink:href="mgnx-20231231.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_NonRefundableUpfrontFees" xlink:to="lab_mgnx_NonRefundableUpfrontFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssued_c7a2df7e-ae4e-4c72-88cd-7f886fe38915_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_1c286a23-28b8-47dd-a78f-a6e505bedf2d_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_label_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d12d2379-f663-4331-b7ce-007a0b34fda5_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_115ef06f-d6d3-4282-9791-067af505e640_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_089cdbbb-da33-4e30-abd0-f20ffebe135b_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_bd697a47-111a-4b02-aaaa-ab3ee9e4f3e8_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_3e874fa8-7e75-497b-bdb4-e45e5cfcb17a_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_176bd4ce-18fe-4a48-b2b4-7745718b1068_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_1f7f6bea-189b-4ef9-8787-080ab75a2b5f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of the Beginning and Ending Amount of Gross Unrecognized Tax Benefits</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_8e618567-abf6-4c04-b2cd-c47b408befac_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_96a5a06f-3580-4038-a227-375815736b93_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_8092920f-4f6c-4970-bf47-65de3c3f1c01_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of product sales</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_da9c9c60-23f9-44ca-99cf-ee86ac097ba5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_terseLabel_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executive Category:</link:label>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_label_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executive Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="lab_ecd_ExecutiveCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_a08a1e46-5bc1-4f6d-8c66-02341ac39e82_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases_c01ab271-0fe3-43cf-aa7f-ae1ca4af7f14_terseLabel_en-US" xlink:label="lab_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from stock option exercises and ESPP purchases</link:label>
    <link:label id="lab_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases_label_en-US" xlink:label="lab_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised And ESPP Purchases</link:label>
    <link:label id="lab_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases_documentation_en-US" xlink:label="lab_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised And ESPP Purchases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases" xlink:href="mgnx-20231231.xsd#mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases" xlink:to="lab_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f093a14b-a218-4b97-a32b-1fd60c07aa4a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_1fcf9f68-521c-421c-ad06-41990c9d38d6_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_aff6693e-b240-4c74-a09b-28f200e7dcb9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_UpfrontAndFixedPayments_0c907379-2d9b-411b-ae14-cfdd27fce9ca_terseLabel_en-US" xlink:label="lab_mgnx_UpfrontAndFixedPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">upfront and fixed payments</link:label>
    <link:label id="lab_mgnx_UpfrontAndFixedPayments_label_en-US" xlink:label="lab_mgnx_UpfrontAndFixedPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">upfront and fixed payments</link:label>
    <link:label id="lab_mgnx_UpfrontAndFixedPayments_documentation_en-US" xlink:label="lab_mgnx_UpfrontAndFixedPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">upfront and fixed payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_UpfrontAndFixedPayments" xlink:href="mgnx-20231231.xsd#mgnx_UpfrontAndFixedPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_UpfrontAndFixedPayments" xlink:to="lab_mgnx_UpfrontAndFixedPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_fc1ca38b-1cd8-4ee6-86b5-e3bbc7d5fd71_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Quoted Prices in Active Markets for Identical Assets, Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureName_terseLabel_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_MeasureName_label_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureName" xlink:to="lab_ecd_MeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_eb3fbfa1-83d7-4201-9205-b9c2127e7536_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net deferred income tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryIndName" xlink:to="lab_ecd_ForgoneRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CommonStockMaximumAmountAvailableForIssuance_e77ace67-f9ad-4c63-abb6-268c3b84376c_terseLabel_en-US" xlink:label="lab_mgnx_CommonStockMaximumAmountAvailableForIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock maximum amount available for issuance</link:label>
    <link:label id="lab_mgnx_CommonStockMaximumAmountAvailableForIssuance_label_en-US" xlink:label="lab_mgnx_CommonStockMaximumAmountAvailableForIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Maximum Amount Available For Issuance</link:label>
    <link:label id="lab_mgnx_CommonStockMaximumAmountAvailableForIssuance_documentation_en-US" xlink:label="lab_mgnx_CommonStockMaximumAmountAvailableForIssuance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Stock, Maximum Amount Available For Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CommonStockMaximumAmountAvailableForIssuance" xlink:href="mgnx-20231231.xsd#mgnx_CommonStockMaximumAmountAvailableForIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CommonStockMaximumAmountAvailableForIssuance" xlink:to="lab_mgnx_CommonStockMaximumAmountAvailableForIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount_4b211e7b-f4b7-4dc8-8fae-283846f7f737_terseLabel_en-US" xlink:label="lab_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred income tax adjustments</link:label>
    <link:label id="lab_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount_label_en-US" xlink:label="lab_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Deferred Tax Adjustments, Amount</link:label>
    <link:label id="lab_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount_documentation_en-US" xlink:label="lab_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to deferred tax adjustments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount" xlink:href="mgnx-20231231.xsd#mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount" xlink:to="lab_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_7b419c94-5e69-44a2-894c-3d2afce8adc6_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_30ebbea8-70a8-403a-9e4a-92dddf1d6043_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0753d95e-9720-4415-850b-d0da6b5d8fd5_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_label_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Additional402vDisclosureTextBlock" xlink:to="lab_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_1cf10681-7772-4991-9945-b57fead7526e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_IndefiniteMember_1aee46e8-c6ad-4ef1-8052-0368c9147ad0_terseLabel_en-US" xlink:label="lab_mgnx_IndefiniteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite</link:label>
    <link:label id="lab_mgnx_IndefiniteMember_label_en-US" xlink:label="lab_mgnx_IndefiniteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite [Member]</link:label>
    <link:label id="lab_mgnx_IndefiniteMember_documentation_en-US" xlink:label="lab_mgnx_IndefiniteMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Indefinite</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IndefiniteMember" xlink:href="mgnx-20231231.xsd#mgnx_IndefiniteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IndefiniteMember" xlink:to="lab_mgnx_IndefiniteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_3765cf48-0b2a-499f-805e-329e7c421117_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ProventionBioCMOAgreeemntMember_dd820de9-b463-4616-a5c9-f968facb8f5b_terseLabel_en-US" xlink:label="lab_mgnx_ProventionBioCMOAgreeemntMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provention Bio CMO Agreeemnt</link:label>
    <link:label id="lab_mgnx_ProventionBioCMOAgreeemntMember_label_en-US" xlink:label="lab_mgnx_ProventionBioCMOAgreeemntMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Provention Bio CMO Agreeemnt [Member]</link:label>
    <link:label id="lab_mgnx_ProventionBioCMOAgreeemntMember_documentation_en-US" xlink:label="lab_mgnx_ProventionBioCMOAgreeemntMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Provention Bio CMO Agreeemnt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionBioCMOAgreeemntMember" xlink:href="mgnx-20231231.xsd#mgnx_ProventionBioCMOAgreeemntMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ProventionBioCMOAgreeemntMember" xlink:to="lab_mgnx_ProventionBioCMOAgreeemntMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_terseLabel_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Securities</link:label>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_label_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Underlying Securities Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:to="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_abcc9543-b3df-4644-ba02-9f1a33cfb1e7_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_32130bba-05cf-47da-8e48-b913f8fa7eb7_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_2f41581b-dc34-46a3-8a54-14878ac3cf9d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RecoveryOfErrCompDisclosureLineItems_label_en-US" xlink:label="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_7749efa7-9e16-4a62-a427-0c16f096d54a_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_NumberOfProductCandidates_73168e13-46fb-489e-96e6-514690b004e4_terseLabel_en-US" xlink:label="lab_mgnx_NumberOfProductCandidates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of product candidates to develop</link:label>
    <link:label id="lab_mgnx_NumberOfProductCandidates_label_en-US" xlink:label="lab_mgnx_NumberOfProductCandidates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Product Candidates</link:label>
    <link:label id="lab_mgnx_NumberOfProductCandidates_documentation_en-US" xlink:label="lab_mgnx_NumberOfProductCandidates" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Product Candidates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfProductCandidates" xlink:href="mgnx-20231231.xsd#mgnx_NumberOfProductCandidates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_NumberOfProductCandidates" xlink:to="lab_mgnx_NumberOfProductCandidates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_4ea346cd-8baa-42d4-b3cf-985fa7df5cfe_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_07ed1fda-520a-44f3-a4f8-d8f0a681ce55_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities, net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_52705820-4465-4381-83ac-25dbcbe4f4c8_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal U.S. net operating loss carryforward</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_7505be5a-f3f1-4372-bf50-27c62423e635_terseLabel_en-US" xlink:label="lab_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential development and regulatory milestone payments</link:label>
    <link:label id="lab_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_label_en-US" xlink:label="lab_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Potential Development and Regulatory Milestone Payments Under Agreement</link:label>
    <link:label id="lab_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_documentation_en-US" xlink:label="lab_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Potential Development and Regulatory Milestone Payments Under Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" xlink:href="mgnx-20231231.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" xlink:to="lab_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions_5d520587-b34c-4ffe-9a52-194ea7e2918d_terseLabel_en-US" xlink:label="lab_mgnx_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increases/(decreases) for prior year tax positions</link:label>
    <link:label id="lab_mgnx_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_mgnx_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Increase (Decrease) Resulting From Prior Period Tax Positions</link:label>
    <link:label id="lab_mgnx_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions_documentation_en-US" xlink:label="lab_mgnx_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Increase (Decrease) Resulting From Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" xlink:href="mgnx-20231231.xsd#mgnx_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" xlink:to="lab_mgnx_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ContractManufacturingMember_4945a26f-f3f5-4614-97e9-fb01c1f6ac15_terseLabel_en-US" xlink:label="lab_mgnx_ContractManufacturingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract Manufacturing</link:label>
    <link:label id="lab_mgnx_ContractManufacturingMember_label_en-US" xlink:label="lab_mgnx_ContractManufacturingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract Manufacturing [Member]</link:label>
    <link:label id="lab_mgnx_ContractManufacturingMember_documentation_en-US" xlink:label="lab_mgnx_ContractManufacturingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract Manufacturing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ContractManufacturingMember" xlink:href="mgnx-20231231.xsd#mgnx_ContractManufacturingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ContractManufacturingMember" xlink:to="lab_mgnx_ContractManufacturingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_35046430-c01a-4e9d-aaf2-23179495c94f_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Stock Units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_4b167f14-05c4-438a-96ad-bcb9615e2580_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of RSU Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_AtTheMarketOfferingMember_df5a2a4e-8f13-4796-a1dc-b55451be8664_terseLabel_en-US" xlink:label="lab_mgnx_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">At The Market Offering</link:label>
    <link:label id="lab_mgnx_AtTheMarketOfferingMember_label_en-US" xlink:label="lab_mgnx_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">At The Market Offering [Member]</link:label>
    <link:label id="lab_mgnx_AtTheMarketOfferingMember_documentation_en-US" xlink:label="lab_mgnx_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">At The Market Offering [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AtTheMarketOfferingMember" xlink:href="mgnx-20231231.xsd#mgnx_AtTheMarketOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_AtTheMarketOfferingMember" xlink:to="lab_mgnx_AtTheMarketOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_A2022GileadCollaborationAndLicenseAgreementMember_68ed6f44-8001-4fa3-a9e8-cc730360db0e_terseLabel_en-US" xlink:label="lab_mgnx_A2022GileadCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2022 Gilead Collaboration And License Agreement</link:label>
    <link:label id="lab_mgnx_A2022GileadCollaborationAndLicenseAgreementMember_label_en-US" xlink:label="lab_mgnx_A2022GileadCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2022 Gilead Collaboration And License Agreement [Member]</link:label>
    <link:label id="lab_mgnx_A2022GileadCollaborationAndLicenseAgreementMember_documentation_en-US" xlink:label="lab_mgnx_A2022GileadCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2022 Gilead Collaboration And License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_A2022GileadCollaborationAndLicenseAgreementMember" xlink:href="mgnx-20231231.xsd#mgnx_A2022GileadCollaborationAndLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_A2022GileadCollaborationAndLicenseAgreementMember" xlink:to="lab_mgnx_A2022GileadCollaborationAndLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_bc42d15d-e1f5-4b79-9fc5-fb6a55263f6d_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_3f811c99-4310-49e9-a42c-5357c5fdbaba_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity-based compensation</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_b6e9d117-99a3-4b75-b886-56a93744f259_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_LiabilityRelatedToFutureRoyaltiesAndRelatedInterestExpensePolicyTextBlock_a2912509-37cb-48aa-aceb-191da91ad0db_terseLabel_en-US" xlink:label="lab_mgnx_LiabilityRelatedToFutureRoyaltiesAndRelatedInterestExpensePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liability related to the sale of future royalties and related interest expense</link:label>
    <link:label id="lab_mgnx_LiabilityRelatedToFutureRoyaltiesAndRelatedInterestExpensePolicyTextBlock_label_en-US" xlink:label="lab_mgnx_LiabilityRelatedToFutureRoyaltiesAndRelatedInterestExpensePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability related to future royalties and related interest expense [Policy Text Block]</link:label>
    <link:label id="lab_mgnx_LiabilityRelatedToFutureRoyaltiesAndRelatedInterestExpensePolicyTextBlock_documentation_en-US" xlink:label="lab_mgnx_LiabilityRelatedToFutureRoyaltiesAndRelatedInterestExpensePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Liability related to future royalties and related interest expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_LiabilityRelatedToFutureRoyaltiesAndRelatedInterestExpensePolicyTextBlock" xlink:href="mgnx-20231231.xsd#mgnx_LiabilityRelatedToFutureRoyaltiesAndRelatedInterestExpensePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_LiabilityRelatedToFutureRoyaltiesAndRelatedInterestExpensePolicyTextBlock" xlink:to="lab_mgnx_LiabilityRelatedToFutureRoyaltiesAndRelatedInterestExpensePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6aefa126-afd1-49c6-934c-eec29de9c191_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_d251b916-a0ed-4b2f-8fa8-45bfe13adb01_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_857ba487-666a-4d84-a62e-6244553a0c66_terseLabel_en-US" xlink:label="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Offering period</link:label>
    <link:label id="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_label_en-US" xlink:label="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Offering Period</link:label>
    <link:label id="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_documentation_en-US" xlink:label="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Offering Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:href="mgnx-20231231.xsd#mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:to="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_6a033ecc-7d63-4997-a5d4-d6622faed5a4_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents and Marketable Securities</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_95623419-82f8-42f2-803b-08c78b67f444_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_5ee51f3b-49d8-4dd5-a544-4fbf450c5286_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of Product Sales and Cost of Manufacturing Services</link:label>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Goods and Service [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:to="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_1df60edb-4d62-4748-99cd-436d4eb6d21d_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_bddfb542-6cd4-43ff-9cf8-ef7950268052_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenditures</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Prepaid Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_3f0c97b1-a7b2-472f-a1f4-ecbe65628413_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock Options and RSUs Excluded from the Calculation of Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_b4d7973e-9325-45fc-a6a9-3cf3c3a16bf3_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_label_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OtherPerfMeasureAmt" xlink:to="lab_ecd_OtherPerfMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_terseLabel_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Available</link:label>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_label_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_2b2309c7-a40a-4dd1-abc6-65d041361b35_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease, Cost</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_c9f77593-5ae5-49c8-8233-59ca1de73a55_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RevenueFromCollaborativeAgreementsMember_3275f40e-1aa0-43d3-96fe-ac95c4ceba48_terseLabel_en-US" xlink:label="lab_mgnx_RevenueFromCollaborativeAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from collaborative agreements</link:label>
    <link:label id="lab_mgnx_RevenueFromCollaborativeAgreementsMember_label_en-US" xlink:label="lab_mgnx_RevenueFromCollaborativeAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue From Collaborative Agreements [Member]</link:label>
    <link:label id="lab_mgnx_RevenueFromCollaborativeAgreementsMember_documentation_en-US" xlink:label="lab_mgnx_RevenueFromCollaborativeAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue From Collaborative Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromCollaborativeAgreementsMember" xlink:href="mgnx-20231231.xsd#mgnx_RevenueFromCollaborativeAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RevenueFromCollaborativeAgreementsMember" xlink:to="lab_mgnx_RevenueFromCollaborativeAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_0b7334a2-17a5-4d88-81a9-477380c6bfb4_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_99e9c865-1a2b-4bf8-afe4-97e9abcf7328_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of shares vested</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_023e028c-4433-4779-b3bf-31f86c0639d4_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement_8017ddc9-d113-43dd-bb38-1d2944fb61e2_terseLabel_en-US" xlink:label="lab_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential milestone payment to third parties for intellectual property under agreement</link:label>
    <link:label id="lab_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement_label_en-US" xlink:label="lab_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Potential Milestone Payment To Third Parties For Intellectual Property Under Agreement</link:label>
    <link:label id="lab_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement_documentation_en-US" xlink:label="lab_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Potential Milestone Payment To Third Parties For Intellectual Property Under Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement" xlink:href="mgnx-20231231.xsd#mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement" xlink:to="lab_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_e8a5aa83-1f02-4d0a-aaef-2b4c1631a961_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Anti-dilutive stock options</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_60b52866-d547-4450-b413-fd6866effacc_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_6327e8f1-7b15-48bb-82e8-6671733cb667_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards granted in period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_9944c768-1726-46fc-a493-46e4f0017d5a_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_LiabilityRelatedToFutureRoyaltyTableTextBlock_d12a2a44-e229-4cb6-bc06-acce80114e9e_terseLabel_en-US" xlink:label="lab_mgnx_LiabilityRelatedToFutureRoyaltyTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liability Related to Future Royalty</link:label>
    <link:label id="lab_mgnx_LiabilityRelatedToFutureRoyaltyTableTextBlock_label_en-US" xlink:label="lab_mgnx_LiabilityRelatedToFutureRoyaltyTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability Related to Future Royalty [Table Text Block]</link:label>
    <link:label id="lab_mgnx_LiabilityRelatedToFutureRoyaltyTableTextBlock_documentation_en-US" xlink:label="lab_mgnx_LiabilityRelatedToFutureRoyaltyTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Liability Related to Future Royalty</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_LiabilityRelatedToFutureRoyaltyTableTextBlock" xlink:href="mgnx-20231231.xsd#mgnx_LiabilityRelatedToFutureRoyaltyTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_LiabilityRelatedToFutureRoyaltyTableTextBlock" xlink:to="lab_mgnx_LiabilityRelatedToFutureRoyaltyTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_a4bb9859-14e3-45d8-8ec5-24b4a07fffd3_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash operating and investing activities</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_76aa9dd6-2ac3-46ad-acf0-fd7b3da87f59_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_31765ee4-d6b1-48b8-bf1c-8c4edfd0b1d6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_ebf7fb80-51e9-4ff8-8c9a-f267d53f8283_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_a427c9e9-5d5d-42c2-ae82-9801690074dc_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1b19bdc1-8563-4dfd-8c94-596462535414_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CostOfManufacturingServices_6de48fb6-7c3e-45ad-8bfa-26553be18e7b_terseLabel_en-US" xlink:label="lab_mgnx_CostOfManufacturingServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of manufacturing services</link:label>
    <link:label id="lab_mgnx_CostOfManufacturingServices_label_en-US" xlink:label="lab_mgnx_CostOfManufacturingServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of manufacturing services</link:label>
    <link:label id="lab_mgnx_CostOfManufacturingServices_documentation_en-US" xlink:label="lab_mgnx_CostOfManufacturingServices" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cost of manufacturing services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CostOfManufacturingServices" xlink:href="mgnx-20231231.xsd#mgnx_CostOfManufacturingServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CostOfManufacturingServices" xlink:to="lab_mgnx_CostOfManufacturingServices" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_c8125aa6-9164-4a6a-827d-ff15eb840695_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_a1d2e2c9-3c40-4ae2-8a75-6a9934b2e7ae_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_db08eb43-0ed4-4824-8c12-2abd34470eea_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation, number of shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_b90bba27-68ac-4b43-8701-d0a89b5b6a16_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, equipment and software</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_208f8e28-b532-4be2-8895-683dd4855baa_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average remaining contractual term, Outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrAxis_terseLabel_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangement:</link:label>
    <link:label id="lab_ecd_TradingArrAxis_label_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrAxis" xlink:to="lab_ecd_TradingArrAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_5869e8ae-db91-4f6c-9741-e98f2a376d0c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_5947312e-200c-4953-b1ca-6c812bd162dd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_a6dc2b16-4461-4d8d-9443-ac066829b4b4_negatedLabel_en-US" xlink:label="lab_mgnx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Operating lease ROU assets</link:label>
    <link:label id="lab_mgnx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_label_en-US" xlink:label="lab_mgnx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Operating Lease Right Of Use Assets</link:label>
    <link:label id="lab_mgnx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_documentation_en-US" xlink:label="lab_mgnx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Operating Lease Right Of Use Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:href="mgnx-20231231.xsd#mgnx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:to="lab_mgnx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_TaxYear2025To2037Member_4d3c1f06-0ef3-448b-a17b-48fefed6ca69_terseLabel_en-US" xlink:label="lab_mgnx_TaxYear2025To2037Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Year 2025 To 2037</link:label>
    <link:label id="lab_mgnx_TaxYear2025To2037Member_label_en-US" xlink:label="lab_mgnx_TaxYear2025To2037Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Year 2025 To 2037 [Member]</link:label>
    <link:label id="lab_mgnx_TaxYear2025To2037Member_documentation_en-US" xlink:label="lab_mgnx_TaxYear2025To2037Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax Year 2025 To 2037</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TaxYear2025To2037Member" xlink:href="mgnx-20231231.xsd#mgnx_TaxYear2025To2037Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_TaxYear2025To2037Member" xlink:to="lab_mgnx_TaxYear2025To2037Member" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_IncyteCommercialSupplyAgreementMember_1cca7b0c-5ffc-465a-acfc-246e5435f51a_terseLabel_en-US" xlink:label="lab_mgnx_IncyteCommercialSupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Incyte MGA012 Clinical Services</link:label>
    <link:label id="lab_mgnx_IncyteCommercialSupplyAgreementMember_label_en-US" xlink:label="lab_mgnx_IncyteCommercialSupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incyte Commercial Supply Agreement [Member]</link:label>
    <link:label id="lab_mgnx_IncyteCommercialSupplyAgreementMember_documentation_en-US" xlink:label="lab_mgnx_IncyteCommercialSupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Incyte Commercial Supply Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteCommercialSupplyAgreementMember" xlink:href="mgnx-20231231.xsd#mgnx_IncyteCommercialSupplyAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IncyteCommercialSupplyAgreementMember" xlink:to="lab_mgnx_IncyteCommercialSupplyAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_79d4d46e-63e4-41a3-828c-f13e4777e5ed_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_label_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoActuallyPaidCompAmt" xlink:to="lab_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_TransactionCost_a45ed1bd-dbed-4c61-94a6-ea6d8da66da4_terseLabel_en-US" xlink:label="lab_mgnx_TransactionCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transaction cost</link:label>
    <link:label id="lab_mgnx_TransactionCost_label_en-US" xlink:label="lab_mgnx_TransactionCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transaction Cost</link:label>
    <link:label id="lab_mgnx_TransactionCost_documentation_en-US" xlink:label="lab_mgnx_TransactionCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Transaction Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TransactionCost" xlink:href="mgnx-20231231.xsd#mgnx_TransactionCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_TransactionCost" xlink:to="lab_mgnx_TransactionCost" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_ca0d06e9-b97b-411c-9cf0-87002f6980c2_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_86886b14-e9e1-4d49-8c14-00048e93bd0b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_7fe65f80-3bec-4e5a-a883-399c9d393803_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_33c7a412-1e14-49f3-9f1c-3227c55397d5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_2ef5f1ac-1328-42d7-a58c-81d578b9ffaa_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ASDHealthcareAndOncologySupplyMember_1e699e5d-dab8-4642-b0d1-87f05ab70226_terseLabel_en-US" xlink:label="lab_mgnx_ASDHealthcareAndOncologySupplyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASD Healthcare and Oncology Supply</link:label>
    <link:label id="lab_mgnx_ASDHealthcareAndOncologySupplyMember_label_en-US" xlink:label="lab_mgnx_ASDHealthcareAndOncologySupplyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ASD Healthcare and Oncology Supply [Member]</link:label>
    <link:label id="lab_mgnx_ASDHealthcareAndOncologySupplyMember_documentation_en-US" xlink:label="lab_mgnx_ASDHealthcareAndOncologySupplyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ASD Healthcare and Oncology Supply</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ASDHealthcareAndOncologySupplyMember" xlink:href="mgnx-20231231.xsd#mgnx_ASDHealthcareAndOncologySupplyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ASDHealthcareAndOncologySupplyMember" xlink:to="lab_mgnx_ASDHealthcareAndOncologySupplyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_AuditorInformationAbstract_label_en-US" xlink:label="lab_mgnx_AuditorInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Information [Abstract]</link:label>
    <link:label id="lab_mgnx_AuditorInformationAbstract_documentation_en-US" xlink:label="lab_mgnx_AuditorInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Auditor Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AuditorInformationAbstract" xlink:href="mgnx-20231231.xsd#mgnx_AuditorInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_AuditorInformationAbstract" xlink:to="lab_mgnx_AuditorInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_045dae23-cd26-4227-a22c-890ade293f83_terseLabel_en-US" xlink:label="lab_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amounts recognized</link:label>
    <link:label id="lab_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_label_en-US" xlink:label="lab_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Development And Regulatory Milestone Payments Under Agreement, Recognized</link:label>
    <link:label id="lab_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_documentation_en-US" xlink:label="lab_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Development And Regulatory Milestone Payments Under Agreement, Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" xlink:href="mgnx-20231231.xsd#mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" xlink:to="lab_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_6ba8de68-908a-4e9d-b213-e0fa189eb2c0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Trading, and Equity Securities, FV-NI [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Trading, and Equity Securities, FV-NI [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:to="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_254c3184-02a6-467d-8e98-d131d0edb4f9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Allowance for Credit Loss</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRevenueNoncurrent_4a2cbc99-f24b-432a-a48d-b80d28f36d7a_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue, net of current portion</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueNoncurrent_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueNoncurrent" xlink:to="lab_us-gaap_DeferredRevenueNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_fb9178c9-34f3-44e4-8eae-baa735ac64fe_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_2299091c-596c-4f8c-a02f-0c487c124205_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sales and maturities of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_a8962ed9-9953-46b5-bde1-6b2f3c233be0_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_c5816d6e-0a73-4a70-af6a-c52cfa2714ed_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_IncyteClinicalSupplyAgreementMember_9d5b3b21-4280-481a-a8e0-5328c03f61a7_terseLabel_en-US" xlink:label="lab_mgnx_IncyteClinicalSupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Incyte MGA012 Supply Agreement</link:label>
    <link:label id="lab_mgnx_IncyteClinicalSupplyAgreementMember_label_en-US" xlink:label="lab_mgnx_IncyteClinicalSupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incyte Clinical Supply Agreement [Member]</link:label>
    <link:label id="lab_mgnx_IncyteClinicalSupplyAgreementMember_documentation_en-US" xlink:label="lab_mgnx_IncyteClinicalSupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Incyte Clinical Supply Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteClinicalSupplyAgreementMember" xlink:href="mgnx-20231231.xsd#mgnx_IncyteClinicalSupplyAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IncyteClinicalSupplyAgreementMember" xlink:to="lab_mgnx_IncyteClinicalSupplyAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_7c832237-36ee-4013-985b-f05a2ad45c80_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_9f447f69-e92e-4b88-9169-308df95d177b_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDeterminationDate_terseLabel_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:label id="lab_ecd_RestatementDeterminationDate_label_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDeterminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDeterminationDate" xlink:to="lab_ecd_RestatementDeterminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_c3773631-c07d-47e6-9c48-7e465492e66d_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_SynaffixBVMember_3be27e02-acca-4324-9fe0-c1dba9dc5563_terseLabel_en-US" xlink:label="lab_mgnx_SynaffixBVMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Synaffix B.V.</link:label>
    <link:label id="lab_mgnx_SynaffixBVMember_label_en-US" xlink:label="lab_mgnx_SynaffixBVMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Synaffix B.V. [Member]</link:label>
    <link:label id="lab_mgnx_SynaffixBVMember_documentation_en-US" xlink:label="lab_mgnx_SynaffixBVMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Synaffix B.V.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_SynaffixBVMember" xlink:href="mgnx-20231231.xsd#mgnx_SynaffixBVMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_SynaffixBVMember" xlink:to="lab_mgnx_SynaffixBVMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_DeferredTransactionCosts_fc3b2281-9114-4465-8880-28581a465c46_negatedTerseLabel_en-US" xlink:label="lab_mgnx_DeferredTransactionCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deferred transaction costs</link:label>
    <link:label id="lab_mgnx_DeferredTransactionCosts_label_en-US" xlink:label="lab_mgnx_DeferredTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred transaction costs</link:label>
    <link:label id="lab_mgnx_DeferredTransactionCosts_documentation_en-US" xlink:label="lab_mgnx_DeferredTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred transaction costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DeferredTransactionCosts" xlink:href="mgnx-20231231.xsd#mgnx_DeferredTransactionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_DeferredTransactionCosts" xlink:to="lab_mgnx_DeferredTransactionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_b319ee3e-434d-4c88-9905-d9e50ea19da2_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increases for current year tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_9e969aa0-de5b-4ed0-bbc4-ad6bb038ccfb_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:to="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_654180f5-fabe-404b-8c44-d5cf3e3edd2d_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_946beee7-c37f-4323-bbac-3c166eec0b36_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_41c9f2c8-b889-4d58-8c38-5d788673cdfd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember_d36ca392-e949-4cb7-94c4-5ea1cdb98b4b_terseLabel_en-US" xlink:label="lab_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2016 Employee Stock Purchase Plan</link:label>
    <link:label id="lab_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Thousand Sixteen Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Two Thousand Sixteen Employee Stock Purchase Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember" xlink:href="mgnx-20231231.xsd#mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember" xlink:to="lab_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_16c17930-54b4-4351-9dcf-0f28ff16dde8_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_UndesignatedPreferredStockMember_39fbac31-6d18-440c-88fa-b3a7ddef04f9_terseLabel_en-US" xlink:label="lab_mgnx_UndesignatedPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Undesignated Preferred Stock</link:label>
    <link:label id="lab_mgnx_UndesignatedPreferredStockMember_label_en-US" xlink:label="lab_mgnx_UndesignatedPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Undesignated Preferred Stock [Member]</link:label>
    <link:label id="lab_mgnx_UndesignatedPreferredStockMember_documentation_en-US" xlink:label="lab_mgnx_UndesignatedPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Undesignated Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_UndesignatedPreferredStockMember" xlink:href="mgnx-20231231.xsd#mgnx_UndesignatedPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_UndesignatedPreferredStockMember" xlink:to="lab_mgnx_UndesignatedPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_7bc8fe29-4e49-4c27-a3a4-68426b6af659_verboseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Government-sponsored enterprises</link:label>
    <link:label id="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_2bce8f12-68f5-44d0-9d8e-1a3384252f5a_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Government-sponsored enterprises</link:label>
    <link:label id="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Government-sponsored Enterprises Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_86858e0d-9cc5-47c3-be01-38f0bacef5be_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of common stock (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_label_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_7f57384f-2acf-4e33-a1cb-6ab9c8da4041_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable lease cost</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_edd9e7b7-7d38-4b15-b2a9-d8042ce748f0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_99ccb7a9-71b7-4930-8d2b-cc718f11c280_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_25beeb9f-fddf-475a-9c0b-52c61e461cb4_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue, current</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_fb103f06-fd30-4cb6-8578-d39f0e201156_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Employee Stock Options Award Valuation Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_5d935bd7-4d14-45b3-bbef-3e477a7193b9_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_c20f28cc-64a4-4ab2-804a-f3da33f339a2_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Research credit, net</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_f96d1775-62bb-47af-9222-d79356457eba_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets measured at fair value</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_15964d4c-fb20-4759-a20b-5b694b8e68c9_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds of stock sale</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_IncyteCorporationMember_b0319da4-bb4b-4e82-b9a0-3dc156cb1cf6_terseLabel_en-US" xlink:label="lab_mgnx_IncyteCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Incyte Corporation (Incyte)</link:label>
    <link:label id="lab_mgnx_IncyteCorporationMember_label_en-US" xlink:label="lab_mgnx_IncyteCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incyte Corporation [Member]</link:label>
    <link:label id="lab_mgnx_IncyteCorporationMember_documentation_en-US" xlink:label="lab_mgnx_IncyteCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Incyte Corporation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteCorporationMember" xlink:href="mgnx-20231231.xsd#mgnx_IncyteCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IncyteCorporationMember" xlink:to="lab_mgnx_IncyteCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Stock Option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_OperatingLeaseNoncashExpense_ca546e10-37e4-4acb-973f-f3145e051217_terseLabel_en-US" xlink:label="lab_mgnx_OperatingLeaseNoncashExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash lease expense</link:label>
    <link:label id="lab_mgnx_OperatingLeaseNoncashExpense_label_en-US" xlink:label="lab_mgnx_OperatingLeaseNoncashExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Noncash Expense</link:label>
    <link:label id="lab_mgnx_OperatingLeaseNoncashExpense_documentation_en-US" xlink:label="lab_mgnx_OperatingLeaseNoncashExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Lease, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_OperatingLeaseNoncashExpense" xlink:href="mgnx-20231231.xsd#mgnx_OperatingLeaseNoncashExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_OperatingLeaseNoncashExpense" xlink:to="lab_mgnx_OperatingLeaseNoncashExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_d5704155-901f-432b-907b-6b34e7f80960_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance at Beginning of Year</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_16b4d9df-cd8f-4006-accf-deb69695621c_periodEndLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at End of Year</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_314e1ff0-2977-49fd-bd40-fab3400c7740_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation expense recognition period</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_b677746c-28d1-4a0e-ba3d-5442949b1157_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total costs and expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_73e422d7-5a0e-4c0f-a4ac-c877a64ad34c_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_cb822f7f-58da-4cc7-a603-a88df4d3c56b_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_e84fec43-65ba-4dc8-ab99-e3cbc2019d89_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation cost related to non-vested stock-based compensation arrangements</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RevenuesFromGrantsMember_758c5d75-f28e-47c3-b2bf-e484c189ea13_terseLabel_en-US" xlink:label="lab_mgnx_RevenuesFromGrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RevenuesFromGrantsMember</link:label>
    <link:label id="lab_mgnx_RevenuesFromGrantsMember_label_en-US" xlink:label="lab_mgnx_RevenuesFromGrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">RevenuesFromGrantsMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromGrantsMember" xlink:href="mgnx-20231231.xsd#mgnx_RevenuesFromGrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RevenuesFromGrantsMember" xlink:to="lab_mgnx_RevenuesFromGrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_77db2c31-483e-4013-a2e1-d1de88d19359_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TabularListTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tabular List, Table</link:label>
    <link:label id="lab_ecd_TabularListTableTextBlock_label_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TabularListTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TabularListTableTextBlock" xlink:to="lab_ecd_TabularListTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_3a4cd9da-2cc4-45e8-8a82-6bd7772a6b81_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. Federal Government</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_92a9e9c0-4728-4090-89c2-28c47dd6fcb3_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_d19faba5-f657-4491-976a-cc86128df4fd_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_GileadFirstResearchProgramMember_38d21836-5e1d-42a3-8dd0-5a128e6c9762_terseLabel_en-US" xlink:label="lab_mgnx_GileadFirstResearchProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gilead First Research Program</link:label>
    <link:label id="lab_mgnx_GileadFirstResearchProgramMember_label_en-US" xlink:label="lab_mgnx_GileadFirstResearchProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gilead First Research Program [Member]</link:label>
    <link:label id="lab_mgnx_GileadFirstResearchProgramMember_documentation_en-US" xlink:label="lab_mgnx_GileadFirstResearchProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gilead First Research Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_GileadFirstResearchProgramMember" xlink:href="mgnx-20231231.xsd#mgnx_GileadFirstResearchProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_GileadFirstResearchProgramMember" xlink:to="lab_mgnx_GileadFirstResearchProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_04f8934d-20bc-440b-9917-2ef42aea3d34_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan_5e8c1d41-ad29-4eae-ad8d-419a2dfc9d12_terseLabel_en-US" xlink:label="lab_mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Eligible age to participate in plan</link:label>
    <link:label id="lab_mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan_label_en-US" xlink:label="lab_mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employees Eligible Age To Participate In Benefit Plan</link:label>
    <link:label id="lab_mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan_documentation_en-US" xlink:label="lab_mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Refers to minimum eligible age of employee to participate in benefit plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan" xlink:href="mgnx-20231231.xsd#mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan" xlink:to="lab_mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_f9975907-515c-459b-9102-c1b5c6cdebcb_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_4b108708-3fcc-470a-83cc-38cbf4f649dc_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_9fb3e3bb-e1c2-4f18-8cc2-294215c5c752_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation and Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_acc49eb5-84ba-485e-934c-8a3ecd36968b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other non-cash items</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_f27e9632-b464-4f5e-9442-6620f3d38674_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_NonCashInterestExpenseRecognized_24e36977-5ff8-41ed-af15-32a5ba12a518_terseLabel_en-US" xlink:label="lab_mgnx_NonCashInterestExpenseRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash interest expense</link:label>
    <link:label id="lab_mgnx_NonCashInterestExpenseRecognized_label_en-US" xlink:label="lab_mgnx_NonCashInterestExpenseRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-cash interest expense recognized</link:label>
    <link:label id="lab_mgnx_NonCashInterestExpenseRecognized_documentation_en-US" xlink:label="lab_mgnx_NonCashInterestExpenseRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-cash interest expense recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonCashInterestExpenseRecognized" xlink:href="mgnx-20231231.xsd#mgnx_NonCashInterestExpenseRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_NonCashInterestExpenseRecognized" xlink:to="lab_mgnx_NonCashInterestExpenseRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_TotalAnnualFixedPayments_7bab2fda-0af6-4dde-9a5d-75502a7ee860_terseLabel_en-US" xlink:label="lab_mgnx_TotalAnnualFixedPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total annual fixed payments</link:label>
    <link:label id="lab_mgnx_TotalAnnualFixedPayments_label_en-US" xlink:label="lab_mgnx_TotalAnnualFixedPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Annual Fixed Payments</link:label>
    <link:label id="lab_mgnx_TotalAnnualFixedPayments_documentation_en-US" xlink:label="lab_mgnx_TotalAnnualFixedPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total Annual Fixed Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TotalAnnualFixedPayments" xlink:href="mgnx-20231231.xsd#mgnx_TotalAnnualFixedPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_TotalAnnualFixedPayments" xlink:to="lab_mgnx_TotalAnnualFixedPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_fe2bf909-d5c5-43fb-9a48-e43ae6a0af5f_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_abc0abad-ddde-46ee-a731-8ea2b9dcdeb3_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Deferred Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_f68d7259-a2c6-4cb8-97d3-4b0608846bbd_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock, net of offering costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_7cdced55-5002-4b15-8193-fe2c044dd819_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Number of shares issued or sold (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_e5c769cd-fc44-4936-8c4a-cdbbae267786_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Costs and expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_3ef75e4c-94a0-44d7-a558-d948ea4a9b48_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeited or expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_edf6f5e6-e9ef-4df1-8d72-64530644bb0d_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_644e2033-80be-4f85-86a8-9916399bebc6_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_IMabBiopharmaMember_8ecdb7c0-c4c5-4bdb-929a-6d8952a92ce6_terseLabel_en-US" xlink:label="lab_mgnx_IMabBiopharmaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">I-Mab Biopharma</link:label>
    <link:label id="lab_mgnx_IMabBiopharmaMember_label_en-US" xlink:label="lab_mgnx_IMabBiopharmaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">I-Mab Biopharma [Member]</link:label>
    <link:label id="lab_mgnx_IMabBiopharmaMember_documentation_en-US" xlink:label="lab_mgnx_IMabBiopharmaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">I-Mab Biopharma</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IMabBiopharmaMember" xlink:href="mgnx-20231231.xsd#mgnx_IMabBiopharmaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IMabBiopharmaMember" xlink:to="lab_mgnx_IMabBiopharmaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubleaseIncome_b2b55b30-34b5-4f0e-a5e3-0202fa42b275_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Sublease Income</link:label>
    <link:label id="lab_us-gaap_SubleaseIncome_label_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sublease Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubleaseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubleaseIncome" xlink:to="lab_us-gaap_SubleaseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ZaiLabLimitedMember_a131424f-61ea-4b3d-9b46-a961464b7184_terseLabel_en-US" xlink:label="lab_mgnx_ZaiLabLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Zai Lab Limited (Zai Lab)</link:label>
    <link:label id="lab_mgnx_ZaiLabLimitedMember_label_en-US" xlink:label="lab_mgnx_ZaiLabLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Zai Lab Limited [Member]</link:label>
    <link:label id="lab_mgnx_ZaiLabLimitedMember_documentation_en-US" xlink:label="lab_mgnx_ZaiLabLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Zai Lab Limited</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabLimitedMember" xlink:href="mgnx-20231231.xsd#mgnx_ZaiLabLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ZaiLabLimitedMember" xlink:to="lab_mgnx_ZaiLabLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CardinalHealthIncMember_9c1d4518-0b22-423e-bd19-44265cef2ea9_terseLabel_en-US" xlink:label="lab_mgnx_CardinalHealthIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cardinal Health</link:label>
    <link:label id="lab_mgnx_CardinalHealthIncMember_label_en-US" xlink:label="lab_mgnx_CardinalHealthIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cardinal Health, Inc [Member]</link:label>
    <link:label id="lab_mgnx_CardinalHealthIncMember_documentation_en-US" xlink:label="lab_mgnx_CardinalHealthIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cardinal Health, Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CardinalHealthIncMember" xlink:href="mgnx-20231231.xsd#mgnx_CardinalHealthIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CardinalHealthIncMember" xlink:to="lab_mgnx_CardinalHealthIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_label_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_GainOnRoyaltyMonetizationArrangement_f173069b-d035-4d9b-86b8-04b33a002af9_terseLabel_en-US" xlink:label="lab_mgnx_GainOnRoyaltyMonetizationArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain on royalty monetization arrangement</link:label>
    <link:label id="lab_mgnx_GainOnRoyaltyMonetizationArrangement_5f4e1fc4-0089-4164-9cbe-e94621771594_negatedTerseLabel_en-US" xlink:label="lab_mgnx_GainOnRoyaltyMonetizationArrangement" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Gain on royalty monetization arrangement</link:label>
    <link:label id="lab_mgnx_GainOnRoyaltyMonetizationArrangement_label_en-US" xlink:label="lab_mgnx_GainOnRoyaltyMonetizationArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain on royalty monetization arrangement</link:label>
    <link:label id="lab_mgnx_GainOnRoyaltyMonetizationArrangement_documentation_en-US" xlink:label="lab_mgnx_GainOnRoyaltyMonetizationArrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gain on royalty monetization arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_GainOnRoyaltyMonetizationArrangement" xlink:href="mgnx-20231231.xsd#mgnx_GainOnRoyaltyMonetizationArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_GainOnRoyaltyMonetizationArrangement" xlink:to="lab_mgnx_GainOnRoyaltyMonetizationArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_24fc82c4-5aea-4e63-a15d-cc017b762dc4_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_588bbb56-b809-449f-8e5b-ad4117b02f88_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_AdditionalAnnualFixedPayments_e2533b6e-21ab-4bf7-ba46-c032302b8989_terseLabel_en-US" xlink:label="lab_mgnx_AdditionalAnnualFixedPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional annual fixed payments</link:label>
    <link:label id="lab_mgnx_AdditionalAnnualFixedPayments_label_en-US" xlink:label="lab_mgnx_AdditionalAnnualFixedPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Annual Fixed Payments</link:label>
    <link:label id="lab_mgnx_AdditionalAnnualFixedPayments_documentation_en-US" xlink:label="lab_mgnx_AdditionalAnnualFixedPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Additional Annual Fixed Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AdditionalAnnualFixedPayments" xlink:href="mgnx-20231231.xsd#mgnx_AdditionalAnnualFixedPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_AdditionalAnnualFixedPayments" xlink:to="lab_mgnx_AdditionalAnnualFixedPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_adea90c8-6c6d-4e68-9a11-139ec54be1e0_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_11d0905e-0781-423f-99bb-3286cc6862c9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">United States federal tax at statutory rate</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExaminationLineItems_2844f925-46bb-41d4-925a-3a45525db4c9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Examination [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Examination [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExaminationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems" xlink:to="lab_us-gaap_IncomeTaxExaminationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6092f823-af06-4648-9746-6c6ad7a84f24_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_09706520-476a-4fd6-9b39-1e845d212c18_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_b44684f2-47c6-4bec-afaf-4a712cc97f5b_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_28bd2021-cd00-48a9-a0d3-339550dd9551_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease, cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_5289edf3-3368-4502-bfaa-39ea171e5bab_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_13d61bc4-9320-4533-98b4-962408556b43_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_d66ce24d-82ce-4d6d-b8cc-b89d01cc75f5_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount_83b0f7ee-c9a7-458b-9243-afde50d9a367_negatedLabel_en-US" xlink:label="lab_mgnx_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Orphan drug credit, net</link:label>
    <link:label id="lab_mgnx_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount_label_en-US" xlink:label="lab_mgnx_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Orphan Drug, Amount</link:label>
    <link:label id="lab_mgnx_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount_documentation_en-US" xlink:label="lab_mgnx_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Orphan Drug, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount" xlink:href="mgnx-20231231.xsd#mgnx_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount" xlink:to="lab_mgnx_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_PrincipalPaymentsOnRoyaltyMonetizationArrangement_69a3133e-4510-44ee-a580-0e7d0dee7020_negatedTerseLabel_en-US" xlink:label="lab_mgnx_PrincipalPaymentsOnRoyaltyMonetizationArrangement" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Principal payments on royalty monetization arrangement</link:label>
    <link:label id="lab_mgnx_PrincipalPaymentsOnRoyaltyMonetizationArrangement_label_en-US" xlink:label="lab_mgnx_PrincipalPaymentsOnRoyaltyMonetizationArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Principal payments on royalty monetization arrangement</link:label>
    <link:label id="lab_mgnx_PrincipalPaymentsOnRoyaltyMonetizationArrangement_documentation_en-US" xlink:label="lab_mgnx_PrincipalPaymentsOnRoyaltyMonetizationArrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Principal payments on royalty monetization arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PrincipalPaymentsOnRoyaltyMonetizationArrangement" xlink:href="mgnx-20231231.xsd#mgnx_PrincipalPaymentsOnRoyaltyMonetizationArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PrincipalPaymentsOnRoyaltyMonetizationArrangement" xlink:to="lab_mgnx_PrincipalPaymentsOnRoyaltyMonetizationArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnAmt" xlink:to="lab_ecd_TotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_83953f5e-8779-440e-9677-45906240d983_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_0fee05a1-aa2f-49ba-9b05-94c0893cc5b7_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_2d022f4c-9042-4d3f-8e2f-753077ff3665_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToPeoCompFnTextBlock" xlink:to="lab_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_806efa58-b38a-443a-96fe-437339d1e5d6_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares_0e2e39dc-75d4-48de-82ac-8143fff3cac9_terseLabel_en-US" xlink:label="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock warrants (in shares)</link:label>
    <link:label id="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares_label_en-US" xlink:label="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Agreement Consideration Received Common Stock Warrants Number Of Shares</link:label>
    <link:label id="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares_documentation_en-US" xlink:label="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Agreement Consideration Received Common Stock Warrants Number Of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares" xlink:href="mgnx-20231231.xsd#mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares" xlink:to="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ba91144a-599f-4ddd-9a5c-958dcd5935c4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_aa28099f-21dd-44da-bd7b-dff9ef5bbf69_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_2972f183-4eda-4910-8d43-3f8c10d590b4_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureAxis_terseLabel_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measure:</link:label>
    <link:label id="lab_ecd_MeasureAxis_label_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureAxis" xlink:to="lab_ecd_MeasureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryIndName" xlink:to="lab_ecd_OutstandingRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CollaborativeAgreementTransactionPrice_41e92152-4c8d-49ec-b3ea-9d7ced14e29d_terseLabel_en-US" xlink:label="lab_mgnx_CollaborativeAgreementTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transaction price</link:label>
    <link:label id="lab_mgnx_CollaborativeAgreementTransactionPrice_label_en-US" xlink:label="lab_mgnx_CollaborativeAgreementTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Agreement Transaction Price</link:label>
    <link:label id="lab_mgnx_CollaborativeAgreementTransactionPrice_documentation_en-US" xlink:label="lab_mgnx_CollaborativeAgreementTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Agreement Transaction Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementTransactionPrice" xlink:href="mgnx-20231231.xsd#mgnx_CollaborativeAgreementTransactionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CollaborativeAgreementTransactionPrice" xlink:to="lab_mgnx_CollaborativeAgreementTransactionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_b90ffef5-cb6d-4b0f-b4cb-c13e9b5a4216_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_9628bdca-d89d-4a71-adc3-3b115bde166b_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_be0faa27-bf8d-4225-bed0-176e3cce98ef_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred income tax assets:</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Components of Deferred Tax Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_271e72b2-a390-4d8d-a7ea-3b9f08056eac_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Components of the Company's Deferred Income Tax Assets (Liabilities)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_7cb27dfe-92d6-43a6-8d99-2e21101071d1_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_e3e2a2f8-d609-4968-bd4c-c2aaaa2fc282_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_StockIssuedDuringPeriodValueStockPlanActivity_788b17e6-e6e0-446c-a939-9a1597c1ed06_terseLabel_en-US" xlink:label="lab_mgnx_StockIssuedDuringPeriodValueStockPlanActivity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock plan related activity</link:label>
    <link:label id="lab_mgnx_StockIssuedDuringPeriodValueStockPlanActivity_label_en-US" xlink:label="lab_mgnx_StockIssuedDuringPeriodValueStockPlanActivity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period Value Stock Plan Activity</link:label>
    <link:label id="lab_mgnx_StockIssuedDuringPeriodValueStockPlanActivity_documentation_en-US" xlink:label="lab_mgnx_StockIssuedDuringPeriodValueStockPlanActivity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Value of shares issued due to stock plan related activity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIssuedDuringPeriodValueStockPlanActivity" xlink:href="mgnx-20231231.xsd#mgnx_StockIssuedDuringPeriodValueStockPlanActivity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_StockIssuedDuringPeriodValueStockPlanActivity" xlink:to="lab_mgnx_StockIssuedDuringPeriodValueStockPlanActivity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_598e0298-7b62-4a66-bb71-41db7b57781e_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_77c74ef6-c52f-438c-98dc-f316afaa3b79_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_4445aa8e-6d5b-4f68-9f7a-56938b5c07ae_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gain (loss) on investments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_c5190b9b-5dba-43df-8e4d-709318cdeea3_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RevenueFromGovernmentAgreementsMember_9a72c11a-4ac5-43a9-aaab-5938cc868fbc_terseLabel_en-US" xlink:label="lab_mgnx_RevenueFromGovernmentAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from government agreements</link:label>
    <link:label id="lab_mgnx_RevenueFromGovernmentAgreementsMember_label_en-US" xlink:label="lab_mgnx_RevenueFromGovernmentAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue From Government Agreements [Member]</link:label>
    <link:label id="lab_mgnx_RevenueFromGovernmentAgreementsMember_documentation_en-US" xlink:label="lab_mgnx_RevenueFromGovernmentAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue From Government Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromGovernmentAgreementsMember" xlink:href="mgnx-20231231.xsd#mgnx_RevenueFromGovernmentAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RevenueFromGovernmentAgreementsMember" xlink:to="lab_mgnx_RevenueFromGovernmentAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoMember_terseLabel_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO</link:label>
    <link:label id="lab_ecd_PeoMember_label_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoMember" xlink:to="lab_ecd_PeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare_e975d122-f9f4-43d8-90ff-a1f00d07cc38_terseLabel_en-US" xlink:label="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consideration received common stock warrant exercise price (in usd per share)</link:label>
    <link:label id="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare_label_en-US" xlink:label="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Agreement Consideration Received Common Stock Warrant Exercise Price Per Share</link:label>
    <link:label id="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare_documentation_en-US" xlink:label="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Agreement Consideration Received Common Stock Warrant Exercise Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare" xlink:href="mgnx-20231231.xsd#mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare" xlink:to="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_3a818a49-c9ac-4243-a085-78567c7eb708_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_ec645f8d-f08c-4aaf-a806-06c79cd52656_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_acd95535-b7c7-4643-b944-8d485bb762eb_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Benefit Plan</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_28384bb5-2ec1-4fed-8947-806a039f6317_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_17e41a22-3796-4650-8b43-36dcd493086a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State taxes (net of federal benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_2f95b35e-ef3d-4f41-b59c-e1a7d9ba632e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_d710eb38-18be-48a6-b187-1fca4c78c1ed_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_9b99576f-ec64-4831-afc0-e8f3e0076a89_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of employee contribution to salary</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_ed6e0ef0-5e8b-451b-9a0f-c4bae0ad7573_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_aeb5e8f4-a9c3-4508-a4e8-0538230bc8b0_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_8b9b8687-77fd-4796-b800-4a8bc0d6b4f0_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_8c9c999d-a103-4ce3-9cf0-23881e8eecca_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_5af2f9b7-c140-4fa2-9bf5-88173e1f770a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Inventory, Current</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_33931a54-285a-4f21-af4e-0c5f79d68cf8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other permanent items</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_78e40ce9-986b-4d33-a85e-8f4d84db8034_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingAggtErrCompAmt" xlink:to="lab_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_faad6989-0738-4a8c-b416-df29fb8f0438_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_TotalPotentialValueUnderAgreement_6e70bb6d-8d7f-49fa-aa37-30ac1edacdb6_terseLabel_en-US" xlink:label="lab_mgnx_TotalPotentialValueUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total potential value</link:label>
    <link:label id="lab_mgnx_TotalPotentialValueUnderAgreement_label_en-US" xlink:label="lab_mgnx_TotalPotentialValueUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total potential value of agreement</link:label>
    <link:label id="lab_mgnx_TotalPotentialValueUnderAgreement_documentation_en-US" xlink:label="lab_mgnx_TotalPotentialValueUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Refers to total potential value under agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TotalPotentialValueUnderAgreement" xlink:href="mgnx-20231231.xsd#mgnx_TotalPotentialValueUnderAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_TotalPotentialValueUnderAgreement" xlink:to="lab_mgnx_TotalPotentialValueUnderAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_A2021ZaiLabAgreementsMember_567349fb-e2b5-4247-bc93-a403c6304342_terseLabel_en-US" xlink:label="lab_mgnx_A2021ZaiLabAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2021 Zai Lab Agreements</link:label>
    <link:label id="lab_mgnx_A2021ZaiLabAgreementsMember_label_en-US" xlink:label="lab_mgnx_A2021ZaiLabAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2021 Zai Lab Agreements [Member]</link:label>
    <link:label id="lab_mgnx_A2021ZaiLabAgreementsMember_documentation_en-US" xlink:label="lab_mgnx_A2021ZaiLabAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2021 Zai Lab Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_A2021ZaiLabAgreementsMember" xlink:href="mgnx-20231231.xsd#mgnx_A2021ZaiLabAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_A2021ZaiLabAgreementsMember" xlink:to="lab_mgnx_A2021ZaiLabAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_725df7e2-0f68-40fb-ac65-84999d8b6ee9_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_6ecf24e4-7a1c-428a-ad7c-c6a03f564874_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provision for federal or state income taxes</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_81db02cf-6284-4718-b5fc-56a5e051de02_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_2a07b48a-3c73-44c6-b7e5-75d9164a0d6a_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization and Nature of Operations</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6b9ccfd7-1f7c-4fc5-b4a6-35563ba6025c_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_AggtErrCompAmt_label_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompAmt" xlink:to="lab_ecd_AggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_0aa2dec5-3b16-4763-878b-a953c52cd56b_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions Charged to Expenses</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_b58b4cd0-c131-4e46-b23e-91294b994c75_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_274725b8-cc0d-4c0e-bdd1-b3040261ece0_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Equipment and Software</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_terseLabel_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Executive Categories</link:label>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_label_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Executive Categories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="lab_ecd_AllExecutiveCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_5f3fdf87-b754-4ba3-a34f-d5c0535a4074_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue, noncurrent</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ScheduleOfSupplementalBalanceSheetInformationOperatingLeasesTableTextBlock_c28431fc-17f2-4adb-abf9-877b01aa104f_terseLabel_en-US" xlink:label="lab_mgnx_ScheduleOfSupplementalBalanceSheetInformationOperatingLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Supplemental Balance Sheet Information, Operating Leases</link:label>
    <link:label id="lab_mgnx_ScheduleOfSupplementalBalanceSheetInformationOperatingLeasesTableTextBlock_label_en-US" xlink:label="lab_mgnx_ScheduleOfSupplementalBalanceSheetInformationOperatingLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Supplemental Balance Sheet Information, Operating Leases [Table Text Block]</link:label>
    <link:label id="lab_mgnx_ScheduleOfSupplementalBalanceSheetInformationOperatingLeasesTableTextBlock_documentation_en-US" xlink:label="lab_mgnx_ScheduleOfSupplementalBalanceSheetInformationOperatingLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Supplemental Balance Sheet Information, Operating Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ScheduleOfSupplementalBalanceSheetInformationOperatingLeasesTableTextBlock" xlink:href="mgnx-20231231.xsd#mgnx_ScheduleOfSupplementalBalanceSheetInformationOperatingLeasesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ScheduleOfSupplementalBalanceSheetInformationOperatingLeasesTableTextBlock" xlink:to="lab_mgnx_ScheduleOfSupplementalBalanceSheetInformationOperatingLeasesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:to="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_b37f7746-5488-4d0b-8685-0d320c5cb13b_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_f778ab71-5f12-4eca-ae42-ad5cbfde0c1d_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CollaborationAndLicenseAgreementsAbstract_599c456f-31ed-487a-97dd-00d6e1473080_terseLabel_en-US" xlink:label="lab_mgnx_CollaborationAndLicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration and License Agreements [Abstract]</link:label>
    <link:label id="lab_mgnx_CollaborationAndLicenseAgreementsAbstract_label_en-US" xlink:label="lab_mgnx_CollaborationAndLicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration and License Agreements [Abstract]</link:label>
    <link:label id="lab_mgnx_CollaborationAndLicenseAgreementsAbstract_documentation_en-US" xlink:label="lab_mgnx_CollaborationAndLicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract" xlink:href="mgnx-20231231.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract" xlink:to="lab_mgnx_CollaborationAndLicenseAgreementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_EstimatedReimbursementForResearchAndDevelopmentT_0af93d54-3284-4170-b884-62141bda0812_terseLabel_en-US" xlink:label="lab_mgnx_EstimatedReimbursementForResearchAndDevelopmentT" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated Reimbursement for Research and Development t</link:label>
    <link:label id="lab_mgnx_EstimatedReimbursementForResearchAndDevelopmentT_label_en-US" xlink:label="lab_mgnx_EstimatedReimbursementForResearchAndDevelopmentT" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimated Reimbursement for Research and Development t</link:label>
    <link:label id="lab_mgnx_EstimatedReimbursementForResearchAndDevelopmentT_documentation_en-US" xlink:label="lab_mgnx_EstimatedReimbursementForResearchAndDevelopmentT" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Estimated Reimbursement for Research and Development t</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EstimatedReimbursementForResearchAndDevelopmentT" xlink:href="mgnx-20231231.xsd#mgnx_EstimatedReimbursementForResearchAndDevelopmentT"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_EstimatedReimbursementForResearchAndDevelopmentT" xlink:to="lab_mgnx_EstimatedReimbursementForResearchAndDevelopmentT" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember_5ad86555-affa-4516-9d7c-29afd0b05348_terseLabel_en-US" xlink:label="lab_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. Federal and State</link:label>
    <link:label id="lab_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember_label_en-US" xlink:label="lab_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Tax Authority and State and Local Jurisdiction [Member] [Member]</link:label>
    <link:label id="lab_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember_documentation_en-US" xlink:label="lab_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Domestic Tax Authority and State and Local Jurisdiction [Member] [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember" xlink:href="mgnx-20231231.xsd#mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember" xlink:to="lab_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryValuationReserveMember_250a41f1-57e1-4a8c-99eb-70381c78de2c_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryValuationReserveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Reserve, Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryValuationReserveMember_label_en-US" xlink:label="lab_us-gaap_InventoryValuationReserveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Reserve, Inventory [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserveMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryValuationReserveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryValuationReserveMember" xlink:to="lab_us-gaap_InventoryValuationReserveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_d94dcbee-6f62-4a3b-a6f0-d374178d8168_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, 0.01 par value -- 125,000,000 shares authorized, 62,070,627 and 61,701,467 shares outstanding at December&#160;31, 2023 and December&#160;31, 2022, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_fe622937-7bd7-4744-8e63-b9cc76295a05_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_a0de7356-7fca-4973-b551-1b8ad7926fb6_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State net operating loss carryforward</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, State and Local</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_8f00c778-9b91-4c75-9bcd-8fa1820a06b8_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_EffectiveIncomeTaxRateReconciliationDeferredStateBlendedRateAdjustmentsAmount_54264624-309b-4cf1-aeb8-0f927ce2b21d_terseLabel_en-US" xlink:label="lab_mgnx_EffectiveIncomeTaxRateReconciliationDeferredStateBlendedRateAdjustmentsAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred state blended rate adjustments</link:label>
    <link:label id="lab_mgnx_EffectiveIncomeTaxRateReconciliationDeferredStateBlendedRateAdjustmentsAmount_label_en-US" xlink:label="lab_mgnx_EffectiveIncomeTaxRateReconciliationDeferredStateBlendedRateAdjustmentsAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Deferred State Blended Rate Adjustments, Amount</link:label>
    <link:label id="lab_mgnx_EffectiveIncomeTaxRateReconciliationDeferredStateBlendedRateAdjustmentsAmount_documentation_en-US" xlink:label="lab_mgnx_EffectiveIncomeTaxRateReconciliationDeferredStateBlendedRateAdjustmentsAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Deferred State Blended Rate Adjustments, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EffectiveIncomeTaxRateReconciliationDeferredStateBlendedRateAdjustmentsAmount" xlink:href="mgnx-20231231.xsd#mgnx_EffectiveIncomeTaxRateReconciliationDeferredStateBlendedRateAdjustmentsAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_EffectiveIncomeTaxRateReconciliationDeferredStateBlendedRateAdjustmentsAmount" xlink:to="lab_mgnx_EffectiveIncomeTaxRateReconciliationDeferredStateBlendedRateAdjustmentsAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_47a8f724-d5ac-43ac-ac50-cde1bdd687c6_terseLabel_en-US" xlink:label="lab_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential commercial milestone payments</link:label>
    <link:label id="lab_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_label_en-US" xlink:label="lab_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Potential Commercial Milestone Payments Under Agreement</link:label>
    <link:label id="lab_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_documentation_en-US" xlink:label="lab_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Potential Commercial Milestone Payments Under Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement" xlink:href="mgnx-20231231.xsd#mgnx_PotentialCommercialMilestonePaymentsUnderAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement" xlink:to="lab_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_f9aa7f79-d231-4ac8-9d97-e2d89d76f8ee_terseLabel_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Percentage of Customer Concentration</link:label>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_label_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllIndividualsMember_terseLabel_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Individuals</link:label>
    <link:label id="lab_ecd_AllIndividualsMember_label_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Individuals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="lab_ecd_AllIndividualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_42b4837e-17f7-4ffb-ba08-2c83748a2844_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest and other income</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_437259af-2271-44d1-a953-a61001547d4c_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_f9329c84-ac67-4984-b0f9-af555f7cfd9f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_3f7b069a-8df5-462a-9565-2f690c093ab5_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_3c4b1c6c-2ca5-41b2-8d8e-ef59bf95950e_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_3f9b590d-e059-4f56-b8d8-0019fa531e06_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of Reported Estimated Income Tax Benefit</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ProceedsfromRoyaltiesPercent_a9d59258-b2ff-4ff1-a607-92d94b20e70a_terseLabel_en-US" xlink:label="lab_mgnx_ProceedsfromRoyaltiesPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential proceeds from royalties percent</link:label>
    <link:label id="lab_mgnx_ProceedsfromRoyaltiesPercent_label_en-US" xlink:label="lab_mgnx_ProceedsfromRoyaltiesPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Royalties, Percent</link:label>
    <link:label id="lab_mgnx_ProceedsfromRoyaltiesPercent_documentation_en-US" xlink:label="lab_mgnx_ProceedsfromRoyaltiesPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds from Royalties, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromRoyaltiesPercent" xlink:href="mgnx-20231231.xsd#mgnx_ProceedsfromRoyaltiesPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ProceedsfromRoyaltiesPercent" xlink:to="lab_mgnx_ProceedsfromRoyaltiesPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_65aba468-267d-41b1-ab5f-46d77a33ff18_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_be84631c-b8ff-4661-88c9-b44cc6a6e492_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_9184a5e7-19a4-455c-b917-1d422f578112_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoName_terseLabel_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:label id="lab_ecd_PeoName_label_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoName" xlink:to="lab_ecd_PeoName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_b17db6d0-50b9-4170-8d39-9c027a48dde5_verboseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Percentage of significant accounts receivable</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_4c2bba02-7411-4977-b771-36a89ddc7c05_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Undesignated preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Investments_835f868a-d688-403e-97e3-7b7f9c73ff9b_terseLabel_en-US" xlink:label="lab_us-gaap_Investments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_Investments_84d423c9-3ace-43cc-baaa-bba037c5c4d9_verboseLabel_en-US" xlink:label="lab_us-gaap_Investments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_Investments_label_en-US" xlink:label="lab_us-gaap_Investments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Investments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Investments" xlink:to="lab_us-gaap_Investments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_95dec156-6b6d-45df-8f9f-5cb2810b13d4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_46dffe04-31ac-4abf-9173-b1ed4801e8e9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_ae40f36d-5ffb-4001-9b31-c04b8656eae2_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Undesignated preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_c88c2608-54fe-45d9-9815-cd5333c4b013_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_label_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_LiabilityRelatedToFutureRoyaltyLineItems_7f9e8de8-2001-46c7-8797-406277f6de3c_terseLabel_en-US" xlink:label="lab_mgnx_LiabilityRelatedToFutureRoyaltyLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liability related to future royalty [Line Items]</link:label>
    <link:label id="lab_mgnx_LiabilityRelatedToFutureRoyaltyLineItems_label_en-US" xlink:label="lab_mgnx_LiabilityRelatedToFutureRoyaltyLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability related to future royalty [Line Items]</link:label>
    <link:label id="lab_mgnx_LiabilityRelatedToFutureRoyaltyLineItems_documentation_en-US" xlink:label="lab_mgnx_LiabilityRelatedToFutureRoyaltyLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Liability related to future royalty</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_LiabilityRelatedToFutureRoyaltyLineItems" xlink:href="mgnx-20231231.xsd#mgnx_LiabilityRelatedToFutureRoyaltyLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_LiabilityRelatedToFutureRoyaltyLineItems" xlink:to="lab_mgnx_LiabilityRelatedToFutureRoyaltyLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_fbc77787-1390-4ccb-b9c9-9b58a112d0da_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_fa78dd32-7b09-4b9f-9bf7-f4b07bdeb1c9_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_b1ad097a-2333-42ea-bfdb-26846109e0a4_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate intrinsic value, Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_7e52aa8d-03c4-49d6-b689-ccf338e1d4a7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deductions</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_aae75680-3a0b-467d-9f05-9568ba488e78_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompRecoveryTable_terseLabel_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery</link:label>
    <link:label id="lab_ecd_ErrCompRecoveryTable_label_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompRecoveryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="lab_ecd_ErrCompRecoveryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther_66e65571-032e-4740-8df8-4b4088ba5006_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Orphan drug credit, net</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_5728d9de-6efb-4a24-9e41-9474f2c0a8e9_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfMachineryAndEquipment_d35673fd-8717-49f8-a8e8-93c59f83e35b_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfMachineryAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sales of equipment</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfMachineryAndEquipment_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfMachineryAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Machinery and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfMachineryAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfMachineryAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfMachineryAndEquipment" xlink:to="lab_us-gaap_ProceedsFromSaleOfMachineryAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_9601c408-129c-4874-b63a-9b26f156b666_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_29cbc970-2bb1-4517-b4ac-4eb4494a9b99_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Furniture</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_IncyteMGA012AgreementMember_a445da06-25b8-4c84-8990-055c998952d1_terseLabel_en-US" xlink:label="lab_mgnx_IncyteMGA012AgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Incyte MGA012 Agreement</link:label>
    <link:label id="lab_mgnx_IncyteMGA012AgreementMember_label_en-US" xlink:label="lab_mgnx_IncyteMGA012AgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incyte MGA012 Agreement [Member]</link:label>
    <link:label id="lab_mgnx_IncyteMGA012AgreementMember_documentation_en-US" xlink:label="lab_mgnx_IncyteMGA012AgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Incyte MGA012 Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012AgreementMember" xlink:href="mgnx-20231231.xsd#mgnx_IncyteMGA012AgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IncyteMGA012AgreementMember" xlink:to="lab_mgnx_IncyteMGA012AgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_91438527-472a-4314-aedb-7bf1e5e8dfc8_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_8373a012-6a9d-49ea-9d62-9075449758f8_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_e3f49544-2789-4d1b-951e-f882b63be3d8_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_f6b4beee-801b-4e09-9115-9f062e0b8ffe_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_e3cd0811-922e-463b-8c4e-ec0c6cc3b192_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_2716a81f-8ee5-4afd-ae92-5e53839f55bb_periodStartLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at Beginning of Year</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_1b2a8287-676e-42bb-90ee-4ed0e6c6c092_periodEndLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at End of Year</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9e6e5b55-61e6-457a-9ec0-2b384edc83c8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ValuationAllowanceDeferredTaxAssetDecreaseAmount_0248b4d5-a50e-4333-a18a-e5f345c0c42b_negatedTerseLabel_en-US" xlink:label="lab_mgnx_ValuationAllowanceDeferredTaxAssetDecreaseAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deductions</link:label>
    <link:label id="lab_mgnx_ValuationAllowanceDeferredTaxAssetDecreaseAmount_label_en-US" xlink:label="lab_mgnx_ValuationAllowanceDeferredTaxAssetDecreaseAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Decrease, Amount</link:label>
    <link:label id="lab_mgnx_ValuationAllowanceDeferredTaxAssetDecreaseAmount_documentation_en-US" xlink:label="lab_mgnx_ValuationAllowanceDeferredTaxAssetDecreaseAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Decrease, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ValuationAllowanceDeferredTaxAssetDecreaseAmount" xlink:href="mgnx-20231231.xsd#mgnx_ValuationAllowanceDeferredTaxAssetDecreaseAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ValuationAllowanceDeferredTaxAssetDecreaseAmount" xlink:to="lab_mgnx_ValuationAllowanceDeferredTaxAssetDecreaseAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_f5a07809-550d-4d67-85a3-bb5d462c31fa_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_87f77b6d-c29d-4b90-bd19-b92c6ff93897_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_bab7272a-4423-471e-b4c7-6fe7a6502adc_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_09d891a6-bbfd-4394-bd75-37d8e62e8b0d_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expected term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_LiabilityRelatedToSaleOfFutureRoyaltiesTextBlock_4ae937cf-bc6b-4499-ab78-f3e2a5714f22_terseLabel_en-US" xlink:label="lab_mgnx_LiabilityRelatedToSaleOfFutureRoyaltiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty Monetization Arrangement</link:label>
    <link:label id="lab_mgnx_LiabilityRelatedToSaleOfFutureRoyaltiesTextBlock_label_en-US" xlink:label="lab_mgnx_LiabilityRelatedToSaleOfFutureRoyaltiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability Related To Sale Of Future Royalties [Text Block]</link:label>
    <link:label id="lab_mgnx_LiabilityRelatedToSaleOfFutureRoyaltiesTextBlock_documentation_en-US" xlink:label="lab_mgnx_LiabilityRelatedToSaleOfFutureRoyaltiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Liability Related To Sale Of Future Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_LiabilityRelatedToSaleOfFutureRoyaltiesTextBlock" xlink:href="mgnx-20231231.xsd#mgnx_LiabilityRelatedToSaleOfFutureRoyaltiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_LiabilityRelatedToSaleOfFutureRoyaltiesTextBlock" xlink:to="lab_mgnx_LiabilityRelatedToSaleOfFutureRoyaltiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4d160f26-239f-4678-8ca0-1cb18aab2262_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_cce8928f-220f-4fd3-9c52-3dc48283d38a_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Undesignated preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_LaboratoryAndOfficeEquipmentMember_d1553d37-0923-4a18-8b24-b01b4ced86e9_terseLabel_en-US" xlink:label="lab_mgnx_LaboratoryAndOfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Laboratory and office equipment</link:label>
    <link:label id="lab_mgnx_LaboratoryAndOfficeEquipmentMember_label_en-US" xlink:label="lab_mgnx_LaboratoryAndOfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Laboratory and Office Equipment [Member]</link:label>
    <link:label id="lab_mgnx_LaboratoryAndOfficeEquipmentMember_documentation_en-US" xlink:label="lab_mgnx_LaboratoryAndOfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">A facility that provides controlled conditions in which scientific or technological research, experiments, and measurement may be performed. and tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_LaboratoryAndOfficeEquipmentMember" xlink:href="mgnx-20231231.xsd#mgnx_LaboratoryAndOfficeEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_LaboratoryAndOfficeEquipmentMember" xlink:to="lab_mgnx_LaboratoryAndOfficeEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_a0fe6699-857c-472a-908e-a81a66ff1ffd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant Other Observable Inputs, Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_c0c31d93-1505-4739-8cac-fe7a4439083a_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_51ab0c9c-de3d-4b17-8bf3-568d7cce6bb7_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods" xlink:to="lab_us-gaap_InventoryFinishedGoods" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_9903e1b1-c183-491b-b2ee-f245e4634e40_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Gross deferred income tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_label_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_833cadbc-5fe6-4cd7-a023-e2737c203d75_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_494616b5-afcf-4276-90c6-6b817baa7dd2_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ProventionPRV3279Member_cc6e9827-db59-4cca-a6fc-9163cb13c2ef_terseLabel_en-US" xlink:label="lab_mgnx_ProventionPRV3279Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provention PRV3279</link:label>
    <link:label id="lab_mgnx_ProventionPRV3279Member_label_en-US" xlink:label="lab_mgnx_ProventionPRV3279Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Provention PRV3279 [Member]</link:label>
    <link:label id="lab_mgnx_ProventionPRV3279Member_documentation_en-US" xlink:label="lab_mgnx_ProventionPRV3279Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Provention PRV3279</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionPRV3279Member" xlink:href="mgnx-20231231.xsd#mgnx_ProventionPRV3279Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ProventionPRV3279Member" xlink:to="lab_mgnx_ProventionPRV3279Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
    <link:label id="lab_ecd_PvpTableTextBlock_label_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTableTextBlock" xlink:to="lab_ecd_PvpTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ac631c8a-0f33-4dc7-a388-f8e5f3f96e64_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_677b09ba-4868-4d53-bb09-64039bf4445c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndTitle_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title</link:label>
    <link:label id="lab_ecd_TrdArrIndTitle_label_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Title</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndTitle" xlink:to="lab_ecd_TrdArrIndTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3a220829-101c-4655-b841-1cd0d08b1719_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b9b6aa5a-414e-4345-bf03-66f7b0416852_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8af5bcd7-a835-4661-8a6b-63f74fb752c1_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_f47ccc04-5da0-49f6-95d6-9e09dfe9ac77_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_StockOptionsAndRestrictedStockUnitsMember_60e6a99b-8157-416c-ac16-5fd34394afc3_terseLabel_en-US" xlink:label="lab_mgnx_StockOptionsAndRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options and RSUs</link:label>
    <link:label id="lab_mgnx_StockOptionsAndRestrictedStockUnitsMember_label_en-US" xlink:label="lab_mgnx_StockOptionsAndRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Options And Restricted Stock Units [Member]</link:label>
    <link:label id="lab_mgnx_StockOptionsAndRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_mgnx_StockOptionsAndRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Options And Restricted Stock Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockOptionsAndRestrictedStockUnitsMember" xlink:href="mgnx-20231231.xsd#mgnx_StockOptionsAndRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_StockOptionsAndRestrictedStockUnitsMember" xlink:to="lab_mgnx_StockOptionsAndRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_bb8036f8-8c4d-4569-8253-70060e422940_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RoyaltyMonetizationArrangementAbstract_label_en-US" xlink:label="lab_mgnx_RoyaltyMonetizationArrangementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Monetization Arrangement [Abstract]</link:label>
    <link:label id="lab_mgnx_RoyaltyMonetizationArrangementAbstract_documentation_en-US" xlink:label="lab_mgnx_RoyaltyMonetizationArrangementAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalty Monetization Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RoyaltyMonetizationArrangementAbstract" xlink:href="mgnx-20231231.xsd#mgnx_RoyaltyMonetizationArrangementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RoyaltyMonetizationArrangementAbstract" xlink:to="lab_mgnx_RoyaltyMonetizationArrangementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_b2331483-f17e-4196-9cd4-f54f4e367dde_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_IndividualAxis_terseLabel_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Individual:</link:label>
    <link:label id="lab_ecd_IndividualAxis_label_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_IndividualAxis" xlink:to="lab_ecd_IndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_9735422c-8160-474a-bbaf-ec34ee43ff27_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_265fa326-efb2-4f17-a625-426f54b0fff4_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_ca313dd7-b7b3-4d2a-8caf-9829cb84f174_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_3cd0bca0-8900-4947-8e19-e96b8d318f01_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_97307c1a-f840-4ce2-ba06-d2da11fe05a8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyMember_6ccf8e2f-95a1-4e01-942d-ae7cbee4b630_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty [Member]</link:label>
    <link:label id="lab_us-gaap_RoyaltyMember_label_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyMember" xlink:to="lab_us-gaap_RoyaltyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_e12a1f82-2cc4-4828-910b-45f5b8b5fecb_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_46b6b992-99c6-4a29-a5a8-cde2875a0cfc_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Fair Value Measurement Financial Assets</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_463249de-edb2-4f75-b148-c8c87229a5f1_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_1ecfda94-ac39-453e-af49-cb338bc847c1_terseLabel_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Software</link:label>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_label_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Software and Software Development Costs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_81597aa6-0866-4686-97f4-b66ef2efe606_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized interest or penalties</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_c0add601-3bf7-4a12-b960-4265d839f524_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity_068b8720-ac0f-406c-a2a6-1fe4c14a88bc_terseLabel_en-US" xlink:label="lab_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock plan related activity (in shares)</link:label>
    <link:label id="lab_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity_label_en-US" xlink:label="lab_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period Shares Stock Plan Activity</link:label>
    <link:label id="lab_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity_documentation_en-US" xlink:label="lab_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of shares issued due to stock plan related activity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity" xlink:href="mgnx-20231231.xsd#mgnx_StockIssuedDuringPeriodSharesStockPlanActivity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity" xlink:to="lab_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_ba5c7e90-2429-47f0-b611-f8ca0cd3497c_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, equipment and software, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_80d05b3f-97c7-43a5-aa8b-5065f796845e_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Property, equipment and software, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_4bc74fc5-1300-4c40-81de-29505d0d3b23_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardExrcPrice_terseLabel_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ecd_AwardExrcPrice_label_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardExrcPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardExrcPrice" xlink:to="lab_ecd_AwardExrcPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_155a4384-8bfc-4377-b3e3-2ff14fc7c185_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:to="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_d356668e-65ef-4765-b316-e0be032f526e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Taxes paid related to net share settlement of equity awards</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_abce8f10-74e3-4a43-8bc3-8963ac2df36f_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_e73dc6ab-26a8-4a1c-9d1f-17ecee4e44fd_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_AssetPurchaseAgreementMember_d099ef7c-aecf-4592-bdb6-3c9a2ce6e0a0_terseLabel_en-US" xlink:label="lab_mgnx_AssetPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Purchase Agreement</link:label>
    <link:label id="lab_mgnx_AssetPurchaseAgreementMember_label_en-US" xlink:label="lab_mgnx_AssetPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Purchase Agreement [Member]</link:label>
    <link:label id="lab_mgnx_AssetPurchaseAgreementMember_documentation_en-US" xlink:label="lab_mgnx_AssetPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Asset Acquisition Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AssetPurchaseAgreementMember" xlink:href="mgnx-20231231.xsd#mgnx_AssetPurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_AssetPurchaseAgreementMember" xlink:to="lab_mgnx_AssetPurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_0bc3b25a-e48d-43df-96d2-7a061edd0fde_verboseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">U.S Treasury securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_e5437f5b-113d-46a9-bf42-13637645eb5c_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. Treasury securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_1832eb0f-54b0-4451-8a96-6e69e1361125_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_JamesKarrelsMember_label_en-US" xlink:label="lab_mgnx_JamesKarrelsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">James Karrels [Member]</link:label>
    <link:label id="lab_mgnx_JamesKarrelsMember_documentation_en-US" xlink:label="lab_mgnx_JamesKarrelsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">James Karrels</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_JamesKarrelsMember" xlink:href="mgnx-20231231.xsd#mgnx_JamesKarrelsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_JamesKarrelsMember" xlink:to="lab_mgnx_JamesKarrelsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_304cca82-821a-4568-91f4-668a40e67fc9_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_a820898a-7f24-43ca-b478-e7ea5b128c13_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_PremiumReceivedOnStockPurchase_ad49749f-24c5-4857-ad49-30772205866a_terseLabel_en-US" xlink:label="lab_mgnx_PremiumReceivedOnStockPurchase" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Premium received on stock purchase</link:label>
    <link:label id="lab_mgnx_PremiumReceivedOnStockPurchase_label_en-US" xlink:label="lab_mgnx_PremiumReceivedOnStockPurchase" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Premium received on stock purchase</link:label>
    <link:label id="lab_mgnx_PremiumReceivedOnStockPurchase_documentation_en-US" xlink:label="lab_mgnx_PremiumReceivedOnStockPurchase" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount by which purchase price exceeds fair value for common stock purchased by collaborator.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PremiumReceivedOnStockPurchase" xlink:href="mgnx-20231231.xsd#mgnx_PremiumReceivedOnStockPurchase"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PremiumReceivedOnStockPurchase" xlink:to="lab_mgnx_PremiumReceivedOnStockPurchase" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_c0f07bbb-1902-4897-aa53-7ec41df013bc_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_3297650e-eebb-4087-a3bb-65aa198ea219_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_fdfb3b2c-1777-488c-bda5-70fba097acdc_negatedLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Amortization of premiums and discounts on marketable securities</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_84b4e419-9988-433c-a217-f53553e36fbe_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_53a5dc02-a9e1-4826-bb30-d95e4d0c3228_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_71faaea8-6380-4e23-a006-07cc8bc6a977_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other non current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_e4c46cf6-4f57-4443-a0b1-d4f42459f8b3_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_Section174DeferredTaxAsset_c4d8598e-65b2-4a22-ab4b-7141855a6e7e_terseLabel_en-US" xlink:label="lab_mgnx_Section174DeferredTaxAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Section 174 deferred tax asset</link:label>
    <link:label id="lab_mgnx_Section174DeferredTaxAsset_label_en-US" xlink:label="lab_mgnx_Section174DeferredTaxAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Section 174 deferred tax asset</link:label>
    <link:label id="lab_mgnx_Section174DeferredTaxAsset_documentation_en-US" xlink:label="lab_mgnx_Section174DeferredTaxAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Section 174 deferred tax asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_Section174DeferredTaxAsset" xlink:href="mgnx-20231231.xsd#mgnx_Section174DeferredTaxAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_Section174DeferredTaxAsset" xlink:to="lab_mgnx_Section174DeferredTaxAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_6d366cca-a794-4727-a9a0-cef0d4b7e614_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_GileadMember_b42700f9-3e2e-453c-8ce6-43d5d917f082_terseLabel_en-US" xlink:label="lab_mgnx_GileadMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gilead</link:label>
    <link:label id="lab_mgnx_GileadMember_label_en-US" xlink:label="lab_mgnx_GileadMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gilead [Member]</link:label>
    <link:label id="lab_mgnx_GileadMember_documentation_en-US" xlink:label="lab_mgnx_GileadMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gilead</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_GileadMember" xlink:href="mgnx-20231231.xsd#mgnx_GileadMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_GileadMember" xlink:to="lab_mgnx_GileadMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_714e8497-1309-4a2d-95bb-6b8a72bafe2a_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted net loss per common share, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_39c6f5e9-309b-4f74-8bab-1f1ac0fcb048_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease, ROU Assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RevenuesFromCMOAmendmentAgreementMember_ae8179e2-ebde-44ce-857d-67daa26410c7_terseLabel_en-US" xlink:label="lab_mgnx_RevenuesFromCMOAmendmentAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RevenuesFromCMOAmendmentAgreement</link:label>
    <link:label id="lab_mgnx_RevenuesFromCMOAmendmentAgreementMember_label_en-US" xlink:label="lab_mgnx_RevenuesFromCMOAmendmentAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">RevenuesFromCMOAmendmentAgreement [Member]</link:label>
    <link:label id="lab_mgnx_RevenuesFromCMOAmendmentAgreementMember_documentation_en-US" xlink:label="lab_mgnx_RevenuesFromCMOAmendmentAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">RevenuesFromCMOAmendmentAgreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromCMOAmendmentAgreementMember" xlink:href="mgnx-20231231.xsd#mgnx_RevenuesFromCMOAmendmentAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RevenuesFromCMOAmendmentAgreementMember" xlink:to="lab_mgnx_RevenuesFromCMOAmendmentAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_64750f75-629e-4d1f-804f-f64596de123f_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_label_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_c1c0157a-3771-4283-a601-a732d962edc5_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_94634313-2bf4-4616-9f36-59a289d71765_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI, Debt Securities, Available-for-Sale, Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_label_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompAnalysisTextBlock" xlink:to="lab_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_afe122e8-21dd-4e60-94bd-52250042bc52_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net deferred income tax asset/(liability)</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_d63d7219-1cec-41dd-8ca6-9da79a0a0edb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrDuration_terseLabel_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangement Duration</link:label>
    <link:label id="lab_ecd_TrdArrDuration_label_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrDuration" xlink:to="lab_ecd_TrdArrDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_8eca9bba-a76e-4bcb-84d6-4c2719891e92_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_299c8bd2-5ae2-427a-b0a8-92fa62897c58_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average remaining contractual term, Vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_0a76cb06-e5b6-48fa-867e-816794940518_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_d9169474-d621-44a5-83c6-ce81cc3a68c2_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined</link:label>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_label_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgPredtrmndFlag" xlink:to="lab_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_3ae8ea43-c71b-42f8-9f34-827729775ffb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrTerminationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Termination Date</link:label>
    <link:label id="lab_ecd_TrdArrTerminationDate_label_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrTerminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrTerminationDate" xlink:to="lab_ecd_TrdArrTerminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_3d497c11-7905-4543-ab0d-69532072dce1_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_96eac753-6d43-4eeb-a953-6981a578457d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_StockIncentivePlan2023MemberMember_ea1d579e-38cd-4e15-baf9-74da294043cd_terseLabel_en-US" xlink:label="lab_mgnx_StockIncentivePlan2023MemberMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">StockIncentivePlan2023Member</link:label>
    <link:label id="lab_mgnx_StockIncentivePlan2023MemberMember_label_en-US" xlink:label="lab_mgnx_StockIncentivePlan2023MemberMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">StockIncentivePlan2023Member [Member]</link:label>
    <link:label id="lab_mgnx_StockIncentivePlan2023MemberMember_documentation_en-US" xlink:label="lab_mgnx_StockIncentivePlan2023MemberMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">StockIncentivePlan2023Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIncentivePlan2023MemberMember" xlink:href="mgnx-20231231.xsd#mgnx_StockIncentivePlan2023MemberMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_StockIncentivePlan2023MemberMember" xlink:to="lab_mgnx_StockIncentivePlan2023MemberMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_04c2b0b1-b574-43f3-948f-5bc349c01110_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0ae62e99-f4e2-4036-a304-5189c1312b99_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ValuationAllowanceDeferredTaxAssetIncreaseAmount_6fc51be9-3762-44e7-bba8-b4521dc89406_terseLabel_en-US" xlink:label="lab_mgnx_ValuationAllowanceDeferredTaxAssetIncreaseAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_mgnx_ValuationAllowanceDeferredTaxAssetIncreaseAmount_label_en-US" xlink:label="lab_mgnx_ValuationAllowanceDeferredTaxAssetIncreaseAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase, Amount</link:label>
    <link:label id="lab_mgnx_ValuationAllowanceDeferredTaxAssetIncreaseAmount_documentation_en-US" xlink:label="lab_mgnx_ValuationAllowanceDeferredTaxAssetIncreaseAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ValuationAllowanceDeferredTaxAssetIncreaseAmount" xlink:href="mgnx-20231231.xsd#mgnx_ValuationAllowanceDeferredTaxAssetIncreaseAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ValuationAllowanceDeferredTaxAssetIncreaseAmount" xlink:to="lab_mgnx_ValuationAllowanceDeferredTaxAssetIncreaseAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_87c0b800-1948-4496-8077-f2d6b693df64_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_1e76bb90-08cf-43a7-ab06-bc9bab8397a1_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_8306e4b8-412a-47f1-84c7-6b156024881e_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4ccf8539-c54d-4129-bb44-941bca3181dc_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_74b7cca3-033d-46a6-9c04-e5505afeffb7_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllTradingArrangementsMember_terseLabel_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Trading Arrangements</link:label>
    <link:label id="lab_ecd_AllTradingArrangementsMember_label_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Trading Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllTradingArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="lab_ecd_AllTradingArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllAdjToCompMember_terseLabel_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation</link:label>
    <link:label id="lab_ecd_AllAdjToCompMember_label_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllAdjToCompMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="lab_ecd_AllAdjToCompMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgDiscLineItems_label_en-US" xlink:label="lab_ecd_AwardTmgDiscLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="lab_ecd_AwardTmgDiscLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_JeffreyPetersMember_label_en-US" xlink:label="lab_mgnx_JeffreyPetersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Jeffrey Peters [Member]</link:label>
    <link:label id="lab_mgnx_JeffreyPetersMember_documentation_en-US" xlink:label="lab_mgnx_JeffreyPetersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Jeffrey Peters</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_JeffreyPetersMember" xlink:href="mgnx-20231231.xsd#mgnx_JeffreyPetersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_JeffreyPetersMember" xlink:to="lab_mgnx_JeffreyPetersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryCompAmt" xlink:to="lab_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ProceedsFromSaleOfFutureRoyalties_4da585a1-9b38-4e16-9d94-9dbf17963182_terseLabel_en-US" xlink:label="lab_mgnx_ProceedsFromSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of future royalties</link:label>
    <link:label id="lab_mgnx_ProceedsFromSaleOfFutureRoyalties_label_en-US" xlink:label="lab_mgnx_ProceedsFromSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from sale of future royalties</link:label>
    <link:label id="lab_mgnx_ProceedsFromSaleOfFutureRoyalties_documentation_en-US" xlink:label="lab_mgnx_ProceedsFromSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds from sale of future royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsFromSaleOfFutureRoyalties" xlink:href="mgnx-20231231.xsd#mgnx_ProceedsFromSaleOfFutureRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ProceedsFromSaleOfFutureRoyalties" xlink:to="lab_mgnx_ProceedsFromSaleOfFutureRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1451cf62-afc2-48bb-a325-7ffad57cc27a_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_fc93f597-4172-4448-816a-800af931c785_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_61f7332f-d9ce-46b4-9e86-7ac2322475e1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeited or expired (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_d4cde0a4-d45c-449b-ace6-4e5744a0602a_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash proceeds from exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_UpfrontPayment_b6b040d6-eef0-479b-9ce6-4b54b8b45136_terseLabel_en-US" xlink:label="lab_mgnx_UpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upfront payment from DRI Health Trust</link:label>
    <link:label id="lab_mgnx_UpfrontPayment_label_en-US" xlink:label="lab_mgnx_UpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Upfront Payment</link:label>
    <link:label id="lab_mgnx_UpfrontPayment_documentation_en-US" xlink:label="lab_mgnx_UpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Upfront Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_UpfrontPayment" xlink:href="mgnx-20231231.xsd#mgnx_UpfrontPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_UpfrontPayment" xlink:to="lab_mgnx_UpfrontPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets_8abad617-779e-432c-b41b-e3ff4fd82558_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Loss on disposal of assets</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfAssets" xlink:to="lab_us-gaap_GainLossOnDispositionOfAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_42326b9f-b50f-4657-8df1-51669517fa02_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeited or expired (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_248be58e-9b54-4451-8e7a-4a18945a5e87_terseLabel_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_label_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_71001528-31cb-4cd7-9611-b164296b4c5e_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Work in Process, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcess" xlink:to="lab_us-gaap_InventoryWorkInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_daacc546-396f-4e4b-8b41-df09fd2fe706_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingArrLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="lab_ecd_InsiderTradingArrLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_bf55a4fb-9b38-48cb-bd11-0796c320aff6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate intrinsic value, Outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_79ae8f5e-744f-412a-af6e-2a946b870569_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_6b78bb90-ea49-4c32-9a9d-0e7387537f93_terseLabel_en-US" xlink:label="lab_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum employee contribution percent</link:label>
    <link:label id="lab_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_label_en-US" xlink:label="lab_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan, Maximum Annual Contributions Per Employee, Percent</link:label>
    <link:label id="lab_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_documentation_en-US" xlink:label="lab_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan, Maximum Annual Contributions Per Employee, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" xlink:href="mgnx-20231231.xsd#mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="lab_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_29c14591-c5a6-4336-965f-de671814e794_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_terseLabel_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_label_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Method</link:label>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMethodTextBlock" xlink:to="lab_ecd_AwardTmgMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_2fa64dda-7719-4f43-94b2-508202aa8b10_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other non current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
    <link:label id="lab_ecd_AdjToCompAmt_label_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAmt" xlink:to="lab_ecd_AdjToCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_ba9c9d5d-f493-4a48-a9c7-a0d14d9214b7_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_bec8717a-e732-4721-8b85-b965afc4b1e8_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred income tax liabilities:</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Components of Deferred Tax Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_662e4974-18a3-45ef-a7e4-0c2b55a44957_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_8cfb9b66-59cd-48aa-8585-c972d07844cd_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_label_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:to="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrAdoptionDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption Date</link:label>
    <link:label id="lab_ecd_TrdArrAdoptionDate_label_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Adoption Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrAdoptionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrAdoptionDate" xlink:to="lab_ecd_TrdArrAdoptionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_46df8ac4-1056-438e-9e47-cc7d85b9e401_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_24cb217c-5447-49cb-a4aa-43f34727a901_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_7c2345f8-1960-4e22-b2af-74e09ab9509b_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RoyaltyMonetizationArrangementTable_4d3a1ff0-603e-4166-87a9-6921a04d314e_terseLabel_en-US" xlink:label="lab_mgnx_RoyaltyMonetizationArrangementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty Monetization Arrangement [Table]</link:label>
    <link:label id="lab_mgnx_RoyaltyMonetizationArrangementTable_label_en-US" xlink:label="lab_mgnx_RoyaltyMonetizationArrangementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Monetization Arrangement [Table]</link:label>
    <link:label id="lab_mgnx_RoyaltyMonetizationArrangementTable_documentation_en-US" xlink:label="lab_mgnx_RoyaltyMonetizationArrangementTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalty Monetization Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RoyaltyMonetizationArrangementTable" xlink:href="mgnx-20231231.xsd#mgnx_RoyaltyMonetizationArrangementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RoyaltyMonetizationArrangementTable" xlink:to="lab_mgnx_RoyaltyMonetizationArrangementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_322bb5f3-dcae-47d3-b60d-8b66bab561b5_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:to="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_02b83ae1-185b-4331-b9b2-6bc414495cc6_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income tax expense/(benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_c0dfb6a1-d47a-40cf-b422-f751d4b3a637_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_21137970-00d7-49c2-9278-91c9ee90c259_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_81e99c79-2858-4296-ab84-9754984f7796_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales revenue, net</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndName_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_TrdArrIndName_label_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndName" xlink:to="lab_ecd_TrdArrIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_6e070bdc-ba07-42de-af6e-37ceab313ab2_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock, net of offering costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_c76bd9a7-6405-4fd4-8294-c8270796b45d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_1cac55f6-fb44-47bf-a333-d95b02a7e152_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory, Net</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_13428cc4-76cf-4e04-b02a-01bca1b9c475_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average lease term (in years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_0744f805-69b0-42bd-ab05-30ade6678985_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseDiscountRate_bf44697e-5a41-4aae-9c87-ef5a1d71bcc9_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseDiscountRate_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:to="lab_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_36f2c778-5b3c-46f6-9026-368d5c594d40_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ProventionPRV031Member_de707a62-f735-484a-b0f9-aa1190b846c0_terseLabel_en-US" xlink:label="lab_mgnx_ProventionPRV031Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provention PRV031</link:label>
    <link:label id="lab_mgnx_ProventionPRV031Member_label_en-US" xlink:label="lab_mgnx_ProventionPRV031Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Provention PRV031 [Member]</link:label>
    <link:label id="lab_mgnx_ProventionPRV031Member_documentation_en-US" xlink:label="lab_mgnx_ProventionPRV031Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Provention PRV031</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionPRV031Member" xlink:href="mgnx-20231231.xsd#mgnx_ProventionPRV031Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ProventionPRV031Member" xlink:to="lab_mgnx_ProventionPRV031Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_1638f1d6-1b2a-4a6f-a6cc-485fbd5f8e7a_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">US Federal tax credits carry forward</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_e8f92a63-6518-439d-a63d-3dd52a914c25_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxPeriodDomain_0f2b097f-0c96-4526-b630-5f396cf75370_terseLabel_en-US" xlink:label="lab_us-gaap_TaxPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Period [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxPeriodDomain_label_en-US" xlink:label="lab_us-gaap_TaxPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodDomain" xlink:to="lab_us-gaap_TaxPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_0a1a9a7b-23f2-430d-b759-bb712259ee68_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock purchased by employees (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_1dd39f0e-8b1d-48c5-ac6f-1ce6355090cc_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_59948f8c-3a5a-4008-8409-55620ac90179_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated useful lives</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_bb816ff8-92d7-45a6-bcc0-e62f7fd2fcb9_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4464d4e6-605c-44fb-a7c2-40d48626382c_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted weighted average number of common shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_FurnitureAndOfficeEquipmentMember_cb394364-411a-4d73-90a2-c0d18b1e2a94_terseLabel_en-US" xlink:label="lab_mgnx_FurnitureAndOfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Furniture and office equipment</link:label>
    <link:label id="lab_mgnx_FurnitureAndOfficeEquipmentMember_label_en-US" xlink:label="lab_mgnx_FurnitureAndOfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture And Office Equipment [Member]</link:label>
    <link:label id="lab_mgnx_FurnitureAndOfficeEquipmentMember_documentation_en-US" xlink:label="lab_mgnx_FurnitureAndOfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Furniture and office equipment are movable furniture, fixtures, or other equipment that have no permanent connection to the structure of a building or utilities. These items depreciate substantially but definitely are important costs to consider when valuing a company, especially in liquidation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_FurnitureAndOfficeEquipmentMember" xlink:href="mgnx-20231231.xsd#mgnx_FurnitureAndOfficeEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_FurnitureAndOfficeEquipmentMember" xlink:to="lab_mgnx_FurnitureAndOfficeEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SummaryOfValuationAllowanceTextBlock_37b32cef-1d47-40d6-bb73-0c8ba27875b8_terseLabel_en-US" xlink:label="lab_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Valuation Allowance</link:label>
    <link:label id="lab_us-gaap_SummaryOfValuationAllowanceTextBlock_label_en-US" xlink:label="lab_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary of Valuation Allowance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:to="lab_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2c2f6723-c472-4173-aa9a-b3ed0ebaaf3c_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of property, equipment and software</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureAmt" xlink:to="lab_ecd_CoSelectedMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_e20d3c61-758a-47f9-a1a6-713e44def681_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_1c87ed6c-6907-4f9e-a4a9-5f7da1685842_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_8e36bd28-a5f4-4d75-833f-767c466021cf_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VehiclesMember_d0a1a079-6941-4018-b7b6-32c42b5a99c5_terseLabel_en-US" xlink:label="lab_us-gaap_VehiclesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Motor vehicles</link:label>
    <link:label id="lab_us-gaap_VehiclesMember_label_en-US" xlink:label="lab_us-gaap_VehiclesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vehicles [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VehiclesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VehiclesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VehiclesMember" xlink:to="lab_us-gaap_VehiclesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_56a65989-09de-4084-a06c-545324f51e32_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expired (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_f61118ca-c3ce-4c54-a183-7e1cce333ee0_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:to="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquipmentMember_08bbe8a6-cbe2-42c8-8059-794a5e9eae2d_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lab equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_label_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ZaiLabMember_7120d313-70f3-4968-a830-cea7f6a8ba9d_terseLabel_en-US" xlink:label="lab_mgnx_ZaiLabMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Zai Lab</link:label>
    <link:label id="lab_mgnx_ZaiLabMember_label_en-US" xlink:label="lab_mgnx_ZaiLabMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Zai Lab [Member]</link:label>
    <link:label id="lab_mgnx_ZaiLabMember_documentation_en-US" xlink:label="lab_mgnx_ZaiLabMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Zai Lab</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabMember" xlink:href="mgnx-20231231.xsd#mgnx_ZaiLabMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ZaiLabMember" xlink:to="lab_mgnx_ZaiLabMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_782f92e2-4eeb-44c5-8e9e-1b8ed07eca6e_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxPeriodAxis_2a1ffef7-53ae-4e62-8e39-d26154a64285_terseLabel_en-US" xlink:label="lab_us-gaap_TaxPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Period [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxPeriodAxis_label_en-US" xlink:label="lab_us-gaap_TaxPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodAxis" xlink:to="lab_us-gaap_TaxPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_e6ead964-44aa-4233-9282-70884cdcb8a6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_9249366b-42bb-48f0-a1c6-c7da9bc97a55_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other non current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_f58e1663-2114-44bb-adf6-0e5a98252819_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RevenuesFromLicenseAgreementsMember_6395b3c6-ec93-4eaa-888d-bf1e3d2926a9_terseLabel_en-US" xlink:label="lab_mgnx_RevenuesFromLicenseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues From License Agreements</link:label>
    <link:label id="lab_mgnx_RevenuesFromLicenseAgreementsMember_label_en-US" xlink:label="lab_mgnx_RevenuesFromLicenseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues From License Agreements [Member]</link:label>
    <link:label id="lab_mgnx_RevenuesFromLicenseAgreementsMember_documentation_en-US" xlink:label="lab_mgnx_RevenuesFromLicenseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenues From License Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember" xlink:href="mgnx-20231231.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RevenuesFromLicenseAgreementsMember" xlink:to="lab_mgnx_RevenuesFromLicenseAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonNeosMember_terseLabel_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-NEOs</link:label>
    <link:label id="lab_ecd_NonNeosMember_label_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-NEOs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonNeosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonNeosMember" xlink:to="lab_ecd_NonNeosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e253a791-427a-45ec-a836-bbe0f7aa98f9_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_fdc51b64-6ce9-4178-a36a-a85d55870150_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, remaining performance obligation, amount</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_IncreaseDecreaseInDeferredRent_e94ed5ab-46db-4aea-8bf4-f9df5adb6dfc_terseLabel_en-US" xlink:label="lab_mgnx_IncreaseDecreaseInDeferredRent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other non current liabilities</link:label>
    <link:label id="lab_mgnx_IncreaseDecreaseInDeferredRent_label_en-US" xlink:label="lab_mgnx_IncreaseDecreaseInDeferredRent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Deferred Rent</link:label>
    <link:label id="lab_mgnx_IncreaseDecreaseInDeferredRent_documentation_en-US" xlink:label="lab_mgnx_IncreaseDecreaseInDeferredRent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The increase (decrease) during the reporting period in deferred rent.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncreaseDecreaseInDeferredRent" xlink:href="mgnx-20231231.xsd#mgnx_IncreaseDecreaseInDeferredRent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IncreaseDecreaseInDeferredRent" xlink:to="lab_mgnx_IncreaseDecreaseInDeferredRent" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ProventionLicenseAgreementMember_efe2ad65-846e-423d-b28a-98bc5d6f25dc_terseLabel_en-US" xlink:label="lab_mgnx_ProventionLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provention License Agreement</link:label>
    <link:label id="lab_mgnx_ProventionLicenseAgreementMember_label_en-US" xlink:label="lab_mgnx_ProventionLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Provention License Agreement [Member]</link:label>
    <link:label id="lab_mgnx_ProventionLicenseAgreementMember_documentation_en-US" xlink:label="lab_mgnx_ProventionLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Provention License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionLicenseAgreementMember" xlink:href="mgnx-20231231.xsd#mgnx_ProventionLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ProventionLicenseAgreementMember" xlink:to="lab_mgnx_ProventionLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_NumberOfPerformanceObligations_644798d8-a333-4ba4-a1a0-a8d5cdda3ef9_terseLabel_en-US" xlink:label="lab_mgnx_NumberOfPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of performance obligations</link:label>
    <link:label id="lab_mgnx_NumberOfPerformanceObligations_label_en-US" xlink:label="lab_mgnx_NumberOfPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Performance Obligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfPerformanceObligations" xlink:href="mgnx-20231231.xsd#mgnx_NumberOfPerformanceObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_NumberOfPerformanceObligations" xlink:to="lab_mgnx_NumberOfPerformanceObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_OptInFee_07dde62d-ba0f-4a13-8d7a-26990bdb6424_terseLabel_en-US" xlink:label="lab_mgnx_OptInFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Opt-in fee</link:label>
    <link:label id="lab_mgnx_OptInFee_label_en-US" xlink:label="lab_mgnx_OptInFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Opt-In Fee</link:label>
    <link:label id="lab_mgnx_OptInFee_documentation_en-US" xlink:label="lab_mgnx_OptInFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Opt-In Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_OptInFee" xlink:href="mgnx-20231231.xsd#mgnx_OptInFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_OptInFee" xlink:to="lab_mgnx_OptInFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ebe1d990-f692-474f-ae5c-edbfa1d6b908_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net change in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_fb8d4ee2-d5ef-41d7-827e-9704dba774b7_terseLabel_en-US" xlink:label="lab_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Clinical trial activities selling price amount</link:label>
    <link:label id="lab_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_label_en-US" xlink:label="lab_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Multiple-Deliverable Arrangements, Determination Of Selling Price, Amount</link:label>
    <link:label id="lab_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_documentation_en-US" xlink:label="lab_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue, Multiple-Deliverable Arrangements, Determination Of Selling Price, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" xlink:href="mgnx-20231231.xsd#mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" xlink:to="lab_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoMember_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO</link:label>
    <link:label id="lab_ecd_NonPeoNeoMember_label_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoMember" xlink:to="lab_ecd_NonPeoNeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_61064524-bbed-4d43-bd2b-6f37c0f81340_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease renewal term (in years)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_1aeff1fc-c5a1-48d3-a6a8-af29cff91cfe_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAxis_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation:</link:label>
    <link:label id="lab_ecd_AdjToCompAxis_label_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="lab_ecd_AdjToCompAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_8e265f77-f2f2-4608-9059-2a314faeda81_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percent of fair market value to purchase shares</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_f0316b02-43ac-4df0-ad0b-3bf74f55b57e_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development credit, net</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TextBlockAbstract_0c0f2521-f1c6-460f-9193-aab401c6d976_terseLabel_en-US" xlink:label="lab_us-gaap_TextBlockAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Text Block [Abstract]</link:label>
    <link:label id="lab_us-gaap_TextBlockAbstract_label_en-US" xlink:label="lab_us-gaap_TextBlockAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Text Block [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TextBlockAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TextBlockAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TextBlockAbstract" xlink:to="lab_us-gaap_TextBlockAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description</link:label>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_label_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_df2f05a5-7524-4ec1-80ad-6ae9ee9e21ef_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic weighted average number of common shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_6abef2eb-4ef3-4b71-a51b-1db9d2f8c7f5_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_fe170137-a0f7-45fd-ac8a-ae68c7887f36_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ScheduleOfInventoryReservesTableTextBlock_eb0eb3bf-cfd1-4cb3-bd70-055439e62f72_terseLabel_en-US" xlink:label="lab_mgnx_ScheduleOfInventoryReservesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Inventory Reserves</link:label>
    <link:label id="lab_mgnx_ScheduleOfInventoryReservesTableTextBlock_label_en-US" xlink:label="lab_mgnx_ScheduleOfInventoryReservesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Inventory Reserves [Table Text Block]</link:label>
    <link:label id="lab_mgnx_ScheduleOfInventoryReservesTableTextBlock_documentation_en-US" xlink:label="lab_mgnx_ScheduleOfInventoryReservesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of Inventory Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ScheduleOfInventoryReservesTableTextBlock" xlink:href="mgnx-20231231.xsd#mgnx_ScheduleOfInventoryReservesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ScheduleOfInventoryReservesTableTextBlock" xlink:to="lab_mgnx_ScheduleOfInventoryReservesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_0cb9c62c-1480-4664-b858-3c71c797eb28_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ValuationAllowanceRollForward_f7fddc0b-ea8c-4f46-b993-fe9b725dc988_terseLabel_en-US" xlink:label="lab_mgnx_ValuationAllowanceRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation Allowance [Roll Forward]</link:label>
    <link:label id="lab_mgnx_ValuationAllowanceRollForward_label_en-US" xlink:label="lab_mgnx_ValuationAllowanceRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowance [Roll Forward]</link:label>
    <link:label id="lab_mgnx_ValuationAllowanceRollForward_documentation_en-US" xlink:label="lab_mgnx_ValuationAllowanceRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ValuationAllowanceRollForward" xlink:href="mgnx-20231231.xsd#mgnx_ValuationAllowanceRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ValuationAllowanceRollForward" xlink:to="lab_mgnx_ValuationAllowanceRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_300c25e4-d665-47bc-ac78-e265bbb5186e_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease_a160b024-7771-4151-9732-9b2104b79df1_terseLabel_en-US" xlink:label="lab_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock, Maximum Amount Available For Issuance, Increase</link:label>
    <link:label id="lab_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease_label_en-US" xlink:label="lab_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Maximum Amount Available For Issuance, Increase</link:label>
    <link:label id="lab_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease_documentation_en-US" xlink:label="lab_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Stock, Maximum Amount Available For Issuance, Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease" xlink:href="mgnx-20231231.xsd#mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease" xlink:to="lab_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_49d939d3-6775-4a5e-ad2a-405c619b70e1_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_2ce2556f-6e31-483b-8057-a8a81be5a29a_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Gross deferred income tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ProventionBioMember_11d5d70b-96b2-4ff3-b465-93485fe6e6c5_terseLabel_en-US" xlink:label="lab_mgnx_ProventionBioMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provention Bio, Inc. (Provention)</link:label>
    <link:label id="lab_mgnx_ProventionBioMember_label_en-US" xlink:label="lab_mgnx_ProventionBioMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Provention Bio [Member]</link:label>
    <link:label id="lab_mgnx_ProventionBioMember_documentation_en-US" xlink:label="lab_mgnx_ProventionBioMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Provention Bio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionBioMember" xlink:href="mgnx-20231231.xsd#mgnx_ProventionBioMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ProventionBioMember" xlink:to="lab_mgnx_ProventionBioMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_73361168-f33e-4610-8353-8d2181686de1_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration and Other Agreements [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTable_terseLabel_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure</link:label>
    <link:label id="lab_ecd_PvpTable_label_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTable" xlink:to="lab_ecd_PvpTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_8ff48e5c-f69f-439c-8810-a146819206e0_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_876f8b16-1a91-45cd-9096-bf3c27053a83_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_StockIncentivePlan2013Member_d68b8e13-1df6-44c9-b537-9d6bac23ddf0_terseLabel_en-US" xlink:label="lab_mgnx_StockIncentivePlan2013Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Incentive Plan 2013</link:label>
    <link:label id="lab_mgnx_StockIncentivePlan2013Member_label_en-US" xlink:label="lab_mgnx_StockIncentivePlan2013Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Incentive Plan 2013 [Member]</link:label>
    <link:label id="lab_mgnx_StockIncentivePlan2013Member_documentation_en-US" xlink:label="lab_mgnx_StockIncentivePlan2013Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Incentive Plan 2013 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIncentivePlan2013Member" xlink:href="mgnx-20231231.xsd#mgnx_StockIncentivePlan2013Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_StockIncentivePlan2013Member" xlink:to="lab_mgnx_StockIncentivePlan2013Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_f0ad5dc4-560e-4114-9d8e-21759f772056_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_7fe85269-b83d-493e-8522-93ac665380ec_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Equipment and Software</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_3965b484-bb27-4297-86ab-05ddfce2128d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_6619a346-5f31-426b-997d-b68d63d430d9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_e2a4cc32-b8e8-4049-9c50-09a4de2d11f5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_PotentialTargetNominationOptionFeesAndMilestonePayments_d74328aa-0d2a-4409-9e2f-2e565c1370ee_terseLabel_en-US" xlink:label="lab_mgnx_PotentialTargetNominationOptionFeesAndMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Target nomination, option fees and milestone</link:label>
    <link:label id="lab_mgnx_PotentialTargetNominationOptionFeesAndMilestonePayments_label_en-US" xlink:label="lab_mgnx_PotentialTargetNominationOptionFeesAndMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Potential target nomination, option fees and milestone payments</link:label>
    <link:label id="lab_mgnx_PotentialTargetNominationOptionFeesAndMilestonePayments_documentation_en-US" xlink:label="lab_mgnx_PotentialTargetNominationOptionFeesAndMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Potential target, nomination, option fees and milestone payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialTargetNominationOptionFeesAndMilestonePayments" xlink:href="mgnx-20231231.xsd#mgnx_PotentialTargetNominationOptionFeesAndMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PotentialTargetNominationOptionFeesAndMilestonePayments" xlink:to="lab_mgnx_PotentialTargetNominationOptionFeesAndMilestonePayments" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>16
<FILENAME>mgnx-20231231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:8dbce59b-e7cb-41de-8446-707f712a2a92,g:3e6229e4-32a7-4caa-a132-cb74eb6cd115-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://macrogenics.com/role/CoverPage" xlink:type="simple" xlink:href="mgnx-20231231.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_93b875f9-7e91-46dc-906e-b2196024141b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_570fa5b0-1a88-4b90-b4f9-d35aad59ac31" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_93b875f9-7e91-46dc-906e-b2196024141b" xlink:to="loc_dei_DocumentType_570fa5b0-1a88-4b90-b4f9-d35aad59ac31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_c10fbc78-f273-4814-9a93-458ec183aae2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_93b875f9-7e91-46dc-906e-b2196024141b" xlink:to="loc_dei_DocumentAnnualReport_c10fbc78-f273-4814-9a93-458ec183aae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_4b1b2a59-3ec5-4610-b5fa-004700724e2b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_93b875f9-7e91-46dc-906e-b2196024141b" xlink:to="loc_dei_DocumentPeriodEndDate_4b1b2a59-3ec5-4610-b5fa-004700724e2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_e3b9959e-e561-4592-9cdc-66e153526d14" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_93b875f9-7e91-46dc-906e-b2196024141b" xlink:to="loc_dei_CurrentFiscalYearEndDate_e3b9959e-e561-4592-9cdc-66e153526d14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_eabbd77d-5d21-4742-bca6-a4e81ce6435c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_93b875f9-7e91-46dc-906e-b2196024141b" xlink:to="loc_dei_DocumentTransitionReport_eabbd77d-5d21-4742-bca6-a4e81ce6435c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_d585b148-d417-4a0e-9f88-142060ee0b96" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_93b875f9-7e91-46dc-906e-b2196024141b" xlink:to="loc_dei_EntityFileNumber_d585b148-d417-4a0e-9f88-142060ee0b96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_524545e8-fb82-4146-8680-4aa7dffb2d9e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_93b875f9-7e91-46dc-906e-b2196024141b" xlink:to="loc_dei_EntityRegistrantName_524545e8-fb82-4146-8680-4aa7dffb2d9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_558628d8-02d6-40ee-817c-4df18c109ebb" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_93b875f9-7e91-46dc-906e-b2196024141b" xlink:to="loc_dei_EntityIncorporationStateCountryCode_558628d8-02d6-40ee-817c-4df18c109ebb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_39e201ca-8aca-4fc2-a9da-3943271f4990" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_93b875f9-7e91-46dc-906e-b2196024141b" xlink:to="loc_dei_EntityTaxIdentificationNumber_39e201ca-8aca-4fc2-a9da-3943271f4990" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_575e05c3-09e7-4ac4-a1cb-8acd5b7b8ecf" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_93b875f9-7e91-46dc-906e-b2196024141b" xlink:to="loc_dei_EntityAddressAddressLine1_575e05c3-09e7-4ac4-a1cb-8acd5b7b8ecf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_27031e27-e53a-4dbe-a64f-27af169f1c43" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_93b875f9-7e91-46dc-906e-b2196024141b" xlink:to="loc_dei_EntityAddressCityOrTown_27031e27-e53a-4dbe-a64f-27af169f1c43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_930d225c-0a75-45c3-b227-eef96e37d925" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_93b875f9-7e91-46dc-906e-b2196024141b" xlink:to="loc_dei_EntityAddressStateOrProvince_930d225c-0a75-45c3-b227-eef96e37d925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_8fa18ec1-01ca-4f4d-86a5-c0d43da8b334" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_93b875f9-7e91-46dc-906e-b2196024141b" xlink:to="loc_dei_EntityAddressPostalZipCode_8fa18ec1-01ca-4f4d-86a5-c0d43da8b334" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_16765724-22ba-438e-a37b-375a15433a87" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_93b875f9-7e91-46dc-906e-b2196024141b" xlink:to="loc_dei_CityAreaCode_16765724-22ba-438e-a37b-375a15433a87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_d68daaf4-6e06-46a9-ae9e-41821e2167c1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_93b875f9-7e91-46dc-906e-b2196024141b" xlink:to="loc_dei_LocalPhoneNumber_d68daaf4-6e06-46a9-ae9e-41821e2167c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_b04847d4-cc50-4b43-a076-7a051773098f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_93b875f9-7e91-46dc-906e-b2196024141b" xlink:to="loc_dei_Security12bTitle_b04847d4-cc50-4b43-a076-7a051773098f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_407876fe-3b24-465a-a07c-67ac5276ff14" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_93b875f9-7e91-46dc-906e-b2196024141b" xlink:to="loc_dei_TradingSymbol_407876fe-3b24-465a-a07c-67ac5276ff14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_790273f0-c952-4e90-a79c-fc57171e73da" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_93b875f9-7e91-46dc-906e-b2196024141b" xlink:to="loc_dei_SecurityExchangeName_790273f0-c952-4e90-a79c-fc57171e73da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_cca86bf9-21fd-4250-9314-ef3ec3dccd2e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_93b875f9-7e91-46dc-906e-b2196024141b" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_cca86bf9-21fd-4250-9314-ef3ec3dccd2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_587f1ab4-bd56-4847-85bf-83daef9f2e3e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_93b875f9-7e91-46dc-906e-b2196024141b" xlink:to="loc_dei_EntityVoluntaryFilers_587f1ab4-bd56-4847-85bf-83daef9f2e3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_6af46b1e-ffe5-4fe3-b9c0-965877c3653f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_93b875f9-7e91-46dc-906e-b2196024141b" xlink:to="loc_dei_EntityCurrentReportingStatus_6af46b1e-ffe5-4fe3-b9c0-965877c3653f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_533011eb-f49b-4811-828a-be22abb436d5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_93b875f9-7e91-46dc-906e-b2196024141b" xlink:to="loc_dei_EntityInteractiveDataCurrent_533011eb-f49b-4811-828a-be22abb436d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_f10eb736-0858-434d-b6f7-3e022f91e758" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_93b875f9-7e91-46dc-906e-b2196024141b" xlink:to="loc_dei_EntityFilerCategory_f10eb736-0858-434d-b6f7-3e022f91e758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_1dfb1155-4d84-4240-93ae-62b0bde53115" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_93b875f9-7e91-46dc-906e-b2196024141b" xlink:to="loc_dei_EntitySmallBusiness_1dfb1155-4d84-4240-93ae-62b0bde53115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_1620774d-a1ea-4517-b353-45ff3131315f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_93b875f9-7e91-46dc-906e-b2196024141b" xlink:to="loc_dei_EntityEmergingGrowthCompany_1620774d-a1ea-4517-b353-45ff3131315f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_f118507e-99c6-406d-a4be-67576782c788" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_93b875f9-7e91-46dc-906e-b2196024141b" xlink:to="loc_dei_IcfrAuditorAttestationFlag_f118507e-99c6-406d-a4be-67576782c788" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_e5cc70b9-6b69-41d3-9b98-f2fd48590788" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_93b875f9-7e91-46dc-906e-b2196024141b" xlink:to="loc_dei_EntityShellCompany_e5cc70b9-6b69-41d3-9b98-f2fd48590788" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_f6d83c07-2dbd-4359-ac99-9a41bf62334f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_93b875f9-7e91-46dc-906e-b2196024141b" xlink:to="loc_dei_EntityPublicFloat_f6d83c07-2dbd-4359-ac99-9a41bf62334f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_cc9ff890-a616-4749-9e59-4cf361da1237" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_93b875f9-7e91-46dc-906e-b2196024141b" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_cc9ff890-a616-4749-9e59-4cf361da1237" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_7c9b2b5b-2fb4-4cd4-99f5-28d6887936e7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_93b875f9-7e91-46dc-906e-b2196024141b" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_7c9b2b5b-2fb4-4cd4-99f5-28d6887936e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_67e66cc8-9c36-4b46-a7ed-8baedb23ca9a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_93b875f9-7e91-46dc-906e-b2196024141b" xlink:to="loc_dei_AmendmentFlag_67e66cc8-9c36-4b46-a7ed-8baedb23ca9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_f896d2c6-280c-4e7b-b40b-24fdf650009c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_93b875f9-7e91-46dc-906e-b2196024141b" xlink:to="loc_dei_DocumentFiscalYearFocus_f896d2c6-280c-4e7b-b40b-24fdf650009c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_2ac39251-22b3-40b2-b63b-22bf19e508f8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_93b875f9-7e91-46dc-906e-b2196024141b" xlink:to="loc_dei_DocumentFiscalPeriodFocus_2ac39251-22b3-40b2-b63b-22bf19e508f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_907c6bf8-2afa-413b-988e-142ff6299de7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_93b875f9-7e91-46dc-906e-b2196024141b" xlink:to="loc_dei_EntityCentralIndexKey_907c6bf8-2afa-413b-988e-142ff6299de7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_bcf0a9bb-97ae-4465-a9ce-6c0a6a54d046" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_93b875f9-7e91-46dc-906e-b2196024141b" xlink:to="loc_dei_DocumentFinStmtErrorCorrectionFlag_bcf0a9bb-97ae-4465-a9ce-6c0a6a54d046" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/AuditInformation" xlink:type="simple" xlink:href="mgnx-20231231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AuditorInformationAbstract_ac2fa118-b823-4cbf-81b1-282257e6fde5" xlink:href="mgnx-20231231.xsd#mgnx_AuditorInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_1904a822-c305-44f0-9237-5a94de15f3af" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_AuditorInformationAbstract_ac2fa118-b823-4cbf-81b1-282257e6fde5" xlink:to="loc_dei_AuditorFirmId_1904a822-c305-44f0-9237-5a94de15f3af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_80f57079-c928-47c4-baef-f45638cfad0d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_AuditorInformationAbstract_ac2fa118-b823-4cbf-81b1-282257e6fde5" xlink:to="loc_dei_AuditorName_80f57079-c928-47c4-baef-f45638cfad0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_389c8966-76dc-41b5-9664-06c24b981896" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_AuditorInformationAbstract_ac2fa118-b823-4cbf-81b1-282257e6fde5" xlink:to="loc_dei_AuditorLocation_389c8966-76dc-41b5-9664-06c24b981896" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="mgnx-20231231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_68c349ab-a490-4c2a-8d4d-5f9e83d1f003" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_41676927-aef5-4097-8c13-7e882c32bcf2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_68c349ab-a490-4c2a-8d4d-5f9e83d1f003" xlink:to="loc_us-gaap_AssetsAbstract_41676927-aef5-4097-8c13-7e882c32bcf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_2768c213-c36f-474b-a55b-25022a2b571a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_41676927-aef5-4097-8c13-7e882c32bcf2" xlink:to="loc_us-gaap_AssetsCurrentAbstract_2768c213-c36f-474b-a55b-25022a2b571a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_31780d8d-bcba-431d-a76b-19726dddafbd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2768c213-c36f-474b-a55b-25022a2b571a" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_31780d8d-bcba-431d-a76b-19726dddafbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments_c80350f7-f093-4db7-bc10-3c803f2b9129" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Investments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2768c213-c36f-474b-a55b-25022a2b571a" xlink:to="loc_us-gaap_Investments_c80350f7-f093-4db7-bc10-3c803f2b9129" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_a130b6be-55eb-451e-ab21-86f16a2c1202" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2768c213-c36f-474b-a55b-25022a2b571a" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_a130b6be-55eb-451e-ab21-86f16a2c1202" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_9435da9d-0225-47ef-880c-bc53f0e4664d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2768c213-c36f-474b-a55b-25022a2b571a" xlink:to="loc_us-gaap_InventoryNet_9435da9d-0225-47ef-880c-bc53f0e4664d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_bc0a3857-f040-4dc8-b53e-bf61fbe4ba60" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2768c213-c36f-474b-a55b-25022a2b571a" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_bc0a3857-f040-4dc8-b53e-bf61fbe4ba60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_c05e88d4-a07c-40f0-8628-5ba262ffb4de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2768c213-c36f-474b-a55b-25022a2b571a" xlink:to="loc_us-gaap_AssetsCurrent_c05e88d4-a07c-40f0-8628-5ba262ffb4de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_3eb12d45-6514-4db8-b249-160a868292b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_41676927-aef5-4097-8c13-7e882c32bcf2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_3eb12d45-6514-4db8-b249-160a868292b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_be5f79d6-3262-4e62-922b-d50d5a2498d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_41676927-aef5-4097-8c13-7e882c32bcf2" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_be5f79d6-3262-4e62-922b-d50d5a2498d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_bc650c78-5bf3-4df2-8060-78d7035dc364" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_41676927-aef5-4097-8c13-7e882c32bcf2" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_bc650c78-5bf3-4df2-8060-78d7035dc364" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_3780e123-0b5b-4bbd-8730-4eb484154e23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_41676927-aef5-4097-8c13-7e882c32bcf2" xlink:to="loc_us-gaap_Assets_3780e123-0b5b-4bbd-8730-4eb484154e23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_80618c99-c141-46be-a512-b9056358a5ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_68c349ab-a490-4c2a-8d4d-5f9e83d1f003" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_80618c99-c141-46be-a512-b9056358a5ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_6fd7e57c-a7a9-412c-be42-6af63363b696" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_80618c99-c141-46be-a512-b9056358a5ed" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_6fd7e57c-a7a9-412c-be42-6af63363b696" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_675206aa-250e-4b0a-a15b-0bd74947513e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_6fd7e57c-a7a9-412c-be42-6af63363b696" xlink:to="loc_us-gaap_AccountsPayableCurrent_675206aa-250e-4b0a-a15b-0bd74947513e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_cd1f59ae-159e-48bf-ba75-523d9d40690d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_6fd7e57c-a7a9-412c-be42-6af63363b696" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_cd1f59ae-159e-48bf-ba75-523d9d40690d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueCurrent_3677de2c-f418-485c-b0c3-951932b44709" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_6fd7e57c-a7a9-412c-be42-6af63363b696" xlink:to="loc_us-gaap_DeferredRevenueCurrent_3677de2c-f418-485c-b0c3-951932b44709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_8af920d2-ade1-4207-bb3d-628f6a29ea06" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_6fd7e57c-a7a9-412c-be42-6af63363b696" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_8af920d2-ade1-4207-bb3d-628f6a29ea06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_6d1d0115-53ff-4530-9168-5f9a0e4d9fa3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_6fd7e57c-a7a9-412c-be42-6af63363b696" xlink:to="loc_us-gaap_LiabilitiesCurrent_6d1d0115-53ff-4530-9168-5f9a0e4d9fa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_039b3552-3437-4fb0-b229-a7506c2433eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_80618c99-c141-46be-a512-b9056358a5ed" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_039b3552-3437-4fb0-b229-a7506c2433eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c8305edb-776f-4dca-b74f-1aa957d41ce2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_80618c99-c141-46be-a512-b9056358a5ed" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c8305edb-776f-4dca-b74f-1aa957d41ce2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_1bfcde40-2a57-4bab-9707-a0637254aff1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_80618c99-c141-46be-a512-b9056358a5ed" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_1bfcde40-2a57-4bab-9707-a0637254aff1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_25c68b92-2740-48ec-b22e-c330b4ba7e87" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_80618c99-c141-46be-a512-b9056358a5ed" xlink:to="loc_us-gaap_Liabilities_25c68b92-2740-48ec-b22e-c330b4ba7e87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_631a4a19-b079-48da-9060-228f31f5f0ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_80618c99-c141-46be-a512-b9056358a5ed" xlink:to="loc_us-gaap_StockholdersEquityAbstract_631a4a19-b079-48da-9060-228f31f5f0ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_0cda17ce-1376-47d7-b34d-04f15d43be1a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_631a4a19-b079-48da-9060-228f31f5f0ea" xlink:to="loc_us-gaap_CommonStockValue_0cda17ce-1376-47d7-b34d-04f15d43be1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_14296286-615d-414e-adf3-8e50e15626bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_631a4a19-b079-48da-9060-228f31f5f0ea" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_14296286-615d-414e-adf3-8e50e15626bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_06b7ef86-925e-48d8-8056-5c848598551b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_631a4a19-b079-48da-9060-228f31f5f0ea" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_06b7ef86-925e-48d8-8056-5c848598551b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_12489e73-67c6-4c3c-ad5d-de6cd1882a11" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_631a4a19-b079-48da-9060-228f31f5f0ea" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_12489e73-67c6-4c3c-ad5d-de6cd1882a11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_26a692ff-2df1-429b-b79f-6f1779fc6383" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_631a4a19-b079-48da-9060-228f31f5f0ea" xlink:to="loc_us-gaap_StockholdersEquity_26a692ff-2df1-429b-b79f-6f1779fc6383" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_891105e3-7dec-415a-b33d-2d5e8cf02409" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_80618c99-c141-46be-a512-b9056358a5ed" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_891105e3-7dec-415a-b33d-2d5e8cf02409" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="mgnx-20231231.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0630e52e-9eec-47f5-b2ed-0786841a2851" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_3b195078-4bd7-4d80-9e14-ccef86747fc8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0630e52e-9eec-47f5-b2ed-0786841a2851" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_3b195078-4bd7-4d80-9e14-ccef86747fc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_bdcd94ce-5c39-46c7-ba31-47e14318b0a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0630e52e-9eec-47f5-b2ed-0786841a2851" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_bdcd94ce-5c39-46c7-ba31-47e14318b0a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_d8baff7a-df62-4162-ac00-7ae223fc020c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0630e52e-9eec-47f5-b2ed-0786841a2851" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_d8baff7a-df62-4162-ac00-7ae223fc020c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="mgnx-20231231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_e5c3b451-9e1d-476a-866f-ea853e3a6a8e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ec44c3f6-0c45-499a-9178-6adaf288df75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e5c3b451-9e1d-476a-866f-ea853e3a6a8e" xlink:to="loc_us-gaap_StatementTable_ec44c3f6-0c45-499a-9178-6adaf288df75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_67c41ae7-48ad-4ad3-a403-c3b1079e4da8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ec44c3f6-0c45-499a-9178-6adaf288df75" xlink:to="loc_srt_ProductOrServiceAxis_67c41ae7-48ad-4ad3-a403-c3b1079e4da8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_08911c99-a8ac-4fee-aa36-01d29cd5dbf4" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_67c41ae7-48ad-4ad3-a403-c3b1079e4da8" xlink:to="loc_srt_ProductsAndServicesDomain_08911c99-a8ac-4fee-aa36-01d29cd5dbf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromCollaborativeAgreementsMember_b60040ac-33ff-4058-b7f3-60a0c24a08ac" xlink:href="mgnx-20231231.xsd#mgnx_RevenueFromCollaborativeAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_08911c99-a8ac-4fee-aa36-01d29cd5dbf4" xlink:to="loc_mgnx_RevenueFromCollaborativeAgreementsMember_b60040ac-33ff-4058-b7f3-60a0c24a08ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromGovernmentAgreementsMember_7cf98039-2e4a-4bd5-8e0e-6d7d652580ff" xlink:href="mgnx-20231231.xsd#mgnx_RevenueFromGovernmentAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_08911c99-a8ac-4fee-aa36-01d29cd5dbf4" xlink:to="loc_mgnx_RevenueFromGovernmentAgreementsMember_7cf98039-2e4a-4bd5-8e0e-6d7d652580ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_6396f28d-b5e7-4add-bb9c-c5aedc132b78" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_08911c99-a8ac-4fee-aa36-01d29cd5dbf4" xlink:to="loc_us-gaap_ProductMember_6396f28d-b5e7-4add-bb9c-c5aedc132b78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ContractManufacturingMember_b8cbbbb4-8342-483d-b7d5-bde58d697200" xlink:href="mgnx-20231231.xsd#mgnx_ContractManufacturingMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_08911c99-a8ac-4fee-aa36-01d29cd5dbf4" xlink:to="loc_mgnx_ContractManufacturingMember_b8cbbbb4-8342-483d-b7d5-bde58d697200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromRoyalityAgreementsMemberMember_3b655484-c0cf-459f-853d-e67ef2716991" xlink:href="mgnx-20231231.xsd#mgnx_RevenueFromRoyalityAgreementsMemberMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_08911c99-a8ac-4fee-aa36-01d29cd5dbf4" xlink:to="loc_mgnx_RevenueFromRoyalityAgreementsMemberMember_3b655484-c0cf-459f-853d-e67ef2716991" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_fde490db-5143-47a8-b7ba-066991bc2495" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ec44c3f6-0c45-499a-9178-6adaf288df75" xlink:to="loc_us-gaap_StatementLineItems_fde490db-5143-47a8-b7ba-066991bc2495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_46baf2c6-5845-45cd-a98c-abb33ce3396b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_fde490db-5143-47a8-b7ba-066991bc2495" xlink:to="loc_us-gaap_RevenuesAbstract_46baf2c6-5845-45cd-a98c-abb33ce3396b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_6b8a4d7f-8e74-4c49-8167-0ecbb992623e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_46baf2c6-5845-45cd-a98c-abb33ce3396b" xlink:to="loc_us-gaap_Revenues_6b8a4d7f-8e74-4c49-8167-0ecbb992623e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_4ff953c1-f463-433a-b99b-0d1fbb4bcc92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_fde490db-5143-47a8-b7ba-066991bc2495" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_4ff953c1-f463-433a-b99b-0d1fbb4bcc92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_4051f614-df86-47c3-89b5-9b4c8505407b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_4ff953c1-f463-433a-b99b-0d1fbb4bcc92" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_4051f614-df86-47c3-89b5-9b4c8505407b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CostOfManufacturingServices_8df1e4bd-ce87-408c-8b6e-05b0862f3da6" xlink:href="mgnx-20231231.xsd#mgnx_CostOfManufacturingServices"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_4ff953c1-f463-433a-b99b-0d1fbb4bcc92" xlink:to="loc_mgnx_CostOfManufacturingServices_8df1e4bd-ce87-408c-8b6e-05b0862f3da6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_1f58a1cb-bb3d-4c07-930e-a46429f849ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_4ff953c1-f463-433a-b99b-0d1fbb4bcc92" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_1f58a1cb-bb3d-4c07-930e-a46429f849ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_48445ae5-eccf-47f7-908c-cf097784c6f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_4ff953c1-f463-433a-b99b-0d1fbb4bcc92" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_48445ae5-eccf-47f7-908c-cf097784c6f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_cb1b1512-081c-4b97-82ba-64838fdd63ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_4ff953c1-f463-433a-b99b-0d1fbb4bcc92" xlink:to="loc_us-gaap_CostsAndExpenses_cb1b1512-081c-4b97-82ba-64838fdd63ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_44198d1d-63e0-4ccf-81dd-601d09aebfdc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_fde490db-5143-47a8-b7ba-066991bc2495" xlink:to="loc_us-gaap_OperatingIncomeLoss_44198d1d-63e0-4ccf-81dd-601d09aebfdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_GainOnRoyaltyMonetizationArrangement_6f85ddad-20c5-4064-b468-bfe3451c1a02" xlink:href="mgnx-20231231.xsd#mgnx_GainOnRoyaltyMonetizationArrangement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_fde490db-5143-47a8-b7ba-066991bc2495" xlink:to="loc_mgnx_GainOnRoyaltyMonetizationArrangement_6f85ddad-20c5-4064-b468-bfe3451c1a02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_4f72eebc-6586-444d-aaab-ff2e289c3418" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_fde490db-5143-47a8-b7ba-066991bc2495" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_4f72eebc-6586-444d-aaab-ff2e289c3418" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_889ad33f-a047-4844-a0fe-11b38971e5bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_fde490db-5143-47a8-b7ba-066991bc2495" xlink:to="loc_us-gaap_InterestExpense_889ad33f-a047-4844-a0fe-11b38971e5bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_4592fe69-0f94-4cd7-a439-7556705dd801" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_fde490db-5143-47a8-b7ba-066991bc2495" xlink:to="loc_us-gaap_NetIncomeLoss_4592fe69-0f94-4cd7-a439-7556705dd801" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_5b4d200a-ce8f-4359-8bf5-a46b0198cf53" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_fde490db-5143-47a8-b7ba-066991bc2495" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_5b4d200a-ce8f-4359-8bf5-a46b0198cf53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_0a2c5704-41bd-40ec-94e8-63d46f027a7a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_5b4d200a-ce8f-4359-8bf5-a46b0198cf53" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_0a2c5704-41bd-40ec-94e8-63d46f027a7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_508440d3-120e-4423-acde-440256600aeb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_5b4d200a-ce8f-4359-8bf5-a46b0198cf53" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_508440d3-120e-4423-acde-440256600aeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_4f78a284-263f-4d83-82d2-f5e232a8d987" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_fde490db-5143-47a8-b7ba-066991bc2495" xlink:to="loc_us-gaap_EarningsPerShareBasic_4f78a284-263f-4d83-82d2-f5e232a8d987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_e82cdb0d-c5b4-497c-98a5-bb79eff21b32" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_fde490db-5143-47a8-b7ba-066991bc2495" xlink:to="loc_us-gaap_EarningsPerShareDiluted_e82cdb0d-c5b4-497c-98a5-bb79eff21b32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c9e9cf31-76dc-407c-a4e5-f17da37ba53f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_fde490db-5143-47a8-b7ba-066991bc2495" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c9e9cf31-76dc-407c-a4e5-f17da37ba53f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_685028d2-c952-4eb2-a06d-46147640a3b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_fde490db-5143-47a8-b7ba-066991bc2495" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_685028d2-c952-4eb2-a06d-46147640a3b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="mgnx-20231231.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_91a9db90-f0f8-4efb-989c-60a91d9d575c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_a39f87dd-5933-4ced-ac7d-b49a0fc6b23a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_91a9db90-f0f8-4efb-989c-60a91d9d575c" xlink:to="loc_us-gaap_StatementTable_a39f87dd-5933-4ced-ac7d-b49a0fc6b23a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_87d09e4b-df48-4fa2-8634-1a82f31cf085" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_a39f87dd-5933-4ced-ac7d-b49a0fc6b23a" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_87d09e4b-df48-4fa2-8634-1a82f31cf085" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6fa015d0-f811-4eee-82c6-0d042f9248e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_87d09e4b-df48-4fa2-8634-1a82f31cf085" xlink:to="loc_us-gaap_EquityComponentDomain_6fa015d0-f811-4eee-82c6-0d042f9248e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_a33e5f64-6bf2-4996-821e-0f736abaad45" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6fa015d0-f811-4eee-82c6-0d042f9248e7" xlink:to="loc_us-gaap_CommonStockMember_a33e5f64-6bf2-4996-821e-0f736abaad45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_0af29f76-08a4-4b56-b7d1-34c7a89b7fca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6fa015d0-f811-4eee-82c6-0d042f9248e7" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_0af29f76-08a4-4b56-b7d1-34c7a89b7fca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_4a4ca3fb-d93d-486c-afcc-2d2ef08ccd29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6fa015d0-f811-4eee-82c6-0d042f9248e7" xlink:to="loc_us-gaap_RetainedEarningsMember_4a4ca3fb-d93d-486c-afcc-2d2ef08ccd29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c30ee7fb-2c3f-48ed-8722-177cefbe4d24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6fa015d0-f811-4eee-82c6-0d042f9248e7" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c30ee7fb-2c3f-48ed-8722-177cefbe4d24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_9b6498b3-b6d0-4c97-b132-51194864d6fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_a39f87dd-5933-4ced-ac7d-b49a0fc6b23a" xlink:to="loc_us-gaap_StatementLineItems_9b6498b3-b6d0-4c97-b132-51194864d6fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_ca434e83-8af2-4aee-aa55-0e38c505e95f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9b6498b3-b6d0-4c97-b132-51194864d6fa" xlink:to="loc_us-gaap_SharesIssued_ca434e83-8af2-4aee-aa55-0e38c505e95f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e655ea37-3f8b-43b0-a0df-d79280d39371" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9b6498b3-b6d0-4c97-b132-51194864d6fa" xlink:to="loc_us-gaap_StockholdersEquity_e655ea37-3f8b-43b0-a0df-d79280d39371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_addcc66e-7246-48b1-8d4a-d3b3ba285c76" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9b6498b3-b6d0-4c97-b132-51194864d6fa" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_addcc66e-7246-48b1-8d4a-d3b3ba285c76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1e3da63f-7295-4b3e-ba60-69c3b6e67da0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9b6498b3-b6d0-4c97-b132-51194864d6fa" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1e3da63f-7295-4b3e-ba60-69c3b6e67da0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_fc6caf7d-a796-4e6d-9c7c-03aceba5f4ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9b6498b3-b6d0-4c97-b132-51194864d6fa" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_fc6caf7d-a796-4e6d-9c7c-03aceba5f4ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity_da7f5b5f-72f5-42a9-89bc-69e2b8dbc606" xlink:href="mgnx-20231231.xsd#mgnx_StockIssuedDuringPeriodSharesStockPlanActivity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9b6498b3-b6d0-4c97-b132-51194864d6fa" xlink:to="loc_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity_da7f5b5f-72f5-42a9-89bc-69e2b8dbc606" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIssuedDuringPeriodValueStockPlanActivity_9d90c424-2f73-432d-91b2-dbab7416df63" xlink:href="mgnx-20231231.xsd#mgnx_StockIssuedDuringPeriodValueStockPlanActivity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9b6498b3-b6d0-4c97-b132-51194864d6fa" xlink:to="loc_mgnx_StockIssuedDuringPeriodValueStockPlanActivity_9d90c424-2f73-432d-91b2-dbab7416df63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_16785732-733b-483c-baac-096aa1a0e50a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9b6498b3-b6d0-4c97-b132-51194864d6fa" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_16785732-733b-483c-baac-096aa1a0e50a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_4c116bc1-a52c-4e7a-9372-aaee376de9e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9b6498b3-b6d0-4c97-b132-51194864d6fa" xlink:to="loc_us-gaap_NetIncomeLoss_4c116bc1-a52c-4e7a-9372-aaee376de9e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_bc15f074-e8b7-4752-89b8-952aedcb540e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9b6498b3-b6d0-4c97-b132-51194864d6fa" xlink:to="loc_us-gaap_SharesIssued_bc15f074-e8b7-4752-89b8-952aedcb540e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_93b970ea-3ab4-42a0-b94c-dc33fcddc364" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9b6498b3-b6d0-4c97-b132-51194864d6fa" xlink:to="loc_us-gaap_StockholdersEquity_93b970ea-3ab4-42a0-b94c-dc33fcddc364" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="mgnx-20231231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_f2ee50de-442c-47e4-a7f1-267e4d527b1e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_a96a45da-891b-4dde-8cd5-6bbe06374168" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f2ee50de-442c-47e4-a7f1-267e4d527b1e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_a96a45da-891b-4dde-8cd5-6bbe06374168" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_171c3a43-e030-41fe-86d5-0a998a1c2c6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_a96a45da-891b-4dde-8cd5-6bbe06374168" xlink:to="loc_us-gaap_NetIncomeLoss_171c3a43-e030-41fe-86d5-0a998a1c2c6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d3954653-4892-4002-9f4d-ee4fac8b5731" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_a96a45da-891b-4dde-8cd5-6bbe06374168" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d3954653-4892-4002-9f4d-ee4fac8b5731" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_82d95de5-9042-467f-8e96-6929cd7aa4ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d3954653-4892-4002-9f4d-ee4fac8b5731" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_82d95de5-9042-467f-8e96-6929cd7aa4ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_3d02eb60-1c21-488a-8c29-2decc27a1acd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d3954653-4892-4002-9f4d-ee4fac8b5731" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_3d02eb60-1c21-488a-8c29-2decc27a1acd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_894dd2c6-d29e-49e1-9db7-8d6dd1990b6a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d3954653-4892-4002-9f4d-ee4fac8b5731" xlink:to="loc_us-gaap_ShareBasedCompensation_894dd2c6-d29e-49e1-9db7-8d6dd1990b6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_GainOnRoyaltyMonetizationArrangement_d091b905-7030-4aad-879a-3ea0e8e4cf8a" xlink:href="mgnx-20231231.xsd#mgnx_GainOnRoyaltyMonetizationArrangement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d3954653-4892-4002-9f4d-ee4fac8b5731" xlink:to="loc_mgnx_GainOnRoyaltyMonetizationArrangement_d091b905-7030-4aad-879a-3ea0e8e4cf8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonCashInterestExpenseRecognized_cdea9e37-fffa-4ee0-b025-a768198c927a" xlink:href="mgnx-20231231.xsd#mgnx_NonCashInterestExpenseRecognized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d3954653-4892-4002-9f4d-ee4fac8b5731" xlink:to="loc_mgnx_NonCashInterestExpenseRecognized_cdea9e37-fffa-4ee0-b025-a768198c927a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_OperatingLeaseNoncashExpense_42598d14-3588-4837-9e4e-f15534287b73" xlink:href="mgnx-20231231.xsd#mgnx_OperatingLeaseNoncashExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d3954653-4892-4002-9f4d-ee4fac8b5731" xlink:to="loc_mgnx_OperatingLeaseNoncashExpense_42598d14-3588-4837-9e4e-f15534287b73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_6af6ff7c-a91f-42ef-8524-744be5a788b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d3954653-4892-4002-9f4d-ee4fac8b5731" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_6af6ff7c-a91f-42ef-8524-744be5a788b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets_da403982-d25e-49cb-9fbe-002e942cf3d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d3954653-4892-4002-9f4d-ee4fac8b5731" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets_da403982-d25e-49cb-9fbe-002e942cf3d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e1962ae2-66ad-4df9-924f-da6ec277d526" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d3954653-4892-4002-9f4d-ee4fac8b5731" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e1962ae2-66ad-4df9-924f-da6ec277d526" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_6c3ea925-c9d9-4f53-85e4-c8edcb84ca36" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e1962ae2-66ad-4df9-924f-da6ec277d526" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_6c3ea925-c9d9-4f53-85e4-c8edcb84ca36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_642e6871-5378-4664-bc59-6275ae5c34ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e1962ae2-66ad-4df9-924f-da6ec277d526" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_642e6871-5378-4664-bc59-6275ae5c34ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_0e8ff735-26ce-4d00-b732-15c506552358" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e1962ae2-66ad-4df9-924f-da6ec277d526" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_0e8ff735-26ce-4d00-b732-15c506552358" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_9c460274-b1af-4007-bd69-2d8e7c46f214" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e1962ae2-66ad-4df9-924f-da6ec277d526" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_9c460274-b1af-4007-bd69-2d8e7c46f214" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_d136dcaf-3a75-40e7-a4ef-4c50927dfc59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e1962ae2-66ad-4df9-924f-da6ec277d526" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_d136dcaf-3a75-40e7-a4ef-4c50927dfc59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_de70645d-293f-4c8f-9d85-7e0cc8c55de0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e1962ae2-66ad-4df9-924f-da6ec277d526" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_de70645d-293f-4c8f-9d85-7e0cc8c55de0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncreaseDecreaseInLeaseLiabilities_1d8f8918-90d9-4f57-91b4-686f8c9da352" xlink:href="mgnx-20231231.xsd#mgnx_IncreaseDecreaseInLeaseLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e1962ae2-66ad-4df9-924f-da6ec277d526" xlink:to="loc_mgnx_IncreaseDecreaseInLeaseLiabilities_1d8f8918-90d9-4f57-91b4-686f8c9da352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_2a0718c6-dcf3-4724-9309-eb102d71a341" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e1962ae2-66ad-4df9-924f-da6ec277d526" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_2a0718c6-dcf3-4724-9309-eb102d71a341" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncreaseDecreaseInDeferredRent_50553e67-0726-4349-b977-73c95ea8bdac" xlink:href="mgnx-20231231.xsd#mgnx_IncreaseDecreaseInDeferredRent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e1962ae2-66ad-4df9-924f-da6ec277d526" xlink:to="loc_mgnx_IncreaseDecreaseInDeferredRent_50553e67-0726-4349-b977-73c95ea8bdac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7ecde947-61ff-4a42-a1c6-2f15699ed1b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_a96a45da-891b-4dde-8cd5-6bbe06374168" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7ecde947-61ff-4a42-a1c6-2f15699ed1b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_8d69d358-4f3e-4fdb-bb76-19b41f7b8987" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f2ee50de-442c-47e4-a7f1-267e4d527b1e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_8d69d358-4f3e-4fdb-bb76-19b41f7b8987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_33e167fa-a154-4fbb-a0f8-963af556a941" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_8d69d358-4f3e-4fdb-bb76-19b41f7b8987" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_33e167fa-a154-4fbb-a0f8-963af556a941" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_e8634337-a87e-4357-967c-be70947c5581" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_8d69d358-4f3e-4fdb-bb76-19b41f7b8987" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_e8634337-a87e-4357-967c-be70947c5581" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8937c1df-6f74-4904-b89b-bf4bf265208e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_8d69d358-4f3e-4fdb-bb76-19b41f7b8987" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8937c1df-6f74-4904-b89b-bf4bf265208e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfMachineryAndEquipment_401388dc-e222-4de8-8ad6-d591835dd4a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfMachineryAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_8d69d358-4f3e-4fdb-bb76-19b41f7b8987" xlink:to="loc_us-gaap_ProceedsFromSaleOfMachineryAndEquipment_401388dc-e222-4de8-8ad6-d591835dd4a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c333cf7b-3faa-4017-8735-0fc98b1a7537" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_8d69d358-4f3e-4fdb-bb76-19b41f7b8987" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c333cf7b-3faa-4017-8735-0fc98b1a7537" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_09fea11f-fa77-405f-9131-3fdfac5011ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f2ee50de-442c-47e4-a7f1-267e4d527b1e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_09fea11f-fa77-405f-9131-3fdfac5011ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1b5058b8-87ec-4a81-96e3-057e15c64acb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_09fea11f-fa77-405f-9131-3fdfac5011ee" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1b5058b8-87ec-4a81-96e3-057e15c64acb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases_0a9da9a0-303d-4533-9f26-f6d76a657bd4" xlink:href="mgnx-20231231.xsd#mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_09fea11f-fa77-405f-9131-3fdfac5011ee" xlink:to="loc_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases_0a9da9a0-303d-4533-9f26-f6d76a657bd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_f21af9ac-09dd-4a5c-821b-b7f32c277a81" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_09fea11f-fa77-405f-9131-3fdfac5011ee" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_f21af9ac-09dd-4a5c-821b-b7f32c277a81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PrincipalPaymentsOnRoyaltyMonetizationArrangement_edbac464-fa5b-43de-b869-a911b943bbb8" xlink:href="mgnx-20231231.xsd#mgnx_PrincipalPaymentsOnRoyaltyMonetizationArrangement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_09fea11f-fa77-405f-9131-3fdfac5011ee" xlink:to="loc_mgnx_PrincipalPaymentsOnRoyaltyMonetizationArrangement_edbac464-fa5b-43de-b869-a911b943bbb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NetProceedsFromSaleOfFutureRoyalties_d9492a20-80cf-4c1a-b987-ddb67c584158" xlink:href="mgnx-20231231.xsd#mgnx_NetProceedsFromSaleOfFutureRoyalties"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_09fea11f-fa77-405f-9131-3fdfac5011ee" xlink:to="loc_mgnx_NetProceedsFromSaleOfFutureRoyalties_d9492a20-80cf-4c1a-b987-ddb67c584158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_091da91d-3d88-4582-8f51-dff00c8efc88" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_09fea11f-fa77-405f-9131-3fdfac5011ee" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_091da91d-3d88-4582-8f51-dff00c8efc88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_aae53831-cd30-46c1-bbc1-65bf78cc1ab8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f2ee50de-442c-47e4-a7f1-267e4d527b1e" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_aae53831-cd30-46c1-bbc1-65bf78cc1ab8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5cbab56c-734a-4b9b-8a12-c375a107cc5c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f2ee50de-442c-47e4-a7f1-267e4d527b1e" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5cbab56c-734a-4b9b-8a12-c375a107cc5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9ce4a5b3-77e1-4e25-9538-b5fb021b4158" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f2ee50de-442c-47e4-a7f1-267e4d527b1e" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9ce4a5b3-77e1-4e25-9538-b5fb021b4158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_491d71fd-ed82-498e-ba40-9427295b6785" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f2ee50de-442c-47e4-a7f1-267e4d527b1e" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_491d71fd-ed82-498e-ba40-9427295b6785" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_aee18267-8eb4-4f69-a2e5-f5c70093e124" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_491d71fd-ed82-498e-ba40-9427295b6785" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_aee18267-8eb4-4f69-a2e5-f5c70093e124" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/OrganizationandNatureofOperations" xlink:type="simple" xlink:href="mgnx-20231231.xsd#OrganizationandNatureofOperations"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/OrganizationandNatureofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_87174b86-04c6-4b93-aa0b-4f0bd32ad1c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_a1605288-a606-4701-8f89-679bb6b0650b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_87174b86-04c6-4b93-aa0b-4f0bd32ad1c7" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_a1605288-a606-4701-8f89-679bb6b0650b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="mgnx-20231231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_23870a58-9a4f-4ee1-98d7-a6868a385c72" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_2e62e9f3-87fa-46cc-9531-7ba84e31e680" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_23870a58-9a4f-4ee1-98d7-a6868a385c72" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_2e62e9f3-87fa-46cc-9531-7ba84e31e680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecurities" xlink:type="simple" xlink:href="mgnx-20231231.xsd#MarketableSecurities"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/MarketableSecurities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_d754fe9e-fa2d-4e87-8892-a6e9aa7a3787" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_3df0341a-627a-4d40-b248-2f1cdfd1c21b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_d754fe9e-fa2d-4e87-8892-a6e9aa7a3787" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_3df0341a-627a-4d40-b248-2f1cdfd1c21b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/Inventory" xlink:type="simple" xlink:href="mgnx-20231231.xsd#Inventory"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/Inventory" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_a5d4ce5c-6a5e-43f3-a46d-3793f6a0f34f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_ba68b93d-0088-4502-bf46-c5807843b855" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_a5d4ce5c-6a5e-43f3-a46d-3793f6a0f34f" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_ba68b93d-0088-4502-bf46-c5807843b855" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/PropertyEquipmentandSoftware" xlink:type="simple" xlink:href="mgnx-20231231.xsd#PropertyEquipmentandSoftware"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/PropertyEquipmentandSoftware" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_503b86f9-b111-445d-a7a9-dd5e4f5d8dbb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_4fe09033-7903-407d-b871-cd0c433f533d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_503b86f9-b111-445d-a7a9-dd5e4f5d8dbb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_4fe09033-7903-407d-b871-cd0c433f533d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="mgnx-20231231.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c61dea5b-e3e0-4dc9-915f-3fb442efb106" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_81752ebb-3d54-41fa-affb-499f7f0a1f11" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c61dea5b-e3e0-4dc9-915f-3fb442efb106" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_81752ebb-3d54-41fa-affb-499f7f0a1f11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/RoyaltyMonetizationArrangement" xlink:type="simple" xlink:href="mgnx-20231231.xsd#RoyaltyMonetizationArrangement"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/RoyaltyMonetizationArrangement" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RoyaltyMonetizationArrangementAbstract_e78414c4-3d32-494c-9672-fede64b5426a" xlink:href="mgnx-20231231.xsd#mgnx_RoyaltyMonetizationArrangementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_LiabilityRelatedToSaleOfFutureRoyaltiesTextBlock_5b09a8da-b7c7-484a-b423-8d83c8517486" xlink:href="mgnx-20231231.xsd#mgnx_LiabilityRelatedToSaleOfFutureRoyaltiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_RoyaltyMonetizationArrangementAbstract_e78414c4-3d32-494c-9672-fede64b5426a" xlink:to="loc_mgnx_LiabilityRelatedToSaleOfFutureRoyaltiesTextBlock_5b09a8da-b7c7-484a-b423-8d83c8517486" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockholdersEquity" xlink:type="simple" xlink:href="mgnx-20231231.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_021eb829-275f-4283-8c3d-c7c5f794b02e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1ddd170b-5e49-4e7b-849d-a88685223413" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_021eb829-275f-4283-8c3d-c7c5f794b02e" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1ddd170b-5e49-4e7b-849d-a88685223413" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/Revenue" xlink:type="simple" xlink:href="mgnx-20231231.xsd#Revenue"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/Revenue" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_a54d0b54-8b49-4d3e-b523-0abdcb35c156" xlink:href="mgnx-20231231.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock_3d876da3-9b9e-4598-b493-71b2760d84ca" xlink:href="mgnx-20231231.xsd#mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_a54d0b54-8b49-4d3e-b523-0abdcb35c156" xlink:to="loc_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock_3d876da3-9b9e-4598-b493-71b2760d84ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockbasedCompensation" xlink:type="simple" xlink:href="mgnx-20231231.xsd#StockbasedCompensation"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockbasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4393926a-2a8a-429f-8c78-78b803e24774" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_60de3010-2dcf-4648-9d2e-c660426cbce0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4393926a-2a8a-429f-8c78-78b803e24774" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_60de3010-2dcf-4648-9d2e-c660426cbce0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/IncomeTaxes" xlink:type="simple" xlink:href="mgnx-20231231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_9c47b21f-a0f3-4877-859e-8e9e89fbdaef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_80f186a0-90bc-4653-b271-48e00a8d6f81" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9c47b21f-a0f3-4877-859e-8e9e89fbdaef" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_80f186a0-90bc-4653-b271-48e00a8d6f81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/EmployeeBenefitPlan" xlink:type="simple" xlink:href="mgnx-20231231.xsd#EmployeeBenefitPlan"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/EmployeeBenefitPlan" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_62b9eaa2-3a3d-483e-8f1a-a8dd4838cc08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_7cd1f970-d0e1-46de-930d-c044d6f48fd9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_62b9eaa2-3a3d-483e-8f1a-a8dd4838cc08" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_7cd1f970-d0e1-46de-930d-c044d6f48fd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="mgnx-20231231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_26cd0f01-a5a8-4786-8cc3-aab76fbf7af5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_fa753fcd-13ca-4dba-9326-eca2f0e2f4b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_26cd0f01-a5a8-4786-8cc3-aab76fbf7af5" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_fa753fcd-13ca-4dba-9326-eca2f0e2f4b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_b655b02b-b6f1-4806-a2ea-867183771ca8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_26cd0f01-a5a8-4786-8cc3-aab76fbf7af5" xlink:to="loc_us-gaap_UseOfEstimates_b655b02b-b6f1-4806-a2ea-867183771ca8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_e78ff984-cad5-4083-9bd3-98ea0b737fd7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_26cd0f01-a5a8-4786-8cc3-aab76fbf7af5" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_e78ff984-cad5-4083-9bd3-98ea0b737fd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_2fb9d000-3504-4f64-83c0-3be43e5b0796" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_26cd0f01-a5a8-4786-8cc3-aab76fbf7af5" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_2fb9d000-3504-4f64-83c0-3be43e5b0796" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_e5c9b80d-c9d7-4dd8-8399-997fdd59d904" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_26cd0f01-a5a8-4786-8cc3-aab76fbf7af5" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_e5c9b80d-c9d7-4dd8-8399-997fdd59d904" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_330d1b29-beec-43dc-9b9d-f9efce25e3b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_26cd0f01-a5a8-4786-8cc3-aab76fbf7af5" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_330d1b29-beec-43dc-9b9d-f9efce25e3b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_a29746f8-6dde-4ccc-9714-d44244e9c66f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_26cd0f01-a5a8-4786-8cc3-aab76fbf7af5" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_a29746f8-6dde-4ccc-9714-d44244e9c66f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_975860b2-1dfe-46fb-9595-64cba41a4013" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_26cd0f01-a5a8-4786-8cc3-aab76fbf7af5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_975860b2-1dfe-46fb-9595-64cba41a4013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_8414e8d0-aa9b-416d-9a3b-5888ab50692a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_26cd0f01-a5a8-4786-8cc3-aab76fbf7af5" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_8414e8d0-aa9b-416d-9a3b-5888ab50692a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_LiabilityRelatedToFutureRoyaltiesAndRelatedInterestExpensePolicyTextBlock_104ac36d-9b88-4c9b-b5f9-2d982de496eb" xlink:href="mgnx-20231231.xsd#mgnx_LiabilityRelatedToFutureRoyaltiesAndRelatedInterestExpensePolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_26cd0f01-a5a8-4786-8cc3-aab76fbf7af5" xlink:to="loc_mgnx_LiabilityRelatedToFutureRoyaltiesAndRelatedInterestExpensePolicyTextBlock_104ac36d-9b88-4c9b-b5f9-2d982de496eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_0500c7cf-d4bc-4c2f-99eb-f5d002df98b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_26cd0f01-a5a8-4786-8cc3-aab76fbf7af5" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_0500c7cf-d4bc-4c2f-99eb-f5d002df98b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock_dfa83fda-257b-4035-b8d7-d55b8d4bbdb1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_26cd0f01-a5a8-4786-8cc3-aab76fbf7af5" xlink:to="loc_us-gaap_CostOfSalesPolicyTextBlock_dfa83fda-257b-4035-b8d7-d55b8d4bbdb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_72eeb58c-e829-423c-b061-bbb9c310b82d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_26cd0f01-a5a8-4786-8cc3-aab76fbf7af5" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_72eeb58c-e829-423c-b061-bbb9c310b82d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_64c545f6-a16a-4f44-93dd-b7e3100da624" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_26cd0f01-a5a8-4786-8cc3-aab76fbf7af5" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_64c545f6-a16a-4f44-93dd-b7e3100da624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_f548ad05-25fe-4fc7-85f9-35d1d4af76e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_26cd0f01-a5a8-4786-8cc3-aab76fbf7af5" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_f548ad05-25fe-4fc7-85f9-35d1d4af76e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_3374442f-0bbb-4aeb-aa11-71a06bcc9b3e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_26cd0f01-a5a8-4786-8cc3-aab76fbf7af5" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_3374442f-0bbb-4aeb-aa11-71a06bcc9b3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_a546a879-6912-4649-b222-fb99641fb665" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_26cd0f01-a5a8-4786-8cc3-aab76fbf7af5" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_a546a879-6912-4649-b222-fb99641fb665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="mgnx-20231231.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_fc2ff69f-bd72-4562-b260-28fe9773b63c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_e56c9bc2-bed9-400a-b412-f302879fa613" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fc2ff69f-bd72-4562-b260-28fe9773b63c" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_e56c9bc2-bed9-400a-b412-f302879fa613" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_e0771c99-f4d6-480e-be34-d011d58ed4b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fc2ff69f-bd72-4562-b260-28fe9773b63c" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_e0771c99-f4d6-480e-be34-d011d58ed4b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock_1fbf863d-bb17-421b-bdc9-cf023b5d9d37" xlink:href="mgnx-20231231.xsd#mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fc2ff69f-bd72-4562-b260-28fe9773b63c" xlink:to="loc_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock_1fbf863d-bb17-421b-bdc9-cf023b5d9d37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_86e14075-e85f-46e3-b6bc-b376b3be61b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fc2ff69f-bd72-4562-b260-28fe9773b63c" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_86e14075-e85f-46e3-b6bc-b376b3be61b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecuritiesTables" xlink:type="simple" xlink:href="mgnx-20231231.xsd#MarketableSecuritiesTables"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/MarketableSecuritiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_464b3035-75be-43d9-b6dd-81487c54ae52" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_f57943c1-9656-4322-b2ce-48ea2c7f9a56" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_464b3035-75be-43d9-b6dd-81487c54ae52" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_f57943c1-9656-4322-b2ce-48ea2c7f9a56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/InventoryNetTables" xlink:type="simple" xlink:href="mgnx-20231231.xsd#InventoryNetTables"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/InventoryNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_f20fdcb6-2997-42f9-bec2-3f4349bb920f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_b78f321b-30f3-4035-a652-3a1647f92dd2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_f20fdcb6-2997-42f9-bec2-3f4349bb920f" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_b78f321b-30f3-4035-a652-3a1647f92dd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ScheduleOfInventoryReservesTableTextBlock_7aa7f8a0-986d-469d-baa5-219018d2a50a" xlink:href="mgnx-20231231.xsd#mgnx_ScheduleOfInventoryReservesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_f20fdcb6-2997-42f9-bec2-3f4349bb920f" xlink:to="loc_mgnx_ScheduleOfInventoryReservesTableTextBlock_7aa7f8a0-986d-469d-baa5-219018d2a50a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/PropertyEquipmentandSoftwareTables" xlink:type="simple" xlink:href="mgnx-20231231.xsd#PropertyEquipmentandSoftwareTables"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/PropertyEquipmentandSoftwareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_b06bbfa6-1a7d-4d60-8037-499b2a2ef112" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_bfa5c5ef-0508-45f1-bbd8-aea62ad8e60f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_b06bbfa6-1a7d-4d60-8037-499b2a2ef112" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_bfa5c5ef-0508-45f1-bbd8-aea62ad8e60f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="mgnx-20231231.xsd#CommitmentsandContingenciesTables"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CommitmentsandContingenciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9be780b6-4ac7-4e75-9426-887e91a38b75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ScheduleOfSupplementalBalanceSheetInformationOperatingLeasesTableTextBlock_070f695f-1715-4946-ae93-df6470d0909e" xlink:href="mgnx-20231231.xsd#mgnx_ScheduleOfSupplementalBalanceSheetInformationOperatingLeasesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9be780b6-4ac7-4e75-9426-887e91a38b75" xlink:to="loc_mgnx_ScheduleOfSupplementalBalanceSheetInformationOperatingLeasesTableTextBlock_070f695f-1715-4946-ae93-df6470d0909e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_c6e6e2b4-98b6-40ea-82a2-efdc53bd54cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9be780b6-4ac7-4e75-9426-887e91a38b75" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_c6e6e2b4-98b6-40ea-82a2-efdc53bd54cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_9f5416d1-a5de-4d6f-9e80-f3aa48857b49" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9be780b6-4ac7-4e75-9426-887e91a38b75" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_9f5416d1-a5de-4d6f-9e80-f3aa48857b49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/RoyaltyMonetizationArrangementTables" xlink:type="simple" xlink:href="mgnx-20231231.xsd#RoyaltyMonetizationArrangementTables"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/RoyaltyMonetizationArrangementTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RoyaltyMonetizationArrangementAbstract_7869275c-b54e-421e-bba8-1670145237c8" xlink:href="mgnx-20231231.xsd#mgnx_RoyaltyMonetizationArrangementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_LiabilityRelatedToFutureRoyaltyTableTextBlock_17c60ef2-c7cc-45e3-97db-48acf5d0cff9" xlink:href="mgnx-20231231.xsd#mgnx_LiabilityRelatedToFutureRoyaltyTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_RoyaltyMonetizationArrangementAbstract_7869275c-b54e-421e-bba8-1670145237c8" xlink:to="loc_mgnx_LiabilityRelatedToFutureRoyaltyTableTextBlock_17c60ef2-c7cc-45e3-97db-48acf5d0cff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockbasedCompensationTables" xlink:type="simple" xlink:href="mgnx-20231231.xsd#StockbasedCompensationTables"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockbasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c751b630-e6aa-4923-8984-1fce68f93d09" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_28614f76-7d90-46b8-9f0e-4cca15698173" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c751b630-e6aa-4923-8984-1fce68f93d09" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_28614f76-7d90-46b8-9f0e-4cca15698173" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_5c714842-df70-433d-a018-70a9581102ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c751b630-e6aa-4923-8984-1fce68f93d09" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_5c714842-df70-433d-a018-70a9581102ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_9ea2b08b-2fc5-4560-9450-359e57efd484" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c751b630-e6aa-4923-8984-1fce68f93d09" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_9ea2b08b-2fc5-4560-9450-359e57efd484" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_13334d41-468b-42ee-a98c-91b914f8e6e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c751b630-e6aa-4923-8984-1fce68f93d09" xlink:to="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_13334d41-468b-42ee-a98c-91b914f8e6e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="mgnx-20231231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_d6c16d80-21aa-4961-ad0c-73d95e233a86" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_b154559a-96d4-41d3-b2e1-6bfe42f8190c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d6c16d80-21aa-4961-ad0c-73d95e233a86" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_b154559a-96d4-41d3-b2e1-6bfe42f8190c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfValuationAllowanceTextBlock_744a98b4-46a0-4ee6-8544-2a66354236f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d6c16d80-21aa-4961-ad0c-73d95e233a86" xlink:to="loc_us-gaap_SummaryOfValuationAllowanceTextBlock_744a98b4-46a0-4ee6-8544-2a66354236f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_9cc6f898-05a8-424f-8290-ea9950688434" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d6c16d80-21aa-4961-ad0c-73d95e233a86" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_9cc6f898-05a8-424f-8290-ea9950688434" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_427c641f-1aaa-4338-acb5-5a80b2216496" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d6c16d80-21aa-4961-ad0c-73d95e233a86" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_427c641f-1aaa-4338-acb5-5a80b2216496" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="mgnx-20231231.xsd#SummaryofSignificantAccountingPoliciesDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_22f2f41c-e8ca-4112-b5ae-f6b02ce4d87a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_73eb8dd8-2709-4214-a3e9-40fa8194b834" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_22f2f41c-e8ca-4112-b5ae-f6b02ce4d87a" xlink:to="loc_us-gaap_NumberOfOperatingSegments_73eb8dd8-2709-4214-a3e9-40fa8194b834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails" xlink:type="simple" xlink:href="mgnx-20231231.xsd#SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_d8411389-c526-459b-ad40-de9a2a8be4c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0f4d55ed-c2e2-4802-9e2d-ef0b573249a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d8411389-c526-459b-ad40-de9a2a8be4c5" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0f4d55ed-c2e2-4802-9e2d-ef0b573249a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4667ad3e-49f5-45cd-92d4-de63bbed65cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0f4d55ed-c2e2-4802-9e2d-ef0b573249a2" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4667ad3e-49f5-45cd-92d4-de63bbed65cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9b05cb24-1883-4715-a969-231f8210f3cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4667ad3e-49f5-45cd-92d4-de63bbed65cc" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9b05cb24-1883-4715-a969-231f8210f3cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_48d630b1-aa00-41b9-a31f-a5d04d3df76b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9b05cb24-1883-4715-a969-231f8210f3cd" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_48d630b1-aa00-41b9-a31f-a5d04d3df76b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_218a0c26-0eb6-4536-ac20-f43b5a48ffcd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9b05cb24-1883-4715-a969-231f8210f3cd" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_218a0c26-0eb6-4536-ac20-f43b5a48ffcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_c55be5bc-4deb-4afb-ac9e-c6ba2347bef2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0f4d55ed-c2e2-4802-9e2d-ef0b573249a2" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_c55be5bc-4deb-4afb-ac9e-c6ba2347bef2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_dfc272bc-9e96-43d1-a7b4-ce1daed052ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_c55be5bc-4deb-4afb-ac9e-c6ba2347bef2" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_dfc272bc-9e96-43d1-a7b4-ce1daed052ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_2ad62ccb-7e80-42b2-af25-5f30aa3aa973" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_dfc272bc-9e96-43d1-a7b4-ce1daed052ef" xlink:to="loc_us-gaap_MoneyMarketFundsMember_2ad62ccb-7e80-42b2-af25-5f30aa3aa973" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_ff963dc7-63bc-4555-b127-9e1f0e487755" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_dfc272bc-9e96-43d1-a7b4-ce1daed052ef" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_ff963dc7-63bc-4555-b127-9e1f0e487755" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_cc56595c-48c5-4ed4-90cd-6333c96e8fa3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_dfc272bc-9e96-43d1-a7b4-ce1daed052ef" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_cc56595c-48c5-4ed4-90cd-6333c96e8fa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_d7258c22-b42f-4cda-99ac-3e4eaff2f1d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_dfc272bc-9e96-43d1-a7b4-ce1daed052ef" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_d7258c22-b42f-4cda-99ac-3e4eaff2f1d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_744f28b8-d19b-4253-a902-f936badc937b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0f4d55ed-c2e2-4802-9e2d-ef0b573249a2" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_744f28b8-d19b-4253-a902-f936badc937b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_fcaf6c59-3d30-47c2-8b3c-4c972f4f9211" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_744f28b8-d19b-4253-a902-f936badc937b" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_fcaf6c59-3d30-47c2-8b3c-4c972f4f9211" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_5f8deedb-8926-45ad-8c6d-862fe2cb7b2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_fcaf6c59-3d30-47c2-8b3c-4c972f4f9211" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_5f8deedb-8926-45ad-8c6d-862fe2cb7b2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d8dac65d-34c8-49c1-98df-0a89e53c4879" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0f4d55ed-c2e2-4802-9e2d-ef0b573249a2" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d8dac65d-34c8-49c1-98df-0a89e53c4879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_e95f966c-3041-489a-8c7b-ca05581fad77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d8dac65d-34c8-49c1-98df-0a89e53c4879" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_e95f966c-3041-489a-8c7b-ca05581fad77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_63c876b7-bcbe-424f-b9ec-932549fbbaa0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_e95f966c-3041-489a-8c7b-ca05581fad77" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_63c876b7-bcbe-424f-b9ec-932549fbbaa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2f44cee3-c510-47c5-bd6b-daae14f5baa3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_e95f966c-3041-489a-8c7b-ca05581fad77" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2f44cee3-c510-47c5-bd6b-daae14f5baa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_f237fa7f-a5dd-4158-ae63-66dda54615e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_e95f966c-3041-489a-8c7b-ca05581fad77" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_f237fa7f-a5dd-4158-ae63-66dda54615e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments_cdc0c037-1388-4557-ac88-b6f5bff49ab3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Investments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d8dac65d-34c8-49c1-98df-0a89e53c4879" xlink:to="loc_us-gaap_Investments_cdc0c037-1388-4557-ac88-b6f5bff49ab3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails" xlink:type="simple" xlink:href="mgnx-20231231.xsd#SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_3972d6dd-8240-4c7a-8c33-fc69b9d767bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_38d57a6d-23a0-4f4f-9ba7-8810a73e423c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3972d6dd-8240-4c7a-8c33-fc69b9d767bd" xlink:to="loc_us-gaap_ConcentrationRiskTable_38d57a6d-23a0-4f4f-9ba7-8810a73e423c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_fb8a61fd-d564-49ec-9666-740f394e7e72" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_38d57a6d-23a0-4f4f-9ba7-8810a73e423c" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_fb8a61fd-d564-49ec-9666-740f394e7e72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_782f62ba-44a7-4527-a2dd-1f80791baabe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_fb8a61fd-d564-49ec-9666-740f394e7e72" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_782f62ba-44a7-4527-a2dd-1f80791baabe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_94f80397-7596-4216-9316-c59c1104175a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_782f62ba-44a7-4527-a2dd-1f80791baabe" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_94f80397-7596-4216-9316-c59c1104175a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_cc3cbd8b-408e-4074-95f5-7680220bbb8d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_38d57a6d-23a0-4f4f-9ba7-8810a73e423c" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_cc3cbd8b-408e-4074-95f5-7680220bbb8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_19e62664-ec44-41d7-9529-53917b660ba0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_cc3cbd8b-408e-4074-95f5-7680220bbb8d" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_19e62664-ec44-41d7-9529-53917b660ba0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_9bf6f020-9082-4f2d-a34c-c3505c061a52" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_19e62664-ec44-41d7-9529-53917b660ba0" xlink:to="loc_us-gaap_SalesRevenueNetMember_9bf6f020-9082-4f2d-a34c-c3505c061a52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_14c8c464-9c7a-46d8-b388-2922e902a4ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_19e62664-ec44-41d7-9529-53917b660ba0" xlink:to="loc_us-gaap_AccountsReceivableMember_14c8c464-9c7a-46d8-b388-2922e902a4ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_b2fa673e-381c-4f95-b5f1-633d1c325330" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_38d57a6d-23a0-4f4f-9ba7-8810a73e423c" xlink:to="loc_srt_MajorCustomersAxis_b2fa673e-381c-4f95-b5f1-633d1c325330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_05369e62-9fda-475a-adf0-0210b782a3a4" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_b2fa673e-381c-4f95-b5f1-633d1c325330" xlink:to="loc_srt_NameOfMajorCustomerDomain_05369e62-9fda-475a-adf0-0210b782a3a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteCorporationMember_3b4c5eaa-f670-4263-ace7-698e98c00455" xlink:href="mgnx-20231231.xsd#mgnx_IncyteCorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_05369e62-9fda-475a-adf0-0210b782a3a4" xlink:to="loc_mgnx_IncyteCorporationMember_3b4c5eaa-f670-4263-ace7-698e98c00455" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember_05d85d5d-704d-4b55-8e19-af09e6900cbe" xlink:href="mgnx-20231231.xsd#mgnx_McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_05369e62-9fda-475a-adf0-0210b782a3a4" xlink:to="loc_mgnx_McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember_05d85d5d-704d-4b55-8e19-af09e6900cbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CardinalHealthIncMember_542e1437-55da-4943-aa29-7f3d28fb3b35" xlink:href="mgnx-20231231.xsd#mgnx_CardinalHealthIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_05369e62-9fda-475a-adf0-0210b782a3a4" xlink:to="loc_mgnx_CardinalHealthIncMember_542e1437-55da-4943-aa29-7f3d28fb3b35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ASDHealthcareAndOncologySupplyMember_e7ab86fd-0571-49c3-a514-4861fc4f316c" xlink:href="mgnx-20231231.xsd#mgnx_ASDHealthcareAndOncologySupplyMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_05369e62-9fda-475a-adf0-0210b782a3a4" xlink:to="loc_mgnx_ASDHealthcareAndOncologySupplyMember_e7ab86fd-0571-49c3-a514-4861fc4f316c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionBioMember_af7412db-9def-459e-94a2-a8eaf2a448c1" xlink:href="mgnx-20231231.xsd#mgnx_ProventionBioMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_05369e62-9fda-475a-adf0-0210b782a3a4" xlink:to="loc_mgnx_ProventionBioMember_af7412db-9def-459e-94a2-a8eaf2a448c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabLimitedMember_c63daecc-ca37-40fc-8608-00fb3f4a71e5" xlink:href="mgnx-20231231.xsd#mgnx_ZaiLabLimitedMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_05369e62-9fda-475a-adf0-0210b782a3a4" xlink:to="loc_mgnx_ZaiLabLimitedMember_c63daecc-ca37-40fc-8608-00fb3f4a71e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IMabBiopharmaMember_ddbaac97-91dc-4ab7-9c26-6de408db3648" xlink:href="mgnx-20231231.xsd#mgnx_IMabBiopharmaMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_05369e62-9fda-475a-adf0-0210b782a3a4" xlink:to="loc_mgnx_IMabBiopharmaMember_ddbaac97-91dc-4ab7-9c26-6de408db3648" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabMember_3ee8d7ee-1cbc-4eca-b949-6b17085ea18a" xlink:href="mgnx-20231231.xsd#mgnx_ZaiLabMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_05369e62-9fda-475a-adf0-0210b782a3a4" xlink:to="loc_mgnx_ZaiLabMember_3ee8d7ee-1cbc-4eca-b949-6b17085ea18a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_8c74a141-711f-4c77-b4d8-1e0cc08e1bf3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_38d57a6d-23a0-4f4f-9ba7-8810a73e423c" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_8c74a141-711f-4c77-b4d8-1e0cc08e1bf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_ec877a29-d6dd-492c-a24a-af756d3aac30" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_8c74a141-711f-4c77-b4d8-1e0cc08e1bf3" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_ec877a29-d6dd-492c-a24a-af756d3aac30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails" xlink:type="simple" xlink:href="mgnx-20231231.xsd#SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_75cd79d3-e65f-43b5-a789-248fd5f5109c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_de34bef6-568d-466d-bf21-fe9f357c5cd2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_75cd79d3-e65f-43b5-a789-248fd5f5109c" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_de34bef6-568d-466d-bf21-fe9f357c5cd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f27c0a9f-70cb-4f99-95b4-4f5030be9f64" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_de34bef6-568d-466d-bf21-fe9f357c5cd2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f27c0a9f-70cb-4f99-95b4-4f5030be9f64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bb41e8b7-7bb0-4f10-879c-98504b29cb65" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f27c0a9f-70cb-4f99-95b4-4f5030be9f64" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bb41e8b7-7bb0-4f10-879c-98504b29cb65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_e516bc65-253f-4ee6-bc2d-db59f8860ebb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bb41e8b7-7bb0-4f10-879c-98504b29cb65" xlink:to="loc_us-gaap_ComputerEquipmentMember_e516bc65-253f-4ee6-bc2d-db59f8860ebb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_f3738924-bb63-4ddb-916a-db57ad476426" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bb41e8b7-7bb0-4f10-879c-98504b29cb65" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_f3738924-bb63-4ddb-916a-db57ad476426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_53195e0b-2e8c-4c28-848d-56f92b3d5681" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bb41e8b7-7bb0-4f10-879c-98504b29cb65" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_53195e0b-2e8c-4c28-848d-56f92b3d5681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_LaboratoryAndOfficeEquipmentMember_3f7652b6-f45c-41d5-93e9-04895f9dccea" xlink:href="mgnx-20231231.xsd#mgnx_LaboratoryAndOfficeEquipmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bb41e8b7-7bb0-4f10-879c-98504b29cb65" xlink:to="loc_mgnx_LaboratoryAndOfficeEquipmentMember_3f7652b6-f45c-41d5-93e9-04895f9dccea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b6086003-9513-48b8-bb8f-6ecd43bd63d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_de34bef6-568d-466d-bf21-fe9f357c5cd2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b6086003-9513-48b8-bb8f-6ecd43bd63d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_49b9be3b-2f25-4f5b-923d-5c93351de504" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b6086003-9513-48b8-bb8f-6ecd43bd63d5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_49b9be3b-2f25-4f5b-923d-5c93351de504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromtheCalculationofDilutedLossPerShareDetails" xlink:type="simple" xlink:href="mgnx-20231231.xsd#SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromtheCalculationofDilutedLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromtheCalculationofDilutedLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1cb9a9bd-14e2-4cb2-b864-1b689838ef28" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d801cb2b-62be-4755-bd3e-8944ffbda7e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1cb9a9bd-14e2-4cb2-b864-1b689838ef28" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d801cb2b-62be-4755-bd3e-8944ffbda7e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_74b6ef0f-7079-4945-acad-f60c64f19978" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d801cb2b-62be-4755-bd3e-8944ffbda7e3" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_74b6ef0f-7079-4945-acad-f60c64f19978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1a346431-97fa-45c0-affe-1e90cea07609" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_74b6ef0f-7079-4945-acad-f60c64f19978" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1a346431-97fa-45c0-affe-1e90cea07609" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockOptionsAndRestrictedStockUnitsMember_15c8a00d-09f2-4dda-8deb-cc77db8901f7" xlink:href="mgnx-20231231.xsd#mgnx_StockOptionsAndRestrictedStockUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1a346431-97fa-45c0-affe-1e90cea07609" xlink:to="loc_mgnx_StockOptionsAndRestrictedStockUnitsMember_15c8a00d-09f2-4dda-8deb-cc77db8901f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_17cc2768-6865-43a9-acc3-2a8e928ae7ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d801cb2b-62be-4755-bd3e-8944ffbda7e3" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_17cc2768-6865-43a9-acc3-2a8e928ae7ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_db4dd1c7-ffb5-4b02-a2f5-715cc7f6b771" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_17cc2768-6865-43a9-acc3-2a8e928ae7ef" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_db4dd1c7-ffb5-4b02-a2f5-715cc7f6b771" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecuritiesDetails" xlink:type="simple" xlink:href="mgnx-20231231.xsd#MarketableSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/MarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_12a3e885-8d4a-4e8f-9265-a7de0c2d0cbd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_948c658a-1b73-47ce-bb38-b657759508fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_12a3e885-8d4a-4e8f-9265-a7de0c2d0cbd" xlink:to="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_948c658a-1b73-47ce-bb38-b657759508fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_2cc90f6a-fba4-454c-8334-29787a6c2c8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_948c658a-1b73-47ce-bb38-b657759508fe" xlink:to="loc_us-gaap_FinancialInstrumentAxis_2cc90f6a-fba4-454c-8334-29787a6c2c8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b33e42c3-5958-4560-8eab-c42d00e349a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_2cc90f6a-fba4-454c-8334-29787a6c2c8b" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b33e42c3-5958-4560-8eab-c42d00e349a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_cef1eb60-0a80-4b8c-b69a-ed812c6a837b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b33e42c3-5958-4560-8eab-c42d00e349a8" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_cef1eb60-0a80-4b8c-b69a-ed812c6a837b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_e511c3b9-dce1-49c3-9ae7-403d5d05b2f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b33e42c3-5958-4560-8eab-c42d00e349a8" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_e511c3b9-dce1-49c3-9ae7-403d5d05b2f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_5124a559-cf30-411c-873d-b77fd67bc10b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b33e42c3-5958-4560-8eab-c42d00e349a8" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_5124a559-cf30-411c-873d-b77fd67bc10b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ea161c02-f143-48c5-8c2f-b75ed1806d33" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_948c658a-1b73-47ce-bb38-b657759508fe" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ea161c02-f143-48c5-8c2f-b75ed1806d33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a4e16237-467c-46fa-9292-8dff035964ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ea161c02-f143-48c5-8c2f-b75ed1806d33" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a4e16237-467c-46fa-9292-8dff035964ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_224448dd-8df4-486f-a9d9-105c318e9e92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ea161c02-f143-48c5-8c2f-b75ed1806d33" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_224448dd-8df4-486f-a9d9-105c318e9e92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_15b5fce7-d882-4b56-8e76-64061514008a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ea161c02-f143-48c5-8c2f-b75ed1806d33" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_15b5fce7-d882-4b56-8e76-64061514008a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d93c252a-b5cd-4551-8d1e-ac1d8a27f35b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ea161c02-f143-48c5-8c2f-b75ed1806d33" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d93c252a-b5cd-4551-8d1e-ac1d8a27f35b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecuritiesAvailableForSaleSecuritiesDetails" xlink:type="simple" xlink:href="mgnx-20231231.xsd#MarketableSecuritiesAvailableForSaleSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/MarketableSecuritiesAvailableForSaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_06fe30ad-f9cc-42b1-b815-29d2a88c960b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_d7194085-efaf-4e76-8dca-88d342a793bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_06fe30ad-f9cc-42b1-b815-29d2a88c960b" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_d7194085-efaf-4e76-8dca-88d342a793bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOther_d87bb2f1-aed3-4059-b624-22d9470d5f2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeOther"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_06fe30ad-f9cc-42b1-b815-29d2a88c960b" xlink:to="loc_us-gaap_InterestIncomeOther_d87bb2f1-aed3-4059-b624-22d9470d5f2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/InventoryNetScheduleofInventoryDetails" xlink:type="simple" xlink:href="mgnx-20231231.xsd#InventoryNetScheduleofInventoryDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/InventoryNetScheduleofInventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_99d53290-795a-4590-8ffa-cd4c08232064" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_89ef86dc-5a38-41b4-895f-f5d855a20a51" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_99d53290-795a-4590-8ffa-cd4c08232064" xlink:to="loc_us-gaap_InventoryWorkInProcess_89ef86dc-5a38-41b4-895f-f5d855a20a51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_e41de324-1303-4615-80cb-22dee8a6a53b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_99d53290-795a-4590-8ffa-cd4c08232064" xlink:to="loc_us-gaap_InventoryFinishedGoods_e41de324-1303-4615-80cb-22dee8a6a53b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_13d5884c-12ed-47b3-983e-a32389768e53" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_99d53290-795a-4590-8ffa-cd4c08232064" xlink:to="loc_us-gaap_InventoryNet_13d5884c-12ed-47b3-983e-a32389768e53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves_8a5d3e65-749a-4fd8-8495-fe7c60000990" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryValuationReserves"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_99d53290-795a-4590-8ffa-cd4c08232064" xlink:to="loc_us-gaap_InventoryValuationReserves_8a5d3e65-749a-4fd8-8495-fe7c60000990" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/InventoryNetDetails" xlink:type="simple" xlink:href="mgnx-20231231.xsd#InventoryNetDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/InventoryNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_73fefcf6-4cad-4611-a387-6f0e3e6ec735" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_dabd04cf-a138-4c4c-b6c1-14e99c56a9d0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_73fefcf6-4cad-4611-a387-6f0e3e6ec735" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_dabd04cf-a138-4c4c-b6c1-14e99c56a9d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_75638779-cb52-445b-bb37-f405dd1a7eb0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_dabd04cf-a138-4c4c-b6c1-14e99c56a9d0" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_75638779-cb52-445b-bb37-f405dd1a7eb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_71662898-f317-4807-92e6-ca179a2463b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_75638779-cb52-445b-bb37-f405dd1a7eb0" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_71662898-f317-4807-92e6-ca179a2463b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserveMember_d009929d-fb39-4e9c-9688-6bcddf04e754" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryValuationReserveMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_71662898-f317-4807-92e6-ca179a2463b4" xlink:to="loc_us-gaap_InventoryValuationReserveMember_d009929d-fb39-4e9c-9688-6bcddf04e754" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_e453ea6b-44d4-4563-bebb-9066d211f112" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_dabd04cf-a138-4c4c-b6c1-14e99c56a9d0" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_e453ea6b-44d4-4563-bebb-9066d211f112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_4d2f2866-c068-4516-96d5-d938114cd1fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_e453ea6b-44d4-4563-bebb-9066d211f112" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_4d2f2866-c068-4516-96d5-d938114cd1fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_0b48983f-f11b-4a37-babd-65d65659fb81" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_e453ea6b-44d4-4563-bebb-9066d211f112" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_0b48983f-f11b-4a37-babd-65d65659fb81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_773fb2e4-f4b0-494f-8ba6-f51d8a63db69" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_e453ea6b-44d4-4563-bebb-9066d211f112" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_773fb2e4-f4b0-494f-8ba6-f51d8a63db69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_3e410219-2dc0-4d3e-a229-45cc881a3676" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_e453ea6b-44d4-4563-bebb-9066d211f112" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_3e410219-2dc0-4d3e-a229-45cc881a3676" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails" xlink:type="simple" xlink:href="mgnx-20231231.xsd#PropertyEquipmentandSoftwareDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_abfccc29-d0f1-4f5e-a79d-c7a12e6bcb58" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_04945da0-1188-46da-a9c6-25832e91ae8f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_abfccc29-d0f1-4f5e-a79d-c7a12e6bcb58" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_04945da0-1188-46da-a9c6-25832e91ae8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6feab077-9bf5-4b8e-aec5-35a3ddfab4b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_04945da0-1188-46da-a9c6-25832e91ae8f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6feab077-9bf5-4b8e-aec5-35a3ddfab4b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_03b3f95a-1959-449e-9dfb-70385fbf04a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6feab077-9bf5-4b8e-aec5-35a3ddfab4b1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_03b3f95a-1959-449e-9dfb-70385fbf04a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_3f20b790-a045-40dc-b4a3-e9d1ec7075e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_03b3f95a-1959-449e-9dfb-70385fbf04a0" xlink:to="loc_us-gaap_ComputerEquipmentMember_3f20b790-a045-40dc-b4a3-e9d1ec7075e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_8da83d1d-ee3f-4a51-b5b5-d931194dc8e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_03b3f95a-1959-449e-9dfb-70385fbf04a0" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_8da83d1d-ee3f-4a51-b5b5-d931194dc8e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_FurnitureAndOfficeEquipmentMember_ecfb224a-56d0-4f84-87ad-f885ec21aa34" xlink:href="mgnx-20231231.xsd#mgnx_FurnitureAndOfficeEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_03b3f95a-1959-449e-9dfb-70385fbf04a0" xlink:to="loc_mgnx_FurnitureAndOfficeEquipmentMember_ecfb224a-56d0-4f84-87ad-f885ec21aa34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VehiclesMember_d48c104d-9f9b-49f2-8741-9c9b50deb274" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VehiclesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_03b3f95a-1959-449e-9dfb-70385fbf04a0" xlink:to="loc_us-gaap_VehiclesMember_d48c104d-9f9b-49f2-8741-9c9b50deb274" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_a98fa465-f727-4d40-b02a-0025b34719b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_03b3f95a-1959-449e-9dfb-70385fbf04a0" xlink:to="loc_us-gaap_EquipmentMember_a98fa465-f727-4d40-b02a-0025b34719b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_2220331a-8af9-4fcb-9207-dce54c845724" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_03b3f95a-1959-449e-9dfb-70385fbf04a0" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_2220331a-8af9-4fcb-9207-dce54c845724" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d0123bbe-ad84-451b-9623-6832cb9343cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_04945da0-1188-46da-a9c6-25832e91ae8f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d0123bbe-ad84-451b-9623-6832cb9343cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_446d3509-881a-4337-bca9-1759869055aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d0123bbe-ad84-451b-9623-6832cb9343cd" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_446d3509-881a-4337-bca9-1759869055aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_2c16b15a-2127-44a3-a80a-eaf9ad91c4ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d0123bbe-ad84-451b-9623-6832cb9343cd" xlink:to="loc_us-gaap_ConstructionInProgressGross_2c16b15a-2127-44a3-a80a-eaf9ad91c4ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_fd16f8b3-e0ef-43d8-82a1-8f01ca074ed5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d0123bbe-ad84-451b-9623-6832cb9343cd" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_fd16f8b3-e0ef-43d8-82a1-8f01ca074ed5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_b6339d1c-585b-411d-b6be-11dec1f81627" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d0123bbe-ad84-451b-9623-6832cb9343cd" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_b6339d1c-585b-411d-b6be-11dec1f81627" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_5759cacf-761b-4320-bbc6-881838d4c2ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d0123bbe-ad84-451b-9623-6832cb9343cd" xlink:to="loc_us-gaap_Depreciation_5759cacf-761b-4320-bbc6-881838d4c2ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="mgnx-20231231.xsd#CommitmentsandContingenciesDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_93f8ed4e-de4d-4ce3-8152-4ebb6917a19d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_526b7f91-1aed-4d99-a7ab-2c0492c0bc11" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_93f8ed4e-de4d-4ce3-8152-4ebb6917a19d" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_526b7f91-1aed-4d99-a7ab-2c0492c0bc11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_a3f6b652-e4d3-45f9-a043-436b1065338b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_526b7f91-1aed-4d99-a7ab-2c0492c0bc11" xlink:to="loc_srt_CounterpartyNameAxis_a3f6b652-e4d3-45f9-a043-436b1065338b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_904160e3-9443-4a9d-aa95-b5275086cca9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_a3f6b652-e4d3-45f9-a043-436b1065338b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_904160e3-9443-4a9d-aa95-b5275086cca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_SynaffixBVMember_97ce37eb-c1f8-40ba-a2af-296e38139408" xlink:href="mgnx-20231231.xsd#mgnx_SynaffixBVMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_904160e3-9443-4a9d-aa95-b5275086cca9" xlink:to="loc_mgnx_SynaffixBVMember_97ce37eb-c1f8-40ba-a2af-296e38139408" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3e3a5255-7f6e-405f-97be-22b13ece9371" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_526b7f91-1aed-4d99-a7ab-2c0492c0bc11" xlink:to="loc_srt_RangeAxis_3e3a5255-7f6e-405f-97be-22b13ece9371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_64e83c6a-8180-482b-80d0-961cc519d428" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_3e3a5255-7f6e-405f-97be-22b13ece9371" xlink:to="loc_srt_RangeMember_64e83c6a-8180-482b-80d0-961cc519d428" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_9d9a2b32-8908-48e2-9c2c-c790626badbf" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_64e83c6a-8180-482b-80d0-961cc519d428" xlink:to="loc_srt_MinimumMember_9d9a2b32-8908-48e2-9c2c-c790626badbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_0a4b84f7-05c5-4a5c-9064-e63ab5446393" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_526b7f91-1aed-4d99-a7ab-2c0492c0bc11" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_0a4b84f7-05c5-4a5c-9064-e63ab5446393" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_c3182f50-152b-4691-aed3-cc030c2f83de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0a4b84f7-05c5-4a5c-9064-e63ab5446393" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_c3182f50-152b-4691-aed3-cc030c2f83de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RightOfUseAssetAndLeaseLiabilityIncrease_2c339b05-2132-4953-b3bb-8eccc84218f9" xlink:href="mgnx-20231231.xsd#mgnx_RightOfUseAssetAndLeaseLiabilityIncrease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0a4b84f7-05c5-4a5c-9064-e63ab5446393" xlink:to="loc_mgnx_RightOfUseAssetAndLeaseLiabilityIncrease_2c339b05-2132-4953-b3bb-8eccc84218f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_caa4be35-0962-4ce0-8a3d-de1f7bf26e7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0a4b84f7-05c5-4a5c-9064-e63ab5446393" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_caa4be35-0962-4ce0-8a3d-de1f7bf26e7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate_469f9327-dd24-4ffc-b535-db145aecbd07" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0a4b84f7-05c5-4a5c-9064-e63ab5446393" xlink:to="loc_us-gaap_LesseeOperatingLeaseDiscountRate_469f9327-dd24-4ffc-b535-db145aecbd07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_4fe0a73a-1a74-4f96-8f2c-3ad8563bf76d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0a4b84f7-05c5-4a5c-9064-e63ab5446393" xlink:to="loc_us-gaap_OperatingLeasePayments_4fe0a73a-1a74-4f96-8f2c-3ad8563bf76d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_86b7417d-bf73-4bdf-ab4f-3020ea3b08aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0a4b84f7-05c5-4a5c-9064-e63ab5446393" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_86b7417d-bf73-4bdf-ab4f-3020ea3b08aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_772eeb46-d7f1-459f-9c1c-77aca8fec96a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0a4b84f7-05c5-4a5c-9064-e63ab5446393" xlink:to="loc_us-gaap_OperatingLeaseCost_772eeb46-d7f1-459f-9c1c-77aca8fec96a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_cd2dbcf8-6db8-4e86-9c00-61f6524b924f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0a4b84f7-05c5-4a5c-9064-e63ab5446393" xlink:to="loc_us-gaap_VariableLeaseCost_cd2dbcf8-6db8-4e86-9c00-61f6524b924f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_3ed73f87-80ee-407f-b743-459e397e80fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubleaseIncome"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0a4b84f7-05c5-4a5c-9064-e63ab5446393" xlink:to="loc_us-gaap_SubleaseIncome_3ed73f87-80ee-407f-b743-459e397e80fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_fce78cc1-c337-42af-ac16-1992abdcd739" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0a4b84f7-05c5-4a5c-9064-e63ab5446393" xlink:to="loc_us-gaap_LeaseCost_fce78cc1-c337-42af-ac16-1992abdcd739" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_389c8367-3f55-4604-b177-e41d85b648be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0a4b84f7-05c5-4a5c-9064-e63ab5446393" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_389c8367-3f55-4604-b177-e41d85b648be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_58e8c8d8-fbbd-4a4d-9754-cd7fd19e15af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0a4b84f7-05c5-4a5c-9064-e63ab5446393" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_58e8c8d8-fbbd-4a4d-9754-cd7fd19e15af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_c84115b6-701a-441b-9018-c6f95b29fd26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0a4b84f7-05c5-4a5c-9064-e63ab5446393" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_c84115b6-701a-441b-9018-c6f95b29fd26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_71e01921-9523-4862-92f0-cdff319eef17" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0a4b84f7-05c5-4a5c-9064-e63ab5446393" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_71e01921-9523-4862-92f0-cdff319eef17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_c8facccf-d0b4-4e03-a491-f4625b6e6480" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0a4b84f7-05c5-4a5c-9064-e63ab5446393" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_c8facccf-d0b4-4e03-a491-f4625b6e6480" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_c23442c8-777a-401f-a0fb-31b671dc02b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0a4b84f7-05c5-4a5c-9064-e63ab5446393" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_c23442c8-777a-401f-a0fb-31b671dc02b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0614ebe0-ceeb-4525-bc8c-b32e980938c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0a4b84f7-05c5-4a5c-9064-e63ab5446393" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0614ebe0-ceeb-4525-bc8c-b32e980938c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_b8e7d7b4-b24b-4ec9-8d0f-436db3d437ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0a4b84f7-05c5-4a5c-9064-e63ab5446393" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_b8e7d7b4-b24b-4ec9-8d0f-436db3d437ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_261f1fa3-bbc6-42e3-b941-579ba162b319" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0a4b84f7-05c5-4a5c-9064-e63ab5446393" xlink:to="loc_us-gaap_OperatingLeaseLiability_261f1fa3-bbc6-42e3-b941-579ba162b319" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_7b292d46-9d83-48d2-867b-fdb6fbebe9e2" xlink:href="mgnx-20231231.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0a4b84f7-05c5-4a5c-9064-e63ab5446393" xlink:to="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_7b292d46-9d83-48d2-867b-fdb6fbebe9e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_40f797ab-400a-49e9-8d56-d2389594a687" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0a4b84f7-05c5-4a5c-9064-e63ab5446393" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_40f797ab-400a-49e9-8d56-d2389594a687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/RoyaltyMonetizationArrangementDetails" xlink:type="simple" xlink:href="mgnx-20231231.xsd#RoyaltyMonetizationArrangementDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/RoyaltyMonetizationArrangementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RoyaltyMonetizationArrangementAbstract_37d6b54f-28e7-4ff6-b65e-28c29bdf0887" xlink:href="mgnx-20231231.xsd#mgnx_RoyaltyMonetizationArrangementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RoyaltyMonetizationArrangementTable_ab9307c1-2cf7-455e-86d9-8f45c35e73b8" xlink:href="mgnx-20231231.xsd#mgnx_RoyaltyMonetizationArrangementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_RoyaltyMonetizationArrangementAbstract_37d6b54f-28e7-4ff6-b65e-28c29bdf0887" xlink:to="loc_mgnx_RoyaltyMonetizationArrangementTable_ab9307c1-2cf7-455e-86d9-8f45c35e73b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_b321ec33-cac4-4265-84a1-8a499765b022" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_RoyaltyMonetizationArrangementTable_ab9307c1-2cf7-455e-86d9-8f45c35e73b8" xlink:to="loc_srt_CounterpartyNameAxis_b321ec33-cac4-4265-84a1-8a499765b022" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_375f471c-c25b-4ff8-ae31-0e2ae9fe6d95" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_b321ec33-cac4-4265-84a1-8a499765b022" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_375f471c-c25b-4ff8-ae31-0e2ae9fe6d95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DRIHealthcareAcquisitionsLPDRIMember_f789e2d2-258b-4d19-82ac-7b805338e2a5" xlink:href="mgnx-20231231.xsd#mgnx_DRIHealthcareAcquisitionsLPDRIMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_375f471c-c25b-4ff8-ae31-0e2ae9fe6d95" xlink:to="loc_mgnx_DRIHealthcareAcquisitionsLPDRIMember_f789e2d2-258b-4d19-82ac-7b805338e2a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_LiabilityRelatedToFutureRoyaltyLineItems_8771e23e-2143-4862-8d0c-68ea77cede45" xlink:href="mgnx-20231231.xsd#mgnx_LiabilityRelatedToFutureRoyaltyLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_RoyaltyMonetizationArrangementTable_ab9307c1-2cf7-455e-86d9-8f45c35e73b8" xlink:to="loc_mgnx_LiabilityRelatedToFutureRoyaltyLineItems_8771e23e-2143-4862-8d0c-68ea77cede45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_UpfrontPayment_7039b17c-4046-4b77-92eb-0faa54fefb39" xlink:href="mgnx-20231231.xsd#mgnx_UpfrontPayment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_LiabilityRelatedToFutureRoyaltyLineItems_8771e23e-2143-4862-8d0c-68ea77cede45" xlink:to="loc_mgnx_UpfrontPayment_7039b17c-4046-4b77-92eb-0faa54fefb39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromRoyaltiesPercent_f782a13e-2aa9-4398-99eb-2ad46a04b333" xlink:href="mgnx-20231231.xsd#mgnx_ProceedsfromRoyaltiesPercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_LiabilityRelatedToFutureRoyaltyLineItems_8771e23e-2143-4862-8d0c-68ea77cede45" xlink:to="loc_mgnx_ProceedsfromRoyaltiesPercent_f782a13e-2aa9-4398-99eb-2ad46a04b333" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_GainOnRoyaltyMonetizationArrangement_cd96a360-b3d5-415f-8f1e-cc4dd47483b8" xlink:href="mgnx-20231231.xsd#mgnx_GainOnRoyaltyMonetizationArrangement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_LiabilityRelatedToFutureRoyaltyLineItems_8771e23e-2143-4862-8d0c-68ea77cede45" xlink:to="loc_mgnx_GainOnRoyaltyMonetizationArrangement_cd96a360-b3d5-415f-8f1e-cc4dd47483b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_FutureRevenue_321fbb28-1d33-4727-9e64-5b56b54dfbf8" xlink:href="mgnx-20231231.xsd#mgnx_FutureRevenue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_LiabilityRelatedToFutureRoyaltyLineItems_8771e23e-2143-4862-8d0c-68ea77cede45" xlink:to="loc_mgnx_FutureRevenue_321fbb28-1d33-4727-9e64-5b56b54dfbf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TransactionCost_b7d4e526-96f4-48c3-b3d8-2b89721603f4" xlink:href="mgnx-20231231.xsd#mgnx_TransactionCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_LiabilityRelatedToFutureRoyaltyLineItems_8771e23e-2143-4862-8d0c-68ea77cede45" xlink:to="loc_mgnx_TransactionCost_b7d4e526-96f4-48c3-b3d8-2b89721603f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/RoyaltyMonetizationArrangementRollforwardDetails" xlink:type="simple" xlink:href="mgnx-20231231.xsd#RoyaltyMonetizationArrangementRollforwardDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/RoyaltyMonetizationArrangementRollforwardDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RoyaltyMonetizationArrangementAbstract_2786faee-f1b2-4177-98c4-7fcfef5cab3f" xlink:href="mgnx-20231231.xsd#mgnx_RoyaltyMonetizationArrangementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_LiabilityRelatedToFutureRoyalties_f1f5d5d3-601e-40f9-9be9-bdd9a19d9645" xlink:href="mgnx-20231231.xsd#mgnx_LiabilityRelatedToFutureRoyalties"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_RoyaltyMonetizationArrangementAbstract_2786faee-f1b2-4177-98c4-7fcfef5cab3f" xlink:to="loc_mgnx_LiabilityRelatedToFutureRoyalties_f1f5d5d3-601e-40f9-9be9-bdd9a19d9645" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsFromSaleOfFutureRoyalties_8192648a-9131-40ef-b427-531cfdef00e9" xlink:href="mgnx-20231231.xsd#mgnx_ProceedsFromSaleOfFutureRoyalties"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_RoyaltyMonetizationArrangementAbstract_2786faee-f1b2-4177-98c4-7fcfef5cab3f" xlink:to="loc_mgnx_ProceedsFromSaleOfFutureRoyalties_8192648a-9131-40ef-b427-531cfdef00e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DeferredTransactionCosts_17682230-6844-45b2-bdbd-ba08fa965c91" xlink:href="mgnx-20231231.xsd#mgnx_DeferredTransactionCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_RoyaltyMonetizationArrangementAbstract_2786faee-f1b2-4177-98c4-7fcfef5cab3f" xlink:to="loc_mgnx_DeferredTransactionCosts_17682230-6844-45b2-bdbd-ba08fa965c91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PrincipalPaymentsOnRoyaltyMonetizationArrangement_809dc1d0-3657-4399-a84d-9c21057d4caf" xlink:href="mgnx-20231231.xsd#mgnx_PrincipalPaymentsOnRoyaltyMonetizationArrangement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_RoyaltyMonetizationArrangementAbstract_2786faee-f1b2-4177-98c4-7fcfef5cab3f" xlink:to="loc_mgnx_PrincipalPaymentsOnRoyaltyMonetizationArrangement_809dc1d0-3657-4399-a84d-9c21057d4caf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonCashInterestExpenseRecognized_fba1b05a-a5c1-4058-95d8-ee0537f085b0" xlink:href="mgnx-20231231.xsd#mgnx_NonCashInterestExpenseRecognized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_RoyaltyMonetizationArrangementAbstract_2786faee-f1b2-4177-98c4-7fcfef5cab3f" xlink:to="loc_mgnx_NonCashInterestExpenseRecognized_fba1b05a-a5c1-4058-95d8-ee0537f085b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_GainOnRoyaltyMonetizationArrangement_142f8adb-d339-4ce4-b2e0-1bce74bfb008" xlink:href="mgnx-20231231.xsd#mgnx_GainOnRoyaltyMonetizationArrangement"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_RoyaltyMonetizationArrangementAbstract_2786faee-f1b2-4177-98c4-7fcfef5cab3f" xlink:to="loc_mgnx_GainOnRoyaltyMonetizationArrangement_142f8adb-d339-4ce4-b2e0-1bce74bfb008" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="mgnx-20231231.xsd#StockholdersEquityDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_988e44c5-0565-41f4-aad2-9888afdd2a20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_8cec61d6-5aa8-47ef-9ebf-04318825f3de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_988e44c5-0565-41f4-aad2-9888afdd2a20" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_8cec61d6-5aa8-47ef-9ebf-04318825f3de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_028719da-d4f8-48d1-a811-6577069cad08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_8cec61d6-5aa8-47ef-9ebf-04318825f3de" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_028719da-d4f8-48d1-a811-6577069cad08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_44f750f1-bf3b-4bbf-be7c-83bf6a59114a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_028719da-d4f8-48d1-a811-6577069cad08" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_44f750f1-bf3b-4bbf-be7c-83bf6a59114a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AtTheMarketOfferingMember_9b07bee6-3628-4cca-ac88-0cfc85637cca" xlink:href="mgnx-20231231.xsd#mgnx_AtTheMarketOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_44f750f1-bf3b-4bbf-be7c-83bf6a59114a" xlink:to="loc_mgnx_AtTheMarketOfferingMember_9b07bee6-3628-4cca-ac88-0cfc85637cca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_658260b3-5a83-4c4f-a000-29f80a567e30" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_8cec61d6-5aa8-47ef-9ebf-04318825f3de" xlink:to="loc_us-gaap_StatementClassOfStockAxis_658260b3-5a83-4c4f-a000-29f80a567e30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_aa336f64-1f53-4e09-a757-040674703173" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_658260b3-5a83-4c4f-a000-29f80a567e30" xlink:to="loc_us-gaap_ClassOfStockDomain_aa336f64-1f53-4e09-a757-040674703173" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_UndesignatedPreferredStockMember_5ed3d48d-4ca9-448f-b562-61a8a96bd7b0" xlink:href="mgnx-20231231.xsd#mgnx_UndesignatedPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_aa336f64-1f53-4e09-a757-040674703173" xlink:to="loc_mgnx_UndesignatedPreferredStockMember_5ed3d48d-4ca9-448f-b562-61a8a96bd7b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_0c0705af-6b67-4f73-bd70-56c409f57aea" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_8cec61d6-5aa8-47ef-9ebf-04318825f3de" xlink:to="loc_srt_CounterpartyNameAxis_0c0705af-6b67-4f73-bd70-56c409f57aea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_03295fed-bdf5-444f-8bfb-bcb2badbcbfb" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_0c0705af-6b67-4f73-bd70-56c409f57aea" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_03295fed-bdf5-444f-8bfb-bcb2badbcbfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteCorporationMember_206c9bc9-1e64-472c-a55c-570a90fa8505" xlink:href="mgnx-20231231.xsd#mgnx_IncyteCorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_03295fed-bdf5-444f-8bfb-bcb2badbcbfb" xlink:to="loc_mgnx_IncyteCorporationMember_206c9bc9-1e64-472c-a55c-570a90fa8505" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabMember_55356315-18bb-4615-b43f-2ef26ef792dc" xlink:href="mgnx-20231231.xsd#mgnx_ZaiLabMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_03295fed-bdf5-444f-8bfb-bcb2badbcbfb" xlink:to="loc_mgnx_ZaiLabMember_55356315-18bb-4615-b43f-2ef26ef792dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_128e4409-cd99-4406-a287-8eb46992f371" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_8cec61d6-5aa8-47ef-9ebf-04318825f3de" xlink:to="loc_srt_RangeAxis_128e4409-cd99-4406-a287-8eb46992f371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_13c41bb7-ae91-4c0f-be02-990694a1b947" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_128e4409-cd99-4406-a287-8eb46992f371" xlink:to="loc_srt_RangeMember_13c41bb7-ae91-4c0f-be02-990694a1b947" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_aee6fead-0993-47da-b1f8-ea56ed43d4b9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_13c41bb7-ae91-4c0f-be02-990694a1b947" xlink:to="loc_srt_MaximumMember_aee6fead-0993-47da-b1f8-ea56ed43d4b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_f9f8b89f-da73-4142-a606-b12f38fd5214" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_8cec61d6-5aa8-47ef-9ebf-04318825f3de" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_f9f8b89f-da73-4142-a606-b12f38fd5214" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_14d2e780-87a4-433e-bcd0-1689c7f9391b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_f9f8b89f-da73-4142-a606-b12f38fd5214" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_14d2e780-87a4-433e-bcd0-1689c7f9391b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012AgreementMember_bc1d784f-466e-40f3-a67d-d46a635dd561" xlink:href="mgnx-20231231.xsd#mgnx_IncyteMGA012AgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_14d2e780-87a4-433e-bcd0-1689c7f9391b" xlink:to="loc_mgnx_IncyteMGA012AgreementMember_bc1d784f-466e-40f3-a67d-d46a635dd561" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_A2021ZaiLabAgreementsMember_e4a0126c-7db2-4f94-8caa-bd12c575dc18" xlink:href="mgnx-20231231.xsd#mgnx_A2021ZaiLabAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_14d2e780-87a4-433e-bcd0-1689c7f9391b" xlink:to="loc_mgnx_A2021ZaiLabAgreementsMember_e4a0126c-7db2-4f94-8caa-bd12c575dc18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_3ff81396-a04d-4d2d-8f3d-205ca22b5e50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_8cec61d6-5aa8-47ef-9ebf-04318825f3de" xlink:to="loc_us-gaap_ClassOfStockLineItems_3ff81396-a04d-4d2d-8f3d-205ca22b5e50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_3120c420-8f33-4c0a-8f00-3ccc3c1a9123" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3ff81396-a04d-4d2d-8f3d-205ca22b5e50" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_3120c420-8f33-4c0a-8f00-3ccc3c1a9123" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_67ff3e82-1a88-4883-845c-533c9c203806" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3ff81396-a04d-4d2d-8f3d-205ca22b5e50" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_67ff3e82-1a88-4883-845c-533c9c203806" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_789ef9af-e64e-488f-8b13-9be0cc16a0ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3ff81396-a04d-4d2d-8f3d-205ca22b5e50" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_789ef9af-e64e-488f-8b13-9be0cc16a0ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_81a94c94-8f34-44d1-a4fd-8b6e5b9fffd6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3ff81396-a04d-4d2d-8f3d-205ca22b5e50" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_81a94c94-8f34-44d1-a4fd-8b6e5b9fffd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_059602ec-7d97-408b-8e48-a7a8ba77aa3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3ff81396-a04d-4d2d-8f3d-205ca22b5e50" xlink:to="loc_us-gaap_PreferredStockSharesIssued_059602ec-7d97-408b-8e48-a7a8ba77aa3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_42f73d63-8b2e-4841-996d-bceeadcee2fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3ff81396-a04d-4d2d-8f3d-205ca22b5e50" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_42f73d63-8b2e-4841-996d-bceeadcee2fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_75913291-bfe2-4073-862c-c18368def1cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3ff81396-a04d-4d2d-8f3d-205ca22b5e50" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_75913291-bfe2-4073-862c-c18368def1cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_03b5b40b-ee2a-4ca6-86be-4156671243e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3ff81396-a04d-4d2d-8f3d-205ca22b5e50" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_03b5b40b-ee2a-4ca6-86be-4156671243e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_27293f24-b925-4202-a1db-2c97d017e57c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3ff81396-a04d-4d2d-8f3d-205ca22b5e50" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_27293f24-b925-4202-a1db-2c97d017e57c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CommonStockMaximumAmountAvailableForIssuance_9409c801-af11-46e5-9723-d728550052a3" xlink:href="mgnx-20231231.xsd#mgnx_CommonStockMaximumAmountAvailableForIssuance"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3ff81396-a04d-4d2d-8f3d-205ca22b5e50" xlink:to="loc_mgnx_CommonStockMaximumAmountAvailableForIssuance_9409c801-af11-46e5-9723-d728550052a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_5fd74512-d40d-444e-9191-2fc1300e719f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3ff81396-a04d-4d2d-8f3d-205ca22b5e50" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_5fd74512-d40d-444e-9191-2fc1300e719f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_4196c4ad-d116-40b0-b499-2e5f8bd48b7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3ff81396-a04d-4d2d-8f3d-205ca22b5e50" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_4196c4ad-d116-40b0-b499-2e5f8bd48b7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_9596c5f5-0bdc-403a-8a1e-f4d7de3b29ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3ff81396-a04d-4d2d-8f3d-205ca22b5e50" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_9596c5f5-0bdc-403a-8a1e-f4d7de3b29ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease_7b21bceb-e429-4d6b-845e-286b3c6bbeab" xlink:href="mgnx-20231231.xsd#mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3ff81396-a04d-4d2d-8f3d-205ca22b5e50" xlink:to="loc_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease_7b21bceb-e429-4d6b-845e-286b3c6bbeab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/RevenueIncyteCorporationDetails" xlink:type="simple" xlink:href="mgnx-20231231.xsd#RevenueIncyteCorporationDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/RevenueIncyteCorporationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_f28e2fb1-8f1e-425a-9fea-bc25c03674fe" xlink:href="mgnx-20231231.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4c4fcf2c-1f94-4c8d-860f-2778ceb07dae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_f28e2fb1-8f1e-425a-9fea-bc25c03674fe" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4c4fcf2c-1f94-4c8d-860f-2778ceb07dae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_7ed15482-b7ff-48bf-b824-c8f14768c20d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4c4fcf2c-1f94-4c8d-860f-2778ceb07dae" xlink:to="loc_srt_ProductOrServiceAxis_7ed15482-b7ff-48bf-b824-c8f14768c20d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7f77762d-7d7c-4ab7-99e7-4d05120be16b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_7ed15482-b7ff-48bf-b824-c8f14768c20d" xlink:to="loc_srt_ProductsAndServicesDomain_7f77762d-7d7c-4ab7-99e7-4d05120be16b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember_7024034d-4f93-4705-8571-7801fc36e35a" xlink:href="mgnx-20231231.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7f77762d-7d7c-4ab7-99e7-4d05120be16b" xlink:to="loc_mgnx_RevenuesFromLicenseAgreementsMember_7024034d-4f93-4705-8571-7801fc36e35a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_46b14598-42b6-4e87-a568-2f7ba74c4b36" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4c4fcf2c-1f94-4c8d-860f-2778ceb07dae" xlink:to="loc_srt_RangeAxis_46b14598-42b6-4e87-a568-2f7ba74c4b36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_56728bf3-a7af-4b45-9672-c59278f4a5a6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_46b14598-42b6-4e87-a568-2f7ba74c4b36" xlink:to="loc_srt_RangeMember_56728bf3-a7af-4b45-9672-c59278f4a5a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_a7507d42-7921-4681-9d3a-2643b11b7470" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_56728bf3-a7af-4b45-9672-c59278f4a5a6" xlink:to="loc_srt_MinimumMember_a7507d42-7921-4681-9d3a-2643b11b7470" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1a3d946b-1b18-4cf7-9c93-eba30c0a5523" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_56728bf3-a7af-4b45-9672-c59278f4a5a6" xlink:to="loc_srt_MaximumMember_1a3d946b-1b18-4cf7-9c93-eba30c0a5523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_c8f2e95d-fca7-4692-97f4-ad80186cb1e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4c4fcf2c-1f94-4c8d-860f-2778ceb07dae" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_c8f2e95d-fca7-4692-97f4-ad80186cb1e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_ba9dd458-51b2-4f39-b60b-6aca927c2f39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_c8f2e95d-fca7-4692-97f4-ad80186cb1e2" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_ba9dd458-51b2-4f39-b60b-6aca927c2f39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012AgreementMember_bf67396c-164b-4b45-a428-18cc2ef76297" xlink:href="mgnx-20231231.xsd#mgnx_IncyteMGA012AgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_ba9dd458-51b2-4f39-b60b-6aca927c2f39" xlink:to="loc_mgnx_IncyteMGA012AgreementMember_bf67396c-164b-4b45-a428-18cc2ef76297" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteClinicalSupplyAgreementMember_5be417dc-e3ca-41eb-965a-0494e04f3127" xlink:href="mgnx-20231231.xsd#mgnx_IncyteClinicalSupplyAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_ba9dd458-51b2-4f39-b60b-6aca927c2f39" xlink:to="loc_mgnx_IncyteClinicalSupplyAgreementMember_5be417dc-e3ca-41eb-965a-0494e04f3127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteCommercialSupplyAgreementMember_1f2efc33-8eb0-4bdc-85fa-2212ab3c975d" xlink:href="mgnx-20231231.xsd#mgnx_IncyteCommercialSupplyAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_ba9dd458-51b2-4f39-b60b-6aca927c2f39" xlink:to="loc_mgnx_IncyteCommercialSupplyAgreementMember_1f2efc33-8eb0-4bdc-85fa-2212ab3c975d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_31300163-5479-4f2e-b344-740100218a5f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4c4fcf2c-1f94-4c8d-860f-2778ceb07dae" xlink:to="loc_srt_CounterpartyNameAxis_31300163-5479-4f2e-b344-740100218a5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_495f3eed-4eb9-4bc5-89f7-45d4ee383b73" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_31300163-5479-4f2e-b344-740100218a5f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_495f3eed-4eb9-4bc5-89f7-45d4ee383b73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteCorporationMember_53a27b57-360f-4bf4-8acd-f184f7399b6e" xlink:href="mgnx-20231231.xsd#mgnx_IncyteCorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_495f3eed-4eb9-4bc5-89f7-45d4ee383b73" xlink:to="loc_mgnx_IncyteCorporationMember_53a27b57-360f-4bf4-8acd-f184f7399b6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4746a641-20d2-43ea-bd82-b1f0c53da3c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4c4fcf2c-1f94-4c8d-860f-2778ceb07dae" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4746a641-20d2-43ea-bd82-b1f0c53da3c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_eb1acee6-b78a-4b7a-b110-b12ec28fac5e" xlink:href="mgnx-20231231.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4746a641-20d2-43ea-bd82-b1f0c53da3c3" xlink:to="loc_mgnx_NonRefundableUpfrontFees_eb1acee6-b78a-4b7a-b110-b12ec28fac5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_95529ac2-8a46-4485-840b-456a92b9b3bb" xlink:href="mgnx-20231231.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4746a641-20d2-43ea-bd82-b1f0c53da3c3" xlink:to="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_95529ac2-8a46-4485-840b-456a92b9b3bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_cef68922-98b3-4f9f-b197-b609df71c47d" xlink:href="mgnx-20231231.xsd#mgnx_PotentialCommercialMilestonePaymentsUnderAgreement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4746a641-20d2-43ea-bd82-b1f0c53da3c3" xlink:to="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_cef68922-98b3-4f9f-b197-b609df71c47d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_7b687541-d11c-4a8b-8c54-dab071ae7d81" xlink:href="mgnx-20231231.xsd#mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4746a641-20d2-43ea-bd82-b1f0c53da3c3" xlink:to="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_7b687541-d11c-4a8b-8c54-dab071ae7d81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromRoyaltiesPercent_6e50d524-beb9-465f-9822-a53d6886998a" xlink:href="mgnx-20231231.xsd#mgnx_ProceedsfromRoyaltiesPercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4746a641-20d2-43ea-bd82-b1f0c53da3c3" xlink:to="loc_mgnx_ProceedsfromRoyaltiesPercent_6e50d524-beb9-465f-9822-a53d6886998a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfPerformanceObligations_6d2edb5a-2a18-452f-945a-203e7e46e100" xlink:href="mgnx-20231231.xsd#mgnx_NumberOfPerformanceObligations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4746a641-20d2-43ea-bd82-b1f0c53da3c3" xlink:to="loc_mgnx_NumberOfPerformanceObligations_6d2edb5a-2a18-452f-945a-203e7e46e100" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementTransactionPrice_a9485451-1d25-4086-aa83-98f0a1bb84c6" xlink:href="mgnx-20231231.xsd#mgnx_CollaborativeAgreementTransactionPrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4746a641-20d2-43ea-bd82-b1f0c53da3c3" xlink:to="loc_mgnx_CollaborativeAgreementTransactionPrice_a9485451-1d25-4086-aa83-98f0a1bb84c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_8c85b9fa-1af6-439c-9290-61f75cabb818" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4746a641-20d2-43ea-bd82-b1f0c53da3c3" xlink:to="loc_us-gaap_Revenues_8c85b9fa-1af6-439c-9290-61f75cabb818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_c9775b05-74be-41f9-b9ff-2ee24dba494e" xlink:href="mgnx-20231231.xsd#mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4746a641-20d2-43ea-bd82-b1f0c53da3c3" xlink:to="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_c9775b05-74be-41f9-b9ff-2ee24dba494e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/RevenueGileadSciencesIncDetails" xlink:type="simple" xlink:href="mgnx-20231231.xsd#RevenueGileadSciencesIncDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/RevenueGileadSciencesIncDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_e40fca46-04df-453a-94ce-050fed901104" xlink:href="mgnx-20231231.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_85f5d0fd-bd92-475e-a4da-c05d9f3ae9f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_e40fca46-04df-453a-94ce-050fed901104" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_85f5d0fd-bd92-475e-a4da-c05d9f3ae9f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_8eeb5d34-0be4-40fc-a6e0-6a385d70453c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_85f5d0fd-bd92-475e-a4da-c05d9f3ae9f5" xlink:to="loc_srt_CounterpartyNameAxis_8eeb5d34-0be4-40fc-a6e0-6a385d70453c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6d4b3023-0252-4773-8f9d-46f9a82f708c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_8eeb5d34-0be4-40fc-a6e0-6a385d70453c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6d4b3023-0252-4773-8f9d-46f9a82f708c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_GileadMember_2e84776b-da5d-49e2-b70f-c639a283d5c3" xlink:href="mgnx-20231231.xsd#mgnx_GileadMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6d4b3023-0252-4773-8f9d-46f9a82f708c" xlink:to="loc_mgnx_GileadMember_2e84776b-da5d-49e2-b70f-c639a283d5c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_4a5b644c-4c4f-439a-ab04-00707b0705c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_85f5d0fd-bd92-475e-a4da-c05d9f3ae9f5" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_4a5b644c-4c4f-439a-ab04-00707b0705c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_4e9ce99a-26d9-40d0-8bc9-a5acc693e3df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_4a5b644c-4c4f-439a-ab04-00707b0705c3" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_4e9ce99a-26d9-40d0-8bc9-a5acc693e3df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_A2022GileadCollaborationAndLicenseAgreementMember_5602e14e-b2fe-488b-a518-61038f5be57f" xlink:href="mgnx-20231231.xsd#mgnx_A2022GileadCollaborationAndLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_4e9ce99a-26d9-40d0-8bc9-a5acc693e3df" xlink:to="loc_mgnx_A2022GileadCollaborationAndLicenseAgreementMember_5602e14e-b2fe-488b-a518-61038f5be57f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_GileadFirstResearchProgramMember_624558e7-2a7c-4ea6-a34b-aa97697a16b0" xlink:href="mgnx-20231231.xsd#mgnx_GileadFirstResearchProgramMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_4e9ce99a-26d9-40d0-8bc9-a5acc693e3df" xlink:to="loc_mgnx_GileadFirstResearchProgramMember_624558e7-2a7c-4ea6-a34b-aa97697a16b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4f1db51-8415-4dea-a104-4a96efe33f77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_85f5d0fd-bd92-475e-a4da-c05d9f3ae9f5" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4f1db51-8415-4dea-a104-4a96efe33f77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_f9c84c83-16a4-44fe-af52-bb6cf7b70739" xlink:href="mgnx-20231231.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4f1db51-8415-4dea-a104-4a96efe33f77" xlink:to="loc_mgnx_NonRefundableUpfrontFees_f9c84c83-16a4-44fe-af52-bb6cf7b70739" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialTargetNominationOptionFeesAndMilestonePayments_5f39744c-9f41-4d16-bf06-d0a761a42109" xlink:href="mgnx-20231231.xsd#mgnx_PotentialTargetNominationOptionFeesAndMilestonePayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4f1db51-8415-4dea-a104-4a96efe33f77" xlink:to="loc_mgnx_PotentialTargetNominationOptionFeesAndMilestonePayments_5f39744c-9f41-4d16-bf06-d0a761a42109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_f3abc706-3821-413a-8794-a0f11e233030" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4f1db51-8415-4dea-a104-4a96efe33f77" xlink:to="loc_us-gaap_Revenues_f3abc706-3821-413a-8794-a0f11e233030" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_7d62f750-b9b2-4b1d-9a0e-2a2f0fd0f41f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4f1db51-8415-4dea-a104-4a96efe33f77" xlink:to="loc_us-gaap_ContractWithCustomerLiability_7d62f750-b9b2-4b1d-9a0e-2a2f0fd0f41f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_2cf9cbff-76b0-4bc8-a600-854c4e5b53b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4f1db51-8415-4dea-a104-4a96efe33f77" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_2cf9cbff-76b0-4bc8-a600-854c4e5b53b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_00162e52-ef5d-4cc6-9a12-b6d89d1d8cd1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4f1db51-8415-4dea-a104-4a96efe33f77" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_00162e52-ef5d-4cc6-9a12-b6d89d1d8cd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_01ebd7a9-5bcd-4ca9-bda1-556987dc942f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4f1db51-8415-4dea-a104-4a96efe33f77" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_01ebd7a9-5bcd-4ca9-bda1-556987dc942f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_OptInFee_531cf01e-5ca1-457c-82fb-13b741a84f9e" xlink:href="mgnx-20231231.xsd#mgnx_OptInFee"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4f1db51-8415-4dea-a104-4a96efe33f77" xlink:to="loc_mgnx_OptInFee_531cf01e-5ca1-457c-82fb-13b741a84f9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/RevenueZaiLabDetails" xlink:type="simple" xlink:href="mgnx-20231231.xsd#RevenueZaiLabDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/RevenueZaiLabDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_af24805a-dd19-4d16-ba17-53642adaf815" xlink:href="mgnx-20231231.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4ea0e5d3-ef5c-4e13-8a3d-0925f13e0f28" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_af24805a-dd19-4d16-ba17-53642adaf815" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4ea0e5d3-ef5c-4e13-8a3d-0925f13e0f28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_2757571e-6872-4c13-ad49-eb499290b1f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4ea0e5d3-ef5c-4e13-8a3d-0925f13e0f28" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_2757571e-6872-4c13-ad49-eb499290b1f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_586c4970-82d9-4220-b484-51fc81361e93" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_2757571e-6872-4c13-ad49-eb499290b1f4" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_586c4970-82d9-4220-b484-51fc81361e93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_A2021ZaiLabAgreementsMember_da6a82ce-b658-4a79-8cbb-7970f2b7da32" xlink:href="mgnx-20231231.xsd#mgnx_A2021ZaiLabAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_586c4970-82d9-4220-b484-51fc81361e93" xlink:to="loc_mgnx_A2021ZaiLabAgreementsMember_da6a82ce-b658-4a79-8cbb-7970f2b7da32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_e5630bca-8eb4-452e-87c5-e90c7bd69982" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4ea0e5d3-ef5c-4e13-8a3d-0925f13e0f28" xlink:to="loc_srt_CounterpartyNameAxis_e5630bca-8eb4-452e-87c5-e90c7bd69982" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d5a7bc08-d3a8-43f6-85b5-fffb04d59c33" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_e5630bca-8eb4-452e-87c5-e90c7bd69982" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d5a7bc08-d3a8-43f6-85b5-fffb04d59c33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabMember_b9a68787-ca31-4dc3-a31a-1017b76f0201" xlink:href="mgnx-20231231.xsd#mgnx_ZaiLabMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d5a7bc08-d3a8-43f6-85b5-fffb04d59c33" xlink:to="loc_mgnx_ZaiLabMember_b9a68787-ca31-4dc3-a31a-1017b76f0201" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_97cdb69a-6e7a-453e-87c7-3533f6dd373d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4ea0e5d3-ef5c-4e13-8a3d-0925f13e0f28" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_97cdb69a-6e7a-453e-87c7-3533f6dd373d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_0aeef096-c68f-4421-a048-e3ad6b681eee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_97cdb69a-6e7a-453e-87c7-3533f6dd373d" xlink:to="loc_us-gaap_EquityComponentDomain_0aeef096-c68f-4421-a048-e3ad6b681eee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_41d90038-1130-4e8d-9bc2-4bb845f3d29b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0aeef096-c68f-4421-a048-e3ad6b681eee" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_41d90038-1130-4e8d-9bc2-4bb845f3d29b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8868b628-5402-4892-8138-f7dcd1dbf06f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4ea0e5d3-ef5c-4e13-8a3d-0925f13e0f28" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8868b628-5402-4892-8138-f7dcd1dbf06f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_5c973d65-b753-4b89-b114-61aa291a8af5" xlink:href="mgnx-20231231.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8868b628-5402-4892-8138-f7dcd1dbf06f" xlink:to="loc_mgnx_NonRefundableUpfrontFees_5c973d65-b753-4b89-b114-61aa291a8af5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_80cefb5e-297e-4cce-90d5-8747215dd3af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8868b628-5402-4892-8138-f7dcd1dbf06f" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_80cefb5e-297e-4cce-90d5-8747215dd3af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_69cbfdf1-ff52-4734-8a1b-3169a8898ff9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8868b628-5402-4892-8138-f7dcd1dbf06f" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_69cbfdf1-ff52-4734-8a1b-3169a8898ff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_f2521bb9-e08c-4306-b52a-0e057aa8133b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8868b628-5402-4892-8138-f7dcd1dbf06f" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_f2521bb9-e08c-4306-b52a-0e057aa8133b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementTransactionPrice_f8f17c2e-1a7a-40ad-afe7-7b92d7c6556b" xlink:href="mgnx-20231231.xsd#mgnx_CollaborativeAgreementTransactionPrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8868b628-5402-4892-8138-f7dcd1dbf06f" xlink:to="loc_mgnx_CollaborativeAgreementTransactionPrice_f8f17c2e-1a7a-40ad-afe7-7b92d7c6556b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PremiumReceivedOnStockPurchase_c5ccfd0b-cfa5-4d95-9433-3c4072abf0eb" xlink:href="mgnx-20231231.xsd#mgnx_PremiumReceivedOnStockPurchase"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8868b628-5402-4892-8138-f7dcd1dbf06f" xlink:to="loc_mgnx_PremiumReceivedOnStockPurchase_c5ccfd0b-cfa5-4d95-9433-3c4072abf0eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EstimatedReimbursementForResearchAndDevelopmentT_e81fb230-ae81-4c1c-ab9a-155fd199c9bc" xlink:href="mgnx-20231231.xsd#mgnx_EstimatedReimbursementForResearchAndDevelopmentT"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8868b628-5402-4892-8138-f7dcd1dbf06f" xlink:to="loc_mgnx_EstimatedReimbursementForResearchAndDevelopmentT_e81fb230-ae81-4c1c-ab9a-155fd199c9bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_115c1b73-2ffe-4bbe-80e2-1bc76837e39b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8868b628-5402-4892-8138-f7dcd1dbf06f" xlink:to="loc_us-gaap_Revenues_115c1b73-2ffe-4bbe-80e2-1bc76837e39b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/RevenueProventionDetails" xlink:type="simple" xlink:href="mgnx-20231231.xsd#RevenueProventionDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/RevenueProventionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_46923529-5fb4-4fa1-b121-c9900455af72" xlink:href="mgnx-20231231.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0e85fbf2-1ce9-4f44-bee5-70ddf3b2ef57" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_46923529-5fb4-4fa1-b121-c9900455af72" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0e85fbf2-1ce9-4f44-bee5-70ddf3b2ef57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_010b9c09-2bf2-4a9d-b5f1-d7a488e44210" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0e85fbf2-1ce9-4f44-bee5-70ddf3b2ef57" xlink:to="loc_srt_CounterpartyNameAxis_010b9c09-2bf2-4a9d-b5f1-d7a488e44210" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d6c669cc-3ef5-4996-aff1-a14e0a158747" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_010b9c09-2bf2-4a9d-b5f1-d7a488e44210" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d6c669cc-3ef5-4996-aff1-a14e0a158747" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionBioMember_470b60d2-2888-4684-80a6-5f7aa9a6fc0d" xlink:href="mgnx-20231231.xsd#mgnx_ProventionBioMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d6c669cc-3ef5-4996-aff1-a14e0a158747" xlink:to="loc_mgnx_ProventionBioMember_470b60d2-2888-4684-80a6-5f7aa9a6fc0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DRIHealthcareAcquisitionsLPDRIMember_afee3330-14dd-4b38-bcef-646f791cf240" xlink:href="mgnx-20231231.xsd#mgnx_DRIHealthcareAcquisitionsLPDRIMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d6c669cc-3ef5-4996-aff1-a14e0a158747" xlink:to="loc_mgnx_DRIHealthcareAcquisitionsLPDRIMember_afee3330-14dd-4b38-bcef-646f791cf240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_89ceba84-823c-4046-9e7b-fbb5b71be1f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0e85fbf2-1ce9-4f44-bee5-70ddf3b2ef57" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_89ceba84-823c-4046-9e7b-fbb5b71be1f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_b1690717-19b4-4c0b-84de-93299b7a2f18" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_89ceba84-823c-4046-9e7b-fbb5b71be1f6" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_b1690717-19b4-4c0b-84de-93299b7a2f18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionPRV3279Member_2e64d0eb-6f60-4428-8163-14bb6b1219d9" xlink:href="mgnx-20231231.xsd#mgnx_ProventionPRV3279Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_b1690717-19b4-4c0b-84de-93299b7a2f18" xlink:to="loc_mgnx_ProventionPRV3279Member_2e64d0eb-6f60-4428-8163-14bb6b1219d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionPRV031Member_2ec1ba9d-7c5f-4255-aeee-582fe87bc7af" xlink:href="mgnx-20231231.xsd#mgnx_ProventionPRV031Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_b1690717-19b4-4c0b-84de-93299b7a2f18" xlink:to="loc_mgnx_ProventionPRV031Member_2ec1ba9d-7c5f-4255-aeee-582fe87bc7af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_8fe6adaf-44e0-465a-a999-2ea1b96678e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0e85fbf2-1ce9-4f44-bee5-70ddf3b2ef57" xlink:to="loc_us-gaap_TypeOfArrangementAxis_8fe6adaf-44e0-465a-a999-2ea1b96678e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_41184408-e8c8-4d5f-a1e2-7161af6595f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8fe6adaf-44e0-465a-a999-2ea1b96678e0" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_41184408-e8c8-4d5f-a1e2-7161af6595f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionLicenseAgreementMember_59137357-f95f-451f-bbd7-51beee9c16f2" xlink:href="mgnx-20231231.xsd#mgnx_ProventionLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_41184408-e8c8-4d5f-a1e2-7161af6595f6" xlink:to="loc_mgnx_ProventionLicenseAgreementMember_59137357-f95f-451f-bbd7-51beee9c16f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AssetPurchaseAgreementMember_45fcac5e-9042-44f1-a519-3a620c15a28b" xlink:href="mgnx-20231231.xsd#mgnx_AssetPurchaseAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_41184408-e8c8-4d5f-a1e2-7161af6595f6" xlink:to="loc_mgnx_AssetPurchaseAgreementMember_45fcac5e-9042-44f1-a519-3a620c15a28b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_2e015e95-750c-46fc-b5f7-983f0e879561" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0e85fbf2-1ce9-4f44-bee5-70ddf3b2ef57" xlink:to="loc_srt_ProductOrServiceAxis_2e015e95-750c-46fc-b5f7-983f0e879561" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2d66b893-3db4-47e0-a55a-968171a711e6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_2e015e95-750c-46fc-b5f7-983f0e879561" xlink:to="loc_srt_ProductsAndServicesDomain_2d66b893-3db4-47e0-a55a-968171a711e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember_fe7de64a-f24e-4009-8f5c-2ebd73959758" xlink:href="mgnx-20231231.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2d66b893-3db4-47e0-a55a-968171a711e6" xlink:to="loc_mgnx_RevenuesFromLicenseAgreementsMember_fe7de64a-f24e-4009-8f5c-2ebd73959758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AssetPurchaseAgreementMember_5dea7763-f6a5-43f0-b882-ea575dbe930a" xlink:href="mgnx-20231231.xsd#mgnx_AssetPurchaseAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2d66b893-3db4-47e0-a55a-968171a711e6" xlink:to="loc_mgnx_AssetPurchaseAgreementMember_5dea7763-f6a5-43f0-b882-ea575dbe930a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_58349b2a-6c95-4bfc-844e-7a8889dc8d25" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2d66b893-3db4-47e0-a55a-968171a711e6" xlink:to="loc_us-gaap_RoyaltyMember_58349b2a-6c95-4bfc-844e-7a8889dc8d25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fa05a100-ebbd-4278-b230-e62ba0ef5223" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0e85fbf2-1ce9-4f44-bee5-70ddf3b2ef57" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fa05a100-ebbd-4278-b230-e62ba0ef5223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare_9fd63d8e-ca7a-492e-a857-f5b188f47221" xlink:href="mgnx-20231231.xsd#mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fa05a100-ebbd-4278-b230-e62ba0ef5223" xlink:to="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare_9fd63d8e-ca7a-492e-a857-f5b188f47221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_052c3dda-c65d-4c55-9a58-5324cc55cb7f" xlink:href="mgnx-20231231.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fa05a100-ebbd-4278-b230-e62ba0ef5223" xlink:to="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_052c3dda-c65d-4c55-9a58-5324cc55cb7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_5f11760d-9459-4edd-b750-720b3686b875" xlink:href="mgnx-20231231.xsd#mgnx_PotentialCommercialMilestonePaymentsUnderAgreement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fa05a100-ebbd-4278-b230-e62ba0ef5223" xlink:to="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_5f11760d-9459-4edd-b750-720b3686b875" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_8adf96e8-8e0d-401a-bd0c-9ebefcb2b747" xlink:href="mgnx-20231231.xsd#mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fa05a100-ebbd-4278-b230-e62ba0ef5223" xlink:to="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_8adf96e8-8e0d-401a-bd0c-9ebefcb2b747" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement_82005fe6-61e7-474b-9b93-6c61870c69ee" xlink:href="mgnx-20231231.xsd#mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fa05a100-ebbd-4278-b230-e62ba0ef5223" xlink:to="loc_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement_82005fe6-61e7-474b-9b93-6c61870c69ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementTransactionPrice_868c5518-72fc-4cea-b74b-d26680f52821" xlink:href="mgnx-20231231.xsd#mgnx_CollaborativeAgreementTransactionPrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fa05a100-ebbd-4278-b230-e62ba0ef5223" xlink:to="loc_mgnx_CollaborativeAgreementTransactionPrice_868c5518-72fc-4cea-b74b-d26680f52821" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares_5be29f04-398d-497e-aa9b-abdc3dc97045" xlink:href="mgnx-20231231.xsd#mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fa05a100-ebbd-4278-b230-e62ba0ef5223" xlink:to="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares_5be29f04-398d-497e-aa9b-abdc3dc97045" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_46341777-37e2-4bcd-815b-805728159ad4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fa05a100-ebbd-4278-b230-e62ba0ef5223" xlink:to="loc_us-gaap_Revenues_46341777-37e2-4bcd-815b-805728159ad4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_FutureRevenue_47504475-291d-465e-b235-d2d1d00ba767" xlink:href="mgnx-20231231.xsd#mgnx_FutureRevenue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fa05a100-ebbd-4278-b230-e62ba0ef5223" xlink:to="loc_mgnx_FutureRevenue_47504475-291d-465e-b235-d2d1d00ba767" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/RevenueManufacturingServiceAgreementsDetails" xlink:type="simple" xlink:href="mgnx-20231231.xsd#RevenueManufacturingServiceAgreementsDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/RevenueManufacturingServiceAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TextBlockAbstract_4927d51e-f047-428c-a3d9-b69924ece8e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TextBlockAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e49f182b-2361-41a8-b8a1-90d33f3a4fa0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TextBlockAbstract_4927d51e-f047-428c-a3d9-b69924ece8e5" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e49f182b-2361-41a8-b8a1-90d33f3a4fa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_ba6a6d49-52c6-435d-9873-920027eb20cf" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e49f182b-2361-41a8-b8a1-90d33f3a4fa0" xlink:to="loc_srt_CounterpartyNameAxis_ba6a6d49-52c6-435d-9873-920027eb20cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a3234af6-514e-4a12-a04a-b08edc86ad81" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_ba6a6d49-52c6-435d-9873-920027eb20cf" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a3234af6-514e-4a12-a04a-b08edc86ad81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteCorporationMember_a452ebe8-fdf8-434f-93ea-ea930d8fc11a" xlink:href="mgnx-20231231.xsd#mgnx_IncyteCorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a3234af6-514e-4a12-a04a-b08edc86ad81" xlink:to="loc_mgnx_IncyteCorporationMember_a452ebe8-fdf8-434f-93ea-ea930d8fc11a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionBioMember_14319136-3148-4703-a0d6-c140bb40f397" xlink:href="mgnx-20231231.xsd#mgnx_ProventionBioMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a3234af6-514e-4a12-a04a-b08edc86ad81" xlink:to="loc_mgnx_ProventionBioMember_14319136-3148-4703-a0d6-c140bb40f397" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_a1248d9f-f349-4139-8732-79fca21ed41a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e49f182b-2361-41a8-b8a1-90d33f3a4fa0" xlink:to="loc_us-gaap_TypeOfArrangementAxis_a1248d9f-f349-4139-8732-79fca21ed41a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bbd42043-06bd-48c0-a23d-41fa97917dd3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a1248d9f-f349-4139-8732-79fca21ed41a" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bbd42043-06bd-48c0-a23d-41fa97917dd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_014b2e7e-b61b-4a6a-a62a-a0ad8c17fdf6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bbd42043-06bd-48c0-a23d-41fa97917dd3" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_014b2e7e-b61b-4a6a-a62a-a0ad8c17fdf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_8db1214d-716e-407a-a667-e328f85eb73c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e49f182b-2361-41a8-b8a1-90d33f3a4fa0" xlink:to="loc_srt_ProductOrServiceAxis_8db1214d-716e-407a-a667-e328f85eb73c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ecef7283-2e09-4c39-8d39-818045a1f7b3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_8db1214d-716e-407a-a667-e328f85eb73c" xlink:to="loc_srt_ProductsAndServicesDomain_ecef7283-2e09-4c39-8d39-818045a1f7b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromCMOAgreementsMemberMember_afacab4a-267a-468f-aa3d-0fc1f166acaf" xlink:href="mgnx-20231231.xsd#mgnx_RevenuesFromCMOAgreementsMemberMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ecef7283-2e09-4c39-8d39-818045a1f7b3" xlink:to="loc_mgnx_RevenuesFromCMOAgreementsMemberMember_afacab4a-267a-468f-aa3d-0fc1f166acaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromCMOAmendmentAgreementMember_6239595c-404d-45af-aadf-08da6174cf23" xlink:href="mgnx-20231231.xsd#mgnx_RevenuesFromCMOAmendmentAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ecef7283-2e09-4c39-8d39-818045a1f7b3" xlink:to="loc_mgnx_RevenuesFromCMOAmendmentAgreementMember_6239595c-404d-45af-aadf-08da6174cf23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionBioCMOAgreeemntMember_befb49fa-12e0-4a0e-a105-585a656de380" xlink:href="mgnx-20231231.xsd#mgnx_ProventionBioCMOAgreeemntMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ecef7283-2e09-4c39-8d39-818045a1f7b3" xlink:to="loc_mgnx_ProventionBioCMOAgreeemntMember_befb49fa-12e0-4a0e-a105-585a656de380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_41e08c2f-a23a-4603-a60f-ddfe7fac3a1b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e49f182b-2361-41a8-b8a1-90d33f3a4fa0" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_41e08c2f-a23a-4603-a60f-ddfe7fac3a1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeArrangementTerm_bf47d965-f8be-436f-b8df-cad74821902f" xlink:href="mgnx-20231231.xsd#mgnx_CollaborativeArrangementTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_41e08c2f-a23a-4603-a60f-ddfe7fac3a1b" xlink:to="loc_mgnx_CollaborativeArrangementTerm_bf47d965-f8be-436f-b8df-cad74821902f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_16055097-6410-4ed8-9ff5-c3a181b5ddd4" xlink:href="mgnx-20231231.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_41e08c2f-a23a-4603-a60f-ddfe7fac3a1b" xlink:to="loc_mgnx_NonRefundableUpfrontFees_16055097-6410-4ed8-9ff5-c3a181b5ddd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TotalAnnualFixedPayments_c5dfb4e1-de58-4149-99dd-6bb9be068c2a" xlink:href="mgnx-20231231.xsd#mgnx_TotalAnnualFixedPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_41e08c2f-a23a-4603-a60f-ddfe7fac3a1b" xlink:to="loc_mgnx_TotalAnnualFixedPayments_c5dfb4e1-de58-4149-99dd-6bb9be068c2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeArrangementExtensionTerm_9e6b4e2c-038e-450a-b0bc-d258517ecbb7" xlink:href="mgnx-20231231.xsd#mgnx_CollaborativeArrangementExtensionTerm"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_41e08c2f-a23a-4603-a60f-ddfe7fac3a1b" xlink:to="loc_mgnx_CollaborativeArrangementExtensionTerm_9e6b4e2c-038e-450a-b0bc-d258517ecbb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AdditionalAnnualFixedPayments_c0038ced-de05-40e7-9e2b-c5dea0fa5c29" xlink:href="mgnx-20231231.xsd#mgnx_AdditionalAnnualFixedPayments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_41e08c2f-a23a-4603-a60f-ddfe7fac3a1b" xlink:to="loc_mgnx_AdditionalAnnualFixedPayments_c0038ced-de05-40e7-9e2b-c5dea0fa5c29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_c0c23799-03c4-4104-afc6-671e87e7c52d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_41e08c2f-a23a-4603-a60f-ddfe7fac3a1b" xlink:to="loc_us-gaap_Revenues_c0c23799-03c4-4104-afc6-671e87e7c52d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_df44ff43-12dd-4328-830f-c65d639fb700" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_41e08c2f-a23a-4603-a60f-ddfe7fac3a1b" xlink:to="loc_us-gaap_ContractWithCustomerLiability_df44ff43-12dd-4328-830f-c65d639fb700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_225f2cae-1c5f-434c-9d7d-c1dd0a974519" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_41e08c2f-a23a-4603-a60f-ddfe7fac3a1b" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_225f2cae-1c5f-434c-9d7d-c1dd0a974519" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_af382196-ccae-4afc-907d-a8e05e494d68" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_41e08c2f-a23a-4603-a60f-ddfe7fac3a1b" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_af382196-ccae-4afc-907d-a8e05e494d68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_UpfrontAndFixedPayments_7feab07e-4e40-45fd-8d68-a65756d2119a" xlink:href="mgnx-20231231.xsd#mgnx_UpfrontAndFixedPayments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_41e08c2f-a23a-4603-a60f-ddfe7fac3a1b" xlink:to="loc_mgnx_UpfrontAndFixedPayments_7feab07e-4e40-45fd-8d68-a65756d2119a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/RevenueNIAIDContractDetails" xlink:type="simple" xlink:href="mgnx-20231231.xsd#RevenueNIAIDContractDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/RevenueNIAIDContractDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_31dfae04-97f9-472c-8f6c-97d886bc406a" xlink:href="mgnx-20231231.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f02aaf57-4a33-45ce-9989-a99d71becd0b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_31dfae04-97f9-472c-8f6c-97d886bc406a" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f02aaf57-4a33-45ce-9989-a99d71becd0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_084d8057-1daa-41c7-bef6-1c30a85f28c0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f02aaf57-4a33-45ce-9989-a99d71becd0b" xlink:to="loc_srt_ProductOrServiceAxis_084d8057-1daa-41c7-bef6-1c30a85f28c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f35f060d-06e5-464b-b013-11f069e01551" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_084d8057-1daa-41c7-bef6-1c30a85f28c0" xlink:to="loc_srt_ProductsAndServicesDomain_f35f060d-06e5-464b-b013-11f069e01551" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromGrantsMember_0d456f57-7ca1-4577-8830-33b1f40ee787" xlink:href="mgnx-20231231.xsd#mgnx_RevenuesFromGrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f35f060d-06e5-464b-b013-11f069e01551" xlink:to="loc_mgnx_RevenuesFromGrantsMember_0d456f57-7ca1-4577-8830-33b1f40ee787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_7b2b69e9-8fb0-4d28-a166-10ae0d7ce675" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f02aaf57-4a33-45ce-9989-a99d71becd0b" xlink:to="loc_srt_CounterpartyNameAxis_7b2b69e9-8fb0-4d28-a166-10ae0d7ce675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f52d9ac6-05b3-4ae2-b942-06392ca3f9cf" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_7b2b69e9-8fb0-4d28-a166-10ae0d7ce675" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f52d9ac6-05b3-4ae2-b942-06392ca3f9cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_65d7ea02-21aa-4498-b12c-3130b1f4a06e" xlink:href="mgnx-20231231.xsd#mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f52d9ac6-05b3-4ae2-b942-06392ca3f9cf" xlink:to="loc_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_65d7ea02-21aa-4498-b12c-3130b1f4a06e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_47efd281-e019-415d-8709-007dbd87f101" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f02aaf57-4a33-45ce-9989-a99d71becd0b" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_47efd281-e019-415d-8709-007dbd87f101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfProductCandidates_d1a0ecb6-199b-4654-a67f-f4a536da35fe" xlink:href="mgnx-20231231.xsd#mgnx_NumberOfProductCandidates"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_47efd281-e019-415d-8709-007dbd87f101" xlink:to="loc_mgnx_NumberOfProductCandidates_d1a0ecb6-199b-4654-a67f-f4a536da35fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TotalPotentialValueUnderAgreement_0228667e-1805-4e87-a839-2e18ea054a69" xlink:href="mgnx-20231231.xsd#mgnx_TotalPotentialValueUnderAgreement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_47efd281-e019-415d-8709-007dbd87f101" xlink:to="loc_mgnx_TotalPotentialValueUnderAgreement_0228667e-1805-4e87-a839-2e18ea054a69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_2448a006-cb70-4fb6-9287-cbbfe8a90b85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_47efd281-e019-415d-8709-007dbd87f101" xlink:to="loc_us-gaap_Revenues_2448a006-cb70-4fb6-9287-cbbfe8a90b85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockbasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="mgnx-20231231.xsd#StockbasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockbasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_87a295f8-94b6-4622-aae1-033d9e88d717" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0a9fbbd7-bc33-436f-8b63-5f590822b30d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_87a295f8-94b6-4622-aae1-033d9e88d717" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0a9fbbd7-bc33-436f-8b63-5f590822b30d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_962cde7e-6a96-47d2-b383-016e16181e0b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0a9fbbd7-bc33-436f-8b63-5f590822b30d" xlink:to="loc_us-gaap_PlanNameAxis_962cde7e-6a96-47d2-b383-016e16181e0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_a1aa003a-34c1-411d-b9fc-f2f675ce26fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_962cde7e-6a96-47d2-b383-016e16181e0b" xlink:to="loc_us-gaap_PlanNameDomain_a1aa003a-34c1-411d-b9fc-f2f675ce26fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember_8e94177f-0281-4e95-9f25-89439d35ee10" xlink:href="mgnx-20231231.xsd#mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_a1aa003a-34c1-411d-b9fc-f2f675ce26fa" xlink:to="loc_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember_8e94177f-0281-4e95-9f25-89439d35ee10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIncentivePlan2023MemberMember_d173eb68-3283-4719-b988-64a8dab80c8b" xlink:href="mgnx-20231231.xsd#mgnx_StockIncentivePlan2023MemberMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_a1aa003a-34c1-411d-b9fc-f2f675ce26fa" xlink:to="loc_mgnx_StockIncentivePlan2023MemberMember_d173eb68-3283-4719-b988-64a8dab80c8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIncentivePlan2013Member_1b24433c-1fee-48c2-b400-f52338722161" xlink:href="mgnx-20231231.xsd#mgnx_StockIncentivePlan2013Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_a1aa003a-34c1-411d-b9fc-f2f675ce26fa" xlink:to="loc_mgnx_StockIncentivePlan2013Member_1b24433c-1fee-48c2-b400-f52338722161" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_21d4aa62-49ae-4b15-8b30-0b32a2ce5046" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0a9fbbd7-bc33-436f-8b63-5f590822b30d" xlink:to="loc_us-gaap_AwardTypeAxis_21d4aa62-49ae-4b15-8b30-0b32a2ce5046" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_96121e11-1681-4bfb-aac6-bc8f20325103" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_21d4aa62-49ae-4b15-8b30-0b32a2ce5046" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_96121e11-1681-4bfb-aac6-bc8f20325103" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_d7108a82-be44-4515-83a5-e9eb88f43836" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_96121e11-1681-4bfb-aac6-bc8f20325103" xlink:to="loc_us-gaap_EmployeeStockMember_d7108a82-be44-4515-83a5-e9eb88f43836" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_07c1c59c-7206-4cd4-8e76-4716de389c98" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_96121e11-1681-4bfb-aac6-bc8f20325103" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_07c1c59c-7206-4cd4-8e76-4716de389c98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5461c8e0-9f06-4c0c-8db9-903cc3b85be9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0a9fbbd7-bc33-436f-8b63-5f590822b30d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5461c8e0-9f06-4c0c-8db9-903cc3b85be9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_1634b8ac-12e2-4eb3-a332-8383fb1d048c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5461c8e0-9f06-4c0c-8db9-903cc3b85be9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_1634b8ac-12e2-4eb3-a332-8383fb1d048c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_5ce0a782-3078-4530-9596-1298698b812d" xlink:href="mgnx-20231231.xsd#mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5461c8e0-9f06-4c0c-8db9-903cc3b85be9" xlink:to="loc_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_5ce0a782-3078-4530-9596-1298698b812d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_98aea995-f000-473e-bd88-e3b1ac7fe76d" xlink:href="mgnx-20231231.xsd#mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5461c8e0-9f06-4c0c-8db9-903cc3b85be9" xlink:to="loc_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_98aea995-f000-473e-bd88-e3b1ac7fe76d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_5b79547b-4550-404b-a196-717547fd2dfb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5461c8e0-9f06-4c0c-8db9-903cc3b85be9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_5b79547b-4550-404b-a196-717547fd2dfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_b558f1a6-5c74-4897-a11b-8b63ffd0f263" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5461c8e0-9f06-4c0c-8db9-903cc3b85be9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_b558f1a6-5c74-4897-a11b-8b63ffd0f263" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_e2d70747-7006-41e0-a2d4-91fceaf979a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5461c8e0-9f06-4c0c-8db9-903cc3b85be9" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_e2d70747-7006-41e0-a2d4-91fceaf979a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7c53353a-6d29-46cf-9c7d-4d3cdacae1c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5461c8e0-9f06-4c0c-8db9-903cc3b85be9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7c53353a-6d29-46cf-9c7d-4d3cdacae1c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_81a803f8-4d02-4170-8806-4927606f9d2b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5461c8e0-9f06-4c0c-8db9-903cc3b85be9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_81a803f8-4d02-4170-8806-4927606f9d2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f8aa5748-7389-496c-9786-0ec58b50f9d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5461c8e0-9f06-4c0c-8db9-903cc3b85be9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f8aa5748-7389-496c-9786-0ec58b50f9d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_c795878f-9d2e-413b-aa92-62fe74cfbbcf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5461c8e0-9f06-4c0c-8db9-903cc3b85be9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_c795878f-9d2e-413b-aa92-62fe74cfbbcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_794df8b2-29e5-454b-97a3-a2fd7fd162f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5461c8e0-9f06-4c0c-8db9-903cc3b85be9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_794df8b2-29e5-454b-97a3-a2fd7fd162f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_5302655e-b788-4977-a8c1-960ea98fda5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5461c8e0-9f06-4c0c-8db9-903cc3b85be9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_5302655e-b788-4977-a8c1-960ea98fda5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="mgnx-20231231.xsd#StockbasedCompensationStockBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_69cc1a70-a11f-48d0-bb1b-c4fde7c4d227" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c4168877-4596-47d6-8d61-7b3e3901992b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_69cc1a70-a11f-48d0-bb1b-c4fde7c4d227" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c4168877-4596-47d6-8d61-7b3e3901992b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_46719c8e-38f7-455b-8921-b553c3a71609" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c4168877-4596-47d6-8d61-7b3e3901992b" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_46719c8e-38f7-455b-8921-b553c3a71609" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9d64085f-7c22-4105-8747-7def621fa442" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_46719c8e-38f7-455b-8921-b553c3a71609" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9d64085f-7c22-4105-8747-7def621fa442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_dc4b412a-a223-44c7-83c4-6a042b282002" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9d64085f-7c22-4105-8747-7def621fa442" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_dc4b412a-a223-44c7-83c4-6a042b282002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_3b420ee4-2117-49e4-974f-9c288f5e9cc1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9d64085f-7c22-4105-8747-7def621fa442" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_3b420ee4-2117-49e4-974f-9c288f5e9cc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_824957e9-a39d-4ff5-b7be-a83547530a5f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c4168877-4596-47d6-8d61-7b3e3901992b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_824957e9-a39d-4ff5-b7be-a83547530a5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_dc8ce1e5-3855-4c55-831f-7fd22797baff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_824957e9-a39d-4ff5-b7be-a83547530a5f" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_dc8ce1e5-3855-4c55-831f-7fd22797baff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails" xlink:type="simple" xlink:href="mgnx-20231231.xsd#StockbasedCompensationOptionPricingAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d14101bb-0a58-47f6-aa0c-ca138ed17d39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ac6fdf9b-73d9-443c-87f1-32938cc8b558" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d14101bb-0a58-47f6-aa0c-ca138ed17d39" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ac6fdf9b-73d9-443c-87f1-32938cc8b558" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f8ea0b14-f42d-43d8-bda5-ad0194fa3ae4" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ac6fdf9b-73d9-443c-87f1-32938cc8b558" xlink:to="loc_srt_RangeAxis_f8ea0b14-f42d-43d8-bda5-ad0194fa3ae4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_58ab4f17-3381-4493-a793-ecbb8b0fd0fa" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_f8ea0b14-f42d-43d8-bda5-ad0194fa3ae4" xlink:to="loc_srt_RangeMember_58ab4f17-3381-4493-a793-ecbb8b0fd0fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b6514423-84a2-49ba-a0bb-be471d314115" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_58ab4f17-3381-4493-a793-ecbb8b0fd0fa" xlink:to="loc_srt_MinimumMember_b6514423-84a2-49ba-a0bb-be471d314115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0697546f-6e29-4b3b-b019-a77f1edcb925" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_58ab4f17-3381-4493-a793-ecbb8b0fd0fa" xlink:to="loc_srt_MaximumMember_0697546f-6e29-4b3b-b019-a77f1edcb925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d749c301-040f-45ae-ae46-fd6ff2f03f77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ac6fdf9b-73d9-443c-87f1-32938cc8b558" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d749c301-040f-45ae-ae46-fd6ff2f03f77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3f602b55-f96a-410e-bb9d-67830255dd5f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d749c301-040f-45ae-ae46-fd6ff2f03f77" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3f602b55-f96a-410e-bb9d-67830255dd5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_634c783c-0418-4ac3-abfa-9a6040a3e6e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d749c301-040f-45ae-ae46-fd6ff2f03f77" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_634c783c-0418-4ac3-abfa-9a6040a3e6e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_33d4c678-29be-4f8f-b7ac-cb95db3d9f14" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d749c301-040f-45ae-ae46-fd6ff2f03f77" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_33d4c678-29be-4f8f-b7ac-cb95db3d9f14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_fc3f23c0-af30-4521-8991-c60c60d234a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d749c301-040f-45ae-ae46-fd6ff2f03f77" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_fc3f23c0-af30-4521-8991-c60c60d234a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails" xlink:type="simple" xlink:href="mgnx-20231231.xsd#StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2acb1124-d081-43ba-966f-df0a5834a819" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1d31942c-e2f7-4907-8af7-a2dd15823d13" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2acb1124-d081-43ba-966f-df0a5834a819" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1d31942c-e2f7-4907-8af7-a2dd15823d13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e5b8a88c-2fc4-4b31-8632-bcfd50a79133" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1d31942c-e2f7-4907-8af7-a2dd15823d13" xlink:to="loc_us-gaap_AwardTypeAxis_e5b8a88c-2fc4-4b31-8632-bcfd50a79133" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b155218b-4d3e-4f79-9b4a-f912b6571544" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_e5b8a88c-2fc4-4b31-8632-bcfd50a79133" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b155218b-4d3e-4f79-9b4a-f912b6571544" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_3f354231-f62f-44b9-9d8b-5ca08faa8c28" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b155218b-4d3e-4f79-9b4a-f912b6571544" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_3f354231-f62f-44b9-9d8b-5ca08faa8c28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_e3dc649d-285d-4823-9ddd-7d9ed214e6a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1d31942c-e2f7-4907-8af7-a2dd15823d13" xlink:to="loc_us-gaap_PlanNameAxis_e3dc649d-285d-4823-9ddd-7d9ed214e6a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_800be13f-426a-479c-ab32-5e7cdfbb61b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_e3dc649d-285d-4823-9ddd-7d9ed214e6a2" xlink:to="loc_us-gaap_PlanNameDomain_800be13f-426a-479c-ab32-5e7cdfbb61b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIncentivePlan2013Member_6231ea56-6c5f-44d8-a001-46ab84d80ca1" xlink:href="mgnx-20231231.xsd#mgnx_StockIncentivePlan2013Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_800be13f-426a-479c-ab32-5e7cdfbb61b9" xlink:to="loc_mgnx_StockIncentivePlan2013Member_6231ea56-6c5f-44d8-a001-46ab84d80ca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13a6e990-23c4-412b-bbb4-ff93ca6cbab2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1d31942c-e2f7-4907-8af7-a2dd15823d13" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13a6e990-23c4-412b-bbb4-ff93ca6cbab2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8d64c90f-0c0c-487f-9cc4-f2d1fa084517" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13a6e990-23c4-412b-bbb4-ff93ca6cbab2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8d64c90f-0c0c-487f-9cc4-f2d1fa084517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_de7fdd4a-4c35-4a88-bbff-2a23d9cf8ff3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8d64c90f-0c0c-487f-9cc4-f2d1fa084517" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_de7fdd4a-4c35-4a88-bbff-2a23d9cf8ff3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_10452ffb-db85-49a4-988a-0e73318e1170" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8d64c90f-0c0c-487f-9cc4-f2d1fa084517" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_10452ffb-db85-49a4-988a-0e73318e1170" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b71e67e7-1f56-419b-bd89-20d3de43ac3a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8d64c90f-0c0c-487f-9cc4-f2d1fa084517" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b71e67e7-1f56-419b-bd89-20d3de43ac3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_57dbfe4d-8738-4b37-8c90-519e52501ec8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8d64c90f-0c0c-487f-9cc4-f2d1fa084517" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_57dbfe4d-8738-4b37-8c90-519e52501ec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_f7bf4c40-34eb-4a92-ae08-23ad9fa8fd23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8d64c90f-0c0c-487f-9cc4-f2d1fa084517" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_f7bf4c40-34eb-4a92-ae08-23ad9fa8fd23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_06218069-0161-4b0e-8e43-08c04ea750f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8d64c90f-0c0c-487f-9cc4-f2d1fa084517" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_06218069-0161-4b0e-8e43-08c04ea750f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_eea69c83-2914-4566-a855-ae0f3d0f60a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8d64c90f-0c0c-487f-9cc4-f2d1fa084517" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_eea69c83-2914-4566-a855-ae0f3d0f60a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_a24e9e09-18a4-4645-bff3-6a7c7f9e3395" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8d64c90f-0c0c-487f-9cc4-f2d1fa084517" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_a24e9e09-18a4-4645-bff3-6a7c7f9e3395" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_034ef461-a5be-4bbd-9350-e985bdbfe884" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13a6e990-23c4-412b-bbb4-ff93ca6cbab2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_034ef461-a5be-4bbd-9350-e985bdbfe884" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8d877c75-588b-4fbc-8dc3-b4348a1b1c6a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_034ef461-a5be-4bbd-9350-e985bdbfe884" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8d877c75-588b-4fbc-8dc3-b4348a1b1c6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_68f5ae66-1e44-43c0-8f29-ba65e3f43489" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_034ef461-a5be-4bbd-9350-e985bdbfe884" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_68f5ae66-1e44-43c0-8f29-ba65e3f43489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_92c072bc-e812-4a8a-a83c-3e42ceca404f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_034ef461-a5be-4bbd-9350-e985bdbfe884" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_92c072bc-e812-4a8a-a83c-3e42ceca404f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_49c33d88-3e26-4c54-aff3-a3259d0a1244" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_034ef461-a5be-4bbd-9350-e985bdbfe884" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_49c33d88-3e26-4c54-aff3-a3259d0a1244" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_896ef6fa-7b44-489e-8847-2b9c2512977d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_034ef461-a5be-4bbd-9350-e985bdbfe884" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_896ef6fa-7b44-489e-8847-2b9c2512977d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_418942d2-8c0e-4b5b-9e4e-cd7226afc532" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_034ef461-a5be-4bbd-9350-e985bdbfe884" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_418942d2-8c0e-4b5b-9e4e-cd7226afc532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_158ba202-334c-400c-a669-f180140d4238" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_034ef461-a5be-4bbd-9350-e985bdbfe884" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_158ba202-334c-400c-a669-f180140d4238" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_e8a140fb-c0f9-4697-ba1a-bfc94f3e8b4f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_034ef461-a5be-4bbd-9350-e985bdbfe884" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_e8a140fb-c0f9-4697-ba1a-bfc94f3e8b4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_27cf5c2b-f81d-43f6-a63e-b58cd787c9a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13a6e990-23c4-412b-bbb4-ff93ca6cbab2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_27cf5c2b-f81d-43f6-a63e-b58cd787c9a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_db9a360a-30a7-4a2a-b083-4bcf00301b37" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_27cf5c2b-f81d-43f6-a63e-b58cd787c9a5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_db9a360a-30a7-4a2a-b083-4bcf00301b37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_5bd322c7-a884-404c-8b6e-e37943793583" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_27cf5c2b-f81d-43f6-a63e-b58cd787c9a5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_5bd322c7-a884-404c-8b6e-e37943793583" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_8e644a2e-1c15-4e0f-8c18-5b4dc569d334" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_27cf5c2b-f81d-43f6-a63e-b58cd787c9a5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_8e644a2e-1c15-4e0f-8c18-5b4dc569d334" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_8d42055a-db0f-4239-b36f-5090256038b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_27cf5c2b-f81d-43f6-a63e-b58cd787c9a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_8d42055a-db0f-4239-b36f-5090256038b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_bb6b7c7b-bf52-40ad-ab8d-fe1ec9bdff40" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_27cf5c2b-f81d-43f6-a63e-b58cd787c9a5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_bb6b7c7b-bf52-40ad-ab8d-fe1ec9bdff40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_4990cbb7-b80d-422a-9ed3-9ed9f9b3a1ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_27cf5c2b-f81d-43f6-a63e-b58cd787c9a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_4990cbb7-b80d-422a-9ed3-9ed9f9b3a1ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f609f40a-d698-40d1-a939-e5fdc3890fde" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13a6e990-23c4-412b-bbb4-ff93ca6cbab2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f609f40a-d698-40d1-a939-e5fdc3890fde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8a77c2ad-a7bc-487c-9d2f-5c1dd61ed9f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f609f40a-d698-40d1-a939-e5fdc3890fde" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8a77c2ad-a7bc-487c-9d2f-5c1dd61ed9f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e770aa98-f4a3-4c3e-b2dc-c0520bdded78" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f609f40a-d698-40d1-a939-e5fdc3890fde" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e770aa98-f4a3-4c3e-b2dc-c0520bdded78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_92f64b61-df24-4f64-b689-8f7baf335afc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f609f40a-d698-40d1-a939-e5fdc3890fde" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_92f64b61-df24-4f64-b689-8f7baf335afc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_ca295e9d-ba07-4768-a3a5-6c880764092a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f609f40a-d698-40d1-a939-e5fdc3890fde" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_ca295e9d-ba07-4768-a3a5-6c880764092a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_aa2f7c8f-da36-48bf-aa0e-78ec5f7b7508" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f609f40a-d698-40d1-a939-e5fdc3890fde" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_aa2f7c8f-da36-48bf-aa0e-78ec5f7b7508" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_148a669b-4cf6-4303-a6cf-3678bcd08882" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13a6e990-23c4-412b-bbb4-ff93ca6cbab2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_148a669b-4cf6-4303-a6cf-3678bcd08882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_c271d65d-856c-45ef-a93a-2c509baf3376" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_148a669b-4cf6-4303-a6cf-3678bcd08882" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_c271d65d-856c-45ef-a93a-2c509baf3376" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_139fa993-6760-432a-9e4d-b002b7e99ecd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_148a669b-4cf6-4303-a6cf-3678bcd08882" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_139fa993-6760-432a-9e4d-b002b7e99ecd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_9afe4ea9-d014-4159-b1ac-60f8f25aa68a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_148a669b-4cf6-4303-a6cf-3678bcd08882" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_9afe4ea9-d014-4159-b1ac-60f8f25aa68a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_09328cd5-407f-4c81-ab3a-dfea3e9c6180" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_148a669b-4cf6-4303-a6cf-3678bcd08882" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_09328cd5-407f-4c81-ab3a-dfea3e9c6180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_626619bf-9b8e-451f-b512-069036969961" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_148a669b-4cf6-4303-a6cf-3678bcd08882" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_626619bf-9b8e-451f-b512-069036969961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_8e95a3e2-0306-49e1-8ad5-20b44212b757" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13a6e990-23c4-412b-bbb4-ff93ca6cbab2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_8e95a3e2-0306-49e1-8ad5-20b44212b757" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_7719a031-922c-4c7f-af1f-d78a97df53a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13a6e990-23c4-412b-bbb4-ff93ca6cbab2" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_7719a031-922c-4c7f-af1f-d78a97df53a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_dc20a3dd-3d90-480f-a4b2-cbdff5224397" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13a6e990-23c4-412b-bbb4-ff93ca6cbab2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_dc20a3dd-3d90-480f-a4b2-cbdff5224397" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_5a7ff6fc-624f-4488-9a13-657c40675173" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13a6e990-23c4-412b-bbb4-ff93ca6cbab2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_5a7ff6fc-624f-4488-9a13-657c40675173" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_3f263ef1-1a46-435a-93f4-e17c2504c226" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13a6e990-23c4-412b-bbb4-ff93ca6cbab2" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_3f263ef1-1a46-435a-93f4-e17c2504c226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_019c30d7-6315-4d40-ae9c-d7b904408610" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13a6e990-23c4-412b-bbb4-ff93ca6cbab2" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_019c30d7-6315-4d40-ae9c-d7b904408610" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_fe558a6d-8b6e-49bc-b9f8-d58c45bf6222" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13a6e990-23c4-412b-bbb4-ff93ca6cbab2" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_fe558a6d-8b6e-49bc-b9f8-d58c45bf6222" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_29b83e02-8e81-4559-a6eb-96e7a4b3f9cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13a6e990-23c4-412b-bbb4-ff93ca6cbab2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_29b83e02-8e81-4559-a6eb-96e7a4b3f9cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_b160e5cd-4407-44bb-b841-dc6141300c42" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13a6e990-23c4-412b-bbb4-ff93ca6cbab2" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_b160e5cd-4407-44bb-b841-dc6141300c42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_6ec37dfd-bf5c-43c5-b718-2018f83ea242" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="simple" xlink:href="mgnx-20231231.xsd#IncomeTaxesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_62b851e8-9064-418d-968e-46de4fdd9fe5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_3c3cf31e-73ea-4829-a42c-63aff1a41479" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_62b851e8-9064-418d-968e-46de4fdd9fe5" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_3c3cf31e-73ea-4829-a42c-63aff1a41479" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_fdbad976-864a-484d-93f2-7b3a6b159bf5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_3c3cf31e-73ea-4829-a42c-63aff1a41479" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_fdbad976-864a-484d-93f2-7b3a6b159bf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_1b8876c8-bd41-49a2-b90e-cfff2d6ba696" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_fdbad976-864a-484d-93f2-7b3a6b159bf5" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_1b8876c8-bd41-49a2-b90e-cfff2d6ba696" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember_78ce14fd-3747-4b52-8f63-3c4919e85ab7" xlink:href="mgnx-20231231.xsd#mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1b8876c8-bd41-49a2-b90e-cfff2d6ba696" xlink:to="loc_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember_78ce14fd-3747-4b52-8f63-3c4919e85ab7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_a4ac5efe-dfbf-49fa-aab8-9c0a6c8ac371" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1b8876c8-bd41-49a2-b90e-cfff2d6ba696" xlink:to="loc_us-gaap_DomesticCountryMember_a4ac5efe-dfbf-49fa-aab8-9c0a6c8ac371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis_5833a1c3-3cdb-48d9-ab46-846f8466d536" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_3c3cf31e-73ea-4829-a42c-63aff1a41479" xlink:to="loc_us-gaap_TaxPeriodAxis_5833a1c3-3cdb-48d9-ab46-846f8466d536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_6d8943d1-9537-439c-be46-6725e1384b08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodAxis_5833a1c3-3cdb-48d9-ab46-846f8466d536" xlink:to="loc_us-gaap_TaxPeriodDomain_6d8943d1-9537-439c-be46-6725e1384b08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TaxYear2025To2037Member_382a85b2-429f-4e69-bf04-f3adaa0d739b" xlink:href="mgnx-20231231.xsd#mgnx_TaxYear2025To2037Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_6d8943d1-9537-439c-be46-6725e1384b08" xlink:to="loc_mgnx_TaxYear2025To2037Member_382a85b2-429f-4e69-bf04-f3adaa0d739b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IndefiniteMember_0a9801a7-1f93-4c19-a496-74cf2c4cefe2" xlink:href="mgnx-20231231.xsd#mgnx_IndefiniteMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_6d8943d1-9537-439c-be46-6725e1384b08" xlink:to="loc_mgnx_IndefiniteMember_0a9801a7-1f93-4c19-a496-74cf2c4cefe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6e724de7-7887-4d7c-95ba-37bb9b974ab7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_3c3cf31e-73ea-4829-a42c-63aff1a41479" xlink:to="loc_srt_RangeAxis_6e724de7-7887-4d7c-95ba-37bb9b974ab7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_02de64ee-4d7a-4e3b-87f1-ae5cd610fea7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_6e724de7-7887-4d7c-95ba-37bb9b974ab7" xlink:to="loc_srt_RangeMember_02de64ee-4d7a-4e3b-87f1-ae5cd610fea7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_4214acbd-1b25-4250-bfae-917d29c14603" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_02de64ee-4d7a-4e3b-87f1-ae5cd610fea7" xlink:to="loc_srt_MinimumMember_4214acbd-1b25-4250-bfae-917d29c14603" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_4326e2a7-c389-4033-a49d-6931d9671e43" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_02de64ee-4d7a-4e3b-87f1-ae5cd610fea7" xlink:to="loc_srt_MaximumMember_4326e2a7-c389-4033-a49d-6931d9671e43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationLineItems_ba3e4b63-55d0-4356-b7e1-4c4bcb15a45d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExaminationLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_3c3cf31e-73ea-4829-a42c-63aff1a41479" xlink:to="loc_us-gaap_IncomeTaxExaminationLineItems_ba3e4b63-55d0-4356-b7e1-4c4bcb15a45d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_b59bee6a-cbb0-402d-a439-b51389d346cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_ba3e4b63-55d0-4356-b7e1-4c4bcb15a45d" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_b59bee6a-cbb0-402d-a439-b51389d346cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_6f7da6a7-f891-4213-87c9-4934f2cac786" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_ba3e4b63-55d0-4356-b7e1-4c4bcb15a45d" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_6f7da6a7-f891-4213-87c9-4934f2cac786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_6c482ad8-fd7b-43cd-a15b-4e54203679a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_ba3e4b63-55d0-4356-b7e1-4c4bcb15a45d" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_6c482ad8-fd7b-43cd-a15b-4e54203679a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_3c6fae31-86a9-44fb-8b6e-207892151340" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_ba3e4b63-55d0-4356-b7e1-4c4bcb15a45d" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_3c6fae31-86a9-44fb-8b6e-207892151340" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_6861436f-6f33-40e2-947c-bdf2f7f39dac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_ba3e4b63-55d0-4356-b7e1-4c4bcb15a45d" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_6861436f-6f33-40e2-947c-bdf2f7f39dac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails" xlink:type="simple" xlink:href="mgnx-20231231.xsd#IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_ea19cd13-64f5-458c-9d83-7a5fa07634df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_f5bde6df-3908-4902-9268-b1b1113f4f1e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ea19cd13-64f5-458c-9d83-7a5fa07634df" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_f5bde6df-3908-4902-9268-b1b1113f4f1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_dd13a8c7-8359-4e0a-8881-9d10f4bfcbd0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_f5bde6df-3908-4902-9268-b1b1113f4f1e" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_dd13a8c7-8359-4e0a-8881-9d10f4bfcbd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_17fec375-32ff-4b5a-a6d7-fcd0e470d8a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_f5bde6df-3908-4902-9268-b1b1113f4f1e" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_17fec375-32ff-4b5a-a6d7-fcd0e470d8a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_ef3de82a-aaf8-4287-85cf-a64c41e27db5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_f5bde6df-3908-4902-9268-b1b1113f4f1e" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_ef3de82a-aaf8-4287-85cf-a64c41e27db5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther_0055ce2c-1edc-4899-84e8-a6de4cb9a1ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_f5bde6df-3908-4902-9268-b1b1113f4f1e" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther_0055ce2c-1edc-4899-84e8-a6de4cb9a1ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DeferredTaxAssetsOperatingLeaseLiabilities_e98cb613-14ae-48ff-a675-3523dbc159ec" xlink:href="mgnx-20231231.xsd#mgnx_DeferredTaxAssetsOperatingLeaseLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_f5bde6df-3908-4902-9268-b1b1113f4f1e" xlink:to="loc_mgnx_DeferredTaxAssetsOperatingLeaseLiabilities_e98cb613-14ae-48ff-a675-3523dbc159ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_8ff66c06-bdaf-44ae-8a93-e1e8a2df4857" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_f5bde6df-3908-4902-9268-b1b1113f4f1e" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_8ff66c06-bdaf-44ae-8a93-e1e8a2df4857" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_Section174DeferredTaxAsset_7f761737-c445-4110-8973-3734c065a88c" xlink:href="mgnx-20231231.xsd#mgnx_Section174DeferredTaxAsset"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_f5bde6df-3908-4902-9268-b1b1113f4f1e" xlink:to="loc_mgnx_Section174DeferredTaxAsset_7f761737-c445-4110-8973-3734c065a88c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_c1855180-ef6b-4e8a-8f87-ec9f3d0b94c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_f5bde6df-3908-4902-9268-b1b1113f4f1e" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_c1855180-ef6b-4e8a-8f87-ec9f3d0b94c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_1d838aa6-d910-4fa4-bff6-284d519c50c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_f5bde6df-3908-4902-9268-b1b1113f4f1e" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_1d838aa6-d910-4fa4-bff6-284d519c50c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_827cd798-5fcc-4c32-8d49-98f1c10fcc89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_f5bde6df-3908-4902-9268-b1b1113f4f1e" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_827cd798-5fcc-4c32-8d49-98f1c10fcc89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_3d4515ca-208a-4479-9d37-3820ab225753" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_f5bde6df-3908-4902-9268-b1b1113f4f1e" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_3d4515ca-208a-4479-9d37-3820ab225753" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_c0968e77-3dcc-4494-86ab-102c8aaca69a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_f5bde6df-3908-4902-9268-b1b1113f4f1e" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_c0968e77-3dcc-4494-86ab-102c8aaca69a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_55a1bac1-fe34-4277-ad7a-8fbaba49b972" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ea19cd13-64f5-458c-9d83-7a5fa07634df" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_55a1bac1-fe34-4277-ad7a-8fbaba49b972" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_142dd371-37d9-4d96-bb79-633af8068dbd" xlink:href="mgnx-20231231.xsd#mgnx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_55a1bac1-fe34-4277-ad7a-8fbaba49b972" xlink:to="loc_mgnx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_142dd371-37d9-4d96-bb79-633af8068dbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_84568754-0353-4303-a081-69202ac13075" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_55a1bac1-fe34-4277-ad7a-8fbaba49b972" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_84568754-0353-4303-a081-69202ac13075" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_ed660100-4547-4f2c-818f-aeb96d54f555" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_55a1bac1-fe34-4277-ad7a-8fbaba49b972" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_ed660100-4547-4f2c-818f-aeb96d54f555" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_73328d1d-1d63-42f6-8903-be3f66876fef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_55a1bac1-fe34-4277-ad7a-8fbaba49b972" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_73328d1d-1d63-42f6-8903-be3f66876fef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/IncomeTaxesValuationAllowanceActivityDetails" xlink:type="simple" xlink:href="mgnx-20231231.xsd#IncomeTaxesValuationAllowanceActivityDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/IncomeTaxesValuationAllowanceActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_e5b1bc3e-d93c-4ec2-b009-ea3d32d86bda" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ValuationAllowanceRollForward_857955f5-a155-4495-ab8b-2f32d7ee1070" xlink:href="mgnx-20231231.xsd#mgnx_ValuationAllowanceRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e5b1bc3e-d93c-4ec2-b009-ea3d32d86bda" xlink:to="loc_mgnx_ValuationAllowanceRollForward_857955f5-a155-4495-ab8b-2f32d7ee1070" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_c8dc5af8-52d5-4418-ae65-b5497110a783" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_ValuationAllowanceRollForward_857955f5-a155-4495-ab8b-2f32d7ee1070" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_c8dc5af8-52d5-4418-ae65-b5497110a783" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ValuationAllowanceDeferredTaxAssetIncreaseAmount_81dd27ed-22df-47e5-a337-a7f50d80460d" xlink:href="mgnx-20231231.xsd#mgnx_ValuationAllowanceDeferredTaxAssetIncreaseAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_ValuationAllowanceRollForward_857955f5-a155-4495-ab8b-2f32d7ee1070" xlink:to="loc_mgnx_ValuationAllowanceDeferredTaxAssetIncreaseAmount_81dd27ed-22df-47e5-a337-a7f50d80460d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ValuationAllowanceDeferredTaxAssetDecreaseAmount_0a2d5186-6190-4941-ba12-2f88939e309b" xlink:href="mgnx-20231231.xsd#mgnx_ValuationAllowanceDeferredTaxAssetDecreaseAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_ValuationAllowanceRollForward_857955f5-a155-4495-ab8b-2f32d7ee1070" xlink:to="loc_mgnx_ValuationAllowanceDeferredTaxAssetDecreaseAmount_0a2d5186-6190-4941-ba12-2f88939e309b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_00b56706-43fd-4f06-83cf-46acc6025f5c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_ValuationAllowanceRollForward_857955f5-a155-4495-ab8b-2f32d7ee1070" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_00b56706-43fd-4f06-83cf-46acc6025f5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails" xlink:type="simple" xlink:href="mgnx-20231231.xsd#IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_e5401a00-0c5d-4424-815a-784d2476e5a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_3cdce6ed-b6e0-45a2-a7cf-cc1bdff836b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e5401a00-0c5d-4424-815a-784d2476e5a7" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_3cdce6ed-b6e0-45a2-a7cf-cc1bdff836b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_5ce6fe7b-df82-45a6-811d-61801c5d600f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e5401a00-0c5d-4424-815a-784d2476e5a7" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_5ce6fe7b-df82-45a6-811d-61801c5d600f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount_eb5621e9-c364-4b13-8e70-d9c797e2a4f5" xlink:href="mgnx-20231231.xsd#mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e5401a00-0c5d-4424-815a-784d2476e5a7" xlink:to="loc_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount_eb5621e9-c364-4b13-8e70-d9c797e2a4f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EffectiveIncomeTaxRateReconciliationDeferredStateBlendedRateAdjustmentsAmount_4c2e59df-30e8-4cdd-b458-42d55d054c49" xlink:href="mgnx-20231231.xsd#mgnx_EffectiveIncomeTaxRateReconciliationDeferredStateBlendedRateAdjustmentsAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e5401a00-0c5d-4424-815a-784d2476e5a7" xlink:to="loc_mgnx_EffectiveIncomeTaxRateReconciliationDeferredStateBlendedRateAdjustmentsAmount_4c2e59df-30e8-4cdd-b458-42d55d054c49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_baeadd6b-61de-4ffb-b46c-75e7f6d5e360" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e5401a00-0c5d-4424-815a-784d2476e5a7" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_baeadd6b-61de-4ffb-b46c-75e7f6d5e360" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount_df75bd53-511b-46e7-9d78-4669104d6685" xlink:href="mgnx-20231231.xsd#mgnx_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e5401a00-0c5d-4424-815a-784d2476e5a7" xlink:to="loc_mgnx_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount_df75bd53-511b-46e7-9d78-4669104d6685" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_4daf49e8-757b-4bf7-9166-a9ce1249f90b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e5401a00-0c5d-4424-815a-784d2476e5a7" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_4daf49e8-757b-4bf7-9166-a9ce1249f90b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_ab80ead5-7a3c-43f5-b442-3ef54d550ceb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e5401a00-0c5d-4424-815a-784d2476e5a7" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_ab80ead5-7a3c-43f5-b442-3ef54d550ceb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_3ce7ebf6-b4b2-4b4f-9e3a-186bacc3e49f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e5401a00-0c5d-4424-815a-784d2476e5a7" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_3ce7ebf6-b4b2-4b4f-9e3a-186bacc3e49f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_81180a2e-57ce-4e5e-800c-89eef98b81a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e5401a00-0c5d-4424-815a-784d2476e5a7" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_81180a2e-57ce-4e5e-800c-89eef98b81a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/IncomeTaxesReconciliationoftheBeginningandEndingAmountofGrossUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="mgnx-20231231.xsd#IncomeTaxesReconciliationoftheBeginningandEndingAmountofGrossUnrecognizedTaxBenefitsDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/IncomeTaxesReconciliationoftheBeginningandEndingAmountofGrossUnrecognizedTaxBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_04136a1c-f6ff-40dc-9881-fc53d1638566" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_8497dbeb-814d-4958-a39b-95b3af57c205" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_04136a1c-f6ff-40dc-9881-fc53d1638566" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_8497dbeb-814d-4958-a39b-95b3af57c205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_eb34ca81-003d-40f1-9d12-bb127a210b2d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_8497dbeb-814d-4958-a39b-95b3af57c205" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_eb34ca81-003d-40f1-9d12-bb127a210b2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_55a291bf-2b75-4fb8-91a4-e836461a3404" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_8497dbeb-814d-4958-a39b-95b3af57c205" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_55a291bf-2b75-4fb8-91a4-e836461a3404" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions_841348ee-0195-4395-b382-86004381a7f4" xlink:href="mgnx-20231231.xsd#mgnx_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_8497dbeb-814d-4958-a39b-95b3af57c205" xlink:to="loc_mgnx_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions_841348ee-0195-4395-b382-86004381a7f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_f195d8dc-2068-4ded-9ffe-ee0bc3bdceb1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_8497dbeb-814d-4958-a39b-95b3af57c205" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_f195d8dc-2068-4ded-9ffe-ee0bc3bdceb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/EmployeeBenefitPlanDetails" xlink:type="simple" xlink:href="mgnx-20231231.xsd#EmployeeBenefitPlanDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/EmployeeBenefitPlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_b473a07f-265a-4e5b-ad97-d54170b442d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan_7fcdfe6f-f0fe-4ff0-8299-d469c992485d" xlink:href="mgnx-20231231.xsd#mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_b473a07f-265a-4e5b-ad97-d54170b442d4" xlink:to="loc_mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan_7fcdfe6f-f0fe-4ff0-8299-d469c992485d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_22471e4f-00cd-4629-bbd8-9d56949c4560" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_b473a07f-265a-4e5b-ad97-d54170b442d4" xlink:to="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_22471e4f-00cd-4629-bbd8-9d56949c4560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage_24cb2cc6-931e-405b-a270-7055b7e81fbe" xlink:href="mgnx-20231231.xsd#mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_b473a07f-265a-4e5b-ad97-d54170b442d4" xlink:to="loc_mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage_24cb2cc6-931e-405b-a270-7055b7e81fbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_9e7e58de-339b-4dee-84e0-05c664e5f459" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_b473a07f-265a-4e5b-ad97-d54170b442d4" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_9e7e58de-339b-4dee-84e0-05c664e5f459" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#AwardTimingDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardExrcPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardExrcPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingArrangements"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_JamesKarrelsMember" xlink:href="mgnx-20231231.xsd#mgnx_JamesKarrelsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_mgnx_JamesKarrelsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_JeffreyPetersMember" xlink:href="mgnx-20231231.xsd#mgnx_JeffreyPetersMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_mgnx_JeffreyPetersMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrByIndTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TradingArrByIndTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_TradingArrAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllTradingArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrAxis" xlink:to="loc_ecd_AllTradingArrangementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndTitle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndTitle" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrAdoptionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrAdoptionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrTerminationDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrTerminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrDuration"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompRecoveryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompRecoveryTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_RestatementDateAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonNeosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ecd_NonNeosMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDeterminationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDeterminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompAmt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_ExecutiveCategoryAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="loc_ecd_AllExecutiveCategoriesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_PeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_NonPeoNeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_AdjToCompAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllAdjToCompMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="loc_ecd_AllAdjToCompMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_MeasureAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoTotalCompAmt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TabularListTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TabularListTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_us-gaap_NetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_OtherPerfMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAmt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_MeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>mgnx-20231231_g1.jpg
<DESCRIPTION>PORTFOLIO TABLE 1
<TEXT>
begin 644 mgnx-20231231_g1.jpg
M_]C_X0#H17AI9@  34T *@    @ !@$2  ,    !  $   $:  4    !
M5@$;  4    !    7@$H  ,    !  (   (3  ,    !  $  (=I  0    !
M    9@        "0     0   )     !  B0   '    !# R,C&1 0 '
M! $" P"2A@ '    $@   ,R@   '    !# Q,#"@ 0 #     0 !  "@ @ $
M     0  %=2@ P $     0  !^"D!@ #     0          05-#24D   !3
M8W)E96YS:&]T  #_X@U824-#7U!23T9)3$4  0$   U(87!P; (0  !M;G1R
M4D="(%A96B 'Y0 %  8 #  ' "=A8W-P05!03     !!4%!,
M            ]M8  0    #3+6%P<&P
M                                 !)D97-C   !7    &)D<V-M   !
MP    >IC<')T   #K    "-W='!T   #T    !1R6%E:   #Y    !1G6%E:
M   #^    !1B6%E:   $#    !1R5%)#   $(   " QA87)G   ,+    "!V
M8V=T   ,3    #!N9&EN   ,?    #YC:&%D   ,O    "QM;6]D   ,Z
M "AV8V=P   -$    #AB5%)#   $(   " QG5%)#   $(   " QA86)G   ,
M+    "!A86=G   ,+    "!D97-C          A$:7-P;&%Y
M
M                                    ;6QU8P         F    #&AR
M2%(    2   !V&MO2U(    2   !V&YB3D\    2   !V&ED       2   !
MV&AU2%4    2   !V&-S0UH    2   !V&1A1$L    2   !V&YL3DP    2
M   !V&9I1DD    2   !V&ET250    2   !V&5S15,    2   !V')O4D\
M   2   !V&9R0T$    2   !V&%R       2   !V'5K54$    2   !V&AE
M24P    2   !V'IH5%<    2   !V'9I5DX    2   !V'-K4TL    2   !
MV'IH0TX    2   !V')U4E4    2   !V&5N1T(    2   !V&9R1E(    2
M   !V&US       2   !V&AI24X    2   !V'1H5$@    2   !V&-A15,
M   2   !V&5N054    2   !V&5S6$P    2   !V&1E1$4    2   !V&5N
M55,    2   !V'!T0E(    2   !V'!L4$P    2   !V&5L1U(    2   !
MV'-V4T4    2   !V'1R5%(    2   !V'!T4%0    2   !V&IA2E     2
M   !V !, $< ( !( $0 4@ @ #0 2P  =&5X=     !#;W!Y<FEG:'0@07!P
M;&4@26YC+BP@,C R,0  6%E:(        /,6  $    !%LI865H@
M?M0  #G?    P%A96B        !1T0  N80  !"L6%E:(        "8Q   ,
MG0  P<%C=7)V        !      %  H #P 4 !D '@ C "@ +0 R #8 .P!
M $4 2@!/ %0 60!> &, : !M '( =P!\ ($ A@"+ )  E0": )\ HP"H *T
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M]5#UWO9M]OOWBO@9^*CY./G'^E?ZY_MW_ ?\F/TI_;K^2_[<_VW__W!A<F$
M      ,    "9F8  /*G   -60  $]    I;=F-G=          !  $
M     0    $          0    $          0  ;F1I;@         V  "N
M0   3\   $2   "IP   )H    R   !0    5$   C,S  (S,P ",S,
M     '-F,S(       $,<@  !?C___,=   'N@  _7+___N=___]I    ]D
M ,!Q;6UO9        !YM  !W4  *CR;:A*                       '9C
M9W        ,    "9F8  P    )F9@ #     F9F     C,S       ",S,
M      (S,P  _^H#_D%23U0      /O*!   4X<  .&.  !OE@  _9T  (NE
M   9K0  I[0  #6\  ##PP  4<L  -_2  !MV@  \N,  "/[   <&P$ *DL!
M 'QW 0 QG $ 8L0! %/C 0"X" ( /Q4" &@> @"'1@( [G " *SF @ N7 ,
M+LP# &(C! #$B 0 (0\% ) >!0#I+ 4 =S0%  4\!0"30P4 G[P% &O!!0 W
MQ@4 <>P% */Q!0#5]@4 C/\%  P1!@#'+08 T4L& /!L!@!*C@8 \ZL& $+,
M!@"H\ 8 &!4' +LM!P#/,P<  3D' #,^!P#@8 < ?6L' #YV!P!-W0< =#\(
M &-8" "@B0@ @*0(  /%" !!R@@ ?\\( &KL" "Y' D 'V<) "_3"0#-,PH
MT90* %H'"P#U5PL ZUT+ %QD"P"::0L 3'4+ "F:"P#(HPL ^JT+ ,;_"P!0
M"0P ,Q , +(6# #P&PP +B$, &PF#  E.0P DE,,  5U# #IH0P !<H, /;O
M# !Q'@T ,DP- $A4#0 [6PT >6 - +=E#0#U:@T P6\- (UT#0!>LPT !NT-
M -+Q#0">]@T :OL- #8 #@!W"PX +#8. +Y0#@!B=0X X)$. (FX#@!MZ X
MCR / ,Q*#P#3;@\ :8T/ +:Y#P!TZ \ ?  0 -H/$ "-'A  ["P0  (Z$  %
M8A  T680 )UK$ !I<!  -740  VG$ #9JQ  I; 0 '&U$  ]NA  ";\0 -7)
M$ !O[A  "@D1 !LH$0 Y2Q$ ;I 1  [2$0"8-!( X(42  W%$@ ^ A, ,%L3
M ,J;$P"(KA, Q\P3 *GF$P 8_A, I D4 (TP% !9-10 )3H4 /$^% "]0Q0
MF(44 '#&%  \RQ0 "- 4 -34% "@V10 <^<4 $0*%0">(Q4 ($(5 !A<%0!'
M?A4 NZ,5 !SB%0 A#!8 %RP6 $1(%@#<<A8 '*86 *BT%@ 2Q!8 )](6 $?A
M%@#![Q8 ^PH7 ,</%P"3%!< 7QD7 "L>%P#\7!< I)87 '";%P \H!< "*47
M -2I%P"@NA< /MP7 "[L%P!+_1< ;PT8 "<H& "W1Q@ F&\8 &2)& !MG!@
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]T
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M$0,1 #\ _OXH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@#__T/[^* /E+]L#]MW]F#]@CX::'\8/VLOB;_PJ
MCX=>)/'.F?#71?$7_"%_$+QU]L\:ZQH'B;Q1IVB_V1\-?"?C'7;?[1H7@[Q'
M??VC=:9!I,/]G?9I[Z*\N["WNNW 9=C,SK2P^!H^WJPINM*'M*5*U.,H0<N:
MM.G'252"LG?7163M$ZD*:O-\JO;9O6WDGV/S@_XB3?\ @BM_T>?_ .:Z_M8?
M_.*KU_\ 5'B'_H7_ /EW@?\ YI,OK5#^?_R6?_R(?\1)O_!%;_H\_P#\UU_:
MP_\ G%4?ZH\0_P#0O_\ +O __-(?6J'\_P#Y+/\ ^1#_ (B3?^"*W_1Y_P#Y
MKK^UA_\ .*H_U1XA_P"A?_Y=X'_YI#ZU0_G_ /)9_P#R(?\ $2;_ ,$5O^CS
M_P#S77]K#_YQ5'^J/$/_ $+_ /R[P/\ \TA]:H?S_P#DL_\ Y$/^(DW_ ((K
M?]'G_P#FNO[6'_SBJ/\ 5'B'_H7_ /EW@?\ YI#ZU0_G_P#)9_\ R(?\1)O_
M  16_P"CS_\ S77]K#_YQ5'^J/$/_0O_ /+O _\ S2'UJA_/_P"2S_\ D0_X
MB3?^"*W_ $>?_P":Z_M8?_.*H_U1XA_Z%_\ Y=X'_P":0^M4/Y__ "6?_P B
M'_$2;_P16_Z//_\ -=?VL/\ YQ5'^J/$/_0O_P#+O __ #2'UJA_/_Y+/_Y$
M/^(DW_@BM_T>?_YKK^UA_P#.*H_U1XA_Z%__ )=X'_YI#ZU0_G_\EG_\B'_$
M2;_P16_Z//\ _-=?VL/_ )Q5'^J/$/\ T+__ "[P/_S2'UJA_/\ ^2S_ /D0
M_P"(DW_@BM_T>?\ ^:Z_M8?_ #BJ/]4>(?\ H7_^7>!_^:0^M4/Y_P#R6?\
M\B'_ !$F_P#!%;_H\_\ \UU_:P_^<51_JCQ#_P!"_P#\N\#_ /-(?6J'\_\
MY+/_ .1#_B)-_P""*W_1Y_\ YKK^UA_\XJC_ %1XA_Z%_P#Y=X'_ .:0^M4/
MY_\ R6?_ ,B'_$2;_P $5O\ H\__ ,UU_:P_^<51_JCQ#_T+_P#R[P/_ ,TA
M]:H?S_\ DL__ )$/^(DW_@BM_P!'G_\ FNO[6'_SBJ/]4>(?^A?_ .7>!_\
MFD/K5#^?_P EG_\ (A_Q$F_\$5O^CS__ #77]K#_ .<51_JCQ#_T+_\ R[P/
M_P TA]:H?S_^2S_^1#_B)-_X(K?]'G_^:Z_M8?\ SBJ/]4>(?^A?_P"7>!_^
M:0^M4/Y__)9__(A_Q$F_\$5O^CS_ /S77]K#_P"<51_JCQ#_ -"__P N\#_\
MTA]:H?S_ /DL_P#Y$/\ B)-_X(K?]'G_ /FNO[6'_P XJC_5'B'_ *%__EW@
M?_FD/K5#^?\ \EG_ /(A_P 1)O\ P16_Z//_ /-=?VL/_G%4?ZH\0_\ 0O\
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MZH\0_P#0O_\ +O __-(?6J'\_P#Y+/\ ^1#_ (B3?^"*W_1Y_P#YKK^UA_\
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M ,B'_$2;_P $5O\ H\__ ,UU_:P_^<51_JCQ#_T+_P#R[P/_ ,TA]:H?S_\
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M_P#FD/K5#^?_ ,EG_P#(A_Q$F_\ !%;_ *//_P#-=?VL/_G%4?ZH\0_]"_\
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MZ_M8?_.*H_U1XA_Z%_\ Y=X'_P":0^M4/Y__ "6?_P B'_$2;_P16_Z//_\
M-=?VL/\ YQ5'^J/$/_0O_P#+O __ #2'UJA_/_Y+/_Y$/^(DW_@BM_T>?_YK
MK^UA_P#.*H_U1XA_Z%__ )=X'_YI#ZU0_G_\EG_\B'_$2;_P16_Z//\ _-=?
MVL/_ )Q5'^J/$/\ T+__ "[P/_S2'UJA_/\ ^2S_ /D0_P"(DW_@BM_T>?\
M^:Z_M8?_ #BJ/]4>(?\ H7_^7>!_^:0^M4/Y_P#R6?\ \B'_ !$F_P#!%;_H
M\_\ \UU_:P_^<51_JCQ#_P!"_P#\N\#_ /-(?6J'\_\ Y+/_ .1#_B)-_P""
M*W_1Y_\ YKK^UA_\XJC_ %1XA_Z%_P#Y=X'_ .:0^M4/Y_\ R6?_ ,B'_$2;
M_P $5O\ H\__ ,UU_:P_^<51_JCQ#_T+_P#R[P/_ ,TA]:H?S_\ DL__ )$/
M^(DW_@BM_P!'G_\ FNO[6'_SBJ/]4>(?^A?_ .7>!_\ FD/K5#^?_P EG_\
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MC^._[1\3MI&I:\NF?V=\-/!_C+5;/_B4Z1J-U]MO[&UT\?9_(^U_:98(9._
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MEG_\B'_$2;_P16_Z//\ _-=?VL/_ )Q5'^J/$/\ T+__ "[P/_S2'UJA_/\
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M_P"(DW_@BM_T>?\ ^:Z_M8?_ #BJ/]4>(?\ H7_^7>!_^:0^M4/Y_P#R6?\
M\B'_ !$F_P#!%;_H\_\ \UU_:P_^<51_JCQ#_P!"_P#\N\#_ /-(?6J'\_\
MY+/_ .1#_B)-_P""*W_1Y_\ YKK^UA_\XJC_ %1XA_Z%_P#Y=X'_ .:0^M4/
MY_\ R6?_ ,B'_$2;_P $5O\ H\__ ,UU_:P_^<51_JCQ#_T+_P#R[P/_ ,TA
M]:H?S_\ DL__ )$/^(DW_@BM_P!'G_\ FNO[6'_SBJ/]4>(?^A?_ .7>!_\
MFD/K5#^?_P EG_\ (A_Q$F_\$5O^CS__ #77]K#_ .<51_JCQ#_T+_\ R[P/
M_P TA]:H?S_^2S_^1#_B)-_X(K?]'G_^:Z_M8?\ SBJ/]4>(?^A?_P"7>!_^
M:0^M4/Y__)9__(A_Q$F_\$5O^CS_ /S77]K#_P"<51_JCQ#_ -"__P N\#_\
MTA]:H?S_ /DL_P#Y$/\ B)-_X(K?]'G_ /FNO[6'_P XJC_5'B'_ *%__EW@
M?_FD/K5#^?\ \EG_ /(A_P 1)O\ P16_Z//_ /-=?VL/_G%4?ZH\0_\ 0O\
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MZH\0_P#0O_\ +O __-(?6J'\_P#Y+/\ ^1#_ (B3?^"*W_1Y_P#YKK^UA_\
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M ,B'_$2;_P $5O\ H\__ ,UU_:P_^<51_JCQ#_T+_P#R[P/_ ,TA]:H?S_\
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M_P#FD/K5#^?_ ,EG_P#(A_Q$F_\ !%;_ *//_P#-=?VL/_G%4?ZH\0_]"_\
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MZ_M8?_.*H_U1XA_Z%_\ Y=X'_P":0^M4/Y__ "6?_P B'_$2;_P16_Z//_\
M-=?VL/\ YQ5'^J/$/_0O_P#+O __ #2'UJA_/_Y+/_Y$/^(DW_@BM_T>?_YK
MK^UA_P#.*H_U1XA_Z%__ )=X'_YI#ZU0_G_\EG_\B'_$2;_P16_Z//\ _-=?
MVL/_ )Q5'^J/$/\ T+__ "[P/_S2'UJA_/\ ^2S_ /D0_P"(DW_@BM_T>?\
M^:Z_M8?_ #BJ/]4>(?\ H7_^7>!_^:0^M4/Y_P#R6?\ \B'_ !$F_P#!%;_H
M\_\ \UU_:P_^<51_JCQ#_P!"_P#\N\#_ /-(?6J'\_\ Y+/_ .1#_B)-_P""
M*W_1Y_\ YKK^UA_\XJC_ %1XA_Z%_P#Y=X'_ .:0^M4/Y_\ R6?_ ,B'_$2;
M_P $5O\ H\__ ,UU_:P_^<51_JCQ#_T+_P#R[P/_ ,TA]:H?S_\ DL__ )$/
M^(DW_@BM_P!'G_\ FNO[6'_SBJ/]4>(?^A?_ .7>!_\ FD/K5#^?_P EG_\
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MH_U1XA_Z%_\ Y=X'_P":0^M4/Y__ "6?_P B'_$2;_P16_Z//_\ -=?VL/\
MYQ5'^J/$/_0O_P#+O __ #2'UJA_/_Y+/_Y$/^(DW_@BM_T>?_YKK^UA_P#.
M*H_U1XA_Z%__ )=X'_YI#ZU0_G_\EG_\B'_$2;_P16_Z//\ _-=?VL/_ )Q5
M'^J/$/\ T+__ "[P/_S2'UJA_/\ ^2S_ /D0_P"(DW_@BM_T>?\ ^:Z_M8?_
M #BJ/]4>(?\ H7_^7>!_^:0^M4/Y_P#R6?\ \B'_ !$F_P#!%;_H\_\ \UU_
M:P_^<51_JCQ#_P!"_P#\N\#_ /-(?6J'\_\ Y+/_ .1#_B)-_P""*W_1Y_\
MYKK^UA_\XJC_ %1XA_Z%_P#Y=X'_ .:0^M4/Y_\ R6?_ ,B'_$2;_P $5O\
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M0_G_ /)9_P#R(?\ $2;_ ,$5O^CS_P#S77]K#_YQ5'^J/$/_ $+_ /R[P/\
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MZ%__ )=X'_YI#ZU0_G_\EG_\B'_$2;_P16_Z//\ _-=?VL/_ )Q5'^J/$/\
MT+__ "[P/_S2'UJA_/\ ^2S_ /D0_P"(DW_@BM_T>?\ ^:Z_M8?_ #BJ/]4>
M(?\ H7_^7>!_^:0^M4/Y_P#R6?\ \B'_ !$F_P#!%;_H\_\ \UU_:P_^<51_
MJCQ#_P!"_P#\N\#_ /-(?6J'\_\ Y+/_ .1#_B)-_P""*W_1Y_\ YKK^UA_\
MXJC_ %1XA_Z%_P#Y=X'_ .:0^M4/Y_\ R6?_ ,B'_$2;_P $5O\ H\__ ,UU
M_:P_^<51_JCQ#_T+_P#R[P/_ ,TA]:H?S_\ DL__ )$/^(DW_@BM_P!'G_\
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MZ//_ /-=?VL/_G%4?ZH\0_\ 0O\ _+O _P#S2'UJA_/_ .2S_P#D0_XB3?\
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M?\1)O_!%;_H\_P#\UU_:P_\ G%4?ZH\0_P#0O_\ +O __-(?6J'\_P#Y+/\
M^1#_ (B3?^"*W_1Y_P#YKK^UA_\ .*H_U1XA_P"A?_Y=X'_YI#ZU0_G_ /)9
M_P#R(?\ $2;_ ,$5O^CS_P#S77]K#_YQ5'^J/$/_ $+_ /R[P/\ \TA]:H?S
M_P#DL_\ Y$/^(DW_ ((K?]'G_P#FNO[6'_SBJ/\ 5'B'_H7_ /EW@?\ YI#Z
MU0_G_P#)9_\ R(?\1)O_  16_P"CS_\ S77]K#_YQ5'^J/$/_0O_ /+O _\
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M .<51_JCQ#_T+_\ R[P/_P TA]:H?S_^2S_^1#_B)-_X(K?]'G_^:Z_M8?\
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M?^"*W_1Y_P#YKK^UA_\ .*H_U1XA_P"A?_Y=X'_YI#ZU0_G_ /)9_P#R(?\
M$2;_ ,$5O^CS_P#S77]K#_YQ5'^J/$/_ $+_ /R[P/\ \TA]:H?S_P#DL_\
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M ,XJMO\ 5'B'_H7_ /EW@?\ YI)^M4/Y_P#R6?\ \B'_ !$F_P#!%;_H\_\
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M\$5O^CS_ /S77]K#_P"<51_JCQ#_ -"__P N\#_\TA]:H?S_ /DL_P#Y$/\
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MZU0_G_\ )9__ "(?\1)O_!%;_H\__P UU_:P_P#G%4?ZH\0_]"__ ,N\#_\
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M]'G_ /FNO[6'_P XJC_5'B'_ *%__EW@?_FD/K5#^?\ \EG_ /(A_P 1)O\
MP16_Z//_ /-=?VL/_G%4?ZH\0_\ 0O\ _+O _P#S2'UJA_/_ .2S_P#D0_XB
M3?\ @BM_T>?_ .:Z_M8?_.*H_P!4>(?^A?\ ^7>!_P#FD/K5#^?_ ,EG_P#(
MA_Q$F_\ !%;_ *//_P#-=?VL/_G%4?ZH\0_]"_\ \N\#_P#-(?6J'\__ )+/
M_P"1#_B)-_X(K?\ 1Y__ )KK^UA_\XJC_5'B'_H7_P#EW@?_ )I#ZU0_G_\
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M:H?S_P#DL_\ Y$/^(DW_ ((K?]'G_P#FNO[6'_SBJ/\ 5'B'_H7_ /EW@?\
MYI#ZU0_G_P#)9_\ R(?\1)O_  16_P"CS_\ S77]K#_YQ5'^J/$/_0O_ /+O
M _\ S2'UJA_/_P"2S_\ D0_XB3?^"*W_ $>?_P":Z_M8?_.*H_U1XA_Z%_\
MY=X'_P":0^M4/Y__ "6?_P B'_$2;_P16_Z//_\ -=?VL/\ YQ5'^J/$/_0O
M_P#+O __ #2'UJA_/_Y+/_Y$/^(DW_@BM_T>?_YKK^UA_P#.*H_U1XA_Z%__
M )=X'_YI#ZU0_G_\EG_\B'_$2;_P16_Z//\ _-=?VL/_ )Q5'^J/$/\ T+__
M "[P/_S2'UJA_/\ ^2S_ /D0_P"(DW_@BM_T>?\ ^:Z_M8?_ #BJ/]4>(?\
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MT>?_ .:Z_M8?_.*H_P!4>(?^A?\ ^7>!_P#FD/K5#^?_ ,EG_P#(A_Q$F_\
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M_P#-=?VL/_G%4?ZH\0_]"_\ \N\#_P#-(?6J'\__ )+/_P"1#_B)-_X(K?\
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M]'G_ /FNO[6'_P XJC_5'B'_ *%__EW@?_FD/K5#^?\ \EG_ /(A_P 1)O\
MP16_Z//_ /-=?VL/_G%4?ZH\0_\ 0O\ _+O _P#S2'UJA_/_ .2S_P#D0_XB
M3?\ @BM_T>?_ .:Z_M8?_.*H_P!4>(?^A?\ ^7>!_P#FD/K5#^?_ ,EG_P#(
MA_Q$F_\ !%;_ *//_P#-=?VL/_G%4?ZH\0_]"_\ \N\#_P#-(?6J'\__ )+/
M_P"1#_B)-_X(K?\ 1Y__ )KK^UA_\XJC_5'B'_H7_P#EW@?_ )I#ZU0_G_\
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M:H?S_P#DL_\ Y$/^(DW_ ((K?]'G_P#FNO[6'_SBJ/\ 5'B'_H7_ /EW@?\
MYI#ZU0_G_P#)9_\ R(?\1)O_  16_P"CS_\ S77]K#_YQ5'^J/$/_0O_ /+O
M _\ S2'UJA_/_P"2S_\ D0_XB3?^"*W_ $>?_P":Z_M8?_.*H_U1XA_Z%_\
MY=X'_P":0^M4/Y__ "6?_P B'_$2;_P16_Z//_\ -=?VL/\ YQ5'^J/$/_0O
M_P#+O __ #2'UJA_/_Y+/_Y$/^(DW_@BM_T>?_YKK^UA_P#.*H_U1XA_Z%__
M )=X'_YI#ZU0_G_\EG_\B'_$2;_P16_Z//\ _-=?VL/_ )Q5'^J/$/\ T+__
M "[P/_S2'UJA_/\ ^2S_ /D0_P"(DW_@BM_T>?\ ^:Z_M8?_ #BJ/]4>(?\
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MT>?_ .:Z_M8?_.*H_P!4>(?^A?\ ^7>!_P#FD/K5#^?_ ,EG_P#(A_Q$F_\
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M4>(?^A?_ .7>!_\ FD/K5#^?_P EG_\ (GZ>?LJ_M<?L]?MM?"2S^.G[,7Q
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M_P#-=?VL/_G%4?ZH\0_]"_\ \N\#_P#-(?6J'\__ )+/_P"1#_B)-_X(K?\
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M(DW_ ((K?]'G_P#FNO[6'_SBJ/\ 5'B'_H7_ /EW@?\ YI#ZU0_G_P#)9_\
MR(?\1)O_  16_P"CS_\ S77]K#_YQ5'^J/$/_0O_ /+O _\ S2'UJA_/_P"2
MS_\ D0_XB3?^"*W_ $>?_P":Z_M8?_.*H_U1XA_Z%_\ Y=X'_P":0^M4/Y__
M "6?_P B'_$2;_P16_Z//_\ -=?VL/\ YQ5'^J/$/_0O_P#+O __ #2'UJA_
M/_Y+/_Y$/^(DW_@BM_T>?_YKK^UA_P#.*H_U1XA_Z%__ )=X'_YI#ZU0_G_\
MEG_\B'_$2;_P16_Z//\ _-=?VL/_ )Q5'^J/$/\ T+__ "[P/_S2'UJA_/\
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M_P"(DW_@BM_T>?\ ^:Z_M8?_ #BJ/]4>(?\ H7_^7>!_^:0^M4/Y_P#R6?\
M\B'_ !$F_P#!%;_H\_\ \UU_:P_^<51_JCQ#_P!"_P#\N\#_ /-(?6J'\_\
MY+/_ .1#_B)-_P""*W_1Y_\ YKK^UA_\XJC_ %1XA_Z%_P#Y=X'_ .:0^M4/
MY_\ R6?_ ,B'_$2;_P $5O\ H\__ ,UU_:P_^<51_JCQ#_T+_P#R[P/_ ,TA
M]:H?S_\ DL__ )$/^(DW_@BM_P!'G_\ FNO[6'_SBJ/]4>(?^A?_ .7>!_\
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M8?\ SBJ[_P#5'B'_ *%__EW@?_FDS^M4/Y__ "6?_P B'_$2;_P16_Z//_\
M-=?VL/\ YQ5'^J/$/_0O_P#+O __ #2'UJA_/_Y+/_Y$/^(DW_@BM_T>?_YK
MK^UA_P#.*H_U1XA_Z%__ )=X'_YI#ZU0_G_\EG_\B'_$2;_P16_Z//\ _-=?
MVL/_ )Q5'^J/$/\ T+__ "[P/_S2'UJA_/\ ^2S_ /D0_P"(DW_@BM_T>?\
M^:Z_M8?_ #BJ/]4>(?\ H7_^7>!_^:0^M4/Y_P#R6?\ \B'_ !$F_P#!%;_H
M\_\ \UU_:P_^<51_JCQ#_P!"_P#\N\#_ /-(?6J'\_\ Y+/_ .1#_B)-_P""
M*W_1Y_\ YKK^UA_\XJC_ %1XA_Z%_P#Y=X'_ .:0^M4/Y_\ R6?_ ,B'_$2;
M_P $5O\ H\__ ,UU_:P_^<51_JCQ#_T+_P#R[P/_ ,TA]:H?S_\ DL__ )$/
M^(DW_@BM_P!'G_\ FNO[6'_SBJ/]4>(?^A?_ .7>!_\ FD/K5#^?_P EG_\
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MH_U1XA_Z%_\ Y=X'_P":0^M4/Y__ "6?_P B'_$2;_P16_Z//_\ -=?VL/\
MYQ5'^J/$/_0O_P#+O __ #2'UJA_/_Y+/_Y$/^(DW_@BM_T>?_YKK^UA_P#.
M*H_U1XA_Z%__ )=X'_YI#ZU0_G_\EG_\B'_$2;_P16_Z//\ _-=?VL/_ )Q5
M'^J/$/\ T+__ "[P/_S2'UJA_/\ ^2S_ /D0_P"(DW_@BM_T>?\ ^:Z_M8?_
M #BJ/]4>(?\ H7_^7>!_^:0^M4/Y_P#R6?\ \B'_ !$F_P#!%;_H\_\ \UU_
M:P_^<51_JCQ#_P!"_P#\N\#_ /-(?6J'\_\ Y+/_ .1#_B)-_P""*W_1Y_\
MYKK^UA_\XJC_ %1XA_Z%_P#Y=X'_ .:0^M4/Y_\ R6?_ ,B'_$2;_P $5O\
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M0_G_ /)9_P#R(?\ $2;_ ,$5O^CS_P#S77]K#_YQ5'^J/$/_ $+_ /R[P/\
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MZ%__ )=X'_YI#ZU0_G_\EG_\B'_$2;_P16_Z//\ _-=?VL/_ )Q5'^J/$/\
MT+__ "[P/_S2'UJA_/\ ^2S_ /D0_P"(DW_@BM_T>?\ ^:Z_M8?_ #BJ/]4>
M(?\ H7_^7>!_^:0^M4/Y_P#R6?\ \B'_ !$F_P#!%;_H\_\ \UU_:P_^<51_
MJCQ#_P!"_P#\N\#_ /-(?6J'\_\ Y+/_ .1#_B)-_P""*W_1Y_\ YKK^UA_\
MXJC_ %1XA_Z%_P#Y=X'_ .:0^M4/Y_\ R6?_ ,B'_$2;_P $5O\ H\__ ,UU
M_:P_^<51_JCQ#_T+_P#R[P/_ ,TA]:H?S_\ DL__ )$/^(DW_@BM_P!'G_\
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MZ//_ /-=?VL/_G%4?ZH\0_\ 0O\ _+O _P#S2'UJA_/_ .2S_P#D0_XB3?\
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M?\1)O_!%;_H\_P#\UU_:P_\ G%4?ZH\0_P#0O_\ +O __-(?6J'\_P#Y+/\
M^1#_ (B3?^"*W_1Y_P#YKK^UA_\ .*H_U1XA_P"A?_Y=X'_YI#ZU0_G_ /)9
M_P#R(?\ $2;_ ,$5O^CS_P#S77]K#_YQ5'^J/$/_ $+_ /R[P/\ \TA]:H?S
M_P#DL_\ Y$/^(DW_ ((K?]'G_P#FNO[6'_SBJ/\ 5'B'_H7_ /EW@?\ YI#Z
MU0_G_P#)9_\ R(?\1)O_  16_P"CS_\ S77]K#_YQ5'^J/$/_0O_ /+O _\
MS2'UJA_/_P"2S_\ D0_XB3?^"*W_ $>?_P":Z_M8?_.*H_U1XA_Z%_\ Y=X'
M_P":0^M4/Y__ "6?_P B'_$2;_P16_Z//_\ -=?VL/\ YQ5'^J/$/_0O_P#+
MO __ #2'UJA_/_Y+/_Y$/^(DW_@BM_T>?_YKK^UA_P#.*H_U1XA_Z%__ )=X
M'_YI#ZU0_G_\EG_\B'_$2;_P16_Z//\ _-=?VL/_ )Q5'^J/$/\ T+__ "[P
M/_S2'UJA_/\ ^2S_ /D0_P"(DW_@BM_T>?\ ^:Z_M8?_ #BJ/]4>(?\ H7_^
M7>!_^:0^M4/Y_P#R6?\ \B'_ !$F_P#!%;_H\_\ \UU_:P_^<51_JCQ#_P!"
M_P#\N\#_ /-(?6J'\_\ Y+/_ .1#_B)-_P""*W_1Y_\ YKK^UA_\XJC_ %1X
MA_Z%_P#Y=X'_ .:0^M4/Y_\ R6?_ ,B'_$2;_P $5O\ H\__ ,UU_:P_^<51
M_JCQ#_T+_P#R[P/_ ,TA]:H?S_\ DL__ )$/^(DW_@BM_P!'G_\ FNO[6'_S
MBJ/]4>(?^A?_ .7>!_\ FD/K5#^?_P EG_\ (A_Q$F_\$5O^CS__ #77]K#_
M .<51_JCQ#_T+_\ R[P/_P TA]:H?S_^2S_^1#_B)-_X(K?]'G_^:Z_M8?\
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M?^"*W_1Y_P#YKK^UA_\ .*H_U1XA_P"A?_Y=X'_YI#ZU0_G_ /)9_P#R(?\
M$2;_ ,$5O^CS_P#S77]K#_YQ5'^J/$/_ $+_ /R[P/\ \TA]:H?S_P#DL_\
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M1)O_  16_P"CS_\ S77]K#_YQ5'^J/$/_0O_ /+O _\ S2'UJA_/_P"2S_\
MD0_XB3?^"*W_ $>?_P":Z_M8?_.*H_U1XA_Z%_\ Y=X'_P":0^M4/Y__ "6?
M_P B'_$2;_P16_Z//_\ -=?VL/\ YQ5'^J/$/_0O_P#+O __ #2'UJA_/_Y+
M/_Y$/^(DW_@BM_T>?_YKK^UA_P#.*H_U1XA_Z%__ )=X'_YI#ZU0_G_\EG_\
MB'_$2;_P16_Z//\ _-=?VL/_ )Q5'^J/$/\ T+__ "[P/_S2'UJA_/\ ^2S_
M /D0_P"(DW_@BM_T>?\ ^:Z_M8?_ #BJ/]4>(?\ H7_^7>!_^:0^M4/Y_P#R
M6?\ \B'_ !$F_P#!%;_H\_\ \UU_:P_^<51_JCQ#_P!"_P#\N\#_ /-(?6J'
M\_\ Y+/_ .1#_B)-_P""*W_1Y_\ YKK^UA_\XJC_ %1XA_Z%_P#Y=X'_ .:0
M^M4/Y_\ R6?_ ,B?J5^S!^U-\!_VR_@[X?\ C]^S9XZ_X6/\)/%%]KVF:%XL
M_P"$8\8^#_MU[X8UF\\/ZY!_8/CWP]X7\2VWV'5]/N[3S+S1K>&Y\GS[-[BU
M>*9_%QF"Q.7UY87%TO8UX*+E#GISLIQ4H^]2E.&L6GI+39V-H3C.*E!WCT=F
MMM-FD?05<I1^*'BC_@XH_P""./@SQ+XB\'^)?VPO[-\1>%-=U;PUK^G?\,^_
MM2WGV#6M"O[C2]5LOM=A\$;JQNOLM]:SP?:+*YN+2?R_,MIYH621OHH<)Y_.
M$9PP%XSC&47]:P2O&233L\0FM+:-)^1A]9H+3GVT^&?3_MTPO^(DW_@BM_T>
M?_YKK^UA_P#.*JO]4>(?^A?_ .7>!_\ FD7UJA_/_P"2S_\ D0_XB3?^"*W_
M $>?_P":Z_M8?_.*H_U1XA_Z%_\ Y=X'_P":0^M4/Y__ "6?_P B'_$2;_P1
M6_Z//_\ -=?VL/\ YQ5'^J/$/_0O_P#+O __ #2'UJA_/_Y+/_Y$/^(DW_@B
MM_T>?_YKK^UA_P#.*H_U1XA_Z%__ )=X'_YI#ZU0_G_\EG_\B'_$2;_P16_Z
M//\ _-=?VL/_ )Q5'^J/$/\ T+__ "[P/_S2'UJA_/\ ^2S_ /D0_P"(DW_@
MBM_T>?\ ^:Z_M8?_ #BJ/]4>(?\ H7_^7>!_^:0^M4/Y_P#R6?\ \B'_ !$F
M_P#!%;_H\_\ \UU_:P_^<51_JCQ#_P!"_P#\N\#_ /-(?6J'\_\ Y+/_ .1#
M_B)-_P""*W_1Y_\ YKK^UA_\XJC_ %1XA_Z%_P#Y=X'_ .:0^M4/Y_\ R6?_
M ,B'_$2;_P $5O\ H\__ ,UU_:P_^<51_JCQ#_T+_P#R[P/_ ,TA]:H?S_\
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M_P#FD/K5#^?_ ,EG_P#(A_Q$F_\ !%;_ *//_P#-=?VL/_G%4?ZH\0_]"_\
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MZ_M8?_.*H_U1XA_Z%_\ Y=X'_P":0^M4/Y__ "6?_P B'_$2;_P16_Z//_\
M-=?VL/\ YQ5'^J/$/_0O_P#+O __ #2'UJA_/_Y+/_Y$/^(DW_@BM_T>?_YK
MK^UA_P#.*H_U1XA_Z%__ )=X'_YI#ZU0_G_\EG_\B'_$2;_P16_Z//\ _-=?
MVL/_ )Q5'^J/$/\ T+__ "[P/_S2'UJA_/\ ^2S_ /D0_P"(DW_@BM_T>?\
M^:Z_M8?_ #BJ/]4>(?\ H7_^7>!_^:0^M4/Y_P#R6?\ \B'_ !$F_P#!%;_H
M\_\ \UU_:P_^<51_JCQ#_P!"_P#\N\#_ /-(?6J'\_\ Y+/_ .1#_B)-_P""
M*W_1Y_\ YKK^UA_\XJC_ %1XA_Z%_P#Y=X'_ .:0^M4/Y_\ R6?_ ,B'_$2;
M_P $5O\ H\__ ,UU_:P_^<51_JCQ#_T+_P#R[P/_ ,TA]:H?S_\ DL__ )$/
M^(DW_@BM_P!'G_\ FNO[6'_SBJ/]4>(?^A?_ .7>!_\ FD/K5#^?_P EG_\
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MH_U1XA_Z%_\ Y=X'_P":0^M4/Y__ "6?_P B'_$2;_P16_Z//_\ -=?VL/\
MYQ5'^J/$/_0O_P#+O __ #2'UJA_/_Y+/_Y$/^(DW_@BM_T>?_YKK^UA_P#.
M*H_U1XA_Z%__ )=X'_YI#ZU0_G_\EG_\B'_$2;_P16_Z//\ _-=?VL/_ )Q5
M'^J/$/\ T+__ "[P/_S2'UJA_/\ ^2S_ /D0_P"(DW_@BM_T>?\ ^:Z_M8?_
M #BJ/]4>(?\ H7_^7>!_^:0^M4/Y_P#R6?\ \B'_ !$F_P#!%;_H\_\ \UU_
M:P_^<51_JCQ#_P!"_P#\N\#_ /-(?6J'\_\ Y+/_ .1#_B)-_P""*W_1Y_\
MYKK^UA_\XJC_ %1XA_Z%_P#Y=X'_ .:0^M4/Y_\ R6?_ ,B'_$2;_P $5O\
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M0_G_ /)9_P#R(?\ $2;_ ,$5O^CS_P#S77]K#_YQ5'^J/$/_ $+_ /R[P/\
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MZ%__ )=X'_YI#ZU0_G_\EG_\B'_$2;_P16_Z//\ _-=?VL/_ )Q5'^J/$/\
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M_A1_Z^+_ -)D?YP-?K1Y84 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % '^B)_P &=O\ R8]^T[_V=9-_ZJ+X;5^5
M<>_\C'!?]@7_ +GJGIX'^'/_ !_^VH_KLKX0[3_'O_X+!_\ *4S]O[_LZSXR
M?^IAJ5?O60_\B7*_^P'#?^FXGBXC^-4_Q'YOUZQB% !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?[F%
M?S>?0'X9_P#!R;_RA6_;/_[MU_\ 6L/@57TG"/\ R4.7_P#<W_Z@XDY\5_ G
M_P!N_P#I<3_*;K]L/'"@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /\ 3Q_X-5_^42G@
M_P#[+G\:O_3UIM?CO&W_ "/)?]@N'_*1ZV#_ (*_Q2/Z/Z^1.H_Q0OVG_P#D
MY;]H?_LN?Q:_]3[7Z_HC"?[KAO\ L'H_^FXG@R^*7^)_F>&5T$A0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* .Z^%__ "4SX=_]CUX1_P#3_I]9U?X53_KW/_TEE0^*/^*/YH_V]J_G,]X_
MGY_X.>_^4.OQ^_['KX"_^KD\'5]3P;_R/L-_UZQ/_IB9S8O^!+UC^:/\M6OV
M<\@* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H _U*O\ @V$_Y0Z_ #_L>OCU_P"KD\8U
M^,<9?\C[$_\ 7K#?^F('KX3^!'UE^;/Z!J^6.D_Q0OVG_P#DY;]H?_LN?Q:_
M]3[7Z_HC"?[KAO\ L'H_^FXG@R^*7^)_F>&5T$A0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0!^K/\ P0Y_Y2U?L(?]ESTK_P!,NMUXO$7_ "(\S_[!9_FC;#_QJ?\ B/\
M77K\)/:/Y$_^#Q+_ ),>_9A_[.L@_P#51?$BON^ ?^1CC/\ L"_]STCBQO\
M#A_C_P#;6?YW=?JIY@4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 ?Z(G_  9V_P#)CW[3O_9UDW_JHOAM7Y5Q
M[_R,<%_V!?\ N>J>G@?X<_\ '_[:C^NROA#M/\>__@L'_P I3/V_O^SK/C)_
MZF&I5^]9#_R)<K_[ <-_Z;B>+B/XU3_$?F_7K&(4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!_N85_
M-Y] ?AG_ ,')O_*%;]L__NW7_P!:P^!5?2<(_P#)0Y?_ -S?_J#B3GQ7\"?_
M &[_ .EQ/\INOVP\<* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H _P!/'_@U7_Y1*>#_
M /LN?QJ_]/6FU^.\;?\ (\E_V"X?\I'K8/\ @K_%(_H_KY$ZC_%"_:?_ .3E
MOVA_^RY_%K_U/M?K^B,)_NN&_P"P>C_Z;B>#+XI?XG^9X9702% !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0!_5E_P9^_\ *2SXX?\ 9C/Q+_\ 5^?LS5\3QY_R)\-_V,J/
M_J+C#LP7\67_ %[?_I4#_1^K\E/4/\[O_@\2_P"3X/V8?^S4X/\ U;OQ(K]6
MX"_Y%N,_[#G_ .H]$\W'?%#_  O\S^1.ONCA"@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M [KX7_\ )3/AW_V/7A'_ -/^GUG5_A5/^O<__265#XH_XH_FC_;VK^<SWC^?
MG_@Y[_Y0Z_'[_L>O@+_ZN3P=7U/!O_(^PW_7K$_^F)G-B_X$O6/YH_RU:_9S
MR H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@#_4J_P"#83_E#K\ /^QZ^/7_ *N3QC7X
MQQE_R/L3_P!>L-_Z8@>OA/X$?67YL_H&KY8Z3_%"_:?_ .3EOVA_^RY_%K_U
M/M?K^B,)_NN&_P"P>C_Z;B>#+XI?XG^9X9702% !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?<W_!,#_E)9_P3Q_[/F_9
M*_\ 5^> *\W.?^1/FO\ V+<=_P"HM4TH_P 6E_U\A_Z4C_9*K\!/<"@#_]/^
M_B@#^4W_ (/ O^4:7P/_ .SYOAI_ZH/]IFOMN _^1OB?^Q;6_P#4G!G'C?X4
M?^OB_P#29'^<#7ZT>6% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M 'ZL_P#!#G_E+5^PA_V7/2O_ $RZW7B\1?\ (CS/_L%G^:-L/_&I_P"(_P!=
M>OPD]H_D3_X/$O\ DQ[]F'_LZR#_ -5%\2*^[X!_Y&.,_P"P+_W/2.+&_P .
M'^/_ -M9_G=U^JGF!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0!_HB?\ !G;_ ,F/?M._]G63?^JB^&U?E7'O
M_(QP7_8%_P"YZIZ>!_AS_P ?_MJ/Z[*^$.T_Q[_^"P?_ "E,_;^_[.L^,G_J
M8:E7[UD/_(ERO_L!PW_IN)XN(_C5/\1^;]>L8A0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '^YA7\W
MGT!^&?\ P<F_\H5OVS_^[=?_ %K#X%5])PC_ ,E#E_\ W-_^H.).?%?P)_\
M;O\ Z7$_RFZ_;#QPH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#_ $\?^#5?_E$IX/\
M^RY_&K_T]:;7X[QM_P CR7_8+A_RD>M@_P""O\4C^C^OD3J/\4+]I_\ Y.6_
M:'_[+G\6O_4^U^OZ(PG^ZX;_ +!Z/_IN)X,OBE_B?YGAE=!(4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M?JS_ ,$.?^4M7["'_9<]*_\ 3+K=>+Q%_P B/,_^P6?YHVP_\:G_ (C_ %UZ
M_"3VC^1/_@\2_P"3'OV8?^SK(/\ U47Q(K[O@'_D8XS_ + O_<](XL;_  X?
MX_\ VUG^=W7ZJ>8% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % '^B)_P &=O\ R8]^T[_V=9-_ZJ+X;5^5<>_\
MC'!?]@7_ +GJGIX'^'/_ !_^VH_KLKX0[3_'O_X+!_\ *4S]O[_LZSXR?^IA
MJ5?O60_\B7*_^P'#?^FXGBXC^-4_Q'YOUZQB% !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M?_LN?Q:_]3[7Z_HC"?[KAO\ L'H_^FXG@R^*7^)_F>&5T$A0 4 % !0 4 %
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * .Z
M^%__ "4SX=_]CUX1_P#3_I]9U?X53_KW/_TEE0^*/^*/YH_V]J_G,]X_GY_X
M.>_^4.OQ^_['KX"_^KD\'5]3P;_R/L-_UZQ/_IB9S8O^!+UC^:/\M6OV<\@*
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H _U*O\ @V$_Y0Z_ #_L>OCU_P"KD\8U^,<9
M?\C[$_\ 7K#?^F('KX3^!'UE^;/Z!J^6.D_Q0OVG_P#DY;]H?_LN?Q:_]3[7
MZ_HC"?[KAO\ L'H_^FXG@R^*7^)_F>&5T$A0 4 % !0 4 % !0 4 % !0 4
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MXO\ TF1_G U^M'EA0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!^
MK/\ P0Y_Y2U?L(?]ESTK_P!,NMUXO$7_ "(\S_[!9_FC;#_QJ?\ B/\ 77K\
M)/:/Y$_^#Q+_ ),>_9A_[.L@_P#51?$BON^ ?^1CC/\ L"_]STCBQO\ #A_C
M_P#;6?YW=?JIY@4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 ?Z(G_  9V_P#)CW[3O_9UDW_JHOAM7Y5Q[_R,
M<%_V!?\ N>J>G@?X<_\ '_[:C^NROA#M/\>__@L'_P I3/V_O^SK/C)_ZF&I
M5^]9#_R)<K_[ <-_Z;B>+B/XU3_$?F_7K&(4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!_N85_-Y]
M?AG_ ,')O_*%;]L__NW7_P!:P^!5?2<(_P#)0Y?_ -S?_J#B3GQ7\"?_ &[_
M .EQ/\INOVP\<* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H _P!/'_@U7_Y1*>#_ /LN
M?QJ_]/6FU^.\;?\ (\E_V"X?\I'K8/\ @K_%(_H_KY$ZC_%"_:?_ .3EOVA_
M^RY_%K_U/M?K^B,)_NN&_P"P>C_Z;B>#+XI?XG^9X9702% !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0!_5E_P9^_\ *2SXX?\ 9C/Q+_\ 5^?LS5\3QY_R)\-_V,J/_J+C
M#LP7\67_ %[?_I4#_1^K\E/4/\[O_@\2_P"3X/V8?^S4X/\ U;OQ(K]6X"_Y
M%N,_[#G_ .H]$\W'?%#_  O\S^1.ONCA"@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H [KX
M7_\ )3/AW_V/7A'_ -/^GUG5_A5/^O<__265#XH_XH_FC_;VK^<SWC^?G_@Y
M[_Y0Z_'[_L>O@+_ZN3P=7U/!O_(^PW_7K$_^F)G-B_X$O6/YH_RU:_9SR H
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?<W_!,#_E)9_P3Q_[/F_9*_\
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0!_HB?\ !G;_ ,F/?M._]G63?^JB^&U?E7'O_(QP
M7_8%_P"YZIZ>!_AS_P ?_MJ/Z[*^$.T_Q[_^"P?_ "E,_;^_[.L^,G_J8:E7
M[UD/_(ERO_L!PW_IN)XN(_C5/\1^;]>L8A0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '^YA7\WGT!^
M&?\ P<F_\H5OVS_^[=?_ %K#X%5])PC_ ,E#E_\ W-_^H.).?%?P)_\ ;O\
MZ7$_RFZ_;#QPH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@#_ $\?^#5?_E$IX/\ ^RY_
M&K_T]:;7X[QM_P CR7_8+A_RD>M@_P""O\4C^C^OD3J/\4+]I_\ Y.6_:'_[
M+G\6O_4^U^OZ(PG^ZX;_ +!Z/_IN)X,OBE_B?YGAE=!(4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % ']67_!G[_P I+/CA_P!F,_$O_P!7Y^S-7Q/'G_(GPW_8RH_^HN,.
MS!?Q9?\ 7M_^E0/]'ZOR4]0_SN_^#Q+_ )/@_9A_[-3@_P#5N_$BOU;@+_D6
MXS_L.?\ ZCT3S<=\4/\ "_S/Y$Z^Z.$* "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#NOA?
M_P E,^'?_8]>$?\ T_Z?6=7^%4_Z]S_])94/BC_BC^:/]O:OYS/>/Y^?^#GO
M_E#K\?O^QZ^ O_JY/!U?4\&_\C[#?]>L3_Z8F<V+_@2]8_FC_+5K]G/("@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * /]2K_ (-A/^4.OP _['KX]?\ JY/&-?C'&7_(
M^Q/_ %ZPW_IB!Z^$_@1]9?FS^@:OECI/\4+]I_\ Y.6_:'_[+G\6O_4^U^OZ
M(PG^ZX;_ +!Z/_IN)X,OBE_B?YGAE=!(4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?JS_
M ,$.?^4M7["'_9<]*_\ 3+K=>+Q%_P B/,_^P6?YHVP_\:G_ (C_ %UZ_"3V
MC^1/_@\2_P"3'OV8?^SK(/\ U47Q(K[O@'_D8XS_ + O_<](XL;_  X?X_\
MVUG^=W7ZJ>8% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % '^B)_P &=O\ R8]^T[_V=9-_ZJ+X;5^5<>_\C'!?
M]@7_ +GJGIX'^'/_ !_^VH_KLKX0[3_'O_X+!_\ *4S]O[_LZSXR?^IAJ5?O
M60_\B7*_^P'#?^FXGBXC^-4_Q'YOUZQB% !0 4 % !0 4 % !0 4 % !0 4
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * /\ 3Q_X-5_^42G@_P#[+G\:
MO_3UIM?CO&W_ "/)?]@N'_*1ZV#_ (*_Q2/Z/Z^1.H_Q0OVG_P#DY;]H?_LN
M?Q:_]3[7Z_HC"?[KAO\ L'H_^FXG@R^*7^)_F>&5T$A0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 ?U9?\&?O_ "DL^.'_ &8S\2__ %?G[,U?$\>?\B?#?]C*C_ZBXP[,
M%_%E_P!>W_Z5 _T?J_)3U#_.[_X/$O\ D^#]F'_LU.#_ -6[\2*_5N O^1;C
M/^PY_P#J/1/-QWQ0_P +_,_D3K[HX0H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * .Z^%__
M "4SX=_]CUX1_P#3_I]9U?X53_KW/_TEE0^*/^*/YH_V]J_G,]X_GY_X.>_^
M4.OQ^_['KX"_^KD\'5]3P;_R/L-_UZQ/_IB9S8O^!+UC^:/\M6OV<\@* "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % 'W-_P3 _Y26?\$\?^SYOV2O_ %?G
M@"O-SG_D3YK_ -BW'?\ J+5-*/\ %I?]?(?^E(_V2J_ 3W H __0_OXH _E-
M_P"#P+_E&E\#_P#L^;X:?^J#_:9K[;@/_D;XG_L6UO\ U)P9QXW^%'_KXO\
MTF1_G U^M'EA0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!^K/\
MP0Y_Y2U?L(?]ESTK_P!,NMUXO$7_ "(\S_[!9_FC;#_QJ?\ B/\ 77K\)/:/
MY$_^#Q+_ ),>_9A_[.L@_P#51?$BON^ ?^1CC/\ L"_]STCBQO\ #A_C_P#;
M6?YW=?JIY@4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 ?Z(G_  9V_P#)CW[3O_9UDW_JHOAM7Y5Q[_R,<%_V
M!?\ N>J>G@?X<_\ '_[:C^NROA#M/\>__@L'_P I3/V_O^SK/C)_ZF&I5^]9
M#_R)<K_[ <-_Z;B>+B/XU3_$?F_7K&(4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!_N85_-Y] ?AG_
M ,')O_*%;]L__NW7_P!:P^!5?2<(_P#)0Y?_ -S?_J#B3GQ7\"?_ &[_ .EQ
M/\INOVP\<* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H _P!/'_@U7_Y1*>#_ /LN?QJ_
M]/6FU^.\;?\ (\E_V"X?\I'K8/\ @K_%(_H_KY$ZC_%"_:?_ .3EOVA_^RY_
M%K_U/M?K^B,)_NN&_P"P>C_Z;B>#+XI?XG^9X9702% !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0!_5E_P9^_\ *2SXX?\ 9C/Q+_\ 5^?LS5\3QY_R)\-_V,J/_J+C#LP7
M\67_ %[?_I4#_1^K\E/4/\[O_@\2_P"3X/V8?^S4X/\ U;OQ(K]6X"_Y%N,_
M[#G_ .H]$\W'?%#_  O\S^1.ONCA"@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H [KX7_\
M)3/AW_V/7A'_ -/^GUG5_A5/^O<__265#XH_XH_FC_;VK^<SWC^?G_@Y[_Y0
MZ_'[_L>O@+_ZN3P=7U/!O_(^PW_7K$_^F)G-B_X$O6/YH_RU:_9SR H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@#_4J_P"#83_E#K\ /^QZ^/7_ *N3QC7XQQE_R/L3
M_P!>L-_Z8@>OA/X$?67YL_H&KY8Z3_%"_:?_ .3EOVA_^RY_%K_U/M?K^B,)
M_NN&_P"P>C_Z;B>#+XI?XG^9X9702% !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 ?<W_!,#_E)9_P3Q_[/F_9*_\ 5^>
M*\W.?^1/FO\ V+<=_P"HM4TH_P 6E_U\A_Z4C_9*K\!/<"@#_]'^_B@#^4W_
M (/ O^4:7P/_ .SYOAI_ZH/]IFOMN _^1OB?^Q;6_P#4G!G'C?X4?^OB_P#2
M9'^<#7ZT>6% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'ZL_P#!
M#G_E+5^PA_V7/2O_ $RZW7B\1?\ (CS/_L%G^:-L/_&I_P"(_P!=>OPD]H_D
M3_X/$O\ DQ[]F'_LZR#_ -5%\2*^[X!_Y&.,_P"P+_W/2.+&_P .'^/_ -M9
M_G=U^JGF!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0!_HB?\ !G;_ ,F/?M._]G63?^JB^&U?E7'O_(QP7_8%
M_P"YZIZ>!_AS_P ?_MJ/Z[*^$.T_Q[_^"P?_ "E,_;^_[.L^,G_J8:E7[UD/
M_(ERO_L!PW_IN)XN(_C5/\1^;]>L8A0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '^YA7\WGT!^&?\
MP<F_\H5OVS_^[=?_ %K#X%5])PC_ ,E#E_\ W-_^H.).?%?P)_\ ;O\ Z7$_
MRFZ_;#QPH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@#_ $\?^#5?_E$IX/\ ^RY_&K_T
M]:;7X[QM_P CR7_8+A_RD>M@_P""O\4C^C^OD3J/\4+]I_\ Y.6_:'_[+G\6
MO_4^U^OZ(PG^ZX;_ +!Z/_IN)X,OBE_B?YGAE=!(4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % ']67_!G[_P I+/CA_P!F,_$O_P!7Y^S-7Q/'G_(GPW_8RH_^HN,.S!?Q
M9?\ 7M_^E0/]'ZOR4]0_SN_^#Q+_ )/@_9A_[-3@_P#5N_$BOU;@+_D6XS_L
M.?\ ZCT3S<=\4/\ "_S/Y$Z^Z.$* "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#NOA?_P E
M,^'?_8]>$?\ T_Z?6=7^%4_Z]S_])94/BC_BC^:/]O:OYS/>/Y^?^#GO_E#K
M\?O^QZ^ O_JY/!U?4\&_\C[#?]>L3_Z8F<V+_@2]8_FC_+5K]G/("@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * /]2K_ (-A/^4.OP _['KX]?\ JY/&-?C'&7_(^Q/_
M %ZPW_IB!Z^$_@1]9?FS^@:OECI/\4+]I_\ Y.6_:'_[+G\6O_4^U^OZ(PG^
MZX;_ +!Z/_IN)X,OBE_B?YGAE=!(4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0!]S?\$P/^4EG_!/'_L^;]DK_P!7YX K
MS<Y_Y$^:_P#8MQW_ *BU32C_ !:7_7R'_I2/]DJOP$]P* /_TO[^* /Y3?\
M@\"_Y1I? _\ [/F^&G_J@_VF:^VX#_Y&^)_[%M;_ -2<&<>-_A1_Z^+_ -)D
M?YP-?K1Y84 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?JS_ ,$.
M?^4M7["'_9<]*_\ 3+K=>+Q%_P B/,_^P6?YHVP_\:G_ (C_ %UZ_"3VC^1/
M_@\2_P"3'OV8?^SK(/\ U47Q(K[O@'_D8XS_ + O_<](XL;_  X?X_\ VUG^
M=W7ZJ>8% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % '^B)_P &=O\ R8]^T[_V=9-_ZJ+X;5^5<>_\C'!?]@7_
M +GJGIX'^'/_ !_^VH_KLKX0[3_'O_X+!_\ *4S]O[_LZSXR?^IAJ5?O60_\
MB7*_^P'#?^FXGBXC^-4_Q'YOUZQB% !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?[F%?S>?0'X9_P#!
MR;_RA6_;/_[MU_\ 6L/@57TG"/\ R4.7_P#<W_Z@XDY\5_ G_P!N_P#I<3_*
M;K]L/'"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * /\ 3Q_X-5_^42G@_P#[+G\:O_3U
MIM?CO&W_ "/)?]@N'_*1ZV#_ (*_Q2/Z/Z^1.H_Q0OVG_P#DY;]H?_LN?Q:_
M]3[7Z_HC"?[KAO\ L'H_^FXG@R^*7^)_F>&5T$A0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M^_['KX"_^KD\'5]3P;_R/L-_UZQ/_IB9S8O^!+UC^:/\M6OV<\@* "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H _U*O\ @V$_Y0Z_ #_L>OCU_P"KD\8U^,<9?\C[$_\
M7K#?^F('KX3^!'UE^;/Z!J^6.D_Q0OVG_P#DY;]H?_LN?Q:_]3[7Z_HC"?[K
MAO\ L'H_^FXG@R^*7^)_F>&5T$A0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 ?Z(G_  9V_P#)CW[3O_9UDW_JHOAM7Y5Q[_R,<%_V!?\
MN>J>G@?X<_\ '_[:C^NROA#M/\>__@L'_P I3/V_O^SK/C)_ZF&I5^]9#_R)
M<K_[ <-_Z;B>+B/XU3_$?F_7K&(4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M/M?K^B,)_NN&_P"P>C_Z;B>#+XI?XG^9X9702% !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0!_5E_P9^_\ *2SXX?\ 9C/Q+_\ 5^?LS5\3QY_R)\-_V,J/_J+C#LP7\67_
M %[?_I4#_1^K\E/4/\[O_@\2_P"3X/V8?^S4X/\ U;OQ(K]6X"_Y%N,_[#G_
M .H]$\W'?%#_  O\S^1.ONCA"@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H [KX7_\ )3/A
MW_V/7A'_ -/^GUG5_A5/^O<__265#XH_XH_FC_;VK^<SWC^?G_@Y[_Y0Z_'[
M_L>O@+_ZN3P=7U/!O_(^PW_7K$_^F)G-B_X$O6/YH_RU:_9SR H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@#_4J_P"#83_E#K\ /^QZ^/7_ *N3QC7XQQE_R/L3_P!>
ML-_Z8@>OA/X$?67YL_H&KY8Z3_%"_:?_ .3EOVA_^RY_%K_U/M?K^B,)_NN&
M_P"P>C_Z;B>#+XI?XG^9X9702% !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 ?<W_!,#_E)9_P3Q_[/F_9*_\ 5^> *\W.
M?^1/FO\ V+<=_P"HM4TH_P 6E_U\A_Z4C_9*K\!/<"@#_]3^_B@#^4W_ (/
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /U9_X(<_\
M*6K]A#_LN>E?^F76Z\7B+_D1YG_V"S_-&V'_ (U/_$?ZZ]?A)[1_(G_P>)?\
MF/?LP_\ 9UD'_JHOB17W? /_ ",<9_V!?^YZ1Q8W^'#_ !_^VL_SNZ_53S H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H _P!$3_@SM_Y,>_:=_P"SK)O_ %47PVK\JX]_Y&."_P"P+_W/5/3P
M/\.?^/\ ]M1_797PAVG^/?\ \%@_^4IG[?W_ &=9\9/_ %,-2K]ZR'_D2Y7_
M -@.&_\ 3<3Q<1_&J?XC\WZ]8Q"@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /]S"OYO/H#\,_^#DW_
M )0K?MG_ /=NO_K6'P*KZ3A'_DH<O_[F_P#U!Q)SXK^!/_MW_P!+B?Y3=?MA
MXX4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0!_IX_P#!JO\ \HE/!_\ V7/XU?\ IZTV
MOQWC;_D>2_[!</\ E(];!_P5_BD?T?U\B=1_BA?M/_\ )RW[0_\ V7/XM?\
MJ?:_7]$83_=<-_V#T?\ TW$\&7Q2_P 3_,\,KH)"@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H _JR_X,_?^4EGQP_[,9^)?_J_/V9J^)X\_P"1/AO^QE1_]1<8=F"_BR_Z
M]O\ ]*@?Z/U?DIZA_G=_\'B7_)\'[,/_ &:G!_ZMWXD5^K<!?\BW&?\ 8<__
M %'HGFX[XH?X7^9_(G7W1PA0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 =U\+_ /DIGP[_
M .QZ\(_^G_3ZSJ_PJG_7N?\ Z2RH?%'_ !1_-'^WM7\YGO'\_/\ P<]_\H=?
MC]_V/7P%_P#5R>#J^IX-_P"1]AO^O6)_],3.;%_P)>L?S1_EJU^SGD!0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % '^I5_P;"?\ *'7X ?\ 8]?'K_U<GC&OQCC+_D?8
MG_KUAO\ TQ ]?"?P(^LOS9_0-7RQTG^*%^T__P G+?M#_P#9<_BU_P"I]K]?
MT1A/]UPW_8/1_P#3<3P9?%+_ !/\SPRN@D* "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MGQH\):@0#\X34]2^,_C.V3<.%+:1)L/)#CY:_49\!96U^[Q6/@^\IX>:_P#
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0!_HB?\&=O_)CW[3O_ &=9-_ZJ+X;5^5<>_P#(QP7_
M &!?^YZIZ>!_AS_Q_P#MJ/Z[*^$.T_Q[_P#@L'_RE,_;^_[.L^,G_J8:E7[U
MD/\ R)<K_P"P'#?^FXGBXC^-4_Q'YOUZQB% !0 4 % !0 4 % !0 4 % !0
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MG+RSG?\ A2OM;3?IE5HSH\O-;WKVL^UO)=T?ES7LF(4 % !0 4 % !0 4 %
M'[U?\&Z_[$'[-?[??[<GCSX+_M3^!+OXA_#K0_V9O'?Q&TW0[+Q?XQ\%2P>+
MM$^(_P (?#VFZD=6\$:[X>U>:.#2O%>N6YL)KY["5KM9YK9Y[:VDA^9XKS'%
MY7EM/$8*HJ566,I4G)TZ=1>SE2KR:Y:D91WA%W2OI;:YTX6G"I4<9JZ4&[7:
MUO%=&NY_:W_Q#,_\$9_^C6]?_P#$@?VA_P#YZ-?GG^N&?_\ 09#_ ,)<+_\
M*3O^JT/^??\ Y-/_ .2/\Z?_ (*=?!#X<?LV?\% ?VL_@1\(=&N/#OPR^%WQ
MD\2^%/!.A76K:IKL^DZ!9&W>SL'UC6[N_P!8U'[,)FC6ZU*]N[R1 OGW$TF7
M/ZOD^(JXO*\#B:\E*M6P].=22BHIR:U?+%**OV22[)'EUHJ%2<8Z).R79'PE
M7I&84 % !0 4 ?W$_P#!OW_P1C_X)V_MU_L I\<_VG/@CJOC[XFGXU_$CP<=
M?L_BO\6_!L/_  C_ (>M/"\NDV7]C^"_&V@:+NMGU*\)NOL'VJ?S0)YI!'&%
M_.>*.(,URS,_JV#Q$:5'ZM2J<KH4*GO2<TWS5*<I?96E[+H>AAJ%*=+FG&[N
MUO):+T:1^A?[>G_!O-_P2=^"G[#W[8GQD^&G[.FO>'?B)\)?V7_CQ\3/ FNM
M\</CEK$>D>,/ ?PO\3^*?#>H2Z3KGQ#U+1]2AM=7TJSEFL-3L+NRNX5>">!X
MW(KRLLXJSO$9C@,/6Q4)4J^,PU&I'ZMAXWIU*T(25XTE)7BWJFFNAK4PU&-.
M;4+.,)->]+1I776Q_G6?"7X8^+?C7\5/AI\&O -G#J'CKXL^/_!WPT\&6%Q-
M]FMKSQ5XZ\0Z=X7\/VMQ<[)/LUO/JVJ6D<]QY;B")FE*,$Q7ZM7K0P]&K7J.
MU.A2J5JC2NU"E!SDTNMHQ>AY<4Y-16[:2]7HC_14^ /_  :8?\$\/!'PVT?2
M?CWK_P 8?C=\4Y]*C'BKQAIOC>?X>>%[?6Y8T-PW@KPKH%D+FQTNSD!CLE\3
MZQXFNKG#7-V8Q*EC:_E&*XXS6I5D\+##X:@G[E-T_:S<>GM)R=FWUY(P2V7=
M^I'!TDK2O)][V^Y+_@G\S?\ P7J_X(C:!_P2VU?X:_%?X'^-O$WC7]G'XQ:[
MJOA*RT[QT^GW7C;X;^/-/T]]<A\.:AK6E6.E6'B;0=>T6#4K[PYJ:Z58:G9C
M0]3TW64O)8[/5]4^QX9XBEG4:M'$4H4L7AXQFW2NJ=6FWR\ZC)MPE&5E*/,U
M[R<;:QCR8C#JC9Q;<7IKNG^&GY'\YU?5G*% !0 4 % !0 4 % !0 4 % 'W5
M_P $^_\ @G?^T/\ \%+/C3JWP,_9R@\(P^)?#_@?5OB%XAU[Q_J^J>'_  ;H
M7AS2=1TC1]VI:OI&@^([Q+[4M6US3=/TJQ@TJ>6[EEFE/E6EG>7$'FYIFN$R
MC#QQ.+<^252-*$:45*<IR4I647**LHQ;;NDDN[2-*5*55\L+:*^NBMHC]G_^
M(1W_ (*A?]#O^R%_X=;XC_\ SEJ^?_UYR7^3'?\ @BE_\O-_J5;^Y][_ ,C^
M9[QOX6E\#^-/%W@JXUC0?$,_@_Q/K_A:;7_"M])JGAC7)?#^JW>DR:QX<U.6
MVLI=1T'4WM#>Z/?2V=I)=Z?-;W#VT#2&)/KZ<_:4Z=11E!3A&?+-6G'FBGRR
M2O:2O:2N[-6.5JS:TT=M-M--/(Y>K$% !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % '^YA7\WGT!^&?_  <F_P#*%;]L_P#[MU_]:P^!5?2<(_\
M)0Y?_P!S?_J#B3GQ7\"?_;O_ *7$_P INOVP\<* "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H _T\?^#5?_E$IX/_ .RY_&K_ -/6FU^.\;?\CR7_ &"X?\I'K8/^"O\
M%(_H_KY$ZC_%"_:?_P"3EOVA_P#LN?Q:_P#4^U^OZ(PG^ZX;_L'H_P#IN)X,
MOBE_B?YGAE=!(4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % ']67_!G[_RDL^.'_9C/Q+_]
M7Y^S-7Q/'G_(GPW_ &,J/_J+C#LP7\67_7M_^E0/]'ZOR4]0_P [O_@\2_Y/
M@_9A_P"S4X/_ %;OQ(K]6X"_Y%N,_P"PY_\ J/1/-QWQ0_PO\S^1.ONCA"@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M"G7@JE.-6*C/D?PMQ3DES*THV;O%IG-.#A)P=KQT=MOZ6QX-722% !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?<W_!,#_E)9_P $\?\ L^;]DK_U
M?G@"O-SG_D3YK_V+<=_ZBU32C_%I?]?(?^E(_P!DJOP$]P* /__6_OXH _E-
M_P"#P+_E&E\#_P#L^;X:?^J#_:9K[;@/_D;XG_L6UO\ U)P9QXW^%'_KXO\
MTF1_G U^M'EA0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '^E?\ \&D?_*+C
MQ9_V=K\6/_4#^$%?D/'/_(YA_P!@-#_TY7/5P7\'_M]_DC]\?VQ_^30_VJ?^
MS;_CC_ZK'Q/7S.7?[_@?^PS#?^GH'3+X)?X7^1_BOU_0AX)_8Q_P9S_#WQ[<
M_M3_ +5WQ6MK/5(_A?H?[/\ IOP]UF_^R2KHEWX]\4_$7PIXD\,V:WS*(9=4
MT[P]X.\63-:0N\MO::HDUPL:7-J9?@>/JM)8'!4+KVTL4ZL5?WE2IT:D)NW9
MRJ4U?NK+9G=@4^:;Z<J7E>__  #_ $&*_+3TC_+\_P""]>N^'?&7_!?3XE65
M@EIJ5EI/CK]E7P?KH>*.XL[[4;+X;_"9-8L[B*4/%<"U-V=%O8I$V>993V[H
MRJ2W[+PQ&5/AB@WHW2QLX]&DZ]?E?EMS+R:]%Y6(L\3Z."_!'^E./@!\"!P/
M@I\) !P /AOX.X_\HU?D7UO%?]!.(_\ !U3_ .2/4LNR^Y'Y2?MX?\$;O@7^
MW5^U/^Q+XG\=^!?"V@_L[?L[:)^T%XI^*'A#P9H^D>%)_BOXP\3:K\!8_ACX
M"\02Z%#INH#PC-#X;\;ZSXBO;9FO#9:5_P (Y9RZ>WBB35+'V\LX@Q.6X+,8
M4ZLYXO%2PL*$ZDI3]A3A'$^VJQYKKG7-3C!;7?,[\G*\:E"-25-M>[#FNEU;
MY;+TT?Y'[ _#SX:_#SX1^$=&\ ?"OP+X0^&_@;P[:1V.A>#_  +X<TCPIX:T
MBTB4*EOIVB:':6.G6D8 R1#;IN;+MEB2? JUJM>I*K7J5*U23O*I4DYSD_.4
MFV;))))))+9)62]$C_)L_:E_9D^,'[7_ /P6B_;)_9S^ GA27Q5\2/B+^WQ^
MU/I&BZ?'NM],TJRA^./CVYU?Q)XAOTBECT7PMX8TF&ZUG7]5EC:.PTNSG>.*
M>?R;>7]PP>,H8#A[+\7B9\E&CE>!E)[MOZM24807VISE:,(]9-;'C2@YUYPB
MM74G_P"E/\$?WC_\$X?^#=;]A?\ 8A\+^'?$/Q1\"^&?VJ?VC([:.ZU_XF?%
M3P_!K?@S1-5D13)9?#;X7ZR^H^%M$T_39 !IWB+6['6O&TMPLM_'K>DV]S%H
MNG_F>;<5YEF,Y0H5)X'";1HT)<M2276M6C:<F^L(N--*RY9-<S]*EAJ=-*Z4
MI?S-?DME^?F?OKIVFZ=H]A::7I%A9:7IEA!':V.G:=:P6-A96T2[8K>TM+:.
M*WMH(E 6.&&-(T4850*^8;<FW)N3>K;=VWYMG09WB7PMX8\::+>^&_&/AS0?
M%GAW4X_)U'0/$ND:?KNBZA#_ ,\KW2M4M[JQNH_]B>!U]J<)SIR4Z<Y4YK:4
M).,EZ.-FOD%NG0_EQ_X*Q?\ !LS^S?\ M(>"O%?Q<_88\(>'?V=_VD=*M=2U
M^+X=^&U71?@M\8;B*![@^&3X9,T6A?"WQ+?/$D'A_7O"D&C^$OMLC6_BC0&C
MU!O$VA_:9'QAB\)4A0S*<L5A&U'VLO>Q&'UMS\_Q5H+[49\U2WP2]WDER5L)
M":O32A+LM(ORMT]5\UV_SFO%7A7Q)X&\3^(O!7C+0M5\+^+O".N:KX9\4>&M
M=L;C3-;\/^(="OI],UG1=7TZ[CBNK#4M+U"VN+*^L[B..:VN89(9$5T('ZQ"
M<*D(5*<E.$XQG"<6G&4)).,HM:-----:-'EM-.S5FM&NQ]]_\$O/^";_ ,5O
M^"GG[3^A? /X>W?_  BOA73;%O%WQ?\ BC=Z=-J.D_#;X?6-S!;W>I&U1X$U
M3Q)K-W/!HG@_P]]JM3J^LW2RW5S8:%IVMZOIGEYSFU#)L'+%55SS;]G0HIVE
M6JM:1OKRPBES3G9\L5HG)QB]*-)U9\JT2UD^R_S[+]$?ZD/[$G_!,_\ 8R_X
M)^>"M+\*?LX?!GPUH6NVMFL&N?%?7["Q\1_&'QC=O D-[?\ B/X@WUH=9,=Z
MXDF'A_1GT?PEIC3SQ:)X?TRVD: _C&8YQF&:5'/%XB<HW]VA!N&'IKHH4D^7
M3;FES3>G-)GKTZ5.DK0BEY]7ZO\ 3;LC[PF@AN89;:XABGMYXI()X)HTEAFA
ME0QRPRQ.&22*1&*21NI1T)5@0<5YBTLUHULUI:VUC0_,O0O^"1W[%'@W]LY?
MVU? 'P>\"^#/&6L_#+QI\.OB%X!TOP;H,GPT\<7GBC6?!FL:=X__ .$1G@.A
M>%O'.B?\(M?Z?=:QX=TJT/B>T\2ZC-KJ3ZDGV^?V99]F,\O_ +/JUZM2$:M.
MK2JNI)5J2A&<72YU[TZ<N9-1E+W.1<NFAE[&"G[1))V::2T>W3HU;H?;W_"@
M?@1_T13X2?\ AM_!W_RFKSOK>*_Z"<1_X.J?_)&EEV7W(_R</^"UND:3H'_!
M5C]N/1M"TO3M%TC3_C?JUO8:5I-E;:=IMC;KI.CE8+.QLXH;6VA4DD10Q(@)
M)"\U^W<.RE+),ME)N4GAXWE)MM^]+=O5GCXC^-4]5_Z2C_0G_P""%7P7^#NN
M_P#!)7]B76-;^$_PTUG5]1^&6L7.H:KJO@3PMJ&HWUR_Q!\9!KB\OKO2IKFZ
MG8* TL\KN0 "W K\MXEQ.(AGF8QA7K1BJL$HQJSC%+V-/1)227R/2PZ7L:>B
M^'L>X_\ !33_ ()R^"/VR?V-OB#^S7\-/ _PW^'7B/XG^-_@%87OCS1/ WA3
M3]8\(>"M$_:"^%WBCXD^(-)DM[+3Y;K4M,^'>A^*+FPTE;VU76KI(=(EGBBO
M7=>;)\WJX#'TL76JUJL*-/$M4I59N-2I+"UH48.[:2=64$Y6?*O>MH55IJI!
MP5E=QUMLE)-_@CZA_9#_ &'_ -F']A?X8:-\*?V:OA1X8\ :/I^FZ?9ZUXBM
MM+L)?'?CW4+*VCMY/$?Q!\8BTBUCQ7K]\Z-//<W\WV2T,GV/2++3-+@M-/M^
M+'YEC,RK2K8NO.HVVXPN_94HMWY*5._+"*VT5W:\FWJ5"G"FN6$4E^+]7U9_
M!M_P>!*J_P#!27X&%54%_P!B#X=LY  +,/CO^T>@+$=2%55!/.U5'0 5^F<!
M_P#(GQ'_ &,JW_J+@SSL;_%C_P!>U_Z5(_K;_P"";_\ P20_X)T_ 7]G_P"
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MP2JT4T,T3-'+%(K1R1LR.I4D5]W7TH5FM&J52S6EK0=K'%#XH_XE^:/]H8?
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M+M&M&;?;VD5V/-QL+2C-+22L_5;?A^1_(77W9PGJGP,^$'BS]H'XT?"?X%^
M[?[3XR^,'Q%\&_#7PS&8WDB36?&FOV'A^QN;H1\I8V<U^MW?SDI';64$]Q*\
M<43NN&)KPPN'KXFII3P]*I6G_AIP<FEYM*R\[(J,7*48K=M)?/\ R/\ :1^#
M'PI\)_ GX0_"[X)^ [3[#X*^$?P^\'_#;PI:E462+P_X*T"P\.Z5Y_EJJO=2
M6>G1274V-T]R\LSDN[$_SYB*\\37K8BIK4KU:E:?^*I)R=O*[T[(]U)12BMD
MDEZ)61Z76(S^&S_@] _U'_!-[_KK^U[_ .@?LP5^D>'W_,W_ .Y#_P!W3S\=
M_P NO^W_ /VP_ABK](//"@ H * "@ H * "@ H _J=_X-#?^4G'Q3_[,N^*'
M_JX?V?Z^+XZ_Y$U'_L84?_3&).S!?Q9?]>W_ .E0/]).OR,]0_R%O^"V/_*6
M']O/_LX7Q=_Z#95^[\/?\B3+/^P2G^1XN(_C5/\ $?EQ7LF(4 % !0 4 ?Z:
M7_!I_P#\HI8_^SDOC%_Z0>":_'^-_P#D=_\ <GA__2JIZV#_ (*_Q2/UP_X*
MD?\ *,[_ (*&?]F0_M4_^J-\<UX62_\ (XRK_L8X+_U(IFU7^%4_Z]S_ /26
M?Y$W[-_QJUK]F[]H/X'?M!^&["'5==^!_P 6_AY\6-*TBYG:UM=8O/A_XLTG
MQ1%HUW<I%.\%GJYTO^S;N5()F2VN966*0C8?W7%X>.+PN(PLWRQQ%"K0DTKN
M*JP<.9+36-[K;8\6$N249?RM.WIT/]5#]GW_ (+K?\$M/V@/AGHGQ#A_:]^#
MWPDO[_2X[O7/AY\<?&FA?"SQYX5U-8=]_H=[I/BR]TV#6KBRF5X8M0\*76NZ
M/J@"2Z7?72RJ*_%<5PSG6%K2I?4:]=)VC5PU.5:E./22<$W&_::C)=4CV(XB
MC)7YXKRDU%K[[?@?R7?\'-'_  5__9T_;<TKX1?LG_LJ^*%^)_@/X6?$"\^*
MGQ$^*^GVEY:>$=8\;VGAS6/!WAGPYX)FU*RM+S7K+1M*\3>*KG6?$=M&N@7\
M^H:5%H=SJL5O<W<?W'!^0XK+77QN-A[&K7I*C2H-ISC3YHSG*I9M1<G""C#X
MHI/F479'%BZT9J,(.Z3NWTNE9)?>_+8_E=^#_P /V^+/Q;^%OPKCU5="?XE_
M$7P1\/TUM[(ZDFC-XR\2Z9X<756TY;JQ-^NG'41=FR%[9FZ$/D"ZM]_FI]K7
MJ^PH5JW+S>QI5*O+>W-[.#ERWL[7M:]G;L<D5S2C':[2]+NQ_HJ?LT_\&E__
M  3O^$_]GZI\>_%OQA_:E\06_E->Z?K.O?\ "IOAQ=218.^W\+_#N>#QM;AY
M,F2&\^*6J6[QA(C%@2M-^48OCC-:UXX6GA\%'HXQ]O57_;]7]U]U!'IPP=*/
MQ<T_P7W+_,_"W_@ZE_9._9H_9*\>?L1>#OV:/@9\,_@EX?U3X:_%N37+;X>^
M%-+T"[\27&E^)?!D6G7OBK6+:#^V?%6HV,5Y=0VNI>(M0U._AAN)8H[@1N5K
MZ3@K'8S'4LQGC,36Q$HUJ'+[6;DH)PJ74(_#!.RNH**TV.?&0A!TU"*CI+9)
M=M^Y_)O7W!Q!0 4 % !0 4 % !0!_I._\&IO[$O_  H#]A?7?VG_ !7I'V3X
MA_M?^)4US2)+J#R[W3_@M\/KC5/#_@.V"RJ9;8>(]?N/&?C#S862#5]!U3PC
M<O&_V2WDK\CXVS'ZUF,,%3E>E@(<LK;/$5;2J?\ @$%3I_W9*:/5P=/EI<W6
M;O\ ]NK2/ZOYGZ$?\%W?VV_^&&/^";OQL\<Z#J_]E?%3XJV:_ 7X./#/Y%_!
MXT^)-CJ-GJ7B'3I%/F0WO@GP+9^+O&>GW(CDA75]#TNUF"B\4UY7#.7?VEF^
M'IRC>A0?UJOII[.BTXP:[5*CITVM^64GT-:]3V=*3ZM<L?5Z?AO\C_):K]Q/
M%"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H _P!S"OYO/H#\
M,_\ @Y-_Y0K?MG_]VZ_^M8? JOI.$?\ DH<O_P"YO_U!Q)SXK^!/_MW_ -+B
M?Y3=?MAXX4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H _JR_X,_?^4EGQP_[,9^)?_J_/V9J^)X\_Y$^&_P"QE1_]1<8=F"_B
MR_Z]O_TJ!_H_5^2GJ'^=W_P>)?\ )\'[,/\ V:G!_P"K=^)%?JW 7_(MQG_8
M<_\ U'HGFX[XH?X7^9_(G7W1PA0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 =U\+_^2F?#
MO_L>O"/_ *?]/K.K_"J?]>Y_^DLJ'Q1_Q1_-'^WM7\YGO'\_/_!SW_RAU^/W
M_8]? 7_U<G@ZOJ>#?^1]AO\ KUB?_3$SFQ?\"7K'\T?Y:M?LYY 4 % !0 4
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M*3<?W--0IOE:7*W%M=R\11ITZ$N6"33CK:[W75ZG^>_7ZD>8% !0 4 % !0
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MA"-.$*<(J,*<8PA%:*,8I1C%+HDDDO(\-N[N]WJ<_5""@ H * "@ H * "@
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M4.(;= /W+V%/"X!X:BN6E0PCI4U_=ITN57\W:[?5W9X_,Y5%)[N:?X_IT/\
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MXV?+#E3BY)KGQ%5TH+E^*3LM-N[/XQ_^"=W_  7\_P""@WP=_:[^%>L_'/\
M:2^)'QV^"OCGXA>&_"_Q>\!_$[5AXJT^/PAXIUS3M*UK7O!2W_E/X0\1>&+:
M9M;T*/P_=:1I-S<V9TO5+6;2[^\C/Z#FO"^5XC UHX;!T<-B*=*<L/4H1]F_
M:0BW&-3ETG";7++F4FD[Q:DD<-+$U%./-)RBVDT^STNNUC_4<K\8/6/Q=_X+
MK_\ !2OQ#_P3,_8KN?B+\,;?2[KX[_%?Q?9?"GX.OK6GC5='\.:M?:9J6M^(
MO'FI:9(T=KJ,?A/P[I5VVDV%XTUC<^*]2\.+JFGZGHJZI92_0\-91#.,P5*M
M?ZM0A[>NHOE<XIJ,*2:VYY-<S5FH*7*U*S,,15]E3NOB;Y8]OZ27Y'\*G[&G
M_!PA_P %%_@/^TQX'^)?QD_:6^)7QU^$>H^+](A^,7PR^(M_'XGT+5? 5_J-
MG!XI?P9ILT=O%X)\3Z;I(N-1\+77A9M(L8-9MK:'5+#4]%NM4TJ__2L?PME.
M)P=2C0P='#5U3?U>M1C[.4:J3Y.=K^)!RLIJ?,^6]FI*,EY]/$U(S3E)RC?W
MD^WEV:Z6/]4J.2.6..6)UDBE19(Y$8,CQNH9'1ERK*RD%6'!!!'%?BAZY_%Q
M_P 'E7@W3KOX,_L._$)K=?[6\/\ Q.^,'@V&[& _]G>,/"O@[6[FW?',B_:?
M UI)%NR(2)MFWSWW?H7 %1JOF5*_NRHX>I;SISJ1O]U3\NQPXY>[3?:37WK_
M (!_ S7Z<>:% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'ZL_\$.?^4M7
M["'_ &7/2O\ TRZW7B\1?\B/,_\ L%G^:-L/_&I_XC_77K\)/:/Y$_\ @\2_
MY,>_9A_[.L@_]5%\2*^[X!_Y&.,_[ O_ '/2.+&_PX?X_P#VUG^=W7ZJ>8%
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % '^B)_P9V_\F/?M._]G63?^JB^&U?E7'O_ ",<%_V!?^YZIZ>!_AS_
M ,?_ +:C^NROA#M/\>__ (+!_P#*4S]O[_LZSXR?^IAJ5?O60_\ (ERO_L!P
MW_IN)XN(_C5/\1^;]>L8A0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MYX+2T@FN;JYFBM[:VMXGFGN)YG6.&""&-6DEFED98XHHU9W=E15)(%+;R2_
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M 65OO&%?E:W'ZO;#Y:VOYJV(L_\ P"%)I?\ @Q]CI6!_FJ?='_-_H>B>,O\
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M3_R5EZW1_*W7VAQA0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 ?[F%?S>?0'X9_\')O_ "A6_;/_ .[=?_6L/@57TG"/_)0Y?_W-_P#J#B3G
MQ7\"?_;O_I<3_*;K]L/'"@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /]/'_ (-5_P#E
M$IX/_P"RY_&K_P!/6FU^.\;?\CR7_8+A_P I'K8/^"O\4C^C^OD3J/\ %"_:
M?_Y.6_:'_P"RY_%K_P!3[7Z_HC"?[KAO^P>C_P"FXG@R^*7^)_F>&5T$A0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 ?U9?\&?O_*2SXX?]F,_$O\ ]7Y^S-7Q/'G_ ")\
M-_V,J/\ ZBXP[,%_%E_U[?\ Z5 _T?J_)3U#_.[_ .#Q+_D^#]F'_LU.#_U;
MOQ(K]6X"_P"1;C/^PY_^H]$\W'?%#_"_S/Y$Z^Z.$* "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@#NOA?\ \E,^'?\ V/7A'_T_Z?6=7^%4_P"O<_\ TEE0^*/^*/YH_P!O
M:OYS/>/Y^?\ @Y[_ .4.OQ^_['KX"_\ JY/!U?4\&_\ (^PW_7K$_P#IB9S8
MO^!+UC^:/\M6OV<\@* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H _P!2K_@V$_Y0Z_ #
M_L>OCU_ZN3QC7XQQE_R/L3_UZPW_ *8@>OA/X$?67YL_H&KY8Z3_ !0OVG_^
M3EOVA_\ LN?Q:_\ 4^U^OZ(PG^ZX;_L'H_\ IN)X,OBE_B?YGAE=!(4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?Z5_\ P:1_\HN/%G_9VOQ8
M_P#4#^$%?D/'/_(YA_V T/\ TY7/5P7\'_M]_DC]\?VQ_P#DT/\ :I_[-O\
MCC_ZK'Q/7S.7?[_@?^PS#?\ IZ!TR^"7^%_D?XK]?T(>"?W-_P#!HE^V_P#&
M/QEXK^._[#GC[Q=K7C+X=>#?AA!\;OA+;^(;W4M7N?A['H_BOPKX#\6>%/#U
M_>W$XTWPCJO_  EWAK5++PO%Y>G:9JECJNHZ1;6\NLZVUS^;\=Y=AX4\-F5.
MG&G5G6^K5W!1BJO-3J583FE:\X^SG'GW<6HR?NPMZ."J2?-3;NDKQ\NC7IMI
MT/[E:_-SO/\ *W_X.-/AJNG?\%I?VEO#_@S2C/?_ !$N/@7K6GZ+IRAYKWQ1
MXP^#7PXM;R*&+.?MNN>(Q<WS(Q'F76I%QM21<?M?"=6_#V"E4>E)8F+D^D*>
M(K6^4867I$\C%+]_*W7E_P#24OT/J[]F;_@TQ_X*%_%W3]-\0?'7QE\'_P!E
MS1;^".>30]?U:[^)WQ,LTF >(S^%_ @?P=$?*PTUM=?$RTU"VD9;>XL8IEG2
M#AQ?'&54&X8:&(QDEIS0BJ-%_P#;]6T_NHM/H[6O<<%4?Q.,/+=_AI^)^I_A
MG_@S3^#5K81)XR_;F^)NMZIY.)KGPS\&?"OA:P-QC[\5CJGC?QA<+"IP/+;4
M6=@,^:F<+XD^/Z]_W>6T8Q[3Q$YNWK&E37X&RP,>LY?))?YGS_\ 'W_@S@\>
M:3H%_JW[,O[9/AWQKX@MK226R\$?&7X:W?@6VU*>++B"/Q]X1\1^,H[::YC_
M '-O'=>!HK5;D1_:=1@MY7FM>K"\?4I24<9E\Z4;ZU,/656R[^RG"GHM]*C=
MMDWO,L#I[D_E)6_%;?<?R,_M-?LN?'G]CKXO^(_@5^T=\.-=^&7Q*\,LDESH
MVL1Q2VFJZ5/)-%I_B/PQK5E)<:-XH\+ZJ;:?^R_$.@WM]I5XT%Q!'<_:;6Z@
MA^ZP>,PV/H0Q.$JQK49[2CT:M>$XNTH3CI>$DI+32UCAG"5-\LE9_IW7=>A<
M_9&_9VUC]K;]IKX'_LSZ!XCTWP?K'QL^(GA_X?:?XHUBSNM0TS09]=N1!_:=
MY863QW5Y%:H&D^S02PO,P6/SH@QD58[%1P.#Q&+E!SCAJ4ZKA%I.2@K\J;T5
M_P !TX<\XPO;F=K]C^K+_B#6^.__ $>[\)/_  TWC'_YIZ^*_P!?\+_T+L1_
MX.I__(G9]1?_ #\7_@/_  3\O/CI_P &\G[7'P]_;Z^'_P#P3_\ @]XG\*_'
M?QSXR^!NA_'W7OB3;Z1K7@3X:_#+P1J_C?Q[X'EO_'VI7I\0W6FV=E?^!F\F
M:S@OM1UJ\UK3]&T+1M0U,B"7V<-Q3@*N65<TKPGAJ5/$RPL:3<:E:K4C3I5+
M4HKE3;53:Z45%RE)1,986:J*G%J5XJ5[645=K7?M_P  _9[PO_P9E>9X75_&
MG[?_ -D\:W%E$[VWA?\ 9S_M'POI.HF#]];+>ZK\9-+U;Q#91W/$5Z=/\,3S
M0+N;3X';:GST_$#W_P!WE=Z:>\\7RS:Z:1P\HP=NEYI=V="P*MK4U\HZ+\=?
MP/Q7_P""4/\ P0:^)7_!57X._$KXQ>#?V@_ WPATSX<?%&;X73Z/XF\&Z_XF
MOM5O[?PMX>\42ZI#-I6J:=;VMI]G\16MK'"_G3--!.[%$\O?]%G?$M#),12P
M]3"U:[JT?;*4)P@HKGE"WO)Z^XWVM8YZ.&=:+ES*-I<MK7V2?==S_24_8;_9
MSU']D7]D']G?]F;5_%%EXUU3X)_"[PUX!U'Q7INFSZ/I^NWFC6WEW%_9:;<W
M5[<6EK)*S"&.>YDE,:J[^6S&-/R/,L7''8_%8R,'3CB*TJJ@VFXJ6R;5E?T/
M4IQY(1AORQ2OML>"?\%9/V$_$7_!1W]BSQQ^RMX5^(&B_#'6?%GBGX?>(8/%
MWB#1;[7],LXO!?BK3_$,]M+ING7EC=2/?16;6T,B7"K#(ZNZLH(KIR/,H93F
M%/&SI2K1IPJP]G!J+?M(."U>FER:U/VM-PO:]M;7V?R/X>?V\/\ @V,^+G["
MG[)?QC_:O\1?M5_#CX@:+\'M*\/:I?>#]%^'7B;1=3UI/$'C/PWX-BAM-3OM
M>N[2T:VG\1Q7SM-;2AX;62%0KR*R_H^6<88?,L=A\##!5J4J[FE.52#C'DIS
MJ:I*^T+:=S@J81TX2GSI\O3EMU2[GQ]_P21_X(C_ !$_X*R>$?C/XO\ !?QV
M\%_!VS^#?B/PCX;O+7Q/X2USQ/<ZY<^*],UG4TN+4Z5J6FQ64%E%I/EL)6G>
M=[CA8EAS+WYYQ%1R.>'A4PU2N\1&I)<DXP453<59\R=[\WRL9T,.ZR;4E'E:
M6U_U1^N\O_!FU\=HHI)/^&W/A(1'&[X'PG\8C.Q2V/\ D9^,XQ7A+C["[?V=
MB/\ P=3_ /D3?ZB_^?B_\!_X)^4/_!,+_@W^_;#_ ."E&@6OQ8@N]$_9[_9R
MN+PVUA\7OB/I6K7]_P"-TM[B6TU.;X4^!+'[#>>,[72KB%[:[UK4];\)>$YK
MR.ZTW3O$E_JNFZI867MYSQ/@,HE[!J6*Q:6N'HN*5/1./MJCNJ?,MHQC.=K-
MP47%O&CAIU5S?##NUOZ+3\TC^@^'_@S4^"BZ)Y$_[<GQ2D\1[3C58?@YX3@T
M3=LP#_PC[^-+B^VA\,5_X24$I\FX'YQ\M_K_ %^;3+:/+V^L3YO_  +V27_D
MAT_48V^.7W*WW?\ !/YY?^"J/_!!']JO_@F%HL7Q4U#6]$^/G[-]QJEGHTGQ
MC\#Z+J6A7?@_4M1F2TTFT^)_@>]N=7G\&1ZW?.MAH^L6/B#Q/X9N=0FL=)NM
M=L=;U/3-*N_JLEXFP6<R]A&,L+BU%R^KU)*2FDKR=&HE'VG*M91<(32O)0<4
MVN6MAI45>ZE'NE:WJNGWL_"^OI#G.M\!^ O&OQ1\9>&OAW\-_"?B#QUX[\9:
MQ9^'_"GA#PII-YKGB+Q#K6H2B&STS2-)T^&>\O;N=SA(H(F(4,[;8T9AG4J4
MZ-.=6K.-.E3BY3G-J,(16[;>B2&DVTDKMZ)(_K&_9'_X-$?VIOBCX=TCQ=^U
MA\=/!?[,J:G;+>?\*X\,>'A\9/B/I\;J/+LO$MW8^)?"_@/0;]L^8PT7Q-XV
M2"/9%<)%=M-!:_$8[CK T)NG@L-4QG+I[64OJ]%^<+PG4DO\4*?EIJ=L,%)J
M\Y*/DE=_/9+Y7/OC5_\ @S4^"<VEB+0/VX_BGINM>0ZF_P!7^#WA+6]+-QM/
MERC2++QEX?NU@5MI>#^VV=U!5;B,D,/,CQ_B$_>RVBX]HXB<7;U=*2_\E^1I
M]1A_/+[D?@G_ ,%&_P#@W0_;@_X)_P#A#7/C!ILGAW]I7X!>&[9[_P 3?$/X
M6V>HV7B3P/I<4FQ]6\>?#34VN-:TO1H8_P#2;[7?#.H^,= T2S62Z\1:KH]N
M@D;Z;*>*\MS2<<.^?"8J;M"C6LX5'_+2JQ]V4NBA-4YR>D(R.:IA:E-77OQ6
M[CNO6/;TOIO8_ "OJ#F/ZD?V'_\ @U\^,7[;'[*?P8_:GT/]J[X:> M(^,OA
MR]\2:?X1U7X>>*-;U'1+:U\0:QH*6]YJ=IKEA:W,\IT@W3&"U2.(3B$-+Y?F
MO\9F/&6'R[&XC!2P5:I+#R4'.-2G&,KPC+1--KXK?([*>#<X1GSI<RO;EV_$
MP?\ @H!_P;,?&3]@K]DWXG?M4ZM^TUX$^*UG\-[SX=Z>/A_X5^&WBG3/$'B2
M\^(OQ/\ !GPPTVVTN[N=;U"(7%OJ/C.UOO(^QSRWB6KV<"B>>-EO*^+\/F>-
MHX*.#JT7555^UG5IN$%2HU*SNDETIV\KWZ!4PCIP<^?FM;11WNU'OYGO_P"Q
MI_P:.?M'_&CX=^'_ (C?M4?'S0_V7;GQ)8Z?K.G?"G2/AY<_%+XC:?I5_;)<
MI:>.I+GQ?X#T'P/XC59$,VB6D_C.XT[)M=8&FZI%=:;:\F8<<X/#594<%A98
MWD;C*LZJH47*+M^ZM3JRJ0_O6II_9O&S*IX*32<Y<O\ =2N_GLD_O/QT_P""
MR'_!,BQ_X)3?M/\ @W]GW3/C'=_&W3_&WP2\-_&6T\37_@:'P#>:3'KWCCXB
M^"&\-W&F6_BOQ=!J+VLOP]DU-=8BN]/6:/5TLCI<36!N[WW\@SAYW@IXIX=8
M9T\3/#N"J>U3Y*=&ISI\E.U_:\O+9VY;WULN>O2]C-13NG%2VM;5JWX>7H?D
MQ7N&(4 % '6> O _BGXF^.?!GPV\#Z1<^(/&GQ \5>'O!/A#0;)0UWK7B?Q5
MJUIH6@Z3:J< W&H:I?6MI"#@>9*N2!45*D*-.=6I)0ITH2J3D]HPA%RE)^48
MIOY#2NTENVDOGHC_ &7?V(OV7?"_[%O[)GP$_9>\(_9IM-^#WP[T7PUJ.IVL
M7D1^(O%TJR:OX[\6F(JACE\7>-=2U_Q+-&47RY=4:,*JH%'\_P"98V>88[$X
MR>CKU92C'^2FO=I0_P"W*<8P^1[E."IPC!?927^9_(!_P=^?MM^?>_ 3]@'P
M=J_[NQ1/VAOC5!:3\&[N$U7PO\(_#5ZT)&UK>U/C3Q7J>DW>X.M]X'U<0J8[
M28_>\!Y=:.)S2I'XO]EP]UT5IUYKU?LX1:_EJ1.+&U/AI+_%+\HK\W]Q_#K7
MZ,>>% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'W-_P3 _Y26?
M\$\?^SYOV2O_ %?G@"O-SG_D3YK_ -BW'?\ J+5-*/\ %I?]?(?^E(_V2J_
M3W H __0_OXH _E-_P"#P+_E&E\#_P#L^;X:?^J#_:9K[;@/_D;XG_L6UO\
MU)P9QXW^%'_KXO\ TF1_G U^M'EA0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MM"K=0O[MKZ66M[?D?H[XN_Y%3Q/_ -B]K7_IMN:\FG_$A_CC^:-3_%$^!?\
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M>69F)+$\DG)K^=*_\:K_ -?:G_I3/?6R]%^1_)7_ ,'CO_)J/[(?_9POB?\
M]5OJ5?<\ _[[C_\ L%I_^G4<>-_AP_Q_^VL_SXJ_4CS H * "@ H * "@ H
M* "@ H * "@ H * "@ H _5G_@AS_P I:OV$/^RYZ5_Z9=;KQ>(O^1'F?_8+
M/\T;8?\ C4_\1_KKU^$GM'\B?_!XE_R8]^S#_P!G60?^JB^)%?=\ _\ (QQG
M_8%_[GI'%C?X</\ '_[:S_.[K]5/,"@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MMKJVED@GB>)V4^%&4H2C.$G"46I1E%N,HR6J<6K--/5-:KH;'^5I_P %_/\
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MB]X[^'=IJ]U"MO/KVB>'/$%[9>'/$;0( L*^(_#Z:9KL<:@!(M010!C _H#
M8J.-P6%Q<4DL10I5>5:\DIP3E"_]R5X/T/#J0Y)RA_*VEZ=/P/\ 1#_X-/\
M_E%+'_V<E\8O_2#P37Y5QO\ \CO_ +D\/_Z55/3P?\%?XI'ZX?\ !4C_ )1G
M?\%#/^S(?VJ?_5&^.:\+)?\ D<95_P!C'!?^I%,VJ_PJG_7N?_I+/\A'X%_\
MEN^#G_95/A[_ .I;I%?N^(_W>O\ ]>:G_I#/%A\4?\4?S1_MN5_.I[Q_"_\
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H _T\?^#5?_E$IX/_ .RY_&K_
M -/6FU^.\;?\CR7_ &"X?\I'K8/^"O\ %(_H_KY$ZC_%"_:?_P"3EOVA_P#L
MN?Q:_P#4^U^OZ(PG^ZX;_L'H_P#IN)X,OBE_B?YGAE=!(4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % ']67_!G[_RDL^.'_9C/Q+_]7Y^S-7Q/'G_(GPW_ &,J/_J+C#LP
M7\67_7M_^E0/]'ZOR4]0_P [O_@\2_Y/@_9A_P"S4X/_ %;OQ(K]6X"_Y%N,
M_P"PY_\ J/1/-QWQ0_PO\S^1.ONCA"@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H [KX7_\
ME,^'?_8]>$?_ $_Z?6=7^%4_Z]S_ /265#XH_P"*/YH_V]J_G,]X_GY_X.>_
M^4.OQ^_['KX"_P#JY/!U?4\&_P#(^PW_ %ZQ/_IB9S8O^!+UC^:/\M6OV<\@
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H _U*O^#83_ )0Z_ #_ +'KX]?^KD\8U^,<
M9?\ (^Q/_7K#?^F('KX3^!'UE^;/Z!J^6.D_Q0OVG_\ DY;]H?\ [+G\6O\
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M_P#>,M_Z\XC_ -+I!@?@G_B7Y']H3*K*R,,JP*L.Q4C!'XCBOST[C\5OVO\
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M5>7=?+\FC^^/_@@I_P HA/V&?^R5ZM_ZL+QG7YCQ/_R/LR_Z_0_],TST</\
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MJ<J<[?5L(K\LDG;1V=K.VAYN,:E4BXM->S6J::^*78_F.K[ Y H * /Z@_\
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MU%T8._Q2M>VR2V7RZ].Q^[/B[_D5/$__ &+VM?\ IMN:^:I_Q(?XX_FCH/\
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H _T1/\ @SM_Y,>_:=_[
M.LF_]5%\-J_*N/?^1C@O^P+_ -SU3T\#_#G_ (__ &U']=E?"':?X]__  6#
M_P"4IG[?W_9UGQD_]3#4J_>LA_Y$N5_]@.&_]-Q/%Q'\:I_B/S?KUC$* "@
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M_P#KS4_](9XL/BC_ (H_FC_;<K^=3WC^%_\ X//_ /CZ_P""</\ U[_M=?\
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * /]/'_ (-5_P#E$IX/_P"RY_&K_P!/6FU^.\;?
M\CR7_8+A_P I'K8/^"O\4C^C^OD3J/\ %"_:?_Y.6_:'_P"RY_%K_P!3[7Z_
MHC"?[KAO^P>C_P"FXG@R^*7^)_F>&5T$A0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?U9
M?\&?O_*2SXX?]F,_$O\ ]7Y^S-7Q/'G_ ")\-_V,J/\ ZBXP[,%_%E_U[?\
MZ5 _T?J_)3U#_.[_ .#Q+_D^#]F'_LU.#_U;OQ(K]6X"_P"1;C/^PY_^H]$\
MW'?%#_"_S/Y$Z^Z.$* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@#NOA?\ \E,^'?\ V/7A
M'_T_Z?6=7^%4_P"O<_\ TEE0^*/^*/YH_P!O:OYS/>/Y^?\ @Y[_ .4.OQ^_
M['KX"_\ JY/!U?4\&_\ (^PW_7K$_P#IB9S8O^!+UC^:/\M6OV<\@* "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H _P!2K_@V$_Y0Z_ #_L>OCU_ZN3QC7XQQE_R/L3_U
MZPW_ *8@>OA/X$?67YL_H&KY8Z3_ !0OVG_^3EOVA_\ LN?Q:_\ 4^U^OZ(P
MG^ZX;_L'H_\ IN)X,OBE_B?YGAE=!(4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 ?Z5_\ P:1_\HN/%G_9VOQ8_P#4#^$%?D/'/_(YA_V T/\
MTY7/5P7\'_M]_DC^H&OC3K"@#R?XP?'CX)_L^^%;SQQ\<_BU\.OA#X1L8);B
M?Q!\1O&.@^$--*0@;H[:?7+ZR%[=.Q2*WLK(7%Y=7$D5M;02SRQ1MOA\+B<5
M-4\-0JUYO11I4Y3?SY4[+S=DA-QBO>:BO-I(_B"_X+:?\'+?AGXO^ ?&W[(W
M_!/'4=:D\(>,K"]\*_%?]IN[L;_PY-K_ (6U&VEL]?\ !?PAT+5;2SU^QT[7
M;69]*USQ_KMKI&HR:>VI:?X6T98;RQ\75^C<.\(3P]6GCLU4?:4VIT,&FI*$
MXN\*E>46X-Q:YHTH.23Y7.6CIGGU\4FG"EL]'/;3M'_/[NY_&1X.\&^+?B'X
MJ\/>!? ?AG7?&7C3Q;J]CX?\+^%/#&E7NN>(?$.N:G.EKIVDZ-H^FPW%]J.H
M7MQ(D-M:6L$LTLC!40U^@3G"E"52I*-.G3BY3G-J,81BKN4I.R22W;T1PI-M
M)*[>B2/["OV-/^#0KXR^/M TCQI^VQ\?=,^"(U;3[/41\)/A/I-MX^^(&F_;
M(HYI-.\6^--6GLO!7AW6K#+Q75IX<L/B)ISR$;-:4QO&WP>8<=X>E*5/+L,\
M3RMKV]9NE2=M+PII.I.+Z.;HO^Z=T,$_^7DK>4=?QV^Y,_:'X<?\&GW_  2J
M\%"W;Q4O[1OQ>DCV&=?'GQ=L]'MKAQC>HB^%O@_X=7$,#'.Q%O&F1,*;F1P9
M#\]5XWSJI\"P=#M[.@Y-?^#JE5?A;R-U@Z*Z2EZR_P#D>4_;S]D7]BS]F;]A
M'X8ZA\'/V5/AG%\*OASJWBV_\=ZGX?B\5>-_%YO_ !=JFCZ#H&H:[<:MX^\2
M>*=;-U=Z1X8T*SDB344M FG1-';1R/,\GSF.S'&9G65?&UO;58TU2C+DIT[4
MXRE)14:4(1LI3D]KZF\(1IKE@K+>VOZ^AX?_ ,%==/MM2_X)<_\ !0&VNEWQ
M1_LD?'34%'I<:3\/];U2S;_@%W9P/_P'C%=.0OESK*[?]!V'7R=2,7^#%6_A
M5/\ KW+\(L_S'O\ @B[_ ,I6OV"/^SDOA_\ ^ES5^Q<0?\B3,_\ L#K?^DGD
MX?\ C4_\1_K[5^#GM'\/W_!W]^V5\0?#2_L[?L/>#M=U#P_X.\<>&=2^.OQ=
M@TO4[JRD\:65MXAOO"'PZ\,ZS!:/ +OPUINJZ#XM\07>EW[7>GZGKMOX;U$V
ML-YX8LYV_1^ \OI26*S*<5*I3FL+0O%/V?N1G5G&^TW&<()JS4>=;39P8VHT
MHTUHG[TO-+1+T_R1_"A7Z2><% '^OG_P1:_Y11_L$_\ 9N'@/_TDEK\(XA_Y
M'>9_]A=3]#VZ'\&G_@C^1\2?\'1/_*'_ .,O_93/@5_ZLW0Z]'@S_D?8?_KS
MB?\ TS(SQ?\  EZQ_-'^7/7[,>0?WV?\&:O_ "1']N+_ +*I\'O_ %$O&-?F
M/'_^\9;_ -><1_Z72/2P/P3_ ,2_(_M!D<1QO(V=L:,YQUP@).!ZX'%?GJ['
M<?XD7QL^+'BOX[_&'XH?&GQSJ=]K/B_XJ^/O%?C_ ,0ZCJ,YN;N?4_%6M7FL
M7"O(?E$=N;L6UM#$$M[:VAAMK:**WBBC3^BL/0IX:A1P]**C3H4X4H12LE&$
M5%?D>#)\TG+NV_O/Z^?^#-KXC:Y:_&?]M/X2?VA>/X9USX8?#;XC+I32EM/M
M]<\*^*M5\,MJ$,#96WO+S3_&*6US+"$-W!8VB7/F"QM/)^#X_I1>&R^O9<\:
MU6ES=>6=-3MZ)T[KM=VW9VX%ZU(]+1?YH_OGK\Q/1/\ '>_;(\!P>.?^"L7[
M5/PQ@$L%MXQ_X*'_ !Q\!PBUVB>&#Q!^TGXG\/QBWW(ZB6..['E9C90X7*,.
M*_?,!4]EDN"K/_EWE>&J.^WN82$M?N/$FKUYQ[U9+_R>Q_L%Z#H>D^&-#T;P
MWH-C!IFA^'M*T[0]%TVU79;:?I.DV<-AIUC;ISM@M+.WAMXES\L<:CM7X+*3
MG*4Y.\IR<I/NY.[?WGMGY*_\%:?^"1GA;_@K'H/P3\+>-_C_ /$+X-^&O@UJ
M_C?7UT+P9H.A:]IOB[7/%MGX;T[3]6UF#6+BV\F]\*V&C:O9Z1+$TO[CQ5JZ
M8BWGS?<R//9Y'+$3IX6EB)XB-./-4E*#IQIN;<8\J>DW*+?^"/RQK45644Y.
M*C?1==OR_4_%'_B#;_9T_P"CT?C5_P"&X\#?_+.OHO\ 7_%?]"[#_P#@ZI_\
MB<_U&'\\ON1_7C\*_ __  K'X8?#CX;?VW?^)O\ A7O@/P?X'_X2/58XHM3\
M0?\ ")^'M.T'^V]1B@)@CO\ 5?[/^WWD<),27$\BQG8!7PE>I[:M6K<JA[6K
M4J<D?AASR<N57Z1O9>2.U*R2[)+[C^-#_@\Q\*V,W@7]@CQL((%U+3?%GQ_\
M*M<A +B:QUK1_A5JR0/(!F2"VG\/R21(Y(A>ZF,07SY=WZ!X?S?M,SI_9<,+
M.WG%UX_E+\%V.''+2F^SDOO2_P C]]/^""G_ "B$_89_[)7JW_JPO&=?,<3_
M /(^S+_K]#_TS3.G#_P:?^$^BO\ @IQ^T_K7[&7[ O[4O[2WAB.TD\7?#/X7
MW\W@EK[8UC;>.?%.HZ;X'\$7]Y Z.EY:Z;XK\2Z/?SZ>P4:C%;-8>;!]H\Z/
MDR;!1S#-,%@YW]G6K+VEMW3IQE4J)=KP@U?I>_0JK/V=.4OY5IZ[+\3_ !W/
M%7BKQ/XY\2Z]XR\:>(=;\6^+O%.K7^O>)?$_B35+W6_$'B#6]4N)+O4M7UG5
M]1FN+_4M2O[J62XN[V\GFN+B9WDED9F)K][A"%.$:=.,80A%1A"$5&,(Q5HQ
MC%644DK))62/$;;=WJWNS JA!0 4 % '^K__ ,&_G[$O_#$O_!-?X.Z/X@TC
M^S/BM\=HO^&A/BL)X/*U"UU;XAZ=ITOA#PW>+(OVFUE\)_#JS\)Z1J.ERN4L
MO$J^(YHXX9+V=3^(\49C_:.;UW"5Z&%_V6AVM2;]I)=^>LYN+ZPY.R/9P]/V
M=**M9OWI>KZ?)61\<?\ !U%^VW_PSG^P19?LY>%-7^Q?$G]L7Q#-X+N([:?R
MKZP^#/@QM-U[XGWZE&+)'KMY=>$/ ,\$T8BU'1/%GB)8I!)9,*]#@K+OK>9O
M%SC>C@(\ZNM'B*EXT5_VXE.KI\,H0[HSQ=3DI\JWGI_VZM_T7S/\T>OUX\H*
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#[F_P""8'_*2S_@
MGC_V?-^R5_ZOSP!7FYS_ ,B?-?\ L6X[_P!1:II1_BTO^OD/_2D?[)5?@)[@
M4 ?_TO[^* /Y3?\ @\"_Y1I? _\ [/F^&G_J@_VF:^VX#_Y&^)_[%M;_ -2<
M&<>-_A1_Z^+_ -)D?YP-?K1Y84 % !0 4 % !0 4 % !0 4 % !0 4 % !0!
M_H,?\&OW[:/['7P!_P""<7BCP+\=_P!K#]FKX)^-I?VG_B;KT/@_XN?'3X8?
M#;Q1/H6H>"?A5;6&MP:!XR\4:+JLVCWMS87]M::G%:/8W%S8WMO%.TUI<)'^
M6\99?C\3FT*F&P.+Q%/ZG1C[2AAJU6"DJE:\>:G"45))J\;W2:TLT>EA)PC2
MM*<(OF>CDET71G[9?M8?\%)_^"=/B#]EG]I;0/#_ .WS^Q9KVO:W\ /C)I&B
M:'HG[4GP.U;6=9U?4OAUXCLM-TG2-*T_QS<7^IZGJ-Y-#9V&GV-O/=WEU-%;
M6T,DTB(?G<!E&:PQV"E++,PA&.*P\I2E@L3&,8QK0;E*3II1BDKMNR25WH=$
MJM+EE^\I_"_MQ[>I_D:U^Z'BA0 4 >D?!O4+'2?B]\*M5U2\MM.TS3/B1X&U
M#4;^]FCMK.QL;+Q/I=Q=WEW<2LD5O;6UO')-/-*RQQ1(SNRJI(RKINA6BE=N
ME422W;<&DDBHZ2CY-?F?[ 7_  \__P"":7_20[]AG_Q+3X!__-_7X-_8V;_]
M"K,O_"'$_P#RH]KVM+_GY3_\#C_F?QI?\':_[3_[-/[2%W^P+_PSO^T+\#OC
MT/!EO^U#_P )>WP7^*_@/XHIX5_X2*3]GG^P%\1/X'U[7$T1M;_L+6CI*:DU
MLVH#2=1-J)197'E_H' V#Q>$69_6L+B<+[1X/V?UBA4H\_(L5S<GM(QYN7FC
M>VUU?='#C)PE[/EE&5N>_*T[?!;;;8_CBK[XX3U_X!_'CXJ?LQ_&+X?_ !Y^
M"7BV_P#!'Q0^&7B&U\2>%/$.GL"8+N /#<V%_:OFVU30]9T^:[T;Q!HE]'-I
MNMZ)?W^DZC;SV5Y/"^&)PU#%T*N&Q%-5*-:+A.#ZKHUVE%VE&2LXR2E&S2*C
M)P:E%V:V_KMY'^C5_P $Y_\ @YT_8H_:C\*^'?"?[5?B/0_V1/V@(K.*U\0?
M\)C/<6?P)\4ZC H2?5_!WQ)O);FR\)V-X%^V/H/Q*N]$FTAY?[*L?$7BW[/_
M &K<?D^;<&YA@YRG@8RQV%O>*A;ZS!?RSHJWM&MN:BI<V[A#8]2EBJ<U:7N2
M\](_)_H_Q/Z%O!WQP^"WQ$TRVUKX??%_X7>.M&O;<75GJW@[Q_X3\3Z9=VI&
M5N;:_P!$U:]M9[<CD312M&1T;%?*U,+B:3<:N'KTI+1QJ4JD&O)J44T=*:>S
M3[6:.$^+'[7_ .RC\"-(N-<^,_[2?P*^%VF6V]7G\<_%7P3X;DEEC7<;2RM-
M3UJWO-0OF'$.GV%O<WL[$)#;R.0ITH8#'8EJ.'P>)K/3^'0J2^;:C9+S=DA.
M4(_%*,?5I'\B_P#P5P_X.E/ DW@GQ9^S[_P33OM:USQ+XDL]5\-^*OVI]4TC
M4O#6D^%=*NX'L;L_!+1]56P\1ZAXJG62XCMO'FOZ7HNG^&Q%'J'A?3O$%Y>6
M&NZ%]WD7!=15(8K-U&,8.,X8*,E-SDM5]9DKP4%I^ZA*3GM-Q2<)<5;%JSC2
MWVY^B_P^?GL?PD3337,TMQ<2RSW$\LDT\\SM+---*Q>6665RSR2R.Q>1W)9V
M)9B2:_24K:+1+1)=#SC]4_\ @D5_P5+^)/\ P2O_ &DO^%GZ%IEUXW^#_C^R
ML/"GQV^%4=]]C_X2SPK:WINM/U_P_),XL+/Q]X+FGOKWPI?WR&VFM]0USPY=
MSV6G>([V]MO%SW):.=8/V$G[.O2;GAJUK^SG:SC);NE422FEVC)7<$C>A6=&
M5]XO24?U7FO^!Z?Z:G[)G_!4S]@K]M7PGI7B7X%?M)_#74-5U"SCN;[X;>+/
M$NC^"?BSX;F.$GL]?^'7B*^LO$,)M;G?:?VKIUMJ7AS4)8S+HNMZG9M#=2?C
M^.R3,\NFX8G!UE%.RK4X2J4)]G&K!..JUY7RS6THQ>AZL*M.:]V2>FW5>JW7
MY'T[\3_VC?V??@EX?OO%7QA^-_PE^%_AS3;3[=>:SX]^(7A3PK8Q6I ,;K-K
M6JV8F:<E([2& 237<SQ06L<LTD<;<5'!XK$24,/AJ]:3=E&E2G-W_P"W8NUN
MM]%UL6Y1BO>:BO-I'Y.?L>_\%G_AI_P4&_X*+>+OV7/V3["Y\4?L]_!?X >/
MOB)\0_CEJND7NG6WC[X@VWC_ .%O@_PAHOP]M+U;>^LO"%C8^)/%=Y<:QKEC
M9ZAXOOK82Z-866@Z"-2\3^YC^'JN593#&8YJ&*Q&*I4:6&C)/V-+V5:<Y56K
MIU&X02C%M4UNW*7+#&%=5*CA#6,8MN7=W227EOJ?N57S9N?Y _\ P6?UZW\2
M?\%6/V^-0M=OEV_[2GQ#T!MIR/M'A74AX7NQU/S"ZT>8..SY&!C _>.'X<F2
M98O^H.C+_P #CS_^W'BU]:U3_%;[M/T/[R/^"*'[?_[!_P +/^"67[&WP^^)
M_P"VO^R3\-O'OA?X;ZKI_B;P/X__ &CO@]X-\8>';X^._%UREGKGAGQ'XQTW
M6M)N7M9[>ZC@O[&WDDM;B"YC5H)HG;\SXBRO,JV=8^K1R['5J4ZL7"I2PE>I
M3DO94U>,X4W%JZMH]&K=#T:%2FJ--.I!-1M9RBFOE<\N_P"#@K]N_P#8>^,W
M_!)#]JGX:_![]LG]E7XL?$7Q)<? C_A'O /PS_:%^$GCSQIK@T?]H_X1:_JQ
MTCPOX5\7:KK>H+I>AZ5J6L:@UI8RK9:987E]<&.VMY9%VX6RS,</GF"JU\OQ
MM"E!8GFJUL+7I4X\V$KQC><Z<8J\FHJ[U;21.)J4Y49J,X-^[9*46_BCT3/\
MU"OUX\H^S_\ @GU^VG\0/^"??[6GPE_:D^'L"ZI=> ]9>V\5^%9I%AM/&_P\
MUZ%M)\<>#KB9XY4M9=9T"XNETK4FAG.BZ]#I.MQP32Z='$WGYIE]+-,#7P57
M15(^Y/\ Y]U8ZTJB77EDE=:<T;QZFE*HZ4U)=-UW75?Y=M#_ %1_V/O^"L7[
M!'[;W@/1O&?P9_:%\!6&KZEY<&I?"OXC>(_#_@'XN^&-5,:/-I.M>!=;U:._
MN6A9_)BUKPW+K_A74Y(Y?[%U_4DAD9/Q;'Y%FF75)4Z^$JN*^&O1A*K0G'O&
MI&-E_AGR3C]J*/8A5IU$N62]-GZ6_I=CZ6^-'[67[,7[.GAK4/%_QT^/_P (
MOA3X?TR$37%YXU\?>&]%FEW(7AMM.TVYU!=4UC4+H#%CI>DV5[J-^^([*UGD
M(4\>'P&-Q<U3PV%KUI/2U.E-I>KMRQ2ZN3275HJ4HP5Y245YM+^O0_&O]CC_
M (.%?V./VK_VE?VG_#6K?&3X/_L]?LX_"+PW\+].^#7C;]HCXA^"_@UXB^.7
MBO6=9^(R?$/Q7H5CX_\ $.AO#X6TZPT?P7!H/A\Q?\))96EZ^M^*;?2[K7[7
MP_H7T&8<*X_ X/!2CAZ^+Q=>=9XB&$I5*\,-",:7LJ;=*,O>;=1RG\#:Y874
M.:6$,33G*2YE&,5'E<FH\V][7Z;'Z*>*O^"G?_!->7POXCBA_P""A/[#\\TN
M@ZQ'%!;_ +5_P'GGFD?3[A8XH8(?'KRS2R,0D<42-)(Y5$4L0*\FGDV;J</^
M$K,4N>/_ # XE):K_IUH:^UI?\_*?_@<?\S_ "&_@WJ%CI/Q>^%6JZI>6VG:
M9IGQ(\#:AJ-_>S1VUG8V-EXGTNXN[R[N)62*WMK:WCDFGFE98XHD9W954D?N
MU=-T*T4KMTJB26[;@TDD>+'24?)K\S_8"_X>?_\ !-+_ *2'?L,_^):? /\
M^;^OP;^QLW_Z%69?^$.)_P#E1[7M:7_/RG_X''_,_C2_X.U_VG_V:?VD+O\
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M .44L?\ V<E\8O\ T@\$U\!QO_R._P#N3P__ *55.[!_P5_BD?KA_P %2/\
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M!-<W,\A"10Q/(Q"J:_&XQE.4803E*348Q6[DW9)+NWHCUC_'(_X*3_M@:O\
MMW_MN_M!_M.W\MY_8OC_ ,<WEO\ #S3;S>DFA?"OPO'%X8^&NCM;,=EK=P>#
M])TFXUE($ACN/$%UJVH-$)[R8M^^Y3@(Y9EV%P2MS4J2]JUM*M/WZTO1U'+E
MOM'E6R/#JS]I4E+HWIY):+\/Q/AJO2,PH * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@#_<PK^;SZ _#/_@Y-_Y0K?MG_P#=NO\ ZUA\"J^D
MX1_Y*'+_ /N;_P#4'$G/BOX$_P#MW_TN)_E-U^V'CA0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % '^GC_P &J_\ RB4\'_\ 9<_C5_Z>M-K\=XV_Y'DO^P7#_E(];!_P
M5_BD?T?U\B=1_BA?M/\ _)RW[0__ &7/XM?^I]K]?T1A/]UPW_8/1_\ 3<3P
M9?%+_$_S/#*Z"0H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * /ZLO\ @S]_Y26?'#_LQGXE
M_P#J_/V9J^)X\_Y$^&_[&5'_ -1<8=F"_BR_Z]O_ -*@?Z/U?DIZA_G=_P#!
MXE_R?!^S#_V:G!_ZMWXD5^K<!?\ (MQG_8<__4>B>;COBA_A?YG\B=?='"%
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M -/0-:O\*I_U[G_Z2S_,0_X(N_\ *5K]@C_LY+X?_P#I<U?L?$'_ "),S_[
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MKOJJHJHBJB(H544!555&%55& JJ      ,"OP@]H_P HC_@X)_;;_P"&V/\
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M+DL=V6)-?T'1I0H4J5&FK0HTX4H+M"G%0BODDCPF^9N3ZMO[SAJT$% !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 ?JS_P0Y_Y2U?L(?]ESTK_TRZW7B\1?\B/,_P#L%G^:-L/_ !J?
M^(_UUZ_"3VC^1/\ X/$O^3'OV8?^SK(/_51?$BON^ ?^1CC/^P+_ -STCBQO
M\.'^/_VUG^=W7ZJ>8% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M_P#(ES3_ + <1_Z;D:T/XU/_ !Q_,_V&:_!3VS_+%_X.;O\ E,E^TK_V*OP
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MB3POX]^/_A[QUX:^)_A/2(?#5G\3OA%XHL?"7B_4_"EM=7=_:>&/$*ZWX?\
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MW%$_7^"L!]5RIXJ4;5,?4]IY^PI7IT5\W[2HN\:B/*QD^:IRK:"M_P!O/?\
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M "4.7_\ <W_Z@XDY\5_ G_V[_P"EQ/\ *;K]L/'"@ H * "@ H * "@ H *
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * .Z^%__)3/AW_V/7A'_P!/^GUG5_A5/^O<_P#T
MEE0^*/\ BC^:/]O:OYS/>/Y^?^#GO_E#K\?O^QZ^ O\ ZN3P=7U/!O\ R/L-
M_P!>L3_Z8F<V+_@2]8_FC_+5K]G/("@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M=8YHF(=>^<%4A.F[\LXR@[;VDN5V\[;:$)V:?9I_<?U'_P#$8%_P4L_Z(?\
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M %!Q)SXK^!/_ +=_]+B?Y3=?MAXX4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!_IX_\
M&J__ "B4\'_]ES^-7_IZTVOQWC;_ )'DO^P7#_E(];!_P5_BD?T?U\B=1_BA
M?M/_ /)RW[0__9<_BU_ZGVOU_1&$_P!UPW_8/1_]-Q/!E\4O\3_,\,KH)"@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 =U\+_\ DIGP[_['KPC_ .G_ $^LZO\ "J?]>Y_^DLJ'Q1_Q1_-'
M^WM7\YGO'\_/_!SW_P H=?C]_P!CU\!?_5R>#J^IX-_Y'V&_Z]8G_P!,3.;%
M_P "7K'\T?Y:M?LYY 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!_J5?\&PG_*'7X ?
M]CU\>O\ U<GC&OQCC+_D?8G_ *]8;_TQ ]?"?P(^LOS9_0-7RQTG^*%^T_\
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MQ@?:AC-?&U/#_#N7[K,JT(WT53#PJRMVYHU**OY\B]#K6.?6FOE*WZ,^"?\
M@HO_ ,',?[1G[?/[.WCW]EVV_9Z^$'P<^%WQ1M=(LO'%Y'K?BSQ_XZN;30?$
M^B^+--M]"UVXE\)Z#HT;:GH-@-0>X\(ZO<7-NKQVL]AO8GT\IX0PF5XNEC?K
M6(KUJ+DZ2Y:=*DN:$J;YHI3E+W9.UIQ2ZIF=3%RJ0<.2,4]]V_EM;;L?#O\
MP3/_ ."T?[4G_!*OPO\ %;PE^SWX$^ ?C+3/B_KWAGQ%XDD^,OA;XA>(;RPO
MO"NGZIIE@FA2^"/BE\.XK:VN+?5IVO8]0@U21Y8K=K>6U594F]+..'L%G4Z$
M\54Q--X>,XP^KSI034W%OF]I1J[<JM;EZWOI;.E7G1345%WM\2?3M9H_3>;_
M (._?^"EDT,L)^"/[#:"6-X]Z?#3X];T#J5W)O\ VEW3<N<KO1ER!N5AQ7C+
M@/*%;_:,RT_Z?87_ .8S7Z[5_EI_=+_Y(_E1K[8XS](/^":W_!4+X_\ _!+/
MXE?$'XI?L^^$OA!XOU[XD^!H? &NV/QB\/\ C+Q!HMMI%OK^G>(H[O2H/!7C
M[X>W\&J"\TV*$RW6I7MF;26=/L/G&*>'R,WR;"YU1I4,5.O3C1J>UB\/*G"7
M-R.%G[2E57+9]$G>VMM#6E6E1;<5%W5O>3_1H_9+_B,"_P""EG_1#_V&?_#:
M?'S_ .B9KP/]0\G_ .@G,O\ P=A?_F,W^NU?Y:?W2_\ DC^9SXW?%GQ)\>_C
M/\7?CIXQM-%T_P 7_&CXG^/OBSXJL/#=M>V7AZR\2?$;Q7JWC#7+30;/4M0U
M?4;31;;4]8NH=+MK_5=3O8+%((KK4+V='N9/L,/0AAL/0PU-R<,/1I4(.=G)
MPI0C3BY.*BG*T5>T8J^R2T.63YI2D]Y-MVVU=]#G_ /C_P <_"OQEX;^(OPT
M\7^)/ 'CWP?JEOK?A7QEX/UG4/#WB7P]JUJ3Y&H:/K.E3VM_87489D\VWGC+
M1O)$^Z*1T:JE*G6IRI5:<*E*:Y9TYQ4H2CVE%JS7R$FXM-.S6S6EC^FG]FC_
M (.S_P#@H1\(="TOPO\ &[P/\'/VGM.TNU6U7Q1XCTW5/AS\3K\1#9;G5/$G
M@JY'@Z],401)+F3X<?VK>LGVB_U.YNI)IY/D,9P/E5>3GAYXC!MN_)"2JT5Z
M0J+G7HJO*MDDK(ZX8VI'22C/_P E?X:?^2GV7JG_  >9_$6734BT3]@3P5I^
ML!3YE]JG[0NN:QIK-C@II-I\(]#NHU'=6UF4D<!A7G+P_HWUS.HX]EA81?W^
MVDO_ "4OZ\_^?2_\"_\ M3X._:._X.NO^"E/QCT.7PW\)].^#?[,5E<QRQ7/
MB#X=>%+OQ;X\EBFRCPQ:]\3-1\4Z%IJ^3\L5WH_A'3M8MI6>XM=5AE$'D>GA
M."<GP\N:M[?&-;1K34*2\^2BJ<GZ2G*/1Q(EC*K5HJ,?-*[_ !T_ _FS\:^,
M_%?Q'\8^*_B%X\\0:KXM\<>.O$FM^,/&/BG7;N6_UOQ)XI\2ZE<ZSK^O:O?3
M%IKS4]7U6\NK^^NI29)[J>65SN8U]=3IPI4X4J48PITH1ITX15HPA"*C",4M
M%&,4DET2.1MMMO=N[]3]_OV1O^#F3]O#]C#]G#X4_LP?##X4?LD^(/ /P?T&
MZ\.^&=8\?^ _C#J?C"]L;K6M4UUGUR_\.?'CPIHES<QW6K7$,<EAX?TR/[+'
M LD,DRRSR_+X_@_+,PQ=;&5J^.A5KR4IQI5,/&FFHQA[JGAIR2M%;R>OEH=,
M,74A&,$H6BK*Z=_PDE^!SG[<'_!Q[^W#^WU^S%\1_P!D_P",/PM_95\,_#KX
MH2>#)/$.L?#/P/\ %O1_&EM_P@WCSPQ\1-)72-1\4_'#QGHELL^N>$]-M]0^
MU>';YI=,DO(+9K2YEBNX+RWA++<KQE+&X>MC9U:/M%"-:I0E3_>4ITI74,-3
MEI&;M:2UMNM!5,54J0<&H).VR=]&G_,^W8_G^KZ@Y@H * /;/V;?@/XU_:@^
M/OP>_9W^'5OY_C/XR_$/PO\ #[0W:)YK?3YO$6J6]C<ZWJ"QE632/#]A)=:Y
MK-QN1+72=.O+F1TCA9ASXO$T\'A:^*JZ4\/2G5ET;4(W45_>D[1BNLFD5"+G
M*,%O)I>GGZ+\C_9P^!GP=\%?L]?!GX6? KX<6']F^!/A#X!\*_#OPK:D1B;^
MQO"6C6>C6=Q>O&B"XU*^2T^W:I>,OFWVHW%U>3L\T\CG^?L3B*F+Q%?$U7>I
M7JSJS[7G)RLNR6T5T226Q[L8J,5%;122]%H?P$?\';/[;?\ PMC]JOX;?L6^
M$=7\_P '?LQ^'4\6_$2"UFS;7OQG^)NF66HVUE=HA>&X?P7\-SH'V"<,LME?
M^.?%6FSQI) U?I_ V7>PP-7,)QM4QD^2E=:K#T6U==O:5>:_1JG3:/-QM2\E
M36T=7_B>WW+\V?R-5]T<04 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0!]S?\$P/^4EG_!/'_L^;]DK_P!7YX KS<Y_Y$^:_P#8MQW_ *BU
M32C_ !:7_7R'_I2/]DJOP$]P* /_U?[^* /Y3?\ @\"_Y1I? _\ [/F^&G_J
M@_VF:^VX#_Y&^)_[%M;_ -2<&<>-_A1_Z^+_ -)D?YP-?K1Y84 % !0 4 %
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M'#_'_P"VL_SNZ_53S H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H _T1/^#.W_ ),>_:=_[.LF_P#51?#:ORKC
MW_D8X+_L"_\ <]4]/ _PY_X__;4?UV5\(=I_CW_\%@_^4IG[?W_9UGQD_P#4
MPU*OWK(?^1+E?_8#AO\ TW$\7$?QJG^(_-^O6,0H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H _P!/'_@U7_Y1*>#_ /LN?QJ_]/6FU^.\;?\ (\E_V"X?\I'K
M8/\ @K_%(_H_KY$ZC_%"_:?_ .3EOVA_^RY_%K_U/M?K^B,)_NN&_P"P>C_Z
M;B>#+XI?XG^9X9702% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!_5E_P9^_\ *2SXX?\
M9C/Q+_\ 5^?LS5\3QY_R)\-_V,J/_J+C#LP7\67_ %[?_I4#_1^K\E/4/\[O
M_@\2_P"3X/V8?^S4X/\ U;OQ(K]6X"_Y%N,_[#G_ .H]$\W'?%#_  O\S^1.
MONCA"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H [KX7_\ )3/AW_V/7A'_ -/^GUG5_A5/
M^O<__265#XH_XH_FC_;VK^<SWC^?G_@Y[_Y0Z_'[_L>O@+_ZN3P=7U/!O_(^
MPW_7K$_^F)G-B_X$O6/YH_RU:_9SR H * "@ H * "@ H * "@ H * "@ H
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M2H4H4J:[0IQ45?N[+5]7J<4I.4G)[MMGEE;$A0 4 % !0 4 % !0 4 % !0
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % '^B)_P &=O\ R8]^T[_V=9-_ZJ+X;5^5<>_\C'!?]@7_ +GJ
MGIX'^'/_ !_^VH_KLKX0[3_'O_X+!_\ *4S]O[_LZSXR?^IAJ5?O60_\B7*_
M^P'#?^FXGBXC^-4_Q'YOUZQB% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M>>1Y79C]W&,81C"$5&,4HQC%*,8QBK*,4K)))626B6B.$S:H H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /\ <PK^;SZ
M_#/_ (.3?^4*W[9__=NO_K6'P*KZ3A'_ )*'+_\ N;_]0<2<^*_@3_[=_P#2
MXG^4W7[8>.% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?Z>/_!JO_RB4\'_ /9<_C5_
MZ>M-K\=XV_Y'DO\ L%P_Y2/6P?\ !7^*1_1_7R)U'^*%^T__ ,G+?M#_ /9<
M_BU_ZGVOU_1&$_W7#?\ 8/1_]-Q/!E\4O\3_ #/#*Z"0H * "@ H * "@ H
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '=?"__DIG
MP[_['KPC_P"G_3ZSJ_PJG_7N?_I+*A\4?\4?S1_M[5_.9[Q_/S_P<]_\H=?C
M]_V/7P%_]7)X.KZG@W_D?8;_ *]8G_TQ,YL7_ EZQ_-'^6K7[.>0% !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 ?ZE7_  ;"?\H=?@!_V/7QZ_\ 5R>,:_&.,O\ D?8G
M_KUAO_3$#U\)_ CZR_-G] U?+'2?XH7[3_\ R<M^T/\ ]ES^+7_J?:_7]$83
M_=<-_P!@]'_TW$\&7Q2_Q/\ ,\,KH)"@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * /N;_ ()@?\I+/^">/_9\W[)7_J_/
M %>;G/\ R)\U_P"Q;CO_ %%JFE'^+2_Z^0_]*1_LE5^ GN!0!__7_OXH _E-
M_P"#P+_E&E\#_P#L^;X:?^J#_:9K[;@/_D;XG_L6UO\ U)P9QXW^%'_KXO\
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M2IYA@*;Y:F-P<)6B^6>)HQ=I14HNSFG:46I1>SBTUHT'LY_R3_\  7T^1O\
M_#OG]O?_ *,A_:]_\1J^,W_S%U/]IY;_ -## _\ A7A__E@>SJ?\^Y_^ O\
MR#_AWS^WO_T9#^U[_P"(U?&;_P"8NC^T\M_Z&&!_\*\/_P#+ ]G4_P"?<_\
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M4DDW'F@VKI-:;I-$N+CHTUY-6//*U$% !0 4 % !0 4 % !0 4 % !0 4 %
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M*PU15*-6-X26GDXM.SC*+3C*+2<6K''*#A)QDK-?UIY'AU=)(4 % !0 4 %
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M?EBY6Y+;*]OBT^X_C\K[PX0H * "@ H * "@ H * "@#_3Q_X-5_^42G@_\
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M_P#@+_R*UW^P+^W786\EU??L5_M:65K"-TMS=_LX_&&VMXE]9)IO!J1H/=F
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!]V_L?\ _!,K]NS]O:#Q!?\
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MQNDU>,IIJZ::NMFGL6H3:34)-=&HNWRT.M_X=\_M[_\ 1D/[7O\ XC5\9O\
MYBZC^T\M_P"AA@?_  KP_P#\L#V=3_GW/_P%_P"16N_V!?VZ["WDNK[]BO\
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M8NG#GG&%[<SM>VWR/ZX?^(,;Q1_TD,T#_P 1@U'_ .?W7PW_ !$"G_T*I_\
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M1,3,CI)XV;3(O"<#AT=!'/K,;LZ.B*61@.'$YGEV#?+BL;A:$E]BI6IQJ?\
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M^'?/[>__ $9#^U[_ .(U?&;_ .8NN/\ M/+?^AA@?_"O#_\ RPKV=3_GW/\
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M][C_ /,QO]1_Z>_^2?\ VQ_$;7Z*>>% !0 4 % !0 4 % !0 4 % !0 4 %
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MC3]M"-23_NTYN,Y?*+%*C5CO3E;R5TONN? U>F9!0 4 % !0 4 % !0 4 %
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M==IMI?9V1T4L-4JI27*H]V^VFRN_R/V;_:(_X-9/A7^Q_P#L(?M._M)_%?\
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MHY8I%5XW5D=0P('[2O+;I8\<@I@% !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0!^K/\ P0Y_Y2U?L(?]ESTK_P!,NMUXO$7_ "(\S_[!9_FC;#_QJ?\
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MJXG$3]G0HQYJD^64N6.B^&"E)ZM)))E1BYR48J[>RV/ZL?V:?^#/G]ISQ?\
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M$/\ ]2[5Z_HK#_[O0_Z\TO\ TB)X,OBE_B?YGE-;$A0 4 % !0 4 % !0 4
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MDGR0TVBK.4WI:$96][E3UHTG5FH[+>3[)?KT1_KE?"'X3?"W]FKX.>"/@_\
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M)>]+VC7FXNCR/VD5[LMTNDOT3_/3L?RN5]H<84 % !0 4 % !0 4 % !0 4
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M H * "@ H * "@ H _UE?^#>O_E#C^Q'_P!B=\1O_5X?$^OP_BG_ )'^8_\
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MMSVO&K!=(55=I?9E&<%=1N_'KT?8SLOA>L?\OE^5O0_'.O?, H * "@ H *
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M+=>J.X_PUZ_H\^?"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 ?<W_!,#_E)9_P3Q_[/F_9*_P#5^> *\W.?^1/FO_8MQW_J+5-*/\6E_P!?
M(?\ I2/]DJOP$]P* /_1_OXH _E-_P"#P+_E&E\#_P#L^;X:?^J#_:9K[;@/
M_D;XG_L6UO\ U)P9QXW^%'_KXO\ TF1_G U^M'EA0 4 % !0 4 % !0 4 %
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M]OKV[E2"UL[.UMTDGN;JYG>.&WMX8WEFE=(XT9V I-I)MM))7;>B26[;V22
M_:/X%_\ !O+_ ,%;OCUH5IXHT7]E36/A[X>OHX);2]^-/BOP=\*-3ECN$$B.
MW@SQ7K=GX^MD$3(YDN_"EO&0X6-GD#HOS^)XIR+"R<)8V-6<=&L/"I76G_3R
MG%TONF=$<+6E]BR_O-+\-_P/1_B1_P &S7_!7[X>:1>:U:?L^^%_B/:V$?G7
M%M\-_B]\-]8U<P@$L]GH6LZ_X>UC5)$X7[)I5C>WTA8>1:RJ'*XT>+\AJM1^
MM2I-Z+VM"M&/SE&$HQ]6TO,;PE9?93]&OUL?B/\ $OX6_$GX,>-=;^&_Q<\
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M1]?\_GY'\\]?4G*% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!^K/\
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M(6T:MH;K#UFDU3=NFL?\SQ/]IO\ X)J?MT_L:>!='^)G[3W[-_CCX/>!-?\
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M48_.HB7A:T?L7_PM/\-_N1^(A!!((((."",$$<$$=B/2OHCG/M']G'_@G/\
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MI_X*[S::U])\,/A':7*@8T:X^./@AM1?(SA);2XN=(!7H=^JH,D;21DCR/\
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MUZQ:9X;7*VGNG;[M#EJL04 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M7PQX8LX+#0?$W[0WP4^*]K;VT"6T*ZE\8-)^'7Q)\5M'!'^[17\9^)?$3#8
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MAO\ @@__ ,%=D5G;]ACXM!44LQ^V>!N%49)_Y&WL!7%_K)D7_0RP_P#Y/_\
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MBOX$_P#MW_TN)_E-U^V'CA0 4 % !0 4 % !0 4 % '^LK_P;U_\H<?V(_\
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M/_!I_P"$\C_X.5/^4+7[8G_7Q^SO_P"M2_!.M^$/^2@P'IBO_4+$$XK^!/\
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M.K2G5DITZD(SIR2I5&E*$DXM72>JW2*KMJC-IM-1T:T:]+'^9SX _P""PO\
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M_!K)_P I<_AS_P!D<^-__J(&OE.,_P#D0UO^O^&_].(ZL'_&7^&1_?1^V?\
M\%8?V"?V"]$U:Z^/_P"T#X.MO&>FPR&U^#G@?4;'QU\9=7NQ&SV]C!\/]!NY
M]2T1;UE,$&M>,'\,^%XIOEO==M &8?F&7Y'F>9RBL-A:GLW_ ,Q%2+I8>*[^
MUDDI6_EI\\^T3T9UJ=->])?X5K+[O^&1]@_ ;XL:9\>O@;\&/CGHFE7VA:-\
M:/A1\.OBQI.B:I);S:GHVF?$7PAH_C"PTK49K1FM9;[3[76(K2[DMF:W>XAD
M:%C&5-<&)H/"XG$8:34I8>O5H.4=%)TJDJ;:3U2;C=>1I%\T4^Z3^]'\YO\
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M?+]QM##U9J\8.W=VBOQM^!]PW/\ P:V_\%>H-+BU"+X4?"B\NY$+/H=M\<O
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M\&_\C[#?]>L3_P"F)G-B_P"!+UC^:/\ +5K]G/("@ H * "@ H * "@ H *
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MW,<#EU-5,;B:6'B[\JF_?G;=4Z<4ZD[:74(NUU<\*%.=1VA%O\E\]D?KI/\
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M:Y=F*_V+%TJ[2NZ:;A5BN[HU%"HETNX6Z&,Z52G\<6EWZ?>M#XIKT3,* "@
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MQT/;Y'^(#7]&'@!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '^I5_P;"?\
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MZ.<Z-!\</!"ZDF " TMS<6^C\]!MU5N1S@8->:N,\AO;V]9+^;ZM5M^"YO\
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M417Q(_[+#\#_ /U,4KVN"_\ D>TO^P?$?^D&.+_@2]8_FC_+\K]D/(/[[?\
M@S9TK2_^%(?MJZW_ &;8?VR/BK\,M*&K_8[?^TQIA\(ZU=G31?\ E_:A8&Z
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MNI.L9XR-Z2E_))?<_=_.Q_G 5^M'E!0 4 % !0 4 % !0 4 % !0 4 % !0
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M*Z_+S79_\-L?Y.G_  4P_8"^(O\ P38_:U\=_LT>/+W_ (2'3-/BM/%OPO\
M'D=H]C:_$/X6^(9KQ?"_BB.T;(L]1CDL-1\/>)M.BDN+;3/%FA:Y865YJ%A;
MVFH7?[?E&9TLWP-+&4ERMWA6I7NZ5:%N>%^JU4H/2\)1;2=TO'K4G2FX]-XO
MNNG^3/\ 7!^#_P 6/A9XC\'_  YT;P]\2_A_KNL7O@WPVMEI.C>,O#NJ:E=F
M'P[:W,HM;&QU&>ZG,5O#+/((HFV0Q22MA$9A^&5Z%>$ZLI4:L8JI.\I4YQBO
M>MJVDEV/:NNC1[G7,,XCQ!\3/AOX2OQI7BKX@^"/#.J>1'=#3?$'BO0=&O\
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M"?#^G>--+NX9HM9\-Z=+\0)O$DNBR 66K:GH>EV.L17VA3:GIE]6!S#$9?\
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M9P1_R.U_V"8C_P!QG+C/X+_Q1/Y0/^#7#_E+W\)?^R5_'/\ ]5[J5?;\9_\
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M^A57Y6>D?XUO_!33_E)%_P %!?\ L][]J[_U?'CVOW_)_P#D4Y7_ -B[!?\
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MA]XAU-/"/Q'7S,JJ>=X#U_Q%!ESY7[S]Z&CW*>S-L+]=RS'85*\JN&J*FO\
MI[&//1^ZK&!-&7)5A+M)7]'H_P &?[*%?@![9_E.?\'&_P"SNG[/7_!6C]HO
M^S[-++PY\<!X7_:'\.JJA#._Q+TO_BM[MPH"EKGXJZ+X_E# 99"A?,A<G]LX
M3Q7UK(\)=WGAN?"2\O8NU-?*@Z1Y&*CRUI=I)27ST?XIGX95](<P4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MB/[<7_95/@]_ZB7C&OL./_\ >,M_Z\XC_P!+I'+@?@G_ (E^1_:#(@DC>,Y
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M%?O1X8V@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M+WG%/Q*-)U9J.R6LGV2[>?1?Y(_U=OV4?V1OV??V)_@[X=^!?[-WPZT?X>^
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M!'COQ9!<K93>%_!OQ=^'_B?Q##>-C;:2Z+HGB&^U*.Y;(VP/;"4Y&$Y%=-3
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MRN?<_P!6,^4%/^S:W*UMS4>?_P %JI[1>CBFC'ZQ1V]I']/OM8^#_P#@X_\
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MZ7EIHONU]+'\7]?H)P!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '=?"_\
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M$G.7\.%HQBKOTBE\CVL/94*?1<OH=+\1O^"ZO_!(_P"%FMR>'_%'[='P>O\
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M 4 % !0 4 % !0 4 % '^I5_P;"?\H=?@!_V/7QZ_P#5R>,:_&.,O^1]B?\
MKUAO_3$#U\)_ CZR_-G] U?+'2?XH7[3_P#R<M^T/_V7/XM?^I]K]?T1A/\
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M]A^U_P##.Q\^\/AC2=/C\(_'G1[!-TI0^![F]N]$\=_9(MENLO@G7Y?$NLW
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MR'^SRO[6UY^W[X[T71M2^+_A;X#>'/@QX8\5^,!I;:+\)_!'A+Q1\3/&NO\
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M .Y#_P!W3@QW_+K_ +?_ /;#^&&OT@\\* "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@#[F_X)@?\ *2S_ ()X_P#9\W[)7_J_/ %>;G/_ ")\
MU_[%N._]1:II1_BTO^OD/_2D?[)5?@)[@4 ?_]/^_B@#^4W_ (/ O^4:7P/_
M .SYOAI_ZH/]IFOMN _^1OB?^Q;6_P#4G!G'C?X4?^OB_P#29'^<#7ZT>6%
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MY1$C1(XT5(T541$4*B(H"JB*H 55  50    !BN L_GO_P""UO\ P7/^#/\
MP3N^&GC'X0_!_P 5Z!\0_P!MOQ+HUSHWA?P5H]S;:Q9?!676+&1(/B'\4Y(D
MNM.TV\T2&:'5?#?@"_;^WO$UZ^E37NFVGA2XNM87ZKAWAO$9K6IXC$4Y4LNA
M)2G4DG%XGE?\*CLVI6Y9U5[L%S)-S2B<U?$1I*RUJ=%_+YO]%U]#\;?^#/7X
M11^+_'G[<W[6_C">[U[QXD7@+X5Z7XCU5WOM3N9/'>J>(OB+\3[Z]U*Z:6YN
M=1UG4O#O@*YN;AG\^5TNGN))3<#'T''M?V=++<#3M&FW5KRA'1+V484J*45L
MDIU4EMM;8PP4;NI-[Z1OZZR_0_NDK\U/0/\ (D_X+"?\%#?BE_P4)_;-^+'C
M7Q%XIU^3X.>!_&_B?P=\ ?AQ/J<C^&O!/@+0K[^P;35;'1X9&TV'Q/XXBTB#
MQ1XPU9?M5[=ZG?+IBZC-H>C:):V?[MD.54,JR^A2A"/MYTX5,55M[]2K)<S3
MEOR4[\E..B45>W-*3?BUZKJ3?\J=HKLEI][W?W;'SY^P'^V_\7O^"?O[37PX
M_:%^%'B+7["#P]XCT0?$;P9I>K7%AH_Q4^&\>JVL_BKX?>)[)9!8ZEI^M:8E
MQ'I\E_!.=#UH:?K^G?9]4TRTN8NK,\NH9I@ZV$KPB^>$O93<4Y4:O*U"K![I
MQ=KVMS1O!^ZVB:51TIJ2O:ZYDNL>J/\ 9/TK4K+6M+TW6-.F%QI^K6%GJ5A.
MOW9[*^MX[JUF7VD@E1Q[&OP!Q<6XO>+<7ZK0]P_C6_X/'?@CHFH_ ']D+]I"
M.VBA\1^#OC!XI^"-W>10(LVI:)\2?!>H>.].MKVY WRQ:)??"C4Y=+@<E+=M
M?UB2(*;F;=^@< XF2Q./P?V)T(8E+^65*:I2LO[RK1O_ ((]CAQT5R0EU4N7
MY-7_ /;=#^7S_@@Q_P I>OV&/^RKZC_Z@/C&OLN)O^1#F7_7A?\ IRF<F&_C
MT_5_^DL_UNZ_##V3_,U_X.QO^4JL'_9LOP?_ /3SX_K]@X'_ .1)_P!SE?\
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MJ?H>W0_@T_\ !'\CXD_X.B?^4/\ \9?^RF? K_U9NAUZ/!G_ "/L/_UYQ/\
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MZWX0_P"2@P'IBO\ U"Q!.*_@3_[=_P#2XG^5'7[6>.% !0!_>3_P9E_\D_\
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M)G=@?BG_ (5^9_H55^5GI'^.E_P4 \+W_C?_ (*I_ML^"M*P-3\7_P#!0/\
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M<'-K/\(E]J&*B_18:K+\XHRQ7\"?_;O_ *5$_P [_P#X)3>%/^$U_P""F7[
MGA\Q^=#+^UY^S_JEY#C(ET[PY\3?#GB/4HV&/N/I^DW*OZ(2>,5^JYU/V>3Y
MG+:V Q27K*C.,?Q:/,HJ]6FO[\?P=_T/]C.OP,]L_P F?_@X0\5?\)A_P6+_
M &V]4$GF+8^,_A_X57G*I_PA/P7^&O@YXU X79+H4@91C]YO)^8M7[APM#V>
M09='O3J3_P#!F(JU/_;CQ\3_ !Y_]NK[HQ/+O^"*/Q7\+_!/_@JI^Q'\0/&=
M]I>E>&K?XR6OA34]5UJ:*VTG2A\2/#VO?#:TU2^NYRMO96^FWWBVVO6OKAX[
M>Q\@7<\L44+R+OQ#0GB,ES&E33E-X=SC&.[]C*-7E2ZMJ%DEJ]D3AVHUJ;>B
MO;[TT?Z]-?A![1_-/_P6@_X-ZM!_X*9_$>#]I/X2?&=/@_\ M"VO@[2O!VL:
M5XUTF[\0?"SQ_IWAS[4/#CWMSI##Q+X$UFSAO9+*^UO3;#Q=I]_I]II\*^%;
M:^CN]4O/K^'N*I9/1^IU\/[?"\[G&5-J%:DYVY[*7N5(NUU%NFTV_?:LERU\
M,JKYE+EE:VVCMMZ>NNG0_AR_;;_X(U?\%#?^"?L>H>(_CA\#=6U#X9:5*C'X
MW_"FY?XA_"J&+SD@@OM5\0:-;QZMX'AFNFCM[,?$+0O!]U=7#1):V\IEA+_H
M^79_E6:6AAL3%5G_ ,PU9>RK[;1A+2I9;^RE-)=3SYX>K2U<=%]J.JT_%?-(
M_,K7->USQ-JMYKOB36=5\0ZWJ+I+J&LZYJ-WJVJWTD<4<"27FH7\T]W<ND$4
M4*--,[+%''&"$10/8C&,$HPBHQ6T8I12]$K)&)DU0'^W!\$/%7_"=?!?X0^-
M_,\[_A,?A?X \5>=G/F_\)#X4TG5_,SWW_:]V>^:_G7$P]EB,13_ .?=:K#_
M , G*/Z'OK5)]TC^ ;_@\0\)_8OVYOV9O&XCVKXC_92M/#!D"X$DG@[XN?$O
M4VR1]YTC\;0J2>0GEK]T*!^H<!3OEF+I_P F.<_13H45_P"XV>;C5[\'_<M]
MS?\ F?R,5]T<04 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0!_HB?\&=O_)CW[3O_9UDW_JHOAM7Y5Q[
M_P C'!?]@7_N>J>G@?X<_P#'_P"VH_KLKX0[3_'O_P""P?\ RE,_;^_[.L^,
MG_J8:E7[UD/_ ")<K_[ <-_Z;B>+B/XU3_$?F_7K&(4 % !0 4 % !0 4 %
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M)XS_ .1#B/\ K]AO_3T3S\'_ !E_AD?ZB%?C)ZQ_%G_P<Y_\%C/CO^SKX_\
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ML_\ [MU_]:P^!5?2<(_\E#E__<W_ .H.).?%?P)_]N_^EQ/\INOVP\<* "@
MH * "@ H * "@ H _P!97_@WK_Y0X_L1_P#8G?$;_P!7A\3Z_#^*?^1_F/\
MU\I?^HU$]G#?P*?H_P V?K;X[\ >!/BEX1USX?\ Q-\%>$OB-X#\3VJV'B3P
M3X[\-Z-XN\(^(;%)X;I+/7/#?B"RU#1M6M4NK>WN5M[^RGA6>"&8()(D9?#I
M5:M"I&K1J5*-6#O"I2G*G4@[6O&<&I1=M-&M-#9I-6:379JZ^X\,\ ?L0?L6
M_"C5;;7OA;^R%^R]\-=<L[J"^L]9\ ? #X4>#M5M;VV=)+:\MM1\.^$].NX+
MJWDC22"XBF66)T1HW5E!'35S+,:T>6MC\;5BU9QJXJO4C;:UI3:MY"4(1^&$
M5Z12_)'U#7$4?R,_\' __!>CX7_!'X5_$;]B?]D+Q[IWCK]HOX@:;J_@'XK_
M !!\&:E'?>'_ ("^%[^(Z=XKT:U\167FV.H_%C6;&6^\.1:?HMY)<?#WS=2U
M36+S2O%&GZ/IDWW?"W#-;$5Z.8X^DZ6$I.-6A2J*TL3-:TY.#U5"+M.\E:K[
MJBI0<F<>)Q"@G3@[S>C:^Q_]MY=/P/X[_P#@B[_RE:_8(_[.2^'_ /Z7-7WO
M$'_(DS/_ + ZW_I)PX?^-3_Q'^OM7X.>T?R^_P#!RQ_P5F^*?[!'PE^&7P!_
M9I\1GP;\>OVB+7Q+JNL_$&UM?.USX;?"30A'H]W?>$KB;%OI7C3QAK]\=,T+
MQ"D5]=>'=,T#Q+>6$.FZ_/X<US3_ +/A#(Z&9UJV*QD/:87"N,8TG\-6O+WD
MIK[5.G!7E'12E*"=XJ47RXJLZ45&.DI=>R7;SZ+YG\#7A3_@HE^WOX(\;GXD
M>&OVS_VH;'QQ)*TUWXBG^.7Q(U6]U1F4JZ:VNK^(K^VUVW=3B2TUF"^M9,*7
MA)12/TZ>5994I^QGE^#=+90^K44H_P"'E@N5]G&S1YJJU5JJD_\ P)G]PW_!
MH+\!-'\(_L5?'C]HBXM+5O%_QJ^/$_@Q-0\A6NU\#?"3POHYTFU^U.@E19O%
MGC;QI-<6\3&"006$LC/*@2#\XX\Q,IYAA<(F^3#X;VENGM*\Y)NWE"E3U\VO
M7T,%%*FY=92M\HK_ (<_J2^-LWQ3MO@S\6I_@99:)J7QKA^&GCF7X0Z?XENH
MK'P[>_$Z/PQJ;> [77;R>.6WMM(G\4#2X]1FGC,"6C2F;;&&8?%X94/K%!8E
MR6&]M3]NX*\E1YU[3E2MKR7M;7L=;OROE^*SY>U[:'^;OXP_X-C?^"R_Q \6
M>)O'7C;0/A1XH\8^,M?U?Q3XJ\2:U\=_#U]J^O\ B+7K^?5-9UC4[R6$R7-_
MJ6H75Q=W4[G=)-*['K7ZW#C'A^E"%.G.M"G3C&$(1PTU&,(I1C&*6R22278\
MMX2NW=V;>[YC^LS_ (-YOV&/VV_^">_[._QG^ _[7</A:ST"Z^*&G^._@YIG
MAGQOI_C:'3(M?T#[!X^MO.L84.D64^I:+H.I6^G&0V\FH7^LZA#!%<7E[+<_
M#\59EEV:8K#XG <[DJ+I8ASI.G?EE>EO\3M*:O;1**O9)+LPU.=*#C.V]XV=
M[::^GH?HU_P5%^&.E?&'_@G'^W!\/M7M?M<6J_LO?&;4M.CVA_+\2^$_ ^L>
M+_"-XJ$$,VG^*M!T:^11ABUL K(V&7R<EK.AFV6U8Z6QN'B^GN3J1IS7SA*2
M-:JO2J+^Y+\M#^13_@SE_9YT37/BA^U]^U%K%E;7&K_#WPGX ^#7@>:>W6>2
MR?XBW^M^*O'%]:R2*19WD=CX&\*:;'<6_P#I+V&LZK:,\5M<31W/W?'V*E"A
M@,%%VC6J5:]2VEU1484T^ZO5F[;7A%]-.+ QUG/M:*_-_DC^]ROS$]$_RFO^
M"XG_  5<^,W[?_[4_P 4O!&F^-?$^A_LG?"KQSJG@[X3_"2UU1[/PUK!\%WM
MQH<WQ.\6Z9I\B67B'Q5XIU*VU#6])N-6%^_A+0M1L_#^DRQF'4;W4_VWAS),
M/E>"HS=.$L;6IQJ5Z[C><>=<WL:;>L*<$U%J-N>2<Y+91\C$5I5)RC>T(NR7
M1VTN_7IV6A^'=K<W-C<V]Y97$]I>6D\5S:7=K+);W-K<V\BRP7%O/$R2PSPR
MHDD4L;+)'(JNC*R@CZ*R:LU=/1KI;M8YCV;XX_M(_'C]I?5?!>O_ +0'Q7\:
M?&#Q#\/? .E_"_PEXB\?:Q-XA\1:;X#T76=?U_2O#T^O7WF:OJ\%CJWBC7;J
M"[UJ\U'456_-L;PVEO:0088;"8;!QJ1PM"G0A5JNM.%**A!U91A"4^5>[%N,
M(IJ*2TO:]RI2E*W,V[+E5^RZ'^J7_P $%/\ E$)^PS_V2O5O_5A>,Z_%>)_^
M1]F7_7Z'_IFF>QA_X-/_  GD?_!RI_RA:_;$_P"OC]G?_P!:E^"=;\(?\E!@
M/3%?^H6()Q7\"?\ V[_Z7$_SW?\ @B[_ ,I6OV"/^SDOA_\ ^ES5^I\0?\B3
M,_\ L#K?^DGFX?\ C4_\1_K[5^#GM'^;S_P=^?\ *3'X-?\ 9D/PR_\ 5Y?M
M'U^M\"?\B>O_ -C&M_ZCX0\O&_Q8_P#7M?\ I4C]0O\ @S5_Y(C^W%_V53X/
M?^HEXQKQN/\ _>,M_P"O.(_]+I&V!^"?^)?D?VAD@ DD  9)/  '4D]  *_/
M3N/\:_\ X*)?MJ?$_P#;W_:S^+?[07Q(\2ZGK%EKGBS7+'X:>'Y]0O+K0OA_
M\+['5+N+P7X.\+6-Q(;?3--L='%O<7YLX+7^V=>NM6\0W\3ZIJU[-)^_Y5E]
M'+,#0PE&"CR0C[6224JM9I>TJ3:W;EM>_+%1@O=BD>'5FZDW)N^MH]E'HD?U
MN?\ !GG^U'\0/$6C?M3_ +(WBCQ#J&M^!_ %CX+^+_PLTO4M0N[L>#SXAU76
M?#WQ#TG1(;F2:.QT'5=0_P"$5UL:98BULK77)M;U,027OB"^G/PW'N"I0>"Q
MT(*-6HZF'K-)+VBA&,Z3E9:RBN>-W=N/+':".W R=IPZ*S7E?1V\M#^W6OSD
M[S_&._X*$Z+:>'/V^?VX/#UA''#8Z#^U_P#M+:+90PH(XHK32_C/XTL;:.*-
M0%CC2&!%1% "J H  K^@<K;EEF72>\L#A&_5X>FSPZO\6I_U\G_Z4S_7?_8U
M_P"30/V4_P#LVWX&?^JP\+U^%9A_O^._[#,3_P"GIGM0^"/^&/Y(_G7_ .#P
M3_E&[\"?^SWOA]_ZH?\ :.KZO@+_ )&V)_[%U3_U)PARXW^%'_KXO_29'YN_
M\&<O[/.B:Y\4/VOOVHM8LK:XU?X>^$_ 'P:\#S3VZSR63_$6_P!;\5>.+ZUD
MD4BSO(['P-X4TV.XM_\ 27L-9U6T9XK:XFCN?7X^Q4H4,!@HNT:U2K7J6TNJ
M*C"FGW5ZLW;:\(OIIE@8ZSGVM%?F_P D?WN5^8GHG^4U_P %Q/\ @JY\9OV_
M_P!J?XI>"--\:^)]#_9.^%7CG5/!WPG^$EKJCV?AK6#X+O;C0YOB=XMTS3Y$
MLO$/BKQ3J5MJ&MZ3<:L+]_"6A:C9^'])EC,.HWNI_MO#F28?*\%1FZ<)8VM3
MC4KUW&\X\ZYO8TV]84X)J+4;<\DYR6RCY&(K2J3E&]H1=DNCMI=^O3LM#\.[
M6YN;&YM[RRN)[2\M)XKFTN[662WN;6YMY%E@N+>>)DEAGAE1)(I8V62.15=&
M5E!'T5DU9JZ>C72W:QS'LWQQ_:1^/'[2^J^"]?\ V@/BOXT^,'B'X>^ =+^%
M_A+Q%X^UB;Q#XBTWP'HNLZ_K^E>'I]>OO,U?5X+'5O%&NW4%WK5YJ.HJM^;8
MWAM+>T@@PPV$PV#C4CA:%.A"K5=:<*45"#JRC"$I\J]V+<81344EI>U[E2E*
M5N9MV7*K]ET/K;]F5?\ @IS^V%\([;]@?]E.U^.OQ2^"6D>*=1\9ZW\(?AE9
M#2/A_::WXSDM4FUCXM^*[*'1-&&C7ESHL3:./BMXI/AK3+ZVN)=$CLKJ2Y9^
M'%_V/@*SS/&O#4,0X*G'$5G>JXT_L4(/FE=*7O*A#F::YKJQI#VTX^SAS.*>
MRT6O=Z?B['Z[_"G_ (-'?^"DWC2VM-0^(OC_ /9D^#5O,(S=:1K/CKQ;XS\5
MV>]0S+]B\#>!-8\)W#1<H_E>-@ID $;21GS!X-;CG)Z;:I4\9B.TH4H4X/YU
M:L)K_P %FRP55[N$?O;_  5OQ/WR_P""3'_!N+X__P"";/[5'@W]JG5/VV(O
M&EWHGAOQIX3\5?"7P=\(-0\-^'?'&@>+_#5]I:Z5K?C/4/B9>75QIVB^)#X>
M\:6=H_@HI+K7A3279H2JRP?,9YQ;2S;!5,#'+O9J4J<X5ZE=2E2E3FI<T::H
MV3E#FIM^TTC.2.FCA?93Y_:7TM91M=->O>W3I]W]4E?%'6?Y*7_!??PO8>$/
M^"P/[<>DZ=!!;6]W\2?#7BB2.W01QM?>-_A=X#\::I.R@ &:ZU/7[NYN7ZR7
M$LLAR6)K]RX8FYY#EK>MJ,H?*G5J4XKY1@DNR5CQL2K5ZGJOQBF?VG_\&G__
M "BEC_[.2^,7_I!X)K\]XW_Y'?\ W)X?_P!*JG?@_P""O\4C]</^"I'_ "C.
M_P""AG_9D/[5/_JC?'->%DO_ ".,J_[&."_]2*9M5_A5/^O<_P#TEG^-[7[Z
M>&% !0 4 % !0 4 % !0 4 ?Z>/_  :K_P#*)3P?_P!ES^-7_IZTVOQWC;_D
M>2_[!</^4CUL'_!7^*1_1_7R)U'^*%^T_P#\G+?M#_\ 9<_BU_ZGVOU_1&$_
MW7#?]@]'_P!-Q/!E\4O\3_,\,KH)"@ H * "@ H * "@ H * "@ H * "@ H
M _UE?^#>O_E#C^Q'_P!B=\1O_5X?$^OP_BG_ )'^8_\ 7RE_ZC43V<-_ I^C
M_-GZV^._ '@3XI>$=<^'_P 3?!7A+XC> _$]JMAXD\$^._#>C>+O"/B&Q2>&
MZ2SUSPWX@LM0T;5K5+JWM[E;>_LIX5G@AF""2)&7PZ56K0J1JT:E2C5@[PJ4
MIRIU(.UKQG!J47;31K30V:35FDUV:NON/#/ '[$'[%OPHU6VU[X6_LA?LO?#
M77+.Z@OK/6? 'P ^%'@[5;6]MG22VO+;4?#OA/3KN"ZMY(TD@N(IEEB=$:-U
M901TU<RS&M'EK8_&U8M6<:N*KU(VVM:4VK>0E"$?AA%>D4OR1]0UQ%'\C/\
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M[T6K=VWJVV>0VY-R>K;NSSNM1!0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M>_X*W_\ 0A_!7_P]OAG_ .,5^C_ZZ9%_S]Q'_A-,\_ZG6[1_\"/]"[_@GCX
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M.OVK/#/AR[M_A5\==+MEL[NYN[2WEET?P7\4TM+>63Q=\/;F\V09N(;C7_"
MN+C4?"=U LVK:1KGT.1<0XK)JL87=7 SFG6PSULGI*I0NU[.JEZ0J62FOAE'
M"M0C57::7NR_1^7Y=#_*B^)'P\\8_"/XA>./A7\0]#N_#/CWX;^+?$/@;QGX
M=OE"WFB>*/"NK76B:YI=QM+(TEEJ5E<0&2-GBE""2)WC96/[72JTZ]*G6I24
MZ56$*E.2VE"<5*+7JFCQVG%N+T:=FO0_U@_^""G_ "B$_89_[)7JW_JPO&=?
MB/$__(^S+_K]#_TS3/9P_P#!I_X3Z+_X*:_M:7O[#/[!O[2W[4ND6%KJ7B3X
M7^ D_P"$+L[_ &-I[^/O&GB#1?A[X!FU*%_^/O2[+QCXKT.^U.Q0I)?:?;7-
MI%+#),LJ<F38%9EF>#P4FU"M4_>-;^RIPE5J)=FZ<)*+Z-IE59^SIRG_ "K3
MUV7XV/\ 'Y^*'Q2^(WQK\?\ BKXJ?%OQKXD^(GQ&\;ZK/K?BOQEXMU2ZUG7M
M<U*?:IGO+Z[=Y"D,*16ME:Q>7::?8P6UA8P6]E;001_O%&C2P]*%&A3A2I4X
MJ-.G3BHPC%=$E][[O5ZGB-N3O)MONS^V7_@T)_;7^)OBG6/C]^PQXX\2ZQXI
M\$>#/A_8_''X.VVM:M=WY^']A8>*](\&>/\ PMH,-X\YL_#.LZCXT\):Y:Z3
M9/::;I&L0ZY>PVCW/B6\E7\\X[RZC"&%S*G",*DZOU:NXQ2]JW3E4I3E;><5
M2G&[U<>5;01Z&"J-\U-[)<T?+HUZ;>FI_<=7YN=Y_EF_M"?LB>%?'?\ P<=^
M,OV6+BP_XH3XF?\ !0?1[[Q)I20+Y8\$?$SQAI'Q5\::9:0#$<5JGASQ!K-G
M8)CR;>U$'[LQ1[*_:<)CITN$Z>-3_>4<J?(_^GE&DZ--OS<X1OYGDR@GBG#H
MZB;]':3_ %/]2^...&..&&-(HHD6.**-52..-%"I'&B@*B(H"JJ@*J@   5^
M+'K'\;/_  =F?\%#?BE\%/!WP:_8A^#OBG7_  +)\;_#6O?$GXV^(?#NIR:1
MJFN?#&"^O/!WAWX<I>V<BWZ>'O%NLVWBB]\96\;V8U.S\/:/HLDU[H^J>(-.
MF_0.!\JH8B>(S&O"-3ZO.-'#1DN:,:O*ISJV>G-"+@J>_*Y2DK246N'&57%1
MIQTYM9>FR7SZ^B/X +2[NK"ZMKZPN;BRO;*XAN[.\M)I+:ZM+JVD6:WN;:XA
M9)8+B"5$EAFB=)(I$5T964$?I]DU9JZ>C72W:QYI_J8?\&W_ .W-\1_VW_\
M@G=I]Y\9M>U7Q?\ %CX _$CQ!\#O$WC?7]0DU/Q#X\T?3=%\.>,?!GBG7;Z=
MGNKS5T\.^+K?PGJ&HWTDVH:S>^$[C6]1N+B^U*XF?\8XMRVCEV:M8>,:=#%4
M8XF%*"Y84I.4J=2$4M%'FI\Z2LHJ?*DDD>QA:CJ4E?646XM]^J?W-+Y'ZY?M
M;?!'1/VD_P!E[]H3X ^(;:*YTOXO_!SXA^ &\R!+AK.^\1^%]2T_2-7M8W!
MU'0]7EL=8TN9<26VI6-K<0E98D8>%@,3+!XW"8J&CH8BE4[749KFB_*4;Q?D
MVC:45*,HO9IK\/ZL?Y1__!%W_E*U^P1_V<E\/_\ TN:OVWB#_D29G_V!UO\
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M>SYN1R4$DW'GEK:^NIC*<I)*4G+EVN[VO;_)'@U=)(4 % !0 4 % !0 4 %
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M*6,PTL)[&KS\JG6E&:]G.5.2E%4I)/F@[*^UGU,)XBE3DX2O=6V6FJN?,/\
MQ%B_\$J/^>?[3'_AG](_^;VNW_4?.OYL%_X/G_\ *2/KE'O+_P !#_B+%_X)
M4?\ //\ :8_\,_I'_P WM'^H^=?S8+_P?/\ ^4A]<H]Y?^ G\4'_  6W_;3^
M#/[?O[?GCK]I'X"CQ:OPY\0^!?AGX=T\>-M"@\.Z_P#VAX3\*VNCZKY^EV^I
M:M%%!]LA?[-(+QC-%ARD>=M?H?#N7U\KRNE@\3[/VL*E:3]E)RA:=1RC9N,>
MCUT.#$3C4J<T=K);6V/[H/\ @UM_Y1"_"G_LJ_QR_P#4^OZ_-N,_^1[6_P"O
M&&_]-(]#"?P(^LOS9]Z_\%DX99O^"5G[?20QO*Z_LP_%&8K&I8B*WT">>>0@
M#A(8(I)9&Z)&C,<!37F</_\ (ZRO_L,H_P#I1I6_@U/\$OR/\?VOW@\0* /]
M"+_@SC\*_8_V2_VN/&WEX'B']HKP]X5\W'W_ /A#OAIHNK>7GH?*_P"$Z#8[
M>;[BORWCZ=\;@*?\F%G/_P &57'_ -Q'IX%?NY_X[?<E_F?L)_P< >*AX-_X
M(]?MPZMYGE?;/A[X0\*ALXS_ ,)U\6?A]X(\O_MK_P )!Y>.^[%>!PO#VF?9
M;'M5J3_\%4*M3\.0WQ#M1J?X;?>TC_)9K]Q/%"@ H * "@ H * "@ H * "@
M H * "@ H * "@ H _5G_@AS_P I:OV$/^RYZ5_Z9=;KQ>(O^1'F?_8+/\T;
M8?\ C4_\1_KKU^$GM'\B?_!XE_R8]^S#_P!G60?^JB^)%?=\ _\ (QQG_8%_
M[GI'%C?X</\ '_[:S_.[K]5/,"@ H _TK_\ @TC_ .47'BS_ +.U^+'_ *@?
MP@K\AXY_Y',/^P&A_P"G*YZN"_@_]OO\D?T1?M!^.-:^&/P#^-_Q*\-K9/XB
M^'GP@^)7CC0$U*![K3FUKPGX,UK7M*6_MHIK:2XLC?:? +J".XMWE@WQI-$S
M!U^5PE*-;%8:C._)5Q%&E*VCY9U(PE9]'9Z::'5+2+:Z)_@C_.+NO^#K_P#X
M*M7$#PQ3?LW6,CC"W5K\';UYXO>-;WQK>6Q/_76WD7VK]97!&2+IBWY.NK?A
M33_$\OZY6_N?^ _\$^,OV@?^"_/_  5C_:-TC4/#7BO]K/Q3X)\*ZI:M9W?A
M_P"#&A>%?@^);:4;+F"3Q+X%T;2?'5Q!>1_NKJVNO%<]K+ TEN8!!--')Z&%
MX8R/"24Z>!A.<7=2Q$IU[=O<JRE35NEH)HSEB:TOMV7]VT?Q6OXGX[75U<WU
MS<7M[<3WEY>3S75W=W4TEQ<W5S<2-+/<7$\K/+///*[2332,TDDC,[L6)->\
MDDDDK):)+1)+9)&!_?G_ ,&;/BFQN_V?OVUO!*36YU/0/C%\,?%-U;JZ?:DL
M?%W@K6](L)I8\[UMY+CP1J*0.5"-)#<JI)1@/S'C^#6)RZI;W94*T$^EZ=2$
MFONJ+\#TL"_<FNTD_O7_  #^S4C(*\C((RI*D9&.",$'T(Y':OSX[C_$7^,7
MPZ\0?"'XM_$_X4>++*_T[Q1\-/B%XR\!>(;'5(I(-1M-9\(^(=0T'4H;V&4+
M(EREW82B8,,[\GIS7]%T*L*]&C6IM.%6E3J0:V<9Q4HV\K-'@R7+*4>S:^XY
M#P[X>UOQ;X@T+PIX9TN]USQ)XFUC3/#WA_1--@:YU'6-;UF]@TW2=+L+:,%[
MB]U"_N;>TM8$&Z6>6.-1EA5RE&$93FU&$(N4I/11C%7;?9)*[\A)7LEZ)'^W
M+\./"[>"/AYX#\%M*T[>$/!GA?PNTS.9&F;0-#L=),K2$DNTAM-Y<DEB=Q)S
M7\ZUI^TJU:G_ #\J3GV^*3>W3<]Y:)+R1_*U_P 'A7C+3]._8'_9T\ O<6Z:
MOXK_ &M]%\3VEH[+]JGTGP3\(/BSIVJW$$9^;R;6^\;Z#'<RH/W;7=O&2!/A
MOM> J;>9XNK9\L,"X/M>I7H-+[J4K>GD<F-?[J*[S7W*+_X!_(Y_P08_Y2]?
ML,?]E7U'_P!0'QC7W7$W_(AS+_KPO_3E,XL-_'I^K_\ 26?ZW=?AA[)_F<_\
M'94,L7_!5.R>2-T2X_9A^$$T#,I598EU[XB6YDC)&&03031%EX$D3IU4@?L'
M _\ R)'Y8RO_ .DTCRL9_%7^!?FS\Y?^"(>MZ?X>_P""LW[!U_J7D?9I_CWX
M>T./[0RI']O\36&J>&])VEBH\_\ M35K/[*O5[GR44,Q"GUN(HN>1YFETPLY
M:=H-3?X1?R,L/I6I^MOO31_KP5^$GM'Y"_\ !0#_ (+9?L:?\$U?BWX8^#/[
M2=C\:(_%7C#X?:?\2M!O? GP^L?$_AR[\.ZAX@\1^&5B_M6X\3Z.5U:TU/PO
M?_;M/^REK:VGTVX,A2]BQ[V5\.8_-\//$826&Y*=5T9*K5E":E&$)_"J<O=:
MFK.^MFNAC4KTZ3497NU=673;]#X5_P"(L7_@E1_SS_:8_P##/Z1_\WM>G_J/
MG7\V"_\ !\__ )29_7*/>7_@(?\ $6+_ ,$J/^>?[3'_ (9_2/\ YO:/]1\Z
M_FP7_@^?_P I#ZY1[R_\!/Y.?^#A+_@I7^S=_P %,OC[\!_B1^S6OQ 7PY\.
M?@_J7@CQ#_PL'PM:^%;_ /MJZ\::MKL7V"UM=:UI;FS^PWD.Z=IH2)MT8B(7
M<?M^%LHQ>3X7$T<7[)SJXA5(^QFYKE5.,-6XPL[QVML<>)JPJRBX7T36JMU/
M])C]C7_DT#]E/_LVWX&?^JP\+U^1YA_O^._[#,3_ .GIGJ0^"/\ AC^2/YU_
M^#P3_E&[\"?^SWOA]_ZH?]HZOJ^ O^1MB?\ L75/_4G"'+C?X4?^OB_])D?Y
MQ-?K)Y9_K;?\$$O^407[#/\ V2W6/_5B^-:_#>)_^1]F7_7Z'_IFF>UA_P"#
M3_PGCW_!RS_RA>_:Z_Z__P!GG_UISX-UT<'_ /)08+_#BO\ U$KDXK^!/_MW
M_P!+B?Y55?M1XY_KY_\ !%K_ )11_L$_]FX> _\ TDEK\(XA_P"1WF?_ &%U
M/T/;H?P:?^"/Y'Q1_P '0T,LG_!'WXUO'&[I;_$CX$33LJDK#$?BEX>MQ)(0
M,(AFFAB#' \R6-.K 5Z/!G_(^P__ %YQ/_IF1GB_X$O6/_I2/\N.OV8\@_OL
M_P"#-7_DB/[<7_95/@]_ZB7C&OS'C_\ WC+?^O.(_P#2Z1Z6!^"?^)?D?V>7
M?_'K<_\ 7O-_Z+:OSY;KU1W'^,S_ ,$__P!E6\_;<_;-_9W_ &6+357T&W^,
M'Q#L-$U_7($\V[T;P9I-G>^*/'>JZ="8I8YM4T[P7H6O7>E03JMK-J,-K%=R
MP6K2SQ_T!F>-679?BL:X\WU>DY1CTE4;4*47VBZDHIVV5['ATH>TJ0AW>OHM
M7^"/]ACX(_ _X3?LW_"WP?\ !;X'> _#_P -OACX#TN+2/#/A+PU9)9V%E;H
M2\]U</\ -=:GJ^IW3S:CK>N:G/=ZQKFJW-WJFK7MYJ%U<7$GX+B<37Q=>IB,
M34E5K59<TYR>K[)+:,8JRC&*48Q2C%))(]M144HQ226R6R/Y\_\ @J#_ ,'+
MGP!_X)^_&KQ/^S5\.O@OXB_:2^,O@-;6V^(3Q>-+#X<_#CP7KFHV%GJ5OX<?
MQ/\ \(_XTU?Q%XATZRO89M?T[3O#=IINEW$D6D/K[:Q%JUEH_P!3DW!^)S3#
M0QE;$1PF'J7]DO9NK5J13<7+DYZ<80;5H-R;:][DY>5RYJV*C2?(H\TEOT2V
MLKV[=O3TX?\ X(P_\%[?V@O^"J7[8WC7X&^)/V??A3\*?A=X.^!/BWXK7FJ>
M'M9\8^(_%T>JZ3XU^'?A/1-,DUO4KK3]!>TO/^$RO);BW'AB&[G^Q">WNH([
M6XAGUX@X8PF2Y?3Q,,57K5IXFG049QIPIVE3JSD^5)RNO9K[;2OJM594,1*M
M-QY%&*BWNV]TDNBZ]C^IJOBCK/\ &4_X*(_\I ?VY_\ L\7]IO\ ]75XVK^@
M<J_Y%>6_]@&#_P#4>F>'5_BU/^OD_P#TIG^GG_P04_Y1"?L,_P#9*]6_]6%X
MSK\<XG_Y'V9?]?H?^F:9ZV'_ (-/_">1_P#!RI_RA:_;$_Z^/V=__6I?@G6_
M"'_)08#TQ7_J%B"<5_ G_P!N_P#I<3_*CK]K/'"@ H _O)_X,R_^2?\ [?W_
M &./[.O_ *9?C%7YGX@?Q<K_ .O>*_\ 2J!Z.!VJ>L?R9_;/7YV=Y_B2_'?_
M )+A\9?^RK?$/_U+M7K^BL/_ +O0_P"O-+_TB)X,OBE_B?YG^CY_P:?_ /**
M6/\ [.2^,7_I!X)K\EXW_P"1W_W)X?\ ]*JGJ8/^"O\ %(_7#_@J1_RC._X*
M&?\ 9D/[5/\ ZHWQS7A9+_R.,J_[&."_]2*9M5_A5/\ KW/_ -)9_C>U^^GA
MG]]7_!FI_P D4_;D_P"RI?!S_P!1/QI7YCQ__O&6_P#7G$?^ETCTL#\$_P#$
MOR/[-]5_Y!>H_P#7A>?^D\E?G\/BC_BC^:.X_P QS_@U8U2QT_\ X*U^#K2[
M6(SZW\#?C7I>EER R7T.AZ?K4C0@_>D_LW2-04J,D0M*V,*2/V'C6+>15&MH
MXC#M^G,X_G)?@>5@_P"-ZQ:_+_(_T\J_'#U3_+8_X.?/ ?B+PA_P6%^//B#6
MK;4(M,^*'@3X$^./",]Y#)';WF@:?\(/"/PWNI=+D=5CN+&'Q3\/_$=F\D.Y
M$O[:]@<^=%)7[1P=4A/(,+&-KT:F)I32MI)UYU4I=GR58/T:>UCR,6K5I=FH
MV^Y+3[C^?< D@ $DD  #))/   [^@KZ@YC_99_X)N?"W6_@I_P $_/V*_A5X
MGTV\T;Q5X(_9?^".C>+=&U"*2WOM'\6I\/= G\4Z3=P3?O8)]-\03ZC920N%
M:)H"ACCV^6OX!F]:.(S3,:T&I0J8S$.G*.TJ?M9*$EY."3/=IIQITT]U"*?R
MBE;Y'Y"?\'6W_*)[5O\ LX7X,_\ H7B>O>X(_P"1VO\ L$Q'_N,PQG\%_P"*
M)_*!_P &N'_*7OX2_P#9*_CG_P"J]U*OM^,_^1#B/^OV&_\ 3T3CP?\ &7^&
M1_J(5^,GK'^4G_P<B?\ *:3]M'_KX^ '_K+/P0K]MX2_Y)[+O3$_^IF(/'Q7
M\>?_ &[_ .D1/]/#]E/7M-\5?LN_LV^)]&\C^Q_$?P#^#NO:5]E9'M?[-U?X
M>>'=0L?LSQ_NV@^RW$7DLGR-'M*\8K\<QT7#&XR$OBABL1&7K&K-/\4>O'6,
M?1?D?AA_P=5_"#Q=\4O^"5=]KOA/3]6U.+X)_'[X8_%[Q7;:3%)<-%X0@T/Q
MY\.=2U&_MX<R2:5I%Y\1M-U2_E"/'8069U.Y\JSLKBXA^DX)KTZ.=*,W&/UC
M"UJ$.;3W^:E6273F:HM+OLM6D<V+C>CI]F2?RV_4_P QJOV(\D* /Z/?^#9[
M_@G9\.?VY?VS_%/CSXW^']'\:?!G]ECPKH_CG6? &NV?]HZ'XY^(/BZ_U'2?
MAOHOB33I$^QZAX8TYM%\3>+-2TV\>2TU>^\-:1HNI:;JFA:EK-L/D^+\UJY;
ME\*>&E*GB,;.5*-6.DJ=*"3K2@^DWS0A%K6*FY1:E&)UX2DIS;DKJ"6G2[V^
MZS_ _P!-S4=0T3PKH5]JVIW6G:!X;\-Z3=:AJ%[<O!I^DZ+HFCV;W-W=7$C>
M7;66G:=86\DLKGRX+:VA9CMC3C\=2E.2C%.4Y2226KE*3LDN[;/5/XROVF/^
M#P_X8^%/&/B#PO\ LK?LGZS\5_#6E7]U8:7\4?BE\1#\/+'7UM&, U72_A]H
MWA'Q+K']C7\JO<:9+K/BC0-8?3_L\FHZ'I=Y/-8V?Z#@^ JLZ<)XW'*C-I-T
M:%+VO)?[+JRG"/,MFHTY1O\ #*22;X98V*=H0YEW;Y;^BLW]]M/P_:[_ ((?
M?\%(_C-_P5%_9F^)W[0?Q?\ AM\/_AE_PC7QYU[X4^#](^'Y\2R6E]HN@^ _
MA]XHNM0U2X\2ZMJDM[?+J7C.>Q^V6"Z=9/':?9_L"7%M---\[Q'E&'R7%T<+
MAZM6MSX:-:HZO)=.52K!)*$8V5J=[.[UWMMOAZKJP<FDK2Y4EY)?YGTO_P %
M9O\ E&#_ ,%!?^S.OVA__57>):X\C_Y'.5_]A^%_]/0+J_PJG_7N?_I+/\=:
MOWL\,_U#?^#6W_E$+\*?^RK_ !R_]3Z_K\:XS_Y'M;_KQAO_ $TCU\)_ CZR
M_-GWK_P63AEF_P""5G[?20QO*Z_LP_%&8K&I8B*WT">>>0@#A(8(I)9&Z)&C
M,<!37F</_P#(ZRO_ +#*/_I1I6_@U/\ !+\C_']K]X/$/[!O^#.;_D[_ /:R
M_P"S;='_ /5G^&J^#X^_Y%^"_P"PQ_\ IB9W8'XI_P"%?F?Z%5?E9Z1_D(?M
M5>*++P/_ ,%I/VD/&NI2P0:;X/\ ^"H/Q@\4:A-=,L=M#9>'_P!J[Q%JUU+<
M.Y")!'!:.TK,0JQAB2 *_>,#!U.'\)3CO/)\/!)=Y8*$5;[SQ9.V(D^U9O[I
MG^O<"" 0000"".00>A!'&,=*_!SVC^*[_@\L^'/B#5/A+^PK\6+2SU"7PQX(
M^('QQ\ ZY>Q1ROIEEK/Q+\/?#;7O#D-Y(H,4%U>VGPK\2?8=^UIH[6\5,^61
M7Z'X?U8JMF=!M<]2EAJL5U<:,JT)V\DZT+^J.''+W:;Z)M>6J5OR/X(:_33S
M3^WW_@S2^&^NMXC_ &Z?B]/87T'AF'1/@I\-]+U1T=-,U37;B^\>^)]>L+:3
M_53WV@Z?:^&[B]09>SM_$=@QVK>KN_.>/ZL>3+:%US\V(JN/512IPB_)2;DE
MWY7V/0P*_B/I[J_/\M/P/[LZ_-3T#_&/_P""A/C+3_B)^WO^VWX]TBXM[S2/
M&?[6_P"T;XGTB[LV5[6YTG6_B_XPU'3+BWD3Y989K&XMY(Y03YJL)"26)/\
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M#>]N[KP=\5+2WMH?-OYI?AKXRM=!\97%EIH5EO=7TW2+[0T*[XM3E@DAED^
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MW\)?^R5_'/\ ]5[J5?J/&?\ R(<1_P!?L-_Z>B>;@_XR_P ,C_40K\9/6/\
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M!2J24(\TK/EC=J[MHCI;44V]HIO3LD?SQ_\ $6+_ ,$J/^>?[3'_ (9_2/\
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M/O\ D7X+_L,?_IB9W8'XI_X5^9_H65^5GI'^--_P4J_Y2,_M^?\ 9Z_[5/\
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M?^I]K]?T1A/]UPW_ &#T?_3<3P9?%+_$_P SPRN@D* "@ H * "@ H * "@
MH * "@ H * "@#_65_X-Z_\ E#C^Q'_V)WQ&_P#5X?$^OP_BG_D?YC_U\I?^
MHU$]G#?P*?H_S9]1_P#!43]I'XB_L@_L!_M-?M)?"5/#[_$;X3>!+3Q!X47Q
M5IDVL^'_ .T+CQ3X?T5CJ>EV]]ILUY"EIJEPR1)>P 3K$[%D5HWX\EP=''YI
M@\'7YO8UZCC/D?+*RISEH[.VL5T+JR<*<I+>*NNQ_ [J/_!UU_P5>O;9H+:_
M_9UTB1NEYIWP;DDN4X_A75O%NJ6G'7Y[5ORXK]-CP3D:>L<5+R>(T_\ )81?
MXGG?7*W]S_P'_@GY]?M-?\%L/^"GW[6VC:KX5^+O[6?CV'P/K*O;ZAX%^&MM
MX?\ A%X7OM/D5E?2-7M?AKI'AB^\2Z5(&)FL?%.H:Y%<$(;CS?)A\OU<'P]D
MV E&>'P-+VD=JE7FKS3[Q=:4U!^<%&QE+$5IZ.;2[1]U6[:6_$_*ZO:,3].O
M^"+O_*5K]@C_ +.2^'__ *7-7C\0?\B3,_\ L#K?^DFV'_C4_P#$?Z^U?@Y[
M1_F\_P#!WY_RDQ^#7_9D/PR_]7E^T?7ZWP)_R)Z__8QK?^H^$/+QO\6/_7M?
M^E2/YVOV1_\ DZ[]F/\ [.%^"_\ ZLCPU7U>._W+&?\ 8+B/_34CFI_Q(?XX
M_FC_ &JZ_GD]T_@E_P"#R_\ Y*M^P=_V3WX[?^I'\-:_3?#_ /@9G_U]PW_I
M%8\[';T_27Z'[*?\&U?_  3E^&7[+?[#7PV_:<U?PSH6K?M%_M5>%XOB/JGC
MZXT]9];\+?";Q,;>\^'_ ,.O#>HW48GTW1;S0;72_&/B9;"*T?6O$>M&VU&X
MU;3O#?AJ2T\#B_-JV,S&K@HSE'"8*?LE23M&=>&E6K-+=J5Z<+WY81NE%SE?
MHPM)0IQE;WIJ[?D]EZ6M\_D?IY_P4F_X*3_ /_@F#\!X/C;\<8O$.OW'B+7A
MX/\ AS\.O!L-C/XL\>^+7T^[U(V5FVI7=EI^DZ)I=E:/>^(_$=_-]ETBT:WB
M@MM3UC4-(T;4O&RC*,3G.)^K8;D@H1]I5JU+\E*G=1OHFY2;=H07Q/=QBI26
MM6K&E'FEZ)+J^WEM_6B/Y)_B'_P>/_'#6KZ6Q^"7[#_PS\.?:+D6FCGXB_%'
MQ;\1+RY>600VAGTWPIX<^&@$]PY3_0K>_FV._D)=SX$S?<TN ,-%7Q&8UIV6
MOLJ-.BE\YRK:+T^[8XGCG]FFO*[OZ:)+\_(_O3TI]0DTO39-7BMX-6>PLWU.
M"S+M:0Z@UO&;V*U:0M(UO'<F1("[%S$%+$G)K\RERJ4N6_+=\M]^6^E[:7MV
M/1/X5?\ @\X_Y&O_ ()Z?]B]^TY_Z<O@/7Z5X?\ \/-/\>#_ /2<2>?CO^77
M_;__ +8?S*?\$X?^"F/[27_!,;XSS?%;X":M87VA^)HM,TKXJ_"KQ.DMSX&^
M*/AO2[BYGL]/UJ&W:.]TO6M':^OY_"_BK1YK?5]!N;V\B!OM%U/6]$U;[#-L
MHPF<8?V&)BU*%W0K0TJ4)M)-QZ.,K)3@_=DDMI*,H\E*K*C*\=G;FCT:7Y/L
M^A_>S^QG_P '17_!.7]I&QT;1?C;K&O?L??$V]\FVO-%^*,%QK_PSFU!PF[^
MQ?B[X:TUM)@TM QW:E\0=$^':(T<D?E,/)DG_,LPX,S7".4L,HX^BMG1M"M;
M^]0D[W\J4JIZ,,72EO[C[2V^36GWV/Z)/!GC7P9\1O"^B^-_A[XM\,^._!?B
M2S34?#OB_P &Z]I7B?POKVGNS(E]HNOZ)=7VE:I9N\;HMS8W<\#,C*'RI ^4
MJ4JE&<J=6G.E4@[2IU(2A.+[2C))I^32.I6:TU72VQ^3G_!:S_@FS\(?^"@?
M[&_Q4&M>%](M?CY\)? /B?QW\"_BA::-:2>,-'U[PEIE[XD'@23542/4+KP5
MX]^QS>'];T.6>:PMKG4;7Q-:6+ZWHNG2+[G#N;U\KQ]!1G)X6O5A2Q-!R?LY
M1FU#VO+LJE*ZE&25VER-\LF8UZ4:L&K>\E[K[>7H[69^+?\ P9MZWI\_[.G[
M:/AN/R/[4TGXU?#G6[S:R_:?[/\ $'@74K#3?.3.Y8/M'AC5OLS%0K2?:@I)
M1@OT/'\6L5ET^DL/6BNUX5(M_A./X'/@?@FNTE^7_ /[*Y',<<CB-Y2B,XBB
MV^9(54D1Q[V1-[XVIN=%W$;F4<C\_7W'<?S37?\ P=<_\$LM/N[JPOK/]IZS
MO;*XFM+RTN?@UI<-Q:W5M(T-Q;SPOX\5XIH)4>*6-U#(ZLK $8K[!<#YRTFI
M8)I[-5YVMTM^Y.7ZW1_O?^ E?_B+%_X)4?\ //\ :8_\,_I'_P WM/\ U'SK
M^;!?^#Y__*0^N4>\O_ 0_P"(L7_@E1_SS_:8_P##/Z1_\WM'^H^=?S8+_P '
MS_\ E(?7*/>7_@)_FV_%#Q#I_B[XE_$3Q9I/GC2O$_CKQ;XATP740AN1I^M:
M_J&I67VB%7D6*?[-<Q^=$LCB.3<H=@,G];HQ<*5*#WA3A%VVO&*3M]QY4M9-
MKJW^9PM:""@ H * /]F3_@G)_P H]/V#_P#LS/\ 9?\ _5(^!Z_G_-O^1KF?
M_8PQG_J14/=I_P .'^"/_I*/Q!_X.XO^47O@;_L[[X4_^JW^-5?1\"_\CFI_
MV 5O_3V'.?&?P5_CC^3/\UFOUT\H* "@ H * "@ H * "@ H * "@ H * "@
M H _JR_X,_?^4EGQP_[,9^)?_J_/V9J^)X\_Y$^&_P"QE1_]1<8=F"_BR_Z]
MO_TJ!_H_5^2GJ'^=W_P>)?\ )\'[,/\ V:G!_P"K=^)%?JW 7_(MQG_8<_\
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M /TN:O'X@_Y$F9_]@=;_ -)-L/\ QJ?^(_U]J_!SVC_-Y_X._/\ E)C\&O\
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M\D1_;B_[*I\'O_42\8U^8\?_ .\9;_UYQ'_I=(]+ _!/_$OR/[/+O_CUN?\
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MKE'O+_P$/^(L7_@E1_SS_:8_\,_I'_S>T?ZCYU_-@O\ P?/_ .4A]<H]Y?\
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M].<>\7;UZ?B?XX=?OIX84 % '^RI_P $SO\ E'!_P3\_[,C_ &4O_5$> J_
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M3J1CRW49.,9QG%133E'EY4TWJGSXC#^VY6G:4=-=FOEM8^</^".W_!M=I/[
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M  7(_P"42?[=W_9#M2_]/FA5[/#?_(\RS_L)C_Z3(RK?P:G^"7Y'^7+^P/\
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M87O&G2J67\M&O2JRNNRA!M]K7Z'CX5VKP^:^^+7]?<?ZR-?AY[!_&;_P5/\
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MKWXA>&BKHNVUFU)Q,Q-Y"%]3Q I2=++*ROR0J8FE+^52J1HRCZ-JE+U2\C/
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M'A>OY[S#_?\ '?\ 89B?_3TSWH?!'_#'\D?SK_\ !X)_RC=^!/\ V>]\/O\
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MKZEEV-Q6SH8:K.'3]YR-4E\ZCBOF<M*//4A'O)7].OX'^SH % 50%50 J@
M #   X  X ' %?S\>X?Y8_\ P<P?M 6OQW_X*T?&C3=+GBN]#^ /A3P!^S_I
M=W$0?-NO"FEW'BSQA!(!G;+I?Q#\=>,=%<$DG^S0QV[MB_M/"&%>%R/#.2M+
M$SJ8IKRJ/DI_^!4:=.7S/(Q<KUFOY4H_K^MC\"*^G.8* "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H _
MT1/^#.W_ ),>_:=_[.LF_P#51?#:ORKCW_D8X+_L"_\ <]4]/ _PY_X__;4?
MUV5\(=I_CW_\%@_^4IG[?W_9UGQD_P#4PU*OWK(?^1+E?_8#AO\ TW$\7$?Q
MJG^(_-^O6,0H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M4Q8/^,O\,C_4KK\7/6/\J3_@Y4_Y32?MA?\ 7M^SO_ZRW\%*_;.$?^2>R_\
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M_P!%M7Y\MUZH[C_#7K^CSY\_NE_X,P?^0=_P4:_Z_?V2_P#T1^TI7YOX@_\
M,H_[G_\ W2/1P.U3UC^3/[BZ_-SO/\0WXK?\E1^)/_8_>,?_ %(=1K^C*/\
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M:<>6$(1A3CA\-*-.,8):1<Y.\KR=]9,Y\53A3G&,%9<B??6\E?\ #T/[MO\
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MK_R:!^RG_P!FV_ S_P!5AX7K\+S#_?\ '?\ 89B?_3TSVH?!'_#'\D?SK_\
M!X)_RC=^!/\ V>]\/O\ U0_[1U?5\!?\C;$_]BZI_P"I.$.7&_PH_P#7Q?\
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MBL(FW&A4?(Z;D[OV55*3BF]7&49QNVXJ+;;YZN&A5UUC+^9?JNOX'XU?#?\
MX,T/!UAXHMKOXN?MY>(_%'@NWOX6NM"^'?P%TWP-XEU;3$D!FCA\4>(_BC\0
M-,T&]FB'EQNWA+Q##;L?,*SA?+/OU?$";@U0RR,*EM)5<2ZD(OSA"C2<E_W$
M@81P,5\51M=E%1_5_D?GY_P4R_9?_91_X)1?\%K/^"7OAWX"^!X_ _PA\#Z3
M^R1\9/'[^(?$VN>)+[7M:TW]K'XDV?BGQWXAUOQ)J5YY.KOX<\(:7(QL5TS0
M-.;2+1K'2+*UA,!]7)\;C<[X=SB>*J>TKU)8_#TN2$8*$7@:+A3A&"6BG4EO
M>3YM9,RJPA1Q%%15DN1N[_OM7U\EZ(_T= 00",$$9!'0CMCVK\E/4/Y5?^"V
MW_!NYXW_ ."CW[06F?M3?L[?&?P'\/?B1JOA+P[X+^(_@WXMP>)8?".M0^$X
MKBST/Q7H/B7PEHWBC5M,U5-&>ST74- N?#-SI]['IUIJ,&K:=<?:X+S[;AWB
MNGE.%>"Q>'JU:,9RJ4:E#DYX\[3E3E"<H1<>:\E)3NKN/*U9KCKX9U9*49).
MUFGMIM:WY'T5_P $6/\ @@?X(_X)<ZQXD^-WQ*^(.F_&O]IOQ5X?NO!]IKNB
MZ++I?@'X9>$+V[MKK4]-\$0:NK:YJ7B#Q$UC9IKOB_44TF8:5&/#NDZ+IUG/
MKEYXAY.(>)ZF<QAAJ-)X?!PDIN,I)U:TTO==3E]V,(7]VFN;WO>E)M14+H89
M4=6^:;5O)+LO\_P1_1#7RATG^3U_P<3?\IE_VV/^QA^$7_K/7PDK]OX4_P"2
M?R[_  5O_4JN>/BOX\_^W?\ TB)_9/\ \&G_ /RBEC_[.2^,7_I!X)KX#C?_
M )'?_<GA_P#TJJ=V#_@K_%(_7#_@J1_RC._X*&?]F0_M4_\ JC?'->%DO_(X
MRK_L8X+_ -2*9M5_A5/^O<__ $EG^-[7[Z>&% !0 4 % !0 4 % !0 4 ?Z>
M/_!JO_RB4\'_ /9<_C5_Z>M-K\=XV_Y'DO\ L%P_Y2/6P?\ !7^*1_1_7R)U
M'^*%^T__ ,G+?M#_ /9<_BU_ZGVOU_1&$_W7#?\ 8/1_]-Q/!E\4O\3_ #/#
M*Z"0H * "@ H * "@ H * "@ H * "@ H * /]97_@WK_P"4./[$?_8G?$;_
M -7A\3Z_#^*?^1_F/_7RE_ZC43V<-_ I^C_-G2_\%Z/^40O[<W_9*=,_]3_P
M;4\,?\C[+?\ K]+_ -,U!XC^#4_PG^2+7[D>*% !0!^G7_!%W_E*U^P1_P!G
M)?#_ /\ 2YJ\?B#_ )$F9_\ 8'6_])-L/_&I_P"(_P!?:OP<]H_S>?\ @[\_
MY28_!K_LR'X9?^KR_:/K];X$_P"1/7_[&-;_ -1\(>7C?XL?^O:_]*D?SM?L
MC_\ )UW[,?\ V<+\%_\ U9'AJOJ\=_N6,_[!<1_Z:D<U/^)#_''\T?[5=?SR
M>Z?P2_\ !Y?_ ,E6_8._[)[\=O\ U(_AK7Z;X?\ \#,_^ON&_P#2*QYV.WI^
MDOT/ZQ_^"1WQ$T+XH_\ !,+]@OQ5X=^Q"P@_99^#G@VXATYXWL[37/AKX-TS
MX<^);"$1LXA%AXC\*ZI9M;,QEM6A-M,?-B>OB,]I2HYSF<)7N\;7J*^[C5FZ
ML'\XS5GU1VT7>E3_ ,$5IY*WZ?(^?_\ @M1_P2>M?^"KW[/?@[P#HGQ%MOA9
M\6?A'XMO_&GPR\3:SIMUJ_A*_EUC2/[(\0>%/%MG8.NI6FE:Y%!I=Q'KVE17
MVH:)>Z3;S)I6JVLUW83=7#N>?V)BJE25)UJ%>$:=:$6HS7*[PG3O[KE&\ER.
MRDI?%&R9%>C[:*2=G%W7;M9_UH?BQ_P3/_X-3;O]GOX_>"?CY^VO\8_AU\5(
M/A7K^E>,/!/P?^$]AX@O_!^O^+]#OA?Z%J/Q \2>.- \.7FH>']%O+:SU(^$
M-/\ "\<.NWZ00:MK/]B6M]I&O?0YOQLL5A:F&R[#U:#K1=.IB*[@IPA)6DJ4
M*<II2DKKVCG[B^&/-:4<*6#Y)*4VG;:*V^=_RM\^A_9U7Y\=Q_"-_P 'G'_(
MU_\ !/3_ +%[]IS_ -.7P'K]+\/_ .'FG^/!_P#I.)//QW_+K_M__P!L.$_X
M)Q?\&\?[+?\ P4F_X)1? 'X]6?CKQO\  7]IKQ%JOQGL]9^(VD&;QWX+\61>
M&OC#X[\+>'XO%?PTUS5]/@B.EZ)HNEZ=:W/@?Q#X+9TAENM7@UN]E,HTS;BK
M&91G>)PKI4\3@X1P[C2?[JI#GH4YRY*T8O>4FVJD*G11Y4*EA85:,)7<9/FU
MW6DFMO1=+'S=XW_X-#_^"CNB:_)9^"?BO^REXY\./-ML]=N/&WQ%\)WZ09($
MNK:#>_"[44LI< ,T&F:OKJ@,NV=SN"]E/CK*)1O4HXVE+K'V5*:_[=E&LKKU
M4?0AX*HMI0:^:_"Q_5I_P0H_X)2_%[_@E;\#_BGX+^,OQSTSXI>)OBWXK\-^
M*&\%>")O$,WPI^&,GA_3-4L+I_"-QXFM=(U'4M=\7MJD+>+=9_X1KPY'>6_A
MSPQ9BRG.F&\G^)XESO#YUB*%3#X:5&%"$X>TJ*"K5N9Q:YU!R48T^7W(\\[<
M\WI>QV8>BZ,6I2O=WLOA7I^NBZ=C]._VR?CWX/\ V7OV5/V@?C_XZU*VTOP[
M\+?A1XR\3227!A!U#5H-&N;;PUX?LH[AXX;G5O$_B2YTGPYHUD[J+[5M4LK3
M<OG9'C9?A:F,QV%PM*+<JU>G#2^D>9.<G;51A!.<FMHQ;Z&TY*$92>BBF_Z_
M)+Y'^=C_ ,&PG[>GA7]D#]N[4OA/\3]<L?#7PL_:[\.:1\,[KQ!JEV+#2= ^
M*GAW4;O4_A+J&K74C?9XK#5KK5_$W@2.69$CMM5\:Z7>W-W9Z=:W\A_5N,<L
MGC\L5:C%SKX";K*$5=RH225=175Q485++I3:2;:1YF#J*%1Q>BFDOFMOU1_I
MR5^.GJG\BG_!37_@U>\!?M3?&3QE^T+^R+\8-#^ ?B_XD:]=>)O'?PH\:>&;
MG4?A3=>)=4'G:WXA\':KX7"Z[X+.M:H)=8U;0)M#\4:9/JVJ:A<Z1/X>T^.V
MT8?=Y/QK4P6'IX7'T)XF%&*A2KTY)5N2.D8U(S]VIRQM&,E*#M%*2D[R..K@
MU-N4'RM[JWN_*VWX_(_,#P1_P9S?M?W]_P"7\2/VLOV;?"FF?:=OVOP1H_Q/
M^(%_]DWX\_\ LW7O#7PSM_M/E_-]E_M3RM_[O[9M_>5[-3C[ )?NL#C)RMM4
M=&DK]KQG6=O/E^1BL#+K.*]$W_D<U_P6T_X(:?LI_P#!+3_@G3\+/B9\./$7
MQ%^)_P >O$W[47@'X=^+/BEXVU:/3M.N/"^L?"CXT^(]7T7PS\/=!$'A_0=+
MN];\'^'[^*35I_%7B:T-G);1^*&LKNYMI+X=XDQN=9K7HU84J.&A@JE6G1IJ
M[4XU\-",IU9>])J-22]U0@[WY+I"Q&'A1I1<;N7.DV^W*^BT6W_!/Y'J^Y.(
M* "@ H * /\ 9D_X)R?\H]/V#_\ LS/]E_\ ]4CX'K^?\V_Y&N9_]C#&?^I%
M0]VG_#A_@C_Z2C\0?^#N+_E%[X&_[.^^%/\ ZK?XU5]'P+_R.:G_ & 5O_3V
M'.?&?P5_CC^3/\UFOUT\H* "@ H * "@ H * "@ H * "@ H * "@ H _JR_
MX,_?^4EGQP_[,9^)?_J_/V9J^)X\_P"1/AO^QE1_]1<8=F"_BR_Z]O\ ]*@?
MZ/U?DIZA_G=_\'B7_)\'[,/_ &:G!_ZMWXD5^K<!?\BW&?\ 8<__ %'HGFX[
MXH?X7^9_(G7W1PA0 4 % !0 4 % !0 4 % !0 4 % !0!_K*_P#!O7_RAQ_8
MC_[$[XC?^KP^)]?A_%/_ "/\Q_Z^4O\ U&HGLX;^!3]'^;.E_P""]'_*(7]N
M;_LE.F?^I_X-J>&/^1]EO_7Z7_IFH/$?P:G^$_R1:_<CQ0H * /TZ_X(N_\
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M (@6YNHE9GM[R\\.>/- U*X67#S->?:T58;B(#YKC&E*GGV*D[VK4\-4A?\
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M4I-W;;=VV^K;U;/0/Y._^#PO_E']^SK_ -GB^&__ %2GQKK[C@+_ )&>+_[
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MA2PSJQ]C3E!\WM:<-6YRTM)Z670Y\1AZ=*FI1YKN:6KZ6D^R[(_DCK[DX@H
M* "@ H * "@ H * "@ H * "@ H * "@#NOA?_R4SX=_]CUX1_\ 3_I]9U?X
M53_KW/\ ])94/BC_ (H_FC_;VK^<SWC^?G_@Y[_Y0Z_'[_L>O@+_ .KD\'5]
M3P;_ ,C[#?\ 7K$_^F)G-B_X$O6/YH_RU:_9SR H * "@ H * "@ H * "@
MH * "@ H * /T7_X)#?\I1_^"?W_ &=K\#O_ %/-&KR<]_Y$N:?]@.(_]-R-
M:'\:G_CC^9_L,U^"GMG^>O\ \'C7_)WG[)?_ &;?K7_JSO$5?JG /_(OQO\
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M4K?S4)N,.9]7&K"/:FEMU3P2_P"7<K?W9:K[UK^#]3\[?A]_P:+_ /!2"_\
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M -ES^+7_ *GVOU_1&$_W7#?]@]'_ --Q/!E\4O\ $_S/#*Z"0H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * /Z9/^#3K_ )2KR?\ 9L_Q@_\
M3MX"KX_C?_D2?]SF'_\ 2:IUX+^-_P!N/\T?V$?MM?\ !O/_ ,$UOVV]=U7Q
MWK?PRUCX$?%36Y[N^UGXB?L[ZCI7@.Y\0ZI=NUQ+J/BCP=?Z'XA^'FLZA=7K
MR7FK:TOA2Q\3ZQ-/.]_X@DF:.:+X/+N*LWRZ,:4:L<50BDHTL4I5.2*224*B
ME&K%))*,>=PCT@=U3#4JFKCROO'3\-OP/QV?_@S2^#IUKSX_VZOB6OAW+?\
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M"0?[ OCG_@FU^QCX<_9J^(GQGN/C7XGM?&'B?QK=:I;IJD/A'P8GB6'2(O\
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MD4S:K_"J?]>Y_P#I+/\ &]K]]/#"@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@#[F_X)@?\ *2S_ ()X_P#9\W[)7_J_/ %>;G/_ ")\
MU_[%N._]1:II1_BTO^OD/_2D?[)5?@)[@4 ?_];^_B@#^4W_ (/ O^4:7P/_
M .SYOAI_ZH/]IFOMN _^1OB?^Q;6_P#4G!G'C?X4?^OB_P#29'^<#7ZT>6%
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MEJ_80_[+GI7_ *9=;KQ>(O\ D1YG_P!@L_S1MA_XU/\ Q'^NO7X2>T?R)_\
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M1\%Z3=ZAX8\>_&7XN7T$>ZWT+P#\%/%6E:C?.1Q'#<?%,_#?1XMIP)'NM3@
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M36'C7C/ZQ.K"_M'2<>3V=&K>W([WY;:6OTZ\-7A14E)2?-:W*ETOW:/Z(O\
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MQ1X4GS-R>[;?WGGU:B"@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * /]$3_@SM_Y,>_:=_[.LF_]5%\-
MJ_*N/?\ D8X+_L"_]SU3T\#_  Y_X_\ VU']=E?"':?X]_\ P6#_ .4IG[?W
M_9UGQD_]3#4J_>LA_P"1+E?_ & X;_TW$\7$?QJG^(_-^O6,0H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H _KL_X(:_\%]OV/?^"9O[
M&>N_L[?'CX:_M*>+/&FI?'+QO\2[;5/A'X0^%^O^%QH'B7PQX"T:QM9[SQE\
M8O .JQZO#=^%]1:ZMH]%FLDMI;*2'4)I99X+7X3B3AC'YQF$<5AJV#A36&IT
M7&O.M&?-"=23:5/#U8\MIJWO7WTVOVX?$PI4^62E?F;]U*VR[R78_3;X_?\
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MX)<:]>Z;\-KNP^)WP)\2:A_:7C']G_Q]?:B/"-SJ4@@CN?$O@K5+-I+[X?\
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MDFU9K2U_T/[*_P#B,"_X)I?]$/\ VYO_  VGP#_^B9K\_P#]0\W_ .@G+?\
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M_P"":7_1#_VYO_#:? /_ .B9K\T_U#S?_H)RW_P=B?\ YC/0^NTOY:GW1_\
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MF48SC*$XQE"47&4))2C*+5G&47HXM:--6:T&M+-:6V\K']GO_!/[_@[A\2^
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M_$6OHCG/ZAO^"6__  <W_M#?L6>$O#7P)_::\*:A^U%\!?#45OI/A76VU_\
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MI)62BHZ^3;^6^Q^Z_P#P2@_X.FM%^"'PB\&?LY?M^>"?&WBO1_AIX8TWPGX
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M]6/+:2M[U]]$=-#$PI4^22E>[?NI6_%H^YOVS_\ @Z?_ ."??[1/[('[4_P
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M^2C",ITJCLVW.;3I12E:FK-^YLSDQ&(55**C:*E>[WT36RT6_=G\WU?6G(%
M!0 4 % ']_O[)O\ P=6_\$]?@3^RO^S1\$/&'P:_;+U#Q;\&_P!G_P"#?PJ\
M47_AKX??!&]\.7WB'X>?#KPYX1UJ\T"\U3]H;1=2NM%NM1T>YGTNXU#1]*OI
MK%X)+O3K*=GMH_R_'<$YIB<;C,13Q&7JGB,5B*T%.KB%-0JU93BI*.%E%22D
MDTI25]FT>E#&4HQC'EGI%+11Z*W\Q^='_!<[_@OE^Q]_P4U_8W\-?L\? 7X:
M_M)^$_&>D?'?P5\3[O5/B[X0^%^@>&&\/^&_"/Q#T&]M+:\\&_&'Q_JLFL2W
MOBS3'M;:71H+)K6&^DEU&&6*WM[KUN&^&,?D^/GBL36PDZ<L-4HJ-"=:4^:=
M2E)-JIAZ4>6U-W]Z][:=LL1B85:?+%23YD]4DM$^TF?R,U]T<04 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0!_5E_P &?O\ RDL^.'_9C/Q+_P#5^?LS5\3Q
MY_R)\-_V,J/_ *BXP[,%_%E_U[?_ *5 _P!'ZOR4]0_SN_\ @\2_Y/@_9A_[
M-3@_]6[\2*_5N O^1;C/^PY_^H]$\W'?%#_"_P S^1.ONCA"@ H * "@ H *
M "@ H * "@ H * "@#^WS_@EC_P<K?L+_L0_L"_L[?LL?%GX3_M8Z_\ $+X1
MZ%XMTKQ'K'P[\#?!_5_!M]-KOQ'\9>+K*31-1\2_'7PCK=Q$FE^(;&&Z^W>'
M=-:*_CNH85N+>.&[G_.<ZX0S+,<SQ>-H5\#&E7E!PC5J5XU%RT:=-\RAAIQ6
ML':TGI;;9>A1Q5.G3C!QG>*Z*-MW_>7Y&O\ \%,_^#F;]A']LS]A+]I#]F'X
M6_"7]K;0_'_Q@\%V/AOPUJWC[P+\'=)\'V-Y!XI\/ZU+-KFH>'?CQXKUJVMO
ML6E7*QM8>'M2E>Z:")HHXGDN(5DW!^99?F>$QE:O@94L/-RG&E4KNHTZ<XKE
M4L-".\EO):?<%7%TYTY049W:LKJ-OPE^A_#97Z.>>% !0!]A_P#!/O\ :$\&
M_LH?MK_LR?M(_$+2_$VM>!_@Q\7/"OCWQ3I/@RTTJ_\ %5_HVBW?FWMOH%EK
M>L>'M(NM3:(G[+!J.N:5:2. DM];J=XX,TPM3&Y=C,)2<(U,1AZE*#J-J"E)
M67,XQE)1[VBWY,TI24*D)/:+OI^A_=W_ ,1@7_!-+_HA_P"W-_X;3X!__1,U
M^:?ZAYO_ -!.6_\ @[$__,9Z'UVE_+4^Z/\ \D?R5?\ !=S_ (*/?!'_ (*@
M?M?^ OC_ / 3PI\5/"'@SPI^SMX.^$5]IOQ>T7PEH/B>?Q%X?^(OQ8\87M]:
M67@SQOX^TIM%DT_QYI5O:SS:U#?/>6NH)+IT$$=M/<_<\-93B,FP%3"XF=&=
M2>*J5TZ$IR@H2I4*:3=2G2?->D[KEM9K7MQXBK&K-2BFDHJ.MELV^C?<_*CX
M'>.-+^&/QK^#_P 2=;MK^\T7X>_%+X?^.-7L]*CMY=4N]+\)^+-(UZ_MM-BN
M[FRM)+^>TL)8K..YO+2W>X:-9KF",M*OMXBFZV'KT8V4JM&K3BWLG.#BKV3=
MDWK9/3H8P?+*+Z*2>GDS_0L_XC O^":7_1#_ -N;_P -I\ __HF:_*_]0\W_
M .@G+?\ P=B?_F,]+Z[2_EJ?='_Y(_F6_P""_O\ P5F_9U_X*J^-_P!FGQ'^
MSUX*^-/@W3_@UX5^)&B>)H_C+X>\#>'KR_O/&6K^$K[3GT*+P1\1?B'!<6UO
M!X?NEO9-0N=,E26:W6""X0R21_8<+Y'B\DIXR&*J8>H\1.C*'U>5222IQFGS
M>TI4K/WE:R?R.3$UHUG#E4ERI_$DM[;6;['SM_P2!_X+$_%__@E!\3?%%[HO
MA>V^*_P*^*;:-'\5OA)J.L76BS276BR2IIWC7P)K*1WMIX?\;:;975W82O>Z
M7J&D>(])E&E:O;1W%GH6M:!UY]D&'SNC!2FZ&)H<WL*ZBI)*5KTZD='*FVD]
M))P>L79RC*:%=T6]+Q>ZVVV:\_S^ZW]NOP]_X.FO^"1OC+2/[0\3?$?XO?":
M_%HL[:#X[^"7C/5=1-QL4M8Q7/PO@^(NCM,K$HLLFIP6K;=QG52*_.JO!6>4
MY6A2P]=7MS4L1"*MWM6]E+\#T%BZ#7Q->3B_T31^=G_!0#_@[9^#FD^ M?\
M W_!//P-XO\ &/Q.UFQ>PL?C9\5_#,'AGP#X(6\C=)=:\.>"+R^N/$WC+Q%8
M)G^SK3Q1IOA?P]9:@UM?WT/BBPMKC0K[ULKX&KNK&KFM2G"C%W>&H3<ZE2WV
M9U$E"G!]?9N<FM$X/WEE4QD4K4E=_P S5HKT6[^:1-^R+_P==_L1_"#]ES]G
M[X6_&[X=_ML>//C%\/\ X1>!/"7Q1\;Z;X.^#OB.Q\7^/M#\/6-AXK\36NO^
M)/VA-$U_6(M<UJ&\U(:EK.D:;J=W]I,UY9P3NZ!8_@G,<1C<57P]7+J="K7J
M3HTW4KP=.E*3<(.$,+*$>6-H\L9.*M9.P0QE-0BI*;:BDW:.K2M?XE^1^8G_
M  7G_P""ZG[)7_!4;]F#X4?!/]G_ .'7[17A#Q/X&^/6E?%/6-1^,7A/X:>'
M]!GT'3_A[\0?"4EEIMQX*^+?Q!U"?5WU#Q;83I#=:9960LK>[<WPG6&WF]GA
MGAO'9+C*^(Q57"3A4PSHQ6'G6E)2=6E.[52A22C:#6C;O;2QCB,1"K!1BI*T
MD]4ELFNC?<]F_P""+/\ P<;_ +,O["/[(_PP_8Z_:&^"_P 819_#W6?']U:_
M%CX:2^%O&%CJ$/CSX@^(_'0DUGP=K6J>#=4T:'1V\1R:;,^D:GXIN;N.R2\A
ML4>X-G!S\0\)XO,\=6Q^%Q%"]6-).A64Z=O94HT_=J1512OR7UC!*]KZ7+H8
MJ%.$:<E+W;ZJS6K;VT[]#^@K0O\ @Y[_ .".VKVCW%_\??'7A>9(C(MAKOP%
M^,=Q=2.!D0(_AGP?XBL1*3\H,EY'!GK,%YKY:7!N?1=EAJ4UWCB:"7_D\X/\
M/D='UNA_,U_V[+]$?/WQD_X.T?\ @FIX%T'5)_A5X<^/OQR\4Q1E=$TC3? M
MG\/_  ]?W."4.J^)?&^KV6IZ/I_RXDNK/PCKMZC-&$TJ5?,:+JP_ V;U))5Y
MX7#0TYI.HZLTO[L*<>63\G4@O,F6,HI>[S2?16M^9_']_P %5O\ @N)^U'_P
M5+ETKP9XITW2/@O^SQX;U6/7-!^!O@K5+W5K34M>MQ<QV7B3XA^+;VUTZ]\;
MZ[IMO=S6VEHFE:!X:TM";K3_  U;ZK+=:E<_>9)PY@LE3G!RQ&*FN66)J146
MHZ7A2@KJE%VN]93>SFXI)<5;$2JZ?#%?97ZO2_Y+L?BR"0002""""."".A!'
M0CM7T)SG];'_  3/_P"#J3XU_LT^$/#?P6_;7\#:_P#M-_#CPU;1:7H'Q9\/
MZU:6OQ\T'1K:-([/3M?'B*>#P[\58K&&)+6QO=;UGPGXH$;O-K7BKQ \<,2?
M#YQP5AL94GB,OJ1P=:;YI491OA92>[CR>]0ONU&,X=(PB=M+&.*4:BYDNJ^+
M[M$_P/Z._!'_  =&?\$@?%>FVE]KOQ@^)_PSN;B 2S:-XV^!?Q(O]2L)"/\
MCUNY?AQH_P 0-'>=>A:PU6]MLD8N",D?)5."\]@VHT*%9+[5/$TDGZ>U=)_?
M%'4L70_F:]8RT^Y/\#F/&W_!U5_P27\*Q73Z#XJ^.OQ*>".5H8?!?P6U;3WO
M6C4E(K=OB)JO@**-IB D9NWMD4L#*T:@D73X)SR=N:&&H^=3$)V_\%1J?@)X
MN@NK?I%_K8_E3_X+4?\ !?MO^"I_PO\ #/[/'@C]GE?A'\(?!7Q;T;XM:?XH
M\5>,#XE^)'B36?#_ (3\<>#]-AO-+TC3].\,>%=,ET[Q[JD][I<%[XMNFO;.
MPD@U^&#[1:R_:\/<+K)*T\54Q7MZ]2A*@X0I\E&$93I5'9MN<VG2BE*U-6;]
MS9G)B,0JJ45&T5*]WOHFMEHM^[/YOJ^M.0* "@#_ $#/V8O^#K?_ ()X_!?]
MFO\ 9Z^#OBKX,?MG7OBCX3_ [X3?#3Q)>>'OA[\#[S0+O7O G@+0/"VL7.AW
M>H_M$:1J%UH\^H:5<2Z9<7^DZ7>3V30276G64[/;1?EV,X)S7$8O%5X8C+U"
MOB:]:"E5Q"DHU*LIQ4DL))*235TI-)[-K4]*&,I1C&/+/2*6BCT5OYCW+_B,
M"_X)I?\ 1#_VYO\ PVGP#_\ HF:YO]0\W_Z"<M_\'8G_ .8ROKM+^6I]T?\
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M0JP48J2:DGJDE9)KHWW/Y4:^V.(* "@ H * "@ H * "@ H * "@ H * "@
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M+DXQDU&^]HR:6R>Q=.2A.$GM&2>GEVV/[T?^(P+_ ()I?]$/_;F_\-I\ _\
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MZBBXS@MES\DHJR;GK(]"GC(V2J)IKJE=/SMT]%?RML?I-\0/^#I;_@D;X/\
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MN5&O#%1DD^62MA*\H3B^DH3C&<;IKFBKIJZ'7FZ=*4H[QY?_ $J*_+0_*_\
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M6$Y*"EA8QYFHV2<HJ^[1I/%TI0G%1G>4916D;:JR^T?P+U^G'FA0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!]S?\$P/^4EG_!/'_L^
M;]DK_P!7YX KS<Y_Y$^:_P#8MQW_ *BU32C_ !:7_7R'_I2/]DJOP$]P* /_
MU_[^* /Y3?\ @\"_Y1I? _\ [/F^&G_J@_VF:^VX#_Y&^)_[%M;_ -2<&<>-
M_A1_Z^+_ -)D?YP-?K1Y84 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M4L4B-')')&Q5XY$8!D=&!5D8!E8$$ BOV<\<90 4 % !0 4 % !0 4 % !0
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M53S H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M#TVM:.'E9\[72I6M%KK&E9;SE%<&+K<S]E'X8OWO-KIZ+\_0_D8K[HX0H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H _T1/\ @SM_Y,>_:=_[.LF_]5%\-J_*N/?^1C@O^P+_ -SU
M3T\#_#G_ (__ &U']=E?"':?X]__  6#_P"4IG[?W_9UGQD_]3#4J_>LA_Y$
MN5_]@.&_]-Q/%Q'\:I_B/S?KUC$* "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M]?T1A/\ =<-_V#T?_3<3P9?%+_$_S/#*Z"0H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /
MZLO^#/W_ )26?'#_ +,9^)?_ *OS]F:OB>//^1/AO^QE1_\ 47&'9@OXLO\
MKV__ $J!_H_5^2GJ'^=W_P 'B7_)\'[,/_9J<'_JW?B17ZMP%_R+<9_V'/\
M]1Z)YN.^*'^%_F?R)U]T<(4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '=?"__ )*9\._^
MQZ\(_P#I_P!/K.K_  JG_7N?_I+*A\4?\4?S1_M[5_.9[Q_/S_P<]_\ *'7X
M_?\ 8]? 7_U<G@ZOJ>#?^1]AO^O6)_\ 3$SFQ?\  EZQ_-'^6K7[.>0% !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 ?ZE7_!L)_RAU^ '_8]?'K_ -7)XQK\8XR_Y'V)
M_P"O6&_],0/7PG\"/K+\V?T#5\L=)_BA?M/_ /)RW[0__9<_BU_ZGVOU_1&$
M_P!UPW_8/1_]-Q/!E\4O\3_,\,KH)"@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H _UN/\ @@I_RB$_89_[)7JW_JPO&=?A
MO$__ "/LR_Z_0_\ 3-,]K#_P:?\ A/(_^#E3_E"U^V)_U\?L[_\ K4OP3K?A
M#_DH,!Z8K_U"Q!.*_@3_ .W?_2XG^5'7[6>.% !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % 'W-_P3 _Y26?\ !/'_ +/F_9*_]7YX
M KS<Y_Y$^:_]BW'?^HM4TH_Q:7_7R'_I2/\ 9*K\!/<"@#__T/[^* /Y3?\
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M-W/)JW)"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /U9_P""'/\
MREJ_80_[+GI7_IEUNO%XB_Y$>9_]@L_S1MA_XU/_ !'^NO7X2>T?R)_\'B7_
M "8]^S#_ -G60?\ JHOB17W? /\ R,<9_P!@7_N>D<6-_AP_Q_\ MK/\[NOU
M4\P* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M ?Z(G_!G;_R8]^T[_P!G63?^JB^&U?E7'O\ R,<%_P!@7_N>J>G@?X<_\?\
M[:C^NROA#M/\>_\ X+!_\I3/V_O^SK/C)_ZF&I5^]9#_ ,B7*_\ L!PW_IN)
MXN(_C5/\1^;]>L8A0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % '^YA7\WGT!^&?_!R;_P H5OVS_P#N
MW7_UK#X%5])PC_R4.7_]S?\ Z@XDY\5_ G_V[_Z7$_RFZ_;#QPH * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@#_3Q_P"#5?\ Y1*>#_\ LN?QJ_\ 3UIM?CO&W_(\E_V"
MX?\ *1ZV#_@K_%(_H_KY$ZC_ !0OVG_^3EOVA_\ LN?Q:_\ 4^U^OZ(PG^ZX
M;_L'H_\ IN)X,OBE_B?YGAE=!(4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % ']67_!G[_R
MDL^.'_9C/Q+_ /5^?LS5\3QY_P B?#?]C*C_ .HN,.S!?Q9?]>W_ .E0/]'Z
MOR4]0_SN_P#@\2_Y/@_9A_[-3@_]6[\2*_5N O\ D6XS_L.?_J/1/-QWQ0_P
MO\S^1.ONCA"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H [KX7_ /)3/AW_ -CUX1_]/^GU
MG5_A5/\ KW/_ -)94/BC_BC^:/\ ;VK^<SWC^?G_ (.>_P#E#K\?O^QZ^ O_
M *N3P=7U/!O_ "/L-_UZQ/\ Z8F<V+_@2]8_FC_+5K]G/("@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * /\ 4J_X-A/^4.OP _['KX]?^KD\8U^,<9?\C[$_]>L-_P"F
M('KX3^!'UE^;/Z!J^6.D_P 4+]I__DY;]H?_ ++G\6O_ %/M?K^B,)_NN&_[
M!Z/_ *;B>#+XI?XG^9X9702% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0!]S?\ !,#_ )26?\$\?^SYOV2O_5^> *\W.?\ D3YK_P!BW'?^HM4T
MH_Q:7_7R'_I2/]DJOP$]P* /_]'^_B@#^4W_ (/ O^4:7P/_ .SYOAI_ZH/]
MIFOMN _^1OB?^Q;6_P#4G!G'C?X4?^OB_P#29'^<#7ZT>6% !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % 'ZL_P#!#G_E+5^PA_V7/2O_ $RZW7B\
M1?\ (CS/_L%G^:-L/_&I_P"(_P!=>OPD]H_D3_X/$O\ DQ[]F'_LZR#_ -5%
M\2*^[X!_Y&.,_P"P+_W/2.+&_P .'^/_ -M9_G=U^JGF!0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!_HB?\
M!G;_ ,F/?M._]G63?^JB^&U?E7'O_(QP7_8%_P"YZIZ>!_AS_P ?_MJ/Z[*^
M$.T_Q[_^"P?_ "E,_;^_[.L^,G_J8:E7[UD/_(ERO_L!PW_IN)XN(_C5/\1^
M;]>L8A0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % '^YA7\WGT!^&?\ P<F_\H5OVS_^[=?_ %K#X%5]
M)PC_ ,E#E_\ W-_^H.).?%?P)_\ ;O\ Z7$_RFZ_;#QPH * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@#_ $\?^#5?_E$IX/\ ^RY_&K_T]:;7X[QM_P CR7_8+A_RD>M@
M_P""O\4C^C^OD3J/\4+]I_\ Y.6_:'_[+G\6O_4^U^OZ(PG^ZX;_ +!Z/_IN
M)X,OBE_B?YGAE=!(4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % ']67_!G[_P I+/CA_P!F
M,_$O_P!7Y^S-7Q/'G_(GPW_8RH_^HN,.S!?Q9?\ 7M_^E0/]'ZOR4]0_SN_^
M#Q+_ )/@_9A_[-3@_P#5N_$BOU;@+_D6XS_L.?\ ZCT3S<=\4/\ "_S/Y$Z^
MZ.$* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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ME=!(4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 ?JS_ ,$.?^4M7["'_9<]*_\ 3+K=>+Q%
M_P B/,_^P6?YHVP_\:G_ (C_ %UZ_"3VC^1/_@\2_P"3'OV8?^SK(/\ U47Q
M(K[O@'_D8XS_ + O_<](XL;_  X?X_\ VUG^=W7ZJ>8% !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '^B)_P &
M=O\ R8]^T[_V=9-_ZJ+X;5^5<>_\C'!?]@7_ +GJGIX'^'/_ !_^VH_KLKX0
M[3_'O_X+!_\ *4S]O[_LZSXR?^IAJ5?O60_\B7*_^P'#?^FXGBXC^-4_Q'YO
MUZQB% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 ?[F%?S>?0'X9_P#!R;_RA6_;/_[MU_\ 6L/@57TG
M"/\ R4.7_P#<W_Z@XDY\5_ G_P!N_P#I<3_*;K]L/'"@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MX0H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * .Z^%__ "4SX=_]CUX1_P#3_I]9U?X53_KW
M/_TEE0^*/^*/YH_V]J_G,]X_GY_X.>_^4.OQ^_['KX"_^KD\'5]3P;_R/L-_
MUZQ/_IB9S8O^!+UC^:/\M6OV<\@* "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H _U*O\
M@V$_Y0Z_ #_L>OCU_P"KD\8U^,<9?\C[$_\ 7K#?^F('KX3^!'UE^;/Z!J^6
M.D_Q0OVG_P#DY;]H?_LN?Q:_]3[7Z_HC"?[KAO\ L'H_^FXG@R^*7^)_F>&5
MT$A0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % 'W-_P3 _Y26?\$\?^SYOV2O_ %?G@"O-SG_D3YK_ -BW'?\ J+5-*/\
M%I?]?(?^E(_V2J_ 3W H __3_OXH _E-_P"#P+_E&E\#_P#L^;X:?^J#_:9K
M[;@/_D;XG_L6UO\ U)P9QXW^%'_KXO\ TF1_G U^M'EA0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0!^K/\ P0Y_Y2U?L(?]ESTK_P!,NMUXO$7_
M "(\S_[!9_FC;#_QJ?\ B/\ 77K\)/:/Y$_^#Q+_ ),>_9A_[.L@_P#51?$B
MON^ ?^1CC/\ L"_]STCBQO\ #A_C_P#;6?YW=?JIY@4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0!_N85_-Y] ?AG_ ,')O_*%;]L__NW7_P!:P^!5?2<(
M_P#)0Y?_ -S?_J#B3GQ7\"?_ &[_ .EQ/\INOVP\<* "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H _P!/'_@U7_Y1*>#_ /LN?QJ_]/6FU^.\;?\ (\E_V"X?\I'K8/\
M@K_%(_H_KY$ZC_%"_:?_ .3EOVA_^RY_%K_U/M?K^B,)_NN&_P"P>C_Z;B>#
M+XI?XG^9X9702% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M-_\ !$/_ )<'U*M_<^]_Y!_Q"5?\%3/^@_\ LI_^';\8?_.JH_UXR7^7&_\
M@B'_ ,N#ZE6_N?>_\@_XA*O^"IG_ $'_ -E/_P .WXP_^=51_KQDO\N-_P#!
M$/\ Y<'U*M_<^]_Y!_Q"5?\ !4S_ *#_ .RG_P"';\8?_.JH_P!>,E_EQO\
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M-_\ !$/_ )<'U*M_<^]_Y!_Q"5?\%3/^@_\ LI_^';\8?_.JH_UXR7^7&_\
M@B'_ ,N#ZE6_N?>_\@_XA*O^"IG_ $'_ -E/_P .WXP_^=51_KQDO\N-_P#!
M$/\ Y<'U*M_<^]_Y!_Q"5?\ !4S_ *#_ .RG_P"';\8?_.JH_P!>,E_EQO\
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M-_\ !$/_ )<'U*M_<^]_Y!_Q"5?\%3/^@_\ LI_^';\8?_.JH_UXR7^7&_\
M@B'_ ,N#ZE6_N?>_\@_XA*O^"IG_ $'_ -E/_P .WXP_^=51_KQDO\N-_P#!
M$/\ Y<'U*M_<^]_Y!_Q"5?\ !4S_ *#_ .RG_P"';\8?_.JH_P!>,E_EQO\
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M1#_Y<<7U*M_<^]_Y!_Q"5?\ !4S_ *#_ .RG_P"';\8?_.JH_P!>,E_EQO\
MX(A_\N#ZE6_N?>_\@_XA*O\ @J9_T'_V4_\ P[?C#_YU5'^O&2_RXW_P1#_Y
M<'U*M_<^]_Y!_P 0E7_!4S_H/_LI_P#AV_&'_P ZJC_7C)?Y<;_X(A_\N#ZE
M6_N?>_\ (/\ B$J_X*F?]!_]E/\ \.WXP_\ G54?Z\9+_+C?_!$/_EP?4JW]
MS[W_ )!_Q"5?\%3/^@_^RG_X=OQA_P#.JH_UXR7^7&_^"(?_ "X/J5;^Y][_
M ,@_XA*O^"IG_0?_ &4__#M^,/\ YU5'^O&2_P N-_\ !$/_ )<'U*M_<^]_
MY!_Q"5?\%3/^@_\ LI_^';\8?_.JH_UXR7^7&_\ @B'_ ,N#ZE6_N?>_\@_X
MA*O^"IG_ $'_ -E/_P .WXP_^=51_KQDO\N-_P#!$/\ Y<'U*M_<^]_Y!_Q"
M5?\ !4S_ *#_ .RG_P"';\8?_.JH_P!>,E_EQO\ X(A_\N#ZE6_N?>_\@_XA
M*O\ @J9_T'_V4_\ P[?C#_YU5'^O&2_RXW_P1#_Y<'U*M_<^]_Y!_P 0E7_!
M4S_H/_LI_P#AV_&'_P ZJC_7C)?Y<;_X(A_\N#ZE6_N?>_\ (/\ B$J_X*F?
M]!_]E/\ \.WXP_\ G54?Z\9+_+C?_!$/_EP?4JW]S[W_ )!_Q"5?\%3/^@_^
MRG_X=OQA_P#.JH_UXR7^7&_^"(?_ "X/J5;^Y][_ ,@_XA*O^"IG_0?_ &4_
M_#M^,/\ YU5'^O&2_P N-_\ !$/_ )<'U*M_<^]_Y!_Q"5?\%3/^@_\ LI_^
M';\8?_.JH_UXR7^7&_\ @B'_ ,N#ZE6_N?>_\@_XA*O^"IG_ $'_ -E/_P .
MWXP_^=51_KQDO\N-_P#!$/\ Y<'U*M_<^]_Y!_Q"5?\ !4S_ *#_ .RG_P"'
M;\8?_.JH_P!>,E_EQO\ X(A_\N#ZE6_N?>_\@_XA*O\ @J9_T'_V4_\ P[?C
M#_YU5'^O&2_RXW_P1#_Y<'U*M_<^]_Y!_P 0E7_!4S_H/_LI_P#AV_&'_P Z
MJC_7C)?Y<;_X(A_\N#ZE6_N?>_\ (/\ B$J_X*F?]!_]E/\ \.WXP_\ G54?
MZ\9+_+C?_!$/_EP?4JW]S[W_ )!_Q"5?\%3/^@_^RG_X=OQA_P#.JH_UXR7^
M7&_^"(?_ "X/J5;^Y][_ ,@_XA*O^"IG_0?_ &4__#M^,/\ YU5'^O&2_P N
M-_\ !$/_ )<'U*M_<^]_Y!_Q"5?\%3/^@_\ LI_^';\8?_.JH_UXR7^7&_\
M@B'_ ,N#ZE6_N?>_\@_XA*O^"IG_ $'_ -E/_P .WXP_^=51_KQDO\N-_P#!
M$/\ Y<'U*M_<^]_Y!_Q"5?\ !4S_ *#_ .RG_P"';\8?_.JH_P!>,E_EQO\
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M-_\ !$/_ )<'U*M_<^]_Y!_Q"5?\%3/^@_\ LI_^';\8?_.JH_UXR7^7&_\
M@B'_ ,N#ZE6_N?>_\@_XA*O^"IG_ $'_ -E/_P .WXP_^=51_KQDO\N-_P#!
M$/\ Y<'U*M_<^]_Y!_Q"5?\ !4S_ *#_ .RG_P"';\8?_.JH_P!>,E_EQO\
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M-_\ !$/_ )<'U*M_<^]_Y!_Q"5?\%3/^@_\ LI_^';\8?_.JH_UXR7^7&_\
M@B'_ ,N#ZE6_N?>_\@_XA*O^"IG_ $'_ -E/_P .WXP_^=51_KQDO\N-_P#!
M$/\ Y<'U*M_<^]_Y!_Q"5?\ !4S_ *#_ .RG_P"';\8?_.JH_P!>,E_EQO\
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M-_\ !$/_ )<'U*M_<^]_Y!_Q"5?\%3/^@_\ LI_^';\8?_.JH_UXR7^7&_\
M@B'_ ,N#ZE6_N?>_\@_XA*O^"IG_ $'_ -E/_P .WXP_^=51_KQDO\N-_P#!
M$/\ Y<'U*M_<^]_Y!_Q"5?\ !4S_ *#_ .RG_P"';\8?_.JH_P!>,E_EQO\
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M-_\ !$/_ )<'U*M_<^]_Y!_Q"5?\%3/^@_\ LI_^';\8?_.JH_UXR7^7&_\
M@B'_ ,N#ZE6_N?>_\@_XA*O^"IG_ $'_ -E/_P .WXP_^=51_KQDO\N-_P#!
M$/\ Y<'U*M_<^]_Y!_Q"5?\ !4S_ *#_ .RG_P"';\8?_.JH_P!>,E_EQO\
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M-_\ !$/_ )<'U*M_<^]_Y!_Q"5?\%3/^@_\ LI_^';\8?_.JH_UXR7^7&_\
M@B'_ ,N#ZE6_N?>_\@_XA*O^"IG_ $'_ -E/_P .WXP_^=51_KQDO\N-_P#!
M$/\ Y<'U*M_<^]_Y!_Q"5?\ !4S_ *#_ .RG_P"';\8?_.JH_P!>,E_EQO\
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M-_\ !$/_ )<'U*M_<^]_Y!_Q"5?\%3/^@_\ LI_^';\8?_.JH_UXR7^7&_\
M@B'_ ,N#ZE6_N?>_\@_XA*O^"IG_ $'_ -E/_P .WXP_^=51_KQDO\N-_P#!
M$/\ Y<'U*M_<^]_Y!_Q"5?\ !4S_ *#_ .RG_P"';\8?_.JH_P!>,E_EQO\
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M &4__#M^,/\ YU5'^O&2_P N-_\ !$/_ )<'U*M_<^]_Y!_Q"5?\%3/^@_\
MLI_^';\8?_.JH_UXR7^7&_\ @B'_ ,N#ZE6_N?>_\@_XA*O^"IG_ $'_ -E/
M_P .WXP_^=51_KQDO\N-_P#!$/\ Y<'U*M_<^]_Y!_Q"5?\ !4S_ *#_ .RG
M_P"';\8?_.JH_P!>,E_EQO\ X(A_\N#ZE6_N?>_\@_XA*O\ @J9_T'_V4_\
MP[?C#_YU5'^O&2_RXW_P1#_Y<'U*M_<^]_Y!_P 0E7_!4S_H/_LI_P#AV_&'
M_P ZJC_7C)?Y<;_X(A_\N#ZE6_N?>_\ (/\ B$J_X*F?]!_]E/\ \.WXP_\
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M &4__#M^,/\ YU5'^O&2_P N-_\ !$/_ )<'U*M_<^]_Y!_Q"5?\%3/^@_\
MLI_^';\8?_.JH_UXR7^7&_\ @B'_ ,N#ZE6_N?>_\@_XA*O^"IG_ $'_ -E/
M_P .WXP_^=51_KQDO\N-_P#!$/\ Y<'U*M_<^]_Y!_Q"5?\ !4S_ *#_ .RG
M_P"';\8?_.JH_P!>,E_EQO\ X(A_\N#ZE6_N?>_\@_XA*O\ @J9_T'_V4_\
MP[?C#_YU5'^O&2_RXW_P1#_Y<'U*M_<^]_Y!_P 0E7_!4S_H/_LI_P#AV_&'
M_P ZJC_7C)?Y<;_X(A_\N#ZE6_N?>_\ (/\ B$J_X*F?]!_]E/\ \.WXP_\
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M &4__#M^,/\ YU5'^O&2_P N-_\ !$/_ )<'U*M_<^]_Y!_Q"5?\%3/^@_\
MLI_^';\8?_.JH_UXR7^7&_\ @B'_ ,N#ZE6_N?>_\@_XA*O^"IG_ $'_ -E/
M_P .WXP_^=51_KQDO\N-_P#!$/\ Y<'U*M_<^]_Y!_Q"5?\ !4S_ *#_ .RG
M_P"';\8?_.JH_P!>,E_EQO\ X(A_\N#ZE6_N?>_\@_XA*O\ @J9_T'_V4_\
MP[?C#_YU5'^O&2_RXW_P1#_Y<'U*M_<^]_Y!_P 0E7_!4S_H/_LI_P#AV_&'
M_P ZJC_7C)?Y<;_X(A_\N#ZE6_N?>_\ (/\ B$J_X*F?]!_]E/\ \.WXP_\
MG54?Z\9+_+C?_!$/_EP?4JW]S[W_ )!_Q"5?\%3/^@_^RG_X=OQA_P#.JH_U
MXR7^7&_^"(?_ "X/J5;^Y][_ ,@_XA*O^"IG_0?_ &4__#M^,/\ YU5'^O&2
M_P N-_\ !$/_ )<'U*M_<^]_Y!_Q"5?\%3/^@_\ LI_^';\8?_.JH_UXR7^7
M&_\ @B'_ ,N#ZE6_N?>_\@_XA*O^"IG_ $'_ -E/_P .WXP_^=51_KQDO\N-
M_P#!$/\ Y<'U*M_<^]_Y!_Q"5?\ !4S_ *#_ .RG_P"';\8?_.JH_P!>,E_E
MQO\ X(A_\N#ZE6_N?>_\@_XA*O\ @J9_T'_V4_\ P[?C#_YU5'^O&2_RXW_P
M1#_Y<'U*M_<^]_Y!_P 0E7_!4S_H/_LI_P#AV_&'_P ZJC_7C)?Y<;_X(A_\
MN#ZE6_N?>_\ (/\ B$J_X*F?]!_]E/\ \.WXP_\ G54?Z\9+_+C?_!$/_EP?
M4JW]S[W_ )!_Q"5?\%3/^@_^RG_X=OQA_P#.JH_UXR7^7&_^"(?_ "X/J5;^
MY][_ ,@_XA*O^"IG_0?_ &4__#M^,/\ YU5'^O&2_P N-_\ !$/_ )<'U*M_
M<^]_Y!_Q"5?\%3/^@_\ LI_^';\8?_.JH_UXR7^7&_\ @B'_ ,N#ZE6_N?>_
M\@_XA*O^"IG_ $'_ -E/_P .WXP_^=51_KQDO\N-_P#!$/\ Y<'U*M_<^]_Y
M!_Q"5?\ !4S_ *#_ .RG_P"';\8?_.JH_P!>,E_EQO\ X(A_\N#ZE6_N?>_\
M@_XA*O\ @J9_T'_V4_\ P[?C#_YU5'^O&2_RXW_P1#_Y<'U*M_<^]_Y!_P 0
ME7_!4S_H/_LI_P#AV_&'_P ZJC_7C)?Y<;_X(A_\N#ZE6_N?>_\ (/\ B$J_
MX*F?]!_]E/\ \.WXP_\ G54?Z\9+_+C?_!$/_EP?4JW]S[W_ )!_Q"5?\%3/
M^@_^RG_X=OQA_P#.JH_UXR7^7&_^"(?_ "X/J5;^Y][_ ,C_ $N*_(#U3\T?
M^"P?[)7Q3_;H_P""='[1'[+'P5N/"EK\3/BC_P *D_X1J?QOJUYH7A>/_A"?
MCG\,OB+K/]IZKI^E:W=VN[P_X1U5++RM+N?/U!K2V?R8IGN(O8R''4,MS;"8
MW$<_L:/M^?V<5*?[S#5J4;1;BG[TXWU5E?T,JT'4I2A&UWRVOHM))_DC^'7_
M (A*O^"IG_0?_93_ /#M^,/_ )U5?H_^O&2_RXW_ ,$0_P#EQY_U*M_<^]_Y
M!_Q"5?\ !4S_ *#_ .RG_P"';\8?_.JH_P!>,E_EQO\ X(A_\N#ZE6_N?>_\
M@_XA*O\ @J9_T'_V4_\ P[?C#_YU5'^O&2_RXW_P1#_Y<'U*M_<^]_Y!_P 0
ME7_!4S_H/_LI_P#AV_&'_P ZJC_7C)?Y<;_X(A_\N#ZE6_N?>_\ (/\ B$J_
MX*F?]!_]E/\ \.WXP_\ G54?Z\9+_+C?_!$/_EP?4JW]S[W_ )!_Q"5?\%3/
M^@_^RG_X=OQA_P#.JH_UXR7^7&_^"(?_ "X/J5;^Y][_ ,@_XA*O^"IG_0?_
M &4__#M^,/\ YU5'^O&2_P N-_\ !$/_ )<'U*M_<^]_Y!_Q"5?\%3/^@_\
MLI_^';\8?_.JH_UXR7^7&_\ @B'_ ,N#ZE6_N?>_\@_XA*O^"IG_ $'_ -E/
M_P .WXP_^=51_KQDO\N-_P#!$/\ Y<'U*M_<^]_Y!_Q"5?\ !4S_ *#_ .RG
M_P"';\8?_.JH_P!>,E_EQO\ X(A_\N#ZE6_N?>_\@_XA*O\ @J9_T'_V4_\
MP[?C#_YU5'^O&2_RXW_P1#_Y<'U*M_<^]_Y!_P 0E7_!4S_H/_LI_P#AV_&'
M_P ZJC_7C)?Y<;_X(A_\N#ZE6_N?>_\ (/\ B$J_X*F?]!_]E/\ \.WXP_\
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M &4__#M^,/\ YU5'^O&2_P N-_\ !$/_ )<'U*M_<^]_Y!_Q"5?\%3/^@_\
MLI_^';\8?_.JH_UXR7^7&_\ @B'_ ,N#ZE6_N?>_\@_XA*O^"IG_ $'_ -E/
M_P .WXP_^=51_KQDO\N-_P#!$/\ Y<'U*M_<^]_Y!_Q"5?\ !4S_ *#_ .RG
M_P"';\8?_.JH_P!>,E_EQO\ X(A_\N#ZE6_N?>_\@_XA*O\ @J9_T'_V4_\
MP[?C#_YU5'^O&2_RXW_P1#_Y<'U*M_<^]_Y!_P 0E7_!4S_H/_LI_P#AV_&'
M_P ZJC_7C)?Y<;_X(A_\N#ZE6_N?>_\ (/\ B$J_X*F?]!_]E/\ \.WXP_\
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M &4__#M^,/\ YU5'^O&2_P N-_\ !$/_ )<'U*M_<^]_Y!_Q"5?\%3/^@_\
MLI_^';\8?_.JH_UXR7^7&_\ @B'_ ,N#ZE6_N?>_\@_XA*O^"IG_ $'_ -E/
M_P .WXP_^=51_KQDO\N-_P#!$/\ Y<'U*M_<^]_Y!_Q"5?\ !4S_ *#_ .RG
M_P"';\8?_.JH_P!>,E_EQO\ X(A_\N#ZE6_N?>_\@_XA*O\ @J9_T'_V4_\
MP[?C#_YU5'^O&2_RXW_P1#_Y<'U*M_<^]_Y!_P 0E7_!4S_H/_LI_P#AV_&'
M_P ZJC_7C)?Y<;_X(A_\N#ZE6_N?>_\ (/\ B$J_X*F?]!_]E/\ \.WXP_\
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M"(?_ "X/J5;^Y][_ ,@_XA*O^"IG_0?_ &4__#M^,/\ YU5'^O&2_P N-_\
M!$/_ )<'U*M_<^]_Y!_Q"5?\%3/^@_\ LI_^';\8?_.JH_UXR7^7&_\ @B'_
M ,N#ZE6_N?>_\@_XA*O^"IG_ $'_ -E/_P .WXP_^=51_KQDO\N-_P#!$/\
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M"IG_ $'_ -E/_P .WXP_^=51_KQDO\N-_P#!$/\ Y<'U*M_<^]_Y!_Q"5?\
M!4S_ *#_ .RG_P"';\8?_.JH_P!>,E_EQO\ X(A_\N#ZE6_N?>_\@_XA*O\
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M"(?_ "X/J5;^Y][_ ,@_XA*O^"IG_0?_ &4__#M^,/\ YU5'^O&2_P N-_\
M!$/_ )<'U*M_<^]_Y!_Q"5?\%3/^@_\ LI_^';\8?_.JH_UXR7^7&_\ @B'_
M ,N#ZE6_N?>_\@_XA*O^"IG_ $'_ -E/_P .WXP_^=51_KQDO\N-_P#!$/\
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M"IG_ $'_ -E/_P .WXP_^=51_KQDO\N-_P#!$/\ Y<'U*M_<^]_Y!_Q"5?\
M!4S_ *#_ .RG_P"';\8?_.JH_P!>,E_EQO\ X(A_\N#ZE6_N?>_\@_XA*O\
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M"(?_ "X/J5;^Y][_ ,@_XA*O^"IG_0?_ &4__#M^,/\ YU5'^O&2_P N-_\
M!$/_ )<'U*M_<^]_Y!_Q"5?\%3/^@_\ LI_^';\8?_.JH_UXR7^7&_\ @B'_
M ,N#ZE6_N?>_\@_XA*O^"IG_ $'_ -E/_P .WXP_^=51_KQDO\N-_P#!$/\
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M"IG_ $'_ -E/_P .WXP_^=51_KQDO\N-_P#!$/\ Y<'U*M_<^]_Y!_Q"5?\
M!4S_ *#_ .RG_P"';\8?_.JH_P!>,E_EQO\ X(A_\N#ZE6_N?>_\C]Q?^" O
M_!#K]L__ ()H?MB_$GX[?M%ZI\%+WP3XL_9H\8_"32XOAOXYU[Q-KB^*==^*
M/P;\8V4EU8:IX*\-V\.E#2? >MK/=I?2S1W;6,*VCI/)-!\WQ/Q'E^;Y?1PV
M$6(52&,IUW[6E&$>2-'$4W9JI+7FJ1LK;7UT.C#8>=*;E+EMR..C\XOLNQ_7
MG7PAVG\F'_!P'_P12_;&_P""FW[2WP9^*W[..H?!NQ\*^ /@9!\/=;'Q*\;:
MUX8U*3Q /'WC+Q(W]GV>E>#_ !*D]BFG:U8YN9I[9C.TD20L(R]?<\+\0Y?D
M^#Q%#%JNYU,2ZL?8TXS7)[*G#5N<+.\7I;8X\30G5E%PY=%;5VZ^A^"W_$)5
M_P %3/\ H/\ [*?_ (=OQA_\ZJOIO]>,E_EQO_@B'_RXYOJ5;^Y][_R#_B$J
M_P""IG_0?_93_P##M^,/_G54?Z\9+_+C?_!$/_EP?4JW]S[W_D'_ !"5?\%3
M/^@_^RG_ .';\8?_ #JJ/]>,E_EQO_@B'_RX/J5;^Y][_P @_P"(2K_@J9_T
M'_V4_P#P[?C#_P"=51_KQDO\N-_\$0_^7!]2K?W/O?\ D'_$)5_P5,_Z#_[*
M?_AV_&'_ ,ZJC_7C)?Y<;_X(A_\ +@^I5O[GWO\ R#_B$J_X*F?]!_\ 93_\
M.WXP_P#G54?Z\9+_ "XW_P $0_\ EP?4JW]S[W_D'_$)5_P5,_Z#_P"RG_X=
MOQA_\ZJC_7C)?Y<;_P""(?\ RX/J5;^Y][_R#_B$J_X*F?\ 0?\ V4__  [?
MC#_YU5'^O&2_RXW_ ,$0_P#EP?4JW]S[W_D'_$)5_P %3/\ H/\ [*?_ (=O
MQA_\ZJC_ %XR7^7&_P#@B'_RX/J5;^Y][_R#_B$J_P""IG_0?_93_P##M^,/
M_G54?Z\9+_+C?_!$/_EP?4JW]S[W_D'_ !"5?\%3/^@_^RG_ .';\8?_ #JJ
M/]>,E_EQO_@B'_RX/J5;^Y][_P @_P"(2K_@J9_T'_V4_P#P[?C#_P"=51_K
MQDO\N-_\$0_^7!]2K?W/O?\ D'_$)5_P5,_Z#_[*?_AV_&'_ ,ZJC_7C)?Y<
M;_X(A_\ +@^I5O[GWO\ R#_B$J_X*F?]!_\ 93_\.WXP_P#G54?Z\9+_ "XW
M_P $0_\ EP?4JW]S[W_D'_$)5_P5,_Z#_P"RG_X=OQA_\ZJC_7C)?Y<;_P""
M(?\ RX/J5;^Y][_R#_B$J_X*F?\ 0?\ V4__  [?C#_YU5'^O&2_RXW_ ,$0
M_P#EP?4JW]S[W_D'_$)5_P %3/\ H/\ [*?_ (=OQA_\ZJC_ %XR7^7&_P#@
MB'_RX/J5;^Y][_R#_B$J_P""IG_0?_93_P##M^,/_G54?Z\9+_+C?_!$/_EP
M?4JW]S[W_D'_ !"5?\%3/^@_^RG_ .';\8?_ #JJ/]>,E_EQO_@B'_RX/J5;
M^Y][_P @_P"(2K_@J9_T'_V4_P#P[?C#_P"=51_KQDO\N-_\$0_^7!]2K?W/
MO?\ D'_$)5_P5,_Z#_[*?_AV_&'_ ,ZJC_7C)?Y<;_X(A_\ +@^I5O[GWO\
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MO?\ D'_$)5_P5,_Z#_[*?_AV_&'_ ,ZJC_7C)?Y<;_X(A_\ +@^I5O[GWO\
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MTW4I.$;7=M]%HT?Q,_\ $)5_P5,_Z#_[*?\ X=OQA_\ .JK]$_UXR7^7&_\
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M:,DE:_6</QKDU.A0IRCC%*%&G"5J$-XPC%_\ONZ/+E@ZKDVN35OJ^_H>8?\
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M-_\ !$/_ )<'U*M_<^]_Y!_Q"5?\%3/^@_\ LI_^';\8?_.JH_UXR7^7&_\
M@B'_ ,N#ZE6_N?>_\@_XA*O^"IG_ $'_ -E/_P .WXP_^=51_KQDO\N-_P#!
M$/\ Y<'U*M_<^]_Y!_Q"5?\ !4S_ *#_ .RG_P"';\8?_.JH_P!>,E_EQO\
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M-_\ !$/_ )<'U*M_<^]_Y!_Q"5?\%3/^@_\ LI_^';\8?_.JH_UXR7^7&_\
M@B'_ ,N#ZE6_N?>_\@_XA*O^"IG_ $'_ -E/_P .WXP_^=51_KQDO\N-_P#!
M$/\ Y<'U*M_<^]_Y!_Q"5?\ !4S_ *#_ .RG_P"';\8?_.JH_P!>,E_EQO\
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M-_\ !$/_ )<'U*M_<^]_Y!_Q"5?\%3/^@_\ LI_^';\8?_.JH_UXR7^7&_\
M@B'_ ,N#ZE6_N?>_\@_XA*O^"IG_ $'_ -E/_P .WXP_^=51_KQDO\N-_P#!
M$/\ Y<'U*M_<^]_Y!_Q"5?\ !4S_ *#_ .RG_P"';\8?_.JH_P!>,E_EQO\
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@#__UO[^* "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H __]?^_B@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@#.UC5])\/:3JFOZ_JFG:'H6AZ=>ZOK6M:Q>VVF:3H^DZ9;27N
MHZIJFHWLD%GI^G:?9P37=[>W<T-M:6T,D\\D<4;,-*-&MB:U+#X>E4KXBO4I
MT:%"C3E5K5JU62ITJ5*E!2G4J5)RC"G3A%RG)J,4VTB9SA2A.I4G&G3IQE.<
MYR4(0A!7E.<I6C&,8IN4FTDE=V2/!_\ AK[]DS_HZ']G;_P]?PU_^::OH?\
M4SC#_HD^)?\ PQ9I_P#,IYW]M9-_T-LL_P#"_"__ "T/^&OOV3/^CH?V=O\
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M %,XP_Z)/B7_ ,,6:?\ S*']M9-_T-LL_P#"_"__ "T/^&OOV3/^CH?V=O\
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M %,XP_Z)/B7_ ,,6:?\ S*']M9-_T-LL_P#"_"__ "T/^&OOV3/^CH?V=O\
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M %,XP_Z)/B7_ ,,6:?\ S*']M9-_T-LL_P#"_"__ "T/^&OOV3/^CH?V=O\
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M %,XP_Z)/B7_ ,,6:?\ S*']M9-_T-LL_P#"_"__ "T/^&OOV3/^CH?V=O\
MP]?PU_\ FFH_U,XP_P"B3XE_\,6:?_,H?VUDW_0VRS_POPO_ ,M#_AK[]DS_
M *.A_9V_\/7\-?\ YIJ/]3.,/^B3XE_\,6:?_,H?VUDW_0VRS_POPO\ \M#_
M (:^_9,_Z.A_9V_\/7\-?_FFH_U,XP_Z)/B7_P ,6:?_ #*']M9-_P!#;+/_
M  OPO_RT/^&OOV3/^CH?V=O_  ]?PU_^::C_ %,XP_Z)/B7_ ,,6:?\ S*']
MM9-_T-LL_P#"_"__ "T/^&OOV3/^CH?V=O\ P]?PU_\ FFH_U,XP_P"B3XE_
M\,6:?_,H?VUDW_0VRS_POPO_ ,M#_AK[]DS_ *.A_9V_\/7\-?\ YIJ/]3.,
M/^B3XE_\,6:?_,H?VUDW_0VRS_POPO\ \M#_ (:^_9,_Z.A_9V_\/7\-?_FF
MH_U,XP_Z)/B7_P ,6:?_ #*']M9-_P!#;+/_  OPO_RT/^&OOV3/^CH?V=O_
M  ]?PU_^::C_ %,XP_Z)/B7_ ,,6:?\ S*']M9-_T-LL_P#"_"__ "T/^&OO
MV3/^CH?V=O\ P]?PU_\ FFH_U,XP_P"B3XE_\,6:?_,H?VUDW_0VRS_POPO_
M ,M#_AK[]DS_ *.A_9V_\/7\-?\ YIJ/]3.,/^B3XE_\,6:?_,H?VUDW_0VR
MS_POPO\ \M#_ (:^_9,_Z.A_9V_\/7\-?_FFH_U,XP_Z)/B7_P ,6:?_ #*'
M]M9-_P!#;+/_  OPO_RT/^&OOV3/^CH?V=O_  ]?PU_^::C_ %,XP_Z)/B7_
M ,,6:?\ S*']M9-_T-LL_P#"_"__ "T/^&OOV3/^CH?V=O\ P]?PU_\ FFH_
MU,XP_P"B3XE_\,6:?_,H?VUDW_0VRS_POPO_ ,M#_AK[]DS_ *.A_9V_\/7\
M-?\ YIJ/]3.,/^B3XE_\,6:?_,H?VUDW_0VRS_POPO\ \M#_ (:^_9,_Z.A_
M9V_\/7\-?_FFH_U,XP_Z)/B7_P ,6:?_ #*']M9-_P!#;+/_  OPO_RT/^&O
MOV3/^CH?V=O_  ]?PU_^::C_ %,XP_Z)/B7_ ,,6:?\ S*']M9-_T-LL_P#"
M_"__ "T/^&OOV3/^CH?V=O\ P]?PU_\ FFH_U,XP_P"B3XE_\,6:?_,H?VUD
MW_0VRS_POPO_ ,M#_AK[]DS_ *.A_9V_\/7\-?\ YIJ/]3.,/^B3XE_\,6:?
M_,H?VUDW_0VRS_POPO\ \M#_ (:^_9,_Z.A_9V_\/7\-?_FFH_U,XP_Z)/B7
M_P ,6:?_ #*']M9-_P!#;+/_  OPO_RT/^&OOV3/^CH?V=O_  ]?PU_^::C_
M %,XP_Z)/B7_ ,,6:?\ S*']M9-_T-LL_P#"_"__ "T/^&OOV3/^CH?V=O\
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M %,XP_Z)/B7_ ,,6:?\ S*']M9-_T-LL_P#"_"__ "T/^&OOV3/^CH?V=O\
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M %,XP_Z)/B7_ ,,6:?\ S*']M9-_T-LL_P#"_"__ "T/^&OOV3/^CH?V=O\
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M %,XP_Z)/B7_ ,,6:?\ S*']M9-_T-LL_P#"_"__ "T/^&OOV3/^CH?V=O\
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!_
M_]#^_B@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@#YV_:^_Y-,_:A_P"S=OC7
M_P"JU\2U]+P9_P EAPI_V4N1?^K3"GF9U_R)LV_[%F/_ /46J?P@5_H&?ST%
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0!_1)_P0._YNN_[H7_[V.OYK^D-_S2'_ '7_ /WB
M'Z9X=?\ ,X_[I_\ [NG]$E?S6?I@4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % '__1_OXH * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H ^=OVOO^33/VH?\ LW;XU_\ JM?$M?2\&?\ )8<*?]E+D7_J
MTPIYF=?\B;-O^Q9C_P#U%JG\(%?Z!G\]!0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?T2?\
M$#O^;KO^Z%_^]CK^:_I#?\TA_P!U_P#]XA^F>'7_ #./^Z?_ .[I_1)7\UGZ
M8% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0!__TO[^* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M5TUI9Q<91O&46_3*\LZ@H * "@!N]/[R_F* #>G]Y?S% "@@]"#]"* %H *
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M@@]"#]* %H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /G;]K[_D
MTS]J'_LW;XU_^JU\2U]+P9_R6'"G_92Y%_ZM,*>9G7_(FS;_ +%F/_\ 46J?
MP@5_H&?ST% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0!_1)_P0._YNN_[H7_ .]CK^:_I#?\
MTA_W7_\ WB'Z9X=?\SC_ +I__NZ?T25_-9^F!0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?_3_OXH * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H _P ;S_@I[<W*_P#!2O\ X*&JMQ.JK^W+^UH%42R  #X^>/P  &P
M!P . *_H3)4O[&RG1?\ (LP'3_J%I'AU?XM3_KY/_P!*9\-?:[K_ )^;C_O]
M)_\ %5Z=EV7W(S#[7=?\_-Q_W^D_^*HLNR^Y 'VNZ_Y^;C_O])_\519=E]R
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M>8_VIL^6[)G#?L]XSM(SCMZ5^F>':5LVT6^"_P#=D\_'?\NO^W__ &P_AO\
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M.OC<194J$.9I)<TY;0IP6W/4FXPC>RNU=J*;3A!SDH1W>GDO-^26OY'^O?\
ML4_L@?";]A+]FKX9_LR_!JP:+PM\/M&2+4M?O(((_$'CWQ??;;GQ7\0/%<\
MQ=>(O%6KM-?W(#-:Z7:?8= TB.TT+1]*L+7\"S''U\SQE;&8A^_5EI!?!2IK
M2%*"Z0A&R75N\I7E)M^W"$:<5".R_'S?F_\ AM#ZJKA+"@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@#YV_:^_Y-,_:A_[-V^-?_JM?$M?2\&?\EAP
MI_V4N1?^K3"GF9U_R)LV_P"Q9C__ %%JG\(%?Z!G\]!0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 ?T2?\$#O^;KO^Z%_P#O8Z_FOZ0W_-(?]U__ -XA^F>'7_,X_P"Z?_[N
MG]$E?S6?I@4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % '_U/[^* "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M?_@]_P#V=H=0$>@?L&_&C4M*R<WNK_%[P-HFH!<C!&F67ACQ!;$[<DK_ &L
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MV0V?V@_9P ?T!T % !0!_F^_MR?\&Z/_  57^-W[:_[87QH^'?P4\%:K\/\
MXN_M2_M _$_P+JEU\:OA7I5UJ7@[Q]\6?%OBOPS?W.EZAXHM[_39[S1-6L;B
M:POH(+RSDD:WN88YHW1?U_+.+LCPV6Y?AJN)J1JX? X2A5BL-7:C4I4*=.:3
M4+-*46KK1]-#RZF%K2J3DHJSG)KWH[-NW4^6O^(8+_@L1_T07P%_X?GX/_\
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M6:]A3C+MI.=2/6]-=$SDQDN6ERK>;2^2U?Y)?,_S*J_9CR@H _ME_P"#.?\
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M:_?*=.G1IPI4H1ITJ4(TZ=.*M&$()1C&*Z*,4DEV1XVKU>K>[[LH^'?#NO\
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MT/Q#8Z=JMA>:5X@T35M)N5FM?L\TUB]SI]Q>Z=-:7MP >_T % !0 4 % !0
M4 % !0 4 % !0!_F0?\ !1'_ (.._P#@KQ^S]_P4G_:V_9]^%O[2?A_0_A+\
M*/VJOB7\-?!/A>Z^!'P&UE]-\%^&O'U_HFDZ//KNK?#B\\1:B8=,MX[:34;[
M59]4GP9I;UK@^;0!_IOT % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M8WAN+:*1&0 'JE !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'SM^U]_P FF?M0_P#9
MNWQK_P#5:^):^EX,_P"2PX4_[*7(O_5IA3S,Z_Y$V;?]BS'_ /J+5/X0*_T#
M/YZ"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H _HD_X('?\ -UW_ '0O_P!['7\U_2&_YI#_
M +K_ /[Q#],\.O\ F<?]T_\ ]W3^B2OYK/TP* "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@#__5_OXH * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MK_;$EU!U55\4/\8_ 2ZY$0N"\=O%\&H_#6YC\Q$OAZ500 JJN5(!^;?[7/\
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M[\,OB_X4\/Q:/K4:O<^%7?Q%X5\516TMS;6#:AH7BZRU.^N9$NE\(Z=9M/\
M9 #^\*@ H * "@ H _@5_P"#RO\ Y+7^PW_V2WXQ_P#J6>"Z_4_#S_=LR_Z_
MX?\ ]-U#S<=\5+_#/\X'\7-?HIPG]U__  9B_P#(!_X*'_\ 87_9;_\ 2/\
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M .JU\2U]+P9_R6'"G_92Y%_ZM,*>9G7_ ")LV_[%F/\ _46J?P@5_H&?ST%
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0!_1)_P $#O\ FZ[_ +H7_P"]CK^:_I#?\TA_W7__
M 'B'Z9X=?\SC_NG_ /NZ?T25_-9^F!0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?_UO[^* "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M="E?P[\0?C)IL<Z.'\0Z]XACUWX<>&K]?(FT+2_#WC&6'[2OBBTGL0#^\N@
MH * "@#_ "LO^#Q7_E+S:_\ 9J7P5_\ 3_\ $F@#^\S_ (("?\H:_P#@GO\
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M0_R(O^"WWQ)O/BK_ ,%9_P!O#Q/?S+/-I7QYU_X;1NN,+9?!K3]*^$.G0_*
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MJ_7R)M"TOP]XQEA^TKXHM)[$ _O+H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * /G;]K[_DTS]J'_ +-V^-?_ *K7Q+7TO!G_ "6'"G_92Y%_ZM,*>9G7
M_(FS;_L68_\ ]1:I_"!7^@9_/04 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % ']$G_! [_FZ[
M_NA?_O8Z_FOZ0W_-(?\ =?\ _>(?IGAU_P SC_NG_P#NZ?T25_-9^F!0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?
M_]?^_B@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@#_+A_X/.O\ E+!\,_\ LR/X1?\ JW/V@* -_P#X-R_^")&C_P#!
M6#4->_:K_;FU7QWXL_96^ $GA[X(_"_X<KK^M:''\4]<\,:9!J=UX1'B+3[N
MSUOPY\*/ASI&K::=0T_P5<Z-?^(O%/BJ46WB+39]'\40ZN ?V4?'K_@VV_X(
M[?'/X::OX M?V0?!GP:UBXT&?2/#?Q,^"M[KG@CQWX1OS'BR\06T\.IW.@^*
M-2LI0LC1>/=#\56%^F^*_M9PP9 #_+D_:O\ @%\<O^"2/_!1/QQ\)K7Q->Z7
M\6_V2OC5H/BKX7?$FRLCI<FMV.BWVD_$#X/_ !,L=/:>\BM4\1^'9_#/B2?2
M/MFH0:?<7=WH-U=7;6=PS@'] 7_!"O\ X)&Z]_P76_:)_:$_X*(_\%$_$OC'
MQC\&K7XIW3^)K*RU"_\ #6H?M"_&;6(;?Q!K/A*+Q#I4MMJ/A/X8_#KPY>^'
M[/4M/\(SZ/?P6.M>%?"G@_5=#LM&U$V0!_9'\:O^#;S_ ((X?&7X;ZE\/H_V
M-O _PJOI?#]SHOA_XB?![4/$7@CQ_P"%+Q[=HK'Q%:ZI;ZO<Z;XFUG39MEU&
M/'^D^+M-OY(_+U?3]0MWDB8 _P MO]MG]FCXN_\ !)W_ (*(?$SX%Z;XWU&#
MXD?LM_%GPYXG^%WQ5T6"30=3U#3XHM!^)7P?^(^GVZ3W2Z3J]YX>U/PSKEWI
M]O>ZC!HVN?;=(6_OA8-/( ?[-/[(OQUMOVH/V5?V;?VD+2WMK*+X\? GX4?%
MU]/LV=[?2KOXA>!M#\4W^D(9"90=(OM3N-,=)298Y+5XY?WBM0!_D:?\'$/Q
M)U3XI?\ !9W]O36M3U"2_'AWXLV'PUTT,W[JPTOX6^!_"GP^M=/MHUQ'#' W
MAV5YE15\V]ENKJ7=<W$TC@'^KI_P30^#^C_ /_@GI^Q/\(-#MOLUKX(_9?\
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M\4FL>%_AQK^E>%[B4GF/^R?%/B+1-<MW7G[;IEJA^1V% '^NU0 4 % !0 4
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MO+SPWIU5&[M&K3<:D5=V4EJ>Y3FJD(S6S7W/9KY/3Y'TS7$6% !0 4 ?E?\
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M:;<^(;K4[S6CXBTR+4I]9FNKC5#<VU[;6S1WLM\SW9GMQ"MNR3MYD0B$1"[
MH /]V']H[X$^!_VG_@#\9?V=/B3:_:_ GQM^&GC+X8^)U2*.2XMM+\8Z%>Z)
M)J>G^9A8=6T=[N/5M'NE*2V6J65G=P21301R* ?XT7[-'Q%^)W_!(3_@JOX
M\6>-K:[TWQK^QC^U%?>#OBQING).LFL^%/#OB/4OAY\7M)TDD*]Q8^,OA[>^
M*++1;Q5E@O+'6;*_A6X@EC\P _VL]$UK2?$FC:1XBT#4;35]"U[3+#6M%U;3
MYDN;#5-)U2UBOM.U&RN(R8Y[2]LYX;FVFC)26&1'4E6% 'F?[0/QK\%_LV_
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M\9\Z)-6\1S?#KP;<0NJ0ZGH7B3Q';&1EAFAD /R1_P"#*3]BO^W_ (D?M/\
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 ?T2?\ ! [_ )NN_P"Z%_\ O8Z_FOZ0
MW_-(?]U__P!XA^F>'7_,X_[I_P#[NG]$E?S6?I@4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '_]#^_B@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#_+A_X/
M.O\ E+!\,_\ LR/X1?\ JW/V@* /[5O^#;7P'8?#W_@B?^PKIEB(B^O>"?'_
M (\U"X1-KW-_X_\ C+\1O%TAG; ,DEG!J]OIB.V=MO801*3'&E '[D4 ?Y5O
M_!XEX9L-!_X*^1ZI9KBX\:?LK_!3Q+JIV@;K^UUGXB>#HVR/O8TOPGIJY/(V
M[>BB@#^Y+_@V_P#AWI?PT_X(J_L*:5IJ0[_$?@'QC\1-3N8HPDEYJ?Q&^*WC
MSQG,]T^U6GFLK?6;72(Y'W%;33;6W1O)@B  /W H _RI?^#PO0K+2/\ @L!/
M?VD,<4_BC]E_X):YJ3HN&N+VWOO'7AF.:4_Q2+IOAW3[<'M%!$O\- ']_'_!
M"JYFN_\ @C[_ ,$[I9W,CI^S'\/[96/:"RMI[.V3Z16\$48]D% '^6A_P7;\
M*3^#/^"PO_!0_2+B.6*2\_:7\<>*U68.KF#QXUIXXM9 'Y\J6V\10RP$?(T#
MQM'^[*T ?Z\G["7Q&TGXO?L2?L@_%+0[R._TOX@?LR? OQ;:W,>!N_MSX9>&
M;^:*5!S!<VMQ-+:W=LX66UNH9K:5$EB=0 ?5M !0 4 % '^5E_P>*_\ *7FU
M_P"S4O@K_P"G_P")- '=_L0?\&E/QP_;=_8\^!_[6OA?]L3X4^![;XY>!4\;
MZ+X$U[X:>+M1GT2*?4=1L+;3M3\1:=KR1RR,M@)I[BTT5UA,QBCAN!$)9 #\
MG/\ @J-_P1!_;@_X).WVAZM\?/#OAKQI\&_%VJMH7A#X]_"C4=0U_P"'.H:^
M+1K]/"^O)JNEZ)XE\%>*)+&.>XL],\3Z'86>NI8ZJWA35?$,.BZM-9 ']G'_
M  :>?\%*OV//C-\.M8_8TT?]G#X$_LK_ +6?@?PS%K5QJ/PJ\,P:!;_M3>!M
M#V077BZ[UW6;O6/&NM?$GPBLEO+XT\/^(/$^O+<:?<#Q;X/%GH-OKWA_P: ?
MV>T >6_'+_DBGQ@_[);\0/\ U$]6H _PJ_@GH?QH\2_%?P)H'[.VF?$K6?C=
MJNO6]G\-M+^#UOXENOB;>>)9(Y?LT/@V#P<K>)GU?R1.R?V./M20+,^5B60@
M _5O5OV,O^#A7QM:'P]XD_9__P""LOB+2[T[)=,\4>%?VI;S1IN"/]*CUR,Z
M8%VDC=<[4 )&>: /:OV9_P#@V"_X+&?M+^)-/7Q!^SN/V>/"6HWVW6?B-^T;
MXOT/P?%IBLY>YN9O!&G7OB/XLZG<.@<P&T\"R6EQ<&..YU*SCD:XC /]!_\
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MI\T(4<+3?2U1RJUEZKV5'T3\SKQSTIQ\W)_)67YO[C^+/]ECX):M^TI^TM\
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MD?/E.F 4 % '??"KP!<?%;XG?#OX7V?B;P?X+N_B-XX\*^!;3Q?\0=8D\.^
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M9;+R)?,V@2!PX&&%?T-DTN?*,KGUEEV";_Q?5J7-^-SPJBM4J+_IY/[N9V_
M^(Z](@_V"_\ @CMXD@\5?\$L?V ]4MY()8[7]EGX1^&RUN"(Q-X-\+67A"YC
M8&24^?#<:'+#<G< ;F.4K'"N(D_G_B&+AGF:IZ7QV(G_ .#*CJ+Y6EIY6/:P
M_P# I?\ 7N"^Z*7Z'Z2UXYL% !0 4 % '\,?_!YW_K?^"=O_ %S_ &I__0OV
M>J_3?#O;-O7!?EB3S\=_RZ_[?_\ ;#^&NOTL\\* /KCXP?L._M(_ ?\ 9O\
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MVEYY4D,.L:%?8BU;PQXBLDED_LSQ+X;O])\0:7(QFTW4K67#@ _A2_X*>_\
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MK7Q+7TO!G_)8<*?]E+D7_JTPIYF=?\B;-O\ L68__P!1:I_"!7^@9_/04 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % ']$G_! [_FZ[_NA?\ [V.OYK^D-_S2'_=?_P#>(?IG
MAU_S./\ NG_^[I_1)7\UGZ8% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0!_]'^_B@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M-_JFJZC=O'!;6UO$AY9M\CE(84DFDCC8 _QVO^"XO_!2[5/^"M'[?_B3XK^
M[+Q(WP8\)6FE_!C]F7P==V=Q_;EQX)TO4+A_^$@N-!ME>2/Q3\3O%VIZIXFD
MT];>35K+3M0\.>$KJ:^D\.6\S@'^G-_P0V_8$U'_ ()O?\$V?@/^SWXNM[>#
MXM:I:ZG\7/C@+98PMO\ %3XERPZQJWA^22%I(KN;P'H,7AOX<R:C%))#J?\
MPAXU&W*P7442 '\1/_!Y-^QAK_PE_;U\ _MDZ3I&?AU^UA\-]$T'7-:MX6VV
MOQE^"^E6'A#5--U1HU,5NVI_#*/X<W>A23R1S:J=)\2I;Q.FAW$M '[B?\&A
M?_!3[PI\<?V49?\ @GA\1_$T%K\=?V8?[=UCX4Z?J4L<=SX]_9ZUK6!JR#2)
MG??J.K_"[Q7KNI:#JVGA4>Q\&:EX&EL1>06FLMI@!_9+0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 ?.W[7W_)IG[4/_ &;M\:__ %6OB6OI>#/^2PX4
M_P"RER+_ -6F%/,SK_D39M_V+,?_ .HM4_A K_0,_GH* "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@#^B3_@@=_S==_W0O_WL=?S7](;_ )I#_NO_ /O$/TSPZ_YG'_=/_P#=
MT_HDK^:S],"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H __]+^_B@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@#_+A_X/.O\ E+!\,_\ LR/X1?\ JW/V@* /
M[E/^#?K_ )0S_P#!/K_LA=O_ .I7XGH _8J@#_+0_P"#RW_E+3X+_P"S-/@]
M_P"K&^-E ']VO_! W_E#?_P3U_[-[T'_ -.^M4 ?KU0!_E@?\'D'_*7+0?\
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M_$K]J'4]&\.Z%H5Y\T:7L?PI^&?B#Q1?^*K=A^]MEN_BAX.DC(C-W93 R6H
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M\7BJ&!PU7%XJ?LJ%"*E4G9OE3DH1M&*<FW*48Q23;;22",7.2A%7<M$OE?\
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MIO@+QQH/@W3$FP(Y?"%_;6ZK:VT*K^)\:8/ZKGE:HDE#&TZ>*C9?::]E5O\
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M^WY_V)?[//\ Z?/B]7YQXA_P,K_Z^XK_ -(H'?@=ZGI']3^\RORX]$_S/_\
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M#8OEC_R[D_W%65OY)MTFW>_M*4=%$[\%4LW2>S]Z/K]I?=JO21_>G7Y<>B%
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MNN?'+QM>:GHWPF@U.[EW3/K*:TWBWXJ65ZTHD.K?#B-IC()F1P#_ %4Z "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * /G;]K[_DTS]J'_ +-V^-?_ *K7Q+7TO!G_
M "6'"G_92Y%_ZM,*>9G7_(FS;_L68_\ ]1:I_"!7^@9_/04 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % ']$G_! [_FZ[_NA?_O8Z_FOZ0W_-(?\ =?\ _>(?IGAU_P SC_NG
M_P#NZ?T25_-9^F!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 ?_]/^_B@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@#\%?^"F_P#P;N?L4?\ !5K]H/0?VDOV
MAOB=^U%X+\=>'OA9X=^$5II?P7\:_"CP]X4G\-^&?$?C'Q/I]]=V'CGX*?$;
M5FUR2^\;:I!=W,&N6^GR65MIR1:9!/%<W-V ?JO^Q_\ LM_#[]BC]F?X._LJ
M_"K5O&&N_#SX(^$HO!OA36/'^H:-JOC+4--BOKW4?M/B'4?#V@>%M$NM0>XO
MY]\FF^'M)M?+$:I:)M)8 ^DZ /P/_P""F7_!NK^Q-_P55_:&TK]I;]H3XG_M
M2>#/'>D?#+PW\*;?2O@QXV^$_A[PG+X>\+ZYXJU[3[ZXL/''P2^(NKG6I;KQ
M=J,-W<0Z[#826MO8+#IMO/'<SW0!^LG[(W[,7@#]C#]FKX-_LL?"W5?%VN?#
MWX'^#++P/X4U?QYJ&CZKXQU'2K&:XN([KQ#J&@:#X8T6ZU*26ZE,TNF>'](M
M,;1%91 <@'T90!^!/_!2W_@W._8C_P""J'[15E^TU^T%\4/VIO!OCVQ^''AG
MX81Z3\&O&_PF\/\ A*30?"NJ>(]6TZ]EL/&_P1^(FL?VS+/XGOH;R>+7HK&2
MWM[)8=.MY4N)KD _7#]DW]FGP'^QQ^S;\&?V7/AAJGBS6_A_\#? VD^ /">K
M^.K_ $C5/&&HZ/HZR"WN_$6H:#H?AG1KO5)C(S7$NF>'](LR<"&Q@4!: /H:
M@#Y__:4_95_9R_;#^&>I_![]I[X->!/C7\.=4WN_AWQQHL.H_P!FWK1- NL^
M&M7C-OKOA'Q%;Q.ZV7B7PMJ>CZ_8;F-EJ5NQ)H _EN^/O_!EY_P3Q^(&M3:U
M\"?C?^T5^SS%<M*7\*3:AX9^+O@ZQ!Y@31T\5:;I7C>%8\D3?VQX\UYYE$81
M[=ED>4 ^8/#_ /P8\?!RVU*67Q3_ ,%"?B9K.CF3,-CX?_9_\+>&=2CAX_=R
MZKJ/Q.\66LLG7]ZFC0)T_<\<@'Z/?LN_\&B7_!*+X!:[#XI^)ME\9?VL-6M9
M89[+2/C5XWLM*\!6-Q!@I,OA#X5Z)X!?6%9]QGT_Q?K?B?1KA-D4NELJOY@!
M_3!\/?AWX!^$O@GPS\-?A;X+\+?#KX>>"])MM!\(>!_!&@Z9X7\)^&=%LU*V
MNEZ%H&C6UGI>EV,.6*6UG;0Q;F=RI=V8@'X:_P#!2G_@W(_8A_X*E_M&P_M.
M_M ?%#]JCP;X^A^'OACX:C2?@WXW^$OA_P (OHGA.]UV^TZ\?3_&_P $/B'K
M']KS2>(+N.]F37DL9(8+00:?;R)/)< 'ZV_LA_LO_#_]BS]FCX.?LK_"O5?%
M^N?#WX(>#[;P5X4U?Q[J&CZKXQU#2[6ZN[Q;GQ#J'A_0?"^BW6HR37DWF2:;
MX>TFUV[%CLX]O(!]'T 1RPQ3Q203Q1S031O#-#*BR12Q2*4DBDC<%'C="4=&
M!5E)4@@XH _DZ^(__!FS_P $J?B%\0?&_CRS^)'[9OPXM?&?BSQ!XI@\ ?#K
MXC_ _3O /@J/7M4NM47POX*T_P 1?LY>)]=T_P +:']I_L[0;'5O$6M7UGIE
MO;6UQJ=X\1F8 _I?\ ?!+3O W[/OA;]G>_\ '7Q%^(VB^&?A38?".;XA?$;6
M-%UCXI^*]%T_PPOA,>(/%WB'2/#N@Z-JWC*]TU%N-3UN+PU91ZAJ9DU"YL7F
MFF\P _G\_9"_X-2?^"=_[%G[2_P<_:H^%WQC_;.\0?$'X(>+[?QKX3T;X@?$
M3X(ZIX,O]6M;2[LXH?$.G^&_V=_">N7=@$O))##IWB+29S*D7^D^6'C< _IM
MH * "@ H * /R0_;Z_X(=?\ !-O_ (*0:A+XM_:&^ UGIWQ8D@,'_"[OA-J4
MOPT^*MPOE"")O$&LZ+"^C>.WM(DCCTX_$3P_XN&EQ1B'3EM87ECD /YWO'O_
M  9 _LY:C>WLGPO_ &[_ (V>#M.>>1M.M?'OPE\"_$B\M;8M^ZAO+_P]XB^%
M4-_,B862X@T[3DE;YEMHA\@ -?P/_P &0_[*FG^3_P +)_;=_:#\6;=OVC_A
M!_ 'PX^'OF?WO)_MYOB=Y&?X=_VC;WW8H _>O]A/_@@I_P $P_\ @GIJ_AWQ
MO\$OV?+/Q3\8_##+<:5\=/C3JL_Q.^)]AJ*P/:_VSH$^J16W@_P-K!MY9X&U
M'X=>#_"%PT-Q/"S&.5E(!^QU !0 4 % !0!_ K_P>5_\EK_8;_[);\8__4L\
M%U^I^'G^[9E_U_P__INH>;COBI?X9_G _BYK]%.$_NO_ .#,7_D _P#!0_\
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M/?EIWA5MY1HU*DVMGR+JD=.$ER5H]I)P\M=5^,4EZG^IM7XB>N?X;>H?\?\
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MRHU*M!3?\TH4IP@Y/>4N7FD]9-LWAB*T%RJ>G2Z3MY)M7MV6RV5D>&?MC_\
M!5;]OS]OC2])\-_M1?M&>*O'?@O1+C[98?#[1],\,?#SX?OJ"R++;ZKK'@SX
M=Z)X6T#Q/K.GLK#2-:\46.LZMHL5Q>6^D7EE;WMW%-U9=D>594W/!82%*I)6
M=63E5JVM;EC4JRG*$7]J,'%2TYD[(F=:I4TG*Z_ELDON25_GMTL?GK7K&1_3
MG_P;.?\ !+O7_P!KG]JS1?VN?B+H5S!^S?\ LG^+M+\1Z?>WEK,ME\1_CYHO
MV+7O _@[2I9(UM;RR\"3R:5\0?&S1R7'V18O!^@7MD]MXS-U9?%\99U# 8&6
M HR7US'4W!I/6CA97C4J.VJ=5<U*GM?]Y)/]V=>$H\\^=KW(-/;24NB7^'1O
MY+O;_2]K\;/5/X8_^#SO_6_\$[?^N?[4_P#Z%^SU7Z;X=[9MZX+\L2>?CO\
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % ']$G_  0._P";KO\ NA?_ +V.OYK^D-_S2'_=
M?_\ >(?IGAU_S./^Z?\ ^[I_1)7\UGZ8% !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!__4_OXH * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MN?M-?LV>*?A-\.;K]G;XC>#K?Q1K/B'P%JEI)XDUCQ3\.[[3-*%MX:\6:UJ
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M^/7_ !#^?\%A_P#HQ_Q__P"%G\(?_GB5]!_K7P__ -#*E_X*Q'_RDP^KU_\
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?T2?\$#O^;KO^Z%_^]CK^:_I#
M?\TA_P!U_P#]XA^F>'7_ #./^Z?_ .[I_1)7\UGZ8% !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!__U?[^* "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % 'SM^U]_R:9^U#_P!F[?&O_P!5KXEKZ7@S
M_DL.%/\ LI<B_P#5IA3S,Z_Y$V;?]BS'_P#J+5/X0*_T#/YZ"@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H _HD_X('?\W7?]T+_]['7\U_2&_P":0_[K_P#[Q#],\.O^9Q_W
M3_\ W=/Z)*_FL_3 H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * /__6_OXH * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M ^=OVOO^33/VH?\ LW;XU_\ JM?$M?2\&?\ )8<*?]E+D7_JTPIYF=?\B;-O
M^Q9C_P#U%JG\(%?Z!G\]!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?T2?\$#O^;KO^Z%_^
M]CK^:_I#?\TA_P!U_P#]XA^F>'7_ #./^Z?_ .[I_1)7\UGZ8% !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!__U_[^
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * /G;]K[_DTS]J'_ +-V^-?_ *K7
MQ+7TO!G_ "6'"G_92Y%_ZM,*>9G7_(FS;_L68_\ ]1:I_"!7^@9_/04 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % ']$G_! [_FZ[_NA?_O8Z_FOZ0W_-(?\ =?\ _>(?IGAU
M_P SC_NG_P#NZ?T25_-9^F!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 ?_]#^_B@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M=_Y=X#_YI#_AU!^W[_T03_S*7P6_^>-1_P 1?\._^BA_\Q.>?_.P/]3N(_\
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M?\._^BA_\Q.>?_.P/]3N(_\ H7?^7> _^:0_X=0?M^_]$$_\RE\%O_GC4?\
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M=_Y=X#_YI#_AU!^W[_T03_S*7P6_^>-1_P 1?\._^BA_\Q.>?_.P/]3N(_\
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M?\._^BA_\Q.>?_.P/]3N(_\ H7?^7> _^:0_X=0?M^_]$$_\RE\%O_GC4?\
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M=_Y=X#_YI#_AU!^W[_T03_S*7P6_^>-1_P 1?\._^BA_\Q.>?_.P/]3N(_\
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M?\._^BA_\Q.>?_.P/]3N(_\ H7?^7> _^:0_X=0?M^_]$$_\RE\%O_GC4?\
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M=_Y=X#_YI#_AU!^W[_T03_S*7P6_^>-1_P 1?\._^BA_\Q.>?_.P/]3N(_\
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M?\._^BA_\Q.>?_.P/]3N(_\ H7?^7> _^:0_X=0?M^_]$$_\RE\%O_GC4?\
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MFL;I/[,U:ZVZ=::OI-]9NZ6^IS65C?6>H73-J-O<6-M;WO[%X3<?Y=P?6S'
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M0F(_[&67?^G9'SO W_(]A_V"XC_TF)_7I7\9G[0% !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M(1X_Y_\ PWI[YZ1D?-6N7>!'%>*HPJX[&93ECDKO#SK5L5B*?E4^K498:_\
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MJM3IK[52;C"/VI)'K8G%8;!TG6Q5>EAZ4=YU9J"OV5_BD^D8WD^B/R^^(/\
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M#[+GS<^9]BN,;<>7SD 'YO?\/0O^J'?^9+__ !?T '_#T+_JAW_F2_\ \7]
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M;_A(O[2_X2+_ (2#_J7]"^Q_8_["_P"GK[1]J_Y8>1^^ /K*@#\__CW^W/\
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M_96F7.H^7_9__"(Z3YOG_9_)W?;8_*W^9MDV[" ?H!0!\F_M0_M0_P##-O\
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MPG_]H?V?_:-REO\ :OL/_"$V/VKR=^_R/M=MYF-OG)U !^EE 'SS^TK\>?\
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M9O*^SMYWF1 'V_0!\6?M,?M?_P##.OBO0/#'_"O/^$P_MSP\->^V_P#"6_\
M"/\ V7.I7NG_ &7[-_PC.M^=_P >?F^?]HA_UGE^3\F]@#YN_P"'H7_5#O\
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MV.TN+KRMVSS/L\+R^7OVOLW;-N[8VW.=IQB@#\IO^'H7_5#O_,E__B_H /\
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M_P"$X_MC[%_8_AW5M?\ ^0=_PA^E?:/M']E?9/\ C_@\GS_/_>^5Y,@!^A=
M'RQ^T]^TO_PSA8>#[W_A"O\ A,O^$KN]8M?*_P"$C_X1W[!_9,.GR[]_]@ZY
M]J^T?;MNW9;>5Y6=TF_" 'R%_P /0O\ JAW_ )DO_P#%_0!UG@'_ (*-?\)Q
MXZ\%^"O^%.?V7_PE_BSPYX7_ +2_X6%]M_L[^W]8L])^W?8_^$'M/M?V3[7Y
M_P!F^U6WG^7Y7VB'=YB@'Z<4 ?//[2OQY_X9X\"Z3XT_X17_ (2_^T_%EAX7
M_LS^W/\ A'_(^VZ/KNK?;OMG]CZWYGE?V)]G^S?98]_VGS?M">3Y<H!\0_\
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MV_9;W[)YVS9Y_P!CN?+SN\E\;: /S3_X>A?]4._\R7_^+^@ _P"'H7_5#O\
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M (5'_;G_  BNK2:7_:W_  GO]F?;O+BBD\_[!_PA>H?9<^9CROMEQC;GS#G
M //?^'H7_5#O_,E__B_H ^I_V8?VJ_\ AH^^\867_"!_\(;_ ,(I::-=>9_P
ME'_"0_;_ .UIM1B\O9_PCNA?9?L_V#=NW7'F^;C;'Y>7 /KV@#X*_:#_ &WO
M^%$?$:Y^'_\ PK'_ (2K[-I.E:I_:W_":?V'O_M*)Y?(^P?\(GJ^WR-FWS/M
MC>9G/EQXQ0!XA_P]"_ZH=_YDO_\ %_0![U^SG^VG_P +_P#B!-X%_P"%:_\
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MD\_[!_PA>H?9<^9CROMEQC;GS#G  //?^'H7_5#O_,E__B_H ^F_V9/VM?\
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MC\[=]AM]OF>7M;9O8 ].H _)O_AZ%_U0[_S)?_XOZ #_ (>A?]4._P#,E_\
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M!Z=\&OV_/^%M_$SPI\.O^%3_ /"/_P#"3W=W:_VQ_P )W_:OV'[+I=]J6_\
ML_\ X0W3?M._[%Y.W[=;[?,\S<VSRV /T6H ^8_VF_VC?^&<M"\,:U_PAO\
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M._\ ,E__ (OZ #_AZ%_U0[_S)?\ ^+^@#]"_@;\4/^%S_"WPO\2O[#_X1O\
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M  4:_P"$'\=>-/!7_"G/[3_X1#Q9XC\+_P!I?\+"^Q?VA_PC^L7FD_;OL?\
MP@]W]D^U_9//^S?:KGR/,\K[1-L\Q@#D_P#AZ%_U0[_S)?\ ^+^@#Z]_9A_:
M7_X:/L/%][_PA7_"&_\ "*7>CVOE?\)'_P )#]O_ +6AU"7?O_L'0OLOV?[!
MMV[+CS?-SNCV8< ^IZ /SI^,O[?G_"H_B9XK^'7_  J?_A(/^$8N[.U_MC_A
M._[)^V_:M+L=2W_V?_PANI?9O+^V>3M^W7&[R_,W+O\ +0 \Q_X>A?\ 5#O_
M #)?_P"+^@#Z1_9G_:__ .&BO%>O>&/^%>?\(?\ V'X>.O?;?^$M_P"$@^U8
MU*QT_P"R_9O^$9T3R/\ C\\WS_M$O^K\OR?GWJ ?:= 'PK^T9^VG_P * ^($
M/@7_ (5K_P )9YOA[3=>_M3_ (3'^P=O]H7.H6WV3[#_ ,(KK.?)^P;_ #_M
M8W^;M\E/+W. >"_\/0O^J'?^9+__ !?T >W_ +/G[;W_  O?XC6OP_\ ^%8_
M\(K]HTG5-4_M;_A-/[<V?V9$DOD?8/\ A$]'W>=OV^9]L7R\9\N3H #[UH ^
M0OVGOVJ_^&<+[P?9?\('_P )E_PE=IK-UYG_  E'_"._8/[(FTZ+R]G_  CN
MN?:OM'V_=NW6WE>5C;)OR@!\L?\ #T+_ *H=_P"9+_\ Q?T >A?"?_@H-_PL
M_P"(WA'X?_\ "H_[#_X2K5H]+_M;_A/?[2^P>9%+)Y_V#_A"]/\ M6/*QY7V
MRWSG/F#&" ?I%0!\Q_M-_M&_\,Y:%X8UK_A#?^$Q_P"$CU:\TO[-_P )#_PC
MWV+[)9K=^?YW]AZY]H\S/E^5Y4&S&[S&^[0!\;_\/0O^J'?^9+__ !?T =#X
M1_X*2?\ "5>+/#'A?_A3'V#_ (2/Q#HN@_;O^%B?:OL7]L:E;:?]J^S?\(+;
M_:/L_P!H\[R/M$'F[/+\Z+=O4 _4.@#P_P#:#^,O_"B/AS<^/_\ A'/^$J^S
MZMI6E_V3_:_]A[_[2DDC\_[?_9>L;?(V9\K[$?,SCS(\9H ^"_\ AZ%_U0[_
M ,R7_P#B_H /^'H7_5#O_,E__B_H _5FPNOMUC97OE^5]KM+:Z\K=O\ +^T0
MI+Y>_:F[9NV[MB[L9VKT !YY\9/B-_PJ3X9^*_B+_8W_  D'_",6EI=?V/\
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M_P +"^Q?VA_PC^L7FD_;OL?_  @]W]D^U_9//^S?:KGR/,\K[1-L\Q@#D_\
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M1U3[-YOD?:/[/LYKOR/.\N7R?-\GR_-\J7R]V[RWQM(!^67_  ]"_P"J'?\
MF2__ ,7] !_P]"_ZH=_YDO\ _%_0!^@'P$^+7_"[_AGHWQ%_X1__ (1C^UKO
M6+7^Q_[5_MK[/_9.IW.F[_[0_LW2?-\_[-YVW[#'Y6_R]TFW>P![)0!^6.O?
M\%+O[#US6M%_X4K]I_LC5M1TO[3_ ,+'\C[1_9]Y-:>?Y/\ P@<OD^;Y7F>5
MYLGE[MGF/C<0#)_X>A?]4._\R7_^+^@#[3_9G_:#_P"&BO">O>)_^$1_X0_^
MP_$)T'[#_;W_  D'VG&FV.H?:OM/]BZ)Y/\ Q^^3Y'V>7_5>9YWS[$ /I&@#
M\T_B7_P40_X5W\0/&/@7_A4']L?\(EXAU/0?[4_X3_\ L_[?_9UR]O\ :OL/
M_"$WOV7SMF_R/M=SY>=OG/C- '#_ /#T+_JAW_F2_P#\7] 'U/\ LP_M5_\
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M_P"$D_MK_B=?\)Q_;'V+^Q_#NK:__P @[_A#]*^T?:/[*^R?\?\ !Y/G^?\
MO?*\F0 _0N@#Y-_:A_:A_P"&;?\ A!O^*&_X3/\ X3/_ (2;_F9O^$=_LW_A
M'?\ A'_^I?UW[9]L_MW_ *=?L_V7_EOY_P"Y /DW_AZ%_P!4._\ ,E__ (OZ
M .X^&G_!1#_A8GQ \'>!?^%0?V/_ ,)9XATS0?[4_P"$_P#[0_L_^T;E+?[5
M]A_X0FQ^U>3OW^1]KMO,QM\Y.H /TLH ^>?VE?CS_P ,\>!=)\:?\(K_ ,)?
M_:?BRP\+_P!F?VY_PC_D?;='UW5OMWVS^Q];\SRO[$^S_9OLL>_[3YOVA/)\
MN4 ^(?\ AZ%_U0[_ ,R7_P#B_H MZ?\ \%./MU_8V/\ PI'ROMEW;6OF_P#"
MR=_E_:)DAW[/^$!3?LW[MNY=V,;EZ@ _5F@#QOX]?%K_ (4A\,]9^(O_  C_
M /PD_P#9%WH]K_8_]J_V+]H_M74[73=_]H?V;JWE?9_M/G;?L,GF[/+W1[MZ
M@'Y__P##T+_JAW_F2_\ \7] !_P]"_ZH=_YDO_\ %_0!^H?A'7O^$I\*>&/$
M_P!E^P?\)'X>T77OL/G_ &G['_:^FVVH?9?M/DV_VC[/]H\GS_L\'F[/,\F+
M=L4 R/B5XR_X5W\/_&/CK^S?[8_X1+P]J>O?V7]L_L_[?_9MJ]Q]D^V_9;W[
M)YVS9Y_V.Y\O.[R7QMH _-/_ (>A?]4._P#,E_\ XOZ #_AZ%_U0[_S)?_XO
MZ /TA^$_CS_A:'PY\(^/_P"RO[#_ .$JTF/5/[)^W?VE]@WRRQ>1]O\ L>G_
M &K'E9\S[%;]<>6,9(!W%_=?8;&]O?+\W[':7%UY6[9YGV>%Y?+W[7V;MFW=
ML;;G.TXQ0!^4W_#T+_JAW_F2_P#\7] !_P /0O\ JAW_ )DO_P#%_0!]Z?L]
M_&7_ (7O\.;;Q_\ \(Y_PBOVC5M4TO\ LG^U_P"W-G]F21Q^?]O_ ++T?=YV
M_/E?8E\O&/,?.0 >X4 ?ECKW_!2[^P]<UK1?^%*_:?[(U;4=+^T_\+'\C[1_
M9]Y-:>?Y/_"!R^3YOE>9Y7FR>7NV>8^-Q ,G_AZ%_P!4._\ ,E__ (OZ /M/
M]F?]H/\ X:*\)Z]XG_X1'_A#_P"P_$)T'[#_ &]_PD'VG&FV.H?:OM/]BZ)Y
M/_'[Y/D?9Y?]5YGG?/L0 ^D: /S=^*__  4&_P"%8?$;Q=\/_P#A4?\ ;G_"
M*ZM)I?\ :W_">_V9]N\N**3S_L'_  A>H?9<^9CROMEQC;GS#G  //?^'H7_
M %0[_P R7_\ B_H ^I_V8?VJ_P#AH^^\867_  @?_"&_\(I::-=>9_PE'_"0
M_;_[6FU&+R]G_".Z%]E^S_8-V[=<>;YN-L?EY< ^O: /S_\ CW^W/_PH_P")
MFL?#K_A5W_"3_P!DVFCW7]L?\)M_8OG_ -JZ9;:CY?\ 9_\ PB.K>5]G^T>3
MN^VR>;L\S;'NV* >-_\ #T+_ *H=_P"9+_\ Q?T >]?LY_MI_P#"_P#X@3>!
M?^%:_P#")>3X>U'7O[4_X3'^WMW]GW.G6WV3[#_PBNC8\W[?O\_[6?+\K;Y+
M[]R 'W50!\6?M,?M?_\ #.OBO0/#'_"O/^$P_MSP\->^V_\ "6_\(_\ 9<ZE
M>Z?]E^S?\(SK?G?\>?F^?]HA_P!9Y?D_)O8 ^;O^'H7_ %0[_P R7_\ B_H
M_2SX:>,O^%A_#_P=XZ_LW^Q_^$L\/:7KW]E_;/[0_L_^TK6.X^R?;?LME]J\
MG?L\_P"QVWF8W>3']T '<4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M_!?]J:1\;? NL>.XM.FN9O![^'-8TW0Y;^* R)IFG>,IM1FFG-Q*/L\-Y?\
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M2BU='PV+PM? XBKA,33=.O1ERU(.SMHFFFM'&46I1:T<6FCWJ3]IK]H#XI_
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MUKX:\/Z)X>MKB43W%OH>DV&DP3SA%C$TT-A;V\<LHC58Q(ZE]BJN=H H W*
M.(OOAG\-]4O+G4=3^'W@C4=0O)7N+N^OO"F@W=Y=3R'+S7-S<6$DT\KGEY)7
M9V/))H J?\*C^%/_ $3'X>_^$7X;_P#E;0!T.@^$?"GA7[5_PC'ACP]X<^W>
M1]M_L'1=-T?[9]E\[[-]J_L^VM_M'V?[1<>1YN_R?/F\O;YCY .AH Y#5_A]
MX"\07TFIZ]X(\(:WJ4J1QRZAJ_AK1M2OI$A01PI)=WEE-.Z11J$C5I"$0!5
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M)-"T;Q!8PW"7<5EK>F66JVD5W''+#'<QV]_!/"EPD,\\23*@D6.:6,,%D<$
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M*LK @@D$8H X#_A4?PI_Z)C\/?\ PB_#?_RMH /^%1_"G_HF/P]_\(OPW_\
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M<NJ+&'N+NYL99YG$:(@:21B$55!PH  */_"H_A3_ -$Q^'O_ (1?AO\ ^5M
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M9)- %N2..6-XI422*1&CDCD4/')&X*NCHP*LC*2K*P(()!&* . _X5'\*?\
MHF/P]_\ "+\-_P#RMH /^%1_"G_HF/P]_P#"+\-__*V@#K-%T#0O#EG_ &=X
M>T72=!T_S7N/L.BZ=9Z79^?(%$DWV6QA@@\V0(@>39O8(H8D*, &M0!P4_PK
M^&%U/-=77PX\!W-S<RR3W%Q/X/\ #TT\\\SF26::633FDEEED9GDD=F=W8LQ
M))- $7_"H_A3_P!$Q^'O_A%^&_\ Y6T ='H7A7POX72XB\,^&]!\.QW;1O=Q
MZ%H^GZ0ET\098GN$T^WMUF:)7=8VD#% S!<!C0!OT <7J7PW^'>LWUQJ>K^
MO!>JZE=N)+K4-2\+:'?7URZHL8>XN[FQEGF<1HB!I)&(154'"@  H_\ "H_A
M3_T3'X>_^$7X;_\ E;0!MZ'X)\&^&)YKKPUX2\,>'KFXA^SW%QH>@Z5I,\\
M=9!!--86EO))#YB*_ENQ3>JMMR 0 =/0!R>L^ O WB.\_M'Q#X+\)Z]J'E);
M_;M9\.:/JEYY$18QP_:;ZSGF\J,NY2/?L0LVU1N- &3_ ,*C^%/_ $3'X>_^
M$7X;_P#E;0!K:-X"\#>'+S^T?#W@OPGH.H>4]O\ ;M&\.:/I=YY$A4R0_:;&
MS@F\J0HA>/?L8HNY3M& #K* .;UWP;X0\4/;R^)O"OAOQ%)9I)':2:[H>F:N
M]K'*5:5+=]0M;AH$D9$,BQ%0Y12P)48 ,'_A4?PI_P"B8_#W_P (OPW_ /*V
M@"]IOPW^'>C7UOJ>D> O!>E:E:.9+34--\+:'8WUJY1HR]O=VMC%/"YC=D+1
MR*2C,N<$B@#M* ,#7?"OA?Q0EO%XF\-Z#XBCLVD>TCUW1]/U=+5Y0JRO;IJ%
MO<+ TBHBR-$%+A%#9"C !SG_  J/X4_]$Q^'O_A%^&__ )6T 6+3X7_#33[N
MUO[#X=^!;*^LKB&[LKRT\):!;7=I=VTBS6]S:W$.GI-;W%O,B2PS1.DD4B*\
M;*R@@ [J@#)UG0-"\1V?]G>(=%TG7M/$J7'V'6=.L]4L_/B#".;[+?0SP>;&
M'<))LWH'8*0&- ')_P#"H_A3_P!$Q^'O_A%^&_\ Y6T '_"H_A3_ -$Q^'O_
M (1?AO\ ^5M 'H5 &=JND:3KMA/I6MZ9I^LZ7=>5]ITW5;*VU"PN/(FCN8?/
ML[N*:WF\FXABGB\R-O+FBCE3#HI !QW_  J/X4_]$Q^'O_A%^&__ )6T '_"
MH_A3_P!$Q^'O_A%^&_\ Y6T =U:6EII]I:V%A:V]E8V5O#:65E:0QVUI:6EM
M&L-O:VMO"J0V]O;PHD4,,2)'%&BQQJJJ   N[2TU"TN;"_M;>]L;VWFM+RRN
MX8[FTN[2YC:&XM;FWF5X9[>>%WBFAE1HY8V:-U96(H X7_A4?PI_Z)C\/?\
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M!2 QH Y/_A4?PI_Z)C\/?_"+\-__ "MH /\ A4?PI_Z)C\/?_"+\-_\ RMH
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M\/?_  B_#?\ \K: ._CCCBC2*)$BBB18XXXU"1QQH J(B* J(B@*JJ %
M% %34M,TW6;&XTS5]/L=5TV[01W6GZE:6]]8W**ZR*EQ:74<L$R+(B.%DC8!
MT5@,J" #B_\ A4?PI_Z)C\/?_"+\-_\ RMH /^%1_"G_ *)C\/?_  B_#?\
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M([S^T?$/@OPGKVH>4EO]NUGPYH^J7GD1%C'#]IOK.>;RHR[E(]^Q"S;5&XT
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M-AJT$$^PQ^=##?V]Q'%+Y;-'YB*K[&*YVDB@#F?^%1_"G_HF/P]_\(OPW_\
M*V@!T?PG^%D3I)%\-? $<D;*\<D?@WPZCQNA#(Z,NG!E96 *LI!4@$8(H ]
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MJ_V/[3Y/VG[+_:%M<?9_M'V>W\_R=GF^1#YF[RDV@'/?\*C^%/\ T3'X>_\
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M%CJEG<Z=J=E::CI]Y$UO=V-];0W=G=0.,/#<VMPDD$\3CAHY49&'!6@#B/\
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MWMX+2""UM8(;:UMH8[>VMK>-(8+>"%%CA@@AC58XH8HU6...-51$5550H H
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MJ1_NSBXNW9J]TUJFDU9I'^?MJFG7.CZGJ.D7B[+S2[^[TZ[0=$N;&XDMIU'
M^[+$PZ#ITK_1:C5C7HTJT/@K4Z=6'^&I%2C^#1_-\XN$Y0EHX2<7ZQ=G^1_:
M[_P3@\1W7BG]A_\ 9UU.\F,\MKX)G\.(Y_AM?!WB+6_"-A#]+>QT.WMU[;8A
M@ <5_"_B;AH83CSB6E"/*I8]8FW][&X:AC)O_MZ=>4OF?O'"]5U<@RR3W6']
ME\J%2=&*^4::1]N5\(>\% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!_];^_B@ H *
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MY%7\6/$',JD*%/.OJ_MIQIPI8/!8&A[U1J$4JBPTL1NTE^]/KX<)<.X:#G+
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M+E+ZO@ZM3"X>G?W(JC)TYU$MN:M.+FW:_+R0?P(^S_V#O^"2WAKX^?"OP_\
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M>&N''GM2M*I6=#"8;D524$G5J3G=JG3O[L;1C>4Y*2C[J4)7;C^]W@W_ ()
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MX?\ #U/]@?\ Z+]:_P#ANOBY_P#,#1_Q"3Q"_P"B=G_X<LG_ /G@'^MW#O\
MT,8_^$V,_P#F</\ AZG^P/\ ]%^M?_#=?%S_ .8&C_B$GB%_T3L__#ED_P#\
M\ _UNX=_Z&,?_";&?_,X?\/4_P!@?_HOUK_X;KXN?_,#1_Q"3Q"_Z)V?_ARR
M?_YX!_K=P[_T,8_^$V,_^9P_X>I_L#_]%^M?_#=?%S_Y@:/^(2>(7_1.S_\
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MC'_PFQG_ ,SA_P /4_V!_P#HOUK_ .&Z^+G_ ,P-'_$)/$+_ *)V?_ARR?\
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MP#_6[AW_ *&,?_";&?\ S.'_  ]3_8'_ .B_6O\ X;KXN?\ S T?\0D\0O\
MHG9_^'+)_P#YX!_K=P[_ -#&/_A-C/\ YG#_ (>I_L#_ /1?K7_PW7Q<_P#F
M!H_XA)XA?]$[/_PY9/\ _/ /];N'?^AC'_PFQG_S.'_#U/\ 8'_Z+]:_^&Z^
M+G_S T?\0D\0O^B=G_X<LG_^> ?ZW<._]#&/_A-C/_F</^'J?[ __1?K7_PW
M7Q<_^8&C_B$GB%_T3L__  Y9/_\ / /];N'?^AC'_P )L9_\SA_P]3_8'_Z+
M]:_^&Z^+G_S T?\ $)/$+_HG9_\ ARR?_P"> ?ZW<._]#&/_ (38S_YG#_AZ
MG^P/_P!%^M?_  W7Q<_^8&C_ (A)XA?]$[/_ ,.63_\ SP#_ %NX=_Z&,?\
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M'_#U/]@?_HOUK_X;KXN?_,#1_P 0D\0O^B=G_P"'+)__ )X!_K=P[_T,8_\
MA-C/_F</^'J?[ __ $7ZU_\ #=?%S_Y@:/\ B$GB%_T3L_\ PY9/_P#/ /\
M6[AW_H8Q_P#";&?_ #.'_#U/]@?_ *+]:_\ ANOBY_\ ,#1_Q"3Q"_Z)V?\
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MW<._]#&/_A-C/_F</^'J?[ __1?K7_PW7Q<_^8&C_B$GB%_T3L__  Y9/_\
M/ /];N'?^AC'_P )L9_\SA_P]3_8'_Z+]:_^&Z^+G_S T?\ $)/$+_HG9_\
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MBY_\P-'_ !"3Q"_Z)V?_ (<LG_\ G@'^MW#O_0QC_P"$V,_^9P_X>I_L#_\
M1?K7_P -U\7/_F!H_P"(2>(7_1.S_P##ED__ ,\ _P!;N'?^AC'_ ,)L9_\
M,X?\/4_V!_\ HOUK_P"&Z^+G_P P-'_$)/$+_HG9_P#ARR?_ .> ?ZW<._\
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M,?\ PFQG_P SA_P]3_8'_P"B_6O_ (;KXN?_ # T?\0D\0O^B=G_ .'+)_\
MYX!_K=P[_P!#&/\ X38S_P"9P_X>I_L#_P#1?K7_ ,-U\7/_ )@:/^(2>(7_
M $3L_P#PY9/_ // /];N'?\ H8Q_\)L9_P#,X?\ #U/]@?\ Z+]:_P#ANOBY
M_P#,#1_Q"3Q"_P"B=G_X<LG_ /G@'^MW#O\ T,8_^$V,_P#F</\ AZG^P/\
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MV?\ X<LG_P#G@'^MW#O_ $,8_P#A-C/_ )G#_AZG^P/_ -%^M?\ PW7Q<_\
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MW_H8Q_\ ";&?_,X?\/4_V!_^B_6O_ANOBY_\P-'_ !"3Q"_Z)V?_ (<LG_\
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M_P 0D\0O^B=G_P"'+)__ )X!_K=P[_T,8_\ A-C/_F</^'J?[ __ $7ZU_\
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M._\ 0QC_ .$V,_\ F</^'J?[ _\ T7ZU_P##=?%S_P"8&C_B$GB%_P!$[/\
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M3_[)7J/_ *ENHU_57T?_ /D19]_V-J/_ *ATS\H\0O\ ?LO_ .P2?_IYD?\
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M1K;0_I\_X(8_\FL_$K_LO_B'_P!5U\,J_E3Q]_Y*S*_^R=P__JRS0_6/#_\
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M.7G*<FWYL_H&G3A2IPI4XJ-.G"-.$5M&$$HQBO)))(TZR+"@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * /G;]K[_ )-,_:A_[-V^-?\
MZK7Q+7TO!G_)8<*?]E+D7_JTPIYF=?\ (FS;_L68_P#]1:I_"!7^@9_/04 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% '[-_\ !#3_ ).S^(7_ &;MXL_]65\)*_$/'S_DC\M_[*7!_P#JKS@^Y\/_
M /D<XG_L65O_ %*P1_5;7\C'Z^% !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!_]#^_B@ H *
M"@ H * "@#PG]I?X$Z)^TK\$/'WP6UW4/[%MO&>EP066O+IZZK)X>UO3+^TU
M?0];CTXWFG&]_L[5;"UFGLDU'3VOK07%C]MMDN&D7W^%L_K\+Y]EV>8>G[>6
M!JN4\/[1T5B:%6G.C7H.HH5/9^THU)QC-TJBISY9^SERI'GYKE]/-,!B<!4E
M[-5X)1J<O-[.I"49TZBC>/-RSC%N/-'F5X\RN?BC_P .#O\ JZ[_ ,P7_P#C
MCK]U_P")AO\ JD/_ #/_ /X$/@_^(=?]3C_S'_\ WZ?L;^R/^S7HG[)WP/\
M#?P;T;6O^$HFTJ]UK5]=\5MI"Z#+XEUO6]2FNYM1ETA=2U=;'[-8?V?HUM#_
M &E>,+'2K7?.\FXU^)\8\3U^+\^Q6=UJ'U15H4*.'P:K?6%A:%"E&$:2K>RH
M^TYI^TK2?LH>_5E:*5C[?)LKIY/E]+ TY^U<)3G4K<GLW5J3DVY.'-/EM'E@
MES2]V"U/I>OESU1" 05(!!&"",@@\$$="".,4 ?D/^TO_P $=_@)\:M9U'QC
M\--9OO@7XNU6XGO=3M=$TB#7_ 6HWD^9);@>$)+[2)-#N)Y<;_\ A']8L-*C
M#22C1)+AVD;]EX6\:>(<BH4L%FE"GG^"HQC"E*O6>&S"E".BA]<C3K*O&*V^
ML4*E7:/MU%)+XO->"<NQ\Y5\+.67UIMRDJ<%4PTI/=^P<H>S;_Z=3A!;^SN?
MGE??\$*?V@([DIIGQA^#MW9[B%GOAXUTZY*;P 3:6_AK4XE8QY8J+U@' 0.5
M/F#])I^/_#KA^\R3.H3M\--X&I"]OYY8FD[7T_AK36W0^:EX?9BG[F-P3CWE
M[>+_ / 52FO_ "8]M^%/_!":TM]1M;_XU_' ZEIL$Z/<^&?AMX?>QDOH4.XQ
MGQ;XBGF:T20CRY4B\*22^66,-W!)M=?!S?Q_G*E.GD60JE5E%J&*S/$JHJ;:
MM=8/#1BIM;Q;Q:C=+FA):'?@_#V*DI8_'\\$]:6%I\O,O^OU1NW9I4;VVDC]
MR?@_\&/AE\!?!&G?#SX3^$M.\'^%=.9YELK$2S7-]>RA%N-4UC4[R2XU+6=5
MN1'&L^HZE=7-TT44%NLBVUO!#%^"9SGF:\0XZIF6<8RKC<74LN>I:,*<%\-*
MA2@HTJ%&.O+2I0A!-N5N:4F_O\%@<)EU".&P=&%"C#[,;WD^LIS=Y3F^LIMN
MR2O9)+U"O*.L_#7X\?\ !%\?&SXR_$KXMC]I$^&!\0_%^L>*_P#A'S\'O[:_
ML<ZM<M<FP_M;_A:6D?;Q 6*"Y_LRR\P8/V=*_>^'O'#^P<DRO)O]6/K7]FX.
MCA/K/]M>P]M[&/+[3V/]DUO9\W\GM9V_F9\!F/ OU_'8K&?VI[+ZS6G6]E]2
MY^3G=^7G^MPYK=^2/H>Q:;_P20^$%W^S1HOP%\?>+KSQ/XJ\*>(/%'B#PA\8
M]!\-0>$O$.A/XFN;6YN-);1)M<\2VNJ:$S6D2WNFZAJ4J3MONM.?1[XK=IXM
M7QBSF'%-?B'+L'#"83%X;"8;&9)B,5+&8;$+"QE"-7V\</A94L0N=^SJTZ2<
M5[E15J=X/NCP;@I953R[$5G5JT*E6I1QU.DJ-2G[62DX>S=2JI4]$I0E)I[Q
MY):GYWZ__P $)OC=;ZG)%X6^-?PKU?1?/=8KW7]/\6^'=3-KD^7))I>G:7XH
MM%G*XWP+K#1J<A;A@!7Z3A_I 9%*DGB\BS:C7Y5>&'J8/$4N?JE5J5<+/E[/
MV-_[I\S4\/<>IVHX_"3IWT=2-:E/EZ>Y&%6-_+GMYGTC\!/^"'G@CPSK5AX@
M_:!^)4GQ%M[*43'P'X.TZ]\->'KUXR-D>L>)9[X^(+^QD&3+::79>&[D,J#^
MTGB,D3_,<0^/./Q5"IAN',K662FN7^T,;4ABL3!-:NAAHTUAZ=1?9G5GB8_]
M.D[->IEW &'I3C4S'%/%*+O]7HP=*D[;<]5R]I*/>,(TG_>:/W3T31-'\-Z/
MI?A[P]I=AHFA:)86FE:/H^EVD-CINF:;8PI;6=A86=LD<%K:6L$:0P00HD<<
M:*JJ *_ :]>MB:U7$8BK4KUZ]2=6M6JS<ZM6K-N4ZE2<FY2G*3;E)N[9^@4Z
M<*4(4Z<(PITXQA"$$HQA&*M&,8K1))))+9'C_P"TM\%A^T3\#/B'\%CXD/@\
M>/=*L],_X20:/_;_ /9)M-8TW5Q/_8_]J:+]N#G3A 8O[4L]HE\P2G9L;VN%
M\\_U:S_+<\^J_7/[.K2J_5?;?5_;<U&I1Y?;>RK^SM[3FO[*>UK:W7%FF!_M
M/+\3@?:^P^L04/:\GM.2TXSOR<U/F^&UN>)^./A#_@A:/"OBSPOXG/[49OQX
M;\1:)KQL!\$_LAO1H^I6VH&T%U_PMNZ%L;D6_DBX^S7'D[_,\B7;Y;?MF-\?
MOK>#Q>$_U3]G]9PU?#^T_MWG]G[:E*GS\G]C0YN7FOR\T;VMS1W7Q%#P_P#8
MUJ-;^UN;V56G4Y?J'+S>SFI<M_KCM>UKV=NSV/Z J_G0_1PH ^ ?VT?^">?P
MD_;'@MM>U6]OO GQ6T;2AI&A_$+1K>._6;3XII[FUTGQ3H$TUK!KVE6UQ=74
MML8+S2M6M'G98-5%H9+.7]$X&\2,XX)E+#T84\?E%:M[;$9;6DZ=JCC&$JV$
MQ$8REAZLHP@I<T*M&:BN:ES6FOG,]X:P6=I5)REA\9"')3Q,$I>ZG=0K4VTJ
MD$V[6E"<;Z3M[K_('4?^"$_QSBU-8M)^-/PGO=&R=]_J-EXOTO4U7C:5TFVT
MC5[5B1G*G6D"X #-G(_9Z7C_ )"Z5ZV19O3K=*=*I@ZM+_P=*K1FO_!'W'Q4
MO#W'J5H8_!RI_P THUH2_P# %":_\J'Z,_L;_P#!*#X5?LT^(],^)?CO7S\7
MOBAI#0W7A^YN=)72/!_@[4HSO74]$T62ZO[G4M;M&PMCK>KW6VT=$OM.TC3=
M12*YB_,^-O%[-^*,-4RO+\/_ &-E5:\,1"%9UL9C:35O95ZZA3C3H2^W0HP]
M]/DJ5:E.\7]/D?!^#RJK#%5ZGUW%PLZ;<.2C0E_-3IWDY37V9S?NVYH0A*S7
MR/>?\$%A=7=U<C]JLQBXN9YQ&?@;O,8FE:0(7'Q@0.5#;=VQ-V,[5Z#[*G](
M/DIPA_JC?DA&-_[>M?E25[?V*[7MM=V[GC2\.^:3E_:]KMNW]G[7?_8:?NE\
M&_AZ/A)\(_AA\+!JYU\?#?P!X0\"_P!NFP_LO^V?^$4T"PT/^U/[,%YJ/]G_
M &_[#]J^P_;[[[+YOD?:[G9YS_@6=YE_;&<YKFWL?J_]IYCC,?\ 5_:>U]A]
M;Q%2O[+VO)3]I[/GY.?V=/FMS<D;\J_0,#AOJ6"PF#Y_:?5<-0P_M.7DY_8T
MXT^?DYI<O-RWY>:7+M=[GYA?M@?\$G1^U=\<_$'QH'Q[/@+^WM*\.:8?#?\
MPJW_ (2G[*?#^C6ND>>-8_X6+X<\X78M1/Y7]EQ>07,?FS ;S^J\%^+_ /JA
MD&'R/_5[^T/J];$U?K7]K?5.;ZQ6E5Y?8?V9B>7DYN6_M7S6O:.Q\GG?!W]L
M9A4QW]H_5O:0I0]E]4]M;V<%"_/]9I;VO;D5MM3Z6_80_8E'[$WA/QYX8_X6
M8?B8?&_B+3=>-]_PAO\ PA@TP:=IK:>+06G_  E7BO[89=YF-Q]IM=G$8@;'
MF'Y?Q X[_P!>L9E^*_LO^R_J&&JX?V?UWZ[[7VE55.?G^J8/DM;EY>27?F6Q
MZO#V0_V#0Q%'ZU]:]O5C4YO8>PY.6')R\OMJU^][KM8^\*_/CZ$_'_\ ;%_X
M)1C]K+XX:Q\91\>CX _M;1/#NCGPY_PJ[_A*O(.@:<FG_:1J_P#PL3PWY@N@
M@E\C^RT\@Y3SIA\P_9^"O%W_ %/R&CDG^KW]H^QKXFO]9_M;ZIS?6*GM.3V/
M]FXJW)M?VKYOY8['Q6=\'_VSCYX[^T?JW-3I4_9?5/;6]G'EOS_6:6_;DT[L
M^A_V#OV'1^Q)X>^(>A?\+//Q,/CW6="U8W?_  A?_"&#2AHMC?68MQ;_ /"6
M>*_MIN/MID,WGVGE>6$\J3=O'S?B#Q[_ *]XG+<1_97]E?V=0Q%'D^O?7O:^
MWG3GS<WU/!^SY?9VY>6=[WNK6/3X>R#^P:6)I?6_K7UBI"=_8>PY.2+C:WMJ
MW->^]XV['WS7YX?1'Y#_ +9?_!*H?M<?&N]^,(^.Y^'WVSPYH&@'P[_PK#_A
M*_+.A0S0_:QJW_"P_#61="4'[/\ V8/(*G]_*&^7]EX(\7/]3<BADO\ J_\
MVCR8K$8CZS_:OU._MW%\GL?[-Q7P<OQ>UUO\*L?%YYPA_;./>-_M#ZM>E3I>
MR^J>V_AIJ_/]9I;WVY-.[/>OV#/V&!^Q'HOQ'TC_ (6@?B:?B#JGAS43<?\
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M/E"7SUW>6OZ%X?\ B=_J+E^.P']B?VI]<QBQ?M?[2^H^SM0IT?9\GU#%\_\
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MX$T_X10ZWI_A[3O!G@[0_!]C9V%];_$7PU!]C^R:'#+;6D.C6D5A$ZV<?FI
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M9!;QJ9(TBTY9Q-Y4UO=VLT*25]5Q7XT8KB'+*>"P635,DQ5''83'T,PI9O\
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M3:<[.K6F^:K6E%63G*R5EKRPBHPC=VBFVW]*5\P>H% !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'SM^U]_P FF?M0_P#9NWQK_P#5
M:^):^EX,_P"2PX4_[*7(O_5IA3S,Z_Y$V;?]BS'_ /J+5/X0*_T#/YZ"@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M _9O_@AI_P G9_$+_LW;Q9_ZLKX25^(>/G_)'Y;_ -E+@_\ U5YP?<^'_P#R
M.<3_ -BRM_ZE8(_JMK^1C]?"@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H __1_OXH * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H ^=OVOO^33/VH?\ LW;XU_\ JM?$M?2\&?\
M)8<*?]E+D7_JTPIYF=?\B;-O^Q9C_P#U%JG\(%?Z!G\]!0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?LW_P0T_Y.
MS^(7_9NWBS_U97PDK\0\?/\ DC\M_P"REP?_ *J\X/N?#_\ Y'.)_P"Q96_]
M2L$?U6U_(Q^OA0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?_TO[^* "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * /G;]K[_DTS]J'_ +-V^-?_ *K7Q+7TO!G_ "6'"G_92Y%_
MZM,*>9G7_(FS;_L68_\ ]1:I_"!7^@9_/04 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '[-_\$-/^3L_B%_V;MXL_
M]65\)*_$/'S_ )(_+?\ LI<'_P"JO.#[GP__ .1SB?\ L65O_4K!']5M?R,?
MKX4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % '_]/^_B@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M@'ZF_P#!,#_@J'^SE_P5=_9]O?C[^SVGB;P_'X<\8:KX%\>?#7Q_'HEG\0?
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M:\=:'H'A?Q/JGA[4K!KG4=,O9+;1/&7AR\_M/P[K.N:',;\VUOJDMU:7D%N
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M\*I?!,OB^/XD1_#-_$-H;KXEV>NOX;_M9Q?J9=)@U0Z<,G3UN?\ 1Z /Z=J
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M>+!?ZBOB[Q-X7LETP67ARZMR;:[N+K[5-;C[-Y1DEC .D_X)8?\ !3WX.?\
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M^%8]?L?#>NW7AM_"'C+Q2TDWAK4M:\-KJD%[':$PZ]:36IG6"[\D _>&@ H
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@#^/3_@Z _P""X7[1G_!-SQ9^S3^SU^Q9\0=!\#?&CQKH?B/XO?%O6M3\
M%^"_'DVE_#<WDGA'X=Z)!I/C;1/$.E6I\5^(].\<:E=WD=E;:G:Q^#=-CM[D
MV>JW<;@'RO\ \&W'_!PA^U]^V[^VUXH_9-_;M^*GASQ\?B;\+M8U[X":C8?#
MOX=_#ZZL/B'\.C)XB\2>%E7P'X<\-+JT?B?X>-XD\0,^JB_>PD\ 0PZ<MO\
MVI?&4 _NSH * .%^)^NZAX6^&GQ#\3:0\<6K>'/ WBW7=+DEB6>*/4-(T#4-
M0LGE@?Y)HTN;>)GB?Y9%!1N#0!_DW'_@ZR_X+?9_Y.E\(#V'[.?[/.![#/PT
M)P/<DT  _P"#K+_@M\"/^,I?"!QV/[.?[/.#[<?#0''T(/IB@#U?P!_P=[?\
M%C_!M\EWXB\6?L]?%>W4H3IGC[X%Z5IME(%ZAI/A;K7PUU("3^+9J"$?P%*
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M[P0-,S2M$B&0E\F@#TF@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H ^=OVOO^33/
MVH?^S=OC7_ZK7Q+7TO!G_)8<*?\ 92Y%_P"K3"GF9U_R)LV_[%F/_P#46J?P
M@5_H&?ST% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0!^S?_!#3_D[/XA?]F[>+/\ U97PDK\0\?/^2/RW_LI<'_ZJ
M\X/N?#__ )'.)_[%E;_U*P1_5;7\C'Z^% !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M!J4)1DKQE&2T::V:TL:E9%A0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M"T4[.2/Z@*_E,_6 H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M9:E-S_K-9LM2;IZ"@#Y3_8V_X->O@I_P3\_X*6_ S]NC]F7]H;QW+\-/A?\
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MVG:[JNB^*9M0'Q(L_LVKZ7IOAI#_ &;<^;HEMYL0 !^]= !0 4 % !0 4 %
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M.;J[31_#6DVFBZ8MU<E4-Q<+964 GG**99 TFU=V  =10 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 ?.W[7W_)IG[4/_9NWQK_]5KXEKZ7@S_DL.%/^RER+_P!6
MF%/,SK_D39M_V+,?_P"HM4_A K_0,_GH* "@ H * "@ H * "@ H * "@ H
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ME.C3KTI5$O:1A.4X<DW%1BY*5.7O1C%.+7NH^**^[/!"@ H * "@ H * "@
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M%L7DF%ABL1B<+4C.M&A&%%U>?FE"<[VG2@K)4W?72Z/SJK],/F H * "@ H
M_9O_ ((:?\G9_$+_ +-V\6?^K*^$E?B'CY_R1^6_]E+@_P#U5YP?<^'_ /R.
M<3_V+*W_ *E8(_JMK^1C]?"@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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MQI+[^U-J\ M]DV@D+G) /NY=PQQ%F\%4RS(\UQU+2U;#8'$5*&NW[Y4_9?\
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M-"E4K5JCY:=*C"52I-VO:%."<I.RV2>B-)SA3BYSE&$(J\I3:C&*\V[)+U.
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MX8LTEGN)OAK>W&G6-G9:-\-9))0#^WN@#_+$_P"#R/\ Y2X>'/\ LT#X-?\
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M2P@'],M !0 4 4=3_P"0;J'_ %XW?_I/)0!_CZ_\&RO_ "G'_81_[#WQO_\
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MJO@W2IOA1^T%\-+73G^,OP"UK5X]9OO#]OJ<LMMIOC'P5XA%EI2^-?A_JMS
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MMI\.IZ5JFE:J++2[K5_!7B_39)+WPQK-UI.GR/=:?K^@S1RW_AR_F< _6N@
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M&PUZ#X$ZG;_!7X!PZE:"[M])^*OB#0;7Q#\1?'%N)4$4&O>$_ >M>&O#^@S
MW/EP?$77KORK2^L-*NP ?Z,= !0 4 ?)W[=O[2=G^QY^QE^U!^U!=?8GG^!_
MP0^(?Q T*SU $V>K^+]&\.7S>"/#\ZAXMP\1>,'T/0E7S8MSZBB^8F=P /\
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M$7PHU'P+J&H:K<*?M_B3_A(5$UQ-:7#T ?O90!^!O_!QQ^W_ /M(_P#!-O\
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MI/$OQ*LR;L:Q'\*OVP_V6_#W@Q_&.E6%Y$-2B@UFX^'?PZ^)UUH]QO2SEO\
MP[XQBCM5GB>RN8)&C=@#_0'_ ."./_!6;X6_\%=OV7KCXV^$/#/_  K3XE>
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MI%QG"2[-/=6:T<6FDS2C6JX>K3KT9RIU:4XSISCI*$XN\6O1KTZ-6/JKX_\
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M?B?Q55_<Y^$!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M *J\X/N?#_\ Y'.)_P"Q96_]2L$?U6U_(Q^OA0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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MKTZ<^5I\O*T>#C,#B\NKO#XRA/#UHI/EE;5=)0G%N$XZ64H2E&Z:O=']"O\
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M:_B+\ _&&M>,[:YN8?W=\G@Z+^ROAQI-^JH;KP]X+T>5T$A?(!_*?_P9=?\
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M:+!/<0V'Q9\&_'GX::T(&<)-9'X->,?B!IT%S&A_?6[>)? &@ML<,D4Z07+
M?9PZ '^N/0!_AE? O]G+Q#^U[^W9\//V7O"NIV^AZY\>OVD]/^%UKK]W;RWE
MGX<@\6^/3I6H^);RT@*SW5GX<TR>\UNZMH666>WL)(HV5F! !_M/?LC?LB?
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MCP]HW@_PAX;TN#<XM-(T#0[33]'TFRBR\ABM+6"%27<C)8T ?S\_\'%FM_\
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M2%0#_1UH * "@ H _P O;_@]+_Y2J_!;_LP[X4?^KW_:9H ^&_@5_P %!/\
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MEF\DFWO/^$<^'UI\.M+MC(9+C2-8OO%^G8MY9+R)@#^LO_@UU_8K_P"&0O\
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H ^=OVOO^33/VH?^S=OC7_ZK7Q+7TO!G_)8<*?\ 92Y%_P"K
M3"GF9U_R)LV_[%F/_P#46J?P@5_H&?ST% !0 4 % !0 4 % !0 4 % !0 4
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MWXRHK\9\7./,WX0EDF&R.M0I8G&K&5\4ZV'IXBU"B\/3H*,:B:CSU)UM4O\
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M+*:U;#4*\\:EAZ5%1K5)^TQ%:M2HI1INZES.;]U+;:VZSO@#_P $E_@+\(_
MEA\3?VZ_'&BVU]?6\#77@[4?'5K\/_A_X3GN_P!Y%I>L^,H-7TF^\0:_'&JK
M+_9.M:5I$%P;NTMEUZ&*WU237B+QAXASG,*F5< 8"O*G3E)0QE++Y9CF.,C#
M1U:&"=&M3PV'?V?:T*M9QY)R>'DW249=P;EV"P\<5Q!7IJ4DKT98A8;#46_L
M3K*<)5:G1\E2$$[QBJB2F_LF?_@F[_P3J^.W@1[_ .&/A7PU_9UU:W.F:-\1
M?A!\2-7UA;"\B0(TL5S#XDU_PMJ^H63O&T\6N:?J<@;"7"J6-?$Q\3O$KA_'
M^SS3&8KVL)1J5LMSG+*-'G@W=)PEA</BJ-.:3470J4E;X=CW'POPSF&'YL+1
MI<C3A#$X+$SGRM*UTU5J4IRCUYXR\S^7_P#:D_9\\1?LO?&_QI\'/$5U_:A\
M/74-SH.OK;?8XO$GA?5(%O=!UR.U$UPMM)=64BQ7]FES<K8:K;W^GBYN/LOF
MO_5O"7$>&XKR' YUAH>R^L0<,1A^;G>%Q=%^SQ%#FY8\RA-7ISY8^THRIU.6
M/-RK\ES?+:N4X^O@:KY_9M.G42LJM&:YJ=1+6S<=)1N^6:E&[M<^?*^D/-"@
M!\<;RR)%$I>21UCC11EG=R%15 ZEF( 'K2;44V]$E=OLE_D@2Z+T/Z:OVH_^
M"4?[.?@/]GCQAX@^$_@KQOJ'Q?BB\&:+X,M8?&.IZDFH>+O$_C'PSX6M+;^S
M[]C8O;7=SK#1S-<>3!:6SR7+7%JD'VB+^5^$_%WB;'\28+#9QC\#3R5O&U\=
M)X&C2]G@\)@L5BYR]I32J*4(44XJ-Y2DE!1FWRO]7S;@_*\/EE:I@\/7EC4J
M%.@E7G/FK5:U*C%<LO=LW/6]E&-W=)73O@Q_P2I_9-^ /@;2O%_[:'C3PUK?
MBK4;96O[7Q-\0O\ A7?PPT"^ 6=].T>\CU7PQJGB*\LD80W=]J6J_8+S[\&@
M6J[7D,[\7.,.(L?6P7 ^!Q6'PE.5J<L)EO\ :6:XBG\*JUH.CBJ6&A.UX4Z5
M'VE/9XB;T1@>$,FR[#PKYY7I5*TH^^JN)^K82E+3W8-3I2J..SE*?++I3CH?
M07B__@E]^P5\>? UUJOPDTC2/#$^J6<L'AWXD_"?QOJ/B;1+>\M\"&;^S'\1
MZQX0UJVCE41ZA!'%:WMS \L4>J6-R8;N#YS!>*WB%P]CXTLXK5L7&E-/$Y7G
M&!IX6M*#WC[58:CC,/)K6G*\J<9*+=*I%.$O2K\)\.YAAW/!TX47.+5+%8.O
M*I34EL^3VDZ-1)JTE9-JZ4HNTE_+A\?O@IXK_9W^+WC?X.^,Q')K7@S5C9KJ
M%O%+%9:WI5S#%?:)K^GI-\ZV6M:3<V>H0QN6DMO/:TG(N()57^L>'<]P?$N3
M8#.L#=4,;1YW2DTYX>M!NG7PU3ETYZ%:,Z;:LI<JG'W9(_),QP%;+,;7P-?X
MZ$^7F2:C4@TI4ZD;_9G!QDETORO5$G[.OP]_X6O\>O@Y\-VA\^V\9_$KP=H.
MI)MW!-&O==LDUN=UP<QVND"]N91C_5PMQ2XFS+^Q^'<[S/FY98'*\;7I/;]_
M##S^KQ3Z.5;V<%YM!EF&^N9C@<+:ZKXJA3E_@E4CSOT4.9^B/ZB?^"R/Q!'@
MO]C#5_#D,WE77Q0\=^#/!4:1MME-E87=QXXOF4+AA;F/P?%9W##Y"MZD#\3A
M3_)_@GEOU[CBAB7&\,JP&.QS;6G/.$<!3_[>OC'./^"Z^$_6^-\3]7R*=):/
M%XBAAU;^6+>(E\K4.5_XK=3^1"O[,/Q8_3W]AW_@F3\1_P!K6QB^(/B36&^&
M?P86\GM+?Q)+8&^\1>,)[*7RKVW\'Z3,]O;&PMYDEL;OQ+J$_P#9]M?I);6-
MEK=S9:E;67Y3Q[XJ99P=4>6X6@LTSODC.6&53V>%P49J]-XRK%2E[24;3AA:
M<?:2IVE4G0C.E*?UG#_"F)SF*Q-6?U7 \SBJO+S5:[B[25"#LN5/W75E[JEI
M&,W&2C^SS_\ !/[_ ()@_L[:=96WQ:/@R'4)XD:#6/C=\8Y-$U/55C#*9+?2
MAXB\)Z%/O>.0L-.T!=S*R ;(PB_AZ\1?%7B6I-Y/]>=.+=Z&0Y*JU*E?I*K]
M6Q>(C96M[3$.R];GW7^K?">61C]<]@I6TGC\:X2E;32'M*5-_P#;M/R.F\-?
ML6?\$KOC@]W9_#OPQ\'/'%[;6C7=U;_##XPZU>:AI]JLD,!O+FR\'>/C):11
M3W-M&9+NV$(EG@CE!,J(W)BN.?%K(>2>98O.\!"4U"#S7)J$*=25G)0C/&Y?
M:;<8R=H2ORQDUI%VUI9%PCC[K#4<#7:C=K"8V;E%:*[C0Q&EFUNK7:[GXI?\
M%3?V5/@+^REXU^%GAOX,Q>*+*_\ %V@>)?$?BC2M>\0#7;&QTZ'4=-TWPRVD
M^?9QZG!Y]Q;^)EO&OM0OQ,+:T$(A:*<S?NGA+Q=Q#Q?@<VQ.=O"3IX+$87#8
M2KA\-]7G.I*E5JXKVW+-TI<L7A>14Z=/EYI7NG&WPG%V3Y=D]?!TL"JL95J=
M6I5A4J>TC&*E"-+DO'G5VJM^:4KVC:UG?X ^!7@&/XI_&OX2?#6=)GM/'GQ)
M\%>$K\0,T<J:;KWB+3M-U*=9$^:+[/87%Q.TJC,21&0?=K]%X@S%Y1D6<YI%
MI3R_*\=C*?,DTZN'PU2I2C9Z/FJ1C%1V;:1\WEV'6+Q^"PK7NXC%8>C*VGN5
M*L8RVVM%M^5C]R_V[O\ @F/\%OAM\.OAYI_[-/@3QIJGQE^)'Q<T'P)X;TJ3
MQ;?ZQ#<V$_AOQ9KVMW-Y!JK?8K/3=.M-"2[U#5YYK2WTJ!/M5W=16:7 ;\#\
M/_%3/<SS/,:G%&8X*EDF69-B,?BJJP=*A*-2.)P>'P\:<J*4YU:D\1R4Z,5)
MU6^6,7/EM^@<0\*8#"X7#1RK#5Y8[$XRGAZ4/;2FG%TJU2;DI^[&$8T[RFW%
M06LI*-ST[X7?\$M?V,_V<_"6D>(/VS/B1X3U_P 5ZPD&^+Q;\1!\+OAWI^HI
M&DMQI?AP+KOAO6?$TEK)(8IK[4]1\G4(8X9E\.:4'EA?RLV\6>-^)<96PW!&
M68S#8.BY6^I9;_:V95*5[1JXG_9\31PJDE>-.E2O3;<?K-6R9UX3A+(LKHPJ
M9YB:-2M.W\;$_5,-&5O@I+VE*=6W64Y6DDG[.&J/H3Q__P $K_V'/CAX"?5/
MA-HNG^![W7-.%QX3^)?PR\6:KXET%RF1:W2Z1<^(M4\):_I,DL9CO18K97MU
M%YL=MK-E<;+B+YO+O%OCW(<P5+-\14Q\*%7EQF5YI@Z.&KK^>'M88:EC,-62
M?N<_/"#Y7*A./NOTL3PCD&/P_-@Z<</*I"]'%82M.I3_ +LN1U)4:D-->7E;
M5[3B]5_*3\4/ASXE^$/Q$\:?##QA;+:^)? OB+4_#>KQQ$O;R7&FW#PK>6<A
M"F:POX1%?:?/M47%E<03  .!7]>93F>%SG+,#FN"DY87'X:EB:+:M)1J13Y)
MK[-2G*].I'[,XRCT/Q_%X6K@L37PE=6JX>K*E.VS<7;FCWC)6E%]8M,^V?\
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M8+AO#!N_V75OEE^SM:2_'.U;4EN%;ROLIOI?B&;Y;L/\AMOM0N-_!CW5X/\
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MY%=*MBJDKK#8=R7)&?)4J3DFJ5&:A4</H,CX=QN>3DZ35#"TVHU<54BW%/\
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MZ:[E06_AN74OM&NWME<NORB?P[X>MM.TS41&\R2:G87?V666%X:_AOCS-_\
M77CC$U,HA+$TZ]?"93E2A%\V)5+EP].<5ORXC$RJ5*=U%JE4AS)-,_=<@P?]
MB9%2CBY*G*G3JXO%-[4G*]247_UZIJ,);^]%VTL?QS?$[QG-\1_B3\0OB'<P
M?9;CQYXX\6>,Y[8MO-O-XHUZ_P!<E@W\[O)>^:/=DYVYK^U\JP,<LRO+<MC+
MFCE^ P>!C+;FCA,/3PZE;I=4[GXCBZ_UK%8G$M6>(Q%:NUV]K4E4M\N:QR^D
MZ3J>NZIIVB:)IU[J^LZO?6NF:5I6FVLU[J&I:C?3I;65A8V=LDEQ=7=W<21P
M6UO!&\LTKI'&C,P%=5:M1P]&K7KU*="A0IRJUJU64:=*E2IQ<IU*DY-1A"$4
MY2E)I12N]#&$)U)QITXRG.<E"$()RE*3=HQC%:MMZ)(_JT_8D_9.^'?_  3S
M^!_B7]HC]H2^TK2_B7<^&CJ/C'6+EH;R+X>>')3#):^ O#KPF3^T/$6JWALK
M?5WTPRR:WKKV.@:0;JUM(;K4_P"1..^+\R\2,^PO#?#E.K5RN&*]E@:,.:#S
M+$JZEF&)3M[/#4H*<J*JV5##J>(K<DYRC2_8<AR;#<-9?5S+,I0ABG2YJ\W9
MK#4M+8:E_-5G+E4^3^)4Y:<.913GJ_\ !/+X^^-/VQ?C1^T5^T1XB@N=&\$>
M&;/PU\*?@[X1,OF6_AW0-1O+_P 2^)VN_+)MY_$FL?V3X,O_ !!?QF3SI3:Z
M? ZZ9I.F1)CXD<.X'@K).&N&\-*-?'XJ6*S?.L9:TL3B*<*6%PJA?WHX6A[7
M&T\/3=K+GJ27M:M1E<-9C7SO'9GF51.&'I*E@\#1OI2IR<JM6]M'5GR4)59+
M=VBO<A!+\4O^"MGQ"_X3S]MSXB6<,_VC3_AWHOA'X>Z>X;(7^S=&BUW6( /X
M/LWB7Q'KENRC^.)FX+8K]U\',M_L_@3+9N/+4S*OC,RJ+_K[6>'HO_M["X6A
M+T:70^$XSQ/UC/L3%.\<+3HX:/\ V[#VDU\JM6:^1^:=?J)\J% !0 4 % '[
M-_\ !#3_ ).S^(7_ &;MXL_]65\)*_$/'S_DC\M_[*7!_P#JKS@^Y\/_ /D<
MXG_L65O_ %*P1_5;7\C'Z^% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MU*%.6*I4O8TZT]72IWE)\B;Y8.\I7G%*?*^5RY=#Q[QO^W;^Q[\.YI[;Q/\
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M>"VCR4DG/E45.M*I5:YIR/Z&RC+J>5Y?AL%32O3IIU9)6]I7DKU:C]9:1O\
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M2;?U7$5\.F_Y?=KQ7I%5E%+HDDM$C]4*_)3ZX* "@ H * "@ H * "@ H *
M/\??_@Y]_P"4Y_[=/_7]^SS_ .LG? B@#_7J\*_\BQX<_P"P#H__ *;[>@#\
M@_\ @N?_ ,$L/#G_  57_8C\5?"W2[/2[/\ :'^%_P#:/Q)_9E\77I@M?L'Q
M"LK I>^!M3U.38UKX0^*6EP+X6U[S)?L.G:F/#/B^YMKV?PC8VS '\!?_!N7
M_P %2?$G_!*?]NW6_P!GG]HNYU7P3^SK\>O%\'PC^.V@>+5GTO\ X4C\8O#^
MJW7AOPQ\2=4TZ_\ )/A^3PQKKW?@KXHK-]C\CPI?7.L:LE[=^!M%LT /4O\
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MB+1[Z'-M>0.P!^KE !0 4 4=3_Y!NH?]>-W_ .D\E '^/K_P;*_\IQ_V$?\
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M+GQ]/I]Q ]CJ?A[P!XGTQU198Q0!_HX_\%<_^457_!2?_LP_]K/_ -43XZH
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M^\;^,M%%K!YUS8^)]/MQ'))&I8 ] ^ ?_!:'_@O=^S!\&_AW^S_\"OB!\1O
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MM(LX=/TO3;&W3]H4)!9V-E;P6MM"@"Q0Q(BC"B@#6_XC/?\ @J]_T2[]A_\
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MQ_N9)--\/:C\/?#^IVT;2-INO:'J^GW+)>V]S;6P!_8U_P &M/[/&L_L_?\
M!&W]GVZ\1VYLM<^/?B+X@_M#SV+0F-X-&\=ZVFC>!KAG./M"ZU\//"7A'Q%#
M*%4+;ZQ%;KO$ E< _P Q/]M_P5XN_9*_X*0_M/\ A$V\=AXI^!O[7GQ.N-!:
M2%_LDR^&/BGJFN>#M7AAS'(VF:OID6CZQ9 F*233[R GRV;"@'^UE\ _C)X0
M_:)^!_PA^/7@&]M]0\%?&7X:^"OB;X8N;:XCNHSH_C7P]I_B"R@>6/ ^TVD5
M^+2\B98Y;>[@GMYXHIHI(D /6Z "@ H * "@ H * "@ H * "@ H * "@ H
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M^!P"MOR0G+'U+?W>7!<DNEI\O6S^AX(PWM\]IU+7CA,/7K^5W%8>/SO6NO\
M#?H?5G_!=[XA?:O&?P$^%4$^/[$\,^*?B!J=LK?ZT^)]4M/#NB2RKV-LOA+7
MEA/&1>39R-N/D?H_9;R8+B'-Y1_CXG"9=2E;986E/$UTO\7UO#W[<B/8\0L3
M>OEV#3_ATJN)FO\ K[*-*F_E[&I;U/P#K^BC\X/Z[_\ @C;\/AX,_8PTCQ'+
M#Y5S\3_'GC/QH[NNV4V=A=V_@:Q5LX80;/!\MW;J?D*WC3IQ/N;^,_&S,?KW
M'%?#1=X95E^!P*2VYYPECZEO[U\8H2_P)?9LOVC@?#>PR*%5JSQ>(KUW_ABU
MAX_*U"ZZ>]?J?R[?M%_$'_A:WQ[^,GQ'6;S[;QE\2O&6NZ:^[<%T:\UV];1(
M$;O':Z0+*VB/_/.)*_K#AG+?[(X=R3++<LL%E>"P]5;7KPP]/V\K='*MSR:[
ML_)<SQ/US,<=BKW5?%5JD?\  ZC]FO10Y4O)'[N_\$5OV3M,MO#>K_M6^-=$
MM[K6-7OK_P ,?!][Z$2G2=)TU[G3/%WBRP5]T:7>K:E]H\+V5XJQWEG:Z/KT
M,;?9M8;=_/WCGQ?5GBJ/"&!KRA0HTZ>*SE4Y6]M6J*-7!X.I:S<*-+EQ4X:P
MG.MAVUS45;]#X$R:,:4\XKTTYSE*E@N9?!"%XUJT>EYRO2B[<T53J):3/E[_
M (*?_P#!0OQG\3?B'XJ^ 7PB\3:GX;^$?@N]U+PGXOO-$O#9W/Q,\16-R]EK
MBWFH6C"X?P;IUS!/I>G:5;W L==V76K:F+ZWN=*MM-^K\*?#; Y7EN$XASG"
MTL5G&.A2QF"IUX<\,KPTX\^'<*<UR_7:L)1JU*LH\^']RE2Y)1JRJ>3Q9Q+7
MQ6)K9;@JLJ6"H.5&M*F[/%5(NU1.2U]A%IPC!/EJ6<I<R<%'\7:_<CX0_M,^
M&X_X97_X)N:%J+ :?JGPW_9GN_&$T)'EM'XUU/PG=^++BS7@?OI_&.KR6D;,
M%+S2JS[2QQ_#69_\9;XFXBDOWE+-.*88*+W_ -AIXR&#A/TC@J*F[;)66R/W
M;"_\)'"].7PRPF5.LUM^_E1=9KU=:=O5G\6A))R>2>23U)K^Y3\)/Z8?^"$O
MP]_L_P"&'QQ^*4T&'\5>-_#_ ('L9G7#"V\$Z))K5X;<D9\FXN/'%NDS)\DD
MM@J$EK8A?Y9^D!F7M,VR'*8RTP> Q&/G%?SXZNJ$.;SC# -I=(U+VM+7]5\/
M<-RX3'XMK^-B*="+\L/3<W;R;KI/_#Y'Y#_\%*_B%_PL?]MGX[ZG%/YUCX=\
M36_P_L$#;H[=? &DV'A34HHSZ/KNEZM=.,X$US+C"X _9O"[+?[,X$X?I./+
M4Q.%EF-32SE_:%:IBJ3:\L/4HP7E%'Q?%6)^M9]F$D[QI55AH^7U:$:,TO\
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MYKMW=>)/%%S;(LOV1=9O8$C2%53^(LIP>9^)7&L(8NM/V^:XJ>)Q^(@KQP>
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M&C0@]'B,3.]I5&K:SDI5:K6T%+E6D4?Q]_%OXQ_$KXZ^-=2^(/Q5\6ZKXO\
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 ?_T/[^* "@ H * "@ H _CM_X*]_\ )]/Q)_[%
MOX;?^H+H=?VGX,?\D#EO_87F?_J=6/Q+C3_DH,5_UZPO_J/3/T<_X(-_\B'^
MT5_V-W@'_P!,WB.OS/Z07_(QX:_[ LP_]/X8^H\//]VS+_K_ (?_ --U#]]J
M_G@_10H _FJ_X+<_M)Z+XG\0>!/V:?"VHVVHCP)?OX[^(LEK,)HK'Q5=Z=<:
M7X8\/R%&V)J.E:%J.KZEJ43"3RX_$&EQ!H9X;N$?U!X$<+U\)A\PXHQ=*5+Z
M_367Y8IQY74PD*D:N*Q*NM:56O2HTJ4E:[P]9ZQ<&?EG'N:0JU,/E5&2E]7E
M]8Q+3ORUG%PI4O*4*<I3DO\ IY#9IH^$?^"8/P8O/C'^V/\ "P?99I- ^&>I
M+\6/$EW'&S16<7@F6&_\.K*VWR\7_C(^'; QNRE[>>Y= _E,A_0?%;/(9)P3
MFWO16(S2E_8^%@VDYO'1E3Q+BM_W>"^LU+I:2C%:71\_PG@98W.\)H_9X27U
MRJTM(^PM*E?I[U?V4;=KVV/Z?O\ @H("?V*_VD !G_BV6L'CT62V)/T !)]
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M%IJLK*>"I'!!&".*_MC.-,HS1K1K+L=9K2UL-5M8_$<$O]LPB_ZB<.O_ "K
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MBEQ_JI'\":(L<F/]AB&Q[5_GIQ&TN)<]<E>*SW-&X]TL?7NOFM#^B<M3_LO
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M_P"&^'_S2=7^HF>=\%_X42_^4A_PY9_;,]?A+_X7-Y_\S='_ !''@C_J<?\
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M ?PP_P#!"3_@MY\0_P#@CS\:?$W@OXB^'O$OCS]DSXK:]9Q_&CX6VKFW\5^
M?%FF%-(/Q3^'FF:K+:6,/C32M/A_L?Q7X8OI=*M_&^CZ?IVEZEJ6FZEX?\/:
MEI8!_J)_LD?\%&OV(/VZ?"FE>*OV6OVE?A7\4_[3L8[Z;P?I_B:QTKXF^'P^
M UKXM^%VNR:;X_\ "UW$^4\O6_#UDEP +BRENK22&XD /IWQO\4?AE\,[/\
MM'XD?$7P)\/M/$;2F^\;^+O#_A2S$29W2_:=>U"P@$:X.Y]^U<')&* /S!^'
M7_!<W_@F_P#&S]MCX9_L#_ 'XUGX^_&SXEOX]CM]=^$>D-XE^#_AA_AY\/\
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MH?\ P<S?\$F/$/\ P4K_ &-=*\=?!'0XM7_:D_92NO$?COX<Z);VV_5OB;X
MU?38/^%E?";3'BQ+)XAU9-%T'Q/X)@D6Y%WXD\-+X8M8K1O%]SJ5J ?PP_\
M!"3_ (+>?$/_ ((\_&GQ-X+^(OA[Q+X\_9,^*VO6<?QH^%MJYM_%?@'Q9IA3
M2#\4_AYIFJRVEC#XTTK3X?['\5^&+Z72K?QOH^GZ=I>I:EINI>'_  ]J6E@'
M^HG^R1_P4:_8@_;I\*:5XJ_9:_:5^%?Q3_M.QCOIO!^G^)K'2OB;X?#X#6OB
MWX7:[)IOC_PM=Q/E/+UOP]9)< "XLI;JTDAN) #Z=\;_ !1^&7PSL_[1^)'Q
M%\"?#[3Q&TIOO&_B[P_X4LQ$F=TOVG7M0L(!&N#N??M7!R1B@#\P?AU_P7-_
MX)O_ !L_;8^&?[ _P!^-9^/OQL^);^/8[?7?A'I#>)?@_P"&'^'GP_\ %7Q(
MU<:W\5)KO3?#.M+>Z#X/U2VTJ7X<R^.X&U62RM=2DTR"6:[MP#]:]3_Y!NH?
M]>-W_P"D\E '^.=_P;C^-O!GPZ_X+1?L2^,_B#XM\,>!/!^B:W\9GUGQ7XRU
M[2O#'AK2$O/V</C%IMF^IZ[K=U8Z78+=:A>6EA;-=740GO+JVM8MT\\4; '^
MLU_PW+^Q/_T>%^RU_P") _";_P":V@ _X;E_8G_Z/"_9:_\ $@?A-_\ -;0!
MW_Q&\"?"']K#X">-OAMXEDT#XE?!+X^_#3Q!X.UFXT+5-/UG0?%?@3Q[H-UI
M%W>:%KNG27MA<)<Z;?M=:/K6G33"WN%M=0LIO-ABD !_CM_M5_LV_MA_\$%?
M^"D.GZ?I>OZKX7^)7P1\:6OQ*_9Y^-&G:?/:^'?BI\/)+FYBT+Q/:6TC-9ZE
MHWB317O_  ?\3?!,US?6=M=OXK\#ZO)J%COGO #_ $7/^"6?_!RA^P9^W_X$
M\,^'_BS\1_ W[)_[4L6GVMKXP^$OQ6\3V?A/P;XAUU2MM)J'P?\ B+XGGT_P
M]XJTS6)L7&G>$;W5+;X@Z67GL+C1M6LK"/Q)J@!_0N=?T%=('B!M:TA= -NM
MV-;.I68T@VC %;D:D9OL7V=@05F\[RR",-0!^8W[9'_!:O\ X)E_L+:!/J7Q
MP_:L^&][XE^SS2Z7\+?A5K%I\6OBIK,L>Y8K>+P=X&GU:XT&*ZECDM[;6?&=
MQX8\-&>*:*76X6BD"@'WS\!OC%X6_:(^!OP8_:!\#6NMV/@GXZ?"CX=?&+P=
M9>);2SL/$=GX6^)OA#1_&OAZUU^QT_4-6L++6[?2=;M(M5M+'5=3L[>^2>&V
MU"\A1+B0 _G_ /V=?^#H']C+]J3]N7PI^P=\(O@/^U'KWQ!\:?%WQ3\)]!\=
MIH?PJ;X>7*>$)O$$FL^/VN+?XJ3>)%\$6V@>&M4\62W2^'GU:+P_ UPVD?:4
M:T !_2O0 4 % '^?K_P?,?\ (2_X)B_]>/[9'_H_]EJ@#^B#_@V)_P"4&?["
MG_8+^/O_ *U3\<J /K'_ (+#_L':=_P4>_X)Y_M"?LRQV5G-\0-2\,-XY^".
MH77DQG2/C7X 67Q!X :.\F^33;;Q'>P7'@77K_#-!X6\6:\$5F<"@#_&_L/C
MU\;OAY\#/B[^R)'KFK>'_A;\2?BK\._B%\3O =[!<VEV_C[X*V'Q \.Z!;W4
M$[1R::MN_CS5&\1Z4]LKZCJ_ASPC/?;9O"U@J '^J=_P;"_\$_?^&'/^"8_P
M]\4^+M$_LSXU?M<S67[1'Q'-U;^5JFE^&?$&EPQ?!SP;<LZQW,46B?#UK+Q)
M=:7=Q17.C>+/''BZQD7*4 ?H[_P5S_Y15?\ !2?_ +,/_:S_ /5$^.J /\_W
M_@RZ_P"4K'Q?_P"S%?BS_P"KN_9NH _TV?B9X \/_%CX;_$'X6>+(/M7A7XE
M>"/%?@#Q+;;5;[1X?\9:#?\ AW68-K@H?-T[4;F/:X*G=A@1Q0!_C5_L^?$W
MXX?\$)O^"MVE>(O&/AF>]\>_L@?&OQ/X#^)7A6:U>PC^(7PSU:TU/P;XND\/
M_P!H;8X[3XA_"_Q#/XG^&^OS>=91OJOA;Q-&+NVCC$H!_KS_ +(O[:7[,7[=
MGPBT?XW_ +*_Q<\+_%CP%JBQ1W<NBW)@\0>%-6:%)YO#7CGPG?+;>(O!?B:S
M21&N-$\1:;I]XT#P7UJEQIUU9WDX!Z'\<?V@_@7^S/X#U+XG_M"?%WX=_!?X
M?:1'(]YXL^)'BS1?"6C^9&FY;*RGUB[M3J>J7!VQ6.CZ8EWJFH7,D-I86=Q<
MS11. ?/O[ G_  4)_9Z_X*4?"3QI\=/V8KGQ?JOPM\(?&'QA\&K7Q+XN\.?\
M(J?%^J^#-*\,:O>>*/#>CW%[<:U#X3U2U\56']CR>)M/\.>(I##<_P!H^'-,
MVQ"4 _!O_@\K_P"42O@[_L\GX._^J\^-5 'A'_!DO_R8/^U?_P!G?3?^J8^%
M] 'X=?\ !Z-I/BRV_P""HGP8UC6&,OAG5?V*_AU;>#I(U98((M+^+_QS_MW3
MY,G:^H0ZM?-?SLBC_0=4TM&)*84 _M?_ .#?K]HK]GOX]?\ !*#]C/2?@1XF
M\.7U]\%O@+\-?A#\7?!FFWMH/$7@?XL^#/#EMH?CH>*="1DU#29/%_BC3M:\
M9Z+>WMK%#XBT?6K?6K":Z@N3+0!PO_!>#_@KY\#O^":?[)7Q1\.1>./#6K_M
M=_%CX>ZWX6^!'P:M-2^U^*8K[Q;;3^'!\4/%.FZ:SWGAWP/X,@N=0\00:AK#
M:5!XMU;0U\*:#>-?W%S<:< ?YWO_  ;/?\IPOV#_ /L9OC)_ZS;\9* /]B"@
M#_'Z_P""!/\ RGZ_9'_[+O\ &G_U5WQ>H _V!: /S^_X*R?\HL?^"E?_ &8%
M^V+_ .L\?$2@#_/]_P"#*_\ Y2H_''_LPCXJ_P#J_P#]E^@#_1#_ &__ -EF
MQ_;:_8I_:<_92O;JRTZ?XW_![Q?X,\/:OJ,33:?H/C:;3VU#P!XCO88U:66U
M\.>-[#P_KD\4.)I(M/9(620HZ@'^3Q_P2-_;F^(__!$[_@IS:>)OC-X6\3^&
M?#FB:UXF_9Q_:_\ AI<::S>*--\%W&OVEKXGDMM*D93-XF^'/B[P_HWC/2[>
MVD1]<7P]<>'[:^AL?$4]R0#_ %Y/@/\ M"?!#]J#X9^'?C'^SU\4_!7Q@^&/
MBFUCNM%\8>!=<L];TN0O&DDMA?"W?[5HVMV!<6^K^'M9MM/UW1+U)=/U?3K*
M^@FMXP#Y'_X*7_\ !3G]F?\ X)A_L]^+_C%\;_'/AN+QJGAO69OA!\&1K-J/
MB#\8?&D5K+'H7A[PUX<ADEUDZ+-K#65OXG\7?83H/A+3)9=1U:\B*V\%R ?Y
MEW_!$S]F'XR_\%;?^"RW@[XN?$:WNO$^C>'_ (YW/[:?[5OC<Z6W_"/9TWQU
M+\2$\/7J*!96O_"T_B*+#P9IFA13I<Q:#J&N:AIT$ECX9OC;@'^O90!_C]?\
M$"?^4_7[(_\ V7?XT_\ JKOB]0!_L"T ?S1?\';'_*%OXP_]E?\ @!_ZL?3:
M /RS_P"#'K_DB?\ P4#_ .RI_ C_ -1+XBT ?W4T ?YA_P#P>L_\I/\ ]GK_
M +,+^'/_ *T)^TU0!_>W_P $@_\ E%-_P39_[,6_95_]4EX*H _S$_\ @Y\T
MGQ7I?_!<#]M.7Q:3*VKW'P-U;P]<(&2WN/"<G[.GPEL]#6U#9Q]A@LGTF\90
M$?5+"_=0=VY@#_5<_8M_:*_9[_:F_9C^#WQC_9?\3>&_$7P<U_P+X8@\,VGA
MR\M)_P#A#(['0M.A;X?Z_IULWG>'/$_@R/RM#UOPWJ,%IJ&D7=H;>>UB'E[@
M#^<?_@Z6_P""OGP._9U_8Y^+7[!OPV\<>&O&W[57[1VB0_#KQIX,T/4O[3N/
M@W\(?$$8NO&GB'QVVFL]MHVO^*- C3POX6\(ZI=V>M7=IXI?Q<]A+H>E)'JH
M!_-W_P &8_\ REB^(_\ V9-\7?\ U;'P"H _TB?VQ_VJ/AU^Q%^S!\:?VKOB
MS;:W?_#_ ."'@VY\8:_I?AF+3IO$>M8N[/2]*T'0(=7U'2-+DUK7M:U'3=&T
MM-0U.PLVO;Z 3W4,>YP ?FQ_P2=_X+L_L\?\%??''Q?\%_ 'X(?M#^ (_@KX
M4\.>*/%WBKXL:1\.[+PQO\6ZO>Z3X>\/VMSX.^(?BZ^&NZJND:[J-G!<Z?;V
MDNGZ!JTGVQ9H(H9@#]OZ "@#G/&'B >$O"/BGQ4UH;Y?#/AS6_$!L5F%L;P:
M-IESJ)M!<&*<0&X%MY(F\F81;]_E2;=A /P/_P"">/\ P<N?\$S_ -NKPSH%
MAXM^+'AW]D7X[74"1:]\&_V@_$VG>%]*CU,!59/!'QBU:WT+X=>.-/O)RT.C
MP/?>&_&M[MS=^!M,,D"2@'[[Z5XF\-Z[HEOXET/Q!HFL^'+JV%[:^(-*U6PU
M'1+FS*!Q=V^JV<\UA-;%,.)XYVBV8;=B@#^4+_@YO_X+"_LF?"?]A'X[?L6?
M#;XM>"OBQ^T[^T+I%G\+KWP/\._$NB^*V^%'A&]U73=2\;>(_B==:1/?V7AF
MXG\-V-UH&A>&+VX@\4W^J>(=-U6'3%T.QU#48 #\2O\ @R<_9S\8ZY^UQ^U3
M^U=+I-Q'\./AQ^S^OP+M]:N()XK2_P#B%\5/'W@?QLEEI-R46WO[K0/"GPMU
M"37K>&5Y-*A\5^');N*-=7L'< _O!_X*$?L8> _^"@W[&_QX_9&^(,L.G:9\
M7?!=SIN@^)GL5U"7P/X]TFXM]?\ A[XZM;3S+>2YD\)^,M+T76+BQANK-M6T
M^VO=%DNH;;49VH _R,?A+\3?VV?^"!?_  4DNM2ET1_!GQV_9^\3ZCX/^(/@
M76)-1_X03XP_#759(&U+1+J>)+-O$?PT^(^AQ:=XC\)>(K:(/;3KX:\8:2MK
MKNBV1M0#_3W_ ."=/_!>S_@G7_P47\&>'9?!_P :O"/P:^-UY::?#XF_9T^-
M'BC1?!7Q"TOQ%<0K]KTWP;<ZY/I6D?%?2$N1(+#7/ DNH3O9-:2Z_HOAG4KE
M]'MP#]B=8\2>'/#NEMKGB#7]%T+18T61]7UC5;'3-+2-EW*[7][/!:*C(-RL
M90"O(.* /Q^_;3_X+_?\$L?V&@=)^(O[2OAWXH?$-F@6#X2_LZR:=\9?'>Z9
MD CU:7P_JD7@CP=.L3QW*VWCSQGX5N;JV>.:PANU=-P!^R=Y9VFH6EUI]_:V
MU]87UM/9WME>017-I>6ES$T-S:W5M,KPW%M<0N\,\$J/%+$[1NK(Q% '^/A_
MP6X_X)A?%W_@CK^WE-K?PV;Q%X=^!?C;QS=?&3]CWXN>&9=1TZ;PK%IOB%/$
M-CX"3Q!;OYNE?$?X+:J=/L8YH[Q=0U#1H/"_C6W6T.M/8Z> ?VB_\$<?^#I'
M]E?]K7X>>#_A!^W5\0/!O[,G[6&BV%IH>I>,?&UY:>$O@=\:9K&UAA7Q=HWC
M6^^R^%OASXIUAT:36O!'BN^T;2VU65?^$(U35(+X:#H8!_5GH7BSPKXHT&U\
M4^&?$OA_Q%X8O;47UEXCT+6=.U;0;NR,8E6\M=7T^YN-/GM3$1(+B*X:$QD.
M'V\T ?#G[5'_  54_P"">/[%OA:\\4_M$?M:_!OP=]F$ZVWA/2?%=EXY^)&L
MW%N@+VNA?#3P*?$7CG5'5VAAGN;?03I^GR7%NVIWEE#(): /5_V(_P!L3X3?
MM^?LP_#3]K7X&6OB^S^%7Q8?QL/"47CS1['0/%+0^ _B)XM^&>J76HZ1INL:
M]:V4-[KG@W4[W2D_M.6YDT>>PGOK?3[Z6XTZU /\Z+_@]+_Y2J_!;_LP[X4?
M^KW_ &F: /[[/^"/7_**+_@FY_V8]^S!_P"J<\(4 ?H[0 4 ?X['[4O_ "L@
M_%G_ +3 W?\ ZUC;T ?[$] '^?K_ ,'S'_(2_P""8O\ UX_MD?\ H_\ 9:H
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M"AK^&?$3%5,^\0LZA0?/*69TLHPT5JN;!JCEJC&U])5Z4Y:;N;:W/W;ARE'
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MY2N))]+TWP<JW4<;9ABURU,JC[1":_G[Q^S6G2R?),EBU[;%YA/,9Q3]Z%#
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MB'CY_P D?EO_ &4N#_\ 57G!]SX?_P#(YQ/_ &+*W_J5@C^JVOY&/U\* "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MH[>1^KFK_P#!7G]A338'ELOB9XA\02)&SK:Z1\-O'L,\K*"1$C:]H.AVPD;
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MWQ>S]I3YK;<T>YVX3,,#C^?ZEBJ.)]ERJI[&:GR<]^3FMMS<LK?X7V/YT_\
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M_P"#C_\ X(G?M3_\%@;G]CNX_9I^('[/_@<?L^0?'R'QFGQS\4?$7PU_:?\
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M$^G2:A%=^+;*WM[2*]DMKJ]FA@M[H _O!H _(;_@N-^P#\8?^"F/_!/CQ_\
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M(W[0_C+35DVFW3PEI-E\-_AO>21 _O%OF\9?%.&-F"B)M-<+O,C>6 ?T5?\
M!O?^R%_PQC_P27_90\ ZII?]F>._B7X0/[0WQ,62'[/?-XM^-IB\96%CJL&U
M3%JOA;P)<^"_ ][&WSQR>%]CG<IH _::@ H _F@_X.+?^"3'[=__  5Q\+_L
MW?"?]F/XG_LX_#_X0?"G7O&/Q"^(>D_&OQE\4/#>I^*OB/J&GV/ASP1?Z;9^
M _A#\2K">P\(^&;GQI;PW%[>:;=FX\8WT8M988HY0 >V?\&^/_!('QE_P2'_
M &7OB=X"^,WB+X9>-?C]\9OBO)XS\=>*_A-J/B;6/"*>#O#FAVF@_#CPC8:K
MXO\ !_@37;X:&9O%NOW+77ANT2WU3QEJ5I;2W=M;Q7,@!^^= !0!\6?\%%?V
M/]!_;W_8B_:2_9'UV73;*3XS?#35]#\*ZSJZ3/IGAGXCZ4]OXE^%_BN^%M;W
M=V;+PO\ $/1?#.NWR65O)=S65A<6\"EY0* /Y4/^"'__  ;J_P#!3S_@E7^W
MOX+_ &E/&?QL_8W\0?!K4_!GCKX9_&[PE\.OB+\<-3\8>)? _B;2/[1T>'0-
M.\2?L]>$?#]SJ&B_$?0/ OB3;J?B#38C8Z/?017 EN%1P#]Q_P#@OU_P35^.
M7_!53]AS0OV9_P!GSQ9\*/!OCS2OCYX!^*DNJ_&36_%_A_PC)H'A;PO\0="U
M"RCO_!/@;XA:S_;$MQXML);*!M %E)!;W?GW]LZPI, >:?\ !N__ ,$H_P!H
M;_@DE^S%\;/@Q^T=XS^#/C7Q7\2?CQ-\3]$O?@EX@\;^(_#UGX>;X?>"_"B6
MNJWGCOX>?#?4H=9.I>'K^5K:TTB]L5L7LY1J+SRS6ML ?T#4 ?S _P#!R#_P
M13_:E_X+!?\ #&Q_9I\?_ 'P,?V=_P#AH0>,Q\<_%'Q$\-#5!\6O^%'_ /"/
M'PPW@'X6?$S[8;'_ (5GK8UD:JNBB 7FE?83J'FW8L@#]._^",G[$WQ3_P""
M=7_!-S]G;]COXU>(/ 'BGXE_"1_BZ_B37?A=J?B+6? M[_PG_P <OB7\3=(7
M0]2\6>%O!6OW/V70O&6F6>HF_P##.F>7JUO?0VPNK..WOKD ^%/^"Z__  ;_
M 'PY_P""NNE^%?BIX#\<:5\$/VMOAGX9OO"_ASQUJFAR:GX+^)GA4W#ZGI'@
M7XI+I@_M^QM-#U:?49_#'C'1(M5O_#<6OZ[%=^&O%%M/I]II@!_&Y:_\&K?_
M  79^%VKZCX;^',/P[BT/7-EMK7B'X;_ +4%EX6\,:G C83^U;#4I?!_B2_M
MTP&6.?PQ<.H(Q"&R  ?LI^PG_P &?6J?#'X2?'GQ]^UY\2?AA\3OVI?&WP ^
M,W@3]G[X<Z1/X@OO@5\)_BG\2?AAXK\(^&?B1\2_%NH^%SXC\:Z]X3UOQ!8:
MEIZZ'X.&E^#-3L+CQ+IB^.=:M_#UQI(!]%?\&_?_  ;L_MJ?\$IOVW/%W[2G
M[1'Q1_9<\8^!M=_9W\=?"2QTGX+^-/BQXB\5IXD\3^./AAXDL;RZLO''P4^'
M.D1:'#I_@O58[NZAURXOTO)].BATR>":YN;, _JW_:L^%6O_ !U_9=_:2^"/
MA2]T?3?%'QC^ ?QA^%7AO4?$,U[;:!I^O_$+X>>(O".CWNN7&FV&J:C;Z/:Z
MCJ]M/J4UAIFHWL5E',]K87<ZQV\@!_)O_P $"/\ @W._;9_X)7_MRZO^TU^T
M)\4OV6?&'@2]^ _C_P"&%OI'P:\:_%KQ%XM'B'Q5XC\!ZKI]U-8^-_@C\.]&
MCT:&T\,:BMY<IKLM['<264<&FW$4L\]J ?VB4 % !0!EZWH>B^)M%U?PWXDT
M?2_$'AW7],OM%U[0=;T^TU71=;T;5+66QU/2=7TN_AGL=2TS4;*>:SOK"\@F
MM;NUFEM[B*2*1D(!_%1_P46_X,V/@?\ &3Q1K7Q/_P""?/Q>LOV:M:UR[O\
M4]1^!OQ-L-7\4_!9=0O9'N O@?Q1HPN_''PXT=)V;=H5UI'Q%T^W280:#'H&
MF65MI1 /YZO$O_!I!_P6A\(:L\/ASP#\$_&JV\\\,&O>"OC]X6TRTEC02(MS
M;?\ ";)X(UF."Z48B6;3;>Y"RJ+BW@_>! #TKX9?\&</_!6'QEJ6F1^._$'[
M+GPATBXN(?[6OO$7Q5U_Q3JFG698&YEM-)\!>!/$=GJ=]''G[/9OKFGVUQ-M
MCEU*UB+7" ']LG_!$#_@B+X._P"",_@;XUZ?IOQW\2_'CQ_^T++\,;GXA:U?
M>$=+\"^#](;X6P^/5T*S\&^&X-3\2:U")G^(VN)JVH:WXJU(ZDEGI,MGINAF
M.[AN@#OO^"S7_!&KX+_\%@O@;X;\$^+/$LOPG^-7PKU'5-;^#'QMTW0+7Q%=
M>'9-9LTM]>\'>*-%EN]+FU_P!XHDM-)O-5TVSU?2M3L=7T31]7TS4%%MJ&FZ
MN ?PGZK_ ,&H'_!;WX)>++P?!RZ^%'B*.Y:YTL^-OA#^T=_P@:WFD/*8U-_'
MXOMOAUXB6UNH<2SZ>+*\V9:(K*0"P!^N'_!*[_@T,\9>$/C)X8_:,_X*C_$#
MP/X[@\*:Y9^+M(_9P\ ZOJ?CBR\9>)M.OXKS3Y?C?X\UW2M.LM4\.PW-M]HU
M/P-X:M];M?%<<EK;ZWXNATI=7\.ZJ :'_!);_@UU_;U_8*_X*7?L^?MB_%CX
MN_L?Z_\ "CX1^)?B9J^MZ!\-?'/QEU3QY=V/B_X5_$/P-HL&B:-XD^ 7@_PV
M\MOJGBO2YM0BN_%=A#:Z;!>R6DM[<0V]G= ']XE '\'W_!,7_@UY_;X_8M_X
M*?\ P._;3^*/Q@_9!U_X4_#'XE?$7QEK>A> ?'?QFU3XA7NF>*_!?CSP[I4&
ME:/XB^ ?A;PW+?QWWB?3I-0BN_%ME;V]I%>R6UU>S0P6]T ?W@T ?+_[;OP3
M\4?M*_L8?M<_LY^!]0T#2/&GQ]_9B^/7P5\(:KXKN=0L_"^F>)_BG\*_%7@;
M0-0\27>D:7K>JVF@V6JZ[:7.KW.F:+J^H0:?'<266F7]RL=K* ?R_?\ !O;_
M ,&\W[:'_!)S]M'XD?M&_M%_$_\ 9@\9^"O%_P"S-XT^"^EZ3\%?&7Q6\1^*
M(?$_B3XG_!SQK9W]_9^.?@M\.-)AT&'2_AWK%O<W-OK5WJ"W]WID46F2V\MU
M=68!_9#0!_(O_P %BO\ @U2^#/[=_P 0/%?[2_[(/CKPY^S)^T7XSO+G7/B%
MX2\1:/?W7P*^+'BF^N))]0\6Z@GAV"Z\0_#3QCK,T\E[XFUWPYHOBC1_$E[%
M_:%WX.M_$6IZWXEU  _F8L/^#7/_ (+W?":_U?PK\,8?"-IX=U2Z\O5-8^&/
M[5FE^$O"FNK#+'#%?7FF:AJG@W7KR$QJL\(U'PR+Q((@KVT4X2 @'Z<_\$M/
M^#2;]L/X1_M7_ ;]K']L'X^_"?P%%\ /CE\+?CKI'P^^&TNO?%OQGX_U_P"%
M_C?0O'MIHGB7Q)JEKX-\.>$=-U;4M&@M;W6=/N_'6HR0&[5=,M9)+>] !_H+
M4 ?Q??\ !7G_ (-)? 7[6?Q,\7?M(_L#_$'P5^SU\4_'6IWGB'Q]\%?']CK$
M'P.\4^*=2GGO=8\4^%=>\*Z;KNO_  QU+6;R1[O5= MO"GB?PM?:A<O<Z7;^
M$8A/%> '\[N@?\&OO_!?3X4ZE?6'PR\/>'_#]I>3>3>:S\./VK_"?A+3-2C^
M=?M$\(\3^&M8G@VQ)\MUI(N-LD0^S_+*(@#[/_9;_P"#,;]L_P")_C2T\5_M
MS?M(_#'X2>$;V_AU/Q/IGPTU37?C1\:->W3"75+&;5M;TGP]X$T#4+Z/,4'B
M=O$'Q %I<NUU<>&]1CA6"Y /]$_X/_##PW\$OA+\+O@QX.DU.;PC\(OAUX)^
M&'A676KF&]UF7PWX!\-:9X4T.35KRWM;&WN]3?3-)M6O[F"RLX9[HRRQ6MNC
M+$@!_*5_P</_ /! #]L7_@K7^U%\%OC=^SC\2_V:/!7A;X<_ .T^%6N:=\;?
M&'Q2\-Z_<Z_;?$/QSXM-[I-MX$^#?Q)TZXT=M.\464 FO-3L+T7L%U']@\A8
MKB4 _HS_ .">G[//C+]DO]AK]D[]F7XB:IX8UOQW\"?@/\./AAXNU?P7=ZK?
M^$M1\0^$?#EEI.J77AN^US1O#NL7FC2W=O(VGW.IZ#H][-;[)+C3;.1F@0 ^
MQZ "@ H * "@ H * "@ H * "@ H * /\=W_ (..OVV)OVV_^"KW[0^N:7J,
MM[\-_@#J0_9@^%L19C;IH?P@U+5=-\7ZG:](Y;;Q-\5;WQ]XCT^[2)&FT74M
M(A<RBUCD(!_I4?\ !"3]C#_AA3_@EK^RO\&]6TK^ROB'XC\%1?&CXO12P>1J
M*_$OXP[/&FK:3K"[5#:EX)T>_P!!^'3NHP;;P=:C?+CSI #]>J "@#Y,_;N_
M96\,_MO?L=?M&_LH>+/LL6G?&_X5^)O!VG:E>1&:#P[XO:U&I^ ?%WE!)"\W
M@WQUIWAWQ5;)Y;YN='A&QA\I /\ ',_8"_:2\>_\$O\ _@I'\$OC=XCTW5O#
MNO?LW?'2X\*_&CPGL8:L/",>I:E\-OCGX+FMHRR/JC^$K_Q;I%LCK/';:U':
M72Q226L= '^T-\6]2L->^ 7Q-U?1KJ'4M,UGX/\ C/4M)O;-O.@U"PU'P7J5
MS8W5JR_ZV&ZMYHI8&4?.CJ1UH _PN/@I\:?BA^SI\5O GQP^"OBZ^\!?%7X9
M:_:^*/ WC'3;;3;R]\/Z[9K(EO?P6FL66HZ5=%4EEC>WU"PN[2:.1XYH)$8K
M0!^MS_\ !QW_ ,%M[Y39K^WI\17-QB%4M/A_\%(+EF?Y56"6T^&$=RDA. I@
M=9,_=.: .2\0_M/?\%W/^"@YA^'T_P 1O^"BG[1=AKD4EL_@'P#9?&6^\)ZQ
M;7'R32:OX/\ ASIEAX6O[...1EFO=7TR6VLK5Y?,G@M3)0!^H'_!/K_@T1_;
M\_:2U?2O%/[7]SI?[%?P?6[MIK_3M=ETGQQ\=O$NFAHY9H/#G@/P_JESH7A,
MW42SV+ZG\0O$6DZKHMR\%^G@;Q':*UO( ?Z,W[$7["/[,/\ P3Q^!^B_ #]E
M?X;Z?X"\%Z>T=]KNIR%=1\:?$'Q.;:*VO?&GQ$\52Q1W_BGQ1J"0HKW5QY.G
MZ79I;Z+X=TW1?#]AIND68!]@4 >1?'KX#_"3]I[X._$+X _';P3I/Q$^$OQ2
M\.W7A;QMX0UD3+::II=RT<T<D%U:2VVH:5JVF7T%IJVA:YI5U9:QH.MV.GZS
MH][9:G8VEU" ?YBO_!6+_@U=_;)_8V\4^+_B=^QUX8\4?M<_LL->3ZGH]GX0
MM#KW[0GPWTF4^:-'\;?#K2+*'4/'%OI.XVT7C'X;Z?JPOK*VDU?Q%X8\&QYB
M(!^:_P"RS_P6U_X*V?\ !.RUA^$7PP_:3^)'ASPEX+WZ*OP0^-?AO2_B'X=\
M)0PC(T'2_#7Q2T35M<\ 6MI(1,FD^%+SPQ%%(S[H"EQ<)* ?=VM?\'=G_!9;
M5-)FTZQ\?? ;PW=RQ>6FO:+\!_#4^JVS^6B>?##XBO->T,RAE,H%QHT\'F2.
M/)\H1Q( ?&E_X^_X+H?\%S-?'AIM4_:S_;*T=-5M_M.@Z#8-X6_9W\-:U"RM
M:WNN:=X?L_ O[._@?48RZ>3JNMQ:)<J-H6[VC@ _U[_V?_"NN>!?@-\$O!'B
M>T73_$G@[X1_#;PKXAL$N;:\2RUSP]X-T;2-6M$N[*6>SNEMK^SGA6YM)YK:
M<()8)9(F1R >NT % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M[RDW*3>[;=VWZL[;X4>"+CXE_%'X<?#JT#_:/'GCKPEX.B,?WD;Q)KUAH_F
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M]S]=S:LL)E&/K0M%4L#7]ERV45+V3C24;:)<SBE;1+8_A&K_ $"/YZ/Z^_\
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M_B/L>!\-[;/(5;:83#5ZWES22P\?G^^;7^&_0^G_ /@N]\0OM7C7X"_"F"?
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M*?/6<*<OF\DR/%YUB8TZ4)0PT9+ZQBG']W2ANTF])56M(4UK=IRM!.2_L_\
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!__]+^_B@
MH * "@ H * /YLO^"CO[ ?[6OQY_:O\ &WQ+^$_PH'BOP3K&A^";33]9'COX
M:Z%Y]QI'A72],U"(Z=XE\8Z-JT1M[VUFBWRV*1RA1) \D;!J_I[PQ\0^#N'N
M$,%E><9O]3QU'$8Z=2A_9^:8CEA6Q52I3?M,+@JU%\T))VC4;6TDGH?EW$_#
MF<YAG%?%8/!^VH3IT%&?UC"T]8480DN6K6IS5FOY;=CX6_X=0?M^_P#1!/\
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MHR7E[?7J/M/_  3S>U^7)Y'Q_P#J]GG-R?V5C;_]>)\O_@=N3_R8_3C]C/\
MX(]_$&\UVS^(W[46F:?X>\/Z-$-3T+X3?;].U?6/%6K1QO-I\/C*6QGN](TC
MP]'.+:6\T?[7>ZCJH,NFZG!I%NLXN?RKC?QHRZ&'GEG"=6IB,16?LL1G'LZE
M"CA*+:C4>!4XPK5L2X\RA6Y(4Z.E2E*K+EY/J\CX)Q+J1Q6;0C3IT_?IX+FA
M.=::UBJ[BW"%*]KT[N4_AFH*]_BK_AU!^W[_ -$$_P#,I?!;_P">+7W?_$7_
M  [_ .BA_P#,3GG_ ,[#P?\ 4[B/_H7?^7> _P#FD_K+_9L\(^(/A_\ L[_
MCP)XML!I7BGP9\'?AKX5\2:8+JROAIVO>'_!NC:5J]C]MTVXN]/O/LE_:3V_
MVJPNKFSG\OS;:XFA9)&_C[BC&X;,>).(,PP=3VN$QV=9GB\+5Y)T_:8?$8VM
M5HU/9U(PJ0YZ<HRY*D(SC>THQ::7['E="IALLR_#UH\E:A@L+1JPO&7+4IT(
M0G'FBW%VDFKQ;B^C:+WQQ^!OPW_:)^'.M?"[XIZ&NM^&-8\N9&BD^RZIHNJV
MH?\ L_7M!U!5:33M9TUY'-M<*LD,L,EQ87]O>:9>7ME<9Y#GV9\-9G0S;*:_
ML,50NM5S4JU&5O:8?$4WI4HU$DI1T::C.G*%2$)QK'Y?A<SPL\)BZ?M*,[/3
M2=.:^&I3E]B<>CV:O&2<)2B_YDOC_P#\$:_VE?AQJM]>_!Y=-^-W@K=-/9/I
M]]I?AOQM86@<E+?5O#NMW]I9W]S'&4C27PWJ>IR7S(\W]EZ=N6U7^I^'/&WA
M?,Z-.&=>UR''6C&:J4ZN*P%2=K<U'$T*<YTXMZN.)I4E334?:U+<Y^4YCP/F
MF%G*6!Y,?0U<>64*5>,>TZ522C)K:]*<G+?DCL?%LG[#'[8T5S]D;]FCXS&7
M<%W1^!-<EM<G./\ 38K5[+;\IR_G[%XW$;ES]RN/^"7#G_UHR2UMGCZ"E_X+
M<E/Y<MSPO]7\[3Y?[*QU_P#L'G;_ ,"2Y?Q_0^G/@K_P2'_:[^*&I6+>,?#6
MG_!?PI,X-YK_ (XU"PNM6CME($O]G^#=%OKO6Y[X YAMM8_X1ZSFP0VI0@9K
MY7//&;@W*:518'$U,\Q<5:&'P%.I"BY=/:8VO3A0C3[RH?69KI29ZV X+SK%
MRC[>E' 4?M5*\HN=NO+0IR<W+LI^R3_F1_2]^RE^R3\*_P!D3X??\(5\.K.:
M[U35&M+SQIXUU58SX@\9:O:Q/'%=7S1YBL=-LA-<1Z-H=GBRTN">9LW6H7>H
MZC??RWQ=QAFW&68_7LRG&%*DI4\#@:-_JV"HR:;A33UG5G:+K5Y^_5<8_!3A
M3IT_U3)\FP>2X;V&%BW*?*Z]>?\ $KS2M>5M(QCKR4X^[!-[R<I2^HJ^4/6/
MQI_;L_X)/>'?VA->U;XM_!#5=(^'_P 5=6>>^\4Z#J\=Q'X*\=ZDR@MJC3V,
M5Q<>%_$=V5)O[ZVL+[3=:N2MU?V=GJ$VH:Q=_MOA_P"+^)X;P]')L]HULQRB
MBHT\)7HN+QV7TE_RZ49N,<5AH+^'3E4IU*$?=ISG35.C'X?B#@ZEF52>,P$X
M8;&3]ZK3FG]7Q$OYKQ3=&J_M2491F]914G*;_"3QG_P3G_;7\"WT]CJ?[/7C
MK5_)R4O/!=M9^.K&XBR=DL$_A&\UC[X&X03)#=H"!-;Q/\@_H# ^)G N/IQJ
M4N(\!0OO#'2G@*D7VE'%PH[=XN4'TDT?GM?AC/L.W&66UYVZT%'$1:\O8RG]
MS2:ZI#O"'_!.7]MCQI<VEMIW[/7CG2ENI8XS=>+HM/\ !=K:HY&Z>[;Q3?:3
M+%%$N7D"PO,0NR*&24K&QC/$S@3 PG*IQ'@*S@F^3!.IC93:^S#ZI3JQ;>R]
MY1ZMJ.H4>&,^KN*CEM>'-;6LHT%%=Y>UE!I+JK7[)NR/Z;/^"<'[)WCG]D#X
M'Z[X"^(>N>&]9\2>*?']_P".KB/PM+?W.F:1%?>&_#&AQZ4U]J%EITM]=PG0
M'GN)X;**V#7 A@>X2+[1+_+'B;QA@.,\^P^89;A\30PN$RZG@(O%JG&K6=/$
MXJNZOLZ4ZBIP?UA1C%SE+W;OEORK]6X7R;$9)@*F'Q-2E.K5Q$L0_8\SA!2I
M4J:AS2C%R:]G=M12ULKVN_S"_;T_X)(_$'4_'WB?XP_LO:;I7B'1?%NIOK6N
M?":*YL=!UCP_K&H,)-6O/"<VIW-IHFHZ%>7IN-3;26O=,O=(>Y-AH]EJ%BL,
M5G^J^'OC'EU'+L)DO%=2KAJV#I*AA\X<9XBCB*%/2C#%QI0E7I5Z=/EI*LH5
M85E!3K3IU&W/Y/B+@S$RQ%7&Y3"%2%:?/4P=XTYTYR^.5%S<:<J;=Y<G-&4+
M\L(RC91_*[_A@O\ ;,_M0Z/_ ,,U_%O[6I ,O_")WW]E<G;\NN[?[$89')74
M" N&)"X-?K?_ !$+@CV7MO\ 6C)^3^7ZW#VNW_0/_'^7L_(^1_U=SSGY/[+Q
ME^_LGR?^#/X?_DQ^F_[.O_!'3XA6'@'XD^/OCGIVES^/V^&?CVR^$WP<L=6T
MB_#>.M5\':O8>&-5\8^(?M@\.6L^FZU=6D^D:=::G<6$.I1VFJ:OK%M;V,FG
MW'Y5Q-XU9=4S#+,NR"I5CERS3+YYQG4Z-:G_ +!1QM&IBJ."P_)]9E&I0A-5
MJDZ4:DJ3E2HT92FJB^KRO@C$0P^*Q&80@\1]5Q$<'@8SA+_:)T)QI3KU.;V2
M<)M<D%)P4DISJ)1Y7\1C_@E!^W[_ -$$Q_W5+X+\?E\1?Y"OO?\ B+_AW_T4
M/_F)SS_YV'@?ZG<1_P#0N_\ +O ?_-)_9?:QM%;6\3C#QP0QL!SADC52,C@X
M([5_$<VG.36SDVO1L_<5LO1'\WO_  4@_8$_:T^/7[5OC'XE?";X4#Q9X*U;
M0/!5E8:R/'7PUT+SKK2/#5AIVH0G3O$OC'1M5B-O=V\D>^6Q2*4 / \D9#5_
M3?ACXA\'\/<(X/*\XS?ZGCJ6)QTZE#^S\TQ'+"MB9U*;]IA<%7HOF@T[*HVM
MI)/0_+^*.',YS'.*V*P>#]M0G2H1C/ZQA:>L*48R7+5KTYJS5OAMV/N#_@DS
M^S)\;_V9OA[\6]$^-W@H>"M4\4>,M#U30[3_ (23PEXD-[I]EHDEI<7'G^$M
M=UZUM@EPXB$5W/!.V"ZQ&/#GX/QAXJR'BG,LGKY#COKU'"8&O1KS^JXS"\E2
M==3C'EQF'P\I>ZKWA&45M>^A]!P;E6/RK"XRGCZ'L)U:\)TX^UHU;QC3Y6[T
M:E1+72S:?E8_6FOQX^Q/E']N+X:>-?C#^RE\9?AK\.M&'B'QKXKT#3;+0-&.
MHZ5I'V^ZMO$NAZC+#_:.N7VFZ3:D6EE<2![V^MHB4$8?>R*?KN \TP.2\79)
MFF95_JV!P>)J3Q%?V5:M[.$L-7II^RP].K6E[\XJU.G)ZWM9,\?/\+7QN3X[
M"X6'M*]:E&-.GS0AS-5:<K<U248+2+^*21_-3\.?^"6G[=NA_$+P)K6K? P6
M>E:/XR\+ZIJ5V?B;\'IQ:Z?I^MV-W>7!@M?B!/<S""VADD\JV@FGDV[(8I)"
MJ'^HLS\6?#^OEN84*.?\]6M@<71I0_LK.H\]2I0J0A'FGET81YI-*\I1BMVT
MM3\MPG"/$%/%8:I/+^6%.O1G-_6L$^6,*D7)VCB6W9+9)OLC^P2OXO/VH^6O
MVU_AQXR^+O[*_P 9_AO\/='&O^,_%GA>'3_#^C'4-+TK^T+R/6=*O#!_:.M7
MNG:5:G[/:S,)+V^MH<J%\P,R@_6<"YG@<FXMR/,\RK?5\#@\6ZF(K>SJUO9T
M_8U8<WLJ%.K5G[THJU.G)^5CR<]PM?&91CL+AH>TKUJ/+3AS0AS2YXNW-.48
M+1?:DD?S)^"_^"5_[>.E>,?">IZA\"A;6&F^)="O[ZX/Q.^#DHM[.SU2UN+F
M8Q6_Q"EGD$4,;OY<$4DK[=L<;N54_P!48[Q;\/JN"QE*GG_-4J87$4Z<?[*S
MM<TYTIQC&\LMC%7;2O)J*ZM(_*</PCQ#3Q%"<LOM&%:E*3^MX%VC&<6W98F^
MB6R5^R/[$:_BL_;#YF_;)^'OB_XK_LO?&OX=> =)&N^,?%O@N[TGP]HYO],T
MO^T-0>ZM)8[;^T-8O-/TNT+I"^);Z]MK<$ -*N17U/!.98+)^*\BS+,*WU?!
M8/'0K8FM[.K5]G249)R]G0A4JSM=:4Z<I=HGE9WAJV,RG'X7#P]I7K8>4*4.
M:$.:5U9<TW&$=MY22\S^7_PM_P $J_V]-/\ $WAV_O/@2(+.QUW2+N[G/Q/^
M#<@AMK;4+>:>4QP_$*29Q'$C/LBCDD;&V-&8A3_5F+\6_#VIA,52I\0<TZF'
MK0A'^RL[5Y2I2C%7>6J*NVE=M)=6D?D]'A#B&%:E*67VC&I3DW];P.B4DV[+
M$WT2Z+T1_75X_P# ?A;XG^"?%'P\\;:5!K?A/QAHM]H.NZ9/PMQ87T)B<Q2#
M]Y;7=NQ2YL;R I<V-[#;WEM)'<01.O\ &V79AB\JQV$S+ 5I4,9@J]/$8>K'
M[-2F[JZVE"2]V<)7C.#E"2<9-'[-B</1Q>'JX:O!3HUZ<J=2#ZQDK:=FMXR6
ML9)-6:1_)]^T-_P2*_:@^%/B:\'PP\/R?&[P#,]Q/I&N^&9=.M?$EG:*_P"X
ML?$?A6^O;:]75%C/^NT#^V=-N53SA-9S2_8(?Z_X;\9>%,WPL/[5Q"R',(J,
M:V'Q4:D\+.=M:F&Q=.G*'LK],1[&I#X;32]I+\>S+@O-L'5E]4I?7\,[N%2D
MX1JQCTC5HRE&7/;K3YX/>\7[J^<_"/\ P3T_;1\9ZM!H^G?L[?$72I)KG[.]
M]XNTC_A"](M@IQ)<3ZIXIDTFT^S1J&?S())FF "6J7$KQQO]+C/$G@; T95J
MG$F6UE&/,J>#J_7:TM-(QI8559<SVM)1Y?M.*3:\RAPSGM>:A'+,3"[MS5H>
MP@O-RJN"LO*]]HIO0_1_Q]_P1V^(W@O]EBSL_!&CZ=\6_P!ICQ%\1?"FI^)$
MTW6O#WA_0_!O@:P\/^,(]1T+PUJWC+4_#MOJ/GZSJ&ARZY?RRVUUJ4MM81Z?
MI<-GIMS<WOYCEWC5EF.XMG/'UJF3\+8;+<92PKJ4,3B*^-QU3$8)TJ^*HX*E
MB94[4:==4*<8RA24INI5E.I&,/J,1P3B:&3J.'IQQN:U<31E5Y9TJ=.AAXTZ
MW-3I3KSI*5YRI^TEI*=HJ,%&+;S?V /^">G[7_P3_:Z^$/Q/^)_PB'ACP-X6
MG\:2:[KA\??##6?L2ZK\.O%VA:?C3/#WC35M7N3<:KJEC:XM-/G\KS_/G\JV
MBFFCV\1/$C@O/>#<YRK*LY^M8_%QP*P^'_L[-:'/[',L'B*G[W$X&C1ART:5
M2?OU(WY>6-Y.,7'#?#6=8#.L%B\7@O98>BZ_M*GUC"3Y>?"UJ<?<I5YS=YSC
M'W8NU[NR3:]U_P""J/[(/[8O[3/QQ\)ZE\)O UYXX^%OA?X>V%EI<3>.OAYX
M>T_2O%=_K&LS>)WATCQ1XLT&_-[>V4/AT76HBSEBN+>UL;:.Z861A@^?\).,
M^"N%LAQE+.,?# 9MB\RJ3JOZAF6)J5<'3H4(X5.KA,'B*:A"I+$\E+GBXRE.
M3A[Z;]#B_),[S7'T98+#O$82EAHQBOK&&I1A6E.HZMH5:U.7,XJE>7*TTHI/
MW;+\P_\ AU!^W[_T03_S*7P6_P#GC5^K?\1?\._^BA_\Q.>?_.P^3_U.XC_Z
M%W_EW@/_ )I#_AU!^W[_ -$$_P#,I?!;_P">-1_Q%_P[_P"BA_\ ,3GG_P [
M _U.XC_Z%W_EW@/_ )I#_AU!^W[_ -$$_P#,I?!;_P">-1_Q%_P[_P"BA_\
M,3GG_P [ _U.XC_Z%W_EW@/_ )I/VG_X)'?LJ?'K]F'3_CS%\<? @\$2^-+S
MX;2>&H_^$H\&^)3J,?A^#QRNK/N\(>(=?2S%JVM:<H%\UJT_GDVZRB&8Q_AG
MC'Q=P]Q55X?ED&/^OQP-/,UBG]4QN%]D\1+ ^Q5L9AL.Y\RH5/X:DH\OO6NK
M_=\&9/F.4QS%9AA_J_MWA?9+VM"KS*DL1S_P:E3EMSQ^*U[Z;,\L_P""L'[&
M'[2G[2WQ=^&GBGX)?#@>-=#T#X</H&KWG_"8> O#AL]6_P"$FUC41:_9O%OB
MC0;J<&SO()1/:P3VXW&,RB160>MX0<;\+\+9/FF$SW,_J-?$9E'$48?4LPQ/
M/16%HT^;FP>$Q$(^_"2Y9RC+2]K69Q\8Y%FF:XS"5<!A?;TZ>%=.;]MAZ7+/
MVLY6M6JTV_=:U2:Z&E_P29_8X_:._9F^(GQ9U[XW?#L>"=*\2^"]%TC0[G_A
M+O OB0WVH6NN&\N(!!X1\3:]/;"*V <RWD5O"V0D3N^5&?C!QKPSQ3EN3X?(
M<R^O5<+CJ]:O'ZEC\+[.G+#J$9<V,PN'C*\M+0<FK:I(O@W),SRK$8VIC\-]
M7A5H4X4W[;#U>:49MM6HU:C5E_,DNQ^D7[<7PT\:_&']E+XR_#7X=:,/$/C7
MQ7H&FV6@:,=1TK2/M]U;>)=#U&6'^T=<OM-TFU(M+*XD#WM];1$H(P^]D4_F
M' >:8')>+LDS3,J_U; X/$U)XBO[*M6]G"6&KTT_98>G5K2]^<5:G3D];VLF
M?49_A:^-R?'87"P]I7K4HQIT^:$.9JK3E;FJ2C!:1?Q22/YI?A__ ,$L_P!N
M[1?'O@C6=4^!@M-,TGQ=X:U/4;H_$WX.S"VL;#6;*ZN[@PVWQ!FN91#;Q22>
M5;PRSR;=D44CE4/]1YEXL^']?+L?0HY_SU:V"Q5*E#^RLZCS5*E"<(1O++8Q
MC>32O)J*ZM(_+,+PCQ#3Q.'G/+^6$*]*<G]:P+M&-2+;LL2V[);)-]D?V$5_
M%Q^UG(?$'2K[7? /C?0]+A%QJ6L^$/$NE:=;F2*$3WVH:->V=I"9IWCAB$D\
MT:>9-)'%'G=(ZH"1V9=5IX?,,!7JOEI4,9A:M25F^6G3KPG-\L4V[1BW:*;>
MR1CB(2GAZ\(*\IT:D(K17E*#25W9+6V]D?Q\?\.H/V_?^B"?^92^"W_SQJ_M
M+_B+_AW_ -%#_P"8G//_ )V'XG_J=Q'_ -"[_P N\!_\TG]=/P5\.ZOX0^#?
MPE\)^(+06&O>%_AGX#\.ZW8B>VNA9ZOHOA;2M-U*T%U9RW%G<BWO+::$3VL\
MUM-L\R"62)E<_P :YWB:.,SK-\7AY<^'Q6:8_$T)\LH<]&OBZM6E+DFHSCS0
ME%\LHQE':235C]HP-*=' X.C47+4I87#TIQNGRSIT80DKQ;B[--73:?1V/ _
MVS/V+/AO^V3X#MO#_BB63PWXV\-B\G\!?$'3[5+K4/#MW>+%]JLKZQ:6V36O
M#NI/;6QU+2)+FVD+017.GWMA=QB8_1<$<<YGP3F$L1A$L3@<3R1S#+JDG"GB
M80OR3IS2DZ&)I*4O95E&2M)PJ0J0?*>;GF187/,.J=7]U7I7>'Q,5>5)NUXR
MCISTI67-"ZV3BXM7/YF_BU_P2I_;-^%VJ7<%A\-&^)^@QSO'8^)?AKJ%EKL5
M]%RT;OX>FFLO%EC)Y>WSEN=#%M'-NB@O+I565_ZER?Q<X'S6C"53-/[*Q#BG
M4PN9TIT'3?5+$1C/!S5_AY:_,XV;A%^ZORO&<'YYA)M0POUNFG[M7"RC.ZZ?
MNFXUHNVZ]G:^BD]SPVR_8;_;$O[C[-!^S/\ &A)/,$6Z\\ Z_IUON)QG[7J%
MG:VOE_\ 37SO* Y+A>:]Z?'W!5./-+BG)&K<UH9AAZDK?X*<I3O_ '>7FZ6/
M/CP_G<G995CET][#5(+[Y1BOQL?8?P4_X(V_M6?$34;.7XDV_A_X)>%FE4WM
M]X@U33O$WB=K3C+Z5X7\,:A>127.?E%OKNN>'=H#.7.$CD^+SWQMX1RVE..5
MRQ&>XM)JG##TJF%PBGVJXK%4X24?[V'P^)OHO->W@.!\XQ,HO%*E@*/VG4G&
MK5M_<I4I-7\IU*?Y7_K5M8!;6UO;!MPMX(H Q&"PBC6,-CMG;G':OX\E+FE*
M5K<TG*W:[O8_9$K)+LDONT)ZD84 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '\1?_  6._P""
M(G[??_!3G_@M#\(?C!J'PZ\,S_L%>$++]G7X6ZUX[E^*/@>RUJV^#F@ZY+XY
M^,[6_@.YUNV\7G6WUSQCX_TC2H+72)O[19=)NUN!:.6M@#^VZWMK>SMX+2T@
MAM;6UABMK:VMXD@M[>W@18H8((8E6.&&&-5CBBC54C151%"@"@":@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * /Q!_X.$_V5_VO?VV/^";
M/C;]E[]C+P?I'C;Q_P#%3XF_"N#QOH^L>-?#7@.)?AAX0UZ3X@:E=6VL>*]1
MTK2KBX7QEX3\#6KZ8;Z*>YL;N\EC65+:6%P!?^#?3_@G'XV_X)E?\$Z/!_P6
M^,.AZ5H/Q_\ '7Q \??%SXWZ?I&KZ3XCL[#Q1KNHP>&?#&D6WB+1;B\T[5(=
M+^&GA+P3'.;&[GL8=9FU@6KN)'FF /V]H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MWEV]K;)%!"FYF;;&BKDDXR: +M !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?
M.W[7W_)IG[4/_9NWQK_]5KXEKZ7@S_DL.%/^RER+_P!6F%/,SK_D39M_V+,?
M_P"HM4_A K_0,_GH* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H ]Y_9?\ B'X(^$G[07PE^*'Q%TW7=7\(?#_QEIOB[4M.\,VFG7VNSW.@
M^9J.B'3[75M3T;3I9(==@TRXD%SJ=HJV\4KH[2K'$_SW%>6X_.>',XRG+*N'
MHXW,<%4P=*IBIU:>'C&O:G7]I.C2KU(IX>56*Y:4_><4THW:]'*<3A\%F6"Q
M>)A4G1PU>-:4:2BZC=/WJ?*ISIQTJ*#UFM%\C],O^"C/_!2WX4_M:?!CPY\*
M_A/X:^)WAZ2#Q_IWBOQ-=>.M(\+:7:WFF:1HNN65EIUF?#_C/Q1+.[ZEJT%]
M,MQ!:1I_9T!29R3'7Y9X9^%N;\'9YB<VSC%95B4\NJX3"PR^MBZLX5:U:A.=
M2:Q&!PD8I4J,J<>64W^\?NK1GU?$_%6#SG 4L'@Z6+I-8F%:J\1"C",H0IU(
MQC'V=>JW[\U+5+X5KT/Q=L_LGVRT_M#[0+#[3!]M-HL;78M/-7[3]E69DB:X
M\G?Y*RND9DVAV5<D?N-3G]G/V7+[3DE[/GNH<]GR<_*FU'FMS63=MD?"1Y;K
MFORW7-RVOR];7TO;:^A_0#^UE_P5E^ 7Q<_9@^('P0^#_@GXP>'/$'BKP_HG
MA/2+KQ5H/@O3?#NF^'[?5]'_ +9M9Y]%^(/B#41Y_AFSO]+M(XM-E1IKF+SW
MCA#M7\Z\'^#W$63<59;GN<X[)<3AL'B*^+K0P>(QU3$U,1*C6]A*,:^6X:E[
MN*G3JS;JJT8OE3=D?I&<<99=C,IQ. P5#&TJE:E"C!UJ="%*--3ASINGB:DM
M:490BE#=J]D?SZU_1I^;'TI^Q_\ %;P%\#?VD/A;\6_B9I7B/6_!W@/5]1UR
M]TSPG9Z7?Z]/J,?A_5[?P[)8VNLZOH6G.+/Q'/I5]<F?4[8I:6T[0>9.(HG^
M7XTRC,,_X8S;)LJJX:AC<PHTL/"KC)U:>'C2>(HRQ*G*A1KU%SX:-6G'EI23
ME**E:-VO5R3&8;+\TPF,Q4*LZ&'G*<H48PE4<O935+E4YTX^[4<).\E9)VN[
M(^Z_^"E?_!1#X:?MB>"?AEX'^%7A[XBZ#I?ACQ3K'BOQ0/'NE^&]*%W?KI,6
MD>&_[*3P[XM\4BY-O;ZEXD^VM>?8# )[06WVKSY_L_Y_X7>&N:<%8_-,?F^)
MRS$5<5A*.#PG]G5<55Y*?MG6Q/M?K.#PG+S2I8;D4/:<W+/FY.6/-]!Q3Q+A
M,[P^$P^#IXJG&C6G6J_6(4H7ER*%+D]E6K7LI5;WY;75KW=ORA\(^*-9\#^*
M_#'C3P[<+9^(/"'B'1?%&A7;1K*MKK/A_4K;5M,N&B?Y)5@O;2"0QM\KA=IX
M-?K^,PE#'X/%8#$QY\-C<-7PF(@GRN5#$4I4:L4UM>G.2NMCX^C5GAZU*O2?
M+4H5*=6F_P"6=.2G!V\I11_4!\/O^"V?[,WB+PE9_P#"TO!WQ"\'^*FL!'K^
MC:;H6F^+?#-S=[=DZ:-J2ZO:7ES97'+I%J^CZ>\(8V\CW(C%S-_*.8^!7%.%
MQDUE.,R[&X15+X>O5Q%3!XJ,-X^VI>RG"$X[7HUJB=N9*-^5?K.&X\RFK1C]
M;HXFA5Y4JE.-.-:DWL^22FFX_P".$;+34_#7]OW]I+P?^U)^T'>?$3X?:3J^
MB^!M,\)>&_!OABQUS3=-TC4Q9:,MY>WLTVG:5?ZG96T4^M:MJDEFBWCRFR-N
M\\=M,SVT/[YX=<+XWA+AR&6YC5HU\?5QF)QN*GAZM2M2YZWLZ=.,:E6G2G)Q
MH4:*G[B2GS*+E%*3_/\ B/-*&;9D\3AH3IX>%&E0I1J1C"7+#FE)\D)2C%.I
M.?+K?ELW9^ZOLS_@G#_P4X\*?LP> [SX*_&7P]XCU+P-'K>HZ_X1\4>%+>QU
M#4?#TNL&&75-$U31;JYTPW>D37R7&JVVHVE[-J%I=WEW;/87=K+;O8?$>)OA
M7C.*LPAGF1XC#4L>Z%+#XS"8N4Z5/$*@G&E7I5X1J\E:-/EHRI3A&G*%.$E4
MA)24_=X7XKHY3AW@,=3J2PZG*I1K45&4J?/9RIRIMQO!RO-24G).37*U;E^\
M/B[_ ,%E/V6M.\'>,U^$^A_$#7_B%XA\/ZKINCZI'X1TWPY8VVL2Z;=6FCZE
MKNK:EJL&IR6FFW+PW"I:Z=J%QL411I#EGC_/LF\$N+:N-P7]KU\NPV6X?$4J
ME:D\94Q,Y48U82K4J%&E2E24JL5*-Y5*<>K;V?T.-XXRB%"M]3AB:N)J4YQA
M)48THJ?(U"52<Y*5HNS]V,G;2R/YC?"/BC6? _BOPQXT\.W"V?B#PAXAT7Q1
MH5VT:RK:ZSX?U*VU;3+AHG^258+VT@D,;?*X7:>#7]58S"4,?@\5@,3'GPV-
MPU?"8B"?*Y4,12E1JQ36UZ<Y*ZV/RBC5GAZU*O2?+4H5*=6F_P"6=.2G!V\I
M11_4!\/O^"V?[,WB+PE9_P#"TO!WQ"\'^*FL!'K^C:;H6F^+?#-S=[=DZ:-J
M2ZO:7ES97'+I%J^CZ>\(8V\CW(C%S-_*.8^!7%.%QDUE.,R[&X15+X>O5Q%3
M!XJ,-X^VI>RG"$X[7HUJB=N9*-^5?K.&X\RFK1C];HXFA5Y4JE.-.-:DWL^2
M2FFX_P".$;+34_#7]OW]I+P?^U)^T'>?$3X?:3J^B^!M,\)>&_!OABQUS3=-
MTC4Q9:,MY>WLTVG:5?ZG96T4^M:MJDEFBWCRFR-N\\=M,SVT/[YX=<+XWA+A
MR&6YC5HU\?5QF)QN*GAZM2M2YZWLZ=.,:E6G2G)QH4:*G[B2GS*+E%*3_/\
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M9_$/5H+9TT32K+P]#X"\(PS+Q''J&HZOY6I:?:_QC^R_"NJ,V-A2'.]>K+?
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M(\T91O%_G.!QM?+L70QF&:56A/FC?X9*SC*$DK7A.#<))-.ST:=F?TX?#?\
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M_A9FG_SF#_7_ ";_ *!LS_\ !.%_^; _X?E_LF?]$\_:)_\ "2^&O_SVZ/\
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 ?__3_OXH * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H ^=OVOO^33/VH?\ LW;XU_\ JM?$M?2\&?\ )8<*?]E+D7_JTPIYF=?\
MB;-O^Q9C_P#U%JG\(%?Z!G\]!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * /V;_X(:?\G9_$+_LW;Q9_ZLKX
M25^(>/G_ "1^6_\ 92X/_P!5><'W/A__ ,CG$_\ 8LK?^I6"/ZK:_D8_7PH
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * /_]3^_B@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H _9O_@AI_R=G\0O^S=O%G_JROA)7XAX^?\ )'Y;_P!E+@__
M %5YP?<^'_\ R.<3_P!BRM_ZE8(_JMK^1C]?"@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H __
MU?[^* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * /G;]K[_DTS]J'_ +-V^-?_
M *K7Q+7TO!G_ "6'"G_92Y%_ZM,*>9G7_(FS;_L68_\ ]1:I_"!7^@9_/04
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % '[-_\$-/^3L_B%_V;MXL_]65\)*_$/'S_ )(_+?\ LI<'_P"JO.#[GP__
M .1SB?\ L65O_4K!']5M?R,?KX4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '_];^_B@ H *
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M7OAS<>--1T[P7J$NI:[=WFK#1;JRTV:?PY'=O&D^B2V.I6"-IM_93S '[NT
M% !0!_'I_P '?7[7?[4?[)7P)_8RU;]F']H#XM? '5?&?Q:^)VG>+-4^$GCG
M7O NH^(=.TCP=H%SIEAJU]X>O+&ZO;*RN;VYN(;2:5K=9Y/.,9D2-E /A+_@
MT4_;O_;1_:O_ &O_ -J'PE^TU^U/\>?CWX7\,_LVV?B+P]X?^+/Q/\6>.M(T
M37G^)_A'3&UC3+#Q#J=];V6HMI]W<V1NX(TF-M/+#OV.P(!_?Q0 4 ?Y8O\
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MCHGB+PUXATZVU?0M=T?4+9I+:^TO5M+N[6_T^\MW>"YM+B&:)F1U- '04 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0!\[?M??\FF?M0_]F[?&O\ ]5KXEKZ7@S_DL.%/^RER+_U:84\S
M.O\ D39M_P!BS'_^HM4_A K_ $#/YZ"@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H _9O_ ((:?\G9_$+_ +-V\6?^
MK*^$E?B'CY_R1^6_]E+@_P#U5YP?<^'_ /R.<3_V+*W_ *E8(_JMK^1C]?"@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MIWW,W@C7]'\9>##!"#!H_A2T\!V>5\]%H _KEH * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M;NC_ (BUX>_]%%3_ /#=F_\ \[P_U1XB_P"A;+_PHP?_ ,T!_P .K_V]O^B
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M^BBI_P#ANS?_ .=X?ZH\1?\ 0ME_X48/_P": _X=7_M[?]$ O?\ PX'PG_\
MF[H_XBUX>_\ 114__#=F_P#\[P_U1XB_Z%LO_"C!_P#S0'_#J_\ ;V_Z(!>_
M^' ^$_\ \W='_$6O#W_HHJ?_ (;LW_\ G>'^J/$7_0ME_P"%&#_^: _X=7_M
M[?\ 1 +W_P .!\)__F[H_P"(M>'O_114_P#PW9O_ /.\/]4>(O\ H6R_\*,'
M_P#- ?\ #J_]O;_H@%[_ .' ^$__ ,W='_$6O#W_ ***G_X;LW_^=X?ZH\1?
M]"V7_A1@_P#YH#_AU?\ M[?]$ O?_#@?"?\ ^;NC_B+7A[_T45/_ ,-V;_\
MSO#_ %1XB_Z%LO\ PHP?_P T!_PZO_;V_P"B 7O_ (<#X3__ #=T?\1:\/?^
MBBI_^&[-_P#YWA_JCQ%_T+9?^%&#_P#F@/\ AU?^WM_T0"]_\.!\)_\ YNZ/
M^(M>'O\ T45/_P -V;__ #O#_5'B+_H6R_\ "C!__- ?\.K_ -O;_H@%[_X<
M#X3_ /S=T?\ $6O#W_HHJ?\ X;LW_P#G>'^J/$7_ $+9?^%&#_\ F@/^'5_[
M>W_1 +W_ ,.!\)__ )NZ/^(M>'O_ $45/_PW9O\ _.\/]4>(O^A;+_PHP?\
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M#_5'B+_H6R_\*,'_ /- ?\.K_P!O;_H@%[_X<#X3_P#S=T?\1:\/?^BBI_\
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M>_\ 114__#=F_P#\[P_U1XB_Z%LO_"C!_P#S0'_#J_\ ;V_Z(!>_^' ^$_\
M\W='_$6O#W_HHJ?_ (;LW_\ G>'^J/$7_0ME_P"%&#_^: _X=7_M[?\ 1 +W
M_P .!\)__F[H_P"(M>'O_114_P#PW9O_ /.\/]4>(O\ H6R_\*,'_P#- ?\
M#J_]O;_H@%[_ .' ^$__ ,W='_$6O#W_ ***G_X;LW_^=X?ZH\1?]"V7_A1@
M_P#YH#_AU?\ M[?]$ O?_#@?"?\ ^;NC_B+7A[_T45/_ ,-V;_\ SO#_ %1X
MB_Z%LO\ PHP?_P T!_PZO_;V_P"B 7O_ (<#X3__ #=T?\1:\/?^BBI_^&[-
M_P#YWA_JCQ%_T+9?^%&#_P#F@/\ AU?^WM_T0"]_\.!\)_\ YNZ/^(M>'O\
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M *(!>_\ AP/A/_\ -W1_Q%KP]_Z**G_X;LW_ /G>'^J/$7_0ME_X48/_ .:
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MU?\ M[?]$ O?_#@?"?\ ^;NC_B+7A[_T45/_ ,-V;_\ SO#_ %1XB_Z%LO\
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M"V7_ (48/_YH#_AU?^WM_P!$ O?_  X'PG_^;NC_ (BUX>_]%%3_ /#=F_\
M\[P_U1XB_P"A;+_PHP?_ ,T!_P .K_V]O^B 7O\ X<#X3_\ S=T?\1:\/?\
MHHJ?_ANS?_YWA_JCQ%_T+9?^%&#_ /F@/^'5_P"WM_T0"]_\.!\)_P#YNZ/^
M(M>'O_114_\ PW9O_P#.\/\ 5'B+_H6R_P#"C!__ #0'_#J_]O;_ *(!>_\
MAP/A/_\ -W1_Q%KP]_Z**G_X;LW_ /G>'^J/$7_0ME_X48/_ .: _P"'5_[>
MW_1 +W_PX'PG_P#F[H_XBUX>_P#114__  W9O_\ .\/]4>(O^A;+_P *,'_\
MT!_PZO\ V]O^B 7O_AP/A/\ _-W1_P 1:\/?^BBI_P#ANS?_ .=X?ZH\1?\
M0ME_X48/_P": _X=7_M[?]$ O?\ PX'PG_\ F[H_XBUX>_\ 114__#=F_P#\
M[P_U1XB_Z%LO_"C!_P#S0'_#J_\ ;V_Z(!>_^' ^$_\ \W='_$6O#W_HHJ?_
M (;LW_\ G>'^J/$7_0ME_P"%&#_^: _X=7_M[?\ 1 +W_P .!\)__F[H_P"(
MM>'O_114_P#PW9O_ /.\/]4>(O\ H6R_\*,'_P#- ?\ #J_]O;_H@%[_ .'
M^$__ ,W='_$6O#W_ ***G_X;LW_^=X?ZH\1?]"V7_A1@_P#YH#_AU?\ M[?]
M$ O?_#@?"?\ ^;NC_B+7A[_T45/_ ,-V;_\ SO#_ %1XB_Z%LO\ PHP?_P T
M!_PZO_;V_P"B 7O_ (<#X3__ #=T?\1:\/?^BBI_^&[-_P#YWA_JCQ%_T+9?
M^%&#_P#F@/\ AU?^WM_T0"]_\.!\)_\ YNZ/^(M>'O\ T45/_P -V;__ #O#
M_5'B+_H6R_\ "C!__- ?\.K_ -O;_H@%[_X<#X3_ /S=T?\ $6O#W_HHJ?\
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M4_\ PW9O_P#.\/\ 5'B+_H6R_P#"C!__ #0'_#J_]O;_ *(!>_\ AP/A/_\
M-W1_Q%KP]_Z**G_X;LW_ /G>'^J/$7_0ME_X48/_ .: _P"'5_[>W_1 +W_P
MX'PG_P#F[H_XBUX>_P#114__  W9O_\ .\/]4>(O^A;+_P *,'_\T!_PZO\
MV]O^B 7O_AP/A/\ _-W1_P 1:\/?^BBI_P#ANS?_ .=X?ZH\1?\ 0ME_X48/
M_P": _X=7_M[?]$ O?\ PX'PG_\ F[H_XBUX>_\ 114__#=F_P#\[P_U1XB_
MZ%LO_"C!_P#S0'_#J_\ ;V_Z(!>_^' ^$_\ \W='_$6O#W_HHJ?_ (;LW_\
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MZH\1?]"V7_A1@_\ YH#_ (=7_M[?]$ O?_#@?"?_ .;NC_B+7A[_ -%%3_\
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M#^RR@ H * "@#^&K_@^ _P"3>/V"_P#LL_Q?_P#4'\+4 ?S!_P#! ;_@K?\
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M_P"$I^'/@_Q]YY\)+XF\9#1_L)\5_P!E>6/$NJ?:18?;M]O]I^R6X!_IV_\
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MO^3X/VO?^S4[#_U;O@B@#_2HH * /\=G_@Y:_P"4W_[>/_8V?"/_ -9U^#]
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M]&O;&SE2QU"PM[=_+N)TR_F!XU)90<$4 ?IE0!\5_M?_  1^+OQC_P"%>?\
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M(+#6K&^O(FOM/AGN(]]O;OM01E)& 1B,B@#\S?\ AB/]KG_HH&D?^'%\5_\
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M8!2 ?CC_ ,,1_M<_]% TC_PXOBO_ .55 !_PQ'^US_T4#2/_  XOBO\ ^55
M'Z7_ +-OP_\ &7PQ^$NA>$?'VHV^J^*;.^URYU"^M=2O-7CECOM6N[FR!O[^
M"WN9GBLGMXR'CQ$$6%&*H, 'O% 'XY^)OV,/VK=1\2>(-0T[Q]I":??ZWJMY
M8I_PL'Q5#ML[J_GGM5\D:3B+; Z#RAQ'C:.E &)_PQ'^US_T4#2/_#B^*_\
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MWH4MI>3ZI?:-$(+#6K&^O(FOM/AGN(]]O;OM01E)& 1B,B@#\S?^&(_VN?\
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M1':2*-Y$"EHT9@%(!^./_#$?[7/_ $4#2/\ PXOBO_Y54 '_  Q'^US_ -%
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MH5MHBVOB/5]?>V>RGU.6_)&IV=LMJDJSV8)A9C,8UWKB)2 #[AH _-#]I/\
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MXA1Y8%4R1HSJHH _(W_AB/\ :Y_Z*!I'_AQ?%?\ \JJ #_AB/]KG_HH&D?\
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M^'_&OA76];M(_'OB:\DN=(TG7+"_U*W2TGTR."Z>:RMYHUMIG2*<L(I&5&)
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MPZ\7:=I/AN?0]'LH[&?Q?K^BRQ7EE'+%=,UC8Z?-:CS&*NLD<KF16&_:X95
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MAV(,2F@#\Z/^&(_VN?\ HH&D?^'%\5__ "JH /\ AB/]KG_HH&D?^'%\5_\
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MQ-K&@>=/J,VD/:21QZ99W,=QMCLYU9Y"CQX50"K4 ?&__#$?[7/_ $4#2/\
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MK6^B^)9-9T:_BN[G5;_18S:6<[&[A%]IUO<SJ[HX81E%BD",&<-L5@#\V_\
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M^,]+U'P[H'BG1=6UFRC\<^(M0DN-/L;V&>X1+*[TZ*VN7V)N6&61%8J!D'%
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M/AC2=-UJ[@N9[V*YU.VM(TO9DO+F.&XNO,N-[&XFC225B789.: /0Z "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M\V2*%(+6;QI\8/',KZ!HEC;P"*!-2\7^+=.T^VC\J+[5&K1J0#_0\_X-Z_\
M@W2'_!-#47_:R_:OU+PUXS_;&U[PW>Z!X0\+>&;B/6_!?[/?AOQ%:11>(+>P
MUZ2WC3Q)\4=;L6F\/^(/$VD!-!T30[C6/#7AF]US3M9U+7=3 /ZPZ /\IS_@
M[[^/<OQ8_P""NVL_#&&YD;2_V9?@/\(_A:+0%OLHUWQ;IM]\;]7OXP?E:ZN+
M#XIZ#IEW*G&W1+:W;#VK"@#^D;_@RU^ '_"!_P#!/OX^_M 7]E]FU;]H']HV
MXT+3;GR\?VCX$^"WA+2M)T2X$I +K#XV\9?$RR$8RD36KL&WRR(@!_8[0 4
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MPSTNPEN='369U> /X+^#?PVT72O"=OXAO8I#;SWOA_P?'K.H0B."XGGBBB1
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MI0 Z@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#P3QG^RK^R_\
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M;>\N]+BUB?\ X1[PM+?P17L'@S0?#EA/'&UF(T /T4H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * /G;]K[_ )-,_:A_[-V^-?\ ZK7Q+7TO!G_)
M8<*?]E+D7_JTPIYF=?\ (FS;_L68_P#]1:I_"!7^@9_/04 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 ?1/[(/_)V?[+W_9Q/P3_]65X9KYKC
M/_DC^*_^R:SW_P!5>*/3R7_D<Y3_ -C/ ?\ J52/[OZ_S\/Z%"@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * /_UO[^* "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * /G;]K[_DTS]J'_ +-V^-?_ *K7Q+7TO!G_ "6'"G_92Y%_ZM,*
M>9G7_(FS;_L68_\ ]1:I_"!7^@9_/04 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 ?1/[(/\ R=G^R]_V<3\$_P#U97AFOFN,_P#DC^*_^R:S
MW_U5XH]/)?\ D<Y3_P!C/ ?^I5(_N_K_ #\/Z%"@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * /_]?^_B@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#
MYV_:^_Y-,_:A_P"S=OC7_P"JU\2U]+P9_P EAPI_V4N1?^K3"GF9U_R)LV_[
M%F/_ /46J?P@5_H&?ST% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % 'T3^R#_ ,G9_LO?]G$_!/\ ]65X9KYKC/\ Y(_BO_LFL]_]5>*/3R7_
M )'.4_\ 8SP'_J52/[OZ_P _#^A0H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@#__0_OXH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H ^=OVOO^33/V
MH?\ LW;XU_\ JM?$M?2\&?\ )8<*?]E+D7_JTPIYF=?\B;-O^Q9C_P#U%JG\
M(%?Z!G\]!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!]$_L@
M_P#)V?[+W_9Q/P3_ /5E>&:^:XS_ .2/XK_[)K/?_57BCT\E_P"1SE/_ &,\
M!_ZE4C^[^O\ /P_H4* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H __
MT?[^* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H _,W]K7_@L7_P $V/V%?BI#\$OVKOVHO#WPB^*,_A;2/&L?A+4/ _Q6
M\2W7_",:[<ZE9Z3JCWO@CP'XFTF%;VXT?44CM9=02]1;?S9;:.&6!Y0#T_\
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M6TT71;*?6-<^%VFZ)I,-UJ5[;02ZEK&HV&EV*.;K4+VUM(I9XP#]JJ "@ H
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M4+=?A9\?[E8+[3[B2TNX5N+7X336LZQ3PR()K::6"4+OAEDC96(!0_XB5_\
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MS4-'U6S=D=%N;&\GA+(R[]RD  ["@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@#YV_:^_Y-,_:A_[-V^-?_JM?$M?2\&?\EAP
MI_V4N1?^K3"GF9U_R)LV_P"Q9C__ %%JG\(%?Z!G\]!0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0!]$_L@_\G9_LO?\ 9Q/P3_\ 5E>&:^:X
MS_Y(_BO_ +)K/?\ U5XH]/)?^1SE/_8SP'_J52/[OZ_S\/Z%"@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * /_2_OXH * "@ H * "@ H * "@ H *
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MLK-))+)(Q9Y)'8EG=V)9F8EF8DDDF@#_ &;O^#?_ /Y0T_\ !/C_ +(/9?\
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M4[[5=3UK5+F]AM[VRTC2@#]?J "@ H * /\ %6_X)C_\IH?V&?\ M(S\!O\
MUH/PY0!_M4T % !0!_&A_P %@?\ @UY^,W_!3+]O3XJ?M@^#_P!JWX8_"W0?
MB%H'PST:U\%^)?A]XJU[5]-D\!?#SPYX)N9KC4]+UBSLIDU"XT.2^@6.!###
M.D4A9T9B ?F-_P 00/[1O_1]_P $_P#PTOCK_P":*@#^2#]N?]E+6_V'/VM_
MCK^R9XD\7:5X]USX&>,W\&ZEXPT/3KO2-)UZX32]-U/[;8Z;?S7%W9PE-12+
MRIYY'#1,V[!  !_5C\/_ /@RL_:)\>> _!/CB+]N+X+:9'XS\(^&_%<>G/\
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M*X\"^*=/-QX,\?:1K=UX>\*W-S9ZGJFF^*/#^J6 TACHM_H=M)<W1AU[3%8
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MGH* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /HG]D'_D[/\
M9>_[.)^"?_JRO#-?-<9_\D?Q7_V36>_^JO%'IY+_ ,CG*?\ L9X#_P!2J1_=
M_7^?A_0H4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!__3_OXH * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M/+X+\!ZP-\J2:IX8O)X7\B6)$ /]3_\ X-__ /E#3_P3X_[(/9?^I-XDH ]
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M)8M;T%=7@U;5KQQI>K'Q39&^MO)O(<3&U@RVY=GRY(!_4[_P3G_X*5_LT_\
M!4;X.>+OCG^RW-X[F\"^"?B9J7PGUMOB#X47PAJX\6:3X6\)>,+M;33DU/51
M/IO]C^-=%,=YYZ;[DW4'DC[/O< ^5_\ @H=_P7O_ &!/^"8GQOT/]GS]IR^^
M,$7Q$U_X<:'\4[*#X?\ PW_X2S1X_"OB'7O%/AO3&N-4DUW2434)-1\'ZSYE
MG'%+Y-NMM*\N9PB@'Z4?LK_M*_#3]L3]GKX5?M-_!U]>D^&/QC\,KXL\&OXG
MTH:'K[:2]]>:<#JFDK=7HL;G[183_N1=3?)L;?\ -@ 'S[_P47_X*6_LR_\
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MX\6ZS\.-)\;>./VIOB'X?O&TW7-)_9IT30O%?A+0]2B8K<6>H?$_Q-XE\)^
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MC47D\0^*[VQBCFNM)\#>#-)@U'QAXZUJ"&6*:;2/".AZSJ$%NXN9[>*V#3*
M?S,?%C_@])_X)Q>$=9OM(^%OP*_:J^+]K9DI#XF;P]\/?A]X;U5@3B335\0>
M.[SQ4MJ5VG?JWA32;H,2OV+"AF +OP=_X/0/^";'C;7++1?BO\&OVI/@C;7>
MU9?%=SX8\$?$/PII;;E#MJ0\(>-&\9&%5)96TGP7JTS;2#;H=NX _J#_ &:_
MVI_V=?VP_A?I?QF_9A^,/@?XU?#35G^SQ>)?!&KQWZZ=J*P07,VA>(]*E6WU
MSPGXEL[>YMI=0\,>*-,T?Q!IR7$!OM,M_-CW 'OU '^/%_P<R?\ *<3]N_\
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M27S^#KW3M9\1>!_'4MI#%/?3Z3X3\7:IXDM-)MYM7U+0=/L()YH@#_+_ /\
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M_;>&H;.&*/Q1\9/$^DN2ESX=\"1WMI'H^FW:M!XG\9ZAHFDR6]SHEOXFGTX
M_F+_ .#9+_@CQXD_;<^+NK?\%=?V\UUKXC^%;3XE:YXG^"VD_$0SZS>?'KXW
M6>M3W?B7XV^,Y]5\QM<\(^!/%0N+?0K=UFMO$_Q'L;Z2\D@TOP/<:5XC /\
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M7B6+5K33D'EV<,,?RT ?:2JJ*J(JHB*%1% 5551A551@*J@     # XH =0
M4 % !0 4 % !0 4 % !0 4 % '^5K_P>&?'O_A:?_!66/X4V=[YFF?LS_L]_
M"WX>75C')O@M_%?C<:Q\9M7O2N2$N[OP]\1/!ME<!<#R=(M 5#J^0#_16_X)
M;_ 7_AF'_@G+^Q-\"IK+^S]7\ _LU_"BU\5VGE^5Y?CS6O"FG^)?B"_EX!3S
M_&^M:_<;7_>#S?WA9]Q(!]Z4 % ',>-O!OAGXB^#/%OP^\::1:>(/!OCOPQK
MW@WQ9H%_&);#6_#/B?2KK1->TB]B/$EIJ6E7UU97,9X>&9U[T ?Y7?\ P1:\
M9>)_^"3/_!Q,O[+GB75+F7PYK_QQ^*'[ _CB=G6%?%&F^*_%YT+X1>(DC/EV
MX75?B1H/PL\1P2/"LPT>_O+>%();MD !_JUT % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 ?,_[9?[3/A#]C3]E/]H#]J7QR87\._ SX6>+/'[Z?-,+8^(-8TC3
M)?\ A%_"=M,<!-1\8>*)='\*Z7DJ&U+6+5"R!MP /\DK_@CS^SCXO_X*H_\
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M^"X7_*(7_@HK_P!FI?%;_P!,$U '^>G_ ,&A_P#RF3\#_P#9 OCO_P"H_IU
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M3F?4M9U>]>?4M;UB\O\ 5]4N;K4;ZZN90#^.+_@TN_X)O_L0?MY_#S]N2_\
MVN_V>/!OQQO?A]XL^!.E^"KOQ1>>)K.X\-6/B71OBG<Z[!I<OAW7M%> ZG/H
M^F27$N6GS90!)$5,4 >-?\'37_!(?]C?_@FIK7[+/Q<_8WTC4_A+8?'34_B9
MH/B?X02>,?$GBK2=.U/X?P>#=8L/&O@B]\7ZMKGBS2X9#XJET[7].FUV\TBS
MN%\.OH=MI/F7D5P ?VL_\$_O#&F_\%/?^"'7[-'@[]M30[OXD6O[0_[*VA>$
M?BE<>*Y4U#Q'XFGT<77AK1?B?_:]TEQ/#XYOG\.Z+\2]%\5#.J6'BF2QU^*4
M:A L@ /Y:_\ @V;^(/Q-_P""<7_!8K]L?_@CW\4_$SZEX6\6ZE\3]-\+P/#+
M;6>M?%_X!F?7O#GCWP[87$KG2=/^)GP"M?%'B/4HE_TO4+'2?!*7CL-$B" '
M^AY0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'S
MM^U]_P FF?M0_P#9NWQK_P#5:^):^EX,_P"2PX4_[*7(O_5IA3S,Z_Y$V;?]
MBS'_ /J+5/X0*_T#/YZ"@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@#Z)_9!_Y.S_ &7O^SB?@G_ZLKPS7S7&?_)'\5_]DUGO_JKQ1Z>2_P#(
MYRG_ +&> _\ 4JD?W?U_GX?T*% !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 ?_U/[^* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H _RLO\ @\5_Y2\VO_9J7P5_]/\ \2: /Z OVGO^"??_  WI
M_P &J'['4GA/1/[4^-G[,/[)/PE_:,^$GV6W\W5=3C\&> ,?$SP5:>4K7=T/
M%GPXEUZ33M%M@QU;QGH?@Q3%));0[0#\,O\ @T%_;_\ ^&;OV]/$'[(OC;6O
ML?PN_;4T&WT7P^EY<>78:1\?/A_;:IK/P_N$:9C#:?\ "9^';GQ?X&DAMD2X
MUSQ)?^ [661UT^VC !_J,4 ?$7_!1[]LWPI_P3[_ &)?VAOVM?%?V*Y;X3^
M;^\\':%?2F.+Q;\3-<DA\-_#+P@1&Z7!A\1>.=6T+3]1EM1)-I^CR:CJIC,%
MA,5 /\N;_@@;^QKXK_X*H?\ !7'P?XE^,GVWQWX,\">+]>_; _:>\1:W$+N/
MQ?<Z1XJA\16>C:ZSHMI?3_%'XM:UH.FZYIA>*>]\+W?B^^M8W32YP@!];_\
M!Y!_RERT'_LT3X,_^IC\6J /[N?^#?\ _P"4-/\ P3X_[(/9?^I-XDH _F4_
MX/F?^/'_ ()A_P#7W^V9_P"B?V5J /U"_P"#.;_E$1J'_9V/QH_]1OX8T ?U
M7T ?S!?\'>/_ "AM\:_]E_\ @3_Z?=3H _%'_@QP_P"1]_X*/_\ 8H?LO?\
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MX#?]DQ_:$_\ 51>)J /]:R@ H _Q5_@A_P IM_A#_P!I4/ '_K6VDT ?[5%
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M=CJV@^ ? ]KJMK/86'B35_#GBC4/$]S8Z@FE>'[/2?L/B6Z /ZLM7_X-#?\
M@C;J/A.3P[9>"_C_ *!K#VAMD\>:3\=M<F\5PS&-4%_'9Z[I>M>!C=*P,H27
MP9)8[V(:S,6V-0#^*'_@N/\ \$"_BU_P2!\1^%_B;X.\::E\:?V2_B'XB;P_
MX,^*=SI<.B>,?A_XT\F\U;3OA_\ $VQTV1]-&KWFDZ?=WWAGQEHGV'2O%/\
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M//L/[6[:M+$UVSR_\%"/A]'XS\D#SO,EMI_VF4U<3L22+ M_:GF@HUD)2JL
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M0 4 % '\2/\ P>C?MO?\*^_9L^ W[!GA/5_*\1?M!^*S\8OBM9VL^)HOA/\
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M(D<:67AKP3X?T_PUH5HL<2I$@M]+TRUA"QHJ*$PBA0!0!WE !0 4 % !0 4
M% !0!\A_\%!/^3"?VW?^S0_VD_\ U3/C2@#_ #\_^#)O_E(5^U)_V9GJ_P#Z
MN[X.4 ?Z9% !0 4 % !0!^5W_!<+_E$+_P %%?\ LU+XK?\ I@FH _ST_P#@
MT/\ ^4R?@?\ [(%\=_\ U'].H _U?: "@ H _P G;_@[B^$.C_#'_@LAX_\
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M+\KC=_PAN_[3W^V?:?/^;S* /]".@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * /G;]K[_DTS]J'_LW;XU_^JU\2U]+P9_R6'"G_
M &4N1?\ JTPIYF=?\B;-O^Q9C_\ U%JG\(%?Z!G\]!0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0!]$_L@_\ )V?[+W_9Q/P3_P#5E>&:^:XS
M_P"2/XK_ .R:SW_U5XH]/)?^1SE/_8SP'_J52/[OZ_S\/Z%"@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * /__5_OXH * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@#_*R_P"#Q7_E+S:_]FI?!7_T
M_P#Q)H _T _^")2*_P#P2(_X)U(ZJZ/^R/\ !U'1@&5E;PG9AE92,%2."",$
M<$8H _S#?^"TG['/B_\ X))_\%9?'VD_")K[P)X7M_'GAO\ :K_9-\1:5']F
M'AWPKKGB:7Q;X3MM 8H50_"CX@Z)KO@2R,GF2R+X+M;Z?<MXA< _U;/^">'[
M8GA+]OO]BS]GC]K;P?\ 8[>W^,'P\TS5O$NBV4IFA\*?$327F\._$OP<&=WF
M*^%?'FD>(=#MYI]LMY9V5M?[1'=1Y /XA?\ @] _X*#?\)3\2O@G_P $WO 6
MM[]&^%]O8_'WX_065Q^[E^('BC2KO3_A)X/U)(V22.X\,>!=1UKQK>6<RS6E
MY!\1?"5ZFRZTI=@!^VG_  :9_P#!/W_ADG_@G+:_M"^,M$_L_P"+_P"V_J6F
M?%>[>ZM_*U'3/@GHD%]IWP1T5BR\VVM:;J/B'XH6TT3XN-/^(NEP7"+-IJJ@
M!_*M_P 'D'_*7+0?^S1/@S_ZF/Q:H _NY_X-_P#_ )0T_P#!/C_L@]E_ZDWB
M2@#^93_@^9_X\?\ @F'_ -??[9G_ *)_96H _4+_ (,YO^41&H?]G8_&C_U&
M_AC0!_5?0!_,%_P=X_\ *&WQK_V7_P"!/_I]U.@#\4?^#'#_ )'W_@H__P!B
MA^R]_P"GGX[4 ?V$_P#!8O\ Y1/_ /!2+_LR/]IC_P!5'XKH _SF_P#@T6_Y
M3,?#K_LA?QY_]1.&@#_6&H _RV/^#S/_ )2R^ /^S+/A!_ZM#X[4 ?W2_P#!
M /\ Y0U_\$]_^R!Z9_ZD/B"@#]@J /\ +A_X/.O^4L'PS_[,C^$7_JW/V@*
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M?@>*:;[Z:;\,?CE\4?AKHMH/^F5AH_A.QL(!V@MHQVH _<"@ H * /%?C_\
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M7_RB?_X*1?\ 9D?[3'_JH_%= '^7)_P;E? +PO\ M&?\%EOV+/!?CC1(=?\
M!_A7Q?XQ^,6L:=<KYEHU_P#!?X:^,?B5X)DO8"#%=62_$7PWX/6[LKA6M;RW
M>2UN8Y8)7A< _P!CV@"CJ6FV.L:;J&D:I:Q7NF:K976FZC93KN@N[&^@>UN[
M69>-T4]O+)%(O=&(H _Q2?VN_P!E[]JC_@C#_P %!Y/"M\-9\%_$K]G[XKZ/
M\4/V>OBS_8KGP]X]T#POXDM_$?PS^)_A-]6M)]%\1:5>+9Z>OB#2&&IV>EZ[
M;ZYX+\1PF^TW5+%0#^['_@GA_P 'A/[&/QUTGPSX&_;I\-:S^R5\7I8[73M3
M\?Z3IVJ^.OV>?$&I%8X!J,.I:3'J/CWX>#4KHF1M+\2>'M<\.^'[=@^H?$6X
M@CEGB /ZU/AC\5OAA\:_!6B_$CX.?$3P/\5?A[XC@^TZ#XX^'7BG1/&?A/6(
M,#+Z=X@\/7NH:7=^7D+*L-TS0O\ NY51P5 !W] !0 4 ?ST_\'0W[5EW^RS_
M ,$?OCU;:'J4^E>,/VD]9\*?LN^%[JWE>)_LWQ).IZQ\1K9O**R&+4O@[X/^
M(VDG#HJRZA"9"Z9AE /Q>_X,G?V/++1_AA^U9^W;XBT:(ZYXU\4Z7^S7\,-5
MN8=EW8^%/!]GI7C[XI3:>Q&9--\4^(]=^'EA+.OR"_\ A]<VR-NCN% !_=O0
M!\*_\%"_^"B'[/'_  3(^ UC^T9^TS)XW3X>:C\0/#WPSLU^'_AF/Q7K\OB?
MQ-I?B'6--C_LR74](ACL18>&-6EN+N6]18FBBB5)))D6@#\1?^(Q#_@D%Z?M
M3?\ AD])_P#G@T ?Q8_\%M_^"EG[-_[?_P#P5/\ AA^U_P# 5/B"GPA\'>#/
M@/X>U4^-_"]IX=\3R7OP[\::]XB\1/9:);:WJ\<ML+'5+>.Q>6^@DN;F.:,Q
M11+'-( ?VG?\1B'_  2"]/VIO_#)Z3_\\&@#[]_X)R_\%ZOV$/\ @J/\;_%'
M[/\ ^S!_PNC_ (3[PA\*];^,.K?\+%^'ECX2T3_A$/#_ (M\$>"[_P"RZC;>
M*-;>;5/[9^(&@>19&TC22T^VSFX0VRQR@'[3T ?Y,/\ P=@_'2?XY_\ !9CX
MI>"],FEU:P_9[^&?P<^ >AQVFZX66^/AX_%37[.T@CRS75KXQ^+&N:+<HJ>:
M]]ITD(#HD5 '^H+^Q=\"X/V8OV0OV7_V=H8(H&^"/P"^$OPPOO)V;;C5_!G@
M;0]"UN_=DRDEQJ>L65]J-U,I(GN;J6;/ST ?YH7_  =E?M^^)/VJO^"CNK?L
MO>&-:U";X+_L7VT/PXTOP]:R/_9FN_&[7;2RU7XK>+9+./Y[G5=-N;G2?AC:
MK<K)]A7P5J,VE) OB#47O0#^XO\ X('?\$IO /\ P3(_8D^'EMJG@JQLOVJ_
MC5X3\/>/_P!I;QEJ%I;R^*[;Q)KEC#J]E\)8=1:'[3I_A;X76UU#X>&B6LYT
MV]\4VOB#Q0RO=:R3& ?N2RJZLCJK(RE61@&5E(P593P5(X((P1Q0!_C#_P#!
M6#X8:7_P3Z_X+.?M,^&?@-:0^#--^!O[37ASXL_"73-.D$%GX,_MB/PC\</!
M^DZ0?W?V/3/"T_B&QT[2(BQ-E8:?:PM-(T)F8 _V=89!-#%,%9!+''($? =0
MZA@K!2RAESAMK$9'!(H _P 7+_@M/\7=4_:S_P""PG[<7B_PQ;WWBJ\U_P#:
M7UWX0>![31X)M2O?$EE\)YM,^!'@F'0[2V66XO7US3_ VDG2;6WC:>Y^V6\<
M<7FR;* /]-__ ((:?\$BOAC_ ,$JOV3/"NBS^&=+N?VK/BMX8\.^(_VG/B0Y
MM]2U:X\67%JNH_\ "L= U9%(MOA_\.;B\FT32K33VBM->U2VO_%UZCWVK*EJ
M ?MG0!_CJ?\ !0>^O?\ @I/_ ,' _P :/!^E7,VIV_QU_;Y\,_LR>&]0M9"Z
MS>$/"WCGPQ^SAX<UBVE7/D:?_P (IX5LM72<[%MK+-Q-Y8CD*@'^Q!86%EI=
MC9:9IUK!9:?IUI;6%A96T:Q6UI96<*6]K:V\2 )%!;P1I%%&H"I&BJH  H _
MR?\ _@XR_;K^*W_!3S_@JA<_LK_"?[7XE^&O[/7Q2G_95_9\\!:%<F>#QM\8
MM4\4Z;X*\?\ B]1N6UO=<\:?$>U@\'Z%=PR&P_X1'PSX8>T*S7NJW=\ ?Z%'
M_!(#_@E!\$?^"4?[+OACX5^"]&T/6_C?XGT?2-8_:*^-2V4<GB#XC_$![.*3
M4K"QU6XMH=1LOAMX6O7N-,\ >%5%O:6&FQOK-_;7'BK6_$6KZD ?I)\5_B+H
M7P?^%OQ*^+7BA_*\,_"[P!XQ^(OB*3>L7EZ%X)\.ZCXEU=_,8%8]FGZ9<-O8
M%4QN(P* /\F'_@W1^'&N?MA?\%U?V?/'GC2/^V)?#OCGXL_M6_$.^\MI-NN^
M&- \3^+-$U8ARV-_Q=UGP8/,D?=&;G>K-,J*P!_J??MJ?M-^%OV,?V2_VAOV
MI_&(MY=%^!GPH\7>/H]-N93 GB'7M*TR5?"/A**4,FR\\8>+)M$\+:?\\8-]
MJ]LIDC!WJ ?Y1W_!*S]D/XE_\%ZO^"L>J3_M)>,=>UW2/$^J>*?VF?VLO&]I
MYUOJ5]X*TG6]'MI_!WAR:-U@\-CQ3K>N>&/AQX7M[*2.+P5X5N)+O0K">U\*
MP::P!_K@>'/#OP=_9P^%6C^%O#.F?#_X)_!CX7^';?2]&TFR30O GP_\#^&=
M,CVQ00J3IVB:+IMLNZ2621H8S(\EQ/(TLDDC '^>;_P=O?\ !6;]D#]L#0O@
M3^QY^RYXV\,_'/5/@]\3M8^*?Q,^,O@BZ@UGP!H6HCPOJO@[2?AUX*\96AET
MOQM+J4>MWNO^+=5\-7%[X8L&TCPK8V>M:KJS:U8^'P#]\?\ @T'^!'Q ^#/_
M  2.A\2^/--O](M_VA?VC?B=\<? -AJ,,MI<M\/[GPK\-?A=I&K?8[B&&:*V
M\0ZI\+M;US2+E@T.JZ!?Z/K%E)+87]K+( ?SU?\ !['\=E\6?MH?LF_L[VEV
M+FS^"W[/6O?$74(HWS'8>)/CCXYGTR[L9DS\MX/#OP>\*ZBP*X^R:I9LK'>R
MJ ?H/_P:1_\ !'#P1X:^$^E?\%1?VA_ T6L_%/QUJFL6O[)FD^)+59K/P#\/
M-+:?0=4^,-GI-U$!%XQ\<:S'K>E>$M6N8FDTCP5ID>O:!,8_&RW, !_<_0!_
MFM_\'L7Q[_X2W]LW]D_]G&SO?M&G_!3]G[7OB3J,$4F8K+Q1\<?&\^EW-E<1
M@C%Y'X:^#_A;4!N4A;/6+<QMF650 ?V)?\&^_P !/^&<_P#@CK^PGX*GLOL>
MK>*_@]!\;-;WQ^7=SWWQ\US6/C':_;U(#BZL=$\:Z1I'ER@2V]OIMO:R*K0%
M0 ?G#_P>&_'K_A5O_!)J+X56=YY>I?M+?M#?"WX>W=@DFR:X\*>!_P"VOC-J
MUZ5R-]I9^(OAWX,LYP,GSM5M 5*%BH!\4?\ !D;\!?[!_9K_ &T_VF+NRVS?
M$[XT>!/@QHUW-'B0:=\&O!EQXPU8V)8;A:7U_P#&BRANI(_W5Q=:''"Q,NGE
M8P#^N3]M[X[0_LP?L;_M3_M$R7"6TWP5_9^^+?Q)TPN54W&O>$_ VMZMX<T^
M'=\INM4UZVTW3;-&P)+J[AC) ;( /\8S_@G5^PU\4?\ @I)^V+\(OV3OAC<-
MI^K_ !(UR>[\7^-;NTGU'3_A]\/="@?6?'GC_6(T>+[0NB:)!<'3;&XO+$>(
M/$MUHGAN*^MKW6K:0 '^S=^QC^QE^S]^P/\ L^>"/V:OV:_!%EX+^'G@RS4S
MRA(IO$?C3Q-/;V\>N^//'6MK#%<>(_&?B6>VCN-5U6Y58XHH[32-)M=-T#2]
M)TJQ /X^?^#X3Q!X0A^#/_!/[PK=6UK)X^U+XG?'3Q!H5WB(WMEX0T3PK\/M
M.\5VP.TS16NIZSK_ (,D8;DBGETA/ED:VS$ ?E!_P:Y?\$6O#G[?GQ/UG]L+
M]J?PV/%?[*7[.'B.#PQX&^'/B&&>Y\.?&7XRI%%XDDT?5;64_9[_ .'7PXM]
M5T[Q%XLT%@NF^+/$?B'0-$U"/5-"3QGI%R ?Z@]O;V]G;P6EI!#:VMK#%;VU
MM;Q)!;V]O BQ0P00Q*L<,,,:K'%%&JI&BJB*% % '^.3_P %W[;2?C#_ ,%T
M/VUO#7PDT^W,_BC]HWPQ\--.L+(*L=W\2+/PQX$^'OBW(MU'^EZC\2['7IKP
MA3,;VXG,A><NQ /]B5KBT\.Z"UWK.IQ16.A:0;C5=9U";R88K32[/S+[4[V>
MXE?RHDA@ENKF::9_+0.\DK8+4 ?X_'[7_P :_C5_P<&_\%E['0?AS?ZM_8_Q
MN^+FE_!#]F_2-7COKO3/A9\ /#EY<QP>++[0O-673K>R\)6/B3XV?$JQLW\T
M:M>^*!;2R)%:*H!_JG?L%?L%_L\?\$Y_V<_!/[-_[.OA#3]#T'PWIEE_PE?C
M"73M/B\;?%7Q@L&-8^('Q$UJSMX9]=\2:S=O/*GGNUCH.FM:>&_#MMIGAW2M
M,TVU /./^"NGQY_X9F_X)B_MT?&B&]_L[5O#'[-GQ,TKPK?;_+^R>.O'>A3_
M  ]\ 3!L@DIXU\5: 1&K*\IQ%&RNZL #^ 7_ (,T/@+_ ,+%_P""G'Q$^-%_
M9>;I/[.O[-GC+4]-OO+WBS\=?$_7O#OP^T6'<1B(WG@F\^)1#AO,(MC$JM')
M*R '^BU^WQ\>5_9=_8B_:T_:'6[%E?\ P<_9W^+GCW09"XC:;Q7H/@C6;GPA
M80N<!;G4_% TC3;0DA?M-W%D@<@ _P <+_@E_P#L$>/?^"E_[;/P=_91\&7%
MUI5CXRUB37?B?XTBC2;_ (0'X2>&3'J7Q"\8D3AH)=1M=)_XEOAJTNMMOJWC
M#5O#VCS2PKJ)F0 _V@_V;_V;?@E^R/\ !?P-^S[^SQ\/M#^&7PG^'>DQZ3X;
M\+Z% 40<^9?:OJU],TE_KWB37+QIM4\0^(]8N;S6==U:YN=2U2\N;N>24@'\
MM?\ P>C?"_P?XC_X)K?!+XJZAIEH?'7PQ_:R\*:#X5UYP@O[3PW\1_AS\1D\
M9>'K=G=2;/7+[PCX-U>]BB225I_">G286&&=@ >;?\&2?BG4[O\ 8<_:[\%2
MA_['\/?M6V?B>P8[]G]H^+_A%X'TK540E!%E;;P1H[.$=G'F*9$0-&9 #^TZ
M@#_)T_X.<[T?&#_@OE\4/AWH$KZG?Z=;_LL_":*&PW/*-:UWX;> M7_L^V:+
ME[N.Z\:QP,L3%HKPO;MMGA=$ /\ 6+H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H _QAO^"ZO[;9_X* _\%0_VE/C'HFKIJOPU\.>*Q\$/@G,+N-M*_P"%6_">
M:X\+:/K&EW,T@C@TKQSKT?B/XE#SI42";QI<[_(1?+C /](W_@G?^VG_ ,$A
MOV%OV(?V9?V3]$_X*0?L)EO@S\*?#OA_Q->V'[3GP<%IK?Q#U".3Q%\3O$L
M'BQ<1^)OB)K/B?7T4[F1-16,N^S<0#W#X_\ _!1O_@C;^TC\#/C!^S]\1O\
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@#Z)_9!_P"3L_V7O^SB?@G_
M .K*\,U\UQG_ ,D?Q7_V36>_^JO%'IY+_P CG*?^QG@/_4JD?W?U_GX?T*%
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?_];^_B@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M^L-0!_EL?\'F?_*67P!_V99\(/\ U:'QVH _NE_X(!_\H:_^">__ &0/3/\
MU(?$% '[!4 ?Y</_  >=?\I8/AG_ -F1_"+_ -6Y^T!0!_<I_P &_7_*&?\
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MSXFUV,^-O'7B?XB^()-0UN[2.>]>Y\4>+M:N808XX[6VFALX$2"WC4 'T]0
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M<$$$;S332NL<4,,2EY)9)&(5(XT4L[L0JJ"20!0!_B5_LF>,;'XB_P#!7?\
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MN8?[,^"'P6^*'Q:OEN#B&6W^'?@G6_%KP-R"WV@:1Y"1H=\KR+'&"[** /\
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M2\)Z+K8D&Z..\\)>!/"?@*1I%B$VI:M;0+' ;A(T /\ 6VH * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@#\;?^"^7[;W_  P1_P $M_VD_BQHNK_V1\3O'OAX? 3X
M+RPS_9M13XE?%VWO?#T&L:1+N7;JG@;PBOB[XCV@.Y6/@TH8W#;& /\ *_\
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M_LI<B_\ 5IA3S,Z_Y$V;?]BS'_\ J+5/X0*_T#/YZ"@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@#Z)_9!_Y.S_9>_P"SB?@G_P"K*\,U\UQG
M_P D?Q7_ -DUGO\ ZJ\4>GDO_(YRG_L9X#_U*I']W]?Y^']"A0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % '__U_[^* "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M('GT?P%JEGH4-RU[J&FZ9J]]# \.CW#1@'^COJ>H?"S]K/\ 9X\96_PU\?\
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M#+=7,DEQ-)(P!_.S_P '3?\ P4CTW]B?_@GAXF^!G@[7OL?[0'[:MCKOP?\
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MTO2].LHIKR_U&_O)H;2RLK2&6YNKF6*"")Y71" ?PI?\&='[,?[27P5_;O\
MVF/$WQD_9[^.'PE\-ZC^R1J.A:?X@^)GPG\>> ]#OM;G^,?PIU"#1K/5?%.@
M:587.JS6&FZC>Q:=!.]W):6%[<I"8;6=XP#_ $6* "@ H * "@#\KO\ @N%_
MRB%_X**_]FI?%;_TP34 ?YC_ /P;R?MN?L\?\$^_^"DGA/\ :)_:@\4ZMX-^
M$^G_  H^*WA*^U[1O"OB#QC=6VL^*-$MK?18FT3PO8:GK,L-S<V[0//;V4R6
M[/&\_EP;Y4 /[ZK[_@[&_P"")]I;23V_[0/Q(U.5!\MG8_L]?&2.YE]HVU+P
MEI]F#_UUNHQ[T ?"O[2'_!Z9^PGX'T?4;3]F3]G[X_\ QZ\8"SE.EWGC>#PQ
M\&?AS]MD0K;&ZU>35_&WC>:.WD_>W=LO@*R$T:K#;:BC2M/;@'\7_P"W-_P4
MP_X*+_\ !<;X^^!/!GC&'6O&=QJ/B&/2/@9^R?\  ?0?$!\#Z/K=\DMO'<Z'
MX-COM;UCQ5XQGLWN?[4\;>*;_5]6M=/:_BM;O0O"\0TNT /[TO\ @W6_X-_;
M?_@F5X8NOVF?VH[#PYXC_;=^(.B2:58:=IMW;>(-"_9S\":K;Q'4?!^@:O '
MT[5?B-XB!-O\0/%^D2W6FVNGQ+X-\'ZC=:')XBUOQD ??G_!P)^V]_PP;_P2
MQ_:/^)>B:O\ V1\3_B;H:_L]?!F6*?[-J"?$'XO6NH:)-K&DS @QZKX(\"P>
M-?B%8-M=?M7A**-D*R4 ?YX/_!L)^QC_ ,-?_P#!6CX)ZGKFD_VC\.?V6K6_
M_:@\;F:'=:'4?AY=Z=:?"RQ,LBFV-U+\7-;\$ZL;"4.]]HNA:[Y<1CMYYH #
M_7AH * *.IZ9IVM:;J&CZO8VFIZ3JUC=:9J>FWT$5U8ZAIU]!):WMC>6LRO#
M<6EW;2R6]Q!*C130R/&ZE6(H _Q-O^"C'[,GC3_@F'_P4L^.WP0\*WVK>&;_
M /9_^-\'C/X'^)XY)!JD'@BZOM.^)?P.\4VM[('6?5;3PKJ7A:>]N(WG2W\0
MV6H6CNTUI,J@'^PM^P!^UCX;_;G_ &+_ -F[]K'PO]DBM?C7\+?#WB?6]-L7
M,EMX=\<VT<FA_$?PDCEW9SX0\?Z3XE\,L[,2[:27_BH _P W/_@\5_Y2\VO_
M &:E\%?_ $__ !)H _O,_P"" G_*&O\ X)[_ /9 M+_]2#Q!0!^P- '\4?\
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MP@5_H&?ST% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'T3^R
M#_R=G^R]_P!G$_!/_P!65X9KYKC/_DC^*_\ LFL]_P#57BCT\E_Y'.4_]C/
M?^I5(_N_K_/P_H4* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H _]#^
M_B@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M9^%_#>@ZUI>C>&DN+G49K+7=?U/7-9U4 ]A_X(;_ /!!Q?\ @C%KO[2.M_\
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M1B\*?M5:!^TS_P *V_X9-%F]^FA_%RT^*7_"$?\ "9?\-+72VK72VO\ 8/\
MPDW_  B=P(2_]J_\([*%_LU@#^U&@#^/+_@IG_P:=+_P46_;B^.W[9J_M\'X
M.?\ "[-0\$WY^&Y_9:'Q#_X1IO!_PS\%_#LQCQ@/VB_ W]L#43X0_M@-_P (
MMI9LAJ']G8N_LGVZZ /ZR?A#X 7X4?";X7_"U-5.NK\-?AWX)\ +K;60TUM8
M7P=X:TSPZ-5.G"ZOQIYU :=]K-D+Z\%J9O(%U<>7YS@'HE '\=/_  4J_P"#
M3-?^"AO[;WQY_;)7]OH_" ?&[6/"NK_\*X/[+(^(/_",MX:^'WA+P*T \7C]
MHWP/_;(OF\+'55D_X1;2C:"_%@4N3:_;;D _K:^%G@A?AE\,?AQ\-TU(ZRGP
M^\!^$/!"ZPUH-/;55\)^'].T%=2:P%S>"R-\+ 71M!>70MC+Y(N9]GFL =Y0
M!_'#_P %(/\ @TK7_@H)^VU\>_VQ5_;]/PB'QP\0:!KW_"N3^RN/'Y\,-HG@
MCPQX.:U_X2\?M'>"?[:%VWAPZDLO_"+Z2;9;T61CN#;?;+@ _KJ^&_@]?A[\
M// 7@%=0.K+X'\%^%O!ZZHUJ+)M27PSH=CHHU V0GNA:&\%E]H-J+JY%N9/*
M$\VSS& */Q7^$WPT^.GPX\8?"'XQ>!O#7Q)^&/C_ $2Z\.^,O _B_2[;6?#W
MB#1[L+YEK?6-TC(6BE2*ZLKJ+RKS3K^WM=0T^XMKZUM[B( _BG_;,_X,J/@Y
MXV\3:SXP_8;_ &G]7^".FZA.;FU^#/QI\-7_ ,2_">DR3.3)9^'OB=I>MZ?X
MUTO1+1-JV5GXG\/?$'6G.[[7XFE^7: ?G)IO_!DM^WC+J7E:O^UG^R-8Z/YF
M/MVF_P#"Y-5U+R<C#_V3<_#?1K7S-NX^5_;6T$ >=@Y4 _>#_@G/_P &B_[$
MO[(_C#P_\6OVG_'.K?MK_$KPS>Z?K/AWPWXD\)VO@'X$Z%K-E(EW#>7_ ,-H
MM=\5ZA\0)[&Z1%@B\9^*+GPC?PH7U+P))*\0M0#^M*...*-(HD2**)%CCCC4
M)''&@"HB(H"HB* JJH 4    4 ?.7[8?[/B_M9?LH?M(_LP-XM/@(?M!_!#X
MF_!O_A-UT(>*#X1/Q%\(:MX5'B/_ (1LZQX>&O#1CJ8OSH_]O:+_ &B(/L@U
M2P\W[5$ ?SF_\$BO^#7]?^"5O[9?A_\ :Y/[<!^.YT#P)X\\%+\/Q^S4/A>+
MEO&^EQ:9_:;>*O\ A?OQ$\H:8J-+]A'AMS>,RI]LM0A+@']85 '->,O"FE>.
M_!_BOP/KHN#H?C+PWKGA3619S?9[LZ5XATNZTC4!:W&R3R+C['=S>1-Y;^5)
MM?8VW:0#^";]H[_@R(>7Q)=ZE^R/^VY#8^$;CS6LO!W[1/P_DO\ 7])(;,,4
M_P 1/AO/8V&N1R*VQG7X9:"]MY0;%YYQ$ !\O^#_ /@R/_;3O=0DB\?_ +8O
M[+OAG2A.5AO?!^B_%?QSJ#VV1B633-:\+?#RVBGQUMUU::,' ^TGJ #^ES_@
MEQ_P;(?L*?\ !.#QCX2^./B#4/$O[4W[3'A$QWWA_P")/Q-T[2](\#^!?$48
M3R_$?PS^$^GOJ-CH.MV;IYVDZ[XL\1^.]?T&\QJ'A[5=&O%CDC /Z0J "@ H
M _EH_P"#O/\ 9DU3XZ?\$G[OXH>'--^VZW^RI\;/ /QAU)H(S+?_ /" :[;:
MW\*/%\%M&JLS6MK>>/O#/BG5F4#[-IGA6XO9&6"UFR >*_\ !F;^T_IGQ/\
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MV71O#/AG3;?2M*M/-E:2XN[@6ULDE[J%Y+/?ZE>O<7]_<7%Y<SSR 'I- !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MD\/ZS9P:AI&NZ!K=C/IFL:-JMA<I);7NFZGIUS<65]9W$;P7-K/+#*C1NRD
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 ?.W[7W_)IG[4/_9NWQK_]5KXEKZ7@S_DL.%/^RER+_P!6F%/,SK_D
M39M_V+,?_P"HM4_A K_0,_GH* "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * /HG]D'_D[/]E[_ +.)^"?_ *LKPS7S7&?_ "1_%?\ V36>_P#J
MKQ1Z>2_\CG*?^QG@/_4JD?W?U_GX?T*% !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 ?__1_OXH * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@#^-_P#X/7_^4<'[,_\ V>YX5_\ 5$?'F@#Q?_@R#_Y-G_;I_P"R
MZ?"__P!0#5Z /[B* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H \U^,
MOPD\"?'WX1_$WX'_ !0T9/$/PX^+W@+Q9\-O'.B._DG4O"OC30[WP]K=M#<*
M"]I=-I]_.;.]AQ<6-T(;NW9)X8V4 _AM_P""*?\ P1__ ."OO_!(W_@J?K^O
MV_P1M?B#^P[X]U;QG\$OB3\3=.^,OP,LD\3_  A_MFYO?AA\:X?AW>?$N+QQ
M8ZYX<U;3] \07VA'PK/XFM/#^J^-?#6F64]UJ:/* ?WN4 % !0 4 % !0 4
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M?A;JUW;O;0^+O$?B'Q?I&C-X]NM%,\>JZ+X:\%:9KNA:[=6WV#7?%&@P!UG
M/YF/^#;#_@EE\5?^"D'[=FG_ +:GQYTS7]>_9R_9_P#B;_PN#XB>/O&B7]Y_
MPO3]H&/5)/%WAOP5::MJ*NGBR^C\82V7Q ^*\\C:C;Q:);0Z%KX@N_'FDR.
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@#YV_:^_Y-,_:A_P"S=OC7_P"JU\2U]+P9_P EAPI_V4N1?^K3"GF9U_R)
MLV_[%F/_ /46J?P@5_H&?ST% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % 'T3^R#_ ,G9_LO?]G$_!/\ ]65X9KYKC/\ Y(_BO_LFL]_]5>*/
M3R7_ )'.4_\ 8SP'_J52/[OZ_P _#^A0H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@#__2_OXH * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@#^=[_@Y-_X)J?M-_P#!4+]CCX-?!;]E>Q\$:CXY\"?M+:#\4M<M
M?'7BV+P=IY\*6/PO^*?A*YDLM1GL;V&XOX]6\6Z.!9L(6>V:XF1SY!1@#S7_
M (-G/^"5_P"UC_P2S^"_[4'@?]J[2_ FEZ[\5OB?X(\5^$4\"^,[7QG:RZ1H
M/A34-(U!K^XMK.T%E.MY<1"*!E<R1Y<$ 8H _IKH * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!\[?M??\FF?M0_\ 9NWQK_\
M5:^):^EX,_Y+#A3_ +*7(O\ U:84\S.O^1-FW_8LQ_\ ZBU3^$"O] S^>@H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H ^B?V0?\ D[/]E[_L
MXGX)_P#JRO#-?-<9_P#)'\5_]DUGO_JKQ1Z>2_\ (YRG_L9X#_U*I']W]?Y^
M']"A0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '__3_OXH * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H ^=OVOO^33/VH?\ LW;XU_\ JM?$M?2\&?\
M)8<*?]E+D7_JTPIYF=?\B;-O^Q9C_P#U%JG\(%?Z!G\]!0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0!]$_L@_P#)V?[+W_9Q/P3_ /5E>&:^
M:XS_ .2/XK_[)K/?_57BCT\E_P"1SE/_ &,\!_ZE4C^[^O\ /P_H4* "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H __U/[^* "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * /G;]K[_DTS]J'_ +-V^-?_ *K7Q+7TO!G_ "6'"G_92Y%_
MZM,*>9G7_(FS;_L68_\ ]1:I_"!7^@9_/04 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * /_]7^_B@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@#YV_:^_Y-,_:A_P"S=OC7_P"JU\2U]+P9_P EAPI_V4N1?^K3"GF9U_R)
MLV_[%F/_ /46J?P@5_H&?ST% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % 'T3^R#_ ,G9_LO?]G$_!/\ ]65X9KYKC/\ Y(_BO_LFL]_]5>*/
M3R7_ )'.4_\ 8SP'_J52/[OZ_P _#^A0H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@#__6_OXH * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@#__U_[^* "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M,^('_B._QO\ _F(H /\ B+ _X(E?]'&?$#_Q'?XW_P#S$4 '_$6!_P $2O\
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M_P $2O\ HXSX@?\ B._QO_\ F(H /^(L#_@B5_T<9\0/_$=_C?\ _,10 ?\
M$6!_P1*_Z.,^('_B._QO_P#F(H /^(L#_@B5_P!'&?$#_P 1W^-__P Q% !_
MQ%@?\$2O^CC/B!_XCO\ &_\ ^8B@ _XBP/\ @B5_T<9\0/\ Q'?XW_\ S$4
M'_$6!_P1*_Z.,^('_B._QO\ _F(H /\ B+ _X(E?]'&?$#_Q'?XW_P#S$4 '
M_$6!_P $2O\ HXSX@?\ B._QO_\ F(H /^(L#_@B5_T<9\0/_$=_C?\ _,10
M ?\ $6!_P1*_Z.,^('_B._QO_P#F(H /^(L#_@B5_P!'&?$#_P 1W^-__P Q
M% !_Q%@?\$2O^CC/B!_XCO\ &_\ ^8B@ _XBP/\ @B5_T<9\0/\ Q'?XW_\
MS$4 '_$6!_P1*_Z.,^('_B._QO\ _F(H /\ B+ _X(E?]'&?$#_Q'?XW_P#S
M$4 '_$6!_P $2O\ HXSX@?\ B._QO_\ F(H /^(L#_@B5_T<9\0/_$=_C?\
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MW^-__P Q% !_Q%@?\$2O^CC/B!_XCO\ &_\ ^8B@ _XBP/\ @B5_T<9\0/\
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M_P!'&?$#_P 1W^-__P Q% !_Q%@?\$2O^CC/B!_XCO\ &_\ ^8B@ _XBP/\
M@B5_T<9\0/\ Q'?XW_\ S$4 '_$6!_P1*_Z.,^('_B._QO\ _F(H /\ B+ _
MX(E?]'&?$#_Q'?XW_P#S$4 '_$6!_P $2O\ HXSX@?\ B._QO_\ F(H /^(L
M#_@B5_T<9\0/_$=_C?\ _,10 ?\ $6!_P1*_Z.,^('_B._QO_P#F(H /^(L#
M_@B5_P!'&?$#_P 1W^-__P Q% !_Q%@?\$2O^CC/B!_XCO\ &_\ ^8B@ _XB
MP/\ @B5_T<9\0/\ Q'?XW_\ S$4 '_$6!_P1*_Z.,^('_B._QO\ _F(H /\
MB+ _X(E?]'&?$#_Q'?XW_P#S$4 '_$6!_P $2O\ HXSX@?\ B._QO_\ F(H
M/^(L#_@B5_T<9\0/_$=_C?\ _,10 ?\ $6!_P1*_Z.,^('_B._QO_P#F(H /
M^(L#_@B5_P!'&?$#_P 1W^-__P Q% !_Q%@?\$2O^CC/B!_XCO\ &_\ ^8B@
M _XBP/\ @B5_T<9\0/\ Q'?XW_\ S$4 '_$6!_P1*_Z.,^('_B._QO\ _F(H
M /\ B+ _X(E?]'&?$#_Q'?XW_P#S$4 '_$6!_P $2O\ HXSX@?\ B._QO_\
MF(H /^(L#_@B5_T<9\0/_$=_C?\ _,10 ?\ $6!_P1*_Z.,^('_B._QO_P#F
M(H /^(L#_@B5_P!'&?$#_P 1W^-__P Q% !_Q%@?\$2O^CC/B!_XCO\ &_\
M^8B@ _XBP/\ @B5_T<9\0/\ Q'?XW_\ S$4 '_$6!_P1*_Z.,^('_B._QO\
M_F(H /\ B+ _X(E?]'&?$#_Q'?XW_P#S$4 '_$6!_P $2O\ HXSX@?\ B._Q
MO_\ F(H /^(L#_@B5_T<9\0/_$=_C?\ _,10 ?\ $6!_P1*_Z.,^('_B._QO
M_P#F(H /^(L#_@B5_P!'&?$#_P 1W^-__P Q% !_Q%@?\$2O^CC/B!_XCO\
M&_\ ^8B@ _XBP/\ @B5_T<9\0/\ Q'?XW_\ S$4 '_$6!_P1*_Z.,^('_B._
MQO\ _F(H /\ B+ _X(E?]'&?$#_Q'?XW_P#S$4 '_$6!_P $2O\ HXSX@?\
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M,^('_B._QO\ _F(H /\ B+ _X(E?]'&?$#_Q'?XW_P#S$4 '_$6!_P $2O\
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M_P $2O\ HXSX@?\ B._QO_\ F(H /^(L#_@B5_T<9\0/_$=_C?\ _,10 ?\
M$6!_P1*_Z.,^('_B._QO_P#F(H /^(L#_@B5_P!'&?$#_P 1W^-__P Q% !_
MQ%@?\$2O^CC/B!_XCO\ &_\ ^8B@ _XBP/\ @B5_T<9\0/\ Q'?XW_\ S$4
M'_$6!_P1*_Z.,^('_B._QO\ _F(H /\ B+ _X(E?]'&?$#_Q'?XW_P#S$4 '
M_$6!_P $2O\ HXSX@?\ B._QO_\ F(H /^(L#_@B5_T<9\0/_$=_C?\ _,10
M ?\ $6!_P1*_Z.,^('_B._QO_P#F(H /^(L#_@B5_P!'&?$#_P 1W^-__P Q
M% !_Q%@?\$2O^CC/B!_XCO\ &_\ ^8B@ _XBP/\ @B5_T<9\0/\ Q'?XW_\
MS$4 '_$6!_P1*_Z.,^('_B._QO\ _F(H /\ B+ _X(E?]'&?$#_Q'?XW_P#S
M$4 '_$6!_P $2O\ HXSX@?\ B._QO_\ F(H /^(L#_@B5_T<9\0/_$=_C?\
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MW^-__P Q% !_Q%@?\$2O^CC/B!_XCO\ &_\ ^8B@ _XBP/\ @B5_T<9\0/\
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M_P!'&?$#_P 1W^-__P Q% !_Q%@?\$2O^CC/B!_XCO\ &_\ ^8B@ _XBP/\
M@B5_T<9\0/\ Q'?XW_\ S$4 '_$6!_P1*_Z.,^('_B._QO\ _F(H /\ B+ _
MX(E?]'&?$#_Q'?XW_P#S$4 '_$6!_P $2O\ HXSX@?\ B._QO_\ F(H /^(L
M#_@B5_T<9\0/_$=_C?\ _,10 ?\ $6!_P1*_Z.,^('_B._QO_P#F(H /^(L#
M_@B5_P!'&?$#_P 1W^-__P Q% !_Q%@?\$2O^CC/B!_XCO\ &_\ ^8B@ _XB
MP/\ @B5_T<9\0/\ Q'?XW_\ S$4 '_$6!_P1*_Z.,^('_B._QO\ _F(H /\
MB+ _X(E?]'&?$#_Q'?XW_P#S$4 '_$6!_P $2O\ HXSX@?\ B._QO_\ F(H
M/^(L#_@B5_T<9\0/_$=_C?\ _,10 ?\ $6!_P1*_Z.,^('_B._QO_P#F(H /
M^(L#_@B5_P!'&?$#_P 1W^-__P Q% !_Q%@?\$2O^CC/B!_XCO\ &_\ ^8B@
M _XBP/\ @B5_T<9\0/\ Q'?XW_\ S$4 '_$6!_P1*_Z.,^('_B._QO\ _F(H
M /\ B+ _X(E?]'&?$#_Q'?XW_P#S$4 '_$6!_P $2O\ HXSX@?\ B._QO_\
MF(H /^(L#_@B5_T<9\0/_$=_C?\ _,10 ?\ $6!_P1*_Z.,^('_B._QO_P#F
M(H /^(L#_@B5_P!'&?$#_P 1W^-__P Q% !_Q%@?\$2O^CC/B!_XCO\ &_\
M^8B@ _XBP/\ @B5_T<9\0/\ Q'?XW_\ S$4 '_$6!_P1*_Z.,^('_B._QO\
M_F(H /\ B+ _X(E?]'&?$#_Q'?XW_P#S$4 '_$6!_P $2O\ HXSX@?\ B._Q
MO_\ F(H /^(L#_@B5_T<9\0/_$=_C?\ _,10 ?\ $6!_P1*_Z.,^('_B._QO
M_P#F(H /^(L#_@B5_P!'&?$#_P 1W^-__P Q% !_Q%@?\$2O^CC/B!_XCO\
M&_\ ^8B@ _XBP/\ @B5_T<9\0/\ Q'?XW_\ S$4 '_$6!_P1*_Z.,^('_B._
MQO\ _F(H /\ B+ _X(E?]'&?$#_Q'?XW_P#S$4 '_$6!_P $2O\ HXSX@?\
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M,^('_B._QO\ _F(H /\ B+ _X(E?]'&?$#_Q'?XW_P#S$4 '_$6!_P $2O\
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M_P $2O\ HXSX@?\ B._QO_\ F(H /^(L#_@B5_T<9\0/_$=_C?\ _,10 ?\
M$6!_P1*_Z.,^('_B._QO_P#F(H /^(L#_@B5_P!'&?$#_P 1W^-__P Q% !_
MQ%@?\$2O^CC/B!_XCO\ &_\ ^8B@ _XBP/\ @B5_T<9\0/\ Q'?XW_\ S$4
M'_$6!_P1*_Z.,^('_B._QO\ _F(H /\ B+ _X(E?]'&?$#_Q'?XW_P#S$4 '
M_$6!_P $2O\ HXSX@?\ B._QO_\ F(H /^(L#_@B5_T<9\0/_$=_C?\ _,10
M ?\ $6!_P1*_Z.,^('_B._QO_P#F(H /^(L#_@B5_P!'&?$#_P 1W^-__P Q
M% !_Q%@?\$2O^CC/B!_XCO\ &_\ ^8B@ _XBP/\ @B5_T<9\0/\ Q'?XW_\
MS$4 '_$6!_P1*_Z.,^('_B._QO\ _F(H /\ B+ _X(E?]'&?$#_Q'?XW_P#S
M$4 '_$6!_P $2O\ HXSX@?\ B._QO_\ F(H /^(L#_@B5_T<9\0/_$=_C?\
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MW^-__P Q% !_Q%@?\$2O^CC/B!_XCO\ &_\ ^8B@ _XBP/\ @B5_T<9\0/\
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M_P!'&?$#_P 1W^-__P Q% !_Q%@?\$2O^CC/B!_XCO\ &_\ ^8B@ _XBP/\
M@B5_T<9\0/\ Q'?XW_\ S$4 '_$6!_P1*_Z.,^('_B._QO\ _F(H /\ B+ _
MX(E?]'&?$#_Q'?XW_P#S$4 '_$6!_P $2O\ HXSX@?\ B._QO_\ F(H /^(L
M#_@B5_T<9\0/_$=_C?\ _,10 ?\ $6!_P1*_Z.,^('_B._QO_P#F(H /^(L#
M_@B5_P!'&?$#_P 1W^-__P Q% !_Q%@?\$2O^CC/B!_XCO\ &_\ ^8B@ _XB
MP/\ @B5_T<9\0/\ Q'?XW_\ S$4 '_$6!_P1*_Z.,^('_B._QO\ _F(H /\
MB+ _X(E?]'&?$#_Q'?XW_P#S$4 '_$6!_P $2O\ HXSX@?\ B._QO_\ F(H
M/^(L#_@B5_T<9\0/_$=_C?\ _,10 ?\ $6!_P1*_Z.,^('_B._QO_P#F(H /
M^(L#_@B5_P!'&?$#_P 1W^-__P Q% !_Q%@?\$2O^CC/B!_XCO\ &_\ ^8B@
M _XBP/\ @B5_T<9\0/\ Q'?XW_\ S$4 '_$6!_P1*_Z.,^('_B._QO\ _F(H
M /\ B+ _X(E?]'&?$#_Q'?XW_P#S$4 '_$6!_P $2O\ HXSX@?\ B._QO_\
MF(H /^(L#_@B5_T<9\0/_$=_C?\ _,10 ?\ $6!_P1*_Z.,^('_B._QO_P#F
M(H /^(L#_@B5_P!'&?$#_P 1W^-__P Q% !_Q%@?\$2O^CC/B!_XCO\ &_\
M^8B@ _XBP/\ @B5_T<9\0/\ Q'?XW_\ S$4 '_$6!_P1*_Z.,^('_B._QO\
M_F(H /\ B+ _X(E?]'&?$#_Q'?XW_P#S$4 '_$6!_P $2O\ HXSX@?\ B._Q
MO_\ F(H /^(L#_@B5_T<9\0/_$=_C?\ _,10 ?\ $6!_P1*_Z.,^('_B._QO
M_P#F(H /^(L#_@B5_P!'&?$#_P 1W^-__P Q% !_Q%@?\$2O^CC/B!_XCO\
M&_\ ^8B@ _XBP/\ @B5_T<9\0/\ Q'?XW_\ S$4 '_$6!_P1*_Z.,^('_B._
MQO\ _F(H /\ B+ _X(E?]'&?$#_Q'?XW_P#S$4 '_$6!_P $2O\ HXSX@?\
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M,^('_B._QO\ _F(H /\ B+ _X(E?]'&?$#_Q'?XW_P#S$4 '_$6!_P $2O\
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M_P $2O\ HXSX@?\ B._QO_\ F(H /^(L#_@B5_T<9\0/_$=_C?\ _,10 ?\
M$6!_P1*_Z.,^('_B._QO_P#F(H /^(L#_@B5_P!'&?$#_P 1W^-__P Q% !_
MQ%@?\$2O^CC/B!_XCO\ &_\ ^8B@ _XBP/\ @B5_T<9\0/\ Q'?XW_\ S$4
M'_$6!_P1*_Z.,^('_B._QO\ _F(H /\ B+ _X(E?]'&?$#_Q'?XW_P#S$4 '
M_$6!_P $2O\ HXSX@?\ B._QO_\ F(H /^(L#_@B5_T<9\0/_$=_C?\ _,10
M ?\ $6!_P1*_Z.,^('_B._QO_P#F(H /^(L#_@B5_P!'&?$#_P 1W^-__P Q
M% !_Q%@?\$2O^CC/B!_XCO\ &_\ ^8B@ _XBP/\ @B5_T<9\0/\ Q'?XW_\
MS$4 '_$6!_P1*_Z.,^('_B._QO\ _F(H /\ B+ _X(E?]'&?$#_Q'?XW_P#S
M$4 '_$6!_P $2O\ HXSX@?\ B._QO_\ F(H /^(L#_@B5_T<9\0/_$=_C?\
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MW^-__P Q% !_Q%@?\$2O^CC/B!_XCO\ &_\ ^8B@ _XBP/\ @B5_T<9\0/\
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M_P!'&?$#_P 1W^-__P Q% !_Q%@?\$2O^CC/B!_XCO\ &_\ ^8B@ _XBP/\
M@B5_T<9\0/\ Q'?XW_\ S$4 '_$6!_P1*_Z.,^('_B._QO\ _F(H /\ B+ _
MX(E?]'&?$#_Q'?XW_P#S$4 '_$6!_P $2O\ HXSX@?\ B._QO_\ F(H /^(L
M#_@B5_T<9\0/_$=_C?\ _,10 ?\ $6!_P1*_Z.,^('_B._QO_P#F(H /^(L#
M_@B5_P!'&?$#_P 1W^-__P Q% !_Q%@?\$2O^CC/B!_XCO\ &_\ ^8B@ _XB
MP/\ @B5_T<9\0/\ Q'?XW_\ S$4 '_$6!_P1*_Z.,^('_B._QO\ _F(H /\
MB+ _X(E?]'&?$#_Q'?XW_P#S$4 '_$6!_P $2O\ HXSX@?\ B._QO_\ F(H
M/^(L#_@B5_T<9\0/_$=_C?\ _,10 ?\ $6!_P1*_Z.,^('_B._QO_P#F(H /
M^(L#_@B5_P!'&?$#_P 1W^-__P Q% !_Q%@?\$2O^CC/B!_XCO\ &_\ ^8B@
M _XBP/\ @B5_T<9\0/\ Q'?XW_\ S$4 '_$6!_P1*_Z.,^('_B._QO\ _F(H
M /\ B+ _X(E?]'&?$#_Q'?XW_P#S$4 '_$6!_P $2O\ HXSX@?\ B._QO_\
MF(H /^(L#_@B5_T<9\0/_$=_C?\ _,10 ?\ $6!_P1*_Z.,^('_B._QO_P#F
M(H /^(L#_@B5_P!'&?$#_P 1W^-__P Q% !_Q%@?\$2O^CC/B!_XCO\ &_\
M^8B@ _XBP/\ @B5_T<9\0/\ Q'?XW_\ S$4 '_$6!_P1*_Z.,^('_B._QO\
M_F(H /\ B+ _X(E?]'&?$#_Q'?XW_P#S$4 '_$6!_P $2O\ HXSX@?\ B._Q
MO_\ F(H /^(L#_@B5_T<9\0/_$=_C?\ _,10 ?\ $6!_P1*_Z.,^('_B._QO
M_P#F(H /^(L#_@B5_P!'&?$#_P 1W^-__P Q% !_Q%@?\$2O^CC/B!_XCO\
M&_\ ^8B@ _XBP/\ @B5_T<9\0/\ Q'?XW_\ S$4 '_$6!_P1*_Z.,^('_B._
MQO\ _F(H /\ B+ _X(E?]'&?$#_Q'?XW_P#S$4 '_$6!_P $2O\ HXSX@?\
MB._QO_\ F(H /^(L#_@B5_T<9\0/_$=_C?\ _,10 ?\ $6!_P1*_Z.,^('_B
M._QO_P#F(H /^(L#_@B5_P!'&?$#_P 1W^-__P Q% !_Q%@?\$2O^CC/B!_X
MCO\ &_\ ^8B@ _XBP/\ @B5_T<9\0/\ Q'?XW_\ S$4 '_$6!_P1*_Z.,^('
M_B._QO\ _F(H /\ B+ _X(E?]'&?$#_Q'?XW_P#S$4 '_$6!_P $2O\ HXSX
M@?\ B._QO_\ F(H /^(L#_@B5_T<9\0/_$=_C?\ _,10 ?\ $6!_P1*_Z.,^
M('_B._QO_P#F(H /^(L#_@B5_P!'&?$#_P 1W^-__P Q% !_Q%@?\$2O^CC/
MB!_XCO\ &_\ ^8B@ _XBP/\ @B5_T<9\0/\ Q'?XW_\ S$4 '_$6!_P1*_Z.
M,^('_B._QO\ _F(H /\ B+ _X(E?]'&?$#_Q'?XW_P#S$4 '_$6!_P $2O\
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M_P $2O\ HXSX@?\ B._QO_\ F(H /^(L#_@B5_T<9\0/_$=_C?\ _,10 ?\
M$6!_P1*_Z.,^('_B._QO_P#F(H /^(L#_@B5_P!'&?$#_P 1W^-__P Q% !_
MQ%@?\$2O^CC/B!_XCO\ &_\ ^8B@ _XBP/\ @B5_T<9\0/\ Q'?XW_\ S$4
M'_$6!_P1*_Z.,^('_B._QO\ _F(H /\ B+ _X(E?]'&?$#_Q'?XW_P#S$4 '
M_$6!_P $2O\ HXSX@?\ B._QO_\ F(H /^(L#_@B5_T<9\0/_$=_C?\ _,10
M ?\ $6!_P1*_Z.,^('_B._QO_P#F(H /^(L#_@B5_P!'&?$#_P 1W^-__P Q
M% !_Q%@?\$2O^CC/B!_XCO\ &_\ ^8B@ _XBP/\ @B5_T<9\0/\ Q'?XW_\
MS$4 '_$6!_P1*_Z.,^('_B._QO\ _F(H /\ B+ _X(E?]'&?$#_Q'?XW_P#S
M$4 '_$6!_P $2O\ HXSX@?\ B._QO_\ F(H /^(L#_@B5_T<9\0/_$=_C?\
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MW^-__P Q% !_Q%@?\$2O^CC/B!_XCO\ &_\ ^8B@ _XBP/\ @B5_T<9\0/\
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M_P!'&?$#_P 1W^-__P Q% !_Q%@?\$2O^CC/B!_XCO\ &_\ ^8B@ _XBP/\
M@B5_T<9\0/\ Q'?XW_\ S$4 '_$6!_P1*_Z.,^('_B._QO\ _F(H /\ B+ _
MX(E?]'&?$#_Q'?XW_P#S$4 '_$6!_P $2O\ HXSX@?\ B._QO_\ F(H /^(L
M#_@B5_T<9\0/_$=_C?\ _,10 ?\ $6!_P1*_Z.,^('_B._QO_P#F(H /^(L#
M_@B5_P!'&?$#_P 1W^-__P Q% !_Q%@?\$2O^CC/B!_XCO\ &_\ ^8B@ _XB
MP/\ @B5_T<9\0/\ Q'?XW_\ S$4 '_$6!_P1*_Z.,^('_B._QO\ _F(H /\
MB+ _X(E?]'&?$#_Q'?XW_P#S$4 '_$6!_P $2O\ HXSX@?\ B._QO_\ F(H
M/^(L#_@B5_T<9\0/_$=_C?\ _,10 ?\ $6!_P1*_Z.,^('_B._QO_P#F(H /
M^(L#_@B5_P!'&?$#_P 1W^-__P Q% !_Q%@?\$2O^CC/B!_XCO\ &_\ ^8B@
M _XBP/\ @B5_T<9\0/\ Q'?XW_\ S$4 '_$6!_P1*_Z.,^('_B._QO\ _F(H
M /\ B+ _X(E?]'&?$#_Q'?XW_P#S$4 '_$6!_P $2O\ HXSX@?\ B._QO_\
MF(H /^(L#_@B5_T<9\0/_$=_C?\ _,10 ?\ $6!_P1*_Z.,^('_B._QO_P#F
M(H /^(L#_@B5_P!'&?$#_P 1W^-__P Q% !_Q%@?\$2O^CC/B!_XCO\ &_\
M^8B@ _XBP/\ @B5_T<9\0/\ Q'?XW_\ S$4 '_$6!_P1*_Z.,^('_B._QO\
M_F(H /\ B+ _X(E?]'&?$#_Q'?XW_P#S$4 '_$6!_P $2O\ HXSX@?\ B._Q
MO_\ F(H /^(L#_@B5_T<9\0/_$=_C?\ _,10 ?\ $6!_P1*_Z.,^('_B._QO
M_P#F(H /^(L#_@B5_P!'&?$#_P 1W^-__P Q% !_Q%@?\$2O^CC/B!_XCO\
M&_\ ^8B@ _XBP/\ @B5_T<9\0/\ Q'?XW_\ S$4 '_$6!_P1*_Z.,^('_B._
MQO\ _F(H /\ B+ _X(E?]'&?$#_Q'?XW_P#S$4 '_$6!_P $2O\ HXSX@?\
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M,^('_B._QO\ _F(H /\ B+ _X(E?]'&?$#_Q'?XW_P#S$4 '_$6!_P $2O\
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M_P $2O\ HXSX@?\ B._QO_\ F(H /^(L#_@B5_T<9\0/_$=_C?\ _,10 ?\
M$6!_P1*_Z.,^('_B._QO_P#F(H /^(L#_@B5_P!'&?$#_P 1W^-__P Q% !_
MQ%@?\$2O^CC/B!_XCO\ &_\ ^8B@ _XBP/\ @B5_T<9\0/\ Q'?XW_\ S$4
M'_$6!_P1*_Z.,^('_B._QO\ _F(H /\ B+ _X(E?]'&?$#_Q'?XW_P#S$4 '
M_$6!_P $2O\ HXSX@?\ B._QO_\ F(H /^(L#_@B5_T<9\0/_$=_C?\ _,10
M ?\ $6!_P1*_Z.,^('_B._QO_P#F(H /^(L#_@B5_P!'&?$#_P 1W^-__P Q
M% !_Q%@?\$2O^CC/B!_XCO\ &_\ ^8B@ _XBP/\ @B5_T<9\0/\ Q'?XW_\
MS$4 '_$6!_P1*_Z.,^('_B._QO\ _F(H /\ B+ _X(E?]'&?$#_Q'?XW_P#S
M$4 '_$6!_P $2O\ HXSX@?\ B._QO_\ F(H /^(L#_@B5_T<9\0/_$=_C?\
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MW^-__P Q% !_Q%@?\$2O^CC/B!_XCO\ &_\ ^8B@ _XBP/\ @B5_T<9\0/\
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M_P!'&?$#_P 1W^-__P Q% !_Q%@?\$2O^CC/B!_XCO\ &_\ ^8B@ _XBP/\
M@B5_T<9\0/\ Q'?XW_\ S$4 '_$6!_P1*_Z.,^('_B._QO\ _F(H /\ B+ _
MX(E?]'&?$#_Q'?XW_P#S$4 '_$6!_P $2O\ HXSX@?\ B._QO_\ F(H /^(L
M#_@B5_T<9\0/_$=_C?\ _,10 ?\ $6!_P1*_Z.,^('_B._QO_P#F(H /^(L#
M_@B5_P!'&?$#_P 1W^-__P Q% !_Q%@?\$2O^CC/B!_XCO\ &_\ ^8B@ _XB
MP/\ @B5_T<9\0/\ Q'?XW_\ S$4 '_$6!_P1*_Z.,^('_B._QO\ _F(H /\
MB+ _X(E?]'&?$#_Q'?XW_P#S$4 '_$6!_P $2O\ HXSX@?\ B._QO_\ F(H
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@#__T_[^* "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H __]3^_B@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M/__5_OXH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M'E24KJ][:'=E&>8/.H5YX.->*P\H1G[:$8:S4G'EY:D[Z1=[VZ'UG7QY[ 4
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M;]OW]J?]H7]I[2OAM\6OB#8^)O!]YX-\7:I-IL7@KP3H4GV_2;.WN+&X2_\
M#_A_3+]?*<L#%]H,$BN1)$Q"%/L?%#P[X2X;X4JYGD^6U,+C88W!48U7CL=B
M%[.M.4:D?9XC$5:>JMKR\RMHUJ>-PKQ%F^99M'"XW$QJT'AZT^14,/3]Z"CR
MOFI4H2T[7MY;']%-?S4?I@4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M $=#^T3_ .'K^)7_ ,TU'^IG!_\ T2?#7_ABRO\ ^90_MK.?^AMF?_A?BO\
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M )E#^VLY_P"AMF?_ (7XK_Y:'_#7W[6?_1T/[1/_ (>OXE?_ #34?ZF<'_\
M1)\-?^&+*_\ YE#^VLY_Z&V9_P#A?BO_ ):'_#7W[6?_ $=#^T3_ .'K^)7_
M ,TU'^IG!_\ T2?#7_ABRO\ ^90_MK.?^AMF?_A?BO\ Y:'_  U]^UG_ -'0
M_M$_^'K^)7_S34?ZF<'_ /1)\-?^&+*__F4/[:SG_H;9G_X7XK_Y:'_#7W[6
M?_1T/[1/_AZ_B5_\TU'^IG!__1)\-?\ ABRO_P"90_MK.?\ H;9G_P"%^*_^
M6A_PU]^UG_T=#^T3_P"'K^)7_P TU'^IG!__ $2?#7_ABRO_ .90_MK.?^AM
MF?\ X7XK_P"6A_PU]^UG_P!'0_M$_P#AZ_B5_P#--1_J9P?_ -$GPU_X8LK_
M /F4/[:SG_H;9G_X7XK_ .6A_P -??M9_P#1T/[1/_AZ_B5_\TU'^IG!_P#T
M2?#7_ABRO_YE#^VLY_Z&V9_^%^*_^6A_PU]^UG_T=#^T3_X>OXE?_--1_J9P
M?_T2?#7_ (8LK_\ F4/[:SG_ *&V9_\ A?BO_EH?\-??M9_]'0_M$_\ AZ_B
M5_\ --1_J9P?_P!$GPU_X8LK_P#F4/[:SG_H;9G_ .%^*_\ EH?\-??M9_\
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MJ9P?_P!$GPU_X8LK_P#F4/[:SG_H;9G_ .%^*_\ EH?\-??M9_\ 1T/[1/\
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MY_Z&V9_^%^*_^6A_PU]^UG_T=#^T3_X>OXE?_--1_J9P?_T2?#7_ (8LK_\
MF4/[:SG_ *&V9_\ A?BO_EH?\-??M9_]'0_M$_\ AZ_B5_\ --1_J9P?_P!$
MGPU_X8LK_P#F4/[:SG_H;9G_ .%^*_\ EH?\-??M9_\ 1T/[1/\ X>OXE?\
MS34?ZF<'_P#1)\-?^&+*_P#YE#^VLY_Z&V9_^%^*_P#EH?\ #7W[6?\ T=#^
MT3_X>OXE?_--1_J9P?\ ]$GPU_X8LK_^90_MK.?^AMF?_A?BO_EH?\-??M9_
M]'0_M$_^'K^)7_S34?ZF<'_]$GPU_P"&+*__ )E#^VLY_P"AMF?_ (7XK_Y:
M'_#7W[6?_1T/[1/_ (>OXE?_ #34?ZF<'_\ 1)\-?^&+*_\ YE#^VLY_Z&V9
M_P#A?BO_ ):'_#7W[6?_ $=#^T3_ .'K^)7_ ,TU'^IG!_\ T2?#7_ABRO\
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M_F4/[:SG_H;9G_X7XK_Y:'_#7W[6?_1T/[1/_AZ_B5_\TU'^IG!__1)\-?\
MABRO_P"90_MK.?\ H;9G_P"%^*_^6A_PU]^UG_T=#^T3_P"'K^)7_P TU'^I
MG!__ $2?#7_ABRO_ .90_MK.?^AMF?\ X7XK_P"6A_PU]^UG_P!'0_M$_P#A
MZ_B5_P#--1_J9P?_ -$GPU_X8LK_ /F4/[:SG_H;9G_X7XK_ .6A_P -??M9
M_P#1T/[1/_AZ_B5_\TU'^IG!_P#T2?#7_ABRO_YE#^VLY_Z&V9_^%^*_^6A_
MPU]^UG_T=#^T3_X>OXE?_--1_J9P?_T2?#7_ (8LK_\ F4/[:SG_ *&V9_\
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MXK_Y:'_#7W[6?_1T/[1/_AZ_B5_\TU'^IG!__1)\-?\ ABRO_P"90_MK.?\
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M'0_M$_\ AZ_B5_\ --1_J9P?_P!$GPU_X8LK_P#F4/[:SG_H;9G_ .%^*_\
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M_J9P?_T2?#7_ (8LK_\ F4/[:SG_ *&V9_\ A?BO_EH?\-??M9_]'0_M$_\
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MU]^UG_T=#^T3_P"'K^)7_P TU'^IG!__ $2?#7_ABRO_ .90_MK.?^AMF?\
MX7XK_P"6A_PU]^UG_P!'0_M$_P#AZ_B5_P#--1_J9P?_ -$GPU_X8LK_ /F4
M/[:SG_H;9G_X7XK_ .6A_P -??M9_P#1T/[1/_AZ_B5_\TU'^IG!_P#T2?#7
M_ABRO_YE#^VLY_Z&V9_^%^*_^6A_PU]^UG_T=#^T3_X>OXE?_--1_J9P?_T2
M?#7_ (8LK_\ F4/[:SG_ *&V9_\ A?BO_EH?\-??M9_]'0_M$_\ AZ_B5_\
M--1_J9P?_P!$GPU_X8LK_P#F4/[:SG_H;9G_ .%^*_\ EH?\-??M9_\ 1T/[
M1/\ X>OXE?\ S34?ZF<'_P#1)\-?^&+*_P#YE#^VLY_Z&V9_^%^*_P#EH?\
M#7W[6?\ T=#^T3_X>OXE?_--1_J9P?\ ]$GPU_X8LK_^90_MK.?^AMF?_A?B
MO_EH?\-??M9_]'0_M$_^'K^)7_S34?ZF<'_]$GPU_P"&+*__ )E#^VLY_P"A
MMF?_ (7XK_Y:'_#7W[6?_1T/[1/_ (>OXE?_ #34?ZF<'_\ 1)\-?^&+*_\
MYE#^VLY_Z&V9_P#A?BO_ ):'_#7W[6?_ $=#^T3_ .'K^)7_ ,TU'^IG!_\
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ME?\ S34?ZF<'_P#1)\-?^&+*_P#YE#^VLY_Z&V9_^%^*_P#EH?\ #7W[6?\
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % '__0_OXH * "@ H * "@#^.W_@KW_P GT_$G_L6_AM_Z
M@NAU_:?@Q_R0.6_]A>9_^IU8_$N-/^2@Q7_7K"_^H],_1;_@@S_R)?[1_P#V
M-'PZ_P#33XKK\T^D'_O_  S_ -@>8_\ I["GT_AY_N^9_P#7[#?^D53]_*_G
M<_1@H * /AC]J/\ X*&_LX_LI7$WA[QCK]]XJ^(B00SK\./ ]O!JOB"UCN4#
MV\NNW5Q<6>B>'(WC:*X$&K:E#JTUG+'>6&E7L#*3]]PGX;\3<71CB,%AX83+
M7)Q_M/'RE1PTG'22P\(QG7Q+33C>C2E2C-.$ZL&G;Y_-N)<KR=NG7J2JXFR?
MU7#I3J)/;VC;C3I*UG:<E)QUC"2/RI\2_P#!>7Q ]W.G@[]G+1[6Q5]MK/XE
M^(5[?W<L8Z23VFE^%]-AMW;KY$=[=+'T^T2=:_7,+]'S#J$?KO$U:52WO1PN
M6PIP3[1G5Q51R2[NG#_"CY"KXAU+OV&5P4>CJXEMOUC"C%+T4GZF]X(_X+QP
M/?0P?$C]GB6VTQMOGZIX(\=)>WT'/S&'0=>T&PM[K*\JK^([/:5VEF#[DY\?
M]'V2IN65\21E57PTL?@'3IOM?$8>O4E'Y8:?X6>F'\0X\R6*RQQAUGA\0I27
MI3J4X)_^#4?LQ^SM^U-\$_VI?"\_B?X/>+HM:_L[[/'X@\.W\#Z5XK\,7%RA
M:&#7-#N?W\*2E)8[;4K-[W1;^2WN4T[4[LVT_E_B/$G"6>\)XJ.$SK!.A[3F
M>'Q%.2JX3%1B[.6'KP]UM:.5*:A6IJ4?:4H<T;_<Y9F^ S>BZN"K*?+;VE*2
MY*U%O95*;U6S2E'FA*SY9.S/H>OFSTC\H/VKO^"J_@O]E;XSZY\&M7^$7BCQ
M?J&A:7X?U*?6]-\2:3I=G,-?TJWU:*&*UN;"ZF'V>&YCBDD>0;Y ^U H4M^O
M<(>$>.XNR.AG=#.<)@J=>KB*4:%7"UJLX_5ZLJ3;E"I&/O.-TDM%8^/SCB_#
MY1CIX&>"K5I4X4Y.<*D(1?M(*:23BWHG8[WX!_\ !2_X0_&#X,_%?XY^+M%O
M_A%X*^$NJZ7I&K2:[JMMKMWJMWJ]F;C3[71[;2[.">[U&\G\NQLM-@AFN+FX
MD!&R))'3S^(?"W.LESO*,@P=>GG..SBC5K45AZ4L/"C"C/EJ2K2JS<84H1O4
MG5DXQC%=79/HR[BG!8W XS,*T)8+#X.<83]I-3E.4HWBH*"3<I.T8P2;;\CX
M+\5_\%Y--M]?E@\$?LY7FJ>%X+N18=1\3_$6+1-<U.R$F(I6TG2_"6NV.BW#
MQC<T7]L:XB,P7S&"9?\ 0<']'RK+#*6/XEA1Q<H)NEA,M=>A2G;6/MJN,P\Z
MT4]$_8T&TKVZ'SM;Q#@JC6'RQSHIZ2JXE4ZDH]'R0HU(P=NG/.Q^N7C+]J#2
M/!?[)%K^UC>^$]2N]'N?A=X&^)A\&VNI6HU*.#QQ9^'KFVT@:K+;I:O+8-X@
MABGO/LB)*MO))';J66,?CF"X4K8[C&7"$,92A6CFV/RKZ[*E+V3E@)XB$JWL
M5)R4:GU=N,.=N/,DY.US[2OFT*&3+.)49.F\)A\5[!27/:O&FU#FM:\?:)-V
MZ:+H?FGX6_X+B?#WQ1XG\.>&8?@'XSM)?$6O:1H45U)XQT22.VDU?4+?3TN)
M(UTE6=(6N!(R*RLRJ5!!.:_4<7X"YEA,)B<4^(<#-8;#UL0X+!5TY*C3E4<4
M_:V3:C9.VA\K1X^PM:K2HK+J\75J0IINM3LG.2BF_<V5S]T*_ C] .3\<^.O
M!_PS\)ZWXZ\?>(M+\*>$?#EFU]K6O:Q<"VL;&W#)$FYL-)-/<3R16MG9VT<U
MW?7<T%G9P3W4T43]> P&-S3&4,OR[#5<7C,3-4Z&'H1YJE25KZ+91C%.4YR:
MA3A&4YRC"+:QKXBAA:,\1B*D*-&E'FG4F^6,5M][=E%+63:C%-M(_#_XM_\
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M7QK3EP-7C%-MYGEJC%*[;=62226[>R2/G>![+/8-Z)87$W>R248GZO?M&?\
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M2ERR:B?7M?&GM!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0!\[?M??\ )IG[4/\ V;M\:_\ U6OB6OI>
M#/\ DL.%/^RER+_U:84\S.O^1-FW_8LQ_P#ZBU3^$"O] S^>@H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * /Z)/^"!W_ #==_P!T+_\ >QU_-?TAO^:0_P"Z_P#^\0_3/#K_
M )G'_=/_ /=T_HDK^:S],"@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M<H]/MH^'N*='FEF-"-?E_A*A.5)2M\/M^>,K7TYE0\U'H?I)^UYX)U;X:?\
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M_)"U_P#L9Y=_Z7,^@X&_Y'L/^P7$?^DQ/ZI?C+\5/#?P0^%?CSXL^+9-F@>
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M=*,E&MBJJ?)%J*4*-&"UG*%-12A=1IT^7GFFX*7Z^?LK_P#!)KQM^RU^T_\
M"KXSV7Q?\+_$'PGX37QK'XBLKCPSJG@[Q!%_PD'P_P#$WAC3FT>RCU+Q7IVI
M*NIZU UY]KU?2&@LXWF@6ZEQ;C\9XM\8,!Q9PIFV1SR7%9;B\6\"\-..*I8W
M#/ZMF.%Q53VTW2P=2D_94)*')1K)S:BW%>\?:91P;7RC-L'CHXVEB:-'VZJQ
M=&5"HO:8:K2CR1YZT9>]-7O.%DKI/8^/O^"ZW_)??@Y_V1]__4T\15]IX ?\
MD]G?_8YC_P"H.'/$\0?^1C@?^P)_^GZAJ?\ !"/_ )+'\<O^R9Z)_P"I3!67
MT@/^1+D'_8TQ'_J(R_#W_?<P_P"P6G_Z=/Z$/VA?^2!?''_LC_Q+_P#4+UJO
MYPX<_P"2@R+_ +'.5_\ J;0/TG,O^1=C_P#L"Q7_ *8F?P+U_H>?SH?Z /P=
M_P"21?"S_LG'@?\ ]1G2Z_SJSK_D<YM_V,\?_P"I54_H_!_[GA/^P:A_Z:B?
MSA?\%UO^2^_!S_LC[_\ J:>(J_IKP _Y)[._^QS'_P!0<.?E_B#_ ,C' _\
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0!^%?_!P?_P4P^/O_!*?]B3P-^TA^SEX:^$WBGQSXC_:2\#?"'4=,^,?
MA[Q9XE\+IX7\2_#SXL^*;ZZL['P=XY^'^J0ZY%JG@?18[6[FUFYL4L9=2@ET
MR:>XMKJR /6O^"&_[>WQD_X*4_\ !//X=_M7_'G0?AQX;^(WB[QO\4O#FHZ3
M\*=%\1Z!X-@L/!/C/4?#NE/9Z;XJ\6^-]82[FLK..6_DFU^>*6X9F@@MH\1
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MG_!1G_I'5\)/_ /XZ?\ R70 ?\1CG_!1G_I'5\)/_ /XZ?\ R70!]&?L??\
M!UO^WM^T7^UG^S#^S]XP_8-^%_@[PE\<?V@_@U\(?%'BVPM/C,+[PQX=^(_Q
M$\.^#]:\061U2Z.F+=Z/INL7.H6S:@K6*S6Z&[5H ZD _O+H _@ _:E_X.]_
MVQO@A^U[^TM^S1X%_8W^!'CBT^"7[0GQM^#GAR]?5/BE=>)?$6C_  J^(7BC
MPC9ZO?:=H^J&+^T;S2_#ZZGJ:6%NMK!(UPT21V\8"@'D_P#Q&.?\%&?^D=7P
MD_\  /XZ?_)= !_Q&.?\%&?^D=7PD_\  /XZ?_)= !_Q&.?\%&?^D=7PD_\
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % 'SM^U]_R:9^U#_V;M\:__5:^):^EX,_Y+#A3_LI<B_\ 5IA3S,Z_Y$V;
M?]BS'_\ J+5/X0*_T#/YZ"@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H _HD_X('?\W7?]T+_
M />QU_-?TAO^:0_[K_\ [Q#],\.O^9Q_W3__ '=/Z)*_FL_3 H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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MRT2'48AT^T?\(ZOB>PCW9"I?2R*/,2-TZ?'?,ZV$X7P.7T:CIK-<SC'$)?\
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M]CF/_J#AS\F\0?\ D8X'_L"?_I^H:G_!"/\ Y+'\<O\ LF>B?^I3!67T@/\
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M )$^*_[&57_U%PAY1_P7E_Y$G]G'_L:?B)_Z:?"M>O\ 1\_W_B7_ + \N_\
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MT>7PIX@@O+[2F^"WQ:U^\MX=9M]-NKOP*VJ^)=!^-'A'6=*TG5/']_X\ /\
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M-/UKXI:]IDU]IG@KP9I]_=VOABSU"3X=?#Z2^U#5?B/\0_&8!_H6_P#!.O\
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H ^=OVOO^33/VH?\ LW;XU_\ JM?$M?2\&?\ )8<*?]E+D7_JTPIYF=?\
MB;-O^Q9C_P#U%JG\(%?Z!G\]!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?T2?\$#O^;KO^
MZ%_^]CK^:_I#?\TA_P!U_P#]XA^F>'7_ #./^Z?_ .[I_1)7\UGZ8% !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M_8;!!/@/Q<P!!*GXB^+=K ?PG;J"M@]#M93CH0>:7_$:./?^AA@EZ99@]/\
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MJP\/R,HU?Q;\$_C5%J^L62#:'?3?AYXZ\$Z)9:FS#<RQW7Q/TD)M5#*^\O&
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M3J5M%>Z;JFEZC9236>H:=J%G-#=V5[:32VUU;2Q3P2/$Z,0#1H * "@ H *
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M7WAF^\;>"?$WA>Q\0Z;<W-I>:)>ZWH]WI]IJ<,UG)%<C[%<3QSR1Q2*9X4>
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MM_+\F/Y$% 'YL?\ !S)_R@[_ &[_ /L7/@M_ZTK\&* /RA_X,F?^3 /VJ_\
ML\.\_P#5*_"F@#^SF@#_ "Y?^"0/_*VUXE_[.\_X*;?^H'^U+0!_J-4 >;?&
M'XP_"_\ 9^^%_C?XT_&GQQX?^&WPK^&^@7GB?QMXW\47JV&BZ!HUD%#SSR8>
M:XN;F>2"PTO2[&&ZU36=5NK+2-(LKW5+ZSM)@#_,[_;._;)_;8_X.FOV]O"?
M[&O[(FA:SX#_ &0?A_XCO_$/A/0M9:_M/#N@^$M)N!HNL?M4?M*W&G&:U;7C
M8:@UCX*\)1?:D\)IXBM?ASX,.M^,?%7B/Q'XN /] #_@F=_P33_9W_X):_LU
M:#^SS\!-+:]O)6M]=^*OQ4UFSM8?&WQA\?M:I!?^+/$TMN919V4 W6/A3PK:
MW$VE^$M"6+3K66]OY=6UG5@#]#: /S^_X*Q_\HM?^"DG_9AG[77_ *H'Q_0!
M_(%_P8S_ 'O^"G/^[^QO_/\ :DH _O\ J "@ H * "@#_+Y_X)6_\K?OCW_L
M]S_@J-_ZAW[5U '^H-0 4 % !0 4 % !0!_EE?\ !:[_ )6KH/\ LY?_ ()Q
M_P#JN/V:* /]36@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#S_
M .)_Q8^%GP1\%ZK\2/C/\2O 'PB^'>A/81:WX]^)_C+P[X!\%Z/)JE_;:5I<
M>J^*?%>HZ3H>GOJ.J7EIIM@EW?0M>7]U;6=N)+B>*-@#C/@I^T_^S3^TK!XB
MN?V<_P!H?X&?'ZV\'RZ7!XMG^"GQ:\ _%2#PO-K:7SZ+#XBE\"Z_KL>B2ZO'
MI>IOI<>I-;-?IIU\UH)19W'E@'N= !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!S7C/Q)%X-\'^*_%\]K
M)>P>%?#6N^))K*&18I;N+0]+NM3DM8I75DBDG2U,22,K*C,&92!B@#^%8_\
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M!\[?M??\FF?M0_\ 9NWQK_\ 5:^):^EX,_Y+#A3_ +*7(O\ U:84\S.O^1-F
MW_8LQ_\ ZBU3^$"O] S^>@H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /Z)/^"!W_-UW_="_
M_>QU_-?TAO\ FD/^Z_\ ^\0_3/#K_F<?]T__ -W3^B2OYK/TP* "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MFW_8SQ__ *E53^C\'_N>$_[!J'_IJ)_.%_P76_Y+[\'/^R/O_P"IIXBK^FO
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M6M_'+X9W<C[G1?$'A;XEZ_/XYE*,(X8+G1/BCH\=O"TLESI^J2^7L /Z#_\
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M&'7=1>])DA.DVUUIE[9Q7%UIVI7D=K<^2 ?I;0 4 % !0 4 % !0 4 % !0
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MU^(S*JADMO%ULLJI-YD: 'ZRT ?Y>_\ P4<_Y7'?AY_VD,_X)7_^HO\ L@T
M?ZA% !0 4 % '\$'_!\EK=G%X8_X)L>&RI:_O==_:LUM&&-L5GI>G_L]V$BO
M_$#/-J\1BQP1;2Y^Z, ']4?_  16\-ZAX4_X))?\$Y]*U152ZF_9 ^!^OJB_
MPV?BSP/I7BK3 PYQ)_9NLVGFKU63<I (P #Y@_X.9/\ E!W^W?\ ]BY\%O\
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M24 ?W_4 % !0 4 % '^7S_P2M_Y6_?'O_9[G_!4;_P!0[]JZ@#_4&H * "@
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MSQ. ?T#4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0!\[?M??\FF?M0_]F[?&O\ ]5KXEKZ7@S_D
ML.%/^RER+_U:84\S.O\ D39M_P!BS'_^HM4_A K_ $#/YZ"@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H _HD_P""!W_-UW_="_\ WL=?S7](;_FD/^Z__P"\0_3/#K_F<?\
M=/\ _=T_HDK^:S],"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MLI*-2#@^6Z:32>ETU?H?D/\ \.-/V3/^BA?M$_\ A6?#7_YTE?LW_$?.,/\
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MZ1A%WM[UM!9-PU@,DK5:^$JXNI.M2]E)8B=&45%24_=5.A2:=XK=M6Z'U?\
M%+X4?#KXU>#-4^'OQ2\)Z5XR\(:N$-WI&JQ.1'<0AOL]_I]Y;R07^E:I:;W-
MGJFF75IJ%H7<V]S'O;/R&4YOF618VEF.4XRM@<91NH5J+6L7;FIU(24J=6E.
MRYZ56$Z<[+FB[(]C%X/#8ZA/#8NC"O0G:\)KJMI1:M*$H_9E!J2Z-'XU^-/^
M"%'P@U2_N;GP%\;?'W@^SGNI)HM.\0>'M#\:16<$DI<6=O<6UWX1NFB@0^3!
M+=R75QL5&N);B0.[_MF!\?\ .J5.,<PR++L;.,%%U</B*^!<Y)6YY1E'&03D
M]6H*$>D5%6M\/7\/L#*3>'Q^)HINZC4ITZZBOY4TZ+LME=M]VSVS]GW_ (([
M_LV_!OQ%I_C#QGJ7B#XU:_I%U%>:59>+;73=-\%6MS;X:"YG\)V*W/\ :\T<
MN9!!KFK:EI1VQ;]+:2/S6\+B/QIXGSO"U,%@J6&R/#5H.G6G@Y5*F-G"6DH1
MQ=1Q]C%K2]"C2JV;7M;.QWY;P3E6!JQKUI5,=4@U*$:RA&A%K9NC%/G?E4G.
M&B]S0[S]H?\ X)6?L\_M+?%GQ'\8_''B[XQ:-XF\3V^@VU_I_@_Q!X)T_P /
MP1^'= TSPY8_8K36/AYKU_"7L-*MGN!)J<R-<F5X4@B9(4\_AKQ;XDX6R?#9
M)@,'DM?"X66(G3J8W#8ZIB&\3B*F)J<\Z&98>F[5*LE&U*+4;)MM7?1F?"&6
MYKC*F.Q%;'0JU534HT*F'C32I4XTH\JGAJDE[L%>\GKM9:+Z2_92_9/^'7['
MW@#6_AS\,]8\::WHFO>+[WQK>7?CG4=$U/54U2^T;0M"EM[:;0/#OAFS33TM
M/#]E)%%)82W N);EWNGC>**#YCB[B_,^-,QH9EFE# T*^'P4,#"& I5Z5%T:
M=>O74I1Q&)Q4W4<\1--JHH\J@E!--OU,GR?#9)AJF%PLZ]2G4KRKMXB5.4U.
M5.G3:3ITJ4>7EI1LN5N]];62Y[]K;]BOX6?MEZ5X*TCXGZ]X^T*W\":AK&HZ
M/)X#U7P]I<]Q-KEM86MW'J+>(/"WBB*:%$TZ!K<6T-I(CF0O)(K!5Z>#N.<V
MX(K8ZME6'R[$2Q]*C2K+,*.)JQC&A*<X.DL-B\(XMNH^;F<TU:R1GG.183/(
M4(8NIB*:P\IRA]7G2@VYJ*:E[2C537NJUDCQG]G3_@EM^SO^S1\1?^%E>#O$
M7Q4\4:HWAS7_  M<:)\0-7\$:UX8O=)\26@L=4AO=-TKX?Z!/=>;:AH?*EOF
MM'CED2XMIU;:/;XF\6.).*<L_LO&X;*,)16)P^+C7RZCCZ&*A6PL^>DX5:V8
MXB,+2L[JGSII<LHV.'*^$LLRK$_6J%3%U9NE4HNGB9X>=)PJI*2<(8:FWHK6
M<K6O=,\1^-7_  16_9U^(FOWWB/X;^*O%7P8GU.XN+J[\/Z59V'B?P9;SSOY
MA.CZ+J$NG:EI$/FM(?L$&OOIEO$8[;3;'3[>%8J][(_'+B7+,-3PN9X3"9W&
ME&,(8BM.IA<;*,5;]]7I*I2K2LE^\EAU5D[RJ3J2;9P8[@3+,34E5PM6M@7)
MMNG",:M!-_R4Y.,H+^ZJG(EI&,4K'G?@?_@A1\']*U&WN?B!\;/'WC*PA(>7
M3/#N@:)X'6[92"L<UW=7?C&X2V;!69+8V]RRG]S=V[ ./2Q_C_G56E*&79%E
MV!J/15<1B*^.</.,(PP<7)=.;FBNL)+0Y</X?8&$D\3CL37BMX4J=/#I]DVW
M7=N]K/LT?L/\(O@Q\,/@/X-LO /PF\&Z1X+\,63><;+3(F-QJ%ZT44,NJ:UJ
M=R\^I:WJT\4,,<^IZK=W=[)%##"9O)AAC3\6SG.\UX@QL\PSC&UL=BIKEYZK
M7+3@FVJ5"E%1I4*,6VXTJ,(4TVWRW;;^VP6!PF74(X?!T(4*4=>6"UE*R7-.
M3O*<VDKRFV]$KV2/3Z\HZPH * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H _D0_X+N_\ !QO\??\ @DU^V1X0_9F^%G[/7P?^*.@>(/@#X,^+]WXE
M^(&M>-++5XM5\4>-?B3X7FTFVM?#E_8V2Z?:6O@>TN8I)!+<23WMP&98XXEH
M D^/'_!UK\&OV</V#/V5_C'XG^&.C?$W]MO]IKX16/Q2_P"&:_ /B6_T3P-\
M,M%U37-?T73_ !)\0?'&IV/B+4=$TJ]&B27.@^%[:QU7Q;XC\LRRIX=T&\M/
M$E '\VGB7_@\D_X*SZOXF&LZ'X9_9*\):%%>32P>#[#X1^+]4TV:S+M]GL]3
MU37/BCJ'B"X>*+8LUUINIZ.9Y5:5(;=&$* ']'7_  18_P"#J'P/^WS\4O"G
M[*?[8_P]\&_L^_M$^.9TTCX8^// ^IZM'\%OBUXMN)TCT_P';Z-XIOM9\0_#
MKQMK(D6W\*Z?JGBSQ9I'C#4XVT>RUC2O$6H>'_#NL@'T#_P6>_X.9/@#_P $
MQO%^H?LZ?!GP58_M-?M8Z?:JWB[PU_PD<N@?#/X*RWUC#>:3%\1O$&GV&HW^
MN^*KF"ZMK_\ X5WX:-E?0:8WF^(?$WA2XN-+M]1 /Y,]9_X/&O\ @KKJ>N+J
MUCIG[)OAW3U9C_PC&D?!CQ+<:(ZE@55[G7_B=K?B/Y -H,>OQD@DG)P0 ?T3
M?\$9O^#KCPM^W!\8O!O[*?[:WPR\&_ ?XV?$C4;7P]\*OB?\.;[6E^#OQ!\9
MWS0VVE> =4\.^*=0U[Q#\/O$_B&Z;[+X5NY_%GB?0_$>KSP: TV@:I/I$&M
M']D- '^;G_P>A?MQ^(/''[3/P3_8#\-ZKY?P[^!G@K2_C;\1]/MKA@-7^,?Q
M(AU>Q\+VNL6OS1Y\#?"]+;4=!F4QR$?%77TGC=([.0 'ZJ_\&@/_  3%\+?!
MG]EF^_X**_$CPQ;77QL_:5G\0^'/@[J&HQ)+=>!?V?\ P]J_]B75UI,,BA],
MUCXG^,]#U>_U.\VM+=>"]"\&_P!G3V]GK&L17X!_9O0 4 % !0!_E9?\'BO_
M "EYM?\ LU+X*_\ I_\ B30!_>9_P0$_Y0U_\$]_^R!:7_ZD'B"@#]@: /\
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M72-7TJ\M]0TO5=+U"WCN[#4M-O[.2:TOK"^M)8KFSO+666WN;>6.:&1XW5B
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M>'O$U[<NQDNI-;^U2[99G50#]DZ "@#^1W_@] _Y11_"C_L^3X2_^J8_:*H
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M-?A4S,NVSO\ Q%+J'QFU98HG/^MN=(TV%FN%CS]GBUNU,NW[3#N /]!J@ H
M_P 3'1O^4PNE?]I*K'_UJ&*@#_;.H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /G;]K[_D
MTS]J'_LW;XU_^JU\2U]+P9_R6'"G_92Y%_ZM,*>9G7_(FS;_ +%F/_\ 46J?
MP@5_H&?ST% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0!_1)_P0._YNN_[H7_ .]CK^:_I#?\
MTA_W7_\ WB'Z9X=?\SC_ +I__NZ?T25_-9^F!0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MRW 3Q&(AR8G'.$W!Z2IX>"?L827V9RYI5)1W2E",DI1:7ZT5^/GV(4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!_EP_\'G7
M_*6#X9_]F1_"+_U;G[0% 'UQ_P &JO\ P1)^$'[5GAGQ/_P4,_;4^'5G\6?
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M> ?&&B:+\0_AU>7&K:?'8K-XE\,6&LVF@:OK-C:Z:ESXF\/:C?V5E81/#;Q
M'^PK^P=\=[[]J']B;]DK]HO5VC;7?C9^SG\&_B7XF6&%;:&'Q7XM\ Z#J_BJ
MVB@0".*.T\17.IVL:Q?N@L(\HF/:: /\CS_@O[XYNOB'_P %E/\ @H-KUW>2
MWTFG?'K4? L<LTK2M%:_#'P[X>^&]G9*S$[8M/M?"D-C#$,+#%;I$H 0"@#_
M %N_V OAGI/P9_88_8Y^%.AV*Z?IOP__ &8?@7X6CM@ '-QI7PS\-6]_<W+
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MJ:=*+;4+@W !_9I0 4 % '^8C_P09_Y6A_C3_P!E0_X*$?\ IV^(= '^G=0
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MAWX9\,ZRX87D^AZ/K7B^ZMHGCL]6NM(UC[;I^G@'XX_\%)O^";W[87_! /\
M:V^%%WHGQSFDU#7;&_\ B#^SS^TA\'KS6O &LZC'X9U.#2_$.G:GH3:A=:GX
M5\2:,]]I/_"1^'/[7\3>&M1T3Q'IT*:WK=O>:K868!_H@>$O$WQF_P""ZO\
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MB>UNDUUX>L?V;=8O_ 4%UM(DT^W\93_&33?$-W;A]KIK$G@2RD*@QG0@2)0
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@#YV_:^_Y-,_:A_[-V^-?_JM?$M?2\&?\EAPI_V4N1?^K3"GF9U_
MR)LV_P"Q9C__ %%JG\(%?Z!G\]!0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?T2?\$#O^;K
MO^Z%_P#O8Z_FOZ0W_-(?]U__ -XA^F>'7_,X_P"Z?_[NG]$E?S6?I@4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M=U]JLO'G[,'P1UN<EE>6UUAOAYH%KXATNZ924-[H^OVVIZ3?!&9!>64ZHS*
MQ /M"@ H * "@#_*R_X/%?\ E+S:_P#9J7P5_P#3_P#$F@#]"O\ @G#_ ,&F
M?[,/[;G[!7[-W[5?BK]JCX\^"/''QT^&L7C74=!\/>'?A]?^%/#]_=:KJME#
M:65OJ.F?VO>6D$%E 9//U>*:>4RNLENC)%& ?D;_ ,%E/^#;K]I3_@E5X67X
M\>$?&MO^TS^RH^J6FD:W\2-#\*7OA;QG\*M0U*6"VTA?BKX,34/$-CIOAS6-
M0N8]%T3QSHOB'4='N=:^SZ9K]EX3U'6?#=CK0!_19_P:P_\ !=5?C;;>'_\
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MZ^.7_!>S]M#X4Z;\)?@?XFTSPWX8@N?A3^S!\!/#J2^-?B)K-WXLU2VOM?\
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M?!3]F"3585N#X7.FZ2C?%_XD:9;R>9 FIZL->TSX>:!K"+%?Z7::;\1+!/\
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MGAGP[;?##69_"WCS7+J^O'33=,TG6_BS)XX\276N-'#&OAZ;3&NY9H-.BEH
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MR;;XN?M.?&[XAZ/)M(^U:=IMMX*^%$D^2,-MU;X8:I:[ER!]FV]5( !_4U0
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M"?Q'_P""3%Y\6]2TG2W\8_LZ_''X6^*/"OB"6UC.LV.D_$'6D^%OBK0-/O\
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M7  /]0^@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M-<U/PS\8/%&O6FE:[X4UFYU&*+3]"OUNO$_AOPLEV+:TCEOK4 \?_P"#0?\
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MMUFDU#QD-!TK4_$>C>./!&@6\*W?BK6=)N]%UKPW8S-JUSX5N/#6EZ[XATH
M^H/^#6K_ (+JK\$?'G@;_@FC^TU%X(T;X._$S6X="_9Z^*VF>%_#7@_4_!WQ
M1UJ:*WTGP#\2;_P]IFE)XQT3XAZBZZ;H'C?Q)_:'B[1?&%YIVDZUK&I^%M8M
MY_!8!_I#T % !0!_B8Z-_P IA=*_[256/_K4,5 '^V=0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 ?.W[7W_)IG[4/_9NWQK_]5KXEKZ7@S_DL.%/^RER+_P!6F%/,SK_D
M39M_V+,?_P"HM4_A K_0,_GH* "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#^B3_@@=_S==_W
M0O\ ]['7\U_2&_YI#_NO_P#O$/TSPZ_YG'_=/_\ =T_HDK^:S],"@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H _]#^
M_B@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@#_+A_X/.O\ E+!\,_\ LR/X1?\ JW/V@* /[E/^#?K_ )0S_P#!/K_L
MA=O_ .I7XGH _8J@#_+0_P"#RW_E+3X+_P"S-/@]_P"K&^-E ']VO_! W_E#
M?_P3U_[-[T'_ -.^M4 ?KU0!_E@?\'D'_*7+0?\ LT3X,_\ J8_%J@#^];_@
MA#_RAX_X)X?]FU>"O_;V@#^-[_@\_P#V%M<\"?M*?!;_ (* >&=.>;P!\=O"
M6F_!/XF7=O;'9HGQ>^&UE?W7A&[U2[ 53_PG7PSV:=HL&)'C_P"%6:TTTJI/
M9Q  ^R_^#03_ (*W>#;[X;S_ /!++XY>*K?1/''A76O$OC/]D[5=>U*"VL/%
M_A/Q#=MX@\:?!K39+MX_^*K\.>)KK7?'7AC3HY+B?7]!\0^([2S@M$\&PQZB
M ?W?T % !0 4 ?Y67_!XK_REYM?^S4O@K_Z?_B30!_>9_P $!/\ E#7_ ,$]
M_P#L@6E_^I!X@H _4;XG_#+P%\:/AQXZ^$?Q2\+Z7XU^''Q+\*:[X'\<>$M:
MA\_2_$/A;Q+IMQI.M:3>1JR2"*[L;J:(2P217-NY2>VFAN(HI4 /\;'_ (*9
M?L4?&K_@BW_P4CUOX>^$/$GB;0)/AQXR\/\ QS_9.^,5LPMM7UCP!_;\FM_#
M3Q;:WJ0QVTOB;PCJVD7'A/Q9LM8[)O&'A76_(M&T>XLS< '^J+_P1^_X*2^"
M/^"I7[$7PV_:/T,Z9I7Q&M(AX"^/W@33Y?\ D1/C-X<L;+_A)K*WMGDEGA\.
M>)8+JP\:>#'EFN)#X6\0Z9:7ERVKV.J0VX!]Y?'+_DBGQ@_[);\0/_43U:@#
M_'5_X(%?\ID?^">W_9P6B?\ IFUR@#_9\H * "@#C?B+X#\.?%/X?>._ACXQ
MLQJ'A'XC>#?$_@/Q3IYVXOO#GB_1+[P]K=G\Z.F+G3-0N8?G1U^?YD8<4 ?X
MD?QX^%/QY_X)3_\ !07Q;\//[5N?#OQQ_8Y^/>G:QX)\7Q6LEK%J=SX*UW3_
M !A\,?B%86;R!VT+QGH \-^+["SG?_2-%UJ*TO%^>>, '^P-_P $R/\ @HO\
M%/\ @I[^R?X"_:5^#^H65IJ6H65MHWQ8^&K:E;WGB+X1?%"RMHQXD\$Z_"A2
MY%LESNU+PIK-Q:VB>*/"=YI&OV]O;B]DM+8 _0B@ H * "@ H * /\GKX>VT
M/QF_X.U;Q-84:M;V7_!7[XDWUN+LF5&@^#'QQ\4ZAX?9=YYBL8_ >FO:1GY5
MCMH8MFT;* /]86@ H X3Q9\+OAGX]N;6]\=?#KP+XTO+"!K6QN_%GA'P_P"(
MKFSM7D,KVUK/K&GWDMO TI,C0PLD9D)<KN.: .4_X9R_9Z_Z(/\ !G_PU_@C
M_P"4= '^:9_P0O\  G@?7_\ @YE^+_@_7?!OA36O"5C\2_V^8++PMJWA[2-1
M\.6<.EZC\08=,AM=$O+.;3+>+3HD2*PCBM42SC14MQ&J@  _TL_^&<OV>O\
MH@_P9_\ #7^"/_E'0!Z#X5\&>#_ NG2:/X)\*>&O!VD37<FH2Z7X5T+2_#VG
M2W\T4$$U[)8Z1:VEL]W+!:VT,ERT1F>*W@C9RD484 _BJ_X/>/$FIVO[*O[$
M/@^**<Z-KG[07C_Q)?SJ#]ECU/PI\.$TO28ICG GFM?&6M/;#&3';W6" #D
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MBAAAB4O)++(Y5(XXT4L[L0J*"S$ 4 ?XUG_!5+]H7Q#_ ,%>_P#@L9\3]?\
M@98MXDM?C-\:? W[-_[-NG6S2/#K_AG0+K1?A%\/-8A+"1[6V\>ZA;OX\ND?
MY-,/BFZ1]L5L=H!_I)?\%G/A\WP/_P"""?[7'PC^&,$DNE?"O]C[P]\+=%B_
MU3IX"\(Q>#?!FJRNJ[]OV;P-8ZC/)&"5*Q,A;:=U '\C_P#P9(GPY_PVY^V
M+D)_PEI_96TTZ(Q2/S!X<'Q;\&CQ0$<CS50ZD?!YD1#Y;LL1D&Z.+ !_I2T
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M8KRS_L_Q#\,/@KX7C\=V?&V#XG^+EG\>?%41X_Y8M\2/%'BEX<_-Y+)O^;-
M'WY0 4 ?R._\'H'_ "BC^%'_ &?)\)?_ %3'[15 'T=_P:7?\H5O@C_V5;]H
M'_U:>NT ?TH2RQ6\4L\\L<$$$;RS32NL<4,42EY)99'*I''&BEG=B%1068@"
ME*481E*34813E*4FHQC&*NW)NR225VWHD)M)7=DDKMO1)+\DC\M/V?\ Q$GQ
MW^,_QL_;6UEK5?A]\.[/5?AA\!!K%_8:-I\NFZ-:7!U7Q(VI:F-+M+*#61J4
MTEM?:E?&VM9?&^NZ1>3QGP_ T/\ *F0XU\2<5\>^.>,IX>KE?!F4YGD/A_AL
MPQV!RG"5IX3!5Y5\3/,<RJ9=@L##'/$RH0Q>8XN&$P\\^QU#$8FG'+X3I\?#
M]6&;8M59U)4<'B<71PD*RI5*CAA%4BIUU2I4YU:EDW64:<)U):THP<HJ)ZGK
M_P"SC^T!\=YVC^.WQJD\+> ;E7,WPS^$D8L([ZUO%C\[3M9UJY@$5U!&(U3[
M-JL7C2V)>1[2YMV_>OM@/#'QE\0:"J>,/'N%RC*\5^]GP;P##V&%C1Q$(RJ9
M?C,PJTN6O"@XQAR8V7$M-^_*CC(WYY?TMEOB=X=>'U%/P_X$AFW$=/E4.*^,
M)?698>K1<N3$X# TYN5&I)R<O:X.>15$HPC6I55[L?JGX5?!7X7_  3T1M!^
M&?@_2_#-K<>6=1O($>ZUK69(GGDBEUO7;U[C5]6:![JX^R+?7DT-A%,UMI\5
MK:A(%_?N%>"^&."<!_9_#.48;+*,E'V]6"E5QF+E&4Y1EC<=7E4Q>*<)5:GL
ME6K3A0C-TL/"E24::_(>+>..*N.<<LPXHSG%9I5I\RPU&HXTL#@HRC3A.& R
M^A&G@\'&I&C2]L\/1IRQ$X*KB)5:MYOU.OJ#Y0* "@ H _S@/^#R_P#8?UOX
M3_M0? ?_ (*,_#K3I]'\._'#1='^$WQ,\2:')?VE]I'Q\^%%E<7_ ,/O$=_J
M:S)]BU;QA\*-/L]'\,C2GBDMXO@CJM[,MO<R13W8!_:O_P $C_V_/"W_  4J
M_8*^!O[3^D7NFGQIJ>@0>"OCCX?TXJ@\'?'7P;8V%C\1=#>R$UQ+IUCJ-[-:
M^,?"UM=3/=2^!_%7A>_G^:]H _2B@ H * "@ H * /\ ,L_X.O\ ]M#6/V[O
M^"BGP2_X)U_LXP3_ !&A_9NUA/AH=%\)QMJ.H>.?VMOC9K/A_1]9\$Z8;'4;
MNSUN?P78V'@;P%96QLK'5M"^(>H_$[P[?+)Y$6P _P!!3]@+]D_0/V&/V+OV
M:OV2O#TNF7D7P.^%'AKPCKNLZ-92Z=IGBCQX]NVL_$KQK:V$[RSV:^./B'JG
MB?Q?);32RS0RZW(DLCN&8@'U_0!_E[_\%'/^5QWX>?\ :0S_ ()7_P#J+_L@
MT ?ZA% !0!_)Q_P=._\ !'9OVY/V:U_;(^ OA0ZA^U7^RGX6U2\UW1]%M+5M
M8^-'[/>GF[UWQ1X36+RX[W5_%_PRE?4_'?P]L;:Z>[U*PNO'W@_2]&U_Q+XJ
M\*V]@ <E_P &J/\ P6/'[8W[/R?L(_'_ ,4+<_M-?LO^$["'X;ZYJ\L*:A\9
MOV>-)%OI&BS&Y:Z:75_'7P?S8>$_%+R6=G=:OX-N? WB1Y_$FO+\0-8LP#^O
M2@ H _"3_@YD_P"4'?[=_P#V+GP6_P#6E?@Q0!^4/_!DS_R8!^U7_P!GAWG_
M *I7X4T ?V<T ?Y<O_!('_E;:\2_]G>?\%-O_4#_ &I: /\ 4:H _AI_X.,_
M^#>K7_$6O^(/^"G_ /P34\.ZQX:^._AG5Y/BE^T!\&OAC+>:-K_B[7]%O$\1
M2?M#_ R#0FMM1TGXRZ3J%LWB'QSX;\.RP7OQ O;<>.O"4$7Q5CUV#XE@'VG_
M ,&Z?_!PGHW_  42\,Z1^R)^UIKVD>'?VY?!>@R'PUXEG%CHVB_M4^%-!LI+
MB_\ $6@V<$=KI^F_&'PYI5K)J/Q!\#:?%#;:]I5M>_$7P19IHEKXR\._#X _
MK#H * /S^_X*Q_\ *+7_ (*2?]F&?M=?^J!\?T ?R!?\&,_WO^"G/^[^QO\
MS_:DH _O^H * "@ H * /\OG_@E;_P K?OCW_L]S_@J-_P"H=^U=0!_J#4 %
M !0 4 % !0 4 ?Y97_!:[_E:N@_[.7_X)Q_^JX_9HH _U-: "@ H * "@ H
M_+/_ (+'?L)_ +]O?]@KX\?#SXX:-I45_P" ?AQX]^*7PG^)4\446M?"/XC^
M#O"&K:QHWB[3-3P)X='D>Q73O&FC^;'9^(_"L^H:;<F&?[#?V(!_F_?\&JGQ
M/\9?#_\ X+8?LQ^'/#%Y>QZ-\8?"_P =_AMX_P!,LV(36?"=O\$?'GQ(M8+M
M,A&MM)\9?#WPGXD<L&*#13LPQS0!_KFT ?X_*$+_ ,'12LQ"JO\ P7R4DD@
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MZW^U-X-U6[Y-K;:KXFL/@'K?A^V/:.XOK3PEXED'&98]//00C(!^J7_!H/\
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M/+XE8003WERI /WOH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H \M^.7_)%/C!_P!DM^('_J)ZM0!_CJ_\$"O^4R/_
M  3V_P"S@M$_],VN4 ?[/E !0!\$?\%%_P#@HY^S9_P3)_9W\2_'[]H?Q986
M;P6&IV_PU^&5IJ5G%X^^,OC:UM!+I_@GP)I$I>YNKBXN9;-=:UPVKZ+X1TRX
M;6]?N+6QB!D /\B2\;]J3_@MG_P4QO;NRTU_$'[0'[9?QJ$WV2RCU&_\._#S
MPW=20VD)FEQ/?67PT^"?PWTNWAFO;DRW&G^"_" EGDN+M"90#_97_9:_9X\#
M?LD_LX?!#]F7X:K.?!'P,^&7A#X::!=WB0QZCJ\'A;1[73KGQ!JPMPL#:UXD
MOXKK7]:DA58IM6U&\E155PH /\R?_@[F_;>_X:9_X*6_\,^>&-7^W_#;]BCP
M;%\,HHK>?SM/N/C!XT73O%WQ>U2 AL)=6 7P7\.]4@:-6M]6^'E^H9U<&@#]
M6?\ @F?_ ,&BW[*?[3?["G[-G[17[4OQA_:J\#?&3XX_#RR^*6K>$/ACXC^$
MVA^$=!\+>-+R\USX;V]M8>,/@WXR\01ZG=_#J[\+:KKPOM:;R=;O[^UAM;6&
MW2.@#[I_X@I/^"9G_1QG[=?_ (7?P _^AQH /^(*3_@F9_T<9^W7_P"%W\ /
M_H<: /X'/VK?@K\5/^"4W_!2/XD_"S0-9U+3?B+^Q[^T3I_B+X5>,;V-8M2U
M#3O"NO:5\0_@IX_GAMTM(5E\2>$Y?!_BR:VMTBMU.HO;1XC6@#_9G_9!_:2\
M&_MA?LN_ 3]J'P"T8\+?'/X6^$?B'9V*3K<R:%?:[I4$VO>%KR90%;5/"/B
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* /G;]K[_DTS]J'_ +-V^-?_ *K7Q+7TO!G_ "6'"G_92Y%_ZM,*>9G7_(FS
M;_L68_\ ]1:I_"!7^@9_/04 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % ']$G_! [_FZ[_NA?
M_O8Z_FOZ0W_-(?\ =?\ _>(?IGAU_P SC_NG_P#NZ?T25_-9^F!0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M0_X/+?\ E+3X+_[,T^#W_JQOC90!_=K_ ,$#?^4-_P#P3U_[-[T'_P!.^M4
M?KU0!_E@?\'D'_*7+0?^S1/@S_ZF/Q:H _O6_P""$/\ RAX_X)X?]FU>"O\
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M*_\ *7FU_P"S4O@K_P"G_P")- ']YG_! 3_E#7_P3W_[(%I?_J0>(* /V!H
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MKNB:C!9ZUX>URPU'0M<T_3]8TZ]LK< ]2H * "@ H _F8_X."?\ @OG\/O\
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MQ[_V>Y_P5&_]0[]JZ@#_ %!J "@ H * "@ H * /\LK_ (+7?\K5T'_9R_\
MP3C_ /5<?LT4 ?ZFM !0 4 % '^93X*_X.D_V]OV /VROVN/@Y\4+#2OVP_@
M#X:_:T_:$TW0O"/Q5\0:QHGQ2\"Z#I_Q=\7VEIX9\!?%^WM]<NK/P[I]K%':
MZ;H'C;PKXZL="L;6RTCPPOAW2;9;.@#]L_ W_!ZY_P $Z=2\.QW7Q%_9I_;+
M\'^*EMO-NM#\)>'_ (+^/="-P,?Z+IWB;5/C'\/[ZZ)/2:^\+:3'M!)VMA"
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M]=NXH[*[N+W1M) /]&/_ (--?^4*7P$_[*;^T)_ZM[Q/0!]7?\%Z/^";-_\
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MA8XHHHU5(XT541%"J  !0!+0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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MKJ&&XBEB0 [Z@#_$QT;_ )3"Z5_VDJL?_6H8J /]LZ@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H ^=OVOO^33/VH?^S=OC7_ZK7Q+7TO!G_)8<*?\ 92Y%_P"K3"GF9U_R
M)LV_[%F/_P#46J?P@5_H&?ST% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!_1)_P0._YNN_[
MH7_[V.OYK^D-_P TA_W7_P#WB'Z9X=?\SC_NG_\ NZ?T25_-9^F!0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M-U, ^P/^#2#_ (*/_$+]GO\ ;OT3]A_Q+XFO[W]GG]KI?$=CIWAG4;Z:31_
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MV*SO0#[H_P"#97_E./\ L(_]A[XW_P#K,?QJH _V&* "@ H * "@ H * "@
MH * "@#^=_\ X.(?^"SL/_!*3]FG2O"_PEEL=0_;"_:)LO$.C_!6"[MK/4]/
M^&F@Z2MG:>*/C-XCTJ[2>TO!X?DU.TT[P+HFIVTNG^(_%\PGO+35= \,>)].
MD /\L/P'X!_:H_X*%?M-6OA7P=IGQ'_:6_:>^/?BZZO9Y+F]N_$WC+Q?XAOR
MUWJ_B'Q)X@U>Y\JQTO3;2.74=>\2Z_J%CH/AO1+.>_U2_P!.TBPDEA /[??V
M.?\ @R;\)2>%=(\0?M[?M7>+U\6ZA;"XU/X8_LM67A[2]-\-2NBO#92_%CXF
M>&?%7_"27$>X)J*V/PNT2S@F26#3M4U*#RM2< ^M_B-_P91_\$\=9TFY3X6?
MM+_M?^ ?$#6MQ'9WWB[5_A!\1_#\%VRR&UN;K0=/^%?P\U6[AAD9//M8?%=B
MUS!&(X[FUE9KD@'3_P#!)3_@W"^,/[$/AW_@J1^S=^T/\8/!OCCX#_MP? #P
MQ\#O!WQ4^#\M]HWCZ+1;VQ^+N@^++_5?!7C#0M3TWPCXETO3O&FG7MA;+JWC
MC09II8T74[WRKN&  \X_X@E/V%/^CM_VM/\ OU\'O_G>T ?S:?\ !PY_P0^^
M!/\ P1VT[]DJ_P#@I\7_ (M?%+_AH*]^.%GXEB^*,7@Y?[%_X5A!\)9M&DT)
M_">@:#C[=_PGVJKJ:7Z7F[[)IYM6M=ER+D \Z_X-[_\ @CG\%?\ @L#\2OVD
MO!/QG^*?Q1^%UA\%/ _@+Q3H5W\,%\)M=ZM=^+->U[2;RVU;_A*]!UV$6]M#
MI,,EM]CCMY/,DD\UW7:J@']2'_$$I^PI_P!';_M:?]^O@]_\[V@#^@+3_P!D
MKP=^PG_P2*^)7[)/@#Q-XE\8^#O@E^R'^T)X9T+Q-XP&ECQ+J]K>^#OB'XB>
MXU8:+8Z;I8N$N=:G@3['8V\?D1190R;V8 _QH/@9_P EL^#O_94_A]_ZEND4
M ?[TM !0 4 <]XM\5>'? GA7Q-XW\7:M::!X3\&^']9\5>)]=U!_*L-%\.^'
MM-N=7UK5KV7!\NTT[3;.YO+E\'9#"[8.,4 ?XBG[8'QX^(O_  4P_P""A7Q?
M^--EI]_J7C?]JS]H'[#\.O#-P7FO[+2O$FO6'@;X.>! 8A</*_A[PG#X0\(0
M&)96D&G(41BP4@' _L\?%_XH_L!?MG?"_P",5CI]YH_Q3_95^/&DZSK/AJ>1
MK.:75OAQXM^P^-/ NJMC?'9ZY:V.M^$-<BP"]AJ%[ <;N #_ '#OA9\2O!_Q
MF^&7PZ^+_P /=4CUSP%\5/ WA/XC>"=9BVB/5?"?C;0;#Q)X=U%0K.JB\TC4
MK2XV!VV>9MR<4 =Y0 4 % !0 4 % '^5U_P=6_\ !5W3?VX_VN=._97^#'B+
M^U?V<?V.M6\0:#=:MIEXLVA_$OX_7+?V3X]\66CP,+?4M#\"VUK_ ,*]\(WS
M">-[J/QUK>C7MSH?BRSD8 _"?_@F?_RD>_X)_?\ 9[?[*?\ ZO;P'0!_N.T
M?Y_?_!Y1_P $R=!TNW^'/_!3[X2^%DL-1U;6])^#7[57]E6X$&IW%QIZVWP=
M^*>IPQ(JPWD4>EW/PQ\2:Q/(POO.^%^GQQ1307,UV ?2?_!G'_P4MU?XP?!G
MXF?\$Z/BUXKGUCQA^SU81_$K]GN36+OS]2NO@9J^HV^D^+O UG-*?.GT_P"%
MWC34-(OM'BGDN)[?0_B'%HU@(-!\*65K: ']N- !0 4 % !0 4 % !0 4 %
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M'\>?'34M.TV*/(_T5)?AAH7PXU<P<8W2:K)<X/\ Q\9P0 ?O=^R_^QK^RO\
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M6=.6\ACECM-7TN255OM!\0::)YFTGQ'H5WINO:/-(UQI>HVD^)* /YWO&_\
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M8+#'MUVYU333X5^*&GO<7'G>9X>TWX7>*VT^+R!'KVK,TC1 'ZSZ3_P<G?\
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M0!_E[_\ !1S_ )7'?AY_VD,_X)7_ /J+_L@T ?ZA% !0 4 ?+/[:G[(/P?\
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MVU?_ (*O_P#!,*PUCP+_ ,(+K-O\7/CA\)OA*=1\/>*_A!XL\.ZBNOR_M'_
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M(&< _N6H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 ?.W[7W_)IG[4/_9NWQK_]5KXEKZ7@S_DL.%/^RER+_P!6F%/,SK_D39M_
MV+,?_P"HM4_A K_0,_GH* "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#^B3_@@=_S==_W0O\
M]['7\U_2&_YI#_NO_P#O$/TSPZ_YG'_=/_\ =T_HDK^:S],"@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H _]/^_B@
MH * "@ H * /\EC_ (.O/VFYOV@O^"OWQ6\%6.JR:AX1_9>\"?#WX">'XH[A
MFTZ/5[71O^%A^/Y8;4-Y4.HV_CCQ[K7AK5+C8MQ<?\(Q:02N]O96:Q@']_\
M_P &\_[+5A^R;_P2'_8[\(_V+#I/BSXH?#V#]HGX@S"W%OJ.J^)_CHX\>:;-
MK:85O[5T+P%J/@OP6RRJL]O8^%K&SG7SK9R0#]$/VT_^3./VLO\ LV?X[_\
MJK?%5 '^'U\ ?^2[_!3_ +*W\-__ %,=&H _WG: /YEO^#MOXD_#OP=_P1K^
M+'@OQ;>:2GC#XN?%3X'>%OA5IUW>PQ:I<^)?#GQ-\._$+Q!?:18EOM%X-/\
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M_GN?\&RO_*<?]A'_ +#WQO\ _68_C50!_L,4 % !0!\H?MS>//VF/AA^R/\
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M]%R@#YG_ &T_^3./VLO^S9_CO_ZJWQ50!_AY? S_ )+9\'?^RI_#[_U+=(H
M_P!Z6@ H * /YHO^#K+]MG_AD_\ X)7^./AGX<U?[!\2_P!LCQ!:_L^>'XK>
M;9?P?#Z\MI-?^-&K"'<IFTJX\#Z>_P /=28$F&;XCZ:VQ@24 /XL?^#5/]C?
M_AJC_@K%\-/'>NZ5]O\ A[^R)X<UC]HWQ"\\.ZR?QAHDMKX:^$5@LY5DBU:U
M^(GB#2?'&G18WSVW@35"A7R6=0"C_P '3_[&O_#*/_!67XJ>,="TK^S_ (>?
MM;:'I/[2GAAX(=MFGBGQ//>:#\7;%KA56*35+CXFZ!X@\97L "R6UCXUT@RA
MA/'-* ?V(?\ !HI^VO\ \-)_\$SW_9]\2:M]N^(O[%7CBZ^&LD4\WG:A-\(O
M'+ZCXT^$NIW!+92VLICXX^'VE0!%6WTGX?6*;G+' !_530 4 % !0 4 ?RX?
M\'-7_!9ZQ_X)Y?LW77[,?P,\4"']LK]I?PIJ.GZ1=Z1>B/5/@=\(-3:YT3Q%
M\5+F2W;[5IOBG7Q'J?A?X6;&M;B'68M;\8P72MX+AL=6 /XV/^"&7_!)NZ_:
MP^&O[:W[>'QE\+M=?L\?LG_LV_M#7'P\AU>UWZ9\2OVE+;X,>*-4\.0VZ2IM
MO=*^#]M=6/C[6)E=!%XOG^'MF%O[.37K:W /R8_X)G_\I'O^"?W_ &>W^RG_
M .KV\!T ?[CM 'R+^WQ^S+HO[97[%G[3_P"R_K>G6.HK\:/@MXZ\'Z$NH)&U
MOIGCB;1;B]^'?B-/-_=1WGA/Q[9>&_$^FS2?)!J&D6LS K&10!_D-_\ !%7]
MI#4?V-/^"K_[&'Q3U.\O/#>E67QUT+X4_$E+EY;&.R\$_%J:X^$?CC^W;1S'
MYEOX>TWQ9=:]-9W4;&WU#0[6YCC6]L[=XP#_ &GJ "@ H * "@ H * "@ H
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MC;18=(UN;Q%?".^G\17$EL ?L#0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M)]3ATK2?B-9:5ID5]K>JWUU'I^F6=II]DDHMK.V@MXXXE . _P"(5#_@A_\
M]&J^*_\ Q(W]HO\ ^>?0 ?\ $*A_P0__ .C5?%?_ (D;^T7_ ///H /^(5#_
M ((?_P#1JOBO_P 2-_:+_P#GGT '_$*A_P $/_\ HU7Q7_XD;^T7_P#//H _
M>CX2_"_P7\$/A7\-/@M\-]+ET3X=_"'X?^#?AAX"T6?4-0U>;2/!G@'P[IWA
M7POIDVJZM<WNJZG+8:)I5C:R:AJ=Y=ZA>O$;F\N9[B225@#T&@ H _)7XZ_\
M$/O^";7[2/[72_MS_%[X(:YXC_:77Q3\,O&:^.;;XN?%K0;$>(?@_IGA;1_
M-Y_PA^A>--.\(;-(T_P9X>AFM?[$^RZF;-Y=3ANY;JZ>8 _6J@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * /Y</^"G/_!SY\)?^"8W[8_Q
M(_9"\>?LG_$3XG:CX'\%^ _%&E^.?"/Q)\-:38Z]?>.?"UGXF@TF_P!"UGPY
MY^@VFG)>Q6<NJV^IZ_-<,LDR:3$ L; '\2GQ*\?_ +=7_!S]_P %/_#5KH/A
M.T\.W6L6-AX3\,>'=-;5-6^%G[+/P T+4;K4=5\1>*_$!M;.34%LY]4U+6M?
M\07=MIVK^/\ QEJ=EX:\-Z99_:O"GA;3@#_5_P#V6_V<OAQ^R)^SM\&OV9?A
M)IW]F_#SX)_#_P /> ?#B/'$EYJ$6C6:1ZAXAU=H52.X\0>*-7>_\2>(KT*&
MU#7=5U&^D_>7#&@#WN@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@#YV_:^_P"33/VH?^S=OC7_
M .JU\2U]+P9_R6'"G_92Y%_ZM,*>9G7_ ")LV_[%F/\ _46J?P@5_H&?ST%
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0!_1)_P $#O\ FZ[_ +H7_P"]CK^:_I#?\TA_W7__
M 'B'Z9X=?\SC_NG_ /NZ?T25_-9^F!0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?_U/[^* "@ H * "@ H _P\/\
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M7TK5)?V^?VKM;BD8:+I_[($^E7\0'R/JFL?&?X77>D2,>@:*TT+6U0=Q*_\
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MRYZL[*[LHQBHTZ<84H0A'UVO</2"@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@#\K/VLO^")?_!+W]N3XQ7'Q_\ VI?V5M(^*/Q>O+#0]+O_ !D?
MB9\;/!=QJ6G^&K*#3=#M-5TKX>?$KPEH&J1:?86T%G&-0TJY,EO&(IS*A8$
M^P?V8OV//V7?V+_ ]S\./V5O@5\.?@9X.U"^75-7TSP#X?MM+N/$&J1Q&"+4
M_$^LOY^N^)]2@MS]EM]0\0:EJ5W;V@6U@FCMU6, 'TE0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 ?.W[7W_)IG[4/_ &;M\:__ %6OB6OI>#/^2PX4_P"RER+_ -6F%/,S
MK_D39M_V+,?_ .HM4_A K_0,_GH* "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#^B3_@@=_S=
M=_W0O_WL=?S7](;_ )I#_NO_ /O$/TSPZ_YG'_=/_P#=T_HDK^:S],"@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MMT?]>O[.G_K6WP%H _SV_P#@V5_Y3C_L(_\ 8>^-_P#ZS'\:J /]AB@ H *
M"@#^#G_@X_\ ^#D@>"AX\_X)]?\ !//QX#XT_P")CX0_:1_:7\(:B"O@S_66
M.N_"/X/:[8R8/C'_ %VF^._B!ILV/"'^D^&O"US_ ,);_:6K>$P#^<W]C[_@
MW#_X*$?MH?L,_$;]M[P!X=L-"L;"P@USX#?"'Q5;WEA\0OVFO#]DT\OBK7O
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M$2AUE\&_"[X?^%95DR763P]X3TG2'#EN=X:S(;/.<YH ]1H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H ^=OVOO^33/VH?^
MS=OC7_ZK7Q+7TO!G_)8<*?\ 92Y%_P"K3"GF9U_R)LV_[%F/_P#46J?P@5_H
M&?ST% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0!_1)_P0._YNN_[H7_[V.OYK^D-_P TA_W7
M_P#WB'Z9X=?\SC_NG_\ NZ?T25_-9^F!0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M>%=*TVU.JR_;HM-T^*[U/Q-K?B/7[V*QLX[[6+I+2V$0!_8]0!_ [_P?*_\
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ME:E9>"(+S3M2TZ\@AN[&^M)H;FTN88I[>6.6-& !_DC_ /!/#P_H/BS_ (*
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * /G;]K[_DTS]J'_LW;XU_^JU\2U]+P
M9_R6'"G_ &4N1?\ JTPIYF=?\B;-O^Q9C_\ U%JG\(%?Z!G\]!0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 ?T2?\$#O^;KO^Z%_^]CK^:_I#?\ -(?]U_\ ]XA^F>'7_,X_
M[I__ +NG]$E?S6?I@4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % '__U_[^* "@ H * "@ H _B2_X/*_\ @G9)\4_@
M%\*_^"BGP]T-[KQC^SI):?"7XWM96[27-]\$/&>O2S^"O$5X45G^S?#KXFZU
M<Z;LC4?Z'\4]0U"[D6TT4% #YF_X,PO^"B=M:S?&?_@FA\1_$<,+W\]_\?\
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MZ;X3_9_\%:_=+;Z-XLU&ZL%L/$VF>7JD%E-<FZM(Y[&Y /Z2* "@ H * "@
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MO$EM'(FH?LSZE_Q,-0\1>,/$FN:K)9FRL)M1U6YEM=.LT?RZ /TS_P""5O\
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MGC'0E7XG>+=.=E4EO!7PYUBW\(12KYMI=R?$[5XU*WN@L(P#_1HH * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /G;]K[_
M )-,_:A_[-V^-?\ ZK7Q+7TO!G_)8<*?]E+D7_JTPIYF=?\ (FS;_L68_P#]
M1:I_"!7^@9_/04 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % ']$G_  0._P";KO\ NA?_ +V.
MOYK^D-_S2'_=?_\ >(?IGAU_S./^Z?\ ^[I_1)7\UGZ8% !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0!E:[=ZG8:)K%]HFDC7]9LM*U"[TC
M0C?P:4-:U.VM)9K#23JETDEMIHU&Z2*S^WW$;P6?G?:)4:.-E(!_G&?M%_\
M!M[_ ,%M?^"D7[=7B#]H_P#;*U;X&> ]*^,/Q&TN3QMXBT7XM6_C*#X0_":U
MO(+&R\*?#GPA:Z<MUJMMX%\'0KI?A71IKC3UUW5+=;_Q'K-O?:OK&N, ?Z!W
M[,'[-/P?_8\^ ?PO_9J^ OA:#PA\*OA'X7L_"_A?28]DEY<+$9+G4]>UV]2*
M%M6\3^)]8N+_ ,1>*-;FC6XUG7]3U'4IP);E@ #WJ@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M_P"BKXE_\/N:?_-0?V+DW_0IRS_P@PO_ ,J#_AD']DS_ *->_9V_\,G\-?\
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M_P"BKXE_\/N:?_-0?V+DW_0IRS_P@PO_ ,J#_AD']DS_ *->_9V_\,G\-?\
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M_P"BKXE_\/N:?_-0?V+DW_0IRS_P@PO_ ,J#_AD']DS_ *->_9V_\,G\-?\
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M_P"BKXE_\/N:?_-0?V+DW_0IRS_P@PO_ ,J#_AD']DS_ *->_9V_\,G\-?\
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M_P"BKXE_\/N:?_-0?V+DW_0IRS_P@PO_ ,J#_AD']DS_ *->_9V_\,G\-?\
MYF:/]<^,/^BKXE_\/N:?_-0?V+DW_0IRS_P@PO\ \J#_ (9!_9,_Z->_9V_\
M,G\-?_F9H_USXP_Z*OB7_P /N:?_ #4']BY-_P!"G+/_  @PO_RH/^&0?V3/
M^C7OV=O_  R?PU_^9FC_ %SXP_Z*OB7_ ,/N:?\ S4']BY-_T*<L_P#"#"__
M "H/^&0?V3/^C7OV=O\ PR?PU_\ F9H_USXP_P"BKXE_\/N:?_-0?V+DW_0I
MRS_P@PO_ ,J#_AD']DS_ *->_9V_\,G\-?\ YF:/]<^,/^BKXE_\/N:?_-0?
MV+DW_0IRS_P@PO\ \J#_ (9!_9,_Z->_9V_\,G\-?_F9H_USXP_Z*OB7_P /
MN:?_ #4']BY-_P!"G+/_  @PO_RH/^&0?V3/^C7OV=O_  R?PU_^9FC_ %SX
MP_Z*OB7_ ,/N:?\ S4']BY-_T*<L_P#"#"__ "H/^&0?V3/^C7OV=O\ PR?P
MU_\ F9H_USXP_P"BKXE_\/N:?_-0?V+DW_0IRS_P@PO_ ,J#_AD']DS_ *->
M_9V_\,G\-?\ YF:/]<^,/^BKXE_\/N:?_-0?V+DW_0IRS_P@PO\ \J#_ (9!
M_9,_Z->_9V_\,G\-?_F9H_USXP_Z*OB7_P /N:?_ #4']BY-_P!"G+/_  @P
MO_RH/^&0?V3/^C7OV=O_  R?PU_^9FC_ %SXP_Z*OB7_ ,/N:?\ S4']BY-_
MT*<L_P#"#"__ "H/^&0?V3/^C7OV=O\ PR?PU_\ F9H_USXP_P"BKXE_\/N:
M?_-0?V+DW_0IRS_P@PO_ ,J#_AD']DS_ *->_9V_\,G\-?\ YF:/]<^,/^BK
MXE_\/N:?_-0?V+DW_0IRS_P@PO\ \J#_ (9!_9,_Z->_9V_\,G\-?_F9H_US
MXP_Z*OB7_P /N:?_ #4']BY-_P!"G+/_  @PO_RH/^&0?V3/^C7OV=O_  R?
MPU_^9FC_ %SXP_Z*OB7_ ,/N:?\ S4']BY-_T*<L_P#"#"__ "H/^&0?V3/^
MC7OV=O\ PR?PU_\ F9H_USXP_P"BKXE_\/N:?_-0?V+DW_0IRS_P@PO_ ,J#
M_AD']DS_ *->_9V_\,G\-?\ YF:/]<^,/^BKXE_\/N:?_-0?V+DW_0IRS_P@
MPO\ \J#_ (9!_9,_Z->_9V_\,G\-?_F9H_USXP_Z*OB7_P /N:?_ #4']BY-
M_P!"G+/_  @PO_RH/^&0?V3/^C7OV=O_  R?PU_^9FC_ %SXP_Z*OB7_ ,/N
M:?\ S4']BY-_T*<L_P#"#"__ "H/^&0?V3/^C7OV=O\ PR?PU_\ F9H_USXP
M_P"BKXE_\/N:?_-0?V+DW_0IRS_P@PO_ ,J#_AD']DS_ *->_9V_\,G\-?\
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M_P"BKXE_\/N:?_-0?V+DW_0IRS_P@PO_ ,J#_AD']DS_ *->_9V_\,G\-?\
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M_P"BKXE_\/N:?_-0?V+DW_0IRS_P@PO_ ,J#_AD']DS_ *->_9V_\,G\-?\
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@#__T?[^* "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H __]+^_B@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M/__3_OXH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@#__U/[^* "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M /\ @I0 ?\19/_6(G]O[_P )_P#_  4H /\ B+)_ZQ$_M_?^$_\ _@I0 ?\
M$63_ -8B?V_O_"?_ /P4H /^(LG_ *Q$_M_?^$__ /@I0 ?\19/_ %B)_;^_
M\)__ /!2@ _XBR?^L1/[?W_A/_\ X*4 '_$63_UB)_;^_P#"?_\ P4H /^(L
MG_K$3^W]_P"$_P#_ (*4 '_$63_UB)_;^_\ "?\ _P %* #_ (BR?^L1/[?W
M_A/_ /X*4 '_ !%D_P#6(G]O[_PG_P#\%* #_B+)_P"L1/[?W_A/_P#X*4 '
M_$63_P!8B?V_O_"?_P#P4H /^(LG_K$3^W]_X3__ ."E !_Q%D_]8B?V_O\
MPG__ ,%* #_B+)_ZQ$_M_?\ A/\ _P""E !_Q%D_]8B?V_O_  G_ /\ !2@
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M"E !_P 19/\ UB)_;^_\)_\ _!2@ _XBR?\ K$3^W]_X3_\ ^"E !_Q%D_\
M6(G]O[_PG_\ \%* #_B+)_ZQ$_M_?^$__P#@I0 ?\19/_6(G]O[_ ,)__P#!
M2@ _XBR?^L1/[?W_ (3_ /\ @I0 ?\19/_6(G]O[_P )_P#_  4H /\ B+)_
MZQ$_M_?^$_\ _@I0 ?\ $63_ -8B?V_O_"?_ /P4H /^(LG_ *Q$_M_?^$__
M /@I0 ?\19/_ %B)_;^_\)__ /!2@ _XBR?^L1/[?W_A/_\ X*4 '_$63_UB
M)_;^_P#"?_\ P4H /^(LG_K$3^W]_P"$_P#_ (*4 '_$63_UB)_;^_\ "?\
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M /\ @I0 ?\19/_6(G]O[_P )_P#_  4H /\ B+)_ZQ$_M_?^$_\ _@I0 ?\
M$63_ -8B?V_O_"?_ /P4H /^(LG_ *Q$_M_?^$__ /@I0 ?\19/_ %B)_;^_
M\)__ /!2@ _XBR?^L1/[?W_A/_\ X*4 '_$63_UB)_;^_P#"?_\ P4H /^(L
MG_K$3^W]_P"$_P#_ (*4 '_$63_UB)_;^_\ "?\ _P %* #_ (BR?^L1/[?W
M_A/_ /X*4 '_ !%D_P#6(G]O[_PG_P#\%* #_B+)_P"L1/[?W_A/_P#X*4 '
M_$63_P!8B?V_O_"?_P#P4H /^(LG_K$3^W]_X3__ ."E !_Q%D_]8B?V_O\
MPG__ ,%* #_B+)_ZQ$_M_?\ A/\ _P""E !_Q%D_]8B?V_O_  G_ /\ !2@
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M"E !_P 19/\ UB)_;^_\)_\ _!2@ _XBR?\ K$3^W]_X3_\ ^"E !_Q%D_\
M6(G]O[_PG_\ \%* #_B+)_ZQ$_M_?^$__P#@I0 ?\19/_6(G]O[_ ,)__P#!
M2@ _XBR?^L1/[?W_ (3_ /\ @I0 ?\19/_6(G]O[_P )_P#_  4H /\ B+)_
MZQ$_M_?^$_\ _@I0 ?\ $63_ -8B?V_O_"?_ /P4H /^(LG_ *Q$_M_?^$__
M /@I0 ?\19/_ %B)_;^_\)__ /!2@ _XBR?^L1/[?W_A/_\ X*4 '_$63_UB
M)_;^_P#"?_\ P4H /^(LG_K$3^W]_P"$_P#_ (*4 '_$63_UB)_;^_\ "?\
M_P %* #_ (BR?^L1/[?W_A/_ /X*4 '_ !%D_P#6(G]O[_PG_P#\%* #_B+)
M_P"L1/[?W_A/_P#X*4 '_$63_P!8B?V_O_"?_P#P4H /^(LG_K$3^W]_X3__
M ."E !_Q%D_]8B?V_O\ PG__ ,%* #_B+)_ZQ$_M_?\ A/\ _P""E !_Q%D_
M]8B?V_O_  G_ /\ !2@ _P"(LG_K$3^W]_X3_P#^"E !_P 19/\ UB)_;^_\
M)_\ _!2@ _XBR?\ K$3^W]_X3_\ ^"E !_Q%D_\ 6(G]O[_PG_\ \%* #_B+
M)_ZQ$_M_?^$__P#@I0 ?\19/_6(G]O[_ ,)__P#!2@ _XBR?^L1/[?W_ (3_
M /\ @I0 ?\19/_6(G]O[_P )_P#_  4H /\ B+)_ZQ$_M_?^$_\ _@I0 ?\
M$63_ -8B?V_O_"?_ /P4H /^(LG_ *Q$_M_?^$__ /@I0 ?\19/_ %B)_;^_
M\)__ /!2@ _XBR?^L1/[?W_A/_\ X*4 '_$63_UB)_;^_P#"?_\ P4H /^(L
MG_K$3^W]_P"$_P#_ (*4 '_$63_UB)_;^_\ "?\ _P %* #_ (BR?^L1/[?W
M_A/_ /X*4 '_ !%D_P#6(G]O[_PG_P#\%* #_B+)_P"L1/[?W_A/_P#X*4 '
M_$63_P!8B?V_O_"?_P#P4H /^(LG_K$3^W]_X3__ ."E !_Q%D_]8B?V_O\
MPG__ ,%* #_B+)_ZQ$_M_?\ A/\ _P""E !_Q%D_]8B?V_O_  G_ /\ !2@
M_P"(LG_K$3^W]_X3_P#^"E !_P 19/\ UB)_;^_\)_\ _!2@ _XBR?\ K$3^
MW]_X3_\ ^"E !_Q%D_\ 6(G]O[_PG_\ \%* #_B+)_ZQ$_M_?^$__P#@I0 ?
M\19/_6(G]O[_ ,)__P#!2@ _XBR?^L1/[?W_ (3_ /\ @I0 ?\19/_6(G]O[
M_P )_P#_  4H /\ B+)_ZQ$_M_?^$_\ _@I0 ?\ $63_ -8B?V_O_"?_ /P4
MH /^(LG_ *Q$_M_?^$__ /@I0 ?\19/_ %B)_;^_\)__ /!2@ _XBR?^L1/[
M?W_A/_\ X*4 '_$63_UB)_;^_P#"?_\ P4H /^(LG_K$3^W]_P"$_P#_ (*4
M '_$63_UB)_;^_\ "?\ _P %* #_ (BR?^L1/[?W_A/_ /X*4 '_ !%D_P#6
M(G]O[_PG_P#\%* #_B+)_P"L1/[?W_A/_P#X*4 '_$63_P!8B?V_O_"?_P#P
M4H /^(LG_K$3^W]_X3__ ."E !_Q%D_]8B?V_O\ PG__ ,%* #_B+)_ZQ$_M
M_?\ A/\ _P""E !_Q%D_]8B?V_O_  G_ /\ !2@ _P"(LG_K$3^W]_X3_P#^
M"E !_P 19/\ UB)_;^_\)_\ _!2@ _XBR?\ K$3^W]_X3_\ ^"E !_Q%D_\
M6(G]O[_PG_\ \%* #_B+)_ZQ$_M_?^$__P#@I0 ?\19/_6(G]O[_ ,)__P#!
M2@ _XBR?^L1/[?W_ (3_ /\ @I0 ?\19/_6(G]O[_P )_P#_  4H /\ B+)_
MZQ$_M_?^$_\ _@I0 ?\ $63_ -8B?V_O_"?_ /P4H /^(LG_ *Q$_M_?^$__
M /@I0 ?\19/_ %B)_;^_\)__ /!2@ _XBR?^L1/[?W_A/_\ X*4 '_$63_UB
M)_;^_P#"?_\ P4H /^(LG_K$3^W]_P"$_P#_ (*4 '_$63_UB)_;^_\ "?\
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M /\ @I0 ?\19/_6(G]O[_P )_P#_  4H /\ B+)_ZQ$_M_?^$_\ _@I0 ?\
M$63_ -8B?V_O_"?_ /P4H /^(LG_ *Q$_M_?^$__ /@I0 ?\19/_ %B)_;^_
M\)__ /!2@ _XBR?^L1/[?W_A/_\ X*4 '_$63_UB)_;^_P#"?_\ P4H /^(L
MG_K$3^W]_P"$_P#_ (*4 '_$63_UB)_;^_\ "?\ _P %* #_ (BR?^L1/[?W
M_A/_ /X*4 '_ !%D_P#6(G]O[_PG_P#\%* #_B+)_P"L1/[?W_A/_P#X*4 '
M_$63_P!8B?V_O_"?_P#P4H /^(LG_K$3^W]_X3__ ."E !_Q%D_]8B?V_O\
MPG__ ,%* #_B+)_ZQ$_M_?\ A/\ _P""E !_Q%D_]8B?V_O_  G_ /\ !2@
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M"E !_P 19/\ UB)_;^_\)_\ _!2@ _XBR?\ K$3^W]_X3_\ ^"E !_Q%D_\
M6(G]O[_PG_\ \%* #_B+)_ZQ$_M_?^$__P#@I0 ?\19/_6(G]O[_ ,)__P#!
M2@ _XBR?^L1/[?W_ (3_ /\ @I0 ?\19/_6(G]O[_P )_P#_  4H /\ B+)_
MZQ$_M_?^$_\ _@I0 ?\ $63_ -8B?V_O_"?_ /P4H /^(LG_ *Q$_M_?^$__
M /@I0 ?\19/_ %B)_;^_\)__ /!2@ _XBR?^L1/[?W_A/_\ X*4 '_$63_UB
M)_;^_P#"?_\ P4H /^(LG_K$3^W]_P"$_P#_ (*4 '_$63_UB)_;^_\ "?\
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M /\ @I0 ?\19/_6(G]O[_P )_P#_  4H /\ B+)_ZQ$_M_?^$_\ _@I0 ?\
M$63_ -8B?V_O_"?_ /P4H /^(LG_ *Q$_M_?^$__ /@I0 ?\19/_ %B)_;^_
M\)__ /!2@ _XBR?^L1/[?W_A/_\ X*4 '_$63_UB)_;^_P#"?_\ P4H /^(L
MG_K$3^W]_P"$_P#_ (*4 '_$63_UB)_;^_\ "?\ _P %* #_ (BR?^L1/[?W
M_A/_ /X*4 '_ !%D_P#6(G]O[_PG_P#\%* #_B+)_P"L1/[?W_A/_P#X*4 '
M_$63_P!8B?V_O_"?_P#P4H /^(LG_K$3^W]_X3__ ."E !_Q%D_]8B?V_O\
MPG__ ,%* #_B+)_ZQ$_M_?\ A/\ _P""E !_Q%D_]8B?V_O_  G_ /\ !2@
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M"E !_P 19/\ UB)_;^_\)_\ _!2@ _XBR?\ K$3^W]_X3_\ ^"E !_Q%D_\
M6(G]O[_PG_\ \%* #_B+)_ZQ$_M_?^$__P#@I0 ?\19/_6(G]O[_ ,)__P#!
M2@ _XBR?^L1/[?W_ (3_ /\ @I0 ?\19/_6(G]O[_P )_P#_  4H /\ B+)_
MZQ$_M_?^$_\ _@I0 ?\ $63_ -8B?V_O_"?_ /P4H /^(LG_ *Q$_M_?^$__
M /@I0 ?\19/_ %B)_;^_\)__ /!2@ _XBR?^L1/[?W_A/_\ X*4 '_$63_UB
M)_;^_P#"?_\ P4H /^(LG_K$3^W]_P"$_P#_ (*4 '_$63_UB)_;^_\ "?\
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M /\ @I0 ?\19/_6(G]O[_P )_P#_  4H /\ B+)_ZQ$_M_?^$_\ _@I0 ?\
M$63_ -8B?V_O_"?_ /P4H /^(LG_ *Q$_M_?^$__ /@I0 ?\19/_ %B)_;^_
M\)__ /!2@ _XBR?^L1/[?W_A/_\ X*4 '_$63_UB)_;^_P#"?_\ P4H /^(L
MG_K$3^W]_P"$_P#_ (*4 '_$63_UB)_;^_\ "?\ _P %* #_ (BR?^L1/[?W
M_A/_ /X*4 '_ !%D_P#6(G]O[_PG_P#\%* #_B+)_P"L1/[?W_A/_P#X*4 '
M_$63_P!8B?V_O_"?_P#P4H /^(LG_K$3^W]_X3__ ."E !_Q%D_]8B?V_O\
MPG__ ,%* #_B+)_ZQ$_M_?\ A/\ _P""E !_Q%D_]8B?V_O_  G_ /\ !2@
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M"E !_P 19/\ UB)_;^_\)_\ _!2@ _XBR?\ K$3^W]_X3_\ ^"E !_Q%D_\
M6(G]O[_PG_\ \%* #_B+)_ZQ$_M_?^$__P#@I0 ?\19/_6(G]O[_ ,)__P#!
M2@ _XBR?^L1/[?W_ (3_ /\ @I0 ?\19/_6(G]O[_P )_P#_  4H /\ B+)_
MZQ$_M_?^$_\ _@I0 ?\ $63_ -8B?V_O_"?_ /P4H /^(LG_ *Q$_M_?^$__
M /@I0 ?\19/_ %B)_;^_\)__ /!2@ _XBR?^L1/[?W_A/_\ X*4 '_$63_UB
M)_;^_P#"?_\ P4H /^(LG_K$3^W]_P"$_P#_ (*4 '_$63_UB)_;^_\ "?\
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M /\ @I0 ?\19/_6(G]O[_P )_P#_  4H /\ B+)_ZQ$_M_?^$_\ _@I0 ?\
M$63_ -8B?V_O_"?_ /P4H /^(LG_ *Q$_M_?^$__ /@I0 ?\19/_ %B)_;^_
M\)__ /!2@ _XBR?^L1/[?W_A/_\ X*4 '_$63_UB)_;^_P#"?_\ P4H /^(L
MG_K$3^W]_P"$_P#_ (*4 '_$63_UB)_;^_\ "?\ _P %* #_ (BR?^L1/[?W
M_A/_ /X*4 '_ !%D_P#6(G]O[_PG_P#\%* #_B+)_P"L1/[?W_A/_P#X*4 '
M_$63_P!8B?V_O_"?_P#P4H /^(LG_K$3^W]_X3__ ."E !_Q%D_]8B?V_O\
MPG__ ,%* #_B+)_ZQ$_M_?\ A/\ _P""E !_Q%D_]8B?V_O_  G_ /\ !2@
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M"E !_P 19/\ UB)_;^_\)_\ _!2@ _XBR?\ K$3^W]_X3_\ ^"E !_Q%D_\
M6(G]O[_PG_\ \%* #_B+)_ZQ$_M_?^$__P#@I0 ?\19/_6(G]O[_ ,)__P#!
M2@ _XBR?^L1/[?W_ (3_ /\ @I0 ?\19/_6(G]O[_P )_P#_  4H /\ B+)_
MZQ$_M_?^$_\ _@I0 ?\ $63_ -8B?V_O_"?_ /P4H /^(LG_ *Q$_M_?^$__
M /@I0 ?\19/_ %B)_;^_\)__ /!2@ _XBR?^L1/[?W_A/_\ X*4 '_$63_UB
M)_;^_P#"?_\ P4H /^(LG_K$3^W]_P"$_P#_ (*4 '_$63_UB)_;^_\ "?\
M_P %* #_ (BR?^L1/[?W_A/_ /X*4 '_ !%D_P#6(G]O[_PG_P#\%* #_B+)
M_P"L1/[?W_A/_P#X*4 '_$63_P!8B?V_O_"?_P#P4H /^(LG_K$3^W]_X3__
M ."E !_Q%D_]8B?V_O\ PG__ ,%* #_B+)_ZQ$_M_?\ A/\ _P""E !_Q%D_
M]8B?V_O_  G_ /\ !2@ _P"(LG_K$3^W]_X3_P#^"E !_P 19/\ UB)_;^_\
M)_\ _!2@ _XBR?\ K$3^W]_X3_\ ^"E !_Q%D_\ 6(G]O[_PG_\ \%* #_B+
M)_ZQ$_M_?^$__P#@I0 ?\19/_6(G]O[_ ,)__P#!2@ _XBR?^L1/[?W_ (3_
M /\ @I0 ?\19/_6(G]O[_P )_P#_  4H /\ B+)_ZQ$_M_?^$_\ _@I0 ?\
M$63_ -8B?V_O_"?_ /P4H /^(LG_ *Q$_M_?^$__ /@I0 ?\19/_ %B)_;^_
M\)__ /!2@ _XBR?^L1/[?W_A/_\ X*4 '_$63_UB)_;^_P#"?_\ P4H /^(L
MG_K$3^W]_P"$_P#_ (*4 '_$63_UB)_;^_\ "?\ _P %* #_ (BR?^L1/[?W
M_A/_ /X*4 '_ !%D_P#6(G]O[_PG_P#\%* #_B+)_P"L1/[?W_A/_P#X*4 '
M_$63_P!8B?V_O_"?_P#P4H /^(LG_K$3^W]_X3__ ."E !_Q%D_]8B?V_O\
MPG__ ,%* #_B+)_ZQ$_M_?\ A/\ _P""E !_Q%D_]8B?V_O_  G_ /\ !2@
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M"E !_P 19/\ UB)_;^_\)_\ _!2@ _XBR?\ K$3^W]_X3_\ ^"E !_Q%D_\
M6(G]O[_PG_\ \%* #_B+)_ZQ$_M_?^$__P#@I0 ?\19/_6(G]O[_ ,)__P#!
M2@ _XBR?^L1/[?W_ (3_ /\ @I0 ?\19/_6(G]O[_P )_P#_  4H /\ B+)_
MZQ$_M_?^$_\ _@I0 ?\ $63_ -8B?V_O_"?_ /P4H /^(LG_ *Q$_M_?^$__
M /@I0 ?\19/_ %B)_;^_\)__ /!2@ _XBR?^L1/[?W_A/_\ X*4 '_$63_UB
M)_;^_P#"?_\ P4H /^(LG_K$3^W]_P"$_P#_ (*4 '_$63_UB)_;^_\ "?\
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M /\ @I0 ?\19/_6(G]O[_P )_P#_  4H /\ B+)_ZQ$_M_?^$_\ _@I0 ?\
M$63_ -8B?V_O_"?_ /P4H /^(LG_ *Q$_M_?^$__ /@I0 ?\19/_ %B)_;^_
M\)__ /!2@ _XBR?^L1/[?W_A/_\ X*4 '_$63_UB)_;^_P#"?_\ P4H /^(L
MG_K$3^W]_P"$_P#_ (*4 '_$63_UB)_;^_\ "?\ _P %* #_ (BR?^L1/[?W
M_A/_ /X*4 '_ !%D_P#6(G]O[_PG_P#\%* #_B+)_P"L1/[?W_A/_P#X*4 '
M_$63_P!8B?V_O_"?_P#P4H /^(LG_K$3^W]_X3__ ."E !_Q%D_]8B?V_O\
MPG__ ,%* #_B+)_ZQ$_M_?\ A/\ _P""E !_Q%D_]8B?V_O_  G_ /\ !2@
M_P"(LG_K$3^W]_X3_P#^"E !_P 19/\ UB)_;^_\)_\ _!2@ _XBR?\ K$3^
MW]_X3_\ ^"E !_Q%D_\ 6(G]O[_PG_\ \%* #_B+)_ZQ$_M_?^$__P#@I0 ?
M\19/_6(G]O[_ ,)__P#!2@ _XBR?^L1/[?W_ (3_ /\ @I0 ?\19/_6(G]O[
M_P )_P#_  4H /\ B+)_ZQ$_M_?^$_\ _@I0 ?\ $63_ -8B?V_O_"?_ /P4
MH /^(LG_ *Q$_M_?^$__ /@I0 ?\19/_ %B)_;^_\)__ /!2@ _XBR?^L1/[
M?W_A/_\ X*4 '_$63_UB)_;^_P#"?_\ P4H /^(LG_K$3^W]_P"$_P#_ (*4
M '_$63_UB)_;^_\ "?\ _P %* #_ (BR?^L1/[?W_A/_ /X*4 '_ !%D_P#6
M(G]O[_PG_P#\%* #_B+)_P"L1/[?W_A/_P#X*4 '_$63_P!8B?V_O_"?_P#P
M4H /^(LG_K$3^W]_X3__ ."E !_Q%D_]8B?V_O\ PG__ ,%* #_B+)_ZQ$_M
M_?\ A/\ _P""E !_Q%D_]8B?V_O_  G_ /\ !2@ _P"(LG_K$3^W]_X3_P#^
M"E !_P 19/\ UB)_;^_\)_\ _!2@ _XBR?\ K$3^W]_X3_\ ^"E !_Q%D_\
M6(G]O[_PG_\ \%* #_B+)_ZQ$_M_?^$__P#@I0 ?\19/_6(G]O[_ ,)__P#!
M2@ _XBR?^L1/[?W_ (3_ /\ @I0 ?\19/_6(G]O[_P )_P#_  4H /\ B+)_
MZQ$_M_?^$_\ _@I0 ?\ $63_ -8B?V_O_"?_ /P4H /^(LG_ *Q$_M_?^$__
M /@I0 ?\19/_ %B)_;^_\)__ /!2@ _XBR?^L1/[?W_A/_\ X*4 '_$63_UB
M)_;^_P#"?_\ P4H /^(LG_K$3^W]_P"$_P#_ (*4 '_$63_UB)_;^_\ "?\
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M /\ @I0 ?\19/_6(G]O[_P )_P#_  4H /\ B+)_ZQ$_M_?^$_\ _@I0 ?\
M$63_ -8B?V_O_"?_ /P4H /^(LG_ *Q$_M_?^$__ /@I0 ?\19/_ %B)_;^_
M\)__ /!2@ _XBR?^L1/[?W_A/_\ X*4 '_$63_UB)_;^_P#"?_\ P4H /^(L
MG_K$3^W]_P"$_P#_ (*4 '_$63_UB)_;^_\ "?\ _P %* #_ (BR?^L1/[?W
M_A/_ /X*4 '_ !%D_P#6(G]O[_PG_P#\%* #_B+)_P"L1/[?W_A/_P#X*4 '
M_$63_P!8B?V_O_"?_P#P4H /^(LG_K$3^W]_X3__ ."E !_Q%D_]8B?V_O\
MPG__ ,%* #_B+)_ZQ$_M_?\ A/\ _P""E !_Q%D_]8B?V_O_  G_ /\ !2@
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@#__U_[^* "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H __]#^_B@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M/__1_OXH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@#__TO[^* "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MFTY4JL5%\O,DE.+C*,H325T]8QDG%?4U?)GKA0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!\/?\% _VG/&
MG[)7P%A^*O@/1/"^OZY)XZ\.^%C8>+K?5;G218ZO9ZU<7$XCT;5M%O/M4;Z;
M"L+?;/)"O)OA<E2GWGASPK@>,.(7E&85\7A\.L!B<5[3!RHQK<]"5&,8WK4:
M\.1JH[KDOHK-'@<29K7R;+OKF&IT:E3ZQ2H\M93<.6:FV[4YTW=<JM[UO(_,
M+]EK_@KU\?/CA^T'\*?A)XH^'GP@TWP_X\\4V^@ZG?Z!IWC.WUBTMY[:ZD$U
MA+J'C34[))DDAC_X^+&X1DWIM5BKI^K<6>#/#V0<-YOG&$S+.:N(R_"2Q%*G
MB*F!E0G*,H+EJ1I8&E/E:;^&I%IV[6/D\GXTS',,RP>"K8;!1I8BK[.<J4*Z
MFERR=XN5><;W2WB]#^AZOYM/TL* "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M&G++JD8PKT92?M,/91C4BV_XO1(_LLK^)3]P"@ H * "@ H * "@ H * "@
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MS-Z+1;(]4KR3K"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@#\C?\ @M5_R9M:_P#98/ __IJ\5U^Q^!O_ "6[_P"Q
M-C__ $YA#XSCO_D1K_L-P_\ Z35/Y]/^">?_ ">M^SA_V4?3_P#TCOJ_H[Q(
M_P"2%XF_[%E3_P!+IGYOPS_R/LK_ .PE?^D2/[?:_@X_>PH * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M/SS_ (B+_P!2?_S(?_>(?\/\/^K4?_,Z?_B<H_XEY_ZJ_P#\P'_X:#_B(O\
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MJO\ _,!_^&@_XB+_ -2?_P R'_WB'_#_  _ZM1_\SI_^)RC_ (EY_P"JO_\
M,!_^&@_XB+_U)_\ S(?_ 'B'_#_#_JU'_P SI_\ B<H_XEY_ZJ__ ,P'_P"&
M@_XB+_U)_P#S(?\ WB'_  _P_P"K4?\ S.G_ .)RC_B7G_JK_P#S ?\ X:#_
M (B+_P!2?_S(?_>(?\/\/^K4?_,Z?_B<H_XEY_ZJ_P#\P'_X:#_B(O\ U)__
M #(?_>(?\/\ #_JU'_S.G_XG*/\ B7G_ *J__P P'_X:#_B(O_4G_P#,A_\
M>(?\/\/^K4?_ #.G_P")RC_B7G_JK_\ S ?_ (:#_B(O_4G_ /,A_P#>(?\
M#_#_ *M1_P#,Z?\ XG*/^)>?^JO_ /,!_P#AH/\ B(O_ %)__,A_]XA_P_P_
MZM1_\SI_^)RC_B7G_JK_ /S ?_AH/^(B_P#4G_\ ,A_]XA_P_P /^K4?_,Z?
M_B<H_P")>?\ JK__ # ?_AH/^(B_]2?_ ,R'_P!XA_P_P_ZM1_\ ,Z?_ (G*
M/^)>?^JO_P#,!_\ AH/^(B_]2?\ \R'_ -XA_P /\/\ JU'_ ,SI_P#B<H_X
MEY_ZJ_\ \P'_ .&@_P"(B_\ 4G_\R'_WB'_#_#_JU'_S.G_XG*/^)>?^JO\
M_,!_^&@_XB+_ -2?_P R'_WB'_#_  _ZM1_\SI_^)RC_ (EY_P"JO_\ ,!_^
M&@_XB+_U)_\ S(?_ 'B'_#_#_JU'_P SI_\ B<H_XEY_ZJ__ ,P'_P"&@_XB
M+_U)_P#S(?\ WB'_  _P_P"K4?\ S.G_ .)RC_B7G_JK_P#S ?\ X:#_ (B+
M_P!2?_S(?_>(?\/\/^K4?_,Z?_B<H_XEY_ZJ_P#\P'_X:#_B(O\ U)__ #(?
M_>(?\/\ #_JU'_S.G_XG*/\ B7G_ *J__P P'_X:#_B(O_4G_P#,A_\ >(?\
M/\/^K4?_ #.G_P")RC_B7G_JK_\ S ?_ (:#_B(O_4G_ /,A_P#>(?\ #_#_
M *M1_P#,Z?\ XG*/^)>?^JO_ /,!_P#AH/\ B(O_ %)__,A_]XA_P_P_ZM1_
M\SI_^)RC_B7G_JK_ /S ?_AH/^(B_P#4G_\ ,A_]XA_P_P /^K4?_,Z?_B<H
M_P")>?\ JK__ # ?_AH/^(B_]2?_ ,R'_P!XA_P_P_ZM1_\ ,Z?_ (G*/^)>
M?^JO_P#,!_\ AH/^(B_]2?\ \R'_ -XA_P /\/\ JU'_ ,SI_P#B<H_XEY_Z
MJ_\ \P'_ .&@_P"(B_\ 4G_\R'_WB'_#_#_JU'_S.G_XG*/^)>?^JO\ _,!_
M^&@_XB+_ -2?_P R'_WB'_#_  _ZM1_\SI_^)RC_ (EY_P"JO_\ ,!_^&@_X
MB+_U)_\ S(?_ 'B'_#_#_JU'_P SI_\ B<H_XEY_ZJ__ ,P'_P"&@_XB+_U)
M_P#S(?\ WB'_  _P_P"K4?\ S.G_ .)RC_B7G_JK_P#S ?\ X:#_ (B+_P!2
M?_S(?_>(?\/\/^K4?_,Z?_B<H_XEY_ZJ_P#\P'_X:#_B(O\ U)__ #(?_>(?
M\/\ #_JU'_S.G_XG*/\ B7G_ *J__P P'_X:#_B(O_4G_P#,A_\ >(?\/\/^
MK4?_ #.G_P")RC_B7G_JK_\ S ?_ (:#_B(O_4G_ /,A_P#>(?\ #_#_ *M1
M_P#,Z?\ XG*/^)>?^JO_ /,!_P#AH/\ B(O_ %)__,A_]XA_P_P_ZM1_\SI_
M^)RC_B7G_JK_ /S ?_AH/^(B_P#4G_\ ,A_]XA_P_P /^K4?_,Z?_B<H_P")
M>?\ JK__ # ?_AH/^(B_]2?_ ,R'_P!XA_P_P_ZM1_\ ,Z?_ (G*/^)>?^JO
M_P#,!_\ AH/^(B_]2?\ \R'_ -XA_P /\/\ JU'_ ,SI_P#B<H_XEY_ZJ_\
M\P'_ .&@_P"(B_\ 4G_\R'_WB'_#_#_JU'_S.G_XG*/^)>?^JO\ _,!_^&@_
MXB+_ -2?_P R'_WB'_#_  _ZM1_\SI_^)RC_ (EY_P"JO_\ ,!_^&@_XB+_U
M)_\ S(?_ 'B'_#_#_JU'_P SI_\ B<H_XEY_ZJ__ ,P'_P"&@_XB+_U)_P#S
M(?\ WB'_  _P_P"K4?\ S.G_ .)RC_B7G_JK_P#S ?\ X:#_ (B+_P!2?_S(
M?_>(?\/\/^K4?_,Z?_B<H_XEY_ZJ_P#\P'_X:#_B(O\ U)__ #(?_>(?\/\
M#_JU'_S.G_XG*/\ B7G_ *J__P P'_X:#_B(O_4G_P#,A_\ >(?\/\/^K4?_
M #.G_P")RC_B7G_JK_\ S ?_ (:#_B(O_4G_ /,A_P#>(?\ #_#_ *M1_P#,
MZ?\ XG*/^)>?^JO_ /,!_P#AH/\ B(O_ %)__,A_]XA_P_P_ZM1_\SI_^)RC
M_B7G_JK_ /S ?_AH/^(B_P#4G_\ ,A_]XA_P_P /^K4?_,Z?_B<H_P")>?\
MJK__ # ?_AH/^(B_]2?_ ,R'_P!XA_P_P_ZM1_\ ,Z?_ (G*/^)>?^JO_P#,
M!_\ AH/^(B_]2?\ \R'_ -XA_P /\/\ JU'_ ,SI_P#B<H_XEY_ZJ_\ \P'_
M .&@_P"(B_\ 4G_\R'_WB'_#_#_JU'_S.G_XG*/^)>?^JO\ _,!_^&@_XB+_
M -2?_P R'_WB'_#_  _ZM1_\SI_^)RC_ (EY_P"JO_\ ,!_^&@_XB+_U)_\
MS(?_ 'B'_#_#_JU'_P SI_\ B<H_XEY_ZJ__ ,P'_P"&@_XB+_U)_P#S(?\
MWB'_  _P_P"K4?\ S.G_ .)RC_B7G_JK_P#S ?\ X:#_ (B+_P!2?_S(?_>(
M?\/\/^K4?_,Z?_B<H_XEY_ZJ_P#\P'_X:#_B(O\ U)__ #(?_>(?\/\ #_JU
M'_S.G_XG*/\ B7G_ *J__P P'_X:#_B(O_4G_P#,A_\ >(?\/\/^K4?_ #.G
M_P")RC_B7G_JK_\ S ?_ (:#_B(O_4G_ /,A_P#>(?\ #_#_ *M1_P#,Z?\
MXG*/^)>?^JO_ /,!_P#AH/\ B(O_ %)__,A_]XA_P_P_ZM1_\SI_^)RC_B7G
M_JK_ /S ?_AH/^(B_P#4G_\ ,A_]XA_P_P /^K4?_,Z?_B<H_P")>?\ JK__
M # ?_AH/^(B_]2?_ ,R'_P!XA_P_P_ZM1_\ ,Z?_ (G*/^)>?^JO_P#,!_\
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M^JO_ /,!_P#AH/\ B(O_ %)__,A_]XA_P_P_ZM1_\SI_^)RC_B7G_JK_ /S
M?_AH/^(B_P#4G_\ ,A_]XA_P_P /^K4?_,Z?_B<H_P")>?\ JK__ # ?_AH/
M^(B_]2?_ ,R'_P!XA_P_P_ZM1_\ ,Z?_ (G*/^)>?^JO_P#,!_\ AH/^(B_]
M2?\ \R'_ -XA_P /\/\ JU'_ ,SI_P#B<H_XEY_ZJ_\ \P'_ .&@_P"(B_\
M4G_\R'_WB'_#_#_JU'_S.G_XG*/^)>?^JO\ _,!_^&@_XB+_ -2?_P R'_WB
M'_#_  _ZM1_\SI_^)RC_ (EY_P"JO_\ ,!_^&@_XB+_U)_\ S(?_ 'B'_#_#
M_JU'_P SI_\ B<H_XEY_ZJ__ ,P'_P"&@_XB+_U)_P#S(?\ WB'_  _P_P"K
M4?\ S.G_ .)RC_B7G_JK_P#S ?\ X:#_ (B+_P!2?_S(?_>(?\/\/^K4?_,Z
M?_B<H_XEY_ZJ_P#\P'_X:#_B(O\ U)__ #(?_>(?\/\ #_JU'_S.G_XG*/\
MB7G_ *J__P P'_X:#_B(O_4G_P#,A_\ >(?\/\/^K4?_ #.G_P")RC_B7G_J
MK_\ S ?_ (:#_B(O_4G_ /,A_P#>(?\ #_#_ *M1_P#,Z?\ XG*/^)>?^JO_
M /,!_P#AH/\ B(O_ %)__,A_]XA_P_P_ZM1_\SI_^)RC_B7G_JK_ /S ?_AH
M/^(B_P#4G_\ ,A_]XA_P_P /^K4?_,Z?_B<H_P")>?\ JK__ # ?_AH/^(B_
M]2?_ ,R'_P!XA_P_P_ZM1_\ ,Z?_ (G*/^)>?^JO_P#,!_\ AH/^(B_]2?\
M\R'_ -XA_P /\/\ JU'_ ,SI_P#B<H_XEY_ZJ_\ \P'_ .&@_P"(B_\ 4G_\
MR'_WB'_#_#_JU'_S.G_XG*/^)>?^JO\ _,!_^&@_XB+_ -2?_P R'_WB'_#_
M  _ZM1_\SI_^)RC_ (EY_P"JO_\ ,!_^&@_XB+_U)_\ S(?_ 'B'_#_#_JU'
M_P SI_\ B<H_XEY_ZJ__ ,P'_P"&@_XB+_U)_P#S(?\ WB'_  _P_P"K4?\
MS.G_ .)RC_B7G_JK_P#S ?\ X:#_ (B+_P!2?_S(?_>(?\/\/^K4?_,Z?_B<
MH_XEY_ZJ_P#\P'_X:#_B(O\ U)__ #(?_>(?\/\ #_JU'_S.G_XG*/\ B7G_
M *J__P P'_X:#_B(O_4G_P#,A_\ >(?\/\/^K4?_ #.G_P")RC_B7G_JK_\
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MSI_^)RC_ (EY_P"JO_\ ,!_^&@_XB+_U)_\ S(?_ 'B'_#_#_JU'_P SI_\
MB<H_XEY_ZJ__ ,P'_P"&@_XB+_U)_P#S(?\ WB'_  _P_P"K4?\ S.G_ .)R
MC_B7G_JK_P#S ?\ X:#_ (B+_P!2?_S(?_>(?\/\/^K4?_,Z?_B<H_XEY_ZJ
M_P#\P'_X:#_B(O\ U)__ #(?_>(?\/\ #_JU'_S.G_XG*/\ B7G_ *J__P P
M'_X:#_B(O_4G_P#,A_\ >(?\/\/^K4?_ #.G_P")RC_B7G_JK_\ S ?_ (:#
M_B(O_4G_ /,A_P#>(?\ #_#_ *M1_P#,Z?\ XG*/^)>?^JO_ /,!_P#AH/\
MB(O_ %)__,A_]XA_P_P_ZM1_\SI_^)RC_B7G_JK_ /S ?_AH/^(B_P#4G_\
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MP_ZM1_\ ,Z?_ (G*/^)>?^JO_P#,!_\ AH/^(B_]2?\ \R'_ -XA_P /\/\
MJU'_ ,SI_P#B<H_XEY_ZJ_\ \P'_ .&@_P"(B_\ 4G_\R'_WB'_#_#_JU'_S
M.G_XG*/^)>?^JO\ _,!_^&@_XB+_ -2?_P R'_WB'_#_  _ZM1_\SI_^)RC_
M (EY_P"JO_\ ,!_^&@_XB+_U)_\ S(?_ 'B'_#_#_JU'_P SI_\ B<H_XEY_
MZJ__ ,P'_P"&@_XB+_U)_P#S(?\ WB'_  _P_P"K4?\ S.G_ .)RC_B7G_JK
M_P#S ?\ X:#_ (B+_P!2?_S(?_>(?\/\/^K4?_,Z?_B<H_XEY_ZJ_P#\P'_X
M:#_B(O\ U)__ #(?_>(?\/\ #_JU'_S.G_XG*/\ B7G_ *J__P P'_X:#_B(
MO_4G_P#,A_\ >(?\/\/^K4?_ #.G_P")RC_B7G_JK_\ S ?_ (:#_B(O_4G_
M /,A_P#>(?\ #_#_ *M1_P#,Z?\ XG*/^)>?^JO_ /,!_P#AH/\ B(O_ %)_
M_,A_]XA_P_P_ZM1_\SI_^)RC_B7G_JK_ /S ?_AH/^(B_P#4G_\ ,A_]XA_P
M_P /^K4?_,Z?_B<H_P")>?\ JK__ # ?_AH/^(B_]2?_ ,R'_P!XA_P_P_ZM
M1_\ ,Z?_ (G*/^)>?^JO_P#,!_\ AH/^(B_]2?\ \R'_ -XA_P /\/\ JU'_
M ,SI_P#B<H_XEY_ZJ_\ \P'_ .&@_P"(B_\ 4G_\R'_WB?HE^P/^WQ_PW#_P
MM?\ XM1_PK#_ (5A_P (+_S/7_":?VY_PFG_  F/_4G>$O[,_LS_ (1+_I_^
MV?;_ /EU^R?Z3^:^(?AY_J%_8_\ PK_VK_:OU_\ YE_U'V'U'ZE_U&XSVOM?
MKG_3OD]G]OG]WZ;AWB+^W_KG^Q_5/JGU?_F(]O[3V_M_^G%'DY/8_P!Z_-TY
M=?T2K\U/I@H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MJLLSK+LWA*6"KJ<H*]2C-.G6IK:\J<M7'9<\.:%].:^A]-5\L>J% !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?.W[7W_)IG[4/_ &;M
M\:__ %6OB6OI>#/^2PX4_P"RER+_ -6F%/,SK_D39M_V+,?_ .HM4_A K_0,
M_GH* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@#^B3_@@=_S==_W0O_WL=?S7](;_ )I#_NO_
M /O$/TSPZ_YG'_=/_P#=T_HDK^:S],"@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MC_/@\<_\CKXP_P"QI\0?^G:[K_1S+O\ D7X'_L#PW_IB!_-N(_WBO_U^J?\
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M<\P'$>4X3.,LG*>$Q<'**FE&K2G"3IU:%:$924*M*I&4)Q4I1T4H2E"49/\
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M"IRWOR2:M.FWWIS4J;\XL]8KR#L"@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H ^=OVOO\ DTS]J'_LW;XU_P#JM?$M?2\&?\EAPI_V4N1?
M^K3"GF9U_P B;-O^Q9C_ /U%JG\(%?Z!G\]!0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?T
M2?\ ! [_ )NN_P"Z%_\ O8Z_FOZ0W_-(?]U__P!XA^F>'7_,X_[I_P#[NG]$
ME?S6?I@4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MATZO[9S?_D4YI_V+L;_ZC5#\0P?^^83_ +":'_IV)_H%U_G0?T>?PT_MW?\
M)Y/[2W_98/&?_ITEK^]_#[_DB.%_^Q-@_P#TVC\ XA_Y'F:?]AM;_P!*/Z/?
M^"-'_)E&C?\ 91_'_P#Z66-?S+XW?\EU7_[%F7?^D3/U#@?_ )$-+_L)Q/\
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H ^=OVOO^33/VH?^S=OC7_ZK7Q+7TO!G_)8<*?\ 92Y%_P"K3"GF9U_R
M)LV_[%F/_P#46J?P@5_H&?ST% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!_1)_P0._YNN_[
MH7_[V.OYK^D-_P TA_W7_P#WB'Z9X=?\SC_NG_\ NZ?T25_-9^F!0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M\0P?^^83_L)H?^G8G^@77^=!_1Y_#3^W=_R>3^TM_P!E@\9_^G26O[W\/O\
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M-*-X8:C?2C13]U::<\OBJ26\M%[L8I?NO_P2*_88_P"%:>&;3]I[XHZ/Y?Q
M\::4P^&.BZA!BX\'^"M3@Q)XDEBE7-OK_C&SD LRJB;3O"LHC\T2>(-1L[7\
M \9./O[5Q4N%<IK7RW UO^%2O3E[N-QU)Z89-?%A\%->_P#9J8M7M;#TIR_0
M>"^'_JE)9KBZ=L37A_LM.2UH8>:_BM?9JUUMUA1=M'4G%?N/7X*??GQ]^W_!
M)/\ L7?M(QQ+N9?A=KTQ'_3.V$-Q*?\ @,43M^%?9^';4>..&&_^AMAH_.3<
M5^+1XO$:OD6:)?\ 0'5?R2N_P1_$1I%Z-,U73-1*&0:?J%E>F,'!D%I<QSE
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M?]D??_U-/$5?T-X ?\D]G?\ V.8_^H.'/SKQ!_Y&.!_[ G_Z?J&S_P $(O\
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M$?%^74[?P]_;=[#/<7HT62_BTW=.-+>X7[(0#^F.@ H * "@ H * "@ H *
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MOLOEHLK@'Z44 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M:AK(\/WFK^%QX<\<^-!J%OX=U>YT2S\0&]_LS[))XET'[-]L^U7'V0 _9>@
MH _&_P#X+Y_M;?'G]AS_ ():?M"?M+_LT>,+;P'\9/ >L_!:S\+^*+OPSX7\
M86^GV_C#XV_#[P;X@1_#_C+1]=\/7GVSP]KNIV2M>Z7<-:M<"ZM##=PP31@'
MX@?\&NO_  6%_;__ ."D_P"T#^U!\/\ ]L7XQZ1\3_#/PY^#GA7QAX.M+'X7
M?"[P!/I.NW_C5-%O;@W?P]\(>%[C4(KG3YO*:VU)[R&)XHY;=(7\PR ']I]
M!0 4 % !0 4 % !0 4 % 'SM^U]_R:9^U#_V;M\:_P#U6OB6OI>#/^2PX4_[
M*7(O_5IA3S,Z_P"1-FW_ &+,?_ZBU3^$"O\ 0,_GH* "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@#^B3_ (('?\W7?]T+_P#>QU_-?TAO^:0_[K__ +Q#],\.O^9Q_P!T_P#]
MW3^B2OYK/TP* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M[1/[#WP[^'7_  5FU#]@WPEKWB&V^&.H_M-?"#X3Z5K^H&QO?%6B^%/B[<>
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MH.FV]YK/@OQ)9S,9;2XL_(_4?%*MEF<<&Y)Q!A:5*53%8_ JCBN6E+$PP];
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M &4";_TU:77]W^&G_)"<,_\ 8N7_ *>JGX+Q/_R/\S_["/\ W' _?W_@B?\
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M^IGX9KXOPN_Y+[AK_L,J_P#J%B3V^*?^2?S/_KS#_P!/TC^-WX5?\E/^&_\
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MX_#B<1&Z;37Q4:7PT_LRGS5/>7LFOSC_ &=?$_P=\%?%OPMXO^.GA;Q%XX\
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M_3K/Z:Z_E@_53^8?_@NS_P EN^"?_9*]1_\ 4MU&OZJ^C_\ \B+/O^QM1_\
M4.F?E'B%_OV7_P#8)/\ ]/,C_P""$_\ R7/XT_\ 9)[+_P!2_2*KQ_\ ^1!D
M?_8XG_ZA5@\/?]^Q_P#V"0_]/1/Z?*_E,_5S^9?_ (+O?\E9^ W_ &3OQ)_Z
MDL=?U-]'[_D3\0_]C+"_^HLC\J\0O]\R[_L&J_\ IU&!_P $*O\ DX'XP?\
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M$K:/^RX/%NNZ)XMT]=)D_P"$L?7P#_3WH * "@ H * "@ H * "@ H * "@
MH ^0?^"@/Q[\9?LL_L.?M;_M)?#NQ\/:GX\^!7[/'Q:^*O@[3_%MG?ZCX7O/
M$G@?P5J_B#1K?Q!8:5JFB:E>:1)?V,"W]K8ZQIEU/;>9'#?6SL)5 /XB?^#?
MG_@L]_P4<_X*+_\ !8'PGX3_ &G_ -H;5O$'PONO@M\:]6M_@WX2T#PWX#^%
MMC=Z9H^G7FDS'PWX9TNQFUR\TFX#/INK^+=1\1:[:B26)-5\J1T(!_H:4 %
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M?PO_ /E70 ?\01?['_\ T>C^TG_X2?PO_P#E70!_3E_P31_8#\"?\$R_V1O
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M\47%H8X&6W^SVT#!?,9R0#\H/^((O]C_ /Z/1_:3_P#"3^%__P JZ /XY/\
M@MI_P3E\!?\ !+3]N+5/V5/AO\0O%_Q.\-6'PO\ A[X\3Q1XWL=&T[7'O?&,
M&IRW=BUOH,,%@+6S-@@MW$8E8.WF$X% '])__!/'_@TC_9C_ &ROV(?V9/VI
MO&'[5_QW\(^)OCM\)_#OQ%UGPSX:\,?#^;0M"N]=264Z;IDVJ65QJ$UM;(J1
MB:ZE,LK!I-L881H ?9G_ !!%_L?_ /1Z/[2?_A)_"_\ ^5= ']C7P2^%ND_
M[X,_"/X*:#J.H:QH?P?^&/@'X6Z+JVKBV&JZII/P_P#"ND^$].U'4Q9PV]F-
M0O;/28;F]%I;P6PN9)/(ABBVHH!Z?0 4 ?YM?_!W%_P5N^)OC_\ :*UG_@F3
M\&_%^H^%_@?\&M.\-7G[0P\.ZC=64GQ<^*?B+2=,\86/@_Q)<6K1C4/ _P .
M-$U#P_(OAWS&L+WQ[=ZO<Z];7=YX5\-G2P#Q_P#X(U_\&IWCW]O'X/\ @W]J
MO]L#XI>*/V>/@1\08;'7_AA\/O ^AZ/??&'XI^ [Z!+FS\=_V[XB;4/#WPT\
M-:[#)'/X/GU/PEXRU;Q+IA.N?V+I.AW.A:CKH!_1Z?\ @S@_X)&?V)_97]M_
MM<B^\MT_X24?&;PC_;>YDVK-Y!^%!\.>9$?WB#_A'_)+\2121_)0!^3/[6G_
M  9>^-/A[J>B_$7]@;]I1_B?#H/B30-2N?@W^T/9:-X7\77&EV6JVT]Y-H'Q
M9\*6UCX/UC55B7?'H^N^!/!%@889Y!XE>X:WL9 #_0=H _A0_P"#GO\ X+B_
M\%!OV$?VM?#/[(7[)GQ#\)?!WP3XA_9X\%?%+6?'FE^ M$\1?%:YUKQ?XQ^)
M/AO4M,M/$'C0>)/#^BZ1;Z=X.TU]-FT+PGIGB2SO+G4+E?$3%K)+$ _IL_X(
MK?%3XC_&[_@E9^Q%\5_B[XT\1?$7XE>./@MIVM>,/&_BS4I]7\1^)-6?6];M
MWU'5]3N6:XO;QX+>&-IYF9V6-<DXH _4.@ H * "@ H * "@ H * /C7_@HQ
M_P H]_V[?^S-?VG_ /U27C>@#_+J_P"#5S_E.1^Q_P#]@3]I+_UE_P",5 '^
MN_0 4 % !0 4 ?Q^_P#!Y3^U[K?P5_8!^%'[,/A/6FTC6/VOOBQ/!XOC@D*7
M6I_"#X*6FE>+?$VE1M&R301WOQ!U[X3&\E5C%<Z9;ZCI,\<MOJ,P4 _:G_@B
M7^Q=H7[!_P#P3+_98^"=GI/]F^,]8^'6A_%WXQS30+#J.H?&+XL:58>+_&T>
MI,H4W#^%I;ZR\ :5/(B3?\(WX0T2&5!)"U 'Q/\ \%R/^"_&F?\ !(S7_AE\
M%_!7[.NO?'K]H#XT^#)_&/@J/4-?A\-?#70],_X2*\\*69U5]*@UKQGXHUZ?
M6;"=8?">D:1HD-Y;-;E/%MM<R_9D /Y]?%G_  <S?\'!_@#PY>?'?Q[_ ,$L
M?!_@K]G;2H8)=4\7>+/V1?VR?#/@FQL+JX2&VO;SXLZU\2K7PW:333O'9PW\
MT*Z6\DT4/]GM<RQ,0#^H/_@B=_P6M^$O_!8?X/\ C'6-*\&3_![X^?!N;P_8
M?&+X1W>N6VO6,<'B*VNCHGCOP#K(BL;_ %GP/KEWI>JV+1ZEI=CK'AG6+&71
M]56\MI]#U_7P#P+_ (.D_P!B[0OVK_\ @D_\8?'<.D_:?B;^R');?M&> -3M
MX%:[M]"\.M'IOQ?TFXG ,ZZ%>?"^^U_Q%>VL9\J;6O"'AJ[N!MTY60 F_P"#
M6G]K[6_VL?\ @DC\)],\8ZTVN>./V7_%?B3]F'6KVYD+:A-X=\"6.@Z_\+_M
M*.S2-#I?PO\ %_A'PK;7F-MX?#,[,[W<=W@ _HOH * "@ H * "@ H * "@
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M /J_OA/0!_'1_P &47_*2K]I'_LQOQG_ .K[_9[H _TX* "@ H * "@ H *
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M\&?\EAPI_P!E+D7_ *M,*>9G7_(FS;_L68__ -1:I_"!7^@9_/04 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % ']$G_! [_FZ[_NA?_O8Z_FOZ0W_ #2'_=?_ />(?IGAU_S.
M/^Z?_P"[I_1)7\UGZ8% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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MKGTR>\\4?L_^)?!/QD\(75F52XL_LNNVW@KQG]J(7S+C1AX \9^*-1O;$R)
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M2%I1HJ'LL-&2U7,N:4JR5M%+D@]I4Y+0_:=$2-$CC18XXU5$1%"HB* JHBJ
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M^9__ / @?\0Z_P"IQ_YC_P#[]#_AP=_U==_Y@O\ _''1_P 3#?\ 5(?^9_\
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M>]X6M:SZ?*\0\,_V]5PU7Z[]4^KTYT^7ZM[?GYI*5[^WH\MK6M9_(S_V%/\
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MY>7K?3U[]M3]E@?M@_!J/X2'QT?AYY?B_0_%8\0#PS_PEF3HUMJEM]@.D_\
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M2#^KQE4Q$X\M7$U;.I)7OR12]VG3O9\L5K9<\I.*:^TJ^'/="@ H * "@ H
M* "@ H * /\ .Q_X/A?^2U_\$^_^R6_'C_U+/AS0!XA^R_\ \$D!_P %+/\
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M+!8:7IMHEQJ6KZG<VFEZ7:7FHW=M:R@'\=W[6?\ P>I?LI_#CQ%J_A;]D/\
M9E^(O[2MOIMVUE#\2?'WBJ'X%>!=76,\ZKX:T6?PMXX\?ZIIDB_+!%XG\/>
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MP?$?XT?$2V^%D&K+;2-##?Z1\/\ PWX9\=:L^E7^W[79RZYXG\.ZPMH8DO\
M0+"[DEM[4 \C^"G_  ? 7;^)=-LOVB_V"K:W\'3S[-7\2?!3XQ27GB72;8L"
M)]-\$^.?"=CI?B"=4RGV2Y^('AF-V(D^VQ@>40#PK_@ZY_;?_9J_X*"_LB?\
M$Q?VB?V6OB'9^/\ X>ZSX\_:>TK4HS#)IGBCP3XKM/#'P$N]6\#^//#=R?MW
MAKQ;HT5_9R7>GW(DMKNQN[#6M$O=5\/ZII6K7H!^S'_!E]_RBC^*_P#V?)\6
MO_5,?LZT ?TQ?M7?'[2/V4OV8_V@?VFM>\/:CXLT3X ?!WXB?&#5?"^D75M8
M:IXAL/AYX5U/Q1<Z+I][>*]I9W>I1:8UG!=7$<D-O)*LLD;JA0@'X!?\$L/^
M#FWX2?\ !4?]KC0/V2_!_P"RK\1OA+K6O>"_&WC./QCXE^(GAGQ)I=O;^"M+
M34[BQ?2]+T'3[MYKY&\J&5;D)"PW.K#B@#^GV@ H * "@ H _*[_ (+A?\HA
M?^"BO_9J7Q6_],$U '^>G_P:'_\ *9/P/_V0+X[_ /J/Z=0!_J^T 8WB/P[H
M'B_P]KOA+Q5HVF>(_"_BC1M4\.^)/#VM65OJ6C:[H&MV,^F:QHVK:==QRVM_
MIFJ:=<W%C?V5S%);W5K/+!-&\;LI /\ #+L=)OOV>_VW[/0O!]]<7NI? _\
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M\>_#[4M-<)=:7-H&KVK/I*74,*ZKX7O- \1Z;Y^C:UIMW< 'Z84 % 'XL?\
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M&*I;AR0J8 /[RJ "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M$6=/\/\ Q[\3Z+KT-KO'G :QJ/PVU_3[FX\O/E'^PK2/> ' 4Y !]Y_M\?\
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M84\S.O\ D39M_P!BS'_^HM4_A K_ $#/YZ"@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H _HD
M_P""!W_-UW_="_\ WL=?S7](;_FD/^Z__P"\0_3/#K_F<?\ =/\ _=T_HDK^
M:S],"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * $X% 'Y,?\%%/VG'TBWF_9^\$7S1ZCJ=E%/\ $S4[610U
MGH]["LUEX-0^6SB;6[62/4-=,<D&S1VLM,)NK?6M2@M_U/P^X956I'/L;#]W
M"4XY;3E'XZL':>+;T]VC)<E!-23JQG-*,L/3E+Y?/LR<$\#0>K2^LR_EA+X:
M*\YI7GV@E'7F?+^,W _S^'^'M7[)I%=D?'GK_P /O"(;RO$.IQ97 ?2K9@"#
MUQJ$D;#^$X-GDCG]^!\L#G_(CZ>GTL:KGF?@1X;9I*E"G*K@/$W/\!6E3J57
M91K\#8#%49W5%*4J/&'LTI59?\8Y4J1P_P#;N"Q']7>!OA8K87CCB'#)M\M;
MAO 5HQ:C9\T,[K4YQLY67-E*O[MGF"CS_4:U/V, L50<DD*HZ\DX  ]SQ^70
M5_D@VHZZ)16K>W^+;IO^?E_525]([NR7Z:*ROM:R2VM8_%[]DK]J_P"&/C?_
M (*&_M4:9H>LW+Z3\=;;P#8_#B^NK$V]KXCU3X'>#]4T[5?+.PS6<6I:>WB3
M6_#[7QM?MVFVBK=QP:Q=:?IU?ZD_2/\ HZ^(/"?T*OH[YAF^5T*>/\(Z_&N-
MX\P=#%>UQ&0X/Q;XHRK&Y5[6#<8UIX'%PR/*,YAA(XAX/,\;^X=;+Z.*QQ_-
MGA]Q_D>9^,7'U#"8N3H\40R>ADE6=+DAC*O"V68BEB5!I-PC5I/&8G!JHX>U
MP]!1E!5YT*)^S%U:VU]:W%C>V\-Y9WEO-:7=I<Q1S6]U;7,1AN+>X@D#12PS
M0L\<L3JR21LR,&!Q7^8&!QN,RW&83,<OQ>)P&/R_$T,;@,;@J]3#8O!8W"58
MU\)BL+B*,H5L/B,-7A"M0K49PJT:L(5(2C*-S^CJ]"CB:-;#8FE"OA\13J4:
M]"M"-2E6HU8.G4I5:<TX5*<X2<90E%QDM))JY^+?[4G[/,OP;\0Q:YX=BGE^
M'?B6[DCTMW+S-X=U1EFN7\-W,\DLLTT?V>.2XT6[N3Y]U907,%P9[C39[R[_
M .C/Z#_TM:7TA.%:_"O%]?#T/%K@W 4:F<*E&G1AQ?D4)T,+3XPP>%HT:.'P
MF)AB:U' \1X#"Q^J8?'XC!X[ PP^#S:EEV5_YP>.?A%+P[S6GFV3TZM3A#.L
M1.&";YIO)LP:E7>35JLYSJ5:3H0G6RW$5OWU;#TZU"M*M6P53%8KY>L+^_TF
M^L=4TF^O=+U33+NVU#3=2TZZGL=0TZ_LIDN;.^L;VUDBN;2]M+B*.XM;JWEC
MN+>>-)H9$D16']W5*<*L)4YQA.%2$H3ISC&<)PFG"4)PDG&4)Q;A*,U).+>B
MN?@L92A*,X2E&46I1E%M.,H_"XM:Q:=FG&S32UT1_;'_ ,$ROVX+3]L;X+^5
MXINK:+XW?#&'3=!^)MC'%';#78YX730OB!IUO#_HRV?BA+.[35+2U$(TOQ-8
MZO EA9:1<Z"]Y_(7B'P=+A3.'+#0;R?,I5:V7SW]@XRO5P%3634\,ZB]E*4G
M[;#SIOFE5IUE#]VX5S]9W@+56EC\)RT\3%:*I%JU/$PCHN6NHOF225.K":2C
M"5/F_2FO@#Z@6@ H * "@#^8G_@Z@_Y,M^ '_9TFD?\ JI_BG7['X+?\E!FG
M_8FG_P"IN#/D^+_^1?A_^PR/_IBL<S^P;\2;KX1_\&SOQ.\>Z=<S6.L:5\(_
MVSM.\/WUN76:P\3>*/B3\3_"GAF_C,:LP-CK^N:;=?P#$7S20J#*E\382..\
M7\)A9I>SGC^'YU%)>[*C1P>#K58?]OTZ4H+1ZR6CV)RVJZ'"E2JM'&AC^5]I
M2K5X0?HI-?=Y'XZ?\&SOA6V\1_\ !2Y]3GC+R> _V</BUXRLF\HRB"ZGUWX=
M^ &E+\BU!L?'E[!YYX8S"VZW S]_XP5O8\(*"T6)S; 8>6NZ5/%8I)+K[^%@
M_2-^AX?"<%+-;V_A82M-6_Q4J=FOY;5']Y_H3#H/R_+BOY:/TH.W^?\ ]5 '
M\)'_  =0:3#%^V=\ -: 'GWW[,6G:9*> QBTGXJ_$JZA#?+@JK:W<%>21E@
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MC\$_^"5W_*43_@NK_P!E=_9C_P#2?]HVOT[C9?\ &&>&O_8#FWX/*#YS*/\
MD;\0_P#7[!_EBC._X+D_\$B=2_;O\*Z-\>O@-!I\/[3WPK\,W>AMX?OKDV-I
M\9_A]92W^LV'@N.]N+A-*TGQKH>K7^IW'@O5+T6.GZG_ &U?Z!XGU*VL1H6J
M^'#PXX[I\,5ZF69FV\GQU:%13C'FEE^)ER4IXEPBO:SPU6"IK$0BY3A[*%7#
MPYU5A6>?Y*\Q@L1ADOK=&+BH[>WIKFE&G=Z*4)-NG>RUE&5URN'\[W_!-O\
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M4G:_-^[K[)2:]V2<?9UHO37]U#^BO_@G%_P<1_ +]I&+0?A=^UK_ &!^S?\
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MPSIOB2#2=0**JKJ>D?V@=,U.+8AAO[2XA9$9"H /\N7_ (.;?^"L_C?]O/\
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M%O\ E,Q\.O\ LA?QY_\ 43AH _UAJ "@ H * "@#\KO^"X7_ "B%_P""BO\
MV:E\5O\ TP34 ?YZ?_!H?_RF3\#_ /9 OCO_ .H_IU '^K[0!^ W_!97_@O3
M^RE_P30^$'Q-\&>%?B;X0^)?[;EWX8U+2/AA\#?"M];^*-0\'^,-6LWM='\7
M?&%M-^U:;X)\.>%I;BW\1W'AOQ'>:;XH\86UO!IF@::UK?W.M:6 ?YR7_!"_
M]BSQW_P4'_X*C_L[>#DL=3UWPCX%^(VB_M$_'[Q-<&2>'3OAS\-/$^F>*]>D
MUO4)!*XN_'GB)=&\!V$I$UQ+K?BZVN646\%W<P '^R'XP_Y%'Q3_ -BYK?\
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M$O"WA^^T%O'?]FK,=.U3Q+\0)=:T[6[FV74=$\+>&8R(Y #](?CM_P &Y/\
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M>/\ 4(4O9/V:_A-XMN_#GPZ\*13*K)I?COXG^')+3Q?XSUV%#B^B^'VK^$-
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MZ/?^#0;_ (*'>+?VIOV*OB#^RA\5-?N_$7C[]BG6/".B>"=8U*5I;^^_9_\
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MW>.?]Z9067Y* /[PO^#3K_E"=^SY_P!E'_:&_P#5S>+J /O3_@N%_P HA?\
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MTOA3^Q5X4U?[1X/_ &3? P\3^/;6UG_<3?&KXRV.EZZ]G?1Q%H;EO"OPPL_
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MGJ93$%W?_#/PAX_\1ZE81R?Q2Z=;_%G2;B=/^6::I;M_RTH _NEH * "@ H
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M&GT/Q-X<\0:-J'A[6Q87DD>E>-O">L+I=Y=:?%87UP ?ZH?_  2K_:U\._\
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M$+ZWI]GX7\8>#]*EE&!;>/=2MU!EGAV@'^JI0!_BK_M(?\IM_CU_VE0^*/\
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M"FL^&]=U**WU;4-"\11Z;J1U;5?#VJ:_J@!PO[ WP/\ VO\ _@X _:U_9/\
MV0?BG\7?$]S\)OV6_@58^"KKQH;*.\@^"O[,GPWO((YO[,L6 T_4/'/B6^U/
MPQ\/-"UG5([F\O[M_!XUUKWP[X0\JT /]&'P1_P;D_\ !&3P5\+=-^%+?L0?
M#SQC86=E!;W_ (U\;ZOXQUKXI:]>)"([K6-2^(L'B+3_ !)8WNH2[[N>S\-7
M>@:#9S2&+1M&TNQBMK.  _S\_P#@XW_X(U^#O^"3?[2/PZU/X%ZEX@U']F/]
MI;2?&'B'X:Z3XFN9-5UOX:>*O!>IZ5'XU^&4WB"0O<>(="TBP\5>$M5\(:YK
M+KXANM+U6YT?69-9U'PW>>)M< /[</\ @U#_ &LO$_[3W_!)/P/X:\;ZQ<ZY
MXJ_98^)GC']FP:EJ-U+=:I=^"_#NE>%_'7PX2X:8DBQ\.^#?'^F> M%"8B32
MO!EM;\RV\S$ _I7H _@O_P"#UC]M_P#LKPC^S-_P3W\):OMO?%=[/^TQ\9K.
MUGV2IX>T.35_!'P>T6\$1/G66LZ\WQ#\07EA<>7Y5YX0\+:@L<NZ"2( ^C_^
M#,3]BO\ X5=^QW\:?VV/$^D^3XG_ &H?'X\!_#R\N(,R+\'_ (+7.HZ7>ZCI
ML[*K10^)OBGJ7B_3-6@3='.?AYH<YD8HJ1 'UA_P=M_L4_\ #3?_  3!U#XX
M>'-)^W?$;]BWQG9_%ZQEMX/.U&?X5^)?LG@WXP:3 =I$-A:6-SX8^(VL2[DV
MV/PU."QQ%( ?SH_\&9G[;_\ PJ;]L7XO?L1>*]7\CPE^U3X)/C3X=6ES-^Y@
M^,_P<L-1U>YL-/A=ECMY/%GPLNO%UWJDZEI;J;X?^&[-8W^5HP#_ $OZ /YW
MO^#JG_E!W^UK_P!C'^S?_P"M*_":@#_+N_8N\"?M2_M'?$RT_89_9<U/5SK?
M[9.O^#/A_P"*O"%A<KINC>+=+\(:S)XXL[GQSJ<-K/?V_@+P%+IEU\1/$R1L
M^GP6OAA-<O=/U"YT+31  ?Z;_P"PE_P:S?\ !+[]E7X<>'[7XV_"73?VP_C=
M)IUJWC7XE?&-]6NO",NKR00G4;'P1\)[75(?!>A>&(;M'.E'7[#Q1XO$+,+_
M ,4W$<@M8 #F?^"B7_!J]_P3C_:H^%/B>3]F/X7:#^Q]^T58:5=W7@#QE\-I
M]9L?AGK&MVT$CZ=X<^(WPTDO+_PW_P (QJ4Y^S7FN^#=*T'Q=I,DL&IK>:Y9
MZ>WAO4@#_.O_ &#?VL_CY_P1_P#^"A_A3XI-I^O>$_&'P,^)VK_"S]HKX6W)
M,4WB7P38>(SX8^,GPMUZQ\]+.YO1%IU\^B37+3V^B^--&\/>);4/<Z/:/0!_
MM5^%O$V@^-?#'ASQEX6U*#6/#'BW0=(\3>'-7M=_V;5=!U[3[?5=(U*W\Q4D
M\B^T^ZM[F'>B/Y<J[E4Y  -Z@ H * "@ H * /G;]K[_ )-,_:A_[-V^-?\
MZK7Q+7TO!G_)8<*?]E+D7_JTPIYF=?\ (FS;_L68_P#]1:I_"!7^@9_/04 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % ']$G_  0._P";KO\ NA?_ +V.OYK^D-_S2'_=?_\
M>(?IGAU_S./^Z?\ ^[I_1)7\UGZ8% !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M\G"N$PN)^O\ UG#8?$<DL/R>VHTZO+S>WOR^TC+EO;6UKZ7V1_5A_P .V/\
M@G2.G[ O[%8_[M8^!G_S"5^*OB[BS_HJ.(?GG.9/_P!VCZ_^RLK_ .A;@/\
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M$KO^4HG_  74_P"RN_LQ_P#I/^T;7#QMKP7X:V_Z <V_]*R@URC_ )&_$/\
MU^P?Y8H_H QT]J_,#Z0_-C]O[_@E=^RK_P %#/#;_P#"U?"Y\*_%K3--_L_P
M?\=O UO9:=\1- BAE6XL],UB5X&L?'/A6*42Q_\ ",^*X;V+3;;4=8D\)WWA
M76=2DUI/K>&.-,ZX4JI8*M[? SJ)U\KQ#<L+5O[K=+7FPM>VJKT7%RE&F\1&
MO3IJF>5F.48/,H?OH<E:,;4Z]-+VD>T7?^)#^Y.ZC>3I\C9_"S\;_@1^W/\
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M]BS+/_3V-/G\U_Y&F0?]A&)_]-TC]VB#CC]*_-OZ_K;_ (8^@/\ /%_X**_
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MO<75I$ELNH7/P,U2^DEU:XO+=([K5IOAMK][JEWJIFO[/P%JT=U%X;^'U_\
MO/!7BQ*4Z&5\4S@E)JE1SE)4X1;YN2.8TXVIQCK&$<72C",&H2Q5-IUL5#XK
M-^&4E/$Y:ME>>$=M5=7="3UT7-/V4F[O2G=\L'\Y_P#!!7_@K?\ $7X1_&#P
M#^P]^T-XLU7Q1\$/B-J=EX ^#NK>)/M6HZQ\&/B+?7$EIX3\)VVH&*XUB3X?
M^,M6FM?!L.A7OVC3_!&N77AZ^TMO#7A9/%+R^MXF<#83'8#$\1Y71A2S'"0E
MBL="E:%/,,)%)UJW*K4UB\/37M_:1<98FC&HI*K5^KG+P]G56A6IY?BI2G0J
MR]G0D[MT*C:4(7;O[*3]Q1:M3?+;E2DC^ZQ3D?Y_STK^;3]!%H * "@ H *
M"@ H * /_]3^_B@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MF/AU_P!D+^//_J)PT ?ZPU !0 4 % !0!^5W_!<+_E$+_P %%?\ LU+XK?\
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MSY_X*B?\'1OBK_@IQ^Q;\3?V//$_[%'A#X6VWQ U;X>ZWI_Q$TWXVZQXNO\
MPKJ7@+Q_X<\9BXMO#MW\-- @U ZOI^BZAX:EWZO9_9+?6YKY3.UL+2< ]K_X
M,GO$U[:?\%&OVF_!D<TRZ;KW[$_B7Q-=6RN1;RWOA'XZ? S2M/FEBSM::W@\
M:ZG';N03''<W*J0)6! /]-2@ H ^9_VTO"D_CS]CG]K+P/:QRRW/C/\ 9H^.
M_A2VB@#M/+/XB^%OBG2(8X5C^<RO)>*L83YRY 7G% '^/C_P0^^(VD_"K_@K
MG_P3W\7ZY>1Z=I9_:;^'GA&YO9L"WM?^%C7TGPZ@EN9#\D%LMSXJA^TW,A6*
MU@\RXE9(XF8 '^U-0 4 % !0 4 ?S<_\%%?^#HC_ ()R?L$^,/%/P?\ #]YX
MO_:J^._@[4Y]!\4>!O@M'I\7@WP=X@LFVW^B^,/BQK\MOX9CU'3Y!)8ZG8>"
M+7Q]J6B:S#/HNOV&D:A:WL-H ?SO?%7_ (/?/VB]4:[7X(?L*_!3P+'ND6QF
M^*OQ1\=?%9@H)$4MW;>$='^#(+,,/);PW:A"3&MS)M$K 'X#_P#!3/\ X+I_
MMP_\%7O G@_X;_M,67P6T7P!X \>1_$+PWH'PE^'>H^&([#Q0= USPY&TNN>
M(_%7C/Q'/9OI.LZDG]G3ZVT$\L<%S*DLME$\8!_5Y_P8]R.?@7^W]$6;RT^+
M/P/D1,_*KR>#_'BR,%Z!G6*(,>XC0'[HH _8+_@ZI_Y0=_M:_P#8Q_LW_P#K
M2OPFH _E0_X,IOAQIFO?\%"/VE/B9?+#-=_#O]DS4=#T:&6,,UM?^/\ XJ?#
MM9]5MVQ^ZGM])\*:EI98,-UMK=RF"&^4 _TT* /B+_@ICX2M/'G_  3D_;X\
M&7NU8/$O[&?[3>D>:Z[A;3W?P7\:1VEXHP?WEE=>1=Q'!Q)"AP<8H _RZ_\
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M'2K7'V_Q?\/GGN$BM[[6M<\#^$M$MI+I #R;_@A#_P ' _QO_P"":7Q*\#?
MKXU^*]7^(O[!/B?Q+;Z9XL\'ZV+W7M9^ UOKMTR7GQ"^$-PLDFHZ;IFE7]RN
MN^+?AY;I?:%XBL%UJXT+1]/\9:D-8G /]8GPSXE\/>,_#GA_QAX1UO2_$OA3
MQ7HFE>)?#'B/0[ZWU/1-?\/:[80:IHNMZ/J5G)+::AI>JZ;=6U]I]]:RR6]W
M:3PSP2/%(K$ _P O/_@\S_Y2R^ /^S+/A!_ZM#X[4 ?W2_\ ! /_ )0U_P#!
M/?\ [('IG_J0^(* /V"H _R$/^#I;_E.C^VM_P!>G[-/_K)7P*H _P!3[]@G
M_DQC]B__ +-._9T_]4_X.H ^L: /\X3_ (/>?^3IOV'O^R ?$/\ ]6);T ?T
MG?\ !J;_ ,H0?V6_^QO_ &C/_6AOB70!_'%_P>(_%#5O&_\ P5O@\#W5UNTG
MX,_LS_"'P=I-E&Q$4$OB2\\7?$S4KN2/.W[=>/XVMH9I@ TEE8:;$V5MTH _
MN%_X-P/@EH/P/_X(S_L5Z?I.AVFD:I\2O VL?&WQ;=P0"*[\1Z[\5/%6M>);
M#7-4E^_=W:^#9_"FAVL[Y,>BZ)I-G'B"TB4 '[BT ? 7_!5GP/HWQ'_X)D_\
M% O!^O1[]/U+]C?]HVZ1MJN;74]#^$_BG7]"U!$;Y7ETS6]+T[48E) :2U09
M7J #_,=_X-7/^4Y'['__ &!/VDO_ %E_XQ4 ?Z[] '^1%_P<U?L1S_L1_P#!
M5[XM:[X3TZ71/AI^T^+?]J+X:W.GH]K;:=K/C;5+]/B?H]G<VWEP6EYH_P 6
M-+\4ZQ9Z=9^2VC^'=?\ "P6*..:VDE /],K_ ()-?MB0?MZ?\$[/V4_VGY;^
M&^\5>.OA=I6E?$TQL@:#XN>!);CP'\4E>W7#V<5WXX\.:WJFFP3*LC:-J&FW
M*^9#<132 '\D7_!Z]^VMY-E^RU_P3\\+:MA[R2]_:@^,-E;3886UN=:^'OP:
MTNZ,)^:*>X/Q2UN_TRZ("R6/A/5! Q^QSH ?IC_P:&?L,_\ #-G_  3EU']I
M?Q5H_P!A^)/[:_C#_A-[>6X@\F_M/@K\/9=5\*?"O3Y5=2ZQ:QJ<_CSQ]9SQ
MR"+4-"\9:!(8@ULKL =]_P '9?[#VN?M8?\ !,;4/BWX%TYM2\?_ +%_C'_A
M>S6=O;&XO]2^$DVC7?ASXQ6-GC'V>/1-'N=%^)6ISLVW^R/AU?0+')<36X !
M],_\&WO[>>E?MU?\$M_@=+?ZA#+\6?V9](TO]F3XN:<9_,OFO_ACH.EZ=X$\
M63K*_P!KN(_''PV/A?6;S5'C2VN?%B^+=/M7E.D3E0#\B?\ @LU_P;"?'#]I
M#]KO6?V^O^";WQF\)_"WXO\ C;Q+I?C[Q[\/O%_B7Q;\.KS2?BGI2122_%;X
M1_%+PG9:[?:-X@U[4+/3]8U#0=1L=!73/$HU7Q)I/C!5U*WT'3 #YO\ "_\
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M % !0 4 % !0 4 % !0 4 % !0 4 % 'EOQR_P"2*?&#_LEOQ _]1/5J /\
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M*KQR0WVE:A=6LL<B.CQRLK*RDB@#_%I_X)FZUKG[/'_!7/\ 8E>VU)[:_P#
M'[=WP5\$:Y>PJ83<Z)/\9]$\!>-+;868Q1ZMX;O]:L)$+-LBO&4EL<@'^U+X
MP_Y%'Q3_ -BYK?\ Z;+F@#_%'_X) ?"SP]\:O^"H_P"P+\-?%MA%JWA;7_VJ
M/@_<>(M(N8XI;36-%\.^+M/\4:EH]]#,K1S:?JUIHLNG:A"1F6RN9XT*NRL
M#_;;H * /X+O^#X;X8Z=<>!_^"?/QE@M+.'5M)\5_'OX8ZI?)%"FH:CIWB'2
M/AKXJT&TN)MOVB>ST6Y\,>(YK*(L8;2;7K]E57O6+ 'T]_P9/>+M1U'_ ()^
M_M1>"KFXN)M/\*_M=WNMZ9%+EH;3_A+?@_\ #*"\@M68?)&T_A@7,ENA\M)K
MB2<(LEU*T@!^A/\ P=8?\H0/VJ/^QL_9R_\ 6B?AC0!_-5_P9#_\G5_MN_\
M9OG@#_U8[4 ?Z/\ 0!_.]_P=4_\ *#O]K7_L8_V;_P#UI7X34 ?S,_\ !D3_
M ,G:_MK_ /9NG@K_ -67;4 ?Z,GC#_D4?%/_ &+FM_\ ILN: /\ %?\ ^",'
M@.P^)/\ P5C_ ."=_A75!$^GG]K?X*^([N"9/,@NXO WC+3?&YL)HR"LD-^?
M#HLI8V&QXYV5_E)H _VPZ /*/CQX9L/&GP.^,W@[55W:7XL^%'Q$\,ZDNT-N
ML-=\(:QI=XNT\-FWNI!M/!Z4 ?XS?_!%;X=Z7\4_^"L__!/3P?K*0S:6W[5?
MPD\3WMK<QB:VOH?A_P");7Q]_9US"RLDUMJ3>&5L)X9%,4L-P\<@\MFH _VN
MZ /(/V@]"LO$_P  _C?X9U*&.XTWQ#\(/B5H6H6\J[HI[+5O!FM:?=0RK_%'
M+!<.CKW4D4 ?Y 7_  ;RW,UI_P %HO\ @G]+;N8W;XQ:A;,P[P7OP\\:6=RG
MTDMYY8S[,: /]ER@#_%7_:0_Y3;_ !Z_[2H?%'_UK;7* /\ :HH * /XV?\
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M#Q'HSSI&\BPW:V.HPQWEMO+VMVDUM)B2)@ #\+?^#JG_ )0=_M:_]C'^S?\
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MD7_JTPIYF=?\B;-O^Q9C_P#U%JG\(%?Z!G\]!0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?
MT2?\$#O^;KO^Z%_^]CK^:_I#?\TA_P!U_P#]XA^F>'7_ #./^Z?_ .[I_1)7
M\UGZ8% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MX.(O^43_ ,?_ /L;?@)_ZO?X=U^B>%7_ "6^5?\ 7G,O_59BCP.)O^1-B?\
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M@#_.(_X-UO\ E*=\#_\ L2OC-_ZJ7Q17]9>*W_)%9C_V$9?_ .IM$_+N%_\
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M'Q3MH--\ ^*96410ZY;> =9N;G3M)TG7KB< _%/]EF)[?_@L7^SG!(-LD/\
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M+\97&J+"+F:YDB35_%7C#5=9U*>::5I+S4KRX=B7(H _R&/^",GQRT?]D?\
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M_!HM_P IF/AU_P!D+^//_J)PT ?ZPU !0 4 % !0!^5W_!<+_E$+_P %%?\
MLU+XK?\ I@FH _ST_P#@T/\ ^4R?@?\ [(%\=_\ U'].H _U?: "@ H YSQA
M_P BCXI_[%S6_P#TV7- '^,[_P $%?\ E,9_P3S_ .SB_#'_ *0ZK0!_M"T
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MM0!_I#T ?*/[>/\ R8Y^V9_V:C^T1_ZJ'QA0!_E9_P#!KE_RG7_8:_[N9_\
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M0SS7$P?5?$FO:QK5[)+-))-?ZC=3,V9* /\ ) _X.9/^4XG[=_\ V,?P6_\
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MZEIK^&_$>L1T ?UHT % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M_*8S_@GG_P!G%^&/_2'5: /]H6@#B_B1_P D[\>_]B7XI_\ 3'?4 ?XWW_!
M+_E,I_P3X_[+WIW_ *CGB&@#_9UH \[^+W_))OBA_P!D[\:_^HUJ5 '^._\
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MXENA%X4^'&LK?LB/';VMP3*4>2'< ?RW?\&47_*2K]I'_LQOQG_ZOO\ 9[H
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MYT6TB)!GNKC0O$6KZT4124L_#UY*<*AH _TU: "@#_':_P"#DS]H70?VCO\
M@LI^V#X@\)ZA!J?A7X;>(/"?P'TB[@*NC:A\&O!6@^"O'<8EC)CG2#XFZ?XV
MAMYHR4DM([<J6'S$ _U0O^"97PCU7X#?\$Z_V&_@[X@@-KXD^'O[*7P'\.>*
M+5HC";;Q5:_#;PZ_B>V,;?.OD:]+J,7S@2'9EU5R0 #[CH * "@ H * "@#Y
MV_:^_P"33/VH?^S=OC7_ .JU\2U]+P9_R6'"G_92Y%_ZM,*>9G7_ ")LV_[%
MF/\ _46J?P@5_H&?ST% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!_1)_P $#O\ FZ[_ +H7
M_P"]CK^:_I#?\TA_W7__ 'B'Z9X=?\SC_NG_ /NZ?T25_-9^F!0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M0BK-,_*/_@TOP+[_ (*"GK_H7[))_P#(_P"U"/Z=OP["OM_'%>YPLO[^>?\
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M%_7]?UZ+8^[]/Z_KMTV%H * "@ H * "@ H * /_UO[^* "@ H * "@ H *
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MQBFI^)]-T?[5XAET2XCL;F?0-*UG4K(W,6DWX@ /W@H * "@ H * "@ H *
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MB;]H']I7]G?]GG_@GS\)M3^%OP]\=?M$?!GP?XX^.'QMT[PUK'Q#\2^$-?\
MB-X;T;Q#H'@[X9VLWB/PEX+MM9T^XN[&;Q-KVN^+==ETF_=M+T3P9KUO;ZG
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M/Q&_C77O&E_X3\=7_AB"_BU'7=/'PZ\'P>*(]/DMM)D\)/<B1 #_ $2* "@
MH _*[_@N%_RB%_X**_\ 9J7Q6_\ 3!-0!_GI_P#!H?\ \ID_ _\ V0+X[_\
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MXFU[7?%NNRZ3?NVEZ)X,UZWM]3@ /[W: /\ 'B_X.9/^4XG[=_\ V,?P6_\
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MKVF_%6W\(0WNH7NL:#'K]G>Z0_A'Q1XF@DM5@,D%RMXUG+'*B&)9TD)B /\
M-B_X.6?VWO\ AM?_ (*M_'*70-7_ +3^%W[-C0_LP_#3R)_-L)HOAEJ&IK\1
M-:MC$QM+I=<^+&I>-YK'5K<-_:/AJV\.#SYX+6V*@'^CM_P01_8Q_P"&&/\
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M_E,7XC_[-S^!G_I'XBH _P! [_@A7_RA]_X)W?\ 9L/P]_\ 22:@#]8* "@
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M7^&_V@O@3^W_ .&="O+SX:_$WP#IOP%^)VK6=L)+3PS\4? M[K^M>"KG6IU
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MZ@W02?$SQ]86NM?$K6]-GV@PZGX0^')T7P[+\Y2;3?BU>(4+1AHP#_1FH *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * /+?CE_R13XP?]DM^('_ *B>K4 ?XZO_  0*_P"4R/\
MP3V_[."T3_TS:Y0!_L^4 % !0!_$C_P=P?\ !'SQS^T7X4\+_P#!1S]F_P (
M7GBOXA_!?P8?!'[1W@?PUI=Q?^)/%'PBTJ]N]5\,_$W2--T^-[C5;_X83:EK
M5CXS1+:[U&7P)?Z=JWFVNC?#Z[20 _GF_P""#G_!Q5XY_P""4]K>_L]?''PC
MXB^-7[&OB3Q#<^([71/#=[:#XD?!+Q)J\L+:]KGPUAUR\L]$UWPUKY1[[Q!\
M.M2U/P_9S>()'\4:'X@T;4KSQ):^*@#^VS0?^#J'_@A_K'A./Q+>_M;:YX8O
MS:"XG\%Z]^SS^T7)XKM+AD9DTV3_ (1_X6:]X9N;MF7RS-IGB6_TJ)V4SZC%
M%F0 'QO\'?\ @ZB^&?[9G_!27]E#]BG]C3X*:U<?"CXM?$?5?#7Q*^-WQMMW
MT/7=0T:R\$^*-;@M_A=X \.Z[-)I+R:KI5C-_P )1XXU::9[%+K3G^']K/<Q
M:I; ']<= !0 4 % '\4G_!VW_P $>_'/[3'@OPG_ ,%$?V;?!]YXM^)WP-\&
MR>"?V@_ OAK2[C4/$WC#X-Z??W6L>'?B%HFG:=&]SJVJ?"R\U/7H?%5NEK=Z
MC=^!-6@U,7%MIOP^:VN0#^=C_@@Q_P '%7C/_@E3:WW[._QV\)>)/C/^QKXE
M\0W/B2RTGPS>69^)'P0\2ZO+"VO:W\.;?7+RQT77_"_B!HVOO$'P[U#5/#]L
MVOR2>*="UW2M2O/$EEXK /[:='_X.G_^"'VI^%(O$MW^USK6@7[6@GF\&:Q^
MSS^T<_BNTNFC+KID@T3X5:QX;GNR0(C<Z?XCO='CD9?-U1(\N #^3/\ X+U?
M\'.=O^W_ /"W6?V.?V*?"_C7X=_LX>)KNS/Q>^*'CJ.VT/X@_&+3]*O+74+'
MP7HGAO2M0U%/!OPZDU6SBU'7)-1U2Y\2^-8H-.TJ_P!.\+:+%KNC^)0#].?^
M#1S_ ((Y>._@\-5_X*<?M)>#[WPGXB\<>#;_ ,%_LJ^!_$^DS6'B*P\$^)UM
M)/%7QPNK*]2*[TA?&>D1CPG\/3)%!=:EX,U'Q9KIAET'Q1X:OKL _N)\8?\
M(H^*?^Q<UO\ ]-ES0!_@M> O 7C;XF^+-)\#_#GPSK7C'QIK7VXZ%X9\.64V
MHZ]J\VF:;>:Q<VVD:=;!KO4+];#3[J:VL+*.:^O)(EMK&WN+N6&!P#_01_X)
M _\ !W'\!=,^"/@+X _\%.;CQOX*^(OPWT#2O".G?M.:#X9U_P")/A?XC^'=
M"M(--TO5_B;H7A>WUGXAZ1\0UL8;>+7-6T/P[XNTWQ==P7GB&ZDT"_NVTR8
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MG6@#SOXO?\DF^*'_ &3OQK_ZC6I4 ?X[_P#P;W?\IGO^"?G_ &6J;_U!O%]
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MP->:W'"GVV;P'XT^%'A3QC>WFA3/ODM/^$R\/^#]4AP]D]K=M'!>WP!\3_\
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % ']$G_! [_FZ[_NA?_O8Z_FOZ0W_ #2'_=?_ />(?IGAU_S./^Z?_P"[
MI_1)7\UGZ8% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M=-4<5756E#6#4X15.+4DH<JULHRGIJK?H8/\_P!*^6/2/@S_ (*2_L/^&_\
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M?\GP?M>_]FIV'_JW?!% '^E10 4 ?X[/_!RU_P IO_V\?^QL^$?_ *SK\'Z
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * /QC_ ."J7_!#/]DK_@KSXF^#GBO]I/X@_M$>"-2^".A>
M+O#WA6/X'>+?AMX:L]1L?&>H:'J6IOXAB\>_"7XERW5S:SZ!:KISZ9/I$<<4
M]TMU%>,T#VX!]6_\$Y?^">GP6_X)B?LT:7^RO\ _$OQ.\6?#[2?%_BSQK!K/
MQ=UKPMK_ (SEU;QC=P7FIPW&H>#?!?@'0S86[V\4=A##X=AGBB!%Q<W4A\R@
M#[OH * /CS]O#]AGX"?\%&/V9_'/[*W[1NE:Q=_#WQK)I6HP:WX5N],TOQSX
M'\3Z!>I?:#XT\!ZWJ^C>(+#1?%&DR">VBNKO1=4L+W2K_5=#U?3=1T75M2T^
MZ /P5^"'_!H%_P $U/@'\:?A#\=/"'QM_;CU3Q9\%OBAX ^+/A?3/$WQ+^ M
MWX;U'Q%\.?%>D^,-$L?$%II/[-&BZI<Z)=ZEHUM;ZK;Z;K.DW\UA)/%9ZE87
M#1W40!_5;0!R_C7P3X-^)/A'Q)X ^(?A7P[XY\"^,=&O_#GBWP=XMT;3_$/A
MCQ+H&JV[VFI:+KNAZK;W6FZKI=_:R207=C>VTUO/$[))&RG% '\GW[5W_!G!
M_P $Z/C9XIU7QE^S_P#$?XS?LF7VLWTM[<^"_#LVC_%#X4:>9\O*OA[PSXQ2
MT\9Z,LERSRBS'Q)NM&LXF6RTG2--LXH88P#XS\.?\&.WPBM=2CE\7?\ !0SX
MCZWI N TMCX<_9Z\,>%M2>TW<P1ZKJ?Q5\86L5QMX%TVC2Q!OF^QD?)0!^Z/
M[ /_  ;@_P#!,#_@GSXGT+XF>#/A?X@^.?QJ\-W$=]X?^+?[1NM:=X^UGPQJ
M4<B7$.I>$?"&EZ'X9^&?AS5K"YCCFT7Q):^"I?&.C&-/L7B9)&GEG /WDH X
MSXB?#GP!\7/ _B?X9_%/P5X6^(OP[\:Z3<:#XN\#^-="TWQ-X5\2Z-=@"XTS
M6]"U>VN]-U&SD*H_DW5O(BR1QRH%DC1E /Y1?VIO^#-O_@G+\9?$NJ>+O@!\
M2OC;^RE>:O?37DW@W0KS1_BG\+=.$^9)(] \/>-8K?QOIBM<,TBV\GQ+O=,M
M82MGIVF6-M'$D8!\B>%O^#'KX(6FJP3>-?\ @H%\5/$&AK/&USIWA;X%>$?!
M^JRVHDS+#!K.K?$+QS:6\[Q?)'<OH5S'%)^]:TE7]S0!_1G_ ,$ZO^"'?_!.
M_P#X)B3CQ-^SQ\);GQ!\7VM;FQG^/WQAU*T\??&!;&\MFL[RRT365TK1O#O@
M>TOK62:VU.'X?>%_"8UFVF>WUHZC"L21@'ZZT % !0 4 % 'P-^W]_P3,_8X
M_P""F7PQM_AE^UE\*[/Q=_8<>IMX"^(>B7'_  CGQ4^&&H:M';K>ZEX"\:VL
M,MYIHNI++3[C4M U.#6/"&OS:;IO_"2>'-9BL;:*, _E@\8_\&/W[/E[K<$_
MP^_;V^,GACPVLY:YTKQC\'/!/CK6Y;;G$4'B#1/%OPZL+><<9N'\,W,9P<6P
MSP ?L%_P3/\ ^#:K_@GQ_P $W/&^B_&FPL_%W[1W[0?AYGN/#7Q0^-AT.[TS
MP'J#.NS5?AQ\/=&TVS\.>'-;@CCB^Q^)=8D\5>+-)G-S+H7B#28KN6WH \8^
M*G_!IQ_P3G^+W[4_Q&_:Y\2_&3]M*R^(WQ/^/WBW]HSQ!H&A_$;X'VW@6V\;
M>,_B'?\ Q+U;2M)TZ_\ V==2\0V_A6/7M2N+6RLKKQ1?:O#I(CMY=<GNU-\P
M!_3[0!\^_M._LK?L]?MF?"#Q!\!_VG?A3X6^,'PK\2F*>^\,>)[:8FRU.UCG
MCL=?\.ZSI\]EKWA3Q/IB7-RNE^)O#6IZ5KVFK<7"6>H0I<3K( ?R,_&O_@R4
M_9+\4^([_5/@)^V-\<O@[H-XYFM_#'CWP+X/^-46E22.SO;:?J^GZM\)=2?3
M(E(BLX=5?4]2CC4&\U>_E)D(!ZQ^S#_P9C_L _"CQ7I_BK]HGXT_&O\ :DM]
M+>VGB\"O#I/P:^'^JS12"25?$5MX2O-;\=7UI)M18[32?B!H 53,EW)?1R*D
M0!^O'_!1;_@A9^Q1_P %*/A?^S?\&?B3=?%/X%?#7]E5/%=K\(O"7[+U]\,/
MASH>E:7XNT_PMIEYHD^C^*/A3\0=(ATG3[;PCI9TFUT.PT0V\LEZ]S)=^>BP
M@'T)_P $R/\ @F7\!O\ @E'^SYKW[-O[.WBOXM^,? _B/XJ>(OB]?ZM\9]>\
M'^(O%B>)O$WAKP;X5OK.VOO!'@/X=Z-'HD.F^!](DL[5]!EO8[N:_DFU&XBF
M@AM0#A_^"WGBG3_!W_!(C_@HMJVI3I;VUW^R;\7?"T<CX"MJ'CGPS=>"=)@&
M<?/=:KX@LK:/OYDJ@ G H _S]/\ @SR\*WGB#_@K]'J]K;2S0>!OV7OC9XHU
M&6,$I9VEYJ'@3P5'/.>BQO?^+K*U7.<S7$0 [@ _U(/B9\.?!GQA^''Q ^$G
MQ&T2W\3?#WXH^"?%7PZ\=^'+J2>*UU_P;XUT*^\->)M%N);66"YB@U31=2O;
M&62VFAGC2<O#+'(%< '\FO[/'_!G+^Q5\#OVI/"'QWU[]H7XS?%GX:_#OQ]9
M>/\ P?\  SQ-X?\ "6E6]W=Z!JEOK/A31?'_ ([TEA<>+=#TV^M8'UFTTKPO
MX0?Q)##':7$EG9R7MO> ']@- !0 4 >!?M3_ +.?@?\ :[_9R^-'[,/Q*U+Q
M3HW@'XZ?#WQ%\-?%NK>"+[2M,\7:=HGB:R>QO;SPY?ZYHOB/1K35[>-_,LIM
M3T#5[%)54W&GW,>Z)@#\;O\ @G)_P;:?L,_\$P_VEM,_:H^ OQ3_ &KO%_Q"
MTGP?XL\%6NC_ !?\<_"+7O!ITOQC:V]GJ=S+IW@OX&?#_6GU&"&W46,@\0+:
MQ,[M/9W/R! #^@Z@ H * *>HV,.IZ??:;<%Q;ZA9W-C.8B%D$-W ]O*8V*L%
M<)(=A*L V"5(XH _F;_9&_X-1O\ @G;^QC^TK\&_VIOAA\8_VS]?^('P/\9V
M7CGPGHOC[XB?!#4_!E_J]A!<P6\'B#3_  Y^SMX5UR[T\"Y=VAT[Q%I5PSI'
M_I00.C@'].% !0!XM^T!^SI\"_VJ_A;X@^"G[1GPK\&?&/X6>*%B_MCP9XXT
M>#5]+>YMMYL=5L'?9>Z+KVER.T^C>(M$NM/UW1KK%WI6HV=RJR@ _DX_:!_X
M,K_V$O'OB"\US]GW]HWX_?L^65_/<W!\'Z[9^&/C5X4T?S9"UO9>'9-6_P"$
M,\:0Z?:H1&%\2>-/%6I3 !I-4W9R >0_#S_@R"_9PTO6K*X^*W[=GQK\;>'H
MYT>_TGP!\)_ WPRU:[MP/F@MM=\0>(OBO:64C'_EN^@7H5?E$.[#@ _IW_8
M_P""4O[#/_!,WPM>:%^R?\%]+\+>)-<L$T[QC\6O$MQ)XN^,/C>U2>*Z^R>(
M?'FJH;^'1C=06]V/"OAV+0/!T%[;Q7MMX>@O T[ 'Z+T ?A]_P %._\ @W\_
M8(_X*G^+3\6OC+8_$SX=?'V+PSI?A.V^,WPG\9R:?JUSH6@-=R:!I.O>#O%5
MEXI^'^K6&G27UVK7%KX:TGQ)<VL_V1O$<<=O9&T /P2U7_@QX^#,VM03Z'_P
M4'^)VG>'5D)N-+U7X!>%=9UJ6+^%(->L_B9H-C;R#O(_ANY4]HEH _1']C__
M (-%?^"7W[-_B:W\:_%X_$_]L+Q!82V]QI>A_&75M,T7X7Z?<V^&6ZD^'W@.
MPT+_ (20R.7%QIGC?Q!XJ\-SP>7'+H+.C32 ']1.B:)HWAK1M)\.>'-(TSP_
MX>T#3;'1="T'1+"TTK1M%T?2[6*RTS2=)TNPB@L=.TW3K*"&TL;"S@AM;2UA
MBM[>*.*-$ !J4 ?S2_\ !1__ (-;O^"?_P#P4"^+/B'X_P"C:U\0?V7/C-XU
MO=4UKXAZS\(8_#VH>"/B+XJU>Y-Y?>-/%G@#Q)I]Q!#XKOKII;C5]3\(:UX3
MC\0WES>:MX@M=4UV[GU9P#Y)_8T_X,\?V9_V7?VBO@]^T1XP_:]^-?Q8U;X'
M?$WP/\7/!?A?1? W@GX9Z3>>+_ASXJTGQAX5C\3WEQ>?$._U+0$U?1[3^U].
MTI]!O=1MM\-OJVG;BQ /ZZ_&7@SPC\1?"7B3P#X_\+Z!XU\#^,M$U+PSXM\(
M>*M(L-?\->)O#NLVDMAJVAZ]HFJ07.G:KI.I64\UI?6%[;S6MS;RO%-$R,10
M!_)'^U1_P9I_\$_OC-XV\1>-_P!G[XO_ !D_943Q#,UXOP]TFUT/XJ?"_P /
MWTI=ISX:TCQ3+I/C:PTV>5O._L>Z^(6H6=BQ:VTC^S=-6UL+4 X']G+_ (,K
M/V*?AYXKTOQ#^T;^TQ\:OVCM'TQTGE\"^'O#VB? SPOK\R2(?LWB"[TK6_'7
MC,Z3)%YB2VWAOQ;X9U0R&.2/6XDC>"8 _7[_ (*"?\&_?[!?_!0_X>?LM?"7
MQHWQ7_9\^&O['NC?$7P]\&O!/[+6I_##X>^';'1_B;_P@#:_9ZOIOC#X3_$B
MWNC#-\.M'N[*YTU=)O)K[4->O];N-8O-02>V /L3_@FS_P $Y/@?_P $M_V<
M/^&7_P!G[Q/\4_%W@'_A/O%'Q%;6/C#KGA/Q!XP;7/%MOH]MJ-N;_P %^"/A
M_H@TN"+1+,6,"^'EN8R9S<7ER77RP#[]H _FE_X*/_\ !K=_P3__ ."@7Q9\
M0_'_ $;6OB#^RY\9O&M[JFM?$/6?A#'X>U#P1\1?%6KW)O+[QIXL\ >)-/N(
M(?%=]=-+<:OJ?A#6O"<?B&\N;S5O$%KJFNW<^K. ?)/[&G_!GC^S/^R[^T5\
M'OVB/&'[7OQK^+&K? [XF^!_BYX+\+Z+X&\$_#/2;SQ?\.?%6D^,/"L?B>\N
M+SXAW^I: FKZ/:?VOIVE/H-[J-MOAM]6T[<6(!_8A0!^)'_!2'_@WZ_X)S_\
M%-=>O/B-\6_A_P"(/A9\=KV*-+_X[_ C5-*\%^._$?V6S2SL5\=V&IZ%XC\%
M^/#;06]C:IJOB/PO=>*X-,L;;2--\3:=I\:0J ?S]:M_P8Z_"N;5/-T+_@HE
M\0-.T3>Q_L_5OV<O#FM:IY>?W:?VQ9_%[0+0.J\-)_8>USR(HQ\M 'V9^S5_
MP9I_\$W/A1K>F^(_CW\2_CY^U'<Z>ZO+X1U?6])^$WPTU0JRN/[2TGX?6B?$
M)MI0*([/XIV=NZ-(EQ;W 9=@!_51\)/@]\*O@'\//#/PE^"?P[\'?"KX9>#;
M :;X7\"^ O#^F^&?#.BVF]I919Z5I5O;6RSW=Q)+>:A>.CWFI7\]Q?W]Q<WM
MQ//( >D4 % !0 4 ?G3^W=_P2@_8(_X*1:/:VG[6'P \->-/$^E6PM/#WQ3T
M&:]\$?%SPY;IO\FST_XA^%I]-U^]T:%Y))D\,>()]:\*&X<W,NAR7 650#^:
MCXH?\&1W[).MZMJ-W\'?VS_V@?AUI-S(TFGZ1X\\$?#_ .*TFF[^3 =2T9_A
M3+>VT3G;;B:!+I8%1+B[NI@]RX!S?@C_ (,@/V<[ Q?\+'_;P^-?BM01YP\$
M?"7P+\/RZ]Q$VN^(_B8(B1T++,!_=/2@#]G_ -B?_@VH_P""3_[$VI:!XPT?
MX'W_ .T#\4_#E]9:KI/Q-_:8UJW^)6HZ;JNGSQWMCJ&D>![32_#GPFTN]TV_
MBBO=(U6#X?MK^FSP6TL.M&>%9R ?O;/!#<PRVUS#%<6]Q%)!/;SQI+#-#*AC
MEAEB<,DD4B,R21NI1T)5@0<4 ?RN?MM?\&C/_!-[]J7Q_JOQ/^#NM?$/]C?Q
M'KYN+C6_"GP>M?#6K_!R[U:>0RMJ^G?#7Q%8A_"<CEC'+HG@KQ-X;\))$L?V
M#P[I\_VB>Y /C/X._P#!DA^RQX:\4Z?JGQP_;1^-?Q8\+V=\;FY\*>!?AUX0
M^#TNJVL;%X--O?$&H:_\5;J*VD(2+49M,M-/O;BW\Y;"YTFX>*ZMP#]S_P!I
MW_@@C_P3^_:4_8>^%'_!/>Q\.^//V=/V=_@[\5]$^,_AFT_9VUGPEX>\8ZMX
MZT7P5XV\"/JGC7Q1\1O WQ0D\8WFN:3X\U6Y\0ZYKEG<^*M5U*RT:23Q"EI8
MM97 !Z1_P2N_X(\_LS?\$AO"?Q?\'?LV>-_CGXVT[XU>(O"OB7Q5<_'#Q-X"
M\2ZA8WOA#3=6TO2X- D\!_#/X:VMI9R0:S=R7B:A9ZI<2S"$PW-O&AB< ^DO
MV_OV'/A+_P %'/V5?B+^R#\<-?\ B'X7^&OQ-O/!-[KFN?"O5O#FA^.;*;P'
MXY\.^/\ 1_['U+Q9X3\;Z! EQK'AFQM=16^\,ZCYVF37D-L;.[>"]MP#X9_X
M)9?\$&_V0?\ @D9\0OBE\2OV;OB)^T?XVU[XM^#-)\#>(K;XW^+_ (9>)-*L
M-(T?6QK]O-H=OX#^$'PUNK?4);Q5CN)M0O=3MS;*$AM89"TI /VQH \_^+'P
MWT+XQ_"SXE_"'Q1<:I9^&?BI\/\ QE\-_$5WH<]K:ZU:Z%XX\.:CX8U>XT>Y
MOK+4K*VU2#3]3N)-/GN].O[6&[6&2XLKJ)7@< _ +]@G_@V _8$_X)V_M8?"
MO]L3X*_%O]K[Q3\3?A /'(\,:'\4_'WP9UKP+=GX@?#CQ?\ "_66UO3/"/P!
M\#Z_=&V\/>-=6N=,^Q>)M.6'5H;"XNEO+2&:QN0#^CV@#P_]HC]FOX"_M:?"
MO7_@C^TE\*/!OQD^%?B7RGU3P=XVTJ/4; 7MLLJV.L:5<JT.I^'_ !%IAFE?
M1_$N@7VF:_H\TC3Z7J5I,=] '\F?Q]_X,J?V'O''B&\UK]GW]IKX^_ /3K^6
MXG_X1'Q-I7A7XU^'-(:60M!:>'[B]?P#XMBTRUCQ&L7B+Q5XHU.7&^76&)Q0
M!P/PP_X,B?V6=&OK"?XQ?MM_'CXA6,%U#+?V'P]^'?@+X4&_MHY5:6T2[U[4
M/BY)9^?&#$9TCF>/<7C 8+@ _JI_8;_X)\_LF_\ !.3X37/P9_9'^%\7PW\(
M:MJ\?B3Q3/<:]XA\4^(_&7BE=.M=+D\2>)_$/B;4]4U"]U*6SLX(4@MGLM'L
M(E%MI.EZ=9A+=0#ZI\:^"?!OQ)\(^)/ 'Q#\*^'?'/@7QCHU_P"'/%O@[Q;H
MVG^(?#'B70-5MWM-2T77=#U6WNM-U72[^UDD@N[&]MIK>>)V22-E.* /Y/OV
MKO\ @S@_X)T?&SQ3JOC+]G_XC_&;]DR^UF^EO;GP7X=FT?XH?"C3S/EY5\/>
M&?&*6GC/1EDN6>468^)-UHUG$RV6DZ1IMG%##& ?&?AS_@QV^$5KJ4<OB[_@
MH9\1];T@7 :6Q\.?L]>&/"VI/:;N8(]5U/XJ^,+6*XV\"Z;1I8@WS?8R/DH
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MGW,>Z)@#^7__ (@J?^"67_1?/V__ /PZ?[.O_P!"K0 ?\05/_!++_HOG[?\
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MS)?RK?2_\)!]DD\N$P65L1(90#]A?V4?V;? O['G[-_P8_9>^&6I^*M:\ ?
MSP%HGP\\)ZMXYOM)U/Q?J.C:%"8;6[\1:AH.A^&M&N]5F!+W4VF:!I%FSG]Q
M86Z ( #Z#H * "@ H _";]O#_@W(_P""7/\ P4!\;>*/BS\1?A/XG^$WQJ\:
M7=UJ?BSXM? #Q9_P@7B'Q-K5XYFN=>\1^&M5TSQ5\--;\07ERTEUJGB*_P#
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MZ;: "@ H * /YN/V]/\ @UH_X)B_MM>*]=^)WAWP[XQ_9.^+'B"6ZU#6=?\
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M%X3CUV[EL[:RG\47.LQZ.$@DUZ:]!U!@#]NOV]OV)_A9_P %$OV4_B?^Q_\
M&KQ%\1/"OPT^+#^"V\1ZY\*M8\/Z#XZM/^$%\?\ A?XC:2FCZGXI\*^-= AC
MNM:\):=::I'J'AG4EN-)GOK>W%I=R07ML ?SB?\ $%3_ ,$LO^B^?M__ /AT
M_P!G7_Z%6@ _X@J?^"67_1?/V_\ _P .G^SK_P#0JT '_$%3_P $LO\ HOG[
M?_\ X=/]G7_Z%6@#[:_X)Z_\&SG[!_\ P36_:B\'?M:_ SXK_M:^+/B/X(T3
MQEH.D:-\6?'GP>USP3+:^./#.H^%-6FO]-\'? ?P'KDUU;Z;J=S)I[0>([:&
M&[$4MQ!=Q*8& /Z(Z /YV?\ @H3_ ,&Q?_!-+]OGQAX@^+2>&_&'[,?QL\37
M%_JOB/QW^S[=Z#H>@^,_$-_,US<:]XZ^&NO:'K7A#4]3NKN6YOM7U;PQ;^"_
M$?B&_NIK[7M?U&Z(E !^,<G_  8Y_#,ZHTL7_!1;QTFB_P .GR?LU^'Y-4'/
M\6KK\9XK1OEXXT->>>GRT ?HY^R7_P &A7_!+G]GOQ!I7C+XOW'Q>_:Z\1:5
M-:7D&A_%OQ#I?AWX5+J%E(LT-TW@#X>:7X>OM8MVE ^UZ)XS\8>+?#E_ JVE
M_H]S;O<1S@']1/AGPQX:\%>'=$\(>#?#VA^$O"?AG2[+0_#?A?PSI-AH/AWP
M_HNFVZ6FG:/HFB:5;VFFZ3I>GVL45M9:?86UO:6MO&D,$,<:*H )]>T'0_%.
MAZQX8\3Z-I7B+PWXBTK4-"\0>']=T^TU;1-<T35K26PU31]8TJ_AN+'4]+U*
MQGGL[_3[V":TO+2:6WN(I(9'0@'\F_[87_!G=_P3M^/_ (QU?Q[^S_X_^*O[
M'^J:]?2WVH>"O!\&B_$7X/6DLX,EP_AOP7XH.G>)O#8GNV>?^S=/^(7_  C6
MGPL+#0_#VD6,4$$0!\O?"G_@R)_9BT'7]/OOC1^V[\;/B7X>MKT3WV@?#_X8
M^"_A)=:E:1L62P;6]9\0?%I[1)2$CN[BVT\3R0>:MHUC.\5Q  ?T07__  1:
M_8/M/^"?/Q._X)J?#'P!K?P+_9]^+]GHD?C_ %WX5ZKID?Q?\1ZOH?BKP]XO
M@\5:W\0O'N@^/)?$?B:?4O#6GV3WWBK2]=M[#0=V@Z'9:3I=MIMM8 'A?_!+
MS_@WV_8R_P""2WQN\;_'O]G+XE?M->-?&/CWX5ZC\(=7T_XV>,_A9XC\.6OA
MG5/%O@_QG<WFF67@3X,_#?4H=;&J>"=(ABN;O5KVQ2PEOHCIS3S0W-L ?NG0
M 4 % 'YJ?\%0_P#@EC^SY_P5I^"7@?X"_M&^+_C%X+\(^ /BGIWQ<T;4_@IX
MA\%^'/$L_B/3/"7B[P;#8ZC=^.?A]\1]*FT.33/&>ISS6UMHMI?F_MM/EBU.
M*WBN;6[ .8_X)8_\$AOV:_\ @D5X$^*WP^_9M\:_&_QMH_QA\6Z%XQ\37?QO
M\2^!/$FJ66I>']'GT2QMM#E\!_#7X:V5KI[6MQ++<1WUAJ5R]P0R7<40$- '
MZI4 ?F=_P5%_X)5?L\_\%:_@UX"^!_[1WC#XR^"_"OP[^)MK\5M#U+X)^(?!
M7ASQ'<>(+7PKXF\(I8ZG=>.OA[\1]+GT5]-\57\\EO:Z/9W_ -NM[&1-2CMX
M[BUN@#$_X)9?\$C/V;?^"1GP\^*/PU_9N\:?&WQKHGQ;\9Z5XX\27OQN\2>!
M?$FKV>J:/H:Z!:6NBS> _AO\-K&VTTV@,LT5[IVHW;W+LRWB0A(% /U,H _,
MC_@J/_P2C_9V_P""MOPB^'OP7_:/\8_&?P5X8^&OQ'3XGZ#J/P2\1>"/#?B"
MYUY/#&O>%/L6JW/CKX=_$C3)]&;3_$-W.T%II-C??;8+21=16W2>VN "C_P2
MT_X))_LX?\$COAI\3?A9^S?XS^-?C70/BMXYL?'_ (BOOC=XD\#>)-:M-7T_
M0+7P[;VFC3^!/AQ\-M/MM+^Q6B3/#>:;J%XUW)*XOEA\NWC /R>^/'_!HC_P
M3J_:-^-GQ;^/WQ+_ &A_V][WX@_&GXC^,_BCXRGLOBC\ 4TX>(_'/B"_\1ZK
M;Z5#J'[,>I7MKH]G=ZC)::197&H7DECID%K9_:9A '(!_3;\,?ASX1^#WPV^
M'WPD\ :7'HG@3X7>"/"GP[\%Z-%CR])\)^"M"L/#?AW34*JBE;'2--L[92$4
M$19VCI0!W- !0 A4,"K ,K J5(!!!&""#P01P1TQ0!_)GXJ_X,VO^"7/B+Q]
MXD\?Z5\8OVY/ %SKOC#6/&&F^'? 7Q0^!6D^&_!,^IZU<:U9Z+X+CU']FO6-
M<TS1/#;SQV/AQ+[7-4U6SL+*S6YU:]NXWO)0#]\_VZ?V#_A3_P %"?V0?&?[
M&'QU\7_%+3OAUX]3X??\)#XQ\ :SX3T;XF377PY\8^&?'&E:A#JOB#P3XI\*
M1WFJZUX5LAKN_P &2VUQ:7>H1:=;:9-):W%H ?GC_P $^_\ @W1_8 _X)WS?
M'R#P+J'QI^/?A?\ :4^&=I\)?BG\/_VH=6^$GQ$\!ZKX-M=9773:1>'_  K\
M&OAZDD]Q>QQ>=)JMQJD,:PPRV=O:W<27( /RU_:5_P"#+3]B#XE^+=4\3?LX
M?M%_&C]FC3-5EGN1X#U?0]%^.'@W09Y96=+;PS)K6L>"O&UOI$$96-+3Q%XT
M\4:AN!;^UQ&5AC ,SX!?\&4W[%'@?Q%8ZU^T)^U#\>/CWI=@T,S>$/"N@^%_
M@CH&L2QN#);:[=VUW\0_%3Z5/'N1[?P]XD\-ZHC%7BUI-I1@#^MW]G_]G7X&
M_LJ_"OPU\$?V=/A=X/\ @_\ "KPC"T6A^"_!6E1:7ID,LVTWFIWTF9+[6]>U
M25!<ZUXCUN[U'7M;O2]]J^I7MY)).P![10 4 % !0 4 % !0!\[?M??\FF?M
M0_\ 9NWQK_\ 5:^):^EX,_Y+#A3_ +*7(O\ U:84\S.O^1-FW_8LQ_\ ZBU3
M^$"O] S^>@H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * /Z)/^"!W_-UW_="__>QU_-?TAO\
MFD/^Z_\ ^\0_3/#K_F<?]T__ -W3^B2OYK/TP* "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * (Y'2*-Y)72.*-2\D
MCL$2-$^9G=CA41%!9F8A5 RQ !H2O9)-WT22N[[))!IUVM^2/Y3_ (S>/#\3
M_BQ\0_'XFN+BV\4>*]6U#2Y+K(G705F^R>';>1"?W9L]!MM-LEBR?+2W"9XK
M^I,EP']F95E^!Y8QEAL+3IU.6UG6:YJ\M-^:O*I)/JI7ZGYAC*WUC%5ZVZJU
M93B_[G-^[].6"A&W3EMLC'^'^G#4/$EL[J3%IL<FH-P,>9"5CM\D]-MQ+%*!
MSO";"-I-?Q[]/OQ$K<"?1XSS+\#6C1S+Q!S3+^!J$HU80Q%/+L;#$YGG]2G0
M?OUJ&(R7*<7DV*G%*&'6<4I.<:L\/&?ZSX&9!#/./L%6K1Y\-D.&KYU4BT^2
M6(H.GAL!%S7P3IXW%4<73A_R\^JR7P*=OHS_ #Q7_/=^!_>W]?UHOR7HB.::
M&WAEN+B9;>WMXWGGG?B.&&%3)+*YP3LCC4LP7YL#CG -TJ=2K.-&C3=2K5E&
ME2IQ5Y5*E1J$*<%_/-M*-]+Z"<H4USU)1C".K<G9)+63T_EBKKH]MKV_AW_:
M(^+5W\<_CA\3_BO<M>>3XT\7:IJ6CP:C*);O3O#$$@T[PGI,S !=^C^&;+2-
M+*QA8@MH/*7: H_ZT/!#PWH>$7A+X?\ AS1CA8U>%N&<OP.:5,)#DPV*XAKP
M>/XDQ]*ZY^3,<^Q698Y>T<IVK*[[?Y;\9\03XIXHSSB";J\N99A6JX=5W>I2
MP-.V'R[#RM[J>&P-+#T6H1C%<ME&*]V/HWQ!T^/PQ^R1^S=80-Y;_$OQY\<_
MBIJT0&TW:Z+>>%?A3X:DE;;F:+3)/"7C)-/3>R6<NK:T5"R7EQN^!X&QDN(/
MI->/&-Q%)/\ U!X,\(?#S*JNC5"&<83B/Q&SZE3][W)XR7$/#<L:^6]:&797
M&3<<-1Y?<SJC]1\.."*4'99YFW%6?8A)->T>$JY?P_@N>_Q1H_V=F*HKX:3K
MXCELZ\SY5Q7])'YY_7_#=CZT^--N-?\ V;OV0_B&"T]S9:!\6_@GK$_W_L\_
MPW^(3^-- @D<%C$'\,?%RQM[2!]A\G39_*7R%0#^:?":M_8GCI])O@GEIX?"
MXC.O#7Q5RJC\#Q$>.>"8<-Y]B(4[*,N3/?#NO4Q56%U[3&TE-^T<C]&XIA];
MX(\.,Y]Z52E@^(N%\3.]U'^Q,X>8X*#>_P#N6?TX4HOX50GR+V;@E])_\$B_
MBY=> /VJ;;P)(RG0?C-X;U7PM>1/.8([?7?#UE=^+/#&I[?N7-PO]G:QH%K;
M-@_\5--)&?-1(I/PO]I5X;8?C'Z/5;C*"<<W\+<^RW/,+.%+VLJV3Y_BL)PW
MGV7JUI4*=2>,RC.*^(2DHPX?A2E%4ZKG2^T^CKQ#/*N.XY0VOJ?$F Q&"G%R
M<%#%X&G/,,%6MM.7+2Q6%A"^OU_3WHJ,OZJ:_P">'8_O8K7MG9ZC97>G:A;1
M7FGW]K/8WMI.N^&YL[N)K>YMYD_CCFAD>*13]Y&9>]=N79ACLIS# YKEF*KX
M#,LLQF&S'+L=A:CI8G!8_!5H8G!XO#U8VE2KX?$4J=6C433IU(QFG>)C7PU#
M%T*^$Q-&G7PV*HU</B,/5BI4J]"M!TZM&I!Z2A6IRE3E'JI=%JOYW?'WA*Z\
M!^-?%7@V\5Q-X;U[4])C>3@W5K:W4B:??+G!,6HV'V:^@9L,\-Q&S $D5_UQ
M>$_'N"\4?#/@3Q#P$Z$J7%_"V3YW6I8>2E#!9CBL'2><98[;5LHS:.-RO$Q5
MXPQ&#JP4I**D_P#(;BS(*W"O$^?<.5U)3R;-<;@(2GO6PU"O*.#Q7^'%X3V&
M*IWLW3K1;29^I/\ P11^+\GPY_;-T_P3<!VT?XV>"O$O@F<^<8H++7=%MO\
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M84HZ-^[SSBTO9N?]6R*$5450JJ-JJH"JJCA5 '  7  %?BA]?_6BLON'4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0!__0_OXH * "@ H * "@#_*E_P"#O+]JK4?CG_P55U#X(6>MS7G@
M;]D3X5^"OAQIND13^;I%MX^\?:39?%3XA:U;(,HNK7EIXF\%^$M<=",/X#L;
M.1%FL9-P!_;#_P &S7[(^C?LH_\ !(;]FRZ_L1--\>?M):9>?M._$346BVW6
MLS?%-H[KX<R,77SH[2P^#EA\/+."U+M MVNHZA"D4FIW (!^L/[:?_)G'[67
M_9L_QW_]5;XJH _P^O@#_P EW^"G_96_AO\ ^ICHU '^\X2JJ68A54$LQ("J
MH&223P !R2> * /\V+_@\2_X**_LY_M-?$C]F?\ 92_9_P#'/A?XKZE^SI>?
M$WQA\8/'/@O4](\2^$]$\6>-H?"F@Z)\.=(\4:3=7=K?^(-!L_#.M7_CVRL9
M9++2;O4/#>DW%R^O:;K>FZ, >P_\&4G[&GCU_BS^TS^WMK^B3:;\-=/^&<W[
M,WPZU34+6>-?%GB[Q+XM\&?$#Q[>>'I'0136W@O3/ _AG2=4OD.QKKQE_9UK
M))+9:Q%; '^A[0 4 ?Q,_P#!Y%_P4>F^$GP!^&W_  3H^'&M-:^-?VD$M/BA
M\<7L;CR[O2_@;X0U]H_"/AJ<1LDT2?$KXCZ)/>221L VC_#35M)O8I;'Q$58
M _%[_@T)_P""<UK^TS^VIXF_;-^(VA?;_A7^Q;;Z7?\ @J*^M@^FZ]^T3XOA
MO4\%21^<IBO/^%:>'[36?'$P@/VK1O%<_P -]1)6.5%E /\ 4'H * "@ H _
MAJ_X/@/^3>/V"_\ LL_Q?_\ 4'\+4 ?G9_P9)?\ )\'[7O\ V:G8?^K=\$4
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M/$'C-5\=^*+"[%W%J/A#PIX@L=6,#Z]IS7(!_K/4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!SGC#_D4?%/_ &+F
MM_\ ILN: /\ &=_X(*_\IC/^">?_ &<7X8_](=5H _VA: "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H ^=OVOO^33/VH?^S=OC7_ZK7Q+7TO!G_)8<*?]E+D7_JTPIYF=
M?\B;-O\ L68__P!1:I_"!7^@9_/04 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % ']$G_! [_F
MZ[_NA?\ [V.OYK^D-_S2'_=?_P#>(?IGAU_S./\ NG_^[I_1)7\UGZ8% !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M2L(M3CA_9 ^.GC*PLY4WAM>^&G@/5_B1X9FB7_GZM/$?A/2KNR/1;N"!CP*
M/\RG_@V)\<7/@;_@MW^Q7)'>2VMAXJO?C/X&U>".5HHM1M?$W[/_ ,4K73;.
MY ($L,?B5-!U".)LJ;NPMG W(I !_L$4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M'-#LXM/TC1=&TNRCBM;'3]/LH(;>VMX(U1(T QG)H ZR@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M=;N_G$5M9V%IIN@Z)9:3X=T?1](L #ZNH * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!\[?M??\FF?M0_]F[?&O\
M]5KXEKZ7@S_DL.%/^RER+_U:84\S.O\ D39M_P!BS'_^HM4_A K_ $#/YZ"@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H _HD_P""!W_-UW_="_\ WL=?S7](;_FD/^Z__P"\
M0_3/#K_F<?\ =/\ _=T_HDK^:S],"@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M0^LYQFF795AW>U;,<;AL%2ER[J$\34I1D]-(Q;D[JR/Q/_;(_;F_99^+.L^
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M4 ?-7[:?_)G'[67_ &;/\=__ %5OBJ@#_#Z^ /\ R7?X*?\ 96_AO_ZF.C4
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M*5QY,9%Q]D_X5#H'CG2&NT*16FJ:WHRRR;KB&"< _P [O_@W]_8W_P"&W/\
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M=5_X2SP_X?G^USSW"RP?9(;B'R5;S)$?"T ?C_\ \'P'_)O'[!?_ &6?XO\
M_J#^%J /SL_X,DO^3X/VO?\ LU.P_P#5N^"* /\ 2HH * /\=G_@Y:_Y3?\
M[>/_ &-GPC_]9U^#] '^@/\ \&K'_*#K]D?_ +&']I#_ -:8^+= ']#] !0!
M^1/_  5__P""5_[,/_!1_P#96^+^C?$?X;>$K?XX^'OA[XCU_P"#?QVT_1M"
MTOXF>"?&?A?1+_5/#-A)XV>Q_M.\\ ZIJ%O#I?B_PAJEY+H6HZ-<SW,,6G:]
MI^B:[I !_CU?LV?'CQU^R_\ '[X._M#?#36M2\/^./@Y\0_"_C[0-1TFX^S7
M1F\/ZI;W=UIKD_NKC3];T]+O1=7TZ[26PU32=0O=-U&"XL;NX@D /]W[3;^W
MU73K#5+,N;34K*UO[4RQO#(;>\@CN(#)#(%DB?RI%WQNJO&V58 @B@#XQ_X*
M7^(+3PG_ ,$Y/V_/$]\D4MIH'[%?[4FKSP3 &.Y2P^!_CBX^RLO\?VIHQ;B/
MK(T@0#+ 4 ?Y07_!O!X?O/$O_!:3]@#3K%Y8YK;XNZOK[M#D,;/PG\-O''BG
M44./^64FGZ-<QS#H86D!P* /]EB@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % ']$G_  0._P";KO\ NA?_ +V.OYK^D-_S2'_=
M?_\ >(?IGAU_S./^Z?\ ^[I_1)7\UGZ8% !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'Y0_\%:/@W^U[\7O@OX8C
M_8[\$^ /'_CGPOJ>NZC?^'O&OC*+PK?N+NPL;;3+GPM9ZI;:?X6U[48PFIQO
M#XF\=^"[*RDELIMVN0R76GI^@^'F=Y'DN88R6=UL1AJ6)IT*5*O1P[KTX<LG
M*I[7V<_;PB[T[>QP^(;:ES*'*K^#GV"Q>,H4OJD:<Y4I3E*G.:@Y)QBDH77+
MIN^:<%T3>Q_G:?M-Z#^TWX<^)MYIO[5_ASXH^$_B4\5S=1:)\5= U?PO?Q:5
M)>2QF7PUH^HV6GZ?#X;:\BFCLY/#5LN@2/%BQ9^M?U-EF*RO&8:-;*,3A,5A
M;J/M,)6IUX<]D^2<X3D_:I.+<:C]I&]G%'YKB*.)I5.3$TJM.>ONU(2@[;>Z
MFE=:6O'1]&SYVPO0?^A'/\\] /H *]#3R^7_  #FT5O33TT_1+Y:;':>"_B'
MX]^&][/J?P\\;^+_  +J-VB)=7_@_P 2ZQX:N[I(V#QQW,^BWEE+<11MAD29
MV52/EQUKY?BO@;@OCK#4,%QOPAPQQAA,)*<\)A>*,ARO/L/A)U(\E2>&HYIA
M<5##SG'W92HJ$I+1NQZF69UG.25)5LFS;,LIJS252IEN-Q.!G44;\JJ2PU2D
MYJ-].:]C[7\#_P#!4C]M#P1!964OQ,LO&UA8*D=O;^._"/AW6;AT7&4OM>L+
M+2/%.I%\#?<ZAKUQ=D?\O"D+G^4>+?V>_P!%GBJKB<31X&Q_".*Q4ISJUN#N
M(\YRZE"<NN%RG,<1F^08&*^Q0P648?"T[:4+7/U'*O'GQ+RRG3HSSJCFM*DD
MJ<,UR["5YM+_ )^XK#T\)C:S:5G.OBJE1W^.Z1]4^$O^"W'Q:LX/+\=_!'X<
M^))50*)_"6M>)_!6XY $DL.LS>/U=R@RZPO!&9<LD<,96%/YWXF_90>'>)K<
M_!OBOQKD5!ZRH<2Y/D?%<UI\-.OE2X+48I\W+S4:LE!*#E4?[R7WV7?2@SZE
M!1S;A?)L;-:>TR[%8W+(OI=TZ\LW^:C..J;]U>Z_3[/_ (+BV64%]^S3=A2Z
MAWM/BU"SI'N^=TAF^'*+(X7!2-IH59A@RHA)'P.(_9*XQ0F\)X[86=11DZ<,
M1X;UJ<)34?<C.K3XWJRIQ<])35*KRQ?,J<^6TO;I_2DP]U[7@BHHW5W2X@CS
M<M]6E+)X*3MJHMQ3>ETM5N2_\%P?!@B<V_[._BJ28(3%'-\0=(MX7?'R)+-'
MX8N7B1FP&D2WE*+EA$Y&#Y%+]DWQ<ZL%6\:.&Z=!RC[2='A'-*M6,+^\Z=%Y
MS0A.26T)UZ5[)>TCN=<_I297RMPX/S"<^7W8SS;#P3?1.:PDW!=VH3>ND3F;
MK_@N.,-]A_9G93QM^T_%K>,@ <B'X;1Y'T([<@9%>_0_9*U+0^M>/$-]5A_#
M5[*ZT=3CK3[-KZ6N];7?!/Z4D6G[/@EKMS\0^B^SDWJ^MG]EI'C'C+_@M3\?
M]5>>+P/\,?A3X/LI.(I-9A\5>,=:@ )V[+]-?\-:0S;?E=I/#<BL>4CCSM'Z
MAPM^RJ\',OITY\7<?>(?$N+BU=90^'N%\KJ;7]I@:^4\19C&*Z*&=4FOYY61
M\WF?TG.+*S:RC(L@RZEK9XOZ_F6*C9KE<:U/%X'#\R75X.2;^S'1'R1\0?\
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M:?V[BG_DSXJBO^,PQ'^#_P!T:/\ 7_#']?M?A)]J% '\7_\ P70\&>&/B/\
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M).3DHM*4TG!/EWVL?7E>$=H4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0!__3_OXH * "@ H * "@#_&;_P"#@G]G[4/V<?\ @L1^W7X3NXIA8>//
MC/JWQ]T&\=-D%_I?[0MK:?&.=K(A5#V^E:[XRUGPZY5<1WFBW4 +>5N(!_K
M?\$SOVB[?]K7_@GW^QW^T2ES%=:A\3OV?OAOJOBEH"IA@\?:9X?M/#OQ&T^(
MKP4TOQYH_B/35.$8BTRT<;9C4 ],_;3_ .3./VLO^S9_CO\ ^JM\54 ?X;'P
MP\36'@KXE?#SQCJL5W/I?A+QSX2\3:C!81PRWTUAH.OZ?JEY%917$]K;R7<E
MO:R);1SW-M"\Q19)X4)D4 _T_+__ (/*/^"2=G9SW-MX3_;%U6:&,O'IUA\'
M/ ,=Y=,.D4#ZI\9=-T]7/8W5];1>L@H _F%_X+G_ /!S)XA_X*>_"F;]D_\
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M_)O'[!?_ &6?XO\ _J#^%J /SL_X,DO^3X/VO?\ LU.P_P#5N^"* /\ 2HH
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M3Y28_#EW*K P;6 /]6:@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * /G;]K[_ )-,_:A_[-V^-?\ ZK7Q
M+7TO!G_)8<*?]E+D7_JTPIYF=?\ (FS;_L68_P#]1:I_"!7^@9_/04 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % ']$G_  0._P";KO\ NA?_ +V.OYK^D-_S2'_=?_\ >(?I
MGAU_S./^Z?\ ^[I_1)7\UGZ8% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M*"//EP1I%'G^Y&H1 3W( &6ZGOFOFMVWW=^V_H>@E;3^OR1\)?L>_P#!-_\
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M-YIXU$Z:-3^V"P-_8B[\G[/]LMO,\Y #^$[_ (@8_P#K*)_YI-_^5Q0 J_\
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M%N5MA>7 !^R/_!'3_@EWH'_!(_\ 9$F_9=T?XJ_\+KU+5_BKXS^+/BKXE?\
M" +\,SKVN>*K#PYH-K"/"0\9^/S9+HWAGPCX>T<3MXHO3>M9/=B&R686L0!^
MJ] !0 4 % !0!^&W_!;_ /X(P+_P65^'7P&\ _\ #2)_9Q;X(^-?%WB\:O\
M\*?'Q>7Q,OBO0M,T9M..G_\ "T?A>=&-B=-2Y6\%]J@N!*T!M(=HF(!\Z_\
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H ^=OVOO^33/VH?^S=OC7_ZK7Q+7TO!G_)8
M<*?]E+D7_JTPIYF=?\B;-O\ L68__P!1:I_"!7^@9_/04 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % ']$G_! [_FZ[_NA?\ [V.OYK^D-_S2'_=?_P#>(?IGAU_S./\ NG_^
M[I_1)7\UGZ8% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M<^(-7TJVO-7\':[<:3<7.GW-_H-_)/I\ES;2*MR(%G:"TDD>UA /4: "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /B__ (*"_&S]H+X
M?LF?%CXA?LI_ ;Q5^TA^T9'HPT#X/?#+PM8V]^DOC7Q QT[3/%/BB*YOM/4^
M#?!GF2>)O$%M%=176KV^FIH%G-:76K0WML ?YV'_  3J_P"#<O\ X*(_ML?M
M[Q_$7_@IO\(?BS\+?@Q>>+-8^-7[1'Q ^)M_IUGXP^->N7FN+K-[X T&33=6
MGU;^VOB+KE[*/$6OVT-A:>&O"J:_>6%_;:\GAS3KX _U!?#?AOP_X-\.Z!X0
M\)Z+I?AKPKX5T72O#?AGP[H=C;Z9HN@>']#L8-,T;1='TVSCBM-/TO2M.M;:
MQT^QM8HK>TM((;>"-(HU4 &U0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M@W'?^6__ ,I#_AQ7^SQ_T5WXS_\ ?SP/_P#,G1_Q'[B3_H39']V/_P#FP/\
MB'V6_P#0;CO_ "W_ /E(?\.*_P!GC_HKOQG_ ._G@?\ ^9.C_B/W$G_0FR/[
ML?\ _-@?\0^RW_H-QW_EO_\ *0_X<5_L\?\ 17?C/_W\\#__ #)T?\1^XD_Z
M$V1_=C__ )L#_B'V6_\ 0;CO_+?_ .4A_P .*_V>/^BN_&?_ +^>!_\ YDZ/
M^(_<2?\ 0FR/[L?_ /-@?\0^RW_H-QW_ );_ /RD/^'%?[/'_17?C/\ ]_/
M_P#\R='_ !'[B3_H39']V/\ _FP/^(?9;_T&X[_RW_\ E(?\.*_V>/\ HKOQ
MG_[^>!__ )DZ/^(_<2?]";(_NQ__ ,V!_P 0^RW_ *#<=_Y;_P#RD/\ AQ7^
MSQ_T5WXS_P#?SP/_ /,G1_Q'[B3_ *$V1_=C_P#YL#_B'V6_]!N._P#+?_Y2
M'_#BO]GC_HKOQG_[^>!__F3H_P"(_<2?]";(_NQ__P V!_Q#[+?^@W'?^6__
M ,I#_AQ7^SQ_T5WXS_\ ?SP/_P#,G1_Q'[B3_H39']V/_P#FP/\ B'V6_P#0
M;CO_ "W_ /E(?\.*_P!GC_HKOQG_ ._G@?\ ^9.C_B/W$G_0FR/[L?\ _-@?
M\0^RW_H-QW_EO_\ *0_X<5_L\?\ 17?C/_W\\#__ #)T?\1^XD_Z$V1_=C__
M )L#_B'V6_\ 0;CO_+?_ .4A_P .*_V>/^BN_&?_ +^>!_\ YDZ/^(_<2?\
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M_P!GC_HKOQG_ ._G@?\ ^9.C_B/W$G_0FR/[L?\ _-@?\0^RW_H-QW_EO_\
M*0_X<5_L\?\ 17?C/_W\\#__ #)T?\1^XD_Z$V1_=C__ )L#_B'V6_\ 0;CO
M_+?_ .4A_P .*_V>/^BN_&?_ +^>!_\ YDZ/^(_<2?\ 0FR/[L?_ /-@?\0^
MRW_H-QW_ );_ /RD/^'%?[/'_17?C/\ ]_/ _P#\R='_ !'[B3_H39']V/\
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MXD_Z$V1_=C__ )L#_B'V6_\ 0;CO_+?_ .4A_P .*_V>/^BN_&?_ +^>!_\
MYDZ/^(_<2?\ 0FR/[L?_ /-@?\0^RW_H-QW_ );_ /RD/^'%?[/'_17?C/\
M]_/ _P#\R='_ !'[B3_H39']V/\ _FP/^(?9;_T&X[_RW_\ E(?\.*_V>/\
MHKOQG_[^>!__ )DZ/^(_<2?]";(_NQ__ ,V!_P 0^RW_ *#<=_Y;_P#RD/\
MAQ7^SQ_T5WXS_P#?SP/_ /,G1_Q'[B3_ *$V1_=C_P#YL#_B'V6_]!N._P#+
M?_Y2'_#BO]GC_HKOQG_[^>!__F3H_P"(_<2?]";(_NQ__P V!_Q#[+?^@W'?
M^6__ ,I#_AQ7^SQ_T5WXS_\ ?SP/_P#,G1_Q'[B3_H39']V/_P#FP/\ B'V6
M_P#0;CO_ "W_ /E(?\.*_P!GC_HKOQG_ ._G@?\ ^9.C_B/W$G_0FR/[L?\
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MO_\ *0_X<5_L\?\ 17?C/_W\\#__ #)T?\1^XD_Z$V1_=C__ )L#_B'V6_\
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M_F3H_P"(_<2?]";(_NQ__P V!_Q#[+?^@W'?^6__ ,I#_AQ7^SQ_T5WXS_\
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M ._G@?\ ^9.C_B/W$G_0FR/[L?\ _-@?\0^RW_H-QW_EO_\ *0_X<5_L\?\
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M_H39']V/_P#FP/\ B'V6_P#0;CO_ "W_ /E(?\.*_P!GC_HKOQG_ ._G@?\
M^9.C_B/W$G_0FR/[L?\ _-@?\0^RW_H-QW_EO_\ *0_X<5_L\?\ 17?C/_W\
M\#__ #)T?\1^XD_Z$V1_=C__ )L#_B'V6_\ 0;CO_+?_ .4A_P .*_V>/^BN
M_&?_ +^>!_\ YDZ/^(_<2?\ 0FR/[L?_ /-@?\0^RW_H-QW_ );_ /RD/^'%
M?[/'_17?C/\ ]_/ _P#\R='_ !'[B3_H39']V/\ _FP/^(?9;_T&X[_RW_\
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M@W'?^6__ ,I#_AQ7^SQ_T5WXS_\ ?SP/_P#,G1_Q'[B3_H39']V/_P#FP/\
MB'V6_P#0;CO_ "W_ /E(?\.*_P!GC_HKOQG_ ._G@?\ ^9.C_B/W$G_0FR/[
ML?\ _-@?\0^RW_H-QW_EO_\ *0_X<5_L\?\ 17?C/_W\\#__ #)T?\1^XD_Z
M$V1_=C__ )L#_B'V6_\ 0;CO_+?_ .4A_P .*_V>/^BN_&?_ +^>!_\ YDZ/
M^(_<2?\ 0FR/[L?_ /-@?\0^RW_H-QW_ );_ /RD/^'%?[/'_17?C/\ ]_/
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M )L#_B'V6_\ 0;CO_+?_ .4A_P .*_V>/^BN_&?_ +^>!_\ YDZ/^(_<2?\
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M_P!GC_HKOQG_ ._G@?\ ^9.C_B/W$G_0FR/[L?\ _-@?\0^RW_H-QW_EO_\
M*0_X<5_L\?\ 17?C/_W\\#__ #)T?\1^XD_Z$V1_=C__ )L#_B'V6_\ 0;CO
M_+?_ .4A_P .*_V>/^BN_&?_ +^>!_\ YDZ/^(_<2?\ 0FR/[L?_ /-@?\0^
MRW_H-QW_ );_ /RD/^'%?[/'_17?C/\ ]_/ _P#\R='_ !'[B3_H39']V/\
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@#_UO[^* "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H __]?^_B@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M/__0_OXH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@#__T?[^* "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MG7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\
MQ,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V
M /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?]
M)*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X
M)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P
M]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU
M !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_
M )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/
MV=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /
M_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_
M & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_
MTDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\
M@EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /
M8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !
M_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_Y
MXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]
MG7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\
MQ,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V
M /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?]
M)*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X
M)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P
M]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU
M !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_
M )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/
MV=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /
M_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_
M & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_
MTDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\
M@EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /
M8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !
M_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_Y
MXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]
MG7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\
MQ,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V
M /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?]
M)*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X
M)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P
M]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU
M !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_
M )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/
MV=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /
M_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_
M & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_
MTDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\
M@EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /
M8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !
M_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_Y
MXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]
MG7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\
MQ,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V
M /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?]
M)*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X
M)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P
M]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU
M !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_
M )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/
MV=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /
M_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_
M & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_
MTDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\
M@EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /
M8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !
M_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_Y
MXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]
MG7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\
MQ,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V
M /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?]
M)*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X
M)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P
M]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU
M !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_
M )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/
MV=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /
M_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_
M & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_
MTDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\
M@EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /
M8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !
M_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_Y
MXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]
MG7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\
MQ,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V
M /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?]
M)*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X
M)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P
M]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU
M !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_
M )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/
MV=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /
M_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_
M & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_
MTDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\
M@EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /
M8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !
M_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_Y
MXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]
MG7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\
MQ,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V
M /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?]
M)*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X
M)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P
M]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU
M !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_
M )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/
MV=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /
M_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_
M & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_
MTDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\
M@EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /
M8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !
M_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_Y
MXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]
MG7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\
MQ,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V
M /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?]
M)*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X
M)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P
M]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU
M !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_
M )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/
MV=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /
M_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_
M & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_
MTDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\
M@EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /
M8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !
M_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_Y
MXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]
MG7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\
MQ,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V
M /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?]
M)*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X
M)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P
M]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU
M !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_
M )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/
MV=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /
M_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_
M & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_
MTDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\
M@EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /
M8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !
M_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_Y
MXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]
MG7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\
MQ,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V
M /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?]
M)*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X
M)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P
M]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU
M !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_
M )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/
MV=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /
M_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_
M & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_
MTDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\
M@EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /
M8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !
M_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_Y
MXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]
MG7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\
MQ,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V
M /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?]
M)*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X
M)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P
M]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU
M !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_
M )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/
MV=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /
M_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_
M & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_
MTDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\
M@EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /
M8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !
M_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_Y
MXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]
MG7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\
MQ,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V
M /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?]
M)*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X
M)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P
M]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU
M !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_
M )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/
MV=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /
M_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_
M & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_
MTDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\
M@EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /
M8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !
M_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_Y
MXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]
MG7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\
MQ,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V
M /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?]
M)*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X
M)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P
M]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU
M !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_
M )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/
MV=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /
M_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_
M & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_
MTDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\
M@EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /
M8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !
M_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_Y
MXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]
MG7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\
MQ,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V
M /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?]
M)*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X
M)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P
M]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU
M !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_
M )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/
MV=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /
M_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_
M & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_
MTDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\
M@EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /
M8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !
M_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_Y
MXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]
MG7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\
MQ,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V
M /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?]
M)*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X
M)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P
M]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU
M !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_
M )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/
MV=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /
M_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_
M & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_
MTDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\
M@EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /
M8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !
M_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_Y
MXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]
MG7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\
MQ,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V
M /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?]
M)*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X
M)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P
M]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU
M !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_
M )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/
MV=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /
M_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_
M & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_
MTDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\
M@EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /
M8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !
M_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_Y
MXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]
MG7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\
MQ,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V
M /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?]
M)*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X
M)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P
M]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU
M !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_
M )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/
MV=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /
M_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_
M & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_
MTDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\
M@EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /
M8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !
M_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_Y
MXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]
MG7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\
MQ,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V
M /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?]
M)*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X
M)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P
M]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU
M !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_
M )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/
MV=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /
M_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_
M & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_
MTDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\
M@EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /
M8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !
M_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_Y
MXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]
MG7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\
MQ,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V
M /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?]
M)*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X
M)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P
M]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU
M !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_
M )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/
MV=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /
M_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_
M & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_
MTDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\
M@EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /
M8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !
M_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_Y
MXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]
MG7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\
MQ,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V
M /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?]
M)*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X
M)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P
M]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU
M !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_
M )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/
MV=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /
M_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_
M & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_
MTDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\
M@EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /
M8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !
M_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_Y
MXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]
MG7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\
MQ,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V
M /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?]
M)*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X
M)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P
M]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU
M !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_
M )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/
MV=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /
M_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_
M & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_
MTDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\
M@EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /
M8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !
M_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_Y
MXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]
MG7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\
MQ,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V
M /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?]
M)*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X
M)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P
M]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU
M !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_
M )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/
MV=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /
M_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_
M & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_
MTDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\
M@EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /
M8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !
M_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_Y
MXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]
MG7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\
MQ,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V
M /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X)9?]
M)*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P]A_X
M)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU !_P
M]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_ )XU
M !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/V=?_
M )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /_$R/
MV=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_ & /
M_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_TDK_
M & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\ @EE_
MTDK_ & /_$R/V=?_ )XU !_P]A_X)9?])*_V /\ Q,C]G7_YXU !_P /8?\
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MO^C<OB!_XD/\;_\ YMZ #_B$_P#^")7_ $;E\0/_ !(?XW__ #;T '_$)_\
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MO^C<OB!_XD/\;_\ YMZ #_B$_P#^")7_ $;E\0/_ !(?XW__ #;T '_$)_\
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MO^C<OB!_XD/\;_\ YMZ #_B$_P#^")7_ $;E\0/_ !(?XW__ #;T '_$)_\
M\$2O^C<OB!_XD/\ &_\ ^;>@ _XA/_\ @B5_T;E\0/\ Q(?XW_\ S;T '_$)
M_P#\$2O^C<OB!_XD/\;_ /YMZ #_ (A/_P#@B5_T;E\0/_$A_C?_ /-O0 ?\
M0G__  1*_P"C<OB!_P")#_&__P";>@ _XA/_ /@B5_T;E\0/_$A_C?\ _-O0
M ?\ $)__ ,$2O^C<OB!_XD/\;_\ YMZ #_B$_P#^")7_ $;E\0/_ !(?XW__
M #;T '_$)_\ \$2O^C<OB!_XD/\ &_\ ^;>@ _XA/_\ @B5_T;E\0/\ Q(?X
MW_\ S;T '_$)_P#\$2O^C<OB!_XD/\;_ /YMZ #_ (A/_P#@B5_T;E\0/_$A
M_C?_ /-O0 ?\0G__  1*_P"C<OB!_P")#_&__P";>@ _XA/_ /@B5_T;E\0/
M_$A_C?\ _-O0 ?\ $)__ ,$2O^C<OB!_XD/\;_\ YMZ #_B$_P#^")7_ $;E
M\0/_ !(?XW__ #;T '_$)_\ \$2O^C<OB!_XD/\ &_\ ^;>@ _XA/_\ @B5_
MT;E\0/\ Q(?XW_\ S;T '_$)_P#\$2O^C<OB!_XD/\;_ /YMZ #_ (A/_P#@
MB5_T;E\0/_$A_C?_ /-O0 ?\0G__  1*_P"C<OB!_P")#_&__P";>@ _XA/_
M /@B5_T;E\0/_$A_C?\ _-O0 ?\ $)__ ,$2O^C<OB!_XD/\;_\ YMZ #_B$
M_P#^")7_ $;E\0/_ !(?XW__ #;T '_$)_\ \$2O^C<OB!_XD/\ &_\ ^;>@
M _XA/_\ @B5_T;E\0/\ Q(?XW_\ S;T '_$)_P#\$2O^C<OB!_XD/\;_ /YM
MZ #_ (A/_P#@B5_T;E\0/_$A_C?_ /-O0 ?\0G__  1*_P"C<OB!_P")#_&_
M_P";>@ _XA/_ /@B5_T;E\0/_$A_C?\ _-O0 ?\ $)__ ,$2O^C<OB!_XD/\
M;_\ YMZ #_B$_P#^")7_ $;E\0/_ !(?XW__ #;T '_$)_\ \$2O^C<OB!_X
MD/\ &_\ ^;>@ _XA/_\ @B5_T;E\0/\ Q(?XW_\ S;T '_$)_P#\$2O^C<OB
M!_XD/\;_ /YMZ #_ (A/_P#@B5_T;E\0/_$A_C?_ /-O0 ?\0G__  1*_P"C
M<OB!_P")#_&__P";>@ _XA/_ /@B5_T;E\0/_$A_C?\ _-O0 ?\ $)__ ,$2
MO^C<OB!_XD/\;_\ YMZ #_B$_P#^")7_ $;E\0/_ !(?XW__ #;T '_$)_\
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MO^C<OB!_XD/\;_\ YMZ #_B$_P#^")7_ $;E\0/_ !(?XW__ #;T '_$)_\
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MO^C<OB!_XD/\;_\ YMZ #_B$_P#^")7_ $;E\0/_ !(?XW__ #;T '_$)_\
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MO^C<OB!_XD/\;_\ YMZ #_B$_P#^")7_ $;E\0/_ !(?XW__ #;T '_$)_\
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MO^C<OB!_XD/\;_\ YMZ #_B$_P#^")7_ $;E\0/_ !(?XW__ #;T '_$)_\
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MO^C<OB!_XD/\;_\ YMZ #_B$_P#^")7_ $;E\0/_ !(?XW__ #;T '_$)_\
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MO^C<OB!_XD/\;_\ YMZ #_B$_P#^")7_ $;E\0/_ !(?XW__ #;T '_$)_\
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MO^C<OB!_XD/\;_\ YMZ #_B$_P#^")7_ $;E\0/_ !(?XW__ #;T '_$)_\
M\$2O^C<OB!_XD/\ &_\ ^;>@ _XA/_\ @B5_T;E\0/\ Q(?XW_\ S;T '_$)
M_P#\$2O^C<OB!_XD/\;_ /YMZ #_ (A/_P#@B5_T;E\0/_$A_C?_ /-O0 ?\
M0G__  1*_P"C<OB!_P")#_&__P";>@ _XA/_ /@B5_T;E\0/_$A_C?\ _-O0
M ?\ $)__ ,$2O^C<OB!_XD/\;_\ YMZ #_B$_P#^")7_ $;E\0/_ !(?XW__
M #;T '_$)_\ \$2O^C<OB!_XD/\ &_\ ^;>@ _XA/_\ @B5_T;E\0/\ Q(?X
MW_\ S;T '_$)_P#\$2O^C<OB!_XD/\;_ /YMZ #_ (A/_P#@B5_T;E\0/_$A
M_C?_ /-O0 ?\0G__  1*_P"C<OB!_P")#_&__P";>@ _XA/_ /@B5_T;E\0/
M_$A_C?\ _-O0 ?\ $)__ ,$2O^C<OB!_XD/\;_\ YMZ #_B$_P#^")7_ $;E
M\0/_ !(?XW__ #;T '_$)_\ \$2O^C<OB!_XD/\ &_\ ^;>@ _XA/_\ @B5_
MT;E\0/\ Q(?XW_\ S;T '_$)_P#\$2O^C<OB!_XD/\;_ /YMZ #_ (A/_P#@
MB5_T;E\0/_$A_C?_ /-O0 ?\0G__  1*_P"C<OB!_P")#_&__P";>@ _XA/_
M /@B5_T;E\0/_$A_C?\ _-O0 ?\ $)__ ,$2O^C<OB!_XD/\;_\ YMZ #_B$
M_P#^")7_ $;E\0/_ !(?XW__ #;T '_$)_\ \$2O^C<OB!_XD/\ &_\ ^;>@
M _XA/_\ @B5_T;E\0/\ Q(?XW_\ S;T '_$)_P#\$2O^C<OB!_XD/\;_ /YM
MZ #_ (A/_P#@B5_T;E\0/_$A_C?_ /-O0 ?\0G__  1*_P"C<OB!_P")#_&_
M_P";>@ _XA/_ /@B5_T;E\0/_$A_C?\ _-O0 ?\ $)__ ,$2O^C<OB!_XD/\
M;_\ YMZ #_B$_P#^")7_ $;E\0/_ !(?XW__ #;T '_$)_\ \$2O^C<OB!_X
MD/\ &_\ ^;>@ _XA/_\ @B5_T;E\0/\ Q(?XW_\ S;T '_$)_P#\$2O^C<OB
M!_XD/\;_ /YMZ #_ (A/_P#@B5_T;E\0/_$A_C?_ /-O0 ?\0G__  1*_P"C
M<OB!_P")#_&__P";>@ _XA/_ /@B5_T;E\0/_$A_C?\ _-O0 ?\ $)__ ,$2
MO^C<OB!_XD/\;_\ YMZ #_B$_P#^")7_ $;E\0/_ !(?XW__ #;T '_$)_\
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MO^C<OB!_XD/\;_\ YMZ #_B$_P#^")7_ $;E\0/_ !(?XW__ #;T '_$)_\
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MO^C<OB!_XD/\;_\ YMZ #_B$_P#^")7_ $;E\0/_ !(?XW__ #;T '_$)_\
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MO^C<OB!_XD/\;_\ YMZ #_B$_P#^")7_ $;E\0/_ !(?XW__ #;T '_$)_\
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MO^C<OB!_XD/\;_\ YMZ #_B$_P#^")7_ $;E\0/_ !(?XW__ #;T '_$)_\
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MO^C<OB!_XD/\;_\ YMZ #_B$_P#^")7_ $;E\0/_ !(?XW__ #;T '_$)_\
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MO^C<OB!_XD/\;_\ YMZ #_B$_P#^")7_ $;E\0/_ !(?XW__ #;T '_$)_\
M\$2O^C<OB!_XD/\ &_\ ^;>@ _XA/_\ @B5_T;E\0/\ Q(?XW_\ S;T '_$)
M_P#\$2O^C<OB!_XD/\;_ /YMZ #_ (A/_P#@B5_T;E\0/_$A_C?_ /-O0 ?\
M0G__  1*_P"C<OB!_P")#_&__P";>@ _XA/_ /@B5_T;E\0/_$A_C?\ _-O0
M!]'_ +(__!O?_P $N/V'OVA/A]^U%^SG\%?&'A+XR_##_A*_^$.\0:I\9OBG
MXKL-/_X37P1XD^'GB'S] \2>*=1T6_\ M7A7Q;KEE%]LLIOLLUS'>V_EW5M!
M*@!^U] '_]3^_B@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * /__5_OXH * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@#__UO[^* "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H _
M_]?^_B@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * /__0_OXH * "@ H * .6\6^./!7@#2X];\>>+_"_@G19
M;R+3HM7\6Z_I/AO2Y=0GBGG@L8[_ %F[LK1[R:"UN9HK593-)%;SR(A2&0KU
M8/ 8[,*KH9?@L5CJZ@ZCHX/#U<355.+C&4W3H0G-0BY13E;E3E%-ZHRK5Z&'
M@IXBM2H0;45.M4A2AS--J*E-Q5VDVEO9/L>;_P##3G[-?_1POP._\.SX"_\
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M']BSQYX/\#W7PANOB(_BSPBWBM=2M_'$/A9;%5UG4-(^PFTD\*:^;@YL#/\
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M_P#!5/XL? /]J-_@9^TE\(O!OAKP;IWB6+3]5\:^%;CQ)+=/X0U?S%\/^/\
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M6G&46KIIK1IJS36EBW4#"@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M<(U%2G&*YFHR:CO:+=K)G].%?RN?JP4 % !0!_+W_P %UO\ DOOP<_[(^_\
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MW;.!IYDQ&?CO^(#<7^P]I]>R#VMK_5_K6.YMO@]I_9WLN?I\7L_^GEM3V?\
M7[)N?E]AF')>WM/8T+>O+]8Y^7Y<W]T_3[X,?'#X7?M!>"++XA_"3Q98>+?#
M%W*]I+/;+-;7VEZE#'%)<:1K>E7D4&H:1JMLDT+R65];PR-!-!=P>=9W%M<2
M_E6>9#FW#F/GEN<8.I@\5!*2C+EE3JTFVHUJ%6#E3K4I.+2G3DTFG"7+.,HK
MZS X_"9EAXXG!5HUJ3TNM)0DDFX5(.TH32:O&26C35XM-_E=_P %J?V>+;QU
M\#-$^/FD6D0\3_!G4;;3]>F2,"?4/A_XNU*TTMXI&0&6X;0?%%SI-[91M^ZL
M['5/$=S\GF.3^M>!G$DLOS^OP]6F_JF>4I5,/%OW:68X.E.K%I;1^L86-:G-
MJSG.EAHZV5OD..\L6(R^GF,%^]P,E&HTM98:M*,&GW]G5<)1Z1C*H^IV/_!&
MS]H"\^*_[-E]\,M>N&N?$/P&U6S\-6UQ))YDMQX%\017NH>#?-).Y6TN2QU[
MP[;1J@BBTK1=+57:3S0O%XV<.0R?BB&:8>*AAN(*,\5**5E''X=PI8VUM/WJ
MGA\3)[NK7JO:QOP/F+QF5/"U'>IETU23ZO#U$Y4/_ .6I27:%.)^O%?C1]H%
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M?_Y:'_#]3]H7_HD/P9_[X\;_ /S54?\ $ .'/^AUG?\ Y8?_ #('_$0<R_Z
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M]H7_ *)#\&?^^/&__P U5'_$ .'/^AUG?_EA_P#,@?\ $0<R_P"@+ _^5_\
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MR!_Q$',O^@+ _P#E?_Y:'_#]3]H7_HD/P9_[X\;_ /S54?\ $ .'/^AUG?\
MY8?_ #('_$0<R_Z L#_Y7_\ EH?\/U/VA?\ HD/P9_[X\;__ #54?\0 X<_Z
M'6=_^6'_ ,R!_P 1!S+_ * L#_Y7_P#EH?\ #]3]H7_HD/P9_P"^/&__ ,U5
M'_$ .'/^AUG?_EA_\R!_Q$',O^@+ _\ E?\ ^6A_P_4_:%_Z)#\&?^^/&_\
M\U5'_$ .'/\ H=9W_P"6'_S('_$0<R_Z L#_ .5__EH?\/U/VA?^B0_!G_OC
MQO\ _-51_P 0 X<_Z'6=_P#EA_\ ,@?\1!S+_H"P/_E?_P"6A_P_4_:%_P"B
M0_!G_OCQO_\ -51_Q #AS_H=9W_Y8?\ S('_ !$',O\ H"P/_E?_ .6A_P /
MU/VA?^B0_!G_ +X\;_\ S54?\0 X<_Z'6=_^6'_S('_$0<R_Z L#_P"5_P#Y
M:'_#]3]H7_HD/P9_[X\;_P#S54?\0 X<_P"AUG?_ )8?_,@?\1!S+_H"P/\
MY7_^6A_P_4_:%_Z)#\&?^^/&_P#\U5'_ ! #AS_H=9W_ .6'_P R!_Q$',O^
M@+ _^5__ ):'_#]3]H7_ *)#\&?^^/&__P U5'_$ .'/^AUG?_EA_P#,@?\
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M_H=9W_Y8?_,@?\1!S+_H"P/_ )7_ /EH?\/U/VA?^B0_!G_OCQO_ /-51_Q
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M_P"6A_P_4_:%_P"B0_!G_OCQO_\ -51_Q #AS_H=9W_Y8?\ S('_ !$',O\
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MX\;_ /S54?\ $ .'/^AUG?\ Y8?_ #('_$0<R_Z L#_Y7_\ EH?\/U/VA?\
MHD/P9_[X\;__ #54?\0 X<_Z'6=_^6'_ ,R!_P 1!S+_ * L#_Y7_P#EH?\
M#]3]H7_HD/P9_P"^/&__ ,U5'_$ .'/^AUG?_EA_\R!_Q$',O^@+ _\ E?\
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M5'_$ .'/^AUG?_EA_P#,@?\ $0<R_P"@+ _^5_\ Y:'_  _4_:%_Z)#\&?\
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M<R_Z L#_ .5__EH?\/U/VA?^B0_!G_OCQO\ _-51_P 0 X<_Z'6=_P#EA_\
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MS_H=9W_Y8?\ S('_ !$',O\ H"P/_E?_ .6A_P /U/VA?^B0_!G_ +X\;_\
MS54?\0 X<_Z'6=_^6'_S('_$0<R_Z L#_P"5_P#Y:?J+_P $V?VZOB%^VI_P
MN?\ X3SPAX,\*?\ "M/^%=?V5_PB*ZVOV_\ X3'_ (3K[=_:']LZKJ?_ !Z_
M\(K9_9/LWD?\?%SYWF?NO+_)_$_@#+>!O[#_ +/QN-QG]J?VE[7ZY[#]W]2_
ML_V?L_84J7Q?6Y\_-?X8\MM;_6\+<08G/?KWUBA0H_5?JO)['VGO>W^L<W-S
MSEM[&-K6W=^A^HM?E!]:% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!_
M_]+^_B@ H * "@ H * "@#\ O^"\W_(F?LW_ /8S_$;_ --7A*OZ(^CY_O\
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MH>!C\_R>A'%X:KCZ,*].%6E*E[[E&IR-<FD&KWTLO0_B7K^[#\&/[#OV??\
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M^C6HJ'W1J5#^IROY+/UP* "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H ^=OVOO^33/VH?^S=OC7_ZK7Q+7TO!G_)8<*?\ 92Y%
M_P"K3"GF9U_R)LV_[%F/_P#46J?P@5_H&?ST% !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0!_1)_P $#O\ FZ[_ +H7_P"]CK^:_I#?\TA_
MW7__ 'B'Z9X=?\SC_NG_ /NZ?T25_-9^F!0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M34^'L$O^?<L5!_\ A56FO_)9H\^_X+1?\F82_P#95? G_HG7J]+P._Y+A?\
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /G;]
MK[_DTS]J'_LW;XU_^JU\2U]+P9_R6'"G_92Y%_ZM,*>9G7_(FS;_ +%F/_\
M46J?P@5_H&?ST% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0!_1)_P0._YNN_[H7_[V.OYK^D-_S2'_ '7_ /WB'Z9X=?\ ,X_[I_\ [NG]
M$E?S6?I@4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M44D?L>'XOX;PM"EAZ%2M3HT*<:5."PM6T8022^SJ]-6]6[MZL;X^_P""J?[
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M]N[_ )/)_:6_[+!XS_\ 3I+7][^'W_)$<+_]B;!_^FT?@'$/_(\S3_L-K?\
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'SM^U]_R:9^U#_V;M\:__5:^
M):^EX,_Y+#A3_LI<B_\ 5IA3S,Z_Y$V;?]BS'_\ J+5/X0*_T#/YZ"@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H _HD_X('?\ -UW_ '0O
M_P!['7\U_2&_YI#_ +K_ /[Q#],\.O\ F<?]T_\ ]W3^B2OYK/TP* "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@#_U?[^* "@ H * "@ H * /P"_X+S?
M\B9^S?\ ]C/\1O\ TU>$J_HCZ/G^_P#$O_8'EW_I[%'YQXA_P,K_ .ON*_\
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M3_NV(_Z\5?\ TW(_SZ*_T;/YN/[T_P!EW_DV;]G7_LA7PC_]0#P_7^>W%?\
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MN9% /Y<_^(S'_@DS_P!"'^VC_P"&?^&/_P _.@ _XC,?^"3/_0A_MH_^&?\
MAC_\_.@ _P"(S'_@DS_T(?[:/_AG_AC_ //SH /^(S'_ (),_P#0A_MH_P#A
MG_AC_P#/SH _23_@F9_P7E_8K_X*N_%?Q]\&_P!F;PW\?-%\5_#GX>-\3-?G
M^+/@;PCX6T:7P\GB30_"QATV[\/?$3QC<W&I_P!I>(+%Q;36-K!]D6XE^U^9
M&D,@!^U= !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0!^1/\ P4=_X+A_\$]?^"7P?0/VA/BG=^)_C"UO97EK^SU\
M&K'3/'?QG:QU"&*ZL]0UG0[C6] \.^!M.NK*>+4-/N_B'XI\))K5D3+X?&KL
MICH _ 2]_P"#W7]DF/Q1'::=^Q1^T7=>"B6\WQ!>^-/AI8>*$4, IC\'P7.I
M:3*2F2P;QQ"%8!0S [U /W _X)O?\' '_!.;_@IOK</P^^#_ ,0M?^%GQPN6
MN%T[X#?'W3=#\"_$3Q-%:V\EU/<^!)M)\2>*?!?CP+;6][>/I'A?Q9J/BRRT
MRQN=4UCPUI=A'Y] '[8T % !0 4 % !0!^/O_!3[_@MO^QY_P25\1?"+PO\
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MT?7?#UY]L\/:[J=DK7NEW#6K7 NK0PW<,$T8!^('_!KK_P %A?V__P#@I/\
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MWFD:QH'B&PLK[4[.Q\1>&=?TS5?#OB"RL]2U&UM-8TN]M[:^O(8TN) #Z)H
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M+-2@TK3)==U'3_C#K%]9:8ES.AN[FTTK4)XH@S1VDS (0#^EZ@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * /G;]K[_DTS]J'_LW;XU_^JU\2U]+P9_R6'"G_92Y%_ZM,*>9G7_(
MFS;_ +%F/_\ 46J?P@5_H&?ST% !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0!_1)_P0._YNN_[H7_[V.OYK^D-_S2'_ '7_ /WB'Z9X=?\
M,X_[I_\ [NG]$E?S6?I@4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M(JZ;*C1GYN*U/I<3Q?D.'I.<<9]9E:\:.'IU)3D[:*\HPIP_[?G$_E5_:?\
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M>6W-7J1Y:CCY4Z,G&72]6-MG;^G:OY6/U<* "@ H * "@ H * "@ H * "@
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MYX>LK:,2W MH[:6ZW0RRO$\(!_0'0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M!/%)L]!UW1_$7AO5K:V.J:/?6>C^*?"]Y-I5]+:II^JZ#JNI '^E+_P;3?\
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * /G;]K[_DTS]J'_LW;XU_^JU\2U]+P9_R6'"G_ &4N1?\ JTPIYF=?
M\B;-O^Q9C_\ U%JG\(%?Z!G\]!0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 ?T2?\ ! [_ )NN_P"Z%_\ O8Z_FOZ0W_-(?]U__P!XA^F>
M'7_,X_[I_P#[NG]$E?S6?I@4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MQ7JMGH?AOPUX?TBV>[U+6-9U;4)8+.PL+.VC>6:>>5$4# RQ52 ?QK?MD_\
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M+I_P=^?\H=/$7_9QOP-_]*_$= 'XC_\ !CM_R5W_ (*&_P#9./V>O_4F^*M
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ML[JTB /8* "@ H _BP_X/;/^3'?V0O\ LZV]_P#50^.* /X]?AE^P;=_'?\
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M6'PR^"<ES;YCGM].^)?B73=<\0:]Y=P/+CU3PU\--:\+W\ :\TOQ%?6Y@:<
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MS>%];^#?Q8N?'<4 ;%Q'IHO]"\"S:A-$3$MY#HT,Z%KB!XP#X"_X,<;77O\
MA.?^"CM["DH\,+X3_9AM=1D\M_(?7FUCXY2Z*@E_U7FQ:>FODQ\N$E##"GD
M_P!"B@ H _Q,=&_Y3"Z5_P!I*K'_ -:ABH _VSJ "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@#YV_:^_P"33/VH?^S=OC7_ .JU\2U]+P9_R6'"G_92Y%_ZM,*>9G7_ ")L
MV_[%F/\ _46J?P@5_H&?ST% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0!_1)_P0._YNN_[H7_[V.OYK^D-_P TA_W7_P#WB'Z9X=?\SC_N
MG_\ NZ?T25_-9^F!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?_T/[^
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M^'V@ZM;?VAIY\#>"O%.H2Z5X6TK4K*^%Y9-H6F6-I=V=TDT!DMY4) /[S_\
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MB?Q/:ZYIS2L8M-A\<?#SPQXA\+Z]#"BR:[K>F?#U&D#:5'%. ?WC_P#!8O\
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M_P#ZTK\)J /YF?\ @R)_Y.U_;7_[-T\%?^K+MJ /]&3QA_R*/BG_ +%S6_\
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M$VH>+_A;XBTB5XFCM]4M;OP7XBTFRU#4;)RMQ"?$6GZY8W$L:IJ5C?VQDMY
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M>P\;? OQ'XK^&7B+PU<G 34M&TS3-8N/ =S=P@'9;^)?!?B#27R3<:;,0I4
M^K/^"4__  3;\)?\$J_V7KW]EGP+\3_$7Q9\*?\ "V?'WQ*T7Q)XLT'3- \0
M6-AXT.D+:^'=431[RYTW5KO2+?2(DGUZTM=%AU2:62:/0=+0+;T ?I70 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 ?.W[7W_)IG[4/_9NWQK_]5KXEKZ7@S_DL.%/^RER+_P!6F%/,SK_D39M_
MV+,?_P"HM4_A K_0,_GH* "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@#^B3_@@=_P W7?\ ="__ 'L=?S7](;_FD/\ NO\ _O$/TSPZ_P"9
MQ_W3_P#W=/Z)*_FL_3 H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /_1
M_OXH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M64&G:7IUK'D[+:RL;:"V@3)VQ1*N>* -B@ H * /\['_ (/A?^2U_P#!/O\
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MT2C*O_:\Q.TQC< ?HS_P9??\HH_BO_V?)\6O_5,?LZT ?8/_  =4_P#*#O\
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MD>S(U38UUJFI7 M8)+F9I0#]9?\ B.+^)_\ TCJ\!?\ B2/B'_YSE 'Y\_\
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MV\_4;[PAX4L/*F98/) /]-.@#_.Q_P"#X7_DM?\ P3[_ .R6_'C_ -2SX<T
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MXF.C?\IA=*_[256/_K4,5 '^V=0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?.W[7W_)IG
M[4/_ &;M\:__ %6OB6OI>#/^2PX4_P"RER+_ -6F%/,SK_D39M_V+,?_ .HM
M4_A K_0,_GH* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#
M^B3_ (('?\W7?]T+_P#>QU_-?TAO^:0_[K__ +Q#],\.O^9Q_P!T_P#]W3^B
M2OYK/TP* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#__TO[^* "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MK-X/^$_PU\:>'M1NVL@_FC3/^$A^*?AQ?M+QB-KRVCBB<M',J@'S9_P8U?\
M(N?\%+_^PW^R-_Z0?M)4 ?WPT % !0 4 ?D;_P %Z?\ E#I_P4,_[-S\4_\
MI9I= '\"O_!GK_RF!M?^S8?C;_Z5^!Z /]5R@#_,@_X/7=,N(O\ @I3^S;K#
M+_HE]^PYX-TR!L<&XTGX]_M!W5TN>AVQ:U9G Z;AGJ* /Z\?^#8SQO:>./\
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MH_LGXD>(]3CADF.F>+O&OC7PS_8%G9W$5KJ>C^$/#,MU'+-IWQ!E@B /[CJ
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M5:;INMMJ7ACQCX2U:TU[PSXATS[5K=Q;IJ6B:S866IZ?-)!((+RUAF5=T:X
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M !_,1_P>T?\ )A?[)O\ V=VG_JFOB70!YY_P9"?\FQ?MS?\ 9>/AG_ZK[4:
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M_P#]:5^$U '\S/\ P9$_\G:_MK_]FZ>"O_5EVU '^C)XP_Y%'Q3_ -BYK?\
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MVZ$WMW\,/'HC:9072V!A^7S-P!^J?_!E]_RBC^*__9\GQ:_]4Q^SK0!]@_\
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MG$*Q'RX$EE"A8B0 ?SM?\&2/_)[O[8'_ &:MIO\ ZMOP;0!_<'_P6+_Y1/\
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MMF@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@#RWXY?\D4^,'_9+?B!_P"HGJU
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M/&?A6UTGQG9PP^'X4L]-U^RMC<74L<DI /M#_B!HUK_I)KI?_B'UW_\ 1.4
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % 'SM^U]_R:9^U#_P!F[?&O_P!5KXEKZ7@S_DL.%/\ LI<B_P#5IA3S
M,Z_Y$V;?]BS'_P#J+5/X0*_T#/YZ"@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H _HD_P""!W_-UW_="_\ WL=?S7](;_FD/^Z__P"\0_3/
M#K_F<?\ =/\ _=T_HDK^:S],"@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H __]/^_B@ H * "@ H * "@#\I/VD/^"X7_!*K]D;XP^*?@%^T)^V'X)\
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M0#[_ * /FO\ :M_:^_9P_8?^$MQ\=/VI_B?IOPC^%-KK^B^%IO%VJ:-XGUZ
M:_XA>=-&TR/3/!^A^(=;FFO3:W)5H=,DAAC@DEN)(8D+T ?F)_Q$K?\ !$'_
M */R\(?^&G_:&_\ G14 :FE?\''W_!$S6;@6UG^WQ\/(9./FU7P'\:]!M^>G
M^EZY\,M.M1[YF^7O@4 ?;/P'_P""F/\ P3U_:=O++2?@)^VC^S5\3/$.HSQV
MMCX/T#XO>#$\=7,\SB*"./P'J.JV/C'-Q*1';$Z&%N'^2 NP(H ^XJ "@ H
M* "@ H Y;QOXY\%_#/PCXA\?_$7Q;X:\!>!?"6EW.M^*?&7C'7-,\->%O#FC
M62;[O5-<U[6+FSTO2M/MDYFN[VZ@@C&-SC(H _#C]F[_ (.0O^";O[7'[;WA
M+]A']GW4/C3\0/'_ ([USQ?H'@_XI6OP[TO2O@EK]QX)\#>)/'NM7EAKVN>,
M--\<G2GTSPIJ]CIFH2_#N*#4]16UDM"^C7<.KL ?OA0 4 % !0 4 % !0 4
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MP%K.I,$MD^+7PO\ BY\.-$C8E5(U#QMXA\#P> M)52PS)JOBBRBP&97948@
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M#^X7_@R<_P"4=_[4/_9Z&N?^J/\ @O0!^A?_  =4_P#*#O\ :U_[&/\ 9O\
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M!^R?_!8O_E$__P %(O\ LR/]IC_U4?BN@#_.;_X-%O\ E,Q\.O\ LA?QY_\
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MJDE]%>ZQK7BR#Q7=1@'^@?\ \&7W_**/XK_]GR?%K_U3'[.M 'V#_P '5/\
MR@[_ &M?^QC_ &;_ /UI7X34 ?S,_P#!D3_R=K^VO_V;IX*_]67;4 ?Z0] '
MRC^WC_R8Y^V9_P!FH_M$?^JA\84 ?Y6?_!KE_P IU_V&O^[F?_6//V@J /\
M2K_X+;?LR>-/VPO^"5/[:O[/_P .-,N-<\?^*?A3!XG\%^'K*+SM0\3>*/A-
MXP\,?%_0_"VF0Y42:KXGU'P';Z!I4;,J-J&HVRNRKD@ _P KG_@C-_P4NU;_
M (),?MS^&OVE+SP7J'C?P-J'A7Q)\'_C7X'TYXK#Q3J?PT\5:CH6JZL/#,FH
M7%GI\/BKP[XG\)^&/$FG6.L2P:=JDVAR:#>W>D)J1UC3@#_13N/^#L+_ ((G
MP> [7QA'^T)\1+O7;BTBGD^%UO\ L^?&1?'EC</;I/)IUU>77A&V^&YN[=V^
MRRS6GQ!NM+>X5OLNHW%NOGT ?PT_\%H_^"M/[0O_  6\\9>(_&_P^^$OB?X?
M_L8_L7>'3XOL_";WR:C=:%8?$'X@>#OA38_%OXQ:C:S1Z"?&GBWQ-XJ\&>$/
M#GAG1CJ<'A&QU#4K#1+[6XG\8>*+\ _3/_@R1_Y/=_; _P"S5M-_]6WX-H _
MN#_X+%_\HG_^"D7_ &9'^TQ_ZJ/Q70!_G-_\&BW_ "F8^'7_ &0OX\_^HG#0
M!_K#4 % '^*O^P=_RFW_ &,_^TJ'[.W_ *UMX/H _P!I;6-'TKQ#I&J:!KNG
M66L:)KFG7NCZQI.I6T5YIVJ:5J5M+9:AIU_:3J\%U97MI--;75M,CQ3P2/%(
MK(Q% '^.C_P69_X);?&W_@CO^VS?)X6C\6Z9\#/$7C:;XF?LA_''0WU:T^RZ
M78ZT-?T/PH?%MNX?3?BS\(;M++3M45;VVUBZ2PT7QW8V]IIWB"P6( _K _X)
ME?\ !XG^SQXF^&OA;X<?\%,=%\5_"OXO>'=/LM'U/X__  ]\&ZAXV^&'Q$CL
MX_(_X2GQ-X+\(P7OC?P+XINXE@DUC2_"WACQ=X;U'4!?ZKI3>%[.YL_"]B ?
MIG\:/^#L7_@C!\+_  E=:]X'^.OQ _:"\0I:236'@3X5_ [XKZ-K5[,8MUK#
M-K'QB\*_"WPAIZ32;8YS-XA>[M$#N]@[JD,H![Q_P0O_ ."N?C3_ (*__#K]
MJ+XR:_\ ";PQ\'/!_P ,OCQ9_#OX6^$](U75/$/B1?!L_@30/$ NO'OB2\>U
MTS6O$L^I7UY,9/#_ (=\.:98V<T&F"UU&6S?6+X _FU_X/DO^1M_X)K?]BY^
MU?\ ^G/]GB@#]EO^#03_ )0Y^&O^SB_CG_Z6^'J /K3_ (.%_P#@F+J__!3S
M_@GYXF\"_#33[*[_ &B?@CKB?&KX#PS^7!/XEUW1-)U#3O%/PRCU!VC6T_X6
M)X6OKVPTI;F6'3'\:Z=X,N=6GM-/LIKRV /\UC_@DU_P5$^/?_!%[]KO7OB!
M8>!M2U[PYJT5Q\+/VE/V?/%TFJ>#M0U[2M"UPO-:O'>6CS^$/BAX UJWOQH&
MHZOHE[+H\MWXB\.ZCIWV'7=5CH _T-_@Y_P=?_\ !%OXF>$++Q!XS^/WCKX"
M>(9;2.?4/ /Q2^!GQ=U77M-F\E7N8!JWPC\(?$[P;J AE+0Q&R\2O<76T/':
M+NVJ ?&W[9W_  >3?L#_  G\-:MIG[&G@7XD?M7_ !(E@FBT#6]>\/:Q\%_@
MW8SO"R0ZCK.H^,[&U^)VIK9SM%.= L/AWI8U:&&>T/BG07DAO  ?K3_P0(_;
M9^/7_!0G_@G-X._:A_:1UC0-8^)WC3XL?&VPN?\ A%O#>G>%/#NC^']!^(&J
M:?X:\-Z-I.GJTG]F^'M)2#2K*\U>]U?Q!>VUM%<:[K>KZD]Q?S@'YC_\%-?^
M#DKQ3_P2L_X*F:U^S#\7/@=9?%[]EFZ^#?PH\81ZAX!NDT#XU>"O$7B?^W9=
M>U6P?7-0/A#QWI=Q#9V\,'A746\&7$$T:747B^*,3V5V ?6W@+_@ZJ_X(B^,
MO#<6NZU^U+XH^&.HF#S[GP?X]_9]^/<_B2Q "_NI9OA_\._'GA6\GRVSRM(\
M3:DQ*LP_=@.0#^6S_@Y0_P"#@[]EW_@HO\#/!G[&_P"QOI/B_P 7^!-)^*VC
M?%7X@?&_QIX6NO!>F:M-X3T+Q!I'AGPS\.O#&O"+Q@UM>7'BF]U+Q#KWB?1/
M"-Y9_P!CV&DZ9INJ6FKZE=V8!^H7_!EK^Q=\2?A9\!_VG/VR_B!H%]X>\-?M
M)ZK\/O 7P6CU.T>SNO$7@_X3W'C6X\8>-[%9&W7'AO6_%7BFT\-Z/=^7$)K_
M ,$:_)%YUJ]K,X!_;Q0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!Y;\<O^2*?
M&#_LEOQ _P#43U:@#_$X_P"";'[4?A/]BC]NW]F#]JOQUX=\0^+?!_P.^*&E
M^-O$7ASPF=-'B35M+M;2^L[BVT4:Q>:?I;7X6\$L,=]?6=O(8_+>YA#>8H!_
M>S/_ ,'M'[!*PR&V_9/_ &O)9PI\J.>+X,V\+OV62:/XFW3Q+ZLMO*1_<- '
MR3\=/^#W^V.DSV/[,_[!TR:[-#-]F\3_ !T^+D<FDZ=<89;?S_ G@#PU%>:S
M"25DF$?Q&T%U"- A;S!/$ ?RT_M'?ME?\%2/^"Z7Q^\)^$O%\_Q&_:.\;"^N
M3\+_ ( ?!OP=<VWP_P# $&H31V][J&@^!?#D,EAI-K;13PP:]\1_&]]J.L6^
MCQ1?\)3XT.E6$;6X!_?;_P &^G_!N_HG_!,>T_X:=_:>G\+_ !!_;6\6>'SI
MNCV.D+%J_A']F[P[K%J\>N>'?"6LR;H?$/Q$UZTF_LKQGX[L(8+&RTT7G@[P
M;/=:!?:_K_C( _HZ_:)^.7@G]F3X"_&3]H?XD77V/P)\$OAIXS^)_BEUDCCN
M)](\%Z!?:[<:?8>9Q-JNJ?8ETS2+10\M[J=W:6<$<DTT<; '^+1\+/"7Q=_X
M*N_\%)O"_AO6KRXNOBK^V[^U$;_QAK%FKW,?AY?B9XUGU_QSXAMH9?,,6@>
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M9DM]'T6X\'Z=_H\4MG$0#\KO^#X7_DM?_!/O_LEOQX_]2SX<T ?N=_P:%_\
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MQ4 ?[9U !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0!\[?M??\FF?M0_]F[?&O\ ]5KXEKZ7
M@S_DL.%/^RER+_U:84\S.O\ D39M_P!BS'_^HM4_A K_ $#/YZ"@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H _HD_X('?\W7?]T+_]['7\
MU_2&_P":0_[K_P#[Q#],\.O^9Q_W3_\ W=/Z)*_FL_3 H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MD>"]*\5:F\S 6MO<P*\Z@']DG_!H_P"&_$7@_P#X)+?\(MXMT#6O"WB;P_\
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M./AA\5M4$O[Z;Q!JL&B:[X5\:7(>[>_\2>%I/%%Y/;R>+H+"V /Z3Z "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H _";]O#_@W(_X)<_\ !0'QMXH^
M+/Q%^$_B?X3?&KQI=W6I^+/BU\ /%G_"!>(?$VM7CF:YU[Q'X:U73/%7PTUO
MQ!>7+276J>(K_P "R^(-9N)9)=5U6\D*.@!^&WC7_@Q\^!-_J,DGPY_;^^+7
MA722X,-EXU^"'@[Q_J,<6[E)-4T+QW\-;:5RGRB1=(A4-\WE$?)0!Z=\-?\
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M/ WBG2_%VDKIFH^+O"/CG08H+C4-)@MM12[\-7KRV$MQ':R6=R8KN$ ^,O\
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MT$OV>]\;_$#Q)=ZMXQ\4R6K7%TVFVNK:S<:9HB7=Q:Z#8:792?9@ >P?M)?
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MI6P_:F^ GQ3_ &K?%_Q"TWP9XK\#VVD?&#QS\(M>\'?V5XP@M+?4[I]/\%?
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MPGHOC[XB?!#4_!E_J]A!<P6\'B#3_#G[.WA77+O3P+EW:'3O$6E7#.D?^E!
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MV\ 'WE0!^)'_  4A_P"#?K_@G/\ \%-=>O/B-\6_A_X@^%GQVO8HTO\ X[_
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M'5D)N-+U7X!>%=9UJ6+^%(->L_B9H-C;R#O(_ANY4]HEH _1']C_ /X-%?\
M@E]^S?XFM_&OQ>/Q/_;"\06$MO<:7H?QEU;3-%^%^GW-OAENI/A]X#L-"_X2
M0R.7%QIGC?Q!XJ\-SP>7'+H+.C32 ']1.B:)HWAK1M)\.>'-(TSP_P"'M TV
MQT70M!T2PM-*T;1='TNUBLM,TG2=+L(H+'3M-TZR@AM+&PLX(;6TM88K>WBC
MBC1  :E !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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MZAH>I:F_B&+Q[\)?B7+=7-K/H%JNG/ID^D1QQ3W2W45XS0/;@'U;_P $Y?\
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MK!?V<5U\^%SK*BS:T'B1=8_LG]R-<%[_ *?0!_470 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 ?.W[7W_)IG[4/_9NWQK_ /5:^):^EX,_Y+#A3_LI<B_]6F%/,SK_ )$V
M;?\ 8LQ__J+5/X0*_P! S^>@H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * /Z)/^"!W_-UW_="__>QU_-?TAO\ FD/^Z_\ ^\0_3/#K_F<?
M]T__ -W3^B2OYK/TP* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M_P!5;XJH _P^O@#_ ,EW^"G_ &5OX;_^ICHU '^\[0!_,Q_P=M?#WX<^+/\
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M/N;>]L/"EI<13+X;\-1W5CK7Q U6TEL--GT_1;'7_$6B@'KW_!"__@KOHO\
MP5V_93O?B-JG@J\^'_QT^#VIZ+X"^/OA^RTK54^'UWXMU#2Y=0TWQ5\-_$%X
M+BVO/#_BFQL[C4I_"EQJ=YXG\!WA;2-<-]I=QX8\5>*0#]KZ "@ H _S:_\
M@]R_Y/&_8R_[-G\3?^K2UN@#[K_X,>O^2)_\% _^RI_ C_U$OB+0!_=30 4
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MZQ:?%:6WL/AX7#.((+O2OB_:_#_4(;YHVFCL8]4T^-X8=4NF(!_L#T % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M'KMI;?:_%WB^Y@RRP7WC+Q=>:YXJOX8\0Q7NL3QPHD2HB@'U#0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!\[?M??\ )IG[
M4/\ V;M\:_\ U6OB6OI>#/\ DL.%/^RER+_U:84\S.O^1-FW_8LQ_P#ZBU3^
M$"O] S^>@H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /Z)
M/^"!W_-UW_="_P#WL=?S7](;_FD/^Z__ .\0_3/#K_F<?]T__P!W3^B2OYK/
MTP* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MC1/#FA7MU:V-]J]GJ>IV5O?H ?JA0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 ?.W[7W_ ":9^U#_ -F[?&O_ -5KXEKZ
M7@S_ )+#A3_LI<B_]6F%/,SK_D39M_V+,?\ ^HM4_A K_0,_GH* "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@#^B3_@@=_S==_W0O\ ]['7
M\U_2&_YI#_NO_P#O$/TSPZ_YG'_=/_\ =T_HDK^:S],"@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MPAX(\&:+8>'?#'AO1;)=MMINCZ-I<%M8V-M'EG*0PKYDSR3REYI9'8 _F?\
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MM7&J7/P]^*\\"6UI#\4-1U2]-KX*\<7K+#XZMUT[P;JTEMXML="G\: ']_E
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MDO+R73?(B\6ZPMPEJZ1W7F0&1=T"F@#]._\ @QG_ .0K_P %./\ L'_L<_\
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MR:G9>"-#MK^1E[,]U%*S#L3B@#V6@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H ^=OVOO^33/VH?\ LW;XU_\
MJM?$M?2\&?\ )8<*?]E+D7_JTPIYF=?\B;-O^Q9C_P#U%JG\(%?Z!G\]!0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?T2?\$#O^;KO^Z%
M_P#O8Z_FOZ0W_-(?]U__ -XA^F>'7_,X_P"Z?_[NG]$E?S6?I@4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M_#_P2]U;_%3P]K%_H5E;7%WH%C\/-8\1>.'L)A+!)K'@W1Y"L;1+/& ?P/\
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M$[I9+VR2ULKE1/)" ?JO_P &,_\ R%?^"G'_ &#_ -CG_P!*/VHJ /\ 0,H
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M&WMH8K>"%!A(H846.*-!V5$554=@ * )J "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@#YV_:^_Y-,_:A_[-V^-
M?_JM?$M?2\&?\EAPI_V4N1?^K3"GF9U_R)LV_P"Q9C__ %%JG\(%?Z!G\]!0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?T2?\$#O^;KO^
MZ%_^]CK^:_I#?\TA_P!U_P#]XA^F>'7_ #./^Z?_ .[I_1)7\UGZ8% !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M<<<5SJ_@'QBMI>3:8UXD%NNK:)J5IJ_A3Q +2Q7Q#X?U9;"R%N ?PO?M5_\
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M ^=OVOO^33/VH?\ LW;XU_\ JM?$M?2\&?\ )8<*?]E+D7_JTPIYF=?\B;-O
M^Q9C_P#U%JG\(%?Z!G\]!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 ?T2?\$#O^;KO^Z%_P#O8Z_FOZ0W_-(?]U__ -XA^F>'7_,X_P"Z
M?_[NG]$E?S6?I@4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@#*UW6M,\-:)K'B+6KDV>C
M:!I6H:UJUV(+BZ-KIFE6DM]?W(MK.&XN[@P6L$LH@M8)KB7;Y<$,DC*A /\
M)J_X*T?%G_@H)_P7)_X*+:2OPZ_9B_:(M_A=:^)8O@I^R/\ #SQ!\+_&_AS3
M/#_@W5==M[27QYXUOM5T:UT'PQK?Q U".W\8?$+Q!JUW!8^%=!M='T'4]8N-
M%\#VFHD _P!'+_@D?_P31^&__!*O]C3P1^S5X,N;;Q'XUNIV\>?'/XCQ0R0O
M\1OC!KNG:;:>(]:M(YU2:S\,Z1:Z9IWA?P9I;I')9^&-%T^;4%GUZ]UG4+X
M_3B@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MJQ'_ ,L#_AT+^PI_T3/Q%_X<GQY_\OJ/^(S<?_\ 0UPW_AKR[_YG#_4KA_\
MZ!:O_A5B/_E@?\.A?V%/^B9^(O\ PY/CS_Y?4?\ $9N/_P#H:X;_ ,->7?\
MS.'^I7#_ /T"U?\ PJQ'_P L#_AT+^PI_P!$S\1?^')\>?\ R^H_XC-Q_P#]
M#7#?^&O+O_F</]2N'_\ H%J_^%6(_P#E@?\ #H7]A3_HF?B+_P .3X\_^7U'
M_$9N/_\ H:X;_P ->7?_ #.'^I7#_P#T"U?_  JQ'_RP/^'0O["G_1,_$7_A
MR?'G_P OJ/\ B,W'_P#T-<-_X:\N_P#F</\ 4KA__H%J_P#A5B/_ )8'_#H7
M]A3_ *)GXB_\.3X\_P#E]1_Q&;C_ /Z&N&_\->7?_,X?ZE</_P#0+5_\*L1_
M\L#_ (="_L*?]$S\1?\ AR?'G_R^H_XC-Q__ -#7#?\ AKR[_P"9P_U*X?\
M^@6K_P"%6(_^6!_PZ%_84_Z)GXB_\.3X\_\ E]1_Q&;C_P#Z&N&_\->7?_,X
M?ZE</_\ 0+5_\*L1_P#+ _X="_L*?]$S\1?^')\>?_+ZC_B,W'__ $-<-_X:
M\N_^9P_U*X?_ .@6K_X58C_Y8'_#H7]A3_HF?B+_ ,.3X\_^7U'_ !&;C_\
MZ&N&_P##7EW_ ,SA_J5P_P#] M7_ ,*L1_\ + _X="_L*?\ 1,_$7_AR?'G_
M ,OJ/^(S<?\ _0UPW_AKR[_YG#_4KA__ *!:O_A5B/\ Y8'_  Z%_84_Z)GX
MB_\ #D^//_E]1_Q&;C__ *&N&_\ #7EW_P SA_J5P_\ ] M7_P *L1_\L#_A
MT+^PI_T3/Q%_X<GQY_\ +ZC_ (C-Q_\ ]#7#?^&O+O\ YG#_ %*X?_Z!:O\
MX58C_P"6!_PZ%_84_P"B9^(O_#D^//\ Y?4?\1FX_P#^AKAO_#7EW_S.'^I7
M#_\ T"U?_"K$?_+ _P"'0O["G_1,_$7_ (<GQY_\OJ/^(S<?_P#0UPW_ (:\
MN_\ F</]2N'_ /H%J_\ A5B/_E@?\.A?V%/^B9^(O_#D^//_ )?4?\1FX_\
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M_P L#_AT+^PI_P!$S\1?^')\>?\ R^H_XC-Q_P#]#7#?^&O+O_F</]2N'_\
MH%J_^%6(_P#E@?\ #H7]A3_HF?B+_P .3X\_^7U'_$9N/_\ H:X;_P ->7?_
M #.'^I7#_P#T"U?_  JQ'_RP/^'0O["G_1,_$7_AR?'G_P OJ/\ B,W'_P#T
M-<-_X:\N_P#F</\ 4KA__H%J_P#A5B/_ )8'_#H7]A3_ *)GXB_\.3X\_P#E
M]1_Q&;C_ /Z&N&_\->7?_,X?ZE</_P#0+5_\*L1_\L#_ (="_L*?]$S\1?\
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M *&N&_\ #7EW_P SA_J5P_\ ] M7_P *L1_\L#_AT+^PI_T3/Q%_X<GQY_\
M+ZC_ (C-Q_\ ]#7#?^&O+O\ YG#_ %*X?_Z!:O\ X58C_P"6!_PZ%_84_P"B
M9^(O_#D^//\ Y?4?\1FX_P#^AKAO_#7EW_S.'^I7#_\ T"U?_"K$?_+ _P"'
M0O["G_1,_$7_ (<GQY_\OJ/^(S<?_P#0UPW_ (:\N_\ F</]2N'_ /H%J_\
MA5B/_E@?\.A?V%/^B9^(O_#D^//_ )?4?\1FX_\ ^AKAO_#7EW_S.'^I7#__
M $"U?_"K$?\ RP/^'0O["G_1,_$7_AR?'G_R^H_XC-Q__P!#7#?^&O+O_F</
M]2N'_P#H%J_^%6(_^6!_PZ%_84_Z)GXB_P##D^//_E]1_P 1FX__ .AKAO\
MPUY=_P#,X?ZE</\ _0+5_P#"K$?_ "P/^'0O["G_ $3/Q%_X<GQY_P#+ZC_B
M,W'_ /T-<-_X:\N_^9P_U*X?_P"@6K_X58C_ .6!_P .A?V%/^B9^(O_  Y/
MCS_Y?4?\1FX__P"AKAO_  UY=_\ ,X?ZE</_ /0+5_\ "K$?_+ _X="_L*?]
M$S\1?^')\>?_ "^H_P"(S<?_ /0UPW_AKR[_ .9P_P!2N'_^@6K_ .%6(_\
ME@?\.A?V%/\ HF?B+_PY/CS_ .7U'_$9N/\ _H:X;_PUY=_\SA_J5P__ - M
M7_PJQ'_RP/\ AT+^PI_T3/Q%_P"')\>?_+ZC_B,W'_\ T-<-_P"&O+O_ )G#
M_4KA_P#Z!:O_ (58C_Y8'_#H7]A3_HF?B+_PY/CS_P"7U'_$9N/_ /H:X;_P
MUY=_\SA_J5P__P! M7_PJQ'_ ,L#_AT+^PI_T3/Q%_X<GQY_\OJ/^(S<?_\
M0UPW_AKR[_YG#_4KA_\ Z!:O_A5B/_E@?\.A?V%/^B9^(O\ PY/CS_Y?4?\
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MJQ'_ ,L#_AT+^PI_T3/Q%_X<GQY_\OJ/^(S<?_\ 0UPW_AKR[_YG#_4KA_\
MZ!:O_A5B/_E@?\.A?V%/^B9^(O\ PY/CS_Y?4?\ $9N/_P#H:X;_ ,->7?\
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M\L#_ (="_L*?]$S\1?\ AR?'G_R^H_XC-Q__ -#7#?\ AKR[_P"9P_U*X?\
M^@6K_P"%6(_^6!_PZ%_84_Z)GXB_\.3X\_\ E]1_Q&;C_P#Z&N&_\->7?_,X
M?ZE</_\ 0+5_\*L1_P#+ _X="_L*?]$S\1?^')\>?_+ZC_B,W'__ $-<-_X:
M\N_^9P_U*X?_ .@6K_X58C_Y8'_#H7]A3_HF?B+_ ,.3X\_^7U'_ !&;C_\
MZ&N&_P##7EW_ ,SA_J5P_P#] M7_ ,*L1_\ + _X="_L*?\ 1,_$7_AR?'G_
M ,OJ/^(S<?\ _0UPW_AKR[_YG#_4KA__ *!:O_A5B/\ Y8'_  Z%_84_Z)GX
MB_\ #D^//_E]1_Q&;C__ *&N&_\ #7EW_P SA_J5P_\ ] M7_P *L1_\L#_A
MT+^PI_T3/Q%_X<GQY_\ +ZC_ (C-Q_\ ]#7#?^&O+O\ YG#_ %*X?_Z!:O\
MX58C_P"6!_PZ%_84_P"B9^(O_#D^//\ Y?4?\1FX_P#^AKAO_#7EW_S.'^I7
M#_\ T"U?_"K$?_+ _P"'0O["G_1,_$7_ (<GQY_\OJ/^(S<?_P#0UPW_ (:\
MN_\ F</]2N'_ /H%J_\ A5B/_E@?\.A?V%/^B9^(O_#D^//_ )?4?\1FX_\
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /_T_[^* "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H __]3^_B@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * /__5_OXH * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@#__UO[^* "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M_P $2O\ HXSX@?\ B._QO_\ F(H /^(L#_@B5_T<9\0/_$=_C?\ _,10 ?\
M$6!_P1*_Z.,^('_B._QO_P#F(H /^(L#_@B5_P!'&?$#_P 1W^-__P Q% !_
MQ%@?\$2O^CC/B!_XCO\ &_\ ^8B@ _XBP/\ @B5_T<9\0/\ Q'?XW_\ S$4
M'_$6!_P1*_Z.,^('_B._QO\ _F(H /\ B+ _X(E?]'&?$#_Q'?XW_P#S$4 '
M_$6!_P $2O\ HXSX@?\ B._QO_\ F(H /^(L#_@B5_T<9\0/_$=_C?\ _,10
M ?\ $6!_P1*_Z.,^('_B._QO_P#F(H /^(L#_@B5_P!'&?$#_P 1W^-__P Q
M% !_Q%@?\$2O^CC/B!_XCO\ &_\ ^8B@ _XBP/\ @B5_T<9\0/\ Q'?XW_\
MS$4 '_$6!_P1*_Z.,^('_B._QO\ _F(H /\ B+ _X(E?]'&?$#_Q'?XW_P#S
M$4 '_$6!_P $2O\ HXSX@?\ B._QO_\ F(H /^(L#_@B5_T<9\0/_$=_C?\
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MW^-__P Q% !_Q%@?\$2O^CC/B!_XCO\ &_\ ^8B@ _XBP/\ @B5_T<9\0/\
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M_P!'&?$#_P 1W^-__P Q% !_Q%@?\$2O^CC/B!_XCO\ &_\ ^8B@ _XBP/\
M@B5_T<9\0/\ Q'?XW_\ S$4 '_$6!_P1*_Z.,^('_B._QO\ _F(H /\ B+ _
MX(E?]'&?$#_Q'?XW_P#S$4 '_$6!_P $2O\ HXSX@?\ B._QO_\ F(H /^(L
M#_@B5_T<9\0/_$=_C?\ _,10 ?\ $6!_P1*_Z.,^('_B._QO_P#F(H /^(L#
M_@B5_P!'&?$#_P 1W^-__P Q% !_Q%@?\$2O^CC/B!_XCO\ &_\ ^8B@ _XB
MP/\ @B5_T<9\0/\ Q'?XW_\ S$4 '_$6!_P1*_Z.,^('_B._QO\ _F(H /\
MB+ _X(E?]'&?$#_Q'?XW_P#S$4 '_$6!_P $2O\ HXSX@?\ B._QO_\ F(H
M/^(L#_@B5_T<9\0/_$=_C?\ _,10 ?\ $6!_P1*_Z.,^('_B._QO_P#F(H /
M^(L#_@B5_P!'&?$#_P 1W^-__P Q% !_Q%@?\$2O^CC/B!_XCO\ &_\ ^8B@
M _XBP/\ @B5_T<9\0/\ Q'?XW_\ S$4 '_$6!_P1*_Z.,^('_B._QO\ _F(H
M /\ B+ _X(E?]'&?$#_Q'?XW_P#S$4 '_$6!_P $2O\ HXSX@?\ B._QO_\
MF(H /^(L#_@B5_T<9\0/_$=_C?\ _,10 ?\ $6!_P1*_Z.,^('_B._QO_P#F
M(H /^(L#_@B5_P!'&?$#_P 1W^-__P Q% !_Q%@?\$2O^CC/B!_XCO\ &_\
M^8B@ _XBP/\ @B5_T<9\0/\ Q'?XW_\ S$4 '_$6!_P1*_Z.,^('_B._QO\
M_F(H /\ B+ _X(E?]'&?$#_Q'?XW_P#S$4 '_$6!_P $2O\ HXSX@?\ B._Q
MO_\ F(H /^(L#_@B5_T<9\0/_$=_C?\ _,10 ?\ $6!_P1*_Z.,^('_B._QO
M_P#F(H /^(L#_@B5_P!'&?$#_P 1W^-__P Q% !_Q%@?\$2O^CC/B!_XCO\
M&_\ ^8B@ _XBP/\ @B5_T<9\0/\ Q'?XW_\ S$4 '_$6!_P1*_Z.,^('_B._
MQO\ _F(H /\ B+ _X(E?]'&?$#_Q'?XW_P#S$4 '_$6!_P $2O\ HXSX@?\
MB._QO_\ F(H /^(L#_@B5_T<9\0/_$=_C?\ _,10 ?\ $6!_P1*_Z.,^('_B
M._QO_P#F(H /^(L#_@B5_P!'&?$#_P 1W^-__P Q% !_Q%@?\$2O^CC/B!_X
MCO\ &_\ ^8B@ _XBP/\ @B5_T<9\0/\ Q'?XW_\ S$4 '_$6!_P1*_Z.,^('
M_B._QO\ _F(H /\ B+ _X(E?]'&?$#_Q'?XW_P#S$4 '_$6!_P $2O\ HXSX
M@?\ B._QO_\ F(H /^(L#_@B5_T<9\0/_$=_C?\ _,10 ?\ $6!_P1*_Z.,^
M('_B._QO_P#F(H /^(L#_@B5_P!'&?$#_P 1W^-__P Q% !_Q%@?\$2O^CC/
MB!_XCO\ &_\ ^8B@ _XBP/\ @B5_T<9\0/\ Q'?XW_\ S$4 '_$6!_P1*_Z.
M,^('_B._QO\ _F(H /\ B+ _X(E?]'&?$#_Q'?XW_P#S$4 '_$6!_P $2O\
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M_P $2O\ HXSX@?\ B._QO_\ F(H /^(L#_@B5_T<9\0/_$=_C?\ _,10 ?\
M$6!_P1*_Z.,^('_B._QO_P#F(H /^(L#_@B5_P!'&?$#_P 1W^-__P Q% !_
MQ%@?\$2O^CC/B!_XCO\ &_\ ^8B@ _XBP/\ @B5_T<9\0/\ Q'?XW_\ S$4
M'_$6!_P1*_Z.,^('_B._QO\ _F(H /\ B+ _X(E?]'&?$#_Q'?XW_P#S$4 '
M_$6!_P $2O\ HXSX@?\ B._QO_\ F(H /^(L#_@B5_T<9\0/_$=_C?\ _,10
M ?\ $6!_P1*_Z.,^('_B._QO_P#F(H /^(L#_@B5_P!'&?$#_P 1W^-__P Q
M% !_Q%@?\$2O^CC/B!_XCO\ &_\ ^8B@ _XBP/\ @B5_T<9\0/\ Q'?XW_\
MS$4 '_$6!_P1*_Z.,^('_B._QO\ _F(H /\ B+ _X(E?]'&?$#_Q'?XW_P#S
M$4 '_$6!_P $2O\ HXSX@?\ B._QO_\ F(H /^(L#_@B5_T<9\0/_$=_C?\
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MW^-__P Q% !_Q%@?\$2O^CC/B!_XCO\ &_\ ^8B@ _XBP/\ @B5_T<9\0/\
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M_P!'&?$#_P 1W^-__P Q% !_Q%@?\$2O^CC/B!_XCO\ &_\ ^8B@ _XBP/\
M@B5_T<9\0/\ Q'?XW_\ S$4 '_$6!_P1*_Z.,^('_B._QO\ _F(H /\ B+ _
MX(E?]'&?$#_Q'?XW_P#S$4 '_$6!_P $2O\ HXSX@?\ B._QO_\ F(H /^(L
M#_@B5_T<9\0/_$=_C?\ _,10 ?\ $6!_P1*_Z.,^('_B._QO_P#F(H /^(L#
M_@B5_P!'&?$#_P 1W^-__P Q% !_Q%@?\$2O^CC/B!_XCO\ &_\ ^8B@ _XB
MP/\ @B5_T<9\0/\ Q'?XW_\ S$4 '_$6!_P1*_Z.,^('_B._QO\ _F(H /\
MB+ _X(E?]'&?$#_Q'?XW_P#S$4 '_$6!_P $2O\ HXSX@?\ B._QO_\ F(H
M/^(L#_@B5_T<9\0/_$=_C?\ _,10 ?\ $6!_P1*_Z.,^('_B._QO_P#F(H /
M^(L#_@B5_P!'&?$#_P 1W^-__P Q% !_Q%@?\$2O^CC/B!_XCO\ &_\ ^8B@
M _XBP/\ @B5_T<9\0/\ Q'?XW_\ S$4 '_$6!_P1*_Z.,^('_B._QO\ _F(H
M /\ B+ _X(E?]'&?$#_Q'?XW_P#S$4 '_$6!_P $2O\ HXSX@?\ B._QO_\
MF(H /^(L#_@B5_T<9\0/_$=_C?\ _,10 ?\ $6!_P1*_Z.,^('_B._QO_P#F
M(H /^(L#_@B5_P!'&?$#_P 1W^-__P Q% !_Q%@?\$2O^CC/B!_XCO\ &_\
M^8B@ _XBP/\ @B5_T<9\0/\ Q'?XW_\ S$4 '_$6!_P1*_Z.,^('_B._QO\
M_F(H /\ B+ _X(E?]'&?$#_Q'?XW_P#S$4 '_$6!_P $2O\ HXSX@?\ B._Q
MO_\ F(H /^(L#_@B5_T<9\0/_$=_C?\ _,10 ?\ $6!_P1*_Z.,^('_B._QO
M_P#F(H /^(L#_@B5_P!'&?$#_P 1W^-__P Q% !_Q%@?\$2O^CC/B!_XCO\
M&_\ ^8B@ _XBP/\ @B5_T<9\0/\ Q'?XW_\ S$4 '_$6!_P1*_Z.,^('_B._
MQO\ _F(H /\ B+ _X(E?]'&?$#_Q'?XW_P#S$4 '_$6!_P $2O\ HXSX@?\
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M,^('_B._QO\ _F(H /\ B+ _X(E?]'&?$#_Q'?XW_P#S$4 '_$6!_P $2O\
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M_P $2O\ HXSX@?\ B._QO_\ F(H /^(L#_@B5_T<9\0/_$=_C?\ _,10 ?\
M$6!_P1*_Z.,^('_B._QO_P#F(H /^(L#_@B5_P!'&?$#_P 1W^-__P Q% !_
MQ%@?\$2O^CC/B!_XCO\ &_\ ^8B@ _XBP/\ @B5_T<9\0/\ Q'?XW_\ S$4
M'_$6!_P1*_Z.,^('_B._QO\ _F(H /\ B+ _X(E?]'&?$#_Q'?XW_P#S$4 '
M_$6!_P $2O\ HXSX@?\ B._QO_\ F(H /^(L#_@B5_T<9\0/_$=_C?\ _,10
M ?\ $6!_P1*_Z.,^('_B._QO_P#F(H /^(L#_@B5_P!'&?$#_P 1W^-__P Q
M% !_Q%@?\$2O^CC/B!_XCO\ &_\ ^8B@ _XBP/\ @B5_T<9\0/\ Q'?XW_\
MS$4 '_$6!_P1*_Z.,^('_B._QO\ _F(H /\ B+ _X(E?]'&?$#_Q'?XW_P#S
M$4 '_$6!_P $2O\ HXSX@?\ B._QO_\ F(H /^(L#_@B5_T<9\0/_$=_C?\
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MW^-__P Q% !_Q%@?\$2O^CC/B!_XCO\ &_\ ^8B@ _XBP/\ @B5_T<9\0/\
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M_P!'&?$#_P 1W^-__P Q% !_Q%@?\$2O^CC/B!_XCO\ &_\ ^8B@ _XBP/\
M@B5_T<9\0/\ Q'?XW_\ S$4 '_$6!_P1*_Z.,^('_B._QO\ _F(H /\ B+ _
MX(E?]'&?$#_Q'?XW_P#S$4 '_$6!_P $2O\ HXSX@?\ B._QO_\ F(H /^(L
M#_@B5_T<9\0/_$=_C?\ _,10 ?\ $6!_P1*_Z.,^('_B._QO_P#F(H /^(L#
M_@B5_P!'&?$#_P 1W^-__P Q% !_Q%@?\$2O^CC/B!_XCO\ &_\ ^8B@ _XB
MP/\ @B5_T<9\0/\ Q'?XW_\ S$4 '_$6!_P1*_Z.,^('_B._QO\ _F(H /\
MB+ _X(E?]'&?$#_Q'?XW_P#S$4 '_$6!_P $2O\ HXSX@?\ B._QO_\ F(H
M/^(L#_@B5_T<9\0/_$=_C?\ _,10 ?\ $6!_P1*_Z.,^('_B._QO_P#F(H /
M^(L#_@B5_P!'&?$#_P 1W^-__P Q% !_Q%@?\$2O^CC/B!_XCO\ &_\ ^8B@
M _XBP/\ @B5_T<9\0/\ Q'?XW_\ S$4 '_$6!_P1*_Z.,^('_B._QO\ _F(H
M /\ B+ _X(E?]'&?$#_Q'?XW_P#S$4 '_$6!_P $2O\ HXSX@?\ B._QO_\
MF(H /^(L#_@B5_T<9\0/_$=_C?\ _,10 ?\ $6!_P1*_Z.,^('_B._QO_P#F
M(H /^(L#_@B5_P!'&?$#_P 1W^-__P Q% !_Q%@?\$2O^CC/B!_XCO\ &_\
M^8B@ _XBP/\ @B5_T<9\0/\ Q'?XW_\ S$4 '_$6!_P1*_Z.,^('_B._QO\
M_F(H /\ B+ _X(E?]'&?$#_Q'?XW_P#S$4 '_$6!_P $2O\ HXSX@?\ B._Q
MO_\ F(H /^(L#_@B5_T<9\0/_$=_C?\ _,10 ?\ $6!_P1*_Z.,^('_B._QO
M_P#F(H /^(L#_@B5_P!'&?$#_P 1W^-__P Q% !_Q%@?\$2O^CC/B!_XCO\
M&_\ ^8B@ _XBP/\ @B5_T<9\0/\ Q'?XW_\ S$4 '_$6!_P1*_Z.,^('_B._
MQO\ _F(H /\ B+ _X(E?]'&?$#_Q'?XW_P#S$4 '_$6!_P $2O\ HXSX@?\
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M,^('_B._QO\ _F(H /\ B+ _X(E?]'&?$#_Q'?XW_P#S$4 '_$6!_P $2O\
MHXSX@?\ B._QO_\ F(H /^(L#_@B5_T<9\0/_$=_C?\ _,10 ?\ $6!_P1*_
MZ.,^('_B._QO_P#F(H /^(L#_@B5_P!'&?$#_P 1W^-__P Q% !_Q%@?\$2O
M^CC/B!_XCO\ &_\ ^8B@ _XBP/\ @B5_T<9\0/\ Q'?XW_\ S$4 '_$6!_P1
M*_Z.,^('_B._QO\ _F(H /\ B+ _X(E?]'&?$#_Q'?XW_P#S$4 '_$6!_P $
M2O\ HXSX@?\ B._QO_\ F(H /^(L#_@B5_T<9\0/_$=_C?\ _,10 ?\ $6!_
MP1*_Z.,^('_B._QO_P#F(H /^(L#_@B5_P!'&?$#_P 1W^-__P Q% !_Q%@?
M\$2O^CC/B!_XCO\ &_\ ^8B@ _XBP/\ @B5_T<9\0/\ Q'?XW_\ S$4 '_$6
M!_P1*_Z.,^('_B._QO\ _F(H /\ B+ _X(E?]'&?$#_Q'?XW_P#S$4 '_$6!
M_P $2O\ HXSX@?\ B._QO_\ F(H /^(L#_@B5_T<9\0/_$=_C?\ _,10 ?\
M$6!_P1*_Z.,^('_B._QO_P#F(H /^(L#_@B5_P!'&?$#_P 1W^-__P Q% !_
MQ%@?\$2O^CC/B!_XCO\ &_\ ^8B@ _XBP/\ @B5_T<9\0/\ Q'?XW_\ S$4
M'_$6!_P1*_Z.,^('_B._QO\ _F(H /\ B+ _X(E?]'&?$#_Q'?XW_P#S$4 '
M_$6!_P $2O\ HXSX@?\ B._QO_\ F(H /^(L#_@B5_T<9\0/_$=_C?\ _,10
M ?\ $6!_P1*_Z.,^('_B._QO_P#F(H /^(L#_@B5_P!'&?$#_P 1W^-__P Q
M% !_Q%@?\$2O^CC/B!_XCO\ &_\ ^8B@ _XBP/\ @B5_T<9\0/\ Q'?XW_\
MS$4 '_$6!_P1*_Z.,^('_B._QO\ _F(H /\ B+ _X(E?]'&?$#_Q'?XW_P#S
M$4 '_$6!_P $2O\ HXSX@?\ B._QO_\ F(H /^(L#_@B5_T<9\0/_$=_C?\
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MW^-__P Q% !_Q%@?\$2O^CC/B!_XCO\ &_\ ^8B@ _XBP/\ @B5_T<9\0/\
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M_P!'&?$#_P 1W^-__P Q% !_Q%@?\$2O^CC/B!_XCO\ &_\ ^8B@ _XBP/\
M@B5_T<9\0/\ Q'?XW_\ S$4 '_$6!_P1*_Z.,^('_B._QO\ _F(H /\ B+ _
MX(E?]'&?$#_Q'?XW_P#S$4 '_$6!_P $2O\ HXSX@?\ B._QO_\ F(H /^(L
M#_@B5_T<9\0/_$=_C?\ _,10 ?\ $6!_P1*_Z.,^('_B._QO_P#F(H /^(L#
M_@B5_P!'&?$#_P 1W^-__P Q% !_Q%@?\$2O^CC/B!_XCO\ &_\ ^8B@ _XB
MP/\ @B5_T<9\0/\ Q'?XW_\ S$4 '_$6!_P1*_Z.,^('_B._QO\ _F(H /\
MB+ _X(E?]'&?$#_Q'?XW_P#S$4 '_$6!_P $2O\ HXSX@?\ B._QO_\ F(H
M/^(L#_@B5_T<9\0/_$=_C?\ _,10 ?\ $6!_P1*_Z.,^('_B._QO_P#F(H /
M^(L#_@B5_P!'&?$#_P 1W^-__P Q% !_Q%@?\$2O^CC/B!_XCO\ &_\ ^8B@
M _XBP/\ @B5_T<9\0/\ Q'?XW_\ S$4 '_$6!_P1*_Z.,^('_B._QO\ _F(H
M /\ B+ _X(E?]'&?$#_Q'?XW_P#S$4 '_$6!_P $2O\ HXSX@?\ B._QO_\
MF(H /^(L#_@B5_T<9\0/_$=_C?\ _,10 ?\ $6!_P1*_Z.,^('_B._QO_P#F
M(H /^(L#_@B5_P!'&?$#_P 1W^-__P Q% !_Q%@?\$2O^CC/B!_XCO\ &_\
M^8B@ _XBP/\ @B5_T<9\0/\ Q'?XW_\ S$4 '_$6!_P1*_Z.,^('_B._QO\
M_F(H /\ B+ _X(E?]'&?$#_Q'?XW_P#S$4 '_$6!_P $2O\ HXSX@?\ B._Q
MO_\ F(H /^(L#_@B5_T<9\0/_$=_C?\ _,10 ?\ $6!_P1*_Z.,^('_B._QO
M_P#F(H /^(L#_@B5_P!'&?$#_P 1W^-__P Q% !_Q%@?\$2O^CC/B!_XCO\
M&_\ ^8B@ _XBP/\ @B5_T<9\0/\ Q'?XW_\ S$4 '_$6!_P1*_Z.,^('_B._
MQO\ _F(H /\ B+ _X(E?]'&?$#_Q'?XW_P#S$4 '_$6!_P $2O\ HXSX@?\
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M,^('_B._QO\ _F(H /\ B+ _X(E?]'&?$#_Q'?XW_P#S$4 '_$6!_P $2O\
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M_P $2O\ HXSX@?\ B._QO_\ F(H /^(L#_@B5_T<9\0/_$=_C?\ _,10 ?\
M$6!_P1*_Z.,^('_B._QO_P#F(H /^(L#_@B5_P!'&?$#_P 1W^-__P Q% !_
MQ%@?\$2O^CC/B!_XCO\ &_\ ^8B@ _XBP/\ @B5_T<9\0/\ Q'?XW_\ S$4
M'_$6!_P1*_Z.,^('_B._QO\ _F(H /\ B+ _X(E?]'&?$#_Q'?XW_P#S$4 '
M_$6!_P $2O\ HXSX@?\ B._QO_\ F(H /^(L#_@B5_T<9\0/_$=_C?\ _,10
M ?\ $6!_P1*_Z.,^('_B._QO_P#F(H /^(L#_@B5_P!'&?$#_P 1W^-__P Q
M% !_Q%@?\$2O^CC/B!_XCO\ &_\ ^8B@ _XBP/\ @B5_T<9\0/\ Q'?XW_\
MS$4 '_$6!_P1*_Z.,^('_B._QO\ _F(H /\ B+ _X(E?]'&?$#_Q'?XW_P#S
M$4 '_$6!_P $2O\ HXSX@?\ B._QO_\ F(H /^(L#_@B5_T<9\0/_$=_C?\
M_,10 ?\ $6!_P1*_Z.,^('_B._QO_P#F(H /^(L#_@B5_P!'&?$#_P 1W^-_
M_P Q% !_Q%@?\$2O^CC/B!_XCO\ &_\ ^8B@ _XBP/\ @B5_T<9\0/\ Q'?X
MW_\ S$4 '_$6!_P1*_Z.,^('_B._QO\ _F(H /\ B+ _X(E?]'&?$#_Q'?XW
M_P#S$4 '_$6!_P $2O\ HXSX@?\ B._QO_\ F(H /^(L#_@B5_T<9\0/_$=_
MC?\ _,10 ?\ $6!_P1*_Z.,^('_B._QO_P#F(H /^(L#_@B5_P!'&?$#_P 1
MW^-__P Q% !_Q%@?\$2O^CC/B!_XCO\ &_\ ^8B@ _XBP/\ @B5_T<9\0/\
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M_P!'&?$#_P 1W^-__P Q% !_Q%@?\$2O^CC/B!_XCO\ &_\ ^8B@ _XBP/\
M@B5_T<9\0/\ Q'?XW_\ S$4 '_$6!_P1*_Z.,^('_B._QO\ _F(H /\ B+ _
MX(E?]'&?$#_Q'?XW_P#S$4 '_$6!_P $2O\ HXSX@?\ B._QO_\ F(H /^(L
M#_@B5_T<9\0/_$=_C?\ _,10 ?\ $6!_P1*_Z.,^('_B._QO_P#F(H /^(L#
M_@B5_P!'&?$#_P 1W^-__P Q% !_Q%@?\$2O^CC/B!_XCO\ &_\ ^8B@ _XB
MP/\ @B5_T<9\0/\ Q'?XW_\ S$4 '_$6!_P1*_Z.,^('_B._QO\ _F(H /\
MB+ _X(E?]'&?$#_Q'?XW_P#S$4 '_$6!_P $2O\ HXSX@?\ B._QO_\ F(H
M/^(L#_@B5_T<9\0/_$=_C?\ _,10 ?\ $6!_P1*_Z.,^('_B._QO_P#F(H /
M^(L#_@B5_P!'&?$#_P 1W^-__P Q% !_Q%@?\$2O^CC/B!_XCO\ &_\ ^8B@
M _XBP/\ @B5_T<9\0/\ Q'?XW_\ S$4 '_$6!_P1*_Z.,^('_B._QO\ _F(H
M /\ B+ _X(E?]'&?$#_Q'?XW_P#S$4 '_$6!_P $2O\ HXSX@?\ B._QO_\
MF(H /^(L#_@B5_T<9\0/_$=_C?\ _,10 ?\ $6!_P1*_Z.,^('_B._QO_P#F
M(H /^(L#_@B5_P!'&?$#_P 1W^-__P Q% !_Q%@?\$2O^CC/B!_XCO\ &_\
M^8B@ _XBP/\ @B5_T<9\0/\ Q'?XW_\ S$4 '_$6!_P1*_Z.,^('_B._QO\
M_F(H /\ B+ _X(E?]'&?$#_Q'?XW_P#S$4 '_$6!_P $2O\ HXSX@?\ B._Q
MO_\ F(H /^(L#_@B5_T<9\0/_$=_C?\ _,10 ?\ $6!_P1*_Z.,^('_B._QO
M_P#F(H /^(L#_@B5_P!'&?$#_P 1W^-__P Q% !_Q%@?\$2O^CC/B!_XCO\
M&_\ ^8B@ _XBP/\ @B5_T<9\0/\ Q'?XW_\ S$4 '_$6!_P1*_Z.,^('_B._
MQO\ _F(H /\ B+ _X(E?]'&?$#_Q'?XW_P#S$4 '_$6!_P $2O\ HXSX@?\
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M,^('_B._QO\ _F(H /\ B+ _X(E?]'&?$#_Q'?XW_P#S$4 '_$6!_P $2O\
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M_P $2O\ HXSX@?\ B._QO_\ F(H /^(L#_@B5_T<9\0/_$=_C?\ _,10 ?\
M$6!_P1*_Z.,^('_B._QO_P#F(H /^(L#_@B5_P!'&?$#_P 1W^-__P Q% !_
MQ%@?\$2O^CC/B!_XCO\ &_\ ^8B@ _XBP/\ @B5_T<9\0/\ Q'?XW_\ S$4
M'_$6!_P1*_Z.,^('_B._QO\ _F(H /\ B+ _X(E?]'&?$#_Q'?XW_P#S$4 '
M_$6!_P $2O\ HXSX@?\ B._QO_\ F(H /^(L#_@B5_T<9\0/_$=_C?\ _,10
M ?\ $6!_P1*_Z.,^('_B._QO_P#F(H /^(L#_@B5_P!'&?$#_P 1W^-__P Q
M% !_Q%@?\$2O^CC/B!_XCO\ &_\ ^8B@ _XBP/\ @B5_T<9\0/\ Q'?XW_\
MS$4 '_$6!_P1*_Z.,^('_B._QO\ _F(H /\ B+ _X(E?]'&?$#_Q'?XW_P#S
M$4 '_$6!_P $2O\ HXSX@?\ B._QO_\ F(H /^(L#_@B5_T<9\0/_$=_C?\
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MW^-__P Q% !_Q%@?\$2O^CC/B!_XCO\ &_\ ^8B@ _XBP/\ @B5_T<9\0/\
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M_P!'&?$#_P 1W^-__P Q% !_Q%@?\$2O^CC/B!_XCO\ &_\ ^8B@ _XBP/\
M@B5_T<9\0/\ Q'?XW_\ S$4 '_$6!_P1*_Z.,^('_B._QO\ _F(H /\ B+ _
MX(E?]'&?$#_Q'?XW_P#S$4 '_$6!_P $2O\ HXSX@?\ B._QO_\ F(H /^(L
M#_@B5_T<9\0/_$=_C?\ _,10 ?\ $6!_P1*_Z.,^('_B._QO_P#F(H /^(L#
M_@B5_P!'&?$#_P 1W^-__P Q% !_Q%@?\$2O^CC/B!_XCO\ &_\ ^8B@ _XB
MP/\ @B5_T<9\0/\ Q'?XW_\ S$4 '_$6!_P1*_Z.,^('_B._QO\ _F(H /\
MB+ _X(E?]'&?$#_Q'?XW_P#S$4 '_$6!_P $2O\ HXSX@?\ B._QO_\ F(H
M/^(L#_@B5_T<9\0/_$=_C?\ _,10 ?\ $6!_P1*_Z.,^('_B._QO_P#F(H /
M^(L#_@B5_P!'&?$#_P 1W^-__P Q% !_Q%@?\$2O^CC/B!_XCO\ &_\ ^8B@
M _XBP/\ @B5_T<9\0/\ Q'?XW_\ S$4 '_$6!_P1*_Z.,^('_B._QO\ _F(H
M /\ B+ _X(E?]'&?$#_Q'?XW_P#S$4 '_$6!_P $2O\ HXSX@?\ B._QO_\
MF(H /^(L#_@B5_T<9\0/_$=_C?\ _,10 ?\ $6!_P1*_Z.,^('_B._QO_P#F
M(H /^(L#_@B5_P!'&?$#_P 1W^-__P Q% !_Q%@?\$2O^CC/B!_XCO\ &_\
M^8B@ _XBP/\ @B5_T<9\0/\ Q'?XW_\ S$4 '_$6!_P1*_Z.,^('_B._QO\
M_F(H /\ B+ _X(E?]'&?$#_Q'?XW_P#S$4 '_$6!_P $2O\ HXSX@?\ B._Q
MO_\ F(H /^(L#_@B5_T<9\0/_$=_C?\ _,10 ?\ $6!_P1*_Z.,^('_B._QO
M_P#F(H /^(L#_@B5_P!'&?$#_P 1W^-__P Q% !_Q%@?\$2O^CC/B!_XCO\
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MUY8W'F6MS-$X!]'T ?_1_OXH * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@#__TO[^* "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H __]/^_B@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * /__4_OXH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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ME5I/_P D/(EXA81/W,MQ#7]ZM3B_N49?F>E^"O\ @N#^S'KEW:V7C'P)\6?
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M7T\OH^YHH7AQ%E[J?RRP6(A#_P #52;_ /*?W'F+Q"PG-9Y;B%'NJU)R_P#
M>5+_ ,F/T7_9%_;M^#O[9,?B:W^'.G>,]!UWP;:Z;>>(M"\8:38VDMO;:K-=
M6]G<6.H:1JFL:;?02364Z ?:+>[0!6ELX@PK\TXR\/\ .^"7A99G4P.(P^-G
M5IX;$8*M.<92HQA*<9TZU*C5IR49Q^S*'13=CZ;)>(,#GBJK"QKTZE!0=6G7
MA&+2G=1<90G.$DW%]4]-8H^U*^&/="@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M/?'+AG+*T\/E6%Q>>U*<G&5>E*&#P+MH_98BK&I6JV>G-'">RDO>IU9QL<6
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MHJ/^(,< ?]"S%?\ ASQ__P O#_73B#_H*I?^$N'_ /E8?\/>OVZO^BE>'/\
MPVW@3_Y14?\ $&. /^A9BO\ PYX__P"7A_KIQ!_T%4O_  EP_P#\K#_A[U^W
M5_T4KPY_X;;P)_\ **C_ (@QP!_T+,5_X<\?_P#+P_UTX@_Z"J7_ (2X?_Y6
M'_#WK]NK_HI7AS_PVW@3_P"45'_$&. /^A9BO_#GC_\ Y>'^NG$'_052_P#"
M7#__ "L/^'O7[=7_ $4KPY_X;;P)_P#**C_B#' '_0LQ7_ASQ_\ \O#_ %TX
M@_Z"J7_A+A__ )6'_#WK]NK_ **5X<_\-MX$_P#E%1_Q!C@#_H68K_PYX_\
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MX_\ ^7A_KIQ!_P!!5+_PEP__ ,K#_A[U^W5_T4KPY_X;;P)_\HJ/^(,< ?\
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M_052_P#"7#__ "L/^'O7[=7_ $4KPY_X;;P)_P#**C_B#' '_0LQ7_ASQ_\
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M^(,< ?\ 0LQ7_ASQ_P#\O#_73B#_ *"J7_A+A_\ Y6'_  ]Z_;J_Z*5X<_\
M#;>!/_E%1_Q!C@#_ *%F*_\ #GC_ /Y>'^NG$'_052_\)</_ /*P_P"'O7[=
M7_12O#G_ (;;P)_\HJ/^(,< ?]"S%?\ ASQ__P O#_73B#_H*I?^$N'_ /E8
M?\/>OVZO^BE>'/\ PVW@3_Y14?\ $&. /^A9BO\ PYX__P"7A_KIQ!_T%4O_
M  EP_P#\K#_A[U^W5_T4KPY_X;;P)_\ **C_ (@QP!_T+,5_X<\?_P#+P_UT
MX@_Z"J7_ (2X?_Y6'_#WK]NK_HI7AS_PVW@3_P"45'_$&. /^A9BO_#GC_\
MY>'^NG$'_052_P#"7#__ "L/^'O7[=7_ $4KPY_X;;P)_P#**C_B#' '_0LQ
M7_ASQ_\ \O#_ %TX@_Z"J7_A+A__ )6'_#WK]NK_ **5X<_\-MX$_P#E%1_Q
M!C@#_H68K_PYX_\ ^7A_KIQ!_P!!5+_PEP__ ,K#_A[U^W5_T4KPY_X;;P)_
M\HJ/^(,< ?\ 0LQ7_ASQ_P#\O#_73B#_ *"J7_A+A_\ Y6'_  ]Z_;J_Z*5X
M<_\ #;>!/_E%1_Q!C@#_ *%F*_\ #GC_ /Y>'^NG$'_052_\)</_ /*P_P"'
MO7[=7_12O#G_ (;;P)_\HJ/^(,< ?]"S%?\ ASQ__P O#_73B#_H*I?^$N'_
M /E8?\/>OVZO^BE>'/\ PVW@3_Y14?\ $&. /^A9BO\ PYX__P"7A_KIQ!_T
M%4O_  EP_P#\K#_A[U^W5_T4KPY_X;;P)_\ **C_ (@QP!_T+,5_X<\?_P#+
MP_UTX@_Z"J7_ (2X?_Y6'_#WK]NK_HI7AS_PVW@3_P"45'_$&. /^A9BO_#G
MC_\ Y>'^NG$'_052_P#"7#__ "L/^'O7[=7_ $4KPY_X;;P)_P#**C_B#' '
M_0LQ7_ASQ_\ \O#_ %TX@_Z"J7_A+A__ )6'_#WK]NK_ **5X<_\-MX$_P#E
M%1_Q!C@#_H68K_PYX_\ ^7A_KIQ!_P!!5+_PEP__ ,K#_A[U^W5_T4KPY_X;
M;P)_\HJ/^(,< ?\ 0LQ7_ASQ_P#\O#_73B#_ *"J7_A+A_\ Y6'_  ]Z_;J_
MZ*5X<_\ #;>!/_E%1_Q!C@#_ *%F*_\ #GC_ /Y>'^NG$'_052_\)</_ /*P
M_P"'O7[=7_12O#G_ (;;P)_\HJ/^(,< ?]"S%?\ ASQ__P O#_73B#_H*I?^
M$N'_ /E8?\/>OVZO^BE>'/\ PVW@3_Y14?\ $&. /^A9BO\ PYX__P"7A_KI
MQ!_T%4O_  EP_P#\K#_A[U^W5_T4KPY_X;;P)_\ **C_ (@QP!_T+,5_X<\?
M_P#+P_UTX@_Z"J7_ (2X?_Y6'_#WK]NK_HI7AS_PVW@3_P"45'_$&. /^A9B
MO_#GC_\ Y>'^NG$'_052_P#"7#__ "L^Q?V _P#@HY^U?\>?VMOA/\)_B7XX
MT76/!/BK_A._[:TZT\$>$](N+C^POAIXR\2:;Y>HZ9I-M>V_DZMH]A.WD3)Y
MJ1-!)NADD1OBO$3PRX0X>X.SC-\KP%>CCL'_ &?["I/'8NM&/M\TP.%JWI5:
MLJ<KT:U2*O%V;4E9I'M\.<3YQF.<X/!XJO3G0K?6.>,</1@W[/"UZL;2A!25
MIPB]'K:VQ_2=7\P'ZD% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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MM&,;1BE%)+^@J%&EAJ-.A1A&G2HPC3IPBK*,(JR2_K5ZLZ2N8U"@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H ^=OVOO^33/V
MH?\ LW;XU_\ JM?$M?2\&?\ )8<*?]E+D7_JTPIYF=?\B;-O^Q9C_P#U%JG\
M(%?Z!G\]!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?HE_P2@_Y/\ ?@)_W5+_
M -4M\1J_-?%__DW?$/\ W2?_ %>98?3<'?\ )1Y=_P!S?_J!B3^S:OXA/W(*
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M^6I5PE+ QL[/ES'%4,#6LUU5#$57\CXWA;#QQ.?9=3FKQA5E7MYX:E4KP_\
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@#YV_:^_Y-,_:A_[-V^-?_JM?$M?2\&?\EAPI_V4N1?^
MK3"GF9U_R)LV_P"Q9C__ %%JG\(%?Z!G\]!0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 ?HE_P2@_Y/]^ G_=4O_5+?$:OS7Q?_ .3=\0_]TG_U>98?3<'?\E'E
MW_<W_P"H&)/[-J_B$_<@H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M-GO\F%_\*%_\B?E77ZX?'G]Q/[ /_)E_[-O_ &2SP]_Z+DK^"O$/_DN.)_\
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0!\[?M??\FF?M0_]F[?&O_U6OB6OI>#/^2PX4_[*7(O_ %:84\S.O^1-
MFW_8LQ__ *BU3^$"O] S^>@H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /T2_X)
M0?\ )_OP$_[JE_ZI;XC5^:^+_P#R;OB'_ND_^KS+#Z;@[_DH\N_[F_\ U Q)
M_9M7\0G[D% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M_P '8O[?O[<7[+__  4N^'WP[_9P_:Z_:-^!/@*^_9"^&'BJ]\&_";XP^._
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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MCJ6L65GJ-O/;30W$5GJNH6NY-UO>3Q,DC 'T'0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0!\[?M??\FF?M0_]F[?&O_U6OB6OI>#/^2PX4_[*7(O_ %:84\S.O^1-
MFW_8LQ__ *BU3^$"O] S^>@H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /T2_X)
M0?\ )_OP$_[JE_ZI;XC5^:^+_P#R;OB'_ND_^KS+#Z;@[_DH\N_[F_\ U Q)
M_9M7\0G[D% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0!__3_OXH * "@ H * "@#^.W_@KW_P GT_$G_L6_AM_Z@NAU_:?@Q_R0
M.6_]A>9_^IU8_$N-/^2@Q7_7K"_^H],_7+_@AG_R:G\1O^SA/$__ *KCX5U^
M.>/G_)7Y9_V3>$_]6>;GV?A__P B?%?]C*K_ .HN$/V1U33-/UK3-1T;5K2#
M4-*U:QN],U*PN4$EM>Z??V\EK>6EQ&>'@N;:62&5#PT;LO>OQ.E5J4*M*M1G
M*G5HU(5:52#M*G4IR4X3B^DHR2:?1I'W$H1G&4)I2A.+A*+V<9*S379K0_A
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M@A/[URK-<LXBRNAF.7U:6,P&-HZ:1DK27+5P]>D[\E2#O3K49J\6G%JV_P"
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MK84 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0!_G8_\ !\+_ ,EK_P""??\ V2WX\?\ J6?#
MF@#^-3]F?X\_$G]D3]H/X%?M.?#=KC3/&_PA\?>&/BEX-DN1<6MAKR^%_$#+
M>:7<R*H^W>&_$(T[6/"7B"*+S8+NPGUC2Y@Q^T1  _W#OV;_ (]> ?VI/@%\
M'/VC?A;?_P!H_#[XV?#GPG\2/"TSO&UU;Z;XJT>UU0:7J:1,RVVM:)//-HVN
M6#$3:=K%A?6$Z)/;2(H![70 4 ?DO_P6[_;]M_\ @F]_P3B^/7Q_TK5(=/\
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MG7M:BFFNVL-'T_R[/3[1<+'!;0KA(T7>TDA:1@#[X_XA'?\ @C%_T2_XV?\
MA^_&W_Q= ']&?PS^'OA?X1_#CX?_  H\#VD^G^"_ACX(\*?#WPA875Y<ZC<V
M/A?P7H-AX;T"TN-0O));N^GMM)TVTAEO+J62YN9$::>1Y79B =O0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M@#[9H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H ^=OVOO^33/VH?\ LW;XU_\ JM?$
MM?2\&?\ )8<*?]E+D7_JTPIYF=?\B;-O^Q9C_P#U%JG\(%?Z!G\]!0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 ?HE_P2@_Y/\ ?@)_W5+_ -4M\1J_-?%__DW?
M$/\ W2?_ %>98?3<'?\ )1Y=_P!S?_J!B3^S:OXA/W(* "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M?4MCC?Y(&>?+Q\M??4?I!9A%?[1PU@ZCMO1S&M05_2>%Q&GE?YGST_#S#O\
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MSVYH/24)+I*#C)=&C\H?B'_P0_\ V;/$=Z]]X \=?$OX;K*S%M):ZTOQCHD
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M[11\AC>"LJQV+KXRK7Q\:F(J2JSC3JX=4U*6Z@I86<DO)R?J>=?\.-/V3/\
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M6?:0A"G"-.G&,(0BHPA"*C&$8JT8QBK**25DDK)&C6904 % !0 4 % !0 4
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M_9\3P[X/O(Y09[.Y\"?#OP[X.\,:MIID>W@\56?B6]MPG]I2@@']O7_!H/\
M\H<?"O\ V</\=/\ TYZ%0!]K?\%Y/^"HWQ&_X)(_L=>!/VDOA?\ #'P3\5O$
M?C#]HGP;\%9?#WCW4-=T[1+'2_$OP\^*_C:YUJ.3P]/;7TU_;S_#JTL(+=IX
M[?RM2N)I-SP1(P!XA_P;\?\ !9?XN_\ !8;P)^TOXL^+/PA^''PENO@;XM^&
M_AW1;7X=ZAXFU"WUJW\;:/XKU*\GU0^);V]DBFLI/#T$=L+0QHR3R^:"RI@
M_H>H ^)O^"CW[4WB+]B7]AG]IG]J[PEX7T7QKXE^!OPSU'QMHGA;Q%=7UEH6
MM:A;7EA906FJ7.F%;^.S#7OFRBT>*:18O*26$OYB '\[_P#P0I_X.._V@O\
M@K#^V=XB_9D^*'[/?P;^%WAS1?@/XW^+4/B3P#J_C:^UN;5/"OBSX>^'K;2I
M(?$.IWE@-/N;?QC=SSNL0N%FM+81N$:0, ?UK>,/^11\4_\ 8N:W_P"FRYH
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M9?"3QCXAT_6_"GQ*-E#)-J7_  IWQ\+;1F\2ZI96L+ZG?>#-<T#P]XIM]/\
MM-SHMMXITS1M;UBQ /Z+Z /\N'_@\Z_Y2P?#/_LR/X1?^K<_: H _N4_X-^O
M^4,__!/K_LA=O_ZE?B>@#S__ (+W_P#!5KXE_P#!(G]E?X5_'OX6?"WP-\5]
M?^(7Q^T7X076B>/]1U_3M'TW2M1^'GQ%\:3:M;MX=GM;V;4$N?!5I91123K;
M""\N)&5Y$B  .!_X-_O^"PWQ9_X+ _"C]H;X@_%CX2_#OX37_P &OB'X1\&Z
M18?#S4/$M_::O:>(O#=[K=Q=ZBWB2]O9H[FWFM5AA6U9(C$S%U+8- ']!% '
M\V?_  6)_P"#E']ES_@EWXBU'X$>!?#$O[3G[6=G9VMQK'PVT#Q':^'O ?PL
M74(Q-9K\5_'<5IK=SI_B.6SDBU6S\ :!H>I:]/I[V\VOWO@^TU71M0OP#^17
MQM_P>0_\%9?$>N3:AX6\.?LH_#S11>M-9^']&^$OBC7%6Q#?N;+4-4\6?$C6
MKV[D\L*+F[L_[*,TN^2W@LT9((P#]*O^"?/_  >@^*=5^('A[P!_P4A^!_@/
M1O NNZA'IUQ\??V>K'Q5IL_@=;ADBMM4\8_"?Q!K7C2X\3:-#-)YFMZEX-\1
MZ7JVF:=$T^E>"_$MZ!92@'\HW_!53Q-X=\:?\%:?VW?&/A#7-*\3^$_%?[97
MQ5\2>&/$F@W]MJFA^(/#VN?$6^U/1M;T;4[*2:SU'2]5TZYMK[3[ZUEEMKNT
MGBG@D>)U8@'^V+0 4 % !0 4 ?Y2/_!WW_RF+\1_]FY_ S_TC\14 ?Z!W_!"
MO_E#[_P3N_[-A^'O_I)-0!^L% '\&7[!?_!V]^U'^UW^W)^S5^RQXE_93^ 7
MA'PG\<_C?X1^%VJ^)-"\0_$.\\0Z%I/B364TV74-.6_U0Z;<:C:PN'C^TV@M
MI)!EH%4[  ?WFT % '\)'_!27_@[-_:?_8F_;I_:7_91\$_LK_ 7Q?X5^!GQ
M&N? ^C>)_%/B#XA1>(-;MK32]+NWO]3BTG5+/3H9I9[R7;#:VZQQ0B.,M*ZM
M*X!_<YX:U237/#GA_6IHD@FUC1-*U26&(L8H9-0L(+MXHRV6*1M*40L2VT#/
M- '\E?\ P7=_X.-_C[_P2:_;(\(?LS?"S]GKX/\ Q1T#Q!\ ?!GQ?N_$OQ U
MKQI9:O%JOBCQK\2?"\VDVUKX<O[&R73[2U\#VES%)();B2>]N S+''$M $GQ
MX_X.M?@U^SA^P9^RO\8_$_PQT;XF_MM_M-?"*Q^*7_#-?@'Q+?Z)X&^&6BZI
MKFOZ+I_B3X@^.-3L?$6HZ)I5Z-$DN=!\+VUCJOBWQ'Y9EE3P[H-Y:>)* /YM
M/$O_  >2?\%9]7\3#6=#\,_LE>$M"BO)I8/!]A\(_%^J:;-9EV^SV>IZIKGQ
M1U#Q!</%%L6:ZTW4]',\JM*D-NC"% #^CK_@BQ_P=0^!_P!OGXI>%/V4_P!L
M?X>^#?V??VB?',Z:1\,?'G@?4]6C^"WQ:\6W$Z1Z?X#M]&\4WVL^(?AUXVUD
M2+;^%=/U3Q9XLTCQAJ<;:/9:QI7B+4/#_AW60#Z!_P""SW_!S)\ ?^"8WB_4
M/V=/@SX*L?VFOVL=/M5;Q=X:_P"$CET#X9_!66^L8;S28OB-X@T^PU&_UWQ5
M<P75M?\ _"N_#1LKZ#3&\WQ#XF\*7%QI=OJ(!_)GK/\ P>-?\%==3UQ=6L=,
M_9-\.Z>K,?\ A&-(^#'B6XT1U+ JKW.O_$[6_$?R ;08]?C)!).3@@ _HF_X
M(S?\'7'A;]N#XQ>#?V4_VUOAEX-^ _QL^)&HVOA[X5?$_P"'-]K2_!WX@^,[
MYH;;2O .J>'?%.H:]XA^'WB?Q#=-]E\*W<_BSQ/H?B/5YX- :;0-4GTB#6@#
M^R&@#G/&'C#PG\/?"OB+QSX\\3:#X,\%>$=&U#Q%XJ\6^*=6L-!\-^&] TFV
MDO-4UG7-:U2>UT[2]+T^TAEN;R^O;B&VMH(WDED5%)H _B(_;_\ ^#S[X9?#
MCQ7KGP[_ .">OP&L_CD-$N;_ $Z3X[_&V\USPM\-M5O;25H8KOP7\-O#\NF^
M.?%/ANYQYT.L>(_$WPWU"01E(O#\EM-#J! /Q&U'_@\0_P""OM[JD>H6R_LL
M:/:(Y9M#T[X*:O+I<JD\1O+JWQ"U36PB]%,6L1R8^\['F@#]'OV,O^#UWXDV
MOB?1O#O[?/[+W@K6O!EW.+74_B=^S')K7ASQ1H$#.HCU*Y^&/Q!\4>)=(\6>
M6"1?0Z;X\\&ND6ZYL;2ZFC73K@ _O(_9U_:-^"7[67P<\$_'W]GCXB>'_BC\
M)OB#IBZIX9\6^'+AI+>8 F*]TS4[*XC@U+0O$.C7:2Z;K_AO6[.PUS0=5M[G
M3-6L+.]MY8$ /6M:OVTK1M6U1(Q,VFZ9?WZPLQ196L[66X6-F )4.8PI8 E0
M<@'&* /X3O\ @G=_P=L_M.?ME_MO_LV_LO>-OV7?V?O G@SXV?$W3O!6O^+=
M#\1_$";6?#FD7EK?74^I69U;5VTII[5+0%GO8!;!-[NB@< "_P#!3S_@\;N/
MA1\7O%7P7_X)O?"GX7?%31? NKZGX<UW]HOXR'Q)X@\#^,M5L'^QWDWPF\&>
M"?$W@VZO_#5A>1SKIGCK7?%4]CXHVB[TSPJ="%CJ^M 'Z$_\&V7_  6Y_:X_
MX*T>*/VI_!W[4'A;X'Z0OP-\-?"SQ!X4UGX2^$?%OA34M2E\<ZIXTTW5;3Q'
M%KWCWQ?IEU!:IX9LIM-;2[#1YHI+B]%T]Y&]NMJ ?H1_P5L_X+N?L?\ _!(_
M3M$\-?$V+Q%\7/VA/&6B/X@\&?L__#FXTN'Q!_8)EN[2S\6?$#Q%JDO]F_#[
MP;J&I6-SIFGZE-9ZYXAU>ZM[Q_#WA/6K/2M9N=- /XM/B_\ \'G_ /P4P\8Z
MIJJ_"3X/?LI_!GPQ+=SOHD$W@_QY\2/&FGV+2$V]MJOB;7_B!IOA?6+J&+8D
MEY9_#K08IY \BV,"LL,8!I?!;_@]&_X*-^#M>L&^-?P._9=^-/A",K_:FG:)
MH/CKX3^-+Q0RY_L[Q;8>,?%WAK3'9 X9KGX<ZNFYD9(E"%' /])_X+?$9/C#
M\'/A-\6X](;P_'\4OAGX$^(R:"]\-3?1$\;^%M*\3+I#:DMI8+J#::NIBS:^
M%C9"[,/GBTMA)Y* 'IE !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M/MKA@-7^,?Q(AU>Q\+VNL6OS1Y\#?"]+;4=!F4QR$?%77TGC=([.0 'ZJ_\
M!H#_ ,$Q?"WP9_99OO\ @HK\2/#%M=?&S]I6?Q#X<^#NH:C$DMUX%_9_\/:O
M_8EU=:3#(H?3-8^)_C/0]7O]3O-K2W7@O0O!O]G3V]GK&L17X!_9O0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 ?.W[7W_)IG[4/_9NWQK_]5KXEKZ7@
MS_DL.%/^RER+_P!6F%/,SK_D39M_V+,?_P"HM4_A K_0,_GH* "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@#]$O^"4'_ "?[\!/^ZI?^J6^(U?FOB_\ \F[XA_[I
M/_J\RP^FX._Y*/+O^YO_ -0,2?V;5_$)^Y!0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 ?_U?[^* "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M6 'FWM]J"W5]?W##?<WMQ/<29>1C0!]<T % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % 'SM^U]_P FF?M0_P#9NWQK_P#5:^):^EX,_P"2PX4_[*7(O_5I
MA3S,Z_Y$V;?]BS'_ /J+5/X0*_T#/YZ"@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H _1+_@E!_R?[\!/^ZI?^J6^(U?FOB__P F[XA_[I/_ *O,L/IN#O\ DH\N
M_P"YO_U Q)_9M7\0G[D% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0!__];^_B@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M<?"O_9P_QT_].>A4 >)?\'IO_**SX)?]GZ?"G_U0?[3E 'R'_P &/'_)&?\
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MNZI>3WL^F?'>^\"023DEH=-^&/ASP]\.-)LXQ@!8+'3?"MK:0 #'E0J>22Q
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MZ9I?CKPU\0;'1;"VM-*\/0:)IMO';* ?WF_\$S/^#A+_ ()[?\%.-2TOX=>
M/&.K_!?]H>_M!*GP"^-<6F^'O$NOW,,>Z]B^&_B:ROK[PA\1A#LGN(-,T?5+
M;QJ^EP2ZM?\ @S2[."Y:W /W-H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M)97EM=8;X>:!:^(=+NF4E#>Z/K]MJ>DWP1F07EE.J,R@,0#[0H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * /G;]K[_DTS]J'_LW;XU_^JU\2U]+P9_R6
M'"G_ &4N1?\ JTPIYF=?\B;-O^Q9C_\ U%JG\(%?Z!G\]!0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 ?HE_P $H/\ D_WX"?\ =4O_ %2WQ&K\U\7_ /DW?$/_
M '2?_5YEA]-P=_R4>7?]S?\ Z@8D_LVK^(3]R"@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H __7_OXH * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MJC_MJ?LXV<[02R0LWA_4/BGX:T_Q=$[Q$/\ 9YO"=SK4-TG*2VKRQ2H\3NA
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M;"Z^'_Q*O=/)?#W&@73_  T%Y;A1-):ZS%<1"2&RNVMP#^_B@#G?%_BWPSX
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M-0UAX["WT;P]HOQHT/1O&MWJ,MSY<5BFGZ&-6EN9;@QI:^4SRE%C; !_MQ4
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MU4626]C]OU^<V=G86YCL;8 _6N@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@#\I_^"V7[;B_\$_?^":'[3G[0&E:JNE?$:3P9+\,/@LZ2B*^;
MXO?%(MX/\(:EIJ$I]HN/!O\ :%_\0[JW#H9-(\'ZD5.5 (!_EU_\$-O^"8NG
M?\%8?V[=&_9W\<Z[XV\*_!WP]\/?'/Q4^,_C'P!/H]KXPT?PQH-I;:)X>AT'
M4/$NA^)- @U37/B-XE\&Z7)_:>BZD3HL^N75M:O-9^9" ?VM_P#$%)_P3,_Z
M.,_;K_\ "[^ '_T.- !_Q!2?\$S/^CC/VZ__  N_@!_]#C0!^*'_  7C_P"#
M9KX$?\$TOV+;3]K7]E'XE?M"?$F#P=\3O"OAKXSZ/\8]9^'>N6.@^ O&XN]
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /G;]K[_DT
MS]J'_LW;XU_^JU\2U]+P9_R6'"G_ &4N1?\ JTPIYF=?\B;-O^Q9C_\ U%JG
M\(%?Z!G\]!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?HE_P $H/\ D_WX"?\
M=4O_ %2WQ&K\U\7_ /DW?$/_ '2?_5YEA]-P=_R4>7?]S?\ Z@8D_LVK^(3]
MR"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MKC]U<:O\/?!/P_U:PT6?/^LL[+XG:_'CA;T4 <Q\(_\ @^$\60ZEIUI\>/\
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M7_DM?_!/O_LEOQX_]2SX<T ?T#_\&G'_ "A/_9__ .RD_M"_^KD\64 ?TCT
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M'[7EAJ^@7?CB'X0I\08/&W[(W[4F@-+8R7;Z#J$/B7PUI]_X@T<10^&/C)X
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M"$R1Z-(5\L@'\M__  6;_P"#B?\ :)_X*Y:?I?[.?PU^'5U\!?V7&\2Z3?\
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MAWQ"D.5O_&U]!!:6L(!^L5U_P>K_ /!,Z/PY]NLOV>OVW[GQ.;9MGA^X\#?
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H _SF_\ @]/_ &WO^$Q^-G[.O[ 7A/5_-T3X-^'Y
M/C[\7K.UGWV\GQ(^(%I=:#\-M&U*#.8=5\(_#R+7?$$/R;9=,^+%HX<LI2,
M_3;_ (,R/V,?^%4?L4?&+]LOQ+I/D>*/VK/B-_PBG@:\N(<R?\*>^"$^J: M
M[I\TBA[=-?\ BCJOC^RU2"$>3=IX+T"XDDE,,*6X!_9=0 4 ?.G[7?[-_@[]
MK_\ 9?\ CW^S!X]6,>%_CG\+/&'PYO;UX%N9-#O/$&D7%MH?BBRA8A3JGA/7
M?[,\3:0Q_P!5JFDV<O\ !B@#_&0_96^,OQ5_X)7_ /!1[X:?%#6]*O\ 1_B1
M^Q]^T7>>'_BCX3MI#'>7EEX1\1:G\/OC1X!$K^1@>(_"S^,/"+3,$7R]2\[
M % '^VMX.\7>&_B!X1\*^//!NKVGB#PAXV\.:'XN\*Z]I[^98:WX;\2:9:ZS
MH>KV4A"F2TU+3+RUO+9\#=#,AP,XH _Q$/VHO&]Q\,_^"E?[1/Q'L["'5+OX
M??MR_%SQO:Z9<RO;V^HW'A3X^>(-=@L)YXE>2"&[DL%MY98T9XXY&=%9E H
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M /T\H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H ^=OVOO^33/VH?\ LW;XU_\ JM?$
MM?2\&?\ )8<*?]E+D7_JTPIYF=?\B;-O^Q9C_P#U%JG\(%?Z!G\]!0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 ?HE_P2@_Y/\ ?@)_W5+_ -4M\1J_-?%__DW?
M$/\ W2?_ %>98?3<'?\ )1Y=_P!S?_J!B3^S:OXA/W(* "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M'_!(CX6>"K/1/B_X-^+7[3GC-K)%U?QQX[^+?CKX>Q-J31D7%SX>\+?!C7O
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M\<8!^PU !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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MQ=X\\;F/7O$LT-QK=^VO_$?Q1XO\3S&]E@A/V>;6I+2V6-8[.WMX_DH ^H*
M/RF_;T_X(H?\$W_^"D&K'QC^TO\ L^Z9=_%46,6GQ?&CX>:QJWPV^*<EM;6\
M5G8QZYX@\+W%I9^-X],LX(K31[?X@Z3XMM='M4$&EV]G'E2 ?E=X7_X,Z_\
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M>0W !^H-U:V]]:W-E=1B:UO+>:UN82642V]Q&T4T9*%6 >-F4E65@#\I!P:
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M^7/[9_\ P1=_X)H_\%"OBOI7QO\ VO\ ]FL?%SXHZ+X'TGX<:;XH'Q@^/?@
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M?[3OB8:#K]K%-#;Z@- \8?&GQ!X7U,Q1W$H6VUC1=0L\L'-N72-E /V@H *
M/Q+_ &N?^#>#_@DK^V=XJU/X@_$C]ES1_ WQ'US4+[5M?\=? O7=9^#VJ>(M
M3U262ZU35/$>B>$KFV\$>(-:U.^E?4=1\0:SX4O=?OKYI;BYU25KF[$X!\#Z
M)_P9T_\ !(;2=;EU6_O/VKO$UA(ZLGAG6_C3X?M]$@4=8HI_#?PU\/\ B,HW
M1C/X@FDP/ED4\T ?M7^Q7_P2S_8%_P"">VF_9OV3OV:? 'PVU^6VDM-1^(]S
M:W?C'XM:Q;S@BYM=2^*7C.ZU[QP^F7#,[G0;;6[7P] SLMGI-M'A  ?H#0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MPHL<4,4:A(XHHT"I''&BA$1 %50%4  "@"2@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@#YV_:^_Y-,_:A_P"S=OC7_P"JU\2U]+P9_P EAPI_V4N1?^K3"GF9U_R)
MLV_[%F/_ /46J?P@5_H&?ST% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!^B7_!
M*#_D_P!^ G_=4O\ U2WQ&K\U\7_^3=\0_P#=)_\ 5YEA]-P=_P E'EW_ '-_
M^H&)/[-J_B$_<@H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M=_%.PU*U*WVC1R0 '^D90 4 % !0!_#5_P 'P'_)O'[!?_99_B__ .H/X6H
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M_P!4\"_$+Q5J-_/ BM=67A"U2Z=Q962Q@'^E30 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % '\[W_!U3_R@[_:U_[&/]F__P!:5^$U '\S/_!D3_R=K^VO_P!F
MZ>"O_5EVU '^D/0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!\[?M??\FF?
MM0_]F[?&O_U6OB6OI>#/^2PX4_[*7(O_ %:84\S.O^1-FW_8LQ__ *BU3^$"
MO] S^>@H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * /T2_X)0?\ )_OP$_[JE_ZI
M;XC5^:^+_P#R;OB'_ND_^KS+#Z;@[_DH\N_[F_\ U Q)_9M7\0G[D% !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M:CI^J6D=]8P-<:??6EY"'M[B&1P#_6<_X-6/^4'7[(__ &,/[2'_ *TQ\6Z
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M<)N*I<+XT^ 'Q7\+6T,@! <?VAJUG-$AR!<0P.!N1: /]B*@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * /A7_ (*2_L)^#?\ @I/^QW\4?V.O'WCCQ-\./#'Q
M/O/ 5]>>,/"%EI6HZ[I4W@'X@>&/B#8+:V6LQR:?<17U[X8@T^[678ZVMS+)
M#(DJ(: /SQ_X(_?\$!_@Y_P1^^)_Q=^)_P ,_C[\2_B_?_%WP'I'@+4M+\=>
M'?"VBV>D6>D>((_$$5_8RZ!^^FN99HQ;O'/^Z6([E^:@#]^* "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * /G;]K[_DTS]J'_LW;XU_^JU\2U]+P9_R6'"G_
M &4N1?\ JTPIYF=?\B;-O^Q9C_\ U%JG\(%?Z!G\]!0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 ?HE_P $H/\ D_WX"?\ =4O_ %2WQ&K\U\7_ /DW?$/_ '2?
M_5YEA]-P=_R4>7?]S?\ Z@8D_LVK^(3]R"@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M;F^(FCS:C;03;_(GETVTD\HJCHS(9' /EW_B!V^$G_20WXC?^(\^&?\ YZ]
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MZ1$'+6?Q1\4>*B$R#Y?@3X3?$+QO*3MQ\BQ>'G:0=#&&#?+D4 ?[)= !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 ?.W[7W_)IG[4/_9NWQK_ /5:^):^EX,_Y+#A3_LI<B_]6F%/,SK_
M )$V;?\ 8LQ__J+5/X0*_P! S^>@H * "@ H * "@ H * "@ H * "@ H *
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0!__U?[^* "@ H * "@ H _QTO\ @Y"_9PG_ &:_^"Q_[8VD16LD
M/A_XO^,[#]H_PQ=2!@-3@^.6DVOC;Q;=1!O^65K\3;WQWHP*DJS:4S#;GRT
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MX#_DWC]@O_LL_P 7_P#U!_"U 'YV?\&27_)\'[7O_9J=A_ZMWP10!_I44 %
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M&,47COXJQ1_"'P_IDN,*IU#P7XG^)M]&6/71654).^, _P!2Z@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * /G;]K[_DTS]J'_LW;XU_^JU\2U]+P9_R6'"G_ &4N1?\ JTPIYF=?\B;-
MO^Q9C_\ U%JG\(%?Z!G\]!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?HE_P $
MH/\ D_WX"?\ =4O_ %2WQ&K\U\7_ /DW?$/_ '2?_5YEA]-P=_R4>7?]S?\
MZ@8D_LVK^(3]R"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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MTR1QW6M:]JEU)=ZYXI\1WZPPC4O$WB;4]7\0:F8HCJ&I7+1H0 >]T ?Y>/\
MP=Z?\%%+;]IK]MSPU^QU\.?$<.J_";]B^PU#3?%S:5>)<:7K?[1/C&*SG\=K
M-):N;:\D^'&@6F@> TBG#7?A[Q8OQ(TPF)KFYBH _JD_X-6O^"=<G[$W_!.7
M2/C#XYT-]*^.'[:]QH?QH\6)>6[0:GHGPJM;&\@^!7A&X5U1U4>&=8U;XB21
M31QW=GJ'Q*OM)NU+:7&$ /Z:J "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H ^=OVOO^33/VH?^S=OC7_Z
MK7Q+7TO!G_)8<*?]E+D7_JTPIYF=?\B;-O\ L68__P!1:I_"!7^@9_/04 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % 'Z)?\$H/^3_?@)_W5+_U2WQ&K\U\7_P#D
MW?$/_=)_]7F6'TW!W_)1Y=_W-_\ J!B3^S:OXA/W(* "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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MF'^K^1_]"K _^$]/_(/^&&?V.O\ HV?X,?\ A!Z#_P#(E'^OW&O_ $5.>?\
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MT_\ (/\ AAG]CK_HV?X,?^$'H/\ \B4?Z_<:_P#14YY_X<,1_P#)A_J_D?\
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M *-G^#'_ (0>@_\ R)1_K]QK_P!%3GG_ (<,1_\ )A_J_D?_ $*L#_X3T_\
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M^#'_ (0>@_\ R)1_K]QK_P!%3GG_ (<,1_\ )A_J_D?_ $*L#_X3T_\ (/\
MAAG]CK_HV?X,?^$'H/\ \B4?Z_<:_P#14YY_X<,1_P#)A_J_D?\ T*L#_P"$
M]/\ R#_AAG]CK_HV?X,?^$'H/_R)1_K]QK_T5.>?^'#$?_)A_J_D?_0JP/\
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M_APQ'_R8?ZOY'_T*L#_X3T_\@_X89_8Z_P"C9_@Q_P"$'H/_ ,B4?Z_<:_\
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MCK_HV?X,?^$'H/\ \B4?Z_<:_P#14YY_X<,1_P#)A_J_D?\ T*L#_P"$]/\
MR#_AAG]CK_HV?X,?^$'H/_R)1_K]QK_T5.>?^'#$?_)A_J_D?_0JP/\ X3T_
M\@_X89_8Z_Z-G^#'_A!Z#_\ (E'^OW&O_14YY_X<,1_\F'^K^1_]"K _^$]/
M_(/^&&?V.O\ HV?X,?\ A!Z#_P#(E'^OW&O_ $5.>?\ APQ'_P F'^K^1_\
M0JP/_A/3_P CJ_!'[*7[-?PU\3Z9XU\ ? WX9>#O%NB_;?[)\1^'O"6DZ9K&
MG?VCI]WI-_\ 8[ZUMXYX/M>F7UY83[&'F6MS-"V4D85QX[B[BC-,)5P.8Y]F
MN-P=?D]MA<3C*U6C4]E4A6I\].4G&7)5IPJ1NM)0BUJD;8?)\JPM6%?#9?A:
M%:GS<E6G1A"<>:+A+EDE=7A)Q?DVCZ KYT](* "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@#_]#^_B@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /__1_OXH * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@#__TO[^* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H __]/^_B@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M$3^W]_X3_P#^"E !_P 19/\ UB)_;^_\)_\ _!2@ _XBR?\ K$3^W]_X3_\
M^"E !_Q%D_\ 6(G]O[_PG_\ \%* #_B+)_ZQ$_M_?^$__P#@I0 ?\19/_6(G
M]O[_ ,)__P#!2@ _XBR?^L1/[?W_ (3_ /\ @I0 ?\19/_6(G]O[_P )_P#_
M  4H /\ B+)_ZQ$_M_?^$_\ _@I0 ?\ $63_ -8B?V_O_"?_ /P4H /^(LG_
M *Q$_M_?^$__ /@I0 ?\19/_ %B)_;^_\)__ /!2@ _XBR?^L1/[?W_A/_\
MX*4 '_$63_UB)_;^_P#"?_\ P4H /^(LG_K$3^W]_P"$_P#_ (*4 '_$63_U
MB)_;^_\ "?\ _P %* #_ (BR?^L1/[?W_A/_ /X*4 '_ !%D_P#6(G]O[_PG
M_P#\%* #_B+)_P"L1/[?W_A/_P#X*4 '_$63_P!8B?V_O_"?_P#P4H /^(LG
M_K$3^W]_X3__ ."E !_Q%D_]8B?V_O\ PG__ ,%* #_B+)_ZQ$_M_?\ A/\
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M?^$__P#@I0 ?\19/_6(G]O[_ ,)__P#!2@ _XBR?^L1/[?W_ (3_ /\ @I0
M?\19/_6(G]O[_P )_P#_  4H /\ B+)_ZQ$_M_?^$_\ _@I0 ?\ $63_ -8B
M?V_O_"?_ /P4H /^(LG_ *Q$_M_?^$__ /@I0 ?\19/_ %B)_;^_\)__ /!2
M@ _XBR?^L1/[?W_A/_\ X*4 '_$63_UB)_;^_P#"?_\ P4H /^(LG_K$3^W]
M_P"$_P#_ (*4 '_$63_UB)_;^_\ "?\ _P %* #_ (BR?^L1/[?W_A/_ /X*
M4 '_ !%D_P#6(G]O[_PG_P#\%* #_B+)_P"L1/[?W_A/_P#X*4 '_$63_P!8
MB?V_O_"?_P#P4H /^(LG_K$3^W]_X3__ ."E !_Q%D_]8B?V_O\ PG__ ,%*
M #_B+)_ZQ$_M_?\ A/\ _P""E !_Q%D_]8B?V_O_  G_ /\ !2@ _P"(LG_K
M$3^W]_X3_P#^"E !_P 19/\ UB)_;^_\)_\ _!2@ _XBR?\ K$3^W]_X3_\
M^"E !_Q%D_\ 6(G]O[_PG_\ \%* #_B+)_ZQ$_M_?^$__P#@I0 ?\19/_6(G
M]O[_ ,)__P#!2@ _XBR?^L1/[?W_ (3_ /\ @I0 ?\19/_6(G]O[_P )_P#_
M  4H /\ B+)_ZQ$_M_?^$_\ _@I0 ?\ $63_ -8B?V_O_"?_ /P4H /^(LG_
M *Q$_M_?^$__ /@I0 ?\19/_ %B)_;^_\)__ /!2@ _XBR?^L1/[?W_A/_\
MX*4 '_$63_UB)_;^_P#"?_\ P4H /^(LG_K$3^W]_P"$_P#_ (*4 '_$63_U
MB)_;^_\ "?\ _P %* #_ (BR?^L1/[?W_A/_ /X*4 '_ !%D_P#6(G]O[_PG
M_P#\%* #_B+)_P"L1/[?W_A/_P#X*4 '_$63_P!8B?V_O_"?_P#P4H /^(LG
M_K$3^W]_X3__ ."E !_Q%D_]8B?V_O\ PG__ ,%* #_B+)_ZQ$_M_?\ A/\
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M?^$__P#@I0 ?\19/_6(G]O[_ ,)__P#!2@ _XBR?^L1/[?W_ (3_ /\ @I0
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M$3^W]_X3_P#^"E !_P 19/\ UB)_;^_\)_\ _!2@ _XBR?\ K$3^W]_X3_\
M^"E !_Q%D_\ 6(G]O[_PG_\ \%* #_B+)_ZQ$_M_?^$__P#@I0 ?\19/_6(G
M]O[_ ,)__P#!2@ _XBR?^L1/[?W_ (3_ /\ @I0 ?\19/_6(G]O[_P )_P#_
M  4H /\ B+)_ZQ$_M_?^$_\ _@I0 ?\ $63_ -8B?V_O_"?_ /P4H /^(LG_
M *Q$_M_?^$__ /@I0 ?\19/_ %B)_;^_\)__ /!2@ _XBR?^L1/[?W_A/_\
MX*4 '_$63_UB)_;^_P#"?_\ P4H /^(LG_K$3^W]_P"$_P#_ (*4 '_$63_U
MB)_;^_\ "?\ _P %* #_ (BR?^L1/[?W_A/_ /X*4 '_ !%D_P#6(G]O[_PG
M_P#\%* #_B+)_P"L1/[?W_A/_P#X*4 '_$63_P!8B?V_O_"?_P#P4H /^(LG
M_K$3^W]_X3__ ."E !_Q%D_]8B?V_O\ PG__ ,%* #_B+)_ZQ$_M_?\ A/\
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M?^$__P#@I0 ?\19/_6(G]O[_ ,)__P#!2@ _XBR?^L1/[?W_ (3_ /\ @I0
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M$3^W]_X3_P#^"E !_P 19/\ UB)_;^_\)_\ _!2@ _XBR?\ K$3^W]_X3_\
M^"E !_Q%D_\ 6(G]O[_PG_\ \%* #_B+)_ZQ$_M_?^$__P#@I0 ?\19/_6(G
M]O[_ ,)__P#!2@ _XBR?^L1/[?W_ (3_ /\ @I0 ?\19/_6(G]O[_P )_P#_
M  4H /\ B+)_ZQ$_M_?^$_\ _@I0 ?\ $63_ -8B?V_O_"?_ /P4H /^(LG_
M *Q$_M_?^$__ /@I0 ?\19/_ %B)_;^_\)__ /!2@ _XBR?^L1/[?W_A/_\
MX*4 '_$63_UB)_;^_P#"?_\ P4H /^(LG_K$3^W]_P"$_P#_ (*4 '_$63_U
MB)_;^_\ "?\ _P %* #_ (BR?^L1/[?W_A/_ /X*4 '_ !%D_P#6(G]O[_PG
M_P#\%* #_B+)_P"L1/[?W_A/_P#X*4 '_$63_P!8B?V_O_"?_P#P4H /^(LG
M_K$3^W]_X3__ ."E !_Q%D_]8B?V_O\ PG__ ,%* #_B+)_ZQ$_M_?\ A/\
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M?^$__P#@I0 ?\19/_6(G]O[_ ,)__P#!2@ _XBR?^L1/[?W_ (3_ /\ @I0
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M$3^W]_X3_P#^"E !_P 19/\ UB)_;^_\)_\ _!2@ _XBR?\ K$3^W]_X3_\
M^"E !_Q%D_\ 6(G]O[_PG_\ \%* #_B+)_ZQ$_M_?^$__P#@I0 ?\19/_6(G
M]O[_ ,)__P#!2@ _XBR?^L1/[?W_ (3_ /\ @I0 ?\19/_6(G]O[_P )_P#_
M  4H /\ B+)_ZQ$_M_?^$_\ _@I0 ?\ $63_ -8B?V_O_"?_ /P4H /^(LG_
M *Q$_M_?^$__ /@I0 ?\19/_ %B)_;^_\)__ /!2@ _XBR?^L1/[?W_A/_\
MX*4 '_$63_UB)_;^_P#"?_\ P4H /^(LG_K$3^W]_P"$_P#_ (*4 '_$63_U
MB)_;^_\ "?\ _P %* #_ (BR?^L1/[?W_A/_ /X*4 '_ !%D_P#6(G]O[_PG
M_P#\%* #_B+)_P"L1/[?W_A/_P#X*4 '_$63_P!8B?V_O_"?_P#P4H /^(LG
M_K$3^W]_X3__ ."E !_Q%D_]8B?V_O\ PG__ ,%* #_B+)_ZQ$_M_?\ A/\
M_P""E !_Q%D_]8B?V_O_  G_ /\ !2@ _P"(LG_K$3^W]_X3_P#^"E !_P 1
M9/\ UB)_;^_\)_\ _!2@ _XBR?\ K$3^W]_X3_\ ^"E !_Q%D_\ 6(G]O[_P
MG_\ \%* #_B+)_ZQ$_M_?^$__P#@I0 ?\19/_6(G]O[_ ,)__P#!2@ _XBR?
M^L1/[?W_ (3_ /\ @I0 ?\19/_6(G]O[_P )_P#_  4H /\ B+)_ZQ$_M_?^
M$_\ _@I0 ?\ $63_ -8B?V_O_"?_ /P4H /^(LG_ *Q$_M_?^$__ /@I0 ?\
M19/_ %B)_;^_\)__ /!2@ _XBR?^L1/[?W_A/_\ X*4 '_$63_UB)_;^_P#"
M?_\ P4H /^(LG_K$3^W]_P"$_P#_ (*4 '_$63_UB)_;^_\ "?\ _P %* #_
M (BR?^L1/[?W_A/_ /X*4 '_ !%D_P#6(G]O[_PG_P#\%* #_B+)_P"L1/[?
MW_A/_P#X*4 '_$63_P!8B?V_O_"?_P#P4H /^(LG_K$3^W]_X3__ ."E !_Q
M%D_]8B?V_O\ PG__ ,%* #_B+)_ZQ$_M_?\ A/\ _P""E !_Q%D_]8B?V_O_
M  G_ /\ !2@ _P"(LG_K$3^W]_X3_P#^"E !_P 19/\ UB)_;^_\)_\ _!2@
M _XBR?\ K$3^W]_X3_\ ^"E !_Q%D_\ 6(G]O[_PG_\ \%* #_B+)_ZQ$_M_
M?^$__P#@I0 ?\19/_6(G]O[_ ,)__P#!2@ _XBR?^L1/[?W_ (3_ /\ @I0
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M$3^W]_X3_P#^"E !_P 19/\ UB)_;^_\)_\ _!2@ _XBR?\ K$3^W]_X3_\
M^"E !_Q%D_\ 6(G]O[_PG_\ \%* #_B+)_ZQ$_M_?^$__P#@I0 ?\19/_6(G
M]O[_ ,)__P#!2@ _XBR?^L1/[?W_ (3_ /\ @I0 ?\19/_6(G]O[_P )_P#_
M  4H /\ B+)_ZQ$_M_?^$_\ _@I0 ?\ $63_ -8B?V_O_"?_ /P4H /^(LG_
M *Q$_M_?^$__ /@I0 ?\19/_ %B)_;^_\)__ /!2@ _XBR?^L1/[?W_A/_\
MX*4 '_$63_UB)_;^_P#"?_\ P4H /^(LG_K$3^W]_P"$_P#_ (*4 '_$63_U
MB)_;^_\ "?\ _P %* #_ (BR?^L1/[?W_A/_ /X*4 '_ !%D_P#6(G]O[_PG
M_P#\%* #_B+)_P"L1/[?W_A/_P#X*4 '_$63_P!8B?V_O_"?_P#P4H /^(LG
M_K$3^W]_X3__ ."E !_Q%D_]8B?V_O\ PG__ ,%* #_B+)_ZQ$_M_?\ A/\
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M?^$__P#@I0 ?\19/_6(G]O[_ ,)__P#!2@ _XBR?^L1/[?W_ (3_ /\ @I0
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M$3^W]_X3_P#^"E !_P 19/\ UB)_;^_\)_\ _!2@ _XBR?\ K$3^W]_X3_\
M^"E !_Q%D_\ 6(G]O[_PG_\ \%* #_B+)_ZQ$_M_?^$__P#@I0 ?\19/_6(G
M]O[_ ,)__P#!2@ _XBR?^L1/[?W_ (3_ /\ @I0 ?\19/_6(G]O[_P )_P#_
M  4H /\ B+)_ZQ$_M_?^$_\ _@I0 ?\ $63_ -8B?V_O_"?_ /P4H /^(LG_
M *Q$_M_?^$__ /@I0 ?\19/_ %B)_;^_\)__ /!2@ _XBR?^L1/[?W_A/_\
MX*4 '_$63_UB)_;^_P#"?_\ P4H /^(LG_K$3^W]_P"$_P#_ (*4 '_$63_U
MB)_;^_\ "?\ _P %* #_ (BR?^L1/[?W_A/_ /X*4 '_ !%D_P#6(G]O[_PG
M_P#\%* #_B+)_P"L1/[?W_A/_P#X*4 '_$63_P!8B?V_O_"?_P#P4H /^(LG
M_K$3^W]_X3__ ."E !_Q%D_]8B?V_O\ PG__ ,%* #_B+)_ZQ$_M_?\ A/\
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M?^$__P#@I0 ?\19/_6(G]O[_ ,)__P#!2@ _XBR?^L1/[?W_ (3_ /\ @I0
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M$3^W]_X3_P#^"E !_P 19/\ UB)_;^_\)_\ _!2@ _XBR?\ K$3^W]_X3_\
M^"E !_Q%D_\ 6(G]O[_PG_\ \%* #_B+)_ZQ$_M_?^$__P#@I0 ?\19/_6(G
M]O[_ ,)__P#!2@ _XBR?^L1/[?W_ (3_ /\ @I0 ?\19/_6(G]O[_P )_P#_
M  4H /\ B+)_ZQ$_M_?^$_\ _@I0 ?\ $63_ -8B?V_O_"?_ /P4H /^(LG_
M *Q$_M_?^$__ /@I0 ?\19/_ %B)_;^_\)__ /!2@ _XBR?^L1/[?W_A/_\
MX*4 '_$63_UB)_;^_P#"?_\ P4H /^(LG_K$3^W]_P"$_P#_ (*4 '_$63_U
MB)_;^_\ "?\ _P %* #_ (BR?^L1/[?W_A/_ /X*4 '_ !%D_P#6(G]O[_PG
M_P#\%* #_B+)_P"L1/[?W_A/_P#X*4 '_$63_P!8B?V_O_"?_P#P4H /^(LG
M_K$3^W]_X3__ ."E !_Q%D_]8B?V_O\ PG__ ,%* #_B+)_ZQ$_M_?\ A/\
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M?^$__P#@I0 ?\19/_6(G]O[_ ,)__P#!2@ _XBR?^L1/[?W_ (3_ /\ @I0
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M$3^W]_X3_P#^"E !_P 19/\ UB)_;^_\)_\ _!2@ _XBR?\ K$3^W]_X3_\
M^"E !_Q%D_\ 6(G]O[_PG_\ \%* #_B+)_ZQ$_M_?^$__P#@I0 ?\19/_6(G
M]O[_ ,)__P#!2@ _XBR?^L1/[?W_ (3_ /\ @I0 ?\19/_6(G]O[_P )_P#_
M  4H /\ B+)_ZQ$_M_?^$_\ _@I0 ?\ $63_ -8B?V_O_"?_ /P4H /^(LG_
M *Q$_M_?^$__ /@I0 ?\19/_ %B)_;^_\)__ /!2@ _XBR?^L1/[?W_A/_\
MX*4 '_$63_UB)_;^_P#"?_\ P4H /^(LG_K$3^W]_P"$_P#_ (*4 '_$63_U
MB)_;^_\ "?\ _P %* #_ (BR?^L1/[?W_A/_ /X*4 '_ !%D_P#6(G]O[_PG
M_P#\%* #_B+)_P"L1/[?W_A/_P#X*4 '_$63_P!8B?V_O_"?_P#P4H /^(LG
M_K$3^W]_X3__ ."E !_Q%D_]8B?V_O\ PG__ ,%* #_B+)_ZQ$_M_?\ A/\
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M?^$__P#@I0 ?\19/_6(G]O[_ ,)__P#!2@ _XBR?^L1/[?W_ (3_ /\ @I0
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M$3^W]_X3_P#^"E !_P 19/\ UB)_;^_\)_\ _!2@ _XBR?\ K$3^W]_X3_\
M^"E !_Q%D_\ 6(G]O[_PG_\ \%* #_B+)_ZQ$_M_?^$__P#@I0 ?\19/_6(G
M]O[_ ,)__P#!2@ _XBR?^L1/[?W_ (3_ /\ @I0 ?\19/_6(G]O[_P )_P#_
M  4H /\ B+)_ZQ$_M_?^$_\ _@I0 ?\ $63_ -8B?V_O_"?_ /P4H /^(LG_
M *Q$_M_?^$__ /@I0 ?\19/_ %B)_;^_\)__ /!2@ _XBR?^L1/[?W_A/_\
MX*4 '_$63_UB)_;^_P#"?_\ P4H /^(LG_K$3^W]_P"$_P#_ (*4 '_$63_U
MB)_;^_\ "?\ _P %* #_ (BR?^L1/[?W_A/_ /X*4 '_ !%D_P#6(G]O[_PG
M_P#\%* #_B+)_P"L1/[?W_A/_P#X*4 '_$63_P!8B?V_O_"?_P#P4H /^(LG
M_K$3^W]_X3__ ."E !_Q%D_]8B?V_O\ PG__ ,%* #_B+)_ZQ$_M_?\ A/\
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MQIZ?/N\MP#^C^@#_U?[^* "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H __];^_B@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /__7_OXH * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@#__T/[^* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H __]'^_B@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MP]Y-VW]V*7Q+8@=YC7EX[Z/BY)RRSB5^T2_=T<=ERY)/HIXC#XF\%YQPL_\
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '_T_[^* "@ H * "@
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MZ;ELI>]%:)QMJOYS;*]\5?#OQ=;WUC/J_A'QKX*U]9K>XA:?3-<\.>)- O\
MAE(\NXL=2TO4;7#*0LD%Q"58 J17],U*>#S+!2IU(T<9@,=AN649*-6AB<+B
M*>W6,Z56E+3HXO0_,(RK86LI1<Z%>A4NFKPJ4JM.7R<90DO5-']OG[%W[0<7
M[3O[./P[^*TWE1^(KW3GT+QO:PHD4=KXU\.R?V9X@:*&/]W;VFJ3Q)KNFVZE
MC!I>JV43GS$<#^#N..&WPKQ-F64*[PU.HJ^ F]7/ 8E>UPUV]7.E%O#U):7J
MT9M*UC]\R+,EFN5X7&.RJ2C[.NDK)5Z7N5+);1DUSQ72$HH_%_\ X+(_#;QW
M\7/VI_V?_A_\-O#&J^,/%^O_  LNK?2]#TB$23RD>+];::XGED:*TL+"TB4S
MW^IW\]KI^GVL;W-[=06\;R+^W^">:9?DW"7$>8YIBZ."P6'S:$JM>L[17^Q4
M%&,8I.=2I-^[3I4XRJ5)6C"$I-(^&XXPN(QF;9;AL+2G6K5,))0IP6K_ 'T[
MM[1C%+64I-1BE>321K?!'_@A?/>Z39ZM^T'\7+K1M2NH$DG\&?#"QL;F72W?
M#B*[\9Z_%>6-U=1H1%<V]AX7ELXIU?[+JU_ $E?+/?'V-.M.CPYDT*U*$FHX
MW-9U(JJEI>&!P[A.$6]8RJ8I3<;<U&G+17@/#^\%/,L;*$VE^XPD8OD?9UZB
ME&36S4:5D]IR6I;_ &@O^"'NF:-X.U?Q#^SI\2?%.N^)-&L[O4(? WQ&CT6Z
ME\2QVMN\_P#9FC^(_#VE:#!8ZU<>68=.AU#17T^]NIH8+J_TF'?>".'/'JM6
MQM'#<2Y7A,/A*TX4WC\L=>"PKE)1]K6PV(K8AU*$;WJ.G652G!.4*=9V@/,N
M (0H3J99BJU2K"+DL/B?9OVME?EA5IPIJ,W:T5*#BW9.4%J?SV(^IZ%J:O&U
M_H^LZ/?JZ.AN-/U/2M3T^X!5E9?)NK&_L;J$%2/*N+:XB!&R1./Z0:I8BDTU
M3K4*U.S3Y:E*K2J1V:UA4IU(/SC*+ZIGYK[].?VJ=2G+SC.$XOY.,HM>331_
M<-^PU\;]1_:'_99^$GQ/UV59_$^H:'<:'XMF">6;GQ+X3U.]\,ZKJ+QC]VCZ
MU+I:ZV8X?W48U(1QK&%\M/X+X]R&GPUQ9G&4X=<N$I5XU\&M^7"XRE#%4:2?
M54(U?87>K]E=G[[D&/EF>48+%U'>K*FZ=9VM>K1E*E.5MESN'/9:+FLK;'EO
M_!3;]H77OV<_V4?%/B'PA>S:7XT\<ZQIGPQ\*:Q;LR7&BWOB2TU2_P!5U>TD
MC9);?4++POH>O-I-Y$ZO8ZPVGWB[C $?UO"SAO#\3<7X3#8V"JX' 4*N:XNA
M)+EKT\+.E3HT9IZ.G/%5\.JT&FIT?:0TYKKDXJS*IE>3UJM&7)7KSAA:,UHX
M2JJ3G.-MI1I0J.#^S/E?0_CT^'?@'Q9\7/B!X4^'?@ZRDUCQ?XZ\06.@Z1;N
M[8FU#4[@1FZO;@AS!9VJM)?:G?2@QVEE!<W<Y$<3D?VEF688/)<MQ>98V:HX
M++\-.O6:2]VG2CI"G'1.<M*=*FK<TY1A'5H_$\-AJV-Q-'#4(\];$5(TX+O*
M3M>3Z17Q2E]F*;>B/Z6?!'_!#C]GJR\&VMC\0OB)\4M?\=3V<?\ :NO>%M2\
M.^'M!L]0Y9QH.B:AX7URX^R1DB$OK&H:A+=K']H2+3C+]GA_EW'>/7$D\;*I
MEV6Y3AL!&;]EA\52Q.)KSI[+ZQ7IXK#QYVM;4*=)0ORWJ6YG^IX?@#+(T%'$
MXG%U,0XKGJ494J5.,O\ IW3E2J/E6WORDW:ZY+V7X8_MK_L?^*_V-OBNG@76
M-3'B?PKX@TXZ]X#\91V1T]=<T=;AK6ZM;VS\ZYCLM<T6Y"V^J6<5S/'Y4]AJ
M$3);ZC!&G[[P+QI@^-LH>/HTOJF+PU18?,,$Y^T]A6Y5*$Z<^6+GAZ\;RHR<
M8N\:E-WE2;?Y_GV25LCQBP\Y^UHU(^TP];EY>>%^5QE'51J4WI.*;5G&2TDD
M?K7_ ,$//VB/$.JR?$3]F?Q#J%QJ.D:!H3?$SX?+<R22G0[-=9T_1?&.BVTD
MKL(].N=0UW0M7L-/A$<5O>S>(+P*[7\I3\<\>>&L-1_LWBG#4XTJN(K_ -EY
MCR)+V]3V-2O@J\DDKU(TL/7HU*CNY0CAX:>S5_L^ ,SJ3^LY54DY0I4_K6&O
M_P NX\\:=>FNT7*I3G&*T4G4?VC^AJOYO/TH* "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H \+_:@UW6/"_P"S1^T1XF\.ZG>Z+X@\
M._ SXMZ[H6L:;.]KJ&DZQI'@#Q!?Z9J=A<Q%9+:]L+VW@NK6>,J\,\4<B$,H
MKW^%,/0Q?%'#6%Q-*%?#8G/\GP^(H5(J5.M0K9CAJ=6E4@])0J4Y2A*+T<6T
M>?FU2='*LSJTI2IU*67XRI3G%VE"<,-4E"46MI1DDTULT?QK_P##<_[8W_1R
M_P 9O_"[US_Y*K^VO]0."?\ HELD_P#""A_\B?A_^L&=_P#0UQW_ (45/\P_
MX;G_ &QO^CE_C-_X7>N?_)5'^H'!/_1+9)_X04/_ )$/]8,[_P"AKCO_  HJ
M?YA_PW/^V-_T<O\ &;_PN]<_^2J/]0."?^B6R3_P@H?_ "(?ZP9W_P!#7'?^
M%%3_ ##_ (;G_;&_Z.7^,W_A=ZY_\E4?Z@<$_P#1+9)_X04/_D0_U@SO_H:X
M[_PHJ?YA_P -S_MC?]'+_&;_ ,+O7/\ Y*H_U X)_P"B6R3_ ,(*'_R(?ZP9
MW_T-<=_X45/\P_X;G_;&_P"CE_C-_P"%WKG_ ,E4?Z@<$_\ 1+9)_P"$%#_Y
M$/\ 6#._^AKCO_"BI_F'_#<_[8W_ $<O\9O_  N]<_\ DJC_ % X)_Z);)/_
M  @H?_(A_K!G?_0UQW_A14_S#_AN?]L;_HY?XS?^%WKG_P E4?Z@<$_]$MDG
M_A!0_P#D0_U@SO\ Z&N._P#"BI_F'_#<_P"V-_T<O\9O_"[US_Y*H_U X)_Z
M);)/_""A_P#(A_K!G?\ T-<=_P"%%3_,/^&Y_P!L;_HY?XS?^%WKG_R51_J!
MP3_T2V2?^$%#_P"1#_6#._\ H:X[_P **G^8?\-S_MC?]'+_ !F_\+O7/_DJ
MC_4#@G_HELD_\(*'_P B'^L&=_\ 0UQW_A14_P P_P"&Y_VQO^CE_C-_X7>N
M?_)5'^H'!/\ T2V2?^$%#_Y$/]8,[_Z&N._\**G^8?\ #<_[8W_1R_QF_P#"
M[US_ .2J/]0."?\ HELD_P#""A_\B'^L&=_]#7'?^%%3_,/^&Y_VQO\ HY?X
MS?\ A=ZY_P#)5'^H'!/_ $2V2?\ A!0_^1#_ %@SO_H:X[_PHJ?YA_PW/^V-
M_P!'+_&;_P +O7/_ )*H_P!0."?^B6R3_P (*'_R(?ZP9W_T-<=_X45/\P_X
M;G_;&_Z.7^,W_A=ZY_\ )5'^H'!/_1+9)_X04/\ Y$/]8,[_ .AKCO\ PHJ?
MYA_PW/\ MC?]'+_&;_PN]<_^2J/]0."?^B6R3_P@H?\ R(?ZP9W_ -#7'?\
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M%7-<LI5<RQDZ=3,,%3J0E7FXSA/$4XRA)7LXRBVFNJT/[*:_B4_< H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MA#*IQJX2S?ME9SJU-JDZVD7[6ZM*,HQ<$E!1C&,8KZKKY(]<* "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M#_\ I54^M?\ @@?_ *S]JS_<^!W\_B]7QWTAMN$?7/ORR8]GPZ_YG'_=/_\
M=TZ#_@O/X<N)_#/[-GBV.W<VFDZ[\3/#EW=*O[M+CQ!I_@S4M.MY&[/)'X9U
M.2!?[L5P1T-<OT?,3&.+XGP3DN:MA\KQ,(=>7#5,;2J22[)XJDI>L?(T\0Z3
M='*ZR3M"IBJ3ET3J1H2BGYM4I6]&?E/_ ,$TO&UEX!_;@^ &KZC(L5EJ?B;5
M/!CEG$:&Y\>>%M=\&:2K,>,#6=<TY@#]YE5>,U^N^*6 GF' 7$5&FFYTL+1Q
MJLKOER_%X?&U=/\ KS0J+R1\APK7CA\_RV<M(SJSH?/$4:E"'_D\XG]K]?PN
M?NY\$?\ !0?]C_Q'^V7\+O!W@+PQXQT3P9?>&/'L'B^6^UVPOK^TN[:/P]KN
MBM:1II[":*?S-6BF5V5HRD4BG:Q6OT+PXXSPW!&;8W,<5@J^.IXK+I8*-/#U
M*=.<)/$X:NIMU%RN-J+C9:W:Z'SO$F25,\PE##4J\*#I8A5G*I&4DTJ52GRI
M1M9^^GVLC\B_^'$7Q=_Z+M\./_">\35^R_\ $P.3?]$_F?\ X4X4^,_XA[C/
M^ACAO_!-7_,_"*OZ!/SP_N)_8!_Y,O\ V;?^R6>'O_1<E?P5XA_\EQQ/_P!C
M?$_FC]^X<_Y$65_]@=+\C^1O]M_P_/X9_;!_:6TR>![9I/C1X_UJ**1=A%GX
MF\0WOB2P=%_YXS6.K6\T!Z-!)&PX(K^R. L3'%<%\+U8R4K9'EU!M?SX7#PP
MM1/SC.C)2\TS\8S^FZ6=YK!JW^W8BHEM[M6HZL?ERS5O(_=W_@A9XZL-1^!/
MQ>^''F@ZMX2^*</BR2,N-PT?QOX6T?3+#9'][8NH>"-8+N.-TRJ<'&?Y^\?L
MOJ4N(,FS.W[G&90\&G;3VV Q=>I4N]OX6.H67]UGZ%X?8B,LNQF%O[]'%^VM
M_P!.Z]&$8Z?XJ$_O/W&K\%/OPH * ,#Q7IS:OX6\2:2B&1M4T#6-.6,#)=KW
M3KBV5 .Y8R!0/?%=&$J*CB\+5>BI8BC4;[*%2,OPL9UH\]&K#^:G./\ X%%H
M_P ]<@@D$$$'!!&""."".Q'I7^D!_-9_=%^Q!JL.L_L>_LS7<#;TA^"7PZTH
MGCB;0?#.GZ'<)Q_SSGTZ1/;;BOX#X\I.CQIQ3"2LWGN9U?E7Q52O%_.-1,_H
M'()*>294ULL!A8?.G2C3?XQ9]2U\F>N?RI_\%QM5AO/VJO .EQ-N.C_ KPX+
MD?\ /.YO_''Q!N?+QV/V06DN>XE''&3_ %QX"47#A+,:K5O;9_B>7SC3P&71
MO_X'SKY'Y!Q_)/-\-!?8R^E?R<L1B7^5CU;_ ((.:1--\0/VA]>$1-OIO@[P
M+I$DV/ECFUK6M=O(8B?65- G<#TA/H*\CZ05:,<NX:P]US5,;CZRCU<:%##P
M;]$\1%?-';X>0;Q&9U+:1HX>%^B<YU))?/V?X']*;ND2/)(ZQQQJSR2.P1$1
M!N9W9L*JJH)9B0% R< 5_+R3;22NWHDMV]DDC]2V\DOP/YR?^"AG_!6&[O9]
M?^!_[*^N/::?"]SI'C+XT:7/MNM1==T%[H_PVNXCFUL%.^WN?&D3"ZO7#GPP
MUM:1VVNZA_3/AOX/PA'#Y]Q;04YR4:V"R.K'W*:>L*V9P:]Z>THX%KE@K?6N
M:7-0I_F'$O&+E[3 914M%7A7QT'K+I*&%:VCT==:O_EU96J/\6O@7\ OBQ^T
MM\0+/X?_  J\.7?B/7[UQ<ZIJ$S20Z+X>TYY0MSK_BC6722'2],@9LO/+YEU
M>3E++3;:_P!2N+:SF_<N(.(LGX6RV>8YMB88;#TUR4:44G7Q-11]S#X2@FG5
MJM+2*M"G&\ZDJ=*,IQ^%R_+L9FN)CAL'2=6I+6<GI3I1OK4K3M:$%W>LG[L%
M*347_8#^Q1^P[\-_V-O!4EGHS)XG^)GB2SM5\>?$2ZMQ#<ZFT)$RZ)H5LS2'
M1?"UG<_/!8I(]UJ$Z1WVK7%S-%9Q6/\ %_'7'N9\;8Y3K_[+E>%G+^S\MA*\
M*2?N^WKR5O;XN<=)5&E&G%NG1C"+FY_M>0Y!A<CP_+3_ 'N*JI?6,2U9SM]B
MFO\ EW1B]HK63]Z;;2Y?MVOA#WC\0_\ @M5^TEKOPZ^%_@OX$^#]3O=)U+XO
M/JVI>-+VPE:WF;P!H0ALW\/-.FV5;;Q3J]^@OA;NOGZ;H5]I=WNL=4G@G_=_
M SA?#YGFV.S_ !M*%:EDJHTL#3J)2C_:.(YIK$<KT<L)1IOV?,O=JUZ=6%IT
MHN/P7'>:5,+A*&7T)RA/&N<J[CH_JU.T?9W[59R5[;QIR@_=DT_Q/_8%_9*D
M_:_^.MGX&U2\O-)\ >&M*G\6_$35=-E@AU2/0;6>"RM=*T=[B&XA75=<U6[M
M+&*62"5;*Q_M'4O*G:Q6VG_=?$3C%<%\/SQ]*$*V8XJK'!Y;1JJ3I.O*,ISK
M5E%Q?LL/1A*;BI1YZGLJ5XJ;E'X/AS)O[:S!8>;E##4H.MB90:4_9IJ,80NF
MN>I-QC>WNQYI:\J3_K3\+?L9?LH>#_#$7A'1_P!GCX02:,EG!8S_ -M> O#G
MB34]3BMT"1R:SKGB#3]2UG6;KC>;O4[ZZN/-)D$@8YK^/,7QOQ=C<6\;6XDS
ME5^=U(^PS#$X:E2<G=JA0P]2E0H0Z<E*G"-M+6/V2CD>3T**H0RS!>SY5%\^
M'I5922_GJ5(RG-^<I-W/P;_X*L_\$]O WP,T;3_V@O@;I+>'O!6I:_'HGQ \
M$0S^9H_AG4=7&=$USPQ#-F>QT74+R.XT[4=(^T36VFW]UI0T>"VTZ>6VL?Z#
M\(O$?'Y_7J<.9]6^LXZEAW7R['RC:MBJ5'^/A\4X^[4KTX.-2E6Y8RJ4X5?;
M2E4BI3_/.,.&L/E]..99?#V5"53V>)PZ?N4I3_AU*2>L82E>$H7M"3AR)1;4
M?$_^"1?[2NO?"+]I/0_A3?:G>R?#CXVW#>&;W1#*9+#3_'$D&[PEXDM+5N(;
M^XNK:/PQ?20-$MSI^K1RWBW+:1IPM_<\9>%\/G/"]?-Z=*FLSR&*Q4*]K5*F
M 4K8S"SEUA&,OK5-23Y:E%QI\OMJG-P<%YI4P6:4\'*4OJN/?LI4[^['$6_<
MU8KI)M*E*UKQDKWY(V_KIK^-S]G"@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@#_]?^_B@ H * "@ H * /X[?^"O?_ "?3
M\2?^Q;^&W_J"Z'7]I^#'_) Y;_V%YG_ZG5C\2XT_Y*#%?]>L+_ZCTS]<O^"&
M?_)J?Q&_[.$\3_\ JN/A77XYX^?\E?EG_9-X3_U9YN?9^'__ ")\5_V,JO\
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MC2CUDXQ1C0HU\RQU.C%\V(QN)47)Z^_6G[]27DKN<GT2;Z']XOP^\#Z#\,_
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M0_NVK_/\_H,* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H _EJ_X.'_^"ZO[1_\ P2 \>_LP
M^$/@-\)O@C\1K;XW>$?B5XC\27?Q=L_'=[/ID_@S6?"6F:9;:&G@WQKX0CBB
MN(]=O)+YK_[>\CQVPM_LRQR^> ?'?_!$S_@Z1^,/_!0G]N+PU^R/^U;\)_@+
M\*=/^*G@_P 5)\)/%'PJM_'VF75[\5?#=K%XDM/"?B!O&WCOQ7I_]G>(O".F
M>+5TJ2U2ROI/%%EH>CP?:WUE(XP#^UF@ H * "@#_/3_ &UO^#R?]H[X6_M7
M_'KX9?LK? S]F'Q_\ ?AU\1M<\"_#GQYX^LOBCJGB3QOIWA*1-!U/Q>]]X6^
M)OAK0YM%\2^(+#5]9\*?9-%LY(_"MYHL=]Y]^EU<S ']4_\ P0U_X*)?%;_@
MJ%^P?HW[5/QF\&?#WP'XUU+XH_$;P-+H'PQMO$EIX633?!UWIUOI]U'#XJ\0
M^)]6%]<K>2&\9M4:W+*GDP0C((!^PM !0 4 % !0!SGB\D>$O%!'!'AW6R".
M""-,N<8],4 ?XWO_  0:\5^*9_\ @L-_P3Y@F\2Z_-!/^T-X<@GAEUG49(IH
M)M.U>*:&6-K@I)%+$S1R1N"CQLR,"I(H _V9: &.Z1(\DCK''&K/)([!$1$&
MYG=FPJJJ@EF) 4#)P!0!RG@KX@> _B3I$^O_  Z\;>$?'V@VNJZEH5SK7@KQ
M)HWBG2+?7-%N#9ZQHT^I:%>7UG%JNDW:M:ZEISS+=V%PI@NH8I 5H ZZ@#^"
M+_@\%_X*$_MT_LW_ !S_ &8?V>OV?OC)\6?V?/@KXM^#&H_%+6O%OP?\5>(_
MAOKWQ'^(?_"=^(O"VJ>%=3\<^%;W2]>N-(\!^'-)\,:HWA?3]5M=-GG\?QW_
M (AL]3>/P\^F@'Z=_P#!IG^VK^UU^V3^PQ\7IOVJ_&OC/XN_\*=^-X\!?#/X
MQ_$&[O=;\8^)]!O/!NA^(M9\*Z]XPU)Y=3\:7O@S4;^"Z77M;NM1UU;3Q5:Z
M7?:E<6VG:?#; ']45 !0 4 % !0 4 ?X_O\ P<M>)?$=A_P6\_;KM+'7];L[
M6'Q%\&!%;6NJWUO;Q!OV;/@T[".&&=(T#.S.VU1EF9CR30!_J^?LBSSW7[*'
M[,5S<S2W%S<?L\_!:>XN)Y'EGGGE^&_AJ26::60L\LLKLSR2.Q=W)9B22: /
MH:@ H * "@ H * "@ H _ #_ (*V_P#!Q)^QI_P2KU"Y^%5W::G^T7^U,=-@
MU!?@/\.];TW2K;P=%>PQW.ES_&#X@7-MJ]E\/5U6S=;W3M%L]!\6>-)[*;3]
M3F\*6F@ZK8:U* ?QN_&C_@\H_P""I/CW6+M_A/X*_9F^ _AH7$ITJPTGX?:[
M\0O$\=FV?*AUOQ'X\\5ZCHFJW<(.#=Z5X+\-02;5S8+\VX \4\/_ /!W)_P6
M;T:[AN=1^)GP1\60Q2;WT_Q!\!/!EM9W"_\ /*9_"H\,WZQ]LV][!+_TTH _
MK"_X-XO^#@WX_?\ !6CXP_%7]G?]H;X'_";P;XL^&?P<F^+=I\2OA%?>+-%T
M;6[:P\:>#_!4^@:A\/\ Q9J7C.XMKVZ;Q=#JO]N67C>.TB.GS6:>'@EY'/9
M']95 !0 4 % !0 4 ?Y?'_!Y9K^NZ7_P5:^&MOINM:MIUN?V)_A)*8+'4;RT
MA,K?%KX_*TABMYHT,C*B*7V[BJ*"<*, ']PW_! :]O-1_P""-_\ P3]O-0N[
MF^NY?@5:"6ZO)Y;FXD$7B?Q)#$'FF9Y'$4,<<489CLC1(UPJJ  ?D-_P=Z_M
MQ_MC?L?_ +-G[+7A?]EGXB>/?@MX>^.GQ&^(^E_%GXN?#+5-4\*>,]/_ .$'
MT#PIJ7@GX?Z9X\T6:UUCPG%XU.N>*]<O6T*_TO6]6MO +6$>H#1#KVGZ@ ?.
MG_!GM^WW^V]^U)<_M;_!G]H[XJ_$[X__  L^%/A[X;>+?!/Q"^+/B#7/'GBC
MP1XJ\3ZMXCTJZ\#KX_\ $EUJ'B#4])\2:/I+:OIN@:OJE_#H'_"*W3Z''IUM
MJ5_%< ']PM !0 4 % '^+M_P5P\6>*K'_@L5^WK'8^)O$%G':?MR?&5;6.UU
MG4;=+80_%/5/*%NL-RBPB+:OEB,*$P-N,"@#_:)H * "@#^2/_@X,_X.!OVG
M_P#@D=^TS\%_@?\  KX._ 7XAZ#\1_@5!\5=9U?XM6/Q"O=7M-7N/'_C/PBN
MFZ8/!WCOPC9Q:='9^%X+D_:K>\N7N;J7$T<2(A /P._XC8O^"B/_ $:_^Q=_
MX(OCC_\ /JH /^(V+_@HC_T:_P#L7?\ @B^./_SZJ #_ (C8O^"B/_1K_P"Q
M=_X(OCC_ //JH /^(V+_ (*(_P#1K_[%W_@B^./_ ,^J@#_1:_9@^*&L_'#]
MFG]GCXT^([#3-*\0_%_X&_"7XH:]IFB)=1Z-INL^/_ /A_Q7JEAI$=]=7U\F
MF6=]JT]O8)>7MW=+:1Q"XNKB4/*X![G0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MK+2X)[^2RT^QM7NGE:WM+>(I$@!XI_Q&Q?\ !1'_ *-?_8N_\$7QQ_\ GU4
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H ^=OVOO^33/VH?\ LW;XU_\ JM?$M?2\&?\ )8<*?]E+D7_JTPIYF=?\
MB;-O^Q9C_P#U%JG\(%?Z!G\]!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!]$_L@_\G9_LO?\ 9Q/P3_\
M5E>&:^:XS_Y(_BO_ +)K/?\ U5XH]/)?^1SE/_8SP'_J52/[OZ_S\/Z%"@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * /_]#^_B@ H * "@ H * /X[?^"O?_ "?3\2?^Q;^&W_J"Z'7]
MI^#'_) Y;_V%YG_ZG5C\2XT_Y*#%?]>L+_ZCTS]<O^"&?_)J?Q&_[.$\3_\
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MB$Z^$K*=.57#UZ,M)1<J56G):-:<LHM;-:=F?H7X0_X*[?MO>%=-ATRY\?\
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M_H8_^6F _P#F4/\ A[!^WY_T7H?^&M^"_P#\[JC_ (@_X=_]$^__  [9W_\
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M?67,ZB2BH2E_117\UGZ8% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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MZMJL6DRZS97KZ='J>HI9F%;ZY$H!^M/_  :%_P#*&_P?_P!G!_'7_P!/&CT
M?U T ?/W[0_[*/[,_P"UMX5T[P1^T[\!OA1\>?"NC:BVL:'HWQ3\#Z!XRM]
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MC_;W@[Q9XAGNO'5O:_\ %(PV,FA>)]8\5.9;Z>[MM:L[>*#3% /VMH * "@
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MS_PC'_\ DZ@#]3/"GA;PYX&\+^&_!/@_1=.\-^$?!V@:/X6\+>'=(MH[/2=
M\.>'M.MM)T31=+M(@(K73M+TRTM;&RMHP(X+:"*) %4"@#?H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H _P H_P#X.T/VWO\ AJ7_ (*>
M:M\$?#.K?;_AI^Q5X5B^#.FQ6\WG:=<?%;6Y+7Q1\9]7A7),.H6>KOX>^&NK
MQ%4 N_AD"JD'S9 #\9OVC/V>?VC/^"5W[7/P^\-^*VO/!GQS^%NC?LX_M&>$
MM7BM9;4Z)XF\2^"_ _QAT<67F/NN;CX?^,[J]\%ZI<*8TF\1>#M701PA3$@!
M_LX?L9_M->$/VS/V4OV?OVIO IA3P[\<OA9X3\?)I\,XN#X?UC5=-B'BGPE<
MS#(?4?!WBB'6?"NJ;2RKJ6CW2*SA0Q /IF@ H _Q&?C'H&C>*_\ @K-\5/"W
MB+3X-6\/^)/^"B7CC0-=TJZ#&UU/1M8_:4U33M3T^Y",CF"\LKB>VF",K&.1
M@K*<$ '^KU_PX>_X([D8_P"'>/[-OIQX-D'Y$7X(_#IVH \3^)?_  ;3?\$4
M_B=I-UIUW^Q/X9\%W<^6MM=^&?Q!^+7@35=-F(*B>UBT7QU%HD^T,<6NJZ-J
M6GYP[6;.D;* ?S!_\%/_ /@SE\6?"_PCXH^,G_!-/XD>+/C'9Z%'<:OJ'[,?
MQ4&B-\3)=)@CDN+[_A6/Q%TJ'0=$\::E:_\ ,.\$>(?#6@:U>6$#PZ?XK\3^
M(Y++1]2 /YW_ /@D7_P5N_:-_P""0W[2EEXB\/7WB;5?@;KWBJPTK]I;]G34
M7>#3?&.AV-T-,UB_T[1]6\J'PQ\6O"EJ+A_#/B*,:=>QWUFOASQ#+=>&;W5=
M+F /]BOX.?%OX?\ Q\^$_P -OC=\*?$%OXJ^&GQ:\$>&?B'X$\16J211ZOX6
M\7:1::WHMXUM.L=S97+V-Y"+S3[R*&]TZ[6>QO8(+NWFA0 ^./\ @J/_ ,%&
M/A-_P2Y_9 \>_M2?%*%M<OM/E@\'_"CX>6UR+/4?BA\7-?LM1G\)>"K6[*2C
M3K%X]+U+7O$^L&&=M$\(Z'KVJ6UGJ5_:V>E7P!_DN*__  4(_P""\W[?,%H]
MWK/QT_:2^,>H736D=Y>/I'P]^$_P\TNXEO)X[<2M<:3\-?@[\/+*]=_(MHY)
M))[C;'%XD\<^(U76P#_0>_X)Y?\ !I]_P3H_93\*Z'KO[3OAF+]M;X[-!87F
MN:U\1QJ-A\&_#^J+$K7FE>"_A)8:A!I&M:*LQ\E[[XH-XSOM2$"WMM8^&XKN
M;1X@#]T(_P#@G=_P3^AT)_"\7[#'['<7AF5527P['^S+\%4T.1$7:JR:2O@D
M6#JJDJ UN0 2!Q0!^;?[7/\ P;5?\$B/VLO#\]DG[,GA_P#9L\7+#,FD_$']
ME6+3O@WJ6EO+N;][X,TO3+SX4ZY$9?++?V]X U"\AA0V^G7VGI)(2 ?I_P#L
M0?LL:'^Q'^R9\"?V3_#?BS5?'6A? OP+9^!M,\7:YI]II6K:_;6EW>78O[[3
MK"6:SM)W:\9##;RR1A44AB2: /JJ@ H * "@ H * "@ H * "@ H * "@ H
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M[>#P[;7GB'Q!X8\7:O)-I5CJ/AO6+KP]X;UD _L0H _RX?\ @\Z_Y2P?#/\
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M>,]4G\6>(_B#\6?#VHW(U76XYIXK0Z9X0T6*"RA$<,4D<\V&>=B #S+X^_\
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MP:;X)CT3Q+J%W#HFG>-_"7A_PO;^&]2DTW_A*=(O-'O=5\5>'P#Z+_X+C?\
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M$%OJ-R="T, _8#_@U!_X*D?MW_\ !0;QI^V3X0_;$^/>H?&S1OA/X1^#>N>
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MT % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH __TO[^* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M_D;?^":W_8N?M7_^G/\ 9XH _9;_ (-!/^4.?AK_ +.+^.?_ *6^'J /:/\
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M('CG5I-<^(_PXTK7/@#\0-5N+F2]O]1U7X.:K+X8\-:MJ]Y.S7-YKNO?#A/
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M[97423VMW:74#/!<VMS \<UO/"[Q31.DD;,C T ?%O\ P4A_:]T[]@K]A?\
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * /G;]K[_DTS]J'_ +-V^-?_
M *K7Q+7TO!G_ "6'"G_92Y%_ZM,*>9G7_(FS;_L68_\ ]1:I_"!7^@9_/04
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 ?1/[(/_)V?[+W_ &<3\$__ %97AFOFN,_^2/XK_P"R:SW_ -5>
M*/3R7_D<Y3_V,\!_ZE4C^[^O\_#^A0H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#__3_OXH * "@ H
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M]:09)V"'^RK6Y>-0J![XR8WRN2 ?S^_\'G7_ "E@^&?_ &9'\(O_ %;G[0%
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M\%"/^R_ZO_Z8M!H _P!DKX??\B%X(_[%#PU_Z9K*@#_,0_X/.O\ E+!\,_\
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M#2]'^(-W:Z/?>!-:U>X._3=#\>:9!HN]X-&L_'FMZW<65I>@']7M !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0!\[?M??\FF?M0_]F[?&O_U6OB6OI>#/^2PX4_[*7(O_ %:84\S.
MO^1-FW_8LQ__ *BU3^$"O] S^>@H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H ^B?V0?^3L_P!E[_LXGX)_
M^K*\,U\UQG_R1_%?_9-9[_ZJ\4>GDO\ R.<I_P"QG@/_ %*I']W]?Y^']"A0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % '__U/[^* "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M +,C^$7_ *MS]H"@#^Y3_@WZ_P"4,_\ P3Z_[(7;_P#J5^)Z /QI_P"#U_\
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MW!I^E:-HND6DU_JFJZG?7+QVUEI^G6-O/=WMW<21P6UM#)-*ZQHQ !_AU?\
M!1;]H#1_VJOV]/VQ/VC/#5Y<:AX0^,7[1_Q>\;^!;N[MY[2ZE^'VJ^-=7/P_
M^TVERJ7%M<1^#(]#BFMYHXY(9$:-HXRNQ0#_ &^_A]_R(7@C_L4/#7_IFLJ
M/\Q#_@\Z_P"4L'PS_P"S(_A%_P"K<_: H _N4_X-^O\ E#/_ ,$^O^R%V_\
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MQJ;2VUK%+: 'R1_P9B_MO_\ "KOVM/C1^PSXLU?R?"W[3O@S_A8OPSL[F?\
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!__U?[^* "@ H * "@
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M>.ZL=1TV_MX[JQOK*YA9X;BTN[:6*>WGB9HYH9$D1BK T 7Z /QS_P""Y_\
MP4:^*G_!+;]A._\ VI?@WX(^'WC_ ,;0?%CX=_#ZWT'XF0^([CPLNG^+SK3:
MA?30>%M>\-ZM+>6\>DJEF$U:&!'F,DT<ZH(F /XO_P#B-C_X*(?]&O?L7_\
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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MJ_$#Q/>ZQK6KZ;H&FV6H>*=1CM;3X>>$;T ^O/\ @S._Y2S>._\ LR_XP?\
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MFC:*^O\ 0=%\#I.=MQ=:?-?+=3WH!\6_\%1O^#IW]LW_ (*&_"[Q)^S[\-O
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M!(BMK>.,<+0!_F#?\'G7_*6#X9_]F1_"+_U;G[0% ']RG_!OU_RAG_X)]?\
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M1M?TQY-&U?7[#1=(T:?4]'\):=XAUT _HI\8?\BCXI_[%S6__39<T ?XSO\
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M3H;O-Y#HU_XV\2:X^@6UV?M-EH*Z992X:WV@ ^\* "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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MK7Q+7TO!G_)8<*?]E+D7_JTPIYF=?\B;-O\ L68__P!1:I_"!7^@9_/04 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 ?1/[(/\ R=G^R]_V<3\$_P#U97AFOFN,_P#DC^*_^R:SW_U5XH]/
M)?\ D<Y3_P!C/ ?^I5(_N_K_ #\/Z%"@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /_6_OXH * "@ H
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M^R!/&_A2UTWPK\6="L(V+&?4O$O@P>#?$D%O$L:0:?\ #CQ!=.7:7@ _T0Z
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M5?CS4+Z[F^)GCK5)?!>CW4DK0^#OACI,[Z3\-O!&FVSR2)9VGAOPC:Z593I
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MM[RSN(R8YK>:.1"584 ;= !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M^#JG_E!W^UK_ -C'^S?_ .M*_":@#^9G_@R)_P"3M?VU_P#LW3P5_P"K+MJ
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MO _@;P]I'A+PAX6T.Q3R[+1O#OAK0+/3]%T32K./]W:Z=IEE:VENGR10HO%
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M!X9T7P;X-\,:5&\DL>F>'O"_AVRT[1-%T])999$L]-L;:V5Y)'6,,[$@'84
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M:59W&O>*_$_@C5->UB>TTNPL=-MI=0O[B2"PLK2SB9+>WAC0 ^G/ W@3P/\
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MP!]54 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!__U_[^* "@ H * "@
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 ?.W[7W_ ":9^U#_ -F[?&O_ -5KXEKZ7@S_ )+#A3_LI<B_]6F%/,SK
M_D39M_V+,?\ ^HM4_A K_0,_GH* "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * /HG]D'_D[/]E[_ +.)^"?_
M *LKPS7S7&?_ "1_%?\ V36>_P#JKQ1Z>2_\CG*?^QG@/_4JD?W?U_GX?T*%
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!\[?M??\ )IG[4/\
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MT,Q&V."<?"[7=/TNT)!>\\7:J8%Q>3N ?B]_P=O?\IG_ (K?]D8^ 7_J!6U
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M;6.F:5IEK%9:?I]E;Q@1P6EE:00VUO"@"10QHB@*H% &E0!_&Q_P>:?L9?\
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M7?@.^VD!V\WX0:5\-XR[D[S"6CQ"8E4 _?2@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * /G;]K[_DTS]J'_LW;XU_^JU\2
MU]+P9_R6'"G_ &4N1?\ JTPIYF=?\B;-O^Q9C_\ U%JG\(%?Z!G\]!0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0!]$_L@_\G9_LO?]G$_!/_U97AFOFN,_^2/XK_[)K/?_ %5XH]/)?^1S
ME/\ V,\!_P"I5(_N_K_/P_H4* "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M['_QJ_:N^)]]IZ6'PW\)W\G@_P .7ES]GN?B%\3-1MIK/X>_#K24C/VF:_\
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MYKC/_DC^*_\ LFL]_P#57BCT\E_Y'.4_]C/ ?^I5(_N_K_/P_H4* "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M'8&41VYG9((+6 16L(!ZC0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0!_,!_P7=_X(H_ML_P#!8+XB?#+3?"?[6GPE
M^#W[,WPAT@WWA7X2Z[X6\<:GJ6K_ !.UA)[?Q)\0_%EUHTR:9J5_#I+6WAOP
ME!Y;KX=T?^VWLVBN?%.N?: #[7_X(F?\$;/AC_P2!_9[USP7:ZYI7Q0_:"^*
M6KKK?QL^-=KHDFBKKT&ES7D?@[P1X7L+N>\O])\$>$-.NIY8+6YO);K6/$NJ
MZ_X@O/L\-[INCZ, ?M10 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M#PG_ -"OX=_\$FF__(U'US&?]!6)_P#!]7_Y(/84/^?-+_P7#_(/^$0\)_\
M0K^'?_!)IO\ \C4?7,9_T%8G_P 'U?\ Y(/84/\ GS2_\%P_R#_A$/"?_0K^
M'?\ P2:;_P#(U'US&?\ 05B?_!]7_P"2#V%#_GS2_P#!</\ (/\ A$/"?_0K
M^'?_  2:;_\ (U'US&?]!6)_\'U?_D@]A0_Y\TO_  7#_(/^$0\)_P#0K^'?
M_!)IO_R-1]<QG_05B?\ P?5_^2#V%#_GS2_\%P_R#_A$/"?_ $*_AW_P2:;_
M /(U'US&?]!6)_\ !]7_ .2#V%#_ )\TO_!</\@_X1#PG_T*_AW_ ,$FF_\
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H _]7^_B@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * /__6_OXH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@#__U_[^* "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H __]#^_B@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M )D* #_A\]_P7E_Z.]_; _\ !+-_\R% !_P^>_X+R_\ 1WO[8'_@EF_^9"@
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M\O\ T=[^V!_X)9O_ )D* #_A\]_P7E_Z.]_; _\ !+-_\R% !_P^>_X+R_\
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M\R% !_P^>_X+R_\ 1WO[8'_@EF_^9"@ _P"'SW_!>7_H[W]L#_P2S?\ S(4
M'_#Y[_@O+_T=[^V!_P""6;_YD* #_A\]_P %Y?\ H[W]L#_P2S?_ #(4 '_#
MY[_@O+_T=[^V!_X)9O\ YD* #_A\]_P7E_Z.]_; _P#!+-_\R% !_P /GO\
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M_; _\$LW_P R% !_P^>_X+R_]'>_M@?^"6;_ .9"@ _X?/?\%Y?^CO?VP/\
MP2S?_,A0 ?\ #Y[_ (+R_P#1WO[8'_@EF_\ F0H /^'SW_!>7_H[W]L#_P $
MLW_S(4 '_#Y[_@O+_P!'>_M@?^"6;_YD* #_ (?/?\%Y?^CO?VP/_!+-_P#,
MA0 ?\/GO^"\O_1WO[8'_ ()9O_F0H /^'SW_  7E_P"CO?VP/_!+-_\ ,A0
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M ,$LW_S(4 '_  ^>_P""\O\ T=[^V!_X)9O_ )D* #_A\]_P7E_Z.]_; _\
M!+-_\R% !_P^>_X+R_\ 1WO[8'_@EF_^9"@ _P"'SW_!>7_H[W]L#_P2S?\
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M>7_H[W]L#_P2S?\ S(4 '_#Y[_@O+_T=[^V!_P""6;_YD* #_A\]_P %Y?\
MH[W]L#_P2S?_ #(4 '_#Y[_@O+_T=[^V!_X)9O\ YD* #_A\]_P7E_Z.]_;
M_P#!+-_\R% !_P /GO\ @O+_ -'>_M@?^"6;_P"9"@ _X?/?\%Y?^CO?VP/_
M  2S?_,A0 ?\/GO^"\O_ $=[^V!_X)9O_F0H /\ A\]_P7E_Z.]_; _\$LW_
M ,R% !_P^>_X+R_]'>_M@?\ @EF_^9"@ _X?/?\ !>7_ *.]_; _\$LW_P R
M% !_P^>_X+R_]'>_M@?^"6;_ .9"@ _X?/?\%Y?^CO?VP/\ P2S?_,A0 ?\
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MD* #_A\]_P %Y?\ H[W]L#_P2S?_ #(4 '_#Y[_@O+_T=[^V!_X)9O\ YD*
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M_P#,A0 ?\/GO^"\O_1WO[8'_ ()9O_F0H /^'SW_  7E_P"CO?VP/_!+-_\
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M@ _X?/?\%Y?^CO?VP/\ P2S?_,A0 ?\ #Y[_ (+R_P#1WO[8'_@EF_\ F0H
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MO_1WO[8'_@EF_P#F0H /^'SW_!>7_H[W]L#_ ,$LW_S(4 '_  ^>_P""\O\
MT=[^V!_X)9O_ )D* #_A\]_P7E_Z.]_; _\ !+-_\R% !_P^>_X+R_\ 1WO[
M8'_@EF_^9"@ _P"'SW_!>7_H[W]L#_P2S?\ S(4 '_#Y[_@O+_T=[^V!_P""
M6;_YD* #_A\]_P %Y?\ H[W]L#_P2S?_ #(4 '_#Y[_@O+_T=[^V!_X)9O\
MYD* #_A\]_P7E_Z.]_; _P#!+-_\R% !_P /GO\ @O+_ -'>_M@?^"6;_P"9
M"@ _X?/?\%Y?^CO?VP/_  2S?_,A0 ?\/GO^"\O_ $=[^V!_X)9O_F0H /\
MA\]_P7E_Z.]_; _\$LW_ ,R% !_P^>_X+R_]'>_M@?\ @EF_^9"@ _X?/?\
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M4 '_  ^>_P""\O\ T=[^V!_X)9O_ )D* #_A\]_P7E_Z.]_; _\ !+-_\R%
M!_P^>_X+R_\ 1WO[8'_@EF_^9"@ _P"'SW_!>7_H[W]L#_P2S?\ S(4 '_#Y
M[_@O+_T=[^V!_P""6;_YD* #_A\]_P %Y?\ H[W]L#_P2S?_ #(4 '_#Y[_@
MO+_T=[^V!_X)9O\ YD* #_A\]_P7E_Z.]_; _P#!+-_\R% !_P /GO\ @O+_
M -'>_M@?^"6;_P"9"@ _X?/?\%Y?^CO?VP/_  2S?_,A0 ?\/GO^"\O_ $=[
M^V!_X)9O_F0H /\ A\]_P7E_Z.]_; _\$LW_ ,R% !_P^>_X+R_]'>_M@?\
M@EF_^9"@ _X?/?\ !>7_ *.]_; _\$LW_P R% !_P^>_X+R_]'>_M@?^"6;_
M .9"@ _X?/?\%Y?^CO?VP/\ P2S?_,A0 ?\ #Y[_ (+R_P#1WO[8'_@EF_\
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M )D* #_A\]_P7E_Z.]_; _\ !+-_\R% !_P^>_X+R_\ 1WO[8'_@EF_^9"@
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M\O\ T=[^V!_X)9O_ )D* #_A\]_P7E_Z.]_; _\ !+-_\R% !_P^>_X+R_\
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M\R% !_P^>_X+R_\ 1WO[8'_@EF_^9"@ _P"'SW_!>7_H[W]L#_P2S?\ S(4
M'_#Y[_@O+_T=[^V!_P""6;_YD* #_A\]_P %Y?\ H[W]L#_P2S?_ #(4 '_#
MY[_@O+_T=[^V!_X)9O\ YD* #_A\]_P7E_Z.]_; _P#!+-_\R% !_P /GO\
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M_; _\$LW_P R% !_P^>_X+R_]'>_M@?^"6;_ .9"@ _X?/?\%Y?^CO?VP/\
MP2S?_,A0 ?\ #Y[_ (+R_P#1WO[8'_@EF_\ F0H /^'SW_!>7_H[W]L#_P $
MLW_S(4 '_#Y[_@O+_P!'>_M@?^"6;_YD* #_ (?/?\%Y?^CO?VP/_!+-_P#,
MA0 ?\/GO^"\O_1WO[8'_ ()9O_F0H /^'SW_  7E_P"CO?VP/_!+-_\ ,A0
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M ,$LW_S(4 '_  ^>_P""\O\ T=[^V!_X)9O_ )D* #_A\]_P7E_Z.]_; _\
M!+-_\R% !_P^>_X+R_\ 1WO[8'_@EF_^9"@ _P"'SW_!>7_H[W]L#_P2S?\
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M>7_H[W]L#_P2S?\ S(4 '_#Y[_@O+_T=[^V!_P""6;_YD* #_A\]_P %Y?\
MH[W]L#_P2S?_ #(4 '_#Y[_@O+_T=[^V!_X)9O\ YD* #_A\]_P7E_Z.]_;
M_P#!+-_\R% !_P /GO\ @O+_ -'>_M@?^"6;_P"9"@ _X?/?\%Y?^CO?VP/_
M  2S?_,A0 ?\/GO^"\O_ $=[^V!_X)9O_F0H /\ A\]_P7E_Z.]_; _\$LW_
M ,R% !_P^>_X+R_]'>_M@?\ @EF_^9"@ _X?/?\ !>7_ *.]_; _\$LW_P R
M% !_P^>_X+R_]'>_M@?^"6;_ .9"@ _X?/?\%Y?^CO?VP/\ P2S?_,A0 ?\
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MD* #_A\]_P %Y?\ H[W]L#_P2S?_ #(4 '_#Y[_@O+_T=[^V!_X)9O\ YD*
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M_P#,A0 ?\/GO^"\O_1WO[8'_ ()9O_F0H /^'SW_  7E_P"CO?VP/_!+-_\
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M@ _X?/?\%Y?^CO?VP/\ P2S?_,A0 ?\ #Y[_ (+R_P#1WO[8'_@EF_\ F0H
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MO_1WO[8'_@EF_P#F0H /^'SW_!>7_H[W]L#_ ,$LW_S(4 '_  ^>_P""\O\
MT=[^V!_X)9O_ )D* #_A\]_P7E_Z.]_; _\ !+-_\R% !_P^>_X+R_\ 1WO[
M8'_@EF_^9"@ _P"'SW_!>7_H[W]L#_P2S?\ S(4 '_#Y[_@O+_T=[^V!_P""
M6;_YD* #_A\]_P %Y?\ H[W]L#_P2S?_ #(4 '_#Y[_@O+_T=[^V!_X)9O\
MYD* #_A\]_P7E_Z.]_; _P#!+-_\R% !_P /GO\ @O+_ -'>_M@?^"6;_P"9
M"@ _X?/?\%Y?^CO?VP/_  2S?_,A0 ?\/GO^"\O_ $=[^V!_X)9O_F0H /\
MA\]_P7E_Z.]_; _\$LW_ ,R% !_P^>_X+R_]'>_M@?\ @EF_^9"@ _X?/?\
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M4 '_  ^>_P""\O\ T=[^V!_X)9O_ )D* #_A\]_P7E_Z.]_; _\ !+-_\R%
M!_P^>_X+R_\ 1WO[8'_@EF_^9"@ _P"'SW_!>7_H[W]L#_P2S?\ S(4 '_#Y
M[_@O+_T=[^V!_P""6;_YD* #_A\]_P %Y?\ H[W]L#_P2S?_ #(4 '_#Y[_@
MO+_T=[^V!_X)9O\ YD* #_A\]_P7E_Z.]_; _P#!+-_\R% !_P /GO\ @O+_
M -'>_M@?^"6;_P"9"@ _X?/?\%Y?^CO?VP/_  2S?_,A0 ?\/GO^"\O_ $=[
M^V!_X)9O_F0H /\ A\]_P7E_Z.]_; _\$LW_ ,R% !_P^>_X+R_]'>_M@?\
M@EF_^9"@ _X?/?\ !>7_ *.]_; _\$LW_P R% !_P^>_X+R_]'>_M@?^"6;_
M .9"@#]C_P#@@!_P4V_X*V?M"?\ !7#]DSX/_M-_M'?M(>//@?XN_P"%\?\
M";>$_'NERV_A/5?[ _9F^,OB?PW_ &K,WARP5/L/B[1= U*QS=Q;M2L[-/GS
MY3@'^E70!__2_OXH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
6* "@ H * "@ H * "@ H * "@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>mgnx-20231231_g2.jpg
<DESCRIPTION>PORTFOLIO TABLE 2
<TEXT>
begin 644 mgnx-20231231_g2.jpg
M_]C_X0#H17AI9@  34T *@    @ !@$2  ,    !  $   $:  4    !
M5@$;  4    !    7@$H  ,    !  (   (3  ,    !  $  (=I  0    !
M    9@        "0     0   )     !  B0   '    !# R,C&1 0 '
M! $" P"2A@ '    $@   ,R@   '    !# Q,#"@ 0 #     0 !  "@ @ $
M     0  %>"@ P $     0  "(:D!@ #     0          05-#24D   !3
M8W)E96YS:&]T  #_X@U824-#7U!23T9)3$4  0$   U(87!P; (0  !M;G1R
M4D="(%A96B 'Y0 %  8 #  ' "=A8W-P05!03     !!4%!,
M            ]M8  0    #3+6%P<&P
M                                 !)D97-C   !7    &)D<V-M   !
MP    >IC<')T   #K    "-W='!T   #T    !1R6%E:   #Y    !1G6%E:
M   #^    !1B6%E:   $#    !1R5%)#   $(   " QA87)G   ,+    "!V
M8V=T   ,3    #!N9&EN   ,?    #YC:&%D   ,O    "QM;6]D   ,Z
M "AV8V=P   -$    #AB5%)#   $(   " QG5%)#   $(   " QA86)G   ,
M+    "!A86=G   ,+    "!D97-C          A$:7-P;&%Y
M
M                                    ;6QU8P         F    #&AR
M2%(    2   !V&MO2U(    2   !V&YB3D\    2   !V&ED       2   !
MV&AU2%4    2   !V&-S0UH    2   !V&1A1$L    2   !V&YL3DP    2
M   !V&9I1DD    2   !V&ET250    2   !V&5S15,    2   !V')O4D\
M   2   !V&9R0T$    2   !V&%R       2   !V'5K54$    2   !V&AE
M24P    2   !V'IH5%<    2   !V'9I5DX    2   !V'-K4TL    2   !
MV'IH0TX    2   !V')U4E4    2   !V&5N1T(    2   !V&9R1E(    2
M   !V&US       2   !V&AI24X    2   !V'1H5$@    2   !V&-A15,
M   2   !V&5N054    2   !V&5S6$P    2   !V&1E1$4    2   !V&5N
M55,    2   !V'!T0E(    2   !V'!L4$P    2   !V&5L1U(    2   !
MV'-V4T4    2   !V'1R5%(    2   !V'!T4%0    2   !V&IA2E     2
M   !V !, $< ( !( $0 4@ @ #0 2P  =&5X=     !#;W!Y<FEG:'0@07!P
M;&4@26YC+BP@,C R,0  6%E:(        /,6  $    !%LI865H@
M?M0  #G?    P%A96B        !1T0  N80  !"L6%E:(        "8Q   ,
MG0  P<%C=7)V        !      %  H #P 4 !D '@ C "@ +0 R #8 .P!
M $4 2@!/ %0 60!> &, : !M '( =P!\ ($ A@"+ )  E0": )\ HP"H *T
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M]5#UWO9M]OOWBO@9^*CY./G'^E?ZY_MW_ ?\F/TI_;K^2_[<_VW__W!A<F$
M      ,    "9F8  /*G   -60  $]    I;=F-G=          !  $
M     0    $          0    $          0  ;F1I;@         V  "N
M0   3\   $2   "IP   )H    R   !0    5$   C,S  (S,P ",S,
M     '-F,S(       $,<@  !?C___,=   'N@  _7+___N=___]I    ]D
M ,!Q;6UO9        !YM  !W4  *CR;:A*                       '9C
M9W        ,    "9F8  P    )F9@ #     F9F     C,S       ",S,
M      (S,P  _^H$3D%23U0      1#;B@  YY(  /.:  #_H@  "ZL  !>S
M  #6PP  G-,  -+V  !@&P$ 6#D! ']5 0#%<@$ A9<! +ND 0!@L $ KN$!
M * 2 @!\EP( 'A\# "J2 P E] , -&$$ &GN! !A_@0 B H% )02!0"@&@4
MK"(% #N1!0 (E@4 U9H% **?!0!OI 4 /*D% )&[!0!;T04 N24& ),^!@ D
M6 8 TH & !ZN!@#,^P8 S4H' /Z&!P"EPP< /0P( +=9"  C: @ %W@(  F&
M" !SCP@ [ID( &&@"  NI0@ ^ZD( ,BN" "5LP@ Z.D( *<C"0!T* D 02T)
M  XR"0#;-@D YCL) /% "0#\10D YE() )5>"0"R>@D ;9D) '^P"0"$Q0D
M!]\) 'W]"0"( @H DP<* )X,"@"A4PH ;E@* #M="@ (8@H U68* (FC"@#'
MW0H JNL* )[Z"@#+$0L UU0+ $]M"P &A L U)@+ !NS"P!KS@L $  , .DT
M#  ,80P ]X,, &:T# #DZ0P +OX, $D+#0#)&0T U48- +53#0"#7PT MVH-
M )=V#0!EO T R@$. )<&#@!D"PX ,1 . /X4#@ 81@X \TH. ,Y/#@!J7@X
M06L.  Z*#@!%J@X !,(. !#7#@"(\@X *!$/ )47#P"/'0\ :B(/ $4G#P 2
M+ \ WS / *PU#P!Y.@\ =6P/ $)Q#P /=@\ W'H/ *E_#P QQ \ .LD/ $/.
M#P!,TP\ L^0/ %_V#P 7$!  92<0 !([$ !(3A  J&40 (M^$ #8DA  C:<0
M 'RX$  GSA  Q> 0 $WX$ ")#1$ 1!81 "A9$0 :D!$ .IT1 *2N$0!;O!$
M#P$2 *@)$@!4%!( L!\2 )\R$@!=0Q( 8V(2 #1[$@"ND!( FZ82 )G"$@ \
MSQ( H]82 /?<$@#WX1( 61@3 "8=$P#S(1, P"83 (TK$P H:!, ]6P3 ,)Q
M$P"/=A, 7'L3 "F $P#>E!, 1<T3  [?$P J]Q, _1$4 *TR% !/4A0 >XP4
M  "N% #=RQ0 +NT4 #\J%0""1Q4 ?U\5 +%[%0":C!4 ,\ 5 $#.%0!>U!4
M*]D5 /C=%0#%XA4 DN<5 (8E%@!3*A8 ("\6 .TS%@"Z.!8 P3X6  =7%@ /
M=Q8 ;Z06 )N^%@!"WQ8 ZQ$7 &P_%P#(7A< Y'P7 *N9%P"#N!< %O$7 &H+
M& "T(!@ @S48 *E,& #8>1@  (T8 #B6&  1GA@ _J48 $JL&  7L1@ J>T8
M ';R& !#]Q@ $/P8 -T &0"="AD 5A<9   I&0!I1AD >%T9 )J &0!EL1D
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M$(0BY3G.348PA&*;E*3:48I7;LD@T2N]$MWLDD?&W_#S_P#X)I?])#OV&?\
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M/_B6GP#_ /F_KK_L;-_^A5F7_A#B?_E1/M:7_/RG_P"!Q_S#_AY__P $TO\
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M^):? /\ ^;^C^QLW_P"A5F7_ (0XG_Y4'M:7_/RG_P"!Q_S#_AY__P $TO\
MI(=^PS_XEI\ _P#YOZ/[&S?_ *%69?\ A#B?_E0>UI?\_*?_ (''_,/^'G__
M  32_P"DAW[#/_B6GP#_ /F_H_L;-_\ H59E_P"$.)_^5![6E_S\I_\ @<?\
MP_X>?_\ !-+_ *2'?L,_^):? /\ ^;^C^QLW_P"A5F7_ (0XG_Y4'M:7_/RG
M_P"!Q_S#_AY__P $TO\ I(=^PS_XEI\ _P#YOZ/[&S?_ *%69?\ A#B?_E0>
MUI?\_*?_ (''_,/^'G__  32_P"DAW[#/_B6GP#_ /F_H_L;-_\ H59E_P"$
M.)_^5![6E_S\I_\ @<?\P_X>?_\ !-+_ *2'?L,_^):? /\ ^;^C^QLW_P"A
M5F7_ (0XG_Y4'M:7_/RG_P"!Q_S#_AY__P $TO\ I(=^PS_XEI\ _P#YOZ/[
M&S?_ *%69?\ A#B?_E0>UI?\_*?_ (''_,/^'G__  32_P"DAW[#/_B6GP#_
M /F_H_L;-_\ H59E_P"$.)_^5![6E_S\I_\ @<?\P_X>?_\ !-+_ *2'?L,_
M^):? /\ ^;^C^QLW_P"A5F7_ (0XG_Y4'M:7_/RG_P"!Q_S#_AY__P $TO\
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M^):? /\ ^;^C^QLW_P"A5F7_ (0XG_Y4'M:7_/RG_P"!Q_S#_AY__P $TO\
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M^):? /\ ^;^C^QLW_P"A5F7_ (0XG_Y4'M:7_/RG_P"!Q_S#_AY__P $TO\
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M^):? /\ ^;^C^QLW_P"A5F7_ (0XG_Y4'M:7_/RG_P"!Q_S#_AY__P $TO\
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M^):? /\ ^;^C^QLW_P"A5F7_ (0XG_Y4'M:7_/RG_P"!Q_S#_AY__P $TO\
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M^):? /\ ^;^C^QLW_P"A5F7_ (0XG_Y4'M:7_/RG_P"!Q_S#_AY__P $TO\
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M^):? /\ ^;^C^QLW_P"A5F7_ (0XG_Y4'M:7_/RG_P"!Q_S#_AY__P $TO\
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M^):? /\ ^;^C^QLW_P"A5F7_ (0XG_Y4'M:7_/RG_P"!Q_S#_AY__P $TO\
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M^):? /\ ^;^C^QLW_P"A5F7_ (0XG_Y4'M:7_/RG_P"!Q_S#_AY__P $TO\
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M^):? /\ ^;^C^QLW_P"A5F7_ (0XG_Y4'M:7_/RG_P"!Q_S#_AY__P $TO\
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M^):? /\ ^;^C^QLW_P"A5F7_ (0XG_Y4'M:7_/RG_P"!Q_S#_AY__P $TO\
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M^):? /\ ^;^C^QLW_P"A5F7_ (0XG_Y4'M:7_/RG_P"!Q_S#_AY__P $TO\
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M^):? /\ ^;^C^QLW_P"A5F7_ (0XG_Y4'M:7_/RG_P"!Q_S#_AY__P $TO\
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M^):? /\ ^;^C^QLW_P"A5F7_ (0XG_Y4'M:7_/RG_P"!Q_S#_AY__P $TO\
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M^DAW[#/_ (EI\ __ )OZ/[&S?_H59E_X0XG_ .5![6E_S\I_^!Q_S#_AY_\
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M^DAW[#/_ (EI\ __ )OZ/[&S?_H59E_X0XG_ .5![6E_S\I_^!Q_S#_AY_\
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M^DAW[#/_ (EI\ __ )OZ/[&S?_H59E_X0XG_ .5![6E_S\I_^!Q_S#_AY_\
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M^DAW[#/_ (EI\ __ )OZ/[&S?_H59E_X0XG_ .5![6E_S\I_^!Q_S#_AY_\
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M^DAW[#/_ (EI\ __ )OZ/[&S?_H59E_X0XG_ .5![6E_S\I_^!Q_S#_AY_\
M\$TO^DAW[#/_ (EI\ __ )OZ/[&S?_H59E_X0XG_ .5![6E_S\I_^!Q_S#_A
MY_\ \$TO^DAW[#/_ (EI\ __ )OZ/[&S?_H59E_X0XG_ .5![6E_S\I_^!Q_
MS#_AY_\ \$TO^DAW[#/_ (EI\ __ )OZ/[&S?_H59E_X0XG_ .5![6E_S\I_
M^!Q_S#_AY_\ \$TO^DAW[#/_ (EI\ __ )OZ/[&S?_H59E_X0XG_ .5![6E_
MS\I_^!Q_S#_AY_\ \$TO^DAW[#/_ (EI\ __ )OZ/[&S?_H59E_X0XG_ .5!
M[6E_S\I_^!Q_S#_AY_\ \$TO^DAW[#/_ (EI\ __ )OZ/[&S?_H59E_X0XG_
M .5![6E_S\I_^!Q_S#_AY_\ \$TO^DAW[#/_ (EI\ __ )OZ/[&S?_H59E_X
M0XG_ .5![6E_S\I_^!Q_S#_AY_\ \$TO^DAW[#/_ (EI\ __ )OZ/[&S?_H5
M9E_X0XG_ .5![6E_S\I_^!Q_S#_AY_\ \$TO^DAW[#/_ (EI\ __ )OZ/[&S
M?_H59E_X0XG_ .5![6E_S\I_^!Q_S#_AY_\ \$TO^DAW[#/_ (EI\ __ )OZ
M/[&S?_H59E_X0XG_ .5![6E_S\I_^!Q_S#_AY_\ \$TO^DAW[#/_ (EI\ __
M )OZ/[&S?_H59E_X0XG_ .5![6E_S\I_^!Q_S#_AY_\ \$TO^DAW[#/_ (EI
M\ __ )OZ/[&S?_H59E_X0XG_ .5![6E_S\I_^!Q_S/>O@S^TK^SE^T=;:_>_
ML\_'[X)_'BS\*3Z?:^*+OX,_%3P+\4+;PW<ZM'=2Z5;:_/X(UW7(M'GU**PO
MI-/AU!K:2\CLKI[99%MYBG+B,'B\)RK%87$89SOR+$4*E'G4;7Y54C'FY;J]
MMKHJ,HR^&496_E:=ON/;*YRCY+^(/[?/["GPE\8ZY\._BK^VG^R7\,OB!X8G
M@M?$G@7X@_M&_![P9XQ\/7-U96VHVUMKGACQ'XQTW6M)GN-/O+.^@AO[&WDE
MLKJVNHU:">)V[J65YE7IQJT,NQU:E-7A4I82O4IR2=O=G"FXM)IK1[JW0AU*
M<79S@FNCE%-?*YQO_#S_ /X)I?\ 20[]AG_Q+3X!_P#S?UI_8V;_ /0JS+_P
MAQ/_ ,J%[6E_S\I_^!Q_S#_AY_\ \$TO^DAW[#/_ (EI\ __ )OZ/[&S?_H5
M9E_X0XG_ .5![6E_S\I_^!Q_S#_AY_\ \$TO^DAW[#/_ (EI\ __ )OZ/[&S
M?_H59E_X0XG_ .5![6E_S\I_^!Q_S#_AY_\ \$TO^DAW[#/_ (EI\ __ )OZ
M/[&S?_H59E_X0XG_ .5![6E_S\I_^!Q_S#_AY_\ \$TO^DAW[#/_ (EI\ __
M )OZ/[&S?_H59E_X0XG_ .5![6E_S\I_^!Q_S#_AY_\ \$TO^DAW[#/_ (EI
M\ __ )OZ/[&S?_H59E_X0XG_ .5![6E_S\I_^!Q_S#_AY_\ \$TO^DAW[#/_
M (EI\ __ )OZ/[&S?_H59E_X0XG_ .5![6E_S\I_^!Q_S#_AY_\ \$TO^DAW
M[#/_ (EI\ __ )OZ/[&S?_H59E_X0XG_ .5![6E_S\I_^!Q_S#_AY_\ \$TO
M^DAW[#/_ (EI\ __ )OZ/[&S?_H59E_X0XG_ .5![6E_S\I_^!Q_S#_AY_\
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M^DAW[#/_ (EI\ __ )OZ/[&S?_H59E_X0XG_ .5![6E_S\I_^!Q_S#_AY_\
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M^DAW[#/_ (EI\ __ )OZ/[&S?_H59E_X0XG_ .5![6E_S\I_^!Q_S#_AY_\
M\$TO^DAW[#/_ (EI\ __ )OZ/[&S?_H59E_X0XG_ .5![6E_S\I_^!Q_S#_A
MY_\ \$TO^DAW[#/_ (EI\ __ )OZ/[&S?_H59E_X0XG_ .5![6E_S\I_^!Q_
MS#_AY_\ \$TO^DAW[#/_ (EI\ __ )OZ/[&S?_H59E_X0XG_ .5![6E_S\I_
M^!Q_S#_AY_\ \$TO^DAW[#/_ (EI\ __ )OZ/[&S?_H59E_X0XG_ .5![6E_
MS\I_^!Q_S#_AY_\ \$TO^DAW[#/_ (EI\ __ )OZ/[&S?_H59E_X0XG_ .5!
M[6E_S\I_^!Q_S#_AY_\ \$TO^DAW[#/_ (EI\ __ )OZ/[&S?_H59E_X0XG_
M .5![6E_S\I_^!Q_S#_AY_\ \$TO^DAW[#/_ (EI\ __ )OZ/[&S?_H59E_X
M0XG_ .5![6E_S\I_^!Q_S#_AY_\ \$TO^DAW[#/_ (EI\ __ )OZ/[&S?_H5
M9E_X0XG_ .5![6E_S\I_^!Q_S#_AY_\ \$TO^DAW[#/_ (EI\ __ )OZ/[&S
M?_H59E_X0XG_ .5![6E_S\I_^!Q_S#_AY_\ \$TO^DAW[#/_ (EI\ __ )OZ
M/[&S?_H59E_X0XG_ .5![6E_S\I_^!Q_S#_AY_\ \$TO^DAW[#/_ (EI\ __
M )OZ/[&S?_H59E_X0XG_ .5![6E_S\I_^!Q_S#_AY_\ \$TO^DAW[#/_ (EI
M\ __ )OZ/[&S?_H59E_X0XG_ .5![6E_S\I_^!Q_S#_AY_\ \$TO^DAW[#/_
M (EI\ __ )OZ/[&S?_H59E_X0XG_ .5![6E_S\I_^!Q_S#_AY_\ \$TO^DAW
M[#/_ (EI\ __ )OZ/[&S?_H59E_X0XG_ .5![6E_S\I_^!Q_S#_AY_\ \$TO
M^DAW[#/_ (EI\ __ )OZ/[&S?_H59E_X0XG_ .5![6E_S\I_^!Q_S#_AY_\
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MC^QLW_Z%69?^$.)_^5![6E_S\I_^!Q_S#_AY_P#\$TO^DAW[#/\ XEI\ _\
MYOZ/[&S?_H59E_X0XG_Y4'M:7_/RG_X''_,/^'G_ /P32_Z2'?L,_P#B6GP#
M_P#F_H_L;-_^A5F7_A#B?_E0>UI?\_*?_@<?\P_X>?\ _!-+_I(=^PS_ .):
M? /_ .;^C^QLW_Z%69?^$.)_^5![6E_S\I_^!Q_S#_AY_P#\$TO^DAW[#/\
MXEI\ _\ YOZ/[&S?_H59E_X0XG_Y4'M:7_/RG_X''_,/^'G_ /P32_Z2'?L,
M_P#B6GP#_P#F_H_L;-_^A5F7_A#B?_E0>UI?\_*?_@<?\P_X>?\ _!-+_I(=
M^PS_ .):? /_ .;^C^QLW_Z%69?^$.)_^5![6E_S\I_^!Q_S#_AY_P#\$TO^
MDAW[#/\ XEI\ _\ YOZ/[&S?_H59E_X0XG_Y4'M:7_/RG_X''_,/^'G_ /P3
M2_Z2'?L,_P#B6GP#_P#F_H_L;-_^A5F7_A#B?_E0>UI?\_*?_@<?\P_X>?\
M_!-+_I(=^PS_ .):? /_ .;^C^QLW_Z%69?^$.)_^5![6E_S\I_^!Q_S#_AY
M_P#\$TO^DAW[#/\ XEI\ _\ YOZ/[&S?_H59E_X0XG_Y4'M:7_/RG_X''_,/
M^'G_ /P32_Z2'?L,_P#B6GP#_P#F_H_L;-_^A5F7_A#B?_E0>UI?\_*?_@<?
M\P_X>?\ _!-+_I(=^PS_ .):? /_ .;^C^QLW_Z%69?^$.)_^5![6E_S\I_^
M!Q_S#_AY_P#\$TO^DAW[#/\ XEI\ _\ YOZ/[&S?_H59E_X0XG_Y4'M:7_/R
MG_X''_,/^'G_ /P32_Z2'?L,_P#B6GP#_P#F_H_L;-_^A5F7_A#B?_E0>UI?
M\_*?_@<?\P_X>?\ _!-+_I(=^PS_ .):? /_ .;^C^QLW_Z%69?^$.)_^5![
M6E_S\I_^!Q_S#_AY_P#\$TO^DAW[#/\ XEI\ _\ YOZ/[&S?_H59E_X0XG_Y
M4'M:7_/RG_X''_,/^'G_ /P32_Z2'?L,_P#B6GP#_P#F_H_L;-_^A5F7_A#B
M?_E0>UI?\_*?_@<?\P_X>?\ _!-+_I(=^PS_ .):? /_ .;^C^QLW_Z%69?^
M$.)_^5![6E_S\I_^!Q_S#_AY_P#\$TO^DAW[#/\ XEI\ _\ YOZ/[&S?_H59
ME_X0XG_Y4'M:7_/RG_X''_,/^'G_ /P32_Z2'?L,_P#B6GP#_P#F_H_L;-_^
MA5F7_A#B?_E0>UI?\_*?_@<?\P_X>?\ _!-+_I(=^PS_ .):? /_ .;^C^QL
MW_Z%69?^$.)_^5![6E_S\I_^!Q_S#_AY_P#\$TO^DAW[#/\ XEI\ _\ YOZ/
M[&S?_H59E_X0XG_Y4'M:7_/RG_X''_,/^'G_ /P32_Z2'?L,_P#B6GP#_P#F
M_H_L;-_^A5F7_A#B?_E0>UI?\_*?_@<?\P_X>?\ _!-+_I(=^PS_ .):? /_
M .;^C^QLW_Z%69?^$.)_^5![6E_S\I_^!Q_S#_AY_P#\$TO^DAW[#/\ XEI\
M _\ YOZ/[&S?_H59E_X0XG_Y4'M:7_/RG_X''_,/^'G_ /P32_Z2'?L,_P#B
M6GP#_P#F_H_L;-_^A5F7_A#B?_E0>UI?\_*?_@<?\P_X>?\ _!-+_I(=^PS_
M .):? /_ .;^C^QLW_Z%69?^$.)_^5![6E_S\I_^!Q_S#_AY_P#\$TO^DAW[
M#/\ XEI\ _\ YOZ/[&S?_H59E_X0XG_Y4'M:7_/RG_X''_,/^'G_ /P32_Z2
M'?L,_P#B6GP#_P#F_H_L;-_^A5F7_A#B?_E0>UI?\_*?_@<?\P_X>?\ _!-+
M_I(=^PS_ .):? /_ .;^C^QLW_Z%69?^$.)_^5![6E_S\I_^!Q_S#_AY_P#\
M$TO^DAW[#/\ XEI\ _\ YOZ/[&S?_H59E_X0XG_Y4'M:7_/RG_X''_,/^'G_
M /P32_Z2'?L,_P#B6GP#_P#F_H_L;-_^A5F7_A#B?_E0>UI?\_*?_@<?\P_X
M>?\ _!-+_I(=^PS_ .):? /_ .;^C^QLW_Z%69?^$.)_^5![6E_S\I_^!Q_S
M#_AY_P#\$TO^DAW[#/\ XEI\ _\ YOZ/[&S?_H59E_X0XG_Y4'M:7_/RG_X'
M'_,O:7_P4K_X)RZWJ>G:+HO[?O[$^KZQJ]]::7I.DZ7^U3\"K_4]4U._N([2
MPT[3K"T\=RW5[?7MU+%;6EI;127%S<21PPQO(ZJ4\GS:*<I97F,8Q3;;P6)2
M22U;;I622W>R0>UI?\_*?_@<?\S[8KSC0\^^)_Q:^%7P1\':A\1/C/\ $SX?
M?"+X?Z3/86NJ>.OB?XS\.> ?!VF7.JWD.G:7;:AXF\5ZEI.B6<^I:A<6]A80
MW%[')>7D\-K;K)/*B'6C0K8BHJ6'HU:]5IN-*C3G5J-15W:$$Y-)*[LM$)M1
M5Y-17=M)'RU_P\__ .":7_20[]AG_P 2T^ ?_P W]=O]C9O_ -"K,O\ PAQ/
M_P J(]K2_P"?E/\ \#C_ )A_P\__ .":7_20[]AG_P 2T^ ?_P W]']C9O\
M]"K,O_"'$_\ RH/:TO\ GY3_ / X_P"8?\//_P#@FE_TD._89_\ $M/@'_\
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MFE_TD._89_\ $M/@'_\ -_1_8V;_ /0JS+_PAQ/_ ,J#VM+_ )^4_P#P./\
MF'_#S_\ X)I?])#OV&?_ !+3X!__ #?T?V-F_P#T*LR_\(<3_P#*@]K2_P"?
ME/\ \#C_ )A_P\__ .":7_20[]AG_P 2T^ ?_P W]']C9O\ ]"K,O_"'$_\
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MS_\ X)I?])#OV&?_ !+3X!__ #?T?V-F_P#T*LR_\(<3_P#*@]K2_P"?E/\
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M9_\ $M/@'_\ -_1_8V;_ /0JS+_PAQ/_ ,J#VM+_ )^4_P#P./\ F'_#S_\
MX)I?])#OV&?_ !+3X!__ #?T?V-F_P#T*LR_\(<3_P#*@]K2_P"?E/\ \#C_
M )A_P\__ .":7_20[]AG_P 2T^ ?_P W]']C9O\ ]"K,O_"'$_\ RH/:TO\
MGY3_ / X_P"8?\//_P#@FE_TD._89_\ $M/@'_\ -_1_8V;_ /0JS+_PAQ/_
M ,J#VM+_ )^4_P#P./\ F'_#S_\ X)I?])#OV&?_ !+3X!__ #?T?V-F_P#T
M*LR_\(<3_P#*@]K2_P"?E/\ \#C_ )A_P\__ .":7_20[]AG_P 2T^ ?_P W
M]']C9O\ ]"K,O_"'$_\ RH/:TO\ GY3_ / X_P"8?\//_P#@FE_TD._89_\
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M_P#*@]K2_P"?E/\ \#C_ )A_P\__ .":7_20[]AG_P 2T^ ?_P W]']C9O\
M]"K,O_"'$_\ RH/:TO\ GY3_ / X_P"8?\//_P#@FE_TD._89_\ $M/@'_\
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MO^DAW[#/_B6GP#_^;^C^QLW_ .A5F7_A#B?_ )4'M:7_ #\I_P#@<?\ ,/\
MAY__ ,$TO^DAW[#/_B6GP#_^;^C^QLW_ .A5F7_A#B?_ )4'M:7_ #\I_P#@
M<?\ ,/\ AY__ ,$TO^DAW[#/_B6GP#_^;^C^QLW_ .A5F7_A#B?_ )4'M:7_
M #\I_P#@<?\ ,/\ AY__ ,$TO^DAW[#/_B6GP#_^;^C^QLW_ .A5F7_A#B?_
M )4'M:7_ #\I_P#@<?\ ,/\ AY__ ,$TO^DAW[#/_B6GP#_^;^C^QLW_ .A5
MF7_A#B?_ )4'M:7_ #\I_P#@<?\ ,/\ AY__ ,$TO^DAW[#/_B6GP#_^;^C^
MQLW_ .A5F7_A#B?_ )4'M:7_ #\I_P#@<?\ ,/\ AY__ ,$TO^DAW[#/_B6G
MP#_^;^C^QLW_ .A5F7_A#B?_ )4'M:7_ #\I_P#@<?\ ,/\ AY__ ,$TO^DA
MW[#/_B6GP#_^;^C^QLW_ .A5F7_A#B?_ )4'M:7_ #\I_P#@<?\ ,/\ AY__
M ,$TO^DAW[#/_B6GP#_^;^C^QLW_ .A5F7_A#B?_ )4'M:7_ #\I_P#@<?\
M,/\ AY__ ,$TO^DAW[#/_B6GP#_^;^C^QLW_ .A5F7_A#B?_ )4'M:7_ #\I
M_P#@<?\ ,/\ AY__ ,$TO^DAW[#/_B6GP#_^;^C^QLW_ .A5F7_A#B?_ )4'
MM:7_ #\I_P#@<?\ ,/\ AY__ ,$TO^DAW[#/_B6GP#_^;^C^QLW_ .A5F7_A
M#B?_ )4'M:7_ #\I_P#@<?\ ,/\ AY__ ,$TO^DAW[#/_B6GP#_^;^C^QLW_
M .A5F7_A#B?_ )4'M:7_ #\I_P#@<?\ ,/\ AY__ ,$TO^DAW[#/_B6GP#_^
M;^C^QLW_ .A5F7_A#B?_ )4'M:7_ #\I_P#@<?\ ,/\ AY__ ,$TO^DAW[#/
M_B6GP#_^;^C^QLW_ .A5F7_A#B?_ )4'M:7_ #\I_P#@<?\ ,/\ AY__ ,$T
MO^DAW[#/_B6GP#_^;^C^QLW_ .A5F7_A#B?_ )4'M:7_ #\I_P#@<?\ ,/\
MAY__ ,$TO^DAW[#/_B6GP#_^;^C^QLW_ .A5F7_A#B?_ )4'M:7_ #\I_P#@
M<?\ ,/\ AY__ ,$TO^DAW[#/_B6GP#_^;^C^QLW_ .A5F7_A#B?_ )4'M:7_
M #\I_P#@<?\ ,/\ AY__ ,$TO^DAW[#/_B6GP#_^;^C^QLW_ .A5F7_A#B?_
M )4'M:7_ #\I_P#@<?\ ,/\ AY__ ,$TO^DAW[#/_B6GP#_^;^C^QLW_ .A5
MF7_A#B?_ )4'M:7_ #\I_P#@<?\ ,/\ AY__ ,$TO^DAW[#/_B6GP#_^;^C^
MQLW_ .A5F7_A#B?_ )4'M:7_ #\I_P#@<?\ ,/\ AY__ ,$TO^DAW[#/_B6G
MP#_^;^C^QLW_ .A5F7_A#B?_ )4'M:7_ #\I_P#@<?\ ,/\ AY__ ,$TO^DA
MW[#/_B6GP#_^;^C^QLW_ .A5F7_A#B?_ )4'M:7_ #\I_P#@<?\ ,/\ AY__
M ,$TO^DAW[#/_B6GP#_^;^C^QLW_ .A5F7_A#B?_ )4'M:7_ #\I_P#@<?\
M,/\ AY__ ,$TO^DAW[#/_B6GP#_^;^C^QLW_ .A5F7_A#B?_ )4'M:7_ #\I
M_P#@<?\ ,/\ AY__ ,$TO^DAW[#/_B6GP#_^;^C^QLW_ .A5F7_A#B?_ )4'
MM:7_ #\I_P#@<?\ ,/\ AY__ ,$TO^DAW[#/_B6GP#_^;^C^QLW_ .A5F7_A
M#B?_ )4'M:7_ #\I_P#@<?\ ,/\ AY__ ,$TO^DAW[#/_B6GP#_^;^C^QLW_
M .A5F7_A#B?_ )4'M:7_ #\I_P#@<?\ ,/\ AY__ ,$TO^DAW[#/_B6GP#_^
M;^C^QLW_ .A5F7_A#B?_ )4'M:7_ #\I_P#@<?\ ,/\ AY__ ,$TO^DAW[#/
M_B6GP#_^;^C^QLW_ .A5F7_A#B?_ )4'M:7_ #\I_P#@<?\ ,/\ AY__ ,$T
MO^DAW[#/_B6GP#_^;^C^QLW_ .A5F7_A#B?_ )4'M:7_ #\I_P#@<?\ ,/\
MAY__ ,$TO^DAW[#/_B6GP#_^;^C^QLW_ .A5F7_A#B?_ )4'M:7_ #\I_P#@
M<?\ ,/\ AY__ ,$TO^DAW[#/_B6GP#_^;^C^QLW_ .A5F7_A#B?_ )4'M:7_
M #\I_P#@<?\ ,/\ AY__ ,$TO^DAW[#/_B6GP#_^;^C^QLW_ .A5F7_A#B?_
M )4'M:7_ #\I_P#@<?\ ,/\ AY__ ,$TO^DAW[#/_B6GP#_^;^C^QLW_ .A5
MF7_A#B?_ )4'M:7_ #\I_P#@<?\ ,/\ AY__ ,$TO^DAW[#/_B6GP#_^;^C^
MQLW_ .A5F7_A#B?_ )4'M:7_ #\I_P#@<?\ ,/\ AY__ ,$TO^DAW[#/_B6G
MP#_^;^C^QLW_ .A5F7_A#B?_ )4'M:7_ #\I_P#@<?\ ,/\ AY__ ,$TO^DA
MW[#/_B6GP#_^;^C^QLW_ .A5F7_A#B?_ )4'M:7_ #\I_P#@<?\ ,/\ AY__
M ,$TO^DAW[#/_B6GP#_^;^C^QLW_ .A5F7_A#B?_ )4'M:7_ #\I_P#@<?\
M,/\ AY__ ,$TO^DAW[#/_B6GP#_^;^C^QLW_ .A5F7_A#B?_ )4'M:7_ #\I
M_P#@<?\ ,/\ AY__ ,$TO^DAW[#/_B6GP#_^;^C^QLW_ .A5F7_A#B?_ )4'
MM:7_ #\I_P#@<?\ ,/\ AY__ ,$TO^DAW[#/_B6GP#_^;^C^QLW_ .A5F7_A
M#B?_ )4'M:7_ #\I_P#@<?\ ,/\ AY__ ,$TO^DAW[#/_B6GP#_^;^C^QLW_
M .A5F7_A#B?_ )4'M:7_ #\I_P#@<?\ ,/\ AY__ ,$TO^DAW[#/_B6GP#_^
M;^C^QLW_ .A5F7_A#B?_ )4'M:7_ #\I_P#@<?\ ,/\ AY__ ,$TO^DAW[#/
M_B6GP#_^;^C^QLW_ .A5F7_A#B?_ )4'M:7_ #\I_P#@<?\ ,/\ AY__ ,$T
MO^DAW[#/_B6GP#_^;^C^QLW_ .A5F7_A#B?_ )4'M:7_ #\I_P#@<?\ ,/\
MAY__ ,$TO^DAW[#/_B6GP#_^;^C^QLW_ .A5F7_A#B?_ )4'M:7_ #\I_P#@
M<?\ ,/\ AY__ ,$TO^DAW[#/_B6GP#_^;^C^QLW_ .A5F7_A#B?_ )4'M:7_
M #\I_P#@<?\ ,/\ AY__ ,$TO^DAW[#/_B6GP#_^;^C^QLW_ .A5F7_A#B?_
M )4'M:7_ #\I_P#@<?\ ,/\ AY__ ,$TO^DAW[#/_B6GP#_^;^C^QLW_ .A5
MF7_A#B?_ )4'M:7_ #\I_P#@<?\ ,/\ AY__ ,$TO^DAW[#/_B6GP#_^;^C^
MQLW_ .A5F7_A#B?_ )4'M:7_ #\I_P#@<?\ ,/\ AY__ ,$TO^DAW[#/_B6G
MP#_^;^C^QLW_ .A5F7_A#B?_ )4'M:7_ #\I_P#@<?\ ,/\ AY__ ,$TO^DA
MW[#/_B6GP#_^;^C^QLW_ .A5F7_A#B?_ )4'M:7_ #\I_P#@<?\ ,/\ AY__
M ,$TO^DAW[#/_B6GP#_^;^C^QLW_ .A5F7_A#B?_ )4'M:7_ #\I_P#@<?\
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M;_\ 0JS+_P (<3_\J#VM+_GY3_\  X_YA_P\_P#^":7_ $D._89_\2T^ ?\
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M;_\ 0JS+_P (<3_\J#VM+_GY3_\  X_YA_P\_P#^":7_ $D._89_\2T^ ?\
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M;_\ 0JS+_P (<3_\J#VM+_GY3_\  X_YA_P\_P#^":7_ $D._89_\2T^ ?\
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M;_\ 0JS+_P (<3_\J#VM+_GY3_\  X_YA_P\_P#^":7_ $D._89_\2T^ ?\
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M;_\ 0JS+_P (<3_\J#VM+_GY3_\  X_YA_P\_P#^":7_ $D._89_\2T^ ?\
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M;_\ 0JS+_P (<3_\J#VM+_GY3_\  X_YA_P\_P#^":7_ $D._89_\2T^ ?\
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M;_\ 0JS+_P (<3_\J#VM+_GY3_\  X_YA_P\_P#^":7_ $D._89_\2T^ ?\
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MLW_Z%69?^$.)_P#E1G[6E_S\I_\ @<?\P_X>?_\ !-+_ *2'?L,_^):? /\
M^;^C^QLW_P"A5F7_ (0XG_Y4'M:7_/RG_P"!Q_S#_AY__P $TO\ I(=^PS_X
MEI\ _P#YOZ/[&S?_ *%69?\ A#B?_E0>UI?\_*?_ (''_,/^'G__  32_P"D
MAW[#/_B6GP#_ /F_H_L;-_\ H59E_P"$.)_^5![6E_S\I_\ @<?\P_X>?_\
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M-_\ H59E_P"$.)_^5![6E_S\I_\ @<?\P_X>?_\ !-+_ *2'?L,_^):? /\
M^;^C^QLW_P"A5F7_ (0XG_Y4'M:7_/RG_P"!Q_S#_AY__P $TO\ I(=^PS_X
MEI\ _P#YOZ/[&S?_ *%69?\ A#B?_E0>UI?\_*?_ (''_,/^'G__  32_P"D
MAW[#/_B6GP#_ /F_H_L;-_\ H59E_P"$.)_^5![6E_S\I_\ @<?\P_X>?_\
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M-_\ H59E_P"$.)_^5![6E_S\I_\ @<?\P_X>?_\ !-+_ *2'?L,_^):? /\
M^;^C^QLW_P"A5F7_ (0XG_Y4'M:7_/RG_P"!Q_S#_AY__P $TO\ I(=^PS_X
MEI\ _P#YOZ/[&S?_ *%69?\ A#B?_E0>UI?\_*?_ (''_,/^'G__  32_P"D
MAW[#/_B6GP#_ /F_H_L;-_\ H59E_P"$.)_^5![6E_S\I_\ @<?\P_X>?_\
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M-_\ H59E_P"$.)_^5![6E_S\I_\ @<?\P_X>?_\ !-+_ *2'?L,_^):? /\
M^;^C^QLW_P"A5F7_ (0XG_Y4'M:7_/RG_P"!Q_S#_AY__P $TO\ I(=^PS_X
MEI\ _P#YOZ/[&S?_ *%69?\ A#B?_E0>UI?\_*?_ (''_,/^'G__  32_P"D
MAW[#/_B6GP#_ /F_H_L;-_\ H59E_P"$.)_^5![6E_S\I_\ @<?\P_X>?_\
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M-_\ H59E_P"$.)_^5![6E_S\I_\ @<?\P_X>?_\ !-+_ *2'?L,_^):? /\
M^;^C^QLW_P"A5F7_ (0XG_Y4'M:7_/RG_P"!Q_S#_AY__P $TO\ I(=^PS_X
MEI\ _P#YOZ/[&S?_ *%69?\ A#B?_E0>UI?\_*?_ (''_,/^'G__  32_P"D
MAW[#/_B6GP#_ /F_H_L;-_\ H59E_P"$.)_^5![6E_S\I_\ @<?\P_X>?_\
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M-_\ H59E_P"$.)_^5![6E_S\I_\ @<?\P_X>?_\ !-+_ *2'?L,_^):? /\
M^;^C^QLW_P"A5F7_ (0XG_Y4'M:7_/RG_P"!Q_S#_AY__P $TO\ I(=^PS_X
MEI\ _P#YOZ/[&S?_ *%69?\ A#B?_E0>UI?\_*?_ (''_,/^'G__  32_P"D
MAW[#/_B6GP#_ /F_H_L;-_\ H59E_P"$.)_^5![6E_S\I_\ @<?\P_X>?_\
M!-+_ *2'?L,_^):? /\ ^;^C^QLW_P"A5F7_ (0XG_Y4'M:7_/RG_P"!Q_S#
M_AY__P $TO\ I(=^PS_XEI\ _P#YOZ/[&S?_ *%69?\ A#B?_E0>UI?\_*?_
M (''_,/^'G__  32_P"DAW[#/_B6GP#_ /F_H_L;-_\ H59E_P"$.)_^5![6
ME_S\I_\ @<?\P_X>?_\ !-+_ *2'?L,_^):? /\ ^;^C^QLW_P"A5F7_ (0X
MG_Y4'M:7_/RG_P"!Q_S#_AY__P $TO\ I(=^PS_XEI\ _P#YOZ/[&S?_ *%6
M9?\ A#B?_E0>UI?\_*?_ (''_,/^'G__  32_P"DAW[#/_B6GP#_ /F_H_L;
M-_\ H59E_P"$.)_^5![6E_S\I_\ @<?\P_X>?_\ !-+_ *2'?L,_^):? /\
M^;^C^QLW_P"A5F7_ (0XG_Y4'M:7_/RG_P"!Q_S#_AY__P $TO\ I(=^PS_X
MEI\ _P#YOZ/[&S?_ *%69?\ A#B?_E0>UI?\_*?_ (''_,/^'G__  32_P"D
MAW[#/_B6GP#_ /F_H_L;-_\ H59E_P"$.)_^5![6E_S\I_\ @<?\P_X>?_\
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M-_\ H59E_P"$.)_^5![6E_S\I_\ @<?\P_X>?_\ !-+_ *2'?L,_^):? /\
M^;^C^QLW_P"A5F7_ (0XG_Y4'M:7_/RG_P"!Q_S#_AY__P $TO\ I(=^PS_X
MEI\ _P#YOZ/[&S?_ *%69?\ A#B?_E0>UI?\_*?_ (''_,/^'G__  32_P"D
MAW[#/_B6GP#_ /F_H_L;-_\ H59E_P"$.)_^5![6E_S\I_\ @<?\P_X>?_\
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M-_\ H59E_P"$.)_^5![6E_S\I_\ @<?\P_X>?_\ !-+_ *2'?L,_^):? /\
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 ?I!_P1\_Y2F?L _\ 9UGP;_\ 4PTVO)SW_D2YI_V XC_TW(VP_P#&I_XC
M_80K\%/:/Y$_^#Q+_DQ[]F'_ +.L@_\ 51?$BON^ ?\ D8XS_L"_]STCBQO\
M.'^/_P!M9_G=U^JGF!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!^YG_!ME_RFI_8P_P"[
MBO\ UD_XZU\WQ=_R3V8?]RG_ *G88Z,+_'I_]O?^D2/]62OQ,]@_BA_X/,?^
M29_L$?\ 8]?'_P#],'PJK]$\/_XN9_\ 7O"?^E5SAQWP0_Q/\C^"VOTP\T*
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@#^]+_ (,S?^29_M[_ /8]? #_ -,'Q5K\S\0/XN5_]>\5_P"E
M4#TL#\$_\2_(_M>K\[.X_P F'_@X)_Y3$_MO_P#8]>!?_5-_#>OW'A?_ )$&
M6_\ 7JI_Z?JGC8G^/4]5_P"DH_&VO?, H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /\ 6>_X-]O^
M4.O[$'_8B^.O_5R?$>OP_BG_ )'^8_\ 7RE_ZC43VL/_  :?^$_5CXH?\DS^
M(G_8B^+?_3!J%>)0_C4?^OM/_P!*1J]GZ/\ (_Q":_HL\ * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@#W/\ 9@_Y.6_9X_[+G\)?_4^\/USXO_=<3_V#UO\ TW(J'Q1_Q1_-'^U[
M7\[GO'\_/_!SW_RAU^/W_8]? 7_U<G@ZOJ>#?^1]AO\ KUB?_3$SFQ?\"7K'
M\T?Y:M?LYY 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % ']'_ /P:K_\ *6KP?_V0SXU?^F73:^3X
MT_Y$57_L(PW_ *6=6#_C+_#(_P!/&OQL]8_@M_X/,?\ DIG[!'_8B_'_ /\
M3_\ "JOTWP__ (&9_P#7W#?^D5CSL=O3])?H?Q0U^AG % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0!_H%_\ !F[_ ,FT_ME?]ES\!_\ J S5^7\?_P"]9=_V#UO_ $Y$]+ _!/\
MQ+\C^R6OS\[C_(H_X+C?\I:OV[O^RYZK_P"F71*_=N'?^1'EG_8+#\V>+B/X
MU3_$?E-7M&(4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % '^PA_P $?/\ E%G^P#_V:G\&_P#U#M-K
M\&S_ /Y'69_]AM?_ -+9[=#^#3_P1_(^K?VG_P#DVG]H?_LAGQ:_]0'7ZXL#
M_ON#_P"PK#_^G8%R^"7^%_D?XH5?T,>"% !0 4 % !0 4 % !0 4 % !0 4
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!^D'_!'S_E*
M9^P#_P!G6?!O_P!3#3:\G/?^1+FG_8#B/_3<C;#_ ,:G_B/]A"OP4]H_D3_X
M/$O^3'OV8?\ LZR#_P!5%\2*^[X!_P"1CC/^P+_W/2.+&_PX?X__ &UG^=W7
MZJ>8% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % '[F?\&V7_*:G]C#_ +N*_P#63_CK7S?%
MW_)/9A_W*?\ J=ACHPO\>G_V]_Z1(_U9*_$SV#^*'_@\Q_Y)G^P1_P!CU\?_
M /TP?"JOT3P__BYG_P!>\)_Z57.''?!#_$_R/X+:_3#S0H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /[
MTO\ @S-_Y)G^WO\ ]CU\ /\ TP?%6OS/Q _BY7_U[Q7_ *50/2P/P3_Q+\C^
MUZOSL[C_ "8?^#@G_E,3^V__ -CUX%_]4W\-Z_<>%_\ D09;_P!>JG_I^J>-
MB?X]3U7_ *2C\;:]\P"@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M_*'7X_?]CU\!?_5R>#J^IX-_Y'V&_P"O6)_],3.;%_P)>L?S1_EJU^SGD!0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 ?T?\ _!JO_P I:O!__9#/C5_Z9=-KY/C3_D15?^PC#?\
MI9U8/^,O\,C_ $\:_&SUC^"W_@\Q_P"2F?L$?]B+\?\ _P!/_P *J_3?#_\
M@9G_ -?<-_Z16/.QV]/TE^A_%#7Z&< 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '^@7_P &;O\
MR;3^V5_V7/P'_P"H#-7Y?Q__ +UEW_8/6_\ 3D3TL#\$_P#$OR/[):_/SN/\
MBC_@N-_REJ_;N_[+GJO_ *9=$K]VX=_Y$>6?]@L/S9XN(_C5/\1^4U>T8A0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 ?N9_P &V7_*:G]C#_NXK_UD_P".M?-\7?\ )/9A_P!RG_J=ACHP
MO\>G_P!O?^D2/]62OQ,]@* /_]+^Q+_@I_\ \HTO^"AW_9C/[6G_ *H/Q_7I
M9-_R-\J_[&6!_P#4FD9U?X53_KW/_P!)9_C:U^_'AA0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'Z0?\$?/^4IG[ /_ &=9\&__
M %,--KR<]_Y$N:?]@.(_]-R-L/\ QJ?^(_V$*_!3VC^1/_@\2_Y,>_9A_P"S
MK(/_ %47Q(K[O@'_ )&.,_[ O_<](XL;_#A_C_\ ;6?YW=?JIY@4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 ?N9_P;9?\IJ?V,/\ NXK_ -9/^.M?-\7?\D]F'_<I_P"I
MV&.C"_QZ?_;W_I$C_5DK\3/8/XH?^#S'_DF?[!'_ &/7Q_\ _3!\*J_1/#_^
M+F?_ %[PG_I5<X<=\$/\3_(_@MK],/-"@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H _O2_P"#,W_DF?[>
M_P#V/7P _P#3!\5:_,_$#^+E?_7O%?\ I5 ]+ _!/_$OR/[7J_.SN/\ )A_X
M."?^4Q/[;_\ V/7@7_U3?PWK]QX7_P"1!EO_ %ZJ?^GZIXV)_CU/5?\ I*/Q
MMKWS * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@#_ %GO^#?;_E#K^Q!_V(OCK_U<GQ'K\/XI_P"1
M_F/_ %\I?^HU$]K#_P &G_A/U8^*'_),_B)_V(OBW_TP:A7B4/XU'_K[3_\
M2D:O9^C_ "/\0FOZ+/ "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H ]S_ &8/^3EOV>/^RY_"7_U/
MO#]<^+_W7$_]@];_ --R*A\4?\4?S1_M>U_.Y[Q_/S_P<]_\H=?C]_V/7P%_
M]7)X.KZG@W_D?8;_ *]8G_TQ,YL7_ EZQ_-'^6K7[.>0% !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0!_1_P#\&J__ "EJ\'_]D,^-7_IETVOD^-/^1%5_[",-_P"EG5@_XR_PR/\
M3QK\;/6/X+?^#S'_ )*9^P1_V(OQ_P#_ $__  JK]-\/_P"!F?\ U]PW_I%8
M\[';T_27Z'\4-?H9P!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?Z!?_  9N_P#)M/[97_9<_ ?_
M *@,U?E_'_\ O67?]@];_P!.1/2P/P3_ ,2_(_LEK\_.X_R*/^"XW_*6K]N[
M_LN>J_\ IET2OW;AW_D1Y9_V"P_-GBXC^-4_Q'Y35[1B% !0 4 % !0 4 %
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 ?I!_P1\_Y2F?L _\ 9UGP;_\ 4PTVO)SW_D2Y
MI_V XC_TW(VP_P#&I_XC_80K\%/:/Y$_^#Q+_DQ[]F'_ +.L@_\ 51?$BON^
M ?\ D8XS_L"_]STCBQO\.'^/_P!M9_G=U^JGF!0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0!^YG_!ME_RFI_8P_P"[BO\ UD_XZU\WQ=_R3V8?]RG_ *G88Z,+_'I_]O?^
MD2/]62OQ,]@_BA_X/,?^29_L$?\ 8]?'_P#],'PJK]$\/_XN9_\ 7O"?^E5S
MAQWP0_Q/\C^"VOTP\T* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@#^]+_ (,S?^29_M[_ /8]? #_ -,'
MQ5K\S\0/XN5_]>\5_P"E4#TL#\$_\2_(_M>K\[.X_P F'_@X)_Y3$_MO_P#8
M]>!?_5-_#>OW'A?_ )$&6_\ 7JI_Z?JGC8G^/4]5_P"DH_&VO?, H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * /\ 6>_X-]O^4.O[$'_8B^.O_5R?$>OP_BG_ )'^8_\ 7RE_ZC43
MVL/_  :?^$_5CXH?\DS^(G_8B^+?_3!J%>)0_C4?^OM/_P!*1J]GZ/\ (_Q"
M:_HL\ * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@#W/\ 9@_Y.6_9X_[+G\)?_4^\/USXO_=<3_V#
MUO\ TW(J'Q1_Q1_-'^U[7\[GO'\_/_!SW_RAU^/W_8]? 7_U<G@ZOJ>#?^1]
MAO\ KUB?_3$SFQ?\"7K'\T?Y:M?LYY 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % ']'_ /P:K_\
M*6KP?_V0SXU?^F73:^3XT_Y$57_L(PW_ *6=6#_C+_#(_P!/&OQL]8_@M_X/
M,?\ DIG[!'_8B_'_ /\ 3_\ "JOTWP__ (&9_P#7W#?^D5CSL=O3])?H?Q0U
M^AG % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '^PA_P $?/\
ME%G^P#_V:G\&_P#U#M-K\&S_ /Y'69_]AM?_ -+9[=#^#3_P1_(^K?VG_P#D
MVG]H?_LAGQ:_]0'7ZXL#_ON#_P"PK#_^G8%R^"7^%_D?XH5?T,>"% !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '[F?\ !ME_RFI_8P_[
MN*_]9/\ CK7S?%W_ "3V8?\ <I_ZG88Z,+_'I_\ ;W_I$C_5DK\3/8"@#__4
M_L2_X*?_ /*-+_@H=_V8S^UI_P"J#\?UZ63?\C?*O^QE@?\ U)I&=7^%4_Z]
MS_\ 26?XVM?OQX84 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0!^D'_!'S_E*9^P#_P!G6?!O_P!3#3:\G/?^1+FG_8#B/_3<C;#_
M ,:G_B/]A"OP4]H_D3_X/$O^3'OV8?\ LZR#_P!5%\2*^[X!_P"1CC/^P+_W
M/2.+&_PX?X__ &UG^=W7ZJ>8% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * /[TO\ @S-_Y)G^WO\ ]CU\ /\ TP?%6OS/Q _BY7_U
M[Q7_ *50/2P/P3_Q+\C^UZOSL[C_ "8?^#@G_E,3^V__ -CUX%_]4W\-Z_<>
M%_\ D09;_P!>JG_I^J>-B?X]3U7_ *2C\;:]\P"@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H _P!9
M[_@WV_Y0Z_L0?]B+XZ_]7)\1Z_#^*?\ D?YC_P!?*7_J-1/:P_\ !I_X3]6/
MBA_R3/XB?]B+XM_],&H5XE#^-1_Z^T__ $I&KV?H_P C_$)K^BSP H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * /<_P!F#_DY;]GC_LN?PE_]3[P_7/B_]UQ/_8/6_P#3<BH?%'_%
M'\T?[7M?SN>\?S\_\'/?_*'7X_?]CU\!?_5R>#J^IX-_Y'V&_P"O6)_],3.;
M%_P)>L?S1_EJU^SGD!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?T?\ _!JO_P I:O!__9#/C5_Z
M9=-KY/C3_D15?^PC#?\ I9U8/^,O\,C_ $\:_&SUC^"W_@\Q_P"2F?L$?]B+
M\?\ _P!/_P *J_3?#_\ @9G_ -?<-_Z16/.QV]/TE^A_%#7Z&< 4 % !0 4
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?["'_  1\_P"46?[ /_9J?P;_
M /4.TVOP;/\ _D=9G_V&U_\ TMGMT/X-/_!'\CZM_:?_ .3:?VA_^R&?%K_U
M =?KBP/^^X/_ +"L/_Z=@7+X)?X7^1_BA5_0QX(4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /T@_X(^?\ *4S]
M@'_LZSX-_P#J8:;7DY[_ ,B7-/\ L!Q'_IN1MA_XU/\ Q'^PA7X*>T?R)_\
M!XE_R8]^S#_V=9!_ZJ+XD5]WP#_R,<9_V!?^YZ1Q8W^'#_'_ .VL_P [NOU4
M\P* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * /W,_X-LO\ E-3^QA_W<5_ZR?\ '6OF^+O^
M2>S#_N4_]3L,=&%_CT_^WO\ TB1_JR5^)GL'\4/_  >8_P#),_V"/^QZ^/\
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MVEM"CS2$R2L"[DL37[)0DYT:,Y?%.E3D[::R@F].FIY$E:32Z-K[F>=5J(*
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MU3KTXMN%VKPG3OJHS2?NMMQ<6KR5I/@KT?8R23O%KW;[Z;I^A^,]>^8!0 4
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M],'Q5K\S\0/XN5_]>\5_Z50/2P/P3_Q+\C^UZOSL[C_)A_X."?\ E,3^V_\
M]CUX%_\ 5-_#>OW'A?\ Y$&6_P#7JI_Z?JGC8G^/4]5_Z2C\;:]\P"@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H _UGO^#?;_ )0Z_L0?]B+XZ_\ 5R?$>OP_BG_D?YC_ -?*7_J-
M1/:P_P#!I_X3]6/BA_R3/XB?]B+XM_\ 3!J%>)0_C4?^OM/_ -*1J]GZ/\C_
M !":_HL\ * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@#W/]F#_DY;]GC_ ++G\)?_ %/O#]<^+_W7
M$_\ 8/6_]-R*A\4?\4?S1_M>U_.Y[Q_/S_P<]_\ *'7X_?\ 8]? 7_U<G@ZO
MJ>#?^1]AO^O6)_\ 3$SFQ?\  EZQ_-'^6K7[.>0% !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!_1_
M_P &J_\ REJ\'_\ 9#/C5_Z9=-KY/C3_ )$57_L(PW_I9U8/^,O\,C_3QK\;
M/6/X+?\ @\Q_Y*9^P1_V(OQ__P#3_P#"JOTWP_\ X&9_]?<-_P"D5CSL=O3]
M)?H?Q0U^AG % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M,P%=57+,RH1<JV7XVE%*[E4PM>$4N[E*FDD)3A+X9Q?I)/\ (^JZX2C\2/\
M@M1_P2%^$_\ P4J_9Z\6:SH/A/1-#_:]^'?AC4=6^"?Q/L;.WL-8\0WVDV[7
MT7PI\<7\*12:]X.\5B"32=+;5'N)/!&MW\'B'13';_V[I.N_1\.Y]6RC%0A.
M<I8"K.,<11>L8)NWMZ2^S.&\E'2I%<LM>1QPKT55B[)<Z^%[?)^7Y'^4==VE
MU875S8WUM<65[97$UI>6=U#);W5I=6TC0W%M<V\JI+!<02H\4T,J+)%(C(ZJ
MRD#]L5FDUJGLUM;I8\8KTP"@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@#](/^"/G_*4S]@'_ +.L^#?_ *F&FUY.>_\ (ES3_L!Q
M'_IN1MA_XU/_ !'^PA7X*>T?R)_\'B7_ "8]^S#_ -G60?\ JHOB17W? /\
MR,<9_P!@7_N>D<6-_AP_Q_\ MK/\[NOU4\P* "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M85(HHD54CC151$4*H  %?@1[9+0!_G#?\'@?_*2;X%_]F/?#K_U?/[25?K7
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MM9N2@G"I=0C\,$[*Z@HK38Y\9"$'34(J.DMDEVW[G\F]?<'$% !0 4 % !0
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M9_$3_L1?%O\ Z8-0KQ*'\:C_ -?:?_I2-7L_1_D?XA-?T6> % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0![G^S!_R<M^SQ_V7/X2_P#J?>'ZY\7_ +KB?^P>M_Z;D5#XH_XH_FC_
M &O:_G<]X_GY_P"#GO\ Y0Z_'[_L>O@+_P"KD\'5]3P;_P C[#?]>L3_ .F)
MG-B_X$O6/YH_RU:_9SR H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * /Z/_P#@U7_Y2U>#_P#LAGQJ
M_P#3+IM?)\:?\B*K_P!A&&_]+.K!_P 9?X9'^GC7XV>L?P6_\'F/_)3/V"/^
MQ%^/_P#Z?_A57Z;X?_P,S_Z^X;_TBL>=CMZ?I+]#^*&OT,X H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * /\ 0+_X,W?^3:?VRO\ LN?@/_U 9J_+^/\ _>LN_P"P>M_Z<B>E@?@G
M_B7Y']DM?GYW'^11_P %QO\ E+5^W=_V7/5?_3+HE?NW#O\ R(\L_P"P6'YL
M\7$?QJG^(_*:O:,0H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * /\ 80_X(^?\HL_V ?\ LU/X-_\
MJ':;7X-G_P#R.LS_ .PVO_Z6SVZ'\&G_ ((_D?5O[3__ ";3^T/_ -D,^+7_
M *@.OUQ8'_?<'_V%8?\ ].P+E\$O\+_(_P 4*OZ&/!"@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M2IUZ%2-6C5BITZD'>,HOM^33LXM--)JQP.+BW&2LUHT>?5J(* "@ H * "@
MH * "@ H * "@ H * "@ H * "@#](/^"/G_ "E,_8!_[.L^#?\ ZF&FUY.>
M_P#(ES3_ + <1_Z;D;8?^-3_ ,1_L(5^"GM'\B?_  >)?\F/?LP_]G60?^JB
M^)%?=\ _\C'&?]@7_N>D<6-_AP_Q_P#MK/\ .[K]5/,"@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MCEV(<,-5P].HO:T]%B%7Y9WY=$I45#UJ1['+]2M)1]HM4[>[_+;S\_P/9_\
MB#6^._\ T>[\)/\ PTWC'_YIZY_]?\+_ -"[$?\ @ZG_ /(E?47_ ,_%_P"
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MQM7Q/^U5M-4ZJ7LX/JN2BH)QZ3Y[;GCXFISU7;X8>ZOEN_OV\K'X@U]$<X4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?WI?\ !F;_ ,DS_;W_
M .QZ^ '_ *8/BK7YGX@?Q<K_ .O>*_\ 2J!Z6!^"?^)?D?VO5^=G<?Y,/_!P
M3_RF)_;?_P"QZ\"_^J;^&]?N/"__ "(,M_Z]5/\ T_5/&Q/\>IZK_P!)1^-M
M>^8!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 ?ZSW_!OM_RAU_8@_P"Q%\=?^KD^(]?A_%/_ "/\
MQ_Z^4O\ U&HGM8?^#3_PGZL?%#_DF?Q$_P"Q%\6_^F#4*\2A_&H_]?:?_I2-
M7L_1_D?XA-?T6> % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0![G^S!_R<M^SQ_V7/X2_^I]X?KGQ
M?^ZXG_L'K?\ IN14/BC_ (H_FC_:]K^=SWC^?G_@Y[_Y0Z_'[_L>O@+_ .KD
M\'5]3P;_ ,C[#?\ 7K$_^F)G-B_X$O6/YH_RU:_9SR H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M/Z/_ /@U7_Y2U>#_ /LAGQJ_],NFU\GQI_R(JO\ V$8;_P!+.K!_QE_AD?Z>
M-?C9ZQ_!;_P>8_\ )3/V"/\ L1?C_P#^G_X55^F^'_\  S/_ *^X;_TBL>=C
MMZ?I+]#^*&OT,X H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * /] O_@S=_P"3:?VRO^RY^ __ % 9
MJ_+^/_\ >LN_[!ZW_IR)Z6!^"?\ B7Y']DM?GYW'^11_P7&_Y2U?MW?]ESU7
M_P!,NB5^[<._\B/+/^P6'YL\7$?QJG^(_*:O:,0H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /]A#
M_@CY_P HL_V ?^S4_@W_ .H=IM?@V?\ _(ZS/_L-K_\ I;/;H?P:?^"/Y'U;
M^T__ ,FT_M#_ /9#/BU_Z@.OUQ8'_?<'_P!A6'_].P+E\$O\+_(_Q0J_H8\$
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /W,_X-LO\
ME-3^QA_W<5_ZR?\ '6OF^+O^2>S#_N4_]3L,=&%_CT_^WO\ TB1_JR5^)GL!
M0!__T/[$O^"G_P#RC2_X*'?]F,_M:?\ J@_']>EDW_(WRK_L98'_ -2:1G5_
MA5/^O<__ $EG^-K7[\>&% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M2C&_P0BW:3<5Z>'H^QA9N\F[NVRZ)(_9?QYXX\*?#'P1XP^(_CO6['PSX)\
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@#]S/^#;+_E-3^QA_P!W%?\ K)_QUKYOB[_DGLP_[E/_ %.P
MQT87^/3_ .WO_2)'^K)7XF>P?Q0_\'F/_),_V"/^QZ^/_P#Z8/A57Z)X?_Q<
MS_Z]X3_TJN<..^"'^)_D?P6U^F'FA0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0!^_O_!L7_P ICOV=/^Q.^/G_ *H_QY7R_&/_ "(,5_U\PO\
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M],'Q5K\S\0/XN5_]>\5_Z50/2P/P3_Q+\C^UZOSL[C_)A_X."?\ E,3^V_\
M]CUX%_\ 5-_#>OW'A?\ Y$&6_P#7JI_Z?JGC8G^/4]5_Z2C\;:]\P"@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H _UGO^#?;_ )0Z_L0?]B+XZ_\ 5R?$>OP_BG_D?YC_ -?*7_J-
M1/:P_P#!I_X3]6/BA_R3/XB?]B+XM_\ 3!J%>)0_C4?^OM/_ -*1J]GZ/\C_
M !":_HL\ * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@#W/]F#_DY;]GC_ ++G\)?_ %/O#]<^+_W7
M$_\ 8/6_]-R*A\4?\4?S1_M>U_.Y[Q_/S_P<]_\ *'7X_?\ 8]? 7_U<G@ZO
MJ>#?^1]AO^O6)_\ 3$SFQ?\  EZQ_-'^6K7[.>0% !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!_1_
M_P &J_\ REJ\'_\ 9#/C5_Z9=-KY/C3_ )$57_L(PW_I9U8/^,O\,C_3QK\;
M/6/X+?\ @\Q_Y*9^P1_V(OQ__P#3_P#"JOTWP_\ X&9_]?<-_P"D5CSL=O3]
M)?H?Q0U^AG % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MU),@]G>TMR?^N8K[S@#_ 'S'KI]6I_A5T_,XL;_#A_C_ $9_GT5^I'F!0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?I!_P1\_Y2F?L _\ 9UGP;_\
M4PTVO)SW_D2YI_V XC_TW(VP_P#&I_XC_80K\%/:/Y$_^#Q+_DQ[]F'_ +.L
M@_\ 51?$BON^ ?\ D8XS_L"_]STCBQO\.'^/_P!M9_G=U^JGF!0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0!^YG_!ME_RFI_8P_P"[BO\ UD_XZU\WQ=_R3V8?]RG_ *G8
M8Z,+_'I_]O?^D2/]62OQ,]@_BA_X/,?^29_L$?\ 8]?'_P#],'PJK]$\/_XN
M9_\ 7O"?^E5SAQWP0_Q/\C^"VOTP\T* "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * /W]_X-B_\ E,=^SI_V)WQ\_P#5'^/*^7XQ_P"1!BO^OF%_
M]2*9TX3^/'TE_P"DL_U,Z_%SUS_,6T3]KG_AB7_@Y?\ C/\ &W4M3_LOP*_[
M>OQR^''Q5EEE\JP7X8_%#XA>(/!/BG4M2&5\ZU\)QZO;>.(820#J/A>Q?^
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M>5&?M,6I=.>R]$K+\%<_TYJ_'#U3_.&_X/ _^4DWP+_[,>^'7_J^?VDJ_6N
M_P#D3XG_ +&5;_U%P9Y>-_BQ_P"O:_\ 2I'] '_!IE\--,\'_P#!+_5_'$-E
M FK_ !;_ &COB;XAU#40 ;JZL/#&E>$/ >E64LG+"UL)_#FK3VMOPD4VI7LR
MKNNI&;Y?CBLYYQ"E?W:&$HQ2Z)SE4J2?S4HI_P"%=CJP:M1O_-)O[K+]#^@/
M]J/XLS_ 3]F7]HGXYVJ6DEU\&/@7\6_BM:Q7\;2V,MS\// .O^+K>*[BCDAD
MEMI)M(2.:*.6)Y(V9$D1B&'RV"H+$XS"89WMB,30H.V]JM6%-V^3.B3Y8RE_
M+%O[E<_Q:O&?C'Q/\1/&'BOQ_P"-M:OO$GC/QSXDUSQAXM\1:G)YVHZ]XF\2
MZG=:SKNLW\V%\V]U/5+VZO;J0*H>:9V  .*_H2G"%*$*5.*A3IPC"$(Z*,()
M1C%+HHQ22\D>$VVVWNW=^I]L?\$L/CMXJ_9O_P""BG[''Q5\)ZO-HTVG_'_X
M;^&/$<D18IJ'@#X@>)+#P)\1-$N8P0LL&L>"?$6NV WAOL\\T-Y$OGVT++YV
M<X:&+RK'T)QYD\+5E!=JM*#J4I+MRU(1?RML:4).-6FU_,E\G[K_  9_L9U^
M!GMG\&'_  >8?#W2K#XC_L&?%6WLHEUOQ7X(^//P]U;45 \^?2OA]KOPP\1^
M';*4]3%:W?Q,\43VX&0KWESG&X9_3?#^JW1S.A?W:=7#58KLZL*T)/YJA!?)
M'GXY?PW_ (E]UK?J?V,?L"_#?2_A!^P[^R#\,M'MOLMEX*_9J^"FALA55DFO
M[;X=^'VU>^N0H53>:EJSWNHWS*JA[NZG<*H; ^!S2LZ^98^M+>IC,1)>4?:R
M44O*,4HKR1VTURPA'M&*_ _*3_@YT_:,\5_L^_\ !*CX@Z9X-U(Z/JO[0WQ&
M\%?L[7VHQ,R7J>%?%VF^*O%WC73[)E95_P"*B\(^ M:\+ZD)$D5]#UO5(T5)
MGAFB]O@W"0Q6=4Y5(\T<)1J8I+ISP<*=-O\ P3JJ<=O>BO0QQ4N6C*WVK1^_
M?\$S_+AK]F/(/[N/^#-OXU^+M2\-?ML?L]:KJVH7W@KPIJ/PA^*_@K2)I?,T
M_P /ZWXNC\<^&/'TMHKY>$^((/"_@21H(B+<2Z-<7'EK/<S/+^:\?X>FI9=B
MHQ2J35>A4EUE&'LYTD_\#G5_\"MLD>C@6[5(]$XM>5[I_DON/[>*_.3O/\3#
M]H;_ )+]\<O^RP_$S_U--:K^B<+_ +MA_P#KQ1_]-Q/!E\4O\3_,_7#_ ()B
M?\$!OVQO^"E?A^#XJZ;=:#\ ?V=7U'[%:?%WXF:=K5U=>,Q!*]OJLWPI\#Z?
M%;7?C>'2)XOLMYJ^H:SX3\)RWT=UI=CXGN]6TS5+"R\+..)\OR>7L)<V)Q=K
M_5Z+BO9[<OMJCTI\RU45&<[6;@HN+>]+#3JJ_P $>[6_HNOX(_J5^%/_  :!
M_L#>&+:TF^+/QT_:;^*VLPB/[4FBZO\ #_X:^%+Q@H\P_P!BVW@GQ5XDMU=P
M=BQ^."8XSL+2.!*/BZW'F9S;]AA<'1CTYE5K37_;WM*</_*9UK!4ENYO[DOP
M7ZGZO?LB_P#!#K_@FM^Q%\4?"?QQ^ OP+U;2OC-X(CUN+PU\2/$GQ6^*OBC5
M]-3Q)X<U;PEK@CT34O&+>"2=2\/:[JVFS,?"NY8KV1H3%*D+Q>)CN),WS&C/
M#8G$Q>'J<O/1A0HPB^2<9Q]Y4_:>[*,6O?Z(VA0I4WS1C9KK=OI;O;^O0_6R
MO"-C_)M_X.%]/MM,_P""R'[;EM:KLBD\7?#74&'_ $\:M\#/A=JEXW']^[O)
MW_X%7[APL[Y!EW_7NJOE'$5HK\$>/BOX\_\ MW_TB)_H-?\ !!3_ )1"?L,_
M]DKU;_U87C.ORWB?_D?9E_U^A_Z9IGI8?^#3_P )Y'_P<J?\H6OVQ/\ KX_9
MW_\ 6I?@G6_"'_)08#TQ7_J%B"<5_ G_ -N_^EQ/\]W_ ((N_P#*5K]@C_LY
M+X?_ /I<U?J?$'_(DS/_ + ZW_I)YN'_ (U/_$?Z^U?@Y[1_F\_\'?G_ "DQ
M^#7_ &9#\,O_ %>7[1]?K? G_(GK_P#8QK?^H^$/+QO\6/\ U[7_ *5(_GD_
M8Y_Y.[_97_[./^!__JS?#%?58_\ W'&_]@F(_P#3,SFI_P 2'^./YH_VH:_G
MH]T_@;_X/+/^2Q_L+?\ 9,_C5_ZE/@*OT[P__P!WS+_K]A__ $BH>=CMZ?I+
M]#^+.OT(X#_3-_X-9_VU?^&D?^"?/_"@_$^K?;OB1^QSXBC^'3QW$_FW]W\(
M?%0U#Q!\)=2ER1LM]+6W\5_#VP@CC"6VE> ],+NTEP37X_QIEWU3-/K4(VHX
M^'M=%HJ]/EA7C\_W=5OK*K+L>MA)\U+EZP]WY?9_R_[=/UJ_X*C?LP#]LC_@
MGY^U9^SS;6 U+Q%XT^$VNZCX"M/+#O)\3/ QM_'OPUCC(!>(7'CCPSH-I/)"
M#+]DN+A%60.T3^'DN,_L_-<#BF[0IUXQJOM1J_NJOW4YR:\TMC:K#GIRAW6G
MJM5^*1_!'_P:M_LN'XX?\%,+7XNZSIIN/"G[*/PV\4?$J66XA\RR/C_Q7"WP
MX\!Z;.I!V7L47B'Q1XNTMFV^3>>"Q,")8HU/Z;QIC/JV3NA%VGC:T*.F_LH?
MO:K]/<A3EY5+'G8.%ZO-T@K_ #>B_7[C_3 US6](\,Z)K'B3Q!J-IH^@^']+
MU#6];U:_E6WL=+TC2;26_P!2U&\G?"06EE9V\US<2MA8X8G<\+7X_&,IRC""
M<I2:C&*W<F[))=V]$>J?XU7_  4$_:IU?]MG]M#]HO\ :?U1[O[-\5?B5K.I
M^$[.]W"YT?X=:/Y/AKX::#.K$A9]#\ Z-X<TJYV!$DNK6>81Q^:4'] 97@HY
M=E^$P4;?N*,8S:VE5?O59+RE5E.2[)V/#JS]I4E+N]/1:+\+'D_[-?P%\:_M
M1?'_ .#O[.WP[M_.\9?&7XA^%_A_HDC0O-;:;)XAU2WLKO7=16,JR:1X=T][
MO7=9GW*MKI.G7ER[(D3,-L7B:>"PM?%5=*>'I3JR[M0C=17]Z3M&*[M(F$7.
M48+=M+^O0_V;_@=\'O!7[/GP;^%OP+^'-A_9G@3X1> ?"OP[\*6A$?G#1?"6
MBV>BV4]X\:(+C4KR.S%YJ=XR^;?:A<7-Y.S33NQ_G[$UZF*Q%;$U7>I7JSJS
M?3FG)R:2Z)7LET221[L4HI16B222\D?P'?\ !VY^VW_PM7]J7X9?L5>$=7\_
MP?\ LS^'D\9_$>WM9\V]Y\9OB9IEI?6%A>QHSPSR>"OALVB2:?.K)+:WGC_Q
M/IT\:O!7ZAP-EWL,%5S"I&U3&2]G2NM5AZ+:NNWM*O-==52@UH>;C:EY*FMH
M:O\ Q/I\E^9_(G7W1Q!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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MA_\ P,S_ .ON&_\ 2*QYV.WI^DOT/XH:_0S@"@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H _T"_\
M@S=_Y-I_;*_[+GX#_P#4!FK\OX__ -ZR[_L'K?\ IR)Z6!^"?^)?D?V2U^?G
M<?Y%'_!<;_E+5^W=_P!ESU7_ -,NB5^[<._\B/+/^P6'YL\7$?QJG^(_*:O:
M,0H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * /]A#_ ((^?\HL_P!@'_LU/X-_^H=IM?@V?_\ (ZS/
M_L-K_P#I;/;H?P:?^"/Y'U;^T_\ \FT_M#_]D,^+7_J Z_7%@?\ ?<'_ -A6
M'_\ 3L"Y?!+_  O\C_%"K^ACP0H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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MI$62=HT+J#D?E]&DZU6E1C92JU(4HMZ).<E!7[*[U\CT7HK]E^1_F.?M,?\
M!SA_P5.^.'C'Q!??#3XLZ-^S3\.KR_NCX>^'_P +?!7@N]OM+T?<8].BU3X@
M>,O#OB+QGJ>LI:A6U+4=-U+P_IEY?R7%Q9:%I=K]EL;3]CP?!^2X:G!5<.\7
M527/5K5*B4I=;4J<XTXQO\*<9-*R<I.[?E2Q=5OW6H+HDD_Q:_R_*W]??_!M
M'\2?VL?CE^P-XO\ CM^UK\4?BC\5O$/Q0_:%\;W?PR\0?$_6]1UJ5OAAX9\+
M>!O"R2>%S?GR['P_)\0=*\?V@M--CATW^T-.O)H8A-+<._P?&%' X;,Z>&P-
M&A0C1PM/VT:,(Q_?3G4G[_+O+V3I/76S72QVX5SE3YIMMN3M?^5)+3YW/T6_
MX*S?\HP?^"@O_9G7[0__ *J[Q+7DY'_R.<K_ .P_"_\ IZ!K5_A5/^O<_P#T
MEG^15\"_^2W?!S_LJGP]_P#4MTBOW7$?[O7_ .O-3_TAGBP^*/\ BC^:/]MR
MOYU/>/X7_P#@\_\ ^/K_ ()P_P#7O^UU_P"C/V9*_2?#[;-O7 _EBSS\=_RZ
M_P"W_P#VP_A\TW_D(V'_ %^VO_H^.OT<X%NO5'^Y'7\WGOG\4O\ P>8?\DN_
M8+_['[X]?^H[\+Z_1/#_ /BYG_U[PG_I5<X,=M3]9?DC^"FOTP\X_P!N[X1_
M\DI^&/\ V3WP7_ZC>FU_.E?^-6_Z^U/_ $IGOK9>B_(_DN_X/'?^34?V0_\
MLX7Q/_ZK?4J^YX!_WW'_ /8+3_\ 3J./&_PX?X__ &UG^?%7ZD>8% !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0!^D'_  1\_P"4IG[ /_9UGP;_ /4P
MTVO)SW_D2YI_V XC_P!-R-L/_&I_XC_80K\%/:/Y$_\ @\2_Y,>_9A_[.L@_
M]5%\2*^[X!_Y&.,_[ O_ '/2.+&_PX?X_P#VUG^=W7ZJ>8% !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % '[F?\ !ME_RFI_8P_[N*_]9/\ CK7S?%W_ "3V8?\ <I_ZG88Z
M,+_'I_\ ;W_I$C_5DK\3/8/XH?\ @\Q_Y)G^P1_V/7Q__P#3!\*J_1/#_P#B
MYG_U[PG_ *57.''?!#_$_P C^"VOTP\T* "@ H * "@ H * "@ H * "@ H
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MI6!R/TSP_E'V69PO[RJ865O[KC62?WQ?X'GXY?PO^WE_Z2?Q,U^B'GG[P?\
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M "@ H * "@ H _O2_P"#,W_DF?[>_P#V/7P _P#3!\5:_,_$#^+E?_7O%?\
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MZG,]9?O(RBY;<T6NAT*RTC9*.EEHEHM+=-+'R3_P5F_Y1@_\%!?^S.OVA_\
MU5WB6N[(_P#D<Y7_ -A^%_\ 3T"*O\*I_P!>Y_\ I+/\BKX%_P#);O@Y_P!E
M4^'O_J6Z17[KB/\ =Z__ %YJ?^D,\6'Q1_Q1_-'^VY7\ZGO'\+__  >?_P#'
MU_P3A_Z]_P!KK_T9^S)7Z3X?;9MZX'\L6>?CO^77_;__ +8?P^:;_P A&P_Z
M_;7_ -'QU^CG MUZH_W(Z_F\]\_BE_X/,/\ DEW[!?\ V/WQZ_\ 4=^%]?HG
MA_\ Q<S_ .O>$_\ 2JYP8[:GZR_)'\%-?IAYQ_MW?"/_ ))3\,?^R>^"_P#U
M&]-K^=*_\:M_U]J?^E,]];+T7Y'\EW_!X[_R:C^R'_V<+XG_ /5;ZE7W/ /^
M^X__ +!:?_IU''C?X</\?_MK/\^*OU(\P* "@ H * "@ H * "@ H * "@ H
M * "@ H * "@#](/^"/G_*4S]@'_ +.L^#?_ *F&FUY.>_\ (ES3_L!Q'_IN
M1MA_XU/_ !'^PA7X*>T?R)_\'B7_ "8]^S#_ -G60?\ JHOB17W? /\ R,<9
M_P!@7_N>D<6-_AP_Q_\ MK/\[NOU4\P* "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M!5G1J.+A*RC*,H/[,X3C*$EHFKQ]UI.-FA3A":Y9JZ[?Y6V^1_"__P ',_\
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MDS_;W_['KX ?^F#XJU^9^('\7*_^O>*_]*H'I8'X)_XE^1_:]7YV=Q_DP_\
M!P3_ ,IB?VW_ /L>O O_ *IOX;U^X\+_ /(@RW_KU4_]/U3QL3_'J>J_])1^
M-M>^8!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 ?ZSW_  ;[?\H=?V(/^Q%\=?\ JY/B/7X?Q3_R
M/\Q_Z^4O_4:B>UA_X-/_  GZL?%#_DF?Q$_[$7Q;_P"F#4*\2A_&H_\ 7VG_
M .E(U>S]'^1_B$U_19X 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'N?[,'_ "<M^SQ_V7/X2_\
MJ?>'ZY\7_NN)_P"P>M_Z;D5#XH_XH_FC_:]K^=SWC^?G_@Y[_P"4.OQ^_P"Q
MZ^ O_JY/!U?4\&_\C[#?]>L3_P"F)G-B_P"!+UC^:/\ +5K]G/("@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H _H__P"#5?\ Y2U>#_\ LAGQJ_\ 3+IM?)\:?\B*K_V$8;_TLZL'
M_&7^&1_IXU^-GK'\%O\ P>8_\E,_8(_[$7X__P#I_P#A57Z;X?\ \#,_^ON&
M_P#2*QYV.WI^DOT/XH:_0S@"@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H _T"_P#@S=_Y-I_;*_[+
MGX#_ /4!FK\OX_\ ]ZR[_L'K?^G(GI8'X)_XE^1_9+7Y^=Q_D4?\%QO^4M7[
M=W_9<]5_],NB5^[<._\ (CRS_L%A^;/%Q'\:I_B/RFKVC$* "@ H * "@ H
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M9+IABJE."@HPM':Z=_PDOR+O[7'_  <R?MX?MF_LX?%;]F#XG_"C]DGP_P"
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MZEK<[2Y6E:RL94\34III<LKRYFY7;O9+HUV1]#?M$?\ !TG_ ,% OVE_@/\
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M,C=&P9<CC(R!D<<5[9BM#^JT?\'@/_!2T #_ (4A^PT< #)^&GQ[R?<X_:8
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?N9_P;9?\ *:G]C#_NXK_UD_XZ
MU\WQ=_R3V8?]RG_J=ACHPO\ 'I_]O?\ I$C_ %9*_$SV#^*'_@\Q_P"29_L$
M?]CU\?\ _P!,'PJK]$\/_P"+F?\ U[PG_I5<X<=\$/\ $_R/X+:_3#S0H *
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MUMI.M^"?B)=6EN3R+:76KV0#C[4>M?,5. ,,V_99C7A'HJE"G4:7FXSI)_\
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M.$,/&7J^:K+E\HRB_P"\ARQLFO=@H^;?-^B/R>_8W_X+U_MY_L;_ !9_:/\
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M,Z.)245B:#49N*VC44HRA4BNG-'G2]V,XK0WI8B=)65G'^5]/3M^7D?N^O\
MP>:>/1I2PO\ \$__  @VM[5#:@O[1FLII1?: S+HY^#3W:J7^94.NL57"%V(
MWU\U_P 0_HW_ .1G4Y>WU6-__ O;V_\ )3H^O/\ Y]+_ ,"_^U/P8_X*M_\
M!9;X\?\ !6+4?AA;?%'X;_##X7^"O@U>>+K[P#X=\!Q^)+[6/M'C:#P[;ZW-
MXJ\3^(-9NH];F$?AG34L?[*T#PU:VT?G>9:7$LAFKZ;).'\-D<:WL*M:M4Q"
MIJK*KR*/[KGY>2$(KE7ON]Y3?FMCGK5Y5K7BHJ-[6OU_X;LC\?:]XP/])/\
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MM/\ ]*1J]GZ/\C_$)K^BSP H * "@ H * "@ H * "@ H * "@ H * "@ H
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0!_1__ ,&J_P#REJ\'_P#9#/C5_P"F73:^3XT_Y$57_L(PW_I9
MU8/^,O\ #(_T\:_&SUC^"W_@\Q_Y*9^P1_V(OQ__ /3_ /"JOTWP_P#X&9_]
M?<-_Z16/.QV]/TE^A_%#7Z&< 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '^@7_P9N_\FT_ME?\
M9<_ ?_J S5^7\?\ ^]9=_P!@];_TY$]+ _!/_$OR/[):_/SN/\BC_@N-_P I
M:OV[O^RYZK_Z9=$K]VX=_P"1'EG_ &"P_-GBXC^-4_Q'Y35[1B% !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0!_L(?\$?/^46?[ /_ &:G\&__ %#M-K\&S_\ Y'69_P#8;7_]+9[=
M#^#3_P $?R/JW]I__DVG]H?_ +(9\6O_ % =?KBP/^^X/_L*P_\ Z=@7+X)?
MX7^1_BA5_0QX(4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 ?N9_P;9?\IJ?V,/\ NXK_ -9/^.M?-\7?\D]F'_<I_P"IV&.C"_QZ?_;W
M_I$C_5DK\3/8"@#_U?[$O^"G_P#RC2_X*'?]F,_M:?\ J@_']>EDW_(WRK_L
M98'_ -2:1G5_A5/^O<__ $EG^-K7[\>&% !0 4 % !0 4 % !0 4 % !0 4
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M_/BK]2/,"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H _2#_@CY_RE,_8!_P"SK/@W_P"IAIM>
M3GO_ ")<T_[ <1_Z;D;8?^-3_P 1_L(5^"GM'\B?_!XE_P F/?LP_P#9UD'_
M *J+XD5]WP#_ ,C'&?\ 8%_[GI'%C?X</\?_ +:S_.[K]5/,"@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@#]S/^#;+_E-3^QA_W<5_ZR?\=:^;XN_Y)[,/^Y3_ -3L,=&%
M_CT_^WO_ $B1_JR5^)GL'\4/_!YC_P DS_8(_P"QZ^/_ /Z8/A57Z)X?_P 7
M,_\ KWA/_2JYPX[X(?XG^1_!;7Z8>:% !0 4 % !0 4 % !0 4 % !0 4 %
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MN/Y%Z^Y.(* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M)0_C4?\ K[3_ /2D:O9^C_(_Q":_HL\ * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#W/]F#_ ).6
M_9X_[+G\)?\ U/O#]<^+_P!UQ/\ V#UO_3<BH?%'_%'\T?[7M?SN>\?S\_\
M!SW_ ,H=?C]_V/7P%_\ 5R>#J^IX-_Y'V&_Z]8G_ -,3.;%_P)>L?S1_EJU^
MSGD!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 ?T?_P#!JO\ \I:O!_\ V0SXU?\ IETVOD^-/^1%
M5_[",-_Z6=6#_C+_  R/]/&OQL]8_@M_X/,?^2F?L$?]B+\?_P#T_P#PJK]-
M\/\ ^!F?_7W#?^D5CSL=O3])?H?Q0U^AG % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!_H%_\&;O
M_)M/[97_ &7/P'_Z@,U?E_'_ /O67?\ 8/6_].1/2P/P3_Q+\C^R6OS\[C_(
MH_X+C?\ *6K]N[_LN>J_^F71*_=N'?\ D1Y9_P!@L/S9XN(_C5/\1^4U>T8A
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 ?["'_!'S_E%G^P#_P!FI_!O_P!0[3:_!L__ .1UF?\
MV&U__2V>W0_@T_\ !'\CZM_:?_Y-I_:'_P"R&?%K_P!0'7ZXL#_ON#_["L/_
M .G8%R^"7^%_D?XH5?T,>"% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % '[F?\&V7_*:G]C#_ +N*_P#63_CK7S?%W_)/9A_W*?\ J=AC
MHPO\>G_V]_Z1(_U9*_$SV H _];^Q+_@I_\ \HTO^"AW_9C/[6G_ *H/Q_7I
M9-_R-\J_[&6!_P#4FD9U?X53_KW/_P!)9_C:U^_'AA0 4 % !0 4 % !0 4
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H _<S_ (-LO^4U/[&'_=Q7_K)_QUKY
MOB[_ ))[,/\ N4_]3L,=&%_CT_\ M[_TB1_JR5^)GL'\4/\ P>8_\DS_ &"/
M^QZ^/_\ Z8/A57Z)X?\ \7,_^O>$_P#2JYPX[X(?XG^1_!;7Z8>:% !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#_6>_P"#?;_E
M#K^Q!_V(OCK_ -7)\1Z_#^*?^1_F/_7RE_ZC43VL/_!I_P"$_5CXH?\ ),_B
M)_V(OBW_ -,&H5XE#^-1_P"OM/\ ]*1J]GZ/\C_$)K^BSP H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * /<_V8/\ DY;]GC_LN?PE_P#4^\/USXO_ '7$_P#8/6_]-R*A\4?\4?S1
M_M>U_.Y[Q_/S_P '/?\ RAU^/W_8]? 7_P!7)X.KZG@W_D?8;_KUB?\ TQ,Y
ML7_ EZQ_-'^6K7[.>0% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!_1__ ,&J_P#REJ\'_P#9#/C5
M_P"F73:^3XT_Y$57_L(PW_I9U8/^,O\ #(_T\:_&SUC^"W_@\Q_Y*9^P1_V(
MOQ__ /3_ /"JOTWP_P#X&9_]?<-_Z16/.QV]/TE^A_%#7Z&< 4 % !0 4 %
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M?KBP/^^X/_L*P_\ Z=@7+X)?X7^1_BA5_0QX(4 % !0 4 % !0 4 % !0 4
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M?^0?\.^?V]_^C(?VO?\ Q&KXS?\ S%T?VGEO_0PP/_A7A_\ Y8'LZG_/N?\
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MWT'[JX2OT7#8BEB\/1Q-"7/1KTXU*<MO=DMFNC6TET::Z'GRBX2<9*SB[/\
MK\CR2MR0H * "@ H * "@ H * "@ H * "@#]/\ X _\$8?^"G/[4/PH\*_'
M'X&?LF^,/&OPL\;Q7UQX2\62^+/ACX4@UZTT[4;O2;F_T_3/&GCCPYK<NG&_
ML;J&TU$Z8MCJ"0FXL+BYMF29O'Q6?Y/@JT\-B<=3IUJ=N>GR59N-TI)-TZ<H
MIV:TO==4C:-"K)*48-I[;+]3R;]KC_@FO^VQ^PCHO@WQ!^UE\$+OX.Z7\0=4
MU31O!CZKXY^&/B"\\07^B6EM>ZPMEI7@SQKXDU46VEV][8F^U">RATZUEO\
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M&DB,H]]-22E%IQ:3BTTTTUHTUHTULUI8P*-, H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H _<S_@VR_Y34_L8?]W%?^LG_'6OF^+O^2>S#_N4_P#4[#'1A?X]
M/_M[_P!(D?ZLE?B9[!_%#_P>8_\ ),_V"/\ L>OC_P#^F#X55^B>'_\ %S/_
M *]X3_TJN<..^"'^)_D?P6U^F'FA0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0!](>!OV-_VO/B?X6TKQS\-/V5OVD/B'X)UQ;E]$\8>
M!O@=\3O%OA;6$LKRXTZ\?2O$&@>%]0TG4%M+^TNK&Y:TNY1!>6UQ;2[9H9$7
MDJ8_ T9NG5QF$I5(VYJ=3$483C=)J\9335TTU=;-/8M0FTFH2:Z-1=OEH=;_
M ,.^?V]_^C(?VO?_ !&KXS?_ #%U']IY;_T,,#_X5X?_ .6![.I_S[G_ . O
M_(K7?[ O[==A;R75]^Q7^UI96L(W2W-W^SC\8;:WB7UDFF\&I&@]V8"A9EEK
MT688)]DL50_^3#V=3_GW/_P%_P"1X#XT^&GQ&^&]U#8_$3P!XV\!7MSO^SV?
MC3PKKOA:ZG\H@2>3;ZY86,LOED@/Y:-L) ;%=5.K2JJ]*I3J)=:<XS7_ )*V
MB7%QW37JK'$UH(^F/V-?V<I_VN_VI_@1^S);>+HO 4_QO^(V@?#Z+QE/HC^)
M(?#;ZY.8!JLF@QZKH;ZJMMC<;)=7T\R]!<Q]:X\?BE@<%B<8X>T6&HSJ^S4N
M3GY%?EYK2Y;]^5V[%TX<\XPO;F=KVV^1_7#_ ,08WBC_ *2&:!_XC!J/_P _
MNOAO^(@4_P#H53_\*X__ #,=OU'_ *>_^2?_ &Y_.;_P5O\ ^"9VI?\ !*G]
MI7PE^SMJ?QAL?C;+XL^"_AGXQP>+;#P//\/X[.W\1>,_B%X-&@RZ'<>*?&#2
M36<_P_GOO[035A'/#J4,/V2%[9VE^LR/-XYU@YXJ-!X=0Q$\/[-U%4OR4Z4^
M;F4(;^U2MRZ6W.6M2]C)1YN:\5*]K=6K6N^Q^7%>R8A0 4 % !0 4 % !0 4
M % ']*/_  3B_P"#97]L+]MWP3X=^,_Q;\5:1^R5\%/%=E!JWA*_\9>%]1\6
M_%?QGHEW'%<:=XAT+X81:GX7ATSPQJ]NS2:;K'B[Q9X?OKZU>SUC1_#^LZ'?
M6>HS_(YMQ?@,MJ3P]&$L=B:;Y9QIS4*-.2T<)UK3O.+T<:<)I.\92C)6.NEA
M)S2E)\D7MI=M>FEEV_(_=?3/^#.7]D.+3EBUG]K/]I"_U;RT#7NF:+\,=)TX
MRA<2.NEW7AW6KE8V;E(CK#-&ORF60_/7S3X^QU_=P.$4>SE6D_\ P)2BO_)3
MH^HT_P":?_DO^1_*9_P6A_X)E^'O^"57[4_@[X >%OBWK/QBT3QO\$?#OQFL
MM>U_PG8^$M5T5->\>_$GP1_PC5S!IVN:U::NUI_PKX:G_;42:.)_[6^Q?V1#
M]@^U7GVW#^<2SK!3Q4Z$</*GB9X=PC-U(RY*5&ISJ\8N-_:\O+[UN6_-K9<=
M>DJ,U%.Z<5+56ZM6_ _(JO=, H * "@ H * "@ H * "@ H * "@ H * "@
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MG_!/O_HXC]L?_P *;X)__.1K\W_U]S/_ *!,!_X#B/\ YH/0^I4OYJGWQ_\
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M #D:_+/]?<S_ .@3 ?\ @.(_^:#T_J5+^:I]\?\ Y _G(_X+\_\ !'SX!?\
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M<)).$X24H2B]G&4;II]&M#GM;1JUNFQ@50@H * "@ H * "@ H * "@ H *
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MKZ4Y@H * "@ H * "@ H * /]A#_ ((^?\HL_P!@'_LU/X-_^H=IM?@V?_\
M(ZS/_L-K_P#I;/;H?P:?^"/Y'U;^T_\ \FT_M#_]D,^+7_J Z_7%@?\ ?<'_
M -A6'_\ 3L"Y?!+_  O\C_%"K^ACP0H * "@ H * "@ H * "@ H * "@ H
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MY&M!!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?N9_P;
M9?\ *:G]C#_NXK_UD_XZU\WQ=_R3V8?]RG_J=ACHPO\ 'I_]O?\ I$C_ %9*
M_$SV H __]#^Q+_@I_\ \HTO^"AW_9C/[6G_ *H/Q_7I9-_R-\J_[&6!_P#4
MFD9U?X53_KW/_P!)9_C:U^_'AA0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M2]Z7M&O-Q='D?M(KW9;I=)?HG^>G8_E<K[0XPH * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * /T@_X(^?\I3/V ?\ LZSX-_\ J8:;7DY[_P B
M7-/^P'$?^FY&V'_C4_\ $?["%?@I[1_(G_P>)?\ )CW[,/\ V=9!_P"JB^)%
M?=\ _P#(QQG_ &!?^YZ1Q8W^'#_'_P"VL_SNZ_53S H * /]*_\ X-(_^47'
MBS_L[7XL?^H'\(*_(>.?^1S#_L!H?^G*YZN"_@_]OO\ )']0-?&G6-#*WW2#
MCT(/\J+6 =0!^(O_  5R_P"")G[./_!2CX8^+/$>B^%/#/PR_:]TG1KN]^&_
MQOT73K?1[KQ)K5A:32:;X-^+K:? /^$M\':U.(M/?5]0M[[Q)X.+QZIX>NFM
M8M3T#7/H\BXBQ>45H0G.=; -I5</)N2IQ;5ZE"_P3CORJT)_#)7Y91PK4(54
M]$IVTDM/D^Z_+H?Y5_C3P=XF^'?C'Q9\/_&NC7?AWQEX%\2Z[X.\6^']018[
M_0O$WAG5+K1=>T>]1694N],U2RNK*Y5695F@<!B #7[53G"K3A4IR4J=2$9P
MDMI0FE*,EY.+37D>.TTVFK-.S79K2QS-6(* "@ H * /HW]D;]F/QS^V7^TC
M\)/V8/AIJWA;0?''QB\3'PQX?UGQK=ZI8>%=-N(],U#5[B[UFZT31]?U6.VB
ML=,NBHL='OII)_)A$2J[2Q\F.QE++\)7QE:,Y4\/#GE&FDYM744HJ4HQO=K>
M21=.#J2C!63??;;R]#^VG]FG_@SN^!_A[^S]7_:T_:G\?_$N]7RKB[\%_!+P
MYI'PS\.13)C?I]UXN\5_\)UX@U[3I"#YES8:'X(OVC;9"ULZ><WYWB^/<1*\
M<#@J=%;*IB)NK+U5.G[.,7Y.=1?D=\,#%?'-ORBK+]?T/YS/^#@C]C3]GC]A
M+]O2P^!'[,?@BY\!?#:'X!_#'Q5+I-YXI\5^+[N]\3:S?^+K36-;NM6\7ZSK
M>HBXU*/2;)YK2TN+72;>2-C8:=9H[(?K.%\PQ69Y8\3C*BJ5?K-:%U"%-*$5
M!QBHTXQ6G,]6G+NV<N)IQIU%&"LN5/=O77OZ'X>5]&<X4 % !0 4 % !0 4
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M#_\ BYG_ ->\)_Z57.''?!#_ !/\C^"VOTP\T* "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * /]97_@WK_P"4./[$?_8G?$;_ -7A\3Z_
M#^*?^1_F/_7RE_ZC43V<-_ I^C_-G[-U\^;A0!R_C+P1X+^(OAW4?"'Q!\(>
M%_'?A+6(7MM6\+^,M TGQ/X=U2WD1HWM]1T36[2^TV]A='='BN;:6-D9E*D$
MBKIU*E&2J4JDZ4X_#.G*4)+TE%IKY":3T:379G\97_!<_P#X-QO@]:_"3X@?
MMA_\$_O!2_#KQ;\.M)U+QI\5?V<_#22R>"/&'@[2H?MGB'Q)\*=%+2'P?XH\
M,Z;#=ZS>>"M);_A&?$>CV<]OX7TC1O$5K!8^*/T'AKBRNZ]+ 9I4]K"K*-.A
MBY652%1Z1A7EISPF[151^]"5N=RB[PX<1A8\KG35FM7%;->2Z-=MC^6;_@B[
M_P I6OV"/^SDOA__ .ES5]IQ!_R),S_[ ZW_ *2<F'_C4_\ $?Z^U?@Y[1_F
M\_\ !WY_RDQ^#7_9D/PR_P#5Y?M'U^M\"?\ (GK_ /8QK?\ J/A#R\;_ !8_
M]>U_Z5(_E5K[4XPH * "@ H Z+PAX4\0>//%GA?P-X3TYM7\5>,_$6B^%/#.
MDI<6EHVI^(/$6I6VCZ-IRW5_/:V-LU[J-Y;6RW%[=6UI"9!)<3PPJ\BQ.<:4
M)U)OEA3C*<W_ "Q@KR=DKZ)=%Z(:5VDMVTE^2/ZK?V:?^#1+]M_XC?V?JO[2
MGQA^#W[-FB7'E-=Z%HS7GQL^(]D.&FAN-*\.W7ASX>J=I\N.>R^)VJ 2!V:W
M,:)Y_P 5B^.LMHWCA*&(Q<EM)I8>B^WO3YJOWT4=D,%-_%*,5V7O/]%^)\2_
M\%VO^"2_P8_X)1>(_P!EWP;\)_B/\3/B9J/Q<\$?$'7?'6M_$)O"]O:?VMX3
MUOPWIU@?"FB^'-!TV70].GM]9G-U9ZMK/B:Y:6*%X]1C3?&WH\-9Y7SN&,J5
MJ-&BJ%2E&G&ESM\LXR;YY2DU)KET<8P5NAGB*,:/(HMNZ=[VZ6VLM#\"J^G.
M8_</_@WF_8K\'?MN?\%+?AQX5^)FC6GB3X6_!7PMX@_:'\>^&-0ABN-,\46G
M@+4_#NC>%/#^JVMQ'-::AHM]\1?%W@V3Q!H]U#-;:WX=MM7TFXC-O=RLGSG%
M.85,MR>M4HR<*U><,)2FMX.JI.<H]I*C3J<C6L9\LEL=&%IJ=576D5S-=-+6
M7WVT['^K6JJBJB*%10%55 5551A551@     # ' K\2/8/PU_;__ .#A#]@;
M_@G?\8[K]G_XE)\8?BK\6M#M=,N_&OA;X(>$O"^O1_#\:S8V6KZ58^*]:\;^
M.?A_HRZSJ&B:A:ZM#I&AWNMW=K:W%K_;"Z4UU '^DROA7,\UPZQ5+V%"A*ZI
MSQ$YQ]KRMQ;A&G3JRY5)-<TE%.WNW.>IB:5)\KNWU44M/6[2^X_AP_X.!/\
M@H1^SW_P4H_:Y^#_ ,>/V;I?&G_"':!^RSX+^&VOV'C[PROA;Q%HWC+2OBI\
M9O%FH:3<64&HZQIUVMMH_C/09#J&DZKJ.F2SSS06]Y*]M+C](X7RK%91@*^%
MQ?L_:2QM2M%TI\\)4Y4,/333<8M>]3EHXIVMH>?B:D:LXRA>R@EJK6=Y?YH_
M"JOI#G"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MMI\K?B?RTU]F<84 % !0 4 % !0 4 % !0!_M/?L:_\ )H'[*?\ V;;\#/\
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M(P\9Q<H*TUVTYK=+=^WW'^<]\"_^2W?!S_LJGP]_]2W2*_6,1_N]?_KS4_\
M2&>9#XH_XH_FC_;<K^=3WC^%_P#X//\ _CZ_X)P_]>_[77_HS]F2OTGP^VS;
MUP/Y8L\_'?\ +K_M_P#]L/X;Z_1SSPH * "@ H * "@ H * "@ H * "@ H
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M]B=\?/\ U1_CROE^,?\ D08K_KYA?_4BF=.$_CQ])?\ I+/]3.OQ<]<;N4$
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M_P#5&^.:\+)?^1QE7_8QP7_J13-JO\*I_P!>Y_\ I+/\;VOWT\,* "@ H *
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MX)_XE^1_9Y=_\>MS_P!>\W_HMJ_/ENO5'<?X:]?T>?/A0 4 % !0 4 % !0
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MYZK_ .F71*_=N'?^1'EG_8+#\V>+B/XU3_$?E-7M&(4 % !0 4 % !0 4 %
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M=-^5-=CU\+#DHQ[S]Y^C^'_R6S^9_0E7RITGX<?\'(__ "A9_;0_ZY?L^?\
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MQE4J\\K^=/V?E8WGA:5.E-ZN2BVFWM;;161_G_U^H'FA0 4 % !0 4 % !0
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M%N>G?JMI0>EX2BVDW9>/5INE-P>V\7WCT?Z>J/@>O3,@H * "@ H * "@ H
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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MX]^&_P 1/"_Q;\#^*]9\.?$OP7XMTOQWX7\:V-TS:]H_C'1=4AUK3/$5O>7
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M%E_>M'\'KZ:6/S^_::_9G^-'['OQO\<?LY_M">$H_ WQ=^'4FA1^*_#,.O\
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MS(7B)1BN#7[[3J0JTZ=6F^:G4A&I"2VE"<5*+7K%IGAM<K:>Z=ONT.6JQ!0
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MF6V,]NC#]S=7"X:O!J<>Y;%M4L)C*B762HTT_1*I-V[72?DC=8&?6<5Z)O\
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M\LG%_9;7W:'F];$A0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M>0E(BD<K)QXS'X/+X1J8RO##PG+DA*=[.5G*RLGT39<*<ZFD(WMZ?\ ^V/\
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MK]QX7_Y$&6_]>JG_ *?JGC8G^/4]5_Z2C\;:]\P"@ H * "@ H * .Q^'?\
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M7LH+IS;_ ').WSL??&K_ /!G-^V!!I8FT#]K']FS4]:\AV.GZOI'Q/T/2_M
M4^7$-7L_#7B"Z,+-M5ISHBNBDL+9R I\R/'V7W][!8Q1[Q=&3M_A<X+Y<QI]
M1E_/'[F?AM^W9_P1Z_;W_P""=D U_P#:%^#LTOPRENH+*V^-'PWU!?'?PI:[
MNK@6EG::IXAT^W@OO"%[J%P5ATNQ\<Z-X7O=5D;;IEO=E7V_1Y;GV69K[N$Q
M"]LE=X>JO95[)7;4'I-);NE*:CU:.>I0J4OBCI_,M5_P/FEY'YAU[)B% 'ZQ
M_L4_\$2?^"C7[>6C67C/X,_ J\\._"W45@DL/B[\7M1C^&GP_P!5MKC'E7WA
MFXUF%_$7C?3,!_,U/P+X;\2Z? \3P3W,=SLA?Q,PXARG+&Z>(Q*E66^'H+VU
M5-=)J/NTWY590?;0WIX>K4UC&T?YI:+Y=7\DS]H?#O\ P9S?M@W5FK^+/VL/
MV;-$OS"K/:^'M)^)_B>U6<J-T0O=1\,^$96B5LJ)OL"LR@-Y"YVCYZ?'V7I_
MN\%C)*^\G1AIZ*<_NO\ ,W6!E_/'Y)_\ \=^-/\ P:/?\%%O &A:AKWPK^(O
M[.OQWDL;>2:+PEHGBKQ+X#\:ZJZ1LXM]+@\=>%]-\$&1ROEH=3\>Z6N]H^=I
M=H^C#\<Y35E&%:EB\+=VYY4X5*4?5TIRJ?=29+P51?#*,O+5/Y:6_%'Y,_\
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M^BSP H * "@ H * "@ H * "@ H * "@ H _UE?^#>O_ )0X_L1_]B=\1O\
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MY*BK\M*I2<%44&V_<DIPDH_8;:5H<L5ZF%JNI!\WQ0:5^ZZ7\S^D"OD3J/\
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M3G7[>>,% !0 4 % !0 4 % !0 4 % !0 4 % 'N?[,'_ "<M^SQ_V7/X2_\
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MRI'%N9B%!-?)T(2G6HPA?GG5IPA9:\TI)1LN][61U/1-]$OR/\0FOZ+/ "@
MH * "@ H * "@ H * "@ H * "@#_0+_ .#-W_DVG]LK_LN?@/\ ]0&:OR_C
M_P#WK+O^P>M_Z<B>E@?@G_B7Y']DM?GYW'^11_P7&_Y2U?MW?]ESU7_TRZ)7
M[MP[_P B/+/^P6'YL\7$?QJG^(_*:O:,0H * "@ H * "@ H * /]GO]@3_D
MQ+]BK_LTK]G'_P!4[X-K^?<S_P"1EF'_ &'8O_T_4/=I_P .'^"/_I*/<[_X
MA:7IOQ6\*_"FY:,:UXS^'OC_ .(6B('Q,^E_#/Q'\-/#?BAGC)^:.*Z^+/A
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M_P#U9&I5^I\ _P"XX[_L+C_Z9B>;COBA_A?YG\=E?>G"% !0 4 % !0 4 %
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MQ \<L3CLT;JP[&OW?($GDF6)I-?4Z.CV^$\6OI6J6T]X_2S_ (-\_P#@KO\
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M]#]$'_X-1_\ @JY&CR-8_LZ[8T9VQ\8Y<X49.!_PB/H*\K_77(_YL5_X3_\
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M9-_R-\J_[&6!_P#4FD9U?X53_KW/_P!)9_C:U^_'AA0 4 % !0 4 % !0 4
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M0I0JUZLL7B$H4XSJU)6JR6D8J4G966BV/=BU&$;M)*,=[)+1'R)XH_X+W_\
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MQ6^G^+?VAGOT\->(M'UU[%+C1_@^MNUVNEWET;99S#,(3,$$IBD"9\ML?HG
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M#U)T:U)\T*D':47MZ--:2BTXRC>+33L4XJ2<6DT]T]C_ ">_^"RO_!-?5O\
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ME&56475?->[AS>]=;IF<JM*G:+E&-K+E[+IHME;T/OGP;XS\(_$3PIX=\=^
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M/^SW_P!JO_U>?CJOVK)O^1/E7_8MP/\ ZBTCQZO\6I_U\G_Z4S_4>TO]M?\
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M;BUW33C))II;PG&I'F@[K;T\K=#\OO\ @X>_X)\>"/VTOV /BG\1+7P]8_\
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MOXL+4JX5ONH-5(?^ TJL(_\ ;IY.+CRUG_>2E_[;_P"VW/Y_:^H.4* "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H _<S_ (-LO^4U/[&'_=Q7_K)_QUKYOB[_ ))[
M,/\ N4_]3L,=&%_CT_\ M[_TB1_JR5^)GL'\4/\ P>8_\DS_ &"/^QZ^/_\
MZ8/A57Z)X?\ \7,_^O>$_P#2JYPX[X(?XG^1_!;7Z8>:% !0 4 % !0 4 %
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M6+]R"4;QBMDM%HNR/HI&5U5T971U#(Z$,K*P!5E8<%2,$$<$8(XKD*/Y_?\
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M'QC.C@Y4Z4K-5<0U0@T]G%3M4G%K:4(2C;KL>A/$4J>CEKV2O^6B/CKX/?\
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M4AA*\?LRA6DH0D^WLJCA436J47':33QQ%-3I25M8KFCZI?JM#_)DK]P/%/\
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MRR5FG&ZO&48R5T^6S3>U.K"JKP>VZV:]5\O0R/\ @J)^P+\/?^"C/['WQ.^
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MB*;=#$J-DO:P2]]);*I!QJ6M:+;@KJ)XV(I>RJ-+X7K'T[?+;TL?DA7N& 4
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MQ$FY5)/EC?W:5/[%*FND(+3S=Y2O)MOW(0C3BHQ5DOZOZL\ _P""A7_!6/\
M8V_X)E:9X0D_:7\7>)!XJ\?P:C>^"OAO\/?#,OBWQUK^E:1-#;:GK*6DMWI&
M@Z/I%K=7$-HE]XC\0:-%?W7G6^E?;I;*^2UZ<JR/,,X=3ZG"'LZ5E4JU9\E.
M,FKJ-TI2E)I7M"$K*W-:Z(J5J=*W,]]DE=Z?UY'PC\%O^#G_ /X),_%_7=*\
M/:M\3/B7\$+W6)UM;:[^-/PQO]'T*WN9.(H]5\2>"-2\>Z!HL#GAM2U?4K+2
M;8?/>7]M'\]>GB.#,\H1<HTJ.)45=K#UDY6_NPJ1I2D_**;?1,SCBZ+TNX_X
ME9?>KI'\A?\ P<^?$GX=_%G_ (*9P^./A9X\\&?$KP7JW[-WP:DTOQ;X!\3Z
M)XP\,ZBC2>+)U:QUWP_>ZAIET##/!+^XNG_=RQ/]UU)^[X.HU:&3^RKTJE&I
M'%XB].K"5.:^!:QDDUMV.+%M.JK--<D=M>_8^^/^#8S_ ((X^!?VBGO?^"@'
M[4'A&P\7_##P3XKO?"_[/WPS\2Z:M[X<\;>.?#CVK^(/B;XDT^[1K#7O#'@S
M4'_X1[PUH]Q#>Z;JGC*UUZYU2&/_ (1&TM]3\SC'/ZF$2RO!3=.M4@IXFM!V
ME3I2NHT8-:QG42YI25G&GRJ/\2\=,)04OWDE=)VBNEUU^6R\[]D?WX>+?%OA
M3X?>%/$7C?QQXBT/P=X+\'Z)J7B/Q3XI\1ZE9Z)X>\-^'M%LY;_5=9UG5K^6
MWL=,TO3;&":ZO+RZFBM[:WB>21U12:_,*=.=6<*5.$JE2I)0A""<I3E)VC&,
M5JVWHDCTMO)+\#^?K2O^#H[_ ().:I\84^%/_"=?%S3M%FUQ-"M_C9JOPMGL
M_@]+))>O81:D][_;;^/['0W=8[AM7U/X>6-I;6,R7EX]O;QW+V_U,N"\[CA_
M;>SP[ER\WU:-:]=:7Y;<BI.7]V-5W:LM;'-];HWM=^MO=_S_  /Z$;:YT+Q7
MH-O>6D^E>(_#/B32(KFUN8)+35]#U[0M8LUEAGAE0SV.IZ5JFGW"O'(AFM+V
MSG#*9(9!GY5J5.5FG"<)6:UC*,HO;HTXM>J:.D_S&O\ @Y%_X)@^%/V OVL?
M#_Q,^"7AZ/P[^SI^U):>(?%?ACPSIUK';:%\-_B5H%[:?\+#\ :';VR^1IWA
M=XM;T'Q7X1T_;:P:?::YJGAK1[1=*\*0M7[%PEG,\TP,J6)ES8O!.%.<V_>K
M4I)^RJR[S]V4*CUNXJ;=YGDXJBJ<U**M&?3HFMU^J^?8_G+KZPY0H * /VZ_
MX(D?\$E_"/\ P5B^)WQP\">+_C-XC^#=E\(O ?AOQ;:WWAOPCIGBJZUNY\0>
M()]&^R3IJ>LZ3%8P6D5J\VZ,7$D\DJ+F%8CYOSO$6>3R.AAZL,/'$.O5E3M*
MHZ:BHPYKJT97[=+'1AZ"K.2;<>5+9=[_ .1_4?\ "[_@SY_8H\-:YI>J?%3]
MHW]H;XHZ;87*7%YX;T>#P/\ #G2]:2/D6.H7=MHWBC78+&4X6Y_LG5]-U!H]
MRVNH6<A69/BZW'F83BXT,)A:+:LIR=2JX^:5X1OVNFNZ9V+!4U:\I/RT2?W(
M_IM^$_PG_9]_8O\ @/X>^&7PTT/P;\#O@+\(O#[P6%K<:I%H_AOPWI,<LEWJ
M.L^(?$OB*_:6ZOK^]N+C4]?\3^)-6NM4U?5+NZU/6-2NKVYFG?X^O7Q68XJ5
M:M*IB<57ETCS2D]E&$(+1):0A"*C&*2BDE8ZDHPC9)1BODD?R,?\' 7_  <"
M? S7O@9\0/V'OV'?'VF?%CQ)\6-+N/!_QL^-WA">'4_AQX;^'&J136_B?P)X
M%\20R-9>-/$?C.P(T37-=T0:AX3TCPGJ6J6=AJU_XCOL^&_NN%N%\3#$4LRS
M&DZ$:#Y\-AIKEK2JJW)5JPWIQIOWHPE:HYQBW%07O\>)Q,>5TZ;4G)6DULEV
M3V;?W)'\&%?IAYH4 % !0 4 % !0 4 % !0 4 % !0 4 ?Z!?_!F[_R;3^V5
M_P!ES\!_^H#-7Y?Q_P#[UEW_ &#UO_3D3TL#\$_\2_(_LEK\_.X_R*/^"XW_
M "EJ_;N_[+GJO_IET2OW;AW_ )$>6?\ 8+#\V>+B/XU3_$?E-7M&(4 % !0
M4 % !0 4 % '^SW^P)_R8E^Q5_V:5^SC_P"J=\&U_/N9_P#(RS#_ +#L7_Z?
MJ'NT_P"'#_!'_P!)1^3W_!7S]K$?L8_\%!?^"+WQ;U34_P"S/ ?B;XF?M-_
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MIFFW][;WE\2Y" 6L,N6(4<\5G&C5G%RA2J3C'XI1A*48^K2LOF/0_CR\!?\
M*Y#\;/\ LDND_P#K"GPCK[ZI_P D!A_^OS_]6=<X8_[[/_"O_2(G]GU?GIW'
M^7;_ ,%S/@A\2?VE/^#@G]HCX"_!_P /3^*?B5\5O&G[-7@WPCHL&Y$FU+5/
MV8/@>C7FH7(1TT[1=(M%N=7U_5YU%GHVB6&H:K>O'9V<\B_LW#>(HX3A?"8F
MO)0HT*>+J3D^D8XS$:+O)Z1C'>4FHK5H\G$1<\3*,5=OD2_\ C^"_(_T-/\
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MC4@X2VZ>3Z->A_&#_P &X?QJ^"'_  3%_::_X*/?!K]N+XQ_#S]GOQEX?O\
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M7WIPA0 4 % !0 4 % !0 4 ?["'_  1\_P"46?[ /_9J?P;_ /4.TVOP;/\
M_D=9G_V&U_\ TMGMT/X-/_!'\CZM_:?_ .3:?VA_^R&?%K_U =?KBP/^^X/_
M +"L/_Z=@7+X)?X7^1_BA5_0QX(4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % ']<?_!G?_R?9^TM_P!FE:C_ .KB^%5?"\>_\BW!_P#8<O\
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M8P>(I+WQM\6/&394<*[Q^*XF)(W%/+S\H7'Z[P-#ER63_P"?F-KS^ZG0I_\
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MIKLUHU\CVS^.3_@\B_Y-K_8S_P"RX^/O_4"MJ^^X _WS,/\ L&I?^G3BQO\
M#A_C_P#;6>B_\&@GP#T;PA^Q3\=_VAYK.U/BWXT?'>;P5'?B!3=)X%^$?A?1
MCI%I]J9!)&LOBSQMXTEGMH6,#K!82R,\J!(,N/,3*>887")ODP^&]I;I[2O.
M2;MY0I4]?-KU>"BE3<NLI6^45_PY_4G\;9OBG;?!GXM3_ RRT34OC7#\-/',
MOPAT_P 2W45CX=O?B='X8U-O =KKMY/'+;VVD3^*!I<>HS3QF!+1I3-MC#,/
MB\,J'UB@L2Y+#>VI^W<%>2H\Z]IRI6UY+VMKV.MWY7R_%9\O:]M#_-W\8?\
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M%^.;"TCM;GQ]^RKX>@UJ6, '4-5\(_$SXDZ?'?3CJ;A=$O\ 1=.W\ VVG6R
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MOXO>,+&W1$7"HJPP(%1>%  ' K^@\MES9=@)/>6"PLG\Z%-GAU=*E1=IS_\
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M>=CE[\'_ ';?<_\ @G\@U?=G"% !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M901TU<RS&M'EK8_&U8M6<:N*KU(VVM:4VK>0E"$?AA%>D4OR1]0UQ%'\C/\
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M$\9Y)AFX4YU\5RZ?[-17)IT4JTJ,6EWA==KF\<'6EJ^6/^)Z_@GJ?J'\"?\
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MA;_LF?QJ_P#4I\!5^G>'_P#N^9?]?L/_ .D5#SL=O3])?H?Q9U^A' ?UU_\
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M]-CHDKQDO[K7X'^*+7]#G@A0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M[AD/##@\5Y5"7)6HR6\:M.2_[=DFOR-NEC_$(K^BSY\_VGOV-?\ DT#]E/\
M[-M^!G_JL/"]?SWF'^_X[_L,Q/\ Z>F>]#X(_P"&/Y(_G7_X/!/^4;OP)_[/
M>^'W_JA_VCJ^KX"_Y&V)_P"Q=4_]2<(<N-_A1_Z^+_TF1_G$U^LGEA0 4 %
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M"DKR>O2*^)^B[>>Q_EG_ /!0G]O#XP_\%&_VG?&G[2WQB:WT^]UJ.V\/^!_
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MU^&/[2&K:U;0P6Y*Q$^5HB)%"2J$[4R%K]\PU-XK):%)[XG*Z5-OSK82,?\
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MX>V'P^O_ !KI,6IP:9JVF:!=WMKX7AL(=89]1BM=&\*C1="ACN"-B:8%A2.
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M2U?MW?\ 9<]5_P#3+HE?NW#O_(CRS_L%A^;/%Q'\:I_B/RFKVC$* "@ H *
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M"X_^F8GFX[XH?X7^9_'97WIPA0 4 % !0 4 % !0 4 ?["'_  1\_P"46?[
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MZ_8;_P!/1.K!_P 9?X9'^HA7XR>L?YD'_!U%^T9XV^*O_!4/Q;\$=4UF[D\
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MN9+E4K+F46TW&^]FTG;:Z78P\NG8RZH H * "@ H * "@ H * "@ H * "@
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M ($[GOG\>O\ P>1?\FU_L9_]EQ\??^H%;5][P!_OF8?]@U+_ -.G%C?X</\
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M^1W_ -R>'_\ 2JIZF#_@K_%(_7#_ (*D?\HSO^"AG_9D/[5/_JC?'->%DO\
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M(C%'1E925(K\'::;35FG9KLUI;Y'M'\<'_!XQ\$/%'BK]GK]D#X^Z1H]S?\
MAOX-_$OXF^ _%^HVJ^8NAQ_&?1?!-[H-YJ$29>'3KG4_A6VE#4)%%M!J>H:9
M8/(MSJMG'-]_P#B(0Q./PLI)3KT:%6FG]KZO*HII>:59.RZ)NUHZ<6-C>$)6
M^%M/R4K?Y(_S]J_4#S#^ZC_@S:^"7B:TTS]M?]HO4M(FMO"&MW/PI^#?@_6Y
M 1%JVN^'D\5>,OB!86V0,C1;+7_AU+/("49]82-?G@E"_FW'^(A?+L(I>_'V
MU><?Y8RY*=)O_$XU;?X7Y'HX&+M4ET?+%?*]_NNC^XBOS@[S_%S_ &X_B-I?
MQA_;4_:\^+.A7R:EH7Q-_:>^/7C[0M0B(,-YHGB[XI^*M>TBX@QQY$NG7]LT
M ' B* < 5_0>74GA\OP-"2Y94<'AJ4EVE3HP@U\FCPJCO4F^\Y/Y7=C_ %^O
MV-?^30/V4_\ LVWX&?\ JL/"]?A&8?[_ ([_ +#,3_Z>F>W#X(_X8_DC^=?_
M (/!/^4;OP)_[/>^'W_JA_VCJ^KX"_Y&V)_[%U3_ -2<(<N-_A1_Z^+_ -)D
M?YQ-?K)Y9_K;?\$$O^407[#/_9+=8_\ 5B^-:_#>)_\ D?9E_P!?H?\ IFF>
MUA_X-/\ PGCW_!RS_P H7OVNO^O_ /9Y_P#6G/@W71P?_P E!@O\.*_]1*Y.
M*_@3_P"W?_2XG^='_P $K/%7_"%_\%+_ -@7Q 9/)@@_:_\ V>].O9L[1%IN
MO?%'PSX?U.1C_=33]3N68?Q*"O>OU?.H>TRC,X=\!BVO6-"<H_BEZ'F4=*M/
M_''\['^QO7X$>V?Y-_\ P<,>%?\ A#_^"QW[;&FK%Y<>H>+/AOXJCPN%D_X3
M3X(?#+Q9-(A'#9NM9G5R/^6JR*WSJP'[APM/VF09<^U.K#_P7B*U/_VT\?%*
MU>?_ &[_ .DQ/Q?KZ YS]QO^"87_  7O_;%_X)I:;:_#/2QI/QZ_9P74#>#X
M*_$C4M4MV\)K<3/<:G_PJCQM9F[O_ +:I/(UQ=:9<Z5XH\'?;9;S4X_"2:QJ
M%[J4_P YG'#.7YP_:RYL-B[6^L45'W[6M[:F[*KRK1.\)VLN?E22Z*.)G27+
M\4?Y7T_POI]S7D?VE?L:_P#!S7_P36_:HU#0?!WCGQ1XG_94^).MSVNG6^B?
M'*QM+;P)>:O<LJ"WTOXM>'[C4_"-G8!F"1ZGX_\ ^%>B:0&);4.T*R_GN/X.
MS?!*4Z4(8VC%-\V&?[Q17>A.TV_*E[4[Z>*I3LK\C[2T7W[?D?T-PS0W$,5Q
M;RQSV\\<<T$\+K+#-#*H>*6*1"4DCD0J\;H2KJ0RD@BOE+6TVMI;L=)_"'_P
M=\?L6_#KP?J7[/W[<?@GP[%H/C'XE^)-3^"GQFN].@AM].\6:II?AN3Q+\-O
M$6HPPQ1AO%,6B:+XMT+4-4E>6?5=$TGP[:2;%T&-I?TO@3,*M2.*RVI+FIT8
M1Q&'3WA%RY*L%_<YG"2CM&4I?S'GXVFERU$K-OE?GHVOGO\ *W8_B0K]%///
M]N;X,^%/^$$^#_PH\#^7Y/\ PAOPU\"^%/)QM\K_ (1WPOI>D>7M_A\O['MQ
MVQBOYUQ$_:8BO4_Y^5JL_P#P*;E^I[Z5DEV27W(_S^_^#P[Q7]M_;L_9K\$K
M)N7PW^R=IWB1HP<K%-XO^+WQ1TYP>RR-#X,MV9?O>7Y3$;66OU#@*%LLQ=2W
MQXYP^5.A0?W>^_Q/-QS]^"[0O][:_0_D=K[HX@H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@#]S/^#;+_E-3^QA_W<5_ZR?\=:^;XN_Y)[,/^Y3_ -3L,=&%_CT_
M^WO_ $B1_JR5^)GL'\4/_!YC_P DS_8(_P"QZ^/_ /Z8/A57Z)X?_P 7,_\
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M]". _KK_ .#.W_D^+]IW_LU*X_\ 5N_#6OA>/?\ D6X/_L.7_J/6.[ _%/\
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M4_\ 3]4\;$_QZGJO_24?C;7OF 4 % !0 4 % !0!V/P[_P"2@>!?^QQ\,_\
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M%?@9-N7Q-OU=SSZM1']@W_!G-_R=_P#M9?\ 9MNC_P#JS_#5?!\??\B_!?\
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M>CPK_P#,+1_Q#^M_T,Z7_A-+_P"7!]>A_P ^Y?>C\._^"V__  6\\#_\%9?
M7P%\&^$O@!XJ^#,WP<\7^,_$UY?>(O'.D>+8M<B\4Z-HVE16EK!IGA_1FLGL
MVTMYI)99)UE6545$*DGZ/AWAR>1U,3.>*AB/K$*<$HTG3Y?9RD[ZSE>_-Y6L
M<^(Q"K**47'E=];=K'^C_P#L<^-=,^)'[(_[+OQ!T6YMKS2O&W[/'P8\4V%Q
M:$&WDM]=^'/AS4D$>/N;/M'EM$P#PNC12*KHRC\DS"FZ./QM*2LZ>+Q$'?\
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M*_\ 42N3BOX$_P#MW_TN)_GR?\$7?^4K7[!'_9R7P_\ _2YJ_4N(/^1)F?\
MV!UO_23S</\ QJ?^(_U]J_!SVC_-Y_X._/\ E)C\&O\ LR'X9?\ J\OVCZ_6
M^!/^1/7_ .QC6_\ 4?"'EXW^+'_KVO\ TJ1_8C_P09\:Z9X\_P""17[#NK:7
M<VUS'I7PHN_!5W]G(_T?4_A_XS\4>"=1MIT^]'<176@R>:K@%]RS+F*6-V^!
MXFINEGN8Q:WK*HO\-6E"HK>5I?H=V'=Z-/\ PI?=I^AZ)_P6._9O\8_M:_\
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MN=6=23A3]BH:-\L;N4[<JCL^RMKA:M2KSN=K+E2LK=[_ *'],/B[_D5/$_\
MV+VM?^FVYKX^G_$A_CC^:.L_P\*_HT^?/]I[]C7_ )- _93_ .S;?@9_ZK#P
MO7\]YA_O^._[#,3_ .GIGO0^"/\ AC^2/YU_^#P3_E&[\"?^SWOA]_ZH?]HZ
MOJ^ O^1MB?\ L75/_4G"'+C?X4?^OB_])D?YQ-?K)Y84 % !0 4 % !0 4 ?
MZSW_  ;[?\H=?V(/^Q%\=?\ JY/B/7X?Q3_R/\Q_Z^4O_4:B>UA_X-/_  GZ
ML?%#_DF?Q$_[$7Q;_P"F#4*\2A_&H_\ 7VG_ .E(U>S]'^1_B$U_19X 4 %
M!0 4 % !0 4 % !0 4 % !0 4 ?ZRO\ P;U_\H<?V(_^Q.^(W_J\/B?7X?Q3
M_P C_,?^OE+_ -1J)[.&_@4_1_FSW3_@L#\9_B=^SS_P34_:W^,_P8\77W@/
MXG^ ?AU9:MX/\7:9;Z==7^A:C/XQ\,Z9+=VL&K66H:>\K6-]=P#[39SJ@F+H
MJRJCKSY!AZ.*SC X?$4U5HU:LHU*;NE)*E-I/E:>Z6S6Q59N-*;CHTM'V/\
M-FU'_@O#_P %=]4MFM;G]NCXMQ1-U;3K3P/I%R.,?+>:3X2LKM/^ 3KCJ.:_
M6X\-9%%W66T/G[22^Z4VOP/+^LUO^?C^Y?Y'PS\<OVO/VJ/VFIQ/^T+^T7\:
M_C2L=R+RUL?B3\2_%WBW1M.N%5E1](T+6-5NM%T<1K)((X]+L+.*/S)-B+YC
MY]+#8'!8-6PN$P^'TM>C1ITVUYRC%2E\VS.4YS^*4I>KT^[9'SK760>J? O_
M )+=\'/^RJ?#W_U+=(K'$?[O7_Z\U/\ TAE0^*/^*/YH_P!MROYU/>/X7_\
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MU?4\&_\ (^PW_7K$_P#IB9S8O^!+UC^:/\M6OV<\@* "@ H * "@ H * "@
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M $PICQL*J5*C\_Q]-TL=C:35G3Q>(A9_W:LX_H=T'>$7WC%_@CYG_P""IO\
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MENV]DDON KNCQ.\4B-')&S))&ZE'1T.UD=& 965@592 5(P0,4P&4 ?VD?\
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M_C__ 'K+O^P>M_Z<B>E@?@G_ (E^1_9+7Y^=Q_D4?\%QO^4M7[=W_9<]5_\
M3+HE?NW#O_(CRS_L%A^;/%Q'\:I_B/RFKVC$* "@ H * "@ H * "@#_ &>_
MV!/^3$OV*O\ LTK]G'_U3O@VOY]S/_D99A_V'8O_ -/U#W:?\.'^"/\ Z2C^
M4;_@\V_Y$C_@GW_V-7[27_IH^"=?;^'_ /$S3_!@_P \2<>.VI^LOR1YQ_P9
MY_M<_8M?_::_8=\1:GMM];L]/_:/^%UE-+LC75-+_LGP#\6+.W$AQ-=ZCIDW
MPTU.UL[?;(MKX?UZ],<J)-)!MQ[@+PP>906L&\)6:_EES5*#](M58M]YQ0L#
M/XZ?I)?D_P!#^SG]J?\ 9_\ #'[5?[-WQQ_9N\8W4FG^'?C9\,/&'PYO=7M[
M:.\N] E\2Z+=:?IOB6PM9GCAN-1\-:I)9:]IT,SI$]]IUNLC!,U^?8'%3P.+
MPV+IJ\L-6IU5'924))R@VME.-X.W1G=**G&47LTU_7H>Q>&_#NC>$/#N@>$_
M#EA!I7A[PQHNE^'=!TNU79;:;HVBV,&FZ786Z?PP6=C;06\2_P ,<:CM7/.4
MJDY3F^:4Y.4F]W*3NV_5E)6T730_R<O^"\_[6G_#8/\ P5!_:0\9Z5J?]I>!
M/A=KT?[/WPU>.7S[,>%OA!+=^']4O=-G!*3:9XE\?OXV\8:?+&%C>U\11%=P
M^=_W#AG _4,FPE-QY:M6/UJMI9\]>TDFNDH4O9TW_@/&Q,^>K+M'W%Z1_P"#
M=H_T._\ @A%_RB*_86_[(_+_ .IEXJK\JXF_Y'N9?]?U_P"FJ9Z>'_@T_P#"
M>2?\'(__ "A9_;0_ZY?L^?\ K5/P.K?A'_DH<O\ ^YO_ -0<23BOX$_^W?\
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M5R52*U2C-:+W9(Y:N*5*;@X2=K:Z6::Z?E\CX6_XC+/@S_T8Q\3O_#T>%?\
MYA:]+_B'];_H9TO_  FE_P#+C/Z]#_GW+[T'_$99\&?^C&/B=_X>CPK_ /,+
M1_Q#^M_T,Z7_ (32_P#EP?7H?\^Y?>C^4+_@K)^WCH/_  4B_;-\7_M3^&_A
MUJ_PLTKQ-X0\ ^&8O"&MZ_9^)=0M)/!OAVWT.:[DU6PT[2K:1+Z2 SQ1+9JT
M*$(SN1FOMLDRR649?3P4JJK.G.K+VD8."?M)N5N5N5K7MN<=:HJL^9*RLE9^
M1_?)_P &MO\ RB%^%/\ V5?XY?\ J?7]?F/&?_(]K?\ 7C#?^FD>CA/X$?67
MYL^_/^"Q=C=:A_P2O_;\M[.%IYH_V6OBU?.B#E;32_"]YJ5],?\ 8MK&TN+A
M_1(FKR\@:6=97?3_ &V@OFYI)?>TC2M_!J?X)?D?X^U?O)XA_IK_ /!J)XPT
M[Q)_P2DLM"L[FWEO/A]^T1\8?"VJP1%?.M+K4$\*^.+=+I0 V^73_%]I-$[9
M#0NB*W[LJOX]QO3<,[YK:5<)0FNSMSTM/G3/6P;_ '*7:4E^OZG] WQR^(NH
M_!_X+?%SXLZ1X.U'XAZG\,/AGXZ^(5AX!T>\CT_5_&MUX+\,:GXCA\*:1>RV
MM[%:ZIX@;31I6G32VEQ&EY=0&2)DR*^7PM%8C$X?#RJ*C&M6I475DKQIJI.,
M.=JZNHWNU=:(Z6^6+=KV3=EULMD?R$?\1EGP9_Z,8^)W_AZ/"O\ \PM?>?\
M$/ZW_0SI?^$TO_EQQ?7H?\^Y?>@_XC+/@S_T8Q\3O_#T>%?_ )A:/^(?UO\
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M(?\ V;UXG_\ 5D:E7ZGP#_N.._["X_\ IF)YN.^*'^%_F?QV5]Z<(4 % !0
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MXC+/@S_T8Q\3O_#T>%?_ )A:^T_XA_6_Z&=+_P )I?\ RXY/KT/^?<OO0?\
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MX*?_ /*-+_@H=_V8S^UI_P"J#\?UZ63?\C?*O^QE@?\ U)I&=7^%4_Z]S_\
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MOL9GBOJ678W%;.AAJLX=/WG(U27SJ.*^9E2CSU(1[R5_3K^!_LZ !0%4!54
M*H    P  .  . !P!7\_'N'^6/\ \','[0%K\=_^"M'QHTW2YXKO0_@#X4\
M?L_Z7=Q$'S;KPII=QXL\802 9VRZ7\0_'7C'17!))_LT,=N[8O[3PAA7A<CP
MSDK2Q,ZF*:\JCY*?_@5&G3E\SR,7*]9K^5*/Z_K8_ BOISF"@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@#](/^"/G_ "E,_8!_[.L^#?\ ZF&F
MUY.>_P#(ES3_ + <1_Z;D;8?^-3_ ,1_L(5^"GM'\B?_  >)?\F/?LP_]G60
M?^JB^)%?=\ _\C'&?]@7_N>D<6-_AP_Q_P#MK/\ .[K]5/,"@ H _P!*_P#X
M-(_^47'BS_L[7XL?^H'\(*_(>.?^1S#_ + :'_IRN>K@OX/_ &^_R1^^/[8_
M_)H?[5/_ &;?\<?_ %6/B>OF<N_W_ _]AF&_]/0.F7P2_P +_(_Q7Z_H0\$*
M "@#]F?^"%7_  4=T[_@FW^W-X:^('C^\NX/@'\5]%G^$GQT^R6LM_)HOAG6
M+VTO_#_CRWL8%>XGF\">*K'2]5U%;*"ZU*;PC-XJT[2[2YU#4+:%_G^),I>;
MY;.E22^LT)*OAKNRE.*:E2;V7M*;E%7M%3Y&VDCHPU54JFOPR7++R[/Y?E<_
MU?\ P_X@T+Q9H.B^*?"^LZ7XB\->)-*T_7?#WB#0[ZVU31M<T35K2*_TO5M)
MU*RDFL]0TW4;*>"[L;VUFEM[JVECFAD>-U8_B,X2IRE3G%PG"3A.$ERRC*+L
MXM/5--6:Z'L+RVZ6/R)_X*'_ /!"[]@[_@I-XMMOB=\7_#GC/X<_&..QATW4
MOBW\$=9T'PEXM\6V-C9P6.CVWCJWU_POXM\->+#HMI:VUAINJ:CH7_"1VNDV
M]MHL&NQZ39V-G:^]E7$N9Y13]C0E3K8>]XT,3&<X4VW>7LG"=.5/F;;<5+DY
MO>Y+MMXU,/3JZR33[QT?STL[=-/P.._X)^_\&_?[ /\ P3Q^)$/QH^'VE_$3
MXO\ Q?TR"2'PKX\^.^N>&/%%SX!DN%FBO-0\"Z)X8\&^#?#VBZU=VLOV(^(;
MK3-4\0V5IY]MI.JZ=;ZAJ<5[>:<49GFM'ZO5=+#X=_'2PT9P]K;9593J5)2B
MGKR)Q@W;FBVE94\-3I.Z3;Z.5G;TLDD?M=J^KZ3X?TG4]>U[4].T30]$T^\U
M;6=9U>]MM-TG2-*TVVDO-0U/4]1O)(;.PT^PM(9;J\O+J:*VM;:*2::1(D9A
M\[&,I2C"$7*4FHQC%-RE)NRC%+5MO1):MZ(W/\JK_@OS_P %+]'_ ."D/[:E
MQJ?POU.ZO_V<O@)H]W\,?@M<S0O:Q>*FDOQ>^//B?%93#[1:Q>.=<M[.VT83
M^1<3^"_#'A&YO]/TS59=1LHOVSAC)WE&7*-:*6+Q,O;8A;\FEJ5&ZT?LH_%;
M3VDZEFXV9X^)JJK4]WX8^['S[OY]/)(^*/\ @EU\;O#O[.7_  41_8U^,_C"
M^@TGP=X+^/\ \/7\8ZS=2^3:Z'X0UW68?#'BG7;IP#_HVAZ!K6H:M<)C]Y#9
MO'QNKT,XPTL7E6/P]-7J5,+55.*^U4C'FIQ7^*45'YD49*%6FWLI*_H]#_8\
M!! *D$$ @CD$'H01P01TQ7X$>V?DC_P4V_X(P?LD?\%4+CX?^(?CC=_$?P)\
M1OAII][H7ASXD_";6?#^D^(KOPI?74VH/X0\1VOBGPQXMT36O#]KJUQ<ZQIB
M_P!FV>K:5J%W?G3]6M[35-5M+[W<FXAQV2JK##JE5HUFI2HUXR<5-)+VD'"<
M)1DXI1>KBTE>-XQ:QJT(5K<UTULXV3]-MORZ'\(G_!=']@GX,_\ !)#]K/\
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M#,3_ .GIGO0^"/\ AC^2/YU_^#P3_E&[\"?^SWOA]_ZH?]HZOJ^ O^1MB?\
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M/^2@P'IBO_4+$$XK^!/_ +=_]+B?Y4=?M9XX4 % ']Y/_!F7_P D_P#V_O\
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M$\>_X.6?^4+W[77_ %__ +//_K3GP;KHX/\ ^2@P7^'%?^HE<G%?P)_]N_\
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MR/%"@ H _3K_ ((N_P#*5K]@C_LY+X?_ /I<U>/Q!_R),S_[ ZW_ *2;8?\
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MTO;2:&YMIHR4EAD1T)5A7\[2C*$I0DG&4&XRB]'&479IKHTU8]X_(C_@L/\
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M;P#7Y5Q[_P C'!?]@7_N>J>G@?X<_P#'_P"VH_J3_:&_Y(!\<O\ LCWQ,_\
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M\Z__  >"?\HW?@3_ -GO?#[_ -4/^T=7U? 7_(VQ/_8NJ?\ J3A#EQO\*/\
MU\7_ *3(_P XFOUD\L_UMO\ @@E_RB"_89_[);K'_JQ?&M?AO$__ "/LR_Z_
M0_\ 3-,]K#_P:?\ A/'O^#EG_E"]^UU_U_\ [//_ *TY\&ZZ.#_^2@P7^'%?
M^HE<G%?P)_\ ;O\ Z7$_SY/^"+O_ "E:_8(_[.2^'_\ Z7-7ZEQ!_P B3,_^
MP.M_Z2>;A_XU/_$?Z^U?@Y[1_F\_\'?G_*3'X-?]F0_#+_U>7[1]?K? G_(G
MK_\ 8QK?^H^$/+QO\6/_ %[7_I4CZT_X-1_^"H/A#X>W?B7_ ()P_&OQ):Z!
M;^/O%]QX\_9CUO5I([;3;CQIK%I%!XW^$TVH2NL5I?>)&TW3O$O@*UE$<.IZ
M^WBS1TNI-;UOPWI=]P\;9-4K*&;8:',Z5/V6,C'XO9Q?[NLDMU"[A5?2')*W
M+&35X.JE^ZD[7=X?K']4?WI5^9'HGX-?ML?\&Y/_  3<_;:^(>K_ !<UGPQX
M_P#@+\2O$<ES>^*]?_9WUWPSX.TSQAK=S,US/X@\2>#_ !)X-\9>$Y-<O)WF
MFU?5M#TC0=3UZXGGOM;O;_47^VK]-EW%N;Y=2C04Z6*HPLH1Q49SE3BE91A4
MA4ISY4K*,9.2BDE%):'/4PU*H[M.+[QTO\K-?@>?_LP?\&P'_!+K]G'Q9IWC
M?Q%X7^)G[3&N:2RW&GZ;^T1XH\/>(O MK?I(K)=R> ?!O@[P-X=U^)4!A_LO
MQK;^*]'97:26PDG2"6'7&<99SBJ;IPG1P<7HY82$HU6NRJU*E24/6GR2Z7L*
M&$HPZ.7^+7\$DOP/PE_X([?%+X?_ +/?_!RU^WK\*MOA;P+X4^+GQ/\ VWO@
M5\/]"M;33?#N@:?K&A_M$IXZ\'^%?#EG:Q6FG:6ATCX<ZAH.@:'9I;6DSS66
ME6%J]T=.MZ^FS^C5Q7"&65O?JSH4,MQ563;E)Q>$]G4J3;NY:U5*<GKO)NUS
MFH-1Q52.B3=2*6VTM$NVBT_X8_O_ *_+CTC^2C]I_P#X-*?V:OCK^T3XT^,_
MP\_:6^(7P0\%?$/Q1K'C/Q-\);3X>Z#XWM],UWQ%J%SJNMP>!?%EYXG\/2>'
M/#\U_=2SZ=HVK^'O%;Z2LCVEO?M8I:6MK]S@^.<7AL)3P]7!TL34I0C3A7]K
M*G>,$HQ]I34)\TDEK*,X<W9.[?'+!0E)R4G%-WY;+YV?3[G8_H:_8E_8Q_9W
M_P""?_P,\/?LR_LYZ*^A^%M#>Y\3:O/K.J1ZOXV\:^)=7%M9ZSX^\9Z@([5M
M1UK66TVTLWGM;#3]&L+/3K'0M#T[3-'TNPTVU^5S',,7FF(EC,7+FE*T(\L>
M6E3A'6-*FM;1C=NS;DVW*3<FV^FG"-.*A!62^_U?]6[:'TYXN_Y%3Q/_ -B]
MK7_IMN:XZ?\ $A_CC^:+/\/"OZ-/GS_:>_8U_P"30/V4_P#LVWX&?^JP\+U_
M/>8?[_CO^PS$_P#IZ9[T/@C_ (8_DC^=?_@\$_Y1N_ G_L][X??^J'_:.KZO
M@+_D;8G_ +%U3_U)PARXW^%'_KXO_29'^<37ZR>6% !0 4 % !0 4 % '^L]
M_P &^W_*'7]B#_L1?'7_ *N3XCU^'\4_\C_,?^OE+_U&HGM8?^#3_P )^K'Q
M0_Y)G\1/^Q%\6_\ I@U"O$H?QJ/_ %]I_P#I2-7L_1_D?XA-?T6> % !0 4
M% !0 4 % !0 4 % !0 4 % '^LK_ ,&]?_*'']B/_L3OB-_ZO#XGU^'\4_\
M(_S'_KY2_P#4:B>SAOX%/T?YLZ7_ (+T?\HA?VYO^R4Z9_ZG_@VIX8_Y'V6_
M]?I?^F:@\1_!J?X3_)%K]R/%"@ H ]4^!?\ R6[X.?\ 95/A[_ZEND5CB/\
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M/Y**6)RU.:6LJ&(<(M^5.=.;BO\ N)(IX%?9J-+LXW_%-?D?L;_P1S_X(/\
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M!X)K\?XW_P"1W_W)X?\ ]*JGK8/^"O\ %(_7#_@J1_RC._X*&?\ 9D/[5/\
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MA+;F=K6W,YTJ=2W/%.VVZM]UNQ\E?\."O^"/_P#T8W\-/_"B^)W_ ,W5=_\
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M "EZ^*__ &2GX&?^J_T^OV;@S_D0X?\ Z_8G_P!/2/)QG\9_X8G\[M?5'*%
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M<V=T\'2EK&\'Y:Q^[_)I>1^<_@;_ (,SYHO%=G+\2_V](K[P-;W<;W]EX&^
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ME1M)2[*JH^TB^LO:*RY5?3"55*"IOXH:6[QZ->FS[:']+_QA^$'PU^/WPO\
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M/];_ /X(1?\ *(K]A;_LC\O_ *F7BJOPSB;_ )'N9?\ 7]?^FJ9[6'_@T_\
M">2?\'(__*%G]M#_ *Y?L^?^M4_ ZM^$?^2AR_\ [F__ %!Q).*_@3_[=_\
M2XG\>'_!J9\</#?PD_X*BGPAXGU?3-(@^/WP#^(7PE\/OJDT-HEYXR@\0>!_
MB1H>FVEU-L4:CJ=KX U;3=/LC*O]I7MY;V4$<]_+8Q'[WC7#3KY+SPBY?5<3
M2KRY>E/DJ4I2:[1]JF^R5]DSBP<E&K;;FBTO71K\C_36K\>/5/Y*/VG_ /@T
MI_9J^.O[1/C3XS_#S]I;XA?!#P5\0_%&L>,_$WPEM/A[H/C>WTS7?$6H7.JZ
MW!X%\67GB?P])X<\/S7]U+/IVC:OX>\5OI*R/:6]^UBEI:VOW.#XYQ>&PE/#
MU<'2Q-2E"-.%?VLJ=XP2C'VE-0GS226LHSAS=D[M\<L%"4G)2<4W?ELOG9]/
MN=C^AK]B7]C']G?_ ()__ SP]^S+^SGHKZ'X6T-[GQ-J\^LZI'J_C;QKXEU<
M6UGK/C[QGJ CM6U'6M9;3;2S>>UL-/T:PL].L="T/3M,T?2[#3;7Y7,<PQ>:
M8B6,Q<N:4K0CRQY:5.$=8TJ:UM&-V[-N3;<I-R;;Z:<(TXJ$%9+[_5_U;MH?
M3GB[_D5/$_\ V+VM?^FVYKCI_P 2'^./YHL_P\*_HT^?/]I[]C7_ )- _93_
M .S;?@9_ZK#PO7\]YA_O^._[#,3_ .GIGO0^"/\ AC^2/YU_^#P3_E&[\"?^
MSWOA]_ZH?]HZOJ^ O^1MB?\ L75/_4G"'+C?X4?^OB_])D?YQ-?K)Y9_1!_P
M:X?\I>_A+_V2OXY_^J]U*OE>,_\ D0XC_K]AO_3T3JP?\9?X9'^HA7XR>L?Y
M>G_!</X[?$O]F+_@X/\ VA?C_P#!W7Y?#/Q+^$_C7]FSQAX3U:/>\(OM._9>
M^"/GZ=J=LDD0U'0=<L)+O0_$6D3.+76="U'4=*NU>UO)D;]FX<PU'&<+83"U
MX<]&O3Q=.<?)XS$:KM*+M*$MXR2:U1Y.(DX8F4HZ.+@U_P" 1/\ 0Y_X)\_M
MM?#3_@H3^RC\+_VGOAD\5I;^,-,_L_QMX2^UI=ZA\._B5HL<-MXU\":JP6.4
MS:+J;^=I5Y/;VC:YX9OM!\206T5EK-J#^59KEU7*L=6P=77V;O2G:RJT9?PZ
MBZ:K225^6:E#>+/3IS52"DNNZ[/JOE^5GL>.?\%8?^";?P]_X*=?LG>*/@CX
MA_L[0?B;H'VGQC\!OB1<VY:;P)\2[*RDCLEO)X8Y+M_!WBR'_BG/&VFQ)<";
M2;F/5[6TDU[0=!N;/?(\WJY-CH8B-Y496IXJBMJE%O6RT7M*?QTWI[RY6^24
MDYK4E5@X]=XOL_\ +H_+Y'^69\*?&?QQ_P"":7[<7@WQGKGA2]\*?&_]DWXV
M6=SXG\#:[_HS3:AX1U<V?BCPE?7$/G1RZ+XLT-M1T;^UM.DGMK_0M975-'NY
MK>XM+I_VFM3PV;Y=4IQFIX;'8=J%2.NE2-X5$M/>IRM+E=K2CRR6C1Y$6Z-1
M-K6$M5Z;KYH_U[?V8?VE?A%^U]\"?AS^T5\#/$T'BGX;?$S08-:T:\7RX[_3
M;D,UMK'AKQ!8I)*VE>)_#&K0WFA>(=)E=GL-5L;F /+$L<TGX1C<'7P&)JX3
M$PY*M&7*UTDOLS@]+PG&TH/K%K;8]J$HSBI1=T_ZMZKL?&O_  4J_P""1?[)
M/_!47POX?M/CQI/B+PW\2/ NGZGIWP[^,WP\U"UTCQSX8LM3ECNY]%OH]0LM
M2T+Q9X6DU&&.];0?$.F7;6$DNI2^&]0\.WVKZE?7'H9/GN.R6<OJSA.C4:=7
M#U4W3FTK*2LU*G.VG-%ZVBIJ:BDHJT854N9:K9K1K]/DS^>JV_X,S_A<FOM<
M7G[>GCZ?POQLT>V^ OAVTU]?F.[=XDE^*%YIS93 &/"B;6!8[@=@^I_XB!5Y
M;++*?/W^M2Y?_ /8)_\ DYS?48_\_';T7]?@?5?Q*_X-XO\ @G-^PW_P3Y_;
MB^(6G>!-=^/7QI\*_L=_M->)?#GQ6^.>HVOB"[\)^(=$^#'C75]%U;P5X,T:
MQT3P+X>U'1-5L[+4M$UV;0=5\6:3?6D5Q9>)(F%<=#BK-LQS7+:+J0PV'GF&
M#A.AAH\JG"6(IQE&I4DY5)*46U**E&#6C@7+#4J=*HU'FDH3]Z6KTB[66B5N
MEE<_S?J_63RC_2*_X-'OC?X<\<_\$[_B%\%HK^W_ .$S^!/Q_P#$\FJZ*)M]
MW#X.^*&CZ/XF\)Z])%_RQM=6U^Q\?:1;J,YF\,W<AQO K\EXZPTJ>:4<19^S
MQ.%@E+I[2C*4)Q_[=@Z4O^WSU<').ER]8R?W/5?K]Q_4-XL\*^'/'?A7Q+X'
M\8:-8^(O"/C+P_K/A7Q3X?U.$3Z;KOASQ#IUSI&MZ-J$!P)K'4],N[FRNX20
M)+>:1.,U\73G.E.%2G)PG3E&<)1T<9P:E&2[.+2:]#KMTZ;6/Y'OVEO^#6S_
M ()S_!'X+_M8?M!>'?%G[26L2^ O@'\=_B/X ^'&O_$+PK)X,\+^)O#GP^\4
M>)_#0^W:9\/],\:ZWI7AW4;"R73;+6?%5W/=V]LL?B.^U]I)WE^[P?&>:XG$
M8'"RIX2/M<5A:-6K&E/VDX3JPA/1U73C*:;NXPLK^XH:6XI82E%3DN;2,FHW
MT5D_*_XGY&?\&KW_  4@\)?LP?M%^./V0OC%XBM/#?PU_:JO/#L_PYU[5)%@
MTO0?CWHQ;1]%T6\NW:.&PM?B?H5]_P (^E[<M(I\4^'_  7I420)JUU<I[O&
MF43QN$IX[#PYZV"4_:QC\4\++WI-+JZ,ESV7V)5']E(QP=50DZ<M%*W*_P"]
MM;Y_FDC_ $=*_)3TS^7K]MK_ (-6?V*?VH/B7XC^+?P;^(GCK]E+Q1XTU;5M
M?\6>&O"NAZ1X\^%EWKVL7<FH7NK:#X*U:_\ #^I>$VN[^XNI[G1M$\60^%H(
MY(;70O#^A6\&R7[/+N-<PP=&%#$4:>-A3BHPG.4J591BK*,JD8SC.R2M*4.?
M?FE+IR5,)3F[IN#>]M5]W3Y:>1\O_"[_ (,X?V;M$U'3KGXQ?MC?&7XBZ?;7
M4,U_IG@+X>>#OA2-2MXY [V?VS6=8^*UQ9QW"CRI9H<SK&S&"2&79(G96X^Q
M<HM8?+\/2=M'5JU*]O.T8T+_ )$K P6\Y/R22_S/S/\ ^#GG]@+]D;]@7P)_
MP3T\%_LI?!CP[\+;/Q&_[4">,=<M9M3UOQGXZF\/1?L\'1KGQGXR\07NI^(O
M$#Z9+KFN3:7;7E^=-T9M9U*+1;'3K6ZDMZ]G@[-,=FE3-:F-KRK.'U+V<;1C
M3I*?UOF5.G!*,;\D;V5WRJ[=C'%TX4U24(J/Q[=;<MKO=GR]_P &R7[>OA?]
MCG]O6?X:_$[7;7P[\)_VMO#NE_"C4M;U"1;;2] ^*&F:P=0^$>LZO>,=EKIM
MYJ&H^(? \EQ,%M+*Y\<6FJ:A<V>FZ==W"=G&&63Q^5^UHQYJ^!DZ\8KXI47&
MU>,5U:BHU+;M4N6-VTG&$J*%3E>BFDO^WE\/ZKYG^GM7XV>L?BU_P40_X(,?
ML'?\%(O'EO\ %WXIZ5X_^%GQC-E;:=KWQ-^!NM>&O"^N^.K/3[>ULM(3Q]I_
MB;PAXR\/>([S1M/M(],T[7/[(LO$B:4EII-SK5SI6E:/9:?]#E/$V9912^KT
M72KX>]XT<1&<XTF[N7LG"=.4%)ZN-W"]Y**E*3>%3#TZKO*Z>UXV3?KHU^!Z
MU_P3K_X)"_L5_P#!+O3?$=Y\ _#NOZS\0/&,-OI'B;XT_%K5]&\2?$N_T5[B
MR,'A*PU;2M!\,:'X=\-W.JP6M[/HOAO0=*_MO4TT^76Y=7FTO1?L&&:Y]F.<
MN$<3*$:5/WH8?#QE"BI6^-Q<IRG)1NDYRERJ_*HIRO5*C"DO=6KW;W]-EIY(
M_4NO%-3_ #XO^#QW_DZ[]D/_ +-Z\3_^K(U*OU/@'_<<=_V%Q_\ 3,3S<=\4
M/\+_ #/X[*^].$* "@ H * "@ H * "@#_80_P""/G_*+/\ 8!_[-3^#?_J'
M:;7X-G__ ".LS_[#:_\ Z6SVZ'\&G_@C^1]6_M/_ /)M/[0__9#/BU_Z@.OU
MQ8'_ 'W!_P#85A__ $[ N7P2_P +_(_Q0J_H8\$* "@ H * "@ H * "@ H
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M -GB_M-_^KJ\;5_0.5?\BO+?^P#!_P#J/3/#J_Q:G_7R?_I3/]=G]C7_ )-
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M;_TDG#_QJ?\ B/\ 7XK\'/:/\W+_ (.]O^4FGPD_[,H^&'_JZ?VAZ_7.!/\
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M^77\3,^"G_!GQ^R!X/U[1]7^./[2OQL^-.G:=.EQ?^%O#>A>&?A#H6OF,?\
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MIP4(KY1BCPI/F;D]VV_O//JU$% !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % 'Z0?\$?/^4IG[ /_9UGP;_]3#3:\G/?^1+FG_8#B/\ TW(VP_\
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MM/ LC?M@>8L9EB:,.8Q^RY&7"%MQ021[@-H=<Y'SZ\/[-/\ M;9I_P"X=O\
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M[1MN=5+?EM3B]I*<;IY5,8Y*U-<O]Y[_ "MHO77Y'3?LL?\ !VM/^S9^S1\
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MI2]K[/VMO9S4K<G/3O>UOC5M]=C&C4]E-3MS:-6O;?Y/\C^HG_B-!_ZQM?\
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M8>M2KJ%&G.;FZ4XS4.:?LN1/EMS<LO\ "*>,@XRC&$M4UK96NK=+_<?SU_\
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M?^U>3VU:K5Y/J/-R^TFY\O-];C?EO:_*KVO9;'?'&V27LMDE\=ME;^0_.O\
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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MY3C2J5W4:=.<5RJ6&A'>2WDM/N"KBZ<Z<H*,[M65U&WX2_0_ALK]'//"@ H
M^P_^"??[0G@W]E#]M?\ 9D_:1^(6E^)M:\#_  8^+GA7Q[XITGP9::5?^*K_
M $;1;OS;VWT"RUO6/#VD76IM$3]E@U'7-*M)' 26^MU.\<&:86IC<NQF$I.$
M:F(P]2E!U&U!2DK+F<8RDH][1;\F:4I*%2$GM%WT_0_N[_XC O\ @FE_T0_]
MN;_PVGP#_P#HF:_-/]0\W_Z"<M_\'8G_ .8ST/KM+^6I]T?_ )(_DJ_X+N?\
M%'O@C_P5 _:_\!?'_P" GA3XJ>$/!GA3]G;P=\(K[3?B]HOA+0?$\_B+P_\
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MA?!9NW73>$QEK.O3BI1J65E[>E[O.TE93C*$TK)N48QBNFCB9TK1^*';JO\
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M-2=D\(E>RTU2\T;O&TK6Y:FW:/\ \D?YW]?JIY@4 % !0 4 % !0 4 % !0
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MFN]BH3E3?-!V:_JS6S7D?V!?LT?\'C&M:=H6EZ'^UU^R/#XDURTM5BU'XB_
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M"OO_  4T;_@JU^TSX._:*/P4'P&'A+X(^&/@VO@X?$<_%#[<OASQO\1O&?\
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M:NW[8)=49T*AB@_9<C+A2<E Z%@,!EZCYY>'UFO^%;;_ *@/_OPW^O?].O\
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MPJOQ,\$:WX,;Q%_PCP_9P\/_ -N'1EUDZ@ND_P!N:.+]K<6IU*R$OVB/@P7
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MG_A:Q^%3>'6\-ZW?:PNH"_\ ^%;_ !(&JB[%ZUL;/[#II@*+,+J7)AKY_/\
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M,^+7_J Z_7%@?]]P?_85A_\ T[ N7P2_PO\ (_Q0J_H8\$* "@ H * "@ H
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M/K-?\*VW_4!_]^&_U[_IU_Y/_P#:'\-M?I!YX4 % !0 4 % !0 4 % !0 4
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * /NK_@G)^WG\4_\ @G#^U5X#
M_:6^%_\ Q,XM(,GAOXD>!IKDVFF_$OX6ZU=6,GBSP3J$XCE%I)=BPLM6T#5#
M!<#0_%6CZ#K36E['I[V5SYN:Y90S;!5<'6TYO>I5%O1K13]G42ZVNU*.G-"4
MHW5[K6E4=*:DMMFNZ[?Y'^N?^S1^T;\)/VNO@3\./VB/@CXBA\5?#+XI^'+?
M7M"O2L:7MFS&2TU?P[K]BDL_]F>)/#6K6]]X?\2:1))(^FZSI][9L\@B$C_A
M6,PE? 8FKA,1#DK49<LET?6,X/K"<;2A+K%IGLQDIQ4H[-77]>1_FU_\'%O_
M  2NA_X)_?M5+\6?A-H<6G_LO?M/:EKWBCP+I^GQ+'8?#3XAP217_CSX7K!"
M!%8Z)'-J$7B;P#&([:W3PWJ5QX:L8IO^$,O;N;]<X4SK^U,%["O*^,P:C"JW
MO6I;4JWG+3DJ_P!]<[M[1(\O%4?9RYH_!+\'U7IU7W=#^=JOJSE"@ H ^O/V
M$_V-?B?^WS^U)\+/V7_A/"(=<\?ZR/[>\2W%N]QI/@/P-I2_;O&7CO6U1X@=
M/\-Z)'<745H9X)=9U5M-\/V$AU/5K&*3@S+'T<LP5;&5_AI1]V"T=2H]*=*/
MG.5E>UHJ\G[L6:4J;J34%\_)+=_UZ'^OM^S3^SM\)OV._P!GWX:_L]?"#28/
M#'PP^$'A*VT'2A<O;I<70MA+?:]XJ\17JI;P76O^)=7GU+Q-XGU5HX4O-8U*
M_O"D,<@C3\(QF*KX_%5<57?/6KSYG;9=(4X+I&$5&$(](I(]J,5"*C'2,59'
M^<O_ ,'$_P#P5^_X> _'6+]GSX'Z_P#:?V1OV>_$M\-%U.PFW6/QF^*MG#>:
M)K'Q0+I^[N/"^BVMSJ?AOX:;3(MSI%YKGBKSRGBVVT_2/UGA3(?[*PWUG$1M
MCL5!<\6M</1TE&AY3;495NTE&%OW=WYF*K>TER1^"+_\"??T6R^\_FUKZTY
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H _<S_@VR_P"4U/[&'_=Q7_K)_P =
M:^;XN_Y)[,/^Y3_U.PQT87^/3_[>_P#2)'^K)7XF>P?Q0_\ !YC_ ,DS_8(_
M['KX_P#_ *8/A57Z)X?_ ,7,_P#KWA/_ $JN<..^"'^)_D?P6U^F'FA0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 ?WI?\&9O_),_V]_^QZ^ '_I@^*M?F?B!_%RO_KWBO_2J!Z6!^"?^
M)?D?VO5^=G<?Y,/_  <$_P#*8G]M_P#['KP+_P"J;^&]?N/"_P#R(,M_Z]5/
M_3]4\;$_QZGJO_24?C;7OF 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '^L]_P &^W_*'7]B#_L1
M?'7_ *N3XCU^'\4_\C_,?^OE+_U&HGM8?^#3_P )^K'Q0_Y)G\1/^Q%\6_\
MI@U"O$H?QJ/_ %]I_P#I2-7L_1_D?XA-?T6> % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0![G^S!
M_P G+?L\?]ES^$O_ *GWA^N?%_[KB?\ L'K?^FY%0^*/^*/YH_VO:_G<]X_G
MY_X.>_\ E#K\?O\ L>O@+_ZN3P=7U/!O_(^PW_7K$_\ IB9S8O\ @2]8_FC_
M "U:_9SR H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * /Z/_\ @U7_ .4M7@__ +(9\:O_ $RZ;7R?
M&G_(BJ_]A&&_]+.K!_QE_AD?Z>-?C9ZQ_!;_ ,'F/_)3/V"/^Q%^/_\ Z?\
MX55^F^'_ / S/_K[AO\ TBL>=CMZ?I+]#^*&OT,X H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /]
M O\ X,W?^3:?VRO^RY^ _P#U 9J_+^/_ />LN_[!ZW_IR)Z6!^"?^)?D?V2U
M^?G<?Y%'_!<;_E+5^W=_V7/5?_3+HE?NW#O_ "(\L_[!8?FSQ<1_&J?XC\IJ
M]HQ"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H _V$/^"/G_*+/]@'_LU/X-_^H=IM?@V?_P#(ZS/_
M +#:_P#Z6SVZ'\&G_@C^1]6_M/\ _)M/[0__ &0SXM?^H#K]<6!_WW!_]A6'
M_P#3L"Y?!+_"_P C_%"K^ACP0H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H _<S_@VR_Y34_L8?\ =Q7_ *R?\=:^;XN_Y)[,/^Y3_P!3
ML,=&%_CT_P#M[_TB1_JR5^)GL!0!_]#^Q+_@I_\ \HTO^"AW_9C/[6G_ *H/
MQ_7I9-_R-\J_[&6!_P#4FD9U?X53_KW/_P!)9_C:U^_'AA0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!],_!7]M+]K_ /9N\.:CX/\
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M#_P2T^PMJ/\ PW_^RC]G7K'_ ,+F\&?;NF?ETO\ M/\ M)_^ 6AQTZ\5Y_\
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MDD\DGDFO3,AM !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M?I!_P1\_Y2F?L _]G6?!O_U,--KR<]_Y$N:?]@.(_P#3<C;#_P :G_B/]A"O
MP4]H_D3_ .#Q+_DQ[]F'_LZR#_U47Q(K[O@'_D8XS_L"_P#<](XL;_#A_C_]
MM9_G=U^JGF!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M=E]P[ONS,IB"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H _<S_@VR_Y34_L
M8?\ =Q7_ *R?\=:^;XN_Y)[,/^Y3_P!3L,=&%_CT_P#M[_TB1_JR5^)GL'\4
M/_!YC_R3/]@C_L>OC_\ ^F#X55^B>'_\7,_^O>$_]*KG#CO@A_B?Y'\%M?IA
MYH4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % ']Z7_  9F_P#),_V]_P#L>O@!_P"F#XJU^9^('\7*_P#K
MWBO_ $J@>E@?@G_B7Y']KU?G9W'^3#_P<$_\IB?VW_\ L>O O_JF_AO7[CPO
M_P B#+?^O53_ -/U3QL3_'J>J_\ 24?C;7OF 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '^L]_P
M;[?\H=?V(/\ L1?'7_JY/B/7X?Q3_P C_,?^OE+_ -1J)[6'_@T_\)^K'Q0_
MY)G\1/\ L1?%O_I@U"O$H?QJ/_7VG_Z4C5[/T?Y'^(37]%G@!0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 >Y_LP?\G+?L\?]ES^$O_J?>'ZY\7_NN)_[!ZW_ *;D5#XH_P"*/YH_
MVO:_G<]X_GY_X.>_^4.OQ^_['KX"_P#JY/!U?4\&_P#(^PW_ %ZQ/_IB9S8O
M^!+UC^:/\M6OV<\@* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@#^C_P#X-5_^4M7@_P#[(9\:O_3+
MIM?)\:?\B*K_ -A&&_\ 2SJP?\9?X9'^GC7XV>L?P6_\'F/_ "4S]@C_ +$7
MX_\ _I_^%5?IOA__  ,S_P"ON&_](K'G8[>GZ2_0_BAK]#. * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@#]S/^#;+_ )34_L8?]W%?^LG_ !UKYOB[_DGL
MP_[E/_4[#'1A?X]/_M[_ -(D?ZLE?B9[ 4 ?_]'^Q+_@I_\ \HTO^"AW_9C/
M[6G_ *H/Q_7I9-_R-\J_[&6!_P#4FD9U?X53_KW/_P!)9_C:U^_'AA0 4 %
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 ?N9_P;9?\IJ?V,/\ NXK_ -9/^.M?-\7?
M\D]F'_<I_P"IV&.C"_QZ?_;W_I$C_5DK\3/8/XH?^#S'_DF?[!'_ &/7Q_\
M_3!\*J_1/#_^+F?_ %[PG_I5<X<=\$/\3_(_@MK],/-"@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H _O2
M_P"#,W_DF?[>_P#V/7P _P#3!\5:_,_$#^+E?_7O%?\ I5 ]+ _!/_$OR/[7
MJ_.SN/\ )A_X."?^4Q/[;_\ V/7@7_U3?PWK]QX7_P"1!EO_ %ZJ?^GZIXV)
M_CU/5?\ I*/QMKWS * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@#_ %GO^#?;_E#K^Q!_V(OCK_U<
MGQ'K\/XI_P"1_F/_ %\I?^HU$]K#_P &G_A/U8^*'_),_B)_V(OBW_TP:A7B
M4/XU'_K[3_\ 2D:O9^C_ "/\0FOZ+/ "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H ]S_ &8/^3EO
MV>/^RY_"7_U/O#]<^+_W7$_]@];_ --R*A\4?\4?S1_M>U_.Y[Q_/S_P<]_\
MH=?C]_V/7P%_]7)X.KZG@W_D?8;_ *]8G_TQ,YL7_ EZQ_-'^6K7[.>0% !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0!_1_P#\&J__ "EJ\'_]D,^-7_IETVOD^-/^1%5_[",-_P"E
MG5@_XR_PR/\ 3QK\;/6/X+?^#S'_ )*9^P1_V(OQ_P#_ $__  JK]-\/_P"!
MF?\ U]PW_I%8\[';T_27Z'\4-?H9P!0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?Z!?_  9N_P#)
MM/[97_9<_ ?_ *@,U?E_'_\ O67?]@];_P!.1/2P/P3_ ,2_(_LEK\_.X_R*
M/^"XW_*6K]N[_LN>J_\ IET2OW;AW_D1Y9_V"P_-GBXC^-4_Q'Y35[1B% !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0!_L(?\ !'S_ )19_L _]FI_!O\ ]0[3:_!L_P#^1UF?_8;7
M_P#2V>W0_@T_\$?R/JW]I_\ Y-I_:'_[(9\6O_4!U^N+ _[[@_\ L*P__IV!
M<O@E_A?Y'^*%7]#'@A0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?I!_P1\_Y2F?L _\ 9UGP;_\
M4PTVO)SW_D2YI_V XC_TW(VP_P#&I_XC_80K\%/:/Y$_^#Q+_DQ[]F'_ +.L
M@_\ 51?$BON^ ?\ D8XS_L"_]STCBQO\.'^/_P!M9_G=U^JGF!0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0!^YG_!ME_RFI_8P_P"[BO\ UD_XZU\WQ=_R3V8?]RG_ *G8
M8Z,+_'I_]O?^D2/]62OQ,]@_BA_X/,?^29_L$?\ 8]?'_P#],'PJK]$\/_XN
M9_\ 7O"?^E5SAQWP0_Q/\C^"VOTP\T* "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#^]+_ (,S?^29_M[_
M /8]? #_ -,'Q5K\S\0/XN5_]>\5_P"E4#TL#\$_\2_(_M>K\[.X_P F'_@X
M)_Y3$_MO_P#8]>!?_5-_#>OW'A?_ )$&6_\ 7JI_Z?JGC8G^/4]5_P"DH_&V
MO?, H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * /\ 6>_X-]O^4.O[$'_8B^.O_5R?$>OP_BG_ )'^
M8_\ 7RE_ZC43VL/_  :?^$_5CXH?\DS^(G_8B^+?_3!J%>)0_C4?^OM/_P!*
M1J]GZ/\ (_Q":_HL\ * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@#W/\ 9@_Y.6_9X_[+G\)?_4^\
M/USXO_=<3_V#UO\ TW(J'Q1_Q1_-'^U[7\[GO'\_/_!SW_RAU^/W_8]? 7_U
M<G@ZOJ>#?^1]AO\ KUB?_3$SFQ?\"7K'\T?Y:M?LYY 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M']'_ /P:K_\ *6KP?_V0SXU?^F73:^3XT_Y$57_L(PW_ *6=6#_C+_#(_P!/
M&OQL]8_@M_X/,?\ DIG[!'_8B_'_ /\ 3_\ "JOTWP__ (&9_P#7W#?^D5CS
ML=O3])?H?Q0U^AG % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0!_H%_\ !F[_ ,FT_ME?]ES\!_\
MJ S5^7\?_P"]9=_V#UO_ $Y$]+ _!/\ Q+\C^R6OS\[C_(H_X+C?\I:OV[O^
MRYZK_P"F71*_=N'?^1'EG_8+#\V>+B/XU3_$?E-7M&(4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M'^PA_P $?/\ E%G^P#_V:G\&_P#U#M-K\&S_ /Y'69_]AM?_ -+9[=#^#3_P
M1_(^K?VG_P#DVG]H?_LAGQ:_]0'7ZXL#_ON#_P"PK#_^G8%R^"7^%_D?XH5?
MT,>"% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '[F?\
M!ME_RFI_8P_[N*_]9/\ CK7S?%W_ "3V8?\ <I_ZG88Z,+_'I_\ ;W_I$C_5
MDK\3/8"@#__3_L2_X*?_ /*-+_@H=_V8S^UI_P"J#\?UZ63?\C?*O^QE@?\
MU)I&=7^%4_Z]S_\ 26?XVM?OQX84 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0!^D'_!'S_E*9^P#_P!G6?!O_P!3#3:\G/?^1+FG
M_8#B/_3<C;#_ ,:G_B/]A"OP4]H_D3_X/$O^3'OV8?\ LZR#_P!5%\2*^[X!
M_P"1CC/^P+_W/2.+&_PX?X__ &UG^=W7ZJ>8% !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M'[F?\&V7_*:G]C#_ +N*_P#63_CK7S?%W_)/9A_W*?\ J=ACHPO\>G_V]_Z1
M(_U9*_$SV#^*'_@\Q_Y)G^P1_P!CU\?_ /TP?"JOT3P__BYG_P!>\)_Z57.'
M'?!#_$_R/X+:_3#S0H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * /[TO\ @S-_Y)G^WO\ ]CU\ /\ TP?%
M6OS/Q _BY7_U[Q7_ *50/2P/P3_Q+\C^UZOSL[C_ "8?^#@G_E,3^V__ -CU
MX%_]4W\-Z_<>%_\ D09;_P!>JG_I^J>-B?X]3U7_ *2C\;:]\P"@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M_P"O6)_],3.;%_P)>L?S1_EJU^SGD!0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?T?\ _!JO_P I
M:O!__9#/C5_Z9=-KY/C3_D15?^PC#?\ I9U8/^,O\,C_ $\:_&SUC^"W_@\Q
M_P"2F?L$?]B+\?\ _P!/_P *J_3?#_\ @9G_ -?<-_Z16/.QV]/TE^A_%#7Z
M&< 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % '^@7_P &;O\ R;3^V5_V7/P'_P"H#-7Y?Q__ +UE
MW_8/6_\ 3D3TL#\$_P#$OR/[):_/SN/\BC_@N-_REJ_;N_[+GJO_ *9=$K]V
MX=_Y$>6?]@L/S9XN(_C5/\1^4U>T8A0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?["'_  1\_P"4
M6?[ /_9J?P;_ /4.TVOP;/\ _D=9G_V&U_\ TMGMT/X-/_!'\CZM_:?_ .3:
M?VA_^R&?%K_U =?KBP/^^X/_ +"L/_Z=@7+X)?X7^1_BA5_0QX(4 % !0 4
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M %^P7_0!BO\ P.E_F'U&7\\?N8?\0;O[2W_1Y7P,_P#"#\??_'J/]?L%_P!
M&*_\#I?YA]1E_/'[F'_$&[^TM_T>5\#/_"#\??\ QZC_ %^P7_0!BO\ P.E_
MF'U&7\\?N8?\0;O[2W_1Y7P,_P#"#\??_'J/]?L%_P! &*_\#I?YA]1E_/'[
MF'_$&[^TM_T>5\#/_"#\??\ QZC_ %^P7_0!BO\ P.E_F'U&7\\?N8?\0;O[
M2W_1Y7P,_P#"#\??_'J/]?L%_P! &*_\#I?YA]1E_/'[F'_$&[^TM_T>5\#/
M_"#\??\ QZC_ %^P7_0!BO\ P.E_F'U&7\\?N8?\0;O[2W_1Y7P,_P#"#\??
M_'J/]?L%_P! &*_\#I?YA]1E_/'[F'_$&[^TM_T>5\#/_"#\??\ QZC_ %^P
M7_0!BO\ P.E_F'U&7\\?N8?\0;O[2W_1Y7P,_P#"#\??_'J/]?L%_P! &*_\
M#I?YA]1E_/'[F'_$&[^TM_T>5\#/_"#\??\ QZC_ %^P7_0!BO\ P.E_F'U&
M7\\?N8?\0;O[2W_1Y7P,_P#"#\??_'J/]?L%_P! &*_\#I?YA]1E_/'[F'_$
M&[^TM_T>5\#/_"#\??\ QZC_ %^P7_0!BO\ P.E_F'U&7\\?N8?\0;O[2W_1
MY7P,_P#"#\??_'J/]?L%_P! &*_\#I?YA]1E_/'[F'_$&[^TM_T>5\#/_"#\
M??\ QZC_ %^P7_0!BO\ P.E_F'U&7\\?N8?\0;O[2W_1Y7P,_P#"#\??_'J/
M]?L%_P! &*_\#I?YA]1E_/'[F'_$&[^TM_T>5\#/_"#\??\ QZC_ %^P7_0!
MBO\ P.E_F'U&7\\?N8?\0;O[2W_1Y7P,_P#"#\??_'J/]?L%_P! &*_\#I?Y
MA]1E_/'[F'_$&[^TM_T>5\#/_"#\??\ QZC_ %^P7_0!BO\ P.E_F'U&7\\?
MN8?\0;O[2W_1Y7P,_P#"#\??_'J/]?L%_P! &*_\#I?YA]1E_/'[F'_$&[^T
MM_T>5\#/_"#\??\ QZC_ %^P7_0!BO\ P.E_F'U&7\\?N8?\0;O[2W_1Y7P,
M_P#"#\??_'J/]?L%_P! &*_\#I?YA]1E_/'[F'_$&[^TM_T>5\#/_"#\??\
MQZC_ %^P7_0!BO\ P.E_F'U&7\\?N8?\0;O[2W_1Y7P,_P#"#\??_'J/]?L%
M_P! &*_\#I?YA]1E_/'[F'_$&[^TM_T>5\#/_"#\??\ QZC_ %^P7_0!BO\
MP.E_F'U&7\\?N8?\0;O[2W_1Y7P,_P#"#\??_'J/]?L%_P! &*_\#I?YA]1E
M_/'[F'_$&[^TM_T>5\#/_"#\??\ QZC_ %^P7_0!BO\ P.E_F'U&7\\?N8?\
M0;O[2W_1Y7P,_P#"#\??_'J/]?L%_P! &*_\#I?YA]1E_/'[F'_$&[^TM_T>
M5\#/_"#\??\ QZC_ %^P7_0!BO\ P.E_F'U&7\\?N8?\0;O[2W_1Y7P,_P#"
M#\??_'J/]?L%_P! &*_\#I?YA]1E_/'[F'_$&[^TM_T>5\#/_"#\??\ QZC_
M %^P7_0!BO\ P.E_F'U&7\\?N8?\0;O[2W_1Y7P,_P#"#\??_'J/]?L%_P!
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M_P#"#\??_'J/]?L%_P! &*_\#I?YA]1E_/'[F'_$&[^TM_T>5\#/_"#\??\
MQZC_ %^P7_0!BO\ P.E_F'U&7\\?N8?\0;O[2W_1Y7P,_P#"#\??_'J/]?L%
M_P! &*_\#I?YA]1E_/'[F'_$&[^TM_T>5\#/_"#\??\ QZC_ %^P7_0!BO\
MP.E_F'U&7\\?N8?\0;O[2W_1Y7P,_P#"#\??_'J/]?L%_P! &*_\#I?YA]1E
M_/'[F'_$&[^TM_T>5\#/_"#\??\ QZC_ %^P7_0!BO\ P.E_F'U&7\\?N8?\
M0;O[2W_1Y7P,_P#"#\??_'J/]?L%_P! &*_\#I?YA]1E_/'[F'_$&[^TM_T>
M5\#/_"#\??\ QZC_ %^P7_0!BO\ P.E_F'U&7\\?N8?\0;O[2W_1Y7P,_P#"
M#\??_'J/]?L%_P! &*_\#I?YA]1E_/'[F'_$&[^TM_T>5\#/_"#\??\ QZC_
M %^P7_0!BO\ P.E_F'U&7\\?N8?\0;O[2W_1Y7P,_P#"#\??_'J/]?L%_P!
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M%_T 8K_P.E_F'U&7\\?N8?\ $&[^TM_T>5\#/_"#\??_ !ZC_7[!?] &*_\
M Z7^8?49?SQ^YA_Q!N_M+?\ 1Y7P,_\ "#\??_'J/]?L%_T 8K_P.E_F'U&7
M\\?N8?\ $&[^TM_T>5\#/_"#\??_ !ZC_7[!?] &*_\  Z7^8?49?SQ^YA_Q
M!N_M+?\ 1Y7P,_\ "#\??_'J/]?L%_T 8K_P.E_F'U&7\\?N8?\ $&[^TM_T
M>5\#/_"#\??_ !ZC_7[!?] &*_\  Z7^8?49?SQ^YA_Q!N_M+?\ 1Y7P,_\
M"#\??_'J/]?L%_T 8K_P.E_F'U&7\\?N8?\ $&[^TM_T>5\#/_"#\??_ !ZC
M_7[!?] &*_\  Z7^8?49?SQ^YA_Q!N_M+?\ 1Y7P,_\ "#\??_'J/]?L%_T
M8K_P.E_F'U&7\\?N8?\ $&[^TM_T>5\#/_"#\??_ !ZC_7[!?] &*_\  Z7^
M8?49?SQ^YA_Q!N_M+?\ 1Y7P,_\ "#\??_'J/]?L%_T 8K_P.E_F'U&7\\?N
M8?\ $&[^TM_T>5\#/_"#\??_ !ZC_7[!?] &*_\  Z7^8?49?SQ^YA_Q!N_M
M+?\ 1Y7P,_\ "#\??_'J/]?L%_T 8K_P.E_F'U&7\\?N8?\ $&[^TM_T>5\#
M/_"#\??_ !ZC_7[!?] &*_\  Z7^8?49?SQ^YA_Q!N_M+?\ 1Y7P,_\ "#\?
M?_'J/]?L%_T 8K_P.E_F'U&7\\?N8?\ $&[^TM_T>5\#/_"#\??_ !ZC_7[!
M?] &*_\  Z7^8?49?SQ^YA_Q!N_M+?\ 1Y7P,_\ "#\??_'J/]?L%_T 8K_P
M.E_F'U&7\\?N8?\ $&[^TM_T>5\#/_"#\??_ !ZC_7[!?] &*_\  Z7^8?49
M?SQ^YA_Q!N_M+?\ 1Y7P,_\ "#\??_'J/]?L%_T 8K_P.E_F'U&7\\?N8?\
M$&[^TM_T>5\#/_"#\??_ !ZC_7[!?] &*_\  Z7^8?49?SQ^YA_Q!N_M+?\
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M%_T 8K_P.E_F'U&7\\?N8?\ $&[^TM_T>5\#/_"#\??_ !ZC_7[!?] &*_\
M Z7^8?49?SQ^YA_Q!N_M+?\ 1Y7P,_\ "#\??_'J/]?L%_T 8K_P.E_F'U&7
M\\?N8?\ $&[^TM_T>5\#/_"#\??_ !ZC_7[!?] &*_\  Z7^8?49?SQ^YA_Q
M!N_M+?\ 1Y7P,_\ "#\??_'J/]?L%_T 8K_P.E_F'U&7\\?N8?\ $&[^TM_T
M>5\#/_"#\??_ !ZC_7[!?] &*_\  Z7^8?49?SQ^YA_Q!N_M+?\ 1Y7P,_\
M"#\??_'J/]?L%_T 8K_P.E_F'U&7\\?N8?\ $&[^TM_T>5\#/_"#\??_ !ZC
M_7[!?] &*_\  Z7^8?49?SQ^YA_Q!N_M+?\ 1Y7P,_\ "#\??_'J/]?L%_T
M8K_P.E_F'U&7\\?N8?\ $&[^TM_T>5\#/_"#\??_ !ZC_7[!?] &*_\  Z7^
M8?49?SQ^YA_Q!N_M+?\ 1Y7P,_\ "#\??_'J/]?L%_T 8K_P.E_F'U&7\\?N
M8?\ $&[^TM_T>5\#/_"#\??_ !ZC_7[!?] &*_\  Z7^8?49?SQ^YA_Q!N_M
M+?\ 1Y7P,_\ "#\??_'J/]?L%_T 8K_P.E_F'U&7\\?N8?\ $&[^TM_T>5\#
M/_"#\??_ !ZC_7[!?] &*_\  Z7^8?49?SQ^YA_Q!N_M+?\ 1Y7P,_\ "#\?
M?_'J/]?L%_T 8K_P.E_F'U&7\\?N8?\ $&[^TM_T>5\#/_"#\??_ !ZC_7[!
M?] &*_\  Z7^8?49?SQ^YA_Q!N_M+?\ 1Y7P,_\ "#\??_'J/]?L%_T 8K_P
M.E_F'U&7\\?N8?\ $&[^TM_T>5\#/_"#\??_ !ZC_7[!?] &*_\  Z7^8?49
M?SQ^YA_Q!N_M+?\ 1Y7P,_\ "#\??_'J/]?L%_T 8K_P.E_F'U&7\\?N8?\
M$&[^TM_T>5\#/_"#\??_ !ZC_7[!?] &*_\  Z7^8?49?SQ^YA_Q!N_M+?\
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M%_T 8K_P.E_F'U&7\\?N8?\ $&[^TM_T>5\#/_"#\??_ !ZC_7[!?] &*_\
M Z7^8?49?SQ^YA_Q!N_M+?\ 1Y7P,_\ "#\??_'J/]?L%_T 8K_P.E_F'U&7
M\\?N8?\ $&[^TM_T>5\#/_"#\??_ !ZC_7[!?] &*_\  Z7^8?49?SQ^YA_Q
M!N_M+?\ 1Y7P,_\ "#\??_'J/]?L%_T 8K_P.E_F'U&7\\?N8?\ $&[^TM_T
M>5\#/_"#\??_ !ZC_7[!?] &*_\  Z7^8?49?SQ^YA_Q!N_M+?\ 1Y7P,_\
M"#\??_'J/]?L%_T 8K_P.E_F'U&7\\?N8?\ $&[^TM_T>5\#/_"#\??_ !ZC
M_7[!?] &*_\  Z7^8?49?SQ^YA_Q!N_M+?\ 1Y7P,_\ "#\??_'J/]?L%_T
M8K_P.E_F'U&7\\?N8?\ $&[^TM_T>5\#/_"#\??_ !ZC_7[!?] &*_\  Z7^
M8?49?SQ^YA_Q!N_M+?\ 1Y7P,_\ "#\??_'J/]?L%_T 8K_P.E_F'U&7\\?N
M8?\ $&[^TM_T>5\#/_"#\??_ !ZC_7[!?] &*_\  Z7^8?49?SQ^YA_Q!N_M
M+?\ 1Y7P,_\ "#\??_'J/]?L%_T 8K_P.E_F'U&7\\?N8?\ $&[^TM_T>5\#
M/_"#\??_ !ZC_7[!?] &*_\  Z7^8?49?SQ^YA_Q!N_M+?\ 1Y7P,_\ "#\?
M?_'J/]?L%_T 8K_P.E_F'U&7\\?N8?\ $&[^TM_T>5\#/_"#\??_ !ZC_7[!
M?] &*_\  Z7^8?49?SQ^YA_Q!N_M+?\ 1Y7P,_\ "#\??_'J/]?L%_T 8K_P
M.E_F'U&7\\?N8?\ $&[^TM_T>5\#/_"#\??_ !ZC_7[!?] &*_\  Z7^8?49
M?SQ^YA_Q!N_M+?\ 1Y7P,_\ "#\??_'J/]?L%_T 8K_P.E_F'U&7\\?N8?\
M$&[^TM_T>5\#/_"#\??_ !ZC_7[!?] &*_\  Z7^8?49?SQ^YA_Q!N_M+?\
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M%_T 8K_P.E_F'U&7\\?N8?\ $&[^TM_T>5\#/_"#\??_ !ZC_7[!?] &*_\
M Z7^8?49?SQ^YA_Q!N_M+?\ 1Y7P,_\ "#\??_'J/]?L%_T 8K_P.E_F'U&7
M\\?N8?\ $&[^TM_T>5\#/_"#\??_ !ZC_7[!?] &*_\  Z7^8?49?SQ^YA_Q
M!N_M+?\ 1Y7P,_\ "#\??_'J/]?L%_T 8K_P.E_F'U&7\\?N8?\ $&[^TM_T
M>5\#/_"#\??_ !ZC_7[!?] &*_\  Z7^8?49?SQ^YA_Q!N_M+?\ 1Y7P,_\
M"#\??_'J/]?L%_T 8K_P.E_F'U&7\\?N8?\ $&[^TM_T>5\#/_"#\??_ !ZC
M_7[!?] &*_\  Z7^8?49?SQ^YA_Q!N_M+?\ 1Y7P,_\ "#\??_'J/]?L%_T
M8K_P.E_F'U&7\\?N8?\ $&[^TM_T>5\#/_"#\??_ !ZC_7[!?] &*_\  Z7^
M8?49?SQ^YA_Q!N_M+?\ 1Y7P,_\ "#\??_'J/]?L%_T 8K_P.E_F'U&7\\?N
M8?\ $&[^TM_T>5\#/_"#\??_ !ZC_7[!?] &*_\  Z7^8?49?SQ^YA_Q!N_M
M+?\ 1Y7P,_\ "#\??_'J/]?L%_T 8K_P.E_F'U&7\\?N8?\ $&[^TM_T>5\#
M/_"#\??_ !ZC_7[!?] &*_\  Z7^8?49?SQ^YA_Q!N_M+?\ 1Y7P,_\ "#\?
M?_'J/]?L%_T 8K_P.E_F'U&7\\?N8?\ $&[^TM_T>5\#/_"#\??_ !ZC_7[!
M?] &*_\  Z7^8?49?SQ^YA_Q!N_M+?\ 1Y7P,_\ "#\??_'J/]?L%_T 8K_P
M.E_F'U&7\\?N8?\ $&[^TM_T>5\#/_"#\??_ !ZC_7[!?] &*_\  Z7^8?49
M?SQ^YA_Q!N_M+?\ 1Y7P,_\ "#\??_'J/]?L%_T 8K_P.E_F'U&7\\?N8?\
M$&[^TM_T>5\#/_"#\??_ !ZC_7[!?] &*_\  Z7^8?49?SQ^YA_Q!N_M+?\
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M%_T 8K_P.E_F'U&7\\?N8?\ $&[^TM_T>5\#/_"#\??_ !ZC_7[!?] &*_\
M Z7^8?49?SQ^YA_Q!N_M+?\ 1Y7P,_\ "#\??_'J/]?L%_T 8K_P.E_F'U&7
M\\?N8?\ $&[^TM_T>5\#/_"#\??_ !ZC_7[!?] &*_\  Z7^8?49?SQ^YA_Q
M!N_M+?\ 1Y7P,_\ "#\??_'J/]?L%_T 8K_P.E_F'U&7\\?N8?\ $&[^TM_T
M>5\#/_"#\??_ !ZC_7[!?] &*_\  Z7^8?49?SQ^YA_Q!N_M+?\ 1Y7P,_\
M"#\??_'J/]?L%_T 8K_P.E_F'U&7\\?N8?\ $&[^TM_T>5\#/_"#\??_ !ZC
M_7[!?] &*_\  Z7^8?49?SQ^YA_Q!N_M+?\ 1Y7P,_\ "#\??_'J/]?L%_T
M8K_P.E_F'U&7\\?N8?\ $&[^TM_T>5\#/_"#\??_ !ZC_7[!?] &*_\  Z7^
M8?49?SQ^YA_Q!N_M+?\ 1Y7P,_\ "#\??_'J/]?L%_T 8K_P.E_F'U&7\\?N
M8?\ $&[^TM_T>5\#/_"#\??_ !ZC_7[!?] &*_\  Z7^8?49?SQ^YA_Q!N_M
M+?\ 1Y7P,_\ "#\??_'J/]?L%_T 8K_P.E_F'U&7\\?N8?\ $&[^TM_T>5\#
M/_"#\??_ !ZC_7[!?] &*_\  Z7^8?49?SQ^YA_Q!N_M+?\ 1Y7P,_\ "#\?
M?_'J/]?L%_T 8K_P.E_F'U&7\\?N9^@?_!+/_@VF^.'_  3^_;O^!?[7/C#]
MICX4_$'PY\)?^%G?VCX0\->$O%VF:UJ__">?!SXA?#*T^Q7VJ2M8P?8+[QG:
MZG<>>#YEI93PQ?OI(Z\K.N+\+FF68G T\)7I3K^QM.<J;C'V6(I5G=1UU5-I
M6ZM=#6CA94JD9N2:C?1)]8M?J?V$5\$=I^"W_!<W_@D1\2_^"LGAG]G'P[\.
M_BYX&^$W_"E-=^)FM:Q>>--'U_6?[9_X3;3_  58Z?;:;;Z&H\K[)_PC=[+>
M374Z8\VU2"*7?*\'T_#6>T,CEBY5J%6M]8C1C%4G"/+[-U&[\SZ\ZM;S.?$4
M7644FH\K;U]+'\[O_$&[^TM_T>5\#/\ P@_'W_QZOJ_]?L%_T 8K_P #I?YG
M+]1E_/'[F'_$&[^TM_T>5\#/_"#\??\ QZC_ %^P7_0!BO\ P.E_F'U&7\\?
MN8?\0;O[2W_1Y7P,_P#"#\??_'J/]?L%_P! &*_\#I?YA]1E_/'[F'_$&[^T
MM_T>5\#/_"#\??\ QZC_ %^P7_0!BO\ P.E_F'U&7\\?N8?\0;O[2W_1Y7P,
M_P#"#\??_'J/]?L%_P! &*_\#I?YA]1E_/'[F'_$&[^TM_T>5\#/_"#\??\
MQZC_ %^P7_0!BO\ P.E_F'U&7\\?N8?\0;O[2W_1Y7P,_P#"#\??_'J/]?L%
M_P! &*_\#I?YA]1E_/'[F'_$&[^TM_T>5\#/_"#\??\ QZC_ %^P7_0!BO\
MP.E_F'U&7\\?N8?\0;O[2W_1Y7P,_P#"#\??_'J/]?L%_P! &*_\#I?YA]1E
M_/'[F'_$&[^TM_T>5\#/_"#\??\ QZC_ %^P7_0!BO\ P.E_F'U&7\\?N8?\
M0;O[2W_1Y7P,_P#"#\??_'J/]?L%_P! &*_\#I?YA]1E_/'[F'_$&[^TM_T>
M5\#/_"#\??\ QZC_ %^P7_0!BO\ P.E_F'U&7\\?N8?\0;O[2W_1Y7P,_P#"
M#\??_'J/]?L%_P! &*_\#I?YA]1E_/'[F'_$&[^TM_T>5\#/_"#\??\ QZC_
M %^P7_0!BO\ P.E_F'U&7\\?N8?\0;O[2W_1Y7P,_P#"#\??_'J/]?L%_P!
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M_P#"#\??_'J/]?L%_P! &*_\#I?YA]1E_/'[F'_$&[^TM_T>5\#/_"#\??\
MQZC_ %^P7_0!BO\ P.E_F'U&7\\?N8?\0;O[2W_1Y7P,_P#"#\??_'J/]?L%
M_P! &*_\#I?YA]1E_/'[F'_$&[^TM_T>5\#/_"#\??\ QZC_ %^P7_0!BO\
MP.E_F'U&7\\?N8?\0;O[2W_1Y7P,_P#"#\??_'J/]?L%_P! &*_\#I?YA]1E
M_/'[F'_$&[^TM_T>5\#/_"#\??\ QZC_ %^P7_0!BO\ P.E_F'U&7\\?N8?\
M0;O[2W_1Y7P,_P#"#\??_'J/]?L%_P! &*_\#I?YA]1E_/'[F'_$&[^TM_T>
M5\#/_"#\??\ QZC_ %^P7_0!BO\ P.E_F'U&7\\?N8?\0;O[2W_1Y7P,_P#"
M#\??_'J/]?L%_P! &*_\#I?YA]1E_/'[F'_$&[^TM_T>5\#/_"#\??\ QZC_
M %^P7_0!BO\ P.E_F'U&7\\?N8?\0;O[2W_1Y7P,_P#"#\??_'J/]?L%_P!
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M_P#"#\??_'J/]?L%_P! &*_\#I?YA]1E_/'[F'_$&[^TM_T>5\#/_"#\??\
MQZC_ %^P7_0!BO\ P.E_F'U&7\\?N8?\0;O[2W_1Y7P,_P#"#\??_'J/]?L%
M_P! &*_\#I?YA]1E_/'[F'_$&[^TM_T>5\#/_"#\??\ QZC_ %^P7_0!BO\
MP.E_F'U&7\\?N8?\0;O[2W_1Y7P,_P#"#\??_'J/]?L%_P! &*_\#I?YA]1E
M_/'[F'_$&[^TM_T>5\#/_"#\??\ QZC_ %^P7_0!BO\ P.E_F'U&7\\?N8?\
M0;O[2W_1Y7P,_P#"#\??_'J/]?L%_P! &*_\#I?YA]1E_/'[F'_$&[^TM_T>
M5\#/_"#\??\ QZC_ %^P7_0!BO\ P.E_F'U&7\\?N8?\0;O[2W_1Y7P,_P#"
M#\??_'J/]?L%_P! &*_\#I?YA]1E_/'[F'_$&[^TM_T>5\#/_"#\??\ QZC_
M %^P7_0!BO\ P.E_F'U&7\\?N8?\0;O[2W_1Y7P,_P#"#\??_'J/]?L%_P!
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M7_@=+_,/J,OYX_<P_P"(-W]I;_H\KX&?^$'X^_\ CU'^OV"_Z ,5_P"!TO\
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MOV"_Z ,5_P"!TO\ ,/J,OYX_<P_X@W?VEO\ H\KX&?\ A!^/O_CU'^OV"_Z
M,5_X'2_S#ZC+^>/W,/\ B#=_:6_Z/*^!G_A!^/O_ (]1_K]@O^@#%?\ @=+_
M ##ZC+^>/W,/^(-W]I;_ */*^!G_ (0?C[_X]1_K]@O^@#%?^!TO\P^HR_GC
M]S#_ (@W?VEO^CRO@9_X0?C[_P"/4?Z_8+_H Q7_ ('2_P P^HR_GC]S#_B#
M=_:6_P"CRO@9_P"$'X^_^/4?Z_8+_H Q7_@=+_,/J,OYX_<P_P"(-W]I;_H\
MKX&?^$'X^_\ CU'^OV"_Z ,5_P"!TO\ ,/J,OYX_<P_X@W?VEO\ H\KX&?\
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M_P"$'X^_^/4?Z_8+_H Q7_@=+_,/J,OYX_<P_P"(-W]I;_H\KX&?^$'X^_\
MCU'^OV"_Z ,5_P"!TO\ ,/J,OYX_<P_X@W?VEO\ H\KX&?\ A!^/O_CU'^OV
M"_Z ,5_X'2_S#ZC+^>/W,/\ B#=_:6_Z/*^!G_A!^/O_ (]1_K]@O^@#%?\
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M_P (/Q]_\>H_U^P7_0!BO_ Z7^8?49?SQ^YA_P 0;O[2W_1Y7P,_\(/Q]_\
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M_P (/Q]_\>H_U^P7_0!BO_ Z7^8?49?SQ^YA_P 0;O[2W_1Y7P,_\(/Q]_\
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MKX&?^$'X^_\ CU'^OV"_Z ,5_P"!TO\ ,/J,OYX_<P_X@W?VEO\ H\KX&?\
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M_P"$'X^_^/4?Z_8+_H Q7_@=+_,/J,OYX_<P_P"(-W]I;_H\KX&?^$'X^_\
MCU'^OV"_Z ,5_P"!TO\ ,/J,OYX_<P_X@W?VEO\ H\KX&?\ A!^/O_CU'^OV
M"_Z ,5_X'2_S#ZC+^>/W,/\ B#=_:6_Z/*^!G_A!^/O_ (]1_K]@O^@#%?\
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M-W]I;_H\KX&?^$'X^_\ CU'^OV"_Z ,5_P"!TO\ ,/J,OYX_<P_X@W?VEO\
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H _];^_B@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@#_U_[^* "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /_0_OXH * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H _]'^_B@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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ME_X:<_9K_P"CA?@=_P"'9\!?_+^O8_U5XG_Z)S/O_#/F'_S.<?\ :N5_]#'
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MW0E'1U(9&4E64@@XKY5IQ;BTTT[--6::T::Z-;6Z'K*S2:U3V:VMTL24@"@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M99-^]0E]9HK_ *=5;0JQ2[4ZJC+UK'[W5_/1^B!0!_+M_P %U/\ DX3X0?\
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M502S,2 J@9)P *_NAM)7=DDKMO1)+\DC\(/8/^&=_P!H#_HAGQB_\-EXU_\
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '__4_OXH * "@ H * /Y
M_P#_ (+S?\BA^S;_ -C)\2O_ $V>#J_HGZ/G^_<3?]@F6_\ I[%GYQXA_P #
M*_\ K[BO_2*!_/OX)^'>L^.M&^)NJZ-&\_\ PK'P"OQ#U:WB0R2RZ''XW\%>
M"[Z1$7YMMA)XTMM3N9 "L-A8W<T@$<;.G]&X_,J.7U\JHUFHK-<P_LVC)NRC
MB'@,=C::?3]XL#.E%=:DX16K2?YOA\+/$4\7.";^J8;ZS-)?\NUB*%"7_@/M
MU-VVC%MZ(^H/^"=GQ[_X9Y_:P^&OBJ_O?L?A+Q1>GX<^.6>3RK9?#7C&:VLE
MO[M\X6UT#7H]$\27!PQ\G1W15)>OE/$OA[_6/@_-,)3ASXS"4_[3P&EY?6<%
M&4W3A_>Q&'=?#1V7-63>QZW#&8_V;G&%JR?+1K/ZK7Z+V59J*D^RIU%3J/R@
M?VT5_"A^\A0!_/[_ ,%Q_C]_9WAWX:_LVZ)>[;KQ%<?\+,\=10R8==$TN6ZT
MGP;IMP%)#V^I:RNMZK-"X1HY_#FDSKN62OZ*\!.'?:8G-.)Z\/<PT?[*R]M:
M>WJJ%;&U(]I4J'L**:NG'$U8Z6/SCC_,>2EA<KIRUJOZUB$O^?<&X4(ORE/G
MG;HZ46?S]6_P\U>7X5:M\5Y(Y(= L/B#X>^'EG*R_NM1U?5O#GB?Q)J,<#]Y
M-&LM%TMKM>-JZ]9'YMWR_P!&2S*BLWHY.FGB*F6XG,II;TZ-'$X3"TG)=J\Z
M]7D_[!Y[6U_-UA9_4YXS:G'$TL+'^].=*K5E;_!&G"__ %\B?9W_  2C_P"3
M^_@'_O\ Q._]4U\0Z^(\7?\ DW?$/IE7_J[RT]W@[_DH\N_[F_\ U Q)_9S7
M\0'[D% '\@__  5[^.O_  MK]K'5O!VF7GVCPO\ !#2XOA_9)')NMI/%#N-4
M\<7BKD^7=PZM-!X8O!QD^%H?E_B;^S?!C(/['X/HXVK#EQ6>UGF,VU:2PB7L
M<##;6#I1EB8>6*9^+<:YA]<SB="+O1R^"P\;;>U=IUWY-3M2E_UY/)O#/[(&
MI:W_ ,$_OB!^U6MI.=3T+XN^'['3HRC-YGPVTJWNO#7B74K1$^_'/XU\5:1'
M<R_/]FM_"&H2.L<0>6O7Q7&=*AXBY=PCSQ]E7R;$3JNZ5LSK2ABL+2GV<<#A
M*K@M.:6-II7=D<=+))3X;Q&<<KYZ>-IJ/_8)!.E5E%>=>K"[ULJ$MEJ<7^P3
M\=/^&>?VJOA3X\O+S['X9O-;7P9XW9W\NV'A'QAMT74KR\Y&ZWT&XGLO$P0'
MF?1(.& V-W^(>0?ZR<(YOE\(<^*IT/KV 25Y?7,%^_IPA_>Q$8U,+_AKO;=<
M_#N8?V9F^#Q$GRTI3]A7Z+V-;W)-^5-\M7_N&C^X6OX,/WT* /Y=O^"ZG_)P
MGP@_[(TO_J;>*:_J[P _Y)W.O^QTO_4'#'Y+X@_\C+!?]@/_ +GK%K_@A1_R
M7?XS_P#9)+;_ -3'1*GQ_P#^1!D?_8XG_P"H58KP]_W_ !W_ &!Q_P#3T#^G
M^OY3/U@_FU_X+<_L[^ O"%S\-/CWX1T73_#VO>-=:U7P=X[@TNWM+&T\07\%
MB^N:-XCN+.VBB\S7#%%JUEJ^J,));^!=)6Y826JO-_3W@1Q+F&,CFG#V,KU,
M3A\#0I8W+Y593J3PU-U%AZV&C.3=J%W1G1I:*G+VW(K2LOR[CW+,/1>%S&C3
MC2J5ZDJ&(4$HJI)1]I3JM*W[RRG&<OM+DO\ #K^:/_!.[Q#J7AG]M?\ 9TOM
M+EFBFO?B%9>';CR#@R:;XILKWPYJD4@Z- VGZI<>:",!1O&&12/U'Q*PU+%<
M"\2TZJBXT\NGB8\RVJX2I3Q-)KM)5*4;?=L?*\,U94<^RR4+IRQ*I.W\M:,J
M4EZ<LW?_ (!_;Q7\('[V?R1_\%;?VM=1^-GQTU'X.^&-9F;X5?!;49M#:RMI
M<6'B'XD6?GVGBG7[E4P+K^Q)GF\*:1YOFQVJV.K7U@ZQZ[/O_L7P<X.I9%D%
M+.L50C_:V>4XUU.2_>8;+)\LL)AX7^#V\4L76Y;.7M*-.HKT(V_&N,\YEC\P
ME@:,_P#8\#)T[+X:F*5U5J/O[-_N8=N6<HZ3/"OV!?V(?$'[97Q*N;*]NK_P
MY\)O!?V2\^(7BVSBB-X?M1D.G>%?#IN4DMF\0ZT()V^TS0W%IHFG0W&IW<%S
M+_9VFZG]!XB<>8?@C*X3IPIXG.,=SPR[!S;Y$H653%XGEM)8>A>*Y$XRKU)1
MIP<8^TJ4O.X<R"IGF*<6Y4L'0Y7B:T4KZWY:-*ZM[2=MVFJ<;R:?NQE_7]\(
M?@G\*_@/X3M?!/PE\$Z'X+T"W2$31:5:(M]JMQ!$(AJ.O:M)YFIZ]JCH,2:C
MJUU=W;#Y/-$:JB_QAG.>YMQ!C)X[.,=B,=B)-\KK3;IT8MW]EAZ*M2P])/:E
M1A""[7/VO!8#!Y=15#!X>G0IJUU"/O3:5N:I/XZD_P"]-RETO8]3KR3K.:\6
M>#?"7CW0KSPQXW\,:!XO\.:C&8[[0_$ND6&MZ5=(59/WUAJ,%Q;.P5FV.8]\
M9.493S73@\;C,OKT\5@,5B,'B:3O3KX6M4H58-?RU*<HR6VU[/9F5:A1Q%.5
M&O2IUJ4E:5.K",X-><9)K\#@_@E\!_AE^SQX4U'P/\)M"D\->%-0\3:MXL_L
M9M2U#4X++4]:2SCO([";4[BZNX+ +8P"VLVN)4M@"D1";57T<]X@S3B3%T\?
MG&(6*Q=/"T<'[?V5.E*=*AS^S=14HPA*I[\N:?*G+=ZG/@,OPN6T98?!T_94
M959UO9\TI*,JEN91<FVH^ZK1N[;+0^<O^"FO_)BO[0O_ &+?A[_U.O"M?2^%
MO_)?<-_]A=?_ -0<4>7Q7_R3^9?]>J?_ *D43^,WP1_R.GA#_L:- _\ 3K:5
M_;N8?\B_'?\ 8'B?_3$S\.P_^\4/^OU+_P!+B?Z$%?YQG])!0 4 ?D1_P6N_
MY,XT[_LLO@C_ -,GC&OV3P,_Y+:?_8EQ_P#Z=P9\7QW_ ,B./_8=A_\ TW6/
MY<_A/\,O$7QC\>Z)\-_",<<_BCQ+%K2:!9R8']I:KI>@:IK5GI$;%D2.XUB;
M35TNUEE=((;F[BEG984<C^L<XS7#9)EU?-,9>.$PKH/$37_+JC5Q%&A.LUK>
M-"-7VLHI<THP<8ZM'Y+@\)5QV(IX6CK5JJI[./\ -.%.<XP\G-PY$]DVF] ^
M&OQ#\;? _P")GACXB>#[JXT#QO\ #_Q!%J5C]HBFB:&\L9'M[_2=5LV,,KV5
M];F[TC6M-F\O[38W-Y8S@+(XHS3+<!GV58K+<;".(P&8X9TI\KBTX32E3K49
MJZ4Z<E"M0J*_+.,)QV087$U\OQ=+$T6Z>(PU52C=-6E'24)QT?+)7A4@[7BY
M19_<;^S9\?/"/[3'P;\'?%_P<ZQVGB*Q$>L:.TRS7?ACQ/8A8-?\-WY 1O/T
MR^#""9XH1J&FRV&JP1BTO[<M_!/$_#V,X6SO&Y+C5>>&J7HUDK0Q6%G[V'Q-
M/^[5IVYDF_9U%4HR?/3DE^_95F-'-<#0QM#15(VG"]W2JQTJ4I><);.RYH\L
MDK21[M7@'H'\7?\ P5._Y/U^/_\ U_> /_54>!*_N+PE_P"3>\._]>\P_P#5
MOCS\+XN_Y*+,?\6&_P#4/#G[4_\ !#3_ )-,^(7_ &<3XL_]5K\)*_#/'S_D
ML,M_[)K!_P#JTS@^[\/_ /D38G_L9UO_ %%P1^S=?B!]R% !0!_,_P#\%A_V
MV_\ A+M=G_91^&>K[_#'A:_AN/C!JMA-F+7?%=A*D]AX(26)MDNG>%+A([W7
MH]TBS>*$MK&1+>?PU,+G^H_!7@3ZGAX\7YI1MBL53E#):-2-GA\)-.-3'N+U
M53%QO3P[LN7"\U1<T<3'E_*^-L^]M4>3X2?[JE)/&SCM.M%WCA[K[-%I2J+_
M )^VCHZ3O\$_\$^/V.]3_:[^-5II.J6]W;_"?P.UEX@^*&LP^9#YFFF9O[.\
M(V%TFTQ:QXLFMI[2)T=);#2;?5]6B+S:?#;W'Z'XC\:TN#,BG5HRA+.,>IX;
M*J#L[5.5>TQE2#WHX.,HS::M4K2HT7:,Y2C\[PUDDLZQ\834E@\/RU,7-:>[
M]BC%])UFN736,%.:UBD_[1M)TK3-"TO3=$T6PM-*T?1["STK2=+L(([6QT[3
M=/MX[2QL+*UA5(;>TM+6&*WMX(E6.*&-(T4*H%?P[6K5<15JUZ]2=6M6J3JU
M:M23E4J5:DG*=2<GK*<Y-RE)ZMN[/W2$(TX1IPBH0A&,(0BK1C&*48QBEHE%
M)));)&A691^#/_!<?XZ_V'\/OAK^SWI%YLO_ !UJC^/_ !A!%)B1?"_AB1['
MPY974>?FM-9\2RW>H1$+\MUX/7Y@.&_H/P$R#V^99IQ'6A>GE]%9=@Y-:?6\
M4E/$S@[:2HX6,:;_ +N,/SSC_,/9X;"Y;!^]B)O$5DMU2HNU)-=IU6Y+SH'Y
M'?L$?LDW7[67C7XIZ)Y96Q\&?!SQMJVGW+_+9_\ "P=;TJY\/_#BSNGRNU5U
MRZFU\ O&KP^'+A&< X/['XA\8PX/P.45[_O,=G> HU(+X_[.P]6&(S.<%_UX
MA'#[.SQ,=#XSAS)GG%?&0M[M# UYP?V?K-2#IX5/TFW4M=:4FCXHTW4-;\(>
M(;#5=/EN]%\1^%]:M=0LIPK07VDZWHE]'<6TH210T-W87]LC[74-'-%AER"*
M^[JTZ&-PU2C44*^%Q="5.<=Z=:A7IN,E=:.%2G)K3=/0\&$JE"K&<;TZM&HI
M1>TH5*<DUIT<9+[T?WF?L^_%O3/CO\$_AE\7M)\E(/'?A'2M9N[:!M\>FZWY
M7V3Q%HX;+;FT77[;4])D.YLR63<GK7^?'$>3U>'\]S3)JU^;+\95H0DU9U*%
M^?#5K66E?#RI5EHM)H_H?+<9#,,!A,;"UL11A-I?9G;EJ0_[AU%*#_PGL5>*
M=H4 ?SD?\%JOCEXD\4>/OA?^R1X*:6ZA>/1O&?BC3K"3_2-=\7>([Z\T3P/X
M;G7='_R#[59]66UD+6]U/XATBY<+-IL#K_3'@9D&%PF79MQCCDH-.M@<)4J+
MW</@\+3A7Q^)CO\ Q)<M'G5I0CAJT/AJ21^8\=X^K5Q&$R:A=KW*]6,7K4K5
M9.GAZ3U7PJ\[/1NI!_91]^6'[*_A/]DK_@G%^T%\/]&M;2?Q;J'[-OQ>UGXE
M^)XE#W/B;QE+\*O$0OW6X9$E_L32':33/#EEA([738A.\;:C?:E=77YY/BW&
M<8>)O#F8UY3C@Z?$^2T,KPCTAA<%'-\-[-<NWMZR2JXF>\ZKY5:G"E"'T<<H
MHY-POF6&II.M+*\;/%5>M6N\'5YM?^?</@I1VC!7^*4I/^=3]@7]D?1_VR_B
MYXH^&>M>--2\"VV@?#;5?',.K:7I%KK,\]UI_B;PEH$=A):W=Y8QK;O'XDEN
M7E6;S ]K'&H"R,R_TKXA\95N",FPF:4,#2Q\L1F=' .C5K2H1C"IA<9B'44H
M0F^9/"J*5K6DWT2/S+AS):>>8VKA:E>>'5/"SQ"G"$9MN-6C34;-I6M5;^21
MV?[=7[ WBC]AS5/ NMV?Q"A\=>%/&5WJ,6@>(+;2IO"OB#1==T!;&\DM+[3X
M]4U6-#Y5Y#<Z9JFGZFQE>VNO.M=/>&#[1P\ >(>$X]I8_#U,M> Q>"A2>(PT
MJL<7AJ^'Q'/!3IU'2I/>#C5I5*6BE#EE43ER[\0<.5>'Y8>I'$K$4:SDJ=10
M=&I"I3Y96<5.=MTX3C+H](V5_P!S_P!BO4+7]O\ _8!;P9^T-'-XOG@U37_A
MKJ_B*ZC5-<GN_#46G:AX6\86>H2(Y/BC1K#5]*!UHJ[ZAJ.GW3ZHMY]LU*.Y
M_ N.:<O#OQ$^N\-M8*+I8?,Z.&B[T(PQ3J4\7@ITU;_9:TZ-7]QHJ=*I!4N3
MDIN/Z!D4EQ'PY[#,DZS4JF$G4:_>-TN65&M&3O\ OH1G#]Y]J47S7O)/\U?^
M"<7C/QI^QS^W=XQ_9-\<WJ'0O&^O:GX U4,[QZ>WBW0;6^U7X?>+M,A=G:)?
M%%BRZ7;0_))<VOBG36O<R:; L7ZCXFX' \:^'^!XPP$']8P&'I9A1LDZBP>(
ME3HYC@ZK25WA*B]K)[0EA*JAI4E?Y;A>O7R3B&ODV(E>G7J2P\_Y/;4XRGAJ
M\%T56/N);M58<VL%;^HZOY//UH* "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MS1_Q"#P[_P"B>_\ ,MGG_P \P_UPXC_Z&/\ Y:8#_P"90_X>O_M^_P#1>_\
MS%OP6_\ G<T?\0@\._\ HGO_ #+9Y_\ /,/]<.(_^AC_ .6F _\ F4/^'K_[
M?O\ T7O_ ,Q;\%O_ )W-'_$(/#O_ *)[_P RV>?_ #S#_7#B/_H8_P#EI@/_
M )E#_AZ_^W[_ -%[_P#,6_!;_P"=S1_Q"#P[_P"B>_\ ,MGG_P \P_UPXC_Z
M&/\ Y:8#_P"90_X>O_M^_P#1>_\ S%OP6_\ G<T?\0@\._\ HGO_ #+9Y_\
M/,/]<.(_^AC_ .6F _\ F4/^'K_[?O\ T7O_ ,Q;\%O_ )W-'_$(/#O_ *)[
M_P RV>?_ #S#_7#B/_H8_P#EI@/_ )E#_AZ_^W[_ -%[_P#,6_!;_P"=S1_Q
M"#P[_P"B>_\ ,MGG_P \P_UPXC_Z&/\ Y:8#_P"90_X>O_M^_P#1>_\ S%OP
M6_\ G<T?\0@\._\ HGO_ #+9Y_\ /,/]<.(_^AC_ .6F _\ F4/^'K_[?O\
MT7O_ ,Q;\%O_ )W-'_$(/#O_ *)[_P RV>?_ #S#_7#B/_H8_P#EI@/_ )E#
M_AZ_^W[_ -%[_P#,6_!;_P"=S1_Q"#P[_P"B>_\ ,MGG_P \P_UPXC_Z&/\
MY:8#_P"90_X>O_M^_P#1>_\ S%OP6_\ G<T?\0@\._\ HGO_ #+9Y_\ /,/]
M<.(_^AC_ .6F _\ F4/^'K_[?O\ T7O_ ,Q;\%O_ )W-'_$(/#O_ *)[_P R
MV>?_ #S#_7#B/_H8_P#EI@/_ )E#_AZ_^W[_ -%[_P#,6_!;_P"=S1_Q"#P[
M_P"B>_\ ,MGG_P \P_UPXC_Z&/\ Y:8#_P"90_X>O_M^_P#1>_\ S%OP6_\
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M_7#B/_H8_P#EI@/_ )E#_AZ_^W[_ -%[_P#,6_!;_P"=S1_Q"#P[_P"B>_\
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M_P \P_UPXC_Z&/\ Y:8#_P"90_X>O_M^_P#1>_\ S%OP6_\ G<T?\0@\._\
MHGO_ #+9Y_\ /,/]<.(_^AC_ .6F _\ F4/^'K_[?O\ T7O_ ,Q;\%O_ )W-
M'_$(/#O_ *)[_P RV>?_ #S#_7#B/_H8_P#EI@/_ )E#_AZ_^W[_ -%[_P#,
M6_!;_P"=S1_Q"#P[_P"B>_\ ,MGG_P \P_UPXC_Z&/\ Y:8#_P"90_X>O_M^
M_P#1>_\ S%OP6_\ G<T?\0@\._\ HGO_ #+9Y_\ /,/]<.(_^AC_ .6F _\
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MS1_Q"#P[_P"B>_\ ,MGG_P \P_UPXC_Z&/\ Y:8#_P"90_X>O_M^_P#1>_\
MS%OP6_\ G<T?\0@\._\ HGO_ #+9Y_\ /,/]<.(_^AC_ .6F _\ F4/^'K_[
M?O\ T7O_ ,Q;\%O_ )W-'_$(/#O_ *)[_P RV>?_ #S#_7#B/_H8_P#EI@/_
M )E#_AZ_^W[_ -%[_P#,6_!;_P"=S1_Q"#P[_P"B>_\ ,MGG_P \P_UPXC_Z
M&/\ Y:8#_P"90_X>O_M^_P#1>_\ S%OP6_\ G<T?\0@\._\ HGO_ #+9Y_\
M/,/]<.(_^AC_ .6F _\ F4/^'K_[?O\ T7O_ ,Q;\%O_ )W-'_$(/#O_ *)[
M_P RV>?_ #S#_7#B/_H8_P#EI@/_ )E#_AZ_^W[_ -%[_P#,6_!;_P"=S1_Q
M"#P[_P"B>_\ ,MGG_P \P_UPXC_Z&/\ Y:8#_P"90_X>O_M^_P#1>_\ S%OP
M6_\ G<T?\0@\._\ HGO_ #+9Y_\ /,/]<.(_^AC_ .6F _\ F4/^'K_[?O\
MT7O_ ,Q;\%O_ )W-'_$(/#O_ *)[_P RV>?_ #S#_7#B/_H8_P#EI@/_ )E#
M_AZ_^W[_ -%[_P#,6_!;_P"=S1_Q"#P[_P"B>_\ ,MGG_P \P_UPXC_Z&/\
MY:8#_P"90_X>O_M^_P#1>_\ S%OP6_\ G<T?\0@\._\ HGO_ #+9Y_\ /,/]
M<.(_^AC_ .6F _\ F4/^'K_[?O\ T7O_ ,Q;\%O_ )W-'_$(/#O_ *)[_P R
MV>?_ #S#_7#B/_H8_P#EI@/_ )E#_AZ_^W[_ -%[_P#,6_!;_P"=S1_Q"#P[
M_P"B>_\ ,MGG_P \P_UPXC_Z&/\ Y:8#_P"90_X>O_M^_P#1>_\ S%OP6_\
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M_7#B/_H8_P#EI@/_ )E#_AZ_^W[_ -%[_P#,6_!;_P"=S1_Q"#P[_P"B>_\
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M_P \P_UPXC_Z&/\ Y:8#_P"90_X>O_M^_P#1>_\ S%OP6_\ G<T?\0@\._\
MHGO_ #+9Y_\ /,/]<.(_^AC_ .6F _\ F4/^'K_[?O\ T7O_ ,Q;\%O_ )W-
M'_$(/#O_ *)[_P RV>?_ #S#_7#B/_H8_P#EI@/_ )E#_AZ_^W[_ -%[_P#,
M6_!;_P"=S1_Q"#P[_P"B>_\ ,MGG_P \P_UPXC_Z&/\ Y:8#_P"90_X>O_M^
M_P#1>_\ S%OP6_\ G<T?\0@\._\ HGO_ #+9Y_\ /,/]<.(_^AC_ .6F _\
MF4/^'K_[?O\ T7O_ ,Q;\%O_ )W-'_$(/#O_ *)[_P RV>?_ #S#_7#B/_H8
M_P#EI@/_ )E#_AZ_^W[_ -%[_P#,6_!;_P"=S1_Q"#P[_P"B>_\ ,MGG_P \
MP_UPXC_Z&/\ Y:8#_P"90_X>O_M^_P#1>_\ S%OP6_\ G<T?\0@\._\ HGO_
M #+9Y_\ /,/]<.(_^AC_ .6F _\ F4/^'K_[?O\ T7O_ ,Q;\%O_ )W-'_$(
M/#O_ *)[_P RV>?_ #S#_7#B/_H8_P#EI@/_ )E#_AZ_^W[_ -%[_P#,6_!;
M_P"=S1_Q"#P[_P"B>_\ ,MGG_P \P_UPXC_Z&/\ Y:8#_P"90_X>O_M^_P#1
M>_\ S%OP6_\ G<T?\0@\._\ HGO_ #+9Y_\ /,/]<.(_^AC_ .6F _\ F4/^
M'K_[?O\ T7O_ ,Q;\%O_ )W-'_$(/#O_ *)[_P RV>?_ #S#_7#B/_H8_P#E
MI@/_ )E#_AZ_^W[_ -%[_P#,6_!;_P"=S1_Q"#P[_P"B>_\ ,MGG_P \P_UP
MXC_Z&/\ Y:8#_P"90_X>O_M^_P#1>_\ S%OP6_\ G<T?\0@\._\ HGO_ #+9
MY_\ /,/]<.(_^AC_ .6F _\ F4/^'K_[?O\ T7O_ ,Q;\%O_ )W-'_$(/#O_
M *)[_P RV>?_ #S#_7#B/_H8_P#EI@/_ )E#_AZ_^W[_ -%[_P#,6_!;_P"=
MS1_Q"#P[_P"B>_\ ,MGG_P \P_UPXC_Z&/\ Y:8#_P"90_X>O_M^_P#1>_\
MS%OP6_\ G<T?\0@\._\ HGO_ #+9Y_\ /,/]<.(_^AC_ .6F _\ F4/^'K_[
M?O\ T7O_ ,Q;\%O_ )W-'_$(/#O_ *)[_P RV>?_ #S#_7#B/_H8_P#EI@/_
M )E#_AZ_^W[_ -%[_P#,6_!;_P"=S1_Q"#P[_P"B>_\ ,MGG_P \P_UPXC_Z
M&/\ Y:8#_P"90_X>O_M^_P#1>_\ S%OP6_\ G<T?\0@\._\ HGO_ #+9Y_\
M/,/]<.(_^AC_ .6F _\ F4/^'K_[?O\ T7O_ ,Q;\%O_ )W-'_$(/#O_ *)[
M_P RV>?_ #S#_7#B/_H8_P#EI@/_ )E#_AZ_^W[_ -%[_P#,6_!;_P"=S1_Q
M"#P[_P"B>_\ ,MGG_P \P_UPXC_Z&/\ Y:8#_P"90_X>O_M^_P#1>_\ S%OP
M6_\ G<T?\0@\._\ HGO_ #+9Y_\ /,/]<.(_^AC_ .6F _\ F4/^'K_[?O\
MT7O_ ,Q;\%O_ )W-'_$(/#O_ *)[_P RV>?_ #S#_7#B/_H8_P#EI@/_ )E#
M_AZ_^W[_ -%[_P#,6_!;_P"=S1_Q"#P[_P"B>_\ ,MGG_P \P_UPXC_Z&/\
MY:8#_P"90_X>O_M^_P#1>_\ S%OP6_\ G<T?\0@\._\ HGO_ #+9Y_\ /,/]
M<.(_^AC_ .6F _\ F4/^'K_[?O\ T7O_ ,Q;\%O_ )W-'_$(/#O_ *)[_P R
MV>?_ #S#_7#B/_H8_P#EI@/_ )E#_AZ_^W[_ -%[_P#,6_!;_P"=S1_Q"#P[
M_P"B>_\ ,MGG_P \P_UPXC_Z&/\ Y:8#_P"90_X>O_M^_P#1>_\ S%OP6_\
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M_7#B/_H8_P#EI@/_ )E#_AZ_^W[_ -%[_P#,6_!;_P"=S1_Q"#P[_P"B>_\
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M_P \P_UPXC_Z&/\ Y:8#_P"90_X>O_M^_P#1>_\ S%OP6_\ G<T?\0@\._\
MHGO_ #+9Y_\ /,/]<.(_^AC_ .6F _\ F4/^'K_[?O\ T7O_ ,Q;\%O_ )W-
M'_$(/#O_ *)[_P RV>?_ #S#_7#B/_H8_P#EI@/_ )E#_AZ_^W[_ -%[_P#,
M6_!;_P"=S1_Q"#P[_P"B>_\ ,MGG_P \P_UPXC_Z&/\ Y:8#_P"90_X>O_M^
M_P#1>_\ S%OP6_\ G<T?\0@\._\ HGO_ #+9Y_\ /,/]<.(_^AC_ .6F _\
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MS1_Q"#P[_P"B>_\ ,MGG_P \P_UPXC_Z&/\ Y:8#_P"90_X>O_M^_P#1>_\
MS%OP6_\ G<T?\0@\._\ HGO_ #+9Y_\ /,/]<.(_^AC_ .6F _\ F4/^'K_[
M?O\ T7O_ ,Q;\%O_ )W-'_$(/#O_ *)[_P RV>?_ #S#_7#B/_H8_P#EI@/_
M )E#_AZ_^W[_ -%[_P#,6_!;_P"=S1_Q"#P[_P"B>_\ ,MGG_P \P_UPXC_Z
M&/\ Y:8#_P"90_X>O_M^_P#1>_\ S%OP6_\ G<T?\0@\._\ HGO_ #+9Y_\
M/,/]<.(_^AC_ .6F _\ F4/^'K_[?O\ T7O_ ,Q;\%O_ )W-'_$(/#O_ *)[
M_P RV>?_ #S#_7#B/_H8_P#EI@/_ )E#_AZ_^W[_ -%[_P#,6_!;_P"=S1_Q
M"#P[_P"B>_\ ,MGG_P \P_UPXC_Z&/\ Y:8#_P"90_X>O_M^_P#1>_\ S%OP
M6_\ G<T?\0@\._\ HGO_ #+9Y_\ /,/]<.(_^AC_ .6F _\ F4/^'K_[?O\
MT7O_ ,Q;\%O_ )W-'_$(/#O_ *)[_P RV>?_ #S#_7#B/_H8_P#EI@/_ )E#
M_AZ_^W[_ -%[_P#,6_!;_P"=S1_Q"#P[_P"B>_\ ,MGG_P \P_UPXC_Z&/\
MY:8#_P"90_X>O_M^_P#1>_\ S%OP6_\ G<T?\0@\._\ HGO_ #+9Y_\ /,/]
M<.(_^AC_ .6F _\ F4/^'K_[?O\ T7O_ ,Q;\%O_ )W-'_$(/#O_ *)[_P R
MV>?_ #S#_7#B/_H8_P#EI@/_ )E#_AZ_^W[_ -%[_P#,6_!;_P"=S1_Q"#P[
M_P"B>_\ ,MGG_P \P_UPXC_Z&/\ Y:8#_P"90_X>O_M^_P#1>_\ S%OP6_\
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M_7#B/_H8_P#EI@/_ )E#_AZ_^W[_ -%[_P#,6_!;_P"=S1_Q"#P[_P"B>_\
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M_P \P_UPXC_Z&/\ Y:8#_P"90_X>O_M^_P#1>_\ S%OP6_\ G<T?\0@\._\
MHGO_ #+9Y_\ /,/]<.(_^AC_ .6F _\ F4/^'K_[?O\ T7O_ ,Q;\%O_ )W-
M'_$(/#O_ *)[_P RV>?_ #S#_7#B/_H8_P#EI@/_ )E#_AZ_^W[_ -%[_P#,
M6_!;_P"=S1_Q"#P[_P"B>_\ ,MGG_P \P_UPXC_Z&/\ Y:8#_P"90_X>O_M^
M_P#1>_\ S%OP6_\ G<T?\0@\._\ HGO_ #+9Y_\ /,/]<.(_^AC_ .6F _\
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MS1_Q"#P[_P"B>_\ ,MGG_P \P_UPXC_Z&/\ Y:8#_P"90_X>O_M^_P#1>_\
MS%OP6_\ G<T?\0@\._\ HGO_ #+9Y_\ /,/]<.(_^AC_ .6F _\ F4/^'K_[
M?O\ T7O_ ,Q;\%O_ )W-'_$(/#O_ *)[_P RV>?_ #S#_7#B/_H8_P#EI@/_
M )E#_AZ_^W[_ -%[_P#,6_!;_P"=S1_Q"#P[_P"B>_\ ,MGG_P \P_UPXC_Z
M&/\ Y:8#_P"90_X>O_M^_P#1>_\ S%OP6_\ G<T?\0@\._\ HGO_ #+9Y_\
M/,/]<.(_^AC_ .6F _\ F4/^'K_[?O\ T7O_ ,Q;\%O_ )W-'_$(/#O_ *)[
M_P RV>?_ #S#_7#B/_H8_P#EI@/_ )E#_AZ_^W[_ -%[_P#,6_!;_P"=S1_Q
M"#P[_P"B>_\ ,MGG_P \P_UPXC_Z&/\ Y:8#_P"90_X>O_M^_P#1>_\ S%OP
M6_\ G<T?\0@\._\ HGO_ #+9Y_\ /,/]<.(_^AC_ .6F _\ F4/^'K_[?O\
MT7O_ ,Q;\%O_ )W-'_$(/#O_ *)[_P RV>?_ #S#_7#B/_H8_P#EI@/_ )E#
M_AZ_^W[_ -%[_P#,6_!;_P"=S1_Q"#P[_P"B>_\ ,MGG_P \P_UPXC_Z&/\
MY:8#_P"90_X>O_M^_P#1>_\ S%OP6_\ G<T?\0@\._\ HGO_ #+9Y_\ /,/]
M<.(_^AC_ .6F _\ F4/^'K_[?O\ T7O_ ,Q;\%O_ )W-'_$(/#O_ *)[_P R
MV>?_ #S#_7#B/_H8_P#EI@/_ )E#_AZ_^W[_ -%[_P#,6_!;_P"=S1_Q"#P[
M_P"B>_\ ,MGG_P \P_UPXC_Z&/\ Y:8#_P"90_X>O_M^_P#1>_\ S%OP6_\
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M_7#B/_H8_P#EI@/_ )E#_AZ_^W[_ -%[_P#,6_!;_P"=S1_Q"#P[_P"B>_\
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M_P \P_UPXC_Z&/\ Y:8#_P"90_X>O_M^_P#1>_\ S%OP6_\ G<T?\0@\._\
MHGO_ #+9Y_\ /,/]<.(_^AC_ .6F _\ F4/^'K_[?O\ T7O_ ,Q;\%O_ )W-
M'_$(/#O_ *)[_P RV>?_ #S#_7#B/_H8_P#EI@/_ )E#_AZ_^W[_ -%[_P#,
M6_!;_P"=S1_Q"#P[_P"B>_\ ,MGG_P \P_UPXC_Z&/\ Y:8#_P"90_X>O_M^
M_P#1>_\ S%OP6_\ G<T?\0@\._\ HGO_ #+9Y_\ /,/]<.(_^AC_ .6F _\
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MS1_Q"#P[_P"B>_\ ,MGG_P \P_UPXC_Z&/\ Y:8#_P"90_X>O_M^_P#1>_\
MS%OP6_\ G<T?\0@\._\ HGO_ #+9Y_\ /,/]<.(_^AC_ .6F _\ F4/^'K_[
M?O\ T7O_ ,Q;\%O_ )W-'_$(/#O_ *)[_P RV>?_ #S#_7#B/_H8_P#EI@/_
M )E#_AZ_^W[_ -%[_P#,6_!;_P"=S1_Q"#P[_P"B>_\ ,MGG_P \P_UPXC_Z
M&/\ Y:8#_P"90_X>O_M^_P#1>_\ S%OP6_\ G<T?\0@\._\ HGO_ #+9Y_\
M/,/]<.(_^AC_ .6F _\ F4/^'K_[?O\ T7O_ ,Q;\%O_ )W-'_$(/#O_ *)[
M_P RV>?_ #S#_7#B/_H8_P#EI@/_ )E#_AZ_^W[_ -%[_P#,6_!;_P"=S1_Q
M"#P[_P"B>_\ ,MGG_P \P_UPXC_Z&/\ Y:8#_P"90_X>O_M^_P#1>_\ S%OP
M6_\ G<T?\0@\._\ HGO_ #+9Y_\ /,/]<.(_^AC_ .6F _\ F4/^'K_[?O\
MT7O_ ,Q;\%O_ )W-'_$(/#O_ *)[_P RV>?_ #S#_7#B/_H8_P#EI@/_ )E#
M_AZ_^W[_ -%[_P#,6_!;_P"=S1_Q"#P[_P"B>_\ ,MGG_P \P_UPXC_Z&/\
MY:8#_P"90_X>O_M^_P#1>_\ S%OP6_\ G<T?\0@\._\ HGO_ #+9Y_\ /,/]
M<.(_^AC_ .6F _\ F4/^'K_[?O\ T7O_ ,Q;\%O_ )W-'_$(/#O_ *)[_P R
MV>?_ #S#_7#B/_H8_P#EI@/_ )E#_AZ_^W[_ -%[_P#,6_!;_P"=S1_Q"#P[
M_P"B>_\ ,MGG_P \P_UPXC_Z&/\ Y:8#_P"90_X>O_M^_P#1>_\ S%OP6_\
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M_7#B/_H8_P#EI@/_ )E#_AZ_^W[_ -%[_P#,6_!;_P"=S1_Q"#P[_P"B>_\
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M_P \P_UPXC_Z&/\ Y:8#_P"90_X>O_M^_P#1>_\ S%OP6_\ G<T?\0@\._\
MHGO_ #+9Y_\ /,/]<.(_^AC_ .6F _\ F4/^'K_[?O\ T7O_ ,Q;\%O_ )W-
M'_$(/#O_ *)[_P RV>?_ #S#_7#B/_H8_P#EI@/_ )E#_AZ_^W[_ -%[_P#,
M6_!;_P"=S1_Q"#P[_P"B>_\ ,MGG_P \P_UPXC_Z&/\ Y:8#_P"90_X>O_M^
M_P#1>_\ S%OP6_\ G<T?\0@\._\ HGO_ #+9Y_\ /,/]<.(_^AC_ .6F _\
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MS1_Q"#P[_P"B>_\ ,MGG_P \P_UPXC_Z&/\ Y:8#_P"90_X>O_M^_P#1>_\
MS%OP6_\ G<T?\0@\._\ HGO_ #+9Y_\ /,/]<.(_^AC_ .6F _\ F4/^'K_[
M?O\ T7O_ ,Q;\%O_ )W-'_$(/#O_ *)[_P RV>?_ #S#_7#B/_H8_P#EI@/_
M )E#_AZ_^W[_ -%[_P#,6_!;_P"=S1_Q"#P[_P"B>_\ ,MGG_P \P_UPXC_Z
M&/\ Y:8#_P"90_X>O_M^_P#1>_\ S%OP6_\ G<T?\0@\._\ HGO_ #+9Y_\
M/,/]<.(_^AC_ .6F _\ F4/^'K_[?O\ T7O_ ,Q;\%O_ )W-'_$(/#O_ *)[
M_P RV>?_ #S#_7#B/_H8_P#EI@/_ )E#_AZ_^W[_ -%[_P#,6_!;_P"=S1_Q
M"#P[_P"B>_\ ,MGG_P \P_UPXC_Z&/\ Y:8#_P"90_X>O_M^_P#1>_\ S%OP
M6_\ G<T?\0@\._\ HGO_ #+9Y_\ /,/]<.(_^AC_ .6F _\ F4/^'K_[?O\
MT7O_ ,Q;\%O_ )W-'_$(/#O_ *)[_P RV>?_ #S#_7#B/_H8_P#EI@/_ )E#
M_AZ_^W[_ -%[_P#,6_!;_P"=S1_Q"#P[_P"B>_\ ,MGG_P \P_UPXC_Z&/\
MY:8#_P"90_X>O_M^_P#1>_\ S%OP6_\ G<T?\0@\._\ HGO_ #+9Y_\ /,/]
M<.(_^AC_ .6F _\ F4/^'K_[?O\ T7O_ ,Q;\%O_ )W-'_$(/#O_ *)[_P R
MV>?_ #S#_7#B/_H8_P#EI@/_ )E#_AZ_^W[_ -%[_P#,6_!;_P"=S1_Q"#P[
M_P"B>_\ ,MGG_P \P_UPXC_Z&/\ Y:8#_P"90_X>O_M^_P#1>_\ S%OP6_\
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M_7#B/_H8_P#EI@/_ )E#_AZ_^W[_ -%[_P#,6_!;_P"=S1_Q"#P[_P"B>_\
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M_P \P_UPXC_Z&/\ Y:8#_P"90_X>O_M^_P#1>_\ S%OP6_\ G<T?\0@\._\
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@#__U?[^* "@ H * "@#^?\
M_P""\W_(H?LV_P#8R?$K_P!-G@ZOZ)^CY_OW$W_8)EO_ *>Q9^<>(?\  RO_
M *^XK_TB@?%/_!&KPGH?CW]H?XR>!_$UFM_X<\8_LM?$;PQKMBV,76D:[XT^
M&.F:A!DJP5I+6YD5'P2C;7'*BON_&W&5\OX:R3'X6;IXG!<699BL/-?8K8?
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MB*SD[U*U>HV^LIU:DKOYRD_O9_<-\.OV9O#'AC]D;0OV6M6AA?1'^$=Q\/\
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MZD(IM*UTMC6G7H5KJC6I57'=4ZD)V72ZBW8^./\ @IK_ ,F*_M"_]BWX>_\
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M_P EM/\ [$N/_P#3N#/EN._^1''_ +#L/_Z;K'X$?\$XO^3W_P!G3_L>)?\
MU']:K^B?$W_D@^)?^P"/_J30/SKA?_D?Y9_U_?\ Z:J'W3_P6)_8T_X5SXW3
M]ISX?Z5Y?@CXCZH+3XCV-E#B#PY\0[D/(FOM'$H6#3?&ZQR2W4I7RXO%,%X]
MQ/YWB'3[<? >"O&_]I8#_57,:M\?EE+GRRI.7O8G+H:/#IOXJN NE!+5X1P4
M8VPU21]!QOD?U:O_ &KAH?N,3*V*C%:4L2]JFFT:_5[>U3N[U(H\,_X)6_MD
M?\,W?&1?A]XUU7[-\'?B]?6.E:S)=3;;'PCXQ)6S\.^,,R'R;2RF9TT/Q--F
M"/\ LN:SU6\E=/#MO"WO>+?!/^L^2?VE@:7-G62TZE6BH1_>8S J\\1@M-9S
MC9U\+'WG[53HP2>)DSS^$,\_LO'?5J\[8'&RC"=W[M&O\-*MVC%Z4ZKT7(XS
MD[4DC^OBOXS/VD_B[_X*G?\ )^OQ_P#^O[P!_P"JH\"5_<7A+_R;WAW_ *]Y
MA_ZM\>?A?%W_ "468_XL-_ZAX<_:G_@AI_R:9\0O^SB?%G_JM?A)7X9X^?\
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M!OF8?*GY!X]Y!]7S+*^(Z,+4\PHO+\8TM%B\(N?#3E_>K864J:_NX/9=?L.
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MLFNR56M5>FTKL_.>(4J7&>!G32YY5LJJ22TO-5805_6$(+TL?U"U_*1^LA0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 ?YV]?Z4'\SA0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?V;?\$H/^3 O@)_
MW5+_ -73\1J_B'Q?_P"3B<0_]TG_ -4>6'[EP=_R3F7?]S?_ *G8D_1*OS4^
MF"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M%2491?+>Z4D[6:,:E*K1:C5IU*4FKJ-2$H/EU2:4DG:Z:OMHUT/W5_X(._\
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MR<7H]-NA\G?\%KO^3.-._P"RR^"/_3)XQKZ_P,_Y+:?_ &)<?_Z=P9XW'?\
MR(X_]AV'_P#3=8_ C_@G%_R>_P#LZ?\ 8\2?^H_K5?T3XF_\D'Q+_P!@"_\
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MYM]]XP^'L9CL-#\0%I#YMUJ.@L;?P[XAE(D=C_8>J75Q+=ZW.(_Y=\8."?\
M5S.?[9P%+ER?.JLY\L(VIX+,7>=?#62Y84JZOB,,M%;V]*$5"@K_ *GP;G?]
MHX+ZEB)WQF"BHWD_>K8;2-.IW<J>E*H_^O<FVZA^%?\ P5._Y/U^/_\ U_>
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!_G;U
M_I0?S.% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0!_9M_P2@_Y,"^ G_=4O\ U=/Q&K^(?%__ ).)Q#_W2?\ U1Y8
M?N7!W_).9=_W-_\ J=B3]$J_-3Z8* "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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MV<6NFZ?>7L[8BMK::5DC(!^//_$2O_P1!_Z/R\(_^&E_:'_^=#0 H_X.5O\
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M1?$6@7E_I.I6ZS12P/):7<JQSQ2P/MEB=% .VH * "@ H * "@ H * "@ H
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MA;PM=73W-C%).LMA!=6Z!=DLJ2$(0#[-H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * /XD_B%_P>I_L[^#_VIM;^
M&&@_L@>.?&?[-/AWQU>>#[S]H"R^*^F:?XUUG1M-U4Z7??$#PQ\&KCP!+8WF
MBR_9[C4-!T/5?B?H^LZSH\ME=W[^'-2>;0H@#^U'PSXCT3QCX;\/^+O#.H0Z
MOX;\4Z)I7B/P_JML)!;ZGHFN6%OJ>E:A )4CE$-[875O<Q"2..0)(H=%;*@
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M-W^I:/J$:G 9[2\E53P2#Q0!W- !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M * "@ H * /Y_P#_ (+S?\BA^S;_ -C)\2O_ $V>#J_HGZ/G^_<3?]@F6_\
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M/@?5/%^I7=W?W&M:M?"Z%\/$=O#;06\">7]GF>27E$(!^A/_  7"_P"40O\
MP45_[-2^*W_I@FH _P G+_@EA_P3I\7?\%2?VM=$_9.\$_$GPY\*-;UGP3XU
M\;#QAXIT74]?TJWM/!>GPWT]D=,TFXM+N6XOO/2*%_M$<<.&=]V C ']-.H_
M\&0G[3\5E</I'[<OP&O=15";6UU'X:_$'2K*:3LEQ?VU_K$]LGK)'IMVP_YY
M&@#\.?\ @I9_P;[_ /!0[_@E[X6?XI?&'PIX+^*/P&@FTVTU/XY_ O7M4\5>
M"O"U_K%_#IFE:;XXTSQ%X?\ "/C;PA->ZA=6.G6VK:GX6_X1&[U74+'2-/\
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M!_BK?\%>O^4QO[?O_9\OQI_]6GJM '^U30 4 % !0 4 % !0 4 % !0 4 %
M!0!_-C_P=2?MO?\ #(W_  2N^(/P^\-ZO_9_Q/\ VQ-8A_9T\,16\VR_M_ N
ML6<^L?&C6?)#(\FER?#ZPO/ =[*C9M;_ .(>C2%74E: /\FD:=K-CI^F^)%L
M]2L],N]4U#3M)UU8+B"RN-9T"#1[_4[/3]1"K#)J6CV^NZ#>7L%O*;BQBU;2
MYYEB6]M6D /]J?\ X(V?MM1?\%!/^";W[,/[2%]J4>H^/M5\"VW@;XQ_.IN8
M?C'\-I&\&>/[J\@7)LO^$FU;2?\ A-M,M'+.F@^)](D+R"59& /T]H * /\
M%7_:0_Y3;_'K_M*A\4?_ %K;7* /]JB@ H * "@ H * "@ H * "@ H _P [
M>O\ 2@_F<* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MS1H?5ZDDE5A?ZJK]Z/R4* "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@#^:K_@Z]_:HU+]F[_@D5\1O"/AK6YM$\6?M3_$+P3^SI
M93V,WE:B?"FM+JWCKXE0J@RQTK7/ ?@36O!.MNR&'[#XO^QEDFO;=J /5?\
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MN/#N@ZEX<:?Q$ ?U:_%SX5^!_CG\*_B/\%_B;HL'B/X=_%CP-XI^'7CC0;C
MBU;PKXRT2]\/Z[8[]K&&2?3;^X2&X0>;;3>7/"5EC1@ ?P4?\&EOQ#\9?LE?
M\%&_^"B?_!+?XAZU=+%IDGC75=*TJ^;R[(_%3]FCXF/\+O%D^C6IXBU#Q?X1
M\1C5KV6 &+4-'\!Z=*TCQV%IN /]!N@ H __T?[^* "@ H * "@#\P/^"F'[
M%'Q2_;,T'X2:9\,/$'@#0;GP%J_BV_U=O'FJ>(M+@N8-?LM!M[1=-?P]X5\4
M/++$^E3&X6YBM$5)(C%)*=RI^J^%O'.4\$8G.*V:X?,<1#,*&$I45E]+#591
MEAZE>4_:+$XO"**:JQY>1S=T[I:'R?%60XO/*>#AA*F&IO#3K2G]8E4@FJD:
M:7+[*C5U7)JFEY,\/_X)Q_\ !-[XX?L@_''Q-\3/B5XJ^%.MZ%K/PMUSP1:V
M?@;6_%VIZLFJZGXJ\%:Y!<7$&O\ @;PS9IIZ6GAN]CEECOIK@7$MJB6KQ/++
M#[_B;XG9#QGD.$RK*\)F]"O0S:ACYSQ]#!TJ+HTL'CL.XQ>'Q^*FZCGBH-)T
MXQY8R]Y-)/S^&.%\?DN/JXK%5L'.G/"5,/&.'G6E/GE5H33:J8>E%14:4MI-
MWLK6NU^U]?A9]X?FW_P4B_8?UO\ ;,\!>!+?P%J?A+0/B3X!\27=QIFJ^,;G
M5K#1KGPKKMB(?$6D3W>AZ)K^H)</?Z?H&H6!_LZ:!#8W<),/VPS+^G>&/'E#
M@C,<?+,*6,Q&5YAA80JT<%"C4K1Q>'G?#5HPKU\/3<53J8BG/][%_O(OWN2Q
M\OQ1D$\\PV'6'E1IXK#56X3KN<8.C4C:I!NG3J2OS1IRC[K7NM:7N?+O_!/O
M_@EE\1OV9/CH?C%\9O$?PR\2'P_X8U:P\"V/@75/$^JW%CXEUQ8],O-9U ^(
MO!WAB*"*U\.3:QI]LML]W+)-JQE86XM5\[ZSQ&\6LLXJR!9+DF&S7"_6,51J
M8^ICZ6%HQGA:%ZD*%/ZMC<4Y.6)5&I/F4$HT4ES<SMY'#?".)RG,/KN.JX2K
M[.E..'CAY59N-6I[DIR]K0I))4G.*M=MSZ<NO[C5^"GWY^</_!2;]C_XE?MB
M_#7X?^#OAEKG@?0M4\)^.9O$NH3>.]1U[3-/GT^30-1TL16<WA_PUXGN'O!<
M74+>5-:6\/DB1OM&]5B?]-\+^-,KX*S3,<;FF'Q^(HXS 1PM..7TL/5J1J+$
M4ZMYQQ&*PL5#E@U>,Y2YK+EMJOF.*<EQ6=X3#4,)4P].='$>UD\1*I"+C[.4
M+1]G2JN]Y+1I*W7H?#7[$O\ P2E_:&_9N_:=^&7QI\<^,_@SJGA;P6?&)U/3
M_"?B#QO?Z_<?\)!X!\4^%;(6%KK'P[T'3I/*O]<M9KK[1JEMLLXKAXA-,L<$
MOWW'?B[PWQ/PKFF1Y?@<[HXO'?4E2J8S#8"GAX_5LPPF+G[25',L145Z>'E&
M'+2E[[BGRQO)?/Y!P?F65YMA<=B*^!G1H>WYHT:E>51^TPU:C'E4\-3CI*HF
M[S7NIVN[(^L_^"EG[&W[07[9%O\ "_PS\+O%?PQ\.^"?!DVN:[KMEXXUSQ9I
MEYJWBG4$M=/TNZA@T#P7XHMI+;1M)348K:66XM9Q+K5^AA>,1N/CO"[C;AS@
MF6:XK-L'FN)QV-CA\/AYX"A@ZL*.$IN52K"4L1CL))2K5O9.2C&<;4*>J=T>
MSQ3D>99VL)2PE;"4J%!U*E2.(J5H.=6248-*G0JJT(<R5VG[\M+'Q1^RC_P1
MU^,WPF_:$^%_Q.^+OB[X.:YX)\ >(4\67.D>$-<\9ZGK=[K6BVUQ>>%1#;:Y
M\/\ P_IOV>T\31:3?WK3:BK?9+26.*&6210/NN+_ !JR3..',URK)L'G>'QV
M88?ZG&MC*&!I4*="M*,,7>6'S'$U.:>%=6G!1I6YIIMI(\')^"<=@LRPF+QM
M; U*&&J>V<*,Z\ZDITTW1LJF&IQM&JH2=Y;1T1_1/7\UGZ8% !0!^$'[>?\
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M_P#.DH_XCYP?_P!"WB7_ ,(\K_\ GP'_ !#_ #G_ *"<L_\ !V*_^8C]%_\
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M'^<_]!.6?^#L5_\ ,0?\.-/VL_\ HH7[.W_A6?$K_P"=)1_Q'S@__H6\2_\
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M?A,;'$Y;_L]>$Y*-7$WE3O:K!)X-+WZ3G#=;[K<_I+K^83]1"@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H _SL?^#X7_DM
M?_!/O_LEOQX_]2SX<T ?N=_P:%_\H;O!W_9P7QU_]/.D4 ?U 4 % '\NG_!W
MY_RAT\1?]G&_ W_TK\1T ?B/_P &.W_)7?\ @H;_ -DX_9Z_]2;XJT ?Z(=
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M?%/X7_">?X?^)+R7A;?3/"7Q*M[KPT5!,EQ?_%BR;:(K25U /[*/^#,#]O\
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ME-#=V-_9SS6MW:RQ3V\LD4B,0#\/?VZO^#B;_@G3_P $[_VBO$G[+O[0U_\
M&M?BGX3T3PKK^M0^!_A?_P )-H$%EXQT.U\1:+'%K$OB'2A<7#:5>VLURD5L
M8X'E\GS6E214 /\ *_\ B?\ M > /%__  4E^(?[4^D_VVOPM\4?MP>+?V@-
M,-WIJ0^(U\ :W\>=0^(MG]ITA+J6.+6QX=N8_.TU;V1$OMUJMTZ@2D _T?\
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M,!BRG2O &INRHV8D;8C@']'W[0/[:7P(_9M_9$\3_MP>/=9UO4/V?_"_P_\
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MQH7B;2VN62T2.*Z::W5I/)+D ^M/VT?^"QO[!W[ WP*^&GQU_:)^*%YHMO\
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M2?\ !Z/_ ,$WO&.M:7HWQ3^!_P"U5\&[?4)EANO%)\-_#_X@^%-#4];K5?\
MA&O'<'C*6T3H?[$\%:S>D[=MB1DJ ?U:? WXW?"[]I/X0_#SX\_!3Q5%XW^$
M_P 5?#.G^,? 7BR#3-:T6/7?#NIH7LK\:3XCTW1]>TUGVLLEEJ^EV%_;2(T5
MS:Q2*5 !ZM0 4 % !0!\L?M:?MM?LI?L*_#>3XK_ +67QQ\#?!7P:WVN+29/
M%&HO)XA\5WMC%'-=:3X&\&:3!J/C#QUK4$,L4TVD>$=#UG4(+=Q<SV\5L&F4
M _F8^+'_  >D_P#!.+PCK-]I'PM^!7[57Q?M;,E(?$S>'OA[\/O#>JL"<2::
MOB#QW>>*EM2NT[]6\*:3=!B5^Q84,P!=^#O_  >@?\$V/&VN66B_%?X-?M2?
M!&VN]JR^*[GPQX(^(?A32VW*';4AX0\:-XR,*J2RMI/@O5IFVD&W0[=P!_4'
M^S7^U/\ LZ_MA_"_2_C-^S#\8? _QJ^&FK/]GB\2^"-7COUT[45@@N9M"\1Z
M5*MOKGA/Q+9V]S;2ZAX8\4:9H_B#3DN(#?:9;^;'N /?J /Q7_X*'?\ !>_]
M@3_@F)\;]#_9\_:<OOC!%\1-?^'&A_%.R@^'_P -_P#A+-'C\*^(=>\4^&],
M:XU237=)1-0DU'P?K/F6<<4ODVZVTKRYG"* ?4-O_P %1OV*++]A[P+_ ,%#
M_B!\7;+X/_LO_$7P_:^(/"_BCXGV-QHWB/45OKW4;"QT/3_!>D?V]XBU_P 6
M7TNE7\MEX5\+66O:Y=6EK<7<%E)!;7+P@'\]7Q5_X/3_ /@G?X4\07^C?"W]
MGS]J?XLZ;I]\UHGBRYTGX=?#W0=9MD8 ZGH5KK'C;5?%#6DB9:VA\0>&_#E^
MQ&VXL[3K0!]5_L=?\'9'_!*[]J?QCI'P[\;:S\3?V3/%NNWT6F:1?_M#:'X<
MTWX:W]].!Y$,GQ-\'^*/%.@>&H'.Z-]3^($?@O1HI%6-M1W2PAP#^FJUN;:]
MMK>\LKB"[L[N"*YM+NUECGMKFVGC66"XMYXF:*:":)DDBEC9HY(V5T8J0: /
MPO\ VZO^#B;_ ()T_P#!._\ :*\2?LN_M#7_ ,:U^*?A/1/"NOZU#X'^%_\
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M .;.@ _XC!O^"/?_ $$/VFO_  R$/_S9T '_ !&#?\$>_P#H(?M-?^&0A_\
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MV= _; E\.VOQ'T'4[:)%EDU3X;72_ CP]?3?O;;3M!^&NNWK[HWN+T '0?\
M!E7^V_\ \(U\4/VD?^"??BW5_*TGXEZ1#^T7\'+.YG\NW3QSX/M]-\*?%;1;
M",D^?JGB?P4_@WQ!'#&L:PZ;\--:N&9RX  /]$F@ H _Q5_VD/\ E-O\>O\
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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MBAQAC89AAJ<JBA'"5GB*&)R:G"+S&G&BJT7F/[S%TZ==<S2IGWY7]='\\A0
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M3'=V_NHJW)+-[*":7U>NO^7%5+_KW/\ ^1#VM+_GY3_\#C_F='61H% !0 4
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MHC'5=:@3[42/DG#O)RC, #_0OH * /_2_OXH * "@ H * "@ H * "@ H *
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MPG=\W1 /ZQ: "@ H _RLO^#Q7_E+S:_]FI?!7_T__$F@#]7_ /@F'_P=:?\
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MSX$&J:78ETLHM>^)_B32Y/%WB+5KCS+^=]3TW19[YM%\-Z'::> ?V4_LA?\
M!G!_P3^^'WPH\-K^U_XF^*OQ_P#C?J.C65SXXN?"OCR^^'/PN\/:]<6,9O\
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M+7Q/>>)M&TA1::,(X@#]KZ "@ H * "@ H * /\ .WK_ $H/YG"@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H _LV_
MX)0?\F!? 3_NJ7_JZ?B-7\0^+_\ R<3B'_ND_P#JCRP_<N#O^2<R[_N;_P#4
M[$GZ)5^:GTP4 % !0 4 % !0 4 ?FQ^W[\8M;L[;P;\ OAM<7DOQ#\?:OHVH
MW,>D2%+^SL;;58?^$=L8Y8Y8I(+S6]?MXI;=HY%>&/2U$QA34+623^*_I;>(
MN8T*/#?A-P?5Q-3BKBG,LKQF+IY;4G3QU##T\PIK(<%1JTN5TL7FF=4J5:GR
MU(SI4,O<JL51Q5.4OZ<^CQP5@*]3._$'B:E0CPYP]@<=AZ,L;",L+7Q$\'-Y
MG7G3FFJE# 9;4E":Y6IUL93C3O.E-13]M_X!ZG\3_@QH_BTR:9K?Q>^$WA_3
MKGQ:VCHL4FL:1+:)-XB"649$R06MU%>Z]I$,Z)LLUUA+"(37;6\E?29\+<PX
MO\.LLXF=3 9IXB>'N382IQ-++*<(5,RRNKA8U<XY,-%^UITL+BJ>(SG+Z-51
M7U6&8PPU/VM?V;GP*X_PG#'&F-R2V)P'!O&&8UZ64+'3<H8''4ZTH99*=>5J
M;G5HSI9=C*L&_P!Y/"2KRY*/.OD#X:Z]_P $Y;KP+X;D^)?@G6]'\>1Z>MKX
MGL[6[^)=S;-J=HS6TM];O8:]):I#J0B6_6VC(^R&X:U*+Y(S^!<$YM]$FOPK
MDDN->&<XP?%,<%"CG5/!8SC+$X2MC*%Z4L;AJN%S;V"I8Z,(XQ48*/U>5:6'
MY;4XM_L7%&6_2/HY_FD.&,\P&+R!XF4\KJXBAPK0KQPM1*<,/6IXG 1K>UPK
MD\/*<KJK[-5%*2D=Y_;O_!*^(*4\,>(692,%#\4]X(Y#9;74QC Y!STP*^HE
MF/T'U'_D0<13Z65;CN[\WS9U&/E^2/GU@?I6W_Y&N5QZW_XP^R[+3 -^FG0^
MC-9U/X!?MB?!'Q'\&OA#J-_<:W\.- T_5_ ]MKD.K0:KIUQHT366EK:7^O/=
M7M]:3P'_ (1Z_N);BYDLHM3LYY"DXL95_6<RQ?A5](3PQS?PT\/*^,>;\%9/
MA,SX4PN<4\?3QN%GEE.6$P,*.)S&O7Q.,P=:D_[%QLZU>M["ECL/*K::PTE^
M=8'#^(/@QQUEG''&6&P\,!Q+F.)P6?5<NJ8.>%Q-+&2A7QG/0RZ%/#X;$4IV
MS+"TX4J2G4PLU3CR*K$\4^$!?]J[]E?QA\!?%"_\78^#)$W@Y[P+#J:QZ8L\
M>@P@S#Y#;Q?:O!M[A0ME8W&D3R[+O[/='\R\.[^/'@5Q!X3YM:?'OAK&GB>%
M98MNGC7A\&JU++,/4]JXR2H\F+X6QD9+V5#"5<NE7BJZA,^YXSMX1^+.3>(6
M5W7"'&_-#.H89<V$<L5[*>82BJ?NOVG-A\^PEO>J5XXA4KTE*![+\.OC1XL^
M"/[$&C>.OB=;0Q>+=,M-2\+_  TL]51TU74(WEN+/PM;7UI<)%.BV-O8W%PU
MK%M,_AG1K60'<ZR']'X-\2<_\,OHPY;Q/QAAX1S[!T\9P_P)A\PC)9ABZ52K
M4PN14\90K1A5A3P5/#5ZTJ,6G5R'*\/4;YYJ3^)XDX(RCCKQWQV0\+U7+*,5
M6P^;<3U\&X_4L-*%*GB,XJ86K2<J;]M4K0I0FTU#-,;4IQ7*N4^&_P#AG3PG
M%^S7X@_:<^/.O^,AXV\:WM[J/@S2;#4-,LFU^^UQI7TJ\U9+_1K^[NY-4O!?
M^(;I[>:U,V@0->HVZ?[0/YI7A)DN'\&<U\9_$O..(X<1<2X[$U^%<NPV,P%"
M>=XS-9U)8+&YH\PRW'8JN\PQ2QN<5OJ]6A*>2T?;TI<U:$X_NC\1LUJ>)N7>
M%_ .79+_ &'D6&H87/,7B,-BZZRW#9=&*QE# _5<=A:-*."H>PRZG[:%;_A2
MG[.;LG%YWAS]ESX=^'_V6=5_:!^,.H^,-.U?5C,/AUX7T/4=)TU=5-RKVVA'
M41J.AZG<2+?W:3ZC-]E>V9/#UB]Y'NFNDC@Y\H\&^&,K\#L?XL^(&/SW!8[,
MJLZ'!&293B,!@HYG*M%X?+*F-^OY9CJTX8O%4\1F$EAIT.3),)+$4Y5:E>')
MOF?BAQ!F/BMA/#O@S"Y37P>"4'Q-FN/P^+Q3P7L7[;,5AOJV-PE.#PM!TL)'
MVT:G/F=7V4N2$'S>J_L_Z/8_LK_LY^*_VG->MXE^('C^S?PK\)M-O465[.VO
M9)?)U9XG6/S#<20/J=Q$JHDVD:'"D=U$-<D2#[3PKPE/P3\(<]\;<TI4I<7\
M649\->'."KT^7V%+$N2>:.G4OS+$5<-6S&4>6SRO*Z-*G7_X59J/R_B'BJGB
MIXE91X69?4G'ASAVM'-^,<51DW[6I047/!J4;*+P].K# 4Y7TQ^-J3E3:P<+
M_H%^Q9^T$GQV^$]I_;%\;CQ[X-$&B^+%G=6NK]-K_P!D^(6VA=XU6WADBNI"
MD;?VI97[>4L$EK)/_6GT:O%G_B)W E*AFN+=?B_A=TLKX@]K95L=3<9/+,[T
MTG',</3E3Q$M&LQPN-3A&FZ,JG\\^-_AY_J'Q;5E@,/[+AS/?:8_)>1/V6&M
M)+&97K=J6!JSC[).]\)6PTKN?M%'[#K^BC\8"@ H _C2_::_86^"O_!0K_@X
M>^.?P)^/%YXYL?!6G_LH>$?B!;S?#[7=.\.ZY_;V@:-\--*L4DOM3T+Q#;-I
MYM?$-^9[86*R23+;.MPBQ/'+_1.3<39CPGX1Y7FF5QPT\0\^Q&$<<72G5I>R
MK3Q<YVA3JT6I\U&%GS62NN5W5OR''Y+A,^X^Q^"QLJ\:,<MI5T\/.-.?/3IX
M6$5>4*BY;5'=<O;70^X_^(6'_@FC_P!#)^U)_P"'3\&__.L_SBOF/^(W\8_\
M^,C_ /"+%?\ S>>Y_P 0TX>_Y_9I_P"%5'_YE%_XA8O^":'_ $,?[4?_ (=/
MP=_\ZVC_ (C?QC_SXR/_ ,(L5_\ -X?\0TX>_P"?V:?^%5'_ .93]%/^"?7_
M  2>_9@_X)JZK\4-7_9XU/XK7]U\6]/\*:;XI7XD>*]$\2PQ6_@ZXUZZTDZ0
MND^$_#3VDCR>(K\7C3O=K,JVPC2$QN9/D>+..\ZXRIX&EFU/ 0CE\Z\Z'U*A
M5HMO$1HQJ>T]IB*_,DJ,.6RC;6]]+>_D7"^6\.RQ,\!/%2>*C2C4^LU85+*B
MYN/)R4J=OXCO>]]-K'Z:U\6?1G\M'C^V@_X)J_\ !P-X&^)3.NC?L]?\%1?"
MDG@O7YLFWTK1?CF;O3-+59%QY1GU+Q_;>"]6FO;F:..-?BOX@E55ATG!_<<(
M_P#7+PFQ6#^/-^",0L116]2KE?+.>G6T,*\1!16_U&DK7FC\SKI<.\=T,1\&
M XEI.A/I&GC;QCZ>]75&5^GUJH]HG]2]?AQ^F!0!^1O_  7!_:SA_9(_X)V_
M&C7M,U+['\1/B[9Q_ ?X6VT$A34+KQ1\1[:]L=5NK 1YE$V@>"+7Q7XACD1"
MOVG3+6VW+)=0Y^_\,L@_M_B_+:,XIX/ 2>:8Z4K>SC0P3C.$9WTM5Q#H4;/I
M-O:+M\KQGFBRKA_&3C+EKXI+ X9+XG4Q"<9.-NM.@JM1><4NJ/2O^"1_[(3?
ML3?L#_ CX.:O8I9?$"^\/#XC?%@;0+@?$?X@"/Q!KFEW3CB:7PI;7&G>#%G7
MY+B'PY'<+_K23Q<?9^N).*LUS&G)RPD:WU/ =OJ>$_<TIKM[=J>):Z.LT='"
MN5?V/D>!PDH\M>5/ZQBN_P!8KVG.+[NDN6C?JJ:9^E%?&GT1_G\?M)?L,Z!_
MP41_X.&_VI/V:_$GQ!UCX9:7J\$WBI_%.A:'9>(+^&;PI\(/!%_#9KIM_?:=
M;M%>$^7)*;@/$H!1&K^J\GXFJ\)>$N1YQ1PD,;.G:@J%2K*C!JOF.*BY<\83
M:Y=TN74_"\QR:.?<>YEET\1/#1FO:^TA!3:=+"4&ERN45KMOH?H+_P 0BOP<
M_P"CTOB=_P"&F\+?_-=7RG_$>\?_ -$Y@_\ POK?_,Q[O_$*\-_T.<3_ .$M
M/_Y<)_Q"*_!S_H]/XF_^&F\+?_-?1_Q'O'_]$Y@__"^M_P#,P?\ $+,-_P!#
MG$_^$M/_ .7'ZY?\$J_^"/?@S_@EMJGQAU/PG\;?%'Q=;XO6'A.PO(O$7A#2
MO# T1?"EQK%Q#):OINL:H;LW9UB19%E6$1"%"A;<<?!<<>(.(XVIY?3KY;1R
M_P#L^=><72Q$Z_M/;QI1::G2I\O+[-6M>]^ECZGACA.EPU/%SIXVIB_K<:,6
MJE*-+D]DYM6Y9SO?G\K6/V1K\\/KC^1;_@[B_P"3>OV0_P#LL?CW_P!0NPK]
M\\!/^1KQ#_V+<+_ZE'Y7XI_[AE7_ &&5O_3"/SC_ &7?^#87XC?M-_LY_!+]
MH73?VN_!GA*Q^,_PT\)_$>U\,7OPGUS5+K0(/%6E6^JQZ5<:G!XWLX;^6R2X
M6%[N.SM4F92RP1C KZ_._&C!Y+G&9Y1/(<37EEN-Q&#E6CCJ4(U7AZCINHH/
M#2<%+ENH\TK;79\_EGASB<RR_!X^.;4J4<7AZ6(5)X:I)P52*DHN2K13:O:Z
M2]#W*?\ X-%?BY'!+)9?ML?#R6\2-FM8Y_@_XFM('N%7]TDMU%XWNY;:,M@-
M-':W#QK\RP2$;:\Q>/>7W2EPYC%'JUCZ#:76T7AHI^EUZH[7X5XNVF<T&^B>
M%J)?>JSM]S/DK0_C7_P5%_X-WOVDO!'P[^-GB+5?BC^SGXED:\MO!:^+-9\6
M_!;XG>"[&\MK?Q%<_"?5/$ME!??#CQ[H O+22]M;;2]"O[.\N-&;Q-HVM^&=
M3TR34/>J9;P3XM9/B<7EU*&!S:BN1XGZO3H9C@<3*+=&./IT)..+PE7E:BW.
MK%P53V$Z=>G.,?*AB^)> <PHT,7.6)R^H[JC[657!XFC%I3>%E45\/7A=72C
M3DGR>TA.E*/-_?\ ?!SXL^!_CS\*?AW\:/AKJG]L^ OBAX0T'QMX4U%HQ#/-
MHWB#3X=0M8[VV#R&SU*T68VFIV#NTMAJ$%S9S?O8' _E7,,!B<KQV+R[&4_9
M8K!8BKAJ\-TJE*3A+E>G-!VO"2TE%J2T9^Z83%4<;A</C,/+GH8FE"M2E:SY
M)Q32:^S);2CO&2:>QZ57&=!_ K_P7[_X*[_'3XL_M%>.OV$_V</%7B7P/\'O
MAIKG_"NOB!+X&U"]L/%/QL^(V8K3Q!H=_J.D/%J)\$Z-J=PWA6P\(V4IMO$F
MI6>H:OK;:G!=Z+INB_U/X5\ Y9@,HPO$V;T*.)S'&T_K>%6)A&5#+,&KRHU(
M1J+E6)J07MYUY*]"#A3I<C564_PWCKBK&XK'ULDR^K4HX/#3^KU_8MQJ8S$?
M#4A*4?>]C"7[J-%:5)*4Y\Z=.,.5_9N_X-6/VQ/BMX*T?QE\</B[\-/V<KC7
MM/M]1M? EUH^M?$CQ]H\=S$)8[;Q;I^EW?ASPWHNHA&0RZ?8^*];N;1BUO?K
M9WD4MK'MG'CAP]@<34P^6X#&YNJ4G"6)C4I8/"U&G9NA.<:U:I#M.5"FGO'F
MC9F>7^&>;8JC"MC,5A\O<XJ2H2A.O7A=72JQBZ=.$N\54FX[22:L>4?M?_\
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MING?$*WN9)'B^&OB=]EAHWQ5T=-Q6"&R5HM.\;6L:8U/PT%O=DVH>'])C/\
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MS_-6_P"#=3_E++\ _P#L"_%G_P!5OXEK^Q_%W_DA<X_Z^X'_ -3J!_.W /\
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M_B@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H _SL?^#X7_ )+7_P $^_\ LEOQX_\ 4L^'- 'R!_P1L_X-
MDO /_!4_]BG1?VLO$/[7/B_X-ZCJWQ%\?>!6\%:+\(M%\96,$/@N]L[2+45U
MJ^\>>'IWDOQ=%Y+8Z<JV^P*LLN<@ _5;_B!V^$O_ $D.^(O_ (COX:_^>Q0
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M"/G[6GQ2_;I_X)N_LO\ [5WQJMO"EI\3_C!X<\::KXLM_ ^DWNA>%8KGP_\
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M0\>_\B-XS_[%/Q%_Z9[R@#_&N_X(&?\ *9#_ ()Z_P#9P>A_^F?6Z /]GV@
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MX/8O^4=?[,'_ &>GH'_JC?C90!Y1_P &0O\ R:[^W'_V7SX<?^J\O* /[@*
M"@ H ^6?VY="O/%/[$_[87AC3WDBO_$7[+7[06A6,L)Q-'>:O\)O%NGVSQ$<
MB1)KA&C(Z,!B@#_(9_X(/>+M+\$?\%A_^">>M:O-:V]G=_M(>#_"<<EV56'^
MT?'L.H>!=&C!?Y1<3:OXCL8+3O\ :Y( OS8H _VC* "@ H * "@#\G?V\/\
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M * "@#_/?N/^#XOQM!//#_P[=\*MY,TD6[_AJ;5AN\MRF<?\*".,XSC)QTH
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M_$;Q9]G3R1=?$#PEK?BOX4ZK>&%0(5:Y\)>"? LT\T>U[N_DOKFX0W$DEQ<
M']M'_!M7\5-7^+G_  1/_8>UK7[K[5J_A7PG\1/A7(VYF\G2/A/\9/B'\/\
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M?@K0[5$2#2?"O@S0['P[H.GQJBHN+73-.MH2P4%V4NWS,: ._H _C^_X//\
MX(Z!XU_X)M?!WXV#0[*?QI\#_P!J#PMI]IXD: -J.F> /BEX+\::)XMT."?A
MHK+7/%VB_#&_NT.5>?P]8\ C- 'YT?\ !CM\0M4C\2?\%#OA1-=M)HMUH?[/
M'Q"TZP?.VTU2PO\ XL>&]9N[< @*VHVFHZ##>95BPTNQVE C!P#_ $&* "@
MH * "@ H * /\[>O]*#^9PH * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * /[-O^"4'_ "8%\!/^ZI?^KI^(U?Q#XO\
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MQ?$F,A&AQMQE"G'+Z%2*^LX=UJ4I9;1<)*\8Y;AISS7&0FDHXFK2PE9>T]E
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MMA:U;#8BG.C7P]6I0K4:D>6=*K2DX5*<XO6,H3BXR71JQ:KH,@H _F>^&/\
MRM"_M _]F,:;_P"B/@O7[1C?^3(Y5_V5$_\ WHGYQA/^3E9C_P!B:/Y8(_IA
MK\7/T<* "@ H _#'_@X-_95U?]H7]@3Q'\1_ =M,WQ8_9-\0:?\ M"^#+JQ5
MAJ8T+PHI'Q$MK.>,B:$V?A)KKQ>BP9FN+SPC96L.))E8?IWA-GE/*>*J&"Q4
MHK 9]2EE&)4_X:J5_P#=')/2TL1RX=WT4*\V]$?%<>97+'Y%4Q%!/ZUE<UCZ
M+C\7)2_CI/=6I7JJWVJ44C]"_P!@#]IO2_VQ?V./V?OVBM.NH+B\^(/P_P!,
MD\5Q0,I_L[Q]H#3>&?'^E2*.8VT_QAH^LVZ!E3S+=8;B-?)FB8_)<69)/AWB
M+-LGFK1P>+FJ#Z3PM6U;"37E/#U*;\G=;H]_(LRCFV48#,(M-UZ$?:I?9KP_
M=UX_]NUH32[JSV:/L.OGCUC^6[]N:UF_X*'_ /!<3]DK]BW3<ZS\'OV(- '[
M1?Q]@B_?Z7;>(+S^P/%-GI.L1K^ZE>^B_P"%4^&HHI?,>V3QOJ1C 1=1CK]O
MX8:X1\,L^XDDU2S#B6M_8V5=)RHKVM&<Z?6T&L;6=MWAJ?\ =/S3.E_;_&F5
MY/'W\)DU/Z_CDOA51\E10DMM?]EI^7MI:*TC^I     8 X '  '0 5^('Z6+
M0!_'+^SO_P K6G[1?_8F^,__ %2'@:OZ$S;_ ),9E'_81A__ %9XH_)<!_R<
M_'_]>:O_ *A4#^QJOY[/UH* "@ H _D6_P"#N/\ Y-Z_9#_[+'X]_P#4+L*_
M?/ 3_D:\0?\ 8MPO_J4?E?BG_P B_*O^PRM_Z81^\O\ P2A_Y1I?L+?]FO\
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ME\:>*+ZY\>>'1I-V$U!M2^%OQ=U#6)/$(N4BFL;3XD>'=,2V1-*N"@!^E?\
MP6H_X-Y_@)_P5UU/PS\7+'XBZC^SO^T_X-\.P^#[7XH:5X5L?&/A;QSX/M;Z
M;4-.T#XE>#CJ7AO4=5N]"ENM0A\+^*-(\4:5J.D6NJ75GJMGXFTVTT73]) /
MPZ^%G_!FC\;M<USPCX5_:I_X*3ZKXH_9[\'7D#V_PY^&OACQE=:G<:1:SJBZ
M/X8/C_Q;=>#_ (=37%B,+JMMX6\6QZ:_[B+1[Q,7"@'Z=_LX_P#!KM\)_P!E
M+_@J1\./^"@GP1_:-M_!WPF^$^N?VAX(_9/M/@7-+_9VE+\%;OX2#3;OXUWG
MQJN;W5=3N[Z]N/&VM^)=0^&\^IZ[JES?1ZB)=0OI]=(!^LO_  6*_P""@&A?
M\$UO^"?WQU_:2EU/3+?XD1>'Y? /P$T6_DMFE\2?&_QM;W.E>!X+;3K@@:O:
M^&)/MOC_ ,2:>F'D\(>$-?965D4T ?@'_P &</["/B#X5_LR_&?]OWXF6]^O
MC+]KOQ#'X5^&IU9)#?M\(?AOK.K_ -L^+C/<!;QW^(WQ+NM8CE%SYBW6G?#_
M $'6[2:2WUG>P!_9Y0 4 ?_4_OXH * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M.SM[_3[VW?&^"[LKJ.6VN86P-T4T;H<#*T >=?\ "BO@C_T1SX5_^&]\)?\
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MCM8T4 _G;_X/:/\ DPO]DW_L[M/_ %37Q+H \\_X,A/^38OVYO\ LO'PS_\
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MJE_P1?\ @]8V::]^SYXR^/&N6:Q#_A)_C7\8OB'J%W</&H$CW/AOX>ZS\.O
M$_GL-[I+X/=$^["L:%E8 _$7_@[1_8O_ &"/V+OV!?V:?#O[,G[*OP%^!7Q&
M\=?M8:9<-XL^'?PU\*Z!XYUKP#X.^#WQ3A\2:%JWC>#3SXPU70G\0>*_ ^H7
M&E7VLW&G2ZC8Z=>SV[7=I:2Q@'H__!CW_P D/_X* _\ 95O@7_ZB/Q H _NF
MH _#?_@HY_P;T_\ !-__ (*2:AX@\?\ C_X:WOP:_: UXO=7?Q_^!EQ9^$?&
M&MZIY85+WQ[X=N+'4? OQ#EF:*VCU#5/$7AR3QA/8P"RT_Q;I2D2( ?P-?\
M!6?_ (-FOVQ?^"9G@_Q#\>?"7B/1OVI/V6O#TL3^(?B1X,T*]\->//AS875Q
M]GM]3^)OPQN+[7&TWP\DLEO:R^+?"_B3Q3HMG(PG\1#PQ#-:K, ?L/\ \&GW
M_!:SX_>,/COHG_!,?]IGQOXC^+?A#QEX.\0WO[,7C'Q9J0U?Q;\.M6^&GA;5
M_&&N?#.]UW4&.L:]X%U/P+H6L7WAB'4;_4+OP7>^&;70-&A_X1S5UAT  _T)
MJ /\5;X\?\IM?C-_VE/^(G_K6NL4 ?[5- 'QI_P4-_:M@_8=_8B_:;_:Q?2(
M/$%[\$?A/XB\6>'M!NY3!8ZWXR>.+1O ^CZC,KQRPZ7J?C#5-#LM3EMV-U'8
M3W#VD<URL43@'^1]^PS^RE^T]_P7;_X*.)\/_&'Q@U+4?B3\69_$7Q7^/'QY
M\=^;XHOO"?@+PZ;"+Q!XDAT+[?I9U:2Q-_H'@_P-X)TJ[T;1K2YU#P]H<$WA
MOPM8S7NE '^A!^SU_P &D_\ P1[^#>D:9'\1_AM\4/VF_$]K:V_V[Q%\6_BU
MXQT&PN-35%-U=6?A3X/ZA\-=$AL))?,^RZ5K*>(A;VS)#<WFH7$9O' /DG_@
MXI_X)U_\$U/V)/\ @C7^T1XA^ W[&O[/'PH^)WB'Q9\ _!'P]^(NA?#?P]<?
M$K2=3N?C;X$\1:[!H_Q$UNUU3QMIPU7P+X7\6Z;JHL-=A?4=+N;VQO3/97%S
M$X!^/G_!DC_R>[^V!_V:MIO_ *MOP;0!_I2T ?XJWQX_Y3:_&;_M*?\ $3_U
MK76* /\ :IH * /\5?\ :0_Y3;_'K_M*A\4?_6MM<H _VJ* /\0N'6?^&2/^
M"J</B+QU;WEG_P ,R_\ !0*+6_&%K=1EK^V7X,_M%K?Z_!/$X9FNXE\.722(
MP8M*""&SR ?[=5C?66IV5GJ6FW=KJ&G:A:V]]87]E/%=65[97<23VMW:7,#/
M!<6MS!)'-;SPN\4T3I)&S(P- %J@ H * "@ H _RLO\ @\5_Y2\VO_9J7P5_
M]/\ \2: /[S/^" G_*&O_@GO_P!D"TO_ -2#Q!0!^P- '\0__![O;^ 3^RE^
MQ)=ZA:V[?%&/]H3QU;^$+THGVN'P#-\-VD^(MK$^=XM[CQ#;_"V6= "ADM;8
ML5*J& /&_P#@QLO-??PM_P %*=/GDF/A:V\0?LGWFE1-(_V>/7[W3OVB(/$$
MD$/,2S3:=I_AE;J1=KLD%FK;U1/+ /KS_@]?_P"4<'[,_P#V>YX5_P#5$?'F
M@#Q;_@R# _X9H_;J.!D_'/X7 G'.!X!UC SZ#)P.V3ZT ?W$T ?YPW_![SX)
MU&P_:C_8=^(\EG,FD^*?@%\1?!-G?D?Z/<:CX!^(=KKNI6<9Z>=9VWQ)TF:8
M8&$OH.O8 UO^#=O_ ((5?\$T?^"GO[ ^K?'7]H#1OB[J7QB\'_'KX@_"CQ:W
MA'XJW7A;1TM]'T'P3XM\-M;Z':Z3-]G5] \:6*27,DTQN[R&\99 (_(@ /W@
M_P"(0G_@CA_T*7[0O_A]-5_^4M !_P 0A/\ P1P_Z%+]H7_P^FJ__*6@#[T_
MX)X_\$)_V!/^"8/QE\4_'G]ECP_\4--^(?C#X9:O\(M7O/''Q)U'QAIO_"&:
MYXJ\'>,M2M;72[BRL[>&^FUSP'X<E6_/F30P6T]O%L2[GW '\C?_  >0_P#!
M1KXHZ[^T1X+_ ."<'@/Q+K?A?X/?#KP'X8^)OQMTK2=4EL;?XH_$+QS(-<\'
M:+XIM;20?VEX:^'WAG3]%U_1-,O'6TN?$WBF\U2^TZ>Y\/>&;^U .@_X(E?\
M&IGPB_:K_9E^%W[9'[=WQ%^(<.A_&C1(O&WPM^ WPIU'2?"__%O]0=7\+^*?
MB)X]N;'7]2N)/&6FAM;T_P *>$[3P_<Z/HUUHMWJ'BJ?4K[4?#VC ']4?PK_
M .#='_@BY\(4M/\ A'_V#OACXDNK58]]Y\4]>^(WQ@>\E0#=/=V7Q.\9^*M'
M+3,-\D%OIMO8J24AM(HL1@ _S1?^#@+PS\%_!/\ P6 _;3\#_L]_#WP)\*?A
M-X&\6?#CP1X>^'_PS\)^'_ _@CPYJ?@[X(?#'PUXT@T3PMX6L-,T+2Q>>.=+
M\2:EJ(L[&%KS5KV^O[SS;ZZN9I #_7!_85_Y,B_8X_[-6_9Z_P#52>$* /0?
MC_\ LZ? K]JGX8:[\%_VC/A3X*^,GPN\2>2^J^#/'>B6VM:4UW:[S8ZK8&91
M=Z-KNF/(\NDZ_HUS8:WI-P?M&FW]K/B0 '\9O[?7_!EY\'?&0\1>.O\ @G;\
M<M3^#VOR)=7VG? CXYRZEXV^&=Q=89H-'\-_%.R2Y^(?@[3E"JD+>+-)^*UY
M-.Y\_5[2WP8@#^-G0/&/_!1O_@A=^VKK6DZ9J7C;]F7]H[X:7MC:^*_#3W,.
MJ>"?B/X2EF6_L+77=.AGN_!OQ6^%WBFW7[7IEVK:EISMC4-&O=+\1:;%=:>
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M(HFU"W^#WC76='URTM!(5>XO$A^+ME?_ &6#=*;&ROKLQF&SEDB /](&@ H
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M:?@Q0!_K(_L>@#]DC]EL   ?LY_!$  8  ^&?A@  #@ #H* /HR@ H * "@
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M^(KC!,>G:5X8^"WQ 2QNY  <";Q3J/AS3(CP%N-0@)( H _V J /\5;X\?\
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MWV;QKHTMK;(\0@CAOIVCF WVX!_9]_Q"$_\ !'#_ *%+]H7_ ,/IJO\ \I:
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M % !0!_G;U_I0?S.% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0!_9M_P2@_Y,"^ G_=4O_5T_$:OXA\7_ /DXG$/_
M '2?_5'EA^Y<'?\ ).9=_P!S?_J=B3]$J_-3Z8* "@ H * "@ H ^"?^"C&C
M>.=6_9YO9/"<W_$FTK7=.U'QO8PQ.;R\T&/S([>1)5<K]CL=4DL[F^MO)WR
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MKW1;.Y::/3H9&_.,_P#"_AK@CZ-N$XDXHIU8^(7&^=Y5FW#MTOK.&P-JDJ>
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M%?U7Q=QU##8O)>#\ [8'A?+:-&4$]/K=>E2;<TMZJP\*,YR>O/7J7LW)'PO
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M9?A,OHOFIX2C"ESM).<EK.HTMG4FY3:UM>U]#Z&KR3O/RA_X*6?\$??V7_\
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M6_"1#YRI;#Q?=?#SQ%XI^'Z6=Y,4BBT[QQ;Q0WSL(&LY6/EU]3A\X\.^.?\
M954R;-:\XM1PV-PJH8[;WOJ\<71H8KFBKMSPS;AOS+<\2KEW%_#'[_ES' TH
MM.5;#5G4PN^BJNA.I0LW;W:RL]K,_IU_X(<?\%X_$_[9WC2T_9+_ &N5\/VW
MQ[NM(O;[X7?%#0M-M_#^F_%L:%83:EK?ASQ+H%B$TC1?'MMI-I?:[87>@VNE
M^'/$&FV&H6<>DZ-J]C91^(OQ?Q+\+Z/#N&EGV0>U>5QJ1ACL#5FZL\![62A2
MK4:LOWE3"2FXTIQJN=6C.4&ZE2G-^R_1^#.-ZF;UEE6:\BQS@Y8;$PBJ<<5R
M+FG3J4XI0A74$YQ<%&G.,9+DA**]I_4[7X@?IAE:YK>C^&=$UCQ)XAU*ST;0
M/#VE:AK>N:OJ,Z6NGZ5H^DVDM_J6I7US(5CM[.QLK>:ZN9Y"$A@B>1B%4U=*
ME4K5*=&E"52K5G"E2IP7-.=2<E"$(16KE*348I;MI(F<X4X3J5)*%.G&4YRD
M[1C""O*3?112NWT2/\R#4)?$G_!;C_@LD4@;6+?P5\;/C"EK;/ATU'P=^SA\
M/8]GGA'5DL-7M_AMH#W7DR9M1XMU(P[O*F!K^T8*AX:^'NOLY8C*\NNU]C$9
MSBWMLG*G]=K6VO\ 5Z?D?SA+VG&/%MES*CC<99=Z.7T.O]V2PU/;;VLK'^FW
MX=\/:)X2\/Z%X4\,Z79Z)X;\,:-IGA[P_HNGQ""PTC1-%LH--TK2[&!?EAL[
M"PMH+2VB7B.&)$' K^+ZM6I7JU*]:<JE:M4G5JU)N\JE2I)SG.3ZRE)MM]6S
M^CJ=.%*G"E3BH4Z4(TZ<(JT80A%1C&*Z*,4DET2/\YO_ (."OV6_$O[$?_!2
M>W_:&^&8N?#7A?X\ZEIO[07PXU[2A]E_X1SXL>&=7T^;Q]8V4T8C\G5-+\8P
M:7XY@:"-([6S\8Z1#&\EQ;W##^N_"C.Z'$G!SRK&6K5\JA+*<91J6E[; 5J<
MUA9--MN$\/[3"RO]K#R>THGX!QWEE3)N(5C\,G3I8Z4<?AYP]WV>*ISBZ\4U
MHIQJ\M=6V5:-KV9_>G^Q!^TSH/[8G[)_P+_:1\/R6IB^)_@/3-5UNTM'5XM'
M\9:>9=#\<Z =A(230O%^F:UI+QY.W[)PS*5=OY=XER6KP]GV9Y-5O_L.*G3I
M2?\ R\P\K5,-5]*N'G3FO\1^WY-F,,VRO!9A"W^TT(RFEM"K'W*T/^W*L9Q^
M1]55X1Z9^,G_  <'?\H@OVO?^O3X*?\ K1?PBK]%\)_^2_R#US+_ -5&//D.
M//\ DE,T],)_ZG88_$'_ (-$K:VO8OV^K.\MX+NSN[3]G>VNK6YBCGMKFVG'
MQNBGM[B"56BF@FB9HY8I%:.2-F1U*DBOTGQ\;C_JK*+<91EF[BXNSBU_9C33
M6J:>S6Q\;X5)-9XFDTU@$TU=-/ZXFFMK6Z'YU_\ !<[_ ()<^)?^"<G[0^B_
MM/?LUV&M^&/V=?B+XQ@\1^"=6\+SWEK)\!OBY:77]O+X.M]3M'6ZT2PDNK27
MQ%\-+SSHGAL[*^T6VF:?PUY]Q]?X9<;4>+\IJ9-F[I5LWP6&='%4ZRBUFN7N
M/L?K+IR]VK-1DJ.-BD[MQK25JSM\_P :<-5.'\?#,<O4Z>7XBM[2A*DVG@<4
MGS^Q4EK!77M,,[Z*+@G>G=_U._\ !(__ (*EZ)_P4>_8[\6VGC;4])LOVH?@
M_P"!+_1/C-X=MQ;Z?)XGMCH=W::/\6-"TF/RXUT?Q4T+)KUMIT2V7A[Q6MW8
MK;:=I>H^'8[G\0X\X(J<(<0X:>&A.629ABH5,NK.\E0DJL)5,!5GJ_:8>Z]D
MYOFJX?EG>4XU>7],X5XEAQ!E-6-:4%F6$HRABZ:M'VBY&H8J$/Y*NTU'2G5O
M&T8RIW_CY_X-T_\ E++\ _\ L"_%G_U6_B:OZ!\7?^2%SC_K[@?_ %.H'Y-P
M#_R5.7?X<5_ZB5C_ $UJ_C _HX* /X$O^#I;]LA/BW^TY\.OV-_!&HOJ/A_]
MGK28M>\>V]@[317OQ?\ B'96=W::,8H!(EW/X6\$2:$L;1,\L&J^*M;TF:&*
MZT^56_J?P1X=^H9)B^(<3!0JYO4]EA7+1PR_!RE&535>[&OB?:>3AAZ<U=21
M^&^)>;_6LRP^4497IY?!3KV>CQ>(2:A9;NE1Y/256<='%G]7'_!(/]C:T_8=
M_8)^"?PCNK".U^(&OZ,OQ3^+]QL5;BY^)?C^VM-5U:QN'54$H\):4NB^!;.8
M1Q&XL/"]K<RQK<SSEOPSC_B)\3<4YECXROA*53ZCE\?LK!81NG3FO/$3]IBI
M?WZS2T2/T_A3*%DN1X/"N*C7G#ZSBWU>(KI2DG_UZCR4%_=I)[GX\_\ !U!^
MQ?<?$W]G3X<_MC>#]+^T^(_V>]8'@_XDFVA+7-Q\*O'NH6UKI>KRF-6DEC\)
M>.WTZV\I5Q'9>,]2U":2.VTV0U^@>!_$*P>;XSAW$3M1S6F\1@KOW8X["0<I
MTTNCQ&%4WYSP]."UF?)>)F4?6,OP^;TH7J8&:HXBR5WAJ\DH2?=4:W*K=%6D
M]HGJ'_!K[^V&?C9^QEXB_9J\3:O]L\;?LM>(Q9:)#=3%[V?X3>/;G4M;\+LA
ME)EN8-!\0P^*-"&UGCTS34T"P"P6YLHVXO&OA_\ L[B*CG5&GRX;/*+E5E%6
MBLPPJA3KWMHI5:+H5O[\W5EJ^8ZO#;-OKF45,NJ2O6RRIRP3W^JUG*=*W=0J
M*I#^['DCHK']-=?C!^C!0 4 % '\X/[1/_!O=IGB[_@J'X*_X*G_ +'_ .U=
M>?L8_%[3=?TGQC\3/!>E?!*#XF^#_BIXO62XT_QQJE\(/BO\,_[#L/BUX.N9
MO#7Q,T=+'5HO$5Y>:KXK%S:^(-8U"YF /Z/J "@ H _GI_X*M_\ !"'5?^"M
M?[3OP&^)GQN_;.\3>$_V7O@=%I$,'[)OA?X1+(/$+76LQ:C\2]7'Q;_X6MIS
MZ/XG^(>EV>E>&$U[_A76J/X3T32+)-*M9[J2_N;T _>_P5X+\)_#CP?X5^'W
M@+P[I'A'P/X'\.Z-X2\'^%= LH=-T/PWX9\.Z=;Z3H>A:/I]LJ066FZ5IMI;
M65E:PHL<%O!'&HPM '3T % '_]7^_B@ H * "@ H * /A?\ ;,_X*6_L,_\
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M#_.Q_P"#X7_DM?\ P3[_ .R6_'C_ -2SX<T ?N=_P:%_\H;O!W_9P7QU_P#3
MSI% ']0% !0!_+I_P=^?\H=/$7_9QOP-_P#2OQ'0!^(__!CM_P E=_X*&_\
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M&NF>$/%^L>']'U-?&/A[1&UGP5K5]9Z:)]7T[Q?X;LO#-A-M-GXTOFNEL[4
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M'QC)X.N/$NE:-8:AK/\ PAVNV/Q$\4Z?K&K:9;W<FB:C'H5Y?6#:-_:>IZ0
M?Z#GQ,_X+A_\$C?A1X&G\?\ B#_@H3^RUKVDQ:7=ZK!H_P -?BQX7^*_C6_C
MLX'F-G9> _AO?>)_%[:C<-']FM;*?1K>62Z(@.Q@^T _S//^"[G_  5O\;_\
M%@/VA+3XH>#_  =XW\$_LB? &.#X<?!OPUX@B69[#6O'0U36=1\:>/9]*>]\
M/Z-\1/BK;^"+M[#P[;ZM?1V7A/X>P:?IUWJL^B>(=7O #^G+_@Q[_P"2'_\
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MW]VL<_V+1_$,JWO@GQ'?"UO);'PSXIUF[M;66\AMP #_ "H?^"=_[<O[2_\
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M6O03Z7XCUSPUXY$$5MXW^(EWI$UQ9>#9O L]]H?AV[OU\5W7BJ/4]!LO#NL
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M<S0[K0ZC\/+O3K3X66)ED4VQNI?BYK?@G5C82AWOM%T+7?+B,=O/-  ?Z\-
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M/ U?T)FW_)C,H_[",/\ ^K/%'Y+@/^3GX_\ Z\U?_4*@?V-5_/9^M!0 4 %
M'\BW_!W'_P F]?LA_P#98_'O_J%V%?OG@)_R->(/^Q;A?_4H_*_%/_D7Y5_V
M&5O_ $PC]$/^":O_  3@_8$^(_\ P3^_8X\>>/OV-_V;_&'C3Q=^SM\+=?\
M%'BKQ%\(O!>K:]XAUO4_"]A=:AJVL:G>:3+=ZAJ%[<R23W-W<R2332,6=R:^
M2XRXPXIP?%G$6%PO$.;X?#8?.,=1H4*./Q%.E1I4Z\XPITX1FHPA&*2C&*22
M/?X=X?R3$9#E%>OE. JUJN7X:=2I/"TI3G.5.+<I2<;RDWNWJ?FA_P %U_\
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M/\MO]B2#0;'_ (+0?!"U_9^>5_ MK^W5#:_#)[)I6#_#.+XI7T.C%VY=K%_
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M'7@)?  _9L'PM$K>-+:PMO[6;Q3_ ,+\^(VP::MFS?V>/#A-XTJ_Z=:B(B0
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M!X]_Q Q_]91/_-)O_P KB@ _X@8_^LHG_FDW_P"5Q0 ?\0,?_643_P TF_\
MRN* /ZY_^"4_[ :_\$QOV(/A7^QJ/BN?C:?AIJWQ&U5OB.? H^&XUMO'_P 1
M/$_CWR5\'CQAX\_LL:2OB)=)WGQ3J)OS9'4-MD+D6-L ?HK0 4 % !0 4 %
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M>Y1]4\-_ 7X9ZSX@UK5[,?ZRVL/&OQ"U+PS8^'+ENJ7MQX \4Q)MVG3WW[D
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M  H(?"%= 6V\6Z1XI;63JO\ PNGXH'53(=)2Q73QIVF",3-<&]DV" @']*-
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MB#Q=K.N>*M5GUO7M6U>_TW2=!TE9;W4+F1X[32=$TO3K2()#;6<84E@#U_\
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M2_\ !1;]N+X[?MFK^WP?@Y_PNS4/!-^?AN?V6A\0_P#A&F\'_#/P7\.S&/&
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M1F\0K\/?!NC>$1KAT<7^JC23JPTC[>=-&IZB+$W'V47]YY7VB0 _,#_@JO\
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M%+/H.L:*NG_\):?VD?&7]B!&U4737/\ PC.KEUMS;BW0S">$ _3_ /X+A?\
M!%#QA_P66T_X >%X_P!L>7]FKP!\#[SQQKUUX/B^!)^+D'CCQAXN@T#3M/\
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M % !0 4 % '^=O7^E!_,X4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % ']FW_!*#_DP+X"?]U2_P#5T_$:OXA\7_\
MDXG$/_=)_P#5'EA^Y<'?\DYEW_<W_P"IV)/T2K\U/I@H * "@ H * "@ H ^
M0?VQ/V:_^&B? NE6>B_8+3QOX;U>UFT/4KW$47]E:E=6MMX@L;B<*SK +18]
M4C5%:1KG3([>(#[5)N_GCZ17@S4\7.&<MAD_U7#\59%F-&>5XO%3]C1EEV/K
M4,/G&$Q-11E+V,*"AF5.*C*;Q&7PHTE%XB3/V3P8\35X;Y[C*F/5>OD&:8*K
M3S#"4%S3^MX6E5JY97HP;454]LY824KI1H8NI.5U32/S>_;(N]>$_@?]GGX<
M>!O&>H_"[X-VEG9WUUIVA:LL7BKQ.+=/[1OOM<.FW$$IM?-FC6YC1HVU2\UJ
M8+<6\ED\?\9_2$KX^%;AOPAX.R#/JO _AIA:&$K8C#Y5C;9_Q!*C%9AF#K4L
M+.C)T8U<11C7C2E&68XO,Z\56H/#G]+>#-/ >SSWQ'XESO):/%?&U?$5J%'$
M9A@^?*,J527U:A[&>(IU(^VG"C-T92@U@L+@J=Z<Y5;>=_'CXO\ Q8^-'A7X
M?^ +'X%>*_ G@'P$+?R/#6EV'B*_34396\=C8-<7,N@VFQK+3UE@MR8)3YMW
M=W$IE>1!'\MXH>('&OB+D7"?">%\.\VX4X4X2HPIX3),OPF;XR.)J4</#!82
MM6Q%;+*%I8/!1K4,/^XF^?%8FM4=1S48_0\ \'\)\$YKQ#Q#7XYROB#B'B!R
M=3-,97RW#/#*K5GB<3&%"GF%;G6)Q/LJE7][#W*%.E!15Y/T?6M>^+_[6E]\
M'?@%I7PCUCX0?#?PU>6J7<36^L3:;#I>DV2VPU.^NK_1]*M%;1]$BOXK&VD7
M_3;Z^-NKM<WL$#_6YIFO'OCWB?#GPGRW@?'<"<)9-6I4Y4HT\QK8+#X3 X14
M'FV/Q6-P. I<^597'%PP5%^_BL=C'34I5\334?G,!@.#_"'#\:>(6*XNP7&'
M$F94:DJ4W+ PQ-3%XRNZGU/#X?#XS&U'''8Z6'GBJJLJ&$PTFU[.G*_VA^T3
MX"\#_&+X'^-/A!\)]0D/B+]FRZT2XMM TYV%L]WH_A^8-I+QAA;ZI.^E7.IV
MWVC;YT7B>QN=-N)X2^II+_1?C!PIPGXA^%_$GAUX?8OGS?P0K955IY+@ZD_9
M3GE^3U85,NG"G*4<7B*F6ULPH0Q"@\31S["U,-.I3<L6JGXKX;<0Y_P7Q[D?
M&G&&&MEOB=2Q\*F9XF$74]EC<QBOKT)27-AZ<,=1PU6=)R5.ME5:-6,91>'<
M? '(_;/_ &/C=2H;GXV? 42+YNQ7U+6+6PM0S[XV&Z8^)-%L8Y)54(UWXGT$
MA?(M;B:U;\HJ-?2-^CPZU1?6?$SPDCK.#E+%YKE]+"ISO%<]6;SO*<,I/_EY
M6X@R;GING1J.$OT.'_&D?&CV4'['@7Q M:#LL-@:M>NU"S?N)93F-7E5](91
MCN67-/WU[!\$?'_PV^/O[/#>-_BM\--,^*OCSX+://HGB*RN-%TC5_%%_ING
MQ&ZM-2L5U:2V$CZCIL$L]RKW4:7>KZ?J[6R+-)]F'Z'X:<6\%^*GA#4XGX]X
M*P7'W%GAAEM3+,WP[R_ 9AGN,RW#T_K.%Q^%6.JTG4EC,!1G5KPG73Q.8X',
M98>+J5(TY?%\<\/<3^'GB/\ V#PEQ/B^#^'N.<;3QV6UH8W&X+*L-B*]3V%7
M"XEX2%1QA@\545*G*-*3HX+$8/VKY$YGS[_PU7^P2IQ_PRS=94X(;P)X X*\
M$%3XA/0\%3]"*_,UXV?19T:\#:SV:_XQ[A5K[O[8::_!GZ#_ ,0I^D!_T=BF
MNG_(]XC7E_T+-#S;XO\ Q^_8M\>?#[Q%X9\(_ +5_!'B:\LO.\/^)](\)>"=
M*N=/U>U;SK-+B?3M;-PVF7;H+3453S2+6>22.WEFAB4_'>(/BC]'CBCA/-LF
MX;\*\?POGM:@JF4YW@,EX:P53"8^A)5:$,1/!YFZLL!B7'ZMC814Y+#U9U:5
M*5:E2/I.#_#_ ,:L@XARW,\Y\0<'GV54*W)F&58S-\^Q5/$X.JO9UG2AB<O]
ME'%THOVN%E+E7MH1C*<:<YL]_P#V2OC9XN^*_P"SC\0O@1X>UM=.^+GA/P=J
M<7@+4+QRLNJ>&[@- MA;3>;&UKJFF!GTFTOQ(O\ 9L&J:->QK<'2KV1OTOP'
M\1^(^-_![C/PERC,XX+Q R+AS'K@W&5IM5,?D59*#P6&JRJ0^KX_+74GEF%Q
M?/!8*CC<KQ=.G)8#$V^"\7>",EX3\2N&?$',<#+%<'9QG6$EQ'A:,;1PF:49
M*<ZU6"BU4PF.C!8ZIA[-XB>&Q^&<H>WHL^N?V+/@1_PI'X0V(UBQ-KXZ\:F'
MQ%XO,\/DW=H71_[(T&6,C?"-(M)Y'GMWR8=5O]4"[83%##_0/T:/"O\ XAGX
M>X>>98.>&XJXH='-^((UX\N)P<>1QRO)IIQC*FLLPDVZU*=Y0S'%X^\G%P4?
MQ_QPX_\ ]>N,\1]2Q$:V09$JF6Y,Z4KT<0E-/&YE#I+Z_B(WIR5E]3HX2-O<
M;?U]7]$GXT% !0!_'E^UC^T%\4?V&/\ @O+\:/VJ+#]DSX]_M#>"-;_9G\(_
M#"SC^%WA'Q#+:/J6L:)\/M1DO8O$47AO6=(N(]-;PQ/9WEI"QG2>X4,R&&1#
M_0F0Y3@N)O"S+<BGGN5Y3B:>=8C&R>,KT>90I5,3!1=!UJ52/.JZE&3T:CI>
M]U^29GCL5DG&^.S..58['T9Y?2PR6&I5+7G3P\N95%2G%J/LG%I=?0^F?^(C
M#QW_ -(F_P!MK_P3ZO\ _.[KQ?\ B$.%_P"B[X=_\"I__-AZ?_$0*_\ T2V<
M?^ S_P#F8/\ B(P\=_\ 2)O]MK_P3ZO_ /.[H_XA#A?^B[X=_P# J?\ \VA_
MK_B/^B6SC_P&?_S,?>O_  3W_P""JOB3]NSXL>+/AAK/[$W[0O[--OX7^']Y
MXYC\9?%NPOK70=9FM/$/A[0AX;L'N?"NAQG5IDUU]2C474C?9--NB(& ,D?R
MO%G U'A? 8?&T^),JSEU\5'"_5\"X.K33I5:OMI*.(JOV:]ER/W4N:<=>A[F
M0\3U,[Q57#3R;'9<J5!UE5Q2DH3M.$/9QO2I^][_ #;[1>A^O]?GY]8% 'Q;
M_P %#_V6M*_;._8P_: _9WO[6";5/&_@/4+CP1=2Q[FTGXC^&6B\3_#[5(F7
M$T:V_BS2-*CODMY(9+S29M0TUY!;WLRM]'PCGE3ASB/*<XA)J&%Q4%B8K_EY
M@ZUZ&+IM;/FP]2IRW^&:C):Q1X^?Y9'.,GQV7M>]6H-T7_)B*5JE"2[6JPBG
MM>+E'9L_F;_X(B_#+]I;]L']L[P#^T1^V%\/_%/AK2?^"=/[,/A7]GCX.VGC
M#PYK^C?VYXV(U_PSIGBF=?$,"1:QKNE^$9_%,NNZC;I*QUJ3P?JD5TMQI\;'
M]H\2L=DO#_#>+RCA[%4*M3B_/,1F^82P]:E4]GA%[&M*@O92;ITIXA4/91E_
MR[5>&J;/SG@S#9CFV;T,?FU"K3AP_EM+ 815:4Z:G6_>4X5&IQ2E.-+VKG)?
M;]E+HC^S:OYT/UX* "@#^"_]J/XL?M1_L1_\%X?VFOVNOA5^R+\4/CSIT8;P
MSI%M:^"_B'%X5UBV\3?"CP9I%UJ%EXG\.^%-;@NO[.E@D3;:K+$\\<D$DL;Q
ML!_4>28#)>)/"_)<@QV>X/*Y/]]-O$83V]-T,?B:D82H5J]-QYTUO9V::5FC
M\1S/%9EDW&V8YKA<JQ.-7\."5&O[*2J86C!M5*=*:?+;II=6/KG_ (B,_P#@
MH?\ ](D_&_\ X!?&_P!O^J7?YXKP/^(0\)_]%WA__ LM_P#FT]3_ %_S_P#Z
M):M_X#C?_F8/^(C/_@H?S_QJ4\;_ /@%\;^/K_Q:[_"C_B$/"?\ T7>'_P#
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MG:37UQ+%"LDA:@#OZ /Y'/\ @\S\:?#S2/\ @EQ\-_!/B6YL)/'GC/\ :O\
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H _RX?\ @\Z_Y2P?#/\ [,C^$7_JW/V@* /[E/\ @WZ_Y0S_
M /!/K_LA=O\ ^I7XGH _8J@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /\[>O]*#^9PH
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M>'["_P!5O];NK2RFU?POJ.H&!]4U2^NE2>\F$/GF&#R[>.**, ]9_P"(AO\
MX+1?]) /C#_X+/AW_P#,30!P7Q2_X+F?\%9?C7\-_'7P@^*?[;7Q3\9_#;XF
M>%-<\#^._"6IZ?X%CT[Q)X4\2:?/I6N:)>O8^$;2\2UU'3[F>UG:UN;><1R-
MY4L;88 'S[_P3+_Y21?\$^O^SWOV4?\ U?'@*@#_ '&J /\ %M_X+M_\IA?^
M"A__ &<QXY_]#M* &_ #_@N;_P %6_V6_@_X(^ 7P%_;"\7_  ]^$7PWT^\T
MKP3X,L_ _P (M9M= T^_U?4-=NK2WU+Q+\/=:UNXB?5-5O[E!?:G=& 3_9X#
M%:Q00Q@'L7_$27_P6Y_Z/U\<?^&S^ O_ ,ZF@#_3_P#^"-OQV^*_[37_  3!
M_8T^/'QR\7W'CWXL_$KX2Q:[XX\8W>FZ)H]UK^KQ^(M>TT7UQIWAS3-'T6VF
M-G86L4GV#3;5)6C,TB-/)+(X!_$]_P 'N7_)XW[&7_9L_B;_ -6EK= 'XZ?\
M$??^"\'QL_X(\^$/C=X-^%?P/^%GQ=T_XW>)/!OB;5;GX@:IXMTN\T.\\':9
MKNE0P:>WAR_MX+BVOH-:\R1;B$2PRVV5E=)MD0!]D?M@_P#!W5_P4R_::^&O
MB3X4?#K0?@Q^RKH'BRPETK6O&'P?TKQ?J'Q<;2;RWEM-4TO2?'/C+Q7K.F^&
MH=1@F=#JWAKPCI'B[3B%DT?Q/I\P,C 'SW_P21_X-TOVT?\ @I#XW\#>-OB)
MX(\9?LX?L=7\>F^*=>^.GCOP_<:+J?CWPE.UO=6]A\#O#.MK::EXUO\ Q79R
M$:1XX^QGX>:39_:=8N-8U>]MM.\,ZZ ?ZT/PP^&G@;X,_#CP'\(_AEX=L/"/
MPZ^&7A#P[X#\#>%]+C,>G^'_  IX4TFUT30=)M%8M(8K'3;*W@$DKR3S%#+/
M)),[NP!W5 'QO^W-^WK^S'_P3J^!.N_M!?M1_$&R\&>$M-6>S\.:#;>3?^.?
MB3XI%M)<6/@CX<>%_M%O=^)?$^I>7Q$CVVE:/9B;6_$NJ:)X>L=1U:T /\BG
M_@KK_P %6_C=_P %<?VGYOC)\0+.;PA\-_"4-[X4^ 'P2L-1EU72?AGX,O+J
M"6X\RX6&V37/'?C"YM+'4O''B<65O+J]Y:Z7I-E!9^'?#WA[2M. /[\?^#6?
M_@D%XQ_X)\_LV^+OVDOVA_#:^'?VE_VK]-\,W,'A#4K1HO$GPA^"6EK)J_AK
MP?KRSJLVD>+_ !IJE\OB[QOH&%ETF+3O!.AZQ#:^(O#^K65J ?U6T ?Q5_\
M![9\*='UC]B7]D'XVR60D\0_#S]J34_A?8:@ "UKH7Q>^%'B[Q3K=LWR[A%=
MZE\$_#;[MP19+:-2"TB4 ?-7_!CI\2-3GT;_ (**_"&[U"1]&TS4_P!F[XD>
M'M*+?N;;4]=M?C)X8\8Z@B?\]+VU\.^!;:5A_#I\(/1: /[Z: "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * /X@?^#C?_ ((+?M__ /!3+]N[P1^T+^RYHWPGU3X>:+^S3X"^%NH2
M>-/B5:^#]:A\5^&_B!\5_$.HQKIEUI=SYM@=-\8:,]O>17#+)*;F)DC:#Y@#
M^G#_ ()._LV_$W]C_P#X)S_LF?LS_&6VT6S^*'P>^&$7A3QG;>'=6CUW1(=6
M37M;U IIVKPQ01W]O]FOK<B9(D&\LFWY: /T.H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@#_.WK_2@_F<* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@#^S;_ ()0?\F!? 3_ +JE_P"KI^(U?Q#XO_\ )Q.(
M?^Z3_P"J/+#]RX._Y)S+O^YO_P!3L2?HE7YJ?3!0 4 % !0 4 % !0 4 ?)'
M[9_P,;XW?!S4[72+?S/&?@\R>)_"GEJ/M-W+:1;M2T.%N#NU>QC*6L6Y(Y-4
MM]-\V2*-6D7^?/I)>%TO$SP[Q<<MH1J\3<,NKG>0+E_>8ITJ368Y3"2BY?\
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#_]'^
M_B@ H * "@ H _RHO^#PC3]3LO\ @L%>7-_(SVNK_LQ_!'4-$5A@0Z9%<^-M
M)EC3U4ZSIFK2Y'\<C+VH _N0_P"#:S4=,U3_ ((A_L&7.DQK%:Q>#OBIITJ(
M<@ZGH_[07Q;TG6I#Z--K%E?3./X7<CM0!^YM '^+;_P7;_Y3"_\ !0__ +.8
M\<_^AVE '^A+_P $%?\ @GG^P%\6_P#@D/\ L0_$;XK?L.?L??$WXA>*OAMX
MBOO$_COXA?LS_!;QIXR\1WL7Q-\<V,5YKWBCQ'X*U+6]8NHK*UM;..XU"^N)
M4M;:"W5Q%#&B@'Z\_P##JW_@F!_TC@_8+_\ $/\ ]GO_ .=Y0!^?'_!67_@F
M]_P3O^'G_!,7]OWQWX _8*_8O\#>./!_[(OQZ\1^$O&7@_\ 9;^!WAGQ5X7\
M0Z1\.-?O=)UWP[XAT7P-9:OHFLZ7>0PW>G:IIEY;7ME<Q1SVT\4J*P /\N#_
M ()E_P#*2+_@GU_V>]^RC_ZOCP%0!_N-4 ?XMO\ P7;_ .4PO_!0_P#[.8\<
M_P#H=I0!_H=?\$#_ -@_]AWXI?\ !(+]A[Q_\3OV,_V4OB-X\\2_#7Q%>>(_
M&OCO]G?X0^+_ !;X@O(?B;XZLHKK6_$GB#P?J&L:K<Q6=K;6D<]]>3RI;6\$
M"L(HHT4 _7W_ (=G_P#!.'_I']^Q)_XBG\"?_F#H ^L/ _@3P/\ #'PGH?@+
MX;>#?"GP]\"^&+/^SO#7@OP/X=TCPGX3\/:?YLD_V'0_#F@V=AH^DV?GS33?
M9K"SMX?-EDDV;W8D _SEO^#W+_D\;]C+_LV?Q-_ZM+6Z /,_^#8+_@CW^PK_
M ,%/?A#^UYXB_:[^'?BGQCKWPM\>_#+PYX%U3PU\2/&G@:71-.\3^&_%6H:L
M#:^&M6LM-U*>2[TNREAEU:ROO(\HQHOER.C 'FW_  < _P#!MTW_  31\(P?
MM9?LE^(O&GQ)_9,FUJPT'XC>'/&TEIK'C[X$ZSK]Z+/P[J=[KVD:9I5IXD^&
M>N:G/;^&[/6;W3;'6O#>O7>A:1K-SX@?7H-6B /4?^#8K_@O%XM_9?\ BUX)
M_P""?_[5_CR\UC]E?XK:S9^%O@KXP\6ZF]P/V=?B1J\ZVV@Z$FK7TCOI_P '
MO'&I2PZ->Z5/*NC>!O$U[I_B>R.B:'>>-)[D _TV* /S'_X*N?\ !4KX#_\
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M4C#1;+X-?!W3[^(#Y'U/4_&WBRYTB1CV:*TTC6U0=Q*_]V@#_1AH * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@#_.WK_2@_F<* "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#^S
M;_@E!_R8%\!/^ZI?^KI^(U?Q#XO_ /)Q.(?^Z3_ZH\L/W+@[_DG,N_[F_P#U
M.Q)^B5?FI],% !0 4 % !0 4 % !0 4 ?C5\9_A3^T%^SE^T!X@^(W[,?A;7
M-;T3XBV%U>W=KH?A:X\36&E7-[=13ZQH^HV$$$T$.S5(AJNDS/' 8[2]2TM6
MF:UU%F_SB\1. _%?P=\7,VXN\&<ESO,,JXMP6)Q3AD^05<_PF7U<9B85LTRG
M'86GA<33I*&84H9CE=25.GR8;$+"T9S^K8E/^TN#.+?#SQ)\.<NX:\3LTR_
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H _]+^_B@ H * "@ H _S:/^#VSX(ZQH/[8_[('[17DG_A
M&_B?^S=K7P?BECB.Q?$GP5^)7B#Q=J+7,HRJS7>C_'+0H[9'VM+%IDWE;Q!+
MY8!^]?\ P9[?'W3OBE_P29C^$0EBCUS]F3X^?%/P%<V/F;KA_#_C^^M?C1HF
MM-'D^7:W^K_$#Q7I%O\ <WS^';T[. \@!_590!_BV_\ !=O_ )3"_P#!0_\
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M\?#MNSH#']ITR6(.9()4C /[FJ "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H _P [>O\ 2@_F<* "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@#^S;_@E!_R8%\!/^ZI?^KI^(U?
MQ#XO_P#)Q.(?^Z3_ .J/+#]RX._Y)S+O^YO_ -3L2?HE7YJ?3!0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MZ7>:Y=:7HMU!I-KJ6M:183W\EO%>:G86[2740!_HWT ?Y\O_  4J_P"#3_\
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % '__U/[^* "@ H * "@"M=V=IJ%I=6%_:V][
M8WMO-9WME=P17-I=VES$T-Q:W5M,KPSV\\+O%-!*C12Q,T;JRL10!_E!_P#!
M<#_@BC\??^"8/[<&C?%/]C+P1\5=>_9[^(GBK_A;G[.OBCX6:%XH\2^(_@1X
MW\-:U9:]=?#?4-1\/6E_JNC:CX UQM.UCX:^(+]DGU?PH^E"/4M4\2>&O%,]
MN ?Z$/\ P1A_;\\=?\%#/V)?!?Q1^,WPR\:_"?\ :#\#70^&'QX\.>+? GB'
MP-I^K^/] TO3KJ3QSX*@US2],AN_"_CG2;_3O$BV>G"6/POK%[JOA21YH]'M
M=0U  _62@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#^;S_ (.2
M?^"C7QN_8]_9-_X4-^R5X"^*GBS]IK]J'2M=\,V/C'X<^!_%OB*/X+?"I8UT
MWQKXY.L^'=*O8M,\<ZW'>'PK\/(DN+;4-.N[C6O&=O<6]SX3T^WU, _F._X-
M?/\ @A5XZ^-/[0-A^W9^U_\ #'Q7X'^#/[-_B[3=0^#7P^^(/AK5_"VI_%GX
MX:(]IK.C>)9]%URSL=1G^'GPKN#I^N-=-;QZ=XH\<_V-H\%QJ6F^'?&FDL ?
MZ6E !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0!_]7^_B@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@#_UO[^* "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /_7_OXH * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H _]#^_B@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M^'VOP"_Z)1\8/^_?@O\ ^:F@ _X?:_ +_HE'Q@_[]^"__FIH /\ A]K\ O\
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M_FIH /\ A]K\ O\ HE'Q@_[]^"__ )J: #_A]K\ O^B4?&#_ +]^"_\ YJ:
M#_A]K\ O^B4?&#_OWX+_ /FIH /^'VOP"_Z)1\8/^_?@O_YJ: #_ (?:_ +_
M *)1\8/^_?@O_P":F@ _X?:_ +_HE'Q@_P"_?@O_ .:F@ _X?:_ +_HE'Q@_
M[]^"_P#YJ: #_A]K\ O^B4?&#_OWX+_^:F@ _P"'VOP"_P"B4?&#_OWX+_\
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M]^"__FIH /\ A]K\ O\ HE'Q@_[]^"__ )J: #_A]K\ O^B4?&#_ +]^"_\
MYJ: #_A]K\ O^B4?&#_OWX+_ /FIH /^'VOP"_Z)1\8/^_?@O_YJ: #_ (?:
M_ +_ *)1\8/^_?@O_P":F@ _X?:_ +_HE'Q@_P"_?@O_ .:F@ _X?:_ +_HE
M'Q@_[]^"_P#YJ: #_A]K\ O^B4?&#_OWX+_^:F@ _P"'VOP"_P"B4?&#_OWX
M+_\ FIH /^'VOP"_Z)1\8/\ OWX+_P#FIH /^'VOP"_Z)1\8/^_?@O\ ^:F@
M _X?:_ +_HE'Q@_[]^"__FIH /\ A]K\ O\ HE'Q@_[]^"__ )J: #_A]K\
MO^B4?&#_ +]^"_\ YJ: #_A]K\ O^B4?&#_OWX+_ /FIH /^'VOP"_Z)1\8/
M^_?@O_YJ: #_ (?:_ +_ *)1\8/^_?@O_P":F@ _X?:_ +_HE'Q@_P"_?@O_
M .:F@ _X?:_ +_HE'Q@_[]^"_P#YJ: #_A]K\ O^B4?&#_OWX+_^:F@ _P"'
MVOP"_P"B4?&#_OWX+_\ FIH /^'VOP"_Z)1\8/\ OWX+_P#FIH /^'VOP"_Z
M)1\8/^_?@O\ ^:F@ _X?:_ +_HE'Q@_[]^"__FIH /\ A]K\ O\ HE'Q@_[]
M^"__ )J: #_A]K\ O^B4?&#_ +]^"_\ YJ: #_A]K\ O^B4?&#_OWX+_ /FI
MH /^'VOP"_Z)1\8/^_?@O_YJ: #_ (?:_ +_ *)1\8/^_?@O_P":F@ _X?:_
M +_HE'Q@_P"_?@O_ .:F@ _X?:_ +_HE'Q@_[]^"_P#YJ: #_A]K\ O^B4?&
M#_OWX+_^:F@ _P"'VOP"_P"B4?&#_OWX+_\ FIH /^'VOP"_Z)1\8/\ OWX+
M_P#FIH /^'VOP"_Z)1\8/^_?@O\ ^:F@ _X?:_ +_HE'Q@_[]^"__FIH /\
MA]K\ O\ HE'Q@_[]^"__ )J: #_A]K\ O^B4?&#_ +]^"_\ YJ: #_A]K\ O
M^B4?&#_OWX+_ /FIH /^'VOP"_Z)1\8/^_?@O_YJ: #_ (?:_ +_ *)1\8/^
M_?@O_P":F@ _X?:_ +_HE'Q@_P"_?@O_ .:F@ _X?:_ +_HE'Q@_[]^"_P#Y
MJ: #_A]K\ O^B4?&#_OWX+_^:F@ _P"'VOP"_P"B4?&#_OWX+_\ FIH /^'V
MOP"_Z)1\8/\ OWX+_P#FIH /^'VOP"_Z)1\8/^_?@O\ ^:F@ _X?:_ +_HE'
MQ@_[]^"__FIH /\ A]K\ O\ HE'Q@_[]^"__ )J: #_A]K\ O^B4?&#_ +]^
M"_\ YJ: #_A]K\ O^B4?&#_OWX+_ /FIH /^'VOP"_Z)1\8/^_?@O_YJ: #_
M (?:_ +_ *)1\8/^_?@O_P":F@ _X?:_ +_HE'Q@_P"_?@O_ .:F@ _X?:_
M+_HE'Q@_[]^"_P#YJ: #_A]K\ O^B4?&#_OWX+_^:F@ _P"'VOP"_P"B4?&#
M_OWX+_\ FIH /^'VOP"_Z)1\8/\ OWX+_P#FIH /^'VOP"_Z)1\8/^_?@O\
M^:F@ _X?:_ +_HE'Q@_[]^"__FIH /\ A]K\ O\ HE'Q@_[]^"__ )J: #_A
M]K\ O^B4?&#_ +]^"_\ YJ: #_A]K\ O^B4?&#_OWX+_ /FIH /^'VOP"_Z)
M1\8/^_?@O_YJ: #_ (?:_ +_ *)1\8/^_?@O_P":F@ _X?:_ +_HE'Q@_P"_
M?@O_ .:F@ _X?:_ +_HE'Q@_[]^"_P#YJ: #_A]K\ O^B4?&#_OWX+_^:F@
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MB4?&#_OWX+_^:F@ _P"'VOP"_P"B4?&#_OWX+_\ FIH /^'VOP"_Z)1\8/\
MOWX+_P#FIH /^'VOP"_Z)1\8/^_?@O\ ^:F@ _X?:_ +_HE'Q@_[]^"__FIH
M /\ A]K\ O\ HE'Q@_[]^"__ )J: #_A]K\ O^B4?&#_ +]^"_\ YJ: #_A]
MK\ O^B4?&#_OWX+_ /FIH /^'VOP"_Z)1\8/^_?@O_YJ: #_ (?:_ +_ *)1
M\8/^_?@O_P":F@ _X?:_ +_HE'Q@_P"_?@O_ .:F@ _X?:_ +_HE'Q@_[]^"
M_P#YJ: #_A]K\ O^B4?&#_OWX+_^:F@ _P"'VOP"_P"B4?&#_OWX+_\ FIH
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M^'VOP"_Z)1\8/^_?@O\ ^:F@ _X?:_ +_HE'Q@_[]^"__FIH /\ A]K\ O\
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M_FIH /\ A]K\ O\ HE'Q@_[]^"__ )J: #_A]K\ O^B4?&#_ +]^"_\ YJ:
M#_A]K\ O^B4?&#_OWX+_ /FIH /^'VOP"_Z)1\8/^_?@O_YJ: #_ (?:_ +_
M *)1\8/^_?@O_P":F@ _X?:_ +_HE'Q@_P"_?@O_ .:F@ _X?:_ +_HE'Q@_
M[]^"_P#YJ: #_A]K\ O^B4?&#_OWX+_^:F@ _P"'VOP"_P"B4?&#_OWX+_\
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M]^"__FIH /\ A]K\ O\ HE'Q@_[]^"__ )J: #_A]K\ O^B4?&#_ +]^"_\
MYJ: #_A]K\ O^B4?&#_OWX+_ /FIH /^'VOP"_Z)1\8/^_?@O_YJ: #_ (?:
M_ +_ *)1\8/^_?@O_P":F@ _X?:_ +_HE'Q@_P"_?@O_ .:F@ _X?:_ +_HE
M'Q@_[]^"_P#YJ: #_A]K\ O^B4?&#_OWX+_^:F@ _P"'VOP"_P"B4?&#_OWX
M+_\ FIH /^'VOP"_Z)1\8/\ OWX+_P#FIH /^'VOP"_Z)1\8/^_?@O\ ^:F@
M _X?:_ +_HE'Q@_[]^"__FIH /\ A]K\ O\ HE'Q@_[]^"__ )J: #_A]K\
MO^B4?&#_ +]^"_\ YJ: #_A]K\ O^B4?&#_OWX+_ /FIH /^'VOP"_Z)1\8/
M^_?@O_YJ: #_ (?:_ +_ *)1\8/^_?@O_P":F@ _X?:_ +_HE'Q@_P"_?@O_
M .:F@ _X?:_ +_HE'Q@_[]^"_P#YJ: #_A]K\ O^B4?&#_OWX+_^:F@ _P"'
MVOP"_P"B4?&#_OWX+_\ FIH /^'VOP"_Z)1\8/\ OWX+_P#FIH /^'VOP"_Z
M)1\8/^_?@O\ ^:F@ _X?:_ +_HE'Q@_[]^"__FIH /\ A]K\ O\ HE'Q@_[]
M^"__ )J: #_A]K\ O^B4?&#_ +]^"_\ YJ: #_A]K\ O^B4?&#_OWX+_ /FI
MH /^'VOP"_Z)1\8/^_?@O_YJ: #_ (?:_ +_ *)1\8/^_?@O_P":F@ _X?:_
M +_HE'Q@_P"_?@O_ .:F@ _X?:_ +_HE'Q@_[]^"_P#YJ: #_A]K\ O^B4?&
M#_OWX+_^:F@ _P"'VOP"_P"B4?&#_OWX+_\ FIH /^'VOP"_Z)1\8/\ OWX+
M_P#FIH /^'VOP"_Z)1\8/^_?@O\ ^:F@ _X?:_ +_HE'Q@_[]^"__FIH /\
MA]K\ O\ HE'Q@_[]^"__ )J: #_A]K\ O^B4?&#_ +]^"_\ YJ: #_A]K\ O
M^B4?&#_OWX+_ /FIH /^'VOP"_Z)1\8/^_?@O_YJ: #_ (?:_ +_ *)1\8/^
M_?@O_P":F@ _X?:_ +_HE'Q@_P"_?@O_ .:F@ _X?:_ +_HE'Q@_[]^"_P#Y
MJ: #_A]K\ O^B4?&#_OWX+_^:F@ _P"'VOP"_P"B4?&#_OWX+_\ FIH /^'V
MOP"_Z)1\8/\ OWX+_P#FIH /^'VOP"_Z)1\8/^_?@O\ ^:F@ _X?:_ +_HE'
MQ@_[]^"__FIH /\ A]K\ O\ HE'Q@_[]^"__ )J: #_A]K\ O^B4?&#_ +]^
M"_\ YJ: #_A]K\ O^B4?&#_OWX+_ /FIH /^'VOP"_Z)1\8/^_?@O_YJ: #_
M (?:_ +_ *)1\8/^_?@O_P":F@ _X?:_ +_HE'Q@_P"_?@O_ .:F@ _X?:_
M+_HE'Q@_[]^"_P#YJ: #_A]K\ O^B4?&#_OWX+_^:F@ _P"'VOP"_P"B4?&#
M_OWX+_\ FIH /^'VOP"_Z)1\8/\ OWX+_P#FIH /^'VOP"_Z)1\8/^_?@O\
M^:F@ _X?:_ +_HE'Q@_[]^"__FIH /\ A]K\ O\ HE'Q@_[]^"__ )J: #_A
M]K\ O^B4?&#_ +]^"_\ YJ: #_A]K\ O^B4?&#_OWX+_ /FIH /^'VOP"_Z)
M1\8/^_?@O_YJ: #_ (?:_ +_ *)1\8/^_?@O_P":F@ _X?:_ +_HE'Q@_P"_
M?@O_ .:F@ _X?:_ +_HE'Q@_[]^"_P#YJ: #_A]K\ O^B4?&#_OWX+_^:F@
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MB4?&#_OWX+_^:F@ _P"'VOP"_P"B4?&#_OWX+_\ FIH /^'VOP"_Z)1\8/\
MOWX+_P#FIH /^'VOP"_Z)1\8/^_?@O\ ^:F@ _X?:_ +_HE'Q@_[]^"__FIH
M /\ A]K\ O\ HE'Q@_[]^"__ )J: #_A]K\ O^B4?&#_ +]^"_\ YJ: #_A]
MK\ O^B4?&#_OWX+_ /FIH /^'VOP"_Z)1\8/^_?@O_YJ: #_ (?:_ +_ *)1
M\8/^_?@O_P":F@ _X?:_ +_HE'Q@_P"_?@O_ .:F@ _X?:_ +_HE'Q@_[]^"
M_P#YJ: #_A]K\ O^B4?&#_OWX+_^:F@ _P"'VOP"_P"B4?&#_OWX+_\ FIH
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M^'VOP"_Z)1\8/^_?@O\ ^:F@ _X?:_ +_HE'Q@_[]^"__FIH /\ A]K\ O\
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M_FIH /\ A]K\ O\ HE'Q@_[]^"__ )J: #_A]K\ O^B4?&#_ +]^"_\ YJ:
M#_A]K\ O^B4?&#_OWX+_ /FIH /^'VOP"_Z)1\8/^_?@O_YJ: #_ (?:_ +_
M *)1\8/^_?@O_P":F@ _X?:_ +_HE'Q@_P"_?@O_ .:F@ _X?:_ +_HE'Q@_
M[]^"_P#YJ: #_A]K\ O^B4?&#_OWX+_^:F@ _P"'VOP"_P"B4?&#_OWX+_\
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M]^"__FIH /\ A]K\ O\ HE'Q@_[]^"__ )J: #_A]K\ O^B4?&#_ +]^"_\
MYJ: #_A]K\ O^B4?&#_OWX+_ /FIH /^'VOP"_Z)1\8/^_?@O_YJ: #_ (?:
M_ +_ *)1\8/^_?@O_P":F@ _X?:_ +_HE'Q@_P"_?@O_ .:F@ _X?:_ +_HE
M'Q@_[]^"_P#YJ: #_A]K\ O^B4?&#_OWX+_^:F@ _P"'VOP"_P"B4?&#_OWX
M+_\ FIH /^'VOP"_Z)1\8/\ OWX+_P#FIH /^'VOP"_Z)1\8/^_?@O\ ^:F@
M _X?:_ +_HE'Q@_[]^"__FIH /\ A]K\ O\ HE'Q@_[]^"__ )J: #_A]K\
MO^B4?&#_ +]^"_\ YJ: #_A]K\ O^B4?&#_OWX+_ /FIH /^'VOP"_Z)1\8/
M^_?@O_YJ: #_ (?:_ +_ *)1\8/^_?@O_P":F@ _X?:_ +_HE'Q@_P"_?@O_
M .:F@ _X?:_ +_HE'Q@_[]^"_P#YJ: #_A]K\ O^B4?&#_OWX+_^:F@ _P"'
MVOP"_P"B4?&#_OWX+_\ FIH /^'VOP"_Z)1\8/\ OWX+_P#FIH /^'VOP"_Z
M)1\8/^_?@O\ ^:F@ _X?:_ +_HE'Q@_[]^"__FIH /\ A]K\ O\ HE'Q@_[]
M^"__ )J: #_A]K\ O^B4?&#_ +]^"_\ YJ: #_A]K\ O^B4?&#_OWX+_ /FI
MH /^'VOP"_Z)1\8/^_?@O_YJ: #_ (?:_ +_ *)1\8/^_?@O_P":F@ _X?:_
M +_HE'Q@_P"_?@O_ .:F@ _X?:_ +_HE'Q@_[]^"_P#YJ: #_A]K\ O^B4?&
M#_OWX+_^:F@ _P"'VOP"_P"B4?&#_OWX+_\ FIH /^'VOP"_Z)1\8/\ OWX+
M_P#FIH /^'VOP"_Z)1\8/^_?@O\ ^:F@ _X?:_ +_HE'Q@_[]^"__FIH /\
MA]K\ O\ HE'Q@_[]^"__ )J: #_A]K\ O^B4?&#_ +]^"_\ YJ: #_A]K\ O
M^B4?&#_OWX+_ /FIH /^'VOP"_Z)1\8/^_?@O_YJ: #_ (?:_ +_ *)1\8/^
M_?@O_P":F@ _X?:_ +_HE'Q@_P"_?@O_ .:F@ _X?:_ +_HE'Q@_[]^"_P#Y
MJ: #_A]K\ O^B4?&#_OWX+_^:F@ _P"'VOP"_P"B4?&#_OWX+_\ FIH /^'V
MOP"_Z)1\8/\ OWX+_P#FIH /^'VOP"_Z)1\8/^_?@O\ ^:F@ _X?:_ +_HE'
MQ@_[]^"__FIH /\ A]K\ O\ HE'Q@_[]^"__ )J: #_A]K\ O^B4?&#_ +]^
M"_\ YJ: #_A]K\ O^B4?&#_OWX+_ /FIH /^'VOP"_Z)1\8/^_?@O_YJ: #_
M (?:_ +_ *)1\8/^_?@O_P":F@ _X?:_ +_HE'Q@_P"_?@O_ .:F@ _X?:_
M+_HE'Q@_[]^"_P#YJ: #_A]K\ O^B4?&#_OWX+_^:F@ _P"'VOP"_P"B4?&#
M_OWX+_\ FIH /^'VOP"_Z)1\8/\ OWX+_P#FIH /^'VOP"_Z)1\8/^_?@O\
M^:F@ _X?:_ +_HE'Q@_[]^"__FIH /\ A]K\ O\ HE'Q@_[]^"__ )J: #_A
M]K\ O^B4?&#_ +]^"_\ YJ: #_A]K\ O^B4?&#_OWX+_ /FIH /^'VOP"_Z)
M1\8/^_?@O_YJ: #_ (?:_ +_ *)1\8/^_?@O_P":F@ _X?:_ +_HE'Q@_P"_
M?@O_ .:F@ _X?:_ +_HE'Q@_[]^"_P#YJ: #_A]K\ O^B4?&#_OWX+_^:F@
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MB4?&#_OWX+_^:F@ _P"'VOP"_P"B4?&#_OWX+_\ FIH /^'VOP"_Z)1\8/\
MOWX+_P#FIH /^'VOP"_Z)1\8/^_?@O\ ^:F@ _X?:_ +_HE'Q@_[]^"__FIH
M /\ A]K\ O\ HE'Q@_[]^"__ )J: #_A]K\ O^B4?&#_ +]^"_\ YJ: #_A]
MK\ O^B4?&#_OWX+_ /FIH /^'VOP"_Z)1\8/^_?@O_YJ: #_ (?:_ +_ *)1
M\8/^_?@O_P":F@ _X?:_ +_HE'Q@_P"_?@O_ .:F@ _X?:_ +_HE'Q@_[]^"
M_P#YJ: #_A]K\ O^B4?&#_OWX+_^:F@ _P"'VOP"_P"B4?&#_OWX+_\ FIH
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M^'VOP"_Z)1\8/^_?@O\ ^:F@ _X?:_ +_HE'Q@_[]^"__FIH /\ A]K\ O\
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M_FIH /\ A]K\ O\ HE'Q@_[]^"__ )J: #_A]K\ O^B4?&#_ +]^"_\ YJ:
M#_A]K\ O^B4?&#_OWX+_ /FIH /^'VOP"_Z)1\8/^_?@O_YJ: #_ (?:_ +_
M *)1\8/^_?@O_P":F@ _X?:_ +_HE'Q@_P"_?@O_ .:F@ _X?:_ +_HE'Q@_
M[]^"_P#YJ: #_A]K\ O^B4?&#_OWX+_^:F@ _P"'VOP"_P"B4?&#_OWX+_\
MFIH /^'VOP"_Z)1\8/\ OWX+_P#FIH /^'VOP"_Z)1\8/^_?@O\ ^:F@ _X?
M:_ +_HE'Q@_[]^"__FIH /\ A]K\ O\ HE'Q@_[]^"__ )J: #_A]K\ O^B4
M?&#_ +]^"_\ YJ: #_A]K\ O^B4?&#_OWX+_ /FIH /^'VOP"_Z)1\8/^_?@
MO_YJ: #_ (?:_ +_ *)1\8/^_?@O_P":F@ _X?:_ +_HE'Q@_P"_?@O_ .:F
M@ _X?:_ +_HE'Q@_[]^"_P#YJ: #_A]K\ O^B4?&#_OWX+_^:F@ _P"'VOP"
M_P"B4?&#_OWX+_\ FIH /^'VOP"_Z)1\8/\ OWX+_P#FIH /^'VOP"_Z)1\8
M/^_?@O\ ^:F@ _X?:_ +_HE'Q@_[]^"__FIH /\ A]K\ O\ HE'Q@_[]^"__
M )J: #_A]K\ O^B4?&#_ +]^"_\ YJ: #_A]K\ O^B4?&#_OWX+_ /FIH /^
M'VOP"_Z)1\8/^_?@O_YJ: #_ (?:_ +_ *)1\8/^_?@O_P":F@ _X?:_ +_H
ME'Q@_P"_?@O_ .:F@ _X?:_ +_HE'Q@_[]^"_P#YJ: #_A]K\ O^B4?&#_OW
MX+_^:F@ _P"'VOP"_P"B4?&#_OWX+_\ FIH /^'VOP"_Z)1\8/\ OWX+_P#F
MIH /^'VOP"_Z)1\8/^_?@O\ ^:F@ _X?:_ +_HE'Q@_[]^"__FIH /\ A]K\
M O\ HE'Q@_[]^"__ )J: #_A]K\ O^B4?&#_ +]^"_\ YJ: #_A]K\ O^B4?
M&#_OWX+_ /FIH /^'VOP"_Z)1\8/^_?@O_YJ: #_ (?:_ +_ *)1\8/^_?@O
M_P":F@ _X?:_ +_HE'Q@_P"_?@O_ .:F@ _X?:_ +_HE'Q@_[]^"_P#YJ: #
M_A]K\ O^B4?&#_OWX+_^:F@ _P"'VOP"_P"B4?&#_OWX+_\ FIH /^'VOP"_
MZ)1\8/\ OWX+_P#FIH /^'VOP"_Z)1\8/^_?@O\ ^:F@ _X?:_ +_HE'Q@_[
M]^"__FIH /\ A]K\ O\ HE'Q@_[]^"__ )J: #_A]K\ O^B4?&#_ +]^"_\
MYJ: #_A]K\ O^B4?&#_OWX+_ /FIH /^'VOP"_Z)1\8/^_?@O_YJ: #_ (?:
M_ +_ *)1\8/^_?@O_P":F@ _X?:_ +_HE'Q@_P"_?@O_ .:F@ _X?:_ +_HE
M'Q@_[]^"_P#YJ: #_A]K\ O^B4?&#_OWX+_^:F@ _P"'VOP"_P"B4?&#_OWX
M+_\ FIH /^'VOP"_Z)1\8/\ OWX+_P#FIH /^'VOP"_Z)1\8/^_?@O\ ^:F@
M _X?:_ +_HE'Q@_[]^"__FIH /\ A]K\ O\ HE'Q@_[]^"__ )J: #_A]K\
MO^B4?&#_ +]^"_\ YJ: #_A]K\ O^B4?&#_OWX+_ /FIH /^'VOP"_Z)1\8/
M^_?@O_YJ: #_ (?:_ +_ *)1\8/^_?@O_P":F@ _X?:_ +_HE'Q@_P"_?@O_
M .:F@ _X?:_ +_HE'Q@_[]^"_P#YJ: #_A]K\ O^B4?&#_OWX+_^:F@ _P"'
MVOP"_P"B4?&#_OWX+_\ FIH /^'VOP"_Z)1\8/\ OWX+_P#FIH /^'VOP"_Z
M)1\8/^_?@O\ ^:F@ _X?:_ +_HE'Q@_[]^"__FIH /\ A]K\ O\ HE'Q@_[]
M^"__ )J: #_A]K\ O^B4?&#_ +]^"_\ YJ: #_A]K\ O^B4?&#_OWX+_ /FI
MH /^'VOP"_Z)1\8/^_?@O_YJ: #_ (?:_ +_ *)1\8/^_?@O_P":F@ _X?:_
M +_HE'Q@_P"_?@O_ .:F@ _X?:_ +_HE'Q@_[]^"_P#YJ: #_A]K\ O^B4?&
M#_OWX+_^:F@ _P"'VOP"_P"B4?&#_OWX+_\ FIH /^'VOP"_Z)1\8/\ OWX+
M_P#FIH /^'VOP"_Z)1\8/^_?@O\ ^:F@ _X?:_ +_HE'Q@_[]^"__FIH /\
MA]K\ O\ HE'Q@_[]^"__ )J: #_A]K\ O^B4?&#_ +]^"_\ YJ: #_A]K\ O
M^B4?&#_OWX+_ /FIH /^'VOP"_Z)1\8/^_?@O_YJ: #_ (?:_ +_ *)1\8/^
M_?@O_P":F@ _X?:_ +_HE'Q@_P"_?@O_ .:F@ _X?:_ +_HE'Q@_[]^"_P#Y
MJ: #_A]K\ O^B4?&#_OWX+_^:F@ _P"'VOP"_P"B4?&#_OWX+_\ FIH /^'V
MOP"_Z)1\8/\ OWX+_P#FIH /^'VOP"_Z)1\8/^_?@O\ ^:F@ _X?:_ +_HE'
MQ@_[]^"__FIH /\ A]K\ O\ HE'Q@_[]^"__ )J: #_A]K\ O^B4?&#_ +]^
M"_\ YJ: #_A]K\ O^B4?&#_OWX+_ /FIH /^'VOP"_Z)1\8/^_?@O_YJ: #_
M (?:_ +_ *)1\8/^_?@O_P":F@ _X?:_ +_HE'Q@_P"_?@O_ .:F@ _X?:_
M+_HE'Q@_[]^"_P#YJ: #_A]K\ O^B4?&#_OWX+_^:F@ _P"'VOP"_P"B4?&#
M_OWX+_\ FIH /^'VOP"_Z)1\8/\ OWX+_P#FIH /^'VOP"_Z)1\8/^_?@O\
M^:F@ _X?:_ +_HE'Q@_[]^"__FIH /\ A]K\ O\ HE'Q@_[]^"__ )J: #_A
M]K\ O^B4?&#_ +]^"_\ YJ: #_A]K\ O^B4?&#_OWX+_ /FIH /^'VOP"_Z)
M1\8/^_?@O_YJ: #_ (?:_ +_ *)1\8/^_?@O_P":F@ _X?:_ +_HE'Q@_P"_
M?@O_ .:F@ _X?:_ +_HE'Q@_[]^"_P#YJ: #_A]K\ O^B4?&#_OWX+_^:F@
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M /\ ARE^RQ_T/W[0'_A4_#K_ .=50 ?\.4OV6/\ H?OV@/\ PJ?AU_\ .JH
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M_P *GX=?_.JH /\ ARE^RQ_T/W[0'_A4_#K_ .=50 ?\.4OV6/\ H?OV@/\
MPJ?AU_\ .JH /^'*7[+'_0_?M ?^%3\.O_G54 '_  Y2_98_Z'[]H#_PJ?AU
M_P#.JH /^'*7[+'_ $/W[0'_ (5/PZ_^=50 ?\.4OV6/^A^_: _\*GX=?_.J
MH /^'*7[+'_0_?M ?^%3\.O_ )U5 !_PY2_98_Z'[]H#_P *GX=?_.JH /\
MARE^RQ_T/W[0'_A4_#K_ .=50 ?\.4OV6/\ H?OV@/\ PJ?AU_\ .JH /^'*
M7[+'_0_?M ?^%3\.O_G54 '_  Y2_98_Z'[]H#_PJ?AU_P#.JH /^'*7[+'_
M $/W[0'_ (5/PZ_^=50 ?\.4OV6/^A^_: _\*GX=?_.JH /^'*7[+'_0_?M
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M4 '_  Y2_98_Z'[]H#_PJ?AU_P#.JH /^'*7[+'_ $/W[0'_ (5/PZ_^=50
M?\.4OV6/^A^_: _\*GX=?_.JH /^'*7[+'_0_?M ?^%3\.O_ )U5 !_PY2_9
M8_Z'[]H#_P *GX=?_.JH /\ ARE^RQ_T/W[0'_A4_#K_ .=50 ?\.4OV6/\
MH?OV@/\ PJ?AU_\ .JH /^'*7[+'_0_?M ?^%3\.O_G54 '_  Y2_98_Z'[]
MH#_PJ?AU_P#.JH /^'*7[+'_ $/W[0'_ (5/PZ_^=50 ?\.4OV6/^A^_: _\
M*GX=?_.JH /^'*7[+'_0_?M ?^%3\.O_ )U5 !_PY2_98_Z'[]H#_P *GX=?
M_.JH /\ ARE^RQ_T/W[0'_A4_#K_ .=50 ?\.4OV6/\ H?OV@/\ PJ?AU_\
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M /\ ARE^RQ_T/W[0'_A4_#K_ .=50 ?\.4OV6/\ H?OV@/\ PJ?AU_\ .JH
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M_P *GX=?_.JH /\ ARE^RQ_T/W[0'_A4_#K_ .=50 ?\.4OV6/\ H?OV@/\
MPJ?AU_\ .JH /^'*7[+'_0_?M ?^%3\.O_G54 '_  Y2_98_Z'[]H#_PJ?AU
M_P#.JH /^'*7[+'_ $/W[0'_ (5/PZ_^=50 ?\.4OV6/^A^_: _\*GX=?_.J
MH /^'*7[+'_0_?M ?^%3\.O_ )U5 !_PY2_98_Z'[]H#_P *GX=?_.JH /\
MARE^RQ_T/W[0'_A4_#K_ .=50 ?\.4OV6/\ H?OV@/\ PJ?AU_\ .JH /^'*
M7[+'_0_?M ?^%3\.O_G54 '_  Y2_98_Z'[]H#_PJ?AU_P#.JH /^'*7[+'_
M $/W[0'_ (5/PZ_^=50 ?\.4OV6/^A^_: _\*GX=?_.JH /^'*7[+'_0_?M
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M4 '_  Y2_98_Z'[]H#_PJ?AU_P#.JH /^'*7[+'_ $/W[0'_ (5/PZ_^=50
M?\.4OV6/^A^_: _\*GX=?_.JH /^'*7[+'_0_?M ?^%3\.O_ )U5 !_PY2_9
M8_Z'[]H#_P *GX=?_.JH /\ ARE^RQ_T/W[0'_A4_#K_ .=50 ?\.4OV6/\
MH?OV@/\ PJ?AU_\ .JH /^'*7[+'_0_?M ?^%3\.O_G54 '_  Y2_98_Z'[]
MH#_PJ?AU_P#.JH /^'*7[+'_ $/W[0'_ (5/PZ_^=50 ?\.4OV6/^A^_: _\
M*GX=?_.JH /^'*7[+'_0_?M ?^%3\.O_ )U5 !_PY2_98_Z'[]H#_P *GX=?
M_.JH /\ ARE^RQ_T/W[0'_A4_#K_ .=50 ?\.4OV6/\ H?OV@/\ PJ?AU_\
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M /\ ARE^RQ_T/W[0'_A4_#K_ .=50 ?\.4OV6/\ H?OV@/\ PJ?AU_\ .JH
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M_P *GX=?_.JH /\ ARE^RQ_T/W[0'_A4_#K_ .=50 ?\.4OV6/\ H?OV@/\
MPJ?AU_\ .JH /^'*7[+'_0_?M ?^%3\.O_G54 '_  Y2_98_Z'[]H#_PJ?AU
M_P#.JH /^'*7[+'_ $/W[0'_ (5/PZ_^=50 ?\.4OV6/^A^_: _\*GX=?_.J
MH /^'*7[+'_0_?M ?^%3\.O_ )U5 !_PY2_98_Z'[]H#_P *GX=?_.JH /\
MARE^RQ_T/W[0'_A4_#K_ .=50 ?\.4OV6/\ H?OV@/\ PJ?AU_\ .JH /^'*
M7[+'_0_?M ?^%3\.O_G54 '_  Y2_98_Z'[]H#_PJ?AU_P#.JH /^'*7[+'_
M $/W[0'_ (5/PZ_^=50 ?\.4OV6/^A^_: _\*GX=?_.JH /^'*7[+'_0_?M
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M4 '_  Y2_98_Z'[]H#_PJ?AU_P#.JH /^'*7[+'_ $/W[0'_ (5/PZ_^=50
M?\.4OV6/^A^_: _\*GX=?_.JH /^'*7[+'_0_?M ?^%3\.O_ )U5 !_PY2_9
M8_Z'[]H#_P *GX=?_.JH /\ ARE^RQ_T/W[0'_A4_#K_ .=50 ?\.4OV6/\
MH?OV@/\ PJ?AU_\ .JH /^'*7[+'_0_?M ?^%3\.O_G54 '_  Y2_98_Z'[]
MH#_PJ?AU_P#.JH /^'*7[+'_ $/W[0'_ (5/PZ_^=50 ?\.4OV6/^A^_: _\
M*GX=?_.JH /^'*7[+'_0_?M ?^%3\.O_ )U5 !_PY2_98_Z'[]H#_P *GX=?
M_.JH /\ ARE^RQ_T/W[0'_A4_#K_ .=50 ?\.4OV6/\ H?OV@/\ PJ?AU_\
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M /\ ARE^RQ_T/W[0'_A4_#K_ .=50 ?\.4OV6/\ H?OV@/\ PJ?AU_\ .JH
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M_P *GX=?_.JH /\ ARE^RQ_T/W[0'_A4_#K_ .=50 ?\.4OV6/\ H?OV@/\
MPJ?AU_\ .JH /^'*7[+'_0_?M ?^%3\.O_G54 '_  Y2_98_Z'[]H#_PJ?AU
M_P#.JH /^'*7[+'_ $/W[0'_ (5/PZ_^=50 ?\.4OV6/^A^_: _\*GX=?_.J
MH /^'*7[+'_0_?M ?^%3\.O_ )U5 !_PY2_98_Z'[]H#_P *GX=?_.JH /\
MARE^RQ_T/W[0'_A4_#K_ .=50 ?\.4OV6/\ H?OV@/\ PJ?AU_\ .JH /^'*
M7[+'_0_?M ?^%3\.O_G54 '_  Y2_98_Z'[]H#_PJ?AU_P#.JH /^'*7[+'_
M $/W[0'_ (5/PZ_^=50 ?\.4OV6/^A^_: _\*GX=?_.JH /^'*7[+'_0_?M
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M4 '_  Y2_98_Z'[]H#_PJ?AU_P#.JH /^'*7[+'_ $/W[0'_ (5/PZ_^=50
M?\.4OV6/^A^_: _\*GX=?_.JH /^'*7[+'_0_?M ?^%3\.O_ )U5 !_PY2_9
M8_Z'[]H#_P *GX=?_.JH /\ ARE^RQ_T/W[0'_A4_#K_ .=50 ?\.4OV6/\
MH?OV@/\ PJ?AU_\ .JH /^'*7[+'_0_?M ?^%3\.O_G54 '_  Y2_98_Z'[]
MH#_PJ?AU_P#.JH /^'*7[+'_ $/W[0'_ (5/PZ_^=50 ?\.4OV6/^A^_: _\
M*GX=?_.JH /^'*7[+'_0_?M ?^%3\.O_ )U5 !_PY2_98_Z'[]H#_P *GX=?
M_.JH /\ ARE^RQ_T/W[0'_A4_#K_ .=50 ?\.4OV6/\ H?OV@/\ PJ?AU_\
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M /\ ARE^RQ_T/W[0'_A4_#K_ .=50 ?\.4OV6/\ H?OV@/\ PJ?AU_\ .JH
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M_P *GX=?_.JH /\ ARE^RQ_T/W[0'_A4_#K_ .=50 ?\.4OV6/\ H?OV@/\
MPJ?AU_\ .JH /^'*7[+'_0_?M ?^%3\.O_G54 '_  Y2_98_Z'[]H#_PJ?AU
M_P#.JH /^'*7[+'_ $/W[0'_ (5/PZ_^=50 ?\.4OV6/^A^_: _\*GX=?_.J
MH /^'*7[+'_0_?M ?^%3\.O_ )U5 !_PY2_98_Z'[]H#_P *GX=?_.JH /\
MARE^RQ_T/W[0'_A4_#K_ .=50 ?\.4OV6/\ H?OV@/\ PJ?AU_\ .JH /^'*
M7[+'_0_?M ?^%3\.O_G54 '_  Y2_98_Z'[]H#_PJ?AU_P#.JH /^'*7[+'_
M $/W[0'_ (5/PZ_^=50 ?\.4OV6/^A^_: _\*GX=?_.JH /^'*7[+'_0_?M
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M4 '_  Y2_98_Z'[]H#_PJ?AU_P#.JH /^'*7[+'_ $/W[0'_ (5/PZ_^=50
M?\.4OV6/^A^_: _\*GX=?_.JH /^'*7[+'_0_?M ?^%3\.O_ )U5 !_PY2_9
M8_Z'[]H#_P *GX=?_.JH /\ ARE^RQ_T/W[0'_A4_#K_ .=50 ?\.4OV6/\
MH?OV@/\ PJ?AU_\ .JH /^'*7[+'_0_?M ?^%3\.O_G54 '_  Y2_98_Z'[]
MH#_PJ?AU_P#.JH /^'*7[+'_ $/W[0'_ (5/PZ_^=50 ?\.4OV6/^A^_: _\
M*GX=?_.JH /^'*7[+'_0_?M ?^%3\.O_ )U5 !_PY2_98_Z'[]H#_P *GX=?
M_.JH /\ ARE^RQ_T/W[0'_A4_#K_ .=50 ?\.4OV6/\ H?OV@/\ PJ?AU_\
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M /\ ARE^RQ_T/W[0'_A4_#K_ .=50 ?\.4OV6/\ H?OV@/\ PJ?AU_\ .JH
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M_P *GX=?_.JH /\ ARE^RQ_T/W[0'_A4_#K_ .=50 ?\.4OV6/\ H?OV@/\
MPJ?AU_\ .JH /^'*7[+'_0_?M ?^%3\.O_G54 '_  Y2_98_Z'[]H#_PJ?AU
M_P#.JH /^'*7[+'_ $/W[0'_ (5/PZ_^=50 ?\.4OV6/^A^_: _\*GX=?_.J
MH /^'*7[+'_0_?M ?^%3\.O_ )U5 !_PY2_98_Z'[]H#_P *GX=?_.JH /\
MARE^RQ_T/W[0'_A4_#K_ .=50 ?\.4OV6/\ H?OV@/\ PJ?AU_\ .JH /^'*
M7[+'_0_?M ?^%3\.O_G54 '_  Y2_98_Z'[]H#_PJ?AU_P#.JH /^'*7[+'_
M $/W[0'_ (5/PZ_^=50 ?\.4OV6/^A^_: _\*GX=?_.JH /^'*7[+'_0_?M
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M_B@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@#_U/[^* "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * /_5_OXH * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H _];^_B@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@#_U_[^* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H _SMZ_TH/YG"@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H _LV_P""4'_)@7P$_P"ZI?\ JZ?B
M-7\0^+__ "<3B'_ND_\ JCRP_<N#O^2<R[_N;_\ 4[$GZ)5^:GTP4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '_]#^_B@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /\
M[>O]*#^9PH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * /[-O\ @E!_R8%\!/\ NJ7_ *NGXC5_$/B__P G$XA_[I/_
M *H\L/W+@[_DG,N_[F__ %.Q)^B5?FI],% !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0!__1_OXH * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@#_.WK_2@_F<* "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#^S;_
M ()0?\F!? 3_ +JE_P"KI^(U?Q#XO_\ )Q.(?^Z3_P"J/+#]RX._Y)S+O^YO
M_P!3L2?HE7YJ?3!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 ?_TO[^* "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M?QA\;?A]X-\0(_A_QEH^N^'KS[9X>UW4[)6O=+N&M6N!=6AANX8)HP#\0/\
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H _FL_:D_X.
MJ_\ @F'^R7^T/\7OV:?'>D?M+>+O''P2\:ZK\//&>M_#3X;^!-?\%-XL\/LE
MKXCTO2-7UCXL>&]1O)/#VLB]\/:L;C1;(0ZUI>HV\'VBWBBNIP#]ROV2_P!J
M+X3_ +:G[.'PC_:F^!]_J6H_"WXS^%8O%7A9M:M+:PUZP5+V\TC6- \0V%E?
M:G9V/B+PSK^F:KX=\065GJ6HVMIK&EWMO;7UY#&EQ( ?1- !0!_'U_P=/?\
M!6#]NK_@F=XA_8EL/V-/B[IOPNM?C'HO[0%W\0H[_P"&OPR^(!UJX\"7WP<A
M\,/$_P 0_"/BA]*&GQ^+=>5UTEK)+S[8IO1.;6U,(!^EG_!NE^VW^T=_P4 _
MX)MZ!^T'^U1XUL?B!\6+GXQ_%7P==>);#PEX3\%17.A>&;W2ET6W?0_!6C:!
MH$<MI%?2PFYM],AFN(UC:Y::8-*P!^[- !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % '^=O7^E!_,X4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % ']FW_  2@_P"3 O@)_P!U2_\ 5T_$:OXA\7_^
M3B<0_P#=)_\ 5'EA^Y<'?\DYEW_<W_ZG8D_1*OS4^F"@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H __T_[^* "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@#_.Q_X/A?\ DM?_  3[_P"R6_'C_P!2SX<T ?R&?L'_ +6OC3]A/]L']GS]
MK3P']HFUGX*?$;1O%%_I%M/]F/BGP=,9=%^('@J6?*B*U\:^!M3\1>%+J7(\
MF#5WF0K)&C* ?[@WPN^)7@OXS?#3X??%[X<:U;^)/A]\4O!/A;XA^!_$%I_Q
M[:UX2\9:)9>(?#VJ0CJJ7VDZA:7 1L/'YFQP&4@ '=T % 'YZ_\ !5+]N+0?
M^"=/[!?[0_[5NIRV,GB/P+X,N-*^%FBWVQX_$WQB\7R)X9^&6B-:$^;>V/\
MPE.HV.J^(8K=9)K;PII6O:D4\FPF90#_ !+/$OB+7_&'B'7O&'BK5;_7O$OB
MK6]6\1>(M>U2=[K4=;U_6KV;5-9U74+N3+W-_J%_=S7EY.Y+RSSM(_+T ?ZK
M'_!H/_RAQ\*_]G#_ !T_].>A4 ?U"T % !0 4 % !0 4 % 'YN_\%B_^43__
M  4B_P"S(_VF/_51^*Z /\YO_@T6_P"4S'PZ_P"R%_'G_P!1.&@#_6&H * "
M@ H * "@ H * /\ 'B_X.9/^4XG[=_\ V,?P6_\ 6:?@Q0!_K)?L??\ )I/[
M+G_9NGP2_P#5:>&: /HN@ H * /P#_X+T_\ !;SP5_P2-^".D:/X(LO#GQ"_
M;"^,=E?#X._#76;F671_"F@6[366H_&'XC6.GSP:A_PB&D:@ATSP]HB7>F7G
MCKQ''<Z9IM]!INA>*M3T8 _S6O@=^SO_ ,%)O^"\?[8/BFY\/7'BS]H7XV^)
M9$\0_%#XN?$767TOX>_#'PW<W<R65SXG\0_96T+P'X/L6-Q9^$/ GA323,]M
M:3:/X#\'WOV)[&( _LJ_9B_X,G?V7/#OA^POOVOOVJOC-\4O&DUE;3:AH7P)
ML/"GPG\"Z5J+HC7FG1ZIXQT#XE>*?%5A:OYD%KJZQ>!KB]0+=2Z+8%C9H ?2
MOCO_ (,Q_P#@E?XDM0/"'Q-_;$^'.H1PA(I=+^)GPU\1:;+*%V^=?V'BGX.Z
MG>S;C\[1V.L:8F[A=J?)0!\/_LJ?\&IW[2W[ 7_!4#]D7]IKX4?'/X<_'_\
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MPZ;X-\$>%#X@\6VVCZAJ&GZ;JNK3'2]-%[)J-EX?@URVTW5;$ _H_H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M430 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!_G;U_I0?S.% !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!_9M_P2
M@_Y,"^ G_=4O_5T_$:OXA\7_ /DXG$/_ '2?_5'EA^Y<'?\ ).9=_P!S?_J=
MB3]$J_-3Z8* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@#__U/[^* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@#_.Q_X/A?\ DM?_  3[_P"R6_'C_P!2
MSX<T ?SZ?M%_L&W<'_!&O_@GK_P4:\%Z6\FFW_C;X_?LR_'(VD'R66JV'QM^
M)_C+X/>++P0HSL=6L+SQKX.U?5+HQ6]M_87@+28W>?4(8Z /[4_^#/+]O_\
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MN9E43- ?&GBL*KB(E'4D@']#7[6O[24?[8G_  ;T?M+_ +4\/@]_A]'\?O\
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MW.H6/A34M9/CC6M-8H;_ $#PQJMK&ZRR(: /\K3_ ((U_P#!/;Q%_P %9?\
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M7M[I]]'+>[M'T+2?"^C7$%G_ ,)#XVU4V6F:>-1M;'3[76M>N+'1;X _$CX
M_P#!Y]JOQR_:=^#7P53_ ()ZZ?X:\(?&+XN_#GX4VNN-^TU<:KXD\/#X@>+]
M)\()XDGM1\"[#2]4.FR:O%J;:#&^G>>EN^GC78S*M_& ?W84 ?S/_P#!1;_@
MZ<_X)V?L*>+M>^$G@,^*/VOOC7X9O=0TCQ+X:^#-[I%C\.O!VO:9(]O=:#XM
M^+NLF;1FU6"Z1[2\M/ 6B_$"31[N"\L==72M1M6LF /P1UC_ (/A?C5-JL<W
MA_\ X)]_"W3=#$S&73]8^/'BS6]5>WR=D<>L67PY\/6<4P&-TS:%,C$'$"Y
M !^LW_!+O_@[)^#_ .WU^T;\,/V4/B9^R7\0/@9\5?C%XB;PIX U_P &_$#0
M?BW\/;K5TTJ]U?/BNYU;0_AAXD\*6TUOIUU# VEZ+XV_TG[,)W@@FEGM@#^F
MC]J[X_:1^RE^S'^T#^TUKWA[4?%FB? #X._$3XP:KX7TBZMK#5/$-A\//"NI
M^*+G1=/O;Q7M+.[U*+3&LX+JXCDAMY)5EDC=4*$ _ +_ ()8?\'-OPD_X*C_
M +7&@?LE^#_V5?B-\)=:U[P7XV\9Q^,?$OQ$\,^)-+M[?P5I::G<6+Z7I>@Z
M?=O-?(WE0RK<A(6&YU8<4 ?T^T ?R!?$3_@[L^!OP_\ VR/''['LG[&GQ7U3
M6?!/[2_B/]FR?QLGQ.\(6FF7^K>'/BA>?#"?Q1%H[>'KBZ@TZXOK-]4AL'O9
M+E;1E@>;SLD 'V]_P5:_X.2OV(O^"8/BG4?@O%I^O?M.?M-:;:/+K'PA^%^M
M:+IF@_#Z\:..6QTWXN_$B^&IV?@O5=0B?SH_#VA^'/&WBVPMO(O-<\.:18:C
MI-W?@'\Z9_X/AOC/_P ) +E?^"?/PP'A7>A.C'X]^*SX@,8?+H/$H^&JZ<':
M/Y$D_P"$3*H_[PQ.O[J@#^FO_@D?_P ' _['?_!66[O?AOX3L->^ _[2^CZ1
M<:[?_ 7XBZGI>HW/B/1K$&34]8^%GC/3TL;'X@Z?HMOLGUJRDT?PUXKTVW%Q
MJ4WA8Z#:2ZQ0!^\% &)XE\2^'/!GA[7/%WB_7]%\*^%/#&DZAKWB3Q-XCU2R
MT3P_X?T+2;66^U36=;UC4I[;3M*TK3;*":[O]0OKB"TL[6&2>XECBC9@ ?R)
M_MK_ /!Y!^PM\!O$FM>!_P!E/X4>/OVR=;T9I;27QQ;ZU%\&_@S<W\;O!+'H
M?B?Q!X=\3>-O$<-E-&YDO;7X<V.@ZG'Y,NA>(=1L[A;Z, _*\?\ !\'\=O[7
M\YOV OA(=!_Z!H^-WC%=7Z_]!H^!6L_N\?\ (O\ 7GI\M '[#_L#?\'>G[!/
M[4_BS0?AG^TGX*\5?L3>.O$4]CIVD^(_&7B*P^(7P,NM8O)DM8M.U#XH:7H_
MAG5/"'GSR1NNK^,O NB>$+&W\V35_%>GB)3, ?UE6]Q;W=O!=VD\-U:W4,5Q
M;7-O(DUO<6\R+)#/!-$6CEAEC99(I(V9'1E9"5(- '@O[5WQ^TC]E+]F/]H'
M]IK7O#VH^+-$^ 'P=^(GQ@U7POI%U;6&J>(;#X>>%=3\47.BZ?>WBO:6=WJ4
M6F-9P75Q')#;R2K+)&ZH4(!_/7_P3/\ ^#HSX#?\%'/VFXOV=+?]F_QA\ K2
M'X:_$?XHZ[\4_B'\5?!MYX.\,^&_AEH#^(]>N]=:/1]'CT_3XM-BGN+K5KO4
M+>QTRVMYKN\=8(W90#Y&_;C_ .#S?]F'X+>/-<^'/[&G[/OB#]JQ/#NIWFD:
ME\7O%/C9?A)\+-3N;,M&][X M(?"_C+QAXVT0W ,":IJ^G> +>\\J2\T@ZKI
M4MCJ-V ?-'[.O_![MHVI>,]'T7]JO]AZ?PMX%O[WR=7^('P-^*;^)]<\.6LC
M;8;F/X:>-/#&A0>(HXMRM?-#\1]&N8X(Y9K*POYS%8L ?VA> _VU/V5_B1^R
MSIW[:WA?XX> 9?V7;_P3-\09?C%J>MVVB>%-%\.60>/53XEN-6:TF\.:QH5_
M%/HFN^'=9AL]=TCQ#;7'A^^T^'6(FLP ?R(_M:_\'KWP-\#^,M4\)_L;?LF>
M*?CMX=TV:\LU^+'Q;\=_\*?T35[BVF,4-_X8\ :9X4\9^*-2\/7R#[3:WGB?
M5O >NK'MCN_#-I(Y\H \<^ 7_![U;77BS2],_:?_ &%O[&\$WEU;1:KXR^!W
MQ7?6O$.A6S2A;F[MOA]XX\,Z39>(BD+>8ML?B'X><&(JLDQF41 ']N?[+W[4
M7P+_ &R_@=X%_:+_ &<?'VE?$CX3?$/3?M^@^(-,\V&>WN()&MM4T#7]*NDA
MU+P]XGT"_CFTS7_#VK6UKJ>DZA!+;W,"X5F /H"@#^:#_@H?_P '3O\ P3I_
M85\:>+?@YX.C\<?M8?''P3JNI>'/%/A;X0IINE?#_P (>*M%O9[#5_#7BWXK
M^))(]-&J:9=VTUG?P^!-!^(/]FZA%+IFJ_V??VUW;VX!^"7B;_@^%^--SJDD
MG@[_ ()^?"_1=%^T$PV?B;X[>*_$VJ?9 >(Y-2TOX>>$;3[01R95TD1J3CR&
MQD@'WO\ L2_\'GO[,?Q@\<:!\/OVR?V=O$G[+4.OWUMI5O\ %[PAXU'Q>^&>
MEW=Y<)%#?^-M)D\*^#O&7@_08E?9<ZEHUI\0&M75;J]@L].-S=6(!_:!H6NZ
M)XHT/1O$WAG6-+\0^&_$6E:=KOA_7]$O[75=%US1-7M(=0TK6-(U.QEGLM1T
MO4["X@O=/O[.::UO+2:*XMY9(I$8@&K0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % '\H/_!1;_@ZO^"W_!/']LOXT_L<>)/V
M1?BA\2]=^"][X/L-3\;:'\2/"GA[2-:F\7?#SPE\08FL-*O]!U&\MXK*T\6V
M^G2&XN2TUQ:33*D<;HH /J[_ (*%_P#!Q]^Q%_P3T^&WPNO?%EAXE^+'[0WQ
M<^%O@KXI:)^S5\-]3T*?Q#X*T;QYX3TSQ9H4_P 7O&-[*FD?#_3;RTU2VBL/
M^);KGBS5X)8-:TGP5>:#*VI0@'\YX_X/B?BQ_P )*ETW_!/#X=GP<"=^@C]H
MGQ(OB5AN& GBS_A4K:6A"94D^"WRV'P -A /ZH/^"2W_  7*_9"_X*XZ!K>F
M?"G^W?A7\>_!&C6FM^/_ -G[XB7.EOXHL=*FECL[CQ/X&UK3IA8?$/P/9ZE+
M#IUWKMC9Z3J^D7%WI8\4>&/#G]MZ*NH 'S?_ ,%7/^#E?]BC_@F-XNU?X(Z9
MHVO?M1?M.:-:^9K?PJ^&VO:-HGA3X?WS@-;:-\6/B?=PZW#X2UVXB_?GPWH'
MA7QKXFTZ P3:_HVBV]_ILUX ?SS1?\'PWQE'B(7,W_!/CX9/X3\V,G18OCYX
MJB\1>0),RQCQ._PTETWS7B^2.7_A$=D<G[QH)5_=4 ?U$?\ !)#_ (+T_L?_
M /!6VWUCP?\ #ZVU_P"#/[1?A/1CK_BCX _$2^TN[UB\T&.9+>Z\3_#CQ/IQ
M@L/B%X:TV::UM]8GBTW0O$.B3W-O)K'ABPTZ\TW4;\ _<&@ H _A _X/5OVW
MO["\ ?LT_P#!/GPEJ_EZCX[U*?\ :2^,EG:S^7.GA'PS-JO@WX1Z->HA/GZ=
MXA\5/X\\07%K,(_)U#P#X=O$$FY#& 8__!MC_P $B/#/Q\_X(T_MT^(_BGI-
MK9:Q_P %(-*\5_!_X<:[JEH9QX<\"?!V/5],\!^.M.+QM)%+8?M#2Z]X@N+>
M*)X+V7X9^%KJ0W/E0Q0 '\JW_!(S]JKQ1_P2U_X*O?!#XA_$=;SP9I?@'XN:
MS\!/VE-#U!_(_LCP+XHU.Z^&?Q2AUR%6 GD^'M\__":0VAD5&U_P5IVY]J4
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /[-O^"4'
M_)@7P$_[JE_ZNGXC5_$/B_\ \G$XA_[I/_JCRP_<N#O^2<R[_N;_ /4[$GZ)
M5^:GTP4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % '__U?[^* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M9$_\G:_MK_\ 9NG@K_U9=M0!_HR>,/\ D4?%/_8N:W_Z;+F@#_&=_P"""O\
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M3X3_ &/?V-/ 'PY^"*/X3\JU\1^(8]-M]2U;P]\&_AO>ZM;:KI/AV#-WKOQ
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0!_G;U_I0?S.% !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!_9M_P $H/\ DP+X"?\ =4O_
M %=/Q&K^(?%__DXG$/\ W2?_ %1Y8?N7!W_).9=_W-_^IV)/T2K\U/I@H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /_];^
M_B@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MPKX6TS03I%I\//$T::;H.G>%D>S(U38UUJFI7 M8)+F9I0#]9?\ B.+^)_\
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M\HG_ /@I%_V9'^TQ_P"JC\5T ?Y+_P#P2:_X*&/_ ,$O_P!J?4OVK]-\"?\
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MC4/%LVH:E-Y]B99-,TQ)8IQ:0/$ ?NY_Q'%_$_\ Z1U> O\ Q)'Q#_\ .<H
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MXX6.4VWAWXS_ !?\*2R@/Y"3^,_ _A?5[:.1A^[$LL?@.Z:$-\Y2&<I\JR4
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M'/P+_;^B+-Y:?%GX'R(F?E5Y/!_CQ9&"] SK%$&/<1H#]T4 ?W1T % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!_CQ?\ !S)_
MRG$_;O\ ^QC^"W_K-/P8H _U5/\ @G5X#L/A?_P3_P#V(/AUI@B^Q^"OV2/V
M=?#:21)L6ZETKX1^$;6ZOV&%S-J%W'/?7#L \L]Q)(_SL: /LF@#_&N_X.)_
M#-AX3_X+4?M^Z7IJ[;>Z^*WA[Q+(-H7_ $_QI\+? /C'56P/[VJ:[>-GJV=Q
MY- '^LA_P3V^'>E_"/\ 8+_8L^&.CI"NG^!/V5/V?_"\;P1B)+N;2?A5X5M;
MS474*NZYU2]CN-1NYF'F3W5U-/*3)(Y(!]@T ?XTW_!P]H5EX=_X+2?M_P"G
MZ?#'!!<?%[2=<=(EVJ;WQ/\ #?P/XEU*8C_GI<:CJUU<2G^*65V[T ?Z^W[.
MUS->_L_? N\N7,EQ=_!WX97,\AZR33^"M$EE<^[.S,?K0!^/_P#P<B_MO?\
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MH\4K(0#_ &\: "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * /\[>O]*#^9PH * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /[-O
M^"4'_)@7P$_[JE_ZNGXC5_$/B_\ \G$XA_[I/_JCRP_<N#O^2<R[_N;_ /4[
M$GZ)5^:GTP4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % '__U_[^* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@#_.Q_X/A?\ DM?_  3[_P"R6_'C_P!2
MSX<T ?T#_P#!IQ_RA/\ V?\ _LI/[0O_ *N3Q90!]K_\%Q/V H?^"CW_  3>
M^/7P&TC2HM2^+'A_25^,'P"D\M'NX?C)\-K6^U/P_I%B[@I;R^/=&G\0_#*Y
MN7!6UT_QK=W0 D@C90#_ #U?^#7#_@H?IO[!G_!1>3X?_%?Q-'X.^ W[4GA#
M4OAA\2;O7)WL-&\*^//"$.I^*OA7XPU6)]CK=V&L0:_\/8PZG[+!\2-1GEB+
M6Z&, ^)O'6L?%[_@O!_P64OFT-M3@\0?MD?M&0Z%X46YB:]D^&/P,T4BPTBX
MO+9&*/9_"3X&>%QK.O?9E07[^'=4O4A^TWK*P!_L7_"+X5^!_@9\*_AO\%_A
MGHL/AWX=_";P-X5^'/@?0H,&/2?"G@S1++P]H-CO"IYTD&FZ?;I-<,HDN)@\
M\N9)&) /X _^#XG_ )*S_P $\/\ LG?[1/\ ZDOPEH _;O\ X-!_^4./A7_L
MX?XZ?^G/0J /PI_X/?OAMJMA\?/V$/B^;/\ XD?BOX0?%GX;1WZ L%U7X?\
MC/P]XGEL[@@8AWVGQ+AFLP[ W'EWWE BUF*@'T#_ ,&M7_!/G_@F#^WA_P $
M^?&VM?M#?LK?!OXO?'SX3?M"^,O!GB[6_%+:O=>+I/"&M>'/"/BSP#J=_9VF
MO6RVFC7(U3Q'X?T2=;.WM[RX\)ZTD9FN;.]D(!_2M_PX!_X(U?\ 2/CX"_\
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M)XP_Y%'Q3_V+FM_^FRYH _QG?^""O_*8S_@GG_V<7X8_](=5H _VA: "@ H
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M?B3X-^&S"V='A34_@W\'?AQ\(M=B!3Y4:+7/ ^HQ2PC'D2H\!53'M !_K/\
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M+?9-&3X1^*OAKH]WD A-GCOXD^#H@SX7,H0$.R4 ?Z4O_!8O_E$__P %(O\
MLR/]IC_U4?BN@#_.;_X-%O\ E,Q\.O\ LA?QY_\ 43AH _UAJ /S,_X+/_\
M*);_ (*._P#9FG[0'_JN==H _P [S_@T*_Y3'^$?^S>_CK_Z:-&H _U=J /R
M\_X+8_\ *(W_ (*,_P#9HGQJ_P#4.U&@#_/=_P"#/S_E,-I'_9M7QP_EX2H
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M'A[XCVWQ9^(=U%",_N[3PUH/B&[0,=B)"#*PC5F !_M<4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 ?YV]?Z4'\SA0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 ?V;?\$H/^3 O@)_W5+_ -73\1J_B'Q?
M_P"3B<0_]TG_ -4>6'[EP=_R3F7?]S?_ *G8D_1*OS4^F"@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H __0_OXH * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M_P"43_\ P4B_[,C_ &F/_51^*Z /\YO_ (-%O^4S'PZ_[(7\>?\ U$X: /\
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MH+SP[X3^$O@6YG ^6WU3Q5XA\2ZYXMTP,<?OK+X9:VH4,=N0JN =G_P;^?\
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!_CQ?\',G_*<
M3]N__L8_@M_ZS3\&* /]9+]C[_DTG]ES_LW3X)?^JT\,T ?1= '^.C_P<H?\
MIN_V]/\ L=/A=_ZH#X34 ?ZV?[*G_)KW[-W_ &03X/?^J\\.T >]T ?XX/\
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MI!I^D^.+?5E /]!GX??\'6O_  1-\9>!K7Q;XA_:4\9_"K6Y;..XO?AOX[^
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 ?YV]?Z4'\SA0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?V;?\$H/^3 O@)_W5+_ -73
M\1J_B'Q?_P"3B<0_]TG_ -4>6'[EP=_R3F7?]S?_ *G8D_1*OS4^F"@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H __1_OXH
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M]J_Q?\0]$\)>+?!MGH_Q>\=?"'7O!ITWQE81Z=JES-IW@OX%^ -:?4(+>/\
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MN ?#/_!++_@@W^R#_P $C/B%\4OB5^S=\1/VC_&VO?%OP9I/@;Q%;?&_Q?\
M#+Q)I5AI&CZV-?MYM#M_ ?P@^&MU;ZA+>*L=Q-J%[J=N;90D-K#(6E(!^TNH
MV,.IZ??:;<%Q;ZA9W-C.8B%D$-W ]O*8V*L%<)(=A*L V"5(XH _F;_9&_X-
M1O\ @G;^QC^TK\&_VIOAA\8_VS]?^('P/\9V7CGPGHOC[XB?!#4_!E_J]A!<
MP6\'B#3_  Y^SMX5UR[T\"Y=VAT[Q%I5PSI'_I00.C@'].% !0 4 % $%S;6
M]Y;SV=Y;PW5I=0RVUU:W,4<]O<V\\;136\\$JM%-#-$S1RQ2*T<D;,CJ5)%
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M]L+XS_%K]K[PK\2_B]_PA'_"2Z%\+/'WP8T3P)9?\(#\.?"/PQT;^P]+\6?
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MY_$^C_$_P+\._$/QO^..@S6E]H'QB_:&U/1_'&O^$-5ML2KJ?@'PUI6@>&_
M7@_4H;H>=IOB&R\+S^,M+15@MO%)5IVG /W=H \3_:2^ _@_]J3]GSXV?LV?
M$&_\1Z3X%^//PL\=?"+Q?JG@^\TW3O%>G>&_B!X;U#POK%]X;OM8TC7])L]<
MM+'4II]+N=3T/6-/AO(X7N],OK=9+:0 _%K_ ()S_P#!MA^PO_P3&_:8T?\
M:J^ WQ4_:O\ %_Q#T3PEXM\&V>C_ !>\=?"'7O!ITWQE81Z=JES-IW@OX%^
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M!H$G@/X9_#6UM+.2#6;N2\34+/5+B680F&YMXT,3@'ZNT % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!_-K^W/_P:X_\ !/\
M_P""@/[57Q9_:]^,?Q=_;"\,?$GXQWGA:]\3Z'\,?B!\%]&\#64WA+P-X8\
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M2-%4 %V@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@#_.WK_2@_F<* "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#^S;_ ()0
M?\F!? 3_ +JE_P"KI^(U?Q#XO_\ )Q.(?^Z3_P"J/+#]RX._Y)S+O^YO_P!3
ML2?HE7YJ?3!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 ?_TO[^* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H _SMZ_TH/YG"@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H _LV_P""4'_)@7P$_P"ZI?\ JZ?B
M-7\0^+__ "<3B'_ND_\ JCRP_<N#O^2<R[_N;_\ 4[$GZ)5^:GTP4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '_]/^_B@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /\
M[>O]*#^9PH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * /[-O\ @E!_R8%\!/\ NJ7_ *NGXC5_$/B__P G$XA_[I/_
M *H\L/W+@[_DG,N_[F__ %.Q)^B5?FI],% !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0!__4_OXH * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@#_.WK_2@_F<* "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#^S;_
M ()0?\F!? 3_ +JE_P"KI^(U?Q#XO_\ )Q.(?^Z3_P"J/+#]RX._Y)S+O^YO
M_P!3L2?HE7YJ?3!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 ?_U?[^* "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M_P 0_P Y_P"@G+/_  =BO_F(/^'&G[6?_10OV=O_  K/B5_\Z2C_ (CYP?\
M]"WB7_PCRO\ ^? ?\0_SG_H)RS_P=BO_ )B#_AQI^UG_ -%"_9V_\*SXE?\
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MG+/_  =BO_F(/^'&G[6?_10OV=O_  K/B5_\Z2C_ (CYP?\ ]"WB7_PCRO\
M^? ?\0_SG_H)RS_P=BO_ )B#_AQI^UG_ -%"_9V_\*SXE?\ SI*/^(^<'_\
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M_P 0_P Y_P"@G+/_  =BO_F(/^'&G[6?_10OV=O_  K/B5_\Z2C_ (CYP?\
M]"WB7_PCRO\ ^? ?\0_SG_H)RS_P=BO_ )B#_AQI^UG_ -%"_9V_\*SXE?\
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MG+/_  =BO_F(/^'&G[6?_10OV=O_  K/B5_\Z2C_ (CYP?\ ]"WB7_PCRO\
M^? ?\0_SG_H)RS_P=BO_ )B#_AQI^UG_ -%"_9V_\*SXE?\ SI*/^(^<'_\
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M_P 0_P Y_P"@G+/_  =BO_F(/^'&G[6?_10OV=O_  K/B5_\Z2C_ (CYP?\
M]"WB7_PCRO\ ^? ?\0_SG_H)RS_P=BO_ )B#_AQI^UG_ -%"_9V_\*SXE?\
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MG+/_  =BO_F(/^'&G[6?_10OV=O_  K/B5_\Z2C_ (CYP?\ ]"WB7_PCRO\
M^? ?\0_SG_H)RS_P=BO_ )B#_AQI^UG_ -%"_9V_\*SXE?\ SI*/^(^<'_\
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M_P 0_P Y_P"@G+/_  =BO_F(/^'&G[6?_10OV=O_  K/B5_\Z2C_ (CYP?\
M]"WB7_PCRO\ ^? ?\0_SG_H)RS_P=BO_ )B#_AQI^UG_ -%"_9V_\*SXE?\
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MG+/_  =BO_F(/^'&G[6?_10OV=O_  K/B5_\Z2C_ (CYP?\ ]"WB7_PCRO\
M^? ?\0_SG_H)RS_P=BO_ )B#_AQI^UG_ -%"_9V_\*SXE?\ SI*/^(^<'_\
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M_P 0_P Y_P"@G+/_  =BO_F(/^'&G[6?_10OV=O_  K/B5_\Z2C_ (CYP?\
M]"WB7_PCRO\ ^? ?\0_SG_H)RS_P=BO_ )B#_AQI^UG_ -%"_9V_\*SXE?\
MSI*/^(^<'_\ 0MXE_P#"/*__ )\!_P 0_P Y_P"@G+/_  =BO_F(/^'&G[6?
M_10OV=O_  K/B5_\Z2C_ (CYP?\ ]"WB7_PCRO\ ^? ?\0_SG_H)RS_P=BO_
M )B#_AQI^UG_ -%"_9V_\*SXE?\ SI*/^(^<'_\ 0MXE_P#"/*__ )\!_P 0
M_P Y_P"@G+/_  =BO_F(/^'&G[6?_10OV=O_  K/B5_\Z2C_ (CYP?\ ]"WB
M7_PCRO\ ^? ?\0_SG_H)RS_P=BO_ )B#_AQI^UG_ -%"_9V_\*SXE?\ SI*/
M^(^<'_\ 0MXE_P#"/*__ )\!_P 0_P Y_P"@G+/_  =BO_F(/^'&G[6?_10O
MV=O_  K/B5_\Z2C_ (CYP?\ ]"WB7_PCRO\ ^? ?\0_SG_H)RS_P=BO_ )B#
M_AQI^UG_ -%"_9V_\*SXE?\ SI*/^(^<'_\ 0MXE_P#"/*__ )\!_P 0_P Y
M_P"@G+/_  =BO_F(/^'&G[6?_10OV=O_  K/B5_\Z2C_ (CYP?\ ]"WB7_PC
MRO\ ^? ?\0_SG_H)RS_P=BO_ )B#_AQI^UG_ -%"_9V_\*SXE?\ SI*/^(^<
M'_\ 0MXE_P#"/*__ )\!_P 0_P Y_P"@G+/_  =BO_F(/^'&G[6?_10OV=O_
M  K/B5_\Z2C_ (CYP?\ ]"WB7_PCRO\ ^? ?\0_SG_H)RS_P=BO_ )B#_AQI
M^UG_ -%"_9V_\*SXE?\ SI*/^(^<'_\ 0MXE_P#"/*__ )\!_P 0_P Y_P"@
MG+/_  =BO_F(/^'&G[6?_10OV=O_  K/B5_\Z2C_ (CYP?\ ]"WB7_PCRO\
M^? ?\0_SG_H)RS_P=BO_ )B#_AQI^UG_ -%"_9V_\*SXE?\ SI*/^(^<'_\
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M_P 0_P Y_P"@G+/_  =BO_F(/^'&G[6?_10OV=O_  K/B5_\Z2C_ (CYP?\
M]"WB7_PCRO\ ^? ?\0_SG_H)RS_P=BO_ )B#_AQI^UG_ -%"_9V_\*SXE?\
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MG+/_  =BO_F(/^'&G[6?_10OV=O_  K/B5_\Z2C_ (CYP?\ ]"WB7_PCRO\
M^? ?\0_SG_H)RS_P=BO_ )B#_AQI^UG_ -%"_9V_\*SXE?\ SI*/^(^<'_\
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M_P 0_P Y_P"@G+/_  =BO_F(/^'&G[6?_10OV=O_  K/B5_\Z2C_ (CYP?\
M]"WB7_PCRO\ ^? ?\0_SG_H)RS_P=BO_ )B#_AQI^UG_ -%"_9V_\*SXE?\
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MG+/_  =BO_F(/^'&G[6?_10OV=O_  K/B5_\Z2C_ (CYP?\ ]"WB7_PCRO\
M^? ?\0_SG_H)RS_P=BO_ )B#_AQI^UG_ -%"_9V_\*SXE?\ SI*/^(^<'_\
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M_P 0_P Y_P"@G+/_  =BO_F(/^'&G[6?_10OV=O_  K/B5_\Z2C_ (CYP?\
M]"WB7_PCRO\ ^? ?\0_SG_H)RS_P=BO_ )B#_AQI^UG_ -%"_9V_\*SXE?\
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MG+/_  =BO_F(/^'&G[6?_10OV=O_  K/B5_\Z2C_ (CYP?\ ]"WB7_PCRO\
M^? ?\0_SG_H)RS_P=BO_ )B#_AQI^UG_ -%"_9V_\*SXE?\ SI*/^(^<'_\
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M_P 0_P Y_P"@G+/_  =BO_F(/^'&G[6?_10OV=O_  K/B5_\Z2C_ (CYP?\
M]"WB7_PCRO\ ^? ?\0_SG_H)RS_P=BO_ )B#_AQI^UG_ -%"_9V_\*SXE?\
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MG+/_  =BO_F(/^'&G[6?_10OV=O_  K/B5_\Z2C_ (CYP?\ ]"WB7_PCRO\
M^? ?\0_SG_H)RS_P=BO_ )B#_AQI^UG_ -%"_9V_\*SXE?\ SI*/^(^<'_\
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M_P 0_P Y_P"@G+/_  =BO_F(/^'&G[6?_10OV=O_  K/B5_\Z2C_ (CYP?\
M]"WB7_PCRO\ ^? ?\0_SG_H)RS_P=BO_ )B#_AQI^UG_ -%"_9V_\*SXE?\
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MG+/_  =BO_F(/^'&G[6?_10OV=O_  K/B5_\Z2C_ (CYP?\ ]"WB7_PCRO\
M^? ?\0_SG_H)RS_P=BO_ )B#_AQI^UG_ -%"_9V_\*SXE?\ SI*/^(^<'_\
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M_P 0_P Y_P"@G+/_  =BO_F(/^'&G[6?_10OV=O_  K/B5_\Z2C_ (CYP?\
M]"WB7_PCRO\ ^? ?\0_SG_H)RS_P=BO_ )B#_AQI^UG_ -%"_9V_\*SXE?\
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MR:5U9OZKKY$]@* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@#__6_OXH * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H _]?^_B@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#_T/[^* "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * /_1_OXH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H _]+^_B@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M;<Q+(48(6#%6 Q0!^:/_  \\T'_HD&K_ /A86?\ \S] !_P\\T'_ *)!J_\
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M0:O_ .%A9_\ S/T '_#SS0?^B0:O_P"%A9__ #/T ?J;0 4 ?$G[07[9^F?
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M+(5,)WJI4,IQ0!\(?\//-!_Z)!J__A86?_S/T '_  \\T'_HD&K_ /A86?\
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M>/"^A>)KSPQ<>*8M;UX:"MI:ZI%I4EM(=.O-0%P99;&^61-MDT1C"(075MQ
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MI7V/^RH;&5W=Y;&^\[SOMRJJJL>SRR23D"@#Y-_X>>:#_P!$@U?_ ,+"S_\
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MTK['_9,UA$\;I+IM]YWG?;D965H]OEL"IR#0!\R?\//-!_Z)!J__ (6%G_\
M,_0 ?\//-!_Z)!J__A86?_S/T ?1'[.'[7>F_M#^)]=\,V7@>^\+2:)H/]NM
M=W.N6^JI<(-0L]/-NL46FV+1-NO%D$A=QA"NT$@T ?8M &1K^J?V'H6M:UY'
MVK^Q])U'5/LWF^1]H_L^SFN_(\[RY?)\WR?+\WRI?+W;O+?&T@'YD_\ #SS0
M?^B0:O\ ^%A9_P#S/T '_#SS0?\ HD&K_P#A86?_ ,S] !_P\\T'_HD&K_\
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M7_\ "PL__F?H /\ AYYH/_1(-7_\+"S_ /F?H /^'GF@_P#1(-7_ /"PL_\
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M5UVN-I)10#QG_AYYH/\ T2#5_P#PL+/_ .9^@ _X>>:#_P!$@U?_ ,+"S_\
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M^TZC9Z<J)=20W"0[6O%D+&"3Y4*A<D$ 'Y]?\//-!_Z)!J__ (6%G_\ ,_0
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M?V?9S7?D>=Y<OD^;Y/E^;Y4OE[MWEOC:0#\R?^'GF@_]$@U?_P +"S_^9^@
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MPK,T4JQ%PYC<+M(!^;G_  \\T'_HD&K_ /A86?\ \S] !_P\\T'_ *)!J_\
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MVG13?VKIUOJ"HMK)I-VZ>2MPL18S'>RE@JC H \A_P"'GF@_]$@U?_PL+/\
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MIZGI;:9<WL6H21R:;,L1E%U%;VJNDRNC &",H=R?, '8 ]GH \-_:"^-EI\
M_ <7CF\\/W'B6*77M.T(:=;:A%ID@>_M[ZX%P;F6UO%V1+8LIC$.6,BX90IH
M ^)/^'GF@_\ 1(-7_P#"PL__ )GZ #_AYYH/_1(-7_\ "PL__F?H [_X5_\
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MPW<>*(M3\4V/A==/M=2BTN2&2]TC6]5%X;B6SO5=(UT5H3"(E+&X5Q(!&58
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H __]/^_B@ H *
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MN?\ Y'H /^'?'[.?_0-\6_\ A4W/_P CT '_  [X_9S_ .@;XM_\*FY_^1Z
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M_P#A4W/_ ,CT '_#OC]G/_H&^+?_  J;G_Y'H /^'?'[.?\ T#?%O_A4W/\
M\CT ?;] !0!\U_%?]E'X2?&?Q2OC#QQ:Z_<:RFEVFCQMIVM2:?;)8V4ES-!&
M((H""_FW<[M(S,S;PN0BHJ@'FG_#OC]G/_H&^+?_  J;G_Y'H /^'?'[.?\
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MO@YX*^"/AN]\*>!(-1@TC4-<N?$-PFIW[ZC.=1NK#3--E9)I$0I#]FTFS"Q
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M?!VG>!O!T%W;Z#I<M_/;)?7DE]=&74KZ?4+EI;B3!;]_<.J*JHJ1JBX+!F8
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M3SW,]AXM>>XFDGF?_A)YUWRRN9)&VI;*B[G8G:BJHZ* ,"@"'_AWQ^SG_P!
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M#C*D<4 ?%'_#OC]G/_H&^+?_  J;G_Y'H /^'?'[.?\ T#?%O_A4W/\ \CT
M'_#OC]G/_H&^+?\ PJ;G_P"1Z /LS1-(L?#^C:1H.F1O%INB:98:1I\4DC3/
M'8Z;:Q65I&\LA+RND$,:M(Y+.068DDT := '@_QC_9R^&OQUN]"O/'UOK-Q)
MX<M[ZVTQ=+U5]-CCCU&2VENC*(H7:9W:TMPI9L($^106<L >,?\ #OC]G/\
MZ!OBW_PJ;G_Y'H /^'?'[.?_ $#?%O\ X5-S_P#(] 'KGP?_ &9/A7\#M9U3
M7O =GK,&I:OI@TB[DU/69]1C^PBZ@O#'%"Z1QH[3VT+&3#, FU2H9PP!]!T
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MXF9!(J[D!RA5@& !\B?\.^/V<_\ H&^+?_"IN?\ Y'H /^'?'[.?_0-\6_\
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M7UEJ#IIUZ]A<_:;!V>W(N(U9@@9CN3;AAQ0!\S?\.^/V<_\ H&^+?_"IN?\
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M_P"%3<__ "/0!Z+\+?V2O@_\'O%D/C3P79Z_#K<%C>Z?&^H:Y-?VPMK]%CN
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M8)VTW6K"?3;Y8)E!,,IMKF41R@$QOM< XQ0!\>?\.^/V<_\ H&^+?_"IN?\
MY'H /^'?'[.?_0-\6_\ A4W/_P CT '_  [X_9S_ .@;XM_\*FY_^1Z /M^@
M H ^:_BO^RC\)/C/XI7QAXXM=?N-932[31XVT[6I-/MDL;*2YF@C$$4!!?S;
MN=VD9F9MX7(1450#S3_AWQ^SG_T#?%O_ (5-S_\ (] !_P .^/V<_P#H&^+?
M_"IN?_D>@#V_X-?L]_#GX$?\)'_P@%MJUO\ \)5_8_\ :W]J:I)J6_\ L/\
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M6M^B17&R0Q;IK2)7*IN\LNJE&(90#Y2_X=\?LY_] WQ;_P"%3<__ "/0 ?\
M#OC]G/\ Z!OBW_PJ;G_Y'H UM _81_9_\-Z[HOB+3M-\3_VAH.K:;K5A]H\2
MW4L'VS2[R&^M?.B$2&2'SH$\R,.A9,J&7.0 ?9- !0!\L?$?]CGX+?%3QGK/
MCWQ;9>(I?$&N_P!G?VA)8Z_/96K?V7I5CHUIY5JD++%BRTZV5\$[Y \G!;%
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M%CX/\#V]];:,VIW>KNNH7TNH7+WU[';Q3.9Y0N$\JT@1(T544)G!9F8@'I=
M'G_Q.^&GACXM^$+WP/XO2^DT'4;BQN;N+3KLV-S(^G745[:@7*QR.B+<0Q.P
M0*7";"VPLI /F#_AWQ^SG_T#?%O_ (5-S_\ (] !_P .^/V<_P#H&^+?_"IN
M?_D>@#I/!W[$7P(\#>*=!\8:%IWB0:SX;U.UU?2VN_$=S<6R7UE();9YH/*C
M$R1R*K^6S!&VA7#)E2 ?7= !0!\E>-_V*?@;\0?%FN^-/$5CXDDUOQ%?-J&I
M/:>(9[6V:Y=$C8PVZPLL2;8U^0$@4 <K_P .^/V<_P#H&^+?_"IN?_D>@ _X
M=\?LY_\ 0-\6_P#A4W/_ ,CT ?3/PM^%OA/X/>$X?!?@N&^@T."^O=01-0O7
MO[G[3?NKW!-PZHQ0LB[$VX4<"@#T:@#S'XL_"3PA\:/"\/A#QM'J,NBPZM::
MR(],O3I\[7EE;WEO!NG6.1O)"7LK,B[2SK'EMH96 /F[_AWQ^SG_ - WQ;_X
M5-S_ /(] !_P[X_9S_Z!OBW_ ,*FY_\ D>@#JO!'[%/P-^'WBS0O&GAVQ\21
MZWX=ODU#37N_$,]U;+<HCQJ9K=H565-KM\A('3TH ^M: "@#Y!\6_L0? KQM
MXGU_Q?KUEXGFUKQ)JU]K.IR6_B*:V@:\OYWN)O(MX[?9#"K/MC09*H%#,[98
M@'/?\.^/V<_^@;XM_P#"IN?_ )'H /\ AWQ^SG_T#?%O_A4W/_R/0!]1?#/X
M;>%_A+X.T[P-X.@N[?0=+EOY[9+Z\DOKHRZE?3ZA<M+<28+?O[AU155%2-47
M!8,S '>T >5_%WX.>"OC=X;L?"GCJ#49](T_7+;Q#;)IE^^G3C4;2PU+386:
M:-'+0BVU:[#18P7,;Y^0"@#YT_X=\?LY_P#0-\6_^%3<_P#R/0 ?\.^/V<_^
M@;XM_P#"IN?_ )'H [+X??L9?!'X9^,-$\<^&-/\1)KOA^6YGTYK[Q!<W=JD
MMU8W6GNTMMY<8EVP7<I12VT2!&8,H*$ ^K: "@#X\\3?L,? 3Q;XD\0^*]8L
M/$[ZOXFUS5O$.J/;^)+B"!M1UJ_GU*^:"!8"L,)N;F4QQ D1IM0$@4 8?_#O
MC]G/_H&^+?\ PJ;G_P"1Z #_ (=\?LY_] WQ;_X5-S_\CT ?4_PX^'OASX5^
M"]&\!>$H[N'P_H/]H_V?'?737MTO]J:K?:S=>;<NJM)F]U&Y*94;(RD8X04
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M_![Q9#XT\%V>OPZW!8WNGQOJ&N37]L+:_18[@&W>)%+E5&QL_+V% 'TU0 4
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@#_]3^_B@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M * "@ H _]7^_B@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M8[B2WM-6U:VU[Q3)9P1"_P!9O6@$M?U7P_P5P-X=X&>+R_ Y=E4<-2_VO/\
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M:II[--:6ML24AA0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M;0]G[37DE:\$K*^UCPW_ (>A_L'_ /1P6C_^$=\2?_F,KW_^(4>('_1.5_\
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M%!J,9RI0O6JJ+;C[?$3<L1B''F?+*O5J2BG9-+0]NKY\]0* "@ H * "@ H
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MF&(H8"I4HUL55G3FJE!*4)2T:3JIJZ[I/R/G3_AV=^W1_P!&\^)__!YX)_\
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ML5UDTEN?P=_&GXK>)/CE\5O'OQ:\6R;M=\=^([_7;F$2-+%IUK*PATK1;1W
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M='_1O/B?_P 'G@G_ .:>OZ3_ .(I\ ?]%)A?_"?'_P#S(?FG^JG$'_0MJ_\
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M?$O_ (8LT_\ F4/[:R;_ *&V6?\ A?A?_EH?\-??LF?]'0_L[?\ AZ_AK_\
M--1_J9QA_P!$GQ+_ .&+-/\ YE#^VLF_Z&V6?^%^%_\ EH?\-??LF?\ 1T/[
M.W_AZ_AK_P#--1_J9QA_T2?$O_ABS3_YE#^VLF_Z&V6?^%^%_P#EH?\ #7W[
M)G_1T/[.W_AZ_AK_ /--1_J9QA_T2?$O_ABS3_YE#^VLF_Z&V6?^%^%_^6A_
MPU]^R9_T=#^SM_X>OX:__--1_J9QA_T2?$O_ (8LT_\ F4/[:R;_ *&V6?\
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MK_\ --1_J9QA_P!$GQ+_ .&+-/\ YE#^VLF_Z&V6?^%^%_\ EH?\-??LF?\
M1T/[.W_AZ_AK_P#--1_J9QA_T2?$O_ABS3_YE#^VLF_Z&V6?^%^%_P#EH?\
M#7W[)G_1T/[.W_AZ_AK_ /--1_J9QA_T2?$O_ABS3_YE#^VLF_Z&V6?^%^%_
M^6A_PU]^R9_T=#^SM_X>OX:__--1_J9QA_T2?$O_ (8LT_\ F4/[:R;_ *&V
M6?\ A?A?_EH?\-??LF?]'0_L[?\ AZ_AK_\ --1_J9QA_P!$GQ+_ .&+-/\
MYE#^VLF_Z&V6?^%^%_\ EH?\-??LF?\ 1T/[.W_AZ_AK_P#--1_J9QA_T2?$
MO_ABS3_YE#^VLF_Z&V6?^%^%_P#EH?\ #7W[)G_1T/[.W_AZ_AK_ /--1_J9
MQA_T2?$O_ABS3_YE#^VLF_Z&V6?^%^%_^6A_PU]^R9_T=#^SM_X>OX:__--1
M_J9QA_T2?$O_ (8LT_\ F4/[:R;_ *&V6?\ A?A?_EH?\-??LF?]'0_L[?\
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M'0_L[?\ AZ_AK_\ --1_J9QA_P!$GQ+_ .&+-/\ YE#^VLF_Z&V6?^%^%_\
MEH?\-??LF?\ 1T/[.W_AZ_AK_P#--1_J9QA_T2?$O_ABS3_YE#^VLF_Z&V6?
M^%^%_P#EH?\ #7W[)G_1T/[.W_AZ_AK_ /--1_J9QA_T2?$O_ABS3_YE#^VL
MF_Z&V6?^%^%_^6A_PU]^R9_T=#^SM_X>OX:__--1_J9QA_T2?$O_ (8LT_\
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M?$O_ (8LT_\ F4/[:R;_ *&V6?\ A?A?_EH?\-??LF?]'0_L[?\ AZ_AK_\
M--1_J9QA_P!$GQ+_ .&+-/\ YE#^VLF_Z&V6?^%^%_\ EH?\-??LF?\ 1T/[
M.W_AZ_AK_P#--1_J9QA_T2?$O_ABS3_YE#^VLF_Z&V6?^%^%_P#EH?\ #7W[
M)G_1T/[.W_AZ_AK_ /--1_J9QA_T2?$O_ABS3_YE#^VLF_Z&V6?^%^%_^6A_
MPU]^R9_T=#^SM_X>OX:__--1_J9QA_T2?$O_ (8LT_\ F4/[:R;_ *&V6?\
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MK_\ --1_J9QA_P!$GQ+_ .&+-/\ YE#^VLF_Z&V6?^%^%_\ EH?\-??LF?\
M1T/[.W_AZ_AK_P#--1_J9QA_T2?$O_ABS3_YE#^VLF_Z&V6?^%^%_P#EH?\
M#7W[)G_1T/[.W_AZ_AK_ /--1_J9QA_T2?$O_ABS3_YE#^VLF_Z&V6?^%^%_
M^6A_PU]^R9_T=#^SM_X>OX:__--1_J9QA_T2?$O_ (8LT_\ F4/[:R;_ *&V
M6?\ A?A?_EH?\-??LF?]'0_L[?\ AZ_AK_\ --1_J9QA_P!$GQ+_ .&+-/\
MYE#^VLF_Z&V6?^%^%_\ EH?\-??LF?\ 1T/[.W_AZ_AK_P#--1_J9QA_T2?$
MO_ABS3_YE#^VLF_Z&V6?^%^%_P#EH?\ #7W[)G_1T/[.W_AZ_AK_ /--1_J9
MQA_T2?$O_ABS3_YE#^VLF_Z&V6?^%^%_^6A_PU]^R9_T=#^SM_X>OX:__--1
M_J9QA_T2?$O_ (8LT_\ F4/[:R;_ *&V6?\ A?A?_EH?\-??LF?]'0_L[?\
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M'0_L[?\ AZ_AK_\ --1_J9QA_P!$GQ+_ .&+-/\ YE#^VLF_Z&V6?^%^%_\
MEH?\-??LF?\ 1T/[.W_AZ_AK_P#--1_J9QA_T2?$O_ABS3_YE#^VLF_Z&V6?
M^%^%_P#EH?\ #7W[)G_1T/[.W_AZ_AK_ /--1_J9QA_T2?$O_ABS3_YE#^VL
MF_Z&V6?^%^%_^6A_PU]^R9_T=#^SM_X>OX:__--1_J9QA_T2?$O_ (8LT_\
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M?$O_ (8LT_\ F4/[:R;_ *&V6?\ A?A?_EH?\-??LF?]'0_L[?\ AZ_AK_\
M--1_J9QA_P!$GQ+_ .&+-/\ YE#^VLF_Z&V6?^%^%_\ EH?\-??LF?\ 1T/[
M.W_AZ_AK_P#--1_J9QA_T2?$O_ABS3_YE#^VLF_Z&V6?^%^%_P#EH?\ #7W[
M)G_1T/[.W_AZ_AK_ /--1_J9QA_T2?$O_ABS3_YE#^VLF_Z&V6?^%^%_^6A_
MPU]^R9_T=#^SM_X>OX:__--1_J9QA_T2?$O_ (8LT_\ F4/[:R;_ *&V6?\
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MK_\ --1_J9QA_P!$GQ+_ .&+-/\ YE#^VLF_Z&V6?^%^%_\ EH?\-??LF?\
M1T/[.W_AZ_AK_P#--1_J9QA_T2?$O_ABS3_YE#^VLF_Z&V6?^%^%_P#EH?\
M#7W[)G_1T/[.W_AZ_AK_ /--1_J9QA_T2?$O_ABS3_YE#^VLF_Z&V6?^%^%_
M^6A_PU]^R9_T=#^SM_X>OX:__--1_J9QA_T2?$O_ (8LT_\ F4/[:R;_ *&V
M6?\ A?A?_EH?\-??LF?]'0_L[?\ AZ_AK_\ --1_J9QA_P!$GQ+_ .&+-/\
MYE#^VLF_Z&V6?^%^%_\ EH?\-??LF?\ 1T/[.W_AZ_AK_P#--1_J9QA_T2?$
MO_ABS3_YE#^VLF_Z&V6?^%^%_P#EH?\ #7W[)G_1T/[.W_AZ_AK_ /--1_J9
MQA_T2?$O_ABS3_YE#^VLF_Z&V6?^%^%_^6A_PU]^R9_T=#^SM_X>OX:__--1
M_J9QA_T2?$O_ (8LT_\ F4/[:R;_ *&V6?\ A?A?_EH?\-??LF?]'0_L[?\
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M'0_L[?\ AZ_AK_\ --1_J9QA_P!$GQ+_ .&+-/\ YE#^VLF_Z&V6?^%^%_\
MEH?\-??LF?\ 1T/[.W_AZ_AK_P#--1_J9QA_T2?$O_ABS3_YE#^VLF_Z&V6?
M^%^%_P#EH?\ #7W[)G_1T/[.W_AZ_AK_ /--1_J9QA_T2?$O_ABS3_YE#^VL
MF_Z&V6?^%^%_^6A_PU]^R9_T=#^SM_X>OX:__--1_J9QA_T2?$O_ (8LT_\
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M?$O_ (8LT_\ F4/[:R;_ *&V6?\ A?A?_EH?\-??LF?]'0_L[?\ AZ_AK_\
M--1_J9QA_P!$GQ+_ .&+-/\ YE#^VLF_Z&V6?^%^%_\ EH?\-??LF?\ 1T/[
M.W_AZ_AK_P#--1_J9QA_T2?$O_ABS3_YE#^VLF_Z&V6?^%^%_P#EH?\ #7W[
M)G_1T/[.W_AZ_AK_ /--1_J9QA_T2?$O_ABS3_YE#^VLF_Z&V6?^%^%_^6A_
MPU]^R9_T=#^SM_X>OX:__--1_J9QA_T2?$O_ (8LT_\ F4/[:R;_ *&V6?\
MA?A?_EH?\-??LF?]'0_L[?\ AZ_AK_\ --1_J9QA_P!$GQ+_ .&+-/\ YE#^
MVLF_Z&V6?^%^%_\ EH?\-??LF?\ 1T/[.W_AZ_AK_P#--1_J9QA_T2?$O_AB
MS3_YE#^VLF_Z&V6?^%^%_P#EH?\ #7W[)G_1T/[.W_AZ_AK_ /--1_J9QA_T
M2?$O_ABS3_YE#^VLF_Z&V6?^%^%_^6A_PU]^R9_T=#^SM_X>OX:__--1_J9Q
MA_T2?$O_ (8LT_\ F4/[:R;_ *&V6?\ A?A?_EH?\-??LF?]'0_L[?\ AZ_A
MK_\ --1_J9QA_P!$GQ+_ .&+-/\ YE#^VLF_Z&V6?^%^%_\ EH?\-??LF?\
M1T/[.W_AZ_AK_P#--1_J9QA_T2?$O_ABS3_YE#^VLF_Z&V6?^%^%_P#EH?\
M#7W[)G_1T/[.W_AZ_AK_ /--1_J9QA_T2?$O_ABS3_YE#^VLF_Z&V6?^%^%_
M^6A_PU]^R9_T=#^SM_X>OX:__--1_J9QA_T2?$O_ (8LT_\ F4/[:R;_ *&V
M6?\ A?A?_EH?\-??LF?]'0_L[?\ AZ_AK_\ --1_J9QA_P!$GQ+_ .&+-/\
MYE#^VLF_Z&V6?^%^%_\ EH?\-??LF?\ 1T/[.W_AZ_AK_P#--1_J9QA_T2?$
MO_ABS3_YE#^VLF_Z&V6?^%^%_P#EH?\ #7W[)G_1T/[.W_AZ_AK_ /--1_J9
MQA_T2?$O_ABS3_YE#^VLF_Z&V6?^%^%_^6A_PU]^R9_T=#^SM_X>OX:__--1
M_J9QA_T2?$O_ (8LT_\ F4/[:R;_ *&V6?\ A?A?_EH?\-??LF?]'0_L[?\
MAZ_AK_\ --1_J9QA_P!$GQ+_ .&+-/\ YE#^VLF_Z&V6?^%^%_\ EH?\-??L
MF?\ 1T/[.W_AZ_AK_P#--1_J9QA_T2?$O_ABS3_YE#^VLF_Z&V6?^%^%_P#E
MH?\ #7W[)G_1T/[.W_AZ_AK_ /--1_J9QA_T2?$O_ABS3_YE#^VLF_Z&V6?^
M%^%_^6GT37S1Z84 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#_.W
MK_2@_F<* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@#_1(K_-<_I@* "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MC7C[T)657#UHV]KAJ\4WRU:,O=E9N$ERU*4IT9TYR]TKYT]4* "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * /_]'^_B@ H * "@ H * (
MY98H(I)YY(X8(8WEFFE=8XHHHU+R222.0D<<:*6=V(55!)( II.348IMMI1B
ME=MO1));M[)(-$KO1+=[))'\>7_!3?\ ;5E_:G^+9\*>"]2=_@E\+[V\T[PB
M()&6U\7Z^-UKK'CR>,?+-#=;7T[POYNXVV@(;V-+2YUW4[8?VEX5<"KA+)_K
MF.I)9[FU.%3&<R][!8;2=#+XO[,HZ5<5:W-7:IOFCAZ4C\3XKS[^U\9[&A+_
M &#!RE&C;:O4^&>(?=.W+1[4_>T=22/6/^"2G[$W_"\/B&/CS\1=)\[X4?"W
M5X3H&GWT&ZS\<?$*S$5W9VK12+LNM"\)[[;5M7#?Z/>:F^D:4R7EH=:MX?'\
M8N.O[!RW_5[+*W+F^;47]9J4Y6G@,MG>$Y)K6%?&6E1H_:A25:JN27L9/LX-
MR'Z_B?[1Q4/]CPDU[*,EI7Q,;.*MUIT=)3Z.?)#5<Z7]7-?R(?L 4 ?S5_\
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M)_X)C?LO?\,U?LUZ$^O:=]C^)7Q5^Q^/?'?G1>7>Z<EY:_\ %+>%9]P$D?\
MPCFB3*UW:2#-KX@U37U4F-UQ_'WBIQ7_ *T<48CZO4Y\KRGGR[+[/W*GLY?[
M5BX]']9KQ?))?%AZ6'ZH_8^%,I_LK*Z?M(\N*Q?+B,1=6E&Z_<T7V]E3>L>E
M2=0_16OS4^F/Y=O^"ZG_ "<)\(/^R-+_ .IMXIK^KO #_DG<Z_['2_\ 4'#'
MY+X@_P#(RP7_ & _^YZQT_\ P0FMX+OXA?M$VMU!#<VMSX!\(V]Q;7$:307$
M$VMZM'-!-#(K1RPRQLT<D;JR.C%64J2*Y?I 2E#+>&I0;C*.88R491;C*,HT
M*+BXM6:::336J>QMX>I/$9FFDT\/0335TTYU$TUM:W0^*?\ @I'^QY/^RA\<
M+IO#=C*OP@^)+W_B/X<W*J[6^CD3(^N>!Y96R?/\,7-U#_9_F-(]QX>O='FD
MGFO5OQ#]UX8<:QXOR&"Q51?VUE:IX;,HZ*59<K6'QZ7\N*C!^TM91Q$*R48P
M=._@\49(\GQ[=*-L#BG*IA7TAM[3#^3I-KE[TG#5M2M]]?\ !&7]LC^S+^;]
MDGX@ZKC3]4EO]<^#-_>S8CL]4?S;_P 1> UDD.U(=5_TGQ%H$7[M!J:Z[:!Y
MKG5M-ME_._&[@GVE-<8Y=2_>4E3P^=TZ<?CI*U/#9A9=:7N8;$/5^S>'G91I
M5)'T? V=\DGDV)G[LW*I@92>D9:RJX?R4]:M):>][2.KG!']&&I_\@W4/^O&
M[_\ 2>2OYIH_Q:7_ %\A_P"E(_39?!+_  O\C_/%K_20_FD_N_\ V0?^33/V
M7O\ LW;X)_\ JM?#-?Y^<9_\EAQ7_P!E+GO_ *M,4?T+DO\ R)LI_P"Q9@/_
M %%I'M7BOPOH7C;PQXA\&^)]/AU;PWXJT35/#NO:9<#,%_H^LV4VGZC9R8P0
ML]I<2Q[E(9-VY"K $>%@\7B,!BL-C<)4E1Q.$KTL3AZL?BIUJ$XU*<U_AG%.
MVW38[ZU*G7I5*%6*G2K4YTJD'M*$XN,HOUBVC^$[]IKX%Z[^S=\<?B%\'==\
MZ8^%-;E31-3FCV?V[X5OU74/#&N)M41%M2T6YLY;N. O'::A]LL"WFVDBK_?
M_"N?X?B?(,MSK#\L?K=!>WI1=_J^+I_N\5AWU_=5XS4&[.=/DJ6M-'\^9KE]
M3*\?B<#4N_8U'[.;5O:49>]2J=O>@XW2TC*\>A^B>A_\%$[S2_\ @F;J7P!&
MKN/B]#K1^#.E3_:/^)A'\%M5L+C5)]9!RIVZ?I"7OPQACA -G8W&D7:2&96Q
M^:5_#6%7Q2I<0^Q7]BNA_;E6/)^Z>=T:D:4:&S5ZE;V>:2O\<HUH6M8^FI\3
M.'"DLNY_]M4_J,'?WE@9Q<G4_P"W8*6%5OA3@SX-_9 _9XU7]J']H#P%\);)
M;B+1]1O_ .U_&VJ6P(;1/ VBM'=^)-0$FUEAN9K;9I.DO(/*?7-3TNW? FK]
M"XTXDH\)\.9AG$^5UJ=/V& I2_Y?X^NG#"T[=8QE>M52U5"E5:V/G<DRR>;9
MEA\'&ZA*7/7FO^7>'IV=67DVK0AT]I."ZG]S>B:+I7AO1M(\.Z#86VE:'H.F
M6&BZ-I=G&(K33=*TNUBL=/L+6(<1V]G:00V\"#[D<:KVK^!J]:KB:U;$5ZDJ
MM>O5J5JU6;O.I5JR<ZE23ZRG.3E)]V?T!3IPI4X4J<5"G3A&G3A%6C"$$HQB
MET48I)+LC4K(L* /@'_@H?\ MD:=^R+\%[F[T6YM)_B]X]COM!^&6D2^5,;.
MY6)$U3QG?6K[E?2_"L-S!/'')')%J&MW&D:;+']DN+R>V_1/#;@FIQEGD*=:
M,XY-E[IXC-:RO'GA=^RP5.2M:KBW%QNFG3H1K55[T(1E\YQ+GD<EP+E!Q>-Q
M'-3PE-V=G;WJ\H_R44T[;2FX0V;:_CFT+0_&GQ8\=Z=H.C6VJ^,/'WQ \2QV
MEI"9)+W5_$'B3Q!?_-+<7-PY:6YO;ZY>XO;Z[E"+NFN[N9(UEE7^UL17P.3Y
M?4Q%:5'!9=EV%<YNRA1PV%PU/2,8Q5E&%.*C"G!=(PA&]D?B-.G7QF(A2IJ=
M;$8FK:*^*=2K4ENV^K;O*3VU;=C^U_\ 8K_94\-_LC?!+1/AYIWV34/%VH^7
MK_Q(\401_-XA\774$:W*V\KHDW]AZ)&%TC0+=TBVV-N;Z:!-1U'49)OX6XYX
MNQ7&6>U\RJ\]/!TKX?+,(WIAL%"3Y.9+W?;UW^^Q$E>]27(G[.G34?WC(LGI
M9+@*>&A:5:5JF*JK_EY7:7-;;]W#X*:LO=5VN:4K_7%?''LE'4_MG]FZA_9^
MW[?]AN_L.[[OVSR)/LV[_9\[9GVJZ7)[2G[3^'SPY[?R<RYO_);DRORRY?BY
M7R^MM/Q/YF?^"$XLC\;/C@T__(7'POTP6N_'F?8F\6V)U3);Y_\ CY72M_;=
MMW\A:_J;Q_Y_["R!1_@_VK6YK;<ZP<_96MI\'M;?@?E7A[R_7LPO\?U2%N_+
M[9<_GOR?KT/MG_@N5_R:9\//^SB?"7_JM?BW7PO@'_R6&9?]DUC/_5IDQ[W'
M_P#R)L-_V,Z/_J+C#\)_@C^T7^VS\!O@GKUY\$M;\:>$_@9+XYO'\0>)]*^'
MGAW6O#-IX\O](\.65U;7GC75_"6KS:1J=QI,/AM(M-_MFSC(>VEM;83W4CR_
MO^>\-<"<09[AX9[0P.+S]8"FL-A*V98FABIY?3K8F<)4\#1QE&-:E&M+$MU/
M83>DHRERP2C^?8#,\^R[ 5)8"I7HY?\ 6)>TJPPU*=*.(E"E%IUYT9N$G!4K
M1YXK:RNSWC]@#]FGPW^W9\<O$OB?X[?&:;5=9T2\@\8^)_!.H7.J7WQ$^)UG
M%-9QR7<FO:C%]@@\,1SO:Z5K+Z?>7^NV=IY%A;V&B6UYIFL1?/>(O%&)\/\
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M>0_J!K^4S]8"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * /\[>O]*#^9PH * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * /\ 1(K_ #7/Z8"@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M*J/ZOE]!IM5L7.,G#G2<7["C&,JU=\T+TZ;IPE[6I2C+^4+_ ()P_LH>*_\
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MZAC&,(QA"*C"*48QBE&,8Q5HQC%6222222LEHBS4C"@ H * "@ H * "@ H
M9))'%&\LKI%%$C2222,$CCC0%G=W8A41%!+,Q 4 DD 4TFVDDVVTDDKMMZ))
M+KV0;>27X'\B?[1GCOXE?\%F/VY]'_9[^#&MW.D?LW?"B\U+RO$LMF9-$L]!
MTJ\CT_QM\:]2LK>43:QJ/B29K?0/AEHU[=V0EL9] @N(_",VO>-M1A_MSA;+
MLJ\!_#NOQ)G^'C6XISF%+VF$4N7$SQ56$JF7\.TJDXVP]'"14L3G%:G3ERU8
MXF2^OQPF6TI?SSG&*QOB3Q32RG+*CIY+@)3Y*[5Z,:,)*&)S2<(O]Y4KNU'
M4I35Z;HK_9G6Q<X_U+? [X)?#K]G7X6^$O@_\*]$30O!O@[3DL;&%C')?ZC=
M-^]U'7=;O(XH/[1U[6KUIM0U:_,40GNYW\F&WME@MXOX\XAX@S3BC.,;GF<8
MAXC'XZK[2H]52I02Y:.&P]-N7LL-AZ:C1H4DWR4XI-RE>3_=LKRO!9-@,/EV
M I*EAL-#EBM'.<MYU:LK+GJU97G4G97D]$E9+UFO%/0"@ H * "@ H * "@
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@#_.WK_2@_F<* "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@#_1(K_-<_I@* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H _A1_P""I_[7&I_MI?M7
MW>C> [BY\0_#'X9ZC<_"_P"#>F:-OU&/Q1?3:C;V7B'QAI4%A>ZE;:I<^/\
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M89YS4'"DN:K# MJG648)2;J8R<HX.E'EO.G+$NG)5*43ZE_X)K?L3Z3^Q/\
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M\+.R?+2CA95)NI69^V]?S\?IX4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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MZ(C(%G9@5 /[UZ "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /%/V@/V
MC_@-^RI\--9^,7[1WQ:\"?!CX9Z" E_XN\?:_9:#IKW;Q2RVVD:6ES(+S7?$
M&H+!*NE>'-#M=1UW5YD-MI>G7=P1$0#^0S]JW_@]5_9.\ :EJOA[]D/]F/XI
M?M$36-Y-8P>/?B3X@T_X&> M1CBE*IK/A[2TTGQ_X^U;3+B(!X+7Q+X<^'VJ
M_/BXM;4Q[9 #\R]7_P"#W+]L2;4!)H'[&/[-.FZ5DYLM7\4?%'6]0VY& -3L
MM9\/VP(7()_L@@G!V@#:0#Z@^"?_  ?!64NL:;I_[1O[ EU8>'Y&4:OXM^"?
MQJBU?6+)!M#OIOP\\=>"=$LM39AN98[KXGZ2$VJAE?>7C /[;_V4OVEOAU^V
M-^SG\(/VH/A+!XDM?AQ\:_!UCXW\(VOC#3+71O$]KI5])/ MMKFF6.I:Q96>
MHV\]M-#<16>JZA:[DW6]Y/$R2, ?0= !0 4 % !0!_DF?'C_ (*F_P#!2?P]
M_P %?/C+\+M$_;Q_:UTSX:Z'_P %(_B)X!TCP!9_'OXDQ>#-/\#Z;^T[K'AZ
MP\'6OAD>(?[&C\,6F@01:+!H0L_[,32HUT\6WV4>50!_K9T ?YS?_!V+^W[^
MW%^R_P#\%+OA]\._V</VNOVC?@3X"OOV0OAAXJO?!OPF^,/COP#X9N_$VI?$
M_P"-VFZAK]QHOAK6].T^76+W3]&TFRNM0> W4]KIMC!)(T=K"J ']BO_  1'
M^)_Q%^-'_!*+]A[XH_%OQOXG^)'Q'\8_!FTU/Q9XY\::S?>(O%7B74D\0Z_9
M#4==US4YKC4-4OVM;6WBEO+V>:YF$2M+([Y8@'ZGT % !0 4 4M1U&PT?3[[
M5M5O;73=+TNSN=1U+4;Z>*ULK"PLH'N;R]O+F9DAMK6UMXI)[B>5TBABC>1V
M55) !_##XQ_X/??A'HWB[Q3H_A+]@'QGXP\*Z5XCUO3?#/BV;]HK2O#LWBGP
M_8ZG<VNC>(I?#\OP5U.70I=;TZ*VU-]'DU+4)-,:Y-D][=M 9Y #^U/X#_&;
MP3^T7\$_A)\?/AM?_P!I> ?C/\./!OQ.\'WA,9F?P_XV\/V'B'3(KM(F=8-0
MM;:_2UU&T8^;97\-Q:3*DT+HH!ZQ0 4 % !0 4 % !0 4 % !0 4 % '^<W_
M ,'8O[?O[<7[+_\ P4N^'WP[_9P_:Z_:-^!/@*^_9"^&'BJ]\&_";XP^._ /
MAF[\3:E\3_C=INH:_<:+X:UO3M/EUB]T_1M)LKK4'@-U/:Z;8P22-':PJ@!_
M8K_P1'^)_P 1?C1_P2B_8>^*/Q;\;^)_B1\1_&/P9M-3\6>.?&FLWWB+Q5XE
MU)/$.OV0U'7=<U.:XU#5+]K6UMXI;R]GFN9A$K2R.^6(!^I] !0 4 % 'Y,_
M\%%/^"V7_!/;_@F+:2Z;^T3\7UUKXL&V@NM._9]^$EOI_CSXUWL%S$D]K<ZA
MX975M*TCP3I]W;/]IT_5?B-XB\':7JL*2+H]WJ%POV<@'\J_QF_X/@=7_MR]
MM/V>?V!]-7PU#N33?$'QF^,MTVN:A\S;+B]\'^"/!Z6&CX3:&LX/'&N9;<PO
M5&% !X%X=_X/=/VN[;4A+XL_8K_9PUK1]Y+6'AWQA\3?"^I&/=\JC5M2OO%]
MJKA/E+_V*REOF$:CY* /VY_X)C_\'9'[/O[>_P ??A;^RU\1/V6OBE\!/C)\
M8O$J>$? E]X;\8^&_C!\,KO66L[J]B7Q!X@NM-^&/BKPXEW%9RB!;7P3XDMX
M9BL5S?I'_I) /ZTJ "@ H * "@ H * "@ H * "@ H * /\ *?\ BA_P=G?\
M%;!^UGXG^)7@[Q_X,\(_!+1OB)JBZ%^RQJOPE^'=_P"$4\":9K4D%IX0\6^+
MKSPO_P +;N=?N],M88_$7B73?'6BW\>M/?3:#;:!I4D>AP@'^I/\,/&J_$KX
M:_#SXBII-YH">/O WA+QJFA:B<ZAHJ^*M T_75TF^)B@S>:<+X6=R?)AS-"_
M[J/[@ .YH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#
M^,']L'_@\<^#?[,?[47QW_9V\'?L9>(_C9H?P2^)7B7X8?\ "T]/^/ND>$--
M\8:QX,O6T+Q-?:7H+?";Q1]FTJU\36>KZ9IEVFO:A%J]A8V^LP/%#?I;0@']
M-G_!/+]MCP#_ ,%$?V.O@C^U_P##G2I?#>B?%SP[=WFI>#;K5H-;U#P-XN\/
MZUJ7A;QGX,U#5(+/3!J$WA[Q-HNIV5MJ3:5I1UC35L=9CTZSM]1AA4 ^TJ "
M@#^';_@\0_;,_:V_9.\3_L 6W[,/[2WQR_9]M_'.@_M+3^,X/@Y\3O%_P[B\
M53>'=0^!<>@R^($\+:MIBZM)HR:UJZ:8UZ)C9+J=\+?RQ=3;P#]7_P#@US_:
M!^./[2W_  2J\.?$O]H7XM_$/XV?$-OCI\8]!D\<?%#Q9K/C7Q9-HNE7^C-I
MFF7&OZ_=WVJ7%GIWVJ=+*&>YD2UBD\F$)"J(H!_150 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0!_G;U_I0?S.% !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!_HD5
M_FN?TP% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MX0_Y*SA?_LHLD_\ 5EACSLW_ .13FG_8NQO_ *C5#^#>O]!C^>#_ $ _@_\
M\DE^%W_9.O!/_J-:97^=.<_\C?-?^QECO_4FJ?T?@_\ <\)_V#4/_343T6O-
M.D_)O_@JK^VNW[-_PO3X5^ -3:V^,OQ9TFZCM+RUD,=WX(\"2R3Z;JOBM'0B
M2WU7598;S0O"TL9C>"[AU;6(9X[C0H8;G]?\(^!5Q/FKS;,:7-D>3UH.<)J\
M,=CTHU*.#L])4J2<*^+B[ITW2HN/+B&X_'<7Y[_9>$^J8:5L=C(-1<='0P^L
M9UDUM.33IT;;-3FG>FD_Y&Z_LD_&#]HOV:O^"M7A7]F#X/\ A;X1>!_V5+::
MST2 W.MZ[+\83;:AXL\47JQMK?B;4T3X63;;G49XU2VM3<7*Z7I=OI^CV\\E
MKI\!K\-XH\'<9Q5G6+SG'\724Z\N6AAUDG-3P>$A=4,+2;S>/N4HOWI*,?:U
M95*THJ=21]UE7&5'*<%1P6'R=.--7J5/KMI5JLK>TJR7U-V<FM%=\D%&"=HH
M]Y_X?W7G_1K%M_X>J7_YU-?/_P#$O,/^BME_X8E_\^#T?^(B/_H4+_PO_P#O
M,/\ A_=>?]&L6W_AZI?_ )U-'_$O,/\ HK9?^&)?_/@/^(B/_H4+_P +_P#[
MS/M_]A+_ (*43_MI?$CQ;\/Y?@W%\.!X7\$3>,1JT?C]_%IO3%KVB:)_9QL6
M\%^&A;!AJ_VG[5]KGQ]G\G[,?-\R/X/Q \+X\#99@\Q6=O,_K>/6"]B\N6#]
MG?#UZ_M.?Z]BN;^#R\G)'XK\VEG[_#W%+SW%5L-]16%]CAW6Y_K/MN:U2G3Y
M>7V%*WQWO=[6MV_4ZOR4^N"@#S[XC_"?X9?&#0O^$:^*7@+PIX^T-9&F@T_Q
M5HEAK$5E<LGEF\TY[N&2?3+[R_D6^T^6VNT7Y4F45Z.69OFF2XCZUE.88O+J
M]E%U,)7J4'.*UY*BA)1JT[_\NZBE!]8G-B<'A,;3]EB\/1Q%/=1K4XS47M>/
M,O=E;[4;/S/@K7?^"0O[#6LW<MU;?#KQ)X=\V1Y6MM"^(/B];16DR2L4.KZI
MJWDQJQW)%"R11X5$18@(Z_0L/XR\?4(*$LSPV)Y4DIXC+<%SV7=T:-'F?=M-
MO=N^I\]4X+X?F[K"U*?E3Q-?E^2G.=EV2LETT/0/AU_P3)_8E^&E_%JNE_!+
M1_$>IPE#'<^/]3USQU;*T9RK#0_$FHWWAS>&^;S/['\P$## * /.S+Q3XZS2
MFZ-7/J^&I.Z<<NI4,OE9]/;X6G3Q-NEO;6\CHPO"F0X67/# 4ZLEUQ,JF(7_
M (+JRE2^?)<^[[:VM[.W@M+2WAM;2UACM[:UMHD@M[>WA01PP00Q*L<,,4:K
M''%&JI&BA54* *_/Y2E.4ISE*<Y-RE*3<I2D]6Y-ZMMZMO5GT*2BE&*22222
M5DDM$DEHDEHDMB>I&% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?Y:W_
M  =K?\%(/B)^T9^WEK_[$_A[Q%J&G_L\_L@2:+I,_A>SEEM=-\:_'#6_#6GZ
MYXQ\:Z] DB_VI/X3M-=M_A_X9BOHFCT,Z9XIO])\L>*]0EN0#]'O^")G_!J#
M\&OC!\ OAG^UK_P4AO/&FNR?%O0_#_Q#^&G[-7@OQ/>>"=%L_AMXCTRVUCPY
MJ7QA\2Z/;6GC>3Q#XITR\M=6@\*>#/$/A*3PKIDUK%KFLZAKE[?Z+X; /Z4S
M_P &XG_!$XZ)_P (_P#\,#?#G[!Y;Q>>/''QG&M[9$V,?^$E'Q+'B/S O*3?
MVKYL3_O(W1_FH _)+]KS_@S@_8X\8W>F>._V&?B=XY_9J\<Z'KVBZO!\/_B%
MK&J?%OX-ZO9Z;J-O=3Z=#?ZPTWQ5\+7\\2NR:W<^*_'5FIABM?\ A&4,\E_$
M ?V2T % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M5+=H_P"S/$>N^&F,R33VZ2@'^4%IG[/_ ,4-6_9[\8_M0V?AVX?X.>!OBYX
M^"&M^)]DODK\0/B+X2^('C71=+@VQ-&T=KH7PZU.75IY)8A93ZOX<@VR/JT6
MP _TD_\ @SG_ &W_ /A>G[!/CO\ 9#\5:O\ :O'7[''CMQX8M[F?==W'P2^,
M%YK/BOPOY9F/VB\_X1WQ[:_$71IO*,EOHVBS^#]/_P!'BELXB ?U^4 % !0
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MJ@*JJ JJJC 50,   8 ' ' H =0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M_P"EOAZ@#^HF@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#_.WK_2@_F<*
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@#_ $2*_P US^F H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M-$"/^%N^/\$%U!'_ ",'3%?VH^$.$K/_ (Q;AO;_ *$65_\ S*?S]_;N=_\
M0YS7_P .&+_^7'^CS7^61_984 % !0 4 % 'YM_\%9OCO-\!OV'OBO?:3=&U
M\6_$^&T^"_@X)YHN)=2^(*75GKOV-[=EFAO[/P+:>+=2TZXB8/#J%E:NI#!:
M_6/!3AR/$GB'DM.M#FP63N>?XVZBX*GECA/"*JI>ZZ-7,YX&A5B]'2J3NK'Q
M/B%FSRGA;,)4Y<N(QZCEF'M=2<L6I*OR..JJ0P<,34IM;3A&QZ[^P+^S=;?L
MJ?LH?"7X2R6$5EXJM] B\4?$:18;1;FZ^(GBQ4UCQ1'>W-F6CU%M"N)XO">G
M7[.[RZ'X>TF/<$B1$\+Q*XJEQEQGG6=1J2G@I8EX/*4W/EAE6!_V?!.$)I.E
M]8A!XVM3226)Q-=VO)L]+A+)5D&09?E[BHXA4E7QK2C>6,Q'[RNG*.D_8MK#
MTY;NC1IKHC['KX0^D"@ H * "@ H * "@ H * .<\6^,/"7@'P]J7B[QUXH\
M.^#/"FC1)/J_B;Q7K6F^'O#^E0231V\<NHZQJUS::?91R7$L4$;W%Q&KS2QQ
M(2[HIZL%@,;F6*HX'+L'BL?C:\N6AA,%AZN*Q-:23DXTJ%"$ZLVHIR:C%VBF
M]D8XC$8?"49XC%5Z.&P]-7J5J]2%&C35TDYU*CC"*NTE=K6R/'?V=_VHO@S^
MU3HGC+Q1\#_$EQXN\*^"?&DW@.^\1MI&I:/INIZW:Z!H/B"[?1(]8M[+4KO3
M;:'Q!;V)OKC3[..YO;6\>P6[TS[%J-Y[W%'!V?<&8C+\'Q#A(8'&9AE\<RI8
M55Z->K1PTL5B<)!8AX>52E3K2EA)S]E&I.4*<H*IR5>>E#S<FS[+,^IXJME=
M:6(H83%/!SK>SG3A.K&C1K2]DJBC.4%&M&/.X13E&7)S0Y9R^A:^7/8"@ H
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MU_U./_,?_P#?H?\ #@[_ *NN_P#,%_\ XXZ/^)AO^J0_\S__ .! _P"(=?\
M4X_\Q_\ ]^GVY^PM_P $UA^Q9\1O%OQ _P"%T'XE'Q1X)E\'#2?^%=?\(:+
M2Z[HVM'4?MW_  G7BK[41_9 MA:?9+;_ %YF^T_NQ$_P?'_BA_KSEF#R[^P_
M[+^J8Y8WVW]I?7?:6P]:A[/V?]GX3D_C<W/SR^'EY=;KW^'^%O["Q-;$_7OK
M7M:'L.3ZK[#E_>0GS<WUBM?X+6Y5OOI8_4BOR<^M"@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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MU:&[GT:XAU>UMK&U\4^#/$\&G:C-X3\76NGZ<-3_ +-U2PU#2=&UO2=3TFS
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M[+#'<0QF:17E9DC,4@!\"_\ !OG_ ,%S?C3_ ,%BO$?[4NB?%KX*?"_X20_
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M?^%_&_Q/\6VREC@ZCXHU?QKH'A_4947:J-:> M(CR&+PON4( 9_PD_X/.?\
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MY;:CH.OZ;/<:/XATBXAN[2:*[BU'3=. /T!H * "@ H * "@ H * "@ H *
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ML->\.ZKK'A_4M-U2[ /LV@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#_.WK_2@_F<
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@#_1(K_-<_I@* "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M#EQ&<95*6E2C0S"A#HG1G]6Q4_62K8./I31_4O7\>G[L% !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0!__];^_B@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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MV/?^";_[/G@30K_X._#;XG_M-ZIX8TF]^-WQU\;>%M$\:>)=4\;7UC%<>(]
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M:0_Y3;_'K_M*A\4?_6MM<H _VJ* /\N'_@\Z_P"4L'PS_P"S(_A%_P"K<_:
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M=6TKP7-M<P?'KQW+!<6\\3)+#/#*BR12QLKQNJNC!@" #_2(_P"#?[_@@O\
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M/^*K_2I_$<%SX=C\.G5X=#U6Y2  _GW_ .#,G]H/Q+\/O^"D/Q3^ "ZA=?\
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MQ&2UU'4/@KXOALW*(VN6?BTR>!HIED0IH7Q!UQC%=30V42@'^LA0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0!_G;U_I0?S.% !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!_
MHD5_FN?TP% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M?@\9/!8ZCBL=A,+5G6PD:5>,,1B*=&4J<L'+#4HSBIW7/0J*ZU1^_G_!2/\
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M "@ H * "@#_U_[^* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M##;6T,5O;V\4<$%O!&D4,$,2".*&&*,*D442*J1QHJHB*%4  "@"6@#^1?\
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MKBV)67[#\3=4T;X;:I;Y RL=[I?BR\LYB,$0SR8*]0 ?P!?\&A7PNT+XA?\
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M2.WGV7\'@K7[*YU7XSZSY"LDCZ8?ASI^I>![JXC<&SU/Q_H<A#AMA /\\?\
MX(@?MM?LL_\ !.S]N_PS^US^U1\/OBO\2M%^&'@'QU%\+O#_ ,(]'\&:SK%E
M\5/%MC;>$;3Q#K-OXW\9>"]+31M)\#:UXZ6WEMKV\U&#Q%=Z#=VUJ@M9+J
M_MA_XC7O^";7_1M7[<'_ (2'P&_^?]0!^(W_  7I_P""_P!_P3S_ ."M_P"Q
MQHGP9^'7P-_:E\$?''X;?%/PU\2OA7XR^(GA7X167A:VC^SWWAGQUX<US4_#
M/Q@\4:]::5KOA36;G48HM/T*_6Z\3^&_"R78MK2.6^M0#Q__ (-!_P!M_P#X
M9Q_X*.:K^S/XHU?[#\.?VU?!,G@NVAN)_)L+?XT?#>'5O&'POOYF<F-9-4T:
M;X@^!K*!$66_USQAH4(D_<I&X!_J:T ?Y\'_  ?)?\C;_P $UO\ L7/VK_\
MTY_L\4 ?K%_P9P>"='\-_P#!);7?$UE9P1:K\0_VK?B[KVMWJC-S=MHOAGX<
M>#]/AED;YE@M+3P\#;VRGR8I+FZN$437=PS@']7M $<D4<T<D,T:2PRHT4L4
MBJ\<D;J4>-T8%71U)5E8%64D$8H _P 1#]F?27^#'_!53X :#X7GEN9/A3_P
M4#^%>C^'KBRD<37!\#_M&:%8Z5+:RY63?/\ V7 T+Y#9922#0!_MYT % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 ?YV]?Z4'\SA0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M ?Z)%?YKG],!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0!^7_ /P64U=])_X)S_'](I6AFU8_
M#32(W7JR7'Q8\$37</4?+/86UW _7Y)&X(K]?\!\.J_BEPWS*\:,,ZKOUIY%
MF7LW\JK@UYV/A/$JJZ7!N:VT=267TETTEF6$YE\X*2_ _EM_X)":3;ZU_P %
M%OV;+.YC$L<.L>.]653C"W&@?"KQUKMI)CUBNM-AD7T901R*_K[QKKRP_A;Q
M;.#LY8;+J&G\N)SO+,/-?.%24?1GX9X?4XU.,<CC)72K8JHO6EE^+JQ^Z4$_
M*Q_>E7^<1_5P4 % 'X;_ /!P)_R9)X/_ .SBO O_ *@GQ1K^AOHT?\E]F/\
MV2N8?^K/)3\M\7/^29PG_8ZPO_J%F!_&M:_\?-O_ -=X?_1BU_=+V?H_R/YQ
M/]/&O\D#^X#^;K_@XQ_Y)O\ LP?]CO\ $;_TP^&:_JGZ+G_(SXO_ .P#*?\
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MH6QC\&Z/:Z3X1#Z=<_V9?W6C7FN6T,4NL7.[_-OQ7XT?''&689E0J.>4X/\
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M_E,I_P $^/\ LO>G?^HYXAH _P!G6@#SOXO?\DF^*'_9._&O_J-:E0!_CO\
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M)XAJE[X ^%O@[QEKGBS7[2V.96L]%\6ZO\--,NYU4)')XBM8V?,@1P#\U?\
M@QP_Y'W_ (*/_P#8H?LO?^GGX[4 ?Z%= 'COQR_9[^!?[37@'4?A9^T-\(OA
MW\:?AWJOSW?A#XD^$]&\6Z*+E4>.'4;*VUBTNO[,U>S#L^GZSIK6FJZ=-MN+
M"\MIT210#^'O_@MG_P &HOP%^'GP(^,'[7W_  3JO_$/P[OO@_X/\2?$_P ?
M?LS^*-<U/QCX-USP-X0TN^\1>,+SX4^)]=FU'QMH?B?2-$LK[5;7PIXAU?Q7
MIWB46@T?0KGPY>?8[74 #\C?^#2;]M_XE_ '_@IIX-_99B\43K\#/VP=,\8>
M&O&7A&_:2XT:T^(O@?X?>*_&_P .O&>D0>8O]F^)9;OP[/X&N+JW5H=4TCQ1
M]GU6WN'TO1+S2 #_ %6* "@ H _S=?\ @\__ &%M<\"?M*?!;_@H!X9TYYO
M'QV\):;\$_B9=V]L=FB?%[X;65_=>$;O5+L!5/\ PG7PSV:=HL&)'C_X59K3
M32JD]G$ #[+_ .#03_@K=X-OOAO/_P $LOCEXJM]$\<>%=:\2^,_V3M5U[4H
M+:P\7^$_$-VWB#QI\&M-DNWC_P"*K\.>)KK7?'7AC3HY+B?7]!\0^([2S@M$
M\&PQZB ?W?T % !0!YA\;OA^?BS\%_B[\*UGAM3\2_AAX^^'XN;A2]O;GQEX
M4U;PX)YT7YFAB_M'S)549**0.: /\4__ ()T_$'P7^S%_P %(?V4/&G[0FB:
M%#\//AA^TUX$TOXW:5XZT*SU[0]"\&KXN@\*?$BZU_0=0L]0MKT>%=%O-9U2
M2V>SN)4NM*1K=?M,<3  _P!G&S_92_9&U"TM;^P_9L_9RO;&]MX+NRO;/X._
M#.YM+NTN8EFMKJUN(?#KPSV\\+I+!-$[12Q,KQLRL#0!9_X9'_91_P"C8_V>
MO_#+_#?_ .9J@ _X9'_91_Z-C_9Z_P##+_#?_P"9J@#W?3-,TW1=-T_1M&T^
MQTG2-)L;33-*TK3+2"PTW3--L(([6QT_3[&UCBM;*QLK6**VM+2VBC@MX(XX
M88TC15 !_BR_M(?\IM_CU_VE0^*/_K6VN4 ?[5% '^7#_P 'G7_*6#X9_P#9
MD?PB_P#5N?M 4 ?W*?\ !OU_RAG_ ."?7_9"[?\ ]2OQ/0!^Q5 !0 4 ?XVG
M_!?_ /;5N/V_?^"J_P"T/X\\,7\WB+X=_#KQ#!^S?\$(K O?P7G@GX47U]H#
M:CH0A\QKNQ\>?$&Z\9^/-*$4:RR6_BVV@\K>@! /ZY_@;_P99_L2:M\%_A-J
MWQX^/7[8.C?&W5?AQX*U/XN:+X&\8?!.Q\&Z)\2-0\.Z==^--%\+6NL_ OQ'
MJR:#H_B&;4--TMM1US4[R:SM8IKBZ>21@ #U/_B"D_X)F?\ 1QG[=?\ X7?P
M _\ H<: ,S6O^#*'_@G+)HVK1^'/VE/VV+3Q"^F7Z:#=:UXO^!6H:-;:RUK*
MNEW&K:?8_L_Z7>WVF0WI@DO[.SU+3KJYM5E@M[ZTE=)XP#^#7]D'XW_%#_@E
M9_P4G^%WQ4\0Z9J&B^/OV1_VB;[PO\7/"EL[+?W.D>'-?U3X<?'#P(CMY0\W
M6_"<_C'PO'+(NQ)+V.X,9V!: /\ ;0\+>)_#_C;PQX<\9^$]6L]>\*^+M!TC
MQ/X:US3I/.T_6?#^OZ?;ZKHVK6,V!YMGJ.G7=M>6TF!OAF1L#- '^0!_P<R?
M\IQ/V[_^QC^"W_K-/P8H _UDOV/O^32?V7/^S=/@E_ZK3PS0!]%T ?YJO_![
M9_R?'^R'_P!FHWG_ *M[QS0!_59_P:Y?\H*/V&O^[F?_ %L/]H*@#_/ _P"#
MBO\ :9\9?M-_\%?OVP[WQ+KDVJ:'\$?B/JG[-7P\TO+"P\+>$_@K?7?A6^T?
M38F9S$M]XZB\9>*-3)<^=KOB'59T$,#PV\(!_I._\$QO^"(/["__  3U^"'P
MTTG2O@)\-?B!^T)!X5\/WGQ0^/WQ#\(Z+XS^(.O^/9+..Z\07/AK4O$4>MCX
M?^&K;4YI;+1/#7@J32["/2[#39=7FUW75O=>OP#]D-2U+2]!TN_U?5[^PT;1
M=&T^ZU+5-3U&YM]/TS2M+TZW>ZO;^^O+EXK6QL+&TADN+FYGDBM[:WB>65TC
M1B #_$!^*WQ8L/CU_P %,OB3\<]*>*33/C/^W5XQ^+&FR0 K"]A\1?C_ *CX
MOLWA4@%8FM]8C,8(!"$# H _W#J /\N'_@\Z_P"4L'PS_P"S(_A%_P"K<_:
MH _N4_X-^O\ E#/_ ,$^O^R%V_\ ZE?B>@#]BJ "@#C?B+X#\.?%/X?>._AC
MXQLQJ'A'XC>#?$_@/Q3IYVXOO#GB_1+[P]K=G\Z.F+G3-0N8?G1U^?YD8<4
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MJ_\ 3+\.J /H;_@ZI_Y0=_M:_P#8Q_LW_P#K2OPFH _F9_X,B?\ D[7]M?\
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?Z)%?YKG],!0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M; 5E6RO+:2C1J0O[/$XG$1A4Q%=746XP2I8:"G%\DJ-:=-\E<L?\$3_V2?\
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M:JB?M2_%5$10B*NL6P554 *J@66     . !BOSW_ (A1X<O5\'Y,V]W]7?\
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % '^4G^T-_P6B_X*!_\$O/^"NO_  4ET_\ 9O\
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MQE_X+*_M2Q21_#_7_C-\/_@+X3UJ71K_ ,/^$]7U76-'\;ZAI?P^^".DS^=
M?A]\)-#\$7ECX@U'^T+^X_X2'6[,ZKJ7B+Q?JWBW5;8 _JJ_X,:O^1<_X*7_
M /8;_9&_](/VDJ /[9?VJ/@!X8_:L_9I^/7[-/C.5[7PS\=OA)X^^%>JZA%&
M);C1X_&OAK4="@UVRC+*#?Z#=WEOK.GY8 7MC;D\"@#_ !=KFR_:Z_X(_?M\
MVSW5C<_"K]J7]D7XK?;=/;4+"XNM#U.?2I)K>'4+6.YCL1XL^&/Q*\+7<PM[
MN PV7BWP+XC9K>>.'4-R ']SWP'_ .#V7]C_ %+X?Z0W[3/[*O[1O@_XIVVA
MVH\00? ^#X:_$'X?ZMXAAA6.^FT*Y\=?$KX;^(M$TO4+@-=V6GZE::W<:5!+
M]@N-9U:2V&HWH!^%_P#P4G_X*X_MC?\ !Q?\1O#G['W[*?P1U+X7?LX> AXC
M^-&K>$+S5Y=:UC5;/X<^&M7U'5?B]\?/&6DZ8-(\,^#O!.@R:D=#\(Z5;7M@
MGB/5[2U&H>.?&%]X*M=. /@W_@VI_P"4WW[!O_8W_%C_ -9Y^+M '^N7^T%\
M)-,^/WP%^-WP(UJ[>PT;XU_"'XD_"35KZ.,2R66F?$?P9K7@Z_NTB/$CVUKK
M,LRQGAB@4\&@#_%:\.ZK^U9_P1^_X*!Z7K%SHC?#S]I[]CSXNN\^B^(-/FN=
M%U.?3EGL;ZUECE2SDUSX>_$SP9J=S#::OILEJ/$'@?Q1%JVA:A;_ &VROHP#
M^Z[P'_P>T_L37?PRL-1^)W[)?[4?A_XQKIT']J^$/ DOPI\7?#9]7VE;@:9\
M0M?\?^"O$HTMF42))=_#07< E6#R+ORFN7 /YP?^"C__  4S_;L_X.(/&/CW
MPW\,OA5_PK;]D?\ 8]^%_P 9/VJ+WX<:=>WFJZ9X3\)?"3X;^)O$FN?%#XV>
M/TT^&RUCQ]J^AZ5J?@[X=:/:Z;I&B6&K>*%\,:+;W-SJ7B+Q9?@&=_P:7?\
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MGQ^19V_Q$\'>,-0T'PSX]\16]L(;4^,[;QGX/U'4[>TBG\1V.O>(+G4O$5Z
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MSP3<7P0-'%=_$>V^)6K:U9Z>[91KZ'X97]VA&1I+K@T ?QT?\%%_VD?VZO\
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MN/#WB>\\(>!? 7BOXB?V[XAO_#E_J5GH6JZMXN\.P^&M2N+76I-)UMK(:;*
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M ,&/A[X?:?M;:GXGTKXP_$/4+'G&Z:P\)ZS&%.5W'Y: /S@_8F_X.(?V^?\
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M\FD_LN?]FZ?!+_U6GAF@#Z+H _S5?^#VS_D^/]D/_LU&\_\ 5O>.: /ZK/\
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M>XM]5H _KB^ /_![Y%'H%II_[4?["LMSXH@2!;[Q7\!/BE'9Z%JC[,7$EMX
M^(.B7E]H85UWQ12?$C7_ #5E\MI(/(WS@'I?Q$_X/@O@S9:0Y^$W[ OQ.\2:
M\\>V-/B)\:?"O@G2+65D&)GD\->"OB!>7\<,AS]E6+36N44+]KM&?=& ?$W[
M$7_!QM_P4>_X*1_\%</V%OA3XI\4^%O@;^S]XA^.=K8Z[\$?@=H]YI6E>+](
M.@>(9!;_ !$\6^(+_P 0>,_%T<4">9=Z;%JVA^#IYX8M2/A."[M+6>W /V:_
MX/"_V'/B/^TM^PO\*?VC/A;X?U'Q9JW[&7CCQ?XF\>:#I-M->:C;?!CXEZ)H
MMAXZ\86UG;1375W#X,UOP5X(U371$@BTSPF_B+Q'>RQ6&@W+@ _D6_X(._\
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MM>-O%&DW*?:=#\8?$JYT[1[?1M)N8[36?#?@K3KG^T0LOCB^TK2@#^T>@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@#_.WK_2@_F<* "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@#_1(K_-<_I@* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MV_M3_M5?"'3_  GJGQ)^#G@"RU[PA9>.--U+5_"KZIJ7BWPWX9\[5],TC6-
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M?C5;>$;=;GQ5<3:H=#M- @\.1!_L$&D1::JV:@'[3T ?ES^V?_P1=_X)H_\
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MP9:W'B3P%XN\+^,9[?1=0T32;Q(9?$+QWMQ86TFI+>,F: /D_P#8^_X(B?\
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M?C7;7?ANVBD8M_9UM)\3/!7Q&\2I8)G$8?Q')>(N%%Y@"@#[G_8N_P"#>O\
MX)3_ +"WBW1OB1\*OV<K?QM\5_#MZNH>'_B?\</$>K?%;Q)X?OH>;/4/#ND:
MY)'X"\.:QITF9=/\0:!X-TSQ#:2D21:J&CA\L _:Z@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H _P [>O\ 2@_F<* "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#_1(K_-
M<_I@* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M:?C_  Y_R4.0?]CO*?\ U/PY_HPU_EP?V.% '^<3^UG_ ,G3_M*?]E\^+_\
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M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?_3_OXH * "@ H
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ML_V4^!4\(ZNWBT7/VK_1?L_]@#4!-]I_T?R]WG?N]U '^"Y0!_ME/::WI_\
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M]^*GP\UJY0X4ZM9VOAGQGX2T-V/+^/+VRC1IKZ+: ?ZK= !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % '\F_P#P>6?\HE?!G_9Y7P=_]5U\:Z /SF_X,:O^1<_X*7_]
MAO\ 9&_](/VDJ /[X: "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H _SMZ_TH/YG"@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H _P!$BO\ -<_I@* "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MG:Z3:V9YX/V;OV=AT^ GP6&.F/A;X&X_\H5>K_K9Q3_T4O$'_AYS'_YI./\
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M49/F&"PV)A2P-!XG#8FC3KTEBJL?;8CW*D91O'$5:O+*UUTL>:ZQ_P $B?\
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M@J$$UTC-XZ371ND[;,\0_P"#=?X227'B[]H?XZW=G<1PZ/X=\-?"CP_?,/\
M1+N;Q%J1\6^++>'G!NM,C\,>#GF+*"D.KQ+&V))EKZ'Z4&=*&7\+\.4YKFQ.
M+Q>=8JE]J$,'16!P$VOY:LL9F,5TO0?8\OP=R_FQ6<9K*.E&A0R^C/HY5Y_6
M,3%=G!8?"-^55']4%?QT?O 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M6^(O$%K=16]UX*U?4=*A-MK,$$Z-%J#PSQ2^7Y\>QF /A;_@JY_P=)_M8?\
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MX2TSQ/ITSJ1MAO=%N-3TR]3.U[:XFC;*,00#_< H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H _,S_ (*O_P#!,KX?_P#!6']F#3?V8?B1\2O&/PIT+2OBKX4^*]MX
MH\$:;HFJZLVJ^%-%\5Z%!I<]EKT;V;Z?=VGBZ]DE:-HKB.XMK5DD,8EBD /
MO^".'_!$_P"%7_!'"P_:$L/AC\:_B#\8T_:$O/A?=ZU)X\T+PYHC>'F^%T/C
M^'3TTL>'^+E=4'C^\-X;KF(Z?:^1_K): /VPH * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#
M_.WK_2@_F<* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@#_ $2*_P US^F H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MUXYKFT?BI\L(.I&C5C;W)+!0JQ3=XO\ M&A97/WKK^;C]9"@ H * "@ H *
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MH$?\%SO^";GQ,_X*H_L.M^R[\)?'W@3X<>+T^,'P_P#B1%X@^(J:^WAM]/\
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?YV]?Z4'\SA0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 ?Z)%?YKG],!0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M'_P8\8_ +5)8T_T;3=4^$GC>\^(6B+<N%&VXUZS^-&N_8P68RP^&;O 46_S
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@#^=O_AP=_P!77?\ F"__ ,<=?TI_Q,-_U2'_ )G_ /\
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M )@O_P#''1_Q,-_U2'_F?_\ P('_ !#K_J<?^8__ ._0_P"'!W_5UW_F"_\
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M9_\ _ @?\0Z_ZG'_ )C_ /[]#_AP=_U==_Y@O_\ ''1_Q,-_U2'_ )G_ /\
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M77?^8+__ !QT?\3#?]4A_P"9_P#_  ('_$.O^IQ_YC__ +]#_AP=_P!77?\
MF"__ ,<='_$PW_5(?^9__P# @?\ $.O^IQ_YC_\ []#_ (<'?]77?^8+_P#Q
MQT?\3#?]4A_YG_\ \"!_Q#K_ *G'_F/_ /OT/^'!W_5UW_F"_P#\<='_ !,-
M_P!4A_YG_P#\"!_Q#K_J<?\ F/\ _OT/^'!W_5UW_F"__P <='_$PW_5(?\
MF?\ _P "!_Q#K_J<?^8__P"_0_X<'?\ 5UW_ )@O_P#''1_Q,-_U2'_F?_\
MP('_ !#K_J<?^8__ ._0_P"'!W_5UW_F"_\ \<='_$PW_5(?^9__ / @?\0Z
M_P"IQ_YC_P#[]#_AP=_U==_Y@O\ _''1_P 3#?\ 5(?^9_\ _ @?\0Z_ZG'_
M )C_ /[]#_AP=_U==_Y@O_\ ''1_Q,-_U2'_ )G_ /\  @?\0Z_ZG'_F/_\
MOT/^'!W_ %==_P"8+_\ QQT?\3#?]4A_YG__ ,"!_P 0Z_ZG'_F/_P#OT/\
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M?^9__P# @?\ $.O^IQ_YC_\ []#_ (<'?]77?^8+_P#QQT?\3#?]4A_YG_\
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M_P#_  ('_$.O^IQ_YC__ +]#_AP=_P!77?\ F"__ ,<='_$PW_5(?^9__P#
M@?\ $.O^IQ_YC_\ []#_ (<'?]77?^8+_P#QQT?\3#?]4A_YG_\ \"!_Q#K_
M *G'_F/_ /OT/^'!W_5UW_F"_P#\<='_ !,-_P!4A_YG_P#\"!_Q#K_J<?\
MF/\ _OT/^'!W_5UW_F"__P <='_$PW_5(?\ F?\ _P "!_Q#K_J<?^8__P"_
M0_X<'?\ 5UW_ )@O_P#''1_Q,-_U2'_F?_\ P('_ !#K_J<?^8__ ._0_P"'
M!W_5UW_F"_\ \<='_$PW_5(?^9__ / @?\0Z_P"IQ_YC_P#[]#_AP=_U==_Y
M@O\ _''1_P 3#?\ 5(?^9_\ _ @?\0Z_ZG'_ )C_ /[]#_AP=_U==_Y@O_\
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M^'!W_5UW_F"__P <='_$PW_5(?\ F?\ _P "!_Q#K_J<?^8__P"_0_X<'?\
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MYC__ +]#_AP=_P!77?\ F"__ ,<='_$PW_5(?^9__P# @?\ $.O^IQ_YC_\
M[]#_ (<'?]77?^8+_P#QQT?\3#?]4A_YG_\ \"!_Q#K_ *G'_F/_ /OT/^'!
MW_5UW_F"_P#\<='_ !,-_P!4A_YG_P#\"!_Q#K_J<?\ F/\ _OT/^'!W_5UW
M_F"__P <='_$PW_5(?\ F?\ _P "!_Q#K_J<?^8__P"_0_X<'?\ 5UW_ )@O
M_P#''1_Q,-_U2'_F?_\ P('_ !#K_J<?^8__ ._0_P"'!W_5UW_F"_\ \<='
M_$PW_5(?^9__ / @?\0Z_P"IQ_YC_P#[]#_AP=_U==_Y@O\ _''1_P 3#?\
M5(?^9_\ _ @?\0Z_ZG'_ )C_ /[]#_AP=_U==_Y@O_\ ''1_Q,-_U2'_ )G_
M /\  @?\0Z_ZG'_F/_\ OT/^'!W_ %==_P"8+_\ QQT?\3#?]4A_YG__ ,"!
M_P 0Z_ZG'_F/_P#OT/\ AP=_U==_Y@O_ /''1_Q,-_U2'_F?_P#P('_$.O\
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M^9__ / @?\0Z_P"IQ_YC_P#[]#_AP=_U==_Y@O\ _''1_P 3#?\ 5(?^9_\
M_ @?\0Z_ZG'_ )C_ /[]#_AP=_U==_Y@O_\ ''1_Q,-_U2'_ )G_ /\  @?\
M0Z_ZG'_F/_\ OT/^'!W_ %==_P"8+_\ QQT?\3#?]4A_YG__ ,"!_P 0Z_ZG
M'_F/_P#OT/\ AP=_U==_Y@O_ /''1_Q,-_U2'_F?_P#P('_$.O\ J<?^8_\
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MA_YG_P#\"!_Q#K_J<?\ F/\ _OT/^'!W_5UW_F"__P <='_$PW_5(?\ F?\
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M /''1_Q,-_U2'_F?_P#P('_$.O\ J<?^8_\ ^_0_X<'?]77?^8+_ /QQT?\
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MO_\ ''1_Q,-_U2'_ )G_ /\  @?\0Z_ZG'_F/_\ OT/^'!W_ %==_P"8+_\
MQQT?\3#?]4A_YG__ ,"!_P 0Z_ZG'_F/_P#OT/\ AP=_U==_Y@O_ /''1_Q,
M-_U2'_F?_P#P('_$.O\ J<?^8_\ ^_0_X<'?]77?^8+_ /QQT?\ $PW_ %2'
M_F?_ /P('_$.O^IQ_P"8_P#^_0_X<'?]77?^8+__ !QT?\3#?]4A_P"9_P#_
M  ('_$.O^IQ_YC__ +]#_AP=_P!77?\ F"__ ,<='_$PW_5(?^9__P# @?\
M$.O^IQ_YC_\ []#_ (<'?]77?^8+_P#QQT?\3#?]4A_YG_\ \"!_Q#K_ *G'
M_F/_ /OT/^'!W_5UW_F"_P#\<='_ !,-_P!4A_YG_P#\"!_Q#K_J<?\ F/\
M_OT/^'!W_5UW_F"__P <='_$PW_5(?\ F?\ _P "!_Q#K_J<?^8__P"_0_X<
M'?\ 5UW_ )@O_P#''1_Q,-_U2'_F?_\ P('_ !#K_J<?^8__ ._0_P"'!W_5
MUW_F"_\ \<='_$PW_5(?^9__ / @?\0Z_P"IQ_YC_P#[]#_AP=_U==_Y@O\
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M )@O_P#''1_Q,-_U2'_F?_\ P('_ !#K_J<?^8__ ._0_P"'!W_5UW_F"_\
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M9_\ _ @?\0Z_ZG'_ )C_ /[]#_AP=_U==_Y@O_\ ''1_Q,-_U2'_ )G_ /\
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M?90HU]^2%/$+EP^)FXJW+AJM2I3HX>=_[1J_@L_I4* "@ H * "@ H * "@
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M (._%?X2MJY\/K\4/AIXZ^';:\M@-4;1%\;>%]4\-'5UTPWFGC43IHU/[8+
MW]B+OR?L_P!LMO,\Y #^$[_B!C_ZRB?^:3?_ )7% %NQ_P"#&:PCN8VU+_@I
MW=W=F#^]@L?V-(=.N7'I'=S_ +5&IQ1'W:RE^G% 'V9\!_\ @RQ_8"\#:C%J
MGQY_:%_:-^/1MIHWC\/Z(_@_X-^$KV,;?,@UBWTK3/&'C"=7((1]'\<:#)&K
M8+.P#@ _J$_95_8J_92_8@\ K\,_V4/@-\._@AX2=;3^TX?!NBI%KOB>>Q1X
MK34/&OC'4'O_ !AXYU>WBEDBBUCQAKNMZHD3&%;L180 'U#0 4 % !0 4 %
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MM5(4Y77/&OBI*%?$QD[QC'#4ITZ=6E6YOVWK^?3]/"@ H * "@ H * "@ H
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 ?@5_P %CO\ @F???'_1[O\ :?\ @-X?2]^-'A/1T3XC>#M*M0-4
M^*_A#1;-8;75-'A@3=JWQ"\):;;1VEIIS*VH^*_"]K!H.E2W.M:#X8T#6?Z2
M\"_%BGPW6I\'\28KV>0XRNWE./KS_<Y+C:\^:="O*6E#*\=5DYRJW5' XV<L
M364,/BL;BJ'Y-XC<$RS6G+/<IH\V94*:6-PU./OX_#THI1J4XK^)C,-!<JA;
MVF(P\51@Y5:.'HU/Y%?#OB+7O"'B#1?%7A;6-2\.^)O#6JV&N>']>T:\GT[5
M]%UG2KF.\TW4],O[5XKFROK&[ABN+6Y@D26&:-'1@RBO[7Q6%PV-PU?!XRA2
MQ6$Q5&IA\3AJ].-6A7H5H.G5HUJ4TXSIU(2E"<))J46TU8_GRC6JX>K2KT*D
MZ-:C4A5HU:<G"I2J4Y*4)PG&SC.$DI1DFFFDT?VH?\$P?^"IOA7]K_0=-^$W
MQ:O]*\*_M,Z'IQ5[8BWTS1OC!I^FVQDNO$WA&!!%:VOB>WM89+WQ7X+MEC\J
M*.Z\1>&+=_#T6K:=X3_@OQ<\'L7P1B*N=Y'3K8SA*O53YO>JU\BJ59\L,)C9
M/FG/!RFU3P6/FW=N&$Q<EBG1JXW^E>!^.Z'$-*&79A*GA\[I0M;W84LRA"-Y
M5L.M(QQ$8IRKX6-M%*OATZ*JPPW['U^%'Z.% !0 4 % !0 4 % !0 4 % !0
M 4 % !0!^7__  4>_P""E/@#]B#P7-H&A-I?C3]H;Q/IKMX)\ M/YMEX=@N$
M>.'QKX_%K+'<6/AVS<&33M'26VU;Q=>1#3].DL=.35O$&C?K_A7X3YEX@XY8
MO%>VR_A;!UE''YDHJ-7%SA9RR[*N>,H5,5-->VQ#C/#Y?2E[6LJM:6&PF)^%
MXSXVPG"^']A0]GBLYKTV\-A&[PH1>BQ6-Y6G"C%_PZ*<:N*DN2FX4XU:]'\?
M/^"67["_C?\ ;%^+5_\ MX_M>-JWC'PLWBF?Q'X2M/%:#'Q@\>Z==^4NNZC9
MF**"7X;^"+NTCL[#1+*WM?#VJZKIEIX8C@D\*>'=;\.W_P"X^,7B)E_ V2T_
M#G@E4,!C?J4<)BY8)V60975A?ZM1E>4EFV8PJ2J5,14G/%4:-:IC92^O8O#X
MNC^=<!\*XKB+,)\5<0.IB,/]8=:@L1OF>,@[>VFK)?4L)**A&E",:-2I3CAX
MI8;#U*$_ZPZ_B\_?PH * "@ H * "@ H * "@#SOXL?%?P!\#OAWXJ^*OQ0\
M26/A/P-X,TQ]4UW6K]\)'&'2"ULK.!,SZAJVJWTUMI>C:391S7^K:K=V>FV%
MO/=W,,3^KDF29GQ%FN"R7)L)4QN8X^JJ.'P].VKLY3J5)NT*.'H4HSK8BO4<
M:.'H4ZE:K.%.$I+BS#,,'E6"Q&88^M'#X3#0YZM27RC&$(KWIU:DW&G2I03G
M4J2C3A%RDD?Q5_%+QS^T3_P65_;1L- \#:9J%KX:@:YT_P "^';QY/\ A%?@
MS\)[2^MUUCQMXOFM?,M(=1OWDM-0\4ZMNGU'7]>N="\%Z"UY';^#]#A_OC*,
MNX7\"> JM?'UJ=2O[E7,L5326+S_ #N=.?U? 8&-1*HZ5-*I2P-!J-/"X6&)
MS#$1IN>85W_-&.Q6<>(_$L*6%ISC3]Z&$H3=Z&69?&4?:XG$.'NQG*\)XFHN
M:5:M*CA:4IJ.%IK^Q?\ 9@_9L^&W[)OP9\*?!;X7Z<EMHN@0&YUC69H8DUGQ
MEXJO8X?[=\8^([A,M=ZQK$T,8 >1X-*TJUTOP]I2VVB:/I=E:_PQQ?Q7FO&F
M?8S/\WJ<U?$RY*&'BW]7P&"IN7U; 82+^"AAXR>MN>O6E6Q5=SQ->M4G_1N1
M9)@N'\MP^68&%J=)<U6JTO:XG$22]KB:[7Q5*C2_NTZ<:=&FHTJ5.$?H&OF3
MUPH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H __1_OXH
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M0:E&24HRBTXRBU=.+6C36J:T:V+%2,* "@ H * "@ H * "@ H * $) !)(
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M 4 % !0 4 ?_T_[^* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H \0_:)^*]]\%/A1KWQ"TS2+36[W2KO1+6#3[ZXFMK63
M^U-8LM.D>62W5I?W4-Q(Z*FS,@0LVT%6 /S=_P"'FWCO_HF/A+_P;:Q_\30
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M&T?CC2=#L=?NY?$FEZ$MEJ%S/:VR1W]OJ%P]P7MD:5GC%AL2,;!^]W%ODV,
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M<Z=;);A+G;$B/]OWL^&($00+\^Y0#]": "@#\;O^'FWCO_HF/A+_ ,&VL?\
MQ- !_P /-O'?_1,?"7_@VUC_ .)H /\ AYMX[_Z)CX2_\&VL?_$T ?J_\.O$
MT_C7X?>!/&5U:PV-SXM\&^&/$UQ96[O)!:3Z]HECJLUK \G[QX;>2Z:*-W^=
MD12W)- '94 ?%?[67[4NN_LZWW@BRT3PKI/B+_A*;37;JYDU2]O+7[+_ &5-
MI44,<"6B<^9]NE:5I&/W8PBKABP!\A?\/-O'?_1,?"7_ (-M8_\ B: #_AYM
MX[_Z)CX2_P#!MK'_ ,30!]+?LK_MA>)/V@OB#K'@S6/!VA^'K73/!NH>)H[S
M3+Z_N9Y)[+6_#VE+:M'= 1B%X]:EE9Q\X>"-1\K-0!]]T 5+^Z^PV-[>^7YO
MV.TN+KRMVSS/L\+R^7OVOLW;-N[8VW.=IQB@#\>?^'FWCO\ Z)CX2_\ !MK'
M_P 30 ?\/-O'?_1,?"7_ (-M8_\ B: #_AYMX[_Z)CX2_P#!MK'_ ,30!^M7
M@G7)_$_@WPEXENH8;>Y\0^&-!URXM[??Y$$^K:5:7\T,'F,TGDQ27#)'O9GV
M*NYB<F@#IZ /AW]J[]J[Q#^SQXA\)Z+HOA/1O$47B+1KW4YIM3O;VU>W>UO1
M:+%$MH"K(R_,2W(/ XH ^4/^'FWCO_HF/A+_ ,&VL?\ Q- !_P /-O'?_1,?
M"7_@VUC_ .)H ^HOV5/VM_$G[0GC+Q#X:UCPEH?AVUT3PP^N1W&F7=_=3SS_
M -JZ=8+"PNB(TA$=W*[85G9Q'AE56#@'W?0!C>(]3?1/#VNZS%$D\FD:-JFI
MQP2$K',]A8SW21.R_,J2-$$8KR 21S0!^0__  \V\=_]$Q\)?^#;6/\ XF@
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M>""ZGTZREN(89I8U:1(7D11)Y8WE,JK(2& !^5?_  \V\=_]$Q\)?^#;6/\
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MN4 _,3_AYMX[_P"B8^$O_!MK'_Q- !_P\V\=_P#1,?"7_@VUC_XF@#9\._\
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MTUF]\.?V#Y&FWTLT%K<_VOXFT709/-EM_P!ZGDPZI).FSK)$BM\I- 'YI?\
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M,FAU.ZNK6.VCM;);I98C: LSLQV$-\H7IS0!\/?\/-O'?_1,?"7_ (-M8_\
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M34[>PNY)(;:ZD2:&(1320_O43$A.4YX H _+K_AYMX[_ .B8^$O_  ;:Q_\
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MW_AYMX[_ .B8^$O_  ;:Q_\ $T '_#S;QW_T3'PE_P"#;6/_ (F@#]+?V?\
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M? ^K>#= \/V</AO5-=-[IU[J%U<O)87.G6R6X2YVQ(C_ &_>SX8@1! OS[E
M/T)H * /QN_X>;>._P#HF/A+_P &VL?_ !- !_P\V\=_]$Q\)?\ @VUC_P")
MH /^'FWCO_HF/A+_ ,&VL?\ Q- 'ZH_"GQA=_$#X;>"/&]]:6]A=^*_#>EZ[
M/96C2/;6DFHVR7)MX7F+2ND(<1AWP7V[MJ9V@ ] H ^-OVM?VF]=_9R_X5__
M &)X8TGQ'_PF/_"5?:?[4N[RU^Q_\(]_PC?D^1]D!W_:/[<E\WS/N>1'L^\U
M 'QO_P /-O'?_1,?"7_@VUC_ .)H /\ AYMX[_Z)CX2_\&VL?_$T ?2W[*_[
M87B3]H+X@ZQX,UCP=H?AZUTSP;J'B:.\TR^O[F>2>RUOP]I2VK1W0$8A>/6I
M96<?.'@C4?*S4 ??= %2_NOL-C>WOE^;]CM+BZ\K=L\S[/"\OE[]K[-VS;NV
M-MSG:<8H _'G_AYMX[_Z)CX2_P#!MK'_ ,30 ?\ #S;QW_T3'PE_X-M8_P#B
M: #_ (>;>._^B8^$O_!MK'_Q- 'ZU>"=<G\3^#?"7B6ZAAM[GQ#X8T'7+BWM
M]_D03ZMI5I?S0P>8S2>3%)<,D>]F?8J[F)R: .GH ^*_VLOVI==_9UOO!%EH
MGA72?$7_  E-IKMU<R:I>WEK]E_LJ;2HH8X$M$Y\S[=*TK2,?NQA%7#%@#Y"
M_P"'FWCO_HF/A+_P;:Q_\30 ?\/-O'?_ $3'PE_X-M8_^)H ^HOV5/VM_$G[
M0GC+Q#X:UCPEH?AVUT3PP^N1W&F7=_=3SS_VKIU@L+"Z(C2$1W<KMA6=G$>&
M558. ?=] &-XCU-]$\/:[K,423R:1HVJ:G'!(2L<SV%C/=)$[+\RI(T01BO(
M!)'- 'Y#_P##S;QW_P!$Q\)?^#;6/_B: #_AYMX[_P"B8^$O_!MK'_Q- !_P
M\V\=_P#1,?"7_@VUC_XF@#]>/#FIOK?A[0=9EB2"35]&TO4Y((R6CA>_L8+I
MXD9OF9(VE**6Y( )YH V: /AW]J[]J[Q#^SQXA\)Z+HOA/1O$47B+1KW4YIM
M3O;VU>W>UO1:+%$MH"K(R_,2W(/ XH ^4/\ AYMX[_Z)CX2_\&VL?_$T '_#
MS;QW_P!$Q\)?^#;6/_B: /J_]E#]J[Q#^T/XA\6:+K/A/1O#L7AW1K+4X)M+
MO;VZ>X>ZO3:-%*MT JHJC<I3G/!XH ^XJ .;\8ZZ_A?PAXJ\316Z7<GAWPWK
MFNQVDDABCNGTC3+K4$MWE57:))FMQ$TBHQ0,6"DC% 'Y)?\ #S;QW_T3'PE_
MX-M8_P#B: #_ (>;>._^B8^$O_!MK'_Q- !_P\V\=_\ 1,?"7_@VUC_XF@#]
M@],N7O=-T^\E"+)=V-I<R+&"(U>>".5P@9F8(&8A0S,0,98GF@"]0!\)_M6?
MM<>(?V>O%WAOPSHOA#1O$,6M>&_[=FN]3O[VV>%SJ=[IZV\45HFW8JV?F&1G
M)8R;0JA,N ?+7_#S;QW_ -$Q\)?^#;6/_B: #_AYMX[_ .B8^$O_  ;:Q_\
M$T ?7?[)O[4GB']HK4O&MGK/A?1O#D7A6QT6Y@;2[J]NGNWU:?48F$INB%C2
M!;#Y0BL7,O+*$PP!]K4 <;\1?$T_@GX?>._&5K:PWMSX1\&^)_$UM97#O'!=
MSZ#HE]JL-K,\?[Q(9Y+18I'C^=48E>0* /R@_P"'FWCO_HF/A+_P;:Q_\30
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M;\1],TRTUF]\.?V#Y&FWTLT%K<_VOXFT709/-EM_WJ>3#JDDZ;.LD2*WRDT
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MV6IW%S:P107FB>(=5:Y1[4&0RI)HL42H?D*32$\JM 'P+_P\V\=_]$Q\)?\
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M>#2-5N]/AFF$<:QB66.W5Y!&JIO)VJ%P* .8_P"'FWCO_HF/A+_P;:Q_\30
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M^#GCJ[^)OPP\%^/;ZPM],N_%&C1ZG/86DDDMM:R/--$8H9)L2N@$0(+\\XH
M],H ^1?VL?VD=9_9UTSP7>:+X9TOQ'+XIOM9M9EU.\NK2.TCTFWT^53$+1"T
MCS-?8)9E6-8L!6+Y0 ^H?#FIOK?A[0=9EB2"35]&TO4Y((R6CA>_L8+IXD9O
MF9(VE**6Y( )YH V: "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M*LHQBDDDDDDK+0M5!04 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 ?__4_OXH * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@#D_&W@;PI\1O#UUX4\::/#KOA^]EM9[K3)Y[
MNWBFELITNK5FDL;BUG_<W$4<JJ)0I9!N! Q0!XA_PQM^S/\ ]$ITC_P:^)O_
M )=T '_#&W[,_P#T2G2/_!KXF_\ EW0!L^'OV5OV?_"FN:5XD\/_  VTO3=;
MT.^M]2TJ_CU'7Y9+.^M7$EO<)'<ZM- [1. RB6)TR!E30!]!4 % '@OBO]F'
MX$>./$.I^*O%7P\T[6?$&L2QSZEJ4^I:]%+=2Q6\-K&S1VNK06Z;+>"&)5BA
M10L8XSDT <]_PQM^S/\ ]$ITC_P:^)O_ )=T '_#&W[,_P#T2G2/_!KXF_\
MEW0![-X"^'?@OX8:&WAKP'H-OX=T-KZXU)M/MIKRXC-]=)#'/<&2^N;J?=)'
M;P*1YNP"-=JCG(!VM '(>./ 7A#XDZ!-X6\;Z);>(-!GN+:[ETZYENH8S<V<
MGFVTPELI[:X1XGZ>7,H92R,&1F4@'B?_  QM^S/_ -$ITC_P:^)O_EW0 ?\
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MU^T Z==V;LXMYY8@)&= KMA0>: /)/\ AC;]F?\ Z)3I'_@U\3?_ "[H /\
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M6SP6/GRW/V=5T_4+.-D\^>60&1&<%R VW  !P'_#&W[,_P#T2G2/_!KXF_\
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M_#VM6B7^C:[IE_HVK6,C2QQWFF:G:RV-_:.\#Q3(EQ:SRPLT,D<JJY,;HP#
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M7PUX@LDU+0];L9]-U6PDDGACO+&Z0QW%N\EM+#.B2QDHQBEC;:2 PH ^??\
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MU#5]3^&.EW>I:K?7>I:A=R:IXC$EU?7T\EU=W#B/640/-/+)(P1%0%B%51@
M H_\,;?LS_\ 1*=(_P#!KXF_^7= !_PQM^S/_P!$ITC_ ,&OB;_Y=T >Z>#?
M!OAGX?\ AO3O"/@[28=#\.:1]K_L[2X);F>*U^WW]UJ=WLEO)[FY;SKZ]N;@
M^9,^UI2J;8PJ* =/0!Y_\0OA;X!^*VFV.C_$'PY;>)=-TV^_M*RM+FZU"UC@
MOOL\MK]H!TZ[LW9Q;SRQ 2,Z!7;"@\T >2?\,;?LS_\ 1*=(_P#!KXF_^7=
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M8 CY2: /FW_AC;]F?_HE.D?^#7Q-_P#+N@ _X8V_9G_Z)3I'_@U\3?\ R[H
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MP]K5HE_HVNZ9?Z-JUC(TL<=YIFIVLMC?VCO \4R)<6L\L+-#)'*JN3&Z, P
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M?P]IGA3PIID6C>']&BD@TS3())Y8K6*6>6ZD1)+J6>X??<3RRDRRNVYSSC
M!T- 'GGQ#^%/P]^*]CI^F_$+PS:>)K+2KM[[3X;J>_MOLMU)";>26.33[NSE
M.^$[&1W:,X5BFY%( /)_^&-OV9_^B4Z1_P"#7Q-_\NZ #_AC;]F?_HE.D?\
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MGB?_ (1_^T/['^U7>IVOV'^U?L/]H>7_ &=>V>_[3_9MCN\[S-OV=?+V;GW
M'F7_  QM^S/_ -$ITC_P:^)O_EW0 ?\ #&W[,_\ T2G2/_!KXF_^7= '=?#[
MX _"#X5ZS<^(?A_X)L?#>LWFF3:-<WUK>ZQ<R2Z9<75E>S6ACU#4;N$(]UIU
ME,66-908%"N$9U8 ]AH AG@BN8)K:==\%Q%)!,F67?%*ACD7<A5UW(Q&596'
M52#@T ?-7_#&W[,__1*=(_\ !KXF_P#EW0 ?\,;?LS_]$ITC_P &OB;_ .7=
M !_PQM^S/_T2G2/_  :^)O\ Y=T ?1NF:;8Z-INGZ/IENEIINE6-IINGVD9=
MDM;&QMX[6TMT,C/(4A@BCC4N[.0HW,3DT 7J /+/B)\$_A=\69]+N?B'X1M/
M$TVBQ74&EO=7FJVWV.*]>&2Z6-=.O[-&\Y[> L9%=OW:A2!Q0!YO_P ,;?LS
M_P#1*=(_\&OB;_Y=T '_  QM^S/_ -$ITC_P:^)O_EW0!W_P]^!'PE^%.I7V
MK_#[P98^&M2U*Q_LV]NK6\U:Y>>Q\^*Y^SE=0U"\C5//@BDS&B/E%&[;Q0!Z
MY0!6N[2VO[2ZL;R%+BSO;>:TNK>09CGMKB)H9X7 Q\DD3LC $?*30!\V_P##
M&W[,_P#T2G2/_!KXF_\ EW0 ?\,;?LS_ /1*=(_\&OB;_P"7= !_PQM^S/\
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MH:/J=NEWINJV-WINH6CEU2YL;ZWDM;NW<QLDBI-!+)&Q1T<!OE93@@ ^<O\
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M$ITC_P &OB;_ .7= !_PQM^S/_T2G2/_  :^)O\ Y=T '_#&W[,__1*=(_\
M!KXF_P#EW0!]-T % 'C'CS]GKX-_$[7%\2>._ UCXBUM;&WTU;^YO]:MY%L;
M5YI+>W$=CJ5K $C>XF8$1;B9&W,>, '%_P##&W[,_P#T2G2/_!KXF_\ EW0
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M\-Z->:G-K-S8VMQ?7,<NIW%K96,UV7U"ZNY@[VNG64)19%B"P*50,SLP!W5
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MWJ8)RIUI=/=A7NO,X'5_V:?^"L?[1#S1?&3]L7X<?LQ^#[UK:Y_X1/\ 9?\
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@#_UO[^* "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /_7_OXH * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M_]#^_B@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@#_T?[^* "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H _E2_P"'Y?[6?_1//V=O_"2^)7_SVZ_KG_B
M?!__ $,N)?\ PLRO_P"<Q^0?Z_YS_P! V6?^"<5_\V!_P_+_ &L_^B>?L[?^
M$E\2O_GMT?\ $ ^#_P#H9<2_^%F5_P#SF#_7_.?^@;+/_!.*_P#FP/\ A^7^
MUG_T3S]G;_PDOB5_\]NC_B ?!_\ T,N)?_"S*_\ YS!_K_G/_0-EG_@G%?\
MS8'_  _+_:S_ .B>?L[?^$E\2O\ Y[='_$ ^#_\ H9<2_P#A9E?_ ,Y@_P!?
M\Y_Z!LL_\$XK_P"; _X?E_M9_P#1//V=O_"2^)7_ ,]NC_B ?!__ $,N)?\
MPLRO_P"<P?Z_YS_T#99_X)Q7_P V!_P_+_:S_P"B>?L[?^$E\2O_ )[='_$
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M ,V!_P /R_VL_P#HGG[.W_A)?$K_ .>W1_Q /@__ *&7$O\ X697_P#.8/\
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M_P#SF#_7_.?^@;+/_!.*_P#FP/\ A^7^UG_T3S]G;_PDOB5_\]NC_B ?!_\
MT,N)?_"S*_\ YS!_K_G/_0-EG_@G%?\ S8'_  _+_:S_ .B>?L[?^$E\2O\
MY[='_$ ^#_\ H9<2_P#A9E?_ ,Y@_P!?\Y_Z!LL_\$XK_P"; _X?E_M9_P#1
M//V=O_"2^)7_ ,]NC_B ?!__ $,N)?\ PLRO_P"<P?Z_YS_T#99_X)Q7_P V
M!_P_+_:S_P"B>?L[?^$E\2O_ )[='_$ ^#_^AEQ+_P"%F5__ #F#_7_.?^@;
M+/\ P3BO_FP/^'Y?[6?_ $3S]G;_ ,)+XE?_ #VZ/^(!\'_]#+B7_P +,K_^
M<P?Z_P"<_P#0-EG_ ()Q7_S8'_#\O]K/_HGG[.W_ (27Q*_^>W1_Q /@_P#Z
M&7$O_A9E?_SF#_7_ #G_ *!LL_\ !.*_^; _X?E_M9_]$\_9V_\ "2^)7_SV
MZ/\ B ?!_P#T,N)?_"S*_P#YS!_K_G/_ $#99_X)Q7_S8'_#\O\ :S_Z)Y^S
MM_X27Q*_^>W1_P 0#X/_ .AEQ+_X697_ /.8/]?\Y_Z!LL_\$XK_ .; _P"'
MY?[6?_1//V=O_"2^)7_SVZ/^(!\'_P#0RXE_\+,K_P#G,'^O^<_] V6?^"<5
M_P#-@?\ #\O]K/\ Z)Y^SM_X27Q*_P#GMT?\0#X/_P"AEQ+_ .%F5_\ SF#_
M %_SG_H&RS_P3BO_ )L#_A^7^UG_ -$\_9V_\)+XE?\ SVZ/^(!\'_\ 0RXE
M_P#"S*__ )S!_K_G/_0-EG_@G%?_ #8'_#\O]K/_ *)Y^SM_X27Q*_\ GMT?
M\0#X/_Z&7$O_ (697_\ .8/]?\Y_Z!LL_P#!.*_^; _X?E_M9_\ 1//V=O\
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M .>W1_Q /@__ *&7$O\ X697_P#.8/\ 7_.?^@;+/_!.*_\ FP/^'Y?[6?\
MT3S]G;_PDOB5_P#/;H_X@'P?_P!#+B7_ ,+,K_\ G,'^O^<_] V6?^"<5_\
M-@?\/R_VL_\ HGG[.W_A)?$K_P">W1_Q /@__H9<2_\ A9E?_P Y@_U_SG_H
M&RS_ ,$XK_YL#_A^7^UG_P!$\_9V_P#"2^)7_P ]NC_B ?!__0RXE_\ "S*_
M_G,'^O\ G/\ T#99_P""<5_\V!_P_+_:S_Z)Y^SM_P"$E\2O_GMT?\0#X/\
M^AEQ+_X697_\Y@_U_P Y_P"@;+/_  3BO_FP/^'Y?[6?_1//V=O_  DOB5_\
M]NC_ (@'P?\ ]#+B7_PLRO\ ^<P?Z_YS_P! V6?^"<5_\V!_P_+_ &L_^B>?
ML[?^$E\2O_GMT?\ $ ^#_P#H9<2_^%F5_P#SF#_7_.?^@;+/_!.*_P#FP/\
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MO]K/_HGG[.W_ (27Q*_^>W1_Q /@_P#Z&7$O_A9E?_SF#_7_ #G_ *!LL_\
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M)Y^SM_X27Q*_^>W1_P 0#X/_ .AEQ+_X697_ /.8/]?\Y_Z!LL_\$XK_ .;
M_P"'Y?[6?_1//V=O_"2^)7_SVZ/^(!\'_P#0RXE_\+,K_P#G,'^O^<_] V6?
M^"<5_P#-@?\ #\O]K/\ Z)Y^SM_X27Q*_P#GMT?\0#X/_P"AEQ+_ .%F5_\
MSF#_ %_SG_H&RS_P3BO_ )L#_A^7^UG_ -$\_9V_\)+XE?\ SVZ/^(!\'_\
M0RXE_P#"S*__ )S!_K_G/_0-EG_@G%?_ #8'_#\O]K/_ *)Y^SM_X27Q*_\
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MSG_H&RS_ ,$XK_YL#_A^7^UG_P!$\_9V_P#"2^)7_P ]NC_B ?!__0RXE_\
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M/_HGG[.W_A)?$K_Y[='_ ! /@_\ Z&7$O_A9E?\ \Y@_U_SG_H&RS_P3BO\
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M;+/_  3BO_FP/^'Y?[6?_1//V=O_  DOB5_\]NC_ (@'P?\ ]#+B7_PLRO\
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MQ /@_P#Z&7$O_A9E?_SF#_7_ #G_ *!LL_\ !.*_^; _X?E_M9_]$\_9V_\
M"2^)7_SVZ/\ B ?!_P#T,N)?_"S*_P#YS!_K_G/_ $#99_X)Q7_S8'_#\O\
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M*_\ GMT?\0#X/_Z&7$O_ (697_\ .8/]?\Y_Z!LL_P#!.*_^; _X?E_M9_\
M1//V=O\ PDOB5_\ /;H_X@'P?_T,N)?_  LRO_YS!_K_ )S_ - V6?\ @G%?
M_-@?\/R_VL_^B>?L[?\ A)?$K_Y[='_$ ^#_ /H9<2_^%F5__.8/]?\ .?\
MH&RS_P $XK_YL#_A^7^UG_T3S]G;_P )+XE?_/;H_P"(!\'_ /0RXE_\+,K_
M /G,'^O^<_\ 0-EG_@G%?_-@?\/R_P!K/_HGG[.W_A)?$K_Y[='_ ! /@_\
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M9E?_ ,Y@_P!?\Y_Z!LL_\$XK_P"; _X?E_M9_P#1//V=O_"2^)7_ ,]NC_B
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MEG_@G%?_ #8'_#\O]K/_ *)Y^SM_X27Q*_\ GMT?\0#X/_Z&7$O_ (697_\
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MS_T#99_X)Q7_ ,V!_P /R_VL_P#HGG[.W_A)?$K_ .>W1_Q /@__ *&7$O\
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M9_\ 1//V=O\ PDOB5_\ /;H_X@'P?_T,N)?_  LRO_YS!_K_ )S_ - V6?\
M@G%?_-@?\/R_VL_^B>?L[?\ A)?$K_Y[='_$ ^#_ /H9<2_^%F5__.8/]?\
M.?\ H&RS_P $XK_YL#_A^7^UG_T3S]G;_P )+XE?_/;H_P"(!\'_ /0RXE_\
M+,K_ /G,'^O^<_\ 0-EG_@G%?_-@?\/R_P!K/_HGG[.W_A)?$K_Y[='_ ! /
M@_\ Z&7$O_A9E?\ \Y@_U_SG_H&RS_P3BO\ YL#_ (?E_M9_]$\_9V_\)+XE
M?_/;H_X@'P?_ -#+B7_PLRO_ .<P?Z_YS_T#99_X)Q7_ ,V!_P /R_VL_P#H
MGG[.W_A)?$K_ .>W1_Q /@__ *&7$O\ X697_P#.8/\ 7_.?^@;+/_!.*_\
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M)7_SVZ/^(!\'_P#0RXE_\+,K_P#G,'^O^<_] V6?^"<5_P#-@?\ #\O]K/\
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M7_PLRO\ ^<P?Z_YS_P! V6?^"<5_\V!_P_+_ &L_^B>?L[?^$E\2O_GMT?\
M$ ^#_P#H9<2_^%F5_P#SF#_7_.?^@;+/_!.*_P#FP/\ A^7^UG_T3S]G;_PD
MOB5_\]NC_B ?!_\ T,N)?_"S*_\ YS!_K_G/_0-EG_@G%?\ S8?U6U_(Q^OA
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '_TO[^* "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H _SMZ_TH/YG"@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H _P!$BO\ -<_I@* "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H _]/^_B@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * /\[>O]*#^9PH * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M /\ 1(K_ #7/Z8"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /_4_OXH
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M'9=/\6Z2+'5+W3O#VHRW27T-QH5I'!!/= 'Z74 % !0 4 % !0 4 % !0 4
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MW_P=B_M^_MQ?LO\ _!2[X??#O]G#]KK]HWX$^ K[]D+X8>*KWP;\)OC#X[\
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M92?-$\8'ET ?M90 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@"EJ.HV&CZ??:MJM[:Z;I>EV=SJ.I:C?3Q6ME86%E ]S>
M7MY<S,D-M:VMO%)/<3RND4,4;R.RJI( /X8?&/\ P>^_"/1O%WBG1_"7[ /C
M/QAX5TKQ'K>F^&?%LW[16E>'9O%/A^QU.YM=&\12^'Y?@KJ<NA2ZWIT5MJ;Z
M/)J6H2:8UR;)[V[: SR ']J?P'^,W@G]HOX)_"3X^?#:_P#[2\ _&?X<>#?B
M=X/O"8S,_A_QMX?L/$.F17:1,ZP:A:VU^EKJ-HQ\VROX;BTF5)H710#UB@ H
M _SF_P#@[%_;]_;B_9?_ ."EWP^^'?[.'[77[1OP)\!7W[(7PP\57O@WX3?&
M'QWX!\,W?B;4OB?\;M-U#7[C1?#6MZ=I\NL7NGZ-I-E=:@\!NI[73;&"21H[
M6%4 /[%?^"(_Q/\ B+\:/^"47[#WQ1^+?C?Q/\2/B/XQ^#-IJ?BSQSXTUF^\
M1>*O$NI)XAU^R&HZ[KFIS7&H:I?M:VMO%+>7L\US,(E:61WRQ /U/H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * /\[>O]*#^9PH * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * /]$BO\US^F H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#
M_]7^_B@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M:^L2>'O OP[AU6UOM+NO&GB7^P]6N[W7-9@O='\(:3:RZSJEAK%]=:%X>UX
M_P!"OX1_\&QO_!%?X3>&]-T.3]D*U^*.JV=G]EU#QI\7/B5\4/%GB37Y<%6O
M]1LK3Q=HO@NPNW&!M\,^$?#]E&0'ALXGRQ /)/VB/^#4#_@CG\;M#O[;P/\
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MM/LUYXC^(?Q.^,GBO7=5D*E9+VZ^T_$"'1;*[D!S_P 2'1M'MH6 :VMH",T
M> ?'O_@TM_X(X_%SPYJ^G_#OX3?$K]FSQ5?(TFG^,OA/\8_B#KSZ??*&,32>
M%_C#KOQ,\+3Z:\FP7NG66F:5++;*T6GZAI<[B[0 ^C/^"&W_  1V\0?\$=?
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M_*6#X9_]F1_"+_U;G[0% ']RG_!OU_RAG_X)]?\ 9"[?_P!2OQ/0!^Q5 !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0!_G;U_I0?S.% !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0!_HD5_FN?TP% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 ?_UO[^* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M"GA;P-<SOC.EW/B/XC)' H8WZS3&.U /C7X<?\'D_P#P56\*^([34/'?@_\
M97^*/AK[<LNI^'-0^&/BCPG=RZ<3B:RT?7O"OC^R?3+D)G[)?:EIOB!()=KW
M-E?1AH6 /WI^(O\ P=X_##7O^"=<O[3W[/7P@\-6O[5G@[XO?#;X<?%K]ESX
MP>)M2N;+P_X=\=:'X[U%OB/X#\5>&8M!O/B'X-34?"%KHG]I)IN@:AX?U35K
M>T\5:#IHU'PS<^(0#]!/^#>__@M;\8O^"QFE_M77_P 6O@Y\-/A(_P"SY?\
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MT6#7=4\5^/-81]%\(Z%97&OZ7:M+:V/B;Q%//=(;'PO>6D5Y=V@!_%;\:/\
M@]&_X*.^,=9N_P#A2WP/_9<^"OA0SS/IMGJ^@>.OBKXRAMW)$-OJ?BG4O&7A
M?PUJ#0IMS-9?#S1?-E#.8UB98$ .-^%?_!Y9_P %3/!^OV5U\2/ O[+/Q@\,
MB51JNBWWPZ\4^"-8GM?,5I%T?Q#X2\=VUII=]L4Q0W6H^'=?M(U9FDTRX<*R
M@']T'_!(3_@LO^SA_P %>_A%KWBWX7Z=J/PR^,?PW.EV_P 9/@+XHU2UU?7_
M  6VL_:5T?Q!X?U^UM--MO&W@/6I;*]MM-\2V^E:/>V]]9SZ?K^@:'=/8)?
M'Z_T ?P6_%;_ (.X?VI/ 7[?_P 1_P!D+3/V4_@#=^$?!7[8/BW]FZR\57WB
M'XB'Q'=^'_#?QGO_ (80^(KJ*WU6#3!K-SI]D-3D@BM4LDO',21F!1D ^S/^
M"OG_  =A_"#]B7XD>+OV:OV,/AWX;_::^.?@>]U7PY\1/B'XKUK5-.^!OPR\
M9Z7<-97?A2*U\/BU\0?%?7]%O8+FS\4VN@^(O!V@:'>(NG0>+-7UBWUG2M'
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MWFEZI9VUY;2Q* >X4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '^=O7^E!_,X4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % '^B17^:Y_3 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0!_]?^_B@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@#_*R_P"#Q7_E+S:_]FI?!7_T_P#Q
M)H _O,_X("?\H:_^">__ &0+2_\ U(/$% '\"O\ P="_\$B/^'?_ .UD?VDO
M@QX8_L[]D[]K/7]8U[1K/2K3RM%^$WQLE$VL^.OAD([=/LFE:%X@#77CKX<V
M8%G;II,OB7PMI%B+#P"UQ, ?UN_\&NW_  5R_P"&_?V2!^S9\9?$W]H_M6_L
MDZ#HWA[6+O5+OS=:^*WP1B\G1O 7Q+,D[?:M5USP]LMO ?Q$O";NX;58/#/B
MC6+XW_CU((@#]YOVZ?\ DR/]L7_LU?\ :$_]5)XNH _R@?\ @VE_Y3?_ +!O
M_8V?%S_UG7XOT ?[$U '^/A_P7]_X*/_ !"_X*>?\%&/'>C^%-5UGQ!\"?@E
MXVUKX$?LO> ]*2>XM-0@T_6;?PYXA\<Z=I=L"VI>)/C%XOTO^V;:[>U75W\,
M?\(5X8F0_P#"/P+0!_<+_P $:?\ @VF_9'_8H^#O@?XC_M;?"/P#^T?^V/XE
MT;3/$7C*Y^)VB:3X]^'7P:U2_M[:^_X0+X<^#=775/!UWJ7A.<1VFH?$J^T_
M4_$.IZY;7M]X9U#0= N+?2P ?OK\1/V,_P!D3XM^$KGP'\3_ -EW]GSQ]X-N
MK8VDGAKQ7\'OA_K>DQPX8(;2TOO#\J6$]N6\VTN['[/=64X2XM)H9T210#_-
M9_X.8/\ @A/X&_X)H>*O!'[4/[*=AJEA^R3\:_%,_@G4_ .H:A?ZZ_P.^*[:
M7?:]IGAW3-=U>ZO-;U3P-XXT/2->U'PS_;-WJ6IZ!J/AS6])U#5KBUO?#L=
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M+[2[T'?)]DF^(/P=@D^(OA+7]BMY8NM+\'VWQ,TE"RX:#Q!+D[HXA0!_J,T
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MC!;W7Q!^(5GH%S>)#G8DMY#\,K2"24*&D2PB0DB(  '[?_\ !G/\,])\&?\
M!);4O&UK8K%J_P 7OVGOBUXHU;4& ,]Y;^&M)\%?#S2[59,;A96(\)WCV]OD
MI%=WVHSKA[J3(!_5O0 4 % !0!_GP?\ !Y-_P4U\5_\ "8> ?^"8'PK\1W.E
M>$;/PYX?^,?[4 TV1X'\4:UJ]Y_:'PD^&FIS(T4C:/X>T[3T^)6LZ6ZW&GZM
MJ6O?#^^WI>>%S'0!N?\ !L__ ,&[WP2^*?P8\(?\%#OV]/AS9_$V/QY?/K/[
M-/P&\81V^H?#F3P-82R6D'Q5^*'A.>%X/&<_BG4X+L^"_!WB#S_"*>%[6'Q-
MK.C^(Y/$VBKX< /[0_'W_!/K]A3XH_#V?X4^//V._P!FCQ#\/9=+O='M_"\_
MP5^'MI8Z/97\#V\[>&I--T"SO/"FH1H_F6.K^&KG2=6TRZ2&]TV]M+R"&>,
M_P J?_@O[_P2QLO^"2?[=-MX2^#E]XBC_9]^+/AVR^+O[/.JZEK<M_XG\)QV
M>H?V=XJ\"WFOH+74;K5/ /BNU6XT/5Y0VH2>$M:\(37^JZEXACU>]8 _TL_^
M"'?[:VN_M^_\$POV7?VA/&U^^I_%&3PI?_#7XN7\\D<E[JOQ(^$^M7_@+7?$
M^H^4!#'?^/+?1-.^(%Q!"D<5N?%0ACBA2,1( ?PC?\'G7_*6#X9_]F1_"+_U
M;G[0% ']RG_!OU_RAG_X)]?]D+M__4K\3T ?C3_P>O\ _*.#]F?_ +/<\*_^
MJ(^/- 'B_P#P9!_\FS_MT_\ 9=/A?_Z@&KT ?W$4 % !0!_%A_P>V?\ )CO[
M(7_9UM[_ .JA\<4 <?\ \&0O_)KG[<7_ &7WX<_^J[NJ /[?Z "@#\#/^#H#
M_E!=^W1_UZ?LZ_\ K6OP&H _E%_X,E/^3Y_VN?\ LTZV_P#5O^ : /\ 2MH
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MPM]BV%IX1^*NG^/?"^C0VLG^B:9H.FR)Y&](HP#_ $_/^"0'[:]O_P %!/\
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M?#*&]O=>DC:7=<?#7P]Y=LGG7MS0!_I(T % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % '^=O7^E!_,X4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '^B17^:Y_3 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0!_]#^_B@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M26,DEK!JGAGQC86L.KZ98-;@'^L%\1OVD_A1^V%_P2@^-G[3/P0UY?$?PO\
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M&C6$=M!X=\9:+XAL;73K'P]/X9>] .0_X.J?^4'?[6O_ &,?[-__ *TK\)J
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M *J'QQ0!Q_\ P9"_\FN?MQ?]E]^'/_JN[J@#^W^@ H _ S_@Z _Y07?MT?\
M7I^SK_ZUK\!J /Y1?^#)3_D^?]KG_LTZV_\ 5O\ @&@#_2MH \ _:P_Y-9_:
M5_[(!\8__5=>(Z /\E7_ (-J?^4WW[!O_8W_ !8_]9Y^+M '^Q30!_B6_ME>
M$M/\>_\ !8#]JOP+JK2)I?C3_@I-\<O"6I/%Q*FG^(_VG_%&CWC1$%2)%M[R
M0I@C# <B@#_;-@@AMH8;:WBC@M[>*."""%%CBAAB01Q111H D<<:*J(B@*J@
M*H  H EH _R-_P#@ZS\.V.A_\%N?VG;ZR79)XK\&_L\>(M04 *@OD^ GP]\.
M%D X_>6OAZUED. 6F>1VRS%B ?Z9O_!*.62?_@EO_P $V)YG:26;]@3]CJ66
M1N6>23]G?X=.[L>[,Q)/N: /\AO4K0?M?_\ !6R\TWQI<MJD?[3O_!1.33/$
M]TWS?;+?XR?M)&RU5@"VT1R0>(IA'&&")'MC7:BC !_MLV]O!:00VMK#%;6U
MM%';V]O;QI#!;P0HL<,,,,:K'%%%&JQQQHJHB*JJH4 4 34 ?R,_\'GOAK2-
M4_X)7_"KQ!=VJMJ_A;]L_P"&,FCWJX$MO'K/PJ^-^FZE:EL$FUNXC;RS1#;N
MN+&RE)_<!2 ? G_!C5_R+G_!2_\ [#?[(W_I!^TE0!_?#0 4 % '^4+_ ,'>
M7@6\\)?\%D?&GB"YLIK6#XH? #X%>.-/N)(RD>I6FG:%J?PUDO+=L8EBCOOA
M[>:>SC.V:QEC_P"6= ']U?\ P;9?%K1_B]_P1<_8HOM,NO.O? ?A#QA\)/$-
MHS*T^F:Q\-OB-XM\.06L^TD)]K\/VVA:U:)G(TW5;+>$<LB@'[GT % !0 4
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M@"6@#_(W_P"#K/P[8Z'_ ,%N?VG;ZR79)XK\&_L\>(M04 *@OD^ GP]\.%D
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M]X:EN8\B.:32+1L%H!@ _O>H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * /\3']L7PKI_CG_ (+"_M3^"=6S_97C
M#_@I3\</"NI[1EO[/\0?M0^)](O-HR,G[-=R8&1SW% '^V8JJBJB*J(BA410
M%55485548"JH      P.* '4 ?XB_P"T#\./#NN_\%8_C;\(I8?)\)ZS_P %
M#_B3\.)+= "8O#NH_M)ZSX8>%%^53Y>FS&-1\HX X% '^W,JJBJB*%10%55
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M7P9^)7A_5=Q4KF :9J5V;A#\K0"12"#B@#_9 H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * /\[>O]*#^9PH * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /]$BO\US^F H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@#__1_OXH * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H _RLO\
M@\5_Y2\VO_9J7P5_]/\ \2: /[S/^" G_*&O_@GO_P!D"TO_ -2#Q!0!^P-
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MF.?MF?\ 9J/[1'_JH?&% '^5G_P:Y?\ *=?]AK_NYG_UCS]H*@#_ %^J "@
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M8/AG_P!F1_"+_P!6Y^T!0!_<I_P;]?\ *&?_ ()]?]D+M_\ U*_$] 'XT_\
M!Z__ ,HX/V9_^SW/"O\ ZHCX\T >+_\ !D'_ ,FS_MT_]ET^%_\ Z@&KT ?W
M$4 % !0!_%A_P>V?\F._LA?]G6WO_JH?'% ''_\ !D+_ ,FN?MQ?]E]^'/\
MZKNZH _M_H * /PI_P"#EW0+SQ)_P0^_;PTZQBEEFMO"WP>U]TAC,CBS\*?M
M'?!WQ1J,I502(H-/T>YFG?&V*".21BJH2 #^,C_@S$^)^E^#_P#@J)\5/A_J
MVI6=B?B[^R)\0='\.6EQ/%#<:QXM\(?$3X5>-(=/T])&#W5Q#X-TGQQJLMM
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MWV:&[TY)0#^M[_AD?]E'_HV/]GK_ ,,O\-__ )FJ #_AD?\ 91_Z-C_9Z_\
M#+_#?_YFJ .U\#_!#X+?#'4KK6?AK\(?A?\ #W5[ZQ;3+W5? _@#PIX3U*\T
MUYX+IM/NK[0-)T^YN+%KFUMKAK265X#/;P3&/S(8V4 _DO\ ^#U__E'!^S/_
M -GN>%?_ %1'QYH \7_X,@_^39_VZ?\ LNGPO_\ 4 U>@#^XB@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H _P 5
M?]I#_E-O\>O^TJ'Q1_\ 6MM<H _VJ* "@#_%6^,7_*;7XI_]I3_''_K6NIT
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@#_1(K_-<_I@* "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H __2_OXH * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M\(:9I6E^$?"8NHK>:[T[2&U^[L;'5==U.  'QY_P=4_\H._VM?\ L8_V;_\
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MO$OC?XFZKHNFWSWNF6][>QV.C^#-(\(Z)%'J%U%K$7B2:&RO[< _=S_@M/\
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0!_G;U_I0?S.% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!_HD5_FN?TP% !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?__3_OXH * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M[4G\(^)M(\8^'I!XB^'_ (A\*^*]/.G^(]!TK4,:9KMDMT+4V=Z+FPN+FUF
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MU\%F^O\ PGKECXDT"X7Q#\/?$GA/Q59&PUG3;.[V6&N6L5TL1M;U+FRFGMY
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M::DU]<>*/VPM4M6E60:+??&/P)'IJ(I!,"RZ9\'-.UCRG VL7U5Y@#\DJ'!
M!^MG[&?_  1,_P""8?[!.MZ?XR_9T_91\#:5\2M+D6XT_P"*_CVYUWXL?$K2
MKX1>0^H>&O%/Q'U3Q+<^"+N: M#.? D?AB&:)Y8WA*SS"0 _56@#\N?VS_\
M@B[_ ,$T?^"A7Q7TKXW_ +7_ .S6/BY\4=%\#Z3\.--\4#XP?'OP ;?P9H6L
M>(=?TK1CHWPO^*7@KP_<?9-6\5:]=#4;G29M6F%\+>XOI;6TLH+8 ^Y?V?\
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MXP_X7Y^T_:)??$[6?%T_CO4O$O\ PC-C\:K;PC;K<^*KB;5#H=IH$'AR(/\
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MV*_ >E^%_"!USXVM\4/#W@+PCIMAH6E>$_AG\$/AIXG^'NG:?I_AW1X+;3-
M\.S:G\6["TT.TAM;2UD/AN[M],C,>EWJ0@'4_P#!DC\*M6T+]C_]LCXSW=OY
M.D_$G]HCPE\/](D="DMV_P )/AW!K6HW$>['FV:S?%J&TAE0>7]KM=0A#&2"
M14 /[9* "@ H * *UY9VFH6EUI]_:VU]87UM/9WME>017-I>6ES$T-S:W5M,
MKPW%M<0N\,\$J/%+$[1NK(Q% 'X8_M+?\&V?_!'7]IW5;KQ)KW[)FB?"?Q7>
MW4UU=^(/V>O$7B#X-13R7#-)<>9X,\+7L?PT9IYF\Z2Y/@G[=Y@.RZ5))4D
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MJ?BCXD^-XK%FEA3Q7\0/%%[JWBC4;&.ZDGO;;0H]0M?#>FW5Q,^D:-IZ,(U
M/DOX&_\ !O%_P1X_9M^,/P\^/GP6_8_3P9\6?A3XJT[QKX \5?\ "_/VG_$2
M^'_$^D2F;3M37P_XL^-6N^&-2^RRG>EGK&BZAI[$#S+5PJ@ '[34 ?BQXD_X
M-X/^"._B[XXZ]^TAXA_8_34/C/XF^*VI_&[7/&'_  OS]I^T2^^)VL^+I_'>
MI>)?^$9L?C5;>$;=;GQ5<3:H=#M- @\.1!_L$&D1::JV:@'[3T % 'Y+?M:?
M\$,/^"6/[<_QJUO]HC]J;]EP?%#XQ>(])\/Z'K7C ?&O]HGP0;W3/"NE0:)H
M-LV@?#GXM^$/"\)L-+MH+3[1;:)#<W*QK)>37$V9" ?I5\*/A?X%^"'PM^&W
MP6^%VA#PO\,_A#X!\'?"_P"'?AE=1U;6%\.^!? 'AW3O"GA'0EU;7[_5==U0
M:1H&DZ?IXU'6M4U+5KT6_P!IU*_O+R2:XD ._H _%3]LG_@WL_X)0_MP>)]8
M^(7Q2_9GT[P3\4O$%R;S6_B9\#M?UCX2>(M9O96,EWJ.NZ-X;G7P#XDUG4'.
M_4-?\1^#-6UZZ<;Y-3W,Y8 _/_PS_P &=7_!(70=6DU'5+G]JSQI9O('30/$
MOQJT&UTF%1_RQBF\'?#;PGKIC;N9M:EE_NRKQ@ _<3]C/_@FE^PO_P $_-";
M1OV2?V;?AW\)[ZYL1IVL>-[73[CQ'\4?$EINBEDMO$GQ2\67.N>/M9L)+F(7
M:Z1=^(7T6TN"S:?IMFFV-0#[GH ^#/VUO^"8O["7_!0[1]/TS]KO]G+P1\5M
M0T6VDL_#OC9CJ_A'XE^&[5_,<6>B?$GP3J7AWQM::4MQ*;Q_#[:W+X=NKQ8Y
M[[2;IE H _#75O\ @S<_X)'ZCJG]H6?B+]K[0+3>S?V'I/QE\$S:7M8Y$7FZ
M[\(=:UO9&/E0C6!(1]^1VYH ^S/V:O\ @V8_X(X_LSZWIOBK3_V78OC/XLTE
MUDLM:_:+\6Z_\6M.#JRNK7/P]U2XL_A/?R*Z(T<U_P" +F> K^XDB#2!P#]Y
MK"PL-*L++2]+LK33=,TVTMK#3M.L+:&SL+"PLX4M[2RLK2W2.WM;2UMXXX+:
MV@CCA@AC2*)%154 'R'^VO\ L ?LC_\ !13X;>&OA#^V/\)1\8?AYX0\;V?Q
M'\.^'_\ A.OB7\/SIWC.PT'7_#-KK U?X6^,O!&NW(CT/Q1KED=.O=3N-)E^
MVBYEL'N[6RGMP#%_8@_X)O\ [%__  3B\+^.?!G[&/P9'P:\-_$G7M-\3^-=
M._X6%\5/B$VM:WH^GR:5IMX;[XJ^./'&HZ>+:PED@6TTJ[L;*0NTLMO).?,H
M ^X: "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@#\6/$G_!O!_P $=_%WQQU[]I#Q#^Q^FH?&?Q-\5M3^-VN>,/\
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@#_ #MZ_P!*#^9PH * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M/]$BO\US^F H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#__U/[^* "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H _SMZ_TH
M/YG"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H _P!$BO\ -<_I@* "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H _]7^_B@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H _*O_@H?_P $7_\
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!_G;U_
MI0?S.% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0!_HD5_FN?TP% !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 ?_];^_B@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * /\[>O]*#^9PH * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * /\ 1(K_ #7/Z8"@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M /_7_OXH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@#_.WK_2@_F<* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#_ $2*_P US^F
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@#_T/[^* "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /_1
M_OXH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H _]+^_B@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@#_T_[^* "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /_4_MH_
M:]_:&_X9/_9H^,?[1G_"N?&'Q<_X5%X/N/%G_"M? $/VCQEXP^SW=I:_V1X>
MA^SW7F:A)]J\U%^SR_NX9/DXX /YD?\ B+)_ZQ$_M_?^$_\ _@I0 ?\ $63_
M -8B?V_O_"?_ /P4H /^(LG_ *Q$_M_?^$__ /@I0 ?\19/_ %B)_;^_\)__
M /!2@ _XBR?^L1/[?W_A/_\ X*4 '_$63_UB)_;^_P#"?_\ P4H /^(LG_K$
M3^W]_P"$_P#_ (*4 '_$63_UB)_;^_\ "?\ _P %* #_ (BR?^L1/[?W_A/_
M /X*4 '_ !%D_P#6(G]O[_PG_P#\%* #_B+)_P"L1/[?W_A/_P#X*4 '_$63
M_P!8B?V_O_"?_P#P4H /^(LG_K$3^W]_X3__ ."E !_Q%D_]8B?V_O\ PG__
M ,%* #_B+)_ZQ$_M_?\ A/\ _P""E !_Q%D_]8B?V_O_  G_ /\ !2@ _P"(
MLG_K$3^W]_X3_P#^"E !_P 19/\ UB)_;^_\)_\ _!2@ _XBR?\ K$3^W]_X
M3_\ ^"E !_Q%D_\ 6(G]O[_PG_\ \%* #_B+)_ZQ$_M_?^$__P#@I0 ?\19/
M_6(G]O[_ ,)__P#!2@ _XBR?^L1/[?W_ (3_ /\ @I0 ?\19/_6(G]O[_P )
M_P#_  4H /\ B+)_ZQ$_M_?^$_\ _@I0 ?\ $63_ -8B?V_O_"?_ /P4H /^
M(LG_ *Q$_M_?^$__ /@I0 ?\19/_ %B)_;^_\)__ /!2@ _XBR?^L1/[?W_A
M/_\ X*4 '_$63_UB)_;^_P#"?_\ P4H /^(LG_K$3^W]_P"$_P#_ (*4 '_$
M63_UB)_;^_\ "?\ _P %* #_ (BR?^L1/[?W_A/_ /X*4 '_ !%D_P#6(G]O
M[_PG_P#\%* #_B+)_P"L1/[?W_A/_P#X*4 '_$63_P!8B?V_O_"?_P#P4H /
M^(LG_K$3^W]_X3__ ."E !_Q%D_]8B?V_O\ PG__ ,%* #_B+)_ZQ$_M_?\
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MV_O_  G_ /\ !2@ _P"(LG_K$3^W]_X3_P#^"E !_P 19/\ UB)_;^_\)_\
M_!2@ _XBR?\ K$3^W]_X3_\ ^"E !_Q%D_\ 6(G]O[_PG_\ \%* #_B+)_ZQ
M$_M_?^$__P#@I0 ?\19/_6(G]O[_ ,)__P#!2@ _XBR?^L1/[?W_ (3_ /\
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M^(LG_K$3^W]_X3__ ."E !_Q%D_]8B?V_O\ PG__ ,%* #_B+)_ZQ$_M_?\
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MV_O_  G_ /\ !2@ _P"(LG_K$3^W]_X3_P#^"E !_P 19/\ UB)_;^_\)_\
M_!2@ _XBR?\ K$3^W]_X3_\ ^"E !_Q%D_\ 6(G]O[_PG_\ \%* #_B+)_ZQ
M$_M_?^$__P#@I0 ?\19/_6(G]O[_ ,)__P#!2@ _XBR?^L1/[?W_ (3_ /\
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M^(LG_K$3^W]_X3__ ."E !_Q%D_]8B?V_O\ PG__ ,%* #_B+)_ZQ$_M_?\
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MV_O_  G_ /\ !2@ _P"(LG_K$3^W]_X3_P#^"E !_P 19/\ UB)_;^_\)_\
M_!2@ _XBR?\ K$3^W]_X3_\ ^"E !_Q%D_\ 6(G]O[_PG_\ \%* #_B+)_ZQ
M$_M_?^$__P#@I0 ?\19/_6(G]O[_ ,)__P#!2@ _XBR?^L1/[?W_ (3_ /\
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M^(LG_K$3^W]_X3__ ."E !_Q%D_]8B?V_O\ PG__ ,%* #_B+)_ZQ$_M_?\
MA/\ _P""E !_Q%D_]8B?V_O_  G_ /\ !2@ _P"(LG_K$3^W]_X3_P#^"E !
M_P 19/\ UB)_;^_\)_\ _!2@ _XBR?\ K$3^W]_X3_\ ^"E !_Q%D_\ 6(G]
MO[_PG_\ \%* #_B+)_ZQ$_M_?^$__P#@I0 ?\19/_6(G]O[_ ,)__P#!2@ _
MXBR?^L1/[?W_ (3_ /\ @I0 ?\19/_6(G]O[_P )_P#_  4H /\ B+)_ZQ$_
MM_?^$_\ _@I0 ?\ $63_ -8B?V_O_"?_ /P4H /^(LG_ *Q$_M_?^$__ /@I
M0 ?\19/_ %B)_;^_\)__ /!2@ _XBR?^L1/[?W_A/_\ X*4 '_$63_UB)_;^
M_P#"?_\ P4H /^(LG_K$3^W]_P"$_P#_ (*4 '_$63_UB)_;^_\ "?\ _P %
M* #_ (BR?^L1/[?W_A/_ /X*4 '_ !%D_P#6(G]O[_PG_P#\%* #_B+)_P"L
M1/[?W_A/_P#X*4 '_$63_P!8B?V_O_"?_P#P4H /^(LG_K$3^W]_X3__ ."E
M !_Q%D_]8B?V_O\ PG__ ,%* #_B+)_ZQ$_M_?\ A/\ _P""E !_Q%D_]8B?
MV_O_  G_ /\ !2@ _P"(LG_K$3^W]_X3_P#^"E !_P 19/\ UB)_;^_\)_\
M_!2@ _XBR?\ K$3^W]_X3_\ ^"E !_Q%D_\ 6(G]O[_PG_\ \%* #_B+)_ZQ
M$_M_?^$__P#@I0 ?\19/_6(G]O[_ ,)__P#!2@ _XBR?^L1/[?W_ (3_ /\
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M^(LG_K$3^W]_X3__ ."E !_Q%D_]8B?V_O\ PG__ ,%* #_B+)_ZQ$_M_?\
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MV_O_  G_ /\ !2@ _P"(LG_K$3^W]_X3_P#^"E !_P 19/\ UB)_;^_\)_\
M_!2@ _XBR?\ K$3^W]_X3_\ ^"E !_Q%D_\ 6(G]O[_PG_\ \%* #_B+)_ZQ
M$_M_?^$__P#@I0 ?\19/_6(G]O[_ ,)__P#!2@ _XBR?^L1/[?W_ (3_ /\
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M^(LG_K$3^W]_X3__ ."E !_Q%D_]8B?V_O\ PG__ ,%* #_B+)_ZQ$_M_?\
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MV_O_  G_ /\ !2@ _P"(LG_K$3^W]_X3_P#^"E !_P 19/\ UB)_;^_\)_\
M_!2@ _XBR?\ K$3^W]_X3_\ ^"E !_Q%D_\ 6(G]O[_PG_\ \%* #_B+)_ZQ
M$_M_?^$__P#@I0 ?\19/_6(G]O[_ ,)__P#!2@ _XBR?^L1/[?W_ (3_ /\
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M^(LG_K$3^W]_X3__ ."E !_Q%D_]8B?V_O\ PG__ ,%* #_B+)_ZQ$_M_?\
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MV_O_  G_ /\ !2@ _P"(LG_K$3^W]_X3_P#^"E !_P 19/\ UB)_;^_\)_\
M_!2@ _XBR?\ K$3^W]_X3_\ ^"E !_Q%D_\ 6(G]O[_PG_\ \%* #_B+)_ZQ
M$_M_?^$__P#@I0 ?\19/_6(G]O[_ ,)__P#!2@ _XBR?^L1/[?W_ (3_ /\
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M^(LG_K$3^W]_X3__ ."E !_Q%D_]8B?V_O\ PG__ ,%* #_B+)_ZQ$_M_?\
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MV_O_  G_ /\ !2@ _P"(LG_K$3^W]_X3_P#^"E !_P 19/\ UB)_;^_\)_\
M_!2@ _XBR?\ K$3^W]_X3_\ ^"E !_Q%D_\ 6(G]O[_PG_\ \%* #_B+)_ZQ
M$_M_?^$__P#@I0 ?\19/_6(G]O[_ ,)__P#!2@ _XBR?^L1/[?W_ (3_ /\
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M^(LG_K$3^W]_X3__ ."E !_Q%D_]8B?V_O\ PG__ ,%* #_B+)_ZQ$_M_?\
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MV_O_  G_ /\ !2@ _P"(LG_K$3^W]_X3_P#^"E !_P 19/\ UB)_;^_\)_\
M_!2@ _XBR?\ K$3^W]_X3_\ ^"E !_Q%D_\ 6(G]O[_PG_\ \%* #_B+)_ZQ
M$_M_?^$__P#@I0 ?\19/_6(G]O[_ ,)__P#!2@ _XBR?^L1/[?W_ (3_ /\
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M^(LG_K$3^W]_X3__ ."E !_Q%D_]8B?V_O\ PG__ ,%* #_B+)_ZQ$_M_?\
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M56\IMF^, _=^@#__U?[^* "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * /_6_OXH * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H _]?^_B@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@#_T/[^* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * /_1_OXH * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@#^5+_ (?E_M9_]$\_9V_\)+XE
M?_/;K^N?^(!\'_\ 0RXE_P#"S*__ )S'Y!_K_G/_ $#99_X)Q7_S8'_#\O\
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M*_\ GMT?\0#X/_Z&7$O_ (697_\ .8/]?\Y_Z!LL_P#!.*_^; _X?E_M9_\
M1//V=O\ PDOB5_\ /;H_X@'P?_T,N)?_  LRO_YS!_K_ )S_ - V6?\ @G%?
M_-@?\/R_VL_^B>?L[?\ A)?$K_Y[='_$ ^#_ /H9<2_^%F5__.8/]?\ .?\
MH&RS_P $XK_YL#_A^7^UG_T3S]G;_P )+XE?_/;H_P"(!\'_ /0RXE_\+,K_
M /G,'^O^<_\ 0-EG_@G%?_-@?\/R_P!K/_HGG[.W_A)?$K_Y[='_ ! /@_\
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M9E?_ ,Y@_P!?\Y_Z!LL_\$XK_P"; _X?E_M9_P#1//V=O_"2^)7_ ,]NC_B
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MEG_@G%?_ #8'_#\O]K/_ *)Y^SM_X27Q*_\ GMT?\0#X/_Z&7$O_ (697_\
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MS_T#99_X)Q7_ ,V!_P /R_VL_P#HGG[.W_A)?$K_ .>W1_Q /@__ *&7$O\
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M9_\ 1//V=O\ PDOB5_\ /;H_X@'P?_T,N)?_  LRO_YS!_K_ )S_ - V6?\
M@G%?_-@?\/R_VL_^B>?L[?\ A)?$K_Y[='_$ ^#_ /H9<2_^%F5__.8/]?\
M.?\ H&RS_P $XK_YL#_A^7^UG_T3S]G;_P )+XE?_/;H_P"(!\'_ /0RXE_\
M+,K_ /G,'^O^<_\ 0-EG_@G%?_-@?\/R_P!K/_HGG[.W_A)?$K_Y[='_ ! /
M@_\ Z&7$O_A9E?\ \Y@_U_SG_H&RS_P3BO\ YL#_ (?E_M9_]$\_9V_\)+XE
M?_/;H_X@'P?_ -#+B7_PLRO_ .<P?Z_YS_T#99_X)Q7_ ,V!_P /R_VL_P#H
MGG[.W_A)?$K_ .>W1_Q /@__ *&7$O\ X697_P#.8/\ 7_.?^@;+/_!.*_\
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M)7_SVZ/^(!\'_P#0RXE_\+,K_P#G,'^O^<_] V6?^"<5_P#-@?\ #\O]K/\
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M7_PLRO\ ^<P?Z_YS_P! V6?^"<5_\V!_P_+_ &L_^B>?L[?^$E\2O_GMT?\
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MEQ+_ .%F5_\ SF#_ %_SG_H&RS_P3BO_ )L#_A^7^UG_ -$\_9V_\)+XE?\
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MO^<_] V6?^"<5_\ -@?\/R_VL_\ HGG[.W_A)?$K_P">W1_Q /@__H9<2_\
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M@;+/_!.*_P#FP/\ A^7^UG_T3S]G;_PDOB5_\]NC_B ?!_\ T,N)?_"S*_\
MYS!_K_G/_0-EG_@G%?\ S8'_  _+_:S_ .B>?L[?^$E\2O\ Y[='_$ ^#_\
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MX@'P?_T,N)?_  LRO_YS!_K_ )S_ - V6?\ @G%?_-@?\/R_VL_^B>?L[?\
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M_P#/;H_X@'P?_P!#+B7_ ,+,K_\ G,'^O^<_] V6?^"<5_\ -@?\/R_VL_\
MHGG[.W_A)?$K_P">W1_Q /@__H9<2_\ A9E?_P Y@_U_SG_H&RS_ ,$XK_YL
M#_A^7^UG_P!$\_9V_P#"2^)7_P ]NC_B ?!__0RXE_\ "S*__G,'^O\ G/\
MT#99_P""<5_\V!_P_+_:S_Z)Y^SM_P"$E\2O_GMT?\0#X/\ ^AEQ+_X697_\
MY@_U_P Y_P"@;+/_  3BO_FP/^'Y?[6?_1//V=O_  DOB5_\]NC_ (@'P?\
M]#+B7_PLRO\ ^<P?Z_YS_P! V6?^"<5_\V!_P_+_ &L_^B>?L[?^$E\2O_GM
MT?\ $ ^#_P#H9<2_^%F5_P#SF#_7_.?^@;+/_!.*_P#FP/\ A^7^UG_T3S]G
M;_PDOB5_\]NC_B ?!_\ T,N)?_"S*_\ YS!_K_G/_0-EG_@G%?\ S8'_  _+
M_:S_ .B>?L[?^$E\2O\ Y[='_$ ^#_\ H9<2_P#A9E?_ ,Y@_P!?\Y_Z!LL_
M\$XK_P"; _X?E_M9_P#1//V=O_"2^)7_ ,]NC_B ?!__ $,N)?\ PLRO_P"<
MP?Z_YS_T#99_X)Q7_P V!_P_+_:S_P"B>?L[?^$E\2O_ )[='_$ ^#_^AEQ+
M_P"%F5__ #F#_7_.?^@;+/\ P3BO_FP/^'Y?[6?_ $3S]G;_ ,)+XE?_ #VZ
M/^(!\'_]#+B7_P +,K_^<P?Z_P"<_P#0-EG_ ()Q7_S8'_#\O]K/_HGG[.W_
M (27Q*_^>W1_Q /@_P#Z&7$O_A9E?_SF#_7_ #G_ *!LL_\ !.*_^; _X?E_
MM9_]$\_9V_\ "2^)7_SVZ/\ B ?!_P#T,N)?_"S*_P#YS!_K_G/_ $#99_X)
MQ7_S8'_#\O\ :S_Z)Y^SM_X27Q*_^>W1_P 0#X/_ .AEQ+_X697_ /.8/]?\
MY_Z!LL_\$XK_ .; _P"'Y?[6?_1//V=O_"2^)7_SVZ/^(!\'_P#0RXE_\+,K
M_P#G,'^O^<_] V6?^"<5_P#-@?\ #\O]K/\ Z)Y^SM_X27Q*_P#GMT?\0#X/
M_P"AEQ+_ .%F5_\ SF#_ %_SG_H&RS_P3BO_ )L#_A^7^UG_ -$\_9V_\)+X
ME?\ SVZ/^(!\'_\ 0RXE_P#"S*__ )S!_K_G/_0-EG_@G%?_ #8'_#\O]K/_
M *)Y^SM_X27Q*_\ GMT?\0#X/_Z&7$O_ (697_\ .8/]?\Y_Z!LL_P#!.*_^
M; _X?E_M9_\ 1//V=O\ PDOB5_\ /;H_X@'P?_T,N)?_  LRO_YS!_K_ )S_
M - V6?\ @G%?_-@?\/R_VL_^B>?L[?\ A)?$K_Y[='_$ ^#_ /H9<2_^%F5_
M_.8/]?\ .?\ H&RS_P $XK_YL#_A^7^UG_T3S]G;_P )+XE?_/;H_P"(!\'_
M /0RXE_\+,K_ /G,'^O^<_\ 0-EG_@G%?_-@?\/R_P!K/_HGG[.W_A)?$K_Y
M[='_ ! /@_\ Z&7$O_A9E?\ \Y@_U_SG_H&RS_P3BO\ YL#_ (?E_M9_]$\_
M9V_\)+XE?_/;H_X@'P?_ -#+B7_PLRO_ .<P?Z_YS_T#99_X)Q7_ ,V!_P /
MR_VL_P#HGG[.W_A)?$K_ .>W1_Q /@__ *&7$O\ X697_P#.8/\ 7_.?^@;+
M/_!.*_\ FP/^'Y?[6?\ T3S]G;_PDOB5_P#/;H_X@'P?_P!#+B7_ ,+,K_\
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M/V=O_"2^)7_SVZ/^(!\'_P#0RXE_\+,K_P#G,'^O^<_] V6?^"<5_P#-@?\
M#\O]K/\ Z)Y^SM_X27Q*_P#GMT?\0#X/_P"AEQ+_ .%F5_\ SF#_ %_SG_H&
MRS_P3BO_ )L#_A^7^UG_ -$\_9V_\)+XE?\ SVZ/^(!\'_\ 0RXE_P#"S*__
M )S!_K_G/_0-EG_@G%?_ #8'_#\O]K/_ *)Y^SM_X27Q*_\ GMT?\0#X/_Z&
M7$O_ (697_\ .8/]?\Y_Z!LL_P#!.*_^; _X?E_M9_\ 1//V=O\ PDOB5_\
M/;H_X@'P?_T,N)?_  LRO_YS!_K_ )S_ - V6?\ @G%?_-@?\/R_VL_^B>?L
M[?\ A)?$K_Y[='_$ ^#_ /H9<2_^%F5__.8/]?\ .?\ H&RS_P $XK_YL#_A
M^7^UG_T3S]G;_P )+XE?_/;H_P"(!\'_ /0RXE_\+,K_ /G,'^O^<_\ 0-EG
M_@G%?_-@?\/R_P!K/_HGG[.W_A)?$K_Y[='_ ! /@_\ Z&7$O_A9E?\ \Y@_
MU_SG_H&RS_P3BO\ YL#_ (?E_M9_]$\_9V_\)+XE?_/;H_X@'P?_ -#+B7_P
MLRO_ .<P?Z_YS_T#99_X)Q7_ ,V!_P /R_VL_P#HGG[.W_A)?$K_ .>W1_Q
M/@__ *&7$O\ X697_P#.8/\ 7_.?^@;+/_!.*_\ FP/^'Y?[6?\ T3S]G;_P
MDOB5_P#/;H_X@'P?_P!#+B7_ ,+,K_\ G,'^O^<_] V6?^"<5_\ -@?\/R_V
ML_\ HGG[.W_A)?$K_P">W1_Q /@__H9<2_\ A9E?_P Y@_U_SG_H&RS_ ,$X
MK_YL#_A^7^UG_P!$\_9V_P#"2^)7_P ]NC_B ?!__0RXE_\ "S*__G,'^O\
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M/^'Y?[6?_1//V=O_  DOB5_\]NC_ (@'P?\ ]#+B7_PLRO\ ^<P?Z_YS_P!
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M+_:S_P"B>?L[?^$E\2O_ )[='_$ ^#_^AEQ+_P"%F5__ #F#_7_.?^@;+/\
MP3BO_FP/^'Y?[6?_ $3S]G;_ ,)+XE?_ #VZ/^(!\'_]#+B7_P +,K_^<P?Z
M_P"<_P#0-EG_ ()Q7_S8'_#\O]K/_HGG[.W_ (27Q*_^>W1_Q /@_P#Z&7$O
M_A9E?_SF#_7_ #G_ *!LL_\ !.*_^; _X?E_M9_]$\_9V_\ "2^)7_SVZ/\
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ML#_A^7^UG_T3S]G;_P )+XE?_/;H_P"(!\'_ /0RXE_\+,K_ /G,'^O^<_\
M0-EG_@G%?_-@?\/R_P!K/_HGG[.W_A)?$K_Y[='_ ! /@_\ Z&7$O_A9E?\
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MUG_T3S]G;_PDOB5_\]NC_B ?!_\ T,N)?_"S*_\ YS!_K_G/_0-EG_@G%?\
MS8'_  _+_:S_ .B>?L[?^$E\2O\ Y[='_$ ^#_\ H9<2_P#A9E?_ ,Y@_P!?
M\Y_Z!LL_\$XK_P"; _X?E_M9_P#1//V=O_"2^)7_ ,]NC_B ?!__ $,N)?\
MPLRO_P"<P?Z_YS_T#99_X)Q7_P V!_P_+_:S_P"B>?L[?^$E\2O_ )[='_$
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M ,V!_P /R_VL_P#HGG[.W_A)?$K_ .>W1_Q /@__ *&7$O\ X697_P#.8/\
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M_P#SF#_7_.?^@;+/_!.*_P#FP/\ A^7^UG_T3S]G;_PDOB5_\]NC_B ?!_\
MT,N)?_"S*_\ YS!_K_G/_0-EG_@G%?\ S8'_  _+_:S_ .B>?L[?^$E\2O\
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M\0#X/_Z&7$O_ (697_\ .8/]?\Y_Z!LL_P#!.*_^; _X?E_M9_\ 1//V=O\
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M .>W1_Q /@__ *&7$O\ X697_P#.8/\ 7_.?^@;+/_!.*_\ FP/^'Y?[6?\
MT3S]G;_PDOB5_P#/;H_X@'P?_P!#+B7_ ,+,K_\ G,'^O^<_] V6?^"<5_\
M-@?\/R_VL_\ HGG[.W_A)?$K_P">W1_Q /@__H9<2_\ A9E?_P Y@_U_SG_H
M&RS_ ,$XK_YL#_A^7^UG_P!$\_9V_P#"2^)7_P ]NC_B ?!__0RXE_\ "S*_
M_G,'^O\ G/\ T#99_P""<5_\V!_P_+_:S_Z)Y^SM_P"$E\2O_GMT?\0#X/\
M^AEQ+_X697_\Y@_U_P Y_P"@;+/_  3BO_FP/^'Y?[6?_1//V=O_  DOB5_\
M]NC_ (@'P?\ ]#+B7_PLRO\ ^<P?Z_YS_P! V6?^"<5_\V!_P_+_ &L_^B>?
ML[?^$E\2O_GMT?\ $ ^#_P#H9<2_^%F5_P#SF#_7_.?^@;+/_!.*_P#FP/\
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MO]K/_HGG[.W_ (27Q*_^>W1_Q /@_P#Z&7$O_A9E?_SF#_7_ #G_ *!LL_\
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0!__2_OXH * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@#_.WK_2@_F<* "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#^[_]D'_DTS]E[_LW
M;X)_^JU\,U_GYQG_ ,EAQ7_V4N>_^K3%']"Y+_R)LI_[%F _]1:1]$U\T>F%
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!_
M_]/^_B@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * /\[>O]*#^9PH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '__U/[^* "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H _SMZ_TH/YG"@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M _N__9!_Y-,_9>_[-V^"?_JM?#-?Y^<9_P#)8<5_]E+GO_JTQ1_0N2_\B;*?
M^Q9@/_46D?1-?-'IA0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 ?__5_OXH * "@ H * "@ H * "@ H * "@ H * "@ H
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M)2_\%';BVFEM[B#]B?\ :5EAG@D:*:&6/X2>*F22*6,J\<B, R.A#*0"""*
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MUI^O:]\.O$-_-=F.WTC0Y/$^E>+M;\^'^S_"[RBY@M@#]^* "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@#_/+_;-_X/)?VGOA5^U;^T!\+_V:?@/^RYXX
M^!?PV^*7BOP#\.?&_CFP^*FI>)/&>B^#M1E\.S>+;F]\-?%#P[HLVG^)=4TZ
M_P!:\/BST:R:+P]?:7#=)+>1W$\H!_8=_P $D/V_M/\ ^"F7[!7P2_:R.G:#
MX>\:>+++6?#7Q9\'^&WO#I'@[XJ>"]7NM!\5Z1I\.HWFHZE9Z3J)MK+Q7X<M
M-1U'4-0B\+>(]#-[?75RTDS@'Z34 % '^?E_P?!ZSJ^D^+?^";8TO5=2TT3^
M'?VK#,-/OKJS$QCU+]GH1^:+>6/S/+WOLWYV[FVXW&@#]DO^#134]2U7_@CQ
MX7GU34+[4IXOVAOCE!'-?W<]Y+' NHZ%*L*27$DCI$))99!&I"!Y)' W.Q(!
M_3W0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!_G;U_I0?S.% !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!_=_\
ML@_\FF?LO?\ 9NWP3_\ 5:^&:_S\XS_Y+#BO_LI<]_\ 5IBC^A<E_P"1-E/_
M &+,!_ZBTCZ)KYH],* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@#__6_OXH * "@ H * "@ H * "@ H * "@ H * "@ H
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M(OBYX,\8-$Q!&I:7X:\-?$+PM;F,XFM_&4XGCE>"T>W /]3F@ H * /YR?\
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M%\&^$M%BGGDNKG^SM T"SL-,M7N[N::\O)H[837EY--=W3RW$TDC 'HE !0
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M_P#PZO+F'?;R^+?B3?0^,/'U]ITF,0ZIX9\*^$?"^ESON#_V9\19H5#)/)M
M/]%R@ H * /R>OO^"%G_  2"U*]O-1O_ /@GQ^SA=7U_=7%[>7,O@YVEN+NZ
ME>>XGD;[<,R33.\CG'+,: /%OV@_^"'/_!(WPU\ _C?XCT#]@#]G32M=\/\
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M[P/?W_\ 8/B*RU'0M1N(-%\2ZDUE%JNGWUC'>_9YY[.Y2(PN ?Y:'@7X6_\
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MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 ?YV]?Z4'\SA0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?W?_L@_\FF?LO?]F[?!/_U6OAFO
M\_.,_P#DL.*_^RESW_U:8H_H7)?^1-E/_8LP'_J+2/HFOFCTPH * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /__7_OXH * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MO['H>E1Q6%A'!H7A[2[9E@0>=+"]S*7FFD=@#]LO!/\ P=7?\%AOA]X,\(^
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ME.M6S6?A+3]/N_%P!V/[6?\ P;<_L^_MF?\ !2"'_@HI\8_VA/BYJ6JIX_\
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M(H [&@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M)8Z5\1?@5\//!>A7B2 7"-!X$\3?![3?"=VC1CS$V^'Y5\G[O[HD4 ?UE_\
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M\3-.NH5BU"Y^!OC'PWJ'PN^'?ATS-$R/IVI> _[6^(6B3;)6@/Q,G?=D+%"
M?Y]GPX\3_%G_ ((W_P#!5;1M9U*.\?X@_L._M2ZAH7BFULU:P_X3?PEX2\2W
MOA?QG86)DD7;H?Q6^&EUJ]G8W(FV3Z#XJAN8IBDB24 ?[4'@;QKX7^)/@GP?
M\1?!&KVOB#P7X^\+>'_&OA#7K%B]EK?A?Q3I-IKF@:O9N0"UKJ6E7UI>6[$
MF*9#@=* .IH _P ^#_@^2_Y&W_@FM_V+G[5__IS_ &>* .7_ ."57_!;SX$_
M\$@?^"$7@ :QHW_"V?VF?BC\=OVB+KX-? _3]2CTZ*6SL-1\.V,WC_XDZL@G
MNO"_P[T_46-E;26UG<ZWXQU>UN]"\.6Z1:?XDU_PR ?F'XV_X+]?\'$'[9VH
M>(?&GP3\3?%KPU\/A<2Q_P#"+_LD?LSQ7W@KPIY/SRVL?C-? _Q!^()DCC>,
MSGQ!\0]1EC 5D$"L00#E_P!GW_@Z2_X+,?LR^/H[?XJ_%VP_: T#1=4AL_%?
MPG_:"^&GA>QOPMG/Y6J6 \4>$M \%?$;P]KGD^9!'+?:SJ5G87BQ7%YH&H".
M:UG /]&/_@DY_P %7_V??^"M?[.Q^,WP>BNO!WCKPA=:?X>^-WP3UW4(=1\4
M?"?Q=?VUQ<6-O)J,-K80^)?"'B."ROKWP7XTL["QM=?M+*_M+O3M%\1Z-X@\
M/Z0 ?J10 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!_G;U_I0?S.% !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!_=_^R#_R
M:9^R]_V;M\$__5:^&:_S\XS_ .2PXK_[*7/?_5IBC^A<E_Y$V4_]BS ?^HM(
M^B:^:/3"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H __]#^_B@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M56UD /\ 0B_8R_;C_9>_X* ?!K2_CM^RE\5=#^)_@6\E&GZM':"?3?%/@OQ
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MMI.L?%?6/VE?VC=9U6,7::[X4\#:I+\2_&__  DC!.8?B3XI_LSP+=SH@/\
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M?LFW-UY@(:6=_@/X#$EQSSLNF!N8_P#IG*G)ZD ^^J "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M>.;NWAS$GQF^"EII/AZ>[OI8U6*U;Q%\+]0\ 0Z9#*!-?7/A#Q+>))-Y4ZP
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@#_ #MZ_P!*#^9PH * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * /[O_P!D'_DTS]E[_LW;X)_^JU\,U_GYQG_R
M6'%?_92Y[_ZM,4?T+DO_ ")LI_[%F _]1:1]$U\T>F% !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!__T?[^* "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H YSQ?X.\(_$'PQKG@GQ[X6\.>-O!GB;3I](\2>$O%VB:9XD\,^(-)NEV7
M.F:WH.LVMYI6JZ?<+\L]E?VD]M*O$D;"@#^-7_@JY_P:'? 'XV:7XD^,/_!-
MBYTW]G;XQ1QWVL77P!U_4;ZX^ _Q N@CW#Z=X0O[M[[5_@]KM]*95L(8IM7^
M''FFQTF'0? ^F?:=<MP#^(3]B+]L_P#:Y_X(T_MMQ>.?#MEXN\!^.OA=XUE\
M#?M#? #Q1<:GX=TSX@>']#U26P\8?"[XBZ&0]N9T3[<WA[6;BPOY_"GB$:=X
MIT,23VD7G@'^RM^S/^T'\//VK_V?/@U^TI\*+NYN_AW\;_AWX7^(_A4WZ0PZ
MI9:=XFTN"_;1M;MK>>Z@L]?T"ZDN-$U^QBN;A+'6=/OK19Y1#O8 _P DO_@Y
M:_Y3?_MX_P#8V?"/_P!9U^#] '^M'^R3_P FJ?LR_P#9OGP8_P#5<>&Z /H.
M@#^/7_@LO_P=9?#W]AGXH^,?V6/V,/AWX5_:%^/O@.[U7PW\3_B+XVU/5[?X
M-?";QQIEPUC>>"8M%T!M-UWXG^*]"NHKFW\66^F^*/".@^%]2ACT8ZUKNM0Z
M]I.@ '\MUO\ \%OO^#D']O+5;_3O@)\0?VB?%EK),\'_  B_[('[,^E/%HK-
M\TD0U_X<_#+6?&]NL4;JS3:QXNN'M8@)3/$NYR <)\<OV$_^#D_XN_!;XM_&
M7]J'1OVZM=^"GPV^&OCCXF_%2X_:+_:/O-+TC1_ASX(\-:GXI\8W3?#?XG?%
MBPU74;>Q\/Z7J%Q_PC&@>$KZ_O?+^QV&D7$\J0, =E_P:7?\IJ/@C_V2G]H'
M_P!59KM '^@__P %_O%U]X(_X(U?\%!]9TZYGM)[SX#7_A&26W)61K'X@>)/
M#G@+4[9BO/D7FF>)+NSN5^ZUM/*K?*30!_!/_P &>W@O0_%/_!8*SUS5DA:_
M^&W[,7QN\:>&&E9%>+7+ZY\$_#N=[8,,O,?#7CWQ#&RQX<6\D[']VKB@#_5=
MH * /\RC_@]>T_38/^"C?[-&HP06\>J7_P"Q7X:@U">/ GN+6P^.'QO_ +.^
MT*#R(FNKY(967<R[HMS)"BQ@']>G_!LC_P H-OV$O^P)\=/_ %J#XVT ?PL?
M\'<OB34=<_X+-?$K3+UK@VW@WX'_  $\-Z.)G9HDTZZ\''Q?*MFK$B.W_M;Q
M5JC,B!5^UM=/MWN[, ?*G[,?_!4#_@NO\!_@/\.?A+^RW\2_VCO#GP!\':1=
MVGPUT;P7^SQX6\3>&+32-0UG4M9O6TG7[OX0Z[<ZM%=:WJ6J7DUY-J]_))=7
M$^9SC:H![Q_P^<_X.5?^BS_M;_\ B+7@W_YQ= 'RI^UY^U]_P6M_;T^'.@_"
M7]KB?]IWXT?#SPQXUL/B)H/AO6OV<K?0X=-\9Z9H7B'PU9:W#?>#_A3X=U5I
M8=#\5Z_8&TFOI-/E34#--:27%M9S6X!_5S_P9/\ PV^+GPVTG_@I)I_Q+^&_
MQ ^'VGZCJ'[(]YX</CCP;XC\)QZO>1VW[2T&OC26U[3K!-1?3X!X?_M!;/S6
MLEOK W/EB[MMX!_=?0 4 % 'R+^VY^W+^S9_P3T^ GB7]HS]J'Q[;>"O >@E
M;#2M/MXTU'QAX]\57,$\VD^!OA]X:$\%UXE\6ZQ]GF:VLHI(+'3[&WO==\0:
MCHWAS2M6UBQ /\OO_@H[_P %@/\ @H5_P7R^/6A?LQ_ KP'XYTCX+^(?%26G
MP?\ V0?A.UYK&K>,KFQG-S9>,?C/K%BMI#XPUG38(!K=Y<ZL=-^&GPVL;.34
M[6ULI+#6?%^J ']:/_!#7_@V"^&/[#4OA3]J#]N"V\)_&O\ :WM#9:[X*\ 0
MB'7_ (1_L\ZBHCN+.\LOM,/V/XA?%;2I-LG_  EUS;MX8\):F@;P/:7VI:9I
M_CN\ /Z[: "@ H * "@ H * /X6?^#U/]M[_ (1;X2_LW_\ !/[PEJ_E:Q\4
M]:F_:'^,-G:S[)X_ '@FXO\ PQ\+=&U"($B?2_%7CJ3Q7X@\ME1H=3^%VE3*
MS*Y6@#^6S_@B=_P6+T3_ ((Y>/OCG\48/V4=,_:-\??%_P (>%? .C:_J/Q=
MF^%\G@#PAI.LW_B'Q5I%E';_  S\?MK*>-M9A\&WE\[S:6M@?!5@L<5V;N1K
M< _H>_XCD_%'_2-/0/\ Q+34?_H<J /P[_X+8_\ !=W1?^"RO@?X&:+K?[&F
ME_ +Q[\"?%?BG4] ^(NG_'"?XDRZCX0\;Z18VGBGP5=:'-\)? ABCOM9\/>$
M-<L]5.M7(TYM$O+./2Y?[:EN[0 _4?\ X,OOVW_^%;_M0_'+]A'Q9J_E>&OV
MC_"(^*WPLL[F?]S#\7?A+87#^*-*TNWW*!>>,/A9<:CK6IS$.3;?"C38EV9;
M> ?Z3% '^>O_ ,'R'_(\_P#!-W_L4_VI?_3Q\!* /VG_ .#0O_E#?X/_ .S@
M_CK_ .GC1Z /Z@: "@ H * /\0GX\^$-'^(/_!5'XS^ O$*W#^'_ !O_ ,%
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M[;K&;_0M=TN\BM-9\,^)M):6.+6?#'B+3]+U[2)G2+4=.MG= 0#Y7_X+%_\
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MAHUCX>"!-WE[X[.SVA,[,@+G H _V[J "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /
M\[>O]*#^9PH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * /[O\ ]D'_ )-,_9>_[-V^"?\ ZK7PS7^?G&?_ "6'%?\
MV4N>_P#JTQ1_0N2_\B;*?^Q9@/\ U%I'T37S1Z84 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '_TO[^* "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#C_
M  C\0? /C_\ X23_ (0/QOX1\:_\(9XKUOP'XO\ ^$2\2:-XC_X13QQX:G%I
MXB\&^)!H]Y>?V'XJT"Y*V^L^'M3^RZMI<Q6*]M('(% '84 % '^3;_P=MZW\
M+]9_X+*?$J/X=QZ3_;NB_!?X)Z)\8+O2IK6<W_Q/MO#MW<^9J;6K-MU:P^'-
MY\.]#NH;@_:K=-)A@F5/+5% /[O/^#:'2=>T7_@A_P#L(6GB,R_;YO"_Q?U:
MU$T;1N- UW]HOXP:WX7 #X+1?\(UJ&E&WD "/;F)DW(5=@#_ #L_^#EZ*2'_
M (+@_MX)+&\3'Q1\'I0KJ4)BG_9Q^#LT,@# '9+#)'+&W1XW5URK T ?ZR/[
M&VHV>L?L@_LJ:OITRW&GZI^S=\#=1L9U^[/9WWPP\+W-M,O^S)!*CCV- "_M
MC_%34_@5^R'^U3\;M$DDAUGX.?LW_''XJ:1+# ES+%J?P]^&/B?Q;8216TD<
ML<\B76D1,D$D4J2L!&T;JQ4@'^/K_P $9/V;/ ?[>O\ P5@_90^!'[0MU>^)
MO WQ6^)OB[Q9\3EU76;J&]\=1>!_ /CGXP:GH&L:T[OJ4S?$#4O!X\/ZO<0W
M,.KWZ:Y=+9ZA9ZC/#?0@'^S=X&\!>!OAAX3T/P#\-?!GA3X>^!?#%C'IGAKP
M9X(\/:1X4\*>']-BR8K#1/#VA6EAI&E6499BEK8VD$*EB0@)- 'XY?\ !Q/^
MTWX-_9C_ ."0G[8MYXD\16.C>(/C=\,]9_9M^'>DSO\ Z?XN\4_&JQNO".J:
M)I%N 3//8^ KKQEXGOS\J6VC>']2N6?='''( ?P*?\&EW_*:CX(_]DI_:!_]
M59KM '^CM_P63^#&L_M ?\$KOV]?A7X;M9;_ ,2:S^S1\2=<\.:9;P/<W6L:
M_P" ='?X@Z)HEE!&"\E]K6I^%K72K$ <7=W"W04 ?Y=W_!NY^V!X)_8I_P""
MLO[-/Q,^)VI?V)\-/'%WXD^!GC77GFCM[+P_9_%W19_"_AS7]8FF*P0>'M$\
M=R^$M3\1W<TD<>FZ#:ZCJ99OL0C< _V/Z "@#_)&_P"#J3]L#P7^UK_P5F\>
MV7PZUBR\1>#?V8OAOX1_9CM]?TN>&YTK5_%'@W7/%_C/XAM93P22)<'0?'GQ
M \0^"KJXX6:Z\*2F R6@MYY0#^];_@V1_P"4&W["7_8$^.G_ *U!\;: /XW/
M^#S7X%:SX!_X*7?"_P"-GV2Z/A3X_P#[-7A06FJ20-':2>-/A5XC\1^$_%.B
MVL^WRYY-+\,7OPYU2Y&\S1?\)%"LB)$8&D /ZL_^#5+]L+P+^TE_P2=^$WPD
MT_7UNOBQ^R)>Z_\ !SXH^';AT2_TW2=0\6>*/%?PEUVUM_,>:3PWK'@#4+'0
MM/U%UCCF\0>#O%FG0IMT@LP!_2G0 4 % !0 4 4-5U33=#TO4=:UF^M-+T?1
M["\U35=3OYX[6QT[3=/MY+N^OKVYF9(;:TL[6&6XN)Y66.&&-Y'954D '^/[
M_P %'_VTOVE/^"__ /P4^\,^!/A3'JNJ^$/$_P 3%^!O[&/PEN[F;3M!\*^"
MM4UN.PB\;>(X%26#2M<\7VUDOQ!^*OB:[CNYM$TFU327O9O#7@K1H;4 _P!)
MO_@D=_P1R_9E_P""2_P5M/"GPUTFP\:_'GQ7H]@GQN_:)UG2X8_&/C_5E$5S
M=:-H7FM<S>#?AIIU^@_X1[P1IESY&RVM=4\1W.O>)3<ZS, ?KM0 4 % !0 4
M % !0 R22.&-Y972**)&DDDD94CCC12SN[L0J(B@LS,0JJ"20!0!_BU?\%??
MVNM>_P""F'_!4?\ :!^+_@@WWB[0/&/Q1L_@[^SSH^G;KI]2^'/@RZM_AW\,
M(M#L\DQ3^.S:+XQFL$9A_P )#XQU+:[>;N(!_H9_ W_@U'_X) ^&O@O\)O#_
M ,:_V:=0^(OQCT;X<>"M-^*_CV'X_?M&:#;>,/B/:>'=.A\;>([+1/#/Q6T3
MP_I%AJWB1-2O+#3=(TJQLK&RE@MH8 (\D ]3_P"(6+_@AG_T9KJG_B2G[5/_
M ,^J@#,UK_@U5_X(@ZEHVK:=IG[)NO>'M2O],O[+3]?L?VBOVF+V]T.^NK66
M"TUBSL]7^+]_I-W=:9.\=[;VVJ6-[IT\L"17MI<VS20N ?YD'@W7OC/_ ,$H
M/^"CVE:O<P26WQB_8>_:>EL];L(FFL;/Q-/\+O&L^D^)=(25LN_A;XB>'K34
M=,^T1L\>H^%_$7G02R0W,<K '^V+\*/B;X.^-7PO^''QB^'>JQZYX!^*W@7P
ME\1_!.LQ;0FJ^$_&V@V'B3P]J 56<)]KTG4K28Q[V\MG*$Y4T ?P-?\ !\C%
M(/&O_!-J8QN(9/"_[5,4<I4B-Y(=6_9_:6-7QM9XEGA9U!RBRQE@ ZY /V5_
MX,_]1L[[_@CMH=K;3+)-HW[2/QQTW4$'6WO)9?"VKI"WN=/U6QG_ -V=: /Z
MCZ "@ H * /\3'XA?\IA?''_ &DJ\3?^M0WM '^V=0!\8?\ !03]B+X4_P#!
M1#]DCXO_ +)_Q>M85T/XC^'ID\-^)ULX[O5?AW\0M+5[WP+\1= #M$ZZKX4U
M]+6]>WCN+>/6M).J>&]0D?2-9U&WF /\@[X)?%3]J;_@B#_P4OMO$-UI,WA_
MXX?LF_%C5/!OQ,\#2W=S;^'_ (B>$%E_LWQAX2N+OR -2\$_$WP9=?;_  SX
M@6SF3[%JGAOQOHD8O;/2KF( _P!D;]E[]I+X4_M@?L^?"7]IGX(ZZOB+X7_&
M7P;IGC+PM?'RDO;6.\5X-3T#6[:&6==/\2^%M:MM1\,^*-),LDFD^(=)U/39
M6,EJQH _A:_X/DO^1M_X)K?]BY^U?_Z<_P!GB@#]EO\ @T$_Y0Y^&O\ LXOX
MY_\ I;X>H _J)H Y;QKX&\$_$GPOK'@?XB^#_"WC[P5XBM&L/$'A#QKX?TGQ
M3X7UVQ<@O9:QX?URTOM)U.T<JI:VO;2:%B 2G H _A'_ .#D/_@W4_9*^#?[
M+?Q0_P""@W[%'A>+X#ZY\([GP_KOQ>^!V@2SR?"OQCX2\2^*M"\(7FO> M#O
M)Y%^'/B'PQ>:_9ZS>:)H=Q!X*U+PY9:E!IGAW2M:B@DU0 ^,/^#+#]IGQ[X7
M_;6^/_[)\VOZS/\ ";XK? /7/BW!X3WO<Z)IWQ6^&WB[P!HUGXF@MG5DTBYU
M3P/XG\0:1K%]:-;_ -L'3/"UGJ2WATK1S8 ']QW_  6+_P"43_\ P4B_[,C_
M &F/_51^*Z /\V;_ (-7OAQX#^,'_!5K2_A9\4?"6A>//AU\0/V:?VCO"?C3
MP;XFT^#5- \2>'-:\$K8ZGI.J6%PK13VMU;2NA^[)&VV6%XYHXY% ,[_ (+S
M?\$0/B7_ ,$B_CI9?%;X.OXI\0_L:_$CQ6;WX+_$N"XO9?$'PB\7)))K-M\)
MO'>N6I2YLO$NB+:RWO@'Q;)+ WC+0M.>\AG_ .$DT/Q):V0!_5[_ ,&X7_!Q
M#8?MJZ+X8_8?_;4\6V>G?M>^'-+33?A3\4=:N(;.T_:9T#2;0E=,U6XD,<$7
MQOT:PMVEU"$%?^%BZ;;RZ]9(WB&UUN"Z /[#Z "@ H * "@ H * "@#PS]I_
M_DVG]H?_ +(9\6O_ % =?H _R%_^#>3_ )31?\$__P#LL.I_^J[\;4 ?[+=
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * /\>+_ (.9/^4XG[=__8Q_
M!;_UFGX,4 ?ZR7['W_)I/[+G_9NGP2_]5IX9H ^BZ /\='_@Y0_Y3=_MZ?\
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M:\/^%-56#2EN+G6-(U"[NYYIIV( /O?_ (A8O^"&?_1FNJ?^)*?M4_\ SZJ
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MMZI?ZY=,?W=MK6L>&],\/-+*P:\U/Q!96*,;B]B! /\ 9JH * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H _SMZ_TH/YG"@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H _N_\ V0?^33/V7O\ LW;X)_\ JM?#
M-?Y^<9_\EAQ7_P!E+GO_ *M,4?T+DO\ R)LI_P"Q9@/_ %%I'T37S1Z84 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '_]/^
M_B@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M[F0. U[?_#W4IX=JR6)LIP)@ ?F+_P $P/\ @D)^VK_P69_:)/BR>R\=Z?\
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M^&&M:9X,\"VWA?6M?^U"SMKGP]X'U;QK97,D,GA7Q'I&I1QWI /P _X*+_\
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M_P"%*_MT_#;]L7PMI'V;P7^U]X!33O&%Q;08MX/C7\&+/1_#&L37!A406?\
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MUB\O=7UK5;NZU#4;NXN9W<@'N= !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MF*7389](\5Z3X;O;P _I9^'W_!\3\1=.\#6MC\4O^">'@SQ?\2(+...\\3>
M_P!HS6OA[X+U*^\M4DNH?!>O?!_XE:UH]NLH:86;>.M9>5&%N+RWV?:& /YY
M?^"E/_!83]O?_@MC\3/ /P_\6Z(]OX+L?$L<?P8_91^ V@^(]8TRZ\9ZG"VE
MVNK3Z;$VL^+OB?\ $:[LY9=-L+^]$T.EP7FJ6W@[P]X<@UO6X-1 /[LO^#9[
M_@B'K_\ P31^$7B?]HW]I71K"T_;$_:$\/:=I%SX;26*]G^!?P?,]AKT/PVN
M;V!GM9O&OBC7;/3=?^(YLYKK3["?0?"OARPF:;0M7O\ 5P#^IJ@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@#_ #MZ_P!*#^9PH * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * /[O_P!D'_DTS]E[_LW;X)_^
MJU\,U_GYQG_R6'%?_92Y[_ZM,4?T+DO_ ")LI_[%F _]1:1]$U\T>F% !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MX[?!WX6_&CPD_FY\,?%;P!X4^(6@9F54E9=(\6Z5JU@CNJJ&D2!7^1/FRJX
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MPS\);OX!^'?@U\*]"^!=_P"&=7\%ZA\&=(^'WA/3OA5J'@_Q!87&E:_X5O\
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MBMJ>G_:)_L-^;+[5:>?-]GEC\Q\@'SQX-_X)H_\ !.+X<^+/#?CWX>_\$_\
M]B7P)XZ\&ZUIOB7PAXT\&_LJ? GPOXL\*^(]&NHK[2-?\-^(]$\!V.L:'K6E
M7L,-YINJZ9>6M]8W445Q:SQ2QHX /MJ@ H * "@ H * "@"EJ6FZ=K.G7^CZ
MO866JZ3JME=:;JFEZE:P7VG:EIU] ]K>V%_974<MM>65Y;2R6]U:W$4D%Q!(
M\,L;QNRD ^0OAU_P3G_X)[_!_P :^'_B3\)?V$OV-?A=\1?"=W)?^%O'WPZ_
M9@^"7@GQKX:OIK6XL9;SP_XI\->!],US1KN6QN[JSDN-.OK:9[6YN+=G,,TB
M, ?95 !0 4 % 'RA\7_V#?V&_P!H/QE+\1?CY^QE^RC\;_B#/IUAI$_CKXO_
M +.WPA^)7C*;2=+1X],TN7Q/XS\'ZUK<FG:<DLB6%D]Z;:T21UMXHPS @'T7
MX.\&^$/AWX3\-^ _A_X5\-^!O W@W1-,\,^$/!G@[0],\,^$_"OAO1+.+3]&
M\/\ AOP[HMK9:/H>B:186\%CIFDZ99VMA86<,5M:V\4,:(H!TE 'FWQ8^#7P
M@^/?@G4/AI\=/A5\-OC1\.-6N=.O-5^'_P 6/ WACXB^"=3N](O8=1TFZU#P
MIXPTO6-"O;G2]0M[>_TZ>YL));*]@ANK9HIXD=0#Y)_X=._\$LO^D:?[ '_B
M&_[.O_SN: +^F_\ !+/_ ()C:-=)?:/_ ,$Y?V#]*O8O]7>:;^R'^S[8W4?0
M_)<6OP]BE3D _*XZ#TH ^JOAU\'OA'\'["YTKX2_"WX<_"[2[QHWN]-^'7@C
MPSX)L+IXEV1/<V?AK3-,MYVC7Y8VEC8HO"X% 'HU !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!\>_
M$[_@GE^P#\;/'.N_$_XS?L-_L>_%OXE>*'L9/$WQ#^)W[,WP6\>^.?$4FEZ9
M9:)ICZ[XL\5>"=5U_5WT[1M-T[2+%K^_N#::9I]E86YCM+6"*, ^LM)TG2M
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M8,^E.=37B]\X4 ?F;\0O^#>W_@C%\3_$ESXK\3_L _!VRU:[OY-2GB\"W_Q
M^%FA-=2L7DV>%?AAXS\'^%X;9F)/V&'1X[$$\6PH ^P_V7O^"<O["?[%DDEY
M^RW^RE\%/@SKD\4]M<>,/"W@K37\?W5G<)LFL+OXAZNFI^.;O373</[-N?$$
MMBN^39;KYLFX ^TZ "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#_ #MZ_P!*#^9P
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * /[O_P!D'_DTS]E[_LW;X)_^JU\,U_GYQG_R6'%?_92Y[_ZM,4?T+DO_
M ")LI_[%F _]1:1]$U\T>F% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0!_G;U_I0?S.% !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!_=_^R#_R:9^R]_V;M\$__5:^
M&:_S\XS_ .2PXK_[*7/?_5IBC^A<E_Y$V4_]BS ?^HM(^B:^:/3"@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH S-:UK1O#6C:MXB\1:MIF@>'] TR^UK7==UJ_M=*T;1='TNUEO=3U;5M3OI
M8++3M,TZR@FN[Z^O)X;6TM899[B6.*-F !_G3?\ !9O_ (.T/BGX]\6>*_V>
M?^"7'B&7X;?"?1YM1\/^(OVJSIB?\+&^)4ZE[*ZF^$-CK5FP^'/@W:)CIGBZ
M\L#\0=8\RUU72?\ A!&M(QJ(!_$[XT\<^-OB3XFU?QI\1/&/BGQ[XQ\07L^H
MZ]XL\:>(-6\4^)M;U"Y<R7-_J^NZY=WVJ:E>W$A,D]U>74T\KDL[LQS0!RM
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M_P"RU?$#_P!2&]K^^N ?^2*X6_[$>7?^H\#^?^(/^1WFO_8=B/\ TMG]!_\
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M?"#_ +(TO_J;>*:_J[P _P"2=SK_ +'2_P#4'#'Y+X@_\C+!?]@/_N>L0?\
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '^=O7^
ME!_,X4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M "@ H ^%/^"F/_)B_P"T-_V+&A_^IMX8K[[PN_Y+[AK_ +#*O_J%B3Y[BO\
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M ."'G_)H_C7_ ++_ .+_ /U OAA7\X^//_)98'_LG<%_ZL,U/TG@'_D2UO\
ML8U__4?"GZ6?M&?\F]_'?_LC7Q/_ /4(URORWAO_ )*+(/\ L=97_P"IU ^I
MS/\ Y%N8?]@.+_\ 4>H?P.5_H<?SJ?VE? []M+]DO0_@I\']$UC]HKX1:9J^
MC_"WX?Z7JFFWGC;18+S3]1T_PGI%I?65U ]R'AN;2YAE@GB<!HY8V1@"*_AK
M/>!N,*^=YS7H\,YS5HULUS"K2J0P%>4*E.IBZTZ<X24+.,HM2BUHTTT?NN S
MW)J>!P5.>9X*$X83#0E%UX)QE&C",HM7T::LUTL>I?\ #<_['/\ T<O\&?\
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MXH?]?J7_ *7$_P!""O\ .,_I(* "@#^7;_@NI_R<)\(/^R-+_P"IMXIK^KO
M#_DG<Z_['2_]0<,?DOB#_P C+!?]@/\ [GK%K_@A1_R7?XS_ /9)+;_U,=$J
M?'__ )$&1_\ 8XG_ .H58KP]_P!_QW_8''_T] _I_K^4S]8"@#\Q_P#@K?\
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M)+O*57E;W]Q1VBCBX$I0ADCJ12YJV+KRF^ON*G3BO1*%TNG,WU/S(_X+E?\
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#_.W
MK_2@_F<* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@#^[_ /9!_P"33/V7O^S=O@G_ .JU\,U_GYQG_P EAQ7_ -E+
MGO\ ZM,4?T+DO_(FRG_L68#_ -1:1]$U\T>F% !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M_8#_ .YZQ:_X(4?\EW^,_P#V22V_]3'1*GQ__P"1!D?_ &.)_P#J%6*\/?\
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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MO@UY[Q0-XA^%?BWPA\;=$@=CA[W4K#6[?X0:[8V,?WGCTNT\2WRKQ%;W+<4
M?T2_L@?\%I/^"8_[<VJ:5X7_ &>OVMOAKK'Q UHQ1:5\+O&MU>_"_P")FJ7<
M@!^P:'X+^(=GX;U?Q/>Q<^;!X6AULQJC2D^2/,(!^H] !0 4 % !0!\3_M@?
M\%&_V(/V"='M=5_:T_:2^&OP=N=2M'O]$\)ZSJ[:I\0_$5DCO$U[X<^''AV#
M5_'.MV"3QM;RZEIV@3Z;;W&V&YNX7900#^:_]H3_ (/3?V"/ -Y>:5^SS^SS
M^T)^T-<V<C)'KWB!_"WP1\$:FHSLFTO4-5N/&_CCRFP"PU?X=:-,@(Q"Y!
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M7]7> '_).YU_V.E_Z@X8_)?$'_D98+_L!_\ <]8M?\$*/^2[_&?_ +));?\
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M*\UG7-;U;4)WN;_5-7U;49KB_P!2U&]N9)+B[O;R>:YN9G>6:1W8L0#'H *
M"@ H <CO&Z21LR.C*Z.A*NCJ059&7!5E(!4@@@@$4 ?T,?\ !-'_ (.5/^"B
M'_!/O6-#\+^*O'>H_M7?LZP/9V>J?![XW:[J>MZUH>D0LBNWPN^)]R][XL\%
M:A;VZ^38Z9J,GB?P*D;2^9X.^V/#J-J ?ZS_ ,*/B1X>^,?PM^&OQ>\(IJ,?
MA3XJ> /!WQ(\,1ZO:"PU9/#WCCP[IWB?14U2Q66<66HKINJ6RWMH)IA;W(DA
M$L@3>0#OZ (Y98H(I)YY(X888WEFEE=8XHHHU+R222.0B1H@+.[$*J@DD 4
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M%WE_:PZOH?AH _JCH * "@#_  )?%/\ R,_B/_L/:O\ ^G"XH P: "@ H *
M/])7_@R-_P"3-_VS/^SF?#7_ *JS0Z /Z=O^"I'_ "C)_P""BW_9B7[773C_
M )M_^(- '^'I0 4 ?Z2__!D=_P F:?ME_P#9S?AS_P!57H% ']L- !0 4 %
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M,U:46M8K;M8_B?\ VXO^3Q/VF/\ LM7Q _\ 4AO:_NG@'_DBN%O^Q'EW_J/
M_".(/^1WFO\ V'8C_P!+9_0?_P $//\ DT?QK_V7_P 7_P#J!?#"OYQ\>?\
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M-?\ DQ7]H7_L6_#W_J=>%:Z?"W_DON&_^PNO_P"H.*,N*_\ DG\R_P"O5/\
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H _%
M+_@X%_X* Z__ ,$Y_P#@F;\8_BW\/M4CT;XS_$>ZTSX"_!/525^T:%X\^(]I
MJJW7B[3D?,<FL>!O!&D>+_&6@K/%<67]O:'I?]H6EW8?:;64 _QN[FYN;VYN
M+R\N)[N\NYY;F[N[F62>YN;F>1I9[BXGE9I9IYI6:2661FDDD9G=BQ)H @H
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M4[;2[#5([35);;2GU)[--.O],N+H _;W_@J1_P HR?\ @HM_V8E^UU_ZS_\
M$&@#_#TH * /])?_ (,CO^3-/VR_^SF_#G_JJ] H _MAH * "@ H * "@ H
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MH/V_?^B"?^92^"W_ ,\:C_B+_AW_ -%#_P"8G//_ )V!_J=Q'_T+O_+O ?\
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M7[N*DX^[*4D?<=?!'OA0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M\NTTO0]!T:VLM*TG3K6,!+:QL+2WMH$&V*)5XH Z.@#^=3_@LE_P;N_LI?\
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M\"?$C3H4;>L-CXX\+:5XGM(E8DEECM]4C0,2<@ YH ],H _P)?%/_(S^(_\
ML/:O_P"G"XH P: /[F?^#(#_ ).!_;R_[(Y\(O\ U-?$U '^B_0 4 % 'PE_
MP5(_Y1D_\%%O^S$OVNO_ %G_ .(- '^'I0 4 ?Z2_P#P9'?\F:?ME_\ 9S?A
MS_U5>@4 ?VPT % !0 4 % !0 4 % !0 4 % '__5_OXH * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MAS4=0L)GMYE>&=(KJVB=H94:*15*2*R$B@#\0/\ AO;]IC_H<-(_\)#PS_\
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MTMX(U:1R6<@LQR: .0_X;V_:8_Z'#2/_  D/#/\ \K: #_AO;]IC_H<-(_\
M"0\,_P#RMH _7_\ 9;\>^)OB?\"? OCGQA>0W_B/6_\ A)O[1NX+.UL(I?[,
M\8^(-'M-EI9Q0VT7EV&GVL1\N-=[(9'R[LQ /H"@#XO_ &VOC'X^^"W@'PGK
M_P /M4MM*U+5/%XT>]DN=,T_5(Y;$Z+J=[Y8AU"WN$C<3VD+"2,*VT,I)!H
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M _5"@ H _ #_ (;V_:8_Z'#2/_"0\,__ "MH /\ AO;]IC_H<-(_\)#PS_\
M*V@ _P"&]OVF/^APTC_PD/#/_P K: /V_P#A-K^I^*OA9\-/%&M3)<:SXD^'
M_@W7]6N(X8K>.?4]8\.:;J%_,EO J0P))=7$KK#"B11*0D:JB@  ] H _/\
M_;G^/?Q,^!__  J[_A76L6FD_P#"3_\ ";?VQ]JT?3-5\_\ L7_A$?[/\O\
MM&VN/(\K^UKW=Y.SS?,7S-WEIM /@#_AO;]IC_H<-(_\)#PS_P#*V@ _X;V_
M:8_Z'#2/_"0\,_\ RMH ^O\ ]BG]IKXO_&?XIZ_X7\?Z]8ZIHUA\/]5U^VM[
M70M'TN1-3M?$7A33H9C/I]I;S.BVNJ7B&%G,3&17*EHT*@'Z@4 9VKSRVNDZ
MG<P-LFM]/O9X7VJVR6&VDDC;:X9&VNH.UE*G&"".* /P1_X;V_:8_P"APTC_
M ,)#PS_\K: #_AO;]IC_ *'#2/\ PD/#/_RMH /^&]OVF/\ H<-(_P#"0\,_
M_*V@#]T/A]J]]X@\!>"->U.1)=2UOPAX:U?4)8XTA22^U+1K*\NY$AC"QQ(\
M\TC+&@"("%4!0!0!U] 'YW_MQ_M!?%'X(ZK\.[;X>:U::5!XAT_Q'/JB76C:
M5JOFRZ;<Z1':M&VH6EP\.U+R8,L;*KY4D94&@#X0_P"&]OVF/^APTC_PD/#/
M_P K: #_ (;V_:8_Z'#2/_"0\,__ "MH ^T/V)/VDOBU\:?'OBS0?B#KECJN
MFZ5X0.KV45KH>DZ6\5\-9TRR\PRZ?:V\DB>1=2KY<A9,E6 !44 ?I?0!SOB^
M^NM+\)^)]3L9?(O=.\.ZU?6<VR.3R;JTTVYN+>7RYDDAD\N6-'V2QO&V-KHR
MDJ0#\(O^&]OVF/\ H<-(_P#"0\,__*V@ _X;V_:8_P"APTC_ ,)#PS_\K: #
M_AO;]IC_ *'#2/\ PD/#/_RMH _>#PIJ%SJ_A?PWJUX4-WJ>@:/J%T8T$<9N
M;W3K>YG*(.$0RR-M0<*N!VH WZ /S0_;:_:2^+7P6\>^$]!^'VN6.E:;JOA
M:O>Q7.AZ3JCR7QUG4[+S%EU"UN)(T$%K$HCC*ID%L9- 'Q?_ ,-[?M,?]#AI
M'_A(>&?_ )6T '_#>W[3'_0X:1_X2'AG_P"5M 'W!^Q!^T9\5?C7XH\<Z3\0
MM9L=5L]%T#3=0TX6NBZ7I4D%S-J#VTQ+Z=;6_FI)$0"DH<*44IL^;< ?H_0!
MR'Q!U>^\/^ O&^O:9(D6I:)X0\2ZOI\KQI,D=]INC7MY:2/#(#'*B3PQLT;@
MHX&U@5)% 'X7_P##>W[3'_0X:1_X2'AG_P"5M !_PWM^TQ_T.&D?^$AX9_\
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M: #_ (;V_:8_Z'#2/_"0\,__ "MH /\ AO;]IC_H<-(_\)#PS_\ *V@#]_Z
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M;[Q7I$]EJ'B'1;&\A_X1/P[%YUK=ZE;6]Q%YD.GQRQ^9#(Z;XG21,[D=6 (
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M/7_A]JEMI6I:IXO&CWLESIFGZI'+8G1=3O?+$.H6]PD;B>TA821A6VAE)(-
M'YH?\-[?M,?]#AI'_A(>&?\ Y6T '_#>W[3'_0X:1_X2'AG_ .5M 'TC^R=^
MUC\;?BI\;?#O@KQKXBT[4?#^HZ=XBGNK6W\.Z)I\K2Z?HEY>VK+=6-E!<)LN
M((R55]KKE6!!H _6Z@ H _"_X@_MO?M%>'O'WC?0-,\6:7%INA^+_$NCZ?%)
MX4\.321V.F:S>V5I&\KZ<7E=+>"-6D<EG(+,<F@#D/\ AO;]IC_H<-(_\)#P
MS_\ *V@ _P"&]OVF/^APTC_PD/#/_P K: /V0_9O\;>(?B-\$O /C3Q5=17O
MB#7=.OY]2NH+6WLHII;?6M3L8V2UM4BMX<6]K"I6*-5+ MC)- 'M] 'P[^V_
M\:OB'\%/#'@75?AYJ]MI-WK6O:GI^HFYTK3-4CGMH-/CN80$U&UN!"\<F[#0
ME-RNP<-A-H!^<7_#>W[3'_0X:1_X2'AG_P"5M !_PWM^TQ_T.&D?^$AX9_\
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MK32I_$.H^(K?5'NM)T[5?.BTZVTF2U5%U&WN%AVO=S%C$JL^5#'"@4 ?G?\
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MZ;<Z1':M&VH6EP\.U+R8,L;*KY4D94&@#X0_X;V_:8_Z'#2/_"0\,_\ RMH
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ML4 ?*'_#>W[3'_0X:1_X2'AG_P"5M !_PWM^TQ_T.&D?^$AX9_\ E;0!]_\
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MW$=S;*"]K=Q36TR,CNC))$WRL2NUPK* ?C%_PWM^TQ_T.&D?^$AX9_\ E;0
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MFZYXO\-:/J$4?A3PY#))8ZEK-E97<:2QZ<'B=[>:15D0AD)#*00* /W0H *
M/R _:C_:X^.7PP^.WCGP-X.\2:=8>'-#_P"$9_LZTG\.:%?RQ?VEX.\/:O=[
MKN\L9KF7??7]S(OF2-Y:N(DQ&BJ #Y__ .&]OVF/^APTC_PD/#/_ ,K: #_A
MO;]IC_H<-(_\)#PS_P#*V@#]/_V*?BYXY^,_PLU_Q1X_U*VU36;#X@:KH%M<
M6NFV.EQIIEKX<\*:A#";?3X+>%W6ZU2\<S,AE99%0L4C0* ?8% 'S_\ M1^/
M?$WPP^!/CGQSX.O(;#Q'H?\ PC/]G7<]G:W\47]I>,?#VCW>ZTO(IK:7?87]
MS$OF1MY;.)$PZ*P /R _X;V_:8_Z'#2/_"0\,_\ RMH /^&]OVF/^APTC_PD
M/#/_ ,K: /0/A-^VO^T+XJ^*?PT\+ZUXJTNXT;Q)\0/!N@:M;Q^%O#UO)/IF
ML>(M-TZ_A2>#3TF@>2UN)46:%TEB)#QLK*" #]OZ "@#\;_VD/VO_CO\./C;
MX^\%>%/$VG67A_0=0T^#3;6?PUH%[+#%<:)I=](K75S823S?Z1=2E3*[,%(7
M.%% 'B'_  WM^TQ_T.&D?^$AX9_^5M !_P -[?M,?]#AI'_A(>&?_E;0!^J'
M[&WQ5\:?&'X13^+/'>H6^I:W'XOUG2%N;;3[/38_L-G9Z3-;QFVL88(-R/=S
M9D\O>P*AB=HH ^KZ /F_]K#XB>*_A7\$O$7C7P5?0Z=X@TW4/#L%K=3V5GJ$
M2Q:AK=E8W2M:WT,]N^^WG<*2FY&PRD$4 ?DA_P -[?M,?]#AI'_A(>&?_E;0
M ?\ #>W[3'_0X:1_X2'AG_Y6T >H_!+]M#]H#QG\7/ASX3\0>*-+N]#\1>+]
M$TC5;:/POH%K)-8WMY'!<1I<6UA%/"QC8[9(G5U."#0!^UU !0!^+WQ\_;'^
M/G@'XR?$/P=X;\4Z=:Z%X?\ $5Q8Z7;S^&/#UW+!:K%#(D37,^G---L,A57E
M9Y"H&]V;+$ \A_X;V_:8_P"APTC_ ,)#PS_\K: #_AO;]IC_ *'#2/\ PD/#
M/_RMH _6#]D/XG>+_BY\&K#QAXWO;;4->DU_7M.ENK6QM=.CDMK&XC6V!M;*
M.*V5T2386CB3>JJ6!?<S 'T_0!\H?MD?%7QI\'OA%;^+/ >H6^FZW)XOT;2&
MN;G3[/4H_L-Y9ZM-/&+:^AG@#,]G!B3R]Z@$*1N- 'Y7_P##>W[3'_0X:1_X
M2'AG_P"5M !_PWM^TQ_T.&D?^$AX9_\ E;0![#\ /VR?CWX[^,OP]\'^)O$N
MEWV@^(-?CT[4[2/PSH5G)+;26UPQ"7-G90W$+JZ(ZM'(O*@,&0LI /V>H *
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ME#-@;CDXH P?^&]OVF/^APTC_P )#PS_ /*V@ _X;V_:8_Z'#2/_  D/#/\
M\K: /V@^ 7B_7/'WP;^'GC'Q+/#<Z[K_ (>@OM4N(+:*TBGNC--$TJ6T"I##
MO$2L4B1(PQ.Q$7"@ ]?H ^$/VX_CG\1_@EI/P[NOAYJUII4_B'4?$5OJCW6D
MZ=JOG1:=;:3):JBZC;W"P[7NYBQB56?*ACA0* /M#PIJ%SJ_A?PWJUX4-WJ>
M@:/J%T8T$<9N;W3K>YG*(.$0RR-M0<*N!VH WZ "@ H * "@ H * "@ H *
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@"CJ&F:;J]L;/5=/L=3LRZ2&UU"TM[VV+Q\HY@N8Y(BZ'
ME&VY7L10!@?\(#X$_P"A*\)?^$YH_P#\AT '_" ^!/\ H2O"7_A.:/\ _(=
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M(#X$_P"A*\)?^$YH_P#\AT 7M.\*>%](N1>:3X;T#2[M4:,76G:/IUE<B-P
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MTBY%YI/AO0-+NU1HQ=:=H^G65R(W #H)[:VBE".  RAMK #(H WZ "@#DO\
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M=^#/!]_<S7E]X4\-WMW</YD]U=Z%I=S<SO@#?-/-:O+(^ !N=B< #/% %?\
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MT5 !0!RLG@7P1+(\LO@WPK)+([2222>'M(>221R6=W=K,LSLQ+,S$EB22<T
M,_X0'P)_T)7A+_PG-'_^0Z #_A ? G_0E>$O_"<T?_Y#H Z*QT^PTNUBL=,L
MK33K&#?Y%G8VT-I:P^9(\TGE6]ND<,?F2R22OL0;I'=VRS$D MT 9>IZ)HNM
MQQ1:SI&EZO% YDACU.PM+^.&1EVL\2744JQN5^4L@!*\$XH QO\ A ? G_0E
M>$O_  G-'_\ D.@ _P"$!\"?]"5X2_\ "<T?_P"0Z +VG>%/"^D7(O-)\-Z!
MI=VJ-&+K3M'TZRN1&X =!/;6T4H1P &4-M8 9% &_0 4 <K)X%\$2R/++X-\
M*R2R.TDDDGA[2'DDD<EG=W:S+,[,2S,Q)8DDG- #/^$!\"?]"5X2_P#"<T?_
M .0Z #_A ? G_0E>$O\ PG-'_P#D.@#I+2SM+"VAL[&UM[*SMT$=O:VD$5M;
M01CHD,$*I%$@R<*BJH]* +- &7J>B:+K<<46LZ1I>KQ0.9(8]3L+2_CAD9=K
M/$EU%*L;E?E+( 2O!.* ,;_A ? G_0E>$O\ PG-'_P#D.@ _X0'P)_T)7A+_
M ,)S1_\ Y#H O:=X4\+Z1<B\TGPWH&EW:HT8NM.T?3K*Y$;@!T$]M;12A'
M90VU@!D4 ;] !0!R7_" ^!/^A*\)?^$YH_\ \AT '_" ^!/^A*\)?^$YH_\
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MB212(T<D<BAXY(W!5T=&!5D92596!!!((Q0!RO\ P@/@3_H2O"7_ (3FC_\
MR'0 ?\(#X$_Z$KPE_P"$YH__ ,AT '_" ^!/^A*\)?\ A.:/_P#(= '51QQQ
M1I%$B111(L<<<:A(XXT 5$1% 5$10%55 "@   "@!] &-J?ASP]K;Q2ZSH.C
M:O) AC@DU/2[&_>&-CN9(GNH)6C1FY*H0">2,T 9?_" ^!/^A*\)?^$YH_\
M\AT '_" ^!/^A*\)?^$YH_\ \AT :FE^'/#VB/++HN@Z-I$DZ+'-)I>EV-@\
MT:G<J2O:01-(BMRJL2 >0,T ;- #)(XY8WBE1)(I$:.2.10\<D;@JZ.C JR,
MI*LK @@D$8H Y7_A ? G_0E>$O\ PG-'_P#D.@ _X0'P)_T)7A+_ ,)S1_\
MY#H /^$!\"?]"5X2_P#"<T?_ .0Z .JCCCBC2*)$BBB18XXXU"1QQH J(B*
MJ(B@*JJ %    % #Z ,/4_#'AK6ITNM8\/:'JUS'"MO'<:GI-A?SI CR2+ D
MUU;RR+"LDLKK&&"!Y)&"@NQ(!G?\(#X$_P"A*\)?^$YH_P#\AT '_" ^!/\
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MUJ&CZ=>W)CC&$0SW-M)*40<(N[:HZ 4 4?\ A ? G_0E>$O_  G-'_\ D.@
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M4WE1I#'YMQ<6TDLGEPQQQ)O<[(T1%PJJ  5/^$!\"?\ 0E>$O_"<T?\ ^0Z
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M6NL:7IVK6L<JW$=MJ=E;7\"3HDD:S)#=12QK*L<LL:R!0X22100KL" 8?_"
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M6 &10!OT % ')?\ " ^!/^A*\)?^$YH__P AT '_  @/@3_H2O"7_A.:/_\
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M%*B212(T<D<BAXY(W!5T=&!5D92596!!!((Q0!RO_" ^!/\ H2O"7_A.:/\
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ME4(!/)&: ,O_ (0'P)_T)7A+_P )S1__ )#H /\ A ? G_0E>$O_  G-'_\
MD.@#4TOPYX>T1Y9=%T'1M(DG18YI-+TNQL'FC4[E25[2")I$5N55B0#R!F@#
M9H AN+>"[@FM;J"&YM;F&2WN+:XC2:"X@F0QS030R*T<L,L;-')&ZLCHQ5E*
MDB@#F/\ A ? G_0E>$O_  G-'_\ D.@ _P"$!\"?]"5X2_\ "<T?_P"0Z #_
M (0'P)_T)7A+_P )S1__ )#H ZV@ H P]3\,>&M:G2ZUCP]H>K7,<*V\=QJ>
MDV%_.D"/)(L"375O+(L*R2RNL88('DD8*"[$@&=_P@/@3_H2O"7_ (3FC_\
MR'0 ?\(#X$_Z$KPE_P"$YH__ ,AT :VEZ!H6A^?_ &)HNDZ/]J\K[3_9>FV>
MG_:/(\SR?/\ LD,/F^3YLOE>9N\OS9-F-[9 ->@"&XMX+N":UNH(;FUN89+>
MXMKB-)H+B"9#'-!-#(K1RPRQLT<D;JR.C%64J2* .8_X0'P)_P!"5X2_\)S1
M_P#Y#H /^$!\"?\ 0E>$O_"<T?\ ^0Z #_A ? G_ $)7A+_PG-'_ /D.@#K:
M "@# U#PIX7U>Y-YJWAO0-3NRB1FZU#1].O;DQQC"(9[FVDE*(.$7=M4= *
M*/\ P@/@3_H2O"7_ (3FC_\ R'0 ?\(#X$_Z$KPE_P"$YH__ ,AT :VEZ!H6
MA^?_ &)HNDZ/]J\K[3_9>FV>G_:/(\SR?/\ LD,/F^3YLOE>9N\OS9-F-[9
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MT?\ ^0Z -_3M,TW2+86>DZ?8Z99J[2+:Z=:6]E;!WY=Q!;1Q1!W(RS!<MW-
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M,26)))S0 S_A ? G_0E>$O\ PG-'_P#D.@ _X0'P)_T)7A+_ ,)S1_\ Y#H
MZ2TL[2PMH;.QM;>RL[=!';VMI!%;6T$8Z)#!"J11(,G"HJJ/2@"S0!EZGHFB
MZW'%%K.D:7J\4#F2&/4["TOXX9&7:SQ)=12K&Y7Y2R $KP3B@#&_X0'P)_T)
M7A+_ ,)S1_\ Y#H /^$!\"?]"5X2_P#"<T?_ .0Z +VG>%/"^D7(O-)\-Z!I
M=VJ-&+K3M'TZRN1&X =!/;6T4H1P &4-M8 9% &_0 4 <K)X%\$2R/++X-\*
MR2R.TDDDGA[2'DDD<EG=W:S+,[,2S,Q)8DDG- #/^$!\"?\ 0E>$O_"<T?\
M^0Z #_A ? G_ $)7A+_PG-'_ /D.@#I+2SM+"VAL[&UM[*SMT$=O:VD$5M;0
M1CHD,$*I%$@R<*BJH]* +- &1JF@:%KGD?VUHNDZQ]E\W[-_:FFV>H?9_.\O
MSO(^UPR^3YODQ>;Y>W?Y4>[.Q< &I'''%&D42)%%$BQQQQJ$CCC0!41$4!41
M% 554 *    * 'T % !0 4 % !0 4 % !0 4 % !0!^+?_!6?_@AA^QY_P %
M:O#=OJOQ,L[[X4?M%>&=#ET3P!^TCX!L+27Q9IE@KO<6/A[QWX?N)K+3/B;X
M)M+YWN8=!UB[T[6=)6XU*/PAXK\*/K&JS7@!_G-?M^?\&W?_  4^_8,;6O$U
MU\'KG]H_X,:9/<M'\7?V<[;4O'UO::7"7D34/%_P^M;,?$;P;#%:*)]4U&^\
M.7?A/3'WP_\ "5W0597 /P7N;6YLKB:TO+:>TNK>1HKBUN89+>X@E3AHYH95
M22*13PR.JLO0@4 04 % !0!ZY\#/CW\9_P!F;XG>%OC/\ /B9XO^$OQ1\%ZA
M%J7ASQGX*U>XTC5K*:-AYEK<>43:ZKI%_%NL]8T'5[>^T/7--FN-+UC3K[3K
MFXM90#_4$_X-]O\ @X=\._\ !3G3H_V8_P!IF/PY\/OVW?">@76IZ=<:6;?1
M_!O[1WAG1($FU7Q)X+TJ0QIH7Q$T.S\S4/&?P[L7N[>XTFTOO'/A'R_#UMXB
MT#P. ?U,4 ?SG?\ !UA\,9_B+_P14_:.U6SMGN[WX4>,_@;\3H((TWR"WM/B
MSX7\&ZQ<*!T2PT#QKJVH7#<;+2UG;MB@#_(XH * /]13_@S8_:*T#XE_\$S/
M'7P$_M*%O&G[-/Q_\5VU_HGF;[JV\!_%VSM/'/@W7'7_ )9VNK^*(_B9I-LO
M7S?#%V?NE: /ZY* "@ H _@9_P"#Y;_D!?\ !,S_ +"W[7__ *1_LS4 ?Y]M
M !0!_N[_ +)G_)JW[,__ &;]\&O_ %7/AN@#Z!H _P YW_@]^_Y.%_8/_P"R
M,_%G_P!3?P[0!_#30 4 ?[]>F_\ (.L/^O*U_P#1$= %V@ H _*/_@N?_P H
M@/\ @HE_V:[\1_\ TWI0!_BQT % '^HE_P &7?\ RBE^+G_9]'Q9_P#5)_LX
M4 ?US4 ?Y1__  =[?#>[\$?\%A?$OB>:!XK3XN?L_P#P6\>6$K)M6XCTRPUK
MX;7,B-C#A+WP#/$3_"4VGH* /Y=Z />/V6/C!<?L]?M.?LY_'RT!:Y^"/QU^
M$?Q<@16*F23X<>/O#_C!8LC&!(='\L]BK$'B@#_=G\.>(-(\6>'M"\4^'[V'
M4]!\2Z-I?B#1-2MG62WU#2-9L8-1TV]MY$)1X;JRN89XG4E6C=2I((H V: "
M@ H _P V7_@]B^.^C^+/VOOV3/V>M,U""\O?@Q\#?$_CWQ);6\RR_P!E:K\9
M?%EO:6.GWBH2+;4'T+X9Z;JK6LNV?^SM4TN[*""[MGD /XH: )(89;B6*""*
M2:>:1(8884:26661@D<44: O))(Y"(B LS$*H)(% '^[S^RK\+[CX(_LP?LX
M_!B\18[SX2? CX1?#.\1,;5O/ O@#P_X8N@N."/M&ER'(X/6@#WN@#_ E\4_
M\C/XC_[#VK_^G"XH P: /[F?^#(#_DX']O+_ +(Y\(O_ %-?$U '^B_0 4 %
M 'PE_P %2/\ E&3_ ,%%O^S$OVNO_6?_ (@T ?X>E !0!_I+_P#!D=_R9I^V
M7_V<WX<_]57H% ']L- !0 4 % !0 4 % !0 4 % !0!__]?^_B@ H * "@ H
M * /(/BW^T'\ _@!9Z+J/QX^-_P@^">G^([F[LO#M]\6_B5X,^&]GKUY810S
MWUIHMSXQUK1H-4N;*"XMYKN"Q>>6VBFADF1$D0D =\)/V@?@+\?K'6-3^!'Q
MM^$7QKTSP[=VUAX@U#X2?$GP;\1['0KZ]A>XL[+6+OP=K.LV^F7=W;Q2SVUM
M>R033PQO)$C(C$ 'KM &#XF\4^&/!.A:CXH\9>(]!\)>&='@-UJWB+Q-J^GZ
M#H6EVJX#7.HZOJMQ::?8P*2 9KFXBC&0"U 'YE>-O^"X?_!(CX>WMQIWB+_@
MH=^RY-=VER]I<1^%/B7I7C](KB.3RI(S/X"_X26W(CD!5W64QI@[F 4X .W^
M&7_!7[_@EM\8=7T[P]\//V__ -D_6O$&L2+!I.@7?QJ\$^'-=U2Y?[EIIVC^
M)]5T74KV\?\ @L[:VDNFPVV$[3@ _1:WN+>[MX+JTGAN;6YABN+:YMY$FM[B
MWF19(9X)HRT<L,L;+)%)&S(Z,K*2I!H ^7/&G[=7[$?PW\4ZWX&^(?[8W[*W
M@+QMX:O&TWQ'X/\ &G[0GPD\+>*?#^H(B2-8:WX?USQ=8ZMI5XL<D<C6M]:0
M3A)$8H%920#F!_P4@_X)X=!^WI^Q?Z #]J/X'_\ S<T >J^"?VJOV7_B7?V>
ME?#C]I#X"?$#4]0<1V&G>"?C!\/?%=_?2,,K'9V>A>(K^XN7(Z+#&Y(Z"@#W
MN@ H * /"/CG^U)^S1^S#I-AKO[2'[0GP3^ >CZL\L6CZA\8_BCX)^&MMK,\
M"[I;;1G\8:WI']KW2+UM=-%S<=A$3@4 ?#%G_P %T?\ @C]?>(_^$6@_X*(_
MLOIJ?'^DWGQ$L=.\.<ML'_%8ZA':^$>O7&M\+\YPGS4 ?HQ\+/C!\)?CGX/L
MOB'\$OBC\.OC#X U*:XMM.\<?"SQMX:^(/@^_N+1E2[M[/Q+X3U/5M%N9[5V
M5+B&"]>2!B%E520* /1J /DB?]OW]A"U\0S>$;G]M?\ 9(MO%=MK,GARX\,3
M_M'_  <A\0P>(8;TZ9+H,VBR>,EU*+68M25M/DTM[9;U+U3:- )P8Z /K>@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M898G#))%(C,DD;J4="58$'% '^=!_P '6O\ P0^^%G[.>B6G_!2+]D;P18>
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M>,SO-<5A+*R^K8C'5ZM"RZ+V4X670_G?&3A4QF*J4OX=3$UYT_\ !*K*4/\
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M[^'%K=M?VWP_\"^$?!%O?.GE/>P>%- T_08KMXMS^6US'8+,R;WV%]NYL9H
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M+2W /F&@ H * "@!RJSLJ(I9V(544%F9B<*JJ.22<  #)/ H _N:_P"#?/\
MX-CO&OCOQ5X)_;7_ ."DGP\O/!_PR\.WNE>*_@W^RWXWTE8O$?Q1U"%$U#2?
M%_QF\-WX\_PW\/M/N#:W6F_#O7;./7/'%U"W_"5Z9I7@Z%+#QJ ?Z+2(D:+'
M&JHB*J(B*%1$4!5554 *J@ *H     Q0 Z@ H _P)?%/_(S^(_\ L/:O_P"G
M"XH P: /[F?^#(#_ ).!_;R_[(Y\(O\ U-?$U '^B_0 4 % 'PE_P5(_Y1D_
M\%%O^S$OVNO_ %G_ .(- '^'I0 4 ?Z2_P#P9'?\F:?ME_\ 9S?AS_U5>@4
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M$^DW<5SHEMXX^(?CGPWX5\%^/((3;2ZF_P (OA1J_BR]\3P) =;UQ=#L]?\
M#.J '^J\         !@ #@  <  =!0 M '^,)_P7S^"VC_ #_@L5^WY\/- @
M^RZ3=_&^;XH6MHL8AAM&^._A3PS\<KFTM85^2&QM;OXBSV]A#&%BBLHX$B2.
M-510#_6U_P""=_Q;UGX]_L"_L4?&OQ)>?VAXH^*O[*/[/OCWQ7>;F8S^+/$_
MPJ\*ZMXI<LQ9F;_A(+G459F8L64DG- 'V-0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M_P#P3A?_ )L#_A^7^R9_T3S]HG_PDOAK_P#/;H_X@'QA_P!#+AK_ ,+,T_\
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M@;,__!.%_P#FP/\ A^7^R9_T3S]HG_PDOAK_ //;H_X@'QA_T,N&O_"S-/\
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M  DOAK_\]NC_ (@'QA_T,N&O_"S-/_G,'^O^3?\ 0-F?_@G"_P#S8'_#\O\
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M_P#P3A?_ )L#_A^7^R9_T3S]HG_PDOAK_P#/;H_X@'QA_P!#+AK_ ,+,T_\
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M@;,__!.%_P#FP/\ A^7^R9_T3S]HG_PDOAK_ //;H_X@'QA_T,N&O_"S-/\
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M  DOAK_\]NC_ (@'QA_T,N&O_"S-/_G,'^O^3?\ 0-F?_@G"_P#S8'_#\O\
M9,_Z)Y^T3_X27PU_^>W1_P 0#XP_Z&7#7_A9FG_SF#_7_)O^@;,__!.%_P#F
MP/\ A^7^R9_T3S]HG_PDOAK_ //;H_X@'QA_T,N&O_"S-/\ YS!_K_DW_0-F
M?_@G"_\ S8'_  _+_9,_Z)Y^T3_X27PU_P#GMT?\0#XP_P"AEPU_X69I_P#.
M8/\ 7_)O^@;,_P#P3A?_ )L#_A^7^R9_T3S]HG_PDOAK_P#/;H_X@'QA_P!#
M+AK_ ,+,T_\ G,'^O^3?] V9_P#@G"__ #8'_#\O]DS_ *)Y^T3_ .$E\-?_
M )[='_$ ^,/^AEPU_P"%F:?_ #F#_7_)O^@;,_\ P3A?_FP/^'Y?[)G_ $3S
M]HG_ ,)+X:__ #VZ/^(!\8?]#+AK_P +,T_^<P?Z_P"3?] V9_\ @G"__-@?
M\/R_V3/^B>?M$_\ A)?#7_Y[='_$ ^,/^AEPU_X69I_\Y@_U_P F_P"@;,__
M  3A?_FP/^'Y?[)G_1//VB?_  DOAK_\]NC_ (@'QA_T,N&O_"S-/_G,'^O^
M3?\ 0-F?_@G"_P#S8'_#\O\ 9,_Z)Y^T3_X27PU_^>W1_P 0#XP_Z&7#7_A9
MFG_SF#_7_)O^@;,__!.%_P#FP/\ A^7^R9_T3S]HG_PDOAK_ //;H_X@'QA_
MT,N&O_"S-/\ YS!_K_DW_0-F?_@G"_\ S8'_  _+_9,_Z)Y^T3_X27PU_P#G
MMT?\0#XP_P"AEPU_X69I_P#.8/\ 7_)O^@;,_P#P3A?_ )L#_A^7^R9_T3S]
MHG_PDOAK_P#/;H_X@'QA_P!#+AK_ ,+,T_\ G,'^O^3?] V9_P#@G"__ #8'
M_#\O]DS_ *)Y^T3_ .$E\-?_ )[='_$ ^,/^AEPU_P"%F:?_ #F#_7_)O^@;
M,_\ P3A?_FP/^'Y?[)G_ $3S]HG_ ,)+X:__ #VZ/^(!\8?]#+AK_P +,T_^
M<P?Z_P"3?] V9_\ @G"__-@?\/R_V3/^B>?M$_\ A)?#7_Y[='_$ ^,/^AEP
MU_X69I_\Y@_U_P F_P"@;,__  3A?_FP/^'Y?[)G_1//VB?_  DOAK_\]NC_
M (@'QA_T,N&O_"S-/_G,'^O^3?\ 0-F?_@G"_P#S8'_#\O\ 9,_Z)Y^T3_X2
M7PU_^>W1_P 0#XP_Z&7#7_A9FG_SF#_7_)O^@;,__!.%_P#FP/\ A^7^R9_T
M3S]HG_PDOAK_ //;H_X@'QA_T,N&O_"S-/\ YS!_K_DW_0-F?_@G"_\ S8'_
M  _+_9,_Z)Y^T3_X27PU_P#GMT?\0#XP_P"AEPU_X69I_P#.8/\ 7_)O^@;,
M_P#P3A?_ )L#_A^7^R9_T3S]HG_PDOAK_P#/;H_X@'QA_P!#+AK_ ,+,T_\
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M@;,__!.%_P#FP/\ A^7^R9_T3S]HG_PDOAK_ //;H_X@'QA_T,N&O_"S-/\
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M  DOAK_\]NC_ (@'QA_T,N&O_"S-/_G,'^O^3?\ 0-F?_@G"_P#S8'_#\O\
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M_P#P3A?_ )L#_A^7^R9_T3S]HG_PDOAK_P#/;H_X@'QA_P!#+AK_ ,+,T_\
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M@;,__!.%_P#FP/\ A^7^R9_T3S]HG_PDOAK_ //;H_X@'QA_T,N&O_"S-/\
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M  DOAK_\]NC_ (@'QA_T,N&O_"S-/_G,'^O^3?\ 0-F?_@G"_P#S8'_#\O\
M9,_Z)Y^T3_X27PU_^>W1_P 0#XP_Z&7#7_A9FG_SF#_7_)O^@;,__!.%_P#F
MP/\ A^7^R9_T3S]HG_PDOAK_ //;H_X@'QA_T,N&O_"S-/\ YS!_K_DW_0-F
M?_@G"_\ S8'_  _+_9,_Z)Y^T3_X27PU_P#GMT?\0#XP_P"AEPU_X69I_P#.
M8/\ 7_)O^@;,_P#P3A?_ )L#_A^7^R9_T3S]HG_PDOAK_P#/;H_X@'QA_P!#
M+AK_ ,+,T_\ G,'^O^3?] V9_P#@G"__ #8'_#\O]DS_ *)Y^T3_ .$E\-?_
M )[='_$ ^,/^AEPU_P"%F:?_ #F#_7_)O^@;,_\ P3A?_FP/^'Y?[)G_ $3S
M]HG_ ,)+X:__ #VZ/^(!\8?]#+AK_P +,T_^<P?Z_P"3?] V9_\ @G"__-@?
M\/R_V3/^B>?M$_\ A)?#7_Y[='_$ ^,/^AEPU_X69I_\Y@_U_P F_P"@;,__
M  3A?_FP/^'Y?[)G_1//VB?_  DOAK_\]NC_ (@'QA_T,N&O_"S-/_G,'^O^
M3?\ 0-F?_@G"_P#S8'_#\O\ 9,_Z)Y^T3_X27PU_^>W1_P 0#XP_Z&7#7_A9
MFG_SF#_7_)O^@;,__!.%_P#FP/\ A^7^R9_T3S]HG_PDOAK_ //;H_X@'QA_
MT,N&O_"S-/\ YS!_K_DW_0-F?_@G"_\ S8'_  _+_9,_Z)Y^T3_X27PU_P#G
MMT?\0#XP_P"AEPU_X69I_P#.8/\ 7_)O^@;,_P#P3A?_ )L#_A^7^R9_T3S]
MHG_PDOAK_P#/;H_X@'QA_P!#+AK_ ,+,T_\ G,'^O^3?] V9_P#@G"__ #8'
M_#\O]DS_ *)Y^T3_ .$E\-?_ )[='_$ ^,/^AEPU_P"%F:?_ #F#_7_)O^@;
M,_\ P3A?_FP/^'Y?[)G_ $3S]HG_ ,)+X:__ #VZ/^(!\8?]#+AK_P +,T_^
M<P?Z_P"3?] V9_\ @G"__-@?\/R_V3/^B>?M$_\ A)?#7_Y[='_$ ^,/^AEP
MU_X69I_\Y@_U_P F_P"@;,__  3A?_FP/^'Y?[)G_1//VB?_  DOAK_\]NC_
M (@'QA_T,N&O_"S-/_G,'^O^3?\ 0-F?_@G"_P#S8'_#\O\ 9,_Z)Y^T3_X2
M7PU_^>W1_P 0#XP_Z&7#7_A9FG_SF#_7_)O^@;,__!.%_P#FP/\ A^7^R9_T
M3S]HG_PDOAK_ //;H_X@'QA_T,N&O_"S-/\ YS!_K_DW_0-F?_@G"_\ S8'_
M  _+_9,_Z)Y^T3_X27PU_P#GMT?\0#XP_P"AEPU_X69I_P#.8/\ 7_)O^@;,
M_P#P3A?_ )L#_A^7^R9_T3S]HG_PDOAK_P#/;H_X@'QA_P!#+AK_ ,+,T_\
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M@;,__!.%_P#FP/\ A^7^R9_T3S]HG_PDOAK_ //;H_X@'QA_T,N&O_"S-/\
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M  DOAK_\]NC_ (@'QA_T,N&O_"S-/_G,'^O^3?\ 0-F?_@G"_P#S8'_#\O\
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M_P#P3A?_ )L#_A^7^R9_T3S]HG_PDOAK_P#/;H_X@'QA_P!#+AK_ ,+,T_\
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M@;,__!.%_P#FP/\ A^7^R9_T3S]HG_PDOAK_ //;H_X@'QA_T,N&O_"S-/\
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M  DOAK_\]NC_ (@'QA_T,N&O_"S-/_G,'^O^3?\ 0-F?_@G"_P#S8'_#\O\
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M_P#P3A?_ )L#_A^7^R9_T3S]HG_PDOAK_P#/;H_X@'QA_P!#+AK_ ,+,T_\
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M@;,__!.%_P#FP/\ A^7^R9_T3S]HG_PDOAK_ //;H_X@'QA_T,N&O_"S-/\
MYS!_K_DW_0-F?_@G"_\ S8?9O[(O[<OPE_;0_P"%@_\ "KO#WQ$T'_A6W_")
M_P!N?\)]I/AK2_M7_"8?\)+_ &9_9/\ PCOBWQ3Y_D?\(MJ'V[[9]@\KSK/[
M/]I\R;[/\/QEP#G' _\ 9O\ :V)RW$?VG]<^K_V=6Q57D^I?5?:^V^LX/"<O
M-];I^SY/:7Y9\W):/-[N2\08//?K/U2EB:?U7V/M/K$*4+^V]KR<GLJU6]O8
MRYK\MKQM?6WV=7Q![@4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MX4U'2]6TG4M),UCJ-MJ%U!<V^H75M=V):*UGB /YX/\ B!T^*?\ TD2^'_\
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M?V9?@@- Z_\ ()\[QF9NO'_(=.M?=X_X%NH _N6_X-K_ .R?^'(G[!?]B_\
M'G_PA?Q1\[[O_(6_X7_\6?[?^[Q_R'?[1]_[WS9H ^M_^"N7PKUCXU?\$O\
M]OGX:>';$ZGXB\1?LH_&J7PYI: F74_$.@^"-6\2:'IUN K9NK[5='M+2T!
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M-H4[HR>;8Z/<W>O_  [OT^8$6GB+P-K5FA4-#!$_S4 ?YB/_  5#_8 ^(/\
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H _SMZ_T
MH/YG"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /Z)/^"!W_-UW_="
M_P#WL=?S7](;_FD/^Z__ .\0_3/#K_F<?]T__P!W3^B2OYK/TP* "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M%7A72_%495E5E;_A(+?4BRLH8,2&&<T ?9- !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '^=O7^E!_,X4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0!_1)_P0._YNN_[H7_[V.OYK^D-_S2'_ '7_
M /WB'Z9X=?\ ,X_[I_\ [NG]$E?S6?I@4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * (Y98H(I)YY(X888WEFEE=8XHHHU+R22
M2.0B1H@+.[$*J@DD 4 ?*7@?]O7]ACXG>+-#\!?#;]M#]D[XA>.O$]Y_9WAK
MP7X'_:+^#_BSQ9XAU#RI)_L.A^'-!\8W^L:M>>1#--]EL+.>;RHI)-FR-B #
MZQH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % '^=O7^E!_,X4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M!_1)_P $#O\ FZ[_ +H7_P"]CK^:_I#?\TA_W7__ 'B'Z9X=?\SC_NG_ /NZ
M?T25_-9^F!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M .FRYH _QG?^""O_ "F,_P"">?\ V<7X8_\ 2'5: /\ :%H * "@ H * "@
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MDZSI=Y%/IFN^']7M;'7/#^L6E[H^M:?8:G975I$ >O4 % !0 4 % !0 4 %
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MJ<\=G:1>?>ZE?W-S/*7=Y,$*H!\-?\16/_!;[_HZ7PC_ .(Y?L\?_.SH /\
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MX7:%KWB73K!MUKX?^(>G"7PY\3O"T)W.QC\+?$/1O$WA^-W(>6+3DF*KY@4
M'V;0 4 ?Y</_  >=?\I8/AG_ -F1_"+_ -6Y^T!0!_<I_P &_7_*&?\ X)]?
M]D+M_P#U*_$] '[%4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '^=O7^
ME!_,X4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!_1)_P0._YNN_[H
M7_[V.OYK^D-_S2'_ '7_ /WB'Z9X=?\ ,X_[I_\ [NG]$E?S6?I@4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 ?__7_OXH * "@ H * "@#AO''PP^&OQ.M;"Q^)/P\\#?
M$*RTN>6ZTRS\<>$M \66NG74\8AFN;"WU[3[^*SGFB58I9K=(Y)(P$9BH H
ME\$?#?X=_#/3[K2/AOX"\%_#[2;Z\.HWVF>"/"VA^%-/O-0,$-J;^ZLM!L;"
MVN+PVUO;VYNI8GG,$$,6_P N)%4 [2@ H * "@ H * "@ H * "@ H * "@
MH * /#X/V9/V;;;58]>MOV?/@?;ZY%?#5(M9@^$_@.+58M3$WVD:C'J,>@+=
MI?"X_P!(%VLPN!-^]\S?\U 'N% !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MUA\C1M:TE9)C( ?IA0!_BK_'DD_\%MOC.3R3_P %3_B)R?\ L[76* /]JB@
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0!_G;U_I0?S.% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?T
M2?\ ! [_ )NN_P"Z%_\ O8Z_FOZ0W_-(?]U__P!XA^F>'7_,X_[I_P#[NG]$
ME?S6?I@4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 ?_]#^_B@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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MGX>\>>#[Q=/\1:-;^(_CU\-O#>N1Z?>M%*;?^TM"U34=+N710YM;R9%9=V:
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M 4 5K2SM+"VAL[&UM[*TMT\N"UM((K:V@3).R&"%4BC3))VHJC)/% '\0_\
MP>]?\FO?L-_]E[^)'_JO+*@#UK_@R>_Y1T_M._\ 9ZOB'_U1GP/H _LGH _*
M[_@N%_RB%_X**_\ 9J7Q6_\ 3!-0!_GI_P#!H?\ \ID_ _\ V0+X[_\ J/Z=
M0!_J^T % $<L44\4D$T<<T,T;Q2PRHLD4L4BE'CDC8%'C="5=&!5E)4@@XH
M_P 7/_@N1^QEH/[!?_!43]JG]G_P1ICZ1\,(O%^G?$GX3V*QB.RT[X??%GP_
MI?Q!TGP]I. &?2O!%]KVJ> ;*23=*R>%3YLDT@::0 _U=?\ @D-^T-J'[57_
M  3'_8?^.NN:A=:OXG\7_L\^ ]-\::Q?2R37>L>/O =@?AWX^UBXEF+2R2ZK
MXS\)Z[J#-(\CDW'S22'YV /T;H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H _R;?VF?\
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M"HOCK0=(\>_ [X3^*OC'X2_:%33M$\/-\7?!7@2RM9O$/P_UOPIHT.EZ??\
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M?U[PY\4]1DMTN6T?X\_%:PO?'/B7Q8LBAWU"Y^'WQ:UN.\\,7,PD>.R\(Z!
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * /Z)/^"!W_-UW_="__>QU_-?TAO\
MFD/^Z_\ ^\0_3/#K_F<?]T__ -W3^B2OYK/TP* "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M /_1_OXH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MXOH[?6?BE\2-1B +ZS\0_'L]M'K'B&[>;?-;:<&L_#>AB1K/PSH6B:8L5C&
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MYXVT"_\ #NJFU>1)%M[Z&SU"2?3[M4\RSO8K>ZA*RPHP /\ &9^"?BWXH?\
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M:.1%>-U9'1U#(Z,-K(RD%65E)#*1@C@C% '^0O\ \'.'[$?@']A__@JO\1M
M^%&BZ5X5^&7Q_P# /A']I?PAX+T'3+?2-$\%MX[U7Q5X3\8Z!H]A916^GV>D
M/\1/A_XPUS2--TZUM;#1M)UJQT2TMT@TU"P!_HN_\&_'Q<UKXW?\$:OV _''
MB&[FO]4LO@S<_#.2[N)WN;B>T^"/CKQ?\%M+>>>3,DLW]E_#^R65I"S[PP9G
M8%B ?P\_\'GEEXNM_P#@JA\++K7)99?#5_\ L8_#%_! #2FUMM/M_BG\;;?6
M[4!B84OO^$@2_N[I8PKFSO-,:7(,1H _JQ_X-1OC)^RWXS_X)-?"'X7?!'4O
M!^G?%[X6ZQX^3]I?P/9-96GCR+XB:]X\\0:CIWCKQ7:>5;ZIKFF^*_!<OA2'
MPSXK9;_3(M(TNV\"VVIB[\%WNE:8 ?TQ4 <=X*^'?P_^&VGZEI/PZ\#>#O .
ME:SK^J^*M8TSP5X9T7PKI^J^*-=E2?7/$FI6>A65A;7VOZS-''-JNL74<NH:
MA*B27=Q,RJ0 ?P1_\'J_[</B2#7?V:?^">?A+6)K#PS<>&S^TY\9+6QO)$'B
M&[N];\0^!?A'H&J);F-39:%)X=\>^)KK2;UKB&\OM1\(ZQ]FMY]%TVYE /I_
M_@T,_P""4?PR\%_LYVW_  4V^+7A72/%GQB^,^K^*-"_9[/B'1;2]_X5)\-?
M!7B+5_!FN>+_  S]OBD?3?&WQ"\4Z/KUB_B"VBBO;'P/H^G6NB7\5CXM\1PW
MX!_;=0!_GI?\'H7[ GPT\":C^SU_P4'^'?A_2_"GBCXH^+;_ . GQRAT72+3
M3K/QMXFA\/:SXX^'7CO5'L8[=;GQ@=#T#QEX<U[5KY+J_P!;T?2O"5NUQ$GA
M[%P ?I+_ ,&9'[3>O?%7_@GI\8?V=?$FIS:E+^RU\=)X_!L<I8C1OAK\:-)?
MQGIFBQEBVY(_B+I?Q4U92" B:PL C5($+@'V]_P=8?\ *$#]JC_L;/V<O_6B
M?AC0!_-5_P &0_\ R=7^V[_V;YX _P#5CM0!_H_T % !0 4 % !0 4 % !0!
M_B8Z-_RF%TK_ +256/\ ZU#%0!_MG4 % !0 4 ?P_?\ ![U_R:]^PW_V7OXD
M?^J\LJ /6O\ @R>_Y1T_M._]GJ^(?_5&? ^@#^R>@#\KO^"X7_*(7_@HK_V:
ME\5O_3!-0!_GI_\ !H?_ ,ID_ __ &0+X[_^H_IU '^K[0 4 % '^6C_ ,'E
MUOI</_!6CP3)8,&NKO\ 8S^#UQK8  \O4U^(_P ;K2)#CJ?[%M=(?)P<.!C
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M^ EGXPMKKQ/X*^#VNZC^U9\9;_4S)J1U"P^%VIV&M:!%K;W.]=2B\7?%W5/
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@#^B3_ (('?\W7?]T+_P#>
MQU_-?TAO^:0_[K__ +Q#],\.O^9Q_P!T_P#]W3^B2OYK/TP* "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * /_]+^_B@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H J7UA8ZI8WFF:G96FHZ;J-K<6.H:??
M6\-W8WUC=Q/;W5G>6EPDD%S:W,$CPW%O-&\,T3O'(C(Q4@'\B?\ P6 _X-3/
MV8_VI_#?C/XW?L$Z%H/[,G[3%GINJ:['\+/#UM::/\ /C+JT,4MVNA-X;5[;
M3?A!XGU>1$L]+\1>$A8>"$N6'_"1^$=]]=>*-- /X.O^">O[</[2'_!&[]N_
M3OBEIVA>(M!\2?#3Q;K'PK_:2^!'B%KK0)/&7A'3]<.D?$;X7>++"=3_ &9X
MBTC4--DN_#VH7=M<-X7\;:+I.JO;7EM:7>GWH!_M&?#WQWX8^*7@'P/\3?!.
MHIJ_@SXB^#_#7COPCJT:E$U3PQXNT6R\0:#J**>52]TK4+2Y53RHD [4 ?XP
MWQX_Y3:_&;_M*?\ $3_UK76* /\ :IH S-:UK2/#>C:MXB\0:G8:)H.@Z9?Z
MUK>LZI=0V.F:1I&EVLM]J6IZC>W+QV]G86%E!-=7=U/(D-O;Q22RNJ(Q !_F
MP_\ !4S_ (.ZOVH_B]\1/%WPE_X)JS6OP(^!5C=R^'=(^-.H^$;#7/CS\3GC
MFDM+O7]$M?$L>L>'OAMX:UG*KX:TVU\-W7Q#AM1#K-UXET#5+\^&]! /@3PI
M_P $_?\ @YN_X*)Z=!XHU_1OV[_&WA/Q+;Q:A#J7[1_[06M?"GPO-I-\BR6]
M[I'A;XV_$GP=YVBW,,B3V</ACPU<VL]K*MQ96TEN_F$ \]_;"_X-KO\ @HM^
MPY^R#\6/VUOVC]6_9[\/> ?A-_P@K^)/!VB_$SQ#XN^)NI7'Q$^)7@_X9:6-
M*M-'\!W'@NX:TUWQKI]]J\M]XZLMFF6U]+9_;[M8+2< _4G_ (,D?^3W?VP/
M^S5M-_\ 5M^#: /Z$/\ @\$UR]TG_@CSJEA:^=Y'B?\ :6^!^AZEY181_8K<
M>+_$L?VD*0&A_M'P]8;0V5^T?9V W*I !^(G_!CUI/A^;XV_\% M=N?LW_"5
M:=\*_@3I.C;A_I?_  C^M>+?B'>>)?(/:V_M'0/"?VH=Y?L?I0!_HH4 % '^
M1A_P=7FT_P"'X'[5/V98A,/"G[.0OS'&$9KO_AG3X8%&G8*/-E%B;)0Y+8A6
M&+<!&%4 _P!.O_@F'_RC5_X)Y_\ 9C?[)G_JA/ % '^2=_P77U#4M3_X+!_\
M%$+C549+J/\ :;\>Z?$K$DG3=)GM]*T9P3_#)H]E8N@Z*K!1P!0!]9>"_P!B
M+_@YBNO!WA.Y\">%?^"F4/@>X\,Z#/X-AT+XV?$[3=$B\*3:7:R>'8]&TZ#X
MD6L-AI2:0UFNGV4-M;Q6MH(8(X(4C$:@'3?\,-_\'1G_ $+/_!4?_P /S\4_
M_GGT >/?%C_@DI_P<'?'K^P/^%Y_LS_MS?&?_A%/[4_X1?\ X6QXMU_XB_\
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M\'%O_*:O]OS_ +*EX7_]5/\ #V@#_7*_9+_Y-5_9F_[-]^#/_JN?#= 'T%0
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MO0C\>/C;%+!]GU%/B=\6K6PURYT75XMJXU/P)X2B\(_#:Y(W(Y\&"17</O8
M_9"@ H \W^,?@%/BM\(?BI\+I)XK6/XD_#?QQX!>YG1I(+9/&'AC5/#K3S1I
M\SQ0KJ)DD1?F9%*KR10!_B7?L1?%O4?V'_\ @H;^S3\7/&]M+H<W[-W[4GP^
MU3XE:=<0O)<6&C>"?B%8Z?\ $O29(HDDD^TKH-OXATXF&.26.8[XD=U52 ?[
MANGZA8:M86.JZ5>VNI:9J=G;:AIVHV%Q%=V-_87D*7%G>V=U SP7-K=6\D<]
MO<0N\4T+I)&S(P- %R@ H * /\B#_@Z0_:$TCX__ /!97]HR#P[J%IJOA[X$
MZ)\._P!GNPO[.1)4;5O 7AF#4_'VGRE"P6[\/_$[Q1XV\-W<9.Z.?1W5PC H
MH!_I&?\ !#[X):G^SS_P23_8%^&.MQO;ZS#^SUX4\>:O92Q^5/IFJ?&*:_\
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MQSI@:WO=9^'GB>XLM*N[R/3KVTUGP]K.F:?KNCRW,*:UX?\ $8!_FB_M,_\
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M!_"HU?4]5CP.-R,W4D4 ?-?[.'['_P#P<(>,/@;\-?%/[+GAG_@H2?V?=?\
M#L>J_"N3X7?%WXB>&_A]/X8O+JZEBN?"NB:7X^TG3['2[J[:[N$6TTZUAFED
MEN0C><9' /;?^&&_^#HS_H6?^"H__A^?BG_\\^@#S;XH_P#!+;_@XM^.'A^S
M\)_&KX!_M_?%_P +:?K%OXAL/#7Q1^('BSX@>'['7[2RU#3;77+/1O%GCO5M
M.MM8MM.U;5;"WU.&V2]ALM3U"UCF6"\N(Y #^M#_ (-$/V#/VT/V'[+_ (*
M6_[6_P"S_P#$'X$6GQ*NOV6IOAS#X\M+"R;Q-<>$8OVB$\:2:7#:7]Y*1I$?
MB3P@EY),D,9_M&U6!I62<1 'Z&?\'6'_ "A _:H_[&S]G+_UHGX8T ?S5?\
M!D/_ ,G5_MN_]F^> /\ U8[4 ?Z/] !0 4 % !0 4 % !0 4 ?XF.C?\IA=*
M_P"TE5C_ .M0Q4 ?[9U !0 4 % '\/W_  >]?\FO?L-_]E[^)'_JO+*@#UK_
M (,GO^4=/[3O_9ZOB'_U1GP/H _LGH _*[_@N%_RB%_X**_]FI?%;_TP34 ?
MYZ?_  :'_P#*9/P/_P!D"^.__J/Z=0!_J^T % !0!_CB_P#!Q9^UCH/[8/\
MP5T_:G\<^"]:M=?^'GPYUCP_\ _ >J63K/8WFF_![0K3POXHO=/O$_=:AIFJ
M?$J/QSJ^DZA;[K6\TK4+*:UEN+=HKB4 _P!1C_@C_P#L\:S^RI_P3#_8A^!/
MB:W-CXK\(? #P9J7C#36A,$FD>,_'L,WQ%\8:+*C<F;1?$WBS5=*FF(0W$MF
MT_EQ^9L4 _2*@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MWO)=4\,Z!/%J,,%K<VUV ?J[_P &<W[;_P#PHO\ ;U\>?LA>*M7^R^!?VQO
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH _SMZ_TH/YG"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /Z)/^"!
MW_-UW_="_P#WL=?S7](;_FD/^Z__ .\0_3/#K_F<?]T__P!W3^B2OYK/TP*
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * /_T_[^* "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * /F_\ 9@_:]_9H_;/^'TOQ
M1_9>^,?@[XQ>"[/5KS0-7OO#%W<1:IX:U^PEDBNM \7^%]7M=,\4^#M<3ROM
M":1XHT72-0GL9+;4K:WET^[M;F8 ^D* (IIH;:&6XN)8X+>"-YIYYG6*&&&)
M2\DLLCE4CCC12[NY"HH+,0!0!_BJ?\%K_CC\,/VD/^"J_P"W!\9/@S?Z)K/P
MS\5_&K4+3PMXA\-2+/H'BNW\(Z'HG@F_\9:1=QJL5_8>,=7\.:AXHM]3@W6^
MJ)JPU"WEEAN4E< _U[?^">/@7Q%\+_V OV'/AIXOM[ZT\6?#S]C_ /9I\#^*
M+35(G@U*T\0^$_@QX+T'6K6_AD"R0WEMJ5A<P7,4@\R.9'23YP30!_D$_M6Z
MC%X _P""S_[2&L>)E;3K;P;_ ,%._B]JVNB<K$;.UT']JGQ!?:@TC,1&JQ06
MLK^86\O:-X;9@T ?[7 ((!4@@@$$<@@]""."".F* /Q8_P"#BCQ_K_PT_P""
M*_[??B/PS)>Q:E?_  L\-> YGT^>2WN!H?Q4^*OP_P#A?XH#21/&WV1O#/C#
M5TU"+=LGL#<P2*\<C(P!_!7_ ,&C/P@^#WQ9_P""NNCW?Q9TO0M;U#X2_ #X
ME_%WX/:7K\"7=N_Q?\/^)?AUH&BZGI]E,WV:XUSPQX5\4^,O%>BRSPW#:1J.
MA0:_8+;ZKI-A?6@!_J^4 ?QY_P#!Y!^V=X!^%_[!'A+]C"WUX3_%_P#:?^(?
MA'Q5<>%;-XWET_X/?"774\4:GXEUY5D\RQM-2^(.G>#](\-1SQ*NN7.G^));
M*1O^$8U%4 /QF_X,D?\ D]W]L#_LU;3?_5M^#: /ZK?^#G#]GO7?VA?^"-'[
M4]GX5L+O5?$OP?7P+\?M/T^SB\UY='^%WB_2]1^(%U*JAG$&C?#"[\;:Z[1@
MMG2U4XC9R #^%K_@U7_;O\'?L8?\%.-%\&_$V\M=(^'7[7G@U_V>+KQ)?7:V
M>G^%/B!J7B+1/$7PLU?49)&6'[#J_B?2#X D>7RXK&7QO!JUQ<066FW>\ _U
MG: .6\<>-_"'PT\&>*OB)\0/$FC^#O O@;P]K'BSQAXK\07T&F:%X;\->'["
M?5-:UO5]0N62"ST[3-/M;B[N[B5@D4,3,>F* /\ $U_X*K?MA6G[?'_!0W]J
MS]K'2([N'PM\5?B;/_P@,>H1R0:A_P *R\$:-I'PY^&4FHVDB1O8ZE<> /"/
MARYU*P*G[%?S7-KYDOE>:X!_L'_\$P_^4:O_  3S_P"S&_V3/_5"> * /\QG
M_@Z?_9LUSX ?\%B_CWXFGTNZL_!W[2.@?#WX]>!;Z52]OJ,6L^$].\'>.?+N
M1F-I[?XF>#/&+/:?)/:65UIK21>3<VL]P ?Z"O\ P;Z_MZ> _P!O'_@F/^SS
MK&AZBH^)G[/_ (#\&?LX?''PW=7<<^L:7X[^%?A'1O#EIXFN8P$D;2OB5X<L
MM*\<Z3=I$;1)M6U30%N)]1\.ZJL(!^VM '.^+O%_A+X?^&->\;>//%'AWP3X
M,\+:7=ZWXG\7>+=:TWPWX8\.:+I\33W^KZ[KVL7-EI6D:790(TUW?ZA=6]I;
M1*TDTJ(": -BQOK+4[*SU+3;NUU#3M0M;>^L+^QN(KNROK*[B2>UN[.Z@>2"
MYM;F"2.:WN(7>*:)TDC=D8$@%J@ H Y+QSX]\"_##PMJ?CCXD^,_"GP]\%:(
M; :SXO\ &_B+2/"GA?2#JFI6>C::-3U_7;NPTJP_M#5]0L-+LOM5W%]JU"]M
M+*#?<7$,;@'51R1RQI+$Z212(LD<D;!XY(W 9'1U)5D92"K*2"""#B@!] '\
M^G_!S'^VE\*?V4/^"5'[0G@3Q;KMA_PM#]J[P;K7P!^#G@;S%DUCQ/=>*?L%
MAX]\016BAY;?0O 7@G4-1UK5-:FC6PM]8G\,:"]Q%J?B72(YP#^.C_@S;^"/
MB?Q[_P %1O%_Q@L[.8>#_@)^SCX\OO$&K_O5M(_$/Q)U+0O!'A30&:,%&O=6
ML)O%VKVL,^V)K7PMJ,H;SX(58 _U(J "@ H * "@ H * /\ &S_X.+?^4U?[
M?G_94O"__JI_A[0!_KE?LE_\FJ_LS?\ 9OOP9_\ 5<^&Z /H*@ H _A9_P"#
MX3Q_K^F_!#_@G_\ "VUDO5\+^,_BG\=?'FM1QSR+ITFN?#;PG\.] \-F[MPX
MBFNX['XI^)_L$KQLT$37ZQL@G<. =1_P9*_"#X/0_LM?M;_'NWTO0KKX_:C\
M?X/A%K&M20)/XFT/X0:)\.O /C'PSIEI<2L[Z9H?BCQEXA\6W5_%9);+KE]X
M1TYM3:]/A[218 ']OU '^7K_ ,'BG[9W@']H7]OCX8?LZ_#K7AXCL_V-_AWK
M_A7X@7EJ\<ND:=\8?B7J^EZ]XP\-6%Q%))%=W?ASPWX=\":=XBD0JVG^)$U7
MP[=1QW^@WB  _IC_ .#.W_E$'+_V=3\:O_3+\.J /H;_ (.J?^4'?[6O_8Q_
MLW_^M*_":@#^9G_@R)_Y.U_;7_[-T\%?^K+MJ /](>@#G/&'_(H^*?\ L7-;
M_P#39<T ?XSO_!!7_E,9_P $\_\ LXOPQ_Z0ZK0!_M"T ?C-_P %^/V'/^&^
M?^"7'[1OPKT31_[7^*/P[T,?'[X*Q0P?:-0?XD?".TU#6UT72(@IW:IXZ\&3
M>,?AS9 E$6;Q@LCNBQ[@ ?PK_P#!JA_P4Q\(?L(_'_\ :R\!?&/7'T[X-?$[
M]F7Q_P#&<VYF7>WQ"_91\(^*OBHEGI44Q\F.^U_X4+\5+81V_P#I6KZOI7A?
M3A#=2+:)$ ?'_P#P2'^ ?C3_ (+'?\%M_"OBSXQ67_"2Z/XF^,OC;]L[]I@O
M')=Z0?"7ASQ8/'>H^&KF&3<4\->+/'.K>$/A7#:(8EL=(\3PQ6ODQ6D:H ?[
M - !0 4 % '^4!_P=.?\$SO$'[%O_!0'Q9^T5X,\*W5M^S?^V=K.J?%'PYKE
MC;E]$\-?&K42=0^,?@"^FB 33]1U+Q%+=?$G0;66*UM+K0?%LVFZ(;S_ (1+
M7!8@'](G_!KU_P %U_A_\>O@M\.O^"<_[4?CBQ\,_M)_"'1K/P1^S_XF\3W=
MOI^G?'3X4Z#96]GX3\&6NK7,L=O-\5_ &EPKX=BT.80W_C#PAIFBZOICZYKU
MEXM>$ _L[H * /PR_P""WW_!:CX+_P#!*']GS7X-/\0:!XL_;&^(?AK4;3X
M?!F.6'5+RSU*\C>QMOBC\1].@E$FB?#CPM<.VH(FH-:7/CS5+#_A%O#I8?V[
MK'AT _S7O^"/W[ WQ0_X*Y?\%'/!7@KQ3;Z]XN\!R>.C\<OVO?B)>R2CR?AW
M'XF77_'#:MK:[/+\5_%35[B3PAX?$ FOY-<\12ZT+-]*T36;FR /]F.QL;+2
M[&STS3;.UT_3M.M;>QT^PLH(K6RL;*TA2WM;.TM8%2&VM;:"..&W@A1(H8D2
M.-510  ?X]O_  <R?\IQ/V[_ /L8_@M_ZS3\&* /]9+]C[_DTG]ES_LW3X)?
M^JT\,T ?1= '^:K_ ,'MG_)\?[(?_9J-Y_ZM[QS0!_59_P &N7_*"C]AK_NY
MG_UL/]H*@#]\8=2TZXOKW3+>_LI]2TV.TFU'3X;J"2^L(=0$YL);VT1S/:QW
MHM;DVCSQQK<BWG,)<12;0":YMK:]MKBSO+>"[L[N"6VNK6YBCGMKFVGC:*>W
MN()5:*:":)FCEBD5HY(V9'4J2* /\_'_ (.UO^"/_P"R%^S[\#?!?_!0#]FS
MP'X8^!/CC6_C9H/PK^+/P\\$6EEX:^'7Q!C\<>'O&GB&R\:Z-X0LXXM+T#QU
MI6I^%/)U:#PQ::;IOB31]4U+7-5LSJ^CR7VH@'4?\&/7Q8\87>F_\% _@=>7
M.JWO@+0[KX"?%+P_;/=S/HWASQ5XDC^)OA7Q4\%D\C00:AXNTOPSX2\Z>WBC
M>>#P8BW+RB&V$0!\0_\ !Z5^S9KG@;]N_P" ?[3EII=TO@GX^? "T\$W6K[3
M):M\2O@QXFUB'6[-Y5RMHTG@7QG\/)+.WF"&Z:UU2:V:86]TML ?T+_\&C_[
M>G@/]HK_ ()Q:)^R5<:BMI\;?V+=0USPWKVBWMW&U[XE^%?C[QGXH\:?#WQO
MI$!",^EZ4VLZE\.=2MX/M#:3=>%-+N]0>WC\4:/'* ?U:4 075U;6-M<7M[<
M06=G9P2W5W=W4L=O;6MM;QM+/<7$\K)%!!!$C22RR,L<<:L[LJJ2 #!\'>,_
M!_Q$\+:%XX^'_BOPUXZ\%>*-.@U?PSXP\':[I?B;PMXBTFZ7=:ZIH6OZ+=7N
MDZMIUPHW07MA=W%M*!F.1A0!^ O_  =36-W>?\$//VM9;6"29-.\0_LY7UZ8
MQG[/:?\ #2?PGLS.XZ^6MQ>6T;$ [?,#'"*S  _F#_X,C_$&FVO[9_[8_A66
M9%U;6OV8M UZPMRZ!Y=/\-?%3P[8:I(B$[W$$_BK258J"J><N[&Y<@'^DW0
M4 % !0 4 % !0 4 % '^)CHW_*872O\ M)58_P#K4,5 '^V=0 4 % !0!_#]
M_P 'O7_)KW[#?_9>_B1_ZKRRH ]:_P"#)[_E'3^T[_V>KXA_]49\#Z /[)Z
M/RN_X+A?\HA?^"BO_9J7Q6_],$U '^>G_P &A_\ RF3\#_\ 9 OCO_ZC^G4
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MW.GZEXN\*IJ0!_K94 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M5U[Q3J5I<ZWJEW?7<\TEY?2_,%"JH!ZG_P .AO\ @E/_ -(V?V%/_$4O@?\
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * /\ .WK_ $H/YG"@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * /Z)/^"!W_ #==_P!T+_\ >QU_-?TA
MO^:0_P"Z_P#^\0_3/#K_ )G'_=/_ /=T_HDK^:S],"@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@#__U/[^* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M-]2L(C%H%]JGBJ"[\4^$+S5X+"QUW1_$UKH^F7VKZYH'B#R #A?@A_P=E?\
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M]'[0?_!.;XK^.?C)^S_X#\6?%K]A;Q'JVH^)O"WC#PII^I>)=9^ NGZA>R7
M^'WQ<M+7[;J^FZ9X:::/3?#WQ*O5D\.^(M+_ ++&K:KI_BN>[TA0"M^Q_P#\
M'6G_  5<_9*^'&B_"F^\0_"']IOPIX9TZWT?PQ>_M+>$/%GBGQOH6D6<?EV>
MGKX]\"^/OAWXE\1I;*%BCN_'5YXMU-+54LXK^.WAMD@ -_QU^W1_P75_X.1?
M%^F?LN>"M',WPHU/7-.D\7_#_P"!WA#6?AA^S9X7^RSV]_%XC^./Q!U?4_%F
ML7&A:(UO;ZQI^B>.?'7B!9=4M+)_!OA74?%DNF6UP ?EM_P5K_8=\._\$X?V
MV?&?['&@^+[GQ[??"7X<_ E_&_BZ>/[/!K?Q%\<_!?P-\0_&]WH]B8XY-.\-
M_P!O>*KJ/PQI]SYM]:>'DTR+4KJ\U$75W, ?Z^?_  30L[C3_P#@G#_P3^L+
MN,Q75C^Q)^RG9W,1ZQW%M\"? <,T9]TD1E_"@#X#_P""\?\ P1H\+_\ !77]
MFO2='\+ZGH/@7]J;X*3ZQX@^ GQ#UN&<:-?+JUO /$OPK\;W-E'->P>#/&S:
M=I4R:O;VE_?>$O$6E:7KEG9WM@VOZ+K@!_F7>%O%7_!4[_@A+^T]?W&GVWQ?
M_8]^-,$0TK6M+U[1;74/ 'Q3\-65YYHMKBUU&VUWX7_&'P4]RLC:?K&ER>(M
M-LKLRW>A:K8:K#]IA /V;L/^#T3_ (*HVGAJ+1KCX0?L1:IK<5LML?%U[\+O
MC)%J=P1'L:_N=-T[]H"P\/?VDS_O<VNE6FEJPVC2=GRT ?!WB_\ :'_X+J_\
M'"7C>P^%MI/\9_C_ .#?[=LDD^'WPU\-6_PS_9?\"7D4@NK'5?B'>Z1;^'_A
MM8S:3YC3Z;XE^*_B#5?$=OYWV/2-2EFN;>SE /\ 7 ^%/AO4?!OPN^&WA#6/
M(_M?PKX!\'>&]4^RRF>U_M'0_#NG:9>_9IBD9F@^TVLODRF-#)'M;8N=H .^
MH * /R<_X+F_ OXM?M*_\$G_ -L[X)? KP/JWQ)^*WCCX?\ AJ'PAX'T%K)=
M9\0W&A?$WP-XGU*TTM-0N[*WN;V+1-$U*[M[%9_M=_);BQT^&ZO[BVM9@#_-
M"_9F_P""V?\ P63_ ."46H-^SY'\2?B!HFA_#][;2I_V:OVM/A_J7B6T\$P6
M*^7:>']-T;Q[;:3\3/AUHL$.Y8/#OA'Q+X6T;;(9DL#+Y<R 'WQXO_X/,?\
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M>W_@_P"'4FGZI.(@OQ,O?#2W&K:EX,21(Y+B?XR>.M4\'Z2MI_:5Q+9&WGO
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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MZ7:S:K>*WB#7=>O+T _4V@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H _P [>O\
M2@_F<* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * /__5_OXH * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MVFV=KI^GV4$5K96-C;Q6EG:6T"".&WM;6!(X+>"&-52*&)$CC0!44  4 6J
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M=1Q.S/$DX=8V8LH!)H ]9H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@!, C!&0>".V/3% 'RCKO[!O[#?BCQ!_PEGB;]C+]E'Q%X
MI,TMP?$NN_L[?"'5_$'VB=_,FG_MF_\ !]QJ/G32$O++]IWR/\S$GF@#Z0\,
M>%?"_@G0M/\ "_@SPWH'A'PSI,/V?2O#OAC1].T#0M,@W%_(T_2-*M[33[*'
M>S-Y=M;QIN8MMR30!OT % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!_G;U_I0?
MS.% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?T2?\$#O^;KO^Z%_^
M]CK^:_I#?\TA_P!U_P#]XA^F>'7_ #./^Z?_ .[I_1)7\UGZ8% !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % '__UO[^* "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M'^=O7^E!_,X4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!_1)_P0._
MYNN_[H7_ .]CK^:_I#?\TA_W7_\ WB'Z9X=?\SC_ +I__NZ?T25_-9^F!0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0!__7_OXH * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MXYCMVCDD3[,OB 6X21U$0#MD ^YJ "@ H * "@ H * "@ H * "@ H * "@
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M!_G;U_I0?S.% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?T2?\$#O
M^;KO^Z%_^]CK^:_I#?\ -(?]U_\ ]XA^F>'7_,X_[I__ +NG]$E?S6?I@4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 ?_0_OXH * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@#_.WK_2@_F<* "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H _HD_X('?\W7?]T+_]['7\U_2&_P":0_[K_P#[Q#],
M\.O^9Q_W3_\ W=/Z)*_FL_3 H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H _]'^_B@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MZE</_P#0+5_\*L1_\L#_ (="_L*?]$S\1?\ AR?'G_R^H_XC-Q__ -#7#?\
MAKR[_P"9P_U*X?\ ^@6K_P"%6(_^6!_PZ%_84_Z)GXB_\.3X\_\ E]1_Q&;C
M_P#Z&N&_\->7?_,X?ZE</_\ 0+5_\*L1_P#+ _X="_L*?]$S\1?^')\>?_+Z
MC_B,W'__ $-<-_X:\N_^9P_U*X?_ .@6K_X58C_Y8'_#H7]A3_HF?B+_ ,.3
MX\_^7U'_ !&;C_\ Z&N&_P##7EW_ ,SA_J5P_P#] M7_ ,*L1_\ + _X="_L
M*?\ 1,_$7_AR?'G_ ,OJ/^(S<?\ _0UPW_AKR[_YG#_4KA__ *!:O_A5B/\
MY8'_  Z%_84_Z)GXB_\ #D^//_E]1_Q&;C__ *&N&_\ #7EW_P SA_J5P_\
M] M7_P *L1_\L#_AT+^PI_T3/Q%_X<GQY_\ +ZC_ (C-Q_\ ]#7#?^&O+O\
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M/^(S<?\ _0UPW_AKR[_YG#_4KA__ *!:O_A5B/\ Y8'_  Z%_84_Z)GXB_\
M#D^//_E]1_Q&;C__ *&N&_\ #7EW_P SA_J5P_\ ] M7_P *L1_\L#_AT+^P
MI_T3/Q%_X<GQY_\ +ZC_ (C-Q_\ ]#7#?^&O+O\ YG#_ %*X?_Z!:O\ X58C
M_P"6!_PZ%_84_P"B9^(O_#D^//\ Y?4?\1FX_P#^AKAO_#7EW_S.'^I7#_\
MT"U?_"K$?_+ _P"'0O["G_1,_$7_ (<GQY_\OJ/^(S<?_P#0UPW_ (:\N_\
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MA?V%/^B9^(O_  Y/CS_Y?4?\1FX__P"AKAO_  UY=_\ ,X?ZE</_ /0+5_\
M"K$?_+ _X="_L*?]$S\1?^')\>?_ "^H_P"(S<?_ /0UPW_AKR[_ .9P_P!2
MN'_^@6K_ .%6(_\ E@?\.A?V%/\ HF?B+_PY/CS_ .7U'_$9N/\ _H:X;_PU
MY=_\SA_J5P__ - M7_PJQ'_RP/\ AT+^PI_T3/Q%_P"')\>?_+ZC_B,W'_\
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MZE</_P#0+5_\*L1_\L#_ (="_L*?]$S\1?\ AR?'G_R^H_XC-Q__ -#7#?\
MAKR[_P"9P_U*X?\ ^@6K_P"%6(_^6!_PZ%_84_Z)GXB_\.3X\_\ E]1_Q&;C
M_P#Z&N&_\->7?_,X?ZE</_\ 0+5_\*L1_P#+ _X="_L*?]$S\1?^')\>?_+Z
MC_B,W'__ $-<-_X:\N_^9P_U*X?_ .@6K_X58C_Y8'_#H7]A3_HF?B+_ ,.3
MX\_^7U'_ !&;C_\ Z&N&_P##7EW_ ,SA_J5P_P#] M7_ ,*L1_\ + _X="_L
M*?\ 1,_$7_AR?'G_ ,OJ/^(S<?\ _0UPW_AKR[_YG#_4KA__ *!:O_A5B/\
MY8'_  Z%_84_Z)GXB_\ #D^//_E]1_Q&;C__ *&N&_\ #7EW_P SA_J5P_\
M] M7_P *L1_\L#_AT+^PI_T3/Q%_X<GQY_\ +ZC_ (C-Q_\ ]#7#?^&O+O\
MYG#_ %*X?_Z!:O\ X58C_P"6!_PZ%_84_P"B9^(O_#D^//\ Y?4?\1FX_P#^
MAKAO_#7EW_S.'^I7#_\ T"U?_"K$?_+ _P"'0O["G_1,_$7_ (<GQY_\OJ/^
M(S<?_P#0UPW_ (:\N_\ F</]2N'_ /H%J_\ A5B/_E@?\.A?V%/^B9^(O_#D
M^//_ )?4?\1FX_\ ^AKAO_#7EW_S.'^I7#__ $"U?_"K$?\ RP/^'0O["G_1
M,_$7_AR?'G_R^H_XC-Q__P!#7#?^&O+O_F</]2N'_P#H%J_^%6(_^6!_PZ%_
M84_Z)GXB_P##D^//_E]1_P 1FX__ .AKAO\ PUY=_P#,X?ZE</\ _0+5_P#"
MK$?_ "P/^'0O["G_ $3/Q%_X<GQY_P#+ZC_B,W'_ /T-<-_X:\N_^9P_U*X?
M_P"@6K_X58C_ .6!_P .A?V%/^B9^(O_  Y/CS_Y?4?\1FX__P"AKAO_  UY
M=_\ ,X?ZE</_ /0+5_\ "K$?_+ _X="_L*?]$S\1?^')\>?_ "^H_P"(S<?_
M /0UPW_AKR[_ .9P_P!2N'_^@6K_ .%6(_\ E@?\.A?V%/\ HF?B+_PY/CS_
M .7U'_$9N/\ _H:X;_PUY=_\SA_J5P__ - M7_PJQ'_RP/\ AT+^PI_T3/Q%
M_P"')\>?_+ZC_B,W'_\ T-<-_P"&O+O_ )G#_4KA_P#Z!:O_ (58C_Y8'_#H
M7]A3_HF?B+_PY/CS_P"7U'_$9N/_ /H:X;_PUY=_\SA_J5P__P! M7_PJQ'_
M ,L#_AT+^PI_T3/Q%_X<GQY_\OJ/^(S<?_\ 0UPW_AKR[_YG#_4KA_\ Z!:O
M_A5B/_E@?\.A?V%/^B9^(O\ PY/CS_Y?4?\ $9N/_P#H:X;_ ,->7?\ S.'^
MI7#_ /T"U?\ PJQ'_P L#_AT+^PI_P!$S\1?^')\>?\ R^H_XC-Q_P#]#7#?
M^&O+O_F</]2N'_\ H%J_^%6(_P#E@?\ #H7]A3_HF?B+_P .3X\_^7U'_$9N
M/_\ H:X;_P ->7?_ #.'^I7#_P#T"U?_  JQ'_RP/^'0O["G_1,_$7_AR?'G
M_P OJ/\ B,W'_P#T-<-_X:\N_P#F</\ 4KA__H%J_P#A5B/_ )8'_#H7]A3_
M *)GXB_\.3X\_P#E]1_Q&;C_ /Z&N&_\->7?_,X?ZE</_P#0+5_\*L1_\L#_
M (="_L*?]$S\1?\ AR?'G_R^H_XC-Q__ -#7#?\ AKR[_P"9P_U*X?\ ^@6K
M_P"%6(_^6!_PZ%_84_Z)GXB_\.3X\_\ E]1_Q&;C_P#Z&N&_\->7?_,X?ZE<
M/_\ 0+5_\*L1_P#+ _X="_L*?]$S\1?^')\>?_+ZC_B,W'__ $-<-_X:\N_^
M9P_U*X?_ .@6K_X58C_Y8'_#H7]A3_HF?B+_ ,.3X\_^7U'_ !&;C_\ Z&N&
M_P##7EW_ ,SA_J5P_P#] M7_ ,*L1_\ + _X="_L*?\ 1,_$7_AR?'G_ ,OJ
M/^(S<?\ _0UPW_AKR[_YG#_4KA__ *!:O_A5B/\ Y8'_  Z%_84_Z)GXB_\
M#D^//_E]1_Q&;C__ *&N&_\ #7EW_P SA_J5P_\ ] M7_P *L1_\L#_AT+^P
MI_T3/Q%_X<GQY_\ +ZC_ (C-Q_\ ]#7#?^&O+O\ YG#_ %*X?_Z!:O\ X58C
M_P"6!_PZ%_84_P"B9^(O_#D^//\ Y?4?\1FX_P#^AKAO_#7EW_S.'^I7#_\
MT"U?_"K$?_+ _P"'0O["G_1,_$7_ (<GQY_\OJ/^(S<?_P#0UPW_ (:\N_\
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MA?V%/^B9^(O_  Y/CS_Y?4?\1FX__P"AKAO_  UY=_\ ,X?ZE</_ /0+5_\
M"K$?_+ _X="_L*?]$S\1?^')\>?_ "^H_P"(S<?_ /0UPW_AKR[_ .9P_P!2
MN'_^@6K_ .%6(_\ E@?\.A?V%/\ HF?B+_PY/CS_ .7U'_$9N/\ _H:X;_PU
MY=_\SA_J5P__ - M7_PJQ'_RP/\ AT+^PI_T3/Q%_P"')\>?_+ZC_B,W'_\
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MZE</_P#0+5_\*L1_\L#_ (="_L*?]$S\1?\ AR?'G_R^H_XC-Q__ -#7#?\
MAKR[_P"9P_U*X?\ ^@6K_P"%6(_^6!_PZ%_84_Z)GXB_\.3X\_\ E]1_Q&;C
M_P#Z&N&_\->7?_,X?ZE</_\ 0+5_\*L1_P#+ _X="_L*?]$S\1?^')\>?_+Z
MC_B,W'__ $-<-_X:\N_^9P_U*X?_ .@6K_X58C_Y8'_#H7]A3_HF?B+_ ,.3
MX\_^7U'_ !&;C_\ Z&N&_P##7EW_ ,SA_J5P_P#] M7_ ,*L1_\ + _X="_L
M*?\ 1,_$7_AR?'G_ ,OJ/^(S<?\ _0UPW_AKR[_YG#_4KA__ *!:O_A5B/\
MY8'_  Z%_84_Z)GXB_\ #D^//_E]1_Q&;C__ *&N&_\ #7EW_P SA_J5P_\
M] M7_P *L1_\L#_AT+^PI_T3/Q%_X<GQY_\ +ZC_ (C-Q_\ ]#7#?^&O+O\
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M/^(S<?\ _0UPW_AKR[_YG#_4KA__ *!:O_A5B/\ Y8'_  Z%_84_Z)GXB_\
M#D^//_E]1_Q&;C__ *&N&_\ #7EW_P SA_J5P_\ ] M7_P *L1_\L#_AT+^P
MI_T3/Q%_X<GQY_\ +ZC_ (C-Q_\ ]#7#?^&O+O\ YG#_ %*X?_Z!:O\ X58C
M_P"6!_PZ%_84_P"B9^(O_#D^//\ Y?4?\1FX_P#^AKAO_#7EW_S.'^I7#_\
MT"U?_"K$?_+ _P"'0O["G_1,_$7_ (<GQY_\OJ/^(S<?_P#0UPW_ (:\N_\
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MA?V%/^B9^(O_  Y/CS_Y?4?\1FX__P"AKAO_  UY=_\ ,X?ZE</_ /0+5_\
M"K$?_+ _X="_L*?]$S\1?^')\>?_ "^H_P"(S<?_ /0UPW_AKR[_ .9P_P!2
MN'_^@6K_ .%6(_\ E@?\.A?V%/\ HF?B+_PY/CS_ .7U'_$9N/\ _H:X;_PU
MY=_\SA_J5P__ - M7_PJQ'_RP/\ AT+^PI_T3/Q%_P"')\>?_+ZC_B,W'_\
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MZE</_P#0+5_\*L1_\L#_ (="_L*?]$S\1?\ AR?'G_R^H_XC-Q__ -#7#?\
MAKR[_P"9P_U*X?\ ^@6K_P"%6(_^6!_PZ%_84_Z)GXB_\.3X\_\ E]1_Q&;C
M_P#Z&N&_\->7?_,X?ZE</_\ 0+5_\*L1_P#+ _X="_L*?]$S\1?^')\>?_+Z
MC_B,W'__ $-<-_X:\N_^9P_U*X?_ .@6K_X58C_Y8'_#H7]A3_HF?B+_ ,.3
MX\_^7U'_ !&;C_\ Z&N&_P##7EW_ ,SA_J5P_P#] M7_ ,*L1_\ + _X="_L
M*?\ 1,_$7_AR?'G_ ,OJ/^(S<?\ _0UPW_AKR[_YG#_4KA__ *!:O_A5B/\
MY8'_  Z%_84_Z)GXB_\ #D^//_E]1_Q&;C__ *&N&_\ #7EW_P SA_J5P_\
M] M7_P *L1_\L/IK]G/]D+X%?LJ?\)C_ ,*5\,ZCX<_X3S_A'O\ A)?M_B37
MO$/VS_A%_P"W/[&\K^V[^]^Q_9_^$BU7?]E\K[1YZ>=O\B+9\KQ+QGG_ !=]
M2_MW%4\3_9_UGZK[/"X?#<GUOV'MK^PIT^?F^K4;<U^7E?+;F=_6RS)<OR?V
M_P!0I2I?6/9>UYJM2I?V/M.2W/)\MO:3VM>^NR/IJOECU0H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H __TO[^* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * /_3_OXH * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H _]3^_B@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@#_U?[^* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M<6__ -%#0 ?\/)?^#J[_ *0L_ #_ ,+BW_\ HH: #_AY+_P=7?\ 2%GX ?\
MA<6__P!%#0 ?\/)?^#J[_I"S\ /_  N+?_Z*&@ _X>2_\'5W_2%GX ?^%Q;_
M /T4- !_P\E_X.KO^D+/P _\+BW_ /HH: #_ (>2_P#!U=_TA9^ '_A<6_\
M]%#0 ?\ #R7_ (.KO^D+/P _\+BW_P#HH: #_AY+_P '5W_2%GX ?^%Q;_\
MT4- !_P\E_X.KO\ I"S\ /\ PN+?_P"BAH /^'DO_!U=_P!(6?@!_P"%Q;__
M $4- !_P\E_X.KO^D+/P _\ "XM__HH: #_AY+_P=7?](6?@!_X7%O\ _10T
M '_#R7_@ZN_Z0L_ #_PN+?\ ^BAH /\ AY+_ ,'5W_2%GX ?^%Q;_P#T4- !
M_P /)?\ @ZN_Z0L_ #_PN+?_ .BAH /^'DO_  =7?](6?@!_X7%O_P#10T '
M_#R7_@ZN_P"D+/P _P#"XM__ **&@ _X>2_\'5W_ $A9^ '_ (7%O_\ 10T
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MO^D+/P _\+BW_P#HH: #_AY+_P '5W_2%GX ?^%Q;_\ T4- !_P\E_X.KO\
MI"S\ /\ PN+?_P"BAH /^'DO_!U=_P!(6?@!_P"%Q;__ $4- !_P\E_X.KO^
MD+/P _\ "XM__HH: #_AY+_P=7?](6?@!_X7%O\ _10T '_#R7_@ZN_Z0L_
M#_PN+?\ ^BAH /\ AY+_ ,'5W_2%GX ?^%Q;_P#T4- !_P /)?\ @ZN_Z0L_
M #_PN+?_ .BAH /^'DO_  =7?](6?@!_X7%O_P#10T '_#R7_@ZN_P"D+/P
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M #_AY+_P=7?](6?@!_X7%O\ _10T '_#R7_@ZN_Z0L_ #_PN+?\ ^BAH /\
MAY+_ ,'5W_2%GX ?^%Q;_P#T4- !_P /)?\ @ZN_Z0L_ #_PN+?_ .BAH /^
M'DO_  =7?](6?@!_X7%O_P#10T '_#R7_@ZN_P"D+/P _P#"XM__ **&@ _X
M>2_\'5W_ $A9^ '_ (7%O_\ 10T '_#R7_@ZN_Z0L_ #_P +BW_^BAH /^'D
MO_!U=_TA9^ '_A<6_P#]%#0 ?\/)?^#J[_I"S\ /_"XM_P#Z*&@ _P"'DO\
MP=7?](6?@!_X7%O_ /10T '_  \E_P"#J[_I"S\ /_"XM_\ Z*&@ _X>2_\
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M ?\ #R7_ (.KO^D+/P _\+BW_P#HH: #_AY+_P '5W_2%GX ?^%Q;_\ T4-
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M*&@ _P"'DO\ P=7?](6?@!_X7%O_ /10T '_  \E_P"#J[_I"S\ /_"XM_\
MZ*&@ _X>2_\ !U=_TA9^ '_A<6__ -%#0 ?\/)?^#J[_ *0L_ #_ ,+BW_\
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MTA9^ '_A<6__ -%#0 ?\/)?^#J[_ *0L_ #_ ,+BW_\ HH: #_AY+_P=7?\
M2%GX ?\ A<6__P!%#0 ?\/)?^#J[_I"S\ /_  N+?_Z*&@ _X>2_\'5W_2%G
MX ?^%Q;_ /T4- !_P\E_X.KO^D+/P _\+BW_ /HH: #_ (>2_P#!U=_TA9^
M'_A<6_\ ]%#0 ?\ #R7_ (.KO^D+/P _\+BW_P#HH: #_AY+_P '5W_2%GX
M?^%Q;_\ T4- !_P\E_X.KO\ I"S\ /\ PN+?_P"BAH /^'DO_!U=_P!(6?@!
M_P"%Q;__ $4- !_P\E_X.KO^D+/P _\ "XM__HH: #_AY+_P=7?](6?@!_X7
M%O\ _10T '_#R7_@ZN_Z0L_ #_PN+?\ ^BAH /\ AY+_ ,'5W_2%GX ?^%Q;
M_P#T4- !_P /)?\ @ZN_Z0L_ #_PN+?_ .BAH /^'DO_  =7?](6?@!_X7%O
M_P#10T '_#R7_@ZN_P"D+/P _P#"XM__ **&@ _X>2_\'5W_ $A9^ '_ (7%
MO_\ 10T '_#R7_@ZN_Z0L_ #_P +BW_^BAH /^'DO_!U=_TA9^ '_A<6_P#]
M%#0 ?\/)?^#J[_I"S\ /_"XM_P#Z*&@ _P"'DO\ P=7?](6?@!_X7%O_ /10
MT '_  \E_P"#J[_I"S\ /_"XM_\ Z*&@ _X>2_\ !U=_TA9^ '_A<6__ -%#
M0 ?\/)?^#J[_ *0L_ #_ ,+BW_\ HH: #_AY+_P=7?\ 2%GX ?\ A<6__P!%
M#0 ?\/)?^#J[_I"S\ /_  N+?_Z*&@ _X>2_\'5W_2%GX ?^%Q;_ /T4- !_
MP\E_X.KO^D+/P _\+BW_ /HH: #_ (>2_P#!U=_TA9^ '_A<6_\ ]%#0 ?\
M#R7_ (.KO^D+/P _\+BW_P#HH: #_AY+_P '5W_2%GX ?^%Q;_\ T4- !_P\
ME_X.KO\ I"S\ /\ PN+?_P"BAH /^'DO_!U=_P!(6?@!_P"%Q;__ $4- !_P
M\E_X.KO^D+/P _\ "XM__HH: #_AY+_P=7?](6?@!_X7%O\ _10T '_#R7_@
MZN_Z0L_ #_PN+?\ ^BAH /\ AY+_ ,'5W_2%GX ?^%Q;_P#T4- !_P /)?\
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M\+BW_P#HH: #_AY+_P '5W_2%GX ?^%Q;_\ T4- !_P\E_X.KO\ I"S\ /\
MPN+?_P"BAH /^'DO_!U=_P!(6?@!_P"%Q;__ $4- !_P\E_X.KO^D+/P _\
M"XM__HH: #_AY+_P=7?](6?@!_X7%O\ _10T '_#R7_@ZN_Z0L_ #_PN+?\
M^BAH /\ AY+_ ,'5W_2%GX ?^%Q;_P#T4- !_P /)?\ @ZN_Z0L_ #_PN+?_
M .BAH /^'DO_  =7?](6?@!_X7%O_P#10T '_#R7_@ZN_P"D+/P _P#"XM__
M **&@ _X>2_\'5W_ $A9^ '_ (7%O_\ 10T '_#R7_@ZN_Z0L_ #_P +BW_^
MBAH /^'DO_!U=_TA9^ '_A<6_P#]%#0 ?\/)?^#J[_I"S\ /_"XM_P#Z*&@
M_P"'DO\ P=7?](6?@!_X7%O_ /10T '_  \E_P"#J[_I"S\ /_"XM_\ Z*&@
M _X>2_\ !U=_TA9^ '_A<6__ -%#0 ?\/)?^#J[_ *0L_ #_ ,+BW_\ HH:
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MQ;__ $4- !_P\E_X.KO^D+/P _\ "XM__HH: #_AY+_P=7?](6?@!_X7%O\
M_10T '_#R7_@ZN_Z0L_ #_PN+?\ ^BAH /\ AY+_ ,'5W_2%GX ?^%Q;_P#T
M4- !_P /)?\ @ZN_Z0L_ #_PN+?_ .BAH /^'DO_  =7?](6?@!_X7%O_P#1
M0T '_#R7_@ZN_P"D+/P _P#"XM__ **&@ _X>2_\'5W_ $A9^ '_ (7%O_\
M10T '_#R7_@ZN_Z0L_ #_P +BW_^BAH /^'DO_!U=_TA9^ '_A<6_P#]%#0
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M_"XM_P#Z*&@ _P"'DO\ P=7?](6?@!_X7%O_ /10T '_  \E_P"#J[_I"S\
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M@ _X>2_\'5W_ $A9^ '_ (7%O_\ 10T '_#R7_@ZN_Z0L_ #_P +BW_^BAH
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M<6__ -%#0 ?\/)?^#J[_ *0L_ #_ ,+BW_\ HH: #_AY+_P=7?\ 2%GX ?\
MA<6__P!%#0 ?\/)?^#J[_I"S\ /_  N+?_Z*&@ _X>2_\'5W_2%GX ?^%Q;_
M /T4- !_P\E_X.KO^D+/P _\+BW_ /HH: #_ (>2_P#!U=_TA9^ '_A<6_\
M]%#0 ?\ #R7_ (.KO^D+/P _\+BW_P#HH: #_AY+_P '5W_2%GX ?^%Q;_\
MT4- !_P\E_X.KO\ I"S\ /\ PN+?_P"BAH /^'DO_!U=_P!(6?@!_P"%Q;__
M $4- !_P\E_X.KO^D+/P _\ "XM__HH: #_AY+_P=7?](6?@!_X7%O\ _10T
M '_#R7_@ZN_Z0L_ #_PN+?\ ^BAH /\ AY+_ ,'5W_2%GX ?^%Q;_P#T4- !
M_P /)?\ @ZN_Z0L_ #_PN+?_ .BAH /^'DO_  =7?](6?@!_X7%O_P#10T '
M_#R7_@ZN_P"D+/P _P#"XM__ **&@ _X>2_\'5W_ $A9^ '_ (7%O_\ 10T
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MO^D+/P _\+BW_P#HH: #_AY+_P '5W_2%GX ?^%Q;_\ T4- !_P\E_X.KO\
MI"S\ /\ PN+?_P"BAH /^'DO_!U=_P!(6?@!_P"%Q;__ $4- !_P\E_X.KO^
MD+/P _\ "XM__HH: #_AY+_P=7?](6?@!_X7%O\ _10T '_#R7_@ZN_Z0L_
M#_PN+?\ ^BAH /\ AY+_ ,'5W_2%GX ?^%Q;_P#T4- !_P /)?\ @ZN_Z0L_
M #_PN+?_ .BAH /^'DO_  =7?](6?@!_X7%O_P#10T '_#R7_@ZN_P"D+/P
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M #_AY+_P=7?](6?@!_X7%O\ _10T '_#R7_@ZN_Z0L_ #_PN+?\ ^BAH /\
MAY+_ ,'5W_2%GX ?^%Q;_P#T4- !_P /)?\ @ZN_Z0L_ #_PN+?_ .BAH /^
M'DO_  =7?](6?@!_X7%O_P#10T '_#R7_@ZN_P"D+/P _P#"XM__ **&@ _X
M>2_\'5W_ $A9^ '_ (7%O_\ 10T '_#R7_@ZN_Z0L_ #_P +BW_^BAH /^'D
MO_!U=_TA9^ '_A<6_P#]%#0 ?\/)?^#J[_I"S\ /_"XM_P#Z*&@ _P"'DO\
MP=7?](6?@!_X7%O_ /10T '_  \E_P"#J[_I"S\ /_"XM_\ Z*&@ _X>2_\
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M ?\ #R7_ (.KO^D+/P _\+BW_P#HH: #_AY+_P '5W_2%GX ?^%Q;_\ T4-
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M*&@ _P"'DO\ P=7?](6?@!_X7%O_ /10T '_  \E_P"#J[_I"S\ /_"XM_\
MZ*&@ _X>2_\ !U=_TA9^ '_A<6__ -%#0 ?\/)?^#J[_ *0L_ #_ ,+BW_\
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MTA9^ '_A<6__ -%#0 ?\/)?^#J[_ *0L_ #_ ,+BW_\ HH: #_AY+_P=7?\
M2%GX ?\ A<6__P!%#0 ?\/)?^#J[_I"S\ /_  N+?_Z*&@ _X>2_\'5W_2%G
MX ?^%Q;_ /T4- !_P\E_X.KO^D+/P _\+BW_ /HH: #_ (>2_P#!U=_TA9^
M'_A<6_\ ]%#0 ?\ #R7_ (.KO^D+/P _\+BW_P#HH: #_AY+_P '5W_2%GX
M?^%Q;_\ T4- !_P\E_X.KO\ I"S\ /\ PN+?_P"BAH /^'DO_!U=_P!(6?@!
M_P"%Q;__ $4- !_P\E_X.KO^D+/P _\ "XM__HH: #_AY+_P=7?](6?@!_X7
M%O\ _10T '_#R7_@ZN_Z0L_ #_PN+?\ ^BAH /\ AY+_ ,'5W_2%GX ?^%Q;
M_P#T4- !_P /)?\ @ZN_Z0L_ #_PN+?_ .BAH /^'DO_  =7?](6?@!_X7%O
M_P#10T '_#R7_@ZN_P"D+/P _P#"XM__ **&@ _X>2_\'5W_ $A9^ '_ (7%
MO_\ 10T '_#R7_@ZN_Z0L_ #_P +BW_^BAH /^'DO_!U=_TA9^ '_A<6_P#]
M%#0 ?\/)?^#J[_I"S\ /_"XM_P#Z*&@ _P"'DO\ P=7?](6?@!_X7%O_ /10
MT '_  \E_P"#J[_I"S\ /_"XM_\ Z*&@ _X>2_\ !U=_TA9^ '_A<6__ -%#
M0 ?\/)?^#J[_ *0L_ #_ ,+BW_\ HH: #_AY+_P=7?\ 2%GX ?\ A<6__P!%
M#0 ?\/)?^#J[_I"S\ /_  N+?_Z*&@ _X>2_\'5W_2%GX ?^%Q;_ /T4- !_
MP\E_X.KO^D+/P _\+BW_ /HH: #_ (>2_P#!U=_TA9^ '_A<6_\ ]%#0 ?\
M#R7_ (.KO^D+/P _\+BW_P#HH: #_AY+_P '5W_2%GX ?^%Q;_\ T4- !_P\
ME_X.KO\ I"S\ /\ PN+?_P"BAH /^'DO_!U=_P!(6?@!_P"%Q;__ $4- !_P
M\E_X.KO^D+/P _\ "XM__HH: #_AY+_P=7?](6?@!_X7%O\ _10T '_#R7_@
MZN_Z0L_ #_PN+?\ ^BAH /\ AY+_ ,'5W_2%GX ?^%Q;_P#T4- !_P /)?\
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M\+BW_P#HH: #_AY+_P '5W_2%GX ?^%Q;_\ T4- !_P\E_X.KO\ I"S\ /\
MPN+?_P"BAH /^'DO_!U=_P!(6?@!_P"%Q;__ $4- !_P\E_X.KO^D+/P _\
M"XM__HH: #_AY+_P=7?](6?@!_X7%O\ _10T '_#R7_@ZN_Z0L_ #_PN+?\
M^BAH /\ AY+_ ,'5W_2%GX ?^%Q;_P#T4- !_P /)?\ @ZN_Z0L_ #_PN+?_
M .BAH /^'DO_  =7?](6?@!_X7%O_P#10T '_#R7_@ZN_P"D+/P _P#"XM__
M **&@ _X>2_\'5W_ $A9^ '_ (7%O_\ 10T '_#R7_@ZN_Z0L_ #_P +BW_^
MBAH /^'DO_!U=_TA9^ '_A<6_P#]%#0 ?\/)?^#J[_I"S\ /_"XM_P#Z*&@
M_P"'DO\ P=7?](6?@!_X7%O_ /10T '_  \E_P"#J[_I"S\ /_"XM_\ Z*&@
M _X>2_\ !U=_TA9^ '_A<6__ -%#0 ?\/)?^#J[_ *0L_ #_ ,+BW_\ HH:
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MQ;__ $4- !_P\E_X.KO^D+/P _\ "XM__HH: #_AY+_P=7?](6?@!_X7%O\
M_10T '_#R7_@ZN_Z0L_ #_PN+?\ ^BAH /\ AY+_ ,'5W_2%GX ?^%Q;_P#T
M4- !_P /)?\ @ZN_Z0L_ #_PN+?_ .BAH /^'DO_  =7?](6?@!_X7%O_P#1
M0T '_#R7_@ZN_P"D+/P _P#"XM__ **&@ _X>2_\'5W_ $A9^ '_ (7%O_\
M10T '_#R7_@ZN_Z0L_ #_P +BW_^BAH /^'DO_!U=_TA9^ '_A<6_P#]%#0
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M_"XM_P#Z*&@ _P"'DO\ P=7?](6?@!_X7%O_ /10T '_  \E_P"#J[_I"S\
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@#_T/[^* "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /_1_OXH * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H _]+^_B@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@#_T_[^* "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /_4_OXH * "@ H
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MJN8J5K>U_M&M[3UM;V5_^X=O(\[_ %WS[FO[7#6_D^K0Y?3^;_R8^]OV9?\
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M/V2?@+%\5? ^@^&O$6N2^.?#OA46'BN/5)=)2TU>TUBZN+DQZ1J.E7;7$?\
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M32=-_9J1T>S49)Q7US7QQ[(4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M8:2Z:?EOB!CN:M@LN@]*4)8JLNG/4O3HKUA"-5V[5%Y'R7_P2*^!_P#PMO\
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MJZF89[FD(U<1)<UJN-Q'[ZO**M[E)3E5E%64:<&E9)'[Q6GA\IRVI4C!1P^
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M<)PJ0A4IM2A.,9PDMI0DDXM>3331HUF4% !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M0+XV_P"?F2?^%]?_ .8@_P!>\C_EQW_A/3_^7A_P^O\ V.?^@;\9O_")T/\
M^;*C_B!?&W_/S)/_  OK_P#S$'^O>1_RX[_PGI__ "\/^'U_['/_ $#?C-_X
M1.A__-E1_P 0+XV_Y^9)_P"%]?\ ^8@_U[R/^7'?^$]/_P"7A_P^O_8Y_P"@
M;\9O_")T/_YLJ/\ B!?&W_/S)/\ POK_ /S$'^O>1_RX[_PGI_\ R\/^'U_[
M'/\ T#?C-_X1.A__ #94?\0+XV_Y^9)_X7U__F(/]>\C_EQW_A/3_P#EX?\
M#Z_]CG_H&_&;_P (G0__ )LJ/^(%\;?\_,D_\+Z__P Q!_KWD?\ +CO_  GI
M_P#R\/\ A]?^QS_T#?C-_P"$3H?_ ,V5'_$"^-O^?F2?^%]?_P"8@_U[R/\
MEQW_ (3T_P#Y>'_#Z_\ 8Y_Z!OQF_P#")T/_ .;*C_B!?&W_ #\R3_POK_\
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M0+XV_P"?F2?^%]?_ .8@_P!>\C_EQW_A/3_^7A_P^O\ V.?^@;\9O_")T/\
M^;*C_B!?&W_/S)/_  OK_P#S$'^O>1_RX[_PGI__ "\/^'U_['/_ $#?C-_X
M1.A__-E1_P 0+XV_Y^9)_P"%]?\ ^8@_U[R/^7'?^$]/_P"7A_P^O_8Y_P"@
M;\9O_")T/_YLJ/\ B!?&W_/S)/\ POK_ /S$'^O>1_RX[_PGI_\ R\/^'U_[
M'/\ T#?C-_X1.A__ #94?\0+XV_Y^9)_X7U__F(/]>\C_EQW_A/3_P#EX?\
M#Z_]CG_H&_&;_P (G0__ )LJ/^(%\;?\_,D_\+Z__P Q!_KWD?\ +CO_  GI
M_P#R\/\ A]?^QS_T#?C-_P"$3H?_ ,V5'_$"^-O^?F2?^%]?_P"8@_U[R/\
MEQW_ (3T_P#Y>'_#Z_\ 8Y_Z!OQF_P#")T/_ .;*C_B!?&W_ #\R3_POK_\
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M0+XV_P"?F2?^%]?_ .8@_P!>\C_EQW_A/3_^7A_P^O\ V.?^@;\9O_")T/\
M^;*C_B!?&W_/S)/_  OK_P#S$'^O>1_RX[_PGI__ "\/^'U_['/_ $#?C-_X
M1.A__-E1_P 0+XV_Y^9)_P"%]?\ ^8@_U[R/^7'?^$]/_P"7A_P^O_8Y_P"@
M;\9O_")T/_YLJ/\ B!?&W_/S)/\ POK_ /S$'^O>1_RX[_PGI_\ R\/^'U_[
M'/\ T#?C-_X1.A__ #94?\0+XV_Y^9)_X7U__F(/]>\C_EQW_A/3_P#EX?\
M#Z_]CG_H&_&;_P (G0__ )LJ/^(%\;?\_,D_\+Z__P Q!_KWD?\ +CO_  GI
M_P#R\/\ A]?^QS_T#?C-_P"$3H?_ ,V5'_$"^-O^?F2?^%]?_P"8@_U[R/\
MEQW_ (3T_P#Y>'_#Z_\ 8Y_Z!OQF_P#")T/_ .;*C_B!?&W_ #\R3_POK_\
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M0+XV_P"?F2?^%]?_ .8@_P!>\C_EQW_A/3_^7A_P^O\ V.?^@;\9O_")T/\
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MSITHNW\Z.'@*BYYS5J?9H8&J[].:=2C3BOG%R:_P^1_6#7\@G["% "$@ DD
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MDC[4KX<]T* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H _A _:^_P"3L_VH?^SB?C7_ .K*\2U_H'P9_P D?PI_
MV361?^JO"G\]9U_R.<V_[&>/_P#4JJ?.U?2GF!0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!^S?_!#3_D[/XA?]F[>+/_5E
M?"2OQ#Q\_P"2/RW_ +*7!_\ JKS@^Y\/_P#D<XG_ +%E;_U*P1_5;7\C'Z^%
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0!_-1_P<P_\ !7K7?^":'[)6D_#7X&:R=)_:P_:F77O"WPZ\
M0VLZ)??"7X?Z1%:1?$#XL6L:YF'B6W34['PO\/F/V>.S\2:Q-XK$]S_PADFC
M:J ?Y-%[>WFI7EWJ.HW=UJ&H:A=3WM_?WL\MU>7MY=2M/=7=W=3L\]S=7,[O
M-//,[RS2NTDC,[$T 5: "@ H _T#?^#('X!W$6D?MW_M1:C8'[+?ZC\)O@'X
M.U3RR%-QI-MXB^(?Q)L!*1ABL>M?"FX:-.4#*T@P\. #^NW_ (*F>%/$/C/_
M ()]?M3:+X765]5A^'!\1.D&[S7T7P9K^B>,/$J(J?/(7\-Z%JRF% 6F!,2J
MQ<*?WOZ+N:Y?DWT@/"S&YG*$,++B:EEZG.W)#%YO@\7E&73;VBH9CC<++FT4
M+<UURW7T'"M6G1X@RR53X95IT8_]?,10JX>C_P"5:D#_ #K:_P!];6T[:'[@
M% ']7?\ P;0^'=;@T?\ :[\5RPSQ>&]3U#X+^'[&X(;[+?:WH<'Q-U'5((V^
MYY^E6.OZ0\R_>6/6+<\!AG_,/]HQC\%*MX297&5.68X>AQGF%:"DG5HX'&U>
M&\-A92CO&&(Q&7XQ4WLWA:FFA^<^(,X<N44[KG7UZ3C?6,)?54G;HIN+2?5T
MWV/ZE:_S+/S4* "@ H * "@ H * "@ H * /_]?^_B@ H * "@ H _G_ /\
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M\91::^X_GJK2J4*E2C5@Z=2E.5.I"2LXS@^646NZ:L?T5_L@_P#!97X>Z?\
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 ?P@?M??\G9_M0_\ 9Q/QK_\ 5E>):_T#X,_Y
M(_A3_LFLB_\ 57A3^>LZ_P"1SFW_ &,\?_ZE53YVKZ4\P* "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /V;_ ."&G_)V?Q"_
M[-V\6?\ JROA)7XAX^?\D?EO_92X/_U5YP?<^'__ ".<3_V+*W_J5@C^JVOY
M&/U\* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M-*4Y/[4Y2E97LOIBOS@\P* "@ H * "@ H * "@ H * /__0_OXH * "@ H
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MUUTLU;0_=N'*#PV1992>_P!5A5:VM]8;KV^7M+'V)7Q9[84 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 5[JZM;&UN;V]N8+.RLX)KJ[N[J:.WM;6UMXVEGN;F>5DB
M@@@B1I9II66.*-6=V55) !\X?!3]L_\ 9 _:3\1^(_!_[/'[4W[._P =/%GA
M")[CQ1X9^$'QF^'?Q&U_0;..>*T>_P!4TCPCXBU>_L]-6\FCLCJ,MNMC]M)L
M_M'VE'B4 ^EZ "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H _'77?^"_G_  2'\,?&K6?V=]>_;(\/Z;\8_#WQ1U'X+ZSX-F^%
M?QY:2P^)FD^+)O ^H^&)=<B^%DGAHO:^*;>;2GU6+67T,F,W::FUABZ(!^Q5
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0!_"!^U]_R=G^U#_V<3\:_P#U97B6
MO] ^#/\ DC^%/^R:R+_U5X4_GK.O^1SFW_8SQ_\ ZE53YVKZ4\P* "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /V;_X(:?\
M)V?Q"_[-V\6?^K*^$E?B'CY_R1^6_P#92X/_ -5><'W/A_\ \CG$_P#8LK?^
MI6"/ZK:_D8_7PH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M;^&/A]8WJ"6"_P#''B 2PZ1YEN6075OI%M#J'B2_M/,C-SIFAWL".KNE?@/
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M%J8W%X7!4%>MB\10PM%=ZE>I&E37_@4D9UJL*%&K6GI"C3G5GY0IQ<Y?@C^
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MK#4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MR2]-I?O;2 7NG6-RLEL@!]GT % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0!_"!^U]_R=G^U#_P!G$_&O_P!65XEK_0/@S_DC^%/^
MR:R+_P!5>%/YZSK_ )'.;?\ 8SQ__J55/G:OI3S H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H _9O\ X(:?\G9_$+_LW;Q9
M_P"K*^$E?B'CY_R1^6_]E+@__57G!]SX?_\ (YQ/_8LK?^I6"/ZK:_D8_7PH
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M(Z, RLI!4@$$$4 ?MG_P3M_X. _^"D/_  3HU?3--\&?&/5_C7\$X);=-3^
M7QXU75_'G@C[!"P#0>"M6U&]D\6_#*X6$S>0/!6LZ;H4UU*+O7/#NNF"&)0#
M_3K_ ."4G_!7K]E[_@K7\&+GX@_!.\N?"'Q-\&0:5;_&?X!^*;ZTG\<_##6-
M2B?[/.EQ;Q6L'B[P+JUS;7L?A;QYI=E:6>KI:S6NJ:7X=\0VNI>'=. /U7H
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MN;FRN(+NSN)[2[MI8Y[:ZMI7@N+>:)@\4T$T3))%+&X#1R1LKHP!4@@4 ?T
M?\$W_P#@Y,_X*._\$^+O1O"NI?$&]_:G^ -G<VRWGP8^/>O:MX@N],TN/9'-
M9_#CXI7?]J>-OA^RVR^5ING&7Q'X'TZ4FZ/@:ZF:0R '^F!_P3(_X*O_ +)?
M_!5?X03_ !)_9R\3W-GXK\+1:7!\5_@OXN%MI_Q+^%FKZG"[VT.MZ;!--;ZM
MX=U&6WO(_#_C/0IKWP]K?V2ZMEN+36+'5-'TX _3&@ H * /\"7Q3_R,_B/_
M +#VK_\ IPN* ,&@ H * "@#_2P_X,F?$FOZA^PW^UCX9O\ 6-0O/#_AO]J&
MQNO#^D7-S)-8Z+/K_P +_"LFM-IL$A*V:ZE+IUG/=10[(9+B(W'EB>:>20 _
MIT_X*3>(=<\(?\$ZOV^?%GA?5;[0?$OA?]BO]J;Q#X=US3+B2TU+1M<T7X&>
M.M2TG5=/NH666VOM.O[:WN[2XB99(9X8Y$8,H- '^&ZS,[,S$LS$LS,269B<
MDL3R23R2>2: &T ?Z6'_  9->(M=U#]AO]K'P[?ZOJ%YH7AS]J"QFT#2KFZE
MFL=&?6_AAX7GU?\ LRWD9DLDU&XL[>YNHH D4MRC7#)YTLKN ?VD4 % !0 4
M % !0 4 % !0 4 % '__TO[^* "@ H * "@#^?\ _P""\W_(H?LV_P#8R?$K
M_P!-G@ZOZ)^CY_OW$W_8)EO_ *>Q9^<>(?\  RO_ *^XK_TB@?GO_P $?/\
MD^3P)_V*/Q%_]1+4*_2/&G_D@L?_ -AN6?\ J73/F^"?^1_0_P"O&)_]-,_L
M(K^+C]K"@ H \:_:,_Y-[^.__9&OB?\ ^H1KE>UPW_R460?]CK*__4Z@<.9_
M\BW,/^P'%_\ J/4/X'*_T./YU/[[?@#_ ,D(^"G_ &23X;_^H=HU?YW\0_\
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M_P"2*?&#_LEOQ _]1/5J /\ '5_X(%?\ID?^">W_ &<%HG_IFUR@#_9\H *
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MB^'_ ,2? 'CJ2WC::>/P=XQ\.^)GAA1UC:65-$U&]:.-9&2-G<*H=E4D$@4
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M559=(&JG4(R64J ]N"2"!R* /3597560AD8!E92"K*1E2I'!!&"".".E #J
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MWS_DY;]A7_LAGQ1_]3[1Z /Z$/\ @TE_Y0N?"#_LL/Q^_P#5B:A0!_2_0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 ?P@?M??\G9_M0_\ 9Q/QK_\ 5E>):_T#X,_Y(_A3
M_LFLB_\ 57A3^>LZ_P"1SFW_ &,\?_ZE53YVKZ4\P* "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * /V;_ ."&G_)V?Q"_[-V\
M6?\ JROA)7XAX^?\D?EO_92X/_U5YP?<^'__ ".<3_V+*W_J5@C^JVOY&/U\
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@#X*_P""FW[<WA'_ ()Q?L0_'?\ :V\5
M646M7?PY\+&V\ ^$Y9OLZ^-/BGXGN(O#WPY\*RS*?.M],U#Q3J&GR^(KZVCN
M+K2O#%KK6K6]G>2V"VDP!_BH_''XU_$[]H_XO?$3X[?&;Q9J?CCXH_%3Q5JG
MC'QIXHU:=YKK4M8U68R.L2NS+9Z;I\ @TS1=*MO+L-&T>SL-)TZ"WL+*V@C
M/*J "@!<'L* $H * "@#Z5_8Y_9A\=?MH?M2? K]ECX;@IXN^.'Q&\/^!K+4
M#:27T'A_3;^X\_Q)XLO[6%XY)M*\'^&;;5_%.K*DD1&F:1=GS(\;P ?[DOPJ
M^''AWX._"_X;_"+P@MVGA+X6> O!_P ./"ZW\PN;Y?#O@?P]IWAG1%O+D)$+
MB[73-+MA<3".,2S!W"(&V@ [Z@#^>+_@X>_X+-6W_!*?]F73O#?PHN-*U/\
M; _:$M=;T/X-:?=-9WL/PV\/6,26WB7XU>(-&G2=+VW\/S7=OI7@O2M0A6P\
M0>+[E99TU'1O#'B33W /\DCQCXR\6_$/Q7XB\=>/?$VO>-/&OB[6+_Q#XJ\6
M^*=6OM>\1^(]=U6X>[U+6-;UG4Y[G4-3U*_NI9+B[O;RXFN)Y79Y'9C0!S=
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M&O?L[?\ AD_AK_\ ,S7M_P"N?&'_ $5?$O\ X?<T_P#FHX?[%R;_ *%.6?\
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M>+5U9BH99EV&J*KALOP6'JI-*I0PE"E42:LTITZ<9)-:-7U6A[#7BG:% !0
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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MH6@VS0:#HMMA=6\0W^E?VJL^@6>JVEP ?8%W_P $"?\ @X+_ ."ENBG]K?\
M:!L=4U_Q;XSLWU[PYI_[5'QMM] ^*.I:+JK_ &VWM=!\ ZE_:$/PLT4E\:7X
M*U^W^'%MI%G%!%8^'K#3!8!@#\B=9TK_ (*1_P#!%']K!]*N[GXO?L=_M'>$
M%LKX/H^LI'HOC7PRUR9;2>.^T>\U;X>_&#X:ZM<6TL$T!E\5>#[^ZM;S3+^
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M+'5=<L=0U:RU?4;77[._@O-3M-4U&VO;A)+B&]NHY%F< _R /VO/$^C>"/\
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M\(7H:1>(/!]WIEKH6I^&/$X!_IZ#! (Y!Z$=,=L4 ?Y&?_!R1\;_ (T^&?\
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MV%?^R&?%'_U/M'H _H0_X-)?^4+GP@_[+#\?O_5B:A0!_2_0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 ?P@?M??\ )V?[4/\ V<3\:_\ U97B6O\ 0/@S_DC^%/\ LFLB
M_P#57A3^>LZ_Y'.;?]C/'_\ J55/G:OI3S H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M 36DO_$&G3:3JT6K:WJHGLYZ /YE* "@#_=W_9,_Y-6_9G_[-^^#7_JN?#=
M'T#0!_G._P#![]_R<+^P?_V1GXL_^IOX=H _AIH * /];+]AW_@UW_X)5_LU
M?#+P+_PMKX$:;^U-\:X] TFY\<?$7XS:SXAU_P .ZEXDGL;>;6+?P[\+[?5-
M/^'&F^%[?46N$T.WU/PQK/B!-.$$>K^(-4N \Q /U@T;_@F+_P $X_#UO':Z
M+^P=^R#I]O$ (XH?V=OA1M4 ;0!O\*N>!QUH \*^/7_!#O\ X).?M'>&=2\,
M_$']A;X!:4U_;30P^)_A=X,LO@]XVTF9T(AO=+\6_# >%=8CFM)=EQ%:W=Q>
M:3<21K%J.G7UF\UM* ?YRO\ P7Q_X()>*_\ @D7XO\)?$WX8>+-=^*_['GQ;
MUVY\->#?%_B:"T3QU\-O'<5G>:O%\-OB--I-G8:'J\VJZ%87VL>#_%^D6.D1
M>((-'\26-]X<T2YT*"XUT _G,H * /\ 6_\ ^#4[XS7_ ,7O^",WP*TS5+R2
M^OO@MX[^+?P8:6:4S21:?HGBV;Q=H%D78EQ'8>'/&^CV5K$3M@M(+>"(+!'$
MJ@']'- '\ZO_  <]?M_:[^PO_P $Q_&VD_#K7#H/QC_:IUH?L[^!M3M9_*U;
MP_X;\1Z1J%_\5_%6E>6R75O>6/@&SU'PYINL6DD%QX?\0^+=!UBVN([VTLTE
M /\ (QH * /WG_X(B_\ !"GXT?\ !7GXAZSK]YK5]\'OV3?AIJ<6G?$_XU?V
M;#J&I:OXA:"VO8OAI\+]*O)(K;6O&=QI]S!?ZOJEWO\ #_@G2+BVU'61>ZCJ
M/A[PYKX!_I"?LO\ _! ?_@DK^REX2TOPYX-_8V^%GQ%UFRMH(]1^(OQ\T*P^
M-?Q \0WL<:I-JE]J?CBUU#1]&GO"@EN--\%Z#X5\.))S9Z':+\M 'O7Q&_X)
M&?\ !+_XKZ)=^'_'/[ W[*>H6%[ ]O)+I?P7\$^%-8MT==A?3?$7A'2M"\0:
M1<JO^KO-*U.SNXCS%.AYH _CI_X+)_\ !H]HOPT^'_C7]I7_ ()>W'C37;7P
MG;WGB3Q9^R%XEOK[QKKS>&[2)Y]1F^!/B^Z-QXJ\1:AHMM$+F/X=^,YO$?B?
MQ#;"^.@^,=1UV+2?">L '\&)!!P1@C@@\$$<8QVQ0 E '];G_!H9_P %!M1_
M9O\ V]-1_8\\6ZD__"H_VT=+?2=(@GG*6OAOX[^!M+U+7/ VL1!V9$C\7Z!!
MXC\ W]O;PBXU+6M1\$2RW$=IHKQR@'^HY0 4 ?X$OBG_ )&?Q'_V'M7_ /3A
M<4 8- ']G_\ P9L? /X&?'GXZ?MM:;\</@U\+/C%IWA_X3?"N]T&Q^*'@#PK
MX]M-%O+SQAXB@N[K2;?Q1I6J0Z=<W4$44-Q-:)#)-%'''(S*B@ ']^'_  [J
M_P""?_\ T9!^R1_XCK\(_P#YD: #_AW5_P $_P#_ *,@_9(_\1U^$?\ \R-
M'TMX ^'/P^^%'A;3O WPN\"^#_AOX*TCS_[*\(^!/#6C>$?#.FFYF>XN6L="
MT"RL-,M6N;B22XN&@M4:>>1YI2\CLQ /D7_@J1_RC)_X*+?]F)?M=?\ K/\
M\0: /\/2@ H _P!)?_@R._Y,T_;+_P"SF_#G_JJ] H _MAH * "@ H * "@
MH * "@ H * /_]3^_B@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MFN;?3AXWT6&SAFU+5_#<EI:>-/"=O!?2:CIFH^'K"+Q;J0!^J7[<7[+/A/\
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M-Y?:SJ]Y>ZG?75U* >K4 ,5$4NRHJM(0TC*H!=@JH&<@98A$5 3DA551P
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M6NA^.8[3^QOB/X8B;<^?^$4\?Z7XE\-.=QS)I3'CI0!\C?\ !=G]M;_A@O\
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MR5?^#:G_ )3??L&_]C?\6/\ UGGXNT ?ZD?_  5C^'_BWXI_\$Q?V_\ X?\
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M 4 % !0 4 % !0 4 % !0 4 % '^5E_P>*_\I>;7_LU+X*_^G_XDT ?WF?\
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M7^RQ<VG[3_@4P0;[V33/A_8ZC:_%72TDC4W+VUS\)M8\8ZNFG0K(NHZ[X?\
M#P>$RV]O+  ?QG?\&B?[;_\ PS3_ ,%)Y_V=?$^L?8/AO^VOX,D^'?E7$_D:
M?;_&/P(FI^+OA)J4Y)VM<:C;2>.?A[ID"Q[[K6/'VEIO18N0#_5)H _*[_@N
M%_RB%_X**_\ 9J7Q6_\ 3!-0!_D ?L<?MI_M&_L"_&NP_:&_97\=6WPZ^+6F
M>'M?\*V7B6[\)>#O&L,6A^)[>*TUJT.A>.="\1Z!(UW!#&BW,FF-<V^-UM-"
MQ)H _6+5_P#@Z3_X+C:MIUUIQ_;*L]-6[C,3WFD?L\?LR6.HQ(WWOLMZGP=:
M6TD9?E$]N8[B+.Z&6)PK@ ^?OV=?A3^W)_P7[_;'T;X>?$[]L'P?X@^,5[H[
M+I'BC]JWXQ2:-#'H-H6NM0\,_"'P1:6>HZAKFJ16=I>ZX_@;X:>%8(&%M>:U
MK+:9;&\U= #_ $XO^"/G_!%_]G#_ ()$?"*_T'X>S3_$CX]_$+3M*C^-OQ_U
MZR%AK'C";3F>YMO#7A30UN;VW\$_#O2;Z>>?3/#UK=7NHZA<>5J/BC6M<OK7
M3WT\ _8V@ H _P Y#_@]\_Y.6_85_P"R&?%'_P!3[1Z /Z$/^#27_E"Y\(/^
MRP_'[_U8FH4 ?TOT % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '\('[7W_)V?[4/_9Q/QK_
M /5E>):_T#X,_P"2/X4_[)K(O_57A3^>LZ_Y'.;?]C/'_P#J55/G:OI3S H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H _9O
M_@AI_P G9_$+_LW;Q9_ZLKX25^(>/G_)'Y;_ -E+@_\ U5YP?<^'_P#R.<3_
M -BRM_ZE8(_JMK^1C]?"@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H _S\O^#XWP;J
MPU;_ ()R?$&.WFDT-M._::\&W=TJN;>RU:.Y^"&MZ;;S-_JXYM3LY-4DMEX>
M5-(NCRL'R@'\"E !0!_J3?\ !!;_ (.*/V1OVC?V</@U^R[^T_\ $GPE^SM^
MU-\(O!GA#X46O_"Q=9MO#?@#XVZ3X3T:R\-^'/%G@[QIJK6OA[3O%>IV%A8P
M^(_ VMZAIVI/KLDESX336=+N7ATD _K/CDCECCEB=)8I462*2-E>.2-U#(\;
MJ2K(ZD,K*2K*00<4 /H * &.B2(\<B+)'(K(\;J&1T8;61U8%65E)5E(((."
M,4 .       P .  .  .P% "T ?D?_P7A^/<_P"S7_P2'_;N^)MA=O9:O<?!
M2\^&.AW$,ABN8=:^.&O:'\%]/N+4J0YFL9O'HU A.5AM)9&Q'&Y !_B[T %
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H _)7_@IS_P $6_V(?^"I_@R\M?CCX M_"?QHLM+DM/ W
M[2/P]LM/T;XM>%;F* QZ9;ZOJ*P"V^(7A&UD"K+X,\:)J6G16LMX?#MQX:UB
M>+6[4 _R>_VF/V??VJO^".?[?6I_#;5?$<W@?]H']F?Q[X;\;?#GXF^"KA_[
M,URR7[)XF^'_ ,1?"LUQ&RW>@^)=(EM9[S1=4@E\AI-8\'^*-/\ M=GK&FJ
M?[ __!,_]KX?M[?L&?LO?M<2Z99:-K'QF^&&GZMXPTC3$GCTG2_B'X>O]1\%
M_$G3]%2ZFN+I=#L_'WAOQ);Z(+J>>Y_LJ.S^T32S;W8 _P Y/_@[C_8<_P"&
M8_\ @I5_PT+X7T?[!\,_VV?"(^)L4MO!Y.GVOQC\&#3?"GQ@TJ#"X>YU'S/!
MGQ&U.=Y"]QJWQ#U#:B)"!0!_>]_P0I_;,_X;I_X);?LJ?&;5=5_M7XA:!X'A
M^#7Q=EEF\_43\2_@\5\#ZSJNL-E@NH^-=,TS1/B(R*<"U\86AV19\F, _P U
M[_@L-\=O&W_!7#_@ME\1_#_P=D/BVW\3_&GP?^QO^S59PS//I=WX>\)^)(_A
MMH6J6%Q&LK0^'?&7CJ^\4?$M[IU"65GXMNKB9(8H76, _P!9K]EC]GGP1^R7
M^S?\#_V9_AQ"(_!?P-^&/@_X;:).8$M[C54\,:-:Z?>^(=1CC+*VL>)=2BO/
M$&M3[G:YU;4[VY=W>5F(!\N?\%.O^"77[,__  58^ *_ []H?3M6TZ_\.:C=
M^)OA1\4_",T%GXZ^%7C*XT^33GU?1)KJ*:QU71=4MC%:^*?"&LP7&B>(K2WL
MY76QUW2/#VO:* ?YM_[>O_!KU_P5!_8=U'4?&7PO\%2?M??"31;A]2TSXC?L
MXV>J7_Q!T>VLI//L[OQ-\&-TOQ#TC58EA:^FF\#K\0= TF.%9KGQ3#*50 %#
M_@G]_P ',G_!3K]@/Q!HW@/XG>-]7_:I^"WAG4TT?Q'\'?VB;S4M0\>:'8:?
M.;/4M)\(?%R_ANOB-X1UC3HX/[/T[3?%,OC/PGH)MA:Q^"UVNH /]-G_ ()W
M?\%!?@!_P4R_9C\)?M0?L\ZE?_\ ".:U=7WA[Q9X-\0BP@\:_#+QYHH@.N^!
MO&=AIUY?VMKJMG%=6.J:?<V]U-9:WX=U71=?T^1K+4X< 'G/_!97_E$U_P %
M'_\ LRS]HO\ ]5?XCH _SK/^#1#_ )3*>!?^R!_'?_U'M/H _P!7Z@#_ #9?
M^#W#^T_^&SOV-O-/_$E_X9AU_P"P+SQJ?_"U?$?]KG^[S:?V(.!GY>>-N #\
M4OV%/^#?[_@HI_P46^ =C^TE^S/X9^$^L_##4/%/B3P=!=>*?BQH/A?6DUOP
MI/;V^KP7.B7,,]U:(C74#V[7!C>XMY([F./[/+#)( ?8_P#Q")?\%E?^A#^
MO_A]_#?_ ,A4 '_$(E_P65_Z$/X"_P#A]_#?_P A4 ?T+?\ !MA_P0L_;_\
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M@3&N #_1[H _F\_X.Q%!_P"")O[0I(!*_$7]GDKQ]T_\+I\'+D>AVL1QV)%
M'\[G_!D!_P G%?MX_P#9%?A'_P"ISXEH _M$_P""Q?\ RB?_ ."D7_9D?[3'
M_JH_%= '^<W_ ,&BW_*9CX=?]D+^//\ ZB<- ']]O_!PM<ZI:?\ !%__ (*
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M5]H7P?\ A3HFIO))J6C?#;P+I6H22C$KWVG^%]+M+MY1@8D:>&0N,##$C H
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M.D9TSQ#XP\2P^7ODEDD /Z*J /\ %6^/'_*;7XS?]I3_ (B?^M:ZQ0!_M4T
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M_LGPQ6_[+/[-4$$<<,$'P ^#<,,,2+'%%%'\.O#B1QQQJ J1QHH5$4!54
M"@#W^@#_ !P/^#CQ0O\ P6R_;X"@ ?\ "Q? QP!CEO@M\,V8_4L23ZDYH _U
MU?V;/^3=/@%_V17X6?\ J#:%0!_"A_P<-?\ !S!\?O 'Q^^(W["?_!/3QFGP
MJTWX/:W>>"OCA^T9H"Z3JWC?Q/X\LK5;;Q1\/?AM=:C87T'@32/ >KR7GA[Q
M+XLT^-/&FH>,M'O;7P]J?AS1M'>Z\5@'XF_LZ_\ !O[_ ,%L?^"G=AHWQ_\
M%_AW6]'\._$""#6]%^,_[:?Q;\0:9K'BO3-:CBU.#Q+;Z1JL7CSXR:AH6L6U
MU;ZII_B"3P6=+U^TN8K_ $>\U*!_- !^L/PX_P"#(?\ :$N[<77QM_;R^"G@
M&."%KB^'PS^%'C?XIQQ)"ADE$=UXM\1?!A=@56'VB:WB"+^\:$@%* /YQO\
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MS_9OMMJWB/X'?&K3+5(_->QF?QCID&Q9);>-XU*@']H/_!#G_@ZE'[7OQ-\
M_L>?M^^'/"W@7XY>/]2@\+_"GX^^"X8O#OPY^)'BBXB*:/X-\?>%KR]DB\$>
M.?$EW&NG>'-7\.W,OA3Q7XAU"R\/P^'?"%W+IRZP ?VIT % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % '^5E_P>*_\I>;7_LU+X*_^G_XDT ?WF?\$!/^
M4-?_  3W_P"R!:7_ .I!X@H _8&@ H _EL_X.W/VS_#W[.?_  2\U[]GZTUK
M[-\5/VSO%FA?#?PQI=K*JZE'\._ _B#P[X]^+/B)T+J/[&6PT_P]X U+ DD>
M3XBV:11;!<7%J ?S9_\ !F#^S#J?Q'_;]^-'[3UY:W \(_LT_ R\\/6EZL1$
M+?$CXWZFN@Z#:&=U,;1IX$\,_$N:XBA(GCF?3'=EAD*S ']N?_!<C]MX?L ?
M\$Q_VFOCGI&K?V3\2M8\)/\ "#X*R13>1J ^+/Q76;PIX=U;222HDOO ^GW.
MM_$AH2P$ECX+O0 YQ&X!_C6_##XE>-/@U\2? 'Q>^'&KQZ!\0_A=XT\,_$+P
M+K\VDZ+KR:)XQ\':S9>(?#6LG1O$FG:OH&J-IFLZ?9WR66LZ7J&FW#P+'>6=
MQ 7B8 _:7_B)I_X+C?\ 1]VO_P#AD?V9/_G*T 9VL?\ !RE_P6R\0:3JF@ZY
M^V]JFK:+K>G7ND:OI5_\"OV8;FPU+2]2MI++4-/O;:7X*-%<6EY:32VUS!(K
M1RPR/&ZE6(H _&CX9?$7Q=\'_B/\/_BS\/M6FT#QY\,/&OA;XA>"M<M\^?HW
MBSP9KECXC\.ZI#@K^\L-7TVSND&1DQ 9Q0!_N4?L9?M->$/VS/V4OV?OVIO
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@#^$#]K[_D[/]J'_ +.)^-?_ *LKQ+7^@?!G_)'\*?\ 9-9%_P"J
MO"G\]9U_R.<V_P"QGC__ %*JGSM7TIY@4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 ?LW_P0T_Y.S^(7_9NWBS_ -65\)*_
M$/'S_DC\M_[*7!_^JO.#[GP__P"1SB?^Q96_]2L$?U6U_(Q^OA0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MQXN\?_';Q1JLBA0USJ#?%3Q'H"32[>KQZ9H&FV@+?,(K:->BB@#^CZ@ H *
M/X&?^#Y;_D!?\$S/^PM^U_\ ^D?[,U '^?;0 4 ?[N_[)G_)JW[,_P#V;]\&
MO_5<^&Z /H&@#_.=_P"#W[_DX7]@_P#[(S\6?_4W\.T ?PTT % '^_7IO_(.
ML/\ KRM?_1$= %V@ H _*/\ X+G_ /*(#_@HE_V:[\1__3>E '^+'0 4 ?ZB
M7_!EW_RBE^+G_9]'Q9_]4G^SA0!_7-0!_D8_\'5>MW.K_P#!;+]INVG=F3P_
MX4^ VB6@)XCMA\%?!&K;$'9?/U:=\#'S.QQS0!_.K0!^@O\ P2:\(:=X\_X*
MA?\ !/'PGK$,=SI&K_MI?LU+JMI*J-%>Z;9_%[PEJ%]8RJX*M%>VMI+:2*0<
MI,0 3@4 ?[>= !0 4 % '^?W_P 'QWA6RBN_^"<7C9(XQJ-_;_M.^%;F7'[V
M2RTB3X&ZM8QEL?ZN&?6]091GAIV(')H _@+H * /]Q?_ ()E:W=^(_\ @G)^
MP5KFH.TM]J/['/[-D]W*QRTUQ_PI_P 'QRS.>I:5T,C$DDECDYH ^X: /\"7
MQ3_R,_B/_L/:O_Z<+B@#!H _N9_X,@/^3@?V\O\ LCGPB_\ 4U\34 ?Z+] !
M0 4 ?"7_  5(_P"49/\ P46_[,2_:Z_]9_\ B#0!_AZ4 % '^DO_ ,&1W_)F
MG[9?_9S?AS_U5>@4 ?VPT % !0 4 % !0 4 % !0 4 % '__UO[^* "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M&BW_ "F8^'7_ &0OX\_^HG#0!_IR_MM?LZV?[7/[('[3/[,5Y+:VI^.OP/\
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MTR.XC:_LAXAT;P/XOTB]NK3/G06NHVFMRPV5PR>1=2Z;?1PR/+:7*1 ']7-
M'^-?_P %[_V1_%_["?\ P5H_:<\/PV-SX>\-_$;XEZE^T[\$=9L/,MK6;P1\
M7?$6I>-=/;0)ML<D:>!_&;>)O >?OP:EX.N#')-#Y%S, ?Z=W_!''_@J)\*O
M^"IO['?@'XO>'/$6BQ_&[PKX?T#PO^TM\,8KBT@U[P%\4[6P^R:KJ3:)&_GP
M^"/'=W87WB;X?ZQ$CV%[HUQ)I#SQ^(/#_B'2], /UBH _EI_X.IO^"FOP[_9
M+_8$^('[)7AOQ5IMY^TO^V-X9D^'FF^#;"\MKG6/"/P0UF\^R?%'Q]XHT])/
M.TW0_$GAVTUCX;>&6NOL\VM:WX@OKW28[^U\(^(A9@'\ZO\ P9D?L6^(?B5^
MVC\6?VV]:T<I\./V:?AQJWP\\):S<0.JWWQH^+]M%ICV^C7#KY-P?#?PLB\8
MKXD2%OM%@/&WA3S L.JKO /]&WX@_'#X._";7_AMX6^)_P 3O WP^\0?&+Q1
M-X(^%>E>,?$FE>';KQ_XQ@TZ;5F\+>%5U2YM4U?7Y-/MY9[;2;1GOKPJL-I#
M-/)'$P!ZG0!^.?\ P72_8U_9:_:O_P""<?[4FJ?M%^&?"4&K?!/X$?%?XK_"
MKXOZG:VEGXI^%'CKP1X+UCQ+X>U#1?$BK'JJ:-JVM:;8:7XE\(PW7V#QCIUT
MVDRVDFH/IEQ:@'^<%_P;%^)/%GAW_@MU^Q5'X21[AO$5_P#&7PWXBL@SK#=^
M$K[X _%&YUU[GRP2R:1#8Q^(+=3A#?Z/9[SM!H _TA/^"_WPHUCXS_\ !&W]
MO_P5H-K)>ZE9?!%_B0EK#"]Q--:?!?Q?X6^,>IK#!$#)),-+\!WC1*@9O,"E
M58C:0#_.U_X-<?VR? G['/\ P5C^'D_Q.U6T\.^!OVD/AWXN_9AU+Q1J=_!I
MVC^&=:\=:YX.\7>!;_5I[HI;I8ZGX^^'WACPG+<S36\.G?\ "2?VG<3I:6=P
MK '^N?0!_/W_ ,')O_!0CX??L/?\$S/CAX,O=6L+GXT?M<>!?&G[-_PB\%1Z
ME#!KEQ9_$;PW?>&?B/\ $#[+&[:A;Z!\/?!.K:G>MK$5L]HOC#4/!F@3W%I+
MX@M[B, _SVO^#:G_ )3??L&_]C?\6/\ UGGXNT ?Z]WQ.^)_P\^"_@#Q5\5/
MBQXR\/?#SX;^!M)FU[QCXV\5ZE;Z/X<\-:+;,B7&J:QJ=TR6UC90M(@EN)F6
M--PW$"@#H_#WB'0/%NA:/XH\*ZYH_B;PSXATVRUG0/$7A[4[+6="US1]1MX[
MK3]5T?5]-FN=/U/3;ZUEBN;*^LKB:UNK>2.:"5XW5B <5\8O@Q\)_P!H/X;^
M*?A!\;_AYX2^*?PQ\:Z9/I'BCP3XVT6SUW0=5LYXV3,EI>1O]GO;8M]HTW4[
M-K?4]*O8X+_3+NTOK>"XC /\2;]NGX9>!OV7/V_?VI/A/^SYXGGU3P!\"OVG
M?B=X4^$GB*UU%M5OK/1? WQ!U.U\*P_VUE_[8U3PXMA:Z5<:W&3'JVH:9)J4
M(\NY04 ?[@GA"^UG5/"7A?4_$5C'I?B#4?#NB7VNZ;"6,6G:S=Z;;7&IV,1?
MYS':7LD]NA<;BL8W<T =%0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!_E
M9?\ !XK_ ,I>;7_LU+X*_P#I_P#B30!_>9_P0$_Y0U_\$]_^R!:7_P"I!X@H
M _8 D*"S$*J@DDD   <DD\  =3T H _%W_@HE_P7M_X)S?\ !.?POKZ>.?C5
MX:^+OQML].NG\.?L\?!;6],\;_$#5M9562ST_P 57VC2:AX=^%VGO/MDO-4\
M>:AI5RNG)<W&A:-XCOX[?2;L _S!?VO_ -K+]M'_ (+L?M]:-KTWA75/&7Q4
M^*FN:;\,OV?_ (!^");K4/#WPY\)&ZFDTCP?X=DOC;PV]A9"2^\3^/O'.L_V
M9:7%VVO>+M>ET30[9;720#_5!_X(S?\ !,KPO_P2H_8@\"_LZ6][I'B7XJ:S
M?7GQ'^/WC[2+:2*T\7_%?Q';VD6H0Z7+=1Q7LOA?P;H]CI'@GPJ]S#927NEZ
M$-?NM,T[5==U2W !_'#_ ,'I7[;W_"=?M!_L_?L#^$]7\W0/@1X9;XW?%JSM
M9]T$GQ2^)EDVG> M'U.WSF/4O!WPSANM?LG"JKZ=\7""TA&V( _7S_@SL_8D
ML_@Y_P $^/'7[5GB_P /VW_"8_MA?$NYN/#EQ?V,3W$?P;^#-QK'@GPHL:74
M;3VIU3Q]=?%'5':/RX-4TA_#=X!-%';3$ _KJ_L/1?\ H#Z7_P""^T_^,T '
M]AZ+_P! ?2__  7VG_QF@#_/@_X/4OV&[?P]XO\ V8OV_P#P5H,-IIGBZPNO
MV:/C#/I]HEM:Q^)=!35_'/PAUB[6W0)-J&N^'I/B)H5Y?3B-H[+P7X:L0\H,
M20@'V!_P9<?MO_\ "?\ [./Q[_8*\6:OYOB']G_Q2OQE^$]E=3YGE^%'Q2OC
M;>-M(TJWW$)IW@[XGP_V[?R%4+7_ ,7(%4R $1 ']$7_  7"_P"40O\ P45_
M[-2^*W_I@FH _P ]/_@T/_Y3)^!_^R!?'?\ ]1_3J /]7V@#\KO^"R/_  3:
M\)_\%2/V&/B;^SK?1:98?%'3(C\1/V>_&6H*J#PA\9O#%C>GPW]HO-CO:>'?
M%]K=:CX%\7N([CR/#GB2^U*VM9=4TS3'A /\L3_@EK^WC\8_^"-?_!1#0_B7
MXAT#Q-I-CX.\5:W\$/VL/@Y=1M9ZOJ_@)/$*:-\1?"UYIDTD42>,_ FN:1'X
MF\,1SS6Z1>,?"UA8WERND7NJ0W !_LL?#CXB>"/B]\/O!'Q4^&GB33/&/P\^
M(_A30/&_@CQ7HLWVC2?$?A7Q/IEMK.@ZSI\I5&:UU#3;RVN8A(D<J+)LFCCE
M5T4 [2@#_.0_X/?/^3EOV%?^R&?%'_U/M'H _H0_X-)?^4+GP@_[+#\?O_5B
M:A0!_2_0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 ?P@?M??\ )V?[4/\ V<3\:_\ U97B
M6O\ 0/@S_DC^%/\ LFLB_P#57A3^>LZ_Y'.;?]C/'_\ J55/G:OI3S H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H _9O_@A
MI_R=G\0O^S=O%G_JROA)7XAX^?\ )'Y;_P!E+@__ %5YP?<^'_\ R.<3_P!B
MRM_ZE8(_JMK^1C]?"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /XJO^"YO_!J]
MIO[5GB_QC^UQ_P $[/\ A$_A]\=O$LFI^(_BE^SQK5Q;>&?A[\8?%%U,]]?>
M*_ /B&>2+1OAU\0M>G>X.M:5K2VG@'Q7JMQ#K-UK'@C4/[=U/Q" ?YXGQW_9
MS^/'[+_C[4?A=^T1\(?B#\&/'^E23)<^%_B'X8U3PUJ$L<$I@-[IO]H6\5OK
M.E2NO^B:QH\]]I5[&4FL[R>%T=@#Q>@ H * "@#]FO\ @F;_ ,%V_P!OK_@F
M'K?AW1_AC\2K_P")O[/FGZC')KO[,_Q4U*_U_P"&UWI,T_F:I;>")[A[G5_A
M3K%R'FNK75O!,UG8?VN8K[Q#X?\ $]F+K2KT _U(/^"6G_!63]EW_@K#\#V^
M*?P&U>?0?&_A;[#IWQA^!WBFXME^(/PH\07D;M;1ZA'"(X/$/A+61#/-X4\=
M:+&^BZY##<V5PND>)M*\0>&]& /T^H _F3_X.Y/ EUXN_P"",GQ,U^WC9XOA
M=\;O@+XZOBHR(K2_\9?\*T61O1?MGQ$M(\_WG4=Z /\ )SH * /]7K_@T1^*
MFE?$#_@CMX.\)V=U%+J?P5^.WQJ^'&N6RN/.M;C4]8TWXI:=YD6=RQS:/\1K
M Q28$<C1RJA+12*H!_3]0 4 % '\#/\ P?+?\@+_ ()F?]A;]K__ -(_V9J
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M[?[:+2WBCC2"",^8S@'X??\ $5E_P6]_Z.D\(?\ B.?[//\ \[2@#T[X?_\
M!WA_P63\&3I+XC\<? +XLQK)O-K\0/@1X?TV"1,Y\EF^%>H_#2Y$>/EREPDN
M/^6N[YJ /ZXO^"./_!T#^S]_P4B\?^%?V9OCI\/O^&9?VI_$]J]OX/AAUP>(
M/@W\7=>LK=KBYT3P7K]]'9Z]X3\6ZA;PW5]H_@GQ3;:A;WL5N=+TCQOK^OS6
M6EW8!^Y?_!0?0?VQ-?\ V1?C"O[ WQ$TCX;?M7:+H*>)_A/J&O\ A7PCXOT?
MQ1JGARYBU6_^'EWIWC?3M4\/64WCW2K:]\-:3KM[;K#H>MWVF:C=3PZ?!>-0
M!_"'_P $N_\ @ZK_ &U_"_[;OASX3_\ !4[Q_HVM_ 3Q;JU[\*/&NJ7GPF\
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M@OQ5I#RS0)JGAOQ1I-WH>N:<\UN\5Q"E[IE]=6S2P2QS1B7=$Z.%8 '^0/\
M\%"/^"*?_!1;_@EA^TUJ>K?#[X9_&_Q9\,?"_CC4/&/[/'[4OP+TCQ3XA^S>
M']"UTWW@K7-?\2?#VS?4?A1\3]$METZ75--UG^P9X-<M+R_\)WFLZ%%::S,
M??7[ _\ P4[_ .#@O]LK]L3]B7X.^+_BW^UW\0_@SH7[5G[.VJ_%>W\"_!:Q
M\%0+\+_#_P 7/"-SX_F^+?Q!^%GPQ\*>(]3\ 0^%TU3_ (3:#Q]XHO/#E_I!
MN+?Q!%=6\AB8 _TR/C]\"/A9^T]\%OB7^S[\;/"MEXU^%7Q;\):IX+\:^&[X
M86\TG5(MHN+*Y4>=IFM:3=I:ZQX?UJR:+4="UVPT[6=,GM]0L;:>, _RS/\
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MQQJ]MH_QQ\ ZIJT^E>$_"6FZOK^I1:7I=K=:GJ+V6GSK8Z=:75]<^5:6TTJ
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M;74M5\-P6NEZ=-XG\:>#]$T2/4-1N#Y-A9->BYNW#+;Q2;&P ?Z:E '\@?\
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MW]N>8;RQNH+B(\I(M 'U#_PJK_@Y*_Z)O_P7!_\ "/\ V\__ )74 '_"JO\
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M_P '*G_!8S1;?]FO2?%/[47QB\!>*K2'2/$MGX%^$W@SX"_#34]#OVCM9_\
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M+G\0Z%:ZQ#X>\0:KXGLM>MO#NA6WA^XOP#\<_@?_ ,%2O^#@+X0?#;2?V/\
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MM_BR+1O"GAK3]-UF\UKP9'X@\074OE 'PS_P1Q_X)J_\%%_AA_P5._8/\?\
MQ*_8&_;2^'G@+P;^TG\.]=\7>./'/[+GQO\ "7@WPOH>FZJ)K_6/$/BC7_ ^
MGZ%HVE6D2EY]0U"_M[2-<9E^9<@'^N90!^!7_!Q'_P $H/%/_!57]B>Q\+?!
MM-,/[3'P'\7_ /"RO@E9ZUK$&@Z/XO6_LUT3Q[\-]0U>^8:5I+>*]!%KJ6A:
MGJ/V:SB\6^%_#=EJ6K:+H.H:UJ,(!_FT? _QU_P61_X(^_$_QC_PJ#0?VJ_V
M2?&VM3KX;\9Z)JWP@U._\'>,)]!O9TT^6^\*>/\ P7XG^&GC@Z=/)>?\(WXE
MATK6E2QU*];P_JITW6;HW@!_<W_P:V?'_P#X*A?M1Z]^W/\ &[_@HIK_ .T?
MXFT3Q'8?LX:9\%=8^,'@K5?AU\-;FYT:;XXCX@+\'_!UKX:\'_#JQEB2\\'+
MXUO/ ?AZU:\F/A]=?GN)[>Q$0!^K_P#P6;_X(W_!7_@KU\ M/\%^*-3C^&WQ
MZ^&)U;5_@-\;;33(M1G\,ZGJ=LB:GX/\7V(\NZU[X;>*Y;33GUW2[2ZM=2TS
M4=.TS7]&N//L;O3-7 /\V+XI?\$SO^"V7_!'3XTW'Q"\)?#+]HOX=:QX6::T
MTK]I/]E.3QEXR^&NN:'<RJOEW7C?P!921V6AZV85$_@WXH:3X=O[Z.-4U;PL
M$V*0#V&3_@X*_P"#AWQEHTGPULOVDOC!>7,T#:5,/"_[+WP6L?'SQ;$A$,?B
M#P[\#+;Q=9ZA'\N-2L+VTUII6\R6_>1MQ .V_8R_X-Z/^"MO_!4GXT-\6_VH
M]%^+'P.\#^+]<LM;^*/[1O[72>*D^*GB>QN7C-U<^$/ 7C::+XE>/=?N-,0'
M0[O68?#W@CR5MHIO%]G"+6WF /\ 3I_8E_8O^!/_  3^_9M^'G[+?[.OAR70
M?AW\/[*7=?:E);WGBGQGXFU)Q<^(_'7C;5[:ULDUGQ;XFO\ -UJ5XEK:V=K
MEGHVBV&EZ!I6DZ58@'X"?\'7O[!7[6W[<_[)?[/=K^R3\(-;^-'B#X,_&;7_
M !UXV\,>%-3T&#Q9:^&;_P #7VCV^J:!H6K:KIFH^*KF+4S!;MHWA:/5?$)^
MT13VVE3V\5S-;@'\3OPV_P""K/\ P<%?L Z/#\.X/C'^V!\-]"\.[=$@\(_M
M&?!H_$*/08;*7R4T+3X_VC?AMXOU/P[:V3)]D@TW2+G34LHD%I;1P1(L0 -O
MXD?''_@XF_X++P:-\$_&%O\ M@?M#>#/$-]:3KX*\,?!^P^#GP2OY;.\@O\
M3-0\?7/@?P3\,/A+/8:1J$-I>:;K?Q*U%['2+^.TNK>_MKP0RD _L=_X-TO^
M#>+Q)_P3/UC7?VM?VM]1\,:W^UCXJ\+7G@OP3X#\):@GB#PS\"_!^M20R>)9
M+KQ-$%T_Q+\1_%,5K::3>WNA1R:'X7T"/4])TG6_$*^)M1N+, _K"UC1]+\0
M:1JF@:YI]GJVB:WIU[H^L:5J$$=U8:GI>I6TMEJ&GWMK*K17%G>6DTMM<P2J
MT<T,CQNI5B* /\H__@L7_P &UO[8/[$/QD\<^/?V6/A!\0/VD?V./$6MZEK_
M ($UGX7:'JWC_P ?_"71=0NKF]C\!?$[P;HJ:IXQ:+PA;YL;?XDVFF7_ (5U
MO1X+#4]9U/0=>O+S0+, ^9/V??\ @M1_P7E_9[\-Z1\!O@[^T5^T+)IGA[1+
M7PUX<\#^,/@OX.^,OB7P_HVGQK9Z;IVBR_%7X6>.?%]A:Z7;HEAIEI#>"VL+
M2*"RMH8X+:VBA /TQ_9!_P""%?\ P5 _X*E>-OB#^W#_ ,%4)/CW;>#O#/PU
M\6>(O#/ASXT3>);?]H#X]^(=)\):[JGP_P#AMX"^'THM?$7PS^&W_"1'3IK\
MIHWA;[?87HT/X;:)->:W>>)/# !X3_P;Y?\ !.S_ (*!?!G_ (+#?L5_$SXP
M_L,?MB?"?X;>%/%'Q/N?%'Q!^)G[,WQI\!>!_#=O>_ CXI:393:]XL\5>"M)
MT#2([W5;^PTNR:_U"W%WJ5]9V%OYEW=00R '^BK_ ,%9/@+\4/VH?^";G[97
M[/WP5T"#Q5\5_BK\#_%'A7P%X:N-8T?P_'KOB*Y^S7%EI7]M>(;[3-"TR2]-
MLUO!=:OJ-AIT<SQ_:[RV@WS( ?Y:GP[^(?\ P7R_X) ZQJ?@/P1#^V]^R_IF
MC7DE[<>#-6\ >(O&'P3FN6DE:;6]'\.^+O#7C?X):[#=R>:)O$.@V>H6NHM$
MR27]Q]GVQ@'M6O\ _!9'_@XZ_;6\,7?PP\.?%_\ :K\=:/XDC71+NQ_9N_9M
M\.>"?$VI-.?LDMI%XO\ @#\'?#?CBW>^+FWNK73_ !!:P3*[V[6XB9HR ?K+
M_P $0O\ @U=_:/O/CM\,OVJ?^"DGA*Q^$OPI^&FNZ)\1?"G[/&IZMI>O?$KX
MI>*M&NTU?PO!\1++0[W4-*\"^![#5+>PU?Q#H&LZA<^+O$*VK^$]5\-:'9:A
M?:C" ?Z-- !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!_FN_\'6G["7[
M;W[0_P#P5)M/B%^S_P#L<?M4?'3P#_PS-\(]#_X3?X-_L^?%KXG^$5UO3-=^
M(3ZCHK^)/!'A'7-&CU>PCN[26]TQ[Q;VUAN[26:!([F!I #\0_!G[.G_  <+
M_#CPOH_@CX>? G_@LSX#\%^';9K+P_X0\&?##]MWPOX7T*S::6Y:TT?0-#T.
MQTG3+9KB>>X:"RM((C--+*4WR.Q -6__ &"_^#@OX_6MSH_C/]G/_@J-XVT_
M4T-K?:?\8=!_:(LM-O87(5H;Z'XJ2Z=9S6[8&X70,) W'Y1F@#[_ /V2/^#0
M;_@J)\=-9T*[_:#B^&?['OP]NY8I]:U+QMXLT3XF_$>#2I,'S=!^'7PQUC6=
M+N]592K#2?%OCWP,T"[Q=SP7,8M7 /[TO^"6'_!%/]C'_@DYX0OH/@AX>U#Q
MS\9O%%BMEX^_:)^),.E:C\3/$-F6AGF\.:%)86-IIO@3P*+R%+B/PKX;@B:_
M:WT^?Q7JWBG4]-LM2B /UHU;48]'TK4]6EMM0O8M+T^\U&2STFPN=4U6[CLK
M:2Y>VTS3+*.6\U'4)UB,5E86D4ES=W#1V\$;RR(I /\ '@_:A_86_P""OG_!
M0K]NGXK?';QC_P $[OVY/"OB#]J#X]W6I6^H^.?V6/CSH/A3X?:#XN\26^A>
M"]+\1^*M6\ V^E:'X/\ AOX1.@Z%=Z[JEY%8:3X=\/\ VV^NE@MY9J /]<3]
MFWX$^#?V8/V??@I^SG\/8?)\%? _X7^"/A=X<8PI!/>:=X*\/6&@QZI?+&6#
MZIK#V3ZKJMPSR2W6I7EU=32RS3/(P![70 4 ?FA_P6#_ &*H/^"@7_!./]J'
M]FBTTZ+4/''B'X?7GBWX0[D3SX/C%\.98O&WPXAMKD_-8IKWB+1+;PEJMU%E
M_P#A'_$.KVY26*>2&0 _SJO^"%G[/G_!4O\ 8!_X*>?LS?&W6_\ @GA^WMH'
MPP\0^*T^#/QMO-1_9'_:!TK0K?X3?%F2W\+:]KOB&_N_ %M:VVC> =6FT#XF
MW$MQ<0V\<W@FVDG?R4=6 /\ 1>_X+$> _''Q0_X):_MY_#WX:^#O%/Q!\?>+
M_P!F;XG:'X2\$>"- U7Q5XN\4ZW>Z%,EEHOASPWH=I?:QK>KWLG[JRTS3+.Z
MO;N4K#;P22,JD _A9_X-;/V"OVYOV?O^"L'A#XC_ !Z_8Q_:N^"'P]L_@A\9
M]+NO'?Q?_9W^+OPT\&V^IZKHNGV^EZ9+XF\:>$-$T5-1U&8-'8V)O?M5VR.+
M>*3RWV@'^F90 4 ?Y]/_  =7?\$/_B_XW^/7A']O;]B+X"?$GXQZC\:YK?P9
M^TA\+O@A\.O$_P 1/%EA\1-$TAO^$8^+]OX.\#:1K.LMHWC'PUI;:!XXU6'3
M8=.TWQ1X?T35=2N+C5_'US-0!][?\&H7Q5_X*!?"CX<>.?\ @GY^VK^R%^UY
M\)/A_P##VQU/XF?LU_%CXU?L]?&'X>>#=(TC4]:M_P#A.O@G>>*_&OA'1=&M
MYAKFM?\ "=_#[3VNFN;F._\ B!8>:EMIN@6  /[(* /X'_\ @\-_8Y_:Z_::
M_:!_8QUS]FW]EG]HS]H/1?#'P<^).D^)=5^!_P $?B7\6-.\.:G>>-=(N[/3
MM>O/ 7AG7[?1KV\M%>YL[;49+::Z@CEEMTD2*0J ?N=_P;!?!3XR?L__ /!)
M#X5?#?X\?";XE?!3XB6/Q3^-^I7W@'XM>!?$_P .?&MCIVJ^/;^YTN^OO"OC
M#2]'UVSM-2M2MUI\]S8117MJ\=S;-)!(DC ']"5 !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0!_"!^U]_R=G^U#_P!G$_&O_P!65XEK_0/@S_DC^%/^R:R+_P!5>%/YZSK_
M )'.;?\ 8SQ__J55/G:OI3S H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H _9O\ X(:?\G9_$+_LW;Q9_P"K*^$E?B'CY_R1
M^6_]E+@__57G!]SX?_\ (YQ/_8LK?^I6"/ZK:_D8_7PH * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M-7\OR);WPSXQT6SUW2'N[4LSV.H1V=[%#J.G3$7.G7\=Q8W*I<6\B* ?&?\
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M6RGOM+^+7QM\#Z#XNBME8RP_#VSU6+7/B1?+M'R_V;X#TKQ%?[FVHOV?+LB
ML #_ ''8XTB1(HD2..-%CCCC4(D:( J(B* JHJ@*JJ %    % #Z /\  E\4
M_P#(S^(_^P]J_P#Z<+B@#!H _N9_X,@/^3@?V\O^R.?"+_U-?$U '^B_0 4
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M?XZ\8_#70=;\3>(M13X@^,K".\U;5;RWDN;N>.RM+6TB:1SY=O;PPIMCC10
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M=S_@@_K_ (Q\3?\ !'G_ ()ZZIXZFNKC74_9R\)Z/;S7DAFG?PMX<N=2\.^
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M[4FE:5\8M2UZ]9%\V>+P+X@L7^%7ARVADW_V;!H'@:RO+:#RA>ZGJE[$=0D
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M-J.K_".^LKVZ^!/B:8L6(AM_#FD:S\-5W,T\TOPSEU&Z._4D9P#^G:@ H *
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MGBOX@ZQXE\0QQRKYD,>I) Q/E"@#[*H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * /X0/VOO^3L_VH?^SB?C7_ZLKQ+7^@?!G_)'\*?]DUD7
M_JKPI_/6=?\ (YS;_L9X_P#]2JI\[5]*>8% !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % '[-_P#!#3_D[/XA?]F[>+/_ %97
MPDK\0\?/^2/RW_LI<'_ZJ\X/N?#_ /Y'.)_[%E;_ -2L$?U6U_(Q^OA0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M?LVCX<?\$_?CC^TAJ5@+;6_VE?C[/HVE7?EX.H?#KX&Z$GA[0IA*0&(B\?\
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M )3"_P#!0_\ [.8\<_\ H=I0!_IW_P#!NY_RA9_8!_[))K?_ *LSQU0!^T=
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M\AAF5U*[) #_ %+* "@ H * "@ H * "@ H * "@ H * "@ H * "@#^:?\
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M:G<ZGX_UO2KN72O$'BQH++3[C5="\)^'=8O #^BR@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H _C?\ ^#U__E'!^S/_ -GN>%?_ %1'QYH \7_X,@_^39_V
MZ?\ LNGPO_\ 4 U>@#^XB@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MC7X_\-7Z?VAX<32],U.ZL/AOX:URTL?$!UF6Y\<7EAI46C^#KS6@#^^>@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /X0/VOO^3L_VH?^
MSB?C7_ZLKQ+7^@?!G_)'\*?]DUD7_JKPI_/6=?\ (YS;_L9X_P#]2JI\[5]*
M>8% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M '[-_P#!#3_D[/XA?]F[>+/_ %97PDK\0\?/^2/RW_LI<'_ZJ\X/N?#_ /Y'
M.)_[%E;_ -2L$?U6U_(Q^OA0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?Q%?\'#.
MK:O>_MTZ%IM\\QTS1O@5X&AT2-RWE+;WFO>,;Z\:%3\HW:A-<A]HY9.>@K_9
MKZ!6&PM'P/Q5>A&"KXSCG/9XR44E*56C@,EH48S=KODP\*;A?1*;M:[/V+@B
M,8Y%%QM>>-Q,IV_FY:,-?^W(0^1^$E?VL?7$UO))#<02Q,R2QS1/&\;%'5T=
M2A1E(96# 8*D$=J:C&;4)14HS]R4)*\90E[LH26SC*+<9)Z-.ST*C=25MT]/
MZ\C_ %#OA9JFJZY\,?ASK>N[SK>L> _"&J:R91B3^U=0\/Z?=ZAY@P,/]KEF
MW# PV1BO^:GB;#87!<2<08/ \OU+"9WFN&P?)\/U6ACZ]+#\O]WV4(6\K'\[
M8R$*6,Q5.G;V=/$UX4[;<D*LHQMY<J1WE>(<P4 ?@K_P<U>!O"WC?_@BG^V4
M?$UE:7$G@_2_AEXY\,W=Q%&T^D>*-!^+G@9;"]TZ9AOM;NZM+W4-#EEA*R3:
M;J^H6+%H+N5' /\ 'QH * /]0_\ X,N] U#2/^"57Q>U2]BDBMO%/[<7Q4U?
M2"Z%5GT^S^"_[/'AV2>)CP\?]JZ)J=L2HP);:1?O*< ']=- 'Y*_\%D/^"47
MPM_X*U?LHZE\&/%%W:^#_B]X(FU'QC^SS\5W@:1O OQ";3VM?[/UP007%W??
M#[QE%%;:1XWTFVCDG:UBT_7-.C.N^']'>, _Q_OVKOV3?C[^Q+\<O&G[.O[2
MGP]U;X<?%'P/>^1J&E:@@FT[5]-GR^E>)_"NLP;M.\2^%->M=MYHNO:5-/97
M<#&,M%=P75M  ?.5 !0 4 % !0 4 :_A_0-;\5Z]HGA;PUI.HZ]XC\2ZOIN@
M>']#TBRN-1U;6=;UB\AT[2M)TO3[..:[O]1U&^N(+.RLK6&6XNKF:*""-Y'5
M2 ?[P_P"\):MX!^!/P5\"Z_$L.N^"OA+\./"6M0HZ2)%JWASP=HVCZE$DD;.
MCK'>6<R*Z,R, "K$$&@#UJ@#_.=_X/?O^3A?V#_^R,_%G_U-_#M '\-- !0!
M_OUZ;_R#K#_KRM?_ $1'0!=H * /RC_X+G_\H@/^"B7_ &:[\1__ $WI0!_B
MQT % '^HE_P9=_\ **7XN?\ 9]'Q9_\ 5)_LX4 ?US4 % '\6/\ P<O?\&]6
MN_M;3:Y^W_\ L0>$FU7]I'3-)A;X^?!31(+>.Z^.7A_P]I@M[/QYX&ME\I[O
MXO:!I-C;:3J7AI/.G^(^A6FFQZ&D?C+1HM.\; '^:_>V5YIMY=Z=J-I<Z?J%
MA<SV5]87MO+:WEE>6LK07-I=VLZ1S6US;S(\,\$R)+#*C1R(K*0 "K0 4 %
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M^!OQ+^#?[5B^'+2^U&]^'_A)?$/P_P#BEJ>G6-M)=R2>%O#_ (JM[GPSXAU
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MUQI]A^S#\/?!-Q):?ZI=>^&EG+\./%,#?]/-KXG\*:O:WG_3Y#/0!^L% !0
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M3.=GCOX2?$/P/(OR_P +Q^(61^VQFW?+F@#_ &2J "@ H * "@ H * "@ H
M* "@ H * "@ H * "@#S+XI?!7X-_'+0H?"WQL^$OPR^,/AFVN3>6_ASXI>
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M_A _:^_Y.S_:A_[.)^-?_JRO$M?Z!\&?\D?PI_V361?^JO"G\]9U_P CG-O^
MQGC_ /U*JGSM7TIY@4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 ?LW_ ,$-/^3L_B%_V;MXL_\ 5E?"2OQ#Q\_Y(_+?^REP
M?_JKS@^Y\/\ _D<XG_L65O\ U*P1_5;7\C'Z^% !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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MJ6/D7G]FZSI=AJFGF;[+>VT<\3"@#RS_ (AO?^"VG_1A'Q _\.!\#_\ YZ%
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MJWBGQWXZU;5/B)\</CAX^NM7U[3O!'AZ]U07/B_XH_$?7II+C4M5U"]U&_\
M)T^RDNFU?Q?XIU*RTJWFCDNY[VU /]:'_@F!_P $FOV4/^"4WP9B^&WP \,+
MJOCS7[*P/Q=^/'B>RLY/B;\6-:M5WF75;^)7&@^$K"Y>4^&/ .BRQZ!H$#&X
ME_M;Q%>:UXCU< _3J@ H _R;/^#M[_E,_P#%;_LC'P"_]0*VH _KQ_X,\?\
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MB=(M/TC3H]1U:_DMM/L[B6( _P!K_P#8+_9/\-_L,?L;_LZ?LE>%KZ/5M/\
M@=\,M"\(:AKT-M]BB\3>+&$VL>._%D=EULU\5^-M4\0>(Q:.TDEM_:GDR2S2
M(TK@'UC<W-O96UQ>7<\-K:6D$MS=7-Q(D-O;V\$;2S3SRR%8XH88D:221RJ(
MBEF( - '^'Q_P4U_:VO?VZOV^/VJ/VJI[FYN-)^+'Q;\0WO@9+OS!<6/PN\.
MF'P?\*-*G20*8[C2_AQX?\+V%T!'$K74$\@ABW[% /\ 6M_X(>?L@V_[$/\
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * /X0/VOO^3L_P!J'_LXGXU_^K*\2U_H
M'P9_R1_"G_9-9%_ZJ\*?SUG7_(YS;_L9X_\ ]2JI\[5]*>8% !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '[-_\ !#3_ ).S
M^(7_ &;MXL_]65\)*_$/'S_DC\M_[*7!_P#JKS@^Y\/_ /D<XG_L65O_ %*P
M1_5;7\C'Z^% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 )@<<#CD>QZ<>G'%'_#
M +0 4 % !0 4 % !0 4 % !0 4 % !0 THC8+(K%>5RH.T\=,CCH.GH/2@!U
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % #555SM55R<
MG: ,GU..] #J "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M(ETC7?#GPGT[P7IGB6QN]_E'2M7LM0M)"506Q.T  ^EO^"='_!NU_P %(_\
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MT$,*I&H!_EB_\';W_*9_XK?]D8^ 7_J!6U 'PY^P]_P78_X*1_\ !.WX*/\
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M/%/B[Q3JMU-\$/#?CQ[;6]#_ &8?#^M693Q+HOPTGN%EU#4-3U.ZN;_3M/\
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M2ZGI_@075[+_ *9K?C+XU_$*YM- O]1=4FNGM/[>U7Q3JR6TZZ5I6J74?D$
M_P!)_P#X(:_\&^'P<_X).:1)\8?B'KNE_&[]M'Q=X;&B^(?B-;V!B\$?"G1]
M019-:\&?!FRU*UAU9$U%MEAXD^(&LQV?B#Q386D=I9:/X0T:]U?0]1 /Z-*
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M<?##4+3XJ^.];MP"KMIFG^(= ^&_AG5]C?O$\:VMK(KVUS.* /P+_P"#*O\
M9@F\<?MD_M*?M7:MI,LWA_X!_!6Q^&WAK4)[=EM8OB'\;-?CG:ZTZZ9 DU_I
M7@3X?^*].U""!V:TLO&%H]TL8O;(R '^E50 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?GCXU_P""
M6G[&7Q!\9>+?'OBCX>:]>^)O&_B;7O%_B*\A^('C6RAN]=\2ZK=:SJ]S%9VN
MM16MI'/J%[<2I;6T4=O K"*&-(U51^D8'Q9XWRW X/+L)F6'IX7 87#X+#0>
M78&;AA\+1A0HP<YT'*;C3IQ3E)N4K7;;/F:_".1XFO6Q%7#5)5:]6I6JM8FO
M%.I5FYS:BII).4GHDDMEH<S_ ,.A?V%/^B9^(O\ PY/CS_Y?5U_\1FX__P"A
MKAO_  UY=_\ ,YE_J5P__P! M7_PJQ'_ ,L#_AT+^PI_T3/Q%_X<GQY_\OJ/
M^(S<?_\ 0UPW_AKR[_YG#_4KA_\ Z!:O_A5B/_E@?\.A?V%/^B9^(O\ PY/C
MS_Y?4?\ $9N/_P#H:X;_ ,->7?\ S.'^I7#_ /T"U?\ PJQ'_P L#_AT+^PI
M_P!$S\1?^')\>?\ R^H_XC-Q_P#]#7#?^&O+O_F</]2N'_\ H%J_^%6(_P#E
M@?\ #H7]A3_HF?B+_P .3X\_^7U'_$9N/_\ H:X;_P ->7?_ #.'^I7#_P#T
M"U?_  JQ'_RP/^'0O["G_1,_$7_AR?'G_P OJ/\ B,W'_P#T-<-_X:\N_P#F
M</\ 4KA__H%J_P#A5B/_ )8'_#H7]A3_ *)GXB_\.3X\_P#E]1_Q&;C_ /Z&
MN&_\->7?_,X?ZE</_P#0+5_\*L1_\L#_ (="_L*?]$S\1?\ AR?'G_R^H_XC
M-Q__ -#7#?\ AKR[_P"9P_U*X?\ ^@6K_P"%6(_^6!_PZ%_84_Z)GXB_\.3X
M\_\ E]1_Q&;C_P#Z&N&_\->7?_,X?ZE</_\ 0+5_\*L1_P#+ _X="_L*?]$S
M\1?^')\>?_+ZC_B,W'__ $-<-_X:\N_^9P_U*X?_ .@6K_X58C_Y8'_#H7]A
M3_HF?B+_ ,.3X\_^7U'_ !&;C_\ Z&N&_P##7EW_ ,SA_J5P_P#] M7_ ,*L
M1_\ + _X="_L*?\ 1,_$7_AR?'G_ ,OJ/^(S<?\ _0UPW_AKR[_YG#_4KA__
M *!:O_A5B/\ Y8'_  Z%_84_Z)GXB_\ #D^//_E]1_Q&;C__ *&N&_\ #7EW
M_P SA_J5P_\ ] M7_P *L1_\L#_AT+^PI_T3/Q%_X<GQY_\ +ZC_ (C-Q_\
M]#7#?^&O+O\ YG#_ %*X?_Z!:O\ X58C_P"6!_PZ%_84_P"B9^(O_#D^//\
MY?4?\1FX_P#^AKAO_#7EW_S.'^I7#_\ T"U?_"K$?_+ _P"'0O["G_1,_$7_
M (<GQY_\OJ/^(S<?_P#0UPW_ (:\N_\ F</]2N'_ /H%J_\ A5B/_E@?\.A?
MV%/^B9^(O_#D^//_ )?4?\1FX_\ ^AKAO_#7EW_S.'^I7#__ $"U?_"K$?\
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M "^H_P"(S<?_ /0UPW_AKR[_ .9P_P!2N'_^@6K_ .%6(_\ E@?\.A?V%/\
MHF?B+_PY/CS_ .7U'_$9N/\ _H:X;_PUY=_\SA_J5P__ - M7_PJQ'_RP/\
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M_P ->7?_ #.'^I7#_P#T"U?_  JQ'_RP/^'0O["G_1,_$7_AR?'G_P OJ/\
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M ,SA_J5P_P#] M7_ ,*L1_\ + _X="_L*?\ 1,_$7_AR?'G_ ,OJ/^(S<?\
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M_P SA_J5P_\ ] M7_P *L1_\L#_AT+^PI_T3/Q%_X<GQY_\ +ZC_ (C-Q_\
M]#7#?^&O+O\ YG#_ %*X?_Z!:O\ X58C_P"6!_PZ%_84_P"B9^(O_#D^//\
MY?4?\1FX_P#^AKAO_#7EW_S.'^I7#_\ T"U?_"K$?_+ _P"'0O["G_1,_$7_
M (<GQY_\OJ/^(S<?_P#0UPW_ (:\N_\ F</]2N'_ /H%J_\ A5B/_E@?\.A?
MV%/^B9^(O_#D^//_ )?4?\1FX_\ ^AKAO_#7EW_S.'^I7#__ $"U?_"K$?\
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M "^H_P"(S<?_ /0UPW_AKR[_ .9P_P!2N'_^@6K_ .%6(_\ E@?\.A?V%/\
MHF?B+_PY/CS_ .7U'_$9N/\ _H:X;_PUY=_\SA_J5P__ - M7_PJQ'_RP/\
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M_P ->7?_ #.'^I7#_P#T"U?_  JQ'_RP/^'0O["G_1,_$7_AR?'G_P OJ/\
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M ,SA_J5P_P#] M7_ ,*L1_\ + _X="_L*?\ 1,_$7_AR?'G_ ,OJ/^(S<?\
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /_UO[^* "@ H * "@
MH _GX_X*Y?\ !N]^RK_P5H^)_@/XW^+/'?C+X"?&#PKX=F\'>*/&OPVT+P[J
MDGQ-\+V\D<WABT\9:=K:QPSZKX.=M0M=$U^WECU%]&U(Z)J;7^GZ3X>CT< ^
MV_\ @E;_ ,$Z?^'7O[-#_LN:1^T3\2_V@O 6E>,];\3_  _;XDZ1X>TF;X;Z
M1XB2UN]6\&>&8]"1G_X1^Z\2_P!K^*OL]W=3);ZMK^J-9PVR7$OF@'Z64 %
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MFU-$M)/'MEINBQ32ZIXMTW2VOM.\.W5]=?8M"?5+K6+6Q;7K31=4TD _IOH
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H __U_[^* "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /_0_OXH * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H _]'^_B@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@#_TO[^* "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@#_U?[^* "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /_6_OXH * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H _]?^_B@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@#_T/[^* "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M?:ZMH7B#P_J5EK.AZUI5]"L]EJ6DZMITUS8:CI]Y Z36MY9SS6UQ"ZR12.C
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M2I4XN4ZDY*,(16[E)V22\S^>/]JS_@M;J[7^K^#?V4="L[/3[6>6S'Q>\7V
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M@I3E"$N/'X[#Y;A*N,Q4^2E2C?IS3EM"G36G-.;]V*^;M%-K^3+]I;_@J/\
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M-CL9C</F$L9B:^)=.M04'6J2J."<)W4>9NR=EHNQ^UE?AA]T% !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MUY:0V_B_P-)>3BVLO^$FM[%$L-2T>XF>WM8_$NFP6,27\Z6E_I&FJ]G<7O\
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MIOI[?&*<:F_^Z4K6U1^8<>YC*KC*&60E^ZPM.->K%=<153Y.9?\ 3NCRN/\
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M^T)J=MX7T3Q7>6FIV7B6\T*Y< _UK?A=\*_AM\$?A_X5^%/P@\"^%OAK\-O
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M_P =^'#=_P!CZ[%H.OZKX6U@V@O[6RO$;3?$.AZOI%U'<6L,D5Y87$93Y02
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MF?:M?#'NA0 4 % 'PC_P4U_Y,5_:%_[%OP]_ZG7A6OO_  M_Y+[AO_L+K_\
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MTH0@M(H];C'"T<%F6&PF'CR4:&6X:G"/E&=?5]Y2=Y2?VI-OJ?HU_P $&_\
MD0_VBO\ L;O /_IF\1U^9?2"_P"1CPU_V!9A_P"G\,?3^'G^[9E_U_P__INH
M?OM7\\'Z*% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M_P#@R7^8?\)AXM_Z&GQ'_P"#O4__ ))H^HX+_H#PO_A/2_\ D ]O6_Y_5?\
MP9+_ ##_ (3#Q;_T-/B/_P '>I__ "31]1P7_0'A?_">E_\ (![>M_S^J_\
M@R7^8?\ "8>+?^AI\1_^#O4__DFCZC@O^@/"_P#A/2_^0#V];_G]5_\ !DO\
MP_X3#Q;_ -#3XC_\'>I__)-'U'!?] >%_P#">E_\@'MZW_/ZK_X,E_F'_"8>
M+?\ H:?$?_@[U/\ ^2:/J."_Z \+_P"$]+_Y /;UO^?U7_P9+_,/^$P\6_\
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M#Q;_ -#3XC_\'>I__)-'U'!?] >%_P#">E_\@'MZW_/ZK_X,E_F'_"8>+?\
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M (3#Q;_T-/B/_P '>I__ "31]1P7_0'A?_">E_\ (![>M_S^J_\ @R7^8?\
M"8>+?^AI\1_^#O4__DFCZC@O^@/"_P#A/2_^0#V];_G]5_\ !DO\P_X3#Q;_
M -#3XC_\'>I__)-'U'!?] >%_P#">E_\@'MZW_/ZK_X,E_F'_"8>+?\ H:?$
M?_@[U/\ ^2:/J."_Z \+_P"$]+_Y /;UO^?U7_P9+_,/^$P\6_\ 0T^(_P#P
M=ZG_ /)-'U'!?] >%_\ ">E_\@'MZW_/ZK_X,E_F'_"8>+?^AI\1_P#@[U/_
M .2:/J."_P"@/"_^$]+_ .0#V];_ )_5?_!DO\P_X3#Q;_T-/B/_ ,'>I_\
MR31]1P7_ $!X7_PGI?\ R >WK?\ /ZK_ .#)?YA_PF'BW_H:?$?_ (.]3_\
MDFCZC@O^@/"_^$]+_P"0#V];_G]5_P#!DO\ ,/\ A,/%O_0T^(__  =ZG_\
M)-'U'!?] >%_\)Z7_P @'MZW_/ZK_P"#)?YA_P )AXM_Z&GQ'_X.]3_^2:/J
M."_Z \+_ .$]+_Y /;UO^?U7_P &2_S#_A,/%O\ T-/B/_P=ZG_\DT?4<%_T
M!X7_ ,)Z7_R >WK?\_JO_@R7^8?\)AXM_P"AI\1_^#O4_P#Y)H^HX+_H#PO_
M (3TO_D ]O6_Y_5?_!DO\P_X3#Q;_P!#3XC_ /!WJ?\ \DT?4<%_T!X7_P )
MZ7_R >WK?\_JO_@R7^8?\)AXM_Z&GQ'_ .#O4_\ Y)H^HX+_ * \+_X3TO\
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M+<0#]-/^(OK_ ((Y_P#0R?M%_P#AC+W_ .:&@#]P?V$?VZ_@+_P47_9^TO\
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M1>/-(T>RGF"6>E?$+PMJ2Z[J<=H#%!K?@>WN8K03:]J]X0#_ $9Z "@ H *
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MY?BJM:.IIK&$&?BW_P %J_\ D\BT_P"R/>!__3MXLK]R\#/^2)G_ -CK'_\
MIG!GPO'?_([C_P!@.'_]+K'V_P#\$&_^1#_:*_[&[P#_ .F;Q'7P7T@O^1CP
MU_V!9A_Z?PQ[_AY_NV9?]?\ #_\ INH?OM7\\'Z*% !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M!_"!^U]_R=G^U#_V<3\:_P#U97B6O] ^#/\ DC^%/^R:R+_U5X4_GK.O^1SF
MW_8SQ_\ ZE53YVKZ4\P* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /Z)/^"!W_
M #==_P!T+_\ >QU_-?TAO^:0_P"Z_P#^\0_3/#K_ )G'_=/_ /=T_HDK^:S]
M,"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M^*/_ $0'P#_X5?B'_P"0J_'_ /B7W*O^BBS#_P (L-_\L/L?^(A8K_H6X?\
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MYL?2A0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M+I]XT(!]I4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % 'Y">,/^"]/_  21\ _M*WG[)/BW]M#P!H_QITOQ:W@#6K*3P]\1
M+CP#H'CB*^73+CPKK_QAL_!UQ\)-%U33]1\W3=9;4O&MM8:!JEK=Z1KU[INJ
MV\ED #]>Z "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /X0/VOO\ D[/]J'_L
MXGXU_P#JRO$M?Z!\&?\ )'\*?]DUD7_JKPI_/6=?\CG-O^QGC_\ U*JGSM7T
MIY@4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?T2?\$#O^;KO^Z%_^]CK^:_I#
M?\TA_P!U_P#]XA^F>'7_ #./^Z?_ .[I_1)7\UGZ8% !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MB"QN(PFB_$+3_"UZT&F6^I>,-2< _P!-6@#_ !P_^"CUGXF_X)]?\%^OC_\
M$#5]+OXKKX1?\%"X?VL/#=C9P_9KF]\)>(_BUI7[2G@B/2FN7A@E:7PUK^E6
M<%P9DMFNHW#R1A) @!_KY?!OXN_#WX_?"?X<?&[X3^(K/Q;\-/BOX+\.^/\
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M4T&[U:\\-7,T:?VAHM[#NA8 _P S7_@O]_P1#'_!''XK_"/QA\'?B=XB\?\
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M4++3OVU;S6K#P+?Z*9&!GOOAO\0D^,WQ$NBLGV>VTS3=*LS$KR6T5V >C_\
M!E9^PQ_;GCK]H[_@H;XPT??IW@:P7]F[X*7=U!OB?Q;XBM]*\6_%[7[$R*I@
MOM \*GP/X9L[V RI/9>._%-@YC:!U< _T+;NU@OK6YLKJ,2VMY;S6MQ$WW9(
M+B-H98V]GC=E/L: /\77]@A?A;^PW_P6)^$7A+]LKPMX*U_X5? []J/QC\#O
MCWHWQ5\&Z/XM\#6>DF]\6?!?Q+XA\6>$O$^GZGI=UI?A*[U-O%SO=:?=2Z6V
MC1:M8QM?6-JP /\ 6\A_X)Q?\$Y[B&*>W_8-_8IG@GC2:":']EWX%R0S0R*'
MCEBD3P,4DCD0JR.A*LI#*2"* )/^';G_  3M_P"C"/V+?_$6O@;_ /,+0!Z;
M\*?V1_V4O@1XBNO%_P #_P!F/]GKX->++W29]!O?%'PI^"_PW^'?B*[T.ZN;
M.]NM%NM:\(>&M'U*?2;F\T^PNY].EN6LYKFQLYY(6EMH60 ^A: "@#^>+_@Y
MT_8+\0_MS_\ !+GX@2?#O2;K6_BW^R_XDL?VE? NBZ99->:MXHTKP=H>OZ+\
M2?"-A%!'->W-Q>_#WQ#KWB+2]*T^">\USQ/X3\.:3;Q-+=(5 /XY_P#@U4_X
M*X^"?V"OVDO&G[+_ .T/XJM/"7[./[6%[X?;3?'&O:@ECX6^$_QPT&&ZTWP[
MKVO7%P5M-&\+?$/2;R/P?XJ\03LEMI6I:7X#U/5[C3_#FF:WJ5H ?ZF4;I*B
M21.DD<B*\<D;!T=' 9'1ERK(RD%64D$$$<4 /H _*#_@L3_P5)^$_P#P2L_9
M"\:_&+Q/K.BWWQI\3Z1K'AG]F_X4S7MJ==^(7Q,GM%MK"^_LEF-RW@?P-/?6
M?B3Q_K31+96.D00Z1%._B'Q!X>TW4@#_ #Q?^#8_]BOQW^WE_P %8?"'Q_\
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M4X-I5(J*O%QBU_4;\*?VT_V6OC-I5KJ?@?XV^ 9)YX(II= U_7K'PKXJL2X
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M&.GJ?9-?$GN!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MVKDU+XPPQ1Q)'(FC7FG?&>WU?QMX1@,7E$1>%M;\*WRPE1%<1Q2,' /[E/\
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M_P#85O8>&? *SV]A>'P;+K&G0:PP!_6A_P &3W_*.G]IW_L]7Q#_ .J,^!]
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M[*?[,DLKO+++^SW\%Y)))&+R22/\./#;.[NQ+,[L2S,Q)8DDG- 'T)0 4 %
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MIIVD6_\ 9C:J ?V14 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % '^3C\4?^#5S_ (*]?\-;>*?A3X9^#VE^-/AIK7Q'U;^P
M_P!J&_\ B5X M/AWJ'@C4M<EF@^('BBVNO$W_">Z9J$6G7*WOB#PJ/"5[XJ.
MIQ7UMH>FZ]!]CO[T _U5/A?X,D^'/PS^'?P]FUF[\1S> _ OA'P9+XAOUV7V
MO2>%] T_1'UF]3S)=MWJC6)OKA?-DVS3N/,?&X@'=4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MKNG0:G=65_J=N]Q+H>J:7=!%O9G@CGC@F\J:*2&, _5F@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * /X0/VOO\ D[/]J'_LXGXU_P#JRO$M?Z!\&?\ )'\*?]DUD7_JKPI_/6=?
M\CG-O^QGC_\ U*JGSM7TIY@4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?T2?\
M$#O^;KO^Z%_^]CK^:_I#?\TA_P!U_P#]XA^F>'7_ #./^Z?_ .[I_1)7\UGZ
M8% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M7%_\/?#.LWTVH_LM?M5^#/&.C7GP\U#4+QKK5[OX=WZWGAGQEX'CUNZ\^_\
ML*3ZY\/[V\O;_P 16WA:XU75KS5KD _0?XV?\'EW_!17XQ:%/\/?V</V=O@9
M\#_%GBV"'0-*\5:78>+_ (T?$?3]8OWCMX)_ NEZY/I_@^36I[AE@T^S\0>
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M"UM;75_&/B5[-$M[93;V5II7A[0;0M8^'/#UAI^EPRWMS%>ZIJ !>_X*H_\
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M*.&C\9?M6>8NT@Q[?V8/VA5.\8RNUL*<XP>.M '^NS0 4 % !0 4 % !0 4
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M6G0I2JU)497G3ER4XN3C2FI)V6GMK[(^&_\ @E_^Q#\6[G]J;PYX[^,WP?\
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MQ&%<ZU!P6(H5*#DHPFFXJI&+:5TFUHC]MZ_"3[P* "@ H * "@ H * "@ H
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M)UL[&WT[1(9U%S9>#O"FF^'O!]C=;K^'0_[5N+S4+H _83_@R>_Y1T_M._\
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M']F[X.^)+8QB;PCX\^,7@30O&BB1 Z,/!ESK8\4O'Y;(YDCTAHT1XV=E5T)
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MTET_P$U]--(TVL:E\-]6T;5/ ^H:BBKY'AF7X=Q:AY^J75S?WX!_6O0!\?\
M[?O[6'AO]AG]C#]I']K'Q/\ 9)+7X*?"WQ#XHT73;Z3RK;Q#XYGB31/AQX3>
M0.A0^+O'^J^&O#*.K H^JJX^[0!_E#?\$.OV-[__ (*H_P#!67X;^%OC/#>^
M/O!7_"0>-_VG/VG-2U'-Q)XB\/>'+UO$&J#72J!)X?B%\4=?\(^$]8W;%>#Q
M9=R[7V>2X!\]:1??%?\ X(Q_\%8X;EQ?7'CO]AK]JBXM+Q$']GM\0? WACQ'
M-I^HQ1Y,9AT/XQ?"B^N(XGS"S^'_ !@K@PLXV '^T=\/?'GA3XJ> ? _Q/\
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ML*_]D,^*/_J?:/0!_0A_P:2_\H7/A!_V6'X_?^K$U"@#^E^@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H _A _:^_Y.S_:A_P"SB?C7_P"K*\2U_H'P9_R1_"G_ &361?\
MJKPI_/6=?\CG-O\ L9X__P!2JI\[5]*>8% !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % ']$G_! [_FZ[_NA?_O8Z_FOZ0W_ #2'_=?_ />(?IGAU_S./^Z?_P"[
MI_1)7\UGZ8% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % 'G?Q$^$'PF^+VGVVD_%GX7_  [^*&E6;RR6
MFF?$3P3X:\:Z?:R3*$F>VLO$NF:E;0/*BJDK11J9% 5B0 * .=^'W[.7[/7P
MDNA??"KX$?!KX97H>:07?P^^%_@CP9="2X#B=Q<>'-#TV4/.))!,V[,@=PY.
MXY /9J "@ H :RJZLCJKHZE61@&5E88964\%2."",$<'B@#YNG_8S_8_NM>D
M\577[*7[-EQXGFN3>2^(Y_@7\+YM>ENRTCFZDUB3PLVH/<EYIF,[7!E+2R'=
MEVR ?1MO;V]I;P6MK!#;6MM#%;VUM;Q)#;V]O"BQPP00QJL<4,4:K'%%&JI&
MBJJJ% % $U #'1)$>.1%DCD5D>-U#(Z,-K(ZL"K*RDJRD$$'!&* /G/5_P!C
MC]D3Q!JR:_KW[*_[.&MZ[%()8]:U?X'?#'4M6CE#;Q(FHWGA>:\20,-P=9@V
M[G.: /=/#WAGPWX1TN#0_"GA_1/#&B6N?LVC^'M*L-%TNWW8W>1I^FV]M:0[
MMHSY<*YP,]!0!MT % !0 4 % !0 4 % 'BGQ%_9K_9T^,&HKK'Q;^ /P4^*6
MK)#';IJGQ%^%?@7QMJ*V\(*PP+>^)="U.Y6&)698XA*$C!(50": .K\#?"?X
M6?"^T^P?#3X:^ /AW8^6(OL7@;P;X=\)6GE+C$?V?0-.T^'RQ@839M&!@<4
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M"_/AK2=,^V 3.TP%QY@$K-(/F)- 'J% !0 4 <!\0?A/\+?BUID&B_%7X:^
M/B9H]K(\UMI/Q!\&^'?&>F6\TJ".26"P\1Z=J5K#))&!&[QQ*SH K$KQ0!QG
M@#]F']FKX3ZLFO\ PL_9Y^!OPUUV)76/6O 'PE\ ^#=6C62/R9%34?#N@:=>
M(KP_NG"S -'^[.5XH ]RH * "@ H * "@ H * "@ H * "@ H * /__0_OXH
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M7E]X N-+^)/A_P -3:E#:F9='T'XA7&@WUQ?O=3J;2TO=:\$^&;3>T4MZUC
M97@ /YT/@A\<_P!NG_@BK^W#>:GH<7BCX%_M$_ [Q3%X<^*?PI\4-(_AWQ?H
M_EVU_>^!OB%HNG7S:1XR\"^+=#OK;4=(U2PO;FWFL-2T?QOX%UVUODT'Q!"
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M!N+^UM;J]L[+4+YO"OPT\#:,D^F:?J7B?6+F?Q+XKOUTVWU/5?%OC'4K**_
M/VY'_!DG^V__ ,(1_:!_:\_97_X6-MS_ ,(DNG?%D^#<^5NV#Q^?!RZSN\W]
MWG_A7(7;^\W?\LZ /PB\'^/_ /@IA_P;[?MPW&E?\57\!?C/X,N=+U#Q7\/-
M6OKC5_@_\=_AY)=WT%@VM:?I>H1^&OBC\,O$T=OJL&C:_IUU_:.@ZG#>S:%J
MOA?QOH,LFD@'^MQ_P3X_;6^&W_!0[]C_ ."G[7/PMAETW0?BMX9:YUCPO=W$
M=SJ7@?QQH5_=^'?'G@?4I42(SS^&?%>EZKIUKJ#6]JFMZ3'IVOVMO'8ZK:Y
M/LV@ H * /\ &S_X.+?^4U?[?G_94O"__JI_A[0!_0]_P=P_\$_/MGP*_8S_
M ."DO@+1<SZ1\.?AU^SI^T%+8V_+:9>>'AKOP9\:ZBL*JJK9ZE+XK\":QK%Y
MOEF;5_AUHR2+%:V\= 'WK_P9M_M__P#"Y?V2_B7^P;XXUO[1X\_93UN3QK\+
MH;RXW7FI_ ?XEZQ=7E[I]FCM)<7,?P\^)MQJ\5_<.ZP6.E?$+P7H]I$D%D
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MW<UK>12V2@'RE^US_P $:?\ @K/_ ,&__C#PU^VY\'?B1;^(?!'@+6+2*/\
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M H * "@ H * "@ H _RLO^#Q7_E+S:_]FI?!7_T__$F@#^\S_@@)_P H:_\
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M=@#^IJ@#\KO^"X7_ "B%_P""BO\ V:E\5O\ TP34 ?YZ?_!H?_RF3\#_ /9
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ML/Q^_P#5B:A0!_2_0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?P@?M??\G9_M0_\ 9Q/Q
MK_\ 5E>):_T#X,_Y(_A3_LFLB_\ 57A3^>LZ_P"1SFW_ &,\?_ZE53YVKZ4\
MP* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * /Z)/^"!W_-UW_="_P#WL=?S7](;
M_FD/^Z__ .\0_3/#K_F<?]T__P!W3^B2OYK/TP* "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@!"0.M
M ";AZC_/M1_6W]?@ Z@!/_K?Y_2@!: "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@#Y?_;=^#_BS]H7]B_\ :[^ 7@*32(?'
M/QP_9@^/OP?\&2Z_>3:=H,7BSXE_"GQ9X+\.R:U?VUI?W%CI":OK5FVI7EO8
M7LUM9B::*TN7187 /Y9/^#<S_@@?^W'_ ,$K?VS?BU\>_P!IO5O@3?\ @?QM
M^S%XJ^$.C1?"_P ?>(?%6NKXKUGXJ_![QG9R7MAJ_@7PO;P:2-(\"ZTLUY'?
M33)>-8PK:.D\DT !_9W0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0!__1_OXH * "@ H * "@ H * "@ H * "@ H * "@ H
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MU+]L'_P%^"__ ,]2@#^+6X_X*&_#6Y_X+8+_ ,%.#X(\<1_"=?V[+7]J;_A
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MC /X._\ @X]_Y39?M\?]E$\"?^J5^&5 '^MO^R)_R:?^S!_V;Q\%?_5;>&J
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M0^-/$UUJWBC7;IR?.U35;DQK' (H8P#Z9_X?4_\ !)'_ *2-_L>_^'T\"_\
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M "@ H * "@ H * "@ H * "@ H _RLO^#Q7_ )2\VO\ V:E\%?\ T_\ Q)H
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!_"!^U]_P G9_M0_P#9
MQ/QK_P#5E>):_P! ^#/^2/X4_P"R:R+_ -5>%/YZSK_D<YM_V,\?_P"I54^=
MJ^E/,"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@#^B3_@@=_S==_W0O_WL=?S7
M](;_ )I#_NO_ /O$/TSPZ_YG'_=/_P#=T_HDK^:S],"@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MXF-"BIJZI1U:BUHIRD]'W5M-FD?BW%,/#')YU\OX:CF_$6(IR=/^U\9BH8;
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M[6-<^+WC[Q9IMM:>,?#6J>$M=2;0]=U:ZTRZ:?1=8OH(7F@9K:5TN(2LL:,
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M'IMCH^C:1IMM%9Z=I>E:9:Q66G:=86D"I!:V5C9P0VUK;0HD4$$4<4:JB@
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M(5(V.ZX=@#_:_H _RX?^#SK_ )2P?#/_ +,C^$7_ *MS]H"@#^Y/_@WY&/\
M@C-_P3ZQQ_Q8N#_U+/$] '[%T ?PJ?\ !\-_R17_ ()]?]E1^/7_ *B?PWH
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MB@!DFF?\'*DL;Q2Z?_P7(EBE1HY(I+3]O9XY(W4J\;HT95D=2596!5E)!&*
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * /X0/VOO^3L_P!J'_LXGXU_^K*\2U_H'P9_R1_"G_9-
M9%_ZJ\*?SUG7_(YS;_L9X_\ ]2JI\[5]*>8% !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % ']$G_  0._P";KO\ NA?_ +V.OYK^D-_S2'_=?_\ >(?IGAU_S./^
MZ?\ ^[I_1)7\UGZ8% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MXKAD'[J?P[\"]+U>V/9?](L?'L\."QQO#%.*WAGV"J?PZ&8U.W)@K_@JK?\
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M0V6[?9V]:K0\H* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@#__3_OXH * "@ H * "@ H * "@ H * "@ H * "@ H
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M: /\[_\ X/B?^2L_\$\/^R=_M$_^I+\): /W8_X-'O\ E##\+/\ LM7Q\_\
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MNOMWB/QE\>?"_BOQ!?;=GVS6_$/Q!L=7U6ZV9.W[1?7D\NW)V[\9XH _W?Z
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M?=""ZB@NH!<6EQ#*(;F"&>/?LFBCD5D !_BV_M(?\IM_CU_VE0^*/_K6VN4
M?[5% '^.O_P<7?L9>)OV+O\ @K'^TQ:RZ7<V/@+]H#QGJO[3_P )=:AM);/3
M=1T+XP:Q?^)O$UAI;*/(B/@SXD3>,/"1M;>4M;VVD:?=^5;6]_:1  _T3_\
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MCU:ST,:;:ZH+D+<G4(;EKA5F+J #]#J "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * /\K+_@\5_P"4O-K_ -FI?!7_ -/_ ,2:
M /[F/^""'Q(^'>G?\$=OV +"_P#'O@NQOK/X$Z?;7=G>>*=#MKJUN(?$7B&.
M:WN+>:^26":)U*212(KHP*LH(Q0!^F/CG]K?]E/X86%[JOQ*_::_9]^'NF:;
M"UQJ&H>-OC-\.?"ME8P1C+S75SKGB.QAMXUXRTKJO0=Q0!_/#_P42_X.QO\
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!_1)_P0._YNN_[H7_[V.OYK
M^D-_S2'_ '7_ /WB'Z9X=?\ ,X_[I_\ [NG]$E?S6?I@4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M:15D>V_X2;Q9-"'GT3PC97",IN50W^LW$$^FZ,AGBO+O3_)S3.,-E5%SG/\
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /__4_OXH * "@ H
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MIJGA75?$=YX>U2V5AMETW6-)O+-F4"6V)08 /]6?_@WO_:S^/O[;?_!*_P"
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M$?A+Q9I%GKWAS7=.E94:2PU?1[^SO[1V1&:WN(V*J3@ '64 % !0 4 % !0
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M * "@#^5_P#X.F_^";_[9W_!1WX"_LJ^#?V,O@X/C'XF^&OQ=\:>)O&FE?\
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M7QCX$@E$QTC1==\0Z)XPT&VDL="LE\:%&U&( _%WX1?L=_\ !RQ^SI:GX2?
M;X7_ /!5KX+>&Y'N/^*8^$NN?'[P+\.4FED(GN8KKP?KVG> K:Y=V9A?17D4
M[!GDCGVLS$ _6;_@GG_P:H_MT?M:?&;2?C__ ,%:?%OBKX;_  XFO;3Q#XK\
M)>)?B:/B7^TY\8C!-%+;Z#KGB.WUCQ3;?#[1-3@#KK>MZYXDOO'EE;9TJP\*
MZ9?WHU_0P#^<7]O_ ,'^#6_X*U?M9_#/X3:#HGA?P)I?[=GQ5^%OP^\.>%K2
MVLO#NB>'O#OQJU7P+X>TSP_962K9V^CV=IIUM#I<%JOV=;-85BRFTD _VTJ
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MXGM5D6&\BMKE7A0 _<:@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H _A _:^_Y.S_:A_P"S
MB?C7_P"K*\2U_H'P9_R1_"G_ &361?\ JKPI_/6=?\CG-O\ L9X__P!2JI\[
M5]*>8% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % ']$G_! [_FZ[_NA?_O8Z_FO
MZ0W_ #2'_=?_ />(?IGAU_S./^Z?_P"[I_1)7\UGZ8% !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M>%M0^('Q(\6Z#I>I:_9:1K6F6$UYX2\,>$](M+R[M=K^--2TAIK&^ /Y;/\
M@F/_ ,I)O^">_P#V?#^R=_ZOGP#0!_N+T ?A7^T-_P $%OV5?VQ?^"EM_P#\
M% OVM,?&CPYI'PH^&_@'P!^S?JFF267P_B\1>"KCQ!->^+OB3<PZD\_Q!L95
MU.Q71O!4UMI?AD/#?_\ "5VOBNRN8-/M@#]N/#7ACPUX+T#2?"G@[P]H?A/P
MOH%E#IFA>&_#6DV&A:!HNG6R[+?3])T?2[>UT[3K*!/EAM+.VA@B7Y4C4<4
M?QD_\'F/[%_P2U[]CGX;?MO:?X5T'P]^T!\._C3X/^%^L^,]/M;'3-5^(/PT
M\>:!XE1O#GB>6WMX[KQ1?^%]>\/>'M2\(W.H7$\OAS1W\76ED@M=6G\D _G4
M_P"#1#Q1XGT#_@LGX'TC07O%TGQO\ _CMX9\:I;-M@D\-6?AZP\9V:Z@O\=H
MOC'PEX4>,=1?+9MT!H _U?: /E?]EK]B3]E;]BSP_P")/#O[,OP5\'_"R'QK
MXDUGQ=XWUK2K:XU'QAXV\1Z]JEYK%_J7C#QOKEQJ?BWQ*T=[?7"Z7;:QK-W9
M:'9&+3-$MM/TV""UC /H/QEX,\(_$3PIX@\"^/?#&@^-/!?BS2KS0O$_A/Q1
MI-CKOAWQ!HVH1-!>Z7K&CZE!<V&H6-U"QCFMKJ"2)UZKP* /\/S_ (*-_!GX
M>?LZ_M^?MG_ ;X2RA_AE\(/VG?C9\._ EO\ ;+G49-)\+^%/B#KVD:1X=N=1
MO7DN]1O?#%I:Q^';Z_N9))KV\TN>YDD=I2Q /];/_@@G:>)[+_@CE_P3TA\7
M32SZJ_[.OAF[M'F:1G7PO?W^K7W@B$&5F816_@NXT"W@4'RD@BC2%5A6-0 ?
MKK0 4 % 'Q+^U_\ \%%_V,?V"[WX0:;^UA\=O"7P@O\ XZ>-;;P+\.[377NY
MY[Z]E>**\\0ZO%IUM=OX:\ Z!-<V$'B?X@>(%T[PAX;FU+38]9UBS-Y#N /M
M.VN;>\M[>\LYX;JTNH8KFUNK:6.>WN;>>-98)[>:)FBFAFB99(I8V:.2-E=&
M*D&@">@#XAM/^"CO[%=]^VC>?\$^+3X^>#)_VM+#P<?&=Q\+$GN#.($B-]/X
M8CU[R/\ A'9?B%::"!XKN_AW%JC>,K?P@3XGDT9=&BFNX@#[>H * "@#\N/^
M"R/_  4,TK_@F-^P#\9OVFD;3KCXD"UMOAQ\!=!U.,3VGB'XW>.8+ZU\&Q7-
MFS1KJ&E^&+:RUGX@^(].\^VDO_"W@W7+2VGCNYK?(!_CGZ-I/[0O[<?[2UEI
M%C_PEGQS_:6_:7^**PK+=W']H>*/'_Q'\>ZT7GO=0OKEX;6W%S?W<MYJ&H74
MEEH^B:;%/=W4NGZ382/  ?ZD?_!)K_@V@_8D_8'\ ^%?&'Q^^'_@7]J_]K2Z
ML;?4?%GQ ^)'A^W\5?#CP)K%S#%+-X=^$7P]\1PW7AVTLM!F46]IX_U_1KKQ
MYJ]U'<ZM:77A33M0B\*Z8 ?TB0Z1I5MID6B6^F:?!HT%HFGPZ1#96T6F0V$<
M8ACL8K!(UM([1(0(DMDB$*Q@($"C% 'YT?'C_@D+_P $Y_VB_BG\-/CGX_\
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M5/!_C;0]+M@6FN=9^(FJ2* CM0!_?)0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % ')>/O'G@WX6>!O&7Q,^(OB32?!
MOP_^'OA?7O&WC?Q=K]VEAH?A?PEX7TNZUKQ#X@UB]D_=VFF:/I-E=W]]</\
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M9CC2,ZSXUT^'-O%(TT0!_LH4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '\('[7W_)V?
M[4/_ &<3\:__ %97B6O] ^#/^2/X4_[)K(O_ %5X4_GK.O\ D<YM_P!C/'_^
MI54^=J^E/,"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#^B3_@@=_S==_W0O\
M]['7\U_2&_YI#_NO_P#O$/TSPZ_YG'_=/_\ =T_HDK^:S],"@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M3\9;?]I?7?$5U\+OB%X3\>0^'YOAAI^FV^LMX7UFSU=-,EU%/&U[)91WAM3
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M32K[PUI.D>#K^UWQ:MX2^%VDZQXIL)_$-O<S:5XJ\4>(KYM+BETOPKHVNZX
M?27_  98_L+^+M1^+/[0/_!0WQ3I]]IG@+PMX)O?V</A/)=V3Q6GB_QCXKU;
MPWXK^(VNZ7<RQJ9(/ FA^&_#_AZ2:W9[6ZO/'>H6GF?:M#NHHP#_ $1: /P)
M_P""N_\ P7^^!?\ P2"^*OPN^$OQ4^!/Q9^+.L_%3X<WOQ&T?4OA]JO@_3M,
MTZRL_$>H^&O[-U+_ (2/4;6Z^U276G//YMK;SPK;R)]Z0%* /YF/VP?^#U?X
MM^/?A]KO@G]C+]E'2_@?XJU[3=4TI?C!\6?'D?Q)USPQ%J%H]G#J_@_P'H7A
MSPQX?M/%.EF0W^E:EXFU[Q;H,%]%;B_\*:K;)+#, ?C[_P $E?\ @@Q^V?\
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M^T/XE:!@X?R_$S21D&&@#_3FH * "@#YG_;3_P"3./VLO^S9_CO_ .JM\54
M?X?7P!_Y+O\ !3_LK?PW_P#4QT:@#_>=H * /YK/^#LCX'>'_BQ_P1F^-/C?
M4+*"?Q%^SM\1?@I\7/"%R;:.2[MKS4_B1H/P?U^."Y(\VV@E\)?%'7+FZ1&\
MNX-A;B5&:*%XP#_/+_X(+_$+4OAC_P %BO\ @GIXBTN_ETVXU3]HWPG\/)IX
M6V-+IOQ:MM1^%FK:>W8Q:II?C&[TZ9/XHKI@,'! !_M#T ?R2?ML?\';W[-7
M[&/[2OQY_9=U3]DSXY>/?&_P'^(>N_#K5=;T_P 6^ = \*:_J.@S"&>_T^YN
M)M4U>ULIV(,(N-':<+G?&",$ _F$_P""K_\ P=&?M2?\%*_A9KW[*WP6^#NG
M?LP_ KXC3:=I'C;3=$\6:O\ $3XS?%#3O-53X(O_ !;::3X2TG2O!WB.^:V_
MMGPIX?\ "$NKZ[';P:%?>*;[P_?ZSHNK 'Z4_P#!MW_P;E?'GPO\>/AK_P %
M!_V\/ LGPK\,_"B^@\:? #X">+[2"3Q[XP\<_P!G&;PI\3_'&CK</)X#T+P)
M?74'B'PCH.LI!XQU3QGI6G:IJ.DZ%H6CVK>*@#_0MH ^&?\ @IK^SI;_ +6?
M_!/C]L;]GB2VBN=0^)G[/OQ(TSPLLX4PP>/M*\/W7B/X<W\@;@II?CS1O#FI
M, 48BTPDD;;9% /\H+_@WT_:!U#]G'_@L3^PIXLM9918>/?C-I7P"UZS1ML%
M_IG[0EI>?!RV6\&5#6^E:]XQT7Q$F6 CN]%M9B&$6Q@#_9CH * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % ']$G_  0._P";KO\ NA?_
M +V.OYK^D-_S2'_=?_\ >(?IGAU_S./^Z?\ ^[I_1)7\UGZ8% !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M%U!#<VLT5Q;7$4<]O<02)+!/!*@DBFAEC+1RQ2QLKQR(Q1T(925(- $M !0
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MM_#?_P!3'1J /]YV@ H _F\_X.O?C/H7PK_X(N?'KPIJ-VEMKOQ\\?\ P/\
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M?#KV+V[#F1IVTZ)H2.6++CK0!_N74 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 ?P@?M??\ )V?[4/\ V<3\:_\ U97B6O\ 0/@S_DC^%/\ LFLB
M_P#57A3^>LZ_Y'.;?]C/'_\ J55/G:OI3S H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H _HD_X('?\W7?]T+_]['7\U_2&_P":0_[K_P#[Q#],\.O^9Q_W3_\
MW=/Z)*_FL_3 H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MPOY?F?EE_P $%!_QGS8?]D@^(_Z/X>-;3_A?]Q(_^DR"'PM>?Y(_MTKG*"@
MH PO%'_(L^(O^P%J_P#Z;[BFMUZH-EZ'^8*W^L?Z_P!6K<QE*]M+6/H.V_;
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M 5E*(Y/+:"XN;CQ=J5W:3JS++9:!> 1@0;](1V?]=C.4OLV.1_X-V_V=S?\
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MTE;NK_B;+9>B_(_:6D,* "@ H * "@ H * "@ H * "@ H * "@#_]#^_B@
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MH+#6]+OK(7UC+/87?D?:;&YN;.6">0 _QR_^"[?_ "F%_P""A_\ V<QXY_\
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M?7;&YT'QOX&UB6W60PVGB3PUJ&H6=K?FVNVT/5_[,\0VMK-?:1:+0!_L>?L
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#
M^$#]K[_D[/\ :A_[.)^-?_JRO$M?Z!\&?\D?PI_V361?^JO"G\]9U_R.<V_[
M&>/_ /4JJ?.U?2GF!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!_1)_P $#O\
MFZ[_ +H7_P"]CK^:_I#?\TA_W7__ 'B'Z9X=?\SC_NG_ /NZ?T25_-9^F!0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MA_PWX?TF!;:PTS3+"V58X888UR[G=-<3-+<W,LUS-+*X!W5 'X0:5_P;J_\
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M>W^('C[2;[X6_#K0[E\%%U>[M?$?C3Q?H:,!M?P#>WB.LUE$& /]5J@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M.O!7_/G//_"##_\ S<'^H>=_S8'_ ,'U/_E ?\.3_P!L7_H)_!C_ ,+;7?\
MYC*/^(Z\%?\ /G//_"##_P#S<'^H>=_S8'_P?4_^4!_PY/\ VQ?^@G\&/_"V
MUW_YC*/^(Z\%?\^<\_\ "##_ /S<'^H>=_S8'_P?4_\ E ?\.3_VQ?\ H)_!
MC_PMM=_^8RC_ (CKP5_SYSS_ ,(,/_\ -P?ZAYW_ #8'_P 'U/\ Y0'_  Y/
M_;%_Z"?P8_\ "VUW_P"8RC_B.O!7_/G//_"##_\ S<'^H>=_S8'_ ,'U/_E
M?\.3_P!L7_H)_!C_ ,+;7?\ YC*/^(Z\%?\ /G//_"##_P#S<'^H>=_S8'_P
M?4_^4!_PY/\ VQ?^@G\&/_"VUW_YC*/^(Z\%?\^<\_\ "##_ /S<'^H>=_S8
M'_P?4_\ E ?\.3_VQ?\ H)_!C_PMM=_^8RC_ (CKP5_SYSS_ ,(,/_\ -P?Z
MAYW_ #8'_P 'U/\ Y0'_  Y/_;%_Z"?P8_\ "VUW_P"8RC_B.O!7_/G//_"#
M#_\ S<'^H>=_S8'_ ,'U/_E ?\.3_P!L7_H)_!C_ ,+;7?\ YC*/^(Z\%?\
M/G//_"##_P#S<'^H>=_S8'_P?4_^4!_PY/\ VQ?^@G\&/_"VUW_YC*/^(Z\%
M?\^<\_\ "##_ /S<'^H>=_S8'_P?4_\ E ?\.3_VQ?\ H)_!C_PMM=_^8RC_
M (CKP5_SYSS_ ,(,/_\ -P?ZAYW_ #8'_P 'U/\ Y0'_  Y/_;%_Z"?P8_\
M"VUW_P"8RC_B.O!7_/G//_"##_\ S<'^H>=_S8'_ ,'U/_E ?\.3_P!L7_H)
M_!C_ ,+;7?\ YC*/^(Z\%?\ /G//_"##_P#S<'^H>=_S8'_P?4_^4!_PY/\
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M.O!7_/G//_"##_\ S<'^H>=_S8'_ ,'U/_E ?\.3_P!L7_H)_!C_ ,+;7?\
MYC*/^(Z\%?\ /G//_"##_P#S<'^H>=_S8'_P?4_^4!_PY/\ VQ?^@G\&/_"V
MUW_YC*/^(Z\%?\^<\_\ "##_ /S<'^H>=_S8'_P?4_\ E ?\.3_VQ?\ H)_!
MC_PMM=_^8RC_ (CKP5_SYSS_ ,(,/_\ -P?ZAYW_ #8'_P 'U/\ Y0'_  Y/
M_;%_Z"?P8_\ "VUW_P"8RC_B.O!7_/G//_"##_\ S<'^H>=_S8'_ ,'U/_E
M?\.3_P!L7_H)_!C_ ,+;7?\ YC*/^(Z\%?\ /G//_"##_P#S<'^H>=_S8'_P
M?4_^4!_PY/\ VQ?^@G\&/_"VUW_YC*/^(Z\%?\^<\_\ "##_ /S<'^H>=_S8
M'_P?4_\ E ?\.3_VQ?\ H)_!C_PMM=_^8RC_ (CKP5_SYSS_ ,(,/_\ -P?Z
MAYW_ #8'_P 'U/\ Y0'_  Y/_;%_Z"?P8_\ "VUW_P"8RC_B.O!7_/G//_"#
M#_\ S<'^H>=_S8'_ ,'U/_E ?\.3_P!L7_H)_!C_ ,+;7?\ YC*/^(Z\%?\
M/G//_"##_P#S<'^H>=_S8'_P?4_^4!_PY/\ VQ?^@G\&/_"VUW_YC*/^(Z\%
M?\^<\_\ "##_ /S<'^H>=_S8'_P?4_\ E ?\.3_VQ?\ H)_!C_PMM=_^8RC_
M (CKP5_SYSS_ ,(,/_\ -P?ZAYW_ #8'_P 'U/\ Y0'_  Y/_;%_Z"?P8_\
M"VUW_P"8RC_B.O!7_/G//_"##_\ S<'^H>=_S8'_ ,'U/_E ?\.3_P!L7_H)
M_!C_ ,+;7?\ YC*/^(Z\%?\ /G//_"##_P#S<'^H>=_S8'_P?4_^4!_PY/\
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M.O!7_/G//_"##_\ S<'^H>=_S8'_ ,'U/_E ?\.3_P!L7_H)_!C_ ,+;7?\
MYC*/^(Z\%?\ /G//_"##_P#S<'^H>=_S8'_P?4_^4!_PY/\ VQ?^@G\&/_"V
MUW_YC*/^(Z\%?\^<\_\ "##_ /S<'^H>=_S8'_P?4_\ E ?\.3_VQ?\ H)_!
MC_PMM=_^8RC_ (CKP5_SYSS_ ,(,/_\ -P?ZAYW_ #8'_P 'U/\ Y0'_  Y/
M_;%_Z"?P8_\ "VUW_P"8RC_B.O!7_/G//_"##_\ S<'^H>=_S8'_ ,'U/_E
M?\.3_P!L7_H)_!C_ ,+;7?\ YC*/^(Z\%?\ /G//_"##_P#S<'^H>=_S8'_P
M?4_^4!_PY/\ VQ?^@G\&/_"VUW_YC*/^(Z\%?\^<\_\ "##_ /S<'^H>=_S8
M'_P?4_\ E ?\.3_VQ?\ H)_!C_PMM=_^8RC_ (CKP5_SYSS_ ,(,/_\ -P?Z
MAYW_ #8'_P 'U/\ Y0'_  Y/_;%_Z"?P8_\ "VUW_P"8RC_B.O!7_/G//_"#
M#_\ S<'^H>=_S8'_ ,'U/_E ?\.3_P!L7_H)_!C_ ,+;7?\ YC*/^(Z\%?\
M/G//_"##_P#S<'^H>=_S8'_P?4_^4!_PY/\ VQ?^@G\&/_"VUW_YC*/^(Z\%
M?\^<\_\ "##_ /S<'^H>=_S8'_P?4_\ E ?\.3_VQ?\ H)_!C_PMM=_^8RC_
M (CKP5_SYSS_ ,(,/_\ -P?ZAYW_ #8'_P 'U/\ Y0'_  Y/_;%_Z"?P8_\
M"VUW_P"8RC_B.O!7_/G//_"##_\ S<'^H>=_S8'_ ,'U/_E ?\.3_P!L7_H)
M_!C_ ,+;7?\ YC*/^(Z\%?\ /G//_"##_P#S<'^H>=_S8'_P?4_^4!_PY/\
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M.O!7_/G//_"##_\ S<'^H>=_S8'_ ,'U/_E ?\.3_P!L7_H)_!C_ ,+;7?\
MYC*/^(Z\%?\ /G//_"##_P#S<'^H>=_S8'_P?4_^4!_PY/\ VQ?^@G\&/_"V
MUW_YC*/^(Z\%?\^<\_\ "##_ /S<'^H>=_S8'_P?4_\ E ?\.3_VQ?\ H)_!
MC_PMM=_^8RC_ (CKP5_SYSS_ ,(,/_\ -P?ZAYW_ #8'_P 'U/\ Y0'_  Y/
M_;%_Z"?P8_\ "VUW_P"8RC_B.O!7_/G//_"##_\ S<'^H>=_S8'_ ,'U/_E
M?\.3_P!L7_H)_!C_ ,+;7?\ YC*/^(Z\%?\ /G//_"##_P#S<'^H>=_S8'_P
M?4_^4!_PY/\ VQ?^@G\&/_"VUW_YC*/^(Z\%?\^<\_\ "##_ /S<'^H>=_S8
M'_P?4_\ E ?\.3_VQ?\ H)_!C_PMM=_^8RC_ (CKP5_SYSS_ ,(,/_\ -P?Z
MAYW_ #8'_P 'U/\ Y0'_  Y/_;%_Z"?P8_\ "VUW_P"8RC_B.O!7_/G//_"#
M#_\ S<'^H>=_S8'_ ,'U/_E ?\.3_P!L7_H)_!C_ ,+;7?\ YC*/^(Z\%?\
M/G//_"##_P#S<'^H>=_S8'_P?4_^4!_PY/\ VQ?^@G\&/_"VUW_YC*/^(Z\%
M?\^<\_\ "##_ /S<'^H>=_S8'_P?4_\ E ?\.3_VQ?\ H)_!C_PMM=_^8RC_
M (CKP5_SYSS_ ,(,/_\ -P?ZAYW_ #8'_P 'U/\ Y0'_  Y/_;%_Z"?P8_\
M"VUW_P"8RC_B.O!7_/G//_"##_\ S<'^H>=_S8'_ ,'U/_E ?\.3_P!L7_H)
M_!C_ ,+;7?\ YC*/^(Z\%?\ /G//_"##_P#S<'^H>=_S8'_P?4_^4!_PY/\
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M.O!7_/G//_"##_\ S<'^H>=_S8'_ ,'U/_E ?\.3_P!L7_H)_!C_ ,+;7?\
MYC*/^(Z\%?\ /G//_"##_P#S<'^H>=_S8'_P?4_^4!_PY/\ VQ?^@G\&/_"V
MUW_YC*/^(Z\%?\^<\_\ "##_ /S<'^H>=_S8'_P?4_\ E ?\.3_VQ?\ H)_!
MC_PMM=_^8RC_ (CKP5_SYSS_ ,(,/_\ -P?ZAYW_ #8'_P 'U/\ Y0'_  Y/
M_;%_Z"?P8_\ "VUW_P"8RC_B.O!7_/G//_"##_\ S<'^H>=_S8'_ ,'U/_E
M?\.3_P!L7_H)_!C_ ,+;7?\ YC*/^(Z\%?\ /G//_"##_P#S<'^H>=_S8'_P
M?4_^4!_PY/\ VQ?^@G\&/_"VUW_YC*/^(Z\%?\^<\_\ "##_ /S<'^H>=_S8
M'_P?4_\ E ?\.3_VQ?\ H)_!C_PMM=_^8RC_ (CKP5_SYSS_ ,(,/_\ -P?Z
MAYW_ #8'_P 'U/\ Y0'_  Y/_;%_Z"?P8_\ "VUW_P"8RC_B.O!7_/G//_"#
M#_\ S<'^H>=_S8'_ ,'U/_E ?\.3_P!L7_H)_!C_ ,+;7?\ YC*/^(Z\%?\
M/G//_"##_P#S<'^H>=_S8'_P?4_^4'ZS_P#!+G]B?XQ?L=_\+R_X6S=>#+G_
M (6)_P *S_L#_A$-;O\ 6-G_  B/_"P?[5_M#[;HND?9MW_"3Z;]D\K[1YNV
MYW^5Y2>9^/>+''62<:_V!_8\,=#^S/[4^L?7*%.A?ZY_9WL?9^SKUN:WU2KS
MWY>7W+7OI]EPED..R3^T/KCH/ZS]4]G[&I*?\'ZSS\UX0M_%C:U[Z[6/UHK\
M>/L@H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H _ /_@E[))\,OV^?^"E7P-U8K;7VH^/HOB#X?MG9?.GT"U\<>-9%OL<R
M;;O1_'_A*Z'RXB%Q@[=Z[OD\AER9MGV&E+6.(5:,;6]VI%3C*]MFIQDDVVKM
M?W3^F/&'#K,O#'PDXFI6]E')X975M=J-2G0C"5WW]MAJL';[2:V/W[!!Z5]8
M?S,FGL<=X\\#>$OB/X1U[P)XXT#3_$_A'Q3I=YHFOZ#JD N;'4M,OHFAN+>>
M,D.#AO-AGB=)[:XCBNK>2.YAAD6*D(U(2I3A&4)KEDI+2WRU^[MNCLR_,,=E
M6-PV8Y;B:F$QN$J1K4,12DXSISAJK6:NI?#)/W91O&2<6T?RR^"_^"??P^^%
MO_!8/X7?!'P%XBUGQ1\/_!ME8_M$:MI^I);G5/!,&AG4-;\-^$]0U*)B-7M;
M?Q%#X-_TZYMK6\FTG6K*WE6>\\W49OA:634,-Q%1H8?7#VEB*T9?9?+S02>F
MG-:UM4FM$T?VSF'BGF^>> >:9]F]"GA\RQG-P_A9T6XK%NI66$Q&*C%N?)*,
M>:\6[7CHVK3?]8JO'&@#$)LP#G@+NSMY.!SCKW.1UXK[VR6B5DM%Z(_AN*O:
M*3;O9+=OM]YQ_B_XE_#KX?:>^K>//'G@[P5I<2-))J7BSQ)H_AVPC1%W.SW>
MK7EI H11N;+C:O)XJ)5*<':=2G!_WZD(:?\ ;S1Z.#RC-<QFJ> RS'XR;T4<
M+@\17;VV]G3EM=7[7/P>_;=_X+<_#OP7HVL> /V2+N'XB^/[J&XL)?BE<6,Z
M_#_P@7,\#W6A6VH6]O/XUURW>))+*5;=?"*"5+E[S74C?39_D\WXJPV'4J&!
M<:E:4;.HT_94[+1QON[[IJVWR_I;PU^C=G.:8C"YEQO3EEF5J7MO[,IU:4L?
MB4G[BJ2@Y0PU"5OA3E5DM+TV?RO>(=?USQ;K^L>*O%&L:CXA\2^(=1N]8U[7
MM7NY[[5=9U:_G>YOM2U&\N7DN+N]N[B226:XG=YG+'<V.*_-J]:O6K2Q-:?M
M:DI.3?G*5]+I:)VM?;MT/[IP&5X'+,#A,LP&'IX7 8/#4</0P]*/)3IPH4XT
MX145VA&*<M7YWU,@<_R_I^M8?$_-]-%K^1WW26W*MK?ATO\ TS^CG_@WF\)O
M<>+_ -ICQVT<RPZ;X<^'?A*UF*.MO++K&J^)M4O8T8KL>6V&@V1D5<M&MQ%O
M"K*F_P#0>"*4H+&UG&T9..'4M-9Q49\J7DIQ=[6L]'V_C/Z6N9T_9<*9*I+V
MO-C,RG%I^[2DWA(S;TT<Z%6,4GKR2MLC^I4 #I_G%??'\6#J "@#G/%_A+P]
MX[\+>)/!7BO38=8\,^+M!U?PQXATJXW>1J6B:[I]SI>J6,VPJPCNK&[GA8J5
M9=X="KJC* ?Y['[=/['7CG]BSX[Z_P##+Q%;7][X0OI[O7/A9XSDA9;'QKX(
MFN<:=="2/_0FU[1DEBTWQ/IUOD:7JJM+ O\ 9M[IUW=[II[&4DE:W];'Z<?\
M$Q/^"R3?LZ^'-"_9_P#VF$UOQ!\(M(,5AX$^(FG13ZSXD^'.FSW$2KX?UW39
M)DO-?\%:<TKOI/\ 9L=QKOA>R#:-INGZQI,6G6NF3*/9:CC+N]+']2OPF_:G
M_9R^.6E6>K?"?XV?#;QO#>P^>EEI'BG3%URWCSPNH^&KV:T\1Z3-M*MY&J:5
M93[623RMCH3GRM="^:/<]KN]9TC3[?[5?ZIIUC:A=QN;R\M[6W51W::>2.-1
MCU84@NN_E]Q_&5_P7Z\>^!O'W[6?PRNO OC+PKXSM=%^ >BZ+K%QX4\0Z3X@
MATG68_B)\1KV72=3DTF[NTL-3CL[RSN9+"Z,5U';W-O*T2I,A;6":3[.WX7,
MYM:6Z?\  /NG_@V^_P"1#_:J'IXL^%6/_!1XXI3Z?/\ 0N*22MV1_2]691_'
M7_P<1Y_X:Z^#>.G_  SEI&?_  YOQ(%:PV^?Z(RGNO0^FO\ @VV_Y ?[8/\
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M>'K0JGW%-MI%G9PE4_@&S"]@* .KH * "@ H * "@ H * "@ H * "@ H *
M"@#A_&GPQ^&WQ(MEL_B)\/? _CVS2-H4M/&GA/0?%-LL+$EHE@URPOHEC8DE
MD"A2221S0!Y/X:_8X_9#\%ZQ#XA\'?LK?LW^$]?MYX[FWUSPU\#OACH6L07,
M0"Q7$.IZ7X7M;V*>-558Y4F61  %8 "@#Z0H * "@ H * "@ H * "@ H *
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MWX59!^.'[&7AUO&O_!2W_@H]\;;NU1T\+:EX ^">@:EC+DZ=HME%XFTY&/\
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@#R7X[_!SPW^T+\&OB7\#?&.K^,-"
M\(?%?P?K/@7Q3J7@'Q'=>$/%\?ASQ#:MI^MVNB^);%'O='FU+3);G39[NT N
M%L[NY2%XI'61 #\:OV2O^#:W_@E5^QG\>_ 7[2/PK^%GC[7?B;\,-1DUSP'-
M\3/B3J_C?P]X=\2?99[6Q\3V_ANZMK73+G7]#-PU]X>OM0BN_P"PM8BL]=TR
M.WUG3M.OK0 _>^@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MB@ "8[M]-S8_F: '4 +0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M'__4_OXH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M,8TX12=N6G3IPA3I0BE&%.,81]U(]#K4\P* "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H _]7^_B@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '__6_OXH * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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MT_[7_P#X2OB+_P"B"H /^(27XI?])I_VO_\ PE?$7_T05 !_Q"2_%+_I-/\
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M_2:?]K__ ,)7Q%_]$%0 ?\0DOQ2_Z33_ +7_ /X2OB+_ .B"H /^(27XI?\
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M /PE?$7_ -$%0 ?\0DOQ2_Z33_M?_P#A*^(O_H@J #_B$E^*7_2:?]K_ /\
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M$%0 ?\0DOQ2_Z33_ +7_ /X2OB+_ .B"H /^(27XI?\ 2:?]K_\ \)7Q%_\
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M_I-/^U__ .$KXB_^B"H /^(27XI?])I_VO\ _P )7Q%_]$%0 ?\ $)+\4O\
MI-/^U_\ ^$KXB_\ H@J #_B$E^*7_2:?]K__ ,)7Q%_]$%0 ?\0DOQ2_Z33_
M +7_ /X2OB+_ .B"H /^(27XI?\ 2:?]K_\ \)7Q%_\ 1!4 '_$)+\4O^DT_
M[7__ (2OB+_Z(*@ _P"(27XI?])I_P!K_P#\)7Q%_P#1!4 '_$)+\4O^DT_[
M7_\ X2OB+_Z(*@ _XA)?BE_TFG_:_P#_  E?$7_T05 !_P 0DOQ2_P"DT_[7
M_P#X2OB+_P"B"H /^(27XI?])I_VO_\ PE?$7_T05 !_Q"2_%+_I-/\ M?\
M_A*^(O\ Z(*@ _XA)?BE_P!)I_VO_P#PE?$7_P!$%0 ?\0DOQ2_Z33_M?_\
MA*^(O_H@J #_ (A)?BE_TFG_ &O_ /PE?$7_ -$%0 ?\0DOQ2_Z33_M?_P#A
M*^(O_H@J #_B$E^*7_2:?]K_ /\ "5\1?_1!4 '_ !"2_%+_ *33_M?_ /A*
M^(O_ *(*@ _XA)?BE_TFG_:__P#"5\1?_1!4 '_$)+\4O^DT_P"U_P#^$KXB
M_P#H@J #_B$E^*7_ $FG_:__ /"5\1?_ $05 !_Q"2_%+_I-/^U__P"$KXB_
M^B"H /\ B$E^*7_2:?\ :_\ _"5\1?\ T05 !_Q"2_%+_I-/^U__ .$KXB_^
MB"H /^(27XI?])I_VO\ _P )7Q%_]$%0 ?\ $)+\4O\ I-/^U_\ ^$KXB_\
MH@J #_B$E^*7_2:?]K__ ,)7Q%_]$%0 ?\0DOQ2_Z33_ +7_ /X2OB+_ .B"
MH /^(27XI?\ 2:?]K_\ \)7Q%_\ 1!4 '_$)+\4O^DT_[7__ (2OB+_Z(*@
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M  E?$7_T05 !_P 0DOQ2_P"DT_[7_P#X2OB+_P"B"H /^(27XI?])I_VO_\
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M $05 !_Q"2_%+_I-/^U__P"$KXB_^B"H /\ B$E^*7_2:?\ :_\ _"5\1?\
MT05 !_Q"2_%+_I-/^U__ .$KXB_^B"H /^(27XI?])I_VO\ _P )7Q%_]$%0
M ?\ $)+\4O\ I-/^U_\ ^$KXB_\ H@J #_B$E^*7_2:?]K__ ,)7Q%_]$%0
M?\0DOQ2_Z33_ +7_ /X2OB+_ .B"H /^(27XI?\ 2:?]K_\ \)7Q%_\ 1!4
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M (2OB+_Z(*@ _P"(27XI?])I_P!K_P#\)7Q%_P#1!4 '_$)+\4O^DT_[7_\
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M /\ B$E^*7_2:?\ :_\ _"5\1?\ T05 !_Q"2_%+_I-/^U__ .$KXB_^B"H
M/^(27XI?])I_VO\ _P )7Q%_]$%0 ?\ $)+\4O\ I-/^U_\ ^$KXB_\ H@J
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M_:__ /"5\1?_ $05 !_Q"2_%+_I-/^U__P"$KXB_^B"H /\ B$E^*7_2:?\
M:_\ _"5\1?\ T05 !_Q"2_%+_I-/^U__ .$KXB_^B"H /^(27XI?])I_VO\
M_P )7Q%_]$%0 ?\ $)+\4O\ I-/^U_\ ^$KXB_\ H@J #_B$E^*7_2:?]K__
M ,)7Q%_]$%0 ?\0DOQ2_Z33_ +7_ /X2OB+_ .B"H /^(27XI?\ 2:?]K_\
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M !_Q"2_%+_I-/^U__P"$KXB_^B"H /\ B$E^*7_2:?\ :_\ _"5\1?\ T05
M!_Q"2_%+_I-/^U__ .$KXB_^B"H /^(27XI?])I_VO\ _P )7Q%_]$%0 ?\
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M .$KXB_^B"H /^(27XI?])I_VO\ _P )7Q%_]$%0 ?\ $)+\4O\ I-/^U_\
M^$KXB_\ H@J #_B$E^*7_2:?]K__ ,)7Q%_]$%0 ?\0DOQ2_Z33_ +7_ /X2
MOB+_ .B"H /^(27XI?\ 2:?]K_\ \)7Q%_\ 1!4 '_$)+\4O^DT_[7__ (2O
MB+_Z(*@ _P"(27XI?])I_P!K_P#\)7Q%_P#1!4 '_$)+\4O^DT_[7_\ X2OB
M+_Z(*@ _XA)?BE_TFG_:_P#_  E?$7_T05 !_P 0DOQ2_P"DT_[7_P#X2OB+
M_P"B"H /^(27XI?])I_VO_\ PE?$7_T05 !_Q"2_%+_I-/\ M?\ _A*^(O\
MZ(*@ _XA)?BE_P!)I_VO_P#PE?$7_P!$%0 ?\0DOQ2_Z33_M?_\ A*^(O_H@
MJ #_ (A)?BE_TFG_ &O_ /PE?$7_ -$%0 ?\0DOQ2_Z33_M?_P#A*^(O_H@J
M #_B$E^*7_2:?]K_ /\ "5\1?_1!4 '_ !"2_%+_ *33_M?_ /A*^(O_ *(*
M@ _XA)?BE_TFG_:__P#"5\1?_1!4 '_$)+\4O^DT_P"U_P#^$KXB_P#H@J #
M_B$E^*7_ $FG_:__ /"5\1?_ $05 !_Q"2_%+_I-/^U__P"$KXB_^B"H /\
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M /"5\1?_ $05 !_Q"2_%+_I-/^U__P"$KXB_^B"H /\ B$E^*7_2:?\ :_\
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MT_[7_P#X2OB+_P"B"H /^(27XI?])I_VO_\ PE?$7_T05 !_Q"2_%+_I-/\
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M_2:?]K__ ,)7Q%_]$%0 ?\0DOQ2_Z33_ +7_ /X2OB+_ .B"H /^(27XI?\
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M /PE?$7_ -$%0 ?\0DOQ2_Z33_M?_P#A*^(O_H@J #_B$E^*7_2:?]K_ /\
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M$%0 ?\0DOQ2_Z33_ +7_ /X2OB+_ .B"H /^(27XI?\ 2:?]K_\ \)7Q%_\
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M_I-/^U__ .$KXB_^B"H /^(27XI?])I_VO\ _P )7Q%_]$%0 ?\ $)+\4O\
MI-/^U_\ ^$KXB_\ H@J #_B$E^*7_2:?]K__ ,)7Q%_]$%0 ?\0DOQ2_Z33_
M +7_ /X2OB+_ .B"H /^(27XI?\ 2:?]K_\ \)7Q%_\ 1!4 '_$)+\4O^DT_
M[7__ (2OB+_Z(*@ _P"(27XI?])I_P!K_P#\)7Q%_P#1!4 '_$)+\4O^DT_[
M7_\ X2OB+_Z(*@ _XA)?BE_TFG_:_P#_  E?$7_T05 !_P 0DOQ2_P"DT_[7
M_P#X2OB+_P"B"H /^(27XI?])I_VO_\ PE?$7_T05 !_Q"2_%+_I-/\ M?\
M_A*^(O\ Z(*@ _XA)?BE_P!)I_VO_P#PE?$7_P!$%0 ?\0DOQ2_Z33_M?_\
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MB"H /^(27XI?])I_VO\ _P )7Q%_]$%0 ?\ $)+\4O\ I-/^U_\ ^$KXB_\
MH@J #_B$E^*7_2:?]K__ ,)7Q%_]$%0 ?\0DOQ2_Z33_ +7_ /X2OB+_ .B"
MH /^(27XI?\ 2:?]K_\ \)7Q%_\ 1!4 '_$)+\4O^DT_[7__ (2OB+_Z(*@
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M  E?$7_T05 !_P 0DOQ2_P"DT_[7_P#X2OB+_P"B"H /^(27XI?])I_VO_\
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M $05 !_Q"2_%+_I-/^U__P"$KXB_^B"H /\ B$E^*7_2:?\ :_\ _"5\1?\
MT05 !_Q"2_%+_I-/^U__ .$KXB_^B"H /^(27XI?])I_VO\ _P )7Q%_]$%0
M ?\ $)+\4O\ I-/^U_\ ^$KXB_\ H@J #_B$E^*7_2:?]K__ ,)7Q%_]$%0
M?\0DOQ2_Z33_ +7_ /X2OB+_ .B"H /^(27XI?\ 2:?]K_\ \)7Q%_\ 1!4
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M (2OB+_Z(*@ _P"(27XI?])I_P!K_P#\)7Q%_P#1!4 '_$)+\4O^DT_[7_\
MX2OB+_Z(*@ _XA)?BE_TFG_:_P#_  E?$7_T05 !_P 0DOQ2_P"DT_[7_P#X
M2OB+_P"B"H /^(27XI?])I_VO_\ PE?$7_T05 !_Q"2_%+_I-/\ M?\ _A*^
M(O\ Z(*@ _XA)?BE_P!)I_VO_P#PE?$7_P!$%0 ?\0DOQ2_Z33_M?_\ A*^(
MO_H@J #_ (A)?BE_TFG_ &O_ /PE?$7_ -$%0 ?\0DOQ2_Z33_M?_P#A*^(O
M_H@J #_B$E^*7_2:?]K_ /\ "5\1?_1!4 '_ !"2_%+_ *33_M?_ /A*^(O_
M *(*@ _XA)?BE_TFG_:__P#"5\1?_1!4 '_$)+\4O^DT_P"U_P#^$KXB_P#H
M@J #_B$E^*7_ $FG_:__ /"5\1?_ $05 !_Q"2_%+_I-/^U__P"$KXB_^B"H
M /\ B$E^*7_2:?\ :_\ _"5\1?\ T05 !_Q"2_%+_I-/^U__ .$KXB_^B"H
M/^(27XI?])I_VO\ _P )7Q%_]$%0 ?\ $)+\4O\ I-/^U_\ ^$KXB_\ H@J
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M_:__ /"5\1?_ $05 !_Q"2_%+_I-/^U__P"$KXB_^B"H /\ B$E^*7_2:?\
M:_\ _"5\1?\ T05 !_Q"2_%+_I-/^U__ .$KXB_^B"H /^(27XI?])I_VO\
M_P )7Q%_]$%0 ?\ $)+\4O\ I-/^U_\ ^$KXB_\ H@J #_B$E^*7_2:?]K__
M ,)7Q%_]$%0 ?\0DOQ2_Z33_ +7_ /X2OB+_ .B"H /^(27XI?\ 2:?]K_\
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M !_Q"2_%+_I-/^U__P"$KXB_^B"H /\ B$E^*7_2:?\ :_\ _"5\1?\ T05
M!_Q"2_%+_I-/^U__ .$KXB_^B"H /^(27XI?])I_VO\ _P )7Q%_]$%0 ?\
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M .$KXB_^B"H /^(27XI?])I_VO\ _P )7Q%_]$%0 ?\ $)+\4O\ I-/^U_\
M^$KXB_\ H@J #_B$E^*7_2:?]K__ ,)7Q%_]$%0 ?\0DOQ2_Z33_ +7_ /X2
MOB+_ .B"H /^(27XI?\ 2:?]K_\ \)7Q%_\ 1!4 '_$)+\4O^DT_[7__ (2O
MB+_Z(*@ _P"(27XI?])I_P!K_P#\)7Q%_P#1!4 '_$)+\4O^DT_[7_\ X2OB
M+_Z(*@ _XA)?BE_TFG_:_P#_  E?$7_T05 !_P 0DOQ2_P"DT_[7_P#X2OB+
M_P"B"H /^(27XI?])I_VO_\ PE?$7_T05 !_Q"2_%+_I-/\ M?\ _A*^(O\
MZ(*@ _XA)?BE_P!)I_VO_P#PE?$7_P!$%0 ?\0DOQ2_Z33_M?_\ A*^(O_H@
MJ #_ (A)?BE_TFG_ &O_ /PE?$7_ -$%0 ?\0DOQ2_Z33_M?_P#A*^(O_H@J
M #_B$E^*7_2:?]K_ /\ "5\1?_1!4 '_ !"2_%+_ *33_M?_ /A*^(O_ *(*
M@ _XA)?BE_TFG_:__P#"5\1?_1!4 '_$)+\4O^DT_P"U_P#^$KXB_P#H@J #
M_B$E^*7_ $FG_:__ /"5\1?_ $05 !_Q"2_%+_I-/^U__P"$KXB_^B"H /\
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#_TO[^* "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * /_3_OXH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H _]3^_B@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#_U?[^* "@ H * "@
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MI2C*$DOAG3FHSA*UFE**NK-75F>P5XIVA0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M3C4IO+TX_A=8 Y/%?0/P]XW4/:?ZKYQR]E@YN?\ X*C>I_Y)Y'GKB'([\O\
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MRLK#*LK#@J1@@C@CIQ7\6VMHU9K1K:UNEC]L/PJ_X*A?\%)M<^$6J7W[.OP
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MU_%7'"2XRXI2226?YLDDK)+Z[6T26Q^W9%KDN57U_P"$_"?^F8'TU7RQZH4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M?YA_PF'BW_H:?$?_ (.]3_\ DFCZC@O^@/"_^$]+_P"0#V];_G]5_P#!DO\
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M ,@'MZW_ #^J_P#@R7^8?\)AXM_Z&GQ'_P"#O4__ ))H^HX+_H#PO_A/2_\
MD ]O6_Y_5?\ P9+_ ##_ (3#Q;_T-/B/_P '>I__ "31]1P7_0'A?_">E_\
M(![>M_S^J_\ @R7^8?\ "8>+?^AI\1_^#O4__DFCZC@O^@/"_P#A/2_^0#V]
M;_G]5_\ !DO\P_X3#Q;_ -#3XC_\'>I__)-'U'!?] >%_P#">E_\@'MZW_/Z
MK_X,E_F'_"8>+?\ H:?$?_@[U/\ ^2:/J."_Z \+_P"$]+_Y /;UO^?U7_P9
M+_,/^$P\6_\ 0T^(_P#P=ZG_ /)-'U'!?] >%_\ ">E_\@'MZW_/ZK_X,E_F
M'_"8>+?^AI\1_P#@[U/_ .2:/J."_P"@/"_^$]+_ .0#V];_ )_5?_!DO\P_
MX3#Q;_T-/B/_ ,'>I_\ R31]1P7_ $!X7_PGI?\ R >WK?\ /ZK_ .#)?YA_
MPF'BW_H:?$?_ (.]3_\ DFCZC@O^@/"_^$]+_P"0#V];_G]5_P#!DO\ ,/\
MA,/%O_0T^(__  =ZG_\ )-'U'!?] >%_\)Z7_P @'MZW_/ZK_P"#)?YG]"7_
M  0>UC5]6_X:I_M35-1U+[/_ ,*.\C^T+ZYO/(\W_A;_ )OD_:)9/+\SRX]^
MS;O\M-V=JX_G#Z0-"A1_U2]C1I4N;^WN;V5.%/FM_8MK\J5[7=K[7=C]*\/)
MSG_:_/.4K?V?;FDY6_WW:^VR^X_H3K^<#])"@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M?$GXWZC:NT5[_P (!\*?'(T;39$7?C5O&/BW2?"O@C1A)$"\']J^(K(7&W9
M9)7BC>*.983$.U"<JBVYXTY<EU_>:2^X]+-O#3B;A_"O$Y_#+\F27N8?&YCA
MEC*N^E+"T)UJUU:UJD:?E>SM]T0.TB*[*R;E4[6QE3CD':60D'@E&9#P59EP
M:[SX#9V[=>C72W]=B:@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M_P#5B_%:OZZ\!/\ DCLP_P"RDQG_ *K,H/R#C_\ Y'.&_P"Q91_]2L8>Y_\
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * /\[>O]*#^9PH * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H _HD_X
M('?\W7?]T+_]['7\U_2&_P":0_[K_P#[Q#],\.O^9Q_W3_\ W=/Z)*_FL_3
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MT$522!@D 'KT7./RR?PP.@ &AYXZ@ H * "@ H * "@ H * "@ H * "@ H
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MO]!\N_Y%^!_[ \-_Z8@?SQB/]XK_ /7ZI_Z6S^T__@G;_P F3?LY?]D]MO\
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M7Z)XV_\ )"8C_L99=_Z=D?.\#?\ (]A_V"XC_P!)B?UZ5_&9^T'\IW_!<?\
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M2RLO-,\+C]2_MC#7^'^SJ7+\L1BK_/\ 2W8]&_X(1:IID/Q:^/&BRO&-9O\
MX=^&]3T^,G]ZVF:1XEDM=6:,=XTNM:T42GLSP\<\>9](&E5>3\/5HI^PIYEB
MJ51_956MA8RHI^;A0KV]&=7A[*"QF8PTYY8:E**Z\D*K4_DG.%_5']--?RR?
MJH4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M]@_LME*W?VL&V /L?_@DC_P4BTW_ (*J_L?:3^UEI?PCOO@E!J/Q \<> 9/
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M\/(O^"=W_1^O[%W_ (E)\#O_ )N: #_AY%_P3N_Z/U_8N_\ $I/@=_\ -S0
M?\/(O^"=W_1^O[%W_B4GP._^;F@#ZC\">/\ P'\4O"6C>/OAEXU\(_$7P+XC
M@FN?#WC3P)XDT;Q=X2UZVMKNXT^XN-&\1^'[S4-'U2"WO[2ZLII;&\GCBN[6
MXMG99H9$4 ZZ@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M=_XE)\#O_FYH E@_X*-?\$];F18;;]N_]C.XF?A(H/VH/@C+(Q]%CC\<,Q_
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M+ 9?-C=% /*/^'D7_!.[_H_7]B[_ ,2D^!W_ ,W- !_P\B_X)W?]'Z_L7?\
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M_P!T+_\ >QU_-?TAO^:0_P"Z_P#^\0_3/#K_ )G'_=/_ /=T_HDK^:S],"@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M[K\K<O>KSL[,_6^O</Q4* "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@#_]/^_B@ H * "@ H _G_ /\ @O-_R*'[-O\
MV,GQ*_\ 39X.K^B?H^?[]Q-_V"9;_P"GL6?G'B'_  ,K_P"ON*_](H'Y9_\
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MV&9G_P"IE4_$^-?^2@Q/_7G"_P#IB!^E?_!"'_DE/QZ_[*%X8_\ 4;GK\O\
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MN"JTXS46U9-QO:Z2/1J\PZ0H * "@ H * "@ H * "@ H * "@ H * "@ H
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M">,K=!'<*]QX9\0ZJEM)%<V]P8+B&>% #_01H * "@ H * "@#_/@_X/DO\
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MD<:WBW$43311I/( ?I70 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M7P'XO^2-OM>AIK^K1S64B_:[)[.Y7S0#^FO_ ()$_P#!WE\4?#'BSP?\"?\
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MBQ11/(Z*0#^@[_B#^_X+#_\ 0%_9L_\ #XI_\RE '[$_\$'_ /@W4_X*+_\
M!/?_ (*3?"7]J7]HBQ^"=G\+/ _A#XMZ3K#^#_B@?$_B&2^\9_#CQ#X2T6*Q
MT>/P[9B9?[3U>WDNI);NWC@LXYY0TDJQP2@'T?\ \'MG_)CO[(7_ &=;>_\
MJH?'% '\8O\ P3@_X(H_MN?\%4/!GQ*\>?LJ:?\ "ZZ\/_"GQ/H_A'Q7+\0/
M'\?@ZZ&LZWI4NLV<>FVITG4WO(%LH2T\Y,*I(Z1J'.[8 ?>_B[_@T@_X+/\
MAO33?:-\*O@OX_N0&QH_A'X^>!++46V@8 E\>3^"=(^?HN[5% (^?8,&@#\H
M+'6_^"D7_!'C]H^6QMKWX_\ [%/Q^\,W-I>7FDR2:IX9M/%6FV-W)]CEU#2Y
M#=^ _B]\/KZXBF$#7,'C#P%K\(D\HW]N6R ?Z@O_  0#_P""R6G_ /!7']F/
M7;_Q[INA^$OVI_@+>:#X7^.WA?0MUOH?B*WURRNI/"/Q9\)Z?*\LNFZ!XU;2
M=<L[_0C<73^'/$VA:M:+)_8]YX?GNP#][* /\;/_ (.+?^4U?[?G_94O"_\
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MEO$?@7X=^'/"^MG2[R6"UDN]..IZ7<FRN9+6V>>V\J5X(68QJ >_4 ?PU_\
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M 4 % !0 4 ?YV]?Z4'\SA0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0!_1)_P $#O\ FZ[_ +H7_P"]CK^:
M_I#?\TA_W7__ 'B'Z9X=?\SC_NG_ /NZ?T25_-9^F!0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M2RW@O@G+Z$>6A@<=6PE&-DN6%# 8>FK)=&XN5M;7M=VN_P"KZOT _B(* "@
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MKX2^//$#VTUZFA^#/B/X/\3ZPUG:[?M5T-+T75[V]-O;!T,TPA,<89=[+D9
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M:P^=PC5C)8?'4H\M.O:\)P5VJ5:*U<4V^6<?>A=Z2C[I_./\1O\ @F1^VO\
M#C4I[*X^"FM^,;)))4M=<^'-S8^,]-U"*)MOVB"UTN<Z_9QR?>BBUC1-+NV4
MC-LIR!_366^*G N9THSCGM#!3:3EA\RA4P56FW]F4JL?J\VMFZ%>K!?S6/S'
M%<)Y]A9.+P,Z\5M4PKC7C)=U&+]JO2=.+\CSG2?V$OVR=:N([:S_ &:?C##)
M*_EJVK>"]5T"W!Z9DN]=ATVTA3_II+,D?^UBO2K>('!-"+E/BC)6HK:CC:6(
ME\H8=U)2](Q;.6'#V>5&E'*L:O\ '0G27WU%!+YL_2#]CS_@D7^T?IWQ4^&O
MQ4^,%UX:^%6B> /&OA3QR/#SZC9^+O%^LW'A77M/UZUTL6GAZ\FT#2[;46L!
M;7.H7/B*6\TY9A(-%O'5X5_,N-?&3AFIE&9Y1DL,5F]?,<#B\!]95.>"P5".
M+P]3#RJ\V)@L15G253FC3CAHPJ<MO;P5F?49)P7F<,9A<7C72PE/#5Z.(]ES
M1K5INC4C44+4VZ<%+ELY.HW&_P #V/Z=Z_E4_5SX5_;8_8.^&?[9?AJT;5[A
MO!WQ0\-V<MKX.^(UA9B\FM;625KA]!\1:;YUJNO>');AI)XK8W-M?:3=S37>
ME7D"W6IVFI??\"^(.:<$8J?L8K&Y5B9J6-RRI/DC.27*L1AJO+/ZOB8Q2BY<
MDJ=6$8PJPERTIT_G\^X>PF>4H\[]ABJ2:H8F,;M+?V=6%U[2E?5*ZE!W<)*\
ME+^;;XJ_\$K?VT?AAJ=U;VOPND^).BQSO%9>(_AKJ5EXAMK^-<E)!H3RV7BR
MR)3:6%[H$$0D)CBGGQN/].Y1XM\#YK2A*>:K*Z[BG/#9I2GAI4WU7MTJF#G9
M[<F(;M9N,=C\NQG"&>X234<)]:IIVC5PLXU%)=_9MQK1^=-*^B;/(]%_8)_;
M-UZX:VL?V:_BS!(K^66UKPM=^&[?([K=^(O[+M63TD68QGLV*]FOXA\#X>/-
M4XHR>2M>U#%0Q,O_  ##>UDGY<M_(XJ?#N>5':.5XQ6=O?HNDOOJ\BMYK0_<
M+_@ES_P3T^.G[-'Q*UGXT_&*3POX>.M_#K5O!=EX$L-5&N^)+2?5]>\+ZR;[
M6+W3$E\.6L=O'X?:!;?3M7U>662YS*;7R-LOX-XL>)&0<4Y71R/)8XO$?5\S
MHXV>85*/U?"SC1P^*H>SH4ZK6)FY/$*7-4HT4E#12OI]]PEPUF&58J>.QKHT
M_:86=".'C/VE6+G4I3O.45[)6]G:T)SO?I;7U'_@K7^RY\=/VF_"WP5T_P"!
M_@<>-KWPCK_C*\\00?\ "3>#_#9L+75M.T&"PE$GB[7] ANA-+8W*%+*2XEB
MV!I41'1CY/@[Q7D'"N,SRKGV/^H4\9AL%3PTOJN-Q7M)T:M>52-L'AL0X<L9
MQ=YJ*=]&['9QEE&89K1P,<!A_;RHU*TJB]K0I<JG"FHO]]4IIW<7\-[=CY%_
MX)H?L&?M7?L_?M1:1\1OB[\*QX1\&VG@WQAI<VL?\)Q\.->VW^J64$%A;#3_
M  QXOUK5&,[JP\T67D1!29I8\KG[/Q2\0>$.(N$ZV69-FWUS&SQV"JQH_4,S
MP_[NC.4JDO:8K!4*2Y5;3GYG]E,\7A7A[.,MS:.)QN#]A06'K0Y_K&%J>]-1
M45RT:TYZVWY;+JT?T;5_,Q^G'\_?_!5;]B+]I_\ :1_:'\(^.O@M\,AXS\+:
M9\'/#OA2^U/_ (3/X?>'?L^O6'C/X@:M=6/V+Q9XKT+4)/+T_7-+G%U!:26;
M_:?*CN&FAGCB_HOPCX\X4X8X;QF7YYFGU'%U<[Q.+ITOJ.8XGFP]3 Y=1A/G
MP>#Q%-7J8>K'DE)37+=QY7%O\XXPR#-LTS*AB,!A/;T88&E1E+V^&I6J1KXF
M;CRUJU.6D:D'=+EUM>Z:7JW_  20_9'_ &A/V8M8^.EW\<?A^/!$'C'3/A];
M>&V_X2OP3XE.I2Z)=>,)=44+X0\1Z^UF+1-3L"3?BT$WV@"V,QBG\KR/&/C+
MAOBJAD$,@S'Z_+!5<QEB5]3QV%]DJ\,$J/\ ON%PW/SNE4_A\_+R^]RWC?LX
M,R;,LIGF#Q^&^KJO'#*E^^P]7F]FZ_/_  *M3EMSQ^*U[Z7L[?M=7X6?=G\V
MW_!2#]@3]K3X]?M6^,?B5\)OA0/%G@K5M \%65AK(\=?#70O.NM(\-6&G:A"
M=.\2^,=&U6(V]W;R1[Y;%(I0 \#R1D-7].^&/B'P?P]PC@\KSC-_J>.I8G'3
MJ4/[/S3$<L*V)G4IOVF%P5>B^:#3LJC:VDD]#\NXHX<SG,<XK8K!X/VU"=*A
M&,_K&%IZPI1C)<M6O3FK-6^&W8^X/^"3/[,GQO\ V9OA[\6]$^-W@H>"M4\4
M>,M#U30[3_A)/"7B0WNGV6B26EQ<>?X2UW7K6V"7#B(17<\$[8+K$8\.?@_&
M'BK(>*<RR>OD..^O4<)@:]&O/ZKC,+R5)UU.,>7&8?#RE[JO>$916U[Z'T'!
MN58_*L+C*>/H>PG5KPG3C[6C5O&-/E;O1J5$M=+-I^5C]6-7TG2]?TK4M"UO
M3[/5M&UFPN]*U;2M1MXKO3]2TV_MY+2^L+VTG5X;FTN[:62"X@E1HY8G:-U*
ML17Y%1K5</5I5Z%2=&M0J0JT:M.3A4I5:<E.G4A*-G&<))2C)6::31]?.$*D
M)4ZD8SA.+A.$DG&49*THRB]&FM&GHT?SA_M8_P#!%CQ=9ZWJGC#]E"_T[7/#
ME].]TOPG\3:O'I>NZ$TN6:S\->*=8G32M9TM'R+:#Q'?Z3J-C;^7#+J>MS![
MBOZ:X/\ '+!SP]+!<7TJM#$TXJ']KX2BZM#$):*>*PE&/M:%6WQ2PU.M3J2N
MU2H*T3\PSC@2LIRK9/*,Z<G?ZG6FH3IWZ4JTWR3@NBJRA**^W49^76K_ +!G
M[9>B7AL+S]FKXN33K,8"^D>$;_Q!9;PVW*ZCH":EIS0Y'%PMT;<KAA*5(-?K
M%'Q"X(KP]I#BC)XQY>:U;%T\-.W_ %ZQ'LJG-_=Y.;I8^2GP[GE.7++*L8W>
MW[NC*K'_ ,"I<\;>=[>9Z]\,O^"5O[:OQ(U6VLKCX6-\.M*EVM<^(_B1J^GZ
M!I]BA('[S3+674_%%Q)C)$5EH%R5VXF,(*L?&S7Q;X&RRC*<,V_M.JM(X7+*
M-3$5)ORJS5+"17G/$1_NJ6QVX3A#/<5-1>$^JPZU<5.-.$?^W8\]5_\ ;M-^
M=M#^M_X%_#V\^$OP6^$_PNU#4;;5[_X=?#KP;X)O=5LXI8+34;KPSX?L-'N+
MVU@F)FBM[F6S::&.4^8L;*'^8&OXYS_,H9QGF<9M3I2HT\RS+&XZ%&;4ITH8
MK$5*T:<I1]URBIJ+:TNM-#]ER_#/!8'!X24E.6%PU"@YQ5HR=*G&#DD]4GRW
M2/5:\@[ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H _SL?\ @^%_Y+7_ ,$^_P#LEOQX
M_P#4L^'- '\G?QR_8Z\0_#/]B_\ 8A_;*TRTN[GX>_M.6?QR\%:[J)\V:'2/
MB[\%_C'XNT6ZTR9@##I]KK?PUOO M[H4$C))J5[HOC*:%'73[AE /].S_@V)
M_;__ .&X_P#@F'\.?#?BS6O[3^-/[),MI^SI\2!=7'FZIJ?A[PUI=O+\'_&-
MRKL]S+%KGPZ_LWP_=ZK=RRW&L>+?!?BZ\D?<2  ?T34 % '\+W_!Y]_P4%_X
M0[X4?!;_ ()P^ M;\O7?BY=67QW^/<%G<8E@^&OA'5[FQ^%7A/48T9DDM?%O
MQ!TS5O&%Q;R+%<V<_P ,?#MPNZUU7YP#^(GXY_L@Z_\  K]C']B7]H[Q?:7&
MFZS^V'XC_:<\0^%-.G$D;/\ "+X2:A\'O!7@_6YK:78]O-KOC2_^*-S:GRA'
M?>'8O#^JP33VU_ 4 /\ 22_X-!_^4./A7_LX?XZ?^G/0J /WQ_:G_;"_9G_8
MD^'.F_%K]JOXP>%_@I\.=8\7:;X"TOQ5XL&IM87_ (PU?2M<US3?#]M'I&GZ
MG>2W]UI'AK7M015M?+6UTJ[D>1!'R <M^R5^WO\ L?\ [=FE>--;_9'^._A#
MXY:5\.M0T;2O&M[X2AUV&+P]J'B"VO[O1K6]&N:1I+F34+;2[^6'[.DR!;63
M>R':& /KV@#S7XP_&#X9_L__  P\:_&?XR^,=)^'_P +OASH=QXD\;>,]<-P
MND^'M#M&C2>_O/LD%S=-&KRQ1)%;6T\\LLD<4,3R.JD ^0/V6_\ @JU_P3Q_
M;6^)%Y\(?V6/VI_A]\9_B3I_A74_&UYX2\+VWBF+4H/"NC7^D:7J>M.VL^'M
M+M/LMG?Z]I%K*%N3-OOH=D3*'9 #[F\8?\BCXI_[%S6__39<T ?XSO\ P05_
MY3&?\$\_^SB_#'_I#JM '^QC\;OC=\*/V;_A5XS^-_QQ\;Z/\-_A1\/--AU?
MQGXWU\W(TC0-.N+^STJWN+L65O=W;"?4M0LK*"*VMIYI;BYABCC9F H _@R_
MX.M?^"HG[ ?[<7[$G[/_ ,-/V3OVF_ GQM\<^%_VI](\<^(/#OA2U\417FE^
M$[7X2_%70)]:N9-:\/Z5:"V35]?TBQV)</<-+>HR0M$DSQ@'G?\ P:;_ /!2
MS]A7]A;]GW]K7PI^UM^TAX&^!_B'QW\8_ WB#PCI?BR#Q'+<:YHVF>";G3;Z
M_M#H>AZM$(;:]=;=Q/)#)O(VHR\T ?VP_LK_ /!53_@GM^VW\1=3^$G[*G[4
M?P_^-/Q&T;PAJ7CW4_"?A:W\41:C9^#](U;0M"U+79&UKP_I5I]DM-6\2Z%8
MR*EPT_FZE 4A9!(\8!V?[6__  41_8I_8/E\"6_[77[0W@CX&3_$V/Q%-X#@
M\6IKLLWB6'PDVBIXCEL(M#T?5G$6DOXBT1+F2X6!-VHVZQ&0[P@!Z?\ LS?M
M5?L]?MD?#"#XT?LQ_%+P_P#&#X77.N:OX;@\9>&8]4BTN37-!:"/5]-5-7T_
M3+SS[![B!92;41_O%\MWYP :_P"T+^T7\$?V4/A+XF^.W[1/Q%T'X4?"/P;)
MHD/B;QSXD^V_V1I,OB/7=-\,Z'%.NG6E]>R2:EKVKZ;IEM';VDS-<7<>0L89
MU / ?V3?^"F'["7[='B3Q7X/_9*_:2\#?'#Q+X'T.T\2>+-(\)V_B2&YT30[
MZ_72[34;HZWH6DPF":_9;5!!)+)O/*!?FH \'_;#_P""X?\ P2V_83\47G@#
M]H7]K7P/IOQ*TZXGLM5^&?P^TWQ1\7_'7A_4+8$RZ;XNT/X7:'XL/@3454!E
MLO'$_AR>17C:-&62,L ?''PT_P"#J7_@BO\ $?Q#9^'+C]I+Q5\.+G4+LV5E
MJ7Q+^"_Q1T+P\\I8K%)=^(-+\-:]I6BVDV-PO=>N=+LX%(^V36W2@#]\?AQ\
M2OAW\8?!'ASXE_"?QSX2^)7P[\7Z=%JWA7QQX$\0Z5XJ\*>(=,E+*E[HVO:)
M=7NF:A;[T>)GMKF01S1R0R;98W10#MZ /\>+_@YD_P"4XG[=_P#V,?P6_P#6
M:?@Q0!_K)?L??\FD_LN?]FZ?!+_U6GAF@#Z+H _/[]LW_@J=_P $_O\ @GVD
M-O\ M:?M/?#SX6>)+O3TU73_ (?++JOC+XHZCITQ:.UU"T^&7@/3/$WCG^R[
MV9'M[76;C0;?19)8Y@=01;>X:( _+'2O^#LS_@BIJ.M_V3=?'7XH:'8^='$/
M$NJ_L^_%B30V1V"FX$.C>'=6\0K#$/GDWZ"DVP?NX9&^6@#]O/V8/VQ/V7?V
MT? ;_$O]E;XZ?#KXY>#+>XCLM3U+P)KT&H7OA[4)HS-#I?BOP_,+;Q'X1U:6
M!?M$6D^)])TG49+;;<):F!ED(!])T % !0!^/G_!?SQ#XB\,?\$:_P#@H-J7
MA9KA-3N/@+J'A^X:VFD@D_X1[Q9XC\.^%?%P+Q$,8&\)ZSK2W,7W)[8RP2@Q
M2.* /\Y?_@UTT3X1^(/^"T_[+%A\6=+TS5S#IWQ<UCX9VNM16\^E1?%GP[\*
M_%>O^$M1GAN_]%;4-)M],U?4_##R*\UKXOM/#]YIP75;>QDC /\ 7KH * "@
M H RM<UW1/"^C:IXC\2ZQI7AWP]H=A=:KK6NZYJ%II.C:/I=C"UQ>ZCJFJ7\
MUO8Z?86=O&\]U>7<\-O;PHTDLB(I( /PR^.'_!R]_P $7_@5KEUX9U7]L31?
MB-KMDTR7$'P2\#?$/XM:*#"VS_1_''A'PQ>_#V^\QPPC_L_Q9=9"^8VR)HW<
M \X^&O\ P=3_ /!%7XB:Q8Z'=_M*>*_AM=:C/]FMKKXD_!/XKZ/HRS,<1_;M
M>T7POXBT;28'Q_Q^ZM?6-C"/^/FYAH _=[X1?&;X1_'_ , Z'\4_@=\3/ OQ
M<^&_B2)I="\<?#GQ1HWC#POJ0CP)X;?6-"N[VR^UVCGR+ZQ>5+RPN5>UO8(+
MB-XE /2Z /\ /@_X/DO^1M_X)K?]BY^U?_Z<_P!GB@#]EO\ @T$_Y0Y^&O\
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M#X>M='M-&%Q ;Z_U$VUC$)%/V@C. #\C/BC_ ,'3?_!%CX8>*+SPFG[36O\
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M4<CQZ!8ZM>.HM[6:1 #_ #(_^#:W]B@?M[_\%7_AM>_$G2G\9_#/X#67B/\
M:;^,#Z\LFHV_B"^\-75M9^!M.U6[NS)'?7NN?%GQ'X4U6_M+MIKC5M%TGQ(X
M5A#<3P 'Q=^T+X!^*'_!&_\ X*R>,O#GA"6\MO&7[%O[4.F>,_A?>:C)+"WB
M?P1HFOZ;X_\ A9>ZP47,NG^/OAIJ'AV37[/$\%Q8Z[J&G2_:87D#@'^R_P#
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M2:CIFM7%I=K$R7%F/&GQ*D\'VUA,6$&IZ3X1\::5)%-$TX0 \S_X,P?V$/\
MA7/[./QL_;_\9:-Y/B?]H?7I/@]\(+NZ@VSV_P 'OAGJQD\;:QID^U2;'QO\
M5(#HE_"Q?;<_"&SFCV+,3( ?VW4 >&?M/_\ )M/[0_\ V0SXM?\ J Z_0!_D
M+_\ !O)_RFB_X)__ /98=3_]5WXVH _V6Z "@#^+#_@]L_Y,=_9"_P"SK;W_
M -5#XXH X_\ X,A?^37/VXO^R^_#G_U7=U0!_;_0!_+Q_P ';O[+'PU^,O\
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MK.A6LPL?$6K6EZ ?[*U '^5E_P 'BO\ REYM?^S4O@K_ .G_ .)- ']YG_!
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MI@4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % 'X)?\$:/^2Q_P#!1S_LX"U_7Q/\5J^8X=_C
M9S;_ *&$O_;S^C?'?3(O"7_LD*7_ *9PA^]98#BOIS^<C^;[_@N_^UM?^&]
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M620VEE9VR22W%Q*RQQ1([N0HJ)-+3NM+;:[=@4976NWK_D?W9+_G\S6)H.H
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M@'ID#CTJ1BT % !0 4 % !0 4 % !0 4 % !0 4 % !0!__5_OXH * "@ H
M* "@ H * "@ H * "@ H * "@ H * /P$_X+R_\ (D_LX_\ 8T_$3_TT^%:_
MHCZ/G^_\2_\ 8'EW_I[%'YSXA_[OEG_7[$_^D4CX&_X(V?\ )[/A_P#[)[\0
M/_39;U^B>-O_ "0F(_[&67?^G9'SO W_ "/8?]@N(_\ 28G]>E?QF?M 4 %
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M\*?_ %0?[3E 'R'_ ,&/'_)&?^"@_P#V4[X!?^HK\2Z /[KJ /R!_P""^_\
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M /[]?&'_ "*/BG_L7-;_ /39<T ?X:O[$/[3>H?L9?M5?!K]J71M$B\2:_\
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M/VH/AK9?\$\OV*O'VD?%;X?W'B[3?%'[2?QB\,_:KCP5KEYX&U6#4_!?PQ\
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M"?Q(^(GQ_P#B?XJC^&_A75+>\-MXLOHI/!\[:#-=:9J.HMI-]J%G? ']I?\
MP;[_ /!$NW_X)%?!'QSK7Q*\7Z!\1/VHOV@O^$7N_B?KGA(7C^"?!/ACPS;W
MDWAOX:>#;[4%@NM?@L=2UG6M8\0^+Y--T3_A(;^[T^RATF/3_#FGW^H 'P__
M ,'I&@:!??\ !+GX+:_J"6T>O:!^VU\-[;P]=M$ANW36O@U\>TUC2()B-\=M
M>6UA!JEU$I"S2:#9LX)@3 !^X?\ P1@U75M8_P""2W_!..\UJ)XKV/\ 8U^
M&F1+(=S-I>B?#K0M&T*;/]VXT2PT^X3T211VH _3.@ H * "@ H * "@ H *
M "@ H * "@#_ #MZ_P!*#^9PH * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H _HD_X('?\W7?]T+_ />QU_-?
MTAO^:0_[K_\ [Q#],\.O^9Q_W3__ '=/Z)*_FL_3 H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * /P2_X(T?\EC_ ."CG_9?[/\ ]2;XK5\OPY_&SK_L8/\ ]N/Z.\>/^1'X
M3?\ 9(T__3.%/WK('Y#_ #TKZC_AC^<4?Y^O_!0+XIW'QC_;/_:)\:2S/-:I
M\2M>\*:+E]Z)X>\"S+X,T0P?._E1W-AH,5Z\6$9;FYG9D4OS^-<08GZUFN*E
MNJ,_80;TO"&D=-/5NRW7HO\ 53P?R2GD7ASPMA(Q49ULLHXZM9)<]7'+ZU4D
M[=5*JXJ]FDDK:67QW7B'Z87])TG4O$&JZ;H&AV%WJVM:UJ%CI&DZ5I\$MU?Z
MCJ>IW$=GI]A96MO^_N;F\NI8[>WAA^>69TB0AF%:4J4J]2%&FG*524::2MO)
MI+R6_79>1SXO$T<'A,3C*\XT\/A*-2M7G+2,*=.#G.4O[JBKMVLC^^K]@;]E
M72OV1/V:O!7PKBAMI?%LT?\ PE'Q+U:W^9-8\?ZS;VKZPT<S']_8Z-'!9^'=
M(DPN=,T:RDD0733L?VO*LOIY;@J.'@E\"<Y):R<OBWUT^%;:+S/\I_$SC:OQ
MYQ;F.=2<E@HU'A<LHMNU+!8><HTO=>TYN]6;M\<W;W4C[7KT3\_&EE4$DX Z
MGTQ_G\\#KB@#^5__ (.$_BO;ZA\0?@#\%K&>7S?"_AOQ'\1/$"+)_HID\77M
MMX?\.QRQA_\ C[MH/"NO2*98QY4.JPB)]]T$?X'C:L^7"X5?"TZL]5I:ZBK?
M*_;ITL?VK]%')'# \3<0./O8NOA\KPSY;27U6/MJDHOM4EB/9O1)>RO<X_\
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M,;*\HI7[(_K#K^03]A"@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /\ .Q_X/A?^2U_\
M$^_^R6_'C_U+/AS0!_0/_P &G'_*$_\ 9_\ ^RD_M"_^KD\64 ?PY_\ !RU^
MP7?_ /!/[_@J1X[\7?#ZQNO#/PF_:;N&_::^#VHZ-YNG6_ASQ-KFM2R_$[PO
MI%W:&"/3K[PE\3(M0U[2;#3OLXT#PIXI\%PP"/\ =,0#_27_ .".?[=]A_P4
M;_X)X?L\_M+S7UK<?$+4/"Z> _C=8VWE1MI7QK^'RQ>'O'WFV<(V:=;^);RW
MMO'FA6&6:W\+^+="WNS,30!^,?\ P=Y?\%!O^&9OV"M&_9(\#ZW]B^*W[:VK
MW?A[7$LKC9J&B_ 'P//INJ?$>ZD,3-):KXUUFZ\+?#^.&YC2WUOPWJOCR""5
MI-,G50#\T?\ @RX_X)^^;=?'C_@I+X\T3Y+07?[.7[/LM];\&XE33-?^,_C3
M3UG4$&&W;PEX$T;6;/<CB[^(VB/*&BNHJ .%_P"#XG_DK/\ P3P_[)W^T3_Z
MDOPEH _;O_@T'_Y0X^%?^SA_CI_Z<]"H \2_X/3?^45GP2_[/T^%/_J@_P!I
MR@#Y#_X,>/\ DC/_  4'_P"RG? +_P!17XET ?W74 ?D#_P7W_Y0V_\ !0G_
M +-_UC_T^:#0!_"G_P &9W_*6;QW_P!F7_&#_P!69\#: /\ 4'\8?\BCXI_[
M%S6__39<T ?XSO\ P05_Y3&?\$\_^SB_#'_I#JM '^T+0!_&M_P>Q?\ *.O]
MF#_L]/0/_5&_&R@#RC_@R%_Y-=_;C_[+Y\./_5>7E ']P% '^?!_P?)?\C;_
M ,$UO^Q<_:O_ /3G^SQ0!^RW_!H)_P H<_#7_9Q?QS_]+?#U 'M'_!U3_P H
M._VM?^QC_9O_ /6E?A-0!_&A_P &@G[+7@[X^?\ !4J^^*/CG3+/6-._93^"
M7BCXO^$;&]B2YMQ\4=7\0^&/AWX/U*6TE1H)&\/:9XJ\5^(]*N7_ 'VE^)M(
M\/ZG9JMW:17%N ?ZJ% !0!_C@_\ !Q=^S7X/_99_X+#?M@> ?AWH47AOP#XK
M\1>#OC+X9T>V4165G+\8_ 'ACQ_XSATRV1$@L=(@^(^M>,[;1]-M42TTS3(;
M33[5(X+5(T /]47_ ()6_%75OC=_P35_8.^*GB"X-YXC\8_LF_ B_P#$UZ9&
ME:^\36WPZT#3?$=\SOE]][K=C?W3H[.T;2F-I)"A=@#_ "V_^#F3_E.)^W?_
M -C'\%O_ %FGX,4 ?ZR7['W_ ":3^RY_V;I\$O\ U6GAF@#_ "D_^#GG]H#7
M/CU_P68_:DMK^\NIO#OP._X07X!^"+"XN&G32-'\"^#]*OO$EM;+O:*&#4/B
M5XA\=Z\L42QA3JY$JM<>;(X!_6!_P2Y_X+[?\$,/V"/V!_V8OV8++XX^)]!\
M3> ?A9X8F^*QTG]G7XS2)K?QI\0:9;:Y\6M>N=0L?!$T>K27WCF^UB*ROFN[
MP+HUKI=A:W+Z?8V:H ??G_$5[_P1)_Z.1\>_^([?'/\ ^86@#^-3_@Z"_P""
MAG_!/_\ X*2?&']E3XS_ +%?CC4/'7BSPI\._B+\./C-J.J_#'QK\/=0@T73
MO$/AKQ#\*H9+KQEX?T-]?A^T^)/B8($L6O/[(V2"Y^SKJ-H)0#^L7_@SQ^)6
MJ^._^"0">%]1NOM%I\%_VH_C9\--"BR3]ATK5--\ _&&6UP20N[6_BOK-YA0
MJ_Z7G&XEB ?U0T % !0!\V?M6?L@?LV?MO?"'6?@5^U-\)/"WQ@^&FLR)=_V
M+XA@N(;_ $35X8Y8;7Q%X2\2:7<6'B3P=XFLHIYX;3Q#X8U72M7AMKFZLQ=F
MSO+NWF /X#_^"FG_  9S?&[X72>(?BE_P37\;R?'OP%%]IU*3]GSXEZGHWA_
MXU:!;#=-)9^#/&DJZ-X'^)5K;()#;V>L#P+XG2W2VT^SC\9ZO*T\P!_.'^R'
M^W__ ,%$?^".WQYUNQ^%7BOXB?!3Q1X7\41VWQ@_9M^*FCZ[;^!?$^H:<84O
M-"^*/PA\1?V?]GU.6P46,7B&R@T'QQI%A<F7PWXETEI4N" ?ZF/_  1L_P""
MRGP+_P""OOP.UCQCX+TB;X9?'+X8-H^F?''X'ZKJEMJMYX7OM8MI7TKQ7X2U
M:-;:7Q-\.?$D]GJ5MHVLW&G:7J=CJ6F:CH^M:7;2P6-[JP!XE_P<Z?'W6O@#
M_P $9OVJ+CPU=W6G^(/B\/ ?P%L[ZUG:W:'2/B=XRTFP\=V\IC9))+?5_AM9
M>,M#EA1L.-3'G+);B:-@#^-#_@SU_9 \*_M ?\%(/&'QX\=:-:ZYH?[('PGE
M\=^$[2]MX+NSM_C!X]UB+P?X%U>XMKE9(7DT#P]'\0=>T:;R_M&F>*-,T#6;
M*6"\TR"50#_4JH * /\ -_\ ^#U[]E7PQX$_:1_9._:Z\,:3;:=JO[0/P_\
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MG>?"S_U*H: /]J"@ H _QAO^"_'_ "F2_P""A'_9?]7_ /3%H- '^R5\/O\
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MW2:% SQ  _VT?$UU!?>!_$%[:R+-:W?A35;JVE7[LL%QI$\L,B_[+QLK#V-
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MI8)HF5XG92#0!JT % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M_DVG]H?_ +(9\6O_ % =?H _R%_^#>3_ )31?\$__P#LL.I_^J[\;4 ?[+=
M!0!_%A_P>V?\F._LA?\ 9UM[_P"JA\<4 ?PG_L=_\$Z/^"@/[;GA_P :>)/V
M-O@'\1_B_P"'/ FL:9HGC34O!>KZ%I%CH^M:K937^FV-V=:\1Z%]HNIK&"2<
M"V6Y\F'9YS1>;$' .1_:L_86_;G_ &/Y-&?]KO\ 9R^.7P<LM8N;C3_#GB#X
MD>%M;A\*ZQ?1+YMUIV@^,<7OA;4[^.*,7$]AINL3W2VXCN'A\EDD(!^ZO_!M
M%^Q5_P $B/VU?CM;^!/VS/%7Q+\1_M2:+J4WBKX6?LZ^*9- \*?L\?%W1/#R
MMJUS90:QIL][XN^(OBK1;73Y=:U_X=ZG>^"-+U#PZMZT.E^/M%LO$RZ. ?ZH
MVC:-H_AS1]*\/>'M*TW0= T+3K'1]$T/1K&UTO1]&TC3+:*RTW2M*TRQB@LM
M/T[3[.&&TL;&TAAMK2VBB@@BCBC1  :5 '^-G_P<6_\ *:O]OS_LJ7A?_P!5
M/\/: /\ 7*_9+_Y-5_9F_P"S??@S_P"JY\-T ?AC_P '9W_*%3XY_P#94OV?
M/_5L>': /YT?^#(?_DZK]M[_ +-]^'__ *L9Z /]'Z@ H * /\;G_@XT\8Z9
MXZ_X+7?M]:WI-Q:W-K8_$SP?X-EDM&1HEU+X=?!_X<_#[6K=BGRBYM-8\,7U
MK>J?G2\AG63]X&H _P!6'_@F'X1O? /_  3:_P""?W@G4S(=3\*_L5_LNZ%J
M0D!#)J.F_!+P3;7\04\HD5W'-%%&<F.-$0DE<T ?YR__  >*_P#*7FU_[-2^
M"O\ Z?\ XDT 0_L8?\&G?[8O[;/[+7P3_:L\!_M(?LT>$_!_QQ\&6_C70/#G
MBX_%'_A)-(L+B]O;%+36/[&\!ZEI?VM7L7=OL5]<P['3$A.0 #Z=_P"();]O
M/_H[+]D7_OKXR?\ SM: /WL_X-^_^#?K]H__ ()$_M(?&GXT?&CXT_!'XF:%
M\3/@BWPOTK2OA>?'9U;3]6/CSPEXK_M#4/\ A*_"?A^S_L[['X?N;;_1KF:Y
M^TS0?N/*WN@!_650!_B8_$+_ )3"^./^TE7B;_UJ&]H _P!LZ@#_ #S?^#OG
M_@D1_P (OX@M?^"J/P%\,;/#WBN\T/P;^U[H6C6>R#1O%<WV70O /QN:W@3R
MX;/Q9C3_  %XZN1]GB7Q1'X,U=HKW4_%OB'4(@#W7_@T#_X*Y?\ "7>&;S_@
ME?\ '?Q-O\3>#+'7/&O[(VMZQ=[KC7/!D)N=;\??!6.>=Q)/>^#2U]X[\$6H
M-Q,_A*?QCI:/9:3X,T.R< _1?_@\1_Y1!Q_]G4?!3_TS_$.@#\??^#&__D>?
M^"D7_8I_LM?^GCX]T ?Z%% !0!_E(_\ !WW_ ,IB_$?_ &;G\#/_ $C\14 ?
MZ!W_  0K_P"4/O\ P3N_[-A^'O\ Z234 ?K!0 4 ?R[_ /!V]^R1KW[1_P#P
M2KU+XF^#=)OM7\4?LC_%+PW\<KZTTV)KB[E^&D^EZUX#^),GV9<YL= T_P 4
M:7X[UBZ W:?HG@W4;MF6VCN<@'OO_!M'^WYX6_;=_P""8'P8\,3:Y%<?&;]D
MOP]X?_9P^+F@7-U%+K$-GX(TF/3/A5XQ>(L+VYTCQG\.K#1PNM7$*I>^+="\
M::8D]W/HEU<. ?R/?M8?\KEGA;_L_#]B_P#]5E\": /VS_X.^_\ @F!X<^-'
M[+VG_P#!1/X7>$;2#XU?LV3:1H?QJOM&L%34?'WP!UZ_@T:VU36Q;*9M4U+X
M2^*+_2[ZPO6C\RQ\#:]XQEU*Z?3M TJ*Q /IK_@U$_X*77G[:/["4_[.'Q0\
M2R:S\>OV+)-$\!376J7;3ZUXN^!.KV]R/A%XDFEG?SK^Y\+Q:7K'PTU1X4F:
MUL/"OA34=6NI-1\3!Y0#\>_^#N[]JV__ &K?VG?V0O\ @DQ^SDEQ\0/B+X;\
M=Z3XN^('AK09X[U+OXX_%R&Q\#_!+X?&*(YM?$N@^%=>\0ZYJ_GAH+?2_B=H
M),L$EMJ<: ']VW[-/P5T?]FW]G/X!_L[^'KEKW0O@1\&/A?\'-(O7!62^T[X
M:>"=$\&6=]+N^8S7L&C)=3,^7:65V<ER30![;0 4 % !0 4 % !0 4 % !0
M4 % !0!_G;U_I0?S.% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % ']$G_! [_FZ[_NA?_O8Z_FOZ0W_ #2'
M_=?_ />(?IGAU_S./^Z?_P"[I_1)7\UGZ8% !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MEO\ @T$_Y0Y^&O\ LXOXY_\ I;X>H ]H_P"#JG_E!W^UK_V,?[-__K2OPFH
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M['QQX1CTC7</:37-QKOAZXN-)U$ _P!=/]C;]JKX:_MO_LO?!3]J[X1'4$\
M?&WP5:>+-'L-7B6'6-"O4N;O1_$GA;6$C+6[:OX2\4:7K7AG5)K.2?3[B_TF
MXGTZYNK&2WN) #Z9H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % ']$G_! [_FZ[_NA?_O8Z_FOZ0W_ #2'_=?_ />(?IGAU_S./^Z?
M_P"[I_1)7\UGZ8% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M()=5TJTOY8(?,\"--Y44T\@BWR'"':1E0:SY_+\?^ :>S\_P.D_XASOV8/\
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MUEZ77XFRV7HOR/UBI#"@ H * "@ H * "@ H * "@ H * "@ H __]#^_B@
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MP\=>%]+\46>FWLUMFWEN[&WU2.UN9("87FB=HOD*T >ET % !0 4 % !0 4
M% !0 4 % !0 4 % !0!X[^T/\9-'_9T^ 'QR_:"\1:3J6O\ A_X$_![XF?&3
M7-"T5K6/6-:T?X8>"M;\;:GI.DO?2P62:EJ-EH<UG8->30VJW4T1N)8X@[
M_E+^ '_!XU^R[^T!\>/@G\!]%_8]^/F@:Q\;/BY\-_A'I.NZIXP^'EQIFBZE
M\2/&.C>#;#5M1M[2<W4]CIMUK,5Y=PVP,\EO#(D(\PK0!_5[\6OCW\"_@%I>
ME:W\=?C1\)O@KHNNW\FE:'J_Q:^(O@_X<:7K.J0V[7<NFZ5?^,-8T:TU"_BM
M$>YDL[26:X2W1IFC$:E@ 1?"/]H+X"?'^RUG4O@/\;OA#\:].\.75K8^(;_X
M1_$KP9\2++0;V^BEGL;/6;KP;K6LP:7=7D$$TUK;WKP2W$4,LD*.D;$ 'KU
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0!_G8_\ !\+_ ,EK_P""??\ V2WX\?\ J6?#F@#^@?\ X-./^4)_[/\
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MG[3OQ[M[>6/0/@)\!/%.D>*K]]5&Z..'X@_$+2!K7@KX8:?;3>4=536KJ_\
M&45E*+S1/ WB'8T- '[>> ?%*^.O G@KQLEB=,3QCX2\.>*5TUK@7;:>OB#1
M[/5EL6NA#;BY-H+L0&X%O )C'Y@ABW;% .MH * /SK_X*R?MB>.OV ?^"?/[
M17[7WPT\,^$_&/C3X+:9X!U?2?#'CB/5W\,:S#XA^+'@/P3K%GJ/]@ZIH^JP
MR'0_$NI/IMU;7RK9:HEE=W-KJ-I!/IUT ?F#^PM_P=0_\$M_VMM T33_ (L?
M$AOV,_B_-96@UWP1\?)!8> UU0JBWY\+_&VRMAX#O]"@G=5M;SQI+\/-=NX2
M9V\,010SM& ?M_IO[9?['^LZ&GB;1_VK/V;-5\-O;"\3Q#IOQS^&%]H;V9$9
M%TFK6OBB6P:V(EB(G$_E8EC(;#KD _ +_@M5_P '%W[$'[+W[,WQF^$'[-OQ
MO\ _M'_M7_$CP)KWP_\ !F@?"'Q%'XU\&_#J3QKH]WH=Y\0/&WQ(\*G4/!EG
M/X-L;Z?5=/\ !NG^(+GQ;JNOPZ3IUWIND:1<:CKVF '\/?\ P;:_L@^-_P!K
M#_@K9^R]?Z#H]]+X&_9L\;:5^TQ\4/%"6,EQI?AC2_A/=IXB\%VU[<86WCOO
M%GQ'M/"?AK2[<RK=%;V_U6WAGM]%OO+ /]43_@HE^R'HO[>G[$7[2?[(VMWL
M&E#XU?#34]!\/ZU=(9;3P_X\TBYLO%7PV\1WL*QR23V/A[X@:!X9UJ^MX56X
MN+.QF@MY89I$E0 _R&OV*?VGOVC?^"*/_!2#0_B5KO@/5=#^)O[/OC?Q%\,?
MCQ\%_$,ITJ7Q3X.O)&T'XB^ KR[B^T6JM?V CUOP9XCA75-&AU_3_"GB^SBU
MK3+:".\ /];?]A;_ (*>_L3?\%%OAYH7CO\ 9A^./A#Q1JNI:;!>:]\)]7U;
M3-!^,W@*_-M%+?Z-XS^&]W>_V_83Z9.TEFVM:?#JGA+5WMIKOPWXAUK3/*OI
M #US]J;]M7]E/]BCP#J?Q*_:E^._PZ^#7AC3;">_AC\6>(+2'Q)KX@_Y<?!W
M@RU:Y\7>-=7F8;+?1_"FB:OJ4[!C':E(Y&0 _P E/_@K?^W]\3_^"W?_  4<
MM?%OPG\ ^+;S0-3N/"_[//[)7P<AMDO/&=WX:;Q!>#0?[2TVPN;G3SXZ^(?B
M_P 1:EX@UB*TN)X-)BU+2_#3:MJ>G^&+;59@#_4Y_P""3O[#]I_P3J_X)^?L
MW_LGM-;7OBOP%X,;5_BAJMI(D]MJOQ:\=ZG>^-OB1-9W:JIO-(T_Q5KNHZ#X
M;N9%65O#&D:+'(JM'M !_'K_ ,'R7_(V_P#!-;_L7/VK_P#TY_L\4 ?LM_P:
M"?\ *'/PU_V<7\<__2WP]0![1_P=4_\ *#O]K7_L8_V;_P#UI7X34 ?S,_\
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MN)TT^"S5=/L[2**QL4BM;:*) #_;$_X)A_\ *-7_ ()Y_P#9C?[)G_JA/ %
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M#XQ^._%/@V>V3MIWB?1=1M_&^GMD^9:>*(IOE\S8@!^_- !0 4 % !0 4 %
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MLJ*.M 'Z2T ?XF/Q"_Y3"^./^TE7B;_UJ&]H _VSJ "@#\$_^#A/_@DSI_\
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M * "@#_.WK_2@_F<* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * /Z)/^"!W_-UW_="__>QU_-?TAO\ FD/^
MZ_\ ^\0_3/#K_F<?]T__ -W3^B2OYK/TP* "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MT?LX_P#9+/%OZ^+;85K#;Y_HC*>Z]#J?^#;SCQM^UD/^I1^#(_[YU?XD@_\
MUJ)[+U_0(;OT_K\C^K.LC4C,BKNSQLQGIC& <]>/H<'C@8*Y /PY_P""M?\
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M !=X9^('A'PMX\\%ZU8>)/!WC;PYHGB[PGXBTJ87&F:_X9\2:9:ZSH.M:=.
M!/8:II=Y:WUG, !);SQN ,T ='0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M_@FQ\7O"GPGB\0ZA?:O??LY?&Z3Q ?A]H5S<EKB6U^&?Q*\.:3XG\2Z'HWF
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M36Z/)L#-L5I 6VJS;0< GB@#^ /_ ()F?\&HG_!0[]C+]OC]EC]J7XH_&?\
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MZ+XL\(17&C>.%_MU;^YN/#O@:ZLX'32[R*Y /ZG: /Y._P#@XN_X(2?M;_\
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M!_39_P $9?V8OVX?V,?V)/!?[+G[='Q!^"WQ4\6_!G4;GPE\(O&WP;\5^/\
MQ5#+\$;:RL'\'^%?&%U\0?AQ\.+]-:\#W+ZKX8T,Z=87U@/ MAX4L'F2\TRY
M>Y /Y</^"KW_  :N?\%!?VZ/^"A?[3O[67PB^,?[&_A[X<?&GQEHGB+PMHWQ
M'^('QLT;QMI]GI_@;PKX;N8=?TWPQ^SWXPT*UN3J&B7DD"Z=XDU2*2R>VE>6
M&>26U@ /[GO@AX(U/X9_!?X0_#?6[FPO-9^'_P +_ '@C5[S2GN)=,NM3\*>
M%-)T&_N=.EN[:SNI+">ZL)9;-[FSM;A[=HVFMH)"T2@'YO?\%O\ ]@?XO_\
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MTCXM;C4M TB[E0;I;"W)V  ^VZ "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * /\[>O]*#^9PH * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H _HD_X('?\W7?]T+_]['7\
MU_2&_P":0_[K_P#[Q#],\.O^9Q_W3_\ W=/Z)*_FL_3 H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M6%@XR%W5^J\)8)X? 3JSBH3KUW-.VKI*G248WM\*DIR26FNFMS_/CZ4/$?\
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M1_\ D*IY(]OS'S2[_@O\A3_P70_X*&X_Y'_P$/\ NEOA+^ME1RQ[?F'-+O\
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M_P"SV_VK/_5[>/* /]?[_@CQ_P HH/\ @FY_V9!^S'_ZI_PE0!^C] '\I/\
MP>/?\HB]%_[.X^#'_J)?%:@#^2[_ (-%_P#E,S\.?^R&?'G_ -1**@#_ $XO
MVVOVH='_ &*OV3OCS^U;K_A/4O'6B_ GX?:KX_U'PAH^HVND:GX@MM+>W1].
MLM3O;>ZM+*>7SQMGGMYHU"G*'B@#^:7]C7_@[O\ @3^V#^U1\!_V7M,_8X^*
MG@'4?CI\1_#_ ,.;'QGJ_P 4?!VK:5X:N_$-P;6#5M2TZW\/Z?/<V-K)M:Z6
M&[AD2#?(F]D$;@%7_@H+_P 'A?[(/[,7Q&U_X1_LG_!_6?VT/$'A34IM'\1?
M$JT^(&G_  S^!RZA;!H[N/P3XLA\->/=?^(Z:=>1O9W&HV'AG0?">HX%[X9\
M6Z]I[Q74@!\6_ C_ (/>_#6I^-=+TK]I3]A+4O"'@&]NK:#5/&GP<^,<7C3Q
M%X?MW=([B\3P%XN\#^$+/Q!'&&><PQ>.M%N(XH_+BCO9644 ?V[_ +/G[0'P
M@_:H^"_P\_:#^ GC?2OB+\(OBEH$7B/P7XNT8S+;:C8F>>QO+6YM+J*"_P!*
MUG1=5L[_ $/Q!H6J6UIJ^@:[IVHZ+JUG::E875M$ >K:IJ>F:)IFHZUK6H6.
MD:/I%C=ZGJVK:I=V^GZ9I>F:?;R75]J&HWUU)%:V5C96L4MS=W=S+%;VUO%)
M--(D:,P /XZ?VYO^#R;]C[X!^.-;^'/[(GP3\4?MBWOA^]DTS4OB=<^,X?@_
M\';J\MY'BNW\&:I<^$_&OB[QO96DL;0#4SX6\,Z%JG%[X?UO6-)>VU"Z /C7
MX._\'P>FW7B[3[+X_P#[ 5YHG@2YG1-4\2_"#XX0^)?%6C6V$#SV7@OQEX \
M*Z3XCEW;V%O-X[\,*JE1]HD93O /Q[_X.J_VLO@'^V[^US^QW^TA^S5X^L/B
M)\*?'?[!W@Y]+UBUAN;#4-,U.P_:$_:+M-9\->)M#OXK?5/#OB?0;Y'LM7T7
M4[:"Y@<1W$/VC3[JRO+D _I*_P"#)W_E'5^T]_V>IX@_]49\$: /V=_X+'?\
M%@? W_!'KX5?"#XI>.?@MXK^-5G\7?B#JO@"QTCPGXJT?PK<Z-<Z5X<G\1/J
M-U<ZOIFIQ74$L4!MD@ACCD61A(7*C;0!\[_\$<O^#@?X7_\ !8+XN_%KX1>!
M_P!G/Q[\%=3^%'PXL?B/<ZOXJ\:^'O%=CK-C=^)M/\,/IT$.D:5I=Q9W<-QJ
M5O<K)()X985F4^4Z)Y@!^Y'QB^,?PN_9\^%_C?XT_&KQQX?^&WPK^&^@7?B;
MQMXV\3W@LM&T'1K(*'FG<+)/<W5S/)!8Z7I=A!=:KK.J75EI.D65[J=[:6DP
M!_&[^U%_P>O?LO\ @#Q9J'AO]D_]DWXC_M&:'8^;;+\1_B)X^M/@'X?U*Z1R
M([[P[X9'@?XE^+M2T22/:\;>)K/P)K#/OBETBU54FD /E;P5_P 'QGB)=6M8
M_B+_ ,$Z=%GT*2>)+V[\%?M*7UIJUE:D*)I[73M<^#%Y9ZI.AW/%:2ZIH\<@
M*Q->Q8,Q /[7?V$/VP_ W[?G[)7P8_:]^&WAGQ9X-\%_&G0]9UC1_#'CA-'3
MQ1H[>'_%GB#P7JEKJ7]@ZIK&DR*=8\-:A+83VM^YN=-DL[BX@L;J6:QM@#T?
M]HW]I7X$?LC?"+Q3\>/VD?B?X7^$7PF\&P1RZ[XP\574L5JD]P2ECI6E:?9P
M7>L>(O$.JS#[-HWAKP]IVJ:_K-UBUTK3;NX(CH _CG_:6_X/:?V>_"'B34=!
M_93_ &.?B)\;-%LKVXLXO'WQ7^(NF?!33=3B@+(FJ:+X2T?PE\3]>NM-O' D
MLTU^\\):L+5D>^TNQNB]G$ ?._@7_@^+UU=8M8OB9_P3JTF7P_-<P)>W_@7]
MI&\M]8TZS.P7%S:Z3K_P;N;+6;E/G>"REUK08I,I$]_%M,S ']K_ .PO^V'\
M._V_/V4/@Y^UY\*- \8^%O /QHT76M6T+P]X_M-&L?%NDMX=\6^(/!.KVFKV
M_A_6O$.CY37/#.I&QFLM7N5NM-:SNI4M)YI;*W /\4K]L?\ Y.\_:I_[.0^.
M/_JSO$] '^UY^PA_R8]^QK_V:G^SQ_ZJ+PA0!O\ [5/[6_[.?[$OP=U_X]?M
M1?%;PU\(OA=X=:&VN->\027,]WJNJW2R-8^'?"OA[2K:_P#$?B_Q/J"P3O8>
M'/#.E:KK-S!;7=U'9?9+.[G@ /XZOVA_^#W+X)^&_$5_HW[+O[$OC[XJZ!:W
M=Q;6_CCXP_%+2/A$+^*!FCCOK#P5X9\(_%"^DLKUAY]K_:GB/0]02U,?VS3;
M6ZDDMK8 \3^'_P#P?%:Q_;=G#\5/^"=^FGPW++&FH:C\/_VBKH:W80;5\VXL
M]%\1_"0V&KRAPQCLIM>T1"K*K7X,9:0 _JZ_X)G_ /!9+]B#_@JMX7U*\_9L
M\=ZCIGQ*\+:9;:IX]^ _Q)L+;PO\6O!]E<2);'53I$%_J>C^*_#*7DD-K)XI
M\$ZWXBT:QN+O3[+6KC2-4O[?3F /U4H _G,_X*=?\'-/[ W_  3@\;>*_@?9
M0>+?VG?VDO!TZZ=XF^%_PJDL-,\*^"-;\M)WT3XA_%765FT/1M6MHF\K4=&\
M)Z1X\\0:'J(_LSQ%HVCW2SK  ?@1J7_!\=X\?6#+H_\ P3B\(VOA\.NVPU+]
MI[6;_6&C&\/G5[7X&:=91O)^Z*@:)(L.UT)GWJ\8!_0#_P $6/\ @X8^&?\
MP6%^(?C_ .#%A^S=XZ^ 7Q4^''PTE^*>LQ7?CCP_\2/A]?\ AZV\4^'/",]M
MIGBJ'1_!'B/^V3J7B?3;B&RNO D5C]ACO6?5Q/!!#=@']%- '\V?_!3S_@Y\
M_8._X)U>-O$/P1\+Z?XC_:Q_:(\*75SIGBWP!\*]6TO1? _@#6[1/WWA[Q_\
M6=3M]4TO3_$,$Y^R:CH7@_P_X[U;P]>0WFG^*+/0M2MA92@'X.6__!\;\0QK
M"2W7_!.7P8^@>=E]/M_VF=;BUC[/F/")K$GP2FLO.4"7]X="V.6C_=((V\P
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0!_.]_P=4_\H._VM?\ L8_V;_\ UI7X34 ?S,_\&1/_
M "=K^VO_ -FZ>"O_ %9=M0!_I#T % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M\.:#9LZI&)98=-TZV6><HKW$PDF?YY&H ]&H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /\[>O]*#
M^9PH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H _HD_X('?\W7?]T+_]['7\U_2&_P":0_[K_P#[Q#],\.O^
M9Q_W3_\ W=/Z)*_FL_3 H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M7-LTQ>=YGC\WQU253%9CBJN*K2ETE5ES<J72,/AA'[,4H]+'>UH>>% !0 4
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M^11]>WMI!J%G=V%TADM;VVGM+B-7DB9X+F)H9D66%XY8RT;LH>*1)$)W(ZL
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M>RL[>&UM+>VC01QP06\"1Q00QH-L<42I&@X514[E%V@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H __3_OXH * "@ H * /\S_\ X/8/BUK/B#]O?]EO
MX)M>>;X7^&'[*,?C^QLPQQ9^+/B]\5O'FC^)7*YVA[K0/A+X%8D*"R1(&)"K
MM /Z1_\ @T5^"VC_  R_X(X^ /B!8P;=5_:*^-?QO^*>N73Q*)I)/#/C"7X%
MZ?:I-R[V5M8_"".>"+(BBN[[4)(T#W$SR ']/- '^'%_P4O_ .4CW_!0'_L]
MO]JS_P!7MX\H _U_O^"/'_**#_@FY_V9!^S'_P"J?\)4 ?H_0!_*3_P>/?\
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M5U2QOY9;=HXEU[X97FKRWE^R_NK;5?#=QOB=(FB8 _R#/V6_ACX>_:5_:P^
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M[;^+=?\ "/A:_O?[.F^)'@;Q=9V6F:CJ/AK0;F[TN'Q7X9UW3M4U+2M*FO\
MQ</%#Z1IM_I]F ?RY_\ !-G_ )2*_L#?]GJ?LL?^KR\"T ?[DE '\P'_  =W
M?!;1_B9_P1U\<?$*]@SJO[.GQO\ @C\4-$NTC!EC;Q1XK7X&:A:23<.EC=6G
MQ<\^:')BEO+#37=#);PO& ?S>?\ !D_\6]9\/?M\_M1?!-;SR?"_Q0_91E\>
MWMGN;%YXL^$/Q5\!Z3X9<+D(6M?#_P 6/'C!BI95E<*5#/D _P!,*@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * /\[>O]*#^9PH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H _HD_P""!W_-UW_="_\ WL=?S7](;_FD
M/^Z__P"\0_3/#K_F<?\ =/\ _=T_HDK^:S],"@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M*]@_*1: "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H _]3^_B@ H * "@ H _RG_P#@\'.K'_@L'?C4?^/-?V9?@@-
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MG;XYZO=\9Q;S:?H&@KG^Z/M>MVHSZD+WH _T _\ @O)_RAV_X*&_]FW^+O\
MT?IU '^5=_P1:T#2_$O_  5J_P""<^EZQ;K=6*?M?_ W5_(;&QKSP[XYTGQ#
MIAD4@AXX]3TNSEDB8%)41HV&UC0!_M?T ?PU?\'O^D6,W[/'[!FNR1 ZEIOQ
MG^+^D6DW&8['6O _A:\U"+IG$T^@:8YP0/W R#Q@ ^#?^#(F20?M:_MKQ!W$
M3_LZ>"I'C#$1M)%\2[98W9/NEXUEE5&(RHDD"X#MD ^*/^#PCQ)J6N?\%@KW
M2[Z2X>U\&?LR?!'PWHR3,QBBTZZN/&GB^5+,'A+<ZOXJU21E3"FZ>Y8_,S4
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MXP>.ET!?%GCK7O@WXNM]4UI?"_AG1O!V@+<0:/X0TS38QIGAGP_HVDPBVL8
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * /\[>O]*#^9PH * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H _H
MD_X('?\ -UW_ '0O_P!['7\U_2&_YI#_ +K_ /[Q#],\.O\ F<?]T_\ ]W3^
MB2OYK/TP* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M=2:]UWY+7DY??HX ']<_J:]4_+TK(6@84 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!__U?[^* "@ H * "@#_,\_
MX/7_ (2ZSX?_ &^_V7OC4UEY/A?XG_LH0> K&]"D"]\6?"+XK>/M5\3(6VA2
MUIX?^*_@-2H8LJRIN"ADR ?TC_\ !HI\:]'^)W_!'/P'\/+*?.K?LY?&SXW?
M"S6[5Y%,T;>)_%TGQTTZ[2'ATL;FR^+RVT$N#%+=Z?J,<;E[>9(P#^GR@#_(
M?_X.@/V2/$'[+G_!7;X_^(I-(:T\ ?M0G2?VDOAYJD<3BUU-O&UJMC\2H))@
MOV==6L/BQH_C26[LED>YCTS4-#U*Y2)-7MPP!^P/_!K[_P %^/@+^RI\)IO^
M"?'[;OCB'X7?#_3/%NN>*?V=?C5KR7<G@;PVGC74FUCQ9\+O'E]:17'_  B&
MF2^++S5/&7AKQ=?P+X<CNO$/BBR\3ZMHD5OH;WH!_<3XA_X*3?\ !/+PIX,E
M^(>O?MS_ +(MCX)BLOMZ>)%_:*^$MWIMY;&-9(O[+DL?%ER^KW%R'C6RLM+C
MO+R]EEBAL[>::6.-@#_-)_X.6O\ @L_X$_X*D_'OX<?#3]F^ZU6\_93_ &:H
MO$H\*^*]4T[4=!N/B]\1_%K:=;^)?B F@:G%9ZGIWA72])T73/#_ ($M=>TZ
MRU](IO%&LWMM8IXEBTK3@#]<_P#@R;_8Z\1#Q5^U=^WIX@TE[/PO'X7T_P#9
M>^&&HW-M(/[=U34M:\/?$GXKW&GR2!$$'A^'P]\,M.-W )EN;C7-2L5FA?3;
MR&4 _JK_ ."\G_*';_@H;_V;?XN_]'Z=0!_EC_\ !#S_ )2]?\$ZO^SK/A5_
MZ?8J /\ :FH _A]_X/>O^38/V&O^R]?$G_U7MA0!^>__  9%?\G<_MJ_]FX^
M#?\ U9ME0!QW_!ZC^S=X@\&?MP_LZ_M06VG7'_"#?'#X 1_#FXU0*9;=/B/\
M&?%FNW.KVDTB#;9F[\%?$#P.^G03[6O6TW69K5IA:7:VP!-_P:1?\%<O@S^R
M%XN^+?[#G[3?CG0?AC\./C]XRT7XD?!GX@^)Y5TKPII'QHDTO3/!7B3PGXN\
M13?\2_0;3Q[X:T;P>?#^MZY-IF@Z=JWA"XTR]U!;OQ-IJ* ?Z)GQ;_:-^ GP
M%^%NK?&SXR?&#X>?#GX3:+HUSK]YX]\3^*=)L/#LNF6L'GE]+O#<M_;MU<+L
MBTW3-$34-3U:[FMK'2[.\O;FWMY #_'J_P""Y'_!1;2O^"GG_!1#XJ_M%>#+
M6YL_A#H6FZ+\'_@:FH6ES8ZO??"OP!/JC:7XCU>RN]EQ87WC3Q#K7B;QJ-*G
MM[:YT.S\0VFAWD3WNFW%S. ?VK?\&3O_ "CJ_:>_[/4\0?\ JC/@C0!YW_P>
MZ?\ )H?[%G_9R'B__P!5CJ% 'YE_\&2'_)ZW[8?_ &:WH_\ ZMCPI0!_=O\
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M/B5<VH>4Z?HOQAM?#6L>!M8OXP"+;2M/\2^ M6T%[[*)_:WC31K*7?)=VH0
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M"EE9EA<J"%? !_IB4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % '^=O7^E!_,X4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 ?T2?\$#O^;KO^Z%_^]CK^:_I#?\TA
M_P!U_P#]XA^F>'7_ #./^Z?_ .[I_1)7\UGZ8% !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MRW@3#\W(U%9WC(/DE'1MX;#3C&I):M7KQARR5E"4=3^D3X9_"_P!\(?"&D^
MOAGX-T#P-X.T.$0:;X?\/:=;Z=80+L7?,Z0*&N[N=AON[^[::_O)]T]W<3RL
M96^XITJ-&*A0IJE".BC%*,%_AC'1>>E]#^0LUS?,\]Q=7,,XQM?'XVO)RJUL
M1+G;;=[)7Y8P7V812C'6UD['H=6><% !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M_P!A>$OC7KWB75#!"F5LM%T;4;Z9B%AMGYP ?Z?= '\K_P#P=-_\$WOVSO\
M@H[\!?V5?!O[&7P<'QC\3?#7XN^-?$WC32O^%A_"OX>-H^A:SX-MM*T_4!>?
M%3QOX'TW41-?PM;-:Z7>7M[$2LLEJD&90 ?'/_!K/_P2*_X*%_\ !.3]HG]J
M'Q[^V9^S\/@WX5^(?P6\,>$/!NI?\+7^"7Q";6?$%AXYM]9O+$67PJ^)'CF_
MT\6^G0M.;K5K6PLY"5A@GEFS& #^F7_@IA_P3G^!_P#P5#_94\7_ ++_ ,;E
MNM)AO[JV\4?#GXBZ-:6MUXF^%/Q+T:WNX?#WC?08;O9!>+%#?7^C>(=$EFM8
MO$7A75]:T3[=ID][;ZK8 '^8C^UA_P &QO\ P5V_9D\;ZMH?AW]G'4_VF/ <
M=[/'X:^*'[/-_IOC/3_$%@IWP37G@>2\LOB1X7OU@>);ZSUKPK'I\=[Y]MI&
MM:Y;0"_E ,G]F3_@V@_X+"?M(^,=*\.7_P"R[KW[/WA&6Z@_MOXC?M#:GIOP
M]\/>'+.>:.&XO/\ A&Y+F^^(.NW*Q(TBV7AOP?J<K^3&MU)9PO'/0!^G?_!3
M'_@U"_;$^'?BG]FWP#_P3D^!=]^TCX(\*_LWZ59?';XU:M\4O@/\*]5\=_M#
MWOQ0^*&K^)]2E\'_ !-^+/A;4=*TJT\&:AX"TCPU8:-%JVE:=X=TW3;&\UW6
MO$L&OZI> ']-O_!KM_P3[_:Z_P""=/[%OQU^%'[8_P )A\'OB#XS_:@UKXA^
M&_#H\>?#3X@MJ'@ZY^%/PK\-6^LG5?A;XR\;:%9B;6O#NM62Z?>ZG;:JGV$W
M$MA':7%G/< '&?\ !TO_ ,$Y?VR?^"C?[.'[,7@3]C/X/CXQ^+/AU\;?$7BW
MQAH__"P?A;\/6TGP[J'@2^T>UU(7WQ4\;>!]*OP^I/%:M::9?7E^AD69K06R
MR3( ?#'_  :U_P#!(/\ X*(?\$YOVG_VE/B-^V7^SX/@YX.\?? 72_!/A'5?
M^%L?!#XA-J_B6'XA:!KLVG#3_A5\2O'&I6 BTNPN;DWFJ6=C8L56&.Y>=EBH
M ]+_ .#I7_@C;^W-_P %'O'7[.WQK_8_\$>$?BC:?!KX8^,?!OBSP#/X\T#P
M=X^N[S5?$]OX@M;_ ,.V_C.;0?"FK6(LDFBEMSXLM=8:ZB6"STJ\,T9(!_'-
MHO\ P2'_ ."\_P +/,\&>#_V1_VW_"%C?2LMQIW@"3Q/;>%[B23=&[75YX/\
M0MX:97$CAYKBZ\LH[EGV%C0!]C_L?_\ !IS_ ,%6OVD_%EM+\</!GAG]D'X<
M_;[>77_&OQA\4:)XD\8WMG-(KZ@_A3X;^ =7\1ZYJNMQ))YJ0>,]0\!:1=2%
MT_X2 31R1@ _TNOV#_V&O@-_P3J_9G\!_LM?L[:)=Z9X&\&QW%_J>LZQ<+?>
M*O'GC35E@?Q/X^\8ZBD<$5[XC\1W5O%)<"UM[32]+L;?3]"T.PTW0M)TS3K4
M _*+_@N-_P &_GP>_P""MVAZ9\4?!?B33/@?^V-X&T%/#_A?XHW6FRWO@[XA
M>&;6::[L? WQ=TW3(FU:>QT^>XNO^$:\9Z,MSKWA5;Z[BFTKQ1I(M=%MP#_/
MP^.?_!M]_P %EO@1XDO-"O\ ]C#QM\4--AGG33?&'P,U?PS\5_#>NVL,ODKJ
M%E!X:U:7Q7I<%QCS(+3Q7X8\.:QY1$DNF0KT (?@[_P;E?\ !9WXVZ]HVC6/
M[%/Q"\ 6%].EK/XH^-&L^%/A?H'AZSW,TE[J</BO7K3Q&;.WRTC6NB>'M7U.
M8L19Z;<RML(!_J1?\$F?V/O'O[ W_!/#]F3]D;XH>(O"7BOX@?!KPIXDTSQ3
MKO@2;5[GPC>:GXE^(7B_QPT6A76O:5H6KW=E80^)XM.^UWVC:9+=2VDMP+*W
MCD2, '^</^TQ_P &SW_!;7Q]^T?^T#XZ\(?L6#6?"7C7XV_%;Q;X7UA?VCOV
M3-/75?#OB/QWKVL:)J2V&K?'>PU2R%]IMY;70M-2L;*_MA+Y-Y:6UPDD* '^
MH9^R=X'\3_#']EC]FGX;>-M.&C^,_A[^S_\ !OP/XNTA;RPU%=+\3^$_AUX<
MT'7M.74-+N;W3+X6.JV%U;"\TZ\N["Z$7GV=S/;O'*P!^-O_  7!_P"" GP7
M_P""N/A[2?B/X9\1V/P0_; \!:%_8'@[XM/I;ZAX6\<>&;>XFO;/P%\7-*L%
M74[[1[*YN;U_#?BK2&?7O",NHWC"P\2:4W]@. ?Y]GQZ_P"#;/\ X++? /Q#
M?:-=_L<^*_BSI%O/<QZ;XS^ NN^&OBKX=UZVMI#&+^QT[0]43QOID%Q@26UK
MXK\'^'-6DC(8Z:F"  <C\+_^#>3_ (+-_%[Q%;Z!I'["/Q=\,R22>3<:W\5;
MCPI\*M L+>W98)+FXU;XA>(_#\=Q;V\:AHH=+74+RZ@0#3;.\.Q" ?V^_P#!
M#/\ X-BO!'_!.SQIH/[5G[6_BKPK\;_VL-#B:?X=>&_"<-[<?"+X%WE]8O:7
M>M:7=ZY8Z?J?C[XBQ6]Q<6MAXHOM(T31O"OG3R>']'O=8AT[Q7;@'[O_ /!4
M;]F;X@_MD?\ !/G]K#]F#X47?AJQ^(_QF^$NK^$/!UQXPU"\TGPTNMRW=A?V
ML6KZEI^FZQ=V-M<?86MA<Q:;="*66-I46$22( ?Y9GC'_@@!_P %P_V;O&%U
M-HW['7QNDU?19F33_&WP#\4^'O&\5Y 2&BO-&U?X9>+;_68H9U"2"WNK73]2
M@XCOK"UG1HE -;PM_P $#_\ @NO^U-XLT0^+?V4_CO)>7+0Z5_PFO[1OCC1_
M"EKX>TP2,\D]_>?$WQ?#XBCTNSS)<-9Z1IFHWLQRFGZ;=W4L<,@!_<M_P05_
MX-T_"/\ P2KO=2_:'^/WBKPK\9?VRM>TF]\.:/K7@X:P_P -?@MX0U:UC@US
M1O <FO:?HVJ^(?%/B5?-M?$/CK5M#T>:/0ROAGP]I&EV5SXCO_% !_1!\?/@
M1\*OVG?@S\2/V?\ XW^$=/\ '7PH^+'A74?!WC;POJ080ZAI.HH,36MS$4NM
M,UC2KR.UU?0-;T^6WU30=<L-.UG2KJUU&PM;B( _S1?^"A__  :*?MZ_L_>.
M/$?B+]B6RLOVO_@+<7E_J'AW3K?Q'X5\)?';P?HWFF6WT?Q?X6\37WAG0?&E
M[90RQ64&M?#G4+^]\0R6\^H2^"/"RR1Z>H!^5GA'_@BK_P %MK.?4_"GA/\
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M,B),\^X _JKH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * /Y,/^')_[8O\ T$_@Q_X6VN__ #&5_87_ !'7@K_GSGG_ (08?_YN/QO_
M %#SO^; _P#@^I_\H#_AR?\ MB_]!/X,?^%MKO\ \QE'_$=>"O\ GSGG_A!A
M_P#YN#_4/._YL#_X/J?_ "@/^')_[8O_ $$_@Q_X6VN__,91_P 1UX*_Y\YY
M_P"$&'_^;@_U#SO^; _^#ZG_ ,H#_AR?^V+_ -!/X,?^%MKO_P QE'_$=>"O
M^?.>?^$&'_\ FX/]0\[_ )L#_P"#ZG_R@/\ AR?^V+_T$_@Q_P"%MKO_ ,QE
M'_$=>"O^?.>?^$&'_P#FX/\ 4/._YL#_ .#ZG_R@/^')_P"V+_T$_@Q_X6VN
M_P#S&4?\1UX*_P"?.>?^$&'_ /FX/]0\[_FP/_@^I_\ * _X<G_MB_\ 03^#
M'_A;:[_\QE'_ !'7@K_GSGG_ (08?_YN#_4/._YL#_X/J?\ R@/^')_[8O\
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MA_\ YN#_ %#SO^; _P#@^I_\H#_AR?\ MB_]!/X,?^%MKO\ \QE'_$=>"O\
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M_P"V+_T$_@Q_X6VN_P#S&4?\1UX*_P"?.>?^$&'_ /FX/]0\[_FP/_@^I_\
M* _X<G_MB_\ 03^#'_A;:[_\QE'_ !'7@K_GSGG_ (08?_YN#_4/._YL#_X/
MJ?\ R@/^')_[8O\ T$_@Q_X6VN__ #&4?\1UX*_Y\YY_X08?_P";@_U#SO\
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % $;11M]Y03Z]^..".GX4?-K9Z-K;T:_X/45OQ_X;\AP4
M 8 XZ_Y_*@8Z@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@#_U_[^* "@ H * "@#G_%GA7PYX[\*^)?
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M(!^F% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MAMX(XUX44 ;] !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 ?__0_OXH * "@ H * "@#AO''PP^&OQ.M;"Q^)/P\\#?
M$*RTN>6ZTRS\<>$M \66NG74\8AFN;"WU[3[^*SGFB58I9K=(Y)(P$9BH H
ME\$?#?X=_#/3[K2/AOX"\%_#[2;Z\.HWVF>"/"VA^%-/O-0,$-J;^ZLM!L;"
MVN+PVUO;VYNI8GG,$$,6_P N)%4 [2@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H X3QS\+OAG\3K?3[3XE?#KP+\0K729IKC2K;QSX1\/^++?3;B
MY1(KB?3X=>T^_CLYIXXXXYI;98WE2-$<LJJ  3>"/AK\.?AG8W>F?#CP!X*^
M'^FW]PMW?:?X(\*Z%X4L;R[1/*6YN[30;"P@N+A8_P!VLTT;R!/D#!>* .UH
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H __T?[^* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * /_2_OXH * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H _]/^_B@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@#_U/[./V_/VK?^&&_V-OVA/VMO^$"_X6A_PH?P!=^.?^%?_P#"4?\ "$_\
M)5]EOK"R_LO_ (2O_A'/%O\ 8>_[;YGVW_A&]8V^5L^R-OW( ?QA_P#$<Y_U
MBZ_\W8__ "1Z #_B.<_ZQ=?^;L?_ )(] !_Q'.?]8NO_ #=C_P#)'H /^(YS
M_K%U_P";L?\ Y(] !_Q'.?\ 6+K_ ,W8_P#R1Z #_B.<_P"L77_F['_Y(] !
M_P 1SG_6+K_S=C_\D>@ _P"(YS_K%U_YNQ_^2/0 ?\1SG_6+K_S=C_\ )'H
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M_B.<_P"L77_F['_Y(] !_P 1SG_6+K_S=C_\D>@ _P"(YS_K%U_YNQ_^2/0
M?\1SG_6+K_S=C_\ )'H /^(YS_K%U_YNQ_\ DCT '_$<Y_UBZ_\ -V/_ ,D>
M@ _XCG/^L77_ )NQ_P#DCT '_$<Y_P!8NO\ S=C_ /)'H /^(YS_ *Q=?^;L
M?_DCT '_ !'.?]8NO_-V/_R1Z #_ (CG/^L77_F['_Y(] !_Q'.?]8NO_-V/
M_P D>@ _XCG/^L77_F['_P"2/0 ?\1SG_6+K_P W8_\ R1Z #_B.<_ZQ=?\
MF['_ .2/0 ?\1SG_ %BZ_P#-V/\ \D>@ _XCG/\ K%U_YNQ_^2/0 ?\ $<Y_
MUBZ_\W8__)'H /\ B.<_ZQ=?^;L?_DCT '_$<Y_UBZ_\W8__ "1Z #_B.<_Z
MQ=?^;L?_ )(] !_Q'.?]8NO_ #=C_P#)'H /^(YS_K%U_P";L?\ Y(] !_Q'
M.?\ 6+K_ ,W8_P#R1Z #_B.<_P"L77_F['_Y(] !_P 1SG_6+K_S=C_\D>@
M_P"(YS_K%U_YNQ_^2/0 ?\1SG_6+K_S=C_\ )'H /^(YS_K%U_YNQ_\ DCT
M'_$<Y_UBZ_\ -V/_ ,D>@ _XCG/^L77_ )NQ_P#DCT '_$<Y_P!8NO\ S=C_
M /)'H /^(YS_ *Q=?^;L?_DCT '_ !'.?]8NO_-V/_R1Z #_ (CG/^L77_F[
M'_Y(] !_Q'.?]8NO_-V/_P D>@ _XCG/^L77_F['_P"2/0 ?\1SG_6+K_P W
M8_\ R1Z #_B.<_ZQ=?\ F['_ .2/0 ?\1SG_ %BZ_P#-V/\ \D>@ _XCG/\
MK%U_YNQ_^2/0 ?\ $<Y_UBZ_\W8__)'H /\ B.<_ZQ=?^;L?_DCT '_$<Y_U
MBZ_\W8__ "1Z #_B.<_ZQ=?^;L?_ )(] !_Q'.?]8NO_ #=C_P#)'H /^(YS
M_K%U_P";L?\ Y(] !_Q'.?\ 6+K_ ,W8_P#R1Z #_B.<_P"L77_F['_Y(] !
M_P 1SG_6+K_S=C_\D>@ _P"(YS_K%U_YNQ_^2/0 ?\1SG_6+K_S=C_\ )'H
M/^(YS_K%U_YNQ_\ DCT '_$<Y_UBZ_\ -V/_ ,D>@ _XCG/^L77_ )NQ_P#D
MCT '_$<Y_P!8NO\ S=C_ /)'H /^(YS_ *Q=?^;L?_DCT '_ !'.?]8NO_-V
M/_R1Z #_ (CG/^L77_F['_Y(] !_Q'.?]8NO_-V/_P D>@ _XCG/^L77_F['
M_P"2/0 ?\1SG_6+K_P W8_\ R1Z #_B.<_ZQ=?\ F['_ .2/0 ?\1SG_ %BZ
M_P#-V/\ \D>@ _XCG/\ K%U_YNQ_^2/0 ?\ $<Y_UBZ_\W8__)'H /\ B.<_
MZQ=?^;L?_DCT '_$<Y_UBZ_\W8__ "1Z #_B.<_ZQ=?^;L?_ )(] !_Q'.?]
M8NO_ #=C_P#)'H /^(YS_K%U_P";L?\ Y(] !_Q'.?\ 6+K_ ,W8_P#R1Z #
M_B.<_P"L77_F['_Y(] !_P 1SG_6+K_S=C_\D>@ _P"(YS_K%U_YNQ_^2/0
M?\1SG_6+K_S=C_\ )'H /^(YS_K%U_YNQ_\ DCT '_$<Y_UBZ_\ -V/_ ,D>
M@ _XCG/^L77_ )NQ_P#DCT '_$<Y_P!8NO\ S=C_ /)'H /^(YS_ *Q=?^;L
M?_DCT '_ !'.?]8NO_-V/_R1Z #_ (CG/^L77_F['_Y(] !_Q'.?]8NO_-V/
M_P D>@ _XCG/^L77_F['_P"2/0 ?\1SG_6+K_P W8_\ R1Z #_B.<_ZQ=?\
MF['_ .2/0 ?\1SG_ %BZ_P#-V/\ \D>@ _XCG/\ K%U_YNQ_^2/0 ?\ $<Y_
MUBZ_\W8__)'H /\ B.<_ZQ=?^;L?_DCT '_$<Y_UBZ_\W8__ "1Z #_B.<_Z
MQ=?^;L?_ )(] !_Q'.?]8NO_ #=C_P#)'H /^(YS_K%U_P";L?\ Y(] !_Q'
M.?\ 6+K_ ,W8_P#R1Z #_B.<_P"L77_F['_Y(] !_P 1SG_6+K_S=C_\D>@
M_P"(YS_K%U_YNQ_^2/0 ?\1SG_6+K_S=C_\ )'H /^(YS_K%U_YNQ_\ DCT
M'_$<Y_UBZ_\ -V/_ ,D>@ _XCG/^L77_ )NQ_P#DCT '_$<Y_P!8NO\ S=C_
M /)'H /^(YS_ *Q=?^;L?_DCT '_ !'.?]8NO_-V/_R1Z #_ (CG/^L77_F[
M'_Y(] !_Q'.?]8NO_-V/_P D>@ _XCG/^L77_F['_P"2/0 ?\1SG_6+K_P W
M8_\ R1Z #_B.<_ZQ=?\ F['_ .2/0 ?\1SG_ %BZ_P#-V/\ \D>@ _XCG/\
MK%U_YNQ_^2/0 ?\ $<Y_UBZ_\W8__)'H /\ B.<_ZQ=?^;L?_DCT '_$<Y_U
MBZ_\W8__ "1Z #_B.<_ZQ=?^;L?_ )(] !_Q'.?]8NO_ #=C_P#)'H /^(YS
M_K%U_P";L?\ Y(] !_Q'.?\ 6+K_ ,W8_P#R1Z #_B.<_P"L77_F['_Y(] !
M_P 1SG_6+K_S=C_\D>@ _P"(YS_K%U_YNQ_^2/0 ?\1SG_6+K_S=C_\ )'H
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M_B.<_P"L77_F['_Y(] !_P 1SG_6+K_S=C_\D>@ _P"(YS_K%U_YNQ_^2/0
M?\1SG_6+K_S=C_\ )'H /^(YS_K%U_YNQ_\ DCT '_$<Y_UBZ_\ -V/_ ,D>
M@ _XCG/^L77_ )NQ_P#DCT '_$<Y_P!8NO\ S=C_ /)'H /^(YS_ *Q=?^;L
M?_DCT '_ !'.?]8NO_-V/_R1Z #_ (CG/^L77_F['_Y(] !_Q'.?]8NO_-V/
M_P D>@ _XCG/^L77_F['_P"2/0 ?\1SG_6+K_P W8_\ R1Z #_B.<_ZQ=?\
MF['_ .2/0 ?\1SG_ %BZ_P#-V/\ \D>@ _XCG/\ K%U_YNQ_^2/0 ?\ $<Y_
MUBZ_\W8__)'H /\ B.<_ZQ=?^;L?_DCT '_$<Y_UBZ_\W8__ "1Z #_B.<_Z
MQ=?^;L?_ )(] !_Q'.?]8NO_ #=C_P#)'H /^(YS_K%U_P";L?\ Y(] !_Q'
M.?\ 6+K_ ,W8_P#R1Z #_B.<_P"L77_F['_Y(] !_P 1SG_6+K_S=C_\D>@
M_P"(YS_K%U_YNQ_^2/0 ?\1SG_6+K_S=C_\ )'H /^(YS_K%U_YNQ_\ DCT
M'_$<Y_UBZ_\ -V/_ ,D>@ _XCG/^L77_ )NQ_P#DCT '_$<Y_P!8NO\ S=C_
M /)'H /^(YS_ *Q=?^;L?_DCT '_ !'.?]8NO_-V/_R1Z #_ (CG/^L77_F[
M'_Y(] !_Q'.?]8NO_-V/_P D>@ _XCG/^L77_F['_P"2/0 ?\1SG_6+K_P W
M8_\ R1Z #_B.<_ZQ=?\ F['_ .2/0 ?\1SG_ %BZ_P#-V/\ \D>@ _XCG/\
MK%U_YNQ_^2/0 ?\ $<Y_UBZ_\W8__)'H /\ B.<_ZQ=?^;L?_DCT '_$<Y_U
MBZ_\W8__ "1Z #_B.<_ZQ=?^;L?_ )(] !_Q'.?]8NO_ #=C_P#)'H /^(YS
M_K%U_P";L?\ Y(] !_Q'.?\ 6+K_ ,W8_P#R1Z #_B.<_P"L77_F['_Y(] !
M_P 1SG_6+K_S=C_\D>@ _P"(YS_K%U_YNQ_^2/0 ?\1SG_6+K_S=C_\ )'H
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M_B.<_P"L77_F['_Y(] !_P 1SG_6+K_S=C_\D>@ _P"(YS_K%U_YNQ_^2/0
M?\1SG_6+K_S=C_\ )'H /^(YS_K%U_YNQ_\ DCT '_$<Y_UBZ_\ -V/_ ,D>
M@ _XCG/^L77_ )NQ_P#DCT '_$<Y_P!8NO\ S=C_ /)'H /^(YS_ *Q=?^;L
M?_DCT '_ !'.?]8NO_-V/_R1Z #_ (CG/^L77_F['_Y(] !_Q'.?]8NO_-V/
M_P D>@ _XCG/^L77_F['_P"2/0 ?\1SG_6+K_P W8_\ R1Z #_B.<_ZQ=?\
MF['_ .2/0 ?\1SG_ %BZ_P#-V/\ \D>@ _XCG/\ K%U_YNQ_^2/0 ?\ $<Y_
MUBZ_\W8__)'H /\ B.<_ZQ=?^;L?_DCT '_$<Y_UBZ_\W8__ "1Z #_B.<_Z
MQ=?^;L?_ )(] !_Q'.?]8NO_ #=C_P#)'H /^(YS_K%U_P";L?\ Y(] !_Q'
M.?\ 6+K_ ,W8_P#R1Z #_B.<_P"L77_F['_Y(] !_P 1SG_6+K_S=C_\D>@
M_P"(YS_K%U_YNQ_^2/0 ?\1SG_6+K_S=C_\ )'H /^(YS_K%U_YNQ_\ DCT
M'_$<Y_UBZ_\ -V/_ ,D>@ _XCG/^L77_ )NQ_P#DCT '_$<Y_P!8NO\ S=C_
M /)'H /^(YS_ *Q=?^;L?_DCT '_ !'.?]8NO_-V/_R1Z #_ (CG/^L77_F[
M'_Y(] !_Q'.?]8NO_-V/_P D>@ _XCG/^L77_F['_P"2/0 ?\1SG_6+K_P W
M8_\ R1Z #_B.<_ZQ=?\ F['_ .2/0 ?\1SG_ %BZ_P#-V/\ \D>@ _XCG/\
MK%U_YNQ_^2/0 ?\ $<Y_UBZ_\W8__)'H /\ B.<_ZQ=?^;L?_DCT '_$<Y_U
MBZ_\W8__ "1Z #_B.<_ZQ=?^;L?_ )(] !_Q'.?]8NO_ #=C_P#)'H /^(YS
M_K%U_P";L?\ Y(] !_Q'.?\ 6+K_ ,W8_P#R1Z #_B.<_P"L77_F['_Y(] !
M_P 1SG_6+K_S=C_\D>@ _P"(YS_K%U_YNQ_^2/0 ?\1SG_6+K_S=C_\ )'H
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M_B.<_P"L77_F['_Y(] !_P 1SG_6+K_S=C_\D>@ _P"(YS_K%U_YNQ_^2/0
M?\1SG_6+K_S=C_\ )'H /^(YS_K%U_YNQ_\ DCT '_$<Y_UBZ_\ -V/_ ,D>
M@ _XCG/^L77_ )NQ_P#DCT '_$<Y_P!8NO\ S=C_ /)'H /^(YS_ *Q=?^;L
M?_DCT '_ !'.?]8NO_-V/_R1Z #_ (CG/^L77_F['_Y(] !_Q'.?]8NO_-V/
M_P D>@ _XCG/^L77_F['_P"2/0 ?\1SG_6+K_P W8_\ R1Z #_B.<_ZQ=?\
MF['_ .2/0 ?\1SG_ %BZ_P#-V/\ \D>@ _XCG/\ K%U_YNQ_^2/0 ?\ $<Y_
MUBZ_\W8__)'H /\ B.<_ZQ=?^;L?_DCT '_$<Y_UBZ_\W8__ "1Z #_B.<_Z
MQ=?^;L?_ )(] !_Q'.?]8NO_ #=C_P#)'H /^(YS_K%U_P";L?\ Y(] !_Q'
M.?\ 6+K_ ,W8_P#R1Z #_B.<_P"L77_F['_Y(] !_P 1SG_6+K_S=C_\D>@
M_P"(YS_K%U_YNQ_^2/0 ?\1SG_6+K_S=C_\ )'H /^(YS_K%U_YNQ_\ DCT
M'_$<Y_UBZ_\ -V/_ ,D>@ _XCG/^L77_ )NQ_P#DCT '_$<Y_P!8NO\ S=C_
M /)'H /^(YS_ *Q=?^;L?_DCT '_ !'.?]8NO_-V/_R1Z #_ (CG/^L77_F[
M'_Y(] !_Q'.?]8NO_-V/_P D>@ _XCG/^L77_F['_P"2/0 ?\1SG_6+K_P W
M8_\ R1Z #_B.<_ZQ=?\ F['_ .2/0 ?\1SG_ %BZ_P#-V/\ \D>@ _XCG/\
MK%U_YNQ_^2/0 ?\ $<Y_UBZ_\W8__)'H /\ B.<_ZQ=?^;L?_DCT '_$<Y_U
MBZ_\W8__ "1Z #_B.<_ZQ=?^;L?_ )(] !_Q'.?]8NO_ #=C_P#)'H /^(YS
M_K%U_P";L?\ Y(] !_Q'.?\ 6+K_ ,W8_P#R1Z #_B.<_P"L77_F['_Y(] !
M_P 1SG_6+K_S=C_\D>@ _P"(YS_K%U_YNQ_^2/0 ?\1SG_6+K_S=C_\ )'H
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M_B.<_P"L77_F['_Y(] !_P 1SG_6+K_S=C_\D>@ _P"(YS_K%U_YNQ_^2/0
M?\1SG_6+K_S=C_\ )'H /^(YS_K%U_YNQ_\ DCT '_$<Y_UBZ_\ -V/_ ,D>
M@ _XCG/^L77_ )NQ_P#DCT '_$<Y_P!8NO\ S=C_ /)'H /^(YS_ *Q=?^;L
M?_DCT '_ !'.?]8NO_-V/_R1Z #_ (CG/^L77_F['_Y(] !_Q'.?]8NO_-V/
M_P D>@ _XCG/^L77_F['_P"2/0 ?\1SG_6+K_P W8_\ R1Z #_B.<_ZQ=?\
MF['_ .2/0 ?\1SG_ %BZ_P#-V/\ \D>@ _XCG/\ K%U_YNQ_^2/0 ?\ $<Y_
MUBZ_\W8__)'H /\ B.<_ZQ=?^;L?_DCT '_$<Y_UBZ_\W8__ "1Z #_B.<_Z
MQ=?^;L?_ )(] !_Q'.?]8NO_ #=C_P#)'H /^(YS_K%U_P";L?\ Y(] !_Q'
M.?\ 6+K_ ,W8_P#R1Z #_B.<_P"L77_F['_Y(] !_P 1SG_6+K_S=C_\D>@
M_P"(YS_K%U_YNQ_^2/0 ?\1SG_6+K_S=C_\ )'H /^(YS_K%U_YNQ_\ DCT
M'_$<Y_UBZ_\ -V/_ ,D>@ _XCG/^L77_ )NQ_P#DCT '_$<Y_P!8NO\ S=C_
M /)'H /^(YS_ *Q=?^;L?_DCT '_ !'.?]8NO_-V/_R1Z #_ (CG/^L77_F[
M'_Y(] !_Q'.?]8NO_-V/_P D>@ _XCG/^L77_F['_P"2/0 ?\1SG_6+K_P W
M8_\ R1Z #_B.<_ZQ=?\ F['_ .2/0 ?\1SG_ %BZ_P#-V/\ \D>@ _XCG/\
MK%U_YNQ_^2/0 ?\ $<Y_UBZ_\W8__)'H /\ B.<_ZQ=?^;L?_DCT '_$<Y_U
MBZ_\W8__ "1Z #_B.<_ZQ=?^;L?_ )(] !_Q'.?]8NO_ #=C_P#)'H /^(YS
M_K%U_P";L?\ Y(] !_Q'.?\ 6+K_ ,W8_P#R1Z #_B.<_P"L77_F['_Y(] !
M_P 1SG_6+K_S=C_\D>@ _P"(YS_K%U_YNQ_^2/0 ?\1SG_6+K_S=C_\ )'H
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M_B.<_P"L77_F['_Y(] !_P 1SG_6+K_S=C_\D>@ _P"(YS_K%U_YNQ_^2/0
M?\1SG_6+K_S=C_\ )'H /^(YS_K%U_YNQ_\ DCT '_$<Y_UBZ_\ -V/_ ,D>
M@ _XCG/^L77_ )NQ_P#DCT '_$<Y_P!8NO\ S=C_ /)'H /^(YS_ *Q=?^;L
M?_DCT '_ !'.?]8NO_-V/_R1Z #_ (CG/^L77_F['_Y(] !_Q'.?]8NO_-V/
M_P D>@ _XCG/^L77_F['_P"2/0 ?\1SG_6+K_P W8_\ R1Z #_B.<_ZQ=?\
MF['_ .2/0 ?\1SG_ %BZ_P#-V/\ \D>@ _XCG/\ K%U_YNQ_^2/0 ?\ $<Y_
MUBZ_\W8__)'H /\ B.<_ZQ=?^;L?_DCT '_$<Y_UBZ_\W8__ "1Z #_B.<_Z
MQ=?^;L?_ )(] !_Q'.?]8NO_ #=C_P#)'H /^(YS_K%U_P";L?\ Y(] !_Q'
M.?\ 6+K_ ,W8_P#R1Z #_B.<_P"L77_F['_Y(] !_P 1SG_6+K_S=C_\D>@
M_P"(YS_K%U_YNQ_^2/0 ?\1SG_6+K_S=C_\ )'H /^(YS_K%U_YNQ_\ DCT
M'_$<Y_UBZ_\ -V/_ ,D>@ _XCG/^L77_ )NQ_P#DCT '_$<Y_P!8NO\ S=C_
M /)'H /^(YS_ *Q=?^;L?_DCT '_ !'.?]8NO_-V/_R1Z #_ (CG/^L77_F[
M'_Y(] !_Q'.?]8NO_-V/_P D>@ _XCG/^L77_F['_P"2/0 ?\1SG_6+K_P W
M8_\ R1Z #_B.<_ZQ=?\ F['_ .2/0 ?\1SG_ %BZ_P#-V/\ \D>@ _XCG/\
MK%U_YNQ_^2/0 ?\ $<Y_UBZ_\W8__)'H /\ B.<_ZQ=?^;L?_DCT '_$<Y_U
MBZ_\W8__ "1Z #_B.<_ZQ=?^;L?_ )(] !_Q'.?]8NO_ #=C_P#)'H /^(YS
M_K%U_P";L?\ Y(] !_Q'.?\ 6+K_ ,W8_P#R1Z #_B.<_P"L77_F['_Y(] !
M_P 1SG_6+K_S=C_\D>@ _P"(YS_K%U_YNQ_^2/0 ?\1SG_6+K_S=C_\ )'H
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M_B.<_P"L77_F['_Y(] !_P 1SG_6+K_S=C_\D>@ _P"(YS_K%U_YNQ_^2/0
M?\1SG_6+K_S=C_\ )'H /^(YS_K%U_YNQ_\ DCT '_$<Y_UBZ_\ -V/_ ,D>
M@ _XCG/^L77_ )NQ_P#DCT '_$<Y_P!8NO\ S=C_ /)'H /^(YS_ *Q=?^;L
M?_DCT '_ !'.?]8NO_-V/_R1Z #_ (CG/^L77_F['_Y(] !_Q'.?]8NO_-V/
M_P D>@ _XCG/^L77_F['_P"2/0 ?\1SG_6+K_P W8_\ R1Z #_B.<_ZQ=?\
MF['_ .2/0 ?\1SG_ %BZ_P#-V/\ \D>@ _XCG/\ K%U_YNQ_^2/0 ?\ $<Y_
MUBZ_\W8__)'H /\ B.<_ZQ=?^;L?_DCT '_$<Y_UBZ_\W8__ "1Z #_B.<_Z
MQ=?^;L?_ )(] !_Q'.?]8NO_ #=C_P#)'H /^(YS_K%U_P";L?\ Y(] !_Q'
M.?\ 6+K_ ,W8_P#R1Z #_B.<_P"L77_F['_Y(] !_P 1SG_6+K_S=C_\D>@
M_P"(YS_K%U_YNQ_^2/0 ?\1SG_6+K_S=C_\ )'H /^(YS_K%U_YNQ_\ DCT
M'_$<Y_UBZ_\ -V/_ ,D>@ _XCG/^L77_ )NQ_P#DCT '_$<Y_P!8NO\ S=C_
M /)'H /^(YS_ *Q=?^;L?_DCT '_ !'.?]8NO_-V/_R1Z #_ (CG/^L77_F[
M'_Y(] !_Q'.?]8NO_-V/_P D>@ _XCG/^L77_F['_P"2/0 ?\1SG_6+K_P W
M8_\ R1Z #_B.<_ZQ=?\ F['_ .2/0 ?\1SG_ %BZ_P#-V/\ \D>@ _XCG/\
MK%U_YNQ_^2/0 ?\ $<Y_UBZ_\W8__)'H /\ B.<_ZQ=?^;L?_DCT '_$<Y_U
MBZ_\W8__ "1Z #_B.<_ZQ=?^;L?_ )(] !_Q'.?]8NO_ #=C_P#)'H /^(YS
M_K%U_P";L?\ Y(] !_Q'.?\ 6+K_ ,W8_P#R1Z #_B.<_P"L77_F['_Y(] !
M_P 1SG_6+K_S=C_\D>@ _P"(YS_K%U_YNQ_^2/0 ?\1SG_6+K_S=C_\ )'H
M/^(YS_K%U_YNQ_\ DCT '_$<Y_UBZ_\ -V/_ ,D>@ _XCG/^L77_ )NQ_P#D
MCT '_$<Y_P!8NO\ S=C_ /)'H /^(YS_ *Q=?^;L?_DCT '_ !'.?]8NO_-V
M/_R1Z #_ (CG/^L77_F['_Y(] !_Q'.?]8NO_-V/_P D>@ _XCG/^L77_F['
M_P"2/0 ?\1SG_6+K_P W8_\ R1Z #_B.<_ZQ=?\ F['_ .2/0 ?\1SG_ %BZ
M_P#-V/\ \D>@ _XCG/\ K%U_YNQ_^2/0 ?\ $<Y_UBZ_\W8__)'H /\ B.<_
MZQ=?^;L?_DCT '_$<Y_UBZ_\W8__ "1Z #_B.<_ZQ=?^;L?_ )(] !_Q'.?]
M8NO_ #=C_P#)'H /^(YS_K%U_P";L?\ Y(] !_Q'.?\ 6+K_ ,W8_P#R1Z #
M_B.<_P"L77_F['_Y(] !_P 1SG_6+K_S=C_\D>@ _P"(YS_K%U_YNQ_^2/0
M?\1SG_6+K_S=C_\ )'H /^(YS_K%U_YNQ_\ DCT '_$<Y_UBZ_\ -V/_ ,D>
M@ _XCG/^L77_ )NQ_P#DCT '_$<Y_P!8NO\ S=C_ /)'H /^(YS_ *Q=?^;L
M?_DCT '_ !'.?]8NO_-V/_R1Z #_ (CG/^L77_F['_Y(] !_Q'.?]8NO_-V/
M_P D>@ _XCG/^L77_F['_P"2/0 ?\1SG_6+K_P W8_\ R1Z #_B.<_ZQ=?\
MF['_ .2/0 ?\1SG_ %BZ_P#-V/\ \D>@ _XCG/\ K%U_YNQ_^2/0 ?\ $<Y_
MUBZ_\W8__)'H /\ B.<_ZQ=?^;L?_DCT '_$<Y_UBZ_\W8__ "1Z #_B.<_Z
MQ=?^;L?_ )(] !_Q'.?]8NO_ #=C_P#)'H /^(YS_K%U_P";L?\ Y(] !_Q'
M.?\ 6+K_ ,W8_P#R1Z #_B.<_P"L77_F['_Y(] !_P 1SG_6+K_S=C_\D>@
M_P"(YS_K%U_YNQ_^2/0 ?\1SG_6+K_S=C_\ )'H /^(YS_K%U_YNQ_\ DCT
M'_$<Y_UBZ_\ -V/_ ,D>@ _XCG/^L77_ )NQ_P#DCT '_$<Y_P!8NO\ S=C_
M /)'H /^(YS_ *Q=?^;L?_DCT '_ !'.?]8NO_-V/_R1Z #_ (CG/^L77_F[
M'_Y(] !_Q'.?]8NO_-V/_P D>@ _XCG/^L77_F['_P"2/0 ?\1SG_6+K_P W
M8_\ R1Z #_B.<_ZQ=?\ F['_ .2/0 ?\1SG_ %BZ_P#-V/\ \D>@ _XCG/\
MK%U_YNQ_^2/0 ?\ $<Y_UBZ_\W8__)'H /\ B.<_ZQ=?^;L?_DCT '_$<Y_U
MBZ_\W8__ "1Z #_B.<_ZQ=?^;L?_ )(] !_Q'.?]8NO_ #=C_P#)'H /^(YS
M_K%U_P";L?\ Y(] !_Q'.?\ 6+K_ ,W8_P#R1Z #_B.<_P"L77_F['_Y(] !
M_P 1SG_6+K_S=C_\D>@ _P"(YS_K%U_YNQ_^2/0 ?\1SG_6+K_S=C_\ )'H
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M_B.<_P"L77_F['_Y(] !_P 1SG_6+K_S=C_\D>@ _P"(YS_K%U_YNQ_^2/0
M?\1SG_6+K_S=C_\ )'H /^(YS_K%U_YNQ_\ DCT '_$<Y_UBZ_\ -V/_ ,D>
M@ _XCG/^L77_ )NQ_P#DCT '_$<Y_P!8NO\ S=C_ /)'H /^(YS_ *Q=?^;L
M?_DCT '_ !'.?]8NO_-V/_R1Z #_ (CG/^L77_F['_Y(] !_Q'.?]8NO_-V/
M_P D>@ _XCG/^L77_F['_P"2/0 ?\1SG_6+K_P W8_\ R1Z #_B.<_ZQ=?\
MF['_ .2/0 ?\1SG_ %BZ_P#-V/\ \D>@ _XCG/\ K%U_YNQ_^2/0 ?\ $<Y_
MUBZ_\W8__)'H /\ B.<_ZQ=?^;L?_DCT '_$<Y_UBZ_\W8__ "1Z /U^_P""
M*G_!R#_P^#_:F\??LT?\,:?\,[_\(/\  #Q3\<_^$U_X:'_X6U_:G_",_$7X
M5> /^$6_X1S_ (49\,OL7VW_ (6;_:W]M_V]=_9O[$^P?V1/_:7VRP /Z?J
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MA*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^
M'_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]
MM"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^
M5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !
M_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0
MAW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!
M9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H
M2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!
M_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'
MVT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_
M .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E
M !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q
M"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\
M%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^
MA*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^
M'_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]
MM"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^
M5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !
M_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0
MAW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!
M9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H
M2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!
M_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'
MVT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_
M .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E
M !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q
M"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\
M%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^
MA*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^
M'_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]
MM"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^
M5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !
M_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0
MAW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!
M9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H
M2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!
M_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'
MVT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_
M .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E
M !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q
M"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\
M%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^
MA*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^
M'_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]
MM"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^
M5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !
M_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0
MAW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!
M9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H
M2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!
M_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'
MVT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_
M .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E
M !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q
M"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\
M%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^
MA*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^
M'_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]
MM"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^
M5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !
M_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0
MAW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!
M9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H
M2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!
M_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'
MVT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_
M .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E
M !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q
M"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\
M%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^
MA*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^
M'_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]
MM"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^
M5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !
M_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0
MAW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!
M9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H
M2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!
M_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'
MVT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_
M .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E
M !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q
M"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\
M%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^
MA*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^
M'_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]
MM"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^
M5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !
M_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0
MAW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!
M9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H
M2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!
M_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'
MVT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_
M .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E
M !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q
M"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\
M%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^
MA*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^
M'_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]
MM"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^
M5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !
M_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0
MAW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!
M9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H
M2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!
M_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'
MVT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_
M .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E
M !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q
M"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\
M%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^
MA*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^
M'_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]
MM"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^
M5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !
M_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0
MAW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!
M9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H
M2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!
M_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'
MVT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_
M .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E
M !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q
M"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\
M%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^
MA*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^
M'_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]
MM"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^
M5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !
M_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0
MAW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!
M9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H
M2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!
M_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'
MVT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_
M .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E
M !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q
M"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\
M%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^
MA*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^
M'_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]
MM"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^
M5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !
M_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0
MAW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!
M9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H
M2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!
M_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'
MVT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_
M .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E
M !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q
M"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\
M%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^
MA*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^
M'_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]
MM"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^
M5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !
M_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0
MAW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!
M9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H
M2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!
M_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'
MVT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_
M .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E
M !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q
M"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\
M%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^
MA*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^
M'_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]
MM"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^
M5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !
M_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0
MAW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!
M9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H
M2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!
M_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'
MVT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_
M .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E
M !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q
M"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\
M%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^
MA*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^
M'_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]
MM"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^
M5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !
M_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0
MAW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!
M9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H
M2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!
M_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'
MVT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_
M .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E
M !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q
M"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\
M%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^
MA*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^
M'_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]
MM"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^
M5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !
M_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0
MAW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!
M9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H
M2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!
M_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'
MVT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_
M .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E
M !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q
M"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\
M%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^
MA*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^
M'_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]
MM"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^
M5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !
M_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0
MAW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!
M9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H
M2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!
M_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'
MVT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_
M .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E
M !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q
M"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\
M%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^
MA*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^
M'_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]
MM"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^
M5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !
M_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0
MAW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!
M9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H
M2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!
M_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'
MVT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_
M .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E
M !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q
M"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\
M%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^
MA*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^
M'_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]
MM"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^
M5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !
M_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0
MAW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!
M9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H
M2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!
M_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'
MVT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_
M .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E
M !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q
M"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\
M%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^
MA*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^
M'_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]
MM"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^
M5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !
M_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0
MAW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!
M9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H
M2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!
M_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'
MVT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_
M .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E
M !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q
M"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\
M%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^
MA*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^
M'_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]
MM"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^
M5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !
M_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0
MAW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!
M9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H
M2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!
M_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'
MVT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_
M .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E
M !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q
M"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\
M%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^
MA*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^
M'_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]
MM"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^
M5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !
M_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0
MAW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!
M9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H
M2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!
M_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'
MVT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_
M .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E
M !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q
M"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\
M%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^
MA*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^
M'_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]
MM"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^
M5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !
M_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0
MAW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!
M9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H
M2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!
M_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'
MVT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_
M .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E
M !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q
M"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\
M%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^
MA*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^
M'_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]
MM"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^
M5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !
M_P 0AW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0
MAW_!9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!
M9+_H2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H
M2O@!_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!
M_P"'VT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'
MVT+_ .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_
M .5E !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E
M !_Q"'?\%DO^A*^ '_A]M"_^5E !_P 0AW_!9+_H2O@!_P"'VT+_ .5E ']!
MW_!MI_P0H_;[_P""8G[<OQ5^/?[5'A[X8:3\/?%W[*'CGX0Z-<>"OB5IOC'5
M'\9:]\7_ (%>,]/@GTRSL[>6#3VT3P!XA>6_9S'%<1VEN5+72E0#^VV@#__6
M_OXH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H _]?^_B@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
<H * "@ H * "@ H * "@ H * "@ H * "@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>mgnx-20231231_g3.jpg
<DESCRIPTION>PERF GRAPH
<TEXT>
begin 644 mgnx-20231231_g3.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BN=^*_P 7
M?A9\"? .H?%3XT_$71/"GAK28O,U+7?$.IQ6EI;+G WRRL%!)( &<DD 9) K
MY\\$_P#!:3_@FQ\0=*;Q3X;_ &@;T>&TE,<GC;4OA_KUCX=0AMI)UBYL8[ *
M#P6,^T>M 'U+17)_!OXZ_!W]H;PG-X\^!GQ(TGQ9H<.IW&GG6M"NUN+22X@;
M9*D<R924*V5+(67((SD&NLH **** "BBB@ HHHH **** "BO&_A1_P %!/V-
MOCC^TYXS_8V^%'QYTG6OB9\/H&F\7>%;:&=9;%%D2.0B1XQ%,8Y)(TD$3N8W
M<*X4G%>R4 %%%% !1110 4444 %%<!^T?^U-^SY^R+X!C^)O[1WQ2T[PMH]Q
MJ$6GV,U[ODFOKR4D1VMM!$KS7,[8)$42.Y"D@8!(P?V5_P!N_P#91_;5NO%V
ME_LV?%A->U'P#K;:/XUT6[T:]TW4-$O0\B&&YM+Z&&>([X9E!9 "T4@!)1@
M#UVBL+XE_$_X;_!GP-J/Q-^+OCW1_#'AS2(/.U37=?U**TM+2/.-TDLK*J#)
M Y/)('4U\[>#/^"U'_!-;X@Z=/XD\)_M W]QX=M9FBN?&LOP]U^'P["5)5B^
ML2V*V"J"#EC.%&#S0!]345R'P8^/_P $_P!HOP_?>+O@-\4-%\7Z/IVJOIMQ
MK/AZ^6ZLVN4CCD>..>/,<VU94RT;,H;<I.Y6 Z^@ HHHH **** "BBO#_AY_
MP4B_8F^*G[2U_P#L<>"/CO9W'Q1TP3G4/!%UI5[:W]N(4#R%TGA3 "$,#GYE
M8$9!!H ]PHHHH **SM3\7>%M%T/4O$NJ^([*WT_1HII-6O9;E1%9I$F^0RMG
M";4^9LXP.37F_P"Q[^W-^RA^WW\.+WXM_LA_&6Q\:>']-UB72K^]L[2XMVM[
MN-4=HWBN8XY%^5T96*[65@5)'- 'K-%%% !117!_M)?M/? 7]D#X4W?QP_:4
M^)=CX2\*6-S!;W>M:BDC11RS.(XE(C5FRS$ <=Z .\HKY0\6?\%Q?^"5W@*Y
MTZS\<_M;:=HLVL0B72(M6\.:K;-?1EMH>$26H,JEN,KD9XKNOA#_ ,%+OV(?
MCK\;H?V;?AE\=(+WQY/ITM_#X5O-$O[*\:UC&7EV74$?RC!Y]CCI0![K1110
M 45#8ZA8:I;_ &O3;Z&XB\QX_-@E#KO1BCKD<95E92.Q!!Y%34 %%>'_ +2W
M_!2+]B;]CGQ]HGPQ_:=^.]GX,UKQ* ?#UMK&E7HCU+YU0B"983%(59T#!6)0
MNNX#<,^X4 %%?-7Q=_X+ ?\ !.?X!?%E?@1\:OVCHO"_C.22)+?PQK7AC58+
MVY,KE(C%$UKNF61@0C(&#G[I-:W@;_@J=_P3W^(7Q4L_@;HG[5?ABS\9ZBZ)
MIWA7Q%)+I&H7CN2$2&"^2%Y68@[54$MC@&@#W^BBB@ HJ%]0L(K^+2I+Z%;J
M:%Y8;9I0))(T*!W5>I53)&"1P"ZYZBIJ "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M7P3KG_!&WX$Q^#O$&FWD>F>#$M=4%A=I(+2\661YHI=I/ER!GW,K8(W D<T
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M(TXLY=*T^)9FB)W>4SQR(&(VDHP[4 ?4/[!O_!;;7_VX_P#@E]\3O^"B&D?
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M.GX3IX@\0#PT\7B?XIII^IH=-CD$(CTN>XO\-+<NHSY";S$EN2YC#0B3[LH
M_GD_X/!O^4CW[,?_ & E_P#3PM?O%X\^ GPO\8_&'P;^T3XBTU(?$OP_AU*/
M1]778K+:7MOY5S!(S#/E';%)@$8:%3G&0?Y_/^#O3XM_"_6O^"D_P"L]$^(.
MC7TOA70E'B6*RU&.9M+8:N24N C'RF C<E6P0%Z5_01XL7PI^TA\!=>TCX;?
M$'3;_3?%OAN^T_3_ !#HM]'=6X\^!X1+')$Q5]I;/!ZB@#\_O"__  7I^+/[
M2?PK_: _:S_8H_9K\,>)/@_^SP\IU+4O%'BVXLM2\8PVT+W-Y-8)%:R1VB);
MH94,Q=I R96,L0L/_!0__@M-\0?$?_!"JX_X*:_\$YK'3((=<AAT_4]1\3WC
M1ZCX2FGO4T^416R1O'<7<5Q)A=\B1A0)AYHVQM\&?\$P_$VA_L ?\$:/^"@/
M[$?[66LZ?X)^*6F6FO6"^$M<O$@O-0?4=".FV;6D;D-=1RSKA'B#*P=&!PX)
MZ?3/V"OVF/@3_P &=GQ%\!>.OAOK,7BCQ+XDM?'+>%7LG^VZ;I7]KZ8Q:6'&
MY,6UHUVZD91')8*58  ^P_\ @E;^W)\6?V0O^"%>@?M:_M>_#31Q\./!/PRC
MU/1=<\-^,+G5->\132WLD>RYM)[*&.UDDFE1=WVF89<LS* 36)\7_P#@XX^(
MW[.?@;]G3]JSXO\ [.O@Z\^"_P"T.DIM;CPEXNO+C6_#'EM"LPN%N+.&*Y>+
MSL,D>T%X90KD!'?E?V//^"DG@SX&?\&O\7Q-^"/P]MOBAKWPK^%]MIWB+PY?
MZ+-<:7;7ESJ+6C0WN5"S+#'(;F:%"2(%4N8UF1S^5O\ P4S^->E_M2_\$V?V
M</VE[[6_'WB?Q:?%>K6GQ#UW4O"UWIOAKP]-^[^QZ'H\2Q1Z?##'! [[+(,6
MY:9M^U% /T*_X/)0/^%T?L6G'_,V^)/_ $I\/5^Z-?@%_P '=_QV^$7Q#^)/
M[%_B/PEX[LKBVCU#6]:N$F+03V^GW$^A-!=30RA988Y%AE9&=5#B-B,@&OWS
MT36]%\3:-:^(O#FKVNH:??VZ7%C?6-PLL-Q$ZADD1U)5U8$$,"00<B@#^>S_
M (.1/$'A[PA_P<G_ +)_BSQ5K=EI>EZ9H?@2\U/4]0N4@M[6"/QAJ;R32R.0
ML:(BEF9B H4DD 5K_P#!T9\9?@3_ ,%.?B-\"?V:_P#@F[K&G?&WXM:5JFI7
M-S<_"J>/5QIMC,+9$CEN[4M$@,RAR2^V$1%I#&&!;C/^#A?XX?!O4O\ @Y(_
M9E\9Z9\4_#]UI'@VT\#P^*]3MM7ADM](D@\5W]S,EQ(K%86CAD21@Q!56!.
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M4=4'A;5H[U+.WNI+B.#S7B)6-V>UG'E,1(OEG<JY&0#TZBBB@ HHKQOXM_\
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M%&OV,OVX+B]A_9.^,R>.8M-D$>I:AHN@Z@;.TD*EQ'+<O;K#&Y49",X9NP-
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M+";-XD%UIU\+:-]FR::2*TF*1(S.7$8*C>N?JW_@WR_X+:_LL:I^P?\ #O\
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M>7[7W[+GAW0O@K\<]82RLY_"WBNXOM:\)QSI+-:7%W'):QQ7B26\,DKK"49
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MW#I=K8>./ 6GZII4FIPV8\W5-+O;9XS:RN""1'-LEC+;MF95 'FDCY.\/_\
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M:?\  ?3[O7=4^$7C:37_ !CH.G0.]W#:1W6LQ2$P@;VV1ZC!<D@$>4&?H,@
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M0-&-E)I@T=+P:G%Y+:@/!\<!M ^[:9O.!A\O.[S 4QNXJ#]A?Q[X/_X)+_\
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M#+DCV3_@R._Y,S^,O_93K?\ ]-T5 'ZC?\%)U5O^"=7Q]5E!!^"OBH$$=?\
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M_P"";7_!670OVV_C;\6OV//B?\.(?!/QB^"FOW&G>*]#L=6-]I^J6T5PUO\
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M &-= T/X':C97F@:/=W'CIY/$RI#<0*=3DM/LHMGMQ*0CQK.)(R)"OG!!O\
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M HHHH *RG\">!Y+Z^U.3P;I37.IJBZE<-IT1DNPA!02MMS(%(&-V<8XK5HH
M1555"J  !@ =JSM$\'>$?#5[>:CX<\*Z;I]QJ$OF7\]E8QQ/<ODG=(R@%SDG
MDYZFM*B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "OBC_ (*N_P#!55OV%OBY\#?V7/!E]X:TCQ7\<_%C
M:9%XT\;QR2:-X6T^.2".:]GBCEA,\A:X1(HS+$F[<TCJJX;[7KX]_P""PW_!
M)']G#_@KM\'=+^#WQ1\5MX9\<Z EYJ'P]\56026YT\GR4N0UNS+]IM68VPE0
M%2&\HAT.,@'FW[*O[1O_  5"TF?P1X\\<>,_"?Q:^'/BCX]^,/ GB^63PFVE
M:WX7BLO$NKZ997\4MK*;>XM2+*&-HWA61#)'^\DRSKP'_!6_XY?\'"4&G^._
MC?\ \$\/#OA+P%\*?A>EXTRZW8VUUXH\61V6[[;?0VM[;RPQV:F.7R4!2:>.
M/S4+B:)1\)_\$;/^"B?[=_\ P2*_:U\#_P#!,S]K'1CXE^"?CWXGZSX1\"^(
M1!\MKJ<7B&ZTFZO+"XP&DMSJB2&:WF&]1*)5";\2_LC_ ,%;/CIXP\%?LOZE
M^S;\!/#[>(?C%\;=/O?"/PS\-P-AO-N(#'=ZI.W_ "QM+*"1IY9F&Q2(D/,J
M@@'G'_! [_@JYXN_X*@?L WO[0GQ[T/3-"\3>"?$=WH/B_4;%#!87AM[6"Z%
MZBLQ\D&&X3>FX@/&[#:K*H^-H?VJ?^#JG]K+5=2^/G[#_AWX9'X4^)[^74_A
M_:7=[X>>\M=%G8RV*70EF\U)_L[1%UD"N&)RJ]!]P_LC?\$E_@_^S'_P2ZU?
M_@E#X0^,MU8:KK_A&X'Q%\5>'I(5U.:XU99(+F^2*0-Y4<BP36T+,O$=M@%G
MC9J_*W]L[_@V:_:O_P""4/@G5/V^O^"7G[;GB6]U#X?:?)J^LZ1+;_V=JJ6%
MNOFSR130.8;U%16=[:6-%=$8?O"1&0#] /\ @JM_P5(_:=_X)9?L$?!KPGXF
MU+0/$/[27Q7EL]!.IW6GH-,L=0$4)U*_6WA*K+'!+/%%&@(#&6-VW!61IK3_
M (*0_&_]BG_@M1X._P""57[37Q@N?B5X5^+7P^M-:\&>.-=T73[#5-)U9Y+Z
M+['*-.M[>WFMI9+"18_W(E1IH@TC@,Q_,C_@N'^T)\4/VRO '_!-W]L7XF:&
MMC-XTTJ>758K>(I;KJ27^E"YD13]Q)<+(BG^# !.TFO;?^"XVC^(?$7_  =6
M_L8Z;X6CD:ZBTSP/<RB+J+>'Q9JLUP3CL(8Y"?;- '[U4444 %%<9\9M$^.6
MMZ991? [QOHNAW:3L;Z76M,:Y66/;PJ@$;3GG->-?%Z]_;O^#GPTUGXGZY\<
M/!MU::+9FXGM[3PHWF.H(&%W.!GGN: /IBBN5\'W/CS7_"6EZ[/K=EOO=.@G
M?_1,<O&K'C/'6M+[%XW_ .@W9?\ @,?\: -BBL?[%XW_ .@W9?\ @,?\:/L7
MC?\ Z#=E_P" Q_QH V**Q_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&@#
M8HK'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\ @,?\: -BBL?[%XW_ .@W9?\
M@,?\:/L7C?\ Z#=E_P" Q_QH V**Q_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_
M (#'_&@#8HK'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\ @,?\: -BBL?[%XW_
M .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QH V**Q_L7C?\ Z#=E_P" Q_QH^Q>-
M_P#H-V7_ (#'_&@#8HK'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\ @,?\: -B
MBL?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QH V**Q_L7C?\ Z#=E_P"
MQ_QH^Q>-_P#H-V7_ (#'_&@#8HK'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\
M@,?\: -BBL?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QH V**Q_L7C?\
MZ#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&@#8HK'^Q>-_P#H-V7_ (#'_&C[%XW_
M .@W9?\ @,?\: -BBL?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QH V**
MQ_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&@#8HK'^Q>-_P#H-V7_ (#'
M_&C[%XW_ .@W9?\ @,?\: -BBL?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P"
MQ_QH V**Q_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&@#8HK'^Q>-_P#H
M-V7_ (#'_&C[%XW_ .@W9?\ @,?\: -BBL?[%XW_ .@W9?\ @,?\:/L7C?\
MZ#=E_P" Q_QH V**Q_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&@#8HK'
M^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\ @,?\: -BBL?[%XW_ .@W9?\ @,?\
M:/L7C?\ Z#=E_P" Q_QH V**Q_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_ (#'
M_&@#8HK'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\ @,?\: -BBL?[%XW_ .@W
M9?\ @,?\:/L7C?\ Z#=E_P" Q_QH V**Q_L7C?\ Z#=E_P" Q_QH^Q>-_P#H
M-V7_ (#'_&@#8HK'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\ @,?\: -BBL?[
M%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QH V**Q_L7C?\ Z#=E_P" Q_QH
M^Q>-_P#H-V7_ (#'_&@#8HK'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\ @,?\
M: -BBL?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QH V**Q_L7C?\ Z#=E
M_P" Q_QH^Q>-_P#H-V7_ (#'_&@#8HK'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W
M9?\ @,?\: -BBL?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QH V**Q_L7
MC?\ Z#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&@#8HK'^Q>-_P#H-V7_ (#'_&C[
M%XW_ .@W9?\ @,?\: -BBL?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QH
M V**Q_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&@#8HK'^Q>-_P#H-V7_
M (#'_&C[%XW_ .@W9?\ @,?\: -BBL?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E
M_P" Q_QH V**Q_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&@#8HK'^Q>-
M_P#H-V7_ (#'_&C[%XW_ .@W9?\ @,?\: -BBL?[%XW_ .@W9?\ @,?\:/L7
MC?\ Z#=E_P" Q_QH V**Q_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&@#
M8HK'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\ @,?\: -BBL?[%XW_ .@W9?\
M@,?\:/L7C?\ Z#=E_P" Q_QH V**Q_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_
M (#'_&@#8HK'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\ @,?\: -BBL?[%XW_
M .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QH V**Q_L7C?\ Z#=E_P" Q_QH^Q>-
M_P#H-V7_ (#'_&@#8HK'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\ @,?\: -B
MBL?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QH V**Q_L7C?\ Z#=E_P"
MQ_QH^Q>-_P#H-V7_ (#'_&@#8HK'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\
M@,?\: -BBL?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QH V**Q_L7C?\
MZ#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&@#8HK'^Q>-_P#H-V7_ (#'_&C[%XW_
M .@W9?\ @,?\: -BBL?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QH V**
MQ_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&@#8HK'^Q>-_P#H-V7_ (#'
M_&C[%XW_ .@W9?\ @,?\: -BBL?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P"
MQ_QH V**Q_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&@#8HK'^Q>-_P#H
M-V7_ (#'_&C[%XW_ .@W9?\ @,?\: -BBL?[%XW_ .@W9?\ @,?\:/L7C?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "O*/VY_P#DT?Q[_P!@%_\ T-:]7KRC]N?_ )-'\>_]@%__ $-: .Z^%W_)
M,_#O_8"M/_1*5NUA?"[_ ))GX=_[ 5I_Z)2MV@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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ML.K1V2@28X$CR@%@ 3\QWD,2?\&45H^!E_B66_'_ (2=Q_(4 ?MU_P % _\
M@I_^SE_P3W_99T_]J+QW=W'B6T\3W5I9> -#\-21R7'B:\NHS);QV[,0@C:,
M&1I2=JH,C<Q1&YSX/_\ !4.WN_V[Q_P36_:O^$-E\-_BQJG@^/Q1X.M]'\6G
M7-*\0:>PF\R.&Z>TM)%NHOL]QOB:':1!(4D< $_@M_P4*^*?Q"\>_L3_ /!+
M;POXNN[AK&+P_<^6LC'$OD:II]E#GUV6T$07T$AQUKZU_P""WWBOQ!X,_P"#
MK']C'6/"TTB7<VD>";&8Q$@FVNO%6K6TXX[&&:4'V)H _>:BBB@ KRC]N?\
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M_P"^J/\ A,?#'_0:@_[ZKL/J32HK-_X3'PQ_T&H/^^J/^$Q\,?\ 0:@_[ZH
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MX>O=/FM--TK[%.&U"!+*YN(UN'GO')9W\PFTB! 1(Z^-I?\ @E'_ ,%$9O\
M@CXG_!#-OV?;DZ]%\9#=)\6SJMD/"P\._;C??VEO\_[5YF\F/[)Y'F]\8YK]
MT** /R\_X*Z_\$+]>^.'[ 7P*^&'[&=O:W_CG]E\6(\$:=JMS':CQ#910V\=
MU;-*Y"0W$SVEO,'<A-Z,K%0^]9Y_^"?/QD_X* _\%R_ ?_!4+XP_ _7?AQ\.
M?@Y\/+'3/#VA^-);,:KKVN1S7]PCB"UGF$-O;R7^[S'<%Y+= BNC,R_IY10
M4444 4M9\.>'O$<20>(=!LK](VW1I>VJ2A#Z@,#@UX[^VQ\/O .E_LI>.=0T
MSP1H]O<1:&[13P:9$CH=R\A@N0:]OKRC]N?_ )-'\>_]@%__ $-: .T^%VFZ
M</AEX< L(0!H5G@>4/\ GBGM6[_9VG_\^,/_ 'Z%9'PN_P"29^'?^P%:?^B4
MK=H A_L[3_\ GQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\
M^?&'_OT*FHH A_L[3_\ GQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]
M"C^SM/\ ^?&'_OT*FHH A_L[3_\ GQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_
M /GQA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\ GQA_[]"C^SM/_P"?&'_OT*FH
MH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\ GQA_[]"C^SM/_P"?
M&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\ GQA_[]"C
M^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\
MGQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH
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M_9VG_P#/C#_WZ%344 0_V=I__/C#_P!^A1_9VG_\^,/_ 'Z%344 0_V=I_\
MSXP_]^A1_9VG_P#/C#_WZ%344 0_V=I__/C#_P!^A1_9VG_\^,/_ 'Z%344
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MHH A_L[3_P#GQA_[]"C^SM/_ .?&'_OT*FHH B2QLHV#QV<2L.A6, BI:**
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M110 4444 %%%% !1110 4444 %>4?MS_ /)H_CW_ + +_P#H:UZO7E'[<_\
MR:/X]_[ +_\ H:T =U\+O^29^'?^P%:?^B4K=K"^%W_),_#O_8"M/_1*5NT
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M]OB://0>JK4WSTFNCYH[7Z<RBWV.JEB:-5V3U[/<]HHHHKXDW"BBB@ HHHH
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O*/VY_\ DT?Q[_V
M7_\ 0UKU>O*/VY_^31_'O_8!?_T-: .Z^%W_ "3/P[_V K3_ -$I6[6%\+O^
M29^'?^P%:?\ HE*W: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH ***\#_:@_X*2?LP?LMK<:/XC\7#7?$<.5'AKP\R
MSW"/Z3-G9!SC(=@V#D*U95:U*A#GJ227F>?F>;9;DV%>)QU:-."ZR=ODN[[)
M7;/?*\'_ &G_ /@HW^S#^RPMQI'BOQB-8\11 @>&= *W%RK^DIR$@[9#L&P<
MA6K\Z/VBO^"J?[6G[4NIGP'\-_M'A72;^3R;;0?"ADDOKS=P$>X4"60GD;8P
MBL#@J:ZC]F#_ ((L_'?XL-!XJ^/FI_\ "#Z-*1(UBZ";5+A3S_J\[8,^LA+
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M>KFTU?0=2CNK>7U DC8KD9Y&<CH<5OU^(OQ,_P""&O\ P4&_X)Z>,+KXU_\
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M_H-0?]]4 :5%9O\ PF/AC_H-0?\ ?5'_  F/AC_H-0?]]4 :5%9O_"8^&/\
MH-0?]]4?\)CX8_Z#4'_?5 &E16;_ ,)CX8_Z#4'_ 'U1_P )CX8_Z#4'_?5
M&E16;_PF/AC_ *#4'_?5'_"8^&/^@U!_WU0!I45F_P#"8^&/^@U!_P!]4?\
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MWQR\?ZE_:_[0NO0^#M)CG(:SM9$NM0N@#@E=I,<2MU#,6;UCK]2O^$Q\,?\
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M\*S3/_DBO6/V,/\ @BQ\7[OXV1Z9^W!^SCIFH_#R\TB\@U2VNO$%I,/-:/\
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MQ_T&H/\ OJ@#2HK-_P"$Q\,?]!J#_OJC_A,?#'_0:@_[ZH TJ*S?^$Q\,?\
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MH_X3'PQ_T&H/^^J -*BLW_A,?#'_ $&H/^^J/^$Q\,?]!J#_ +ZH TJ*S?\
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M_9VG_P#/C#_WZ%']G:?_ ,^,/_?H5-10!#_9VG_\^,/_ 'Z%']G:?_SXP_\
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MO^">0CT+2IE:#6_BK>*8+F=3PT6FQ[?,A'4&Y=5<G/EA,+*WS=\$?AK\5O\
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M/[.T_P#Y\8?^_0J:B@"'^SM/_P"?&'_OT*/[.T__ )\8?^_0J:B@"'^SM/\
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M?&'_ +]"IJS_ !/XL\*^"='?Q#XS\3:?I&GQ.B27VJ7J6\*,[!5!>0A02Q
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M-RM>RN?B.#P_UO%TZ',H\\E&[V5W:[\D==_9VG_\^,/_ 'Z%']G:?_SXP_\
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M *&M '=?"[_DF?AW_L!6G_HE*W:POA=_R3/P[_V K3_T2E;M !1110 4444
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M/&8:="I\,E9V[,Y<BSG%\/9Q0S/"I.I1DIQYE=7B[JZTOKYGX8:W_P $E_\
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M1_'O_8!?_P!#6@#NOA=_R3/P[_V K3_T2E;M87PN_P"29^'?^P%:?^B4K=H
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M)'&<"-6*5[]^PM_P3\_9M_X)Z_":/X7? #PB(99U1]>\1WP634=9G4?ZRXE
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M$6?8<U[Q\'_^"#'Q#U3RM0^.?QFTS2(SAGT[P[:M=S$?W3+)Y:(WN%D%?/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%$+.U\*:+K8\&_$)HA]I\!^(;I!+,X&6-E-\J7B\$X4+* "6C4<G[#K\TO\
M@HY_P;B_ /\ :.O+KXR_L<:A:_"OXA+*;I;&TC:/1-1N =P8QQ#=8R;@#YD
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MIZ)Z7OH:4L3"H^66DNS_ *U/HRBBBOS\Z0HHHH **** "BBB@ HHHH ****
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MWO\ X%M1_P (/I'_ #\WO_@6U;%% &/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\
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M#Z1_S\WO_@6U'_"#Z1_S\WO_ (%M6Q10!C_\(/I'_/S>_P#@6U'_  @^D?\
M/S>_^!;5L44 8_\ P@^D?\_-[_X%M1_P@^D?\_-[_P"!;5L44 8__"#Z1_S\
MWO\ X%M1_P (/I'_ #\WO_@6U;%% &/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\
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M?]R7_+N3Z1>FR2;NSFYL1AOB]Z/?JO\ ,_;?_A!](_Y^;W_P+:C_ (0?2/\
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MYO?_  +:MBB@#'_X0?2/^?F]_P# MJ/^$'TC_GYO?_ MJV** ,?_ (0?2/\
MGYO?_ MJ/^$'TC_GYO?_  +:MBB@#'_X0?2/^?F]_P# MJ/^$'TC_GYO?_ M
MJV** ,?_ (0?2/\ GYO?_ MJ/^$'TC_GYO?_  +:MBB@#'_X0?2/^?F]_P#
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M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !7E'[<_\ R:/X]_[ +_\
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M@!^SKX-M? O[%FMZ5\3OB%XBT^*;3+K3I#<:7I$<Z!HI)RG,TY##;:J0P/\
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MUM45ZV+SW.,?EU# 8BO*=&C?D@WI&^]E^79:*R(C3A&3DEJPHHHKR2PHHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "OG3]O;_@EM^R)_P42\+'3_ (Y> UM_$-O;F/2/&^B!8-5L>NU?-VD31@D_
MNI0Z<D@*WS#Z+HKNRW,\QR?&0Q>!JRIU8[2BVFONZ/JMFM&3*$9QY9*Z/P?U
MOX4_\%>/^#=_Q-<>+OA5KC?%#X%&[,M]"+>6;3$C+?,US;!C)I4Q_P">\;&)
MF*!GD^Y7Z3?\$Z/^"S_[(/\ P43T^W\.>%/$'_")^/\ R=UYX!\17*+<NP&6
M:TEX2\08)^3$@ R\:#%?6]Q;V]Y;R6EW DL4J%)8I%#*ZD8((/!!':OS,_X*
M+_\ !M_\$?CUJ%Q\;/V(M6MOA7\0(IOM::7;!XM%OKA3N5E6(;]/DW $/""@
M(_U627K]7CQ/PCQ_%4>)X+#8QZ+%TH^[)_\ 3^FM'YRC9_X8HX_95L-K2UCV
M?Z,_3:BOQ,_9Q_X+:?MV_P#!,CXDVW[)_P#P5V^$7B'6=,M\16'BYXU?58X
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M2P&'G5DW;W8MZONTK+U=DNI$ZE.FKR=CZ!^,?[1OP*_9[_L'_A=WQ6T7PO\
M\)1K46D:!_;%ZL/VV\D^[$F?U8X5<C)&1GM:_D=_;Q_;Q^.W_!0GX[7OQN^-
MVL_WH- T"UD;['HMGNRMO I_ LY^:1OF/8#]<?\ @V[_ ."JGQV_:%\W]B/X
MW>&]:\4?\(OHIN= \?QQ--]BLX\*MIJ$A_[YAE)+-C80<!J_8^+? S-N&.$8
M9LJRG4@KUX:)13V<']KEVEWWCV.&CF$*M;DMIT/UQHHHK\'/1"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ KRC]N?_DT?Q[_ -@%_P#T-:]7KRC]N?\
MY-'\>_\ 8!?_ -#6@#NOA=_R3/P[_P!@*T_]$I6[6%\+O^29^'?^P%:?^B4K
M=H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^+O_  =F?LD>&_-M_@K^SCX[\5S1Y"2ZU<VND6\I]596N),?6,'VKV7X1?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M'((Z@@@@$$5NU^%GQ+_8$_X*K?\ !"7QOJ'QZ_8-^(=_\0_A69C<ZWHZV;7
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MQ+!I'QEUCQE=0YWVGA#PO<R9/HLMRL$+?42$>]?,GQ)_X.S_  KJ.H?\(_\
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M,YPT*-U4$ '[B4444 %>4?MS_P#)H_CW_L O_P"AK7J]>4?MS_\ )H_CW_L
MO_Z&M '=?"[_ ))GX=_[ 5I_Z)2MVL+X7?\ ),_#O_8"M/\ T2E;M !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5^?O_!2?_@WQ
M_98_;8-_\3O@[';_  R^)$^Z9]5TFS']F:K-U_TNU3 #L>L\6U\L6<2D 5^@
M5%>WD/$>=\,8]8S+*\J51=MFNTD])+R::,ZE*G5CRS5T?AI\)/\ @IC_ ,%0
M?^")7CZP_9T_X*0?#+5O'GP\\SR-%U][HW$X@7C=I^HM\MTBKS]FN")%&U<P
MCBOLWXQ_\'(W_!.'X;>$O WBWP;XPU'QBOB[4$34].T>T,=WX<M =LT]Y%(
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MX@TTZO,A'\0DOVF8-[@YKZ$T'P]H'A;2XM#\,:'9Z=90C$-G86R0Q1CT5$
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M^!;5L44 8_\ P@^D?\_-[_X%M1_P@^D?\_-[_P"!;5L44 8__"#Z1_S\WO\
MX%M1_P (/I'_ #\WO_@6U;%% &/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\ @6U;
M%% &/_P@^D?\_-[_ .!;4?\ "#Z1_P _-[_X%M6Q10!C_P#"#Z1_S\WO_@6U
M'_"#Z1_S\WO_ (%M6Q10!C_\(/I'_/S>_P#@6U'_  @^D?\ /S>_^!;5L44
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M &/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\ @6U;%% &/_P@^D?\_-[_ .!;4?\
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M#Z1_S\WO_@6U'_"#Z1_S\WO_ (%M6Q10!C_\(/I'_/S>_P#@6U'_  @^D?\
M/S>_^!;5L44 8_\ P@^D?\_-[_X%M1_P@^D?\_-[_P"!;5L44 8__"#Z1_S\
MWO\ X%M1_P (/I'_ #\WO_@6U;%% &/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "O*/VY_P#DT?Q[_P!@%_\ T-:]7KRC]N?_ )-'
M\>_]@%__ $-: .Z^%W_),_#O_8"M/_1*5NUA?"[_ ))GX=_[ 5I_Z)2MV@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "O*/VY_^31_'O\ V 7_ /0UKU>O*/VY_P#DT?Q[_P!@%_\ T-: .Z^%
MW_),_#O_ & K3_T2E;M87PN_Y)GX=_[ 5I_Z)2MV@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M4+=HI[?1[:*>)^J.L2AE/N""*V* /!?^%??\%#_^C@O G_A+O1_PK[_@H?\
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M_P!'!>!/_"7>O>J* /!?^%??\%#_ /HX+P)_X2[T?\*^_P""A_\ T<%X$_\
M"7>O>J* /!?^%??\%#_^C@O G_A+O1_PK[_@H?\ ]'!>!/\ PEWKWJB@#P7_
M (5]_P %#_\ HX+P)_X2[T?\*^_X*'_]'!>!/_"7>O>J* /!?^%??\%#_P#H
MX+P)_P"$N]'_  K[_@H?_P!'!>!/_"7>O>J* /!?^%??\%#_ /HX+P)_X2[T
M?\*^_P""A_\ T<%X$_\ "7>O>J* /!?^%??\%#_^C@O G_A+O1_PK[_@H?\
M]'!>!/\ PEWKWJB@#Y<^-4__  4"^$'PJUSXF:C\=_!MQ!HUB;B6&T\,XD<
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M@O G_A+O1_PK[_@H?_T<%X$_\)=Z]ZHH \%_X5]_P4/_ .C@O G_ (2[T?\
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M[16=G  7E?<IVC/?B@#S[PUX6_X*%^(?#FGZ_#\?_ Z)?645PB2>%VW*'0,
M<<9Y[5>_X5]_P4/_ .C@O G_ (2[U[%\/K&[TOP#H>F:A;M%/;Z/;13Q/U1U
MB4,I]P016Q0!X+_PK[_@H?\ ]'!>!/\ PEWH_P"%??\ !0__ *."\"?^$N]>
M]44 >"_\*^_X*'_]'!>!/_"7>C_A7W_!0_\ Z."\"?\ A+O7O5% '@O_  K[
M_@H?_P!'!>!/_"7>C_A7W_!0_P#Z."\"?^$N]>]44 >"_P#"OO\ @H?_ -'!
M>!/_  EWH_X5]_P4/_Z."\"?^$N]>]44 >"_\*^_X*'_ /1P7@3_ ,)=Z/\
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M/=VFA^,)+K5IX0"MK"8&4.W/3/% &)_PK[_@H?\ ]'!>!/\ PEWH_P"%??\
M!0__ *."\"?^$N]>]44 >"_\*^_X*'_]'!>!/_"7>C_A7W_!0_\ Z."\"?\
MA+O7O5% '@O_  K[_@H?_P!'!>!/_"7>C_A7W_!0_P#Z."\"?^$N]>]44 >"
M_P#"OO\ @H?_ -'!>!/_  EWH_X5]_P4/_Z."\"?^$N]>]44 >"_\*^_X*'_
M /1P7@3_ ,)=Z/\ A7W_  4/_P"C@O G_A+O7O5% '@O_"OO^"A__1P7@3_P
MEWH_X5]_P4/_ .C@O G_ (2[U[U10!X+_P *^_X*'_\ 1P7@3_PEWH_X5]_P
M4/\ ^C@O G_A+O7O5% '@O\ PK[_ (*'_P#1P7@3_P )=Z/^%??\%#_^C@O
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M,#Q%XZ\0^&/A?XT^'&JZ[K4OA?Q%=Z+=:UJLD&JQVL#7UG)%<1I";!66..1
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MC+=:^+O^"B'_  <1?!W_ ()]_%:[\':E^R!\7?''A+P]K,6D^-OB?X<T#R]
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M#X^_ KXK^(M6\(?"WXU>$O$NK:!)Y>NZ7H'B.UO+C37SC;/'#(S0G/&' YH
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M=T?PA-"^H:1I^MPZG)8.LEXPW3QPK:^:,!$9F,;D[: /6/A[I_P[_P"";/\
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MQ#U?QYJ\:\EK70M'G2+(_NC4-4TUL^J"O@O]J_\ X*W^,-:_X*<W7C[X5?\
M!+#XX?'RQ^"=O>:%\)Y?"WAB[CTDZM<#R]5UGSDM)S*Q"+:0.$*)$D\JEOM(
M\O[<_9ET/X^?&+]NC2/VCOCO\+]1\/R^&?V6_#VENUUIDMO:GQ#K=X]]K5M;
M>8.?L_\ 9FG(XR60R*K<T ?FI_P<B_LM?L _LF:E\%OB(WP9^)FE>,;CXOV.
MN_$OX_\ A_P_>7EQ+IY,KW)GOI'BM9]1EG6*6&%'4PK"VQ8X]D3_ %/_ ,'*
MO@;X#?M:_P#!#+Q9^UGX \/:%XAN+;1?#?B/P/XQ_LI&NAIMQJ=D2T,SIYL4
M;VUU(Q3(^\01G->F?&G3_P#@I)^W7\&/CC^PC^TO_P $\_"_AK0O&,&IZ%X+
M^*$7Q&L+_1Q82EDM=2FL@QOA<V^([A$$2B26-%)MP-X]#_:=_P""=&J>._\
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M ()OC_@I!^Q5_P %W?$O_!.#XP_MM>,?CY\.-6^%#^,YM7\;W,UQ<Z0K2K'
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M*87%Y8QV%W=0)&T"$R>9(D*>7'C=)O0*#N&0#PK_ ()NV_\ P4<_8H_X+O\
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M?O\ P%_PB^D:?+X0O-/T;Q9XGO)IK4&,715Q9,K6Z)-&C0RW4"L-J_O7[_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M8W?QG_:&\676@>%=/V_VEKB:#>WL%DI94#SM:0R^2A9U4.^U<L!G->/>'_\
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M)XEEAE <!@&1U;! (SR!0!K4444 %%%% !1110 4444 %%%% !1110 4444
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MOJ?B:.>6"%;+4+>]""&##2&0V_EYWKM#;OFQMKSGXS_\$Q_A'^T1^WS\%/\
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MU.+XU>'6TVQ\+?9[J%M)>-;=;>1Y\,)@1;C>H1/ODJ?EPW@WPI_X-F]3L?\
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MI\,W/AY%OM=U2#2=/6W:*^$NVTB(6"W2W6$I&JK@A0%'W+\.O^"7?QD\%_\
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ME'X7\)Z)J^FZIIFI27/V[45U V3&2.1$\NW,36:X4K)Y@<@F/J/5/@3\9O\
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M[_93^(O[<O[$_CG]D;X<^*-%T&?QYI:Z?=Z_K232I81":.1G2&(9F8A"H!=
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M_P")? [W]SI$IMXWP$BN81=8<E5#L@ ?<WF>7LDQ?$O_  0,_:,UOX8_L6^
M+?\ :!\%)+^R'XC;6/M3Z5=E?%$@U.SO(XMH.;0!+-4+9E),A8 !0#[3?_\
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M2O\ @G3X,_X*C?MC:IX;&LR>#_CHS:9I#2E%O+ZYUC4[2UB=ARL9GGBWD<A
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MB,DQB.ZEA:5-I)*[6&,G&*]&HHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\XT#]CO]D;P
MK\7Y_P!H3PO^RS\.--\?73N]UXXL/ ]A#K$S.H5RUXD(F8LH )+\@8->CT4
M%%%% !1110 4444 %%%% !1110 4444 %%%% 'FGBK]B_P#8[\=>+;OQ_P"-
M_P!D_P"&FLZ]J$GF7^MZKX$T^XN[E^FZ2:2$NY]R36YK_P"SW\ _%?C3PY\2
M?%/P/\(:EXB\'1F/PCK^H>&K6:]T-",%;.=XS); @8Q&5KKZ* "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
D* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139842282326128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 01, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MACROGENICS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">06-1591613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">9704 Medical Center Drive<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Rockville<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">20850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">251-5172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.01 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MGNX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="nump">$ 322.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,432,013<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Portions of MacroGenics, Inc.'s definitive proxy statement for the 2024 annual meeting of stockholders are incorporated by reference into Part III of this Annual Report.</span></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001125345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139842282319712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_AuditorInformationAbstract', window );"><strong>Auditor Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Tysons, Virginia<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_AuditorInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Auditor Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_AuditorInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139842282419088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 100,956<span></span>
</td>
<td class="nump">$ 108,884<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Investments', window );">Marketable securities</a></td>
<td class="nump">128,849<span></span>
</td>
<td class="nump">45,462<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">10,367<span></span>
</td>
<td class="nump">56,222<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, net</a></td>
<td class="nump">1,221<span></span>
</td>
<td class="nump">1,451<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">9,946<span></span>
</td>
<td class="nump">10,161<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">251,339<span></span>
</td>
<td class="nump">222,180<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, equipment and software, net</a></td>
<td class="nump">21,847<span></span>
</td>
<td class="nump">29,575<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease, ROU Assets</a></td>
<td class="nump">23,846<span></span>
</td>
<td class="nump">27,335<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non current assets</a></td>
<td class="nump">1,386<span></span>
</td>
<td class="nump">1,378<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">298,418<span></span>
</td>
<td class="nump">280,468<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">6,443<span></span>
</td>
<td class="nump">4,899<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">24,239<span></span>
</td>
<td class="nump">28,998<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue</a></td>
<td class="nump">21,651<span></span>
</td>
<td class="nump">9,988<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liabilities</a></td>
<td class="nump">3,775<span></span>
</td>
<td class="nump">4,726<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">56,108<span></span>
</td>
<td class="nump">48,611<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">59,243<span></span>
</td>
<td class="nump">59,480<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liabilities, net of current portion</a></td>
<td class="nump">30,196<span></span>
</td>
<td class="nump">30,106<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non current liabilities</a></td>
<td class="nump">258<span></span>
</td>
<td class="nump">258<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">145,805<span></span>
</td>
<td class="nump">138,455<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, 0.01 par value -- 125,000,000 shares authorized, 62,070,627 and 61,701,467 shares outstanding at December&#160;31, 2023 and December&#160;31, 2022, respectively</a></td>
<td class="nump">621<span></span>
</td>
<td class="nump">617<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">1,254,750<span></span>
</td>
<td class="nump">1,235,095<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(1,102,752)<span></span>
</td>
<td class="num">(1,093,694)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">152,613<span></span>
</td>
<td class="nump">142,013<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 298,418<span></span>
</td>
<td class="nump">$ 280,468<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Investments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(h))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Investments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139842282247920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">125,000,000<span></span>
</td>
<td class="nump">125,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">62,070,627<span></span>
</td>
<td class="nump">61,701,467<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139842284359632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 58,749<span></span>
</td>
<td class="nump">$ 151,941<span></span>
</td>
<td class="nump">$ 77,447<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of product sales</a></td>
<td class="nump">619<span></span>
</td>
<td class="nump">3,351<span></span>
</td>
<td class="nump">2,651<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_CostOfManufacturingServices', window );">Cost of manufacturing services</a></td>
<td class="nump">7,603<span></span>
</td>
<td class="nump">4,033<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">166,583<span></span>
</td>
<td class="nump">207,026<span></span>
</td>
<td class="nump">214,577<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">52,188<span></span>
</td>
<td class="nump">58,949<span></span>
</td>
<td class="nump">63,014<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total costs and expenses</a></td>
<td class="nump">226,993<span></span>
</td>
<td class="nump">273,359<span></span>
</td>
<td class="nump">280,242<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(168,244)<span></span>
</td>
<td class="num">(121,418)<span></span>
</td>
<td class="num">(202,795)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_GainOnRoyaltyMonetizationArrangement', window );">Gain on royalty monetization arrangement</a></td>
<td class="nump">150,930<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Interest and other income</a></td>
<td class="nump">9,686<span></span>
</td>
<td class="nump">1,660<span></span>
</td>
<td class="nump">680<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(1,430)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(9,058)<span></span>
</td>
<td class="num">(119,758)<span></span>
</td>
<td class="num">(202,115)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized gain (loss) on investments</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">56<span></span>
</td>
<td class="num">(54)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (9,059)<span></span>
</td>
<td class="num">$ (119,702)<span></span>
</td>
<td class="num">$ (202,169)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic and diluted net loss per common share, basic (in dollars per share)</a></td>
<td class="num">$ (0.15)<span></span>
</td>
<td class="num">$ (1.95)<span></span>
</td>
<td class="num">$ (3.37)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Basic and diluted net loss per common share, diluted (in dollars per share)</a></td>
<td class="num">$ (0.15)<span></span>
</td>
<td class="num">$ (1.95)<span></span>
</td>
<td class="num">$ (3.37)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic weighted average number of common shares outstanding (in shares)</a></td>
<td class="nump">61,929,198<span></span>
</td>
<td class="nump">61,433,124<span></span>
</td>
<td class="nump">59,944,717<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted weighted average number of common shares outstanding (in shares)</a></td>
<td class="nump">61,929,198<span></span>
</td>
<td class="nump">61,433,124<span></span>
</td>
<td class="nump">59,944,717<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenueFromCollaborativeAgreementsMember', window );">Revenue from collaborative agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 28,990<span></span>
</td>
<td class="nump">$ 119,303<span></span>
</td>
<td class="nump">$ 63,294<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenueFromGovernmentAgreementsMember', window );">Revenue from government agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">1,556<span></span>
</td>
<td class="nump">1,923<span></span>
</td>
<td class="nump">1,804<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">17,939<span></span>
</td>
<td class="nump">16,727<span></span>
</td>
<td class="nump">12,349<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_ContractManufacturingMember', window );">Contract Manufacturing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">9,833<span></span>
</td>
<td class="nump">13,988<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenueFromRoyalityAgreementsMemberMember', window );">RevenueFromRoyalityAgreementsMember</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 431<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CostOfManufacturingServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of manufacturing services</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CostOfManufacturingServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_GainOnRoyaltyMonetizationArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain on royalty monetization arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_GainOnRoyaltyMonetizationArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_RevenueFromCollaborativeAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_RevenueFromCollaborativeAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_RevenueFromGovernmentAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_RevenueFromGovernmentAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_ContractManufacturingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_ContractManufacturingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_RevenueFromRoyalityAgreementsMemberMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_RevenueFromRoyalityAgreementsMemberMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139842283365904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,244,771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 295,884<span></span>
</td>
<td class="nump">$ 562<span></span>
</td>
<td class="nump">$ 1,067,150<span></span>
</td>
<td class="num">$ (771,821)<span></span>
</td>
<td class="num">$ (7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">23,126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,580,653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of offering costs</a></td>
<td class="nump">117,818<span></span>
</td>
<td class="nump">$ 46<span></span>
</td>
<td class="nump">117,772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity', window );">Stock plan related activity (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">482,004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_StockIssuedDuringPeriodValueStockPlanActivity', window );">Stock plan related activity</a></td>
<td class="nump">4,959<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">4,954<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized Gain (Loss) on Investments</a></td>
<td class="num">(54)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(54)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(202,115)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(202,115)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,307,428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">239,618<span></span>
</td>
<td class="nump">$ 613<span></span>
</td>
<td class="nump">1,213,002<span></span>
</td>
<td class="num">(973,936)<span></span>
</td>
<td class="num">(61)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">20,438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">160,480<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of offering costs</a></td>
<td class="nump">1,085<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">1,083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity', window );">Stock plan related activity (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">233,559<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_StockIssuedDuringPeriodValueStockPlanActivity', window );">Stock plan related activity</a></td>
<td class="nump">574<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized Gain (Loss) on Investments</a></td>
<td class="nump">56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(119,758)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(119,758)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,701,467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">142,013<span></span>
</td>
<td class="nump">$ 617<span></span>
</td>
<td class="nump">1,235,095<span></span>
</td>
<td class="num">(1,093,694)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">18,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">167,270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of offering costs</a></td>
<td class="nump">1,039<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">1,037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity', window );">Stock plan related activity (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">201,890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_StockIssuedDuringPeriodValueStockPlanActivity', window );">Stock plan related activity</a></td>
<td class="nump">247<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized Gain (Loss) on Investments</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(9,058)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,058)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,070,627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 152,613<span></span>
</td>
<td class="nump">$ 621<span></span>
</td>
<td class="nump">$ 1,254,750<span></span>
</td>
<td class="num">$ (1,102,752)<span></span>
</td>
<td class="num">$ (6)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued due to stock plan related activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_StockIssuedDuringPeriodSharesStockPlanActivity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_StockIssuedDuringPeriodValueStockPlanActivity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares issued due to stock plan related activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_StockIssuedDuringPeriodValueStockPlanActivity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139842278984432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (9,058)<span></span>
</td>
<td class="num">$ (119,758)<span></span>
</td>
<td class="num">$ (202,115)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">9,645<span></span>
</td>
<td class="nump">11,865<span></span>
</td>
<td class="nump">11,258<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of premiums and discounts on marketable securities</a></td>
<td class="num">(5,004)<span></span>
</td>
<td class="nump">403<span></span>
</td>
<td class="nump">1,607<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">18,373<span></span>
</td>
<td class="nump">20,438<span></span>
</td>
<td class="nump">23,126<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_GainOnRoyaltyMonetizationArrangement', window );">Gain on royalty monetization arrangement</a></td>
<td class="num">(150,930)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_NonCashInterestExpenseRecognized', window );">Non-cash interest expense</a></td>
<td class="nump">1,430<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_OperatingLeaseNoncashExpense', window );">Non-cash lease expense</a></td>
<td class="nump">3,489<span></span>
</td>
<td class="nump">3,341<span></span>
</td>
<td class="nump">2,690<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other non-cash items</a></td>
<td class="nump">423<span></span>
</td>
<td class="nump">2,882<span></span>
</td>
<td class="nump">2,035<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets', window );">Loss on disposal of assets</a></td>
<td class="nump">111<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">45,855<span></span>
</td>
<td class="num">(45,836)<span></span>
</td>
<td class="nump">12,696<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="nump">230<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="num">(6,424)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">215<span></span>
</td>
<td class="nump">11,009<span></span>
</td>
<td class="num">(4,188)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other non current assets</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(14,045)<span></span>
</td>
<td class="nump">3,225<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">1,281<span></span>
</td>
<td class="num">(10,860)<span></span>
</td>
<td class="nump">7,125<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="num">(4,823)<span></span>
</td>
<td class="num">(4,638)<span></span>
</td>
<td class="num">(607)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_IncreaseDecreaseInLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="num">(861)<span></span>
</td>
<td class="nump">9,364<span></span>
</td>
<td class="num">(3,780)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">11,426<span></span>
</td>
<td class="nump">48,821<span></span>
</td>
<td class="nump">9,264<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_IncreaseDecreaseInDeferredRent', window );">Other non current liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">258<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(78,205)<span></span>
</td>
<td class="num">(86,959)<span></span>
</td>
<td class="num">(143,830)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of marketable securities</a></td>
<td class="num">(239,683)<span></span>
</td>
<td class="num">(120,602)<span></span>
</td>
<td class="num">(231,208)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from sales and maturities of marketable securities</a></td>
<td class="nump">161,299<span></span>
</td>
<td class="nump">194,940<span></span>
</td>
<td class="nump">200,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, equipment and software</a></td>
<td class="num">(1,764)<span></span>
</td>
<td class="num">(3,623)<span></span>
</td>
<td class="num">(6,201)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfMachineryAndEquipment', window );">Proceeds from sales of equipment</a></td>
<td class="nump">64<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="num">(80,084)<span></span>
</td>
<td class="nump">70,715<span></span>
</td>
<td class="num">(36,609)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of offering costs</a></td>
<td class="nump">616<span></span>
</td>
<td class="nump">1,085<span></span>
</td>
<td class="nump">117,818<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases', window );">Proceeds from stock option exercises and ESPP purchases</a></td>
<td class="nump">553<span></span>
</td>
<td class="nump">574<span></span>
</td>
<td class="nump">4,959<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid related to net share settlement of equity awards</a></td>
<td class="num">(306)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_PrincipalPaymentsOnRoyaltyMonetizationArrangement', window );">Principal payments on royalty monetization arrangement</a></td>
<td class="num">(157)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_NetProceedsFromSaleOfFutureRoyalties', window );">Net proceeds from sale of future royalties</a></td>
<td class="nump">149,655<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">150,361<span></span>
</td>
<td class="nump">1,659<span></span>
</td>
<td class="nump">122,777<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash and cash equivalents</a></td>
<td class="num">(7,928)<span></span>
</td>
<td class="num">(14,585)<span></span>
</td>
<td class="num">(57,662)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">108,884<span></span>
</td>
<td class="nump">123,469<span></span>
</td>
<td class="nump">181,131<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">100,956<span></span>
</td>
<td class="nump">108,884<span></span>
</td>
<td class="nump">123,469<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-cash operating and investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Capital Expenditures Incurred but Not yet Paid</a></td>
<td class="nump">$ 505<span></span>
</td>
<td class="nump">$ 118<span></span>
</td>
<td class="nump">$ 508<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_GainOnRoyaltyMonetizationArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain on royalty monetization arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_GainOnRoyaltyMonetizationArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_IncreaseDecreaseInDeferredRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in deferred rent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_IncreaseDecreaseInDeferredRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_IncreaseDecreaseInLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in lease liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_IncreaseDecreaseInLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NetProceedsFromSaleOfFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net proceeds from sale of future royalties</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NetProceedsFromSaleOfFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonCashInterestExpenseRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-cash interest expense recognized</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NonCashInterestExpenseRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_OperatingLeaseNoncashExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Noncash Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_OperatingLeaseNoncashExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PrincipalPaymentsOnRoyaltyMonetizationArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Principal payments on royalty monetization arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PrincipalPaymentsOnRoyaltyMonetizationArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Stock Options Exercised And ESPP Purchases</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482312/912-310-45-11<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfMachineryAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sale of machinery and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfMachineryAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139842286480912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Nature of Operations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Nature of Operations</a></td>
<td class="text">Organization and Nature of Operations<div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MacroGenics, Inc. (the Company) is incorporated in the state of Delaware. The Company is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer. The Company has a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. These candidates are being evaluated in clinical trials sponsored by the Company or its collaborators or are in preclinical development. The Company&#8217;s clinical product candidates include multiple oncology programs which have either been created using its proprietary, antibody-based technology platforms or enabled through its technology licensing arrangements with other companies. The Company believes its product candidates have the potential, if approved for marketing by regulatory authorities, to have a meaningful effect on treating patients' unmet medical needs as monotherapy or, in some cases, in combination with other therapeutic agents. To date, three products originating from the Company&#8217;s pipeline of proprietary or partnered product candidates have received U.S. Food and Drug Administration (FDA) approval. In March 2021, the Company and its commercialization partner commenced U.S. marketing of MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. In November 2022, the FDA approved TZIELD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (teplizumab-mzwv) to delay the onset of Stage 3 Type 1 Diabetes (T1D) in adult and pediatric patients aged 8 years and older with Stage 2 T1D. Teplizumab was acquired from the Company by Provention Bio, Inc. (Provention) in May 2018, pursuant to an asset purchase agreement. In March 2023, the FDA approved ZYNYZ&#8482; (retifanlimab-dlwr), a humanized monoclonal antibody targeting programmed death receptor-1 (PD-1). Retifanlimab was previously developed by the Company and licensed to Incyte Corporation (Incyte) pursuant to an exclusive global collaboration and license agreement in October 2017.</span></div><div style="margin-bottom:6pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s multiple product candidates currently under development will require significant additional research and development efforts that include extensive preclinical studies and clinical testing, and regulatory approval prior to commercial use.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The future success of the Company is dependent on its ability to identify and develop its product candidates, and ultimately upon its ability to attain profitable operations. The Company has devoted substantially all of its financial resources and efforts to research and development and general and administrative expense to support such research and development. Net losses and negative cash flows have had, and will continue to have, an adverse effect on the Company&#8217;s stockholders&#8217; equity and working capital, and accordingly, its ability to execute its future operating plans.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a biotechnology company, the Company has primarily funded its operations with proceeds from the sale of its common stock in equity offerings and revenue from its multiple collaboration agreements.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management regularly reviews the Company&#8217;s available liquidity relative to its operating budget and forecast to monitor the sufficiency of the Company&#8217;s working capital.  The Company plans to meet its future operating requirements by generating revenue from current and future strategic collaborations or other arrangements, product sales and royalties.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company anticipates continuing to draw upon available sources of capital, including equity and debt instruments, to support its product development activities.  If the Company is unable to enter into new arrangements or to perform under current or future agreements or obtain additional capital, the Company will assess its capital resources and may be required to delay, reduce the scope of, or eliminate one or more of its product research and development programs or clinical studies, reduce other operating expenses, and/or downsize its organization. Based on the Company&#8217;s most recent cash flow forecast, the Company believes its current resources are sufficient to fund its operating plans for a minimum of twelve months from the date that this Annual Report on Form 10-K was filed.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similar to the other risk factors pertinent to the Company's business, including significant equity market volatility and availability of funding in the biotechnology sector, as well as potential issues in the global economy, credit markets and financial markets as a result of significant worldwide events, including adverse events involving financial institutions or the financial services industry, inflation and rising interest rates and geopolitical upheaval, might unfavorably impact the Company's ability to generate such additional funding. Given the uncertainty in the rapidly changing market and economic conditions related to these uncertainties, the Company will continue to evaluate the nature and extent of the impact of these uncertainties on its business and financial position.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139842286558144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Principles of Consolidation</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, MacroGenics UK Limited and MacroGenics Limited.&#160;All intercompany accounts and transactions have been eliminated in consolidation. The Company currently operates in one operating segment. Operating segments are defined as components of an enterprise about which separate discrete information is available for the chief operating decision maker, or decision making group, in deciding how to allocate resources and assessing performance. The Company views its operations and manages its business in one segment, which is developing and commercializing monoclonal antibody-based therapeutics.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the financial statements in accordance with generally accepted accounting principles (GAAP) requires the Company to make estimates and judgments in certain circumstances that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. In preparing these consolidated financial statements, management has made its best estimates and judgments of certain amounts included in the financial statements, giving due consideration to materiality. On an ongoing basis, the Company evaluates its estimates, including those related to revenue recognition, fair values of assets, inventory, preclinical study and clinical trial accruals and other contingencies. Management bases its estimates on historical experience or on various other assumptions that it believes to be reasonable under the circumstances. Although actual results could differ from these estimates, management does not believe that such differences would be material.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents and Marketable Securities</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all investments in highly liquid financial instruments with a maturity of 90 days or less at the date of purchase to be cash equivalents. Cash and cash equivalents includes investments in money market funds with commercial banks and financial institutions, securities issued by the U.S. government and its agencies, Government Sponsored Enterprise agency debt obligations and corporate debt obligations. Cash equivalents are stated at amortized cost, plus accrued interest, which approximates fair value.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company carries marketable securities classified as available-for-sale at fair value as determined by prices for identical or similar securities at the balance sheet date. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Classification of marketable securities between current and non-current is dependent upon the maturity date at the balance sheet date taking into consideration the Company&#8217;s ability and intent to hold the investment to maturity. </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities consist of Level 2 financial instruments in the fair-value hierarchy. The Company records unrealized gains and losses as a component of other comprehensive loss within the statements of operations and comprehensive loss and as a separate component of stockholders' equity. Realized gains or losses on available-for-sale securities are determined using the specific identification method and the Company includes net realized gains and losses in other income, along with interest income and amortization of premiums and discounts.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable arise from product sales, amounts due from the Company&#8217;s collaborative partners and contract manufacturing work performed by the Company.  The amount from product sales represents amounts due from specialty distributors. Accounts receivable that management has the intent and ability to collect are reported in the consolidated balance sheets at outstanding amounts, less an allowance for doubtful accounts. The Company writes off uncollectible receivables when the likelihood of collection is remote.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates the collectability of accounts receivable on a regular basis. The allowance, if any, is based upon various factors including the financial condition and payment history of customers, an overall review of collections experience on other accounts and economic factors or events expected to affect future collections experience. No allowance was recorded as of December&#160;31, 2023 or 2022, as the Company has a history of collecting on all outstanding accounts.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's financial instruments consist of cash and cash equivalents, marketable securities, accounts receivable, accounts payable and accrued expenses.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of accounts receivable, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of their short-term nature.&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for recurring and non-recurring fair value measurements in accordance with the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements and Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 820). ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements. The ASC 820 hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 &#8211; Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 &#8211; Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data.</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 &#8211; Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity &#8211; e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC 820 hierarchy.  </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers between levels during the periods presented. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets measured at fair value on a recurring basis were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:51.616%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.612%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.584%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.852%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement at December&#160;31, 2023</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,665&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,665&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,179&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,179&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,043&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,043&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,627&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,627&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220,514&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,665&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,849&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.958%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.108%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement at December&#160;31, 2022</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,564&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,564&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-sponsored enterprise</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,811&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,811&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,626&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,626&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,001&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,564&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,437&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:15pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Total assets measured at fair value at December&#160;31, 2023 includes approximately $91.7 million reported as cash and cash equivalents and $128.8&#160;million reported as marketable securities on the balance sheet.</span></div><div style="margin-bottom:9pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Total assets measured at fair value at December&#160;31, 2022 includes approximately $46.5 million reported as cash and cash equivalents and $45.5&#160;million reported as marketable securities on the balance sheet.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents, marketable securities and accounts receivable. </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains its cash and money market funds with financial institutions that are federally insured. While balances deposited in these institutions often exceed Federal Deposit Insurance Corporation limits, the Company has not experienced any losses on related accounts to date.&#160;The Company's investment policy limits investments to certain types of debt securities issued by the U.S. government, its agencies and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The counterparties are various corporations, financial institutions and government agencies of high credit standing.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's revenue relates to agreements with various collaborators, MARGENZA net product sales and&#160;contracts and research grants received from U.S. government agencies.&#160;The following table includes those counterparties </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that represent more than 10% of total revenue earned in the periods indicated:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:68.119%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.620%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.620%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.683%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incyte</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">McKesson Plasma &amp; Biologics and McKesson Specialty Care Distribution LLC (McKesson)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ASD Healthcare and Oncology Supply (ASD)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provention</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zai Lab Limited (Zai Lab)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I-Mab Biopharma (I-Mab)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16%</span></td></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Amount is less than 10% for the period indicated.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table includes those counterparties that represent more than 10% of accounts receivable at the date indicated:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:72.946%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.363%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.632%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incyte</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health, Inc</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">McKesson</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ASD</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zai Lab</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provention</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84%</span></td></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Balance is less than 10% as of the date indicated.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When the Company believes regulatory approval is probable and expects future economic benefit from the sales of a product candidate to be realized, the Company capitalizes manufacturing costs (whether internally produced or through third-party contract manufacturing organizations) as inventory.  Prior to receiving its first approval from the FDA in December 2020, the Company expensed all costs incurred related to the manufacture of MARGENZA as research and development expense because of the inherent risks associated with the development of a product candidate, the uncertainty about the regulatory approval process and the lack of history for the Company of regulatory approval of drug candidates.  Subsequent to FDA approval in December 2020, the Company began capitalizing its MARGENZA third-party contract manufacturing inventory costs.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory is composed of raw materials, work-in-process, and finished goods, which are goods that are available for sale. The Company values its inventories at the lower of cost or estimated net realizable value. The Company determines the cost of its inventories, which includes amounts related to materials and third-party contract manufacturing costs, on a first-in, first-out basis. The Company performs an assessment of the recoverability of capitalized inventory during each reporting period, and it writes down any excess, obsolete or unsaleable inventories to their estimated realizable value in the period in which the impairment is first identified. Such write downs, should they occur, are recorded within the cost of product sales in the statement of operations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property, Equipment and Software</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, equipment and software are stated at cost. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation or amortization are removed from the accounts and any resulting gain or loss is credited or charged to operations. Repairs and maintenance costs are expensed as incurred. Depreciation and amortization are computed using the straight-line method over the following estimated useful lives:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.046%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.754%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory and office equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter of lease term or useful life</span></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses the recoverability of its long-lived assets in accordance with the provisions of ASC 360, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property, Plant and Equipment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC 360). ASC 360 requires that long-lived assets be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of the long-lived asset is measured by a comparison of the carrying amount of the asset to future undiscounted net cash flows expected to be generated by the asset or asset group. If carrying value exceeds the sum of undiscounted cash flows, the Company then determines the fair value of the underlying asset group. Any impairment to be recognized is measured by the amount by which the carrying amount of the asset group exceeds the estimated fair value of the asset group. Assets to be disposed of are reported at the lower of the carrying amount or fair value, less costs to sell. For the years ended December&#160;31, 2023, and 2022, the Company determined that there were no impaired assets.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liability related to the sale of future royalties and related interest expense</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses the relevant accounting criteria under ASC 470, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 470) to determine whether the upfront payment received from the purchaser should be accounted for as debt or deferred income depending on the facts and circumstances.  If the criteria in ASC 470 is met, the Company accounts for net proceeds from sales of its rights to receive future royalty payments as a liability that is amortized using the effective interest method over the term of the arrangement. The liability related to future royalties is presented net of unamortized issuance costs on the consolidated balance sheets. Interest expense on the liability related to future royalties is recognized using the effective interest rate method over the life of the arrangement. The Company calculates an effective interest rate which will amortize its related obligation to zero over the anticipated repayment period. The liability related to future royalties and the related interest expense are based on the Company&#8217;s current estimates of future royalties expected to be received over the life of the arrangement, which the Company determines by using internal sales projections and external information from market data sources, which are considered Level 3 inputs. The Company periodically assesses the expected payments and to the extent the Company&#8217;s estimates of future royalty payments are greater or less than previous estimates or the estimated timing of such payments is materially different than previous estimates, the Company will adjust the effective interest rate and recognize related non-cash interest expense on a prospective basis. Non-cash amortization is reflected as interest expense in the consolidated statements of operations and comprehensive loss.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Upon changes in facts and circumstances, for example as a result of a modification to the existing agreements, the Company re-evaluates its rights and obligations and accounts for the change in accordance with the respective accounting guidance.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue recognition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue under ASC Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s (ASC 606) when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Collaborative and other agreements</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into licensing agreements that are within the scope of ASC 606, under which it may license rights to research, develop, manufacture and commercialize its product candidates to third parties. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, upfront license fees; reimbursement of certain costs; customer option exercise fees; development, regulatory and commercial milestone payments;&#160;and royalties on net sales of licensed products. The Company may also enter into development and manufacturing service agreements with its collaborators.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each arrangement that results in revenues, the Company identifies all performance obligations, which may include a license to intellectual property and know-how, research and development activities, transition activities and/or manufacturing services. In order to determine the transaction price, in addition to any upfront payment, the Company estimates the amount of variable consideration at the outset of the contract either utilizing the expected value or most likely amount method, depending on the facts and circumstances relative to the contract. The Company constrains (reduces) the estimates of variable consideration such that it is probable that a significant reversal of previously recognized revenue will not occur. When determining if variable consideration should be constrained, management considers whether there are factors outside the Company&#8217;s control that could result in a significant reversal of revenue. In making these assessments, the Company considers the likelihood and magnitude of a potential reversal of revenue. These estimates are re-assessed each reporting period as required. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once the estimated transaction price is established, amounts are allocated to the performance obligations that have been identified. The transaction price is generally allocated to each separate performance obligation on a relative standalone selling price basis. The Company must develop assumptions that require judgment to determine the standalone selling price in order to account for these agreements. To determine the standalone selling price, the Company&#8217;s assumptions may include (i)  the probability of obtaining marketing approval for the product candidate, (ii) estimates regarding the timing and the expected costs to develop and commercialize the product candidate, and (iii) estimates of future cash flows from potential product sales with respect to the product candidate. Standalone selling prices used to perform the initial allocation are not updated after contract inception. The Company does not include a financing component to its estimated transaction price at contract inception unless it estimates that certain performance obligations will not be satisfied within one year.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts received prior to revenue recognition are recorded as deferred revenue. Amounts expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as current portion of deferred revenue in the accompanying consolidated balance sheets. Amounts not expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as deferred revenue, net of current portion. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Licenses. </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When the Company grants a license to its intellectual property, it </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">determines whether the </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nature of the intellectual property to which the customer will have rights is functional intellectual property (functional IP), which has significant standalone functionality, or symbolic intellectual property (symbolic IP) which does not have significant standalone functionality.  Revenue from functional IP is recognized at the point in time when control of the distinct license is transferred to the customer. Revenue from symbolic IP is recognized over the access period to the Company&#8217;s intellectual property</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the license to the Company&#8217;s intellectual property is determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and when (or as) the customer is able to use and benefit from the license. In assessing whether a promise or performance obligation is distinct from the other promises, the Company considers factors such as the research, development, manufacturing and commercialization capabilities of the licensee and the availability of the associated expertise in the general marketplace. In addition, the Company considers whether the licensee can benefit from a promise for its intended purpose without the receipt of the remaining promise, whether the value of the promise is dependent on the unsatisfied promise, whether there are other vendors that could provide the remaining promise, and whether it is separately identifiable from the remaining promise. For licenses that are combined with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The measure of progress, and thereby periods over which revenue should be recognized, are subject to estimates by management and may change over the course of the research and development and licensing agreement. Such a change could have a material impact on the amount of revenue the Company records in future periods. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research, Development and/or Manufacturing Services. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The promises under the Company&#8217;s agreements may include research and development or manufacturing services to be performed by the Company on behalf of the counterparty. If these services are determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes the transaction price allocated to these services as revenue over time based on an appropriate measure of progress when the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. If these services are determined not to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes the transaction price allocated to the combined performance obligation as the related performance obligations are satisfied. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Customer Options. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an arrangement contains customer options, the Company evaluates whether the options are material rights because they allow the customer to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">outset of the arrangement. The Company allocates the transaction price to material rights based on the relative standalone selling price, which is determined using assumptions regarding estimated costs, discount rates, post-option development timeline, the probability of technical and regulatory success and the probability  that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until, at the earliest, the option is exercised. If the options are deemed not to be a material right, they are excluded as performance obligations at the outset of the arrangement. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes development milestone payments, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For arrangements that include sales-based royalties which are the result of a customer-vendor relationship and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company analyzes its collaboration arrangements to assess whether such arrangements involve joint operating activities performed by parties who are both active participants in the activities and are both exposed to significant risks and rewards dependent on the commercial success of such activities. Such arrangements generally are within the scope of ASC 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 808). While ASC 808 defines collaborative arrangements and provides guidance on income statement presentation, classification, and disclosures related to such arrangements, it does not address recognition and measurement matters, such as (1)&#160;determining the appropriate unit of accounting or (2) when the recognition criteria are met. Therefore, the accounting for these arrangements is either based on an analogy to other accounting literature or an accounting policy election by the Company. The Company accounts for certain components of the collaboration agreement that are reflective of a vendor-customer relationship (e.g., licensing arrangement) based on ASC 606. The Company accounts for other components based on a reasonable, rational and consistently applied accounting policy election.&#160; Reimbursements from the counter-party that are the result of a collaborative relationship with the counter-party, instead of a customer relationship, such as co-development activities, are recorded as a reduction to research and development expense as the services are performed.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a complete discussion of accounting for revenue from collaborative and other agreements, see Note 9, Revenue.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Product sales, net</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company entered into a limited number of arrangements with specialty distributors in the United States to distribute MARGENZA. These arrangements are considered to be contracts with customers and are in the scope of ASC 606. The Company has written contracts with each of its customers that have a single performance obligation - to deliver products upon receipt of a customer order - and these obligations are satisfied when delivery occurs and the customer receives the product.  The specialty distributors subsequently resell the Company&#8217;s product to healthcare providers.  Product revenue is recorded net of applicable reserves for variable consideration, including discounts and other allowances. Shipping and handling costs for product shipments occur prior to the customer obtaining control of the goods and are recorded in cost of sales. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reserves for Variable Consideration.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from product sales is recorded at the net sales price, which includes estimates of variable consideration. Components of variable consideration typically include discounts, product returns, provider chargebacks and discounts and government rebates. Variable consideration is estimated following the expected value method in accordance with ASC 606 and includes such factors as current contractual and statutory requirements, specific known market events and trends, industry data, and forecasted customer buying and payment patterns. The amount of variable consideration that is included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized under the contract will not occur in a future period. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Customer Discounts and Service Fees.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may provide customers with discounts which are explicitly stated in the contracts. These discounts are recorded as a reduction of revenue in the period the related product revenue is </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recognized. In addition, these contracts may include written service arrangements whereby the Company pays fees to customers who provide services such as sales order management, data, contract administration and distribution services, at rates which the Company believes to be consistent with fair market value. The Company has determined such services received to date are not distinct from the Company&#8217;s sale of products to its customers and, therefore, these payments have been recorded as a reduction of revenue within the statement of operations. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Returns.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consistent with industry practice, the Company offers the specialty distributors product return rights pursuant to written contracts and/or Company returned goods policies. The Company estimates the amount of its product sales that may be returned by its customers and records an estimated liability and a reduction of revenue in the period the related product revenue is recognized. The Company currently estimates product returns using industry benchmarking as well as other information available, such as visibility into the inventory remaining in the distribution channel, since the Company does not have its own returns experience. The Company's estimates of product returns may be adjusted in the future based on actual returns experience, known or expected changes in the marketplace, or other factors.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provider Chargebacks and Discounts.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chargebacks for fees and discounts to healthcare providers represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices charged to customers who directly purchase the product from the Company. In such cases, customers charge the Company for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers. The reserve for chargebacks is established in the same period that the related revenue is recognized, resulting in a reduction of product revenue. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider by customers, and the Company generally issues credits for such amounts within a few weeks of the customer&#8217;s notification to the Company of the resale. Chargebacks consist of credits the Company expects to issue for units that remain in the distribution channel at each reporting period end that the Company expects will be sold to qualified healthcare providers and chargebacks that customers have claimed, but for which the Company has not yet issued a credit. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Rebates.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to discount and/or rebate obligations under state Medicaid programs, Medicare and contractual agreements with and statutory obligations to certain Federal and State entities. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue. The Company&#8217;s liability for these rebates consists of invoices received for claims from prior quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimates of future claims that will be made for product that has been recognized as revenue, but which remains in the distribution channel at the end of each reporting period. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customer discounts are recorded as a reduction of accounts receivable on the consolidated balance sheets. Allowance for product returns, provider chargebacks, government and other rebates and service fees are recorded as a component of accrued expenses and other current liabilities on the consolidated balance sheets.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Contract manufacturing revenue</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into agreements with third parties to manufacture their drug substance at its GMP facility. The terms of these arrangements typically include an upfront payment to the Company to reserve manufacturing capacity, scheduled payments during the manufacturing process and reimbursement for materials used to manufacture product.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue over time on a straight-line basis as the manufacturing services are performed, as the Company believes that its efforts in providing the manufacturing services are incurred evenly throughout the performance period and therefore straight-line revenue recognition closely approximates the level of effort for the manufacturing services. Variable consideration relating to the reimbursed materials and other reimbursed costs incurred to manufacture product are allocated to the related manufacturing activities and are recognized as revenue as those activities occur.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Cost of Product Sales</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of product sales relates to sales of MARGENZA.  These costs include material, manufacturing and shipping costs, as well as royalties payable on net sales of MARGENZA and inventory reserves.  All product costs incurred prior to FDA approval of MARGENZA in December 2020 were expensed as research and development expense.  The Company expects cost of product sales to continue to be positively impacted for the next four to five years as the Company sells through inventory that was expensed prior to FDA approval of MARGENZA. </span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Manufacturing Services</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of manufacturing services consists of the costs to provide manufacturing services to produce certain bulk drug substance under manufacturing and clinical supply agreements with third parties, including salaries and benefits and related stock-based compensation, materials, overhead and other related costs.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expense, Including Clinical Trial Accruals/Expenses</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenditures are expensed as incurred. Research and development costs primarily consist of employee related expenses, including salaries and benefits, expenses incurred under agreements with contract research organizations (CROs), investigative sites and consultants that conduct the Company's clinical trials, the cost of acquiring and manufacturing clinical trial materials, including costs incurred under agreements with contract manufacturing organizations (CMOs), and other allocated expenses, license fees for and milestone payments related to in-licensed products and technologies, stock-based compensation expense, and costs associated with non-clinical activities and regulatory approvals.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-to-develop agreements may contain cost-sharing provisions whereby the Company and the collaborator share the cost of research and development activities. Reimbursement of research and development expenses received in connection with these agreements is recorded as a reduction of such expenses.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trial expenses are a significant component of research and development expense, and the Company outsources  a significant portion of these costs to third parties. Third party clinical trial expenses include investigator fees, site and patient costs, CRO costs, costs for central laboratory testing, data management and CMO costs. The accrual for site and patient costs includes inputs such as estimates of patient enrollment, patient cycles incurred, clinical site activations, and other pass-through costs. These inputs are required to be estimated due to a lag in receiving the actual clinical information from third parties. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected on the consolidated balance sheets as a prepaid asset or accrued expenses. These third party agreements are generally cancellable, and related costs are recorded as research and development expenses as incurred</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Non-refundable advance clinical payments for goods or services that will be used or rendered for future research and development activities are recorded as a prepaid asset and recognized as expense as the related goods are delivered or the related services are performed.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> When evaluating the adequacy of the accrued expenses, management  analyzes progress of the studies, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates may be made in determining the accrued balances at the end of any reporting period. Actual results could differ from the estimates made. The historical clinical accrual estimates have not been materially different from the actual costs.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines whether an arrangement is or contains a lease at the inception of an arrangement under ASC 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. For leases where the Company is the lessee, right-of-use (ROU) assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term of the lease for which the rate is estimated. Certain adjustments to the ROU asset may be required for items such as initial direct costs paid or incentives received. The lease terms used to calculate the ROU asset and related lease liabilities include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for operating leases is recognized on a straight-line basis over the lease term as an operating expense while the expense for finance leases is recognized as depreciation expense and interest expense using the accelerated interest method of recognition. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss represents net loss adjusted for the change during the periods attributed to unrealized gains and losses on available-for-sale debt securities.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period. All stock options and restricted stock units (RSUs) are excluded from the per share calculations as such securities were anti-dilutive for all periods presented. The following table presents the number of stock options and RSUs that were excluded from the calculation of net loss per share:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"></td><td style="width:44.036%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.377%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.015%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.377%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.015%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.380%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options and RSUs</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,129,251</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,514,013</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,395,421</span></td></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has implemented all applicable accounting pronouncements that are in effect. These pronouncements did not have any material impact on the financial statements unless otherwise disclosed, and the Company does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139842286452864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Marketable Securities</a></td>
<td class="text">Marketable Securities<div style="margin-bottom:9pt;text-indent:31.5pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale marketable securities as of December&#160;31, 2023 and 2022 were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:49.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.650%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,177&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,179&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,041&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,043&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,637&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,627&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,855&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,849&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:49.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.650%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-sponsored enterprises</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,812&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,810&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,655&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,652&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,467&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,462&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company's available-for-sale securities held at December&#160;31, 2023 and 2022 had contractual maturities of less than one year.  All of the Company&#8217;s available-for-sale marketable debt securities in an unrealized loss position as of </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and 2022 were in a loss position for less than twelve months.&#160; Unrealized losses on available-for-sale debt securities as of </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2023 and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022 </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">were not </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">significant and were primarily due to changes in interest rates, including market credit spreads, and not due to increased credit risks associated with specific securities.  Accordingly, no allowance for credit losses related to the Company's available-for-sale debt securities was recorded for the years ended </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2023 and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022. </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not intend to sell these investments and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost bases, which may be at maturity.</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded interest income of $4.0 million, $1.7 million and $2.0 million during the years ended December&#160;31, 2023, 2022 and 2021, respectively, which is included in interest and other income on the consolidated statements of operations and comprehensive loss.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//320/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-6B<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-6B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br> -Publisher SEC<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//946-320/tableOfContent<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 940<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//940-320/tableOfContent<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//942-320/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139842287181472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory, Net</a></td>
<td class="text">Inventory, Net<div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company's inventory relates to the manufacturing of MARGENZA.  The following table sets forth the Company's inventory, net of reserves (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.761%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">409&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">960&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,042&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,221&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,451&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:31.5pt"><span><br/></span></div><div style="margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to FDA approval of MARGENZA in December 2020, the cost of materials and expenses associated with the manufacturing of MARGENZA were recorded as research and development expense. Subsequent to FDA approval, the Company began capitalizing inventory costs related to the manufacture of MARGENZA. The inventory balance as of December&#160;31, 2023 and December&#160;31, 2022 is net of a reserve of $3.1 million and $4.9 million, respectively, for unsaleable inventory. These reserves are reflected in cost of product sales during the period they are recorded.   </span></div><div style="margin-top:3pt"><span><br/></span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.952%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Inventory Reserves (in thousands)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at Beginning of Year</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additions Charged to Expenses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deductions</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at End of Year</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ended December&#160;31, 2023</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,917&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,798)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,119&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ended December 31, 2022</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,035&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,882&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,917&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ended December 31, 2021</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,035&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,035&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//330/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139842284989664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Equipment and Software<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Equipment and Software</a></td>
<td class="text">Property, Equipment and Software<div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, equipment and software consists of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,542&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,489&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,759&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,604&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and office equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">706&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">713&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Motor vehicles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,452&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,474&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,620&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,974&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, equipment and software</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,241&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,660&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88,394)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84,085)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, equipment and software, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,847&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,575&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense related to property, equipment and software for the years ended December&#160;31, 2023, 2022 and 2021 was $9.6 million, $11.9 million and $11.3 million, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139842287833360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has non-cancelable operating leases for manufacturing, laboratory, office and warehouse space in Maryland  The Company&#8217;s leases each have one or more five-year options to renew</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In December 2022, the Company amended the existing lease on its headquarters space to extend the lease term through 2035 in exchange for certain concessions from the </span></div><div style="margin-bottom:9pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">lessor.  This amendment was accounted for as a lease modification, and the right-of-use asset and lease liability were remeasured at the modification date, resulting in an increase to both balances of approximately $14.0 million.  </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents supplemental balance sheet information related to operating leases:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.092%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.013%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Weighted-average remaining lease term (in years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.1</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2023 and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 2022, t</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he Company made cash payments for operating leases of $5.9 million and $6.9 million, respectively. As of December&#160;31, 2023 and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 2022,</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the Company&#8217;s ROU assets were valued at $23.8 million and $27.3 million, respectively.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease cost for the years ended </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and 2022 were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.225%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.946%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.948%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating lease cost</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,459&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,597&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,316&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,451&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Sublease income</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,109)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,076)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net lease cost</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,666&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,972&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the maturities of the Company&#8217;s operating lease liabilities were as follows (in thousands): </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.473%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.327%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,084&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,209&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,927&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,049&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,003&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,276&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,306)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,970&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In-licensing arrangement</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, the Company entered into a non-exclusive license agreement with Synaffix B.V., a Lonza company, (Synaffix) to develop, manufacture and commercialize up to three antibody-drug conjugate targets using Synaffix&#8217;s proprietary technology. The Company made an upfront payment to Synaffix upon contract execution. In March 2023, the Company and Synaffix amended the agreement, adding four additional targets. Assuming all seven targets are successfully developed and commercialized, the Company would be obligated to pay up to $2.8&#160;billion for development, regulatory and sales milestones. Finally, pursuant to the terms of this license agreement, as amended, upon commencement of commercial sales of any products developed from these targets, the Company would be required to pay Synaffix tiered royalties in the low&#8209;single digit percentages on net sales of the respective products. The Company may terminate this agreement at any time with 30 days&#8217; notice to Synaffix. Amounts paid to Synaffix under this agreement are recorded as research and development expense in the consolidated statement of operations.  The Company incurred $2.8&#160;million and $1.0&#160;million in expense under this agreement during the years ended December&#160;31, 2023 and 2022, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139842284904192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Royalty Monetization Arrangement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_RoyaltyMonetizationArrangementAbstract', window );"><strong>Royalty Monetization Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_LiabilityRelatedToSaleOfFutureRoyaltiesTextBlock', window );">Royalty Monetization Arrangement</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.  Royalty Monetization Arrangement</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023, the Company entered into a Purchase and Sale Agreement (Royalty Purchase Agreement) with DRI Healthcare Acquisitions LP (DRI), a wholly owned subsidiary of DRI Healthcare Trust, for the sale to DRI of the Company&#8217;s single-digit royalty interest on global net sales of TZIELD (teplizumab-mzwv) under the Company&#8217;s asset purchase agreement dated May 7, 2018, as amended (the Provention APA), with Provention. The Company retained its other economic interests related to TZIELD under the Provention APA, including future potential development, regulatory, and commercial milestones.  </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Royalty Purchase Agreement, the Company received $100.0&#160;million from DRI for its single-digit royalty interest on global net sales of TZIELD under the Provention APA (the Royalty Interest). Additionally, the Company has the right to receive a 50% share of the royalty on global net sales above a certain annual threshold (the Retained Interest). In addition, the Company was eligible to receive up to $50.0&#160;million upon the occurrence of pre-specified events tied to the advancement of TZIELD for the treatment of newly diagnosed type 1 diabetes. This milestone was achieved in July 2023 as described below. The Company is also eligible to receive an additional $50.0&#160;million milestone if TZIELD achieves a certain level of net sales (Sales Milestone Payment). </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $100.0&#160;million proceeds received from DRI for the Royalty Interest were recorded as a liability related to future royalties, net of transaction costs of $0.3&#160;million, which was to be amortized over the term of the arrangement using the effective interest rate method. At inception, the Company accounted for the Royalty Purchase Agreement as a financing arrangement because the Company had significant continuing involvement in the delivery of future royalty payments to DRI and other existing obligations under the Provention APA. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2023, the Company entered into an agreement (the Tripartite Agreement) with DRI and a subsidiary of Sanofi S.A. (Sanofi), whereby the Company consented to the sale of DRI&#8217;s Royalty Interest and related milestone payment obligations to Sanofi. The Tripartite Agreement eliminated the Company&#8217;s obligation to deliver payments to DRI related to the Royalty Interest and removed all of the Company&#8217;s other obligations under the Royalty Purchase Agreement. The Royalty Interest will be paid directly to Sanofi by Provention. As a result, the Company&#8217;s royalty rights are only for the Retained Interest. This change in rights and obligations resulted in a change in the terms of the liability related to future royalties which was evaluated by the Company in accordance with ASC 470-50, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt &#8212; Modifications and Extinguishments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company concluded that the execution of the Tripartite Agreement resulted in a modification to the liability related to future royalties.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the terms of the new liability related to the single-digit future royalties and the original liability related to future royalties were substantially different as the Company no longer receives payments for the Royalty Interest and therefore has a significantly reduced liability to make payments in accordance with the Royalty Purchase Agreement. The new liability related to future royalties was determined to be de minimis.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result, the Company recorded $100.9&#160;million within other income on the statement of operations and comprehensive loss during the three months ended June 30, 2023. There was no modification to the Company's Retained Interest in the Tripartite Agreement.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2023, Sanofi reported achievement of the primary endpoint milestone event related to the $50.0&#160;million milestone noted above. Given that the Company has no continuing obligation to pay the Royalty Interest to Sanofi, the Company recorded this milestone within other income on the statement of operations and comprehensive loss during the three months ended September 30, 2023.  Also in September 2023, the Company and Sanofi executed Amendment No. 2 to the Provention APA to incorporate the Sales Milestone Payment obligation from the Royalty Purchase Agreement into the Provention APA.  In addition, the Company and Sanofi terminated the Royalty Purchase Agreement, which did not result in a material impact to the financial statements given the fair value of the liability related to future royalties was de minimis.   </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes to the liability related to future royalties were as follows for the year ended December&#160;31, 2023 (in thousands):</span></div><div style="text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.636%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.580%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability related to future royalties - beginning balance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sale of future royalties</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred transaction costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(343)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty revenue payable to DRI</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(157)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense recognized</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,430&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on royalty monetization arrangement</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(150,930)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability related to future royalties - ending balance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_LiabilityRelatedToSaleOfFutureRoyaltiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability Related To Sale Of Future Royalties</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_LiabilityRelatedToSaleOfFutureRoyaltiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_RoyaltyMonetizationArrangementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Monetization Arrangement [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_RoyaltyMonetizationArrangementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139842284904192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders' Equity<div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's amended and restated certificate of incorporation authorizes 125,000,000 shares of common stock, and 5,000,000 shares of undesignated preferred stock, both with a par value of $0.01 per share.&#160;There were no shares of undesignated preferred stock issued or outstanding as of December&#160;31, 2023 or 2022. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, the Company entered into a sales agreement (Sales Agreement) with an agent to sell, from time to time, shares of its common stock having an aggregate sales price of up to $100.0 million through an &#8220;at the market offering&#8221; (ATM Offering) as defined in Rule 415 under the Securities Act of 1933, as amended. The Company sold 3,622,186 shares of common stock resulting in net proceeds of approximately $98.2&#160;million through December 31, 2021 under the Sales Agreement. In April 2021, the Company entered into Amendment No. 1 to the Sales Agreement which increased the amount of the Company&#8217;s common stock that can be sold by the Company through its agent under the ATM Offering, from an aggregate offering price of up to $100.0&#160;million to an aggregate offering price of up to $300.0&#160;million. During the year ended December 31, 2022, the Company sold 160,480 shares of common stock at a weighted average price per share of $6.87, resulting in net proceeds of approximately $1.1 million, net of underwriting discounts and commissions and other offering expenses. In March 2023, the Company terminated the Sales Agreement and entered into a new sales agreement with an agent to sell, from time to time, shares of its common stock having an aggregate sales price of up to $100.0&#160;million through an ATM Offering. During the year ended December&#160;31, 2023, the Company sold 95,000 shares of common stock at a weighted average price per share of $6.60, resulting in net proceeds of approximately $0.6 million, net of offering expenses.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139842283451968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_CollaborationAndLicenseAgreementsAbstract', window );"><strong>Collaboration and License Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock', window );">Revenue</a></td>
<td class="text">Revenue<div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Collaborative and Other Agreements </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Incyte Corporation</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Incyte License Agreement</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, the Company entered into an exclusive global collaboration and license agreement with Incyte, which was amended in March 2018, April 2022 and July 2022, for retifanlimab, an investigational monoclonal antibody that inhibits PD-1 (Incyte License Agreement). Incyte has obtained exclusive worldwide rights for the development and commercialization of retifanlimab in all indications, while the Company retains the right to develop its pipeline assets in combination with retifanlimab. Under the terms of the Incyte License Agreement, Incyte paid the Company an upfront payment of $150.0 million in 2017. MacroGenics will manufacture a portion of Incyte&#8217;s global commercial supply of retifanlimab. In March 2023, the FDA approved Incyte's Biologics License Application (BLA) for ZYNYZ (retifanlimab-dlwr) for the treatment of adults with metastatic or recurrent locally advanced Merkel cell carcinoma. Incyte has stated it is pursuing development of retifanlimab in potentially registration-enabling studies, including in patients with Merkel cell carcinoma, squamous cell carcinoma of the anal canal, MSI-high endometrial cancer and non-small cell lung cancer.  Incyte is also pursuing development of retifanlimab in combination with multiple product candidates from its pipeline.  </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Incyte License Agreement, as amended, Incyte will lead global development of retifanlimab. Assuming successful development and commercialization by Incyte in multiple indications, the Company could receive up to a total of  $435.0 million in development and regulatory milestones, and up to $330.0 million in commercial milestones. From the inception of the Incyte License Agreement through </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company has recognized $115.0 million in development milestones under the Incyte License Agreement, including $15.0 million received following the FDA approval of ZYNYZ. The Company is eligible to receive tiered royalties of 15% to 24% on global net sales. The Company retains the right to develop its pipeline assets in combination with retifanlimab, with Incyte commercializing retifanlimab and the Company commercializing its asset(s), if any such potential combinations are approved. In addition, the Company retains the right to manufacture a portion of both companies' global commercial supply needs of retifanlimab, subject to the separate commercial supply agreement. </span></div><div style="margin-bottom:9pt;text-indent:42pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the Incyte License Agreement under the provisions of ASC 606 at inception and identified the following two performance obligations under the agreement: (i) the license of retifanlimab and (ii) the performance of certain clinical activities through a brief technology transfer period. The Company determined that the license and clinical activities are separate performance obligations because they are capable of being distinct, and are distinct in the context of the contract. The license has standalone functionality as it is sublicensable, Incyte has significant capabilities in performing clinical trials, and Incyte is capable of performing these activities without the Company's involvement; the Company performed the activities during the transfer period as a matter of convenience. The Company determined that the transaction price of the Incyte License Agreement at inception was $154.0 million, consisting of the consideration to which the Company was entitled in exchange for the license and an estimate of the consideration for clinical activities to be performed. The transaction price was allocated to each performance obligation based on their relative standalone selling price. The standalone selling price of the license was determined using the adjusted market assessment approach considering similar collaboration and license </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">agreements. The standalone selling price for the agreed-upon clinical activities to be performed was determined using the expected cost approach based on similar arrangements the Company has with other parties. The potential development and regulatory milestone payments are </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fully constrained until the Company concludes that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and as such have been excluded from the transaction price. Any consideration related to sales-based milestones and royalties will be recognized when the related sales occur, as they were determined to relate predominantly to the license granted to Incyte and, therefore, have also been excluded from the transaction price. The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur. </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From 2018 through December&#160;31, 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">it became probable that a significant reversal of cumulative revenue would not occur for development milestones totaling </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$115.0 million</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> related to clinical and regulatory activities related to the further advancement of retifanlimab.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Therefore</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the associated consideration was added to the estimated transaction price and was recognized as revenue. </span></div><div style="margin-bottom:9pt;text-indent:42pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$150.0 million</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> allocated to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">license when it satisfied its performance obligation and transferred the license to Incyte in 2017. The $4.0 million allocated to the clinical activities was recognized ratably as services were performed during 2017 and 2018.  The Company recognized the $15.0 million ZYNYZ approval milestone as revenue under the Incyte License Agreement during the year ended December&#160;31, 2023. The Company recognized revenue of $15.0 million, $30.0 million and $15.0 million under the Incyte License Agreement during the years ended December&#160;31, 2023, 2022 and 2021, respectively, all of which was related to development milestones.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:42pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Incyte Clinical Supply Agreement</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:42pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, the Company entered into an agreement with Incyte under which the Company is to perform development and manufacturing services for Incyte&#8217;s clinical needs of retifanlimab (Incyte Clinical Supply Agreement). The Company evaluated this agreement under ASC 606 and identified one performance obligation under the agreement: to perform services related to the development and manufacturing of the clinical supply of retifanlimab. The transaction price is based on the costs incurred to develop and manufacture drug product and drug substance, and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. The transaction price is being recognized using the input method reflecting the costs incurred (including resources consumed and labor hours expended) related to the manufacturing services. During the years ended </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, 2022 and 2021, the Company recognized revenue of $1.9 million, $0.7 million and $1.5 million, respectively, for services performed under this agreement. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:42pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Incyte Commercial Supply Agreement</span></div><div style="text-indent:42pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, the Company entered into an agreement with Incyte pursuant to which the Company is entitled to manufacture a portion of the global commercial supply needs for retifanlimab (Incyte Commercial Supply Agreement). Unless terminated earlier, the term of the Incyte Commercial Supply Agreement will expire upon the expiration of Incyte&#8217;s obligation to pay royalties under the Incyte License Agreement.  The Company evaluated this agreement under ASC 606 and identified one performance obligation under the agreement: to perform services related to manufacturing the commercial supply of retifanlimab. The transaction price is based on a fixed price per batch of bulk drug substance to be manufactured and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. The transaction price is being recognized using the input method reflecting the costs incurred (including resources consumed and labor costs incurred) related to the manufacturing services. During the years ended </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2023, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022, and 2021 the Company recognized revenue of $4.2 million, $0.3&#160;million and $7.8&#160;million, respectively, for services performed under this agreement. </span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%">Gilead Sciences, Inc </span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022, the Company and Gilead Sciences, Inc. (Gilead) entered into an exclusive option and collaboration agreement (Gilead Agreement) to develop and commercialize MGD024, an investigational, bispecific antibody that binds CD123 and CD3, and create bispecific cancer antibodies using the Company&#8217;s DART platform and undertake their early development under a maximum of two separate bispecific cancer target research programs. Under the agreement, the Company will continue the ongoing phase 1 trial for MGD024 accordi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ng to a development plan</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, during which Gilead will have the right to exercise an option granted to Gilead to obtain an exclusive license under the Company&#8217;s intellectual property to develop and commercialize MGD024 and other bispecific antibodies of MacroGenics that bind CD123 and CD3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (CD123 Option). The agreement also grants Gilead the right, within its first two years, to nominate a bispecific cancer target set for up to two research programs conducted by the Company and to exercise separate options to obtain an exclusive license for the development, commercialization and exploitation of molecules created under each research program (Research Program Option). Gilead nominated the first of the two research programs in September 2023.  </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Gilead Agreement, in October 2022 Gilead paid the Company an upfront payment of $60.0&#160;million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assuming Gilead exercises the CD123 Option and Research Program Option and successfully develops and commercializes MGD024, or other CD123 products developed under the agreement, and products result from the two additional research programs, the Company would be eligible to receive up to $1.7 billion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in target nomination, option fees, and development, regulatory and commercial milestones. Assuming exercise of the CD123 Option, the Company will also be eligible to receive tiered, low double-digit royalties on worldwide net sales of MGD024 (or other CD123 products developed under the agreement) and assuming exercise of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research Program Option,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> a flat royalty on worldwide net sales of any products resulting from the two research programs.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the Gilead Agreement under the provisions of ASC 606 and identified the following material promises under the agreement: (i) a license to perform any activities allocated to Gilead under the MGD024 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">development plan</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">; (ii) development activities regarding MGD024, including manufacturing, research and early clinical development activities, necessary to deliver an informational package of development and clinical data, information and materials specified in the Gilead Agreement during the period </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which Gilead can exercise the CD123 Option; (iii) the CD123 Option and (iv) the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research Program Option</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company concluded that the license under the MGD024 developme</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nt plan</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and development activities are not distinct from one another, as the license has limited value without the Company&#8217;s performance of the development activities. Therefore, the Company determined that the development term license and development activities should be combined into a single performance obligation (Development Activities). The CD123 Option is considered a material right as the value of the exclusive license exceeds the payment to be made by Gilead if they exercise their option to obtain an exclusive license to develop and commercialize MGD024 or an alternative CD123 product, and is therefore a distinct performance obligation. The Company determined that the Research Program Option does not provide a material right, as there is no discount on its standalone selling price.</span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC 606, the Company determined that the initial transaction price under the Gilead Agreement was $60.0&#160;million, consisting of the upfront, non-refundable payment paid by Gilead. The CD123 Option and Research Program Option payments are excluded from the initial transaction price at contract inception along with any future development, regulatory, and commercial milestone payments (including royalties) following the CD123 Option and Research Program Option exercise.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company will reassess the amount of variable consideration included in the transaction price every reporting period.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:13.5pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company allocated the $60.0&#160;million upfront payment in the transaction price to the Development Activities and the CD123 Option based on each performance obligation&#8217;s relative standalone selling price. The standalone selling price for the Development Activities was calculated using an expected cost-plus margin approach </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the pre-option development timeline.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the standalone selling price of the CD123 Option, the Company utilized an income-based approach which included the following key assumptions:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">post-option development timeline and costs, forecasted revenues, discount rates and probabilities of technical and regulatory success. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is recognizing revenue related to the Development Activities performance obligation over the estimated period to complete the Development Activities using an input method reflecting the costs incurred (including resources consumed and labor hours expended) related to the Development Activities. The Company has deferred revenue recognition related to the CD123 Option.  If Gilead exercises the CD123 Option and obtains an exclusive license, the Company will recognize revenue as it fulfills its obligations under the Gilead Agreement. If the CD123 Option is not exercised, the Company will recognize the entirety of the revenue in the period when the CD123 Option expires.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and 2022, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company recorded revenue of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1.5&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$0.2&#160;million respectively, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">related to the Gilead Agreement. As of </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$58.3&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in revenue was deferred under this agreement, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$2.2&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of which was current and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$56.1&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of which was non-current.As of December&#160;31, 2022, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$59.8&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in revenue was deferred under this agreement, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1.8&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of which was current and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$58.0&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of which was non-current.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2023, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company and Gilead executed a Letter Agreement through which Gilead nominated the first of the two research programs contemplated in the Gilead Agreement (First Research Program), the Company granted Gilead a research license, and the parties agreed on a research plan for the First Research Program under which the Company will provide research and development services. Gilead paid the Company a $15.7&#160;million nomination fee.  The Company evaluated the Letter Agreement under the terms of ASC 606, and concluded that it is a modification to the Gilead Agreement that results in a separate contract since the modification is for additional goods and services that are distinct and at standalone selling price. The Company determined that the license and the related research and development activities were not distinct from one another, as the license has limited value without the performance of the research and development activities. As such, the Company determined that these should be combined into a single performance obligation. Gilead also has the </span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">exclusive option to pay the Company $10.0&#160;million to obtain a license to exploit the research molecule and research product with respect to the First Research Program. The Company determined that this exclusive option does not provide a material right, as there is no discount on its standalone selling price.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC 606, the Company determined that the initial transaction price for the First Research Program agreement was $15.7&#160;million, consisting of the non-refundable payment paid by Gilead. The Company is recognizing revenue over the estimated period to complete the services using the input method reflecting the costs incurred (including resources consumed and labor hours expended) related to the research and development services.  </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company recorded revenue of $0.8&#160;million </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">related to the First Research Program.  As of December&#160;31, 2023, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$14.9&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in revenue was deferred under this agreement, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$11.8&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of which was current and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$3.1&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of which was non-current. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Zai Lab US LLC</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, the Company entered into a collaboration and license agreement with Zai Lab US LLC (Zai Lab Limited and Zai Lab US LLC, either singularly or collectively are referred to herein as Zai Lab) involving collaboration programs and license-only programs (collectively, the Programs) encompassing four separate immuno-oncology molecules (2021 Zai Lab Agreement). During 2022, the Company and Zai Lab agreed to discontinue research and development of the lead program, and in August 2023, the parties mutually agreed to terminate the 2021 Zai Lab Agreement. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the execution of the 2021 Zai Lab Agreement, Zai Lab paid the Company an upfront payment of $25.0&#160;million. Additionally, as part of the consideration for the rights granted to Zai Lab under the 2021 Zai Lab Agreement, the Company and Zai Lab entered into a stock purchase agreement whereby Zai Lab paid the Company approximately $30.0 million to purchase shares of the Company&#8217;s common stock, par value $0.01, at a fixed price of $31.30 which represented a $10.4 million premium over the share price on the stock purchase agreement date. The Company was also entitled to receive reimbursements from Zai Lab for certain research and development costs incurred by the Company and milestones and tiered royalties on annual net sales of products in Zai Lab&#8217;s territory assuming successful development and commercialization of the Programs.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the 2021 Zai Lab Agreement under the provisions of ASC 606 and identified the following material promises: (i) exclusive licenses to develop, manufacture and commercialize the products in Zai Lab&#8217;s territory for each Program and (ii) certain research and development activities for the lead program. The Company determined that for the lead program, the license was not distinct from the related research and development activities, considering the early stage of development of the molecule and the Company&#8217;s significant expertise in this area and as such, the research and development services were expected to significantly modify and customize the license. Therefore, for the lead program, the license and the services were combined into a single performance obligation. Since the other programs each represented distinct intellectual property and there were no other services included in the 2021 Zai Lab Agreement related to these licenses, each license was considered to be a distinct performance obligation. As such, there were four performance obligations included in the 2021 Zai Lab Agreement.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company concluded that the estimated transaction price was $40.4 million, consisting of the $25.0 million upfront payment, the $10.4 million premium related to the purchase of the Company&#8217;s common stock, and the $5.0 million estimated reimbursement by Zai Lab for research and development activities for the lead program. The potential milestone payments were deemed to be fully constrained until the Company concludes that achievement of the milestone is probable, and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such were excluded from the transaction price. Any consideration related to royalties would have been recognized if and when the related sales occurred, as they were determined to relate predominantly to the license granted to Zai Lab and, therefore, were also excluded from the transaction price. The Company re-assessed the transaction price in each reporting period and when events whose outcomes were resolved or other changes in circumstances occurred.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transaction price of $40.4 million was then allocated to the four performance obligations based on their relative standalone selling price. The standalone selling price of the performance obligations was not directly observable; therefore, the Company estimated the standalone selling price using an adjusted market assessment approach, representing the amount that the Company believed a market participant was willing to pay for the product or service. The estimate was based on consideration of observable inputs, such as, values of other preclinical collaboration arrangements adjusted for the Company&#8217;s estimate of the probability of success for each Program. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue related to the lead program license and related research and development services performance obligation was recognized over time as the research and development activities were performed. The Company utilized a cost-based input method according to costs incurred to date compared to estimated total costs. The transfer of control occurred over this time </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">period and, in management&#8217;s judgment, was the best measure of progress towards satisfying the performance obligations. The Company recognized revenue allocated to the other programs at a point in time upon transfer of the licenses to Zai Lab in June 2021. During the year ended </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2023, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">no</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">revenue was recognized under the 2021 Zai Lab Agreement. During the years ended December&#160;31, 2022,</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and 2021, the Company recognized revenue of $16.8 million and $20.3 million</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">respectively, under the 2021 Zai Lab Agreement. </span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provention Bio, Inc.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, the Company entered into a license agreement with Provention pursuant to which the Company granted Provention exclusive global rights for the purpose of developing and commercializing MGD010 (renamed PRV-3279), a CD32B x CD79B DART molecule being developed for the treatment of autoimmune indications (Provention License Agreement). As partial consideration for the Provention License Agreement, Provention granted the Company a warrant to purchase shares of Provention&#8217;s common stock at an exercise price of $2.50 per share. If Provention successfully develops, obtains regulatory approval for, and commercializes PRV-3279, the Company will be eligible to receive up to $65.0 million in development and regulatory milestones and up to $225.0 million in commercial milestones. As of December&#160;31, 2023, the Company has not recognized any milestone revenue under this agreement. If commercialized, the Company would be eligible to receive single-digit royalties on net sales of the product. The license agreement may be terminated by either party upon a material breach or bankruptcy of the other party, by Provention without cause upon prior notice to the Company, and by the Company in the event that Provention challenges the validity of any licensed patent under the agreement, but only with respect to the challenged patent.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, in 2018, the Company entered into the Provention APA pursuant to which Provention acquired the Company&#8217;s interest in teplizumab (renamed PRV-031), a monoclonal antibody being developed for the treatment of type 1 diabetes. As partial consideration for the Provention APA, Provention granted the Company a warrant to purchase shares of Provention&#8217;s common stock at an exercise price of $2.50 per share. Under the Provention APA, Provention is obligated to pay the Company contingent milestone payments totaling $170.0 million upon the achievement of certain regulatory milestones.  In addition, Provention is obligated to make contingent milestone payments to the Company totaling $225.0 million upon the achievement of certain commercial milestones as well as single-digit royalties on net sales of the product. In March 2023, the Company entered into a Royalty Purchase Agreement with DRI; see Note 7, Royalty Monetization Arrangement, for additional information. The FDA approved the BLA for TZIELD in November 2022, and the Company recognized $60.0 million in revenue related to this regulatory milestone during the year ended December 31, 2022.  In November 2022, the Company and Provention amended the Provention APA. Under this amendment, the milestone for first approval was split into four equal payments, all of which were received prior to June 30, 2023.  Provention has also agreed to pay third-party obligations, including low single-digit royalties, of which a portion is creditable against royalties payable to the Company, aggregate milestone payments of up to approximately $1.3 million and other consideration, for certain third-party intellectual property under agreements Provention assumed pursuant to the Provention APA. Further, Provention is required to pay the Company a low double-digit percentage of certain consideration to the extent it is received in connection with a future grant of rights to PRV-031 by Provention to a third party.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the Provention License Agreement and Provention APA under the provisions of ASC 606 and determined that they should be accounted for as a single contract and identified two performance obligations within that contract: (i) the license of MGD010 and (ii) the title to teplizumab. The Company determined that the transaction price of the Provention agreements was $6.1 million, based on the Black-Scholes valuation of the warrants to purchase a total of 2,432,688 shares of Provention's common stock. The transaction price was allocated to each performance obligation based on the number of shares of common stock the Company is entitled to purchase under each warrant. The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such were excluded from the initial transaction price. Any consideration related to sales-based milestones and royalties will be recognized when the related sales occur, therefore they have also been excluded from the transaction price. The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur. The Company recognized revenue of $6.1 million when it satisfied its performance obligations under the agreements and transferred the MGD010 license and teplizumab assets to Provention in 2018. In 2019, the Company exercised the warrants on a cashless basis, and subsequently sold all the shares of Provention common stock acquired through the exercise. No shares of Provention stock were held subsequent to the sale of stock in 2019. During the year ended December 31, 2022, </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">it became probable that a significant reversal of cumulative revenue would not occur for a regulatory milestone of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$60.0 million</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, t</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">herefore</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the associated consideration was added to the estimated transaction price and was recognized as revenue. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2023, </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022 and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021, the Company recognized revenue of $5.6 million, $60.0 million and $1.3 million, respectively, under these agreements.   </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 27, 2023, Sanofi completed its acquisition of Provention and the Company entered into a Tripartite Agreement, as discussed in Note 7, Royalty Monetization Arrangement. Also on April 27, 2023, the Company and a subsidiary of Sanofi entered into a Side Letter Agreement which specified certain post-closing covenants and also accelerated certain payments due to the Company under the Provention APA upon the closing of the merger between Sanofi and Provention. The Company evaluated the Side Letter Agreement as a contract modification under the provisions of ASC 606. As a result, </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">during the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">year ended December 31, 2023</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company recognized $5.5&#160;million related to other consideration under the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provention APA</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Side Letter Agreement. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2023, the Company recognized $0.3&#160;million in royalty revenue under the Provention APA based on sales of TZIELD. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 7, in September 2023, the Company and Sanofi executed Amendment No. 2 to the Provention APA and terminated the Royalty Purchase Agreement with DRI.  As a result, the remaining $50.0&#160;million milestone under the Royalty Purchase Agreement was incorporated into the Provention APA.  The Company evaluated the amendment as a contract modification under the provisions of ASC 606 which did not result in any additional revenue being recognized during the year ended December&#160;31, 2023. </span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing Services Agreements</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Incyte </span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, the Company entered into a Manufacturing and Clinical Supply Agreement with Incyte (Incyte Manufacturing and Clinical Supply Agreement) to provide manufacturing services to produce certain Incyte bulk drug substance over a three-year period at one of the Company&#8217;s manufacturing facilities. Under the terms of the Incyte Manufacturing and Clinical Supply Agreement, the Company received an upfront payment of $10.0&#160;million and is eligible to receive annual fixed payments paid quarterly over the term of the contract totaling $14.4&#160;million. The Company will also be reimbursed for materials used to manufacture product as well as other costs incurred to provide manufacturing services. In July 2022, the Company and Incyte executed an amendment to the Incyte Manufacturing and Clinical Supply Agreement which extended the term for one year and provided for an additional annual fixed payment of $5.1&#160;million (July 2022 Incyte Amendment). </span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the Incyte Manufacturing and Clinical Supply Agreement and the July 2022 Incyte Amendment under the provisions of ASC 606 and identified one performance obligation to provide manufacturing runs to Incyte, as and when requested by Incyte, over the term of the contract that is part of a series of goods and services. The Company determined that the transaction price consists of the upfront payment received of $10.0&#160;million and the annual fixed payments totaling $19.5&#160;million. The Company will recognize revenue over time on a straight-line basis as the manufacturing services are provided to Incyte, as the Company determined that its efforts in providing the manufacturing services will be incurred evenly throughout the performance period and therefore straight-line revenue recognition closely approximates the level of effort for the manufacturing services. Variable consideration relating to the reimbursed materials and other reimbursed costs incurred to manufacture product for Incyte will be allocated to the related manufacturing activities and will be recognized as revenue as those activities occur.  Materials purchased by the Company to manufacture the product for Incyte are considered costs to fulfill a contract and will be capitalized and expensed as the materials are used to provide the manufacturing services. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2023 and 2022, the Company recognized revenue of $9.7&#160;million and $8.7&#160;million, respectively, under the Incyte Manufacturing and Clinical Supply Agreement. As of </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2023, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$7.0&#160;million</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in revenue was deferred under this agreement, all of which was current. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, $9.6&#160;million in revenue was deferred under this agreement, $8.1&#160;million of which was current and $1.5&#160;million of which was non-current.  </span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provention</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, the Company entered into a Manufacturing and Clinical Supply Agreement with Provention (Provention Manufacturing and Clinical Supply Agreement) to provide manufacturing services to produce certain Provention bulk drug substance. Under the terms of the Provention Manufacturing and Clinical Supply Agreement, the Company received an upfront payment and payments in accordance with the manufacturing schedule.  The Company was also reimbursed for materials used to manufacture product as well as other costs incurred to provide manufacturing services.</span></div><div style="margin-bottom:6pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the Provention Manufacturing and Clinical Supply Agreement under the provisions of ASC 606 and identified one performance obligation to provide manufacturing services to Provention. The Company determined that the transaction price consisted of the upfront and other fixed payments totaling $4.6&#160;million. The Company will recognize revenue over time on a straight-line basis as the manufacturing services are provided to Provention, as the Company determined that its efforts in providing the manufacturing services will be incurred evenly throughout the performance period and therefore straight-line revenue recognition closely approximates the level of effort for the manufacturing services. Variable consideration relating to the reimbursed materials and other reimbursed costs incurred to manufacture product for Provention will be allocated </span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to the related manufacturing activities and will be recognized as revenue as those activities occur.  Materials purchased by the Company to manufacture the product for Provention are considered costs to fulfill a contract and will be capitalized and expensed as the materials are used to provide the manufacturing services. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized de minimis revenue during the year ended December&#160;31, 2023 under the Provention Manufacturing and Clinical Supply Agreement. During the year ended 2022, the Company recognized revenue of $5.3&#160;million under the Provention Manufacturing and Clinical Supply Agreement.</span></div><div style="margin-bottom:6pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Agreement</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NIAID Contract</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company entered into a contract with the National Institute of Allergy and Infectious Diseases (NIAID), effective as of September 15, 2015,&#160;to perform product development and to advance up to two DART molecules, MGD014 and MGD020 (NIAID Contract). Under the NIAID Contract, the Company will develop these product candidates for Phase 1/2 clinical trials as therapeutic agents, in combination with latency reversing treatments, to deplete cells infected with human immunodeficiency virus (HIV) infection. NIAID does not receive goods or services from the Company under this contract, therefore the Company does not consider NIAID to be a customer and concluded this contract is outside the scope of ASC 606.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since the inception of the NIAID Contract, NIAID has exercised the two options contemplated in the original contract and executed modifications such that the total funded contract value as of December&#160;31, 2023 is $25.1 million. In addition, the most recent modification changed the period of performance under the NIAID Contract to end in July 2023.  The Company recognized revenue of $1.6 million, $1.9 million and $1.8 million under the NIAID contract during the years ended December&#160;31, 2023, 2022 and 2021, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborationAndLicenseAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborationAndLicenseAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaboration and license agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139842284989664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-based Compensation</a></td>
<td class="text">Stock-based Compensation<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2017, the Company&#8217;s stockholders approved the 2016 Employee Stock Purchase Plan (the 2016 ESPP). The 2016 ESPP is structured as a qualified employee stock purchase plan under Section 423 of the Internal Revenue Code of 1986, as amended, and is not subject to the provisions of the Employee Retirement Income Security Act of 1974. The Company reserved 800,000 shares of common stock for issuance under the 2016 ESPP. The 2016 ESPP allows eligible employees to purchase shares of the Company&#8217;s common stock at a discount through payroll deductions of up to 10% of their eligible compensation, subject to any plan limitations. The 2016 ESPP provides for six-month offering periods ending on May 31 and November 30 of each year. At the end of each offering period, employees are able to purchase shares at 85% of the fair market value of the Company&#8217;s common stock on the last day of the offering period. During the year ended December&#160;31, 2023, employees purchased 81,541 shares of common stock under the 2016 ESPP for net proceeds to the Company of approximately $0.5&#160;million.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Incentive Plans</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2013, the Company implemented the 2013 Equity Incentive Plan (2013 Plan).&#160;The 2013 Plan provides for the grant of stock options and other stock-based awards, as well as cash-based performance awards. In May 2023, the 2013 Plan was terminated, and no further awards may be issued under the plan. If an option granted under the 2013 Plan expires or terminates for any reason without having been fully exercised, if any shares of restricted stock are forfeited, or if any award terminates, expires or is settled without all or a portion of the shares of common stock covered by the award being issued, such shares will become available for issuance under the 2023 Equity Incentive Plan (2023 Plan). As of December&#160;31, 2023, under the 2013 Plan, there were options to purchase an aggregate of 11,805,515 shares of common stock outstanding at a weighted average exercise price of $15.45 per share. As of December&#160;31, 2023, there were 854,114 unvested restricted stock units (RSUs) outstanding under the 2013 Plan.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2023 Plan was effective as of stockholder approval in May 2023. The 2023 Plan provides for grants of stock options and other stock-based awards, as well as cash-based performance awards. Initially, the maximum number of shares of the Company&#8217;s common stock that may be issued under the 2023 Plan will not exceed 4,850,000 shares. If an option expires or terminates for any reason without having been fully exercised, if any shares of restricted stock are forfeited, or if any award terminates, expires or is settled without all or a portion of the shares of common stock covered by the award being issued, such shares are available for the grant of additional awards. However, any shares that are withheld (or delivered) to pay withholding taxes or to pay the exercise price of an option are not available for the grant of additional awards. As of December&#160;31, 2023, under the 2023 Plan, there were options to purchase an aggregate of 418,122 shares of common stock outstanding at a weighted </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">average exercise price of $5.31 per share. As of December&#160;31, 2023, there were 51,500 unvested RSUs outstanding under the 2023 Plan.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following stock-based compensation amounts were recognized for the periods indicated (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,190&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,094&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,337&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,183&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,344&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,789&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,373&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,438&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,126&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Options</span></div><div style="text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for stock-based compensation to employees and non-employee directors in accordance with ASC Topic 718, </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation &#8211; Stock Compensation</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company estimates the fair value of stock option awards using the Black-Scholes option pricing model on the date of grant using the assumptions in the table below. Stock options granted to employees generally vest over four years and have a term of ten years. Stock-based compensation expense for stock options is recognized as expense over the requisite service period, which is the vesting period. As the Company has not paid dividends since inception, nor does it expect to pay any dividends for the foreseeable future, the expected dividend yield assumption is zero. The expected volatility is based on the historical stock volatility of the Company&#8217;s own common stock over a period equal to the expected term of the options. The risk-free rate of the stock options is based on the U.S. Treasury rate in effect at the time of grant for the expected term of the stock options. The Company used the simplified method to calculate expected term during 2021.  Beginning in 2022, the computation of expected term was determined based on the historical experience with similar awards, giving consideration to the contractual terms of the share-based awards, vesting schedules and expectations of future employee behavior.  In addition, the Company  estimates the expected forfeiture rate and only recognizes expense for those shares expected to vest. The Company estimates the forfeiture rate based on historical experience and its expectations regarding future pre-vesting termination behavior of employees. The Company reviews its estimate of the expected forfeiture rate annually, and stock-based compensation expense is adjusted accordingly.</span></div><div style="text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:56.211%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76% -96%</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88% - 92%</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86% - 87%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5% - 4.8%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4% - 4.0%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6% - 1.6%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.88 years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.95 years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.25 years</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity for 2023:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercise Price</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contractual Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Years)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,098,929&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.58&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,367,777&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34,608)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(365,942)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(842,519)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,223,637&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,974&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of December&#160;31, 2023:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,892,753&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,509&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,346,207&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,692&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2023, 2022 and 2021 the Company issued 34,608, 120,900 and 332,767 shares of common stock, respectively, in conjunction with stock option exercises.&#160;The Company received cash proceeds from the exercise of stock options of approximately $0.1 million, $0.2 million and $5.8 million during 2023, 2022 and 2021, respectively.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant-date fair value of options granted during 2023, 2022 and 2021 was $3.83, $6.84 and $15.20 per share, respectively. The total intrinsic value of options exercised during 2023, 2022 and 2021 was approximately $0.1&#160;million, $0.6 million and $3.3 million, respectively.&#160;The total fair value of stock options which vested during 2023, 2022 and 2021 was $16.4 million, $19.6 million and $20.2 million, respectively.&#160;As of December&#160;31, 2023, the total unrecognized compensation expense related to non-vested stock options, net of related forfeiture estimates, was $19.5 million, which the Company expects to recognize over a weighted-average period of approximately 1.2 years.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company awards RSUs to employees. RSUs are valued based on the closing price of the Company&#8217;s common stock on the date of the grant. The fair value of RSUs is recognized and amortized on a straight-line basis over the requisite service period of the award</span><span style="color:#252525;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes RSU activity for 2023:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.163%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.268%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.954%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Grant Date Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">415,084&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.83&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">707,635&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.88&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(135,396)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(81,709)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.17&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">905,614&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2023, there was $2.3 million of total unrecognized compensation cost related to unvested RSUs, which the Company expects to recognize over a remaining weighted-average period of 1.2 years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139842285366368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes <div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2023, 2022 and 2021 there was no provision for income taxes due to taxable losses generated, fully offset by a valuation allowance.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The significant components of the Company's deferred income tax assets (liabilities) were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal U.S. net operating loss carryforward</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140,706&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163,071&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State net operating loss carryforward</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,350&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,784&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development credit, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,251&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,084&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Orphan drug credit, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,330&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,703&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,078&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,585&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,442&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 174 deferred tax asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,421&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,192&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity based compensation</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,217&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,228&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,617&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,663&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred income tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373,412&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381,310&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(365,010)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(372,267)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred income tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,402&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,043&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:13pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease ROU assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,372)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,522)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenditures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,030)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,521)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred income tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,402)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,043)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred income tax asset/(liability)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes valuation allowances to reduce deferred tax assets to the amount that is more likely than not to be realized. In assessing the likelihood of realization, management considers (i) future reversals of existing taxable temporary differences; (ii) future taxable income exclusive of reversing temporary difference and carryforwards; (iii) taxable income in prior carryback years if carryback is permitted under applicable tax law; and (iv) tax planning strategies. The Company's net deferred income tax asset is not more likely than not to be utilized due to the lack of sufficient sources of future taxable income and cumulative book losses which have resulted over the years.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The activity in the valuation allowance on deferred tax assets was as follows (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.970%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.859%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.859%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.859%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.861%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at Beginning of Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deductions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at End of Year</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ended December 31, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372,267&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,257)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365,010&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ended December 31, 2022</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">327,592&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,675&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372,267&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ended December 31, 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,192&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">327,592&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the Company has U.S. federal and state net operating loss (NOL) carryforwards of approximately $670.0 million. Of these NOLs, $65.5 million will expire in various years beginning in 2035 through 2037. $604.5 million of NOLs were generated post December 31, 2017 and carryforward indefinitely. In addition, the Company has U.S. federal tax credits of $94.4 million which will expire in various years beginning in 2024 through 2043.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of the reported estimated income tax benefit to the amount that would result by applying the U.S. federal statutory tax rate to the net income is as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States federal tax at statutory rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,902)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,149)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42,445)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes (net of federal benefit)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(163)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,385)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,806)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,024&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">473&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred state blended rate adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,841&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research credit, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,168)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,569)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,243)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Orphan drug credit, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,374&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,846)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,449)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other permanent items</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,301&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,362&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,199&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,950&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,604&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,079&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,257)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,675&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,192&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense/(benefit)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,376&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,197&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,126&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases for current year tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">449&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">965&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases/(decreases) for prior year tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(369)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,821&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,376&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,197&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023 and 2022, of the total gross unrecognized tax benefits, approximately $7.8 million and $7.4 million would favorably impact the Company's effective income tax rate, respectively. Although, due to the Company's determination that the deferred income tax asset would not more likely than not be realized, a valuation allowance would be recorded, therefore, zero net impact would result within the Company's effective income tax rate. The Company's uncertain income tax position liability has been recorded to deferred income taxes to offset the tax attribute carryforward amounts.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2023, 2022 and 2021, the Company has not recognized any interest or penalties related to the uncertain income tax positions due to the fact such position is related to tax attribute carryforwards which have not yet been utilized. The Company does not expect its unrecognized income tax position to significantly decrease within the next twelve months.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's U.S. Federal and state income tax returns from 2004 </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">forward remain open to examination due to the carryover of unused income tax credits, and from 2004 forward due to the carryover of unused net operating losses.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Internal Revenue Code (IRC) Section 174</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For tax years beginning on or after January 1, 2022, the Tax Cuts and Jobs Act of 2017 eliminates the option to currently deduct research and development expenses and requires taxpayers to capitalize and amortize them over five years for research activities performed in the United States and 15 years for research activities performed outside the United States pursuant to IRC Section 174. Although Congress is considering legislation that would repeal or defer this capitalization and amortization requirement, it is not certain that this provision will be repealed or otherwise modified. If the requirement is not repealed or replaced, it could increase our U.S. federal and state cash taxes and reduce cash flows in future years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139842287232192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Employee Benefit Plan</a></td>
<td class="text">Employee Benefit Plan<div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2002, the Company established the MacroGenics 401(k) Plan (the Plan) for its employees under Section 401(k) of the IRC. Under this Plan, all employees at least 21 years of age are eligible to participate in the Plan, starting on the first day of employment. Employees may contribute up to 100% of their salary, subject to government maximums.</span></div>Employees are 100% vested in their contributions to the Plan. The Company's contribution to the Plan, as determined by the Board of Directors, is discretionary. For the years ended December&#160;31, 2023, 2022 and 2021, the Company's contributions to the Plan totaled $2.1 million, $2.3 million and $1.6 million, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480794/715-70-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//715/tableOfContent<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480126/715-20-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480266/715-60-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139842282179104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (9,058)<span></span>
</td>
<td class="num">$ (119,758)<span></span>
</td>
<td class="num">$ (202,115)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139842283335008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=mgnx_JamesKarrelsMember', window );">James Karrels [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MtrlTermsOfTrdArrTextBlock', window );">Material Terms of Trading Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">James Karrels, Senior Vice President and Chief Financial Officer, adopted a new trading plan on December 8, 2023 (with the first trade possible under the new plan no sooner than April 16, 2024).  The trading plan will be effective until April 15, 2025 and covers the potential sale of up to 490,000 shares of common stock. (1)</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">James Karrels<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Senior Vice President and Chief Financial Officer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">494 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">490,000<span></span>
</td>
<td class="nump">490,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=mgnx_JeffreyPetersMember', window );">Jeffrey Peters [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MtrlTermsOfTrdArrTextBlock', window );">Material Terms of Trading Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jeffrey Peters, Senior Vice President and General Counsel, adopted a new trading plan on December 8, 2023 (with the first trade possible under the new plan no sooner than April 4, 2024).  The trading plan will be effective until March 20, 2025 and covers the potential sale of up to 370,842 shares of common stock.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Jeffrey Peters<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Senior Vice President and General Counsel<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">468 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">370,842<span></span>
</td>
<td class="nump">370,842<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_MtrlTermsOfTrdArrTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_MtrlTermsOfTrdArrTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrDuration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrDuration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrSecuritiesAggAvailAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrSecuritiesAggAvailAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=mgnx_JamesKarrelsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=mgnx_JamesKarrelsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=mgnx_JeffreyPetersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=mgnx_JeffreyPetersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139842282297648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation and Principles of Consolidation</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Principles of Consolidation</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, MacroGenics UK Limited and MacroGenics Limited.&#160;All intercompany accounts and transactions have been eliminated in consolidation. The Company currently operates in one operating segment. Operating segments are defined as components of an enterprise about which separate discrete information is available for the chief operating decision maker, or decision making group, in deciding how to allocate resources and assessing performance. The Company views its operations and manages its business in one segment, which is developing and commercializing monoclonal antibody-based therapeutics.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the financial statements in accordance with generally accepted accounting principles (GAAP) requires the Company to make estimates and judgments in certain circumstances that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. In preparing these consolidated financial statements, management has made its best estimates and judgments of certain amounts included in the financial statements, giving due consideration to materiality. On an ongoing basis, the Company evaluates its estimates, including those related to revenue recognition, fair values of assets, inventory, preclinical study and clinical trial accruals and other contingencies. Management bases its estimates on historical experience or on various other assumptions that it believes to be reasonable under the circumstances. Although actual results could differ from these estimates, management does not believe that such differences would be material.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash, Cash Equivalents and Marketable Securities</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents and Marketable Securities</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all investments in highly liquid financial instruments with a maturity of 90 days or less at the date of purchase to be cash equivalents. Cash and cash equivalents includes investments in money market funds with commercial banks and financial institutions, securities issued by the U.S. government and its agencies, Government Sponsored Enterprise agency debt obligations and corporate debt obligations. Cash equivalents are stated at amortized cost, plus accrued interest, which approximates fair value.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company carries marketable securities classified as available-for-sale at fair value as determined by prices for identical or similar securities at the balance sheet date. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Classification of marketable securities between current and non-current is dependent upon the maturity date at the balance sheet date taking into consideration the Company&#8217;s ability and intent to hold the investment to maturity. </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities consist of Level 2 financial instruments in the fair-value hierarchy. The Company records unrealized gains and losses as a component of other comprehensive loss within the statements of operations and comprehensive loss and as a separate component of stockholders' equity. Realized gains or losses on available-for-sale securities are determined using the specific identification method and the Company includes net realized gains and losses in other income, along with interest income and amortization of premiums and discounts.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable arise from product sales, amounts due from the Company&#8217;s collaborative partners and contract manufacturing work performed by the Company.  The amount from product sales represents amounts due from specialty distributors. Accounts receivable that management has the intent and ability to collect are reported in the consolidated balance sheets at outstanding amounts, less an allowance for doubtful accounts. The Company writes off uncollectible receivables when the likelihood of collection is remote.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates the collectability of accounts receivable on a regular basis. The allowance, if any, is based upon various factors including the financial condition and payment history of customers, an overall review of collections experience on other accounts and economic factors or events expected to affect future collections experience. No allowance was recorded as of December&#160;31, 2023 or 2022, as the Company has a history of collecting on all outstanding accounts.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's financial instruments consist of cash and cash equivalents, marketable securities, accounts receivable, accounts payable and accrued expenses.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of accounts receivable, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of their short-term nature.&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for recurring and non-recurring fair value measurements in accordance with the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements and Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 820). ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements. The ASC 820 hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 &#8211; Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 &#8211; Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data.</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 &#8211; Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity &#8211; e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC 820 hierarchy.  </span>There were no transfers between levels during the periods presented.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents, marketable securities and accounts receivable. </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains its cash and money market funds with financial institutions that are federally insured. While balances deposited in these institutions often exceed Federal Deposit Insurance Corporation limits, the Company has not experienced any losses on related accounts to date.&#160;The Company's investment policy limits investments to certain types of debt securities issued by the U.S. government, its agencies and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The counterparties are various corporations, financial institutions and government agencies of high credit standing.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When the Company believes regulatory approval is probable and expects future economic benefit from the sales of a product candidate to be realized, the Company capitalizes manufacturing costs (whether internally produced or through third-party contract manufacturing organizations) as inventory.  Prior to receiving its first approval from the FDA in December 2020, the Company expensed all costs incurred related to the manufacture of MARGENZA as research and development expense because of the inherent risks associated with the development of a product candidate, the uncertainty about the regulatory approval process and the lack of history for the Company of regulatory approval of drug candidates.  Subsequent to FDA approval in December 2020, the Company began capitalizing its MARGENZA third-party contract manufacturing inventory costs.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory is composed of raw materials, work-in-process, and finished goods, which are goods that are available for sale. The Company values its inventories at the lower of cost or estimated net realizable value. The Company determines the cost of its inventories, which includes amounts related to materials and third-party contract manufacturing costs, on a first-in, first-out basis. The Company performs an assessment of the recoverability of capitalized inventory during each reporting period, and it writes down any excess, obsolete or unsaleable inventories to their estimated realizable value in the period in which the impairment is first identified. Such write downs, should they occur, are recorded within the cost of product sales in the statement of operations.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Equipment and Software</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property, Equipment and Software</span></div>Property, equipment and software are stated at cost. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation or amortization are removed from the accounts and any resulting gain or loss is credited or charged to operations. Repairs and maintenance costs are expensed as incurred.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses the recoverability of its long-lived assets in accordance with the provisions of ASC 360, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property, Plant and Equipment </span>(ASC 360). ASC 360 requires that long-lived assets be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of the long-lived asset is measured by a comparison of the carrying amount of the asset to future undiscounted net cash flows expected to be generated by the asset or asset group. If carrying value exceeds the sum of undiscounted cash flows, the Company then determines the fair value of the underlying asset group. Any impairment to be recognized is measured by the amount by which the carrying amount of the asset group exceeds the estimated fair value of the asset group. Assets to be disposed of are reported at the lower of the carrying amount or fair value, less costs to sell.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_LiabilityRelatedToFutureRoyaltiesAndRelatedInterestExpensePolicyTextBlock', window );">Liability related to the sale of future royalties and related interest expense</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liability related to the sale of future royalties and related interest expense</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses the relevant accounting criteria under ASC 470, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 470) to determine whether the upfront payment received from the purchaser should be accounted for as debt or deferred income depending on the facts and circumstances.  If the criteria in ASC 470 is met, the Company accounts for net proceeds from sales of its rights to receive future royalty payments as a liability that is amortized using the effective interest method over the term of the arrangement. The liability related to future royalties is presented net of unamortized issuance costs on the consolidated balance sheets. Interest expense on the liability related to future royalties is recognized using the effective interest rate method over the life of the arrangement. The Company calculates an effective interest rate which will amortize its related obligation to zero over the anticipated repayment period. The liability related to future royalties and the related interest expense are based on the Company&#8217;s current estimates of future royalties expected to be received over the life of the arrangement, which the Company determines by using internal sales projections and external information from market data sources, which are considered Level 3 inputs. The Company periodically assesses the expected payments and to the extent the Company&#8217;s estimates of future royalty payments are greater or less than previous estimates or the estimated timing of such payments is materially different than previous estimates, the Company will adjust the effective interest rate and recognize related non-cash interest expense on a prospective basis. Non-cash amortization is reflected as interest expense in the consolidated statements of operations and comprehensive loss.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Upon changes in facts and circumstances, for example as a result of a modification to the existing agreements, the Company re-evaluates its rights and obligations and accounts for the change in accordance with the respective accounting guidance.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue recognition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue under ASC Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s (ASC 606) when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Collaborative and other agreements</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into licensing agreements that are within the scope of ASC 606, under which it may license rights to research, develop, manufacture and commercialize its product candidates to third parties. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, upfront license fees; reimbursement of certain costs; customer option exercise fees; development, regulatory and commercial milestone payments;&#160;and royalties on net sales of licensed products. The Company may also enter into development and manufacturing service agreements with its collaborators.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each arrangement that results in revenues, the Company identifies all performance obligations, which may include a license to intellectual property and know-how, research and development activities, transition activities and/or manufacturing services. In order to determine the transaction price, in addition to any upfront payment, the Company estimates the amount of variable consideration at the outset of the contract either utilizing the expected value or most likely amount method, depending on the facts and circumstances relative to the contract. The Company constrains (reduces) the estimates of variable consideration such that it is probable that a significant reversal of previously recognized revenue will not occur. When determining if variable consideration should be constrained, management considers whether there are factors outside the Company&#8217;s control that could result in a significant reversal of revenue. In making these assessments, the Company considers the likelihood and magnitude of a potential reversal of revenue. These estimates are re-assessed each reporting period as required. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once the estimated transaction price is established, amounts are allocated to the performance obligations that have been identified. The transaction price is generally allocated to each separate performance obligation on a relative standalone selling price basis. The Company must develop assumptions that require judgment to determine the standalone selling price in order to account for these agreements. To determine the standalone selling price, the Company&#8217;s assumptions may include (i)  the probability of obtaining marketing approval for the product candidate, (ii) estimates regarding the timing and the expected costs to develop and commercialize the product candidate, and (iii) estimates of future cash flows from potential product sales with respect to the product candidate. Standalone selling prices used to perform the initial allocation are not updated after contract inception. The Company does not include a financing component to its estimated transaction price at contract inception unless it estimates that certain performance obligations will not be satisfied within one year.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts received prior to revenue recognition are recorded as deferred revenue. Amounts expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as current portion of deferred revenue in the accompanying consolidated balance sheets. Amounts not expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as deferred revenue, net of current portion. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Licenses. </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When the Company grants a license to its intellectual property, it </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">determines whether the </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nature of the intellectual property to which the customer will have rights is functional intellectual property (functional IP), which has significant standalone functionality, or symbolic intellectual property (symbolic IP) which does not have significant standalone functionality.  Revenue from functional IP is recognized at the point in time when control of the distinct license is transferred to the customer. Revenue from symbolic IP is recognized over the access period to the Company&#8217;s intellectual property</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the license to the Company&#8217;s intellectual property is determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and when (or as) the customer is able to use and benefit from the license. In assessing whether a promise or performance obligation is distinct from the other promises, the Company considers factors such as the research, development, manufacturing and commercialization capabilities of the licensee and the availability of the associated expertise in the general marketplace. In addition, the Company considers whether the licensee can benefit from a promise for its intended purpose without the receipt of the remaining promise, whether the value of the promise is dependent on the unsatisfied promise, whether there are other vendors that could provide the remaining promise, and whether it is separately identifiable from the remaining promise. For licenses that are combined with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The measure of progress, and thereby periods over which revenue should be recognized, are subject to estimates by management and may change over the course of the research and development and licensing agreement. Such a change could have a material impact on the amount of revenue the Company records in future periods. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research, Development and/or Manufacturing Services. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The promises under the Company&#8217;s agreements may include research and development or manufacturing services to be performed by the Company on behalf of the counterparty. If these services are determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes the transaction price allocated to these services as revenue over time based on an appropriate measure of progress when the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. If these services are determined not to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes the transaction price allocated to the combined performance obligation as the related performance obligations are satisfied. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Customer Options. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an arrangement contains customer options, the Company evaluates whether the options are material rights because they allow the customer to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">outset of the arrangement. The Company allocates the transaction price to material rights based on the relative standalone selling price, which is determined using assumptions regarding estimated costs, discount rates, post-option development timeline, the probability of technical and regulatory success and the probability  that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until, at the earliest, the option is exercised. If the options are deemed not to be a material right, they are excluded as performance obligations at the outset of the arrangement. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes development milestone payments, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For arrangements that include sales-based royalties which are the result of a customer-vendor relationship and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company analyzes its collaboration arrangements to assess whether such arrangements involve joint operating activities performed by parties who are both active participants in the activities and are both exposed to significant risks and rewards dependent on the commercial success of such activities. Such arrangements generally are within the scope of ASC 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 808). While ASC 808 defines collaborative arrangements and provides guidance on income statement presentation, classification, and disclosures related to such arrangements, it does not address recognition and measurement matters, such as (1)&#160;determining the appropriate unit of accounting or (2) when the recognition criteria are met. Therefore, the accounting for these arrangements is either based on an analogy to other accounting literature or an accounting policy election by the Company. The Company accounts for certain components of the collaboration agreement that are reflective of a vendor-customer relationship (e.g., licensing arrangement) based on ASC 606. The Company accounts for other components based on a reasonable, rational and consistently applied accounting policy election.&#160; Reimbursements from the counter-party that are the result of a collaborative relationship with the counter-party, instead of a customer relationship, such as co-development activities, are recorded as a reduction to research and development expense as the services are performed.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a complete discussion of accounting for revenue from collaborative and other agreements, see Note 9, Revenue.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Product sales, net</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company entered into a limited number of arrangements with specialty distributors in the United States to distribute MARGENZA. These arrangements are considered to be contracts with customers and are in the scope of ASC 606. The Company has written contracts with each of its customers that have a single performance obligation - to deliver products upon receipt of a customer order - and these obligations are satisfied when delivery occurs and the customer receives the product.  The specialty distributors subsequently resell the Company&#8217;s product to healthcare providers.  Product revenue is recorded net of applicable reserves for variable consideration, including discounts and other allowances. Shipping and handling costs for product shipments occur prior to the customer obtaining control of the goods and are recorded in cost of sales. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reserves for Variable Consideration.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from product sales is recorded at the net sales price, which includes estimates of variable consideration. Components of variable consideration typically include discounts, product returns, provider chargebacks and discounts and government rebates. Variable consideration is estimated following the expected value method in accordance with ASC 606 and includes such factors as current contractual and statutory requirements, specific known market events and trends, industry data, and forecasted customer buying and payment patterns. The amount of variable consideration that is included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized under the contract will not occur in a future period. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Customer Discounts and Service Fees.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may provide customers with discounts which are explicitly stated in the contracts. These discounts are recorded as a reduction of revenue in the period the related product revenue is </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recognized. In addition, these contracts may include written service arrangements whereby the Company pays fees to customers who provide services such as sales order management, data, contract administration and distribution services, at rates which the Company believes to be consistent with fair market value. The Company has determined such services received to date are not distinct from the Company&#8217;s sale of products to its customers and, therefore, these payments have been recorded as a reduction of revenue within the statement of operations. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Returns.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consistent with industry practice, the Company offers the specialty distributors product return rights pursuant to written contracts and/or Company returned goods policies. The Company estimates the amount of its product sales that may be returned by its customers and records an estimated liability and a reduction of revenue in the period the related product revenue is recognized. The Company currently estimates product returns using industry benchmarking as well as other information available, such as visibility into the inventory remaining in the distribution channel, since the Company does not have its own returns experience. The Company's estimates of product returns may be adjusted in the future based on actual returns experience, known or expected changes in the marketplace, or other factors.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provider Chargebacks and Discounts.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chargebacks for fees and discounts to healthcare providers represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices charged to customers who directly purchase the product from the Company. In such cases, customers charge the Company for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers. The reserve for chargebacks is established in the same period that the related revenue is recognized, resulting in a reduction of product revenue. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider by customers, and the Company generally issues credits for such amounts within a few weeks of the customer&#8217;s notification to the Company of the resale. Chargebacks consist of credits the Company expects to issue for units that remain in the distribution channel at each reporting period end that the Company expects will be sold to qualified healthcare providers and chargebacks that customers have claimed, but for which the Company has not yet issued a credit. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Rebates.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to discount and/or rebate obligations under state Medicaid programs, Medicare and contractual agreements with and statutory obligations to certain Federal and State entities. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue. The Company&#8217;s liability for these rebates consists of invoices received for claims from prior quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimates of future claims that will be made for product that has been recognized as revenue, but which remains in the distribution channel at the end of each reporting period. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customer discounts are recorded as a reduction of accounts receivable on the consolidated balance sheets. Allowance for product returns, provider chargebacks, government and other rebates and service fees are recorded as a component of accrued expenses and other current liabilities on the consolidated balance sheets.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Contract manufacturing revenue</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into agreements with third parties to manufacture their drug substance at its GMP facility. The terms of these arrangements typically include an upfront payment to the Company to reserve manufacturing capacity, scheduled payments during the manufacturing process and reimbursement for materials used to manufacture product.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue over time on a straight-line basis as the manufacturing services are performed, as the Company believes that its efforts in providing the manufacturing services are incurred evenly throughout the performance period and therefore straight-line revenue recognition closely approximates the level of effort for the manufacturing services. Variable consideration relating to the reimbursed materials and other reimbursed costs incurred to manufacture product are allocated to the related manufacturing activities and are recognized as revenue as those activities occur.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Cost of Product Sales and Cost of Manufacturing Services</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Cost of Product Sales</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of product sales relates to sales of MARGENZA.  These costs include material, manufacturing and shipping costs, as well as royalties payable on net sales of MARGENZA and inventory reserves.  All product costs incurred prior to FDA approval of MARGENZA in December 2020 were expensed as research and development expense.  The Company expects cost of product sales to continue to be positively impacted for the next four to five years as the Company sells through inventory that was expensed prior to FDA approval of MARGENZA. </span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Manufacturing Services</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of manufacturing services consists of the costs to provide manufacturing services to produce certain bulk drug substance under manufacturing and clinical supply agreements with third parties, including salaries and benefits and related stock-based compensation, materials, overhead and other related costs.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses, Including Clinical Trial Accruals/Expenses</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expense, Including Clinical Trial Accruals/Expenses</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenditures are expensed as incurred. Research and development costs primarily consist of employee related expenses, including salaries and benefits, expenses incurred under agreements with contract research organizations (CROs), investigative sites and consultants that conduct the Company's clinical trials, the cost of acquiring and manufacturing clinical trial materials, including costs incurred under agreements with contract manufacturing organizations (CMOs), and other allocated expenses, license fees for and milestone payments related to in-licensed products and technologies, stock-based compensation expense, and costs associated with non-clinical activities and regulatory approvals.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-to-develop agreements may contain cost-sharing provisions whereby the Company and the collaborator share the cost of research and development activities. Reimbursement of research and development expenses received in connection with these agreements is recorded as a reduction of such expenses.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trial expenses are a significant component of research and development expense, and the Company outsources  a significant portion of these costs to third parties. Third party clinical trial expenses include investigator fees, site and patient costs, CRO costs, costs for central laboratory testing, data management and CMO costs. The accrual for site and patient costs includes inputs such as estimates of patient enrollment, patient cycles incurred, clinical site activations, and other pass-through costs. These inputs are required to be estimated due to a lag in receiving the actual clinical information from third parties. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected on the consolidated balance sheets as a prepaid asset or accrued expenses. These third party agreements are generally cancellable, and related costs are recorded as research and development expenses as incurred</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Non-refundable advance clinical payments for goods or services that will be used or rendered for future research and development activities are recorded as a prepaid asset and recognized as expense as the related goods are delivered or the related services are performed.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> When evaluating the adequacy of the accrued expenses, management  analyzes progress of the studies, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates may be made in determining the accrued balances at the end of any reporting period. Actual results could differ from the estimates made. The historical clinical accrual estimates have not been materially different from the actual costs.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines whether an arrangement is or contains a lease at the inception of an arrangement under ASC 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span>. For leases where the Company is the lessee, right-of-use (ROU) assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term of the lease for which the rate is estimated. Certain adjustments to the ROU asset may be required for items such as initial direct costs paid or incentives received. The lease terms used to calculate the ROU asset and related lease liabilities include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for operating leases is recognized on a straight-line basis over the lease term as an operating expense while the expense for finance leases is recognized as depreciation expense and interest expense using the accelerated interest method of recognition.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss represents net loss adjusted for the change during the periods attributed to unrealized gains and losses on available-for-sale debt securities.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</span></div>Basic and diluted loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period. All stock options and restricted stock units (RSUs) are excluded from the per share calculations as such securities were anti-dilutive for all periods presented.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has implemented all applicable accounting pronouncements that are in effect. These pronouncements did not have any material impact on the financial statements unless otherwise disclosed, and the Company does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_LiabilityRelatedToFutureRoyaltiesAndRelatedInterestExpensePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability related to future royalties and related interest expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_LiabilityRelatedToFutureRoyaltiesAndRelatedInterestExpensePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480981/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Topic 705<br> -Publisher FASB<br> -URI https://asc.fasb.org//705/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 60<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482053/820-10-60-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 330<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482105/912-330-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//330/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 270<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482989/270-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481569/310-20-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-11B<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-6<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139842282320288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Summary of Fair Value Measurement Financial Assets</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets measured at fair value on a recurring basis were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:51.616%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.612%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.584%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.852%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement at December&#160;31, 2023</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,665&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,665&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,179&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,179&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,043&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,043&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,627&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,627&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220,514&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,665&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,849&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.958%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.108%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement at December&#160;31, 2022</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,564&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,564&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-sponsored enterprise</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,811&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,811&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,626&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,626&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,001&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,564&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,437&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:15pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Total assets measured at fair value at December&#160;31, 2023 includes approximately $91.7 million reported as cash and cash equivalents and $128.8&#160;million reported as marketable securities on the balance sheet.</span></div><div style="margin-bottom:9pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Total assets measured at fair value at December&#160;31, 2022 includes approximately $46.5 million reported as cash and cash equivalents and $45.5&#160;million reported as marketable securities on the balance sheet.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Summary of Percentage of Customer Concentration</a></td>
<td class="text">The following table includes those counterparties <div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that represent more than 10% of total revenue earned in the periods indicated:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:68.119%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.620%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.620%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.683%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incyte</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">McKesson Plasma &amp; Biologics and McKesson Specialty Care Distribution LLC (McKesson)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ASD Healthcare and Oncology Supply (ASD)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provention</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zai Lab Limited (Zai Lab)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I-Mab Biopharma (I-Mab)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16%</span></td></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Amount is less than 10% for the period indicated.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table includes those counterparties that represent more than 10% of accounts receivable at the date indicated:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:72.946%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.363%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.632%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incyte</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health, Inc</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">McKesson</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ASD</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zai Lab</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provention</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84%</span></td></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Balance is less than 10% as of the date indicated.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock', window );">Estimated Useful Lives</a></td>
<td class="text">Depreciation and amortization are computed using the straight-line method over the following estimated useful lives:<div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.046%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.754%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory and office equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter of lease term or useful life</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Stock Options and RSUs Excluded from the Calculation of Net Loss Per Share</a></td>
<td class="text">The following table presents the number of stock options and RSUs that were excluded from the calculation of net loss per share:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"></td><td style="width:44.036%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.377%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.015%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.377%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.015%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.380%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options and RSUs</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,129,251</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,514,013</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,395,421</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Property plant and equipment estimated useful life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2C<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2C<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-16<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139842284800576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Available-for-sale</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:31.5pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale marketable securities as of December&#160;31, 2023 and 2022 were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:49.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.650%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,177&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,179&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,041&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,043&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,637&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,627&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,855&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,849&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:49.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.650%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-sponsored enterprises</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,812&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,810&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,655&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,652&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,467&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,462&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139842284891552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory, Current</a></td>
<td class="text">The following table sets forth the Company's inventory, net of reserves (in thousands):<div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.761%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">409&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">960&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,042&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,221&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,451&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_ScheduleOfInventoryReservesTableTextBlock', window );">Schedule of Inventory Reserves</a></td>
<td class="text"><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.952%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Inventory Reserves (in thousands)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at Beginning of Year</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additions Charged to Expenses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deductions</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at End of Year</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ended December&#160;31, 2023</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,917&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,798)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,119&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ended December 31, 2022</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,035&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,882&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,917&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ended December 31, 2021</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,035&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,035&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ScheduleOfInventoryReservesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Inventory Reserves</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ScheduleOfInventoryReservesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139842284862848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Equipment and Software (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, equipment and software consists of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,542&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,489&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,759&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,604&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and office equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">706&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">713&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Motor vehicles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,452&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,474&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,620&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,974&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, equipment and software</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,241&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,660&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88,394)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84,085)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, equipment and software, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,847&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,575&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139842278105776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_ScheduleOfSupplementalBalanceSheetInformationOperatingLeasesTableTextBlock', window );">Schedule Of Supplemental Balance Sheet Information, Operating Leases</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents supplemental balance sheet information related to operating leases:</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.092%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.013%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Weighted-average remaining lease term (in years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.1</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Lease, Cost</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease cost for the years ended </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and 2022 were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.225%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.946%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.948%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating lease cost</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,459&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,597&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,316&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,451&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Sublease income</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,109)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,076)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net lease cost</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,666&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,972&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Lessee, Operating Lease, Liability, Maturity</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the maturities of the Company&#8217;s operating lease liabilities were as follows (in thousands): </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.473%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.327%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,084&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,209&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,927&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,049&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,003&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,276&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,306)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,970&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ScheduleOfSupplementalBalanceSheetInformationOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Supplemental Balance Sheet Information, Operating Leases</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ScheduleOfSupplementalBalanceSheetInformationOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139842287186960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Royalty Monetization Arrangement (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_RoyaltyMonetizationArrangementAbstract', window );"><strong>Royalty Monetization Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_LiabilityRelatedToFutureRoyaltyTableTextBlock', window );">Liability Related to Future Royalty</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes to the liability related to future royalties were as follows for the year ended December&#160;31, 2023 (in thousands):</span></div><div style="text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.636%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.580%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability related to future royalties - beginning balance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sale of future royalties</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred transaction costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(343)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty revenue payable to DRI</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(157)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense recognized</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,430&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on royalty monetization arrangement</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(150,930)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability related to future royalties - ending balance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_LiabilityRelatedToFutureRoyaltyTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability Related to Future Royalty</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_LiabilityRelatedToFutureRoyaltyTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_RoyaltyMonetizationArrangementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Monetization Arrangement [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_RoyaltyMonetizationArrangementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139842285324256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-Based Compensation Expense</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following stock-based compensation amounts were recognized for the periods indicated (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,190&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,094&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,337&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,183&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,344&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,789&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,373&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,438&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,126&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Employee Stock Options Award Valuation Assumptions</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:56.211%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76% -96%</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88% - 92%</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86% - 87%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5% - 4.8%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4% - 4.0%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6% - 1.6%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.88 years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.95 years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.25 years</span></div></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity for 2023:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercise Price</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contractual Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Years)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,098,929&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.58&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,367,777&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34,608)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(365,942)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(842,519)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,223,637&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,974&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of December&#160;31, 2023:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,892,753&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,509&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,346,207&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,692&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of RSU Activity</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes RSU activity for 2023:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.163%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.268%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.954%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Grant Date Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">415,084&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.83&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">707,635&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.88&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(135,396)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(81,709)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.17&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">905,614&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139842286504512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Components of the Company's Deferred Income Tax Assets (Liabilities)</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The significant components of the Company's deferred income tax assets (liabilities) were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal U.S. net operating loss carryforward</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140,706&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163,071&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State net operating loss carryforward</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,350&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,784&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development credit, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,251&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,084&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Orphan drug credit, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,330&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,703&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,078&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,585&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,442&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 174 deferred tax asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,421&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,192&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity based compensation</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,217&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,228&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,617&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,663&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred income tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373,412&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381,310&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(365,010)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(372,267)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred income tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,402&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,043&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:13pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease ROU assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,372)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,522)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenditures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,030)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,521)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred income tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,402)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,043)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred income tax asset/(liability)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfValuationAllowanceTextBlock', window );">Summary of Valuation Allowance</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The activity in the valuation allowance on deferred tax assets was as follows (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.970%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.859%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.859%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.859%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.861%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at Beginning of Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deductions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at End of Year</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ended December 31, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372,267&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,257)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365,010&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ended December 31, 2022</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">327,592&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,675&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372,267&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ended December 31, 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,192&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">327,592&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation of Reported Estimated Income Tax Benefit</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of the reported estimated income tax benefit to the amount that would result by applying the U.S. federal statutory tax rate to the net income is as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States federal tax at statutory rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,902)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,149)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42,445)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes (net of federal benefit)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(163)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,385)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,806)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,024&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">473&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred state blended rate adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,841&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research credit, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,168)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,569)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,243)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Orphan drug credit, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,374&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,846)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,449)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other permanent items</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,301&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,362&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,199&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,950&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,604&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,079&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,257)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,675&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,192&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense/(benefit)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Reconciliation of the Beginning and Ending Amount of Gross Unrecognized Tax Benefits</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,376&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,197&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,126&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases for current year tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">449&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">965&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases/(decreases) for prior year tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(369)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,821&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,376&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,197&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 12<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfValuationAllowanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfValuationAllowanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139842287217408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>Segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139842279024208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Summary of Fair Value Measurement Financial Asset and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 91,700<span></span>
</td>
<td class="nump">$ 46,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">128,849<span></span>
</td>
<td class="nump">45,462<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Investments', window );">Investments</a></td>
<td class="nump">128,849<span></span>
</td>
<td class="nump">45,462<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">220,514<span></span>
</td>
<td class="nump">92,001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">91,665<span></span>
</td>
<td class="nump">41,564<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">31,179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">Government-sponsored enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">45,043<span></span>
</td>
<td class="nump">32,811<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">52,627<span></span>
</td>
<td class="nump">17,626<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets, Level 1 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">91,665<span></span>
</td>
<td class="nump">41,564<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets, Level 1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">91,665<span></span>
</td>
<td class="nump">41,564<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets, Level 1 | U.S Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets, Level 1 | Government-sponsored enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets, Level 1 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs, Level 2 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">128,849<span></span>
</td>
<td class="nump">50,437<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs, Level 2 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs, Level 2 | U.S Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">31,179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs, Level 2 | Government-sponsored enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">45,043<span></span>
</td>
<td class="nump">32,811<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs, Level 2 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">$ 52,627<span></span>
</td>
<td class="nump">$ 17,626<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Investments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(h))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Investments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139842282122944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Summary of Collaborators that Represent More Than 10% of Total Revenue Earned and Accounts Receivable (Details) - Customer Concentration Risk<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Sales revenue, net | Incyte Corporation (Incyte)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of significant accounts receivable</a></td>
<td class="nump">53.00%<span></span>
</td>
<td class="nump">26.00%<span></span>
</td>
<td class="nump">31.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Sales revenue, net | McKesson Plasma &amp; Biologics and McKesson Specialty Care Distribution LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of significant accounts receivable</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Sales revenue, net | ASD Healthcare and Oncology Supply</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of significant accounts receivable</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Sales revenue, net | Provention Bio, Inc. (Provention)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of significant accounts receivable</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">43.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Sales revenue, net | Zai Lab Limited (Zai Lab)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of significant accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Sales revenue, net | I-Mab Biopharma</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of significant accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Accounts receivable | Incyte Corporation (Incyte)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of significant accounts receivable</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Accounts receivable | McKesson Plasma &amp; Biologics and McKesson Specialty Care Distribution LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of significant accounts receivable</a></td>
<td class="nump">16.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Accounts receivable | Cardinal Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of significant accounts receivable</a></td>
<td class="nump">18.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Accounts receivable | ASD Healthcare and Oncology Supply</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of significant accounts receivable</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Accounts receivable | Provention Bio, Inc. (Provention)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of significant accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Accounts receivable | Zai Lab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of significant accounts receivable</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481027/954-310-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=mgnx_IncyteCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=mgnx_IncyteCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=mgnx_McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=mgnx_McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=mgnx_ASDHealthcareAndOncologySupplyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=mgnx_ASDHealthcareAndOncologySupplyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=mgnx_ProventionBioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=mgnx_ProventionBioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=mgnx_ZaiLabLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=mgnx_ZaiLabLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=mgnx_IMabBiopharmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=mgnx_IMabBiopharmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=mgnx_CardinalHealthIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=mgnx_CardinalHealthIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=mgnx_ZaiLabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=mgnx_ZaiLabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139842282420464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Estimated Useful Lives (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Software</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mgnx_LaboratoryAndOfficeEquipmentMember', window );">Laboratory and office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mgnx_LaboratoryAndOfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=mgnx_LaboratoryAndOfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139842287853024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from the Calculation of Diluted Loss Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=mgnx_StockOptionsAndRestrictedStockUnitsMember', window );">Stock options and RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive stock options</a></td>
<td class="nump">13,129,251<span></span>
</td>
<td class="nump">10,514,013<span></span>
</td>
<td class="nump">8,395,421<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=mgnx_StockOptionsAndRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=mgnx_StockOptionsAndRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139842277908160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 128,855<span></span>
</td>
<td class="nump">$ 45,467<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(22)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">128,849<span></span>
</td>
<td class="nump">45,462<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">31,177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">31,179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">Government-sponsored enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">45,041<span></span>
</td>
<td class="nump">32,812<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">45,043<span></span>
</td>
<td class="nump">32,810<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">52,637<span></span>
</td>
<td class="nump">12,655<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(15)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 52,627<span></span>
</td>
<td class="nump">$ 12,652<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139842287853024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities - Available-For-Sale Securities (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Debt Securities, Available-for-sale, Allowance for Credit Loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeOther', window );">Interest Income, Other</a></td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income earned from interest bearing assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139842278107888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory, Net - Schedule of Inventory (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work in process</a></td>
<td class="nump">$ 261<span></span>
</td>
<td class="nump">$ 409<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">960<span></span>
</td>
<td class="nump">1,042<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, net</a></td>
<td class="nump">1,221<span></span>
</td>
<td class="nump">1,451<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Inventory valuation reserves</a></td>
<td class="nump">$ 3,100<span></span>
</td>
<td class="nump">$ 4,900<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480581/330-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139842283608704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory, Net (Details) - SEC Schedule, 12-09, Reserve, Inventory - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at Beginning of Year</a></td>
<td class="nump">$ 3,119<span></span>
</td>
<td class="nump">$ 4,917<span></span>
</td>
<td class="nump">$ 2,035<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense', window );">Additions Charged to Expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,882<span></span>
</td>
<td class="nump">2,035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Deductions</a></td>
<td class="num">(1,798)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at End of Year</a></td>
<td class="nump">$ 3,119<span></span>
</td>
<td class="nump">$ 4,917<span></span>
</td>
<td class="nump">$ 2,035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column D))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C(1)))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C(2)))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ValuationAndQualifyingAccountsDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column D))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_InventoryValuationReserveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_InventoryValuationReserveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139842277921568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Equipment and Software (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, equipment and software</a></td>
<td class="nump">$ 110,241<span></span>
</td>
<td class="nump">$ 113,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction in progress</a></td>
<td class="nump">1,112<span></span>
</td>
<td class="nump">356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation and amortization</a></td>
<td class="num">(88,394)<span></span>
</td>
<td class="num">(84,085)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, equipment and software, net</a></td>
<td class="nump">21,847<span></span>
</td>
<td class="nump">29,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">9,600<span></span>
</td>
<td class="nump">11,900<span></span>
</td>
<td class="nump">$ 11,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, equipment and software</a></td>
<td class="nump">3,542<span></span>
</td>
<td class="nump">3,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, equipment and software</a></td>
<td class="nump">9,759<span></span>
</td>
<td class="nump">9,604<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mgnx_FurnitureAndOfficeEquipmentMember', window );">Furniture and office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, equipment and software</a></td>
<td class="nump">706<span></span>
</td>
<td class="nump">713<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember', window );">Motor vehicles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, equipment and software</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Lab equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, equipment and software</a></td>
<td class="nump">46,452<span></span>
</td>
<td class="nump">46,474<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, equipment and software</a></td>
<td class="nump">$ 48,620<span></span>
</td>
<td class="nump">$ 52,974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mgnx_FurnitureAndOfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=mgnx_FurnitureAndOfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139842283372336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_RightOfUseAssetAndLeaseLiabilityIncrease', window );">Right of use asset and lease liability increase</a></td>
<td class="nump">$ 14,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average lease term (in years)</a></td>
<td class="text">11 years<span></span>
</td>
<td class="text">11 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Discount rate</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating lease payments</a></td>
<td class="nump">$ 5,900<span></span>
</td>
<td class="nump">$ 6,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease, ROU Assets</a></td>
<td class="nump">23,846<span></span>
</td>
<td class="nump">27,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">7,459<span></span>
</td>
<td class="nump">5,597<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">1,316<span></span>
</td>
<td class="nump">1,451<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease Income</a></td>
<td class="num">(1,109)<span></span>
</td>
<td class="num">(1,076)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Lease, cost</a></td>
<td class="nump">7,666<span></span>
</td>
<td class="nump">5,972<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">4,004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">5,084<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">4,209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2027</a></td>
<td class="nump">4,927<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2028</a></td>
<td class="nump">6,049<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">46,003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">70,276<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(36,306)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">33,970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 166,583<span></span>
</td>
<td class="nump">207,026<span></span>
</td>
<td class="nump">$ 214,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease renewal term (in years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_SynaffixBVMember', window );">Synaffix B.V.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement', window );">Potential development and regulatory milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 2,800<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential Development and Regulatory Milestone Payments Under Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_RightOfUseAssetAndLeaseLiabilityIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Right of Use asset and Lease Liability Increase</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_RightOfUseAssetAndLeaseLiabilityIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_SynaffixBVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_SynaffixBVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139842283642000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Royalty Monetization Arrangement (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 08, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_LiabilityRelatedToFutureRoyaltyLineItems', window );"><strong>Liability related to future royalty [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_GainOnRoyaltyMonetizationArrangement', window );">Gain on royalty monetization arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="nump">$ 100,900<span></span>
</td>
<td class="nump">$ 150,930<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_DRIHealthcareAcquisitionsLPDRIMember', window );">DRI Healthcare Acquisitions LP (DRI)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_LiabilityRelatedToFutureRoyaltyLineItems', window );"><strong>Liability related to future royalty [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_UpfrontPayment', window );">Upfront payment from DRI Health Trust</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_ProceedsfromRoyaltiesPercent', window );">Potential proceeds from royalties percent</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_FutureRevenue', window );">Future revenue from DRI</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_TransactionCost', window );">Transaction cost</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_FutureRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future Revenue</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_FutureRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_GainOnRoyaltyMonetizationArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain on royalty monetization arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_GainOnRoyaltyMonetizationArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_LiabilityRelatedToFutureRoyaltyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability related to future royalty</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_LiabilityRelatedToFutureRoyaltyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ProceedsfromRoyaltiesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Royalties, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ProceedsfromRoyaltiesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_TransactionCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transaction Cost</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_TransactionCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_UpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_UpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_DRIHealthcareAcquisitionsLPDRIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_DRIHealthcareAcquisitionsLPDRIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139842375497152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Royalty Monetization Arrangement Rollforward (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_RoyaltyMonetizationArrangementAbstract', window );"><strong>Royalty Monetization Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_LiabilityRelatedToFutureRoyalties', window );">Liability related to future royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_ProceedsFromSaleOfFutureRoyalties', window );">Proceeds from sale of future royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_DeferredTransactionCosts', window );">Deferred transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(343)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_PrincipalPaymentsOnRoyaltyMonetizationArrangement', window );">Principal payments on royalty monetization arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(157)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_NonCashInterestExpenseRecognized', window );">Non-cash interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,430<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_GainOnRoyaltyMonetizationArrangement', window );">Gain on royalty monetization arrangement</a></td>
<td class="num">$ (50,000)<span></span>
</td>
<td class="num">$ (100,900)<span></span>
</td>
<td class="num">$ (150,930)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_DeferredTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred transaction costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_DeferredTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_GainOnRoyaltyMonetizationArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain on royalty monetization arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_GainOnRoyaltyMonetizationArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_LiabilityRelatedToFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability related to future royalties</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_LiabilityRelatedToFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonCashInterestExpenseRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-cash interest expense recognized</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NonCashInterestExpenseRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PrincipalPaymentsOnRoyaltyMonetizationArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Principal payments on royalty monetization arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PrincipalPaymentsOnRoyaltyMonetizationArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ProceedsFromSaleOfFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from sale of future royalties</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ProceedsFromSaleOfFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_RoyaltyMonetizationArrangementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Monetization Arrangement [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_RoyaltyMonetizationArrangementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139842284533120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">14 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Apr. 30, 2021</div></th>
<th class="th"><div>Nov. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 15, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000,000<span></span>
</td>
<td class="nump">125,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 616<span></span>
</td>
<td class="nump">$ 1,085<span></span>
</td>
<td class="nump">$ 117,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_ZaiLabMember', window );">Zai Lab | 2021 Zai Lab Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of common stock (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31.30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds of stock sale</a></td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=mgnx_UndesignatedPreferredStockMember', window );">Undesignated Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Undesignated preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Undesignated preferred stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Undesignated preferred stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Undesignated preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mgnx_AtTheMarketOfferingMember', window );">At The Market Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_CommonStockMaximumAmountAvailableForIssuance', window );">Common stock maximum amount available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">160,480<span></span>
</td>
<td class="nump">95,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,622,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of common stock (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.87<span></span>
</td>
<td class="nump">$ 6.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds of stock sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 98,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease', window );">Common Stock, Maximum Amount Available For Issuance, Increase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CommonStockMaximumAmountAvailableForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Maximum Amount Available For Issuance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CommonStockMaximumAmountAvailableForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Maximum Amount Available For Issuance, Increase</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_ZaiLabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_ZaiLabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_A2021ZaiLabAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_A2021ZaiLabAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=mgnx_UndesignatedPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=mgnx_UndesignatedPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=mgnx_AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=mgnx_AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139842284450432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Incyte Corporation (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">24 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>performanceObligation</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 58,749<span></span>
</td>
<td class="nump">$ 151,941<span></span>
</td>
<td class="nump">$ 77,447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteMGA012AgreementMember', window );">Incyte MGA012 Agreement | Incyte Corporation (Incyte)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_NonRefundableUpfrontFees', window );">Non-refundable upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized', window );">Amounts recognized</a></td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_NumberOfPerformanceObligations', window );">Number of performance obligations | performanceObligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_CollaborativeAgreementTransactionPrice', window );">Transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 154,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount', window );">Clinical trial activities selling price amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Incyte MGA012 Agreement | Incyte Corporation (Incyte)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_ProceedsfromRoyaltiesPercent', window );">Potential proceeds from royalties percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Incyte MGA012 Agreement | Incyte Corporation (Incyte)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement', window );">Potential development and regulatory milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 435,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement', window );">Potential commercial milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 330,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_ProceedsfromRoyaltiesPercent', window );">Potential proceeds from royalties percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember', window );">Revenues From License Agreements | Incyte MGA012 Agreement | Incyte Corporation (Incyte)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember', window );">Revenues From License Agreements | Incyte MGA012 Supply Agreement | Incyte Corporation (Incyte)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember', window );">Revenues From License Agreements | Incyte MGA012 Clinical Services | Incyte Corporation (Incyte)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,200<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 7,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborativeAgreementTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement Transaction Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborativeAgreementTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Development And Regulatory Milestone Payments Under Agreement, Recognized</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonRefundableUpfrontFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial fee received from collaboration or license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NonRefundableUpfrontFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NumberOfPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NumberOfPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential Commercial Milestone Payments Under Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialCommercialMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential Development and Regulatory Milestone Payments Under Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ProceedsfromRoyaltiesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Royalties, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ProceedsfromRoyaltiesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue, Multiple-Deliverable Arrangements, Determination Of Selling Price, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteMGA012AgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteMGA012AgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_IncyteCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_IncyteCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteClinicalSupplyAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteClinicalSupplyAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteCommercialSupplyAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteCommercialSupplyAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139842283468288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Gilead Sciences Inc (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">7 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 14, 2022</div></th>
<th class="th"><div>Jul. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 58,749<span></span>
</td>
<td class="nump">$ 151,941<span></span>
</td>
<td class="nump">$ 77,447<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_GileadMember', window );">Gilead | 2022 Gilead Collaboration And License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_NonRefundableUpfrontFees', window );">Non-refundable upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_PotentialTargetNominationOptionFeesAndMilestonePayments', window );">Target nomination, option fees and milestone</a></td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,300<span></span>
</td>
<td class="nump">59,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,200<span></span>
</td>
<td class="nump">1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,100<span></span>
</td>
<td class="nump">$ 58,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_GileadMember', window );">Gilead | Gilead First Research Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, remaining performance obligation, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_OptInFee', window );">Opt-in fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonRefundableUpfrontFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial fee received from collaboration or license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NonRefundableUpfrontFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_OptInFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Opt-In Fee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_OptInFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialTargetNominationOptionFeesAndMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential target, nomination, option fees and milestone payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialTargetNominationOptionFeesAndMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_GileadMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_GileadMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_A2022GileadCollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_A2022GileadCollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_GileadFirstResearchProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_GileadFirstResearchProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139842282261840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Zai Lab (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 15, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 58,749<span></span>
</td>
<td class="nump">$ 151,941<span></span>
</td>
<td class="nump">$ 77,447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_A2021ZaiLabAgreementsMember', window );">2021 Zai Lab Agreements | Zai Lab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_NonRefundableUpfrontFees', window );">Non-refundable upfront payment</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds of stock sale</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of common stock (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31.30<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_CollaborativeAgreementTransactionPrice', window );">Transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_EstimatedReimbursementForResearchAndDevelopmentT', window );">Estimated Reimbursement for Research and Development t</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 16,800<span></span>
</td>
<td class="nump">$ 20,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_A2021ZaiLabAgreementsMember', window );">2021 Zai Lab Agreements | Zai Lab | Additional Paid-In Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_PremiumReceivedOnStockPurchase', window );">Premium received on stock purchase</a></td>
<td class="nump">$ 10,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborativeAgreementTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement Transaction Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborativeAgreementTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_EstimatedReimbursementForResearchAndDevelopmentT">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated Reimbursement for Research and Development t</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_EstimatedReimbursementForResearchAndDevelopmentT</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonRefundableUpfrontFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial fee received from collaboration or license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NonRefundableUpfrontFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PremiumReceivedOnStockPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which purchase price exceeds fair value for common stock purchased by collaborator.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PremiumReceivedOnStockPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_A2021ZaiLabAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_A2021ZaiLabAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_ZaiLabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_ZaiLabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139842279099392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Provention (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 08, 2023</div></th>
<th class="th"><div>Nov. 30, 2022</div></th>
<th class="th"><div>May 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 58,749<span></span>
</td>
<td class="nump">$ 151,941<span></span>
</td>
<td class="nump">$ 77,447<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_ProventionBioMember', window );">Provention Bio, Inc. (Provention)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_CollaborativeAgreementTransactionPrice', window );">Transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares', window );">Stock warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,432,688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_ProventionBioMember', window );">Provention Bio, Inc. (Provention) | Revenues From License Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_ProventionBioMember', window );">Provention Bio, Inc. (Provention) | Asset Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_ProventionBioMember', window );">Provention Bio, Inc. (Provention) | Royalty [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_ProventionBioMember', window );">Provention Bio, Inc. (Provention) | Provention PRV3279 | Provention License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare', window );">Consideration received common stock warrant exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement', window );">Potential development and regulatory milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement', window );">Potential commercial milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 225,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_ProventionBioMember', window );">Provention Bio, Inc. (Provention) | Provention PRV031 | Asset Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare', window );">Consideration received common stock warrant exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement', window );">Potential development and regulatory milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 170,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement', window );">Potential commercial milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">225,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized', window );">Amounts recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement', window );">Potential milestone payment to third parties for intellectual property under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,600<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_DRIHealthcareAcquisitionsLPDRIMember', window );">DRI Healthcare Acquisitions LP (DRI)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_FutureRevenue', window );">Future revenue from DRI</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement Consideration Received Common Stock Warrant Exercise Price Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement Consideration Received Common Stock Warrants Number Of Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborativeAgreementTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement Transaction Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborativeAgreementTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Development And Regulatory Milestone Payments Under Agreement, Recognized</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_FutureRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future Revenue</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_FutureRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential Commercial Milestone Payments Under Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialCommercialMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential Development and Regulatory Milestone Payments Under Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential Milestone Payment To Third Parties For Intellectual Property Under Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_ProventionBioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_ProventionBioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_AssetPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_AssetPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ProventionPRV3279Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ProventionPRV3279Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mgnx_ProventionLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mgnx_ProventionLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ProventionPRV031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ProventionPRV031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mgnx_AssetPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mgnx_AssetPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_DRIHealthcareAcquisitionsLPDRIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_DRIHealthcareAcquisitionsLPDRIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139842279037136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Manufacturing Service Agreements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">7 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jan. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 58,749<span></span>
</td>
<td class="nump">$ 151,941<span></span>
</td>
<td class="nump">$ 77,447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_IncyteCorporationMember', window );">Incyte Corporation (Incyte) | RevenuesFromCMOAgreementsMember</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_NonRefundableUpfrontFees', window );">Non-refundable upfront payment</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_TotalAnnualFixedPayments', window );">Total annual fixed payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,700<span></span>
</td>
<td class="nump">8,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
<td class="nump">9,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_IncyteCorporationMember', window );">Incyte Corporation (Incyte) | RevenuesFromCMOAmendmentAgreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_TotalAnnualFixedPayments', window );">Total annual fixed payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_AdditionalAnnualFixedPayments', window );">Additional annual fixed payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_IncyteCorporationMember', window );">Incyte Corporation (Incyte) | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_CollaborativeArrangementTerm', window );">Collaborative arrangement, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_CollaborativeArrangementExtensionTerm', window );">Collaborative arrangement, extension term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_ProventionBioMember', window );">Provention Bio, Inc. (Provention) | Provention Bio CMO Agreeemnt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_UpfrontAndFixedPayments', window );">upfront and fixed payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_AdditionalAnnualFixedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional Annual Fixed Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_AdditionalAnnualFixedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborativeArrangementExtensionTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Extension Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborativeArrangementExtensionTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborativeArrangementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborativeArrangementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonRefundableUpfrontFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial fee received from collaboration or license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NonRefundableUpfrontFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_TotalAnnualFixedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total Annual Fixed Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_TotalAnnualFixedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_UpfrontAndFixedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>upfront and fixed payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_UpfrontAndFixedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_IncyteCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_IncyteCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromCMOAgreementsMemberMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_RevenuesFromCMOAgreementsMemberMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromCMOAmendmentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_RevenuesFromCMOAmendmentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_ProventionBioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_ProventionBioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_ProventionBioCMOAgreeemntMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_ProventionBioCMOAgreeemntMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139842284427040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - NIAID Contract (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 58,749,000<span></span>
</td>
<td class="nump">$ 151,941,000<span></span>
</td>
<td class="nump">$ 77,447,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember', window );">NIAID</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_TotalPotentialValueUnderAgreement', window );">Total potential value</a></td>
<td class="nump">25,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromGrantsMember', window );">RevenuesFromGrantsMember | NIAID</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_NumberOfProductCandidates', window );">Number of product candidates to develop</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="nump">$ 1,800,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NumberOfProductCandidates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Product Candidates</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NumberOfProductCandidates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_TotalPotentialValueUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Refers to total potential value under agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_TotalPotentialValueUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromGrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_RevenuesFromGrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139842277749840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>May 18, 2017</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 616<span></span>
</td>
<td class="nump">$ 1,085<span></span>
</td>
<td class="nump">$ 117,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based compensation arrangement by share-based payment award, options, outstanding, number (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,223,637<span></span>
</td>
<td class="nump">10,098,929<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.11<span></span>
</td>
<td class="nump">$ 18.58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod', window );">Offering period</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Employee service period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Options granted, maximum term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding nonvested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">905,614<span></span>
</td>
<td class="nump">415,084<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember', window );">2016 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based compensation, number of shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent', window );">Maximum employee contribution percent</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Percent of fair market value to purchase shares</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Common stock purchased by employees (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,541<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mgnx_StockIncentivePlan2023MemberMember', window );">StockIncentivePlan2023Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based compensation, number of shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,850,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based compensation arrangement by share-based payment award, options, outstanding, number (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">418,122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mgnx_StockIncentivePlan2023MemberMember', window );">StockIncentivePlan2023Member | Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding nonvested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mgnx_StockIncentivePlan2013Member', window );">Stock Incentive Plan 2013</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based compensation arrangement by share-based payment award, options, outstanding, number (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,805,515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mgnx_StockIncentivePlan2013Member', window );">Stock Incentive Plan 2013 | Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding nonvested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">854,114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employee Stock Purchase Plan, Maximum Annual Contributions Per Employee, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Offering Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mgnx_StockIncentivePlan2023MemberMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mgnx_StockIncentivePlan2023MemberMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mgnx_StockIncentivePlan2013Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mgnx_StockIncentivePlan2013Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139842288008448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 18,373<span></span>
</td>
<td class="nump">$ 20,438<span></span>
</td>
<td class="nump">$ 23,126<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">9,190<span></span>
</td>
<td class="nump">10,094<span></span>
</td>
<td class="nump">11,337<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 9,183<span></span>
</td>
<td class="nump">$ 10,344<span></span>
</td>
<td class="nump">$ 11,789<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139842278093808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Option Pricing Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">5 years 10 months 17 days<span></span>
</td>
<td class="text">5 years 11 months 12 days<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">76.00%<span></span>
</td>
<td class="nump">88.00%<span></span>
</td>
<td class="nump">86.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.50%<span></span>
</td>
<td class="nump">1.40%<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">96.00%<span></span>
</td>
<td class="nump">92.00%<span></span>
</td>
<td class="nump">87.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.80%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">1.60%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139842283157824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Stock Option and Restricted Stock Unit Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning Balance (in shares)</a></td>
<td class="nump">10,098,929<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">3,367,777<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(34,608)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited or expired (in shares)</a></td>
<td class="num">(365,942)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired (in shares)</a></td>
<td class="num">(842,519)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending Balance (in shares)</a></td>
<td class="nump">12,223,637<span></span>
</td>
<td class="nump">10,098,929<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable (in shares)</a></td>
<td class="nump">7,892,753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest (in shares)</a></td>
<td class="nump">11,346,207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract', window );"><strong>Weighted-Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning Balance (in dollars per share)</a></td>
<td class="nump">$ 18.58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">4.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">3.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited or expired (in dollars per share)</a></td>
<td class="nump">9.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired (in dollars per share)</a></td>
<td class="nump">19.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending Balance (in dollars per share)</a></td>
<td class="nump">15.11<span></span>
</td>
<td class="nump">$ 18.58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable (in dollars per share)</a></td>
<td class="nump">18.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest (in dollars per share)</a></td>
<td class="nump">$ 15.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-average remaining contractual term, Outstanding</a></td>
<td class="text">6 years 8 months 12 days<span></span>
</td>
<td class="text">6 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-average remaining contractual term, Exercisable</a></td>
<td class="text">5 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted-average remaining contractual term, Vested and expected to vest</a></td>
<td class="text">6 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, Outstanding</a></td>
<td class="nump">$ 16,974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value, Exercisable</a></td>
<td class="nump">4,509<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate intrinsic value, Vested and expected to vest</a></td>
<td class="nump">$ 14,692<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">34,608<span></span>
</td>
<td class="nump">120,900<span></span>
</td>
<td class="nump">332,767<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Cash proceeds from exercise of stock options</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 5,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value of options granted (in dollars per share)</a></td>
<td class="nump">$ 3.83<span></span>
</td>
<td class="nump">$ 6.84<span></span>
</td>
<td class="nump">$ 15.20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="nump">$ 3,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of shares vested</a></td>
<td class="nump">16,400<span></span>
</td>
<td class="nump">$ 19,600<span></span>
</td>
<td class="nump">$ 20,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost related to non-vested stock-based compensation arrangements</a></td>
<td class="nump">$ 19,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense recognition period</a></td>
<td class="text">1 year 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mgnx_StockIncentivePlan2013Member', window );">Stock Incentive Plan 2013</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending Balance (in shares)</a></td>
<td class="nump">11,805,515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract', window );"><strong>Weighted-Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending Balance (in dollars per share)</a></td>
<td class="nump">$ 15.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning Balance (in shares)</a></td>
<td class="nump">415,084<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">707,635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(135,396)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(81,709)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending Balance (in shares)</a></td>
<td class="nump">905,614<span></span>
</td>
<td class="nump">415,084<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning Balance (in dollars per share)</a></td>
<td class="nump">$ 8.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">4.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Exercised (in dollars per share)</a></td>
<td class="nump">8.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited or expired (in dollars per share)</a></td>
<td class="nump">7.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending Balance (in dollars per share)</a></td>
<td class="nump">$ 5.97<span></span>
</td>
<td class="nump">$ 8.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense recognition period</a></td>
<td class="text">1 year 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Awards granted in period (in shares)</a></td>
<td class="nump">707,635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Total unrecognized compensation cost</a></td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units | Stock Incentive Plan 2013</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending Balance (in shares)</a></td>
<td class="nump">854,114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mgnx_StockIncentivePlan2013Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mgnx_StockIncentivePlan2013Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139842282333760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Examination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Provision for federal or state income taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Gross unrecognized tax benefits</a></td>
<td class="nump">7,800,000<span></span>
</td>
<td class="nump">$ 7,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Unrecognized interest or penalties</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember', window );">U.S. Federal and State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Examination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Net operating loss carryforwards</a></td>
<td class="nump">670,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember', window );">U.S. Federal and State | Tax Year 2025 To 2037</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Examination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Net operating loss carryforwards</a></td>
<td class="nump">65,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember', window );">U.S. Federal and State | Indefinite</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Examination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Net operating loss carryforwards</a></td>
<td class="nump">604,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">U.S. Federal Government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Examination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">US Federal tax credits carry forward</a></td>
<td class="nump">$ 94,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=mgnx_TaxYear2025To2037Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=mgnx_TaxYear2025To2037Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=mgnx_IndefiniteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=mgnx_IndefiniteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139842277858480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Components of the Company's Deferred Tax Assets (Liabilities) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred income tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic', window );">Federal U.S. net operating loss carryforward</a></td>
<td class="nump">$ 140,706<span></span>
</td>
<td class="nump">$ 163,071<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">State net operating loss carryforward</a></td>
<td class="nump">33,350<span></span>
</td>
<td class="nump">44,784<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credit, net</a></td>
<td class="nump">68,251<span></span>
</td>
<td class="nump">65,084<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther', window );">Orphan drug credit, net</a></td>
<td class="nump">33,330<span></span>
</td>
<td class="nump">35,703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_DeferredTaxAssetsOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="nump">9,078<span></span>
</td>
<td class="nump">9,585<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">17,442<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_Section174DeferredTaxAsset', window );">Section 174 deferred tax asset</a></td>
<td class="nump">48,421<span></span>
</td>
<td class="nump">43,192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Depreciation</a></td>
<td class="nump">16,217<span></span>
</td>
<td class="nump">15,228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">6,617<span></span>
</td>
<td class="nump">4,663<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred income tax assets</a></td>
<td class="nump">373,412<span></span>
</td>
<td class="nump">381,310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(365,010)<span></span>
</td>
<td class="num">(372,267)<span></span>
</td>
<td class="num">$ (327,592)<span></span>
</td>
<td class="num">$ (263,400)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred income tax assets</a></td>
<td class="nump">8,402<span></span>
</td>
<td class="nump">9,043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract', window );"><strong>Deferred income tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets', window );">Operating lease ROU assets</a></td>
<td class="num">(6,372)<span></span>
</td>
<td class="num">(7,522)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses', window );">Prepaid expenditures</a></td>
<td class="num">(2,030)<span></span>
</td>
<td class="num">(1,521)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Gross deferred income tax liabilities</a></td>
<td class="num">(8,402)<span></span>
</td>
<td class="num">(9,043)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred income tax asset/(liability)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_DeferredTaxAssetsOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Operating Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_DeferredTaxAssetsOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Operating Lease Right Of Use Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_Section174DeferredTaxAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Section 174 deferred tax asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_Section174DeferredTaxAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible tax credit carryforwards, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139842283278448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Valuation Allowance Activity (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_ValuationAllowanceRollForward', window );"><strong>Valuation Allowance [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Balance at Beginning of Year</a></td>
<td class="nump">$ 372,267<span></span>
</td>
<td class="nump">$ 327,592<span></span>
</td>
<td class="nump">$ 263,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_ValuationAllowanceDeferredTaxAssetIncreaseAmount', window );">Additions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">44,675<span></span>
</td>
<td class="nump">64,192<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_ValuationAllowanceDeferredTaxAssetDecreaseAmount', window );">Deductions</a></td>
<td class="num">(7,257)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Balance at End of Year</a></td>
<td class="nump">$ 365,010<span></span>
</td>
<td class="nump">$ 372,267<span></span>
</td>
<td class="nump">$ 327,592<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ValuationAllowanceDeferredTaxAssetDecreaseAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Valuation Allowance, Deferred Tax Asset, Decrease, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ValuationAllowanceDeferredTaxAssetDecreaseAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ValuationAllowanceDeferredTaxAssetIncreaseAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Valuation Allowance, Deferred Tax Asset, Increase, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ValuationAllowanceDeferredTaxAssetIncreaseAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ValuationAllowanceRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Valuation Allowance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ValuationAllowanceRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139842278199632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of Reported Estimated Income Tax Benefit (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">United States federal tax at statutory rate</a></td>
<td class="num">$ (1,902)<span></span>
</td>
<td class="num">$ (25,149)<span></span>
</td>
<td class="num">$ (42,445)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State taxes (net of federal benefit)</a></td>
<td class="num">(163)<span></span>
</td>
<td class="num">(7,385)<span></span>
</td>
<td class="num">(12,806)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount', window );">Deferred income tax adjustments</a></td>
<td class="nump">5,024<span></span>
</td>
<td class="nump">308<span></span>
</td>
<td class="nump">473<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_EffectiveIncomeTaxRateReconciliationDeferredStateBlendedRateAdjustmentsAmount', window );">Deferred state blended rate adjustments</a></td>
<td class="nump">1,841<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Research credit, net</a></td>
<td class="num">(3,168)<span></span>
</td>
<td class="num">(4,569)<span></span>
</td>
<td class="num">(10,243)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount', window );">Orphan drug credit, net</a></td>
<td class="nump">2,374<span></span>
</td>
<td class="num">(10,846)<span></span>
</td>
<td class="num">(1,449)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherReconcilingItems', window );">Other permanent items</a></td>
<td class="nump">1,301<span></span>
</td>
<td class="nump">1,362<span></span>
</td>
<td class="nump">1,199<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Equity-based compensation</a></td>
<td class="nump">1,950<span></span>
</td>
<td class="nump">1,604<span></span>
</td>
<td class="nump">1,079<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(7,257)<span></span>
</td>
<td class="nump">44,675<span></span>
</td>
<td class="nump">64,192<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense/(benefit)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_EffectiveIncomeTaxRateReconciliationDeferredStateBlendedRateAdjustmentsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Deferred State Blended Rate Adjustments, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_EffectiveIncomeTaxRateReconciliationDeferredStateBlendedRateAdjustmentsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to deferred tax adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Tax Credit, Orphan Drug, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherReconcilingItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority noncontrolling interest income (loss), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, increase (decrease) in enacted tax rate, prior year income taxes, increase (decrease) in deferred tax asset valuation allowance, and other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherReconcilingItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139842284505472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of the Beginning and Ending Amount of Gross Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Beginning balance</a></td>
<td class="nump">$ 7,376<span></span>
</td>
<td class="nump">$ 7,197<span></span>
</td>
<td class="nump">$ 6,126<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increases for current year tax positions</a></td>
<td class="nump">449<span></span>
</td>
<td class="nump">548<span></span>
</td>
<td class="nump">965<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions', window );">Increases/(decreases) for prior year tax positions</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(369)<span></span>
</td>
<td class="nump">106<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Ending balance</a></td>
<td class="nump">$ 7,821<span></span>
</td>
<td class="nump">$ 7,376<span></span>
</td>
<td class="nump">$ 7,197<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unrecognized Tax Benefits, Increase (Decrease) Resulting From Prior Period Tax Positions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139842288048480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan', window );">Eligible age to participate in plan</a></td>
<td class="text">21 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Percentage of employee contribution to salary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage', window );">Percentage of employee vested contribution</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Defined contribution plan, employer discretionary contribution amount</a></td>
<td class="nump">$ 2.1<span></span>
</td>
<td class="nump">$ 2.3<span></span>
</td>
<td class="nump">$ 1.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage vested of employee's contributions to defined contribution plan</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Refers to minimum eligible age of employee to participate in benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>81
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MDFQ3^8%8%8?,;R$7GR#B$->0(,\>/J:BA9P\O&-)CKO+-#?3<ZV9]F,PDTI
M/?S'E$6Y0L>LH!OG>[FB/KML0.N33*Q9H__K+[CG_&ZR]Y/$7ICM[,QV;.K]
M(?=3:+<*W3^OF,FI/1P[S8\F2]:HFI:Z.TO=:I8&29+2"-VQ%1?*Y,VNHT1J
MRA'/&E736V_GK5?-VX2)D >Z"2+H&8PE=T!IV^A*6YTUOJ;/TYW/4VOJO%0(
M;?,ZE#X4X7=&A=6K7:W9Q*3I8I-):V!-DV<[DV<5VYZ@,')F U]Y9;5KS6DD
MC;75&E;3X/G.X+DU45>)"M4S%&+$T&T:SY@P&;-K. YNNCV,B<F<-;2F.>P4
M@ZM3Q=X=6X1ZJ(""O*6QL7H>$!H/O+O/-U>W(V]Z@D:W7LODU:Y1U^P>2> J
M9D>)SP544:IKZPF:*FB0B OD\311XAG^!^8<L*L/KXR6K4%U+9/",JEB^9X^
MH5$ [32<AW[FVU*9#T@ZO2;NGN,>-O:X]N"Z?@ONP5;2V/H=! &HRY/M!?H$
MWZ'/B;E<[9+GITX'C5D0ZE[<@SP$LAH*0'NC_6. $"Y("-M9YK5]3]]!U;[G
MCXG1NEWNCOL/:Z!LL]5C !(N" G;T>:UU5TSG@B^#A/?7-1VS?'0:/08M(0+
M7,)VRGEM=,*E@IKX=[@J[ZGLBL0YZSI&I\?@)5P $SY 3)E/F.N7&[,+N(X1
MD.Q1=6T5B(3M7/.)ZYYCLN2)#2$.B) N;G;QJ1$A[*%U_16$A.UX<Q\J@",^
M1YB\G;U#4^:G DK2:-*NY/$XAJ%IJJ#?.4$K .8UC5*&WC@M!Z,5=+QR286Y
M-SH&1Y&"HX@=?P!_@S!9H.ES/..1R?H!@?'-[5_&=8-C(!,ID(G8H69;F.CJ
MR5_29,%*^?" T.U@.AS\:71X#$(B!2&12H3TC451\R&!<1(J,)705@,TDC(U
M-]8#FM^9:5'*LT?5=5JP$:G$1E]Y!)Q+13ZI$<;ELP-*M]QH[QCL0PKV(978
M9SOMSF>A69L$,DC--NV*9<5X#/ A!?B02N STB":KS'K)06Z-6[T:5<L\WD,
M[B$%]Y!*W)-54N0!W"VX, XJ!W0&OL]  @2"7,SH]1CD0PKR(79PV7B=QC2*
MT(=4PFMIKK%VG=(E%'M<77\% A$[O6S\7<5,+'23O $%M03,BU<T,1=JS;4B
M>UQ=HP4+$3O!C+SK.S1(@U#!3&2@% -6SZ;;UQ%=&'W:]<H6<.UA-6VZ!>ZX
ME9:-IDL8-6VE>$"FM!3M<77M%=3C5EHHFJ2S*/2AZ#@U=JL;E6ZFHK<CUWV7
MD%;WHKU^8>88@.,6@.-6 IR7;#W5'"W1YU1!!4TTNAH-_B1@V>1#KM;;RZX>
MZ;C$T2M):Y/'O>TN.Y!LEZ'EWN(>=/<SO;(Y9S LFI<##JA.-$#P1.JYS9CZ
M@M^P)/1A"@X_TOI-ZLW8, FS$7@E^-,STHV=9<OA<VC^:LFR_3Q$\TV<F+&,
M1T!-ZE)8\B@ _D)0$BA\E6RQ33:\41Q-J%!H-!KI6+4,Y<M](>-:J]U;W5I7
MT)AK9Z<!9$.09459SW= H+QO. 9^N05^N16WYO;W=:[AH7&\/B!6MF]E#ZOK
ML4 OM^(6W<;C9J>NW*5=[OJ[T>,QD,LMD,NMA%QZ05> Q5$2L"?TD9F',;N4
MXS@8DZ[;Z1I]'@.]W *]W(H[=-=A0A,_!*_373=U)42V\0$SA_S0R@_=6LW'
M!6H"F3WN_]IO[QTDT3"9G:^1R-=;-_F9DMW3W1F>079RI5U\GA\ &E/-HA)%
M; ZA3NL4VIS(S]3D-XJOLF,I,ZX4C[/+):/09>L/X/V<<[6]T3^P.]G4_P]0
M2P,$%     @ <8!G6.U]MT$Y @  N@4  !@   !X;"]W;W)K<VAE971S+W-H
M965T,BYX;6R-5%UOFS 4_2N6)_6I"E])5J6 E#2M%JF=HG;K-$U[<. &K&*;
MV::T_WZV(2R3$M07\+7O.?<<P[UQ*^2+*@$T>F,55PDNM:X7GJ>R$AA1$U$#
M-R=[(1G1)I2%IVH))'<@5GFA[\\]1BC':>SVMC*-1:,KRF$KD6H8(_)]!95H
M$QS@P\8C+4IM-[PTKDD!3Z"_UUMI(F]@R2D#KJC@2,(^P<M@L9K;?)?P3*%5
M1VMDG>R$>+'!)D^P;P5!!9FV#,2\7N$&JLH2&1E_>DX\E+3 X_6!_<YY-UYV
M1,&-J'[07)<)OL(HASUI*OTHVB_0^YE9ODQ4RCU1V^5&IF+6*"U8#S8QH[Q[
MD[?^'HX P=490-@#0J>[*^14KHDF:2Q%BZ3--FQVX:PZM!%'N?TH3UJ:4VIP
M.ETV.=5HP[O/:^XI]K2AM8=>UE.L.HKP#$40H@?!=:G0+<\A_Y_ ,WH&4>%!
MU"H<95Q#-D%1<(E"/XQ&^*+!9.3XHC&30A[;1+^6.Z6E^2E^GW+<\4U/\]E&
M6:B:9)!@TPD*Y"O@].)3,/>O1]1.![73,?9![1V5#&W6I^2-$TS#$16S0<7L
M0RJ^$@:G)(RC;R57&ET05E^CGZ+A!;J_WXZHF@^JYA]2=2^RLW_K.,.W=R6X
MND3/5!:44W)*E'?43PQDX::&0IDQHKO6&G:'P;3L^O%?>C?5'H@MHU %>P/U
M)Y_-O<EN4G2!%K7KSIW0IM?=LC3#%:1-,.=[(?0AL 6&<9W^!5!+ P04
M" !Q@&=8PO*3L+D%  "A%P  &    'AL+W=O<FMS:&5E=',O<VAE970S+GAM
M;*V8;6_;-A#'OPKA%7L G)BDGC/'0&IG:(&V">IT>\W(="Q$$CV2LIM]^IUD
M1[)%2G: O&@C67?'_Y%'_DB.MT(^JQ7G&OW,TEQ=#U9:KZ]&(Q6O>,;4I5CS
M'+XLA<R8AE?Y-%)KR=FB<LK2$<78'V4LR0>3<?7;O9R,1:'3).?W$JDBRYA\
M^<A3L;T>D,'K#]^3IY4N?QA-QFOVQ.=<_UC?2W@;U5$62<9SE8@<2;Z\'MR0
MJRF-2H?*XN^$;]7!,RI3>13BN7SYO+@>X%(13WFLRQ ,_FSXE*=I&0ET_+L/
M.JC;+!T/GU^C_U4E#\D\,L6G(OTG6>C5]2 <H 5?LB+5W\7V$]\GY)7Q8I&J
MZG^TW=OB 8H+I46V=P8%69+O_K*?^XXX<"!NAP/=.]!S'9R]@U,ENE-6I35C
MFDW&4FR1+*TA6OE0]4WE#=DD>3F,<RWA:P)^>C*]^S:_^_)Y=O-P.T,?;[[<
M?)O>HOFGV]N'.;I /^8S]/N'/] 'E.3H824*Q?*%&H\TM%SZC^)]*Q]WK=".
M5F8\OD0.&2**J6-QGY[O3H_=1Y!OG32MDZ95/*<KZ4)*GFO$E.):7=GRV05P
M[0'*N76EUBSFUP.8/(K+#1],?OV%^/A/6W;O%.PH5Z?.U>F+/IDRM4(P:B@N
M'_B_1;)A*21O'<5=J* *52X FPG!./+\\6ASF(_-+ Q#MS8[4NK62MU>I5^9
M?.::/:8<*1X7,M$)MZK<A?$/FZ?0>M12:9JYGNM3NTBO%NGUBKR)8U% [\$2
M%G/H2E!KD^B9$K'C!RV%II7G4]JAT*\5^KT*/^<;&%XA7X8HY]HFSK?T'R4M
M;18CUR-V:4$M+>B5=B_YFB4+Q'\"A11755T*O>(2EKK#*6E3'1B"HLAM5Z9I
M1##Q.V2'M>RP5_:#T"P]0V%H-$X]XCCMNK280?>'V"XRJD5&)_H6T"XUC'HY
MQ]=9)16Z5XFEWC+).ZLA,N60T&V7JL4J\@+/KIG@ACZX5_4=:&8ZR9]0R@'&
M0_3][@>ZZ>SA?;0C&4YH5('-+'"<+K4'K"3]:JM2S6'W<;H8]J&.2M$)#:4V
MJR#L$-KPC?0B95^Q/>*H93A#EX1M>1:[$+M^E\ &2L0YB\!IPAZ3M%KIK1@F
MO7![*X??*]IQT@W?2#_@:G:LV4L7.(A)+=]UG?:X6-@61E''J#1L(R?A)@O>
MNSX?#)A5OHDTZE)C";29@?ZNLFK01_K9-^-+#CH70&> 8&'O89-LE/A>FW\6
M,Q#8I; A(.E'X)=RF3O9BR;&G.!@L=TK-*W<@/H="AO8D;?0[I12$V:>#YO!
MME33S U]TL%ETC"/]$.O/=X5Y)!8UO+70I:G1:MT$VE>1,VI9C-SNVA-&_+1
M?O(9A? 6[=0$G(-)U*:+W0QWE AM.$C?RL$394)-S%&O720GC(ZU'ASUSD'A
M*7TFYV"W&^+VE+/9P?[#Z]A9T(:'M)^'<RWBYY5(%URJWZH=G'ZQGTO?%8CO
M%>TXZP:(M!^(4Y%E4$2J3'Z(\"4F@$:)X(!:<'1Q@0CUAACC\A]2*]C$ I$*
MO1(R^8\OALBG0QS@H4^#"E0^&0:8#%T_>#46A58:/I7[2Z;1#(YLV2.7NPQ>
MKR,J7^LG.H1U1:UY==.4OEB'PX)KXRAE,R)!1\DTL*8G8+U8).7Z -5='JHN
M$IB-;)U M5N%6DZDU',##[?%V@P=#T==-=[ F?;#&78715:D3/-Z4R$RJ*M5
M>2FX@;50*/OD-$E\8:QT%ILNP0VK:3^K#P4O^#*)$^L!BIH<OB $T\"C;94V
M2QPY?M1Q=4(;:M-SJ*TLRXA5LLECXE&?M.%GLW,I/K [EMN F_:#VUB5=V?5
M<^5'Q@64]?ABL[,=7T8']Z?EY?57)I^27,&9= F.^#* .2%W]\&[%RW6U97J
MH]!:9-7CBC.071K ]Z40^O6EO*6M;^4G_P-02P,$%     @ <8!G6#8KH1B5
M @  J@8  !@   !X;"]W;W)K<VAE971S+W-H965T-"YX;6RM55UOFS 4_2L6
MFZ96ZL)7/JJ.("4D52MU;=1TV\.T!P=N@A5C,]M)NOWZV8:@I*-K*XT'\+V^
MY_@<8R[1CHNUS $4>BPHDT,G5ZJ\<%V9YE!@V>$E,#VSY*+ 2H=BY<I2 ,XL
MJ*!NX'E]M\"$.7%D<S,11WRC*&$P$TANB@*+7V.@?#=T?&>?N">K7)F$&T<E
M7L$<U)=R)G3D-BP9*8!)PAD2L!PZ(_\BZ9EZ6_"5P$X>C)%QLN!\;8+K;.AX
M1A!02)5AP/JQA00H-41:QL^:TVF6-,##\9[]TGK77A980L+I-Y*I?.B<.RB#
M)=Y0=<]W5U#[L0)33J6]HUU5VQLX*-U(Q8L:K!44A%5/_%COPP' [SX#"&I
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MMQL6KUA1-^"_K_.\^OZA?G[_^"\DL_\ 4$L#!!0    ( '& 9UB0SADBOP@
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M.6U@Z^S4CQ/3!J"B/C:=V"H2)F-F2&^&.,W<R VO4=4-CN0EC'G$7MW$7#>
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M6TYLK)C&H3E@@"JAH6_Z &+1*!ZIAZ1G%.)FE)2ON1J6E4K:*M_MP(E';*C
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MB7H'AX/K\9YB'WU @E1SG HWS9*;X,@^=;Y\???Z]UN!(OO\_!5JDFK@K$B
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M(*^-17HG'6JU3))0J5$T,(#G4KB29<**@ZK I*;KJ-J.8<PD4:*!QN&#AN%
M,&,^+>Y73&D^+PH*T9#<11,YY7HA&V!MTIFR0.M?8MF@WNPY1SV@;T6R,K(I
M:K)WB#&,)!==YSE@T(SE&6"W,J^8+Q *3L-E"\JH5*I[?R<:1B@4W.MT5.NE
M4:V#*:!A/5M*N9[-L\"%I@B?4P+,"P19 NWJLGR/05K6@!WO92U3VY@SRAEJ
MYM9T\7 0;+F6VG#$FHYA'.H5NY@RI;>-.L-8TB!!VB$254'%%"_!%AURD?=Q
M 0Y!G2JV>TG9G;GGP=T$88>P4+H^.NBS3%BI.091IW#/CP:89>9+ZF:ZH#Q
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M2N;)GKF;HAZ8_6'V &@N@# .6N\"/F$&P3K\+5L0RSAQGFV*JLMP,)=L5]7
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MDZS<6B-,%>)AU_8C*1_-/EX4W:\H0/-M!HG(2O#]>D!!3::D;)\N"ZP]]/W
MU(-9V6LAH:HV%Q(%;%%B6EH+%W"[KH+COB\.O%=DS1%4''L"@LO)JKTAEP7-
M48RT)>OVB>6G/)=XT"#PFG8'_*U@P9Z@8=OSLZ48N^*6;(8>78CY&4ZS/[9F
M=V\++_*4U21 ]A[0N%L!"!HHPMG@[T6>%:D3M2799Q<M4P*Z6J*AE,@"\7Q
MM?MGDO'PU(> U>^-.C D\#N_H#*,;BF7S+!\7N'F<W1C+L*6LA!JUL%(4:^-
M:0FMCT-DG@52?."0Q,#1LU4=S?M*IOT^1(MNG+C,@$2XB/N/UZQ7LW)E,7AS
MG]^":#A!U9$UJ+!'/!9@1&[O$$F=NOUHA,0KQF#:@;<! RWZZ4@I<6M-).P*
M":) #?ZVA3_9T8?+J[?'\W>\:]=1G1U=7KT[SEY<G.66@CY:.!#B]\&-]O0(
M/G$,PI8_22C(6I4Y>CFP-14(1Z1HL\A@@A!FYOUPQ<0ZM2C5MY?H ^QT@6%<
MX^5[B3<M()6W2,&.D'3D'"!Z_SH4*@7!YZV,4*R:_8"TWR:.8PXV0]0/:DH$
MA6VM80OZPK+9_!ZM6OTD8WPW8<T\-T7N).;3HB1B\=HYY*G>7;=HU+_,4)%?
M/'\E5N,Y?3\_?\5;SW-58YN=3:*A*=8_@_R%:W\=6OPCMCP';X#38NBNTLR&
MB(FQP;\4>DFAN_@5T/'6B)@'B)JPP@5@U[ ))84_T12+WU88(,=%8""(QBQA
M, T!IX-MC..RL)U33, STU'N0PV. S25C(1&;RV1W@!H4?O6!*PQ<*/4R1J?
MJ+(31"$$''5<NQK]7XPU%#X:HET(6ATJ!YX*2*P;Q2).AT39=EU+%B'O1\2@
M>N-@*Q7CO7WRH+V5A85-&QHS.LO1?@) ,NM/05Y[I\.!J]76N QOD@HXFA]6
M/XO<CS$Z9CV*Y\'@A1B$B#7<,A ,NA!W>GV:AP6PI&>7&]!,GB3QC[IX1;#>
MQ0!A0J@YU$*>HO=M6=&R),1R#: UJF\/2Q9=5.L+Q"3K1"B65(_8>JJAR-K#
M^\/^<#;$K*ZF?2TTT(]F-(LK,OAWF2O@:D0>FD[M&I=@=IW)\\[8\NP>%00;
M.6UA2TL717;@ ;L[(\$,IC1&5I #Y*&Z<M:/G>@,PC\\<XO_-"VG9#;H#FG<
M@7""+HO&DF79/A/# _,\'\;;-:_YYK>$YBZ\R'Q0S00L&-NP)'_\<D&EX\A3
MB_3'M@<@5&ZJ#+XDH%YBUG0<8/M-]LUY_OSY,_N!N.'B%4;,LA\[FO)@W6V8
M[?SK;\)M\C5&STY\B)[%%)+/GC[+SYX^"8_)UW=IX,Q,\^PB?W[Q=;A?OO(*
M[T;S47$,R[@ >^C9^5.[LO.+%_F+I]_\"I1>_#TH?7J>/WO^U'[01=R#I.S)
M1?[B_#RBEK\NX^C\:T#*\W"_?'T0CE:(HV\N\K.S<POIL[/\Z9.O"84/&6:6
M"D,<Q40K03'_YIOSTZ^S'<I'$A&:(/++3@I=_ ULV^F+V0?G8X82ODM<^U-:
M\=^YI(O%)3U]?OKL[UG2TV<+S_V:%;UKX0M&;-10?0>KJ?KL<^6_&)ED/4/2
MP_L60R85>51!D:2"NK1#<Y:+Q^YP;/4O):E( XFOF3_4T51W;^P8IBH1ZW]Z
M"L!5O4'J4JI@/BL0K8^-6XLG";_CWI]F?]E6=< L!9-;7\5H$=D<9JAVTV..
M_I?2P2T?>#B@%WH(_?2AHQU2EL6-P7Q^/\K988@ +9\8@$"'X&!"GIJL"RA"
MU5V,@D"_LTD4V->Z*@\R7Y)=P1V5+&5_V'-Z;RQ+[DR7Y$FN1"+@!BT2_-09
M3ZX[M+:49BCKST_MZZ*DJ"#&^R0*0UG_WM)%0GX$$D#-LR*4G40:$#$@.HLN
MA($U3E5&_ /F%\@"Q[,9(5T=( >39@J^!FK&F(\YU)K#<& 17H.W9E)J$1R-
MN;88^?IX^?GWW_WQ/RXIT)R&2VT8UHN[Z1T:*QG@-+(*9K$QA#I):X4DZX^I
M'RE>G8@Q]BM&""0V"1$58++.L2-V?O85F> D/779 %03G6:UBM 10V]U_3+[
M=[B#2[1F= 1)5?CG')BF/(!J>_;DJ^SB^5=PQU?9Q_+?'%C.3?8)[,]=D?VV
MV.U?96^KMFZOL<"&LJ)ZSU4((K]#"GBOD62DG!]^>)<=Z9W'H/^_ROX5_KN\
M>I_]P<$SVY*\7ACN3QB@;:\/V=6PWX-\.()[CFGA^,"GKL6P(@Z)EYX^P<O_
M4539#\4JE $=R85C^.W\&:P$[OS^Y"/< 9#OMT4'*SFB"\<TZ/ES'.62HV1@
M"%*,.>!;:V<8L1&O_Q,;.Q<JMOE>LZD+.RF;>/$,EP3[ /P"I,(XSO'7[/P%
M_A1V318/&W'^S"*3M\C@^U^S%T_QTEO1?1-$%:&2*X45O7\I7  A[Y*47JP0
MX& XW42J_0:%!!KW[2JXJ!Q+]AI #E'GE6O<INICJH59&!$:N+I$V<&Y1JU%
MH+12J@[*8E_U](,?Y5XP)PP^ ;@VDG*";6U(@_$,0'=$*!T5+X"GTZU/<-L/
M2\F<MKLN&LE&^6,.%0B:3K'2#D=KA1 H+(,+KSK0]@$_8;T?WE\B_P>: %(X
M&]6F<!QW34%O7@N0*N9N8WF/^'T13'+[@HRD2+R(0(J9<?D523L9?A37A2G0
MJVO86O$3+YR#?'&4^0WCA0R-*$[TYBDJR=5-4ZJ!/Z63Y"?E<XKR"ZL2S@,H
M0RMJ*#@Y'08U<S=<1SA E%\-*P\6E80=$.N15N]$_\K!9D?JTOT,N'T O03J
MX.VS7%5)T2#N+ZZFN T%+:#D,&MX4C4G@I=<RS8PFHQZ%[1%J&K (#]>F(M$
M4HBN&!N&$M!70P<!,A4'(!L!'Y1YP31(%\IUUB:W2Z//E$^$ (EFUCB3,IHJ
M% 0&SV"G,C20=<"&$,6]R"84YQPG(*8#!.;R"6G/I.P46LG+<G:2:B"5IIE0
M2\JQQ0AX%#5KL[<2WYB-\.12*Z/YS'5[VV3,W+RQ[<JW-1:" J*'!O=*=%+<
M%^;QRF[$>!-22P*_21@*&1K66G4[*?A@<:0Y?93T5QCS(? (.HR#;JG&"AZ&
M59<@<7+)!4M.ST2%=(-30VQ<^I!6/J"HQ&_](:=ZK7VH*;H"#^$6IXHWN.0&
MKS>D94 (Q6GVTYY,_[Z2D(30?IX *O[KNO*!]U3H&*]AV U2/HF*'^6?!(Z3
M>@1&RJX-!F52(DT^&I668#4<U>6B#R&U&20 R$9F+52"C7/-E&\Q]=GAYFFE
M+>7K29.S.D  HI:(ZN$4O:H(]Z20HNBXJF3HTY(/8"OLF#C!2G0M]$ 6&.55
M(AV"WL 4?@TVM7]); 5#=F;3GF0'T#X^[JQ>^#!T347ZZOQ,+OV@5CY7";6;
M304KC6,]T_M<X1U5#@%IH['#3L,5IB-9<M6.JNLP,XELI4!N7/9]9 8L'FJ;
MZY,?R"'@H%2:P"2)())L*@Q0IF'QRDE- PAA+20M$4ZJT283!V.I3YZ#OHET
M#M:ZT'ADB2.Y3Q*-\,D&AX'NI].3E83U $B2&%"/Z\5B"8>;*5E^)KKFFODU
MK4A60Y"GZ1<RTRPT40X?I' SH@EUSN<)SEB_I$ C)X1P$N48J.(?S(]8QSTS
M._$:/8]Q?+8NAT:3"J*L*.BQH="P+6I8:5Z\CTX[CZ4)6:ZA!X6]B7.SI.7P
M!1.%'W8(2C)MG#(U)WHTHT?JT8:W-V(RK5U7\U(M')=88A7W4NUA*D F;93B
ML(]E1? MZH([\4A3)>N+C#Z%- 6/J8_!2F2KK2$:&QBS$'5)NIO<%19V,+AW
M=7V:?1!CD*6!FW>26?%RB8G=!I-A4]HV.0Q&<6"G4_!/E7I'%C?5T6%^FRFO
M:P_@KFD(I@N924DDJJU]AWBIW0U)@%BQ4*).!A-("J]1!#S]&H3&>PP^'<G7
MXS0MI;X.T=(>E!*&MJ22* U^D%220N1.5?XJZ"^1'U3!NNJYRV3CR/>0\CPN
M'96Z'*9F#;N,ZL._EZW6]8"X$>B9;OMTBY+"$8GR,$URX9LZBBB .]17/GI=
M+MV0@RY>JC=C/0.7NWM301SUH*.:)QPL;.!8&;)N$4[H.A2CW"OT(U6CS1#-
MA% JDP:C99(DB?!@M,[H^O;> CQT+T;TUFIYW ,!,A+E3G100F6,$U*P2SB)
MWGI=#K7DU1>'9HEU6X'CJPCA[1;P8XTXKN1OKFLC&-@XA(%UMI.5^&/"]:'H
M&)N%$V9&V<9E?@LUSUIG;;HS9@3&2#$%+KT/K[F1ZS/NEZD-X;"', XPT\]:
MPL<!&OG9=J(1HYE*@DRZQ:S3:>K)M*B!,\<3'PL0C\4=]4CFA85''FV"?$6P
MFGX6K<OHM.R.;C&X2601=B;LM4?["./*9IANI.UZ["*\IG)K=(["H"BMQ"VM
M#Z$KI5\:.!5K3,U4!'$G6[$"$3X,U$=U^VA:3,B0'%[8U5"T)X[N'_6)Q/0G
M)M_4C'A;ZZ+#S17Z_LH:=G'%C'6YH!IR$O'NEV*WKQU+:/:6.*RTLX5Z@2XJ
M3]HQI@M2-'?N)&WJ$A5!+L6H\R31-+1J GG)B#>%D49-7P_5FOLE/T\;PR9-
M!K2K,?\15?N/[;XJL^=GS_,P#G'ANY#0(#C>20UP)G6(\, QUT%3DD]_;5><
M^:-825N+B[ZKO(:/R#MVW4U5<K<;6?-L@DG$FXC$!V*([1U1[$@)D,9XC1:N
M*,_'V&3D8FA],C.("FN]S'36L142I9Z&N1J=W(@\Y'G;>5$"I:J[18@U,(?0
M3^K:;A!XW[L]N+-'U;$&2@Z*!MJ*(W^L)4F*\%=P]_AVTTN;4%[D,!J-'H5G
MT]HBT^#,E7)XV\UQ[."=O4FYY,%3(Q<<W1PG H?W@&CJB$S 8XLX#T/Y#2G(
MA6FFG35"]$6D>^.@B&:;68N::++DH!L,'\Y#, 5^X3X87=>SQIH V]T1.S!-
M9M*NC&I//#= U0!PXU.Y% .R=Q(EBP )B+(SS:.YQ+KE*'ZNP?<\B?F/>ZG9
M6IJ$Y2666'7K3-);O%=(>)H)\F[$;H>]*&^MJU232G;#Q.2I"K?C'-FX&O>E
M5'UCQ0$7L:M_HJO=..=?P4JKW6KH? @<AIYI-(-?&1%']<<@9G#1X7&3F\B3
M'$&"(2P? :6'\*IR9UZ(9AD,C49Y\#8$RK5B=63FX+91]2E1!1.%S9-(J[R)
M5XL,G.2]28[;G#=[O!1>-CNC8II;;:LF-(.GZC!$>KF_=4$PJ%V'J]!M+L+&
M]"V9"=2',7"VAJ)6M*@O37M[LFUO\^5,$Q7N2H<$L7D53W\)=0N/D7#F$,0]
MZ1AY[J8EF!.IP;IL+8TT6%8 2!AYPJ,T6[ #4Z&$]0<484^UGP0QL G%!>$5
M4A*N(HDQ])6DC!)#5P(HR"&^YZ:E@\[(WE3^8+>:+4,45,*'"L/(WVH;"NN"
M\#\"4WV )X\3:]??L5:R?K4QW&9V6;(E%<1(?ITOQ-1@4[@^6(\R:!8TA#%>
M2+F%4TXPV]+4:AF@$*8(Z\)TL&EMB^W<)A0B"8/0Z01[5\F))M,./S:8N,:;
M9A.3%.EJ<<6R-B)5.85#9&E(*XT8,P+*/EYH8&-)@>8/<B'G5[7H;'[.'].N
M>@FZG8BSM9[/3+$VIFCR&@]**-W8"9HHY,J;II9U;)FDA,Q822^9((38>&*+
MS43].&L&P*SF> X[#:TKM,DNJ'BI&Q9>H7HD[#EU%$R4TSU*-Y<=W*&G)G)L
M>E2"X"Z484]ET^)<E1%GXDBH!^*M/AA9QW>-F<\2LP7:BG:T;"4KL3+1>78:
MJ"."7'\R9T+A@M;43'/]9/I&\@.M2T4L+/S$E]9H2I"%(:@;,#RQ81:F(YNU
M2N>,D0 3\N>.VL [:8Z2=*U8DH%FQY.=2MO8%.%25 \/"MW1 !4Z+5@ERV2J
MN384=L.>?>EBT\NA'J0P8$O<?FHUA\,PHC:60CS*=&M#.&IF<_S''-.2&!M/
M!D8G142J/E%_>*]86TOL&X3WRD7360U<Q!)&Y4^E,LL4W.UC=<S4QTNRRQ1R
MEE!S$'$ZWC18IMK%.!?&W#Z_P'I7/._,MH7-GF= ,:WD? >-WY'@Y&34&#+U
MJ)"-:>=X?^Z(T>I*M(+U?VTU8]!S#3J/EHE)CU)Z4B>U7U)'F=J&O9^W#['P
MU?KG-CG!':.QZ&C.O(2Q3>I*[7ZB0%(@XAYA5</0$,T7]<)01^:.[S\=J[V+
MI<16I1OQ&A^H<"48M#CL5E@EO#1%^!TFD/$#&Q.\#YGI-(W^)&"/(O1BB>[;
MJB'K!/A8W'83]<$[UA0R*Z.GA<U,TJW318VM&!Z!8)8U B"&W$NJWA+#(O4+
M@S*:QUK(#AF">OC3:<M<2#_R:D.:2[O]*/Y%\:?%^$BP1@)CVX![&F><!/-H
MPB4O%]W3J96DJS8G&3QDB[1E*PURA%\Q:$)F>HM:BFZ>U%O*1&2QQO/?E$4+
M1=<RM@CY]^!ZR>152UP[+B6JDX8X&.>I3S@V$AB2LMC']KXVH2<7+ ^IBDMJ
M$4QU(W43]%6,@(O1*;80U=XSLL2Y7%J;E7(!".X6-5L0$4QE&B)"*9>]'SK,
MGY/@CT63H$?WIC1M)Y::C)(GTR:)>ITG.>U'?$NL.%,=/C>2.$Z\J4#DZ[93
M.X%<(RIK$4]J!B:A4GJ:/4BUUNL8F>!"1:6?R2@<_1!$FI@:4,&*N)X,N;O(
MCIUQ>-::ZDSR,ZHHC+M ]8OI]OL>M+%&$9THL)%_>_+QK!@'S-%Q(N$^7I+M
M.-7TZT8J/P1GX#UX3F@('7GV%5E:X4W6;UPX$45J221MP$,N>)$":.-0!11X
MT!WGN*8#&;38(HD9@Y!!FP$B5V[NW.H0^B8(2:QP=; 8*(CZBJL83?=O-'VI
M;SK$$-@#/V@V**@YH/DN%DHOA[NHWW@2#Y9*RT*'90XBPZ (:46J0"D#?\9H
ME V<CP^MP@0;.S^"$=3@*DS?IY!AF.UC(E*O8BXF2@MO3ON;>)4Q8&F=RD5\
M+ ;V1&$OG8Z$2%BY;5%O(F^&UHR#&@[>Q?%&AUG]7]D#\^F,L>Y/ (]&1)0,
MH;9@U$@_QYS!?K K&:$S&*,EY<5C_1[GLO#T!"H%H$")V@UV #J;!Q-O,$/)
M=<ID@I,7+$D!TWH3X$#7"&N<U[$/[]Z]0SC_?^_?O0(_V#4LYY9@)*%DDE!J
MQ/UI+S7 WW.II0G]HWW/Z=TT&;)XN*G54W(KS1O$CKA2V@O28^DWG>B4&I84
ML.*XEYI!\/ DK4M4L,'#5U2[:8%D+ 8;03[#N['IJA@!RLM,KXV=H^0(O:4=
MFHOE+Y8N*0$L$8AI6@CXM.5!]P8ADW.21T?RV5!>#+#%P(]T/X1#-3HN0 $#
MH#^13)F5R2A@L,H[GXL#]J[<\J&TK*=#$@W,]:1-QSX7*X431SVDYR+IQ1A(
MPE+C30Z1L_FP"%9?U+EN(6B>NJ*S/N,\%*^6Z=>!\%)Z<[M$ULP2VD'J[.5D
MXL(OL_*]]/0QY!T_2=X1L-%+#$2#<_#@?+8O],O8K9RF,A\B!<)3?ES,%9(\
M ,;*\2%K6VSXX]3$;+J,L3<^O'G*(K&H<#$#1AOUL'036XV2$.%S@4-:*1_[
M=Q%-X;2=>^&U^Q6*P(('@G,EK3!)T"48,:DG&$\9FFE@\WD8^&$;0DR0<7%-
M&$3#J11X73PE9\8#]V7%ZK+,P[G4-HF>&]<[-_41W"G(ATQBSF3%5@Q5"9/&
MV,IYSGQD9E72$8IQ0RJ3,ZN\29GI$3.5CWE 1$1PY.0LH\GA-JG3^8_046!/
M1RTIDG.*/873AJ_4J$C]JI&@%<R$1LJZMGQI/)60[>SO<KAL*D#)4$^)G*%M
M["G@[0\G,_DT%$^Y,VF&0L4%LKK<G@Q[/4E=RG0)8W)09'HD?=$U='I!VIZ&
M2PU3@J^B-1?LZD^+O=3#H,2-O \@%FK$BE3QRD+]H&JB$XY<B (&5&XK3C>A
MF1(CS";T)HJ!Q1IOG%NW>$03$EWO=FEL.@+#QMZ]D4+MA"BD80D3<L&$5X-1
M2D]8F@&DE&:;-?33\(2\:J*5X$(=1)(6R:(=3\G7J'_#)1.BZ)A;^:B3:* F
M)A&8?X>_2:&E.1RW;4;;& (NRIE,>/8>X>7L9PJ$Q!=>F#*1Q%/4!OW;;<NE
MV&V_U=/F6,Q4^\(< IV6F\1'W"_<K8+])58P</LS&4"W=&[D)'IFZHG4,M*2
MX3B9NOUVJ2:??4=UV(NS%_FH)NW2CG(D-QWK02SR/9Q&F9Y6G$! QXEP\,Z'
M"E9<ES1WQ-;->$8HACS+Y.CQW![$2(=/FH+ZR0YS.DB=4/ ?R'--\H 8>#&'
M2H$@Z^FX6]521^?'B9P?Q\0&&,@<RL ]^]G11<)=<;[0D4*^D%-] S2F\;8X
MCDG0)U3KM>8G<=>!+_! #.SF[,W1NSA0C7-*R+&CF\V;1O@4FO""K+GCHF?;
M9&*1G'T1#1-IPI4:NXEFC%3ZRA&PA81Y3X(9GTC-(S[FSX2W(C*.(PJDN/$.
M@./1Z0)N1%\6WSF19PRWN")R=I*C%_? OM>4VEQ$'X;!3#&ACQ$$"21)0WE
MQ42!) R4("(4A2=#Y71(CBO6J0)*'HW47+8G2V5RXXPX(@5+$T3$WWNH@UIT
M-KH2I*?HV1"7(0X>O!??8T3T27:KO+=$%E\CX;(_MC#L-Z&4G5J^[6GKF'I.
M#%-J0UASW63!QS"A9S904Q\U$AJF(^3/'X"NTOZGA@:XZK7L-=SDPA$.6CF5
M2L;4&Y*C9],B_' 0=] D"]6]*0.@DL5&^UY3M'%$,BNEIRV.'FNET&AMKNM%
MM7_">0ELJ^U"A2H?/VY21X8BN0#I1%UY?T=,BF6G#"XG L08@*%Q\CB"H8L@
M\/H7=BI:T50GB*&0V7BS5N7@^R+BP4.BO3H?:2O49)CSQZ7&@81%R2%+?@D<
MBZ'Y.D/[^I_PD@%+[7K6.6IW8.GP/JLM_%/'HV<H"Z.$O^6N;K'H8D%,&@T+
M)5@C=Y)C;$IN87E2%TUV!W(61_[#\OZLRWMGES=*\(_.;K"'M[.9&NN@TS"5
M1B,>4$IZ2KL:-=-"?>>TV#R@/P]P=@Z49\,7B 3D\(1547X9O1AB?$Q9!S?1
MJ3!_GI^_LK54:8W-J(A7LF\SG4+"^G+.FZ"(1+[ZW*:T2,7 (!H.[:Z!8@)2
M7Z@R5=_&@>76C;;F22<_L2(,MZ9.GC704D=O;RER]7)<6=#1U8'.5L-!:39T
M2)*QU>A;#>ZK@];NC/N#/I@D2BMVY32ZR;,C0@-KH#Y,&@)_735R-4ZD,;L%
MEW:4?:3.U_B>*RV<2TN6N10X2;F9N/W[A/@DNY9]<&ZF8T#SYU'D$PE%^HW.
M+= ?ONP19:4<?#)JYO&JS@SUWV%%F)QBZITG.8MYR<J(FE9#>*LI;6Y0M5[H
M>4BTN:1SK<^\Q]=G4<D,1C\B=L#74YP%VT;-*?&72;'%;&XNG!#VLEBC\^#U
M@$21%_'<N]@55^@)X--&V]%;TJ)A*F=IXA$&PJ0SIR1MTQ=#T0+"<D+)I"3+
M0DAPF@@;:TH]E" 8 %*=E]@K.>?/@Y/C36PSUF4_@&SF7G(T<](/$=!GEMFG
MK(@,IH*\VN/FC"N9\1 8+9%?L")2K:")ESV8*$/!D>FIR25Y\!B@P4=#9^1>
MWJHZ"ITNM(G81BNF0'G;SH&K#V1H/,Y]O!,A@8])U:!V8G<Z:?M_,LO:)<67
MH,;%C91LZ"&775JYIMPB87-.*KM%HZWPX:5.L84\'$(6_1T\ 4>61G8^9SWT
M&*U8^:/ODK!<B443C:MSM(/+M PB+;*D5Y3>-F$!]C4U9O&_&YDMXW7+_H67
M/NB;Q%CH1V=5WW@XGBP734W]S5KR'ANB.7\9"LOR^%(",1*(==BZ>3>R;M['
MUU[9GRCGZMS8 EJPFDUVE;1K(#_K!L2CJ\3YB\8*QKZJ>$(N&>]6[-!K1,A[
MF)V]Z+6,GD^#H0YZ#L+Z\),Y$RM5 >%]%?%-BM'GF(A'TE-$@V5!Q6%Q,)XA
MH28M8(COG SGV=]*BI/4TZ0A0ATBQ!A%X-.F#Z'WN_'")"H>"@=VS ZG_3?!
MYRQV1A 4?2(-9J5 ;C:V:L8B9B1 +)$E'3\QB&E4F4S/E6THKD@E/63M*"&3
M%UREM2=Q-CK%6 ]/D[>0D( 1V$0M@8&&[Y]W[DL,A<GP05^"T)@<,&#:624<
M1.<G6DZSKX@2*)*$:VR')U@)1(Q,ALXA%'1W23E$XWRYG6O,)H\G)"L5^S+H
MK8KW\V"S3LB+ZSH#;Y T+>L"MA(H9C7THW3)^#CN QWE1>=@%X*74_M>T,_J
M>UD55"5IKE"]( J:W;5$)+%Q3O9&]M'AN2+5FLN@BAV>#DV70D>T<:Y&7;:I
MLY4TJ,7SOO6,<C+D:4IJ@E?;P)M@PM@KGW+F/Y<I#1(#.4?+(0:KQ>-5FN6#
MDYJ;-C4U2=+@5FO3% 4G@'ZZ/HU#<></R,(]XEW>VB).2J,#)R2AUB1-E*=*
M5Z?4TS?$*99Y\U&]@>GQXN<(+"5Z>D6-#;@(T#[:LY,B$B9KK1S=\5GY=[/E
M.!4\?:5+< 0?[(<MO&U0G+L[6HF2%RH^*#R2CU_C*QE\H1+B"O'1V):80)Z\
MC;0H7S_NW[Q^7'GXIX3_N_86_B4 WX/;]>8U(.+:O0--Z#E2_NVC\T?F*F8?
MOGUT>?[R\N+18W@RWO[F]1X\N(\ .>Y*[3;PZ-GIU\\>L8FO7_IVCT-B*@^P
M3A]!V,&J\0;X?=.VO7[!"?!D70+OS7\#4$L#!!0    ( '& 9UB2-W4ZX@0
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MP@;,D'%9H.;(L0#>+ZT-VPT;Z'X&S/\%4$L#!!0    ( '& 9UCO0=+O[ ,
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M/((W[)T;>KSA_SD'5]QD0IE:(_R]6!FKJ1K^.>1R S@Z#.ANR(6I6(:S@*Z
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M(M=P,LT\4(/D#PLC.R>S&VE(M-VTIE<2E070_Y64YK"P <9W=_4?4$L#!!0
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M6HA2Q1P+$K!?_!-\#]P#-U1BFX-\%8D%G"D47I$ HNA)KD^2O2=+1(!4A!&
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MU@IIUH:\=Q!4"( ^AE>'AQABU@73,@\,R&I': 0BT4##4E6DF,F<(8D,O &
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MRJX/HS+Z%]*_ &-#B84(32I(*6(L*S8\1+P2<R^8C_ 9(+GG8[H(O"B:8:X
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MIZ%S!5FRPF+E2'RH68ASY$L2PA/TVIB2,"$,9'4B=,(:U"'4A %30)%2N5\
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M/7/9-E *M'NJ%Y[__/%O%X=%0VL@T:VYT^#@E($OBFD\BD&&JPJ^'HF/S!.
MN)CL(KR>C";=6[#IJB*<U98+[5:BTAK7%MB\#R9>I7$V@2!KFM6:;J8CB(KS
M@2QH0DL$>M%3';$USC]T UK7P_+'&D@]76LR(J!<FSG/>(SR-+1R=L:+RWR4
M[^WCXOAOK$SS@95Y%FJ'P+Y>H)1#P;34"VW*6#)1 3<W;.P (N;PP%+[8U"_
M,TU5MM7*Y ](==_!^8%QE J--T!.$DD.[>11>G0(>;(Z3Q85%P5G]5?R?!EX
MF#MP+A3>J\$JO* N?$E]%5?I)$KR2[[,4]"?R45+Y@(3/N<\7O826[=0(R\R
M[OG9;$)W:32+BXOC++/\-[9Z&Z:]*'*$*(MG(I\.:$>H&2 F&\I:#F<ET2Q/
M^B+M_GL".:2"YZ!CQ0P:Y=&DN"3-XB@E[O 4=TS!7G(>-LL+)B@Y^2/P-&I*
MD@B[@'LWI$@6)_1;I/A-+B];WO?G8[PON@3932*4&7[CZ:6X@0*K-H>/4+@6
M"UM@:['IP]Z/3*B<&I_W03C&<O97UT\D_KYDJ(J)H]%E2' ,63$U:^J>(I7#
M@G#_GWS==YIYVTQ>".32M.#_Y)+:1!$E:4$.L$0Y'6_3%@WR!7I2\0<68%S;
MH! V,<E![HO)?M+XO%3MY04+"&3DR/3SG+@SI4R"K<W[X)6A<C-N'H=*/M$E
MNAUG&G4^]\:C>IYQ;?2P%TQ'LQX+220>#,"186@I;\'-YABM@; +_V!7J4#8
M^&AH6)!47Q$!V#:\(\2^KBB*JW4TY#K#W:DG?E:'1&(8I %/DZN@W9/\:L")
MH^.[YU;"/,"W+6D@[]\116C_N[(FH&@P^P"4=]JO6Y[T!USQD#4V6-UZ"0&#
M@5VB]/N3T,OF2M6]@N2V(QX)VXGVL("3@6'96SUO '0';324(3C?_W*^\;C5
MDJL'R4:/=8U(HN4)*@95RXIW6E95W ';P)]T@1NFR)*<[QJ@<.\A?2CN26,/
MR"]I>D^'*>30CG<?1$:41@6+" @7!,D/:NE8N*#!X 0&*=CAP3!):G6'R.Q4
M!44V?.3W,">XK?_PB.4-,TF!^<,W2VLVB 9 OXNI571^3&R0U5%WLB^D@2/9
M,\S\ 1E-W;A#@UJ.%/'BC]=X1M!C-DJ;I0^4"L@ =-)P ')C2O2A#Y]O+@X.
M/S@7H<-#QD4M!1NU):2('V7=T!:QI>HA%>E@\J9!F$CI'\W<B>L%]QCFD-CV
MLB.H/C#8;+N M2#/P:)-!Y7U\:.BMB6&!:Q"+Z;#!NBZE?>T629A<JL](PT/
M0H%93S=8<A-V6DO"A& ;=8C]8F'+1>4!U]$G @Y)H'D'?(L$)Y,_+,/ )=C,
M'Q&T;:QKZ*00BB,,PRCL(1IAJE=8@5MQ=S 0CF96VE4#B.Y <0NHI5 Q..$5
MS>O<TL+NWC7A0>M,\G*$2NLVRQTLM!V ]NW],2KS=,9K6H_L1 H29.^TH[HJ
M481\!-+Q[WZ%3OIP)JZQU2;4UW3\08;HMJO#@?:I?=="NG4+NB$G^!"'GRZ9
ML$#Y=I,>=M?'CK7'@T\.&V57_&&%? UL#E\?^J?]MYOK\,EB/SQ\^/E)6I2+
M0VR6F!J/II,S8</'E'#CS98_8,R-]V;#EVLE818-P/NE,;Z[H07Z+UI7_P%0
M2P,$%     @ <8!G6#_=B6'  @  !@8  !D   !X;"]W;W)K<VAE971S+W-H
M965T,3DN>&ULG91M;],P$,>_RBD(-*2J2=-N3*.MM'8#]F)2U6GP O'"22Z)
MF1^"[:SKM^?LI*%(VX1XD_CA_K^[LWTWWVGS8&M$!T]2*+N(:N>:BSBV>8V2
MV;%N4-%.J8UDCJ:FBFUCD!5!)$6<)LE9+!E7T7(>UC9F.=>M$USAQH!MI61F
MOT*A=XMH$AT6MKRJG5^(E_.&57B'[K[9&)K% Z7@$I7E6H'!<A%=3BY6,V\?
M#+YRW-FC,?A,,JT?_.2F6$2)#P@%YLX3&/T><8U">!"%\:MG1H-++SP>'^B?
M0NZ42\8LKK7XQ@M7+Z+S" HL62O<5N^^8)_/J>?E6MCPA5UG.R6/>6N=EKV8
MYI*K[L^>^G,X$IPG+PC27I"&N#M'(<HKYMAR;O0.C+<FFA^$5(.:@N/*7\J=
M,[3+2>>6U[(1>H\(*U18<@<;P=0\=H3V!G'>8U8=)GT!,TGA5BM76[A6!19_
M V**:0@L/02V2E\E7F$^ANED!&F23E_A38=$IX$W?8&W1<<-TG-RAU0M?+_,
MK#/T,'X\EW''FSW/\\5R81N6XR*B:K!H'C%:OGLS.4L^OA+M;(AV]AK]WZ_E
M/S!PH^A0DW0$KD98:]DPM0>TCF6"TTLJPOHMRXW^C(KG%F;)Y.3A?2<^\9M^
M]!ZH)8 _1NR]6&CI\@W<]177RW09@#?;]1CN@X&KN0V,$3 ACO3,@4!F':03
MV",SUHNI-P S""AXQ3.!X#0TS#B>\X8Y!*[@$-,(* O:417H;K7DAG %VWM2
MY\B_@3%<#TXE;>;T> W/6L*UC7<P29*W?>2<>A@3U+&(WF8_*3EO4.E'-"J\
M)RI'+EMIQ\]=?'Q4FQ)-%3J0)8>M<EV9#JM#D[OL:ON/>=<A;YFIN+)T1"5)
MD_&'TPA,UW6ZB=--J/1,.^H;85A3HT;C#6B_U-H=)M[!T/J7OP%02P,$%
M  @ <8!G6 4TY:9C @  B08  !D   !X;"]W;W)K<VAE971S+W-H965T,C N
M>&ULK55K;YLP%/TK%JNF5EIC'GFT&4%JPJ956J>H6;?/#MP$JV SVR3MOY]M
M"$LC$D53OX#O]3WG/FP.X9:+9YD!*/12Y$Q.G$RI<HRQ3#(HB.SQ$IC>67%1
M$*5-L<:R%$!2"RIR[+ON$!>$,B<*K6\NHI!7*J<,Y@+)JBB(>)U"SK<3QW-V
MCD>ZSI1QX"@LR1H6H)[*N= 6;EE26@"3E#,D8#5Q[KQQW#?Q-N 7A:W<6R/3
MR9+S9V/<IQ/'-05!#HDR#$2_-C"#/#=$NHP_#:?3IC3 _?6._:OM7?>R)!)F
M//]-4Y5-G!L'I; B5:X>^?8;-/T,#%_"<VF?:%O'#@8.2BJI>-& =04%9?6;
MO#1SV -XPR, OP'XAX#^$4#0 ()S ?T&8$>-ZU;L'&*B2!0*OD7"1&LVL[##
MM&C=/F7FV!=*Z%VJ<2J:DU>TD6@.PEXAE@"*J4QR+BL!Z!H]+6)T>7&%+A!E
MZ&?&*TE8*D.L=&[#@),FS[3.XQ_)X_GH@3.52?2%I9"^)<"ZZ+9R?U?YU#_)
M&$/20X'W"?FN'W04-#L?[G? X_/AWHEN@O8< LL7_,\Y=(V[INMWTQFQ&,N2
M)#!QM!I($!MPHH\?O*'[N6M4[TD6OQ/9FS'VVS'V3[%'/[10WK.$%X NOW,I
MK[I&5U.,+(61Q4UT?>L.;D*\V9])1Y3GW8X.X^*..',GO$$;5W>"]S[2 L3:
MBIU$":^8JF]]ZVWU],[*R(%_JG6VEL5_-+5(/Q"QIDRB'%::TNV-M*R)6OAJ
M0_'22L&2*RTL=IGI?P4($Z#W5YRKG6$2M'^?Z"]02P,$%     @ <8!G6%8@
M\._;!   JA@  !D   !X;"]W;W)K<VAE971S+W-H965T,C$N>&ULQ9E;;]LV
M&(;_"N$!0PNDT<&'.)EMP''7+1VR!4G670R[H*5/%A%)5$G:;O[]/E**9!42
M'7L.=A-;$M]7?'E\S$RV7#S)&$"1;VF2R6DO5BJ_<AP9Q)!2><YSR/!)Q$5*
M%5Z*E2-S 30THC1Q?-<=.2EE66\V,??NQ&S"URIA&=P)(M=I2L7S-21\.^UY
MO9<;]VP5*WW#F4URNH('4'_F=P*OG,HE9"EDDO&,"(BFO;EWM?!]+3 EOC#8
MRIWO1$=9<OZD+V[":<_5-8($ J4M*'YL8 %)HIVP'E]+TU[U3BW<_?[B_LF$
MQS!+*F'!D[]8J.)I;]PC(41TG:A[OOT5RD!#[1?P1)J_9%N4[5_V2+"6BJ>E
M&&N0LJSXI-_*AM@1#-T.@5\*_.\$XRY!OQ3T3="B9B;61ZKH;"+XE@A=&MWT
M%],V1HUI6*:[\4$)?,I0IV8WV"$A"/(H:,BR%9D+0;,58$<I.7$4OD&7<X+2
M[;IP\SO<^N269RJ6Y.<LA+!%O[#K/=]BX&"T*I__DN_:MSI^A."<]+TSXKM^
MG\B8"FC+M?BO+HW*]:O&[QO;?H=M6Z.?D>4SN<E"MF'AFB9M?5"8#MI-];R_
MDCD-8-K#B2U!;* W^_$';^3^U!;\1&:-_(,J_\#F/ON=9Q_NUPD0SUT./WB[
M[4#F(<]5ZQBZMIM&-)'0EM0J.S+IL$HZM%:J*^4C")S4M".HW;,SJ%5V9-!1
M%71T=)?:P]I].\-:94>&O:C"7E@K]9FF(,EO5 A()/G[%M(EB'_:PEE]#IVR
M)S)K1!Y7D<=OL62-3YG_1&:-_)=5_DMKE]_B\!6,)F8P2\*CMIVSK06LMH>V
M@+V.C6%Y1AX@8UR0+RP <H?FN-_C9*192!8Q@XA\PCF9!3K3'U&$A<09H<7B
M2RC)$,14F3!/:$80O7 W-".=C,L-\=V6J9BH&$C$A%1& "3G4K(E+@7K3!.&
M?JS=C$O&B>0\,[?Q<IX+EA!O9/P&[\_)(Q9NO';+DH0L@4 4@2$_=%6H*95#
MHQR:5 '?@)#F?3E7F%5'DQ0K@KVUSHGB9'#IGKFN6^[D^G[ TQ2C(6\%3^?D
MG??>,E8\MX8KU[X:8D^T4I1=UNC 5HJRZH^< MX.,WK6^CTRE;3GLNL.'HFM
MV:WO.#:[7V?WC]K)+;RRQU&)=>O.9I<=&[1F4\^*?K/=<!_7@NI?7:WI[#:#
MRP$)Z7/[,'X+^/1J^O3LI#A?K02L<$$G\PUE"5UV#.K"961<],_B#8;"U<.=
M.)M&FKWEFO6LV=&S@]YG7/0$/),[4'IALW&&W>G0;>94;LW<-4IZH[=@#>]$
M2%BVP5L IE<3IF='S*-YP^Y[<"OL >'&"+4AQR^ FS[&6?!U)B'YOU!C4)'&
MZU'CEHH@1MEAJ-&_<,_& [\+-6R#I&9RSXJ\W9AAES5[K;7;WP*UO9JU/3O(
M=G.&7??JX=>:^42DWCRNJI'1M[/?$7RQQ[&++^RR8X/6$.G;8?"U?+''9C :
M=_*%77ILPAH5?3O8O9(O2I==;L!% ]>,[_AB?[FBGL[.:7 *8F4.R24N.[B,
M%0?#U=WJ('YNCI^=NGAQBH]+WHIEDB00H=0]OT @$,7!>'&A>&[.EI=<*9Z:
MKS'@BBQT 7P><5P6RPO]@NK?$[-_ 5!+ P04    " !Q@&=80'O5HWDJ  !'
ME@  &0   'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6S-?5N/W$:2[E\AM,!:
M#;!;ZK;'EF\"Y);M-8[E$21[%CB+?6"1656T6&2927:KYM>?N&9&\E+=WIFS
MNR]25Q69E\C(B"\N&?G-?==_\'OGANSCH6G]MT_VPW#\ZMDS7^[=H?!7W=&U
M\,NVZP_% !_[W3-_[%U1T4N'YMG-\^>?/SL4=?ODY3?TW=O^Y3?=.#1UZ][V
MF1\/AZ(_?>>:[O[;)]=/](MW]6X_X!?/7GYS+';NO1M^.[[MX=.ST$I5'USK
MZZ[->K?]]LFKZZ^^NWF.+] 3?ZO=O3=_9SB53==]P \_5=\^>8XC<HTK!VRB
M@/_NW*UK&FP)QO&'-/HD](DOVK^U]1]H\C"93>'=;=?\>UT-^V^?O'B256Y;
MC,WPKKO_-R<3^@NV5W:-IW^S>W[VBR^?9.7HA^X@+\,(#G7+_Q<?A1#FA1?/
M5UZXD1=N:-S<$8WR=3$4+[_IN_NLQZ>A-?R#IDIOP^#J%E?E_=##KS6\-[Q\
MSZN1==OL?;UKZVU=%NV0O2K+;FR'NMUE;[NF+FOGLZ?ZU\4WSP;H&AMX5DHW
MWW$W-RO=7-]D;[IVV/OL^[9R5=K ,QAS&/B-#OR[F[,MOG;E5?;I=9[=/+_Y
M]$Q[GP9"?$KM?;K2WM*,_^/5Q@\],,Y_+LV8V_MLN3W<35_Y8U&Z;Y_ =O&N
MOW-/7O[KOUQ__OSK,Z/]+(SVLW.MO_RN\+7'17N+;;=#P2S>5O!%W9;UL7'T
M\VW7>IA-1;\O3>+_0S?9KWN7E>$;5V7;NBW@Z:+)/#3A8%,//H/WF[%RV0!/
M%TQ\:@L_WW:'8]&>J*<:OK[?=TT#3'K?0FM^W/BZJHL>EBC/WA1EW_WHVKKT
MV6__)_NY/M38);YI?Y+OK[)730-=#ZXOM0_M&U^!U6Y]00+#9_OBSF4;Y]K,
M-?!Z2W.I6S,W>.R*IJL#+L>^A]GA6(^NAQ=PGEG7.OF,[.7=#BEPE?UU^A6,
MH7<H4VJ<9^$S'".\+)0I8" X\F-?>Z#9!H0L4*8N]_#^L<#>LJKV9>_@C[IE
MB8WK 4M8W!5U4VP:E\'71.)R7[NM&57ERII$[:'XX/H\@\?L5_C(KN_&8XX3
MPE\J_&H/;#MT6=$T78G] YMT8U\ZIF;AO?,>GX-N:#QMZ5*"W:&8I366H2#A
M\5UX%K0"_[09H1%H26DIY,IE]C"_RMV!@CEB5_@RT.T *PP<5_\=OSMT;5<V
M70L<"-*MWG35Z1)E>86DZ(NC&P=@DJLS&_,O86/^Y>R.^0U6!I;J>S_4!US^
MI3WWYUH@<H$(H17&U9 ]LK*IB)_["BD-JF389SO7PA1Q^\ O[DB;(\JZ8]S'
M3W]\]>KM!2SA'V,-ZYAL1%ACY(O,A5$AF7\?JUWHMW3]4.#_=5^.!QA36U(C
MQ9 5VRTH86H0YM'U-(9#V/'()@-LY:8N-G53#[2O>UC1=I2.W$= (1Z_QD^]
M:V@K(K,WG1][(ACL2IP1#$<:I&=-FU?93ZT0$F<.H_&/D%.Y<")^ (G@X2,(
M+>)*(,8J07! 0A"=J0@\$B%K"YAGN_J.MN/(8ZLKV16\!+#[D:F'$T@/%,2P
M'78=/K]!29TG:^;NBF9D$02]AX'F,A"F0>==H"?T(%2'_\L.T !VG&?;HNXS
M;,PERU6W\.S0]:<<J5H"'P-VP,F,%4ON\-6 @T:NZ\>B84IUN/'BFI6T/F\B
MI7%W3@8.<\WV-2"BGAI%G@ 5@'P.L@I^NX-U[48O3<,HQ\.1Y0DQ80V-@AR'
M"7J<Z08G67B0"2@51T E(A<M^Z*Z !J-NSW"1Q@\"CC >RB9QP8Y$#B[S[9]
M=Q!^,F0V?%-UT&G;A1'PB/P(PHN;<+19[JE1&)DN]#F)]'F02)^?E2>WA=_G
M&?Z;?0\[&];1J;9[4_0?W$ $>.] ==$V69)8_]P>4HTI3.Y1B1!/^2'(E#U@
M:A!<30W-VNU9MX#+1GZ,A%R!),/F"<E^^3RKBI-'OFA0;10L>W"3X\]'T%"P
MDYVP08D#=W'@5SP5XN#)3[J'_72@H&#<"<: L\VVP$TRKJB(@*/;#TR4=![U
M,!*7YJ#6 H5JX%[8D9L3#?RWJ_=7V:Z[<WU+[*2PJ)"=DV<_QA_?'U&D]?#V
M]P8LX),G4).;(>LV3;TSFA;4!<AD0@^3GX42E@ (4$A<54A5$&W]4/_=82,>
M]/&Q@?U'^YS$''3O?%#3Q?'8=Q]E+T>9,@%018^X3DA)C&/(4C:PK<%&8704
M0,TE8(M+#R/$,<66\9D*P%!_(#P%Q 1BX#Y## 0\![('!0E\\ #OFJ*W70G/
M;(J&5"F;R,A!0!0911GT\?)H-VZX1_0HH)"(W7;MI7XFW **#4>2C<>.U4)@
M9&+7U6%D X,RH'(WU121GO_Z+R]NKK_X&J9#6E 0-2P,] CO :PF"&386?0,
M#>'*[E^[#-@=*#^8^<\(O+*;E;VIF@Z6Y)*7!%!G7\#V.Z7+COJFATTSMB"4
M&^*H'>A.T>$=XDA:\8B(L7-5(@?0/WOT%(!DQ8=I[TG?!AQUVRG(7'B5<2OT
M%#!UTB6HG_(#D@TDUB>T,Y!,[])!H]SA,:.U-.=2RV8$^ ./CEZ@2>:/@+&!
MQX11 [<='"@DMF^LL@^"J07^6*<A F@B&CS?'1S@*4#%.Y95NE_E-Z8$;_#
MZ$"M0PWJD7Y$_$70YIR:^B*HJ2_.*I%7:H:]<Z4#<0,$6])$?[J1+'S7Q^\*
M$HJDMD$F52. 4UP8Q)<"UA!_J5J?;:82K%$POY"3@&V 38:6%!AQ5$L> ]3^
MXQ9! X%-=$VI$13ENK3+6X%[7A@48F8VO_U\>,0F18/B G9D7V]&P$>(6Q9F
M3:!C@F9Y\P\JGE1,D$QIT'5&'!I0NVRJ!#4GLHD$)QBF"* (8LJ(<]'$+=F*
M]_0"BN&J&S?#=FR"&9[*A7O8)H0ZMR :9$0USB5."[T#CH?5U!\ 7^T[V!]D
M$#3J^ZN1#H=NF"B;B)!Y4O2\D@"1[@(1<4?#Y]V(^H)0MRR?3@N ,9KJ@(JA
M5S8R2;8K/$6F@"5*4+@U!H"V51W\+,?BQ&M%P)=&Q5Y!8+B<#( [LNX0N:,/
M-)FW3T"R;OW$X0%RM^T.(&9T6+ F: ,,_&XI=H%8<-MQ0&MKN8>K[)?.K.Y]
MX46LL[:&D;T&,AXV, 3UVV%O\/]-GA6IO;DG$6PG+5T"N3KBH93)RH<%T8L@
MB%Z<E2$_('[X&RDKZ/>'L"X_1;VV))C.-KKL#7Q$3Y9=/_$K6M:HXW(-N>;+
M&"5?XG'S); ?"\RV"KA.C7'F>P1LI[C15[;-(YLD81,=%@IKF ?)8CL&1^2=
M$T\($!&^1%[%[ZRQNG%E,7KSG-^#&+M$;9NUB'$F\B",$253CT3JU:.$N"U^
M8S#F 8Q(:&C5_8)<'9?6>)G?(_,6"'J^Z^"_[.D/K]Y_=['\Q&U7103P]-7[
MVXOLQ<WS/#,<],:. T?\.GA'/+V";UR 8N"_Q,MH@7B.QBLL30V"''>?F61
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M#HP[D%AW2D7L#IFRZ_N.T"NO1Z2@.C  UQ73M?WT46LK$PN+-K:F=9:CPVP
M2:^_!7GMG38'UFG7X#2\"5%B:W[<_"YR/[I>>>N1FQ8:+P2\(M5PR4 PZ$3<
MU>XJ#Q-@2<]>"B S&=^T?]0J+H+!(V")&:%A[Q09U]YW94W3$J_4#H;6JKX]
MK:'/J-97F$GFB:-84SV"2U5#$3+%Y\/Z<*#-S*ZA=2TTAH20G\45&2>'S!7P
M;20>PKRNPBF856?V/!LR6%RC@L9&=FY8TM)%D1WV@%V=B6 &V(_.*-P!\E)3
M.VOZSW3&578&'WX9\.&7Y[V='8P4C3S5%[>@\^HA>U?[#TO \+_>FL$-%N[1
MYCIV:+/5!),"=Z34+VW3')'@MGML6T&C!("H(0&0^6/1HV*X*=I+^1QS0P9R
M1-0D\P2AKKE,E[VC4:1L727P$'Y'O'&5_?N^;H*/C)QJG:^CN4J"Q#35;0>,
MZ7XL'3SR S<'M@F]A.![[(D9;\4OB@N#\=]A$E]!&P7%6;2 4,N?C.M' RN!
M1+@?BXD5^HEU)L.Z-G5YDOX2+S.NJ$24AM.10S'DL'VLVSA/?,;B"31D$2>0
M]GBYZU&$*L]0E)C?.C9%26X)=#B(&4A1XL'R1<)^-"08-?>*H^S%?$#"N!Y]
M*.H.4T.YC/0'RJ^P!;9G/>,Z.R .!@]T^&HIGC,0KY_'G)GG9S?M3QKY6DR$
M>>2[P+4N\=7&\!2[%^@A$MAW.&N/7J%-4*1LG7LUR8,=OP'K:5L/T7G%/B0T
MRX);J41BL!-9 V'D+TSYNRR.]4 _^(DW"YW]8%2  !9?(JQ@2UN2>P 6I"R#
MGB)G((_[ZA)7^+3F'NOZ7=&*F]%?,* 1,EUAJ@FVUHF (?"($Z][$%^!/F&^
M/[Q^A?L^^!INGJ.EE 1&V=JLR(W <P$9B$[Y&%L6[12'2<KIS:MW/W[_R_]]
ME9%OPSO4*HSL.?^ >%":GUB?T 7JJY;%KY]A!39%8BO+"\83&5N1!(@YR';B
MT/J<:^"_THE7FSQD1?F!]P9[5C0;1$E#)M2\&10U_;B+XP L^WX$9/?'*. (
MJ1YY]2SY-PX6.W*7KF>@[2/X)7 '+Q\B?_VBEJP97%^<37$?HJD@1= />UFW
MET*77.-Q:/.B(.DJ'\)5Z(K +Y;L)3(DBJFF$[>#2FX<D DE@8D']"!?%CIK
M^A KKHS3GEI?B(L%&*>^2O;W3+H*&3$:#5!_L6'K0 UAB@>)323.&6#2I@,"
MYO(7\IYQ@NIHQ=/-_EY* E*>9D8MR6L9[?0H:BJSMA7WOXA#<PF"JH>XZN[;
MC#<W+RS8'5V#F5! Z+'%M1)#-ZX+[_':+L1T$=1)P)WB)P'+N*%AKG5_D$@>
MBR,-UB J>8_(E(9'HT-K;4\!?G@99EV"Q,G%NRY>4H-==8'32, TII6&M,XJ
M-Y,0>GU60;WML<7AE%,P_Q@"SN\!-MW#<!=UWC^SR73<-W'<-^<5:UP.C$MV
M[>[R9S ZJNP5V52+PS[;XK+3]H%N4G\BL;YLV3G7X^;%\-ME0PV([;?B0T31
M2MEXI,O1M/GT<Q"LD;1O&[6*(Y'/$38FQEZ?S61]^7/PJ$V4(\4RT6'&$*3O
M3D43X%\?7!WBF1"UN+@._YT#.+="8!(3$:,/ML3]"^)2,H20[I]] 71_C<C[
MJ7R\2 UMQ46DJH\ 3!#72QR',0SFFBE>T6R47L7#)N3#XF/DNI3,#$S)W#K"
M*1*CY?P!B8IPJ+T4_\$DD>DGEKUA/L!F,GJ47@<WI$HZ<86C>B*-Z4 ;<MA1
M027R<(^9[SXB-)<NR$DG+R'\Z*'EO"QOTDAB_-M1Q D;"PLHH6_<1?0(^?%%
MIQ0]&&T<UV15U"PQS8Q1"%531$&T<(>!QC@>-%5H'S),[!X,?R(4F?!;I\')
M1PY(<N\>) <E)TQITM1;MTJ3B.R;$C$>[935IEG3W=< DI4@O-PR_)@HA#/Y
MN^N[. S,LD6O NM49?[H0GHL.12WKFYFU)\<9%U)?-%D&Y-&N" P;*QSX^(N
M?8BNN<$#"U#->+O91)*- YOI=PV@LC$G/]NT;=IHQC>:26JU!:@F0J9N6O:%
MS? 8$![=U<U$YH6)QSW:!OF*PVJ'1;*ND]-N=X30 *D&Q+V2BT>N_B-&J]'&
M-\TPG2,4&S#E?D<Y-PBD0J,HK03"-J>0/CFL-9R*->9F<NN>W5:L0&0?!NZC
MY"WT7\W8D, QK&H(0PHH_D7?2!)I:)-O&R:\]=YK<TMI%G\RD>DJ^PVS#D"U
MM#M&CBNJ(2<1[SX6AV/C6$)SDBN;H <;>@Q\ >8C^<MA=35QV9*Y=Y=I]K&H
M",K\G:0?)IJ&9DU#7L-!)M1KU/1NK.FYLQ X'JZY/G_LY9UD0;^+6="+L.5Q
MK9A<ZEG.&_&7#VG7$63\VAWK,OO\^>=YINV0/+@5&TW<=;>2"Y))C!=>N.!\
M&/*UZJ_=AAVP9.%UC1@6A]JKT4M)D !PZY(3Q,EPXX ^*6EA5Q_8,F8;1@$H
MX17U3!D\4).[E=>5EQGC7+.>06A9'+60C,YX*,I?-<Y;[=P(7Y0^-A&PA#VC
MV)D(:\8<#-8T'+O%P?O!'?U7V=/Z0LV[DY*!EN*IO]!PCQ+\:WAZ^K@Y I/L
M@;C7J35Z%=Y-XS;F7!)'(?&QNXMX\&;Q(=VOC^X:]^/3NXM$]/$:$$\])3!Z
M80GGH2F_)56]TLT\T5.8OHA\/\3\-]&Q"W-1L"A3#EK*2(3E$<P'O_(<M*[S
M 91RFV3YQ4,+4>BEX3P4XI[S<1L8<.M3"1G=2&>9DD6 N''0%7.2UER"L]GW
MF*O+,$\\E=,C4(S;9LY$\8#4?96)_YW7"AE/C^)Y-]ENIZ/ "(U9*[B3U3">
M1,IPZ$&#]/-,AZ\DHP8#/YP@I):2SG;KG/\:9EH?-F/O@[LC'#-"0/ZU$7&4
MVP%B!B<=7C<>U3SQ;"84R@XU8),!QZLP@_="!(C0-)H'P>Z1459*53^->9TX
MLD]<P4QAO;MRPLUXV40&6H;A@,Q@\TTIM_,'U-<%(<"P,BJF^71*W8;S4ZEB
M#OXI/FZQ(A@48>(L=)F+L#!#1X"%\O%&]C&3"X(F]:'M[B_WW7V^[A^GI C)
M/J-M7L?SV2%\] P99XE ?(P+_67]/+P]DQJLRRI)J,0@/A!A8I-/@@,!D:9"
M":-2Y!=,M9_X=C$9T07A%1RIKB:),0ZU.+H3R,T>1MHA?N#DU9/VR'9=_F@#
MGS$J"BK9ASJ&J]EI&_@:L<!3,!I&>/,BP=W^S%P)A^M9*AN/8LF69&<@^_6^
M$*C!H+PY6=LV:!:$Y!A')8_H%8?%;-B_7A]0<)B$>6$0RZ0XQ]-%QBG3L]D8
M,EYA[6HYB#S/]&; Q/DSU)N 8^2KU1G+W(A5Y?"LR-+@#)]LS#C0(4UD9DF!
M\ =W(4>%-/:_W.>OZ4$T<3%?BME7+?O361M3&D>%9PM+-S7'9@JY]B9AL(JI
M\Q0IF2KI-0A"A(T'K:W__-=%& "]FA.MMAN:5SBUL:+B)4U&]@J%A?$(!&8U
M-(T<B"W=4DSC@#:CR+'YZ4*A74AQF<NFU;YJ(\[$I%%;R%M],$''Y]K,%YG9
M#MJ*=D2VXF+>&/<T&PV4;49."((S(=PJQMI"A)*@;V0_T+I%'_+<Q:I7OTZ0
MA>Q?BUIR <.L=$>8M4[[C#X),KZW@#G$<1GW3AI9(5TK2#+P[+2S*TG)G1-<
M$I;@1>$["?G6U)6P*>D+&!,*N_'(5GVQ'>0<+"D,6!)WG*/F<'XT:F/)AZ#X
MG)Y/0LUL3LPN;5H28]/. '22;Z8>$O6'SPK:6MN^07AO7(3."G"12B?  %?9
MJX--$>),2HWISVV\)"9&SF]Q>@<1I^W-W7:J78QQ8>#V]0VF'6$9$IMRNWB\
MCKQKR7%#]222X.1DK>G(U*+";4PKQ^MSQENL,]%$HO^VV4R'GJO[>S+-J^QG
MQGW^:IZQL@/^&OP$&PY^&1]B_I&USVV8A+/Q8ZK$$KR$MJ.O(>!^XD!2(&(>
M82QV;(GGBV:EJ:?FB9_>7BC>Q8PNJ]*->(TOU#@3=%J<#AM,UEKK(OP.'4C[
M81O3>!_3TU7J_4F&/8D5"!(]=G5+Z 3VL9CMQNN#3U3DO"NCI86)HB@HA"$4
M0 J%)T,PTYH,(#K_2\HY$6"1VH5!&2U3+<2I#$,]_NTT'9EW49AM"+AI)C7Y
MO\C_M.H?"6@D;&SK^D\]GC-G'G6X9N6B>3I'23IK<Z+M,4NDZ;"IDR/\BDX3
M@ND=:BEZ>)8E)AT18HUE6W2+%DJN=6H1\1^@]1KD522NV>SBU4E='$SSU":<
M@@0>25D<8^ITE_"3"\A#<GD"VJ'O8DX6)74.=?3%"^@4+$0ID$PL,2[7YF:E
M7!@$9^*;)8@$IIQR$:%T4.8X]IC-1((_IGJ!'CV:A)J#(#5I)4^ZO=,C9@)J
MJ)_D\+G8EI@GHSI\J24QG'A1@<FKKE><0*81Y2B();4P)N%2>ILM2$7K3?1,
M<'J5\L^L%?9^""&-3PVX8$.[GH#<.;9C8QS>M5"=67Y!%85V5[A^-?#_T(O6
MURBB$P4V[M^!;#PKQH%R=*PT/,=3LMG\&@C>RK$ H1E8#YY#*\)'GFU%EE;X
MD+4;5T[&RD$#"1MPDRM6I RT=:@""JP-P]&V>4.&+#9=8P$0\M 6!I'K;N[=
M1H.<GHG$"E<;BXZ"J*\X]\J<K(C0E\ZD!!\"6^ GC4L%-0<\W\?TSG5W%YWE
MF/F#)3^LT&9Y!Q$P*$* DW+,RK _HS?*.LZG-10PU,?&CU $-;@*T]?IR-#-
M]B81J>]C+"9*"V\*Y,RLRNBPM$;E*CU6'7NBL-=.R2,1-FY?--NX-T/N^$F!
M@W>QO4EMA?\I/+ <SICJ_F3@$41$R1"R'":'E)8V9\ /=B83<@8P6E*$7E,U
M!XEEX<DT2DH@1XGB!ML G='&P!OT4')V)4%PLH(E*!#<!&8<:!IA9F85CT,\
MN'8XSO_=Z_>@P ^XAN7<VAA)*)D@E(*XOQZE),]/5 C0NOX1WW-X-PV&K-8#
MLWI*'J5^@]@14THSV =,6*63_2FP)(<5^[T4!L'+L[ N<<$6#[:J=M.#=#$M
M;3+RA;T;SGY;^4@#Y6FFWTV-HZ2BR]H*+?GR5Y.HE '6&,2D6@=ZVD2E!YV0
M27G#2848Z\J+#K;H^)&<[7!@L>=4&   PZ5$RJQ,1@&#Z0OYDA]P<.6>Z[BQ
MG@Y!-(#KR>$"^QX!L[FA'L)SD?6B#R394M-%#IZS9;<(YH$TN2XA:)ZFIM)3
ML1_R5TOW56"\E-_<(9$UBXQVHF?=1RGF5_CUK?P@/[T)<<>W$G<$:@SB U'G
M'+RX'.T+6?YV*>>AS,=(@?"6GZ:5A2 /#&/CN-C&'H\I<6AB,5S&U)O6.YQO
MD9C>N!H!HX5Z7+B)4:,$1+B47@@KY5/[+I(IG&1^<+QVO4(Z6K! L*\D@3]Q
MN@00DUJ"\03WPK$;GX>&'[<@M DR3JX)C:@[E1ROJR>0%RQP7]:L+LL\E'*T
M0?3<F-ZYR8_@\TU<; AC)AM&,92O3!IC+R40N71275(IG;@@M8F9U=Z$S&CP
MO>,C/A('1$($0T[.B<\.#J=&YS_"1V%[NK8*&]/'DU#S8RHIJ$CMJHF@%<J$
MXU]-8_>EL51"M',X9W#94("RH58+6N#M5^U)EC^<>O>I*YYB9^5X&$5Q@:PN
M]Y?C48N/2L(P44P*!J557(N^I4.DZ:$:G&KH$FP5S;E@4W^>[*46!@5NI(QO
M3-2(N;%BE85,1M5$E^RY$ 4,I-S7'&Y"F!(]S,;U)HJ!Q1HOG*LZ//Z.3#>X
M0^J;CH-AL/>@IU /B'&B[)8"<@'"*V"4U!.69C!2"K,M OW4/2$5HCMQ+C1!
M)&FZ+N)X"KY&_1N^,BZ*GG<KGSB/ #6!1 #_3G^7E$]3)*UK)\L8'"ZZ,YGQ
M[#.RE[/?R1$2ZU2;-)'$4M03Q/?[CI/"NV&OE3Q8S-3'PM0D3---XBON(Y\=
MA#$F@H$/;1( NJ>:/#/OF<DG4F2DR<NQ,S7[[51-//M,=MB+YR_R24[:*]O*
M4WGH0L_#R^=0Z2>M6I>,@$YUL_/.AUQ:G)<<,XD'SF+])71YEDDES-P6N:'"
M/B:U?[;"' Y2(Q3L![)<DS@@.EYBC0L$8P.5/5,M]?3Z(I'S4Y_8" V9@E1\
MTCA[>I/LKMA?.!M#MI!3?0,\IOZVV(X)T"=<ZS7G)S'785]T.XI@)278L*$&
M^Q278T\/F^+<7 P@7&&Q5#9P\<!.3)*S]>.929-=J;Z;"&,DTU?*:Q7BYKT,
M,#Z1FD^YA(IQ;T5B7$022'+CF0''2IXRW$B^+)9ISC,>MY@B4L+"4;U]6/>F
MCK46%LB';C"33.BC!T$<27(,-I!BID"2#900(J2G)TWE5*O %56J@))7(S>7
MW>5:FMPT(HY$P=0$$?$/'D571&>]*T%ZBIX-?AG:P:/W8GM,F#Z);I4/ILAB
M56.7_=)!LU^&5'8\TY]4W<30<P),Z4!$Q7F3!5?#0,MLI"/E."B[Z8CXRX4P
M5=K_UE(#[P=->PT/N7#P7#.G4LF86D-2UBM-P@\%&8,F6<GN33< *ED\'CQH
MB#:V2+!23M?%UF.N%(+6=M>LJOU+CDO@N=(^9*AR&4H3.C(<R0E(EVK*^S,^
M*9:=TKB<8XX^ ,/C9'$$H(M#X/FOK%1$T90GB*Z017^S9N5@^6('S>Q+XF;6
M7I@>J[P5<C),'4K)<2!A4;++D@_VLAA:SC.T%?-#S5O+[5KS$K4[;.EP#<4>
M_FEBP0R*PBCC[_F(KB"ZF!"3>L-""M;$G&0?F[);F)[D11/NP)W%GO\PO;_I
M]&[M]"8!_LF)<UO$DV%JS(-.W53JC7A$*ND5K6K43"OYG?-D\T#^/(RS=Z \
M6_Z"6  C*OW.;8KRPZ1.\;1:3 \/42V+ORWW7]M<JC3'9I+$*]&WA3-+LO6E
MW(Z0B$2^VMPFM4C%P"@:#G'72#X!R2]4F:K%H3'=NM5#@E*WE;8B-%?129X*
M>*FG8N)%KE:.*PLJ"QCX;#.>E&?#64T"6ZU6MWTH#UI/9SSL],$@49JQ*T6!
M9N].& W00'.:'4W\<]G(]320QMLMF+23Z".=P8U70VCB7)JRS*G 2<C-^.U?
M)\PGT;7L!^<63@QH_#R*?&*AR+_1N 7^PTNJ4%9*.?[)81ZOZLQP_QD486**
MJ76>Q"R6)2L3:IX-X:VFM+%!U7KAS$.BS26<:VWF(][F0"DSZ/V(U %;3VD6
ML(W"*;&72;'%:&XN.R&L95&A\>"U3I7("U9+E&,>3L456EUQ?N1W<K%(!*92
MT@P+U\DF7:CMLD_O*: )A.F$E$D)E@67X#P0-M646AXA  #)SDOP2L[Q\V#D
M>./;C'G9CV";I9K[D_HD036_8YE]Q8K(4"K(JR,NSC23&9K;:HK\"HI(M8(&
M7HX 4<:"/=-SR"5Q\.B@P5?#R<BCW 8W<9VN'!.Q!ZV8 Z7J^HFS#Z1I+)4Y
M78D0P,>@:E [\9P\:?M_\I:U4XIWE\7)391L.,TNJ[1Q;;E'QN:85':/H*WP
MX8Z!>)@]E$Z*]@Z6,Y&I$<[GJ(<6_XF9/UJGU^Y*3)IH79,C#B[3-(@TR9)N
M%KMOPP1LN7(S^4\FL&4Z;UF_4%!7+[9@H1^-5;TD:-I9+IJ:3EIKRGL\FLWQ
MRY!8EL>"KP(2:.LPNKF=H)N@8*Z2GRCFZMP4 :V@9A-=)>T:V,^: 6P+DR'(
MQE\$*^C[JF.A0@+O5NQ0B6:R'A9[+P9-H^<B6726GYVP/OS$L*Z:JX!0"SA>
M[!-MCIEX)#U%/%@6E!P6&^,>$F[2!(9X35.XUN5>0IRDGF8'(M0@0HJ1!SX]
M]"'\?IXNS*)BH;!CQZQP>OXFV)S%P0B"8DBDP:(4R,W"UNU4Q$P$B&6RY,1/
M=&(:52;=<V8;BBM228^9.TK(Y**#-/<D]D;%)+W4>90*SR1@9&RBE@"@X0VQ
MSGV(KC!I/NA+$!JS4@?F.*NX@ZCJF]UIMOR^C"()N,;C\#16&B)Z)L/)(11T
MYZ0<DG$YW<ZU9I&G'1)*Q7,9=,G/PWNPK1+VXKS.L#=(FI9- 4L)'+,9ATFX
M9%H5]>0&+4=:"%VN[#55[]3VLBJH3L)<(7M!%#2;:XE(8G!.>"-[X[#"25UQ
M&E1QP,M!Z:MP(MH85Y-3MJFQE1Q0BV57M50L 7GJD@[!*S;PQIDPM<KG._.?
MNRD-$0,[1^00G=5B\2K/<@FG]JY+H29)&EQJ/31%S@G@GWY(_5!\\@=DX1'I
M+A6QQ4AIM>&$)11-4D=YJG2U2ZT#(D:Q])M/\@W,&2]^CX:E3$_EOZW#10;M
M(YZ=)9$P6VOFZ(%+%I_?EM-0\+Q<=C $'VV'K=PZ(\;=F:-$R<4ZCW*/Y--;
MY22"+UQ"NT)L-,82LY$GEV/-K_,(3>IBVJKFCYG4[7)-2MTS,Z>Q%&"8[N^D
MR@&G9L5R"0,5@:0"I^B$'#@G>2#L^..;MXC!ZB:4;_]SU1%@&TQ+P$TTB_CO
M^SLWF2,>8RCIM!'>Q5Z-C3-5FJ0V)@-'^Y:M^)H63]A2YJT6_]3SBI80B9OV
M3+S:I*O3*6CTXX"==8DI9%)Y7B(.*YF^2?QA=OE/M*;WL@IN"X]R[);9>'GN
M2?NAI"\.&AU'7(Y8CU!8SWE,7H_&\&162^<4Z2Z/YI1>;$BHE4IQH4R@<0>)
MME;08,7]R&$BG*D6.I'EK"9%7'77AI\G18V7EWGYH+9JI<E!FWFT?#D/CY:2
M\H_B&YPY<ZXR4[Q=^?K\Y<BWXMU61\)[,K%Q2/K+<C;[8OFF_TI7MXMU69EH
M;/IHA9!I6"FL"<D%7<"E$TU>8PB2Q6D,ZYA:HM<H30N3Q!+5;968TXQ,^ +T
M<+(YY9,0A$BJ.=M&IY6=86#LC)2"V@^7Q9ZX402K+I>[Y50GV +A0AVJT0_0
M 24L'8T0M,+NXH^XU4:: 55NPL/'?BI=T [S*@T,A1@^%#[.YD%R7#W =>'G
M%3%E41AK0CD$KT[-]8,24F@]8-/-V'R8JC &QPLGYL)5S>/QB/+KG+*TP2]8
ME:)7&2#GU])BJW0]IN1D(31P=*(,_<&F"#>JCSU&Q:WL:F+>\EE1$:\]OCY_
M*_$[RXCVV,OWX3+QG\+,;I4DO_9R31==5?U,GUV4'_]8_W^F^^S=V5T%MA7?
MHS79B[JQK];?9Y8#3C_ RNJ5:\RT[G!LNI.+*B'>POX 2^01 0;9PLPX9;7@
MA@]B([D*('MZ^^ZO_H+O&@?DOY.,^5K1*0X7K*0B) ?B[8EC>A?*)WYR$[ED
M1*O,X2,,NCDF&"R]PMPP<23!1(@^,-$S%Q_ ;-_0;-/0<CDAOBV0Q?7PVFHA
M[=LF7]7MY:Q@%<,=S.WOFFY'.WUM]VKGN=#<#_/["Z@VIE)K A>6<IN!)PE=
M#2'K97J23(ZU4'^7'HP6@;=:!GLI4!32$$S%K S?=<F2/Z(VU21;Z.Q;@=N#
M!4W#!B.1C3K-#DK*N:2A]9D52$ZL>-7B;<J(R86)::PSL<@>&O+<LX:G%;C.
M[*1=4_9B,(!FJ82<?CQ-]X\5"P2#XKX6=W5.FULBT4,=1%2>@230/V,Z!=\P
MTV1AL8$='-4FY4#?]!PG;##1,1S69D$K]\(M]1MC]G+'E$8OTG"!O.+:'AB/
MXXRAF5/9&$&8&_5+/2+':=FUN/&/L+\N%:3$$<<[T1B"<\$F 4?1:U\Q8"J
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MF_'QE]\<016^*?H=;KO&;>'5YU=?_.4))TCIAZ$[8I-X$&KH#O0G^FE<CP_
M[]NN&_0#=H"WJ='P7OX_4$L#!!0    ( '& 9UCI<<$D- 8  #@0   9
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M33#9;/U.K1?>E.%M.#<>LS%\+O&TEY8)<+XPQM\O6$'[GP6'_P!02P,$%
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MC5>@\Y76;K?P%[2_Z^P74$L#!!0    ( '& 9U@4T<^=% ,  +L&   9
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M"\?N;(=2?OW.21LZK51H7^*WN^>>._N>#%9*/Y@"T<)3*:09>H6UR[[OF[3
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M=*.)S<*J9:U#<V5)U>II0;\1U,Z SG.E[';A K0_IM$?4$L#!!0    ( '&
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M0_!J\S<H/*J&TFJD?8(\>P4G)3V*@@0H(Y+X$Q3Y*[B1YN%DIJDZV5EBD;%
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M"TSHE"PS]9D__DE+0AV#E_),%G_!8QD;M4"ZE(K/R\8Z@SG+U__)S_)!5!I
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M%Q]GE$RH, 'Z]RGGZNG"G+C>G+ ?_@]02P,$%     @ <8!G6 _Z(U I!@
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M4QB;"R-7U;F$J31&YM7/)6<SKLH,]OY<2O-T41;0G(49_0]02P,$%     @
M<8!G6//^]I^[ @  R@H  !D   !X;"]W;W)K<VAE971S+W-H965T,S0N>&UL
MM99M:]LP$,>_BO!@;+#53WEHN\301U;H(#1T>S'V0K'/B:@LN=*Y;K_])#MQ
M,DA45NHWMF3K_OK=G>R[22W5@UX!('DNN-!3;X58GOJ^3E=04'TD2Q#F32Y5
M0=%,U=+7I0*:-48%]Z,@&/D%9<)+)LVSF4HFLD+.!,P4T5514/5R#ES64R_T
M-@_NV'*%]H&?3$JZA#G@?3E39N9W*ADK0&@F!5&03[VS\/0\C*U!L^(G@UKO
MC(EU92'E@YW<9%,OL$3 (44K0<WM"2Z <ZMD.![7HEZWIS7<'6_4KQOGC3,+
MJN%"\E\LP]74._9(!CFM.-[)^CNL'1I:O51RW5Q)W:X=F\5II5$6:V-#4##1
MWNGS.A [!N'@@$&T-H@:[G:CAO*2(DTF2M9$V=5&S0X:5QMK \>$S<H<E7G+
MC!TF\S8;1.9DSI:"Y2RE LE9FLI*(!-+,I.<I0PT^4JN-#(3",C(O8:\XN36
M1%233Y> E'']>>*C0;+"?KK>_KS=/CJP_26D1R0.OY HB.)_S7WC2>=.U+D3
M-7J# WH7LB@K!$7@L6*E.3VXC\FI8;^#4UW2%*:>.>@:U!-XR<</X2CXYB",
M.\*X48\/$,Z4^:(4OGPA,VXC345&KC:PY/>M64YN$ K]9Q]YW /YH",?.&.[
MS7[59I_;[.^C=.O$Y 6HT@ZB84<T="K-98XU5;"/P6GYQDB-.JY1CSD>]4 ^
M[LC'[Y1CM\[K.3[NB(Z=2M>5$@RK_4EVFKXQ5"<=V$F/23[I@3P,MC_]X)W2
M_(I0&+R:Z'"G%(5.L5NZD(JB-.7(!E/FIAB!^T_N5GQK'+?5)HQZ/ -A'W4H
MW!:BT%DM_N<0N(6&A\^ O].9V"[O!U5+)C3AD!NIX&AL?M.J;9S:"<JR:586
M$DWKTPQ7IMD$91>8][F4N)G8_J=K7Y._4$L#!!0    ( '& 9UC2UBG6W (
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M2ZO##25+RLL =7_%F'PZ*1_0_GO XG]02P,$%     @ <8!G6% X0+12!@
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M?X26NT+F:1.L6I#RK/Y/GQL0!P$X.!) F@#2"2#>D0"W"7"[-1P+\)H []0
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MH=1TL*UGP7;3HL"&1K!!'^R4A%VPD$8D E6+H=1TL*VQP79GH\!.C&##'MC
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MA:.M[9,\Q'-<-;,BVK[.UXC=K'0^U%0?Y]RB&J7Y1FF!45IHBE;5W][I7Z7
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M!N#KT^&N04N_VUY^S>=_Z_;Z^V8C)%?YY9^AK=.03X;)=<Z]%B6.86FII"J
M/X$5?O^=&S@_#MDV)EDT)MG=F&3KD<@.[)YT=D],[.%O!&\()<IP#A1+2)!D
M**UDQ0'Q>BL0&,P11MISC1Z3+&K(9C69/J6?0F=A/^V[]]6(]4@3.K!DVEDR
M-5IRSUD,D B4<I8C@2D@EI[DB9'W7$_&)(L:LF!/<7?JJ$_/F#''7(]$=N!A
MT'D8&#V,( 7.]=.D$J? S3M9S(0<],W(=:YO8Y)%P9%O%_[$[[DVYHCKD<@.
M7)MUKLV^\N21(B8EIJC$+_JP$TB_C+<G8KY_(N(O)^*0H\9QSG5T3+)H=NRH
M.YWU'#T.ZB?(F2&%'FA_U6E_9=3^=U9<Q%ADZN54@EJ'1/"L:C$!0_(:J<Z5
M=TRRZ.HXT4W\?IH[#NK+:XHXD'?>R3LWRON3JEB_=3//C[R^&$C>JX$PUW'F
M_;AH*&[JS(]4.H[KJV2*:%2R]^JL'/BVKHB%RL15(9MWXJZW*[IOZEJSUW_K
M7J_<@?Y(%>E-3?V%OJGP/V*^)85 %%(UE',Y4^<1;ZKFIB%965=Y&R95S5A?
M9H 3X#I W4\9DZ\-/4#WUT7X/U!+ P04    " !Q@&=8M4JL/M(&   Y/P
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M%4^K8-V#-,[*3_JE.A$; 9K3'N!4 <YV0/^%@%X5T-LWH%\%]+<#AB\$#*J
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MP$P_6&U0-PQ*\RK:YINEX?%XM*VUME;#;:5!S2LH+431FG)<FU>.T4PX8,2
M&72P\J"^%93F5;3FP-.=E_@MK8:[USBHS=22\F3L;"<-44F;DEK[1X[9/ZJJ
MP-OR7=%U509>E&7@15T&3G49&%9EX!$)LYE@5+8K#^H@5;2=D2];9]&%9O6@
MM"F4YD-I 906HFBEEKL;TVA3)AZ*.=A2WXNU-,MY?_76>I[W13&[>6O[I7WJ
MVBW;/?O4+V=QK_'EI/)K*A[B3)*$S74JZW@TZ!!1SM,N5Q1?%I-X[[E2/"T6
M%XQ&3.0-]/XYY^IY)4]0SY:?_ ]02P,$%     @ <8!G6$[X *P>!P  F$8
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MK#C%U/:M\+O/X?%1KK(&AF%T<]5<VNJYUJF$>2IAOB)8Q[K;QKI;J74+2@*
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M\ZE'+EDB.4X&.?% TC 2KT>FQ'Z4M>D7S(N<Z>QAV@ZY1LQ2D/=) $$58.(
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M)2:>P)4!?I\SO""*BNJ@3&4G_P!02P,$%     @ <8!G6'H[W!%Y"   4U,
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M7Q22?"I$DO^G2YE5_:/N^O6(\"'?1'-Q-5!=?BZR1S&8_?4O=.S\K4L62%B
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M;&,\>W;C^8<V5-B9?953T]KS'9\>NT/02D,HC4%I'$4S)=%XS9[=:ZY&I_U
M5FZTT-_.[OIN][6=U5L*2%H I850&H/2.(IF*J8QGSWWQ&.5!W6CH;0 2@NA
M- :E<13-E%GK9(=7;.O3KO+MK>NM0>]HU*-TZOAJZ#L<^+#'.F#/=< >[/!G
M.-Q>XW![5FL3N,ZW5]1;*J.C=3[UST='.H%:U% :@](XBF;JI+&HO5<LZI<F
M2+U6^?9*>FL$ZDE#:2&4QJ TCJ*94FJ,:V]\ZID3U)N&T@(H+832&)3&4313
M9HV#[=D=[!];Y4/-ZIIF;!CR1_3H:Q/06D,HC4%I'$6K-#%L'>V7B.RA/+4Q
M5_/D;5I4I]CMK^Y/AOQ8GH=X</V&?@BK\QT;3'7<Y&V4/<1I3M9BJ9#.^43U
MG5EU@F/UI)";\@#!>UD4,BD?KD2T$)DNH%Y?2EGLGN@*]N=HSOX'4$L#!!0
M   ( '& 9UB$SCW%2@,  !$.   9    >&PO=V]R:W-H965T<R]S:&5E=#4R
M+GAM;,5776^;,!3]*Q:KIDY:RV<AZ1*DI'1;I56*FG5[F/;@P$U !<QL)VG_
M_6Q#**0D:B6DOB3^N.?XWF-?<SW:$OK 8@".'K,T9V,MYKRXU'46QI!A=DX*
MR,7,DM ,<]&E*YT5%'"D0%FJ6X;AZAE.<LT?J;$9]4=DS=,DAQE%;)UEF#Y-
M(27;L69JNX&[9!5S.:#[HP*O8 [\OIA1T=-KEBC)(&<)R1&%Y5B;F)>!:4B
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M)E7S:!YW0!+@.D"]WS F7P=Z@?I?#.&_4$L#!!0    ( '& 9UARXHR:N D
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M>/XR\,;?>%;C%EMJ0UHR;B%PW +0FKK4U<,#CSJ*/; :L=A2&\*2$0N!(Q8
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M*[?K@J^X#;Z*U^#K=8(T"3Z"3%J(=T>+MA83.66NJ(5\=:ZHA5SWZ%SI)='
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MD>@%ZON",?DPT0J:MG[\/U!+ P04    " !Q@&=8HX1^NQL%  #1&P  &0
M 'AL+W=O<FMS:&5E=',O<VAE970U-BYX;6RUF5USFS@4AO^*ANWL)C-U0'S:
M6=LSK4F[G6FWF:3I7BL@VTP!L9(<)_]^)4S @**8'7*3@'W.Z\,C<:07YGM"
M?[$MQAP\9FG.%L:6\^+2-%FTQ1EB%Z3 N?AF36B&N#BE&Y,5%*.X3,I2T[8L
MW\Q0DAO+>?G9-5W.R8ZG28ZO*6"[+$/TZ2-.R7YA0./Y@YMDL^7R W,Y+] &
MWV)^5UQ3<6;6*G&2X9PE) <4KQ?&!WAY!6<RH8SXF> ].SH&\E+N"?DE3[[$
M"\.2%>$41UQ*(/'O :]PFDHE4<>_E:A1_Z9,/#Y^5O]47KRXF'O$\(JD_R0Q
MWRZ,J0%BO$:[E-^0_5^XNB!/ZD4D9>5?L*]B+0-$.\9)5B6+"K(D/_Q'CQ6(
MHP3HOI!@5PGVJ0E.E>"<FN!6">ZI"5Z54%ZZ>;CV$ER(.%K.*=D#*J.%FCPH
MZ9?9@E>2RXERRZGX-A%Y?/DECTB&P0_TB!F8@!7)"I+CG#- UH!O<?D)RI_^
M8"#$:TPICF4P^, 8%D%G7Q-TGZ0)3S [!V<AYBA)Q=$$W-V&X.S=.7@'DAS\
MV)(=0WG,YB871<N?-J.JP(^' NT7"@QQ= $<^![8ENTHTE>GI]N*]/#T=*A(
MOSH]W6JGFV*@ZM&RZ]&R2SWG1;UJ")+#L'$Q$J@<B4L5V8.8JQ:3+>B2%2C"
M"T/T&(;I S:6O_\&?>M/%><QQ<(QQ:Y&$FN-B%./B*-37W[",:8H!7<7MQ<@
M%XU=M'"*>))O0$H8 Q&B]$GT\SVBL6J(#NI!J2Z;^L,2NE9@^7/SX1B^(LQW
MK "VPT)MK4.QCB36PNK66%TMUEN../X_/ ^R_A$HQW$\JX.S'^6ZP=3MT-26
M.)3F2&(MFEY-T]/2O!&*B$9;(%JP6$4?Q/:@$(L]!Y'H)0E_+T&K8'H]3/[4
M]CJ3;J6(\JP>3&V%0V&.)-:"Z=<P?2W,[[38HAS$=+=YC9^OFHQ.=S(JHKS
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M-;D#A2ES*3<2OU/<>AUL#F:EA";_S"7G! _?FJKRWZ$,MA[&PQ[:>G:M&UK
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M&8*'2=6FP0/BP4U.6VN.'6RWW?X]QTX:FI*&#?4E\>5\WSGG\^V,MU(]ZA6
M(4\9%WKBK8S)+WU?)RO(J.[(' 3.+*3*J,&N6OHZ5T!3!\JX'W:[0S^C3'C1
MV(W-5#26:\.9@)DB>IUE5#U/@<OMQ N\W< =6ZZ,'?"C<4Z7< _F(9\I[/D5
M2\HR$)I)010L)MY5<!F/K+TS^,9@J_?:Q&8RE_+1=KZF$Z]K P(.B;$,%'\;
MN ;.+1&&\:OD]"J7%KC?WK%_=KEC+G.JX5KR[RPUJXGWP2,I+.B:FSNY_0)E
M/@/+ETBNW9=L"]M1UR/)6AN9E6",(&.B^-.G4H<]0# \ @A+0'@(Z!\!]$I
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MBIJEZ!B9NU=\+@W6!*ZYPC(/E#7 ^8649M>Q#JK",?H-4$L#!!0    ( '&
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MYWNV*]A<V/IRG0HVDD6J3 &R]<-G3!(!N20*"9V3+2S/8)#SAA#GO^4 \T9
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M_D]97ZQ=_?7?'MT];TS5'O-9_TO-[ U02P$"% ,4    " !Q@&=8!T%-8H$
M  "Q    $               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4
M Q0    ( '& 9UA'B7:N[@   "L"   1              "  :\   !D;V-0
M<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( '& 9UB97)PC$ 8  )PG   3
M          "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @
M<8!G6 7?7+0'!P  Y20  !@              ("!#0@  'AL+W=O<FMS:&5E
M=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( '& 9UCM?;=!.0(  +H%   8
M          " @4H/  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4
M    " !Q@&=8PO*3L+D%  "A%P  &               @(&Y$0  >&PO=V]R
M:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ <8!G6#8KH1B5 @  J@8
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M965T."YX;6Q02P$"% ,4    " !Q@&=8J@;2B.XG  !FA0  &
M    @($'/0  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @
M<8!G6)(W=3KB!   $@P  !D              ("!*V4  'AL+W=O<FMS:&5E
M=',O<VAE970Q,"YX;6Q02P$"% ,4    " !Q@&=8[T'2[^P#   C"0  &0
M            @(%$:@  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4
M Q0    ( '& 9UBTEP)+1 ,  (,'   9              " @6=N  !X;"]W
M;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ <8!G6$)I#!@%!P
M;1   !D              ("!XG$  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX
M;6Q02P$"% ,4    " !Q@&=8[YS))(<(   R&   &0              @($>
M>0  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( '& 9UAF
M";N[>P0  .\+   9              " @=R!  !X;"]W;W)K<VAE971S+W-H
M965T,34N>&UL4$L! A0#%     @ <8!G6!:/92/H'P  ]X0  !D
M     ("!CH8  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( '& 9UA6(/#OVP0  *H8   9              "
M@6C#  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @ <8!G
M6$![U:-Y*@  1Y8  !D              ("!>L@  'AL+W=O<FMS:&5E=',O
M<VAE970R,BYX;6Q02P$"% ,4    " !Q@&=8Z7'!)#0&   X$   &0
M        @($J\P  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0
M   ( '& 9U@I!=7)' ,  #,'   9              " @97Y  !X;"]W;W)K
M<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ <8!G6 >,]*,- P  :0<
M !D              ("!Z/P  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q0
M2P$"% ,4    " !Q@&=8%-'/G10#  "[!@  &0              @($L  $
M>&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( '& 9UA"*(P[
MT@,  #T)   9              " @7<# 0!X;"]W;W)K<VAE971S+W-H965T
M,C<N>&UL4$L! A0#%     @ <8!G6/S&EYKF @  I 8  !D
M ("!@ <! 'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4    " !Q
M@&=8'DD-QNX$   @#   &0              @(&="@$ >&PO=V]R:W-H965T
M<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( '& 9UAXK5-<. 8  (00   9
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M970S-"YX;6Q02P$"% ,4    " !Q@&=8TM8IUMP"  !S"   &0
M    @(%V* $ >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    (
M '& 9U@9(MBV,@0  #,5   9              " @8DK 0!X;"]W;W)K<VAE
M971S+W-H965T,S8N>&UL4$L! A0#%     @ <8!G6,I:F$2\ @  R@<  !D
M             ("!\B\! 'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"
M% ,4    " !Q@&=8F)P)CHL"  #J!@  &0              @('E,@$ >&PO
M=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( '& 9UB&:+VF/@,
M /0*   9              " @:<U 0!X;"]W;W)K<VAE971S+W-H965T,SDN
M>&UL4$L! A0#%     @ <8!G6*\E9P'N!   *B   !D              ("!
M'#D! 'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4    " !Q@&=8
M4#A M%(&  !V*@  &0              @(%!/@$ >&PO=V]R:W-H965T<R]S
M:&5E=#0Q+GAM;%!+ 0(4 Q0    ( '& 9UB\-CV@#@0  % 6   9
M      " @<I$ 0!X;"]W;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#%
M  @ <8!G6.?,X.R[ P  QA   !D              ("!#TD! 'AL+W=O<FMS
M:&5E=',O<VAE970T,RYX;6Q02P$"% ,4    " !Q@&=8M4JL/M(&   Y/P
M&0              @($!30$ >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+
M 0(4 Q0    ( '& 9UA.^ "L'@<  )A&   9              " @0I4 0!X
M;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @ <8!G6*F<3BQ#
M!0  X"0  !D              ("!7UL! 'AL+W=O<FMS:&5E=',O<VAE970T
M-BYX;6Q02P$"% ,4    " !Q@&=8&/7?U_ $  !>'@  &0
M@('98 $ >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    ( '&
M9UAD([@)G <   I)   9              " @0!F 0!X;"]W;W)K<VAE971S
M+W-H965T-#@N>&UL4$L! A0#%     @ <8!G6'P#^;4>!@  VC0  !D
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M=#4S+GAM;%!+ 0(4 Q0    ( '& 9UARXHR:N D  "M(   9
M  " @;R' 0!X;"]W;W)K<VAE971S+W-H965T-30N>&UL4$L! A0#%     @
M<8!G6$Q)4$<\!   XA<  !D              ("!JY$! 'AL+W=O<FMS:&5E
M=',O<VAE970U-2YX;6Q02P$"% ,4    " !Q@&=8HX1^NQL%  #1&P  &0
M            @($>E@$ >&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+ 0(4
M Q0    ( '& 9U@JUZ-^\ (  .\(   9              " @7"; 0!X;"]W
M;W)K<VAE971S+W-H965T-3<N>&UL4$L! A0#%     @ <8!G6#CZ3@TN!
M)@X  !D              ("!EYX! 'AL+W=O<FMS:&5E=',O<VAE970U."YX
M;6Q02P$"% ,4    " !Q@&=8MRE@\$(#  "="0  &0              @('\
MH@$ >&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+ 0(4 Q0    ( '& 9U@!
MEX%G!@,  $0*   9              " @76F 0!X;"]W;W)K<VAE971S+W-H
M965T-C N>&UL4$L! A0#%     @ <8!G6+Y=T?8M P  ZA(   T
M     ( !LJD! 'AL+W-T>6QE<RYX;6Q02P$"% ,4    " !Q@&=8EXJ[',
M   3 @  "P              @ $*K0$ 7W)E;',O+G)E;'-02P$"% ,4
M" !Q@&=8.OPGMBD%  #T)P  #P              @ 'SK0$ >&PO=V]R:V)O
M;VLN>&UL4$L! A0#%     @ <8!G6)@;6I[[ 0  RR,  !H
M ( !2;,! 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @
M<8!G6'32QF+> 0  6B,  !,              ( !?+4! %M#;VYT96YT7U1Y
><&5S72YX;6Q02P4&     $0 1 "3$@  B[<!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>238</ContextCount>
  <ElementCount>349</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>82</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="mgnx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="mgnx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="mgnx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="mgnx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="mgnx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="mgnx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="mgnx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="mgnx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - Organization and Nature of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/OrganizationandNatureofOperations</Role>
      <ShortName>Organization and Nature of Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="mgnx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="mgnx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/MarketableSecurities</Role>
      <ShortName>Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="mgnx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="mgnx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Property, Equipment and Software</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/PropertyEquipmentandSoftware</Role>
      <ShortName>Property, Equipment and Software</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="mgnx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="mgnx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Royalty Monetization Arrangement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/RoyaltyMonetizationArrangement</Role>
      <ShortName>Royalty Monetization Arrangement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="mgnx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="mgnx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/Revenue</Role>
      <ShortName>Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="mgnx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Stock-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockbasedCompensation</Role>
      <ShortName>Stock-based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="mgnx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="mgnx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Employee Benefit Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/EmployeeBenefitPlan</Role>
      <ShortName>Employee Benefit Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="mgnx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="mgnx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="mgnx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://macrogenics.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="mgnx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>9954472 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://macrogenics.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="mgnx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>9954473 - Disclosure - Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/MarketableSecuritiesTables</Role>
      <ShortName>Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://macrogenics.com/role/MarketableSecurities</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="mgnx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>9954474 - Disclosure - Inventory, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/InventoryNetTables</Role>
      <ShortName>Inventory, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="mgnx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>9954475 - Disclosure - Property, Equipment and Software (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/PropertyEquipmentandSoftwareTables</Role>
      <ShortName>Property, Equipment and Software (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://macrogenics.com/role/PropertyEquipmentandSoftware</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="mgnx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9954476 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://macrogenics.com/role/CommitmentsandContingencies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="mgnx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9954477 - Disclosure - Royalty Monetization Arrangement (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/RoyaltyMonetizationArrangementTables</Role>
      <ShortName>Royalty Monetization Arrangement (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://macrogenics.com/role/RoyaltyMonetizationArrangement</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="mgnx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9954478 - Disclosure - Stock-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockbasedCompensationTables</Role>
      <ShortName>Stock-based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://macrogenics.com/role/StockbasedCompensation</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="mgnx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9954479 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://macrogenics.com/role/IncomeTaxes</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="mgnx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9954480 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="mgnx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9954481 - Disclosure - Summary of Significant Accounting Policies - Summary of Fair Value Measurement Financial Asset and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Summary of Fair Value Measurement Financial Asset and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="mgnx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9954482 - Disclosure - Summary of Significant Accounting Policies - Summary of Collaborators that Represent More Than 10% of Total Revenue Earned and Accounts Receivable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Summary of Collaborators that Represent More Than 10% of Total Revenue Earned and Accounts Receivable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="mgnx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9954483 - Disclosure - Summary of Significant Accounting Policies - Estimated Useful Lives (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Estimated Useful Lives (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="mgnx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9954484 - Disclosure - Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from the Calculation of Diluted Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromtheCalculationofDilutedLossPerShareDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from the Calculation of Diluted Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="mgnx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9954485 - Disclosure - Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/MarketableSecuritiesDetails</Role>
      <ShortName>Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://macrogenics.com/role/MarketableSecuritiesTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="mgnx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9954486 - Disclosure - Marketable Securities - Available-For-Sale Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/MarketableSecuritiesAvailableForSaleSecuritiesDetails</Role>
      <ShortName>Marketable Securities - Available-For-Sale Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="mgnx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9954487 - Disclosure - Inventory, Net - Schedule of Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/InventoryNetScheduleofInventoryDetails</Role>
      <ShortName>Inventory, Net - Schedule of Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="mgnx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9954488 - Disclosure - Inventory, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/InventoryNetDetails</Role>
      <ShortName>Inventory, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://macrogenics.com/role/InventoryNetTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="mgnx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9954489 - Disclosure - Property, Equipment and Software (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails</Role>
      <ShortName>Property, Equipment and Software (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://macrogenics.com/role/PropertyEquipmentandSoftwareTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="mgnx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9954490 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://macrogenics.com/role/CommitmentsandContingenciesTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="mgnx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9954491 - Disclosure - Royalty Monetization Arrangement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/RoyaltyMonetizationArrangementDetails</Role>
      <ShortName>Royalty Monetization Arrangement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://macrogenics.com/role/RoyaltyMonetizationArrangementTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="mgnx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9954492 - Disclosure - Royalty Monetization Arrangement Rollforward (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/RoyaltyMonetizationArrangementRollforwardDetails</Role>
      <ShortName>Royalty Monetization Arrangement Rollforward (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="mgnx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9954493 - Disclosure - Stockholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockholdersEquityDetails</Role>
      <ShortName>Stockholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://macrogenics.com/role/StockholdersEquity</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="mgnx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9954494 - Disclosure - Revenue - Incyte Corporation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/RevenueIncyteCorporationDetails</Role>
      <ShortName>Revenue - Incyte Corporation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="mgnx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9954495 - Disclosure - Revenue - Gilead Sciences Inc (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/RevenueGileadSciencesIncDetails</Role>
      <ShortName>Revenue - Gilead Sciences Inc (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="mgnx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9954496 - Disclosure - Revenue - Zai Lab (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/RevenueZaiLabDetails</Role>
      <ShortName>Revenue - Zai Lab (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="mgnx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9954497 - Disclosure - Revenue - Provention (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/RevenueProventionDetails</Role>
      <ShortName>Revenue - Provention (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="mgnx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9954498 - Disclosure - Revenue - Manufacturing Service Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/RevenueManufacturingServiceAgreementsDetails</Role>
      <ShortName>Revenue - Manufacturing Service Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="mgnx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9954499 - Disclosure - Revenue - NIAID Contract (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/RevenueNIAIDContractDetails</Role>
      <ShortName>Revenue - NIAID Contract (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="mgnx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9954500 - Disclosure - Stock-based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockbasedCompensationNarrativeDetails</Role>
      <ShortName>Stock-based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="mgnx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9954501 - Disclosure - Stock-based Compensation - Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-based Compensation - Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="mgnx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9954502 - Disclosure - Stock-based Compensation - Option Pricing Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails</Role>
      <ShortName>Stock-based Compensation - Option Pricing Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="mgnx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9954503 - Disclosure - Stock-based Compensation - Stock Option and Restricted Stock Unit Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails</Role>
      <ShortName>Stock-based Compensation - Stock Option and Restricted Stock Unit Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="mgnx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>9954504 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="mgnx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>9954505 - Disclosure - Income Taxes - Components of the Company's Deferred Tax Assets (Liabilities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Components of the Company's Deferred Tax Assets (Liabilities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="mgnx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>9954506 - Disclosure - Income Taxes - Valuation Allowance Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/IncomeTaxesValuationAllowanceActivityDetails</Role>
      <ShortName>Income Taxes - Valuation Allowance Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="mgnx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>9954507 - Disclosure - Income Taxes - Reconciliation of Reported Estimated Income Tax Benefit (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails</Role>
      <ShortName>Income Taxes - Reconciliation of Reported Estimated Income Tax Benefit (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="mgnx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>9954508 - Disclosure - Income Taxes - Reconciliation of the Beginning and Ending Amount of Gross Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/IncomeTaxesReconciliationoftheBeginningandEndingAmountofGrossUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes - Reconciliation of the Beginning and Ending Amount of Gross Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="mgnx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>9954509 - Disclosure - Employee Benefit Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/EmployeeBenefitPlanDetails</Role>
      <ShortName>Employee Benefit Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://macrogenics.com/role/EmployeeBenefitPlan</ParentRole>
      <Position>60</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="mgnx-20231231.htm">mgnx-20231231.htm</File>
    <File>mgnx-20231231.xsd</File>
    <File>mgnx-20231231_cal.xml</File>
    <File>mgnx-20231231_def.xml</File>
    <File>mgnx-20231231_lab.xml</File>
    <File>mgnx-20231231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>mgnx-20231231_g1.jpg</File>
    <File>mgnx-20231231_g2.jpg</File>
    <File>mgnx-20231231_g3.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="682">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="39">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
    <BaseTaxonomy items="15">http://xbrl.sec.gov/ecd/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>88
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "mgnx-20231231.htm": {
   "nsprefix": "mgnx",
   "nsuri": "http://macrogenics.com/20231231",
   "dts": {
    "inline": {
     "local": [
      "mgnx-20231231.htm"
     ]
    },
    "schema": {
     "local": [
      "mgnx-20231231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "mgnx-20231231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "mgnx-20231231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "mgnx-20231231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "mgnx-20231231_pre.xml"
     ]
    }
   },
   "keyStandard": 287,
   "keyCustom": 62,
   "axisStandard": 24,
   "axisCustom": 0,
   "memberStandard": 31,
   "memberCustom": 44,
   "hidden": {
    "total": 6,
    "http://xbrl.sec.gov/dei/2023": 4,
    "http://xbrl.sec.gov/ecd/2023": 2
   },
   "contextCount": 238,
   "entityCount": 1,
   "segmentCount": 82,
   "elementCount": 620,
   "unitCount": 6,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 682,
    "http://xbrl.sec.gov/dei/2023": 39,
    "http://xbrl.sec.gov/ecd/2023": 15
   },
   "report": {
    "R1": {
     "role": "http://macrogenics.com/role/CoverPage",
     "longName": "0000001 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://macrogenics.com/role/AuditInformation",
     "longName": "0000002 - Document - Audit Information",
     "shortName": "Audit Information",
     "isDefault": "false",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorFirmId",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorFirmId",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS",
     "longName": "0000003 - Statement - CONSOLIDATED BALANCE SHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-2",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
     "longName": "0000004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-2",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
     "longName": "0000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
     "longName": "0000006 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-29",
      "name": "us-gaap:SharesIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-29",
      "name": "us-gaap:SharesIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "longName": "0000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://macrogenics.com/role/OrganizationandNatureofOperations",
     "longName": "0000008 - Disclosure - Organization and Nature of Operations",
     "shortName": "Organization and Nature of Operations",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://macrogenics.com/role/SummaryofSignificantAccountingPolicies",
     "longName": "0000009 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://macrogenics.com/role/MarketableSecurities",
     "longName": "0000010 - Disclosure - Marketable Securities",
     "shortName": "Marketable Securities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://macrogenics.com/role/Inventory",
     "longName": "0000011 - Disclosure - Inventory",
     "shortName": "Inventory",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://macrogenics.com/role/PropertyEquipmentandSoftware",
     "longName": "0000012 - Disclosure - Property, Equipment and Software",
     "shortName": "Property, Equipment and Software",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://macrogenics.com/role/CommitmentsandContingencies",
     "longName": "0000013 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://macrogenics.com/role/RoyaltyMonetizationArrangement",
     "longName": "0000014 - Disclosure - Royalty Monetization Arrangement",
     "shortName": "Royalty Monetization Arrangement",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "mgnx:LiabilityRelatedToSaleOfFutureRoyaltiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "mgnx:LiabilityRelatedToSaleOfFutureRoyaltiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://macrogenics.com/role/StockholdersEquity",
     "longName": "0000015 - Disclosure - Stockholders' Equity",
     "shortName": "Stockholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://macrogenics.com/role/Revenue",
     "longName": "0000016 - Disclosure - Revenue",
     "shortName": "Revenue",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "mgnx:CollaborationAndLicenseAgreementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "mgnx:CollaborationAndLicenseAgreementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://macrogenics.com/role/StockbasedCompensation",
     "longName": "0000017 - Disclosure - Stock-based Compensation",
     "shortName": "Stock-based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://macrogenics.com/role/IncomeTaxes",
     "longName": "0000018 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://macrogenics.com/role/EmployeeBenefitPlan",
     "longName": "0000019 - Disclosure - Employee Benefit Plan",
     "shortName": "Employee Benefit Plan",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R21": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "ecd:NonRule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "ecd:NonRule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "longName": "9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesTables",
     "longName": "9954472 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://macrogenics.com/role/MarketableSecuritiesTables",
     "longName": "9954473 - Disclosure - Marketable Securities (Tables)",
     "shortName": "Marketable Securities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://macrogenics.com/role/InventoryNetTables",
     "longName": "9954474 - Disclosure - Inventory, Net (Tables)",
     "shortName": "Inventory, Net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://macrogenics.com/role/PropertyEquipmentandSoftwareTables",
     "longName": "9954475 - Disclosure - Property, Equipment and Software (Tables)",
     "shortName": "Property, Equipment and Software (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://macrogenics.com/role/CommitmentsandContingenciesTables",
     "longName": "9954476 - Disclosure - Commitments and Contingencies (Tables)",
     "shortName": "Commitments and Contingencies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "mgnx:ScheduleOfSupplementalBalanceSheetInformationOperatingLeasesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "mgnx:ScheduleOfSupplementalBalanceSheetInformationOperatingLeasesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://macrogenics.com/role/RoyaltyMonetizationArrangementTables",
     "longName": "9954477 - Disclosure - Royalty Monetization Arrangement (Tables)",
     "shortName": "Royalty Monetization Arrangement (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "mgnx:LiabilityRelatedToFutureRoyaltyTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "mgnx:LiabilityRelatedToSaleOfFutureRoyaltiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "mgnx:LiabilityRelatedToFutureRoyaltyTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "mgnx:LiabilityRelatedToSaleOfFutureRoyaltiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://macrogenics.com/role/StockbasedCompensationTables",
     "longName": "9954478 - Disclosure - Stock-based Compensation (Tables)",
     "shortName": "Stock-based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://macrogenics.com/role/IncomeTaxesTables",
     "longName": "9954479 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesDetails",
     "longName": "9954480 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails",
     "longName": "9954481 - Disclosure - Summary of Significant Accounting Policies - Summary of Fair Value Measurement Financial Asset and Liabilities (Details)",
     "shortName": "Summary of Significant Accounting Policies - Summary of Fair Value Measurement Financial Asset and Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-2",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails",
     "longName": "9954482 - Disclosure - Summary of Significant Accounting Policies - Summary of Collaborators that Represent More Than 10% of Total Revenue Earned and Accounts Receivable (Details)",
     "shortName": "Summary of Significant Accounting Policies - Summary of Collaborators that Represent More Than 10% of Total Revenue Earned and Accounts Receivable (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-86",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-86",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails",
     "longName": "9954483 - Disclosure - Summary of Significant Accounting Policies - Estimated Useful Lives (Details)",
     "shortName": "Summary of Significant Accounting Policies - Estimated Useful Lives (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-102",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-102",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromtheCalculationofDilutedLossPerShareDetails",
     "longName": "9954484 - Disclosure - Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from the Calculation of Diluted Loss Per Share (Details)",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from the Calculation of Diluted Loss Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-106",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-106",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://macrogenics.com/role/MarketableSecuritiesDetails",
     "longName": "9954485 - Disclosure - Marketable Securities (Details)",
     "shortName": "Marketable Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-2",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://macrogenics.com/role/MarketableSecuritiesAvailableForSaleSecuritiesDetails",
     "longName": "9954486 - Disclosure - Marketable Securities - Available-For-Sale Securities (Details)",
     "shortName": "Marketable Securities - Available-For-Sale Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-2",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://macrogenics.com/role/InventoryNetScheduleofInventoryDetails",
     "longName": "9954487 - Disclosure - Inventory, Net - Schedule of Inventory (Details)",
     "shortName": "Inventory, Net - Schedule of Inventory (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "us-gaap:InventoryWorkInProcess",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-2",
      "name": "us-gaap:InventoryWorkInProcess",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://macrogenics.com/role/InventoryNetDetails",
     "longName": "9954488 - Disclosure - Inventory, Net (Details)",
     "shortName": "Inventory, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-116",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "mgnx:ScheduleOfInventoryReservesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-119",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "mgnx:ScheduleOfInventoryReservesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "unique": true
     }
    },
    "R40": {
     "role": "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails",
     "longName": "9954489 - Disclosure - Property, Equipment and Software (Details)",
     "shortName": "Property, Equipment and Software (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-2",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://macrogenics.com/role/CommitmentsandContingenciesDetails",
     "longName": "9954490 - Disclosure - Commitments and Contingencies (Details)",
     "shortName": "Commitments and Contingencies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "mgnx:RightOfUseAssetAndLeaseLiabilityIncrease",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-2",
      "name": "mgnx:RightOfUseAssetAndLeaseLiabilityIncrease",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://macrogenics.com/role/RoyaltyMonetizationArrangementDetails",
     "longName": "9954491 - Disclosure - Royalty Monetization Arrangement (Details)",
     "shortName": "Royalty Monetization Arrangement (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-137",
      "name": "mgnx:GainOnRoyaltyMonetizationArrangement",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "mgnx:LiabilityRelatedToSaleOfFutureRoyaltiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-135",
      "name": "mgnx:UpfrontPayment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "mgnx:LiabilityRelatedToSaleOfFutureRoyaltiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "unique": true
     }
    },
    "R43": {
     "role": "http://macrogenics.com/role/RoyaltyMonetizationArrangementRollforwardDetails",
     "longName": "9954492 - Disclosure - Royalty Monetization Arrangement Rollforward (Details)",
     "shortName": "Royalty Monetization Arrangement Rollforward (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "mgnx:LiabilityRelatedToFutureRoyalties",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "mgnx:LiabilityRelatedToFutureRoyaltyTableTextBlock",
       "mgnx:LiabilityRelatedToSaleOfFutureRoyaltiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-2",
      "name": "mgnx:LiabilityRelatedToFutureRoyalties",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "mgnx:LiabilityRelatedToFutureRoyaltyTableTextBlock",
       "mgnx:LiabilityRelatedToSaleOfFutureRoyaltiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://macrogenics.com/role/StockholdersEquityDetails",
     "longName": "9954493 - Disclosure - Stockholders' Equity (Details)",
     "shortName": "Stockholders' Equity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-139",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "unique": true
     }
    },
    "R45": {
     "role": "http://macrogenics.com/role/RevenueIncyteCorporationDetails",
     "longName": "9954494 - Disclosure - Revenue - Incyte Corporation (Details)",
     "shortName": "Revenue - Incyte Corporation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-148",
      "name": "mgnx:NonRefundableUpfrontFees",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://macrogenics.com/role/RevenueGileadSciencesIncDetails",
     "longName": "9954495 - Disclosure - Revenue - Gilead Sciences Inc (Details)",
     "shortName": "Revenue - Gilead Sciences Inc (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-167",
      "name": "mgnx:NonRefundableUpfrontFees",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://macrogenics.com/role/RevenueZaiLabDetails",
     "longName": "9954496 - Disclosure - Revenue - Zai Lab (Details)",
     "shortName": "Revenue - Zai Lab (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-175",
      "name": "mgnx:NonRefundableUpfrontFees",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://macrogenics.com/role/RevenueProventionDetails",
     "longName": "9954497 - Disclosure - Revenue - Provention (Details)",
     "shortName": "Revenue - Provention (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-187",
      "name": "mgnx:CollaborativeAgreementTransactionPrice",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "unique": true
     }
    },
    "R49": {
     "role": "http://macrogenics.com/role/RevenueManufacturingServiceAgreementsDetails",
     "longName": "9954498 - Disclosure - Revenue - Manufacturing Service Agreements (Details)",
     "shortName": "Revenue - Manufacturing Service Agreements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-196",
      "name": "mgnx:NonRefundableUpfrontFees",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://macrogenics.com/role/RevenueNIAIDContractDetails",
     "longName": "9954499 - Disclosure - Revenue - NIAID Contract (Details)",
     "shortName": "Revenue - NIAID Contract (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-206",
      "name": "mgnx:TotalPotentialValueUnderAgreement",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://macrogenics.com/role/StockbasedCompensationNarrativeDetails",
     "longName": "9954500 - Disclosure - Stock-based Compensation - Narrative (Details)",
     "shortName": "Stock-based Compensation - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-212",
      "name": "mgnx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails",
     "longName": "9954501 - Disclosure - Stock-based Compensation - Stock-Based Compensation Expense (Details)",
     "shortName": "Stock-based Compensation - Stock-Based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails",
     "longName": "9954502 - Disclosure - Stock-based Compensation - Option Pricing Assumptions (Details)",
     "shortName": "Stock-based Compensation - Option Pricing Assumptions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails",
     "longName": "9954503 - Disclosure - Stock-based Compensation - Stock Option and Restricted Stock Unit Activity (Details)",
     "shortName": "Stock-based Compensation - Stock Option and Restricted Stock Unit Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c-11",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails",
     "longName": "9954504 - Disclosure - Income Taxes - Additional Information (Details)",
     "shortName": "Income Taxes - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CurrentIncomeTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CurrentIncomeTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails",
     "longName": "9954505 - Disclosure - Income Taxes - Components of the Company's Deferred Tax Assets (Liabilities) (Details)",
     "shortName": "Income Taxes - Components of the Company's Deferred Tax Assets (Liabilities) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-2",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://macrogenics.com/role/IncomeTaxesValuationAllowanceActivityDetails",
     "longName": "9954506 - Disclosure - Income Taxes - Valuation Allowance Activity (Details)",
     "shortName": "Income Taxes - Valuation Allowance Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c-11",
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SummaryOfValuationAllowanceTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "mgnx:ValuationAllowanceDeferredTaxAssetIncreaseAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SummaryOfValuationAllowanceTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails",
     "longName": "9954507 - Disclosure - Income Taxes - Reconciliation of Reported Estimated Income Tax Benefit (Details)",
     "shortName": "Income Taxes - Reconciliation of Reported Estimated Income Tax Benefit (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://macrogenics.com/role/IncomeTaxesReconciliationoftheBeginningandEndingAmountofGrossUnrecognizedTaxBenefitsDetails",
     "longName": "9954508 - Disclosure - Income Taxes - Reconciliation of the Beginning and Ending Amount of Gross Unrecognized Tax Benefits (Details)",
     "shortName": "Income Taxes - Reconciliation of the Beginning and Ending Amount of Gross Unrecognized Tax Benefits (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c-11",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-33",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "unique": true
     }
    },
    "R60": {
     "role": "http://macrogenics.com/role/EmployeeBenefitPlanDetails",
     "longName": "9954509 - Disclosure - Employee Benefit Plan (Details)",
     "shortName": "Employee Benefit Plan (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "mgnx:EmployeesEligibleAgeToParticipateInBenefitPlan",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "mgnx:EmployeesEligibleAgeToParticipateInBenefitPlan",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20231231.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "mgnx_A2021ZaiLabAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "A2021ZaiLabAgreementsMember",
     "presentation": [
      "http://macrogenics.com/role/RevenueZaiLabDetails",
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2021 Zai Lab Agreements",
        "label": "2021 Zai Lab Agreements [Member]",
        "documentation": "2021 Zai Lab Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_A2022GileadCollaborationAndLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "A2022GileadCollaborationAndLicenseAgreementMember",
     "presentation": [
      "http://macrogenics.com/role/RevenueGileadSciencesIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2022 Gilead Collaboration And License Agreement",
        "label": "2022 Gilead Collaboration And License Agreement [Member]",
        "documentation": "2022 Gilead Collaboration And License Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_ASDHealthcareAndOncologySupplyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "ASDHealthcareAndOncologySupplyMember",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASD Healthcare and Oncology Supply",
        "label": "ASD Healthcare and Oncology Supply [Member]",
        "documentation": "ASD Healthcare and Oncology Supply"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Policies [Abstract]",
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r643"
     ]
    },
    "us-gaap_AccountsReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableMember",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable",
        "label": "Accounts Receivable [Member]",
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold."
       }
      }
     },
     "auth_ref": [
      "r608"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r227",
      "r228"
     ]
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "crdr": "credit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Amortization of premiums and discounts on marketable securities",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other current liabilities",
        "label": "Accrued Liabilities, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less accumulated depreciation and amortization",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r143",
      "r502"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive loss",
        "label": "AOCI, Debt Securities, Available-for-Sale, Adjustment, after Tax",
        "documentation": "Amount, after tax, of accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r755"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Loss",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r9",
      "r25",
      "r415",
      "r418",
      "r454",
      "r516",
      "r517",
      "r756",
      "r757",
      "r758",
      "r769",
      "r770",
      "r771"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional 402(v) Disclosure",
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r697"
     ]
    },
    "mgnx_AdditionalAnnualFixedPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "AdditionalAnnualFixedPayments",
     "crdr": "credit",
     "presentation": [
      "http://macrogenics.com/role/RevenueManufacturingServiceAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional annual fixed payments",
        "label": "Additional Annual Fixed Payments",
        "documentation": "Additional Annual Fixed Payments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital, Common Stock",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://macrogenics.com/role/RevenueZaiLabDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-In Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r379",
      "r380",
      "r381",
      "r531",
      "r769",
      "r770",
      "r771",
      "r837",
      "r857"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation, Amount",
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r703"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation:",
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r703"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote",
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r703"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment To PEO Compensation, Footnote",
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r703"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r57",
      "r345"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash provided by (used in) operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Amount",
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r667",
      "r679",
      "r689",
      "r715"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined",
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r670",
      "r682",
      "r692",
      "r718"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Adjustments to Compensation",
        "label": "All Adjustments to Compensation [Member]"
       }
      }
     },
     "auth_ref": [
      "r703"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Executive Categories",
        "label": "All Executive Categories [Member]"
       }
      }
     },
     "auth_ref": [
      "r710"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Individuals",
        "label": "All Individuals [Member]"
       }
      }
     },
     "auth_ref": [
      "r674",
      "r683",
      "r693",
      "r710",
      "r719",
      "r723",
      "r731"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Trading Arrangements",
        "label": "All Trading Arrangements [Member]"
       }
      }
     },
     "auth_ref": [
      "r729"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r374",
      "r382"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromtheCalculationofDilutedLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Anti-dilutive stock options",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r205"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromtheCalculationofDilutedLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities [Axis]",
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromtheCalculationofDilutedLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromtheCalculationofDilutedLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities, Name [Domain]",
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://macrogenics.com/role/RevenueManufacturingServiceAgreementsDetails",
      "http://macrogenics.com/role/RevenueProventionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangements and Non-arrangement Transactions [Domain]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r409"
     ]
    },
    "mgnx_AssetPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "AssetPurchaseAgreementMember",
     "presentation": [
      "http://macrogenics.com/role/RevenueProventionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Purchase Agreement",
        "label": "Asset Purchase Agreement [Member]",
        "documentation": "Asset Acquisition Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r145",
      "r174",
      "r210",
      "r218",
      "r222",
      "r265",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r410",
      "r412",
      "r434",
      "r497",
      "r564",
      "r643",
      "r656",
      "r798",
      "r799",
      "r842"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r152",
      "r174",
      "r265",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r410",
      "r412",
      "r434",
      "r643",
      "r798",
      "r799",
      "r842"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets measured at fair value",
        "label": "Assets, Fair Value Disclosure",
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsFairValueDisclosureAbstract",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets [Abstract]",
        "label": "Assets, Fair Value Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_AtTheMarketOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "AtTheMarketOfferingMember",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "At The Market Offering",
        "label": "At The Market Offering [Member]",
        "documentation": "At The Market Offering [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://macrogenics.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Firm ID",
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r661",
      "r662",
      "r675"
     ]
    },
    "mgnx_AuditorInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "AuditorInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Information [Abstract]",
        "documentation": "Auditor Information"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLocation",
     "presentation": [
      "http://macrogenics.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Location",
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r661",
      "r662",
      "r675"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorName",
     "presentation": [
      "http://macrogenics.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Name",
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r661",
      "r662",
      "r675"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://macrogenics.com/role/MarketableSecuritiesDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross Unrealized Gains",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r239"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/MarketableSecuritiesDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Gross Unrealized Losses",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r240"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/MarketableSecuritiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Amortized Cost",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r236",
      "r273",
      "r496"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 2.0
      },
      "http://macrogenics.com/role/MarketableSecuritiesDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Securities",
        "terseLabel": "Fair Value",
        "label": "Debt Securities, Available-for-Sale",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r237",
      "r273",
      "r490",
      "r774"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price",
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r726"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value as of Grant Date",
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r727"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r722"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing, How MNPI Considered",
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r722"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Method",
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r722"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Considered",
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r722"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Disclosure",
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r722"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Predetermined",
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r722"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationNarrativeDetails",
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Axis]",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Securities",
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r725"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r724"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures",
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r723"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table",
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r723"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation and Principles of Consolidation",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital Expenditures Incurred but Not yet Paid",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r31",
      "r32"
     ]
    },
    "mgnx_CardinalHealthIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "CardinalHealthIncMember",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cardinal Health",
        "label": "Cardinal Health, Inc [Member]",
        "documentation": "Cardinal Health, Inc"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r141",
      "r614"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash, Cash Equivalents and Marketable Securities",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents at beginning of period",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r90",
      "r171"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net change in cash and cash equivalents",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r90"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changed Peer Group, Footnote",
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r701"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Domain]",
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r146",
      "r147",
      "r148",
      "r174",
      "r199",
      "r200",
      "r202",
      "r204",
      "r208",
      "r209",
      "r265",
      "r292",
      "r294",
      "r295",
      "r296",
      "r299",
      "r300",
      "r305",
      "r306",
      "r309",
      "r312",
      "r319",
      "r434",
      "r525",
      "r526",
      "r527",
      "r528",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r552",
      "r573",
      "r592",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r738",
      "r761",
      "r772"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Line Items]",
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r147",
      "r148",
      "r208",
      "r305",
      "r306",
      "r307",
      "r309",
      "r312",
      "r317",
      "r319",
      "r525",
      "r526",
      "r527",
      "r528",
      "r630",
      "r738",
      "r761"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Amount",
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r702"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Name",
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r702"
     ]
    },
    "mgnx_CollaborationAndLicenseAgreementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "CollaborationAndLicenseAgreementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration and License Agreements [Abstract]",
        "label": "Collaboration and License Agreements [Abstract]",
        "documentation": ""
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "CollaborationAndLicenseAgreementsDisclosureTextBlock",
     "presentation": [
      "http://macrogenics.com/role/Revenue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue",
        "label": "Collaboration And License Agreements Disclosure [Text Block]",
        "documentation": "The entire disclosure for collaboration and license agreements."
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare",
     "presentation": [
      "http://macrogenics.com/role/RevenueProventionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consideration received common stock warrant exercise price (in usd per share)",
        "label": "Collaborative Agreement Consideration Received Common Stock Warrant Exercise Price Per Share",
        "documentation": "Collaborative Agreement Consideration Received Common Stock Warrant Exercise Price Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares",
     "presentation": [
      "http://macrogenics.com/role/RevenueProventionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock warrants (in shares)",
        "label": "Collaborative Agreement Consideration Received Common Stock Warrants Number Of Shares",
        "documentation": "Collaborative Agreement Consideration Received Common Stock Warrants Number Of Shares"
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_CollaborativeAgreementTransactionPrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "CollaborativeAgreementTransactionPrice",
     "crdr": "credit",
     "presentation": [
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails",
      "http://macrogenics.com/role/RevenueProventionDetails",
      "http://macrogenics.com/role/RevenueZaiLabDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transaction price",
        "label": "Collaborative Agreement Transaction Price",
        "documentation": "Collaborative Agreement Transaction Price"
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_CollaborativeArrangementExtensionTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "CollaborativeArrangementExtensionTerm",
     "presentation": [
      "http://macrogenics.com/role/RevenueManufacturingServiceAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative arrangement, extension term",
        "label": "Collaborative Arrangement, Extension Term",
        "documentation": "Collaborative Arrangement, Extension Term"
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_CollaborativeArrangementTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "CollaborativeArrangementTerm",
     "presentation": [
      "http://macrogenics.com/role/RevenueManufacturingServiceAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative arrangement, term",
        "label": "Collaborative Arrangement, Term",
        "documentation": "Collaborative Arrangement, Term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember",
     "presentation": [
      "http://macrogenics.com/role/RevenueManufacturingServiceAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement",
        "label": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]",
        "documentation": "Collaborative arrangement transaction between parties to collaborative arrangement."
       }
      }
     },
     "auth_ref": [
      "r836"
     ]
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://macrogenics.com/role/RevenueGileadSciencesIncDetails",
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails",
      "http://macrogenics.com/role/RevenueManufacturingServiceAgreementsDetails",
      "http://macrogenics.com/role/RevenueNIAIDContractDetails",
      "http://macrogenics.com/role/RevenueProventionDetails",
      "http://macrogenics.com/role/RevenueZaiLabDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration and Other Agreements [Line Items]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r409"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r286",
      "r287",
      "r609",
      "r795"
     ]
    },
    "mgnx_CommonStockMaximumAmountAvailableForIssuance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "CommonStockMaximumAmountAvailableForIssuance",
     "crdr": "debit",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock maximum amount available for issuance",
        "label": "Common Stock, Maximum Amount Available For Issuance",
        "documentation": "Common Stock, Maximum Amount Available For Issuance"
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "CommonStockMaximumAmountAvailableForIssuanceIncrease",
     "crdr": "debit",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock, Maximum Amount Available For Issuance, Increase",
        "label": "Common Stock, Maximum Amount Available For Issuance, Increase",
        "documentation": "Common Stock, Maximum Amount Available For Issuance, Increase"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r646",
      "r647",
      "r648",
      "r650",
      "r651",
      "r652",
      "r653",
      "r769",
      "r770",
      "r837",
      "r855",
      "r857"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://macrogenics.com/role/RevenueZaiLabDetails",
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in dollars per share)",
        "verboseLabel": "Common stock, par value (in dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized (in shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r552"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares outstanding (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r73",
      "r552",
      "r570",
      "r857",
      "r858"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, 0.01 par value -- 125,000,000 shares authorized, 62,070,627 and 61,701,467 shares outstanding at December\u00a031, 2023 and December\u00a031, 2022, respectively",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r498",
      "r643"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure",
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r707"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Net Income",
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r706"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Other Measure",
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r708"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return",
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r705"
     ]
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred income tax assets:",
        "label": "Components of Deferred Tax Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred income tax liabilities:",
        "label": "Components of Deferred Tax Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r157",
      "r159",
      "r165",
      "r491",
      "r506"
     ]
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Comprehensive Loss",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computer equipment",
        "label": "Computer Equipment [Member]",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark [Domain]",
        "label": "Concentration Risk Benchmark [Domain]",
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r38",
      "r64",
      "r65",
      "r226",
      "r608"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark [Axis]",
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r38",
      "r64",
      "r65",
      "r226",
      "r521",
      "r608"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type [Axis]",
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r38",
      "r64",
      "r65",
      "r226",
      "r608",
      "r740"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration of Credit Risk",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r126"
     ]
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskLineItems",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk [Line Items]",
        "label": "Concentration Risk [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r608"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Percentage of significant accounts receivable",
        "label": "Concentration Risk, Percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r38",
      "r64",
      "r65",
      "r226"
     ]
    },
    "us-gaap_ConcentrationRiskTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskTable",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk [Table]",
        "label": "Concentration Risk [Table]",
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r36",
      "r38",
      "r39",
      "r64",
      "r110",
      "r608"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type [Domain]",
        "label": "Concentration Risk Type [Domain]",
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r38",
      "r64",
      "r65",
      "r226",
      "r608"
     ]
    },
    "us-gaap_ConstructionInProgressGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConstructionInProgressGross",
     "crdr": "debit",
     "presentation": [
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Construction in progress",
        "label": "Construction in Progress, Gross",
        "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "mgnx_ContractManufacturingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "ContractManufacturingMember",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract Manufacturing",
        "label": "Contract Manufacturing [Member]",
        "documentation": "Contract Manufacturing"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiability",
     "crdr": "credit",
     "presentation": [
      "http://macrogenics.com/role/RevenueGileadSciencesIncDetails",
      "http://macrogenics.com/role/RevenueManufacturingServiceAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "label": "Contract with Customer, Liability",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r321",
      "r322",
      "r323"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiabilityCurrent",
     "crdr": "credit",
     "presentation": [
      "http://macrogenics.com/role/RevenueGileadSciencesIncDetails",
      "http://macrogenics.com/role/RevenueManufacturingServiceAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue, current",
        "label": "Contract with Customer, Liability, Current",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r321",
      "r322",
      "r323"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://macrogenics.com/role/RevenueGileadSciencesIncDetails",
      "http://macrogenics.com/role/RevenueManufacturingServiceAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue, noncurrent",
        "label": "Contract with Customer, Liability, Noncurrent",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r321",
      "r322",
      "r323"
     ]
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CorporateDebtSecuritiesMember",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Corporate debt securities",
        "terseLabel": "Corporate debt securities",
        "label": "Corporate Debt Securities [Member]",
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment."
       }
      }
     },
     "auth_ref": [
      "r633",
      "r635",
      "r854"
     ]
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfGoodsAndServicesSold",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of product sales",
        "label": "Cost of Goods and Services Sold",
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r489"
     ]
    },
    "mgnx_CostOfManufacturingServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "CostOfManufacturingServices",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of manufacturing services",
        "label": "Cost of manufacturing services",
        "documentation": "Cost of manufacturing services"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostOfSalesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfSalesPolicyTextBlock",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of Product Sales and Cost of Manufacturing Services",
        "label": "Cost of Goods and Service [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cost of product sold and service rendered."
       }
      }
     },
     "auth_ref": [
      "r742"
     ]
    },
    "us-gaap_CostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostsAndExpenses",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total costs and expenses",
        "label": "Costs and Expenses",
        "documentation": "Total costs of sales and operating expenses for the period."
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostsAndExpensesAbstract",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Costs and expenses:",
        "label": "Costs and Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingenciesDetails",
      "http://macrogenics.com/role/RevenueGileadSciencesIncDetails",
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails",
      "http://macrogenics.com/role/RevenueManufacturingServiceAgreementsDetails",
      "http://macrogenics.com/role/RevenueNIAIDContractDetails",
      "http://macrogenics.com/role/RevenueProventionDetails",
      "http://macrogenics.com/role/RevenueZaiLabDetails",
      "http://macrogenics.com/role/RoyaltyMonetizationArrangementDetails",
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Axis]",
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r176",
      "r177",
      "r301",
      "r307",
      "r455",
      "r617",
      "r619"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provision for federal or state income taxes",
        "label": "Current Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r400",
      "r405",
      "r763"
     ]
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer Concentration Risk",
        "label": "Customer Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r226"
     ]
    },
    "mgnx_DRIHealthcareAcquisitionsLPDRIMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "DRIHealthcareAcquisitionsLPDRIMember",
     "presentation": [
      "http://macrogenics.com/role/RevenueProventionDetails",
      "http://macrogenics.com/role/RoyaltyMonetizationArrangementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "DRI Healthcare Acquisitions LP (DRI)",
        "label": "DRI Healthcare Acquisitions LP (DRI) [Member]",
        "documentation": "DRI Healthcare Acquisitions LP (DRI)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
     "crdr": "credit",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesAvailableForSaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities, Available-for-sale, Allowance for Credit Loss",
        "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss",
        "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r238",
      "r273",
      "r277",
      "r278"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Available-for-sale",
        "label": "Debt Securities, Available-for-Sale [Table Text Block]",
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Gross deferred income tax liabilities",
        "label": "Deferred Tax Liabilities, Gross",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r71",
      "r113",
      "r396"
     ]
    },
    "us-gaap_DeferredRevenueCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredRevenueCurrent",
     "crdr": "credit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "label": "Deferred Revenue, Current",
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r750"
     ]
    },
    "us-gaap_DeferredRevenueNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredRevenueNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Deferred revenue, net of current portion",
        "label": "Deferred Revenue, Noncurrent",
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r751"
     ]
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsDeferredIncome",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "label": "Deferred Tax Assets, Deferred Income",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r835"
     ]
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gross deferred income tax assets",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r397"
     ]
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred income tax asset/(liability)",
        "label": "Deferred Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r834"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred income tax assets",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r834"
     ]
    },
    "mgnx_DeferredTaxAssetsOperatingLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "DeferredTaxAssetsOperatingLeaseLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "label": "Deferred Tax Assets, Operating Lease Liabilities",
        "documentation": "Deferred Tax Assets, Operating Lease Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal U.S. net operating loss carryforward",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Domestic",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r835"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State net operating loss carryforward",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, State and Local",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r835"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration",
     "crdr": "debit",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforwards",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Deferred Tax Assets, Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r835"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsOther",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Orphan drug credit, net",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible tax credit carryforwards, classified as other."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r61",
      "r835"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development credit, net",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r61",
      "r835"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r835"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails",
      "http://macrogenics.com/role/IncomeTaxesValuationAllowanceActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Valuation allowance",
        "periodStartLabel": "Balance at Beginning of Year",
        "periodEndLabel": "Balance at End of Year",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r398"
     ]
    },
    "mgnx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets",
     "crdr": "credit",
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Operating lease ROU assets",
        "label": "Deferred Tax Liabilities, Operating Lease Right Of Use Assets",
        "documentation": "Deferred Tax Liabilities, Operating Lease Right Of Use Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesPrepaidExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesPrepaidExpenses",
     "crdr": "credit",
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenditures",
        "label": "Deferred Tax Liabilities, Prepaid Expenses",
        "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses."
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_DeferredTransactionCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "DeferredTransactionCosts",
     "crdr": "credit",
     "presentation": [
      "http://macrogenics.com/role/RoyaltyMonetizationArrangementRollforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Deferred transaction costs",
        "label": "Deferred transaction costs",
        "documentation": "Deferred transaction costs"
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "DefinedContributionPlanEmployeesContributionVestedPercentage",
     "presentation": [
      "http://macrogenics.com/role/EmployeeBenefitPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of employee vested contribution",
        "label": "Defined Contribution Plan, Employees Contribution, Vested Percentage",
        "documentation": "Percentage vested of employee's contributions to defined contribution plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "crdr": "debit",
     "presentation": [
      "http://macrogenics.com/role/EmployeeBenefitPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defined contribution plan, employer discretionary contribution amount",
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
     "presentation": [
      "http://macrogenics.com/role/EmployeeBenefitPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of employee contribution to salary",
        "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent",
        "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation expense",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r44"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization",
        "label": "Depreciation, Depletion and Amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r214"
     ]
    },
    "mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized",
     "crdr": "credit",
     "presentation": [
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails",
      "http://macrogenics.com/role/RevenueProventionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amounts recognized",
        "label": "Development And Regulatory Milestone Payments Under Agreement, Recognized",
        "documentation": "Development And Regulatory Milestone Payments Under Agreement, Recognized"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based Compensation",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r343",
      "r347",
      "r375",
      "r376",
      "r378",
      "r637"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]",
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Annual Report",
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r661",
      "r662",
      "r675"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Financial Statement Error Correction [Flag]",
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r661",
      "r662",
      "r675",
      "r711"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r696"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Documents Incorporated by Reference",
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r659"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. Federal Government",
        "label": "Domestic Tax Authority [Member]",
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile."
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. Federal and State",
        "label": "Domestic Tax Authority and State and Local Jurisdiction [Member] [Member]",
        "documentation": "Domestic Tax Authority and State and Local Jurisdiction [Member] [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic and diluted net loss per common share, basic (in dollars per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r166",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r197",
      "r199",
      "r202",
      "r203",
      "r204",
      "r206",
      "r423",
      "r424",
      "r492",
      "r507",
      "r623"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic and diluted net loss per common share, diluted (in dollars per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r166",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r199",
      "r202",
      "r203",
      "r204",
      "r206",
      "r423",
      "r424",
      "r492",
      "r507",
      "r623"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss Per Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r34"
     ]
    },
    "mgnx_EffectiveIncomeTaxRateReconciliationDeferredStateBlendedRateAdjustmentsAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationDeferredStateBlendedRateAdjustmentsAmount",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred state blended rate adjustments",
        "label": "Effective Income Tax Rate Reconciliation, Deferred State Blended Rate Adjustments, Amount",
        "documentation": "Effective Income Tax Rate Reconciliation, Deferred State Blended Rate Adjustments, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred income tax adjustments",
        "label": "Effective Income Tax Rate Reconciliation, Deferred Tax Adjustments, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to deferred tax adjustments."
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount",
     "crdr": "credit",
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Orphan drug credit, net",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Orphan Drug, Amount",
        "documentation": "Effective Income Tax Rate Reconciliation, Tax Credit, Orphan Drug, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation cost related to non-vested stock-based compensation arrangements",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r377"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation expense recognition period",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r377"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "crdr": "debit",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total unrecognized compensation cost",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "us-gaap_EmployeeStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockMember",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationNarrativeDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Stock",
        "label": "Employee Stock [Member]",
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Stock Option",
        "label": "Employee Stock Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum employee contribution percent",
        "label": "Employee Stock Purchase Plan, Maximum Annual Contributions Per Employee, Percent",
        "documentation": "Employee Stock Purchase Plan, Maximum Annual Contributions Per Employee, Percent"
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan": {
     "xbrltype": "durationItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "EmployeesEligibleAgeToParticipateInBenefitPlan",
     "presentation": [
      "http://macrogenics.com/role/EmployeeBenefitPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Eligible age to participate in plan",
        "label": "Employees Eligible Age To Participate In Benefit Plan",
        "documentation": "Refers to minimum eligible age of employee to participate in benefit plan."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r658"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r658"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r658"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r736"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Public Float",
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r658"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r658"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r658"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r658"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Voluntary Filers",
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r737"
     ]
    },
    "us-gaap_EquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquipmentMember",
     "presentation": [
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lab equipment",
        "label": "Equipment [Member]",
        "documentation": "Tangible personal property used to produce goods and services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://macrogenics.com/role/RevenueZaiLabDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component [Domain]",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r136",
      "r160",
      "r161",
      "r162",
      "r184",
      "r185",
      "r186",
      "r188",
      "r194",
      "r196",
      "r207",
      "r266",
      "r267",
      "r320",
      "r379",
      "r380",
      "r381",
      "r401",
      "r402",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r422",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r454",
      "r516",
      "r517",
      "r518",
      "r531",
      "r592"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Valuation Assumption Difference, Footnote",
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r704"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneous Compensation Analysis",
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r667",
      "r679",
      "r689",
      "r715"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneously Awarded Compensation Recovery",
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r664",
      "r676",
      "r686",
      "r712"
     ]
    },
    "mgnx_EstimatedReimbursementForResearchAndDevelopmentT": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "EstimatedReimbursementForResearchAndDevelopmentT",
     "crdr": "debit",
     "presentation": [
      "http://macrogenics.com/role/RevenueZaiLabDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated Reimbursement for Research and Development t",
        "label": "Estimated Reimbursement for Research and Development t",
        "documentation": "Estimated Reimbursement for Research and Development t"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Category:",
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r710"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r426",
      "r427",
      "r430"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r426",
      "r427",
      "r430"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Fair Value Measurement Financial Assets",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]",
        "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r62",
      "r63",
      "r109"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Class [Domain]",
        "label": "Asset Class [Domain]",
        "documentation": "Class of asset."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByAssetClassAxis",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Class [Axis]",
        "label": "Asset Class [Axis]",
        "documentation": "Information by class of asset."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r63"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r302",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r427",
      "r459",
      "r460",
      "r461",
      "r628",
      "r629",
      "r633",
      "r634",
      "r635"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency [Axis]",
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r426",
      "r427",
      "r428",
      "r429",
      "r431"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Quoted Prices in Active Markets for Identical Assets, Level 1",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r302",
      "r327",
      "r332",
      "r427",
      "r459",
      "r633",
      "r634",
      "r635"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Significant Other Observable Inputs, Level 2",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r302",
      "r327",
      "r332",
      "r427",
      "r460",
      "r628",
      "r629",
      "r633",
      "r634",
      "r635"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency [Domain]",
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r302",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r459",
      "r460",
      "r461",
      "r628",
      "r629",
      "r633",
      "r634",
      "r635"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Recurring",
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r425",
      "r431"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value of Financial Instruments",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r17"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instrument [Axis]",
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r274",
      "r275",
      "r276",
      "r303",
      "r317",
      "r420",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r505",
      "r627",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r787",
      "r788",
      "r789",
      "r790"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r671",
      "r683",
      "r693",
      "r719"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount",
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r671",
      "r683",
      "r693",
      "r719"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r671",
      "r683",
      "r693",
      "r719"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery, Explanation of Impracticability",
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r671",
      "r683",
      "r693",
      "r719"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r671",
      "r683",
      "r693",
      "r719"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Furniture",
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_FurnitureAndOfficeEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "FurnitureAndOfficeEquipmentMember",
     "presentation": [
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Furniture and office equipment",
        "label": "Furniture And Office Equipment [Member]",
        "documentation": "Furniture and office equipment are movable furniture, fixtures, or other equipment that have no permanent connection to the structure of a building or utilities. These items depreciate substantially but definitely are important costs to consider when valuing a company, especially in liquidation."
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_FutureRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "FutureRevenue",
     "crdr": "debit",
     "presentation": [
      "http://macrogenics.com/role/RevenueProventionDetails",
      "http://macrogenics.com/role/RoyaltyMonetizationArrangementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Future revenue from DRI",
        "label": "Future Revenue",
        "documentation": "Future Revenue"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnDispositionOfAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnDispositionOfAssets",
     "crdr": "credit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Loss on disposal of assets",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property",
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property."
       }
      }
     },
     "auth_ref": [
      "r760",
      "r792",
      "r793"
     ]
    },
    "mgnx_GainOnRoyaltyMonetizationArrangement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "GainOnRoyaltyMonetizationArrangement",
     "crdr": "credit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://macrogenics.com/role/RoyaltyMonetizationArrangementDetails",
      "http://macrogenics.com/role/RoyaltyMonetizationArrangementRollforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain on royalty monetization arrangement",
        "negatedTerseLabel": "Gain on royalty monetization arrangement",
        "label": "Gain on royalty monetization arrangement",
        "documentation": "Gain on royalty monetization arrangement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling, general and administrative",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r575"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "mgnx_GileadFirstResearchProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "GileadFirstResearchProgramMember",
     "presentation": [
      "http://macrogenics.com/role/RevenueGileadSciencesIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gilead First Research Program",
        "label": "Gilead First Research Program [Member]",
        "documentation": "Gilead First Research Program"
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_GileadMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "GileadMember",
     "presentation": [
      "http://macrogenics.com/role/RevenueGileadSciencesIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gilead",
        "label": "Gilead [Member]",
        "documentation": "Gilead"
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_IMabBiopharmaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "IMabBiopharmaMember",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "I-Mab Biopharma",
        "label": "I-Mab Biopharma [Member]",
        "documentation": "I-Mab Biopharma"
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ICFR Auditor Attestation Flag",
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r661",
      "r662",
      "r675"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of Long-Lived Assets",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r97"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Axis]",
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r284",
      "r285",
      "r576"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Domain]",
        "label": "Income Statement Location [Domain]",
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r576"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority [Axis]",
        "label": "Income Tax Authority [Axis]",
        "documentation": "Information by tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority [Domain]",
        "label": "Income Tax Authority [Domain]",
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r386",
      "r390",
      "r395",
      "r399",
      "r403",
      "r406",
      "r407",
      "r408",
      "r530"
     ]
    },
    "us-gaap_IncomeTaxExaminationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExaminationLineItems",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Examination [Line Items]",
        "label": "Income Tax Examination [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income tax expense/(benefit)",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r133",
      "r195",
      "r196",
      "r215",
      "r388",
      "r404",
      "r508"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in valuation allowance",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r832"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "United States federal tax at statutory rate",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r389"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity-based compensation",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount",
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r832"
     ]
    },
    "us-gaap_IncomeTaxReconciliationOtherReconcilingItems": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationOtherReconcilingItems",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other permanent items",
        "label": "Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority noncontrolling interest income (loss), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, increase (decrease) in enacted tax rate, prior year income taxes, increase (decrease) in deferred tax asset valuation allowance, and other adjustments."
       }
      }
     },
     "auth_ref": [
      "r832"
     ]
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State taxes (net of federal benefit)",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r832"
     ]
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "crdr": "credit",
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Research credit, net",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit."
       }
      }
     },
     "auth_ref": [
      "r832"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Accounts receivable",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other current liabilities",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r487",
      "r759"
     ]
    },
    "mgnx_IncreaseDecreaseInDeferredRent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "IncreaseDecreaseInDeferredRent",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non current liabilities",
        "label": "Increase (Decrease) in Deferred Rent",
        "documentation": "The increase (decrease) during the reporting period in deferred rent."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Inventory",
        "label": "Increase (Decrease) in Inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "mgnx_IncreaseDecreaseInLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "IncreaseDecreaseInLeaseLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities",
        "label": "Increase (decrease) in lease liabilities",
        "documentation": "Increase (decrease) in lease liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "crdr": "credit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other non current assets",
        "label": "Increase (Decrease) in Other Operating Assets",
        "documentation": "Amount of increase (decrease) in operating assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "crdr": "credit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other current assets",
        "label": "Increase (Decrease) in Prepaid Expense",
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "mgnx_IncyteClinicalSupplyAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "IncyteClinicalSupplyAgreementMember",
     "presentation": [
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Incyte MGA012 Supply Agreement",
        "label": "Incyte Clinical Supply Agreement [Member]",
        "documentation": "Incyte Clinical Supply Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_IncyteCommercialSupplyAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "IncyteCommercialSupplyAgreementMember",
     "presentation": [
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Incyte MGA012 Clinical Services",
        "label": "Incyte Commercial Supply Agreement [Member]",
        "documentation": "Incyte Commercial Supply Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_IncyteCorporationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "IncyteCorporationMember",
     "presentation": [
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails",
      "http://macrogenics.com/role/RevenueManufacturingServiceAgreementsDetails",
      "http://macrogenics.com/role/StockholdersEquityDetails",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Incyte Corporation (Incyte)",
        "label": "Incyte Corporation [Member]",
        "documentation": "Incyte Corporation [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_IncyteMGA012AgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "IncyteMGA012AgreementMember",
     "presentation": [
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails",
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Incyte MGA012 Agreement",
        "label": "Incyte MGA012 Agreement [Member]",
        "documentation": "Incyte MGA012 Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_IndefiniteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "IndefiniteMember",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indefinite",
        "label": "Indefinite [Member]",
        "documentation": "Indefinite"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual:",
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r674",
      "r683",
      "r693",
      "r710",
      "r719",
      "r723",
      "r731"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r729"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r663",
      "r735"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Adopted",
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r663",
      "r735"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted",
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r663",
      "r735"
     ]
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Interest expense",
        "label": "Interest Expense",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r116",
      "r163",
      "r213",
      "r441",
      "r577",
      "r654",
      "r856"
     ]
    },
    "us-gaap_InterestIncomeOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestIncomeOther",
     "crdr": "credit",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesAvailableForSaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest Income, Other",
        "label": "Interest Income, Other",
        "documentation": "Amount of interest income earned from interest bearing assets classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryDisclosureTextBlock",
     "presentation": [
      "http://macrogenics.com/role/Inventory"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory, Net",
        "label": "Inventory Disclosure [Text Block]",
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory."
       }
      }
     },
     "auth_ref": [
      "r279"
     ]
    },
    "us-gaap_InventoryFinishedGoods": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryFinishedGoods",
     "crdr": "debit",
     "presentation": [
      "http://macrogenics.com/role/InventoryNetScheduleofInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finished goods",
        "label": "Inventory, Finished Goods, Gross",
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://macrogenics.com/role/InventoryNetScheduleofInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory, net",
        "label": "Inventory, Net",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r615",
      "r643"
     ]
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryPolicyTextBlock",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory",
        "label": "Inventory, Policy [Policy Text Block]",
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r140",
      "r149",
      "r279",
      "r280",
      "r281",
      "r488",
      "r620"
     ]
    },
    "us-gaap_InventoryValuationReserveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryValuationReserveMember",
     "presentation": [
      "http://macrogenics.com/role/InventoryNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEC Schedule, 12-09, Reserve, Inventory",
        "label": "SEC Schedule, 12-09, Reserve, Inventory [Member]",
        "documentation": "Reserve to reduce inventory to lower of cost or net realizable value."
       }
      }
     },
     "auth_ref": [
      "r764",
      "r765",
      "r766",
      "r767",
      "r768"
     ]
    },
    "us-gaap_InventoryValuationReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryValuationReserves",
     "crdr": "credit",
     "presentation": [
      "http://macrogenics.com/role/InventoryNetScheduleofInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory valuation reserves",
        "label": "Inventory Valuation Reserves",
        "documentation": "Amount of valuation reserve for inventory."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r754"
     ]
    },
    "us-gaap_InventoryWorkInProcess": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryWorkInProcess",
     "crdr": "debit",
     "presentation": [
      "http://macrogenics.com/role/InventoryNetScheduleofInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Work in process",
        "label": "Inventory, Work in Process, Gross",
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r753"
     ]
    },
    "us-gaap_Investments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Investments",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities",
        "verboseLabel": "Investments",
        "label": "Investments",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments."
       }
      }
     },
     "auth_ref": [
      "r495"
     ]
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecurities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable Securities",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "documentation": "The entire disclosure for investments in certain debt and equity securities."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r117",
      "r118",
      "r135",
      "r232",
      "r234",
      "r432",
      "r433"
     ]
    },
    "mgnx_JamesKarrelsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "JamesKarrelsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "James Karrels [Member]",
        "documentation": "James Karrels"
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_JeffreyPetersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "JeffreyPetersMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Jeffrey Peters [Member]",
        "documentation": "Jeffrey Peters"
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_LaboratoryAndOfficeEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "LaboratoryAndOfficeEquipmentMember",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Laboratory and office equipment",
        "label": "Laboratory and Office Equipment [Member]",
        "documentation": "A facility that provides controlled conditions in which scientific or technological research, experiments, and measurement may be performed. and tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease, cost",
        "label": "Lease, Cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r447",
      "r642"
     ]
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease, Cost",
        "label": "Lease, Cost [Table Text Block]",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r840"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold improvements",
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Lease, Description [Line Items]",
        "label": "Lessee, Lease, Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r446"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Lease, Description [Table]",
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r446"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r445"
     ]
    },
    "us-gaap_LesseeOperatingLeaseDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseDiscountRate",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discount rate",
        "label": "Lessee, Operating Lease, Discount Rate",
        "documentation": "Discount rate used by lessee to determine present value of operating lease payments."
       }
      }
     },
     "auth_ref": [
      "r641"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Operating Lease, Liability, Maturity",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r841"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r453"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r453"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r453"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r453"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r453"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r453"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r453"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less: imputed interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r453"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease renewal term (in years)",
        "label": "Lessee, Operating Lease, Renewal Term",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r839"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r174",
      "r265",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r411",
      "r412",
      "r413",
      "r434",
      "r551",
      "r624",
      "r656",
      "r798",
      "r842",
      "r843"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders' equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r114",
      "r500",
      "r643",
      "r762",
      "r791",
      "r838"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities and stockholders' equity",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r139",
      "r174",
      "r265",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r411",
      "r412",
      "r413",
      "r434",
      "r643",
      "r798",
      "r842",
      "r843"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_LiabilityRelatedToFutureRoyalties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "LiabilityRelatedToFutureRoyalties",
     "crdr": "credit",
     "presentation": [
      "http://macrogenics.com/role/RoyaltyMonetizationArrangementRollforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liability related to future royalties",
        "label": "Liability related to future royalties",
        "documentation": "Liability related to future royalties"
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_LiabilityRelatedToFutureRoyaltiesAndRelatedInterestExpensePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "LiabilityRelatedToFutureRoyaltiesAndRelatedInterestExpensePolicyTextBlock",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liability related to the sale of future royalties and related interest expense",
        "label": "Liability related to future royalties and related interest expense [Policy Text Block]",
        "documentation": "Liability related to future royalties and related interest expense"
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_LiabilityRelatedToFutureRoyaltyLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "LiabilityRelatedToFutureRoyaltyLineItems",
     "presentation": [
      "http://macrogenics.com/role/RoyaltyMonetizationArrangementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liability related to future royalty [Line Items]",
        "label": "Liability related to future royalty [Line Items]",
        "documentation": "Liability related to future royalty"
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_LiabilityRelatedToFutureRoyaltyTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "LiabilityRelatedToFutureRoyaltyTableTextBlock",
     "presentation": [
      "http://macrogenics.com/role/RoyaltyMonetizationArrangementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liability Related to Future Royalty",
        "label": "Liability Related to Future Royalty [Table Text Block]",
        "documentation": "Liability Related to Future Royalty"
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_LiabilityRelatedToSaleOfFutureRoyaltiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "LiabilityRelatedToSaleOfFutureRoyaltiesTextBlock",
     "presentation": [
      "http://macrogenics.com/role/RoyaltyMonetizationArrangement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty Monetization Arrangement",
        "label": "Liability Related To Sale Of Future Royalties [Text Block]",
        "documentation": "Liability Related To Sale Of Future Royalties"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer [Axis]",
        "label": "Customer [Axis]"
       }
      }
     },
     "auth_ref": [
      "r226",
      "r632",
      "r801",
      "r852",
      "r853"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails",
      "http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails",
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r288",
      "r289",
      "r290",
      "r291",
      "r342",
      "r486",
      "r515",
      "r543",
      "r544",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r610",
      "r611",
      "r626",
      "r630",
      "r636",
      "r645",
      "r800",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849"
     ]
    },
    "mgnx_McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "McKesson Plasma &amp; Biologics and McKesson Specialty Care Distribution LLC",
        "label": "McKesson Plasma &amp; Biologics and McKesson Specialty Care Distribution LLC [Member]",
        "documentation": "McKesson Plasma &amp; Biologics and McKesson Specialty Care Distribution LLC"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measure:",
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r702"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r702"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingenciesDetails",
      "http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails",
      "http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r288",
      "r289",
      "r290",
      "r291",
      "r342",
      "r486",
      "r515",
      "r543",
      "r544",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r610",
      "r611",
      "r626",
      "r630",
      "r636",
      "r645",
      "r800",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MNPI Disclosure Timed for Compensation Value",
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r722"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Money market funds",
        "label": "Money Market Funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Terms of Trading Arrangement",
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r730"
     ]
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer [Domain]",
        "label": "Customer [Domain]"
       }
      }
     },
     "auth_ref": [
      "r226",
      "r632",
      "r801",
      "r852",
      "r853"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Named Executive Officers, Footnote",
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r703"
     ]
    },
    "mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "NationalInstituteOfAllergyAndInfectiousDiseasesMember",
     "presentation": [
      "http://macrogenics.com/role/RevenueNIAIDContractDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NIAID",
        "label": "National Institute of Allergy and Infectious Diseases [Member]",
        "documentation": "Represents a collaborators with which entity has an agreement related to contracts and research grants received from U.S. government agencies."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r170"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by (used in) investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r170"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r91",
      "r92"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss",
        "terseLabel": "Net Income (Loss)",
        "label": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r92",
      "r115",
      "r137",
      "r156",
      "r158",
      "r162",
      "r174",
      "r187",
      "r189",
      "r190",
      "r191",
      "r192",
      "r195",
      "r196",
      "r201",
      "r210",
      "r217",
      "r221",
      "r223",
      "r265",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r424",
      "r434",
      "r504",
      "r572",
      "r590",
      "r591",
      "r625",
      "r654",
      "r798"
     ]
    },
    "mgnx_NetProceedsFromSaleOfFutureRoyalties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "NetProceedsFromSaleOfFutureRoyalties",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net proceeds from sale of future royalties",
        "label": "Net proceeds from sale of future royalties",
        "documentation": "Net proceeds from sale of future royalties"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recent Accounting Pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_NonCashInterestExpenseRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "NonCashInterestExpenseRecognized",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://macrogenics.com/role/RoyaltyMonetizationArrangementRollforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash interest expense",
        "label": "Non-cash interest expense recognized",
        "documentation": "Non-cash interest expense recognized"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-GAAP Measure Description",
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r702"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-NEOs",
        "label": "Non-NEOs [Member]"
       }
      }
     },
     "auth_ref": [
      "r671",
      "r683",
      "r693",
      "r710",
      "r719"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r700"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount",
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r699"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO",
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r710"
     ]
    },
    "mgnx_NonRefundableUpfrontFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "NonRefundableUpfrontFees",
     "crdr": "credit",
     "presentation": [
      "http://macrogenics.com/role/RevenueGileadSciencesIncDetails",
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails",
      "http://macrogenics.com/role/RevenueManufacturingServiceAgreementsDetails",
      "http://macrogenics.com/role/RevenueZaiLabDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-refundable upfront payment",
        "label": "Non-refundable upfront payment",
        "documentation": "Initial fee received from collaboration or license agreement."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r730"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r730"
     ]
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash operating and investing activities",
        "label": "Noncash Investing and Financing Items [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of operating segments",
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r773"
     ]
    },
    "mgnx_NumberOfPerformanceObligations": {
     "xbrltype": "integerItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "NumberOfPerformanceObligations",
     "presentation": [
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of performance obligations",
        "label": "Number Of Performance Obligations"
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_NumberOfProductCandidates": {
     "xbrltype": "integerItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "NumberOfProductCandidates",
     "presentation": [
      "http://macrogenics.com/role/RevenueNIAIDContractDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of product candidates to develop",
        "label": "Number Of Product Candidates",
        "documentation": "Number Of Product Candidates"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r210",
      "r217",
      "r221",
      "r223",
      "r625"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease cost",
        "label": "Operating Lease, Cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r448",
      "r642"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r443"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r443"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities, net of current portion",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r443"
     ]
    },
    "mgnx_OperatingLeaseNoncashExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "OperatingLeaseNoncashExpense",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash lease expense",
        "label": "Operating Lease, Noncash Expense",
        "documentation": "Operating Lease, Noncash Expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease payments",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r444",
      "r451"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://macrogenics.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease, ROU Assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r442"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average lease term (in years)",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r452",
      "r642"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwardsTable",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Loss Carryforwards [Table]",
        "label": "Operating Loss Carryforwards [Table]",
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "mgnx_OptInFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "OptInFee",
     "crdr": "credit",
     "presentation": [
      "http://macrogenics.com/role/RevenueGileadSciencesIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Opt-in fee",
        "label": "Opt-In Fee",
        "documentation": "Opt-In Fee"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://macrogenics.com/role/OrganizationandNatureofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization and Nature of Operations",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r108",
      "r522",
      "r523"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non current assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r144"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized gain (loss) on investments",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r154",
      "r155"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive income (loss):",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non current liabilities",
        "label": "Other Liabilities, Noncurrent",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNoncashIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other non-cash items",
        "label": "Other Noncash Income (Expense)",
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other."
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest and other income",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Performance Measure, Amount",
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r702"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount",
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r669",
      "r681",
      "r691",
      "r717"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Amount",
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r672",
      "r684",
      "r694",
      "r720"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r672",
      "r684",
      "r694",
      "r720"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r698"
     ]
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "crdr": "credit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Taxes paid related to net share settlement of equity awards",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r169"
     ]
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "crdr": "credit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Purchases of marketable securities",
        "label": "Payments to Acquire Debt Securities, Available-for-Sale",
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r167",
      "r233"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of property, equipment and software",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Issuers, Footnote",
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r701"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Total Shareholder Return Amount",
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r701"
     ]
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "presentation": [
      "http://macrogenics.com/role/EmployeeBenefitPlan"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Benefit Plan",
        "label": "Retirement Benefits [Text Block]",
        "documentation": "The entire disclosure for retirement benefits."
       }
      }
     },
     "auth_ref": [
      "r324",
      "r325",
      "r326",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r635"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Actually Paid Compensation Amount",
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r700"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO",
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r710"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Name",
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r703"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Total Compensation Amount",
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r699"
     ]
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationNarrativeDetails",
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Axis]",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationNarrativeDetails",
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Domain]",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829"
     ]
    },
    "mgnx_PotentialCommercialMilestonePaymentsUnderAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "PotentialCommercialMilestonePaymentsUnderAgreement",
     "crdr": "credit",
     "presentation": [
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails",
      "http://macrogenics.com/role/RevenueProventionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Potential commercial milestone payments",
        "label": "Potential Commercial Milestone Payments Under Agreement",
        "documentation": "Potential Commercial Milestone Payments Under Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement",
     "crdr": "credit",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingenciesDetails",
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails",
      "http://macrogenics.com/role/RevenueProventionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Potential development and regulatory milestone payments",
        "label": "Potential Development and Regulatory Milestone Payments Under Agreement",
        "documentation": "Potential Development and Regulatory Milestone Payments Under Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement",
     "crdr": "credit",
     "presentation": [
      "http://macrogenics.com/role/RevenueProventionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Potential milestone payment to third parties for intellectual property under agreement",
        "label": "Potential Milestone Payment To Third Parties For Intellectual Property Under Agreement",
        "documentation": "Potential Milestone Payment To Third Parties For Intellectual Property Under Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_PotentialTargetNominationOptionFeesAndMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "PotentialTargetNominationOptionFeesAndMilestonePayments",
     "crdr": "credit",
     "presentation": [
      "http://macrogenics.com/role/RevenueGileadSciencesIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Target nomination, option fees and milestone",
        "label": "Potential target nomination, option fees and milestone payments",
        "documentation": "Potential target, nomination, option fees and milestone payments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Undesignated preferred stock, par value (in dollars per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r305"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Undesignated preferred stock, shares authorized (in shares)",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r552"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Undesignated preferred stock, shares issued (in shares)",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r305"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Undesignated preferred stock, shares outstanding (in shares)",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r552",
      "r570",
      "r857",
      "r858"
     ]
    },
    "mgnx_PremiumReceivedOnStockPurchase": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "PremiumReceivedOnStockPurchase",
     "crdr": "debit",
     "presentation": [
      "http://macrogenics.com/role/RevenueZaiLabDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Premium received on stock purchase",
        "label": "Premium received on stock purchase",
        "documentation": "Amount by which purchase price exceeds fair value for common stock purchased by collaborator."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets",
        "label": "Prepaid Expense, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r282",
      "r283",
      "r616"
     ]
    },
    "mgnx_PrincipalPaymentsOnRoyaltyMonetizationArrangement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "PrincipalPaymentsOnRoyaltyMonetizationArrangement",
     "crdr": "credit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://macrogenics.com/role/RoyaltyMonetizationArrangementRollforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Principal payments on royalty monetization arrangement",
        "label": "Principal payments on royalty monetization arrangement",
        "documentation": "Principal payments on royalty monetization arrangement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://macrogenics.com/role/StockbasedCompensationNarrativeDetails",
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of common stock, net of offering costs",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sales and maturities of marketable securities",
        "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale",
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r167",
      "r168",
      "r775"
     ]
    },
    "mgnx_ProceedsFromSaleOfFutureRoyalties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "ProceedsFromSaleOfFutureRoyalties",
     "crdr": "credit",
     "presentation": [
      "http://macrogenics.com/role/RoyaltyMonetizationArrangementRollforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sale of future royalties",
        "label": "Proceeds from sale of future royalties",
        "documentation": "Proceeds from sale of future royalties"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromSaleOfMachineryAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleOfMachineryAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sales of equipment",
        "label": "Proceeds from Sale of Machinery and Equipment",
        "documentation": "The cash inflow from sale of machinery and equipment."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash proceeds from exercise of stock options",
        "label": "Proceeds from Stock Options Exercised",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r15"
     ]
    },
    "mgnx_ProceedsfromRoyaltiesPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "ProceedsfromRoyaltiesPercent",
     "presentation": [
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails",
      "http://macrogenics.com/role/RoyaltyMonetizationArrangementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Potential proceeds from royalties percent",
        "label": "Proceeds from Royalties, Percent",
        "documentation": "Proceeds from Royalties, Percent"
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "ProceedsfromStockOptionsExercisedAndESPPPurchases",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from stock option exercises and ESPP purchases",
        "label": "Proceeds from Stock Options Exercised And ESPP Purchases",
        "documentation": "Proceeds from Stock Options Exercised And ESPP Purchases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProductMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProductMember",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product",
        "label": "Product [Member]",
        "documentation": "Article or substance produced by nature, labor or machinery."
       }
      }
     },
     "auth_ref": [
      "r631"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails",
      "http://macrogenics.com/role/RevenueManufacturingServiceAgreementsDetails",
      "http://macrogenics.com/role/RevenueNIAIDContractDetails",
      "http://macrogenics.com/role/RevenueProventionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Axis]",
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r224",
      "r489",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r613",
      "r631",
      "r644",
      "r741",
      "r796",
      "r797",
      "r801",
      "r852"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails",
      "http://macrogenics.com/role/RevenueManufacturingServiceAgreementsDetails",
      "http://macrogenics.com/role/RevenueNIAIDContractDetails",
      "http://macrogenics.com/role/RevenueProventionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Domain]",
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r224",
      "r489",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r613",
      "r631",
      "r644",
      "r741",
      "r796",
      "r797",
      "r801",
      "r852"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment, Type [Axis]",
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://macrogenics.com/role/PropertyEquipmentandSoftware"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Equipment and Software",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r127",
      "r131",
      "r132"
     ]
    },
    "mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "PropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated Useful Lives",
        "label": "Property Plant And Equipment Estimated Useful Life Table [Table Text Block]",
        "documentation": "Property plant and equipment estimated useful life."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, equipment and software",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r142",
      "r503"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Line Items]",
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      },
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, equipment and software, net",
        "totalLabel": "Property, equipment and software, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r494",
      "r503",
      "r643"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Equipment and Software",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r127",
      "r131",
      "r501"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Property and Equipment",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment, Type [Domain]",
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated useful lives",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_ProventionBioCMOAgreeemntMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "ProventionBioCMOAgreeemntMember",
     "presentation": [
      "http://macrogenics.com/role/RevenueManufacturingServiceAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provention Bio CMO Agreeemnt",
        "label": "Provention Bio CMO Agreeemnt [Member]",
        "documentation": "Provention Bio CMO Agreeemnt"
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_ProventionBioMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "ProventionBioMember",
     "presentation": [
      "http://macrogenics.com/role/RevenueManufacturingServiceAgreementsDetails",
      "http://macrogenics.com/role/RevenueProventionDetails",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provention Bio, Inc. (Provention)",
        "label": "Provention Bio [Member]",
        "documentation": "Provention Bio"
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_ProventionLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "ProventionLicenseAgreementMember",
     "presentation": [
      "http://macrogenics.com/role/RevenueProventionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provention License Agreement",
        "label": "Provention License Agreement [Member]",
        "documentation": "Provention License Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_ProventionPRV031Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "ProventionPRV031Member",
     "presentation": [
      "http://macrogenics.com/role/RevenueProventionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provention PRV031",
        "label": "Provention PRV031 [Member]",
        "documentation": "Provention PRV031"
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_ProventionPRV3279Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "ProventionPRV3279Member",
     "presentation": [
      "http://macrogenics.com/role/RevenueProventionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provention PRV3279",
        "label": "Provention PRV3279 [Member]",
        "documentation": "Provention PRV3279"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure",
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r698"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure, Table",
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r698"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingenciesDetails",
      "http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails",
      "http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails",
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Range [Axis]",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r288",
      "r289",
      "r290",
      "r291",
      "r325",
      "r342",
      "r370",
      "r371",
      "r372",
      "r462",
      "r486",
      "r515",
      "r543",
      "r544",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r610",
      "r611",
      "r626",
      "r630",
      "r636",
      "r645",
      "r648",
      "r794",
      "r800",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingenciesDetails",
      "http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails",
      "http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails",
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Range",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r288",
      "r289",
      "r290",
      "r291",
      "r325",
      "r342",
      "r370",
      "r371",
      "r372",
      "r462",
      "r486",
      "r515",
      "r543",
      "r544",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r610",
      "r611",
      "r626",
      "r630",
      "r636",
      "r645",
      "r648",
      "r794",
      "r800",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849"
     ]
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesReconciliationoftheBeginningandEndingAmountofGrossUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r664",
      "r676",
      "r686",
      "r712"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingenciesDetails",
      "http://macrogenics.com/role/RevenueGileadSciencesIncDetails",
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails",
      "http://macrogenics.com/role/RevenueManufacturingServiceAgreementsDetails",
      "http://macrogenics.com/role/RevenueNIAIDContractDetails",
      "http://macrogenics.com/role/RevenueProventionDetails",
      "http://macrogenics.com/role/RevenueZaiLabDetails",
      "http://macrogenics.com/role/RoyaltyMonetizationArrangementDetails",
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Domain]",
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r176",
      "r177",
      "r301",
      "r307",
      "r455",
      "r618",
      "r619"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "presentation": [
      "http://macrogenics.com/role/RevenueGileadSciencesIncDetails",
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails",
      "http://macrogenics.com/role/RevenueProventionDetails",
      "http://macrogenics.com/role/RevenueZaiLabDetails",
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "documentation": "Information by form of arrangement related to research and development."
       }
      }
     },
     "auth_ref": [
      "r385",
      "r831"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "presentation": [
      "http://macrogenics.com/role/RevenueGileadSciencesIncDetails",
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails",
      "http://macrogenics.com/role/RevenueProventionDetails",
      "http://macrogenics.com/role/RevenueZaiLabDetails",
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others."
       }
      }
     },
     "auth_ref": [
      "r385",
      "r831"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://macrogenics.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r384",
      "r850"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Expenses, Including Clinical Trial Accruals/Expenses",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r383"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date:",
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r665",
      "r677",
      "r687",
      "r713"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date",
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r666",
      "r678",
      "r688",
      "r714"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement does not require Recovery",
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r673",
      "r685",
      "r695",
      "r721"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationNarrativeDetails",
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Stock Units",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r102",
      "r499",
      "r519",
      "r520",
      "r529",
      "r553",
      "r643"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r184",
      "r185",
      "r186",
      "r188",
      "r194",
      "r196",
      "r266",
      "r267",
      "r379",
      "r380",
      "r381",
      "r401",
      "r402",
      "r414",
      "r416",
      "r417",
      "r419",
      "r422",
      "r516",
      "r518",
      "r531",
      "r857"
     ]
    },
    "mgnx_RevenueFromCollaborativeAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "RevenueFromCollaborativeAgreementsMember",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from collaborative agreements",
        "label": "Revenue From Collaborative Agreements [Member]",
        "documentation": "Revenue From Collaborative Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_RevenueFromGovernmentAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "RevenueFromGovernmentAgreementsMember",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from government agreements",
        "label": "Revenue From Government Agreements [Member]",
        "documentation": "Revenue From Government Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_RevenueFromRoyalityAgreementsMemberMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "RevenueFromRoyalityAgreementsMemberMember",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RevenueFromRoyalityAgreementsMember",
        "label": "RevenueFromRoyalityAgreementsMember [Member]",
        "documentation": "RevenueFromRoyalityAgreementsMember"
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount",
     "crdr": "credit",
     "presentation": [
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Clinical trial activities selling price amount",
        "label": "Revenue, Multiple-Deliverable Arrangements, Determination Of Selling Price, Amount",
        "documentation": "Revenue, Multiple-Deliverable Arrangements, Determination Of Selling Price, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueRecognitionPolicyTextBlock",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Recognition",
        "label": "Revenue [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources."
       }
      }
     },
     "auth_ref": [
      "r574",
      "r612",
      "r621"
     ]
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueRemainingPerformanceObligation",
     "crdr": "credit",
     "presentation": [
      "http://macrogenics.com/role/RevenueGileadSciencesIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue, remaining performance obligation, amount",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue."
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Revenues",
     "crdr": "credit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://macrogenics.com/role/RevenueGileadSciencesIncDetails",
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails",
      "http://macrogenics.com/role/RevenueManufacturingServiceAgreementsDetails",
      "http://macrogenics.com/role/RevenueNIAIDContractDetails",
      "http://macrogenics.com/role/RevenueProventionDetails",
      "http://macrogenics.com/role/RevenueZaiLabDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues",
        "label": "Revenues",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r174",
      "r211",
      "r212",
      "r216",
      "r219",
      "r220",
      "r224",
      "r225",
      "r226",
      "r265",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r434",
      "r493",
      "r798"
     ]
    },
    "us-gaap_RevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenuesAbstract",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues:",
        "label": "Revenues [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_RevenuesFromCMOAgreementsMemberMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "RevenuesFromCMOAgreementsMemberMember",
     "presentation": [
      "http://macrogenics.com/role/RevenueManufacturingServiceAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RevenuesFromCMOAgreementsMember",
        "label": "RevenuesFromCMOAgreementsMember [Member]",
        "documentation": "RevenuesFromCMOAgreementsMember"
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_RevenuesFromCMOAmendmentAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "RevenuesFromCMOAmendmentAgreementMember",
     "presentation": [
      "http://macrogenics.com/role/RevenueManufacturingServiceAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RevenuesFromCMOAmendmentAgreement",
        "label": "RevenuesFromCMOAmendmentAgreement [Member]",
        "documentation": "RevenuesFromCMOAmendmentAgreement"
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_RevenuesFromGrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "RevenuesFromGrantsMember",
     "presentation": [
      "http://macrogenics.com/role/RevenueNIAIDContractDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RevenuesFromGrantsMember",
        "label": "RevenuesFromGrantsMember"
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_RevenuesFromLicenseAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "RevenuesFromLicenseAgreementsMember",
     "presentation": [
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails",
      "http://macrogenics.com/role/RevenueProventionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues From License Agreements",
        "label": "Revenues From License Agreements [Member]",
        "documentation": "Revenues From License Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_RightOfUseAssetAndLeaseLiabilityIncrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "RightOfUseAssetAndLeaseLiabilityIncrease",
     "crdr": "credit",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right of use asset and lease liability increase",
        "label": "Right of Use asset and Lease Liability Increase",
        "documentation": "Right of Use asset and Lease Liability Increase"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RoyaltyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RoyaltyMember",
     "presentation": [
      "http://macrogenics.com/role/RevenueProventionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty [Member]",
        "label": "Royalty [Member]",
        "documentation": "Money for usage-based right to asset."
       }
      }
     },
     "auth_ref": [
      "r802"
     ]
    },
    "mgnx_RoyaltyMonetizationArrangementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "RoyaltyMonetizationArrangementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalty Monetization Arrangement [Abstract]",
        "documentation": "Royalty Monetization Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_RoyaltyMonetizationArrangementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "RoyaltyMonetizationArrangementTable",
     "presentation": [
      "http://macrogenics.com/role/RoyaltyMonetizationArrangementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty Monetization Arrangement [Table]",
        "label": "Royalty Monetization Arrangement [Table]",
        "documentation": "Royalty Monetization Arrangement"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r730"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r730"
     ]
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://macrogenics.com/role/RevenueZaiLabDetails",
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds of stock sale",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Domain]",
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of common stock (in shares)",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://macrogenics.com/role/RevenueZaiLabDetails",
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of common stock (in dollars per share)",
        "label": "Sale of Stock, Price Per Share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SalesRevenueNetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SalesRevenueNetMember",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales revenue, net",
        "label": "Revenue Benchmark [Member]",
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r226",
      "r739"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromtheCalculationofDilutedLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock Options and RSUs Excluded from the Calculation of Net Loss Per Share",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246"
     ]
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://macrogenics.com/role/RevenueGileadSciencesIncDetails",
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails",
      "http://macrogenics.com/role/RevenueManufacturingServiceAgreementsDetails",
      "http://macrogenics.com/role/RevenueNIAIDContractDetails",
      "http://macrogenics.com/role/RevenueProventionDetails",
      "http://macrogenics.com/role/RevenueZaiLabDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r409"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Components of the Company's Deferred Income Tax Assets (Liabilities)",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r106"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of Reported Estimated Income Tax Benefit",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r105"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock-Based Compensation Expense",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "presentation": [
      "http://macrogenics.com/role/InventoryNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Inventory, Current",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r79",
      "r80",
      "r81"
     ]
    },
    "mgnx_ScheduleOfInventoryReservesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "ScheduleOfInventoryReservesTableTextBlock",
     "presentation": [
      "http://macrogenics.com/role/InventoryNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Inventory Reserves",
        "label": "Schedule of Inventory Reserves [Table Text Block]",
        "documentation": "Schedule of Inventory Reserves"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Table]",
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationNarrativeDetails",
      "http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails",
      "http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails",
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r344",
      "r346",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock Option Activity",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r14",
      "r54"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Employee Stock Options Award Valuation Assumptions",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r104"
     ]
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of RSU Activity",
        "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]",
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock by Class [Table]",
        "label": "Schedule of Stock by Class [Table]",
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r47",
      "r48",
      "r49",
      "r50",
      "r51",
      "r52",
      "r100",
      "r101",
      "r102",
      "r146",
      "r147",
      "r148",
      "r208",
      "r305",
      "r306",
      "r307",
      "r309",
      "r312",
      "r317",
      "r319",
      "r525",
      "r526",
      "r527",
      "r528",
      "r630",
      "r738",
      "r761"
     ]
    },
    "mgnx_ScheduleOfSupplementalBalanceSheetInformationOperatingLeasesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "ScheduleOfSupplementalBalanceSheetInformationOperatingLeasesTableTextBlock",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Supplemental Balance Sheet Information, Operating Leases",
        "label": "Schedule Of Supplemental Balance Sheet Information, Operating Leases [Table Text Block]",
        "documentation": "Schedule Of Supplemental Balance Sheet Information, Operating Leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities, Trading, and Equity Securities, FV-NI [Table]",
        "label": "Debt Securities, Trading, and Equity Securities, FV-NI [Table]",
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of the Beginning and Ending Amount of Gross Unrecognized Tax Benefits",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r640",
      "r833"
     ]
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Percentage of Customer Concentration",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r36",
      "r38",
      "r39",
      "r64",
      "r110"
     ]
    },
    "mgnx_Section174DeferredTaxAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "Section174DeferredTaxAsset",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Section 174 deferred tax asset",
        "label": "Section 174 deferred tax asset",
        "documentation": "Section 174 deferred tax asset"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r657"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r660"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee service period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period",
        "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r637"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award vesting period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r637"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r364"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited or expired (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r364"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Granted (in shares)",
        "terseLabel": "Awards granted in period (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r362"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r362"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationNarrativeDetails",
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding nonvested (in shares)",
        "periodStartLabel": "Beginning Balance (in shares)",
        "periodEndLabel": "Ending Balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r359",
      "r360"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning Balance (in dollars per share)",
        "periodEndLabel": "Ending Balance (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r359",
      "r360"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-Average Grant Date Fair Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r363"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected dividend yield",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r371"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r370"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r372"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationNarrativeDetails",
      "http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails",
      "http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails",
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r344",
      "r346",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Exercised (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised",
        "documentation": "Number of non-option equity instruments exercised by participants."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation, number of shares authorized (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r639"
     ]
    },
    "mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offering period",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Offering Period",
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Offering Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r353"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r353"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r366"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Expired (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements."
       }
      }
     },
     "auth_ref": [
      "r358"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-Average Exercise Price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeited or expired (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r357"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "documentation": "Net number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r811"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average grant-date fair value of options granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r365"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value, Outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationNarrativeDetails",
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation arrangement by share-based payment award, options, outstanding, number (in shares)",
        "periodStartLabel": "Beginning Balance (in shares)",
        "periodEndLabel": "Ending Balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r351",
      "r352"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationNarrativeDetails",
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price (in dollars per share)",
        "periodStartLabel": "Beginning Balance (in dollars per share)",
        "periodEndLabel": "Ending Balance (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r351",
      "r352"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value, Vested and expected to vest",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r367"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested and expected to vest (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r367"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested and expected to vest (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r367"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock purchased by employees (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period",
        "documentation": "Number of shares issued under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationNarrativeDetails",
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Domain]",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r356"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expired (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired."
       }
      }
     },
     "auth_ref": [
      "r358"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited or expired (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r357"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r355"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options granted, maximum term",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r638"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Expected term",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r369"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value, Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average remaining contractual term, Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average remaining contractual term, Outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average remaining contractual term, Vested and expected to vest",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r367"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "crdr": "credit",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of shares vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value",
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock."
       }
      }
     },
     "auth_ref": [
      "r366"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percent of fair market value to purchase shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent",
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesIssued",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance (in shares)",
        "periodEndLabel": "Balance (in shares)",
        "label": "Shares, Issued",
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Significant Accounting Policies",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r172"
     ]
    },
    "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SoftwareAndSoftwareDevelopmentCostsMember",
     "presentation": [
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Software",
        "label": "Software and Software Development Costs [Member]",
        "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Axis]",
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r146",
      "r147",
      "r148",
      "r174",
      "r199",
      "r200",
      "r202",
      "r204",
      "r208",
      "r209",
      "r265",
      "r292",
      "r294",
      "r295",
      "r296",
      "r299",
      "r300",
      "r305",
      "r306",
      "r309",
      "r312",
      "r319",
      "r434",
      "r525",
      "r526",
      "r527",
      "r528",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r552",
      "r573",
      "r592",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r738",
      "r761",
      "r772"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://macrogenics.com/role/RevenueZaiLabDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r24",
      "r136",
      "r160",
      "r161",
      "r162",
      "r184",
      "r185",
      "r186",
      "r188",
      "r194",
      "r196",
      "r207",
      "r266",
      "r267",
      "r320",
      "r379",
      "r380",
      "r381",
      "r401",
      "r402",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r422",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r454",
      "r516",
      "r517",
      "r518",
      "r531",
      "r592"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r184",
      "r185",
      "r186",
      "r207",
      "r489",
      "r524",
      "r542",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r552",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r571",
      "r574",
      "r575",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r592",
      "r649"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r184",
      "r185",
      "r186",
      "r207",
      "r489",
      "r524",
      "r542",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r552",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r571",
      "r574",
      "r575",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r592",
      "r649"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Price or TSR Estimation Method",
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r668",
      "r680",
      "r690",
      "r716"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_StockIncentivePlan2013Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "StockIncentivePlan2013Member",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationNarrativeDetails",
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Incentive Plan 2013",
        "label": "Stock Incentive Plan 2013 [Member]",
        "documentation": "Stock Incentive Plan 2013 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_StockIncentivePlan2023MemberMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "StockIncentivePlan2023MemberMember",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "StockIncentivePlan2023Member",
        "label": "StockIncentivePlan2023Member [Member]",
        "documentation": "StockIncentivePlan2023Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock, net of offering costs (in shares)",
        "verboseLabel": "Number of shares issued or sold (in shares)",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r72",
      "r73",
      "r102",
      "r525",
      "r592",
      "r603"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued (in shares)",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r72",
      "r73",
      "r102"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Exercised (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r72",
      "r73",
      "r102",
      "r356"
     ]
    },
    "mgnx_StockIssuedDuringPeriodSharesStockPlanActivity": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "StockIssuedDuringPeriodSharesStockPlanActivity",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock plan related activity (in shares)",
        "label": "Stock Issued During Period Shares Stock Plan Activity",
        "documentation": "Number of shares issued due to stock plan related activity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock, net of offering costs",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r72",
      "r73",
      "r102",
      "r531",
      "r592",
      "r603",
      "r655"
     ]
    },
    "mgnx_StockIssuedDuringPeriodValueStockPlanActivity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "StockIssuedDuringPeriodValueStockPlanActivity",
     "crdr": "credit",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock plan related activity",
        "label": "Stock Issued During Period Value Stock Plan Activity",
        "documentation": "Value of shares issued due to stock plan related activity."
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_StockOptionsAndRestrictedStockUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "StockOptionsAndRestrictedStockUnitsMember",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromtheCalculationofDilutedLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options and RSUs",
        "label": "Stock Options And Restricted Stock Units [Member]",
        "documentation": "Stock Options And Restricted Stock Units"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders' equity",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r76",
      "r77",
      "r94",
      "r554",
      "r570",
      "r593",
      "r594",
      "r643",
      "r656",
      "r762",
      "r791",
      "r838",
      "r857"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' equity:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' Equity",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r173",
      "r304",
      "r306",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r318",
      "r320",
      "r421",
      "r595",
      "r596",
      "r607"
     ]
    },
    "us-gaap_SubleaseIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubleaseIncome",
     "crdr": "credit",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Sublease Income",
        "label": "Sublease Income",
        "documentation": "Amount of sublease income excluding finance and operating lease expense."
       }
      }
     },
     "auth_ref": [
      "r450",
      "r642"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Axis]",
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SummaryOfValuationAllowanceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SummaryOfValuationAllowanceTextBlock",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Valuation Allowance",
        "label": "Summary of Valuation Allowance [Table Text Block]",
        "documentation": "Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "mgnx_SynaffixBVMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "SynaffixBVMember",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Synaffix B.V.",
        "label": "Synaffix B.V. [Member]",
        "documentation": "Synaffix B.V."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tabular List, Table",
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r709"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "US Federal tax credits carry forward",
        "label": "Tax Credit Carryforward, Amount",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "us-gaap_TaxPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxPeriodAxis",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Period [Axis]",
        "label": "Tax Period [Axis]",
        "documentation": "Information about the period subject to enacted tax laws."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxPeriodDomain",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Period [Domain]",
        "label": "Tax Period [Domain]",
        "documentation": "Identified tax period."
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_TaxYear2025To2037Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "TaxYear2025To2037Member",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Year 2025 To 2037",
        "label": "Tax Year 2025 To 2037 [Member]",
        "documentation": "Tax Year 2025 To 2037"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TextBlockAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TextBlockAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Text Block [Abstract]",
        "label": "Text Block [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_TotalAnnualFixedPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "TotalAnnualFixedPayments",
     "crdr": "debit",
     "presentation": [
      "http://macrogenics.com/role/RevenueManufacturingServiceAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total annual fixed payments",
        "label": "Total Annual Fixed Payments",
        "documentation": "Total Annual Fixed Payments"
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_TotalPotentialValueUnderAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "TotalPotentialValueUnderAgreement",
     "crdr": "credit",
     "presentation": [
      "http://macrogenics.com/role/RevenueNIAIDContractDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total potential value",
        "label": "Total potential value of agreement",
        "documentation": "Refers to total potential value under agreement."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Amount",
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r701"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Vs Peer Group",
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r708"
     ]
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Receivable",
        "label": "Accounts Receivable [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r120",
      "r121",
      "r229",
      "r230",
      "r231"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangement:",
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r729"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangements, by Individual",
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r731"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_TransactionCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "TransactionCost",
     "crdr": "credit",
     "presentation": [
      "http://macrogenics.com/role/RoyaltyMonetizationArrangementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transaction cost",
        "label": "Transaction Cost",
        "documentation": "Transaction Cost"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instruments [Domain]",
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r303",
      "r317",
      "r420",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r505",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r787",
      "r788",
      "r789",
      "r790"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption Date",
        "label": "Trading Arrangement Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r732"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangement Duration",
        "label": "Trading Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r733"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r731"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title",
        "label": "Trading Arrangement, Individual Title"
       }
      }
     },
     "auth_ref": [
      "r731"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Available",
        "label": "Trading Arrangement, Securities Aggregate Available Amount"
       }
      }
     },
     "auth_ref": [
      "r734"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination Date",
        "label": "Trading Arrangement Termination Date"
       }
      }
     },
     "auth_ref": [
      "r732"
     ]
    },
    "mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "TwoThousandSixteenEmployeeStockPurchasePlanMember",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2016 Employee Stock Purchase Plan",
        "label": "Two Thousand Sixteen Employee Stock Purchase Plan [Member]",
        "documentation": "Two Thousand Sixteen Employee Stock Purchase Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://macrogenics.com/role/RevenueManufacturingServiceAgreementsDetails",
      "http://macrogenics.com/role/RevenueProventionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Type of Arrangement and Non-arrangement Transactions [Axis]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r409"
     ]
    },
    "us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "USGovernmentSponsoredEnterprisesDebtSecuritiesMember",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Government-sponsored enterprises",
        "terseLabel": "Government-sponsored enterprises",
        "label": "US Government-sponsored Enterprises Debt Securities [Member]",
        "documentation": "Debentures, bonds and other debt securities issued by US government sponsored entities (GSEs), for example, but not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB). Excludes debt issued by the Government National Mortgage Association (GNMA or Ginnie Mae)."
       }
      }
     },
     "auth_ref": [
      "r803",
      "r851"
     ]
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "USTreasurySecuritiesMember",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "U.S Treasury securities",
        "terseLabel": "U.S. Treasury securities",
        "label": "US Treasury Securities [Member]",
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)."
       }
      }
     },
     "auth_ref": [
      "r622",
      "r633",
      "r635",
      "r851"
     ]
    },
    "mgnx_UndesignatedPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "UndesignatedPreferredStockMember",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Undesignated Preferred Stock",
        "label": "Undesignated Preferred Stock [Member]",
        "documentation": "Undesignated Preferred Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Security Market Price Change",
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r728"
     ]
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrealizedGainLossOnInvestments",
     "crdr": "credit",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized Gain (Loss) on Investments",
        "label": "Unrealized Gain (Loss) on Investments",
        "documentation": "Amount of unrealized gain (loss) on investment."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesReconciliationoftheBeginningandEndingAmountofGrossUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Unrecognized Tax Benefits",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r387",
      "r392"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized interest or penalties",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense",
        "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return."
       }
      }
     },
     "auth_ref": [
      "r391"
     ]
    },
    "mgnx_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions",
     "crdr": "debit",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesReconciliationoftheBeginningandEndingAmountofGrossUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increases/(decreases) for prior year tax positions",
        "label": "Unrecognized Tax Benefits, Increase (Decrease) Resulting From Prior Period Tax Positions",
        "documentation": "Unrecognized Tax Benefits, Increase (Decrease) Resulting From Prior Period Tax Positions"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesReconciliationoftheBeginningandEndingAmountofGrossUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increases for current year tax positions",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return."
       }
      }
     },
     "auth_ref": [
      "r393"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "crdr": "credit",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross unrecognized tax benefits",
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate."
       }
      }
     },
     "auth_ref": [
      "r394"
     ]
    },
    "mgnx_UpfrontAndFixedPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "UpfrontAndFixedPayments",
     "crdr": "debit",
     "presentation": [
      "http://macrogenics.com/role/RevenueManufacturingServiceAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "upfront and fixed payments",
        "label": "upfront and fixed payments",
        "documentation": "upfront and fixed payments"
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_UpfrontPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "UpfrontPayment",
     "crdr": "debit",
     "presentation": [
      "http://macrogenics.com/role/RoyaltyMonetizationArrangementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Upfront payment from DRI Health Trust",
        "label": "Upfront Payment",
        "documentation": "Upfront Payment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r41",
      "r42",
      "r124",
      "r125",
      "r128",
      "r129"
     ]
    },
    "mgnx_ValuationAllowanceDeferredTaxAssetDecreaseAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "ValuationAllowanceDeferredTaxAssetDecreaseAmount",
     "crdr": "debit",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesValuationAllowanceActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Deductions",
        "label": "Valuation Allowance, Deferred Tax Asset, Decrease, Amount",
        "documentation": "Valuation Allowance, Deferred Tax Asset, Decrease, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_ValuationAllowanceDeferredTaxAssetIncreaseAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "ValuationAllowanceDeferredTaxAssetIncreaseAmount",
     "crdr": "credit",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesValuationAllowanceActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase, Amount",
        "documentation": "Valuation Allowance, Deferred Tax Asset, Increase, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_ValuationAllowanceRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "ValuationAllowanceRollForward",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesValuationAllowanceActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation Allowance [Roll Forward]",
        "label": "Valuation Allowance [Roll Forward]",
        "documentation": "Valuation Allowance"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ValuationAllowancesAndReservesBalance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowancesAndReservesBalance",
     "crdr": "credit",
     "presentation": [
      "http://macrogenics.com/role/InventoryNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance at Beginning of Year",
        "periodEndLabel": "Balance at End of Year",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount",
        "documentation": "Amount of valuation and qualifying accounts and reserves."
       }
      }
     },
     "auth_ref": [
      "r178",
      "r183"
     ]
    },
    "us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowancesAndReservesChargedToCostAndExpense",
     "crdr": "credit",
     "presentation": [
      "http://macrogenics.com/role/InventoryNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions Charged to Expenses",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense",
        "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense."
       }
      }
     },
     "auth_ref": [
      "r181"
     ]
    },
    "us-gaap_ValuationAllowancesAndReservesDeductions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowancesAndReservesDeductions",
     "crdr": "debit",
     "presentation": [
      "http://macrogenics.com/role/InventoryNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Deductions",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction",
        "documentation": "Amount of decrease in valuation and qualifying accounts and reserves."
       }
      }
     },
     "auth_ref": [
      "r182"
     ]
    },
    "us-gaap_ValuationAllowancesAndReservesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowancesAndReservesDomain",
     "presentation": [
      "http://macrogenics.com/role/InventoryNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]",
        "documentation": "Valuation and qualifying accounts and reserves."
       }
      }
     },
     "auth_ref": [
      "r178",
      "r179",
      "r180",
      "r182",
      "r183"
     ]
    },
    "us-gaap_ValuationAllowancesAndReservesTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowancesAndReservesTypeAxis",
     "presentation": [
      "http://macrogenics.com/role/InventoryNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]",
        "documentation": "Information by valuation and qualifying accounts and reserves."
       }
      }
     },
     "auth_ref": [
      "r178",
      "r179",
      "r180",
      "r182",
      "r183"
     ]
    },
    "srt_ValuationAndQualifyingAccountsDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ValuationAndQualifyingAccountsDisclosureLineItems",
     "presentation": [
      "http://macrogenics.com/role/InventoryNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]",
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r178",
      "r179",
      "r180",
      "r182",
      "r183"
     ]
    },
    "srt_ValuationAndQualifyingAccountsDisclosureTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ValuationAndQualifyingAccountsDisclosureTable",
     "presentation": [
      "http://macrogenics.com/role/InventoryNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]",
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r178",
      "r179",
      "r180",
      "r182",
      "r183"
     ]
    },
    "us-gaap_VariableLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable lease cost",
        "label": "Variable Lease, Cost",
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases."
       }
      }
     },
     "auth_ref": [
      "r449",
      "r642"
     ]
    },
    "us-gaap_VehiclesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VehiclesMember",
     "presentation": [
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Motor vehicles",
        "label": "Vehicles [Member]",
        "documentation": "Equipment used primarily for road transportation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted weighted average number of common shares outstanding (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r204"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic weighted average number of common shares outstanding (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r197",
      "r204"
     ]
    },
    "mgnx_ZaiLabLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "ZaiLabLimitedMember",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Zai Lab Limited (Zai Lab)",
        "label": "Zai Lab Limited [Member]",
        "documentation": "Zai Lab Limited"
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_ZaiLabMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://macrogenics.com/20231231",
     "localname": "ZaiLabMember",
     "presentation": [
      "http://macrogenics.com/role/RevenueZaiLabDetails",
      "http://macrogenics.com/role/StockholdersEquityDetails",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Zai Lab",
        "label": "Zai Lab [Member]",
        "documentation": "Zai Lab"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c),(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(2)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2C",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2C"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "60",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.24)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-16"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-21"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "330",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB TOPIC 5.BB)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480581/330-10-S99-2"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(CFRR 211.02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205/tableOfContent"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//360/tableOfContent"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480091/360-10-S99-2"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//810/tableOfContent"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "940",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//940-320/tableOfContent"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//942-320/tableOfContent"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//946-320/tableOfContent"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11B",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-11B"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-15"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "10",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-6"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "270",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-6"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1403",
   "Paragraph": "(b)",
   "Publisher": "SEC"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(210.5-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-11"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column C(1)))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column C(2)))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column C)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-1"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-2"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-1"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//320/tableOfContent"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-10"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//330/tableOfContent"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-1"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-4"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//715/tableOfContent"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480126/715-20-S99-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480266/715-60-50-3"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480794/715-70-50-1"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482312/912-310-45-11"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "330",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482105/912-330-50-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(h))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482663/740-10-55-217"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii",
   "Section": "6"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r739": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r740": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "825",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B"
  },
  "r741": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4H",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H"
  },
  "r742": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Topic": "705",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//705/tableOfContent"
  },
  "r743": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r744": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r745": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r746": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r747": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r748": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r749": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r750": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r751": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r752": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r753": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r754": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r755": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14"
  },
  "r756": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r757": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r758": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r759": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r760": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r761": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r762": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r763": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r764": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4"
  },
  "r765": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column C(1)))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4"
  },
  "r766": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column C(2)))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4"
  },
  "r767": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4"
  },
  "r768": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4"
  },
  "r769": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r770": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r771": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r772": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55"
  },
  "r773": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18"
  },
  "r774": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-1"
  },
  "r775": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11"
  },
  "r776": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r777": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r778": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r779": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r780": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r781": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r782": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r783": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r784": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r785": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r786": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r787": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r788": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r789": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r790": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r791": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r792": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-5"
  },
  "r793": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r794": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r795": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r796": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r797": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r798": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r799": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r800": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r801": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r802": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r803": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r804": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r805": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r806": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r807": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r808": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r809": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r810": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r811": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r812": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r813": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r814": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r815": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r816": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r817": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r818": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r819": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r820": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r821": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r822": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r823": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r824": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r825": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r826": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r827": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r828": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r829": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r830": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r831": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1"
  },
  "r832": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r833": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r834": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r835": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6"
  },
  "r836": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r837": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r838": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r839": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r840": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r841": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r842": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r843": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r844": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r845": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r846": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r847": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r848": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2"
  },
  "r852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r853": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r854": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480109/944-80-50-1"
  },
  "r855": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r856": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r857": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r858": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>89
<FILENAME>0001125345-24-000060-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001125345-24-000060-xbrl.zip
M4$L#!!0    ( '* 9UC.9*5LYQ0  #":   >    97AH:6)I=#$P,3!B;V1O
M<'1I;VYG<F%N=&XN:'1M[3UK<]NVEM_W5V"3V5[[CJQ(MA++CV;&3;.=S-Q-
MN[7O=OII!R(A"35%L  I6??7[SD'( E2I"TY=B5[U9DFD43B==Y/7$[36?3Q
M<BIX^/'?+O_]Z(C]J()L)N*4!5KP5(0L,S*>L-]"86[9T9%[ZI-*EEI.IBD[
M[AT/V&]*W\HYM[^G,HW$QWR<RW?V\^4[FN1RI,+EQ\M0SID,OW\C!^,A'_7&
MX][9X/U@%(R&@[X8\; GAO#ER:#WO_TW\"H\;M\QZ3(2W[^9R?AH*G#^\]/C
M)+U8R#"=GO=[O?]X4WDN%7?I$8_D)#ZGU<*O8P5[<S\'*E+Z_&V/_KO 7X[&
M?":CY?G?;N1,&/95+-BO:L;COW4,C\V1$5J.[8-&_DN<]W%R^KAPJX%Q(AF+
M?'5V29_OIG(D4];O=?N]RW?X0KZIU:UQ/8'=C52:JMGY\0 F\'81P(D*_>3;
M&*RUC?_B@58_B5@&IL.^Q$'W<J0_7J<JN&4_)ZE4,?M)<UC65Y7*0."/!X =
M)^SSGYE,E_@&K%[.!?LEXO%A]1Q:3^!#]0#^R$PJQ\LG/X%^[00&ZYT .TBG
M@GWW=GA\W+O(=_1,*Z,1SV4*!Q&L :U/:I;P>/G,B[KWN.A<^A>''99DVF2(
M&ZEB,C6L'2]V^$1Q>;MQG%-NV 1I#?@SG.A29>Q@)X_,\H6IBD*A=^'H&""8
MLKP*S@VP,H"C% Q1+LYF(Z&9&C,SY1JFAG_A]T!',WC<\CDC4C96.IVRD8C4
M8H>1U9[\+IQYE['?5:9S&2$-,]GH#Q$0,^!1E!\T"+:9 0"%+%!Q*/%A^&B\
M,Y\*+61,C\!?^ YQ#/R,'RJBZ&JBA4 %I)//L9C*8,H M(RG*0^F0#LX("Z"
M!@R43I0FG<=-9">1FB%_@B>7L)5//"$8_ M)CU8<JY2)NP3  HK.DH5B#$=1
MC#'*TN(K?]%*W[-F1$%8])3/+6[.!(]!"_//8NVQ.GB&/,'U\5$DND\A=S^B
M<&\=J/&U%"?/GQ@I#0SA"# QXHD1Y_D_+D)IDH@OSV5,^$0O7507]AX6-A<:
M5 P>N5EH0ONS4P7/AMWAZ1"UP106FH;YQ$Y1[)*B^"X-5W\;G'4''TY;?P8-
MKO6W>X<==D].3M8:]ATMV2X;#L: %/_^S<F;_(6$AR'@POEQ<L?Z52!%8KQR
M-O98WMP#:5)BW:A'VA)T=_!^5_2NLYH8^>[M^^%%38EV1WK/:?7PK-8^!3S(
M\[-N[]Y#:"""/?R:X?<C<%5DP60?[ 'X\@#X^4[H0(*F](L&TXXEH"A=HY:T
MA^7+@^770M&]+A3=BI)[7:IGEO'NH?SRH'RS3(CE[B'X4B'X^2Z18(Z@,H_R
M<P_"EP?"_Q$P>SQAUVAM9I'X^\L XCNRNQXT$6G61]J(M9%Z*^OO-8YMOY)Q
M"(;M^1$^].R0;7:O_'V;GA5?0J/A7S6/AL?]TPL#(CT&W,M49MBUT'-4V]*I
M5MEDR@1'1TCA$F!SAZ8AL)DN8QMX"-PWJ4JVY:A_V._(KH+;6"TB$4[((6(J
M1+@5^+$?ENBTU<S 4?$TT\+Y$Y5FHR43$0!7JU@&C >!2%(> _3@-YX!N&-D
MD]:5%C..[J 9_: T.:7@?>>V1/=_AYS#&1",-BGZN>A_] W!4[S)%ML$WA62
M/6UF!U62/?GP#"1;C\+=XX_\L$7 5X_KI-\=XEG<% 2,KM&) CD8YV"$+UKC
M:YW"[YEH-9>&W*7.E?HXM^B,AP(0*N$ZM0/!]*$+XP);^&<<"0-3P)AZ@;8@
MS1M6_9H=^YJ_T <6P@Y2-1$X:(?MN#>]7/0N^-4!7DMR/H\ ="J48RE"@"HL
M#V$"W$(+0 OXI[A#'F*YQ4)+8O7(>"R6(7\@IL! 0UGZG$2-QP ^[05"D*-\
MDX#8,XQO9QB_ \ "('9APZE:!$)2G*!&=YU[J=\G6'3K*). T,EL  ; ;.F<
M'CG2(J*P2,X,3$U(A2*"%>BEI71%'$0&,D&OGQ^GR/4/#%G$1[A;1%-O(+,T
MJ9@Q4$= +Y$&0S0XY(S+..4R7I%N)!-CNU+8OPYI:HS!6,&Z\L(>>7< >2FL
MI05WR@A('II><LT6,IW>(]/N1^E<SI3(#.#^8O%/S)%<8"C$&J">,?!]Y)SI
M0HBX/B/A;",UK4[J8F\U BKCF2NK7_G:!?M@44 %T1Y#=T<?\^*Q IB>#;P2
M-E$\V%.K4:3FR)0+5)]/:3'AFI[";WGP9P:H1G/4G:_XILD2&%< %R,E+=$2
ML$QI'M&O*,)3F(?GJS,=1-X9R'I"ON_>#DXO2/PG6J"4X#:4CCD/H/(7T?>"
MUJQ^X!9CF:FPJ3E\ :LV,#IH$F!(@GI0RSK)A46^)C%+(K6D(^,>C8S',&8D
MX!%0\@S0HB:+QGLD'Z#\,7&1[40!J2Z)T.S:5O;?3C!^CF"B[(F?DS0#>=6:
M->CHJU>^PD=&15G:_LI&?A;OSZDN?3T3<30"KGA[Q,=P3N<\6O"E>?.4>8^M
MBWEJ'K.E]#R?G>>4AQB*F H\G=P>@<WW03H ?HU*L_'8LOUAJK(H=*:8E026
M(>QY\Y9Y\R>58?XK*GF&S!\P?9SR"3QI+CEH$H&1L!J0UYY>"0IDQ YD'$09
M,>$D'%O5L:+&ELZ8 ) G6N*3!9/\9_>ZR\; DY$-?[[^\M-7=A601G$,Y] !
MZUB2)^9S.=X-,#+# \M]Z>&<A7F^MX@O#LL?4GP%.#GJ(6P&5K$*"QX;E)MG
M1GG[7D@0$G02P Z)-9.&-4)2L#8=C# '1 LI/2E_#;^%M^@'^B" 30>4B#G&
MPT')DVG@@<*LFS2TZH<^V:G\W>_>]C_T+E;_W.54)EAYMV<Y_,:Y3,/N6:_]
MYV_(95IWV*W&A @!C[NG[U?B1.[+G7%7KV;6MR'D+N^MF>9^6&[9WVZ/(A2!
MLM'4<U+;\:E',(15,?\8B#Q3&<=Z +G.Q=PS;W*[:'>#54>O%_-VGM$U0V4E
MD>$E F6-B/W_=X'V0,+N"Q9H>VGR;=)DYQ'ZM3.N^S-\GK+DX^'7*G@P?-]M
M!GG5*V(?VQ)?NZ+*(7*Z;C<$#)C(V@+J:,O?4V"Y":&V<9G[P?KL;M>_VBDV
MQ,J=]H/; 2_!X*3;[SVJX.EL8VN^!N:^)<=FA6C$@]N)5L"JCAR8QO1?SN[]
MW,:-,Q-?DB?]7G)Z/DQ^B(VQ+VNR@[^J$P')@(=WT,[??,@\\=K66ED+4WXD
MUVT2@5N,"UP9IL487=Q%\I!N3U%[YJ+T8LD;)G-5NE0\[\K6K.??1E^)QY[>
ML_:5V.S@*GT0;#@ZK^XGW;AH-?'7++;YO-@V3VI;+38>BUS/UV)C0\SRNT/P
MQMX0U:R-U&52N#+)A,HD@5]CJK;-D"566>6..PN&YVP>L1D@-NFXD*=ME4*W
MH?E"!0)Y\E:9A;5&RX7Z"#:UJ]ID@;$;/]5KZ?6_P(X6+O.@>5$V=ZB>^EUN
M"G,_4YF"7509MWA@HV#M[JH:>( 3$5.\O;DU2!E$M]E(Y1%CCP_,UXHBM3";
MU#CLS)DTTV6_V^;H^8F253!C@9 Y[[[6W28-/]3WY;X\SS)7 VD8"3Z2,^DR
MSU;2-9\:Q&@2;@G$!_SP(6?>-F!Y+2B/A7VHI3)*4 9M&@PO&;6M3KH*\6AM
M>E\H#;ERX/L.0!*TDI#;#\! /^6-=_R,&4Q7]&@:('SV6B \VFD(GQV(PQJ0
MG<I?E!9JX;+QR25BB"2!0TO,N+= :R@^!!K&9*HB718')MT])WP/T,3J7PFT
M@YV&]A#65X-VRN]L?<F?F0"[H:[ =+\1,%M2)VJB:)QI2KBKB21)&7:(WZ1C
MN'(JEV2ML\AF6..!95'^B"V@PVS$L58SEL*JB2+P[Q$)JED63<@,H%2^$$Q4
M^+??$C&7>YO4*S2Z_1\JG6@I%7QD!<*.:TO'K=J2J\OW=KIME*0<3JS#1L75
M+ZQ<,1L[/L[68(H0Y'[WN=9:%-AZWIR I@X$6KI9HN+B>63GKBB@A:>_&DPY
M:<64O/'14QI5>^VR@1*(@3I[#VSZPI."V(AT@1P3K' ?(1WI8++R8JHPV-;J
MG$$N2@PYS#3B/#H&$<?1AUU4+\)[";?%*XY2:OX<8M^EU8GJ#*:XD.#D=TXV
MV$1NC14TVJN9Y'G3T8+I7H5 8M*DH/G"#I!8@T#ID(I?O-J<8@4J$+!ZF,4O
MCW3EC:L#^G+)&E.X_DJZ>S9RF>9 Q[]$Q "PT = ZK0#PP8'\K #?_YQ2'L[
M!=WU8'Y8E2OE/+"X5$N;Z [KM4VO"51\)"-T1,+^BQWY,'1@"81&_H7]Q:0*
M-TL[WV&BVTV%_T8Y#$L1XQ/D^*D+ZUR52/X/OK ])!# 0!X5L-7IX]E\+OW>
M<'O@DSL)OH";:8<%4Q'<=MB(Q[<LU'Q,M >L3V!MM$V^ W/J*<7T=D&QF[#P
M=7F>N_010-0Q(Z<2Y]-&U@B&[XS(Q9DAH3"!EB.K\N6VV0!L,]QQ1567XSS8
M0/(,?JJ(RHK@ SLGR4!2!"!002J 1GF_&V6?M[//V]GG[;PXEKB;/-&S4KU:
MW+PX'?D4JANB:&72PM4Z*RIZ68RN%FCJMFG]ZW'7*GNUXE+I5R,OYZ\>-PIY
M&XMT1=1RK7D\<?ZQM1"B:MV\N%AJ,QX,6OT;-Z#V;S](6+2R:C0.1P),?*O>
M!( :Z)3.C?3"CL>"910:Y3<"VZ<*XX7BZXZ#?##7&D.P2IMR6Q)M!RD=8X+K
M2**;SB&)M7= (.Y#D,^-*1*@%4H $7#^#1V5Y"/ZQ#-D#/LXXO."*9UB<TF0
MP^G4.)K<$%"V80XW^*1K[06&#X&OPWZ4)G<F*63D/)V^)ICN9K2P?_QH@(99
MF9Y3PNXU@2S<39 -JR C !"YH L!'7JA+-SA+<![35 2.PFE%9G&6[)AI%4W
M?E!<AY3V' I+@)@1-77ZL1]++!,R)&HZ<>RT7(HLM,S2>26P'N\DK!%"M9[^
M#V0(/X,UNDVP3'86+"&UDBJLC'X/:22.T>=@N'4[K-@'+\XT;-[^UX:T+#R(
MB8)/G09902D'%)^KY"F45O2(^EFA-<WX2,U%V?:R;H#9M!.7S6T;*J8R\NPL
M2KD_D(>L79IU&+G(+?/$*&]5+?'8X@9\D%G'T.842_F,Y$1H0"N,LZV!5XQ=
MA3;'&2/AKC^O,NG1C;>U\D(F"XK:R;K>:!3;0P#5DDI*8,G7Z.YXW^KN^,T+
MV?\\@K7;)*XM)P)=E9ZI)B@-:Q[*X04#$[T(RK;Z33+;L)TZCGJY\ORNDKF@
MRF.@Q'D#_S:NEW@<,B1GW_V&LS;-ABG;+@W#9C-@GSHB!S_] O<H+ ES0TD2
M-K6CZ=("?'3D-22OK)I2[1*^U"J*:BVK^0P;Y1G\U2L.Z)3)&=2\WMV!H. (
M;^%3"$M!*BR2J<@2]5H&PDJP),385.<'0WR5@& >\ O%7$0JP4O5J3SMUR*-
MD-TX$BU2!=V)_*?K./BK -R:YPI@VAZZ]X[QL$.G8K*9*?-1X%4+8?NHZVC8
M 92':3LL4H%K,XML"VC[/GPA\4#PRB\1P)-MX+.53)8:JVI)?/&GO#_WI6SM
M?47CP!O1LE,A#V"%.2HT4@IF6\)8U)S<EQC&I1Z5O:5S=[57+10K[TSH@FMC
MLM9D),_U7:$>1ZPXCY6")H,3;27.>J9H80-8[*_U["\RMYL!V00R_W@65&8)
MTC;WQ7@3@<3,*&.+AA91,RT7U(;"81:#K*"=XE(JQPIG-J-S(/K&;\9<1G0_
M2K7Q.PR5[R5/@DP*VF\78_L(]S["O8]PORAE[D-[[ HU]C&(+^M3W'(8Z[.]
M986WW9!3ZMRBED"YK)8FH,!*BZU1)V,[]&AI73OVDJB:6A?Q!0D;#&WFU0 A
M)H/*D2N[HEO."U6%7O+=?Y$<@VR.@9/;O@ZO)KG[M!6!&HV_[4=#6THF*WG\
M%#(O2C\F1?5GJ_\PGJMH7BOH\LHL.R1.5>;J+%UQ'J_IPP[GE(S3/ ++X8A
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M-D_\PL[C.B!+_'F>K#X[/SLX/VQ_#*Y0^>PYS<WSPPDL".$?GAT_6SID*D=
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M-TE81F S+$()JT<C0)KQU.,D+>#_FR#=M2#]'9!&D3,CA=-UP+:TO +C>J[
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M.A6?@#(3]%/R0#.BV=8GVK;%% -7GPMEV.]@[X'MO9'$"Q93%*=TI4FJ8]=
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MT16\D2K@!JS 2X7O\!:W0.<,1B(K,'%QLV58L.+!LJS9AR[1I9"9Y1 9Q=?
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M\1)FJ<1/"UDIEZGP09+]#?'@_^7P_O&#A_>?#W6R@'\F^31]_?]02P,$%
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M/KVDP+O0 AU [D(JA!K.N:V ;Y6LN<C<3\8I4^$0L7P)LS8P.L3PJC00F+?
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MLDL;IR+)7"5=P0UP^;!5A2$OOOW*S5@)[,L"C!4M9V7S1N=7SK;(SBV'J"-
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M$[AS K?&"7PY4>D*_IG;1?;F_P!02P,$%     @ <H!G6,WO$JJ"%0  _(\
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MLG.ISL\.3H>G"+=S +9Y[%_L'*X#0N*O\GCU&CQY/FB_/#@8EM=>T=@\/JS
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M?*Y4NOPV9P0:WM'WL;'J'>5K.6"W,M.5GUTP#B8!L"%YEL9.;>E!R%0!(&<
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MXX<N%AP.SG8G,KJ3(M-@(YC=L5%<56LB8"&90 "[* V@[\Z= $2#/D<:F[D
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M263I,&($E!IRBN(MA;'2SP(5WD#.)WZD4AKX!T?\HY.%(^"K$1[50 D%.9(
MJX01LS2F/!%42(()4:Y(N.06)]C3H K6O*U]X(B!JO>/''9\PFI*::?U^P-Z
M!-968G4]+4]Q4VC*40T EW?EA9<S:Z@23CSGM\8UPH5$'JLN<39PNMX(^(UB
M<SCFS0_'W2U3"/I8OWZ)A!YNH4 *+U\QM340<>(VZL%?<&2.1,_QLLA%H?@7
M7K1)/^%W6[@;\@WAX2*Y4?B?;(!!@,WN\=&6"@60\ '=<:_^2Z>&S*4$B:,
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M[PUG4WW::CA=7#3=M8X#LQ[Z\B5F]+ 2KW2Z$//4FI3( Q8MV@,H(>?FZ/=
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MYU89!5QA$&UD+<-+#$M"GH>I-3#%,D,L\:?:&)AGE"CP:H% _"+D7(U"@8S
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MUCAZ "3,I@18@\QZ!-W6?ET42@@SI5.T2 D_=%J- Z>.J6>-%O^RI<L51_P
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M3U G:6M-L")2OU =$8@,EL(Z,8,S7YG.M2A[]$K5%#PR*L&LM)R)R5>>'5\
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M 2U^02.HV=4PJA+H44-HMQ\_!-8'\I=6$8-V2A^]PUKM@(42*T:3@G!2[$W
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MJKE?%HT0JT$:'8[L=[4;W7&0\,?$OHY\;_#8>O&I>4?J5M'ST&+/@XP3@N-
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M<MYTT@1DU+V]+/C,6#F8*Y*B]XK"$]@6 !L\U]'AA:>*'WD+RDF*M8EW5C!
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MDM5RP!"]S.D0;!;*;Z,K$EI!6O\DB.ZXL1#V;O6""2\3D8D<O$0U,G9"##+
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MOP5/GA9(I[>;JLV,F>*6^#]//M7N?4.!S$5>SOY<U.=M7PZJ']-/_2EA8%;
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MS/BAXFF)W=?YY6,7C+D]23<0;7JS< GM5\_^\J->@O>!]=\M(<A)/TM6OQ]
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MTDSNZVBF7KO4S.>M+<'^6D;74=69+=9LDZM/F)AF8BA2!,D0B^SK,KMZYA-
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MF_XCP@!9\Z2)CRH;0*1RR>]D6AY>&#@T+ &V' "8]]#94LT;-X6RR<3NIZH
M:(C(;3[]<'1# @/$8D-R89<\NG?Z]H2T \+RK,IW)F%D)/JR#; <56N)11\&
MBP,)45[:G",SY?!\%NXQP>4=K[Y&?6UFQX"<]KK1I)^&2,.XLYN^''8^I6Z,
M) 8[ 4<\C^(V"C_'OA0FK>H\U&[T&D;$1D_M>N2F ,FYWHSR!@^_?3*D51X,
MO"?-IB6.&50J+FIYY8LQ%5=5>7+47=3HUU)8_W3Z*O--0K%_9@<\DM# FO;>
M,6N86@QS^FX#^M4]W(4O^(QY_I?!^B5])3XA)H1TA;1HR-V%QJ_2L7C%TT:$
MO7+/I<H+O1/7WF_/ER<G]TV2;2,;D!XS_ $EO 'L&ON=!@3UNQ-W*8&+$TO>
MXD#CD< YOMT;.,=G&J$=#JSV9!3OB:22CYMI(9[G?SFRE)^V]0PLCQ9K: <F
M% _;;E.L,F?%10V6=M%'["$C$U)4,ZVU$).6'7?=+PK_@?4?^ >:_(+ZI&0O
M<MN.P]/-G+V7;!'"G)R<(_][[SD7TY%-C&W7)B"D6993/>%@E5Z:8;'V&OKX
MSSB2_Q+<P'NG?W[Y2DS&*G^/@KJI>H@O3%\9"%/2$X97@ TQSL[P#;C*"WJU
M1P^9;E4*:)P&AN.6OPO?94D?&?=:>A6HU0I#82QX=,)$"D\2+R\CS;:W?/KV
M]*@#@K%4FPTE+ ?DW;4DY((V(1A7=I*$5>:;;YE/%JPSQB2++A9^SA#]:YZ)
M3V7*L$9%%W/(PH!T0T'6QT</OQ*RFN.$R-+-@Z6)M2SG!X'<&]UGN?D&H(K*
MQ^<-S9@)F/#9C*-AE?\>!5TLJQ+,69B?@3J!A4'H?*"?.WK1-E\C/>6JOG!;
M4&SU*1D>J+#6!0;A&O%L]I?N+94.7QE5O_ZGK+K]\T9.KDD;4-?&,&O .444
M,Y:P:H[A<^GB7^AGABNL*9)*Z( V%*JICY_'$HWK C.3YWO+Q/2M\D4PFK_&
M"^,%>+N%N?^]V5JKK;*(^MQ\OX9B\8/=Z(0=W8)* )C7B9=;,X-,1Y5?H6;N
MAB3#K2@#19[AI/]</5R0=:/@;R&1CI^,<DQ%B[3\ZQ<OGPNW$*Y[E:<MAVJ,
M7IYPC;!::TN\Y$BU@3F)&<*@4'?/RHZ2.!]XQ441# QSSCB2'+;YO/']SLT7
MESEK E#HH(VJ?4VM]DI<0(U)Q[.GROIJ)H%?T"\RI:4I8#M$.B+B#=*G<>8O
MDM)D\MM%^%ISWA?2!:JDY2Z9KBU>54%OX)T%%PZ*GE'?=>D8KJ4LY+D6%E34
M(G3:NV*;1FG!6^XV3:T-X: _%IKMZ*$(^:F-3IC6/;0X+Y;!MF23QB5#S]RP
MQ\YK5:8IR7';W54QSFI.NXJB9I_"U-->G(DXS"6GI 4GBPC>B,0-K[=&C7M(
M.85,I(%#VX:*#S>$Y=V9G/K3LGF55I!.*<.7DQ#/*T[79;/7/E?'BYNQ([-3
MJN&\)ON^VL-%/"6C&5,@EF'+)/$MS 1K[TQSUNBJ,#+LJ;A_"4!!DD9G/Y53
M5![FA8.+&="-G2P<EO\-4:(T9RHF)'(8K/.MJ*3J0>E*CIHG2TMT+C^-<EA.
M:(.TL)EQH2W<WES #K50GRYJVO.\%L(NY)*'3\6L>FR@&75 .9/2,LGQ$"&W
MV#2Y21$CU5 EG0SYKDT$5P %;5"FM94I%?OPCTP28,+?X"M\!BC;;)G'NA.R
M:T87^RD 6K&3L[;:1I?#G9V#X4@O8%,+Z"_,8R]E\+"!_UX8V4"8 UX!F[Y%
M#!19X'$A9)RZ<"@"(F(NQBB-*+B72+)/)CP<<RM9IJZ00\ 2EL6B(A ;A7 X
M$U"HT,KE8)H';]=B1Z%*P=!"(;$GI_QX]IQ<]W+I0CR[R[A ("--.=:-<#:R
M>%8B9GZS?9G-X Q.W#]YRUWOE)(CJ'_% ->!0@)G(X"_*O/S.JQJTL^$)KW6
MSJ][=\VR MX"2^'*3CM_)GYPV;K;#] "#MF80#G?2*;0($A=S&QRL7O773-_
MTE/UYF-NF+$U%'A5,SE<^QB7(:]*12\MQ)P1S7S!(BQP;, SJU[KLIGW0DL!
M1EM$-RD83@"V0EA>T7X6LC-OZW%+$RZ"OJ 9\>"L +DL@+P8.1Z_.<Z\0E$L
M$UT+L@$(;FLDK@6MAS,N_M86Q+EGT[Q47BZ.1JBQ: 7#(ZU4)KLJSTMQ' =+
MG--T1CGH,Q4I[$IKJGIKA[D*7WM%6^KI\>RO*1J):V>+AC5U1"%P59 M*[N5
M)">ZHG@G-2*P\RSBG/N3^(QBE0ZF!AM('ODBK!:>G+F'SH5OTW69,M[Q NK0
M8OLG\P D3SR]H7]#H"%;<1Q5S9CHK?2=[E)I%;T(K,40!C57]14IV-#$,M;(
M4#?3V"NS'ONW3U_QPN%ST_LZO(@8KZ@33#Z)L@XM*W TQ$EG=X:E:!(<1EPV
M*326OUH7YPW"?W 7=O \'?W8&(*F/Z2_$MR1TF)E(25N(A1JR\27':Y:\>YH
M=M%'P.H_<TY)1A)/69!D/[BE05-M>9(=F%<A,C\.VP@#A74'LF=VHYWHO4-O
M,84?)8\P>'@JS6LOBH)4VL7/4[]*7"##\2*IY$Q(FH^A.^UE:?%E>"UZ^"RU
MS&S\(VF_BG72_F1J8!(N?H]0%,DI]MW#JH6H=BERE632=6FL59\"SK'@-2?0
M\=K%T6@2"VGBZ8C\#.8-_EB"8$=+$+ND:PTK)17.;K6@=R[*M>%_/%PD@:QK
M*X^:]TS\$% &)N<@D[6FAP;S$,,)*51<Z\:FZ]87QW2XSK6;TWQ- ;Z8?'JI
M0XW6UVB_VYL:[5TQ.B>PQ<^"W[DZ*]K_^+>'WSQX\OAA-GOTX-%C).0N\L7L
M\>/OT7-XA*)*$6*?9EN0F_/HN^\91AN\DJN"J2)7K#<>@@=X)2X^S9*@--W<
MV.Z&>N5]_<VW=O$+]'',7AX_.U:\]:L+^L>O(6RU!V(7F;(:(C*$=GLI^2#!
M,K\@ 7C-DW,*$_5BP^9X6CT( 1[OQD'<V5FE4>F*FFH159'3@4#FM0&_6H$.
M5,5GB4%9F4$A.OV->AOE0'\C_ G9=3+B,I?X;TQV!/A9.Q7U]H5@=[8NFC7I
M+O[&C*.7B!#1;H0Y<!/(&I!0A^Y97ETB4>/[+)DECMHTPWTOR[:I.?YLD& G
M!F4A:2O>KR/,FGI@JF(AH6OWKD3V=UD4"_334(@<)2 ECY^K"".Y@TPEG0O$
M#>]"W&W%9>%&ST&\XKDF#EWZIF%H09?'5O;2W)LM%C%E:Q)DKRAFTQ?/PJJ3
M <[#$5]H=-46UK*#DB>=PPMD29"C#S'3GJ:JJ36QJ!6T$89)2TW[N3'G_G4L
M4*59=T[6#,=INF;^9$5XMZ*T\4Y42]E[:^;O2'P6E'V4-^RP7-7WUPO.KO)S
M+;7GK8(L>36*N\_)1NYOXTUQ58AI1X58U06',V02D*!AKUC$JV1>9P?0I'-"
MH"P,E1AF?)OA>+F+N['C2KZ^7_C[_()"7-XB8:]TTFM7N$B&>Z?YU3 \8;:H
M=Q-L_X['-;D]F2VXWQ4:9E$52,Q&[/$$_I$JT.&9PB7-,B"<5 2])9=9[%K.
M)U&U"_,4POD2"95K[LJ"K5%HE5?.YB).M-U[T/$45Q(/AGX$(5M;0T@QS-OF
MIW"@S+O1F<"C#FQ-8N $^VHK07URI7T'OSH-;EM<4 WO4E6W;1'RZ3ZZ ,Z-
MSC=CT6'$\@G4689N&,M4ACDAA#@_CEW+[S1=-BX?9\-D[44T\8.32D\6&(K]
M)(GYK8B,TN'NS]4PO*'9G[W2WMU755Y+RHW3ZW$8@%#6[^GBI/4!81NZBF8L
MUOFV;5#Z$HYK,+WDDK.D:@AJQ]]]_>]&BYF7ULI 5L*0[GSAW#J>"E"6,^9"
M>IB%>^%N1'8W;=(/"^TTV(,0\CZ9/8._0TOP>0CAI:#UHI;&T_U;<O1R/Z.W
M?/97FE,1H"=/,?AA9ZCKB-WG(?CAMGEA;DA?\TJ5J7\L6X+#/6MF+S:SU_2-
M+$P,@&Y40R\W8:.\J+/96V(D.6%,RN>DN D+YVZ-9/#C="63L?^<8_.BIHCW
MD9Q *O[#/#(6"E/S/:N1$/5Y3P$SUW$4P24%W-*IJF@(.A=HI0]?^%NX)2]U
M^@J)?W"T(T?.Z2! [7ID:[F1=K$0HB*_I>[6+&?)-'_.2<[,P:C0&"ZA_]$5
M.A5;B:F(UDQM;C9I=&?WGCU_0>CIQHI#X?Q;K4NISH>_:BLPU@TY:DBVVKEY
M1.T5]+6W17!H6!N=!2<0J*/*TTS&\)OP _8.Z;^X<LC4/.'Y6>/HBC*OXC_3
M/9SH$=2A.[!V)DNMK&65<Y=[M4@6.)<GS\,QONYL"&W@F*Y]#YT?4J9)4T=>
M(*8Y8QHK*M0YCBD:-HVX,+!A7I!AEU8S9+6H@R=?(&]OFYC[])[J;T^5Q#U\
M_SE^FCGX O( "F"PE<FQ227*T[BDE6H]I_^6,FD]%]VC7."*RDNUD.Y757&>
MZ$49R0:6-7ST@L R5]Y#G+U9%_F[V5_6ZIY(9T(^&LD0@8771@*03&).E1E6
M;<[D4<G,SHM6!0;S[IW'__]6J*QB]$[SNJFW*RK37C2JS<RA1 2U(/RIU(-P
MF<I$"XBBA/!V32L&&\_#32,L'[W4IX-6M%?QDH!-G^ >SQ=QA[%*AS9E()$5
M&Q$=#<I]7FHA=):%%AY4.@;"S?JP-ZO9O8:J0.S1#O]66ONF @FT_=(>,]/'
M/+T@%UI&XZ1?A*#9.D7N,SO#2)$GK";*]AM70SH-C)!!9;-ND.JK2KDGKP47
M %ZD8VOKCST^E/B7;5$HO.XB;W,%^;H+S[Q^!2Z.A)=CRM]#V_-;84H;G.64
MD;'4#.=8& 5$^JI;+#W$8#!&Z?H6YP#6:,T9E$Z*>XN"H ?TXPH*;9E!LIB+
M$KR&890) G\E:=5-<UXH!8:IA_.2ZHKD)H [D>>4S;[[ZM]UI47GAGM%1,!#
M\DFC5[/$4E3[\(R'BMGG+\M9]=5-TO)W)K+[N1!6>GKA9[$8LI<+V.M<L1FQ
M&38; !I&Y+0D61*SE+0B@U_CBS"6*ZC\.+FB$2R2[A4E&_2I,*XL\P%B9]#@
M?**%3"%9;&V091O=K,P71/"PQ?R"&YE1.; SN3.3V;=SV0X1_7<5<Z[JJ/D*
M&(N&TGWD4 KW:\]9M !/ A,:$\/2"J&T=-2&$!:>5!V(D(ZY(]-2!B[L'$AK
MLCB>W7P'3=4Z_]5KSM_O3<WYSIC!4U4ZW4N[IU4_@C=RU&VLC]+DH[7/JO&Z
MKB5\HH(97'#.NFJ!3R(,U53!"*6M5S DQY:JG7*WW:&+ L8%44\QSCD'^HIM
M%D<7>+EP^O?<3W<9=EW-='>$ED3!'PD/B3TFKL]O.:J^GG.M<O[.,X1@UO\1
MR_.I\38G%E*\X1* 8J>>OQ?_R;4&_UA"P^M%)![;OX5->=F5*DO267Q5G'7$
M,!V.,\*14=QQ=75UO*)2T#E*0<?AJUQ8I&X-*I]AXB\VF_4/7WY9ML/O?FEU
ME2/'T?9E5\R/EAC!R.4>%;'T+V'U=PV%*!3KYA1SGU5&N8F)8J58*Z$75"]O
M&VW.9$H+WD_$1MW6W&0IB_,C9OG>F^>G]W_0"J'JX]'T$_KLX8.C_\Q(LI,H
MB-!_/OK[_Y,I?GOTU^_HQ]0*OF7LG33$(3*F>#[\>V%4\:J=+@)]>+'DG=9A
M,_<">WDCZJH/']-W'GY];W%?8T;WSO:^)QQ2/OS^\5>H9N+.4( $Y7B(=6U"
M6M]-HIX;W']9.1K<D0$Z'W9&X &>GX8UASYXNY TX>HU[M&:"ROD^+RYO)\-
M+JFYA$['3L"Y1O\W'$LE]HO?"$YDWK+2-J4G5 *6!G6X@JQ0&AY[''(>'*0=
MAN71@]T.$CUNN?C?7Y3??)_GRZ^_>5!\_]TW7WW]\/'W\V^+Q;?Y\MO'^?=%
MOBS^OX???W%'O:HG\LFF6?_P>"C,0@8]%6;Y)"9^!XWBV^<O9P]/CF<,\QO_
M_Z]?O/G/V8\GIV]_??WF+IS0-ZPTO&5U#NKF!I<'9-3E^$*I&G#TBE)UW*]L
M#*!7P^X:)-$S(]RJ%LJG9A>!:=:T%& KVIP7J; 5UD'QY5H5![AWWQ &)C=L
MS(AE]TX?T1FM8+*H+>.H:AIN#S'3IMQNE;03BM("Y^4S(?A0JNM-"VXS7->:
MG*563E%\4UT6U@6@3V$((0=)X_,BTS22X"PA)HK/8C-EJ1@C'DCXH)JAUA%"
M'S[P@#K DN:6 9FZ9G>!ZTECH\HZ4(@<Y1G=<J L(T7N%[NO*/WGRUS"YMRS
MD<N/(/:$GE=.]%Z$T-H2 <#\8 *#MR3WAG(M]_&)8/A6>F+#BPH'_-U(9EUK
M/-[TJU7.\KZOZ05_E+5QPI"ML(K(@[3ZQGXZP%;:276/ZG[%E*-8 UQ^B1YJ
M)R-#E:**+M@E>N*\;K9-KPM65ZH25""9JI6 M+C4-O@C=Q)W=J=29#MTE2M%
M)M^*O\7KDTV@ $J!CR%9=?X>52;#2C^>_5=\-NG,D#(X/R8AK C]O;UV[RRL
M#5"P=9*E\HM%\U2=^*08H? R)^Q2O^9B0>I12X&%B4-(I08M)CLV^'6#$&/M
M?/ K$3?&[YPHPV@ZC,)/&Z\E=6E8IP3_1W_D*Y.;*U[SC<#D!XFW&TJ\_58H
ML4+8O%0FV> @T0Y&04Y8R<RDZ5/V'-\)G[341W[C+(EW2-]<ZOVL+-=T$<24
M,J3$#L#+YJP-"[%O.$%+\DPA;BQ7^5D(E);JD?2UEC7EX7DCVO*?>H?,N(JC
M0/@4&8J6\H6=@D@'/NK56;TPS!HZ(#V!PB)LGBU LXL&EK')TEVD?7[QD*>J
MWTHZT:X2A0Y]<9,8Z7JB<2@Y? [.3:\R#7D7HE)H:DD[+JH2F!GSN@X;[S8W
MWJDM0XCLN?TD+B497>KBV%P((\?[M6!^A0\O4[PP3M&M$W=J^@UU,G-)Y[V>
ME6$C$3[&+3ZWVKE3UYGR"8XLVW]9LOE4E4QM]P2W.3<N;?TFB M?=J9*JA#T
M7<C]SOQNU@V<C1YMN"F-'6OT3+MVZ$W*X8>5?O,C!D9,V3O<0>-7X+*'X+*Z
M+Y,$+%3/1P:0VJ_7G* /9G'%)I8BKJK*F+*F7.+G]EMF_]=G8.(8K$%B+".2
M(<J[LZ9/ ?$EQ]+O%YMU4#2)K3PLH-M;0+]."R;0?"+%0!"/KF1:&O36<'*A
M<RL),RV"6I<H)"L*<=*C40P]ZNG&@",((Z.J*CLM"2TR6UF.C(.I-*D4% DD
MQE]4@C\A7[KB,GZ7MNB;EBJI=A'!UN%PONT5!SHK*4M&]@;S33DOU19IQVR:
MS$+:BE-+@Q^:4-'9X )4J)SR91VJSVD0I5?-1,UQZF^N15*=XH&C::HYDJ*C
ME-[-91L/:^VF:^W%6(YV0"Z6>%+,U ,%CT7&=HUK62&<7J^%ZHMU!ZGDE\BT
MT;?8RO ?.^YT9;DE97SSG))Q_5W#U']M3)0HW( +)8PGN7;4I:=G_94D4OS9
MS-[JR$-E=!.,>=]Z.FG'-JBQSL%&WN:Z?>N:,%G3^Q*$4"-%C>C(A>] HN@2
ML;Y81KF&I,4IPUNND!-HUC, AB'F.99NDNIK^";UP2&D83YR(+H$/:')OKS:
MHBMTB:M-U%5]W0&-5%QT)H^ARFMJ>]SU7M3FVBTETY>(O?&Y3QHZ$%*JCXB=
M9I?BD>-6B9([AP5\NW$)W$=8&BJ"^-"X:E  ZTIT"]>JP\ Y38/R,!.3Q#<I
MN).LEUPD(C2(;*!@8E^A/B1/8TE=<9[TU+1-7IZ\_NGY+W\["0%W'L+["TX5
MOP1SY:,'CQXJ*G0!&JZ<<]R\E)5'1+(^+A-$CV/$F>%"X6Y+ CN!0Q4<^I'K
M4_-+1*!DL%3ND6 :N>2WA]5ZJZL513:_2*WQ6U9FZ;K_P\>-,+'IHI001[(Q
MJ=R9U2M3XO:,^=SA)Y"3&)-04 SS![TF@2;SGZE)-9_85GP*A1-C7Q?G@'@P
M+0THMPX6\9;76,_BP30#])]U$X:?H=Q* B:UJMT5@&'B3P_!6)C?<03"&B-I
MH]3 \B3NL\&*#4$9/$X.>?QS7K-2_B4A10_W!G-]V+?_P+YU7G:,\*VY1"IM
MR"\46DU0@VV[9DN^[H: ?OCJ65^BJW5=K@LXXI'OWZ?.9W)WUDKFKA#*5A6N
MR0,0:$)8%JF"_>ARR&!$"1(D4%0A@7FW$%_6D^&E_ZG8!SE)E/-Z*:#NIDT[
M1UEX/F=5S:*%9&-57C3-0C2GN7W\</;<WAK^ZZ[BDJ0STMI2,[5VU!M7/X>!
M2;QZG.]JJ33Q@:260([^6=@"%R%2##X)I=.$.Q.UZS%)OQYG=B0JU[ZA]H6A
MG_ G0UD#65*'%76["0I'A?KA"F9:*9Q:8M)Q3IT?1:4-HU.8!1$\+]YGODR/
MGA-R H#<(QNX$8]*[J281G*.6;ZY;DC)IV_S>CX(-UV]W]SU:IN\L:4L_IN@
M[::LO,-7&Y#RFY[!E<3):M5=$1?2[&WP&;B$YA9X0E-IBL3_K/>*]]GY9CLF
M<#!_TZ(\5.2A68,&G/BB!^M_VP67E-E4R %*R7F[Q)^/@!V!L9<U1YHF*AB)
M7#%LP*:HD4JN5#6%4\^J?*CX9-<KWXV0;>62D8!CZ29. L8'\<?-QHF&=S=J
MZ#JLIYNNIU>)$..\+;NBN^5GO&%#YV?E;E*)!XH!BA61L%!.3X1,FGZ#$-!5
MV/-DTVE>1K(R"N(?J=K736V?=9M^ 9;B!'4W(#.^#L>S([D@VH2,^=7OQ@IL
MM\F7R\QC]P]@C4^35=_E+5 :.Q+5*\@"=9\:Z$99(%'ZD2OB*<Y2O/E=Y<A1
M^5SA'C$T,'@'05\A618"3$YD"[</TC7,9V:DP<;]J=PTTKFKH01=C,#,_FE-
M^L\0!7G;4NV*+SA5F/\@K#,BJ'1?\#L<*I^?R%F1%+;BHQE#W:DI5$&Z32/4
MWA# -,4)8_,0<O!,OX5-T6Q85D7*FH4R9M7%H2!XJ_-Z8A1@L<2W,%YCP<16
M^96R 40WC]U0Y3!P-+NBLNY/THG3$])]\%E-5<;K!R)&ND:\+)QZ_I;![*Y2
MG;_#LKG-99,H?I+L/=B4.]8B_DC%2?UC7"?U1*MD*O(R2%X=)OF645H>8525
M:N+)'O3E1J-4UW%RAG:7C=&I]YWE,B<;7>30%YB^.^+U9LJT($EM3[W(^- ;
M.,^'U7*K)D&)11U\S61#MM+/NR@K8[0'<ZGCC\],17G0E,.J%1XHUU)Q)GS0
M722+ID5;Y6&:;SG649),Q 69;<\DESK\4AH]2&5@W=0>-99&QA_;8A?/%GBA
M826<-8LMMQB%A_B]/P=1H+,"/^9A%;;2>1L/*\_].>RD$Z8T0:,W9Y5082J$
MF-K3AEZPQEU)%60(%9U,V!Y6\"T?:ZQ7$NE=7#F8G5?7H9FNW#ZL62\>7&T-
MN4PHRTPZ_UGF"K(5S:KL"J;(Y;7BL@.3F5=.S"(?3 3/R%O%*R6BH?T&\;+F
M'6 9+3N0<+;R.<R""D]F=+#RYT^(8Z)0DN)@M.DMGU#G<]NOY8=I@LD9YB=$
MK-,S:40PO[0)G@  2+^1L%Q6.,EIQ+_-^V#X5U1&;*2WXXG/;$V,RB%_=<O!
M_3"J=\E/;HT>6#=>!:P U/141UB2V=9X\#*8.DAC<;['EQK7)'I*]6$^KLT,
MZQX[6+];MGZC3*$V@H,)6!EY-]+YMQ$6AJ'Z^S7@1XG7I:_6;.NNYIM1F_<!
MQY;BV!X=<&Q_V/WXFQ?MG7:ETQZ0+M+QQ6/<"% \7#G6>B$GLDG8BC?@]U5X
MO[6_:8+.;=2].7IO6(V\HPM"HY-A".*1[&D\P52<D%\N\_.Z"4[??%2T2>,;
M[H<H(G'LA!'?'=E\3.?;359-2HWWF9BK7H/8YW5D@TB(JA34_6S P7 ZE7ZB
M7[[RQZ3\8W8:1_<N,'G=<,,<>'/VE3?G<^(N/ILNV_0BOGT&H7TGM7-U7;>M
M"5J?[(*/:8N>2LA_3";ONMT;6Q@IO:&<4.-F1"A-I" >D*['!U*CDC)M1@#_
M3;I^/O;IWZ:&\B/&Q<\'6"&-E_2Z1- /AR#Z%GTTMR>*FN1*A<0JD8[CE9:-
M,6*._2_YZA1X[,EA'F]Q'@%/%5HE]FXY&B*965:O8NX(4LJJ@H5W7U+J"&[5
M-RF^8<=\S'SIA![F\W;GTT[ON16=IXP[)MJE,T<^G7!S62?[S=W83S0\'\#:
M'M;9/W^=.0Z6*=?_8+1O>Y-[Y:JS;;2Z1#8!I@@AWY;:U[W3U[]V]XU>;%#3
MDW! \(@<OI9M<. 4Z=K#%R1"EKK&KW-A5<:O70IETX2!L5:,2A1'##Z''TI*
MG>49"0-\#N5XI26VXA^=*X>%=)L+B6U^!)=QSPJ8[E'](!K\G%CJBGDK0&=5
M!MD$_ZU@Z"15M J W6*MQ&$ER3 4[UG6.,SS849O<T8+@H[2!%)';(.02.J2
MQ(59=K#0Z^"9<==UY!J\+!O611B4+@=+P S(] K84= \S/FGB<6JK>NUN$F8
M3DPO26OL5#/D819O<Q:]]=W54IMTJV2SHL16#,<_,Z+HK"OISL[>2C0HOALU
MI<2"B0#"7/MM>]C$MSS]"?2OG<6SV65C23>QFFI[WI$Y\W08*2T!U;Z(AGN"
MA+((]K__F#:\#R8Z#TOFTWAO2Y*NAJ>=]H@@*3/!8N%H!W>&[H>IN\6I\QQN
M'#XE-!2'P;_-P2<5SJ/8"TI6K-R8:*1/9YP7]9S1VJIA-)'L '#S,%^WN5FX
MJK7P @!":0Q@;55</T,W0&+<&:C!02GD+BF%[&-)6ZB:D0T,@U)T/(0#CIXJ
M)YENL/68Y $UL\MW?</\HJ3FI+->AP\K,XY<RM<2QD"68VR9Y>;(R OY 79D
MA?3YGEL1/X1C UJE5O!8^$^L:&VM#TLIV'59KM(X>3T)TE]JU([?;"*SG*P/
MOC[:'X(MJKCS@77!K?1/=.2SIR68*.?=[.=R'@:@F)UP&A3O?^_ISR?WU2LS
MDNBQZ@1_Q250=W!GAHT,Z8O1PS/%\ XF^?!6EWD+VNYNDY]S-#'<,(/IC()Q
MQ.$M +VR)G(GEG@;FJECTJ8+JR"G74E)A]G_Z<.6??3@T2-@C^JZ(8,DG-U5
MTTD_$LW0JPO28GF$@N'6PA'!U1^ T1X8_7AO@-&?:822'B &JH7+PWX5-;6Q
M;?J_]^&4DI/FK*SSZ)5+@J4-NW.9USC- , KPFL5_$\%*A.;]Q$(,S=$)ZEG
MHI()JH:EXT->%9N<Q&G+^>S-Z>F??V%HC':2L])K%Q$]5-C%?KC*.Z&[1Y[=
M6%14D])J]L)Z__9B9*1^/E%&-O,AL@%L.GH+XDX,Z/.7$:3KJ;"N,^T)3_Z*
M-)@T@54023KZLR!-/V3$S\P2*=$U^JDG6-Q K[$(*YF.*B9<"%_[O5\0N6/%
MZ.X&2K-Y/1?Y%,N''A!#MULQYM9F[J@;=5.1O#/.JB%6R"F9]!5X.E!4()]4
MOTKMTWS-^KR1])D*./!E#@'UIYQ:U*>-!RE)(@_9OX9):?\W,3R'N;O-N4/S
M:Z8"9.$T"!XS=Z62I[NIPA:2SP[S<*M)CO*R%/AP6X8#C*JJL1OY,/*W-_)E
M_7M?:U_X8:!OLT[=P<.D@YI%W1=M?L5.Z0%$]LFSX$HA6)1_#T<S2#JE(Y)S
M'Q H#)'&85O<[D1<-E4X:JDNRQ[0@K=!E+4++FYU0$W?-J"R[+H>:,H8/^=5
M"('#QGA6Y.WLSR#; ]?>JV"?R@4I1K!GE)'&78?T.*D(>\R[J +,C2O',!XC
MR5>]JZ=E"8%MO_'^]&$KWNHZ:#9Y$F+Z(\MT4$ :<YB&6RWX=<*JV!9T,LV;
M=MV@,S'"A2,[+YU<9]3ER7DUP9H280=ET9=%V*F4)(C[5]6\#S;U-MWJE:;3
MV;]+4P2QYI$HJOMTC_#UU^$1T[R SR,R:])A'F\SN;/LNYSE=%2-K>#&H*<_
MGS!_%:'2"D-0F)";_IV46)MSJC>-2UW7%K'^T7FE6;Q+95C-BE.:NSRO=Y7S
MH V.UE[/Z4A5@)8[)+4?EVIMEM*W_#S=J>Y79Z3<.-E*R>F% >*/95BD;][8
M19=-.]G?3(5#Z\C%]DW2?;'4*&7XLB./B!D :ZX=\!TG?T3L+8N"( A<M0US
MVIJF^E!EPY5'Z:O$TQHUQIC\4*][/'L]@>JA$@A@!IDPJ39$%5]O!]62\5,N
MV5$W0>U##>$3V:*IR7 \!@MR"!;PH^$(J)#0P5N[[>!)A;1U,L)F7Y;,%CIC
M-^ R?@EN60BIJK)H)\U4,^HB/LS@[1[Q8^.H,[DLQ?3&+N^//5D<;AWE[ISB
MW65?'2;SDT\F_281U*4)P8=**^T$#YJ1+)>X&+PU8\GN"?WS,)>??F/R9$F7
M;G0$FZJ<B_W,%\UZ@]C)N4Q_#(?ZI-ZRVP9XGO5 8&4:)D78#,R?C>$&D[HY
M@JA(_9>+YD**3#!6).7S-?S>=9JV"EZ$J.QV=C50G/,P6Q#,R;Z+1 T6/>^D
M)P1U/.0AHG C:=YF,_9-Q]Z[TRRR)Y;N((?U@S.<)]5\D=@- ]EW1>=D=*5S
M7*[JG'J$(UV17(R^R9XVT$P@!%N*CX#2 _K=<"6ZPX2WQXV)*LZXA[#N%\O)
MEJM=35:<K*J:L-L7&:]Z%D@/<[]>TV=+49?@4,3T),XFV&T_AJ]J%YDAL&:S
M31@<PEWG76GH7%W97IV H>0C^#A Q-BY=!-'(>%%-OX1,:L[8IE^*[))5!IS
MH@O831" U5:(DZ3;GE&"$QUYB3!1^$(8TIR1W((-5& \!\[Z+\K)$-D7)=(F
M%MRJJ8I@N;1%D./78C>$WT,@LQ0YF<U>_O3LP:.O.$I_^=/I@T??Q**&W0BL
M3ZNFQL?YNC2$]0AUN:M-8 PI/F"!/1;XJP,6^ ,C%%;I+)_G4+\< $>%40^[
MBTTL<F+Z"0-M%4I,^VL=3K2F580A-\[:MNB5J"_9NJDZB+][>B_.EC'N=V0.
MEL$4L_\.S.P.G1_*!<HUA!YYU2S@</"_5)*CGIN:F D5AK^1XSB\L[&5I]RG
M[E!:PW;3\)UM9UUQB;K+F*SOD".[54"?BEZ6W;SO6)3,5(JEXZ016/LXN@B?
MY>U">RVZ>;,NXMEBG+.'Y,RG3:\IJZ5E]R/-HG81!_M#,/E2NB/+3=%Y6/6D
M5.]*9,G8D2.W,:_"R;" ^UC4YV%5+%P/5/)S*Z+ZDEW7K(J$<T"IX[I\94$$
M8IINA^4ZK*5;S9];Z.RB96KQ8/^37/*V+S=62??,GMPM.>'=TKL^_/:)]RYC
M0'*8ST\^G]<'?#0[BIPP)GLH,0TW./10C)8M=D!>4=-?LC8Z[;8XS/;M I7'
M=)TNQTYTG5U:P1W.Z6%^;A6V-.Q'RB9]K0:)-OAEFQ!GYW"VZ8O2O'28LD\W
M95/&T_4K[:)>F@8O:"+OX!Y_YAD,KD?P9^,Q1PYG9 X9''.;HEU-E)P=F2FB
MI_#/;LUP O&NPT^(5!6+02ZBKK0TUT[2(=3%>8,47A/5CBX)_9WJS>6KABA0
M07> Y>?O>5A2GWI)R7'[XO73I)JBX=7(><JEQ)*LF<.TW6I[D2NI^<@X K='
MS'A(RX, A_%FI!Q#635##M$J8&5V_D,D6DOYAPY(XMN,<AP<+Q8*8QGA;&OS
M'<+1?W@J[E*-^^V%H-2ADM(.5#*"DS%=:/K32&MC(*W'.5S@3#\ZD;M#<N60
MQ;W--=]3$U#1T;QI6U#7]2E]+S+L!;=JFQ4CX.N1\G2ICC#;L\[Q:V%FM>SH
M+YHSHS-XL)JN*\G6+8I\<W%P.F[?Z4 !V*:27 8K^%(T.96F8\E:S<4,\0"'
M.;O54HOXAY[GQS'1I2* AVC^UN>CRN?O4,DT92)AS3X$Y)^P7D6T>W7"L3CT
M2<ZV20U[$#HATCW,T:?)),-Y(/1!^$XMDGQFRWQ2Q(,?8.68<75B?F/FY#")
MMRKU,6_JAH L[*L1))LGJC,M-Z"KTKH-S9?;9PB!JP;83N\&AEW<-FW902<[
MF%5JP@5#35^WD)4D4"J[BBCQ$N==05U;4%M%_T=5SC>'N/A3U8-634WA;]R\
MK.$'GMR%B0HPOUYD*"3IB"X;!))DN0G:7!,15)CH+R74Y,SCH=_V]O$>=<'Y
MJ+98AYEBRDD^5<> L)R(H 58'HQWV,+4GM-WDKVJB_,\Z;Z"Q;?@DD6\E)Z"
M(&K,$[R/\-M3:6%)*]\)ZR0MWO.^7(#H@P$O73-KYH K.UUD&?]A2KX8=3FY
M,@'F:UDAX0_HN[;4, VW$UZ:;O\]GIW0#8P><X"I;@NM'&BY ==%"0+-NEU_
M1M#ZZY[OQ>NGG;3V'A&.5ORTS"& I+^ 2_X=Y08V1$=VSIAB$WU-$U+#]#?3
M#P]7JG4:$*?&@C--MJX72)F'P)4PYHXH.IL JWF*:/H:9>4;9#H*1:Z-T_'(
MGV0*:9AP6_@\%)[6;FW$QSD77YA\G,@F6%\Y=[W6-\J._4MBD[_>&VSRX<2Z
MZ8F5<@%S06QB#Y:HPC8M&U_99]-F>EA(/T04GS7I/).<(A'$Q>">*VCC\Z;H
M,(=][6KN3+[##/*'.?P4.3!U_TW%F3=G)!,?S)N<:HEKV&T<.]E9<"F1(5"&
M\D,L</L;<HVVNS,&M%!TU[?$4F>2#(8[H>T9 2]D7.&O:#5 ?2BJ"03G*ILY
M'OK)AA1L;M0.R1<*DUU*J*F(;EL^ Q$8YU]-]:7L850QT8"SNUO307Z40PY#
M7(WHRKF+F)Q=FLN2Y'A.TN^HQ,A"6X=6Y:+#(,LIBWJ=[%]RKAFXLDEJQV/G
M/&.>R6%\@?X@) 2][$!P^2_4IS]!'5A*'JE2D/5C1[&>F_2Y<@_IAQJQ/]#&
M*MH *IRIX)N1T+WU<P\Z3HT$:5%"0.!B/SN,WSHZ%D!?BDM(O4Q%8\*;$[ZS
M* 7OLE1[(-?@3A-H3)0K1&S->D9W94*0<?>X<!.$;X;SIW(M9Z99L;LSC-:J
M%L^(-&S;E2Q.$VZ52;LHC \XI9;V6/K=3.)6U0MSJ-K@C+0]8TA8%B-1L]BD
M@^9%5)%=%3&!76/8A5?LEENYC'=DE[[MZ@-Z1UZ6,6J7[;/)5&M!>$A)LG"0
M#]TA6+*)8^1X-K2Y-,X\,$5,:&$YN&17LF"O"G5:)Z9S\L1C SHO%QSIVQ0-
M<S%9@OMS+>[ZS$U*:F0)M3></4&)/V^#E1NNID43IH"6$U'E\ DL3UJ%F>8<
MB.B:-.,^<;5>+DES5LQSTGF=5KPBB$A[Q#,QM;!I\J!"4ZS"^;^!R?1X:.'(
M)?R!UEO%*^'MD,\U/70#S2_J-%P3[B'X'L(\@X,,0E%MTY]?""*B&CXS'9\Q
M(\,B,65AVEYK8MG(YT6O59)%']YIF]0\+II. M-SU#.050N+9RX$1TZ>+LQ.
MC<4@='V Z2Z2,[$K-F=4.4'@N[C,@;H9]>#1V2-I^<AE$MYZ%7QL<%VR49)%
M4X[Z\/;2IZ+.:.SI_BP<:E2A""Y'1:-OITO3FG6/S%/>7=*D9>G5D.@HJR"?
M0,O*G2!A"=1'^658THA'^4")K((\R/1OA4X1[Q7HF1DV5PNG[,C+D^,NZD\*
M4I068%M<F :>2C,9E=9 2]%QR;#,4Z-U.M<-OD@<NR@)I=_EON^I,=179+9'
M>B"PN\/H.4F]].RWFU#WIC!],=6$P=+]R/"#$I=GZPA?V O8LB=I-KI!RUFT
MGAB2B%4TSY?--<$3108N.&6SM_J"WC7!%9#.#X<OMT;9).7AT=GT7]*"U2Y4
MT%HMB/P^-JU&BAZ6];*'.T-NV?$&Q4&(A$!N]>%'5X4Y8)4L=_B58^\C!'AE
ML 4:1A$^8AU>BZY4U(MU\&&4%$?B=3TLSON\#>:FD,;;A'3E:'@)IFNERO$B
M_5A/#WF,A2\), "Z'J ))S2<Q$''Z8G_<@\SV8MHR.QNUEPKS$@'AM=C_+UO
MRVXA?,(WL8!WQDW_K8 $NX1B])]U$SR@X"[,+VIH2,;7'X38URBR^Y/VNKH)
MSZDCA%O$F< R"L<DV("XDN4?:A_/&R>&B4%-Q"Z#O;,#!.@(?=DM^?T;(N-/
M8I0?Y[-?UU04^[L$-L].7K_%B+]]_>+9\U_>#H;KIY*.>)1U:88WVE([&%=0
M-Y$QJW$F7#7M.^AB%BJM]]%S2[F'HJ7GC@$)L*0=/#>R?W(VJE\C"IL1L;4J
MPN46W0>B[MT1_?'L.;\T/+:7)Z]_>O[+WT[LR*Z-T)T>@$:4>(7%KX7K141C
MJ#J&RP\&W&8E@Q2B+6!?,]P ZU*2A9SE7=>WN3AM&QM&6#RE0Y1S;V)7\6-P
M&L06!I^S80CH2W:2A%-YD[^C"2 WA9T)<1^S)(B@#8$2*"7R+LIV<42G_]8F
M);/&, G0.9.>O.,'EP&S)8&18;?-L"X8VP&#A9GL <? G*R#=4X%[GHQ&RH\
MZO//*U+0($8!2%<S$U1;Z,%*8M1A(LT[XQPCM96/GEB7D#0R+!83::BHAET<
MSYXQKOKC^^,MA3G9Y!D]*+$AU^6N-&6^KP>4FT$750H51/ "@@<)$T&GEPRZ
M)N*F%A ZK/J21FNV+M<%^ZA3W5G'&B!@&OF*RH$20S*R<Y0/I^ZLZZ@8V7.(
MW"/D4DIL.\_7&!#BO:LG:>_\3YV;J)UBZ/_B&I>DVWE]F@'*+98$$V1YT30+
M2,SP@.ZELOC)[%T1YJ8JO$?"&8)SJAG><$W$LM3'K@^5:>=02/.)=JQ.[EI.
M'DR6+;2FD2CWYLQUS\=U]/4WVS7W@ NU/>4=*CGGF-60%=>%[##>Q.T7+$HM
MKH1H@S/\'WSI13"M<T'*J(#WG ZVELGUK@HZT3HZ!)J29(? O]^T"\'QD;(0
MF ?ZSI[>""/UI!'*2+5NUYT9X%F7_ ^W2\JQ7RXA\=T.S48D+(Q3C8-)WCL;
M<($>(#0>0O/-WD!H/M,(77-8EPLXOMOT2!/#O821+S>C9,N4L4BJ%2GTDC,$
MW45S!?5N;'#*.M+JA\*)MN%937T>_IS/*:/0A=/+N#B9:]?<U2VV4E\+E3#W
M*:?A&IQ929I,B*P(7!NAO3$ ,SJC)O+@%]BPBT:Y^\T<Q_V+!E&V"72QL^*\
MK(T_R,AC)QTVJ:PM\WD!0TKG]&; WCRHQ2%*4Z<\#$^(15+/[Y_ I.P<M81)
M>?_.XZ>2Y[^24T5=I3@$'$_4P3@@>>3BDBM:__,>!+]V=BFWFYZS']Q62S!B
M%G/$ELYA"H=CW"-VUA#$Y+QA7L$*:>"6-B,\";#6]C5'LM?2P:K#Q7\?>6DH
M;\PXO-/=J*Z8+Q/K:<.851V965ZA*X*6C0%>F'L=0\TU\VDW\K)DGI&D%NVS
M7.HQRDY,WID?HW/R.A.5JYU.QH<F;M<\F5W<E@7Y7_76/7[8*_)*^AX#BY%3
M:8];#31+*X78\3 C5TWEK,V ZOMZ+O5" NBP^"F;<3'#?>B96MH(G4%UQ]Z_
MN7Z^P8$D?^:4G!<%,@ZDFVU.EBEO6TKJKXR2&:*.X3\D?;&1H"_FJQ$+H,A#
MY31RL)9 "S-PFYFZFBK-Y VIMWFQ\>OL(_#@K[NXHQ,,DL[/5+YW&%MS!9\+
MLWST^+JDGF?X2@E=S?'9AC;WBVU7AC$FH:;8\NX3+^M\V[1.MM,RKRL"1B"5
M#AG/#;4&T(%(R?-EDQ@2#>CV[_@X3!Q'X@F[N#DB*.YH!A.>&$R>\3HC6ULP
MU[YN^)S/4-AY5$?V<%6\V$V;X[)?=@+PE*)*),#3BKZ"2-HF-8DV#8?E/;B1
M'^B[<N"W4[+0':*<BET4A'VDFXT7TD!?X+I4'KFIG)KE:O)U'1XA?F5)'?6V
M-LV!$N6V&^,,:<(]K^I3V,G;,?"C%?G *CA[-:.%++=SP)_?^BQ1R3NOF%4V
MS!/R<R4GT@#^<K'P83)NFQ]8<%H@='();/BNP.2UG'X,87_-O*2QW#@H/$]6
M1 XS>)LS.$18 *K3^'(V0KJPVR@K;+1WEP5G,P[[Z]:-7=@W86N59NT*P2;G
M"Z#(#:YY.)<^^U0->4XLO$ IL2VZ>5N>%8F9L]P D30;Y2 7Z-4B"BO7NEF+
MT!Z2$>UV>"$IK>M%#O-]V_,=-E]1GU,*<1F3XAFLI4SA@C9H&3QYFC61S#K,
MRVW/BR ]A(%HF43T<VKD)T@Z)^LEEFR+<G76MQUR<H>^PT_A-Q+-3RL(2Y6!
M[+LAF(A,YWD!"^F2]9Q]N;GFJ'RR:=8_/+X[F9"W4P*5::'B QJ.5O62@V9>
MH@)%G2$KR-.?Z"]%3*6;R&-P8J(;D)(T._)==J&T:=NWW)P5=;$47+1$"3N]
M%"/;C2BM,&\7L[JY$FB!$S?C&@: V03]U=>,U/D?'LR=0H0*)ME9%5(I0T6%
M$%2%(("K-2]EURS@ !Z6WW%,*'*A!N_"[2*S=^&%JV)Q#OU!^8R[&'BYI^E)
MJ],PW!XPC2YX'QI0.9KJS 'ZNKZ]++:$@KHH*Y3USHH*^36$;XT?7/]J.4I#
MU.-+$Y01^-%##:6R=9%W H.GAA4"-KIKH+(3 7 $XG$W0#6MDPIT66O=![B-
M6F#LX 1SI9V=,RE;9N=$1KVY55Y51%M%/3> GOD%A6VW>T%M]["20GOW\?=/
M?ITV*!:]]S7)L@D=N<<7Q#5L5/;"Z#Q3=;CI]NUV CM $^5D=ZEWJK/^C,PP
MK>&J*UD8!((E2\.;G:\X_J+M4[8\5WE;H]]&/>ZK4M6#1><:;ML>)M(-'A96
M\3507)O2]ES(,9&.ED]TF*2;,..L>U6-*)X)F=;VYYUJ4$AO+U=D7-7B>/87
MQ_;A5P\*'M>V\2OZMJ4I$EG;(=7J8%T)\1Q9B$'# >P1%U&Q4NC1?I6FW<A.
M\,'F>RT0'#!C'C/V[0$S=OT(2<RG?>/2RR;GK-=9O09;ROU1D>PFE880,5;7
M4J?MQ[L:AF,++F')$C,/\CY_*[=Q4X 4'(2V7V^R> A<!)=NW($JC0H"IY(O
M+[-)R'PV!2ZS]K>/:4O(E*R.;_<_O9SQM7&L0N"G/#A+=IQDX!P2[!.,T2HX
M2-3RAP>)CH/.:U5J8#JO\G(U(3K]?_K@=C]Z\.@10*YUW?3H[$6^W)@SDFZ:
M5Q>4$WRD_9S+5#][4@-;K*J7W6:ZO+!C"OZGN-P):-G8/V58',W+JMCDW2;\
M?3Y[<WKZYU\<(0.TC<6?C)VJLHS!EK!_IRX#E-29Z 0.9H"UC]U4<854 OUB
M<>.>*_P(@0]EW]O,1>S8]V,"&W([N2-UZ&&DKN@AO_>9IPM>H'0&DZ&!Q09T
M.I@G1MUE$:48+7D.:'*;NUX>.J,8L1@"1$8!NJP^0 +,^T#Y]L.TW]ZT"T3G
MS/AO%HX< ;67/*V'4&N45,B(.2,CXEDB@)##/AS:1Y.']G7,*QHDM/[&MKK2
M O;!"GR:Y>!8&!#,YY90)M]6OD=\)\VF.,S/)]/*HUS*$-(A#$@M*MA)EODP
M&9]ALT!L0PZY7=')H13V*0 X;;'NV7!Q5 ZVIWUL%$I"64'J ?1 YV-)^< 5
MOR8E[@WSK)E:2]%R<PDU';$QYP:Z)5(GICU'*&@IB?C>U-E9\S[\5:[E69!H
MV&>4I&ZE#V2Q[98AMK;6K6)UUFZ;HQ"50GSU??#R-MOCV5-'71 UZR32,T?1
MTBZ6,+UD1W/:<]$\.87#77'=6'E(L Z9%=^2ETT3-,IC5QGGOAEE&WE*G [[
MU4;W<"5"!;\CSMG'!7KB*T\"6>3AT@+&6*Z$&@"T_&KI'.T=5!D33FH#I2Z)
M96T]8%:G"= XPA2,N0\E6WF>5#LS+ $^-L<-/4RC[#@INDB#,@L/6<L%1Z6:
M7IY:</((D!Q27EE++5T&$."P.K^'U2\J>T4-=GKM\%]TZ)5CCET_(.>$'*E7
M+)!X+E L87^5W*(-?8Z4[D98KJNM$T>-N4FU%$1J%DP#(?PZ[2XU-FSN=;=&
M0&(O=7P]_D%\NTLLA.PI@Q_Q<_3=9O3"/SZ+AFG^T\M7"24,3H*.RK,]M^Z&
M0[7?H-DFG2]D(\,^V#C:1Y5MB=P@-;2MBC;"*X0S*^YSD,\!UQ".E8;[8/6S
MR ND;#N.W[&[:%IN* C7$R);,@-A01!.NL)3#!9C6;/:-U &*5$/XRJ070P7
MK>?RH!-D9D*(L2S;E8CS1+F$L&((:("NQVGEA./9FZ*8P95Z\.177!W<::_"
M*C]Z:;GVU_'7K]VO\;N'P:<\ R<23A^+LMV1EU)!1RTX3'CLIMPM[@!;E\4:
MA7BYTLG+F@-",T&GKQUK:A3"DEF6576T!$\S-8?-W^7G.&(;='.W0B_KBX73
M#'.#'OY\YD0]T48>;8^PA*2?-&MC.U0D&_>R%MW0(%PS(.NP&$6V=90^V[J%
MI8=/ @$B]Z%LAV1\OEL_;=+_X*!XEZ8J<I4/&#$M6;?=$-!'%6B[;@2H*TGW
M.%^S$2Y[@RFUS( .F,X$?3DW)Z0'IFD1A:6A<F>.U2FI-$7)J^LXS-ZX%Z8*
M7=R.3D<[)8Q$%LLRF\'"J@\<1W1)!P=]\'MO?V5MO> >Y!47R=PJW,WR=D[$
MCQ,EM.O>2LJ!E&&%#E,GPTTK=-'F5T*!%0],[I,&A6FC5-Y=4?X=M)FHY86I
MJ3I/YICIKF "VP@CQ%ILP9#)!.W%O-<8@3T_[R$O\A6V<1J!->V$ZYR/\'-3
M#9XOC)<&Z FANK%#V0UTG.HA0<Z:5NE&0A9%&^TD9/Q2VF#3V#XV.6+HXG@.
M5@4YFQ.C%<ROF>5J"VR.GC5HI7>'#2$\PB*>-BM&(:HL>&.3I\Q(SO2*I$ X
M_)M5VA8<GJ/<V$+J!%MFJ"&/$!0?7BXBQ H7#3, QRJ=AR#N=@EYF!G'$<;M
MHEP/:N%C<SD6%W \5:?/7OY*E [YO!2":_K'F;N?];O^HTV^=\;9_JU@7A9O
MVQTJD;VQI6HKX&.*MSQ'C#]H9$.DY#2TX0"B,)ZH#,5E, )6Y$1S9,1 4\'X
M&0^^3,J4)?.\[HT3,K&=G^)*92..K <AC@ZP(0\;^FYO8$-W)1XBB$^($81C
M=0[W7N#!93>["-^LMDE['D#7\4@@=#6S7?N=&/EA@>U&4<LB#UGYD9A)M _#
MI<!R[ZFA^,Z%Q^@S2E!(@P7<C1_$ZQ;O20"8SA1B" 6[E1$\A)A"-[D<D&H'
M$D./G\)/BNQ5,#C>R""%L?.I,B,Q99ONSN/XJ$1==Y6W/#H 9'ES!:BZ<DG7
MZ-9_LS$B0<&^N /5?+55_CN=X!1:ZA>&2@*F-) 1+CD7AN_96=DXOD/W)12V
M03.S^T+!8E'J(9XW&E$)G)PTGLM-+XCMEU[FPKTU2Q,D9Y\2(!DS5):>JP[?
ME;$7GU"?X8WPL/10%WWXK>?C)-L-5J#CV<]$\7/-&Y:U8_P1%86PD^44<(%X
MZ94N%/P:><,F*%P)\U7,V[Z$_QGUD)D"R_D0@Z>+Y$9O6;[5)"2P?J\9S82.
M*;KCB=<0!\?2#?&RZ7D9:84,R2)[4%0[6#Z%L;Y^>CC4,Y8CLC(#)B/0<'KV
M)4&*:93GWIE1@5/K[;E;YKMF.+X@"\>3 F (<;;,_S(O*J;^ & N+/7MB,DJ
MO!L3HM,EFYX:7R ^%*YWI"')\ MLON#RK0@,])$,O@V=RP7:< ;)@,J1BEJ'
MR'";<4DHO!.A&,3?%U40?,C"ZI[KCJ32X21M"JMND N+;)&%K*V-#N_&:.2'
M(;TCT+-99EC,64$1@&[*_4LSOA$4$-ME)M7%B<*2.)."+VZ@DH:&6!R(/=?,
M!00.U=3LUUNQ_8,%#N[#:=.N=L-='7(88?'C_*%\ '6R!%^X"I$<L8&Y-$E:
M)@NWP*D_=9X3,3QTV^E):YHGK1!@)6W*LV:QW4FVFR\63)JK^"I^>[$*W4"9
M0INHG%UHBP_X&_)\?$&,)AV?:P)6RCW9(O(+Y#/Z'V0T!01+*0T9H22=>1H]
MAH]/5.[?DF?I[*D89CLHRZ*-:ZO\0U'.YIH?[^:YCXO?&K80GKF6K5@G)2$N
M'$K*?301(N[./XZC0T2#V2A(A!5=%E<N4L2"=)!WBRV-AL$<UJG(TA%!Q7/
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MWC?W:YQ"S=NVOB7NTR-"W]&DHO\82DZ1WRZ@BTNW?%06?W8IBW\LHNMME H
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M!GM@D2+Y*80J?" V)^1)J#DT@"P7.8K;LCLF5?&HW@#E0\9RC\V N-+ F63
M_0[ L>7J>+UX$:<1A+*-&5D:QU<Z1H!C9, G=SU/5(]?CA]$A ^G-CNYD?+X
M[EVI-.?3;PE P_*Q8G[$W-:_WXU\_L"BS?[BM]@3B8)V89R$HD@X;<U! +4P
M&2:AJVLG7#5D7O5+B:5EK  ! A(<4AZ+1I%N@2S  /U5(B6JK1$+6:K""X#\
M4+N:1ZK*:-G9I5,59."1XTM:-J01012_F/]WTW:SLQG/O$&A.,;6YOB;0044
MQ'WRY_K)K4<(F7"VZ&*-+: E>'[0AY3Z#]B/(YR>P6@M_J>L%G\OEV$ESC@F
MUM5XL:N:LD#!-?_Z]SP&H146__ GGF#MOA*LWYJK2S@R,14!=1ATSA&QZ>)&
MI.;NS*Y!%V[F(;7IP=_PBX)8VO!166?DB,J9L8G,NEI+)X!,?4'=KRB;U(@L
MEX%7W+EL!7O.]*'J_/12Y+KI5J!=KOX*4Y%I,ILF=@"^TD&.@( $ RV%=8Z1
MUAR'^<-PTI@C%X5V([<^2__D59 VV(R4_1%NO3@NL.(-$A=P2T75!/UU,YX[
M-,!X7.!$?7!'[\B60/@%HKOATMZ<]H RK0L-#V(F?E1=9=U7=(MI*0;BPM1-
MHG6)E);(W=_ #I?2[%V%$I-T(P+LZ!M1=Y;K@%D5;M$ UWD=_-&-%%G D&H#
M=XCH98GH%^@PJH_W,3"?NY U!)8R]R:NQ&VE^#K),T:SRSA$JW$3*>N2(%Z4
M*C%K<3FNMTZTW6C]DIA,<=]2U%5'CX;>$!EL%J7!IDJ_;C9._![D.P6C%8,5
MT3]$*0$*DJ%MB#MW1'$:AYKY75DZ LWOIO9C0!J3:,I00ANU4(GAEYR*Q#\P
MKR_OK"YC;IOJ4L5(6I-/9FV&H:7]@/X:7'N68MM$P\CU&3"? Z<8A)8<'0W%
MU?9*F0@J"/58D2D>&XZC(1P]L?[_+9%SOSL;Y-SG8HU>5GTW<F\T[[KX-(M2
M6X@;[VN6U46QSD @+;HP-KU.NYJ\" CM+;0_?#.S%>.@_&2/7NJJWK)2P:'L
M44;.GZ-&-=W<:^<-1[\#EQ2@QH@"ANB&+! $'BP]E4GT&2DM:5! *[4K,:&S
M&;L:7<]5Q[L;/Y+U$9Q_[/;H1(*KY [G?@!69OFZS:B]XGBB]@&=BR0YX67P
M7=J5#\E)K(Z.T5A3Q31VY$\B=@?,@21A$#'>!7HI*&7UO6T(^+3NT3-T"%_P
M\E">8!_^E:B#Q2T19F;DCQA$!B_^V@=2=[W-%-!&I#@L/K_#]6$G[D'MVT_O
MOF7EBIJ.5XV>.6#.Z&D11_VYNU'0T#VB#$LF=U3G1M4VI4AD/])$H!+6G@77
M)]+.:_%S!>V8FQ5OA?(@6NK\P"<ZE?X@V!V:'<6$"0;/>TF8O4% /O1PVR]F
M'L:DS%AN7O+E4^L)Z>T_T]YG]96;E5^@C ]\&Y+N3[Z]>?L4'_ ?K[Z[^L>K
MFU<OKU2?P=XMU,#+6EOS;MX&^[#W'LR.FCQKS:BY1YB3Y^$MW>!OSB:6Q&X@
M>MY2VT?H#).'I*O!E3;^LY1IQ'#;]8,VS^Q(8 0\;_\@,U:]" 43^,ZV@\X3
M^I;_]S &PG#CH=;M<HF)3^,[<@]'VQU:)+Z7(I3)"=@SZ<;?YNK_5:L/RW+U
M 53"Z0Q\$P88];QI!/#/\EK?^E/>+5Y0<[[_RW.NB=,38+U<F[ER&XTJK_"7
M(K9JD(B-E>[[T/+"RWOD9L2U/U6<S>[TL&#PFU97B_O].9<&BD. 21Z4U3Y>
M(S@!TW5R/?$,U.GQUL0_&CH>WNN7U-0M<(MO8WTB8^)[X;&1=H(43*^CUHL0
MNZTUX9V@.8BF$^^;6@X_/"5(U\F;D=ZT8[602 % =!S-U>X<F2D?HJ.WY">U
M@V@'/UG7/N2V'@>I4PD%CHE?3IFL(DT(YS#^$:P,RIQ+2 ])3^Z,8<-Q,_8O
M\.^"2I>_P'DZ$Q0/P]SB8AS*GV"9&)GCA_I2'T=9(<I\X?9Q5M$/.S9WVGKU
M_<\S2YB">K5M)_WI/UMYXG/Q1LSTZ>;F3$?D=I0_N?NDJW_&7 +9/N9%8/60
MO%I>CI%N3]>@A$KDBO#+(%.,0U5'>'Y=E]U8NXG5Q];.WNF7X26]9=]NL=OT
M4]ZS/_6BY[=$8DV>7#RJRC1 4*0:A.CA,V,/&%+:D:HN2,W96M:KFL!< "IY
M5I9*G2%0OL#O;3M70HQ,&?N\] S=3Z P!50+?(Q!DY,'M6@*RP>J]8""4R8H
MC.D$X/'@(<"@Q(PK$YN"S[%TPYUSN25M.EA")>XUT3X4#S9P<6 ?=\JT7>"-
M@EW% Z&-3/R$9==10R*]M)A)#M!"*L/DLUEZT ;D6)/_X+)ZZQ&)7FLIXZ)M
M[,,C;VZ[4]5IE<LFD<%J1F+L4V5H8FC7HV^\_-'ZMNH_]-XRJJ8,*'U_J_;F
MC<PPAC:.60C#;EV\* ]PC)^C5_'>":$2%?DM6[*IW7/DD>-:4QTW[&U%G3W,
M_]/O7+<G<!@PC<$V*UF^+1(;+R*@P<C:=W7IS6"_ FT?"%'P,BLEZI*%9Q/I
M0B./.^ZLSX+W[.FO;V$1LKY7EB&SHS2B0"^BND+#%C4IZ-F2=HS!09O_#=B?
MLBFO%R_I8D'V.%P&R1Q2V=0ILP*?+%3_FX)&\*JIPE'56ZX[BT%2*KM55/:V
MY?H<O<:=RVK*R:F7PE90\[Q$YA+!.X;?G3![LI>$J8DJ=A/PC$3Q2W=L@; 4
MJ8K\<=*551]TGS@'T0):SW]:&$EIMB?XMYX)FE;$U2,8AUY338[3)^GRN$]J
MS*XU?((V>CU:G]-+YTA>H[%Z2=^_\[&PP_[?;=TN@71)5#"#DV>7$Y"ZLL8A
MYELV=4CW:/:ETZ?U%_$."[7JE9@#P$ST+*Q3M'-_;$5!E\]<KB:N32V$23-N
M6W@$IK6D@Q*J;UQ&U3-$L!?9.\-'_4C4Z[MJS32V6]>&PA]J:=.I;P<C(4+%
MXKGTPFE:2MRAMZ-_]1*O_=\?.H"ZX+]?]5W)9=OORGVI222FG5P,TOLHUT&<
M#G[JA[*Z*YM"^$6$B"=S,F3.A' D7 <83H4ZGB%!3>$%0H(1Q\7W2/BKX$6$
MJB6(8@./8T%LCO!Q;QV4%HWF I\%.FH9H%=&M*;_\7^>_>&+YX';U.^3)<*#
M*%-CN&%.0QJ/_)0!"L\RSI*PF#0H&)GGKCU*KJ3?,4$7/C:=D%A43NK0V*3B
M'_D/UXMW,"_;T>\XV*$*(O117TTT0.$=T-SZ18OQ0J*M%]X-?NW]"ZC%)WM=
M$>:POO<OWKYY8?'@_NJE=@:*Y6=$:*W]FX%4.&-(<N)\?0A'A +:,*!" FZ/
M40-4NOP_:FK3@I%F(]SKP2!6VEI+J=874YNIYP4K"#Z8W_OUJ/IHN<5,#T-D
MRK!I]@CPGF(V "0'4XE(9)RI/U_*_%&9__?G4^:_=!5]9%<1;N-F1!PF9R;!
MD/H;@+ZN@7S/N#"VBT5Y(J$L<)&P>'1-A'[ESZJ"XC3,Z@U0%M@65)5(LGG!
M MO0P5CC8B9^: P[-".3:\ MVH.Z@S8@KA:B/!P48C%9#:[^]R_^^L6SKR_K
MX;'7@Z2U<!4PD!AE7JF@YS[HKY5V5\!'?DU<87[TPL'QF\W<1+PA=F;S;M!E
M;GZ=N8&BKS114;=3#9&$TD464D8GX0N4HRL/JI%PF:;'G*:D7T(Z, H*EM8\
M-R2TK0>G1$.0Z:@AB!LIZ^;#/W\9@%ULVKIJ8PRR@\:ND4,7-K3,G"/AJ9&0
ML/DQ0I!-::NI/1=23;B*-E6-_\>G97"& P3&RDD(1S<;7*2FEW^+#@;NLO@>
M??$UCG,7$VA_R%0&G;'"B(S1VMQ#7@;Q' S]OTS98YMUJ71NI!8'*7AI_5 $
M'[4G2[^5:]S0W9/8O<S<K[+9HII]Q*J U>9ZT1_[ :BD*4C==*4_F4?D@;86
M/>24*5P2]0?^]H75Y%?9BE*F")@"+G7:$W8MP&K9>XJ4B8LW01PO^GUA3]D@
MA]9U %20'D\HH@B< [8_IMVDS$"YQM0?"(^(J,B#'M%^ +W'"*WG@$+'Y+-Q
M$D9I38PJ3&<(Q?IO?X[5"%GT]]YZ"]DQNB0H9+'+9.J)G)C'O'O%0@-!+FHJ
MJ'$G<F( GURWF*$F#*:]!">#\2I@)$"2K_(#5V&VFHI])1<?U(I+:1!L>74+
MSP[WQQ8-+A:",[8<Q%3@+S#7X;9869NN/00=2TX:H:9F,"A7GBOB*/&)EGI0
M%@W>A%4CI.QO :+H&JY)B,,VG3#8A*L9?H6R]@CK.*1X .2#J1%6"F!G6K6(
MA5)5PAED0%X5]2Q1H>\=5?A1Q [\]DAHG"3;_)NN\!.DQ,C&)BZ9W65JUWA-
MN8AT,H/H1>\<3C:M7BYK5%UO6_:#M(2@#;PY*\=FM:,:]_?8"0DB.0Q3D.I4
M0!SRENNCM:@]*QV6X_U=-E4HC@)N!-4#L:2J[?F\\:J!7LO8QNO%S0JT0BJ0
MV"OB7>NO7SFB)._''I$'T>W.%%?RP/5"@2:O&90</%$>Q7!VM1KW(]4.?2P(
MZIZ(:\"DW$]8C/.;_/\^NWY&WUZ2?B/B)H)E_(0%J+/-5YE[&*OJB&HRX6;4
MM#;3GMMNN&49D)=9D3O_3,6,<UU$:C"6P&)*^ %] PWU1!^\8P?6==-2D8-E
M)M-"XVF!$T(3ILZD],9PQS9@L=!>4R/8 ;LWY@!6/@3Q?V8H9:@Z8W\U'TLD
MFGHD(1<??<C\8<Y6*%3PP-O4[5T?5J+NW:'=.G1U,-N@C0O"WX67"]V4!4-?
M/CCLITIL&.D\SL*+O;>S^@"BI0[D2&2A,!X#D\\KPO;1ZP2W@!_&O)^IW6H)
MHA"H._7CZ->V77LW[()7:(ZY)#&D[@D;PW.T.48LF$MWU(/7(>R26M8%5TQ(
MC#BIG(>9W0]ERJ "#!C DLV)1]R9&193L0[S RI8WK_A?ID(5Q9N0&=&<E!,
MJ'+TFN05!=2P-OEH)B[FE^6&)<&J58',@  ;2CD YDTQ%L&^\O>EYV= B2*$
M&C9,>"1<P@"#D"Q^N))4TC)<3WRP)O"-J5SU!!*A@W&7:T66H1DBX3B0WAVK
M&@M&X+LC"!H]RPCG+4L"W<O:W;*;NU(,EUB\V8:4T\]_?KL1!/A08%A8//;6
ML6$Y=6R<Q>"57+'U/4#0P.+C]ZMU*28D>/%64!</$6R1C"'KMX\-FW:B"S"N
M((!\+!PJXQ#&Z-'IT7E2G3GL;TG?X/U5P1AI<3 6QY3<SB\RUVR3GLP-V@P.
M".&UVJ96I* W012_0)\\X*HBE(\9\]S#G10B%6]IS\E:6Y8S)2!V:^J:F:HS
M%)(9$$7T3N NS[.J&5EM\*C-BN(\0MR]&CZ9GGO,)L0/0[L=S1P0IEBYR@9C
MYGE+;,6,<Y](4R<2$3"FD<U\-AY8D"*Q*-<QLQV'1Z'UFS<?-OHG>X\-H/<B
M.J%2X WDQW)TIU-[_Y9 KS^<#=#K-QHA]B^\3UYU$Y8V0)R+ARNEQZ3MCJW0
M+*2*NC)L'&4S*C= KP(/)=N*UK$28A!9'CTC4L>0IWAL1WB^&OG$:M69@.\=
M*2Z%!FMB\3O#I,UKFX#2M%A*84.NGV::@;;%FR3"PS/NO5#O*/2M*0*>>9,!
M,E7U/OS#CC-#)[4":F3_JPAJ3@J8<8^;@,KWL'!*Y#(F=#GV(A.8O+#P^577
M9G'\=&AP_B$P\(CECRSO/;QN";S>M/&?H4L&H674_Q#!_$_U$Q28. /_N?,^
MT0J#E0$RT;8O@6$>TKE@KETPZ2M7,':<*H83&,9]76&#/F3LZLI'(VNYFCP2
MI7TY]\8[G<.'IH<P#Y=*M79(>VT_H.N#0N&".$&0]0U.T9UWR=4?L@M<&CYX
MA8.3R%""I/7#MJJ62P@2])9]\ 9^,*PF;QT0(TJO!P0,TI 377P//1>'VC$-
M%(FR'MJF9_@X=YS0/9,.%:K0DMD%[VQ1;OT37B^^R[T&MH?Z&ZV%YI/8-BV;
MDXJ,3!I1IITGM,,XEM*QB(8)TD64'M'YDUM<+]Z1:+:T)L\:A5,M)\7/[S?A
MAC;L",ZN=K8BO)_X<--1P-OU(:G$*2+M5<BT(9$_MTJ<<],))+PA]-5H(1,6
MQG7;HSR!/Q-%DW=^BQ(5SRE*LP5G0_V>[=8$=Q5V0N\GHR@]4/2^HD?C^I#9
MNC(>:P? :>2+B021 V$B5IST?!@;7* 0 0"VEE<T(H7@) ^,;5B @E"/;JVE
MJ(B/2@HV:^\<B_HG_\+T '%X,4-#ZM=Z>>M?P+2;0ELY]Q:]TBQ.8CNP^#<9
MXA$%*,UZ-+W7872P?$9SRR0^?KDV;H,T+/U'U40_&Y_DK3=*./-&LE;WSI']
M,IHG2C6EZ5-#8Y3T) 5*,XW4_?V!0FH7]1L3].L<,YP_1*DI2;^1G<\,J%1V
M$=@'Y4R :G()%X],ORJ'"A8T[J+0I%:0^^L]02;^U1-#\I X0VX=N)JXVV[#
M 3?0+YJF-SX4D(R.CG@5QA"'WVV 8G0E\?9DR^ 3T=21V8 T2]O8M0&-Q+8<
M33M4:\92(Z:'\5;Q-FYAQ3"?'Q+HB$":O2><$V=M+4=4$N,,2)$@+&3E2AC(
MR+VEXD.R[F'0X6EL_C]JD2N(BVCECT,Z"X!WO D<39.)IPJZ]FHG!?A0FO?#
M@'Q0= =%?\28#\9@&KNO60JBSX@V& 1<I&Y-4\0[=W"K7>-WQQ:_'DJT,P$>
M^^22C/%/[$IN["?H +<>$RD^+CE:+0P0,"::%+"#Z$O9 TT)A7RV$FVR+4)5
M/NVAK@AFPZ@#/GLL559(_>M%A*);3Z36'"Q+;_83/BL+B?WE0 @T;&%2),X.
M#:HA'9KGD-?1P@>-Z+@WE/#,7+,%TB^_P<X3[? ZWMLC4T% %2Z@1J >Y\>I
MZXX^)+P#[C2+TBI_\O:&$.].Q96XD?)?0)0J'2'P+[DA=<-QSG2T_.V?_./U
MWWLB;Y3/P5"1MXC-MJ$$Q*-5:. >1E#\Z(+18N\<&]ROOOX2/_[5UU^)O_Q*
M<(]OV:J\:$G/XMF?OOY#@6>)WS5KF)8?=GP'J3>CBXV;WQR&Q."#WX1*;D,)
M%'X$ !-^]:?G_CD*)K^]7OP5D\S(MI2Y$'^,C(LP_?8[;U78XS&E*>+KWVZ!
M% GL@%[*/P!: []9F\7OOX!$!427T$-]\/$3X.%OE?"_;N_0N=9OFT^3]\L-
MQY1:-D3@P_$ [CFAQKP[2K3G %RIA)ZA+J-+TSNB(<;J7^W?9'VTY'V3@8NF
M8,T$$($*E-L(UOBL7W[Q!4VX_\?7UWR-TQB2.R)'EN57$ONA'TV_-)/]#&6Y
M&%7RAS]^<?T%!*.U!-MRG5E8AUW?TPO^Z7?7OPO7$U\%E%L(L1?8HM#1,2.K
M--B&W&RRMK#'0X/+@98@F:A3XT[18_B9>7.$]-$[*55 >Y?8$F*T3S)VLNW,
M."2CO 1^.,<VA/EA#.6VP/5&.,S@6M  @D@.("'U03G:6F]=!B'CZ"A3@B<W
M^B64&1&:2@092=A9<)'&SUV##^ZOAD<Y7;Q(_;Q1:8'<%8_Q=-V@4SSWNN@W
MX2O%[!RRD,Q;L=$SF\5LC9CF6BN?M9VH "ZP"%"D=*RBE_H7(=-ZB;@8A[BR
MQIMS<%[?<-+B,WS!3W!+%-H->[@\(%AEPM'3B9RL8: -I1:T6KP<XB^J25DF
M%QC[O+.KBCZ,7J#@+PT\% (R^9LZ[J'>7<3YIQ-EBW.,X 47*7Z,[83$@C=H
M%N3)M?R'!AKUI@W-''H!DCU(FR\Q@C2MEW@0X^6PG"IRP\FL8.BGT!8_3)6)
M Y8^#G&WA&IG+2R*<^V[V#066M 09\/%"R*Z$GC&7RL0&5J\6U6< 'W5</N7
M_\=Q )>-R*;Q#9C>DZ7^T@4%RQ=?4'6Z1GZAL**M;-)L\(1&7,)7!"0-Q&,:
MHT#1G!/I<R9PM,T,R9,F^. ';N[0PY'?PG=.6S.&EG(=!RQO"I4%M&. Z4R[
M-38MG(_^IS\O+K7_J/;_Q[.I_5^:K#ZVR2H6QD6[$4E!5KUWH ;F<L,BQI[
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M)?';?EX^*IW[V;3-O7>AY$[-1WDFN.1#TW&! ]H?-$WP*!,=PDV,A).MECO
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M# 7X<229 !Z/)BF$?0*RM;T*9%&> ?ZTX5@5_#V@_2I#;+40"H^>M]4T:I)
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MOV\)7<[$BV%&LU-WQM6T6-S&'+NAW/M=.:QV5^_+G_Q#+&[\<*]#&5K,D1A
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M4IX?]K%W=)%WFL< 8B^ND%3$JH$'CUP1[$@U8.P=:E$9)7)XDU6[)LD$W!,
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MKYALV8G3$AX5YR-1MXO-83W=8:&"& X&4_>8LF*QMH0@F?'(%FHILIH%HQZ
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MONJWAI%KW65Q=*>'Q=-&J$.L&2,,N:38'/,SR8W>'57?P>6+'<8]FX@E72Y
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M_\\K$6$GI$I<8#X3_Z'5 -NQO4>JZVW8"P[:C;W==F.GM:N &+S9Z!+AVVA
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M%IQZIL;Z*62_1^PVH#A".&##C#PC>*D[47&/WN4*QZ-)^Q*5**#JP8&!@^7
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M"KQ&\E/Q25 ,&=Q82S:L%JKY&(\N4Y[J<2<%#5['1QL *-+N5XER4!=(JC1
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M$6Y.TYR  DRC\2LO<+$V( MF&3X@ F(NOMXQF<4&X07/\/6N23(R?WT$[V@
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M ^]]!R8NV,CN@ST:T5T17\LQCLR&(A[2CQK$)C/@55.-@.1W4J8<T&(..S0
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M6B1%%8];'"*WCV!%N,NC&G%TED=Q@F57.GQ[2*-W\BS9=9XZ),:0@@7-4L6
M<#Q1"^=6@4EL*GREOH]_Y?,]^# KYOX1\Z?0R!7>PP ./Y[FB0,'>:J]^.EZ
M[] O?LJ_A#L4[C:V;Y9TE=XX;$TWC' 2VK'W#L/0(;J>H]',>P 0:N4X!H7M
M%E-N89L^,W@]^JQ[Z7"2F4* $#A?61T#,VU@3S)_)9V_TCF._)7#S<<3<HL5
MOVP+8&X'@SAB::9F$AG>4%C%TI((690IJ6R,_Y<B57SU0*;$O\.&GV&X0MR>
M&ZZ]L_%MN7>'T/YO2_1&I%QBW-TIR"8P0]"1.)..B]<$#_LAT SFYS33)0[_
M#G6X2##)CU\=(F/]D"9*]J5^2&\?OPCQ..98ESFCR"O\P(G\E7E)?4A*+XV>
MXA:8J(K<@IA8QF0/*B,88?12LN>-V-8/O(UY\4OT!2ZL%+;W*Y[[^XN_.6;+
M+\"27%G85Z+AS0LSOL,DGOL8[?#X; (6^D\RA$7D41PN=]_[&,&P\$+"2#3U
MT:]K^6.6'\A<Q!9+AV#_-D%30[?UYIC@0+W;6.Y921@59.8CZ+=$K>L7:O/#
MZ"/B6&V:XA]PTX(R^\Q$;1)Q3:G-L<K<,]C.U6Z]P>*T8G8J_WNDM"=VQ?"-
M<4SR3#\$_G]A:BO+\9OECZW4"E%MP=.J1-PI>>30!<T8EVR"6FP$+MXMJ5-,
MYG+"NH"C'6HK:ZVA1-T68X'CV;SPGJR3B,(;4_A(%W']F5_UDS0'AIR?XHRG
MH0?J-+_T>!T%6P!+0A"5(W':*^6E%J'#BR<XR2*;)BZW"L8N)I)@@"^RAU)Z
M%@J_36<=UM=X-)N->>>+VCD8\V*QBM9Z)]]?UA)F::,VJDVD!8".Y4>)<-JL
M>.'&<%R=E<:B2>%K-K-"/6XY\V0FBU<L\"Q"9A@#8GT,14=Q49PZ*0RT.'L"
M$W<#?TZB;=H]0,*@ !BL][W,G*-'8T\)"MZ9S+4ICJL.-A(U.PB5E'N$%:U/
M111T)EMU[HK$90\I/F<"MQ]H"SR38'X)>@@RRA-)V*(<>$9>QY)\'K'XTPU1
MVY*HW2]JDSMRRG+5HHJ)V'<54","9^A$9\[@]N_0X@)*P910_%)*:,V=^2]^
M)+T8%@T6VE\3UL]@A4WU[?EXP@'5T:_4T$,^==QBO(SF&' (5DP$49+,YD8R
MUF9@1H$X+49U=D8$7:0)H;@2^N"Y_Z)&S*#(W8F+"#^9=6VS!">6SQKY:'56
M^,N2J:++C^5]B%,47B!>,,+2G&#)D<8\3':>\@G EWCBI\]4SMACS1,7V"\#
M9'A=#Q<T3".+%"'72^M!^&+</I8OPRNCI"';7J2H_^9C?QD%K6! '%;=C-U7
MGN89Z<$*AV36&8E'/T69'0I!^@LU33R;+V5B.;&O/?&%82U5Q(A,HF9R(]LO
MVB=1=NLB#\S<&"*Q'R=LLP^.L*C^:49(I*\05J:T+ 2SI<&^.B8366ZPC!_<
M;+!\L0[N,0N6+3:,%FJ )8;2+)TO$=LZ@*: 8USDT.%+^JE:IGAK3P /\Q70
MG<0^R >MIM;)R -;#HL)/Y(/5_U!_V.6;_("/WCVF*%X&WUA/L# *F53FTMM
M9PBV$N";2VME38G/MD<!M$WX8YB$/9"C(C(>*: S(X;%@#05D@M-2]C2-Y[C
M!^2_],GT"_D':('/"OGV[8$GWCE)MP:X[%D)!GQI&@YMK*!,E,:1Y4W843-1
M$P7E+$^L*^F1947N192%O,$63P-JJ]OG'[36I^;,63#'D$7P=6D60?_I]YM'
M<G=_VW_\WGNZZ]]OUUVOW$10:\/FA0K"3&<:Y@,VBBA[&LUUX@P/QJB13. K
M8W]UEQRFK[H8],7O#H3*K+8B[]></?2K]?.SXSKWX036:#!Y )M_I"/8YD6C
M0AR0V/]=H8;Y^=YUT"&(A%1[GM<S7;3U;FW]N4)XH!NXZV?P>63]I"80Q/9I
MA;'<Z*+>KESJ_/=__33SPDN0]:[)0^^@3VV]FB=OX@0;+J8#Q[GQ>[9]2;=R
MR14P/6/3\_\&RX,9;+4OW.7*L1H(K*8J7=AOJ5_(!WW&47N'B9&-6@=%]6-<
MZD(&%W^++O&T-_;C<G==&OAJG=ML^9.JYBSEUC%9RJN T4P#XWO@V4_8,: _
M>O),1 ?\XE?;-7Y$&&C4*H3ZACY%PGHA/<@&L^WPE=MLI;?)]W;GF/?P4;PS
MM7+Y/SJN\6\ 3FK[BUR]Q1N>K,!.7J%5+@?4P5Y0?X+8(@]@6K!^3KP@<&S1
M42I&U.>R;9=EY)!M[#"C==:7BC;@:NRC$+$Q]B9"!262VZ0C)/:'V+0$O<=G
MCCL3S4R?QX622 @^C3T%[$;?=1WV,?RS-_4L&T0\>U[C8Y6PFM.9]T;M,!(M
ME]<+B*\VV5>;(B\)VS@)4S<J,(R:"(53M 4%56\][EZ$9UF<IOX8K'2_,D?G
M=H4E'DU 0/YW!?2,Q=-/XD:]Y^<>MNSH38)9TCOAY,)T@POQI H!SD(VJL4G
MT:A<-KHU!;@I.HEH@9>$+TR8]'$+I"KYD)HB.2^CUZN 1R/5CD+N='**U^:"
M>%WU].YZJ0:*__\ @WCTC3R@^R2O6,M^Q:Q8:Z\2:[^)SFY78 CYU-[E]=N*
MLTY9Q%EC"VGVG?5TT6I[E69J[7W$&6B0]79-Z32TC<79PI%]T#[FB,G-BK,.
MLNR<0$NKA.\MTE*BNM#7M]@^U\NSA;16U&TO&$46&OGKP+WP@,HE669T'[1I
MG5>-%+>H(R-C*TS(X+R_R-6,CX1C<9&14AT4!#29,_V5L@ZCK&@?JQ<Y[^NB
MQR?]:?EQUT;>)X/UH4AZQK)T,1&;]D6X^R=K;N'1B<B*$>^;Z?/EHR<]$30+
MFXEV"ROG(H/K/XT5K1'.,LFY>QQ)SD<@N[2/RP0!,B/7-LZ8%S=DQD(J+[LK
MW+OE]V-R9^[54F=N4B1('F]^ZSU>8Q'E;?_QYNZW>_(_?SS>#:[OKM#).R!/
MO_>>R,/CS9\W]T_D[G[P<,-_L$YCB'PZ)?&2XF08?3JUX?X%R"V/TIRC!&_7
MEDOPS5FFHU7*(?:7D367=S*N@GC7\UG@YG8#]A]E08_(72HV]IC$QAYX;*R7
MQ,9N+6^28Z<IGEVU\;P4?'\\,WH]\;R/ =XSHJ=XG"G[-4K;O4XG>WW7#<\%
MN]HR? 7'J&S<5O ]-IDMXOM3N$U=9Q^Y\8N(.%R++YYR)0+'"\<DE*&B\BF4
M)*H?IT7$R?8BB+))XL)<LZ(])%*PQ_8'_7B='ZNP--&#A0%#R0#UAU3FP\>X
M:@#3B#!=TK:3S#:1T@-?3+PGA=-X81.;)D^4":"LAU8:I4I6[BDK40A ".F8
M>"V.6HCM*(TU);[[Z(["]PAY]>$/AS$ ZUKHP_D_7/7Z7S_R5!;L%89#!1D&
M9]K?+6;*KLK30!&)\W>4J/J /7#FZ:D<WW3C3C\J59Z"P!4S/G!<A$+6S'5(
MM09BY0DZ*/9BR3R6C?->_*C<>J:8;AFZ(D$?K=]A_1]UT05-I(;PW3!#@G^_
MS:T)!?.,/9[%I:./[]\A7(,\[BSD+:M.RS$YZP!8S;XPOK(65DAF<76LCN_R
MZQ_'WEFCM\.GVL62/I7TE5$:E:Z$VDIR\3)]WDLN3C6+,+F0)94C=RS*01)8
M1@'!-H8_3&K>XFUN4?G&.S3$%.&%0[S5GD U8MI-](8@@[R;[V@XDY:'LH\U
M)<,$7'U)ME8ZGRL6BTR4\>$"WFP/]R&=20:;SS6=J9++%KFL3>"(FBQ>DFJ#
M9NNOB4J8F(6[]@*-'\GVM*:G61:#+5&P#W:Y8>YSR.K?XD/>_'9C-"!//.$X
M_FDTOD"XFX0?"]."Q=@ =B3L3=CN@D\'R,P]YIUW7\>4E=EMP^U88YQH04N5
MH,6#W,@<*HT8[:?.3D@A3E<N\;C?C9T0*ZW/(=84(23CDL4XU3Y5)?$*UC\3
MF,Q]B/U&HOF 6-<CLOO% WAB.[^NXUZ"Z\7NC$H9YV'C:I0TMICW$9NNB,K,
MF<XWKS3NNHIJ0USZ) 2V87E&.$$J&:+]HL@Y3OI-<!H+7RB6K:9@.XQOWY2.
M7F)]=TE+)LPFL^),_F])N0'W3LS=5/V\=FAI6*87#=;:XF*T,BN63ZOVMTIV
MHM#F1<.8>T,6JEGQ50Y;]5PYJY)9SZKLIZ#5B,H#/V@?-VES=<2EEL:^2RV-
M5*DE^5!?0\_"B@"5)56 \]C>;RU@7GVP=.+R0#6#8O36],R*!K<L,4HE&N;M
M?GD@6'WR/RU6"F&AT.;I2H?R7+SY[.S_M' ]EEYZ4B_ZPF26RTR,5"TD1MHL
M28QTB:0X;+"3$?JA]_A$[N[NMLW<Z'1R]\P^@EP.M;8BE^/QYNJI_SA0R,W_
MO;GZ@\U%Z=_>WEW=//*>OU?]QX?^8^_IAOS6__/F$3M%+V\.7=HRU;_SR231
M< Y1RSED6CQJ&V+,(P@AN/S9V)&DL2IVF /= W6+5+NFI!?43,^GY!U\P C7
MX(4[,O'BL@Z3PAYF<Y?=GV^IJO=H8CT3I3IO6#NA;-PG7O_IP B/R[%??&!/
MB8=3?4SE1!GZE*LXE21TC<N]=[& 'S.0*U?QRG^+5Z[ YS?Q1OM1'\0*^V[E
M&C-0_QVR*2EQ$> '_:.PU?W*$=8SQU%CD1FGDRO79#K7U]"WF IXQ?V:W(\;
MC"U#G(&HK\/?%T5T'X4["WW$8MQ%,J.=@@KGOE$TI680%&-,I*6S]UOIE+?D
M6+/.#%W5D>[*1O'2(=R7K#_I. BFGS]]LKSJ!,.[SRR\6P5E\E,"UIF)8VSU
M:+EA0S5N,\:^<Y/;/_CC5]UB*?!"@Y^;O"DRZ9-.S,+M+Q9V\$$)7?44YWFH
MZE*AGTCZJ_[WAYO[0=Z2[/+P:A%"/9'D:%91Q^>_L2BTEPG:3#F;B,VK]%/O
MDC6 &+VZZ9,',- >\0.2]*R/):R0!3//*$*L[L@Q!8R1*]]H$55;RC$#8)C'
MNZ=_D/[?[T$Q^OWN 90D.+W'I][=/?EZ<W\#&A,.T. _9XK3]]Y][S<V@83]
M\_'F&RA1UV3PU+_ZV^_];]<WC_ K3T_PZV?+>2*H^D;<5P?NC[$U9<X-X;#E
MXU1Y6TWV<]&N-/8%[LBA@^CM_?3;K\3;OR9O[R=O3X+M@D-3_$QZ+*9XPS-4
M9KB>]8(H =\6,+FJA'Q;KRZM@8I8E'$?9IX#ZPYF^/'IL0<7($]+5\3P(&X3
MD;O[ZQNX'J]OSMGDB;B11SVYEP;8![@ERG40XP'3 8H=.3-+K17\%K'GX\)"
M'L5"'G0/V.\IM9S#,YY:*V 85PEUS,;2&_/A\>[^ZNX!KL1D\!:YO1'SN08W
MCW_>7>49(W1B7)7TCA;1-?S=$:71Y%+O!0S"W?B(5![BE_22E]Q&+QF(EZS@
MCK/TU6I%^&K56ETZ:S=RUOZYO4S=H(O:$3IKF\NUF9O_^_O=USLQ?3-C+"<9
M7/U^<_W'MU+-9UM2KJI_9-ZMI(^8Z1I\&#*+J.*<79;;,-4]D4*[<G;7IOWA
M%Q"@S8^L.61/E:2EX,';J=1X+?-5.H,_R<:*[QT_)KP8%QQ= #A#_ )6;NM3
MGWZ._O(%TR5L_>VSY;#WLR]]F3VBC&X'['SXCX4L['2K755#<1AX\#\S>K&0
ME%6@YJ?%S]MJM=UH9OZH5E4S/U_V**U5K357/^H36QI?'A  R?3?E7HEN0T8
MO3]KTY]$G97+> 0+'1_8]M\?F.S22:H(,T/JRI;%A8%9-'&R-0H/MW(@TOVJ
MO^\;.:E,3 ]C:B=V:P'K:>QA;YG_L\&]JG8JE[?D@OSZ23_.Q:MLY;-J$2*M
M6'Z<6*9I'Z#C'@/5C%C^*LJV!JQL2S)7F?&IJ4?,7+CX^IDQUV"F:K$_6[5X
M-5.U^,WU)?>5&\"-8^8^[#YYUMPW2.6]_"("+9+A2HW9]C$S'"R^>=8,=X4E
M]K=88B_9K,Q(K=>.F,UP\:W39[-[UDLB<,E:EYKDM5+#M7[,O :+;Z_BM4_,
M(WOD;G2M=&[T##8G V-,3>P9D2=V49(P. Z=RQK7YD=[XEG4;'*3R_I7F7&Q
M6S"FO!;4F6FKJ+!_QRT\1 9\.GX>_\SRB3]V7YTH()Y9W"H>P%OXL,8[@5N=
M[8Q\U""OEP[D-S_'UM *CA'/;(R96'[NV",O 8TGX(DJ7D$-%AGY2:S)A)H6
M+R)/8IZ8!C_3(RNS])<%2N<>YZ?34,RL/)02)#VMZH-[O$E/K:5)3SC>C"-B
M\,?W[[W'?VPWS:A$?+&N\^U&%<%GF494+R2-2"U+7]R57-N:9F05S4!8:Q^,
M:0=WO]WWGOYX/,9LPX?0\T/=21H+I"JKF$,T*KNKH[JC-C^8'S,:CO4,=HNI
MW7HC:L^( 7H/'XSS-4%A>R-,-S/Y52<:'?+L0]&"!MZ"=^.0CG5[%#4GY<V?
MQ#1AIF.%#GR+/3!IG'&@%)%NI]JL=_*FB#3:U;9:+R1%I%5MJ<4DFP #U]O:
M.R:; %<?R!\PIZ'/NT!:RW9$V)_=,F]MH:?NS"[/_0"/:D=G<EA+=W0$W/;U
M[7/QCM3#;0?;V0P,N-_(WUP0(<\2CJ>U(Z$.H3J-_,5< @37]^5H]IJ&IT*^
M5Z^K"GD8PQ\2JW)'^]H1>^)G*X!7&1OL<6[([TV?_1G5V2\"-4<\Y$ALQE7&
M(8X$F[ 6^0JW!(6W$ZU$YLL7QJ P_Q)'YA3,0-9!SXDL1/&FE*F)A([ZX>I3
MW4BZ80N/*;I T:]I G:"0YJ-K4XCK]E8[U0;:\H!-OT<;#VU4XC96*^#+=LH
M9%%JM:%UBRF<J%7KG=6+VOZ*$*ZGP\3]%_Q/_%:$%>C8,3*'8*WAO@2%CIX
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M0XY$?N(=\IU2)R17X[$^]'2,D<FK1%XE\BK9D!+OPCS[E6)22)=;,C$A#;)
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M*U=7X#T*2I#4^H2TR%X<0X8B&)Y9#:!;3'54\Q>6EOD % =.6N(MGI4+Z[1
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MG19<$(\T&(\TZG5%U1;#\))'3I1'.@>$W"K/2I'++8RE6Y7+9E?I-AI*6]U
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MP!]*HW-"<Z3.%5E96GDQO?46!2YFQTC$G")B-IG04G#K+ZW69@/M.K(G[+%
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M5E/&/4\13RMO]OR 6BUS.V6SH"26WNTR+QI+W;)AZ1S"YYGE6+E2;,^MS*!
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MDLQ[A^3W;/CA5GT6#?B&9AK1E@C12)\#*%YP*()![6&4]&W6PD6M"HQ&T#9
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M,=8G,8\"_W7N-_6P5F</"M>[&@R)3X"? MM@*I="SSAUE.Y1'B#W,W 2Q^?
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MYQFD@3F#?[8D6#5_*Z[2J^[%=[XA2 D> #L9ZDUUCR\:$/:B>Y8;^CC'/0(
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MET29N@79DJ4%5R9+J]V9#LJ6768(K,BX7:&TRQ.-?(4&Q;JBR@N$,[7*257
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M1P@?5%&;5N] \XF!X*P/Q\._*S*P$@+/5X]E#B*+R-?UG-3W,M7\::+E=IV
MK8*2&=<)<J1#GLC&/L\+>]NM*XZ41GCK'B_F,CXZ>N%&YS)V:<I\->(VE9GT
MRB"<2:_:,;A:@JK-W$B+1W*6Z4/327!4.@L_G!OAIH?./G1E0T0JS/.00?;
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MQ(BI+PZ/LV'O9]A6:"S&5_W77+EGFSK%U"3._63;0H,]H.@;./+1O%0C,E%
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M;=QRTP;K^>+DJK:Y1W:[($9PY;M?L.J5N@+/VD(Q?TX0C3Q[^ ST0^;(O_*
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M4;I$AJ5GA3DL@W]- !-T" I[=M.]E_ATB1;Y*M1C4_ -,YHW(KLN;8;_D<#
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M-< V6U4#_3Y0PN6Z?N7]I(0?5@T\A0 >J0;ZB"MZF&3P(ZB!I]SX$]3 D&S
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M)EZEM-\L8Y-#K.36PU\*V28]T=+5!A15G_KI(L1:-R#B0#)+FD]2,%T%-3'
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M_^(+)!Y%MD\LMI03!8_X,_;;Y+4C7$XP=^%Q+ K#$'EG[CE#$A!O:CLL?2*
MJ=(+AF5=:#$-/QJ=XP;"U/6(,+%_('L%6/T=OWP@\'X04R AL&!979CH"?3"
M 2(#7(@E @F0$4:/V3]8.CZ>-KO:H_X)X=D.QC0;8R52=(1ON0M#>+L76/"
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M-+X/YPFBCRKUL^TCU ]A7\!MYH;9CYDWQ$_/W@F?)]8 M7)X^X!.Q(Y."X&
M'D/A40&%!Y8_CI1BQA/ 0-&W(YI&#8,?A0#/T9+/H0]NZ*B2V ZS%S; (ZI-
MV$;/LD:Z(9%>U]!T6>T-3#(TK9&I6CUBC<AW&1V8J^CAT3?HOE!W  7E<"<K
M':%>50!0R9 [0"&C%=AO73^ [3%:^%B!^VC[ ]@-8%6*-0%,E6F)L"1D>!E$
MW^&+\I4"KJ>SB?M*B! ]5+B=6$[!#Y-;I;G%3M^(3R]YIW(@]0AN'-R5E;SE
M VHHV/&V/T95$;[_V1IX[D_$L0>^H$GRFQ]O*<6$-_@C?F+A6ZCXD8BTJ *"
MP"6P%-T6.80 L#J 9\,88O 9(AK<F?L!-28@PL&*3,3Z]<1W7T_L1RS:>_E(
MOKFW%CKC[!D(_8T3+3F^,:?G P$'[X:AAZ*>,I1VUD^/^F+.B- ;YF(]PE8!
M^$"BUR$8S]*WQ5L FQX0U0NBS9"JZ+8'LQM:K_@D-F]D](Z0S$*8PH\XWTA+
M#V?X@DHKR0G1PJUK*'T$<CA8S3AZ#3P2Q_NS]6)/P^FE QP_R?[HWQ(O'B%\
MQ"3AQ#!"/UQ,.NQ_(!4KN/\IX@';$WQK GH $"9\^ T-!YC;(VZS#@7Z*1M
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MX\JZ>'"'K_!_XV ZZ?]_4$L#!!0    ( '* 9U@.TN6>FA0  &O<   1
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M,/3(87Y "Q@XG"3P_@R@@Q<8V5R''"2T9*M YC6#=(G8,W21OX864O?AIQ\
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M;1!4([J$'OZ7E )Z]C-D 45D,>*N@WSF:T*EYJ.$ZJ.P'[%O.<3GM/R/+$_
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MS(.K^RF(& F3\H7SSF=6;\+:[#FFYAQ9T2_KF8:DC@315'+06#=-0*$A%B&
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MJ+#6!)^C#[GUZ2I+@WMD)4JWPS%KC%(KNFE]\>D2Z-[XY"@,WXQ//Y^SGOK
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M\[A-25CCP#BRSI4,'D)*$D1PZ(4+:)MWZVF%O=VQ^8Z(ED=XCO$4100C:A5
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M.DIEN6]^B_]HW_@6,KZI\JT;&Z_@O,8PPT^347YU^KFV75XD<"VA"2&8E#R
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MGI7@-.L6U[5F@&,-Y=I(%Y/&@FP=^_-?8?@ZQ)5QHJ4VDFO@+M:2\O0I*EE
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MKC[U6+/*-I+ZI(7(>L@J>S\/\\4D7_[SK%Z33TX_3\:+O;%2U]N4H_$!#-I
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MO -'0)D>ZG5N/<V7_SP;SL]KENCT;'%H?C+_A-,/G\)X*8 WD_$7G-&TETM
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MR'B07"H^#P")$@ **@'01.J,YF8D]^H$8*P7R>)'$):32)FS < F*0:@;,X
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MB-TFO>H*]R94=;YXR8F2+E8/B:7;$4S;L6UO.Y^DGK^=-B"IK/>^<&^-DI%
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M_4X)&WP<S^R'[6<G>W(7AJ8B'0/4Y5^(I=ZH:%G75F]$S5GH@W#V37Q7LSG
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MH"1 C3_>L!?3IM=]2]9LG6=Z+$+T]#%WEC]/U+U%=S^-_]DZ5!977&:YZNM
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M1:E G;2Z"/"LU)%20!NR"[FP@/WB70^@T>P@NB!OB+4F)&)_ 5;OA!DU%CT
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MT["W74^]? S;M,=+_/&ZC83$48?#,<H:+E4JLI,*8W=6$B53YQ_/?%PNY*-
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M<?$GG&RG+QMG"._#P4E-N1H&.X$M.I^W+@G+"2D4#8!L7+FQ__)]/Q'";H%
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M)I]2_C!V_)NC@C/^3!$A3HGCGQS(%R%2"D*^0N)H=GXG,,Y4J_J&'D\"JEO
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M <.V*;X.^T<5%?'S*-D*X F8T[-VBCPFXI$J&W0214N]._.<LJ!A'Y>6_U<
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M^AL'8!O2+[C\B;4/N-#3FV7+#BW !=E4M,<6]%LF(WQ_H14< -\5>&U9-.<
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M^ZW:[WF-)0^-S)L6+"SWG:S_HI)N$YN2MS_(2#^H&E^F1R]C:/">?"3:!4/
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MES;/RX_==\)B9*7S6,VI=><04+-Z%-7A&U4>.F2U*+5G:60L>9/#C3,?K?]
M?."2&T^D+PRB%@F8B><HMN6!32CVQ>4O/ELV][ \V;M1K2C47>0K1-(]IPG,
M?RT@1_].0!Y L4.P+"<>FMA+%:->2\1PP_D%1IL)^$9V32+Q^#@^IW^BIVTY
MEBZI9:B'*_F&%9WHUPH&"4BF@O^J5[!J^?*!_H*!]!%TSB>6[X6B(7_4&-MH
MY[Y[)8_K'24D8NQB]IV%_\S>V>DTG^<1YTVSTN>Y#2_(M2=>I=Y+,[ILXA@
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MLD8*$84.)U_^[]<T%"(*.LZA68$\C3V_;^8F@8IFAHCMK?1=UU,_(S!JO(\
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MW7SG(@JNHH+640"<=*Z!9']6=&4/"HZ,0P[ %NB/EY^7UZBL#\0=.(SD=+\
M::QTI7"Z/<L#)P;GRTZQEG-O_S*3X3IDM%[2O%FA$G%*-8AWJ>) ]<9[3E&H
MO$%N3VR S?1&2VXX[[+><H2,\ECOT'!H*%5O\/ X%V!0ZP0AZX+M2[/-;XQV
MXYU,WH!Z[%OTIG"Q.^SCIS8S6#TM],VGB[[@,+O>L1OCF2@DWN2*C/EYELX.
MTWO!#9N=*7T)%S_J1&(M!G:YF>3Z:=!UL0L2/N+WN2GI*IFE938U:N-0KL'3
MGLO$E6/QZ5][?7(_EU,24Y+2G97S^L9T7JU80U)9 INHG\P)0X#!STA;<\*G
MU[W^^WW< W\O)8\BP0/+4*$/]U?X%U)   ;P;NPKSG;H@3:&MQFFR((<JW_M
M1$ZN(HI%F*[#>J")3EI)145AN=<QNZAK8<3>M0WZ+\#['"H_P0>8-]J]PJ&V
M)?,CL!OVR=..C0.3/P]AV*'!X\G<QVQ21P^H[-24O'5NHZ)@_"0_"PW9L;%,
MQ9B4UII:SQ%#LS(PXYWS@\IC<KF%"T:(8<I>5I5*HB8ZN$*]-=TQ:04G@T,R
MH:M1.3(&9)NVTDMO6L3-KZ#>[G5PHG'*=AROL7F$LH_8>UG5)FX!%4RVI.Y$
MO:7O-D*!2LR:.Y 3NY]I'1UD+0=N[C 0*V0DRX"FK>F[O3-E[@>)NHTLKBF@
M[5Z^<8QCTF;&34RV;#M;?3Y3WT:!>"O-^9':F:I]G=G.MG;%)TZ:[TDJ*:I^
M56=6IALTF+FR"*C0V4Y8\   26AS]6 )Z$X<$2+D! ABMVQH=./A;P)I$-"+
M(5RN 'G,Y&0_PF]^1L<()_O1&(9D;$>.+D<AYX'F>/9S["77\5$7(<*KYVJH
MO[ORY.7WGYV^7C<T?GICWR=L3-NUK]\Z@]_.M:?)FH>T./J01OJC0G ZC9)]
M(;4G%BX6BC@H[SVX6%$6,N@;FCM-8M\@0P]1H_&"SN*F9?ZY>G<7?YB^V^''
MN_FC-J[L_X.X0XAX0#3EAH4*$8HUF+5E/4&\-[1^J\'F*Q#3 )B2C( _2&Q/
M/2@'R8(1Y<9P 0S$G]EM!!0*>$^%(^QJLA!QX<+2.\A.B!"!>E8UR)T]YX4(
M63]0U0DJ\.1"<$P-_[0SX?@EZK-CI'4I#Q(7W03,ZVJWE$'.I+458,,.\UE)
M( J+AKMEH!+W/?]1O0P/33#F>%206'8\';RI)?O*3&*%M_3G>:JD0!(,0"W2
MM^*%B):C/0?&%C+<4.RUQBR&WWU5U*CN3DVL%86C]9SC@J]N59G^ZI)B_\[=
MV]VKJ5Y:*[^D>R^/HM[C_*C8]T"Q^J?T#T43544]%J*7[>_&@Q,I1-S-X7G@
M-%U*L <Z!BZPO[>A=C0>!26:A8@] EFP[QTN1Y5MG4")MPQLH0T6A.YV<ZD8
M)T7(/PSCZG&K,].S(F0R(HJ\0T+"TTG^OI$X7W^9SL]D%U%'*?::BDF5'MZ^
M6&6?,8VFVUM65(VC#&8GI:<ZXG0V='.A%7!!('H:7@$[D-I:N4 [0.Q#[5I=
M7]M!IC)VL]%M8UJS+1?/JE<F:HU;WS?:RIE]D-^?._9:'GQ(3M=U\)EI4IF?
MXS0&_WJX:S[8V7&VY(RY&[6VS%Q&B*C1G HT5)#IL_AP"B-'ND[LA!GC=Q*H
M3%U\R+3PDX,7/*!?L!\_TU0QU0<Y<?HO-8(U_OFN+GI/M@KB&<M[EME&#\N,
MCX],#*W";WATX7CJ =UL_AMCF]E)?+Y!Q^G^DO@@7 ,C)NY9)JWO*8 ?_N&Z
M3DC<'UMH[;"5N#(TGM%+2,%TZPE$HK9(4]FV9/"P;A7EJ,OHJ& 44Z5SY/06
MG.21%ID.I/Q!?V/)J[8G)HU_?9A7FO=G*0+AM#!B]-;$?KQB^HL<E9=>$*8+
MQ-L)&JV%"'//#<__:+X(1_#O=L.K_Y_.%_G7&C$+(2+*#+B&!>U_=M)O)8V>
M;:LU?3B)I 6V^C%0L:ECI^/C,5&87<'J8P8SW.ZO!X?F)C'W)UM_$?Q2I-Z%
MVHQWL;EKFN31,6T8^)AWTU>^]BDU-"J64IK>(W[Y4.KRXK>5T<HRG?#'!H27
M@3Z76<4C5QJP4\DC)%"#SGI)>FD-2;1,#K=7J#A<T6:ZU>0!S47@85L;J06"
M$_APZWCBL_E,KVMEFL-W*87#Q ,?-N\^](H=_/4/[6/Y!)A!/>BTL!=R8I/A
M1S)J6G'%+_-QYNC7S]=Q8?KYX?W<H$*M:DJD6_P2O1<U9;#4IWVR\F2=3&C
MY2>/IY\\GJH\.I7ZP3"3_X6S[?,_LI?VE<Z^@%PW\X0D.@0]65QS(6)P?4+D
M>R!I76*&RM7L .8U[<PQ;87PJ]D/,XP2/Z6,+?$5IH6!?_:&-V #L'%4V%_"
MXNU7ZL0SK,P46,9!O\.*[N=T+-8QD=OP!H B6'.&'5T39X@-Y/@QQ"I\&+[;
M9K&-+Z/L.:+C3PJ\,X8R=9^FS,LXUD9.57-7-.L+B=J)[+6%:?M3T;)I#>G'
MI=34+C[ZJEHJQ9Q5EJ3=#8@+&+GBNMBD4VK.4F_O9*G/4TPW;/(+[J>8=')J
MR_)S=R4E;'(T<8UQW"+UVT2">!OQ7'C4\\V3UK1*@8@$3T;0VJA0QT&RM'EG
M(7T0ITRYP!V7>#MDYPHFEM>V']P- HR:F'XGSB=*1]#IF9>?#U52ON>F;,ST
M;=\SG'NGLW)7N_E>0V5G*GUZ*A_%<21I'EY74:>^?B)1(N(SGN(X%TFT"%W!
M?"H3[(1]^=9!#AV2Y+F^ L^R*XV'C20%[]VV<;;4MB<RKEAQ9-I1TM!I7*VH
M>CM5(K=_-LOR54W?,UP!FWRG_%;5284],]P%AT%=7S]'09?O]C6B J/TLLZ5
M\+Y$0N3YE<X\;%WN]@8#O4$Z:P"G?S!_;[MAIYL'X6S94COG[APTEL6:JH(J
MH!_# T]S_U_X)V+YSY;BP+0F]F4L/^.4.LQ2M6/X>F,AXH!ACZ#)<SW_)N;G
M,<O[0L25<.@@-WG*6H#< VMS1?YC8''A-SA\C3D'&I?_!*;<$_[EA.AY9KL0
M(8::%")&+PM"@S=*9OZ7;Y#^'W]!?7L >XP0(>)#,K&?R@U._3G6QA>;YK\,
M)=S&<F&!\78^)V<[&/BW ]')"Z\;=[,P'53!SNU"A.H%/I6ZN&!T#)B_6N*T
M?!D)/0B@\C;!7N9-CI82.(AI)?H-EU_[[WX&Q1Z>/A3$"5ULXRQ,"!$L\0DY
MI-A\XW%0A2/3#$@8JA?AJWML!@S1SWT:D4.:P17'>UJE#8S*GLW7.)_J[BZX
M36\J6G"V7$SO/D";ETZ5?*+/P7OC/VH2E)T.][?:9N^K]55]_DE+LZGS6%R*
MM47;B[D*D7M/E?>INVGJ1E)XR7-H@1+L;^^F [U(?@S IA%@\/[VA/Q0B+@(
MJZ,='ZGL$)C('W\BOQ@4. -!U'4EMA+W&Y]"5 6:?A<B<("\8!"SCX+>A/=C
M(I,7":AB[PV]%DWU5EETE*8F),40E6@*M^F#^5L2S&]WGCKFBLN4JOCT;#CG
M0..>>0G7#S>KTRM$GZ*LTZ=7 ^H5-*05'3S-4Y]/JGTZ]IQ?:&8?>COZQ+>I
M/HKT@UMK^J66 ZE/4RQ'?2F.2SU;0!N.7AM]*_$P#$HM;/@#RSHE-4KA%YH!
M<8)"B=3#E(Y6P<[AFP3CW*]=\K;O5EJD"XM==-CEO6&?8^/#8]_/_^NH#"==
MM8%9\X*(Y@+7@U2V](=X?V\+/&7XO> IE7D$#:IZ\G<+$5]@SA<M[N@1/,@$
ME]>0,-4_>]HE1&R_"JPG+&RPL-/%/RQ^CJ\0%2(F<DGLB]1D%-L.F?R7X+,0
M09'*N!/D)_4%+]="%Z-8BT(Z?9!Q'JC2(MC+GAXBE[C0OFWXQ=4[35IZJ_JM
M90/.0U7ZM^I/AQP:"#X9<_>DR]6MY1BS-(]+-TD[URZHEQPV2"E3';J=9F;E
MK;8"+\_<WG:US\[&\/K,VZ==#C3_,**N6=[@8G2"#3Q80VX!:YK'M?N4*!D.
M[.3[%&N)N8=8TX-#Q[QEMQ7ZE(Z8ANW2=K'4S/]*.U<CWN*_)7E'<)+7XUBW
M]2;[>W-U*Y^.155S4Z9#OE?3=F=G1F8"_GQ3V(S]@67;]FS 7/JR1R!GG4SB
M2^AR2/.*L#HZK9\A$(-%Z_=]PVLT:I?U4H80<9!H][==RXF76 H5DKI-D,#2
ME)I0FPFRU$T]K>X3:R":05($@[RW,T.AW_*Q1DHP/TXRL:UV85P;]H]SLK_W
MB_VE*>@MB2S'AG'I[MP50NSVE$CW^;2CND:5BY'%0RKFCERC_M34D=Y"/V97
M)C2J[DR;=*24!7P__,)E-$VWH:[F"U1(OMG*6^"B_M9/D49B6XL2)^WYCXVT
M?12EV$MESTU+\/D,8MTN1770CKE0&*<>IA5,W>QS(/*8@FW$^=]> WN^J9SC
MN(;<;O/U(;NTR1[^KBU/TNK^(S^AI3T@CJ)N^K7",B3Q/,W1VLTLT*Z1<X,R
M/U#(/H5)6T#50>6 "58,F%A!T]#F?3=9 @U!.V8;(;#B7*Z?+@9!,.606W;N
M?(W8Q.S3Y2LQ6ZN3_&NMP<RO)F;\K_Z'18RLR(@_1HDMJ/O%B@]+S+-O4%G?
M:E$;9@.O^JHI_:N^Z-J>[PH<I "IQ,_3M3RT1&=8+V+9/DVR7Q^R*@>@"(X*
M3)=!"T[MLF:4R,TFH-VI(>319T.::>?7H=XV-==-]^+=1H^TVB<[F*<9H*>F
M%I2%B#]?XN<B,W'A'ZA-ATF?R#^'CV\U_ME=?B)/=D"&1*&W^V);W23[=9$L
MC"ATF#T@CC=EH*/)TJJ^C/H^2#Q_W5&/5E75T#9(453F:&0*$7'I0_/,WJJ.
MJK1<<GE7P,TZM<27>'RSKW-PX?)P)DLM9=#TW/K^KIT%ZU;.::4.8$[V 4K<
M.HH4/+]/UL"$7 H"#OVZK.UV SJ6@><&-*I\Y2[WH6\%C3F='PP:?;RLP[*^
M,'!S*F:IY>++NABY,O71RWEOJ][&Z4^DZ(M?4MG;J77,W";%_Y&SE9;FY:*<
M1-U\:Q/*UB*:BT\0YCEJ!"T0:^(W-&[!VYFS,1W8+9 >OSPH>T_?R9-(:;!V
MTHF-;"N[?[79I8V,[V]Y\!R,:#4R?EV.H1ED_%G 45C]<]S'0% 2>O#U!\Z;
MI5\[.=K!1P;5)ERSQPR\=0^'K?1G%^[D)EH94ZY*Y8[L\CA?9JX6X@*A9VLA
M\35DZS)H&,_]<Z@>$^'!!KA:H"7[>VL@+>QX^'(R\3!(9A:1K@:\4Q\7W7Z.
M7=,<\_:PWBF*A+? /F#]QBSKH5(36DH1T=QN-OQ1??!N>'/:WHN^0:Y]V3YA
MM).^M](YG\99.@T>0/-[Z!JH#;_$,3[52()(,SK*KZM:EL K39+;R7L):,[V
MIK8^@>ZW1I6!1CD\YIWB;QSK:$/7#=2?AC(PNK8#8GGLZ!?9I7B,)4^T.H.8
MKLTO<Z(.^>KZ!MJ2',FYK;>'+F.UBM--I(Y\\0[.=P/#SNAZ.AYYJE\Z4&9%
M/NE]:\E\P]BX_:B-_N3]DGVUF>96AHTKO>K%UU,=O_#E837TCCI12%H]"_MZ
M$G2<A,)L'/)Y_^]HJ)M8Y[2.X_<)$5/)LW+<7'Z>H2_/F?@9D,'@,/<W_&)T
M  7"#4Y.\21)8HXH\FI0ARYRR;NV)/E3U6<-W0;/5N>&%UF['TB/:YJZ#FJ]
M0S74/TF:W_BJ*)VS?>?9'<:?[%^N3IJ+Y<=G)80$^"<H >?;0LY//WTZ-<4*
M62ZB*ZW."G;\W#5=X+\%)K+&Y:UCC'8-0OH<TH3QFS<&F"9J@LV";%'\1,DR
M^B"U_BT8R!1%V?=!IHPM]769,\R%,Q9CIDTK5\;I\^XMZN5NUB5ZB5FW/[ED
M68S:)[#!;/3]EI5V!XWRM$N=QZ(MU)75U=+- E?*Y&Q;!PK>.A0J/HP\)3O:
M[Z?$];L$.Y8NXI%NQJN?0YN_.#&*GL#.I-(\\84/2A:R>8&_.2YY8$='],WZ
MS8PQ2]_\5!\++\+UOH]_YKF-IAS$DI)CP>"37<?*Y^B,)$7Q[+K VI1$UO#(
MW&@N=3B;4D1E:QHM.?QPA4PX3I!,()?/^<&J@@-S!HQB)F\!A]NIF]"&UL'L
MU(FE5[GXF"YN./L:OJY9]L?=M?<4(6(3/K"-)EVC.SB3QI1[JT4PCIR4(\E@
M>WP*FDKQ,3SSOG+*^\8D>;UTVZZRZ4>YMFD:YG?);L?BV^RY@8GG:VQO/PKR
M-S.VL^_S2]]1_0DHMP]TD'-CK;MSI0:KJ7XG2?ETSEX92+)2<!]8A ,ZIG]R
M5H@XUQV&^G<,1![V%B(T,;58Z"'$)8Y0JY);_48SN(_!?)X#P:47DGE&. M6
M13(6A CQ;S\/;([YG6?[)N3(LH'8>HGBCCS<N!)')EZWS(MTGCU$TGQ/Y8@5
M'LQ8N6(I__#T0<?/?$?LG<+TB6\3S\T+2B[:7DQSVF=/Z$\S_<CXU33LI/-.
M"_G^K!(5?>>E4=\\BQ73.0"2&!6(;>:_ID[ :%CY ](&WO7$T"OUX@UW&?HS
MK5%:)1S/)I)D58^4%IEY7^>Q[L[3D1/+"8V;^S"5^Z\HCBTR?'>-M:]\#1NN
MS#_S%[A.WCF]WJB^@,]\TQE\ZI%JP.<2DR/34:E6@T?6%/BLR 4OB@GEE7:A
MXOGGNA'SI&^]J]8==- @5" BRC,F[ (_\##@,*PZ%_T+P).3L<UT14B)<Z.8
M81U+E2VOMRX&?9CHZ"KK7Q<RB(KU0QBO4Z%FE*&*U0:W><MCLS:]P3Z'T=+[
M;@4MO'_XC'@!O74:?\$*)675:.1P9+#$Z9ZGD]C$K+FWOZU-<]N;<;4Y<ZU1
M'==7P<K[C-NE4_Q#;$?*<,NH3WK1<'@PD!*@7UNFLXM9"8AUZX6,BTTCY%-&
M/D3F>4MOI.5=:=M5O?+AYK!T;SFGS?"8H7&:<N+]X(V1-JL]431__Y#Q/L>0
M=?DRD\RY#=1 ,60"*_>M&D)$'HJW2XA@4,!U(:)7&RLCR)T2(E8EG@ 3BV@A
MXF@V<*4,H@CF@!73:3B:Z *1==[/0PN.TZ"Z'BS$27?&83$7+8YJ/0_]1MH*
M:4_VB!4],SJD=V<4ZR<.-/MSU)E*X[HUT&^RA_N 2NQY%W^C?&YA@_9HEK6?
MROO;80=:-90O6%J7\[2 <JM'%;!.0:M4YIO36].6B>E55>T5.,?I&1O7FAHU
MGXA0OU?K#FXC#WA20L26$5BA,(BC*/:%AN.3[T@B:Z1=D 6H )2X>@]CMA U
M1N8S.Z)U$JW6:986#NSCQ07>F:;WZ\6?>^^I&\.ZS#DGY,@-!&^/M'9DC^<_
M/_J6O%F/\;'NA'<A_E.2LK+4@V<#-YC5B<:'.Z4.U ::9J-#M.,^CZ<?"$I+
M>PJDK:ZRUL-0=7!*;,_$K^(L=OXL.X5^HXT/BCY'L_:5%SW">NWJRB=%68>4
M8F?L#1:D7/>'*$42AJ&S&WI"Q,-L*S>Z0Z(0P4;[^4&/OFU\%R)(L#"&/0;+
MNBD95*-#TBZ3'9!4O UXU9=CRJ"V(*,%(J!N&'-A&0&&OO,'4WB7>*:)S]BL
MQAJ]N'IKINB-^5.WKJ)B@@9>"3H_&^KZ^**R9YQ=+?9G-F8=9$#'367'FRN\
M!X^*9):IU<=A:F>GI^X=>.O4N!QFN5Z1%#XX[3P<%Y?(\EF#D6(QN8/V(P&Y
MF@KCI[E@"^'BSZGG6[B<Y58A0LX[O+ F"N.%20RO23"2PA]?TE9(2[_#4%#L
M>&= 3V)MN9]JZC^9O-LKU/G<J[]\I_OJM^?..[[@S)\;GGH:^"#?1:?0)-.M
M?V=,HL&@-#1X<+XY=<[;/R5E(?RUM?M@4UNI4X2Y4]R*,W9F>"+Y6RHWC__,
M$,53$WPBR5*]EA4['S"P42@Q0[M)ELE8L4N8+HZBJ161J-*2;GM"G5_&C'3G
M85IJ#2\=BK2SJ[QS&H<@IS9=]7;WQQ.4T<GBCI+I))%4<SM@[)Z??DC"Y7[5
MP\8?6)+T,;X7D*#2AGE@I E^X.@Q46UTE+=F&3C)3$Z$'#@[VV7S;VV_R-%+
MJ.I:WKV0<?5*]D.5@:J=3Y22(W[]J_P/AC%PVJ901!)WL> MKK=8Q'Z2)LG,
ME5J),[TWFAH041/ZW:@;#E8G8GL&O8;,FN2=$G3/],WX;0?CVW?C4YE58]0G
M>_N)XN!^Y /!;YW#_I.+,K(OHHLM&=G2K$]-S%.A)G]N3PE*!+7+FSR>W%"7
M*3947;GH[.-6_-;,I=36.P#[89]1S",<S_QALL4XEN$"6ZSO7K!"Z-JY4T&M
MO<NB7X-%X>M94JI?]B]J/(L;^M3>_DFRAE))J8ZVE8OP\5)*VOO;@SV'KYU+
MTG6XN'TB\:W>H5'?ZM&QFCKB36[/"IQI42E47RKH0P=559+KE1D56-Y96#P7
M^^B]0VXMK!]=Y?5(>1G<&\;($$SWJ.(M!V>3<WC-79%^2BTE7D8[V*R^W6+;
M%R'EC,BSAPOUVP=?D1<<= ;/F*GM7O8P[Z\$/6R]5HXZZ,^/$([\</+ADSNL
M4S (]7FQ/_[!C=ZOS=2LGF<8&,@FINCK9VI8)"$B!,[.BJMLM<;4>\!4+NQ"
ME_Q@G>2O8J0.2OQM"MP;TK0>MEKQQ#_W2Y7_PMZ;0+.]]7OCZ:@]JJJ*HN1T
M4$71@6J5Y'1 24E+S26G(Y&2JJH@I%6JYE/CJ2E54]60&H,B)8:BJN:B1)*J
MFBHQQ(\DO[P_Y[[WWN=]UO/<]WG?>^^Y]_]?[UK6VE96%K_?WOO[&?;^[N\F
MY<8(%"@BV*%X#DF8M'83FU\/CCMZ D*%K[09.<F5"TO_5(U$"!]XGV8"9 3V
MB&#S]QAE2.C;$9A5,FY)*!4L@GG329\-X4(]Z?JD)FTN\@.G[?N!/W-[77*J
M'=PF%,'B$XEW(9J6!R +F[_ NTT)8W>N2#-I,[<@"WS9,_2V.% B@E&@OC=[
M!,;TK:A-P2=\_NF>9,[:/<EN=TE3(\ S3/Y=.4&$)YD':=PEY;!O[+I#I!#0
M95X5<_]NR)]YH&&$"-%>['/.'-A"V2*"38I@Z((I$>RG7*$_&8QM"VV"<TT6
M3/C^M@O/Y^"=G8(]R]!8>@-03]P8>(<17DW?3LD;8ZS K]&F^U77=MZ^_<OM
M'P[E_%/_8%K/?U0CMII JG]#G@_%/(3S#(E^(EA?*UM!<".2]C4@#!H6.[SP
MZ(:!!M)Z1(E@4+C!MEU)]3]VQB'O(L?2R!P,9E@:W/J<(V<I3(,8Y:0PN<9I
M+ W-TGZ*.&B>)[C*\6D4^C1)X>H.= ET7S+LZ_W'.B.=UW4_B9&AAA2HE 4Y
MR3I^_N%2B_7>RO0G:-9YZ3(C-WN&V1687W72#X\_-!1B=C3TL,HI5;??_2@I
M#"R_O\1!JW;7FJRS>^6PW(?4ZG:**5J[_:+^,XUS&1].DP!_%F@/@!*!38D*
MDHTQ&PF4=PXCO##.-#NJKO16%H%^AL;A97MGH5\%=OFE!>NGU:9GZO3O')VL
M#DGU,97^\GGD+&4#Y_)89$Z(FW7&TP][7O7FVJA;W_U2=.5K3GQL@]'\B,9@
MKGNR)EN];$#3T+IB;8F'="2!9_(S-#A*>H\-L*RY4(0FAQ%#7,<*\*\/U.,\
M*,\EQ#2D:W+J\OTS@ AZ,B_.2^G;\P+7ZN84W5I>2IZ=D]$>'O5!7)/.L9<E
M)_>]S-;WOJ9N?4TA?D)N:T_JE8Q#Y2[R1ODZ_5&ZUW)ZS%W[.^XC7\<,EH+;
M)X7E"%G".7J=%+#"03.1LVJ(QSBEJ)9H$:R\/":8L8.(VF@B]840OG"VI\9T
MK,K[LNQ>?Z'JN^3S/C\]Z_!Q\21X:!4%:LB]J_+&MA&N&A'AQVDE93C+T/A=
MJ6XJ7Z?:1@X7)-WT+#55,T)U^%/F<3\N5/%-H=X>A5=@&AE;W=+EA.EU&P5J
MPN0Y;X)6(;Q%KWHTCQO7/'18NJ&KQ9,9VG\?OX6@WV[]*,5O=#IP&U>)*CZ.
MY9B]_/4-<6M25ZI+>&-_\Z%!OLINYJ39R,%,M5[/^:@+?F_23[@[2%U:H!U?
M<8WE/U\9YHM!__0=A._(F75C<^&@-&=S!,>*K3O13(X8HC6+8'!@FA?1#9'
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MRAACALUELP9""KU/+3I2UBK G>&*M21OJBC%X7'>7EF=!01'^E!1VO9<=US
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MWPM\*(1W?PV9JY"V"K*&'JUZB"'8-<>SPPSAT<)"'<ICV5FN8I,()DEC2M0
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M\AN\G2*0F08EJ,)4))84JGP,:.7O%!AR!MXAAQ[3DYV@]SI<LW4,IX'<)C@
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MF!Q^*(8E%A)X&.S!E-DVH==/3IAR3!H[HQERB)\)I\U<TS?W&&BPM>' X\9
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M>?^@+]K-H$]B)$!R("*)7.7G<Y-!A8O0=MSH5710,(YAQIK@F<6T(MC*$\?
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MR%5YIAZ=)UVO^YJW--F?9H.V<TN_^LG$0MERA%C7.5W&.?BK'^T$T\31;^3
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MZV/ "2HTS1Q^(*[8Z/N*@%V^NE)ORGQ7:)M%ZND NJ:G(2RUN&<%U%?@U8V
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MM7.PM^FZXL<KV$JA53NR0EC,Y(@0</[ "XW1,2O*)#2BX=0-%^%T1[_?4.Z
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M0%^\@\9@EZ=+]F!/L6-!V_!$A1!')'YK@EM!4F0(G>!U3E3@$]$7D<9-#:=
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MG$?8K=;+F+&(Y+Z'BC'%YDX4PP'[T94!]13L!EC"+ZSYD [0DDYF3VRY3E3
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M_P)@?&""E*%E-O?&/%G*&)_5.T?+>$.7U] ]OKF\W]+;IGW\W=%,;:-8'=T
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MLEM(TKY5[_8_E(TSX'V&.<>_]9F9.I8?D/;]VV%R]+\ ,4HIWS&D91WU6\P
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MH0>V !T?EI4@59(UR/>!#6+>M6ZOYF&#4C=4Z%P]J)43VH0%LRE(#F1PF_!
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M"C833""T6HL]-M27=.9Q#K:?3;-,L[X]52I:4]<PW:T\PF@M_AW/27VF)37
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M!T^Z ]^]+'#\.TJ.GTWW?06GRLB&)7L<I"/O'S:H4L(\K$#&(BTV>DUF7]_
M^"!OFHRM0O&P090G;! C"M6IC5J;I[6P0:.8.NGH=!)MIJF::[NW(%J7Y8::
M98/H'K\O<2*D&>;L7LDAC<& NX:^9K>5:'@7/IE85J"ROK%U_!76AZ2I&9&"
M(4JFKT_32K_-NG77DH\,+=UIUMBDI@=]K)QIB/B*:-5UTTE<F2W>J'G%!PPR
M5!GH72]F$1L4"/FZ3S..EV&60F"0&,*)+64EWCUT @.V&"74W2>*2Z-,.\L\
MO]_\GAK=%(CE'EL1E5Y5$+2^I1KSVX!?J7^1\(V"2%RE/<9:N \9C+T=PPK_
M^(&VL+O$EVB%3O??-K '#BOR.4M\;HL,HVZF4_I)^(UB2A<;U-="*Q9*+5QQ
MOS+.>$Q9GG::##1PT5<SG8Z6!,RZHL$3&CR_PYQ7&L-RJII$4W;?.3KV!SW1
MNPH)B+XX3)G(]VL.];*0WWX44O&^-_";[/!CDT .29^<X1?=??#;=A'5NMER
MAWE[,@2GXC:V)\[O,OY0(U_8\5WKV%Z4I%U=TX1ZN\W=":4?]83Q!G&#S>LX
ME2J5 *\LXN;PLES 9L"/-)%BQ/<,H"90R52ISPK69Q46Y&\[[EQ64(YK$<4L
M<803EQBJ4Q4IQ@8=VV7B&1 R_GF.*.(Q+9R)W86>1?S\4'"AT0YM1N%[A=0J
MGW%!F@-1_]S$K.I=*VUZH:= AO(2R=KU.*W>2E*E-JN?],LKFQ;(/RR3LR!]
M^G9S#4+N9J;37KF%571?%8&@;-(5M60^Q#!.3RPJ']*N-(HH'=5H<<L:BAJ\
MC7*!4@)D>N%Q':*<FWR3 1K5,Z3*?- Y4>>U"'DU_W!, W\!"#>=V# 8I6;W
M98>Q0;!W'1-_M<2,U!?PO$9^31]JRI%+O_8Q.5HXZ9=#061BANQDAIN>1JGH
MXPRW=[M3*0J^DQWVNH]PD2?].J99V9('^M95A1GQ]J!*N>.FJ7_?N'C6^,]7
M)U>@4B%Y6R\84)(*EXO+'-#:*R%.P>5/L$%>#:U4B:8RW[!IK<N:V>NTG=5P
MS1IS[9<2EE<T87KU/K,-)L+<H?(PB[SEJ=5SP;6[B6&\Z)_]+$Z84*&DP&:Z
M'JO/ZA?F?-L?529EG$QIS@8]X/6\AS:EHA-"N=Z-*:H@'^T32\E$/]5<-YU/
M(J*;M$=94P,#WIE_".ZY*MULN^:4H"%:TV'Y*G$9J_$$XN5;B7/YE875O%3M
M'(&3'X=$[8(3P:<9-F_+4DGH%P7'J1(XJ> AB>Q_@*;_3.Z)7'H6/B3O!#N(
MZQTTYD:.M?38:_Q^_0RJ(B]87@T;K3RY\<0FPR$+)Q7B%FX<ZG1Z(9202.!I
MTRC_YMLA":0N@/G6A*(MB;OY\#X)B;$&7:N@8PX<7N_[OQFA(4?L!?)C]M!S
MQ]*[?;_Z';_@M,MOIC@9;LB.YQ67Y:CCRKI:-M$[<#8H!KL7)4,&,P0AW2C*
M4[^<\%>0>I3W2 Q1&<,&G8S;P[\TI-5H)45+=I])]PZ!P0V'2Q6G-:G&GF?H
MV6D(J_M*\D</YH_WV=8ZT1U;['NGTVDONT9_%%<N-V3E;A0N>VI4BOEO2F.!
MTD*F[>'0>]1"'.$D80'#N37BU,I%>&P]'SAZ-EIN=&$J=(M_E7*K:F7^J(U]
MDTGV!PCO7^^=%$.8X:8-?SLBZOJS4C4;*E8#*E9:-,NYXB1T_4<2R092^!S[
M\OAN"]O:7V995]$M5+WJN:E*Y_<F:Q;97<4#2\(:H=,)W156YI43_@Z,#K,F
MS&_PETDF,S[3,[Q\-;LQ)S 7.SOT).HM]%NWCZ<7#"Z2%5G96IGPBL<?<=D^
M#5:6>CE10WF]XA0^TZ0QPR;@5YI#P*Z)9,FVRI%HCD"OZ^\5C][IPISNT&-<
MX&B^?!V3P@D]C07+1 ,N:AC!4ZG>7+_'(4<K86_HEE5#VMPQ6)D)+K7HI;,Q
M]]/4=E<)Y5B!-8\@@;\V8).%UGGBM/I2@89?IAGNB59AOW+"Z!P1U]=QD@+O
MP9Q"Q'R GFU3(&U=1$CVYKA-O22C3@)UQN^F&=?)O)=I:H)SN56^Q!)AG>A"
M+YV+)O#08ZF-?\QF'O.R*#55BW.VR9?/(&;(6%CPQV8-JZ;D^'\,N%(U!EOQ
M:?J&RN%B7.0D^&/>G 4MY('Y&5K405I433MT1G+Q57-XL2_Q^.0DK3R4XDEV
MM;=9W0?S^4SBY\AK5A3""_56<S-7 !6%B@RM,O8O023=F)P+__(P-#^2=D:0
M?,I[0B:A5V-O7=TF(\W*,5%KR<[6/C5/O-A.JOC)3:LFM61DF_EQD_);"Q$N
MOZ%PB_F@08Z35(.WLPFQ!)HIZSH;M-H^40&,L&YKHP^8A[7YHT+_9AK(Q$V"
MB+[G$B064\O5!8U%U<,WC.FV,&>E5X54# U+!3]3T7-:U&V]0&C<A1]GZ *6
ME)\D;$*'N.]^;TDDBA>W]2R0X842;YDUJ5C+H; FZ ^<SSQ7U*U<7)ON^NN=
MLKD'Y=[;0G-(F)W\5*6]W0-"P:2@!D'1<W,VQR'S9+FI2>18PWR:B?1*8>\A
M?!"6Q*"4>RCZ-3:(V,T&V6JA*^_FLHQ^.S"3WT$.TN_D$+HXE,;])QM44O<[
MEQ-W&J@?+UC?H#0[ S[4JO2B*/T,A U"#*+6AB79(+.2X/_9/BCF\BE)Q/!_
M4D5.B?_'2SYH5ELO"%J .[.X )Z97?BYKL4Q7!G 1=E9 ,<SW"@Q"Y"XXN=C
M,PQ#JD)?-!=%)C%:!1A5VGC8@!(!BIVG\?5.>FZ+O($_![1X^=Z<>',LR_G,
M2Q\.CNJXO_%?):\M.\U=J9:WI5YX@Y(6M9.WZ1ZGJY,NR,D_2OS]:<XZT+Q.
MNT^@J*CY?MLZ_N?R2'L(\Y;EY+IBJ)O\P8C-V)ZN;L M#MVBOX8_U.#A^6A-
M'J;U;<_\:&JM:VE*N[Y1_5?:'9^X,<?\U R,$E:(/&ZNJSZ9XV^4\VMJZI<O
M4H63TT4XZ2:"P<_YS(@>8EUB8J*O?F@Q_-RDV3+?/?*2&(;&^D5?!1S(=+'<
M)YY4X;@"^D#7JN:CH4)$DAG=KJ&Q]1^HNZ.EE"HS;7-\;."QJY%ETBOYA+:J
M1?N8]!2=7:)_5AC+8>NF/;+69"-DI]Q"PV. 95D1#<TNG$%>H\#7?3BW<PX0
MX=S.IH2&D9CY.H<NMR-SXOS=UX#I/HFSE+-4^Z:+FO8MKYHJ_0LD.T;1R7I!
MU<,!@0Q#W+?!T,K5EKC/P=^:MOY,>8S3Z];JF>PQO9#L]L0 1M<)E=\VMB^^
MT&DV,Y[8$FM7+% O>@\K*.C;Z]N"NGLP:#)9CXLT&]]KY[$9W\,)V]<U3H3@
MH";MG*]V2\NVES[U'>-;ZS]RQFC#JUPFN&I<:=HI<FB:S(.__..M,J069=\/
M*(\EIR<73:6HKX^[%?1B\CF,T [S5>$#@6+%][6)_//#UED$RH( Q,%(^?Z]
M\W\P+#7:";2F&(-KOCI>0S]CE7>_&]TIB!37ZA'^TD^""G4>_7.B3:'*+XL@
MW3^C'-#NFJY6GNDM<.ULNFW>HB4_#[WAZC;,7*,HD&<>BXH/2B+^&L9I6)]1
M\H>'#[A!%G[[HM!)Q49#8I62Q0(AH?(?!\)J:__FKDU]7G+D9*<@?924\K\R
M O&_!C@\YF;!#9XRU#B1DXY:XIYO1#%G\:R&A \5!Q;GV*"T!([S-!.8-WKR
M /R")>L[&S1&1F5\C_Z*(/T?% EXC8-U)_;8H(&+J/L0.G^')&J5 F"@"51+
M!GH'?/#;C VR>ELP+ 8(,,'+P]DL'@XLRL8QFPGK&2N8 PR@B8V'_(C*8H.F
M5U K.3$]J!-8P'+;V,['Z[;U<(]\T?//GRT$[8RETI^"1&2>09LEY%BI$(H?
M:OT:-8'FQ,PT4&<\!"9)O)XD6C/=%FCM%&;Q4<)?[FX8&U)M(6<,A%98"C5?
M]$QPOYSSVTN7DPODIO0"R"[MW,35.=TD-HC/>27B #X>FJ]IS$A/J9._\"U0
MC#<ASZ__*'=BZ)\3A1O^+8'WDHM#E>^,/<^LMPX4ZRVH/I-7>.('[O-DMHOR
M&O8W>%*LQ2A%*KE<5"X\_)+5.2.G-Z^.5#PUD7H*^D3ND%V##"K0[@/-18>*
M,.9O!C\5TZUU;Q[A0G9@".3VL)0H^1MM!2'"'><GHV40S^$\<\:ROQ^XX([2
M=:)68CTO^785WH/ ^NYEB<56>"SC=*[KR0T9I*><+,=G5*.O\)H)Y<Q,A.U.
M]1_D3I/[JY!E! Z"NZ!G(3;,]WOM0OWN0#_X ]\QUH@[UT2#[@5L.FD^3D]W
M$9+8H4HUW(^72<US]NO0SR8;%J3CH%)RD2=22"_J!Q7>5H6VAQ'IK6M[4ZZU
M7S]U\^U5O*YX"2$/V_ZZR>W_&Q8I+(MKQH;A+Q"?2(Z,P",S#9](S8Y/L4'/
M]KP>9:#038SSXZQ3HXM;@!QA(Y*$G]GIFAY'^'3F(+4,K@.CU.-_.B4\,Q#R
M;<F/*VA >0B\I;@!&*?6B2J]ZR1Q33L$=CK4S+]U#WU[?"^RU7*NKFHJR_)9
M@;Q_00!=45_E]V]GD_>]M%A;U[(#(R65)[V0\RDR]GZZTE68!ZU/=J$_T'MA
MS S4 _C,/DT&T"7-/T/5A7?CP*2MIPP(MTC6\"4# CG_K[[R2#)&%$CTTL$F
M(JW*:[?:)O=,EE,ESZ[0SLW [,-THO!D[?5HA6MX10OEJHJ)K.^73N[&::N$
MG76[W.XV&T"_&@NK=I1*8S5L(K@VY [KX#E0&Q+]$7*N$#"DWV9-8LZP)!AF
MB/4'K13?)JI#4FC^<0U9\^$"I O7,Z0N^0'%9U9)TWT6+612+*(8J+AE&Y5&
M&X.UO'LB%( NWJ"\%FWP7?/+QEJH-J)GZ$[=1*<5>H.2C9N(:J7%F;$<RR:&
M9O\LX0R'Q!XE[S]CJ!UV)TMNTZ#RD/:3=]]KX+F!P2[1WE<$TA#*M/ECXL[=
MR9 5;'TS.J)--38]JKW'QL4BU?66HLGR9+$#GW6(/X?7U,\KKDPD)1=-&PNE
M0Y<:X\IRS-7'9W!HDB?KS#/.ZO08^H!^,2<I'Q=DOD&"L8!:=\1TDJ+>=;HY
MPX RE/"U[;H'6478?9 OGJ7ZZR#TO9ON?Q)Z)/[,FN]RUWY78V;&,W)^S5UH
M:GT=4M^ $H"ZLC([F_=<;[$^]9E/Y,DU+ZP.S04*3!,2TN=<4_=7M,(*17H[
M',>-3R@_-R/VNKB82\_[[&\MC_SHIEDS7[/DHV<@]2I=(S/%"XW9)\JI_&3"
MR\M?0E"-GQ1%+=!>QQOZRLE\ O[[]VX]UL F(.5(:[PV/1$;GX6FM:[!G+U&
MZ^M;6Z\Z#^Y?^.9U^H10H\HY96?;2T,*@7.CL0Y.P^8W>0P_3Q*=\^[%E$N?
MW&2#\!_8( <"< 7/.(^G'?;#>8"4>4<)[]PZ[;1&$ B-DN\T4$ BJ"<P_BH]
MX!?$B4=]TYUPL9'TKCF>Q%U=!.I#CD873,?M76+ 37-XC^IJ]"6.^CHWK-;F
M'>0VW/9-UI#@$9?$G)2=-U>W*8<GEF3.#6;)&48*O.W*"!#$.[DXL$%':V?
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MYZ%%T/W@HS7U6M#76&&6A<BK?':=Q>\C0>'R*N5:T+/(?%C#2XEW!$,#"E3
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M);2K[,G58IS=:4NI\<:B;\=[=>P6$^45W$RN4)I<5N:7>\\&6'[M=PFN^MF
M><NV_5_--WA3S:HB/5*+SU3K)@%Z/$ 08UT+/KT;U2*+:;5H@E+G3LQ.]RQ=
M#Z>H.%%#7E^A-2\^2THW:1B"5.-F_S+5$$E0%#[,R/8Z<;_>LDC*CYR?TI9-
M7M8=BLO<L_RQ^?MHI2\AQPQA_1A3THQ6#NONT^]>JV4:?>&,BF/7)Q<D#YM@
M%U2C:#J_ >J%R-W.*M^8VX 7;:'-0Q:(7[#VX(+:=<0C;3LI$68=]JSKHP06
MC'JE4;#OO<_4\W=']M'8*T0I_/3% (7Y=!<;.^?0!UZOT_1#FOVJHQ2?)HP
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M25I(SRAAW03$C%C$C&K@T2S9S@TBRE)L&:O(=<MQ95)VV-_3&:Y1';LA1+0
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MZY@*7=>=49T5/F0#B[ART':^=/_F0_/=4 Z4=;^VMJZJKKZZNCYJZ//0_HH
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M/W9/$]/T;9CWN748#8]IW(0.ZSW#/?,WR0:?:+@?%8>5&JZH^,LL .7Q"N/
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MPB[D[8;_6I(,=O:;1D&Z^8^K5JHEETTMAK(,5[S,/I42[J7/?8]LF26)[>B
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M0G+W1RC7*S]*@HTZ /0893Z^"VQ=.H(&B3,#_TI4IX "*8[H,BM\$.X- \\
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M;T[K+V^/&F:JEVK$2KL?10WI6@3P]C-55,>RW/Q[@-E^V/(H T?#Q;0<Q*B
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MJ]E,&$M%$.)^8)_ 4.PWO!P^S8<\!V2,3Z)M6 "C.W$S>R+7 ,%(=+\P9.A
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M2S._W;&I>;:X950_T"DMQ"[M52X=+]477[YH>E7?PBU"<6*@8"?_(SD&/EV
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M3^Z&=:"X[C"Q909/$%<O>)Y\"$(96-(2&V\'?LTOY(SO3LR0(&@Q>F9TZ(!
M(<4P$C2-9U-[F$9OOJ)36XT-&%-)]/7]8&RG4NSBN:T!$3"J[\9@+?)F0WW]
M!]<(MC+->3KV3M2U%YGM>,>*@R_*KN(MM.ZL'TPCJ(2>6$5V!?K;/AJ^6O-E
MO&@TR^J1__*:X:6/L'="*ZZ,0H<Z<HLD[Q]$U7:[V\//2\++1CX?81 !%QLX
MU#;7A:10-B9L&>O1F\OOU2MFDTY'T94S;N6*%H9Z_18R^JE:9G"N M<UFN 8
M5!9/M-.FC*51ZO]*.PF+%75_8;EA-J+58<M)%-BGCWP(PQT7(T ,K 3G*E=
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M3](EEEFY3_1LI\V%FV^EWM_X'MMA;6V3(<B5VI,I&ZX*VRB>B$!7HNX"K2;
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M]3SKM>4&$0!_T]BP!-I>A86HA\AZ_XV#<YZRSXR20-<5^94!A+#48\=EJ7\
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MNV@^KV^]*ME-E=B:?;[JPT-#VIXFW7URU4=85?:O"&68O%F@1%H@:\(_0#C
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M*G'T<U&!0(PEEP"]9N2^ZPQ!Y@E@ZAU78#\.,"W($X'/MUA'N9IL0?I<)$&
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MGH+_*L7M,X9^,C=-%<6^L0?[^4X_]],2L'#A*[!O]7&:2Q@&U5?@LY TYL$
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M&UBQW"&C-[_?.'O*X*?X(PO(6,ERT "ZOCL0.OR(Z8;3+9$"0 NE;K3Q!OT
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MIQI9/A*T^N>F0E/EJ.#J1QU/"_7S3IJB-JIF3.]FOA.1].HR-%U<U2JU*],
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M2UVR?>70E-RMTONQ6#39'94IGV<F\"KLR:H*=K5(-SM<O2>QRF4[.<,S]V*
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M$>^&@__*SQGA$55W\(R/D\:,QBYI/E]GQ]H<=G(7FL^ 0&=_,C(9:.9%N")
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MZ9:VXO#=$2F ,#PJOR9VMEPO_YX],P3_,$0)AGEO*O-%S85!@,G;GH+Z7$4
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ML!$BOO.?;ZC43]]\/<;U)X!R,?X)0MKRY<UV!>+?<#\L:)BT\3L84^A_GC]
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M&-Q[E/QS-',D$+1<@\?W\(ZM;K?]X$CR13<YEU%Z&]=Y]=M#76AFK,/9K,
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M7YY1B;-GB'GX8FP_E;V=$<<+U^YC !YPECS$/2J ),D7<P\"T/?*8!9,RD<
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MAP4<($>#<LR#\EH/*PDMNG!&4%II1BF :!61,/>S+<:=B6P9/4X,5MU<R7A
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M?>4?&B<*"M?4$B_K[Z<NL;44%*\J+0I&UG",3.$,^-[D("Y$.G4'I@D^YAW
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M-C)EJ\ZSUJKF1H!UK5>8H[1TEY!83MJV10-^_V9G.^>X'\^@5R?F$RD]K.O
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MH"J>IZ]^"LAO1\=KOJ>(9[ZD>H0-<\[$V_AR%I#=2'IU-H,CKR4<=/A13<V
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M^XDF!C92*5'2;Y$W8Z-/??K[4S9VR-0(!,.! LB@EE99A\%#[-\0+CTO=*\
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M;S\BC1)!D##9DT:Z'.0/4%@W@5*8>% PT,A4GT+'*5:FV^\;;L4+!3VCHV%
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MP68"1,UCR,G20W;QRI< ^%F?6C;;'KNTB%JSP PJDM?IOGTJQ.WZ5PZ6_[J
M>X%LZ#9P7!G[,HJ3JHO8U;GJKX&U9Y "I-,)U[NN9E_', NXP ,NX!C,EEW&
M?S.#A9!"E23-^1V<F_V5"_2=8>XC+=P!OSG'(5Z'YG2>I;5P@6VHG]_=: <'
M^*T53/P'&-Q?/*"FHKG )G\NT(;']9"7_9+ F6>0%S;EU@([[B;V;W>B9C(S
M^2"DPJ+@(?SL*])V.J:5# OP(79XCD,FS\WJ'0%G+A?8+M@)L:-ODUGK&L'I
MUYDJ,E ?I@GG/?#BRG^ RO\Y@&\B0$W"<1PRJ-2WD1<CO(<Q,'V "]@W4JS#
MY#<C-$ZE<H$OH_!3FFFH+4.>"]Q S.(6YOT-\G6=FW^V29BA('4L;'X F3U8
M*J $^<=2WL!8K1=B8VW@9Q74XL/92\CL1FZ66<,0'VKAF2<Y^5S@VSC9#43>
MOI.\I#<PNR:S!9Z-1(Y1,&;MAOP]= R6!CZFIGPZ^Z?F6E\J>S<+R9N#$-),
M75-EHG\^S3+7@15I)2S*-X*?W^/A9V/;/H@S7;B TRB<LIZ#*EJT[,5\7/A[
M::#\+ V]"(:^&N8^L@T%O;IS##.'E- 979&.UM#S7$" W?G-E#1%_5,'QVH(
MRP7D5*FC'+R3,!?H@0EV?;"8V=H*AB.7(A2#H>$G\,O+Q$G5$0R! !U;0/R>
MR4+\_@X9\7LIK&4]>5&O$1QX80;__K@C%MY0Y[R:S:[P7/9Y]R>WP$N*B,M<
MQB =$X!!.J:EGQU3BSK4NAM\]_-93:>7HVM7^(CWX0UA+JME:YN(C[3,_F.3
M[?\S$?_OGZKJYKDQSXUY;LQS8YX;\]R8Y\;_9C?NX;DQSXUY;LQS8YX;\]R8
MY\;_9C?N_>G&C%E8X.<W*2Y JUQ@(YJ30)(,W<+)0.NA!@.'&\!R\CV2LD<B
M^RQS9RXU0[!6^2E;&6JCS'ZF>_\@"T$)-$>KF1&=3T,"!J4QXF7&TVG3TB-'
M7=?TQ#MNOM'3JY3?65CM4]^;A7+9>,SG?:7TL^K;X>/CN<K>=>7TSNA<Q9?F
M\24YF=5N28ZUG=]4X;W(IH7G@9_ 94LNT%@U)@3[6:\09EN,V:]'V<)"\,5;
M8495*WHK\ DNL#T%K+?$3&%8![@ =9@9Q06T"C$#<:FKM\C0/A3[M5ZN XL0
MP@5^_K9#(S*E@/ #]?/7##'H4",7R+!&_<-/15D4<SKKN,!O8),<EF'5N28$
MOP<A?_9E+O"Q$+\T)@=?](8W(Y^@(E1@ T^.<(%W&-H.(J3HRD&LPP7#UL8=
MX@*3U@9KS$3D39H(SE-<()6OMPCT60"_H9A;;-EBJO ]+O"* $N1=X'?"[,Y
M@6U@JB0B=R\7:+\W8TU^LT)>%(+N%\'\C[D HF_0#&D01N,PJWWF<.U5<GL\
M4M^W<X'Q^B7%T2^LT54^]LF?O]'Z'!=XBK112.)&>;>@V#//D=P^@AU'N@O*
M W"1LI;B/1^VP+[W1VBM0.)N].(8R#B-6;W) \L#RP/+ \L#RP/+ \L#RP/+
M _NG@$5Y(R]H@)1A+*0 SB6Q_'$?,.5131S+Y8 Z"&3$TG"/:42QX<!3-.R#
M)>P.C8=2&9RXSESW(7PC?>?'Q4"))?E N5ZZ\8D]),-'M_;L"!JL$G<Y^J5J
M]_UGI4;%P3ORMP4?CCN64>Q?:)B;6ZF6&U' _UO2>+E3)<@06KA&/JPKPG"
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M0H^T^+G?[*;7_ FN&P8"JJI\3GFY>VU-ZI2]I?]!+5N_<G_%03WI%",H9NE
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M0L_30W65%Z6S\!$$";W&RW[/9[P8-)95VHH5HS5:C:6M5%1#CH(/]"XI%?R
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M(S8]WZIP9Y'.!I1BGV:V-BU(0F2: 9YM7@05M>KI,35JQM"[H%3K:G<_]/9
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M%_+_Z.:";]':9D;#'8P9AA*'D2[F M<Z(47,G#7SU'DR_MRGSI9X2>I M)]
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M].)7%=!5GB$3JFOF8HXI4]+'97 !^E>.2C5AUNC0<9G?@H5[I$JQ]Z7;V$?
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MNMK7D4,CHNYR#X4- 51'*_WG4Q!7P'I9S+6OQM:,@?#0$*;X<C'S6E*01GJ
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M.,@Y\(;RLX>[ ;["/_M>S_<J>A@7V/^8=9X+#-:$>B(SJR?-?LUI*Q=(;(S
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M=9V&G;J]_(J\C*VJ'RE)7?D@X'5RG5COT==1WV1?X6N.HR8#$(N*X0+OG;S
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M?4\SO'NYH<QN?,G(?OYS^01W#]#,OC\5T"3H_V#QB*>,P'GM1R.#CH//A"[
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MT0=FOJW@]HYHEX. ?;K)L!(]CRZXXX'ZAIJ9;@OQ-M1SJ+_6&> 7B#ENA0G
MG-;X=^"O(:D4)X_D++/7R<_E99R%;$0AH7K=ZZD(8<2?*C;$01[$"YIB='(D
M8@^]D(J,66>CYI"'?%(NGY'U2'C;[>?M=]@W#^D\5N5!&&I&%"PQ;OCD,)N
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MW+V$^INC.I?/.$F@6^^-21H?^TR5EVAOKQHX,.^&WM:]@B7,K-@#L_7<W1D
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M.L.+M,$HU$H9QHBV>'5DK>_Q5-PF/J[95$&Q9]FQB"1YUAT:6_EFD/2F[9^
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MCH#_I[+E"\+H!,ZM"\K_OWE/<X1*\*VBWDNX!PG;38A&/4"17:2^I=V-* 1
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M^_HCKJ588OQ#C.?9G=]H(<+R+#>CGH_IR_:SV\RG/K.VGL.98U<.TE.M^]$
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M-K.P[@E"3+::/(LJ1=S@OV/$<UJ)YMA7Q5+R#SUFDAX7$I 9B6S)0,?>,6&
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MJ#^EN&C0+(P?6<<DZXO?(ZJ,8K*"]#,GX;'9!J L)\E!)IS<1O.GP(6GQU&
M1UG.#07W_.4'U\C[P;'*5MWK^GHDK9=SK<<,7#/9<]IF*/3Z[Z4F?;S#";??
M],>6O^34G>JA=?UT,.\RZ%G.,24H*PENUN7_KA.D3$K9](?LE7%F&C6H\7_:
M]2\&GNYT[JU2/8&5J9.UMG^3/-?.'_#^@_VVZFV,]L23S7[?DCS^W.?ZZU&B
MC_(6S8,?CG]$^BJ5,!<"+&(#*R/-4H;@H#Z+6PIIXT&!'U&'TU7Z.?582K[X
M Z*\++W W2^X(X2&5\XV 6U?"&_S4F+O__JTX EZ=;!V"5W963;Z*2/7Z+?"
M;W6^>O0U_+QP>9L/8^AIR%E9&YM)7N_UL[V/:)X7L#<7LW3-M-32TH^,LG:>
M=RK\5'WN'C/0JUL"JW'_?CVVGP+XLV8!"6P7%-\+;\-;.]]J1IT1_8.2(UF"
MK_<)CG3ABXBQK1DDA+29Z0N,]H81^V*>E@O/YUE<964VW&\Y\$I*2SO(*/[V
MZ$6C;N!M)^7'^\;".YG+!I"H54%*JPY@\O:SN@3%OPG?R-"<-_VD\&;^_7 6
M/66M;:REN-N9#88U!D[=D\#&4J^%"6NA1Y/ ^"T@CL[$F$E@%G3P:+'X+_K:
M2[2*%U!0<4;?U5D@[*!\\[HK@;W2DL!HTVIITA.%$A@.S7]/':PBK1NE9""$
M>T,$=M:\3/%6C _@:-W0EP?\G*4!J<W9&QK+,^8_]XQPT*W0L-E^8)U;3^FD
MEP(<'6-F#<RTJ-0=D:'U"?<:RE=8XJ\])']X]P99[#V_4^/MZ_Z?SH8-\U[6
MRX:32)OVRLD>*UJF68GWVZ*%19HJZ3L$]=N=%VHL5A+HE2?@Y6(%:,1G)# "
M\BYY_1>R$FF7Z!7#;SZ:*EN/%.6O=7VY:[:1%]8^K@P4Q(HJBEDSJS5\E^B\
M *7:D!1^VMNB:6S#_- $IG+:>#GLYEQV^-[ZX14KU[CB0V B8XMG);?;I71K
M\+.W5W)5/]K4^+59AMKH/<SS[XL_G_CMT9"6=PKD<[$UE*9SC*E]E*IE,8(5
MAQ!^<<%]W:TEVOH* =K92F /$=70"D1#9KQ[=(*^$TSPY%$>A,PK@;0+?20+
M#D4AP(3VH-Z:/J,<C)L>_M%0.MY=Z+_:7AAY<^&BY[1)=DYP4$1$F&G]H/%1
M6\.RS]^H+CN2CEL]VY^SV>KP_?VEN]JUK0SBL9H*CVRN/<Q>K=BS9X?UAIL&
M(WL/W:>\I@GE!OD9A!$9\1:N0%/\):QV=%R=9YR$@A.#UW;(CUGP(XJAH)J]
MP:T107*JS98M_)Z9\H"LQ-, RE]8!@7J*KM,SC*;,;]_A-T3=W>]_FJI]J=C
MJTUOBN7ITJ(O-:*F9^;'?D4\]NT^*S>_-]*U#MEV=+YV(0D.C/2A)\4",4.?
MLA@\N%B[UN9]9>'Y-.K%/XB9:#8#W)\NE$MU!3SO#+)>T=X99SH![8\'TPV(
M5SG#O&\-O<^-Y3O" BF*;0V=ABG[+[I_V--C&[?_5H@+(@KSX/?[_JP*,^=<
M!Y>+4\7:?B7]I=\B=."G.Y>=(-81BOZD(]ZJ*$" F?SMHG*R.;G34\/.WIT0
M0S9F1#6IC)=<&__=QI!9JDK!@3Z<E0*F\ZV.>A[\GI&>G 3F>J_-P5SG8J3C
MF3<QO8*_ZBIJ1+G:G_[(\ $O7COA6EW0D*<>X5B*"*TR#ZD\I'V015SH=&*:
M9?Q]Z^=!4P'=:K5CML%P>+#&O5@O)?'NH5,.IS9 L['SRSV3G2-[=7KV26!8
M2,+\D<(="E[+F#29HG:2['CVA6'%0D_0[RJHR&L6"XO'_5D[&]6F;A]%QL_I
M*^G<JGW+8T49I6P&68YI,GYZI4O=._R'G;;.%#SU%B+BRMN>7.W_U7SH^&T6
M][AW=9)*F2?'0_'0PRQ(G(?NC+P6<?QV=N]CG/-<9[]F659__F_T)9V?7<UW
MT!^08ID6P=ENP7E*DS,Z *-LH4MKH6ROCT"^0VX:,?IDG,8?UGKW*YT]EQM"
M&SV9HXKA(1,K*8K$ST/!?SP@/GDA9_)B<'X/,NJ";LHZ^W$1%H=]R0WHE!.5
M7*]K?ES(A& &KKQ3_S8S4OZ;YT/HQ[-U*]2_0Q8W:8V1X9 XH5*:K% (HFV+
MVGH R6T1.! MFE!; 7X2&[V9Z-A"536+S 4I+:A=P%P6(<\/NRDN_\+,C2%\
MK?W# BSV*YY_[%4;(2" H&"P_P7,K/;I@?,N>=/]G3><#SD]HSD$MS ?TTXT
MXL_:M<\Y!%:O5EBZ%-EH?]!X9&,NA]5HD/7 B+=",+C18*!RS,*J'\(0W'"W
M4V](@&K#42<F4FPBM*A[U7=K1A"N1[A&"/0=]%3-M*W#>]>\K7FJIIWS</*A
MVZ[X?[ZY&6(?WZS?YJ/T#-OB8*_GG^%O8CB0]I4\3!<*J>/=W:M+B2G6H"D/
MTT:10ND)D6#_Q(E2/2$!B.4@[HFUB*@ 06@=<Y*'OB.T+@!S3P<(##/&RF;1
ME8MUE\/]M&*YQ\:OJ?EO,=X6I*#-N;'TJM^1'S+EE&OJMW+H5+-+Y-[LE-RU
MPZCN;05U'J;TM%B!$TD33&4S$EE;&W<++P$A[^J V#9"[/@VZ%/WYS/[W@*L
MY/H3T)^R>+/]N4Y<99?#P,GI]:^NW8W"?7;^U0WWK%9[4?G+N= JH'+*KMEV
M/L'\&].F-,/NME&.V!$'X*CWC2F;*!-EU&IRK*&C#'*7\'2O&(E7OGF:U_02
M2\(!E%CR'RS;J_,;UG-DX#N(4=@O/]*,B(/G>@F!PI5QZ:<2V$WVQ=.MWKMO
M/:';I[9\H.BT]&5I4$O4=R.U]:K-2'^%!SC-#@?TY$E@IO2'X SN]"5*(4ZH
MNI?'L :;H-"6!.JPZVR^0]IVXR0FGK6QWE/30J4@ES!I9\'!Q;KTJ7E782#5
M)%>_E_#SWOGYP/E<AP+E>'0KL5M6%Q49E]7PR=ED5SPY.2,73:W*=;0?,"=I
MO'UI+2CMF O#K>A8+\K@#MV*AE%V4H"@CK7ZQ .B!/1U2@QU \.+E0P)D^)*
M<VE^.#"?@/ICBN^I"(9-.O<) R<)JL2V%Q4#B_-J1%Q;6MJ1J>P= .O^_"(S
M8!.5'$BR#NVM3 L+_2Z!V;"WJW56["FOUCK<+,#;*IO<<L_"DBH+F05TY;,W
M&J;/XL>G 9?^/;N*EK3[$O&=:3UU/>;NOS'>3TI'A0S05 *3]EWK8HQ2^^J.
MI^XT1 ]U3/;A#QF-UTU28FH[[M>[&6K_N*H:0(]60P*(^X&)F<Q;%<3]2W>B
MCVW0TTX=;KUQP-:YYNR%3TB_WM+=3$$QLQA=^T)8FACT)$WX:"D! ^ IWVA\
MR#LVW(3\]![)#OKW'_+[FV0F6AZU]1=K ^T-F,-AK2?B["!F$V>$D/,3'X7^
M=[^2L:V4E50Y961W%%/'#,SC7<_A4+9*8%=M]/.NO 7R/[$(%#-KQ$\SB\=?
M/KR>V6@MKVOWTK'8^*"5'$W[[7#F]T#CV3ZM"+T#E::_G$,N?Y[LG#<LF;]5
MV=A9VE^?\N/W_^/9\Z_$L.K F7O"UUKZIF(/RH@$)K@L-!J<\LTF?X/,M($Q
MD7X, 3@BAQ=LT0_F7HL_(RJX!7=Y\I/1CU4R+OB+#5/.]1'V 9AFD<'EL<*V
M@,DL1^L^Z_B0"(U*$]][B[B=[E]G,I#Q(6@9#/(3SSYTX5KCHJO 4_MC\NYA
M7KX?'>^VV'"\ZH-R1-]CY.[31ZVMU%*JLAD;KGW_.8Q*H:<EN&1(8*<AV#_$
M$,K_AH1M#5TH+^"DS]:P15*G>^N=7Q!O=K91*Q)=IGS9(ODFEA)J#S[,@OV9
M>N6/._@,Z=BJB"U(L<ITU][$M&%,E)EK2::,WW6]V>\U0NK^+M\G/RH-RA]G
MG;!CMHD*G7+<Z/YC2X]?<-W\,Y^IAP5D/_$_FZ\EX_^$W=N+@[_X)7PJ/IV1
MEOG2;SA)_+#8S0-?6_ D(J1@&ANR*(<=_^JO=+2A]/N3[Y4?'XV,84<M-91W
MG$W0<&CGU19K2RU_K=+(5WKFG9J +<BHQ9<E72,R^NO"21"^J?+2.Z@5->WH
MZ+4&Z<K3^%SA:=!RDKY->!J(%/;4\_%E1'?GZOZ2YWVE<A=0K#S/AIJO(4E&
MW_\,T=/GS#4'?QO]4V>/O5H:$NXNXVG6%]";=2C!M_/X0AWJD7N;*"W5?;M>
M6Z&UM5+&"CD+ :&<NK@#5R5]AQ(('XJ=H'$M@,\NT/+#3"+N5G;+=]#.MLT)
MC>BY=OG$SJ;;C[,O!G46$Q'M)J%U;%ELQ&7-Z/;<%Z.C^$'EVZ3J04>*^=5=
MA]Z&&LO?*^6QI]_@\M@-)@F"*NTW??%CVAJ]8;:C]_O_M K ZZR&X;1H[U==
MWG3^'YO&US;'\^%#N GRPPG&D"._O>>6!Z*%@1 Z\^1=002$279W]8S@<=E2
M%8#S<MRBK&,K7DW^?"-("']Q(+I@>C;JO/@][[&*^5+70%8>D3QB"QN7P*+V
M"'TYQ:P8"G >%YL>/(Z^9V8P21^J:2<CJL*/TD; X@ZL=+L=O.WWB&4/ 6F8
M$NLIG<RW_ SJZBKR5_!OI-HI$ROP%37*1":#KRWN8ZP2P2TG$94,P,]VK4[_
M<>(9[0TT[A9>_X7U6US$ ST7=-8MV[>[-#4-?[R]\R2B;R^,\E1:J%97<-$2
MBI':HLR0&-RB[?S7X*9:;]EDV?94WCP_JK;VXJ+IE8&2S])V+>:6,(HG&KCF
MF\0U"X(<](PHWN<N6X"+KI3 $K.E^P,YE]H'YEL0B,:#0UB-YW(N[J4[IE0R
M=2YQ&:<W]>;=(2^?DP9P$+(U"^U[N4(9Z"L$X-%M_(H ;$T"RHQDWQ?XR,FX
M]FHZFXM@=T??<IO;)_O#,J#, Z1Z)G]VL4OM9,_T66T::X*MIHJW/9/ 'H>)
M^]#\VRH_Q2^A 2^N^TD!(FAWC,QM^6=%\62MIJL+>+5MHA=F@1.!IY>L''H%
M''1+>$B7_A:#9?(0O%ET_DFR@E%9=_WT0:G/Z(GWN*35C8/-N)$$_O6W@[HY
M/*M8GC*[NUVDW'+SL_RY/D.X(M%_YAU9:U!7+W/3CT[K/C-5MHRL)S%,1GMI
M3,XTB4JH^@U#U]V&T</" BX'!$=&!A-\O'P(1F/?OX_VC&"'L2-6S(L71T?_
M^K!-"3B=HLL\.[7G?*YI>=$C&+HEEM\/MM#(7RC .>HP=;(@(6)3[G.AAZA,
M;$"R!+YS2[(#2\0J/$+;& 4+3&)M4W]@]6/#+Z714VO'O$X8KA-_ZUL'!D/6
ME2>W4($Q*G"6-2S=M+H]153*<YS(ND?NQ4GW[C(3K)#<@(P61P9O>VQ!<\+/
MBRRPA9VUG%S_1_Z0U:\# U6E!USE(I^J7X)/5HBW?195H-GGR:,,)8I7]\YI
MAB] Y_H"_57STF[=Q[S0NQJEFXJ)&>W#G[4W)W^=P6TSPL0=]3_R[LP@$_1M
M&2BW/GYO4S4,C!)O/RUZ68^!EIDL-%&=1!;;N/E)'2\[!7#% ;19=\"]9?BO
M[" >/+DR96=G 3ALCAI3G:WPS_C9/B]/S&QQ2>\QS<)8]]0;-P8K*/%.KA-3
M<:^T9C/9*5]Q_*.B9Q1OUA;1HP#$/<HV0[C,C$K6XZNJE)W@./';@'@_V'!%
M6]5J_#"/7\S!R']0W?\/R\4/6+_N) +W'W]2[^=/H2*:WPDQY4MP$-*+7'.!
MLUTP'OZ@<8_P6%]IHRIV;(6@5L@+;I=KFNB.OAV,?7.UKHJR-V!X[V>ZPOF/
MP"^7VOR9CF_8OWZM$UM3 5LTJ)72F@+J$+AOV1+84.H9,,KX[G62<X[P))C)
M.SJI5,KNI#^0G9B'$PEVU/.-/%3I<XBR^<_@:GGPQ"6D+-%N6Z,ZTV; S!T?
M'ASZ8<_#C^M$[I16695!D<8@I&U;4742V*]GSZ7$^_P&&%,':G'B/Y98$MB9
M[S#RGY0F;\;$,.8!%;"A#F6VH*LV/1788<F]XNUU8-8+X7'>9^IEP.$G.W#P
MSA7>L2<E'L3@-E=7# _#T<5F)T663&UA)_S]9<K.IW@&NU4C_8IHX*L4'R?>
M5B"J$3/SR<RU<\5*TROIMADL_C,0B0\Y=N&KY[&$"4QBK6;F7RW>Q\)RV?0'
ME=Q#S-"5$-QN_W:%D;"C=RB1"O^K)#Y'K$ZR A#-B/7$&@ZE#:Y,I+Q#;Q=*
M/Y]6T^*E)-8[%KK[B=6 'W?S3PX:KQ84OQRKO^'N[MX:FQ:X<.+/RS8''JV5
M 0AE3+QA  Y<1_'6'@$%3.4P[LS6_\G:9*:)SQ?N$CTE[0WS#1*]#9K(0IY[
M0P'_U#=4]0E7YV%:YY7];]/B\I@#XW;83OL^LQ-LG4)Z'O"]_O,Z\3,68$'X
M*K_6*)E :3I&EA)WD_5K:J(X X4!A<*+X(1>VN%J"4P1I=FY_74QD6SS!WY_
M7>:[V]L\5<'@ [D*CRP*);!F-2/5FZ\\+.4@?HL&PHUG+].%FJ(&DI3 >\K$
MBKR7/("07;23OCA0R@ZL9NPFRTRYJ.WH-QP[G^NH6.=/V98+!H?EV)@]["K*
MTFHM),@7Q ;IP<@<2E,.!7"<WTH*$CU>*SM,)%GS#)48>RE7$=PQ+[8]M=!V
M3QC*7)1=57K)_[UA7-;RM FC>5YQIC8MJAC//C]+VEU(5''?&;ZQH'SXDC3?
M]E^3B)7^S*I:%F;X<BT@SLKET24P9WI<P!3QJ-AVNX($5IZ^7P+K+U#X?92^
M(G^5Q=?MD,"F]1S!D_3%;>+;_RG2MO]Y+^@7&'!?F' L3/2%(9H-$0XNQDA@
M&19KQ78%K>B_@!FQ+V(9"@-CS%4-^H^*Q7?_\B?^+WU!2WK_]W:"_^5V O,6
M\=8U+;D$&D'DX[CH$7F?N!.]:\)=85 =MT-XC,>M>N::P6JFQM?JY<^2X6!4
M3ON\S%^KU](';U]MR-?L>@&F-&-K'I@9Z8WEF=2--J\3GT%7#LZ^%H1"0U&F
M7/- G.8QA)H4J<83I".#RNUH:?(1(;J/S@%^)BYFZCS5*R&% XQVF<  Z0?U
M1D4G>R\$F%@NE82Y]'CXJ^WD#<9>NY[IU .37AH4;*8T3:LHUL08HC=1FBP9
MOBERX\2"IDNOZD"6P.A4SN@0>,\H:5^*$\^X&:X<,*Z6<J;O"-5_8)ZD/FG*
M12VX%43"F["&AYL*_ERWRM(2[IV$QGW-[O!_H^Z]HYKJOG;1**^B(D:Z@A ;
M("#$0E%:5 0$7HRB4H6H2!<C A(@9*LT::(@\ I"5)K42%=:@% $1*0+""%!
M1$I@1R%N2;)SP^\;WSGWGG'N'W?<,;[O=_Z Q1CL)"MKS?G,Y]EK[CGIE(1&
MC%7 WE]F<:BF3(+W+2B9O\M**U<V858\5D^WN)K>D"BW2_*?^Q@- >(6$C+*
M:+)=DRUZ";>@RCWB5@')"<=>?![/DO\FT$B!5BL;&?S++*V,IP9Y,)'2.*AP
M(GK9-W69&1V>$_^H9^)94Z<W E.T#!VDL\39)NLYYP_]2!^ 2GQ[IBWM*E3
M#F*H9#"7%>;'7!+S"0"V<;@TT,AFS*%$VUE%(<S@?'1G5:3M9/\NIH*5J[_D
M*4RO*(R4$9K.^E,/HP5$X9]"[M2:CH!_8:;NDW]&42%5*O^))EJ L$'NO""Z
M*(X 5 $PL(,GF0PK8#BFB9QFR)1!K8'[!(BRX0=%"_H-I<^]OL\+$!("A,>I
M7SY*!N"G#Q>L@0+>B1<31 NP$GO@GX A*#QG;C@HI";V<-\I3 H%TA$:TI
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MX_5O2^$6QSGO>REB9KRG^><YLPF\8F=CRQ>=H14CN<]2%V9S&IPP_ZQQ39[
M(\!4'P4ZM(W@WTZ5IDYE A(Z/Z[W\T@ZJ 1,10<GZ_6/SFE?N?,/T;%49$!H
M:%1&+[ 3LCI?#D7G>E5CKE4-F#^ ]\[[*[.6J+7(3R=^J\_FF^AFBWLYB<?-
M)/+JDOEM#DY_5"94)I99:N:F4M1--CW]H9@08ZI7V!C% C692;H:LN_4)@2P
M@P[ZC?"$?)TSODZ2UO-,W9WQ'$\H6J:7UA/*,>VKPBOQ1* 'PDL>P=L)' XV
MGBI;K#*D@]WN-*_O]CV:F>R:-Y=:1AAH7J-$UU_B6!_KL*H?0@<<^MZOA3 @
MCZ;!R"O\!*)K]EPJJBIH<83=,14=+UYK7N"#$G,#.]IQT3;.9W6[[Y7/ZU-H
MRPI>%UPD9IWFR@BX5LI-W&*R=XT/<GP6L9;<004)B3Q)O99:1:$HCMS/SVM4
M6=CJYJ_Y^ &C-WQ87^HKSJQ<S,J@P:I#Z2C8D_!,3[*8Y/M-14A$AG_N-JW\
MM:]J+XJ&Y,DZP6)J[ Y8[#A[H&FL.GLJF+2+J CYR"Q'-V[F_?5Y-8;G%NQ1
M1,B;;]<,:G/9._RRK]*K_LHT?5?G]==S"S*I"5[YGF/N&7F>(8KQ:=CB!>.]
M0J5^2AB2=/7@K2G3O9 J9E'4KX!X!^3!LOR7 H0W5G:4>(W].V)UR_?J8=X&
MAICOYA$+Z#JXW'K/_["O&],9997FR,8\JIQ[);3;,\,\KS<$UXNXJA]:TB(_
M,V#D74B429;F_<5_1/7D2YVJIX(CS<+MH,H9[X9FG<KC/L6=Q<778FA\7(OD
M_'Q$-SZ_]PU/8VAEP??,N;9X_;Q\KWQK?1?OM0"]O:@L%'B+PI,;YZQG7(42
M1:'G7!1I;*PW!MX#"8,",S6?#3" M@F%9A<5-B?2#1T;@-[^0^DPB(U=P8E\
M69@\6NY96G_<E8G:X2UO'AF8845A823&YD?T;Z:F&X8\$>6L]T#EK-<H);4#
MX&64(OS990<_L:I7"1H_QW^Q:"SG N4S48_JMQ80I%J45# RY(Z"[#%(MZ/-
M9J[1*,M7L5%IOJBT)H8HPW@D00F@+SX/O!E:4XF  S%3*^@OH6U"<*9ZT$>G
M.0QP1V1P<1M7=QY6AGS8KP(6KOL9IX'CS)2E!WY3 L0N.FOCN4JL&.&713*M
MYG$6/BV(K8I]EW2H1).B=0/!DQ "0B!UBKHFRI,LQ>XA?0(J\Z/JKS![1TV8
ME+AI]@SE4;W\YB(F_2%]IW)?2:61Z]4RL.3C,)N0W>*B];;?\*1HC':=&%?<
MR>Q=WXT1;2=?]^^S%_K139BWB;%D\)X'3R*YB2RN5>\S14X@2QAK0]1%R9Y<
MW@'0O&DY3DF)'38#Q?#B%%AX)CZB7AP4("RC6?M/W%YV:AMQ/^1<>LLW\,A#
M5:%UZ>,@-0&"%<X]+W301EW",KQ-@^W15!L=V2CEDW5\H'$##UU>59?.;4;M
M*#8\RN"2I7\ 6PSUBKQ1;N_9.][G_4C[[7*"/9E]/;_Y%JS,?K8V\9W,Z,;+
M0*'F+Y%+<O_;=!;NM "Q*9I_WY<ZE4L'L=3'Y/*)%^G.T:U&N+\'>'C0R7FH
M-\7U%?$:J/AEQ%!IQ.[Z3?C3 -%B9EYIT\BJ\L/OUAB:R^'AVR^KTPFOSVR
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M^6KHXFSVYE@=K/CDU[S,HLG-/+K&1_49^T5CW<>E\7SH5J%-TDR1-6<VW,O
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MWDXYSD9^N0#ACAE=YIRI[X</DC[A1##NN)W>C0<A#P9E-,,.1$>HZC^N>2U
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M,B>+GPMKP4-*QE GU\M+"0/UL9U:R;L,K[R"3)AZ35SDIE%"6IOCRN3^P<4
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MM.<G9)YFY:$"CD_@V&Q A^]O7^Z8%AJ9=+<3&OLQ%Z#;$ALMNV]X?5>0#MH
MZ]8VUD:8L^JCTPB/)\]_> <&4?2)%I)/7,?:QPO(60)?4S3>PDW#,N$N^-$-
MHWA]?V@+)!E]]FTB53$L.7<B3P^YH-LZ&"U@WP4,!UYHD5IKY#4B'83"P(3W
M'^-KZ3&/[ UK&YI&GJJK(0V:@^,UEO7$Y.6<;NM!F  MW]+*<H.,%1O#8.K]
M1L&H-G5E3__;I3EG2ZC8QWFF0DNB0W3>5YUW!$/;"'@B0=*T-)&J133L'K]
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M22BRH2,[[*]HW05''?0 TYZW7"#.S*X)7ZYYRYETI?8<00X^?'\[=;"#YSN
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MRI(<0UNB(&\N<#(N9XK\MN>KV?>A.C?/>9H17W*825>C_45O1BP60M!;[TA
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M,%UB-F.G?XQQ/K M<.NJRRR)HMKM$4!@OTKK?CE#N =S_.VD%'?3BW?E0^'
M+PR-IX@'!)B*EQ%/7O;CW T]&8GXOM$;8ZGIB$8MKL9Z=9SBC^\GNX-AY047
MC!<^C[O),#*?J!??80*DB_MZ1.%]$P3=66 6$T T1\8#B04(QX2H;9< LOU%
MFB$/[@P-C"7?Z^XDS29<NN5Q_<^;@=+='65<0TN]C2JX6ZEF]OF!QN^8  ]2
MN27ZPC,5R^4,@E^#P2D"L>='=<5(6T$V<65HNKO?VU-S0UU8)F6Z0'I2XQ%P
MI[QX>JY0I^115L*WRWB7]CEWPF '\@3L%I'@.4Y[2>@_UY8>_-)#],6(.R2^
M.;JYSJ*5)QWFJ[W]+:RX$^JE5-X;]05<M0?KC3!.6>$OEZ#PPSDX8PLQ+F*W
MDPN*NJG[ N:+#;TF]VA6;!'9BMR1;:84$G?14(+3H)BPRS+7(?+I!_INH$R;
MAL1?6D)XXQ,4STD;2G!K]I4AF%S.=#QN[<CH5<$,- CV9W&A?&I-!=OCO.#E
MJ![,7I]0'.:]HW<@[7X]26W6$&;!DMK*S^[J6132U?.W&N0XUHJYH/A"D_;A
MA]6%IFB=].VSW@]BJ(F@0/I'G =F"D-^"G:@%)& QM4D19W$]D4$1Z=J-,R9
MU,>;=2I-@R=9/$VGICYV%=LR\6WXF?Q?G<VC\;L3P\35$]Y@[N!#'1O30//I
M0-J=-[PG,NUED]W'EBU0O/E%^#'(N\U3"8JW!BM+2^:ZGN0)U(QP&&I@:1@C
MWF^&'M*9[T+X#R=*66+5'P2P?=@4Q-'*!,0VE!7WFGCZ2Q!?1.W^>4%KK#;4
M?KRB#M8CV!O)=^'!-X5U<ZU?"%)_:.GX)IFD8'KT'-WSMXE[6LKL-0V&+^KW
M%$EL<D:C1.NI\EWRQ9$A\P_KX O@Q>J%2JLX+)\2CL<:ID>![/5Q&113TMK'
M-;HCW_;>/BFW&H;U\+4(-TG8<<JX\V9>DB1SGTMO^? E\E63XRNT=)WZ\H?*
M.%NR]?W[:P3MN6=%2Y+X=3TLL7#"Q^NNX#3=VDZCQ[WG=K6WM<'ZH&6RB_%.
MCD:B77FZ0?U1&5Z!EV+6W2(\HF6[B.1<RY8C=E6Q3?N5(=H;LK(Q^6X7(URG
MRKRVG-*G[>7- YWO)L$NZXI>*C80S&7HQK4^V:49/A36/&?/%I,C#ZE[9B@U
M5&8XO:Z?=:]+?Z,?ZL*3WN!Z=*1<2)!JPYZMWC1-;Y(V378YHR!U%ULP;WPG
MK]S1C *E-^*^[2*@7E198466P,K'TG?P![1W5Q28@"?/@(P,W<4KK, 3^3+"
M:'='K.O^$&,"3B%)W:$,040KJR[!JY)VHGX@SU",V^>U**'!I>[3<[,O("$I
M#?.3UW<2[WR0R+9\,S\\?#KU.WG#VD/N:OJ*:RYBE8.7R/=EL,.^T(GB-OG%
M642A#_JU_6MHEE[?U.B47!Y7)EH=<O&U;T:<F?N/<@[,G7/M;BW72R6'T/:7
MI4:+Q/@Z?<LQ)=,W(3W3-PVKXW! 1*LGSHD)8'=+"W)Y3;M&TB5HJ6 JM8,&
M]8>U;GZT3SA<?P*[4]Q*N"8,7F4"VH."5_.?PL;*'RWJ<A,*V\HU^9.7W^CO
M<&B,55C'P"U 93K6[DS 1)/%W14=D02?=+/G.7=XHTV&S..NZ6?BVK?%BVUI
MYGEK_L@SX,7*GX?6=CQR&VEGR(1V W_SW$''3"]8D0H^%,P%&O=GAL5[8A<N
M;*3G3S^%N_3)?2]#64-3AU*R-QA\?Y9QB'LO)O Y)4M$M6G]ZGO6VR?E"COD
M;>>TYJX#2:FPN'SF=CPDQ<G3VLRG,OAQW9)X1[]9:<EB9KJ^!9Y79Z=9WQ1Y
M?4>J[:9M3<KV42MZ0P!>YN!4O&XU'I2=5@2Q75B?3D7ZLF^'T^-G];11VRG+
M53U>_E#?4^_ZO;Q/)9P?TM 3K+PAL7LV><.D2$,9.I ",4O12"Z^VX;2> NK
M"L.+HLZTZ769)!K)V>0/D6\FN_#ULNM?TC=)AG@G0YH>0H8*2D<@RA6?80X4
M#%[A%8X=9D.R[S9UXPPT;DV]N"'0MVZI:S*J%1N[::C"75UYZ<[JWP<!->O5
M?0+%%2_\+<2;KZ1)=KE,%7!(]HVIQG6;^Q5*5Y']#O.,_(%:6X>F86)#/RS5
M*^IZU>$\-8J<7PJ_QB0?BO3+J$N6Z!IL#!WN?V3Q@P,3X(CCW$Q7C:Q>9T@@
M7-T;RK/RK,_0+KS[@]QO]%U0T%[#>+M@E["W:GR37-/1YZ'6"8^/(MK&/Z\+
MHJ2_[6W.%H[7WU?W/D@3DU3O2PD^'=#'ZU30 %0UCO?1QTH-AW;ZFF="NRC!
M\E LW^9@;J-N"V,46+NPM4X5?SB]AN/$TJT@I++E)JNWE).?QWD:=F+P(RN6
M-]P$,JW2W[S+6ZM)V@8Z"715./K#XE>AY-KGNDKO8#MG U]V-#GP6_7=&"U\
M["#!]GYIPX CU/_Z<(JT$=>F)4:-CG'4>8[VA"2&99K]\/6\WG?+N8A0;.0_
M;6K]3,M"OU<!JJ=^FXNPC=8BS),,)3P5R:P"Z74\39A> 7,G<$3._TI$=H#/
ML9ALGK>!%+=.F %R%'P(R+'9.)*/UH0LN,Y?&W/B[0G&0 ^KZZI>*Y[3$[6Z
M]7Z*+8 _T"7KN24;^_LETDM/A7/1G>VG>4.+HLB?,!K*FYWZ63!E[JW#&_O:
ME &C=0ENW_-IT43UN:#WS[2O& I4%VGT6\:#K(P4PU6A9D7@E_KY(>.I&:J.
M6ZPJ[3)<F"9&')N( XD'#OZ\NMN/[).O(!B:3AA@7\:DOAD>V;XD6SNQ=_KZ
MC''%&\+1>G>:AY?,6RR)W]/B@PO?^\>531<D@#'9H\^K499Z'OT@"S>_B>DB
M53[=;3V1V0["ITD-HQKI9EEMR1V-J@=66QB2WH\X+XDA8-K"1<0BUKX2'+8C
M+ZLE@:894=*)?YMJF[6W\%<.*?&W92J*#<8IAYR$S# !6H,TD65[_O.\[L"Q
MW863:GW\OXUVF?=6YH_-R1I)^Y,XMS)OF'MS:5N-<]=4[ 9F:_:X]G3%>0<V
M:OH.HP3\%O+*-'Q_T*=6("XT7MO%/R=BA2N(+H1QY..G%JJ0D,'0?=N4J$PE
MY).Z\>JH/LG5/MZF'_,R8R6+;!=ULM967VKKIU*D=05U>+<'!;B1@U.T-_<"
M0]/4Q;0NJ-QL(?F)#N_T;MSYO@+6Q[DHS' LLFV;H.=F8==(I9 W%:@9U$#M
MXK;S^"..+@W9"X1KW@&Y<WL!3T1=<SVL=)#FPY>@3VJ"]^N]V>&/.F9Y.QZ*
MF5X<>'XA1:#2.R<^3W*BU2K1:CD\$'HVU9 J,(2R35&7AA6OCCE]&'^4T=K$
M[2_5*F$:-H*&I$]_SZQ-, I4;R,_G/AZ%-1BOF_\5PL8T:K'!#ACIJH(EFAB
M'N%N]QO=6*5@=I$'+89L;:'F(XGL;FUR^IVFI'T9XUMWH%K&TOEW'9VGFBH_
MV0^I!;1?D"3 RE.]4KI_V=<8DS$-[7A"CS=RXQ:2FA?NM7PX!'4O'N\><-8R
M27$*+'I,,L+5A#E(2?N]7()VZH,.;JU-&'+\01&D/F<,,@' II-+3$#T/#>)
MG0F(U.(D=A'.(?@VY\&5-434FU1YV?1#">@JKBYLYE"F*OA>W$CU\S\3]:Y+
M[?E^/T$ "7VYM57"&X&.[EYYE_S)&M;@TSF D:5GQ,1!._?L4>DF1H;Y'T;2
M5J<\'2,ZGJR-IFB!.%%V!=>EXQR^[]E]-X0LQ">"I"@L=7RZAIX&DRN>@]J=
M(=9V#$:_@]2,3OR8D[E/'(S$W!.]_)0A.EJF==O<4;.<INHL*+.\PR_RO7+A
M1& 5KPZW]V0I1MJ'"7@?A"TF5-R86;*&F+5++)^_3Q[O#H]>^I(;-RMIVDE(
M9 +2WH9)F:910DJ7K'900)$Q)L!EAR*CNE5!6NAH0+PN]X29$/,Z@YK[RR)B
MW4D\??>Q0\K]1KM_G!?P_$ PY+48JZ;(?TM)E+QL_^C4HT%1RW&=E96[$4UP
M$2(B-A!QSDR(ST$1)L37BWJYG%2B00EZ8)6B7P?YX3KZ7$]E'CBS>U?=.%5Z
MU<ZV2UW'P5))L"2T3"7O=$P<MT:29^_%$B/?F!#>:G+ "Y/&KW1VTD("C)_8
MWA8T^ 9^-3!)CY@0!M-V\U(."88T&!@(J@7(>I<O?9"HK_^P5%-9@7WC/K-9
M[U!=59O]4S?T[])P@NE+DH]O;<D]<U:\K&P4(1RFCE:'F\29^F1^6SK[W,@W
MV8%G8N3)3:X;R2[VERVY7$>LLO3C=6[:*EC.OXMI3*J,\<B'ZU(V&>="J+<"
M@\T;1V#\B\@8Q$6/;8G=O(F<$3_[\ZY!<8_C9J%]91OM'<*6BEA_, ?4-Y7O
M1C&^A*R%^PR7[A@*?_A"4ZK/27(.OVS:(MVL2L.",+H;$TP QCJF>"X(R!^U
M-%N0/"OYH)-@^H(<P[5NEKC# 05#/6='%X,B/V,H,H-;1:2T#@@B3#D:9D6,
M[1# ?K&$/$1>+*VN:[J)"-;,?S$.)83PFH]N*ZT[.T]7!;Y>^//3_*G;)%2B
MY$+O((V?L)7$;L:OHW9_E5U'WM_25@/#;<1IV.MUQBY%:M3$X)E6R<#TKFC&
MHY<(@:>4C8H<5=O3IAXZ0)LX;BG57+OQR\E/%NA:YDO#5&!1W@SZF=4W] 10
M'CZ"P[*2ZLX4\#XQM8SDXW6IVV/)EFYF]'6B/0A('NT'Q7NY^,(FI#VWAN=%
MWQQ-BO ZO\L,OR_"N9\IT_IA@F^LRZ0G+]SW\PC*%#?N3CV5!S$+4P>*'F:M
M]V[T]@@;N6<]]G$UR58>TV]""<![D9I-EWQ:BGN'=5,9@TBB"1,PA2-_H"2X
M$ZOPR2WJ"*YY**2\ZNSF/,\C"6,J3\)9XY<-1+< 6R?.NMV\W3=[79;-GB+$
MOFB*K6RJ1WHWX-/;,IW0HQ:%&?/5TED'UV!)J'])2Z2P;<>AG7NT]7V1\HTZ
M(_=IDV\)LI=:F@:_E0:E;6M2[5E)\]V/P3-N.%YQDNR+>>66,3\ZNY9J#JM,
MO+^W-DX.4.WW*?C>+T>XMU/V^K*(4MPW:8<KF*2V)OXL[_B'3E?2U:RTV#4L
M9.C.N$_ZRBBU.^]VC3_,9Y:7EKZ;2E^UOI+.Y1+O;XJ1TD%6H@=V3F5BBBNK
MW]'0B%8=G"LF$H%EV^99N SG$_*C/ [D;6,(L1.$;BK%DD>5/OC;>/9.BXVM
MR'UN"7=\EV_YP@;\@DM&=7\BXJ'RA^?H\TR DS/.RAJS?=Y2?-*M93H=#5%R
MY$ D"A]\GQN&R+@/P<$=A]F"*E\8V#!R=O?&#RA\]TKB2J0R?:99>YFA.X0D
M&AC/V"\BMZ(+:.Y82J-$S%):=UH+ /D'$Q#F_OLCZ'WXE= NS@WP,_&CP:T.
ME5JG;P#1/=V, Q@N8P5FL_CP(*[XFUE/7IAWW_H*9T>(.^>6<D??K^L^\.^P
MZ0=(E?&1EFST;ZN3YU/Y*$N/G/:C';+ 3L;34#U+TY;BA2L>3 " OD5/1RQ^
M!%<=;-LOA=CCF8"VES!GQM6O-)F )<$A IA=/MZ)'N]8LM8@NB*8,NI)Z\/4
M;!X%WM/"SG&F&R[U32\,/C3!3W ^CS@1X9BI>^+3/NEYJ]E1C<S,X(Q1?!"I
M*213[L)];8->ZFZ).WKM@Q7G<GWG2SS1L['(**E, 6HPU9VH&*8$&[2#=AMX
MP+M'$1<9XC1MB@&^!,,'NT]"1FJQXS/ J8\<.])1Y6EN>]QR0BCTM*B-%V;E
M[-T:I*-0Y_Y(@OSTO-4U]V^[LR6W!F[>:'4*O&($YM8NQ$/U2Q-GTF'%H^L8
MK*GGC83I1-VRZ$Z'3WY9SRR"K(-,YOV=/V*F[ E)ZWSSQKE@A9:KK !TPSU%
MG)E_:!UH;$S)(BGCW^8'H2-ABDZYKHKA:LX&2#ZWHU^QM8R72(IN;\LM/OEQ
M<,ERRZ_>J;<XB^**4IST2AJL,\TW"2)3:H\+"9)!F%(9#\=O)*V Q*&D>#X"
MZ<6+592^TCI.%^*WNDZM^E(]2)&O_1R-X=%V7!SL+ -]_KO8LYJ*9-NHE>%4
M@X(ZO<N@G*DF@ZD*+]>;K$JL/E^X&J\Y-+ ;E")'-'^C$J<PDZTD T96'5YY
M2V*3]]$/O/+,,82PIH=:2!F-G/L"3X$/V-< /W-,YQDWUE'N+%ECA1P-:@VR
MO%JG^TL;@'%^UD(=MPD[=QM7OG?<&_ISNCP>5)0O.MSY[&#3AR! :XRN4XBJ
MT\^_EKDH)*W\=.F.H(X)YC5&%--WECC,+9M!5L[3KY7V,3^T&"SN4RQM5 T-
ME-XP>VV$.H,VPBICY]2]A#.)ON%;]9B<'_NPH@TD+V,$7(O\;#REV,$0)B9T
M?J#9I0]&5_.2A#. $31U>I6G4L>HO%__P67L?GJGXB.(4<G9Z L=\S-WQ.%+
MX4T@@O"--H+W!ZWG1F\N7_PT!J^*)E\BEV>Z3=\D^S:]E!#RFS"*C$PG77B4
M9('2Y=N4&D-O7RTR77T88R306**)_C@XU4X^H"-Q;H8&71HN[;9,P&6(ZBLM
M,#"Z22]XB?T2!_MZ*D1Q5KGJD>"ZOTR4Q57)W=FF+KZ/KP2LWDIG7C'$KW(2
MLV2Y'PZG\KC?Z-"2Y^&3WN&V]$\VK]?.A.I8I0S'Q,^B<F_W4B+E^I?M^/0L
M[*T*BL=2W-R2'<]-TP8,H>[-B?JK7W"\X,4J8"6BO<QMIYUQB56]\GXOS<\^
MLX\X#4WW1X9U]C>^SQ8,\>T(2DWQ+M)YJ)I2Z'IDE)<_VW&*G'9PL<F3";!(
M"A3I/,SZ[<G-A%\2V]QNQ5_QAR1U[O8\4G<@5I?H)&$Q1EB(Q6/ZU$BLH8(,
M?S>_"H]G%G=45]W:ZFW.>,$RV6*+S"M-J-_TV=WYE9^ PX!$&^24%0'4Z(0?
MY)T*7%BDSQU:YXS3G!Q1\Q1EST>I:F7EV.V39KBFD=HJWY!BUU2!NTUNPW9N
M*H6*QAI$W=C*)BV2FOJB8J%98\IY=OU/7;MB 9)X$E=1&RJ-UIAGAW+^$:Y^
M[G2W.D@Z'VKY1N34<FZ1W8V4<S^,4.J]K/3#M=YUKC01;.G/<7%-P"C4GY!E
M#!GVVSD_N9[H;I5]K7E43J[:X)&PH.-+^1+O8D-IF[MH75?0\ 3F1NU%^,&7
M788;+29;D-.RZ49RH6513);%;3Y7L\R2WJJTZWD")@^_YR$;/N;U]Z/*0\**
MS<)5+2VN"9A$:A9)W35[H$_[[K%;.&/G/CV-3 )>9@(6L<!*Y&OEX&;>UG3=
M#N.8'6@R8XZX\@Z]ELV=[22;P,Y*U3'*<HJ03!%YT!A'I'#74QFYK+$O]P5P
M#KTP=L)6")]5MV6?C[\FHHK@;HZ)C?.K2M$2DZX604^FBADIZ-V6I<S:"SVE
MO.QEC:!W9D.P_H,PR=HI_=(EU8TBGY;X'#@WHA4*=D((;;X(XHBK3@#2Q!./
M7!<C'Y'DLPK<&%P1>G!SWB-DI+_@MFGK^<8'<\8?XT&GO$"[N^.G$O^TP;V:
MM4W[FBURVE9^@%NM7@O$@X*HU:31J*AHE%&*KD>.P/?\].4P,?&D&S#_Y"?2
MTOXY4:U[2BGZ%6%K)4R 4I&^:4()NK?6YQ[=9V3_'#NDK<]B&..A+*=@6EV#
M&\$*@58$^\Y1!>M,"<.[O=_GOM4V5->_OK=26_=:-\(U2S1^BD^ YH.23G8S
MBH?XHBR3EXU0TN^>%QGE"\;AU?2D;C]/]$Z&&,G9H!RW120';B8+)(LFYTE6
M+TEB ^NP/Q?9J]T?CRH+@>]5-(XIVVYJ*]X?V5YNQ(WZGWLO6_JL[.H=T0/5
M@  %[F9LT\VBE\[I?[Y1.IWU.FY(/T5_[)I^O/I8B:D^U[II&-K4-_5=V#6N
M99;TBC/S>AHNI</IDYGWVUT[TR26=IVKV4HT*!D"IB-Y<(OEP IDV\Q,EHPQ
MR2L*).-6DR"K>I$F]S5O7&ER)2[E;+;8A#+'A4#W!^%__]TPI.QAR9X9X=P&
M'+V%8%-;4$&?Q=ZP?I8;-^R=ZA%%YK[R"'M4+IPMP6V((KN;Y!\!Y>*79!/8
M)'X;+XK+]',_8V@D50:.53=%B:V>Z;<^3,$M-H)/A??FPBY1"IY5[1E-IX6E
M?N,@>_R:2[I)5BW9QQ3;Z](.DAX>2*ZN<QOPL7+U*ZKH!..<2PH3P,FFT/+^
MO%/CGHGQ]]5:0D@*50/1:HAS0DS?>3A"$_I(2; A2KS!VHC4#L-$2!*&V*_E
MV)):/IX@\0KTAD9WQ,Z.:!+G-+3;NG9L9^HK!%J)>_^.IGN)8M/9=#.R*+[#
MP75I]TBJMT91MDCV3\D_0AI^N)GEQ: -Y9RL)C64MG=&8[#T+U4QE7'#^:ZF
M)5J@ZT&W(Z3/9A8P :F92U+#26MY VB%*MZ1'\(X==!;VBDFX/4N$_!W$E6-
M"9@<(;$"SA#$C5E+R%NE,@&76*\)/V("T!6ZJZ!K3$#C,G*?RH+DFX)^9;U1
M!=&S14$P>G8Z..@JMA-KV2I,0,^9*":@(O7GFY["=DXB_B8#R>=8+PT_@1,9
M0_9$<^"4+=EW LOQZT8#N9'$T:UQMZ=R'"9'G#"L'K>_TVA"[?-P>32F+,3;
M;CEA^5U <%MCQ HW]N-PZ&/SR..W'IC5 0$B.C8P@\-84)<CLN\Y=][@'=YT
MBZS3=D)B=SCT4V#F.6*ETOKQ&LHB+F<K===LD#Q._(_T'F3IO\_\$RB[AG?D
MIZI.^XM)FAIZ2$KU>@?I_W9H^W/5:(TQ&!"4:.N..],BO];P+"FJ"^6L)5+:
M<U[N<UW])\;"R",+CG[9%R-S?XN<?V*3*6NX/T8[0;AGZM.^<J@<5*Q*-CU:
M/BW>\L4M!)([D9?\&(.3'MV5HKQ*U8>:MRY!V\BK=ETO'LV&Y+_8YI684MR_
MLVB_?9GH2WY+1-/$P6PPCX+ VONO<B,MJF+[*R=@V@&W&G4="4(G#N7V'PD3
MC*6]J@0;S6MP;_CEE39C&Q](@!-7:<I9S[L4-VS&3Y1?*$WR<][6 HES5OK?
MF(SQ-'>_:Z<UF^A3,!U_K\UN?7\*[O*J7Y(*8P\<?UV9;A6O[Q.L@U(74],6
M*B\3Q?",HVNLP@+"_\=EN\"%;DRL/3$?Q+\)YD3@@2P9C*1>W]'%,KH98XQ.
MJBZY'.U>L,/XRN@?:\)4T=$#,V1^K;ELN[4#KP<<@TP )8B7_F"'UH-@**P!
MF(#(',38!2;@2QH30&#\!3;S8S>C^MX>\L>(;.%F!(PRBD,R^O=:!NDY+NP+
M[U9?/C]L,<Y8/FPQMR5_WQW1_)U-@N38C226,*Y0&KM9U9']#)(8LW[+#3D%
M]F1\H;[H>1+[-Q4QN<]1N=H_^($L$^?1G3;P.]O* 4W['*,P@/$4QP3P_@ @
MVK_B-B(1*P9,  GQ.Q"%9-=R8@+.<; ".+3)GYY!3V "SKA$5C<'4Q6VD=/
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M*[P8O$FJ^^MGS/]#!H$ROC !U4":DE78_@Y+%[6)_#Q$G R,,@HE [=W*/=
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M5 IX0G7,@]XJ=!S?4.(.)136V2?LTQ+3_]FQ]R[5>L'Z2>/;VV3\<DCCVS^
MJS]87S_JV\92V*=1\L6WX]KRPK-QWX[NH,?E!@]L!T;^S[_ 7J4%6)F#E<X;
M&&=E9&P:V+XR8)26,9!@!&-[CB+3**W5().0KU")LDL+:[9K5?*6XN_$?<HS
MEZ>VXB);/%7&.:O:H;X.!#'D!950DSM\1 =0S[8/ -;@K'".E.KQ1&'%MY ,
M'E&T:@T:_@NC>@G_#L^@B@-4)C*XC"NAXL N7H0)1@CGR @'J6R%,U6;T[U(
M"EV,_R7!#,"@\K0!C?.6-50]>(?P*9Z@2OCG&/(!L(&N8!49_"^%LA_392M_
M+N).[;,D(G2D!?DP($']*%U2NA]6A1.!0L]+B!D@ D6]HER"==])ZDI5V AA
M[%S\("K=S&7.JF5\*57YL]7>3BJ .F^HI.0+PRWO^2OM'(S0<M4Q>-KY(9-M
M5HW^++2J(+S]-OG/A0Z3!'1L+J6T? B618PRN)0.MF\W5 *4T02B<(20>ZMQ
ML0A&M4=+$OG^-6R+VKIWR(&GE-3_4(PK >Z":\^)6IW?4[Y(3T 'Q%*+OZ2G
M-@.)J+OUE_34> TN/8';Y%?1R $G0\A?:S0IP(M>'#9U1)VKN%]@\[PZ>5O3
MJE'8S%\-'?[Y\A?4M&GO9>"HR2SRK(FY24";3U)6J^^.$'SI2D^3X-*Y1BIC
M\(1?(+%AO?\G6@Y.,\&Q#[5B-2$F5FPC3+<X0#IOL">4=V0>J_>JZ,1)RJ&_
MX:Z.F(HSYUE0&6.\:I0Y:RI^&09_,>>X5JOG*5^8,R3([,:9,R^ \Z/[]UH?
MSY^DN.,K\A*!%>F4SFU1+8#Q+&:)3;J;-UZ9/!V)Z0YDAE^N]5>-$-:AQ'VH
MS74.N5IQLRVZPSU<0%"*OKVV=TQ#8*.+\(Q!>=)L&:Q:QL:S5YWZ>AO08-4*
M6FYX%.KNF-> -0%IL,$/>P4\/;3#1O##X/%05J!K_CWM/GU""%DZ1UZ(S= N
M53*!-8VO5"U.8IP-;-=&R:BOYM;R;AU#N'DCA$/]:Q6L9]G/T=FBG@^#,8=;
M"$KG?_'TI@0=;OZ>-C<@0@12DX=%&4(5G+/Q\G 8<E>:D/>AM3 S,?TE(;2W
M@G96)$NCS%%R.\F(A6H127;!Q64_Y(YWPGF$YTM=$B\F=H-OPB,=T=7\O% A
MKQ38LP)YJ.X;,]SPMTPCZ>L8]1X^R=R!J_W?F7I=N/UI**^8.B4D&3634OVP
M.DST2O*)\4B=+4%PG2K ^ @G2PCX;@(2$ASJ,R:@7#"D6LB;(:>>PVJ0 :6-
ME76&K^C (*:1;ZM[MZ-D 3.!G:U.EF T#A*J2L0\8Y:TGP8<Z7]CX?_'L!!0
M>#6.@+>+G+DA[MC,WM$"C8'ED! 2FVBZ)/<T/@@<(60!9J*;./WY"('-M^"C
M/\-]*MBH%] '[_](/-RH3H5]8*6GSH!V&U2B#=83IUI\/+ZVY3KXTD9E"/^*
M/4]PB*II W?P05-O@(]+FSN<8Z.S&-4$9N;?*R%Z)9!RJ85JQ0CA;(>NAHJR
M<:&6X6)-1EVQZ2(I^5'H)3LC#D)4;ARMZU7&(C7,7LJO%>.UW\\D,"M1>^P5
M+*MST3NSBJO<!(E7XMDGIZ)ZO$ \@:@R%!U$%\>W#V/!B,$3A&T&U$?WANQY
M115HSA@Y_/7YO%3:8!.WX<$JRFJE& +*49/**K,T/04<=@_0Q7I(18I?JCI=
M(I+]\269/UC$SMG0(U&HWN4SMA,;+0FR$8* V$56+65'6E!&D]W3N-E] J?1
M9#>>C=UFJ$EV/_!3K/:L1G4'S=@_61T^2='Y%TE[N*1?VKS:F0<D=*&=+]?X
M^ B!+)UZA^>F3BL\+"W,,Y5X^GPD&(3*8SHM5,MI9UC&RBAU--B/MLIPUM4X
M>BM8&:F-[H<ZI;JGAD("TH%&7FVV-.GXP*/7_@I5<3I\XB0K\%]JL'ME#15T
MV2.,I%Q7"205>*;L:DB870N<A;5IFHQ2?/5'2Q7DW-!U"%ZJR!M<65C%_G!R
M,J3G*Y*=5^XLPXR M(/%\V5(+C<\DJ_1>1^%B9LDL+?"G\)'V-G#%*BM5Q$\
MG/1+PO&IQ!K^/_/5C=@XU7;@(GQ9/J#KTV#@$.)Y>*83]<46P0)(2#J(5<IG
M9=R$GMN@5%O41D#-XK6,$ RFAE*@2ZC(N.Y/K68O+44">,@?-\+/8$@E-H.=
M@*PK3*!;8+,<^&:20:MU"%3R'6HA:<\/\*NSF'_XY/)OJD ,5BW= !+?4NG<
M5S8 1:5I^MT;+H8D?"D?.!]5XD(YE1Y>*.6TCG:PJ3D2D4>,9UN1*,<BL;ML
MS,=5!):[<DB36!Y/O5CDK4DL"R#9V9#L,M9?B66RE*BT^115^U=Z930QBJ=7
M]@T;>,8BY_)"+XRI^K:3Q0U[0<V!5>;AD5%?*H5X)TNQP9=*X6@GRZ9[=GBI
M, *A9ZM/^;?'&3 2$E])2D^&T]:3DCCS8089.,6,HAVR!FPF8'0<O ON(%36
MCTUG2Z \Z$A(\%9PJF^!@X__;X6T&(S:.\AD4X?<&#&SM6.^.;.M>,</7BLP
M=S[_:>!+K8"*$DLKO]0*_@Q/GQM[\4NMX'8H23ZLJ17$J>EQ;U5HHY;4$G (
MY(*FRKN>N3YRM,J[8I!I??>O*N^O4NSEDT:3T2IOT(UAZJ]XE9<Q>'QX6?>'
MH\2Q?Z-I,6^,\/Y&';CS,'NTO]&0)&B.+QYM;Q32/;'J!M,@$AFE8KKZ1K6#
M&!_O;F0YC1#,CN#F^G(B85@'25+?!VNZ02XB ;(PGJ1:0I?%"GPMW#Q5BTFR
MB^I3Z$(_2S+94V58H*DVJ(7Y>+5A=16\=(RB\FNO>T>?,-K4E(T9AMB,-C6!
M0&^;Z_5QM*DIA_>L9_.*T:8F0-;8Q@;.0I/!&\.G9O] NK-KS&"P=*6F;=]2
M2=LPVK9_#?)31@22@*<P@!Q#]KW/%T0*> WJJ(SA5E0OYFUX$OE3DF>BXLBO
MQ*BO"<=D/RV\E2'_H5<!WLJ0!>RF3W!\M)4AN T3A4Y.Y>#"7ULOX>TPSS.V
MIQSVYZ\T>TQ@I6[7CL1>0G,@\<_,M4_D>&\N1Q8;SG&JSX$E'"DDL08(Y;B-
MI&EH+79G7,JF.+>RK]\(O=1E/D9&_\<2;/IJ/;I_9E:Q0L7-%;CN#W7-'X:\
M(A8KAJ3V0@N_]LQ@]W7.-PEB;$7((#83*N7HA8P04&,T -/=O\1^)PJ<J8WC
MW[9B1RB)@1K<0O8-/QFDE!^+?JP8?DY0=?S+8$:V./4"+#Z@HLJ"+\+9D*;W
M4H;$<2$/=390XU34MGD=.RL\7Y)']U$$2P:Q2K\>]^ 84CMA+F;: HMGRE+/
MJ6@(/1\J62N6^FHJQ_0\R/U]OJ6F</P:"&22IZ9NS'\[,&AU'>_!C^/\6U-V
MA&HR7OK6X8@9$=AHZ=L"A ,CI&6T]*WI6NTT<?U2^HY%V#F *W,QJQ_P7V4X
MQ'-._$'[P4OM[M6W-!U*D]52O$/)0A(<O%K3H93DV=83,MJAA##:"OU[A#?\
MU]02=OTM4]BACN=9:08B]';+4U4+8=E9R$.9A0*T;N,(.4(,:LT)UQYMFOI(
M,WZ!"35-4TOXV:&P%V-=S5FM=SX$5:5\ &_CF@KIAS1HVK@TF06YYUG5ES8N
M"5U DK'[]>)I0EXE<#IK$9Z<H%$E(A\\NV LG7YD<+96S']U0W1#5QS>\3;1
MO3/N/.5+Q]N7(INFXTV3:Y[R?NZ7CK<F2BT"26EXQQO&N-2+]=<JW D*QM=U
M$5(;1]-W<E[N5CS:=Z(9M GI_])X,HV8Z^Z8^:7O))!FB%&M1%3IM!%"ND+%
MX9PX&9ZZGC2550_GT51FE1=S.%^ZJF&45G+<X$M7-=Z]8B@MJ"B\HXZ40+*H
M?I9GK/I<KSI5NF, I<4B@0IFU7K*B?^-C_\+X&-:P;@T]9-;7@4MEQ"Z--K(
M'EAAS[#($WN9?6;@^6#18Z;(J%:A$BTW08-#O1-O:L4H,[OXRMTCA"G,_5W@
M]W'Q+MK ZZMH$DX^=#B\\%#FYK?AL$13W^M]@<ZL6-U5T_N#UF#8O\C5>OZ9
M)+S?)1(0Y6<=>+\+\-33V:4"-TV_BY0(X$1JO&>T1[ M/+U*A/<(YE^/[O@%
M"B0$6F)IZLA;OBY@&UQ)N-$.S39(7A@_.Q[?QA,FQZ(*WP:=?'S 1)YSDK47
M^D<^.T8VO;-%!93<F1,6971-9\%LK+FPV01'\5P(GX2*27O]OG"$D$/-#N0
ME6:1F"]9.>RJ*J[WZWAJ4+6>=$40J9K1);$8RJ/*[C!%F>VO!<.P+.MX*,?S
MNEB4C4W5:X,!/T_P/_88W-/.;\\'#4-\E(,CA,G$-_N=*SBR\\ V%JCC.FL&
M@" X#/E##$!X#K[ZJ.\J%1W!*E]9<<U0A@3ON5J1 #:OOE4T8/H#\1; (5HG
M735C$S935$:<K=3#9FIK>B\7-'XD26E*&@@>0'4D_H9\F0&P@#T&\Q@*2DM
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MG[5\(Z[%TM]L\R94M3\KJ7MH0&T_5NRU>:_-9>Z@X2<R-A&PC"4KT4U0:P;
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M_-PQ^R=AKJI=/E-PD%TAMNUK7]&&><M6XL*<SF<PZ[T)$2]>X.9)4O[V8!Q
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M,MLS60NQHL!D9<HK$\K^=.&!(FBO^EBD(M-HH!S+G/HO]PUSQ9P"KO%.!MN
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M5&B:Z9_1)?&QYW/LGG^R6^DP3_/ZBNN)Z;1[CS?EMG4>.,69/&#\$3?WSV!
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M\?MAW?&>+?H7"14O[_?!"Z>0OM]4_F4-(Q-?0;[X<V,T&3:G7ON*](X[R'R
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M8IA%;YD?M4:BCRMMF>J]A5TU>?P(X1VS.[CG#>D+'"QF!M*UJXN9=C.1L)E
MBR*CC)EP6=; _$@FJS?<<7K._\%K\)8N@><)M:5]X^P=:E/N2/)(XG9//S2+
M6%-/0FG2;K!...K*D08Y:=FLT0<,)*+#4;+I$4<KI%)X*'_==OI)-3^,7/LC
MIJ*>CW7K(UVM.X7P94=B9KENZ_4"N*4NJI,(&8-X[F6K14"J67.K5-1T:M'N
M#MK]1E9&)J-IJ+FL7W2BXPZ9#9H<SW>B.V5-V>"L,M9%@*3EY5QWN%2SY3TU
M4S7)^J?DX"M31/K/1?",$>OD*CF%VOUTQG4,@6@Z27$R'(Y]E<<P&"I;(CA4
MT][EKDP84\R?J(Z7>T_;U'2.C=9V<?;+V5:'3MT=NYF7/  ;TA3N2%QZZB&O
M)V#5O<Q;$O[(T,G1/*=8L^M\672'H4JZ6&G^"9E @S+!]Q^\G,<S#[[LQY8[
M3-M(R;A17L9)Z-X^G]&0,RIGY2/[TJS1\4XVHF#K!^&SJ!'K!)0RH&!V;QBE
MRI!J'JH,65A7=U4:WE-S54\;]JE.<AV+%^S-@?^Q".K/QDRM(=F@EPUV9:\>
M_-P(PIF\XRI38HC*5C\@D(UF(ZR;]+J+' 48(D5LD&J^XWDVZ-,%2<).WN$U
MNC ;U"JMSXOJUQ<?T9>@;<,@_"W2\#-G)N)^^ :E#>N"%[=,KC4'Z_'<3%YG
MK5J.;PESNI>M[SOYB)ZGFP^KSMV\7/]\5U^=$JY!2E2[C5<".*2[APW^]-^7
M',:[W.%J" _7AAC-D3RE.H-$O9\'LC9%YA0T]!49Q2U;<MHF#.O2V3:0Y?<M
MWP#6;Y[S;5F-ZJGQ8R;S;'3IQ.=]+/FZ6W!(< #$JTK@8WVNOR!-N*E+,JW@
MA'/$W;^6;_C,56BXZ]C]2Y=%W](W\8L[S$?=,M1@S=<<6-K54>5JMFKF&G-5
MFW164C*HS1]FZJBH"315"+46(4P+TS\?(4YS(Y=[K<+ 9QA'B-Q_L$&^6=R;
MA"TL[:8JYQENNA7]JJL79(H-0M"YIUO:J?3MRH,6H^D?CT,':7PA;]"//+4^
M^&RB\$S<ZR5E-LB.FCLQ&8DX9TFHI#:E,G%50*BF!AV4]?<([^"_7M5$%-TM
M?ZV/AN\YJYV&5"\#/ZHN0;$IF<Y-LW7+*QF*$^'8U[!:#L;Y(-38@@CC.N7?
MB'#]/UCSPTU:[\!GV*"V,H!,X#9Q[8=J'UZM)KFS^)3B=(F/%?YFV5&=7:\'
M@K.N"@^N-_$#6?LP[Z7;#F0OG'YC?:]"#57#+-LS1Y3:IKG"W)AOXI>_K2P3
M:B+&F_,K=D(7.-"/'O J+TQ#;*DO"[D]]J ^",]CG+O,!^G4YGK>VM%#)^I9
M9KS1IAD1(H8$*G6CO8Y D!0T7#46R "[:Q-0;<7!RW#/K\/9H)-V":Q)C_D'
M&F!XS53'O>/=KU&P#BX=-LBUX@U*CJY$5UH7\/J(]MQ;^$"'P6VL5U</WW$G
MCR\O?\M >52LDZDWF%$WSAEMP!RI>^Y669/A7.;V 0$[=*^)[? /X_ID_" F
M#P*PQT<PFH0 L[1%TQLL:-2=O\B]Y</3WJ!%7F7(;M-,FJ+^A??@F 5> 'VI
MT-58X?SW*4R<KJ ;E;K[#GR5B7W:Y,(&6>T(:4D=-C/S-[U)WDQ/NM-Z]H)]
MT9:6'H;J*SN;!9MN02R_Z.[TC  SJS"Y.G2C]=G1-2LJS)HZ3O5?)D#&X8B9
M%//-0S"5BQEGM&E,W'X6QL^0WZ5<I>T[?*UQ#V&#3L 8EZ),A!22]E[7\0%M
M24?BM]XM;;V[H8&%+X>ZZ19I(, :)&XQ-@B/S*X[QTP#/CG XZ=L++A26^:#
M5OO[]W3!5<O4Q\O+.=OA)?8_:>$76:V%\85[A++(>P52:+=-+:W+2][A7K,3
M+?M)C>"(B=6X(?!+-J@6QCC_'C4!%MI&7<6\6"7NS^AJ_?N0HYU +H40Y78&
M8DY_999Z+9#+&6JO@B0X-MF@J:C/LFBT-"*#ZGJ"$L@T^YR7#)!Y-FA:]W6I
MH?@&9)I@1:CSC\CMIFOPD@,8KA-.#-GNSM7L2X!YD M;W"6N:=JN?>NY,S1X
MR:_.L__+.OOXR6M4 7"%V',*^!8;%/,O2A+[3!L7I\;C#YC'#C#/+3%P]5A9
M]!]@FFF$'74IF/G>N6_5X4#L+ZBB"SUEM>GZTO;>CQ8')[H478ZN_4(R0VFB
MI7FKI4);984P2D8-IDPYSE8U[]M6_42&Q+%!Y7 2G(G8@-GG:,& W@/U%#0<
MIX[5X_N;E[P?*6TMTT]C9@)OT +ST6U?(:<Q[4R[#NV7]8!?R;%XE$O.A V:
MUEP-!0-(66U*3M"OWI+8Q>MN:^+2^#Y]049V$]8EQ57PS!1F"3/?Z(PI@),%
M%6*7X[ ;& D5W-)J+BSKXW)R_4$U.@OD'^J>K@*DC&FU/E(D1^=&#&Z)GYB>
MG\8HU(<T$NXCP;^6@3Q:!*XTZNKC3C1:JJ<]H8*Y:%'785R86# Y_B#.I2YA
M8<O3%K!:',GE[:BAT^;2;7W_N[JTIXR%FUWSBN@/6KRW4Y@PUL!J![$"[, :
M.UQNP4LI @PR*X:&]T5X_Y@A1NIN8J(A%?X;PLR\O2S+(M.I2*M)-NB<! I=
M.C8]$^ ]!\:KT7JH<5_ -9Z;;\AUU"9:)/<3U)6;[QV<O^^G>,V?I3R(D[_C
M/<\W+E'C[:"H<)O2YQ..<_W;_;GM$/Y>N)Z!IL^WXS-W*D?PFRTET<AV]<4O
M/2N"[CC-\>B'2U>#1]+!_->-S0PBRDQR;NG!;=^-KM5);%OEF 3N5$5@3^:X
MI8,O%&1+#!K6J*>97*O!"[_+=ASV2_9/-H4;JF"(B'C(8C164 '1@>*F+9'[
MG(;W7_HRC/.1N+:)#3&4I2I3<:9+?9,>AJ-F*B*Y7WCO;RH-_RF1IK,4<'HX
MQBE"P)%VVT:=#=I8=KA;D,%L\UP=B]#K*G*,=8LIXMJ#C^7+H6-/5;)!/:\.
M.0$\ ";TU(L61]6@/2$AXED*M/Q\9+L3A?L)GG$B5Y2\&K?MHUHB;,H&G44B
M8"G6/B&6+::-C4^DXB[5F%[*FS:,][_R[H<MIQ KD 1)$/!5[R._L>66P3]M
M)_K_I&SSQ'=8Y7BEQ()YXJS3Q=(T3AA.9BBB$>JSEM^<L,;MS@I6XAVVG;:=
M;4WK7Y%H#Y/4_!,XRQQS-%S&A3!7V+=)2ML.J=A:J,4P> :)4EN88[7-Q?,+
M2!Y2;5+A&?$;M)A\IVY4%9QBIM?_(864\P>\[.Y$=8GW\Y(BGT3^3-NRA[N5
MK<7/;TADMW#_B7R5[7>[,"[_%)+QM@;A\ZS/VWBDQDB@S:;\];,NR_:Q5+=C
MB@]M\M5X^TTS1UP.ML_<K:HN-K=L7[K$98)\+:$4K//>]MVTS<6LQ]5YF@O&
M,W/HE]H8QEGL4K9C9F<! TZ#AN??WR:,/FJ"%:Y[-?G(%<S A9I+SE]+TQX^
M]NE(EA:X:AA049>"\$Z7^]?&U\S3;HLZPFC:-@_[T8N8C[0B9#C&LEJ9IF7%
M@AM62[!!_TB;H9=O_/2D:@ 8W8F0969&&+V+,*7,MZ"4(NX,"PGCN6=GU^0*
MD)#6Z53/L/4PR><28\R!PK)I=;YNI[$?M=/:$M2< GA#PLU _I4('Q(5T2G@
M]<85%L?JZBUQ%7AF4%66V#7L-=_;''S*'V< \XT1"%_;L2ZQS"&QL.*+##$;
M6X'B/?W&YS$YZL0>PVA"9HY.3Z_WY@!BKD[UTDD'_*MMR.+3MO4?Z]]08P^4
M_0-U2=?(&J&)9G*WSGZD?7K2&SO3>,^WZS'^.M6:]3(BE<B]9\AXF8A@-GOO
M%. 1FW;>,]Z-(;IP9$B_E-)6N$L=8I/Y@0W:5&4.TS3(/R.NT(S([<2[8P,M
M^L*T/]O$CK'FU,%3Z!D(.>$AGQ"8BJ/>;1I%5[$6J.":R+BM_06/W0A,S>SF
M+I8LOZW"FAP(=)Z99,+H4.4N=Q9^2P]??CA_N1#ML14J0X=Z#O8,;J[M.F4E
M:RS#_KWKMV#9ZG8U@C6R_M%+  WO WZ$=V$A4JKUH?6(OGY%EP_[^AS,!C9H
M,<N=.D;9CHH XCGG:X:J_GER%/+.&I8,M)RH(O2/C^>=L4YR$Q!@5]NP]\6W
M5F9G(M,W].]D#+K,.[)BB&Q0_,*Z(NS%)_0]M%=DH$ %:H)NNJX_,"HS1(W
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M C'NQ4GK),VO^>:)[H+R9A)]7EY#UJ2WS6,U@U5LD!MV"H3J7#C%,"9_C3"
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MQD2(#"&9*=$UL3G\R#3H#78]_0KJ=JZR@'ZK249PZ&NW2B0NKF7[V+3YA/%
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M^B^5OPQ8%CZY^?D <JJ:1Q5K+HDLID?"!20522S95'RX)HY'_#G'3,0KBY6
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M><>=9:J=PM>#XY3;@7K.R<-:!U#:Y/<4() ROX(0;:*TV5-\<6/Y0B>0.TE
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M9Q8S%G;15NZU E\^6F0#9O(G=(:=YSK58GM%?AA4MLM]=T%\)WOK&Y4RBE3
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MY%2N9UHL7:]3.='<.\7O4,G($,CWXT*N;F>LWDT+SW _<G#\D6SB^TU<R_2
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MGS8K85BJLRPM5*<#O@01@':>0!&-W "=^9 XH1X4I[EN8VW?3UYT2S-/KH'
M*:&L@K#M_3UXFC&,=P5)"^>(\R$O*$ C'R(&C2;_1INP]H3S(1>OS?(A^S\-
M\VQ@J"X^Y&.@X%-[3_$A/V[P(:+#"P2N)"R& -[!*O(A0Q'(EYK#VX>^4<'
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M<=T-^(2]#/HNH*3?3!8>!75I3T,+C'IF^JN9\P.4UG<NS:QO60P#H3[Y?0V
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M5^KS(94* \WN^S.M,Q27/"*'C_@%'+G%6?E9>3[_B(#P.?(AR>3>EC[<C]2
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M1'+US9B;,<8&)Y*UO=?.\4/2#YYLS)3U0>=Z+:5?/!JA"#]18])Q\6V\F,C
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MF!IO5DPT2E1\)?5"ICYM7?JXMT3=:"/%SN\+6D4>8MX">*-T]Y<A'3_\RCE
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M7 _#M=Q'S\&&_!U<2;4K8%?*!S:/6%D4]A+:6ZY8'N% K,(OG\FS$HZ,F\^
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M<>L5?K=9LYMH'?A:9:2,V>]WLI50--PH;>@Z\BBL%_>_*":XW$B#];3*@7;
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MX^Y(7WL#J\3_;Y0?7/&A#[)>Z@FQY_ UP8DD=T3B$#IY@P+MG.% (NNQZE5
M>@-&LWSET;P0]B1:BUJ44=!5WN,3'$!8_EW7O! /-YL\4>7D>W/[4KFAH)+E
MB.9I7TVGL]!_0"A#ERG(RFB5]43R<B >B>'R^T$M8)3\TD@B8X$#@: ?D\F_
M;Z3=CN$+4OO'H3-#9Z(94V5TIIPJYQVF[S+A5S^W,AV__JUZ8 $FBFLW)7+Q
M6JFG&S]EM3BXUL5P80_#:J!/=2_3E"B[T2T($:8]^ G(;V^*#-=UGK:99Q[7
M.S?$@5#.T_:_'F':<!L4YG9B-5-PL\.];NS^6]L$>U>?D'\0_9-L07,P(X0+
MWFR!VXP+GE46_H*17?@#S!#0J_R@=(?97:P@NH=Z(&?_9T]<F-^<(G#@V<P1
M=0.=*P_;PK)U(+B*RQ!<A%T;::JO$T'<6)\"MNBN0 4!E;>*ER=Y7490@BI(
MP2BU[_C(HS14HGE:,9B^.?)7S:P#&/!O[I934UUXNL/ZVHF8"[:W_N%E6& _
MSE<KM<&_!"P8/4-X6$R1VF3@3_2.@$IFQ#K[P%45>R).W,?+P\?G'3C3W51[
M6#^ BI,!$TSM?^UL'%XQ=.K[].)!7D3W],#(5QY:!EL(RXI@2[/'\8"I10).
M/ @A^+.$ED7_%UAE/@!O_Z&BL<88HR)/K%0+$4^U>RYK=SW#FIO(G+I<^<+N
M43>,G(BCT.C:1('57=O1OKPV;EI.XWK2B5:UU2:+]3S&+0Q? OTV!0]C?]9!
M=F7-Z@YPS1R&H\"ZD ?1^L;-3O?W7!][S<OL-&3>^#OWIO6EEY@GL+E(IM@E
M>F$D_20K$N>-G"[]5-4\ULK'E*9EQ+:H$%9>5+PN!1D,[=K*2$?Y-Q_URQ,:
M%S\8D9L,AF/5H^#(3W8I=PY#-]]Q$0+&;IO>94JHL/E#W J8(>/$1!GFI>$-
M75.&.7:B]<0X,?8C\\IBOPA49,H,]\:B=.:KH_=#'Y@X]A@ZPW"(F-6O0^^S
MJP+H!&H8SK0Q8O?Z,ZX&Z&O3@P!:':0#:!1EDFS!"_JTR>\#'J7XY*&MVG.%
MA@/_%+5S(V=J)M\GCFJXB)K4$T>W5R_:73I*K(_7.J^]?_;5$TP?(YA-1G"E
MQD(>J2:X$SI50W\*1"15_I17'=JYV*)"#8U7GUOMG!=H\56,&P*#J8BG01+G
M7'ZR%8&)-T.N/72G8K6@THN_6BY5&A2C0VW&-6:JH)OH_UB$TA;DTL&_N2KC
MV1CSS'#+[6)RW@J7%>"\U4SI=JRWY?<KW3/(TSU/-"OE$!V(F,B'4F\G G-T
MIF9ZL.*AX1*#Y>A0LDR;\(<R=<-][$]<UB8[7Y.Q-E["_C(/W("%<R#5 RFE
MN Z$/VV1_FJ4+?,5?/&/7Q8Y4RN*&4C//4H3<0Q'$8W?>"I9CB\2?4L>T$T%
M6CS7CS_!$0?7=AB7,4=8:5@A-'1!L@V^[R="D"V.N3BL5@L_A$:2Z3>FG;K$
M3)LVK,;<HT5\D9TZLXL6I>C83IE89^]I-C$XM-0[PTYK,N#S JR' V'*AS'$
M,>HTV!H!"*"O##&U"I=ATE@IIO-0*Q0<[<R\E^3N6PS.4'"=9E"7+),ZVKW2
MO_WG5JK1LEVM4L,4('(F%[W=C) $WTY_[83?].0![-B"?QY(\V2JLYI(OL@H
MG#3[$NBA3UMJ'_PR3]83H=TE076-;C55/%V$QR*%-UH,W( FF,BRG7 =OA3M
M04Z?.T2KC#VS7;IQ8?+&9*W%(8<5"9F$:+URKZ.\OPE1B\)[5PY?$^T3#D>J
M&M7[];^:J4'UU<L^HL7=X-T[]*>P):F:ETSZLL3F'Z0Y70%-WWAAA< P6F7;
M' \KKQ9ZP%/&IBCZ#6C)Z%YT ';C-%@"%J.+SWHG35MI2\]:;E)53$U5?)S,
M-(/R"QW;TNG"$EP?LYP'E98Z61Z+J#59AACF+DWQ:P;[!%C.4&0/X(4QQB$:
ME?Z7!Z,P'L#S=O:Q2??<$+YDKWF;L3.?1ZZ;MC1/19_(A'2R&A$+>%*-!5/,
MJ0W/SY;$CKM*3>BB@!F*40_T$!-3!9A%? AXXSFG2D.]8!Y;G#_@Y:@5[SZZ
MZ&)G!00LSQ_>B?U@9#"RHR819D(?_3=FXV;*=1=3D[$G>@6 TA,]&$8!N!>[
M (_ "@ XLD5DJ\AH5V1DB]Q"(M1S#@I$1FPW:%VL'=$0%!JU&-[..E6]*56N
M=BO<.%A!,1Z"0R  _WOU7*]GLM[@%EXCB$ID1"RR%K[6XT[+H"R1!P\SG4#>
M A^D5*O8%^;->I $4+LM1'^VRH.XMRN/N9YTPJYIMU,@[,P6Y?O$T[=?!HO!
M2 N:8G>:C]_DB(,QA'>3PI5:-YBF+<.(A3>XVHT.G!Y% Q^%JS;8C7-_*LWN
MO] (]%'GR6$(8R^J54U_I#$83W5#Z<8R"D,HAE8!Q#;$Z/'_LY U'OZG-HCL
M#D,/U^X8>)MVZ=HX!91CN'%#H,K3503L]W'7Y$ B6KSRO5#^>FD+E7%Z,G6!
M81Z&3W]5^-8F2GJR+>)T55/($;23X01]BG8;8L!G<6D-Q65&=[G>*\Q$C^H&
ME4XQ[5@Y+?INQ74Y"_CI2POU49I.\R]PA]5>M*)'RG1#\PWDGY?;>P\["<0;
M40B=ER]93/AI /F=K7PQ$S=EG^"L\( ) M2],-HE0WJ!Y<6UWV2>RT??V[B9
M.:I?Q:IH/;+L2P!1ZP_7(Z:W%A%D.1T^MZ$[#5GLJZZ:X,/2O*D^W0.+E!^1
M^3,K,K,-O+L!E$11T*=[[LA0R^V%P<,_<]6 C!B-+,%0LNLI8*+4K0(,[=21
M+_65^Y51]C-S(./R1,Z[9<?X[*%9^Q4)K?/3+C.F1X9,:$WO(6Q>W,*>V2/@
M#SD=!GI[CGMU(7S"'GE9_,[*ZD1-D2SJXG'+A7'0P,&>KV-NW9>>8#MQ[6\=
M#Z1QJ6.[#(:GV*O/[PS3AK:TV/VAXI6"=1+1"2<R!;J*HGOWI2\RH.3'ZJ7O
M[TG$^AR^I&!S [H\]Y^*D\5-;6]W9OH%V =1#"]9J6_JWAL,/4\K,]@LL7J,
MY#7_W/CQYG:GG43)&3P'X@)W6TC@'A7'/>J8AJ#R(CV7U8BYJ<YE3GZ>',B^
M5IF?,@$:WG[=:52+*)V(O+(R$;>'3L3Y\$#1()DJAQ-.%V[]>]V:AR7G^3\N
M2\%1X&4XV[(4<&)_OD0Q8E?BIN\]T9,%Q;G#_C>WE806*.!$,7J.X++MP^RO
M5<Q# ($\?Q ,H/RM)\!Z[<<THDAA97].RZ7C%[ZTG*\DM,\Z:.8(J1V8Z[Y\
MWLK%ZH9DNH\8!W*_8?Y'%6\ICMR'6UC&_Y;&+>3AP&@[$G/Q%+<3D>E<&XXB
MMM6YFZL<"$VD$K?7?8/WVT8;3@SC2B,QQ647@N-(GGPM5OZTOBY</:H#+\QT
MQ??(_#O-&Z<()I5C0@!Z_J(D[4SXY82,D]%E.8^IC/7?5T8UOH\JS;O+Q1<\
M4&RY!5O?^M^^+K%)X^[NCVL_CJ#H8^Y$LOEM "6RO%$'-)&M$&O$R@_TE1^4
MP/X%THI/)+K3_KJN]E(Q(Y*MKO]W99E+BRD*Q95*-YI(K6'Z5/FDNT]@0RBF
M#)<"[7_(C420E=RSUD?+Z.1 IA%$C[4D"DOVRAA*TY2DY0"6 Q<4A&(7+*)^
M&,^O.U8T4Y+K6O\"(Q]A)R]Y'P;M.G]_V,Y,3&"^^D?/GCM*4W]H-LX=QKC$
MP+&L8&*>/&-<&M"7N&=@U UGZ W&PG[GD^[U0MA-Q?_C6@?8QSWN,\YW [3&
MOZ_L0'S)Z,@D)5$WIFMZ>+IAA\O5BEAKB/UL0:17YF=;29JAK6D@#=FE0CKP
M=3F@\9RK$PCMK#,\#7D4]5<B4SJ2P?67C@I6HIXF=D9>:02#%\6.Z2'D><"0
M$/\#=Y%_;N)4! F>8=P<5;I5+J9W$B24H$FFXV_,A@?FA;:-^]X;7&]#W,4M
M4)!?"&S9##:?&<,$S6LX@B"V*F).#HW2XT$#L1MA;T%P9N%[15Z%MZ-M&L1R
MR[OU+!B,2&CA*^J,RZK$W/0S/9QESP/6<O^:-@?BRR7P-Y'U]0D<R%V$.%>#
MN /P]<0%(WFI^D:\>V%]]_QS^N/!&";\^^M73EP3=A@LJ%1&-6G,W4Q8M)^@
M %@\.TG5UO\4[V_L#=Y-?ZXC<(EHKR)&CDLX4X!@#L1FJ?L=A/V :^H1!*@X
MV(&:T>=V] /#"CLT)\[E]YWP\/GJ^_)"58 '&2GNY;\J?X2&ZD;*YW@S#":)
MK#/TT]OQ/@9@P!OP#@=RD]T^MI YM]'9J@ 4%='Z#D3[^S[<QWZC_"ZF.*8X
M*L]&;+^-C13WS?\.PGWQ<"&_SX(MM/,?;+L/63]/)L63#C*UWH)P,HRX00YS
MZFY5 0B1M;%FD@;/J1M/=KYH(.3 %(OJT;?UH^N#<;4?4.W3]+J7,R=V6]7P
MG;E'6S.I&RY)J3R,1*[]T&RU59(L8B$.5J45KVL4>B'OW3*)7W,^XL *-;@A
MIW;^Z9]2IT& TU5C]]37TGE#F'U%!EO)5]\^L8=T\JPESJ2P^1@,#6Y$&[3P
M 964X'4;2KQ;-P<BV"J&>0 ,]O1!__[B,ZES()XZ* %:=,A?!NZEY:,G7/0T
MQX,0O'HY-*A]\UB@"]QRV&.LTE?C8\6.M$;X6&WY=9X5B[_0/)3=#L0!3VY,
M>"R0>)D:8"A%3=<>'=H^=Q"@QR_\*?Z.,GT>$&NF\,_0N@8+9EP="S\6,S)Q
MT#KCH;K]$._6%G<X)7QP@,7@-"^;+X5AB3D/$AE7V9\?(:6Q\AA=&K2+].2Q
M(9$62S%+[)+%<<%"2/4N32^6LA'Y^PRA\H^[A%9B_JD?V="3=_&448O[G1C%
MY>DBSEZV=>MABJDO(;@S,, =VMG<+\KFYV68,Y6V?HD:@Y&,$TATM[TP?FW4
M!W^H58VI-;J=GJMX2?=+(#YJ[N2%K8^D)KM<,7>M2\X\#,Z?YY.X3??J(?P&
M&>=1TZ$<B'5&_$\>YB)BH7]PSS0RBK0VA.4"YXH/$/,$,;;Y'Z6'*YW^'2%>
M-KP4<F;>8G0#;CD!WZE7\_(]L8HZS('DIDAU>K%'_Z"_#!X\&A].2" MU,Y7
MZ>8JA88^#V+H&U"7"YOC[R:8X:X,8<P6!4_>JI 22*'*G>DV-6(,N^RIJ_#^
MT\;#>OU?6+*'^F\]_]]Z_O]?/3^%8$H:T:F37/V  /ZUF+98W'VZT9U%<]VZ
M.L(68Q[YX/!"TM&C$Q?35$AZH3$OZE6FK^*-W3=<&30?E7[V>J)X?\^+Y.F[
M9WNY4A2#!WPEF2)N'?. -6Z:T8,7(WE=4MF0Q/;/U^CJ2,;K*7HZQL\NXN,0
M8KHH7&G? O(OG]_XZ3NDQJ$S\U=H\#C=$ TMT5GO"YF:D9%P9K'NK<DA"*X4
M']%RGL)5]#A#(.,Y$_$6;=71>F345P,%Y4HZ1YN(< J+]_HHQ3144,5PN+8Y
MU.62Z>C]\L7K:JKW?=\0Z\)%3MVY=N,-SU,0#T@NX+N;29 5A"16E'D93"MA
M*M-(D=S,>&Y<UX>B)MJI4TD>A(%6ME63NI<7H?N],]-RNK@,0U>_R#O3/7Q,
M)S?>WX-+.3SLE4)\7U-N0?MPX$51^@Q7Y/ZYX53%RM<[PT2,?QO"JH(C?0:@
M-)!B7]>4W'-C&.-!N[?]4S+WY##JV'$?U&$TO&UY$2:+?NQ)EMHA"=F?#W]Q
M_><^IBZNO9A+[$D1N/J,]<LT(WH:*Y]YC@!R,R-A[56N:(89&$PM5Y9SZ\"+
MLM5!)CH"!U6**0_:G]N'!):>:)"$YM%9CL#W;R(S*TWTTH6D=[$?H P[D[$V
MQ%C"W-S<P)R Z?5C1"(Q0B74QP>=+! :BA:^$W'P6+3MQ=L1FO;4&$WK>/&;
M8J>X27%@D0W]\[PZ#G,:=*'BIS;HNZ +Q5>A/?<8.$I%"F/DP74/"DNBSV04
MX[[H)'ARL3N7#XPN"7MV*1#?W521Z$-=%^W\73X6X.HSH0.+<,^\[5_D8OIH
M'^MO7'L)LI84A?,<!!66.CXH=#G&=[\O9_<CA-E'L?VP:3OW3*H%%-2#":&7
MVC(#SEURA IB$& 2!<GOU:%ID&@Z5)9W:Z3G1,(^)HF;&-=(FR]14V[LSS.F
M',CX# W[!('$+0P-@HH]9(L(#J2ZD,04"Z8F/MV&"F,"0!H5*N[%@?!HKGOW
M3EK_F2?OTZ%3N/$,%00[U!.8G A%5U)Y8[<3)3@0'Q_;CYG9K7Q5P'I\_&P%
MOFRU;OHE+]U?+Z5PUEL&6QY0M+PK4Y0B]\W1M?!R3DM31);$VY<]Q4:$.6-9
M9X<>;#I]&9V^:5AO_+?*17^1_9"A_T6MLBU^;B3W(+@DTA51G_CDS\K:_"L<
MB#> 6 M>N);194NO^45L *=H,8.&-(NH=-2)K-!!T$@/YHC1&5F/BS"-5[!O
MI6%S8D/NMD0_09210,U)N@K7<_^LR6&!.4:3)Q5PW19CS"K3%)B?1G6;Z<JB
M%(9T?3QN$S G1C%+-O@U'HIM/ 4ITN-^O."13D_,#N6(^U)F2)M>#?<4J]@N
M!##'1:[!Z<B%NJ0"G _&"-AX/K^(:&_(>SXX9M$%?7$<*?ESVC"AV?Y,X6+8
M\4%7\$'RV8YIL'=U*?:X/5<$Z[,%$UCUW$00AU@H11[8YF(D!S)%$L!YV]]C
MO6H]&AO-;!;@IF78BDS@O(!FHZ5EW<M^ L9V5%>A:/#=P##.'42YTE3XDJ5_
M*:3RL$**>?JPVKA/8F [EY;64WG9;Q\3(;B$2N9A%;:5 C<<Z1Q(S;-AQ'9_
MQ0U>AMY_UA3.C63"Y%"%E9UP4$E\[%]$71'@L7X)A7TE[7)FT@F4._ER:D5_
MUF7UUB&(;DW<MP6>[5'VH4J\%9>$H6@CL@W97MRSUGMTMA=\WI,=L7C";>)^
M1M(UJ/WMIJ^4,=_S_P=Y[QG4Y!9&C>*QTD3I/4?I77J+<!0! 0G2JT1$NG20
M ($<E5Z/E*!4$0*$@*$%I$8(! $!Z=))$! 02"@A0 @7O_GFSIVY=^Y\?^[<
M.W-GWID]\_YX_^R]U[/6?I^]UG! 7K)!_P? &II0]H:X2.-T_,>?X[984_?B
MK*VQ_PU#Y-^>DVQ\M.!_-_I@@J]>Z:=;%/B][;RLA_I+2?+BZ==?_TO6=O]/
M#&P%6)^=(Y7S^:4/SBZ#Z2@P^]0HR8,&%Y0ZY_OR^F<,J$=2JQ[@7?%![&_[
M<V([[E!.>@7^Q4?;_U^\R/I[BG:3C;!#$X4U[)Q#?>"5$]WSO<FBJELWV*3K
M0;Z:?&"JK5]SU**0]P%'S%Y>U?AR%#9%% :ZZ]H0G*Z#>;Q6PZOE/0]Q2Q7C
MU99FTKM=X0J?3PHOX"*=)CMNH<.88[+;*FWRO7K/&*0JRXO/8>&ESBV8%]2.
M*D9JX3O4)[!=V(Q6;DM2.^+>Z]4BKM\171(,)]E3>4W8/\]S\IQ,,0>%A1<R
MN'4,2 X'>QD,\Z7CEKP:._!_O:F6 &SW0S:U/5= BQZ@HAN!P!_?KMS477+9
ML,UX0N;B9(_VUHA$C)A\HTV=QNE<@\ HB:=('6Z:.#D4LS45$WJ"OK$ *=1F
M;JZ2A]72[A),@\'9%L>+AY-QQ&73QGI[5UQXCN2_KZ?1X^=PJ],=,,7H/MW!
M%!"GS":H"A1!7AM/;^Q^1J*&GC1'UJ_$&@WVK'OJ] Z0Z'_!/?((=T(_SC.E
MH2H_SH'%M%2EH2;689P-V]%%T3-8TB.VBYZ+-W0]%F.*ZFQC0LG+_HE*U$-+
M<NA. M"\8F-!F+3XIDT:*O!B091\>?!W&&NIUV1.X>WG1M5-<]X<RX_JZL95
MM9.9W6GEKZ VWV3<Y@SS ]/4KY/XG(*.[;0@4#%IC7R0.L_!M*P:/^<1EW=F
M'/\6: 0!6 "%K.-+TZN&(29L+ :.;_HJK*S)9C>E1Y$VE@CC6,#3]FI#F5U]
MK1;5JJ)FWGX_R>.<3C#)] ^M#/L]5O8K K8E0[[:Z2Q#?864#9.*(CL20\MQ
M=^6W_6Z%DA9?;[79?I1M,?YZCIG=&YO==4>(Z>UE/:$V78DTLG9WH23*N9QY
MY<=OX2?&Y)#=E,IPA)UAZ$%^2$WHG/<L'=K++.#P'<9Q\"L R[+RN)QE[&9\
M=2*\[<<WBZXN,WJ!RX2W3R;-#YW?:%)U>KZ*EMX"Z@'=B_$M96C217UP'/B&
MP*,<1Q(<44Q-MY\"\A'S,I\?:OEE(]=G5NLKURD1.O4MO!\F@9KB^3/AN4(/
M>RH=]>6+PGIQT4ID&^MW(R7=JF<,F*#%%Q6N4K:XQ\6I7;B"^]4.JI+F"(O0
M"OLF/?9*Z?Q/V>M&E?_-*B^UH;CB\G<W?!@3?ZZ52(=*:'$]0?."E/.7><T>
ME)OD9!HYF#NE'ST<;]C< IAC1T--[*M"Y>0IFZ#Q%WZ/>P,]HERU9Y_,#/.M
M:E9OW\[@>[S[*:4< 7.V0($PTJ$50ZI2UN5,#>5"KEK!25D2/)-*R:;ARN3U
M^U8KDJ8:_>P!6<YI2LGUIF&F=J=_?E]8T[L!3##O7SI*D/AEM>SJ#1UATHL.
MMA&HLG#Z)["GLU\]2KP]JKIM[$=V> ?.U:VDLNMG!7UT,:4"C8<Z+7];C!'+
M<*G3&I=Z%HCB W-NNJP3Y>XGX\8^E/ G5NR-%_A:G#'DV.B,Q2BQ" ?48@*_
MYR,?AWB-/D9*P]IR@)5/\%,K27%%"SJ&I]AHSG-6(G!B#MDC&';.FH*&NZ)9
MZTB(4K)W;MO,''9V)CTNI#W8^L:B4T517RSFH:\SH[,EZWS[J$S,-"?,C3#I
MG[<V)Y&S>C2^;L:7BDS.?R*M^*$#;<)ERV:P3]B>KP09(02Z'H\>8P422! @
M5JW[*4DQW_-[*B]&LZ6H+5O2JJ#TH&[5>(B2$26;\SO^=^!YP9D_38F^36.F
MBA$7 8-G#(P*/6;<5$<S<G1M^7H1^PQ R]=H&WC/HPP;MW^RO**64]R.@"/=
M?C*:5Z%9B:4?H[")@>C$.7_XVM$VLSS8NO\.I.6SM#(JNWR WUC#:]RN,NO
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MT+NAK$-OT-5-/XADB=B#A]R']Z9$,!Q.<@TY-A:RMA2OX*!&_NIV>J&\G\[
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MY^#5:AN,M*)3W>&+N8/V+->PD.RQ#A98IS3L^>*_.E=&V\ GGI QG,-B$D;
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MAU8@KK]4P9 KIEHKZXRA5=[0PLI;SS0\W-&V@7@ [C?K88O7$:/JD3GP12Q
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MT.)4[K5E1TY/#@17-?+*/D .F%36X%QJLWZ.GLX;M32,38Q5H'FL(6;QRK+
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MLMBABJOC_%\OLFS3=>C#-@YEKSY W ^-,>0=W$F[X^.IADTA$>LV4_G%'F'
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M/2;-KW>PMX_%92/Z!-CD(:K^7&!J=-?Q=,)>R'L,]X6VCYA396+.39-X#5V
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M>.YETF .5$OH6ICA--N;2E2>LV7W"(\+3,Z?(T.2,A @BR"[%TJ9=B_DM+=
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M!),!O;G;Y;YE?54^#NT_FS)-JR!YW>K87Y/,8<#!\E^;X;XE7CLJB].3:EM
MO%E0HVL1F6D@J,\*OVH^4-- "G<'QR.D*V.9[CQ.\70)&#_=R'_K/-HDBK*J
MHV3FR/KB6-3 .5$>'+R/NTZ?5:&>U7*)%@]K-LXB;4H;DGQW<>_O\T#?V@(E
M>A9)%F8_WG2:JD2@MYB7M@SL3.2'KSE"XGM-9- "+LTD]]1/TU]Y277)KZZ2
M^>Y#)_9Y%5@@>X(??Y$6M#)>AN%-V'*FPWN%'-E4Z<+._B)#Z!Z^*P"C52O1
M*6.F,I'MD%L6NMH_:/^<JP)$] RX[HQAZ\D2-C[7H\NSS;*2>OB%KM#RV8QC
M8X&3WC5ZQD!@F6CP^8%I5V)NG:4>A$M\GOQ-4PR[7#6C]$4$TYJSI;:;+KUY
M6,3X62")JB?TWGI(F#WM27KG?05F0YZMC=.(5(@6EQM3R#P7[_="Z>OFU8/A
MG4%]/FROB+\/I8;N4#V?GE:1>2.V3NQ'* $4CICLATACX[#@5.Z2/A_Q[=SZ
MHU8ZX]T*)[OH!>PED=CI9^,?J9GE3S[6FJNVTJ3(F%&15[C;3V8<YGR?&E!O
MD/I+HW23]TLL<7,'#6BCE="G6PUP_U=OFMP)FH8CA>"K1KT)-8R^JDDI;5/C
MF_V+5,YG=$.**[C;8_O6/X!O5VE<8Y3U,X;8;*()=OH-P;UV%:I+\JO DNHQ
M[3K0SF4VOO7@-X"X8CCWK&X\#1 N['_//=Z<_$@[QMDV_K?\]AD#"LB_Q/:[
M358#K5;RHE? D,Y><R#B];1&U?63M!%-(^4%8'L?!+^Y WVPS-9''4[0P5BO
M:)P+M/KO12=.Q/UJ9S:J5/7Z=Y^%=6F4CT4R3!/6>0[?S_[D-A0E 4CO((N@
M'#JG/\[T_NA:CYPT,  RUBTITC8&O>RE/M#!6*+H+2R=\=?SAN\S G*4' =*
M7AA@#%+>^Y8@6[ZAP51+7QR4ZM=X4+7R"J?=]<E%8S_#:ZQ+RDOZ$.F%8[-@
M&R \>K5*Q?H[*YSH,HMNS-O;(ML"R%&-V3Y0E2TAH8>8TS>.LYU>E[@;:_1\
M?7Q97E(F)\FE=QP[F60#.B\I5O9R*AJ@! /QE0E)E96<%\ ]HUGE4L:F_19^
M%EEY05EYK4'G96VB">6QY26:873^B#W/&!&%)XK5Z;X#4.6;:#F+;XHHAHMG
M#)9F-VT///X%[)IYP"B:Z?0/A.$^VKG(?9MVE?ZEB%Y4\<>"_1KVYR?:RS.&
MND#"SJD1"E#*1DO\#*/C(46G^BJDP],]Q3.&&F_=X]"B&C#)XKPT*J;/"-![
M?'G.OZ_+,D5<X('U1>' %+YSIOFX5F*&;$;+/"HZ#8^G%Y7"N-1>YO <OFSD
M#E0Y#&NZX>#PY8V":D]W,LO-O^G[&5H?TRUD3@J#4S5 I8NR4GC+_!:#.[:9
M1Z+1-SE_CC_[-&LD-M'.KMNN,#V[!([1]0"\H3-3C99F']ZN)0UE^PLCD8BV
MQT^H.=W!!AD^"V+C,ZJLJG1T17C3U6\>W(U8M['JME89&;MG9PQWJ9FZ^$"U
MT+0AQ?I,9%*UA'%F9M:=SYZ--50'(YK*K[$&ZXS5'%4CY^!,V B?.UA/IO-Q
MY^,D<\0EA&A&J+?C8;;'@F7V8D:#=0EG3A%]#L"TKYNB6Y?3"[BV:>,3*M:$
M.V.X047C=A-&/LE"K9<&U=:Z%P1;,4'J76O_&W=O_@_E&_^/3DFV-&7?IU"R
MEVR)F3:$D'TW2;*;A) Q4]G7*<0[69*=D'TW,9:09 ]99F3?9BSC9A9G^ISO
M.>=QEK_@_.3Q&(_'?5_WZWJ]GLM]7]?K,AVY6-UTM4KSR'MF/TXM.4"F/O=;
M<"TR+:Y*Q(6M0?JINM?EBXY#Q>'=8XG\W&QEZ60+^X60HM&(&V6/TI<&B?ZD
M1B@T?B'$J60\OW;!-ES4UO#%P>?/FY[M?3>O T\JMG,/J70ZG7W="BH)J!'3
M.M6J6@[2#W"*)]:M_/3H59Z99AU3%GL[6,IS@YO70Y+ARX[!=P2\UM5Q9OI7
M<4L?(EBUO05,N\8*>5J28N_3$[\-C+4_6M-R>* @AA@W=Y(ZS,8=;&J3/$V
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MJ[D+\65:S]V))9XN$A0I2LZU&T%*$^S,6[[.N+\X06]#UV9W2*/=L),P<AK
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MH!5O? KI"3BX/+?D'57!1%1YSHH!"?DV]SM#*RS;B,MQ+8KE=Q\UIKB+G9U
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MG,.-YVU1GKS?-^ZON#'M--//!-6_1G'^:_.O,"XPOH2(P8*\ES+$8YZ\F>C
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M$$&,--BN\2"W\7V=4+DB3D*_4:S85T?>="I2:,87UV#9W>J/H.DG]G2I@@R
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M%M]BW/BF,DU)\?+4 MD6<"W_GN%7%)1KP,#,CY9IKUBV:QT<=Q#PV>=ZO9_
M8^G_WSWK29BIZPN%;V!/%5^A!=%NV3'\\"=$Q7;%R*SK0"8A4D\BEK"@3_0)
M"RDW+%BEN_8KE)8**P_OQ5E8I>Z:M]34O+EQ.5W]-Q/U.DJ3ZD4JW!0F31 F
M-EE("HLJ"%'J4R!M 1P+57P1$N9^N7[!^-Q<4-3#JKJ3YEES^K6IAS4TC7&V
MQWP:7GSCJ04"\]$76/9&/J';_T*(YG .-UO%2,T;1 29>PBIA1^0,OKE+P\Q
M!FZ24+,XO:&:.'5_FJ)A9;WQ%(\DWPM52Z+M])U7<@\[HW/9KS#9T248T/FF
M CVD0(MBS,T0U>D8M!+Q";P8THT^%Z#(AS0FP;OL.!7O$4]7$A!BGMAS7C7P
MJ%]K&I H3=YB3^C%)I)H7=I\7$BKL?E832@W+M!*VAU?Y!.0J6LRLB'W)<G;
M:&N)K^DM$^T+;#[E&%07&D7E8:&S[5.NTD=7 SQA,2UHXH+1"%W*SO;0I/P#
M*:3==' >&VL)?Q(O75F;W#W%5UFT\LM Q%@J:GLOKO,N(N!4XHG]P1[%0_%L
M =A&ZK\U#:/&EI_ )(:3>,.,[GN"GL^:(S^SE:)_J.UCY*OK_[QT!N\P8#6L
M'>TIRK(P0>69NPU(S=,\)JR)!QL8(N(>$$" 5#;]L;.EVI+*RXJ"#GHL*V=Z
M*!\D1Y!:150M!E=X"]^?\FG-63L*[;^TV3I0^Y6%K,+(_QKZH-#@!L,]GO*F
M9?NTZ/IXU0YB4.) &.7NX.-?_\UR"O>\G'*;/=W@JDZYLPX':U["0\[?O6+!
M@?BB[=/<>=**,<)KL&ETNZ,"+0D[GP=C5'NX8<L+L7_MQAV11@V_;._#-Y(5
M(Z'2:^G+8;5!3C^>JWXH77WG=M3U]K*TY,CV!:G^IQVOT+5IWV#Q6>=HGU$L
MU(O _KSP=.C==K@@2@B0)2 B%;S+)9KB5^@J1'(V@>.*F#41.N+."]2TQ*3>
M\-Z:SYH-^IPN+7X+;/?_W_,@]ID9DZ0(A- 2B&J$Y<[B3SOEF@$DL1[<BV$E
M?+DRYH3;-?O;FMZSD$VXP+HJ0P)EC2?]?5: 34&&_@AM0R<O^@8FPE.-N2\-
MJU2?N1N?ZT/O8;[CF*R[#H7@6[/@\5TJKM%=.DF[D6+I[D=^$^G[QM^IOHR4
M3*?^ZPZ80/&F^K9%HE5Q'4?[&-R,%I./G=.\@Q@.UU1S!3U%$DVM?[Y.Y?JC
M0:Z8UI3M1U>K<U\L6.@WX[]3X&(R]6<.7F9V7GNZGT/CG,.H&50BE@2S':S<
MO-F=<!^?N[@?I),Q0>>T@/PXVJ6S^A)IM7-34@3=3NE/NW)M$.K54"4V51*B
M')AS^/JFPW#F1"A#^UT*5[3DNL;">AL8%-OEC<)_J9"/J]D5&;/P/"QZ='5?
M5!LA\SM#=J=J*\3^1"3Y0Y8LUT1S9,=S19GW:]JZQR#IX1+,N#$@S;)97X#Z
M[LA:74=\(,2[O<E$8F_?.P:QT>I^SI*-SP"6XP1X'5!M'14C55G;&ER&5,F?
MA?U6$0W>\LF:/>K7'9>7I*)Q8J=*NX,.^T5E]H! ^:(29ZV,1>;8KC[99);;
MFT+)!2F5*H]:\^4TXLUS-$:?M/7'7E]YTA!4PIY1+?<@V&U7VV#2Q'#7,GVF
M6V$M!=(LD_8BQ4D9+2YVE81A"";@HRTI.Z&69M8E)D/BW&A*K*WPM'H^NZ81
M\:?AM%YA2A*7LGGD+&N'W=2T+F]MC8D=CD>/EO;F&U[IC_R9LTR<NFSA.#/S
M(J>5VV;Y1AQYCYOJO^1M2_<VZC6J#G:56I7%E&KLKQF5>20M9>JUN>NU;1/U
MW/ZM<]'=9SCO4^A1JD$QO=.1G5'6D4M+:Q-&)$1B#9:]M;^E#!)9IE*_4_8Y
M\+!MP/U+;YF=G6YCTJQ TI3\6YR("4,C 8,&' :8:W.6\4XR_VFVE<O?ELR2
M"0H(5JY9RF2^8_K"?F#W9MTT+?M-OJ7-:<B4ZJCGXXLZQZ#=-171I)WXPV$'
MKJHA26RJXI3EMN$HS&T.,W&DF$;#A)"J"?FSR8N<E>BG?X!UA_2>?N&/YVGO
M";_55/F9?-?AXRWR[#6 :Y3[.+:N\)W+N=)0VI?G5$T/N':%4N#02\B[I^5<
M/W8%S>C"/0LB\O42G>:+]7T]^RS_4!! :@I2!-S%)%(A,LL$-$;3=4$WT*'J
MXTV.9C23=:GKF0N3\X<^FZ/4"(20/R%T@)JS\-1Y?TN](C*N1>D+ENFUGO>@
MN@'$=&ZV[=H=^+S!QB2J^AN <'IWI]0RJ$7[Y3;UFB<8\K[(P?^@8I3N@'7#
M1L.(M6U:U"= 8G4P>58)>+\@'V@8.OUF92)]<]WMK41@XL1]/LLAR.$RE]5^
MU)E%[*3(S227U,54#MEVI[6R"D>!EZA9RY5%NRS#0->_C5E2ZQ\2;_*&E  E
M8Q)T%A.*RDI.7UH2=(U1RS>H#+8,'R$/$^FM<F+>A3CPJ:#!'JXT^PX%'R\G
MHDZ6L 0B4W0BGF]G$@4D_?@9=G"J8IFNL@0WF4?J".J/#/@"(B?KJ&\S*O?E
M:;/V_))-MLA6+WK4FZNS<UJ%IA.)W&!'[/L_EF*PF^--#*EW!+%$MP>V70PM
M[4:?@/+>AL(J-:\3LJ.%,JOJCT8(H:8CN";)J@IGKS:NB53N;NV_D]^G,>^.
M8"XM_RE<'%B$+!">?0B0MG.)R-<T],=V[;=H49Y+_"9Q<+\\?,$)PP^7QJ0?
M@RJJ$F00BQL>=J-4IHJ5W-VPHVW&HZI2H6)G:/'*F//]X/=^)%A/UG52;G/Y
MI&%FQ SV]1>+ZLAS7D1D_8LUU)WZ! U?Z!+].JGZVM&!B!5.>U;0$O[Z6U[=
M<L8E3#%B&RZ0HTB\1/;"NLTCU;Y^S[$HU704;PVD"]1&8?I&%9I")M;0"G,U
M\$X(8#LG1E="ZMJT4!""2'U2:G-!VV:[O^? B_V:^^>;>SSS.&3=,-3=&-DC
M7.3SN8U$T5ZE_N?]S._GO^Y;3E2<T8(A9/V?EPU>;J[>L1_DWO_1(QK;.H:T
M\&"(9:8B6OK>PT6#7D@SEJB-F+SYH(XX6T&Q!";NU3>-JX2L'X/.("$A*_<*
M]8;])QI'-!T(_<RA0_FS9<6AN1UDJ]C*69NIE:.]:_63M9$S5-I"-O]8E@R&
M]9%G'\^5D<+8GQ8W[*8MBW*M6,**/=78E1M]S2*_9JP[3=N/6F#OSC](OY:O
M26A57KZAG\KQ 7DN8L&VYJ7C\]8KS7[:9D6IR5!'1M"S_[UAI[J2U @,JW<"
M*4Y2+<1CPU$<K:,M4@3* !=Q\@_U 8DWH7_2,RZXR/9J _KTZL15X_S5*8O6
M;Y43+QP\IOYKJV\<+JN9*R46XKS.6J7BU:-N= QWN0JLF'8_*IZ(TE1J45X8
MC'I6J-*_/_4UQ6.T],HNGM9GWGA)J*KX+\F5:Z+KL:=+@TQ5_IM/BSHUQ<V:
M%O>;S8T,X$Y\&1*G#CUL^NQ[VW5)+[#/H>?H(U!A#.""!BXO111]%4(5$^?(
MKLVD\%_O%FM0*J-4J4!"?YS*/.H(+;"V8ZOS@Z=EN!0ZW /!V6137=HN$Z05
M9TT'U L$KK0>@WZ[+UP,"Z=)O/E<L%EE:2=QX*5(E7S6>@.IU.%B5&V'HIL[
M/&UU<)\>R^[*D<S(TON;/)I.7X2QP0H@P$5%W-S&,2@2(H*2-CP-Z7)4(QZ#
M7F\\#<!Q($ZM)'E:1?YYEWV9L-##MWI=JE>RCCT\M>XB.A7U5C"M9J!*I$!I
MA.55I_,R+Q586PN_T;)PALG=/\%@:GAB'PY^]J?A 4J^8N&Q]*^X'=R(WXL=
MGR9C*E3W+XS*4T'@I\JAIUT7V@IYZ &8**0A@DAO9_))G$&>R/L=9&;*(*JC
MK;12!_6?IR:4%CA>P9X2F^7I/^:-('D,;N>.2'4V,[B!=K,LCLV;VL&-YC(O
M\B#AO(]1M=E/N8Q(^19.#&YWTXEGN)J&MQ_W7?NQ+$@VM2YP'/P,2OA;^1/2
M,H9Z$7^FY^U0#T$4A=-/]^X_X)H5+I9*,CIETCU\C3T/\^7G+NOB#57/#WV]
M+H<OK@M66$7B1DL%COI,3 Q*W<5T6,#[+4^YV;%+$MPZB9F\^N_"4)9&=$O8
MEW_K?1)S@$#*66!"N^K)UX\]1]MOVH17]<Z*GV]7*(9$UPK?=[8'*\ Y 3/+
M:K=O'=-] )-;Q<(QB.7YP0??K9,UV^J+H]<F,^W6@W7B<*;)H>-2_#J!VSRH
MGF[KB(COLB.8)A+O%:='J:E&CL-ZET8F33*\:S]0TY#R0& %T@[ S",BH?SQ
M>A7 ;I>06L1>QYJM</!^R(HWY^;X']ZJ$4*2P?JDTBG+U%W]3ADNV-==KWYP
MLDL0=8)G,ZJ?^)X4X#7\/$'(QR,#AC7)-TI?OZ$-27"Z.G;MOR]0KEC:DGB9
MQM6-C+^Y/XY!S;S;>GNQB!S:?__<#@X-2%EM^/H%X W%1U?F.%I47/%SI]RL
MGK->)B$2:F/H@\Z7"^6;\M+XTY>: P,(QCSVT^+]9.UQQ*/[P[SF=/&^9\'9
M,?:>K(_7C:>7&HH)OD"T; _+JUPQC]BDM&96)R(Q49B-[:8?A=UGRY:^&%<6
M@<]XUW35<9!-7WG%[*7&V-*A\\^Q\C5SGWS+VL7E)%MKNBI=CNH Q)%Z>H1Z
M.N&Q8E=&D5:$,H_'N[-S^LBXFX]^C!\YOGO24#/L'\+KQYN8YL3#]Z*2)&+W
M81);5X5,D_M^E4?I1R&; 5MX#D\NN^=LQI>4DO%BTGB9Z42Q9:Y?\LRD)!;<
M[>Q[(U(\*,/!QK)4K31UR.$BZR:KKENWM&1H(8/9:X%5 C8<5EN/0Y]=;<H?
M!F"$V5IOXFX77<SS0W=:45V#V#2NZ4/U6>_(LES/ :=+[P\CRITK/YJ/.*?*
M>INN!^*"JM\^VLTZ^X.DXGYWO5&+[:FZG'YX:)G*G>%.D^5ZM<J**'*L_V&C
MP_WA(L*B/DMKQXT(>SZ_B'Q!K%-\.LZR,+!7T3U?^OGF('M&2U7MJ/WGFF28
M%7J^J>WTT#:4E2H&)'E_$KM(/.B2(IJK.8G;?5 VY@/,.H5F9IK[7\M];4?/
M][-=C$Z]+[:$'S(?D$9\USS1,QX9FNF2,7Q4)R5M/<$9S(L44^2\PV6 C\_4
M]+XWDYP4;T$;Q7PEL8#97  YB[2:_#@RVRK:U39!KW8F7^9\U6K@$HH+U94-
MGB9$;3I18$&*WRF&M0<,LWG&XV6><&#P%'_$-G^7XX7XQ/8:+>Z'S-$73]N_
MX>>E,?7<B.UK@$63ZA??:Y;RZB1/C9&>'66)4DLG"ETFG'?_1''NMRS+YW@6
M/UXU\FS54)PVAP,*&9B-"G(ZL$C<)?L"=PG@N+GSCVM:JH@YB0A.=ZZRRM&
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M2C\M;8SRO: VQI.$Z_&&:F[#N#O&D^U2+Y]WCJ>I:,IDN'R?T?]3%2$333.
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M\A*8!-$MLC A-*53^.72.:I+>3\TVM@%=9@L3;CK&BH?(.\]:S.#U*6J8*_
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M7:O#ILQM4[.AEL%SFX\E9@TMAYYG;#KSU<;[8+0M(NHET39]%4OFWJ/A<#K
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MK4-[B'V7[ZY:_")AP;:AYWY2[RW?+._;<:Z,PN?%TGO2GH];2T(=:FRCEWV
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MO]8G;2/:',Y\^"Z"52MKW5MD%3V\)?'N;+R7I+=!C 2<HC82S5W9WKF#7-7
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MD;"V6\]OD;T6NS,4=*IR="9M?!W_O"K2.E9>8J&E-JO_4REL\>]6@'[$A?+
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M3S12&EV/@JF+P^2H>JIZJ;GD.SV\)+$Z</PX2'#,:DGU\WQP1#2=?UOP&MX
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MM>6R_:XJW\M3C>V^WYR+OG:IIKQOB9<2@PVPE=PN'OY.7DIN*X:DMPZ<G+^
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MV+H[77Z8$8F9)]B! 8U&A\4E#N/[EH>1$,[*S%5[/"/W3YNPCSB+?*8SG^-
MN\X0 FA/" 5V(&9^"V3&J63EA-1)0[-6D'_@6\K5'A.IG%8V3LIE2@96HY>
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MCB@=@]00P-ND75BA@!/$$Y=IZ5 B#Y_K+$1D^:6)J9V:9.HD^)Y!3/9.'?D
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M9WFLD9S?3PA7@XT47QG$BD%/N&SG@:;#ANN*3)$3RQ4-"HG:(] !57K--S;
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M:XIU2]%:S^:YF[+:BGEU3UO?_'*<^^O,C'582.\8CMQC_QI]_=&R<*V#RT3
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M-\BPB[[6*E)E_R[UBT*YHGHLNC02OA'"<];'"^0]IEI-N!1Z+DZ<-;0;G)%
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MALY8_WCY(;$RU7.T1$MIRZ)XR3SBWWA-X&M8'2@&\6+H'1L@Q# CQQM-U.H
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MN+ZL)0RI8>C)^)= ?21[RSQ''!W/%']]>S]I]#"^JQ4B3DGWFQ"-KOGO5W
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M.:W5\^D"%8SA:-&X=2E]Z:_KU,C5]G=N\G7/ N#&=:[3$-SYT6V\#\)+?T0
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MLOT]A^SK01Q@*Y[C]]?A9LX(/39"X]!IL9MA68C0N4=GX%*"$2K@,0 >.Y-
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MRN^TJ%4;^9M.?K[O*2)TF$QV58K(,@N8$[T:[X*)8GK82@"W'QN?*[JSCW7
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M(V[3*H[G0NDEV86':X[6MSOX7T?^5=L/^VS36VW7933?"TM].)&B55._*AU
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M80.7(CB'7<5FK_HZ!]?,?N/!^#MI[YR#>;"+H60.\XFDTS>O>^OD^?Z'#CC
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M%596\MAQES=E[*?BQ@JAY]"2R><-S%RS196[3\?</DI\;.7[KX=L@8*'\1E
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MJ4WG?*WO<20ZX0SPZ3&$>05W!O@G]["%#.2CVVP1J:ETUPY=D9-0U"%P>UO
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M=>R\28D/U](QGZ"LNO(1.Z0\WC]D]V4Z<AO);,^*^*Y8G@$L79L=J,?E;#?
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M*2<C# ;:MA(Z&@8VDL@(2 XA;#*?"IV3,3(\V-A6#R48EFIU,Q5>+NWKWY/
MFCCDJ4KJ5/VAS)G%M']5[&9F6!SLGG]YZB/TX'=XF&I)BN]NL7[-#;]F6"5X
MJ]?=A%9^W,9= O-0FW,A8_:+S:M>-<J'%[W5Z\>61- :FQ6G>C)EK3:[1[G$
MVEL.689HW]7ZDC7GY5FC'\M57[:M69,ARTK(O6-6+$(&RNT:<\HLF)O=@UOK
MD%Y-7%^1$S++<[X"SJ16?=F,;7!_[CP[_=ZACQ#Z?')JDF9R)QSK,_Q&,I\A
MV:#W8Z(-N3^I)\C@\-;@$O? 4Q$G$-$E3M8QTKB<]W<?%=N4J?#UA1;=RO+1
ME/*[2\K?.IOE20)6&0?<Q"MP/3;*UX[85$@J+*C8+%ZP3A8KVMFH^SSM5F+;
MBCS+F07S)TXA1XY+(GOE\@N!+&B@SG0V&@WA >*X:VQ,$[,KA:ZN>C&+XO3;
M=^G>R;,Z<9Q AF]CW8[Q90Y*[>2W]Q0?/WI3]M<A[S]B"52\/IBK1[=0*,KS
MA%J>M1XXB=B/1NS>CO=PZA6-3_96UF4<E72XD$/IW_LXPT3#:V>QUE3!]P,F
MG:\.3*IE"@B82%F$J%IEF,23+NP-+FG05T*+V*Z%71S&WBJZOF%G"AMR]C#M
MHUN$F%ET3 KGSM4RG_S=8"@5N0M71FURBPGP""E;=#*)J^M5=UM%OZ@?X?L/
MJ4^M9JB:._9Z,8\LTH[J' 7G6<D\0"#Y[7&#V2U9-@5F,BF]+_XR4'<Y3Q+4
M*F5X6R3[V&2HA/@8&Q%SF*23.6[S[Z'RMKH#AOH"&!&IGIC=YM*C5\V-WUTI
MLCH1F/CHJ?C'7M]3QLZE*&?"W%,R:$V.)M:A7X>AHHF[6HXQS<ZT-3/'HJIP
M::O=3J@8K=:3"Y0FQ0<O5+"L%#H/D,'E?'*>T/Y2:];IN/)'@X/:8</ 1]0,
M:#5V9K^7@3Q5]-V)9#OK>-)NLDA<!T6S(KG,2C=G[5EKX9C\MIAD;+F!+V7Z
M<5&?+KN^V; _ 5>S/?=C[_:HHB22\C7ED5+FWH*=>C;S.CVM>7>K<FEA.J67
M!N_.=-.Y$=_P6[[;<T3[67]"]FP53E@C5,?$G&,^)S]WPB&H>HBXBA;AYY^=
M\LNP#',?]OEXC(L1 R&"\QE4DS@3YU:3=C&@L%%"(K.GOD_H,A,F,$QV>TZY
M4@;>?,-?$!"VNQ,K(Y*0:5AY*$.*7FQ=R7WL)B.<F%NR$1>78_7\:>^NL#?%
MI'4#[9P_ON$[YX\]6AI)I(R03*_2+:QMO51\LTLSL(I(SU*3"],?:NOZS_#K
M,R."!@MQ:WZNK[>& @N@82,P-!*O5.H@A#KP_G..?RFL.+Z16NLKP>]) O$M
MYA[<_$VW#/K?!:_28-42C8.-#\QT&?=W51JL"KV2D&V7W#V4Z>6\#2/UE_N1
MD87>1?LRXZLW1^YX=_WC.0@KL<+%+-!FRL9%.M>OZ_0!Z_R!_F.2CE>ONN7M
MUI;JSA*1ODFL*]'O*[*H</CV[5P:^7BHN=,;G1^-OB%![D%^81Z!I_,^/@:G
MG5QIO8JM?15]+4GJK9TMS.-FOX&7$A2.=_4JW%)I.NKQ6P11]URAHD5@,EWW
ME<5/VZG0Z"%E_'E>87G8SM?HXW"@CZ6_AKIN[?*PL]987["O^^81;B8/F*O7
MVT^,#4[="8^T23+%-N'L@( _#(_@#O=0+*-<'XA]&^,!G6Z2:4N7B18C^%KK
ML##ZV,C<B/]U[+6!]=KMZ#6T.&Y_?+Y*_8EHIH-'7)FR#?RFVR*X*"[ 'KTK
M\4J)]*,JCNZUTX]*VF\U;;B1OC2:R%G;/#71*;*FG3W"#4!(OK$QL_"IK9*0
M<IIZEZ67WFQ#?['A7\-7,<X_O_Y.<^ED?/8<Q1LQHG^DS5M 1OA\I9CTC&WV
MXS>"XVUKOE^^VPYL>%0]?$I')(A&M?=H5;]W;?3QTIH1=T5%Q94X<M<ME]')
MNC[J=A8A*M\?"+J-$B8WY+=_O\QIXK;Q[[YDTVO%!%RU@I3 ;OJG%_2J+3YW
MVY)*%F%E9L13[WS%,?>!*FNKFN%Y\%.*.BN[D"9\:6;HJVG1^$9"I6&_8+FX
M6KGS!K_=*91UW,E0^Z[]MOA:C:"-[U!!=+MU;L< +M'_T:*!N8=%A2-;^9+@
M,<I@\AUBJ[;[AU>I24]SKWI$=EPMM:+T!'_4&RW:;Q?QSJ5')</0NSU(X>NB
M>;/ZH0@M^Y4%"K*5!U0'</9W4WB 8!L21YAK6$$6+:5_=ML]K%Z+_@U_ 1S-
M]=6IW]R?_6U92U/"^Z6K28B:GGIFK["2_4#GVVZ+^A?#7VOM,F?,[>9_+%"1
M.YBGZMWC^W6O5>P<[QK-P-]V3,AY:CZ>7W=,4F]18]=8WH)=3,3%TK2\BW:U
M&4?@)$J+E]FNV*+(OM^M)P:2L0.=5JGZ-O.%V#%2B*IU2L&NX4_X$F.*12@K
M-14U5TU\X77_1@AA+T=WR,"4*=K5%/,RHWZP150I"E6G$7?L+ ,A"CWH13??
M'Y.'ZS\)Z[MF&@JWYG4'Q/9RQ.<?AUS2O?&N4D;M]7#Z]S+W@A36T440NJQ^
MZ<];61>;'HFRK1-6K^E.'J)TA1Q]4998I0@./_D<U)98Y/0BR334LGC\8@U]
M=2()%EQ[BG-GH+J)"3R@MHWO)C%C$8=-Y]3UVZ51%',E2DYFU%SJ3MPQCI]6
MA-1]Y#Z(3-DW>3Y+3I5MVIS$/K?@V)JVR;9*DVK)(+0RJG8$2I;7Q'VK%*_*
MI'_V\#U:DEJ18]=I175G_C5;3$I,[YA[89G^L>/6$927M-BH7O"C#-H/#BE%
M>:C34[)E+/]P(1-C]T N?Y]8$1IQ(:[!)\W6UPKK5K>Z>JHWQZH^[E/_2A_[
M+,Z+1>06<4*8<>VWY>2'.(I5#I AY>PPQQ'[_/T2J]K;$#&P'K;15CNX$1YJ
M$6U6X;@8*OYLTK9IUDN[Y>4/T9;Z 9CX^L"I1+J%Q.OKKQ;_\GGU]O1EC\O&
MEP\LCE#>,(YE+%FS@BI,$):TZ)(++B-7L5VF0<;*J$S&[IY,OYSQKH$4!\L2
M:1&2=(](<8:>%EW#NR/D4.O&X0J=K[73^4D??-@G.@4!%G&BM]M0"')GSM.5
MJ(1XI]L-93C4:S=]\'MR2(H.)9,6_JD&9Z 3+E[EOCWC>4GQ%^D0RLDBK->"
M46@Q[1RKP^.XU\X9"5$/:'D\KB:Y1KWDW .=H[U,217MP.,E%M&&-0(7"DKT
MM,IL$EG61-48Y39_5_72U1ZFV-'L!T+[$Y(7C(3C24Z!19(] 1.F%BK''C^5
M6+V@=TK1?6,;+*C-)PXUR);MQ)$&^SOZHV%I*(_^J9X)$QG]HB[0PD6P/L/W
M#@DKK='@[DYRY)N@WLY][_J+%YF8RPU[G0[)&DZG>2FFD97Y?[T\&U738N>7
MRWA9?BG3U5H@Y@'&6<+N2IE3ZZZ1$NWXUW1YL1++X/E>9?+,):8ST?$_5A=H
M_6-U@1VUJ\X^/D;RPI48O8?)[LM+HP$S.9FEJM-.ZZC]9=]/T!$CL]#AT)4B
MT(2EU0(UEG.LP&YJZE[?"+UZ,"*;_H4C4 !AK),LAFI-\48AY92(F8-,0DQA
MS(90,U>6X7R]U<15-UMZ:ZDB)[U38T?_JQDI[=VD_1GT8H]O7:-4DZ,5286+
MMI75 \^^E)\4$L\A"=JF?[KI2_,NK-_\NK__II1,5[^$V7XK7,PYL1FY/*DC
M'<2Z("M61O%D=H]XW7AS1:WA'6X+"FLNP:K@%N#-F.X=]7('ASBR&@GT@#V0
MM3G3MHV(K7+\TJ21XJ^9=:5N*,3<U^)>I8%)4*6;<U$E*9A\O?'>A^MY18FH
M(I =LP3&[:;?PKM>UG;QJ4JB,A;IBE:X.Z-53F[]$SUU*OL5>V-CY?;=*D+<
M/6ZJ6SB;2SU5?B+Y7>7Q9)]S<34%EY)5CW057K40RLT^%Y38:F]U:?BN]K@Q
MLS/\!9TX$/J:#*E*+*^".BQS,+3=?%L[2JJ;JKD3K]$ZJ!YRI.7TW%7Z!2B)
M<+48,[5H5HR,QY:E[$!++)Z8SJ7P#8!WTHX3LNJ5A,'4M5C"' _8YS6%2>'W
M:$XJ6T<F]UQ+B8$%:BE)G625ISO$\E4/CJBN#I[?@RX/0WDWAE=IMD1D9#$?
M.&9]6#^J!4*KY0,=>CZ7,I'ON1Y=5K<^;?80:T(*/Q*\^GJK%-=1Q$.F"FFF
M2@KY/W=;&R,7]/>A1S'081[ $3.YS'V0WMFV%4J@YP50R4)XC_*S#,L@>D"U
M*4-3")=SVE!6Y2MKUGRD,GCRM"?%L?KED-_JDW3;%_D4MHI,KF:=5@VM]X=$
MPHSTZ+Q]U-M;4[:[-?SN/0%;_JH,B>VDNYK8[<UP"BS1VW_$IL3I2EJ1E?;I
MLN@?I]P560<TJ0-O]M\X>3CCTJM+:[;6!;TK1T8MKZ1?24_VDGZ8+)9EX')'
MU+[99'JV;H&S/XAU#7H*;F/$1<)2WC,&9.@>4Z ]*W_W<-UI3'O.A6R/(@??
MBOW/:YORRP(K3</%S K,BKM_N^M1^42!'!9R2%?:K)B FNO?B2M38:B1CO;Y
M>JQ_6VZ01<OR#4:(4TV9->+. ,O&W6BB867>M,$J>,7<;$518OW4N*2';GF#
M1%R'D8B:Q>'HXG/63W=>$"GQ'OF42SSNUO=&<;MJ3Z_QJN;KJBB4A($[B&00
MHB+4<3L693!BD)*=.1HM@55K"E]&[ZZ_F_FP].QO8\/H(E\]C[Y/&244X;Z6
M(8?I=]4N9W6RCA.,%K)/"L4?+_='_]7>O^O!LR\V'[ VSX>MBYP>%4E=T/:V
M3589\C^>^%B^3^H"D_!X+K#NV[+K;D^I(KOH'P6$V$OOCD>GU=%U=78I#-<,
MDCP)%DAAOM1X27QIDFH@=8,H4<XQ!=>HUN_+#>7!3AX0O<KQHS?G5A/)YDBK
M@15MB9'@-]EGX]A>ID/^>QLRU)O5"-CT'\XG0+/D6YP;Y!=%,6^K!TOP)U7R
M-3*WB4J&9SEE'@H>57GAS!8<+2B:5[]COPBYZ;X)%),8MW51-Y&Q+5(Y7F7:
M5KJO2&K-J,'@X*:S&5$S8I0 .J($=>Y5M<G ?[O)C06;35]J7Q^#,LJQ=A$R
M]6!=\F1!'EZ4'N_$\!Q5N)<XZ;.9\^7AYV_'\L<OMS1^T_ SK(G&[^L*C\CW
MZL(E:I<,%9>65\9@&1Y)CV_,;RQ;?TQ\5L2T+%QL>G.KIYR?J3NGN@]8;K94
M-ZJ?ZK!*U1PC;3>U?-"_N%Z'9]&"/ER9/F?Q3@T-J08L;WBQ#Z9&TD*CVDZ2
M4OUX@-<V,+/?@7@6-()NXCH-I8@[C4JG?(C@"Z)C^@6].><W&]N>&98H9H<5
M%-5-G(R.V!.H /5R_RA)^9M0\Y$Z2ULK.'#A]+6(PC5TI=ZQ(NY?Q:4]<8W2
M$=-6UK6G2^/:%+ONW+B%688&NKE7/0C6R=,&J)>LI5W+8H_AFOXW*]JW6/BI
MIF^8:53^)3@=I?4?^^N\1T.'&U:6V*B(KOQMT,,BO@2+ZU3W[8HP8-[.+3Y9
M-.<JU"&=R7? .[MB"A3KD]Q# JN@68I$0GA Z:*;8M[3!SUAM@TM#<&-V.LY
M1\CB3"/*C/P\GJ)6ENE^*T?R 'F[%?%E]WB75<E&Z<94V4CT36BWS>G'Q4,=
MG3JZO3G[7!(49B=O-HAX-,K)[-]MOMMEB:':Y?+^;K 'PL,BQX8Q?6F=>/QQ
M:?.1.JQZJ-DZ"49FL0\3!@VXSPA@&N3+ _K]R9H\(%Z@"[E^G%[%4>M#_7@;
MCM[D >F$@9->?.5]D\QYCP0YY(D3<,+"BBB_2K,H&#@LF$#=-H_8E+HY#HM[
M$CF?$!L\@$]?3V[T\X#?Z(0?U2CZ#\)++ZYH/TV)!^S2C"5S6)__]PLAEV!S
M'G!F@@COZN !:U<Y7^!1E!0?:F\4#<GH[M*7";\T;,HD)Y):!_RT_UIY-KJ"
MUR;1:)_SI>M'Z#7-(VISY*@SPUJ?*U=6-%?]_LB3DPEK_NOA8<(7?Y&_/U+P
MVND?,A0OA51+7J2(Z.VQ2'ZAK:0'95L%Q9SJR:7:%M.5ATG*%]Y=B<*7K:G-
M'ZA1ZY=ZD/CHJEO%ERZL<JEE,G;(RO)68AIIY_,"985U\XK+Z$BD+(? /LGO
MT0N=Q-AQIA,NZFS:1=++%I/<B\P=23CQT_84VL=2 \\%LY&Y+0J[%.Q/9HE,
M^NCA64TI&7DC,DP)Q,<I]"/&+?R[W$SDWO1DNO<899Q4<<!\E^.WT2+URL=>
M$BJV\BI!CUT\&A\HJ70.=5V]GG'IKFZO@PU)7>G2LR$P;3T0>TG]TC'?35LH
ME"]R,KD/(PY"3JH!24TFB6VR/FN3)N+-="ZF8QBWUK'VSCZX[+F/WO8Z[KLB
M4AR@ZC,C._A5YZ:?E/V[@(]3O>T:)WI?^#MJNQSVNG \ !'_-"D6DYA\-\S)
M(7LH127SBXF(TTEV.&*D>BHPC>%=E!)S0XMVJ>C4("[1?JE7Q<?"D@?(ZJ*^
M/OZY.AU2QRR/SZ4B3$GX?6!HDN$AWX=.6GIJ$M):$5M!XRC-KW2V7^>2[$VC
M/>??N)-POAX=OS?H;(;I9NO=2MVF6X!,L#TQY8]0IS22W"PKUW:'&S>S DGL
M)')<?J7JM)_9Q(C9HWZI[CMV<ED:6U-NF)^O^.T+URV:0/W([M/YF*)^^U,J
M>L&:=9_[%#X"#Q-$M!$)F/UU_2OFUSX:=A=]R8QG-0G$K#M\RO3%(*" RUA/
M<6G7,C-Y_+<IMYDI@_'-O(^LIX&!(9KK#7MNCEEW-/H95!WA-]1C^ V?OI)K
MQT)HEIGRHG:]--LT4^\"B\=6I$M[29*=$1[9GKB6<5$UN^,D@]GFG>K*@Z2P
M4INGK*LR/WHLON4^R@V@$>:(?.\AT4&>B&+%O(0H3/>SS+AXK5:A#L/#PQS]
M@+D4?:.1C22TZ-(+)ZQRF((T?YH8:'MFJM*7JD2<S+6<HJ;*&VY_SGQIK#!D
M1(>2*-D-^\&I;RY$D?L4VZKDCA%JKZQ5J\J)CJM3BTT^#OQ^X$]P?" =F/2\
MH'>7CL*(]2J]I5?@T2<SF6226Z'R0)F@&4+ZUF.?D8]QVJ4V17*8ZXN=-/MF
M)R<6=X0'Q'V$WQ#7T2AO(D>AC3^4M<FJUP3&%F8<=_<KWY\;_J'A(.030M4/
M'>XV3P*D),0#^N[Q $0O-QWU.3]B$ 69XOGB>Z'!A'/&\"@/>)HE3*![8GG
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M(,!O*)1[()^2<IM0#'4<?ZC&^U$<'4_^:581&R;QY,_.FIPC?+Y;.T.@E/&
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M$*:U5\[=>T^!\E_Y5\KD1K; '[P3]BD$/NL^X%,B?2CF_/DMMB)GMMC: *4
M_Z<3P(^RL3S@S>.(,0SK!@^0Y0$;=E!I)(IB36^(56_Q8TJ\-MS=VIC_KK]S
M1AMLB-7XNG+>\]/8)&9<3:ODJU^FK7<R:'Q[J$/!+OGO4ME+'ZX(;.KQ?1MX
MG;A\2COYQ6=4W<**Z_-%$Z[Q3)4'&.?\(C4*;K!X">K$+>0^OIGS^,!6_0\
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M,11O?C&P$LR6(4HM;9Y_:.I>2)N<>4AZ[S#E?";-K?#;UC1/JS[58J]3 $B
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MW,<K,]B%;4R-F +%V!=W9)=IR:$ZEE,6E]^$WRPYW6/@)^5X^'RZ__[!BS1
M/U7DO>MBOMQX<.^NM!FVY6"=F9!J@D*:Y%QS\XO\&9I7IEB:=YIRH0GV4,J'
M,T4%%_X0BXS@BP:*"#R.6K^BE<K1;5/E 1]M >0_HXLB'E 30.$!4OACD-E3
MG$DW+:6MC)&KOW)KX4I;W4B5-N[C [9=<^/+'3 L%):=KZK4D!R7*O*;@V7B
MD]<"+5<$YHD)9'<$K<&2J12O+:S?33N'_;XY4W;G&A&LQMONF=0O^[%0AU'
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MPPI]=7).6/<GN*;^O=>?3VU/_7%##O-5LM*PX-XF4,3A7^:E1; :<#M%A6<
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M5"MOSO<VG^$*9C&9\)O.@\$CRF4Z$KJ*%\3G&_YV9)1&#>'X B*PLF+D]B5
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MF[Z=)6A_M>]J5W2?+VE[:2PHAX#"Z9:0'$KMTD(?6PABQ'::Y<OC3=G!N47
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M?]XWO-)]3F&T(>,S<4\5S7\LQ,22]K/!YTBG-X=]C\U02]AV^,)NT&H\B!?
M/KIPD>LT!]5D;WY4@N/:.D"%(,0(5O>\0!X<_VC"-XA@SBG[F*0MA;G5'VIU
MEUT;6+ =O@Z8MU"\B7<(TA&[<$<ZLF$=_,M#B-$@N$SN[UV?QQ##030=>P\=
M.,E6=?X<J2Y3U\,J<!Z[&S<69G=O<$]D.,(2DDZ0IWBG4,.Z8#+X($;^#ASM
M=#5+T,C .)\;P&BSO\3I%M<-Z>OGEA>@S3"FZ#"D/NV27I.AT;72+46;7H*^
M]ZTSIBJ*-^P69#<4[._Y6Q-0PE!6"=:[VGVB;D!^K.-F2PNGSP=:HO=#0R2;
M$1<R?&LVMO5>/ERYTO&[I<0'([$?C[AV@M[\6EC'4H(;+0$OSN"J:+>-!9NJ
M5.9[!<Q8$&S3#N@&YB#"!HVXDLH)?M+VPWF6Y_YXXUH<M/V+FBIX78]>7EW(
MY9KA P$;MH(;6[MC2=9E_N:.I2B2BO3@X%CGS:E&S9O-[^KI/=RPVZBGKHCC
M2OLR<PB*+VP,'V5<NG#@2 :(O[4 ?(N 1HX+03.QG4N*.+0S<)$1YB!S:K#I
M"#\G'!/$J/ ]\3W(9 2[Z.G'#.RQ?U#\MJBNJO:;[+T%%Y;3X4CP_?6 P**,
M@^-G4OPHL;#=>,B,@0K0?GK$_$ AH>TXO^RB1)+Y\3)[&"<V>J7Y8/?E_/"2
M5O3U3_[.HP$0$\=OF4<,+]L.V$K,,D%X9R[RY]?T[!2!W!?>0<HN-S\D*YG0
MAN W<HA2<RT0KC.'PM. C4<@.1[%?51>RD*S34A^S:OO66\FO]C5BC/66TA+
MX"Q7/6(H0AK(FH;+ "5=-ST+Z9/BG:;Z%>7C-C/Y4O[2[BC.T>=]U^)\0DJL
M,3>X,C?:=>^67]A^6T2/?0O #V!H2#1%*D(?;SJ /\KJ=JD;,)XW4)JE3DZ.
MO".5^IU]783P\]1XGO?!8[9N]<@K9NA3%UN]AQM/5QDEMM(3#TE\66__:U,S
MC'. 7UZQM.#;P/Z<:ERN$#SX042S)24[I4/KV+TI1I[NV6[=6L!(NM>]I-SR
M$^F6D)K[_SWG8B#Q.XIH7Z%;6<'19:9VS_Q:Y%F"]*=V>RK,;R!GJ0[%N3-%
MB\^^:[A;:>B6/QL\L//-UDZ0-\^)Q6EF],7DF;&ZHXDRI]GRS70/M-T T;OQ
MQ= ,>=B@_#*9'-)<FXQ(\)ZBN[EX!5MK?^KR$__F]6\^(,-"27#@2U5SU"A<
MZS/:_F[%YRGVC_.O)8L,0U-O:T:X1R-N;IA/+-44LX0D$GY9TX,7VEE+W01)
M@3P"!V?H%^^L8-@:O[W$7OISA&A<6E3=G*:HYVB ?1SU\<>?IKOS-*6>FQE&
MNT2&[["$)$=H\1-A_I,V'7EJPT9+$-36$MK\S8I/\82V5O8%LRN+Q"]Y(_C4
M(H;><U/P_NNJ)LGWQ>+61835L061#F' V\";<>DV0'XY%7WSW5-&P%.7#]3Y
MF\F-GU#H8A3GJ?BDOU/=8&="Z=5<S Q8:0EEJ&1U#USF]V]H"N<<78AE:<Q(
MM#+MNQ7R97E67I6=%>^_.E'5J4"*\]C4^$+)\">*IG]P<(]_6CGGSP>NB5W&
M4R_B;$'<F'_301BI_$S"Y;YD$1EKT7)@Y,=%'!@B$44(VW;XV>QSZG'&VP#W
MC""SQHK#S"<(BU-MDH'CV$U4Y5MJJ?)62E&:%RTACX?%6 9,-!?&NP8TSQCL
M\!>]N3D<]=B/ZAQ#J,%65#8YEG_UO/J$6L'O>:M2^1 5(%M?FSEJDG<B325!
M=5O7(;%O6?__%JS 5O_CT,2_C1$._:>S'+\5"4&WFP@^>O;3SCRY\V<!NL^C
M/M%[4K_3L5$"C=F&IC.A;A;=*3SQHO<\72#NL=MSL=,5OA@Z<3.NT=U:PF!F
M0J<[.)-C&0FA]O&4M;F>?A02@2>MPPD8(M1EG6$+00L]%T.XA_'60YKWE"OV
M\([X,0#4G>#O'X>66G8B>;#,*597';/4JFSVN7DUZN@^2YB;$(21N\Q/IJ!E
MK77?<HWPP8Z.&VL. QZ,>W*6']-PH!LW1>\!VE8!.T,9Q"X$>1SD+#D,+_<T
M8JP<AJ_H:]6T#"TM/+%/,)O0:0Q)#D,T(N[.Y%$96Z7]1 L3-S)B"^+K-PM!
M48.$5@0)X5H[2YDN1-89=@>WV*N8S9!3:AMI#R(WD009Y:YS\H/ID=5N[IT&
M/E?]Q/M:]OR\?^8< =C?U[$ZVJ3 0G.>\LLB-('*N=$Q)R"5H6+0W6+\W3M>
M-FH4JX3_D]U++/#+-&%M*7"P[Q3H#=5R_7BE+2-*M?Z6L/[O@AWSHLD/C.7)
M6)TE4'LXQ.$FXQG8A+(G:W+Q%ATLB;O,L,"V$FIH,3QKE*RG&OGY6!$YR=R.
M;8.H0C7!&& 9E)B1BHS5BU%S8WK.9,#IT2"]D/,@P?.OXKP2V/02)>4&ST7T
MGHUHV/:+]:FUE/&L:5@;+/IQOSQW_Q@>\82&QXXLS4A\0I<E@.-O[GP8<O Z
M^60=^8I%V3:0()4RW8.,A+!N"4&M4 %4T*_ 05X>H?A!J"8S)X:NXIL(?H#,
M-/E.;87VR1?2]R3+H2;LK(Z>O;O?G!RM;"7WJ*M)<,S^YQ&B[4B>JJ!"%)!+
MW,TF0Z0(([SGN?=F5D=O\0XYVGV5W'BI\.FV]]P2$"0WG^6=1N:9"$%,_,3I
M$7Z&T8K>[=HC>'?664?M EVI^.0B':]'+R76SO>+'CM#%H(D],H,> KB'/;V
MX@ &\8ZNV$8?!"<0@+XY%69X[\*R6M1O!>#ES:*9=G+,$FP)X&KXV$X2!8/;
MZS?Z$.A/(O2WIYR]=\I&<6-P ;AS"3!/F)9@(ADIJH*._-K\E^!H(4AQ10C:
MBM_.\NTL9H=TYM\QU8Y;.1 AC1[SU&1!B05S:Y])TQ^SG%DG,3OS ZZ7 -D+
MLPV!(?)OM]_,]HB^&TDPI&VG3'^" 7I9;2G;$+BC[32R08(Q\^";C>3J9B"+
M-3&=WTF4;=-(NN2JS29V4&*F#K)C*DR&S_55HK/S5C<[;[;;YPL"2C@I_'K*
M]&,(ZWR^"N!L!7#9)3-8IA5CW*"0Q-)NM]!O0^2J&#\<F09/4VX3=M1ZZ+0%
M"_8VQUMA+99B>1#5FM(3&E&,4$:\IB5X05RPHT\T)_Z"0SPSH).URN&)/"4:
MT(+'GL,;M52SLQ9^<(V!M-V(KN^XQ?=V!K$"+9[GH(N=$+3%W7-K U>_>9HH
M/FD><8BPFSJ[UA>/,3^"IK\(Q,J!"(1A,5X8H?43@;28P"H1;/W!^L*Q&UPI
MAD,B1O+EERV<7?HOWE-4GEYJM9MF9]:7TG2O>$[N _X2A31SN:C^9,(YKGX=
M9] \6^_-?HE/6)ZB,7?_G-M2MPAA.".CM<>Z8P2J>/,!BF^*&#KDS.4V;A=R
M%RG7H-O3PD']TC918@'.MPEVL*);GK1[9ZYA.Q N]YI"OF\2089UP]\#A/\Q
M_YA_S/_E1CC\GYA8&P3X+42P]=930NMI(>A/B!1@0W^2Y/,T8C!_ RF G3"]
MX<T P@,7ZS14[E/-+FD#2%L/U<VR(6W8ZZCBB3Z]NAQ8<BU6W-U_+/AF>.)8
M\#2D#<93MA""-EE5BZ#=)V(R>ZD-EK(Z-K63GT_PWVJ$O4.1VS?&8ZJ#[]#D
M>,<J)JGX8\!M!EK/>B]&QZ'?V +1X;F5/="H%#I@A)7]@$MQO-\]S?8Z)+'V
M1D?G8/6N-R\-J^\YWD^,*KIV?$_4;QK%(-/_KQ<7;S7WY1X4] A!4E_"B'<)
M-8272%4/VW>#[D#?M(APTV3A&K:[;?M,R/2)6<6B[:T]AW45;_MJ19K28F$;
M!=MYJC&?)^C:;; 8F"1FR5'Z&S@6NH%%C-K;:,O^5-SKJ3A8VY%[WG_!U3&*
MN5M\0Z2%:>2Q%"6@KXVPTUR%0;P+-6?O3*=#-N*4VQO&$IHN,G)O?E,Q._D?
MMY.5N/NO+=:7T=[U[,C+*49E9ATEDPV?VV*FTT[]YB;*':H$X""1F<*&"R13
M1),*;QJ-$ =L.CUUA\R11,"+$\B_)U#4U.,WPFX959Q>'+-L:JIYT(Y]3,/-
M=-PDWVW1Q#V@O98KN5/!.W[=J\R?6 R@2&IB@F("ZW?D>^UV LL!^]Y^&KE0
M6 3-*@7RVZ 0[,^[^DZG)>OA?=GIG8O&Q+L1:E$,'&9)?_D%220TZ:JL6C++
M.DSBMA%DIPM\#^:RAB5XX/>_AW?_8_XQ_YC_RXUPY']-<1LB81LH_D+0SYN9
MMCIRO?#A0#37#G\.N,B6M +2V><OI'2HFL)V1&C.16QAC9(97NA-=<6,$-:G
MW-S.Z,I&QE8UI:PX@RL=D(F;'\:H3-Z-N;7,PM! ,:X]"TXWB!%LX.T%4*SS
MK0VQ\4'(K?@#+'BLN1@]1PA2!M+/LF,3](T@VV:#J="TH"49_T&[TGFW*!?J
M<5DRV:&Y[>"S(O^[!:J/?NT,>7P%UR^BF[*-<%4(&E_MI-5H=_%M&)NRVHBJ
M'[ZF 6W=].Y$(EZR'!?5?6*8N9+C(7%V-!"X7)_3ONJ6D9OTKJ3XS^-/P^.W
MZ),G0I^_$6/!%\!"T,;MHCPM>F#K48'AAXA^2$U^.TS!CHT62.6>;[MY- &Z
M#[=TGKT@D!Y<H6E9W,!N=9W;-?'>[V87T6OKH('Q>[T<%T%[XX@1(FPB_(CK
M"!-K"?/]^G=P@W_,W]_\F."T"$'I?_!+"0N3+<9"T!R)K1=NL)GP^F);/N?<
M1^1:;5O>Y2 A2/W*A*#S@1#$MWY&V"(GN)7?=_SO<4W-K]QD<U+P"O8MF%"]
MRO\+W@KCNWHJ$K-G8#\T *+@=?FJ$.2(*QQZ3?@8<%\(>M\G)@0]O9"R**#T
MM:_)_BT6Z1_SOV/$A:/_.?W\8_XQ_P8W^X*E<@4.1SB/A*":8&!,"'HVUD%:
M;E(4@O;%;B.,VZ<2YH:VA3X<X\758+GR7D+0BOQ3GIKSVF:"Q=\"%7_)A,MP
MU82@U^."'AKG.FRCZ"5\<)=;T(E"T,<4!H6K54/C.S)2X/N$H-1WYX4@+W,)
M0?$Y6..:$ 0#?SWS=UBG?\S_E@$+Q_Y!SW_,O]O\@Y[_H.?_@08L[/\'/?\Q
M_V[S#WK^@Y[_!QJP<.#O@Y[@7AIU3""I( 1M?,^/CCAHQ;+G5/)+FRQ8"8Q$
M@?R@.1IRAP06YSFQ]<9X&DK,=\6^17,I8=,I8D".733VJE&XM08IZXS],()@
M@O"C9TK<%Q\2.2D8.'!TX;@0M$GR-D/DTE64;B%H)P\#V?:)]=$31AX,!"L#
ME[GM2%:65K5 .7/>@4V+YNF5NKOY"T&L%#0*'781$^+[!44^9&<>H)88&=[]
MKX"18/0E4Z89!H"&03M2&==.'TND7(5OG,TS8"G$!XG^#RAS( %![':/NB&>
M#3W<:>GDZ )FA0CF'1HQ4O%4=CC=]7E*#VX]O+)#ZX>&@FGXRDC1\W?3D*>4
M#2W'\ ?YQ2U2 'B&\E((4D#@5NE'.R:ES&VFL;M=9ZFCJ1CB5V+ =;^L_MD6
M]:' \*MO=W06=W@Z%3YQ_2"NZ+7K1+FEQ>7_,;E0.+\):H$KX;CPXPEH,-7Y
MY=KI6Y5 ][3VPG=V &,INA8I9U7Z >?K.":  ! W-C2C9)Z%4DI.?>90.#DU
M^[RUU+K$OR%HGMJ4@ G#'+ [(_[#20B*VD-H?2,$U4%XLO,<#JMOH9A=,UVR
M,#2=+SY/V]&B";0Y$.B7$]@V#FS'EJ?3S>H[X/!H+;9O)UAA%GSQQA_/ITY0
M;5_L+<3IT[^-[P,)1OW^Y0D"%]AT%9(5L-0. ?81F:;YU;Y10M!E#()S'\BA
MYX-QR Z*//&J0.0?*>VJFY&[9S/S-%A?HI<G'K%6&?J%#*0T$G>:Z\#>Q"LY
M/;",4>IQ'Y!7GKRQYN ,'[2$82C3.4(0N:\M'SA 6$AB37#J *NB^3S%_J8K
MU*DD(J#3\1:C3YD6+>GY"_G6;%@T2;+'8%GEM!GBE337=E1OX^&YM<V/BN;.
MC:.RG)V5/.Y)3!K]3Q25^,'%7Q"";M=2KO:!A*!6JQ8-P:M12,WJ0D8XZWLK
MLHZ0( 3YZN@%+[4+0;NSND(BMK.^=.^PHF?4502%@;MD^[OC%HW,C)JRY_3$
MC!X]:[173:Y[4 V"?)7Y?Z&UJ@6[FW,'D.,: M*K# (3S+Y-I[3"8NND*VH%
M!D#^C(IDZTT9FMV>M(G9X) &)O/^S>0JW+U7ND88&-/MR2/UW>7E7[*V6D*B
M8+*$Z8440$.B/=?IBUV_P(AW!GC)2=(]3\/K 9"9[L$F .'5CBGEG:@&PK"E
M^M/XLLECE<L3T1L08>.7O(-!'\VUA2")4$*K,MXZ;$=EU0R<*O[RC'W26E8"
M=.-\5J;3AUO<KSS)9[BALU=VPL<7M*?W;+BV16+18.$V-_3GT<MD2A0)>Q=2
M#>ZFB/.NL6BQ5VNY!C(I.^R?HJ;461E3%3O>=J5B&3]/F<LYW<_SI1\S]KN"
M_3B8U>&V^2&_J"'B$0<"6U"(L)48^U^6XN>]@YL"18M13,'T =I?>+)P3BH_
M12#+D^1G-/T\M69ZM(PE:&]OV0M$TX6@A)"\P\./V;YM<! @X)/*\G?P/%A3
M";J9:\3XI0H]:/MCEV>S'$Z<X=L;->Z]8OQJWD[VU".V_71)JQ 41R5EY.4^
MPY\"?CZX^V9F?DDH;9RC%)O TRX"HKZ]Z68:.ESGF"&23MCJX7_XY+PZ^=T[
MY$.'.*M'(/GSFNU->$-13)D"M^GPMD;D+2J9*<4>8A"C%P5JUM,K[&'8]B:#
MZ:78,_,* N4AGCT1*&[:-Q,V,2\$[<+%VHX9\27;UYQC77T2VJF34Q45?FT6
M6CN\Q><)@$8W3ZZ&#N?)K7*P8Q%'<>"7;E_:8(IX&#L'$&>4M.6&(>K8YP$$
M,OWWZK' !+YD)^?_8>_-@YI8^W71(&I$Q,@@41"B(J(BLI1)&1)G1,2H* @(
M45&9A"P5)&I((_,@H+*$)2R(RJ0BHHS*D! 2P&$I,Y$@9%*12;I50DLZR6W6
MW>><VE7?K3K[UKUUOZJ[^:<IBKSI]S<\O^=YQZL>L;@4NN73$<^7W1%>"$D\
MN"?"R,&K>]+:]6Q%;3T;HPC\#UJ$*-C^D["#JVQ<<4^%H:HP_=TR,I0XKI";
M!OG-@;GRH_1M,*Y\;,A@=L._.04?Q#*$2GCOK)KX.:R,B,?T4[T_ Z?J'0QE
M#34A@SK?.4\+-"TR=[9@L#-S.V8=R?!B])! ;R%L.CU.@5+]%$P5)JA<P.4"
MF@Q+F$+NL'$#.)ZL.7"CQ+QQ2QMOQJF8?>\=L0 U%6MUIT:/=8C< 1:GNM^F
MW7N1.J&]<Z(BFDA789+NH-Y/(OUD^&FK,%Q7^2X5YL?]>^K*U9ZH$U .U/F+
MYJS":%E.X%28]PG1.#B9HEP0J\(X?Q83$&MV%4F%L3? L(O0%'_%!'<K0MR[
MJT(M9:-@7E]1*:5_)"?B,;).<4\:DCLF3YH(M>C] KNL6'<N_[@4MS'9(.MM
MW<,U&(:HX_][RO?_T@/;1J@A(WJ:,D?4GE&P.T=IJWC&LOM*FN=H(YU<,DCS
MY/#K:I*E.)T38X+/Z;EKRZ)"SA;2"-Q\L[[=^K;:R=2(Y55PU5OG%\]K7C2D
MCQUZ'B-23U'<8(L>"I^A#9MX0?Q$P)\M,.<R#2*$"3GG4LMH_'W=="M(O3E[
MQO:6Q+!4;F1^V(=*H#DWWP[.NC@45&O+M_HZ]M"Y^.^^PZ-[WU5;;/7%1/U"
MWS<@6/ T[]Z(=_[+TD%G_\*O@JAOI8^&WM:_J>RN&@O:-!E6M."ITK>Q:LM^
MN79NL-'C@VA8KB3 VWR4"V(6D\0-#:O:5M#7*NXG23LRXHZ;?+PPLAW%_M@[
M;%'2FNMH%'T6+Z8-B^TF%F&_,+0QV)=->FJC2O0_8F" LX)H2EG+% OA=9[C
M4R4'/\]A9U0K/,5[;@JG(X,!O2HJ-NCY=63/MS^<D;.!ZC^GQ6TMI 3",L3B
MK#0CCJ+=@(7<.=[I>YE27**Q)3B=[FA!/W8LJ0+")MAHD5WJFNLV?]\D7/CF
MJO9VH\^SCIEKAU_BO<.FMZ=CP'M@EVE+2PLO>9$^N#/!I3@G:&&;WN:]3[[O
M&W^85/1G_-P.+ JY$RC;QRY"XYQ .MMX$,#1AF6=<)24K.=#-GVB7 'CSTHL
MT_GZM;_I^^2&[O*&?0KAW&9[I\'"E),O*_KHSB5#>XA?M=BY*QXMPW)NH^W,
M;H)V?C6UHP1-G@F["T&-[O*+A)@EF[+T:A:Q#BBM8WT^Q'XY:0U843^FY7Z^
MAZMA!PCAK4+E@EZY<\AE!AXLF2@2E<^AY4R_63)"6H$X2*G7^_S.O*LPO" E
M)>>O ">YK\,*,Z</"[QAUK7LFX^?./^=2L-.E-V9R"\*"'HXPK_,GXE25.%K
M[/K<6R("K@5$Z)!#(H,NJ3OB]?E+[-WF@O4MU@=O[_W[AA;&^U]0U1^4&P *
MPK/W&"Y$ *A2BDT)I>N"M>+(^&JJ ?RCI;8FYXZB)+%A\WWOQB^/'KOY%W@%
M>U=+! .M[RW"!XG?99=Y'GW=^U\OQR!7_J^@"&N&K'B$,N&=EX]2!MHYHN=-
M0K!$%I>&E;>;-=OL-AYOPGECI@D);/"$"@.OP;=<BZL"F8B>E>QLQ8M;O,/.
M4A6&,$!?\^/,^;GI:^%R;,QMSXL[6V]5+E^1U&$EG@VEYJ&-8&UZN)95"T,#
MLDQ$3HE#@P>IUE0=FH]7=\..>\%]:3>SO<\]+_SH.\*7C>_0M"GC/5^QQ# %
M\_4?2VQNV",QPC43"7RZIR3T2/LN4)A@'4KF$5?V52_/&B!W_G32?Q/E>JS7
M\BGA4TP[^5E-_K?1<[].Q^ O-7=@I9$Q*'NFPB9X'FDYS16MOW% &&7>*-$<
M:D^N(F!I_@=?P!>@MWMKV1 NN=K'#;^G@GF<3\0'U:W-U.HKNA8ZMR[K^<,/
M09?7?1D[U%A=E>(EQ2@>_^,AY)VB#! ]!T"WC ^>DD+27';PI""5*US 6M<N
M#C5I?0Z['@))+52=0:!Y\]./HQY7#SZ<9BT "<E5?WK(I,X]1QR\(N8V[JG]
M<;8F??G)*]MG+^W]UW[2$J(5@M/*!/<0=(2[2H*$M7RN:TAR4;I>)L]X,<P1
MF\\+6K;A;@1Y*7UK9]5;VG520\ZU%^+XB]_K5JZ9/4D"#Z/Y8"G+ .F4):0
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MY&I=\K&&/ J7M;@/<;@V1U%RL(]J\>GZ9\QW80P)O#*,Z(:T*5=W_\2AP;^
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MSO1..3#C[&TK5B[:?;'EG@]MTJ?RMO.)S?&(\X*=EW^5W>C 3N 174"IB:;
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MAIT"E!K#]RE.3"ZUOU+V HZ=BU^[/,+WTGZ8+#*R_3(O,ZB^JUNI[YDR%?2
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M] DF9P\U$"_K7--!WU6. ;:C_: @RZO1A!Z A%R+@ .*/,< J%MDUU(?JO4
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MY72#T[S[W]S#!'@MJH^RB%SNFVF?]HJ:V)85-YF\-*HG:$'YR +-Q62W[ ;
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MH>H>R@B]6D@M;%[6.O'TWAEQQ*C%D;(!IWVEY GZVI[*L&,?E>'/0# 9VFF
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M5IP'([-T9"*%+&-/59G5?](6D#,^K5J.F)K)2U@"NQ'%GCHUHAA=I.4)TX$
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MQR5(>D%(@Z,\A[;GE=X]I9><5\';)PG.$-7.XOFE,'QSCLF0TVZ![#KV)>W
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M5'N>P+GVP:XX2E =4PE,RRZG9M;>FVI]V]BAJY\"UM>&Y1CL1ZU\NN9_S</
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M+=E48[V]^D;X%F7Y1R4-97.50RJ'UL4NY\?N7'?OSM44C,]_]TA8_I]SZ>\
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M@K>$L4J-+.U&"(OAOH<#IT9* ."/CDJ6&64_,7Z.)HMZT'U(L 3[=5*^4M7
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M]>5[(0.]<]\&!TY <W/U5+G7#)T*IY\-PI)#O3;G3GTJGKZ<T];$67<$ [*
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MI<1\X\/OY^(YN2;T?;#M@T.R\F3JRW>>HIKDJ(%=CWZ%1TK#WXLQ85]2O!R
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M%W]$5:S<+-LL!^#XKP/[BT@[$HJI@?#!B+^&U\2DF38+L)6A3)QWR]K1KK;
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MN2-68Y5\J])P%M,;#&]UP(VM4^# UX^0-J8\G#F7_=.;<BZ6D(HN<R<Z;W>
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M<C[F"//CX!+(*-G>1?R9)O3_HS_H\OH',6N9+VY\SF]RT_I%1(TLE'T>2!1
MQ\GP)H#'X!O)PZ&"E\!5PNH0P>(Z3>@+X>JE, DVF2$DSX5]1 4YXA?VUK<(
MQ5GT-'+DS@&NMV7+([^5#.ZDZ+/MB>X2FU<3XZM0C_ &X?6\QG9#Y*T (K9_
M9 NQC)Z'LLDF4G^><"BN[D)0WWQII,!X&)G?^5!VZ-:\-K"THO,G%\SOWY9
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M4*@]'(!!,@ T,C! Z"$@O$ZJTO&(9O\ATVI]R:*3-.SMH\<51*5%PXXNLGU
M0.Q^9SDKD6 N^T3S9LK_L79>?1,[E(KHQ,'SY"P3Y#-89:;*:!\'M*F;X7FB
M/0=XS$JPZ611*+@$6>6U]KDI@3>+64#F+O^2YG*)'9[\CT5Z=B/0D1$+:*-6
M^96D-FTL6XB"8LVY"E'^<Z2C1[V/T]AWW*'T  $',V0246 L]43WW^^_U&1R
MS=?T2,V>N4<U;<E[$[A2$Q:A^+Z;L(?V!L2P0\G\&B_5 \)ORAWP=@G10*D)
M"1()AJ$D V6 B(&!HT]W\A@E-NU)M?/H24K/)R.[S^>NO/0#U C)N&Q@:QGS
M.+CV'.N*#G8QX\_.6#"OH? Q=8NJ>!83R%CNH[21S6*N-FQ06L+=T+38Z&ID
MNQFLV6*"2U/JL4Z->9C,8F)_MG;5N8B*/KL?Z#G376738YVS?]PV<\Z V[/Z
M9\R =Y6=*[5^+4)7TYP=$L06WD91Q6/R&EN/'6QFZ@F=NPH5\9A+:?-HG9</
MOL^Y%%U*6<QK-O%,0HPI#?))EV[#;S.C0Z*^Y&]5?3]=[8C5'_#DDCJ[&/\"
M_J?!TSYS-)#'@!$@9*$,F13'7!".&E>;_)OJ'LM>Q]KYY^=E]OJR& YN"=5+
MLN'WZSN?0?BK=4;%8S1+&:UL3;E#Y#NLX\OGE7?*/GB\66!U[IJFNMF5\#D(
MG6"G@) 'R#_,DXPC1C+\578 8^X@A2L"QLM$9N$&Q+*1R\NAUAI)"9F4^UX\
MZ<04@RF>S>:+^NHB@O/]_+SA:*<Z"$C(8_>$5?JXDD]BD&]L83L0RX:* .%M
MO.SX1%O;!W8PF6\D9C;;^0PQSG;#GAS@HV"^=>K*/VV]O6"ZJ.\ZV?+UW%_\
MJGX=M_MNV#JV4"SHCVG%564JEVK+RV$0&CN(XMD2JNE#F"CQ3+!VL0LF1YFY
M*7&R7+J$9!@\XYI3[AP54T*B[NFFG@EX^-&KQ;+WP=-/7A_WFM:_VJ>A_+?X
M2@"= JX!T!$!'RN>;&KG1YS,;A)4L*2.A93UII-)'2.9_#I AV !+YKVKH%R
M:UA>(T5[E(3Y?94D8PKCL,PO_TSA:/1E7Q7SVL_E80\ZPVQ>OL( 75D"9!%.
MH>$+;R,F5;-KM,;I%X3&J[:W2YS 8%Q\.L5O08]]Z_;05,F:@J97S,N[K P/
M )M7AF_0G**+6,H5-HJ%2"=0,\D!80O!>.8%,:JBW5M!_9_$%=YPID0K?LN:
MS@;4V8]"1ERV$3R+\:BOEEDD-?">P#/^N&OOF3J#RSH?0?E-@OQ>ID1;\;>P
M:](!"$8V4O=UT/24V^!4F4_+ME_FQK"_D&A$W2=;,= +6.R%2/2?6+W1[Y/@
M+?MZP/5YF/1[Z38*&I6<<1"YD%L?(T>Y>)R4]M[<5E9,XO?MCFYA)8-5-<U[
M]OL??A8ZN*"K[IC,SJGG%$&BF,6D'J?LZU][:_J@Y8^(\&"]DXU WYO85<_O
M<.9V+WCT#U<G/6F56_<1_WU-&^[<-''>6F[S:EZ2.@3B!=!A8AI)QU%IZ"\_
MKGH A@++1OQTH8!VZ5F")7JSK.0):>5G+2YMYP>;*Q$M?J8R;'*4KX=/S!ZC
M ]VTC:<IEQ6G>W]N%%9W6@^7_O3I?YCRWM$-*U\).RH<D78 ]T6V%M! [*G+
MX3Y\/% &BO ,D44+=B[5"41=M<G1_($MG9YLQ.%_*X_<7LI]-)H^+'%7;/P@
M[B8_*I]*[XHPUOKE"G)ZD%U]2E3'SWNN*OSA&Q"N3X1#1;C^J<9!@QLBW\,4
M&H@&;&Q=C-T^X[N*/;QD9838[K$W_E;&E>:%1V(Q8+Z%4G]:WJ**MP<5!-IK
MG):Z3SN?+L2FLA[!\Z !+J!+,QAF&R+FOLH38:8HZC5]WN 7Y*ZT*9/I#&ZI
MZ*LS%4D7?:WS>;CC)M[>VKK$47'<]-1XX%D,<@@03@L8#>?*% MI;9>C)@@M
M!50/6"%6V;UMOZ=Z$G4?U6,78K[.V?$+Z,<M6[ET9QARZ53*I;\F,:I1%%Q/
M-6B@/W8=7>MM2+O)W<^9'VUF,0R_]7">;*I9SUAN+8#NP$U33;0E]><:MZG8
M(M95*I:2KM<<\6B3UVK'W['#*-3S[.1#+]7D-5/=5EA@5&=1\,GUZ4>D P>Y
MX;#(^US<A[ O@?H4+)>]A&JG(%#(WBDGUG+.&%VE6IXINE=>%'!F><:^5.TE
M&DB+X<6+65$YI<PS8;HY:6F5Z#\S.HMWR*LSRK88RCOV73V^X?>$I1OR');I
MG3R!0>7Y:Q:,R@<>$P[$PFOQ4JG,9'/[LU'OS,8K,2("_<_T2]''0D%S?&5[
MG'= R]6YSO*!A4J:S0:_+?4U'[/&Q7;1:+3<R!:^8<>2H&S:(%#)D&I?"9"7
MX(7X\1'LM<H1OGUIMH24-KBM6]2%-SQ-O0W$TU8H#W3W$G1N"H[V-Q]8@IW@
M(HO&('PS4%FHU#>2#\&;A:I%DRWFVV7T\0&9%6DN)9"81'P,I[8B1AW?9(QX
M:\MM^E>M"HM@)G?&@UFX:I.)7(SQTGJ+ =[=1G2IZ$RF4,W^S7SD[(_R5#VD
M$@MA+6&[U BJ. 9O+57N[1T,#=-$S>0Z(-H #:50=<7 ,K_5==ZDQ/4-G5$X
M[5"3EO%C(X,X\W4ULOD58$&0]]&B2\9:,U9(+QJ7O 7P>O(X&4H]#E?)-.65
M:#A-KSW%AC*Y8!Q;CZHO(XDSFYTG5M^J;"-JP4"3^<H/5OGE'P(.QL)%IS(=
M(8\[ 3?"4/ET?G'Z;UJ_""#G^+^M6DV111L5QT;9U=$\ENX@;.<"MSUR(FA2
MG/-?9',18]A,R-"G,#A^N Y[LPC*LW?%P2:>*=8DHWZ8WMSAU3^"K(8SC1@L
M8559K8)VMQ #%O8I30]"*=AX-4,'/S;PQA_J>O(0'!JK6]Z%AUTU1\!DG$%=
MH%AW\:@#YG4JYS;%GYCV/IKCKQ_=B$$NH*XQR:"!R>PSN/X88OV *O,!U1.>
M%G_>2:!.2J7['>!+T,2/Y@7]<C)\"-G@4,JI:Z^J;75_<]-)8\8%)6>/:=W
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M:F?3A4!3>[*O]KMKSRKX)Z <N.@@E)>B9[U,9AY_-R@S\*'FQ=$E <<U&&J
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M@2;K23B?T$<)V;P&>!/7*X#N_/"",()F\_V!UB:Q_TNRK\9!^S^MRQPY&U\
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M)QOR%M;:G5S(+'S^+#ETZX3*],S)4C/-<VRG^+ 9<>*PD-'OC$^4*G &/P9
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M(5\+!G=4TMW?VVS6<.Y<7-U956KA^KCF2JM[YT2HH*J2E;#"2I2V_#".D,Z
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MF.<HL1M?66@4D?#G]_9A'*V--D"N+"N7^=!>\JO($\_RJ;LRA'-^BF=!6<V
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M[.&?)NM0?C9[-?X<7"ZYR/ILF*:1ZK?_2=R>FC]'IZVJ<PKOV:W%13)8!#$
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MD4_9VGX08/EFAUUH5QTA].<M>!^ MI=_+!R14BJK<5MC"7V1$]]G&H54>KX
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M<&$:JN'K@T#HSY%F\:%&6^,##8=QZ"J.2!68?FV!!MDK<+>:<$<P]X];%'I
M9#YS\#CCV#&O!/F4':?\ZL7(^8R/R<-D7O7TAASY_:J_\%_WJ75S5 '!:WQ?
M2D-V4UVAI%5:++^+KCWB]>L<'@\#NR"+>K$U>@A@IW@\S6P1.=>872UIN7XO
MF&?V;8UF;=ZZ>RK3WO)D4)!->/P%T6OEKH//2W?*\QSQ4/48VN<5@F[PCF;J
M4?=+#FWJ\8]KY.NQ#Y]_!/,].M'W]X?YVW*\R?C1RDTS$]).A[ :%]._A7"9
M QW#\AKZ-4!0P0-?X#5:9'ZM,EN*BB#F2YKM.%.M"5J.'(MK,5TCN6"DFEL$
MWT"_HX;V#3\ZS:"RE'MC7K[70Z16^R8D=JP5M5>/16U7<4'G@MC\L(?"$)T<
M+L%4$#>4CMB0&XGI1I-QI[O0Q:[0?>"J M=GJ@69,TK,XP7C)G.1'7#NZH$?
M'%U*BE=W1."/@;D_@*K GO-!\WB:AEDX MOF'SNHWGQ!#"I1+0[DCBP8'^KE
M CS"3OE]0/@7$B'$)P0(P6N#Q,L=B$\-3+\7= G-9U(V[<L):&J/#]C>[;A)
M_ERT>=WPV.G>PAZ;UER#SC>=QR%$YV-LS$PK4BSYNG(2QB;W>IDUA2[U[@6#
M1L$@OJ:[Q+V1H,/6*G&'_D26A\TZ0BG:]2[T1[L:#W.-RCJ+5-<]3R6JUV-$
M3\I4\^__<F D1L2>^?2]L6K6KUO8[+Z&N8>_)SJO3>;K)#N</G ,F;66:@&1
MN:K0(OG?:DW[Q *Y2V,O?R!%%"X9$E;7/R F>A F*H5?[%)/G48[GAHNM3R.
M'PSKPTOWD_M"I';R/.SYQ4N$<!Y)!0$J(7O$X@M7I3Z@R2TD!J3RF,C2@D:2
M)=J@:RM)/0,(E_5HABPTEV[]@(L!MRRL6PX-7Q["SQ\?U)%XI-Z'4QK0E1T1
M[O,I&=SIMK^-$JZ7C1A]O#;M7UX07&VXTHSU-:=XM-?>P+,G4H=M:%?9JOF@
MX]E*'&K(#ITIERG^7T3IR=0@"$3G.3&IYM#-P0W=;#>HM^$\VIH!<QH9\VV<
M>X:['5?F8\EUC;S(<5FDR,2SX2+G9$5*4_B(T9S!_/"3V472F-3&!!L<.H!J
MP)XBM<M8B+>!/)O"DK01/_B6D*@"!W!I&^%R_-4":"&<(8HQW%G5R0)_=Q6\
MC)C4]X:#)QM_9GX+,:S=4<8I[N\?]&DWN2?JVZ%_W(BAQS;@Z*#&U*WP15Y2
M1V]+G9HDX,J A[<3E><%%SAQWKV]6VTN>N-KK!,CO1YX5KRCY=8G^5TM]&0L
MN 2$W/&P311XG#G@*@7ES!QTWFR:9?IE&O&9A(Q8-LEOJ5W&)QM]X5[Z0N]I
M074[93OA=IFV,^\%.R0==K;U6SI@?&*V?WCX7#7IT?_U78/*L\.59X?_%S.@
MHN.?9P'WO\L J0K<OWFHL 2$U^%1-X9T%*NR1R&. K=/RS<6>)+\GT7W._D:
M1]U17?)32&CD7U;@]&U.2?#<])3!WR0!W+#?1]+075ULRR&W^3^YO(]5]O,T
M>#YV#'!CY7.ZH8']5N-G%W<)4V^JP)C 7YEI3((IRLRQ,COY\"H:ASF Z+#@
M.-E\^*>'A%%/G/EJ;?(:1V5U1J,"-Q>L/AM&6T@-H0L_?FE\P@[W*Z.<]^B<
MPFN3 UT:*N'L3NXT,Y5J>_^H>T1QP>M9\J__;\H73X:.,F%K/'<27I; D9D/
M4+X+!I]*<ISE=R/:D\KAO-X&TU6=501#F%"OP&F)J;I$1[?\4:\ZAMUU4;3L
MN7N+44QA7GQ)"$V'5>?JYE0@F?.,]W+%;]BPPN"-*NC<=@FSX2+-HD)>A>"A
MGF_>.XNZ$&-)D;/$DTLP"+1WGYOML^Z;";C#3<WS6;5::^:7!B,%+NE"E+_J
MILT'1I)Q2.=,9QCL<CQR.>$%(]YT+42>T!&- L$$GKM/QP\KPX8ZR_?LM<P@
MPAR:P5COQ<E0? K;140P'#5:3Y&.[UC?\G"DS@CRN%TVXB7NKNFSY>L'KE$[
M^@*XG0[;8;G(:0F6.CC)+F)%5'512^YZ<B\G@-BOP(G"$&M\8AY)<I<\"#9,
MR>_X=2^71"8@"X)*@E>-BEI'D!-668WXY.\O>:EL+[,J!X.ZQ<\DPQG+8L&'
M;?\+\W4N'SKF#ENT(X8UZ#P%3N85"&I6N?>/N\";92K(6ABKUN<J< U1/]IY
M>,&QVOGY8=9WIN<7R]R0_1"'3EL^1G/H9D6+C4*>;^.B"RJ@A (FO*P^@T.W
MB9GGKC]NNIK=^P(H 6!S$-&+%N 1W4GI":AF0@@1W0PSFCZ-\_7K+((][*2#
MUC!'8BIZO]"6842Y)0RJ:U?_EN6.U08G:Y^40TQZZ,2%Z*-EP\G?#W!P<M7_
M=-7XWQ4OOX3Q9*C;>FD^%B\OPKT*W,/>1M84>Y$"9T:?!_:[7@?'.N=%W>Y%
MDBK#9 9^"MP/@V)DL>>T*KCY/UOZ__TF1D^V6(%[U8^V\J7AP&QL$*<I_G4A
M6$+]*5V$J4$E7WY8E.YNIL!=?WM0@?-S5$,+#P#/IA4X #^R[Y_A.2G-?\C@
M%>__U;*"W$EXHSVJ7OR/]DW[.'[I<>0YG-/1A-G!I(V0A=CJ#G*@UXH:(>IC
MFQ0QYAU!B'"1T/+V:M:BB; 33SCI'I*S:7-RYAX59XM.G?^D?QP_<]IZ "#
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M=\-LG_J-+7.ZZ_>WC1T/<(QQZ%X1LYOE]<KY:G$#K:.;^^YS9+'IH9MES.C
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M:(^GS&[&ONA6_N',F?IH0=QZ-](JE>R1?U^X0JW7-/,<L?01ST:E><\W5%S
MME?@6\HE5(C'/^2!CW[)X+KDZ :4099=XJFI)>;% G5S\_K.S4.B#,3TZ=U!
M@X(C0YISD*3UOWY6YW@96:$S]Q6,,]'_,Q# O!@D:=<PNI07>CO4H:,ZB%-W
M_-D8JK&NNC&KPV'@=-Z00[RFW<_Z6RUUW^[;2]!QX;[C_N#+I ]YHLIBT5^#
MXE5['R9:\4\D"MOW3B$%WT6@^,<?HGF5!?JE;8S,K=W&?UE*1N+/--@GR1<+
MR;=_RX[\X;C"<,[)<3!LF)>?,IR9D4O^.84'TM.]HT"4ARU\+ !:-!ORW6Z8
M'KL+H5TFXO8OHZG+'(P##A; Q1;!T#S&^ -#7P45)B\=8W(>HUFO WG#U.;I
M)TA;:'$$5QCG/">7Z>C0$K./ ([E@@G!9J(*!7D,DR//#N,]->:#YFIH-.\+
MCG>O.ED\1TRU<9(BSQ9>176I91DN?_BAOFKJX_C=L=*DE&=5]26P?*?,RE!_
M?C3GTPCLP)ZIW3/=10XZR#3/I\F?V!G46[7A]9XW<@)6XJKB8',II5/=J'Y<
MI<*&,IF3\HT<5NY2L/9B_AR)(R*L8UZ9O%SP[.BMK6&)@$E28L&JE'8AS)ZQ
M87V@ROE\*L-:1<5'N:<0X;4+G6R*GO)= #YMX0XOU-A#)G[US6%/F8'508M?
MEIO#SJUN J7\0>KZ6OV7T.9^9BA3(V5)<.^7(,2EO,D<Z.##SH=+%&JL07;Z
M #Y2S5EK7SSU18LK#U9*IMN8 NX"D72]PV]3?0M(J!YL[ PBWGKTKZS,F.=:
M,F5!?C \]Y9=C;:JT;=:39A^#O<MCACYY?NFO'-3"M0\H5[ZCEH:.?BRE07'
M$-:8RX+/X")ZP1(S7NZ<5EQ8?=1R;>%>#<37HO,')])#C>X(LZ--B.D'-):C
MMHAG_(QH6/>YY%_L"ON6RD=6I;A1DROH M0/IVK']V+E F%N8Q5;\G!5@HC&
M$9^38M<13U7W<_F-[2MVFQD$!UL%.?DKK:/;+G6MU<VU\4>24;MT3)S?5YW@
M]#8/J[05XYF.F]TNI19LFC-:5?<SNKB4+YU3H-:?:ZNNZY-*)]X>( =;2Q=S
M\)3?\!OT4UFU3,ALM,X=;?(@XZ1]/1ZFF,<;;T&H8C;TO)YH%N#)>B];\=Z!
M0DX07]+_KF4!-MPR$:O^.N%O<#]#N&DGNA"KMT"ED 0<KY8JZ2X>DJPC2ZTS
MR>)X35<M@4WYE,7SS$10R(>OO)+=M\YP,OPM,P8,QCH3$T-#O<I?FR#$GWPP
ME=0>K*+GG\3&?+VE1"*]:('VF.[+F"@<OM1-R?7(F,E5!V)=?0,^\3_0OUV7
M1MI#FAN[R2B\N,#<-_3K ,VG@**P20M"S&MAH_F\\#MD4._!@2 JIL4X= DZ
MX]3L:():$;S_(=6 A(V6_5 $\Y1Y$'?'&^;-K^CT0^O@(-$?O>#L!&9L=QZ>
M<^B8UA>2'D#W9 AQFN[##/65;_$VVM1W$]P^IMN7^QN!YR)XH.WZZ6JZH-?/
M!*(DE7LLNPE/ELS+ROEE=L8B&?U*A:/G[26:7Z9AI538BA?W=)AZ+3,BD/N8
M.U..@6HQ)JRT.%1,VZV]HVN1G/:C8MWP,(>!I[D!.!Z/^AE]5(F'/?W:_4GF
M@J'G]5ZCYJ00I:;)AW)S82>Z\S1<H<3U1U0+SO"C/%'_HEW90(WT7_%I$@.;
M/FG02:1IALATDU=5N<8GW^Q([M<,#JE%C8N='74PZ_HZ-/_ VKB$H._'+)R$
MG=&EM#6%VKX^?LV>76IR-F[Q'Q: 9+2I2'E.XED0;#L=E-S5)DY%%#K9V@?-
M=NK(PN3N=ND()ELT7[;.NSJV'RKY8+0<2]=1J) -F)W5;-70-C!.(<SO8_=E
M#+UF'QPASFDY8+H.(_QD#[@B.Y\I$\UMSSISF68(\:S>S;/UJ(%98:2#,D^-
MHTU]T!NE)4T>Z5(E(1"96#5= 6<1(HG78Z+S3H_RRN12NI$1.-TJ <\O9;'L
M&Q\?K22/'+Q1WX<'DHQ8@!F8+963]H!JT\&7E88A$8G6F.(@CNY7C@F#T'/-
MZ*^3.J?(PK=^&G@'HX+>[LR:-C5[SU6$8SSF_:H-/,6!=P@+9[X1SEWN)KH8
M(J _+3V6^8W0$NHNJP;Y(I&I\P_1T1&E'9R0,C/DP)-EY"]2%$RK61FI:XZP
MZAWB?_5MI=1XKG/""2F8>*>U->=7:*'WV@(EDFT63Y![F5]8@"X<0W>_E'D7
M/WQXX[8"37@)<93]%R/\-@OP[@6(^;D2<O38C:0 60FFKX1%, ?S*[<W_V !
M3IPA#\?!GV>59T3B,3+K,D!>NA%9W"85:OU292806?<!#^&"9OS\L6YSI!]^
M+INK+5UDHCPCN="@N )9:I?=>DL!IT((4\(/<['SA*,2'=-MFK/F<KM%)L)C
MZ#9:W:J;4-KG]S#R^5VTE)5/SKIUH':Z0(GESZ/G6/&O#9D7'"X,"P842@A^
M+T7OZ)4@SR@]JLTI,-&[X:2?J^,<7+R(/#JDR;  [==;/&ER_UJT.].F. V'
MD'!=P--4$S@,&%-6H:58&J39=0'1<8?$'H5Y_K%L@ZID<[)S+EIZ[=4X5S"E
M%7+?7988_(\#VM<+)$!8X+\I;-?QH<Y *Y,W@T#V_I,TEB2=H7J66?X>[VNE
M73,G*V($GGZ8$BTAV#=84L^[#82F^7C""U7:B86)R-A"@]G2RH"GNA\I[SUJ
M"OM$7XUDMBJ'#%TV6M5.3L8M-BWL0,+.(::!"(:)EAX$NLA!3YU>8"2QW4N)
MFG\7F8.IKP:D_8DX"BM LS6 &/L&]I('F'UYL>R*^X W<_08\UXC!R/Q%O H
M9H!TP#BXR0)\LD<<!3 C0.Z0PRL08<1&,MV8K;L4[+&_S@FSWQ]^C06H'&+K
M-'0-]ZB_PB$?^UH;G+PL0/%UQ)_[S.C\H>@C )WMAU/T2-7,OMXW+,"^P.@Z
M?6T(]],_&_%]&,A^JQ5XA0ZDY5UBMI<@5DORA_CH? Y,X^WV89K8-OLP*@9S
M!/O,?2A9C:,)LYGYH<^O)>85%N!+[S$6X!&8!0"/@\1US@<I$L#=^7RKP.-M
M HRJ75MJ8=FJO<NWCZTP$57+3"/55Y&M\XU7=" 4F^A%VHO:0/%U616?&<.P
MJ\'E+C(TT<"D_IWGO,]IRC\CA8LC/4J;H[7MC>HEI.Z>JZ=\CPW1.&]6G9V%
M"A2X3_W*>];Z=LUMNL0/LG^$=KZJ['5\L*0%2D)BT&Q.Q[*Q/"!YA<^0!7A[
M@:[. D3(WU!>2/K7"F1D#,5,Z2@OM6 %0HJ<\9#SI*T\_H:]QOPQ+EO0K/FX
M$7$!FOK#X?I!36T&1![XRVCA_MGA]2%;>/@?C*Q294$K#$&G5=K(>3T0KX 9
M*\&W6 L6N<KQ%*<OK)XG'7!N7$2_?ZQ3W8]5LT!M\)276LY04N)"0+#+H],0
M\&=$,NZXEAM-G6Y'1K1OBR(+R-P1WE=BMP.6LTQD;,:P&YO[<F)VH\5Y0L%/
M*L=K9IMA[[L^]2JW),KE?O5U<@!?1-SSV0I]0WB>?R+WZ1#"ND<7/#UN9N5N
MA5(W+]<MC4^QDK*,^+CQXTE*CE#$QX5?ZDD0B$R/=?OCBY0T^X/",,,.,_.(
MQ1F;A(]CLP9!K18&=_$*/'0_ZBQ^(1)491!5JWVW2U04'&//)I77\/-5XI=C
M"?D"0@X.\?'-43*"JS,OYHS-XV =<@'BDW"SDL-W>B7.-Y=[7&Z?C;Z434Z2
M3M=2D:2IY&IUBL &\3<=1Q-<@(<TFP/+K&A<3(!/3=F<FI@]K__94%E18R,_
MM/'Z[0S!J!$KV+2J)/WO@U\OD<H:HS,/&#.D!?KY3#R*?O6R#Q5']$Y*[@J6
M*PQA&'>^<HN>:E=YF7SY:6W-MWU-CJE (9A=<J;(WOS5T9]M<2#U&H8V<N<J
M$]$=>D41@C59K)+%T6Z9E%I6*OLJB*A)%J&<T_6B45(&SO?QI=*>.S2C.*U1
MQLG,Z ;PH_3G86+KU@=((YZ)4VW].1_7#.4JUCJSII82-W G<5#P]'8/KHH%
MZ&8!+L&!Y+'IN;57%VI:QFK+E1XHX2ZX"Q;]N7Y_2HFL(8[F'3_>&>AYQ>W3
M>#FVYE?*LYK;N#T@)_DZ1]R.HWQ@)KHC/2S(JL F<P9?R9,O\5S;%!+8H*EF
M:&>)E Z\&)<O3=]5&H MJ<TTR.HAI5_XH(5VK% 209:)E*81;+7$C;F='XQ9
M]KR^3(=,!":?A+M2Q4KG^WQ=%UO!=\C#$5>RW-*FIX,P- ,P62^Q5/W:+#C<
M<C0@UU".T&7P<"I0,R5>KBM98?<@N5%.D'\C4[O01#]HS3;AY&VS.,?]FV']
MQ9>+9JBE1HD>-8UYI7FB:2_BC/<4N,G5>4"AUSG92:(!Z]_ &SWU2A[=+^)R
MKLIX#IJ#,;A5#CJ/<3M3FGRP 25CV^=/D[8J"3A>V PBXOF>-_>*8.@0&N-A
M<XS %^$6M"E;+I81?%R%-.CO@]=JAMD^:\PEOA40AWR%J[ GTY;*E\J&#1/A
MZY>X;?@TJ EZ]T<+C8#3WVN#ASSUG$WT98(->RZ8FHBMJ65$/C<U2"Z(1FI,
ME.HG0,=0?%)]C&?QHS)5)FVQU^=20!(L@%L^]>I\ 0:J(GJ%@6R[-D]]MK:C
M)@_$;W=Z;PR4VY@:F(DYP'1N3\C5:HMJZVH=JJIDR<=B[/3;LV:=&D\8,;N[
M\K0M"NV+A2*K^H/>W^F7N36H70:UA.E)\PLJ(FVF&26FK:\L/'Y\#WH.]W+X
M?#%'S$*YVR@5"L*X! L7+&GL6D3?GBX-^,4[6JB33ZZG7^"D/)YH40^&+GH+
MP"U)B#CK4;W1P')CNQ$M<!'G1MB:D_?=U#MC\@KE(88G,\M6_/:>YB_=8 &D
M7I.)<2L$%ZTP3JD>O/I4;8%IY',);[>)AUAAO?MC^6[6B8%CF:7[&-(Y"PU3
MM5??FWC-X:EI>&OA.6VDJJD<]H9I]B[H0WX\Y*R6&0E"@"2V\08-S<FU&"]"
MSD/<!=]'9-0VJF"SG8RZIZV*QFIA?'7C>ZM.%Y8JF^O?%>H_#C_*OC[H\V'9
MYO4@Z;9?!Y$T3N;!DN]^"-DKSHA#"L99EDI\1)\6GTONKVPP:CAK!1<)2'?4
M-K1(KWM!?0K<&E+)>7%@/_(<X?@OV9>?T#3< _G^JUU55*PUVV***>)Q--PQ
M:&#>&"S>T%)/^OHJ]" ZBV G, _=;)$J7U&Y/;0Q["M1"+YZ^\L^W9.P;'A7
MC.@(OUE#-.;Z8%:0;8[D28,.\*S=O?@QQ>A6AGS4M:+'*6869O;B8<,=_-/$
M*BU-C*3&>^CP:2G-N5+'BMS9N5)%U.6CF6V'_//_VC".^&G(R$%L0*GL&ER<
M?V9J/A0(6J!F,C_O;#.TX[2XV2?-[0P?,=B'1Z6 PQSA<&.B C=D[7(>Q[@R
MVX/U",H=O,%>&WG8ABQSG[]^TVY-!QC>'V=<U42(V5N/>9[@OV _K)+3O8F5
MOY)]!!:)_$R CN7IY$JG^5BM+I\/S$4_+(]8SM6Z5S$.\BV_WSA_,\W5O/]A
M0N$A\DSMJI$QMU1/X.H MP28D",]<[NX#+N]>KGPV51S-91Y! >PV4#$UJ/M
MXECMPHPFVVS7 "^NU?DZ]2TBHCKO)-*5GB6*&\LY= O.YQ.$M,'F$;>2F O&
M(\1/=0T&<6/6XWA.OX5A83WBA)%:__LP@7Y2+:GFV6+E8?XD<++1P33 )TW:
M!6645I:K;E6V9J0QE"BYA1WQFP<DK/04N\5A3,L(^1.DML$0&<:'";1@G)^#
MH>Z96R&F,(MEW.Q+YNE;!- T[O-,=/="I.C--NH[TD%G93!3<72_6<B8FX]J
MWV'\?A,_2= (OBQZ=:0 2G1R-H:9J- ,'T!JTR??*VS5X$H6P?P^/TR2D:G/
MJ-+!SJZQ\ ;!AE>IZ+?=E@_] H UC&7!FD9(I7FN?2!DZQ!O,]V!3<\G>3[
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M(*RC954 EL3<U/;E'MY_O83#'3U=,ZG<0-]:"2/[W WZ)X\Q!6?N[M @NT=
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M,D=UJ+&.A\M#^2<=L!>1OP5G44SU5F!)1JUE:FL<CDHXF1;[MP]R<H'9!_A
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M=$J2&'00$]=X>&A3W/0D*&5/8<F.)I5()+K3T#N7)H_T:>Q\Y.K[;>I[]5#
MUDC$C:Z_9I*:%+.>;!7,H'"F[5(L7U_F0\OQ/NNY#[>>N;QGF3V?BG&7O[(X
M%[H-ZG@J7C!"1L.JL/ENX*-6^U&)R&-D^9K2?.$)_?TW[/G&*Q/#@W&3F?0Q
MC!C[#ES;W4))9O2IUE7/UBFXQ'KXAU@1C.D]K?SQ81IJC]&(N?<?#BZZ8!_O
MJK\Q2B108YQ6)-N/9'CEB=2+1>ZIHW>3^=F&#-Y%\7TD!884OXV$]^O.T!ZD
MQ4"H@IDZ/6S64W3IGH)ION4'OPP-;(-%W3YLS<N9A!;V[2]O4YIN^"NK!KN*
MM>9(7O5M03[\PLDL>7ZKZ]D[G][6$VH 4KS&S$[LIU+[P8JTTL/!KLJMD>_\
ML,*&TJ'WJ&T];:O8=MW]Y!8ES#ZC&2W&Z\:XA;/I+6*:UKZB+FVIJ^2<]XFU
M>3B##XOFY/CG-8[O:J(LX^9I\Y,*:.WF:\]KM;3(3SQNL^TOSY>?FJ-WV<OO
MLVD_GY=O$VT6-,<\G:?=,_:^_DFNN&5P_I[S-L2?8-8O^:;9?MHA2\]H<K)M
MD]&IL/1JV^:N7399OGT59G=^-U3[-=_:KO<IZA%0?+;8F["@?0%2^V&X!WP.
M$Y;;C+8U8N-Q]] 9JC=;B-4LV36"UP:ODR?J")MKQ/<%B6&RCI&RC L#NR8V
M:AIJ3V+=+S ST<AH8 \H^!,M,@)V_%D??&Y>O#[S8U9M#N99ATHWVZK#8_#2
M@E:1Q=77]6=,!"Q5<Y"[]KH,1F3]+NS'IYX*<8ZYCEDZT_5FF,U%I'N<J3A4
MI;,@45IU**7ET.ZC_9_7_\$L@3DR983"&7UW1>MYF[BB RZ;>:LGICDK54I%
MRC?.*'>CK3ZS3L)%3'%C+4X7NV(>1)=A1J;,:#UNW._'14C=F?K+%X5,*F*(
M+E/%"/7.N7CTD'X %\%_?NO2!\:N/%>PHC7<X:G7L+1N'<-BI7V;=;'N775O
M</Q7-&-[4I;Q4T9L<[3>.?O]^#C4+3[Z[+7C*B?;/$5MEHL@ _9,?Y\93Z:B
M]&&ZIM3NU^JA6'D[NS#AN>C$R]<I*QZ.)-374<!YP4T6CV.A03T[.))OP:9:
MXY58DOC3#-3C&N*(%K,-#)PAQC;R@&$T"\ME1VS4E"!>C R6M(9/D D:_,M=
M)>^J:_OT94*\ ^\%"NL6-'C2U/:-A2:SW(?TD1Q*283[O23BH5LJ[O)?3GPC
MM^)U$ENN@U_\^0+S.>2'K>9(LX3E9H$$&4/\W]=RI?KS=#4FI85Q5QL2T=F?
M3YZ>GCQ%.#"MY%#T9.&M"[AR7+#&Q):E)W)>8\D^6L&TTX9P_'!']OI "5^U
MI[O]DD=#]9\7C.P['#NV&=P;\$]O:/ /3E!3HRKX='KB?!N 0\8/:Z'VHKW*
M-&EZ_.W][*"2Q7Z+4ORE]WV;4BHVG2QCT)Q*#:)5^1<M.FZ+5M J87:[C-M/
MBF-O(" K6'8,3H$R>*"&1-R<^K,#/CMO@GV.KA;3>,3O-![QS?"(242%5CLF
M253W2QVD!2[/\&<'?<4*_W#_BZ&$(?N<N=Q8@XJ%E)&"2Y(UW:0P^O!*C@R"
MBS"1_.\$ D1!?+ DV[D*(N'(U^6DU?NSSN!O]Q^I<W/8&PS$4 3][V1:F+<!
MO)%RSF.7<@Z!4=3C.:ZFEYBG/PVY0/&B>05C8%WS<$9'= U_UST#!_/'9]$]
M&&C/4Y87'E8^#P6!)B?H"-!DB/8KPT "Q(<DP49%)_Q!D%K@*_DZODF:!TP,
M]U=I/!#9%RE5/Y3T'%<0:H)]/<C6QIO07)^KFUO83G?$E^F[T?A=EWMX0(?V
M5AZ.Z1_>L[X%__LDH'.&@D2O'B7]^9(EYP(7<4T2[J!5W/_60?37'@CIR,E@
MGZ'W,-]PGE#\,'ME,[3B*#[8&'==NEIB]W-_D3BWT!1FT&"]@%8,&Q=8Y*KH
MCJ'!"<//=NS35^[_JNF_@2'D'(K[=+3V^6/>K4K63KS?,!J'^A[$U.>\P-N&
MX0I#ZV9,5EKH2K20A)LK*GW=W1B)T'YJ>DPPK#=4&EZ95;J8(&/5:K0OE)K)
MU*VS_X'^%M[Q&]9&O*>!S@-<Q$TN@B5FR \LF[%AO=*) D][0Y=XF+ NJ6JI
MYR(&E>@%]]%5&7"_5+&@+))=5D/#LO1Z0(4ZZ 50HX( "@<1877MJ 0T/Q?A
MO18-1T(_@]PAC0+]Z174Q@=A-$ J=*I-K,3CY0])C2=6OWJ.2_O%9SZ??=AB
MWK?B\7Y0(]MAJ>MBGW)%L/FRGNE]])<U9C?G#>!/!'7]F$PZ:<6/=<S'I><^
M[%T4 9*A,)"/-E2N5ZSJZ[T S4W?2JI6LNPB^^HD S,&:V8\"C6(#^OEQ$93
MFG$T)2S!<)_N5 +>GH86 -_R<!#HZ>=3= OTR!2TUX^EX8.NZOEHH5(1(.<7
M$4*K:+/PZAY"2<$B@>7R2@Q29JC7SEM[7T=,>%(Q?*/C%OF@^7FGZF7G@("Y
MP9IL)YX-S?MH-&6Z%%B/QX(*\IQ_O%=AGQ?S=FSL8#\ FA*XB'L07Q"TMA(
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M-R$* DI5I$F+BG0!Z9T<1*2$(DVBA$1%0/H1!!2$*%6:D2X(1$B (XA1JH!
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M&K@Y'>#WZ0<\')N^*S41)X2Q]3:)F&7<!$->:/2WMF?B==9:<78=8 ZM)J!
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M&+:O>/X[@6F,MJ$O;!"XA+:P#=R@_,92-<!$ICZ&M*M7I%O"S]"P[65#P$%
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ML 0;!)/!?-KY9"%AW2/U9W\Y7EVF"<];K[ ?\S;6=2A1(OL$>#<HV.^BI"=
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M\?_>W.J^)<)1PM=T]-]<Q/$&N%CN:.)U!]Z?Q.:S9AJBS^XU$"AE"TWZZ[-
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M_Z4X^R_J.1-=\M?S]]9N6NU I\\R]$!_IBR8T-\C P:\1&WZ-@$%S0$O0_/
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M>=$G-A;^<ZZ-/7O@;E_@N&)J[\=D?L>I @%/FW<Q]O8_G\[8_"R.O(2_EN.
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M^NY9V,4/Z&?Q=[=4RRU,'*O>\^!TT>FTXV^=GO(7KC[R3/(Z)31KHB:X(=7
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M7S3[<ZH.6O*@O"D$G>U1@^)[S+&/1$[E.(VE:<;'SA)%=B2BT$:@FW"YO;@
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M[7M:>ZC9I?/7.<TM(>O+VXY51-CM3+,/34JV-[F0]4_IL2LE\@R[]HGO_V
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MZ%7# DF4KQAE?8/0U"3?%Y":.&>QVL522D1Y]J(R=RS$;1JANA[PUL$%O%R
M.3?1PJYXZ$>.)C#ZH#AH65CYXF,-A_(@[X?0.5"]L.C6%?"X_HQ^<%'=NR?
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M'"X@PNCSXFAC@S6+\%JXDUZ-;Z6J),EG]+YB;&L&2GBX&/JI>?J,ZQ+G9YQ
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MY@(NY8E8P W]18+BXV8U!41>[<K .EHSMHJ>!,NZ!V#6AUC8A.9Y!^1L ?%
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M$<I"U120NI<T-".71R<J<IUTVO,#N<9.F']0TDY8IZ8='6"Y2"=C)M=Y43E
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MC[UC@PD/$\[$M2!P]D]:S%7@2*TY8@7IM3 33>QA5ZE;PRPYC6%$=X,*7@M
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MC",4KULC)_N<"+0OUL710]3CMRCML&MUI$"QH)=;5FVS])* ,#B$<5I6##?
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M8YU_?&X2;+'^^F7?H_OW:TJ71:W8F[>D+_]$]//90J%G/3D>RYH_]W4P]&'
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M?G+V?ZR9C:"JOG,X"P8\@[:'H6K8_!Y'2D[M(HQI_$_M[+WG#^;[Y5.%E^\
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M^Y4D)CCB'XYYVEY.\7:G><QX]DZOZ+:Q[72T?#@^^ZN;FM?UB/.G\J^;BBQ
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M>PG%3=^+SYU7'3N\T%OH[&V".) 7?W5<6Z%SN2/IX9;:M=_>Q,=U8^".3/M
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M^!QNQ/A/IPXA'7T[*".CQ61C01<4HLI<LAI#S@ZSC7GVK?X<0OYN\Y8[YL?
M,+Q_(72=_'6Q:N)_@PS2_YT?X$XFM'7\9^VX\C&H[!_]R1K6G\$YT=6"&=Q4
M,NV!1*!Z!WQCSN#J"B?VD-^&#%__7[[B_U\_P)FN_S:9&/_9$35XA'GES/ 9
MW O6V!R2(745? )=K'X,G(_S\D%.2>*\/.N4CLG4E5#&GLKJ5TB';+\#I2/G
MU%72@^=?R083HP@Q3:G'('B5A;*O"'.O6[;@".T"E3D6".:\Z>2&@T)>*U"#
M!2(]ASHH0^'.W ;HET2[7[1)DP)"[P! F+N8>^;>BH3#WC=IEE59K1L&T)%
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MQ):-K;_W<].(*R(O5*?]S!UOFGZ7$/?;F72'LG.W=0[A@([7W).LP78I<TP
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MB)E>98$WIL0<.E@R\N2'9T^I@XMV9.ZY#_\ZJ'WUO\$6]P0J2RRL:@5V@Q<
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MP[I9';?=T@75B[@_-FD?_NW=V. *\W^9*2I.#+[34-MT:O_M(<=(V!R'_V@
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ML5\=/+?AMZ%E"%WJ;4IY#HG"IP2^08&*5Y?TG_]94W-HT'_7?*/XN)5;"?<
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M<-B(&@FYE)Y]0CW6X]1O?\_^?;UW<!EBTOH0-BJ9HCG 0')UQ-WQHJ1'^&X
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M OCL-@#R[D!LLQBIB'KVEA0('1>2FX2Y^/A^L\H^CK'*2C#Q\S?BKSK9WK"
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MJ_F*&HXYLNMDY;TS:3[52(I4W[;-_/)QT1;V=>?MB=3,:%P>9HO>:"L7>@-
M/N34W/6=5?\4RS*K:^A/T:[<1?^%O7>/AZKM]\>76Z6(28FB3*7HA X.%<UT
MN".)"2&4N4LEI.E )L:L(N=PEZ*XF4I(0LXE9G*^RXV<BS('.9NL%::56;/F
MMSS/_N[7?GZ_O5^_O5][[^=Y[N]K_JBWEU>M>7^N=7T.[VNNZW/15_>>3=L
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M(#HY//N%RE$R+T(*3'FS-^%9.E;R6 K\&'HO)P46/06K"%)@N)/AC/NLEOB
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M^PE*WE>3NR,8UOS/9]LV"3>YM):X+=<M9K=/Y.I&!P5%KCWM=_)]"*#@-IM
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M" X+WZX_"P^%5AQ8']5HM;B\_NOXZP_RP^!_Z1 83OW?%Y$8G059M2#K_:0
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M4.BT4E1NUL4=;K_[L1;UN'VBN]4Z!ZYL?B#P,23X!&9PPTIBM6J/C"1G/%2
M9O><><]>THL9GF"VD38BJ7A=8 E9I#YDK$"4^WLKM?#R=)[0^/7*JXVB1%CW
MAM^='GK.D0Z_M_>SWAP.3A9IN?T^)0P2S&GV\Z4<;BWVV7VV]R@N&WZ6F-FV
M3P63:@ZV;=X\5;G)NJBDO;AINVU)2 .EO5B\;''/N^KJ=Q_7E!85%<U^#>KF
M1D\/Z9O?MOZVSH$C<F@(KGSJJ-"%JTEBO K4E9203]&4O)*)PK#T#^P,7$.&
M)Y<&6L2*;;P"@U\2GKK0?'S)AY&/63W[%C?:IPK'L56N-=JW<UO4R]13GAV4
M^\Y%M<)P2X<ESW 1_AOK116$%^VPPXDNO'C<7JO.434GB\TI06>>T]U$U!<=
MOA<R.\QUTL?L))D"4 TI_2K:'20P>) QNHVN8PDO+=S/3]GI[U+A+&"I7P?W
MWOV+G/N#BJZ8'<W#G61>%D>>L1OFB +;<K,D161/7XTCA5!<U+K.N!1"/2>L
MV[G0>Z:A.B?U$.;F8TU<?&[F;G??.L0G.#B EI&7^Y0>7Y-\NRRFKF L>;["
MCP!$0: @5!(O1P/;&5Z\W5<$Q/$?XI\9JG#8IR/N^]73^01M^I*ZGI6U,Q<*
M'ONX6F30E/]8O$E_,$I 4QJ;891JWKM5'AZ6/Q(0&-PY</<A\:/".*Z*%0K0
MRQ MS(BS$,,S2:'>39+)V$SP;TX)* 4YT/^1M,B[I^;-/O"<#_NG3L:&?IKR
M<>^RV\QO(IJ*=]^BUJZ18Q_HS.8>Q[)28#H_A@PQ2%D&J=D?4$7<KX..??!N
M<[4M-XW"-J/@2[S0M1Z,3>SRI;Q)(R >CX^/JO_:6&@E]&6N&;G\R2)W3L#5
MY]5\@#2.ST,JR,NAEG:C:N+^;N&T@-+3+0AF11O%ST.L>?H3-?D1S&40.X)/
MC,"5J0:UF[FY+L>-[GRHW=<VQ[#W<;L?DC=-7N+#U.F>.%50%"<^5FYM?7*1
M@FCW_Y3<_ATB1U%"4)_98XJYOW90;J)V?"FP.-:\1;27X:?OVGY4W6)X_R71
M27\15:=%??*'&=JB>^+U?(7OH!10;?2A3MW*-90"2^;A(?Q1W'4"$N?FBLNT
M,UX@<M\4E"STDTO 7\URL.KT.DDVR/N5^((29KZ3'XFI(5F8HNH0&HRD0VT-
M=;G].GSR3=8\U"$HDQY4$QC'[M$((SH5P6#=IN EM:Y.#QF[LT(O0>U'BTUJ
MWKED .BOLWU\0(]\Q&L"V3AQ@[W.I]RYETW$?M=>U,TDCU$NJ4A(M!75)Z&
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M()'Q)_N#5:7D DMTB98HY3WHG?]QJ!\4QN;2QPY G)@*+7\^*XJUB*T\I@W
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MZ.5<QU=M!^+R/7./'[?5:2WQ59\4VK%3%*NYY[_MJTCA7SZ:U4>_4OU2>XM
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M2F5R0@5UGKPC"E.UQ?NLJG_TWQ$U:G=PTU3QJ]7*GH#W3.O,U![;-HDGE-%
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MMOM/9Q0,IK8LPP9B_UEEE3I+D2,!2QXW<+#7JNP$]@ZM;9)?3PX+O6O%^=\
M/,4EW\?C;.]B+#%75XJ"-6N'JUJBAB*^)_6E^8?,>$)7@M__WFK^T:'JNSE?
MYPJI18N!:7ME"#IC[S;XQD['TN]!#F.JF;E9H/88MA339;_^S!4V]4P(@X*F
M^_8GEK%@ X;W:@.&$9)A&$@]XBMT2J:3RHM/Z$HGVV4,O:MA)_!F@M^2E2C5
MGK*=HQ+^ T<W:@\SNF1LZ;+B\KMKG?,S#^Z&5;]I4<?Q2K7C?-)5O0W>W[C^
M>2RL^AV1F5B1Y38M3?1K"1:\Z3]A$)640;AFFV2*U.;8$AXKW+E5;+1F$V/
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MKEF?X]"-6]Y5PCX_-K$]!,S3Q"3)24A6/,(>^-\G==G_=5(W)-28!N*G.M-
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M1XUJS&(?AG7D&!:^Q;8$\B;6BG "E069S28;&E+A'IL[',BP0D($%GK,I:I
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M3@\\;UD@"$KE+> ^IVRA>O[<B"[#I1U*MDF)D5ZB29']ID9L+%))(]_Q(L7
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MK#':E5CBY:S-I<K]^#5-XXX?K^[LF" M4;N^W5G&&YSZ'G=.=%&K-PYO=-!
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MC*--Y"VR"\8-I0/W#GZD>+FKF[\IM4Q^(\8G):UU3Z(-[JCS%-D-P0]1ULG
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MW.*-BC(+=UH5-*^^(7W0*>J>-Q4TJ6_VUTX4K]IVLD!:3C;Y0FQJ$QM]AXX
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M;/OX>8FPWZ?T8!>>B[PN@"+^%A7^(FF#XCY%&Y^."P9><R'B$7<K]XV":PU
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M$]S%5""-)+1[KLP6)*_<P[#4,N2"I]TB2J1Y]%M*L<?TM&!V2$,S&P7\?]5
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MJJZNOKJ^OKKFA3+*Q?%.75W="ZW_J)ON6/!"[.\C+Q4*[5[JCAS]ZU8Y!.)
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M'B/^0UHV+*;^/1BK//</ [? L>2#:/611+L5,&'"J*4-K$4SY3#7:5EM<T>
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M?*M&570HK86)I NO5WKWYCC38F.J-G[_KN<$D0-?RQF+6@]@@$'PX@9+?MC
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M3O5IWNK>ZEV5LE(V54G5[Y&RZN8S2+W1J60<5YPW$6W'$WC:?\3:K_YN:DC
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MVI\E^8BS#,N *SB;%W<-_]5D4*HH.%]= ?9)!.';YX5$ OWJS[.= H( 8Z
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M"-R?;4^/N^/V NTL2$(:L^H8S+B"YUQMY$'9.BY2)5I6\S?75M5595RM'=0
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M4!%/*:!M3KGSV;T-^XJ!OQ9<&[$W^K_SY:(#&_0#?[T.(ZBXGFQ19\FMM%R
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MW7AHPX"E8:N2!?LG=\I\Q(NA,[E(O0LYE21W'@[6:+VUFEYD\R+PUF5U[2Q
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MPXD(Z8SH9'^5;0M1).\80=6+[[G9A4;1#:U ,AAJGQ;@;F+E\.KU<9--*-@
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M],Y%-!G;_$3A^US%AY ;\$'B%%^-;I$:MGB92PMJT".9 NO<D^JP!=@@XA'
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MLH &,'0)U79:[N<8 O +R\^P2:;(YSO('U02V?!I+>B-T%^]L#().VB]JBR
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M^1?ZAI4]#B71"B9=0Z97!WG1&#S7#WJE8VG#50\X_B$DW7\)R^-TSW:]JL!
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M3,)WI34>0%\HB?B2UH17HCB_D23@+Q-B<%AS!3+>&63$,W=""P*#R'J:$*\
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M=)H SR^A5V7$&L:9:\,FP(_I&*!_ICN T+946?09D?SP\+IQ?<\NYB:REM-
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MQ5_(D8(C\-P)\J(-?:9 @G%GE!&04J?WK]%;V<U^U43^]A"B[+K,1IR&GR=
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M]%(-4(?'HQ**AK+Q$NGI;)$QQ8Y0T54^%$E<6;N=<@MR.2$,[(;MD>VEW7
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M?,+,<T\MX3'N"W'K]=[4[9*54^<1PJ@ZH+#STZ!V4H06=(N4^CSU+TY\Z\Q
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M<S5C;GYWM[8,5'97IAJOSBE-(JL$7\ .ZD('WS7T,=W7HZ.> !VR?.5G>%R
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M&1RW^//G+Z4+V*[3_^?I1*DQ,D>$6!\6OI!@RFY!?:B1]S54S%4K2S :T>N
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M"'?T!G=A";?L[1*94&YNG01SR[\OJ0!"=>::-"BZ@6FV1?RF6B-P=RM7+-^
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MMWP45?L>V**\\C%FD8BLOXWBRH0$@UVNH+V]2.<@;U:1TL;5K"=L(/JIT\K
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M;\'1%SQKO&W<D,]L[B075S$$.A,7_^J#MP#(YS(A*NEZB'PCU"B-6)">>1+
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M],FD:D'& NGZI9:!"2.'FBQ6TO:A)BPV,R%3]:+NJLMT_>,8'I[;S%K<*<&
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M=7XY9M[P"&T,,?E6+3A)6%%D!W5/S)Q2UWP[+HTP4A;/(=7 ^NOYQWVB QP
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MDT].L-RW[%.Z//$NN>-3&>W2*]+]OGL:GJS/_YXJTFEY++9>"./\&*Q(G[A
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M#TSUZ+3\GZXM/6%E%Q_[O[$)O_:[PD9I>D+W1&'$>B'XM3#-/6+3I><N9'H
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MT[_ _$MDUC^KZQ=6Y[#AAW%)$F6'R"8JA$@VXXA-8 7LQI]UK]X]"CSHCV^
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M0@_3;.Q:,6$6RG/-Y.#767!G%!T'RU_63#'T>,&; SI]MI473JFVO?6\@5K
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M-1@_HTN?<705C)ROMY53[KAA*,B-2-3=LAW]2Q*61D"U5!+<K;$;"N0&)V!
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M,().DA/ #Y]=WZ A]@.,QSQ1WU)GT+)E8"2[%)AQ7OEIAWFT"8DQ0K$:MYM
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MW; 4-JR9L NV ]\]+@(,I <0V"A)W+$>BM\*>A_/JD=[#*'WL=]?<,BJ$..
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MR"W=T-]PD4D 546:%T7',-F*%4!I#$#D%E1TJVMJ^AL9C"CUC^"TP*8BI89
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M85&J"'Z0(86SXRA/-,V[;@2"%(M!GE,1V'0)=%1N@^]TY9T&PP.*][Q81D'
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M?V M[,0*(II?CF0F4T7XM0V!; W"!'+>=\-WFB2VLH'>YTR9FP9FV5U/>!K
M=A1ZW\APJ!WT+U>>RN") ?ABU:PD)WB@A*WAZ## XNSXIKYB&2Y..]\=Y*\6
M!8Y*T+ ^VN6\N"CEN+Q9Y/P]!Q$)%^WD(A6WH=3$@L)3/9FT]T$Y>_T2D^/)
MJE6JP1X/'F'7DU)Q?L:V2;'K)09]K.>KMIN0=#?Z'SVEKDY]BQM=IF]S=_.&
MF4A0;Y*IUQPG/XH22@YNCW!^B3B(7,*R<]H[A#B^&R$)!&=7A$N>=E$:+W//
MY2E51-C41?;LK*[^F"YN^O343RWGEFKR !V;FW%'S*@K"K34^AGW7"_Q2Q%;
MR5ISX7M@NYM*X^WDBB6_21U-!=I5]!PXUR46IOONEG>O54EIJJBAAF[_W4&[
MU<26$4M#-4MSOX6J/;Z^;VJ2!!MS#%\J]MCUC(7%N8<##TG>M6J3**Z+I0OA
MS.B_-9$:993?"6.?1\Y86[UKXY6A[I;>^75WCJ)BJ%;3';[KL^9GN+%4U1]U
M@TC;XO=?3&6O_U7<V+SCP'F%F_&WB)V^?D2_F0'H+"!H*H%^(8'*DSP)PXO\
MQU2$X$<V H!&!WD+1]^'/PG:L*%1L/USVK/U:HSG:7A1I)2.<1C-4<_64B-K
M(3ICL'5XCJ>0%J9(HSVRS\H"PO+.6G(;[.@K6)(:JT'W9,J X<G<!')\ZQ>;
M^VV6!U?.V14=R@_60XG(WM)/^EUDZX>8?_'3L_;:@SEK=]O7N7-G'N2J7NOQ
M[N'B1VSC!GXT]/ONJ'YVS:T]BM#\-X$9 2OOFN_EP%S!"9%87B!@.$&(M28I
MQ^'L6= /V+@6M[.U/<N^<-J  3&F0:1T]].9Z@S=!+*361@+?A!K#M]WU@V3
M5O<MU] -GMLRKC2)TXK(3=M0T/1,=U_KWZM3^\Z1UA:L[' U)R8_Z,V,M6W5
M(YT?$C\+6+N'__PV,H[XJMIQL,L.&IUA$4CVMB.I>^R8M':HMXE-8*F&F+LM
M^GEPA3#PU'ZK3<*S::<S[C2H)]2ST9R'Z<#HE43#<-$6-PW^"Z.='$W8WF$7
MFE15=B9+" HQ2$F>8S K7/K;@/$_8(C)!BR2_3HNNC+Z9]@3Q#!9#J@.C,9^
MI3V^_X?^N<:V<=^&5$1P9O^7AM,OY?96F1M[.OB/3+T50LWI6H1G!'GNKE?@
MM73:'F9A_T]GI_/])7J'IAKI=QDN;JOK,DQEGK@,L^:QX/2PH)=126PEQ<*J
M-R'S)AY!-2,H.G)$]&I9(S#YU._-QZ:/9:A(TM[ECQ(M>(G>RIB5/12>?L$,
ME'W7"%9\\#VHU*!CY.#M_>LW+N0E^\':[6%KZ'9:K7JZ.N!T0TGNX\LJ*7BI
MQQU^HW>G65)QSEQX(W*,;5P9,D.[W:?B>+W!WODC[X8KR^7@YP[S$KM\TS/7
M6-X8R;4U.;?.YA/ILU>%E0[)=Q>$#=*4_$K6EY=<%-M(@RM#P:<1>_GUA)O^
M^_#CU$- 2 3.D[/!30?A+**8%?O2P#)J>(-]DL@L46/KOF(7&6M^6;4$8_(Q
MX^+"*+ QX;J'-9+_=BF"*UM;>: 373!#*Z:7\>F18$;-OD%*-.W7*X2[0\T'
M;K#6#:4KEX"D')4O9ULLTHY##31S"S<&90-1PST#W\W70!Y5]ME1:VR\_6Y:
M]JR8K7:_B?;;?I-35E8G&D=+Y!_=P[NX"#&%0@)0L_"*#C+/GD]9GK?X_":#
MYEP&I@.E8K9MZ_U)EJ[6/><!P[GOZ-$;IND.2TJ45,F9XG^>V]MPDSC)L;<S
MTD2/I2@%JZ+V)'+]SHY#!9)^$W<F,#P#8WFCYRVA]_!R'_^MPIC;YP??+AY<
MT)"1+LV825Y"ES>5R\Q]1-XF1LHP]ME-3,Y+;%PZ'\J>1]$=!'!^/O6H,^\R
MIR!F5T[!W8P;;@>_!V>BH&"PNM%A\B;D%L''Z>XBYK[[H [I "/_"ZW0S--K
M31#V6DB8)SP20N_8IY[[_EPDZC/0T^+^_MRW0.Z*BD7^I5DJX<ZDHOU<80]1
M-<!WXZ6Z<M^T ?IZ*]LN,R-;]6VAK4I>[;&^XW?57#474'=RH8?Y]4AFMMMA
M?J,&3B47V\Y-XQ<C1+&6?_<TF.5@(SXQ*E9;QZ#-;J+@BP)L3B4'CSB&#7,!
MO&+G<*A03V\RE?2V Y?DY,UU+BW;/CUH_LX:FD.[8>\2J11=&/EYR:BET=LF
M2]W:.Z(PNM5=^>(KVDQJ(?M4!U1&)=">^_#U#Y6-CF'Z(8^EH=][SV2KR5XX
M&)^KBO7I)N^-M2*(GR4CO.2=C<534JN0Y[2AH&X85QEPH.2"9!:C?7$TA-6>
M:&1XOV8<QNEZBM?@:7UO<,Q%ES0,M"U:]9<@=N>MXWKH1C'J(P'E'Y>R6#49
MXWK!2!<[NN!8JUV6@ILC[66#\?4E>]JMTX?J*E5-.0]3]5X^^*PLV9/DC4C\
M=VFBY17N!-F:BDAA]\9/#Y)EZ91?Z1_J&+FNU<C[FQ"O3<@S85GYBRJ.-6,Y
MY'-"V)/M+I0]M'>C6XV5AXU,\K$U;&(TNZE_1<Q6BF,6HYVUG?8/1B./ALO0
M?!423-8E\Q/(0R:%,W+YRW;H'_B 5Q.YKSPXAX9NWM>_C5ERV9G6FZ4@I6AQ
M/X*K[66;2_[&G#R1W]&E8J&J\LYLG'95B,13=2N<_7LHF.BD+"<WJ])0TS._
M?X&WYO'72D?[UJ*X6^T^7H(.$G#56-2".(&,K-*09RL_F_M9!8BTD2!N=-9B
MK*(HNC*\3A1C[#3O'S0?8AIQ%1XF$L6SRY]UMD\8ZUS(R:7E^ZSZ%T(](L$F
M Y9/>6CPW6LM#M[L\KEKGHXBT;UI"QDIGA;DD]D#\87?S$TE'A34HG7=4UE:
MIY3<-'6.E%@W*G]VR*XI3\T(H#8DV1)O9Y/_O4]HUB,P\])(T*@643BHH4R_
M*U 0T[3Z2[Z(-!S!6F&T8<)W1C(JVCD<P5%R:]=\JEDPD=XTP@"21XE*OCHN
MV)S$,XL(#9;*+6HC''H?+M,U[^ST3?6<B.V(7BK?;@:7#KY;"E-1*@[__0TV
MU]!MQU4S*IFK#;5;+]%SA:N;57(+AUU>U1B[3$Z%.V[L)33#MXYF#.T?=!G
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MPEKO+O?W?$O5^C1B.2:_9L)NOK=MRW?M@!Z6(4@R8Z%Y)@DNFQ#2/.0^4HK
M[!#*%*"=+=,&CVD"KL%W8AU9@RU=.\%T-C019Q:^H3[#[KT$D)]IAS6&N/;E
MBW*6&Y[V6I5]3#T2XXR)LG^Z(_3VI2.PUH<QK 07ND"CQTB6Z:OGR'&H91,/
M3@L. ?@7G@7)%"S186#E7"4%.EV=89)/7S.@4D(#O3&[,GV#'^&'[Z=]^'&#
M5WY.9,->&%]AJ-Q%">#)59[$+#><GUH*E['C4)[S] /8E#B#8D?3A6\;[$DB
MY0X'363U%(C]I$;D8)Q3LF6 N6J.2URGR(5>RD*.X'M]0]I5:,_[_U8.JT@
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MUKQ>7/WV2L<^N6\E'-%VW;0_#>@3(?"<&^V2I$:,N>.J]C:^K'"J#)J8403
M6LBM3IZ8:&54M+>XD [@T!B73%D!$N?>5V(4SGERSU\CX]M2QZ4!1XON!D-F
MF.6LT\GJ/A88SB+L2;@SXE4SD)B[5_A0^+KO__O]YY\8-4)$U.*>$S[:*]R9
M&M!SPPFG5L$)X2H\RL2*LA5C C8ANR?IJ$BYR)+#=>,S;G]Q2HK/CGN_G;'4
M0$S8?M<YIT/<C?GC7>?/.Y&M,'"KK#KV-/171!L2\%B=6PLK:4;2%D='A17+
M2+<BK;:GP0,(;$88#/RJGCQXGBTF06_:7ZPQJ7"'Q=,*E&VF?^B"P#Z@@2O"
M<>H6"?9PA!G[@T.-XQ2T=-$9E2'S(JS?840QW%5P*,BP4>O3HPB#N7Z\ LZX
MNW(4N1\;Z/+T''L#%A,<8V3/[CP9&*CYG"UV4JW6=VI[&T*5T$R& =:$.$85
MLM5_9+*U21;IJP:/9D@(D-@:;CQGUY,<GBD(\V6Z^,MCN]B'A2NDT<6B)VAV
M$S(\:,L1:WKN,5BE%N>BID:11/L T\<,0X,_+_0Q3HLL;_P-0PAZF\IKYE8V
M[N".<$0^$49"6*CGU-,X-8Y*;-CB/FSVR*U[58;7)Q/;T<!"!;G+DX*U:UV_
M=>-':3K;7\SGD4-C00F]Q6GF0'[K[!&1)2T.1; OA9_$LV,;\NV8RO,)G [F
M0@3V-X:P#[OZB0H%^Z533R1^XX[@*>09QIY@Y=YCML<JHNS#4;:).KO^.#:E
MO-HM4HS_B@3N(.>V [GT1X38IKND!*2<D+-:"M<\.>X397\R@&$)BK1M]RBA
M#[I@+?ZX</I7\C)M/"I[\$?N;KOV-?T!VNQ8WM\P"@RP\0>/>LW9")?[*1"]
MH<>3!9.#.2BF(PT];&_DB 'B6M#E*ZLT:)2!8FH^6(\"JE^%OD7E@KDL5.OA
M8X>54=5 8EI0INM^VB7=I<^/5L^ZKDU]>!R^9ZO!2IA\GKPMVVL;05?&ZMSH
MAB&6PF;$XZ!L9&SV,;"14(3S&FR L>'2RC$-5BS*+M!A_=O(1K/B=C DU^SM
MQ0(0=CGI6_^RK+]'?8; O$H^NN"I_-7],(%H*#L+V<P +A/!4]4EA=9IW$%"
MN3^=(6IVG*GFHZ@/= X^#7JY*^#/F _U2'DUL>F5ZN,]G]Y _RQO0B*,&M1"
MV5!0;?E18TEEQ7FF_W#8A%>LCJS'CORL_-\Y3-1.,Z/)MVVK LWRJAN36C<N
M018@R+X(MA>-M OG#@9PMK.46WW%&:T,*/X4J$Q'[V\(8744*L<.H@'_A""U
M13%LILG'M('KFK<BKG4'JXW*WJ[.D)TP[Z"I/]AY?QLO0] % [S@<_: (3</
MB&H/#^,^!SLY7BP*K0GFA!56A4W(=B,KEE#^>#NLACS:5>A?#-J9"!=-XG*:
MC*+&]^71V>LPI\J>!CA+A'/B=+MW@%+6Z_3JU<>P(;'_5O\3?-\FI(+T1,BE
MFH8[_KM40LV68YW A"62H#@38)!>5_,47EFB11]Y&,/&*)<U-@"_!+5O0:)I
M9?_\!.'L%U_4W_USMO9V >0?[74G(3R_+?MO0G,UZ4,73P+*3>M%^A ?-TD*
M<VY1AG>A!P=C=^UTGMJ$R/ "@3@WP+N'YX'Q]RK\T4'&PIE>-+[WRJ&C-38>
M1SA_C;1^FS?.ZOKWP/;U_?\1#_*[(5KA].J(;W. _SNG'T/?;AV]?6#L$W?I
MY5#1SOM)AY\508:4+K,?(U\U#<L+Q+9>7ST4M"$K*<U-(YFLJ#;D*!(-/@&0
M;0_=]('LN(G%:-(.'>0N]/_"W7M&-;5];Z/AH$9JZ"@(\0B*2K-0E)*HJ(B(
M06D"0E1$FA@5D"@AP4)O-D!!B B(U$A7A 0(Y2@B4@0!)06E!W84PI8DF[LY
MXW?'N.\8]\M][WO__W=<ONP/&>P]U]IS/O-YUEYKSFF!PMEF C+.9 4A#U-6
MU4&C!<#(:UC+LM7#A6EA"SU6L-B'7.# @$FLXTD(+4@RXF)(#;S++N1M!&C-
MU V0&C'W O05\$LQ(9I&&LX%UV5IN3:S?.<2:0'7+7%YQ,3#]7V+WS5FU&^Y
MYOE=+]F.@$YB_='@'H9 B3\?9VS:/;0D2 ;%0HP[OCOD*@E=/@3ZC+E%FU#,
M#@T(O+4>N<(B=F_[_2G!J\/G279C.-5 )X2&@].-ZQ(_L"@L^Q_C(:;]0&DY
M1I_\G:HA"N9,3M@R>DD2 +6))5L3].XJQM^PAJ5 3.0V%CQ.HOQ\-ZF>Z_93
M88X9A9IB"6 2>^<TQ,0")U@RWO[X2DISI''+J.Z@@?))?FH;3>F;'7<^"6->
M8\>M%^K%D6X6YS)BCYH[>GY/E09O&$HV?_8>:8N GVDL>;()_6)! HR$(0+6
MYW<IV'.IX$Y*(JZ-EE2+5<9HD2(3F1;X>SSZ7I(>_UDFN2PDUU\N?-OM_)E1
M>;Y+1@(9/3V@$9HQ&#BH1M?H)=F%!&&'-%NO=1 N!B.P:VKPX.XQ]L?A?N5)
M"N!(B1\.CW4]=,6DT8VM'AV6'7B&$;UYL!3:YF]F]DO^%S9FSED0[R^Y8"O
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M09E+B!W^,ABW0-1LOR6HU0'F$Q:QLV\,&IQR;8.*UAO-K2"J_TZ=O2>Y9"F
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M3CW[3C78\N-9=O:+G)BPP)W.Q2X!-<>?39MJ#=\[F^FI7UV:^I,%2<$* ZE
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M4U'>X"O.#M)].!2DZ(F@Y/(0*A*B$S L_< #IZ;H2B0),/C?LZ37RDQIR92
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MU\*5-=B,#*7Z[V_,A-+)E^M2<_.'K5IJED,H4@6G71NW%_$S/"GLP\X706K
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MX.BY:8_I[J  ;6>G1DW^O_/G+F?ROPD[>#/.=_)MIA[?=_3DLP7\7P12?WV
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M\Q2/6K%U-,AQCE&Z*&3AZFKXO';D/OB;(6 _>7SKM2Y,N!7,H]@:>$@= E3
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M\592$GHQW")=Y)+G8R!KX=17>[M?L5P[P_+5'3WAAWFFDK_*7A =WBT5W#?
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M+W&Y,?WM8HR-&?BY%<.:'E)^T+4G1;+XPF?H2"C:7+O<28/0NCP<.7#8QB*
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MY2KRGX\'M+A$0B(G!J2?7.7[+K]^@N<JC7@1,Y8SBA,W#J-/4W<>8;#EF(M
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MEY&2:*0#;7ALXE^];/2H3;8.K$%@/_:&&@M7RZZ9_O+[V7[ A@MZ<HH+6E7
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M^=?_EI&A-/ZY:,0Y_)% <T'&(_>U[N?1<P;K(PK(+"#%T*W^/,85]W8OTK4
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M*6L[-KW+5J"7T(0(B2Y_=9/>(":2R[8]A@O7M1OR!SZL?^K=1OK/-"INPW5
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MAI0\YDW60=*Q,< P+D /',;T7F,=(U4V50R]$LP='KI-./',@4U\]P"QA_J
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M-O,6?K9HAFR*X46'4#*>:G.B)2@<BS%D&"%C7%"<OG=KD;A$>EV,'1#C:V[
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M5IIG;=0GA;H>E$G[OT2W15>:?>AIER=6>>F6&>MTM[1]YH!5/Z<I,,C82,0
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M>:;2^3D[G5+/C%;-]%_5I3^$<A^=S+BD"*!4^E;;A? ^<$'56++T<9)HY_5
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MIG9QP/<,4G_T0*@9JD8M=2E$_CGZ(-7%C2!_:M%1YT*;6Y";T.F6MIJ&X,E
MM4O",UY65BK25>5BMX[\JMGPB+IHTHRKY]T,<;-2>[FJB6?$[R=/_+%?N3Q)
MD0;BNJU6:_EJ WJ/6G:A8U5F;^[V]AB;KR5"C97"[-X\4RR[EO%+9K&DI$VU
M;SN0#FKE+TQR7\KB,Q!-Y]0O3(P02VF-TM-U$A#0=W7N/LW1ASI53_AA5V<R
MK"GHI9NU[G+"_,Q[;& WA YBOD$$]\LGT4'$NV@AB@(0] X8(BB7%"-"NIA^
M)W:^\0V2D;^P?M3)0AQ>* H2-+TQAI0O&"Z=S^XPO=N2:3RN-1?H(^]S>GS'
M=W.1+4 X+9JBVK7Z-N\J<X9Y:>R7T$[I:G'I-V^QEV(C54-J#K^7C18Q"]Y[
M5S:Y'"U[=4A(?@!1SI[T136UDXO-I%/Z;E'48:#SL.18?+[!X,:Q9/?@@KG/
MQ=5@GZT9HB^%@^GPW;1B\P[%<@G^LO-,6X;FT'N'C9.C&"6-X.]GDTZ\N7[/
MUDWX=6QDXSF;"F([]8,I264@CQL[&4A$G%^"G-[>7M(#1Q7)J_M5QUCFH?=V
MTR7&^E^KLBB7,DM_3Q"YA#D.'C:OR'S=(K4K3W[JKR5%+<<X5R>A:[97&?KA
MD@W4M.[I%,VMJ(=<0FC<;9F@*(26ZC$Y&A68!+&Q2UB/'2 JS=9X6S/2O=F7
MS1P&BQP];]HZ#K+,/XF&/!3V.#<DD_M<M5WQ'DD@3#G'XT'IF/]=RX*M#:L"
MJ_ALL]4B*Q/V;LM(%54)G)LP[,W#)(A=HMKHAV,/@J3!Y[14ZV7DZ$N\EF68
M[1_7TI;]S9Z>'-%8F<@60 $^>6 8@M.J*9^?1]X L$H+V1Z%C@[01B<ATI:5
MQ<+/K*]IW*G<M:%!V^#H(!LY,S[S#+)!:RNG5IJ/]1+4#2][S0,[V1P5R:^M
M-.AR+JWR;!'4RF%-,.CGE ?#/*PM;+)NY5)?>TR]E"VKF\-5+#3RW2S)-/'/
MX!)<X>]N7#*Z^'Z%M3L4[3&TM9K9-\P*"X=,*:$N0VH@6-/M>3I((HULA)JY
M3T+3<L6K=U!@S'(,'D7FND\'[<_"0 3(L<@C]*&0/1UD>(V8V;>3C.+NY$#"
MJ/%:7!Y9!PO)P00TQV8PC9_X.O/6!IKCH-)G0PBX.IW*\T*5HH:/U_@ML-%:
M ?6P^]8"(L*N6<:MA YZ:*(@CO]1HO8%L:9:'AWI[GRC^3FBXD&"A^MKR3_&
MT[#S@^TFTD%JSY8@CY<&H_,A826-@7XM20K,49^>//F VYC,*37#:%T+$BM,
M-[*5OO?:]_.B:'"IRJ^!M(T5.NB%?-C,-OY30QU+3_U$GM)38@CB%QS0SW_
M>M/ /XL+H?^I>?:.EF2&;$KC[9:KRRB"*A$VY<BV2AO4D'4[1(954":T:@Z&
MGN.Y=C63#_B@AX9%'Y%3-)8I2(.3]6%8_^;G.B>W5;=>2'28"F!!H'IUP3F0
M"F6 =A]-I%4YJS&ZPCX[I#RX_V=Q8CA"7M;GO92?\X<9([^2#=Y4G6"7 #\O
M6?.FC6<^KG\-$^\IG*_CT1-XT:N7E?B<<_5EIDU#8;XY>+[4T"_1T-^$*^%A
M%EPJMF>Z>[HTJG>,D=2A&2F;;=5PH)^7S6>5A (WWG&]_0 ZZ'0@M1ZI0Y(Q
MF<0\\HT]&?[:0( P_X3-T4'G@Z@F*(V[G<2G:+EB="E@>+AA?JVCF3@W;S/_
MT_2JPWQGM!*UH-W*COD]>A4NV"S$GFY9T*=F>?8;UJ4&8CU\8Z)@R"1/^7VN
MH<WG)T89.3<-N2(#6^Z7]^>D!O3J4[5?*,PV-YM*]PU/E$>7;-]H$-N1NAN?
M(*YKO"EAT-P:W';H/8 OC&*PD.# DFP\I"OQB<_N_D[,PI6Q;($9C"WQ4UNR
M9I/WMX=S*3F^ \^UDB?O!>1=SI\JMHTJZY!\T *A%<IW.5W1ID;+H_4)9=IT
M$%-!$!U4/%(%PZ6J]ZJ7;$&(45/*"8/O/%&<@2&OLOU3FWK1/%XW*^(P0;3!
M\CFML^<_#U[Y2AU8:G_P;AT1D3-8G"&:86VGLH&I)08ZMK?\''RF.&TD,GW&
MV#3ZHQ$M=(B'A0Z*M"S&[-H6C&!P]?#=1YQTT(PE48(6.UT^1M2@&47200\2
ML'O8G!\,U8M*H;X[0>@@7RT+ANVQ \G:M$_4]Q11'V\"Z<I$& 1(TE#)4&KK
M^#8UU]OZL$GY&]?JL&_18OU-I\]Q+HUI-N-CMRN#+_I6G?SA[$7V$>SW-\"'
M9KA$!ACL6E2/1);E2]2[6N7.*QZD%IC/_C$W0-RMA+F]'6VU?$:<]"Y:,9ET
M#FSRY*S-U!D1^4GM -:7AKGPJ.[J.,A%J$X0<W$R'G8*R+1N2<6=,7@88=AB
M+\.=0 =5-T]4Y\V9U#="E"8G)Y1_LGUZCV'Y=.ODN"KX]<IW=\.@FC<4.7[)
MGV/I-GO#F#K!>Q-E)O:W+[[.BR%OA8GF<3'%]UIZWBB(+E<)K8^H]YX<G)76
MM#> #((IG)G8 "#^<!.X/AJK@XG.'! 1PZ3*=?6=R<5!.+'>S=7ZQ9/7]S=M
M@R]6"J^H_>"F@UP0'7%)?'\IU&\/QR+.RREN5Y0]XK<U7/!,5T^UFND_L:&X
M1:RKY_P1WK!MM,GCZA.GZEF*S%GAV:NA(I!.4Z+$HQZ&Q5.V!?_(IVB0JFH4
MANK_K/'($YRH?NC!AGROI,\:NBAY-Z /)?APPNFJRN>/)./6XXPS">8+!WZ*
M[U*;' -KR+JW/#/ /&:S$\3)U9V&?$-S<CWL#1@054X]HH,:=F)VHO BT43M
M?KY?NK<SFDG6?^V_3*SIEJ.^WY5&'R_;A'Z%E4.#*TJ)CWCS,JO1]TN+5LY?
M<[9M6-\:.RZ:H&3_E3^<:YEIB#BW2][ XWTIV;[R5T^PU<M<AY?_>Y1'_RG^
M2X364VHU9GD<Y@DAJ_@FHDXJD49PHV[TKLV3$NKK%CY:Y8V2M[FH3]G*C.SQ
M$8P.,O-$]S"CWKGM??MO4';\]PK(J 3EH@;-IXWV$TX[5*=YG6BCAJ_008RH
M325 BA$,J9!,9K" 7^M43NL]VY/[_\>[_$_Q'Q.__<O[NO]K*] HSD6BV4XL
M'X/QH[SED]73EW<[FB+;78.)BP:-S]BPSB44#4MBSBN[4C%M]JGR8L_G]355
MOW5,5!5=5DR0(5=CA6LS++M^:!KFF&?(,Y__6I]:5VIQBP[R,L\,/J<D969Z
M+/7'XQ1 A?M!4?Q( *M!FUD5\:/C56&57W:.:3EN&BC%;*V_>:83;1I6R[*%
M)@[U9\*X@Q+=3(&6)10/;&Y'<8=Y\_EH(]$DS<4%$KT?$R0D*1%^-=3<,>!>
M6Q)O;''JZO#U,=./=K>0X#B*4#\2GH5S>?TMW^):ES-?;>2=IR+1RNKUJR2E
M7*G/MUH+/YA%!!O<-N%=2Z=%O-RK2)/HL4:T3"0I=_@^ZW^YYGDQP5)22D?)
MQ\W<9ZK-D\'X3"<@ %)^2XT.TL8DH(CS"(:SO=K<10,O?C#RA=_YY2EJSK!C
MA4W8].,(&FJ:#NJQPRRC-/]6:@+D=!B4-F:-XM%B=IAW<M>2(+I%)<=5^2H*
MT4%@4UAB8(N2INBN7NV$:)3!6XJF"[XXY-,W'6@DEK<YZ2EL=(%_N64'_*3W
M5@+M8M15MJ2^4/.+O1:]_:J"9>GNXNK>'XIB\Z0GYMHM&^-CCYNXEIX()+F3
MGH7XY-IQ=]2EJYG[M OC%F6;J!,>GO5AI>@*./&/13XG)XHF-1_)(O;V(W$Q
M <E.&-)O@J1N]F==;RN$WW#Z"^K$--Y]M=3)+QS]2>N5C:3%EV;?&T9';RHN
MP%A4O/'AU;<;E':?16IO(:$5*U%?/M)!C]*1FJZ;3KGZ1D1L[W'3OR[T[M-
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M)U035-L(S.#?'@S[?U7-T$ !=Z W_;P+-NTB.X<_8&9G@_HC0IZ_T-SUK/X
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M4_]"Z?P_WO#WH3BW4;@E-""12>&"'R9,8%PQ25:+EY!PDM'O1'0DQ9J Z+P
M"/6(2(]"&8D_:VC%;%X\?OXYN1?&T2X4[$WP0,*HZ03;QY?'J[Q=OK7KO/L1
M?Y3W*\3^+K@"A7N#(5JA9Z)IYX9PR7%:,.J;?=/XK.O1Q.0^.XD(BAE?'^8<
M$-S3^O*DJJ/0N-)6*YDE&NFV).FS-37&8A_KX_.X,,G[PRO]$@2(JOD_H8Y!
MH !Y]+8W:>U0F!%N[,*^H>LQ6Z-+;+Z_41X21>J(=B,]-,DVXD@DQ=FW9 [
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M58\PP5$E1Y2Y,NEXFLET=,MMPA<:$RR1?:.I,>USLO].:'E+P*O?*$5H ,H
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M,^'?^;KZ21 DD )H0M9,WG G*<<@P>+I:-%VNVKD92")>H^)>\2&4 LX1T3
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M*2I3"(&Q8=;D&^6#DYX2(]XN+,!EY+/F;#6-/#YYG[NM$&FG]?&QL=V?YF!
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M5:YPS+X"NLO)6FZ!;<=YWJDV0$]BLDA4?@_MP4E<A21::[ -)XQ-_;PMP/*
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MU9^7K.694T_*WD_+)V)K5N6SI[;-XS)JU/VN?3_]UPGU(8-*$->*>!L&6/)
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M2U?8/"%PSH)5+;O1N3@!D,632!0=F4 ',95_*:DG)0"%#35,8C!U.O3^@MS
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M& FJ?YS+WJ%^C"U'0+EVXW;<MC RJ1JS>%GQ#*)5,W4,'K6?_#VQIL>&B]/
M2QF'+QLXK(S:BYF0+>D>(27)SQ?IJ:9AN$\\YW/!(R,?^I1_JF^R5YV;\C@
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MLA'QKXTY\:*A7@Y.L/OI\=]T8=)_E&RD7"R)49Z'2,/'56XH0YW"6=A]#S6
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MTTGFF=$BO.Z?5OK^BU5KK@WHD,(WEF&7,T,..-XSUROOL;?6U5<&),,GY:D
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M< !JFST-6D@Z413=+[E$H"C5>9,JCQ96#$5X@2%78?J#@)UY#ZF.<]>BO 7
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M_^C?O;<[?^VLO9+4/O6<>LZSJ^J<TSF%;5%'<"B!9/2<6"G:P<R??0KV8L1
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M)JZ)> &M"E]6C=D7' 2U<@(C7\*,O47M/I&_6LJ]!E"K_5'9&6_8T*V>$9N
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M:D!R!=M&.O_L^=$^'=7:4%X.:UV_OEDY^?SG*U#?SR/3%8[64,\P*^XOV9D
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M^(</P9T92".ZL'-</92GQ?U=^H)XI]K#-SS/2IYT#3H:HH8)?Z/NU&ETOV*
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MU\E75OPEOM>JE,#XX/KL3:3UT]KTEE.E(>MY2VD8!\!;;?@+M^Y*:;EWTV>
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MT84F4;QZN9)W&)P85Y=PLR*%AGQ97U3E^OA_P!W2_\#_2#B[ZC]S2C.^>UC
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MD+N;)%SN'R'?,XZFAF/TK.F [U+;NVKAFNFU80FO\"4##/^5BC B QQ7@LD
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M2E.#/P]_VIK!SD ,0B\+=NFFL]S[H+:G<XB/-H4\2&GIY6@$-Z74/# M9>9
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M.4:>;]G3@3,/2QWP'DL"OTO[/8H\2&[LUM#5]Y$8MPWS3C-E3=H#5JPH$J_
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M'["F0BSVLBJ7_$2%] U9#.SN3!F')W]K^S,EK/$::"!SW'\@F^,]]>J_S@.
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MMX@/ 1Z#.7S(8&"'%N\@;#?^TV *$B =XT.^GUWE0TA_!KE"O@10388/Z7_
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MP3OT5TU/MM]H']$WUDJFC=;#]_V8"- I)(%H][JW$WI*3K/?+X]5'EL+7G@
M,0ER(P=KF8TU7$B_/!7R%(][6R?MZC8P[IZ0\63[U=/I&M=%KMS9UJ,N! ID
M46P$OG,:*1@<\MEH7C^Y=C.#[#LWR7Y?O ><9!K: $YDQ@R4BM]W=!Q[^I6G
MVYR';;EKD;MSL :QP>J,Z]IUV4[#UI</W@OH=:<MDL9LS4J R;4Y BB>2#M
MI$=T6\N];^D@TOLC6&G@/U@+!E0(['-\BZ^9M08*.XM%F(9Q(22.OE?D@>4R
MS+('\RK+5'U*Y_>@:-%NEZ6M3W\KKA5]!2-:,[<:2:M25N>6<Y385S#N--Q#
MLA!6'ZBC*DN/XR1!\^X.Z=$&#6S8&\R(]5@PPERV?7Y.;C'_BALQ\5;9B+O5
MVZ%OJ59I0W<W'[6W3-W'Q>,[W9&T5D*-()LDD39#"'VF 5P">XW[ N'[$IF,
MD&<C.:??#=.9PBR1O)_#@]V$?8B+;ZRXA0"[LR6QU#NL+&#K\7C4]^3PZ(KH
M7F S?J/"1,NU>>0,,LTV32##(@7WE:;T&)6](8N80G$?\;NP)[2_K+T\:QC'
MB62J]!3$I%VR;F^L8 3C&;L*Z3$WEO8W'LG/P^^MWT]\B$CSWEY+V;\KOQ,-
MFBC^G5Y:C>KLT.?LY>;C],!S)\E3!?=2GH/+=&0&7/KD=[9Q=Z/R"69$8GVO
MSU[Y:MR!I<7F1]FJN^W>(X?QM":J#T@!PNB&W>]^)P(<O+1 54HQ3OK#L?J&
M0U(]/-GAMLLMYP.M JZWQ 54E*<9=,@:G%NA?$^S\E++OJ_\]']^G>7_Z0;C
MO&K"/H-18SEPBW"&N&&\Q$T)C!8M@@*5QUZ>>"EU1$XAHRG^MW&_DQ+4UF\/
MS)FY<Z&],:G$/3Y2I\'CW,"X^M<\'S,('P*; ]4,WZ\=^+N?%D][2Q"["TVM
M4$OYB?2WG5*C$I3Y$/_IF>Q"#:P(<=F-U+V6!NAEZZ65N0456.>5T+A"_3=C
M)^PF[IH8[5^8V=EZ'V^)!*)Z5ZR4LQBVD]XL-I"8FK>%(Q,]<'USLM7'JO+$
M7/0S1$V\>PF[UKY?DO+)=RM.4J.V[_VV'BJ?2.DJEA]Y]#4CF'%?Z+<[;\_,
MW^T:]' >!2;Q=_>G3" ?$L!L6GDP7S:*54*'F8:$F(I@?=K'.-8EE)"C1Z,'
M03.<RA3V;%T;9I(V?+<(W:40TN=?/*0*X5'_ULDP3X )?(A& K.7^ZJ".K<U
M:EB_C3<Y^I\]+0L[!>.I [Y3CZ/(WL6;=5/K1L69*HRT'1*(MW\^(<XRU2BS
M4D-5O.Z7&&-&4T*XD@%E'I98+VZR+99RIK6%*1?/B2"Z3-4[*5SEG1[5^U_8
M>].H)K:U7;18J*@(01!0$**BH@+&!D3I@J(B"S$J2Q 0HLN&3LQR 1(EIE"$
MT A9=J @!$4:142E4X2$D #+!NE!@I!.I9<*0BA)I7**_9U[QKWCGA_[C'O'
MM[]SQOX!E5&IS)HUWW<^[_.\LRDM,U)[F8>A1\5!W$@[JH57%I<+!?;H@B,%
MM,VRU&>1Y"7HWRI G^8.V9*B[RVJNH5L>MT60<#3MMT<>U\YL_8615(<7IMA
M%)>P,Y=J^J[[A(*8M4[CQT^LD@_HG^DK9(UC6R&27!WJ+_J*V,/+1,4$*85_
MV4D@CNE$-R/[&-XOH)IG+T)_N++4:03W,->=]_;_N5CF37:31J1^=%:;*<(X
M=PQF],T8I0^4^[ Q>$Q"]D'UY=T-S0(O4 <.%WU_4,B_V4<UE(.0O$29&!GY
MB+>*T6[#3$2WMDQ%*P_\"'6/%-5H<CD][;T](T9\;TQYU?QK.L2_-]SY]^'_
MH(.&JO/_/L'O7WT@?FQ$<1ARWL2$^AR%"GCI)Y.J@,/-#&LUQ0(,1WZ@32B@
M+)F=GMQD*S\!/SAK#MDVSE,^0?&AGI:+/_L'C1<CO\FN^Y(2RUY]7673[;"F
M^%FFY/(O9U;XA?KNB:M=P<<8FILRT6D[S1L#(G.0>XRV1D)(-$@7''BAV$*[
M(#/GL@1FO"[-<$M,>)P^_Z2?JBYYY!OV>K=17W%W_,:-#J=%._K-RVHZ+6GF
MSP3??RN_"X"E 8SB071MJS6H2XWV?-E5AM,)OD2O?#!B=YKOG7&N.'>XXB_A
M4$8V*TK3VM;+6^[)C0P^KV?MN=/RS[WU1XV GV;H0GW%[U2B?([R^FP\[&U@
MG7I5!CM""L\N!_N' ?N/,^LY.I&N#)X*T*HV,#%90X;=':**J.#.C"!;M].A
ME\_3O=^5_16#F^#.;C9.;^S?A!U+,=CU1_!%2)""S*2M?P@/\%D5&F/>$JV
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ME-N.M6C ZV%"O9,5%)CP=$KXRW!5=J(DKJ(S(L7V4*O[VN(E]#6MXXA-(;?
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M8$@J6@/,;BW"?0!.8%)< [LI%\$$6'L#TQG?@2ENE@:"7Z,"S"B(GA]:WRS
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M6&EU!C97;*=>N;-3;#B6,=8;MOS<F7-/@]1GOOUW3BNK1!>Z8=99\X^,$/=
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MTYMXIA"A2RH R8V58^Y0^ADJ00N93&LUB0J 3N&13.(85I?3[6(0S3&J <)
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M!4SET?4.:DQ@LF_>:>0"U,T#X?7D>LHUI[6=94VK2 (->:!L8XHHC_TJOG_
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M!'4D$A2E=&>;/<<0XP7(W6X./;VUYPEQ[+%B>\_'%O?5EOWX#J?U<"A)%G%
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MCM=9(< T!=Y2(L<XU[50"7/,;%9SRLZ5? TFZEDG@$&<V+2HK:.5)!.JD_
M5%#O;U2WA<1Z#+.X'J)QG=6'GH9J9T+-/EG)Z0  /CP"@(E,/N'G?D(J<6Q-
MP%H5T/6@)@<G_XA9Q2E*^9@3(HPAO@CDD@S1%K"LA)^B+F;48='1I[I;T% 9
M:100,G/CZL6R<4VJYSXOM%5&2I[JJKS9NPOZF#RWO^CQ9PO-Z/ EGNXZ&O $
MR'4#PU@I+,A'"*]+>R.+<H8(B81(5N*,"HBC:]&;P#G6S*U\(_D54;2]O!4U
M@?5(2;V7^N%;?*.&(E "ZE[&F$M@DY2D#U^-QI4.>80N ? C6+R:<U]YS9H%
MKQT8U8+4Y:3*JO).VA%1LU:S!)>4O;*,YP<S) .IA&<.1V3SY!]/+">%YP8+
MON?9QB,$:UE>,[+JDD&<28MB]Y^Z:H@KR,4 Y'G%:Q%)X"FJ1):H\^S"FT2X
MU'[==OH"9/^;R@I[:U*R4.MIR?=JLZ@G_C%/0+$='%AZH/4XGXE'-C0%Y]\Y
M'+T]1J,'A(+,$?TWW$JA%E;D51_:G[(C[$0I<^%(P!H9:S3KR8C@MD&7*0%B
M)9SKY9M:PS;Y;R]@\J;>6]RLYQ_*MH,:LI:GZXW,X!)HKL&!<Q]2MRV=TL%]
M1_\UW?3?B<1_'_Y/.ZBK6OZ?B41B"D7P \49*%E$C*L)HB7DT9^0BYPD<QTC
MB9L9V188ZFHW2P;BG:R#LW5:'2Y*WJL;L$JXHN*%Q'@GFU==UO;XQ<J2G:V1
MBLM'QA"OLZG%#WO?/@H8JO2.P7<<8,I&&NTHH]&$L:TRAJAFNHZY?%"H-L5)
M"=@&:YI?MZ)Y%%.W_-@-A6$4]SO=-,1T4[)SZ]ES#JZ!H6<R#I1$:E^KL+M0
M<6XL!VVM*'5_GX.3NJ-F3,A0:09BG@W?MK-5 =N3 !H(T:)X[:M_I\#FAM=S
M$ZH2 XB"J-UINYEFT:YZ-*VX4Y''[J3D)QZ-R=^M\0>@8,RR^MBW'%$FV="!
M_! F2@-Y()-5^DOHHN>V3!HIEPI*"#Q_HZ$>W>U3-:ZU=L4#J<5AWZ($&7&5
MO*)>BS^*MQ5L8X6DV,6 1T!-]@::-=PGPFDB1V![J7 ^0H*#I?XVD> "ZGAM
M%9HI 1?"C -;WI[KMO,J?W3,_VC?_(TYKTJK4G=<KXCJZMYF>X@7%6:].0:T
M)T,^)'C[=!T'VD<61'.)I7M?*-928Z7UT]?I\^! :2"RIBJPP<I6W)>?%2HA
MF]#V0;N=3-&_J^#STO7/!LK3Q9T-N1MSY8JC_8Z'C4^5:9W]\:O:3\R&BQMA
M3?0&1Z("D%]-,)E]?P^ ERT'8SA#QB@!B_,/6CD_^0?5_J<7@K\)(;=Q>%W^
M/2S"_ZI,K;91' LF+B2P-7M@9D.V/?0G;'A(EL))?1:&YQJ];>U75N\,$W,6
M[MDRO/KBT%EK:E.ALB<#Y#CC'_UCA@4^D07YEL"6'Z]@D$6!HR#;QJJ!6JV3
MTB&X!XMUU%W=;FWL53VT'::FIOHMD\HSE_=*T'%N_U:T14&67]_6TM-X.OCK
M:%I@U?9]]]4'6/"J<63Y>C$'MB0V<)+)\R;)/60_6(-85Q+WG.:13NYT(ARE
M[4GV2Z(8!+'UT4:F1QD<*6I\?H-\U$]843XFN%.YZ?+M97,*U93+6[#J_<U"
MEB2CVFP,ZO4:Y9VP5&$LI//IYG!)-.1Y&$J]%RE5D)AVWK%6M)V$)+HI[-[X
MT!W4:H)8_(DAV:=&R:,V%7"QV+_\?8]-OU77>8J.QCAI=B7&1#NF[O)4P MB
M'=AKX0Z?O@C1&R5I#V0&=7C&-&H1V]#MNQX&96;UH/:7FR1=/QBL@X1:ATF:
M3D\2JJP*>LQJ_+:%QL=\?J?VF=Y/K&2.8LIMCEB9;=,L")7?[43<\Y =K>4U
MQG5R.8J#ZJ>3'=Q+J 5\8BC*A^3,?%_CZ'W/IM1.4 \KCG5,^B_\Y$SO*_(U
MO+9/#0E&3F$=0KR"Z=<Y2@QLALTG*[.-XR_J.<L"&TBIP?FAEU*>$2//%R&.
M$(FG].7M81%'+$?9YJ$R:5S-$K4/-+/9GSOX:.<5^-*H6/ 'X:B#K0,U5QW]
MR+"K[/WAUG*KK0>";_O[#_7KR-)C;'K]+\@UPYKFL<*EH#8W<LL3M\<]#?4M
MZHH5V(]I(-=C=DW,^NZZ]\(D\LLH/@MV:^>]'.HBZ]#Q,// +1Y1C[UT6%!<
M76E@%)B"K E?W70VO2B,FA&88&T_%L6=^2*@%VA?D3@>]B <]#NN_1Y=J*XX
M"$_+-RIOHE8H9@@<)U 9+K_'@>US723C.L@&J#EY#-$O\:<:U'W7DY+TA@3%
MS?&(5VG)59H3Q>'(X^ 701.?^X($7H^ZB@=XRP_'T#5![D:.:'B\1XHN7*,X
M0@V5'Y9Q1I5/T?=.:^&4@GX_FKF,E(!:!9-U'.RE%'ROM:<O;7N6&,)?Q3'*
MA3I#=3.DA22'[BZ!O/2T89SHZ%0->7=%!T L\OW_&_:145 $DW]:@1")HUC#
M,25.6<+ASO@6(F)T'E/_)"5+!8P^0ELX,Z\=?)SQ;8X >'L<,4G'_ M1 ?%N
MLQN/]]%;^A>U$DM1'-H[<ZY YMLZ9H44V[O#/0]))PMHYUJ7/!%]'O%-RQ6/
M)QEN_?7GZPZG52%_^>4P/(['X%\+H3.X6:FCPXP%C4!1KI-=JT.)#A)44PT;
M0FLE$\*S+30K**"4<E%&Y,^<?9IWJE3&Y*=LW0\]K+J=W245>Q6;:K'ST@'T
M*_8XXUA/@ED_+8BS^01SL(R$/N(L"%*7CZ-:&BK@]G;8&_V(EQ:@]R<W ,IC
M6.UKZ'Q#/'2( )L'CEDI-@05G]9(14)%BC!0[/$M]X^*;5XJ0!\U'?&EI%:K
M4:(+MY]JCVB*(K=8T0C%PUK+'S;OZK;94?UXX=P5^"]1"GWT$[Z<@.AJRC^]
MA-^*F-KN8MQUX7P;DAYB"^="MR3G4IX,R2]]3SZ_O0T)AWB2>?%KVFV2UX06
M:48G]"\K+BDC+PZ:V589$G!YVY*_U!7/("9B^EXQ-X"Z; IG@KYCE5<RZ&:-
M!0W2.KH^0X0%1P=CIR==/Z./5D<]0=R@ R],[Z<?YPNN<7!QS3V_?EZ;;MG[
MM$/]9P3VI&DJ@.O,.8>#M^.Q$*GG9!F$7\C@D7O,Y7JPCQ27C(>N]81$S13$
MT8VP/OJJW7J$I4MSD0W(]]SA)*.;:'MK*MH<=H@=5PE_;;<J?FI9\GN+=;*6
MV0&,J">?JW7*^?\^4UK2B.(.*N\@YV5$^1[E74X(><%@V-,@XLL!/FLY'"KQ
MKW_X)H :54?$AR$:><'T-6_V, /E^IP4-AX.Y$6%6_>'53R6]"W9H\X]'^U8
MJ"'2^,>+&S3TJ*[H EM(B'&8/L5N9#4<)W,5$:XCT;;UE(6AK 7Y4$TS$]&0
M.GKN::FVE:38HXLY2T=,E[32]H@YBX?8RUO&Q>8-OB8-5XJ"*XOU\Y]FFV7[
MKU-7Q&&MNA-KU?-T?9#[>S6H^"U(.!?50';"/B)<#\\#MHK*I[(D]!IQHXR1
M^HQNZ2;;:_&)@BP6NSP;9.O$\E*@X96A-APF<G3F4]?JX!.M*5?S!C5^',+J
M_!;\NQ?K9%VS(UER3$ZWLT9ESOB7PEDI]:"91Y:?!Y>K@,E*7H?:&!Z*)"$Y
MX_)R[&*FG())USNPAS/^:Y%B$U53_K \O8%<SAQ]$R@)PJ[XE#TBGF[@Z,*-
M7.HKF7F=8J7DTU.:HVQI<+8'MQJ27Y%$7]Z&T]T?5F)9-N*XUZ+XW%MD>U53
MYUV-:1>%*<@= >>L@<\_'.141HTVR<+=X*)'0Q5RW\I4XIED\ASX#9=NPZF,
M,_"/Q-I>O9&,BR2KN=%=RJILTCC2Z'W?P8N4Z-!@.\%1@(8]YMS9^?6U#NZ*
MO;25,K 6#YLWUU'PB'JKT\I@0_9R&=C8G%25%ALJB^_E&>6]JN@L8S*R=:&]
MI1(2#L8=[2CV'2!E-K13>_DSY:F9%^WA<!(TGF#6CNPIB*'-3HJN![F&U1<5
MH?3V[#G*4O96V/90&_$DIX?7X!6P!8L]9SH$ MJ?\'M1S=[NPQ#K:K4M)>)N
M5[6)F*3C)PC%:,_4J?B!/?>#-U.!>^.134<F5^"F=N?@9!@/BKU'_+J=50DJ
MKX-S.5,9]$4'-6;>TAN%$\&8PRHS"[@$I5?VLAS<5RFJ/;MKB W-65F.&L$6
M<J'R+FUE(;57'J/,KEY_432>"&H[V!\G.'C(B*)3WC/,1,LIG*:/LU-O,<P1
MTRL?APKB*N.?2EYU(!YBCE[HP2&+\T^#[#8F/HT!5Y(A3'#"!,;88LQ=P,YJ
M=]%\!Y/3LD;Y<=E 0F.B0RCD?JQK+<0N$8\;VI2GW@*E8'R_E8<]AFO7HOC>
M&5[W"HZ&5NTMSAV>T4@(*RMV6E9<EO7K_,@W?^!&)#P4-[MY6.!;<6')%*%G
M0-Y7*O/N21\S7?X2<JWM<W%W_V'J:T_1]9!->]R\;+.:#Y[+W%5:8Z'@YF+&
M!>B&6._8S1&-LP0*^:.62&(LZ_D ;P?G%'X!G*.E.R"QJ4PX+6L>PQ<W7C3O
MN=G-G?F8F3]DI,'33/$P-XA#;/.IZ0UIZ>Z42#'+)*CRF YN,AVV=2J/A!CB
M(]V)JSO.R/2;>: ZJ<3]J7%LT?MB#W'*1H_#'@?[5$">R9[QC ML6^(0/GC+
M3V%UG[/I#4P1TU> W+\-9_+O8*WEJ7Q=[J$[H0(\.LLXFLCJCH@Q5_=7KTH[
M(D;>X 3&8OT.6[GW!:9)4U[]K5T;3U9=W?>E,JCZ:\3Z5P"HC7]>B9B\Q9[2
M1'EG4DNO%F\:T3R/+A#BRHPM/.Q)U7!N="'55>I1')?TR$M>+&/PY%5,9/6!
MX]H;RYD) 9JRYL3QM1-G7G5_=EWM&4,7!G.@Z.E1Z<;X6R/XYXR&]WC=RW>W
M#ME1ZEF_A%09]4D<:K-75D'?D^GRVGO.54Y+4P_K;I5O_O;\FCK4CB[$=+N&
M!]HNA Z1K_5;*C.<=&@6K>!I8L] 8UJ%@,)?BD4 PV'Z#I@CT]R=TN4WOG#$
MU(YQ $I-?D#%^]\P\X_FV1E>4P%E-LE+A;L[:4<*J=$'.R<O.ZN/D6#K 71^
MN^QD Z=,(Q:+KP5$/$WO,=56!-:%FORND)]M1SSS;?(&&D@) OFMQW ($3\H
M"/OV/@W2X#79'NR(U#+GOQ0T!CZC?@N;1UD40#:/MY&7 RI@#S/!Z1>(44]2
MHW:+&7RMA>_K3=7A9#%A,=6P@6W4\=?; FIL'=VRC6"-UQFL;+V:-V;CL0K]
M_DY\Y,YUSVU=GE<!8F,)NG!V:<DS92%'E(0O_QI?DN,/2_#7ULOFX8SI?PO+
MU\:T?7I[84;[ 2Z19E,@A&-=%[N(F=>S@;3^/IN4+7O:OA.^1]R2"+5]B Q"
M\9KKZC._*K&6$$UIZ;G EW.H6]&%*Q5VU!_U3K8MUB-A=C^DY-$NMM;K]$:K
M4(I^M2\GT4F/VLYW4F]%')_UW4WI?W-1#!IOB[MXT:%M,%L'&LO8F5>H\9S>
MR8*B\:,JX(0HS.^ ,I%SFIR,KH?3HT\[/F-*0($WJB/\!=;C78J]OK.H64R)
M1^W@6 G.2-#+O#O8),$#;O92N[)##WQBB&GX3T0Y3OF**!*1>CGU 3MD\:62
M&O" C,*TI)U4^-$[!/VL7ZA@K='<D5TW@V>\OX=9VS,-F\6*^8@]5"*.CUMT
M07[!RRXBM& P>PXD+W@\M (_T@YY8X0B!F/YUXB+V',1B]95D)!'N>8T!^+P
M6.J#-W140 ^Z#(IG!C\86DQRZ@A]WU7V,M7?Y>!=XZQ=,^[)(_G1R8G^,<0/
M'!1GAY&MY[2M&!4P@V<38N'RF!S<=T]4:P;[ CO-_6_LO7E44]FV+[PIU B(
M$5!0D$0%Q :,#4TIF*B4A8H86T 04C9(D\*(@$2)V2C2"[$IX0A'HB*BTBJ$
M%!@)(0'*0J0'"4(Z._H=E; ER<[;G/N]-]X=XWYCW&_<;YQ[WAOUCW,,82S6
MFFO-.7^_N>>:B\@?340#W+"O_"*@"4.]::\.^+ 47T'2YGU*!"=_8ERXAT6]
M1P(*^]_WZ8 S;/4ZMI$.F 2Z/^M//T1]TDVFB#AOII,!LX%BK0-.D9<,"N\7
M-A ,'\!>#<^/IO= GB*:\; Y<R4<)_]V^?P[KXA\>L7NCO<]OXY^XE1W\]Q6
M/GO@V&42?HX#@"PD\2GR#@_MQ/8/-Q^)6'L(ME$?1EJ"'*MW1[^\*%1["9EV
M[<Y6;G==IL6A7(_C"E8BVU2S-BYFEF5>=G25N#=Y<M?D5J/#G9.[?N48+<".
MFTDM-+@FM=4PHM?)5N5I;\\T!-#3'."6)\;DDB^W,9QAMM38!UE\Y$SIMPC/
M)KP)LHB>[IF&2)UZ+KK<+P@7>B<V%#2EQE@DCW$!_'4^=)@ _]BD^OM,$5(_
MJB^(C ;+LM$)A0Y(1DE+K1OU/,ZDY]LMY\(T)DESGALGB*5)AT8USI_@6!GW
MLJW:W3\YHR1:2Q.9!@U=#!;T\JB/Z/:(Z5:;@P!RC.FFT5-21HO4AS4_:W/=
M8\&'X7DNL)42/ @?EX^@X[]RGU[4FLK RTWRJ1'Y[P(](B)C'JTKH$99W^Y2
M]3P?"'@8BXTXTW%AE1XR]K]RC_\?KTML0U=U#N4"V4U@>:QF8;+"-:U3:'F5
M4J$#Q@XHR LU%^#5BL6.9ZR$'<?HBB/9(I()$W?I=P_56L>X.IQSMW/ KF_8
MRN8XBRME/*N2/\RMPVVOZ4_A$0,T%F$R/^N N<0YL-5,*ALO98DF4IFV<,S#
M,-R"#N(6C3'-,#S/1IF<6.GMTKNWXPRRG&[?%+0:NG2W*</Q%\[.GIG<S_,?
MW?<>HWC+M*1#F<.7#NNGHIN!CBWH(Z[55M9:4"7/T$4%2.T;6O6:E>,=Y,3I
M*5$KWG_(@FW%&<,WIKB3+DD)5R7&Q*7A@RX5[;R=BEFUM[8EBYKED@7TQ%\Y
M2R(TSO<^#Z[()O=&MV$54:I,+9MHQ_R3;:F)4Q,9)SJ+HVEII'DQ1L86398K
MV<R<OUN:\V,?A.5T#R8Z:@X4<%J05.VCFJ BN_1C0Q+Q^>ST0DJXBQ$-/*N'
MC(#_1WS[9:*<3-"*8AJR!2CP9!K3/55WM'=XQ)@)<:>*UN;LN!#&O8JPZ4)^
M9%C6\&\%\*"@;&>AQR=Z;UU.0V.1G*47Q@]+=7[,D2RAGY]+X(R%"&_4Z6E^
M @4K^%(NFY.L,4F76USC88-E*^';T%I1WNH[R'KD-7O!&0YY;N!0D'.'O['9
M8:5] N="M'K 4U8F>A$0L8Z I4K.M#E?LO>K*.=V\LBRHA*/G1"2?R\>/"XF
M:7 SW4+%[/H;X993HQ_4U##F1O/X=_!)+X@E,*9Z6*9>8Z]H;<@F+?VV-O>N
MLYTAZ_$QF$+FS=U[XW/'HB]_8+Y(4!R1BWJ[U)DZ,WAM%KL >0,:,ZT#&;.U
MV5:B&F\=H%E38N_';D3/_$;XT1O5.]B?DE+SD5T8UC.5M>5T\?5PXF+4TE'H
MM44BVA@P;%E5(!_SW0.U?$S1T\[TWRNE0#_AES(%N#E*US&VV@?V5]3S.19-
M>(/"JSQCJ-DO#3O&OL*?4U;FU')^C$'&O)DFB]@I%[/N/ RD^MN4=[DOD;7@
MO=MB;(++J#C'MLHZ[(A7(_[+*K@0:6A!28=WMI,>LHD/;:=\WQNB,6M%WA"$
M^&F/IVT8]8Z9]-DG/'0(F3^L?8(ZZS(Q7A4/KU8',-9W@%3\U5I36*M,%R*F
MRC,9CX<D\Q GNJOP(DU$6O!VR-\FJ"\TFVFH'$R__U8L"'YX-%QLG\S8<?T#
M31-Q:99Y5GD\\UD@*!A&W<?>SYK-JA%"WXA*4JW<7!61A_\=<JU[X>U$28F=
M^U%IR !?1'?Z@^]*OOG;3CT@25RN%YKLQRAGFC_MF>G6S9CIF#6"#.",E.#5
MVKG#.=[?:G )D*LJ2LMF8%;>5QHU\/LR2H;%?S;%@<$/AV[1BQKS[)7F+Y\,
M;[D]R+XWY&/)O&U^^Z&M:?_GC2,64OSPS,7*2&U*#,IV8S5FH.JT]K;[R:C@
M"TH+09!YC[NG<L>E+1^M^N?6VC)V*WVJE68-T\Y)]\_<$#P)0Q9UNWO;7XUN
MV6=[N*MR8$X'#):] K0__BM\+_C/?2C[.G.F.W5 Q 2\E^G"?,,OM[@Z";K^
M!+O*OA.)FJ *#OL2CVU*7.8?&$HRKHS8,^^CM6\]";NBE[$=^ZHJ<).\(3_9
MH< &T+J@ VTDG<3#1_#//!L)_011#?F&G"6ND+MJ5N3-X?V>O!&LSX.7$Y_<
M<QQG.Z7A!IQU0-J6,M8H9]=RG+>83MCV^\W=>]<7_(Y1!:+!B3&D#D1:D/DS
M'9:#=0 +K,"P?#;(P$S0R/TX]%$U*0VXX^36NB#,PER,3W.X?V+A<)Y9+UCA
M[OUP@PXX\C3,Y1S*+E?I:TZ1@FG7^(M *1KAH0,32>R%SB_7Z !/^(8:SVR/
MS</#^3*WL'FQV5E!)DKS0DBM\(S_J>S]+W16?:L".[?RM0GCI=>;.F _1DVE
MNS4,6L&797A#^*N@YF5ABOMR!6U^*',=5/JRD'_G> E,$^4$EU;<'U8=7/#(
MR]MK+X_#JV(8M[U.UO\1):4+M(]YM$BH%3'T5?^D\:PH3S[\ KZD/J<YIGQ9
M>B=J;7__L"MN(?Q=;GS>R.!3:M"NY2]N"B(^9#F%9&Y>TG[T-T, J;)"L.EP
M024*@*^<I^L%8,)H8I)H[_UG@C5$[/)?L$?F/\S4GU^I][6P80+>>E*E4OJP
M(A\QK+0YI-.4J[Y<MS8X682'RIFKAU4F&Y%Q[S4&O)W2EA_<WO9CWG17;@UO
MZ5P3+7T; V@V]O(HJ-E%HG]HG'&14UZ3JY",W5>:-\H^=/*VYO<UG80*9<Z/
M.,M22_,['4Y"GP3L*V+C(6Z2>.08'[>HHNM]554@^=!+GE]?/*D-@\Q=BV[(
M>]@(,;@6+1'35!G=T81T4M6;9[*1=&.2>HWM2SA*O35,_*'L1G&H!#M.<\Q_
MH<2RG(T,3K=KO)4XOU]M6%[57>X$F2.QU_-%SR3? @ /'M;[ZCJ6K+;5F&NK
M^2'X-/SSB::)^8246BO&04A3X_W]J@>.(WMY8DY ZWQZ9WUVI\>6H2!'B,F=
MG?52IMTF=-I Z?,T'N.,W]WZ(>,/S'=SU!,? *69.J J1&.B5OCOEFM)HCP;
MV .3,N9,NP)R"H4O70,Z-,N+O:B@JM58R_?K_)!'2>0OJGQ5<B(/- B_R+MX
MNRK_]'3V50[%)#2R;V0*P)>CE%&#VZ .9[;F+6Y#<,Q>]!QO4)^F1^WT<XA@
M+G\E=X$/*7EA-QJSE.OX\JUNPEH[",RT+T]R"BV=)&!"$;L>NZ\%2FPZQZK_
MUN.?]*8E]AJ<4KTV8WVSQ2A)O8WX[/V9  /B,LWF]+VNBV]->?KX!=?X;5R!
M#[5<2\1YJ(Y_6/6;_A>^J@ZUTU92!"N]QKQ(1NHC2#V%^+Z-S8<X>:_AKX$]
MA?!7Y:%]QM6F.D 8FR-)=E\"?=I9?7-3=OI1.%(QI^J<<<&PE^F[<LS4<M1O
M4N!\I?W,(WQ-JA5PF3*AD;@"3E!N:@)G58(+Z,+&6L=:]B$E/M4YH.20#^9P
M=XS1WUMB([?RSNIMTG[VV<I?*0:T[O_L#ZF?:&(UXKU)A>*DBO,PRFJ>]HHX
MWWA+=(!=LB'8YW4#'.XTO'"G5Y-:05.;HY%GTOR)9IGO]!QPZS^_D0HS%12L
M(KW7 <P?P(&#.J#;46G)=U:"B+<$97L#]CK ]\[Q;^]0?F6'"]0!4>#TY512
M13BRG'3N7R"^_"7^24+7_K\7!V _$I#Y]V:^*(3K@/*RT5G$!8Q5RF/($NU]
MTJ^7O'S@X[)+7KM>J DI##OHUNX*3C7<JO!>1V^]>_P"\<[3SY3YWT9@]W2U
M$0OO51K*/2_.NVPM O#-O1K+F6*5/]OXX:!8V$BJ*FS$&JU[ =U2N;&WDXR+
M8]PB5Z;+26)R $F<MX1_ZK9MPD'R5:9U97;CQCYD.)#44#,A##Q^BEX27/5W
M?>UB,(+T?1-+W(RTL!5\Y*EDT7X,_"MC/=22G,&T8[A#9YXX#M3>D4N6PE["
M+=>FXX2+-.:6*G[AD.^Y/J](6@S-^MWYJ8-;*UJI489['W?TOXYOK,,/Q16A
M+OPV'_)2YRXYT<[<RARPW/? <WKKAUX1Y;(EISCB"@G\A12RE;A;,5&U=L3W
MC\6_S;NBIT'CG. <*$T)VHHJ;C/C $R=1S+-ASLA,\7=LK00.% Y_Y(AWHC.
MWM?#LXXLX*8RC!0T;$!X3D/QQ:I;C^!T(5<<F_)-_=B)OT@\&.0=4C!DL<6G
MH$ ,,,4S$R)Q=("H""LFJ#*T23$14?N[$"R<+QTL5/\$>WKP?L^2-PET@ G/
M3$%""9IHXV>?]XLZ%<K6)%Y,A&N*88U@:^_E;RO]$D45KU9AOO6AD7GFT>-8
M\!3*Y]:ZCAG+R&(/!4H_Q%:RJ72>#10GY,\>=:)<G2X34O'SC]'CA$$;E%,9
M#I-NOS,HT*<&\9V>TUW$Y>%5W(T>3SQ._%K\;3+MS]4]'ZGQV!8*?"4.,4!Q
MH:>;&CU",@]HDP[X>R) IXS-W'VYB?HD\%1KWU<%=FRU,E95KN5$LY-)L]WU
MY'@\_"!:B:^+O! ;=M_OU=;2U(<[704_=DQ0E+A\%0%+C]TWW[:+,T#>URE[
MW;MJ+N;[I&8]'*C 9[+->090E R;Q"&9P"-R/LL)"S#<H.(HSPM/AIG+E$QN
MQ -ZU)ZL+V[4M2%97D7]?F<F]<-.AEBFE@4G=?19GP!0&$N [>U'R5(0MD\>
M#82L5+N@M0$4#X@K:/.03YCVUQ^G63'V])[.%>%---15MW?^V2 G+![V?_DQ
M.RSZ2_/#4,_=;1V'(@KZ$P'U^7\$"QA=?H*4]'Z0] M?[: #4$H]B8$X /,\
M*+A)^<+ <R:T.7>3D1+)K/V8Z</_:!R!<DV,(_@GRKAH>+45T40'C&S1X.]A
MOV'0L7Q('S"4YR3M-5)E,E+9U% #3)]$C!)1L_H(W_Y'F49Z-+^/+ ,S-&CH
M/=Q5Z\Y8H^2F\((5],GTER0/B)Q8T&LFXN;XW'C0]^X8G" Z*QZ^T?S@LX5%
MSNRDHDA\7YF[YP-1HQ(@$1$ %#S 0[M8B7F&%>U$ NPJ[QW;K'!YOK-;$ZG@
MIS.WP'%FX=Y++"R(.%1'&7%U+I;$O]M%J"S/<R[(FU^$WEQ5YISA+:K8JP>C
M5H&9#0HJ*!6]HP?4CO0BE4*;-%FVE ZBI];(F6+@H61)DS,U7JX93B,D SI7
MY$^YXL [#GT2Y206P1R:4]G"$01',:''B<2/^+.F[9#",C^JY8Y0XX?A]_!I
M*#B/\!VS4TCZ>A$C _4J?]CS2&V"$+36>%]2DS1[H6^FKQW<#\@(*3G!W;6Y
M\PMG;?N>( QRK8#8&0[!]7^C,=P,7ZWH\Z;?C ?+&6W"R'E54R:>6WE*WB:!
M$]5AD\>:WVZN/G'VX*[W.PXH8M8,[RE?)H\G_1&"S+=![3T:A3LE,Q7\T[<G
MZOJMR744_5IGN^PQ(_7F(/I%^<A>/#;F< ])_@QR38JAKJS*W5L#ARG4/ET\
MPNQK3V)EDCE4Y >/&$=Y;C5 :L]&YAY!M](,#QV<2;9X"B09B&UW20P^@VF<
M"2: E3_M+ZDTTP'U_="B1^Q%$RF?*CB[(DHLY(2D,IZS<HGCZ)BT<[1 >:3Q
M1HAE:9:R44]M_/\OL,#?Y7,M-*8)*CUT\=='2%C&=G4H0Q^_)(:5Z'^:GT\W
M_(J8LQK!Y(C[8;6K:CH),<V'L/6LE-K9W.Z=8ST9A7N>4P^$;_*_,*]J8X!=
MPY^O];YA1^^J;9BMI/() 6$^\H;]7")LA_A22:(S?L%P#2:A*8T7H? X^9A>
M%L!3FO//#BZ'$^5D<_I32#)BF3C0FPV6'FL(?>Y8\MOYGK-"VF),AY.>LFQL
MIB.Y6LM"]^8!&^N^"2I3O8*=3RIOU2'&2@;1':K-):0SE]'-]K<S#LQG/0TE
MT9XK784$<SJA875$9 '5M:=7[$8E/QAV5*TMTF[Y..'5\:D"F")<!O5K%R(M
M> QBK=&'K:3]^&0=,!=92*?L@VCQ#.O"P.&<C-IDF=;1L+^_]DFI9+AF_-DE
MIPS'P<*2D9I'A:54_]L-@T7%X:[BVP,M7?=PS[;A\_!<O,;TEFHVJM0;X>SY
MG+)^3^DRN.6)QKY<N3);:E0&']4!2VJM71*.RT<R<!,B\X^D1+R)N]'\8L*X
MD_'*G9?.;-WC91/>_(NJ*.I\17P<.)JH7L)L <MI@A<DU.>K]L._$A=J;#HU
MVTOA1YWU'@V#[LIJ5I#2H>T=-7:L3..I]$S7D#>\S)I+[OO8\["RRJ_'S2V.
MCNP!IJ_$DU;S:61X1;+&#$0,MQ?A%R,=* 8>OQ.K/.S74-B@S)=]?%;$<($+
M[3@<GL_Y#2-YRZ"7#07L#$6G@S2MTY,+)SR$JWH].=OG9--"<(?CF;YT"C)O
M!%WNCL^67T8L2YK&?!67W(]Y;(#*THC.H3XY1CO-DN)<?H<H0M9<^KV =ZN^
M? Q6KAAXNL%E:O_NJIV M@&:TIB15>90\FBV@OSVI$!2D7R%8:5VT/S<07"B
MX!D$**8UE;&*<9+V.-VNEJ^TS]"02H<D)AS09*#IT5!;J[Q?8N$MO[.LO((;
M\8L@8EZHG@)\EJTQ"4$,[J*'!X8K'C/.::_S3]^'6/*L(FD)138PE89MQ+/R
M2)OH;D'=3M94GPZ+G3!;26ZLQ<4/# <M:5]'JHSX]C>.G_D?_?T4CXB8"\9U
MF&'C[I*7DR4MM[M.4 .:+Y2<.6[WFQ<MTFJGTZG[/GJ*TP>/W$95C)D33UJ"
MH'8E>$F!/"?ZDA7V0HE87TH;3:J="U=#12(?9"UDD8YMXHMC1<+MO6,G<JPN
M;0O%K8<[Y5BCX=.KQNV,(HI#:Q+S_#9SU]UX'L]LVX\AR?D&<$ 3T[*7L40!
M&H?B-D!@FM.+%JRH=J%R'ZL03A RE[?'+,;U[^]P;L'Z<%]T.@=NG!9[<GGE
MM9R\GH\6,[WIT]HP7R\I:8CQ&G3+?F0<4+KDRR/P,FXC*<'[:7BL?\E@(L12
MF)<$RV[GJ63C(56=E33KH3QB\D^=LS)'J 6A$85ATS&US=Y;Q!T]BY=?T_^F
M0 Q:425G:]- :5807HEDJ&U@K"@/WX6L)24%R"G7&,&*,E-ZKPC90)[-3<%>
M'9L *R?,A.(C50DZP, W978Q<3&$7,VV/Y3C[376Z3GK!A!-X1(TIGS5S->C
MF^\T3CQM)3(+>VV*A)$J@\N$3T#9:<U).'H0E]"TD7Z.LK")=54'+. 9UOS>
M]1YB)[\%SY0^^M7[,M+B<F(</A8?YSJ:H%Z,M%#*0P0OR#-61/XW*WJFG/]"
M_H)BP+* OS;-V0J*G@M<N(]=^$I\ VZ]TOV1RBL4V_?H_[$BKSCZEX?Z2AWP
M'[\O]/TF&MQMQR+*P/#6?N:?7P:-7KCQ^[@"%?=\]@;/K9R62A3<2=/BXE+L
M?-)"5Z;F;#YQPW*SS6G/@P_3 "1;!X2Q8><$9*Y6O8?^XK#R-1[#B%03Z0G'
MLN0C?I0^?E-A7:UE#;_ZSJ.X?I(>S-JIY,;S?A2>;W@&%29%6]N$OA-'[?7W
M ?Z8:9LX)Q\4+&7.H:<U-5ARZ[$I.@ _:>UX/Y=<":N5'@>5^.23+RX+2UJF
MKO),"C5;(6[*HKH-+8_HN9X]E;OS3_*]'!;]IC^]!NI-8KA*^=C06E,H-KF2
M9  ?$EZ,R,N02>;!U-WE;;RM]SY/,U9'''_XN69=-HWZ:.AB1 8OLK_O[=O^
M[=0(0]O]HI3[V^9\ )CN2"<%VL:';;EC&<JF)K"2-6:MMF>EL"V)=JT/CL&2
MQI,*]MAJJ0X8J]9LEMVU$(B=DH6U/\ -,M!@J+%3F(=K_R9WNFLH..-=V+].
M-#5EX7LHGOF<[EF?@XG7V,M8^C"9;$E.Y%G)QBSJ\RP[LN3CRN@6?6%-1-6-
M_+"1V,?' B4#1HY;WHC?'@L:.#;PVN;KNC,K[^3]#'Q^K*\L5'6C9TT?%#B0
M: 2S872KB)N8+1=#DA"'D0YM_E'X&102V$,T@YO\>;&$R"?TF_U"BP6P:Z-E
M]^".8R.#&R!VBO,KF\Q520]2+5<!FJYGZ&EP :4W77)N48[1\U7UW8[^1ZZ'
M<B6+-0:XG)2'9C\T/V(L[>2P5M>)&R9]_Z;_94_R+(!9Q6P$H9]:X97X4;.2
M(62C]BXI&*\?1C&MK#97D.$R1?_=6'F3J&0-O/,]\?[,)5G/;G>O*&EZ]3W'
M>9_J;L GECRX<)*^IW7]=?U)GW\@6))/1W1)G%>7T];8O9V3)1:^SZL[8P)M
M?)Y7=46_)._C)99,.#@;$[]L+B'\6GHO]LK'GH^KE^59A!9DW$#=A:QUI@W$
MG+>@P)(?VK)'3>G1 2=U )9!4#JK6VUK>NM("^E\Z4#EN6,;+@3A9\&DHQ5P
M:.DIXHD7=+N^^4=V9=Q=K"\KPL.;8A$#Z[!B,*Q5CA5/'7JN ^Z?GU(0KBC:
MIS_ASN="++)RSH8O.N"/*#=0_/VQ_D1K'Q<Q?HWNBAO2/&C;J0F3\M^B* VW
M69EY>VM)S]TRS5FE_36BT\Z3L:?D5*]^]'3J@&,][OIACP..S:[F=D7P[(VU
M+T617K-?1\QS TAG[B=9T4]PN6D_+KOBE#1W^<ZTQ<=3=W@N/+#L<.:/[4=,
M3'8\B'\* /MG5>I]DBQ$S!@$6"$E+T!%,_15 "XB+J67OGY+OU4G6>#N_)#.
MK:_I?O+A)*K7<QU3Y-_7_WZTI(#N/A)P-5,NWE68N7FA_O=^N '5W2U08%6[
MALJ].)%<:Z4)@<UIJ3<OV4@G&B."G>Q^/T]P4.70&HS=Y(R+9V^PS+=0Q6$^
M?YB[N1F%=MD!.Z%TQ'@YJ@17QOK>XLE6$X8[W*>L.TK*G9^NC%7L>Z9-L!T6
MR++&FV3G[T""B0[S TAB7&3DHW>/3M0^?Y&:LU%/B]4LAS=!V5*,4*LO(]?I
M@)DXY 7UU_=(@B$=<!G!H<8,L9.B__@#]VO6]+X,:ECXF?%W%Z:FOC39C=^/
M[@B4'#MVK-FV6&\H6N][E#H$#6T6H#2'!.TO2YOV;=0!*+]54?$6Q%6?:S$=
MS*4H8L0O)FZ%@7YXTXX>=X^R(?\-[;46FH.0;_(X\541O2BHQC+CS2V7DO6U
MYE,6'6+QT>V_ZDT11E$.8"0CC'(AJFQB5 W9U'O4L><R%WW> )^L"S()I(GR
M;"W-DQ>U-,B/@F=@OE^OQOLIOG+@W9Y>_S<5CP=?[/)XMS'14$]!JN*/ZJE1
M7"_82;2B4V78,1;T&^,X?$&&M>K3>$(3*-23;8&S(<W0X*;RMA@=,$\\HN\+
M!R@(LZC<%5NQ#98?;G26Q;AEK*14I=_Y%3?>\V?<V7F4MPF( 5\]4S+U(X^@
M8,]A-I+F> K*C#6[>RLE9G O2L@3$Y6'Y&94_T%6X:N",&Z26EZ6Z1[Y>$@N
MKC^Z+,![S7CCGSO&'*J^[&/\":B3XHG66@Y?F@L^PVL6DNK%L8D@=:)/+>";
M]^[(I&L(\MR$IW"(''_51Q'G99&(V- ]]K<QJ/E^7F>;8V,?!%#!MY9WN\R_
M#(M1OG'#\C%&]BL;"D$QZ.I)65%IB=I?6)AT@N&(;P0-[\Z^'"$P%O&-[)3$
M+OR*,:5EE82'FM=6@-G*K$<UOWOB+18Q: @^!YZ2]'VJ']17GBXL0(V=J@,6
MQL1E'&J4F+M[%.YV<'7U036P@!%XH0B^TKJK]D55%>\%]#$A*I]^O+2D))CU
M4XJX_\(VO(LF"/6!=-),*AW'W$2?4EV!R]1X^[3:=1JR\DV9TKZ)B!+JQ.]J
M\N>P4K@WJ-NV)^92&&^KC)_A3TI$PV55^,%7YZ;/WWK@%[8A>X/'\:7X%_>P
MXK3_F?/2%&C+2=(4$/+2 ?W]BH5HD.-3\7TIC",P-TKV$EN_"2YGG-;>TQA\
MI,<)3PQ%!\QIJ[5D^$*TI(I37.Y:E2#?2)T8$U#T1'1@%J#5AY= 'K+8T5X(
ME/76D:_D6> ,86^(72^F7='HR9Q[W+?+3>[1J;O27W5^FQAK711>\RG5^="L
M"\:72JB6F?ENIE.NYZH=M^'*MN%,U)[,UZ2*3V.Q$-</7JO>RU@!D1M929:*
M@@9)HGMD?L.3 /_A]<)(&K4TU/>/X]V\#?) HE71;QT:LNREQV[E_-NJU%SO
MKC%_SQ-ZFF&X%YDW\[K@-GJ1R(RZQ939!1I']YU!.O),(=_&%A>UL*<-_;DI
M?(9I0\<T(6NH^_K'W;VW(E@-\UL=9@B<>;ULEC,Z0CAZ=C>[>V!0/A5"B_?I
MU!RKROQB1+Z&[K%S"UE.%MU=9Z2.?5Z3+O3/>KF\G;'PC$/P[YWCXPR3>_"Y
MKP?*:ZJ?=Y72' MO;M3[DP&B^QO'EUXG<?"-E!12I443I6\!72&?:/"^H"$K
M).8L%J7R4V+CRU*OB(@PNRD5)H'I1(^KGSX>%^<53;UDM;-SS,##_L;'5S:_
M8T9O)V:4WCD9\NAMO>-HI3H@SNK'17>SC )V'32B>^QZ,VJ3Y+3MS>OWZXZF
MOKJ'?4WN)R%S7Z"+:D<7E<CP[:AU17I1+N,'5RL]=T+$6Y#"6[D-%B@GZN9(
M!#GFS^36X)[VS R(+\^^PB-%JKP#&OPGV[K.1-_AA"5"W-]KLWHZ_C3Z!5L-
MHNXMGF( !O,3*%@P1'(99XJ;!7M 9=M90MP/4-H(TU:YK*WRQ](S!--F=6S#
M="-?'K%?^VA<[E/3$W/WYTGQ#ISLMU7[L<?O89O)_9N0N2@4F(7"Q"M7-$?+
MX0_J(&:+C5S2L'63X"))V$]8R+J&DAS@!)1T^<E(3N.MAR[ID%#.OL+;NJ&R
MB[&[A*S-)]Y:5[1Q<.XZPJ,J3D72._WQB7CV#\2%R&L2AHAC +"5;+N4=A4T
M9+A1920 WAU39D*_%KIE=FZSXTN6:B(]YE*<J.;^;OO;XJ_^/3%60T=?97V
MZS"E;9@/R6.WT-D=1&<7# JV,=<%,&*TI>#IR\H0>0D[X1L-=>&/&2=AK=0T
MSPS2JIX]";,\%,J>QUQ#)PB?Y[JUQ!W)5N\(7#ZYN>?#\>J7.4;47?< =;^4
M7"=)G&DU,Y$, LA<V(]N+R/4L^;YT=WJ<&:!(2+<<DMLLE-#\/-.'<!U]RVB
MUMIV[]W>'S/.*0[?<O6U%SEF;=0V7,4V?):D:DIC$H<8E.F V4;=Z]Q]U7N9
MK_,6]J*P,=21)*/15Z)!'PY6[A1%%OO<'$:9U<K\^RT*L\*?'CBZ]#=E(:L[
MBT^L=(NS]:B*)]GPY<83L&VLBMV/_ET=0!6$\5Q5R^!F:>MH>3ZIYBNYWJ-X
M=/,2DA@)T3>=?TYOND%M"@K,2-([?(A<<EK82*E('FV019#DB8G52=ATU \Z
M6T?)6:+FL$!&]803:0'\:7_/">A(=Q?I\U1(G268N*R:2YA7[G3N]7. 6;Q_
M=EQ10-Q(0.[:QZ(>;M97_W?U7JNR!N4N::&O=A3K-[Y^6+068!Z<;PPP-VGT
M4?.ZR)>R)!781G(ROQ)3)^DS9I@HHV2^*24:7RG!',]"J51J4D*9N,')93J^
MS?VXLE"$L^AZ?>#='O-^O_88(_?RJ#.!-L& ]M[,C4%3=,ELV!6-8FO5(?2B
M0W""TD9UK%UCK,0?ZR)P(L FR@^3 R%2U1.Y(_EPEE?)H<-*7*IL;2YM%CW!
MOVNBX)+G >6<"IG7 '/Z>\'OU=UVU-QG/V+JINTU2]"=G)74$5,=$Z!N%;\0
M]9AN>4X/"8 [9>I+IK.M3Z2!QAIG%&VD_.GZ\R;X2MAZXM&%7[?A.> SBL:T
M]1\9D[@P_FGM+?YI-L!PZ?U0=;/S ,R*HL8J\.G^#3QI>FZ@ESS[VCAG8BGQ
MSMG7X]%6$6=ZA6V;GO<-N;3+ ,QGXW^-EP_^4W=^89EZ%R@ 4'Y X?0V2G!(
M.[N2/)I/$H'7)&8<8](A95/&.B()Z42L+X5_W=WVC6\<=JW&(@%Q@D'AEL/F
M6\S3"X:RJOS7I1<>]8@(7N!UMO]./,F;.8MA")/5&S76<"R$D88DE+CK0>DR
M<E(Q8[F4@.FC4"V+M^ 2"B?6]Q-+Y-:>OKV3Z=7!6=27'KZ],8'DH]VT\74Q
MQ@>1+],?XU*!K>'_X _*7!7*KA,8_W#TGHU@"K[2OHGR=KJUD63!7#WB)2?A
MX*=-"MJ8C33%61OMUS?4,<R2L5&(M9CG*+,F?ADW6FS7%=P1;:7_9'C.IR-=
MQ,ZGE*#!8P"S@+$(=H4^J>CP;D@A]:TWG@,::AS@W=(QHSH\EK$IL@R^U;"1
M'B= EI0G>[4Y[>S5'"^F(BN[I!W?1N@.)2$S_E89<2]MY>^G,@! PU!.::Q\
MT7-X &8KRBP9>Y1-H_[.998:#V5(BB9*81P,AI:)F_8$!C3@''L(:#Q<$$Y]
M%"JQKAS#[[.8YF@'VLH[HM76+J^]5'%6;@%^\LO Y@TH@J\&!888S=M6\G0U
MN]_H.RC<?A*ZAPV%+Z$_4X&"Q<PEX>:6[&22E,V?/6EUU^5PSB IQ8+H!E<4
MOB@<L!"3&\B+Z<U[NE<@WRSOWGY'T$1R &8Y@P13H4\R4M*8NQ5448<S@,-D
MQB3$W7TM:B?UZ&XS7(._V(*?<_#)OSH-K.M_GV$VY?+DRPK"3@ XWS5SE)9^
M2N?A900\''(,\F6Y$V022]A5)(YI9,G)!G3N3YT,3QE[09AKV(>!L(N#"<4!
M06$72^^>8]LUW-86JSKMFVWW_G@/*\"R^!"U3&/"5KSAN*9TJJC=1$.J;\3:
MH!;(2(Y/J\5_YL[9=^@5M+-A\"4ZM5U^!K353EC#L%6"JC<5*WYZ%L\0R'0
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MW;F>CX,JL?A+SY&\GO&Y9R(>[3M(O: X>OPV-N:FBP_EQ"K]CQ/_8?(43P'
M]R\T*#YZSIUY3^60M64\:?!\/.DN']Y"EI($_'0*Y$D6>S7Q3;]Y+X"%4CT(
M(Z(DY+F\K$)C=VL"+^R)9C]$N#+^38M3;;SER&5](R\(HML?ZCP=%MW?U.TT
ML"?NYZ[*K99?ZO0UKT'I+29):2'$PJL_:<R^-C(7J0.&5:0JB]') NW-1I^D
MD2,=C$-*DI"Y4&F>N#"EF36F [#4BX_25U2=I)<-;CZXZTY[/*G_SWC2'2SL
MAE>AMI1T"@TKAV"^['3"4VURDPZHLLAP(ERVW'O^ZX6+UW! ,IC!=!A.Q6W+
M]JJ!6I/'$'RX9O-A.#7<W)V?NP #=<Y$4Z11!T!OV9#/1-]POU\'O[(6A[PY
M)V%V@0L8?S!&CG!A[ZA'S=!TC\SV4(2[/ZO1.$ V4/#A=J//Q*X(WZE#M@?M
M +!\YH$830PB1L<*!>MU0#]!]7P&HQP>QE=-L1AZH')$3DEAV@["&UNEV<F\
MG6&R%WR3?>O.1+\(/$-+R7$79U2:T;[89WM7WOIS3>:U/TZ=Q6:#<@SM*OO;
M=4F*!&81E^B 3V7;\&W9&I,$9*Y$1H-MV$(P@SU?0U!**/ 8IA&T@FF-V?Z/
M7DJ]W>IN?C:%H[97MRDZQ\:B)\SH=PB*&J];9WM-O</;-\X5[9L/Z<'6_W'J
M=72F!IK_'B91)6IG-ZPVH';N/>RWQ^@Y)36%_..-TM\DR"!)Y3+3=;0G!B9M
MPW_&HKHL!O^<SS\%JA>#85AM&"L]6D^+;=/;AC< !5ZD4^PKI"KNZ $ERGIB
MF]C84$MN8EGM4OB%*&<.O]3^MJN09@U3A1>K\F6$U(NX$O/^%K,C4-+#]$MV
M P\?9XNW=SLY^EMI,;[=T<UU6.4ZF*(T$TGF,NT86U&:5+)C9+<R64BRHOLV
M(>9=HZ6%SUYT:CRDVG--(DOG#YP/%78-Q3W326R:;51=L\/>^]>3T-4,\KU>
M;LFZ4QCN2-V:3GDK#N+<;CM27>GJHWP3<6:1T:J\=_S;ZWW6V/X,W$C8AC<#
M!63-X3P,>NBH,ST>-<<^Z-/C5&NTCSEN,8R(K&F)E)V1R:8E?=]=7>NB&K;Z
MX+@*DX8BS-6ML*MG_7-Z$V+DJ]8;,L$XAB@]&W!KEF_$9DO)5R4+>+35;I%?
M'()PYZ]';T@R_O)^/T9MU_8OD0'X2_R+"\:8F@*^>L3L(JG.2"QUP*0_G%6;
MG4!Z7RXCJU>?(VC]CY,W;=$!-UPB=,")UR#RH)MTU5 ';&O]=.^?C^+:"; =
M1L.>J".KGU*F"VIM?#_6HG[GU0LY7OT0]3]?'8BY"?SW^<W\<9H.V+_!7A5!
M$=F/;_]O5_-?XI\E\+KN?X>*E!UH.+K.#T&1]&D^[ ".93S<2;4EXF&^P@TK
M)@DM#L[1/Y2@R+I%5=#,!WZR0H[Z:[Q?*@>O&=XL%A]:W\]V!$A=;H@!1KV;
M)?Z$&-Q0FS'B<C3A%R5IB![LND-9H /^9NM*,:FU"FB&FN1[QUZM.JW\E,#;
MN2JU>;=I3>/XZ(NW^I_!_Q!%+:D%E&3-LD%WB)Q1*YSIN3073.>YRMFCK97:
M=+4G8J(]T>RCQO836V-59([V%AI;P]2.K3<^7N"'Y(9DU>$_FX!H%&YD;,I\
M$XNN5'H7MX779;XQ(J(,_4UO?>^*G*!76R?Y@@P?:JCV%(M<<UQL\U;_NQ"-
M0GPT"M5+.+&:164>'40S:IX)U#2J5CM])BY[K@SD"OCZ(_[<5&?"0IBUKRK'
M>M-A.%<QMJ-_)[BX--6N^T-C0OY0K3E4F/QK:3"WB^9TB1S0&3T0U*4_QH*=
M68B!L=)7E:\MJ[5D#DA,-=9/Z+&JP]IL1@ ^4V,G]XXBQP6 Z?REO-5K6J2!
M&,&*T9^GLVY#:E%]9V/M:N76WV*W!"<]D;W<5!]F$Y[#>9>S'C-]:S_F^WUT
MTL,ZH-)"LY+/M1]M46_VDUPJW ,;J[=*Z)*#W-VDV$*X4\&Z=J:Q,-CAZ/<S
MH P+GY0Z>EY8VC]\?<VW<$"M0.9=A?54^"0=P"6->8$G^8@IS8JQ 9XM"]R9
M+ZBBZ'_V+Q.1\$>%ZXB13.8RC6N.3$\4LI?[XW<80)3_"W[_$VZ%?S=#YMNB
M6]7&[$:AX2Z)N$R%ZR;.]91AK32KX&3HDUP[T<"_DK>E _7.Y9K(=2PYJ']T
MZ&)!=GIE,YUW7$8R#:WRS5:&<J?/YT?=;[(;;2V!3U*2(\J!+Q-)%.@B"J;[
MCT(%G$\-$WULU0OXDN+X#\1\F>2',,K<VE7TX) -3VX:VS>(6T4Z(%%\&SX:
M^V#W8WB3A\\US^5OWRA_TH._ZH#9Y]#)<QED-85AHNP=%:JQ&KRRL(Z<+%E8
M:<0RU.R$7RD)_NW)#5I?P72-,S?5W5I&,J*[J .@3Y?'>-L?+:GTIHEH"ORB
M<&X-KO#QVR$?YE+>%\Y!/7CF[J8KJH @S2[TW[O,=WAC=XL0&?4[/X2=F.<
M\458,:TIVWPC>UXH:?ZW2UYJ/WA%Q/9KYR?DDK3"W;]#M,3*OUE^VG^$U^U.
MMKLJQB1.]J?OQZI.W,-^HB+S[V@+,*-C,[V_X.\%?I)TK!G27FL#849ELFS3
MB+!\9=;SP57*@<?7%G043-27Z<-3Y+,/'4XK;2_]67LX'M_$U2QI4;NV*BF(
MX:U21O0+3K;:2.4#&RE:%_D/&RYNL,A$UC3@Z_'8H9L*P\+]$"4562GYV6^R
M_>@1 S<%BNT.#O]WL\B_Q/\)XJ_\U5_B_S:AK^OY=TA-[H5@U\XTM-NM)$LM
MZOGPJD+A@/$X[Z1ZR^XP*%L1=S2@,MM5,LL]I,R+=(6WDW[@*-("C<C/<*(>
MC69X3N,;MGKL?W$CPFG_?OV/-'B3$6)H'T%U;03AE<DBT$1H)&D%E3I ]6O"
M(=XN\<<QQ[%?F4X,8GMMA[3%]>V8$SYEVB6A\$J]%27-4G,CPJOZ-WWU&SA7
M:FPAYPII*20CAB<QGRJ;2"5BE)1XYY&[.&I<1%#_3F5F B@;.'AIC?Q+!](A
M.9#4="#/:TEI,2U"7NV71_5*N7W_+/;]"++LR<RK:F [0XLB+V@(></7&E8"
M13I@SA%0X'#D-S:+PAT!MJ^1+-0!(6>+]=2%(:.E)0EM8\&_1B_[N@U/0=Z
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MS+)WP4+%7>-O99GXJI>-R<K\AM0+9]K"+]K7%P58_4&<3?]9%GB@VS,I)B-
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M1A:A4[E\I*'30_X@%E=12M#^EIE]FHGY07Y?G6/GQ3NU$+OQ:JK9JI&Q.#I
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MML$.JC^B<=(!-*9G9^@ ]A=TP/A-F,<.190.H'!].DN[V4,'E#VFS<V1P'0
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M!AA@X-\2H'_>((@!!AA@X-\2H'_>2X(!!AA@X-\2($:O30888.#_ #!Z;3+
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MZ0#I[J$?!!/923_EH8J"^1)-+6A2P9J.CI913"U.I" 3E;%V4E>.<!&PRZ^
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M[[H6C.C+9T)-1J8*:U%UH(]S)&FE3CK@/ F#3VR7B; 3:JD9I3PB(+6)$71
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M= R^'7R9!N,M76C]>]HSL2+D^$5WS7_>&BF<H_#F=W!@/H7VVW$G.._Z77/
MP]Y+EV/8^=,UJPE:6?;RT4>6[5!LDL:D"-? ^;/9>U0A0@\^()]GN$6<WTQ
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M@IW<2,YE@"58_SH/.+1J1 <S..BI.#; S4[7IY1+G$!I)'-VD*=JD$6^^ O
M7N>[V(B2V;9S7'-)"WBN!S?&^X-H,^]53=N9()*?.(W?2[,Q=,482"5I=?[3
M>>-PE/: Q-.:/.''R02I%J YXL[.EP56>07\B=\?>0\MDP.4HQCGN  ZR\"X
M >UD2XH?/0?'3KM!\HI2OT2[G$Z<+>S !%O.W1SV\7PYW=Z5!2:9'9_*(3%!
MG6DIT=LRF)?IG4/K^)ED!^78$9'"?I<LX3/^ERE_02;,_VMOD &#D/Q=\!5K
M:)(Y)K3F^"6V%#ZQ0A$'="2#NHV;JH-[Y_EQ4&GM9[5I"G?N?)$,;(S\$O0J
M%P3YI4P[+TC9,V8E1YF5=ZB7(F=C^D8]ZJ3-F9<8\>1EX@.!")K.V0?+J5E:
M%S0N>VM>BOT^+&(G502"_#-/\L-L=5.=4"R+7N6ZB26@IUR)XG$H3D3 8F&'
M5_@QK#,[*OLL5M^T+4M^E DBL ^I2A8CQ F,U,5^?@][IS9OQ-A&EO2DG.U#
M_,A!L\U,BXRC\&<%#0S\^#W[0#;)M7;KD.J%&DN!8O&MV=/WB9B.G3@FB%.=
M%P@@U$8A><B<Q,%PQ4%A1&ZKL!19O9RH)K71LK'(<KGV[L)7Q_:SN=V.]=R/
M7_Y=NIY"6H60(F?5PX0S/8MAG:].T/\-@DXP9.=)EF!^1$DW@Y./^J[;B>AU
MWKH;3GV-=+:UVO+-U)R5"8;R'AA*V)8I2WP-K\$DBW#PL+V\Q8*9+V[_A2[B
MH<!=><:Y4_1")FCAXWSU8"OZ;R;H#]PYVDD@[#--"^!C[[1WM02P3F2.0\OJ
M\6U5]"+T=$5Z 9@=L=.FY T?G@(<.!,HI0%]*?4-*3Q:W-?/@UMV@)@H!H<(
M$Z2)IPJ@%Z(66:>N7@*"$I7D (DXNB#+)]NSIDTN%DH[+F(53OA/_,(7Z#Y+
M,W[S8YS&W66"]M8_LS%$GK'>%,X$#6,8G?/ =8"5G<&2]]!A#\I3(*>,]HJ>
MAG:-BU$7^3JJ@#E/@P%"I!1B:'.!6X2O<$S!ACJ4! ZC6998P2_,V\-@-U)=
M TL-O9ZFI-3ZZ<$O/R2N$XUVZ]CKA_X[OJ'WOT,X 3BQZI95BT$-[GB2-GI*
MKQ7*JWX% 6O!08$UL@<Q.7T!$HH[#830:^5"\X9]FI5V.J#GFVQ+K1%O;$G+
M6+]"($"O=J1:NS.VRFT(\:%+^'(:0?9%\O)L"_0\="%VGN2+[HZ;*:0< ,;4
M&XRQ>7;6;(2J<P+CSL0X+H1\%X1S2_WZVKOFPDX]?6'[@-8&S5+E:-15H%8_
M78=L-*((Y;"QL84/N?, A3:DH<AC:>>&H 4V:LQ_P5,FZ-[\M"D#+$AOQG&A
MAM$0U'F$!\6=_L\!^!Q2$A@G&Q)J_D97P"&7*A1+MX1:</<FD7(%#NY[/Y'V
MHR]<QK;+JNO$\?%]AM^P 85)Y5LR1$EN$**0IMG)RLH%)B@71F<1T&,R"P"R
MS4%^C+-,T(=9J,>&$/ <"*'R,_IQ$B.3$+<JDFL42APXQW#01&;JV8[A1&Q;
MD[X+[9=&7Q;^:_HOJ#WZ^0Z@ND'A K!%:SAA>K'Z:9HC/<'77G.;TX5LD.[O
M3-XAN*3PQM_4]RWWP D.-T'(_.,\[WI-GP#ZY=<?5EV2Y>T*>@K>D%Y8Z<('
M0ZOEVF?9B-TMF(BLTT ]:;23GPER&T)ZD0X[TBPCFY2+3G*NM KGY]G-/N"C
M)]1.'5RY0\@9\^G#Q@\:86L:(K6-V$9709_!(6@O"" IONG+DB(_ 5<O,I2"
M!>H+$!R#UE2D\!F2<PBV.QPG2M,:JUYUBE_1(\D%*>2G6(Q/SU;<_#SFFQXR
M2I/YK%,$WR'JHS5K&D/?@A@B4/=Y0"UEL:"QV+T!NFE)%4/> WP)WW=NU([0
MO*D:&^_F.[P$UM.>]:(&B[+_ 'A,67:<=JU$[_0#V73E*-SUGS-*]-I)?\UH
MMCTY2U:Z:UF04S6=_%GN!4X**4"B?Q5E@I[#(:"F,TI9F@^FGT]^GCBP.[$;
M[>[XU?_9SZMLZ^ @-.D=A,;[H=6F*PTOR.! ]<U?5A7GE*,TUZ02=H1H$N1^
MFD>MB"'9X>,BF!MAJO=Q\NU*'>!:>H,8<OVQA1;KJM+8^6E(*?Y*9PW^',)2
MZI2J$=HE?])V]R*^?>M^MQ$@S 39A'7X.5Q4KA5XFP W\9@X?AESKDQFI2JA
M%V\OKD]]I"^$3:I*COA+O>I_]B+'BM<TE:$O3\EAL=9;8)()*IGLP.XW76*"
MQ,(X6!7^$;T^RN&?.DF+J/*B\K/J_X"_F';5\O@46NV_#TG8AZ&58%IF]F8S
M$^3*0S)D@BPL0SV6ZP89V@QI)JC20XT)&G>0V-^%'5U>@E+D6]#KYB)4/&:/
MQ CY#U\3^L_POT, ,X?^ U;NZ!G)$H61VN*Q]W+2E"/=G!_'2S[[J*MS^6.=
M!+F!NR*:HS(^[[PW+/P&<>S++SL;;_A400V\/&UUHGO66M&E(BO&I]8#T@[>
M*B0)PJ;PE&0@E]0@[?>A?<)F,VTER/[#B_1683'(C+J0]I(7 'C>Z=V@GJ-X
MAW@:ZN+L2[\6,8X6'*[:&;9-&;C_SH_(NN)(WBCS_@G[]<P6YCH] +$*1J^,
MN[ON40)2T,[+=4W7+?(%LT;!*V&E.R-5&]^SJ[R.<D3V QBG8TB<#.[Y:&$%
M@%XVY37,X%U=:4?QIOVKT2D>J^KDH=B\-5[ZCWG>$.VZ(F= ':DLK%/%Y_N\
M)-]12BQ-XT UG:V]6MQ]"NM5_HR857HB*-Z'(#:-DY_JE<.,2TE#C%NL_6JZ
M)G^X0MZP@YTU-QBP"7T=S/&A5JH:/H;G.!BS)'*0<,32>4&CZ)YE.7H\[ \F
M:,TU0IHJ].]^:KQHY\<$B;"8]ZD5FBY5?(#Y][NPX>ZO<=6>/EZ93WX2H'X%
M_6.1L<8$41O0CPYH8ZA/:%4HR00-B.&:RS?F1.@Y:)<83JI%H(..;W8X[/1^
M@ :]6*E41*$A);+I#!S4E7\C[_><AS!?D.(8Q$A9>5IP'8RF)[G210CHJ(M(
M=0A7.](8-J49:7;G%[$:[RNHVYO, Q&GW1UQ6#IK^S*ML,\ 7V5&+\,K$+,N
M%)ODV_5)%?Y8V2&^,HIK6J%L.(X &;69O/7U&"GD@%W4$6/8=_ 238ELCL-\
M=L\2)<G%J-XNTI8YX+JS84S:"=^7T1U/NY1K_3E 7\NP,23X'[M'3TS <QI2
M3RLM]^V1ZNP*K;VQUV,%;K40BRO<?1WU>$(PNCIW<=:2H\6GRHCC$P-R3GOA
M!CCNRLQ[YNV3N3)B E+F\!ZWB8S**%O%0A=4"*#!X-BB>B$L]<.>U).9H##D
MT^15I]"=SKG30[('UX2'SNNC\VQ7:P7B(',\\]CQO@3J6OY%MCVDZP<[]JB2
M]7:YSJ<9F;]N66T^DH1A9%0&FIYF[XX:15)O:XT:+SXYCC83OIX4X"GU\]U+
MB[TD10/*]C:UYA6,A\7=!?B:[$[[._8\%D!/,<)5JVY.O!((*( [G,IZ_H^G
M6]ZD J<>C%NQ\893@%,9/<O,Q?I+@N+JD@,?2<G8W#(WWK1S(J;>-=6\-"[:
M9JI,_?KKMCV8N9SCCS2[\LL_<=*#WJ\H;[IUHX7);5T7W]*:\Q5*9OJRYK3:
M;=1C2H$PTV_#"ES2)I.*F08$&859$:UO]6,':@_7#41JOGVMC/0H;8Q0$54B
MZXB@.=*HZ^.KCL4&N.O8FVH<QBNE-EAMDWP#3G^#O%^.IRMVX2(K! -?5T&?
M'*F$A*7@:P*2/?O&T::>1Z+HU_/?8"%(K86X*8T%2##-_LNZ\&6R; AI_J^O
M$SXR-E.;!VI2!]=<X@<8(T9BV(9PE8CR)?-D@1^OOVB7Y0)"L;<1+] "Y'/R
M)QVRQ#G#^V\K2ECFBJF8P^NM#3*2XS_4-HKEVI3?1#%!'XU+PWIVUQ6+>Y-L
M$#;&F?<JK!_J(._$:384EDQEA9 G%U+^AKJA0^8D 7TRCR'5*ZQ)__DSVT^/
MG$R&L%;R-Q*(,OS$1]X>I:N'?\N6BTH-]?+K27^O\*&6-EHW;7Y0^W'72['-
MY<C3T#6B;8!6P>AM%LBW4T24OC$NYVSST*S.N.QZ45?M7B@;.)4@M4"^O9QO
MH=10JW@/$Y2O3'%E+UFCV'A[0A==*37T"/4[J.]9,O6C2*>\7QMS; WUT@18
MI(I2I@]2&F.KW4^Q#9CZIH((Z'C 6[X2YBL45RT:(=K@<UR02@G47:2Z?JC;
M$5V\>5GJ::D&^%,;=,M?W_V?X]DS>?5+!NH;'00,Z1E<*WG"7$2W4/$NXUK&
M[XN;R54Q;BJ?7.5^$0D"F^Y:F\5J@4FV7@8&AX8?!Y02R''!,(BZ//+D^,H$
M TS3(FN]QU1T/*,KZ.TJ]!L[WL^Q=])HT,L4L-(V>")9O';HP6_;QUE?M>VJ
M>O\CF>OBT$#ECQN.IV%3#?M,4(#N,=3)X1S?ZCRFLIAS+?!C:] /[RF?V2?\
M4A7"AD2SI6V#F3>C26L#L_>(6T/4K$$&)Q?5V]:FO&E.B?0R1R+.$=?($L4^
M#2YMC(/XMI&N#IW=+/[^9T<SAU:G>19<%S G=)'#+8O%78>45S^^&9SQV"XT
M,<W$;U%7L7,L=2JL-#A251Z64-M!&L-L;!=U;\<TQ:4S;J%FH=BX;EO.3"&B
M<A>>;Q[QCOP\<J?=!DSQ^Z!Z/\!#8OK%@9I(*T7E2D&5N\#?_)5IH:^N].GL
M38[^QD%(:/!8"++J>IMI1]O Q3(M;/<S1S'*FGG7&$:*>R]G<ZNR<FCW6].#
MC.4+KSH6-U1>KHWD]SU,,#2P?A@,+\9([D'&Y&C<'W49+=F@]C\*73L6@V[O
MUG89AK\H9*^2/%N88W)Z(9)A1/9C&$#.S^ L<)L),K#0[@V[:TR0Z+;]6B03
M-/9+AYQ"X^>D7)O$B4U9,4;1'#[W%-&\",/']A!B2EAU(UQ\'#O(N;:%UR8[
M9,-?QHC1F:#09_'+?;8Q)K;U36KT;&_A&1A8-SZP.XCF%]9;8D9X,=>0&]QE
M29FRN%&6Z$8@^_*5.DH9Z$OYD UN9YZ:#O:^3$91KBD2R!4/3 4N+M>I( ^*
M1BF(!B/+3-W;@%27-#%)NJY?]/?:+C9?&O(WI&I^ZPK9B?*4O ^YH,[ML:@]
MSO@Q_;:\8/X!A0D"(U*T/TY8*\2=7[NA;7+\HT]0G[-;!GL0TR8VD>GO^CKJ
M%B.<:'"Q!\#(^K_T#J.,^2?I*L+[IHBOL/&5Y:'EKILK+HNBBU*^UW])/?0>
MHBW*]-].-;CV[)7Y/?&7UFUZ:4E6:#%M>+_P1/67@^ O!^K;_Q+X)\/IA3A9
M &Q,XD_*!X0(GC7-3K*9&.!#R\0TB:PXGO3#1:A/3<YT0K'YL8]0P'<;[?RL
MKE_KY%ST%_>)_OKT/5I4JP-?3Q6'=8A['6W:RK_D$U))W0I=TI9G3U"I+AHJ
M/(AXD#?FKO>SIGG=9&1>(V[QQ8Q06++P^?:%<>VZL>(P<[72J!'CX,)[ 0H3
M*9$K,!<W@.6:].B)ZB*HB7E>A?D3@&SO<M]?-6F<F"N(=0_)_*$F@<]>/P[]
MWG#]\\O]T#OO'S=!P<$K$^6!71N>ZC/&8S=1@]$(_,V%S8(*J-!=LX[>.Z&P
ME"[O&.3+ZQ/1UZXX"][RU+L 2^J*@2X72_FL$']/J8O?ZVP'/Y152#"\$.Z-
M&@A1+V_.^%U=:'"8T?A8UY@QJPY!@-NAG#0P 1J&.CLZJD>J#=J_HMR>=B7R
M:;6%H'WUVV'5W9.FWO[>7W_-V]?M8>1N9*T_&WVRB0Y^<[F=+VV1G)JLE%L:
MU?U,BNC1?U!L8:#_./"3)JUZH?GGP]O!GA?S4 >A[2-MCJN$(JWX&(Y7^09J
MN2>=45L[XHU^7A;HBVB2\<Z%640A98[^Q5>H>6:3Y@4))5J\V,*28D-R 9LQ
MN;OF'H'"]_Z(=O+__DL?[04XA83RO ?<,V3@"PYB4[9S7<^DG^6C%384=S=1
M0IU\5^R8(/D$JN*XV)IFIHH>Z>\5V G\"_"T".7Y:)-&/A),ICF<KB3;;\7F
M$/\4YB()A!>,O:S^+E[SU;6)[!IR,//]&39R^;>&IZ>J4N\DC][OH\K&VL(.
M58%V.W-3+EOUOOS8K',9:X[9DV_.*L ?EN5*16BP1[:WUM_MVDVT*[]8.BTI
M:]=X_\=ND5DH&_=7<KE$;^'VK7&[#//<'8M<$QW1V7BX^VS%8"!+<GQ%S6?O
M.X0Q!.>#F"#:=ND*F@@&6(KO$94):J]A/1GD&6:"[.[&,4*A1_#W3-"RT?_S
M4T5,4#B4,$_GV6&"SDW-,T&J&O171.CQ129HJ8"-"4HUG-T!1 ^WQ,B%E!06
M!RIWS NINC)!9PIJ"3OA_[C9J.W01'"\I)6?^X6DB90B1<Q4DUB.FU+"\O8R
M'$DMNE$G1/LF$6$L<$3M9 A\!VR5>[_6\W.N*]R^]^(;7\Y!AH-X5DG'>$%^
M?Q3&P?OP>LI-L8MK 79T\(>J)V\]@CK-NR<I!Y+/DN[J31GG]X&=S]B,P4>C
MQFO?IJ\%"">P*O4Z/?8EU ,3E$S)XK&U8MQ$*C<UDR'M$XVIGN4'(4TUH9 +
M")6 8L./+EDBM55?DWO7O60O^C:+:-DVENHKZ1U-]I&Z8YQ:ZS<+HY;]U5TY
M$'8]#U5'<GMND'[^;/50#DU<+CP]V\#G\5K3G$_!UUM3>R_CCQBAP#><DN;M
M]E,&:U*)ME,!YA=W:Y^7/!1P5^W>O>#L3U9>T.H(]Y*Q[82<Q4G0U"=JQ5.Y
MYD*(,*X-I<^YG6K8']Z&9Q#/W2ID*IYY>+ */PA16%7ODT!5>M5;%R:=*';P
M9%+RAYOU;B\?J2Z->ZK+R/.^0H8S?[Z!MX&L?&0M<3A93K934FN:<!OAGFE:
M:)$XD0S/FTA3&,\7<,FP/L83!@%9\:W[^8AW5^3M2.!6)HAWXVW-1ULMHFVS
M=,>QW>3H8\$<_(1"LW@'9?K%H>G7.P9IJN^XDI>OSXU,WSJ/TH@@"81X/!.S
M!']:L=+E3D]H:ZO@+H.SK$1?@Z([P=GD=NRP;Z;_5,!(PAA5T Z=UA8?\D2)
MH_Q1/*5"T?''Y'3&-?/'M9,)4]W5)D.T6?H7/'P^&H:5BQ'HP@LTZ='+W[BD
M\#.$AQ16#3()7F?6#DVT1*?180J.-_O@O%U":.R<W6! Z3K,!>MI:H*+GQ,P
M'*US#;GCP-U"U[C11KW8WV65\=@ZX(G#G3P>X^*(<K>]NF*]^/,Q*@KU><4F
M!7FC1R\&E;I=#N@X)<S]F'$I;[MJM\YI<OZYE,JF],0EYT%):UO*!\:9DU0.
M /.8K(C9LB9[/&@DT9N34P(]2'[M#<W5$^^P^\>S"6N'#+7&KYDB\9.ZC([&
MYE'DG5K)9?<PD_K):Y%">OK">\:T^UTOH:V3;7W!KY&/;I_SA0^J= PGNFI>
MR%$TR8)Q?/0TP-0&2Q']??(W<Q[42EJ$0!L6*H3+#<K>1#LKZVMR6PF:&LBG
M5,?=_,8=9:,QU6N4'^C\8UWT2XXD^C$?;0+UZ7^P)XW.C*-!.)D@,0SC#,OB
M/Z]=[&;D9Y]S8P.J 6\B$Q297176 0N""M/X9',6=@013@ZDE2[,!X:XQ,.^
MP 4YR+J%"DMT/&R@EW3U=0N?G/!)#\\H,52/0\.O?ZI]"6*"O" _/U!*25I;
MK511&HA>IB[\R8DTW\52$L<"T9 GD0OVRJ%(W6%<ZB+ZY*R=7)]L[@):$'[,
M! 4K*C_)=1>4Z8E)NU/VEWK1O]9&./ +1 P@(4>[O\@XDT#^T#''-\$$5:*4
M:.]B_O6SF*!3$XL]XSY,T 46(^J-.9%A,2_.ZE/2=9!LI./)#L:U446SB*UR
M57M(\.9+&_F2UCHV&DJ<-%?O06@6[]Q;J[V \+*;5-5@_67IW)F_74_0 Y]U
M1UT;?8HFUHV4J3H3HM+S6Z;XO[GXS[>P'Y<R0:V?F:#=, @'$S353F,-/)H5
M\A=D3.;_RN^;K%LL(Z'5":7(>J"/7]1_!I,S6=Z<]?9>)^A"%IKBC6*AZ<@5
MB_?0:?[WT+]A@%HW$=,)YC"DGD3>(^$[T,((+\)A'.T>5=L>V&EI8(^B/<@%
M[G?5VO 7DDRXSJUTSET:Q7)Z"G0DK ZM3Y?9/&GH3]I8&UY_%VG]R>+XM^Z)
MXU$FZ%0(:T A&H25(W8R2\,8"JJ!T$8*)_8.M\!4"<8/)@A;&^*S\R=J%'\"
MQXOT)U7$%-5\RUF=YZ6!/R-ZY_\:SPO;'%E/^S.M/VE\(*2HWR/=>L<GM6S;
MM5K&0P'SLO\2: ?%2[L.6)+$6]Z!V^:#\.=4P:1T0FW(Y^3Y]BPVX TA4* 5
MQSW\+,M?M@)=5<WUQT#[$VQ 8WU!4U/:?4?%I=^C]K.JM3PZ(J!W8O_-4J0J
MC/1&G%;(0V%QT+>XA5I&E6%K).NRLI;[267HBU-8G%SE X@Q026C[0HG]NW_
MVTYIYSS)V&L:M4*1I8?@W3'3*095M6.*\T'S)Y%PXLX9*X<_E91Q=^T5]P?_
MF';G%.^=]NR.5N3BEGELIAKS?+3LMIZD]D\VV@?H0C:Z4J +!MRTI/'JM4'^
M],5'O M"+"Y.1B$]R'*+EEUXWK(LT?']60%#[+BJ%QG2K3PQ8C>M4P'$F=[N
M=_KR4RA=SV.'QT-%'SL[D)Z/[=_ZS+IV4+U0TL-Y0 RV&;BP)=<..<<$.<$^
M."A-E&W=-#4%4LB#K0T"7?,1[QCY\#\ZO<L&B;#P:523JIIZ_BV/QF;Q%@K+
MMG>\^6K+Q=$[)W$MG&T5' DCZ>$!<?:N3.$5#2"=RH'J88A7UT=:X2;%6]"A
MQPYXEQN&LCH*V;RK*.%15?TO=I5/ S%:XYLO4]R34JUYWX/_@3Z- ZXI;Z*9
MH#]'Z%]1DHRQ^4J+G,6=4P@TL;NU=#YXNK %<][C#3#:)GPQ?J>+<9X<1SG\
MT&1-O+3=Y.OEP6*3:*4[;@[B$ZIFR[9KVUO8TON(SZ.\;)2:_]IC9()D(8#J
M!L.DE33(^!%'$&"4#TZSRKO>$%#>8!@-L@9G 4"E@!<35 R+6&7;'UW4:L$$
MS5?[O5>$AL @.%Z:.C!(FK%.FU@Q(;%DQQFW+ 52Y_C2AU0?^E^KQ_2D@XQW
MR9FWY>'3B;>U @L'J1OWP\5.K+()+4 V1ZEJC%[&:28HQ).J1.,#G$GR+9Y%
M^J6_$+8$OP\*<J?@RL>='4:MWF7KR<=7DK(I-56J_!3*WOITNOVZ_ ,OK[,I
M,KP7KH," O]M;Q!B.4MJO&."$KL8\W@*$B^(/H"O5Y]@C"O\EY=Y4*,PD@'X
MIR6EG_SVP^+\=#;% 3 D#W8Y")"("(UVQG4R)6BZHC /<%$S-)HP?5SUR4YC
MZ6=%<<FZ<IM,H8! @A+J!0B<CB:TSY.TT,=:<9M3+'1T8N&.+PB=H46[O$*5
M1_Y!CV>"%HH:=MKDIJH(AL'J7$CY6N 2*:SC%D*N5=!_5$$"V_QRTL[3UD3/
M5+2N >^!X&K?.?JAU]()0KNC25J#@(@?C7MCT9+&PTZ! %4LUW45N+"X$P$]
MCP(AY#N%%<G9$:KRBHQ&HC[:--0?@]4WV-KY.VW9'WS7/(;WIO=US?#($\<Z
M+*DHS$*X^RQ44T6[#-)$6*"34,1V(-^6Q4]:^;M)CH#_$X ^'FU2)D#8W02A
M(4TRA-GKT_?5Q/\BK815;WB*/QKV:=1^'SEI,++?IV<K).W6$LOI=CT"9/['
M>^75_^C>^/]7@0F28(* ^QJ4.18SYK,2F.4^_R=2OC003RC<-"=8X<ZN?;/M
M7X%/0OBP]3)(8W*V9<CK)RHA614,8<"CM,,<U @\YRAF[_^'C9Q.B:9GH=T&
M 3&_K3<D:CM*VF/P%/(-8)N+&H!6NP9C$>7.6!7QB":]!3P;S7&X,^43M>*E
M.@086#]L?9??]FG$ZP+BON6#R]>>:)]@#$"^96\I$L S\A03>C;>W>N/3Z;M
M^,LX?H1A=T]A^]TZ=<B$HKW2-6+V&;L?=R#&)+_(:Q-(Z1+/FZ7%;H?:902-
M\^ "-Q"+^2X!W9_=YJ19)U>%-"/5AE<#BEY@(('!(;88PV8_4O%!R-Y0<P(*
MUS<U&-NG_A,=^[2ILBYK^FETF=/'H,J,\R<8&!B)L .(U+,X,PS!Z,=E()0>
M'%U G::IO/T,Y@%26$PWBF[E98C#E6U\YS<-"=DG9P>3:R91EV@/ .R"OJ7^
MIZ O 5;5L"N/OQA6W^ZL*,UUMT&]VG(9^%CY'GT+33)E38)\2F<V)TV$&!>=
M3=*'1@C?!+I=<[2\2]<A59#.!U^4.WI\/HG$$ZD,OK@.>ZDK[(_(!?DLW+NU
M\R<BK-WF%-;?D:V]$,!T,$3B^[3&WD,S_W4K!!B-KY$2\Z\MZE$CR0[720>'
M$5C8WPV'D64*F&E;BL^8_<(HTBGGYRR7O!5^M#K0MC>L'<+?).DN"VE7OQX-
MG_PV;XT)4]60F0SU\K67?0JF2 /WR%X$)JA[,)@)XL(I(R7))_&1.$&D#4DK
M%'4-X.FP*!8U7F?PD]]^A)>OUL9XJG2_<7Y-4?XGJE]]5\++9P.;U44Y+;NU
M' )2O\LZLER6FM%4YT&WRJ*?@X498]F\.9ZOJ8;)8'::!.#O^?KF 202(J!(
ME=%$GT%(36SFY1I\0^PWZSF0U;\Z9E8;GEY]1RGV="V&34^M6;9 ?M=A6+C(
MPMF@/=3\+1NUN2KR*"4>Z"ZR5\SS2XG+0ZH!AJ0]O;KD7<161[EW'DT1N$_:
M[3V8_UX3JR.:M?C"&Y'0K2YB/M$"'0I@G%EBS6TVNE4%Z@SE6'VWLW6?\ GO
MZ17;?S)DN;X<J248$]:*!Z]'<6.7DQ;PP<F"P8*:V"]EW3T!.Y%<B_>WM/^J
MK9E0%XK<]A2^"IYE'=5"YCS)<-5'G-0$^]J]Z2<0ZFRN@[P/V>PCF2O<NR#@
M7I:F"XA:J93$?U:L!W&S\YXXJJ6RQ$8K%D;2CION:]^;$M_L8:5_JJJS[VQ/
M'NT!/>G9*(YKW<:VKQX?L- O]Z0),*UXY+S;A_9"L!DUA?(J'?M2LN*UM=G7
MF*#-!]2;;NAOD,U4DCC%D#0?I0B[X@;[@\;INN IWSF]G W/=Y^F8_-GEW[B
M<:-E8FD#(WX>71I<396:?+RAHFF@XY+_V8N"_[GGUG^&_W\%*'/XWZUSQS+D
M&"W9E9;=F"ON4&[<3>0-82ER3;E'P=2ZX!!YLJ.<<XM_^G&BRMO,2Z--BHM7
MA'2B9Z9LV]E3N8)?ZYY7'10-KJ<^2>E0OT78Q&59)JQ 3%N&,ZU'<^C92<1[
MSC8O\[6V;EM)C6<KS+SU%;1]+)9#=$*\N?'#F[O3Z19JNFG,29+NQ&>P?L$X
MKE&W^2Z<-_DC+BVKGB1/>0= J4H(0V,2M!5V&GP2@)F33TY&8KGDJ0$=C.M4
MS6;_0KB-?O]1,]D!6[%^^R@-%55@2T\3JML<LCGZ.),W,BB*4T=W^$_R+$HN
M[OUPG?SF\VJHS;3T "DKE (VR+<9*MPD^=S:SRRQ+)5U95?N=[V1:++5M_N+
MWU+3"GD2[*CI>P6N,6U>_"X^^NI2OXVO&&DTJ!)9,BU=$_ 8X>J].]EM^!-#
M>4[/5]7*1S0N6K:?5G4FZO,\AIU;FZX$2KN%+]5%/8ZE[!A'MCD2P#QNY^<Z
M3V[1-TF*^Y;<+9.F97>N:_>BJJXN9DD2D(HOA!^G];&%8& ;BFYTTQ.1415K
M;0G%D I'[W/IKPI/]YAZFQC%C,*%-1T_.EOG6UET$_C>51,V<Z$>X7GCBN)B
M IONHR:Z)IYOQ#T:A3^23!>TVM!3,ZWE)!;H3P9?)<&"\\9W?(^JZ[#Z?C;Q
MBU9CS[!!NXP54_*-XC+W0WD=+R?7E[A 6@07MHR?)&K4$:[Z8R]<'B76Q02Y
MK2!ZG+Y%QJBJE*PYKDH,Y_TF&/!^K2XR#C8KO!=0/9J8+ZF[5>/[] Y-V%IC
M_:>@5(BPO]DKD^+[ SKBXE*5&3/5S[#)$:)E\5H5D]%OLT5I[O00M+/7M$B7
M!A'<)1?RH9,A9W^]^X%@';FV P9&=Y3JQZ_;2ILZ$KP$W-(<;ZDM]5 ?5"K?
M.?-'GWR9MU1@[.-NFFV[%63S5XK2<3+GC%E' *3(^5/VW+B1:4IUY\+&^&&B
MR/;>KC2<SP\M=*7]2-,5MG'WEWA->8\@DC'/8_@KY,A21G",4"@_F4R?Z[8E
M@2F&P GJ+72;.1/$H=PBTL($D=+1CDQ0FR$3Q*<53=/UA0*:3!"69<<UD3"B
M#'(J2FYKUI+-D'HU>PN]YN"7X+7D308+D 7XZ*94]&V6D1M3PX]#IV[=A3D?
M9#MM,4&_OOY$H="EPPQQJ)QX?9\_[$6C>%]EMB<]._087TM!31YBU_<"9-&N
M-'?L/?_ /(:0P_%<[_RCR7[A3T;L_?^ZA>ESZ!2&$I2L-Q@%.ZTJ3HQQL>*>
M:GJ2/"DH$(4,3WEQ <*'>+NB0_[SGQDP<%B;;AP_)_NP$YMJ./H<Z=Q!NYMX
M![ER*?AS?O^!@]MDZQXT@F[*(UCW?(F2+^ANB.M.B>UYW=2SYW3+S,-@@E+C
MLV']HADKSI%LSY.4XD2@PQBGRZF"ZR8"5>G$G;#)MSOBVN2N3(6GKNI6*H<A
M!_5OG9:630"&ZA[,7ZM;5CFO7#'AF<)<S1]Y, Q572J()O,;P;/P)!8&GH3[
M:US@;X;ZZ^8T$K(!$:]-_<^_\HZSPW!7@0&%KA<T_46Z[O34]^V5-GX&7_U*
MG6V2G7=D.]^BZQ7BU44]GI2GZ52$74-B7K-Z'?G5:&$=7"_HCJ#G/9,.RUK=
MNM0\UMSI?F$LQS6J\Z(&YO]@G)J.\@K&<S3Q+%C>HF=YZCT>VA* -87%S:X[
MB-;;QIUW]V!-]S^QA6]@V<LTG6S7T>4!>>1;1XP"?!*C'%9 '6E_W W68Q!,
M_MZ_JUHEUS?^%:&J#M&[9UK(9Z)''1?T%6."O'2R!AVN_>(]D5JVV@ -KRZE
M<W8(&J17K*;E5R>_RXHKLYI>?^>0ZRHQ(U-.R0[@G4AY.W).-(AXZ;IWNV2Y
MVV1Y:*D!3KC<3NV=B6F^38R.2:FN][3/NJEWAFB#KHSB4&H;WS4IWVN"B<OU
MSF<Z=;FC9G7O&,CX*SKMS1,A-.XXBBCPX=WQ/X#]FP6/->LT?W5A1)PE:2DQ
MO>'/(8< ECNU+GL>_\%P>+-U8'*N)!*?NX23)<_9ZILP)F+5TRHC?WP=\S:U
MV DW+HS(/*;JCN[6%/8_0T"O=?2EK\>!9?$6I2K&+!GHE\3R:S-?XW[[RX31
M+AA2E*L:/**BYJ-MRFZV1'$R04*KY&E-:%U</J"ECYM&SS2]W7=TZ*"]682W
M:M[J@2O@(PQ/F/<?35?(YJNI?D[YV"W\YW?B]IR2QY&SPQDYN=?1K%0F0+20
M<BS][(GJ9(+.^%X\R ;3>(:PS2X\0AI%",J>!?EPZG?X=F2 O7RG94-6B*NO
M$&/W?J.^%&?1;XZ>.XGZ>/ET1&;WI4YQ#9XLHH11TEBQ,RDWY8UXD[,ENT&2
M?VOY97$+8P_-.,,S;4?\'+H^7WE7%#WTSJ^$5]G>[:K.-Y#QB^91)P2=EGD:
M.CUQL;R\G*CMN;40<RWH]#.CCYUGC4-B)7(?G_[XI>3Z^Q(0R+)5UR0C(^]7
M_HU_/?+FRFL./)MGU/;C=43C=7MDN/4>Q:]^5+R6S49S9YV4*Z.;";I\4#K(
M X01&A&6G2I)/R;3"L/5KZS7"G/7C\N^/!,0E:FA5VL;QS7K8/>DB[AHE*"A
M$O-C*:^N,24@E,XI0M:*N<-QOHU095CN*/GP5G[HCZ+V2QQ&D=5.NF5'WK>"
MG;:[TC";B[R)3\O*]^JV^7KDSS1@7^%ZR])?%X<F?/X]MVT4MYV1/MXSNNSU
M%M$=RN*'Z.QO+T/07-NYCF3EKO/M=W1]!KD1&]^_9II"ZC\!EMJDSJ.0[WWA
M.[G__/[[JIW$X6UU9>^!ZQG%HZ5)"^DQS14"<@9YR,6#DI\E<$JS4E)R&)?L
MJ>_%/;I&G18ZF-<5UX??KM*C)77G*>1C/=(&(:Y]/MCA8C4)U@XY!:!;YO@K
M_=*N"+2GO1#TS;7KY34,\/U=E$PUJON9#1^3>U[77"]1X/];ZO91K&O:LO6
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MFXWDP+NT49EZ85"N(13@1TJF!G<Z:!<=:?WQP7BKBL1,@5H<JT!]7$U&_A>
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ME>?*L[R!;>(K*;LP^7B0Z#;9)=T#-.QE\G.\L).&TB/!N1@QNLF =Q>_PL$
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M;$0#A>;GO>L\6;ZF[>9KJ,?[<*O'N,UU$?);"V$3$&:6?CD%I;4TOL-TR5%
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MSWXZ(NG-L&G(#JNH<?KQ]?/TF3,.%1_6WU7Z4X)TV/GI_KUP&Q.I88S11I#
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M??NMVPRJ_Y92OV-YF#5 0ZH=?0#1D(LLVQ^O#UYB(K]G'7@!]>>HSZ#II&7
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M_/18J^SX%N[Y=EFD"+-ZG+(V?FW?^UP%2M 2;R1:3:RB<RZC@*=UJ!5*LM5
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MNQA. K>XF\XI,PD?TH8/BPWI,\[^7_+0W]7^+X9[?AZ'U>>07UC.6W7F1-R
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M#2O95I2) W $Z1'%0VS=P<Z&.B6GX5\"HH87A7AJP#RNP@A.:QB\"4>UZ*M
M [E!K=S.YIS- RFEI27[_)^D^QW #AV/!XZX8T%J7CDVN2#-#6DY9*S&=Y>W
M?RI)BN&V?FUJ<AOY38G]SDIC# T?[S<.K?NTNH?I77>S_?>1BE=?\S&MC&$C
MA?HBY,5JI$O$JE-X?_*5&..IIO(EU*/_P'_S).'R3)F9\/7^-NRJ]2\P7X,4
MIM#?GTC,%;)CQ<Y!@QHD[I8D?)(MYO'8QH.08?+%4G%..,($3O(28PZ6"!#O
MP2]CZ44.D(S##L!D?N@FS^<OSD>++7RLFG1\\@I)-JT_-W60HY9W.[W=5&BM
M6=:T*#[& 0% ^!4B+S"4!0*V$L]'&$"-:2)N'8QO5MA!M"(^F3Z;0TZBZN:/
MTS9#6O=)^502'"@T_CM63_M@55U?F;#'7,W0;2!"JZ;ZNE=P3MR7R6%C<5$F
M"M\1*-%?J(0+\!_S0$('U@4&P";1IWG4"MQJ2LC2\-=&?(X87?@6<FGPQ3[O
M36TA%5(B1<?8O;CU%"/'9^D&5?0FMCI43@]WTN I-K/#_W)>BA9_R/V7&!J$
M@H+)3VDMO$K_V93%SSSZ63PM*J$GW/)5<_0]6[N(QQ-68Q><;J6Y"0-OH:_%
M/?M]V!\E6]@:8"!S#^#YA43PY#U-? )^Q0QC.16'Z.0):Q7BT#<^-JG*V-0!
M>L@IYC68TCF"K7TS<2XMP(HZ,B6GD>O[D1))7E&>-.R=>+CO@LQ(O_1L\8B]
MDMP":"C#@O93UY@HML$8 !XW'7:KGRMN,M4>\]4=,.\<8O"9J9-%O=3H@@Z1
MVD:$&;"WP.40MBF[NGL4QH&PQ[$^ZEX^8UE( 7;%G2HQN5GGQ^V"7/QRW ,E
M>?_XW,';Y6/6>8BC#7BUII2.#=8>K'@P[MXU.L9]>/NQMW/@H^!!293*YM<C
MM\4/>H9]O FZ3;::ML<W;5IACW_;KE!]C/@8&EZHBMX&MPC+,SB5LPOU]3L_
MDIIQ&UY ^,O46$'03%S4:7G>^T'51XY\8NJ@5J;+8YC6WI3]X4*=-J0_%VR>
M#KC0G5P)IZNAW-'@!\KCY(\(4JV45W$".NE<=!.&2^?/7N&$&F,;:R.J,PLH
MTI/0AR(P6^3:>B^0O+KHEN\NJ*H\B;:> K0.:KF#K<5>?51,L/#U.8+U5#-[
M\T"544K$,I0$PZU48$XB]' +1=<=9$P62K?+\/([,W+?=W&VLB,0L]F&P<C;
MWM4L4CX)9M#Q"%PDL]5[+>YHIT5!!QFB4A.S6L?>S<".9J7?;__+I3H)ZVD#
M6/ 4DZN%X>I*4NA"RT3I-B)%((N&VB1)<)+E2W2JPH[H._XKA+8!Y#2^#O-.
MG\'J4LI;:MJC@H4$;(/QP&7^G4!V7X3:P5_-F=]'UPS$XP=L&M@8D-/4N93B
M5J^_M&MZ'K6<8EH_JMLEPPHP:L$K5'V,FD:UP0]W207?=?3O7GCI'8=W[GE:
MNF-'_J*KI:6B:W^QE!1G>/\/95^ OYD@>5!VGZE0F4'PQ03!L..<E5UH$4&F
MC^B\K7PY CN3L[:(?GVR2=2!HG!D:Q'&OJ53&CZ/&@I?.'KY:$FY/780$-^4
M;J?NEK_ ^T^E$Y\S6G5C4W!8&0D\.95DX=VNH=%OBW_T0,*M29(1"]*28LEB
MWF*XW+7;UN.^_,G>4'P5B[0K:OE ZZG3"*7#AY0/Z4I^(/.YB<:UMF"F&$"!
MC<14GFK=*:HWJ"N)!_\D>L/[A>K9#P^[$:#B)H[&:6_+W-+@F(Q[X=7Z.\#D
MA]G:.E2OC/O\*;V@LR:FX=)XS!B)KRW3'X/:&WV5>EE8+EZR#L2V,K!C RNX
MG9"R@-.:[L*_S;AJ6)UT3KN6DU"%3YI':86&6NCMRQ9;IW^@EP9S#YVNXPSE
MK:M@!5T0U^-6R(L1AEN"1<8([S45DI.!LTA,%N@A_;F2MW$@7$SR1J#ZN=3S
M=1?/I:?*.[I4%B4]1#W3G__<FZD,;Y=XN^[;&&K8Z+LB+H3GD,-KC)G*V B^
M.(JI+^>62RC$H4V2 ;A?NA.CR5QK58]EZ&^$7:S2U.)[LINS<4L@ER#MF$]>
M9_(^CW6%>%@>'QG^6-7?EW7=99WFZ4_.NH?YV!])_W4%\,LF))PA.N+=.9GC
M/"K@&VB&:"R9@SWV.T)R%R%?]Q9NX9P:9_(C#0FF8P9]2G,-R%M6R%L'@ 9#
MW!9:&[ZZLYG#_56O6-Y793J$EU1 15/-L<":[]SPRN\<-84YW!H]0[C*P=CZ
MV+'A:1>F!N7!N&(/>++EDZ6.;T7AQ*\@:[/1$'W-@8$5ZK\4*C5(VZ&T07R%
M:0,93>ODK&.KP21) Q*]OQ%ZJ5:@M-EZD$%6:%-/@%,)X;FZ<59.(#*":\:V
MFT3WC%IB NE/Q6=JNL@6Y:I8C7T!G*&Y#,YCKY;B=%ME;PD2_A-3D/#+ [V^
M/)=?QOL1A]C$!;B9,:/L]X$#P9+FG/(6TVO ZO#8%QQAJ("A275YV66K6@B3
M!+>JCW7&BAC/8+<F2R/!BZJM5))PB*H5\<KF.N8K3](ASZX[)M6B]7*T.?Y,
MW0DN(:4N$/1HUO+5@ (J\YMLK?7:4I9<?A 2,\+.N'BO["*KP^IXW\7P=K5#
M%/&6_M +PK[/O:S65]81C]#2V[)_8X&F_YZG3IY$ 5ETF;[W/&I;,$B4WRUN
MF)*?XNEN5996(0ZT!/GFNHB5YG$DY!B,XM[,$Y0\)A_S$R'GB6_P7TR\,/(<
MPP:F_##-^"AZ%F&]BS8@QF +--CB)[EUJQ&49BG]Y,C6(7]=Y,5"&F31/L2H
M5X#/?;2;>%6S]:L&JO )W(&J</-23)O7DBK)WCH/,+&E-C_#:?+IS+?>"S,$
M-"F[XC4GN<XS()-PZ6&0_F;(]0L*^(<^R9!>6JA !_ 3>:QOZ>;$Y6/ZFV$[
MT:D?H>;,=&)E5!MVV?BW>N:*':P2!%B>?X6P20$O>R[Z[YI'%;D(L"GZZ('P
M$=?I5^V% MXJ'PK9J\^X:B=FK 2Q\,3/5 =,TL::063HN5XF]T576!JN)0@P
M5[E*& *77-%:M3AM>CD0* _SJ& Y1S[KR6WF7NLYN$PO8,M&>R79;]KH/ H\
MR8.W$63:V<+.>)HJT*CW>'Q4+ZUYR91@(0%O#^S7S*U.-[R:MZ0"(47EQ"K/
M*J8FY5NSQ/I"99MABLSY[QSM*]/2>P&B/WMDAL7C.5/<>OQK +;R4"RE OQ;
MO,4R9VB_*.=[#D?,A"8.]4XJUKL4C+:5?.<M5>A[$T)+@@$T2^_<.FX(]^8X
MV%!&/3@XW7;S8/^,5$W;J;NX;QI0"1[=,&B/+V"N =X4"IE2;0N.W/)T%QI&
M9'G#8N#++B9(P$OW<)8#8^HE]EBQZL*BZ&V/)F#A7J=E/L@W_29'IC:8DQ0&
M%QZ1%])4OP,L9IL1B7B%PPJA))[NI^JAX%SAV<WTR^SUPR&1^C9@:9W-)A<\
M9KR&;0!&WD@@3_)4N*YAYI-*<YD+B:QOQSL$G=O;%"K%Q?N%O1>Z52?*N3U?
MOS5E^OS>XSTU>0<(M'$]$NMWZ5?U;7DE>7N3M.*IF6(:!9@S]12[@(:#>+X0
M/]QV&%)G@N_(*8#VC-AH'QS+9]"9RUAJCJXP$20*JN\]"O'(^HLXH=.B>*Q]
M1;:9]"2$.YMB2Q"1]2FWDSZ4/AX_7B732G3NOA"/[Q<I5&Y*5_ZKFG#G1P])
MI)S!*CW':ZX!ELIT+VFGU1T+7MUL2=L"IPC%L>Y09[-/U)'D*:OKWP<5EM"6
M%W.+JX:DKED)M?ZW7I#B\I6G_KW3"O[MCWF4&1.V;9,@H2+II=1?9B!/J=M6
M\ENA(;]5IVY+A)8,<(%/'5"A:'/&W:=M?L J_X(7P#*J"0OT;\VVR;2XW991
MYWK>[]K=Y?E8-@ &UDR>112SJD*E14C@DIJ]/#[*PJ2!5,<ZR#BIN>NW51H8
M)3"?XUS&Z7,)ZQ(_.+R"O&4$R.&?(2?R-%$SJ.;8P>YHCY7Q@%<XZBCZ%C4*
MMN"7<XWXS!9./*"Y V!1E2&FH.V:8@V%W;4C(!"<39?A <'($9>#F3YG.-55
M??K?CM0>^^K)VT^.4#5X5K@5#1<%63-;F?!FO&R5USN%$W=0A)^TDQ)L=9*>
ML 8L]3?UX5;"HRYZ7DW1ZC]A@G!)VMFH\_X$2SU"(WO#[@._O$=*7J"EYV1Z
M<"F?D\%3H:V178 O/2ZK N=1PJEXVPV0:8/UDTDL5W\UQ+Y\5NBZ9*Q;WR$U
M.+SCT% Q/7;-%IZJWIL@99G3/(K$T)[ 8@ ^HN19WQA4V]!L(H@7ET"%+7.Z
MOOLDN18#MA:(<>5\N'.QM*9-DG8VUE\I3VWL:TNMW<2K]<JS11S^3P)L%'V\
ML(E8,:>Y5)VS1';II?.:Y?<5.W>?C]"]G=WO)(S'A<.O$2=S1]P[B&;T_==W
M+[)8F<])E$3E]OP@7\&B;94*)C3K)QB5PW!BBY?'M2JYX=FFMJC[XUX!!4]W
M27J2KL=39Z0+A1FVXOG/\*#'5.H@4:.MB7-MU#RWI49KT-=H(2*$C 2V*/1
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M3Y?CCTEUM]S]G;/:=NWCX-HEKR*"3,JH:)%TC_YL/7;%-#4TR]B[@;8]\?"
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M;0W(3*+N+?1R.%L( TVT==W&%\+C, =ZGIY);G?M8;7;>*OJ.IVKKDK8ZG<
MI6>,HD)0F^2 _.8\*GB8J>Y+ZV%68B9_2?\<I5BK'1ELM +6T9;)+.'*, $I
M-,1E6T0:H$X0\=1(/[__%=(S5AN>\X^7GU<;L(5Y?M;%R*O>#_4#MT*F 9M*
M<; EAHY7PFE0=\*;0,F 8AYULAHT;,2B8#=!>6+HC.MQAVRWOGR0DVA^3_M
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MTWFW2./:K24];B8[VDI.4Q;J)%[Q"[S;O6EM<N&JT+[2LN3#:LGBE+F'U1J
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M(RY^D#MQX98Z3G92 AJ?E$#."\4C$':U4P+KY@(0KY\KJN2.1G++-/$91Y7
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M,'HQ!C%&,5YFO,9XB_$^8QEC-6,C8P=C/^,$XP+C&A-@XF(28=K&I,*DQ63
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M01,I$P^38A.\J:9IK&F+&;>9K5FVV92YDGFP>:T%HX6IQ0V+CY:RE@&6-5;
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MXW>]_W<^_O,9_.S!/YSA>69+?1LKN]^ZPS>:!,!L.J+!LI%W[@/ 50J Z#,
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MP->5%^C[\0+>)%Y@6,(+F)MX =\@+[BRS L4^%$@0Q0%TJ10P'<["AC*HX#
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MO4J3.D'KT=Y7%WN75#3YDIA#S3@WD5_HXJQ?LI"GWO<]3TJTV56@-W/Y[9=
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M.B>_<=?+P/!Z<XGRUU;[>-#O>+#M#.J:U;3*4Y% A#:1+C&S ^TEL64S6 I
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MJ:XYJF<O>0\KBDWV2Q!@'K<Z\_E;[_!$S00F?G&:*VC"CV DVOX3L%<=H.1
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M@M+O<1S6<F';?J![M*#-^0)7,:+19ZUM.O ;D*"?0Q*11CN0H!'Z 5KNP-,
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M::9@0Q,PE9[5*T;$(7GT'Z8":\<?7=^)]62ARE6VR$'K(?JU8WQB'NE\'3>
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MJ%A?3GE^W",[Y]1R\W*;+*R3P)@!Q<B\>F*8B5_4<1OM'LF\>QC5-_R8?B1
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M:E/)@X;2+[Z2,,XXSWV%"Q0C]M!.BA+$" _LRBGD( 9JKV1Y045(R0%6>JP
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M1J('5;*3FA-?E8^3EF& GHPV %CY -<%8)1!6[-92)@U;X>!-@+JH&[OI"J
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M?>M?RZ]U"LU5_C&DT&6J<;6Z86/TI,)@JJ.\B4S?S*9O:C*J,*RGIW:#/VF
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MBK5XV/P@+$T5&8,N17$>=*2SX\QISLV[X"+KR31'4;<09X8,_;K#0-DAS"5
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MI$XAXEV%:!O1T;K^;YV<NQ1_!F&5:=W=\5D"=0,35DH*"]:]&VQMG6S)JOQ
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M[U'L8V6S;M6$.96OG!/>ZV?N_T4K 35##^,V,,%T8CG35C[@1\D?[,F'.8I
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MV\?A)% I;LD!1M$9'LGXY-<V5N 4JI,2RT<@N'YT6 %NT,T(537E2!&PVFP
M/^!=[N,I H;Z3_;LML3>)FRX>B>.=%Y9"G.+U[3NM,EY'W3?[Z_;7P^C?IX
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MYU;FS])]32NFE#T_"OE6>C\ LE![RN=%_U4@_[_Z :U1)C]1-X\#]10> 8U
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M8O2 )=Q&D6V6QTF":.9 YWUC 99I:>6<IP*+F!*@F_A=9@1] (QH&49^E9&
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MX\BZX)T K9#Q46IP/>.;BJ/#F[T[4QNC??OXB'J,4[EUUJ9=DM3?+);%T&Q
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M/#["*.,@_.JV;!CF3+4.XQW]H6J45V!$%_O10 =2F&L3TF<>)%<2PQ)KLUO
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M=">%NLG(K%EL-PRXEVY0SO[[PY^D_X2TTM6%'>#78YV\KTD^BP:P3>E^;7N
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MBQ&<J6/WQ:9H5\I!:<("NZ&"=]@#9+"3.%3N"*8Z_5][  2>1[^TEX?HZ@=
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MBEO)H[%QZ\UGS)TV:9M_>N=TE3.'-LPUAQX]-VOQ7+&":_?Q(NJ\![@MR+R
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M:TW#)*+ 1<A IYC16<R/+<DPGYOGC+B)1:I^ZNEE"RO!^8MI,\X+8^E:<X_
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ML'Y6*4^;[RS]>A.F]_--C6(PK;$J'HJMAA"^YKTL&FN>!:I-L&K8%H&,M#U
MA"5X)@]SF)<OR#&**Y$6R/A0/; BW]Q$BR9E(>"TM8XO,W6]WW9Y3],GQTM"
MOG[AR<G*A4;[V-5@UH)E64V+*'=E);>^&2CI?NY-27 >_.AD599GEPT*KQN0
MDK>DJ%C^,WD<<LQ.96HN/7F T\_N_PVS&]1T.60[O*D6<G=8P\7/:!BDD>5A
M/%)6$31E;SH2M/1&=4O@FO407B9JE73O8U,4#-:K4O2PGE ?<X?WY8TM&4+^
M*3:YPWFRF>ZBF<Y.C5[E$@B;T?@G 4X3/CYJ/Q:Y$FQU9BK]0U>H-@G[RA5
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M1/#UG7B;QP6]BH*<G)K=@UXZ;4H@BTZ?1M'_3(M.@VE_8:HN5K5XZ$#>Z0K
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M@;N8*=L=\VY"0\^.B1@3BCQ&ZZ+>9.HB_=@YR ="2!UZ'CDZ 7\>-JU_,60
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MG >/Q1!Z5DU:]A/NCW23HTIK'1%1-WUWLB_DV+;,%7GN/%QXV6EA]4IFTB9
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MS?B9S-B-)84+'33$: 5L[2Q[GB$^05W68#0V"4 '# TP>HSN9DBXZ^5R+]7
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MKG!RA!RUT"8 N;Z$OJQ#3L2+8$P9\6^%#E>D80<<*UQJ43E.X[@R(RU*L]8
MU3C^^X]-79D1(88-;&3=.+5$6/*>>!GG%?C655LD_P_Y&81-H7&><F]F87^!
M@IY/J%#5G[')&4CW^F>NW+,;B9\"DG2XDK7\0\-27'%GUBRSJK[[L!I.IQXN
M.V\'E33<YRF3F>CBHMBX*CZV(%G.=F+Q1HSK^O5%Z$'JKHR$ZB_O-\^8W^[3
MA!_W/'1TA(X+GFP<)K#(SK 3AK9O\\>.FL4FLCZ;4TV?%EUOP>&?5$Z4YJ!_
M1@E%GOF_)^&CS"%X 8B!A'%/1-1#2"OX(OXHA602AL38,\"TJJA2?55&!LV;
M\K /#="'FI!RLLYXMZ9L%1+VJ=Y08_<>@S%<LM.IN-G;S(CHD?4[@^,6\@WI
M,Z\)[/LN31*73L2YA&2$*Q-/+MI%;WW><$V(D6%[]E=L517 '#A],;F5DB'8
MU?-?^WD#/:2!;;6Q[@TS(I'TF5195E9955%>417>V]75*[V\C%1%3CH@E_%X
MFDW4$?396U'2#XWB+@Q82=C^ 4G6'JT=^.H<6!G@T0 A$K@24OQ#FQP(.W&Q
M'B!Z++LP<FG=L1L<<^<QDV_EGFGC%YA"JPN$9+FKX28H^^;'SS$-,]5_:V[.
M<9V_:]!9T?I\3YV8B7S ._TTK=9ZFX8_O6SS-VPO%O:]I*;B[ ]>>[JT\;/+
M%M%H:JG$6MQ2!?:6\MX#$Q_A9>K+27ZO\H._8XFM#=CH=!;V80UNZPT72C]9
MP21EO[/L*[S/AKA$F#)]]3"PM[-?@R202-P3>K;#5*+64^9[.[>T/.8[O?[?
MJ,J9N0'^R\N_=UKRTK2_BL@DSS+,U-N@/P0@52Q;'LK%Q;.."T 5[QF*_,P\
MPHAN*/_6>RSO]>"N!)4'<ST!.G2(3!$QR.6. Q.KW=NF\?4$SA5(.'RGCO)D
MAX=Z#9V"P?DM6I1-R,%7:"J]E?^5P%,V69#BGA)ZTW,F++H 5%[("!2 K-2E
MAV);!:#54RC>JR9@WC?V,W2? -1$D>?HUPI \<[8G:T, <B(%(RI<OVT FUT
MI>1V8Z$C@2PM 2CI#YZ0DR^-!A\ %CXSO@(&,Y!5]BKGJ-"+SL]G;^S&1,.A
MB==04<!^0PF,2W^P^**0Z&(NX]CIL+\$('%DL#9&CS_2E.X187AVCB_*Q(9L
M$"0[$)<Y$@/CKW/0BTTZ3OII/6UR\7C  QW>_<\ ,4AO951/.IWMYWKR/&VS
M"&I7W,$T2RZZ]VD^GV1F72"A@K&J@]2>#Z=GE9*E_*:6AFA!X-A=5K$_3"A%
MW=!]DUJ$)0&(AAHUGRBM8%H*0"ZP(_,!6J6D8$U5MR8?5\,LY,>Y;,.,.]&T
M%5+1^,(AUAG#5C.FQ71+KK\JB13C+S;FE$=^LW9T)OL,O2"-+F]\>1;9HM\3
M8O\B10WE=3(5_^5<*JL,6XGK;"\RYJ *<*SM^SQ%PNE^OA9E8A7V<[0A6YZ]
MG^',HC-8T0@$4XI&B"-20[#'2<[.@-IB$^0H%X4H71@_F6:?==U1.-3#S,IT
MEHPA(TZ>'5IT+NGVWTXW(7.G#[VSE,XT=E;2,</KO,5)$57N/8OI#PPT\UX3
M@ CFWVDM??>C<IR:/U$8E+67587<]T"]%#"M O]LPLM,:Q2 >&J>G+C?!*"$
M\QX"T)]^E(VD^/_86"/_]QNK$V"@TKABBG>$<YS,!8;XOV,\*X38'F[-RR[=
M4*&^E7D*?O6G "3!]2KBY:PW8@\_W?1R1'J4]\KTMB!]Z*+\-!\>WNT#X#XW
M&(\;9S=:#/F2NRYTNUJ%Q5Z\!G=I5E)6-_[4%Y=4.N1XOA]QOOH^0='/HKE+
M)H*4,LTP'EH/HG3_(P#!X ?8&D(APU6BK>YABS3*B(1P)6@&YSNN,RAON*IY
M/^<,SP@GO>!&)4O&+C87\;<S8L<;B]AST8Y5^;?1T=N7/JDP:U*4;3,7!C*+
M;#(S"ZY6*9G!_)4,G#U*4HA."CGF']>EEG6$FPG$BP;<3(FCZD)#2&([,@(=
M!C6WM9"*C7(*0X,HZ86 .];O9&WZN%*Y1D7HTE5+G<,L)M5YKM>I\_G)2D;[
M^DUEQ<=@Y>\^1^KDCI'0S6O5+=KY6 _K^\2^M9F:6V9Y2MP75FN!W%0!Z'4]
MOY/*L%EE*Z8M^]'-U??SN^$D; ,<PAZ]%X4@$O9JXP-I$-F%-N^]]T7EZ\?U
M^NHTZ"YVYF@!*$A?+SC-1_.22O<YKZ/>BZ6[.7G'_2X[R&P4MM(_)19:0NF%
MIETG7)&X'U;%E@'&SU%5\"\"D J!K0SEYC7R#Y\2@#PH'%LA4UMG#@0/) '_
M8)6%;-U;1(@;"#D#.%U(?@A)0E!ZS\\=@2\3.(K\9DJ9QU+C)'@D?E+H/$*=
M+&:75AGA06>[FV6^ 2?9"1?YI]E/7 AO,*)Y1H7HH19QIQ4XT9D-;]PA,KSA
MVII'59COW;\L-5YN:=P?5OS62^JM];/8PH;- N^ \ND"2][5:8C\T&R8KE&7
MF4I*L(ND /0">JG.2@ 2$:JD>B4A%A_H(29PS-%42V?L;^B*W<1-8BT,7 =?
M9U>.:S*I;_1M5"G#J*-X*D]OJ.R82!=.SF-3SYNZ;[&MHV_+MP#,36^!G3("
M-#;BMW_RJGAQ%"1\F,):9U_S8':P'K##D).K>\T+NVF\^P;A'W/0$0VN2N45
M9>1^?24Z]=C"(*LF-;K4861!6T?T=(*I>Y"'/Z)P;FLD-<4?$03M<EM;<G5T
MH94E?TVQM+VP@#M47YD\WZYC'?W<JP;18JK9.RX>>WO]^AAR?MH[8GJ+>]I
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MO9=1/9!YI' 2=@,(&H9JPK\&@#OJ[?AYWD=?%/LF7SNX=UR5L16Y28EXT?9
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MC=*[ 40ZM:1 WV(L)K>7O!]X(;16#\YIH%_TU5<=\Y:RH##E"O'-^TM)N6S
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MQ8F(A#?<=*#-W</YXK_33N*N^?JD3'&':5WWUY,I[ZD]OO!SF%676_^']"S
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MQ&%)P/( QQAS24=X9<RK"=@PI9&L_<./$DV5KD/1+&XVDL5(C.QHGV-51>S
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MD+]E9E%;,>9X=(9700-Q#EVDVF92[ G57@+*H4O.'#F,#$]HUAZP"&P%\$T
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M;B^V8,+#Q 2'$UDG<TYFQ^E59F8F/.1*BVJ]..(0JH9G)9XEN%!WM9%E!A%
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MP0;^A&*Z /NY@NO(();.9:&PG@V)_6J4@Q@8H_7!?"BZWKIV"9M+ZWZ. T\
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MII\5-^H'@TH<Q#M\1E-$ .JG%WGE^#$.HO;K95(S0 V#_@&:2Y'KR>0@,M,
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M UY!<$1X6)A?WNCX>/<N- IE+#H^(*_>DG-\((-ZG3D<%V W8-&W7/:(,>V
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M5O_ZEQEE(WNN8DG/IV#L4ZA+?% 17O8[@5F"(7_>:V7Q"UW$;@G>=NX2=4]
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MN!=1RJITW^IFZ7KU<'0PH]O2?@"14>7A%R+.]CL-!O$L?(2A-0YZIY/EGO[
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M[/,O9+KE$) )=-F3/0P?_*M;LSSD>VX@WW.25E[ BZ5A@'4S:*41EP!^.X-
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MIC,"$G_Q41T7>0^!11-H6UP7( !U9<LOAH_Z\(F/6OB!:(@+)2%?EN:V+->
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M/-A5R=*UW6 9!@5+V5HP*_;_SNPR1^*S.[9%@::[Y#E59&T(-_TB1,1^JU/
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MCGX0W0-VD^F62-P(N1J^=))]&A-:FZ'T"CR)X:/O7WW,>2@EC9+^OJ- CN8
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M-%G*9[A8^>JEW;[@C8LM*1G:PDJP*]97P B#I-W>Y0_=,+?IJTM0T-TOQ$W
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MVP=VUG6TZMP.(!UF.<S*="081-!4X$*L5ULTKUB&=\?Q#"!VRW='+>K%?%\
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M& %E6=GTE1T.1:U<,=+ Z@*^Y!?^M'?[$PBD=R\6]=RKJ8W(I8R(22;N J'
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MR;,7WC$0S/*A):DI%T%^S"^D"CJJQ?&_L??>44UN[[IHEBY%5$1!I).U1$!
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M KX+DC??PN>$D259-Z_S;4.V=M /BZ9/+U"J\<L380#:;[I3C22!]:.WO]D
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MK/M7F(><U_SP0NF=?M\>6;&:4P1I*6?4#/".;QD2KGQH[M\X/;I,G ?+"V*
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MY7UD.03Y1)WG\22/O(MU^>:M,[\:7M41UH[-F915+4]RJ7*UZBPE?^\CCO@
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M)3P)"Z0BC\N5/"JK("Z5O>J$M]YCBT9V.&0I'W"ZM3CX(%#17 I\TK,X*^-
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M=.$^_2'H23IZ*9FIP<GV'W;O>85LE$!&S.)VWN6GU_*/O.&CG/C7Q_M29_&
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MP;[V&FB:E6+]5;P17O?EO(>G>RX*=&(J6%8:;RI[VQ1JD<%'5*E],27@<*?
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M-ZG563H\*^KIDL*EL[+&C^J8GMZT #'T1+#KY8$(BA04;J?XTZM'Y[>\QS+
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MU4"M*0_EO*U$VT]77^LI*2HS(O.9Z\CCE!GF>L6:OC?KP4:'_]_ITD1B$A@
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MT1U&Z*I_4D[/%Y0QOZ9[.\>EIDPU$&.<YMO;]=)L.T]:?6]G)A:.]5!_ +;
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M,9*IWVQ$&'0S:=J=?X@OJ7!@9]!I7:'Z[5^1G"K[8=/WY KW02OC7?V[-&*
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MPN#I;6\2\RJL[::(7M;"MC>,_$SKL<EFC6\QG-WGK[9F&>9.WPB(:M9L DZ
MY'*97_^Y?@!Z%H$X=PR 'UW 9;I0F[Q<C&I=Y0VQEN8LYDT))7(0&K+CWYLH
M8MG#PU=A4PS/A;A@Z3C9L[27;2]&M6C?)Y1>F8+N33<*5T8.-?ZO <&[LKIT
M_D&K(+_Q)H87% (J\#!]U I]!,V1T)N**J;"J=+P9JH,?9(@"F<JX]!EBFG!
MQ\?3CN+RW?("KB+<Y )P21HK)-C#C4*S3EP!L8Q:T+ @T+QEDG^_^CR.<<"X
M_ :CV"3MRZ=);XNEBDV* 5:/WJ#P;R6;T[4Z H*DY<!$#A0YB($V$V&IBT!?
M;A)V8@%)!E7[*)U\\HHQZD:&,@[2QH-.PS5F_;*TVUH.&S"0!CTB[;#\?I[_
M@;"N.@%%\.A4(>;\%TY1%710='>W[>)P.S/O-7U^J;4B!;\8YIR<W 5<_UY.
M?*4W+EQJK4"X8]BDJ,V74K&XZ/X4KD5>&0 >I-2P\N<G.#RS/L^'P'DBZ$)6
M!0_QV)54Z2FF6M&D+BQ%K2WLE6[N^Q80XRVLND9NA'5BJ^R23=^U]+== #:.
MT5^/6;MZ^^J>#/9] 6XC_M)2<YZ_)>D,I8WK5C#V!F<KB$I^O9 AJQ)%"YXQ
MJ"]6;E PR_@ZXA[BOJ4D:-"<D,3.*_R>#3K#DDNCH23 ?%@R@R?W@97_,U&(
M<,NJ Z!E%75C#GDGF!?,U&75'("N!J5=,F1&<W.43L=Q\56',KR23G3!M"P7
MTYTEU3<>IBE1]D=\/;GC@.ILGM+F"//[65'!K)RO 6$/<)VBVZ^0)'(-UO,I
MOE:K\;W0I<'-=U_.?4&3]8]!\QXANSPAFFLVDTPX?8W*1D\@5$["RF "+]Q!
MDA+%)PMD,3+X"L)J<RX>Q,L)DDTDE50<V^=\78FL)>WDX6C@77WN*ZVD;GBC
MUJE]SL^J1U36F_**J2L1YCS W\^9Q+K/W<\4+E7-6![6*<*U9\Z0#$#E[A?=
M^*T3W"VA!Z>S"$F<R%T?$2QHCNL;WH= DM6B:)-]\,?E@IV8U68U7-Z<<_]6
M43J+B\"P<%(PNI]Z"U:]RL6!IU+7P*V&F;RS3==(EC2I#:]3CL@!%S8;R'ML
M4Q3%/SW'1RBW":<CE- 39MOI'^HDJP[]H28T>8 I$>ILV:/QGN5E=4I *BHL
M8S.20J_EUDVSN81-(.5#KQIO.(:DF#/F)L\GANOUJ%7#<OS-,8%:$?3?@R,/
ML8K:=%T]+<MOQ?H8FYUH]?6E7\X]YQ$K=4\Y?K6'K, _7.-PP)BIU?,!=:N-
MC@]>J#2H,]IT)]CNCP_JML=XYS1W8[JP?XQFO EF5:8N;RI3%EZ&OP9Q-D'G
MTA>N%Q&VF$B-.TF$3T&6[MN\Y-T0>KJ6D:Q)6%?5K^\10IPB'>CW7?X;,^1P
M!T@X\E QGPQ0^@S],S6>7=<Z%<XX33KJL;]"</<2DVQUWTHF=OQ P%2$P=$W
MAZ?*?,6H="9+MW1GF!8_#49O$U&SC?1>8R>FA,JD\WS'!RKA9AF6_+1JLB1/
M(B+;;^=AZ9\OB'UAA'Z'S#='O%3;Y3T87Q\NWEZ.$10^/?[H*A>4V#C$9#Q\
M(1E&IDO&J[(])I4M=%BA%ISZ^@3#S?/G5,6H\@NL5?!4->2_-)YQB-.EUH>?
ME!/BR<VL@L1*4]&;,H+PZ"5@+0G[\I)A4 T6M"%O!/6XN+N+]&ICV^,\RJV"
MNZ OWU2ABJA6K=F<,*-7F#W?/N_46YX-4IS; Z5_$RY$2G!U]I]00J\AC.GR
M8G,,U(Z,R] -FS*V6J67YV" >4M7^YPMM1NBCJVOJ=_[)$.)[&?O,_WZ-<<T
M[2?Y@0^.%Q+G77(L*X,.R80[ZV>\XIS6JB*S:P-OT;4\BF2V2$R4+WMZ]$+O
M>9G#%Z3>6BH%H7>88*;K]\+M+$TKSJG"1N+\%Y.!/ZF>1R8MR19/'NRK@Q1A
M\@9(";3FO6#UI1ZIUN+5<>FWR$KZ3!8C46 X'EE!EFN&] -OI5,[T^P,3[=^
M318TT13QUL+UR1,<8MDTLTEM^/W#Y0(P:DZ,8H08,[P9(4B0;9A4'6[X,O>>
MDR!@:933/=YQMOG&NC5<2*SSC6<]@A!><KL"J%BJ>UKI)GIN)"$T :I4T#>C
M^Z@Q)1*U1_HYH-MP?YRW[XM@F7[L;<>JM,-BU%T]WH_3T8_YRQC*68!/[Y:'
M3PK=3P*%R5D$Q^U<8.*$JXLCFYD_N6>Z:CK,N>/:C%V&;7+RN"R1Z.'G9E\^
ME?$@ZWQ8P::0 [XJFC.$"VTY]:74KUIA7O7D2,2QM7%$=P2BM8OH9=N%#NB[
MR@/[>45WRP*Y";P-_#I(DSZYDD^+U)Y%%V*CS,*- @7[7NG5]X9(5"4>YKOK
M]P:^N'H5$_]\D-H%2C[%^,Z10YH3&0)R>^]7;X<?P[30+HY\X>+$_SH$+?!F
M%R+$; '3BO_'TXP'?U^P1O\3AQM4AB4/"2\:0)L4!$U@BY!@4'6+]P@B)'[8
M"U26$^0PBI1U]%M,N6 U[DLZI!)9I20-MQLF@;H^NSF\&*_;30P96GCQYMO3
M Y-YSUE"++:JSYA>M%CR>FD;RJ6WF6'!DC"V<O:?AH@^HWD#63BO U;?BPH3
MRW,V%>5-=@BEX-4SR'*E+A7"KDC@!U4/T"!#9%4F>?[]S+B+O3M 7.C  E/I
MD,= SN;3+8?X\)U^ GC4*$0I,?-(^J?7(TZ#L<'>QR%S&CXC>OSU*]Y/B@IK
M55C5K']]@&W6G/?LS@7--V[L^6M@IH52<WR+]][HX7GYZPY/Z!F2/V-FAZ*%
M!H7E@C#=(IK[//L?2NH_ W^JJ&_Z<T5]\5*!$6)MB9 F\F<:Y,HSJZ-(PQ^O
MP)\!V0#Z.A?0L9]P+YN\3ZUFM<GN40?,6?SR[V.+)&"-R=;<9_UHB2ZS-UZ8
M[L:KV;T^ABO;[[_\'NV#D_*R)#@^]I"=]I;=DU\GNG8G-F6+$>Z=0)K3I<XB
M.O&2"XI]9;?N,O?1]W=XDZ6GLNY8@=\\BYA7"!6,A'A",@VP9+[P/%"QC^3Z
M>IR03XN9&.8YWL^=S(7\>9YUA4$F.T'[@0,YX=89HI]W9.%DX$7P3><CBB]!
M6J53[JU^N?PH19.I4Z7- \+EQ*0?3]?V)SW43AZ^[1U_X^1AAN[B,0=O:V99
MW(,7839X&R^'%.S=T78LL93V$<XCKT=L_0=A!7TV- "<$VZ%;'FYK/51![,H
MX28FO$3*;.B0E'"\(12WU9FD6]9\AZ7CE4?P6:5RT-G^:4P==YRW,A K<*E\
M,-#DF&%XS<WQU5CFC>FZ;Y.G1[I[P^.FO>AU"75I"%9 RXEB+@^H?6#E42?U
M^@_H_Y+9WS!U-U7JP2=*R84FZ-Q NUWCLNH35QL3#!WV]&T+A54-)- \C3;<
M[&L;#-MK-ASQ!OO%?'Z^ $$?=UX#7JRN*BZM>NHF9Y7)*L@ 7,:[T]]XJ\R9
MQZXM(O_:BF7N)N';28H#OK^(496]*F_SV;F[H5U<M/2K=R_&DNX64"_RW+*R
M1G-TKXV2=]SN[_$CC.QE2E6<];&N9E<[U)Q7MZ<Y437LU&L#?M!6]3T?UCYC
M:NRM7OY\]SG;K;MJ:G6L3^I.9>4[7._$5L.G-2?7[?N)!1&O7-HJO[^TX4@*
M>@=."8W&$S80&L^)4:OG'Y*D^YU#8\P^L#:6851ZRB?@K?R+B;Z!'@'NEEF7
MB+HY[A;E+8R>=8LZ^BFO3=?.MQ>E7O>,Y^Z[O*_J?/\"\8M5NGR,Q3Z+^H ?
M+8Z%#[7V?[K4WMX<?\8F43=,?H1-G)X +A(DEYKC6)W^UCQ1'.0GBB6;!!^L
MT5QA^;J;I,EF*I',>5"BYL;[M+QROE\ICV8=L8:VEN^$/V>4T+2WEIWH%W$&
MA\OYL+]&;8YT7?Z*T*1+]E)]3U*XCY:<W=S$P\&'D5WAB1G4H:8^7"$-4DSC
M:0Z@)^;XR7U+XZ@[]_6WM6?P*5Q*->:N/YC83W] 4NP38J1&>W&\A!RN,W5]
M31I"5S:O713]3%F7I5(MOV\L:9/,)WEB6].AF,6\GQ+57/YIDI6RXJ'=QM[V
MK>HMS[_W[*KUWM8B<+D_W9V<0.!NXC^Z^L1]C7=2>SW;811X#\L_B=_^)-[C
MUTS;V^G75BL_.C1B9H%D,LIHZ;\-,#6%NW!Y!N&SF+N (J25!G<0I$C[SOFF
M@]>':]U46;R@6E<)RX)NV5>IK$U]S21KN2C=<<VP3Y(@NS)I_MY6=T8!I48_
M*:S H8&_0%OET3%:7RA_[8-#LI_;5\G@$(-2@5RD,A$.^[J!\YUHFYN@?<4E
MSV74-R>=>8,SQ/3\28UD+2D#WA[&GS%R%.XAMSEI9PD"+^;Q9@FK(3PMI_>#
MT\K6.>R]W@WO?0));WH4579>6/8E26:0DI2(&EH#3RG<?D(L*R]39%5FVCE.
M#RVD8%QI$!+'/@&-BQ-_C"\U2N[[DIKRFEY)[*#V!]T+=%^1E=[ E^FGW"4I
MTE1:I-\VONX&?7[CMWU^=/1X@K.SS]/T]U*"@#(&1_!T/NV#;+<;1R=MRYS=
M)2N_GKCGF1GCGJ/?\(KH?"M\6\:""^R(6!1"1WD.G"XB+)G93X\L::S[@N6R
M[I;I\>Z776*M)6W@L:N*NMR2N2-E-WKEE)03K=L#OQ#<^'+W A6/85:"OA=3
MYVTH^-O.6R\T!Z3LPOJ= QB?IHV4S"7?59:TQ .>DV\<DN(2\X9_%+AO.;PF
MU+Q3G4,(J?\XD.-DGS1DKM[[*:0;>KQP;?]HK:$[(U15;<X:R3<_EHK5Q2@O
M8J?E!U@!U!':D)" '_$6].'Z:"K*5,)Z@"SKKHE!L.>A?,(.*6G;:L>NB^7I
M)$M&B^]&!5\MHR.^+X/CSN>-D?58=WU?%(+9W;=YP5VQU6??B(X5=#\9G?;G
MTM3:]UCM?=G->5ROF)GC/)GQX,G&!VQ#)S=!+('.'2-_)2"QLY_P=O:&.M52
M]!3P;FC<X'MYU)%'VM$2<(I+-I47L:IC',!,OZTLKH)-],P*_VG'QMQEGT.R
M^4]5UHUW%P-])I^PT'/.DC@0L*1IQ?,4?%QJB<-YX[OH ]@/DP0S,/05M%V4
M9+*6= VTY&?9BZB0SL#!Z!1@P)A3B;L'8\"[:2-4&9/=)[FO+_KN]6&MZ]**
M2'P9O+?EMQ8]M6CGM@+B9L*HX;X.D3ZA MR]#B,C9\^NZ=_3]I9?8Y5D7?6F
MU</")NV0U:<NJY_VVYZ'==2OJ8=::K[:Q"3N5E9OB#?VJ)^Z. DZ]=)&_[=>
MU?^PUB(4L9MW')[#,206%D"G05,^#MZT!42Q))F*8VZ_R,M!6LI\:T9[*\D\
MJ']SV\-,,4IRG/NA9<7AP=ULO+SO@KN"BP)W:+7RXO,[RG#5"[?(=C)C\LV;
MLMZZCFM=DMO*F.TY@O*?I:>'Z,[=^YEN;O:^4XO*_-[RF;_?K5@N"L?U4:C3
MT;@."?@+OH\#O^CR)4LCH/?C.$+;WB*/LNAL7(*IH,&K8;,V5@$2PI/QDV@Q
MZL*^?C;\NZ'HZEF <P40R"*8L.6M-F$%JU*,4H9.92UNX1W^/VLMHMEH4+D.
MDMV/6(J:B1') FPW68FF1/-EN"KLRA8N!3S#XF6M>^1GY,[%;=8NT6.!CIP-
M=WD/@L\5S""XZL*9*>&54OFHL$?=+N 9@:6H."(M<K&Q+2P^T)G:(?3SL7U^
M("0L1Y,4Q-K7U=X^?D.V_,'SXI#<')_N-]-AE)&T?\!%]7_&12U_PD73:X27
MR$V30@*YC:6$^%4[[PIX@[R?9,Z7J,: A^6J)6J.5([GNJQ)_*,-<B15 >[2
MCWJA8 U7-*]L\*BY^WZ'SOPSLLS8_MW:Z*Y00I;U7:Q7PZ?&CTN-S]K.@J'X
MTORH].+A75W?OPIZ.;<ARM.LMS=_7[GB]NJ=ZP^MN')(<;7R"\77RQ<7$(LA
M Q4=8I2\R2^009/)1K@36)V+W)(S6M)KT>$^EQ!-EN&K1-Z!=TE+619:JE^&
M@LYECB;V8L!;"..3+;L2_(QHM"NG-P2-N^_)5Z6'^F>S*R\^1T=4M\63F*S6
M[]U/1JS69:SSS!EEJ&A8B%'G6Z*Z)#=8J 4:N4=9I(?DT/8V=3>F 5<7+?G+
M8;2\*&["2.\JKI+5J2F(1!@G^8-3BP5X*Y>DCS#.B->.ORA0U@?[$\#X-PJK
MNX<,=, ++B>R\B<>R7$PCRUO7LWU<J@[=\YJL>14ELWUZ?"T8P9B5-$$:[EC
M#(UX78:8L6 #*11])V,@[)+C UX]!@)A*^ +4'!K=:<>F&QN@='!,WWL2DYG
M:26P7ILL$RS%=8L9H&\BX?@J<%'Z>**)%!@7E@M&\9D8+QX8=[I]-I.!7V^N
M5W((>'GIAC:%.XY/RZD #>*S2Z7.<'^,-R, YVLLW:$L\W#V)@]9FZ@'C@S2
MX^C!2"\+F[CAT\5"JQ#-7$?9%0LVI?A\MJD8A1(=0&C(-V!<@;#P'H M]0;^
M;$;TO]4*U)I-2O,]F,80  [RFPHV<!W )GYDOV=- J]DS-.9(%U4393W(>\Q
ME!Q7PS=;9>OZ9P.>,2=&G<ZQ-HM1WG!C_@SY"V9DBQ/&H9+[]OMW,<KQQ;%(
MX^*0\OC]+4.#I8-#@^6YDXS.JEW^%C:,XO1!/W;0.]%UZ+^G=0UT,5LF))G>
M6)J-F]K%<"JC6@\-"N+\!X<6OQ,;0@GQ;NR\CLF'^I^P'GF6 X7UG(]DQ'TJ
MSK+Z^AR6Q/#)7Y66BZ@X;FSD!U,>OK9G^<!V/A'"^O/-&?K?RM;PY2HTN4TO
M@,HD\-INTX_@S:[';2S&U%HS"V>=5ZSNDVWTK$<\ED!5.U=SG'-&\#3DW,)2
M8T/(&YO,+U_FHHJ*\HJP&KWSS;7V[TRZ)(V>%\;&+]#SO-L'71N'-S,+!B51
MBW*"TZ),LCZYEK"M;(/P*+DQ%9M<0=T(283N[@J<>JPHB,_R2OQFG,#@4F4N
M(>3MI4^J/'MV]&++G._>']+\XT4._F>\KQ<:",K>?]^,P41DAM?8VJNW.?AX
M;F8\X*ID>ZZ*BW9[.#;RWLKN1X:BO+ <\UA$AR26MO!-I'M =ZL[@A318[)J
M,%#K(/A6D^7-6@:9<8E;@MT=2]VTL;-3:.A0&R3]!KS6A2]?]]B_G[#ID\3W
M,.^!*?9P<.JRW%<PC9*A 5S<_]1*)FKD^:C&8RKX9#N\(JA.42'TFY<8=?T+
M6=^0CB!L7O#4Q"?:I:0[D)SH$?-@<%5UJ*27OA@E@Q 8,8K+O'?A\FOJJ3+>
MJQ=\AP4;=(*ME^_Y+X$%%8)NXTKN#@KJ_/?$=AW0^\KXA%=;%O;HJ]?8E-D)
M@4+=D8E*?'O#=#$4M:2(Q^I[80-4&(E1OCEJ@CH@_#%$"#MH"<;33O(F20$<
M=,(/Z&BSGK0.+;HFL@+>KU]U/!9TR3[)+:46[53]WG#Q@O H$)0\"'05![Q5
MXHQ!7Z,%S(:N[DZ+O3#&^.",$T>^*+5.6H-93\-IS3<+.%\;IW$T_#\,UU'X
MOW:XSC#N'652GI.'F73DH07/"1+H>VI]0#5K'>D(DB1VC@]7IE6/_^XJ%='$
MXBK+8^^)4>^D^X?T6H&W@5<O=SSJ<%DVF)*_5HW]]G0VID! .)-FZ-:22(U[
MYIP<E[2M??*+POQA&M9S_U?V8% AAS8"$%C_4/J"_KO2%\[?-K22 5"3#6VJ
M1A;1'DD=K#5P4V3?:W"=D1;/$4G@$HD5:?T&T&XQJI > 7GRI98*BA]1E[K>
MUO!F)H;FRFZT8SJ/''[JK)V@#11X&D1($7(_Y@$3)[;QJ*<7&_5W!(IH[P3Z
MPS2+;7](97S]YU(94%637KE/E>'7N'Z<]-@B+1(Z\ON8OE-M9.Y(XOP-A_R7
M8XN^U4%)US/3QZYO[.X=[8JY^WU/SQG"F4;I+SG5UHTKWGV,JNIXXJ[^WD+#
M.O;JDPMQ#UZV/7>ZH=L>8RS_[9-784)7%Z8=-V&]-/J*W$98::27!DH)"D'S
M)5V7?+/F7_-:LIG*HZG*&"FF=L[= DLBXF=C:#085ZETD!FQ^N7T3^?#O(1W
MKT\.]_@PM[=.^2E-D(Z=^]"Q[>B@[7*WX*T6D\U7!*U84<V7-2UN+C-13<?6
M:"H^X>=%%0PT#A4 QL@K7#Y7VP"CUXO".2=C7<T$ET0Y6H%7;E:Y>R <D=7B
M=N):K'<^9-?B]_*W&\=+=#^;07F*FI6DY4\Y/;5GGX>R_*CP+Z\1:X]3^/=Y
M$"JB$,Q^R D)*Y\@!:7(3&=HC>@^Z61(_YE3=6EC8M1FYJY1IXN1Y[9+^ YE
M<!LE@D,=6&V/5Y\*Z"9L&LGY]?RQ+'3"9JN2;<M,/.:>UVI@O'75#51+=[7&
M6L\%#/I5&P60OQC,>)$=<;$ J(Z%-FD*;B/Q.X'DGP<*A<<,;K_@NT7WI1SD
M-D84$"-[%8"UH'M5JF0SZ5 _<=/I2PGZ[*0$1C8GQ)#]0$_XJI4Q271L\Y#S
M(JJ,%C(8$9CB^NEL;>N(8!>U L&UUV/U]IZ-!^R>;)=0;7[@6&HEV?3 _557
M?E2.N7VB;L[+/,L+#"!S$?/?52BEY+C^RK!@\H0N7#Q'R*I,UYH#B(U?^Z:@
M&T:%@]V]Y8NGVR.4.S*UK7P*Y@<9!1.-G9T(5)]I3UCSD@"JCAR+W:7L2.Q>
M49)F*+OVU-+D.TDK"XG#'\[NG<,8E9GD$W@Y1:+?@'DNZV]1J,J7_"B$^W_6
M7UOV&Z:8RO--A%[1!'O$J%(DPK;CP7&"00UG&G\1,[\+010=[FE2T U , \_
M5A:=T>3OZY!$B=EP-:N/AGAY#!94#Q(];9Q$7M4;=-W<Z 7.M$$]:\+CEAC5
MFG0L$+AK"Y<WBE'FGF 7>ZHNXC\E0#XW-;%=Z$&R%-W">0-W<0RU2D:$T!4,
MRK84Y7.CQ^_[SE*V@9I.C$0S/N4V(_+^!9TNGT79GI[RG/G'UQ95WR9YWM/2
MZD5^M*!NG<?-M&=]67U9HY+OFKW4-/RC;6@V!N-K=D[2=(FK)CHS=I78VKH:
MN++M #IV(EYH1_I5Q,!Y-D9P"J@?)@-\4E%@W(N:3*<:G;MZ5.GQ/3H%?/0=
M$MYS;;YV<C]%TF=]STA)3VS#[E]^-N7NUB;J=D=K=E,K=3HT%JYKY*)EE)P*
M/(@_O^+.IRLEA@]XF0J:TELLN\+3]F>:>8J<VRX#J770-H2CK<B,$^B+TJF"
M=R"..UPD2L9Y8V6\;SS,\J)UQ[>8;(:NL^2<.%$D=0>]Z<NZ:*7T&Y08:*MD
MWI&5U60=WEQ*QL-$[A<5/Y8==^V4\,B:.?EI,>IRQ>%=!N67]Q:<PQVP:4[!
M"R/UNY.+DJ/3/FD'0_L02'6=\&.>@%->"*>_VU_YSZB2M.^J9@61_[&W[]?Z
M3@6Z&C9?R7GWP,#@2I6ZP[:L3=>6KXM\W/S*R931A*N0]DM\(>HB(Y;+\YP/
MAXZ\\3;1%-T!+AV',3773[R%,*+?N6US4VL[/B_L3L+64"0[QMPT6V;?W[0K
M;$$BS?+@.EN5)$N*S$=9=_J7/-CHR?D7S[BNEL#G8S()>X'^%P9;"*4QI[5;
MFT;P*U(+!AM$G=[EV!*"*MEJE,7S8D&R-D+7N.,EQ:*GL[[&JM.)-?*)-:)K
MKI)V#90",V(:9-Q&.K&],LLWL>J=B^]CB<?OCV=.,@T^;?)C%JE!CZMRB?@;
MZ4@NC]LBLBB:-YF'S69+D54A(_'N"BR+I"QCR(?+Z3(3W.37IO#'!2^^:4WA
MP_N^75;+!P_RDL2H4X6QE6&$RH3%MOBB>V7N_2/9'B5%;_D1+"^NT%5#\;![
M!FC8>+J@@%WWT?.[L[,N;;?JYN3*OD$_\L64&Z/>:2:.GZQ2)F]<O7:MD+'-
M^3[[B)0\_AG3:W82@Y^!T*,1 D'#B;S25H9FJ2O.JF72#TN<FO*,:JZOK6]6
M31W[^7/L^D,I'^=+RB&Y:L^:U<\?BSUF9V-6E]YMKMKMM3.^FW@TUC54^;48
MI8X'L9'0)IFC2&2["U3\1O(<P$7>R):O^\"YXZ1"J\#<D6<\BYMP4^?-1P0:
M.]KRY2CGUJVW1#\H\\@>+^K2&HY?RU9:5\A+#]+)%OR4F/RN$]^@43_:DJ7D
M<C+$R&H'-MC*6^<N%NMIM<?&6>.YH"G51/5EIBT^0C,^9!X@]YICHN)GU?;_
MV=]#$R=:A(:0C2@;/@CM$:682(W@^S'W,;*0K3L76->)T=F=75WQ4\\5<"J.
MVI6,YPU'Z/KX'JEVV]GZV4;UV0NOH/G/#]]>-NHHL]^V3KX0NT';0O?788.V
M;M,MN?G/<U:;92>9'EYW[=3#*=[,K-FB"*X WD5683LD!([@&2&6I(DO&%5:
MW@1Q-@:GA@84M4*A Y,NT5/RP>..IB%GM*$C.48S3F?T:JIOJ$9OCN>.'TC&
M-^]N R0^STAVOM(OW%OX,#UGM5:FS<,GHV;U.CV=_I9))]U."$8K;&^'7R=$
M_P30.)Y_(R3;<E*48;)#C*I:!BUCGVUE2D)H_KTV$UVPP>+]QC/0,;#I=Y6?
M2:DRS3_/AB62UX&N*KTO?,)V762P23?8^^J6.P7C#K4QL$W@P1W!AKBNX*?=
M&^[3+AOK,](BXZD'734<"IS&Y1V<OUJ[;"GYWMAIQHV>+^L:'6'ACBQLH9?L
M_\]LC32C0>5A*&.?8)D8E9\-(K0X,R+9S2I4C-KAT@)_N(I9]#O6 0S8BE$;
MX$I9<-<DYB,54E(1HU2-A4C^Z&P_A&2!Z'[3, Y*C/I8MU6,.DL0ICZNB8&W
MX>H09)</_1R?L_W\_W%6QK_T(LR"UWP2AD"V2VHN<)O;<E$&4TZ,JOZJ]>LG
M+NN^TJJD'UU>K(WPYG%'A[W!^16&X?T'3-,3SU<V.'S3.[+RPS?(/FW$L,7)
MK8Y6'M^8G#3X9-]E61=%WP/E8_:;9WU,<9[6VH6E-@^??WN2%AB:XV47\"J]
ML#-WO&@!,TX5ZI*;6&MP/O1;N'6X2Y3;)CLB:PAKF;O :QRW;W2+VL3"R[66
M)PE5):(H2YS \[Z17I8S)QBH3CH:>WS1+Y_6VYG_<<=&'/?T9Q72*M5<F0WK
M+%H]&E2:YA[T+59>+7BA_<XK]?,%FJSZ1!M[[@>03("V.2-A+C<27B,2VF-K
MJ.%=VYR B7(AWMMI/LI(BC;*WWT=(VVRO6*G(VP$NKT]O,+!<*>_]X;@Y \Z
M]R9S6JINQ-=%9)]/AM<W=!>S7+@GQH6V*R<TZ\'/\@\TBLJ]G6URAK4.:(A1
M8?ZEH4<I6%FSSH8DW J61-N-0$+0D84N>M8? B^+,P(940Q9#>8L9?O&3H!K
MM$/1OV[Q(]S+UZHI_>YELIRG_X3EQT]\.,<PNZ>(J[JQ,TC.VFEK7^*9-N>3
M/%%XI&U;]OFX.WOKFAKVV+^+A^6MY\\6!&H8[VJF/!_T"'72F"9/G,G0\$MO
ME6O\I,69&P'H14C<.4A2%3T4HSPY$:Q\=J6T*GHM:0]XB*OI*V$AA_5+E#O<
M81E&#\ZJ=GR3P'/U@57:AEO+3O:'V:?=Q>K%6,"\=)V/ROA*G:=O0,C>Q3ZH
MT:EL(:70=;N55/HYV2V'C7?$&K^N.:RATZSC8+;0@.01A/[P'*? 8'3=:99G
MXZU%!*T!%XB=4]5%5::M$ZH][OSD_ISG!DFJ[_B_E9!_#E0N:N5\I7%9$<DG
MHOW3W7Q2-6;J@PN[\<VX,]P3D4)-Z;GG1WT?UASRK\FY,AOPY%+(2<96ATF5
M+<[S0>2+&D4%B3O)JUG0FOE99VP9[.LS;O7;?XNO+)_?!TOGB5%/6N%:S/Q5
MPN(G,4K19P@LA<TGJN!!W-S!M0'G  H>1E!8\TX@2X6L&BK!1RBHQ-,_Q'YO
MXR9N@&+4DMCO7?M%-815UWQ>4ON5$:,L<J\,,%<#]V$SGC/AE=*E_XR.\%]Z
M 6X0>!>)4!RNF[/4UHU9/ MF$9Z!MR 7.ES>SYI](Y%Q"U2#518P77/DZT&8
M'P@3EE@A1M6?7U*_$2J522%!DL@M)P\@M'?ZUP9@O TOPMGQW^'J,L=8LT_(
M^FSFV;_H:3#CQF+4*B%0KPB<1PLWD +%J*RX?F,RI@8WC?L,C ]B1<=>AIX&
M^EK$J#6+[_A'8'-J-1[Y(!(V7DD?+K/ U*:)400$_(\>;YL087X ]TX"IJE_
MU5*$4B<JQ"@U+:$1T.D/6B+I:CYRG"H'C]\7H][>X"SZF1[IIX!I"VDBNL_"
M]WG*\#"\#DEF3PPA\I)R=!\6SL5+.+;RB!#E+6=N'+&^5ZK^Y\6H6]C3\"4Q
M2LM)]'SZ+\H^RQ=Q"-BT%Z,&M=S08E3>5GZ6&'6BQ)=$E0<^1M%%X>=8L_E9
M$I 'O!4S.D"(27T';4;BR1!NVA9WEB+<0$:^/BI&<>W)R5PDQNS#+0HC$-_3
M5+I^\ 8Y5H3NCV =V?]7/8OH%X3!?N$LZ%.[->$&ZDTQ:FY9$@L[($;-9Y?^
M(97P,35!HH\*)OX +C 6%KX#C\T@.078IDT8A*QD&S#;\-+QY_>#".XPRH<K
MSBWDUU0#\C204N\M>/"? #+_/0_Q/WM.]2^]_)?&C6U:)O[VK^3]J%,2+;B5
M@"\6>;4"/]Y06A\"*6<$+T6_FZP.QI]NW\E?E\6EWL7(D4+Z%)=;LP?S"UI>
MM=,#*%+C)1YW:[/T(JCG/+1?:)6ZFGNY>_I-%SA\>WFU?R^T3MLZ57/EW>JO
M.C\>C'-'[9^X7U^PHZW14RB<*"CUZTJ4C_\U9VN]9M[U8[0:3G>^@(UDIKY1
MIB+D+\IA>:$?F"Q[W[H[T(>RDG0";.&C:WMEW[?.%H7H=B_,HC<$WSG5/%3:
M\B,HX6N_I4-LUY&APQ_![:<:KD&[1;D*R^]4M9K7V*5%I%EX8P,R5IMVSCFV
M7LNTL6A^GC31&UEOW_7/>RF]+K$S7WDO.J1IZ#X>78R/F7A<%_,SH<C:ZF/R
M/=?/[^)='NT]=GQ34HE/B0_O;7L,B3)W %R.I!DUH&(G?&!4_O(B;7)9)DF"
M;SQ&[R+)\MD?4M5YY8*G/]1QWOR@R&S2&5[%R]XSUGW\UEA?PMY+O]IH\B\[
MKO9\ZJ6W;??5/<YV57;A<;,T TD.]N(-?HUU8M?@=*PWQY@E,T$$26AH8\N$
MUM)4/P"NQWFZO1.C*H=XGMTEGH/-8A3B" 54>-FEJRUTV6&$ 0P[%@G<$"JQ
M9LQYBL&2P?M:PF3$PCX,P)[U& 7D50^PP)V>%<8F0Z?%*"]W?J1+1)=S-%$2
M6L\SB(:(P.N02S5G"_FR7Q-?0 <+W\=7UFQSHL<$#!2W<2XL&[2:,%CC^3XB
ML<V$KM!-W6"3HLN:;!UTX'!??1Z\GX8I M21./H!P@]TPY)(KI!0AK\1BMAW
MYZ9NLI9!^UZ3/W/RK<I7#L4/2*UFC#" *)9<@'-,DTG\ '&#EZ#PNLD67HHH
M5[D5DN)>+#EI?J'T+1\=!5F^_"Y&732=+\:L.;>WN$[F?E*MN[*7;2)62WZC
MJ]>APF%=6#Z?47 E?&?N58<:BY=7;P_>:9K\S*823>>I7_3"0C[^_7+?H%1B
M8CA;$!PZM:6.+]7G6(._1Y P"EF7$I96,X"+,,&RR]#]]PI23APM>9BL5,HM
MG3QH8ZDP%Z%2QG!^+%U9>]ON[.]K?;@\,(G<(',X_H8COK.=)OFH[#HISLK
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M8E2<ERB/-5$,(M#YU-:L:1AA,C<:6!-*1?#S^Z-GR6N6)E*;"2P)U)2ZA4U
MQ576H!:A*$B4:.RXQ)!4R)-5K&GE!MS$9DRRD8L9_PUP#WI%OU3]5SU%QQ%X
M]8(8I9XON@E,M,*(?8PIOF+W=2)\X&$^3BA-%Z,R\KM?0/) '^5'F+,0C\2$
M O@;@G&/F&@!8\OI[,T2HGD),>K<:4!T\)=!GB6$G<;52+)>4%;\3W($R?_:
M-L^RWS#BIG\M3?C7;HFD8WAFC0L6GA,(H/8\PR,B"4I:O^SY/'RTF":ZV8^;
M_1[S5HRJI<'*HG!-GFT7[C$.-+*$3X0*SBWMFM\1H^SEJJ.$3"3>/WZX#_[
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MV/4JOS_28B=!X+)4O?AZ;=L"@""4<@^. (U8O-71V;>X%6)4-4M9J$)O_#H
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M^XP56C]2HWAO L7ZH'$ZP+!+Y=DP-'\501A%5D)I_+)?=Z@:VK\QVX$6BMS
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M-JT/!2'"5GAZ"Q(XOXRIM?#H,$#U%N3KO]:2Z4-@KBKL2_#)<!&XPSBUJ(8
MC@AR\)B9<)T6*/S\&>I"^)G<*%E]@ Y?NS_R2"/SXGR1(#K,7B-U'']V3Z*G
M>,Y KLLD7UP8X7*;.A4WL7V'@[<:F<;3^<[Y>N:BO/7TS%3HS2SC;:.)0@Y*
M>$$"-XK*N9DU@<(;>EH3N>I#E O0GD>?\M$>1Y&M<UHD5(E#W_-B1Z.O(->&
MQCR;C]?.-J:^A/[0$8B4DF95]3AO7NRT;I:ODQ.8J&[NQ!N(XYPY'Q>WJ[O7
MK)]::AKDH2*1+BJ1RDSPV?ZIX5XU@Z/&9"'C;F.R.:+Z4S1.2W]OB\Y-GOYD
M2-AYH ?VJ@H7"N9%OI)E]6OYZ> ]1?88+;8@:K7.P"0/W1+J64C=+)-=IM'*
MDC=*^7MS,YL(-23K'S)#B6>D[E-HEMK1XP1'IP.IU5P>#=/N]HV*K1*J=?#&
M:G,*LVK[3/\J2?Y**V86?N<@W70M0G+;PDER*IX[6:D1<@YVI\W6H0OS99/[
MLR6?@88OR/P/=NG^N;%^SCRDLQ=_;5;D/FE"V;<_R.^L\72F"_G;)%]47\71
MI8XE^2!G78[;6;^*U,(O1%BLF?I[7%[O,LM.N#'3?BFF("+?ZE(,BM?\2>O
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M3VMJ,$ ?F \I3*\Q0)KM@ ?P ![  W@ #^ !/( '\  >P -X  _@ 3R !_
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M!#EU>U24\I7,Y2LW,D$^M^"B;2*FV$^%TL+1C>;P ^^@+$D,.IL'/W:X?XC
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M)01BIX^^@7^  U(G0V"ZAZH!$].L-.>".#/6,]P@C#@&- P#23'][H)H4?R
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MD&2%BT0?[HQ!FHB@2?X,\$<07<=KR1:&%7D.V[>J\AGF"NPGI_DYGLRO'9Z
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M"D;Z^E=59I_:^:#P'HQC&1X+(9OT!L/)IM-C!"M@<@9^!)EYBF;_SX]QW&?
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MZ[?+;I/?Q3K9YNL&E#L.Q'>ZJ>[>X?:4S#N?2M.00MDWJ5^HD']LZM/9:UH
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MB5)GM.(?P*>YJ V4N>F[X^UJ=(/QUAM%WI-JC$+ NE/SG@28N!Q^[_696F=
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MYD,68]?*+_LZ76EO>3OKVAD@]Z$FWFYD^<T]YQF[OX\R2MAQD(AM'(.3;UL
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MB\FC%7*,>[9GLTI$?1[3Y#6"7+**,U/U84Q.ML?].0L0:6?I@12M[J%85WG
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MWGE?HIQA@RYJ6CMV(K*M7D@JS59>P'U /A#78I&=;8Y[B^[49H'N0J:=J1I
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MYTTO\^%LBQ%UQK,O2T<"\[VA4FU"28>%/'^@O4(4:P:6+$Z?@/Q$:I'*\1%
M[-)4NK@'4FV HFU^BT=70(%F,II_$>H$)&A KY= O3:5*RN$1K^17'"G<Q8'
M.*)S18,$SZ?[3:8M6&2<+A&L,L\UAL_9[?L7K]![?M_:\(H%J@_N2)Y6(5KT
MS DC9N8S\HE5?P!Q9G"[6O)D3&MP:*6+<ZZ"9:W#[OH=:V)[HIOB;-#8C:@O
M..]XWE<1=:6]+%!9("8!J=8MKI;]\YOB\5 +@62"O+I7',&#3.@U:9";+2SQ
M#%HSU*]^MEBD%:H@77J@GQVA=JM%K7/!S[[#)$.R(&?!I/+<F%^*Y;Y-=75\
ML%^(D<'AA:JENMV.MV %8(J,[L1+,@6! :)*LB)SDH@7\3FS.OI/O$C+R)9E
MQH+QY-.^5X[GQI]>,1<SLS9_E5X@9%=3WJ_(HVBQ?M_QBQ:F[L&IP,RA5(&7
M%:*O+.;+P-&5DJ7.(U7&7Q*OEQ_('#BEF#UV)]NHB4LC!<]K%;F*5TZT2I)+
M3HWB+N"$?BBLYM,GOK.))S?>M_#C!U.56$C=!M5/O\SGRE L5,K)9?!![:5P
MY_B;[4*N/7[ZK_X,\5]H;4D2X3+,5"N-=3Z,EH0^2E8,V?XBE7!@K^\6-2 K
M_&G@C6& 9O$B_Z[5HPC?P2X]E0$(YJ!M3EE!*;!E\6&EC%)E8H_;A=3&5>.B
MAMGE32TZ'X9J#431('0PQ8A@$>LT%*$Q&.H"E%4BEB;6.Z:CFTI\3OLX94:V
M@M\ZSUA VXA;/*[*;S-1(FT9W@75*5/^2_7WFU,,,RZB>=A06CNK/E3]IMC>
M0 Q#(&XG0.$7W5>_%CF.%R7TD:0O]H%C>PRFMN^5O&^R-,U2:SUC&? +@,MV
M_WP3YJ(L_U3>IB2A),8"+)\2'OF>N%KXP\0&J[%J7%_@IU&YBCQ*"T!WRJ.]
MX=/VU!P@F5+0T:X&:!0!SKVG 0WU05A/^SE*6W2;/PMT8NL%797H-QSB5T#7
MGZQ?F;AC<*/Y0P,-6A+8/N'@:AOMF7*"!;H^#Q/2#H@"[!7_V>$^%6PO%(Z8
MM"L&\[PHP61.! +EME!CN\_5>Q(E$Y$>@R::62DNPR86RVI,WL]U+I-\283)
MCJY$CZO7-$KM$V]L5.^6F*P)^[ZR3Q.SRQXNFUI!_GXJKCJCG 5:R4=]F0/L
MD":_;QV"N[% IW<BV'N=N_& $3L5[<Q3\"3(,FR7+P,]O\'.AJH<=.U1*CL%
MO8NBZ:&)CK]OC\^5AE @VC!F5*LI"Q09PB9!T*/,<\PG+-!5'2_FJ1[T#B^:
MD CS@QU>A-<U,06P9_ '(Y;_\52P_Q_.=)HJVSD$R* W;<FIU#L,'/3D:KL>
M( M)0$%=D7JC%1K9L#/ #DW(G!S]4O,#TMT''?Q_L?>F44UT7=M@(2H"8I11
MF:(B(C(I,BA35 1$;H@CR)A;42%$B A(A)BHR#RI*"@H41$1F60(R""1640%
MF0E"!A1DB%100TDJ21?/^ZU^^UO=:W7WCU[K^]%_J+5(JG+./M>^]K5/G;./
M7DM"Q)KYB%$%1UOU\7&6<V-U=O.O$Y9J[I=U&0_Y^UA)-CJ/^ %R4_<OPW_8
MI"N;4IU[<M5,!']VWQ] %;H]4KTP74>*NO>V*G]G_W?UV_E=LJ6$:)*VRB?0
MTY%P/4T'*)HT4=CXV3Q4^[,9OBYWS%ETROG(\_/O[][*2+[/[('$B+*E\;S.
M)_B0'46Y>=??W\1O0:1[8GZ:XKO#_(-()"GI]=Q@VJG4O>+].QV7C=9#/-V)
MJ367&WTJ$[X6_SWY^N&YL]^#E0B6&4F-/$=7HV<"FU,<<6@$V=TKR_M4FT76
MW:5L1O[0*PPBW:1)& <DDRY; \FWW+Z6U2*6 P?C.:Z*++FU7A[QO[N"=S9I
M! +OC4K\?VF@K7_Z=Y9]MZ%8-"X?B;GQ81AW]_ KJ&YAWF.#^ZD@C!O>VCCI
MO<@?=3!7/5;35C?H/X=A7HG=N\,)3+)Z]<U"#H"[D AUC](LUA55VNB!8XU:
M0>/K>NRVD*1Q P>#M,T;!LW&M'\U:V]YC>5%J];WF*$VL-["5HT93[Y.]W05
MB.YOOG9:]$Q65QXS0U'C"]1N[GZ8_?'E1.BF$/_X_"C2QJ.%7AL_FCO-!>TX
MNWMC4-"CEX.MCGFG]I6^%%:XC/WUT^<LU7[7-!D(.)BKIW#<_7[DWJ:>0C3%
MLL"MN/8>Q[7M,O/K4BGC,;IR"E;$"%J@#?P:3GS;F"47/2<^!Z)3S!X'"<:[
MVV@;/GU^^E2VL8OKNG6+7G,1J7.0;!M6.&U8%KKB7L._%Q+(LTLX15)'D\^!
MVY.UYCXU"24/_BTZ6J#/7OCL14KS(QL%7!S'+FY\<+SD^7F0;.(_:3J^]O,"
M3%'2T'3S%G?[*=U-]7'][B8H6IFK8$+)>&3I_;,&\[Q.? 9S[/_5/+TT/$=E
M0[B_1E00RQ#J,K0Q?PRAL/WH6A88B(.?UC>Q!)=P6M3?OYX?E?GSGQ43QC0P
M<@I^VM>*$X0RI*F_RUK#I:!T";#:FMKIBXQ=G 08V2O*9?S9#A7M1_^(WX_F
M^O/EQ2?D)]*%SAZ)C#\OB8'2HLJ7_ZFM9L!@O\$M)."@'66B[*PVHFB7ZW[T
M%(*ZU?$2X,,Y&"4!SLE/,,1Y2Q$ M8@'7"5VH&Z)5T+S8!@WO8F:N.2654JV
M19)Q$V5(K=WJ0B4^./I%]Q-2AF-][Q^9-S?GKM$L7G_5J+_Z(,_K:Y-"__$6
MP]T?KJ.Y!"3I^L88)"/B:)6&*-8$-K@40O^D(^@3/6399W]P/NL].TM-%<N[
MF,>^\Z1TO]Q[.,D492K[\;*CO>EZU*+F$Y1-!>0"=KA!^67DD H0'1O<: +E
M-5'04&@9?"3=L4)[SX#-*HXOSGL(QK"%C\FM$2C(*?P3L37J<]&Z^YJ=@8N+
M+R9)^9GR[K>D>Y9GP?D;$./ED%S^ 1=A%8R #WJT()S>$]X]FB=([;'1.O^"
MX_#X(TZ3[(DOF%:_TIIX*OR3O?KYS*8JHRKO<[?/>@ 2(,1[2WCUE9NBI]&<
M8* A^E)7R-#!;6H**VH^;ME#W+WZ[\U@F6R@<GFUX1%J4R"#7:">!2L&"&PJ
M185FZ3&9&$UB6>,NDA[G)&5M/SD4TR(\K-96YY1L?M6\8Y#78,#]>X&@#)97
MN^X+?W^(1]8C#,>6W;DDA16O*43L:#<@ =@EU K56N'16=SJW_,W:J(P[8Q-
M\#;<ZFF*92U?5 623K3XK>*O(,3[U(.,6^?3O ?YR<SJ7+,:EXC7S@Y?7[ [
MULC,OOV_6>(-'X8B!9K]C5NI35OA &$4:<\_T47S(U."P4;(EG][]."YAW:;
MR"<@')A+C1=O:\B*K>FST>7O')]M<3A@ZH.#3U<$/S-P]MV/J4B']D@+EJNW
MW!IEL]H9D!XF+:+,LA6]:KY4; 7+5]>_&3-CR3<0BKV'82SX.6?#^=/%#5I\
MG6.]\,F7KWZ-^9+=!YYO\YYF;Y99-%ANL18.)*7#RAIB99.Y #9UF/JNCC5"
MV4896FH:H&QV.A]:(702T<2:,U>LTO)7==SM#/.7 /*HCD(.3^ZS*^O" &S-
M8218V?"[UF;L ,1*?W##6<= 2UC1TDG4 /L7O,WO[L",QK=@5MK)_P4?Y-="
MT6 71Z_],9:;GAA\?DOF[&&^6JLU8QWD-YSG.,BL:5&(V.[D&3RV'U.%ADR5
MQ*[) B2MK."#W1+@E"!O/_JK+D".% 906-0*/5AIBO,2*A1ZP\$@K1F[SL^\
MC1%O]LG1I<2[O=&RW\A=QR*+C97Z8;&4E=R BR9.C6I(@#E7[9]#3C>Y!F,A
MLZY]BV-/9'[I\*7%*!_1]=]&E"E7*%*X6SQ P7P))BJ\X6N7+&_7D;9_Z;V%
MN13W,+]S(GW#S';977Z]6NZV6WG<X9"2N7RCM?^B@RCM-#"B U8L$U3P*>G@
M;)N?+I0LU(.&_.I=K9VH3&M[\&<LN'BB__QY5<$7^"B8E63CP7%=L2_F#+&!
M:GFS"E'K6^C>6=G>#G6 ./-9ICXW+7!;6N"%5-VXTX_/)9U^?O1+I\;3'?RZ
M]>]GCE3</GG; :!:XNB+L.8\0@]-HNQ&?3)%E"G>RH+)&=RLYE3_=JH\V0,=
M3U'<7L#A<\<01!UY6],7$9VNC)]<^&PPN<MHUJM).4?]]*)]Q?+6$',4I!O)
MVP*R! <0YXZG=-*J.MH6AW2@ )# ;7\X@=Z$B0M_6C+;E>>%7[I?5>#2Z_KI
M=F/=+^-GHU)U,09OYC>V =0\&=A1 6D0 O\G\3QS"1!W$"V^^$-ZZ0[]3=I/
MYOA/S;\>1^U#53GTAMH\3Z7+ NO3YZ[8')7Y%LD;0]RR%_GE"X@DMX[P=6IB
MH#&!OGM.0?07FRTQ*QLWX&MPRG8[/#_U>Y)B7,&_=FA0]Y=#<D*PW5921K/B
MUU&;$U[%G6:Z[S!RRZ?TR-#%+9E1SV^3, ('T:L_HDTA<DXOH;A%CEXL\7NU
MC#95X$:;P*D=T"QX-?KX=(I_^,QE0(:%+C>!M9!L=66UZ#4<^H1L./2'E8BI
M8+2:*+&\ \7:,8+XG@;,<Q(*-S@?HCC><:1/O)UDWRHV! ?O&'VYHRA/0Z.E
M1UPCQ#'!H;9?JT-] >J1)S>E5J[?OSGM@,S3E:$IX4]6/4$U8T?KQ>NLD=YZ
M4MXUZO0C5,R:4"WGMW#;$U_ZXBE;(4^AZ;0ZI@VU@>2^U.YL-#]'/L4UF%<D
MG>#0XNG7K 3;7_<W["F$%E"J^,4#>?4]9T]_/P? :5C(MDRPR>IW];QPJWA0
MGG/=Z4Y1?G>SS-!SG\?MN'5H;:>"YH/L6*SR9UE=EQU2"3(_YV&E/6+Y,T(%
M:I/'>;Y?K'#W+&M#>'?"N#0XACA.,%C#S;IN@O!IV3KHBO!8O%/,R0S/7F/8
M%9QWOS53V79N<$DFS=P;>MB++WY6?3[SN@U.,",!8A(9[,<8T$T", U::17S
M/ 4JOX2B#V$/@:6,$GLV=7FF*"-PO2>IPY[.5TW6]&IMW-(;V]:"]ZBN]'GN
MWKY7&Z?W"7_<83]J@0'1A/M)TFW('<=Q"52Z78:HFB%//B:\1*H17.]3&,^^
M#:62I4K@J_UV6T=$!8=="OV3O;6U:M,_][D+#KGP!HO"9U8^EQ:A)0!W%Q'2
M88E68O!EL.EZ1)4'[$=_67R'3;63$SVWDX'1HB=BC>I7$@!%L83W@$YMZ=+5
MM?^:E> ;]/C2+5&1262[B.!=V,MFHD/37OF%;RO4E)()Z:8;S'(L;Z/2J"'I
MD 'Q/R\).X-NBP=H51ZQ-AH3UO4HGA::@XE_VD^.Y(=Y5H>/!=A@4 U;"$6$
M.L?'A19G^V![[@,RAG/UNZ?R;&C"A=W7J3;C"#YBAJG_7M,Y65L%714:40:U
M+?K^S>A*=N>OI<K"<EDY;D/9S ^LCO%===X7I"-JZU6S3/6UK^47?0=DOE K
MIF"MY7"QL@;B<WD&36@5,T8:NN+%TV(_A_-X+BO93@T4UX-U!LF/RYD=A:1Z
M#BN1C"T.=-9M6B@UMXUN5L?%FPTG^<U$?7^<_?53D)3HGQ]1DXG<:VJ'^7IQ
M]%235CLM_NJ'_B6!5N+XEUY!3..:O*#,<K_I[.H[KTZ[A/H7XK-3[_6,#;-&
MNLU+QHK+L43#.X=3]F-0U) R:&^.6+8/:=R\Z%F#L]!8W#,D =2'N+1;O[%R
MLTO]=C(0DOW(6MQ8E942;HW;$%C>5NS"U=KAXV-Q/YI@_L'AHO^-[PODP?O;
M3B)=1%*G1(1!91#P(2RB"\4+3TQC1@E@31NZ1B:9&JBP:VRZ$)4P]$Z=U?'8
MGFM$8X;?JLO<2R_GC#Z >>;$<X<:QX)JW)X<V8_Y(@'$.JL1S[1%!(V](%L"
MM&Q!E)U%N)0(35X)];'+F AZFQ!<HSCU067@X@05"7#DTZ U(5/ZR&!.,W6]
MC64!J:!ERKUOY:(.MM_M_BNOG-$MH7NKW_S:HN1<>16 =_.S8"U9I/.UH E/
MAYL^XNW93\$X\UV:T1H1M.OJC&&[#;*P)1)LI0_P/W6TO#U@%'&5C"5N8YJ2
MT@8#N?VI*93@[.3\&F;3#NFE'<OB5 ZS;%.66-9?N)*4Y05%3M!2EFCMU.1<
M[3TM);"!Z)&9"S:1^3/^I7>]O7$Z%ZW<54RB<N+CZ;/1MTCFJ'5!8ILJOG;F
M#VI5>/3%MDF <J &UAX5;D@]_R]V6 (("HFH,,;)8!?.5L).T]TU![1-H]7^
M7CYLI_//>K7;D0!J9![:7@"K"<6ROY A.,POAYQ '6\HGYV>9L#AX=KLV1*@
M'15?&>BWM0Z<BF>.F)<$N/%-;D5@-&"+^NIRR\R4BZSVP:5O/5\-O_SXOJ5.
MN%>&5_)?%78]J4U<QD)6#DYH;G*3L42%,O:CQP/@]4KBHPAJ5BXB&F%5O@28
M.<"5 T0W$'F*_#?FOMH[!!:KZ*(Z#TZ_:@\>#6:1]P2'7KR[9H[5T0U:<I)A
MAVSE&QYJ2M 8?20B+F=/5YE=D5G\XG4 ]6?-\H$!D %NN3[*RJ+E(H(D;-OJ
M[Q&S*,06;*/)I\'12O:1+^SJP5_V0YPOQF<BW..NR8V>C'?,W"Z5%ZV8>G?/
M?@T6>(P*Z1/GD"QQY1L(PT&G2@"ZT5!:<(/*!#5!@)8WDP(E0'- VU+K^,Y^
MLCF7JKH_2Q7-5/>YPHSZ(=XP,.[=:=SH.<A<F<B\^%+FKKB5!B*Q:?B$8 '2
MY4\(DJ 3$^GK(27V_-Q0&%ZF;5X#OOS%T&Y3X/C&FOHO(1'\PD_1T:5!JK21
MVWA!Q=4ATZ_['9J2F#OR,T_W7Z=@X'\1*W51V5D8E$WP2PC[#K-. @25I5E9
MW"_T&?[$1S515H!Z<;!6L?=H;:HY6MX;/@1E<#";<*,^IID)A'%%L/[!D</2
M(4P \P(W$B.(!9UX 4)K6$WTPD[C-"G#!41U8./MU* <CI9ENX75E1QND8),
M6_8Y]1>T *Z&@H[[4%6]J]^X[*#!#S,>X51E6D0HD1JF.G):^KL$&)T2R]4*
MEPL.F9&MSQ11!C$:OZEKH P_.J%;EKP3_%[2G=)H3*H;MODB/Z;QSDKNZTQU
MG0Z6:%L&Z_IM$3>#MSS*-63_0&7J>S6E_W[BR\#:?4)Y)B%NJ 5=@>5YET 1
M(;HIL^IM'<V8=3-E(2GN!@GA&CA-*.EKU2OIOXJSKS?^JGI_^ EJ #TL+5Z'
M14!P!FG,?CC@";P#K&E%J2)TT,V-3O:U;D&O901^4G,"'3J2_Q059O:R#H'$
ME-_8#:0"SL^:$IR?\ZKJ1,Y(PXD7I#)<]N1&L_1U8SZ)/#8@@IZL\V^GF(/$
MEG2YV48K*);;K4!2:K)3[2L8@%TG4!MGZW!Q9!/.V/9^Z;#"V6PQ/>)\/M[J
MVIO-GZY2(U<U[$]=6)L$B(.H>!9D317+Z@DQLU[I<3;27),4'-VQML FL](/
ME@%794-;#:#'=]AV%M!3+CK>W:KDP6AM1/KJ$:CFR!N/E)&O7TL%*=+<5"4Q
M*EB4:&R>P.:KS5$1&K62RC7/./GE#^96G: XL^UZYOF>>1L<9]0ITZQ+ER%8
M*KX5;+E!- .(DQ''R*6"[NG# 6(Y*N>Q]VG1/8K1]GHN3=YSE 5-</12PFMA
M#3ZQR2+KA#S))(*V9@:U=<;+P*UG%*U,<CK&M[S5*^!JF?\9Z'\P\E)FV@@@
M+PI=*$BF5DF<"P69\]QYGCV_X!UZI9VVUS\7)_@R:7^ZKNV:67I0D\TSPZS%
MRT[--AKS-0>KA]14&S7 ZH?%A)I+WMU&U8]WVF\YBII$<24 K(T(CY7]H%_A
MJQ\20(ZR%@G2ZFZ/(VWI!8E/0=IU.VV2B>]-?3D':KX/J:B#-Y$0''**/)PW
M*$8'#A5J;,[MU8]LV[@ZJXD(V8R*9=,G>%$M!Z$2L$7P#)(GDD[ZD%J\08];
M9"K[K=[DJ0O]J)9Y=8*V]=U=&RL>&[Q3SZG(N[ M.(&-: Z>M!!/7B/*H9[#
M*HF_:ML.1KRU%U!!1@M"^V2W'%^P++Z,;AMV$HQ/-3:3IZ[%X>TT&]7=G_P*
M2N4&:PUV'_6UXO8:9%IV!OW[\*@T+,*PORU7L9LS6J9?T1VQ+*PBRBR WF)2
M8%FAXS1-.4("0*<QJ*U@W.W<C150 !_=?%ET]R_YP*NWGY\QRY)^,XQ[O+=J
MG*][6&"OZ+1#!M'QJY$(W721<98(Z1*;3)@![S!TU^ZV0$37)[&4831B3SE4
M?*X4=J-G=?HSTI$)A[=6J5V$;.SP3X>YI*W7G4P>JN*B)H(!!)[+4A R"9A;
MWH!F"W'**-VTRE5#[?J-FR$B)[>>[W\<BX;WI3=[[0!I\60G#DIN9KN",]*X
MAQ$;7D&CA]9[7GMXJ'KR)W$?I;O\'0;_7W,RG2[B=<B WDPCH*N1P56.[J#*
MVNPN976"\@+3_C_S-^Q6?3D^<R8/4:2*X5IN+NA4ZOK4A"OT:_8G^(]O-<KW
M1>S5/FT"H]DX!1;S@5O>E0J >H$*!EO"&_*:T*]1<V7L>2:!VW&K2N0DZ!+E
MVVCD0=T^@_22G=L'&^7(N_GNCPE%D#]'+5Y[84_DTZ AKU-MN97\(X3P\K<,
MONX'DI>0YT6,J>J< L2Y+__':2/QHGH&NPX'_L."]$**7D*6$U,\^1=!#-6J
MUM53[*QF(XM9;GR;_+ZZ9)/U^$:T7HMX96-@>:A"02M6D730.R<@B7#JX?9;
M;V0X6$1E"QC#E[M/WD7)B-\SZ'Z,/*.FPW_0Z\?A;6 )7/UNHEO<V0<3N#]T
M[OWQ#BO:D!+RV&T_()P0Z"+D7[2\M+0:G6:&BLT6U_/U!!X( 47/!J-;>B@]
M2VKQO].E9I?&>,W>P]->U-;N-21:6ZYZKVZ=Z=8#81,3[&C]4D9/<*E>?>9G
M@R>HZ9-(DG-SS<H-[S?_WIRV.^V>U$(ZCRZ\0%9=+A(A_I1K*T)D=:!UNI(W
M61\*"^488-=WLD6K&ERY.J$3N(V!?C(]$WV_S]>5J]E=J.=J[0OQ_,E.&^__
M=.GC(>^-TES$6!ZP&DJP$7G<$ZB%2[V)N>#KPB5;E36C5GF1]_-+6*WSTMZ0
MAE,%.##^TBRV+N;X->J)),>;$Z:^LN[C!M$GKX[[OG( *%3*$ .\@F3K#,$Y
M?FX1^(LCFFI+9W:WUFE]%R"D@9&RL>8((/^"F>SP3T3;1]0-Y*M<XIIA*%?F
M3ABAE&S71\9S<M[;NP27O+>0 4#T#1IXE04KQ7#5DGZS%,AG(&NA,PSTT:T?
M!*>GT17DFW$;X$W/#"L-@R.Y&V$UKA._U>)2^WAXZA.23FND]7$'[X,'B8"X
MK%&9?!K"\_LXW3%B8UB3WQU'T44P)DX.YJ)70Q--2R6E= YK_;2:]1WC8A.>
MUL2%I,#)RK?TC*[ZOC)>:=4L9%16$F+$!7[O!'[ADAF;[)3(4A"5BTIB:8BW
MD?0XEBTX.::HK-5N+Q3#==5KSMW4^PQCJ!]61+!TSZ0%U6<%TV-3+MO^S+O"
M]QP>_>KKHFPL!3>1*0A6VAGL3(Q<Q&P9"HF]0SPMX1$-SY"M$N!6T3L_X M9
MC>W)E-F=7HF#W?E.,38XTX\3X7N<V/Y!8+JY\3I_#X!/C4?RMZ@I6&G1NY]G
M2-&A?*31LZY?+ WI'?OS6+&+@TV;"X>VW=[,Z$<8C'.&Y'%2:+/FT- Q?*;Z
M8^ZS.N:HWQ%%2T"\7'UY%"T@B1HHJR"B(%V4U1"FUVIR:WS'VX&J(H7+$RVY
MV\''O,8:CK"R8';)..\IJ>;P%_-D%]%6D5<O)S5G^*MI<JK%PE+[:>-\8"ET
M;*O378_#$ZF;OMT9WNJ88+FGWD+EV$G%CX?E5KL!3U!32@)$\<6\8+#O4\L[
MDB-H\>K8U(90X0FR/2B:P-=-9@C-?F2K)<&Z3V>.[?9.MK7G4A,;7#@8J2 L
MGO[TK;;<H(V_4>R/8+LE><+[$&XU ,DT4<%HM;E-KV9?GX9F!1ZB(ANMIUC2
M:ZUH!PD0>V)B4["1#\][=DP;JPF=/:-Y*+[V9O/LT3>'[>D5?O\HRB)BRV0X
M6BRG+]2B-CG::?J0_Q'=:30C17.O/'RNL0.)S;>SO&1:3>(7AV8Q(X8V$6RC
MRQIH)5)HF?;G)5N38W5]GV/+1#<%U'4S3'I^518@S7L%P"M%%0SV=Q2BX>?T
M$?"ZB.Z)]\V@-3O:B+>&M#6K^&3*.NBXS0'.<(C-,43)HZ")?]):3F>U1N'?
MML=R@XU*/8T4]Y9F$R+P-G>_2<]B1YW$\AI"&<H[UHI&=7*$Z!EEAU\@0M&;
M8(1!ISBHYC)4( N\#0="B<\(5GX/B]HLXMDDD\UI[8/M?:>J7+W]^,;E3R 7
MM\;S?7K\-?TAAKR0_1@+S)ETR"I>H"YZ2R5@XJ@5>BW$&XBHQL:0_?GQGH-5
M&"E27@=%$\*BXA0&DSDE 6W'+9.<XBE&LTO5"5E6%V)>.DCU&=HX)4]6Q?EK
M*KE$7)026?Z?*S=\/R\!9)(DP >_X.6Z,W(28%H"<%T!ZE4:N!_[UQX'*['$
M[U6S)$"A3,(.:<'J_[R>F"IC^@M>BW(8_L2XJ/1V-#-^PO*&G2QLW>?2)GH[
M$7S6>I,YX5ML@;I);-5AU:E6[5U\Y9[V!2\2H3G;O;)L?%M(L-G(30L \Z L
MA0I>G8>57-XQQWXF@P4<-9XSOWV\[U)R6Q3U5H,**&RV>OCUH):U6 FKX05]
M.;LYY,( >4/^X1OW#(TC5P+=D#/2@3PD>%LV^)?@HRS;,,MF\FBJOW;P?-QL
MFUX+%27>#)VP/S$X>PKQ84+')=('[T,_J.4V*L7C&37!B9MV2HF\R K0&%@O
MR(#LP5\3W4U8%8>)Y5UP*N0]!5#'.S_#F'\&JT[_8:V;"?3[ ./M=/K"KT6[
M!C"[=#/+\H=QHX=353X5']<_*C73_S\VTI4+O2BCN(JL.0-P'(O8EY[5@98F
MJX"$:Z5&V['*029Z"62/:'_E,%^\W6KP0L;JO F4%N&HO>$)U^<D)_O!B#5&
M7WVZB2JO\?>D_SZ RI%./D<ZN;=!IYB%1\M35E$&<&J\BYV'R?^,:T/1R_MC
MBU:$;L]NW,P?FTK*["_M8[B#+S+"-]X7JBKO 7PA:^0)3ZA-%C;!I9Z!#!6Q
M J6?MC*X5%#<:% +=MRTVP*=< G^H$7?PD&I6Z:D['Q>49W!?NMU@7F@QK[F
MDLP?&:&YN!\1J&6\>)#A GT2[H+/@)CVLKCL2E&NB2*DXY$F"N<Y_'MS,EB^
M->ID$;&4A&VMOK)HT3NCO9'O^# /BG%S25 0/"1.=KR19KV4YN/$<EJ(1)H7
MW<"P'] T?F-&?@D>-4)-:JVN5$Y[/-_M PHA4D2;<0R_3(!E"1'SRA#Q'T+J
M<==(YT/]V_K)Z.*_F:%M)ADAU;T-M8^V7K]F3T2>YRA*,F2<F5^!6,M>O)GL
M6P%AA":P R@J2[ QX:8G"BS5+1/^J#2^[;]H&&Z+:8IR$BPFT"6 *LXE']=U
MGH.3]R0POP_DE[1]53U^(/@R>)UJBU.ALG\CJDZ/&FMS@)I'-A+1,$'49*L0
M&GDPD=OU6(\SU#(FXUGM",Q$J9263P1[M"G@MYXO><J7B8/W45J#WU16S>Y'
MGQ)WX, K3K!BO:" GW8'G&]'0C%K9$];'>^WUX4[5*%]($6SCZ+.8KG)W%E+
M4R*CN>G*/[35;WS^P3H!W4#?_!WX_%0J7:NW65-Z*8A>6_VVNJ:AXLW-GY]_
MKBD--N:=3XLFY. G//]]4Y.[/?#%S<"'VY).C^3=M?!PW'G@":H9236+Q.N6
M*Z>$+T\](QJE3)'2Q:A"5&X['2K@V"HUUXGIJ!MB-219=WURX/R$UKJA5B_#
M4((B%']$34TAWX_YZ?(=[XWLJV2:>;ZS"H#Y@+ %E2?%1B&W-#E3MHC[E[ "
M)FS$=^(U<5E,Z7\LHX+LN>;@ZAK^U%$H.4#P>(MQ?IK11=*528RUJ_?(!I,:
MKY*^EXJW4;^I$B"AB<%.I_Y>+WK! -_;2X!/CP&J$TO*S@PR$-R&T"!5$ .%
M,(M@6X@%=C>A56W6,;]?[Z6_ &FM*(7I<7WP[T!5D^W[OC]*^4&9+P3O?=R,
M2FW>'^J].+X?LY:\3'4'J4W&9'GA82A/X#X8@4[O)1\'X]O' MBKRP2H6P>I
M"-R:W_60PT+!^:,NOGXXI=%.BY1<'7KV7KJ./SKGPK/I8,'K(X X:<?_!P".
MUDMFL!%7?XUJ(0YG<+ \"<#WF$##.R7 =>3Y)XK(^M5\2BQB*'GKCCW)R?7'
MGI((G(+X. ;7-<#+V9#I\J.J*_HMYE#Y7:,3N/[P$H-/;Q.D09-6QG(8EBV
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MK:^\^@YC*E9&>'F: ;JQ5*'J[OT0#901Y$,.')']B;AVC&:J#F<QO2I8_4/
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M09ZJ /)H]IVM^4S0Y)ZA"JA> *MIKQ4>'4[V$'-529D>@%FS!MHM)L"Z@'P
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M@*+A&[GR"=Q'\V\XB1U(ET/_(1HY9?4"JOW[FP649C>-^UT:MH!*\*3^>4"
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M,K_^DPH4"W=15%(D1/FJ[R/3_+!959L[CNO@+XM[8-"[RC3JOK05-$NX I6
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MIW]M67L$<V_O$;6_-%=HY>X;#B.T8)%5:F"))81;*I8H*464J)YC [W-;"R
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MCA]G8Q<_;1[(V>U=<7Y[R<;Q-WY=1FU'_7;Q_'N:G3Q[APY'\?8S!5'B<Q#
M&8SL: >)'-Y[S8I%2Z/<%$/UTZG_3 >K%/EZQ=]Y]=T,J_!CW5':&SU^DF-O
M6$5-EDTT7PW55VW4Z4?4H.23UBP2=M,/OJ=GBBZV[]?4H]=_QO:$9S];(;E1
M:4Y0]%9^T74J986YIU+HGC<QIMQ_T7^J@!E[^><_F? 3C;ZERGFI5K0>S=4W
MTO&NF&HK^HZ4G H*K&_>[YSO=M;W$A"RRB%&:,40U4E>UAN!V&;V#Z:<A6))
M6G$"3D6D>3PQH,CHO2"B^-TEEK4W%X\UWA[;CA "5&<&%^S/;Z)HS]T7LK3
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M?JD!FD@QIV#KP[AHU/UX5<,I;&@71?(P:6@:/1HEMD(&B;XI@^PDK&6.[VU
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M]!4U[6B%Q0$0'T/?--WC\2/93_0/R3Q+57BUFGQ%^Y_V@$!SY^C(4*KK84*
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M3AUR:03GC^=<,3T.P6H=!*ONI!]0C+X>YWP=X-;\6MYY&C&]PE:8I1*=NU#
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M.G&P =K5WY=<6.=R[#PPZAD'E8=W:']V5OM#BT6^^?=8 0FY;!%2+)P'2Z,
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MZQ?O/TI-CXXXJS.-%.RMC)XNAJA@8L^$:WJE=*"UD%EMCZ,B16=;52+N6!*
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M$D']D+NU=5.?N04X:B("\$2*<2=G=.HY&3Q84#; :>II(1YBLFB174*"UDT
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MK&Z\U1FHIOMU!L,["%*M<D2-W*?5:&NN[,+J)'JVRS GM?Q\9.FT.X@D-__
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MC,PY/2;SA&&QQ2-22HQ%Y5V]AJ#45YT6;>NKA6YMBAF7U7_4,W8_G3*KWS<
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MCTJ^, @$$>X2U+Y*G@ !>(TO[EYDE]I^ZUVP.71:8"G"]QA4W<:O;8CU*88
M-]#V?IG!C+ZK]Z!)8KWO,<&RVI!#?YJ*^%:SKFSU.[(\SATF]SUU..U/\XTT
M*0JY0 CM#E8=Q(VL)P3!_X X-EZ#5#(Y_; CD->YEH6DPC&/#P>47CKPT^XI
M?#_U1XOP8*?LHC:4^&YLO8!VMYH> YMWF0 ;23IL6*T!]$\0[^'O-QMT[B+C
M>:4>]BE'!T*]B':,Y-MZ$F/77O_7E<SR-PD>MQ,#O\4<OG!^E:Q 7A0"-*8B
M 6L=/BYQ;>&\HL[N8LJ(=4LT$IG0*6"C>'\9^0#2C5A3N>V&:0WKH"?Y4]/\
M$6!-R84CQ'RH^* @YNW%]SWM_'H[;?O@ ^C[2TZ?C0^ JK$<?M9^"@X>QOUC
MO8W[8BXQJ(*L"=+8Z+ALW;K>\^>;%+!H]4E OBH+N[B@XF/NJCQU8]'CV&5*
M:W'<BOQWLG.#LX@T6UD/MV.4 .Y3CL+24=N<2C5V,6TH;; )J,)$,@. .(PF
MPQ8<YHP#;"#)6Q^DL7 )&$4<GY%LM$FL$[\C QU_G?-C.B_(C+(1S&_(PJ8^
M@XZ.AKT=Z4,MTN!52_:*;@1H&^XN!0?MIO3X"ZG$Y&Q]$!?_J1!)-!)Y,T&>
M?F\^XO9QCV6^"&+8\^\.)#\/:WD=S*R9W-KGH;]U8/SCWF>RM<@]>^&X#Y@K
MEL@,34:\$8SE=[()<<S5"T8QWH8- @ZK<X,8I[[BUV<H68HZ] 9<8'OK@A-Q
M)B./&7:\O_IE]Q\&#M\HY26=GG7R^+"225SUNO8-"C:E; :0T:P69MV\1EN-
M1 MFZ&V+Y:TO[VM<,6NM=016O.JO ^</;<WXWL[*\&\.,+CLKDG?4>7ZY^KV
M)TF7OSKMV*S5 2K#:V($[.P=W71<$&8DMBF-HGC/.9V-U8#DP&G7/H;]RT.[
MM5A'!72V59:.?=<.<KF7^Y]W6MN/U2RWW-[@0[J#9-IG>5BN7K0=:#1N6.L
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M7Z"X7SKG)9G_6+Q?MP2?!\5.^L2/>,:*XU.^NVB<:84_\/5E$RN!'D0G-["
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M9QK$HC&%<>@ :R&9[D\9^\&SPVI04]K9%NV?UK;94QN2;.+AJ3F=WW]-U45
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MS+%'CBL!7TZ$[93DK;' YK7*@L2U'(J43?C<D\+<6I+2#Z(5E!CV?)S@"'6
M!@P)7Y"5N;-/^\WK_FMC1K5OCLBWH32^F.66GQ(Y6-D"(TE+79&6W1587/:7
M+M)1Q(NE=8)N4JNGV(Q'$6-BDF@[F7]S<KD=JS2'>!6T8,J-S>%W$O<#M,27
M E]@A$LL_?>?E1$*2O5@.8=,[ECNMUG/PO>V%>SI,XY6NOD)PUBQ2#./S5J
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M?3AY]2KHH2L"U[N!9D$/N: SSRP@V__'V?9IY3,.UBKVHVUQ20&.^@=R&0%
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M/I+6V<6C;*\>,X$#$R9[.?.N6^H.T9&,P+\)57]*77AXZWF<71S/*3Q?CZL
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M?A9%7LK&9E*?)L)(FUE E(U GLY%"\PQ=]"AU#OT+8*0R;<FDUV)V2>ANV$
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M!6B$W\_+C?IA<PU>6FI'B&VWC=20*==57[2YJOFN56,B^\]O-&I0@QK4\&\
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MDQE+4@P^G'PSO]$;<&,$^D<<?%!AJP+Z#VW$*#8XR]Q4P#VY+$(%5.>).E2
M[2-TR=Z2GO&46$$)!IE'T.'\;-NKH0)T]BM3"5_IRKL$*!\.5@$?'J'K>"YM
M^*D*V/)#@OY"-+&&A00?!,":&QQ?Q@2.XX]5K*";@*./T-55ZU3K5.M4ZU3K
M5.M4ZU3K5.M4ZU3K5.M4ZU3K5.M4ZU3K5.M4ZU3K5.M4ZU3K5.M4ZU3K5.M4
MZU3K5.M4ZU3K5.M4ZU3K5.M4ZU3K5.M4ZU3K5.M4ZU3K5.M4ZU3K5.M4ZU3K
M5.M4ZU3K5.M4ZU3K_'=TAB^4XT&N/:)%?Y/EV(8LIFV0$NJTR1[ME3A0F%%
M,ASRUFN]\'"LT,D=0EXZU%4:&D16VEQ,C_2"3]>OS[D^X>%;ECI@VO0']62$
MYLA,0-6B?KRI&M2@AG\"4+6JBYD:U*"&?P)0M:F+F1K4H(9_ E"UJXN9&M2@
MAG\"4'6HBYD:_F/05$B&E,L)MZO_?"EJ^ N#IMQ:!43N!=]<IDU1 14Y*J @
M3VP%SH8Y*L!,-P[\EJ("'MD_439$<?ZXT\#Y1E$!!YZ:?;U)#PQ?LU=CXU1
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M^G30V.N3SY-\R*GI1YN?8+Z]_U/\W\^NCHF]X+KH/]^*JN$O#!A9$%H[[ZJ
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MG-BJ%;PZ\:A;YUU,,QN5%[46M;HWD26EFM4X7? 4,=;VRIDK"5YXL5\-:4[
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M=AV$BZ^@;F&,]=_SY$%S'M!?.=?JU14)IYY?FG4$QM__[WV '!KD5_&F2,)
M=<TQ]3;83G9442!MLK)I[TD!5[+5J,4]$JT+)"V$[MJ')\@1K;9SJ;6*@*,A
M.SXMR4PH]*)-S5GG^B45E]&<@F2YUC<>G(GP>?-:Y?LMN29N11RE('?>Z$B;
M[8X2^1$OA"/K09YMJ&D<MB+JT_TW0$"K@\DQKYR>.JBXC;&$?L'O]=V[=S(V
M'6!O1-([7>]?=NL8L+RD))R\K"KE\6TP+=R%+CFR>VG+:V=5O-C/_=41?;'A
M.V-?HA:N@G1)+'4)J'8F@!A<QN]@1%.2[-WMM0GU>OY6O?9. ;%G/K?"+C:C
MG\KB*=W![0V>75QD$P?5C3@Z8"D]$:HDK..=(O%W\ZJMGMJ&ED7R=-R%1&V+
M3NZ%(^JYH2P -FMM5>/U[\CGU=B;B>GY@$>]^;EHNB,@+1,R]">!E2P='-2-
MD;@[67M@7F(31:Q8]<'O>O,UL=_F >\!GU^?CYIXC[?Z_7Z^TL3^D-KW1+!E
M@O8YFY@$RDZ#RWC?PMF]NBK_"" G'-0W%;?3D!V<=@0-D+NA/\/4RTI"@.#-
MP#-@!7M9$4)]40L#*0$#8=\L?-L$2S'#\:EA?GF6Z,VNZ'+4$<D3>UM$V961
M<922/;@7TO<6>3%R!/JH)BL)P"FI#A^6]7@/*BY35I)U4 #A0K%B_19>*F5%
ML]E'_UT0IXN22C89M'K'$'6E1?+TO-XP\UR0LC+6/NB/!O*3F+M[Z.7.A4BT
M8[/<\(4E76$L.3NE\AU7Q&H+NY=H372Y&6L'E#RC+M_-K)MHY:VEA/#4_9%J
M"34#=7C0<U+,P8EFT9W!X-X:GE:(9[:V<\1=.DT_RL^NW>=\T0.7<UH?;@IY
M*\[(#OO^"&=D%M^+!W_B0HPYU+"E#'_!$26AAA(*\'?YP2YMP)NN5N,-CZ%/
M?[%V;!AHBH,E'7RG5O[K!.%3ZM&!V5)+0)5YP47/> ?\K&IPA]E0DY*P#/%7
M*?5A)OA *6IS%2(.8M.(+>L6498X"^V -YK"YJ([=ZM\R27B"+&2H,<<CGMB
M85] @8'4;R2#LI=7O'-]XRYH/5G5NC'1))5 =H*B44,M^4J6J@)_=M#L&$>V
M!P8R>,'5$*6KK9.\"=&)B'B 'D48$LW3D*SZCB9#<PK[$090LX)%0^$DJV-/
MGS8UPS897X&-*H%WF;[[@:>%Q $BLIV&W@8Q#6?\H2[R ^!4$>Q' /\2H 86
M2L+6/Q<^0'.:).G!;O_6JS;?=D@-8>.F<6(YER).F$8"SC+5;3D]]YC).#O5
MUTM_%%NH'<G<LCF+.AQ)Y>MW-F3GL*Z^<W8HK0B-#5L\O;I=Q_'##UG.FP*O
MQH.! @C/PQ#K+A%12H08;5SHD #9MN,F;HT,MIVB:',34H83H+ BW=Y%[&?B
MA@N2XL-/AFMFTREK:L-(1Q_!M$S4%[8JIAI,VEJ]KF>(/J)6)7Q_I+RG?;XX
M9?,CJ%?M$U4:@;OB"[#%%$_KN(G-IA#G$B\8T,1>4K3+:R+"A)PK--4L3TA6
M))2>>><4.I]4) SY]K>]IB1LIW> 6URLV\A7CM3(S3W[DP.IW1@8]N_QJ\2%
M FF1H,8,U2[&"?%F6'FY_5;Y7G8'6&/ZJH(?MJFQNG+P&S>9;7J=?R*ST720
M1835G)+VW\FXG$TVA5Q2C;<>F3@X^,X4?TZ8(!%<^964SEU.7H<+E49]:*1]
M5@6AB('DXPU_T_;"Q<DUL]JAVT\[KNKV.N/Q3P.A;&C?LD+BETH<V1M!81G9
M$N' 8@FFG@$%=V1-4I:RM?:(GD;+.'E[GA:,4U,I:ZS<UK"<[S U?1IJ_W"^
MC]B(LA/!PBE] ]*?8>'-&Z=L),>KXMR>75A<=\)H!%UICFE%(72Y*ZH'N2S0
MSY*UU?#!6T(@E1]7GXHM8[_RV5Q?BIA@VHQ%_N;Y)F+]#H[VQ]\GFW<D[(<3
M'Z3[0BZ)J%$I<N&#I*TJE+QYJ,DY*KB<E(Q#89D%#5M&Q'5OV'"3F5D"":<L
M)8&POM^TQMH]YDZHP:>+XMK$(J_Z+LDK3?^!IG.KWQQ;PA##&K3M-V^$+RY]
M[4A)9" _<3 M?C]%F&M SI/[8,\-.&E-;G(3)J=]F+T:YEU"/9G8!ICZC+*:
M>2F4)S(X*3Y6GS;1#FBBSK\7M?'WE5243&/&L$K?5X<(']AT)#5R&E*1>^,^
MPL3]^C : ->+1G!,-"-V5N@>9Z:WTZIQ1B]C;\)>VS97GK,:K[5IB2@="S'>
MA41'@!$;Z/D4$3>EMD?C.++C'5_\>:S-?SNOMZSYE4BP-%0ONQ#H'_EWCOYU
MQLI^@SB=/6DT??NMD(F,G>?/2 5J/(KOLM0&(L,6S4^X9W5X* FKHMZ9N8'+
MI^:R_V0V[7K@9YK%_./EO@)+M]BVDO#^Q)EP%>PAMY*(&N(TN+A>D</6_.A/
M1'B022NWEM-I+M4;)9NR_)&VI<4ESB73 S[%LK_\%T/>@R-M;!5H*%_RMCAY
MY&!E3D?WJ3 \A%'/,H&3T> )X/4(N@X?_J6?V*]Y59XS2@)%.BU70UR\D'-"
MP6*$TSH.('+(>L1CN(DJ?&?8QM[63 ;ZV>9,Z[GVANQ*L9^ZE'42%/6L0(K;
M2/>G;)?7C6^L&K%DLG8M32S94QH/;N8M(5MC;T ]; 42C:E'0='MF,E(LSX+
M5-Q%5TG\#(7WKGO\A/K!C5YU QB A)HU&@9A70U_?(S.X;N_+'+TH^WMLW>/
M733^T3JG3@A,ELAQX=]208,.](P&" L21#P.;8F]B?PXZ_Q0I%L 3!%S.[QJ
MPWSWY/@]KG5Z$ IJL5:9?FN^*")JAD:'G5N1?-]H)V.=_YZZ:1]8=U;FZ_"3
M*N2"K3B&!UHT&$0:I<G.#/(8G#>>K=$"]1H@J6'B<B0U4[#8(BHNMKU (Z?-
M>">\A'?Y*R^U8/EC>$=Q&9+0UM!\4RR-:/,AI:!61HJ>Q-E(]\-6KW:.M=D8
M&P\.M#];@PL]@310'$>2@%(_^:HS\QVO>BZB =#K;ED6=) 3';6UJK<I5$C5
M9@:()C($SK5F?V?.=188P5V7[PWO-SXK$ZSX.N*HQ__]&?"QQ!%H2WY&12PC
M#B "N3=[0+!0YH,J-BZ^AZL7DM0![A:KM3%&9X6O><%Z96+28H0KSDF+FEU!
M!W7)IEV,6$4B0ZRU>;[_F[VAD.G9KM<0-U23R\E@X;$[ESP33RDDK@!;FKG0
M/H8FLI])HBXL_*(KF_K9G77NH-@29J3;^_1EL@8D/!V$ZP$_'/_QG_&NBJXH
MU'Q;H0:!<HF+[.9BRXJA>DP]%J:)7#IIH^='CO?CU$/E[Y!T^/SJOV2XMH2S
MDGN9HM.T2^9^9*(U=T?MP^>D%!*J+Z:LF')]P#QF-2V-]1THKP%T^&=\WG=4
MR'8>4ON&9VI+V=C0N#GR'0^#]A'R"D3BV3!<"XZ2).0G$*\UVK/J5524?BM#
M-\2'Q&G2N=<3^]MGMVT??3Y42S@K)O6>?+;D:G[$C/O/#IO;;5F?HCK_^/_:
M+.V_>YR7_0WWX$8!Y @F<>O!-F]0>)<"'9FFZJ%G!MBFS/0CU0@ Y708* DI
MED]-.N:)":8TS1[81;RYZ-X9@^B4;^\ >;#+8ZB^;79QR_U0_S7)>Z [.;GY
MQ2GH[M*//D&Y*HJE&)\"G;5!M4MDMQ!W,;B<14+41-Q1-_$_#:%D51PXCEF%
MK;6W*_?9*QB5M-.(O#JU2_9^HN[1]D-(VHN)_=4CGTH/O"IBYC@-+;_PQPG@
M_2PT)W:1NN-FKU/46)%6,0V]GB!N\D-8-W<EMI%E/[B#_(KQH*V(F>?&::=I
M-='O'O>F/1LV&.> @5&E7M(G]=E=ARN?I'VR/,WTCZ>44A$;$J8E0T+E3"9Q
M81->)MCB7-IT#'9I,:; 76FG$0I4Y#N".MWM@.F'!Z)*[K."X2)Q3JKEM)RD
MBW!<F^&&:8.#R;?WE(9.B[4"]L)+*\1/K,HTYEM;4=7Y8XI'%.&;!>T[)[6!
MBMLQ;4AM!A9Q1B/$B<-9[YF&$OT6W:&O=CQU^OD'C=2&H:9E5H^;B!(' _&O
M;N#*T-SF++V2^Y-5?EIF[?[ L,^(;S4^H#_.7@17D7>"+5LHPKO&.K#?S(B!
M?@?M#4_V5S/$:W>@[&]HS!SQK45B)7:")2P/*/[Q?NDG$FN7A+O<%\EK\UQ>
MZ:*X6TAG;-K#0MX0P/K _/?EMX)#[WOUK!ZZ\:U&/SOZT _7-?-\_\RFQXBB
MOOMOO15YW7K=SA],$AR)!4R+];E34R%E966WK\>FI_ZS_T3])=V=;I;]?WO\
M=#O-*OBZ2^#/SMO;MVR.IW1\P31H<F=$@&F,X9Q$1RHEM"37<^('9#M6##3Q
MC#-:X>SYATN,,-V(?@!Q@TX-#[_=Q!V5BDN\+'MTIH:AHCL7YE*CTJ\'Q9S.
M=B3*U!1_4()!->PYI9J"WYSS;#\72F,M1SR%O*3<0/ZSNL_31%'<BH&#@TTN
ML=K7*;7V[@\[XL1&_@>JJ0_/1$=4ZUU=V&Q,HB*V<ME6)2')$Q_Q8B9/7)$<
MR7W$LE94-?T8",\Z9X\32=0$L<U?K!_A/%?O\Q7<A^^0>O<$L74I^P07JBI]
MQCYP+AZ,H4'A(U(\D=8:PAWRH:* %5!^1DG@"W39&I,5<FN6?TS0E]D[,*/5
MSFB7>Z]5V2]!#-N%^F5M;@(5I.UHXS6=5\-6[PY:?2&_[O]![9,1 >2JH0"N
M'DT8J(XOUM'#QQ]^$*SN((!XW@.Y<! S&ZDY;LG;2(60-KI7(F:DH(!\/=:M
M7HXZ(1?%^Z5AY5^YB0U@A\/OXV'!!R&/JZ>2J8/L[>C)099EG<$QK&D$#.QC
MF40_],]W^AER+TX.CZ?T=0FYJ.%=O \,9(,P'5CRAMV.=PHSI2[YPX-?G,&V
M=BU!C\*\E/#AQ4D2S^8A>U?0.K]H?%SWR_M:Z/PUW.3\H(A[(?.LX&X"\)J"
MKL.5U](N[#5/G1>$PX>2@*=GJ ZO]4)/FX.3\'66309Y)_9Z^$)=H[AGR;22
ML*+TKBO+6]*3S!#;26DT*+M6&$=VJ]!%<MI>E?HQ]\VU-'@4FR77"%:<L;7T
M()L0T#Z<*/?A>KVH8+OB+TIX(_BFJ*-@P^,LH8WT2D-&THW;X]W;&Z(O@R%$
MK8\V/A674/>[YG;E^6:9EG&X,A(--VKE-]0]?>#/7!&W+S"A3>]E/#"U^[]X
M4>]_RM#\S^7_R$_^?U"&YK_CYW7^@Z5KQ8*Z+P8^7U821I4$[ 55BB<\)5D=
M?ZB@.$RV"'$PIO8@P15CL:V4NN2+-=0JUBY%58TK1;0SUCPNVX#2I20D>QB$
M9XG!W2</,P*4!/6)!%KK^-;:+];'IPLV52()#[A6HB=7": ?#3HK0'55,<,*
M3#T1:CL(^]<J'L#%,D\Z8[1+?+7A\9<H=S<JE'0C1*#1%!BY*:CQ,4V;99/U
M\\#LM_3BZ^X!G>2U\)5.C^M;]Q+86\&6CS3H$ UQ8:E!3IAZO=""$?0 7AH+
M\#5E\4DO)%K )=3A_O@DN,S>\'[*J.0Z<26SM8T&O[Y5_';9CIE[D-DEJRUM
M_*D4+]7)"F17#J:.6T;#3F:/7)1'(!,_RTGM%+[$E[&"]5/V9T'@IRQ(4U1>
M$EOL'$7_4!IM'2 &VKUJ%;_(M),$O_8V&0DM@H:]US^YTJLV :" CI)@&HRI
MBY2$T[.R5"5A,$=D06"_PRV*>_?G9$ #-W<;&JDD#!0D.@*) BAVKEWA+Y?4
MSYA -.G=2$"398I4P/:3?==+=E1(!&L^&NOJU_]B>+93DY+4J;EH.N_PN0?+
M_M1\?I& +DRJ+M2-Z6C@HMKZ,CH</:,0"MZ,M%+6S*(1,/TX4H&S)[^KT\BS
MQ>?>K8@'3$9KL]Z I<X='Y8];!EZ[Z-M=.*UF;^'K*V&'SPXKNFUZ<G-NP1%
M(,YG8@P/N'[;IB5*0JJ)&, B_E#Y_@5GY9]Q4BIBX3G<DI\4Z>S-6%>!F2+-
M?@-4-R9>6@;-^0Y@&T-YAE$<?1KB>032YZ"[)3^>"Q.-X>)EL<'%H:\*_4/0
M8..W6$J5[W0$;6M^6>(=H3'NG$NIS%S9 *9A)7='=NZ^YV?CKTA%W<3TDL#?
M+=X_A3A=U(NY'ES+RF"Z.T,M(^HGZ=M+ 9D?WO]ZT7R1BCQ425##<^L7/U&"
M0+E##V[BJ13DBR.P'&SA4)9%IC+^Y72T<<776->H:4UJ/+BL:6M%DP:C1F'B
MD2>F76E>'R(;V13NYN[_Q1D)CHE9M++*[;:7Z_H 75]'2J]Q/,4&%%:"G_'1
M1+;J*VX"TA^5A(><CD@5#,<IR+4"V8)[?PM)23@3YR:K&&#A"*9IV,$'6JCI
M9'4D1I17DE@#R1%YEX^NK4W2-]J:@SG6>)^AU)#H)=_"@GI<*/SY)H]K'^L\
M#8Z>L2B;C#>>EJMA7=S:''2=(6YJ _B L0-29CJ7A@:<BX*S9+G(>W%CGGEZ
MCQJZNWHH,F/%9X8&XME38Y#QCC?VE;(8W0U97V2$BA1+]?M*\6B^#+;,.RSL
M[)T?7=AC645\1GWC*0,A8&9 ;L/<-M)"6=ZTY.1[WU;[QOSH=O[[%YU1/0;(
M@/?*%IN4ID Q_3$V5DZWV5(0\-W:0T]FX)"9=V\T/L[*$1#%R -1K\=(B_QW
M]B!@8!]HR"Q$'17WV21DSK=:OVIR^N'D_$B[(M8C;N.PS/1QUH'J,.MC_5_G
MZC-I,]U6];[,M+$N7!/2&ABH\1=8==\ /B:N"[M)6+L':IYN>S'B/A II_!)
M_O4UCP9F3F0.OWX]O S3VOZ;K\]8Q[J53@:7,S?]>FBU8Z$F#UY'PR7=O(MG
M/ _>Q')2$E[_'D^Y24*VJZ&Z'W"5_DK^:PA8:UP,45P0S9)0@1K+%"K^%:I+
ME=![C,?H.<;:L%E&;1ZXVKUD' ENK1H[_G:RV;RR-\_=@ 6W$9.%#?I5AIWU
M=0M5.A?F61/:1YHM\*8:8RWSY;<L1W3XS  )D&02\_;OZ0 AE^\D 1(L_U[]
MY_4-=0.1AF[TT_)*WP[=7Q85$E313Z#P _7[03.I0$D( %H8BB!N@JX*5D6K
MG$-SJ3-/%I:I(-RYCA4GA:A^;"!L486+L!4ZT!UL%_[&'\ 6QYKTD/?9;I1+
MLF;SP,N[SZG%HS'"V75^^_=&O'<*$XT&_L6]=L+5@/HNJ9#X918/6G>R"9Z.
MXC?WHGI]M;Y_S_!$H:@%,@E-N,<\JJ26 ,ESF%UU5:BONFX."%UZOJ1<K-4A
M\1WM:*#_>2V>,ESPOVE.S,6(H0BWY".M,GDF$4IZ_74LE+:*%XIC[(!W[94_
ML@X!FLWKSOB$<Y>7EMIW;]G1;)KW).Q/2VK,TOS?'*_W:Q,H?Y"0C16HWN<)
M;-D((%6-$?%& ]HH@/UA6(H9^_HS\_R1_/N(QG3KO%K;>_ALW;Q>'B-0R-'3
M_-,JPZFC^HS!'^-QJ=GNNPZXGOK+QQ$FL#^![>= ''@GC?P7*0GMUV!<F^]^
M0?C>)7N&]YS7%"KWQUX(:B@S3\24-_HMQFOZR634"%826F\V'0W#K\>'PUE;
MSTDH6H*/#=%I934QS3J3T%0]>>U@>9C56)RU^]Y6N\F:K[7T,><<Z:IX=@P>
M[@_9FY_V@L+'M*JD&Z&6?7LDM.7LOO$U@Y+4%RX1 :%R&_17^(_?CM]?[Z8Q
MY;]JX-/J-:OU]62? R+/.*K-!?Y7E*LBBDHP(@C=F>-6=\VLE21F'@T3"?!?
MZZ-;MQ=2KF8A/<\P_2%IT;7D3^U574*[>Y=M7A]9^X)58DH(Q)%3L*HFK^<2
M6%_?2JW;9R700H\@NV%#^>Y'UY_?049:_2V@GK'UKY?#;3%"XL;9[K<6!K$D
MN^"Q$^,JBJ%_U74J$A#@A5 N\:IZ6FEK6%&*6^Q-S& 1I96F@D,VWW\K7)'V
M:7SL8&5J_HG:ZMKZ^K2)(\-194<^[8]4$-L:C#+O5M#Y?\GX_NGW!%,VUK(J
M OZ\6B)J_$2^#=&D#;$<Y%O8+[BZE)!8<WVZ+P- ?X:S\R&3UH8[M_X$0T,N
M&" T,>7*;$U^@6]KP<9^>YV2@^.GCWIY/=S4'\_>CQ[&O0-/:X6W"C;*G7FM
MX&B;[  2$&@M6MV34E.11M-N<@HJ_F08BT>[5X%FK\$Q280?<N2#6==*4P)H
M =362YU@NJQ?<;O9#$<_HQV6YA5IN'FCW,V/PW%=24T4.IXVTLMLVB[8)'V=
M&_AJ9]\2O*JOQL\F5NVZV_.FL>G4>X^?9'OB W:6]B;()4>V6<$QO7;SGRR9
MMX*[Z=J;]_D"$>FR]\W4?ZI_W)0UV*OVO6WA1.7_8_%1D0:VE N617)P+0<Y
M4T;)4STN-0-6L^GZH'[S#N3%I_$E26&@)PQT]*S].&X\-/M&:T3_,&H#C5R,
M_+5@[\NSD;$__9%R.^-7U7F-0B*,HVA")MMBFK(&%%8+ZE>4/'SW73:NCB04
MHIMZ+0ZGU@]8,A(+%D.\!/+SLZ5>7;(,FMM0;>S0ZX&'9Z(_;W&^NC$>+!E!
M=;[(8J"1&:Y\)?L%6%V?:"GWLW-'CD'FHI%D1N(=2K ?M8,J&K.@=I$W/4Z_
M<H:\'2Z_)2;JGGF5J#V5^_2?6SKL7A69UD*-PD:<!-.5A#^H>/?W\V;^5A)"
M.8I?V>8XMN7]N[4>E(152L)8;$LWK(-IC,G]611ZUNGFW7BTI*-L*,)?)2ND
M>;/B+NI]V_#J#Z,_: HLM8H_13IL4554?\TP.]@;6;;+J6]&./ UPY!:U1_9
MJ'EZU9C7)#^JQN.\]7DX4UN3'G(J:=.Z[2$/;0\MS2" URBHD:O(G+JP?!Z.
M:X&Q;H<2X$J3G9R,U'FM.E^J'\'N$6A%&KY^6SOT^N*.6QLF=H[OEA& R8Z%
MF97& ER$J^.NMGB\N2'"]-7$C(X<\'N[_\)SAZZ9;]"GT./RFLQ7".X#&JA;
MII(@&\<[4LWLIL+DNU8= NF")%/%(^+^U,J<=ZOK.XE\;7?U)9>2++3JN"?+
M.QCWQMI;PL+"I&4B_K7U!$":51AB2TJ,--)IQ0S[9VJH*Q#&_H%((S7G@1-N
M?G;[^W"7B%20W![5IFSW&/:)RVC2RWZT[]:&2ULDCCC;:ET@H-\6&L!:U\LF
MXQW>R6,0$PLV5%V:'SNNR";OG.(?.?XLYT<?)J^%K#ED'R6T.+Y70MR1* &U
MF+$^]?PCSH\?I8JO;SVVZ1#QRUI\#(]CZZ?8"P=5WV)_6P]'5_E,LBFUB B2
MMU_=T#KE$U0&Z8L/EMWSQDGQ@ 1F)XHR?EZ^[GEQYT\_K5=5[.+]._J,SH/.
M>,;/V ?CUGFDR/OFX.B\D64+4;MXQCYC+_/Z8Q%,B]G5:NT2NC@F^RCR),HN
M^J?/Y=M/W5@6^0ON0,=_(: /\#9)D*"V#BZTGX)LN9?S8,=T+&V4)DY.#3!T
M.H7W_<(N9M<O9XWSK-R7OJH>.O?X]X4Z]CVH03HTZP8+4+T2&6LHZN>DT\A)
M(9 I6+6]K-Q$NX-<K-_*U6:2J+]=*6T^SSTG<1Z2;OKI![])B*JSO6^?H]K\
M^"&U]T14WV5O%4Q$<5?&-$R*IU9VV>OA @YG.;_?+6]$;QM'_#LIVI-9*GRW
M,)?]-8]Q!%A>:7*^D"A4Q9;//<DE(MM7_W5X]_Y9,(B2,3RRS=9UT7%D,WQ(
MKIGN%D.N3,,[>8Q/P,)!X6T>%.F"ZF3)U.'D-#8187_!_;+6LPM4.Q/QD;P%
MLFD)^8HT&0IG5WI;CRGT.P$]J^]AZ"[CHN*_-U4.SMBOHDND;C\/G^0ZC\Q8
M9NP=EADZ$B=BQ16H\7>Y\U3&>=YBRDG:I8(EG,CT )L.6AK9%BEMV;-Q:[BT
MR:0(7;ODSY/_U"=)]VH'^-ZT3O52A0!,8V'4!A2/06')^&((; /YI[J%=>E"
M(H'YF9+B;]A+UD;M!ED_&B6GK;A8SOS=.N<X#*0U!8MWSPA<AZ,V8:^YOB%F
MV3_M"'0-K$J5$+ *BK#KR3I44\&[O7W<A^6- !LWLX_%V .2CFN7OBZ?UMW#
M.6>@.N=, ",C_V]-=_S[I4D6IN:CF"O:%LH.XO&]'HFZMZRY2U@Q:B*+@OBN
MVF=]'T167&:OJFW@G4Q\R4]\&R$X;D?XW'-N$^=+92&Q*D05I?.$8G#Y&R85
MTSPL9T]>.".M;T#*1+/:?ULG*@E4N+A50$"ZCITESI[)E4J"2X+/_=.K-O\W
MV.+0;(2GRTK""=Z;:E%FYM5RKI Z>A3/$)H8BT]M:LQS18Z)?'U?.0]N^_1D
MB!3P>##\P\D/U*@HR\]9FS+WJ[VQ5,$L!=!OLL1 D0"Q,),J"<634-=B?4"_
M)O]<ORG_WMS";"M*%/O]<HHR<;>SJ,3O^"]@FK=?(_Y^.?OUR"Y_K$>P:';'
M\>?GHJ%HT8V7GXVKW"F7:EP#(SZ]?MDU[0AP<&[[G21]BCOX'APE[R)S)1]M
M>3):!\!?,4X:Y8A.)H&;,8NCXG+N0U_FF$\5LX=?ML/>!BH^"(]7WIOZ;8N<
MF%+8>_1U??;4^$)P[P:0]3:=O#=YLM.XY3FHC0+/E,)G4TG0A A\!FH@75WD
M)4Q452)( :'KK-./J^LA[J7(T4@P>7P-O._!J6:@#M[<*)%;G/H\S.\<\8'.
M7U-Y;*-_R&F]VKP!V/ZK '+BSMN5@3@1-<IRE80))T?@-15=AZ?M2Q:6^IS!
M%OP20$V6T:J3I?HQ$H ?(00ZZ,!JEET? U-#(Z$\)/G9N'4=IU5)T&TR9X@I
M:U";WJ;==U.U@66(V&.P-G;#>3*P.3]8EK%7UC]\@LC%Y<PKZAB(Z<Y*RV"J
M;#OL7R$#EV+#!4L9JQ#MX0^,MWO@"N%09DG%GM#3UZO:0L:W(@'1$JYT;0"#
M<K@92D[<;O_@YHG/CI2!@_&4G@2,>%U)N%:/J>.R\]2$E(:/+&54'$\Y1!'B
M2C6QP!CBH-H",;$]SVU93@>@#Y[AI-@8?"@/2)=&VY(N-ID(29H(PV7G[>0P
MBFLC37M*[^H+KXY8L9''SQMVK,85AZ!P^;O@??U-SD53S<!(I-R=YC02.28U
M].ZO76;2\&CP:]G!85\+)^K3NAL^YNEN8ZX?ZIY<<@YYG^22,5BRRA$0[Y$#
M3@^QU[A['".-YE '*HK]/(5=4AA*_MFM>Q_1H@T!9!=[+?.NVA<>$=M]K)F\
ME6M4IC6H\URSJ,-\ ^X(#(/_\EFY_SG,]3^7_P,_^?_X8:[_CM]H_G\U(R[C
MH?HZLD7)F(;#@D!'OD&&^_MO#S9O9X*NM"L X<[GOD\BY#G$'Y8?A;!KISYI
M^'9+WAF *]&=3Y[\YC%"A<O>]2[:;[)0(-V!AEBU81K /:R%"QV.(0.H)VS)
M7H%HR8\PG8X@)^'-L\?S9RP9&LB7UI53[&V(IT3+P^S-=/3)TCT5J,,56VY5
M"VQRN, KW??6%54QPX@.Z/.$30#D[?:A=^QH0CM0YR)=NR)1Y/PDM>(T$@#M
M<M[8MO]Q4]V^+3)0G;R4>9QN.S=Z8XD<B?[UZ7[VP(47SX 9&I0NHEW$EK+,
M$09$$Q6D$Y/91NAFR":1O0X!]B8L=3!K+5C>M[W)H?#-K$9!Y-70AK@&]]]>
M;'K\I_WG#ZYKKA*%1(R("_#KU;B!(-RLT?*?E80I-R@[?D'G"'O![TZ<1'!&
MA-F"DSU["XFM7,1!+JHK.0E_D:U$FL\J"6(7,>\RH,<V=&''/_+S7#ATA#J(
M8\Y^6K8F.:ZX_7%0]8IG;V.BQP]M'#Y5"#CB8U5&@ZA<9#-1BO]V\7>XKE;N
MQ'XA6(J16"S$7;X7Z6XIV#&,'N$_'4F_ R75BGJ6(=7/;/,5^?>>GJW+M?I[
MR-Y%I-".JJZO;WH,%=1<NUE^=O;T>J"_'OU)#5LVI"3L1Q#<!2XI"=K@%V='
MM7_[W\ O[&XN=(#ZABC;"H_7PA39,45V\QK6*N2B&%@VSB3ZP,$)9Z.V1.')
MG=H9@\YDL>;LBNYS]\]$BR+'GM+;R,!@^894DR_A->GZY\E[TPA8!&XP/+OZ
M[J(VTZ,D!#\1T12' >,055PY"O^F?+<&QXJQ[F)<$R@<K2X0,/$6U2_1F*:^
MDK!EX4MEU\#1:]@ ,'\?]70$WA?AIM%6)).7_TO=),9:7B Q\]%4)6(C5IM1
M$N#F. H-4HQY(\DMY)V]J WC/N+4R5^>EU@SSTGZ]F=ALT'X7:/.:Z4^Z?DF
MQVH?#\R&;SRQ@B29?58QUHUIX?%S*6GRL ^2?!2)@T'1P87Z!F +[XJQ8?UC
M)>&RCL2FS;?[YDSA<*E%^=PH,Z&E>?O ]>FV9@=H1SGN%M6?7E>*_,YO+A@*
MWX2'QL&%8S%FJ)Z+$$17=PL7,4O:!*,%*HJB9F.OT#H:@"W&U5]>K"C.)TIN
M[[\38O#_&I_F::)'H]95A?A4?BG_ZE9-2K+?JR3PSU\=/Q,/5-6H8 :"FI&$
M[;S@662+9U?%(I8;U&3;>0V*EK4B6:)9 V3?1(^O0_1>R*73_=2 =U_]V'/Z
MN<WYY:&VK&'HK4^/*C4@9IVLNO#Z;CPEZT 8V+*%HT8'X.3D2$ /\92M5.3;
M.XE W8\-M!34IN(C3!^9/_BD</K\#V<ND"OO"GR1:])92RF5^J3^:57#Q7'#
M]-#;N9M/1UFJU"H)*U06ZK2!_60RGOD*>>U<M.^0RK_];[5)FV>,>'"IDA!$
MO(SI(/IR"FH/S;567/9?XAYHC\LLC;%N>N%'-S&P<FI\^XC6'[M>G?LASK,]
M5U99YO]\>[^K%584M<OZ="'Q\\+7LVY2WO_$K0<55\ EO&^Y[.6'U.:?L[L$
MGT,I51.*O.(6DL*C8&TA\?9'0B%Q._(>RFOC&F,:+!JR5K*8**)<$6BB<5!)
M^]^GO*L+67NA\A*11<#*RF-7,R@>C[<E_J%'"/<O5$7=(V,%'![TBY(PAG7*
MICHL ;ZJ;+/B=A']E6W 3_U6E)4H"0[J;C0Q__GZ&>/E<'-^\';UZ'7L@_4B
MHYCPL/0QVKZ7*GAF4%DAC8*"95.*//)J;)"K$O5U!,>GH]!7@[+2G4TFWE#S
MDW!W;FH349RW__2UR-G53#N_2W-[1LZV/5<;VY[[H37VU<X/+V3_J$[._^LL
M=CI&#$/"'DX#E<4S,?"IX9Z>_B85N2N3TV)0]F)13Z!9NR"IX5Y9L65:X4Q-
M 37)9J6KW>J,';F=BUC=?_X1S_8!6^XH"94]J,Z 3-++.RM(XM76S\Q")1)J
M!S79H+Z5L0[1H!FY/G"MX"1C9M4P^Z(XY*N;ID50NUL1$MM^P3B>_^KM^0R9
MKV!-2.^[M^ ]K_9"8-3L/X4\QL\A54Q='??'/D4V>SN3)BF>^2Y?AVY /.'H
M%M=RLT3[6%$9Q=,OVI&FC<0>@PJ:(D<K:F/?G(@[VN;SH?+VN_WKOQBT'6Z\
MZ/USF2/ %4!15+1P5H9[9B5'QE 2AF\@[H[ RQYT+9Z1FM'E=)P9&YCF2H*'
M7RT!+#*[0OGG,$Q5I.<*L+P=>/X9# HO\3[_V8.8<15_T9(H7Y./%1)EB?_"
MO@M);<(-2H 6*,,[<ND &@7-7?S*D0I2 979KR0^X]F% [_5C.1F=+7FA9VT
M/W?R;I?VT_;YCHE6QDK6WH2?']6E>7_S"ZQ1;-LR-VZ^7NW[%-C22(&.*#0Q
M=1SVEJR <JXT;Z&3BMBO>>N^FG,N48RBEF84UT)U&>6TT3/^*Q".0P,Z[G+1
M/K1XTL96^M;<ZGWQQ5K2VKA+PY]E7A:;<0 ZT:TI-SK2V7UT@&1A961SN*:>
M-U"KJ9D2/L.8"1>YI;MUFS=&7Q^?ZI\:WS]1__B22U*(WZ;4T;6NA/I_F>_&
M3@F@&'UIOF0V=6'[?@(OP# LB$ZY3*LFMG$UF+<GVO2BL\K*:^$(\7@Z,2T*
MT)D>[JLY/^+IXQ)?8;_A-A)D?C]\<Z_P*>SP*N.EJ[AL[W@\Q8\B3.!"9^=F
M]HB!-[-"JC11'L;4D\A2D1+Y'D1_+](HHB5CZT>B%&8BL[:*9,RRNG:$#3@I
M"<N&$R(*WR$]'085B>6EM14KQYEU\F-0NWMI1]%'S-"CCY/R[1%Q6D=$FUDK
M)Z):;LZ(C=R8_1+0O%/E-3S^Y1FH@JUATHZ\6ZD2E/=KO_V/] =^?MJJKC%1
M45:#_4&N03'JIU0P=P ZQVEWUQ>#J%Z%; XVCC^!]?2S-R$VHFK-8)=$*TH"
MJ,9>Q]HX<FH)^=>0VA[5J1_=EG5=VV:_Y->N&@)8JB3,X"ZUV5F^#APM8??0
MYA_8;W $)E;C=)D/OO BK\6][AJZ44D8>B)W/*0VMU5)6*H 7ZQ=*-1'D^V5
MXM+7''8@L#L.J2%].,WAQ+@\BI.(*R+NF&#O\';_OY%TB2ZH$SF\_D]&))AN
MK V-M,=JCH7^IGWZ.D7'\NCWP,2G,_KGPW^6]=^.!\O,9HCR/<Q@V4-%&AC(
MX0.M/HGE17=9GH@^--$^IT6W*6B(3A&TG;?&*4CZ,K^6I($T]QR'7E<84Z\]
M#+6Y&LX@;5*=3B/\![0\88/W(1U\$40V D<UD2]*POV_+%6P1X,JV#8EH289
MO2>0C"CN.HDY6&W=$T= >GA!4%^O1XWRE(2M)<BTDG"Z4<;"3>(N>H$[[B\5
MR*99]'8WIEZ,$X2*W%!)F+9%=^-8OQHIY7?-[,8#Q!L>DCV]TVU<(M_*%ACT
MI(1;/JZZ-TDFLN)R_&KEFMCLR]K!F:_FL1D[WUMW181&A47HQ/QN<DA-'L"D
M=(P;(!=%@";S2TON*TX*"D@8*T(*=D#<E,CG+(6-'S22:MGM%[QW./+[(_MI
MHZ-N3;5/:W)47UYBCJE:JO3UJGV80/5T),7)O& B8CHB%<"^[9XR/NL\4&W3
M05GVD1A%NK%Z)+/9C'GFBRBG[>D/JY*#ANP7#O(0O1:GSUT^;G3WW!-'RBL&
MID5%7$M1=]R@P^S7!C)NJ*P,$!8GD&U9/G!$F(7,?2UY%5(B*N=$7UWF7F"'
M9 D_)I#U=UY>;&=* .^2_M/?#5+]L@O3Q&_8DKVP<Q;WQ%QV+S!?'L7'K6[7
M@UB:8T<!$2"WX67RYD/Z[JLJ_.ZK?OZ":0;@MV3@MUS!;[G-.J,D#-H=+B1^
M>;=0U(CR_@>^BR+/LXOX7K2-@(U3A.\I8S9=O$H*JATK\4S'5D]K(W0QM=,]
M%O?EZIS+Z-'0:*OL$M$-A&M<:7;%*G_IAZ';#76P+K "=9"LL=3:UR\>_N(T
M5&YA)7?MZ+RA^SL!5!5 X0QT5?<S"N0AX+N(BUC1,) :R1F5R!A03Z*]*ZSO
M OE!_2Q?B4 'W3-HOR=82%HZAERB:R)-E,+QBLOVGB7,HF-U5Z:KWGR$/_)U
M0N<N-#(YCGC'72LN = ^&F)*G9D-" Z&>+*EBIL6X=OU3&M@M0SRFH^TU6BP
M>N+>DHI,MKF3A+9&'5"Y=ZXL85?\YT^!1PB4OSB( ]$3B89&9"J*JY@JXM;F
MKP]=;OY14?H/PKD34K"V/Y)''+UW#:H0SK8#FM,DQIU)#UDV]FLTN,:>?/V7
MJV&7FU9=MQ]:K(HG:PG&2L(_R7C@.X(S)2R<'P==Q'BT1 [^U\_A_MOEI=60
MCWCK7@"?\WAC U@7-5$P7TC6.;2P&^,%]S-=4!VMN$I-$,Q7V-LY&B]4KT[X
MUX.W+\[R&!SYEH+%>)R;0R_B*2-'97BBE!6)+,'CWU,4C!7R5Q/ O"[4V$'.
M %L_*1J;C;&NYM5#V( 0?#/W+#1"W!T;.N?SEG46Z0HL0HIHKNCUL%F*R!")
M"85F#]:&+L^:-&B^*U;8Z7U^'FT8'X*WTYXG[*.F\.J),W3(7%8-1TOS ^24
M<5845(K9]C7KO\5>YX KR[]RU6ATV[^,U8?+[0^1K9D&=BT2B@9_DKRK.@D@
MMF9?".<%G@W?<3?3=;\:'X!5]^&JPM6J'\\YB.5*PKS9%MR/4@RL*N9=RW/P
MO^*BE82^W8[ WRXIEIP,'N0J0+8,?<BM7T3*H#R:D-HLGX]#DB0'!NR/Q4#U
MG>=H'^=OCZW=L1E/,IS$^RX&![/KLEQ_JQ_7@=?7/];IB-CX6$WNR5J*] BY
M_%W"G%8JAZ=5P:MI4H6YHJX$MAES[TQ-T$)Y[HP:3>+*R4?CFPY,+[U%9["S
M<V_<(@?>0/6ML[:Y:^)TH$:!6#DHWB)WAER?@@>R8C?6HZLR?PU'\%#6P;Z%
M KJ+R^&1MNF8,,D(ILT>XFK7E/D\.U!VGD]+1S= LYVVQK7;"=E)P]C$D1'+
M/(\3M[V;[.+JR;X&!*SVHVHW9HT>AZ*? 0G@ZN;=Z-YF]UW/N&IL(V:/./H*
MZ68?^96(I\J,/@3O> 3G;/")"+CW,KMO><V(ENZ/)78/KQ(7/LQ\R0>QZ0!J
M:>AJB<QBH&!UPPA[/<:G:;$W,TM]6WL,)HV-$4X8'"PV&CQT!?LTT.9#3 GO
M_?'-_V+O3:.:RKIVT4TAHB!&0$!!B1UB29-204J:1$5$141%04"(BDH3(671
M10D)BO1";$HHH2 HK0)&I%.Z *$I1?I.@I &D5YV%,.&)#MW\][[ZSOO.-=[
MSCCGUGE'?LW!T.QG[;GF>N8SUUI[K=@5NU\FN(0KBL[_;YXBDH.#O\-_H-_S
M_G^?II*9?[*1DZ0N?0/RJ;;F)^K0:80'NP7:S)BE,?<PM@$WC]3BO;KG**-U
MG*\GKG#F$57U[,/#N6-,4^R?_X"Y1L3(2SO^4R9!)5L[%!<045[71EW:&7R1
M!OW<W."@"MD>@EL@?9%K<ZCHD-AD;QGL]"@;BFZXF=4IO@"Z/[.Q\[[<@=V<
M9HTO[BK@QPT>!FD)EN@KVGY(,P*8W!8:I#^;&B 8@97L1H;4/Y5J48N3IT5&
MWYENL8['^^$]4+>#2\^:B^7$%9#6X;YK\P;QC!CVUG?:%GF(V)++DQ?/(G4
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M9T<8<(K)TJ<5SLA/JI"??$!^LI7*S<0)O>G:S.^K>Q!=/$_EMK<O'-]['Q'
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MF:M,<[#N,X&(6R._S+5,!3U@[T<U,B!]G%CGXK].;-_%]$E "Y]#*@)'(4-
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MVM5CUW3-X5:)]X"?"R\&; CPKME6"IZIV=5YUT>(4=^68%D<3OEZ4O$;012
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MZC%[O*;<Q2@+$+LNC4 D2LK0+YEB=1WAGTO+LXQPCL;2IPM:8NM.2ST^9_G
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M&4MG:_:ET*--<9HDAZ9%A6)?[>W%#)+76;?959.ZE$B&[V_L5(O^LIHR '*
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MRS]AS1PXJ2CM^@>N.LO,/\;(J%!F?BA._@.HL%M&A3+SWPEQ&17*S(_$R7\
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M)?O>'793$_RMOYP#I(.L?K='R5_.@9D3/O[V"*],5_=NP/>^OCY"33[]#6V
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MM#.I0#/W1PT'.QII(-(9NR+T$7!6N67E9'WJWZ;B;\H\]7  .ZG;BI9<%BI
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MSXE9@M\I3<&M!59+0[9L-_KK/(P_R-9'=S_,G[ZHT45F9K690'Y\,T;G^S&
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M21U*U &7\)46V+QWQ3!-P1JTR,J8M% 5]AP.WO_R5UQYZ-Q3FW"9SN9+ O2
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M=FW#@=[P.U74=E#O_AU8G]5>W>^"@GY\>+ >9G*4RPCE:AQSM]H\5>X94:
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MSYY,YME[/>OW^ZVUGZQG]'YPT=E*\VHIDW)P*2P='0,[#7*;H,CK[IKBC5.
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M,#0:IS>I8'6R^')6EX"09/UIE)<E@_/+.N,3R3CUFCV_K\LEA8_ND[WKH9]
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M6@[C'0X^#+W-!+S.9F/TP'YK.=4<<S,';%B/_@Z]HTMT92":;+X=W89]K$L
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M#!13Q03<-M[(H .B+A3K$I-Q3_VJBB4Q\)/%5Z7,[D'.;WI450'.'1_O  #
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M+TU'2%%!XIB1F) +Q1T=2^LP5>-?&N9L\,/=-747?JQ$?J^/W;<\-\"L5+Q
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M4:$MT8UD: L:5AOCZI5SL1K!"[ '9 Q6\=H:YX9E>;/LFLND+6 T&R=+ !S
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MZYV[)UL2*7Z%>)(&%%^,+3Y])8;9'OM\:+HCW*+=Y/S<4S?Z!?0H6D^*:N0
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M)27LED6$KM?8P847OM]D?\I#".;)/R(WNA!]2C^U@].\P9E\\-[!SQLGA9J
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M.!_!>%J]]4X\<RV$X^62WU1"JJU?3XK<LJV]J1#U)*-W<_Q2N KBOJ\LCAQ
MWR A9-PXC@-/SBD0LGL0+65Z _"GIOIJ6NK3L,JCQ#T"X 9-Z]4566MMPR38
M:.SYBJQH;?2VX853W42'WT/>#UK%CLWZHR0"I#KOXD!WTZ$)B>(DJ.4"E8$)
M'2= #!M <8*'T:VL&WJ;6?0^V!'L\NW/KZ<<KDUTI]54T@38.&OLBMSGG3Q
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M7E+433K/_3II_:@3.?SIU&6O\QC_!H%_*R54EP$(IH-EW\T9O7Z"?L7B%G'
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ME'CF&@%PP]KV";Q=7"%1GLPNRD*,?%+V &4[4T= C9_S"CT4?I.C^MWL;='
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M+'7D$%Q=$J3=V>A?J!B3=CY0@$NM!^A4TT+;8/W%[?<??GNN?[MQ\RU9*8'
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MN1X5D6J&75M9JF3EUS-<_#!O2_L9+HT9((,<UM. ?G7TWAC?"-]\0K'LR#>
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MU !0;0D5O)=8A5/"#I[YO!&#Q*!8?</@8MLY6 [_,6$=@C$I"$=3ANFLLO@
MY8[XY+M^F]H[%+%@U<M".+L%V7@?R\NV!Y\P(=-C*<ZKMK3?FKG>LBQGB/_K
M8B$LM+Q/^WW"YWV,.D!Z"UC)6<BA*3G++1Q?7@@(M"CA5^!&F:T,\"1Q;*_
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MME])U(UU-'60F,B6][]:%+"85<4<YQZ/*8(]6L6G UG1'%:PIG;")\ _57C
MW88P6H:2CW(O. V1+U@.<M#*:0WV"' >&-5W;[AX86;$BM%LFO2KNGKWYY2L
MB]OH6W\$R$KHRTMZ_D^NLD!,EI,V?2P:42?-)('!(CTPG_F)4B9Z!#$E^KRU
MEV:+I3.$54TJO,#%K/O%0<Z&6]JP:4T&WA22<W_Q@8D'5,N160^"T!G[.0F-
MHRA:"VF='/ X)YVAN[PDA4L2D+H(*8PU5%]PXC#L#=XAQ7&Q;1\OC+2.ZPXN
M_+:V@RRFO3*[EOGOMLKB<F]*J& A*\7BMO+/2@99Z!#]<O81^]AE&T(Y&4Z/
M1N192YBC0^(K@& 3B!($Q@(&,">A5%ZB012AJ3ZV"8X678-,FPEQ2Y@:8MOR
M&NL5Y@S-KU%/7D*^;8!2&!-+R12XI1M=FOMN]F306@NR[<RIX?8F67L_#,RF
MZ3U_T7]NH+ *TD^;C#FLF%57R\9(#Z#(-@!"T/!$T*/U\T B76,*\<F;R+/"
M<HG\H;PWXDU$#<IE7<,6CF:8Y[9KX[0"(5;1\@;[4$@@AO[J&8A+GG-W:$3Q
M.&_QORRO6:Q:3CYLK<>2_=)XPH5>S-?CU7:@_PQ#;$WQ=_I]V#J+:]I*7/W>
MSOIA^(N7/_!]H9N,^HE;[QS86W5!9F$( ]ROD^AU",9TB/ .MYD&88G;Y8)*
MI'/1*27ZQA^-G,0F<ZH/N^KOB3D'AIIWYYNCU!<%)^X=49"1^B^7M?2_LI2L
M*1.MC_3.BP=J'MO4;;63FXV!D-6NTO>"]"TG1T^I#,J@K&G= *+0*]X$M.RD
MJ0?RUJ#.2%P7Y#:^ _HK6X.CA"A25NF:GH6KH.W?WSWB>7V-TBA\^E5D14X,
M<S4B"K&:<)QK?XWRWC=QQ-0I<;MV(KU@ZARNG32KC.:S2AH7OW,XW),T2A>1
MI P\EG+D^[8T^T:XF)".[*9 ES(_Q7YWZ-%I)RA1M_A'7[UYU?A!OL9P1?DO
M:;H)D\VL<Y*!#($6"H'_B<$%674M@!;UVM!\X['96C03^2UA1K%MVO>W^ZP)
M1#:"7:V$=921?0=\52EY8LL]YTMDP6P[(-51[/?M&I5<!X5D=]9*BXT8P@4F
M_9+I/$.72W4AJ&_&$^J@)]E//;E!4?YIYR!_40UM\[/!D!#R#"N>7==0ERC<
MO\49^\OK(?:' +7R6\YG(QRJ\V;^152!J0_2ASMDQ:B*B:-Q/BLM%Z$SQ9NN
M+V$6[\'Y-P@72C /L?_B8-,Z-$YO!EITT#"MAWOV/-<YOXV_BCF16!>[U["H
MN$TYXA!\#XA\]@>UPJJKU4T[?FX)8_20=<<IQ08WB5[EJC*J1Q^RW/\^ -5+
MP<K7IF?.D#38FR"Z8*OEB==_;Z^JD.P?EM@)QL[^.$2>):^A$$_TA:C*:@R&
MZVRTH4<_E%O\_.Z_GA1W40_!<7Q2/"('N;5S4II,P+D;-!Q%QW;0VF$"JP57
MGWG^CFTIJ)"UOUD9KNQY=H@E?ZZZZCDK0?&5V8^GTD'OMZ\?R\(1TA?+>X3@
M_H!MV^N[8CE\!J_:@WJJJM]<<7HU8HZ\BTID"H#5TSS?+,\ %E9!8@ 6]3!N
MD26$4G6'68(+9'>+K5PII5^R1+#/7MYO>BT#EPE)L!434<Q#<_:I7%O8LH*Z
M'S2IB&BW,FW&CC+LH,IBA3?VCSP\J"?JX+Z2_&]JKR8=;O_XU^OR0^PK5/F,
M= *P07%76F\\#<W'L;GZLWMWUM="'9SFCZZB&[!CN60'RI;,LULC<&O<!$\8
MX7SFR@"K=%9-G9XB>2TAZ5)Q:D]EF#H[@-874"F#Q.- ?[+DD0J1S"V<<-=K
M$^L(1IOG/V7:X&R!EB'"CS@.=P3I)(QRT$3J)EAN;0" ?FYM98X HK!;_*?D
M&+NV[B5.9;DO*'"\GQLP$6EDSM&5N,.>2E$)!>=\=&X64$+;K7P=-'CSWBY?
M- ]<7*:ZCEP,HD_@B]",M5A)%^O1.GD*QN3'<?;0W*R.D*D35+L[+Q8A)0+*
M<V'IEKV&B7<4[>#<4-._VUM'E$,.;,KBRMV2O8]ZXV::"ASM*,T!0@ NYFR+
M?JK$#^IM(<EY(,<>1><2L-2]H')=NLO;M]>41.^"K+([LG-/INZY[=-TK\BZ
MU>U9W0\;PHN<_ZH<=),^)GRV0(DA9]8 MPY8J&"]7B;ERQ6')CC8>AIQ:0%[
MD3=T@292T<O]XP:AE@1;:K;D$&\"_%3@V<7LQ]LW#]%T*5V=$7?4%;=RF72\
M"?4PE%'R8]>KS-?LX<^LA'_NU-:*(.52[<TW:!_>R8'!:.CHA*]W DD\T(FL
ML6?"M9_M)SY!N:Z!4199(2D@T>6EV^7BUR_ H8+X#?$_+X[515_&B.T0I?*L
MXP1^%D[W]L?[YZ1-B,$1A?S;G8 _<S3H6MK7)V>+,G'CUP^BU#41G:-&240I
MI0Y1U!(R5<;'B5<#08XH"M;AY^F-NU K\%TN_2Q&RMZQ,1.,:G<IO(1Q9E_;
M<V)DSQ]7"D[)BM'L&[M:8O*N215%I2X* !]M4%I^9I@[-_-30$ZU_&*6[C'I
M#7>COMB1'O7EXBVLQ5ESLI;WCDC%8\\>.]]98?]49A%:OFN50I>HE[74<F0!
M?AFO+CN)JC!;X ';B=KA;B;%0;P_2U;P:9"V:2K?M"^D9CA>YG*.ZF#%;#GF
M-S_CK?JUOXYNE9666QN6+V%:[01T%4K2ZUW Y:]6^.I/S^\& "PS<31OY[UG
MKWU_BM0OG[JE=P0#I *S:0)O0A<!="=Q&2U6M<!S]GE4N^R$!0)O8D WX _'
MB0H@_.W(FK_^DN9\/Z&4$;UL[4L=IX^<.G+J3^>2U#^>/KUE\/36RM,8]$OF
M9@?&Z@:AG22Z"5\5?(Q %+J@.L&Z9[_Q:L/ ?];RTC8<OWQ#33,I',<EG@7;
M6M-^E/Z8'[T5A#_9O&&9RE[V6SZR GK8$H6G3W>AW\O'72][TT8%=< 3(T;"
M=QP^2[N3\>1FR"HT^Z\\,F@TLV+C46/A "?H]SF6J@'_Z.9COJO787)M_G/
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MK&NG$9\BRDSMTTD=-7Q?O6U;G!3$ EK-Z?Y:6+',ZD0Z03M ["2013@>%2W
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M<8]0!6H"*?Y)@T)[Z.+D0C+W.\=^;(RLAG=V!=E%$;@'Q>D"NP\YYRX__N?
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MEE\3)X;H+U]:[7QY\'B#Z[&=J\I+8S7[<6ZR C9)-PR[$K..*"T,Y?6F/%_
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M?[BM;7CB?>?["0U[ X,3OG6UM;5UF1?K:;3ZQ+,:,3%XI^U)JG=WI)FZ3[K
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M1:@!<1^&@=/$ASH,$ PYK#3F\,VC'[#K(1:#[VF=SG5P"5G?$C^II1ITZYN
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MJC5J6"6N/0$F='"J.0NO4:UHE$S?4]NO@H#P&?:&T7ZXH\DF2Z9Y%*.9V/2
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MC_64*2_U%EF<;L=EHA3)SK'\WFL,??%!_&<(S<^[L3E_[F1R![S^=4O2HH,
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M[6:!=!QX&IUHM$.2*^.ZM"2;KOEAD2TTR_8UYD>GDD_2Q^> #2VF)#_73:_
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M;GM/>OEZ=V_5W3_8"?8J-YTM--;>A.I%+9A)$6MEK+S-B(I':<]2]B=S\S*
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MZVC'KP L0"%$WR1UXEC6]UE9((=.1#E)G-HC./^.YL5HLSXV(R@F;-F2/@!
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M=8RW[BQ1VWE[J221^.@$[U]FW'6SS9:M=8?EA$]DM%A\OEF&[22 F[62W67
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MLS($N$]JE^+I.8$'Q'1M[8WNWID=%_;N]7HVVC9:8%3C.IMSZF]'>*3]3WS
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M@EZYPZ7-?J:025V]W+^#KH^:>8KZ(JK4)[B3$+6I]Z]\Z?;Y3B+OL7BLZ89
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MCO%I_ E?[T@AS#,RBA6H6;IVXI@LTGKK]*GB5$*XT=%P@WB<L<VG]$8K2SO
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M<YCAQ5(%3[[]B.>FKB NV0S\"8B-E]$F4U7=$S  3234I!&_M=;0\W.WXL^
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MWY__4+[ -%A<.JZ!PM:;Q(^5,=?&\C[?0?<<Q/L 46*LD2A%@!?GBL7'XWW
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M8.I?#JQP9 F&\7Q@RY,-\B+1%M@@6V12^4&&7C<G&[X)_7E+D2>2C&>5ZFB
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M=6"H2!].+I*5J_SH8BO_ 6?<VCJH@)4?%$Y.*0[O*WT*S:%^3/IXT^"XG51
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M@[WWC&KZZ]H&PQ\5%3#2FQ 50:0J75H0I4N7W@2DBXBT(($@TJMT >DU]!9
M6J0KB)$.H2:(2$\00B0A##[S9=ZY[UF+];QKWC5KWOO3X0-9V=EG[VM?US[[
M]SMVL$J#M%6^;*>[<,&T>RRW%8PYI2H<',5J[7'$-G#.2]!E;&OLW3P6+VIX
M5.^QW51^/==/R&?Y0-=*O@/A6X4%G/IQ+A-P75E(243O1 %X\PHR%K7T?U=
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M07 _2X^6(INXG<R2+TD%<6E/_ @5MY"UH0S0ED5S=#EIH UC+),!M[, L_G
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M5&,((4*FTE"$>NH79T8!X?+R9T/U@OK4F+/RUI?'.4B/75:H.[&Z *HX06;
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M_S+/M65LY'SUJ7713=87]*0M88ME*5?@M]8;JY)NM@R=HHWK6?SG9WL%N5Q
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MTO/C?+#[[FP+P7J<\P2P NM'7H:(;U<G;PSW[/JAD?$'9OP2)1U'IJ$^&@=
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M(<KKC:(W*1*QA;1 ZTKHMJA=O]*:AW7'-<R%%=5NXR$;T2T#I,29!$4%%XR
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MZ&NLK*H;4'3*V%JD6&^_2;^R3.EE].P_SR-ZBC_V4>U,R*5]+&',3S-MG;A
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M@G)V%>"SJ0]4.,\00]:WZIQ(M8E7MK%20IE-_CCU+*=AQL#TT<2,0P1Q3/^
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M$T!QLO1*'>HV+8FLP>!;SMM2H]\EH\,5M!&3A$/(>-*U=,H^<+3.<6Q-H)+
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M=6&$8\CGA_1L_U[R,=LA7VG=.8;>_.$MQ<BP_%*#$#TS>BN,XGNM/Q3R%*@
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M3MW<)8AG.W4)50I.J4'M_!OR>MODDZZ'9$:&TP$(."J>1W=\L]Z^2R,P,E7
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M>PI(ZWMW/?&ZAV1X]7.&C.[5'',G=WS#=$I4P#4QQN?)'1FX,AZ,1WCNQ(E
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M[ILJP/]WLE3S<9W7LIBO-C'%?R_U],>GZ!T)(#B[W2P=)AJ ?#<P1JPU'M5
M@8F3-(7/I_R_?NJ@E:/+X9J_KIB?]5[:\7';\Y0K:S==>K40O]>:ACC4'S+%
M)S6."3[EOJIN5^SRV)0[[W+>D,;HI'35P+9'K>;D)L.B?C7L ;7.(@O;2#>5
MKU<^8H1!ZR>*1Q/.@Z$\D4;+CW.-M.\K4%_97MC7'?&1O?.72J'I]'5]\7\V
M>E;E&01$$(<,%Q60*HS9H#S)[?OPAZ>.3Y+! B?4S133Q>\O4@%U>9B)109O
M;N4GW+*,>R#_+>N;6 ZK@)9YT*P*V.H&@ =9T$G>U(\G/8.5][Z3A\UIR$8
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M]OK@@?1S5YX@UC=^]C^+_RM9+AKYFO5^77GP? S=IIZ=HL!P8'TY5;\,3!1
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M76;>C2M>M-62T??E!Z[N?6!N$,?>_.S+EM4+-MPG?*+\A\%S?_#HK# X+)"
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MTJF-%,(F].9IQ9W*Z9QJ@5_,V&[GC4#1&'P,['5"DU)D%Y0X'@D2*'%W\W&
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MNZ&5S]W7]MC\;LG3IT]+8LQ'5S\N-&^UC?!T\J3V1_'YL_MC9Y_<?6_GSB,
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M )!56PCHSE0%<#1!SN' # 4 'XPD(HFF6)&6#()$H (0Y@(DB8Z+_(2I%%,
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M66EU<27K@OF70HO"OY(C N*-J3XQK;NS;OQ^72WT?U='I-<$=&$7II$GSU0
MOU"6("72<_+;M(5^,E=Z*UV#4]%,"Z/Q)UOL";25$JN8-^49^;%V.\6;UUI\
MYRRA=FU[?OGQ=P4PAWIPL[5S"]DCR,Q-PF:(G<V.P*-/"5\9_0S$]C.FME!<
M[3JD +A]*^39],5'>:$^K&9T,6SKW/YX]9T/<[MWGI7H>DKZ"E<OV]69]OE
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M;,DLU@4_\ 4SN3; L]!U2LP_3HHU/W/-:49)U<$9&2L_;ADZ_TK/1G1C-Z
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M:9SUU17-A/CE[?>13:*FZI_:ZJPOQG=D>F:_%CTYU9[GLD95OO ?.09\2VF
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M )O4@774D#JW](OT^Z<?4&FJDVT*(-I> 02X+*+IXR'M3OX(3^=AA"DWA:\
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MA_%#U:9<BA9="XG"FG97R^]7J8C4R 34$0F=V(@'R2NI#?8SX* DSA6["%'
MA:H$JP 7 C6@EKZR]3'E0$?H>[OCX3/38RWP]MJ)2S=JMCLNZB74]VEWAO(T
M$<]Z&XMT,:A.C=M1C8L9%+&E<^27]O%+/KO;@PP]/>7K#[<]"6(^)@?EWNP;
MZJ3FQ_19NR[5/_P_UNM)?"K.O(V\$@HND^ ]*<A*0HI=R(/N0?[IKI$"28KH
M4S+YC_@P4)]V##[S$&:*I%<T9Z?MZK(+ZE<G.)GIOKEQ[-7:5=H'=T>2/HWB
M7?<]VKHJY#(^9*$\VPHQMP@.M"<BA'Y!7>_I.U?=8EO?4:[8_XSX'0^+,#ZI
M(WTE)L=/+?$SOG9C\TCY^;JB9T=S  7@^?H?=TWJ4I#5UJ@F*)I =4PQ;>>4
M>C*?),Z?OB*)SL9/VM?A77 7MU>WMB([2ZP>TBB $[='/ D($L\VN3466DF<
MVW/4;_GZC_RM#_SSUB1=.ENEV@N=(B(FG_&NZWT^-H=3"-78TC70PY+Z[,Q"
MZOK^N+C3R/"&K#M<B:&@#M+[+#GTMO]]J.RH$2XF[IO1057;\X]2@ZTC^9DA
M:@.UR#X%X'L! .U 81H%#B*.=."E5RY_*)07T'0E_6). [C(#R+2*,(0#5_Z
MYF8[_5P_FYF\:YE[RMII+G[VEP,,AH?.^NIDL"]KKQX.#D2WT\;2DTV6DEJ3
M "AU C5(D(5 W"-0S7[4 8[@>G!ZL,7T>K9>HC#XQL(J+#CKK,3^BR_J*"DX
MFFR7.BO?3^P^SHOE%Q]?F(.<#'[]YV1Q)'2&4@RAFHV[71#K@T3$U/3JN--F
M,W%*(Z^[WQW)ZE]5MGM!7Y"N- N)DU(2Z82*KHF?B:7H*LFM%"YOMI<=_4#F
M'GC>_DD%8'OL*6%R"JJ9IP "G2GXR<,EIN#"<@R<+@CQ6>&?;=T.GE$ ?%WG
M#M9@4P[52&R?2XBF;;5../';S9X>U%J2RXG%EOIO>&-7_QQ>5WOB1HD6 !5W
M '0B;M;U%!9O=#%^_O"QHB)ZZ,V<8FF)J%!5',1KY,1RB/J')"XQH6.+_%JH
M(7498%*8^I'EK59>G<N_^)6JS>ZO2-LT3]-R6._QS=4W(J$_W*:?H)A;*3L%
MU1SX#L;8L$;#Q(+9U'O#POJX:Y9C*@J@UD0($A%#,WW(X!CUM\]UE"#GN;.A
MTNQ/+G-]V4Y>ZQ-WLJYOT1K5T@6F5*5+<$XRJ,8!$F8I )41"#_,[O1&CD;5
M9IBU3P+&HY2 /"1=Y!)CY_7(@B5^*'S6:1)TTHUU4R)*\_2]MN%CU3-@^1J5
M.\31,4R=A@]62><SX,.%AZ1=9?(GJ*>0H[T=WL657G@& W Z7IU$9,G[5Y(%
M_?W'Z*;6HW>YFNWUM8C1%IW:S[^6?#7]>E9Z^S<5>= _[X\FI-21)_>2D\%1
M$^\5"J#S;O4=HO3==&9L*, TEB ]<*/T"OZ9+^D]C 7T^?YZKF5""'&NTA3:
M0O-]2[AAN4@<[FAP"IXQ:GF+AW6LSS^1AG>&&ZZ!SS\W2,L]]=7#/VU_S] !
MIXV5ZU^J8(\X\!Z7F+X5B#FNUCMY%*9+;7TWAN>Z: 5P2G#Y(G0U-/'C+7*H
MR_RW\,2V=JND65\VW3*._;R=4\78G:&S?]G-5_<H-W0B08("$ X0$;.QT<+I
M>=,%GI"OE^Z0N$79D0D-U:;]^&Q*(=5SB./D)<X7R%P9Y\H&;(G3K"Z=H^/O
M[[@L&C[SE^<NO<%<UC>2SD"IRM1ZW'S&L5ZPU!35=L+F=-S#6@2EGYZ+II_\
M.U"-<"7;:TJ&[!?#['21^NH!NL[SUN6MR[Q(#LFV5MG&57\Z_:K[AO'S,?1>
MI/VXG .%A'1/8'.>RRP1KO2._'Y93R%8@RU):]N)6T'L^,9"IIV/A-1H4W&,
M1*027O"/='3\;I..9^QBK]ZUV4-=^UK&O6S=)#JLB.-W!Z:2OC\C3';3.T X
MW!1=N%V:AEPFQG%.9NG6,HK38T*>?&Q#R7C=JR!:7(8A9HXDCIIJ;BU$&&(0
MGS]Y_C;I:5?X#L*0.&_-# 'M:JO@Y0VOI81&[V6XJEW3<P=2M4BYREZ*M9#*
M*)%&U;[,3NBJ @#057ZB;J-TOX112TX\A2#@/NU^O6'RK'OW3E\1>X?M<P 3
M<(3=3,2,.+VNS=R'$&7; TAEX:A9DE,]XR=:F!"<XTLWATVOG(&#[XL+P7KO
M)9UA 3T\W<&TJ?K/L8S#K(K6&T&G87:<*$(E9'VC1:;QU9+]A"$RJD/&#H#X
MF'BX*S&2YX'?#R!/(L%W(9BZC@+X_0T-;V**=26?%<"!C;ZJ\N,/5!&\=*/Z
MH)I.CJ;]/*S901J"?_\+-5&$Y>?35K1_-[?NMV[LC>#:N-21B$AC0WG/XR=V
M:G #;[]?J!]J+M*/R=X<WOB3[7UQB*;I>W2-%%O2LJ^D'R!V,A'K+BF^($6]
MI7^PUTB55LC9M M":"[VAF[28F'.GD6S;,74J(=JLC<AG,UMRYGU9H6N[_@&
M3ER.NB72ZHNN6 "R:%NJ?A]V?>LC,@==*B6_$DY.;RI1PP)+QD:GE\^E<=C<
M59(4Z17D^4/_A_WXA[')#&&H!S&:(NIX=QGVW N?N7T2EH\],:<<2^'25R76
MKG,2K[BZL_IFR/SA@SU.VFW&#U2F\.0V\\#TOA!4"C8W2V:>TNW6(-"EG8//
MU5I3-%$CB:I7EYUJWL#%O (F5SCL]>L@ILLNE\PXV&V1:E'R<# #O=EP[V,(
MWFT\TM1Z,QOO<& G%V0%JY:"F#B,, -D%NCR:;LZE]?4/Z:+[I& R33/TSF#
M>-2E7*TZR@^[4=5N;GGT>)M(SRTVE*A./?-FQ^+LINVLC%W?C,/V$UM>_[,;
MM5LO92B 5#_Y73P+QM(\%$ [@7*'^%477R,O@!\M*=-/:<A6VS"P H[^?H+,
M'.\'#2](/$6FM6/)V4 7MI#FBT0(!5<Y\ZI<*P+I*Q%(0N!6N"7:&8A7EB91
M7+K&7X;Q-(;/LS)<"V:FE>7Z5?PYWYO/F]MWM,?Y::E3I#IG%F)4P]"@6>52
MUXO&KM#6"ET( Z[BMAUP?G2HNEDMIM<RJGNKK+74?$%KHU/;:/O-'1O2GC;8
MF@/0+0?4H%<!K/I=(I!?=[E,FDJF["=,F4$U^N!'+0AVQIFO8W8W*H C/K$/
M5,?S(L$,//7:VF+['TIXV.OT$7PQ+#C)+55!!_ 2N*X OH91RB?DF6.X;\N/
M\K:0!N2X+5-#1LDR6YJ%O-!>A794GLFVI-*[ZCCSL+54,W?8Y:KE<&*$7QXK
M^G"YV<DG@\1S\U[E(ZE<O7M'D91:?IVCM%JKSL/U=D&WG=OY_7BT$E]ZTOV/
MAVH#L;Z+G9FY_KS3DG2IB?Q!&%Z0G:,+/-4BQG1I:DBJ52$[=X;%&?.[2"Q$
M-'_!^KW78TAOQ?V_7EN,6AS=HX()*1KHN3NT_0@DI"30M9_)?*:[ ENNX2:X
M5]"$W;I#9>THZAJ/2/F]&%, ^]K-<R:/,M_6+(^TU?M_?Y'CW3"F1L'SMAY4
MX\(Y04%6?1YUDEG0 .0RS-F".,",(TC <9'Z>D]DJXBLY=^\7>P2I0 T[((*
MK*2L@IU6H^.I 7TK.DRNO7Q]W;-J0\ORQKE_J?9PA#D"^#P%;R]G^"F >9PS
M*8AI7!S-5&(FC:E"+L!?>_I]&N6'N"0X@PKM0UAB\BS?</9RV.$%+RYCYZLV
M.T>Q%Z%N8L+&NZB0FMSE"O?&/O=Y0*7L@8.KGCZI! C?ZB5JF!H3)SX')4G"
MTN/M5]/;P=)PO%>>[Z5BDGQ+HBMTX_)F#K@E+-6=W4S5JA,02@5S>N_OLJOK
M$4VZO9)Q*HSW$[ZGXPSQ:!*=49;24RG>=4.V&/LP%1*-KI+M&+[H_)=@MOU:
MJ@.>.:\$X!%XT9>J3?<%P]Y+X:XD2]5S&U*%O/BXG:UC5KTK9-MMPJ/M7,LK
MTI).WZ=Z>D1O:[/;KP*/H0OS,0T!\M3>'$F5^N/%Y.)'UT]U;+&*8,SLQ=JF
MQJ[\@L2(P254ML'6\4Y0Q4[M09)#[6^(7W"SIY^AJ20]SHYBG31/X-=2M3YG
M\%7^T,5F@A!*X0B?D^!?4VIX6MU(G)@UNE7F3%O72<[N^]3H@MR /6OH\YN9
M>./L>(6/6-=3YN!-H-JQGM?1%ZX::-YYQIKT,B2E18*/&,A2$KIDN)_8<[*?
M$ >>2.EI<X:#;T@X#<T?>FA:R&>1^@9!K3<)R1+KJSD5[H)4J'A@&3PKC\.7
M^"5#Y:YMKT3JE-H6/[JAQ.J#FNBLZ"VY3FMP'?6:JNS@='6]G<"(N^4LCLA>
M?M]>A5[CK=6!"H@T%;@$=Z,BGP#[7]+%S'I]<C&5M+O#_.MY?WL-Y*1J0.>"
MGQ\$@>*_'GELVU"K(L/M?M8;?.)OH.D+><AR0?QC^_54K^ GD#"'3TE!W23K
M]U7$G&BWH,]"&KD7XVK'XN@&ZRWWIN3[>ZMBG4C,/>=BUTAT;];$J=7[(R&&
M#S=%"YW>"PCW_IHCI4$^!Y,EV%*,RRFSN'N7FM?YUH.+:4%SJ$YU++:N)"LF
MX>;.GKNH*^(75M#]_D-"N<L=Y)'^'WFKECMN(8UN%8;H(11\4M!($MT:O6IF
MO)UN_Y@:%6I@S^]Z?+0ZC26"M <W9'RZ7-#]'"A[DIM+\?#V+ +^R-M^N372
M)@-OO?!FS=X)VR7 5PUY(J,,POY4 #Y7@8]X5KM%@3UYET%X-PE9IALYJ^@^
M5-LMSZ.O1,_+[UFPU6G$MN\KQP=R2YZVTVQ/6J=@QD,O32M@#K<:/'#R=)!)
M6=8[5K^!=^?8-OACQ4[<[2CP2\(G4A)'R*' 9PFC60^H<0V,&:BS)(!+(<;4
M%>'JDF7&]#<2"M6L-MN%9_Z8OIZBBFY%HDXE6U][1]LJ(1Y(6[/P^I;'6Z?Y
M^0@0&R=,;:UL'3)E"UWEZ :"ONJJ.SN6E4@HM1!?390?,Q)2V\W[Z)^F6F^X
MH-ENH42?R_^<^FGK$A;_7:[/<6K1,6]?O<CD /<78$L*-F?3=(<C9T#"0JBD
M"'D+7S1C$JC#M;H>4!S;FJ;5%38[C*2-VTB8O*R^/JDJX]J&\OE(>JVA4=3K
MJ8D:NF7)TZ*RKM'5S%&+\5'=NHO6\79@#D#/4=ZW4<(/"/_Z]VV:?\3[-L:@
MD G!#@*\FYP[!ILY(6$2>TPF&JN'X@X%Z#6^4 #)AH9MHU;FYU[8=!;YS=/+
M3GWL9TT.S/X9@<2.JT/S)0XQ^^[F?.AURAED3>TJN^]_?DUO,V'2G]X+P7L$
MR$H&ND!7G)?Y!/6 W:Y5+<X9L%]U%8H!RUQJ"CT],T6=A8_>?RC-,"P4N21D
M&^K1'PHI"U\>M[X(Q=$.LC4E;UFI)AWLFYT)!B.1I&<<>"\3L9V0YLD9)GB?
MRR4A*PEQ%M,;_%UQ%9QI2Q>SKU3LBY8Y((=<G(L2,P?_"EJ/)Q'=>Z6LG5N#
MQ!1D)\T+LKLI&!)HAFTZ$C3](.LV\OLF:;\\G2.\0YI5RDD6%*?7>Q'%T.40
M$SUZH<$=AK/$)0K=<F,URWZAY/.5LI6C96.SD>2.Q:=ELPI/_^2O0PYZ[,O2
MRXZ[E#\4OH6T=XBM#W^I:F8_O^-;T=1C5ECI7W$D^5[G\+)#RVN[KN\]X;8R
MIC9HWI%S6?<!4O_TOVJ;^/'IJ?]XNJ;24OYS \_Y*4OB4QNRO,FE+.I=*\E:
M>A%QL&0?*:MPF$<_U>IH-K)38%19[IZPE#2L*C.E@? 207'C2-MJ]ASX6G&3
M#$3U;[J?@ONN?74T0FW@?MO*LAL^X2?<;R>L=C3^%/G?V'O3J":V;FTTB(JT
M$1&0-FY!T(T0&QJE*VP0$3$J"@)"5$2:@-EN0*+$%()T(J*RA2UN"%LZ%3 B
MG=)%"(U]Z)$@I$%%!*2B&$I2J7S%>]X[[OG&N.>.>\:]W_G>.\;YPV+D1U6M
MM>:<S_/,M=9<SD6]LR,.[M57.'L?/>[=<)S_82A,\LC7;^>GYSTO/OK[NQEN
M^GFSX:5T.?7&T/"&MBZE,>JT!<;Z-LDP/XO@PNN,\Z3GT?Y<3(YW/*43H;AG
M?%5' TBI;:-K))0]? !BL,<L?R?IT7IX V/3&+U<6V^\/H%+@K(?1" FH;5V
MCR=YY"L=A2$:5Q3FYX2$I?!.X4*^@JE$4VW%AL[M<K3JUFH9]K]FURQ7G49U
M?71IQ\Z@HL\7;"JR;Y<,M19L\!XX]XBC'W\O7NV TO>%$71D/",O8U,(L!FY
MDY3!R[D<O<[9"7W1K/H$;H<&11'ZEG=HCP=;F_$- 5XB0CPQYL\>RT.3+?FK
MH:NCJYOM-]1%EKR#2[B[Q*MJSE?_-'F"0W> @K>$JYAJC,=8Q0-T-7R"<G$C
MQ.T$ALI$@8D584M%NQXS?2&K4F%FJK/1P)O'3*N+)/>J+L2]Q-=CM=DHIRVW
MM<3QNPMA0BBFBJA)S2KT]? =<5:GW69?FKF0R)G1PUA$TH=UCSW#A%0%..J0
MF)1J=3)CU/3\ZI[HLJ=!;C=M3A_0ZS)ZIH@$[F)6QR(ZO:A*"F6)Y,$@TP",
M)&>N#UGRJ6C./C\3FFR-S=J6K'U-VZ-00$Y@JE;__DMU3<:9((B96+N;%9/]
M&_Z'2!;/%N2!CP<1+8K@S"4(D)R&8XO@<[S>_;V]'=@D/9R5.5/30)U&-XK&
M,%N7[B8^9ON(3ZDO_OCJ/2GD1+VE$N=<E56&,(.XI[NB(F(-;@[DF4@B82VI
M+T8OW)[-\.R$L9<95HBE^.)?M;F=28[DXG8PXF:CEG]+V>?!Q%=]C7:B "+W
M_"QQ)8WQ?9]8)S'N(__S?%[&AX-O"PAC"[O+%A(@Y\/YT#[B,%>$J?8:LPIB
M:B/^Q-J43(8ZG#O17V,4*U3*0'M!P:>!6K=%3,W0-:IRW#):=NCT= 65OEWX
MAG2@5Y#IV5"%48H[3"@B$RD8EJR0XQZ9=Y)DX?B,:@4X#3.7/+!E!_T(-"[D
M/N/#YF1.Q@7I3C!C_AC;T-GY16G Q>R+0<+D2R)5-IZ^!7+E_M'A/DO4HGW?
M+@;2;)[K1<Z-(([0>PO+_KR!8HH+P0%CQ?< :!<YD;^JV?@%UA%+605=0<B]
MHN\ZF&X#:#!>,M61@" 92^C@P56@Q-J[777>3,MTJ5<OI&5+!MMS+XY?IBN7
M4):3PWC&?PNY*^!K8YY,'ZKR%_MU2O,K(CSS _N'ZDZ_*3S].G*X;M7P-=NQ
M56.K"O#?=V%"K!X0_,%<*L>=8B[L)Y3C(JE##2W.^G#0PGI ZB!].]:*9CA<
MY7?J!AQ[L..B_<!,.X^<@3C<]6-)]F<0VO#J5G7X5.N+QNH6'K4#CH;U(TV7
M>2EI/^XDX5#,:KKPO.]M0#4!T<(T+6',T\_3OXU<.=>>1Q*R4D[7/[WY5<;0
MI/7NJQ'SXU<WYIX+:VPB^#>+YY*LCVZ.G'+<(JS [ZL:HIZZ[J(@"^CZ-QQ_
M2VMH1[5@4$A=3AOK9)AU.>H)V,IANNAJ,2G=\4C9NU!C ^A34O%PTVAQ^63N
M:)G3PSO%81<NEA\Z%D@.?-\2&:EB??-Y:A$&,A%@RW,V%+@*%!0SEUO/#/E+
M?/MK-DEU$'.Q]87RYM52]8';]QC=P$KK'PV]%?3@M4FOSX:? _&.6]1'1DHY
M(TN_C?;,^30T-HE34B.2WN?K]3IN5)!A"K:E8@$3,9GO!(0 JQ@]0#4I)8?#
MKV9/!Q33_$+INO>&JIU-8 >(O/?[#Q!/ \C?X^]XB%,R8AQ@NL]8)G[:U_KH
M+&MIJ%_UN=$U737I%L?Q7VK_3^S]B9?\E)4A-E)UM(-<#4X'B9B//4(@#R$U
MM?%(X43=X_/>Z"_BZD<EZ=!,J^=JVNM(S"<(X?D&4.-^H[T>92:G(@OPWP(P
MG[%"7S'68FTNV!+@K C[B-P;Q+59Y72? 2",S+/S[0_2#7L(>SWC%;%7(%0Y
M3MED\2="FO-Z]#5D^?XS%N!"::)%:K\TOGL&#%V(!YXWH!HILBN@,!,+?>4$
MW<:=!6&$(;XZ0%%5!7C4ELC%#A&%@XV1<> ),77?]QO>_.D78A\WL4_J:(=-
MQI0U6?NSPMB0XY;]"F@: &W/' 91@TE4^;S4AGY\( :<!M.:U:!Q9!T[8_,K
M@&>C S.A*ZJ !IFBWW;G3S"<-LDA0%<0]R='6N_2>M8JZS@6X607^J+?V/G4
MQ!GYDRK[-YPZ%;;AAX%'W+!/Z#O'",G<IA>JUF?^[OIC[:JEQY:O4T2^@X(Y
ME@8,NHBYB%:.5'5']RRY!B9)"J0^DOVW@TLOECX?<%Y\GA J-5S^<Y249W?K
MTYEOR)!M4-PI14DLJFX$I5S^P81-.B\38T!5./9((U"MU+GNS6CQW8FZ0;.M
M/RZN=M/+_\+SW;M:J'NNGQ"M@D/O5C,U:'$NW]\F_1W*6U__+>E%3W2#D</T
M(B-T#W/JMYWCYP,CFGUN-[SZ3CAC5^MB&_H/ZL7IE62+6Y%-V.S=H8/PS7D*
M93TT)YF&R\92NGNFCMH^:-:2%=A,GZ_N;[8=3'C!2DH9<AVJKM?I.+BI]B_S
M/YX1ADY@0>"CXY;$.E2Y\&%68C6!-TPZL'_KXLRAID=.>[PNO9LMP+_F#D>A
M&N^PMR0P>/GJC;"2U!(A=('!JJ34Z1CAQ;U2X<.JAP@9GA%9 L=2)\J$I&7P
MXW$.P[ .DKTMU6X;^/8E< 5D69>A'UM#Q5-X*ROW6L4[\=%EVEC0>4&_ &>*
MTX6#TPMKJLIP3#E=!S:'&MKMS3,0=:DSW;4K^!%\2\QJRU7KHNBKTL9:>/>2
M9YZQU:IE?A8.34$>XL@$3%C??4G%,]6'X-B#.0'7%65FGQ41&!#\)/XT  6Y
M?(D5HU^.FX^2Y:]3E/BCZHOEN#^VP13T+7&,B6;#F.$2,'N%V2O@3Y9NJ'*_
M8,;^&U]8/)TSO59TI.[*Z0# 6_SV%M!28?FIJ?:8F^5X2K3Z":U]N<>JE],*
MO:^IWQ6-T93Z 2B8U<H?\B,-J8YQVZ<5W:%S+&G@,!+5[T@0$P+8GL[?181$
MQDKF,EK@G+#CQEU7ZZQP8R/([@IQ7%SQ(3>?N91)2$=<2R;]3I?&/"A-J'YU
MT511ZM47/0WX],Y$Y_FU<@_WU#AXI*M[>/9%'F_J_:&J^B1P].M+R=N/IG7U
MU?4);@DB'NU#<FC V V]5?=Q/QLD,;)T=C!UB' 8+BMCO&8J.BZ![$D9^6MZ
M&GW%1$_X;,D+(5=M$EW=O>%,]+3=@1HHZ58K[,79;>#_ZF_+NJ3HR!5OO\:E
MG9FQ_&HU4EJ S\?&J1+\EK9P+EA7=ILPO7!X*[,]6@&- J'0.J0D2#@HN\[.
M!.;3."Z$IP 4E8D8KL> UM#882&]R^ $;NV\=D;(AIC3 >+>UMP49^6JV\:]
M?K V-.?[..NC^-8'3RNFV*TM>TM(JVWF6<%%>RKL8>6X>U03ARP<>/H-%(RJ
MS@S[^$.=TRW2,'CO#$EVO='N@5DA5"IDU$7:Y'&GMXC4UTQ=NA]>V[-LG)2@
M;REK<+WW)HF@&6-Q/EK5'-3@358%X,"2'TE)R;=.!!=/G//./7.[A.=_-(P7
MDU1M>TY'1^>WXJ;B6[>*Z]VHE# *U? W?__MAK^UJ(6MW'/O0<&BD7\G+Y62
M&=AW?8L$J@'9=6XZ>3Y^<E8!W2''051SI"1]X42?'!><XB7']<>.A2_\7_]/
M\?12$=7XBIGB2]H,^MS\6:;,C7A/4:;-%F0POZ6Q%Y:,9+=]IL:P$:[B'%:8
M]W(AO $1HSPY;MUA>!Q[CH>$CCVT4LC#H=&@X#GXTYXU'(>^F<,X,5H>4H"?
M9?SS((8A"]YFLK-W83/.DCI94X0URV2J"IX4-C\E#G4? J:)6O1E6.SW#/GM
MR,'QC"#O9EW/#&[4IP:=TQM<@+X95)E4%C#)ASP6CCG85C)NKOWZMU25\:+.
M+O#X+\5YJ"*LYGZ6ZV#UI\&?<MS$7_=??'%QGO]?KC\5$1I;\(GT<[_Y-%^.
M"R*T4&6GF8F8T*_& +@<@/82D\''.5/N$%_2!5\2@'@*H<9N.D#XA&'Z>=2V
MK[RBQC-$6/<L4]O/E*_>2!!,3@P<+,C4I_EY@,:TUCEW?\N=1ZDKPT8-!CXU
M5D$E=PQ="#V$:0.I+:(AJVC6@#L%YM-:T!@'7(FNA"=)<>IQK:-K*SWN>1]@
M28Q"W!H,B-7X%9^K'C5C+"HMVC_=B+JC[V2R'.?17%.?9HHCB+RDP0QNOJDL
M!=-&+(P11Y!7C(Y0@*KQ#K(AXMC3>*+4T_D66#;A3!B@;D"<1'M&!Z=ZCQZ;
M;#:Z"'CE+U-)CVW.'C(:._!: <W@0^$+QTJ$=5,M4F,Z(*MO_A76VC$@QX63
M>>G;,SM'EXAMJX(I#\(!Y68%VK4WI'CK3"4/>Y)Q2AG=#9IE0WFTPF,]N?Q#
M?=9$K5!C[:;0O[N)JQMP:![JC'+Y2X%PX'+S9EA;ZH)L@[CMI"1CYU["7K%;
M(OW(R;K<BQ]\5_B-\O:66(P0_'L>9ENZ[1!K9,:<>!BJ7]'TL*PP7,<^HZ+I
M]7&"J$:Z!]DJ!A$M-U1EIYB$66I"3(-8Q'K'E53T%<%AHK0/R\-S;B#KX=1<
M3*$35QYSU-QUG1R>N_^.<.3,634+0Z\1^]W)-GJ859]AJ4Y* BT@;@K=JU0I
M &BKU[G!>J=L^S/AU='>Z1\&!\U:7S1N_^U2[:: (=Z>E@(U, U8WK@6RA0.
M9C(L:'*<=Z(+9,XA+H$+14H9-L/YEK-49=AN5[-8-[7&]R>AOG<VP_[KU^TW
MOK6Y%.#%%Q)1'1:B$X>J<'7SJ=.-5.GO:+_[>.0:E)0RNDA,3.V +J?1IW4%
M,ZV1CI=?OGY5 #O1\G(T%-!N5!%R2T+U8$(+QN8UBX9#C57ABT*2!FS2JJ_]
MYW#879C<FNN:GU@09OO@=^]ASYX(RPT"I:(#]S"B?A2+>:^!DTSX,+EVL)4Z
M;,?1=QM"UF+:R9FL3OOT==2PC:G7K.(7YFR<_W7^:/_)&JHFG=CGJ*!Q6ZW
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M )(802*^6; <UBI&B(C3%#R61K 0,#&:,G@M@769+1$H82YR#W)B<D- N+;
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M7J_^V;Y&B0RRP>SN%-&8%7:!9'V&@S\ZYP$B7V=X_(71E_^Z0ZURZ.&A.1W
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M29463(223:WH@*3KI O@E7X%"B]P1_LBPV\FP:TZ2*#/=, 64X 3KN6OWM]
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M:@!)5"]0PI2JTW3 T#_G:<S$T"!<?_:[5HT1F>@ ,\%IVM$\Z/!*O2VM,S"
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MHK<HJ.-X55J[(NC(Q157 X[3H[6.T '#;VFA]VG>H&''?X0Z&?:G)C;U"QV
MLX>;>4T%X"K02^25'AL;(R+8XG,&%]FVK3$4U4#H_<;Q76 P[I+$UE UBZ>F
M^(#P7]FBE8TA!YA39*YC"%\]6BD/@5$H[4LV*P8%\+XW?X%_0I/FXR5HV,";
MK.F :HL8\CGEP=92G24UZQF.R.BCT8_[>1&)PZGO-LK'UQ,@LSKHMH0I+Y(/
M,6'+F)C!$!XLB$L)3Y6E,#6:IG@F)@@,I\ \:00DK42B+W#K'BN9]7@4V1J(
MRA1[J*8_3:G^^Z#T"AWPM[<7U\-Z(Y$N5[X^@V&'/I;PY:7LZ_RF8,?PB*<N
MF>O?)#8_W2ZWU38"#SR/K?CB%9\7DE=T?;G4;").0+%.R^"%@C^K":S^]OK*
M 3.A&I<:TLJ.T"*D8H& -=@?G9.NU1J7-U4QGIP7X9O*.S$B+3&];VRV8Q1G
M=+_5CW/.W2K ZCEMQP4]_W-&J7LE,/ZZ\G?IQLGOGC#+<NVH%A&33+_% L.S
M2I]&;,P+SMR"74 >AG;<:\-]PEW]<2_O]MGS"8FS9B^=)0)-;'N-ZQKF)C)]
M<Q@CL<50<1)1QW=14^[DUW1 ,?L6ZN4S(.6MG1P=\$BSB0XPG4>!B<R4^%WH
M\;E.U-H36@A#]T?D[+C1E.F *CH 3P=0;[;R6>TF)(!WK!^B-K/:4>M89;#!
M/.B0\\_I2'$HJEY'3D%.C2LE8ZX'=2P"Y:(#]L],R.S,,G@F,>82XYIQ*\:M
M1X'%WQG LWV/FCRGP+CQ.JAM"97;LUM,+4"<H]9@'K< YXO:J5P/J!];.6#I
MK0F$.APMM016EZTR]+!Y9%\(W/%"IV _>13X7%@PP^B]<S \\W3\@RF^OV3(
M'EKS3Z^BLU:45PD#/I9Q3R:NEAKF7^5>.OMN_=&&229.C%6M5\Y0SFW$&-0X
M?_UG>C;S*9/ [+-<X5SL+#H3P=[OW#JNQ5@-%99-& D7T 'L@\<7Z8"A/@H_
M'="Q?8?QU"4[F%%AQHA\M-5DR%=_$3K@C3H=,,Z60 NO!U$DBVBNM115<CEA
M8N%TA!_>*RS[!F$P@0)V*AG,=? 0OC!6KARG/O/@2W4EIGY$O*$Z43^O);S/
M?.1W_JLW&Z>6FD,]DWUP+H&ZL,2)<%Z5MD=5FSJ&BNBS?(W7<\TLQ-3?+5A>
M33=N'TC6E[+Y^2-Q-0#G_=[.4]6*);(@JH"_\:FO*W^7L>2W]OK5_#S))O_$
MEZ8[J90+$[2[5J0PQO![8>>.LN"6K4T=<X<*]5ZTC@TZ8/V<))&,IAE0^F@M
MYG3 :+0$,6,^X5!(\S(=X*3+@$J1K2'MUW?P(C2>01R:$-K[-+(_B(J/H"(9
M U3020?<9M"&VN#:)0;W@%.]R/)%E$R)#N#QG[-9B^NB/8Z:VH"'$C[H8R$%
MZBTL*)', ):(+"_U%1WP^T47FGQ9CY**8B04DH$<9E]Q2!J!8K#0:3W&W1EV
M9YW[43.#9U$]J,F+J+T]X!H-\VYPG'$C108ZRQD![CL7!:XLBFN^.>YMC >%
M3J>$+= !0/OSG&Z7$RQJ?U", >\1<\X96)O6O "Y.D4[^[7IH,; %((![SKR
MG"OWM5:5-L?1G\^FNM0/_<5!+L;#R0C9!O_E>.DX22DO/HM/*8DP2A'_P[SH
MKT3N&U[FS-+P=*\20\.L^\B!=XO3ZPO"7VFW?(4\[A%F&_+@,0;O9]P;3Y<6
M>=@XMPT\'%4JK?<J*^2[M"P3*>(=#.QKYZ;F1.9"N"/0864-G_"28[F66FOC
M(47*N['I8.XB,XL2\U)FV'"F^RW2.X%WT&_YJ ^8\-I/S0:X?J;.>Q+)IUL^
MPFQ&%7_/+765/&A_*>#5]JM2@K6)R?_ZZV',P-W[S.&=^*O# ? 7^VZJ'O;#
MQ=*>,T78NCM'NN_&;"S6Y;@-GZ7OO;/ F,][D:67JP/RD.UT@"![6IK8Z R.
M%KM[VQI1:GP';Q5J1M:W2/CYRSJ?=(UII[YQLJWT/.H.(3Q4AASR5FIZ%%/C
MD7\TD&(5Z[NUPK_3[[^H'1 KOD8@@5/6^M9_C-146EBTFJ@F#/0P$-/.C5 N
M7&5@;W^\P>,"=%I;CER\P*YG40]-=Z'UU?S8$Y2!"9;T>'D5IN6&(B(GDNX"
M/*)82,W/N^Z7=[_-%:=F Z7:S?) 52UEI7@)T:;>^X&V<S]-IR7Q\X;WPO77
M=>3=)QMW,C9^2_OB6SC#AM>^SYGOBM!8DQETYTK8I?7/=$"/JEKE)M9;&;[U
M&R@--67$ -N8PUU$#H@.^+K"SN"_7O!1<JP*@D&%IPJ(&"P=\#J;B6PT#WT]
M*SRR3P><0"@Q^'M+HYMVB5C[&^.J1.,FC&?A)BDW9SEK":TAE;^UVTGDO6^(
M.WZG:JI$K]M![P@>3CZBL+>YW" Y9CKM4HSO:CNF.UT7>,^F\A=?8+=:\_V[
M1EC9QT1XS*=CB,MZF=+%Q.58V)<&W[R>^X0I)(@YHF]-MQ#$JL<NL"_3FV^;
M9ZB4#'E4;#Z7FI$TK?3EJ7XM'7"RF1JN+8NX1<;.8Z:K\?X9/G_.UQ<6'A,G
MSH57[+]\XP'EH)A>Z_?)6[>QS%E*$R%L%>8];QP;;WB>\L.=<V9F<O4;O'KV
MU]I;/ ;T^-#?* ['5I+OS9]RY=USBH7DQAW9#KT4Y>+[Q4&:=XM[)F^'!F:I
M]9J7S2^<L:C@Q%%<1 3OJ'6UCW2,)'6:^0S#2RI^<X6^,(O-J?'Q-ZN*Y3(Q
M =>B"&8@=EBK)#62H1>-Y$PDLY2V3^OAC5130TX7X%YZ&$ULBH71=@PG!%[<
M5'F[G#_X=.9C\A"&C=##;<72@U!5-RXR%]JW+B 5/UH=PXX:^]G5"N[ E$OT
M?GGK2%I^]9'L5W@>49OP[M, MXA7IN=N)3&'<G[0NK&)FH846TU*<YC3(4^5
M0!X/\[CA8RP)D.!T6_WK':(!*F:_E#Q>B;4$GOF>/S%#/KQ]'E]6T6QFAGYK
M&CM<.Y,7WR-V([!^X"JDAG,5C@3U-Q=Q&\^.$G>7-M^MWGLJ,U2X15T@56#8
MM#?_0^P%^V?SW] >_K->]3^;_QJ<_$>O5XV*@5!X-1:VMK?$&&G-@]J$O&('
MU:*F)!,WNE!G$5I2;_-?:RH3#/5;.5:#!R7<JM,'VV,"@2D\-[1'1U[=+>MD
MVO%_!?;%S,^"R>(]H7\JE*$(IN S%!4RVE/LH T:,LLSIGV#XC:4E^+AM*
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MHQ^UJ<'!\+351T Z(%@8]2V//$'KHP-BZ(#]O\B.T %MAN?_YLSPQ%4!I^B
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MR_(HPLROL/^=AU6!F=E1^1\"QD(O*8.9FAVRHM=V[@12DS=0C7GY(4=45M3
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M,\OZJQR/-2_>&JK668S@VYN,R[O=>FF&.OCCJKZ/U\&$;RUG3^G>Y"5-2G"
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MO[1E!G@%_0+0%GZ[OB)MP"2RSPL8/UL*Z41O'1M@BM)JOS8J@AA*U^#^?H=
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MZL)CR=HI4U_J78RU^Z24U&]:I]O?>_&MJ 3#QL_CWW(5+:?,+=1G%E66V7[
MX<\)-XQY(I9,R-I!2C,B$:OZR_:#Q=R(DAR7:*<724: *W5&[=L33+JPO2\H
M; =7B:Y1LNS;=D2>YPI&CA;OXN>9K%?;VFIC B,-X6ZX,$[9KP^]=$O*0^F
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MQW>-[X;K@XWUQKZUZ. J56#/]\(+OHLH5J4XAW%YL?\Q/:ZE_R4TZ"EU#ET
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MC H1/& G[L:I7?3E2HM2$%+I");?"+0+G,I-7;8=E79^@&XRD $AJ?<NY<:
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M!M]V%FZ9?OOLN=$#/?62-%NEE+)?M>N-*MI^E0+NW&F0,V,M?\CW]%>GB+F
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M@7Q_W?Z:D[1Y(!"O!B:<1,I_"ZBJ:A%=BLW(>.W\%OPWK%!:_#;+5=Y(8=3
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M;S#X^S5@BE38Y%7^Q>VG-(RU[5S5_VZP8C=3\*AWU5 LJ:U+H,#_^"6-)^8
MEPVPSE3V<MI^3BS<(&JNZCN-;<G(+4?HVE<0Q<?,*CRL5J1#V5LX8H >:J%!
MREPR85KG$?EN0)A_6CA7IG!_TWCDQZ94HD"HT$G2Q,A-MO<TKY0F &=3^D.
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M7O]IHFQ6*>R._^F2\G!B?+!%SK_5-$@*T3>V/X++F&8(C6ED40*ZB=SZ B'
M?1Q[4GU2ZY+3J;-[JRN/5$-CT0&!R7.'X.AZ#YWB3H3$S4U<[&<B4K"O7'?+
M?)\TG(*RQ4#A6#/IDY$@"<X6ZB-!'0QK_A@+M\(^*_I3O-4S*HME2IJ@*_+'
MPOP'CY!@4K/JFH1KO?<)\J/]AEI=O]Q\Y7P=>DJ^6>(>OOCKNEMNLEJR[X!>
MY-2L_ECX9-=,KXO!C)^_WQ>7DQ5EJ3JV)U.7'M(*/_[X[-V]SM;''"VE9X.F
M,$$AO06L]P#/,I:3ZY9V$;U]'>YZ2'6FV?GA69B$#9NF;_P\\<IZU79..?_'
MH#=#Z7EQR*(H=JL]DS\]^O#YP-XU9H%A&:<>!A/J^6.(QE;,K?Y\CYN7TV$O
M.U$"8;6/Z:I9>3BW@2C]:YKD4?@PT6?PN!MM%QPZXB![M9"1HG (&LV4.+DH
M;M_CPQ+(!-I-+&5.;Q9ZTO94POG"0\AY^":_NN7^[PFIPI&42WZ[A_>65#X\
ME[@?>AFZI R:#2TQ,CG*Z[#0RQAGZR]V?O/JSH;7TA]*_BSNWL;8XSD1VI]R
M66 F2O@E!@;,1YPCG*SA,>')\23%H:6=E.EMOD.2HB=^&=%N4&FMT%ZU[?DD
MJ%3JY#O2YF0;EK296VO*;?714??'@++O>DU\>0T;H<A2FI,8T"1B]Y_:F8N%
M30,O>).WI/ Q%C-KB5\X(,5(J,E8POQEPC?!)*[H'VFT@00=B?UM[8 HNJ'O
M[0158J 7A$,M\=P)+,^"&4Q$15T,Z)"%GE@ M\&7Q<!1CYN6^ &Y_R0CBSO_
MPTS+;TP$AU8S_6X$"?YL<>M+9OYE@<L!/:GM@BXXF+[*IV_%A][Y6W@IFN;S
M@FC"1O6=]V8NY@^:WD2D\QJ^?3E!]6JN^EI=9:N_+I@(,#GOP4^^-G"Y\"CB
M+ZJ@D;-:KF:B[^I6=R%+H1RUW!L0LXEQ)RGHMGX@0][EO96U/TT9&MC?^S,R
M_[.>/D/^9RN\QN[DLF PHZXZ?X*@TFD2*^\[)Y@_%L85Z3GV_LH_S$>J[4UM
MN_RTF3V4F8SZ[]-34].C%8_YW_>J;=N>AN,K8'UX0A_4,,7L7?H B(E[3.NM
M;GM1GP5_:S)5!5D.,L.?C5LY1K<(:X*ZZ&JP(7N=IJN;W7/XDIIOVXV2G^6E
M'VGN+^#H1H._!K\I'^#@Q_\\LM$*ULN@J]%W1("N@@Z*@1*OFR7M2F@?0Q4Q
M>0Z+ 6Z)AFXW_2-^ZAO4TF068#JD6 *A#U^LBW6 LWBU4I/#;GRO*)V2" _H
M8W@N+OAG[%2<'Z^5H1 ,NO\$'*6N)*9/F*D7]X]7>:1DN+1>!5^\]<WL=R,+
MNGQ4\Z?F[V;3(->]BO97LWV434WGYO2?^[8.1,Z\U+#]&O=)$B$Q.=7@]T<D
M> ,H>M)R%_QIOA^C.RPWP*:74<=B(?9'OU:O&/AUCCH93/0>EX2Q,B(TA<@)
M!Z68WD;]Y;SR::%P.\VB$Y$1'J')=E!0+=KQ,NC<_54II[!+N?XW<6SD<A#O
M!M[ANWXF',L!<4W71^3TFAU="94\ _S>'D3SI1@X7]L2YH]LD4 DP'IL'/O]
M.;2\GB &_(E84LN!4A!!V?!RY'IFT\CTMJU;W6 &EWC[BQBX=9T'ALT:/-M>
MJ5H0\DO]!/GYOI?$XL!/ 3$^;*FZKFDL'BJ4'GY]GNY%?D&>V^3QB>2VZZKG
M5=^-#KY!Y$!Y>[_+?A9[TY.6<@/^;!9GJ^D9H+W/6$)K$XNB:D51O&"UNF&O
MK*^B]Y:#\L;+<K;8OI:,MP>TFQI7W;,/##3>UEO6\?8B]EEOM;AFQ=-X\O.D
MW85-LH=R+>+--Z[_^]RZ77\>]B!!3K&K$0,X F.GU:(JBT#HH-_&62XQFNEK
M%)NZ%M+(3',@7^1.^[+868WM\NYL:@0K_E-8$6$-?V7<KW9<9MHJOO=\V /'
MFZH;L.S0BD6G#DV3;_1Z&-8:GI*#AINWJ:;>Y\68"P(@TNW 6KQ+E)N?V]XZ
M.#B1M"*C,U#-MJ'=\VIZ092S?6I#P%U?Z=)MEUK6W#/VD9C%0XZSG\;JQ4#Y
M[)2[<#?]+6&K4+NVO&DV8C[A(3???P:_PT*;C[.ETJR@ON;].?E_8QYW;G%U
MB/B5>_ODW]K3#U-ZGWQ85_-@!>Z[!=:NG6@?81MF_<#Z0TRO]BC5C'(-U:Z?
M8!2$R(G2 @QV'RN]A6SF?V!2.,3(7M6>_5=:B:&N>_C/D_WT\I;R"J3&[Q_@
MZ5W!O-85\*\6'PMFP2R8?W\C@5B#]2S7;06GA '>JIF3!XS;@CC.-\<ZM0,I
MVD]?]=6<RAIJDEGYZM%LVN,O1\T?O),!5&S%P#G"S>TU!N"BS8]\Y"-Z-UE<
M3'5J;M@V=H>_6C9YY>[+;IF';Z6O-DT_DG%_SI54>&%/NG[DAEE9?QT%TM#7
M])W,^NWX6T=%KVY<W)FWY?.)@7K*FOAV8[Z-["%-6\TW,SG1JFOU/QR/R4DK
MM  ._IUMK8%\>;J,CHSI>C>L.-'])#5J\RVG!\E%=YS\WRXWSQ31I><C: 9=
M)O:2W$16OO2)05'Y,ZI"@YEU8<T,.&UORIJ_D?JT\N:ZY.D+K14AEZZ^+?B=
MS3MQ3$V]D;;K;KW;)/7]K$G3*?V\NOS;+<ZYNUN?"9S"$JU^#ZML/])\.N<P
MJG[ _FJW&%B4\PZKV-ZZFE?QEY],PS44P#O.'.H(&(;7>TVWZ-YV[??SKS&
MV@^^<HM/(]2"_')N:4%$[XKA:QR?[ZZVP(E7 <L)HY;2\(SCGZ=1;V"E#079
M_K$&JYL6Q?;5',IVLUU<T(QC#X_@&_&X=YRPZLX QA)D(^R@Q?<*5:6&<E.9
M/B[4'WY?G-Y!$B)W1^D/^-*LJ:<04?!9Q$#7HVWX$IO0:9H7Q.0=BS9,S&&;
MU6OD/_/9C KW\H-N_=J1/^.VBQ\15JH=>AP:JESDH,-X,;"G7:DI][/K!PG4
ME@@Y8V7+NI9I!ZQ!*7!<SB <;?T1_9O^CCU4*2"%#9>DWDQ_*P:6_/JB_.7M
M<ZH;;V]^\F !2PS<7F'XS;0[T/9,5XVM=MX<*L_LR4^8''8 D /_8YF14"&*
M!D\QV5X"$?R1R[P)%BLWS*Y$K/C6A=D35^9G"DYE#<9*TW9VS,[T#HTTXU?2
MCAA\Z:+AN7[;UNULQ.HPXTL>QOA^]LZRK+P3+N3RM?@9.8A9OX*V%?:"9KE-
M^0.D 1H1,KI%6TFA37S=.:6AV&$LDM(KC[[\V^^R>LC[M[4"Y8'*PB1@YH4D
M,@9RYF9_;R=](J)OVIL8(GO$W!+/LO_S"(#H&@4)S2-^>]<G!O;86"I[8Z+R
M'1$V!)%GDN@RK"(]5\W'8YIBPA+/:\&&$/@B$5$)$@,;,N%*,>#5^>=)Y2.,
M*:XEOL_DSZ'$+ECA4H-E]76(!O9=C:@7I?;^L(;=A2XTHVZC/@ZS^6U 7\+0
M][=-32,T _A)V9) .3=N<W'V6T&N[YM3S-X:B=SV0!Y>ENUA]8*:S*+_C165
MNK'L$8&)*!,\1;KCVO<ZEIW(=8@D*")6G:P3;OW?MGW;%LV[H?C9WM>7%[L(
M3GB;U5%SBNOVVV_T;K<')/KU*[(B9+3YZMH>_5D#@]>$_[XH+/$N;^I%E,NG
ML"..+H\C&W)>?(F_ $AJ01LDA4E8U4H3 YQ/LZKP;)/'TC]/%G(R&#@C"SS4
MRBJO<HY"Y=!6NFG7,:.5R*&>=7MZC!G*R#EH$/Z!F$)"AXIMY:X45NV5#SLO
MMR@[EB/:U\X]Y(P?9C6GX<=+;L<]:U'-6;_QV?H-1_8X*AT]:KDL!UB6!@"
MK*/D"^#?X,B,KO\@VY!VK.L"7+1K^VTB!>RG<)(]KM8IPZ>$&UI&A&J;6E;1
M]>%:OEM+$C'RQ,LK$54=!'E8*7*9C-:^U?=R2R3G;3!7[J7+>(L!62;G+@&
M;YZ1&G061,%]?"8OM3* OR')UF+KR%+ZX@E!MJFAX%@O<8EFZI*B]5$S0L=X
M8]S%K6\DYF]B097!_SK+HL!:?8BB>9.KW]3\E31&$:69N+R?Y/JFXS/;G3K0
M$#2T-.0Z^3YN<>,E:M@!!>MCQSW[M0[<S7DMB5PDGHT-=W5N+F 7"\[")B^M
MOX\S5C&]'4*PAI7>3K__-MY>KX6Q$C'ENN\V3D1=S-D^13EOD47ATY;XF4$*
M97'&"C:;I51:6G)H /LTWZNG+-I0R)+=U)R[YM!>U;R+S5$O;N?D/+54E##Y
MXT=IN S3)/_9^B_ZY[QK_S'DJ9= 0@P4V>:+@<GW_(\ O;-#"A=%,WE&[69I
MK(>"(L^?_FBQ@]<FXPSU,I\?W"J5_LRWZD9S8LZG]^9-06<"=]:$"N/_O#H@
MF7+9'FWN+;VA^<&.,97OY-A-[U21VH&R@@P*4E0\EME]I1S>OI&UQE%:^!"L
M)P8*,3U9SRC4C3)9E& N!N3I;YC%_LP;:SB173^.PR:<-NNO.G)O'IZK"+RG
M$12:!*!>1,Y7C!*DI['B?U&1Z!G3:SB,453;WN!+D47L8<T<ZFQC+%^2*X19
M3O;T@1:SX8A3]^VKT,$N7FFI/:'ALRC)SBW,-[AKJQ+%,)AX!V1_0Y?+8?10
MA+)3%W]$5]'<1-FE*9+<B-OG9W^VRU,5.'/A6'()W<^WCLL9*$W-3(.SCD*$
MAYEP>>/0FA[]5#L#*Y;K[.U?.-SDJOOVBP7)%^[;5DC.4F#3K>C2-JR5;T6Y
M3&]2!$%+5, \SP@;TH$?9_F<<86DIU;,&\4B:N!(N\*$Z<43XPE#V^&($88<
M[%Q/MPA1\#-\CG%^G:(/JE_+MU@JT?NKJ6/J%Q8CD\'XR1K@OWU6 \L!X *@
MOA@P , [NHAR.Z<L%I)$992$=)I%QUJAX?T@?ATE:E59].IP-6MXENL@BURJ
M+"D-H^\[[^>/KF^GG)(]=3KJW79YK;LF1QQQOS!^"0E"W'KI.]'7S$*;9J:\
M!^A-3><53*4+"?!<4U#RXSNH/I_84+!L<NCO2^]='C.Y:RM[CCY^5.BI]:1#
M^E//OT5YM6#^BPS^#@-"F/U;T<BQ::RBNI7((J'7 X4@8DG8) :>)LJ!W'-D
M,?#A#)?9AR2C-XN)B$*8&!A]+08BOJ)O&3\=B-X,1*M.50S\&$A'U^)7@QVM
MX4RHV%@,C&T""WZ;BB3/@;"NC!AHP\@7URJZ3QQ/I7<285N:"79)N<W_^DLG
MQ0#I.V5>ZCU&;@>5Q4"R)(I/%.J G1:B9R 4#_N*@7;_6#B8=DH,6!EBO]OP
M'BLRG]2CS"_#/^4>8TGFB9$8V":-$(T$!\3 LZO"/6* JPUA94GJ()X/P"PT
M_ 3VTV&/L\3 CE 1^)8YKK85H]CM)/0\#J:3IK![[/DAB,3N;,?%TN;.*B)/
M@A\ADJW ?EIFJP-Z67H>2Y]@QS:L8@FYP$0^X?]W%P: C9(CN'F5"WWHJG,,
M9!2'#7T=,9!V'LN"B[C@[U=$[F^PR$NDT,[6%0-+C<*9B& <*PFEF_$_MW +
M$/TVXN_W^&^HO1BP[&>@2QLP_YX$6=_%P-GV>5U&B0,J3Y(#?T]WBH$5N#O$
M<4\6"79) G\\(B[ M #3 DP+,"W M #3 DP+,"W M #3 DP+,"W M #3 DP+
M,"W M #3 DP+,"W M #3 DP+,"W M #3 DP+,"W M #3 DP+,"W M #3 DP+
M,"W M #3 DP+,"W M #3 DP+,"W M #3 DP+,"W ]%\.4T0_L\AHNA5*%'1@
M7@H5 \NJ6<,KC?'PL6$(<XH_V' C _:U$SHC.G@H7@R< \]BKC+G#2O^1FV0
M]>R(@;I^ 4[O0[&0R*:]K6N'$,_7.UHDL0O%@._I2Y]M!(P^0H$HQ4W)^?XD
MZ:B@;N#;=@M=(]/>"2'!@4QW^7')U6)HQJYQM<7<-^*1S,BL7Z0STX3"98[,
M,D'-D]1WI6X#GUJ3D+(:OQM^@D#:KIE_]:M-]* _>Z:"G%02CDG!7#9/BC")
M.4[%\[Q"#/U_X<+%P$INM_,1OW6EBVZ:@#C?:T$,+YTL;DJ J\O;0%GE*^5E
MJF%AX>F>YC9*@N0<T/(&GD9OKUG".^!A+G,+'> ^^?YP#7$E-,7''YWO8NV_
M5#^Z6M:A.'^-#CDX4,\ZQJ4SU[I.M4YWJ:L,NZL@8GXYOCWW;."DK9, =N4?
M*K!*CALR%022][=99YJ7GGOBM72_O.WW(UG("^HPNH0H!A8K0N6W#8U!',T4
MHC3&&/Y]91>O8"G-$=))3G>WOARI6<*?*><P5S:56OY8-;([ O?PSIMMQ6!6
M);';=_S78\[?I_E/[%(N"'0<1[,?CB(&3_J:#R4>OWX^0N[)UX]@]88S)JX5
M+,]Y=PTC[F1)S]>[J1H.J+MSP^F4?3_G4C42UB<R*H^YXG- Z" 17N=PNPZ'
M'(""6ICL5G>H+C./JH/V-:;*P40N><"]J)2_,[KE8OKDD#E?-@$BE\M3Z2AQ
M6H:(@R\+G0Y6,\N[#6<M]AH\<:Y2'_YAU*4P49IPT6:YUQH9+@%GDG[K _3Q
MTON1.UM]'%MS/[[CKPS@5UA$ZX>Y?HK:_'Z#:5C^HW-*FS[=/N5SVKNK-?MC
MMIVRW>B/F:U/W>3<)!\TY HZ W)&?%KZ,VT'[4]E^YI_C*B>]LFYE*5LHGIB
M1FF=:)OS[PKZA3\OT7ZE(*M,T:6Y%S'ONHKNF)#Z#[:.6*=#1H[W>;HA=9H3
M0X;E$)]_+N:%.VPN=-6"QJ)I)AK%7&&,&VLN[ML6G\V9985>)K&W U(DC^)]
M8AWBWWV1_*V$\8,ZX6\QT+6G#B\&>-OA:(S31(!KD1@(52=HWG@Y++1!E^ER
MXDZ-9K';$J>X+TN'X^)&;SQQX(>M^W%ES.M1_=8[?$O\9^<I&Z$VS4(41O0T
M"L$7>34,)(NLZAF++91]N='VE*-10W+.C54E<T'7^J(LG'-V>2_.KWO*8RCZ
M)+7<-ISVF]M%WO:LMZ.Z:=D.8/Y9\#)@%#G%F5V"[(;JJCFQ&C")-60">449
M#\3@&U,5^!XQ67 HZQIZ_TJJ>^_CO/&D_-JAY.SC)W1;33*_EG3LVURY?#$
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MY=/KJ!PFM>&"9PTGOGK'Q@0YZ0#$%;BZCQL;0@-I]CM[&O1=FZY+#8K6]NR
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M)<94X%.3$YX7LOW'VXY[41<E:LIN%HZ$7Z?FTGG$KHES82V$,=WT*G)YWL?
M"^YNUW&1T_\N,5*[4%0P8J=V%RBB5V7=?S0L/%K8(\PJ*O#I"Z@Z>_],<+Q+
M\ENY_/6J\M+R2]8DZ\:&DL8EOWP8S;92^=Y<V]+7([-2Y)'7(=OAC7([M)VB
M3M["V@V[/PI 5T-H&EC:(.-MZ:BVS0F,_$OH4%CI8PZ"?#"NL;53?+OIQ[Z.
MZ;&:PZ[W=P;:7'C5\0>^!T,./K+45I:2)MNMF"M2I@H/>#>?>8(8PWB(U(CJ
MWMCYM!0>[1/8RCB$LG'^W]P"IG12,'O\=/PO+@T_#;Y=(TA)J*:;H@ 0YW J
M:1,S@]$A@T,3Z5A^/ JKR.T1W1[DH'1R 5,D7?M*2L$S$YI]*"_3:I6XQ65&
M=!=^AE> D84?Q$VQ>FU %^3#^OA]8K%J'5\L!6#SO(G)!T"=-V\5^QV_)'QB
M-]0B\;O,6S9,Q+,7'6,2Q9.IUL#B +8E%JX62UJ:(OLE':$O):GRALEB9'<Y
MN.9]PUM9/* A#)!?M?EC[MFPW93>P5K4!O8#-<3I FXB>TLW>RWB")K5,Q*R
MM."+$+'!MCTP<C*-%201+0RPHR8AO@6C.O-OSQR UM8$ (7>QYT>?KD-W8UW
MQ44MFSL?\26"AZGP5A*J#LGM@+J=_'.3,?P%@'^:.NPK >HFA=ND7 $'![,9
M%RGSK$?*..JP2V-D:DJV1TLA'%OKF57^I,7H_F.?Z&\Y0$B(?4[_YSKU!T3-
M_]=$A0W@2B$@KA1-A?*TE;B&/Q59E)^]K2I*G/9<J1F#/SS",L'^YHO<'OA1
M^H!0!8COB, _2<BR0=EU+,7$LYMH.!Z)W<9>#A'K)Y,Q:N1>CS$<U*$UB#V/
MI=D:; U@]+RAVRZXY.3BTH<(I6,Z99-+YM;'*8S0MWU>;_\,K[,/5L41I@8?
M$$SA/FA2S!GO >7N<)%\.\L-Q-=QXV>78(:U- ':U0<?,ZD[DLZF.J]\=NF'
M>U6%E\)SY@USJM^ JN=9G/>';L_^TI<O0Q-C*'$4V!RC:#\93P-\S.&Y2QR%
M)9T3FM^]_3-Z)A('775=-WTS=U85A)G5MB38*:[Q2U^\2+QE81\-+:D7'.S@
MMS?=%"\G <]91P-59K%QJL6SV["AD28VRN>S6U%+13;/#CD)*Z3O\;)7$#Y^
MBKH4"8!O#9*2R*;M]G8</)D0V#:L'_QJ,-KO>->&,J<P5^JASI7M0=^RGUV:
M.<![F=2_]M7]SSB4.ZPJ%L&_FC53$XFE9HC.*]EKQ0,V(5#&(V*I(D&,;R :
MPAK':]I#WT=V.$,VB=FNYW-&=?R%[\N_WGQ2E%/K$9>5XQ?FNWFE2V;$0PL#
M''"7A.S&4OY\GA*7G0.FH2;IXY 2]^%#C"$'#.,@NM,>Q]!.'\*U]:\Q-/>C
M](Z;$+Z5I$G*@O'RXKS6)-P,*7XNO2/+9NKT%IHE#2GNLC?V3:JY,(C(LI=M
MI425&^MY2YEO)05-\.M49]TPQSIFSHXOUP@BQD<&2B K,GCKQX2$BT P+:9*
MB1M_'Y5_I] /;@8'/?@P%WQJ,+2.4H8)->O6*2RLT,5MF:3E^J:TI<$6_:=N
MC$C+;D1E_D88SY:D-TPFT/3M5224),Y"^R!)VA6,>U2'9??1T<50<ZQU)E&+
MZ=L0:?V1[(K>+!@II?J%+9ZZL7"G\U>OXP*'HOK=(?-*5N+#_K>K4)6O2MQR
MGCF3)':LIR:*#,@FH_1'" 7>+2;H(2Y0\=,^BI0F8:@.ZZ&F/<$'O0<]UB:[
M=@0OTIH\;#]P?%VX72O^)Y79C"Z>NPW4,N9C">TOD5"%^+JL12"O2.K . R*
M8L6P!FCNF5"?,1_-"PG+A@.-?#W@\/""T39_S]"*V>.1605A(4]H:_*K>"\R
MOGJ</D&8^H1UQV3W&!,5KX!3M%ZN[#D(E>Z TB47XKC,]/W/@KJQB$K(6\C:
M"FVK;[W_H8FBP=K55NTJ@?O_CCC5<>-4P=?Y..+95DQ+?L&8'?X^\.88>05&
M(*XC&(OJ>BG??@ _@XE,-07P9L4_D%*V<T*)FS:'''#LQG_.CL"_CI+_SVW^
M=93\'V@ 9<]_V^["/5ALT$Q<1-9']I<_*X%O@C]J15J%92^_5'5L0,Y++%0;
M;U>%=4)7SKY\5ME3)H<+AS+6',O)Z#>YX52[Y]0#=5QZ'1%3;\CFCF]E:?'H
M+R!-,+%V%ARU%?I=LK=X"!^F5G<NTA)FR@LLU)KJA5*PSZNO+_/)J8AW6KMT
ME3A+TZ.XB7]?N]N3";TW94$57;X]17R_EHNRV<_N@B/)'K$22HRTZU1G@RA
M_VKDU<A?^G/ %Y@BT:/_]D*'/?-.]., _L5_3L1)Y_;A5L 09(:J8REL/EGQ
M@+=R5%@U&CG3V"*DN,$,L%O3\<"]$6-CT#7A*E7 N3R@7YFUX]?> 'U2_+FI
M=9:Y%96I6[^E/BPHSW_)>[%(!2WF@/O28)/F\2",8O!@%PE!'3&!Z1*J#LO_
M>?LR]BIV^\ ZL"(A"@*:V:MY%X'*,Q60???-P*PE8,@^G[X=X-J+44&/1B*/
M_*$A*1@K'9V5/569+3(]_]:@\5?3ZTXIAM?_?@J]-GCB[KAGOL<*9S>W^1[.
M\T[%4*QXF,BK6TD19P&Z?']B+*7<=6A\4,Q18;>*5-F_PBY2)2Z.O!XQZ3C'
M6P''^D"4V.E,US_K^Z36_'B+#5.T*U5G^K^D//*A)%O54+TN=1--]G27W;KA
MNQ(_$H<#DOC--ZB(;M_@5ON;F*>H<.)K):ZTO'N=JN+I?V#_#9E5)/+%Z902
M/43G6Q^M2I')6PA'[8*&KEI'1WE!G";2DKH@*?>JSZ]5D&XV.0?PRX>5N(/E
M:'<)./4G]8L'DRH0?>0M*W="VXR3%0_/1T==4)G5V$X<VHA!4RI09TO&LQ;T
M 'Y*7!]'''ZQC!1?.7>QU4-*N2PRM-\FGL#O:[4WDU(-/0/TR-9@>L.NO(#?
M/#V%<$N#_AEN<AF&X3Z%>'3)CFS_JJ):5Q^+4W)WG$)'B8M=BY+@TD9B"6>"
M#M*.55?5@/QZJE!5X/,K^.>GGS<<<\P:T^8]'YLE<\Q+G$*G.U%B"D-.7N8D
M[BR?V(_$VCPQUR),'/K'5A8<B?770Z$SX-_Y?FF]?C+S5FL*Z2C\&M+PA <A
MM?9N[])F<5J<?@0X%#O5OW\#,NN7B/@-FBM.O9MW;I2F&:Z7_%IC"[Z' @;?
MOBEAP&:.B$&_E"K$Z/N:C&-".*M#EJ8H9=&"MGK1Y0I"W6UWGT7@A;1%XSF?
M 1V8)M&-"Y>\=6*)[(8:KR7[NWY!2E[@OP]A&/X2(4'4B?O8S&)</?XZ?*U%
MZG!8XI[ LV=W UK64?F)95WLU<QO7VGS1F9"7J4W/<8$#@\E=3S\L>\K0'#Y
M<]%UCY;MQ-&2[<3!N9LL6'IX$ZC$,5KDO_KH86R!"LIB*%W)L@.*3(QC1BAQ
M9[B]Q1'H+XA>1@0/AQC>#LB!O<01:VY[8(KX_.<;SL2=EM^WW?@P[K)YB;-I
M*YX/"*S0#[2I[>2%2ISD*4A2XM;YJ^:!G'K"9=XOG6>Z[37 5Q+1I>F((M-G
MF4= SB66M>3]'J\5I^,#SN7PVJ;>;DLONT&/BCA=$;"/9*KU:I7_M7S\H]9_
M0Q[^ES9/*!>)\+865$-5FK8X,!%;_$]@5:EYC?HV$8$9U40K%R5-.>R>*#=0
M;&NXG>T!NM<>7%-X_9/'2$9JW-KT0=&5\\1T6KLU=_[P+\#X7997SNAVXE]*
M',BP10P$<[?T-V&B(Y C?,308CK*S$'N%<:4$5XP:]35'3M(%)HT9A@4>O)N
M/ABC:V4*1(N0;:S]=Z6BY0$,1=%3NNYL0FRU64A>8+?^-[[D#\*40'%_[JI1
M+T?F"![E"%IZ,\5S(NV2\9*RTK+GT;82T64K@' \L.#,\E0#_A*Z387@..13
M+(Y(CYQ,++?P\NRT]'1Y)9=GWCU]*\;!MXDW#Z0T<#5'R9IPLEBDSI37ZS?X
M[.%*J/IPE!/D'C_M%*'XD/V07A$N])XZSNG_)'QS+PM;#W,%.0B6MKA*W *:
MA-I [-N%+BP1;V$;,GLDW]*+F$/2R?$:B7_Q%] ]%3'+VRE,K9$2+_&(U#*@
MWF"0L+AW=\03%W#P=R=DO31Z-;X4#+[Y $YMZG&&_L!+"(B!+>:Y"Y CHC,F
M$X ]XS\A@X9-[^6F[&[C3>#0120H-[ J-O<Z6"EEOPQA2)0X5=:I]GGC0597
M=BL:$^+)IDY%?@'Y3!NI$>-(5 %7=5C[=Q7T^5__/J)\P#2FCQ,VJI7LKBV#
M9'/%O8O-V.QI+@,%:7FJWQ\0OA:@BQ*4N)L%BDI@7&2/R>H"HWQ5!7%8]2<9
M2PX-_  "? 0 78S,Q%GW@<]CG')*,T>%^:NLSO1[[HNY<_URQ LR&A7',RWL
MO234!+NP=W1!<<7%EO27AJKFJ*:&(KULLI>/+J1+1<+8IC_ZACWY$^Z0>2.@
M73S]:EKW;(>XI^YQ)TM%HIW_,\;9Z'XN/Y=U!#I:U!EW*M,)LB[O7/C9KN4/
M%>0I4*>'J.1CL^-&$4N/\?TI2T=Z]-/CK)2X-,H*"@,PW!&F=\\JQ;P>M:J"
M:/4*&R=:J/G)DY!C T>]VFY##GF?Y\[70?I.SPKWJ:#/K.;\8^Q8P,+!!.YH
M^&SW*Y J65M>.%IYF!8865$$BNJ$J7GY Y]>WI!^1]$?>S)&OX]&K'B<(95Z
MK+GUVN^";P:N!<M- 8I[_.$8%I:9!4?%-/1 *QYN'(FT2;-%EE7N!Z>$^S,M
M+Y*0I3X=>])WW6CJFHJP"E?D#)9$KW7=^,B&FEMSW2;H5*N!6_G:3XU?6'^I
MH!\XX'M*:;I"BW )@ .K-;#$I8_K;&/_@BP"!PI\B^%P,;\^6M6K?<BKR-:C
MC6W$I.SM"AV[-<^B,?6A;W9=>(!=_*HSE1E;<:9J=0\(QQX0H&1P<GRNGBMH
MKMR,W:H_C9G-VB;?BW8+"WTL(+5;2IP&5>IWI7IW%,BMO;!Q;/,N&XYM@^B*
M?@I7P)\?T*W50'XO\38_6OKRAL;F@(?^>B&[C')PT1Y8GU%8GQH^0-TJRFE2
M+R#U:R1>?0UMDUW!X&-7(WD%U'117&!=!N\0N^KL!L.RRNG9S#_E[AU!B/>@
M9I#U^K7T%EV16=Q4[\1I5W)/79L#5]8(XJ=W81! !=[8 0$BN0--2XD;O0H3
MMQ-[,27G#M3]P?^BQ0</TN36I"31[(F,&,H' :JY!0R_S K!3 + /7&#- UF
M2)/^*G@9U#0^C*YOG6K1"M@S*A+(*'XO[=A%]/  V15;_DW;FU]WUU1L^F:E
M@N:D4YXK<>-M4?-N5W)*^;5O7P7LZ0WZQE["5&.:TKZ]7LHC^G^*VG1].]&$
M-9<G;/]QE]-_XM<Q%[A KH:^UWON+7SOCZX$PP46>(E?BF_\F3.-_%14MTXL
M6E[;FAY@<352JL@X&W!BP7A##$ 0@5X<V-KEH.(:SY#9(IM[&AY@)C11=% \
MK+=O[I8Z<)%MDT'18AV"&9*W[O24PTWD^9#:S9R/I#3[A9*^M5%<K0#]FLO&
MOX%9"7GOB]\7,C_\'=ACIX47B, @#J+KUTP$J31A=AU&C;B-#-W1C/3QDW)'
MIL )]$NRIQ2,WG!^B.C!B=*BO6^=P*$F8/&."%)OZ+9YG6?+VM'UN\YVWY[E
M7O8#M/KKGM#)VJU%GU05OL/_VX]#*3<XL#U!)L+"$B,DE\*9X3(OD,>54:Y0
M*M)3?<&O>?.K4=?IRCI:7*4^Y2IY57]V VO8_1B$+?W%K%7VEB5U3_T]E;C$
MH'VIUUI48P".*!80WQ,MK9Z[RE0%M\W!56D%GX%CF2GRR2N0>3=>6\B\G!\P
M8^MG&U!;J/Q=VHH;+A9ZS3[K8"-QC8U7N(N'-4%W[(^][9\"FK;]01BGHXN>
M*# &5\E2E;L =61[KX+)3I;&DQUR9T2_]"6'U2(A+7F?P[25?DT^7>P^/AN>
M@!SAJ4+SRQ^OIMHI<<T\D^J3QLV;<  32\SXGW]@P3-$^WZ;$ _(3@,+^-/!
M[-:E*HHW0!V?]CT>@,UZ%-=> 8J]"'4[L>3(/TG;_:M8Y__4YE_%.O\QP:UL
M_>]W+_Y+- 3( <N!%6P,L)<"8@Z&<URAK7@&$\&'!25"ECM$:<!X&7G-@J!'
MD'L];06SU TB"HCZP[852MSP]TI90-J^+K9@0_)#F+^K!Z%L+D*3PPQ/$$<P
MVC?O&-:U')W[HL CQ'CV A@8I.IA,HPRT9P#LP=:I*0ZB[.?_=T&MG6'_KW/
M'=T,FX0\>6-1[?V ?MV+]^J\6$'^/M-DC"=$YXUVVU99<DY*:_Q59]7G<G@+
M!UV\4/&0(GY%(P#B7,[2ZHUR0B %/*!!ZGW340LL\ -9 (Z]'#G8@Z[@Y46(
M-5</-MX8\6R.LS=X.J+7T]S0\B2W^#5PWH'WT+ [Y.>>CSNT\. /+EVD'\RS
M&R.O@TP'MMV4);V$R_/'A---1;Y/20T]<(?MU;6=UL[E%C9?>\/*H3[FE[RH
MMRO&>XX8K]RTP^+9JW='5.0E&.$-PT0@QH-;HU!U# [B_08QBK]-B,DFJ@@V
M.UL*^370GI'&CW*1R)M-FQ!&-Z8(&3$9W,81]JJ/H_I^::?A=  4"&Q]; #]
M &%Y>=:3D]+;D&%58D_AM($+O2]ZWZ?&L'F'31[% $LX(&T2WB) U8U +UD?
M+)+_POX[?< 05I5P+T<VQ]L3PR&#^LCYZ2GH9L2Q$_$2IZDS<W?DC?JL;Y]V
M,*F[\-8L,;N]+).T /Z#^=P\\T)-<I/ES 69VTIBTFSX.*;E\#;LKJK3_"63
M+$P+SG> BN*S=0*U1BDZ[/4L=_!HX\1C^I# ,@'3#XF\+6#-U&S(GKJR.U,.
M:PK]KCP:<3:-VHUC K%*G#@'BP0O %Y#;=;&. H2KBC@Z<%C]>T!L\65H('L
M82<K:)"&'Q7NGL5?<IF,Y^L.=94UM57O\C78%23EJ#OF!F[VS'_1:N],#PEB
MA >KH/<YX)X6^%?WBWQQH1)7TIT@WS%<M2SO(F\MD^;]$F9 (LG]HL^5MWF:
M\,W'([/L'(NFB^?#D\=:YL.E>[JL1-JPY_=A%XLR]_0!@^H:?K>];<'QW_!C
M&!AI8Z;2:+ =H8'X/*$A;07:B'&;]:S-^0@=/-Z#ZL/]\M_I54?SDJQH<<8;
M$LZYLU5A7\G$[F#[;5(J$;X0)$-)/<C!DT6P5[WP7@CL0R&,^:RL[#H+MN*_
M V Y()X[YG+XP(5T)'Y)<Q41HK(+">1L>UOVQG;4!'$!E;AZ#>]#W4==4@Q^
M[V;8.TJHER-=^R]?+;*-1[99W\M@ ENGAK7?7B,\LK>5GP?J&BC@[VE7V-H]
M*#F06'XV66RTRZ,\$26RNS?!E5(EKI9XI<VS<4C$/+P+"JYY"J?M:;=>O^&:
M2P2IGFO(C&J\<+"9X=!86ZZV(H8 K^M!#&/E?[);@;*!',A/MD.1#_@3>_GB
MGB2R(6OU=?*"8>,-<MU;X(QT?KJ 0SB&'&X[9WFB8R*[IY#08 YH^P2PUWRW
M>-P36I!I\'/<*C/Q3-L42)@:QS)"-+.C$5@"G.!\3):2TJPG'!M]MD SXPER
M:[BCB6W6;2;?7R2E+(/SQ"V7IENTZ<*<U[A/@79-W.B(?)\/VW\$!Z]A:7Y\
M,$]110DFQ%# _9B2+VVFE>M-$*5;RR@XV-JBL-"JZ-?EC&JOP9;E@;QS; .0
M<+$L(MA"[QCD?B5XU5^>=6O>%W-R1[JK.%?"QA3F@@S+DH)C,<"=H0E,G>#U
M@#JON7 5+7>7)(RW21E)1%SUBD&'L]3%B*7B/N7T1BD#]N2M\;I[QL8FLB6M
MVN L1Y<5)7T[MD8[\(+/"HZ I_LB:3VY4?QV#?VE)<[^<"/E.14Q3 !=!)L1
M9H^]$;:.?@=3T_U\0Z2N7DV>I 9*2D^66>O4A/%:7G4W<C /IC7IH9O!_MQT
MQM+T2O>!U1VAPX5%#V^/!IC$KS<]0.ADP"8)B%&(?"^R',[!/$4$#Q$-^I%(
MQ3W$X^E'.!3YLZ<PR&O0K,YCVCPSRH6D0Y_]QC'*9.V%H_/>FZ8;DRHAS=R<
MP3$C.X^P^_@&NSMM#\&S%2IHNMV%[+S1V>C4HL<BC]$,MR=^]/R1C-OW0^9_
MX^2/S#Q;\_[^=,J7TM=!X7[A0:8APD]]KTUUZE:[Z)2=*]QN^?^ W>6G3\ZN
M.KIC0T/,TP>G;U!Q*J_-8M:I(GV84R?Y\*_AM7QA5"-Q'O\DM[>G61_?:$04
MFUVUWP'9#H:G5IL\\:3S%L=*HS\DDBZSS,5&JK1G :$3?D?!"PE/X*K!IG3]
MHUVRS)-/X 17<,Q[+?\!G$SMJ*4\F(2M>F0&4,MX"H8];3>ECHT.&"<1^-@K
MN+Q5MDUR3=7#5_L"]6GUQQ#K;&:XY&#GAKOA?<?AU/H>+^A+[LP/@^U0_.6;
M=?0PS8;MJK.Q__?6;;""QQ=?YLS5C\+K_9J*S <G)XY*1$F\M?#%AS!^-QR0
MS8_GF</)]1G&=R5&JNZ06HWOR3./ FJ%VR<*X&PO_JO[O\W8ZEW]_N=\7/11
MR !=V">W8KDJ8L<IXGOZ \G2&G.9S]R7K5G#CO@$Q&)0\[  7<^8QS*O 3&5
MEA ZEK;<DSA!3YP< E/OV!^,,K="39.BW1Q<<[P/33+Q5S%RCW%^<2KQV1"R
M!!M/CI3:2ZK+VMA:+KJJ[QY71ED>R+:&NDL&D[GCG 7]8^ZS8?&IL_G$7K<9
MVXS//?I/^V(5#]>D_G7&9%S[L^JT30REJ05=;*'$_=6%BCBR(]4D)>XI1S*!
M S"ID:[$K2V0;P9Z><@*):XK1%*%FU7'_#2$N!<#]1LEC"5P^C@?T_Z7P[=W
MA[641(C.RFFR_??/ S):6<1A!6>"Z/>]>G(UP_R"$O>KZZL%^)^[YVH)P/,
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M1=:/A:?O,+!<B0ND)58E-/(39X$F3N( +JTILB)-4D1TJP+Y<0_!M_YND==
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M:(GK:G_<$P0G<9;2C+[YL;:^?=#/%:1HG!UHIVSZ?,;#\3)Z'O>+-ZB.:F
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M'P]OTD.T4J5%6/"Q'U7@RL1]8GLA.:JJ=E*\G*%S"4I.@1XT96R2>$[&]0D
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MH2-G;%H-G9V$FD_Y\C7<X^U+B]^$Y,+W/38:HEI)!X\I2]+1Q?<4N =#\E?
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MWV#MO-_#4\_A]L:A?.IX_0-JBZ#M[CHM'TG4VQ^)QGPE9.Z,D7P"Y$)82&\
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M#C^%]\JR"0^;IB(Z(?5>BR3.[%KAI-([4;:D55H+QX>OS7X'AQ'B4\D2;L#
MP,1/Q$WBXO;Z08,Q88D:\TN?S<$MY9MYASO,T]-7XJ472TI*.R<"I]HL/O21
MNLK'/<*-;!O>+RP*+ PL6N44[F'M='K9JLJ*RJA= E:4CL.S^*6[>H[;X0@B
MC VK;@??7P$N*W"RY:@Z.+X369Z)G[XO3^%\Z02]VV66I"CR;)'-#CO"00PQ
M80BN7LSX20-+"?*TI&]HT>2*CZK39^8.+ '?+P+.,V5O&/) 8&!1)$ [WUT^
MGC@^M'T8?1_AY)S<&61/BAU3(Q:NZE;YVN Q>"!D3V%85N^7 1M),VOU<(C:
M%9UTN_5O*BMK*U^7U;"B?GSXH1947'3Y0G(X)=U?Y)?+>AUURN]%E-^3[,<;
MEV7?M[@4NLD!XY.8C4=78/)4X$KU)F2093T('</WE]71E\/:HJ1@D4\TQ!2V
M<]M5W,]0*8*^QN7(%<&D 36VM;G*\M9F4:+31YO0G "ZSL]0/YMM_B]&V6L[
MIIV=SO8$?F!FOXO(FXMB%_N:4I9[CG*@8\#-OE2KHLG(<FMF)$.G!@B<";%-
M$K0OH]X'XMG+)"[UEW[N7!)@O*43V2$@6H53LZ_SH0MFK>]756KA:/LQ8>?0
MV]*^W>1@XHX$RT=>I%YEJ\&_H7E=]9;N[*YU!;3#\#9AT 6CRVTC9XNR'?ED
M?<3F_H?A<[&C1:&.16GG@Z]6UA$^<A #0':#BI<F8+9YQ8]1>JHYJY)A"%X8
MVG\6&J[-&AYJ[F.O@]U$D_IP=C,#3PM^;K=OQ^@-%XI5*O?IX6%\N<6#4('S
MELECX53D>';+!M5I?[LEGIX>IP?/>@U_WNOKZZO"<@L+.]$2'$0)"C9TVM/4
M^+/TH,J2 TEK2]^VKKA28%V:?Q^WE68D E21 U!EC"@E#C6%^I)KE@F3K#3(
M7-NMT+7J'#B]87AUY^74T.*7SRBS9CT_'A3X]RVRW!M^/NQ*T ;]Y$,Z2C#F
M5:HNIX>&P7H\0#D3=.[^I:Z:_;+=9*^_FNGM_@J<A@F4\<\'$?,Q2^]Q1PE.
M_$MYQ>HR'/XK'EV<(EF03I'YHI_098\O>7JXR_\JU[C1\+E*-94$]361-#\%
MW%^M7=NH#1<XNFY:E/MW=<F;/Y70!U?_-U5+7:NKR[O$6YB3/XHF @.#OE;7
MUE:GF5*<K)W\TBB)!07Q3U:Q6*P8XS,O'G5NR#H4YGUJ+0Y<SH&\%#AX-Y?/
MJYN,95O+[\\UPN%H7V4F,,K!.U>KF>I4KO0F');_B0)JH"I^LU&U+ZK8&I+8
MIWN:&2)"XI^GRWNML'SO4_VQ1CGLSX&*KZ^'-W6X</.4D+=@/0N ' !=L-X>
M#"0N1GS@5(':%O BN3^[V< MD6U&<1^I5N#.(T<DO7=+QH?QL$G.=4F-U\I4
MU^[8>T4TQW([:169*PCQS?\\.IN:6+,I[:[J;/__!\W*A4R9 _@^"-T##IRT
MW8!IRH/R4 GM^5?!N8!V08%[.("X8%K,A44*G'N?2R9>^C)SKFA*;F;\3 =U
ML7\SGY13*/D8)O*/N.C6B0#/ ]*D;_+<_:W6Q^=ZC<TV%^21C(IBG^2,5G8.
M!QC$B/_)N5!97EH>ZY'XY(MW\O*+UU?$G/!31HYQ@H$!;:$JLNPBNBA<$BYD
M11=6:("-A/(9L7(. L#+!$^0[EIC[>K>G8P8QCP;DR]; 1^VK5X9]/1QUBNN
M@7,1*<_K+Y6^[5%*:!%!&>3?9D!.D[<X\U%MVA:)ZL0:&8%V5*+*Y<09+X*\
M.)(U+4!96 -Y*=PJ7% M8&J.#APJ$9%U* /?8HC306Y>DJ,Y_B%%8ZEA?2%M
MZT:F.%N/Y6<:8U:GB:&8*$PFG1;@>1)RD'A3@4,:CRWPF6M%>@7[T['Q*HNB
M+!+VFT@>/W&N=V>K?!-E2%OJ UMG42S^&-,M'7 ,?4ZQ\HT65QBM<6$YWJDT
MR&!<F2^.Z3P82MGITF28I_I[*<T#(C43X74$1">ZR5:G<[)X,]L,;>24?S9(
MC0X=S,L8V$-%+"1)N?%T ISEX8=DKX\6M6L,?K==*3/,MP_/I @'A(1-UU=A
M&GLD3[>UH9I(L^0,MCK:P='<8MO%#TY2X!;7Z$NLN1XYR93$/=;-!AJ/RZN.
M9EYL:"KP*QURRA[7+2QI]<W_-.SNK.-B)\%&]>+__80)JSEBS:F<Y"IP<[.A
M1WB:]-8UGLHB^PE*,367:VP*_7BVF?(R -"DKZ9.-@W;PB$BH_7;5EG>4-$:
M3V-&>F_+8SAQH!LYR-:]^=_[#&ZK3KO8$3ZD("LD,A"VE,[!A?.T"[ W_O;F
M;'A(=@$..2O/8.M33UC?]CCU!DI-+')Q@CN$LL1MJX?J!9-XQ+S;_*G.6,<A
M2;UP<AEU/RF(,Z"Q=B6A91+1%\A,*7/-Y/BY50RQWI:'WI#]1#P4UX2NJNK-
M2<KH'12:-!L17.%3_*(EY\_8#KVDNIV"GQ:YEXE/"Z&*UI?:O_4Q6W?Y[R\[
M*7#6&% _C/_ZQ_^.&MC_N?QG"H;?'Z +C10X2T\%[BI1@0LW LWEJSA?[RIP
M50H<*L%WV6!>]*1%WJ7 S5Q%XTU_%\JW_H^/^K__ BBZ__<5>R7'X#Z(C&4E
M+*;_+<]&/$6>3@U@N0(W<464#NB-[W>$GPD<:SP$> UJ*JFJM_BRV84.^GIX
MWTB-AHB'#UCU:,OFS17RD$.U&F:QSRAK(K*Z<1$2J!75G%O@TX%8?Q1/F;F(
M6KCM"?%^+Y=5OI18\E.X!6U7SJ7XO"TV)ZF.VBYFG#B7?XII3F8%[%"]EO;3
MT<(*1YN6'07K;X#\5Q@\]U1'=<AW +]@?4<!R<"\-S$$2I7>@(X^@(1D(V[!
MOJ!BVHX"!:ZALD-,"Q-Y$HY5_#*[;&.2/YY6F0@JOT]U/]4L7:LL!="%NS%@
MQ45 N$@2)^@3DS$>B(?]\Y'E<H:M\;@5D$Q;!QFV2,UR:2185#QZ7\.>*\W8
M EWM;,FG[8&#S^?7^T<(/0@&9SY1TYMZ*[G<R@R#N/V]Q39./DKH(XRJG^1
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M]!9URP1Q(C>M\T?O):HOZ['#\T.'5D<"[[ZAZIAI+)BB?P2AH\$)Z&[XG0R
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M&3HY":\BBO> 5W(':61Y"GUG_9+.BB*B5T=0*!Y'<X%Z'GU+,RLV"S4,"A.
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M2P6>M5^,S6$SB>/5R;DN\S$\G:EPC^H@@I>NTY["-$;<M(?AT'ZNU]:/3?\
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MYS)_69\3;=E5UZIU#LXWZC]YTT.F@EMTG5$;+,; 0/&$-9;<%<.29>R[T;6
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M7R$LU/55V@7XR^:_W@I3_DZ!OT6 9_RI4_ZT/CQMS8\ZNAT. >G:]%4(H+3
M;Y)6Z<ZP700$3 WNB^(6*[8__>6.__$"]3/C'U/^WX5E2XY^FHUR#-.O0.:C
M"V&%,9O[^-L0$-G=#@';2@0,$2<+ 8L^"_"A,A@$O+'&@V:1$+#P% ).A-'"
MX-]?_KGER E$ GPO6)=ZW1,. 5EE@A# 'N / 0H1^RD$1C-L%A!PK!Q&?0<G
M]N'?Y=.XX)P8XA?R$@3(%?S-J1Y"@,D'#/VI&P00S44@()65JLZWPPT!;YWG
MY*AJ6IJ,L_^$D?D_0  ]_ .2JK0P0^V!K5AP0$"?C#U5L@6S^0D"(J[1F[';
M-ZDZC#_%V['4QFRZB KC OI&V?_<9.$C!+PDT/2)$+!_J!@"PBP3Z)8PTG?[
ML=OT*&PDGO0-W(* M"%,R_UYQB$"1#QI- VSI8HIO,.XP"M5&%(Q)P1TLOQ-
MUR6 L5\Q$*!]1X4NL+E!=^;X*14! =]Y<72>>_"]NQA"%L8!L7\>?0X""$GS
MO71[8PC@S$A@'.+.B%T$.UL(Z"+2<QE]0/ME& *:2W0A0)H#])5;DX" WWI;
M[$'OH #&F5?@<PI>C(/8'\Z [IWXO5=,/$P\3#Q,/$P\3#Q,/$P\3#Q,/$P\
M3#Q,/$P\3#Q,/$P\3#Q,/$P\3#Q,/$P\3#Q,/$P\3#Q,/$P\3#Q,/$P\3#Q,
M/$P\3#Q,/$P\3#Q,/$P\3#Q,/$P\3#Q,/$P\3#S_)'CVW7=\:'\T'D)W8$DO
M&&=/(?5D$WM!!)PH# &A:>MTT=%Z[9U>D-&I-?#R>MSZ1\I,.0U+/REC@1D/
MPE4&+"\A-\^-;]8;M#%,\@4;4/QY$%PT[$]L$453%L;^Y2?>81VW)C&XM+A?
M)>ACGY:R.?ER9J3STAV\^ X$W,J5M+?<L1M-+]5/V]$:3/RZ&52]DS0QVOA1
M9+EHSW'X+_\YSS]>.* !YB_,F,(4IOP;"#3(#&9,80I3_@WDGW!?;:8PA2E,
M^?OEGW";$*8PA2E,^?L%&J%/P-UG3M'[81R8^PFQ:&5:$EH A9F'K?,1,:Q?
MW6''M/A0>3^DV-G:A44J/U8^ZD.6+9#A(28<5:Z8"9@3$M13'*'<LRFYOW(M
M5>4,K"N-JIE&/U$& 3G25  "FN=F(.!M^!,.,$".>MH6 FY8@0<@(*P5#P$Z
M[ ",M&D/JG^D_U%!8H$ MA@,/5H @!._X4E^_K2SSK.L=#Y>"*!Q*P(8PA?,
M[,K&_K7>3QQ461D(V+_@PF@_(A$"FH9GML.P3V#@'1L(V+[5QVB?0PP"0HKQ
MRVQP $[Z4 ,!W[/>L-"%#2" U0(SP(L&,$0O) 3T:U]A9?IE^F7Z9?IE^F7Z
M9?IE^F7Z9?IE^F7Z9?IE^F7Z9?IE^F7Z9?IE^F7Z9?IE^F7Z9?IE^F7Z9?IE
M^F7Z9?IE^F7Z9?IE^F7Z9?IE^F7Z9?IE^F7Z9?IE^F7Z9?IE^F7Z9?IE^F7Z
M9?IE^F7Z9?IE^F7Z9?K]U_<+UX6 V30(J,)3>6OF9]IG^%!P^C$X!!P$00>*
M.)5C$,VQ2A<EX5KL#Z'B91Q-1]!25F OD9Z6!4H&_@Y^(1_/PQ: NI;DGEII
M"!BKSO+45'.%[>0(WZUL &C3;SB@4>9S%IC"%*;\&PC4QPQF3&$*4_X-!.IG
M!C.F,(4I_P;"?&H\4YC"E'\+83XUGBE,8<J_A?RO3XUGV5*@'S.@> 1ITV(5
M86$"6,(&&TJA951+:YAJX5 H%YLULOBLAX-CW"6-=[%5T=#YNI?T1M'G\ZX+
M+W_Y[:G(P53<4/W%V3LU<62U!J%VOKAF;;FLT$*]V<PC'=XMIJ5')>JVW:5T
M3,R-]:96MLLWZXVQ][PE46H.!7U%9*Y2_D G#9W;<<JUP:^(>*V:QO9O&U2X
M[DX2!+R]3=* @$/TRQ"PN(*_"P&1+ 38MDHOGG3?'@*Z6-LQ+5>Z(. [QX'=
M>_"] &DXR59N0NGWVUZDC-E7Y9B3VJ[S!:+P'Y_I"A_,J/?<TF8YV&VF>A1:
M*+5W11L7GB4L*LV=<!X]]+0FL46.UK6^*[Q'PM/9:O/NV$]84G\'N7SR7#=O
M\&ZT8$X$W4S/&?G<?B"IV>Y<Q6#]@I& KCV?= 9+@/F UA#R=3<ZX:>CD<\7
MU6<\;F(_'"JDI;+Y;?)'+PX6=\P@=C3L1A.M<=I'Y[B%DKW& T,?#S</+[G3
M9X=BD<A]VO>$R81G^--H'G1?X[%*\FXS_)1KHPSI)T&:S][I?LCM?C\.F=^3
M],B'$[S+W=1E"X]=JK":F6P>:.Z?FLB(D5C_(485T?RL@!9L1\CV/#1[B'JQ
M*NR;*;G]8Z TO%1P$'?=T,KH5;JAJD&J5[+%S%V?X\).UU1C>5Q&<K8?#=Q*
M:3SVQZ,4-=Q"HK55<6N>+XR[WL)_%AX.YZSWRI^TL;,'%3Z]EB7;QF4N9>QH
M%.-/@)A;P^NE9?41\<@*A%*Z#CQ)U'OOYK1-L4.$LEEH.%RQ\R&/V(7;;?,D
ME%X/[U*H_*EH7Z<+MJI;UQ4\50QMI8H%[JUJ:G%Q14:;I!R_[-8? ]KD&MW6
MF^CI;NL9&73<RX. B._T <RV/IH5,XMOQU.G+'["J%>$3T% 5F,P!(1<@@#Z
M7;@T8S0\?0D!?<(L/UHPFZ2_?9LQ!/S*&@[_CL1B9KOP$/""A7[NL#,$7$%Q
M?/QST[2>& ($D&SQL2.CQO!H-&O0Q9$'VFCZ#&&_/;I>R>\<YI%4]_75UC^:
M9]8OA\[3HA=;@F&;>E=+SF/2^['CJ>?"N;@.K1[S:E;9+.2R1I]UO$W[81_V
M*O!VH7D2Y=NJ& 0\J?@)WT% P+,WZ%Y\%2_.8?:9$CP,RZW$7KY,9R>'[B19
MHL(W' )D-,7F,A"R[9:U5Y3;\U?,'Q^N>#R)K]C.J(RV2-@TDB/E1X)&<3?]
M?U0\*'I=)?_A0C>"G6T<P1^:N72-HU3?!W=-(%#_G8?XSW$XKU-MY;SV=/.]
MA1P7"Z^%@O4J@:+^C'5^21_,?7983LI>U$_6+7=R&IV-BW([" :6DP6)CW"D
MM-D2_^E?R-A(S8O=ER/B)PPR@J5,/E2_PY^4BY,9</&3.E@])+-TXVQ\8."+
MO!O9ND?@^=[P0RB$^I?-KHEXK]?J >&L[-&5SFFY1\UR^4WSD84&*0.%W4;&
MWDFQ;^8FJWH[R5\],NYZO2@1)5GR2%]^G%QE&6<J.N1$=?*[,*$W;JNXEC X
M XKKKN<6T\?Q[)JN92!!AS0:3O6;1?*U9J],J(19F!C*5++;&#RC$-+K6HO=
MU'/73&;N3**>-?_F7A/;&.\4>^:/-FP**NW3$$I$\1.19$:V+,'#GOD5C+92
MY-Q_1BLY(;BN;[L.Y VK=K(;6Q^=>(]PQQ<37^T$+/(VZ \MF[0XK%XPRA3V
M1#BK2IADYDOH^2B9:$SN/H9E5>W5;F==@8G1)S&5V>@.6$5O-%UFS'+9NB:J
M%%<IQP&J_#9"'Z2]+ 9C[@S=B[29BI'*T*AYUGX]PG(D+WIZ9=KJ[L"W.+%K
MDQ%C#\79(*"4JA?RI<BT6)=-U:+%T;WOVT[EP[''1D:WED)G<]5[XH[47C,V
M*<K0C</>QX[M.3WXW?'HL$F^49AZVD*F?J)^;TKKA.+0BF+ZHQ#X\6TY4*9F
M'3%GB[Q.6HP@!<Z^SBIUWR_#OG79#Q) )MP<G<@K]F</QSH?@X!F7P69[J\D
MPJD?/PZA]R))XJ'O/CP&T_=& HW"!>+T?Q:IO\3(J)O>73'-@("[$Q=CD%]@
M!Q )"FY5$@/Y3S]U^(D+/(R./[?Y:B+V'AXS7)FPW&M$[Z/WOJ./4,1W\L?6
M,97XBI9.!UK6-_%)K9::XULQB,H ['VNCS?/CHG>#TJGFQ>NT7(1CKUK 0MK
M#?ERE3M!O4G8U/ZEA1H52>.&]:S]RH!:Q][.WH[:6F1GMT< $B>STU@M.\3-
M#=QB3:3Z@JU$W#@$$.7BT!?!QDZKH2"U60]E=EWC=R0JK[]ZZUC=T(/*8DMI
M!WS#X(.N1+N922FEUO5Z+YU%?<NU(]-M5Q/G4#&JG[Y]D.C+C6H?]BTT;>EX
MF'7"VJ=8PM1W>3A=GWO!T]K;8]RF:+Y+OO+]U]-!'BX]IN]()LFN!;4?.R[J
M2YK$HB5DOB7J;C60M>ELF>1\LV'G!")K,RYBFIWT?4:("S6VBE8D2X^IQG_O
MS%UYS=/_X'C,UN6G@WX.;+_&%!@5V$) SB86>*^N>&^K9$:^;<[7.YYE[.[#
M\@TVL^P8G,FDY.N!N)'&GLMPA5;P:?RKB::[I"$)7[^]U>%@;*VZXCQ=V&I2
MISNO$<"3+#<FO9!QXV3=)]-?WSGDJ1"FN"T+6,4.1E683!!",J\T:JU*+#;&
MT,]@?PG40A0M2IK75-'[2]<O>R"=,)0(I$@/!-AN_7"GW%'")ZWT+6S3D=07
ME,D=)T;4FAP#8VP'-<4I1J#(=5*L0#+96I<L]PD^@1D3>/#^O0[W:U'2ZT*_
MXI745*&T^A'%3.=;RFO7%0]6;8G74'>C@XX4AA.&6TEE6M5* S$9'5L<3C^C
MG^NO.WCY9EU/7O$-$QB2\)';0R^X='Y_7W8YSOJ/['0B\:I> <V=HWOM[8[=
M2.RKI5.[K\0U,+V--E64+0>,8]'8N%NZ[4)9=IZ;>>KH_J,L!R^>J3A:W#<)
M+]< 9S_/S:L^[GY(49_)K]<VN/OJ] 3?7TJB;IADZBN)ZY>(ZY=*=&3J^YTC
MJON=^>I\M%E/GRLT*?;M@)=K7I+N]_YDIU,=[/J7](V3K;V2K>N\W*^G#RME
MVYRR4R3GAVF=1EG8DMOCE=8U",(G2=VA=:]KRU8J GC5_9)U3+]($3.G]815
M94J)>K*>/YS"1T;XR\Y'GY]A>=JZ:%FOQ7(@HC"Z[5Z1I&70Y5-;IH4J_3*)
M>FKZA@7-1SN,Y&/<U7]^)Q8,X>QR7(US^=13SJ^?:O7#)!J8KR4V/ ?%R!0Z
M6Y*[0Z&="[;"F2!UV7M@Q"HKH1W#?2(;Z5BP=E[IPP"5Y^VT:]U;J\X$K9$E
M"_)A[&,RMT'#L1Y;,FY;[@1X5#TYRSY:08^X),:OB9?<\2Y$%,?=\7,QS>UI
MY+\>+YS#-<*S6-+;4R$,-TXN7$#I&)\?:+FWE^PT0,IBY9\L\BGDFT[7XJ]G
MC(HV^F2-Q3F4YNU90^4S"XVM3J1=[<![^*VNZJP=2G?(FW-K>D\N?1N=T6[2
M.A@:X!36):EA\SH@SD_.YK8I$4/QGC;7/.K5&#0U?$?18K.=G>UQX-=>LE8X
M*,](]-K!VK<KU>;VI]%"*-TVNH"K2/26%4G: LU%#GYEM+ID5YJYDUT((JU1
M(E\B;AI@CD=-LITO/;)7O+B%/W#);=M9"]9%?G'<Q' P*^%AZVS>P(#0]O)
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M#;^:<-^,F2BTY#.5*2YW 4KO&]#ZZ)"0KG_NLK+ S[%K*H*(DY/X8ZO890@
MO.%.(3VHZ!(9:4/K /.3AE84(?5X$=[Y:1ZW(<(UBH]#3IWK'C+RU ^W,>DZ
M#OU;J9+OEWM-MK_C+*\IV7XTM=/]@B'=P#V% %(U!+@G<(!8XPJ*;CB:S=7?
MGK/J<.+ED8VY(Z<5\8>LD4WC_KP?'[\^5WE*,(E@(2)R"NXP+QM,2V@:BQ63
MV)RKZ"COE,BA+82[3\SG([^A4,'6P8U57&VS]?C5E]WJ[^.6[YXAFPPBW$J/
ML7TI2IAHIS<H4%AP\RP[[_YC9MN+V>D$=>;P"? *>"LBU.Y(L"2<&YR\V>^[
M?M[6\X<!^WE^F7JS-RO^"O:VVAX!BK>TG1Q\SFYZ>(H]THF_D#EEWIC_S"=6
MG(-\W?C5?(I%Z"?S4O-*EZM&)4G-H[FG!D.2SRU(]$A979?<]1 -4%L\5NV8
M<H]DB=8QKY=H.Y&]\*S*S=O3\/R <<RX2K\(4>XIGJ0S,X[]-*'T:H9?G,S:
MEL"K>6'_CR3+8:K@[*I-8K2UC(@^J2TKWSVQ]6#&'W?<IL_4\669FP^NA2@5
MT4.P*&*KZOY@O)Z0LFZ(89%YMJY@7+)<=JD-CU'N(0FIP,J'I&_CIIG)"=A.
MD$^2T RW\Y,?+JEMV.M[@W6Y%IMMTEF_H@$!TH\T$-%XDBYR;+5=X! M_VF0
M"HYZEJP8V9N/BB&@)<BR>'?VB>PC:;=($!#K%_>H>=7(6=+3PW>IO^R;Z2\S
MQE7WNKZJZ<9INC]IN?T:SA/1\[!P(D^0)[29N'#!%>,<V72+,!3V6^-14[,W
MV%9]=^T@^X/?_)8[5!^;731#=UN;%0WI3>I(^BV9R%X>"A";N$&_W2A%522+
M-_5&:2F#5G/@^F#+ZX-DWEQBM^EXY]+X'41^3W][H*.\:8 T<IV:L2J>J)KK
M;A,9VT>0!9/V5\6[+]9.6SSI?F>$8'OA4'C/I;#,JDU)Q-\HQT\_5\WNU8"'
MC\YF=4EO._F%_@<ALZ#3OBF,N&*"E2WWE-/36?[QQ=JX7\N\+*F/G@<!L[%X
M[JJ92-A[4[H ^="WT<&@"V!("2C^6_J<1;H3J63?*&+.]ES_0I+,PO*H]71Q
MWKAV;>+HS8KRJHC??VT_B1$#IY(=-J?E+4LT>507]_R.!Z-:+[2O>A7;LUGK
MR<B9,'KA_EIM48^W?Y('_>.GL;H7KUX.%'QMS(]Z+9SQ&._XQ:B$CU:WHB]O
M>_94[MOW^[KT8QK._@7H%CQL35K&$XE#:LKEV%A;C3>)=0\/MS3*D>9T#C74
M2VYV*Y9=T^6^T;-VK2CQ"NX%J>=A?OL=-9.<;*-7\GY.:CWZ%T,=0UIJ)/3&
MKTM(54_H">=SZ72>[7+D7A"_+BD?_=%C)"]1SVUR7!2M@?["N'=UL)RH2=U!
M320%@4JP #%Y*^8DN[$@!=*;"GNAX->V[W\+LBAQ>^2_CPR_C_JTY:MAJ&(^
M+!*-D=W?TAXJ77R/F$#AVZ65#U?=83WFX+*H)*%ONG+_10^F8$L&-GS!)%/]
MPXO\JH"A;+T/T]RK \GWZ>+G9ZU3B )[57K$;-%<(3%A,[N9[7WOV&R]2;IM
MFT(Z8CI%+9]K.X]"/WJ <MSV>URN#563?#T-?0_5'O4 +0(.&'J<SAZK*&W,
M+783%KK4-M.H@^&H/&PD&C9'&T;;<_"#^SS#5O<M]2L'$2N#G1<E0_1F4CI2
M!% 92C\^WN,NK4#<7G%JNJ,U._MNV$'*9J*=QSXS(%>M(X7F6K7@P;$DLK-,
MB_?#CPW.?15F#[9#<J-@K>H.9$:&9>:%9,_\D977>K%ZJ++4;N"H:/AI]ZOU
M$DA_L<9)&XI!G(9IN""\1BO3D:;T2<A=.V[3U='L%%$>U,>;=SU\GI2I[G<G
MH- \6T)TZOAO<A<D H>6!))SEM:&]>@.+?RG;R:<*O"AW+GL$GA3R3S9Z4*^
MZS4O:XG!1T;3:TFQB19>"3,8DC8F9K\G@1PRAV@2C*G-(>%CJ?PJ\964\P_[
MK% 5S6G[YIE*K?4>]-R?MBP6F7+?8C(2UBY+B)G;H";D>JB!7US,OWC7[U^,
M;IWU*N]<,719"FD=+#673UHIF+N0;QB,19KAHK"ZGTZ-$P2C/RG3XAYS<)[:
MCG.[%"IHD']9;<)\9KSI<@H^ .^&&8]ILJ_"$8[0>5!;-F3=B&W5>L,<,!=)
M%?'*F71KV]6M'O(HG;WDKFY4Y;QCQ67RHNMME[[5N?%+0!,>JVH07?X5ELZ8
M-Q:V+[Z(U1UV=[C\^I*2DVYB96&'2=6Q(?&NAL2%W?7BNL>PK,4]P^-+1W]J
MZNA7+E,LS1;?SN9W'Q)-PQ]MF]["?PRN@JM" +$5 BK$:3RP> @ 54 ,!/3L
MX TA()+2:K\M080 *M<+"-AJV<. $7L6M$.+,)!7$ )>$NA"]I1+F'YC< ,"
M0C 1C ,W7/[V;? YV(+]-M\+S*PEDNZL]6<9%4;_9%\AM^9,*M8>U50CL\RU
M1VJ=!R=;.)>%CY-V(ZN0APUR3VO<W)33-"M;,:]S#E$LO19X6KG-QE#YK'N!
MC?JJP&*2U-Y(N>TU"'B+0LZ)<Y,;D?8<49W>0<IF3PAU8VM& O%*9F:26]I'
M(W(E/TQ4SIN4ZD@FI+]**\^RDK52U0M:.DE:-'L^NSR4']5FVFI1D'4M1>_6
MMX6P7.N<(9=K1A=C;IDG[JY<7>7NWRNG*%+9R*SK(N2/GV"L01J+!+D8I8+L
M$:4;\UM\5T@-T540$.6W[,_"1]7?=@^L77_[XJV=/2T!<7VK;.[V?@3W$H@^
M]=E':)6S8^1$B*^$"K+DWHKU:[X3I;@-=WW.I/AW^;VWB2%:]I*=C-N?JGPX
M<[0Z?2G=GI ->US*&,!<[Q^K>;<7TBI0'VU(NFL?*7#WNH7P-%[L+.(9['A9
M_H"OH"LOA\)-$CK4L7];(V#*4G!*;UU&<4P\6:,[T#?QINVW>YBPBY9!&!XR
M+XS#I+CPA7-MCH@%IUBWVX>ONAO%'9+3"V)J9LEFR:Y-N;\_I[2Z$C=?5>?>
M:-+E>-*L<LQU\FL6XFM>!L5DX9;AQODRS'$L-_T\V#XOUP+G#3(B+Q8JE\_U
M\KOSJ3<6^HG<Z&\;O&A@J]ZFXD^13<NURFU\F3/6%I1Q6GU@9.#7<V$ZF* %
M?G,VD<Z' >;V^HH740*<V?J27ZIX-H8+!NX,N_6FE[HE6 TEY_QTWJ(K\-F?
MCBJ-;M'KJ0JH_;*#)QS9"15QN:9Q74*LG':4W@XCZ<J%)U$U2;L)&#?5^JMS
M,%ZPV&BPZD.CP)A;>D*8(NZ(ZVZ?S)" 1:3G]LMUS:L%8-2;1-[ADY.W!F0J
MH[KJK)L"E#[:?Z'.M#4J+99WE:MACM8K"[*&%IN$=*T8Y\:4QA8:W4DLC@AS
MZ>0P8/<=EG4SRS57+NX^)&:(3GE.NLY)=)U3<#+)=>N/TPF+7;C.+2+F=RS^
MA)*8R<A2Y9LW&VS*M0EP6B-CTDQL/$QB)6!^I;K27H:7YDRB! WJ1JA.I';3
MH2HYSJL^Q,Y#7&[J,Z$_/?0-NN\+=I_L=A[R,Y2S;!PZVSAXYL/KYLV.'QT:
M[!8#I(TV:<+%+M(XC)LB,- ^' X[E&Z<:\!^X9Y;8&7!W/>!6V^(=D&5A6;9
M1AGY)L9F9U4-AW*[6X($(PA$-\?WN:K2FJ?U03U]O]NYIYW4%=(4APK;-E^)
M2TA<5>'C$[:BJ]$[(*"2(PI^'QYOQPI6$9>7>/>U<MG38A0_1&U2=68SKZ,<
MR,IAFC:I:H;#SS+BU'*_5EMWY[TL/,=?<J]]/<B6\,).\K/\GM9Y^<52O:&F
MX<>:RNK)-LVC,15>QH4_3 WFL]0KJS.T1,2[BA;4PF'\>A^OZ2N]J2Z.2-(O
M5:X>46^#@./S1V7N)?P@Z Y73F'T!GY."6R>UKXQ4KDJ8Z./K_;8V9WPS/;@
M68C[QOZTCE'!O4T__ZE#_94%Z9";TL.?1<35JX.EUW*^#^>+N=XNUC?B"DW3
MY==I+8N#]3U\)7F-1Z+J@I'\*]'J9-&D&#M#Q?YLJ^1_@D_.F/)_0 [L>9!9
MZ<>V*!)!BN2-.+H0&(, W]//D%ACJ :SF7[;,T=<1M5]W(5Y1I"^,H8ELDYD
MI\HT7L- ![6JUP8H84O-&M2]^Q?P)4[3Q\EHU[19!4W%3;_PKH>6=QZ=-FT;
M"=/1YKMV*EH_Q_RDOL*.GT@WCX285,[TTI=[J$'QYCDIHEL[__K%X:*^PLYK
M)S2WG26]%]#C=IK]CQY9^^J>A0 .'"T>\UV0G $!1S(Y("!#<ITQ9?*US6QM
MB4) \SYCVFQQH#=\PW0R9N/FQQAJ/9SX$P+*>VDL: 4,D2N+,:4ZZ5*O-"I#
M /:E.)UO% (6ST" W29\H1U#O S_<Y62T<K8$OTIGA]/BNJ#@+WWV?0S]H*8
MWJXD"&!;9;3P*P87 -N<QY->8R% C@,,QJSY0,"5F=@9\+?O&.KXG]]FDXO#
M+RWJ04 8X_1[D?#1^H0]KQD0@?B/M5,M_(X:!+Q!MB&IYWSA] <%?W,1L-5I
M7>J'#:IX/@1T$N@P>XH0!/2IS*O0.=5A$*!LBFEAFT?N[25BB,$8^CV.GQLB
M]#O^=*[!_WL]]V_Z"3YWB%Q#I7Z!DQKQ$"#/NK_[' )D&=7:449%_A]?R1NE
MM\.WV<%N" @U8F0CW2DP\B_@)!W].Q:TMX> %R&TP,\,]Z<9KV\SK@F%(3#Z
MPA&[?YAZG^%:7)O1DQT)X-,@#PB 7T)0Y7 0T'65R8+)@LF"R8+)@LF"R8+)
M@LF"R8+)@LF"R8+)@LF"R8+)@LF"R8+)@LF"R8+)@LF"R8+)@LF"R>)_8Z$5
M1WN!G\W" Q#@CA!>@8 3:%[KH"LUY,,Q1#8($+2#1]=KY"T+>/573CE?Z2OC
M%<RXC#%[OH&>G#/4;&>QR?'XY:O:2VLQ/2WGZ'KE.>$3G=\7 RK?+SL4STO,
MGGGW(CVE*- M6?Y4Y+0"84!?N)?-9'/1PR#%>]5OQ4G3(,U9-8KXT/UDT>UL
MR8U)DUB1+_R#>6OS)NA=)<MQ&_?5K%W;H /;_P3+]___$U@7G,JK0C_A3DN'
MSZ9/GV&,-6<(>)9^*&+]*L7&E?/K.)C07"U '&SD#1(8KG__AQ75A&R7>;I[
M.G<NQNKE_8\@DGC'79ELT^L\%XQI4O$7"+0%, ?MJ^!4H;,0<.@AK53)U@[#
M2V<T_&LC+^ALFCY+(%%V'N%K01CQLF3;(SA9O*:69#B,C:WR4+_0^P><*$U&
M1F[\.-,Q8V^;^N@N1_L&%XAO?:T\[*FTP0]FM]C)CLI.Y=2-!"%*W:SIQ3XB
MK^K3!.*+??S]%<H7TO5>OM@T!,S[@G3G8,=6S"=&PWY..1,>M[Z*D<DK?;.2
M5J>5ZRXIE),Z.A&TLWOK1D0**M?\]N=S3^"U<%!1=V>75J^EAI[ GV3T S8&
M4VG1FA"' 7P1XX168?4/I-U6/+\[EO,^"1.YC1! L6F3&I;"_&9X;5<F?H1Y
MB-J='?:E9 IWWHZX7OO,<FKM^,XC[VL'Z$_M>=%B*/_9T69&/,/P!MF(M!.Q
MX=/'R>)Q57AQY,3]0:I2SI1;Q825R*]B^ 8;^_+EG7DYGT!-7G*QWKG"7?!V
M^):P_)PGC*CY]E@ EG-)S5/OJ0DB4?55)Y_!4?U<.].O+@,I]N[6CZK4;[V:
M?NY\G8/MMF T@2AA,W'/_7;VX9V80C%A5QN7-NI \+F,[YC7*NL82A"Z'U.-
MC*OJ#IQ#QOL5(P_=64G\"CH2E9\73=L$72:EOH[OS)\8_VZL:?XX-=?#\S=_
M+9%AF1]*#=>N;2@-M"[8M-(IJ-NS"1%TCM_!FQ_#-F\>WW)#N?E6:$FU.5S\
M"4:HM'BWK_*LW.?*EP1ORKCU^V2GSB[ILH;G?SEDE*NC/@SW[[STZH3Q=<5W
MO@[\!9M#+1WRJ.@?G2^'BCT]K52W)(W1';![XCV8XUKR5#-0:LX=R1\D!H;-
M,6(R^D+5[_*K=IRC?NPG-V_TIW273HXC3LZ,&;R3Z<E\7#$VU5K'5AS@\$A[
MEZI'T%1K4_-X@(W>%,J.W.Q8&6Q:4D/S7<SGNY^B+\=IY'=QF!@XT.*PI-_
M;VU:=$U/H;I*0#7=*/Q\G+0.O]NR>?ZQ=PTEN9U*HKFP"E$<7U$Y;0K3)(;W
M7'?<6:1E>O[$P'3SM<D)1+MR]]F9R(%E+UU7USG%NG**<WC]P_0[9[1S.N<,
M+.76JS2DC(5?^:US6=4->/AVRR[VZ@[B6Q)R+9Z=DCL4="4[G+@;%01KM52O
M[3TQV&HX4II:9QFA?>GS0G1:0TR\C;6I<QC.'(Q(F[]H2O;!1>?;<-F3&R6_
M2'P#OVM>2FQR/"M9*7)^8<WYJ/<(H;#!6< B],U"0)&9:YOWJWG)1)HA;E%D
MH?EOGXTV\C__F>'>!@0<#(* I&\D<5HTG!/S\^20U':" .;;LW9&,YY6$%#H
MVYLQB]V#,>8JW"DL3;%W[1P^)F&BMZ<7E)SXGK]S IRD53PQI<(]1)_D.91B
MFCM(3]YOJOA+WK=)Q%\<G"#%_]RW"+6;H9\[H;T&7[E;;$_<@8VC>ETQAFKP
MY:5S6LZQE['[#0E+$%#@:42% .NL3N0HI08>6V72(OFLJT6R*#81 0!JHJ\!
M'MK'FD3[IZ K;8GJS5=,D:?>M36@7Y,BP>8 _ 8]70OFULR80D4V<%LSY[XQ
MFKJ$=*+*K5/QXQ 00KF>($XW<-P7N;A([VC;"K(?!U\CR<'6_E3$;".^+VGO
M*YV"9O3BER.@! 3\GD3$T[,FE#"95$8>($+=HK?S8^EY(_#L2QM[?+.8-0YV
M",@[\]@SM]!U7SD34^(V6EUW/R77RM;-^G5VL.:C:G4TUI%ERFYZ^D[7%_:J
MTMQ*$X279DDYX3A2Y'U1HF:1:9%%H5&<@'>Q>251/T72RSM3/T4TZ]C#Z!&3
M5^FQ]U(F746*&#.N1'=!,Z=W<L[ZJ3;)]9KW>E(U_;"EGV1QJP&J+IFO??IL
M_QD;6SX[,B[:+_/<\(&C'KDKZ0L_?X8>.W68C3V'?#WKR9D+!^_C^Q^4A=V1
MM4IS*/[2T0@[$))EC0@PRXW(-\K)K*MMK=AKYS'A\;),KQR544]9-7VV?G0H
M^6VC7@[&TIZDRW%\!0VC15$O8PI:I6^!^/9I#;)LXOMOO(,G]T<)!I(B@(D$
M,D@M6#0XQYSKK(1D.OT*&<=CP-ENF>Z;CF1-<P*M1ZI3@E^5:Y9-.1XW5*3
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MJ(/<&W0,J^;?>+LP00_4\72#$M2Q=$8T>!#S1^TE9*'>69<,>=DBO%#2=A2
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M#2X' #&JO]@?S!6?\<BW;S@16W.,R&G)X&+YOU<&=C^T^57!M0JU['7CK56
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M&8I7H%SGR7<WP\D($7HBDGMUP^LGW%EK)+D+RMV8W)<1R@2)B@OE9:[T[*7
MP6RXJ)UW? S?Z:#!DJE$2)RVQ6!>4/?4@)Z"IV"8SWJ.C.F:\M;A2'D?]6EI
M_,& U41&*<:?RN!KESMK\"H1J_VW;KVML;-=O*F DXC'H11JIE55EXH;,OO
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M,B"R+K?*P^Q^9:![$*LL:WKN"]S=1F"B:+:YT6/FVT?IX??TU@;0R!\_QT(
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M0@A6# EWZAQ&65,P7^H9%71P0MC@&:JUC;7YE#;\8;'!>'.1BUUK7)X'8MV
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M4C/O#^!R(EP:>X*@HW[M9EFTSWRN:_-2%CP75,?)LZM36>[VW11*).Z5\=L
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M4$#9-F:N>V#ZT#NC5YQQ>LIV/SCZ#Q1=AG]99%RC3ZV7[-JC^%AY)E(QQ9H
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M\>#?'T."1)QIZMFGD@_-)Y]J>/$2!(2PP5IT4AJ3F^.BJZQG./ ^X"/1FY]
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M@((WU,$R;#F.^^S*6?&L*,6@HQ=;&^A,K0AKVCF<P'C1PQU='FG:QEE5M=/
M>\.8 VR0'%Q'?-1N=B%9-Q^:<JT^IZ?\*4IQO$J$$R@G=&,9LM$@&@@D+9X
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MY,>'OG0 B8S3CT[/'PEY3L#)1*UB'>T?0##;^6L';= %>^7;2I$Y5883L.N
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M9 1?G$MI>VA49^% G,GX)%K.D/HI_U##5FMA2W&??J0H@+I;3G@+RPD=;@1
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MJIYS]_=G!0EHUSW7<:"E"1FF9SJ>:0&KD4*398C$.<-US"K_1I7*&U[3%(U
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M?U8I*3V7).*)-JW)'J5WNQI$G]S6L;CK@.:.=;<MSM^V/)YZO>BWI1N5T?V
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M1:_7K?E'D3P?$* P".XO@@:RQ2P(N>+P<+*ZPL[ZH-26'MV7;>!B]_Q9]X]
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M]\6+]?<\KNHJOW_?WW^6W3!NYBXG/0BAD2]4:#G<^;N/F7J7^"U^!^&C\M5
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MHAH!$+EMS+1W'E?%VL#ZNW9<[@X3I4(!<$Y$U?(-?,\,?CMXV/N>KP?8+0^
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M"QW=7111QYRKO1HU6_62K@VG^28.7@S&296)0%DN> 94E2U15+.<D$T#D55
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MC]I4ZZC/;1WV\QNON9!U(8<6>:SH?<#.D.#@D(7>-1>\+U2L,:K)R'BZYG1
M0,!.$]>%.@]V+]E[HSTU%8<K+QXWH2;;YQS:.60OWQZP>W!F<G2U;U^U%N-K
MB<-VY:70'J_^Z=(3WHF?NK_UT2++(C]Z7P\[SAC]K<) !250P8/<8>]^V2I%
M S>\9SC 8T!:S<8SS6&>.%"]>2ZA ?&_=XNA?Y#!]!"N^^'\*.2N6S*1N;ST
MBW>N917-)-*Y]9?P2['M-L3C.%6%%Y8_/@C>AZ++#J$: : ^SQ]E*VY# 9*&
M?+2/:^P=YI*^BZ#+/-Q?]9*K&68,U2D>]$VWD)=L=-$6E5+VWQZ.9+H635:N
M.=WPH3<./^J$^=R9 CNIHQJ8@E>SQ11\?HT $T_W01\)-[G1[(M O='X2Y9C
M.WZX\?NA=^@*AFE;[E)/EODIO_.4Q+E[',-Z:XL<;6EU#V*YZ<L%/G[8QK>P
MNG%LSO1W? <=P]5FS']"$1:C&37 $HK4%!J.TDX/+1SG&G!/]"2,.4'??[M_
M^.E@XUJFX5#]F>+11T<)TNUN!YLW?B+_DIFWY"7U?3FJI5S;:[@ZGW%+/'0%
M")O'I1(?I$2>)*UE]6UQ!-1(BYC;^J,RJF*]*8N')^?(5YF&1;L9)V?DI>=V
MP621^:%6D]01W\"C7WP:/2OSU.>41^O+ .$M 9XKO,%]=I*P<(:N$X!!6ZVD
M*](E%IH6_V5D1Y.QB!#O_>XBOS#4I*+NHBUF0F'I!LO>>KO("Y-1L2Y90ZFV
M1/M1U];:K) [ZA.AUYG&(FZ*A0:4Q.,NI[TJ8;AV-!I!ZE>0(P]=*G=D%24B
M!QZ.?KGTZ=[W@'H?G8*O=V.C3O8U;SRWQW)4/S_A=Q5TAW*J,!M>Q4$, E"-
M8W+/\$NUO.E$P!3Q SM:T*T#+L%R%]8 =\$,VP!.FAHCO*WNCQ66GJ-"5KP1
MQP&6 9/22\S<GWFX/XHSM5PX1+2U1:PNEGPYX!]AAXO](5?6X>_'O"'D8NFX
M59'"6@ISQ0)I-(07=B?(O5G=_/*V&& !8E0!'M8"N3PE35E]3O*SD8CLA)5+
MR%T]@*C@$_HQ@7B5CR<P'GSG9<[M?%X++?3Q_K;LCJIB,XG,7 S[R2E,(SA3
M3D).@J69Z2Q#9@"8\5C(-8%/P<?H]CD'B0_$KS^ZY11&^'OR_2<M"(,E642W
M74,G[:6A^W(%7A4UN;_@O[W!]GT6MN)G!-"+^IXL)KV0$(:+FEAD12E&;I9%
MW8T"<$Q7>%M^$'Q+8A5O#Z\QGHO-;"U/S#6HH1OZ3O(7I[2..8#[;SV!G;XY
M+XMZ559O&<-RL2N,8[!Y9-CF,V(LD47VGFPT&"=7"3JJDSQK QWW]S;:,PU!
MJS9@.;_TH4?$$@^Q;3I!$Z%*1A(K?_4='/ON]R+AM\L;E^[&A</Q6*J(OX89
MM"IZT$(;.I4NCT#?DK3?31._LGAEC#\D0O94K^$_>E;#/\R/SN..(]:*W*GI
MDNZ02HZ7QN,]Q<XT$3MKL?J<,]"\E/P[D,H!/0'8RJ<%&(Z04).9YF+;E"Q"
MLDNLA&+@(;0N]? "NV]%2:8-@AC7;?%^$W5EG(<?)OJ_9 P=\ LWN78ILO2O
MV?'3&TG]Q_\,^A#'Z$#,"D! /-0!P*LYTIU@AQ!HP5(\L Q=,UDWW;1^QC:)
MHXD8B\G)I&V#HEYN&#G1I+O<ABVRU1BOJ^$^67L[_[T@G)]2T?_9R"GD]J?[
MYS[Z^_?8_T[H<4260W(3UI"@TE'J+ ^"DV1_*FXK=^7P[ [(J@E0_])H-MCH
MB.#ANR#G-VA1N7KK,GJ9?<-2)8U:]I88%;EK[/66E\\K^S\^S]7Z?6V&??KM
M9/79R1V$*QSP[&QS3QK' A"R@2HJCWR9J\5:A83 -TK@2B%Q,!V4BRA7ZMTA
MK0Z3AAHVU-'D5%A*NBTB:]#J&KF/=Q>,7ZCUSWT@\V=.!A?Y!U*/_O3.Z/\M
MCA '@*%%4W1Y(/J&6^4CO5'.ZB,_XTI-Y:2PW+6P-2C?"PZ60UPANY5[=8Z>
M7!U -1,$!8[7:4^SF79Y 9/&@QEW7KRL[G_X(FMP-#_C/"8CGZK/]NP@Q G
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M)V$[=($J;MNVD)YK9F';7A+V(>]P&@MXS;G^+6#6W"8P&#Z2=3CY+<G,QI)
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MZG>'%NX+;MQ*S3<"TNSR A59UDTFZAJ>%X<6C*._?#U4C?F6+8U5""H +3>
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M"V7W-F&(?Y4CJA=E!*#E#&H=.&C7Q]D>29TO.A8TQB1/I0V[ :HDK(<IC4/
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MA)+>[X9U3D(-HO&=R#JD]ZVQUR?X$I1UZ0DO>/G];]1[;@P<=+T-#71T3-2
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M?27)1338Z(CNI0?W?5XHGW]7W8K3K%&[5+#'Z31([B X0I<J/XWJ=)[RY_E
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MM=5^%5OI2W5Q;QK>9@6K+#+%69"]#%$=E*A_WS 0R8?,1YLS'7A?<#O<8(T
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MXWR-;*(EMN+ \TQUVK)T (!<&99(-W.];:SR&;/" 5^^*I3215@_&O'X-V%
MPR#W142#K/RGU\=MN]43HOSN8(A!7$$W==Q7B-K [(R$+UTGP:9=M<FZQ3&
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M3X,!YFEQ=SXP>-:Q 3FMC[)I.S\^[JH]+X&0%BK=TH.^C#QX.G!J8C$V]KW
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M '"*%L-OOF^F2@MU854P^W39-4>F DS@OSS>KD%M5[.@UI+/S:9CD/ZE:!%
M)O<:P$G /6^[>>)'19#LJ-[UHK.G%'=!Q8+K4$VQ9]G=T5!7U=[P%Y-Y%ZZS
M=Z9C%K&(;%86<8J]M#@!;4FYD:%SZ]0^H3%LUWO6OY[_'/R23-O8XV.)&W[W
M9"+BEA,*A-=/31NIGQ)($VUW!TV=AMZWU+@)4&H/0@56O!A3OO *KT&Y\?4'
M8CE3CI.AG@ S:_+;47?C2,>$0%6!@%[A+OH">__]$S0Q1H4-&;'A'%5$!AWI
M?CM&&:(UG5?P74Q$;DB,^=, >847.)@R12<SS1]B!\PQGZTW4$99S-74%:-
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M$KF(>$J#9"A%Z"TN.M:-H>U?BEH .&6XJCY80<BC)4:"3!XCF6H/OK.I33K
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M';)>,R'&#[XT2<S@*LBP6NO??H$&QS $/9*D;88U1/FJK-2T@919EA@C;9Q
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M^JR(T5JOW#G?OL([%K>#9'B9NU^9.N.K(\F+;)>"JHZ\(*'^H"SE1LN,AL_
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M=2A]#2E:2G0[M*:JHJ<\F!-UKOE;:)W+J%/J$U(NFU+5K+IVREJERC&@7BO
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MT[/Y,CN)BK>:G#+ONS8W;",IDD=-[.H$RWT/AZ8NQ\<55M1M&FVZ;'?CP;/
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MU,HY6%*#]G_9#%"*=7C1_E$EZ9_SEYGXY9(UKV1*(. :4XPY,]#RVF^*%JI
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M3 I<VS"(3/%8U<?M>!9 K'85?197ZY0P_!<FR@C@3 [+L*]8L0IZA[[>=#.
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MF9%.YE=Q-P*8DZ2CJ$>BKX631<=Z7U08Z'H^=7#5B[/\KNEV6^ <[$S8$!Y
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MPMA":@M_Q6^4>-N^:582I2? *7*]1*KG[M9<%TA2+:&DUQ?#EG]2Q*/%!LS
MA[99:JO=>(TF'1U/\;JN/7KW*/<P%II3/_##=^_EV RG7VY"]2C,Q3%3HL,D
MT6,;EC5B8=)4PF-]FP"ON_F3MJSG%!S?8O?^3'&OKMH!+:==Q(@'W1"YG+#7
MEN@K SOX7OYJF;XO?<Q+MF*)?#K0!D&;==0R_(T9S'+B=6F=3,)H>8GYREL2
M)<9_D768\ZQ%DB<V=BQXA0>0(F/;!/2_%,_ ^6],HD0KYTXC&Q3*IG+0!#-+
MT]%<='S[];(7E<,)XG(I/I$[28\_9\D5-+\[G_J+>+;X2>M@GO$]NZ"[Y41G
M>00])B)=L=8[#97)W)/DGO76X\>5.[[T[=/WS;V'<-6.,-KLC1ZECN,A.6B>
M]UA1.& ]A9L"OL.(^!8!&XMZ.N(9"]9I*(X^U7Z<CM3LY?TY<;%PT6XYKS-9
M!=6J+;F:A[H7O;_&HRU=2J-HWQ"S@^POR(84ULFD6!=:O99Z0UAQ]AW*_GAK
MAN="8DWK]R83J-E5K,"-0:2J9YA(JP..EGS_1:++O!M^Z(23EZ1*07=@Q6)-
M@H4_CVQ['B, %)S:@YU.Q9975GUT8*:U8J4,-;JI<"=UDTJ*RJ&E+S43^,?+
M_"^+?%.:CZL\TDF_>/XAQ>*"_JMGKG;G6_@-J"91WM;X,T)'O\XD?B_?<D%[
M"BN\N5ZU$>H#/AA.B)!,T]/87[LHK91L:384 *X5#ZYF*FL91>(^Y"!S^FUO
MWR4!9O"_<-)C[!K#D@T9TJ(*UD/%L+\FJ-!<VW\:6?%[>NWOB?4U>AH;,KC?
ME.G*&B0)XZ<)RPO4-,KSVC=_8/L8<.J>U8BE\984N[A<M'L 2[SWA5K%4-)C
M>3GE+X=.([[J*R06;43=NY)KJHO^UBY@6<.&Y'MW7V]UZET$"CR&1F&??H.D
M?(\WRX[]UT\-R5NQ&CZO6_\-,;WX"[MWO4MYO4-_W51SX_)ZMV9)O[ERV>F'
MQQ),Y"=-[CE,1'G>,CV6RH:<SQ(1SA+.$L\1;U.4%TY*,/5.<#Q6<9GUT+<J
MN/!1Y=8=UC@;,HW'E_].HNN&=9$$ZDZ+1)^GD(3G:["XAL.3FKPB*R,Q^K9N
MOOF][@^F]P8"0[')KA(5/<+C"T=#8[2^S;(AX1@CBFZ=>>O##)7NNN.'ZJ_4
MJCY-(N^7%<PN,+[KI!"5FG'R =VVVK]+?'RK1*K++=E#Q_&DHEVAI4ZL>5EM
ML=U)2S56O4ERPGKD6UHQYO3J\_]<U3;!_V^?9=/_^3;WKP8RB<Y/X/243M;<
M9P++E-'%JK?AC$&T C6/4SJR3'HYX?7'!)G$U!^UI_WV8$..+F.93VZ1-EMZ
MFP'2F@YVFPTQ84,L+W&ZYR,;<A:Z<.#]?K@0VO\2%1>IM<:+3K&L&F+H47QA
MUM^UNE47@L=])(T)7EH1F1[J *8VQF$VZM-%R*BU^$[M)@IJNE0'XRF:G4^Y
M2RRX=>J/6W;!<):6];N9.0DCK7DONR3=P8_7"D5T;=U.!AVF)1ZO]A#[-5#*
M$,+<!7T#@. 96"OL>3!4LYW,AN#TKY'-0PH??T QX<9#JT6;W:9/3ZHQKFS.
MK_B/^!P>O??Y$CV+R?=5X_+<P^,V:4;&\+&S84)B)TQ\@I2NA7_L1_Q9+$R'
MW\#W_(T0F0[X42=5NUUYM%AX,OY:^%@X:67^7M=OK 4)N#0%^PGB:5=',#(/
MCW'*)H&P$^AG9@.V;RH"O,/D!C;Q(N>E'\(5&%9:\(-ZQN\/3Y;P(J75UDGQ
MU8&GWB$N2NU.Z%8OTO))MO-KD,RY<RQMC1Y](RATL^I26/$7=(J]0L$%Q 9O
M3,&^AS8%XG;F75NO"YB^#!IK0E;E=1L;4@E;@974:H2#1,H4U*DV"*6V=Q$Z
M3=\K\>M(Z??B;SYW[0P^GFOCV<1";B;O>OK92S ! >#"6SJ4D/J^\)+!<3H8
MA?C&&'^A%()9TRP8EW!,X+2 -V0?&_*K8J@.-U_%VE=%YL="P]IF$)<K?X(;
M%&R<UM\\MPU3P>14JW 5BET;YH53<_#^J"T[9,F->RN(;D.=&8^H&:](4FV*
MQPUI3?<^W881*07_WR@1*=)LK%T'+!=0V6,N1TL>.1A#N$8Z<>^J>5^(0MZ#
MWN$QQG]B[[VCFNC:]M$H*BIB1#H"40'I8*$H+2J/(""&*@I"5$2:$%&0""%1
MZ2#P" (J0D!ZC5*5%B$4!:47 2$%$6DR$0@#:;_Q._^<]YS?J>L]Z_W6.@]_
M9+,FLV;MN?:]K^NZY]Z3'<A6V"B"Q(V)O2B$C$%7C28F:UP%HUNR](#,-AK\
M)5S0-T2+Y"ER,&"&G(BY<L9H(Z'ZSC#7=#6LX]3,-XMTZB3%_8[4Q\ZJ#AN2
MF5](V78=KN33#<^80(> 4QZAOG91A^/Q#IX7 ]#:&(5VR!G)*V6<YY8WFN=L
MM2;%F^S%%GQB](BYSKD=!-)J? ,2E\2;4CF[#34G7@4\_04N12;X[VUEF$S!
M#5JMD;\N4=Q5+$T2[0NUV0&R1ML=*:=*48LC'X83&NEV3P8W5#X1)CK7'J$_
M*B\>.BT69(RZV!\X:7IY1+MLM4G9HK)^J,8:9?,NKH=R<;#L6FC&Q,+$^_&3
MFGZ:FJ^30^-C,P]'24U92-M:2%JF6JZI]N=>#/)U?*5JEW]1*TC-(<,V\N19
MU2[[9R^?N(M-^"G&/LN]>/S5S)_73%[E#;E+M;O9I=RW/&:YU+3?'*"P/3A>
M@WR8%W(\>%JPO5S64@<ABGVAV7AR\-<53V T*K#<L!6/:$H^XJ@WX&-@$NU9
M9.5S1F]@TFC/[^/2!]@+CX\;O#K5^D(+Y4:]W$J_^E;-T%PTKMQ>.J;@)9BJ
M-CQK;;6DHGPS,WV%]R QT2/#/>#9\F+)\$P^OKJH5<?;<O)4SL7C 3\GZQ']
MZ1P1-'VDD+8\IFS'O%A^7>D54;19&1O=5J]36='9"'2DYO]T$W_SZM!&FW79
MSZS#H??OO/92M& (;WO[27D%F7@E50,C-=AJ6U10658J'%F66Q*E5G[53"L/
M4W<\%[TG+[UU,'[]]0#7\-&=JIP4R[+I[K5&1\LWS>GY4O:YDG.]%W-=!ZV]
M>D=+.%YLT^^8"7/66Z!P,1+P=6#R2"Q75/MX(?$U3A]XDIR:WM:LEKRU7WI
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MQXLBBD!H+$.V\OM+DUQHJF8;:?/^O+GS76!BA \C#A. F^3/2/I1)H8K;*(
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M852N%=Q,3:QH,%+MCHN9&"-7_+>%;\/D<ZJ8R1%0G49]V&C-U&;(UV'HD,W
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M%*4?64W:/Z^?)G,IEB&)/5<8&W'I#HKUQ<KRX=4$57_)3V^;WB4Y1@B?;>W
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MX;?0*7'5*:MIS/R62=N!<&.2^6\ [%USOY&_I9H9NA/*,AEO1 BQ3HVO/<G
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M['!F*IR.R2B4MRI&Y1@?3DD[*A!TY.2C&S42?:J5-F9J"CE9V@@J#G&3O&T
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MHPEV=93'BST4+."?QQ+ZPQC>+8! QA*1LOA;T(.9<7EDR1@="@:"AE%8G./
M>A++--236N/E,+6%D$$W&AZO6LG73%SX%(DJ 5VO8.WR/&ZVTM6W7Q>5NG)#
M2+=R#_O)_[TBN>_S=%..(+?O#SLP!%=T.=4Z(1:*BM4&434QIA-X;J#Z2^]
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M4HZL4UI= H89KJ T;3AN$L\7>^1K0)1O7$V[#9!J0C_4MB^W@U84VOOG"3)
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M]#U'H)"' Q!2AJ;SB>P7)70-?.\EXA:W6?SA,,S^H@AK^IT+;Y?$>+N:\X6
MH=20 *^ 4O3-)8/8O/*O2^&,\#H(ILC-AIM6"MGG;) C6(A89]VU,QL[$&KK
MG#O8%QZ);)_]$X/'GHU\ =V:>0'=X+8=]Q)!2<?(8'RA)":M>>TWP/6^))8G
M=Z1&.H^^!ROFR4+@:;/V<3+%MT\#U4ON.3G_=;.A>.4BT)]N:,/ R?K!#=I2
MB,;NR)YFCDA[2_UXPYJJY=T]^'=<TI4[RYT+/A &8"Z GO1@JG47AA2,!-XF
MM6HFTH/[]> G 'R/AK-&8M[K6=9%+"'J^:BA]SWO6_+U6+OZL9B3-0$V7;*_
M.BJ77;Y/;7< O%]V((WJ>, A$]2,Z+8F\7+X')FV! 1A>%J<80PZTK3$8\X0
MJPTUJD$[2NORU)]B.2+T0>Q>--)EXE<C5B*@^%A+M*P=#=8K:.I$-V4XY)5<
M*/?O_'>P.2X&=@Y6B0>\QII9FF1067K?67&J[X=XC;B&T^AFVE%[I1?J0BD9
MI6I>OPHAL:\P75^1#;QK;*82@B6\PGC*3FQWI<]3V9D$(SM&?G JYS2(+ O8
M)A/<=05MH=,<Y-XE;BZM'4\,RTS,?QM?4:36.TAEGZ9YY$67?K/PJC$KO\ H
MB$X\!^T-CB<#T="U >K:?ED]VM1J!?,4Z\JDQEVPYAA=/'X]5B'FU/O.M@2%
M5*:="]&'#LW4_O3K[7/+WE4I=3FY6M3W$"]4^<S?</K]V#N<47)#(DLTCW/H
M+KLD5A(,Z";S()K:3P*3V[\)Q?P IMOZ((B] @H#5EHR2)07DM[?BTEVV9KL
M$,-6^(M)>22RFW'@4[?&C #!0W/$KD[1AM;VIU?&[R.(2IR#@<S]8#3G8 53
MD'68_?BNM9!6VA8T,<JAK@)-[AN='B@G<.,A*?;TU):6&#C@_*XV'[7P;I3H
M-/%CK/TL2CL]-)@Z>-HLA5[:X9I\$\+9QXV#K1Q/KKN<91=+H[YBKJ\GIM3$
M-;SCC" ;6KQY7ZK*\N_Y+RYA_J<VU%5-B27,M6,DK<P9XZDU+>3L).KMS<9V
MPOZI+M][^-(!^7_IYV#6,4'@>0J.Q$LA]R(?<)&-7@GRS,,(> G627HN]A$Y
ME(J30<=R]6U4]TQ[THH@R6GYM)GW'9&.&M*%$#&%Y .0W0743/+^SM.Q WA9
MN!&G%WXLSR58""T_'T@F9(JCD9<?KKJ Y%ZL(%>P"(&^7:3>W.>'L^[9DFU3
M/?#CK&/RO\<V!GIR_SB\"C5JS][#^8@%S/!?7Q$X!W=3B#_LYQCOLH;&N-[B
M@R#&NR;&OK5QHU0*VZ<E8Z&5%JOTK>#C!BF^!IO:6&-Q8>27=\1=8.[)J^G7
M'S6.IIR COI#./OQE$5K4*]_'M:+2_78?=^5QNGF6KV%2,['I:O?4F*_[MR+
MUOU\SZ(_%,PS(;X<>\%5Z5,$W9#&_A3:9$,@PJJ>3GYT5\*'KC^UQINF/:C7
MP],#5WQZ#L)R8#_D3LS/3% EF"4\\T$75H_+N(O<QQE#0CFPCN;$=B,NR)/D
M^OO",:)P:;]M!>0T'2UL2A_*?(N2>N?7ZG*Q*=?%,?.NEO@<&#XW2;PTJJE=
M=.2SX'$(O!GD$C<O!M/%Q6I4:0.(8!Z+'<;RP_G1Y/XC@OS&'6 T%2G&B@6G
MPRIGO:\W (<*WO;KQ;\>+\^,.M[8W[TNC,SCUXDC#4APQZ 109G!/< TP[I@
M7Q$T03)+1-X,S"F+'<%*(_R126297] ^F*A22J>B?ZP(W9= ?N1R**<2["B=
M#"MR))#*AJJH&E$(T*3]W'9X2XGK^:"\*'B!S"0PPKO)^U^OKNYA '<\J!-,
M.X2C\_>1&]=9POS=X<7*8^VH-ROP$R".J>CLCHK2K*.2A9"6BN758"KEF <<
M6[I<+#/Q.NO7]B+5SMTE0.I0J64YH6?J;HVU)9 9_P%Q"'&3JU^T<"RQ"YR#
M)L$!3 ,PSF;<\#S5^I^+K;$%3 2'A!=@>;Y9EMO[+AG>O_])R9R'/P;*.0D&
MF!!IS:Z!L.[Y/GZJI81KI(M/7*!D2\IUZ+O=6SFZ%I' -8PXVG_E N#8/3S-
M0X571/!?,O2FDA.10BPSFH;NE<Y/FZG6LBQGNM(CFPF^_9:^W=NK5Y;>'U.+
MO,Y#6Y_>@7 .[AYT6\#UJ3^LF,1YQ]X'=%<G@-$1P@UO#*F9D1/G"#038/R@
M>71SVU-KT/G5K#-*=^X8<7.SM:UEM%.6)0YLH^]T;V]HK8D!-0DENG42O-NW
M,5TZ"$HAK)Y+$4=6&%[ ^NH4<&AH8_O N@(=T1.<1&(YI,[#4LB'M_A=7=V1
M??#CT=H6T=ZZ#(=\Q\0&:>-)N RPE8 M(VBL?7%L??UB3S2'KV0'HMRU*\UV
M(-,)L5,[D.UA[.&?/"P,GE*,J(U8.\E$@^OS<IG,8Q:AH?0IQFU0)81IC;8@
M&.B6*\;-:XG#_F'9@$BJV>9P8M0V<JFJ%&2:PL^F]LE)*6[,+5YM!0904A<'
M<,@E<PIL9/@#'CR[R.'C$B4Z"/$ TXA<_0V0YX-[H F3&Z"C'1W6LW:V'[F?
MHX=!H;[W"B!%JF^U#\HQW8DE&S5:"ID?YD0G=?;&:X:U%<S>")BU7>7Y;<=H
M9.-W+Y+;@0 AUGWK_[!DN /H7WR&>%?6O1&:B*PW7:53[]WHIV(?Z4A_+2.6
MTO]DA 6&.DSP+U]=RM0I6^_12BY6;P#(">KED_L?%0L1==)O3*[RL(\@*''<
M1B^[\W,.RC*/?T/+][@DI-*&28[S\))2D,Q(I@\]JM?E-G9J:'FF&R/8KA%Z
M^_&W.32"VEA<437SU=_1@?%'ZD]2&%D4G;K:&I:+\WRU= [6G%:Y_''Y;4:9
ML\1^!P<);V]#4?F'![IDY)1Y6$$8%/8!L@G)DE[;?>_42,<]VK1T[";AN7.4
MTJE,QZSVTRV00%^)%@&3M@/APQUZ^=JU^G2_3DU&2WE \1ZZ-'B6AHG?K D+
MLX:Z^^=W)FJPBT;>C;OQ;/?OWC:"Z1K&-^)9(FT<OO-,-<['V*-<[-\?HP(&
MS#,1:<UDT3#\0:PLF-<K58"&44Q[,F7!NV LTV6JA&@(*X.)H0,N61J?G3W=
MXYA7.RB'W5_CX^.ESYNT>[PF'WD:#UQQX O76%_+*JL-3_!#>+^JM#[G)"\J
M>]FA?U;_OT[;]/;FVB'!Z7Z97<$98K]PVK]7%L=TB+E[4]_H.=^[XOC+\@^5
M>;XCP#/RG ,G:S!=EC'R5#(I@N'>-,H=DEO8N$[1/((X7&0<%]C@KC?_AR M
MG6[J0F1)LG%H8,D%T8,0\&_-*$<\:$QW"9!5<FB:#(,*@ 77ZNLS"21L(E?N
MDK_Z<OAW.7-W]5AR.:I_M7P>D?C')9$P++@B/B7^GYU7CA2RI%\$&8H+X^]K
MG<#%2ODO15"'Q= &1/?6WV'[&C*00C%G\2V=>/KQQ 2?"9V"09]5GG4,B9\#
MU67C.S5 S?4/R/KAU;^ '2.*[INLP<V2B/V,.V#>/#3C;EO!A\<F(11++63B
M92"]N('8G.<?8T+5DOJP]^51(F>R=O9?7C,NS9W@*LUP# I/8C*21A#!,% E
M\5%,,!7Y,%?N-$S<K@LK]=31.@W1:)WY:YW<TQ35G-H0?+B9I9 ?3$B=C;H<
M8TI;B^BS.5\1<ZGY[FB#!3];VGV<95%Z'U,6#\$\46+)[I%)Y/ /,I'*Z9]R
MK:=#/^^QNLE5_\"QDPMI,7_#;DJ'_J[P*.'B>-O=W;Q5&-/55/?^OXZMOIFC
M3"VAYZTY_] <$XC&^$!)HE;TM+>3W87SO!F[&U6T_P\;5:;^=QM5Z#P<?CL@
MCU;>:\W'@L11,01K&,L4:T+G[3D8EF2XC[)^&.R\IZJV=K:[PENS!)K8L&9L
M(?&V>)*J\;W%*<OWH7WZ\R?WV?,?OLRK?#Y9>$%]2GO@W<>I[@5ZB3I!.J'K
M4E6\FUTARM#2W#^(S^:.35N*/Z,5SIL!.+6[RS1ZGGB?9E=N)S14NZGJ<-LV
M7L[QN-6I$.N<Z38-Z#,NE&0@]G#T62?8Y>T!-&@R<G^G*LMP)"AV/QI[N6FR
M/13XW3MW9"PH+"!3EJ73WDS4V)+%7":N*8XK-M1VMJ8,J;A0UU9_O7;Z$K[Q
M[IYC>N'YQS[M:O<)WI%S-L]O',52U<P3>$YUS:L9IYUBC1VI4D5'32A)A129
MWPY%F9C?3E]7R%1Z>&J5<+# L2+EP_R)\3FD Q\Z3<?_1"@Z3>VJ;<6!<L42
MQ5>-#:Z-3]@:4QM+VR_!8*XWY[*?QGC1@R^!2/I3JNF#&(MYK#3:9WG^@YS*
M"$N<.FO7,W<,#^26,6H"SH_WY96X>" 'O*@=/D8NI(B4@X;UM#<+C]4/&R8S
MR0\-/1]^JOK1HAB<V;T "ER3?^:I-E^G7?O>'_W9+5MMC-&XR.>/KCR4_:HP
MAU/A79V%V=,OJ1/C;:AXEC>Q*@EGTJ[C<E?%O,;,)F?1RBV;]GW>W-]L&K6&
M>P??/>X7R>E!B/W"^ <?0J_/ZW&!+8D,91T%BKM7^L5.L8P!I>3VX[YOP;Y9
M6BU0C"U')-WM,/1P7XJ*I](=MX\^71VD@ONZSH<>&?C3J1;RPU).N&?AKUQH
MKH_^E[G2$Z)BKL\\0YX2*/EA)\-4U75<BH=T4%V>XD8MN<?<FA?"_W*$/Y[$
MZ94E]5^OT_>7T&^EHPN-7$Y6N+MH>T%1!W[KFS&#(Z@,<R:73^QS6!FQG;%Z
M7'3SA8NS+, R $G5? X,4!<SX,>677Q[F*EKII: TJ.M=7'D5R=\O$YJ6$?[
M.X"=\#(TT,<736%>&U60N_ND%__EB0AGFI(0F+-PYD>(H\Z76DEOU99K*F,5
MS[Q.@ 9<0]TEH_6MA6P+C\.O+7P26_A<T/@4+I]Q^UFU!P^O@**T4')A2,Q8
M@ERZ^5C:O723067B[MZ*MQ.XF[%(3-=IO ]73\(^8)H6NQ!BZ'F*7E_P?K3K
MY>"D1'NZ5BI<'"03\O?G:\4*@RN6[YCA==5^X5%AY:0MZ0$+?ANC'I_H@:IH
MOV9+=3]R%5C6P])Y=ELQ.NY#R'[3C-Y)Y^"Z;LIOM_U*0H[3/_[><V8::*L-
ME?Y5L2LRN].[T7WDZ;LK?S5%/O]6A]^[7Y,T4#>N3%AQVPKP5!LKE[LE=DSH
M1^%2G^I&]HVW6X''*]A^4W0J\^@"4K*3+T8'Y :;K"NUN1<I, UBN[??'#G@
MNU]M3<DFY8Q7_>2FQB5U=Y34Q/U\Y+MEL:"L PO%DR%&.1,3#7--9L4^A6>?
MV7S92+L&/&LU\# @5EDV+!IW*/UR>&D[4%Q(=+3)CO25,#=$K^X7/TD8YD\K
MDVKP'5U2-A]4(69-"J>3U4M\6Z<;=B#/K4EVG .SS',Q)\:U=#(?"L+Z=B \
MAD2S .^ XQGI=.BEAH'VV\OYLFN]35B<Q-7^6\US4NWYOZ\^,^H"YG(..DUM
M8^-9MZC?)HL,)#<B#QE=4K57*'?5P!D)YZ@":96>O]:U?),?QNN3$,Z56PC5
M033L9+?9L-8.))@P2U++E<@/>)6C.^[O[!QJ&_%T:OH\[!E<&3Q-C^X2=]2%
MGP2=Z>+=S>&W;'^0>^!\=+E,!05,#'*IUO,R03[SR4CBI9O_3BU_O?+[>+^Q
M<)?/7Q]-8<='M>"JQLVIO/HJ+8N@XG28DB-/.J%9"C2T%Y>=,!?U#&;QJ;'2
M9&$?/,[0!49=?\KQTWU:#%>/'-#&' J0RB:>H2C8.#M_V3CY4U0$>]Y=M%X&
M?ZBP3F)5]D"OAU63:OQQT=F6(15Y?<\Z4>WRQ!J[=_$J SL0LU1X-[B[_W.<
M71^K^>V<-CEN]QS#NQ6R8H$86A8L<5*L[E-Z,Z_5E%=BSQ_@^J_9$C3&+A!_
MPO@D-G7(T(82DW^*\7P.!K-7&DC\C*%>*LUGPB?CT.9WEOR_YKMG!O!VM_S0
M>>LF>,40QFKOW8'4FVBR<C1<+%@BI1A+6"WOJF\$4YQU@@Y]%(:1GD&3>^1.
MTP7QR5MMZ7IF>1:C#55O[E8%GKP[J/SMVW#TFYF^IA\7*MP)Y6:WATZ^)NTC
MD0?DCH6TZ\_K$+S\*,?O$Z[7#A\T%E53;:SLFLAQ=,"I>UD5%N3D*!NDJ&".
MW$,X4+^D?W<RSU9ROZ'J6%DYV"?S..YJVIFCX0L*-70=+LPI6*5R^*2I2&%P
MAG$:7*%R S+4G1Z<W(B!_GR"@LL"0T\Q;U=:"VO1_82(4)-RE(%[QP1[M<YE
M9O@VW=7U\XK J<N.-T[*S,G< -[+Z5)9'GK"B5U4/UJ5>9.2J$LQ#&JNQ9O\
M,$S-/EN%:&6;9I>=U691J4UST0GX'ADO)5+I4&5P;5S%]E'EM9PJV\!+AZUL
M48JKN1\Y%Q'4QY@ Q+;..DEI!R* [<%Q? *8I]FA%*[X5P4#N#EP"W('H@-+
MW8'<6$1LJGSABN XT1W(Y\1^IAQG\EUKW^Y;JC4!R:$]3RG]/7Y7,1WJG3*7
M'T>WJ6:Z6*?K[UY>M8(4G X?VOB$R,HXWKQQP5DQM)EAQ55^C_1S_H[5+<-W
M:W)N<V8\=#I2!BS9Q:R LLAG6A&T'<@J;I_S>;ESJ./87I>,)T5Q/TY\>.I^
M8J])L#S5^FD:_>R#$]K?ED/D]C<V)?#/>)4K39L>-'_+5%*2B,@R=3\D/ESU
MZ=*90'3DY/>7(NVSSA>"/NE-PU[CZ_&LP^OVN<O#'NS7G'^G24XFVJ&P1&[O
M7V<M;VQK>V/D7>C%Y=Y[I>Z<L1.<>)U8ZG]D(/AH@/5A)S?5=QS'GDXCVZO%
ML/@[2Y]+4C,9&2C1 W;1'@G[L[\OZ[0K>33J5VAAH+8&B*H!_7_</K\.3$Y)
M0;%=#\S<<:]T+'14_3EO=20<]#=98^^)@8,1%$P\7&B4Q0LL=F^;QK'D7\RD
M!FI=& UT((WM8XX-JOPM;^]L?7KW#RE]M5E\.Y[X*2PZU.C+.W/RT/,,[\Q!
M>DZ]P("HJW1:CT5^3=3&C\)6A::TH_O\B.7[I.Y2LH]*]"K@30F>M:#!"0(5
M91POY3]2;NFL!?]E'6EN^=G:67=H['WZ<#$>M3[=_ '9:-UM&4JUSKR!/MKF
M/<[2H4D[95E:=\NIU3^D::CUN/BW'?O,Z/X1[;JBE*7?:*3ZBVF9Y>2P,I3Z
M$[1+_GU(:.C$WTZ/\3+H[(W;Q/"RM&XKF[#:B5M8U3QU;RN4GGFURKC9QAV\
MGLYGX&\GWVOHX>JR==LW>1V7&NR^5T$M&I77E,^<)RUNJ#$O<%D6OFL4T6T\
M,&P'DNBRF&8H'WS;T1),IFBHV="5XANE=1$__XBG>P;J_$G4E+FA<LOP?(#G
ML6_5R:CC6\U/(A ,1T$PL[O0(K%,'>Z=V.5U'#:WT!+OXN1FKX)+.<'(2C>\
MXD OEK,7CB^<MW(;R9R7S!/TF?8V4WWFDO.S_->-VR,Y+K:9IIK7%LPV0]Z4
MX+J_5Y,'Q6(EP"J:9P"U  J-.4__9_KCD7["9)1UTI9-P$E%40MW1>G(GB-B
MLX>= B>2/^\I3-E.IFW$:.FJH@OKH4,%Q8IAM0V1)25!]H4E8?6!GV?DKOG-
MJVZ,IJM;6B$3LCT=PJ.C:\UFFI+8;NQ4#.4)692C".9=HN/68"_\$0)P,51>
M;O,?.>C$GZ]H9K]-;Y-G*<:[_Q@9?<&TZ'Z<(WZ"0WB;Q#^#DKHSH#^QN?[Q
M_6*?88E:]^2'VWW'B@,*[!]5]$M?(@YL,-CDP#47!OKSZ%RZ@>'FF1K51@V8
ME]WJ*4V!OAN51%R^7:[PP?VE/ZUG>VX<F7KZ!.Y_.-K*;J$B\*A@Y#S[RI+4
MI;P7* .?^)=+C"BKU%=+#!>K)V6H2;J+$RK?IRA0MB@!ZQ7 5ZH[F1M>VQL<
M&'Q$_39!ZE**Z#G<]]:)2IJ:?8]CA<'$RGB1_X2_V5"92Z/"HFWIHEJ+U9T@
MVZ<333,(MT='K0Z76ZD>+I?H/IQB?O*1;9J72(.YBD+6Z'&OO[>Y@%$= V&_
M[%3@?"U6I<,>Q![DRMWU>#SU,*"(+5OA'.;FL CAGQH,]_V*'?6-$W<MQ1A=
MWYO&?=J85U3.9$DG/KEIKR3*]J**"]V><^QRNJ*),/IT:A4Y%<J7<QO\0N1Y
MU!,]02H_,XKS*+I89G5B(4@WQ)P$RPI)<'U^H[ZU\38H$'0LLY;0)ZKL&3!1
M7FKTLX)8KKRD^ M7@M#_'V'JYOK6<-P.Y&<5%<>"+V!8XS%XAF;H#L2X<'@'
M<N DDO7F?_"4WP[$#41P4CJYY$GXY;@#&3S/3BW<@8R4G]Z!= MP_Z$*!6_"
M2,.<]&A&,O<[2KN;_)_G(Z;@T!W(*UP"'F#F[$!^7\7\]]B=.9,)'L-W8=(0
M?"Q?^H]U&J8[,QEQ2",,(X ^-F/VGK[XH-V: NI8I+H[(G-_".I:'UZ*NH.T
M")2I,^H)?^WPX'ARV8'CF1%4N3.^SS4#'U"7(QV"<WZ$EJ3VFS?<8<6*2_WL
MNW:;GE99S97<@V:O7RT&!<!=-]KNK?]S/>2]P71J+X7N9&_@%,:;1)AX\7I\
M>?8"R=APTJ$#%U#U*_.G'+YP>&PW-^1X8BAOR1#X6989NVK-T!18H>!Z<3 0
M':,"Q!:'D?>RSM 34S:]\8T3AE93NAH5/PV,V%D>,Z4CAI/I)XJ5?SR8TS'S
MTF [4J:$;G,<NX6[?SC_L,Z[@6FD-\)Q&5\ )X.YH6NU*:*BZB;^H=^?IF7[
ME'S^=O-INSM>>?Y*VXE>7Z&J^ ]>)[4[RXWA1&A\C8O,YS"<G/_M[&M9_O2.
ML0!+&P:,)>1%1?1JQ<<>!.F!= 05E]DIX[8BIP)<V39ISC2$T6 'W/P?.R\9
MK$;8+8V@XZR("^T))#-J1F1@UF5:I(ULW E1NL<9G[]6@9G4O][.K]V?=R<(
MRTJ-#=#?W[J%,@][HW^IM'9"5?5.5FJ(;3U*-^?)&J (%8\C_. 7C^_Q=%NY
M>MLI153YC'(WZGWEDU24N^)D$KL9UVW=_C^GB *1L ,!#7DX? 1:9MR<((!E
M"2,HB%2K5!HRC7/X:3^L4;?NU3=MER$L4&#3?@_1A>$[PB$9DZ)BS%J(6X->
M_>&PGZWI_0\WAZ%+=NP2 OSLA$8P!"&/H4RO@_\B$Q'!:RXK#"*[UM#H7B3S
M>(PA_;0?7C!69D ]_QYNC9\./==R:>I0F[JK5AEH04G];^R]>UA,_]\OO!)"
M:E"*4H,B)'W1@<JL2$(R$5*C!DDG&21-FF:E=)*,8WW5MR:2T$EG:II1TP%)
MY].DYA Z:PTUEF9FS5[][GL_S_U<SW7OZ[KW'WOO/_8?M9IKKC[S>9]?K_D<
MWC<9A[M7O[[?2?,1/3:"NR7)$DJ,C)0U$ %EXZ-9QD)(F1ID#T.1+,L,!*SQ
MU&W/NPJI(Z0:'H$I5 #JOCKVM\_JFIC:MYJEACEM/]B>M^;XK:[Z^B[5 &J'
MX9&U$1N4Z1';S#'@,TPP;@T&U9#,O6TV!X3]%S\'6KNUF,LM&D^V!H<3OME4
M)J@1#W:<>5/(*7ZSYV@ Z<6ZR&/6'BLNVVKGCD^8C3EZ@,32LL+7A661GS]^
M_+P@+V_SA,G3DX%Y@8%/CL4,\ 8T]Y^.--S_-%YKQVSG,/Q@J )0T<*BTQ]C
M \W239[:"J"3"$LBP&YCB:,">'!<_I@SSJ<O5@"C;^%^('R>+7X^V@_!3O@>
M[FP'@$$7)%1ZC*8%-]S.?][VO)VV76Q]N+UD0GL0SWU\LJ2,Q^ J@/B_3C86
M#!/]J$>GI_R\.?#S8D/' !$9%W#]W(.>0TKH 0@^48"L)V*8&C$D3R3FT!:+
MMY2&%U#W23;0#>G-X(H2F'>*O1,)WE(0/#\^Y_V%<RJV8GYTZ2ZK0.VZBKW+
M&K8\SC_ID.,7:!H[S<#YAPCP(UAFFC^&573'4@ZR,42FP:DAF")/"G;GH:W,
M.=.5C$A(;W+_?HK,,6?XVHD41B1JZ,';^#ZU@;V(W98?G(/<U\4@M)Z?IX5.
M<%567I$;":"+G57^W*1_!&%?%9FF@20*B7^)I$I>B55N@%Z<:-=THR[3'T\K
MN\R("9P5P8'; MU%8= X3H6J<>HM?/Z?BN@RASX;%[&J8X<9TTHU%JY_<92T
M6FF$"5]IEBVC2$QG>X>A7'*A912(X=18ALHMF8.XLN$:?RG;#.D2\6O)VNBZ
M ][P;R(UN99N1++6#;?>&Q.L;>&I#C]/%4ZJ]/1?Y,3:H9UO6!U;(L SH.##
MY!\'XH2U O#)$>'E1YC*P\I2HPS<;8C"Z8&$%)FFB^2\V&$\2YSM*C[!@!OK
M!S8C9T2FRS\(&AN=K,D=)9-8%"Z5F8K56+LH+P;</?-3*:)]<-NPZTQB"9ZG
MI>7ZJW^DS3YL\;(-*BWX^6Q5V09Y.GTE%11TO\,D0+41#[CRG94].U9H.I<*
M.D8=:)D*)_1>EKY9H^_=.?TE:]+<R1TEY9'<.K(K.LT#^OKW_?@^ZHP[G('[
ME3%[XSSG?$$LNACIE:Y .]*U8?3Q,^K08&PTW82V \E^=;(F,)_F8E3-A3^.
MO=-AY]X3#4B/%[7:A.920Z?=COF;/!T>T&O+2A%Q#[2?*03D6"F,VF83+ (U
M,;_8B!I2 TCIDJ&#B(_46W8,+HCZ).OMH4*NB#?LTE!^W>D&>-5>Q-%&DEW?
MWKZTOMOFT_<3@/+,I\ZK:::>;=,FN%/M%\S3M-U>L]J"$_''B\L[KE:Y.G8$
M?BWN,.MW)%;>"7 <4QT[D%7**JZ((86EAIZ+]!TP\EZMFC5R_7SL<S_>EH3L
MDR,ZA'M>?L_]K XG^U&R1U+.IYZ9>ZW,BIYVQF_5B;(3%B<*[0/]_ (U3TA@
MAU5_U=][^@+@V.*_5V%16T!;!!M%0AA;Z@4'.3%3X?@#XM@&<A3!#%8 M8YI
M5LO+V>)UOZOY2ZA7&KCI:[OOVZP;>&JS<S" N)CD?^5E9;(#S$Y]?L"8YRO9
M:JLD7PQ59R2C!I68&^Y$_/FD)#^S)F-) C)T1C!UW\UPO\W.=9.QI=9_Y[5^
M[EE#,.F@N6R]M6J?3TIHW*_S#^_B1M?_V_>J,X.H*C;&W(]E\J)DR7SHCN=J
M"B^4;<9#FZ.JE\KTD3=7J\7NDQZQW(W"]L'UL#OB^-[IBG?A Q+:@W+GN0N#
M54KF7%&2*O^';V[C&;6F?PZ9W@$GULVNDW8]J<K 23[_JU@H ",(L6:B+MO%
M>/0]Y1U9OO=<!FYJ#R;%.NCCVMD^? I @F&:^=#TLM<9N Y_0$@WH#DC?G!8
M34KL'=1$9@=;UO"51Q;I'A<GUY*UAO47POE_5WI4=]C8B4CR[?N+YQE<FR_Z
M8?-JZZJ-[U2&#)GP*0IB:&C5+5&&JNU!;Y=P!;!+A&0];7H*]T%?ST7SN570
MZ,;?]#,_?]GBGW 6H5ME!LB0T)JH+]- LN QC&3>*$CU3KY-UT:ZN?1=<&E'
MY(YO6TECZ/*.4H]-;B<VGKT6O^5VW/TUWDK1P'5[(!2;5R)Y/HKAJW,8!N,A
MI7"C,$3RNP]\S1&>17[5L!>B//2SU%(2*R'*#"OR'\LS);BR7GGQ.#VDE]X=
M.#3^2_1%J5Q B>/@V$:^JB).#-L*IM2:JI9V-MU"'KP;,&JU<<LP_Y;4&NI;
M47\C#,K6S=DSO"6PKB%U_K=?1RP7 8BCB"'34D$74F"O.NWTA<@#*0UM).B+
MKSU^D6;@"H^3M5E&!?X\K>>YRTCX)6[(107@FLS];3%N6Y'@1M(J40#)]Y9H
M*DUSWDWRK"5T^7.9D=$=+#6!B?R%J#5UFRIG?(RC@6GJAI <YVX2\]S +?5@
M1X',^)7_7;^*W"/;6#QO*8E<\RRT;,16GQL41/&F[/KV%>:YN]N9-'5V?BJL
MQD#_W,#-[<UFN85VB[<:'-A<M*UAE?_G<4T-6_QCU KSB1:HVHBN._83(=<Q
M8>>"WCW\4V55J4Y5A:WH7U27.F9ON:3-S-+B>E[SS8+@REWK15V^ ZI_EQHG
MG"A[K+,R<G\6H-+#F0/Z<7J;)4_@VH'M\E34"IOSA## -5)73A&:UN)5J9*&
M@V_?NNFKFGC+S%^.FCP=57_=I "631S?/'F7NZVJHN2PIO*7%T"&NK;(L@X7
MPU1A;7Q!G<0R/*A,,X$)=Y^4DE?2[,47;PB8BT822K_HV=42UG':S1+^.FIY
M^N*6P8^92VO^ >A7#BB >?685'OL\J#3EK/I_+@E_]> Z2WWS3Q3M7)TWWX/
MF74W^I09\AUO:J8THPL7#.)KP#MTC1+Q9#5XBZS.-D5T_I2Y41N$4"+-<I"O
MZK'?X([+<C9'Z.%XO"WKT=DD(]_[P^_CUVHYKW!6>?;?SX-80/!EBNQY@42F
M (JRA-!LVS^<KW*-!VJ&I=:5H.!%RI;R+).?B%2R'^D7-J]$+O17^C6*-83T
MEX%>HET+*>=B;*J?T,XAIJ*P,"<WDPX;=S"A(%#[7&M:!'Y\"':9C1'0US2*
MK\JVHOW5V>Z!!(NCWA$TD >"-+=KQIZ(3[V[7A+GV:[:#3_#DZ8W3SZ]A7[X
MTN05IE?WC_!\I#V@S_SWTPQZG9B6YH*E*A/2+/J'@7E=B5@(,7N8!UAPTDN]
MVVA@3+E86G]OI()9.\;]6I35B%@?+H;+N0_+W\;_,*,L'=;?<8=W1#UGTVN5
M7ZG2T_0F?6/Y78+-&+/X-V/-VR)Q=Q1+#2:ZB\ON46^8VE@.XN)!9725[*@8
MO$E9?OR8!P*>$F?]COYQ[8<+X=X:MW5S]POP$WG2M="';/037D+!SX.F253_
M"$)L!NX.:H/I;P_G#-@;=H1I)W^B "[@>RL%D_$FM\]2%B"_!K5OF)GJ;+BG
MG(F;?VK,J\X4G_3^^_ZIF,2E@S[>KGML;92K0=A]%D9EU^I=Y'/35V+N$8-^
MS,OI_Q)^OXWOB10*^2J[@Z]2[ZABE6/%*5^KJS\_]]SI75L1%&QL:(%>R(^S
M!9W,JEP.=9OU@VZMP;IJ7@Z=N1.E>L;'VWY,3*M9'FV?7..88#U!F&D[$$C9
M_"/OZYVP@!R_<Y%4#\/XWI4'9@O4((;D5+9!'R_/-O'$BK<J-&8F6Y&!F[XO
M9W"^MD'>S5)+8B1Y)L]FNZU^YB"&$!6 &D%C6(*N0;+%N'=\-1LPY(7],UY
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M[;P&H,]?*/^L1%4Q.39@/Y&W,).^I)U0 .US.Y30ZQBQ@F3/B5@JD]BRK17
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M'FO?[K;MD^>FZ^AO2':\:7L6_6)U*&3\K,ZSI#')<P!MXX@LH!X<FN@HJ58
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M(X0XMCO>7Y"R*ZC!_6N1>8UY\3XE^2J(.PH)[H-3]S@]OQ4 +OL&]"?0%M_
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MU7AOS$KWH!7!S"5H([FLX5UJXV.?5E2+=@4)$AO9WW(;(!>"]9#RZ,S\[(!
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M^IJY+UX"JC9UA+W6&I]OO^&W8>4H.Y$AAX!&E=HWS,OYN>X0[;<P>KO0%C]
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MB'+VPSB)6=#%\+,:99<KM=S;N:1FJ["-"P^Q.OBOSM2(H@8>5CR$D]HT<I+
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M(D(8XB'Y"6(,E2L^0F5H$8UFNH W7WX!C^00!'T84>KC@NA]C08@ &R"G)Z
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M\L"LBE>#_JU['_>S;_[DH SXO(,JCQ&^Q2*V##@JM8PG#.SDR;<P ,03"F=
M0A[M"D5/I/E:V^#YK4,BPA7*!:Y CTE=)5+*,5^>J3&4]*O#26!PK.K<"=+&
M'X.>+0]WN7Y[!("W]9!U&( L.IF**@1(#@315:F+)KR;I.F$(!_! 2&W^.3'
MDY,T*)6W^>^LHR*UIG0'K[_?1IG32?XT98II?U3RJ,< Q;CV\8V(J-*0//DA
M,X&MG,1POB >IH3*/ B0JW#$AB\&83;O\2 A%!QQ<>R-=%&9]&X8SCH)UT 1
M(Z:,A8A;IN.HP/L9([_6G@,FJ[4+LE1"W5$MD7M%'"95\$S22OE?_U#']Y(0
M[=\R0,](LDP&C"R?3RQY(J;9XKN3$ TG&:!_$MZ+T:LD_BQ:XHPYN8*Y_X,[
MCW*PK;2,\6D:<S=XR2YZ.CCWHMZ)^ V_!'R+;Z:+G<\2YXJ;Z5U>0TC&!9)$
M'7-"O[8^^5D5M^7+?W4EWG_O - ,QCX7*<F '$Q:UJK)@(8,1C;Z%_OG07 ,
ME 'DI(D\+? ]'YV0 9):</\=9)#Z]W]YI_]O\T\:JB'<@2H^D.B25=MLMD V
MY1P3VJQ&S55KYU+8[1C],)1U6:_ONYF6XO':WO!'?9]>PG?#(LQ*:M8\&^QU
M"B49M+XY>T7/QO,WZZ/+G>[6XRV.O-Q#45J[8ZTM*M/GO/U&B$?>^IPMJ91.
MF<Q910SZW^%<B/&\E[CV9(NBDWJ2&)[L?QJK 9W84GMCKJ3_+.=WZ?N9*I:E
M<#Y[YDRC"GEP<TX3XX50P."]/(NOI;<P%LXT^ V+B3.I>.TN)<5UI.5N*>/J
MXF6%T+=S9E9_GBJ#MY;*@,PD7;W7X9N;[+O46]=I)J9Y'Q./=!ZZ.#8ZWN0]
M:1!F'D<[ \VG/ND*6WO;E]R2X*CCKVZ=<ABP42#[MXC;R;]=6+^$R=E1MT,L
MMV=^V=;@*%<89MVL.JKP=[$/O^5 ]A!RPN4.DQQMN'H@?!NG<'-O1L2Q9Z-E
M%Q3@:'<!&-V-^5W\]1C6IG3)!K2'M6Z'?D"6+T.:$[;M\0YNWE)&4&KJ2_CU
M%J/*\*N"/UZ&U1VHIR,O2S)SVFZ'%7^;\A7TX"U2WCR'_4CPFS\MZ^NVJK8-
M?AU\>^!HDW[<#UJV0YB(Q!]J9L0W+J+S3-I(:M]D@!+%:A%HFJ=3=\5J0HB^
M&P*'8_SH_F:"#PW/?D>\2WX,QYDY!I+ITXT4N\Y"'V4GW*$3Q6^/%:Z^6"#:
MA+%[;DGUM[G3?T%B4NNK=.OB34WN[6>>=N[;7J"FW_;CZ-<G1CK+8L9_!.O/
MQN [V0*,[R_^)JJY'AZ%7TY]BRK50.X)=TOX<*YH87.7E\AW;F7QZO%DSI>?
M,T9RTK.E*T7+\[9D!XDOU9K?C:RPM='9QE>X\"Z1Z'3#!_XUP/L5P[0O/N!H
M9%95&E<J!5_3[=]OWIS8'M%FZ9G2R][24;#KV$.6MSN3V19E.-<^(GS'$>A
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M)UK2[C$07GU6(+'_]>F'X.TH0YT73QA#_W.K&1]D<*;QP\)60I4)HI+%U+:
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ML\IXNL71ID,_+:Y3K2A>(K.6=VN[#*=6"U-,K*NN?Y8!D<GKEN6?VF\+R =
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M>M!CZ^#0-TE$1GBYS5GM0DEXV1FW;7G=>W%#1V[B;C.A/67PB@HD$)?(?BS
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M3BL''WDL8E6)I_OT6_$$CQ_'J#?'"YK*R$Y-1DM+?'<FA?;,1/Y*@:1D>5/
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M.^F"XXC'Z1W;_>T&NE@5ER)[H3C/^1]M"SPKF+&>+172[?!'SR]NP)KI"]J
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M;3:"SV*-%.*M4*?"=O4)Q2P/5KG%LQQD_0X[ O^4@JU!YDNM6W[-MK5N-VP
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M#/!\NYH7>R/LBHJEK*<TB97[+!EJ9&_Z2<4E1I-RP" =<QJ4KA?ZG!F:-I$
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MS9N%!\'\F2"><K#W3NH$5Y%K! ;1Z+91OY>4W @M^)E 2::[C& N>_2PO7U
M(T@LPR9 RGU@).^@,UC_YQ^#?S<<*(%L%-J[<!;HH1C%AV"FJ@28L',^L]3*
MR-3+9Y;/B-$2+S_.-0IHO(TU]GN<O'I_+"\6E("OGG)/+S)6LJL<1<?%]3)'
MYM1P&2!Z$-O7:8#3%XZ1.H(;$YG(K>WB-1I 5.O";[9Q#<=^9&' 31SHPS.Q
M&]%^8-$+\Y!YWO%83U4:P&L(@PT.ZA=W9IV$?U"U1'H&IL\U!'G.U.+N1J1G
MK!\_A_?0 -S4[A8,\JWBY^>-EF15Z*LA+\^K>\OIJUB;>+9<=F.B!J8F02$E
MF%E8PV':R4"H>7Q?.-=QJ=X^\#!D(>/.WXL&*W(P-]3T37 J& ([W:SLGLP[
M??D+R7.I;$KHC9V@D*/(G9W[K#',GG(OWKT\96/@R=XPT5+FV+Q8O45=6D=$
M+."-V&?V<:.JU<^ U::)%,V'OZ]_^TT#<"Y](=E^Z;[L&GPHUQCH]]&#C]='
M+WK%&&A0_SKZ3$V8V]Y2@$.#(Z3VD(=__G<]!7CW*/=D^FI(_0;C!CY2_(-B
M_854@4.=V3RB 3HO.K<)-@9YAST9VWT.U6:/W%+I?8II&,.$ .][WME;_I7]
M!3/RN*:6EV2WHS5H*:W9X%]7.G+W5W\!^S(SE7D(+[J$Z 1.P[%Z#?B6140G
M#1 3)![U35[R?M-XJ A4B8!*0)=IV^E<IMQM#I'9.YDP:T@@W2#%XCF=%3/V
MCJ8LGZ97YN_D>5U2+)#+&#A0RGP]Y*L3=3+3#6EFISB2C M"QY*@UB1S@B(V
M>+,^HS5J, 6G^(9BLQ@UOC2R'2J98'#@@_,4-13,A/2%/*WMZNA_GK#\L<$V
M=.3Y4\F1U2.V\Q/#,Z)#Q6NR-P9:O4F*&6VH6!BOSADH^W H+U2%]):@:#'<
M+.\NF(@LHFCA36,:/8O7IX,#-*TP1IMD("ND/JTS)\NACZ?>T93SV\C]+U'[
MUUCOZF^2/*GW>K' ]-MDP=!) 2 A5A0]Q?]-C\1 >/@II?5%5)O:_O6]*'49
MG961/@^_N9"UGH%J\CLJ_PBQA0;(-STNH@'PWRBV-,"*8=SGS=W;;E/'WV N
MSM,T@'#H]P7T!!;/C/N+&LKYZ>_5&CLBS(<\=%+1F4E<A 8LL!N8J('J-'T'
MY*$*0.J1;7&LP >CS9<IZ@1D6#E&:)D0FO1B7)4O5'S(MU=V!E/[=C78".):
M%WDN?IO?)JW$&E,R4TWY]+S&*9KZ$?H +AE)N2UL;J2<_"RS5)^UT5MYK\'6
MI(3[6A?J:E7#A:2NZ/X=:VO;/V6E=IK,*/#]=!H@4N485=5+ [#DD$W"!*I@
MV%L46^FP +/V-C6YQMUN?BD;F9X^S(2OJ]3T> ,7E;^;V+A$O:Y$S/B+?X"B
M=%+KH$M7:8#!PKD8[6M*$0 ?W0F_WY^>G[28%\<)L.<7 *)54=LW &M +")4
M!N;,.":3/C)';7YT\B5U9IE.SA!;R(Z?=Z> Q/3NZ4N]P"T:@&"BPO##R=Z4
M=/=;@K[%:KB 5UB1A;$V:'P0HEDALIE'3035[?V)S;C><>=&H&NH27SX'ZAX
M;V>L=PI0_.%SF/0"WE%>DIA!.B;L?G-FH0K\_>;OBXT>^*7%W7"G?2JGZ5GH
M55(4#LZZJ:-&H $F?\E#ME42V-LSZE4+1>#8;<VV^I?*?#>-W4IJ6MS4$_82
MRBW,5^J;QT>\UT-YKW@8:^82_J6?2M0*Q&=0^=RZ4?% 5J@;?K-SNAW2<I["
M6D BMSM=QGLUB48N@A6Y2=U6\/;YRR/HS8GA7PGW2/HF([_L\ER#X2P;X\1]
MC0\^-](.AA=^<L2"0I[#[EN?B0! *\G/0P?&6S#L6[6$E,7LI'SW4'E\PN@\
MYX>.2W8!N^W#[3@@@V-C<CY_A66G/2B%%_E3F:NOH _F<;%#)/!/Y2V)S^4P
MYA86&L --@/'\G7 _H":XA%;*+(Q." ?VQVOI;ED?-Z*Q$H([O&T:3O"%*$@
MWIJM6%Y(N<)*-1B\]N%J;7UE9H""2_*TG7D-7*X\R_[SNF]=MG5A3295_X@]
M@*MC 9])DFP3N4[MF("JT !,SI'*BIRP-G5<@L[F?8+"V^/:(OL-Y\GF2\,H
ME]A]X_&#%O1QE%5E7:SZMN+'7"8.@?/QK*8K,"KS(5YSR;03&$L# 'XA(H&,
MS=*4^\.^WI'S4E_&,$  B:$S5V$$W3#5:,SS0S4HX7<4VM-DO&T#[*>D>V8K
M?8N0YB=N[,&*0*U)<E/U]UL4MS;)^I#7-SY0_Z!X#J\>&NV2')=ZC0MOGC%S
MUHMIMI84Z"YYN=6)-IGC:EE>GJ'R=YVTYCC5A5,MD!#'B$)D*RI1HTQ]BA@0
M*AQ 7(\3^<X==._-ER[#-^UAW"[<69LG+>7O%>80!GPOE2F*' 2UGH8JD94H
M!L/;A4G,[CK $?E0WNG2=,>1>S0 QV>*DAP^U:(JZYP"M'-!4-;PMLPZM.5V
M<9/R23>@1):#M3:UN(SZ[O*$3BQPH(_MAX>--,=)YOA/(;<],1QL4S\K"8P=
M%_5F'HRZU'R 3RF6:\GGV\YI_7';!;?F9)T^9Y+?W'L4VJR[IPALI\#7P=B3
M7GGA-%0&'_IVD3U*AW^H46"QA7F=L)[)'GG +.5[K&A2';\SPWVA]#!E0,G(
M+S!0/7V/2L2M'!&#XQH^K*1P]O?\1P=.:"/_MDYV\FL/BB152^& $]E.!J4"
M#P0;U(8,@FH3V/*7@!%'3F4G.JP!(]]TY!KQBK&2^/X*/Y$\R9,>Q\@DS'M[
MF]ETC'?):G#+C[^0VM8R^JONH$0>6.OGUP0@>I,D)RA<^43_DW*?4BY-4,]0
M?W@39-BC!&F !!0E]$BQ QAMWPWGTY_ &/_]EAT.;&6)'&B:#0$32?(,#'9%
M@N]D!&7-.L^BJWO3 .3F?\;I&W'2+OY5.PRMV(J*@3% 7<I([7?P49TPQDV=
M,P23PD51CKF NYT$TJL.U0KDIG^]8LQS\UW?0(S\#7".:G##+07>_IWERP$%
M?DD H&#+$Q1)M9;*9$T6H 3C^;;%\"BL&QRS$-/"HB*@,G"JCZ"$,T$MP=@#
M7G<@7'/'NSN(5*'Z&LR(@M\QRZS*[R@4YMQG&N +)KK\U]P-S1 WDQ%4!0 8
MO/:?8@\ '730\7\)[-DM[HBI@59GC$VKZ$4H+Z'Y815!-:M%;_S*VZ>-^-I8
M--X+JHWS.'WCGBO":)170!)]0Y^W$'F,,OSJ7>7L(.NS],5JGT4>*FZS,Q9G
M%JQAN?S[*2)EPDA[PG+]JU+L/MMYG /C!=?JY+*($GZ<E,<6P=9 91O_B]/#
M,/7 L2!?(>KG:PH7F(@DP+Z97MQ8P!LO3 _KX6F #GA4?7PFL-69QST# -%1
MP,]<M5BCLE>-[8"NUD6OX[3O8G_]^I&'<>3=4#P'%D]$?H),&_]^F^RR&E&Z
M]Z!KJ.3.)KLEUC;3 ^O1B$8[SJ25-_< O0D>87@'HXP1 OCMHU_9U4KY>I^#
MP_+XI)=)32 )-!X?WY1M5><DD?ID3N 5*-6%45JTQ4'MM$CNPANJ]2^W??/]
M@6\+;XB(LUJF)YF=(WI,;#1E"=8UYX8CA-MEV2F_J@@P:M.07TE2;GX>%[1>
M\4SP<QE/3SG ?F-PAK^QUTX"<5[-W5?2Z<5\XW%!C1,UHZD6/$U6M%Q7VKG:
MZ48RN=@VX8 FO9)$I@PZBANFN5>'#Z]MF]\!-1TJ%D5C88L?87M/%C#ZQW\B
MHEN.X$XV.A :X,KLZ^.PO_^K_%(;Q@+\B7L!/$X+Y*.62R%6?P([0O5Y2.'H
MU)9.Q3[$YM70\[#%.Z/Q>IIZP6S-H^?7O;;@$P.DJZ@M+AC9 FI71:H@,.K#
M2&:(\Y@&H[G;WA^]*Z%W"(5OX&8C6CS>W 1^/]8K0PFY*-RX[/))QBB>FSCT
M9<(^&/@9&Y]N.SW4-1'QY0 6T8>Q$6C8^[V<,U)KBX:I!_S"8=@N?)?!4\WC
MG#<E? R&D_,5YUW?:U2BR\:-;*T[+)8#0C_+&_9??TT=6;PM^-PLS^:4-?>5
MTM+2B/-J@%-OS@+X+Y;]DOU[HY&1?R75?]ZX5F)98E=:>UFA///?JO,#&():
M:P@P;E[%K\,?J&(/'[_A9F%A8?_XC5)\ZAG@X^EO-, E6 3@[SL\WV_?8D+#
M_FS!WCH[1+U# T0 A/0/F:G<@#,,-, H\.-'1C,&?_@>'T4*, W\RQG_D>$9
M#7 9UO:&-9\200.<!_@!;CX[8,"+8F^Q_6M;.M7PKP5\=('O'YF=@N,I4J<*
M7U'T?XG^%0OXPZ4AY*8J\,-)L?^Z&O(?K"W21O\Q;Z*##CKH^'\)=TYM 3EN
M@5&6^[74\Z?( )(F<1COFM:7L%S[-E0M0)"QCN1,T)@3C\3U;*A3Y_BBH+KR
M\3"O>OS8V)[XCQNW!HI)KRUH@)C^6*W5T>=^WI)*/25/KSGO;7(9#K!')R:'
MIWCU]^SPO:[5VVD>HP$L\=T=6^WME!#[5TBM]JA7HG,K=0]*0W<*W'A,K/'X
MG'7+CJ[SLEFZH.L)&@E2EJDZ-XX3@8OYS>HD\!*,Y'(R90SG@JJ1>K&5;!^P
MBK'4J\^VH4I+VRJO[R*-</(PZNUAQPVI-^LB6C595(Y=3GVAR8W?&J_CGG^>
M<<3VO@H:3'TAT!B2KJ'S4Z:AV";AH+&B!UD+UMP=)7_6P"/E^O9V?VVV'2&F
M/_!*B"R(IIJA*S^X>CA5:*@%?/;3RRDDQX3N91E;6L#EU4(W;\L81=T1N,]2
M7LA_8?/K!6OX&</:H=2#AQYK.RBOIEH*&IB]'/"]S:"S\^M>KX'LLUV^4O?Q
M('EX$G#QHT-HQP(&% 1KBR'%'06\/!DB7ZP@]N2[89/BL..;8CO0:S1 2MS)
M\$2T?F)$ ]Q0@PV)KJYO:#.)IH6**L8ZXS*HJ5NP\DJ2- WP]FP0&^,E/X82
MZXN'/Q.YN299TBQ#1](=DA+F&F0]_?:<\=I6*?%/CK- R8;7O2QR8V3%ASQ_
MRPL<_7UQ!_EDCNP%?7",:;1CJRW1+R:)+?*^*RT742"%#W;5VL^ @4=N$=#3
M"I^"0RP=DM[=#BXY]QD-9[V4AC'W"Y!#:UNN59F(HCX,S(R:I'/RR*ON%&H:
M89$[4\B%9Y^/G/&[O)3'/8W =NO>:YC+"3B-T9]?2/S?C39&?N?+3$XPU_N$
MUQ0<NO?W7S-?SLX_KJ;(D,"+WN]$V2F*^%YL=Q2:!F F*;4)ND,R11*08N6\
MQ,VK*=_EJAX,.SC.S\T:JZSD%3L9:1/S0GQ\@@.U)I1Z9:EE>@ERVE)F>6=,
M$L1[S\DGS[78:?:8EF<%(585?+)7M&Y_>+P?/\%E*0#O&B6F;8YY]IA<3U#3
ME?2R]UUOXUZ_(ZW'O<2O/W?_0&-T_Y_<]FAC](&=#CKH^&?@U#6E;)8E@6ZU
MBV>#%OTO%C,LLT\W$%5( N2' <(!FKB%B''<7H?#=ZRS((0E$Q8/%8)I!=OO
MWAZCQ/2T2S,3^ZX<"37QF<T(S:_O&WE[7M52VVIA?V])],O;]?ANH1J_7N<U
M,A(Z_;FF7F<@C$0&+LJU\5.RN,A(\5_ES9B-AY7HN<,\^\39\>D"3[4I>9>
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MGHDW)ZTJ1[3\H4=7D^S>]T*I'DXC;(YZ<3\G)M,BMK[:!N3VQ2;6/^*?=_$
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M@#QDC2*3OB0%<OTE_K)$P.VR:8/SFZ\#K ;C%>T"/4C^?8-V!ONR>-".>:%
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M3:I,9$.H.%<\ZQZIM)]9T41%NK%)C<IGRY#2&<* _YTPJHT\0F6_)-JJU]$
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M>F]\W5OT,K$T'>VB=.MK>D#P%=D0EWPT;7OX2091:#[@93'R$K_/NP<R"DQ
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MI>(5:$KXXY\3S1..9/3K/)_O>FZ*Z_IVQ;Q_<6.3O$+_S**G88J4_]8R@0G
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MX?"S]GQ]"3F+Q .Z^5)Z"X/QD3MZEV;-!CA+/$@U>J8-XQ?CJ$P=D9+]6G'
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MTJC[>R\EWEWZ,]PZ2K#2Z<TJ+)2==9V(EH5JR+<V20S.:U@1Y!RZ#*V1;V"
M,K0-.C[3B1?A2B!;$]U;LV6!U+QYG3.50#$-OO>GK9?UA7&!0 V,5)ZW_53:
MO?*A38Y,">:&U)5:\VD/YH4).R\ILZ43-=P/=&T5VK]$A9XC?OKBD5V+5JU]
M\B175_/4FT/5P8DENE'.=@.D87.2]IJ<]8=\K<=%R>FSQX)BN\\?;90=FM,K
M53A4?,S)4.A"DO)\T:%"<_&$(MWA0**:1K6$GVB='W#*-[/,D3N:T9M;H+28
MYXGG9SLBC+3T.L;&G1>=C\285F0X'Y;!VSSO6M@7.ZTPOUY_\J;,W47&2*DT
M0D(WU0;F8Z/5PK%6WZJ;_]%>_RIN(?=&[X50N*=8F'G(@V,*B(6\'.S-V\6A
M-H-I5G(?VG=Z;N1S1B=,*W'_]]4_5.Y_N8W@?[GXIP7^!"71:,2ZC+E#AW:8
M[OMHX>V\=V3TEH-41,V$]<#*LJ]J">Y:W8/G/R86'Q\$75*WOZ1$B3G]IP,-
MG>O".=AF)RT>>^%?TID.9]7S&Y?Q"*R"FHO&"&DT;F MYQG!L"A^R^U;-SRH
M<KVQ]KB-4J=+^=#]N9C"GBYFEN2#0F.FE7S7K?IAYT7+I*5X"GYYF:6(>4@O
MS:0=YZ>M1B"4"R<=5H<0(C.@5_70.<1(BP\0WEM?4S^@YF,(K;WA@]_>[U'I
M98_HCCBX?N@/OFU\-:;1X<6=!9=RB4OJ8H;"U8A'3E%MKN>L*%P)W6I)TY?=
MW##K1(5^LN5(.H>XJTU3ST5/3-[5P_R5,Q-VV/JMY 9Y4BL@N1X%&DFUJJ0G
M1$H^GFX.C]Q!ML+%V0<!B9DP>"?Q4/.)^4K M0WTQ8]RA0JI97O1UFP.OLT0
M<^/.H&=]=M/'^=;5JS6#&_%UTT9QS%7S(97[I<I*2INP?H0*O5.]+(M2"4KM
M73;P[H?DE^TN]#&R29KL\?B"ND\C)$NS0B.H'N'L*2N%%H720_DF%Q/FM%":
M[0BS"$)X2?KL)C6VC7;[SU"AKF'@![.T5&2(5(>5K-2@600F_>&K^ 17^.].
M:AEI6A1CR]B*U)%"PTU?63#T$X.6D:0=M3RO[T1/XAM7[\RT&WZG6ENA(*6:
M-3PX63&X7.H[=S>:WXW[KN>BTEG3=->+_P;=,!)X2AIJL\ZLV/+L6#CLY&69
MKJQUR[XW+W=?<552]X/77I^_&Q]0WK=N56:N2A6;,@TFG[=)R>Z/\_F3M"K>
MBMK/5J,B(Z:. ?*B>NNMSC @()]]<5SAE$%8CB?W6 SI0G5KXK>Y:3N]-4=\
M9N#@S>^VR:;;FPD]Y;:-<R+9ZM\2VNY9!1BU$R=I"G><Y1\V+9OXR"V[B:9^
MQ%TS:S7/#<]_:KCAZ9(3M=QCHIJJ[%.98MU\GRO6K(Z18<A^*8O7N0P8T+[>
M3;*CJS_;/"@VAY:>NFS>*H_I@3E5)7+]ECBA-Y.[;0?'7M7W,G>'?(5-UPGY
M1_6M81HT6JK^N-*'%C\4Y,U;>@U_6O?F.KLLRO=_J#<YP WKI!3- M_U]E=L
MT3?=!,D_&:@]-SCD%[-9F QD#@PX2V2+CE)#,>?IN"]PLF![FO,>1O#3I9)&
M14J?)!!)(J"UVW0.#2S?KJ&OX#^BGTXJ!1X,N%X>SSI9JI;CDK\@&1;]]D&0
MYV9F<7$ FTK#1;TIZO%OO$9ZK3E#M]WN%D_\0BVSD(CNL/J[:%;_0'I5F\MB
M#\M-4GJ@1"M5X=I81\+)TQO91V@?98?EW.H2/:B++K0//\K,^W/,$X0M<[7P
M![5>Q/UJW':1ZX"_[:G"=LMV]$7 "W1J8>W$:'BN/BQKIQZ]U5I2<$;#]7<3
M,(S]6KZLK_T]YT%"0)0&^\:OD(&B#PB\JE5FQ?LUMGW15%P7OOQW,]FA? OI
M_&4MU+34)>QM6=]F'")MM:?/&R8!@/($Q[KP!R6B<YQ]"@BE[6*\Z@"-3A1E
M=3>"R_\YSH\?\$=8T8YKZ_K<877 CV7HE2J-L">ONE!??<RLC5BJ#7YL^+7V
M]/(:Z%S0A,.IO^UZ7:.Y;5]FQWW5I7.3XI]?%*:CO5XGN9K^DU&BCQ]?JW^-
MO_,.KWK:BL#7VN9_S\I4+*K%I2CL<;.LR#4H1MLD2L8^SW.]JZE.MKLG2-)Q
MJSHS>N[/I;I<SZG3_4%)4.\CW2%YWF3GG%ROM*0ME:IE\P$'J0E03M[S]IR-
M;<H@:N;8%T@V';LA\=":-$RP3QFA%QIZ!?XBDN0(:SK)>:?-L^9[G,5.RAD$
M)[Q*2._1AK4D+?/3+=IAE9T=\./LDXR[(BHYU(,/%WJ[N#>EIX[CKKS\SH4Q
MCB=_(MEY9_R;5A^I;12B?)'<74.;\ACD\%,;MP3:WIQ%95%F8>X).0)#! EY
MA,Y)%4<]R4?D0$5YB[]S[YV7WO?-)73OLE'JH)VS>O4[]U*NHITEH4FKG+M\
MT]ZHMG73&%:-I/\[#<CW/47LHEP6809SWF_&T*?PU' F4DCGS.2U@.#<&^]-
M-=.F6[%*H1XK*E7$I3=SR<I0)X_,FTGZ:X&3QANO-S)#2_3I?:*-"M\O'F@E
M"C\8WA-7&%?];Y]21()B/2,Q/[ZE4*.CK";!HBS&=$)KM-C BEF1B&R@FBB2
MJ)^&UK[W8KM4PWZJR!=0ER;J<^U''_SR'5IP>&E1Y?;M:Q;QH10SDY,Y>$/G
ME%_2])Z.R),L?68M6PE4/5)\1WHH)5]&$NZW^]>HG=6[?RKGX1'B/SR(U>?,
M"8X-Q[F76][3O82K*)\:8#FDCZ'FJJO'.'PL&T5+3AGS.?\XF<V#V.=T^SF'
M8I*$ #56&/L0YQT/XG'0@6+:,K\)/RH;P^8O10_: %''A#VGCH14A862'L.8
M9V/WL \M9'3?)+,<C3\*AEZ6-Q\Y6=!3?..1KW+8TBJID16C\2CID+M9?OA.
MATO,E_[NK-1_[:T^ 47<J8:"284CMFYB^AE!85O+8N)"=B& ]*GN=:6.$*Q
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MZPW]AZTY7 6R)\&\?E^/6$YM?YGLI_Y_)DPFIH51?Y@0(15[O>>:BB?I,_%
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MR4C7+]H3Q& 'CNYIRA;K_((58J">JRW#F(%.@BW9DJ,8FQ(I9*)!P*-ZTYC
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MM<-EV4YI'7I9Y*9VTP7OS$RY:BF'XZ&6GSY_+@\M5FP(:HB5%%$K:;M:V[H
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M:,2CP/F*5HE?V:L;KC;_;%G1XQNR5Z<_"FQ,QG1.J8!;$F:?"I"O1?'HV16
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M-ZA_O0Q*X&YTRK9W@?FQOPH*:=0N[ISSC )3RYTO*JLJT@)Z9NC9Z:QU(0Y
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M8FP;8P S4 &B#^-_W.ROJX#1)NQO:/@#8N)"'"8,$/X83#?7.?F]' ?C39F
M"E@H1!9ST$?KL3D_\/\U$K.42SK]U94!H"B7_^);MU2A(& M[!>3&2P1XATF
MX]=44.(+>1&AXB=.U&#QNU*6$7*Q/O5+L_@MMUG[W9/Z?_J)QA&YX9UI+M98
MUZ.+-'E %/BA$=/:B"];2L_!9O]1D-'UR&0AUIFIT9A%35 !"T:9\QK%V9;B
M60_@L8$=+U_CG)EW)G-D. /2=?(U'5U%C/G6+J@^&WSL]:^POT;.:L^-6L1'
M=:G8;#4)!5E#JR6EL/5L0$',5F2F437'% FKUA\RYM0$J8"$8GJT.U3[,ZCI
M<?UE/YE&=?*CO*?U<M] >?>C_8Q6I^.70]24&;B$]2!1;[,!5+T4"J(NP-H]
MNZ7!]QFAI3*/-U0CAA%%8PB:Q27&=\\_@+ ;06VGX_<6!Y\;EW@D#]PSL4&@
MY3$!.6Z)/X+W6<\<W=SZX"4PW9@OYBO_:S"NH"#H\RL%GO&&FN7T^X0>&F*C
MC^W](>8H-O"O0U->XF% SD(<\K&]80I/%?"Y46&O D9VH2ON$WZ2E=$@;5S@
M)U_=RO?GQ^.@97.0IVL#M5>C^MX<Q#"7_KMZ8G@=PQ6^SK9(6=S!6<,T&A(<
M^K?[(Q[ C#_)F0:MM@4+TSQ:EE;Q7L+?^.BR;F/KPH< = !ZK@+0A2DR"TGY
M%1M.$AO>2Q'X>B'@ +BPMX@?!E/%>V)SD>9&,C'-X\BX$)MO5$_4'S9BFK$:
M_CJ:[WUQ2XO36DFE5D3)=Y8QE?*C=[M:X_2./E_TD98(SF0:(&S)[U$3F=!'
M^6"<L3#/>R2\\0V82#9H^T5*#,=2'U4O_ZA -\K"XLYEU&)6,H>:1V[@C&'R
M?)C;\,24US(H&'M21'DT:'2?F(JG1QH+G4^4D%!]HKP,CH_BT21]^Z'/S0.<
M:Z6L.8R+\(HGE[RVP'9/BMQGQ>2BYV'4Z.R!VBEA]+F\XI>R@L]K(/@VHM>\
MMXUKZ=7GL1O.'HM3PWAOHM7VSUX\SW5Q3$OTAL77[]PGR'"IQ=P%OVU@ET/*
M:]!,_F0F<^Y>C:EWS$;A1 !8_$.9E5]-4AZ^M_ ^H8Z#;!C M+9,=WXJ5/[+
M<Q:!5WZ'G^6764@7T@J/H%8O^<7<SE&R 6*Q/<B+,I_ATUF:E9?^27&@]"6_
MK*7*=,B81\@=KEJ1KCA:5=85PIH5Y#GKD1JJ@XO1FB^Z+BQK1HU( Q9UA,1V
M1/[;!?'S'5@G)*J (%IRF#'GNJT)9V'0WZ[/?/P%LS+""CR#A ;8LN;\+[V!
MY15!(YEVK)R [O"SV K9X1@E1]P;?%Q]ZK3L-[H E^:+*K-F8HVPM[E1QCC$
M;1L_558I^UU#U/G"<.X.?2P*:W_VHYWG*(F@ZB(4M\I71Z3CH2LG*0O[AN =
MOV\$./Q[PRKEC<;$/C%HA F),&T<-?"9:OK$%G,:^='&WV^?&.!K'AV6%C!L
MD':XR<N=5&?Y(/!F[XQB67PM*:'?-+UAJD8J+9PL_$LFM74\@JX=&-=V55Y3
MPZK!8I)T/8P'N??*NV0-9@=?ZQX%V4S>R-@(C[-*LTP2Q:_X+=:V7K;&/ZYR
M+Q?R6WN]85K"DD[&*HX6XTWFIY3(16M:G[X IJSQ=#Y!95%G.FDH=J"Z2+D"
M9.Q]GH7S#%F!N/D:TPAI:VO;(1W/JKUGWT+B.3]U?^3MIEWS>5B>7CX>EAOX
MUQSBGH[[I:\3YY8-X3EDNI'.;.45,%"(F.=+;X-7G/;WKX-?CT?SSCH%*VR9
MK3Z+RCIXCH\8FUL8]@6"X7X=)%$$ZO94;LI'"K;ZYKI)@F<U'F ?@L$DP]*1
M)\OB%8Y[^0#VEB^Z#<)T2DWSH@"R\?2.]LS-K5[BL+H%V^ZE!BCV,D!8VI\#
M5]:?6NVU#9(YOLE<%G9O,1)9=&Q#RJ1V4+6 EN!D=#G4N?-7A7VMU*SUQ&*B
MX$<MF 1J,VWHQ%JA/G,>HJ@6ZF.F].+Z4-)<^H\WY&5M3EYBY_#Z1$KID*<\
M-BSRD4_#3<M:4NH_WQ<.W)P3[6;R,"HL1"V-,R(@Q898!=5ARSK7A( ZR,6=
M':'2"*].ZY/%[3:11JXE67L[;=VW3US:$;PF1&%R>6QL[/3I)"WZJ?3M!S>[
M:/PA0M5G\2Q4QB^U1PU_R.-XR$;X'T6CL>MH9!Y]K+M&!0!5?R%GVO<E>R&5
MA78Y.BGWZ0K)_"NYSS(SKCF%#9CNDV155^F\3)*W5\_/C(V+>3 T@=RDS0O"
M%@/*2\JK?%%3<Z(*T,/,$$A"D@H5VX^AL[IXKOE>@1<8<Y"=XA3+!A][N),[
MR5M?'3S 2O#\_JC*H)7G%E"Q(Y2DC5RL]5G7+KV#1RU#FL#W97&"^F<H<!Q9
MYVEE_T; 3P!/<GK5C\B,6#8%J\9"QN/8I?972R.T2?7M=4[5^0*4 EL>;11'
M#/ENCZX+I!*XP783\B/Z>SM+39;8HB[$#WZCNHI(K!>$-PM[O8Z51*ZOQ_32
MJK&-\=5$+G6T1/+G:W$+&I$S&!Y=6^@O2&<OJ6RW$2XX<L3I-U\'6^X_=-'Z
M7O?A[C+[S!\QMJ^]=G2[@)^]1$:-A'AV:7DU*998:E03?&R$K<U<3U>O$>JB
MAD]VI-:&KK@B^;BTVZ.XO$-JGGXA?\1NSC\A2IK;99](2P_NZ_9S%RX$K8XB
MB'[_WVHK+P!%P^P_FX32H.D[!4:%*J#0$LZ, N^RD746V)YN.0ZG2D)@#^Q9
M9>!TTT,5, ^)V0JG7RFB%]0)\M)CQ?RY@U/L!*=-A<,'\HJR<@8S;6\)KA<\
M#31:IVO*36>?"';NZYB8=Z-:ZVW=ZFE(L@1$K$CH?'5Y%)X]&[%./AR%VF8U
MQ,N/MS 76T3S3[-PR%U[*3Q?SKH>:NIZ,+FVRDPVGH1:Y?\I9ZY&7LAT)OS!
MY[_N%HXO@T/C"H)$XSI>64.A2J^Z*.(K\ 4!74B5"$W0#2V,,$48UNZ07T,R
M0I+=RSJ((EP_VH,^*[IX"S(N;+M@F)%<94&_/C%>6X)<%]@'N5.WP,U7;5.,
M**]3JJH'W,^9N6C@B;YZ&U_43&)!)1ZUSD$#\:-K94T'E8\]JG6%].0ZHH;3
M-K$628UQO 3&4C3D,8'3'84^FM=Y7H^5&5&?7U]8=!JN"Z=&<T>N<K?"N3XK
MNJT+;=:IH6G,5FHIJP$4<"2&G'HJBVQ=)1NON^.D#?\6C^4,6!U_9Y_ V)*#
MDF!FJ@C4[$?8>S-W6MMR=//C2DU7-Q_I'E_(M0H?ZYP,/AGTVF=B:NJKNC*?
M+[H#3:10$0NV\HYP]*X*>*K_QD#M]_+_X@G$'TNFMYFA=TW,&KY\R_21N.'(
MG!:-7_C'LW"3>6]$G@?UG$!P"%N@O_<^88@9!=9#V.P<%; J#M=5!-33SUBC
M CJ>&N-J#/S/%N()OHA/G+A+0E:Z*C.4N*GM]M0&H&*/VO$_\WBZN/W%Q_%_
M?3SM0GP#H40<^IK34'TOK+Y9P,=Q,512#T#.>,ZB$.*(\%X"8LF*)>-LJGH)
MWX]OX$6WE(<@WA(B$860@L?]/L-385&E Q+J//\GCQF[D)+Y6>9N R8<G>)!
M\@+D@"@K8N<CLR4=DUHC8>W22>VP.N/9&I/J$@A9BT>J6H:#&W4FUL_6?X"4
MT/)V4[UET]1%\QCJT#E9REW1HU^3Z9$4[.0F_KCZ.SPC<\L :-#7X_GVU'7+
M/R=T]ZBAQ] #"$UQ9OJ!.,VK>0XUJ)RMP0^$>I(;'+9S[],;WTP]Z;#QWMZ[
MOZTP-%NCSL>LXPRWO$Q&B>*%B9U]EE>UV6;;6DT&:QWJ0"T&3&?U?PW*- "(
M+ZB+0/]F9*4%:GI"04>=$0TX8X\*B/6%(ZJ9NFU.KL&P<*],)U<%S"9K#F5N
MOYT[Q-:O<F!L?=DN[:?J!4WQDR8KL_5K*,J[EXNVY 69+8#MKM\HQ19WT=Z
M-"X-6:L0E3 <RTI:(!J4-(]Q-'X/5$9//HS8BATY\>%QSQ8K6\I@;W;R*.J6
M$]#\SU^O,AHKI!_VVDWJ[\A:I(Z4(;AV+/]30+"1V7< T:KS_/BCABWPDH?(
M?*X,$&>@FQ'H&86<^K3'VVM; 7*@T4RK2]#_880Y3W:8=?YX9?NDX^S=7>TC
M3&W9]<2@2!K'?R\ O2"B^OGR,IP:G1-^OBCW51:>?2:U:>*D4#5_D73I[!WM
M=?R>"F*=MFT18[W,TJ5][L3'"RONWD<WM:#N.4,EQW9TZQ_IV;0&N=WGHO$.
MGZ$7!5F='PN)TL 7]\IECP,$4!)FAT_]0):X?'1$9+4MNU1*D]B.W;[\&$QT
MHLSDUK_^ UM$E38=#54!^I'7O2[;.K)'P3E;'@_9]Z]ZT2%U 3^8R"\I,_FB
M'"%\WE7*D=R5\MP+4!^DA'.9N0)Y+>-+KN=?SD=MD"VB/T7Y\;L=ZKLR'O4?
M10[4INXH&2+_A5P0I<S,^]>KV4_,TGYT-V^XV_.\QF0[/(+-C55FGT67!Q/J
M.;VL 8\$7HB\NFB2&$_5<=(6\>=X^6R8>Z(,3V67!_I.R@6?TZ\>:RH:FNB/
M-0)/M?_.VO$&G/6?:\;@LT2I%0Y/VY"+S[#6Z5O5EWIBG6")??RR)(II4 7M
MZCF&B<Q5;!O;V9BFPQV@S*PMH&>X=Z*&06O*+GGTV\/?*WS>?S_#Z^:M$G]<
MJ/,0 '$6(^K@(]9@W>L@B0?N\J(,(3<^99*RR-]G>2OGN#*U:@GR4"&MP"W4
M%M(*,)KJ^UVM#7E7I4G#RV,G*3H!W>7@W+R.<V>JX/XGN:2H$/GK-MMQK8"J
M!0"F9)Q0 4M92=#HL2X5\*OGH@M17*"8A[6'QX^>5AQB&"N?A 3KD?3P/#3#
M:5OD &ON8-@R+5/7^DMDTZY@U'+64\;;?_USZNP]3V5VWQ &&N_RB4Q=7C%Q
M\CQA,%\^%\?V%R&:"D"LEL<G\'%652E/B!>YQO/]O6G[9?W),G,)*7J2E$2<
M7[66G']>!<@\AR"=8,9.^/?N%K+IL35NOJ+>K''#P1O-#XX._:C&YJN JQ8*
MC7VO (P#B6*(\&9J,A7&\]\U/O=>B41XG4\@.S V(+TB_E4'TA7N.(ZBZI@:
MLG^-.=%<R%2(Q($X.]B?41=NG79RJ4SG3L6V_C2<@NBZ,X5!"N_KZ582A8N&
MS!</R3B:VL>T9PJIY<)Z3D_W%IE%@A7_#-23)FE.P#112\3]X3'OQAQZ92.F
MWC7.T)<T)SE@=X,L,B0L0WI&_27!QXR8HJ(')^XC*X<<SK "_!X'^BQ_W0V
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M+IQ(M1,3HRSQT4'6%NO[IRMU.(MIG=DIXE*U)H5YN>E@EVT T$5C"[CR_DA
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M&@P(I!E1OME]B"'8(OQN?5;\YD#?)N^RF!:O^K S25G&>9PN^LF\UFNY'CA
MGU#2/ZDLO0DTW%C 70'4)OSR:9R6M$QC*)<5Q_''\[BM)0Z D!G#NY%O=.#G
MJ=Z9)8$DKC-TT%?2TBJ<;6S'V_M=NTGU\LGSJV+H@IZ)S\?GERK-CZ.MA#+;
MAN)/[I( C-H9(HJ=^ITD+41?WJV>E-K_HS7D9<!\T=30QV(1=2TM'=T3*.9
MY 3D,) /QWB\CA[N:Y^:OUOB5^7&>+0X):I$:>ZE7+H;J)I%3&.0U3&.L@SZ
MS@)9C;!]TDGP5ZV*D?G/FWV:!"W&QN9<&E?T[*FBWJ*?UX=V$7&T%>A0]S]E
M?<BJPN81M6V'<2@'$/3A/[6B6E:HL@W(;@F3I,A8D*;D==\,D>?4C+>VHNJ!
MK+BBPE_DN]IAGW<5/O"[ANSN^$70&G O*[S!1BWZK$N&KWW8JO1+G@D#J%/
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MA9YNCVYK0RD9[M]7=3.$M<S?0H,\@.KW]'GL"MCV7;6H)_G3( Z@ K]9*[]
M3& "2!6FUES+&YX 5M2MH5N#^J4W<]X%FZ2$OH!M&RW),3,JCW>Y?W W?&TZ
M]_W77&[9@_'W7<*I=//,ON$#G1N4K*3'&/]P%#E7B!$,2UDFV9<3,V_1Q+G+
M43-MG^2KT7Q<[586WC_*M@RJS!IW+EZ1^X26MI\3K^K$'=[4^;UPYK;FZ2IV
M7??WIYD;>A10.K^J%=&Z*3T)$YO=^F/)YZ<3^7B2&;(K\P;K"(AO*7)SC,;P
M=X7KY?MWP^SZ)TUU.-&9INY[&BN&-[ZJ@ZE;6J!UGFN7Z!D](60X$T!_*J+Y
MV_B(@SIU8+#!S3E9\M +N"6UI>-OJ[M(65>DNH_$0P>=2*=F_$Q#7O.6)IGO
M.:4P/R!=#32DD#5#*.K?AO5E'(X?61$FUTO2;LRFQS2V#[P:'R9"G-C"AXKZ
M]Y_3[:"\&/I>(4?Q^*4YG^K.VFW0>N_*)8;N"89QJ=__492IU.X63NUN).F
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M4'<HS4)2#;0)* ]%5LT*R-& C^/ +>$4,QPEP+=DNU#!PSJ(DF3M&$RE4E_
M8I%2G.[68OI)L:JO6STQQ.KI^C>YN6]2X[+.^NFN[_KU6+=><:SM1J.#TZ$^
MTU<>>ADGNRI5EN8DAZ8^\. Y!#'UZ]M*W?:Y^Y<'*N$RMRK"BMBZ7P8:GK/
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MEU/+B8,HOO+IBFG8+ 65UY :V42*U;;4AP+=9N:PJ@ [60)IB([#1;DV_!$
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MT[OQX)&2,*E$\FEF#=NV+18]\2M&B#"3)PWV_@)N9!1R@^^XI=GN$VW;ELB
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MQ^/0P8<C==*8K0#X6,BG.W7<!5DM>>DXOP<?H.///^]=]\!-_HV:ID^BWH?
M>I8!\);6V?,)%@N<D;4#HAF8ESOZO::JS:%$QE?UBHN'$L\T[CQW688:(T#G
M)#7!V<WR0C]*V.5 THV^6)YA3/PLR=);'G.<;%,S2J1,/ VPFY7@EDE261>
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MXNN1-9^LU\!KHY<KZ!Q9=[^@7';>=G']A*[@NX!9P>+&6V/@VU[+1EU%,?
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M9W+\0>?0C'%?G2Q/\=*(TVV5,4UR"WUC[TY1G,OU^[*? .XO -[*CJ4OIZV
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M)4Z2#RTJR_W/'GE0\FC/!>I3W%3Q_PWSZ/__OL@BP@G)5N!QT_^WN^=UI",
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MQ:JOA>"E<$C:1-*_4G0YQ]C<RU@/Z0J98F-2ZFA.IG* V^74BZQUEAL&;NJ
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M[6D9B^<=8NZ-D@B#+W1<C:_[,_68NW971GGN^9H7:ZY[SOC-VT-OQD]?K-1
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M[+MN=K<*? -9;O"TI['YC>$S+U6G-VRTUE\+*"T5$:H'@F#[/AWIW4P85!Q
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M]NUQC7N:F7JDEF>=7K&_)[Z['!TA?=3Q>]C6L*X1H6FQU\[+,=0[M&10!]6
M4NJ,:2?Y1HCC>L@QL73-1F-&"NJ<[S_4/=NN4;SRS@SC3Y^.FWP:_R0*5S[_
M3HL]1BD,8CS)WY8^_][.N_<W.%DU6M6"R<O;XH822.]L>AQ??GD;L+=^C;"G
M21[^_$71D8T5?1$#S^E7?Z8?GK-M>7?WCJ9;73E'_\L'I8:Z^Q^S4>Z:S$9)
M/> 9K[B.-_>14+$9JIL'AB$]"FMXE*,?$QX2(9+OY$CP4*T1XC6>RG^@VY8^
M0V8_A:GTO?;652N917JXX^/GQFDUI,$.;&:+JC(Z(U%0EB]DO$D4]L"]'P5E
M&<G1K?-9=D\J.8=^9M$1QWQFRDX^]+[TR/.9OR%BJ?"^S&0H<O'AB_[C*2=F
M70DWH=T'UE/;92>IMK@#"4);6WM'L!F]2N=&*%9NFLF?!?<DVGVSG\.:BW1)
M^ZS]6_59MG"$ZIQO/^_-PT"1_5RF=<-/C/U:Z2R]J/C]#&[?D"BB*R?O-I*V
M^76,:K$F*A>$<1"'<&S&%^5:),,KL48\-9HNRJPQX&W/HC603F(_0^_'6E1W
MBK)7)D#B1A$GF6TQ-)%QZ=2]OC?,J+UMHW87??;!TVY%VH[;K7=9V"&0)(DA
M']U=:&BY&-HA%IVV/KU^;AAU%K<T@:HZV/BJH&!K4-ZI"NWG5<#F7;M8]RV.
M ZH'JI-J0-)JW\>14W]?19[-?CLA2*$>XB9>Y94;YBR A!FRC!FH!S(D2[=O
M\?VTBCO+%W%1 PT<$HML^^VV<\$(9@7;W;K'//%!IBVN\?N1_*$1H+9K*B)5
MU_FSV,_)FGP3[!4(L(P.2LAG.#-8SEK)Z$)I@6%6E&YQL\-[1=[]84.:K:)$
MIAN_IY+?0]GT<'@E[7YXUH=<\,&P7DMLK,WO&I^_H_KY$EHC512%:9<H@U@
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MGT"Y5_36?0E=\?CT8IHRX9BF$%"G./3@@5:@HTK@>U63?1W#$,W*C/]^-"H
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M'$+JE.YC?=4SKS_@FCV%J@4!HLQ)E2U0PS#%=,,P 2*SQ7V$X.PN'XJ(4,U
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M82K%+\%3<7*LEEV(7R,OG"9QMG2MNW2T#Z?FWLK'W+#\LOC]B<FFZTU?5_N
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MT,S)-"CUM!_*]E-_M"51QR3(,3E?<T<Z3[7P3E_$'9%Y*' 8SY0.'\12X1A
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MR)0H'3R;J'1#-H8%OT"S6+)["IP)W;H(?V!S+:\K3B;JBD,R\:"M)']JJ=$
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M64=;$VR*4GY-)ZV8M9QE\RC-O3EHJG>X+/9I10.Z1X:)?EX;&=)$Y_#:F>B
M<6Z:<CN 2GU.N] !?$SUKH37#,R,-1NA,#>UE.</6"J<7LW6Y#G(61HA4TC+
M9<Y? #4-X\!>0X-'QTG15%;43/%A.2ZPS>]U\'@HWM9K\>SK[P[C+S2?)\PN
MB):U1^;.I'/VA5J+F=X_5?4=!NJ4,NS#R:R,T9\5>Y"7MD)W3^,8?"'T;A,E
MU#LL<$'3I1]^L&4T4WD )Q!G'8JG0SV:'I3]=?<\&QX>$2',YV#7M#@J=4(^
M9]W%,4\4LP=A;T.-P/E,($S!'.WB)</-/X5FIZ/4Z%7])MIS&5>75QY&&]]J
MT$M>/SYTX*CP";[M>LC[A5_:X E6)MPFCH.J^U%BE0>H!'2^1\@@(]S:R)8)
MFK7774N[L*U9 84SSU(X_=K>O,FT$2BQR&C@YH+JH'LZ<(!C=CR&%>NCJ<W@
M&J/> K?[\',#V/OB<QTAW7)@>62'3$?B_3:'Y;,:FD@?2U^AYJ/'HJ\)@&KX
M3QQ?L_L1\TT$RVQT"#09WKIL=*4F.<OX8,7WPLN%3PU\QF;T.I?\,Q9'\ EF
M$2'Y.DNMUYT@,679#[OVBY!KP!KJY3A/^@MCYL#9*" _P4X4":<$31U:42,K
M9\0YAE]?4>D^L%FDJ7,J-D9,'^;=[M2>]\3U_JD#]4%_^_ ;I'8@F9(+EBLG
MP*Z_\B5O).O]4"V?8R@A;U\NZFN-YAYIF.^[S5]PYV9_NV^KCH:ZY$ZA 7+F
M'T^%3Z.X&]*$+O*#*N*;+=0@L,\.B$YMQO"9O@JP["]X%;2B//6B;=;'9E3[
MV+W(1LF:D?O+ [7VX9UJ$)A%ESAS]&\!EZ%Q4!&6AL:_AC49]CYNB09.)TYW
M:X!HXNFX!1OOB(!72C,5B]<2KGX\DGOR&D*#2\A,<RW7"14XB\6O:2_^WC]8
M#EC8MYL,*/.K@5Y '$<%$D-5&+@9C!4&-DG1%%_J <O ;M_EB:JQ(R^'%=4:
M1@27X];^220L8CJ>(3@0#"6=6MV#+)X3 W+ IHJ@Z!7!R:C?8HUC(10!]\4W
MUL=Z;9XXV&D>+S#/'#1-V^&5)A;TP<%[4!> BTS)T!\'W;G\Z1E1*MTS&QA!
M\UL*VVUAGRDWK@_JUHM]U3T#O<.8AP(W.8;L%G"4ZZ U<]X0 +,):8.RFBA^
M=\[G>87,'N)"U(Z%:S8_?%^_T">2*F/SQ;,ZPNK+!V_-M<%L:6PMNL<7BW_C
MI<B<K7N<).A--4-*4VY,,A20-L0 +C^EN0R_R5I267!XA.3Q]),S$R7>'P'3
M \<L]?_L<S:Y@75 7S^&.<_-<#R&/^[<!*+E<9>W]T:@<^%3!\\ARA5=E[2-
MR*"!@I%<I/VVB:,::V:?"5.9.,Z %7U>^LRGZC(&&4H .D6CQ=9H+<1,?/'.
MR)A(8J2B!<NC!^<;&W,6'MU[K\="&2))_E-I0J?R,C[A.$-A8=KS!;8 O >7
MB=%.-G:I /&XH$6^0RP8QU:Q'R(A">OBN1)E=U(V'=P*#4Q)F+8AFFCQ.,6/
M7L<01O<8,5AII^K)!8/P] )5I?+:IJJW^04$DE[S79R7L;VUXOT49=5#03R<
MGOEV#V#KS( HE!Q-**")\E^DYZ*OH>>3!R@H8S#Y]???Z$44=-+P]%:R38]_
MF*/#W7BE>U5<A58;EP/R%RUN/#]PQY3!+0X(]V,;M6DR6*HNXS-:M*X01]#"
M5KB!,33$*UB!3_GWG,"Y?)[0"%W9_+4/]>>KO[#O*/:8>.!9?Z+GIQC<!']R
M.F499&(MMFEZ.4/NV\HA$ N\G@\2LBD):O0*E#LR^>'2!2V2N^MJOB2;B_//
MV9\2B3>=<,$D,G8A@L'30ZZC+(*6J]#%"(H[_9DQ%]&. ^DX2 [XFWT/.C0G
MB,3:3$H150;?1@1H+"K?[]^VI41%]?8=%CZEH(F$;IX&8@?@+1B:;"AYE/('
M/*LRS1 !A=X%NGCIUC^PK@AR+Z I4-S=&A+\1BY^_V:<6?^@A.5-YK=.XM:B
M*1[>B[CG=1+<Y[1@PI@$/L:$/1(]A!;H"O1YB4.-4=P[QJJ_WAXC-D\%DI=4
MW92G1E]D6?EEC\Q_4PSY]#X> K-DFH,R7 N,&8W^8/!L40UH N .4Q)?@>S,
MKM!J60G:2; [+CJ:=R4Q-.K5\M*+_'?[IU4KQ),O,Z\LRS\PT@OSD-L_K#A$
M[X+A7]S^39.) F 4+:#@GK'47^5[VAMS7?SX;S2?J$!_(E>M7LTYO>[I+:$1
MRP2GN[:-$OB\:RLNL4]XZCCVK0I8 _RXN!_"87WH+I[DG\FAT*00FC(TS3_4
M65O9ZA&8\/=< 9^5P(-<!1K5RM+YQ"'>P'TG'F?W@C$& VY9OM->]%_-^P9L
MW=6F*05H&KO%\M#3G*EBY4'VOI=,CQ6Z7JX<AAOHG#E4=A>5QIB  Y?1$C0%
M^DL4]WZI!Q0HZON+)?&0$59&Q76EZ%X;W:]R@HU)*S&UM6N=8L/ZS,"OY+/&
M\>KC>MW6&MXC22M,D8>C>RXP,6>H7<H>1 )]/3MEA:4%P S X[V./30EO\QY
M^=TVVAO-E1] VI56O:+PH$_[P9?!KW+&E=>B6>&/,("'=!%LX12#IP\P9'#'
M4,UHQ\FG]R#OT%)(.[O&F;#9R>W)T!.GRV=J!IJK!*U?O$DZE5)+2W#"\=T5
MJBW=E69P%?DSEVN0O)'9Y4$]NV]*&8)+H]XU"^8<J=WJ;O-P4_;V2#^MD$F/
M3>MH10_3$;QHQK!4F+]6)<LBNL?[# PXK[UH)8@!&U94?C Q;&<:;9>Y!)I9
MKZ T875B=0=O2W/;ZJK^[_G5SKS2U#4IK2<-5V;<\J)]%-4%N [+Y?U.IHE-
M$6%]>Y!D'' >OGA 6Q;$64]@W$!3HN8I*UN[2UGLW9U%=H4G:@A\9W,MHITX
MVQ7KB=C36/PH(AW#38-1#\8Y G)8LL*YAMD:E-KG'^)&MNLUAUP$O^U!%J20
MAJ'2Q[PYCXT<>KQHW#K,=+RQ^R1%0]B6<5(P@?F\)7P!3=C1JJ ?QM(\C-BM
M2J]+>_X-[7^/A U8)OG)U.C>R?@C4'(-OB*>*WL//8D&[*"@YGC/UI(P@RN*
M" =57080G-;XT%.$S<)G;=F_*K6ZY^L]W<Z*]O&XR!]:"7%<>G2.%5$P.NH3
M@=HO-F1'Z<0=!;82F9KSTKT@Q40IP-G@+S9^"]'\*FS7M=1CU)O>51QB_C@F
MO6/]\\WV/Q4945$?ZVB"5?BM-%AP-JB_1*FAYW5SK9B_0O[=(.JO5_D3BM03
M@W^D/&_Z%%9JGB([1()Z%TM\//93\NS[$Q!*':C21A.IH[S;OXQE#H"E6YLQ
M/84:,I$&YGK@XE<\OG7+O$T>NND))DRJVZ(FM=N6E_1+SBIU+I\!!$560A ?
MAP7$Y9A G>TM_>T_!?],SX!?0"1"6Y*'6*+"7P9T:+U@QY0%4E$S5?"Q&ER9
MV(.?A]FO#VL@S2PC'I3M9Q?2N_8@_E?L&+PR9,M-DQ4M;[)';Y-=^0\3KK01
MY^YF4^+77?[6<0GXLGM*K9"N<9'CQWZW'<E+FW%!H#B9E=+*W%(F*#ZFMK+\
MHKZ-O@R:KP8R!R'QU2B2[_>-1<NHZ@'Y8_%O6RTK>VY:L<6<Q3Q_#Z&?!C T
MT1_$BC[M11\\QSN[I6B\97*<?"C5%AE,VH/P1]GQ@/FQJR7?8[W#2[_SZ G&
MY!YK;SL;SB?^\8%R0=OOEG=QP4R1_8YSI^=A\:\94LP/8:@9;"/F?I=@";)V
M6WP"I>D59_.D>333).KA^S>"W4^+)%]F+.DT)6:%K(VPR&_O04 EER$LJ  E
M;>&U[_Y>D0)YE-/W( $P+O.RX0C"4J6^1V<=YW>#FK"PW?"(4RTM+27&/#=R
M.>2\!7I%/HR*WMB# !&U#ZG&Z!ZK;E&P]#S]F8D2*.Y(QFZ^(@R2$1DM7\B*
M<D'N7N?KGPGQUJ5>]TO\^71GS1H1"I'>,CG#/X.8QZPFDSBHYG$J=NE8:0;W
M5Q/.AEF_0)J\?SE8N'JIO7O*YDW"-N%H4ZO!2^3]"$78J=?GV8ID=/A\&-P%
M^UQ'(#/(9JNCY[3LUT"B[T=I"PRQER/*OW:P/_HA4YCUPF1'Q%;]0+UEZTG9
M,OGZRANU Y?_^-,$[!C<>02F=HQOJA*PPN"]@5D'VB4@+S=@#R(4B6X^W&YX
MH])LVKCZYW:MHV_GNWG%0!^.XX7#S(7.AH5NR3)Z<(!MJ T1T8=-*(1FZO/&
M#A@8'<"(!%B_"BP\_$3Y<9"XV*2J]2W]CB$)],./A4>6[LZ_D[G5P!SQ!_ 9
MH,[@Y@),*6?I+[MY0)VMWCU(L\6]\N]0_JYP8*._H WF>\?"YV!UM,#*XKO)
M4INU>T=2WEL[C?CJ\/*#JMHT<77B/E<?@UL=Z*1(M=(S7Y#I=0/PS9>?HD*%
M!W'^TQ'1J%E;SN;"Z7/7A5XL=!#L[VEM9*\K;"M3"L%V8,B%N562F(IB @ON
M6X6E%LM/(K9HJJ^0/XC1_:&L#FV,F9FK<YH;TV(CJB67J9KU.3Y6U3Y4G<H#
M"@IBU__Z,WC6R,&$IU @'+OI5.,%;EQH:0686_:^EK&E$FGR760*KC_SA&'P
M4=ZZGT]\CUPJOY1TF"^ E81;X&?P^)%+B98TT:H!#&"-7=RBV$_06(AO859&
MV<E1_+S(X984WP,CZKL)_@%'#KG/7F%<.\@]T2BR<6.6[$(3TR5N#.XO6BH,
M_P0*V*$7J+TK.K,,F8"(((R0L??JN(1GH+M?E=DGQ7R#/8A?<WM.N9#G %=.
M 8_\@Q!U21\ ]9!L1RAE3IT4_7<D[LQ$YJ/"JQ.30%!XC&8E/\<02S-_9V#1
M1W:H]JFN=X[2;RIAWF@Y$,;@TF:B3@W&U"ULFTO:"\#B'CELJE]J/"'.@WC@
M6N.TS]M9^6G2S%&%8+&4,7$.>AR[!D(^@-64P5L^NXL5_H=:*A0G"!;T&LI!
MIUMX?;S:I_6D.U/6"FR+[83/3WJ<ZC]_RJ+_A:^2M<-9!5&J*=4SS@:L ((I
M?N3Q 4Q"M\"$/DX8B>@SO)U?4 YF7\[_..*<I*L@Z9NF"N5.&VNX+*XF'!G;
M5D=,IDG'DUUZC;9HXFV4D5F_V+%CX%R_G-*;3R%1;TT\;)Y(@%D>#UD'U)+2
MHE+R SSX.J$*7T)0*ZBI8LE96C#5(.X<$)T4^;MSN@7!^GW6_4XU^G;@6E.>
MPMF?;G=I :S;G0Q>3WHU%L&_N/0.*H(Z07-F^HHNV^?@U&KQJTKDQI!4=H:6
M9DNP.F[S]$GOEJ;)V0%"[H+8*:L"0_N8\"9(\LBE/8@L<P$X88'P11N*%_B,
M>CO.C/X8>ST6GG*[-0=9N%(2A1$Z6O#RV^PM0_?EQICLEK5"HKFBZ8'#_&OO
MW5U[,_<@5LQ_\!0*-9&(.T;/11UE?"@VGEV?,@[W(0<[S.K7<&\/NF(LIWPF
M-7QB1V?]>((%\B<#;*Q<A"!OANN>,KU# ES21 B,Z,,"#G2[?JC0+W7I._ >
MEX+%RVV%U?8U:_5&VY+7-/H^7)DS^)$WKCMHU/&%=;>3P;6?&M$ :E(#T#W'
M]],@#QX!7Q!N >QY>,DH=42*$6)QC.BVO.]<Z<\HI1<4TY"2P@&AVW_0QUF*
MABN86D=';A#V"[6!6 :W('F+$CAI; APK%KVLP.#3Z(X4K]@^N5D$Q>_NG\O
M:(@YP'4D+Z0BAY#Z^UP19\SCS;KQ?5/=,R["F(,!P1LD;ZHJ3:@KW8%,Q_7'
MCKF/]AE$<\_-'3?U>^XYF"YP"CO)F]DO^-1[6>?>@_#9_:+9;B/F5SFF?8?/
M:_=B&N"D'"K,"^Q<+;@7%5RC-44(>^%==66<J-Y@O#[IX6HJ'7S+=?W8^6V)
M?'XU-Z7C_3:?.'Z)<%Z5M#J<Q5G7#P6U833!T@$X8(_(A,J@ _D7!K2^@"U
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M8VY&8_ ''@<>A=VEA5(E?]PVAO'" J1/A&P91_.5ZGS?\HGV5WK?G+ TPG/
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M,:WGV9K#I9@&F1VX%KJG"\U30:_!7M5>HE+.,]=X[&1<Z.HXWP*4.] !5^:
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MWDUZ<53V8A4>.\BTN%4402R]J*9;(LZ\@6R7VC+F0PP.6DSJY"V*F0C,I]R
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M/2@-DC8X.'JA*?WB5 BQK2WAV(,>-F\A?586)TL(_]G+45L'P5,#+@9MQ2I
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M0\/V=2::.$1"])H(DS5GRG^GT(Y7! E_V_[3*NRU8*F^!(/J,3<C4B9#[F#
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M_ "?\*(Y&Y,+&@,#O='6QNRS5I9!-+>P(TD]WFA(7T%_&FZZZGRH4APOGTE
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ME/\,*EY:S3\&T&O%2[(IQG[,?/C5=/"H$1.F5<G6LA\W_MI4&1F#J&IISQS
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M,_AR>)\C9?5!2E,]:[AT?YIG?%_>EO?5U1>"&/\#T$_21ET,%-SBCZK\&L7
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M,/08&.:":#X>XDU4[,00IA$$L\8[N^UV,F/NJ<95!.$Z+W>^'\^-;8VBS_\
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M$##9IJC43-Z@@:(\,6L[D%UAQ'X+1JD/T."^9Q1A>U97%M^0DYIX!!E%;@R
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MD6CGWLFC<KWG:[WZ^%DK^?E9+R-HL#-)5VJW9YZ)S(MN&8.[17Y'A"FF#OQ
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M0*H7SJ?X:HTW:(7PZ&M99FH=]D3?.LL@\<SUN$M2U3T=]2D[%(?G+,=9V(^
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MM7![@?TV*$P*6 '>$M8[4<SDP"+R=2 ;9[W)V<8OM#ZQ-FF0SY( <WF#S64
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MRL^[$$\92?]F(*LC,:F3/\C7 [[CWV!6@'-J]9B:HY[\<YY;E%B-(HB0MH%
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M\#:)B,-1PEXR1H ?W@!RIA:$*)K?\;7[&/0C>>06M= GGARRK$:5@9\!2M_
MO<A;'PQ87,CR;VYH;>U\X;Z7]:3(/'OK5-VYD\EQ\4=ZK&TTR..'/)+CW6UX
MUTHC6L9553;;6B2%XVB"[:UZ77?[:<;I%Z9ZV <S-69$@Q\31ZI6;N;79HUJ
M/*\Z7/%;H1M&LAWXZT'MO*0H\'+OH!;>IMH>+K!W4+LO=&;OH';]JB_T!@8X
MIKIB$2)91D0F1D%'T]+?N0+K5R-\66B.(W)V,O1O=R<P=_25\<A#H?Q6HEJQ
M^C*O/<=\TIP6['@G>]2&9]//5.EVTB]6/ CI(<Y!58$0U8^,>H2YK]"%]Z$^
M1SL)?O7Y5CMH\^&0S>Q-_76*)2F@RR8)6J<5@Y:DV:=,Z1N] +RQ5B-V8S\O
M/(U5XWN(AW<5*2F,%+;Y?)LO0O?D:)H^]JK*LER%/JL!/C]-U*T^5G3>5DY)
MH][B4^.0T[C/ZQ9QU2[8>#8E'&B;488F0P2CN("0KGPT\K:*[^IF_PD]U#&>
M9<+^CQRDKUWBM_A=/)):U0D8=J^RXE#[SC%=]V>(Q14-ZKE$S9UC(-99^S=%
M&EYG_8-2K%97*CC&$Z&\20D<#>Z*QN;=G]YUA\DOHXU,!.R2I/Y-)VB7IJ8F
MOCOU14;>%3]I+&:A,?3N:CKHTVV%:- 16>Q/#YI $X,3-Y/YH)")(8GB3. Z
M[X4M/$:^7W=OP@^;J6'I%G@AZ2AQ:&2_>/3AI9YM7MNGI]1.T:$<I(S@;F K
MZ8.Q><77.T,",V-7<C\%O%Z=D'=W:M#E;<7@Z^8'_O*40AB/8/J9YYL!&(GI
MS@\31TB(XE!OI4\-@ZDG+OL9?9L-/9K0_$@F[59/I23:D)Z P:<CZ]=H BAB
M%Z)I@$GMNG8F%YJ+Y7HR\158'Y]^ZQ\2@\4]+8BZ2M,HAXO',S@A4[$2]"T&
MNPX3>0^1,I<'RR<8([#&J6Y,!EIERH;^\A R3&MB^9Y8KMZ7RC5DH^LAO;3^
MQV:_#+K/E6Z@T>N0[C#(?OQ<#NGQ^Z5/=T9[--<L6SU5:\!K_EM6$Z=TBDU?
M2U_;;%R K*O#)? X=K@^J1J)#]@'W.XT':RON-HXK%%U:E2JJ2'AD)#VS!G!
MJX<_V.4(V,\,/RNW^&R]LCBY&.(K<,G$_-_S2.'?)8&[H'J%92Q)@5()! 63
M\B@)P(U7H15G6F8K-[5/?4.S\75*$_"/]P?)^E:?"@RK)J9,@I.[;BCW-+"_
MLSZQ>,E/ WMUK&R'_97<[2AYQB".= XYB6*PYY&EYRAO]U*IP%W)AVM*G7]9
M,OU?V92=RD"6=Q^^/?JY^.TPXOZG7YEY[#+<FVL(DG4FH,.*1_9&GL7A\U;:
M2YSARD", .Y6I-T,W$EEL^-Y9?70\QUX02W'A?/[H6.Q9^T7VN#I?TU#'WN2
M\1%*NF2E.]/E>IRT19..,OQ]?QR@=C9^;#KQX8;=Z@D^\B%0)_',(;YS@CMC
M8AF_#55>B@L?&;R399=Q(O]\O5[$N9SR[G 7Y7$=O6<!X,NIOUXP; +RW)9\
M? HB^D+7CJ_R.;PZ0[842[2_?$J$M_W W?S(*/ \1F#OB1Z4Y+\+>E!%4R";
MG0M(@>R/&I.N??S#\O13<7>T;>/[8T->5R#;,])/GJ8*6AC2H\JCVB&DJYAQ
M?@:' B$(08+V^O@1E2."Y%'X=-]*T:I,J_[956G/&)FM&F'K,W(.*Q!HU[3D
M[?="O+<=+'J%8_(Z77-K7*]D5#]K*2T*=]T1O=S543R;F[6\"ZJR*6:26QIM
MX3_;]_J'DMNXO5QPL0EP(7HZU',@ <**\5SC\8H2)25U^REW7>R=40FWD>_H
MLZWU.SGI=,WZI_'^:\;!88D/HUVG!"!/L(.",+LAC><1UGEF6(V6B$D+K"^E
M*?#XHX\&1QQXS,:BH07(1&2-<&<F']-5=<1X0-,Q)"LHOTGPC#-F0K4WOZF;
MKMJ^]>!T 0'#Y8761J<,_;:1>K+\HGDH/O?385L%<R)OM;L<HV@7%#?*4(:?
M:J8G14G )1J F&)+XKNHD\[>_("_RGEY=.*H1KJ1DT?TZ8T+/\YH\;"NV8_8
M+[.VHV*0[% /%%L_'AK+.%A+HCP*JO(6K1\[K=>H.;OY YMWF=;U"!TV>_W]
M1$RLU%7;2V,763LG$)W@ XAV"R@^UFX75-?;CDH6E6RX2T2-SUD-:5 +N"\K
M%36,\5O$X%/NFQI>D?M\3D*,ZYU4M$F4Z8_IZ8%=T*'V=B8ZC3&^/H&')\V0
M2;VT8SSOR>P8!M9G%Z2ZK+/>N*W2\F6RCF7-?J/T*I0@2,+09&&DO%U0A]8-
M>M7/,,@$TLVF/@SV8UVM): QZ PD;A=$<AH 9'=!W>#Q7@9[&56,=H$TD+BJ
M^707=%LLPAF:\FB>K-EI%'!G+,\^I/V*7!6AM>FQT)&C_L;(',>\0033_,;J
MVM,$J(S#<8 $.8020A9"SH"3D <-1>=%YS+T/0A+W]<TI@Q7L9='-965C8-X
MU>I_?])\RILX53-%CO>-&JFM*#.[:"0BE=%@V3DM3!J(]SV<0[ Y_'TA][7=
MPTFOL0<'W"?73H^ ;FT96(%<BU(46=* ?I)Z!T1\HT]%H7OG=8./1-J*ADK1
MXI"3NII+B9I-J]IW[/I3(K?QRDZ<KV\OY',AXS7FM???5JSVF5M?SG"<TC:R
M_7D)8SE-67?)?$^:3+D3M7]&%&[QX$.D=]NQ8*6A-FL3FXEW$1:HJ:^_@V)C
MPYU.Y6,+;.;JS'+']#:HMXZ1:R8F>\X,A-.A0 YSB1H8'Z9U'ZW=RTR%"=TK
MR$:JACQ0"9"&O2D<?;8+PMW$&/\AOCGB&J>S/HE1Y?3^MDK/W8:)%!O+A8J<
M+3WXY9G/KK)S2QH.8=_:M*_D:+G:*J$MK'J"DF0%9+<GLBW6%3NW@VF^3+](
MU/BUPQ3"FR9%;]DTT W-\!NV(UW^B*?0-X2#<G;B-9.9BVR4":B$M!,P>%::
M0+5"4]*J$ZJ+.\3JU.'.SPX_D^E':F -(_9+@>3B3'=!+EM/^TSOQUZ6OU,0
M#[8#1@+I@FUB4-Y2@'L7Q.H(Y]]NU9EY3W/Q >]T%$I]"]AZ0T&/J^V"HFFC
M+(CVLTSHF\F,50CH&O@NN=7UL)N!QM-T1JK/L)2M:_3%B-+-I3&!BA6[H&1D
M7#<"\S/T6&%0R<*GG7>?&$:;%F:$,KGU]T",'_.7U!C?()RESJH36@SVR3"O
M$RNUVU$*F"$1R*WFAKS? S.N.7@8H!M 41YI5.U"CO<2"S.<DW1/OW1_<PQ9
MF>V<!>6BVB_E=#>T_03[A.RW%$AMF'EDK P^"W9:ATE$=2-JL%WT.2)TN9B$
M<_52;[:"M0L)@Y$7!WBEJ''YT#$D9PUR38>KS'"C1GT7-'2K,NX[<:;!<J=X
M9FT_$W0Z$21SC/"RZ%R/C4BH.Q((QG'"T,/S5D76K%AMU&V2*DT0PF!W) M?
M)VVMC.+?7$ &!V/XF9L*\GG]<WMYH2YSW^PEQ5=@'%W3Q2U[$*BF\.<30B\C
M7Z\8OG"R$:&I97J3D1*(]FH,Z0)"*"#@\"<R?^=!-'X0;B]>C@&.'/B9V4LN
M'@>4TP&/]!>T4:7NR&D2# *91811,#&M$50#F@U'E"C<]UOK.<BJ!&?W0Y?5
MG;#+IWW*=T'Q$/-=$+( 1^/TICTA#]!$U4G^&RVT4_0ZFDU)80UW2$?N3J+!
MJ9OYN/7N.QCRX1":H#!^"UIG1A,85]%' 5N]R<%M7&GW=D&95PQQ'9F;T$ZX
M![64YPUFMB*I#(*V>,?8MT*^!)1%]D-JH:0X)NU9C]@%Q?B9T:1VS&BT:::2
M.-O/A-!.F=$D;$A:C'/@"1?:C9_T :"JGF[\I9>>Z'9A%_3A#9--3C$QN@1]
M:!?T<1=$E86FZ2,QNR"A'8F]3\6\VON4)U.9;(];O^.:.>C<-_F[C^D6/$9<
MW)E%*UK ,\<A@-%&YO9V&_.#C<4,GD@91E0 @J1206YA2#-=I]@4N"24G TA
M7=BH_XV9F:&SVG^KR<"0M\2I"'&L!U/%]#+Q0B_K&$(>RQ$SW#+:Z]"WK28^
M;U9VPLK\D$,U5?C>Y(=)]:_B;=VFGY^_ PMA,N!]E??%*IK*/1:W_M%P+^U5
M?M][O*J% 81&2= 8!'YN )##I38B.HPJ0K<ZJ(PMREH\5X$AYF;NS$9_Q-XG
MFA"D\XCD NA;A)\-Q^017>[[RE6J$%BCL1!4=+O2 T1&[V?@5*KS$!ZGT1OY
M-"NW!YU]7JJM.V;_,- W?[/<L_J<5)>HSU"!T^!$3/U<)X[GJ2%QOE"]IED%
M,%&V?RE3\D8VO5.9JT+IH\P8^C9:F#\!*>>IC>[7V 7Q7QW^_O%OO@U*8!V"
MSOW:V@7MGVA4K#SDQK0TX!+$0/\:XV #Y!^MN[/ Q4/0OSL9-2:@_Z"6=R 2
MZ*,T-OI3M(@WXDB4'MS<ACLTP#PU\M>K-]Y<PM!.4<4^2QE)(8V#WTDO\M<'
M ,5,FL <Q9NI!_YPYA#C6V8D6RAK/+ /<YV&[,/R5]YX?]7^R$J_ *(O_/!S
M/7.8>@FCQ.#=N[.^F EH=\YH-JUP4J\ &>L?D"SW6K",KKK:]"P6'E]]T5NG
M@O1[Q6ZU/10\P*/ERX.:;U7Z<*<_T$;[ZS&Z_8FXL6+@]2XHZW'(LT*LQ:OJ
M%8T[8UUW++,X?J\P;D$EH;ZJDW$,SF%R^3K%@AX#5Z@ G ERK>7HHZ/!>DT/
M_%52>4YH6@Q+:W]EM]3>4G]X]U<.';?02^,O8+"S4$\Q<46W]5!C%'MBY-V>
M/$H%))D6#(_5J^AL]WQY"5GGO'J$5TF68%GWD#LB;WF4>I+&37_(X/?Z2XI-
M#TP2)4J2Q"A\S^-\XM;[Q]&B8;,Z8:]\N5JRK$'S((E-F #Y9Q!P,.OG/71%
M7C>-<X8)*(7U3=D1OZ=>O:98"032:BDY$K/;X2),N_//;WV[;L'M]R/_[=KR
M9\L_6_ZO;WDW2@JPP2.%/$.BCI#M\H,-3C,.Q5)M1L2^QA+E16YE:1UT,<?'
MLFENAU##F+C1J'LG-)XQB"!9KDE> UA[G.[]HN Z+GO7.D]JS"@$)TP@3WV^
M,,?6U9T+TCBFO%F4LN-_A$AC(F>0/]K9.<>2&#?&[U(J7#QLN=JLX6Z7KOMY
MR(S8M)STEUC>3]3C-%.F3=_+O-$)/TZ6SRSW^OH6(MIYB^PZ^3JPUM7IQ>1=
MWL43?NC?T6?/6X33 P%'(B0.*:[/?H.LA]\%=3DC^ #$U=0O;T<W_*[;'"A^
MQU5"B,&7=2H=X&&3?H^99*4(T9G^CO] 4A5IB9(-P#RJC$6U*+<K1'X'<ZM,
M,IR<KZ$&>#\>J#Y_&A1\HSO*E'9U+R\!<^!7H/@D23T,_<5>PD $7S 40M,X
M12]V'A3Z\L-<RC7HS4)YD&XYF5(!UXWNI\; 7D2:Q;2:8/?/[$4\N7QB.G2C
MB!]YM);L!>'7G^17O_K[FHH1MXIQ3'14I^#^GCT&$ SV&B;9!3$^(YH4OAN*
MPJT+F9:93V&2;SZ\&T\]5*8V0^=8>,NIUB.5[?O4K^(7OB&2#'LZUVKP//"K
M 7Y=E^_5I7L1FM,J7G*_"LQL=>L7>_,/S_?^"V8:)?#M7_KW"R[$WV%,-U-
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MYFJD+@>4 $>T?X>R:).1[;UD^,4-""G#TREC4P+Z4V!QCKS=%H::R%=& "E
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M40%]%JIK:ZA8WVC?4&^M5)?[6E#G[C"\E@8IUX9\WZ(LT?,P_KBD"C(_Q1=
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MI4\,;+WXIL'I*+8<KE*X7-7*@=C_-<I+[)=!-#V(2;S]F1!0CI3 >,*T*#+
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M+N.$05D:;8"RY:R$*$GVKY*TR13 _M'"G^9/GJC.$FT($)FMWH'T[.\^@HP
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M"D !BY>X ]E+8KZ&^6 )6#P&N(J50]K-FFHQ/"896I3@^(E!@Y;$SI4\P<"
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M4X&R>KG9#AEGSJ4;##KZUU:>^NATF<Y6C#TG?J'ET3WJ;BR><$#992+PYS)
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M!90MBH4KG[WM6[M<I#=VB>N33]^:41];<$FA>Z181Q@&+MKAMK"^"%/%?+>
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M;P^.0I!24C#Q[@-(-VIB$E*-M .1M3F41YMJ>>;G>N::?K*L>.[@A8;,T,;
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M!",\">;M^I52]U0+7(JW7F-]F)+WM4:MYIY;<:3BE\9;!A2KBY#E[[K2@J]
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M03NY<7'9V+W3=*2&C 5Q^P%RGG_XD]\[G5N3[K6/E03XZ]\K4_8QT-)&BO2
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M17Z(EO--VY[$+GY?$&!Z='O9=VO%SC]7^8G@HZIKD# TA5\-C ABP#5SXL%
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M$C8));C.91<_6A*E6YY$LQ/#+N98MM<.Y4Q[:\8'Z!F[WB-%:7;5=A&X3NZ
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M"9-KU\=H_:^>-^'TO1I=)*CQD7O#S(P#WO\X=NSB%1</U%7!5ERG+B5\=3*
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MX#J[R?)KWE,:M96P/,^>3L0=&<><K^KX\(P4O=#T*_*JZ@ZB;-$\'77GSNO
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MQ=>-V[/GZ/R'Z8ZNC:[N#C\%9J8[?D,;_-1Q\7<%W981T'("OG6\.(R+,0?
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M3]Z66.71U@F%<ECE//R8K_C5FC_H.+DT1IGNDVV)@Y8ZZ,C79D+M!F6;4GW
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M57*<S,1:9!LR4C94C8L2'4-&3V^<+Z^9=MB*VA*<(*MV6"1W!7^.$9F[D,^
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MNA>@8;F.<> MT^I8K^KDSGM/:_\5S'.?.\O<OMZ];^\[>-_[#M2OY5,[(2_
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M&>01CPPSL6Z3U*'*O/TD_]\%!.V[2UIV@.+'.-]X#*-A5><8'C,=YQ89H_@
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MFD 2(@J1$!QF. J@GR&.$QYD?LKT.ZRY8VSB':ECJ?KE)]9RI:I#%B5X5/R
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MJ>K[%YA1 R?^#S9/LSOU&UE 3YA^$XBMR[^1:.?R=^SFGW$67+K]YV![_FN
M&2?CZ+7 G/3M[(MKN0H_X0?>9A9G&4(TB5/H)T$,4:RRKU$6RK]Q)#SEP8R,
M>E/O#S^UIU'^!!0UR]XY!UCHJ5Y["0W]=?K"&2NNXS(X4B\'@\^J!(X+=KA4
M3SSEO-/CBYXQ?H #C!#D09!!)*TS2*@70VEI\]3S?<0S[JB;X\RM8K9]Z&YV
M?>@:=D#+C[.N?V:-8::%RFQ%:Z!DDNEV]M?HJB7B&0">V_;0_'-SV==PL$^.
M5>_"5^E[8R^I00]"-UUN.@W^24J$JWN5MU2IQCJ7*_8A7^$5E7^_6O.':MLP
M'B-"LC3*H-2NTJR)6 I33B,8((*PEP@AF%&I,&W*$ZM<U4I0,0**;7<I%0R:
M=WP!5>'XR:)Q@#ZT>O;2)("9*=Z6!7"U T="M>4"U&R ;QTC#@TM8^$=V6#Z
M=&<USXSA.+3<S >PS<-1$DEMUKIZOZY*^9N[5?Y?=:W$-WS%1;YN7<.*C]KU
MJSS!:VE1RE_<%N^_XX=\53]^PZ4>7%4WQ7+YH2C5F6^1Q!AGC,4PP%2=MC"3
M5J#PH& )"1E.$Q%E9DD\TS(\L3;;9U_=R?0%J*N*=B)<@*T0[25-?6_3BJ$L
M@4Z0^K56%/!-"0-::0S/B9-_#7J:]$>:8S,%_,-,KT5JU#R8.\NKFIC=F9.R
MY@'_94;73'1M*VCL=?!>A'X21YRK;EC$5Y= *23"IS"EB#/!/.*SV*IFQAX9
M+>W@H$J&9G]Z+63T]*J-H)9I7*UP[T>$LRA_<50$9P4O]D>?N<3%4=%>%K4X
M_IC=$GO_\+@LGCEO2RT>]^U+8[3)_VFN&V^+-5[V_UV5SOE4K/^3KV^VZF,W
M4O/2H:]_P8E(!$D]&/D\@T@(>5ZE&88BB!,6A2(-4J/SZJM),K'%6/,(-GTS
M@O:O$:EQ?:S7FW,]-?67F$G[2^#MY6Z_-M]6G.V=[]8X;)AK"X2IQ-=GO@8[
MH=Q'<+TZ_HZT^>O),>N^\>K3=;A#O3Y#MAU:'W/)Q?M>GY.K%=VHMA%O-BTS
MJH'] J,@H9G<M2(6,8@"&D#,TP!FJ>?'F><EB%&S)JUZA"?>:5HV0)\/T#$"
MR&:G?10SIEU:-;'5VR*F0,Q,HSL"RZ))JYGDSOJT:I*=N56K&1@ON[4:OF^G
M6+:IKVTAYCKX9?O+_\AYJ<JJ/+?1&3[Q,\*H#]-(M8"6!UME&",893&*@RB,
MD&^4T6I$?6(5L\M!!UO"]1W%I\O?+6-;S,#54R^306:F8\Y#RUBU6$GM2+^8
MT9Y5R5C!<JAI[ :Q"-1I.D+NM2KMVB@L8L91*D@,$QIRB"(L-0L1& 9Q%(6$
M^RE/B'98S@"AJ>V4MAWIPUX_ULJH'^LH5L.*PB4"AG;'',(;1,PX L$N/L82
M#+/0& T)!P-AAMZ?+^Q%0XJ](!>=Y\W4$^/YXHJ*\G(C3:VBO%ROY?FOGN\/
M2WRWH*D?1!C',/-C!!&.,4R#A$$A_(B3%'EQIE6T?IC,Q*KIZNV'&]!2!CW2
M0-'66YPC, WK)7?"&SK\K>367H=Z8@U489,#-%:(_,O.^!@9=I;%J2=:MS0U
MG[8[IOS*5](,65ZNV"5[R%>Y"C!1&8+[E46QSP(>4-6W#'ERG?( ICB)8(RS
M+$0DX G6BNTUHCKQLFUYJ&UKO,>%V5E$#T&],XAS7,Q6=!^2?08FK,]J)+.C
MDX<>S5E/'$8P')XTS%Z>.7?WTT91_RSJ?ZTN-^O[HE2>W04C7LH)"J''5?/L
M-$ PI7X  TQ8B%#B<6Z4GN.<PXDU4'-!5%=2V[O>NP"KFJ%>*4:\Y>D5LCQ/
M3J">4GO5:;&_LK/,V_RTG;J&;;#C^P?(S1R#]+63,$_R]]?(MAR#UUE:Y2@A
MR_S)MH:.RB%;R]U$96_6!;]_+8NJ6I#,(P0'"8Q33"%2JCM-/!\R#Z<9B4B,
M_=@HGW*0W,3:MR-^ 7A'MC9\JD*L_S3N%SZ"G)ZF=(>'F=K;05%3KF'8TE8Y
MYI*ZP_Q,+2E=Y6L.$YLW?U-+\!?YG'IOO4Y=[<^;M3R+KE3,RC]Y?G>O[O:?
MI"EZQV_X0Q,N^K98U4D+&[R\Y>5#L B\5*0\2"&)PD!J$7683#-YF$Q#QE :
M102;FWWSRC"Q:NK8@+CA Y0=(]).W'("Y,@/%Z#'_KRENFWFWL!B_'%G=':;
M<EOMHR?8!>A$ ZUL8"L<Z$D'E'@_3O'O,Z;F!ZD+;B/!7ZID^!E3Y+J:^#FL
MV'2[KAN02/;JXMK:#:[[;TT=&/RRQ_,_3)I:[PDXK(S/D\U,1QX1RUD-\=-R
M6':CWAMJQ@;4QT38[SE]] D[P_!SEWC]41J9;W%9/HLFO:>J4]T741IG/,4<
M,I+Y$(F8PBQ!/N19*@(<)C'SC,(A1^A-O*RVU($B#_;HMU4K#".4QO#3,X0<
MHF*V(,\"Q-BHT!33D0$P1FW6S5I3],.-5?<UVQ[S5<7YCH;JH[LM@/%5;L<5
M5=D'G+W_3N6C;8G=*$-)Z =<(NY1B+(HA,2G&,;JEI\P/PX8L\C4LV)&:V6<
MG<^G6/L'R%75U+H08Y.D9=JXW@9K/?4Q'7263>\5.^HXLU4NBJ,+L.7I O2Y
M @U;SG-=SH+%D1*RXV%6U7063(<*Z[S!+&(BWW'!54SW+?[>T<EYM<_ C3I2
M?!9?*WXIN5M7"QPS&A _A@C%ONH^RV"&4 @Q]>(X#3*"".I4V+#VLN;!0G/9
MVCK+NG_]S>>O ->D#0()K= =5EK3(F:EL#INZF(,/7Y>J#!0\P0^"R"Y I>S
MH&D0KSDUJG:!G-.@:Q;G>0XR@P&@5@//%QEZCMQ[(:-G#62AUB6=_^2XE(!'
MMT7@A4D;7X582'WAQ=#C(I3J.R40^PF!*!620Q93'&N5'!HB,K5O1RX#118H
MNJH=CJ)LH$5.0:.A=AT(;.CP.2;K>'"9OM &VM&!\'8*T&S"S13;B%"#NNO4
MN_.IIQ'N]S30V+,62N9J19_7_&WQ\,!+FN/EE\WCX_)YVU.H_<1\2G%"Y%$W
M$D*>=^,(JRIG% 8HYA$*(Q'Y6O>8^B0G5D -#^"W7R\]/P!OY4LYQ4OPQ3S/
M1 ] #<7D'!8S-=4BLJ,/&@9VO<=L=)8>.@8:S#E*=OIL'"U'RLU(WD%5IS?2
M?(K/2+(]-6CVIIU?4%IPG\7[:IT_R&-GM4@RAIA4=C ..8+(QR%,55=>X<N?
MDR3A$6<F=P#[PT^L[-110G7'ZLB9>>T.D-!SQ]G+9Z:U#D6[ -?%,J?/X%O[
M7YT"W,9>M>/2.7*7'0P^JQ_LN&"'#JX33YG?0E_SXK*^SEX^JS($ZN+\\F&M
M>QM]_.V)U]+U^\^@HUJ7OC@(=!GVW^HB,+S(W AOMM#.D]OH!GM8-*N;[!-#
MSG:C/2Q2_V9[Y$D;-T*)Y2S1KNC0 B.Y5_F$048X@XC&/LP0CB'',4L9CF.&
MM>IO'!M\^I"0CII!7;BC*.AX"NQE,_00],1Z>YY8)KX >_$L?0"Z8AH>_X_+
M,7SL/WAGQN/^<6[WC_DGGC'/1W^_6N?KYP_YDC=9% N*/>;%/(,D4QY#WZ<P
M4^7*T\3S A%GJ4>U>MD?&WSBQ=^0 XI>FWFDGW#^ H?AY7^N=&;+WT PHXSR
M4Q)8Y9&_&&RV[/%38O1SQD\^8YDJ0.\YVRREE7MF)]DF "J-TS0F/H(\X^JJ
M%64J^1-!S_-0RK.0,$^K+LTT[$V\;#MFU3'-45-GNS UQY.J=PY^O:DRTT&O
M,4OF ?F3@.DJUMXM<_.&T4\"[(L(^6FH3!#WUX;G5^\V_%)(G:<N73Y(7A>)
MX'$D4@^&A%.(N+H'2=,0AEE&,Q9F8>H9%?6VXF+J0]8]+SE6!!U&]YU$5$^-
M3HZ3F;;4B>Y;%X#PVE-R 6HTF_O/#T-%5]R&]XWA,D=XWTD>?ISPOC&8C,+[
M1@<[-T5AC]I;5<IUM5Z$(4TP\@/H<VE6HDR$,%.-0\(@2&@4A5G"M&J+Z9&;
M6/\T<5#+782-;3;"4:CT](T[ ,P4RY!":8E/D8HP)*3S3(2CQ%XI$6%(\--Y
M"(-OV5:CX(]RJVB+&'4?:\!%)'Q,H1\&*40!2R".4@I3GT5)2C(AS-+'CU*9
M^L*DH=GU :KJB@N%JFP/:,. 44CN,&!ZJ_ML& RO3EH$6GH3K.1!@9Q5ESA&
M8^:B$@-BOJPE,?2PQ3W*Y9=W_\'Q<GU/Y1'D<L4^KVBQ+.Z>F^B#+E"*QUG&
M(P89)G+%QBB Q&,^3!/A19@D7A!HE8W1ICCQZI4L@!T/]=KMN&@C7@PN*[00
MU+B8<8V+V7(>A\0F4$H+&X/;'=<8V5WYG/'YF%T"F8@[>#.D-=!\UT4F<NW=
M(1F]:*,-FPJM5RM1E ]-J0.]=M(C;T^X;MORO3VB.JVBC40W6:!.(+!<EB^A
M<+4.1Z4:7GVG7Y]QS8W*L+_2QA^WRNE[XLNB+GXE5^\-O]LL%>[/O^5+7JV+
M%>\\#5]7<L1M[..NF=3"0Q'#/ @A94$L#P^!/#P$@3P\9!YF/,A"H=> T T[
M4]LI;8?A71=!HYRT<['64'FS(FBF&7NL <D;V#$'MMQU=9HJ4/.WBW.^Z/7J
MFQ5SHZ3 &;&WS1"<>@Y,LP4=03:2.G@NE3GS"!TA<I!4Z&K4<T,=VIHZN_LX
M9376'0C;8CNUEZ:Y_(X)3AF/4YAY*8:(9PR2P \A]P3VTXR3@'IV$0T&7$R\
MI;SC9-V[_KX +0<7VYJAZ^>]?__P._QT=6YL@LDLZ'F[)L?6=+.9!-8S@@DL
M8'$>,V#"PRN%!EC =#H"P&8P.P6GOK<>F2><+]6H'XKR"U[RR^6R^!-+).3/
M;TLN+7E596@11(B&?HJ@%V!I.\<)@RG/4LC\T&<>9P0)K13K<YB86[UMN8+R
M( ,KR9?\7<<9D+\##6]UF2PS]68U!WK:;6IDSU1N^Z!^L0356+F=@XHCW6;%
MPJRJ[1R0#C7;66/9*K:F',6-M"!7&_ZI6+7W:0N$ TIHED$1( )1&&"(42I-
MM-1C02K"F"5X\<1+4NCKKQ.T3)92GZ+!BFHKIY0-Z0NPXG5/O.[R\+$H!_U7
MAMCI:AT'>)BJEA:(FPZ('567BF-$,&?:X12=F57 B+@OU_G8"^9)&JT#\4->
M/ERQA2"9GZ2J_QBJJ[MP)$T/K'KGX"2,,(V1T.H_]F+DJ3UPK4]9$0-7[_1S
M,_;%'UY_9PEE=UTP)H]12L91WJWR,?9'FBT9XZ@ _4R,XP]8MVBAG+-*!037
MV^B*_895K\[U\V=QN,?N=M]%$&29E_E4M12G$(F40NP% GH4I0GU Q1X1N%P
MEGQ,'EC3<-6$XRM[O8FM>6A84Q'[=>O8\@^^5OR!:LN9<;\7JVG0VTIG -=L
MX>_CJJC6L'9,*5 US'RG/63. <A=<QDK+N;N.G,.5$?:T9PUG&V^YI=[OERJ
M# B\>E[@-(L#SC*8J2K#*"81)(S[,":!"&D0AH1KN5J/#S^QCFI3&VN*H"5I
MFK6YA\:X>7">C&:JPD@\B]S-8U*<D;VY-]S,^9O'1'F9P7GTJ6D3?%2$_JT$
ME2]HE/HQBSGTI*4-$4X\B$6,(8T"*G"0^,BLQH\Q!Q,O1OE%Q-.D].PPU-OS
M)T7&; F;IO+423PU3_-G\;R 8^8,GAW]'S)[YP4\MID[+P>R+ZRX;"H+'J][
ME[&(A"3P(0I2#Z+45^F$W(-1&*34"T7LX\2TK.(0P8D5S'Y11>V">';8#6N:
M*1 Q4RQ=A<!E5UK2737%05S,:RFZPN>\2HJG<');1U%'5ITJBH/CS%Y#44>J
M8Q44M=YSW%[W8[[B5VO^4"T2FH9!$"8PC#F'R/-#F*41@2I3(L ,130U"B(9
M)SF]1^9T;UGP3;$!:CX,HT,TL-3VM3A$R-BM<BXX[MKOOI!WZA:\.X(_1AO>
M%P!HM^)]^::=@OC$_[RD=2,4:8I):BOY5UKKGZHIW=G\J>IWUN4[%YE *!%Q
M!GD62'5!TA1FOOPQ]%(FLHCY26)41<>4@8F5QPVG=>SGEB6PSY.9RC!&5T^!
M3(F9F3J1G)S&:IXJL+9@.-(UQN1GU3RVX!SJ(>MQS*O1WO!*VJ[UV.^X:CB=
MKVI3]IW\I6Y-VJ$Q)E<@6])@CS90Q/5+T@[",*PF7")@I@XLA3>J2ZLCF55U
MVL&!9ZM1JR->OU*MUO-VMH$\GI3*.?..-_^]6NUG<R]HF"1A'/J0>@F#*.$Q
MS"A*8<)1'"%I'\0QTVM>IDM2Z],]IU?91'421J'4V_B=P&/K1ZDI@I\ZVG\'
M^0H<%%5PMZOK2NIH%Q\E-^NNK2O\X2ZM_9Z%(_7+\PH+D7]_\WOKX0H)#Q+N
M!1!3BE5X(X*9X!ZD/B,X8S2*8OW$QL/1)]ZD.W+@S<^__VS@^7L!@H;[\QS1
MS-;HGE0VCLT7XAEX,<\1T\YEJ3>)9O[)4U(,.B-?O#2?Y_$4OWMNQI,/G=/D
M=+\X=K40-"1!D/HP\U7Q,VD P#1-/1BD4>IC^2-%L4$OYD%B%E: 1:_E;:CO
M^J#>O56CS4.\-#3'6>*?%]T\B<@V_4//$/W,'J'Z$%@V #TAFEZ3S\.77Z&1
MYPG^CS?K//6P95NHU:["P"W^_H:ON,C756?_5/)0M%DJ5T5=Q+:QVZ]YF1?J
MZ>NBRA4CU8*$?L9YR*7U@E0/#N7+S+P(LHQ''L=^QK!6&7ZW;$U_/=QP4^<]
M=8>:9Q50L<;?P6/'AF%[*C<SHG<,FA]G,S7:YZ_N-=QQ> &VYZ@MCVT=[W8>
M&C;KEZY'9\*\8Y93X%QUVG+#U+P=NIP"^:*SE]O1S71L5:X7-_Q1?MKWDM;V
M.OJM<O[R\A&7Z^=/^(&_*QYPOEID/(LSC#W(>$0@XLR#A% $,8L)\<*44J%U
M'61$=6(-V2<*%%7PK:&K>98R0W!8Y4V&BYE&LX!$6SE9B3BD>^2 /;TC?]KI
M'#-:LZ@4*_$[C6'WLL6ES&;)?8]$_F597K+B49ZH/BSQG?9]S/'7I[Z*49TT
M%%GH TE8_E-S,]%R8' 7<T)ZC6N8\P4WO($9EAE\4^0=+%H-X>PN84Z,.=_]
MR[!0>U<O(X_:G6W>XNI>_5^%>CSAI;IB57<\94[E^.H?Z@)%_5_TGES$$?+3
M_Y^[MVV.&T?21?\*(F[$/3T10@=?0!+<^TF6Y5[?X[9T;?=,[/:'"KS*W"D5
MM61);>VOOP#)JF*]D0 *I#SGP_3(4A&9^;"02"023P8R@5(-#E& *,0,(<@3
M)F.UU>$\XHNG)E;XNE;NP6QC<Y%.-E_V0\W,%R@ELSFK8?H'L9,.R!I0\5"L
M=.\2?6NL%6&WN[GLG>0HI4*(#+(XDSI3'JL8B3 8LS!-A6 !C=/NG=RN# _*
M9GXC&[W\O ^AS]3>XDV8;2]GP]8R!E."KD #;$^>)IW;J +:CY"&N&[OE_TG
M_&TGO0#E:1=YF2ZS;AZ]P':X9_0SJ-N2]8$4U=_)\EF\>VT8HVZ6I*ZO?Q3U
M H4LEQ'#D&*<0\03K):C&,.$9QBG6<RXM+K,=5;2Q*%D(PPTTL"?6IYE[?!Y
MA,Q<DA>[[=R-A<G6CF/4'$].X;R<62?\J+F'DWG\ 9<.U'^5W[Z7S[5:'KX6
M/]9"K&X?GY;EJQ!?UR7[YWVWB=2EQIOCWSAE),XC*'*D9B^C&<P10S 1)&2<
MYI@BH^2.F_B)IW04A"G8J  :'<!&B:8XWJ;_LS6T!L=_DP)FYPN4*F"C"^B4
M&<3.I?K X?MIT69[2C =&W'[!]6R9;<K)L--O:U'G;'MMZO%^XW!G4>9X0[]
M7^4B3%F8Y7$ $T21VF\F(<PYDS"0$98R3#D7>+(;]'^5D_OM*)GP_KS"SRPD
MFQ 5.^?L=G?^K_*-;L[OH'B+>_-*^L][:WX'S45WYGO#.(2)FN&\+AY6NFKJ
MONKJ-QK'MBG\S"4E+ YARD,,$0H8Q%@22&.2*=<B T-67B-I$SN3OGBPE=\N
MOA:ARRAF!N&>3R3L',@0""Z!W"@:%G&;3U3<PK3+T+&+R$RM'0S 1@>9+]XR
MM6<OO#)^R+%V[.MOY8NH5OJ;\/6I7-6E&OZV.2ZMBEK4^QS"W3<VHPQ+$:E-
ML&AVPKJ+3TP03#&*4IH2F2:Y'9>OBQHV7W8GFM^=2K#>Z 3$3BG+FC 7I"/*
M!)9AI*"5B5I=>*""5RQ@2.)8@9U$,K%JMCHUS@Z+SD^ LEF(.S5VELO45W 2
MN9Y"AY20'OVS#TQ\%<RYJ#!O>=P%(!T5PUTREF,W'J*;8[2;^:I@XEY47[^3
M2BQPBA,L @YSQI1SRE@,J0A"&&,9J)A8R(0:W5$>$S2Q VK85#5Y>_GX6*Y
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MG>&>?).AT%E=D!T0AY[&\FDWAW*W_BZJCL6NO22X83PDC*%<T 1BI._BX43
M/$8,8A(+QN,T3S'=-.CY9M$[_9Q HXFPWY7GF[T3:<0WM^8:4L1B+1XMRPC.
M(V;F%BX#P(TDLS%Z0P2YN;G;B3W/%&[?8'W,-%]]UL_*F;?=^IBY1UW71Q]P
MF\3;**.\9O_]7%3B^H442UWG^Z&L-,_^;@OV7M#U0D:9R-,X@A2E2(4'>FHC
M%,$TC0(9\QBG&7*8VI9JS#/A[]7OOZM0K%D)'TGU3]'>2Z^WNMA-?UNLS9S"
M%- YN8J-(CK;VJD"M,2]3,M6.2C+"GX=ZE=B[4,<D?#D66RES^IO'*$Y]$*N
MPS@<K"E?=]/X.A7NBWK=>;O>-? ("15)9!E,I,00A8)#(L,$QA%)* G5?T-L
M?)0V)FWJ:L5M4-$IX$#"/0J8P2&93QCLG,=9!,".SL G&!;G7CY!<3OIN@@<
MNS,L4V,'3ZU&!YGOG,K4GKV3*>.''/Q:<VO^>K5Z)LL/Q8]=FF>144(CR0D,
MB$PAXEQ%5B3A,$N2("*9$-B,G'M0RL1^K&L_V,@%4@L&3YUDB\E[%B(##^;#
M<#O/U=K<B@2-S$V2UXO-%H[*A^UN#LH% SN_-&;;H#\Z^_!\?FA,_SW_,_IA
M1XJUYWJM-H[5C=9WM>YZIA7U/[M"5RDB*O,@ASQA"42QI,H#(0P%BHE(B?)+
MB;1)_8[(F]@7;:2#/?% R[?D7!N!S6R;YA$,._\T@,,$5S0-S?1%LC8B;5ZB
M-3/3C\C6#!_S=&=L\XLVB;0@E 6$$@ZY#CA0*@0D61Q"+$A$<Z[K7HPN=1K*
MFWC.;Z\J52U!RH6WO ZP,IOH'A&PF^@G[VEM?]E*G_ .UFDSI[ID=2#M;6]1
MG39]])K4F<=<+PSH0;ZJP*TI*KBFM7(ES#2)>.;IZ;ZLW4G"5B+X<R/3:S7\
MH%7>BN%/2YFY%G[0U.-2^.&/NWT'FVJACW7]+/C[YTH?.S8<]4U-0_U9_-7\
MJ5[(%/,L:CIQ,[73913#/.,Q1#1( XQ12JG5160SL1,O/5I(TSRIE)I"\U&%
M6'7;>'K5\MN64LUV?6&VI:/_I5 ?:#0T[+=K"7+&.!,\26 2!)&"-DP@#O,8
MJB"?!0AQKOZU>!$5+=\.YKYX\V38LPZ+FI[GC610-"JI+RJHRR6?'%@SA^H?
M+#O_VC8C;14 K09=)Y0KT"JAB9?_:C_AL5V G=V^^IV;"9VWT;D5$$<=SNV>
M]M/M8QLSB(1E:<XXE PAB/(XA9@A AFGE(@HS3)LU-Y\3-#4&8"COA__=EGC
M#\N@RH?9EGO]HT8@D\158X9-U!OD;2*K,6/'>H7XBJU.4O+VRHC?O1[5CC8\
MO6TKY/I#64E1K)_5M^?CJO4FBUC(+!&(P1R1 *J@((,D23#D.5+[?T1RBO"F
MF,,P1O"OI4.MAYV;Z&2V(830O!3BDBAB@O=D&'*\$?87U\3WU=TKC*>OX&3M
M?$M^WJE]!7J*ZZM]]\/-_.Q#FNEP]17_3*#AO,'2=! ?1583BK)GV^OJ95[#
MB'XKUDNQ$%RF,A$I%+F0$'$90KU9ABE*XB!%B-+ :&]\:O"I#W^U#+TO"Z-?
MZ-\V55^&! \GP1CV>Y>::.>P;*VSXLT[9X837=[18+.QY)TSHT^.=_8S]DS-
M'U=UH3[YK>)-87LAZONJ9->\?%*+^8<E>3!E;!X=:.K<42L??*L(;S;JG1;=
M#962"=XL;IU&YJS.XP@-3S'OX-@FB:UP 7]J=3R1/QN;[40"/3[Z;&30QH;V
M2:'-'W),39#ZN]I#Z?^[_>_GXH4L=?W#!U)4NI&WV-VD6Z@U441!'$,<4 &1
MQ G$*<&:%"F-\YP*RNQR%::2ITY>Z'H__3UO"O_$3A7+%(8QD(8YC2G@L4QR
M;)!I?NAIH78"2@_0* )VFGC,>]@:[RL18BQWWLR(+1Q'J1+K 1P*+C_^3NB[
MHGQ20?TCZ4IVL/)A-&,!9$A7.E%.81[E!*8<YTE$\H@)(Z=Q3L#4\0)4(L%6
MID69X2DPAB>^#Q,M5_U]ZUPX'4^9:5%(>:&Y;C64IB_5KFYRP)3!DLE3S\U7
M+3F@]5ZAY-#G'-.LSW0IU-:_*_FA$4T2&@<P1E0Y"AD(2!(1PT A)@F*:)0E
M#M?=]J4X9#@=;K-M9(Y5 IG 8IB0M+?2+9=H:)E]YN^D ;Z2=ON#SYMO.VG8
M4:KL]*<<UN#_)(7ZLGXJ'G6:O?/')(Q#%"$)TU 0M0;''.84I9#D:8A21+,0
M&Q&9GA,P\1JL) +U!.AD@E^Z7Q@>%YR%Q6 UOM!8N\EU:*?#:GS*3(O5^$)S
MW5;C [,]K<8#I@RNQJ>>FV\U'M!Z;S4>^IR#T[@A%2]69/GO@BS7^M)[]]7)
M-8-J$F(8T"B"*(H%I#S,(4)1FC A(T&,FA,."9E\<]]*!:U8B[ET#A0#M^'!
M5-N-^IZ55WI]=O$?YVRV\"$>;'?S(Z<P\.1,1FP:="CGGIW/J8QHO^=8QCYK
M?W1P_?"POJTJ?038=BQ^+]0T?BQ6.K2V[/=H,M;$_D2I4#4; Z 4*5>B?*[W
M3]5UCW"E&=BI9GZ(8(35L/^9 B8[7^2 D&=>/EL,G,X5C 3,=K1@8V[_=,'J
M.9>V,:18W:V^E*_*G;S^KKX-Z^)_#LL %C+,XB#-*>1!K+;^7/V$4ZJB#K55
MB4D01$2:AQDF$B?V$5H%H+[H5:L$>.QI <A.#9O6*28X)A*)4#($@P"K("U,
M$<P9%5#D*(W"+ N3W(8QR"^<%V=5W@I5@WC/]W?.SN&^%3 VW7H\ ^38L>=2
MH"R;]U@8/=S QV2@&9OX6-BUW\C'YL&9:W?UJ=CZ]>.J7E?--ZMN:."^?2>K
MKAKM<[EZ$;5R7?\0Q<-W]?_7+Z(B#^(W-?3ZO?)IV\.T180DPY'RPPG1^3:1
MQI"$"8>,!6%&LS3B#"V>VFL&:U*M#3/9/X%I-G/TT$#C:?I./!2KE:Y">4>6
MS44O72+,R^625#50P[;EPG-5"_O\9B084TJ3%%(<Z#1*+B$6"86$HU!]-8)(
M8MQ],VY74Q>"O^GW8F.>\;="/?!_Y%=B.+SXF52=\%CI\A+UUD[0,Q2TA*IK
M9>JN@'UK[178V LZ@T%C,= F]ZI;?H+B]@E>X5M7P_LTZ5^C?'Z"E^BMWGX*
MW1QR!=><%UK<:78N$25Q3%,!HY!0B*C,("4HA2R(HSB(*,ZQ>9)@4-34&<2M
M[(OIVX81,]BX>L/!,D6X@^!2-K=A""RVJ-Z@<-N;.D-BMR<ULG)P,SH\PGR[
M4"-+]K:?9D\X5E$O25W?R>8R^:=B)3YJROH%X8+D <,P92G7&T$,<Q*&,(QS
MP1)$12B,B"8'I4Q]@*IEZMLX+<_!GUHN: 1;]C0[#9%9^'NQX9;'J0XVVY<X
M#]GDJYSYI(QY2Y>'S#PJ4Q[\\"5T3=_(CUV1LQ-ET\D1IOL.=K1-FF%L)W9"
M[J9!\[SR-YV6] 8<3H,FG^9Q&G[DPB^HICU>L6)9-*'#]M<=O4'7H?-Z_4&H
ML<E24TH]ZQ[+N^=5)+X(0Q[D02)@D.%0U^Q(F.>4PCC"*6,I3B-F%"=/HMW$
M:]4?JZ9PKB';JH%L-0%K-87(&M0;C4"E_FS;#-WG*[+T.G,#;^>G;J44K&GS
MV?-86B38UUN_@DY%L-7Q\)DK</VH^RA-X-Q\HNC;'7K1[6T<J$]8S[I<KT+L
M2Y@^*)3*5<-*_R*JU_?/XEO9R;Z3MRM9JIG1)%,>UZ:53!9#3NPS.TW 1A7
MGYLNWITV.@KNZ3,Z02\";]@Q3HB;G<OS#)E579,# $[E339R9JMR<C"^7^SD
M\OB%(=WM#_)8K!JWM=OS1A@AF4<)U/R;$(4<0?4O F."DB1*.$6.(=HI:1.[
MC]X"WI-^09I@&#K+T.E20)RW;-98N <V0S;Z#E1.RGJ;P&/([+.!Q.!#$W<Y
MI_U6P]L,1!KDD<11#(D,4N40D&;H1:G.&!*>$8QD9'0WRX\Z$SN+7B*C:0'<
M.^GM] .-@AUQ:M<-?=OMSB#Y,<4K,O,Y\P'O?K9^LB7Z!!DE/UC,W0_]M#(_
M9SOT0>"<NZ$/CVK/N7:[6A?K5^5W/W(U8B$+ULAM>:4709X%:1(%$&4I@4CR
M%.8TSF$H,$IX%$;,K*W@J*2)O5HKNUGV]Z6#5KPY+=LP7L-^R"L*EBD@5P"L
MF-N,C'.B<1L>>39.-R,#^P1O9@^X[F!>U)AE]?I9K!<4H51'(FJFZC8"5# 5
MKA )$<G4+&5Y)A-JMV'9#3[Y_J03U70'L-V*]# PW7FX66:[T=@:]7G *(<]
MQ;'VWK80O:%GWC$<&W6\03CQ&;>)\TGS..@E56WS*5<XA)#Q0"URF.20!#R&
M<9PG2<"Y^F]H,VNV(T\\91HY5TWS#+OYLC/=;+(X&60W4SI;;H9LL9XF1WI[
MFB.[<6>=($?F',Z.XP_838VZ6B^^Z W']8^B7B01S@67>AZD&*(DB""5A, X
M%R3,0I%08K28[(TZ\91HY*BMDI)DN/?<MWEX/CA;8KD3U"5I]5I%"4OPNWJE
M:C_0[0 'S3*>'B?-&)H:ZH'>M%#_VDV)_;%FF0XGU=],A=-_=%LA/A0KLF(%
M6>XJ;ILO21CS-*0,P3S6FZ(DCF&.J?IG&J$ )TE*D56#P#-RICY/VDCMU>);
MS9PQF,S6%@_&6QX*.=AMO?*,6.5I'3HG9=95:<34PS5J[..NR8NF,SEI"AS>
MDS6Y>:ZJYNYKFC(1(0YQQ 1$/.608L;4?W(>A(QEB4SL<A>G!<V3NNC)UO=?
M".BDVV8NSH!EFKBX' *GO(6U]0YIBV'3+LA:G!EXYJ3%L'G'.8N1SSM<'MF6
M(>T5?>P7CJA?WE2"%^N[ZND[6;VOGA_:H_D%CFD@,R$@RTFFEEZL66J1/I3A
M0FW5<A*GF5E[GLN5,?J^7]*%IQ4(N)((6*."16[$ ]C#[F F ">M=;MJ_G#3
M8=OAK16T*Y_Q@+7%!9C9,'>[(#,]]G8W:;S -7C3YC()\]W$\8+$WDT=/R,Z
MK"+W5:$D/)'EYA!LE 0E56M#&,<J!DQ"W=A-=W5/<  #D?& "Y$%46#+N6.M
MA<.2X4# LU5K>U71,^N,/?H&2\DT8#HM'S\A@!;KPZ1 NJT)G@&U6P"<\1AT
M^O:CSN?HG2W><^[NH]A7;G\KUV39E#9\+Y?JD2_KE461]NFG)]Z2-T)!3ZJ*
M;];/U<JZ\/J,[<,NTX_9=F[1U6*KNNEAHYQ*I,\,.5LU]+!)_<+GD4^ZI;'O
MJY(_L_6FSTN<)[%,!,19IIF- @'S---[Z3S0^6N>8ZOD]=[H$T^Y3I9=>GK?
M?+.DM+-1MG%&(V:< -HZ_WS2 $]9Y_VQ9\TUGS3K,,-\^D.N>>6;\E'%)\U%
MY[;5_-WSNEZ3AN1J$4@A@H2$D)!(0I13 G,:)#!'+,!YS%A",[OL\I"X>7+,
MK0;MC?JNOK<&/2UL<\V# )IFG'W!XI1W=D;$(?]L8N@%6>C!X6?.19N8>IR1
M-GKJS?O)M\WNBZH98=L5^8"5Z?:'J%A1"Q5HLQW50<2#*)*Z WV (HAXK*D'
ME7?)DCC(,BGC-#4ZL?JIK)K8=6U4@!N*N(T2H-'BS=K57_ U, M4?@I=)ZR$
MN9QO<,LHV#.U:979,Q84*]":>X)M</^K-,DUC)_J+;XUY:!7F_XU. >G>(W>
M2 <G4<ZA/0G_KV_EO2BU]A]6]AU)3C\^\;JDI#[7Z\8=?2O!_>W=GA?3/JE<
MKTI3DI,A&,:S11X0L'/>IL9/T51DV%:W/B)GQIRO=<BP47O=0D8^ZKH9_H=8
M+O_WJOQK]560NEP)_K&NGW52*4B%) F&-,8$(A2K?7 J!41Q%L<Y#T7"C9H'
MCTJ:9PNLA<-_:NE@(QZT\FTWO^< ,]WW>H#!:<OK@(##9G?$N@OVN>=&GGF+
M.V+@\>YV[($+[XA=P*QW=H3IOHM;H=,3ZXU:Y_MVU=L3ZXV:?/;NE3=BO;:3
MG6X.0$L=3;Z(ZX=*--'HC8HL"\T2U=Y_9D+]D?=R/_]HSHG7=7N'\DZVN:!%
M("*A%AP&LX0CB# 7$$>$01RB6$H9,V+&V.)=LXD7KI;_]*].=--TH6FT4-OT
MWO7Z)H;]RIOB:^>%]K0$6S7!GIY@H^A>LAAL=.WN5X,[V:6/W^JMV/0'?:.W
MX]A4=-:W9-F5= (DAUN9^A0X8__3"7#:;YHZA8"9SQH^;2FV*,G#$"$"DSR7
M$''.84X2!O,$<\:3/$Z8%2/1Y2I-O<CUN(;&L\'T.!M\ =N9A_<U<4;?Z2W,
MG(Z?B&+-'V9OG?S^]#9D;?X ])9V/A[9\1+OIN/-N]?MC_]>*&]?L>^OG\2+
MPE5?5B4DPH'VHU&H_"A"G$#*,PJYE+F0":4RM:)Z-!,[L</<=<<"6]G-V=?G
MZ[^[7?4U ]/,T_F'R,Z;78*._85@*V-]W0\V$SKO=6$K((YN#]L][>8ROH@U
MT8VU;TFENUO6UTSM2)X;"K;W0A:L6"^B/(MDB&.(A/(4* \#B#F*82PQ"P,5
M? 74*O8:%SGU2=5.(."M1#O78 ":F5OP"X6=2]C(!AOAX)<^,)W\\SD5:[=@
M;JPGEV @<%9W8 [ H2NP>-+^M+FC76E6,\,3YMXC$\_53M*_F9\:]\T9GH47
M6&(WU3HAWA;:,XH['?7VQYGM>/>$\OTCW5-_=FR!5CX^%NN6.G2EPO+56DT?
ML6*%J)W/AZS&G#)7NU6CB>3V%)GZ%,D) U_]PZQDS]M7S 66HWYC3H/8^_U>
M,?&F^\#'%?],'H7I,G!^A(E7!2W"?$48,'1\@?!CH]W4[LG<]O.X DIL\5)P
MW89ST'ZK963</*=596#8V1:9<=/Z:X[!I[T=^'ZKR*K63#/EJBD97*!0Y%&8
M1! QS-462S!(8T%@SC,F>(A$E/,+CW(/94X\0WOBP)-Y7;H-:,-S=R(H;-?H
MTR=U?70LJO9MT+GX]/,2E/R>:YJCY>.L\IS=#J>01T.]]?GB.=L,3@[//NI.
M8L?*ZJELCR*;[H@W^F9U]7I3<K&@>2"ED ED5'<IIH&$%#$*61B+G"8$1:%E
ME>6@O(F]X>V&U*VGPE7;$E*A!CI%@-;$GMYN",9A'SD!.';^T0<N3L1W!M9>
MQ'\W-/[L-'@&QIYBPS-YS&U7?EW78EUW!'O;W7>>:G)R1B#'.6]H_"'A+(8Q
M#<.$<A&FJ16A_TDI$T_T3AH@C6S#K-4P+&9)B8N-M9NXK;BK#2OE)#F&09,\
MY1).RY@U9S!HYF%N8/C#SCFRIW+5D-[(]T(*-3;_1GZTHK9?0RH"24B402KU
M%B6*$D@%#V"8I2)F3.182)O9:21UXMFZD0N*EKVO:<KL,G/-(#1.+_H%QCJM
MV(G7[="V"&G^PE:%J?*)YD;[RR,:R)P[?V@.PXF\H<7#CJ5\[+O@STMQ2L**
M?RH(+9;%NA#U-T*78G=E+\I"D44T@B3. XBX<B$D$T2M[;D,<)"D@C"K^CTW
M/:9>_??FSOJ[:"K'R.KU?]6[F=1C"NTFU"\]?0UKV"]]'V:N: :4[9S31J%S
MKDF?@_34 G\VB@&O=RX]@>.K^LY1BWE+[BZ#ZJC.[L+A7#,6UYRK[V;=;(;N
MJONJ?%%Q@UADC$89EP+F$4\ABDD*,<]S&(DH#(,PR$)NU%)I3- \.8I.=F\7
MOI%OFYDX Y=I2N)R$)QR$0[V.V0@AHV[(/5P9N"9<P[#YATG&T8^;W^VJ=?=
M:[9^)LOEZSTI^-_K$W2#UL0*=J/.$&SLBM([K8!6"[S4OX)S!);FQZ:6& [/
MZVGAL]_B." W 7>#&R).)[*6HF8[I76#H']RZSB"?;NX)@$JJB=2K5_UP7!3
M8B9B$9%(8LC3((<H3S&D'#'((D(T4R*+<&3:.>Z4@,F]R$YD4U9@W5#N)"K#
MSL"'K;93WM),JP9S0[9<T&ONY+"SM9T;,JK?@6[P<PXE$\T]Q(8*@K]_KHK5
M0TNYU)2_-W^[5V_V6G=B4('#(L.8AIE(H4B%;G60,DCR.(<Y"9,\8Z'@@=$Y
MH;WHB2=F>UWW2?T.5&U+=$ ZR1;% G9@#L_::2&R3 0TZ+1Z@%:1CM6NN^72
M?D K ZZGALVBU&(R^-PJ+EJL2MD1*("B!92K7ZY+4)__"O[JJ03#"8_!2@R[
M$><KR'"R=*\NPVT$QQ-:M2WCQ?)9EX!\%4R)T_F4VQ]L^<P%_Z!,TU'7<_MU
MNY.;>PE*HR;L^K2]")SD6 11CF%&TP@BDJ:0TBR$*.0THTF6X="HW-2W8A-[
M[[Z:8*<GV"@*]+<#]%35DW![$4=IV^X_+KC$[>T-FJ6*W^*]V"T9L[X2^\-N
MS_CY.A_WI=:\1^J>P3PZA?<]OIN3OGMJB#Q6#TTO]$WGFD66L0P)F4*6:*+^
M&#.88\Z@C,.42$)BFEE=[SXM9F('NA4*EEKJMI>2G1,\@Y"92[O<;CL'M3.Y
M$7BUH9/P0,UC9I(GGW%&R*P>8-C0P_D\\FG'V;G^+BKM!RKQ7:SJ;>/ 3V5=
M7[^08JD/ISZ4U5>R[#F1'9'L9[&^D]_(CP5"*"$$"YCRA$(D4PQSF1&8I'F,
M:<*"C%B%4+X4F]@#_+&J!%D6_Z-6Y@=2K, O2Z7?WW0OM6+U(EI5;-V!KU=B
MZ$#> &A+EW/S\0J\%W3="XBNP%8W*,L*:NVNP&_-*]":_^T*$*G>)^AQ'NMS
M=Z6H1T?E&3I?KLV76O,Z0\]@'KE/W^.[W_4]VWR')6$>T)S"A%.B@B*N.XT@
M#K,@CT/,N!#$JA78&_8NZOC\ZK9%3Y>Y*7M7!JT9,8T0-/-Y;].\Z%37HBN_
M;8ML#/1XT?EM&QC9&'WJ&K/GYD5-&NR+>!&K9Z%W6;_I:YJKAD9K<TVI[GK?
MY22+6!BJJ4Y8HHMR<D@(4=-?Q4R,X11+:E1P:"YRXEG?Z=!F*1ZV6@"R5<,B
MOVV&H<%Q@'=D[.;]!A0M'^P4V-T=K,?[#;JB8Y'U]XZ26[9_'"U/67TK>P>S
M^68CS9?%M[)L+WMO]Z1]Q=.]*+LOIF$QT_:!B1W7_>V=><W1SHIAY^-L@)U_
MT8U<_#4L/:FT4S'/;I39ZG2.%.^7X!S_<6YR_+T63)M$ZT+D6<+#*((RETA'
M_1CJ>\60A#((>) Q%N-Y*/)/ZC?Y1J'/!UYM^,!9;_^PH=$'8M/YK2%K:+80
MSS4'3VJ?WVPE9N/6/_TB#4*1MWT]MON5BQG<#WOU;0^HWO9%S46Z?_$+>S/J
M??L7-R,#_R"LT_'PGQ;[UFP9/C#SQ\D_+,8U9::P6:T[T47]SYM*\&*M?UK$
M!(>8H!RRG#"((A1#$N $9CA),Y8)F@5&:Z>!K.G7P9UD?:K?2@9:M&V"[#Q>
MIODQ+RC8+C=] +2LJSX&5^"^7!;L%?S9_?\D]^4,+/>6-SLO:>:TV:C)QUFS
M\4?L[Z]=/ZLQRNJ3?DG-NLQ2E.A[_#+ :FX3HD)B'*0P2%F6,YY$:6+,KG,P
M]M2%5:TTL!%G?BGM$(/A^7JA97;ST]@HJYMF9]1WNEQV.-9L]\G.&-&_0G;N
M(VY+XKT^P2I7URO>'&O=E_6Z$NNB:ALXB)60Q;K'P[F[_T08SY,D3B!5JR-$
MJ5HO:8Z0YDK'":59&@DK^AI712:>@+>/3\OR50C0J=#46-NMHLX0FRVQ<P!G
MFZ;>B-^@5GN^3.;+=D\KL+,:LR[/EX)UN'9?/-Z%75_:*_ =>3:_TWN)YTH7
MBK\C=5'_L2II+:H7?1C_<?7TO-8TIRM6+(O&;;Y[;1Z_69*Z?E\^DF*UB'",
M$:4)C 0+(9*"0YRC#*I(@01Q+M,XS)SZQ'A6=.J00XL#C3SP9RO1M96,[S=D
MYA!_!MPM R(;R-W[TTR$A^^.-K[5?)L>.!.!?;9KSE3R7-M2ZXJH;^3'OIR&
M\4"3EJ@O[7+[&5$OPDR@D$01C+,\5=%D$D!,==.=E#..\CC *;'QO9;R)W:I
M+;?&6DL"OZS45"\E4,N+J,@2T':AM"Q=LL77S'-.B)J=0[R54K FY]RCC_JB
M0=S7;$-;TA A:>UZGV]*.Q_U;5V?W<2= /+68=Q.^LQ=QYV@.>Y$[C;,Q364
M]Z2ZJQHQ[17#[1%/)/.$QHF 0L9<A84HA#3)&10AR7A.21I'5O7H!C)GK:A\
M(A5X:2[&ZE-0KG/V56U]$FJ#*,_"0- 8PQ!3 1$F*:0ASF H&4$LP_H:^^)%
M5+1\(TS[LO]E4#5-R'M%RC8QWZ];5?(UWU2K07>/W>/IH(/%_@M9STI\JWK6
M,0@&REI''W7SP;JCVTHTC7^J@CXWC/OJ6_,[^5$\/C]>KU;/9-G_H[Y7N,G*
MJ1_U\<$BIWF>9*F$.M.O/$H<0B)9  66L0B"+"78Z@Z@!YVF+C-KI9"'AL]
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MQ(P$,&0TQ(30*$HM6[J/RIS8$V\TN *-#ON$4U?N&W(3-,WB8L\86?K?<O4
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MG.4X)46,"0L2/TLSGV=&I3D#,*8.JFBHJ 5[A11@R1:D0)L)TA!_AB7*$=7
M>(H-P<:B94#2@(S)MQL9DS_L9&QHS5F$S8"H3NI,'K7H]Z_.O+N''U]7C^6'
M55U4Q><E_6'<Z/_DVU,?3 HHNBL?E!K_^NWFBVJI4I>27FY8$C= ^/A!=3G-
MP(N3 7+1GPJVJS[]@X39->@_O>1\G?D'2=IKR3_\Y 7AB7S<",W/&*'_YO6&
M%^]6A1I#P^2/=VOUJ^NG3;VA*V7&_ =76?KRF6=>T1_\EJN+9_G[KE',$UW>
M\>K!7P19QM*\"'!$>8!)D%"<>S3%62!H'*19PB)0$<W;(6UB;=.A@6F#!ZHZ
M1!#;88+DR@]7J*%*E^WQEB[5YDDU.[<(8;P)]D("'6\"X7]&.*3WI7SJ?2GJ
MU_*I'=57J*,;M82C+>6H1SI2M#N.G[RI[70997D;A,T?BWD;= ]%;-X6AG:G
M_C>^^4#K^YMJ_2RMM.+]RQ\2X2^K9N:%!/>.;<IG?0'2C)I^DK]K2^\D&=OJ
M!4\ZOBSW8LRC7+J]J: XC1..4S].,I(1+_)!)[8;M"8^;16&2"S7?]=(?<.H
M[+!#=(L>["1UM!MFI^#\/(:=8.K>6+.XPU =5[\H)"6G?T5;/-$.T2NT0Q7M
M<)VD7,4M^QR=&(Z0FE7;NV7DH:9VO#H\9OBQK:#4*;>E6O66/ZZKS:+(_#@C
M"<%%'/B8$!KA-&0Q9CSU&0MIG#+CH.$Y(!-KP XLVL%%#6#SF.%9_HP'#5U0
M#<S:@!,,BAF.4605-#R[Z&Q1PS&R^F'#T6?MXX8W%2\VU</**FRX]_*<44,%
MF"N770W0AL<,]XDV#QE:TWM!Q'"/U$GBA2>INBA<N+_B[-'"DP2="A:>?M#.
M:]CVOKL6G\L57;%273?+HU)+;JV+4U\6(>4IIR3$+/%S3 *1J@(.@M,@28(L
M22(A0+E(1E GELQ>?\JU0%LT4 \/F,EOQDHSB]XY@V"B;,";JZ:$_ 7]V?[O
M)+/(07QP9'F;P9S5L :QX=!NAKULFU1RIW6]MK4_JA:YH-R2@Y<GEOP>-/31
MN+OP>5+'3^*+J82)[ZED$V.B+9).SA!V0>[)X8HSIZ"<(>@X$^7<@W:'\9<5
MJU0/K(^\^=\OJ[9-1'U#7U05T2(L2)8PW\=)YD681&K63.X5.,ZB,/"2H&#<
MAQS$HQ"G-H];:"I-5X&#G;CC_#([;9UR 2:J'6CT2P?\5Y6INN7+S0A?P">J
M,:V.3M-Q>+.>I,;D'YZBYB_:R?X'W5I5%W;K^X;ZW=/F?EVIR9&++.:4)5&(
MXT(*/.$\QS13_\Q2GT9)2J*D@$C] *RI ^UM UD%^JK)TZ\1W4+7S62;WP)K
MB(;89Z8$'#$%)OXM/[XW_&C@HAU@=V)O0)TC@1^"-*NH&Y!\*.0FK]C,-U(+
M2@4B[;#RF=_(+T!QK>G;UO8&Y-0OHB3C.$R9*A3T(YQ3D>&$%#3(B$="9B3B
MAO F%O,A!" C?\;Y-BS;$W #)M]#L&U:31IP!#(,R2EG+(<BV7PJP)%(QF0.
MCT8:7V;&$4G&-.V/2C)_S;)]S-F&!_MCL1<>84&NQF3F44(P"46(,Y(*'.4L
M)!GS?-_W%L^\RM?&76$,04.^Z3X"YI_T%A2PI8LQ[RB/ YYE6!"55>F%,::A
M1W#DIQGSY6>;9QFHG\X$G+LH(CL1W\P,P2FX 3LU#-K5..Q+ R375;,94[#S
M=I !,N.H+0ST?0MK<M<!<+E<_TTE78?5[IVOVDRH7L2"17ZN)ADDL507A"<X
MSVF*<Q(%?L%2:5[&QK8E%/K4 :2BT#?+AJK6CH$&1N:4;($ICUZ?SPX5U0#K
ML$>%JH)N$+H"#7:WXR# *)V2DW8FJGN.PNQ76XX,6K/@1>>S;6WIW;-TK1>Q
MK26]><J7)?N\7-/-(DV8EZ>>AWUITTJ-F\4X]9($BZ"(\S@+"Q$;C?4\N?K$
M&K4MIVP (@T16C;:9\6P[KR80)ANA-!F42%Z@H8+:D/[J\U<%7J"D.-ZT%,/
MS=Q/Y]MZU:3A-[V1>[?:72.%8N'S),[SS,->RH1T-&FBKLQBG+,LIWD:9@GU
M%RO^0[7R,W.7ID37Z-O/FF^_C[2Y"'20[&/MDVZ7F8_VZEOP6I5<$G_<$(#:
MONY[.3E;(MY 3QL JU^[EXT)JO^,'C8 ICOK70.!Z2:JN.],]WJQ_E:MZ_J/
ME;3KENK2YC=:KMYSL:ZX:F^<AE[,22X-,C^@F"3"QREA"8YS/XJ]@*2I;Y2W
MY!2KB:TY#1KM8",%_,*XI!WW[8)OD_/4>63N"O6;?9_D_Q7*-:J.&TR[9-U$
M43X[G%XU!'@1&\?B@Y<M?F'*=],9\]VJZ#7'_"H]XB?I)%^O;A5:E:JK6BD-
M7W7_5)-7Z]_+%?^RX0_U@C FTBC,,(M(H31KAO.<$)P1/V<T]%._8%:IX2ZP
MF^W"XJIM_*HKZWL(HPYCI,N+6B3U4WVL]03A&OVI$$<:<^#8$;=[:J:J7VVG
M8"K[53;)/M'=)3-=)\0[P>UU$N==LO5L@KU3(';*_:9:/_)J\Z*N]C>J*X$T
MR1^UI0XK*1]=9SJ![4!?(0V\:5;2@9^D -R86$<"-0YO5B$Q)O_PPS=_T=+M
MV\[(J._64GPD.>62?].A^W; QMWZ5$WX=J3TKB9\^_TG)$^8M$RP%X;28(E5
M2VWF$<RCR(NHX$+D1M.>IT1R\DO3+<JJ^T_5(8U6?*-'$:G?JI^9:MKPV&_:
M\-0U;5AOQZGO6F3\#Z!?.<7V&KJ9K[QI,(UXL%];?-64 =1@C'Y1./^J_CS0
M:6.+?:_3QC038"?DKRO7= H4Y_54)V3RD>,Z)2R+/@#+95ODUHM/UFT&K&D[
M@($UIE; RR4Z4:0'F'@TR(!A'>B2=J >.T/V>"8TK$.  7%VC0*&%IZO7X !
M>7MM TR>MQ)!J12DT*\?'L&"=_#F#.)V<(;VKSA 4G=(LY&L74 N7,(&*'4O
M:&<HLQ6OP^7F%*HSI!R(TKFG['O9?"QK9AI[._O>A)]4OZV+@BD=A"=5IN8V
M$#9*V46M7?97G+VURTF"3K5V.?V@19+P_Y)^;,5?;E0/'C.SX-QKTWU9+3#4
M0+,IASI%)2#5]$)J[;))]ZEVE"(Z0,E@%NBI]^9+]!S >B^7<^@YN-[MM695
MCLPSKU[T:,B'C:D!<WZ%B0V9_:0A0-;V"-WCAXX;DF'ZH0<3=4 1A 6@PV><
M0JL3:&#9V8ZA<=+Z9Y'!TQ8'TDVU9IP7]6>)63/$_O/31MH1M^L7NM356:2@
M41I1'V=YF*H2:#7K,"/R/[GPDRP._=2HBZ89N(DEM8/?]!.N)0:JDY;0.*"J
M0P)PU(WSS^!X=\H5\*W.W P!6 ).&6-G%US(()B]8$SOH/4POLI\MH0Q17N6
MA?E;=C=8M[SF\J7[=ZOB(W_FRW5S/;:+PW1-X._6-[P2Z^KA\[K2 ^7K]R]W
M$N:[GV6]\$GD,Q$'F H68)+F.:9A$.%$"%I$"6-!0B%75DZPFEB!=CCJZ]\>
MEOW X=5V%(4*=+2H(OD?U"![A12RZ$^%+C"AQLW&F5U&S;X=,,T]WTZ KYF<
M<L[1O9(;G&:]2'+*QL.;([>+VZEAO9PR8BM^+YV'\IGOKJV^\<VUN*,_;]:5
MSG??;*HR?]JH)$V)$:WZN3."9:&(L@03/U&5U"15<S$H3CV/BBST69)&$$7L
M"*^)5;'&4@_<WJ*)RO;6664+_ J\]W>U&V;:]15X#'1S-7OW,-R_U+_2]_S2
M&)28JK:[5>/[]I#52E>C.\EMOF,6.E*TKK":5=4Z9N6ALG6]_,SUG$<%1)J>
MNWO:%AC5\F@0O%06>GTP5NDWN?A&]6#=9F,N8E\D81@(7&2,8Q+G!&<\C7%"
M61 & 4DB6+/4MT'6Q,J^144E0U=JFF!9M:6BQ7JYI%6-'J6RTF6C<U6-NOTH
MS Z-MX'L=&>.@TK4X_+3QM9'&TGL;N)@C]X30P4US;H?-3+H_C1?[>HDV_C:
M5:YNB?IGU,-.LI'.*F>GP<ZZ<F 7"E-M EL4=J7Y!6$%]RC!!8F8ZFJ28\IX
MC F/$D*H%WL!* PU"G'JV[0VN[D7=N4M:&5MZR;%:/T(:"]ESDNS8\@IARZ)
MUVO@G5*?HLN ,:7N2C!&X,U=@F%&_HD2#,,7+>[L_GB4F*XVK<9:Y''N$:^(
M,>?"PR21\I]I^<\CDJ<YB?S0O(_<_MH32WH+3$T9T":,_J8_WGY!_R^GR\T]
MNJN>3$=EGV*,P<V;/;DPL>TH;0'9TP2X/+.GS>ZFS)1&V)78:2H&[[\.7IGO
MLNLTKGLW6V<>L;,-5/FY"B%<KSZ6]>.Z&>9W+9IZQT5*<UK$?H(3U<"<A '#
M.?%SS$,AB"C2((K2KL/2G;EY, C4Z"O;[Y-T!]<;"KPJ"BXT G2IS *JX</L
M@6'^F=D"E[/#2J$HL%UQD1H=M(.MF-%5 +:EFML"0-6)B"V?=.K.=;G45T>_
MT7KWO/K%7:G;H'>_<V=,&+'*D2$Q#&M6(\*([$,#PNREB>* ]3G'Z-C]^;*Z
MX56Y+@[<H,[.N:E*QA<D"(,XSP3.(T]@$D<)3@OAX\B/XRSR$T$]HQ2BUR+@
M_[>Q/=<;[2B*]XK;YSY>5X\$[$Z%Y-2LJ8:N$\&YCC:DB9LQ*C?1MLP5?W.-
M_MN*M$VT.>"8VE1XV,^%_URNOF\>-I^J:EU]6%<59PH1/:PY(&G.HY3C3/K*
MF$A7&:<\H9A0/\U(1".>&C4=, ,W\3&R'9V^&PS[7;IPS:6!1@?M\!F;_6S#
MS6'M[YY',%WME#U6,^?'J;YH^OS \K//H1\G]=1$>H.W;"=X/LOEU]7+?ZRK
MOZ3:4=&YNEXDON?Y49#BT&<Y)JQ(<!;[/L[]F 19G!,6@3I/G@8SL=@K6,I>
M>&R@04=UGF2,F1UW.;DP"=["DT912W0+\ZIIZ.AR'.<0:<YF<)X$,O/@S2%"
MCZ=M#C[]1M-25+^+QM)8%)0R%I$8AUDL/5%.<ISFQ,>%\#)1!((G7CQ3UW$X
M]A;!-5M'=/XFY!:;Z<C;G'F#_AF)(;HS4>N#_H,2/X[WXI^2W='#_&TYENZW
M9/8\C1,HP.N3)9A2/KGKV?([H#G$^9>G-)<TS#.M?7YWW25BG$2K0MV!96<K
MU!TGK5^H:_#TS(92*PV]"N(OJTU52CQ9DWV9BRBB1.1MC6\JO:&\D(Z0EV0Q
M"P./"F&40C YIA/[4N]^_*BTX20/OQ8L>FYZ%/=0FLDB&MVUB>T?EWLQN[6S
MM6=ZZ*M)<-VNOI6,5E,FO[89,XKG/\-H,66W,Q/%&*#ED: '1]?U$R\^/JFN
MU8V9HW&I3R.]2#+*4Q%QG! BFJ$K5,0<!S0C<9XF7A2#QA1;X#!U!NGZX4%J
M"YTI>M7ZL:C4&%[@V5JPVE!#3\M "]U;HP:=JT;%UE>G56V_T)@*N5&].TR'
MNM6>/:ZTI@4&\^I#>Q8=:;H+EK+(9?WT\+A<OW"NP=[(;_)>KJZREK[2G^7#
MT\.[U>J)+G4MLJJ*4[I4(M2])7]D*BLRSI-4#Q/DE&282),59S0KL,>3,$VB
M,!%9:)P"ZP2EB35<BPKB+53$>NBH?!$&RS)ULPW#ZNYUF O3?AV@-K.^0U#G
MT5VACNL-DF@/2Q4K0]WK5^CFE;8 D!\\^U;8I17/MB6PO&2GW!M,9W8#:;XL
M:*><V4N>=KNR[43I6_ZC5/78J\TW^L 70<9\$F4^9A&-,0G#&&=Q)'#!X\1/
M?<*3##A4>A_ Q"=) Q+M8"(%%#I:^H GXYD@EU(*5.LP(BUF3)^FY((QTP<+
MSCQI^C0YQ\.FSSP'CZY_W53+.UX]U-?BKBJD9W''?V[>2Z3^,NW^>7Z%R6TQ
M^9)*)]+0=4.0XXB[>3_0 4Z,WS.X80),N(SH1W\J3)!&Q=&%PSBM5A<. \O.
M=N$P3EK_PL'@:?LVZ%_YYGY=@*7QS.M3Q^_[3=$;T( I F<H'I<Z!\3"1.X$
MG1,(V A9%W5^/UQS]M[O9X@ZU?W]W*.VN8BLXM)N_<B;__VRTK?6NX$\3?59
M(&A,BH+B)/$S3 0)<4;R $=>*AE*:9K['BQ3R0SPY$E&3=+):KU":M"B.AIL
M2O<,N6@6@'7(&<N;^@8N^J7#X%>5?=-PJC<<;)A/%DF.$+*=)3T: 9TY"1+"
MB..D2-#;%D=Q-]L$T N__\[4A^YVL,WA7)LK<#/\/5(-#EY+*H&G[5D"G7:Z
M/T6,W1G;7VB^@_4$^GNGZ:F_VU?UU*J#7O6XKM0)]%XZHH++PX3QG=V6TXQE
M151@0;(0$TI2+'^38.H5/BFRP"=F$T5!4">6M2T>J(^(RH78H@(OZ1EGY7@\
M9Q(&P<34@#>.C60KPB^J\1F',GNICS'AIRI^S%^V,[:5OEFO=&JH^*@6KWAQ
M1W_V!H%OV];FG*6)GU#,DS# ) E\G.9IA/,LCJA@)/=Y"DF+, <]M<YH@7?-
M@3?T)UKNL !V"09PU,SXGH9/,-6QPT&%K[8,DVB@'AZ3-/&%D^_($ < GM48
MAS/DT""W6 %NA[Q[*DJYL_JZ(XX#3K*$8#^ETM*(N, TX01[+,A58BW)(F-+
MH[?NU'9[ PEXW].G>]PLL*0&:)^;$ (ZU$^@;75L]]>9[6 ^@7S_Z#WU9WLS
MO,D.^K0J5,_+1<I$GN5QC*-,.B4DI12GD3Q#698$A9>DA$A' &AR[T&8R;QN
M"Y_0)S5:0X*%V]3[?#&WGZVIM;.5C0FULHE/$G.1_;N_XNRV[DF"3MFUIQ^$
MAWZTO\PV3W2Y?+FA9?'O>CO;'7PE8[+6Q/*U'SMI<4$*&?1<_TO/4V@0,H\8
M&7%H/)+DFCEP^].(+Q/<\D HMPI'&0&8+4P%(;<?O@*]!Q?T&\ZKWZKUTZ-.
MO:WJSRNP? \L,;%8*\A(@T8M;%5'O-ZLUJ9'YQ@+Q@78$?4PN1TB? )1-:#1
M2D*'UIU-, V(Z\NCR>-P,6SR)]X537MQ;;L92M_QFY-?NS2@  ;J&0K'A>LR
MXF R=2IYR(Q6D"R=)\E*A$XL-YODG">E+S #3]G%5M\Q:>L^+57D]B-_K#@K
MM?TB?UYR71VW*MX]J*%&_Z5_W_63U2UIY=^V36D7)"Y$2AG!OA>I#%K5CXV3
M!#.6%&F4RY\]'Y;JX JUR9,A?N=UC>@.6U3TT-7=>&D/3UBDUMG^F,5Q9^6Y
M79RHQ^<^BE=HBZ1F>1_-JVT?Y*NFF?*5?F2+K;M L&O^.0H3.T-KUB"R:V8>
MAIB=K_\Z'2':5IMJUMQ@7]^ L#SP$X8C(O4RR5B.*:%4ZFH1DB1(:.;-,[(-
MAO?$%E@/B]<=Q0;<33-]_@;W"*;N77:1Z!'SECHRN]V"-])CPA3K?U3'">!6
MN.X_ 05O6QOW@:NAT<LOJX+__-_\99&P("212+&?Q1XF/ AP'E"!$\*]C.99
MY&4YK#CN ,+4*KXI'&N!(@T52;#0^KA#OHQ?"%U,+4Q9@@FUJ)$[0\P%17*'
M*\Y<)7>&H.,RN7,/6C1,N%V_T.7FY>MZQ3OKLJ<&[I2$+T@14E\(#\=>R#'Q
MXQBGTD;#<1;XU)-_]8E17,L4X,1"V&* ^B@<U)8I+ R;F1MS<5A&I^ -3&1?
MB2V #@..V6/7/V",38[Z 0!H':SV-UEGOEI^ %5[E?J0]RRCCTN](;PX;1I]
M^JE^Y(LP"/(\$B$N&)6J,"E"G,=>@=,\CG.:1[&?1Q#/U0SLQ I1]S_ N?98
M6-^SX0UX8)S0C).&44#G_+%W^D[VJ?HTPB)XW Y$L:NHG!G0>6-N($8<1=1@
M;\.O]KZM5[=/2^Y[>>2K&NGJ8;4I]-P2PQN^LPM,+.T2+E: D8*,_;TC7I5]
MERO%-O,;P/.,&+\(=,(#F$2;D>]L8(L1E597A.=7G>VF<)2P_H7A^,/6!= J
M:8;^;&7Z/5]Q46X67I"G(>4^]M,H5XUT?)QG>8#CG!%?Y5 S%B\VZPU=FAW5
M9^" I'4+S?AS_;(KLFA/X__^2]Y !H:#S_')["!V0#U,3EO"5<U$"Q+]\GZ,
M<)N:Y2&RW!4IGX0R=U7R$*DGRI ''[]06-\];>[75;EY^;A^H.5JP;Q"Y#'U
M<4'4P#2/"9R3(, BB?R"Y"&-0Z.:AS% $Q^NO:]V"QC]V8 V])Q'6044V L8
M8"VQ -KM1?8,8:YE]A#,ZPCM&6+/2NVYY^W$]MN3FN%\+;9-"+[S'[K><A'X
M?IADB8<]K]!7N0'.@B3%F<\RSC./!1&H^_-92%-;Q1JN*M=;;QMDU"UHF-R>
MYY69X#KA - FWA*_ZP[R?8QXL.".$N9(<L_#F55T1\D]E-WQ%RRS.NB2U[?\
MF:^>^#>^^<H5F$7J\RQC28:#-$JQFD^(:9X2G"41R5(BDB2#S>@X!67JP)6"
MB:H&Z!5:<</6(,.<,1/3B^D%1N<;2$B:8>S^@59_H3\;D Y/UD&27-WFGX0Q
M[]W[$)E'-^6##]MFA']9%;KB%90,WKXT]4%H7+Y[3,YXP,>:$IBTG$CZ5M-:
MBO*Y+%1?9S>EO6<)NB#ENUMIYFSO P*.$[T/'W Z7T2/+OG&_]9_J1<Q]Q(O
M+QC.J2=MRJ#@S421,&&<YJ$?TCQP,%%D'^K4CJ$$0E7+&&EDL;UY(O+4TF:G
M$%SA)O]:0TU.,[8:GFNNF06\<-%=V1OXJ$&@+2J^:H8L72&)1?. 0]L41/6T
M8T .8+Z%P1^GV6 XZN/,RW8*I!G1"&P)L__2=-]N.Q)UBK8NITEP]"$>+#[K
M%W>:L,-/Z\Q3EH<0N^?%TY)?BW?/M%RJY('/ZTH9>M\YDQ^NZNCR^W88)TOB
MO,AH@F/B19B(@N TR AF:9"H>88YB8QZ4%A!G_A0^LCS#=J!O4);E+!85[B6
M2)E-]G3 9\/3:2KNP21]A''?C1D'/ZAL&.#JP +!GO?@LF'+T0%FM8CM18AT
M*>56OWPL:[9<UT]5K[^$SRB+(A%CD1."29(+3,,PQ$46Y5Y $^Y'( -X"-CD
M%R(M:&6W <,S@SPRTQ>N*(>IARU4M /KN'X?0J"S&Y$!4#/?BHP3?7PS8O".
MG2QO [:_JW[-!P41MUS=OW1_5!DF_L(/29 R1G 2,X$)]PA6<HT]/V?4SS-&
M$E 6(12!B65^6]!$VX*FI>Y&+E=ZT(5M+YQ6T'&98!Z;Z8<I.0?3&;N;%PWM
M1%G8%IWF"9VMY$Z1V'+"D7(!@Y]5X=@RYU )6:_CHM77A_5WON1, OPJ >P=
MIM8MO\ZO.;&.&6EQI?Y,5R^HPPZUZ%W2"&R ?^.![ZE8!U,REER;I4W8.#\<
MM0L; /2*;</&R1]N'V;POD57V@>^*M3MB<[G]=2$[]2+<)SE'B9!7F":RW^&
M'BUX'"=IEAJ9+4<K3ZPKMK"0 @;H3;M'_;",7T033(@-R8%UJ#V%NEV/VKV5
MYNM2>XJ O3ZU)Q^P,_A5FQW.]P]SY5:HX1VWJ@56+@B)LX3CB!(?$THYSEB:
M8"XBZA>)-/,9*"MJ#.#4<<(6%*J,>X,9L\K,3G?) )BT-9"OT)%]OF7*K9,F
M8E!*'=G=H^!FM;--B3^TJXW?LY-W57?X\I56?_'-YZ=54;>)0F$L I8D*8[R
MD&$2BQAG7A#C,$Z+B$49*8@'D?+38":6;0T4/6BH2"BP, $_PQLSL;Z<8I@P
M-\0V )&&.$$:U3!1CN3V#)!9I768T$,9'7G:HG?!3;56,3W5$.OVWU[HMY]>
MP1,OH;&J'0@C3%)"<>Z)#%/J^YF7IR1F1F(Y &-BF=P!10U40,W]&:8,RZ,C
M4F'">$3EN"R:?P/F704N)]NND8#Y)L,Z!PS3,]@LX,RK\_4'&,9]KR7 R*-V
M!_T=_?FAXD6Y^4"KZD6L*]7SJ!G*M_#C,!5^$6,_#ZBTZ6.!:<SDN9]&(B\B
MD?*$0D[[ 5@3JY<_OJ//7#*%+G5=(=-8U(@I/%"+",P(&.*;F27@B!LP#:1*
ME1JHJ ]V=,XDV"0PH,Z173 $:5;CP(#D0PO!Y!7+N6VTOG^W*M3_J%2B9[I4
M=17O&D#28= Y:@N>BBR@<8CCR$\Q";-"2GA8X+ HHH!F/F$!Z%K.".K4<7()
M7+>89>H'OD,#.*;-B(%FHNZ<+< 8>,<1_4,/@RM$6SV@O'R-A<.Y;!"B78UD
M,X(Y[S0V"!N.!K&!7K:V )JTU;;8UA-![F6)P![+8DPBZ=[G<>CA2(19S$02
MA0G(QS]8?V+I5P=<.Y+)K@CYD!W&A[DMD? #W)0^FT/[%!7N#NJ]U><^G$^1
M=N) /OG8S-VE]6_K)K/\RZK!:.%1GV8TR7$0BD >UEZ!\R3*<)XG?A!$&><Q
M:+ZJ4^RFO_S>%I"@1_G0O6Y0E;\@_O"X7+]P7NM$&]TU&IIIXW:;S!3&JS$?
MIFX<M(!N$.X*7.0>-3B_@2;/0ZQ\[5;.)W'[9S1L'F*KL[;,@T L&R+6-=_4
MGVE9:;-JES6Y+;[QBR+,A,=QFOMJ.B>+,&6QP#[C<1A%7N8Q!NJ%. 9QZC0!
M#=^D?,>286:ZT"D;8/JM 7V%%/#& =I+8)Z@KLF86%>-#D?AS=OCT)3\H_:&
MQB_:2?_9"2-_U%P\+7\O!5]$6492D3(<TDBU;/)2G!(OPU$4!QYEF><GH"0'
M Y@3:X!/]:9\T.W_GC1(M"R?!ZI,K3EGI@@<\P-\.=,?4[0_I>@*-2@@A8,[
M90 @V)$Z,($XJT( L.!0)4!>=9%.?+VYYY6[3.*3RTWO1PVEPVJ47&0.GV;5
ML!:8B$O 6"F 0;,D"0_2[R@_^#2,5TP-'B1Z."MX^%7;[$?I?MROE\67AT=U
M":M[5+7W[GF>^K$0*<X"U0XNHC'.&?,PCP.1B"(0+ <F/IZ%-;%NV$)&90\T
M-/GQ/*?,; !'],.D?D=Z'^H$F5(&U#E+<SP/:>8,QU&2CY,;QU^QD^2# J2N
M =W'<OG4=4ZOKY\V]49:?^7JQX*0F!2$QSCV(H8)$3FF"0ND[5^0- [B, U
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MVM0;:<B6JQ_2SRW9HA"!\"(:X41=21+.?)QZM, QY1F7_Q?X7$!.4A#TB36
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M2N=O]>OCO],E/^P1&U#"6!C@/.4I)A[)<,8B#WL9)04/"M\WZ]EN WQJ$>^
M8[&N<"W!0XMK 7PT<]:FX@Y,\!46:(?&%=KGE$(%TB[6HB87S@5G-;H T#/7
M[,*9<ES#:[&&34WO>J,R/>CRCE8_^.;;^J%<-;:%]GP^<Z[J4;Z62UYOI#G2
M^D;UHDA(&*248D]WS2">5#8\$#C@41PQ/TP\;F0Y7(+$Q$JG00:MMMA<H74S
MJ4E(A'1T_:%#"5) :\GQ8;4T%Q^!-\8=0F@#8"9Z;!&;@:N0TN7IN6M9WGS
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MW8\5KCA<+,U@]D0M9CYLY/ 5U],49M<W<6"_F>N?/&CSF7LV\92=:)B1#+5
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M[3V]-\[[:GQ8+#>B6:^7TWB\KF^SGQ>G5:T7+H*.*A-]H8:GR/F3VH.+1=>
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M)F<;2Y(A6MJ82#5T[\@J=%8(X-8F\BM09;%3M[/'**-=B1LW<70 Q32(5#J
MVRWQ-!^-\BY*B";7E&EO(7(I0'/NZ?BH3(P<RA5[VV43B2;^UWX,[@$BFRCH
MF]7J&/,D!245UE?"4,VYL&G#HC4PE"YIIM'KUF\C5]?OQ,7:4Y;;T-B7L7N#
MXALNIXM,VUBN&VF/&Z-$T&B-05J0Q450,C((+!?(U@O'LO32MA\1L==,EZ=\
MHS@()H<QN1NP7"9)K3XO[K#T-T<BAA7F>L/2];H1VD>D;:^F:SRK9/ZPH>PC
MIL67^>933F=AAIQ3,@;!"F7HZHT<7%8!LHPRUJ[MR;9^/!MZ3]W59QT"Y*X
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M!BL[U]+L)Y-.==0]4WSV5U$/?^C  X@&5%"/&Q7C(UK'Z*)4H8Y30*O!*V'
M.8N>!^FB;9TQ\21CB+8N\T_'WP@6FUMB]CS0@4GXZ2OB^LV\+)9'IY$V.DRA
MDG*: [AUVS/+BO&Z +=<UP$7A@Z1EY +68PL,\_\@ZAK3-/H?=4&@MD=]MB3
MBK"#UX'-'FH*_=8VDD&#(BJR.RL_66VD0U<%(!F\6L:L56I]S]Y!RKCF__
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MV@\%B,.AQBL<A!0UT+Y9%((;U7S\R_[4CNN>#(_40:77J6>Q6U.8E[@.T]F
M;6[.%WBZ/C>W;ND)!CN*(HKBM6UEG:?'N8"H T(QL<8F57:V=5/XX1K=O#L^
MBKA\7RY25C[AETU08&(E1E<GV@C+:G=.KB!(K,U,2B"35D77_ Z^DYANV\X\
M!@LW.G(U8?U/K90N?NNB!<]9NYW*AXNY2QL7+%SSP ;79@=3]G1JL"T3A]>?
MV=$YD<Y#TL* TC[23:\89/1!!!=1I9]G,&ZSWE$35E36&C,D@:(VZ!'@463
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M4S)=5]T_R99[Q9P&+*%VM"!M[W(*X%R62@3K9?-4A7WH_&F>Y1^#L&T-.;@
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MJGN_D+16IUL1B9O(2=4+7F_Y&NT(C@5 TM A>YX4ML;5/>1T&@MH ZI68N@
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MXSB,[8%3KS2-@3!?NRWW7AOM!LR3?!887G GA,X)450DG]#JI^1!2";!!Q/
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M7SV^3$\;R(7DK;M'161)&P)&.W30.4_HZ44"5!D;=+;<TMJ#J*ILO.VE7@/
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M-[@F@F]<=O1AN8@78?U^^2DMOR-_-SG@.D4JA6'@=<Z [FD&;YB @.P56IG
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MR$I&G1QAP&@Y[H4UX"G&*YQR4DRR0]/?+;EKG^5/H>E$+PPLCBJ045S*U[P
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M1Y;]*:/][D#MLXOUU\5R^C\I3JCBPAL72C]8=+V2Y^ X9WCZ&)X]C03#Q;&
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M1EKC!=YU$4)4@AB900=6;E^)!+-Y]HLI*T:S$X(=!WICJ&:K)O9N<-I#!B,
MU$>4"6[@Z]D\OD[?TVSQK="T=;6N:Z&"\((RAR$DXR!$T&#*#$_EB&">&=Q7
M;5AUV-8HP;4/"!Y6 U65R A ]H\T3\LR6#B>Q?/I?%I<CU(6?Y<H[@4C*0E@
ME*).VE0&]XCR+,N,R3(51Z4RS#IMK&WZ]W! JR^5$4"MPDV&8<)*G2PX;B.(
MG"5X[5-I(RJ%EIPX.9JWAE][E9^=0%>$0_R\(\M^!&@_FVW^3HJ/D[[59#PN
M3$@T2?1VI 019"EFQFBOI.$R;;5WN3:BN^WLY O%>N'E?A./^L([J2O-JV?N
MDC<RG7\Y6ZTNSJ_>O:O?9CZWT' 7F;U(',<=9J3H15#O :%KT !G!<Z1 ,%1
M;E*D.O+:UQ<OY0[3!95CMAXTCQ:]<AZ@=)P&SBPW(9B2"O[S#G. .\P^F!WN
M#K./^%O/OBHD;2Y"<FF*[ZF +!@>8#P:\-%)<!%]+9$==TETP>QSLZVN%WPI
M]Y&]A+TXE/-C@,LV'I3&>9$Q%.2\-#H1EH/3^$,*WAM/2D5+IU?V+H!I/IUJ
M/V'=%_<>G&LL\-^F\U+>O=VX5Y(*P3@8X4HW,.\ F>%+:R1-(T?C2VM,6[RS
M:&.A[R.R10W^M1;\55W_=>LA9;44*H-*I4;"\\W@40QV-)JZ%(.WK(K@;R_:
MYB*CFN#WYM\(;A,JQ,-1"QLXH4 $R2"DPU X"04YJIQ9)CSKVAD0/^_.#O%)
M&LG^E-'^UDV7F\E3MP+Z<EE3&KB]GGZ?1HSB/V+8,N%9$89,AVQ5F>%-$GAO
M(RAM.&%2QCB>B^2N1)W\C5TOE-92DD$@\U)UZ,\%!OW3V71]N6&)XB(@]0$%
M1C&X=P&/8I\=6*=0A(XGE493N]N=K)/O*34Z/3H -B]-DSY.5_]\NTSI71FD
MG%;K*]/"HPAH1X!9GT!DD\%K%P"]4!D]>@R9=KKI::5'CQ%U\EVM1J-%!T-F
M+#JT3QG!4V;E<UJ>TTD./#,>"+C,"<J)43#64@B*X'\CXQC9CZ6VY%EJ3K[E
MU<%:TQXD>ZO+][3TBS;E)U>OF0Y=U8<-J\_"&OW8]>4PI2A]5AZX+&5O)HSC
M>9>YX"EE B(I%UO<HT>D5(:8R]L9(M30G\^[CU^OE*M:*UB Q$K.L"4:C,.?
M.18CE8;Q2*LW=?OYO-L3L\,][_81_PB<H;NS7)+TQAD3@.4@RDTT'DV*,_ A
M1TF<MI37QF[_H4TG\.S;"P1/#FWJ(Y$1P&E_QCTQ-,-3B4Z2\:7I5HDOM 7K
MA8-L*?-*:BK%T4/2$Q_:U M6QQC:U$?&(\#YT[-8>.92H+\*63$,/$2I;X](
MFPR.F.R<"6Q\@W1.:Y!3+[ST&J331W@C0.*= <B)QZ"$C<",C"#PH,&]QP@Z
MVA09%4E5OW_H/5K\!%Y(#SF^]Y;'B+"TU3%#B$^4HQ*P\LJD;0#G\9"028>8
MO5?4UPX"QW1B[B_)IT>+]V%K\SD73\VG56@EDY,*5)#%4D8#CA ,O93S!G]%
M@CO2G-]C#0SO);K.<W[[\'$$5J+"S2SE3B5K";!2CBKPR ;OO8"<+0].!>_\
M(/?DP^?_G,#HMD-.MR/+_I31_K E[L?%;/9VL2Q_.#%1B6!)!E):8 FC2ZDL
M\B.S2#,ZFD+2T63 /4G)R&.+RG@<KE_RON!X62JR[6$;D\XQ8C@G I<@G#$H
MDYR!.;1.-F23\V@&HQS4B']\BE$1F8,WY^\#D[WUY-NF9>"GM5NN1Z$M_\"_
MN%[=#(ZA1$B6LX?HC2PSV 588QR0I#FG)E&J:\]9J4O!B::XC5=/#@#(& Z3
M3:2T&8[T^N+'7+T-Q:M;3^NKZXD"<>(U34HG#33+,K?&^C)RSR)P(X])<!=X
M]8ZNO7=YHCEH \)\6$'WA[*]@O(\?2FOS:.P]<CGG*;KBS(O[*9WK8X^)Q'!
M:&[*TPV&;R@#D-0FR22A:71#BAXAXT23R\9K]0^%RHO0EQ^-GG\P(6N?11 $
MN$@>G43+P"5B,-QST69G<F1CBR4>(>-$1RV.5U\.A<JA^O)YQ.$W48P:HBP0
MJBC:#9+ X/$*Q 0BDM.2Y-%,(3HH_![?K,?Q*LQA,#DP_'XS'\L!L_%%RSWZ
ME@DI.66#X< L%2"D4N!*!RXT')E'DA5Q8W/''A!QHC,CQZLKA\%D#%'X@0SX
M<S.1[&P>;TH?%N6W'MH0QT2RB5B@QB%?E)#@<^:@G XZV\2Y'=M1TY6V$YTD
M.5ZM&@14+T#9;H5^5\RY[]@^-8OS)GV>H-.;!1[D3I8J/N\C6"X))&ND+W&D
M,:,I_*Q)^(G>/X_C ?/XT'L!^MIY2FXT&@V6!&E*HFOV9596X. %%\913X,:
M9%+9\*2=]MMH ]"WFM/< X&G\\"Z,S_JT0>T)QFD3)8NH3-/DT#;6ZIZ3686
MO%,R\5S85#M%]HCDG>C1>#IJV@B)IW"&/L>::^J[<<>R0#1#\Y4,9253Q)7>
MZP%X$BRDX 011^^Q597"TWY>?@&J.AP>7X*V/O(Z^21_2N,.'HU!AK R)E8*
M<"6"=YQ)&XFC;$0EG_O1>-HOX"] 8X?$Y$O0V9Y"G1BK4E;9@?;% S$V 8I/
M _,V,$F9U3J.36=[TGC:K_ O0&>'Q.0IZ&REN%Y08P6+#$P@18;2@TTB08B:
M,>5RD'PT]5<#W"R-]MG_!#2T 0)?7N[ DZRATGB'^@.<BP""D !.*0N9&D(%
MB8+Q$6<4'*R<H\TS.'WE' *!+^#4?/Y=^4EN)>.0*=E#(-F"4%:#=]2!S\&*
MS)/QQ[];&I3BTTYL.'TU/B)>7X!VG\4X+3]QLQ_]!6\U#=0AR\ \9$/+Q*8R
M$T[Q!%X:=$6,#M:-+?_H28).]!YX'-D,]: R%KWQSS/#]_;D/Z;2# 5__]5B
MOF'-A9N5UL9L$KUU7!$'G#@-PC&T*L1PM(\A(XF$>CY(5X/CDGG:V0L505ZK
M9_:1$/<"E'*W![^+172"_@AG+&APZ).@-X\NO?$J0>+:"OP?EV:0 JCCDGG:
MN0KC5<JA$?<"E+*W/[Z;<R8I@48L 0U4@D@D@PG4@/0B!JELQ(A\9+I:C_H3
M]5U'K\*-\#D6S:YSF_T..3&=KZ9A,]QC8J)@1$H'T9?9(HQ;\%QED,02)A7A
MQH\M;MQ)S&EG(@RL=\W1,Q8UJN-#W&4$G7BOO X:@_PL&;H*+H+S)D).- 7K
M8\YBD/9%@U!SVND!XSW *N%G+)HTZ-7OV9<ORTV'@7LF1UA+@O<:O"$H/X:!
MLDV1EQ]LMIX[ZL+(#JR]B3WM)(#Q'FC'0=\IJ^F;?UU,UY?OYBBLBTT^T_OU
MU[3\_-7-MRS\?3'_ON'B[:+:K(A%.X7N@+(&C5BDX"SZ!$GF&+BQ),<T%MW<
MB\(3]3 ;OTH,#Z:_AZIMJ\*-TSJPXB!HORE=#V C0Z<[T!@5+99H-"V7^Q)W
MHD\21T#X\95Q#[B=3NWDWNRYUY4T:4V<0_%EX7CIWXL>#(L! I&,^!@3^C(G
MHXPOHJ'M2]+% \!6<>)N S5$&5VQX &+?G11M2PKX16%F!GZ,O@+\,I8,%E[
MESF7+H\F$NQ SXF^&IR0NM4&U6FW&GU6<-L$PQ1O[$]PS,ID(WA'- BM##CN
M)*A@#-%*$,M&T\BC/WDG&MR=D (.#+D7KH_W'7/G6-;!9(B.*W3,?0;G2 )M
M4I!HKK0DI^-Z[A,'CN\%XB7IXB%P._5*I^[,N9=QL''87Z,Q>>NFR\V5\6U!
M4V%*_8E'USTC"SGAX%3(P)4V/D1BC!E-N>(P+#A1O3Z9"]3!X/CWN&%]EGV3
MP#2-2D8P4@40,N5BJQVP((G=1 A:O4 5?O'WLL,IS@B-0"\4_^WN=)]G'^4V
M.VLY**T(RG_S"BPP1B&$>8W'0PI'[Q!R+.)?_*WP"[ $0^+Y13L"5XDAW1EG
M74XB.0N1E&[X5%KPU 50))O,I'/*G,Z%6$_B7_Q]]0LP!$/B^44;@EO%]<]S
MC5C.3(@2!-$9 6 H.(_>5,S)\62#HF8THTNK4O[B;\Q?@ D8#,DO6O][Q%**
M*46MSV"]21A+T0Q>4@9$6<*55=8J>C+:7_E&8'PW>7\KW1\(Q6.YW7]R\.ZC
M3)V89"5:,J2+$Y23312,0WO'B!>"48QV9/7<R?[;/-&\_TJWY .+=03GUH?E
M(J045V^1]X]/B-::6D<X!<M80*."I['+J)-1&V=US)*[VH?*LYLZT:YW=5!9
M5V0CP."A-31][YAB8,3Q&(%'E( P!-DC/(-0:MLD8X+;T62M#W@S.KYV<HW?
M-H\ IQ>@;0^F,GQ>K-WL7G&:=#IGE0,H)C!Z$\: =92#DCH(HK2D>GP3PI^G
MJY->V9]Z=1S@C$69_/,\\4^6?UXSY,:FT G/3/&4*5 G2A0G'5B>!22J Y-$
M!,8&>=P?@)9N#_;D)6M-:X2,0%/>G'^;+2Y3^I26WZ<A/2Z5FUN"#0=6&P-Q
M^\]?+5;KWQ?K_T[KCRDLOLRG_X/>+J$V<!(U*%X:Z$1!P"4;T-OUE@A!C**U
M[[P'(Z:;KHPONZ6.KHP#(R]96;969+'<_E;Y>W22DY3&J7C54DY8'\#;;"!*
M$X3T63%6.QGTN!1V4ZOQI8J,7*T.1],(=.UH)9/,>L,386"2H2"DM( R]6!5
MTA@P\FS#:(H$AZC/I>/+P!A[,O4!"!J!9@UF=WY\Z>H?W6?;Q%-%D@P1 \A2
MJB4\2M,("C$H*B@G)(B3.=">([:;[HTO]6'D9UM5C+UD97S<"5 I<!US+$WD
M0IF=+,%K:E!OJ,EHQ!P['0U\PJ7\?__C@=8AKO^Y^:/-GQ0I?DSY_RG__\?'
M=S?R/G>H9%_2?!I6_RLLSJ^D_6Z./TV?W5_I5L>R=_.\6)YO/OTZK=UTMKJ+
MJM44Z;[7R^K\R_RO#8,H_G?#I*Z?_H\?6[]/U':%.]:C'AGIKW6:1XR #X/Y
MS=H_&KW=]'E3S!M)DP%+5+$S)N+)65(,5$PBQVC1<ZV,R2>V<ZA"O_^6RI2=
M^9=?%ZO5*[=<7N:K#)#5Y]+5<<(##YG3!!JU#81AZ"P(%C "=CE3)ZC0MC*U
MSVRI;>5.+63</X%JRF$$Y\0-F\XNUE\72_1/S_Z:KB8Y>A>M5F"4*%2(,IPI
M,] >#V]/I44[/Y3NW-E)6Q!5%?:B.N='B9_7B]+Z?$*],5H% SZBER2L8^ M
M21!RSBPJ[Y2M_:*Q:R\C,40'R/E9Z.S!](;@*?[*!+>,GMDTW";#S4O5WCKA
M__^*_WKVOR^6TU6<AB*KWU)I!G#UXT2;D"B::N!:Z#+\%(/DK#A@1&&I348Z
MKY_SD0[>Q=APM0\(%BTD,@*[=4WKJ\7%?+V\W!+AA L2-P0Q^XRLRPZ<\^@G
M!(*!J7$8Y-1.?GMT(VU+':LBJQ[#1X :Y,E5=+@QX=)P[F@H&(\>37C$T]\+
MM.A"9?R?BI+7/N+N;* M2H;TC?;G\YA LM4:%8T5/%*PDJ-EY#: 3[A]I9E,
ME!OAJW=+NK>%M@?5 <+<!8L].-O:W<&]_W=R2Q25_+Q@A.NM!>2&.2,] \$L
M6L"D+/A,!&3NHG,D:FY])T]FQP(CD?T^$EM49E]K"+R;QY2G\^DZ;3=/G#6$
M.@TTV])5E183:15H$3(+(N >62?9W_]RVY.AFM /8EA#::^6Z\G'\B"RL7@J
M:29BTJ#1>P(12QMKZ1TZRMY;;[5X$*L\;O_QJ[=L/_[JA]V_LV#;\O@AW(+]
M^3D&$%QCE\6D1$IEQTAXXAZ,SA1<>552E.3DJL&@I>D_0%CWQ;T'YQH+_#>T
M5N<7Y]N-"T8QOO$1J&<23RA)\'!R"2S5D=E A2*=TN*?$?F=11L+?1^1+6KP
MK[7@W5^W-\Z92@S/J=)$$P3AO)Q3$93E-%JE:1)5!'][T39G?C7![\V_$41\
M-Q<F;_YRY]/Y]1/J-M_!.YZ$5QRDC*7'D53@=:+HO@@?/)5.R-H]NY[<4-O>
M&4=Y4CE8#B, U:N+9>'G+9I*UD+Z)<W1)UY/O+0^)>4@>(_4H-XAG\H43(D>
MM8U<J) KH^KI'8WD-OQPT2\&D\,(4/5ZNVRYW5VMTGJU6Q\_7?C_F\+Z\P(I
MGBZORMU5UM$I-,S96&0?HQS*P#P0E@N,P%S0IO:5YV$['LE->G54'E&.(T M
M4OD*5YVN;Q-V=EZ>$B8JX"'AHH$<M2^I9ZB 5.+/DA2,<*6M&^ 6?M=VV@;?
MP^&ME@1& *8_YLN;7#\D:VO(5Y^_NO5_+2YF\=WY-Q?6;W)&I9E^+]S\Z-;%
M,5$8>W *1CE4%)']5<4#(]I81M'<5Y^SO-].V_IWPT'P"'(;+SIOV/HAS=UL
M/4VKLWE\-\=UTVJ]=4DFRB@JRA1TE3%B$B0QL$('\#&SK#.WL?J$X@.VV[:/
MU]%Q6EV"U< Z6%9SR;1>S$NERR*OOZ;R2S>_7#WP77Z=.C^=30M/ZN0\'[!P
MY8SH6BPX0KYT<M2&6)HOB"Q!2%/&;1H.VLGLB%9<Q-H1Y8#YTC\8_SX_X/8-
MS5GZF%3,P"TQZ/T2U#>F#'CJ*:4\BTQKSXWNM+&1!-,'HN1!*%U=)B,XL'M$
M8M<Y4).(#'0F:#!<HD^2B -C#$5.4I*%S\''VK[D'MML"\(!P+)_#+V7Y$X+
MG)LTS[-MFN>$ZEQ*NB1PEG-)YW3@5-200R1):!)-]3: ^^ZU[17/J&"ZOPS'
MB-5'[QQ6'U&^N,^ODY1Y3(:5C-&,/&4&E5*&C#2BETX3T]'7KE'IN<6VET$-
MD%E18J<#R$VI\(00*4-B 6B*95B]M6!$,D7CD@C>.NIJ>Y)]]M?V4F@T4.PO
MJ]9)@T]8_^1P@1]QXR19$[Q"UYP*EY"L7#2KF'_)>/2!2ION7?_L*HKIO&;;
M.YSA8#4DZ\=HV:Y_XRKRF^#^E0I$@8^NM&5$FHRS'!)-QK&8A:G>K/R9+;5M
M3-[ ?AT@D=8FZU/:E(=1+>Y3-=%9*ZJYAB"$!$$I 6,U!ZZY0.JD,Z:;B=J]
M1MMFX0.;I$JL':,)*M=-V]_;WH;?Z3 SC]<7Z8]W^BB=/":!&BFI(9"R*N^/
M!J/SC%YF"A9=3^*M"(-'K17H:-O/NXVS=E39CQ'_5ZXIC88;YQ1$BPHLLA/@
MT?0#,R)*:H,D8?@$F\X!PV"]KUO<JO3F_QA1](_E8K6:&*9#U-: S*%,A. ,
M3!06K,DT4(*_:6HW@WE\)XV;03> 47\![ ^CTLUJ&!B5IM-78IK-%O]V\Y F
M/ I)97 H>C2M0FBD)J*[P0TCSC,FM:S=X[_#MAIW4&X L -%TQ]M]@IM\_3%
MK5.= 5H/B/H='=A 2A,FC=N.16>$%25EQP,E+*!)#D[9VB-M']M'X^;!#1#5
ME_DC,%@[N'3K2N:&55(ZZEV@D!,7(!C2Z$IMBLG>>2=*$5KMUH3==S>2].3C
MO/,?*IW6]QJ/DW+W4O!C&1_T/O^Q2E>Z-:&"1;3%%./P:$%$J\![--"*<Y<-
M42;Z>]4_SU_*=EY]E"_X!\-@QQWM,#(9VWEYB\H/R_3-3:\C9G0ZA51&2P&$
M2[X=!4H,!6413<A<3O2 #Z*[-S;*!_I:*!Q.1*-"WLU1<>?5(RI%*,$X69:>
M7YD%,-1D<,E;%24>''(HP#VVGU$^MP^%LX,%<BB\/@\7?=XBJ?BFFG-F(HU
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ME-+EJ:0>G290@_0K94O5)$*'!#P*!CXLDGS6N*PUINB<F::NC\\X/ K_8-<
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M#-KVT;,M50QVZT*&*=#RCZPJU<Y%LN["EF5/W^K>>U_GC8 'K]_470M1*@P
M>3#^X"ON[.MM%_CE4L)SXQO7Q>_;/ T>+O"87?<2">\M?NS_%QKQ'*1E-BW"
MB9"JO(YH]V:^?6)Q4$R0J\<=-/P$!)?OXR>P.W$_6+L>S2A]OPSAY>ZKS;5D
MD/?%$=81V\LX0K.%_9T)=Z-JO&4#J?R,X=2(E]0:TWJO9Q(CJOS+SI\EX *E
M0&+73==' 1W7 Y?=:!U_8[!,$NG4J[%6/,8BVQLN4\]9?!?,=N+I "\F<",Y
M5(4H7,EDU;6!'J BRTH3W]O?XMM;^\\IY;5Y:1\O>9VTJKI<I]+R*5SZ/<*E
M#TI7_5$VP#K&_CX=VGFI2AU9&JEUP_MRPCV DJDK*X8!7US/$;*HK8MO97-B
M4B]N:QL<QE,*F=FN+S%:\A/GH;-LW;HIOLK#*^8R:*I@7A4)36^Z#R-\^3(7
MAPV,5)URJS6$TS="? X'=?DT;8/=_IQ7[H8Z7<9X'-,VG65<.Q-@!)4,&HZ
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MGB+</!,>DX%<JI;O*!;0;%TX; I]C^U>\7!?,9_6@OQVYO1H@\L_*H/G#L[
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ME]YGJG>^D=ZNOP/]7C?+]5U$H+< X/$?94S1TOX208]Y?X\Q7^8W/)7QH+\
M2.E<J?X"H,=.CC)W62@8BNHM%&1_[9T^*_TN/Z._C*_7O@XG]V4Q[R\".-$/
M,-@H")3NBA"4&X?%QJW@WJX^5YL]X6VC:@!5H_1W^3W6@BAMK+>KKYL_]18$
M/0YT/J6V]%CYY7F/7=T]3FYY<OA:JZ^WZW_R]UI_;]CYLBJ)<L43/*O./*32
MH>J<02J#RD4DC.':U7A4M0_VV,6Z-+,J+*("B.#5CZ/FX&7G:@[.SMGHXZ>3
MT04VH&;G[]GYU7\.+]C%\./PW6AXN3[45[?1>6HZ] C.:%F/6YPI/+KHFJJ,
M.'5UI)K.H'H32Q]SU2CLTG73 6[H46R>12U-L4.+S'W-9UV_2.559L!BGL$.
MFKJ8B>04PTY:,77/#HK+?&EX0BUF>(*' <)+##77H.-(JLXC"Y5/7$LJF\83
M(K!]+E6"-0YXJFK:[&2JU@VKNS+4)6JQ$K;7ZQ0 00<CA?.V)RK8<V.#VO;(
M]^US3')QUDLZT+:KM8-"\15'8#2/(;!=S6Q!6A[__-/AT1M;,TZU9NZF2-[(
M%)DZMGK$PRVZ<0+\)N@AW&5)=?W(@\..B^W.;[[OS/.]0U]V>\GUF.?"[)Q_
M2<4<C]3%*P=[>P<=/4ST\OQ_</[=ZO3BSZO<:!5\=0)NLYQS63N*TXD4R;+6
M^U@[3M?JPP[#:ZYVW'*)1CEIP'.G56F[I^'JQ.Y:PW.]KVN:'[C&2ZXAHOM"
M_9<&-0L.>@0%33NJRM+&(=QTR#AUD%5ZR77L \YC-74MII!1TU?;OLR?H&(9
M).P3@1+^;[:'';")FHD;>QP[+Y;!I'7B]>(Q0;Y.N'2Z*1V;O<9(CA*\["%M
M]WOL"0WT/3:&N8,"N?$=F:MFZ2"Y4CY[M'7\1YU3Q2]_/ST=7EZ>7]Q!Z^ZP
M+GBU0$6 76/I6_S$H757JU[+.D[!S0//)IT]&6+I10D#[.^]V]D/B:?5S&^A
M<S&U5Y/:5=\#&]423_;&W^ _07Q7X<>@'8G22U3-J3V;FKC"XSTWZ57GR 5L
MU/_^?70Q?,?>CWX;G7WX_U'-A@ZU9,&?S2JJR]N5PU=LQIDJ.OB>R-8>HFYN
M[9E3Z3DM:=+H,6@:5TG3'9[>@8">/ X_RN.P%J1OI3)LUB+TO1/9<M[U\>3T
MXOS#\&QT>CE@H[.[X%AGUK"BWTUPHD:S\/P!+>V]TM0JI[9U3J+/N9JE(K[&
ME7UGCK 1:;!FLQ3;\Y5: V&C(6HUC*JZ/2^T@HH[PF'$>,;&"FX'!FI=:W5;
M6SO41QYI]4'D,@)-!G!H=U7CI 5$&@0V@?/M#ZJSAK!_+NA69$*(P,:@+K"9
MBFV#M 7#C&WAG#KIL[C/M@UW.KI^&[?(JKHWKN^5[8>)+9WPY+L<VSV*8H:G
M(^-M09LZ:O M=&;\4Z&_KK;%59*0_EH4]BBI6\Q#$O*+2-3=?71*3!<VLO9Y
M$*$Z3P<1R\)&+1R4/*@[)BL=;EYP!!AZ)68:.\2WCJ=8&!$=*72<=M6OO.I@
MCB<06_>*[Q.>B4%S@@&66=WP&BVT.[7Q[0Z+#6G+GC]==3:L.N6[DZD7P+@*
M>H,F^.R1?F/A.Y%;\/KVJR)NMTR=MLX7] QX9 ]$K@X$++Q*[IS_C:!JT!Z<
MO$-!%_3 *JXF80]:&+&DU'6OW%O$#.+:+=ULK?3!< VH\C..XH7Z]R'DR26Y
MO-/M8.U6MV)YI]OO;2YTPE1<SME.<(=L>_U:/Q+Q'<]$^S8H=!=V:\8E>>:.
M5-A<*,I"(P8]RS:V/2:.C7<UW0!W_O,0-^0*&<FCW9&'N2?UN2,]WY(?R2/O
MX:F'XQ;[9:SB.?PW*;+TU_\#4$L#!!0    ( '* 9UA18'3'&00  .T@   ;
M    ;6=N>&5X:&EB:70R,RTQ,C R,S$P>&LN:'1M[5IM<^(V$/[>7[$ETUQO
M!A-+?N/MF+DC)&6:$(9P3?NI(VPYJ#&2*XFD]-=7MH%+#IB2FYLC7."#!T?:
MU3[[[.-X=FF.]21I-<>41*T?FC]:%IR*<#JA7$,H*=$T@JEB_!9N(JKNP++F
MN]HBG4EV.]: ;>S"C9!W[)X4ZYKIA+86?IHGQ7WS)#^D.1+1K-6,V#VPZ%V)
MA7'DNU'L80\%KATYH[B***G62!"Z;D"\/U')F)KMA8W2LX2^*TT8M\8T.[_N
MXDK@I;KQP"(]KB/;_JF4;VTU8\&U.4\:^^)KX6;%F:;_:(LD[);7<TBEPG2Q
M'(I$R/J1G7\:V8H5DPE+9O4W0S:A"GKT 09B0OB;LB)<68I*%A<;%?N7FIA,
M>/GMPSQDXR=AG"X@()P%W?G]E^Z'[A"P4T%/(WX,G,A;@UV+U%@9MX]B#TVR
MJ2QMQ+WJ922T%I.Z8_QLZ_=;)Z5]U;ON](9P=0;=WFFGWS$7<SOHG'>OAYU!
MYQ3Z'S]<=-OPOMV^^M@;=GOG<-8=7'XY]!T!O:$0"JXRX6D!>DR!\5#(5$BB
MF> PFH&D,964A]E2OB,622(>,G4.Z"U3>K[U6AO=9M)3QT=>M;%]*KXZ=+P5
M].,CY-N;PTQ)%!F,5D)C77?\I\7YUU1I%L^*/S$>&=1U"U5W02/"!@NJ+'!\
M^],;3S*%[(J7I6%]:<#/9T).X-JJ0D]4P'$<"]4P#H*WD%*I">-96<TK$9NH
MC:D([^ JS?T0'D&79T\&=D^AGQ!>7NQTH//WE.G9RGIF@VVT81U$#)<DE.*<
M<A:J<K9<*7\?18'WI"C4FJK(_KT']OJJ>(U<.GO-9:V*\('+!9?N/G.) A\?
M=+GDTMMG+K'C5P^Z7'+I[S.7CHUK!RZ77 9[S66 \(8WXM?(976?N?0<SS[H
M<LEE;9^Y]''-/^CR4]/!?C%D>L]L.N# ]ORO(DOX3KA\.1VD9W.)7*?J;^#2
MA\XD3<2,TGDGJ3^5X9BH5Z#.E]/^>;XZL>NA]8SBYZF3\&C+1G3-P-H7@O/^
M-=I93\@<_R4$.X\(]AS7>;N6L^WIVE'>3=!B*D'25$CSGA#ET\I+8AXKQ40A
M*.?#R3(\,#TVVU1*P^5T)1NVB(051C'CA(>,) ;"\KUC74[R)G9F3N/8.#,U
MSZG*M[)L2,:-!^-82Y& N*?RD>,BRDQ!:_TR'B;3R(22CW:8@O><3XW9(#>;
M,X=LZ]?U7$$L9![7C!()E&>>X)2&=#*BLLB&@_)T.-OR^OEH;'?Z.CYR@X;*
MK]"17.D"T/&14VW 'V)J<GIQT=^[B=]PIDP-EN$WED7#R [G=-L%O"JMC2%_
M-IM/A6+9LZ@N:4(RU:Q,ZQ>&<Y#V)Q,R,CJ=ZE63_QGPSZ_%SPU.\I\Y_ =0
M2P,$%     @ <H!G6*&1>96>!P  ;B4  !L   !M9VYX97AH:6)I=#,Q+3$R
M,#(S,3!X:RYH=&WM6FUSV[@1_MY?@=K3G#-#R:)>_"(YGLF=T]9SDS:39N;Z
MK0.12Q%CDN !I&3UU_?!@M2+95^4)HUUGF8FLB@L%HO=!\\N %ZE59Y=7Z4D
MX^L_7/VQTQ$W.JIS*BH1&9(5Q:*VJIB)7V*R=Z+3::1^TN72J%E:B7ZO/Q2_
M:'.GYM*W5ZK*Z+K5<W7JGZ].>9"KJ8Z7UU>QF@L5OSE29Z-^TC\?GI_USWI#
M&DEY.>T-AY<#ZA%1+QG\*SQ"5XC[/K9:9O3F*%=%)R4W_GC8[YZ/RFJR4'&5
MCL->[T]'+'I]E>BBPG@&_?U7KV9'647W54=F:E:,>4I'OFO;'.E,F_%QC_]-
M7$LGD;G*EN,?/JF<K/@;+<1'G<OBA\#*PG8L&95X0:O^3; )YO'CHC$9>C)5
M4#N%L.^,?O?/O][^>/M)#,)NN&WQYL2EF6'N4UU5.A]?EL]E[&T@_A'!"/&S
MID+- A&1J52R%%4JJU?'HXO)_E.8E#*.@;%.1DDU/N_C%PZ)*F+@9]P9G#W;
M-,-N.XWO/_JV6_H7W9%SPZU(Y9R$H;FB!59GE2HKWA9%+3/QD4IM*J$+\6=M
M<A'V.C^+1!O(D"AA@HX%P:>QN*&(\BF95\?A66\R" .WB@=")^*]C(S^"T(:
MV4#<%E$7L;Q\&;'L'UPL?Y06P4"X\J6X*_0BHWA&@0^I\;&,-4PH--@8(TA5
M"%DL15U4IB;, /S,5(W 29'CR2C ()$1?C)"YZH2E?9R.P(%,&"M-$LGDLL[
M8IBL=%K\%L,8#)DQSV,,)Q I UZ'6('NL"0F(Q:IBE)A:_>Q[K\@0XT2-X%<
MV0P)P.62A:I23-"6%+&!&_B,]!S=8C%=;KKAY8!P\/L!(8E$%0BS0\PZK $0
M"'$TFXUV58!G@"\%/:J(LMJQ#*"S$<, L%,F6XH2D7>@=6#.LC4J&T#8!T,#
M^+%RB@,G46<0 !0U\,+#6;8GDC852:87ML6IH9FRE9$82+H?O=VP,MB FVV-
MV;'VY2!N>'"(^[05GE?'%_WP?&(;3#5UA*,)G20*CQRX6R$-,400<C7-B!,;
M 9?33-G4B3NQ'!3I:-(]Q\I&F;8U^CGR-#KS6"F-CBC&SU:< !HQ 6L^_N_N
MHU06,Q)OP4L?ZPP2X4!VPM$)O>:NX2CV3_X18Y$I/$:=?N'(:P.Z'DK.EKT'
M2K8&2C!0F\ W 0T)5P5\59T5]L\."*7R<%!ZV>V=.S_<D,66  'CQ/9Y- 4N
MYT:RMOMW<<EO2D!&,Y)/I[HV4 "&FBO+O <I*EB/JZ[7C+G)NH8RR5!K\ND:
M+D'#R*Y1@3UAB]69BGES9^NI5;&21KD)*)_U.0\43E-M72;FE6DY;3-+:DLP
M"-LZ[E1*8#RJ,^G('=-B(]89'3U\?;!9UN#;E)P@^!?]*?XJOCTL*$\/!\H-
MX6XC>6_6V@'T_GRW-ZZQ%N8J=G"55A?2$;NT@+HK+QV&I8E;/ 'A2DY5IJJE
M2_*/#>M6%T./4>47QI;H1GG*^>.^F5!9FQ*HMER41)$V,1O A>J,"M0:&<"-
M%BK=JG$B*,(]@+&Z5 D*?T$0C@X'PBT;OYO+K&;*<@&F)$&IJ.8(C7VDY%O5
M%'M0L']\O IDR*(CZ-/Z6G.JZ^II"_9)$G(E3:Z03CZ_^Q'3MD3G54C>$["'
M$><&>!FHBP\'=2UQ^GCNXL+MPIL2CEL>!=\7T*5+ZSJ*:N.BOY%#']&::UOA
M]\AMH1+8!T6_UDC!4'WR1)<$, :1/9!N#,?6B?@ P9TM\#&2M^NUMRJ5=E5P
M. IDV%/,N8']T?#V4F3JCK+F-.&!?/#5+OIJJ!_4GFQT<$C_[_9D?!09MXLD
M6!.5X\U-H*XYRT'M"RJ0G6IV99I$15MI8U=)GW^ RCQ7547T&UEAJE%6N/98
MP3Y6<@(X@X2M(WG\=75UNP;IUUK!?%YO=1'QH</K_V^]_I?)_FV&4@VEHP+8
MW(;7;9TC14!'D[!76Z %R3N7@7WIQCF8BTX^_VS/B+X(<\UNQ1\W/$)N,D9'
M2RMN>Q*?3:F*+@ 9*LK EP$6-8"M<T $7N+)-#GET=.T%Y;B#V]O]!:9/#'@
MC@"!)Z8[0(</K!N,!3X1JF*NLSFY;%C(67/N;AJ&I+S,])+0NDBUIT6YA6 @
M[IN4"MTG<; ;=<2XXAU5(S$%",ETX.U,EI;&[9<)&+S,Y'*L"O89=YILX\K=
ML,Y=&D %T=R5,J9\<W/Y>C[HC@87[OZU,O@?MP,W5[-=OIH]K>+=MF&OVQL-
MGFSN=<,GVWY+;=CO#L.+;ZYV..SV^Y=[J3UE3WAOP-^VE,6;H\'1@Z"->R+D
M>+7ZOHUHO[QWPI.-"VZ'CIU ZO+[TP'?T[\Z'@+]_.FOD_V%I+]37B']V?S8
M+!CX9PQ9P:=FHO7*[\;)V_?T[[LWW4!\2/'G^1W\A3[T9+/Y>L?W]N4';.&5
MRZ*<N']*%27BW3U%M3L)$'_WQ?$.13^/K2<?_-$4TL>.B:\?O!*S0L ID_]S
MVLYUPHT[Z>$:VS/">VFBU'\]YY<5AO[AR6SXX.6@4EN^0QS[8_(Y[;PNM%[S
MG.]ZZRYRBH5?5[M=/O.&4?/IWW<ZY?>L_@-02P,$%     @ <H!G6&VM[H":
M!P  ["4  !L   !M9VYX97AH:6)I=#,Q+3(R,#(S,3!X:RYH=&W=6FUS&[<1
M_MY?@4I31YXA*1XIFA(E:\:)G53-I,VXGJ;?.KC#'@\5#K@ =Z397]\'P!U?
M1,F6[4S,R#.F>,3N8H%]\.P"N*NB+M7U54%<7/_IZL_]/GMMLJ8D7;/,$J])
ML,9)/6>_"'*WK-]OI;XSU<K*>5&ST7!TQGXQ]E8N>&RO9:WHNK-S=1J?KTY#
M)U>I$:OK*R$73(J71W+,^2@]/Q?\Q93.)EF6BF$^S*8B)9'0=$C_28Z@"O&H
MX^J5HI='I=3]@GS_L[/18#JIZLNE%'4Q2X;#OQP%T>NKW.@:_5GHQZ_1S+XQ
M;N>PEYJZ-N7L K9J>E_WN9)S/0N#/(K&.H7,*&-GQ\/P[]*W]'->2K6:??-.
MEN38WVG)WIJ2ZV]ZCFO7=V1E'@6=_!_!2W02'I?M(&!'24W=H)*1'\:;?__U
MYMN;=VR<#$:[8_B0]U_)V9L>^QOW]G[DUI)R/9:1K66^8G7!ZV?'D_/+QX_A
MLN)" '9]17D]FXZZF$@M *E9?_SBJXTS&73#^/U[WYV6T?E@XJ?AAA5\0<S2
M0M(2"[8NI&.OM&ZX8F^I,K9F1K/OC2U9,NS_R')C(4.L@@M&,,*<"O::,BI3
MLL^.DQ?#RW'2\PM[S$S.?N*9-3^0EAEB>J.S 6)Y\31B.3JX6'[+'8*!<)4K
M=JO-4I&84R^&U,98"@,7M %!HP<N->-ZQ1I=VX8P E!V8&\$CK,23U8"!CG/
M\)-EII0UJTV4VQ/0P(!SW*Z\2,EO*<!D;=/A-P%GT*4*U(\^O$ F+:@>8AKJ
M\$209<M"9@5SC?_8Z"_)4FO$#Z"43B$G^/2RE'6! ;J*LN#@%CXSLX":8.EJ
M>QJ>#@C'?QP0$LNE1I@]8C9A[0&!$$>SW6J7&CP#?$G8D3I3C6<90&<KACW
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M=6%W87)D9W)A;BYH=&U02P$"% ,4    " !R@&=8%P/!NN86  #?K   '@
M            @ %D*P  97AH:6)I=#$P.&5M<&QO>65E<W1O8VMO<'0N:'1M
M4$L! A0#%     @ <H!G6,WO$JJ"%0  _(\  !X              ( !AD(
M &5X:&EB:70Q,#EE;7!L;WEE97)S=6%W87)D+FAT;5!+ 0(4 Q0    ( '*
M9UBHUU]:N  # .1,&@ 1              "  418  !M9VYX+3(P,C,Q,C,Q
M+FAT;5!+ 0(4 Q0    ( '* 9U@.TN6>FA0  &O<   1              "
M 2M9 P!M9VYX+3(P,C,Q,C,Q+GAS9%!+ 0(4 Q0    ( '* 9U@8S8FJ7AH
M  +W   5              "  ?1M P!M9VYX+3(P,C,Q,C,Q7V-A;"YX;6Q0
M2P$"% ,4    " !R@&=8VB*LB'QB  #R>00 %0              @ &%B ,
M;6=N>"TR,#(S,3(S,5]D968N>&UL4$L! A0#%     @ <H!G6)39@4Y37A(
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M.3<M,6-L87=B86-K<&]L:6-Y+FAT;5!+ 0(4 Q0    ( '* 9UA18'3'&00
M .T@   ;              "  :=L*P!M9VYX97AH:6)I=#(S+3$R,#(S,3!X
M:RYH=&U02P$"% ,4    " !R@&=8H9%YE9X'  !N)0  &P
M@ 'Y<"L ;6=N>&5X:&EB:70S,2TQ,C R,S$P>&LN:'1M4$L! A0#%     @
M<H!G6&VM[H":!P  ["4  !L              ( !T'@K &UG;GAE>&AI8FET
M,S$M,C(P,C,Q,'AK+FAT;5!+ 0(4 Q0    ( '* 9UAZ-Y7\G0,  $0,   ;
M              "  :. *P!M9VYX97AH:6)I=#,R+3$R,#(S,3!X:RYH=&U0
M2P$"% ,4    " !R@&=8>W*4P:8#  "[#   &P              @ %YA"L
M;6=N>&5X:&EB:70S,BTR,C R,S$P>&LN:'1M4$L%!@     3 !, -P4  %B(
$*P    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>mgnx-20231231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:mgnx="http://macrogenics.com/20231231"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="mgnx-20231231.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <instant>2024-03-01</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">mgnx:JamesKarrelsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">mgnx:JamesKarrelsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">mgnx:JamesKarrelsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">mgnx:JeffreyPetersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">mgnx:JeffreyPetersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">mgnx:JeffreyPetersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromCollaborativeAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromCollaborativeAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromCollaborativeAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:ContractManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:ContractManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:ContractManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromRoyalityAgreementsMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromRoyalityAgreementsMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromRoyalityAgreementsMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromGovernmentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromGovernmentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromGovernmentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:ASDHealthcareAndOncologySupplyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:ProventionBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:ProventionBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:ZaiLabLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:ZaiLabLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:CardinalHealthIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:ASDHealthcareAndOncologySupplyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:ProventionBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mgnx:LaboratoryAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mgnx:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mgnx:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mgnx:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:InventoryValuationReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:InventoryValuationReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:InventoryValuationReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:InventoryValuationReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:InventoryValuationReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:InventoryValuationReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:InventoryValuationReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mgnx:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mgnx:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:SynaffixBVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:SynaffixBVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:SynaffixBVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:DRIHealthcareAcquisitionsLPDRIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-08</instant>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:DRIHealthcareAcquisitionsLPDRIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-08</startDate>
            <endDate>2023-03-08</endDate>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mgnx:UndesignatedPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mgnx:UndesignatedPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-31</instant>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-10-31</endDate>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-10-31</endDate>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-31</instant>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-10-31</endDate>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteClinicalSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteClinicalSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteClinicalSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteCommercialSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteCommercialSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteCommercialSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:GileadMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2022GileadCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:GileadMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2022GileadCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-14</startDate>
            <endDate>2022-10-14</endDate>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:GileadMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2022GileadCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:GileadMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2022GileadCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:GileadMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2022GileadCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:GileadMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2022GileadCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:GileadMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:GileadFirstResearchProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:GileadMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:GileadFirstResearchProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2021ZaiLabAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c-176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2021ZaiLabAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-15</instant>
        </period>
    </context>
    <context id="c-177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2021ZaiLabAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c-178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2021ZaiLabAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2021ZaiLabAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2021ZaiLabAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2021ZaiLabAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV3279Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ProventionLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-01</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="c-183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV3279Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ProventionLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-31</instant>
        </period>
    </context>
    <context id="c-184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:AssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-01</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="c-185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:AssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-31</instant>
        </period>
    </context>
    <context id="c-186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:AssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="c-187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-31</instant>
        </period>
    </context>
    <context id="c-188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-01</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="c-189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:AssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:AssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:AssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:AssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:DRIHealthcareAcquisitionsLPDRIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-31</instant>
        </period>
    </context>
    <context id="c-196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromCMOAgreementsMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="c-197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromCMOAgreementsMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromCMOAmendmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromCMOAmendmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromCMOAgreementsMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromCMOAgreementsMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromCMOAgreementsMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:ProventionBioCMOAgreeemntMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:ProventionBioCMOAgreeemntMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:TwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-05-18</instant>
        </period>
    </context>
    <context id="c-211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:TwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-01</startDate>
            <endDate>2017-05-31</endDate>
        </period>
    </context>
    <context id="c-212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-01</startDate>
            <endDate>2017-05-31</endDate>
        </period>
    </context>
    <context id="c-213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:TwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:StockIncentivePlan2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:StockIncentivePlan2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:StockIncentivePlan2023MemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="c-217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:StockIncentivePlan2023MemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:StockIncentivePlan2023MemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">mgnx:DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">mgnx:DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">mgnx:TaxYear2025To2037Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-237">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">mgnx:DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">mgnx:IndefiniteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-238">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>mgnx:Segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="performanceobligation">
        <measure>mgnx:performanceObligation</measure>
    </unit>
    <dei:AmendmentFlag contextRef="c-1" id="f-33">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-34">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-35">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-36">0001125345</dei:EntityCentralIndexKey>
    <ecd:TrdArrDuration contextRef="c-6" id="f-50">P494D</ecd:TrdArrDuration>
    <ecd:TrdArrDuration contextRef="c-9" id="f-51">P468D</ecd:TrdArrDuration>
    <dei:DocumentType contextRef="c-1" id="f-1">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="c-1" id="f-2">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-3">2023-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-4">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-5">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-6">001-36112</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-7">MACROGENICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-8">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-9">06-1591613</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-10">9704 Medical Center Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-11">Rockville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-12">MD</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-13">20850</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-14">301</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-15">251-5172</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-16">Common Stock, par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-17">MGNX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-18">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c-1" id="f-19">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c-1" id="f-20">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-21">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-22">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-23">Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-24">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-25">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="c-1" id="f-26">true</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="c-1" id="f-27">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="c-1" id="f-28">false</dei:EntityShellCompany>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-29">2023</dei:DocumentFiscalYearFocus>
    <dei:EntityPublicFloat contextRef="c-2" decimals="-5" id="f-30" unitRef="usd">322500000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-31" unitRef="shares">62432013</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="c-1" id="f-32">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Portions of MacroGenics, Inc.'s definitive proxy statement for the 2024 annual meeting of stockholders are incorporated by reference into Part III of this Annual Report.&lt;/span&gt;&lt;/div&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c-4" id="f-37">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c-4" id="f-38">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c-4" id="f-39">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:MtrlTermsOfTrdArrTextBlock contextRef="c-5" id="f-40">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;James Karrels, Senior Vice President and Chief Financial Officer, adopted a new trading plan on December 8, 2023 (with the first trade possible under the new plan no sooner than April 16, 2024).  The trading plan will be effective until April 15, 2025 and covers the potential sale of up to 490,000 shares of common stock. (1)&lt;/span&gt;</ecd:MtrlTermsOfTrdArrTextBlock>
    <ecd:TrdArrIndName contextRef="c-6" id="f-41">James Karrels</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle contextRef="c-6" id="f-42">Senior Vice President and Chief Financial Officer</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-6" id="f-43">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrSecuritiesAggAvailAmt contextRef="c-7" decimals="INF" id="f-44" unitRef="shares">490000</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:MtrlTermsOfTrdArrTextBlock contextRef="c-8" id="f-45">Jeffrey Peters, Senior Vice President and General Counsel, adopted a new trading plan on December 8, 2023 (with the first trade possible under the new plan no sooner than April 4, 2024).  The trading plan will be effective until March 20, 2025 and covers the potential sale of up to 370,842 shares of common stock.</ecd:MtrlTermsOfTrdArrTextBlock>
    <ecd:TrdArrIndName contextRef="c-9" id="f-46">Jeffrey Peters</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle contextRef="c-9" id="f-47">Senior Vice President and General Counsel</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-9" id="f-48">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrSecuritiesAggAvailAmt contextRef="c-10" decimals="INF" id="f-49" unitRef="shares">370842</ecd:TrdArrSecuritiesAggAvailAmt>
    <dei:AuditorFirmId contextRef="c-1" id="f-52">42</dei:AuditorFirmId>
    <dei:AuditorName contextRef="c-1" id="f-53">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="c-1" id="f-54">Tysons, Virginia</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-2" decimals="-3" id="f-55" unitRef="usd">100956000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-11" decimals="-3" id="f-56" unitRef="usd">108884000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:Investments contextRef="c-2" decimals="-3" id="f-57" unitRef="usd">128849000</us-gaap:Investments>
    <us-gaap:Investments contextRef="c-11" decimals="-3" id="f-58" unitRef="usd">45462000</us-gaap:Investments>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-2" decimals="-3" id="f-59" unitRef="usd">10367000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-11" decimals="-3" id="f-60" unitRef="usd">56222000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet contextRef="c-2" decimals="-3" id="f-61" unitRef="usd">1221000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-11" decimals="-3" id="f-62" unitRef="usd">1451000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseCurrent contextRef="c-2" decimals="-3" id="f-63" unitRef="usd">9946000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="c-11" decimals="-3" id="f-64" unitRef="usd">10161000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:AssetsCurrent contextRef="c-2" decimals="-3" id="f-65" unitRef="usd">251339000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-11" decimals="-3" id="f-66" unitRef="usd">222180000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-2" decimals="-3" id="f-67" unitRef="usd">21847000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-11" decimals="-3" id="f-68" unitRef="usd">29575000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-2" decimals="-3" id="f-69" unitRef="usd">23846000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-11" decimals="-3" id="f-70" unitRef="usd">27335000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-2" decimals="-3" id="f-71" unitRef="usd">1386000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-11" decimals="-3" id="f-72" unitRef="usd">1378000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c-2" decimals="-3" id="f-73" unitRef="usd">298418000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-11" decimals="-3" id="f-74" unitRef="usd">280468000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c-2" decimals="-3" id="f-75" unitRef="usd">6443000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-11" decimals="-3" id="f-76" unitRef="usd">4899000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-2" decimals="-3" id="f-77" unitRef="usd">24239000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-11" decimals="-3" id="f-78" unitRef="usd">28998000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DeferredRevenueCurrent contextRef="c-2" decimals="-3" id="f-79" unitRef="usd">21651000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueCurrent contextRef="c-11" decimals="-3" id="f-80" unitRef="usd">9988000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-2" decimals="-3" id="f-81" unitRef="usd">3775000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-11" decimals="-3" id="f-82" unitRef="usd">4726000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-2" decimals="-3" id="f-83" unitRef="usd">56108000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-11" decimals="-3" id="f-84" unitRef="usd">48611000</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredRevenueNoncurrent contextRef="c-2" decimals="-3" id="f-85" unitRef="usd">59243000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:DeferredRevenueNoncurrent contextRef="c-11" decimals="-3" id="f-86" unitRef="usd">59480000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-2" decimals="-3" id="f-87" unitRef="usd">30196000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-11" decimals="-3" id="f-88" unitRef="usd">30106000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-2" decimals="-3" id="f-89" unitRef="usd">258000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-11" decimals="-3" id="f-90" unitRef="usd">258000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="c-2" decimals="-3" id="f-91" unitRef="usd">145805000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-11" decimals="-3" id="f-92" unitRef="usd">138455000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-2"
      decimals="INF"
      id="f-93"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-11"
      decimals="INF"
      id="f-94"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-2" decimals="INF" id="f-95" unitRef="shares">125000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-11" decimals="INF" id="f-96" unitRef="shares">125000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-2" decimals="INF" id="f-97" unitRef="shares">62070627</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-11" decimals="INF" id="f-98" unitRef="shares">61701467</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c-2" decimals="-3" id="f-99" unitRef="usd">621000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-11" decimals="-3" id="f-100" unitRef="usd">617000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-2" decimals="-3" id="f-101" unitRef="usd">1254750000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-11" decimals="-3" id="f-102" unitRef="usd">1235095000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-2" decimals="-3" id="f-103" unitRef="usd">-6000</us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-11" decimals="-3" id="f-104" unitRef="usd">-5000</us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-2" decimals="-3" id="f-105" unitRef="usd">-1102752000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-11" decimals="-3" id="f-106" unitRef="usd">-1093694000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c-2" decimals="-3" id="f-107" unitRef="usd">152613000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-11" decimals="-3" id="f-108" unitRef="usd">142013000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-2" decimals="-3" id="f-109" unitRef="usd">298418000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-11" decimals="-3" id="f-110" unitRef="usd">280468000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues contextRef="c-12" decimals="-3" id="f-111" unitRef="usd">28990000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-13" decimals="-3" id="f-112" unitRef="usd">119303000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-14" decimals="-3" id="f-113" unitRef="usd">63294000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-15" decimals="-3" id="f-114" unitRef="usd">17939000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-16" decimals="-3" id="f-115" unitRef="usd">16727000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-17" decimals="-3" id="f-116" unitRef="usd">12349000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-18" decimals="-3" id="f-117" unitRef="usd">9833000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-19" decimals="-3" id="f-118" unitRef="usd">13988000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-20" decimals="-3" id="f-119" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-21" decimals="-3" id="f-120" unitRef="usd">431000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-22" decimals="-3" id="f-121" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-23" decimals="-3" id="f-122" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-24" decimals="-3" id="f-123" unitRef="usd">1556000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-25" decimals="-3" id="f-124" unitRef="usd">1923000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-26" decimals="-3" id="f-125" unitRef="usd">1804000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-1" decimals="-3" id="f-126" unitRef="usd">58749000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-27" decimals="-3" id="f-127" unitRef="usd">151941000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-28" decimals="-3" id="f-128" unitRef="usd">77447000</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-1" decimals="-3" id="f-129" unitRef="usd">619000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-27" decimals="-3" id="f-130" unitRef="usd">3351000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-28" decimals="-3" id="f-131" unitRef="usd">2651000</us-gaap:CostOfGoodsAndServicesSold>
    <mgnx:CostOfManufacturingServices contextRef="c-1" decimals="-3" id="f-132" unitRef="usd">7603000</mgnx:CostOfManufacturingServices>
    <mgnx:CostOfManufacturingServices contextRef="c-27" decimals="-3" id="f-133" unitRef="usd">4033000</mgnx:CostOfManufacturingServices>
    <mgnx:CostOfManufacturingServices contextRef="c-28" decimals="-3" id="f-134" unitRef="usd">0</mgnx:CostOfManufacturingServices>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-1" decimals="-3" id="f-135" unitRef="usd">166583000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-27" decimals="-3" id="f-136" unitRef="usd">207026000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-28" decimals="-3" id="f-137" unitRef="usd">214577000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-138" unitRef="usd">52188000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-27" decimals="-3" id="f-139" unitRef="usd">58949000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-28" decimals="-3" id="f-140" unitRef="usd">63014000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses contextRef="c-1" decimals="-3" id="f-141" unitRef="usd">226993000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="c-27" decimals="-3" id="f-142" unitRef="usd">273359000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="c-28" decimals="-3" id="f-143" unitRef="usd">280242000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-3" id="f-144" unitRef="usd">-168244000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-27" decimals="-3" id="f-145" unitRef="usd">-121418000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-28" decimals="-3" id="f-146" unitRef="usd">-202795000</us-gaap:OperatingIncomeLoss>
    <mgnx:GainOnRoyaltyMonetizationArrangement contextRef="c-1" decimals="-3" id="f-147" unitRef="usd">150930000</mgnx:GainOnRoyaltyMonetizationArrangement>
    <mgnx:GainOnRoyaltyMonetizationArrangement contextRef="c-27" decimals="-3" id="f-148" unitRef="usd">0</mgnx:GainOnRoyaltyMonetizationArrangement>
    <mgnx:GainOnRoyaltyMonetizationArrangement contextRef="c-28" decimals="-3" id="f-149" unitRef="usd">0</mgnx:GainOnRoyaltyMonetizationArrangement>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-150" unitRef="usd">9686000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-27" decimals="-3" id="f-151" unitRef="usd">1660000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-28" decimals="-3" id="f-152" unitRef="usd">680000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:InterestExpense contextRef="c-1" decimals="-3" id="f-153" unitRef="usd">1430000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-27" decimals="-3" id="f-154" unitRef="usd">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-28" decimals="-3" id="f-155" unitRef="usd">0</us-gaap:InterestExpense>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-156" unitRef="usd">-9058000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-27" decimals="-3" id="f-157" unitRef="usd">-119758000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-28" decimals="-3" id="f-158" unitRef="usd">-202115000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-1" decimals="-3" id="f-159" unitRef="usd">-1000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-27" decimals="-3" id="f-160" unitRef="usd">56000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-28" decimals="-3" id="f-161" unitRef="usd">-54000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-1" decimals="-3" id="f-162" unitRef="usd">-9059000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-27" decimals="-3" id="f-163" unitRef="usd">-119702000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-28" decimals="-3" id="f-164" unitRef="usd">-202169000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-165"
      unitRef="usdPerShare">-0.15</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-166"
      unitRef="usdPerShare">-0.15</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-27"
      decimals="2"
      id="f-167"
      unitRef="usdPerShare">-1.95</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-27"
      decimals="2"
      id="f-168"
      unitRef="usdPerShare">-1.95</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-28"
      decimals="2"
      id="f-169"
      unitRef="usdPerShare">-3.37</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-28"
      decimals="2"
      id="f-170"
      unitRef="usdPerShare">-3.37</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="0" id="f-171" unitRef="shares">61929198</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="0" id="f-172" unitRef="shares">61929198</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-27" decimals="0" id="f-173" unitRef="shares">61433124</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-27" decimals="0" id="f-174" unitRef="shares">61433124</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-28" decimals="0" id="f-175" unitRef="shares">59944717</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-28" decimals="0" id="f-176" unitRef="shares">59944717</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesIssued
      contextRef="c-29"
      decimals="INF"
      id="f-177"
      unitRef="shares">56244771</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity contextRef="c-29" decimals="-3" id="f-178" unitRef="usd">562000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-30" decimals="-3" id="f-179" unitRef="usd">1067150000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-31" decimals="-3" id="f-180" unitRef="usd">-771821000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-32" decimals="-3" id="f-181" unitRef="usd">-7000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-33" decimals="-3" id="f-182" unitRef="usd">295884000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-34" decimals="-3" id="f-183" unitRef="usd">23126000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-28" decimals="-3" id="f-184" unitRef="usd">23126000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-35"
      decimals="INF"
      id="f-185"
      unitRef="shares">4580653</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-35" decimals="-3" id="f-186" unitRef="usd">46000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-34" decimals="-3" id="f-187" unitRef="usd">117772000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-28" decimals="-3" id="f-188" unitRef="usd">117818000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <mgnx:StockIssuedDuringPeriodSharesStockPlanActivity
      contextRef="c-35"
      decimals="INF"
      id="f-189"
      unitRef="shares">482004</mgnx:StockIssuedDuringPeriodSharesStockPlanActivity>
    <mgnx:StockIssuedDuringPeriodValueStockPlanActivity contextRef="c-35" decimals="-3" id="f-190" unitRef="usd">5000</mgnx:StockIssuedDuringPeriodValueStockPlanActivity>
    <mgnx:StockIssuedDuringPeriodValueStockPlanActivity contextRef="c-34" decimals="-3" id="f-191" unitRef="usd">4954000</mgnx:StockIssuedDuringPeriodValueStockPlanActivity>
    <mgnx:StockIssuedDuringPeriodValueStockPlanActivity contextRef="c-28" decimals="-3" id="f-192" unitRef="usd">4959000</mgnx:StockIssuedDuringPeriodValueStockPlanActivity>
    <us-gaap:UnrealizedGainLossOnInvestments contextRef="c-36" decimals="-3" id="f-193" unitRef="usd">-54000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments contextRef="c-28" decimals="-3" id="f-194" unitRef="usd">-54000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:NetIncomeLoss contextRef="c-37" decimals="-3" id="f-195" unitRef="usd">-202115000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-28" decimals="-3" id="f-196" unitRef="usd">-202115000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="c-38"
      decimals="INF"
      id="f-197"
      unitRef="shares">61307428</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity contextRef="c-38" decimals="-3" id="f-198" unitRef="usd">613000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-39" decimals="-3" id="f-199" unitRef="usd">1213002000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-40" decimals="-3" id="f-200" unitRef="usd">-973936000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-41" decimals="-3" id="f-201" unitRef="usd">-61000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-42" decimals="-3" id="f-202" unitRef="usd">239618000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-43" decimals="-3" id="f-203" unitRef="usd">20438000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-27" decimals="-3" id="f-204" unitRef="usd">20438000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-44"
      decimals="INF"
      id="f-205"
      unitRef="shares">160480</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-44" decimals="-3" id="f-206" unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-43" decimals="-3" id="f-207" unitRef="usd">1083000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-27" decimals="-3" id="f-208" unitRef="usd">1085000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <mgnx:StockIssuedDuringPeriodSharesStockPlanActivity
      contextRef="c-44"
      decimals="INF"
      id="f-209"
      unitRef="shares">233559</mgnx:StockIssuedDuringPeriodSharesStockPlanActivity>
    <mgnx:StockIssuedDuringPeriodValueStockPlanActivity contextRef="c-44" decimals="-3" id="f-210" unitRef="usd">2000</mgnx:StockIssuedDuringPeriodValueStockPlanActivity>
    <mgnx:StockIssuedDuringPeriodValueStockPlanActivity contextRef="c-43" decimals="-3" id="f-211" unitRef="usd">572000</mgnx:StockIssuedDuringPeriodValueStockPlanActivity>
    <mgnx:StockIssuedDuringPeriodValueStockPlanActivity contextRef="c-27" decimals="-3" id="f-212" unitRef="usd">574000</mgnx:StockIssuedDuringPeriodValueStockPlanActivity>
    <us-gaap:UnrealizedGainLossOnInvestments contextRef="c-45" decimals="-3" id="f-213" unitRef="usd">56000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments contextRef="c-27" decimals="-3" id="f-214" unitRef="usd">56000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:NetIncomeLoss contextRef="c-46" decimals="-3" id="f-215" unitRef="usd">-119758000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-27" decimals="-3" id="f-216" unitRef="usd">-119758000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="c-47"
      decimals="INF"
      id="f-217"
      unitRef="shares">61701467</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity contextRef="c-47" decimals="-3" id="f-218" unitRef="usd">617000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-48" decimals="-3" id="f-219" unitRef="usd">1235095000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-49" decimals="-3" id="f-220" unitRef="usd">-1093694000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-50" decimals="-3" id="f-221" unitRef="usd">-5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-11" decimals="-3" id="f-222" unitRef="usd">142013000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-51" decimals="-3" id="f-223" unitRef="usd">18373000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-1" decimals="-3" id="f-224" unitRef="usd">18373000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-52"
      decimals="INF"
      id="f-225"
      unitRef="shares">167270</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-52" decimals="-3" id="f-226" unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-51" decimals="-3" id="f-227" unitRef="usd">1037000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-1" decimals="-3" id="f-228" unitRef="usd">1039000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <mgnx:StockIssuedDuringPeriodSharesStockPlanActivity
      contextRef="c-52"
      decimals="INF"
      id="f-229"
      unitRef="shares">201890</mgnx:StockIssuedDuringPeriodSharesStockPlanActivity>
    <mgnx:StockIssuedDuringPeriodValueStockPlanActivity contextRef="c-52" decimals="-3" id="f-230" unitRef="usd">2000</mgnx:StockIssuedDuringPeriodValueStockPlanActivity>
    <mgnx:StockIssuedDuringPeriodValueStockPlanActivity contextRef="c-51" decimals="-3" id="f-231" unitRef="usd">245000</mgnx:StockIssuedDuringPeriodValueStockPlanActivity>
    <mgnx:StockIssuedDuringPeriodValueStockPlanActivity contextRef="c-1" decimals="-3" id="f-232" unitRef="usd">247000</mgnx:StockIssuedDuringPeriodValueStockPlanActivity>
    <us-gaap:UnrealizedGainLossOnInvestments contextRef="c-53" decimals="-3" id="f-233" unitRef="usd">-1000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments contextRef="c-1" decimals="-3" id="f-234" unitRef="usd">-1000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:NetIncomeLoss contextRef="c-54" decimals="-3" id="f-235" unitRef="usd">-9058000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-236" unitRef="usd">-9058000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="c-55"
      decimals="INF"
      id="f-237"
      unitRef="shares">62070627</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity contextRef="c-55" decimals="-3" id="f-238" unitRef="usd">621000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-56" decimals="-3" id="f-239" unitRef="usd">1254750000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-57" decimals="-3" id="f-240" unitRef="usd">-1102752000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-58" decimals="-3" id="f-241" unitRef="usd">-6000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-2" decimals="-3" id="f-242" unitRef="usd">152613000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-243" unitRef="usd">-9058000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-27" decimals="-3" id="f-244" unitRef="usd">-119758000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-28" decimals="-3" id="f-245" unitRef="usd">-202115000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-1" decimals="-3" id="f-246" unitRef="usd">9645000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-27" decimals="-3" id="f-247" unitRef="usd">11865000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-28" decimals="-3" id="f-248" unitRef="usd">11258000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="c-1" decimals="-3" id="f-249" unitRef="usd">5004000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="c-27" decimals="-3" id="f-250" unitRef="usd">-403000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="c-28" decimals="-3" id="f-251" unitRef="usd">-1607000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-3" id="f-252" unitRef="usd">18373000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-27" decimals="-3" id="f-253" unitRef="usd">20438000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-28" decimals="-3" id="f-254" unitRef="usd">23126000</us-gaap:ShareBasedCompensation>
    <mgnx:GainOnRoyaltyMonetizationArrangement contextRef="c-1" decimals="-3" id="f-255" unitRef="usd">150930000</mgnx:GainOnRoyaltyMonetizationArrangement>
    <mgnx:GainOnRoyaltyMonetizationArrangement contextRef="c-27" decimals="-3" id="f-256" unitRef="usd">0</mgnx:GainOnRoyaltyMonetizationArrangement>
    <mgnx:GainOnRoyaltyMonetizationArrangement contextRef="c-28" decimals="-3" id="f-257" unitRef="usd">0</mgnx:GainOnRoyaltyMonetizationArrangement>
    <mgnx:NonCashInterestExpenseRecognized contextRef="c-1" decimals="-3" id="f-258" unitRef="usd">1430000</mgnx:NonCashInterestExpenseRecognized>
    <mgnx:NonCashInterestExpenseRecognized contextRef="c-27" decimals="-3" id="f-259" unitRef="usd">0</mgnx:NonCashInterestExpenseRecognized>
    <mgnx:NonCashInterestExpenseRecognized contextRef="c-28" decimals="-3" id="f-260" unitRef="usd">0</mgnx:NonCashInterestExpenseRecognized>
    <mgnx:OperatingLeaseNoncashExpense contextRef="c-1" decimals="-3" id="f-261" unitRef="usd">3489000</mgnx:OperatingLeaseNoncashExpense>
    <mgnx:OperatingLeaseNoncashExpense contextRef="c-27" decimals="-3" id="f-262" unitRef="usd">3341000</mgnx:OperatingLeaseNoncashExpense>
    <mgnx:OperatingLeaseNoncashExpense contextRef="c-28" decimals="-3" id="f-263" unitRef="usd">2690000</mgnx:OperatingLeaseNoncashExpense>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c-1" decimals="-3" id="f-264" unitRef="usd">-423000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c-27" decimals="-3" id="f-265" unitRef="usd">-2882000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c-28" decimals="-3" id="f-266" unitRef="usd">-2035000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:GainLossOnDispositionOfAssets contextRef="c-1" decimals="-3" id="f-267" unitRef="usd">-111000</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:GainLossOnDispositionOfAssets contextRef="c-27" decimals="-3" id="f-268" unitRef="usd">0</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:GainLossOnDispositionOfAssets contextRef="c-28" decimals="-3" id="f-269" unitRef="usd">0</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-1" decimals="-3" id="f-270" unitRef="usd">-45855000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-27" decimals="-3" id="f-271" unitRef="usd">45836000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-28" decimals="-3" id="f-272" unitRef="usd">-12696000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-1" decimals="-3" id="f-273" unitRef="usd">-230000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-27" decimals="-3" id="f-274" unitRef="usd">-55000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-28" decimals="-3" id="f-275" unitRef="usd">6424000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="c-1" decimals="-3" id="f-276" unitRef="usd">-215000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="c-27" decimals="-3" id="f-277" unitRef="usd">-11009000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="c-28" decimals="-3" id="f-278" unitRef="usd">4188000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="c-1" decimals="-3" id="f-279" unitRef="usd">7000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="c-27" decimals="-3" id="f-280" unitRef="usd">14045000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="c-28" decimals="-3" id="f-281" unitRef="usd">-3225000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-1" decimals="-3" id="f-282" unitRef="usd">1281000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-27" decimals="-3" id="f-283" unitRef="usd">-10860000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-28" decimals="-3" id="f-284" unitRef="usd">7125000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-1" decimals="-3" id="f-285" unitRef="usd">-4823000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-27" decimals="-3" id="f-286" unitRef="usd">-4638000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-28" decimals="-3" id="f-287" unitRef="usd">-607000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <mgnx:IncreaseDecreaseInLeaseLiabilities contextRef="c-1" decimals="-3" id="f-288" unitRef="usd">-861000</mgnx:IncreaseDecreaseInLeaseLiabilities>
    <mgnx:IncreaseDecreaseInLeaseLiabilities contextRef="c-27" decimals="-3" id="f-289" unitRef="usd">9364000</mgnx:IncreaseDecreaseInLeaseLiabilities>
    <mgnx:IncreaseDecreaseInLeaseLiabilities contextRef="c-28" decimals="-3" id="f-290" unitRef="usd">-3780000</mgnx:IncreaseDecreaseInLeaseLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-1" decimals="-3" id="f-291" unitRef="usd">11426000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-27" decimals="-3" id="f-292" unitRef="usd">48821000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-28" decimals="-3" id="f-293" unitRef="usd">9264000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <mgnx:IncreaseDecreaseInDeferredRent contextRef="c-1" decimals="-3" id="f-294" unitRef="usd">0</mgnx:IncreaseDecreaseInDeferredRent>
    <mgnx:IncreaseDecreaseInDeferredRent contextRef="c-27" decimals="-3" id="f-295" unitRef="usd">0</mgnx:IncreaseDecreaseInDeferredRent>
    <mgnx:IncreaseDecreaseInDeferredRent contextRef="c-28" decimals="-3" id="f-296" unitRef="usd">258000</mgnx:IncreaseDecreaseInDeferredRent>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-297" unitRef="usd">-78205000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-27" decimals="-3" id="f-298" unitRef="usd">-86959000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-28" decimals="-3" id="f-299" unitRef="usd">-143830000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="c-1" decimals="-3" id="f-300" unitRef="usd">239683000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="c-27" decimals="-3" id="f-301" unitRef="usd">120602000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="c-28" decimals="-3" id="f-302" unitRef="usd">231208000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="c-1" decimals="-3" id="f-303" unitRef="usd">161299000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="c-27" decimals="-3" id="f-304" unitRef="usd">194940000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="c-28" decimals="-3" id="f-305" unitRef="usd">200800000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-306" unitRef="usd">1764000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-27" decimals="-3" id="f-307" unitRef="usd">3623000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-28" decimals="-3" id="f-308" unitRef="usd">6201000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfMachineryAndEquipment contextRef="c-1" decimals="-3" id="f-309" unitRef="usd">64000</us-gaap:ProceedsFromSaleOfMachineryAndEquipment>
    <us-gaap:ProceedsFromSaleOfMachineryAndEquipment contextRef="c-27" decimals="-3" id="f-310" unitRef="usd">0</us-gaap:ProceedsFromSaleOfMachineryAndEquipment>
    <us-gaap:ProceedsFromSaleOfMachineryAndEquipment contextRef="c-28" decimals="-3" id="f-311" unitRef="usd">0</us-gaap:ProceedsFromSaleOfMachineryAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-3" id="f-312" unitRef="usd">-80084000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-27" decimals="-3" id="f-313" unitRef="usd">70715000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-28" decimals="-3" id="f-314" unitRef="usd">-36609000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-1" decimals="-3" id="f-315" unitRef="usd">616000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-27" decimals="-3" id="f-316" unitRef="usd">1085000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-28" decimals="-3" id="f-317" unitRef="usd">117818000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases contextRef="c-1" decimals="-3" id="f-318" unitRef="usd">553000</mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases>
    <mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases contextRef="c-27" decimals="-3" id="f-319" unitRef="usd">574000</mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases>
    <mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases contextRef="c-28" decimals="-3" id="f-320" unitRef="usd">4959000</mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-1" decimals="-3" id="f-321" unitRef="usd">306000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-27" decimals="-3" id="f-322" unitRef="usd">0</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-27" decimals="-3" id="f-323" unitRef="usd">0</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <mgnx:PrincipalPaymentsOnRoyaltyMonetizationArrangement contextRef="c-1" decimals="-3" id="f-324" unitRef="usd">157000</mgnx:PrincipalPaymentsOnRoyaltyMonetizationArrangement>
    <mgnx:PrincipalPaymentsOnRoyaltyMonetizationArrangement contextRef="c-27" decimals="-3" id="f-325" unitRef="usd">0</mgnx:PrincipalPaymentsOnRoyaltyMonetizationArrangement>
    <mgnx:PrincipalPaymentsOnRoyaltyMonetizationArrangement contextRef="c-28" decimals="-3" id="f-326" unitRef="usd">0</mgnx:PrincipalPaymentsOnRoyaltyMonetizationArrangement>
    <mgnx:NetProceedsFromSaleOfFutureRoyalties contextRef="c-1" decimals="-3" id="f-327" unitRef="usd">149655000</mgnx:NetProceedsFromSaleOfFutureRoyalties>
    <mgnx:NetProceedsFromSaleOfFutureRoyalties contextRef="c-27" decimals="-3" id="f-328" unitRef="usd">0</mgnx:NetProceedsFromSaleOfFutureRoyalties>
    <mgnx:NetProceedsFromSaleOfFutureRoyalties contextRef="c-28" decimals="-3" id="f-329" unitRef="usd">0</mgnx:NetProceedsFromSaleOfFutureRoyalties>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-3" id="f-330" unitRef="usd">150361000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-27" decimals="-3" id="f-331" unitRef="usd">1659000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-28" decimals="-3" id="f-332" unitRef="usd">122777000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="-3" id="f-333" unitRef="usd">-7928000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-27" decimals="-3" id="f-334" unitRef="usd">-14585000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-28" decimals="-3" id="f-335" unitRef="usd">-57662000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-11" decimals="-3" id="f-336" unitRef="usd">108884000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-42" decimals="-3" id="f-337" unitRef="usd">123469000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-33" decimals="-3" id="f-338" unitRef="usd">181131000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-2" decimals="-3" id="f-339" unitRef="usd">100956000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-11" decimals="-3" id="f-340" unitRef="usd">108884000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-42" decimals="-3" id="f-341" unitRef="usd">123469000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-1" decimals="-3" id="f-342" unitRef="usd">505000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-27" decimals="-3" id="f-343" unitRef="usd">118000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-28" decimals="-3" id="f-344" unitRef="usd">508000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="c-1" id="f-345">Organization and Nature of Operations&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;MacroGenics, Inc. (the Company) is incorporated in the state of Delaware. The Company is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer. The Company has a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. These candidates are being evaluated in clinical trials sponsored by the Company or its collaborators or are in preclinical development. The Company&#x2019;s clinical product candidates include multiple oncology programs which have either been created using its proprietary, antibody-based technology platforms or enabled through its technology licensing arrangements with other companies. The Company believes its product candidates have the potential, if approved for marketing by regulatory authorities, to have a meaningful effect on treating patients' unmet medical needs as monotherapy or, in some cases, in combination with other therapeutic agents. To date, three products originating from the Company&#x2019;s pipeline of proprietary or partnered product candidates have received U.S. Food and Drug Administration (FDA) approval. In March 2021, the Company and its commercialization partner commenced U.S. marketing of MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. In November 2022, the FDA approved TZIELD&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (teplizumab-mzwv) to delay the onset of Stage 3 Type 1 Diabetes (T1D) in adult and pediatric patients aged 8 years and older with Stage 2 T1D. Teplizumab was acquired from the Company by Provention Bio, Inc. (Provention) in May 2018, pursuant to an asset purchase agreement. In March 2023, the FDA approved ZYNYZ&#x2122; (retifanlimab-dlwr), a humanized monoclonal antibody targeting programmed death receptor-1 (PD-1). Retifanlimab was previously developed by the Company and licensed to Incyte Corporation (Incyte) pursuant to an exclusive global collaboration and license agreement in October 2017.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s multiple product candidates currently under development will require significant additional research and development efforts that include extensive preclinical studies and clinical testing, and regulatory approval prior to commercial use.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The future success of the Company is dependent on its ability to identify and develop its product candidates, and ultimately upon its ability to attain profitable operations. The Company has devoted substantially all of its financial resources and efforts to research and development and general and administrative expense to support such research and development. Net losses and negative cash flows have had, and will continue to have, an adverse effect on the Company&#x2019;s stockholders&#x2019; equity and working capital, and accordingly, its ability to execute its future operating plans.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a biotechnology company, the Company has primarily funded its operations with proceeds from the sale of its common stock in equity offerings and revenue from its multiple collaboration agreements.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management regularly reviews the Company&#x2019;s available liquidity relative to its operating budget and forecast to monitor the sufficiency of the Company&#x2019;s working capital.  The Company plans to meet its future operating requirements by generating revenue from current and future strategic collaborations or other arrangements, product sales and royalties.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company anticipates continuing to draw upon available sources of capital, including equity and debt instruments, to support its product development activities.  If the Company is unable to enter into new arrangements or to perform under current or future agreements or obtain additional capital, the Company will assess its capital resources and may be required to delay, reduce the scope of, or eliminate one or more of its product research and development programs or clinical studies, reduce other operating expenses, and/or downsize its organization. Based on the Company&#x2019;s most recent cash flow forecast, the Company believes its current resources are sufficient to fund its operating plans for a minimum of twelve months from the date that this Annual Report on Form 10-K was filed.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Similar to the other risk factors pertinent to the Company's business, including significant equity market volatility and availability of funding in the biotechnology sector, as well as potential issues in the global economy, credit markets and financial markets as a result of significant worldwide events, including adverse events involving financial institutions or the financial services industry, inflation and rising interest rates and geopolitical upheaval, might unfavorably impact the Company's ability to generate such additional funding. Given the uncertainty in the rapidly changing market and economic conditions related to these uncertainties, the Company will continue to evaluate the nature and extent of the impact of these uncertainties on its business and financial position.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-346">Summary of Significant Accounting Policies&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation and Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, MacroGenics UK Limited and MacroGenics Limited.&#160;All intercompany accounts and transactions have been eliminated in consolidation. The Company currently operates in one operating segment. Operating segments are defined as components of an enterprise about which separate discrete information is available for the chief operating decision maker, or decision making group, in deciding how to allocate resources and assessing performance. The Company views its operations and manages its business in one segment, which is developing and commercializing monoclonal antibody-based therapeutics.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the financial statements in accordance with generally accepted accounting principles (GAAP) requires the Company to make estimates and judgments in certain circumstances that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. In preparing these consolidated financial statements, management has made its best estimates and judgments of certain amounts included in the financial statements, giving due consideration to materiality. On an ongoing basis, the Company evaluates its estimates, including those related to revenue recognition, fair values of assets, inventory, preclinical study and clinical trial accruals and other contingencies. Management bases its estimates on historical experience or on various other assumptions that it believes to be reasonable under the circumstances. Although actual results could differ from these estimates, management does not believe that such differences would be material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents and Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all investments in highly liquid financial instruments with a maturity of 90 days or less at the date of purchase to be cash equivalents. Cash and cash equivalents includes investments in money market funds with commercial banks and financial institutions, securities issued by the U.S. government and its agencies, Government Sponsored Enterprise agency debt obligations and corporate debt obligations. Cash equivalents are stated at amortized cost, plus accrued interest, which approximates fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company carries marketable securities classified as available-for-sale at fair value as determined by prices for identical or similar securities at the balance sheet date. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Classification of marketable securities between current and non-current is dependent upon the maturity date at the balance sheet date taking into consideration the Company&#x2019;s ability and intent to hold the investment to maturity. &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable securities consist of Level 2 financial instruments in the fair-value hierarchy. The Company records unrealized gains and losses as a component of other comprehensive loss within the statements of operations and comprehensive loss and as a separate component of stockholders' equity. Realized gains or losses on available-for-sale securities are determined using the specific identification method and the Company includes net realized gains and losses in other income, along with interest income and amortization of premiums and discounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable arise from product sales, amounts due from the Company&#x2019;s collaborative partners and contract manufacturing work performed by the Company.  The amount from product sales represents amounts due from specialty distributors. Accounts receivable that management has the intent and ability to collect are reported in the consolidated balance sheets at outstanding amounts, less an allowance for doubtful accounts. The Company writes off uncollectible receivables when the likelihood of collection is remote.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates the collectability of accounts receivable on a regular basis. The allowance, if any, is based upon various factors including the financial condition and payment history of customers, an overall review of collections experience on other accounts and economic factors or events expected to affect future collections experience. No allowance was recorded as of December&#160;31, 2023 or 2022, as the Company has a history of collecting on all outstanding accounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's financial instruments consist of cash and cash equivalents, marketable securities, accounts receivable, accounts payable and accrued expenses.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amount of accounts receivable, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of their short-term nature.&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for recurring and non-recurring fair value measurements in accordance with the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurements and Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASC 820). ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements. The ASC 820 hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1 &#x2013; Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2 &#x2013; Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3 &#x2013; Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity &#x2013; e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC 820 hierarchy.  &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no transfers between levels during the periods presented. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial assets measured at fair value on a recurring basis were as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:51.616%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.612%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.121%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.584%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.415%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.852%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement at December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:51.677%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.958%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.115%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.554%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.108%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement at December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government-sponsored enterprise&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:15pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a) Total assets measured at fair value at December&#160;31, 2023 includes approximately $91.7 million reported as cash and cash equivalents and $128.8&#160;million reported as marketable securities on the balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(b) Total assets measured at fair value at December&#160;31, 2022 includes approximately $46.5 million reported as cash and cash equivalents and $45.5&#160;million reported as marketable securities on the balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents, marketable securities and accounts receivable. &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains its cash and money market funds with financial institutions that are federally insured. While balances deposited in these institutions often exceed Federal Deposit Insurance Corporation limits, the Company has not experienced any losses on related accounts to date.&#160;The Company's investment policy limits investments to certain types of debt securities issued by the U.S. government, its agencies and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The counterparties are various corporations, financial institutions and government agencies of high credit standing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's revenue relates to agreements with various collaborators, MARGENZA net product sales and&#160;contracts and research grants received from U.S. government agencies.&#160;The following table includes those counterparties &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;that represent more than 10% of total revenue earned in the periods indicated:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:68.119%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.620%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.620%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.683%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.622%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Incyte&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;McKesson Plasma &amp;amp; Biologics and McKesson Specialty Care Distribution LLC (McKesson)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ASD Healthcare and Oncology Supply (ASD)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provention&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Zai Lab Limited (Zai Lab)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;I-Mab Biopharma (I-Mab)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;* Amount is less than 10% for the period indicated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table includes those counterparties that represent more than 10% of accounts receivable at the date indicated:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.946%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.363%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.559%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.632%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Incyte&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cardinal Health, Inc&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;McKesson&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ASD&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Zai Lab&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provention&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;* Balance is less than 10% as of the date indicated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When the Company believes regulatory approval is probable and expects future economic benefit from the sales of a product candidate to be realized, the Company capitalizes manufacturing costs (whether internally produced or through third-party contract manufacturing organizations) as inventory.  Prior to receiving its first approval from the FDA in December 2020, the Company expensed all costs incurred related to the manufacture of MARGENZA as research and development expense because of the inherent risks associated with the development of a product candidate, the uncertainty about the regulatory approval process and the lack of history for the Company of regulatory approval of drug candidates.  Subsequent to FDA approval in December 2020, the Company began capitalizing its MARGENZA third-party contract manufacturing inventory costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory is composed of raw materials, work-in-process, and finished goods, which are goods that are available for sale. The Company values its inventories at the lower of cost or estimated net realizable value. The Company determines the cost of its inventories, which includes amounts related to materials and third-party contract manufacturing costs, on a first-in, first-out basis. The Company performs an assessment of the recoverability of capitalized inventory during each reporting period, and it writes down any excess, obsolete or unsaleable inventories to their estimated realizable value in the period in which the impairment is first identified. Such write downs, should they occur, are recorded within the cost of product sales in the statement of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property, Equipment and Software&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, equipment and software are stated at cost. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation or amortization are removed from the accounts and any resulting gain or loss is credited or charged to operations. Repairs and maintenance costs are expensed as incurred. Depreciation and amortization are computed using the straight-line method over the following estimated useful lives:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:49.046%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.754%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory and office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shorter of lease term or useful life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assesses the recoverability of its long-lived assets in accordance with the provisions of ASC 360, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Property, Plant and Equipment &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(ASC 360). ASC 360 requires that long-lived assets be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of the long-lived asset is measured by a comparison of the carrying amount of the asset to future undiscounted net cash flows expected to be generated by the asset or asset group. If carrying value exceeds the sum of undiscounted cash flows, the Company then determines the fair value of the underlying asset group. Any impairment to be recognized is measured by the amount by which the carrying amount of the asset group exceeds the estimated fair value of the asset group. Assets to be disposed of are reported at the lower of the carrying amount or fair value, less costs to sell. For the years ended December&#160;31, 2023, and 2022, the Company determined that there were no impaired assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liability related to the sale of future royalties and related interest expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assesses the relevant accounting criteria under ASC 470, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASC 470) to determine whether the upfront payment received from the purchaser should be accounted for as debt or deferred income depending on the facts and circumstances.  If the criteria in ASC 470 is met, the Company accounts for net proceeds from sales of its rights to receive future royalty payments as a liability that is amortized using the effective interest method over the term of the arrangement. The liability related to future royalties is presented net of unamortized issuance costs on the consolidated balance sheets. Interest expense on the liability related to future royalties is recognized using the effective interest rate method over the life of the arrangement. The Company calculates an effective interest rate which will amortize its related obligation to zero over the anticipated repayment period. The liability related to future royalties and the related interest expense are based on the Company&#x2019;s current estimates of future royalties expected to be received over the life of the arrangement, which the Company determines by using internal sales projections and external information from market data sources, which are considered Level 3 inputs. The Company periodically assesses the expected payments and to the extent the Company&#x2019;s estimates of future royalty payments are greater or less than previous estimates or the estimated timing of such payments is materially different than previous estimates, the Company will adjust the effective interest rate and recognize related non-cash interest expense on a prospective basis. Non-cash amortization is reflected as interest expense in the consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Upon changes in facts and circumstances, for example as a result of a modification to the existing agreements, the Company re-evaluates its rights and obligations and accounts for the change in accordance with the respective accounting guidance.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue recognition&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:40.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue under ASC Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customer&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s (ASC 606) when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Collaborative and other agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into licensing agreements that are within the scope of ASC 606, under which it may license rights to research, develop, manufacture and commercialize its product candidates to third parties. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, upfront license fees; reimbursement of certain costs; customer option exercise fees; development, regulatory and commercial milestone payments;&#160;and royalties on net sales of licensed products. The Company may also enter into development and manufacturing service agreements with its collaborators.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For each arrangement that results in revenues, the Company identifies all performance obligations, which may include a license to intellectual property and know-how, research and development activities, transition activities and/or manufacturing services. In order to determine the transaction price, in addition to any upfront payment, the Company estimates the amount of variable consideration at the outset of the contract either utilizing the expected value or most likely amount method, depending on the facts and circumstances relative to the contract. The Company constrains (reduces) the estimates of variable consideration such that it is probable that a significant reversal of previously recognized revenue will not occur. When determining if variable consideration should be constrained, management considers whether there are factors outside the Company&#x2019;s control that could result in a significant reversal of revenue. In making these assessments, the Company considers the likelihood and magnitude of a potential reversal of revenue. These estimates are re-assessed each reporting period as required. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Once the estimated transaction price is established, amounts are allocated to the performance obligations that have been identified. The transaction price is generally allocated to each separate performance obligation on a relative standalone selling price basis. The Company must develop assumptions that require judgment to determine the standalone selling price in order to account for these agreements. To determine the standalone selling price, the Company&#x2019;s assumptions may include (i)  the probability of obtaining marketing approval for the product candidate, (ii) estimates regarding the timing and the expected costs to develop and commercialize the product candidate, and (iii) estimates of future cash flows from potential product sales with respect to the product candidate. Standalone selling prices used to perform the initial allocation are not updated after contract inception. The Company does not include a financing component to its estimated transaction price at contract inception unless it estimates that certain performance obligations will not be satisfied within one year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts received prior to revenue recognition are recorded as deferred revenue. Amounts expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as current portion of deferred revenue in the accompanying consolidated balance sheets. Amounts not expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as deferred revenue, net of current portion. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Licenses. &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When the Company grants a license to its intellectual property, it &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;determines whether the &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;nature of the intellectual property to which the customer will have rights is functional intellectual property (functional IP), which has significant standalone functionality, or symbolic intellectual property (symbolic IP) which does not have significant standalone functionality.  Revenue from functional IP is recognized at the point in time when control of the distinct license is transferred to the customer. Revenue from symbolic IP is recognized over the access period to the Company&#x2019;s intellectual property&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;.  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the license to the Company&#x2019;s intellectual property is determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and when (or as) the customer is able to use and benefit from the license. In assessing whether a promise or performance obligation is distinct from the other promises, the Company considers factors such as the research, development, manufacturing and commercialization capabilities of the licensee and the availability of the associated expertise in the general marketplace. In addition, the Company considers whether the licensee can benefit from a promise for its intended purpose without the receipt of the remaining promise, whether the value of the promise is dependent on the unsatisfied promise, whether there are other vendors that could provide the remaining promise, and whether it is separately identifiable from the remaining promise. For licenses that are combined with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The measure of progress, and thereby periods over which revenue should be recognized, are subject to estimates by management and may change over the course of the research and development and licensing agreement. Such a change could have a material impact on the amount of revenue the Company records in future periods. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research, Development and/or Manufacturing Services. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The promises under the Company&#x2019;s agreements may include research and development or manufacturing services to be performed by the Company on behalf of the counterparty. If these services are determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes the transaction price allocated to these services as revenue over time based on an appropriate measure of progress when the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. If these services are determined not to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes the transaction price allocated to the combined performance obligation as the related performance obligations are satisfied. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Customer Options. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If an arrangement contains customer options, the Company evaluates whether the options are material rights because they allow the customer to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;outset of the arrangement. The Company allocates the transaction price to material rights based on the relative standalone selling price, which is determined using assumptions regarding estimated costs, discount rates, post-option development timeline, the probability of technical and regulatory success and the probability  that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until, at the earliest, the option is exercised. If the options are deemed not to be a material right, they are excluded as performance obligations at the outset of the arrangement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Milestone Payments. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of each arrangement that includes development milestone payments, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Royalties. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For arrangements that include sales-based royalties which are the result of a customer-vendor relationship and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company analyzes its collaboration arrangements to assess whether such arrangements involve joint operating activities performed by parties who are both active participants in the activities and are both exposed to significant risks and rewards dependent on the commercial success of such activities. Such arrangements generally are within the scope of ASC 808, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASC 808). While ASC 808 defines collaborative arrangements and provides guidance on income statement presentation, classification, and disclosures related to such arrangements, it does not address recognition and measurement matters, such as (1)&#160;determining the appropriate unit of accounting or (2) when the recognition criteria are met. Therefore, the accounting for these arrangements is either based on an analogy to other accounting literature or an accounting policy election by the Company. The Company accounts for certain components of the collaboration agreement that are reflective of a vendor-customer relationship (e.g., licensing arrangement) based on ASC 606. The Company accounts for other components based on a reasonable, rational and consistently applied accounting policy election.&#160; Reimbursements from the counter-party that are the result of a collaborative relationship with the counter-party, instead of a customer relationship, such as co-development activities, are recorded as a reduction to research and development expense as the services are performed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For a complete discussion of accounting for revenue from collaborative and other agreements, see Note 9, Revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Product sales, net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company entered into a limited number of arrangements with specialty distributors in the United States to distribute MARGENZA. These arrangements are considered to be contracts with customers and are in the scope of ASC 606. The Company has written contracts with each of its customers that have a single performance obligation - to deliver products upon receipt of a customer order - and these obligations are satisfied when delivery occurs and the customer receives the product.  The specialty distributors subsequently resell the Company&#x2019;s product to healthcare providers.  Product revenue is recorded net of applicable reserves for variable consideration, including discounts and other allowances. Shipping and handling costs for product shipments occur prior to the customer obtaining control of the goods and are recorded in cost of sales. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reserves for Variable Consideration.  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue from product sales is recorded at the net sales price, which includes estimates of variable consideration. Components of variable consideration typically include discounts, product returns, provider chargebacks and discounts and government rebates. Variable consideration is estimated following the expected value method in accordance with ASC 606 and includes such factors as current contractual and statutory requirements, specific known market events and trends, industry data, and forecasted customer buying and payment patterns. The amount of variable consideration that is included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized under the contract will not occur in a future period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Customer Discounts and Service Fees.  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company may provide customers with discounts which are explicitly stated in the contracts. These discounts are recorded as a reduction of revenue in the period the related product revenue is &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;recognized. In addition, these contracts may include written service arrangements whereby the Company pays fees to customers who provide services such as sales order management, data, contract administration and distribution services, at rates which the Company believes to be consistent with fair market value. The Company has determined such services received to date are not distinct from the Company&#x2019;s sale of products to its customers and, therefore, these payments have been recorded as a reduction of revenue within the statement of operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Returns.  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consistent with industry practice, the Company offers the specialty distributors product return rights pursuant to written contracts and/or Company returned goods policies. The Company estimates the amount of its product sales that may be returned by its customers and records an estimated liability and a reduction of revenue in the period the related product revenue is recognized. The Company currently estimates product returns using industry benchmarking as well as other information available, such as visibility into the inventory remaining in the distribution channel, since the Company does not have its own returns experience. The Company's estimates of product returns may be adjusted in the future based on actual returns experience, known or expected changes in the marketplace, or other factors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Provider Chargebacks and Discounts.  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Chargebacks for fees and discounts to healthcare providers represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices charged to customers who directly purchase the product from the Company. In such cases, customers charge the Company for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers. The reserve for chargebacks is established in the same period that the related revenue is recognized, resulting in a reduction of product revenue. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider by customers, and the Company generally issues credits for such amounts within a few weeks of the customer&#x2019;s notification to the Company of the resale. Chargebacks consist of credits the Company expects to issue for units that remain in the distribution channel at each reporting period end that the Company expects will be sold to qualified healthcare providers and chargebacks that customers have claimed, but for which the Company has not yet issued a credit. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Government Rebates.  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to discount and/or rebate obligations under state Medicaid programs, Medicare and contractual agreements with and statutory obligations to certain Federal and State entities. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue. The Company&#x2019;s liability for these rebates consists of invoices received for claims from prior quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimates of future claims that will be made for product that has been recognized as revenue, but which remains in the distribution channel at the end of each reporting period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Customer discounts are recorded as a reduction of accounts receivable on the consolidated balance sheets. Allowance for product returns, provider chargebacks, government and other rebates and service fees are recorded as a component of accrued expenses and other current liabilities on the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Contract manufacturing revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into agreements with third parties to manufacture their drug substance at its GMP facility. The terms of these arrangements typically include an upfront payment to the Company to reserve manufacturing capacity, scheduled payments during the manufacturing process and reimbursement for materials used to manufacture product.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue over time on a straight-line basis as the manufacturing services are performed, as the Company believes that its efforts in providing the manufacturing services are incurred evenly throughout the performance period and therefore straight-line revenue recognition closely approximates the level of effort for the manufacturing services. Variable consideration relating to the reimbursed materials and other reimbursed costs incurred to manufacture product are allocated to the related manufacturing activities and are recognized as revenue as those activities occur.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Cost of Product Sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of product sales relates to sales of MARGENZA.  These costs include material, manufacturing and shipping costs, as well as royalties payable on net sales of MARGENZA and inventory reserves.  All product costs incurred prior to FDA approval of MARGENZA in December 2020 were expensed as research and development expense.  The Company expects cost of product sales to continue to be positively impacted for the next four to five years as the Company sells through inventory that was expensed prior to FDA approval of MARGENZA. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cost of Manufacturing Services&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of manufacturing services consists of the costs to provide manufacturing services to produce certain bulk drug substance under manufacturing and clinical supply agreements with third parties, including salaries and benefits and related stock-based compensation, materials, overhead and other related costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Expense, Including Clinical Trial Accruals/Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenditures are expensed as incurred. Research and development costs primarily consist of employee related expenses, including salaries and benefits, expenses incurred under agreements with contract research organizations (CROs), investigative sites and consultants that conduct the Company's clinical trials, the cost of acquiring and manufacturing clinical trial materials, including costs incurred under agreements with contract manufacturing organizations (CMOs), and other allocated expenses, license fees for and milestone payments related to in-licensed products and technologies, stock-based compensation expense, and costs associated with non-clinical activities and regulatory approvals.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Right-to-develop agreements may contain cost-sharing provisions whereby the Company and the collaborator share the cost of research and development activities. Reimbursement of research and development expenses received in connection with these agreements is recorded as a reduction of such expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Clinical trial expenses are a significant component of research and development expense, and the Company outsources  a significant portion of these costs to third parties. Third party clinical trial expenses include investigator fees, site and patient costs, CRO costs, costs for central laboratory testing, data management and CMO costs. The accrual for site and patient costs includes inputs such as estimates of patient enrollment, patient cycles incurred, clinical site activations, and other pass-through costs. These inputs are required to be estimated due to a lag in receiving the actual clinical information from third parties. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected on the consolidated balance sheets as a prepaid asset or accrued expenses. These third party agreements are generally cancellable, and related costs are recorded as research and development expenses as incurred&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Non-refundable advance clinical payments for goods or services that will be used or rendered for future research and development activities are recorded as a prepaid asset and recognized as expense as the related goods are delivered or the related services are performed.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; When evaluating the adequacy of the accrued expenses, management  analyzes progress of the studies, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates may be made in determining the accrued balances at the end of any reporting period. Actual results could differ from the estimates made. The historical clinical accrual estimates have not been materially different from the actual costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines whether an arrangement is or contains a lease at the inception of an arrangement under ASC 842, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. For leases where the Company is the lessee, right-of-use (ROU) assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term of the lease for which the rate is estimated. Certain adjustments to the ROU asset may be required for items such as initial direct costs paid or incentives received. The lease terms used to calculate the ROU asset and related lease liabilities include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for operating leases is recognized on a straight-line basis over the lease term as an operating expense while the expense for finance leases is recognized as depreciation expense and interest expense using the accelerated interest method of recognition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive loss represents net loss adjusted for the change during the periods attributed to unrealized gains and losses on available-for-sale debt securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period. All stock options and restricted stock units (RSUs) are excluded from the per share calculations as such securities were anti-dilutive for all periods presented. The following table presents the number of stock options and RSUs that were excluded from the calculation of net loss per share:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.036%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.377%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.015%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.377%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.015%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.380%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options and RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,129,251&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,514,013&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,395,421&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has implemented all applicable accounting pronouncements that are in effect. These pronouncements did not have any material impact on the financial statements unless otherwise disclosed, and the Company does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c-1" id="f-347">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation and Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, MacroGenics UK Limited and MacroGenics Limited.&#160;All intercompany accounts and transactions have been eliminated in consolidation. The Company currently operates in one operating segment. Operating segments are defined as components of an enterprise about which separate discrete information is available for the chief operating decision maker, or decision making group, in deciding how to allocate resources and assessing performance. The Company views its operations and manages its business in one segment, which is developing and commercializing monoclonal antibody-based therapeutics.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c-1"
      decimals="INF"
      id="f-348"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c-1"
      decimals="INF"
      id="f-349"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:UseOfEstimates contextRef="c-1" id="f-350">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the financial statements in accordance with generally accepted accounting principles (GAAP) requires the Company to make estimates and judgments in certain circumstances that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. In preparing these consolidated financial statements, management has made its best estimates and judgments of certain amounts included in the financial statements, giving due consideration to materiality. On an ongoing basis, the Company evaluates its estimates, including those related to revenue recognition, fair values of assets, inventory, preclinical study and clinical trial accruals and other contingencies. Management bases its estimates on historical experience or on various other assumptions that it believes to be reasonable under the circumstances. Although actual results could differ from these estimates, management does not believe that such differences would be material.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c-1" id="f-351">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents and Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all investments in highly liquid financial instruments with a maturity of 90 days or less at the date of purchase to be cash equivalents. Cash and cash equivalents includes investments in money market funds with commercial banks and financial institutions, securities issued by the U.S. government and its agencies, Government Sponsored Enterprise agency debt obligations and corporate debt obligations. Cash equivalents are stated at amortized cost, plus accrued interest, which approximates fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company carries marketable securities classified as available-for-sale at fair value as determined by prices for identical or similar securities at the balance sheet date. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Classification of marketable securities between current and non-current is dependent upon the maturity date at the balance sheet date taking into consideration the Company&#x2019;s ability and intent to hold the investment to maturity. &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable securities consist of Level 2 financial instruments in the fair-value hierarchy. The Company records unrealized gains and losses as a component of other comprehensive loss within the statements of operations and comprehensive loss and as a separate component of stockholders' equity. Realized gains or losses on available-for-sale securities are determined using the specific identification method and the Company includes net realized gains and losses in other income, along with interest income and amortization of premiums and discounts.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="c-1" id="f-352">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable arise from product sales, amounts due from the Company&#x2019;s collaborative partners and contract manufacturing work performed by the Company.  The amount from product sales represents amounts due from specialty distributors. Accounts receivable that management has the intent and ability to collect are reported in the consolidated balance sheets at outstanding amounts, less an allowance for doubtful accounts. The Company writes off uncollectible receivables when the likelihood of collection is remote.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates the collectability of accounts receivable on a regular basis. The allowance, if any, is based upon various factors including the financial condition and payment history of customers, an overall review of collections experience on other accounts and economic factors or events expected to affect future collections experience. No allowance was recorded as of December&#160;31, 2023 or 2022, as the Company has a history of collecting on all outstanding accounts.&lt;/span&gt;&lt;/div&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="c-1" id="f-353">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's financial instruments consist of cash and cash equivalents, marketable securities, accounts receivable, accounts payable and accrued expenses.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amount of accounts receivable, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of their short-term nature.&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for recurring and non-recurring fair value measurements in accordance with the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurements and Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASC 820). ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements. The ASC 820 hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1 &#x2013; Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2 &#x2013; Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3 &#x2013; Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity &#x2013; e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC 820 hierarchy.  &lt;/span&gt;There were no transfers between levels during the periods presented.</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock contextRef="c-1" id="f-354">&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial assets measured at fair value on a recurring basis were as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:51.616%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.612%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.121%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.584%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.415%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.852%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement at December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:51.677%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.958%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.115%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.554%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.108%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement at December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government-sponsored enterprise&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:15pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a) Total assets measured at fair value at December&#160;31, 2023 includes approximately $91.7 million reported as cash and cash equivalents and $128.8&#160;million reported as marketable securities on the balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(b) Total assets measured at fair value at December&#160;31, 2022 includes approximately $46.5 million reported as cash and cash equivalents and $45.5&#160;million reported as marketable securities on the balance sheet.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-59" decimals="-3" id="f-355" unitRef="usd">91665000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-60" decimals="-3" id="f-356" unitRef="usd">91665000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-61" decimals="-3" id="f-357" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-62" decimals="-3" id="f-358" unitRef="usd">31179000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-63" decimals="-3" id="f-359" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-64" decimals="-3" id="f-360" unitRef="usd">31179000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-65" decimals="-3" id="f-361" unitRef="usd">45043000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-66" decimals="-3" id="f-362" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-67" decimals="-3" id="f-363" unitRef="usd">45043000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-68" decimals="-3" id="f-364" unitRef="usd">52627000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-69" decimals="-3" id="f-365" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-70" decimals="-3" id="f-366" unitRef="usd">52627000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-71" decimals="-3" id="f-367" unitRef="usd">220514000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-72" decimals="-3" id="f-368" unitRef="usd">91665000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-73" decimals="-3" id="f-369" unitRef="usd">128849000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-74" decimals="-3" id="f-370" unitRef="usd">41564000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-75" decimals="-3" id="f-371" unitRef="usd">41564000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-76" decimals="-3" id="f-372" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-77" decimals="-3" id="f-373" unitRef="usd">32811000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-78" decimals="-3" id="f-374" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-79" decimals="-3" id="f-375" unitRef="usd">32811000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-80" decimals="-3" id="f-376" unitRef="usd">17626000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-81" decimals="-3" id="f-377" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-82" decimals="-3" id="f-378" unitRef="usd">17626000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-83" decimals="-3" id="f-379" unitRef="usd">92001000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-84" decimals="-3" id="f-380" unitRef="usd">41564000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-85" decimals="-3" id="f-381" unitRef="usd">50437000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-2" decimals="-5" id="f-382" unitRef="usd">91700000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:Investments contextRef="c-2" decimals="-5" id="f-383" unitRef="usd">128800000</us-gaap:Investments>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-11" decimals="-5" id="f-384" unitRef="usd">46500000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:Investments contextRef="c-11" decimals="-5" id="f-385" unitRef="usd">45500000</us-gaap:Investments>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c-1" id="f-386">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents, marketable securities and accounts receivable. &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains its cash and money market funds with financial institutions that are federally insured. While balances deposited in these institutions often exceed Federal Deposit Insurance Corporation limits, the Company has not experienced any losses on related accounts to date.&#160;The Company's investment policy limits investments to certain types of debt securities issued by the U.S. government, its agencies and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The counterparties are various corporations, financial institutions and government agencies of high credit standing.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock contextRef="c-1" id="f-387">The following table includes those counterparties &lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;that represent more than 10% of total revenue earned in the periods indicated:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:68.119%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.620%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.620%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.683%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.622%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Incyte&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;McKesson Plasma &amp;amp; Biologics and McKesson Specialty Care Distribution LLC (McKesson)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ASD Healthcare and Oncology Supply (ASD)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provention&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Zai Lab Limited (Zai Lab)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;I-Mab Biopharma (I-Mab)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;* Amount is less than 10% for the period indicated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table includes those counterparties that represent more than 10% of accounts receivable at the date indicated:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.946%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.363%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.559%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.632%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Incyte&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cardinal Health, Inc&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;McKesson&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ASD&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Zai Lab&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provention&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;* Balance is less than 10% as of the date indicated.&lt;/span&gt;&lt;/div&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-86" decimals="2" id="f-388" unitRef="number">0.53</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-87" decimals="2" id="f-389" unitRef="number">0.26</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-88" decimals="2" id="f-390" unitRef="number">0.31</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-89" decimals="2" id="f-391" unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-90" decimals="2" id="f-392" unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-91" decimals="2" id="f-393" unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-92" decimals="2" id="f-394" unitRef="number">0.43</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-93" decimals="2" id="f-395" unitRef="number">0.15</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-94" decimals="2" id="f-396" unitRef="number">0.30</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-95" decimals="2" id="f-397" unitRef="number">0.16</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-96" decimals="2" id="f-398" unitRef="number">0.25</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-97" decimals="2" id="f-399" unitRef="number">0.18</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-98" decimals="2" id="f-400" unitRef="number">0.16</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-99" decimals="2" id="f-401" unitRef="number">0.15</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-100" decimals="2" id="f-402" unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-101" decimals="2" id="f-403" unitRef="number">0.84</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:InventoryPolicyTextBlock contextRef="c-1" id="f-404">&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When the Company believes regulatory approval is probable and expects future economic benefit from the sales of a product candidate to be realized, the Company capitalizes manufacturing costs (whether internally produced or through third-party contract manufacturing organizations) as inventory.  Prior to receiving its first approval from the FDA in December 2020, the Company expensed all costs incurred related to the manufacture of MARGENZA as research and development expense because of the inherent risks associated with the development of a product candidate, the uncertainty about the regulatory approval process and the lack of history for the Company of regulatory approval of drug candidates.  Subsequent to FDA approval in December 2020, the Company began capitalizing its MARGENZA third-party contract manufacturing inventory costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory is composed of raw materials, work-in-process, and finished goods, which are goods that are available for sale. The Company values its inventories at the lower of cost or estimated net realizable value. The Company determines the cost of its inventories, which includes amounts related to materials and third-party contract manufacturing costs, on a first-in, first-out basis. The Company performs an assessment of the recoverability of capitalized inventory during each reporting period, and it writes down any excess, obsolete or unsaleable inventories to their estimated realizable value in the period in which the impairment is first identified. Such write downs, should they occur, are recorded within the cost of product sales in the statement of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c-1" id="f-405">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property, Equipment and Software&lt;/span&gt;&lt;/div&gt;Property, equipment and software are stated at cost. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation or amortization are removed from the accounts and any resulting gain or loss is credited or charged to operations. Repairs and maintenance costs are expensed as incurred.</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <mgnx:PropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock contextRef="c-1" id="f-406">Depreciation and amortization are computed using the straight-line method over the following estimated useful lives:&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:49.046%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.754%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory and office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shorter of lease term or useful life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</mgnx:PropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-102" id="f-407">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-103" id="f-408">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-104" id="f-409">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-105" id="f-410">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="c-1" id="f-411">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assesses the recoverability of its long-lived assets in accordance with the provisions of ASC 360, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Property, Plant and Equipment &lt;/span&gt;(ASC 360). ASC 360 requires that long-lived assets be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of the long-lived asset is measured by a comparison of the carrying amount of the asset to future undiscounted net cash flows expected to be generated by the asset or asset group. If carrying value exceeds the sum of undiscounted cash flows, the Company then determines the fair value of the underlying asset group. Any impairment to be recognized is measured by the amount by which the carrying amount of the asset group exceeds the estimated fair value of the asset group. Assets to be disposed of are reported at the lower of the carrying amount or fair value, less costs to sell.</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <mgnx:LiabilityRelatedToFutureRoyaltiesAndRelatedInterestExpensePolicyTextBlock contextRef="c-1" id="f-412">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liability related to the sale of future royalties and related interest expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assesses the relevant accounting criteria under ASC 470, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASC 470) to determine whether the upfront payment received from the purchaser should be accounted for as debt or deferred income depending on the facts and circumstances.  If the criteria in ASC 470 is met, the Company accounts for net proceeds from sales of its rights to receive future royalty payments as a liability that is amortized using the effective interest method over the term of the arrangement. The liability related to future royalties is presented net of unamortized issuance costs on the consolidated balance sheets. Interest expense on the liability related to future royalties is recognized using the effective interest rate method over the life of the arrangement. The Company calculates an effective interest rate which will amortize its related obligation to zero over the anticipated repayment period. The liability related to future royalties and the related interest expense are based on the Company&#x2019;s current estimates of future royalties expected to be received over the life of the arrangement, which the Company determines by using internal sales projections and external information from market data sources, which are considered Level 3 inputs. The Company periodically assesses the expected payments and to the extent the Company&#x2019;s estimates of future royalty payments are greater or less than previous estimates or the estimated timing of such payments is materially different than previous estimates, the Company will adjust the effective interest rate and recognize related non-cash interest expense on a prospective basis. Non-cash amortization is reflected as interest expense in the consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Upon changes in facts and circumstances, for example as a result of a modification to the existing agreements, the Company re-evaluates its rights and obligations and accounts for the change in accordance with the respective accounting guidance.&lt;/span&gt;&lt;/div&gt;</mgnx:LiabilityRelatedToFutureRoyaltiesAndRelatedInterestExpensePolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="c-1" id="f-413">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue recognition&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:40.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue under ASC Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customer&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s (ASC 606) when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Collaborative and other agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into licensing agreements that are within the scope of ASC 606, under which it may license rights to research, develop, manufacture and commercialize its product candidates to third parties. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, upfront license fees; reimbursement of certain costs; customer option exercise fees; development, regulatory and commercial milestone payments;&#160;and royalties on net sales of licensed products. The Company may also enter into development and manufacturing service agreements with its collaborators.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For each arrangement that results in revenues, the Company identifies all performance obligations, which may include a license to intellectual property and know-how, research and development activities, transition activities and/or manufacturing services. In order to determine the transaction price, in addition to any upfront payment, the Company estimates the amount of variable consideration at the outset of the contract either utilizing the expected value or most likely amount method, depending on the facts and circumstances relative to the contract. The Company constrains (reduces) the estimates of variable consideration such that it is probable that a significant reversal of previously recognized revenue will not occur. When determining if variable consideration should be constrained, management considers whether there are factors outside the Company&#x2019;s control that could result in a significant reversal of revenue. In making these assessments, the Company considers the likelihood and magnitude of a potential reversal of revenue. These estimates are re-assessed each reporting period as required. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Once the estimated transaction price is established, amounts are allocated to the performance obligations that have been identified. The transaction price is generally allocated to each separate performance obligation on a relative standalone selling price basis. The Company must develop assumptions that require judgment to determine the standalone selling price in order to account for these agreements. To determine the standalone selling price, the Company&#x2019;s assumptions may include (i)  the probability of obtaining marketing approval for the product candidate, (ii) estimates regarding the timing and the expected costs to develop and commercialize the product candidate, and (iii) estimates of future cash flows from potential product sales with respect to the product candidate. Standalone selling prices used to perform the initial allocation are not updated after contract inception. The Company does not include a financing component to its estimated transaction price at contract inception unless it estimates that certain performance obligations will not be satisfied within one year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts received prior to revenue recognition are recorded as deferred revenue. Amounts expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as current portion of deferred revenue in the accompanying consolidated balance sheets. Amounts not expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as deferred revenue, net of current portion. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Licenses. &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When the Company grants a license to its intellectual property, it &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;determines whether the &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;nature of the intellectual property to which the customer will have rights is functional intellectual property (functional IP), which has significant standalone functionality, or symbolic intellectual property (symbolic IP) which does not have significant standalone functionality.  Revenue from functional IP is recognized at the point in time when control of the distinct license is transferred to the customer. Revenue from symbolic IP is recognized over the access period to the Company&#x2019;s intellectual property&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;.  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the license to the Company&#x2019;s intellectual property is determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and when (or as) the customer is able to use and benefit from the license. In assessing whether a promise or performance obligation is distinct from the other promises, the Company considers factors such as the research, development, manufacturing and commercialization capabilities of the licensee and the availability of the associated expertise in the general marketplace. In addition, the Company considers whether the licensee can benefit from a promise for its intended purpose without the receipt of the remaining promise, whether the value of the promise is dependent on the unsatisfied promise, whether there are other vendors that could provide the remaining promise, and whether it is separately identifiable from the remaining promise. For licenses that are combined with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The measure of progress, and thereby periods over which revenue should be recognized, are subject to estimates by management and may change over the course of the research and development and licensing agreement. Such a change could have a material impact on the amount of revenue the Company records in future periods. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research, Development and/or Manufacturing Services. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The promises under the Company&#x2019;s agreements may include research and development or manufacturing services to be performed by the Company on behalf of the counterparty. If these services are determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes the transaction price allocated to these services as revenue over time based on an appropriate measure of progress when the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. If these services are determined not to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes the transaction price allocated to the combined performance obligation as the related performance obligations are satisfied. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Customer Options. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If an arrangement contains customer options, the Company evaluates whether the options are material rights because they allow the customer to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;outset of the arrangement. The Company allocates the transaction price to material rights based on the relative standalone selling price, which is determined using assumptions regarding estimated costs, discount rates, post-option development timeline, the probability of technical and regulatory success and the probability  that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until, at the earliest, the option is exercised. If the options are deemed not to be a material right, they are excluded as performance obligations at the outset of the arrangement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Milestone Payments. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of each arrangement that includes development milestone payments, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Royalties. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For arrangements that include sales-based royalties which are the result of a customer-vendor relationship and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company analyzes its collaboration arrangements to assess whether such arrangements involve joint operating activities performed by parties who are both active participants in the activities and are both exposed to significant risks and rewards dependent on the commercial success of such activities. Such arrangements generally are within the scope of ASC 808, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASC 808). While ASC 808 defines collaborative arrangements and provides guidance on income statement presentation, classification, and disclosures related to such arrangements, it does not address recognition and measurement matters, such as (1)&#160;determining the appropriate unit of accounting or (2) when the recognition criteria are met. Therefore, the accounting for these arrangements is either based on an analogy to other accounting literature or an accounting policy election by the Company. The Company accounts for certain components of the collaboration agreement that are reflective of a vendor-customer relationship (e.g., licensing arrangement) based on ASC 606. The Company accounts for other components based on a reasonable, rational and consistently applied accounting policy election.&#160; Reimbursements from the counter-party that are the result of a collaborative relationship with the counter-party, instead of a customer relationship, such as co-development activities, are recorded as a reduction to research and development expense as the services are performed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For a complete discussion of accounting for revenue from collaborative and other agreements, see Note 9, Revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Product sales, net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company entered into a limited number of arrangements with specialty distributors in the United States to distribute MARGENZA. These arrangements are considered to be contracts with customers and are in the scope of ASC 606. The Company has written contracts with each of its customers that have a single performance obligation - to deliver products upon receipt of a customer order - and these obligations are satisfied when delivery occurs and the customer receives the product.  The specialty distributors subsequently resell the Company&#x2019;s product to healthcare providers.  Product revenue is recorded net of applicable reserves for variable consideration, including discounts and other allowances. Shipping and handling costs for product shipments occur prior to the customer obtaining control of the goods and are recorded in cost of sales. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reserves for Variable Consideration.  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue from product sales is recorded at the net sales price, which includes estimates of variable consideration. Components of variable consideration typically include discounts, product returns, provider chargebacks and discounts and government rebates. Variable consideration is estimated following the expected value method in accordance with ASC 606 and includes such factors as current contractual and statutory requirements, specific known market events and trends, industry data, and forecasted customer buying and payment patterns. The amount of variable consideration that is included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized under the contract will not occur in a future period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Customer Discounts and Service Fees.  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company may provide customers with discounts which are explicitly stated in the contracts. These discounts are recorded as a reduction of revenue in the period the related product revenue is &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;recognized. In addition, these contracts may include written service arrangements whereby the Company pays fees to customers who provide services such as sales order management, data, contract administration and distribution services, at rates which the Company believes to be consistent with fair market value. The Company has determined such services received to date are not distinct from the Company&#x2019;s sale of products to its customers and, therefore, these payments have been recorded as a reduction of revenue within the statement of operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Returns.  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consistent with industry practice, the Company offers the specialty distributors product return rights pursuant to written contracts and/or Company returned goods policies. The Company estimates the amount of its product sales that may be returned by its customers and records an estimated liability and a reduction of revenue in the period the related product revenue is recognized. The Company currently estimates product returns using industry benchmarking as well as other information available, such as visibility into the inventory remaining in the distribution channel, since the Company does not have its own returns experience. The Company's estimates of product returns may be adjusted in the future based on actual returns experience, known or expected changes in the marketplace, or other factors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Provider Chargebacks and Discounts.  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Chargebacks for fees and discounts to healthcare providers represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices charged to customers who directly purchase the product from the Company. In such cases, customers charge the Company for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers. The reserve for chargebacks is established in the same period that the related revenue is recognized, resulting in a reduction of product revenue. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider by customers, and the Company generally issues credits for such amounts within a few weeks of the customer&#x2019;s notification to the Company of the resale. Chargebacks consist of credits the Company expects to issue for units that remain in the distribution channel at each reporting period end that the Company expects will be sold to qualified healthcare providers and chargebacks that customers have claimed, but for which the Company has not yet issued a credit. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Government Rebates.  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to discount and/or rebate obligations under state Medicaid programs, Medicare and contractual agreements with and statutory obligations to certain Federal and State entities. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue. The Company&#x2019;s liability for these rebates consists of invoices received for claims from prior quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimates of future claims that will be made for product that has been recognized as revenue, but which remains in the distribution channel at the end of each reporting period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Customer discounts are recorded as a reduction of accounts receivable on the consolidated balance sheets. Allowance for product returns, provider chargebacks, government and other rebates and service fees are recorded as a component of accrued expenses and other current liabilities on the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Contract manufacturing revenue&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into agreements with third parties to manufacture their drug substance at its GMP facility. The terms of these arrangements typically include an upfront payment to the Company to reserve manufacturing capacity, scheduled payments during the manufacturing process and reimbursement for materials used to manufacture product.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue over time on a straight-line basis as the manufacturing services are performed, as the Company believes that its efforts in providing the manufacturing services are incurred evenly throughout the performance period and therefore straight-line revenue recognition closely approximates the level of effort for the manufacturing services. Variable consideration relating to the reimbursed materials and other reimbursed costs incurred to manufacture product are allocated to the related manufacturing activities and are recognized as revenue as those activities occur.&lt;/span&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:CostOfSalesPolicyTextBlock contextRef="c-1" id="f-414">&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Cost of Product Sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of product sales relates to sales of MARGENZA.  These costs include material, manufacturing and shipping costs, as well as royalties payable on net sales of MARGENZA and inventory reserves.  All product costs incurred prior to FDA approval of MARGENZA in December 2020 were expensed as research and development expense.  The Company expects cost of product sales to continue to be positively impacted for the next four to five years as the Company sells through inventory that was expensed prior to FDA approval of MARGENZA. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cost of Manufacturing Services&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of manufacturing services consists of the costs to provide manufacturing services to produce certain bulk drug substance under manufacturing and clinical supply agreements with third parties, including salaries and benefits and related stock-based compensation, materials, overhead and other related costs.&lt;/span&gt;&lt;/div&gt;</us-gaap:CostOfSalesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c-1" id="f-415">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Expense, Including Clinical Trial Accruals/Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenditures are expensed as incurred. Research and development costs primarily consist of employee related expenses, including salaries and benefits, expenses incurred under agreements with contract research organizations (CROs), investigative sites and consultants that conduct the Company's clinical trials, the cost of acquiring and manufacturing clinical trial materials, including costs incurred under agreements with contract manufacturing organizations (CMOs), and other allocated expenses, license fees for and milestone payments related to in-licensed products and technologies, stock-based compensation expense, and costs associated with non-clinical activities and regulatory approvals.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Right-to-develop agreements may contain cost-sharing provisions whereby the Company and the collaborator share the cost of research and development activities. Reimbursement of research and development expenses received in connection with these agreements is recorded as a reduction of such expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Clinical trial expenses are a significant component of research and development expense, and the Company outsources  a significant portion of these costs to third parties. Third party clinical trial expenses include investigator fees, site and patient costs, CRO costs, costs for central laboratory testing, data management and CMO costs. The accrual for site and patient costs includes inputs such as estimates of patient enrollment, patient cycles incurred, clinical site activations, and other pass-through costs. These inputs are required to be estimated due to a lag in receiving the actual clinical information from third parties. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected on the consolidated balance sheets as a prepaid asset or accrued expenses. These third party agreements are generally cancellable, and related costs are recorded as research and development expenses as incurred&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Non-refundable advance clinical payments for goods or services that will be used or rendered for future research and development activities are recorded as a prepaid asset and recognized as expense as the related goods are delivered or the related services are performed.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; When evaluating the adequacy of the accrued expenses, management  analyzes progress of the studies, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates may be made in determining the accrued balances at the end of any reporting period. Actual results could differ from the estimates made. The historical clinical accrual estimates have not been materially different from the actual costs.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c-1" id="f-416">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines whether an arrangement is or contains a lease at the inception of an arrangement under ASC 842, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;. For leases where the Company is the lessee, right-of-use (ROU) assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term of the lease for which the rate is estimated. Certain adjustments to the ROU asset may be required for items such as initial direct costs paid or incentives received. The lease terms used to calculate the ROU asset and related lease liabilities include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for operating leases is recognized on a straight-line basis over the lease term as an operating expense while the expense for finance leases is recognized as depreciation expense and interest expense using the accelerated interest method of recognition.</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="c-1" id="f-417">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive loss represents net loss adjusted for the change during the periods attributed to unrealized gains and losses on available-for-sale debt securities.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c-1" id="f-418">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;Basic and diluted loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period. All stock options and restricted stock units (RSUs) are excluded from the per share calculations as such securities were anti-dilutive for all periods presented.</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c-1" id="f-419">The following table presents the number of stock options and RSUs that were excluded from the calculation of net loss per share:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.036%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.377%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.015%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.377%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.015%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.380%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options and RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,129,251&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,514,013&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,395,421&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-106" decimals="0" id="f-420" unitRef="shares">13129251</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-107" decimals="0" id="f-421" unitRef="shares">10514013</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-108" decimals="0" id="f-422" unitRef="shares">8395421</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-423">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has implemented all applicable accounting pronouncements that are in effect. These pronouncements did not have any material impact on the financial statements unless otherwise disclosed, and the Company does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock contextRef="c-1" id="f-424">Marketable Securities&lt;div style="margin-bottom:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Available-for-sale marketable securities as of December&#160;31, 2023 and 2022 were as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:49.707%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.647%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.647%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.647%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.650%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:49.707%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.647%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.647%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.647%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.650%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All of the Company's available-for-sale securities held at December&#160;31, 2023 and 2022 had contractual maturities of less than one year.  All of the Company&#x2019;s available-for-sale marketable debt securities in an unrealized loss position as of &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2023&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and 2022 were in a loss position for less than twelve months.&#160; Unrealized losses on available-for-sale debt securities as of &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2023 and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2022 &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;were not &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;significant and were primarily due to changes in interest rates, including market credit spreads, and not due to increased credit risks associated with specific securities.  Accordingly, no allowance for credit losses related to the Company's available-for-sale debt securities was recorded for the years ended &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2023 and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2022. &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company does not intend to sell these investments and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost bases, which may be at maturity.&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded interest income of $4.0 million, $1.7 million and $2.0 million during the years ended December&#160;31, 2023, 2022 and 2021, respectively, which is included in interest and other income on the consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock contextRef="c-1" id="f-425">&lt;div style="margin-bottom:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Available-for-sale marketable securities as of December&#160;31, 2023 and 2022 were as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:49.707%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.647%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.647%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.647%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.650%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:49.707%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.647%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.647%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.647%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.650%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-109" decimals="-3" id="f-426" unitRef="usd">31177000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-109" decimals="-3" id="f-427" unitRef="usd">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-109" decimals="-3" id="f-428" unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-109" decimals="-3" id="f-429" unitRef="usd">31179000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-110" decimals="-3" id="f-430" unitRef="usd">45041000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-110" decimals="-3" id="f-431" unitRef="usd">7000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-110" decimals="-3" id="f-432" unitRef="usd">5000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-110" decimals="-3" id="f-433" unitRef="usd">45043000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-111" decimals="-3" id="f-434" unitRef="usd">52637000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-111" decimals="-3" id="f-435" unitRef="usd">5000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-111" decimals="-3" id="f-436" unitRef="usd">15000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-111" decimals="-3" id="f-437" unitRef="usd">52627000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-2" decimals="-3" id="f-438" unitRef="usd">128855000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-2" decimals="-3" id="f-439" unitRef="usd">16000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-2" decimals="-3" id="f-440" unitRef="usd">22000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-2" decimals="-3" id="f-441" unitRef="usd">128849000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-112" decimals="-3" id="f-442" unitRef="usd">32812000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-112" decimals="-3" id="f-443" unitRef="usd">5000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-112" decimals="-3" id="f-444" unitRef="usd">7000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-112" decimals="-3" id="f-445" unitRef="usd">32810000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-113" decimals="-3" id="f-446" unitRef="usd">12655000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-113" decimals="-3" id="f-447" unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-113" decimals="-3" id="f-448" unitRef="usd">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-113" decimals="-3" id="f-449" unitRef="usd">12652000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-11" decimals="-3" id="f-450" unitRef="usd">45467000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-11" decimals="-3" id="f-451" unitRef="usd">6000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-11" decimals="-3" id="f-452" unitRef="usd">11000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-11" decimals="-3" id="f-453" unitRef="usd">45462000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss contextRef="c-11" decimals="INF" id="f-454" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss contextRef="c-2" decimals="INF" id="f-455" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:InterestIncomeOther contextRef="c-1" decimals="-5" id="f-456" unitRef="usd">4000000</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther contextRef="c-27" decimals="-5" id="f-457" unitRef="usd">1700000</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther contextRef="c-28" decimals="-5" id="f-458" unitRef="usd">2000000</us-gaap:InterestIncomeOther>
    <us-gaap:InventoryDisclosureTextBlock contextRef="c-1" id="f-459">Inventory, Net&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All of the Company's inventory relates to the manufacturing of MARGENZA.  The following table sets forth the Company's inventory, net of reserves (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:60.011%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventory, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:31.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to FDA approval of MARGENZA in December 2020, the cost of materials and expenses associated with the manufacturing of MARGENZA were recorded as research and development expense. Subsequent to FDA approval, the Company began capitalizing inventory costs related to the manufacture of MARGENZA. The inventory balance as of December&#160;31, 2023 and December&#160;31, 2022 is net of a reserve of $3.1 million and $4.9 million, respectively, for unsaleable inventory. These reserves are reflected in cost of product sales during the period they are recorded.   &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.952%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.622%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Inventory Reserves (in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at Beginning of Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Additions Charged to Expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at End of Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year Ended December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,798)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year Ended December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="c-1" id="f-460">The following table sets forth the Company's inventory, net of reserves (in thousands):&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:60.011%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventory, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryWorkInProcess contextRef="c-2" decimals="-3" id="f-461" unitRef="usd">261000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess contextRef="c-11" decimals="-3" id="f-462" unitRef="usd">409000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods contextRef="c-2" decimals="-3" id="f-463" unitRef="usd">960000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods contextRef="c-11" decimals="-3" id="f-464" unitRef="usd">1042000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryNet contextRef="c-2" decimals="-3" id="f-465" unitRef="usd">1221000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-11" decimals="-3" id="f-466" unitRef="usd">1451000</us-gaap:InventoryNet>
    <us-gaap:InventoryValuationReserves contextRef="c-2" decimals="-5" id="f-467" unitRef="usd">3100000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryValuationReserves contextRef="c-11" decimals="-5" id="f-468" unitRef="usd">4900000</us-gaap:InventoryValuationReserves>
    <mgnx:ScheduleOfInventoryReservesTableTextBlock contextRef="c-1" id="f-469">&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.952%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.622%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Inventory Reserves (in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at Beginning of Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Additions Charged to Expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at End of Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year Ended December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,798)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year Ended December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</mgnx:ScheduleOfInventoryReservesTableTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-114" decimals="-3" id="f-470" unitRef="usd">4917000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense contextRef="c-115" decimals="-3" id="f-471" unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesDeductions contextRef="c-115" decimals="-3" id="f-472" unitRef="usd">1798000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-116" decimals="-3" id="f-473" unitRef="usd">3119000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-117" decimals="-3" id="f-474" unitRef="usd">2035000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense contextRef="c-118" decimals="-3" id="f-475" unitRef="usd">2882000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesDeductions contextRef="c-118" decimals="-3" id="f-476" unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-114" decimals="-3" id="f-477" unitRef="usd">4917000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-119" decimals="-3" id="f-478" unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense contextRef="c-120" decimals="-3" id="f-479" unitRef="usd">2035000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesDeductions contextRef="c-120" decimals="-3" id="f-480" unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-117" decimals="-3" id="f-481" unitRef="usd">2035000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c-1" id="f-482">Property, Equipment and Software&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, equipment and software consists of the following (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.706%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.631%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Motor vehicles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(88,394)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(84,085)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, equipment and software, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation and amortization expense related to property, equipment and software for the years ended December&#160;31, 2023, 2022 and 2021 was $9.6 million, $11.9 million and $11.3 million, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c-1" id="f-483">&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, equipment and software consists of the following (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.706%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.631%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Motor vehicles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(88,394)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(84,085)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, equipment and software, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-102" decimals="-3" id="f-484" unitRef="usd">3542000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-121" decimals="-3" id="f-485" unitRef="usd">3489000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-103" decimals="-3" id="f-486" unitRef="usd">9759000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-122" decimals="-3" id="f-487" unitRef="usd">9604000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-123" decimals="-3" id="f-488" unitRef="usd">706000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-124" decimals="-3" id="f-489" unitRef="usd">713000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-125" decimals="-3" id="f-490" unitRef="usd">50000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-126" decimals="-3" id="f-491" unitRef="usd">50000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-127" decimals="-3" id="f-492" unitRef="usd">46452000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-128" decimals="-3" id="f-493" unitRef="usd">46474000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-129" decimals="-3" id="f-494" unitRef="usd">48620000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-130" decimals="-3" id="f-495" unitRef="usd">52974000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:ConstructionInProgressGross contextRef="c-2" decimals="-3" id="f-496" unitRef="usd">1112000</us-gaap:ConstructionInProgressGross>
    <us-gaap:ConstructionInProgressGross contextRef="c-11" decimals="-3" id="f-497" unitRef="usd">356000</us-gaap:ConstructionInProgressGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-2" decimals="-3" id="f-498" unitRef="usd">110241000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-11" decimals="-3" id="f-499" unitRef="usd">113660000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-2" decimals="-3" id="f-500" unitRef="usd">88394000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-11" decimals="-3" id="f-501" unitRef="usd">84085000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-2" decimals="-3" id="f-502" unitRef="usd">21847000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-11" decimals="-3" id="f-503" unitRef="usd">29575000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation contextRef="c-1" decimals="-5" id="f-504" unitRef="usd">9600000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-27" decimals="-5" id="f-505" unitRef="usd">11900000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-28" decimals="-5" id="f-506" unitRef="usd">11300000</us-gaap:Depreciation>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c-1" id="f-507">Commitments and Contingencies&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has non-cancelable operating leases for manufacturing, laboratory, office and warehouse space in Maryland  The Company&#x2019;s leases each have one or more five-year options to renew&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In December 2022, the Company amended the existing lease on its headquarters space to extend the lease term through 2035 in exchange for certain concessions from the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;lessor.  This amendment was accounted for as a lease modification, and the right-of-use asset and lease liability were remeasured at the modification date, resulting in an increase to both balances of approximately $14.0 million.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents supplemental balance sheet information related to operating leases:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:76.092%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.011%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.013%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Weighted-average remaining lease term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2023 and&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; 2022, t&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;he Company made cash payments for operating leases of $5.9 million and $6.9 million, respectively. As of December&#160;31, 2023 and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; 2022,&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; the Company&#x2019;s ROU assets were valued at $23.8 million and $27.3 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease cost for the years ended &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2023&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and 2022 were as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:76.225%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.946%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.381%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.948%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Operating lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Sublease income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,109)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,076)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2023&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the maturities of the Company&#x2019;s operating lease liabilities were as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:86.473%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.327%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36,306)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;In-licensing arrangement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2022, the Company entered into a non-exclusive license agreement with Synaffix B.V., a Lonza company, (Synaffix) to develop, manufacture and commercialize up to three antibody-drug conjugate targets using Synaffix&#x2019;s proprietary technology. The Company made an upfront payment to Synaffix upon contract execution. In March 2023, the Company and Synaffix amended the agreement, adding four additional targets. Assuming all seven targets are successfully developed and commercialized, the Company would be obligated to pay up to $2.8&#160;billion for development, regulatory and sales milestones. Finally, pursuant to the terms of this license agreement, as amended, upon commencement of commercial sales of any products developed from these targets, the Company would be required to pay Synaffix tiered royalties in the low&#x2011;single digit percentages on net sales of the respective products. The Company may terminate this agreement at any time with 30 days&#x2019; notice to Synaffix. Amounts paid to Synaffix under this agreement are recorded as research and development expense in the consolidated statement of operations.  The Company incurred $2.8&#160;million and $1.0&#160;million in expense under this agreement during the years ended December&#160;31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="c-131" id="f-508">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <mgnx:RightOfUseAssetAndLeaseLiabilityIncrease contextRef="c-2" decimals="-5" id="f-509" unitRef="usd">14000000</mgnx:RightOfUseAssetAndLeaseLiabilityIncrease>
    <mgnx:ScheduleOfSupplementalBalanceSheetInformationOperatingLeasesTableTextBlock contextRef="c-1" id="f-510">&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents supplemental balance sheet information related to operating leases:&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:76.092%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.011%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.013%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Weighted-average remaining lease term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</mgnx:ScheduleOfSupplementalBalanceSheetInformationOperatingLeasesTableTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-2" id="f-511">P11Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-11" id="f-512">P11Y1M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:LesseeOperatingLeaseDiscountRate contextRef="c-2" decimals="3" id="f-513" unitRef="number">0.120</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:LesseeOperatingLeaseDiscountRate contextRef="c-11" decimals="3" id="f-514" unitRef="number">0.120</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:OperatingLeasePayments contextRef="c-1" decimals="-5" id="f-515" unitRef="usd">5900000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c-27" decimals="-5" id="f-516" unitRef="usd">6900000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-2" decimals="-5" id="f-517" unitRef="usd">23800000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-11" decimals="-5" id="f-518" unitRef="usd">27300000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:LeaseCostTableTextBlock contextRef="c-1" id="f-519">&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease cost for the years ended &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2023&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and 2022 were as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:76.225%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.946%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.381%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.948%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Operating lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Sublease income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,109)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,076)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost contextRef="c-1" decimals="-3" id="f-520" unitRef="usd">7459000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-27" decimals="-3" id="f-521" unitRef="usd">5597000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-1" decimals="-3" id="f-522" unitRef="usd">1316000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-27" decimals="-3" id="f-523" unitRef="usd">1451000</us-gaap:VariableLeaseCost>
    <us-gaap:SubleaseIncome contextRef="c-1" decimals="-3" id="f-524" unitRef="usd">1109000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome contextRef="c-27" decimals="-3" id="f-525" unitRef="usd">1076000</us-gaap:SubleaseIncome>
    <us-gaap:LeaseCost contextRef="c-1" decimals="-3" id="f-526" unitRef="usd">7666000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c-27" decimals="-3" id="f-527" unitRef="usd">5972000</us-gaap:LeaseCost>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c-1" id="f-528">&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2023&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the maturities of the Company&#x2019;s operating lease liabilities were as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:86.473%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.327%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36,306)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c-2" decimals="-3" id="f-529" unitRef="usd">4004000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c-2" decimals="-3" id="f-530" unitRef="usd">5084000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c-2" decimals="-3" id="f-531" unitRef="usd">4209000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="c-2" decimals="-3" id="f-532" unitRef="usd">4927000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive contextRef="c-2" decimals="-3" id="f-533" unitRef="usd">6049000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive contextRef="c-2" decimals="-3" id="f-534" unitRef="usd">46003000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c-2" decimals="-3" id="f-535" unitRef="usd">70276000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c-2" decimals="-3" id="f-536" unitRef="usd">36306000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c-2" decimals="-3" id="f-537" unitRef="usd">33970000</us-gaap:OperatingLeaseLiability>
    <mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement contextRef="c-132" decimals="-5" id="f-538" unitRef="usd">2800000000</mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-133" decimals="-5" id="f-539" unitRef="usd">2800000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-134" decimals="-5" id="f-540" unitRef="usd">1000000</us-gaap:ResearchAndDevelopmentExpense>
    <mgnx:LiabilityRelatedToSaleOfFutureRoyaltiesTextBlock contextRef="c-1" id="f-541">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;7.  Royalty Monetization Arrangement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2023, the Company entered into a Purchase and Sale Agreement (Royalty Purchase Agreement) with DRI Healthcare Acquisitions LP (DRI), a wholly owned subsidiary of DRI Healthcare Trust, for the sale to DRI of the Company&#x2019;s single-digit royalty interest on global net sales of TZIELD (teplizumab-mzwv) under the Company&#x2019;s asset purchase agreement dated May 7, 2018, as amended (the Provention APA), with Provention. The Company retained its other economic interests related to TZIELD under the Provention APA, including future potential development, regulatory, and commercial milestones.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the Royalty Purchase Agreement, the Company received $100.0&#160;million from DRI for its single-digit royalty interest on global net sales of TZIELD under the Provention APA (the Royalty Interest). Additionally, the Company has the right to receive a 50% share of the royalty on global net sales above a certain annual threshold (the Retained Interest). In addition, the Company was eligible to receive up to $50.0&#160;million upon the occurrence of pre-specified events tied to the advancement of TZIELD for the treatment of newly diagnosed type 1 diabetes. This milestone was achieved in July 2023 as described below. The Company is also eligible to receive an additional $50.0&#160;million milestone if TZIELD achieves a certain level of net sales (Sales Milestone Payment). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The $100.0&#160;million proceeds received from DRI for the Royalty Interest were recorded as a liability related to future royalties, net of transaction costs of $0.3&#160;million, which was to be amortized over the term of the arrangement using the effective interest rate method. At inception, the Company accounted for the Royalty Purchase Agreement as a financing arrangement because the Company had significant continuing involvement in the delivery of future royalty payments to DRI and other existing obligations under the Provention APA. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2023, the Company entered into an agreement (the Tripartite Agreement) with DRI and a subsidiary of Sanofi S.A. (Sanofi), whereby the Company consented to the sale of DRI&#x2019;s Royalty Interest and related milestone payment obligations to Sanofi. The Tripartite Agreement eliminated the Company&#x2019;s obligation to deliver payments to DRI related to the Royalty Interest and removed all of the Company&#x2019;s other obligations under the Royalty Purchase Agreement. The Royalty Interest will be paid directly to Sanofi by Provention. As a result, the Company&#x2019;s royalty rights are only for the Retained Interest. This change in rights and obligations resulted in a change in the terms of the liability related to future royalties which was evaluated by the Company in accordance with ASC 470-50, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt &#x2014; Modifications and Extinguishments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Company concluded that the execution of the Tripartite Agreement resulted in a modification to the liability related to future royalties.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined that the terms of the new liability related to the single-digit future royalties and the original liability related to future royalties were substantially different as the Company no longer receives payments for the Royalty Interest and therefore has a significantly reduced liability to make payments in accordance with the Royalty Purchase Agreement. The new liability related to future royalties was determined to be de minimis.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result, the Company recorded $100.9&#160;million within other income on the statement of operations and comprehensive loss during the three months ended June 30, 2023. There was no modification to the Company's Retained Interest in the Tripartite Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2023, Sanofi reported achievement of the primary endpoint milestone event related to the $50.0&#160;million milestone noted above. Given that the Company has no continuing obligation to pay the Royalty Interest to Sanofi, the Company recorded this milestone within other income on the statement of operations and comprehensive loss during the three months ended September 30, 2023.  Also in September 2023, the Company and Sanofi executed Amendment No. 2 to the Provention APA to incorporate the Sales Milestone Payment obligation from the Royalty Purchase Agreement into the Provention APA.  In addition, the Company and Sanofi terminated the Royalty Purchase Agreement, which did not result in a material impact to the financial statements given the fair value of the liability related to future royalties was de minimis.   &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes to the liability related to future royalties were as follows for the year ended December&#160;31, 2023 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:68.636%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.580%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability related to future royalties - beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Proceeds from sale of future royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred transaction costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(343)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalty revenue payable to DRI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(157)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain on royalty monetization arrangement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(150,930)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability related to future royalties - ending balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</mgnx:LiabilityRelatedToSaleOfFutureRoyaltiesTextBlock>
    <mgnx:UpfrontPayment contextRef="c-135" decimals="-5" id="f-542" unitRef="usd">100000000</mgnx:UpfrontPayment>
    <mgnx:ProceedsfromRoyaltiesPercent contextRef="c-136" decimals="2" id="f-543" unitRef="number">0.50</mgnx:ProceedsfromRoyaltiesPercent>
    <mgnx:GainOnRoyaltyMonetizationArrangement contextRef="c-137" decimals="-5" id="f-544" unitRef="usd">50000000</mgnx:GainOnRoyaltyMonetizationArrangement>
    <mgnx:FutureRevenue contextRef="c-136" decimals="-5" id="f-545" unitRef="usd">50000000</mgnx:FutureRevenue>
    <mgnx:UpfrontPayment contextRef="c-135" decimals="-5" id="f-546" unitRef="usd">100000000</mgnx:UpfrontPayment>
    <mgnx:TransactionCost contextRef="c-135" decimals="-5" id="f-547" unitRef="usd">300000</mgnx:TransactionCost>
    <mgnx:GainOnRoyaltyMonetizationArrangement contextRef="c-138" decimals="-5" id="f-548" unitRef="usd">100900000</mgnx:GainOnRoyaltyMonetizationArrangement>
    <mgnx:GainOnRoyaltyMonetizationArrangement contextRef="c-137" decimals="-5" id="f-549" unitRef="usd">50000000</mgnx:GainOnRoyaltyMonetizationArrangement>
    <mgnx:LiabilityRelatedToFutureRoyaltyTableTextBlock contextRef="c-1" id="f-550">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes to the liability related to future royalties were as follows for the year ended December&#160;31, 2023 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:68.636%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.580%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability related to future royalties - beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Proceeds from sale of future royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred transaction costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(343)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalty revenue payable to DRI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(157)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain on royalty monetization arrangement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(150,930)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability related to future royalties - ending balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</mgnx:LiabilityRelatedToFutureRoyaltyTableTextBlock>
    <mgnx:LiabilityRelatedToFutureRoyalties contextRef="c-11" decimals="-3" id="f-551" unitRef="usd">0</mgnx:LiabilityRelatedToFutureRoyalties>
    <mgnx:ProceedsFromSaleOfFutureRoyalties contextRef="c-1" decimals="-3" id="f-552" unitRef="usd">150000000</mgnx:ProceedsFromSaleOfFutureRoyalties>
    <mgnx:DeferredTransactionCosts contextRef="c-1" decimals="-3" id="f-553" unitRef="usd">343000</mgnx:DeferredTransactionCosts>
    <mgnx:PrincipalPaymentsOnRoyaltyMonetizationArrangement contextRef="c-1" decimals="-3" id="f-554" unitRef="usd">157000</mgnx:PrincipalPaymentsOnRoyaltyMonetizationArrangement>
    <mgnx:NonCashInterestExpenseRecognized contextRef="c-1" decimals="-3" id="f-555" unitRef="usd">1430000</mgnx:NonCashInterestExpenseRecognized>
    <mgnx:GainOnRoyaltyMonetizationArrangement contextRef="c-1" decimals="-3" id="f-556" unitRef="usd">150930000</mgnx:GainOnRoyaltyMonetizationArrangement>
    <mgnx:LiabilityRelatedToFutureRoyalties contextRef="c-2" decimals="-3" id="f-557" unitRef="usd">0</mgnx:LiabilityRelatedToFutureRoyalties>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-558">Stockholders' Equity&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's amended and restated certificate of incorporation authorizes 125,000,000 shares of common stock, and 5,000,000 shares of undesignated preferred stock, both with a par value of $0.01 per share.&#160;There were no shares of undesignated preferred stock issued or outstanding as of December&#160;31, 2023 or 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2020, the Company entered into a sales agreement (Sales Agreement) with an agent to sell, from time to time, shares of its common stock having an aggregate sales price of up to $100.0 million through an &#x201c;at the market offering&#x201d; (ATM Offering) as defined in Rule 415 under the Securities Act of 1933, as amended. The Company sold 3,622,186 shares of common stock resulting in net proceeds of approximately $98.2&#160;million through December 31, 2021 under the Sales Agreement. In April 2021, the Company entered into Amendment No. 1 to the Sales Agreement which increased the amount of the Company&#x2019;s common stock that can be sold by the Company through its agent under the ATM Offering, from an aggregate offering price of up to $100.0&#160;million to an aggregate offering price of up to $300.0&#160;million. During the year ended December 31, 2022, the Company sold 160,480 shares of common stock at a weighted average price per share of $6.87, resulting in net proceeds of approximately $1.1 million, net of underwriting discounts and commissions and other offering expenses. In March 2023, the Company terminated the Sales Agreement and entered into a new sales agreement with an agent to sell, from time to time, shares of its common stock having an aggregate sales price of up to $100.0&#160;million through an ATM Offering. During the year ended December&#160;31, 2023, the Company sold 95,000 shares of common stock at a weighted average price per share of $6.60, resulting in net proceeds of approximately $0.6 million, net of offering expenses.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-2" decimals="INF" id="f-559" unitRef="shares">125000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c-139"
      decimals="INF"
      id="f-560"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-139"
      decimals="INF"
      id="f-561"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-140"
      decimals="INF"
      id="f-562"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-139"
      decimals="INF"
      id="f-563"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c-140"
      decimals="INF"
      id="f-564"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c-139"
      decimals="INF"
      id="f-565"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-140"
      decimals="INF"
      id="f-566"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <mgnx:CommonStockMaximumAmountAvailableForIssuance contextRef="c-141" decimals="-5" id="f-567" unitRef="usd">100000000</mgnx:CommonStockMaximumAmountAvailableForIssuance>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-142"
      decimals="INF"
      id="f-568"
      unitRef="shares">3622186</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-142" decimals="-5" id="f-569" unitRef="usd">98200000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <mgnx:CommonStockMaximumAmountAvailableForIssuance contextRef="c-141" decimals="-5" id="f-570" unitRef="usd">100000000</mgnx:CommonStockMaximumAmountAvailableForIssuance>
    <mgnx:CommonStockMaximumAmountAvailableForIssuanceIncrease contextRef="c-143" decimals="-5" id="f-571" unitRef="usd">300000000</mgnx:CommonStockMaximumAmountAvailableForIssuanceIncrease>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-144"
      decimals="INF"
      id="f-572"
      unitRef="shares">160480</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-145"
      decimals="2"
      id="f-573"
      unitRef="usdPerShare">6.87</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-144" decimals="-5" id="f-574" unitRef="usd">1100000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <mgnx:CommonStockMaximumAmountAvailableForIssuance contextRef="c-141" decimals="-5" id="f-575" unitRef="usd">100000000</mgnx:CommonStockMaximumAmountAvailableForIssuance>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-146"
      decimals="INF"
      id="f-576"
      unitRef="shares">95000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-147"
      decimals="2"
      id="f-577"
      unitRef="usdPerShare">6.60</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-146" decimals="-5" id="f-578" unitRef="usd">600000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <mgnx:CollaborationAndLicenseAgreementsDisclosureTextBlock contextRef="c-1" id="f-579">Revenue&lt;div style="margin-bottom:9pt;margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; Collaborative and Other Agreements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Incyte Corporation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Incyte License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2017, the Company entered into an exclusive global collaboration and license agreement with Incyte, which was amended in March 2018, April 2022 and July 2022, for retifanlimab, an investigational monoclonal antibody that inhibits PD-1 (Incyte License Agreement). Incyte has obtained exclusive worldwide rights for the development and commercialization of retifanlimab in all indications, while the Company retains the right to develop its pipeline assets in combination with retifanlimab. Under the terms of the Incyte License Agreement, Incyte paid the Company an upfront payment of $150.0 million in 2017. MacroGenics will manufacture a portion of Incyte&#x2019;s global commercial supply of retifanlimab. In March 2023, the FDA approved Incyte's Biologics License Application (BLA) for ZYNYZ (retifanlimab-dlwr) for the treatment of adults with metastatic or recurrent locally advanced Merkel cell carcinoma. Incyte has stated it is pursuing development of retifanlimab in potentially registration-enabling studies, including in patients with Merkel cell carcinoma, squamous cell carcinoma of the anal canal, MSI-high endometrial cancer and non-small cell lung cancer.  Incyte is also pursuing development of retifanlimab in combination with multiple product candidates from its pipeline.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the Incyte License Agreement, as amended, Incyte will lead global development of retifanlimab. Assuming successful development and commercialization by Incyte in multiple indications, the Company could receive up to a total of  $435.0 million in development and regulatory milestones, and up to $330.0 million in commercial milestones. From the inception of the Incyte License Agreement through &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2023&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company has recognized $115.0 million in development milestones under the Incyte License Agreement, including $15.0 million received following the FDA approval of ZYNYZ. The Company is eligible to receive tiered royalties of 15% to 24% on global net sales. The Company retains the right to develop its pipeline assets in combination with retifanlimab, with Incyte commercializing retifanlimab and the Company commercializing its asset(s), if any such potential combinations are approved. In addition, the Company retains the right to manufacture a portion of both companies' global commercial supply needs of retifanlimab, subject to the separate commercial supply agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:42pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated the Incyte License Agreement under the provisions of ASC 606 at inception and identified the following two performance obligations under the agreement: (i) the license of retifanlimab and (ii) the performance of certain clinical activities through a brief technology transfer period. The Company determined that the license and clinical activities are separate performance obligations because they are capable of being distinct, and are distinct in the context of the contract. The license has standalone functionality as it is sublicensable, Incyte has significant capabilities in performing clinical trials, and Incyte is capable of performing these activities without the Company's involvement; the Company performed the activities during the transfer period as a matter of convenience. The Company determined that the transaction price of the Incyte License Agreement at inception was $154.0 million, consisting of the consideration to which the Company was entitled in exchange for the license and an estimate of the consideration for clinical activities to be performed. The transaction price was allocated to each performance obligation based on their relative standalone selling price. The standalone selling price of the license was determined using the adjusted market assessment approach considering similar collaboration and license &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;agreements. The standalone selling price for the agreed-upon clinical activities to be performed was determined using the expected cost approach based on similar arrangements the Company has with other parties. The potential development and regulatory milestone payments are &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;fully constrained until the Company concludes that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and as such have been excluded from the transaction price. Any consideration related to sales-based milestones and royalties will be recognized when the related sales occur, as they were determined to relate predominantly to the license granted to Incyte and, therefore, have also been excluded from the transaction price. The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur. &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From 2018 through December&#160;31, 2023&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;it became probable that a significant reversal of cumulative revenue would not occur for development milestones totaling &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$115.0 million&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; related to clinical and regulatory activities related to the further advancement of retifanlimab.  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Therefore&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; the associated consideration was added to the estimated transaction price and was recognized as revenue. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:42pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$150.0 million&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; allocated to the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;license when it satisfied its performance obligation and transferred the license to Incyte in 2017. The $4.0 million allocated to the clinical activities was recognized ratably as services were performed during 2017 and 2018.  The Company recognized the $15.0 million ZYNYZ approval milestone as revenue under the Incyte License Agreement during the year ended December&#160;31, 2023. The Company recognized revenue of $15.0 million, $30.0 million and $15.0 million under the Incyte License Agreement during the years ended December&#160;31, 2023, 2022 and 2021, respectively, all of which was related to development milestones.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:42pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Incyte Clinical Supply Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:42pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2018, the Company entered into an agreement with Incyte under which the Company is to perform development and manufacturing services for Incyte&#x2019;s clinical needs of retifanlimab (Incyte Clinical Supply Agreement). The Company evaluated this agreement under ASC 606 and identified one performance obligation under the agreement: to perform services related to the development and manufacturing of the clinical supply of retifanlimab. The transaction price is based on the costs incurred to develop and manufacture drug product and drug substance, and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. The transaction price is being recognized using the input method reflecting the costs incurred (including resources consumed and labor hours expended) related to the manufacturing services. During the years ended &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2023&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, 2022 and 2021, the Company recognized revenue of $1.9 million, $0.7 million and $1.5 million, respectively, for services performed under this agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:42pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Incyte Commercial Supply Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:42pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2020, the Company entered into an agreement with Incyte pursuant to which the Company is entitled to manufacture a portion of the global commercial supply needs for retifanlimab (Incyte Commercial Supply Agreement). Unless terminated earlier, the term of the Incyte Commercial Supply Agreement will expire upon the expiration of Incyte&#x2019;s obligation to pay royalties under the Incyte License Agreement.  The Company evaluated this agreement under ASC 606 and identified one performance obligation under the agreement: to perform services related to manufacturing the commercial supply of retifanlimab. The transaction price is based on a fixed price per batch of bulk drug substance to be manufactured and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. The transaction price is being recognized using the input method reflecting the costs incurred (including resources consumed and labor costs incurred) related to the manufacturing services. During the years ended &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2023, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2022, and 2021 the Company recognized revenue of $4.2 million, $0.3&#160;million and $7.8&#160;million, respectively, for services performed under this agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%"&gt;Gilead Sciences, Inc &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2022, the Company and Gilead Sciences, Inc. (Gilead) entered into an exclusive option and collaboration agreement (Gilead Agreement) to develop and commercialize MGD024, an investigational, bispecific antibody that binds CD123 and CD3, and create bispecific cancer antibodies using the Company&#x2019;s DART platform and undertake their early development under a maximum of two separate bispecific cancer target research programs. Under the agreement, the Company will continue the ongoing phase 1 trial for MGD024 accordi&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ng to a development plan&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, during which Gilead will have the right to exercise an option granted to Gilead to obtain an exclusive license under the Company&#x2019;s intellectual property to develop and commercialize MGD024 and other bispecific antibodies of MacroGenics that bind CD123 and CD3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (CD123 Option). The agreement also grants Gilead the right, within its first two years, to nominate a bispecific cancer target set for up to two research programs conducted by the Company and to exercise separate options to obtain an exclusive license for the development, commercialization and exploitation of molecules created under each research program (Research Program Option). Gilead nominated the first of the two research programs in September 2023.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the Gilead Agreement, in October 2022 Gilead paid the Company an upfront payment of $60.0&#160;million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assuming Gilead exercises the CD123 Option and Research Program Option and successfully develops and commercializes MGD024, or other CD123 products developed under the agreement, and products result from the two additional research programs, the Company would be eligible to receive up to $1.7 billion&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in target nomination, option fees, and development, regulatory and commercial milestones. Assuming exercise of the CD123 Option, the Company will also be eligible to receive tiered, low double-digit royalties on worldwide net sales of MGD024 (or other CD123 products developed under the agreement) and assuming exercise of the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research Program Option,&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; a flat royalty on worldwide net sales of any products resulting from the two research programs.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated the Gilead Agreement under the provisions of ASC 606 and identified the following material promises under the agreement: (i) a license to perform any activities allocated to Gilead under the MGD024 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;development plan&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;; (ii) development activities regarding MGD024, including manufacturing, research and early clinical development activities, necessary to deliver an informational package of development and clinical data, information and materials specified in the Gilead Agreement during the period &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; which Gilead can exercise the CD123 Option; (iii) the CD123 Option and (iv) the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research Program Option&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company concluded that the license under the MGD024 developme&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;nt plan&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and development activities are not distinct from one another, as the license has limited value without the Company&#x2019;s performance of the development activities. Therefore, the Company determined that the development term license and development activities should be combined into a single performance obligation (Development Activities). The CD123 Option is considered a material right as the value of the exclusive license exceeds the payment to be made by Gilead if they exercise their option to obtain an exclusive license to develop and commercialize MGD024 or an alternative CD123 product, and is therefore a distinct performance obligation. The Company determined that the Research Program Option does not provide a material right, as there is no discount on its standalone selling price.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with ASC 606, the Company determined that the initial transaction price under the Gilead Agreement was $60.0&#160;million, consisting of the upfront, non-refundable payment paid by Gilead. The CD123 Option and Research Program Option payments are excluded from the initial transaction price at contract inception along with any future development, regulatory, and commercial milestone payments (including royalties) following the CD123 Option and Research Program Option exercise.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company will reassess the amount of variable consideration included in the transaction price every reporting period.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:13.5pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company allocated the $60.0&#160;million upfront payment in the transaction price to the Development Activities and the CD123 Option based on each performance obligation&#x2019;s relative standalone selling price. The standalone selling price for the Development Activities was calculated using an expected cost-plus margin approach &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for the pre-option development timeline.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the standalone selling price of the CD123 Option, the Company utilized an income-based approach which included the following key assumptions:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;post-option development timeline and costs, forecasted revenues, discount rates and probabilities of technical and regulatory success. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is recognizing revenue related to the Development Activities performance obligation over the estimated period to complete the Development Activities using an input method reflecting the costs incurred (including resources consumed and labor hours expended) related to the Development Activities. The Company has deferred revenue recognition related to the CD123 Option.  If Gilead exercises the CD123 Option and obtains an exclusive license, the Company will recognize revenue as it fulfills its obligations under the Gilead Agreement. If the CD123 Option is not exercised, the Company will recognize the entirety of the revenue in the period when the CD123 Option expires.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2023&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and 2022, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the Company recorded revenue of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$1.5&#160;million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$0.2&#160;million respectively, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;related to the Gilead Agreement. As of &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2023&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$58.3&#160;million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in revenue was deferred under this agreement, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$2.2&#160;million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of which was current and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$56.1&#160;million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of which was non-current.As of December&#160;31, 2022, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$59.8&#160;million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in revenue was deferred under this agreement, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$1.8&#160;million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of which was current and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$58.0&#160;million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of which was non-current.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2023, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the Company and Gilead executed a Letter Agreement through which Gilead nominated the first of the two research programs contemplated in the Gilead Agreement (First Research Program), the Company granted Gilead a research license, and the parties agreed on a research plan for the First Research Program under which the Company will provide research and development services. Gilead paid the Company a $15.7&#160;million nomination fee.  The Company evaluated the Letter Agreement under the terms of ASC 606, and concluded that it is a modification to the Gilead Agreement that results in a separate contract since the modification is for additional goods and services that are distinct and at standalone selling price. The Company determined that the license and the related research and development activities were not distinct from one another, as the license has limited value without the performance of the research and development activities. As such, the Company determined that these should be combined into a single performance obligation. Gilead also has the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;exclusive option to pay the Company $10.0&#160;million to obtain a license to exploit the research molecule and research product with respect to the First Research Program. The Company determined that this exclusive option does not provide a material right, as there is no discount on its standalone selling price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with ASC 606, the Company determined that the initial transaction price for the First Research Program agreement was $15.7&#160;million, consisting of the non-refundable payment paid by Gilead. The Company is recognizing revenue over the estimated period to complete the services using the input method reflecting the costs incurred (including resources consumed and labor hours expended) related to the research and development services.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2023&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company recorded revenue of $0.8&#160;million &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;related to the First Research Program.  As of December&#160;31, 2023, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$14.9&#160;million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in revenue was deferred under this agreement, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$11.8&#160;million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of which was current and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$3.1&#160;million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of which was non-current. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Zai Lab US LLC&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2021, the Company entered into a collaboration and license agreement with Zai Lab US LLC (Zai Lab Limited and Zai Lab US LLC, either singularly or collectively are referred to herein as Zai Lab) involving collaboration programs and license-only programs (collectively, the Programs) encompassing four separate immuno-oncology molecules (2021 Zai Lab Agreement). During 2022, the Company and Zai Lab agreed to discontinue research and development of the lead program, and in August 2023, the parties mutually agreed to terminate the 2021 Zai Lab Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the execution of the 2021 Zai Lab Agreement, Zai Lab paid the Company an upfront payment of $25.0&#160;million. Additionally, as part of the consideration for the rights granted to Zai Lab under the 2021 Zai Lab Agreement, the Company and Zai Lab entered into a stock purchase agreement whereby Zai Lab paid the Company approximately $30.0 million to purchase shares of the Company&#x2019;s common stock, par value $0.01, at a fixed price of $31.30 which represented a $10.4 million premium over the share price on the stock purchase agreement date. The Company was also entitled to receive reimbursements from Zai Lab for certain research and development costs incurred by the Company and milestones and tiered royalties on annual net sales of products in Zai Lab&#x2019;s territory assuming successful development and commercialization of the Programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated the 2021 Zai Lab Agreement under the provisions of ASC 606 and identified the following material promises: (i) exclusive licenses to develop, manufacture and commercialize the products in Zai Lab&#x2019;s territory for each Program and (ii) certain research and development activities for the lead program. The Company determined that for the lead program, the license was not distinct from the related research and development activities, considering the early stage of development of the molecule and the Company&#x2019;s significant expertise in this area and as such, the research and development services were expected to significantly modify and customize the license. Therefore, for the lead program, the license and the services were combined into a single performance obligation. Since the other programs each represented distinct intellectual property and there were no other services included in the 2021 Zai Lab Agreement related to these licenses, each license was considered to be a distinct performance obligation. As such, there were four performance obligations included in the 2021 Zai Lab Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company concluded that the estimated transaction price was $40.4 million, consisting of the $25.0 million upfront payment, the $10.4 million premium related to the purchase of the Company&#x2019;s common stock, and the $5.0 million estimated reimbursement by Zai Lab for research and development activities for the lead program. The potential milestone payments were deemed to be fully constrained until the Company concludes that achievement of the milestone is probable, and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such were excluded from the transaction price. Any consideration related to royalties would have been recognized if and when the related sales occurred, as they were determined to relate predominantly to the license granted to Zai Lab and, therefore, were also excluded from the transaction price. The Company re-assessed the transaction price in each reporting period and when events whose outcomes were resolved or other changes in circumstances occurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The transaction price of $40.4 million was then allocated to the four performance obligations based on their relative standalone selling price. The standalone selling price of the performance obligations was not directly observable; therefore, the Company estimated the standalone selling price using an adjusted market assessment approach, representing the amount that the Company believed a market participant was willing to pay for the product or service. The estimate was based on consideration of observable inputs, such as, values of other preclinical collaboration arrangements adjusted for the Company&#x2019;s estimate of the probability of success for each Program. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue related to the lead program license and related research and development services performance obligation was recognized over time as the research and development activities were performed. The Company utilized a cost-based input method according to costs incurred to date compared to estimated total costs. The transfer of control occurred over this time &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;period and, in management&#x2019;s judgment, was the best measure of progress towards satisfying the performance obligations. The Company recognized revenue allocated to the other programs at a point in time upon transfer of the licenses to Zai Lab in June 2021. During the year ended &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2023, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;no&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;revenue was recognized under the 2021 Zai Lab Agreement. During the years ended December&#160;31, 2022,&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and 2021, the Company recognized revenue of $16.8 million and $20.3 million&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;respectively, under the 2021 Zai Lab Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Provention Bio, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2018, the Company entered into a license agreement with Provention pursuant to which the Company granted Provention exclusive global rights for the purpose of developing and commercializing MGD010 (renamed PRV-3279), a CD32B x CD79B DART molecule being developed for the treatment of autoimmune indications (Provention License Agreement). As partial consideration for the Provention License Agreement, Provention granted the Company a warrant to purchase shares of Provention&#x2019;s common stock at an exercise price of $2.50 per share. If Provention successfully develops, obtains regulatory approval for, and commercializes PRV-3279, the Company will be eligible to receive up to $65.0 million in development and regulatory milestones and up to $225.0 million in commercial milestones. As of December&#160;31, 2023, the Company has not recognized any milestone revenue under this agreement. If commercialized, the Company would be eligible to receive single-digit royalties on net sales of the product. The license agreement may be terminated by either party upon a material breach or bankruptcy of the other party, by Provention without cause upon prior notice to the Company, and by the Company in the event that Provention challenges the validity of any licensed patent under the agreement, but only with respect to the challenged patent.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Also, in 2018, the Company entered into the Provention APA pursuant to which Provention acquired the Company&#x2019;s interest in teplizumab (renamed PRV-031), a monoclonal antibody being developed for the treatment of type 1 diabetes. As partial consideration for the Provention APA, Provention granted the Company a warrant to purchase shares of Provention&#x2019;s common stock at an exercise price of $2.50 per share. Under the Provention APA, Provention is obligated to pay the Company contingent milestone payments totaling $170.0 million upon the achievement of certain regulatory milestones.  In addition, Provention is obligated to make contingent milestone payments to the Company totaling $225.0 million upon the achievement of certain commercial milestones as well as single-digit royalties on net sales of the product. In March 2023, the Company entered into a Royalty Purchase Agreement with DRI; see Note 7, Royalty Monetization Arrangement, for additional information. The FDA approved the BLA for TZIELD in November 2022, and the Company recognized $60.0 million in revenue related to this regulatory milestone during the year ended December 31, 2022.  In November 2022, the Company and Provention amended the Provention APA. Under this amendment, the milestone for first approval was split into four equal payments, all of which were received prior to June 30, 2023.  Provention has also agreed to pay third-party obligations, including low single-digit royalties, of which a portion is creditable against royalties payable to the Company, aggregate milestone payments of up to approximately $1.3 million and other consideration, for certain third-party intellectual property under agreements Provention assumed pursuant to the Provention APA. Further, Provention is required to pay the Company a low double-digit percentage of certain consideration to the extent it is received in connection with a future grant of rights to PRV-031 by Provention to a third party.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated the Provention License Agreement and Provention APA under the provisions of ASC 606 and determined that they should be accounted for as a single contract and identified two performance obligations within that contract: (i) the license of MGD010 and (ii) the title to teplizumab. The Company determined that the transaction price of the Provention agreements was $6.1 million, based on the Black-Scholes valuation of the warrants to purchase a total of 2,432,688 shares of Provention's common stock. The transaction price was allocated to each performance obligation based on the number of shares of common stock the Company is entitled to purchase under each warrant. The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such were excluded from the initial transaction price. Any consideration related to sales-based milestones and royalties will be recognized when the related sales occur, therefore they have also been excluded from the transaction price. The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur. The Company recognized revenue of $6.1 million when it satisfied its performance obligations under the agreements and transferred the MGD010 license and teplizumab assets to Provention in 2018. In 2019, the Company exercised the warrants on a cashless basis, and subsequently sold all the shares of Provention common stock acquired through the exercise. No shares of Provention stock were held subsequent to the sale of stock in 2019. During the year ended December 31, 2022, &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;it became probable that a significant reversal of cumulative revenue would not occur for a regulatory milestone of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$60.0 million&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, t&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;herefore&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; the associated consideration was added to the estimated transaction price and was recognized as revenue. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2023, &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2022 and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2021, the Company recognized revenue of $5.6 million, $60.0 million and $1.3 million, respectively, under these agreements.   &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 27, 2023, Sanofi completed its acquisition of Provention and the Company entered into a Tripartite Agreement, as discussed in Note 7, Royalty Monetization Arrangement. Also on April 27, 2023, the Company and a subsidiary of Sanofi entered into a Side Letter Agreement which specified certain post-closing covenants and also accelerated certain payments due to the Company under the Provention APA upon the closing of the merger between Sanofi and Provention. The Company evaluated the Side Letter Agreement as a contract modification under the provisions of ASC 606. As a result, &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;during the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;year ended December 31, 2023&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company recognized $5.5&#160;million related to other consideration under the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Provention APA&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and Side Letter Agreement. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2023, the Company recognized $0.3&#160;million in royalty revenue under the Provention APA based on sales of TZIELD. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As discussed in Note 7, in September 2023, the Company and Sanofi executed Amendment No. 2 to the Provention APA and terminated the Royalty Purchase Agreement with DRI.  As a result, the remaining $50.0&#160;million milestone under the Royalty Purchase Agreement was incorporated into the Provention APA.  The Company evaluated the amendment as a contract modification under the provisions of ASC 606 which did not result in any additional revenue being recognized during the year ended December&#160;31, 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Manufacturing Services Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Incyte &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2022, the Company entered into a Manufacturing and Clinical Supply Agreement with Incyte (Incyte Manufacturing and Clinical Supply Agreement) to provide manufacturing services to produce certain Incyte bulk drug substance over a three-year period at one of the Company&#x2019;s manufacturing facilities. Under the terms of the Incyte Manufacturing and Clinical Supply Agreement, the Company received an upfront payment of $10.0&#160;million and is eligible to receive annual fixed payments paid quarterly over the term of the contract totaling $14.4&#160;million. The Company will also be reimbursed for materials used to manufacture product as well as other costs incurred to provide manufacturing services. In July 2022, the Company and Incyte executed an amendment to the Incyte Manufacturing and Clinical Supply Agreement which extended the term for one year and provided for an additional annual fixed payment of $5.1&#160;million (July 2022 Incyte Amendment). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated the Incyte Manufacturing and Clinical Supply Agreement and the July 2022 Incyte Amendment under the provisions of ASC 606 and identified one performance obligation to provide manufacturing runs to Incyte, as and when requested by Incyte, over the term of the contract that is part of a series of goods and services. The Company determined that the transaction price consists of the upfront payment received of $10.0&#160;million and the annual fixed payments totaling $19.5&#160;million. The Company will recognize revenue over time on a straight-line basis as the manufacturing services are provided to Incyte, as the Company determined that its efforts in providing the manufacturing services will be incurred evenly throughout the performance period and therefore straight-line revenue recognition closely approximates the level of effort for the manufacturing services. Variable consideration relating to the reimbursed materials and other reimbursed costs incurred to manufacture product for Incyte will be allocated to the related manufacturing activities and will be recognized as revenue as those activities occur.  Materials purchased by the Company to manufacture the product for Incyte are considered costs to fulfill a contract and will be capitalized and expensed as the materials are used to provide the manufacturing services. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2023 and 2022, the Company recognized revenue of $9.7&#160;million and $8.7&#160;million, respectively, under the Incyte Manufacturing and Clinical Supply Agreement. As of &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2023, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$7.0&#160;million&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in revenue was deferred under this agreement, all of which was current. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, $9.6&#160;million in revenue was deferred under this agreement, $8.1&#160;million of which was current and $1.5&#160;million of which was non-current.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Provention&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2022, the Company entered into a Manufacturing and Clinical Supply Agreement with Provention (Provention Manufacturing and Clinical Supply Agreement) to provide manufacturing services to produce certain Provention bulk drug substance. Under the terms of the Provention Manufacturing and Clinical Supply Agreement, the Company received an upfront payment and payments in accordance with the manufacturing schedule.  The Company was also reimbursed for materials used to manufacture product as well as other costs incurred to provide manufacturing services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated the Provention Manufacturing and Clinical Supply Agreement under the provisions of ASC 606 and identified one performance obligation to provide manufacturing services to Provention. The Company determined that the transaction price consisted of the upfront and other fixed payments totaling $4.6&#160;million. The Company will recognize revenue over time on a straight-line basis as the manufacturing services are provided to Provention, as the Company determined that its efforts in providing the manufacturing services will be incurred evenly throughout the performance period and therefore straight-line revenue recognition closely approximates the level of effort for the manufacturing services. Variable consideration relating to the reimbursed materials and other reimbursed costs incurred to manufacture product for Provention will be allocated &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;to the related manufacturing activities and will be recognized as revenue as those activities occur.  Materials purchased by the Company to manufacture the product for Provention are considered costs to fulfill a contract and will be capitalized and expensed as the materials are used to provide the manufacturing services. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized de minimis revenue during the year ended December&#160;31, 2023 under the Provention Manufacturing and Clinical Supply Agreement. During the year ended 2022, the Company recognized revenue of $5.3&#160;million under the Provention Manufacturing and Clinical Supply Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Government Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;NIAID Contract&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company entered into a contract with the National Institute of Allergy and Infectious Diseases (NIAID), effective as of September 15, 2015,&#160;to perform product development and to advance up to two DART molecules, MGD014 and MGD020 (NIAID Contract). Under the NIAID Contract, the Company will develop these product candidates for Phase 1/2 clinical trials as therapeutic agents, in combination with latency reversing treatments, to deplete cells infected with human immunodeficiency virus (HIV) infection. NIAID does not receive goods or services from the Company under this contract, therefore the Company does not consider NIAID to be a customer and concluded this contract is outside the scope of ASC 606.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Since the inception of the NIAID Contract, NIAID has exercised the two options contemplated in the original contract and executed modifications such that the total funded contract value as of December&#160;31, 2023 is $25.1 million. In addition, the most recent modification changed the period of performance under the NIAID Contract to end in July 2023.  The Company recognized revenue of $1.6 million, $1.9 million and $1.8 million under the NIAID contract during the years ended December&#160;31, 2023, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;</mgnx:CollaborationAndLicenseAgreementsDisclosureTextBlock>
    <mgnx:NonRefundableUpfrontFees contextRef="c-148" decimals="-5" id="f-580" unitRef="usd">150000000</mgnx:NonRefundableUpfrontFees>
    <mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement contextRef="c-149" decimals="-5" id="f-581" unitRef="usd">435000000</mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement>
    <mgnx:PotentialCommercialMilestonePaymentsUnderAgreement contextRef="c-149" decimals="-5" id="f-582" unitRef="usd">330000000</mgnx:PotentialCommercialMilestonePaymentsUnderAgreement>
    <mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized contextRef="c-150" decimals="-5" id="f-583" unitRef="usd">115000000</mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized>
    <mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized contextRef="c-151" decimals="-5" id="f-584" unitRef="usd">15000000</mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized>
    <mgnx:ProceedsfromRoyaltiesPercent contextRef="c-152" decimals="2" id="f-585" unitRef="number">0.15</mgnx:ProceedsfromRoyaltiesPercent>
    <mgnx:ProceedsfromRoyaltiesPercent contextRef="c-153" decimals="2" id="f-586" unitRef="number">0.24</mgnx:ProceedsfromRoyaltiesPercent>
    <mgnx:NumberOfPerformanceObligations
      contextRef="c-154"
      decimals="INF"
      id="f-587"
      unitRef="performanceobligation">2</mgnx:NumberOfPerformanceObligations>
    <mgnx:CollaborativeAgreementTransactionPrice contextRef="c-155" decimals="-5" id="f-588" unitRef="usd">154000000</mgnx:CollaborativeAgreementTransactionPrice>
    <mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized contextRef="c-150" decimals="-5" id="f-589" unitRef="usd">115000000</mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized>
    <us-gaap:Revenues contextRef="c-156" decimals="-5" id="f-590" unitRef="usd">150000000</us-gaap:Revenues>
    <mgnx:RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount contextRef="c-157" decimals="-5" id="f-591" unitRef="usd">4000000</mgnx:RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount>
    <us-gaap:Revenues contextRef="c-158" decimals="-5" id="f-592" unitRef="usd">15000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-158" decimals="-5" id="f-593" unitRef="usd">15000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-159" decimals="-5" id="f-594" unitRef="usd">30000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-160" decimals="-5" id="f-595" unitRef="usd">15000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-161" decimals="-5" id="f-596" unitRef="usd">1900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-162" decimals="-5" id="f-597" unitRef="usd">700000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-163" decimals="-5" id="f-598" unitRef="usd">1500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-164" decimals="-5" id="f-599" unitRef="usd">4200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-165" decimals="-5" id="f-600" unitRef="usd">300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-166" decimals="-5" id="f-601" unitRef="usd">7800000</us-gaap:Revenues>
    <mgnx:NonRefundableUpfrontFees contextRef="c-167" decimals="-5" id="f-602" unitRef="usd">60000000</mgnx:NonRefundableUpfrontFees>
    <mgnx:PotentialTargetNominationOptionFeesAndMilestonePayments contextRef="c-168" decimals="-5" id="f-603" unitRef="usd">1700000000</mgnx:PotentialTargetNominationOptionFeesAndMilestonePayments>
    <mgnx:NonRefundableUpfrontFees contextRef="c-167" decimals="-5" id="f-604" unitRef="usd">60000000</mgnx:NonRefundableUpfrontFees>
    <mgnx:NonRefundableUpfrontFees contextRef="c-167" decimals="-5" id="f-605" unitRef="usd">60000000</mgnx:NonRefundableUpfrontFees>
    <us-gaap:Revenues contextRef="c-169" decimals="-5" id="f-606" unitRef="usd">1500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-170" decimals="-5" id="f-607" unitRef="usd">200000</us-gaap:Revenues>
    <us-gaap:ContractWithCustomerLiability contextRef="c-171" decimals="-5" id="f-608" unitRef="usd">58300000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-171" decimals="-5" id="f-609" unitRef="usd">2200000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c-171" decimals="-5" id="f-610" unitRef="usd">56100000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiability contextRef="c-172" decimals="-5" id="f-611" unitRef="usd">59800000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-172" decimals="-5" id="f-612" unitRef="usd">1800000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c-172" decimals="-5" id="f-613" unitRef="usd">58000000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:RevenueRemainingPerformanceObligation contextRef="c-173" decimals="-5" id="f-614" unitRef="usd">15700000</us-gaap:RevenueRemainingPerformanceObligation>
    <mgnx:OptInFee contextRef="c-173" decimals="-5" id="f-615" unitRef="usd">10000000</mgnx:OptInFee>
    <us-gaap:RevenueRemainingPerformanceObligation contextRef="c-173" decimals="-5" id="f-616" unitRef="usd">15700000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:Revenues contextRef="c-174" decimals="-5" id="f-617" unitRef="usd">800000</us-gaap:Revenues>
    <us-gaap:ContractWithCustomerLiability contextRef="c-173" decimals="-5" id="f-618" unitRef="usd">14900000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-173" decimals="-5" id="f-619" unitRef="usd">11800000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c-173" decimals="-5" id="f-620" unitRef="usd">3100000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <mgnx:NonRefundableUpfrontFees contextRef="c-175" decimals="-5" id="f-621" unitRef="usd">25000000</mgnx:NonRefundableUpfrontFees>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-175" decimals="-5" id="f-622" unitRef="usd">30000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-2"
      decimals="INF"
      id="f-623"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-176"
      decimals="2"
      id="f-624"
      unitRef="usdPerShare">31.30</us-gaap:SaleOfStockPricePerShare>
    <mgnx:PremiumReceivedOnStockPurchase contextRef="c-177" decimals="-5" id="f-625" unitRef="usd">10400000</mgnx:PremiumReceivedOnStockPurchase>
    <mgnx:CollaborativeAgreementTransactionPrice contextRef="c-176" decimals="-5" id="f-626" unitRef="usd">40400000</mgnx:CollaborativeAgreementTransactionPrice>
    <mgnx:NonRefundableUpfrontFees contextRef="c-175" decimals="-5" id="f-627" unitRef="usd">25000000</mgnx:NonRefundableUpfrontFees>
    <mgnx:PremiumReceivedOnStockPurchase contextRef="c-177" decimals="-5" id="f-628" unitRef="usd">10400000</mgnx:PremiumReceivedOnStockPurchase>
    <mgnx:EstimatedReimbursementForResearchAndDevelopmentT contextRef="c-178" decimals="-5" id="f-629" unitRef="usd">5000000</mgnx:EstimatedReimbursementForResearchAndDevelopmentT>
    <mgnx:CollaborativeAgreementTransactionPrice contextRef="c-176" decimals="-5" id="f-630" unitRef="usd">40400000</mgnx:CollaborativeAgreementTransactionPrice>
    <us-gaap:Revenues contextRef="c-179" decimals="-5" id="f-631" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-180" decimals="-5" id="f-632" unitRef="usd">16800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-181" decimals="-5" id="f-633" unitRef="usd">20300000</us-gaap:Revenues>
    <mgnx:CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare
      contextRef="c-182"
      decimals="INF"
      id="f-634"
      unitRef="usdPerShare">2.50</mgnx:CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare>
    <mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement contextRef="c-183" decimals="-5" id="f-635" unitRef="usd">65000000</mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement>
    <mgnx:PotentialCommercialMilestonePaymentsUnderAgreement contextRef="c-183" decimals="-5" id="f-636" unitRef="usd">225000000</mgnx:PotentialCommercialMilestonePaymentsUnderAgreement>
    <mgnx:CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare
      contextRef="c-184"
      decimals="INF"
      id="f-637"
      unitRef="usdPerShare">2.50</mgnx:CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare>
    <mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement contextRef="c-185" decimals="-5" id="f-638" unitRef="usd">170000000</mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement>
    <mgnx:PotentialCommercialMilestonePaymentsUnderAgreement contextRef="c-185" decimals="-5" id="f-639" unitRef="usd">225000000</mgnx:PotentialCommercialMilestonePaymentsUnderAgreement>
    <mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized contextRef="c-186" decimals="-5" id="f-640" unitRef="usd">60000000</mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized>
    <mgnx:PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement contextRef="c-185" decimals="-5" id="f-641" unitRef="usd">1300000</mgnx:PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement>
    <mgnx:CollaborativeAgreementTransactionPrice contextRef="c-187" decimals="-5" id="f-642" unitRef="usd">6100000</mgnx:CollaborativeAgreementTransactionPrice>
    <mgnx:CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares
      contextRef="c-187"
      decimals="INF"
      id="f-643"
      unitRef="shares">2432688</mgnx:CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares>
    <us-gaap:Revenues contextRef="c-188" decimals="-5" id="f-644" unitRef="usd">6100000</us-gaap:Revenues>
    <mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized contextRef="c-186" decimals="-5" id="f-645" unitRef="usd">60000000</mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized>
    <us-gaap:Revenues contextRef="c-189" decimals="-5" id="f-646" unitRef="usd">5600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-190" decimals="-5" id="f-647" unitRef="usd">60000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-191" decimals="-5" id="f-648" unitRef="usd">1300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-192" decimals="-5" id="f-649" unitRef="usd">5500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-193" decimals="-5" id="f-650" unitRef="usd">300000</us-gaap:Revenues>
    <mgnx:FutureRevenue contextRef="c-194" decimals="-5" id="f-651" unitRef="usd">50000000</mgnx:FutureRevenue>
    <mgnx:CollaborativeArrangementTerm contextRef="c-195" id="f-652">P3Y</mgnx:CollaborativeArrangementTerm>
    <mgnx:NonRefundableUpfrontFees contextRef="c-196" decimals="-5" id="f-653" unitRef="usd">10000000</mgnx:NonRefundableUpfrontFees>
    <mgnx:TotalAnnualFixedPayments contextRef="c-197" decimals="-5" id="f-654" unitRef="usd">14400000</mgnx:TotalAnnualFixedPayments>
    <mgnx:CollaborativeArrangementExtensionTerm contextRef="c-195" id="f-655">P1Y</mgnx:CollaborativeArrangementExtensionTerm>
    <mgnx:AdditionalAnnualFixedPayments contextRef="c-198" decimals="-5" id="f-656" unitRef="usd">5100000</mgnx:AdditionalAnnualFixedPayments>
    <mgnx:NonRefundableUpfrontFees contextRef="c-196" decimals="-5" id="f-657" unitRef="usd">10000000</mgnx:NonRefundableUpfrontFees>
    <mgnx:TotalAnnualFixedPayments contextRef="c-199" decimals="-5" id="f-658" unitRef="usd">19500000</mgnx:TotalAnnualFixedPayments>
    <us-gaap:Revenues contextRef="c-200" decimals="-5" id="f-659" unitRef="usd">9700000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-201" decimals="-5" id="f-660" unitRef="usd">8700000</us-gaap:Revenues>
    <us-gaap:ContractWithCustomerLiability contextRef="c-197" decimals="-5" id="f-661" unitRef="usd">7000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability contextRef="c-202" decimals="-5" id="f-662" unitRef="usd">9600000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-202" decimals="-5" id="f-663" unitRef="usd">8100000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c-202" decimals="-5" id="f-664" unitRef="usd">1500000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <mgnx:UpfrontAndFixedPayments contextRef="c-203" decimals="-5" id="f-665" unitRef="usd">4600000</mgnx:UpfrontAndFixedPayments>
    <us-gaap:Revenues contextRef="c-204" decimals="-5" id="f-666" unitRef="usd">5300000</us-gaap:Revenues>
    <mgnx:NumberOfProductCandidates contextRef="c-205" decimals="INF" id="f-667" unitRef="usd">2</mgnx:NumberOfProductCandidates>
    <mgnx:TotalPotentialValueUnderAgreement contextRef="c-206" decimals="-5" id="f-668" unitRef="usd">25100000</mgnx:TotalPotentialValueUnderAgreement>
    <us-gaap:Revenues contextRef="c-207" decimals="-5" id="f-669" unitRef="usd">1600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-208" decimals="-5" id="f-670" unitRef="usd">1900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-209" decimals="-5" id="f-671" unitRef="usd">1800000</us-gaap:Revenues>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c-1" id="f-672">Stock-based Compensation&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2017, the Company&#x2019;s stockholders approved the 2016 Employee Stock Purchase Plan (the 2016 ESPP). The 2016 ESPP is structured as a qualified employee stock purchase plan under Section 423 of the Internal Revenue Code of 1986, as amended, and is not subject to the provisions of the Employee Retirement Income Security Act of 1974. The Company reserved 800,000 shares of common stock for issuance under the 2016 ESPP. The 2016 ESPP allows eligible employees to purchase shares of the Company&#x2019;s common stock at a discount through payroll deductions of up to 10% of their eligible compensation, subject to any plan limitations. The 2016 ESPP provides for six-month offering periods ending on May 31 and November 30 of each year. At the end of each offering period, employees are able to purchase shares at 85% of the fair market value of the Company&#x2019;s common stock on the last day of the offering period. During the year ended December&#160;31, 2023, employees purchased 81,541 shares of common stock under the 2016 ESPP for net proceeds to the Company of approximately $0.5&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Employee Stock Incentive Plans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2013, the Company implemented the 2013 Equity Incentive Plan (2013 Plan).&#160;The 2013 Plan provides for the grant of stock options and other stock-based awards, as well as cash-based performance awards. In May 2023, the 2013 Plan was terminated, and no further awards may be issued under the plan. If an option granted under the 2013 Plan expires or terminates for any reason without having been fully exercised, if any shares of restricted stock are forfeited, or if any award terminates, expires or is settled without all or a portion of the shares of common stock covered by the award being issued, such shares will become available for issuance under the 2023 Equity Incentive Plan (2023 Plan). As of December&#160;31, 2023, under the 2013 Plan, there were options to purchase an aggregate of 11,805,515 shares of common stock outstanding at a weighted average exercise price of $15.45 per share. As of December&#160;31, 2023, there were 854,114 unvested restricted stock units (RSUs) outstanding under the 2013 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2023 Plan was effective as of stockholder approval in May 2023. The 2023 Plan provides for grants of stock options and other stock-based awards, as well as cash-based performance awards. Initially, the maximum number of shares of the Company&#x2019;s common stock that may be issued under the 2023 Plan will not exceed 4,850,000 shares. If an option expires or terminates for any reason without having been fully exercised, if any shares of restricted stock are forfeited, or if any award terminates, expires or is settled without all or a portion of the shares of common stock covered by the award being issued, such shares are available for the grant of additional awards. However, any shares that are withheld (or delivered) to pay withholding taxes or to pay the exercise price of an option are not available for the grant of additional awards. As of December&#160;31, 2023, under the 2023 Plan, there were options to purchase an aggregate of 418,122 shares of common stock outstanding at a weighted &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;average exercise price of $5.31 per share. As of December&#160;31, 2023, there were 51,500 unvested RSUs outstanding under the 2023 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following stock-based compensation amounts were recognized for the periods indicated (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.243%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.631%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Employee Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for stock-based compensation to employees and non-employee directors in accordance with ASC Topic 718, &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Compensation &#x2013; Stock Compensation&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Company estimates the fair value of stock option awards using the Black-Scholes option pricing model on the date of grant using the assumptions in the table below. Stock options granted to employees generally vest over four years and have a term of ten years. Stock-based compensation expense for stock options is recognized as expense over the requisite service period, which is the vesting period. As the Company has not paid dividends since inception, nor does it expect to pay any dividends for the foreseeable future, the expected dividend yield assumption is zero. The expected volatility is based on the historical stock volatility of the Company&#x2019;s own common stock over a period equal to the expected term of the options. The risk-free rate of the stock options is based on the U.S. Treasury rate in effect at the time of grant for the expected term of the stock options. The Company used the simplified method to calculate expected term during 2021.  Beginning in 2022, the computation of expected term was determined based on the historical experience with similar awards, giving consideration to the contractual terms of the share-based awards, vesting schedules and expectations of future employee behavior.  In addition, the Company  estimates the expected forfeiture rate and only recognizes expense for those shares expected to vest. The Company estimates the forfeiture rate based on historical experience and its expectations regarding future pre-vesting termination behavior of employees. The Company reviews its estimate of the expected forfeiture rate annually, and stock-based compensation expense is adjusted accordingly.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.211%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.639%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76% -96%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88% - 92%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86% - 87%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5% - 4.8%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4% - 4.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6% - 1.6%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.88 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.95 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.25 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity for 2023:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:49.923%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Exercise Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Contractual Term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,098,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,367,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34,608)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(365,942)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(842,519)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,223,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As of December&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,892,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,346,207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2023, 2022 and 2021 the Company issued 34,608, 120,900 and 332,767 shares of common stock, respectively, in conjunction with stock option exercises.&#160;The Company received cash proceeds from the exercise of stock options of approximately $0.1 million, $0.2 million and $5.8 million during 2023, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average grant-date fair value of options granted during 2023, 2022 and 2021 was $3.83, $6.84 and $15.20 per share, respectively. The total intrinsic value of options exercised during 2023, 2022 and 2021 was approximately $0.1&#160;million, $0.6 million and $3.3 million, respectively.&#160;The total fair value of stock options which vested during 2023, 2022 and 2021 was $16.4 million, $19.6 million and $20.2 million, respectively.&#160;As of December&#160;31, 2023, the total unrecognized compensation expense related to non-vested stock options, net of related forfeiture estimates, was $19.5 million, which the Company expects to recognize over a weighted-average period of approximately 1.2 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company awards RSUs to employees. RSUs are valued based on the closing price of the Company&#x2019;s common stock on the date of the grant. The fair value of RSUs is recognized and amortized on a straight-line basis over the requisite service period of the award&lt;/span&gt;&lt;span style="color:#252525;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes RSU activity for 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.163%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.268%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.115%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.954%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Grant Date Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;415,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;707,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(135,396)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(81,709)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;905,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2023, there was $2.3 million of total unrecognized compensation cost related to unvested RSUs, which the Company expects to recognize over a remaining weighted-average period of 1.2 years.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-210"
      decimals="INF"
      id="f-673"
      unitRef="shares">800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <mgnx:EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="c-211"
      decimals="INF"
      id="f-674"
      unitRef="number">0.10</mgnx:EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent>
    <mgnx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod contextRef="c-212" id="f-675">P6M</mgnx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="c-211"
      decimals="INF"
      id="f-676"
      unitRef="number">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod contextRef="c-213" decimals="0" id="f-677" unitRef="shares">81541</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-213" decimals="-5" id="f-678" unitRef="usd">500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-214"
      decimals="INF"
      id="f-679"
      unitRef="shares">11805515</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-214"
      decimals="2"
      id="f-680"
      unitRef="usdPerShare">15.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-215"
      decimals="INF"
      id="f-681"
      unitRef="shares">854114</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-216"
      decimals="INF"
      id="f-682"
      unitRef="shares">4850000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-217"
      decimals="INF"
      id="f-683"
      unitRef="shares">418122</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-217"
      decimals="2"
      id="f-684"
      unitRef="usdPerShare">5.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-218"
      decimals="INF"
      id="f-685"
      unitRef="shares">51500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c-1" id="f-686">&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following stock-based compensation amounts were recognized for the periods indicated (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.243%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.631%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-219" decimals="-3" id="f-687" unitRef="usd">9190000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-220" decimals="-3" id="f-688" unitRef="usd">10094000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-221" decimals="-3" id="f-689" unitRef="usd">11337000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-222" decimals="-3" id="f-690" unitRef="usd">9183000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-223" decimals="-3" id="f-691" unitRef="usd">10344000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-224" decimals="-3" id="f-692" unitRef="usd">11789000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-3" id="f-693" unitRef="usd">18373000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-27" decimals="-3" id="f-694" unitRef="usd">20438000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-28" decimals="-3" id="f-695" unitRef="usd">23126000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1 contextRef="c-225" id="f-696">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-225" id="f-697">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c-225" id="f-698">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c-1" id="f-699">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.211%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.639%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76% -96%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88% - 92%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86% - 87%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5% - 4.8%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4% - 4.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6% - 1.6%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.88 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.95 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.25 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-1" decimals="INF" id="f-700" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-27"
      decimals="INF"
      id="f-701"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-28"
      decimals="INF"
      id="f-702"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-226" decimals="3" id="f-703" unitRef="number">0.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-227" decimals="3" id="f-704" unitRef="number">0.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-228" decimals="3" id="f-705" unitRef="number">0.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-229" decimals="2" id="f-706" unitRef="number">0.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-230" decimals="2" id="f-707" unitRef="number">0.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-231" decimals="2" id="f-708" unitRef="number">0.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-226" decimals="4" id="f-709" unitRef="number">0.035</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-227" decimals="4" id="f-710" unitRef="number">0.048</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-228" decimals="4" id="f-711" unitRef="number">0.014</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-229" decimals="4" id="f-712" unitRef="number">0.040</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-230" decimals="4" id="f-713" unitRef="number">0.006</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-231" decimals="4" id="f-714" unitRef="number">0.016</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-1" id="f-715">P5Y10M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-27" id="f-716">P5Y11M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-28" id="f-717">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c-1" id="f-718">&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity for 2023:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:49.923%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Exercise Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Contractual Term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,098,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,367,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34,608)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(365,942)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(842,519)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,223,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As of December&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,892,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,346,207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-11"
      decimals="INF"
      id="f-719"
      unitRef="shares">10098929</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-11"
      decimals="2"
      id="f-720"
      unitRef="usdPerShare">18.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-27" id="f-721">P6Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="c-1" decimals="INF" id="f-722" unitRef="shares">3367777</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-723"
      unitRef="usdPerShare">4.97</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-1" decimals="INF" id="f-724" unitRef="shares">34608</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-725"
      unitRef="usdPerShare">3.73</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="c-1" decimals="INF" id="f-726" unitRef="shares">365942</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-727"
      unitRef="usdPerShare">9.49</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="c-1" decimals="INF" id="f-728" unitRef="shares">842519</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-729"
      unitRef="usdPerShare">19.12</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-2" decimals="INF" id="f-730" unitRef="shares">12223637</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-2"
      decimals="2"
      id="f-731"
      unitRef="usdPerShare">15.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-1" id="f-732">P6Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-2" decimals="-3" id="f-733" unitRef="usd">16974000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="c-2" decimals="INF" id="f-734" unitRef="shares">7892753</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c-2"
      decimals="2"
      id="f-735"
      unitRef="usdPerShare">18.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-1" id="f-736">P5Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c-2" decimals="-3" id="f-737" unitRef="usd">4509000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="c-2" decimals="INF" id="f-738" unitRef="shares">11346207</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="c-2"
      decimals="2"
      id="f-739"
      unitRef="usdPerShare">15.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="c-1" id="f-740">P6Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="c-2" decimals="-3" id="f-741" unitRef="usd">14692000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="c-1" decimals="INF" id="f-742" unitRef="shares">34608</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="c-27"
      decimals="INF"
      id="f-743"
      unitRef="shares">120900</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="c-28"
      decimals="INF"
      id="f-744"
      unitRef="shares">332767</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-1" decimals="-5" id="f-745" unitRef="usd">100000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-27" decimals="-5" id="f-746" unitRef="usd">200000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-28" decimals="-5" id="f-747" unitRef="usd">5800000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-1"
      decimals="2"
      id="f-748"
      unitRef="usdPerShare">3.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-27"
      decimals="2"
      id="f-749"
      unitRef="usdPerShare">6.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-28"
      decimals="2"
      id="f-750"
      unitRef="usdPerShare">15.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-1" decimals="-5" id="f-751" unitRef="usd">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-27" decimals="-5" id="f-752" unitRef="usd">600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-28" decimals="-5" id="f-753" unitRef="usd">3300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="c-1" decimals="-5" id="f-754" unitRef="usd">16400000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="c-27" decimals="-5" id="f-755" unitRef="usd">19600000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="c-28" decimals="-5" id="f-756" unitRef="usd">20200000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c-2" decimals="-5" id="f-757" unitRef="usd">19500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-1" id="f-758">P1Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock contextRef="c-1" id="f-759">&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes RSU activity for 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.163%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.268%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.115%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.954%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Grant Date Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;415,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;707,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(135,396)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(81,709)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;905,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-232"
      decimals="INF"
      id="f-760"
      unitRef="shares">415084</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-232"
      decimals="2"
      id="f-761"
      unitRef="usdPerShare">8.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-233"
      decimals="INF"
      id="f-762"
      unitRef="shares">707635</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-233"
      decimals="2"
      id="f-763"
      unitRef="usdPerShare">4.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="c-233"
      decimals="INF"
      id="f-764"
      unitRef="shares">135396</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-233"
      decimals="2"
      id="f-765"
      unitRef="usdPerShare">8.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-233"
      decimals="INF"
      id="f-766"
      unitRef="shares">81709</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-233"
      decimals="2"
      id="f-767"
      unitRef="usdPerShare">7.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-234"
      decimals="INF"
      id="f-768"
      unitRef="shares">905614</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-234"
      decimals="2"
      id="f-769"
      unitRef="usdPerShare">5.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions contextRef="c-234" decimals="-5" id="f-770" unitRef="usd">2300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-233" id="f-771">P1Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c-1" id="f-772">Income Taxes &lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December&#160;31, 2023, 2022 and 2021 there was no provision for income taxes due to taxable losses generated, fully offset by a valuation allowance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The significant components of the Company's deferred income tax assets (liabilities) were as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.706%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.631%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal U.S. net operating loss carryforward&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State net operating loss carryforward&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development credit, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Orphan drug credit, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Section 174 deferred tax asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity based compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross deferred income tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;373,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;381,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(365,010)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(372,267)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred income tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:13pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease ROU assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,372)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,522)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenditures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,030)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,521)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross deferred income tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,402)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,043)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred income tax asset/(liability)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes valuation allowances to reduce deferred tax assets to the amount that is more likely than not to be realized. In assessing the likelihood of realization, management considers (i) future reversals of existing taxable temporary differences; (ii) future taxable income exclusive of reversing temporary difference and carryforwards; (iii) taxable income in prior carryback years if carryback is permitted under applicable tax law; and (iv) tax planning strategies. The Company's net deferred income tax asset is not more likely than not to be utilized due to the lack of sufficient sources of future taxable income and cumulative book losses which have resulted over the years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The activity in the valuation allowance on deferred tax assets was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.970%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.859%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.859%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.554%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.859%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.554%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.861%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at Beginning of Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at End of Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year Ended December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;372,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,257)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;365,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;327,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;372,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year Ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;263,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;327,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, the Company has U.S. federal and state net operating loss (NOL) carryforwards of approximately $670.0 million. Of these NOLs, $65.5 million will expire in various years beginning in 2035 through 2037. $604.5 million of NOLs were generated post December 31, 2017 and carryforward indefinitely. In addition, the Company has U.S. federal tax credits of $94.4 million which will expire in various years beginning in 2024 through 2043.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reconciliation of the reported estimated income tax benefit to the amount that would result by applying the U.S. federal statutory tax rate to the net income is as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.243%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.631%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States federal tax at statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,902)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,149)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42,445)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State taxes (net of federal benefit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(163)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,385)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,806)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred state blended rate adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research credit, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,168)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,569)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,243)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Orphan drug credit, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,846)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,449)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other permanent items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,257)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax expense/(benefit)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.243%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.631%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases for current year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases/(decreases) for prior year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(369)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023 and 2022, of the total gross unrecognized tax benefits, approximately $7.8 million and $7.4 million would favorably impact the Company's effective income tax rate, respectively. Although, due to the Company's determination that the deferred income tax asset would not more likely than not be realized, a valuation allowance would be recorded, therefore, zero net impact would result within the Company's effective income tax rate. The Company's uncertain income tax position liability has been recorded to deferred income taxes to offset the tax attribute carryforward amounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December&#160;31, 2023, 2022 and 2021, the Company has not recognized any interest or penalties related to the uncertain income tax positions due to the fact such position is related to tax attribute carryforwards which have not yet been utilized. The Company does not expect its unrecognized income tax position to significantly decrease within the next twelve months.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's U.S. Federal and state income tax returns from 2004 &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;forward remain open to examination due to the carryover of unused income tax credits, and from 2004 forward due to the carryover of unused net operating losses.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Internal Revenue Code (IRC) Section 174&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For tax years beginning on or after January 1, 2022, the Tax Cuts and Jobs Act of 2017 eliminates the option to currently deduct research and development expenses and requires taxpayers to capitalize and amortize them over five years for research activities performed in the United States and 15 years for research activities performed outside the United States pursuant to IRC Section 174. Although Congress is considering legislation that would repeal or defer this capitalization and amortization requirement, it is not certain that this provision will be repealed or otherwise modified. If the requirement is not repealed or replaced, it could increase our U.S. federal and state cash taxes and reduce cash flows in future years.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-1" decimals="-5" id="f-773" unitRef="usd">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c-1" id="f-774">&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The significant components of the Company's deferred income tax assets (liabilities) were as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.706%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.631%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal U.S. net operating loss carryforward&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State net operating loss carryforward&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development credit, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Orphan drug credit, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Section 174 deferred tax asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity based compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross deferred income tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;373,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;381,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(365,010)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(372,267)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred income tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:13pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease ROU assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,372)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,522)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenditures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,030)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,521)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross deferred income tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,402)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,043)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred income tax asset/(liability)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic contextRef="c-2" decimals="-3" id="f-775" unitRef="usd">140706000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic contextRef="c-11" decimals="-3" id="f-776" unitRef="usd">163071000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal contextRef="c-2" decimals="-3" id="f-777" unitRef="usd">33350000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal contextRef="c-11" decimals="-3" id="f-778" unitRef="usd">44784000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="c-2" decimals="-3" id="f-779" unitRef="usd">68251000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="c-11" decimals="-3" id="f-780" unitRef="usd">65084000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsOther contextRef="c-2" decimals="-3" id="f-781" unitRef="usd">33330000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsOther>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsOther contextRef="c-11" decimals="-3" id="f-782" unitRef="usd">35703000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsOther>
    <mgnx:DeferredTaxAssetsOperatingLeaseLiabilities contextRef="c-2" decimals="-3" id="f-783" unitRef="usd">9078000</mgnx:DeferredTaxAssetsOperatingLeaseLiabilities>
    <mgnx:DeferredTaxAssetsOperatingLeaseLiabilities contextRef="c-11" decimals="-3" id="f-784" unitRef="usd">9585000</mgnx:DeferredTaxAssetsOperatingLeaseLiabilities>
    <us-gaap:DeferredTaxAssetsDeferredIncome contextRef="c-2" decimals="-3" id="f-785" unitRef="usd">17442000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome contextRef="c-11" decimals="-3" id="f-786" unitRef="usd">0</us-gaap:DeferredTaxAssetsDeferredIncome>
    <mgnx:Section174DeferredTaxAsset contextRef="c-2" decimals="-3" id="f-787" unitRef="usd">48421000</mgnx:Section174DeferredTaxAsset>
    <mgnx:Section174DeferredTaxAsset contextRef="c-11" decimals="-3" id="f-788" unitRef="usd">43192000</mgnx:Section174DeferredTaxAsset>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c-2" decimals="-3" id="f-789" unitRef="usd">16217000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c-11" decimals="-3" id="f-790" unitRef="usd">15228000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsOther contextRef="c-2" decimals="-3" id="f-791" unitRef="usd">6617000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther contextRef="c-11" decimals="-3" id="f-792" unitRef="usd">4663000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-2" decimals="-3" id="f-793" unitRef="usd">373412000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-11" decimals="-3" id="f-794" unitRef="usd">381310000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-2" decimals="-3" id="f-795" unitRef="usd">365010000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-11" decimals="-3" id="f-796" unitRef="usd">372267000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet contextRef="c-2" decimals="-3" id="f-797" unitRef="usd">8402000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet contextRef="c-11" decimals="-3" id="f-798" unitRef="usd">9043000</us-gaap:DeferredTaxAssetsNet>
    <mgnx:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets contextRef="c-2" decimals="-3" id="f-799" unitRef="usd">6372000</mgnx:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets>
    <mgnx:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets contextRef="c-11" decimals="-3" id="f-800" unitRef="usd">7522000</mgnx:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets>
    <us-gaap:DeferredTaxLiabilitiesPrepaidExpenses contextRef="c-2" decimals="-3" id="f-801" unitRef="usd">2030000</us-gaap:DeferredTaxLiabilitiesPrepaidExpenses>
    <us-gaap:DeferredTaxLiabilitiesPrepaidExpenses contextRef="c-11" decimals="-3" id="f-802" unitRef="usd">1521000</us-gaap:DeferredTaxLiabilitiesPrepaidExpenses>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c-2" decimals="-3" id="f-803" unitRef="usd">8402000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c-11" decimals="-3" id="f-804" unitRef="usd">9043000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c-2" decimals="-3" id="f-805" unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c-11" decimals="-3" id="f-806" unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:SummaryOfValuationAllowanceTextBlock contextRef="c-1" id="f-807">&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The activity in the valuation allowance on deferred tax assets was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.970%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.859%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.859%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.554%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.859%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.554%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.861%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at Beginning of Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at End of Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year Ended December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;372,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,257)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;365,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;327,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;372,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year Ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;263,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;327,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SummaryOfValuationAllowanceTextBlock>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-11" decimals="-3" id="f-808" unitRef="usd">372267000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <mgnx:ValuationAllowanceDeferredTaxAssetIncreaseAmount contextRef="c-1" decimals="-3" id="f-809" unitRef="usd">0</mgnx:ValuationAllowanceDeferredTaxAssetIncreaseAmount>
    <mgnx:ValuationAllowanceDeferredTaxAssetDecreaseAmount contextRef="c-1" decimals="-3" id="f-810" unitRef="usd">7257000</mgnx:ValuationAllowanceDeferredTaxAssetDecreaseAmount>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-2" decimals="-3" id="f-811" unitRef="usd">365010000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-42" decimals="-3" id="f-812" unitRef="usd">327592000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <mgnx:ValuationAllowanceDeferredTaxAssetIncreaseAmount contextRef="c-27" decimals="-3" id="f-813" unitRef="usd">44675000</mgnx:ValuationAllowanceDeferredTaxAssetIncreaseAmount>
    <mgnx:ValuationAllowanceDeferredTaxAssetDecreaseAmount contextRef="c-27" decimals="-3" id="f-814" unitRef="usd">0</mgnx:ValuationAllowanceDeferredTaxAssetDecreaseAmount>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-11" decimals="-3" id="f-815" unitRef="usd">372267000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-33" decimals="-3" id="f-816" unitRef="usd">263400000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <mgnx:ValuationAllowanceDeferredTaxAssetIncreaseAmount contextRef="c-28" decimals="-3" id="f-817" unitRef="usd">64192000</mgnx:ValuationAllowanceDeferredTaxAssetIncreaseAmount>
    <mgnx:ValuationAllowanceDeferredTaxAssetDecreaseAmount contextRef="c-28" decimals="-3" id="f-818" unitRef="usd">0</mgnx:ValuationAllowanceDeferredTaxAssetDecreaseAmount>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-42" decimals="-3" id="f-819" unitRef="usd">327592000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration contextRef="c-235" decimals="-5" id="f-820" unitRef="usd">670000000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration contextRef="c-236" decimals="-5" id="f-821" unitRef="usd">65500000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration contextRef="c-237" decimals="-5" id="f-822" unitRef="usd">604500000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:TaxCreditCarryforwardAmount contextRef="c-238" decimals="-5" id="f-823" unitRef="usd">94400000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c-1" id="f-824">&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reconciliation of the reported estimated income tax benefit to the amount that would result by applying the U.S. federal statutory tax rate to the net income is as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.243%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.631%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States federal tax at statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,902)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,149)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42,445)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State taxes (net of federal benefit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(163)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,385)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,806)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred state blended rate adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research credit, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,168)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,569)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,243)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Orphan drug credit, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,846)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,449)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other permanent items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,257)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax expense/(benefit)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c-1" decimals="-3" id="f-825" unitRef="usd">-1902000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c-27" decimals="-3" id="f-826" unitRef="usd">-25149000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c-28" decimals="-3" id="f-827" unitRef="usd">-42445000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="c-1" decimals="-3" id="f-828" unitRef="usd">-163000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="c-27" decimals="-3" id="f-829" unitRef="usd">-7385000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="c-28" decimals="-3" id="f-830" unitRef="usd">-12806000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <mgnx:EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount contextRef="c-1" decimals="-3" id="f-831" unitRef="usd">5024000</mgnx:EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount>
    <mgnx:EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount contextRef="c-27" decimals="-3" id="f-832" unitRef="usd">308000</mgnx:EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount>
    <mgnx:EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount contextRef="c-28" decimals="-3" id="f-833" unitRef="usd">473000</mgnx:EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount>
    <mgnx:EffectiveIncomeTaxRateReconciliationDeferredStateBlendedRateAdjustmentsAmount contextRef="c-1" decimals="-3" id="f-834" unitRef="usd">1841000</mgnx:EffectiveIncomeTaxRateReconciliationDeferredStateBlendedRateAdjustmentsAmount>
    <mgnx:EffectiveIncomeTaxRateReconciliationDeferredStateBlendedRateAdjustmentsAmount contextRef="c-27" decimals="-3" id="f-835" unitRef="usd">0</mgnx:EffectiveIncomeTaxRateReconciliationDeferredStateBlendedRateAdjustmentsAmount>
    <mgnx:EffectiveIncomeTaxRateReconciliationDeferredStateBlendedRateAdjustmentsAmount contextRef="c-28" decimals="-3" id="f-836" unitRef="usd">0</mgnx:EffectiveIncomeTaxRateReconciliationDeferredStateBlendedRateAdjustmentsAmount>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch contextRef="c-1" decimals="-3" id="f-837" unitRef="usd">3168000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch contextRef="c-27" decimals="-3" id="f-838" unitRef="usd">4569000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch contextRef="c-28" decimals="-3" id="f-839" unitRef="usd">10243000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <mgnx:EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount contextRef="c-1" decimals="-3" id="f-840" unitRef="usd">-2374000</mgnx:EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount>
    <mgnx:EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount contextRef="c-27" decimals="-3" id="f-841" unitRef="usd">10846000</mgnx:EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount>
    <mgnx:EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount contextRef="c-28" decimals="-3" id="f-842" unitRef="usd">1449000</mgnx:EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount>
    <us-gaap:IncomeTaxReconciliationOtherReconcilingItems contextRef="c-1" decimals="-3" id="f-843" unitRef="usd">1301000</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
    <us-gaap:IncomeTaxReconciliationOtherReconcilingItems contextRef="c-27" decimals="-3" id="f-844" unitRef="usd">1362000</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
    <us-gaap:IncomeTaxReconciliationOtherReconcilingItems contextRef="c-28" decimals="-3" id="f-845" unitRef="usd">1199000</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-1" decimals="-3" id="f-846" unitRef="usd">1950000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-27" decimals="-3" id="f-847" unitRef="usd">1604000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-28" decimals="-3" id="f-848" unitRef="usd">1079000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-1" decimals="-3" id="f-849" unitRef="usd">-7257000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-27" decimals="-3" id="f-850" unitRef="usd">44675000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-28" decimals="-3" id="f-851" unitRef="usd">64192000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-852" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-27" decimals="-3" id="f-853" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-28" decimals="-3" id="f-854" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock contextRef="c-1" id="f-855">&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.243%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.631%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases for current year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases/(decreases) for prior year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(369)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-11" decimals="-3" id="f-856" unitRef="usd">7376000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-42" decimals="-3" id="f-857" unitRef="usd">7197000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-33" decimals="-3" id="f-858" unitRef="usd">6126000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="c-1" decimals="-3" id="f-859" unitRef="usd">449000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="c-27" decimals="-3" id="f-860" unitRef="usd">548000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="c-28" decimals="-3" id="f-861" unitRef="usd">965000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <mgnx:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions contextRef="c-1" decimals="-3" id="f-862" unitRef="usd">-4000</mgnx:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions>
    <mgnx:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions contextRef="c-27" decimals="-3" id="f-863" unitRef="usd">-369000</mgnx:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions>
    <mgnx:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions contextRef="c-28" decimals="-3" id="f-864" unitRef="usd">106000</mgnx:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-2" decimals="-3" id="f-865" unitRef="usd">7821000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-11" decimals="-3" id="f-866" unitRef="usd">7376000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-42" decimals="-3" id="f-867" unitRef="usd">7197000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate contextRef="c-2" decimals="-5" id="f-868" unitRef="usd">7800000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate contextRef="c-11" decimals="-5" id="f-869" unitRef="usd">7400000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense contextRef="c-28" decimals="INF" id="f-870" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense contextRef="c-27" decimals="INF" id="f-871" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense contextRef="c-1" decimals="INF" id="f-872" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock contextRef="c-1" id="f-873">Employee Benefit Plan&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2002, the Company established the MacroGenics 401(k) Plan (the Plan) for its employees under Section 401(k) of the IRC. Under this Plan, all employees at least 21 years of age are eligible to participate in the Plan, starting on the first day of employment. Employees may contribute up to 100% of their salary, subject to government maximums.&lt;/span&gt;&lt;/div&gt;Employees are 100% vested in their contributions to the Plan. The Company's contribution to the Plan, as determined by the Board of Directors, is discretionary. For the years ended December&#160;31, 2023, 2022 and 2021, the Company's contributions to the Plan totaled $2.1 million, $2.3 million and $1.6 million, respectively.</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <mgnx:EmployeesEligibleAgeToParticipateInBenefitPlan contextRef="c-1" id="f-874">P21Y</mgnx:EmployeesEligibleAgeToParticipateInBenefitPlan>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent contextRef="c-1" decimals="INF" id="f-875" unitRef="number">1</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <mgnx:DefinedContributionPlanEmployeesContributionVestedPercentage contextRef="c-1" decimals="INF" id="f-876" unitRef="number">1</mgnx:DefinedContributionPlanEmployeesContributionVestedPercentage>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount contextRef="c-1" decimals="-5" id="f-877" unitRef="usd">2100000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount contextRef="c-27" decimals="-5" id="f-878" unitRef="usd">2300000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount contextRef="c-28" decimals="-5" id="f-879" unitRef="usd">1600000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
